<SEC-DOCUMENT>0000950170-25-018852.txt : 20250212
<SEC-HEADER>0000950170-25-018852.hdr.sgml : 20250212
<ACCEPTANCE-DATETIME>20250212161538
ACCESSION NUMBER:		0000950170-25-018852
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		130
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250212
DATE AS OF CHANGE:		20250212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ascendis Pharma A/S
		CENTRAL INDEX KEY:			0001612042
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36815
		FILM NUMBER:		25615027

	BUSINESS ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
		BUSINESS PHONE:		45 70 22 22 44

	MAIL ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>asnd-20241231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-12T15:28:08.4301+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:asnd="http://ascendispharma.com/20241231">
 <head>
  <title>20-F</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_79aff695-ba3e-4877-855d-965b2bbc4f62" name="dei:NoTradingSymbolFlag" contextRef="C_d0434620-73bd-43f1-9192-7bca1ecaf642">true</ix:nonNumeric><ix:nonNumeric id="F_248eefb9-7521-454c-9b3c-9a1e89150e7f" name="dei:AmendmentFlag" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950">false</ix:nonNumeric><ix:nonNumeric id="F_15aa6fee-b1a7-4e81-82af-61b80378d3cf" name="dei:DocumentFiscalPeriodFocus" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950">FY</ix:nonNumeric><ix:nonNumeric id="F_c807c7d7-9a5b-4210-a450-51316b53fb8a" name="dei:EntityCentralIndexKey" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950">0001612042</ix:nonNumeric><ix:nonNumeric id="F_f487bf8e-d837-43ab-b0e3-34496c9a8875" name="dei:AuditorName" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950">Deloitte Statsautoriseret Revisionspartnerselskab</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="asnd-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_802fb420-5428-493a-87b7-02e34b108386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:BoardMembersOfGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_809a9649-b6e0-488d-b7e5-4e1442b1f755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80c10e22-bf47-4313-871c-4161cd400123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81e30392-2ae2-46f2-9e52-85bbd8e7a714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81e385ec-89e0-41e0-9a86-a4f0e9abe54c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaSverigeAbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8254a47f-7720-4dbd-860f-ccd3f90e8bcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8373ab39-153b-4580-8eaa-20b64be0b669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83fd201b-7c83-4ee4-a0da-02d9df8447b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_842cce4b-c4af-4a45-9074-b4aeeba66138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaGrowthDisordersASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_860b08a9-36e4-40f6-9b25-30137702ac03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8868a6a4-46c9-401e-8496-50e9fd14cdcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88ae6c08-23fb-4240-bf5e-678082269ff6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">asnd:USDollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88ae85e5-4346-454d-9c63-a628775940b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_890d9573-96a4-4975-ad2a-83e24165cf64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_899ab35b-66a6-40e5-96b1-211674a39c3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b7cf227-3c27-4452-bf1e-f4d1f142fedb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bdc1384-8c1b-4199-954a-92a67517fd1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c791550-835c-4e22-a26b-97ea8127f804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cdbb2f3-5894-447e-9e13-0a00148c6b78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d641cf8-4f3e-4466-b341-181115f04c36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d88cc9c-27a2-4ff0-b63b-b1a040391061"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e586c11-342f-42e1-8ae7-79f86b29e744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e72405c-35f1-4928-85aa-52168ce828ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ec23a67-4cba-4228-abd5-b5b3f4e8d2dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9076fd44-ae75-413e-8321-bdfaee1f0a4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_907adb7e-5f6a-4552-b8e4-ca87be7ab73c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9133c0f6-7b07-41ad-a86d-58e8adc23e5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95c2771f-cee1-4eb7-beba-a54cb5701188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">asnd:OfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-20</xbrli:startDate><xbrli:endDate>2022-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_962ef1c5-8d47-4bc2-b07c-320d06c0970d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97992a0e-7ccc-4554-a974-5d01c776b4ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99479b14-1e7c-41fa-833c-83e794f18d01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9952b4f6-b45f-4d1f-886d-8e1f0d262e6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99536d97-e9f4-4fd6-9215-dd6f7d4b7755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99a808e7-1efe-471a-ba2d-6422ec451ea7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a087241-0b3a-4cac-b087-23c132bb156a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a3e4976-f3f3-4e99-a326-5bb0cb57fee4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c347efe-55f5-41f7-aa5a-2ffa52fa30b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9de36237-7daf-4d9a-ba1a-4f2827faaa62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e598379-6e17-4151-b88c-4b34a9189ddb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e913d68-9472-471d-b85b-01401c7287b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9fb94f08-5f01-4b31-86eb-19c1c44186e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a04879c9-d225-42da-8adf-2501801d997b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0ccec1e-9a89-4166-b4d2-16f6ff5ce9da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a10a1719-791f-4cff-8b86-2f3b720e2290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a18ad5cb-63e0-41e5-a54d-935b4eed3032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a29fcdf1-c976-4997-a302-2bd939c278f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2de7ead-6804-4136-a02b-31e903c48f97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a34d3224-7646-4cf8-a9ef-f7fdd1eb668e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4416a56-3759-43a1-a9b2-a168da37fe04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a71bc062-4b22-4a9f-b52c-19753e5e74b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a75c561c-801d-4844-bed5-502cc157a1d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a91db531-c49c-48c0-bb87-a56fc4db3411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:LicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9a130e0-614f-4ba0-8504-fd5085a02099"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa8178e7-5d8d-4ed1-9503-6b67ad186cec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abc0c365-74db-4b23-b2e7-0dd10c9811b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acb528c2-5f7d-4cf9-a36c-de007de3786b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acf61556-e87e-41fe-93fa-052e2f231a3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adc00162-0324-4973-874c-008dcc36d3e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ForeignCurrencyRiskAxis">asnd:UsDollarsToEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae50ae32-8fd9-4440-ae86-c935aac5e3c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae64dc13-b337-4595-88a9-3361adbfd7eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae91164c-7a61-4403-923c-7fc72b5f637e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aee0a664-90db-4cac-b252-ca13f6feb6bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af321344-ada0-4c87-bfd0-d2a98cd2590e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af95c18d-a439-48f1-b6d9-6b5ef3fa583e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0111fc8-8791-4de0-8ed0-9f981def15ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:ExecutiveBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b03741b3-c7aa-47e4-82f2-f5538b555142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0636a60-1301-4427-9e48-8459c64a7333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1595989-ee89-44d6-aafc-6d121568fc57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1966962-eeea-4f7a-8501-53f2cca4ab33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1fd592a-4621-4c11-bdbc-d9f0a9de718a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b27a3e9d-f494-4d9d-bd82-cffda92ba702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3502041-2bf1-4ab4-81d2-63ddd7dc8027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b387065d-0625-4be8-ab94-2a3823e3c97f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b47e07a7-681a-4a20-87be-95dd4075cfa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:NorthAmerica1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4c60161-4bc0-4ca2-859b-eb4baf374e64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b54750ee-5812-44ea-a167-8b84bead592f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b870ca23-2010-47dc-89f9-9194ace53db0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8d9ea02-e435-4914-b63c-68ab0e65dc37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_baadc1e0-f0c2-4168-8df0-bf220f892569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb236f3a-aca3-4607-b4e7-a59b9fc6910f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbd12530-7f01-426e-9852-87ca70290753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbdc53c3-a7cf-4fbe-959f-538eec284f61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcd65bae-11a9-4b6a-b98a-ae8d9426e936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdf66293-e3a2-42d2-b55f-314d364082f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be71380a-a9fd-4b8f-a8ae-7f8c29ba0800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bedad476-b3c2-4ee5-9d07-5861655b6c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0c25b57-fada-4810-aa6c-9f3de313c6c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c14c8f3b-ece8-4326-a6b7-270fcafc68bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">asnd:OfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1719aa5-a73d-4b30-a0d6-6c4e89f62175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c34a3e33-ac79-402f-b220-5f595dd5eff5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4078876-b7b4-4937-95c6-d2ea84904d2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c590a703-806b-44d7-bbfc-d91f2b5829c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5d54e1a-4387-4b3f-9267-06a2d3748214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6d5894a-3b43-479b-98c1-26c26fcd5ea8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaOncologyDivisionAsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c82c67d1-a374-44f7-a579-4e1e136065a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c85c746c-f722-410b-b4c5-502ed85c8382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8c66292-7409-42ed-b072-96cc8d5b02e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:ExecutiveBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca101549-cece-44e2-ba4d-877e6b9eb760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca9626d8-b4fd-4cc7-bdcd-fa03f5df98d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caa0fd3a-8a0c-4ca4-8011-0a2b36ac28ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cadf2de7-5782-4672-b259-cd1aa743fad5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb788b59-28a4-4544-81e7-493092e53b2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd1cf60b-5c30-41db-bb07-b8145572e517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce3072bb-3b3b-4d2a-bccb-396e6f23ec7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce33c6e8-bd62-455a-8699-8dfef4b1bdb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf967fba-0da6-4929-9134-641e84170ee5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">asnd:VISENPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfabba9a-1d15-458c-ad60-0eb6d48d0908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0434620-73bd-43f1-9192-7bca1ecaf642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">asnd:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:NonexecutiveseniorManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0e6faf1-bbd1-4b27-8ddf-0087e182b6af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d35422da-96a1-4b03-a5f4-c8f5b78cbe7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d388a1d4-7923-4886-87c3-db6a6873ba8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3c3de28-899d-4a79-acfe-c562d328512b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4f709dd-434a-4841-ae2c-e267badec1c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d556afe9-f715-43bc-a19e-5d09f686c664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d615a83e-1e17-46ec-8765-e218963f27dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7878707-fcf3-4173-a198-76e206226458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8c37193-f5ce-4085-a584-6f5700a291cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9262209-f85f-4e2f-897d-34d234660e65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da8aec68-6586-4ef6-93e5-b5045f7afa40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc3e7a3d-39f1-4a98-b6c7-22b916d6a2b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc50b8f4-013f-4948-b862-ea14c2c8fd6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcff91fd-f804-4f83-86d2-4d7c9b912c4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de19d30c-2832-4cdc-86a5-8ad0e3007775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de89026c-3236-40fc-8ba9-ac03b1732258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">asnd:OfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-20</xbrli:startDate><xbrli:endDate>2022-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df13e31f-e944-44b8-beee-0157e82a5356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dff571ea-763a-4c63-ae50-c0952c31cb00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e06fb832-2f86-4a43-92b1-f2a822f36e49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e160c34a-290e-4f9a-863a-46afc6a82950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e223f34a-d64a-4201-8c13-a2f49a7b3064"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e22f7140-0ffe-4e0a-a8d2-1e98ce4c62eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e25082d1-732f-40fe-9427-652d8be5beee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e29b5f04-553f-4038-b41c-77cb6a63aa4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e33638fe-cef5-4937-a3e7-51501477ed4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3aa91fe-cef2-4bec-ad73-cb9c151bddb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:AvoroCapitalAdvisorsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e44fd0e7-0d85-4f4b-ad6a-35d537142fea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:OtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e49c3b45-39cc-414c-9238-0fc9d4cf659d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4a0772c-d105-4d5c-9ccb-ae5d02f8ddb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5fb59de-879c-4977-985d-bba088bed9ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e63719c7-8c13-464f-8f95-1d2f452eab96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8188af8-6919-44f5-81ea-b527b574937c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:NonexecutiveseniorManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e89a7181-8fc3-4108-a58d-ec31314fe7a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eaa235d8-4b02-4581-b70a-16400278b006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebade161-c91e-4828-aa55-97f5b6c7acab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed783084-e2f1-44fb-b106-1b2f859597c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed8dd2df-2263-4f73-959d-fdeab1aa780d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edbced58-0020-4b9f-b70b-56ced58a8fef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ede99a4e-c051-431e-8269-8505ec9267f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee56b8dc-dcf9-4371-a111-224749172b3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaIberiaSLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eea8b977-0335-4240-bf23-27c15cf887d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">asnd:SalesDeductionsAndProductReturnsInUSMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eede36b7-749c-4397-a6fe-904bd2d680fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_efbe723b-7de5-4c59-b063-c40de816c3c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:NovoNordiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0eb7759-5474-4185-9c25-f280c2655d1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f11efc41-6c49-4566-86fb-9cec96206a41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1426637-e196-44bf-aad5-b8473714e9cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f187930e-0517-474f-8e2c-b180dcc37681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1c55158-db93-42ec-aaad-60afdd713f36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1f075ea-35d2-48db-b997-3ec5409d09d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2f1dbaf-420a-4683-bcef-b0e869189327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4572716-6c6a-4a6c-bfcd-471d23516aed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f52014a4-e011-4fe5-9aa6-e94ae66aa8c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f52b4a1b-71e1-49b5-9cfd-93e6bb5fe135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f664c695-e007-4c41-b59a-806a6f163104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6aae539-4c18-4dfe-8da2-d2171008ea12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6d717ce-7ddc-4b83-a7fa-1c03e30a43a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7ae32c9-c10e-4691-be89-cfbdb2954133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7c738af-0b0d-4113-8fdf-04db859fac4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">asnd:SalesDeductionsAndProductReturnsInUSMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8b920cb-268c-4f19-9195-5e81009361e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:NonexecutiveseniorManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f960e0c7-e224-43a0-8029-5e940f7b7580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa515c36-ae39-4b8b-a4b2-2f0389428d27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:EntitiesAffiliatedWithRaCapitalManagementLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa785ab0-f0fb-4f0a-875b-f650331743e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa84436d-cca3-4949-bad3-f7258a333f34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_faa6d408-e3a2-423c-9170-2e7df293488d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ForeignCurrencyRiskAxis">asnd:UsDollarsToEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc853c6b-d56e-49d4-8dc9-d729edce2941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fda59e11-28d9-4e33-b9c1-3a2479007ef5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe0a0e9b-7ab2-4d20-a211-cbee6ffa77c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feb4fcb6-91c3-427b-a969-26daa054341f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_feba8166-348b-43f4-8af8-7e1499e6fa81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff216df6-44c5-401c-bf8f-32cde3f221b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff4b86e7-7c5f-4451-a272-76662d19dc47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_005327b9-9514-487d-af81-293c04b4477d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:EntitiesAffiliatedWithJanusHendersonGroupPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01ae896f-3989-4a7c-b794-121862812d86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01c97f44-492a-483a-8df7-8e652f65a658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_033bc73d-e8d5-42c6-ac92-2eaa55a1e3f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04565d75-339f-4b1f-80d9-f0daababe60e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:GrantedIn2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_056508e0-3110-42be-99e5-6e860f20e4ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_064343af-8b3e-4e2a-a81b-a1a721a1cc58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_067306de-0170-4c89-8d3c-7bb661db3689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06c5062d-ba03-4445-bb86-eada28395df3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06c71b52-a8d3-4d87-bf07-1b59116e44d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0872112c-3272-422e-80db-297cf18bfc6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09099e4b-a592-4705-af54-4663f508c0b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09e22d4c-5ff0-4832-b86c-6b6f62d31ccc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a586051-2c0f-41e7-b728-a06658a765b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ce01933-8d1d-47b9-bd72-1cbedc695da5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0dd10c76-089d-41db-b834-45504dc6b09e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ec0d4cb-d376-4f19-aa95-a67c8572996a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:BoardMembersOfGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f2a0f3d-caa6-4b26-aaab-9aaaa98975ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1023a06c-46a7-4e4f-9c42-a6c64923b098"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:GrantedBeforeJanuary12022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11acfac4-6200-472e-926e-c7090b67f933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12093c28-729f-40fc-bcf0-fb862cb3c696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13311653-2a29-4400-a0d0-0f4bd2ca8d98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13fbb09d-e7fc-4533-b7b0-f7775229adc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13fd56c8-1e8b-413f-83b9-57936192571d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:EmployeesAndConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_149a0f63-60f1-4bf3-a3df-4dce7568cfc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15890a8d-80cb-48ce-91a1-44903b524f91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1668bba6-5e09-4a0b-b002-c5fc87f94355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGranted2012UntilNovember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16b2d798-c4fd-440d-9eb5-813b6bf52dd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16d1bca8-ddc8-4770-922a-085d984adaa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17f4bf17-9d0d-4701-ab69-f29d52ef6948"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18e923c0-37b2-4527-b1aa-aed2087ad549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_198d936f-6bd1-467c-a662-6a993e1856a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19fef29a-9741-4124-9e26-bd7da6782741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a2f2ecc-ca46-4afb-a7cd-7481a3e39b7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a5af062-57bb-4ae3-b3ed-605c63a78bb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b8ce618-fe68-4762-9808-37cbe7002b0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:WestfieldCapitalManagementCompanyLPUsaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c7b2ee3-857c-4937-90c1-54e53d319288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c836450-3243-4763-a839-055b50eb15c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:BoardMembersOfGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cc8cf22-cda6-4602-8545-8e4460115453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cf2be05-dcfb-45c8-9384-2927abeec697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e102ae1-1402-4ff8-81ac-0692bcc874ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fb6099b-b6a9-4b5c-bd7a-11c2717591ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaBoneDiseaseASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fbabba9-e169-4afa-9ccc-063e93641d68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_207ec930-b486-406c-b0ae-aba7cbf1c9d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2095e981-5419-41f2-8101-1fb2cbaf9c75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20d58111-b66a-4385-8104-172f2b4acdf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2177e743-fed9-4015-b87c-ce85408638ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21c7c051-dbdf-4831-9602-654f3d0b55c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_223c5789-12ac-442b-9056-83ed832b3d73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_226c442b-8147-46aa-8d42-d133bbb66af0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_232653f8-2ada-40f7-9e2c-695fe89927f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2390a6d0-d171-4a09-ad5f-63eca2811521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_242430a3-5c4f-44b2-aaf8-4987e49091d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaOphthalmologyDivisionASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_261c864d-d4ee-42aa-9967-1744c5af33fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27d1c1a3-108e-4619-be6f-517ff8d95133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27f6fcda-5a1b-42d3-b991-c9dc1d11267b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28990820-f3d2-4e15-9edb-17e010681d57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28fafa94-b070-4d32-863b-5393bdb99f92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_290761ca-44a9-486b-94c7-76f97082cf35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a779f6c-3cd0-4eeb-9e62-6c93f2d9b872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2aa2a1e6-92a1-4029-9027-67625a630a7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b7ffa79-9374-4323-9f4f-2e90fd4a0ef6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bf202a7-c410-46ac-9503-77f09f3365ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c4ca528-c486-4e2a-a517-ae7410edc2c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2cc5cf2b-65b2-4978-a13a-8486ba2a64ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d560ff6-c2e3-4c74-9daf-9f9c9310753d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fbbee2c-6ce9-4cf9-b0ca-0215da8f8db4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fbd9ed0-f949-4f61-a72f-c83438fb93d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:NovoNordiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:LicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30407527-3185-4f61-a488-03f2f38c8ed3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaEndocrinologyGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3069879e-b2eb-487f-8359-3b2b3ac38c1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">asnd:EyconisIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3168c70b-da00-4f8f-8797-f6fe0d465589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_334ba08e-f8aa-49c1-ba15-fe73942f5b92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesYorvipathMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3421ed33-b354-4de8-ba6c-72beee95c70a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3566e5f1-2b87-4f68-9039-a9df104b1f9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_358f6ff6-9ffa-4fee-a3d7-9f7f0de3c554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaSwitzerlandGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3661dd57-860c-4ba7-8646-271ddab5954a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:EmployeesAndConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_368d07a7-0ac6-4e17-b820-a12da4602974"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaEuropeASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_368e4795-3132-443f-a38d-3b93be4d5965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37c216bc-caec-48d1-a992-8f1efaf4610a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37e1d239-86ce-49d1-96d5-a76ae721217a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3816caa9-d60e-4738-924c-a8108f43fcb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38539fb6-76a9-4121-aee9-0b1245ac6af1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3925fc10-a57d-420c-9fea-0099a4bfa974"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaUkLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39ca7b17-a1b7-43d1-90e6-efe3a598d636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a4c34db-9705-4e82-a924-1e8c85b0d587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cc100f5-a109-47f1-b3b1-58aae09fcce4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e1079df-bb69-43bf-854f-2f912ce24f92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ForeignCurrencyRiskAxis">asnd:UsDollarsToEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ebd12a3-760c-4570-9d25-6d885ea5aee9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3eec860a-880d-4d1a-8ff7-1ca361a35484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3fb58189-b760-40f5-9cd3-b00fa343a398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3fbba848-2455-4bc9-8198-43983057fc5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_407f4eb6-3395-4dbf-ba53-ec52500920d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:ProcessPlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41603f99-a66e-44cc-8e76-6000fc1c3438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41772ede-2e6a-48e2-9da6-829133e5685d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41c2635e-b2f9-4eb1-bb72-637889040d79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41e4375f-476d-430a-af3b-9f5b61fe72c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaEndocrinologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4321d0de-54cc-473c-8f2e-2c4823e23921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45262f50-d25a-4678-b31f-4e249ad2d3e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_481783fd-70ee-498b-bb3d-a524d1a98f13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49956232-8f1a-430a-8b06-3dce7628da9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:LicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49d4878a-31c4-4c19-8814-8507aefe88cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:ExecutiveBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b2b9d36-6d18-4c57-b0cf-ce1f8e06c2d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bdf2506-3db5-4bb3-83af-af102c9194d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bf7540e-9443-41e7-a47a-27a0973802ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d1a30fa-1a02-416f-ac4b-3fd4e5452e6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ea532ca-6e45-43f5-a284-db382e2c5785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:GrantedInTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f2fa65c-bf90-4026-9207-c814f7259be3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f865b62-7fe6-48cb-a856-16fdbcba2ac2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:NorthAmerica1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5089591b-f114-41f5-b652-8a708640665f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5123e0db-851b-4c25-82f5-35f4482ea47c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5268a2fe-772c-411f-b537-63cfb4081aac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53acf53e-ec11-4160-8b53-30c8a273f237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_560f9631-6b06-4d31-b7a4-554f86183c74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_569d3447-2d47-452c-82a9-30b1fb7255bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56b18c35-7b90-45e6-8446-e4893174d8bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5704c912-f30b-4de5-815d-6a09d374ba34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58152c33-7510-459f-b8e0-76242c88205c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_586a6210-5549-40bd-9d66-c8900f389cc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5906116e-01cd-49ba-bcce-49cd3733e697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59c262f0-8854-4bf0-83be-ade20e2ca796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59c4cbcd-b4e1-4274-bcd8-37e7ffa78cb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a3d122d-f872-479f-9175-de42cc96d53a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a4ab42e-9a10-4f66-a061-557f147450fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ForeignCurrencyRiskAxis">asnd:UsDollarsToEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ad9dcf6-e1be-4e09-aa88-8cd0c222bbea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bb64963-abad-4e25-ab29-a2838c4dfeb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:EntitiesAffiliatedWithFmrLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c050805-6399-4923-924c-dd423a9d5ceb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c780cf2-8af2-49bf-b6f2-420dbaa22f76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cafe9c3-115f-42e7-b1fe-9c5f8f86ddce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ebf1592-e85e-4a79-a0d3-03fb135c3e71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5feef7fd-c380-41ec-b991-b148e59ce71f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ff345a3-c70a-47dc-8ae4-ca0d2489d12e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">asnd:USDollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_600ece57-712e-4eef-9dfc-9e4fee4bc4fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_606a172c-a572-48ab-a9dd-9b6578193b08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60dcc078-2bdb-4155-9a0b-c75618972125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6114a2f7-6ec9-4c7c-b156-f0fa2cd47f7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaFranceSasuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6143b456-2c40-4d0d-b967-c6ff15edfac7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_614a19b6-1595-4cfe-87c5-0d0f93542d8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64cd1be6-0716-4e13-b266-fb646a8370c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaEndocrinologyDivisionASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_653f32e5-e4d2-4129-866f-b2bb9319ac6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65837925-044a-445d-bd2b-f455d164b262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66ac9391-e29a-452b-a56e-75aa88249b65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">asnd:EyconisIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_694aa851-7e2e-42d3-96e9-18ff2f6e9d67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69523622-60fc-4677-8a69-32400c599999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_696a9b0f-6d34-4970-b7ae-11c29efc2267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:ProcessPlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a0a5caa-b991-40a9-a3ec-b387124678ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a56e38a-0002-4f9e-838d-06508b6db3f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b2baac5-581b-4df4-9270-e2e0408d280d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bd94bcb-874a-40fa-b4c0-feb805cf48ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e4e8da6-c1ef-49a7-86f8-5273a8cae8d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f53dfac-7f4f-46ee-9afc-402949c6590a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_716e887c-c3f0-4b61-9538-8f3e8a6c55f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">asnd:VISENPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73e96a30-9b6d-4a88-a50d-298076e408f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:OtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73eda4e7-aa61-4748-bc17-dba1d8cc2584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_743e733f-a355-45f7-b231-d9ba29e7a99f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74e6cf72-5a9f-4f1c-832e-143795728beb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:GrantedIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7571783b-8274-4446-9034-fc8030ee4785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75afca32-d330-4c6c-a9ea-5bd565d35e9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_772d30eb-6104-4b18-9139-ee54a0993371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_774802a0-e760-4cd3-bbed-f1a84d8730e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">asnd:USDollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7905e7f5-2269-4e2c-bda4-a38c3e7ce9dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79b3b481-791c-4f9d-93a9-e3bfa50ce43f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79e45519-2936-42c5-9260-a018560072ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a48f51e-d7c8-4ea7-acf8-8fd05459ee2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a59ec21-ecbe-4301-8893-0be00de06cef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a98677e-a082-47ea-899e-37bc59fd1b58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ad7edb9-5f0b-41bd-a762-0755697fa11e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7af1f25a-54be-46a2-a19d-533e859fbdd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b687297-3e1b-4c67-8d9f-f309d8615de2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaItaliaSrlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7be35a31-a654-4c37-9e6a-3b77cff84b05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cb30aff-4382-400f-aea5-7f16e02f70c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d04bb96-8341-4c18-bd8d-f80c0f0f0430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGranted2012UntilNovember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d30fefe-a9c7-49d1-868a-e9fe7915fa00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e301002-0bf6-4196-80df-8e9527a1f352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e41aefc-f66a-4182-a859-776c8cd1970c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e7e620d-71e2-4c5d-bea4-731d5ebd213b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7efbf712-b44b-41d4-8aa1-40e3199ec917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">asnd:ForeignCurrencyConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f2fe9bf-d689-489c-be69-cbf182477f84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f3a1b06-4e11-46ed-92ce-904b7a6a233b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Days"><xbrli:measure>asnd:Days</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>asnd:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_XBB"><xbrli:measure>iso4217:XBB</xbrli:measure></xbrli:unit><xbrli:unit id="U_Y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_DkkPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_CommercialCustomer"><xbrli:measure>asnd:CommercialCustomer</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Multiple"><xbrli:measure>asnd:Multiple</xbrli:measure></xbrli:unit><xbrli:unit id="U_EurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Employee"><xbrli:measure>asnd:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_981ef46d-800a-489f-82bc-a5ff60bd4f50" fromRefs="F_df87669d-0bb6-45ab-a330-8acae0137258 F_5af142f2-1bb4-4ef7-aeca-efe68deab74c F_df4ae6a0-4b34-4d5f-9c35-e466cec1e95e"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc" fromRefs="F_26c6c861-b5ba-4cad-92f6-32f39a3a1d2c F_9f2d3364-03ae-45be-ba44-fc988fb90336 F_622aab91-b932-4187-809f-7b78f896c4f7 F_831a4081-f4f8-4711-96ad-78b29be79f6c F_7ffbe158-e7ca-41b1-9e0f-c9494aadcac5 F_0b4fb44d-7574-4a84-b61c-87d8d0bbab45 F_cac9b5bc-a669-4d09-ac9d-3ac7b871ead1 F_7c603b92-996b-41cf-90f1-b6f38706f824 F_cd3efa0e-9e4f-49f5-9e6c-a40915c3d8f3 F_54e300fd-d8b7-4a41-9130-5dd43498563b F_8d1634f1-4c08-4418-9ecf-dfe6024613dd F_f794aad9-2a63-4872-87b9-837f20bc715f F_199ad878-35ff-4014-a37f-42eb7ed9c375 F_33c31fb0-9baf-4529-80e9-43922ebe0918 F_42b6f182-c1d6-40a4-9e57-6b2a81baa418 F_06324db9-e461-493f-a1a5-d89ab3895f83 F_7c855bd6-e7de-4717-b7e5-c5bff55a7780 F_399b9146-169e-4bb4-ac80-cafd1f58cce1 F_d72c75d5-ea0e-4320-874c-0aae05cd4401 F_e1de2081-8c19-44b6-82ed-be5e61e997ed F_c9d6d57b-425c-4fb7-abbd-e4a278a46eb8 F_40b093c3-640c-47a0-8b85-489d8e14a1a9 F_70808046-e0cf-4475-87b4-4b385a38274d F_382097b3-b5ef-4436-b499-30711f816121 F_69813962-ec68-4626-9ef5-779670aa2f2a F_ffaab183-18e2-4e1c-9a96-7eea9fcc75c4 F_803a9650-095b-429c-9575-ef2db55e6637 F_9ba2ab12-59c9-4705-b8c1-3ab3fc76f27d F_d74833a8-604a-4949-a863-f60de5785367 F_deb67055-8a85-4ee4-ac53-976b2ed93a91 F_303a6812-2e52-48fd-a43a-203a98780c2d F_e7255016-a092-43b2-8fff-0447b82b8834 F_ef27783e-2ebf-4cee-8123-7b88ae2ac3c7 F_62a04fe8-9b69-41f4-82de-ade1f995608e F_c07633cd-f507-41e3-830f-c087650184e2 F_0bc3769e-460e-4b91-afc4-7d3ba0080ceb F_1fa26a62-cdd0-4509-ba50-f296557bdcb6 F_85f364e0-22ad-4ce7-9f7f-8121531aa5f7 F_caa57351-8417-4791-a585-bd145240387d F_e7085e38-ade3-403e-81da-e57c0a1e414d F_937b3cd9-fe7a-46a9-b361-3cd9f805fe0f F_60695fa5-1167-441b-b831-7560770cf08c F_d8e56e66-8575-4b72-a1ed-bc5d29c3d221 F_589fd958-2fd9-4861-8eb2-fb211220f782 F_d6b826e8-8b76-4bd1-baa0-57dac5ae1ea1 F_165c922b-2c8e-4822-90e5-0f02ac5c20e0 F_07c24fc7-73aa-4d3c-9add-a4464165d707 F_75208953-26c9-4ba5-80b9-b728a6b86e17 F_1837bd4c-bdab-4625-83ce-5792ca88d901 F_16f605bc-c449-4a9a-b897-ab5afc18d588 F_61f5ba9c-d6e7-47af-a120-b0300560d6c6 F_084cf33e-da27-4b65-bb42-3f6c5710074a F_5214d3b0-47a3-45d2-997f-784799e392c2 F_592df39d-6fe8-4376-b652-663628839d40 F_923af3dd-3ff9-4806-b536-4946e4597c7f F_f2eca86f-a27b-425d-89ae-8dd08e821786 F_3795a0fc-3033-47f0-99ff-bd301132860f F_8a80a850-f6a7-4854-b3a7-e27ae4e96591 F_4e401866-c4ae-4461-ae46-80951396f0fa F_7f5c30a7-dd20-4a79-8b75-5e53ccb86d9d F_e69b6562-90e1-4217-895d-b444dfba7743 F_4fe891d7-42a9-43d8-ad45-1edeb55f7bd5 F_9943a8d6-82ce-4009-8273-13bf6b24f302 F_23a507de-e21f-48de-ae21-fd24dace1e42 F_850c6404-d676-4a1c-bd80-6f8bb47928b0 F_980c6c3b-e596-4b9c-8d92-e02450c398a0 F_9d96335a-f6d9-4330-80ec-545283d4af99 F_3a82fc0d-07aa-432d-b4fb-c0d3dabb40b7 F_556f4c14-5887-4ee4-8d98-2a04d59d2952 F_9a7e5e95-c04c-4327-96d6-0bb984adb4a0"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_ad99817b-a41d-42b8-9f90-df4b869212dd" fromRefs="F_fa2dca79-f11c-4eb0-a55e-cfc987c5b8ed F_6f90b4e9-624c-4747-b8bf-fa9904dc08fa"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_062eca23-28d3-4fb9-9904-0f75070ffc1f" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20-F</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7658db8d-01a8-4c8b-934f-498ff5ee66b6" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:DocumentRegistrationStatement" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_55d2a485-1e34-4633-b3fc-5b793e5f5ef3" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b86ac277-cb11-43f8-9f7d-dbb0b1682957" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9226a83a-8bc7-4d0e-8741-6f970aae7107" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98dcaae3-fd64-4f41-bf8b-b6a6e67a9d4b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_f976769d-70ed-4ab8-acac-f9220998cb09" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_bc175d5f-81ab-40c2-b853-0a8be8c6ce69" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:DocumentShellCompanyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of event requiring this shell company report</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission file number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f4daf37-059f-4ae5-85b4-71c1eb76fa2c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-36815</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_347d7e8f-a8b9-4062-a8d7-1d328c6141b7" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its charter and translation of Registrant&#8217;s name into English)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_398aa369-698e-406d-8346-37be778566b2" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Kingdom of Denmark</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Jurisdiction of incorporation or organization)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81a7d00c-e000-45cb-a8f4-42d62b2109ec" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tuborg Boulevard 12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc216ab5-c002-49e2-a5c2-c598266d2c76" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DK-2900</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31a4ec3a-14a6-484a-ab60-25b261014172" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hellerup</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49239040-d625-4684-b431-1a142d6fa5c9" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Denmark</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96be01a1-7a2b-4b84-a837-fd3532e68f12" contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484" name="dei:ContactPersonnelName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jan M&#248;ller Mikkelsen</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ff7728e-8c9c-4fa5-a45e-57c9d7ed40f3" contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tuborg Boulevard 12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f77e7dad-4165-44c2-954b-c1095da26ff3" contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DK-2900</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a50715ea-958e-46a1-8775-d61213690866" contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hellerup</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00516d2d-5a7e-4f44-930c-fb1bcfc76d7c" contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Denmark</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Telephone: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_963efabd-49d5-4d56-871e-c310907ff7e2" contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+45</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3d24f44-af51-4ac1-b8c4-f18a681dd7f0" contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70 22 22 44</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered or to be registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"/>
    <td style="width:12%;box-sizing:content-box;"/>
    <td style="width:40%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9401645e-142c-43dc-8d23-a976f331dd87" contextRef="C_d0434620-73bd-43f1-9192-7bca1ecaf642" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">American Depositary Shares</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, each representing one ordinary share, nominal value DKK 1 per share</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7ce2cf68-65ba-4026-9cd6-ca596af792d0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ASND</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b8daa188-6941-415e-bcbe-fee28efcd0a5" contextRef="C_d0434620-73bd-43f1-9192-7bca1ecaf642" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bb917abc-69e2-4944-83cd-aef470fe655f" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ordinary shares</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, nominal value DKK 1 per share*</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5969f263-f298-4f36-90f0-229d885a351e" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">*</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Not for trading, but only in connection with the registration of the American Depositary Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered or to be registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5663288-ac11-4e7b-9a0f-a9154df1ae32" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,689,487</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares (including 845,887 ordinary shares represented by ADSs held by the registrant and its consolidated subsidiaries)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as of December 31, 2024)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d15c8cb-c7ed-441d-b58c-20571366e834" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Yes    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db9e8d1b-a481-4d83-a58f-3e95d9f40db4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note &#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c74f7e6-5354-4d1d-86f8-19b282e05253" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c3f7e24-6b15-4337-babc-2eb15db5669d" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24%;box-sizing:content-box;"/>
    <td style="width:23%;box-sizing:content-box;"/>
    <td style="width:22%;box-sizing:content-box;"/>
    <td style="width:31%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_3d8ea4e4-3e65-419d-9e07-352e5f81f6b4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer  </span><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer  </span><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company  </span><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_57881f63-3a2a-4d90-9a13-f7be1264b562" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_3fbbed3d-e616-49c5-a0a4-c8607b7c28c5" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0afb559-d48e-41a5-9613-c0b768b93a85" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.2%;box-sizing:content-box;"/>
    <td style="width:61%;box-sizing:content-box;"/>
    <td style="width:17.8%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. GAAP  </span><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_06c01ec5-94a5-4ea4-b837-7b685d30d29e" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:DocumentAccountingStandard"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">International Financial Reporting Standards</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;as issued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">by the International Accounting Standards Board  </span><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other  </span><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Item 17    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Item 18</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Yes    </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_be1ce262-75b8-4d64-8e90-f1de1f2a5f16" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:42.44%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:25.56%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Auditor Firm ID:</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Auditor Name:    </span><span><span style="-sec-ix-hidden:F_f487bf8e-d837-43ab-b0e3-34496c9a8875;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deloitte Statsautoriseret</span></span></span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Auditor Location:</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_eee925cc-e849-4448-b21b-528831b8f9e5" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1294</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:5pt;font-kerning:none;min-width:fit-content;">    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revisionspartnerselskab</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_4328e719-b7cf-4ff8-90ae-080d3d630eb6" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="border-top:0.75pt solid #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:82.8%;box-sizing:content-box;"/>
    <td style="width:8.2%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#general"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">General</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#special_note_regarding_forward"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#sum_of_mat_risks_asso_with_our_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Summary of Material Risks Associated With Our Business</span></a></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_identity_of_directors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Identity of Directors, Senior Management and Advisers</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_offer_statistics_and_expected"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Statistics and Expected Timetable</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_key_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Key Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_information_on_the_company"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Information on the Company</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4a_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_operating_and_financial_review"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Operating and Financial Review and Prospects</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_directors_senior_management"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Senior Management and Employees</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_major_shareholders_and_related"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Major Shareholders and Related Party Transactions</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Information</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_the_offer_and_listing"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">The Offer and Listing</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_additional_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Additional Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">155</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_description_of_securities_other"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities Other than Equity Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_defaults_dividend_arrearages"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Defaults, Dividend Arrearages and Delinquencies</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_material_modification_to_the"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Material Modification to the Rights of Security Holders and Use of Proceeds</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_control_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16a_audit_committee_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Audit Committee Financial Expert</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16B</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16b_code_of_ethics"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Code of Ethics</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16C</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16c_principal_accountant_fees_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16D</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16d_exemptions_from_the_listing"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exemptions from the Listing Standards for Audit Committees</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16E</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16e_purchases_of_equity_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16F</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16f_change_in_registrants"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Change in Registrant&#8217;s Certifying Accountant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16G</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16g_corporate_governance"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16H</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16h_mine_safety_disclosure"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosure</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16I</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16i_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16J</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16j_insider_trading_policies"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policies</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16k_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 17</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_17_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 18</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_18_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.07013888888888889in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 19</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_19_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">II-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="general"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eral</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As used herein, references to &#8220;we&#8221;, &#8220;us&#8221;, the &#8220;company&#8221;, &#8220;Ascendis&#8221;, or &#8220;Ascendis Pharma&#8221;, or similar terms in this annual report on Form 20-F shall mean Ascendis Pharma A/S and, as the context requires, its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements are presented in euros except where otherwise indicated, and are prepared in accordance with IFRS Accounting Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board. All references in this annual report to &#8220;Dollars&#8221;, &#8220;USD&#8221; and &#8220;$&#8221; are to U.S. Dollars, and all references to &#8220;euro&#8221;, &#8220;EUR&#8221; or &#8220;&#8364;&#8221; are to European Union euro. Throughout this annual report, references to ADSs mean ADSs or ordinary shares represented by ADSs, as the case may be.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="special_note_regarding_forward"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This annual report contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the commercial availability of our approved products; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commercialization of our products and product candidates, if approved for commercial use; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commercialization, marketing, and manufacturing capabilities of our products and product candidates and associated devices; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, timing, progress, results and costs of developing our product candidates or any other future product candidates, and conducting preclinical studies and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our pursuit of Oncology as an independent therapeutic area of focus and our development of product candidates related to oncology; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eyconis&#8217;s ability to develop, manufacture, and commercialize TransCon ophthalmology assets globally;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the potential market opportunities and patient populations for our products and product candidates, if approved for commercial use; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the potential advantages of our products and product candidates over existing therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our existing collaborations and license agreements and our ability to enter into new collaborations and license agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations with regard to the ability to develop additional product candidates using our TransCon technologies and submit Investigational New Drug Applications (&#8220;INDs&#8221;) or similar for such product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to benefit from established data of clinically validated parent drugs or pathways to which we apply our TransCon technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations with regard to our current and future collaboration partners to pursue the development of our product candidates and submit INDs or similar for such product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our development plans with respect to our products and product candidates; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our pursuit of additional indications for TransCon hGH; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop, acquire and advance product candidates into, and successfully complete, clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the implementation of our business model and strategic plans for our business, our products and product candidates and technologies, including global commercialization strategies; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our ability to apply our technology platform and algorithm for product innovation to develop highly differentiated product candidates to address unmet medical needs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to apply our TransCon Technology platform to build a leading, fully integrated, global biopharmaceutical company;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our use of our TransCon technologies to create new and potentially best-in-class therapies;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and hire qualified personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments and projections relating to our market conditions, competitors and industry;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations with respect to ongoing and potential litigation;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of international economic, political, legal, compliance, social and business factors, including inflation, tariffs, geopolitical conflicts and energy shortages; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effects on our business of the worldwide pandemics and the ongoing conflict in the region surrounding Ukraine and Russia and the conflict between Israel and Hamas.   </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These forward-looking statements are based on senior management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this annual report may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section of this annual report titled &#8220;Item 3.D&#8212;Key Information&#8212;Risk Factors&#8221; and elsewhere in this annual report. You are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this annual report. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. Given these risks and uncertainties, you are cautioned not to rely on such forward-looking statements as predictions of future events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should read this annual report and the documents that we reference in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. You should also review the factors and risks we describe in the reports we will file or submit from time to time with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) after the date of this annual report. We qualify all of our forward-looking statements by these cautionary statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, certain information included herein or elsewhere (such as our website) is informed by various stakeholder expectations or third-party frameworks, and therefore should not necessarily be interpreted as rising to the level of materiality as defined under U.S. federal securities laws and regulations, even if we use the language &#8220;material&#8221; or &#8220;materiality.&#8221; Particularly in the ESG context, materiality is subject to varying definitions that are often different (and more expansive) than the concept for U.S. federal securities laws purposes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="sum_of_mat_risks_asso_with_our_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Material Risks Associated with Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including those described in &#8220;Item 3.D - Key Information - Risk Factors&#8221; in this annual report. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a limited operating history and we may incur significant losses in the future, which makes it difficult to assess our future viability.  </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek additional financing to achieve our goals, and a failure to obtain this capital if needed on acceptable terms, or at all, could force us to delay, limit, scale back or cease our commercialization activities, product development or any other or all operations. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are substantially dependent on the success of our products and product candidates, which may not be successful in nonclinical studies or clinical trials, receive regulatory approval or be successfully commercialized. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process with uncertain outcomes, and we may encounter substantial delays in our clinical studies. Furthermore, results of earlier studies and trials may not be predictive of results of future trials. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our sales and marketing efforts may not be effective and we may not be successful in our commercial efforts.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition in the biotechnology and pharmaceutical industries is intense and our competitors may discover, develop or commercialize products faster or more successfully than us. If we are unable to compete effectively, our business, results of operations and prospects will suffer. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-parties to manufacture preclinical, clinical and commercial supplies of our products, product candidates and their device components. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parent drug, drug product and other components of our products and product candidates are currently acquired from certain single-source suppliers. The loss of these suppliers, or their failure to supply could materially and adversely affect our business. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating results may vary significantly from period to period and these variations may be difficult to predict. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the U.S. Food and Drug Administration (&#8220;FDA&#8221;), the European Medicines Agency (&#8220;EMA&#8221;), and comparable authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to market those products and decrease our ability to generate revenue.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are sued for allegedly infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in such litigation could harm our business. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The potential effects of geopolitical conflicts, such as the military conflict between Russia and Ukraine and the conflict between Israel and Hamas could materially adversely impact our business, including our clinical trials, supply chain operation, regulatory timelines and commercial activities.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Worldwide pandemics could materially adversely impact our business, including our clinical trials, supply chain operation, regulatory timelines and commercial activities.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The summary risk factors described above should be read together with the text of the full risk factors below in the section entitled &#8220;Risk Factors&#8221; and the other information set forth in this annual report on Form 20-F, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations, and future growth prospects.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_identity_of_directors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1 Identity of Directors, Senior Management and Advisers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_offer_statistics_and_expected"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2 Offer Statistics and Expected Timetable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_key_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3 Key Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserved</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalization and Indebtedness</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reasons for the Offer and Use of Proceeds</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factors </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business faces significant risks. You should carefully consider all of the information set forth in this annual report and in our other filings with the SEC, including the following risk factors which we face and which are faced by our industry. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This annual report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this annual report and our other materials we file or furnish with the SEC. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; above.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history and we may incur significant losses in the future, which makes it difficult to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are applying our innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients&#8217; lives. Guided by our core values of patients, science, and passion, we use our TransCon technologies to create new and potentially best-in-class therapies. We currently have a pipeline of multiple independent endocrinology rare disease, and oncology candidates in development. We are also working to apply our TransCon technology platform in additional therapeutic areas to address unmet medical needs. On August 25, 2021, the FDA approved TransCon hGH, known by its brand name SKYTROFA and its international nonproprietary name lonapegsomatropin-tcgd in the U.S. for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone, and on August 9, 2024, the FDA approved TransCon PTH, known by its brand name YORVIPATH, for the treatment of hypoparathyroidism in adults. SKYTROFA (lonapegsomatropin), was granted marketing authorisation by the European Commission, or the EC, as a once-weekly subcutaneous injection for the treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone on January 11, 2022. In addition, in November 2023, the EC granted marketing authorisation to YORVIPATH (palopegteriparatide), as a replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have focused substantially all of our efforts on our research and development activities relating to our products, SKYTROFA and YORVIPATH, our product candidate TransCon CNP, our product candidates in oncology and our proprietary TransCon technologies, as well as on the commercialization of SKYTROFA and  YORVIPATH in the United States. We have a limited operating history upon which our shareholders and ADS holders can evaluate our business and prospects. Going forward, we may incur significant losses from our operations. We had a net loss of &#8364;378.1 million for the year ended December 31, 2024, and a net loss of &#8364;481.4 million for the year ended December 31, 2023. Our total equity was negative by &#8364;105.7 million as of December 31, 2024, compared to a negative balance of &#8364;145.7 million as of December 31, 2023. The net losses we have experienced in prior years are not necessarily indicative of our future results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Apart from the FDA&#8217;s, the EC&#8217;s and MHRA&#8217;s respective approval of SKYTROFA and YORVIPATH, none of our other product candidates have been approved for commercial sale by the FDA, the EC or similar non-U.S. regulatory authorities. Our annual operating expenses may increase over the next several years as we incur additional commercialization expenses and continue our research and development expenses. Although we have begun to receive revenue from commercial product sales, we may incur substantial operating losses for the foreseeable future as we execute our operating plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Possible future losses would have an adverse effect on our shareholders&#8217; equity. Further, the net losses or net income we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a reliable indication of our future performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited revenue from commercial product sales and rely significantly on our TransCon technologies and TransCon products and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">YORVIPATH has only recently been launched in the U.S. and consequently we have had limited revenue from commercial product sales of YORVIPATH. We are yet to commercially launch SKYTROFA and YORVIPATH in the EU outside of Germany and Austria. Our ability to generate revenue will continue to depend significantly on our ability to successfully commercialize SKYTROFA and YORVIPATH in the U.S. and the EU, complete the research and development of our other product candidates and obtain the regulatory and marketing approvals necessary to commercialize such product candidates. Our ability to generate additional revenue from commercial product sales from SKYTROFA, YORVIPATH or other approved products, or pursuant to milestone payments or royalties from collaboration partners depends heavily on many factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completing research and development of our product candidates;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining additional regulatory approvals and pricing and reimbursement approvals for our products and product candidates on our own, or together with our strategic collaboration partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiating favorable terms of and entering into collaboration, licensing or other arrangements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to commercialize or co-promote, and/or the ability of our collaboration partners to successfully commercialize, our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing and sustaining a scalable manufacturing process for our products and product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market opportunities and patient populations for our products and product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining market acceptance of our products and product candidates, if approved, as viable treatment options; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any competing technological and market developments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, assessing, acquiring, in-licensing and/or developing new product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how, and our ability to develop, manufacture and commercialize our product candidates and products without infringing intellectual property rights of others; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to prevent, avoid, and possibly recover from severe cyber attack(s) with impact on our intellectual property, e.g., data breach and ransomware attacks; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attracting, hiring, and retaining qualified personnel. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In cases where we are successful in obtaining regulatory approvals to market one or more of our product candidates (such as the approvals we have obtained for SKYTROFA and YORVIPATH), our revenue will be dependent, in part, upon the size of the markets in the territories for which regulatory approval is granted, the accepted price for the product, the availability of competing products, the ability to get reimbursement for our products at any price and the extent of our royalty rights for that territory. If the number of patients suitable for our products or product candidates is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the reasonably accepted population for treatment is narrowed by competition, physician choice, treatment guidelines or third-party payor restrictions, we may not generate significant revenue from the sale of such products or product candidates, even if approved. Limitations on our ability to generate revenue from commercial product sales or pursuant to up-front or milestone payments and royalties from collaboration partners would likely depress our market value and could impair our ability to raise capital, expand our business, discover or develop other products and product candidates or continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our revenue includes provision for a variety of sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales deductions attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangement. Provisions for sales deductions attributed to commercial arrangements are recognized when the related sales takes place and measured using the expected value method. Provisions for unsettled sales deductions and product returns are estimated on the basis of a percentage of sales as defined by individual agreements and contracts, and for government rebates by individual state- and plan agreements. Further inputs to the calculations are based on payer channel mix, current contract prices under eligible programs and current inventory levels in the distribution channels. Inputs to the calculations are subject to estimation and assumptions and are based on historical experience and other factors that are relevant, and which are available at the reporting date. These estimates and assumptions are subject to material uncertainties and could result in outcomes that require a material adjustment in future periods.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek additional financing to achieve our goals, and a failure to obtain this capital if needed on acceptable terms, or at all, could force us to delay, limit, scale back or cease our commercialization activities, product development or any other or all operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, most of our resources have been dedicated to our research and development and commercialization activities. We have funded our operations primarily through issuance of shares and convertible debt securities, royalty arrangements with third parties, and payments to us under collaboration agreements. As of December 31, 2024, we had cash and cash equivalents totaling &#8364;559.5 million. We believe that we will continue to expend substantial resources for the foreseeable future, including costs associated with research and development and commercialization activities. The Company maintains the majority of its cash and cash equivalents in accounts with major financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we currently estimate that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next twelve months from the date of this annual report. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the manufacturing, selling and marketing costs associated with our products and product candidates, if approved, including the cost and timing of building our sales and marketing capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt, and amount of sales of, or royalties on, our products and any future products; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sales price and the availability of adequate third-party coverage and reimbursement for our products and product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to collect payments which are due to us from customers and collaboration partners (if any), which in turn is impacted by the financial standing of any such customers and collaboration partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, timing, scope, results and costs of our preclinical studies and clinical trials and manufacturing activities for our products and product candidates, including the ability to enroll patients in a timely manner for clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time and cost necessary to obtain regulatory approvals for our products and product candidates and the costs of post-marketing studies that could be required by regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cash requirements of any future acquisitions or discovery of products or product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of preclinical and discovery programs that we decide to pursue or initiate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential acquisition and in-licensing of other technologies, products or assets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time and cost necessary to respond to technological and market developments, including further development of our TransCon platform; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of development, regulatory and commercial milestones resulting in the payment to us from collaboration partners of contractual milestone payments and the timing of receipt of such payments, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our progress in the successful commercialization and co-promotion of our products and product candidates, if approved, and our efforts to develop and commercialize our other existing product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market opportunities and patient populations for our products and product candidates, if approved, and our ability to obtain market acceptance of our products and product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we purchase ADSs prior to granting rights or awards for such shares under our equity incentive plans. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional funds may not be available if we need them or on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, scale back or cease our research and development and commercialization activities. Furthermore, uncertainty about the interest rate environment and an increase in interest rates, may make it more difficult, costly or dilutive for us to secure additional financing, which may have a negative impact on earnings and cash flow.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our holders of shares or ADSs, restrict our operations or require us to relinquish rights to our products or product candidates on unfavorable terms to us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations or royalty arrangements with third parties. To the extent that we raise additional capital through the issuance of convertible debt or equity securities, the ownership interest of our shareholders and ADS holders would be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our shareholders and ADS holders. Such financing may result in dilution to holders of shares or ADSs, imposition of debt covenants and repayment obligations, or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic partnerships with third-parties, we may have to relinquish valuable rights to our products or product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in September 2023, we entered into a $150.0 million capped synthetic royalty funding agreement (&#8220;the SKYTROFA Agreement&#8221;), with Royalty Pharma. Under the terms of the SKYTROFA Agreement, we received an upfront payment of $150.0 million in exchange for a 9.15% royalty on net U.S. SKYTROFA revenue. In September 2024, we entered into a $150.0 million capped synthetic royalty funding agreement (&#8220;the YORVIPATH Agreement&#8221;), and together with the SKYTROFA Agreement, the Royalty Pharma Agreements, with Royalty Pharma. Under the terms of the YORVIPATH Agreement, we received an upfront payment of $150.0 million in exchange for a 3.0% royalty on net U.S. YORVIPATH revenue.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are substantially dependent on the success of our products and product candidates, which may not be successful in nonclinical studies or clinical trials, receive regulatory approval or be successfully commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have invested a significant amount of our efforts and financial resources in research and development, including with respect to our proprietary TransCon technologies, and in commercialization activities. Our near-term prospects, including the extent of revenue from commercial product sales, will depend heavily on our successful development and commercialization of our products and product candidates, if approved. The clinical and commercial success of our products and product candidates and our TransCon technologies will depend on a number of factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome and successful execution of our ongoing and planned clinical trials of our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and that of any collaboration partners to establish and maintain commercial-scale manufacturing processes for our products, product candidates and device components; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether our product candidates&#8217; safety, purity, potency, tolerability and/or efficacy profiles will be satisfactory to the EMA, the FDA and similar regulatory authorities to warrant marketing approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the EMA, the FDA or similar regulatory authorities will require additional clinical trials prior to approving or issuing a positive opinion in order for our product candidates to be authorized, if ever; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of adverse side effects of our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the occurrence of adverse events that implicate the TransCon technologies, including among any out-licensed product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timely receipt of necessary marketing authorizations or certifications for our product candidates and associated device components from the FDA, similar regulatory authorities and notified bodies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and that of any collaboration partners to successfully commercialize our products or product candidates, if approved for marketing and sale by the FDA, the EC or similar regulatory authorities, including educating physicians and patients about the benefits, administration and use of such products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieving and maintaining compliance with all applicable regulatory requirements; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the potential market opportunities and patient populations for our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our progress in the successful commercialization and co-promotion of our products and product candidates, if approved, and our efforts to develop and commercialize our other existing product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain market acceptance of our products or product candidates, if approved, including by patients and the medical community; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain market acceptance of the device components of our combination products, and of our combination product candidates, if approved, including by patients and the medical community; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and sustaining an adequate level of coverage and reimbursement for our products and product candidates by third-party payors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our and any collaboration partners&#8217; marketing, sales and distribution strategies and operations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and that of any collaboration partners, or any third-party manufacturer we contract with, to manufacture supplies of our products and product candidates and to develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practice (&#8220;cGMP&#8221;), or similar requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforcing intellectual property rights in and to our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">avoiding third-party interference, opposition, derivation or similar proceedings with respect to our patent rights, and avoiding other challenges to our patent rights and patent infringement claims; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continued acceptable safety profiles of our products and product candidates following any potential approval. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of these factors are beyond our control, including clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any collaboration partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that we will be able to successfully commercialize our products or that such products will be approved in additional jurisdictions, and we cannot be certain that any of our product candidates will ever be approved or successfully commercialized, or that we will ever generate revenue from sales of such product candidates. If we are not successful in completing the development of, obtaining approval for, and commercializing our product candidates, or are significantly delayed in doing so, our business will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our sales and marketing efforts may not be effective and we may not be successful in our commercial efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to launching our commercial sales in 2021, as a company we had no prior experience commercializing approved products. The success of our commercialization efforts is difficult to predict and subject to the effective execution of our business plan, including, among others, the continued development of our internal sales, marketing, and distribution capabilities and our ability to navigate the significant expenses and risks involved with the development and management of such capabilities. For example, our commercial launch of YORVIPATH in the United States may not develop as planned or anticipated, which may require us to, among others, adjust or amend our business plan and incur significant expenses. Further, given our limited experience commercializing products, we do not have a long track record of successfully executing commercial launches. If we are unsuccessful in accomplishing our objectives and executing on our business plan, or if our commercialization efforts do not develop as planned, we may not be able to successfully commercialize our approved products and any future approved products, we may require significant additional capital and financial resources, we may not become profitable, and we may not be able to compete against more established companies in our industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors which may affect the success of our commercialization efforts include, but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to hire and retain required and qualified sales and marketing personnel, including in connection with any specialty sales organization for specific products or product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to provide sufficient training to develop and strengthen the technical expertise of our sales and marketing personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to provide required support materials and resources to our sales personnel to help them educate physicians and healthcare providers regarding our products, including the proper administration of our products; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our resources to meet and timely fulfill supply obligations to our customers. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we or any collaboration partners may be required to build and/or maintain marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third-parties to perform these services, and we or any collaboration partners may not be successful in doing so. In addition, arrangements we enter into with third-parties to market and sell our products and product candidates, if approved, in one or multiple geographies might not be successful, and We may not be able to enter into such arrangements with others on acceptable terms, or at all. To the extent that we enter into such arrangements with other companies, our revenues, if any, will depend on the terms of any such arrangements and the efforts of others. These efforts may turn out not to be sufficient.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The acceptance and commercial success of our products and product candidates, if approved, will depend, in part, upon the degree of acceptance among physicians, patients, patient advocacy groups, third-party payors and the medical community.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even after obtaining FDA or other regulatory approvals, our products and product candidates, if approved, may not achieve significant market acceptance among physicians, patients, patient advocacy groups, third-party payors and the medical community. The degree of market acceptance, if any, for our products for which marketing approval is obtained will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety, purity, potency and/or efficacy of the products as demonstrated in clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects and overall safety profile of the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perceived safety of the TransCon technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the convenience and features of the auto-injector or drug delivery device used to administer the drug; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which the product is approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">education of, and acceptance by, physicians, major operators of clinics and patients of the product as a safe and effective treatment and their willingness to pay for them; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration of our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages of our products over current treatment options or alternative treatments, including future alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of supply of our products and their ability to meet market demand; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">marketing and distribution support for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the quality of our relationships with patient advocacy groups; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coverage and reimbursement policies of government and other commercial and third-party payors. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our products or product candidates that obtain regulatory approval do not achieve significant market acceptance or commercial success, this could harm our business, results of operations and prospects, and the value of our shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our estimated market opportunities for our products and product candidates, if approved, are subject to numerous uncertainties and may prove to be inaccurate. If we have overestimated the size of our market opportunities, our future growth may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business plan is based in part on our estimated addressable markets and market opportunities for our products and product candidates, if approved, which are based on a variety of inputs, including data published by third parties, our own market insights and internal market intelligence, and internally generated data and assumptions. We have not independently verified any third-party information and there can be no assurance as to its accuracy or completeness. Such estimates, whether obtained or derived from third-party sources or developed internally, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. While we believe the market opportunity estimates underlying our business plan are reasonable, such information is inherently imprecise. In addition, our assumptions and estimates of market opportunities are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including but not limited to those described in this annual report. If this third-party or internally generated data prove to be inaccurate or we make errors in our assumptions based on that data, our actual market may be more limited than our estimates. In addition, these inaccuracies or errors may cause us to misallocate capital and other critical business resources, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process with uncertain outcomes, and we may encounter substantial delays in our clinical studies. Furthermore, results of earlier studies and trials may not be predictive of results of future trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidates, we must conduct extensive clinical studies to demonstrate the safety, purity, potency and/or efficacy of the product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process; the results of preclinical and clinical studies of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical, biopharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience delays or setbacks in our ongoing clinical trials, and we do not know whether future clinical trials will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delay or failure to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reach consensus with regulatory authorities on study design or implementation of the clinical trials and/or obtain regulatory authorization to commence a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reach agreement on acceptable terms with prospective contract research organizations, CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify, recruit and train suitable clinical investigators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain institutional review board (&#8220;IRB&#8221;), or ethics committee approval at each site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacture, test, release, validate or import sufficient quantities of drug product for use in a trial;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruit, screen and enroll suitable patients to participate in a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have patients complete a trial or return for post-treatment follow-up;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ensure that clinical sites observe trial protocol or continue to participate in a trial; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">address any patient safety concerns that arise during the course of a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">address any conflicts with new or existing laws or regulations; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate or add a sufficient number of clinical trial sites.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us for a product candidate, by the IRBs of the institutions in which such trials are being conducted, by an independent data safety monitoring board, for such trial or by the FDA or similar regulatory authorities. Such authorities, or we, may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or similar regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we are conducting, and plan to conduct, clinical trials in sites outside of the United States and the EU. Conducting clinical trials in foreign countries presents additional risks that may delay completion of clinical trials. These risks include the failure of physicians or enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. In addition, the EMA or the FDA may determine that the clinical trial results obtained in foreign subjects do not establish the safety, purity, potency and/or efficacy of a product candidate when administered in EU or U.S. patients, and are thus not supportive of approval of a marketing authorisation application (&#8220;MAA&#8221;), in the EU or of a New Drug Application (&#8220;NDA&#8221;), or Biologics License Application (&#8220;BLA&#8221;), in the United States. As a result, the EMA or the FDA may not accept data from clinical trials conducted outside the EU or the United States, respectively, and may require that we conduct additional clinical trials or obtain additional data before we can submit an NDA or BLA in the United States or a MAA in the EU. The EMA or the FDA may even require us to conduct additional clinical trials in the EU or the United States, respectively, before we are able to submit an NDA, BLA, MAA or other marketing application for any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If there are delays in the completion of, or termination of, any clinical trial of our product candidates or if we are required to conduct additional clinical trials in addition to those we have currently planned, the commercial prospects of our product candidates may be harmed, and our ability to generate revenue from commercial product sales from any of these product candidates will be delayed. In addition, any delays in completing the clinical trials will increase costs, slow down our product candidate development and approval process and jeopardize the ability to commence product sales and generate revenue from commercial product sales. Any of these occurrences may significantly harm our business, financial condition and prospects. Clinical trial delays may also allow our competitors to bring products to market before we do, which could impair our ability to obtain orphan exclusivity for our products that potentially qualify for orphan drug designation. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (&#8220;EU CTR&#8221;), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;), to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the EU CTR introduced a centralized process and only requires the submission of a single application for multi-center trials. The EU CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU IT portal. Once the CTA is approved, clinical study development may proceed. One of the main aims of EU CTR is to increase transparency about clinical trials, which is done by making documents and data from the CTA publicly available through the Clinical Trials Information System at the time of decision about the clinical trial. There are few exceptions to this, and release of personal data and company confidential information may be controlled through redaction. The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR. Compliance with the EU CTR requirements by us and our third-party service providers, such as CROs, may impact our development plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is currently unclear to what extent the United Kingdom (&#8220;UK&#8221;), will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is derived from existing EU legislation (as implemented into UK law, through secondary legislation). The extent to which the regulation of clinical trials in the UK will mirror the EU CTR in the long term is not yet certain, however, on December 12, 2024, the UK government introduced a legislative proposal - the Medicines for Human Use (Clinical Trials) Amendment Regulations 2024 - that, if implemented, will replace the current regulatory framework for clinical trials in the UK. The legislative proposal aims to provide a more flexible regime to make it easier to conduct clinical trials in the UK, increase the transparency of clinical trials conducted in the UK and make clinical trials more patient centered. The UK government has provided the legislative proposal to the UK Parliament for its review and approval. Once the legislative proposal is approved (with or without amendment), it will be adopted into UK law which is expected in early 2026. A decision by the UK not to closely align its regulations with the new approach adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization in the EU for our product candidates on the basis of clinical trials conducted in the UK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain of our product candidates are in various stages of preclinical development and we may not be successful in our efforts to successfully develop these products or expand our pipeline of product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A key element of our strategy is to expand our pipeline of product candidates utilizing our proprietary TransCon technologies, and to advance such product candidates through clinical development. Certain of our product candidates are in preclinical development and may require significant time and additional research and development before we can submit Investigational New Drug Applications, CTAs or other equivalent foreign regulatory applications to regulatory authorities to begin clinical studies. Of the large number of drugs and biologics in development, only a small percentage of such drugs successfully complete the EMA or FDA regulatory approval process and are commercialized. Accordingly, even if we are able to continue to fund such development programs, our product candidates may not be advanced to clinical studies or be successfully developed or commercialized. In addition, our preclinical product candidates may not demonstrate the advantages we expect from application of our TransCon technologies in preclinical studies. In such event, we may decide not to progress any such product candidates into clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Although our research and development efforts to date have resulted in several development programs, we may not be able to develop product candidates that are safe, pure, potent and/or effective. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development or commercialization for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the research methodology used and our TransCon technologies may not be successful in creating potential product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competitors may develop alternatives that render our product candidates obsolete or less attractive; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates we develop may nevertheless be covered by third-parties&#8217; intellectual property rights or other types of exclusivity and we may not be able to obtain a license from such third-party or the license terms may not be acceptable to us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market opportunity for a product candidate may change during our program or we may discover that such market opportunity was smaller than initially expected so that such a product may become financially unfeasible to continue to develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may be demonstrated to have harmful side effects or not to be effective, or otherwise not to meet other requirements for regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, or reimbursable by third-party payors, if applicable. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are successful in continuing to expand our pipeline, through our own research and development efforts or by pursuing in-licensing or acquisition of product candidates, the potential product candidates that we identify or acquire may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize a product pipeline, we may not be able to generate revenue from commercial product sales in future periods or achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">By expending our limited resources to pursue particular product candidates and areas of focus we may fail to capitalize on product candidates or areas of focus that are more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have focused on research programs and product candidates within the endocrinology and oncology therapeutic areas. As a result, we may forego or delay pursuit of opportunities with other product candidates or in other therapeutic areas that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our nonclinical studies and clinical trials. If these third-parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for, or commercialize, our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have the ability to independently conduct clinical trials or IND-enabling nonclinical studies. We rely on medical institutions, clinical investigators, contract laboratories, collaboration partners and other third-parties, such as CROs, to conduct clinical trials of our products and product candidates. The third-parties with whom we contract for execution of our clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third-parties are not our employees, and except for contractual duties and obligations, we control only certain aspects of their activities and have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third-parties to conduct our nonclinical studies and our clinical trials, we remain responsible for ensuring that each of our nonclinical studies and clinical trials is conducted in accordance with the applicable protocol, scientific standards and legal and regulatory requirements, and our reliance on third-parties does not relieve us of our regulatory responsibilities. We and these third-parties are required to comply with current good laboratory practices (&#8220;GLPs&#8221;), for certain nonclinical studies, and good clinical practices (&#8220;GCPs&#8221;), for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products in nonclinical and clinical development, respectively. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors fail to comply with applicable regulatory requirements, including GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the EMA, the FDA, or similar regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot be certain that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP or similar foreign regulations outside the United States. The failure of our contract manufacturers to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our products and product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if any. If any of our product candidates receives marketing approval and subsequently causes undesirable side effects, the ability to market the product candidates could be compromised.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesirable side effects caused by any of our approved products or our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or similar authorities. In the event that trials conducted by us or any collaboration partners, or trials we conduct with our product candidates, reveal a high and unacceptable severity and prevalence of side effects, such trials could be suspended or terminated and the FDA or similar regulatory authorities could order any collaboration partners or us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if we successfully develop a product candidate and it receives marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. Foreign regulatory authorities may require us to adopt similar risk management measures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the event that any of our product candidates receives regulatory approval and we or others later identify undesirable side effects caused by one of our products, a number of potentially significant negative consequences could occur, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw their approval of the product or seize the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or any collaboration partners, may be required to recall the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof, including the imposition of a REMS or requirements for similar actions, such as patient education, certification of health care professionals or specific monitoring; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or any collaboration partners, may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product may become less competitive; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, a number of adverse reactions have been reported among users of daily somatropin, and we may observe and be required to report similar adverse reactions for users of SKYTROFA. This reporting may result in Dear Healthcare Provider letters or other communications containing warnings or other safety information about the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the foregoing events could prevent us, or any collaboration partners, from achieving or maintaining market acceptance of our products or product candidates, if approved, and could result in the loss of significant revenue to us, which would harm our results of operations and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competition in the biotechnology and pharmaceutical industries is intense and our competitors may discover, develop or commercialize products faster or more successfully than us. If we are unable to compete effectively, our business, results of operations and prospects will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The markets in which we intend to compete are undergoing, and are expected to continue to undergo, rapid and significant technological changes. Some of our products and product candidates are for fields in which competitive products already exist and are established. We expect competition to intensify as technological advances are made or new drugs and biotechnology products are introduced. New developments by competitors may render our products and current or future product candidates and/or technologies non-competitive, obsolete or not economical. Our competitors&#8217; products may be more efficacious or marketed and sold more effectively than our products and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of several pharmaceutical and biopharmaceutical companies that have commenced clinical studies of products or have successfully commercialized products addressing areas that we are targeting. A permanently PEGylated long-acting growth hormone (brand name Jintrolong&#174;) developed by GeneScience Pharmaceuticals Co., Ltd. is available in China and the Somatropin Biopartners product (LB03002), is available in Korea. Novo Nordisk has received regulatory approval of once-weekly somapacitan (brand name SOGROYA&#174;) for replacement of endogenous growth hormone in adult patients with GHD in the United States, Japan, Europe, Australia and Saudi Arabia and in pediatric patients with GHD in the United States, Japan, Europe, Canada, Brazil and Saudi Arabia. Pfizer (in collaboration with OPKO Health Inc.) has received regulatory approval of once-weekly somatrogon (brand name NGENLA) in more than 40 countries for pediatric GHD. Other experimental growth hormone therapies are in different stages of clinical development by various companies, including Genexine Inc., I-MAB, and JCR Pharmaceuticals Co., Ltd. In addition, Takeda owns the rights to parathyroid hormone (brand name NATPARA&#174;), a treatment for hypoparathyroidism. Parathyroid hormone was voluntarily recalled in September 2019 in the U.S. and is now only available to a limited number of patients through a Special Use Program offered by its manufacturer, Takeda. In October 2022, Takeda announced manufacturing of all strengths of NATPARA will be discontinued globally by the end of 2024. In addition, we are aware of several academic groups and companies working on making longer-acting agonists of the PTH receptor, or PTH1R. Other companies and groups are developing or commercializing therapies for hypoparathyroidism, including Calcilytix (a BridgeBio company), Entera Bio, Extend Biosciences, Massachusetts General Hospital, Amolyt Pharma, and MBX Biosciences. Other companies are developing therapies for achondroplasia, including BioMarin Pharmaceutical, Inc. (&#8220;BioMarin&#8221;), and QED Therapeutics (a BridgeBio company). BioMarin has received regulatory approval for vosoritide (brand name VOXZOGO&#174;) in more than 40 active markets for the treatment of achondroplasia and is developing BMN 333, a long-acting C-type natriuretic peptide (CNP) for multiple growth disorders. Tyra Biosciences, Sanofi, ProLynx Inc. and Ribomic, Inc., have achondroplasia programs in various clinical stages.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other companies are developing toll like receptor agonists for cancer immunotherapy including: Seven and Eight Biopharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Bolt Therapeutics, Inc., Surge Therapeutics Inc., Canwell Biotech Ltd., BioNTech SE and Tallac Therapeutics Inc. Other companies have Interleukin 2 program under development for cancer immunotherapy including: Mural Oncology plc, Medicenna Therapeutics Corp., Anaveon AG, Xilio Therapeutics Inc, Werewolf Therapeutics Inc., Sutro Biopharma Inc. and Philogen SpA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to product-based competition, our TransCon technologies face technology-based competition as we believe other companies are developing or evaluating enhanced drug delivery and sustained release technologies. In particular, we believe Nektar Therapeutics, OPKO Health, Inc., ProLynx Inc., MBX Biosciences and Serina Therapeutics, Inc. are developing technology platforms in the areas of enhanced drug delivery and/or reversible linkers that may be competitive with our TransCon technologies. We also expect that technological developments will occur at a rapid rate and that competition is likely to intensify as various enhanced delivery and sustained release technologies may achieve similar advantages.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that our competitors will commercialize competing drugs or treatments before we can launch any other product candidates that are ultimately approved by regulatory authorities. We also anticipate that we will face increased competition in the future as new companies enter into our current and target markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, to the extent we are developing TransCon product candidates that incorporate already approved drugs, we face competition from the pharmaceutical companies which are currently marketing such approved products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These pharmaceutical companies can generally be expected to seek to delay the introduction of competing products through a variety of means including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">filing new formulation patent applications on drugs whose original patent protection is about to expire; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">filing an increasing number of patent applications that are more complex and costly to challenge; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">filing suits for alleged patent infringement that automatically delay FDA or foreign regulatory authorities&#8217; approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">filing suits that challenge our marketing and promotion efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing patented controlled-release or other &#8220;next-generation&#8221; products, which may compete with TransCon product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing exclusive contracts with third-party payors; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changing product claims and product labeling. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any one of these strategies may increase the costs and risks associated with our efforts to develop and commercialize our products and product candidates and may delay or altogether prevent such development or commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors have:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significantly greater name recognition, financial, marketing, research, drug portfolios, drug development and technical and human resources than we have at every stage of the discovery, development, manufacturing and commercialization process and additional mergers and acquisitions in the biotechnology industries may result in even more resources being concentrated in our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">more extensive experience in commercializing drugs, conducting preclinical testing, conducting clinical studies, obtaining regulatory approvals, challenging patents and in manufacturing and marketing pharmaceutical products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">products that have been approved or are in late stages of development; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaboration arrangements in our target markets with leading companies and research institutions. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to our products and product candidates that we successfully develop, we will face competition based on many different factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety and effectiveness of such product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of and specific circumstances relating to regulatory approvals for these product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability and cost of manufacturing, marketing and sales capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our marketing and sales capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the price of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability and amount of third-party reimbursement for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product&#8217;s convenience and ease of administration compared to alternative treatments; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of our patent position. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with our competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our competitors may develop or commercialize products with significant advantages in regard to any of these factors. Our competitors may therefore be more successful in commercializing their products than we are, which could adversely affect our business, results of operations and prospects, and the value of our shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our proprietary TransCon technologies include a new approach to extending the residence time and duration of action of a variety of drug products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our TransCon technologies have been developed to improve the delivery of a variety of drug products. However, we cannot be certain that any of our other products or product candidates using our TransCon technologies will be deemed safe, pure, potent or efficacious (or that any of our products will be deemed safe, pure, potent or effective for other indications), nor that any aspects of our TransCon technologies will yield additional product candidates that could be commercially valuable. Further, our TransCon hydrogel carrier system has limited experience in humans and our drug molecules based on albumin avidity has no experience in humans. As a result, our TransCon hydrogel carriers and our albumin avidity based drug molecules, when dosed extensively in humans, may fail to perform as we expect. Failure of any of our product candidates to be successfully developed, approved and commercialized may result in our TransCon technologies being viewed as an ineffective approach to developing drug products which would harm our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply our TransCon technologies to both approved and unapproved parent drugs to extend the half-life of such drugs in the body, and to enhance the overall benefit of a given therapy. Even when applied to approved parent drugs, we have generated limited clinical data on our product candidates using our systemic TransCon technologies with respect to safety and efficacy for long-term treatment in humans. The long-term safety and efficacy of our TransCon technologies and the extended life in the body of our product candidates utilizing TransCon technologies is unknown, and it is possible that our product candidates may have an increased risk of unforeseen reactions following extended treatment relative to other approved products. If extended treatment with our products or product candidates utilizing TransCon in our ongoing or future clinical trials results in any concerns about the safety or efficacy of our TransCon technologies, we may be unable to successfully develop or commercialize our products or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited clinical data on product candidates utilizing our TransCon technologies to indicate whether they are safe or effective for long-term use in humans.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our products and product candidates are designed to transiently link a parent drug molecule to select TransCon carriers via our TransCon linkers. Once injected, we believe that our prodrugs predictably release the unmodified parent drug molecule over time, thus preserving the parent drug&#8217;s original mode of action, and, we believe, the parent drug&#8217;s original safety and efficacy profile. We believe that our TransCon carriers remain bound to our TransCon linkers and that they are cleared from the body predominantly by renal filtration and biliary transport with fecal excretion. We have limited clinical data regarding utilizing the systemic TransCon technologies to indicate whether they are safe, pure, potent and/or effective for long-term use in humans, including the safety of any degradation products that may result after the TransCon carrier and TransCon linker are cleaved from the parent drug molecule. If treatment with any of our product candidates in our clinical trials results in concerns about their safety or efficacy, we and any collaboration partners may be unable to successfully develop or commercialize any or all of our TransCon technologies based on such product candidates or enter into collaborations with respect to our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on certain collaboration partners to develop and conduct clinical studies with, obtain regulatory approvals for, market and sell product candidates, and if such collaboration partners fail to perform as expected, or are unable to obtain the required regulatory approvals for such product candidates, the potential of such product candidates would be significantly reduced and our business would be significantly harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on our collaboration partners to conduct certain clinical studies. For example, in November 2018, we announced the formation of VISEN Pharmaceuticals (&#8220;VISEN&#8221;), a company established to develop, manufacture, and commercialize our endocrinology rare disease therapy candidates in Greater China. In connection with the formation of VISEN, we granted VISEN exclusive rights to develop and commercialize our rare disease endocrinology products based on our proprietary TransCon technologies, including TransCon hGH, TransCon PTH and TransCon CNP, in Greater China for use in all human indications, subject to certain exceptions. As another example, in November 2023, we announced that we entered into an exclusive license agreement with Teijin Limited, (&#8220;Teijin&#8221;), to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP for certain endocrinology rare diseases in Japan. As a further example, in January 2024, we announced the formation of Eyconis, Inc. (&#8220;Eyconis&#8221;), a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate. In connection with the formation of Eyconis, we granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. We may also enter into collaboration agreements with other parties relating to our other product candidates and technology platform. For example, in November 2024, we entered into a research and development collaboration and license agreement with Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;), pursuant to which we granted Novo Nordisk an exclusive worldwide license to our TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive license in cardiovascular diseases.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our collaboration partners do not perform in the manner we expect or fulfill their responsibilities in a timely manner, or at all, if our agreements with them terminate or if the quality or accuracy of the clinical data they obtain is compromised, the clinical development, regulatory approval and commercialization efforts related to our collaboration product candidates could be delayed or terminated and it could become necessary for us to assume the responsibility at our own expense for the clinical development of such product candidates. In that event, we would likely be required to limit the size and scope of efforts for the development and commercialization of such product candidate, to seek additional financing to fund further development, or to identify alternative collaboration partners, and our potential to generate future revenue from royalties and milestone payments from such product candidate would be significantly reduced or delayed and our business would be harmed. Our existing collaborations and any future collaboration arrangements that we may enter into with third-parties may not be scientifically or commercially successful. In addition to the risks inherent in the development of a drug product candidate, factors that may affect the success of our collaborations include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may have the unilateral ability to choose not to develop a collaboration product or product candidate for one or more indications for which such product or product candidate has been or is currently being evaluated, and our collaboration partners may choose to pursue an indication that is not in our strategic best interest or to forego an indication that they believe does not provide significant market potential even if clinical data is supportive of further development for such indication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may choose not to develop or commercialize our collaboration product or product candidate in certain relevant markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may take considerably more time in advancing our product or product candidate through the clinical and regulatory process than we currently anticipate, which could materially delay the achievement of milestones and, consequently the receipt of milestone payments or royalties from our collaboration partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may have substantial discretion under their respective agreements regarding how they structure their efforts and allocate resources to fulfill their obligations to diligently develop, obtain regulatory approval for and commercialize our collaboration products and product candidates; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may control all or substantially all of the aspects of development and/or commercialization efforts under their respective license agreements and may change the focus of their development and/or commercialization efforts or pursue other higher-priority programs and, accordingly, reduce the efforts and resources allocated to their collaborations with us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may solely be responsible for or have substantially all of the responsibility related to obtaining and maintaining all regulatory approvals of our products or product candidates, and we or our collaboration partners may fail to develop a commercially viable formulation or manufacturing process for our products or product candidates, and we or our collaboration partners may fail to manufacture or supply sufficient drug substance for commercial use, if approved, which could result in lost revenue under such collaborations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if any of our agreements with our collaboration partners terminate, we would need to identify alternative means to continue the development, manufacture and commercialization of the affected products or product candidates, alone or with others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may have the discretion to sublicense their rights with respect to our collaboration technology in connection with collaboration products and product candidates to one or more third-parties without our consent; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may be pursuing alternative technologies or developing alternative products or product candidates, either on their own or in collaboration with others, that may be competitive with our technology, products or product candidates on which they are collaborating with us or which could affect our collaboration partners&#8217; commitment to the collaboration; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may experience financial difficulties.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timing and amount of any milestone and royalty payments we may receive under agreements with collaboration partners and the value of any equity we own in our collaboration partners (such as the equity we own in VISEN and Eyconis) will depend on, among other things, the efforts, allocation of resources, and successful development and commercialization of our products or product candidates by our collaboration partners. We cannot be certain that any development and regulatory milestones will be achieved or that we will receive any future milestone payments under agreements we may enter into with collaboration partners. In addition, in certain circumstances we may believe that a particular milestone has been achieved and the applicable collaboration partner may disagree with our belief. In that case, receipt of that milestone payment may be delayed or may never be received, which may require us to adjust our operating plans. We also cannot be certain that any equity we own in our collaboration partners (such as the equity we own in VISEN and Eyconis) will maintain its value or grow in value.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may form additional strategic collaborations in the future with respect to our proprietary programs, but we may not realize the benefits of such collaborations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may form strategic collaborations, create joint ventures or similar structures or enter into licensing arrangements with third-parties with respect to our independent programs that we believe will complement or augment our existing business. We have historically engaged, and intend to continue to engage, in partnering discussions with a range of biopharmaceutical companies and could enter into new collaborations at any time. For example, in November 2018, we announced the formation of VISEN, a company established to develop, manufacture, and commercialize our endocrinology rare disease therapies in Greater China. In connection with the formation of VISEN, we granted VISEN exclusive rights to develop and commercialize our rare disease endocrinology products based on our proprietary TransCon technologies, including TransCon hGH, TransCon PTH and TransCon CNP, in Greater China for use in all human indications, subject to certain exceptions. As another example, in November 2023, we announced that we entered into an exclusive license agreement with Teijin to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP for certain endocrinology rare diseases in Japan. As a further example, in January 2024, we announced the formation of Eyconis, a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the formation of Eyconis, we granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate strategic partners, and the negotiation process to secure appropriate terms is time-consuming and complex. Any delays in identifying suitable development partners and entering into agreements to develop our products or product candidates could also delay the commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. Moreover, we may not be successful in our efforts to establish such a strategic partnership for any future product candidates and programs on terms that are acceptable to us, or at all. This may be for a number of reasons. For example, under our collaboration with VISEN, VISEN has a right of first negotiation to develop certain of our endocrinology product candidates in Greater China, so our ability to negotiate such a collaboration with suitable third parties in that market may be hampered by such rights we granted to VISEN. Additionally, our product candidates and programs may be deemed to be at too early of a stage of development for collaborative effort, our research and development pipeline may be viewed as insufficient, and/or third-parties may not view our product candidates and programs as having sufficient potential for commercialization, including the likelihood of an adequate safety and efficacy profile. Even if we are successful in entering into a strategic alliance or license arrangement, there is no guarantee that the collaboration will be successful, or that any future collaboration partner will commit sufficient resources to the development, regulatory approval, and commercialization of our product candidates, or that such alliances will result in us achieving revenues that justify such transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek orphan designation for some of our product candidates and we may be unsuccessful, or may be unable to maintain the benefits associated with orphan designation, including the potential for market exclusivity, for product candidates for which we obtain orphan designation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs or biologics intended to treat relatively small patient populations as orphan drug products. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, orphan designation is granted by the EC based on a scientific opinion of the EMA&#8217;s Committee for Orphan Medicinal Products. A medicinal product may be designated as orphan if its sponsor can establish that (i) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the medicinal product will be of significant benefit to those affected by the condition. Orphan designation must be requested before submitting a BLA or NDA in the United States or a MAA in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a drug or biologic with an orphan designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug or biologic is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug or biologic for the same disease or condition for a seven-year period, except in limited circumstances. If our competitors are able to obtain orphan drug exclusivity prior to us, for products that constitute the &#8220;same drug&#8221; and treat the same diseases or conditions as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time. The applicable period is seven years in the United States. The applicable exclusivity period is ten years in the EU, but such exclusivity period can be reduced to six years if, at the end of the fifth year, a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our business strategy, we intend to pursue orphan designation for certain of our product candidates. For example, in June 2018, we were granted orphan drug designation by the FDA for TransCon PTH for the treatment of hypoparathyroidism, in February 2019, we were granted orphan drug designation by the FDA for TransCon CNP for the treatment of achondroplasia, and in April 2020, we were granted orphan drug designation by the FDA for TransCon hGH for the treatment of GHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in October 2019, we were granted orphan designation by the EC for TransCon hGH for GHD, in July 2020, we were granted orphan designation by the EC for TransCon CNP for the treatment of achondroplasia and in October 2020, we were granted orphan designation by the EC for TransCon PTH for treatment of hypoparathyroidism. In July 2021, we were granted orphan drug designation from the Japanese Ministry of Health, Labour and Welfare for TransCon PTH. However, we may be unsuccessful in obtaining additional orphan designations, and may be unable to maintain the benefits associated with orphan designation, such as orphan drug exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obtained orphan drug exclusivity from the FDA for YORVIPATH for the treatment of hypoparathyroidism in adults, and for SKYTROFA for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous GH. However, even if we obtain orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect those product candidates from competition because different drugs can be approved for the same condition, and orphan drug exclusivity does not prevent the FDA or foreign regulatory authorities from approving the same or a different drug in another indication. Even after an orphan drug is granted orphan exclusivity and approved, the FDA or foreign regulatory authorities can subsequently approve a later application for the same drug for the same condition before the expiration of the exclusivity period if the FDA or foreign regulatory authorities conclude that the later drug is clinically superior in that it is shown to be safer in a substantial portion of the target populations, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan-drug-exclusive marketing rights in the United States and in foreign jurisdictions may be lost if the FDA or foreign regulatory authorities later determine that the request for designation was materially defective or if we are unable to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any biological product for which we intend to seek approval may face competition sooner than anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Affordable Care Act (&#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until twelve years from the date on which the reference product was first licensed. During this twelve-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that any of our future biological product candidates approved under a BLA should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Jurisdictions in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier approved reference products. For example, the EU has had an established regulatory pathway for biosimilars since 2006. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to manufacture preclinical, clinical, and commercial supplies of our products, product candidates and their device components.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own facilities for manufacturing our products and product candidates. We depend on third-parties to manufacture and provide analytical services with respect to our products and product candidates and their respective device components.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, to produce the quantities necessary to meet anticipated market demand, we and/or any collaboration partners will need to secure sufficient manufacturing capacity with third-party manufacturers. For SKYTROFA and YORVIPATH, we believe we have secured agreements to provide for sufficient manufacturing capacity with third-party manufacturers; however, our estimates of market demand may be inaccurate and third-party manufacturers may fail to produce sufficient quantities on a timely basis or at all. If we and/or any collaboration partners are unable to produce our products and product candidates in sufficient quantities to meet the requirements for the launch of the product or to meet future demand, our revenues and gross margins would be adversely affected. To be successful, our products and product candidates must be manufactured in commercial quantities in compliance with regulatory requirements and at acceptable costs. We and/or any collaboration partners will regularly need to maintain access to facilities to manufacture commercial supplies of our products and product candidates, if approved. All of this will require additional funds and successful completion of inspection or audits and approval by the FDA, other regulatory authorities and by notified bodies with respect to the device components. If we and/or any collaboration partners are unable to establish and maintain a manufacturing capacity within our planned time and cost parameters, the development and sales of our products and product candidates as well as our business, results of operations and prospects, and the value of our shares or ADSs could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and/or any collaboration partners may encounter problems with aspects of manufacturing our products and product candidates, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production yields; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">quality control and assurance; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shortages of qualified personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with FDA and foreign regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production costs; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development of advanced manufacturing techniques and process controls. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluate our options for clinical study supplies and commercial production of our products and product candidates on a regular basis, which may include use of third-party manufacturers, or entering into a manufacturing joint venture relationship with a third party. We are aware of only a limited number of companies on a worldwide basis who operate manufacturing facilities in which our products and product candidates can be manufactured under cGMP or similar foreign regulations, a requirement for all pharmaceutical products. We cannot be certain that we will be able to contract with any of these companies on acceptable terms, if at all, all of which could harm our business, results of operations and prospects, and the value of our shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we, as well as any third-party manufacturer, will be required to register such manufacturing facilities with the FDA (and have a U.S. agent for the facility, if outside the United States) and other regulatory authorities. The facilities will be subject to inspections confirming compliance with the FDA, and other regulatory authority cGMP or similar foreign requirements. We do not control the manufacturing process of our product candidates, and we are dependent on our contract manufacturing partners for compliance with cGMPs or similar regulations for manufacture of both active drug substances and finished drug products. If we or any third-party manufacturer fails to maintain regulatory compliance, our business, financial condition and results of operations may be harmed, and the FDA or other regulatory authorities can impose regulatory sanctions that range from a warning letter to withdrawal of approval to seeking product seizures, injunctions and, where appropriate, criminal prosecution. Pursuant to our agreements with VISEN, we have provided and may in the future provide, clinical supplies of our product candidates and commercial supplies of our products to VISEN for its use in clinical trials and commercialization. Pursuant to our agreements with Teijin, we may also provide Teijin with clinical supplies of our product candidates and commercial supplies of our products for Teijin&#8217;s use in future clinical trials and commercialization. In order to fulfill these supplies, we rely on third-party manufacturers over which we have no or very limited control or power.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also rely on other foreign contract research organizations (&#8220;CROs&#8221;), and contract manufacturing organizations (&#8220;CMOs&#8221;), such as WuXi Biologics. Such foreign CROs and CMOs may be subject to U.S. legislation, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. For example, in January 2024, there was Congressional activity, including the introduction of the BIOSECURE Act (H.R. 7085) in the House of Representatives and a substantially similar Senate bill (S.3558). The BIOSECURE Act was passed by the House of Representatives in September 2024. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies &#8220;of concern&#8221; without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We do business with companies in China and it is possible some of our contractual counterparties could be impacted by the legislation described above.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our contract manufacturers cannot successfully manufacture our product candidates or products that conform to our specifications and the strict regulatory requirements of the FDA or similar regulatory authorities, they will not be able to secure and/or maintain regulatory approval for the use of their manufacturing facilities for the manufacture of our products. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a similar regulatory authority does not approve these facilities for the manufacture of our products or product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our products or product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our products and product candidates. Any significant delay or discontinuation in the supply of such materials would delay commercialization and the completion of our clinical studies and harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are a limited number of suppliers for raw materials that we use to manufacture our products and product candidates, and there may be a need to identify alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our products or product candidates for commercial sale and/or our clinical studies. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Although we generally do not begin a clinical study unless we believe we have on hand, or will be able to manufacture, a sufficient supply of a product candidate to complete such study, and we currently envision that VISEN, which relies on us for clinical supply of our product candidates, as well as Teijin, which we currently contemplate will rely on us for future clinical and commercial supplies of our product candidates, would do the same, any significant delay or discontinuity in the supply of a product candidate, or the raw material components thereof, for a clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our, VISEN&#8217;s or Teijin&#8217;s clinical studies, product testing, and potential regulatory approval of our product candidates, which could harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any inability to obtain suppliers, including an inability to obtain, or delay in obtaining, approval of a supplier from the FDA or other regulatory authorities, would delay or prevent the clinical development and commercialization of our products and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business exposes us to potential product liability risks which are inherent in research and development, preclinical and clinical studies, manufacturing, marketing and use of our products and product candidates. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product liability claims may be expensive to defend and may result in judgements against us which are potentially punitive. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products and product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a diversion of management&#8217;s time and our resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize or co-promote our products or product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is generally necessary for us to secure certain levels of insurance as a condition for the conduct of clinical studies. We believe that our product liability insurance for clinical studies is sufficient to cover claims. We currently maintain liability insurance with certain specified coverage limits. We cannot be certain that the insurance policies will be sufficient to cover all claims that may be made against us. Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry product liability insurance covering commercial sales and use in our clinical trials in the amount of $20 million in the aggregate on our primary insurance policy and $100 million in the aggregate on our excess insurance policy. Any claim that may be brought against us could result in a court judgement or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various limits, exclusions and deductibles, and given these various limits, exclusions and deductibles, we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. Product liability insurance is expensive, difficult to obtain and may not be available in the future on acceptable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to continue to significantly increase the size of our organization and we may have difficulties in managing our growth and expanding our operations successfully.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we advance our products and product candidates through the development and commercialization process, we will need to expand managerial, operational, financial, sales and marketing and other resources to manage our operations, preclinical and clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities or contract with other organizations to provide these capabilities for us. As operations expand, we expect that we will need to manage additional relationships with various suppliers and other organizations. Our ability to manage our operations and growth requires us to continue to improve our operational, financial and management controls, reporting systems and procedures across a global organization. Such growth could place a strain on our administrative and operational infrastructure. We may not be able to make improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we either internally, together with collaboration partners or through third-party contractors, as applicable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our general and administrative functions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify, recruit, screen, retain, incentivize and integrate additional employees; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manage our internal development efforts effectively while carrying out our contractual obligations to third-parties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish and build a marketing and commercial organization; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to improve our operational, legal, financial, compliance and management controls, reporting systems and procedures. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur significant costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and regulations regarding corporate governance practices. Our senior management and other personnel need to devote a substantial amount of time to ensure that we maintain compliance with all of these requirements. Moreover, the reporting requirements, rules and regulations increase our legal and financial compliance costs and make some activities more time consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as members of our senior management, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;), and the related rules of the SEC, which generally require our senior management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Section 404 requires an annual management assessment of the effectiveness of our internal control over financial reporting, and we are required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal controls over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we grow our business and enter into new activities, and as the reporting requirements increase, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our consolidated financial statements may be materially misstated. We may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of the ADSs to fall. In addition, as a public company we are required to file accurate and timely annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of the ADSs from The Nasdaq Global Select Market or other adverse consequences that would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operating results may vary significantly from period to period and these variations may be difficult to predict.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating results are expected to vary significantly from period to period due to a number of factors. Many of these factors are outside of our control. These factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of regulatory approvals, if any, for our product candidates; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount and timing of revenue from product sales; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential market opportunities and patient populations for our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation of intellectual property litigation by third-parties or by us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount and timing of operating costs and capital expenditures relating to the expansion of our business operations and facilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of the commencement, completion or termination of collaboration agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and amount of payments to us under collaboration agreements, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the introduction of new products and services by us, collaboration partners or our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in preclinical testing and clinical studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements for clinical studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs and expenses associated with preclinical testing and clinical studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exchange rate fluctuations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the regional and global effect of inflation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the adverse impact of multiple interest rate increases implemented by the U.S. Federal Reserve; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of license fees for the right to use third-party proprietary rights, if any. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenues in any particular period may be lower than we anticipate and, if we are unable to reduce spending in that period, our operating results will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may consider strategic transactions, such as acquisitions of companies, asset purchases, and in-licensing or out-licensing of products, product candidates or technologies. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our senior management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">up-front, milestone and royalty payments, equity investments and financial support of new research and development candidates including increase of personnel, all of which may be substantial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exposure to unknown liabilities, including potential indemnification claims from a potential spin-off or out-license of certain of our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption of our business and diversion of our management&#8217;s time and attention to develop acquired products, product candidates or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">higher-than-expected acquisition and integration costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lower-than-expected benefits, from out-licensing or selling our technology, intellectual property or any of our subsidiaries or, from in-licensing intellectual property or purchasing assets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">write-downs of assets or goodwill or impairment charges; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty and cost in combining or separating the operations and personnel of any acquired or sold businesses with our existing operations and personnel; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may disagree with our strategic partners about decisions affecting the business, which could result in litigation or arbitration that increases our expenses, distracts our officers and directors and disrupts the day-to-day operations of the strategic venture, including by delaying important decisions until the dispute is resolved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our strategic partners may take actions that we oppose; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our strategic partners might experience financial distress or become bankrupt; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment of relationships with key suppliers or customers of any acquired or sold businesses due to changes in our senior management and ownership; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to retain key employees of any acquired businesses. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, to the extent we enter into a strategic transaction that includes ongoing operations or shared ownership and management, our strategic partners may take actions that we oppose or we may disagree with our strategic partners about decisions affecting the business, which could result in litigation or arbitration, distract our officers and directors and otherwise disrupt the day-to-day operations of our business and the business of the strategic partner or entity. Furthermore, to the extent that our directors and officers serve on the boards of our strategic partners, such directors may be required to abstain from board decision-making in the event of a conflict of interest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, although we cannot be certain that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks, and could harm our business, results of operations, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Royalty Pharma Agreements place restrictions on our operating and financial flexibility, and if we fail to comply with certain covenants in the Royalty Pharma Agreements, our results of operations and financial condition may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023 and September 2024, we entered into the Royalty Pharma Agreements with Royalty Pharma. The Royalty Pharma Agreements contain covenants that impose on us certain obligations with respect to payment, diligence, reporting, intellectual property, in-licenses, out-licenses and certain other actions, as well as indemnification obligations. Among other things, these covenants require us to use commercially reasonable efforts to manufacture and commercialize SKYTROFA and YORVIPATH in the United States and to develop SKYTROFA for a new indication, and limit our ability to create or incur liens or dispose of certain assets related to SKYTROFA and YORVIPATH. Compliance with these covenants may limit our flexibility in operating our business and our ability to take actions that might otherwise be advantageous to us and our stockholders. Pursuant to the Royalty Pharma Agreements, we have granted to Royalty Pharma back-up security interest in certain assets to secure our obligations under the Royalty Pharma Agreements. If we are unable to comply with our obligations, Royalty Pharma may be entitled to take possession of such assets, which could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange rate fluctuations or abandonment of the euro currency may harm our results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the international scope of our operations, fluctuations in exchange rates, particularly between the Euro, the Danish Krone and the U.S. Dollar, may adversely affect us. Although we are based in Denmark, we source research and development, manufacturing, consulting and other services from several countries. Further, potential future revenue may be derived from abroad, including from the United States. We currently attempt to limit our exposure to exchange rate risks by maintaining cash positions in the currencies in which we expect to incur the majority of our future expenses; however, for a variety of reasons we may be unable to maintain cash positions in the currencies in which we expect to incur the majority of our future expenses and we may fail to predict the currency of our future expenses, accurately or at all. As a result, our business and the price of the ADSs may be affected by fluctuations in foreign exchange rates between the Euro and these other currencies, which may also have a significant impact on our reported results of operations and cash flows from period to period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently do not enter into foreign exchange contracts to cover our exposure to exchange rate fluctuations, or any other form of exchange rate hedging arrangements. If we fail to manage foreign exchange risk adequately our business, results of operations and prospects, and the value of our shares or ADSs may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the possible abandonment of the Euro by one or more members of the EU could harm our business in the future. Despite measures taken by the EU to provide funding to certain member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the Euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of individual currencies in one or more EU member states. The effects on our business of a potential dissolution of the EU, the exit of one or more EU member states from the EU or the abandonment of the Euro as a currency, are impossible to predict with certainty, and any such events could harm our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the end of the Brexit transition period on January 1, 2021, Great Britain (England, Scotland and Wales) (&#8220;GB&#8221;) has not been directly subject to EU laws, however between January 1, 2021 and December 31, 2024 and as a result of the Northern Ireland Protocol, different rules applied in Northern Ireland than in GB; broadly, Northern Ireland continued to follow the EU regulatory regime. On January 1, 2025, a new arrangement called the &#8220;Windsor Framework&#8221; came into effect and reintegrated Northern Ireland under the regulatory authority of the UK&#8217;s Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) with respect to medicinal products. The Windsor Framework removes EU licensing processes and EU labelling and serialization requirements in relation to Northern Ireland and introduces a UK-wide licensing process for medicines. In addition, new legislation such as the EU CTR is not applicable in Great Britain. While the EU-UK Trade and Cooperation Agreement includes the mutual recognition of Good Manufacturing Practice (&#8220;GMP&#8221;), it does not contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards. There may be divergent local requirements in Great Britain from the EU in the future, which may impact clinical and development activities that occur in the UK in the future. Similarly, clinical trial submissions in the UK will not be able to be bundled with those of EU member states within the EMA Clinical Trial Information System, adding further complexity, cost and potential risk to future clinical and development activity in the UK. Significant political and economic uncertainty remains about how much the relationship between the UK and EU will differ as a result of the UK&#8217;s withdrawal.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These developments, or the perception that any related developments could occur, have had and may continue to have a material adverse effect on global economic conditions and financial markets, and may significantly reduce global market liquidity, restrict the ability of key market participants to operate in certain financial markets or restrict our access to capital. Any of these factors could have a material adverse effect on our business, financial condition and results of operations and reduce the price of the ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks associated with our international operations, including seeking and obtaining approval to commercialize our product candidates in jurisdictions outside the U.S. and EU, could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We engage extensively in international operations, which include seeking marketing approval for certain of our product candidates in foreign jurisdictions. We expect that we are or will be subject to additional risks related to entering into these international business markets and relationships, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for drug and device approvals in foreign countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing drug import and export rules; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lacking or reduced protection for intellectual property rights in foreign countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in laws or policies governing the terms of foreign trade, and in particular increased trade restrictions, tariffs or taxes on imports or exports from or to countries where we manufacture or sell, or our partners sell, our products and product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different reimbursement systems, and different competitive drugs; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign taxes, including withholding of payroll taxes; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential liability resulting from work conducted by distributors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we originally planned to conduct the Phase 3 foresiGHt trial utilizing sites in Belarus and Russia, but instead we engaged alternative sites for the study following the outbreak of conflict in Ukraine, which adversely affected patient enrollment. In addition, the manufacture of our products and product candidates is dependent upon third-party manufacturers that are based in other parts of the world, including the United States, Europe (including the UK and Switzerland), Japan and China. This manufacturing process requires that the components used in our products and product candidates are transported long distances, through multiple countries, which increases the risk that issues in the global supply chain or other disruptions to the international marketplace could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The parent drug, drug product and other components of our products and product candidates are currently acquired from certain single-source suppliers. The loss of these suppliers, or their failure to supply could materially and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH drug product in vials is manufactured for use in clinical trials by Vetter Pharma Fertigung (&#8220;Vetter&#8221;), pursuant to our agreement with Vetter. TransCon hGH drug product in dual chamber cartridges for commercial and clinical use is supplied by Vetter for use in our drug delivery device made by Phillips Medisize A/S (formerly Medicom Innovation Partner A/S). The intermediates of our proprietary TransCon linkers are made by CARBOGEN AMCIS AG under an agreement with CARBOGEN AMCIS AG and accompanying purchase orders. For products that utilize soluble TransCon carriers, NOF Corporation (Japan) (&#8220;NOF&#8221;), supplies PEGs. Furthermore, NOF is responsible for coupling the TransCon linker used for TransCon hGH to methoxy PEG, under manufacturing agreements and accompanying purchase orders. Our growth hormone parent drug as well as our TransCon hGH drug substance are supplied by both Fujifilm Diosynth Biotechnologies UK Limited (&#8220;Fujifilm&#8221;), and Lonza Ltd. Our PTH as well as our TransCon PTH drug substance is supplied by Bachem, Switzerland, pursuant to our agreement with Bachem. Vetter manufactures the TransCon PTH drug product in cartridges and assembles the cartridges with a drug delivery device made by Ypsomed AG. CNP drug substance is supplied by Wacker Biotech, Germany. Our TransCon CNP drug product in vials is manufactured by Vetter pursuant to our agreement with Vetter. We do not currently have any other suppliers for the drug substance, drug product or other components of our TransCon hGH, TransCon PTH and TransCon CNP, although we believe that there are alternate sources of supply that could satisfy our clinical and commercial requirements, we cannot provide assurance that identifying alternate sources and establishing relationships with such sources would not result in significant delays in the commercialization or development of our products and product candidates. Additionally, we may not be able to enter into supply arrangements with alternative suppliers on commercially reasonable terms or at all. A delay in the commercialization or development of our products or product candidates or having to enter into a new agreement with a different third-party on less favorable terms than we have with our current suppliers could have a material adverse impact upon our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to identify additional product candidates based on our TransCon technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An important element of our strategy is to develop new products and product candidates based on our TransCon technologies. Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the research methodology used may not be successful in identifying potential product candidates; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects or other characteristics suggesting that they are unlikely to be effective or safe products, or that they may not be sufficiently differentiated or offer substantial improvement over the currently available treatment options or standard of care in a given therapeutic category.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to develop suitable product candidates through internal research programs or otherwise, we will not be able to increase our revenues in future periods, which could harm our business, results of operations and prospects, and the value of our shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are highly dependent on the services of our President and Chief Executive Officer, Jan M&#248;ller Mikkelsen, and if we are not able to retain this member of our senior management or recruit additional management, clinical and scientific personnel, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified personnel. We may not be able to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, we are highly dependent upon Jan M&#248;ller Mikkelsen, our President and Chief Executive Officer. The loss of services of this individual could result in delays in product development and harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may have difficulties in attracting and retaining key personnel, and if we fail to do so our business may suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on the principal members of our senior management and scientific staff, the loss of whose services could adversely affect the achievement of planned development objectives. In addition, we could experience difficulties attracting and retaining qualified employees in the future. For example, competition for qualified personnel in the biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. As such, we could have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For us to further expand our product development plans, we will need to hire additional qualified scientific personnel to perform research and development. We will also need to hire personnel with expertise in clinical testing, government regulation, sales and marketing, and finance, and might need to hire additional personnel with expertise in manufacturing. We may not be able to attract and retain personnel on acceptable terms, given the competition for such personnel among biotechnology, pharmaceutical and healthcare companies, universities and non-profit research institutions. Although we may be successful in attracting and retaining suitably qualified scientific personnel, there can be no assurance that we will be able to attract and retain such personnel on acceptable terms given the competition for experienced scientists from numerous pharmaceutical and chemical companies, specialized biotechnology firms, universities and other research institutions. Our failure to do so could adversely affect our business, results of operations and prospects, and the value of our shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our information technology systems, or those of our CROs or other contractors or consultants, may fail or suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity, which could result in a material disruption of our product development programs and other critical business functions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, our information technology systems and those of our CROs and other contractors and consultants are vulnerable to attack and damage from computer viruses and malware (e.g., ransomware), unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures, malfeasance by external or internal parties, human error (e.g., social engineering, phishing). Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and certain of our service providers may from time to time be subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our and our critical third parties&#8217; operations, it could result in a material disruption of our programs, our operations, and ultimately, our financial results. For example, the loss of clinical trial data from completed or ongoing clinical trials for our products or product candidates could result in delays in our regulatory approval efforts, and the loss of research data could result in delays of our research and development efforts and it would be expensive to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our products or product candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a security breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of personal information, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to applicable privacy and security laws. Any security compromise affecting us, our service providers, strategic partners, other contractors, consultants, or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary or personal information, we could incur liability, including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive position could be harmed and the further development and commercialization of our products and services could be delayed. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our business. Furthermore, federal, state and international laws and regulations can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties, fines and significant legal liability, if our information technology security efforts fail. Laws around cybersecurity are also developing, and changes in such laws may require additional compliance costs. For example, in the EU, more stringent rules around cybersecurity are being adopted, such as the NIS2 Directive, which requires in-scope entities to implement heightened cybersecurity measures and responses, including with respect to security incident handling and reporting obligations. If a security breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of personal information, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business has been, and may continue to be, adversely affected by health epidemics, pandemics and other outbreaks of infectious disease.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public health threats, such as COVID-19, influenza and other highly communicable diseases or viruses, outbreaks of which have from time to time occurred in various parts of the world in which we operate could adversely impact our operations, as well as the operations of our customers, end users of our products, and our and their respective vendors, suppliers and other business partners. Any of these public health threats and related consequences could adversely affect our financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The potential future measures put in place as a result of any future epidemic, pandemic, or health crisis could cause disruptions that could severely impact our business, clinical trials and commercialization activities, including by causing delays to our clinical trials, interrupting our supply chain, restricting access to our facilities, placing restrictions on our workforce and the workforce of our partners, or delaying interactions with regulators.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any future pandemic may cause further disruption to global financial markets. This may reduce our ability to access capital on favorable terms or to access capital at all. Furthermore, sustained adverse market events (such as a recession or depression) resulting from any future pandemic could materially and adversely affect our business and the price of the ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The extent to which any future epidemic, pandemic, or other health crisis impacts our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the speed and extent of geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the affected areas, business closures or business disruptions and the effectiveness of actions taken in the affected areas to contain and treat the disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global and regional economic, political, health, climate and other conditions and events could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our results of operations could be adversely affected by global or regional economic, political, health, climate and other conditions and events. A global financial crisis or global or regional political and economic instability, failure of banks, wars, terrorism, civil unrest, outbreaks of disease, such as COVID-19, and other unexpected events, such as natural disasters, internet security threats, and damage to global communication networks, could cause extreme volatility, disrupt our business and increase our costs and expenses. Business disruptions could include, among others, disruptions to clinical enrollment, clinical site availability, patient accessibility, conduct of our clinical trials and commercialization activities, as well as temporary closures of our facilities and the facilities of suppliers or manufacturers in our supply chain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, trade policies and geopolitical disputes (including as a result of China-Taiwan geo-political instability) and other international conflicts can result in tariffs, sanctions and other measures that restrict international trade, and can materially adversely affect our business, particularly if these measures occur in regions where our third-party contract manufacturers operate. Countries may also adopt measures, such as controls on imports or exports of goods, technology or data, that could adversely impact the Company&#8217;s operations and supply chain. These geopolitical risks could also adversely affect VISEN&#8217;s activities in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, global credit and financial markets have experienced volatility and disruptions over the past years, including concerns about declines in consumer confidence, declines in economic growth, increases in the rate of inflation, increases in borrowing rates and changes in liquidity and credit availability, and uncertainty about economic stability, including most recently in connection with actions undertaken by the U.S. Federal Reserve Board to address inflation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The military conflict between Russia and Ukraine has increased the likelihood of supply interruptions and made it difficult to conduct business operations, including clinical trials, in the region and in nearby countries. We originally planned to conduct the Phase 3 foresiGHt trial utilizing sites in Belarus and Russia, but instead we engaged with alternative sites for the study following the outbreak of conflict in Ukraine, which adversely affected patient enrollment. Such developments could negatively impact such operations or require use to delay or suspend clinical trial activities, which may increase product development costs and harm our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, on October 7, 2023, Hamas, an organization designated by the U.S. as a terrorist organization, launched a series of coordinated attacks from the Gaza Strip onto Israel. On October 8, 2023, Israel formally declared war on Hamas, and the armed conflict is ongoing as of the date of this filing. Hostilities between Israel and Hamas could escalate and involve surrounding countries in the Middle East. To date, we have not experienced any material interruptions in our infrastructure, supplies, technology systems, or networks needed to support our operations as a result of the conflict between Israel and Hamas.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no way to predict the progress, outcome or consequences of the military conflict in Ukraine or its impacts in Ukraine, Russia, Belarus, Europe, or the U.S, or of the conflict in the Israel-Gaza regions and any potential increases in hostilities in the Middle East. The length, impact, and outcome of ongoing military conflicts is highly unpredictable and could lead to significant market and other disruptions, including significant volatility in commodity prices and supply of energy resources, instability in financial markets, supply chain interruptions, political and social instability, trade disputes or trade barriers, changes in consumer or purchaser preferences, as well as an increase in cyberattacks and espionage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the COVID-19 outbreak, including developments involving subsequent COVID-19 variants, significantly affected the financial markets of many countries and resulted and may in the future result in a variety of regulatory orders, guidance and restrictions. Similarly, global climate change could result in certain types of natural disasters occurring more frequently or with more intense effects. Some of our corporate and operational functions, including certain of our oncology research facilities, are located in California, which has experienced severe earthquakes, droughts, fires and other natural disasters in the past. We do not have multiple-site capacity for all of our operations in the event of a business disruption. Furthermore, parties in our supply chain and our customers are similarly vulnerable to these global or regional economic, political, health, climate and other conditions and events. Global or regional economic, political, health, climate and other conditions and events could result in a variety of risks to our business, including our ability to raise capital when needed on acceptable terms, if at all. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which such conditions and events could adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulatory and Legal Requirements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the EMA, the FDA and comparable authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products are subject to extensive regulation by the FDA, EU legislative bodies and other regulatory authorities in the United States, the EU and other jurisdictions, which regulations differ from country to country. We are not permitted to market any drug product in the United States until we receive marketing approval from the FDA. Equally, we are not permitted to market any drug product in the EU until we receive a marketing authorisation from the EC or EU member state competent authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining regulatory approval of an NDA, BLA or MAA, can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable U.S., EU and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions or other actions, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning letters; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil and criminal penalties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of regulatory approval of products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">total or partial suspension of production; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending NDAs or BLAs, MAA, or supplements to approved NDAs or BLAs or extensions or variations to marketing authorizations. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining approval to commercialize a drug or biological product candidate in the United States, the EU or other regions, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the EMA, the FDA or other similar regulatory authorities, that any drug product candidates are safe and effective for their intended uses, and that any biological product candidates are safe, pure and potent for their intended uses. The number of nonclinical studies and clinical trials that will be required for FDA, or EC approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering drug or biological product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a product candidate for any or all targeted indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The time required to obtain approval by the FDA and comparable authorities is unpredictable, typically takes many years following the commencement of clinical studies, and depends upon numerous factors. The EMA, the FDA and comparable authorities have substantial discretion in the approval process and we may encounter matters with the EMA, the FDA or such comparable authorities that requires us to expend additional time and resources and delay or prevent the approval of our product candidates. For example, the FDA or EMA may require us to conduct additional studies or trials for drug or biological product candidates either prior to or post-approval, such as additional drug-drug interaction studies or safety or efficacy studies or trials, or it may object to elements of our clinical development program such as the number of subjects in our current clinical trials from the United States or Europe. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or result in a decision not to approve an application for regulatory approval. Despite the time and expense exerted, failure can occur at any stage. Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the EMA, the FDA or other comparable foreign regulatory authorities may disagree with the design or implementation of our, or any collaboration partners&#8217;, clinical studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which approval is sought; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the EMA, the FDA or comparable foreign regulatory authorities may disagree with the interpretation of data from preclinical studies or clinical studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of an NDA or BLA, MAA, or other submission or to obtain regulatory approval in the United States, the EU or elsewhere; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or any collaboration partners, may be unable to demonstrate to the EMA, the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers responsible for clinical and commercial supplies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, FDA and foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the EC in November 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EC&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may however have a significant impact on the pharmaceutical industry and our business in the long term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failure to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. Additionally, if the EMA, the FDA or comparable foreign regulatory authorities require that we conduct additional clinical studies, place limitations on our label, delay approval to market our product candidates or limit the use of our products, our business and results of operations may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even if we ultimately obtain approval for any product candidate, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, may impose a REMS or similar risk management measures, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could harm the commercial prospects for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional time may be required to obtain marketing authorizations for any of our product candidates that we develop as combination products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 9, 2024, the FDA approved YORVIPATH for the treatment of hypoparathyroidism in adults. The approved presentation for YORVIPATH includes a pen-injector device we developed with Ypsomed to facilitate patient administration of TransCon PTH. As such, the pen-injector version of TransCon PTH is regulated as a combination product by the FDA and other regulatory authorities. Combination products require coordination within the FDA and within comparable regulatory agencies for review of their drug and device components. The EU regulates medical devices and medicinal products separately, through different legislative instruments, and the applicable requirements will vary depending on the type of drug-device combination product. For instance, drug-delivery products intended to administer a medicinal product where the medicinal product and the device form a single integral product are regulated as medicinal products in the EU. In such a case, the MAA must include &#8211; where available &#8211; the results of the assessment of the conformity of the device part with the EU Medical Devices Regulation contained in the manufacturer&#8217;s EU declaration of conformity of the device or the relevant certificate issued by a notified body. If the MAA does not include the results of the conformity assessment and where for the conformity assessment of the device, if used separately, the involvement of a notified body is required, the EMA or the EU member state competent authority must require the applicant to provide a notified body opinion on the conformity of the device. By contrast, in case of drug-delivery products intended to administer a medicinal product where the device and the medicinal product do not form a single integral product (but are, e.g., co-packaged), the medicinal product is regulated in accordance with the rules for medicinal products described above while the device part is regulated as a medical device and will have to comply with all the requirements set forth by the Medical Devices Regulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the FDA and comparable foreign agencies have or may have systems in place for the review and approval of combination products, we may experience additional delays in the development and commercialization of such product candidates due to regulatory timing constraints and uncertainties in the product development and approval process. Moreover, although we anticipate that the device component of any combination product candidates we develop will be reviewed within the usual time frames expected for the underlying drug component application, and that no separate marketing application for the device components of such product candidates will be required in the United States, the FDA or comparable regulatory authorities may delay approval or require additional studies with the device which may delay the approval of the combination product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in April 2023 the FDA issued a Complete Response Letter in response to our original NDA submission for TransCon PTH, in which the FDA cited concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product. Although the FDA subsequently approved our NDA for YORVIPATH, there is no guarantee that we will not encounter similar challenges or delays with respect to any other combination-product development programs we may pursue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even after a regulatory approval for a product candidate, we are subject to ongoing regulatory obligations and review, which may result in significant additional expenses. Additionally, our products and product candidates, if approved, could be subject to labeling and other restrictions and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The governmental regulation of the development of products, including SKYTROFA and YORVIPATH in the U.S. and EU, and our other product candidates extend beyond clinical studies to approval required for their sale and monitoring of such products after sale. This regulation, approval and monitoring is the responsibility of numerous authorities in the United States, the EU and authorities in other territories. Following any regulatory approval of a product candidate, we, any collaboration partners and the manufacturers of our products will be subject to continuing regulatory obligations, including safety reporting requirements, regulatory oversight of product promotion and marketing, and cGMP or similar requirements. Furthermore, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These regulations cover all aspects of manufacturing, testing, quality control and recordkeeping of our products. If we or any collaboration partners or manufacturers fail to comply with applicable regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs or similar requirements and GCPs for any clinical trials that we conduct post-approval. As such, we and our third-party contract manufacturers will be subject to continual review and periodic inspections to assess compliance with regulatory requirements. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. Regulatory authorities may also impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing studies. Furthermore, any new legislation addressing drug safety issues could result in delays or increased costs to assure compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the Federal Food, Drug, and Cosmetic Act, particular restrictions are placed on the distribution of human growth hormone products, including TransCon hGH. The distribution of product samples to physicians must also comply with the requirements of the Prescription Drug Marketing Act. Manufacturing facilities for our products remain subject to periodic inspection by regulatory authorities and must continue to adhere to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and the FDA&#8217;s cGMP requirements. Application holders must obtain FDA approval for many product and manufacturing changes, depending on the nature of the change. Sales, marketing, and scientific/educational grant programs must comply with the U.S. Anti-Kickback Statute, the False Claims Act, as amended and similar state laws. Certain payments and other transfers of value to U.S. licensed physicians (as defined under statute) and teaching hospitals must be reported under the Physician Payments Sunshine Act. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to U.S. consumer protection and unfair competition laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will also be required to report certain adverse reactions and production problems, if any, to the FDA or foreign regulatory authorities, and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription pharmaceutical products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA or foreign regulatory authorities approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning letters, fines or holds on clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or revocation of existing regulatory approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension of any of our future or ongoing clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications submitted by us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on our or our contract manufacturers&#8217; operations; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA&#8217;s and foreign regulatory authorities&#8217; policies may change and additional government laws or regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the EU, once a marketing authorisation is obtained, numerous post-approval requirements similar to the above ones also apply, and as in the United States, advertising and promotional activities for the product must be consistent with the approved summary of product characteristics and therefore off-label promotion of medicinal products is not permitted. Furthermore, the advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU. The requirements are regulated by both EU regulations as well as national applicable regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory requirements relating to the manufacturing, testing, marketing and sale of pharmaceutical products are subject to periodic change. This may impact our development plans. Changes in the regulations governing us could increase costs and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, companies developing pharmaceutical products are facing increased demands to publish clinical trial results. Any such publication by us may, in addition to the additional cost of the publication, lead to investors misinterpreting the published data due to its technical and scientific nature, which, in turn, may adversely affect our business, results of operations and prospects and the value of our shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new drugs, medical devices and biologics or modifications to approved drugs, and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections at domestic and foreign manufacturing facilities from March 2020 until July 2021. If a prolonged government shutdown occurs, or if global health concerns continue to hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third-party payor coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors in the United States are essential for most patients to be able to afford treatments including our products and product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for drug treatments by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our products, and potentially attract additional collaboration partners to invest in the development of our product candidates. We cannot be sure that adequate coverage and reimbursement in the United States, the EU or elsewhere will be available for our products or any products that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. Third-party payors increasingly are challenging prices charged for pharmaceutical products, medical devices and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug is available. It is possible that a third-party payor may consider our products or product candidates, if approved, and the generic or biosimilar parent drug as substitutable and only offer to reimburse patients for the generic drug. Even if we show improved efficacy or improved convenience of administration with our products or product candidates, if approved, pricing of the existing parent drug may limit the amount we will be able to charge for such product. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products or product candidates, and may not be able to obtain a satisfactory financial return on products that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs, biologics and medical devices will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs, biologics and medical devices. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our products and product candidates, if approved, and on related parent drugs. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Many countries, including the EU member states, established complex and lengthy procedures to obtain price approvals, coverage and reimbursement. These procedures vary from country to country but are commonly initiated after grant of the related marketing authorization. More particularly, in the EU, potential reductions in prices and changes in reimbursement levels could be the result of different factors, including reference pricing systems. It could also result from the application of external reference pricing mechanisms, which consist of arbitrage between low-priced and high-priced countries. Reductions in the pricing of our medicinal products in one EU member state could affect the price in other EU member states and, thus, have a negative impact on our financial results. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products or product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. As an example, many EU member states review periodically their decisions concerning the pricing and reimbursement of medicinal products. The outcome of these reviews cannot be predicted and could have adverse effects on the pricing and reimbursement of our medicinal products in the EU member states.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our products or product candidates. We expect to experience pricing pressures in connection with the sale of our products and product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and contract manufacturers are subject to significant regulation with respect to manufacturing our products and product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on third-parties to manufacture products employing our TransCon technologies. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP or similar requirements outside the United States. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. All entities involved in the preparation of our products and product candidates for clinical studies or commercial sale, including our existing contract manufacturers for our products and product candidates, are subject to extensive regulation. Manufacturing facilities are subject to pre-approval and ongoing periodic inspection by the FDA and other corresponding governmental authorities, including unannounced inspections, and must be licensed before they can be used in commercial manufacturing of products employing our TransCon technologies. After regulatory approvals or licensure are obtained, the subsequent discovery of previously unknown manufacturing, quality control or regulatory documentation problems or failure to maintain compliance with the regulatory requirements may result in restrictions on the marketing of a product, revocation of the license, withdrawal of the product from the market, seizures, injunctions, or criminal sanctions. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA, BLA, MAA or comparable regulatory filing on a timely basis and must adhere to cGMP or similar regulations enforced by the FDA and other regulatory authorities through their facilities inspection programs. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third-party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent suspension of production or closure of a facility. Any such remedial measures imposed upon us or third-parties with whom we contract could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new pharmaceutical product, withdrawal of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through submission and subsequent approval of a supplemental NDA or BLA, a marketing authorization variation application or equivalent foreign regulatory filing, which could result in further delay. The regulatory authorities may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. Furthermore, interruption or delay in supplies from one contract manufacturer may cause delays further down the supply chain, as certain contract manufacturers may rely on delivery of materials from other contract manufacturers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed, or we could lose potential revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operations involve hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a pharmaceutical company, we are subject to environmental and safety laws and regulations, including those governing the use of hazardous materials. The cost of compliance with health and safety regulations is substantial. Our business activities involve the controlled use of hazardous materials. Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of accidental contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and European, U.S. federal and state or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In the event of an accident or environmental discharge, we may be held liable for any consequential damage and any resulting claims for damages, which may exceed our financial resources and may materially adversely affect our business, results of operations and prospects, and the value of our shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance matters, including related social expectations and concerns, may impose unexpected costs on us or result in reputational or other harm to us that could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is an increasing focus and rapid and ongoing developments and changing expectations from certain investors, customers, consumers, employees and other stakeholders concerning environmental, social and corporate governance (&#8220;ESG&#8221;) matters. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continue to grow, which may result in increased regulatory, social or other scrutiny on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, we have undertaken, and in future may undertake, various initiatives to improve our ESG profile or respond to stakeholder expectations; however, such initiatives entail costs and may not have the desired effect. For example, many initiatives rely on methodologies, standards, or data that are complex and evolving. Our approach to such matters also evolves, and there can be no guarantee that our approach will align with the expectations of any particular stakeholder. Stakeholder expectations vary, and in some circumstances conflict. For example, various policymakers, such as the EU and State of California, have adopted requirements for certain disclosures or other actions on climate and related ESG matters. Such requirements are not uniform, and may not be interpreted or applied uniformly, which can increase the cost and complexity of compliance, along with any other risks. Simultaneously, other stakeholders (including some policymakers) have sought to constrain companies attention to certain ESG matters.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure or perceived failure to meet the standards set by various constituencies, or to successfully navigate competing expectations, could damage our reputation and our relationships with investors, governments, customers, employees, third parties and the communities in which we operate and expose us to increased regulatory risk, put us at a commercial disadvantage relative to our peers and materially adversely affect our business, financial condition, results of operations, ability to participate in debt and equity markets and the value of our shares or ADSs. Various of our suppliers, business partners, or other stakeholders are subject to similar expectations, which may augment or create additional risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply or are found to have failed to comply with EU, FDA and other local regulations related to the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA and other regulatory authorities, as well as courts. For example, we are restricted from marketing SKYTROFA and YORVIPATH and any other product candidate that receives marketing approval outside of its approved labeling, also referred to as off-label promotion. However, physicians may nevertheless lawfully prescribe an approved product to their patients in a manner that is inconsistent with the approved label, which is an off-label use. The FDA or other government authorities may allege or find that our practices constitute prohibited promotion for unapproved uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Over the past several years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various U.S. federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the Federal Trade Commission and various state Attorneys General offices. These investigations have alleged violations of various U.S. federal and state laws and regulations, including claims asserting antitrust violations, violations of the Food, Drug and Cosmetic Act, the False Claims Act, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;qui tam&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim, or caused a false claim to be submitted, to the government for payment. The person bringing a qui tam suit is entitled to a share of any recovery or settlement. Qui tam suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a qui tam suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a qui tam suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (1) FDA or similar foreign regulations, including those laws that require the reporting of true, complete and accurate information to the FDA or foreign regulatory authorities; (2) manufacturing standards; (3) U.S. federal and state fraud and abuse and other healthcare laws and regulations including foreign requirements; or (4) laws that require the reporting of true and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials or falsification of clinical trial data, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other U.S. federal or non U.S. healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to global anti-corruption laws, including but not limited to the U.S. Foreign Corrupt Practices Act, and non-compliance with such laws can subject us to criminal or civil liability and harm our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business activities may be subject to the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and, therefore, involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these requirements. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from allegations, governmental investigations or other actions or lawsuits stemming from a failure to comply with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including civil or criminal fines and penalties, disgorgement of profits, injunctions and debarment from government contracts, as well as related stockholder lawsuits and other remedial measures, all of which could adversely affect our reputation, business, financial condition and results of operations. Investigations of alleged violations can also be disruptive and cause us to incur significant legal and investigatory fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our failure to comply with trade compliance and economic sanctions laws and regulations of the United States and applicable international jurisdictions could materially adversely affect our reputation and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business must be conducted in compliance with applicable economic and trade sanctions laws and regulations, such as those administered and enforced by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control, the U.S. Department of State, the U.S. Department of Commerce, the United Nations Security Council and other relevant sanctions authorities. Our global operations expose us to the risk of violating, or being accused of violating, economic and trade sanctions laws and regulations. Our failure to comply with these laws and regulations may expose us to reputational harm as well as significant penalties, including criminal fines, imprisonment, civil fines, disgorgement of profits, injunctions and debarment from government contracts, as well as other remedial measures. Investigations of alleged violations can be expensive and disruptive. Despite our compliance efforts and activities we cannot assure compliance by our employees or representatives for which we may be held responsible, and any such violation could materially adversely affect our reputation, business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations related to &#8220;conflict minerals&#8221; may cause us to incur additional expenses and could limit the supply and increase the cost of certain metals used in manufacturing our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2012, the SEC adopted a rule requiring disclosures of specified minerals, known as conflict minerals, that are necessary to the functionality or production of products manufactured or contracted to be manufactured by U.S.-listed companies. The conflict minerals rule requires companies annually to diligence, disclose and report whether or not such minerals originate from the Democratic Republic of Congo and/or adjoining countries of Angola, Burundi, Central African Republic, the Republic of the Congo, Rwanda, South Sudan, Tanzania, Uganda, and Zambia. The rule could affect sourcing at competitive prices and availability in sufficient quantities of certain minerals, including gold and tin, which are necessary to the functionality of our products, including our TransCon hGH auto-injector. The number of suppliers who provide conflict-free minerals may be limited. In addition, there may be material costs associated with complying with the disclosure requirements, such as costs related to determining the source of certain minerals used in our products, as well as costs of possible changes to products, processes, or sources of supply as a consequence of such verification activities. Due to the depth and complexity of the supply chain, we may not be able to sufficiently verify the origins of the relevant minerals used in our products through the due diligence procedures that we implement or the information that we receive from our suppliers may be inaccurate or inadequate, which may harm our reputation or subject us to SEC enforcement risks. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as conflict-free, which could place us at a competitive disadvantage if we are unable to do so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to obtain regulatory approvals in non-U.S. jurisdictions would prevent us from marketing our products outside of the United States.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market our products outside of the United States, we, or any potential partner, must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our products. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed in these &#8220;Risk Factors&#8221;, as well as other risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, medicinal products can only be commercialized after obtaining a marketing authorisation. For additional information, see &#8220;Item 4 B. Information on the Company - Business Overview - Foreign Regulation.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the U.S. and the EU, approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA or EU approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA, EC, or EU member state competent authorities does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA, EC, or EU member states competent authorities. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval, EC, or EU member states competent authority. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in any market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to healthcare laws, regulation and enforcement; our failure to comply with these laws could harm our results of operations and financial conditions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to healthcare, statutory and regulatory requirements and enforcement by the U.S. federal government and the states and foreign governments in which we conduct our business. The laws that affect our ability to operate include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under U.S. federal healthcare programs such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows, or should know, it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives) and teaching hospitals, and ownership and investment interests held by physicians (as defined under statute) and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state law equivalents of each of the above U.S. federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European and other foreign law equivalents of each of the laws, including regulation regarding advertising of medicinal products and reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our activities being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to significant penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in U.S. federal and state and/or foreign healthcare programs and imprisonment, any of which could adversely affect our ability to market our products and adversely impact our financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention and security of personal data, such as information that we may collect in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. Complying with these numerous, complex and often changing regulations is expensive and difficult, and any failure or perceived failure to comply with any data privacy laws or security laws, our policies and procedures, our contracts governing our processing of personal information or any security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive or confidential patient or consumer information, whether by us, one of our partners or another third-party, could adversely affect our business, financial condition and results of operations, and could result in negative publicity, government investigations and enforcement actions, claims by third-parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, California enacted the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the &#8220;CCPA&#8221;), requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information, (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information, and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Additional compliance investment and potential business process changes may be required. Similar laws have passed in other states, and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the Federal Trade Commission (&#8220;FTC&#8221;), has authority to initiate enforcement actions against entities that make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5(a) of the FTC Act. Even when HIPAA or a state law does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair and/or deceptive acts or practices in violation of Section 5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Additionally, federal and state consumer protection laws are increasingly being applied by FTC and states&#8217; attorneys general to regulate the collection, use, storage, and disclosure of personal or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, the General Data Protection Regulation (&#8220;GDPR&#8221;), imposes comprehensive data privacy compliance obligations in relation to our processing of personal data of individuals within the European Economic Area, or EEA, including clinical trial data, or in the context of our activities within the EEA, including a principle of accountability and the obligation to demonstrate compliance through policies, procedures, training and audit, as well as regulating cross-border transfers of personal data out of the EEA and the UK. If we do not comply with our obligations under the GDPR, we could be exposed to fines of up to the greater of &#8364;20 million or up to 4% of our total global annual revenue in the event of a significant breach. In addition, we may be the subject of litigation and/or adverse publicity, which could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the European Economic Area, or the EEA, and the United States remains uncertain. Case law from the Court of Justice of the European Union, or CJEU, states that reliance on the standard contractual clauses - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. In relation to data transfers from the EEA to the United States, the EU-US Data Privacy Framework (&#8220;DPF&#8221;), was approved by the European Commission in July 2023 as an effective EU GDPR data transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the European Commission approval of the current DPF to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Relatedly, from January 1, 2021, companies have had to comply with both the GDPR and the UK GDPR, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a UK GDPR data transfer mechanism to U.S. entities self-certified under the UK Extension to the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Council of the European Union adopted the NIS2 Directive on November 28, 2022, which replaced and repealed the existing EU Directive on the Security of Network and Information Systems. The NIS2 Directive establishes cybersecurity risk management measures and reporting requirements for highly critical sectors, including for manufacturers of medical devices. This includes requirements to implement appropriate technical and operational measures to manage security risks, including measures with respect to business continuity, incident handling, encryption, and data access control. Important entities and essential entities will also be required to report cybersecurity incidents within specified timeframes. The NIS2 Directive became effective on January 16, 2023, with EU member states having until October 17, 2024 to then incorporate the NIS2 Directive into their national law, although, as of this date, national transposition legislation has only been fully adopted in a limited number of countries. The NIS2 Directive requires EU member states to impose administrative fines for breaches of the NIS2 Directive of up to &#8364;7 million or 1.4% of the total worldwide turnover of the entity for the preceding financial year, whichever is greater for certain &#8220;important entities&#8221;. Other entities, considered &#8220;essential entities&#8221; may be subject to administrative fines for breaches of the NIS2 Directive of up to &#8364;10 million or 2% of the total worldwide turnover of the entity for the preceding financial year, whichever is greater.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation and adversely affect our business and results of operations. Further, we cannot assure you that our third-party service providers with access to our or our customers&#8217;, suppliers&#8217;, trial patients&#8217;, and employees&#8217; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations and financial condition. In addition, if our practices are not consistent, or viewed as not consistent, with legal and regulatory requirements, including changes in laws, regulations and standards or new interpretations or applications of existing laws, regulations and standards, we may also become subject to audits, inquiries, whistleblower complaints, adverse media coverage, investigations, criminal or civil sanctions, all of which may harm our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legislative or regulatory healthcare reforms in the United States and in foreign jurisdictions may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates in the United States and in foreign jurisdictions and to produce, market and distribute our products in the United States and in foreign jurisdictions after clearance or approval is obtained.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, legislation is drafted and introduced in U.S. Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business. Similar risks exist in foreign jurisdictions. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional clinical trials to be conducted prior to obtaining approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to manufacturing methods; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall, replacement, or discontinuance of one or more of our products; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional record keeping. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of these would likely entail substantial time and cost and could harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the trend toward managed healthcare in the United States and the changes in health insurance programs, as well as legislative proposals to reform healthcare or reduce government insurance programs, may result in lower prices for pharmaceutical products, including any products that may be offered by us. In addition, any future regulatory change regarding the healthcare industry or third-party coverage and reimbursement may affect demand for any products that we may develop and could harm our sales and profitability. For example, in the United States, the ACA was enacted in 2010 with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, established annual fees and taxes on manufacturers of certain branded prescription drugs and medical devices, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts, which, through subsequent legislative amendments, was increased to 70%, starting in 2019, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been judicial, executive and Congressional challenges to certain provisions of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted, including reductions in Medicare payments to providers, which went into effect on April 1, 2013 and will stay in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several types of providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, in March 2021, the American Rescue Plan Act of 2021 was signed into law, which, among other things, eliminated the statutory cap on drug manufacturers&#8217; Medicaid Drug Rebate Program rebate liability effective January 1, 2024. The rebate was previously capped at 100% of the average manufacturer price for a covered outpatient drug. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently, there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Most recently, in August 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;), to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated, and the impact of the IRA on our business and the pharmaceutical industry cannot yet be fully determined. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including through constraints on reimbursement, imposition of mandatory discounts, discounts, restrictions on access to certain products, transparency measures, and programs for importation from other countries or bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional U.S. local and national healthcare reform measures will be adopted within and outside the United States in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our products or product candidates or additional pricing pressures. The continuing efforts of the U.S. government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, including TransCon hGH, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, similar developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;), amending Directive 2011/24/EU, was adopted. While the Regulation entered into force in January 2022, it will only begin to apply from January 12, 2025, onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our intellectual property related to our products and product candidates is not adequate, we may not be able to compete effectively in our market.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our ability to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">protect our trade secrets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">apply for, obtain, maintain and enforce patents; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operate without infringing upon the proprietary rights of others. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will be able to protect our proprietary technologies from unauthorized use by third-parties only to the extent that such proprietary rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. Any non-confidential disclosure to or misappropriation by third-parties of our confidential or proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Where we elect to pursue patent protection on our proprietary technologies, we file, prosecute and maintain international and other national patent applications covering such technologies, including in the United States, Europe, China, and other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, 62 patents have been issued to us in the United States, 21 of which are directed to our TransCon technologies, nine of which are directed to TransCon hGH, ten of which are directed to TransCon CNP, one of which is directed to a combination of TransCon hGH and TransCon CNP, six of which are directed to TransCon PTH, one of which is directed to TransCon IL-2 &#946;/&#947; and twelve of which are directed to the TransCon hGH autoinjector. In addition, as of December 31, 2024, we have over 365 issued patents in jurisdictions outside of the United States, at least 87 of which are directed to our TransCon technologies, and 182 of which are directed to TransCon hGH and/or our other product candidates. For additional information, see &#8220;Item 4 B. Information on the Company - Business Overview - Intellectual Property.&#8221; We are not aware of any challenge to our issued patents, in the United States, Europe or in any other jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current licensors, or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims or inventorship, although we are unaware of any such defects. If we or our current licensors or licensees, or any future licensors or licensees, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our current licensors or licensees, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of our patents or patent applications, such patents or patent applications may be invalid and unenforceable. Any of these outcomes could impair our ability to prevent competition from third-parties, which may harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 1, 2023, the European Unitary Patent system and the European Unified Patent Court (&#8220;UPC&#8221;), were successfully launched, creating a single pan-European Unitary Patent and a new European patent court for litigation involving European patents. European patent applications now have the option, upon grant of a patent, of becoming a Unitary Patent which is subject to the jurisdiction of the UPC. In addition, conventional European patents, both already granted at the time the new system began and granted thereafter, are subject to the jurisdiction of the UPC, unless actively opted out. This is a significant change to European patent practice and deciding whether to opt-in or opt-out of Unitary Patent practice entail strategic and cost considerations. It will be several years before we will understand the scope of patent rights that are recognized and the strength of patent remedies that are provided by the UPC. While we have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, doing so may preclude us from realizing the benefits of the UPC. We have opted our current European patents out of the UPC, but if we do not meet all of the formalities and requirements for opting our patents out of the UPC, our current or future European patents could remain under the jurisdiction of the UPC. The UPC provides our competitors with a new forum to centrally revoke our European patents, and allows for the possibility of a competitor to obtain pan-European injunctions. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations. It is uncertain how the UPC will impact granted European patents in the biotechnology and pharmaceutical industries and our European patent applications, if issued, could be challenged in the UPC. Moreover, the decision whether to opt-in or opt-out of Unitary Patent status will require coordinating with co-applicants, if any, adding complexity to any such decision.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be highly uncertain. The patent applications that we own or license may fail to result in issued patents in the United States or in other countries. Even if patents do issue on such patent applications, third-parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. For example, U.S. patents can be challenged by any person before the USPTO Patent Trial and Appeals Board at any time within the one-year period following that person&#8217;s receipt of an allegation of infringement of the patents. Patents granted by the European Patent Office may be similarly opposed by any person within nine months from the publication of the grant. Similar proceedings are available in other jurisdictions, and in the United States, Europe and other jurisdictions third-parties can raise questions of validity with a patent office even before a patent has been granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. For example, a third-party may develop a competitive product that provides therapeutic benefits similar to one or more of our products or product candidates but that has a different composition that falls outside the scope of our patent protection. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to our products or product candidates is successfully challenged, then our ability to commercialize our products or product candidates could be negatively affected, and we may face unexpected competition that could harm our business. Further, patents have a limited lifespan and patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date excluding U.S. provisional patent applications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. If we encounter delays in our clinical trials, the period of time during which we could market our products or product candidates, if approved, under patent protection would be reduced. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, geo-political actions in the U.S. and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the U.S. and foreign government actions related to Russia&#8217;s conflict in Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the U.S. without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection of our proprietary rights is uncertain. Patent protection may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we might not have been the first to invent or the first to file the inventions covered by each of our pending patent applications and issued patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any patents we obtain or our in-licensed issued patents may not encompass commercially viable products or product candidates, may not provide us with any competitive advantages or may be challenged by third-parties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any patents we obtain or our in-licensed issued patents may not be valid or enforceable, or the scope may be narrowed; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our current licensors or licensees, or any future licensors or licensees, fail to prosecute, maintain and enforce patent protection for our products or product candidates, our ability to develop and commercialize our products or product candidates could be harmed and we might not be able to prevent competitors from making, using, selling, importing or otherwise exploiting competing products or product candidates. This failure to properly protect the intellectual property rights relating to our products or product candidates could harm our business, financial condition and operating results. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how on their own without relying on our proprietary technologies or information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even where laws provide protection, litigation or any other dispute resolution proceedings necessary to enforce and determine the scope of our proprietary rights may be costly and time-consuming, and the outcome of such litigation or dispute resolution proceedings would be uncertain. If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our products or product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Patents may be unenforceable if someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcomes of proceedings involving assertions of invalidity and unenforceability are unpredictable. It is possible that prior art of which we and the patent examiner were unaware during prosecution exists, which would render our patents invalid. Moreover, it is also possible that prior art may exist that we are aware of, but that we do not believe are relevant to our current or future patents, that could nevertheless be determined to render our patents invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability of our patents covering our products or product candidates, we would lose at least part, and perhaps all, of the patent protection on such product or product candidate. Such a loss of patent protection would harm our business. Moreover, our competitors could counterclaim in any suit to enforce our patents that we infringe their intellectual property. Furthermore, some of our competitors have substantially greater intellectual property portfolios, and resources, than we do.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We license intellectual property rights from third-parties. Such licenses may be subject to early termination if we fail to comply with our obligations in our licenses with third-parties, which could result in the loss of rights or technology that are material to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are or may become a party to licenses that give us rights to third-party intellectual property or technology that is necessary or useful for our business, and we may enter into additional licenses in the future. Under these license agreements, we are or may become obligated to pay the licensor fees, which may include annual license fees, milestone payments, royalties, a percentage of revenues associated with the licensed technology and a percentage of sublicensing revenue. These fees may be significant, which could make it difficult for us to achieve or maintain profitability. In addition, under certain of such agreements, we are or may become required to diligently pursue the development of products or product candidates using the licensed technology. If we fail to comply with these obligations, including due to the impact of global pandemics, on our business operations or our use of the intellectual property licensed to us in an unauthorized manner, and fail to cure our breach within a specified period of time, the licensor may have the right to terminate the applicable license, in which event we could lose valuable rights and technology that are material to our business, harming our ability to develop, manufacture and/or commercialize our platform, products or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the agreements under which we license intellectual property or technology to or from third-parties can be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our products or product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional products or product candidates that we may seek to acquire. The failure to obtain or in-license any compositions, methods of use, processes or other third-party intellectual property rights at a reasonable cost or on reasonable terms, could harm our business. If we fail to obtain licenses to necessary third-party intellectual property rights, we may need to cease use of the compositions or methods covered by such third-party intellectual property rights. Furthermore, we may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to prevent disclosure of our trade secrets or other confidential information to third-parties, our competitive position may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patents, we rely on trade secrets and proprietary know-how. We seek protection, in part, through confidentiality and proprietary information clauses in agreements with our collaboration partners, employees, consultants, outside scientific collaboration partners and sponsored researchers and other advisors. Although we generally require all of our employees, consultants, advisors and any third-parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, and endeavor to execute confidentiality agreements with all such parties, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property or who had access to our proprietary information, nor can we be certain that our agreements with such parties will not be breached. These agreements may not effectively prevent disclosure of confidential and proprietary information and may not provide an adequate remedy in the event of unauthorized use or disclosure of confidential and proprietary information. We cannot guarantee that our trade secrets and other confidential proprietary information will not be publicly disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. We may need to share our proprietary information, including trade secrets, with our current and future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. The failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are sued for allegedly infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in such litigation could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends significantly on our ability to operate without infringing, violating or misappropriating the patents and other proprietary rights of third-parties. Our own technologies, products or product candidates may be found to infringe, violate or misappropriate the patents or other proprietary rights of third-parties, or we may be subject to third-party claims of such infringement. Numerous U.S. and foreign issued patents and pending patent applications owned by third-parties exist in the fields in which we are developing our products and product candidates. Additionally, we are aware of patents owned by a competitor that are related to CNP variants. In particular, BioMarin owns a patent in Europe relating to CNP variants, against which we filed an opposition in September 2022. At first instance, BioMarin was required to restrict the scope of their patent claims. Both parties have appealed the first instance decision with oral proceedings on appeal scheduled to take place in the fourth quarter of 2025. Further, BioMarin has alleged that the same European patent, expiring May 2030, is infringed by our &#8220;development program&#8221; relating to TransCon CNP, and has initiated infringement proceedings before the UPC. We have not received the documents filed by BioMarin before the UPC at the time of the filing of this Annual Report on Form 20-F. We believe that this patent is invalid and not infringed by us. However, should the UPC decide in favor of BioMarin, such a decision could harm our ability to bring TransCon CNP to patients, prior to patent expiration. There is a risk that BioMarin will allege patent infringement in other jurisdictions and before other courts. Furthermore, BioMarin also owns a re-issue patent in the U.S. relating to CNP variants. Although we believe that this patent is not infringed by us and/or is invalid, it is possible that a court or other form of tribunal would come to a different conclusion. We thus cannot be certain that our technologies, products and product candidates will not be found to infringe these or other existing or future patents of third-parties. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending patent application may be incorrect, which may negatively impact our ability to market our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, import or sale of our technologies, products or product candidates. We may not be aware of patents that have already been issued that a third-party might assert are infringed by our technologies, products or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that patents of which we are aware, but which we do not believe are relevant to our technologies, products or product candidates, could nevertheless be found to be infringed by our products or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may face costly and time-consuming intellectual property litigation with the NDA holders, BLA holders and Orange Book patentees of the products in respect of which we seek to obtain FDA approval. Companies that produce branded biopharmaceutical products for which there are listed patents in the FDA&#8217;s Orange Book routinely bring patent infringement litigation against applicants seeking FDA approval to manufacture and market branded and/or generic forms of their products. Accordingly, we may face patent litigation as a result of our submission of NDA and BLA applications to the FDA or as a result of submitting an MAA with the EMA.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property litigation involves many risks and uncertainties, and there is no assurance that we will prevail in any lawsuit brought against us. Third-parties making claims against us for infringement, violation or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our products and product candidates. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Defense of these claims, regardless of their merit, would cause us to incur substantial expenses and would be a substantial diversion of resources from our business. In the event of a successful claim of any such infringement, violation or misappropriation, we may need to obtain licenses from such third-parties and we may be prevented from pursuing product or product candidate development or commercialization and/or may be required to pay damages. We cannot be certain that any licenses required under such patents or proprietary rights would be made available to us, or that any offer to license would be made available to us on commercially reasonable terms. If we cannot obtain such licenses, we may be restricted or prevented from manufacturing and selling products employing our technologies. These adverse results, if they occur, could adversely affect our business, results of operations and prospects, and the value of our shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries have been characterized by extensive litigation regarding patents and other intellectual property rights. The defense and prosecution of contractual or intellectual property lawsuits, USPTO interference or derivation proceedings, European Patent Office oppositions and related legal and administrative proceedings in the United States, Europe and other countries, involve complex legal and factual questions. As a result, such proceedings may be costly and time-consuming to pursue and their outcome is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation may be necessary to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">protect and enforce our patents and any future patents issuing on our patent applications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforce or clarify the terms of the licenses we have granted or may be granted in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">protect and enforce trade secrets, know-how and other proprietary rights that we own or have licensed, or may license in the future; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine the enforceability, scope and validity of the proprietary rights of third-parties and defend against alleged patent infringement. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our intellectual property. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings and some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent or other intellectual property litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or amended such that they do not cover our product candidates. Moreover, such adverse determinations could put our patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope to cover our products or product candidates or to prevent others from marketing similar products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interference, derivation or other proceedings brought at the USPTO, may be necessary to determine the priority or patentability of inventions with respect to our patent applications or those of our licensors or potential collaboration partners. Litigation or USPTO proceedings brought by us may fail or may be invoked against us by third-parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management and scientific personnel. We may not be able, alone or with our licensors or potential collaboration partners, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In addition, during the course of this kind of litigation or this kind of proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for the ADSs could be significantly harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technologies, products and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (&#8220;Leahy-Smith Act&#8221;), signed into law on September 16, 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications filed after March 16, 2013, are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a &#8220;first to file&#8221; system. The Leahy-Smith Act could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technologies or our ability to enforce our proprietary technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since June 1, 2023, European patent applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. For additional information, see &#8220;If our intellectual property related to our products and product candidates is not adequate, we may not be able to compete effectively in our market.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain of our employees and patents are subject to German law.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, over 100 of our employees work in Germany and are subject to German employment law. Ideas, developments, discoveries and inventions made by such employees are generally subject to the provisions of the German Act on Employees&#8217; Inventions, which regulates the ownership of, and compensation for, inventions made by employees. Under this act, we face the risk that we may be required to pay additional compensation for assigned patent rights and disputes can occur between us and our employees or ex-employees pertaining to alleged non-adherence to the provisions of this act that may be costly to defend and consume our management&#8217;s time and efforts whether we prevail or fail in such dispute. In addition, under the German Act on Employees&#8217; Inventions, certain employees may have retained rights to patents they invented or co-invented before October 2009. Although substantially all of these employees have assigned their interest in these patents to us, to the extent permitted by law, there is a risk that the compensation we provided to them may be deemed to be insufficient and we may be required under German law to increase the compensation due to such employees for the use of the patents. In those cases, where employees have not assigned their interests to us, we may need to pay compensation for the use of those patents. If we are required to pay additional compensation or face other disputes under the German Act on Employees&#8217; Inventions, our results of operations could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The USPTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Although an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Losing our patent rights could enable competitors to enter the market earlier than would otherwise have been the case.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to secure trademark registrations for a commercial trade name for our products or product candidates in the United States or elsewhere could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use various trademark rights in our business, including, Ascendis, Ascendis Pharma, TransCon, SKYTROFA and YORVIPATH. Trademark applications for TransCon hGH, TransCon PTH and TransCon CNP have been filed in the U.S. as well as the EU and other countries across the globe. However, our current or future trademarks and trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks, and we may not be able to obtain trademark protection in other territories that we consider of significant importance to us. Furthermore, other than for TransCon hGH and TransCon PTH, we have not yet registered for a commercial trade name for any other of our product candidates in the United States or elsewhere. During trademark registration proceedings, our trademark applications may be rejected. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third-parties can oppose pending trademark applications and seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing our products under new brands. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third-parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has approved the use of SKYTROFA for TransCon hGH and YORVIPATH for TransCon PTH in the United States; however, any name we propose to use with TransCon CNP, or our other product candidates in the United States or any other country must be approved by the FDA, EMA or any other relevant health authority regardless of whether we have registered it, or applied to register it, as a trademark. For example, the FDA has approved the use of SKYTROFA and YORVIPATH for certain indications in the United States and the EC has granted marketing authorisations for SKYTROFA and YORVIPATH in the EU. The FDA as well as EMA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA, EMA or any other relevant approval authority objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third-parties and be acceptable to the FDA, EMA or any other relevant approval authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to enforce our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents are of national or regional effect, and filing, prosecuting and defending patents on our products or product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. For example, patents with claims directed to dry pharmaceutical formulations of TransCon hGH have issued in the United States, Europe, and other jurisdictions, but related claims were rejected in China, and our subsequent appeals were unsuccessful. As a result, our patent protection for TransCon hGH may expire sooner in China than in other jurisdictions. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including India, China and certain developing countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights in such countries. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third-parties. Consequently, we may not be able to prevent third-parties from practicing our inventions in certain countries outside the United States and many countries in Europe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and product candidates and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These products and product candidates may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products and product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that we or our employees have misappropriated the intellectual property, including know-how or trade secrets, of a third-party, or claiming ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we have wrongfully hired an employee from a competitor or that we or these employees, consultants and contractors have used or disclosed such third-party intellectual property, including know-how, trade secrets or other proprietary information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims that former employees, collaborators, or other third-parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third-parties involved in developing our products or product candidates or as a result of questions regarding co-ownership of potential joint inventions. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our products or product candidates. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may have relied on third-party consultants or collaborators or on funds from third-parties, such as national governments, such that we or our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third-parties have ownership rights or other rights to our patents, including in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products, product candidates and technologies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Indebtedness</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations, and impair our ability to satisfy our obligations under the Convertible Notes.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had $575 million principal amount of indebtedness as a result of the 2.25% Convertible Senior Notes due 2028 (&#8220;Convertible Notes&#8221;) offering. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our shareholders and our business, results of operations, and financial condition by, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increasing our vulnerability to adverse economic and industry conditions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limiting our ability to obtain additional financing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limiting our flexibility to plan for, or react to, changes in our business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diluting the interests of our existing shareholders as a result of issuing ADSs upon conversion of the Convertible Notes and the ordinary shares represented by such ADSs; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the Convertible Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under our indebtedness, including the Convertible Notes, and our cash needs may increase in the future. In addition, future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to raise the funds necessary to redeem the Convertible Notes for cash following a fundamental change, and our future indebtedness may limit our ability to redeem the Convertible Notes in connection with such fundamental change.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of the Convertible Notes may, subject to a limited exception described in the indenture, require us to redeem their Convertible Notes following a fundamental change under the indenture at a cash fundamental change redemption price generally equal to the principal amount of the Convertible Notes to be redeemed in connection with such fundamental change, plus accrued and unpaid interest, if any. We may not have enough available cash or be able to obtain financing at the time we are required to redeem the Convertible Notes in connection with a fundamental change. In addition, applicable law, regulatory authorities and the agreements governing our other indebtedness may restrict our ability to redeem the Convertible Notes in connection with a fundamental change. Our failure to redeem Convertible Notes in connection with a fundamental change when required will constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our other consolidated indebtedness (if any), which may result in that other indebtedness becoming immediately payable in full. If the repayment of such other indebtedness were to be accelerated after any applicable notice or grace periods, then we may not have sufficient funds to repay that indebtedness and redeem the Convertible Notes in connection with such fundamental change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in the indenture could delay or prevent an otherwise beneficial takeover of us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain provisions in the Convertible Notes and the indenture could make a third party attempt to acquire us more difficult or expensive. For example, a takeover will under certain circumstances constitute a fundamental change, and the noteholders will then have the right to require us to redeem their Convertible Notes for cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if a takeover constitutes a make-whole fundamental change, then we may be required to temporarily increase the conversion rate. In either case, and in other cases, our obligations under the Convertible Notes and the indenture could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management, including in a transaction that noteholders or holders of the ADSs or our ordinary shares may view as favorable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accounting method for the Convertible Notes could adversely affect our reported financial condition and results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Convertible Notes are treated as a compound financial instrument with a foreign currency financial liability component (&#8220;host&#8221;), and an embedded derivative (&#8220;derivative&#8221;) related to a written option to exchange a fixed number of our shares for a fixed amount of Convertible Notes that is denominated in a foreign currency. The derivative is not closely related to the host, because it is exposed to dissimilar risks, such as volatility from the Company&#8217;s own share price. Accordingly, the derivative is accounted for separately at fair value through profit or loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The initial fair value of the host was the residual amount after separating the embedded derivative at fair value, net of transaction costs attributable to the host component. Transaction costs were allocated to the host and the derivative in proportion to the allocation of proceeds. Transaction costs attributable to the derivative were recognized immediately in the profit or loss as a financial expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The difference between the principal amount of the Convertible Notes and the initial fair value of the host is amortized into interest expense over the expected lifetime of the Convertible Notes using the effective interest method. As a result of this amortization, the interest expense that we expect to recognize for the Convertible Notes for accounting purposes will be greater than the cash interest payments we will pay on the Convertible Notes, which will result in lower reported income or higher reported loss. The lower reported income or higher reported loss resulting from this accounting treatment could depress the trading price of our common stock and the Convertible Notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the derivative cannot be measured based on quoted prices in active markets, or other observable input, and accordingly, the derivative is measured by using the Black-Scholes option-pricing model, where the pricing is exposed from changes in the Company&#8217;s share price. Since the fair value is exposed to development in the Company&#8217;s share price, the profit or loss is exposed to volatility from such development, which could result in lower reported income or higher reported loss. The lower reported income or higher reported loss resulting from this accounting treatment could have a negative effect on the trading price of the ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the accounting method for reflecting the ordinary shares represented by ADSs underlying the Convertible Notes in our diluted earnings per share may adversely affect our reported earnings and financial condition. We expect that, under applicable accounting principles, the ordinary shares represented by ADSs underlying the Convertible Notes will be reflected in our diluted earnings per share assuming that all the Convertible Notes were converted into ADSs at the beginning of the reporting period (or, if later, the date the Convertible Notes are first issued), unless the result would be antidilutive. Accounting for the Convertible Notes in this manner may reduce our diluted earnings per share.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Ordinary Shares and ADSs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The price of the ADSs may be volatile and the holders of the ADSs may not be able to resell ADSs at or above the price they paid.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of the ADSs has been and could continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to commercialize or obtain regulatory approval for our products or product candidates, or delays in commercializing or obtaining regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results from, or any delays in, clinical trial programs relating to our products or product candidates; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to apply our TransCon technologies to therapeutic areas other than endocrinology, including the therapeutic areas of oncology and ophthalmology;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of regulatory approval or a complete response letter to our product candidates, or specific label indications or patient populations for use, or changes or delays in the regulatory review process; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements relating to current or future collaborations or joint ventures; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of therapeutic innovations or new products by us or our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements regarding the parent drugs that we use in developing our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse actions taken by regulatory authorities with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes or developments in laws or regulations applicable to our products or product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any adverse changes to our relationship with any manufacturers or suppliers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of our testing and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of our efforts to acquire, license or discover additional products or product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any intellectual property infringement actions in which we may become involved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements concerning our competitors or the pharmaceutical industry in general; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achievement of expected product sales and profitability; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacture, supply or distribution shortages; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated fluctuations in our operating results; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMA, FDA or other similar regulatory actions affecting us or our industry or other healthcare reform measures in the EU, United States or in other markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in financial estimates or recommendations by securities analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of the ADSs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales or purchases of ordinary shares and/or ADSs by us, our senior management and board members, holders of the ADSs or our shareholders in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic and market conditions and overall fluctuations in the United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation and hostilities between Russia and Ukraine and between Israel and Hamas; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effects on our business, operating results, prospects and financial condition of potential future pandemics such as COVID-19; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the loss of any of our key scientific or senior management personnel. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of ADSs. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of the holders of ordinary shares or ADSs were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our senior management would be diverted from the operation of our business, which could seriously harm our financial position. Any adverse determination in litigation could also subject us to significant liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ADS holders do not directly hold our ordinary shares and do not have the rights of a holder of our ordinary shares.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Danish law governs shareholder rights. Our depositary, The Bank of New York Mellon, is the holder of the ordinary shares underlying our ADSs through its custodian. The deposit agreement among us, the depositary, and all other persons directly and indirectly holding ADSs, sets out ADS holder rights as well as the rights and obligations of the depositary. In addition, our depositary charges and/or deducts certain fees to holders of the ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ADS holders may not be able to exercise their right to vote the ordinary shares underlying their ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions of the deposit agreement and not as a direct shareholder in the Company. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (1) the notice of the meeting or solicitation of consent or proxy sent by us and (2) a statement as to the manner in which instructions may be given by the holders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, we may not request the depositary to distribute this information which could effectively limit the ability of ADS holders to direct voting of the ordinary shares underlying their ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADS holders may instruct the depositary of their ADSs to vote the ordinary shares underlying their ADSs. Otherwise, ADS holders are not able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, they may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for instructions from ADS holders, the depositary, upon timely notice from us, will notify the ADS holders of the upcoming vote and arrange to deliver our voting materials to the ADS holders. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that such holders can instruct the depositary to vote the ordinary shares underlying their ADSs or to withdraw the ordinary shares underlying their ADSs so that they can vote such shares directly. If the depositary does not receive timely voting instructions from an ADS holder, the depositary may give a proxy to a person designated by us to vote the ordinary shares underlying ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that ADS holders may not be able to exercise any right to vote, and there may be nothing an ADS holder can do if the ordinary shares underlying their ADSs are not voted as they requested.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">An ADS holder may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADSs, which may be evidenced by American Depositary Receipts, are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason subject to an ADS holders&#8217; right to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting or we are paying a dividend on our ordinary shares. In addition, an ADS holder may not be able to cancel their ADSs and withdraw the underlying ordinary shares when such holder owes money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we issue shares or ADSs in future financings, shareholders or holders of ADSs may experience immediate dilution and, as a result, the price of our ADSs may decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may from time to time issue additional shares or ADSs at a discount from the trading price of the ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, our shareholders and holders of ADSs would experience immediate dilution upon the issuance of ADSs at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preference shares, ADSs or ordinary shares. If we issue shares or securities convertible into shares of our share capital, our ordinary shareholders and holders of ADSs would experience additional dilution and, as a result, the price of the ADSs may decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You may experience future dilution as a result of exercise or conversion of warrants, RSUs, PSUs and convertible notes.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, approximately 12.9 million ordinary shares that are subject to outstanding warrants, RSUs, PSUs, convertible notes or reserved for future issuance under our warrant incentive program are eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and the terms of our convertible notes. Exercise or conversion of warrants and convertible notes may take place at a price below the market price of the ADSs at the time of exercise and may therefore result in dilution of the value of the ADSs. In addition, to the extent that RSUs or PSUs settle into ADSs, we would also issue to the holders of such RSUs or PSUs ADSs held by us.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a substantial number of our ordinary shares or ADSs in the public market could cause the price of the ADSs to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our existing shareholders or holders of ADSs sell, or indicate an intention to sell, substantial amounts of our ordinary shares or ADSs representing our ordinary shares in the public market, the trading price of the ADSs could decline. If our outstanding warrants are exercised or ADSs subject to restricted stock units and performance stock units vest and settle, additional ordinary shares or ADSs may become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act. If these additional ordinary shares or ADSs are sold, or if it is perceived that they will be sold, in the public market, the trading price of the ADSs could decline. Any sales of securities by these security holders could have a negative effect on the trading price of the ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal shareholders and senior management own a significant percentage of our shares and are able to exert significant control over matters subject to shareholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our senior management, board members, holders of 5% or more of our share capital and their respective affiliates beneficially own approximately 60.0% of our outstanding voting securities. See &#8220;Item 7 A. Major Shareholders and Related Party Transactions &#8211; Major Shareholders&#8221; for information relating to the determination of the number of shares beneficially owned by an entity or a person. As a result, these security holders have the ability either alone or voting together as a group to determine and/or significantly influence the outcome of matters submitted to our shareholders for approval, including the election and removal of board members, payment of dividends, amendments to our articles of association, including changes to our share capital or any mergers, demergers, liquidations and similar transactions. This may prevent or discourage unsolicited acquisition proposals or offers for our ordinary shares or ADSs that our shareholders or ADS holders may feel are in their best interest as a shareholder or holder of ADSs. In addition, this group of shareholders may have the ability to control our management and affairs. Such control and concentration of ownership may affect the market price of the ADSs and may discourage certain types of transactions, including those involving actual or potential change of control of us (whether through merger, consolidation, take-over or other business combination), which might otherwise have a positive effect on the market price of the ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate affairs are governed by our articles of association and by the laws governing companies incorporated in Denmark, including the Danish Companies Act. The rights of shareholders and the responsibilities of members of our board of directors may be different from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our board of directors is required by Danish law to consider the interests of our company, its shareholders and its creditors. It is possible that some of these parties will have interests that are different from, or in addition to, the interests of our shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims of U.S. civil liabilities may not be enforceable against us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are incorporated under the laws of Denmark. Substantially all of our assets are located outside the United States. A significant portion of our board members and employees reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce against them or us in U.S. courts, including judgements predicated upon the civil liability provisions of the U.S. securities laws of the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States and Denmark currently do not have a treaty providing for the reciprocal recognition and enforcement of judgements, other than arbitration awards, in civil and commercial matters. Consequently, a final judgement for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in Denmark. Danish courts are likely to deny the recognition and enforcement of punitive damages or other awards. Moreover, a Danish court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate for actual losses or damages. Enforcement and recognition of judgements of U.S. courts in Denmark are solely governed by the provisions of the Danish Administration of Justice Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the lack of a treaty as described above, U.S. investors may not be able to enforce against us or members of our board of directors, our executive board, our senior management or certain experts named herein who are residents of Denmark or countries other than the United States any judgements obtained in U.S. courts in civil and commercial matters, including judgements under the U.S. federal securities laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As a foreign private issuer, we are not subject to U.S. proxy rules and are not subject to certain Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We report under the Exchange Act, as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although we are subject to Danish laws and regulations with regard to such matters and intend to furnish quarterly financial information to the SEC, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i) the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii) the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iii) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until four months after the end of each fiscal year, while U.S. domestic issuers that are large accelerated filers are required to file their annual report on Form 10-K within 60 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, our shareholders and the holders of the ADS may not have the same protections afforded to shareholders of companies that are not foreign private issuers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our status as a &#8220;foreign private issuer&#8221; allows us to adopt IFRS accounting principles, which are different from accounting principles under U.S. Generally Accepted Accounting Principles (&#8220;US GAAP&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted and presented our consolidated financial statements in accordance with IFRS as issued by the International Accounting Standards Board and as adopted by the EU. IFRS is an internationally recognized body of accounting principles that are used by many companies outside of the United States to prepare their financial statements; and the SEC permits foreign private issuers such as our company to prepare and file their financial statements in accordance with IFRS rather than U.S. GAAP. IFRS accounting principles are different from those of U.S. GAAP, and SEC rules do not require us to provide a reconciliation of IFRS accounting principles to those of U.S. GAAP. Investors who are not familiar with IFRS may misunderstand certain information presented in our consolidated financial statements. Accordingly, we suggest that readers of our consolidated financial statements familiarize themselves with the provisions of IFRS accounting principles to better understand the differences between these two sets of principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As a foreign private issuer and as permitted by the listing requirements of the Nasdaq Global Select Market, we rely on certain home country governance practices rather than the corporate governance requirements of The Nasdaq Global Select Market.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a foreign private issuer, in accordance with the listing requirements of the Nasdaq Global Select Market, we rely on home country governance requirements and certain exemptions thereunder rather than relying on the corporate governance requirements of the Nasdaq Global Select Market. For instance, the Listing Rules for The Nasdaq Stock Market (&#8220;Nasdaq Listing Rules&#8221;), for domestic U.S. issuers require listed companies to have, among other things, a majority of their board members be independent, and to have independent director oversight of executive compensation, nomination of board members and corporate governance matters. As a foreign private issuer, however, while we intend to comply with these requirements, we are permitted to follow home country practice in lieu of the above requirements. Danish law does not require that a majority of our board consist of independent directors or the implementation of a remuneration committee or nominating and corporate governance committee, and our board may thus in the future not include, or include fewer, independent directors than would be required if we were subject to the Nasdaq Listing Rules, or they may decide that it is in our interest not to have a remuneration committee or nominating and corporate governance committee, or have such committees governed by practices that would not comply with The Nasdaq Listing Rules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since a majority of our board of directors may not consist of independent directors, if we decide to rely on the foreign private issuer exemption to The Nasdaq Listing Rules, our board&#8217;s approach may, therefore, be different from that of a board with a majority of independent directors, and as a result, the management oversight of our company could, in the future, be more limited than if we were subject to The Nasdaq Listing Rules. We intend to follow home country practice with regard to, among other things, quorum requirements generally applicable to general meetings of shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, Danish law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in Denmark, thus our practice varies from the requirement of Nasdaq Listing Rule 5620(b). In addition, our shareholders have authorized our board of directors to issue securities including in connection with certain events such as the acquisition of shares or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us, rights issues at or below market price, certain private placements and issuance of convertible notes. To this extent, our practice varies from the requirements of Nasdaq Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. Accordingly, our shareholders and holders of the ADSs may not have the same protections afforded to shareholders of companies that are subject to these Nasdaq requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We qualify as a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We may no longer be a foreign private issuer as of June 30, 2025, which would require us to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers as of January 1, 2026. To maintain our current status as a foreign private issuer, either (a) a majority of our ordinary shares or ADSs must be either directly or indirectly owned of record by non-residents of the United States or (b) (i) a majority of our executive officers or directors may not be U.S. citizens or residents, (ii) more than 50% of our assets cannot be located in the United States and (iii) our business must not be administered principally inside the United States. If we lost this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors and members of our senior management.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently intend to pay any cash dividends on our ordinary shares for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, our shareholders and ADS holders are not likely to receive any dividends on their investment for the foreseeable future. Because we do not intend to pay dividends, our shareholders&#8217; and ADS holders&#8217; ability to receive a return on their investment will depend on any future appreciation in the market value of our ADSs. There is no guarantee that our ordinary shares or ADSs will appreciate or even maintain the price at which our holders have acquired them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors should be aware that the rights provided to our shareholders and holders of ADSs under Danish corporate law and our articles of association differ in certain respects from the rights that would typically be provided to a shareholder of a U.S. company under applicable U.S. federal and state laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Danish corporate law, except in certain limited circumstances (which require as a minimum that a proposal for inspection has been supported by a minimum of 25% of share capital), our shareholders may not ask for an inspection of our corporate records, while under Delaware corporate law any shareholder, irrespective of the size of such shareholder&#8217;s shareholdings, may do so. Shareholders of a Danish limited liability company are also unable to initiate a derivative action, a remedy typically available to shareholders of U.S. companies, to enforce a right of our company, in case we fail to enforce such right ourselves, other than in certain cases of board member or management liability under limited circumstances. In addition, a majority of our shareholders may release a board member or manager from any claim of liability we may have, including if such board member or manager has acted in bad faith or has breached his or her duty of loyalty and only if a minority of at least 10% of the shareholders represented at the relevant general meeting have opposed the decision, may a shareholder bring a derivative action on behalf of our company. In contrast, most U.S. federal and state laws prohibit a company or its shareholders from releasing a board member from liability altogether if such board member has acted in bad faith or has breached such board member&#8217;s duty of loyalty to our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, distribution of dividends from Danish companies to foreign companies and individuals may be subject to non-refundable withholding tax, which may not be creditable or deductible under the tax laws of the country in which the recipient shareholder is resident for tax purposes. Also, the rights as a creditor may not be as strong under Danish insolvency law, as under U.S. law or other insolvency law, and consequently creditors may recover less in the event our company is subject to insolvency compared to a similar case including a U.S. debtor. In addition, the use of the tax asset consisting of the accumulated tax deficit requires that we are able to generate positive taxable income and can be restricted by future amendments to Danish tax law. Further, repurchases of ordinary shares or ADSs by Ascendis Pharma A/S may have adverse tax consequences to the Company or shareholders under applicable Danish law. Finally, Danish corporate law may not provide appraisal rights in the case of a business combination equivalent to those generally afforded a shareholder of a U.S. company under applicable U.S. laws. As a result of these differences between Danish corporate law and our articles of association, on the one hand, and U.S. federal and state laws, on the other hand, in certain instances, shareholders and ADS holders could receive less protection as an equity holder of our company than they would as a shareholder of a U.S. company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Holders of our ordinary shares or ADSs may not be able to exercise their pre-emptive subscription rights and may suffer dilution of their equity holding in the event of future issuances of our shares.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Danish Companies Act, our shareholders benefit from a pre-emptive subscription right on the issuance of ordinary shares for cash consideration only and not in the event of issuance of shares against non-cash contribution or debt conversion. Even the shareholders&#8217; pre-emptive subscription rights in the event of issuances of shares against cash payment may be disapplied by a resolution of the shareholders at a general meeting of our shareholders and/or the shares or ADSs may be issued on the basis of an authorization granted to the board of directors pursuant to which the board may disapply the shareholders&#8217; pre-emptive subscription rights. Such shares or ADSs may be issued above, or at market value. In addition, a shareholder may not be able to exercise the shareholder&#8217;s pre-emptive right on a timely basis or at all, unless the shareholder complies with the Danish Companies Act and applicable laws in the jurisdiction in which the shareholder is resident. Furthermore, the use of pre-emptive subscription rights in relation to future capital increases in our company can be restricted for U.S. residents according to U.S. securities law. As a result, the shareholding or holding of ADSs of such shareholders or ADS holders may be materially diluted in the event shares or ADSs are issued in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares or ADSs may be issued at a discount to market price in rights offerings provided that the resolution is approved by two-thirds of the votes cast and the share capital represented at the general meeting and in these cases a restriction on the ability to exercise pre-emptive rights may materially dilute the value of the ordinary shares or ADSs held by the shareholder or ADS holder in question. Rights issues may also be carried out by the board of directors according to valid authorizations in our articles of association.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, ADS holders in the United States are not entitled to exercise or sell such pre-emptive subscription rights related to the ordinary shares, which they represent unless we register the pre-emptive subscription rights and the securities to which the pre-emptive subscription rights relate under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary will not make rights available to ADS holders unless the distribution to ADS holders or both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if we offer holders of our ordinary shares the option to receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the offer to holders of ADSs does not require registration of any securities under the Securities Act before making the option available to holders of ADSs. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case our shareholders and ADS holders will receive no value for these rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our ordinary shares or ADSs, the price of the ADSs and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for the ADSs may be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or performance of the ADSs, or if our commercial sales, clinical trials or operating results fail to meet the expectations of analysts, the price of the ADSs would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause the price of the ADSs or trading volume to decline.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be a &#8220;passive foreign investment company&#8221; for U.S. federal income tax purposes for our current taxable year and future taxable years, which could result in adverse U.S. federal income tax consequences to U.S. investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;), and U.S. Treasury Regulations, the determination of passive foreign investment company (&#8220;PFIC&#8221;), status is fact-specific, and generally cannot be made until after the close of the taxable year in question. Based on our market capitalization and the composition of our income, assets and operations, we do not believe we were a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2024. However, this is a factual determination, and the application of the PFIC rules is subject to uncertainty in several respects, and we cannot assure you we will not be a PFIC for any taxable year. A non-U.S. corporation will be considered a PFIC for any taxable year if, after the application of certain look-through rules, either (1) at least 75% of its gross income for such taxable year is passive income (as defined in the relevant provisions of the Code) or (2) at least 50% of the value of its assets (generally based on an average of the quarterly values of the assets) during such year is attributable to assets that produce or are held for the production of passive income. A separate determination must be made each taxable year as to whether we are a PFIC (after the close of each such taxable year). If we are a PFIC for any taxable year during which a U.S. Holder (as defined in &#8220;Item 10 E. Additional Information &#8211; Taxation &#8211; Material U.S. Federal Income Tax Consequences to U.S. Holders&#8221;) holds ordinary shares or ADSs, the U.S. Holder may be subject to adverse tax consequences, including (i) the treatment of all or a portion of any gain on disposition as ordinary income, (ii) the application of an interest charge with respect to such gain and certain dividends and (iii) compliance with certain reporting requirements. Although we do not believe we were a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2024, the application of the PFIC rules is subject to uncertainty in several respects. Whether we will be a PFIC in any year depends on the composition of our income and assets, and the relative fair market value of our assets from time to time, which we expect may vary substantially over time. In addition, because the value of our assets, including unbooked goodwill, for purposes of the asset test will generally be determined by reference to the market price of the ADSs, our PFIC status will depend in large part on the market price of the ADSs, which may fluctuate significantly. For these reasons, we cannot assure you we will not be a PFIC for any taxable year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each U.S. Holder is strongly urged to consult its tax advisor regarding these issues. See &#8220;Item 10 E. Additional Information &#8211; Taxation &#8211; Material U.S. Federal Income Tax Consequences to U.S. Holders.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If a United States person is treated as owning at least 10% of our ordinary shares or ADSs, such holder may be subject to adverse U.S. federal income tax consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a U.S. Holder (as defined in &#8220;Item 10 E. Additional Information &#8211; Taxation &#8211; Material U.S. Federal Income Tax Consequences to U.S. Holders&#8221;) is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary shares or ADSs, such U.S. Holder will be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group. Because our group includes one or more U.S. subsidiaries, certain of our non-U.S. subsidiaries will be treated as &#8220;controlled foreign corporations&#8221; (regardless of whether we are treated as a &#8220;controlled foreign corporation&#8221;). A &#8220;United States shareholder&#8221; of a &#8220;controlled foreign corporation&#8221; may be required to report annually and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by &#8220;controlled foreign corporations,&#8221; regardless of whether we make any distributions. Failure to comply with these reporting obligations may subject a &#8220;United States shareholder&#8221; to significant monetary penalties and may prevent the statute of limitations from starting with respect to such shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due. Further, an individual that is a &#8220;United States shareholder&#8221; with respect to a &#8220;controlled foreign corporation&#8221; generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a &#8220;United States shareholder&#8221; that is a U.S. corporation. We cannot provide any assurances that we will assist investors in determining whether any of our non-U.S. subsidiaries are treated as a &#8220;controlled foreign corporation&#8221; or whether such investor is treated as a &#8220;United States shareholder&#8221; with respect to any of such &#8220;controlled foreign corporations.&#8221; Further, we cannot provide any assurances that we will furnish to any &#8220;United States shareholders&#8221; information that may be necessary to comply with the aforementioned reporting and tax payment obligations. U.S. Holders should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be adversely affected by changes in tax laws and regulations and the interpretation thereof.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our tax liabilities could be adversely affected by several factors, including changing tax laws, regulations and treaties, or the interpretation thereof; tax policy initiatives and reforms implemented or under consideration; the practices of tax authorities in jurisdictions in which we operate; and the resolution of issues arising from tax audits or examinations and any related interest or penalties. For example, legislation has been enacted or is currently under consideration in a number of jurisdictions to adopt and implement Pillar Two of the base erosion and profit shifting (&#8220;BEPS&#8221;) project initiated by the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;), which is designed to introduce a global minimum tax rate of 15% for certain multinational groups. In December 2021 and March 2022, the OECD published model rules and related commentary to support member jurisdictions of the G20/OECD Inclusive Framework on BEPS (including Denmark) to implement the Pillar Two framework. Denmark has transposed the rule into its tax legislation effective January 1, 2024. We are not subject to Pillar II rules until the consolidated turnover of Ascendis Pharma exceeds &#8364;750 million and certain other conditions are met. The ultimate impact of any such changes on our tax obligations remains uncertain and will continue to be monitored by the Company.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are unable to predict what tax reforms may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could increase the estimated tax liability that we have expensed to date and paid or accrued on its consolidated statements of operations and comprehensive loss, and otherwise affect the future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to shareholders and increase the complexity, burden and cost of tax compliance.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_information_on_the_company"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4 Information on the Company</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">History and Development of the Company </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were organized under the laws of the Kingdom of Denmark in September 2006 as a private limited liability company (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anpartsselskab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ApS) and then transformed into a public limited liability company (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aktieselskab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or A/S), effective December 17, 2007. In connection with this conversion, our legal name changed from Ascendis Pharma ApS to Ascendis Pharma A/S. We commenced operations in December 2007 in connection with the acquisition of the company that invented our TransCon technologies, Complex Biosystems GmbH.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our registered office and principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark and our telephone number is +45 70 22 22 44. Our agent for service of process in the United States is Ascendis Pharma, Inc., located at 1000 Page Mill Road. Palo Alto, CA 94304. Our corporate website address is www.ascendispharma.com. The information on, or that can be accessed through, our website is not part of and should not be incorporated by reference into this annual report or any other report we file or furnish to the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). We have included our website address as an inactive textual reference only. Our ADSs are traded on The Nasdaq Global Select Market under the symbol &#8220;ASND.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The SEC maintains an internet site at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information relating to the development of our company, see &#8220;Item 4 B. Information on the Company &#8211; Business Overview.&#8221; For additional information relating to the Company&#8217;s capital expenditures, see &#8220;Item 5 A. Operating and Financial Review and Prospects&#8212;Operating Results.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Overview </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we develop TransCon-based therapies that demonstrate best-in-class potential to address unmet medical needs. Our portfolio of approved Endocrinology Rare Disease products and product candidates addresses hypoparathyroidism as well as growth disorders such as growth hormone deficiency and achondroplasia. To create additional value, we have established partnerships to develop and bring to market TransCon-based products in large therapeutic areas including Metabolic, Cardiovascular and Ophthalmology.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vision</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As announced in January 2024, Vision 2030 is our vision to achieve blockbuster status for multiple products and expand our engine for future innovation. This includes:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Be the Leading Endocrinology Rare Disease Company</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Achieve blockbuster status (&gt;$1B) for each of TransCon PTH, TransCon hGH, and TransCon CNP through worldwide commercialization</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Be the leader in growth disorders and hypoparathyroidism, pursuing clinical conditions, innovative life cycle management, and complementary patient offerings</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expand pipeline with Endocrinology Rare Disease blockbuster product opportunities</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Create Value in Additional Therapeutic Areas through Innovative Business Models</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtain accelerated approval in oncology with registrational trials ongoing</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursue TransCon product opportunities in &gt;$5B indications</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maximize value creation of these product opportunities through collaboration with therapeutic area market leaders</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Differentiate with Ascendis Fundamentals</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outperform industry drug development benchmarks with Ascendis&#8217; product innovation algorithm</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remain independent as a profitable biopharma through lean and flexible ways of working</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Let our values Patients, Science, Passion drive our decisions to success</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our products and product candidates combine our TransCon technologies with clinically validated parent drugs or pathways, with the goal of optimizing safety, efficacy, tolerability, and convenience.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply these technologies using our algorithm with the goal of creating product candidates with the potential to be best-in-class. Using this approach, we plan to expand our pipeline with Endocrinology Rare Disease product opportunities in large addressable markets. In addition, our vision is to pursue TransCon product opportunities in &gt;$5B indications in other therapeutic areas and maximize value creation of these product opportunities through collaboration with therapeutic area market leaders. We believe our approach to product innovation may reduce the risks associated with traditional drug development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Algorithm for Product Innovation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img148586500_0.jpg" alt="img148586500_0.jpg" style="width:624px;height:150px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When we apply our TransCon technologies to clinically validated parent drugs or pathways, we may benefit from established clinical safety and efficacy data, which we believe increases the probability of success compared to traditional drug development. As illustrated above, our algorithm for product innovation focuses on identifying indications that have an unmet medical need, have a clinically validated parent drug or pathway, are suitable to our TransCon technologies, have potential for creating a clearly differentiated product, have a potential established development pathway, and have the potential to address a large market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Program Summaries</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have two marketed products and a diversified portfolio of four product candidates in clinical development in the areas of Endocrinology Rare Disease and Oncology, and we are working to apply our TransCon technology platform in additional therapeutic areas such as the glucagon-like peptide 1 (&#8220;GLP-1&#8221;) class, where we believe we have designed a potentially best-in-class, once-monthly program.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Our first marketed product is SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (lonapegsomatropin-tcgd), developed as TransCon Growth Hormone (&#8220;TransCon hGH&#8221;), which has received regulatory approval in the United States for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone, also known as growth hormone deficiency (&#8220;GHD&#8221;). SKYTROFA has been commercially available for prescription in the United States since October 2021. In addition, SKYTROFA (lonapegsomatropin) was granted marketing authorization in the European Union (&#8220;EU&#8221;), Norway, Iceland, Liechtenstein, and Great Britain (covering England, Wales, Scotland) as a once-weekly subcutaneous injection for the treatment of children and adolescents aged 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone. In the EU, SKYTROFA has been commercially available for prescription in Germany since September 2023.   </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Our second marketed product is YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (palopegteriparatide), developed as TransCon PTH. In the EU, Norway, Iceland, Liechtenstein, and Great Britain (covering England, Wales, and Scotland), YORVIPATH has been granted marketing authorization as a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. In the EU, YORVIPATH has been commercially available for prescription in Germany and Austria since January 2024 and has also been available to patients in other countries under named patient programs. In August 2024, YORVIPATH received regulatory approval in the U.S. for the treatment of hypoparathyroidism in adults. YORVIPATH has been commercially available for prescription in the United States since December 2024. As of February 7, 2025, 908 new prescriptions by 539 unique prescribing healthcare providers in the U.S.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Endocrinology Rare Disease Pipeline </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8211; Two product candidates in our Endocrinology Rare Disease portfolio are currently in development spanning multiple indications and geographies. These product candidates are TransCon hGH (lonapegsomatropin) for adult GHD and children with Turner syndrome and TransCon CNP (navepegritide) for infants, children, and adolescents with achondroplasia. We are also investigating TransCon CNP in combination with TransCon hGH in children with achondroplasia. In addition, we plan to investigate TransCon hGH in other established daily growth hormone indications. Through our strategic collaboration, Teijin Limited is developing and, if approved, plans to commercialize TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. In addition, through our strategic investment, VISEN Pharmaceuticals (&#8220;VISEN&#8221;) is developing and, if approved, plans to commercialize TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare diseases in Greater China.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oncology Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; In Oncology, we are leveraging our TransCon technologies with the goal of enhancing the anti-tumor effects of clinically-validated parent drugs and pathways and to provide sustained modulation of tumor microenvironments and activate cytotoxic immune cells. We initiated clinical development of two programs: TransCon TLR7/8 Agonist, an investigational, long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (&#8220;TLR&#8221;) 7 and 8, for intratumoral delivery, and TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(onvapegleukin alfa) for systemic delivery, which is designed for prolonged exposure to an IL-2 variant that selectively activates IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with minimal binding to IL-2R&#945;. During the fourth quarter of 2024, we closed enrollment in our BelieveIT-201 clinical trial and to dose expansion cohorts involving TransCon TLR7/8 Agonist in the transcendIT-101 and IL-Believe trials to prioritize our efforts on TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon Product Candidates Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the rights we have granted to Eyconis, Novo Nordisk, Teijin Limited, and VISEN as noted in this annual report, we hold worldwide rights to our TransCon technologies and, other than our royalty financing arrangements with Royalty Pharma as noted in this annual report, we owe no third-party royalty or milestone payment obligations with respect to our TransCon technologies, TransCon hGH, TransCon PTH or any of our other product candidates. The following chart lists our product candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img148586500_1.jpg" alt="img148586500_1.jpg" style="width:624px;height:249px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pivotal ApproaCH Trial (NCT05598320).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">sBLA submitted to U.S. FDA, PDUFA goal date July, 27</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New InsiGHTS Trial (NCT05690386).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">reACHin Trial (NCT06079398).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">teACH Trial (NCT06732895).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">COACH Trial (NCT06433557). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals&#8217; Phase 3 trial. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Japanese riGHt Trial.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PaTHway China (NCT05387070).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PaTHway Japan.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ACcomplisH China (NCT05246033).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BelieveIT-201 Trial (NCT05980598).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IL-Believe Trial (NCT05081609).</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain an intellectual property portfolio comprising over 425 issued patents and over 525 patent applications as of December 31, 2024, which includes patents and patent applications applicable to our products and product candidates with claims directed to composition of matter, process, formulation and/or methods-of-use for our products and product candidates, including a product-specific device and core TransCon technologies. While our TransCon prodrugs may incorporate already approved parent drugs, TransCon hGH, TransCon PTH, and each of our other product candidates are new molecular entities and therefore eligible to be granted new intellectual property rights, including new composition of matter patents.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global Commercialization Strategy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are establishing a global presence to commercialize TransCon products and product candidates, where approved, to address patients&#8217; unmet medical needs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., we have established an integrated organization to commercialize our approved Endocrinology Rare Disease products, SKYTROFA and YORVIPATH. Our U.S. organization includes sales, market access, patient support, and medical affairs teams. The sales team engages with healthcare providers and present products, usage and safety guidelines in accordance with the label. Our market access team engages with health authorities, insurance companies, and payers to help patients in need of our products gain access to them. Our patient support team facilitates reimbursement support, out of pocket assistance, provides educational resources and product training. Our medical affairs team provides scientific exchange to the physician and medical community. We have also established a network of specialty pharmacies to support product distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, we are expanding our presence by building integrated organizations in select countries, which we call Europe Direct, beginning with Germany, where we have launched our Endocrinology Rare Disease products, SKYTROFA and YORVIPATH. We are establishing commercial infrastructure in other Europe Direct country clusters, including DACH (Germany, Austria, Switzerland), France &amp; BeNeLux (Belgium, the Netherlands, and Luxembourg), Iberia (Portugal and Spain), Italy, Nordics (Denmark, Norway, Sweden, Iceland, Finland), and the United Kingdom &amp; Ireland.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond the U.S. and Europe Direct, we are expanding global reach for our Endocrinology Rare Disease programs through exclusive distribution agreements with geographic market leaders, which we call International Markets. As of December 31, 2024, we have established eight such regional agreements:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acino Pharma Proprietary Limited (South Africa)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adium Pharma S.A. (Argentina, Brazil, Colombia and Mexico)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Er-Kim &#304;lac Sanayi ve Ticaret A.S (Central &amp; Eastern Europe, Turkey, and certain countries in Eurasia)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neopharm (Israel) 1996 Ltd (Israel, Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pendopharm, a division of Pharmascience Inc. (Canada)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specialised Therapeutics Asia Pte Ltd. (Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SRS Pharmaceuticals Pvt. Ltd. (India and Philippines)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vector Pharma FZCO (Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar, and Bahrain)</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, we are making our products commercially available in select markets through exclusive license agreements with partners with local development and commercialization expertise and infrastructure. In China, VISEN has exclusive license rights to develop and commercialize TransCon hGH, TransCon PTH, and TransCon CNP. In Japan, Teijin Limited has exclusive license rights to develop and commercialize TransCon hGH, TransCon PTH, and TransCon CNP.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon Technologies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our TransCon technologies are designed to combine the benefits of conventional prodrug and sustained release technologies to solve the fundamental limitations seen in other approaches to extending duration of a drug&#8217;s action in the body, with the goal of developing highly differentiated product candidates based on efficacy, safety, tolerability, and convenience. In addition to retaining the original mode of action of the parent drug and potentially supporting dosing frequency from daily up to six months or more, we believe that predictable release over time can improve treatment safety and efficacy, increase the likelihood of clinical development success, and provide intellectual property benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon molecules can have up to three components: a parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic pH and temperature conditions initiate the release of the active, unmodified parent drug in a predictable release manner.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the type of TransCon carrier we employ, we can design our TransCon prodrugs for sustained localized or systemic delivery.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img148586500_2.jpg" alt="img148586500_2.jpg" style="width:624px;height:233px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Technology Components</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Carriers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our TransCon technologies incorporate three carrier platforms that can be used to provide sustained localized or systemic drug exposure. These biocompatible carrier platforms include our TransCon systemic carriers and TransCon localized carriers (self-eliminating hydrogels). Our carriers inactivate and protect the drug through a shielding effect, which may prevent rapid excretion and degradation of the parent drug and enable benefits that include improved injection site tolerability, reduced systemic adverse effects, and low immunogenicity.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Systemic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Our TransCon systemic carriers are used to provide systemic drug exposure and are based on soluble compounds such as methoxypolyethylene glycol (&#8220;mPEG&#8221;) or other natural or synthetic polymers, as well as our albumin avidity approach, where 2 or more albumin binding moieties are incorporated into the drug molecule to facilitate sustained exposure. Prodrugs created using our systemic carriers are readily absorbed into the bloodstream after administration, thus minimizing exposure of the subcutaneous tissue to active drug, which we believe may improve injection site tolerability. TransCon hGH, TransCon PTH, and TransCon CNP utilize mPEG as a carrier molecule. mPEG is widely used to improve the pharmacokinetic or pharmacodynamic properties of marketed therapeutics. Below is an illustration of our systemic carrier:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148586500_3.jpg" alt="img148586500_3.jpg" style="width:500px;height:164px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Localized</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Our TransCon localized carriers include TransCon hydrogels based on PEG, hyaluronic acid, or other biopolymers. TransCon hydrogel is designed to self-eliminate to soluble, biocompatible molecules after the drug payload has been released. When applied for localized delivery, the TransCon hydrogel enables the release of a parent drug at high local concentrations within the target area while minimizing systemic exposure. We believe this may widen the therapeutic window for parent drugs that suffer from significant systemic side effects and toxicities, facilitating the development of highly efficacious product candidates with improved safety and tolerability profiles. Below is an illustration of our hydrogel carrier:</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148586500_4.jpg" alt="img148586500_4.jpg" style="width:466px;height:170px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Linkers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reversible TransCon linkers are designed to enable the transient conjugation of a broad range of therapeutics, including proteins, peptides, and small molecules, to our TransCon carriers. We have a large library of TransCon linkers that may be applicable to various types of parent drugs, and that can be tailored to potentially achieve half-life extension enabling daily, weekly, monthly, and half-yearly dosing and to customize the potential pharmacokinetic profile for each individual product candidate with the goal of optimizing the potential therapeutic effect. TransCon linkers are self-cleaving through a process called intra-molecular assisted cleavage, which causes the linker to release the unmodified parent drug. We can tailor the release properties of the linker to a given therapeutic indication and parent drug by modifying the linker structures. We believe the self-cleaving process of our linker avoids many of the shortcomings of conventional prodrug technologies, which often depend on metabolic processes, such as enzymatic degradation, to convert the prodrug into the active drug. The rate of metabolic conversion of prodrugs in these types of processes may differ between patients, and even within different tissues in the same patient. As a result, conventional prodrugs do not always offer predictable release of the parent drug. Our TransCon linkers are designed to predictably release an unmodified active parent drug at predetermined rates governed by physiological pH and temperature conditions, which are tightly regulated in the body. Consequently, we believe we can design our prodrugs to release the unmodified parent drug at predictable rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parent Drugs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our TransCon technologies are applicable across a broad range of therapeutic classes and are currently used to create long-acting product candidates with best-in-class potential based on proteins, peptides, and small molecules. By primarily focusing on biological targets that have been clinically validated, we can leverage available knowledge regarding a target&#8217;s activity. Based on this selective approach, we know what drug levels must be maintained in the body for optimal efficacy and safety, and we can design the release half-life and dosing frequency of our TransCon prodrugs to maintain these levels to achieve the desired pharmacological effect. We move a product candidate into development after it demonstrates the desired profile in non-clinical models. Furthermore, based on the established translational relationships between preclinical animal models and clinical efficacy, we believe experimental results generated in animal models are highly predictive of clinical results and reduce the development risk for our TransCon prodrugs. This strategy is designed to reduce risk and increase productivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This approach has enabled us to develop two approved products and generate a pipeline of product candidates designed to address significant unmet medical needs and to become potential sources of significant revenue for our company. Because our TransCon technologies leverage clinically validated parent drugs or pathways, we believe we may benefit from a higher development and regulatory success rate compared to development of drug compounds without established biology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon Products &#8211; Endocrinology Rare Disease</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Growth Hormone (hGH)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunity for Recombinant Human Growth Hormone</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Growth hormone deficiency is a serious orphan disease that affects both children and adults. Children with GHD are characterized by short stature, metabolic and cardiovascular abnormalities, cognitive deficiencies, and poor quality of life. GHD in adults is associated with increased adiposity, or fat mass, as well as psychiatric-cognitive, cardiovascular, muscular, metabolic and skeletal abnormalities. In childhood and adolescence, growth hormone plays an essential role in normal longitudinal growth, muscle and bone strength, and distribution of body fat. In adults, growth hormone contributes to body composition, cardiovascular function, and bone health. The current standard of care for GHD has been daily subcutaneous injections of somatropin, a recombinant human growth hormone (&#8220;hGH&#8221;). These daily hGH therapies have been shown to be safe and well-tolerated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In both therapy-compliant children and adults with GHD, daily subcutaneous injections of hGH have resulted in improved body composition parameters, bone density, cardiovascular outcomes, and quality of life. Growth hormone-deficient children who are fully adherent to their daily hGH treatment regimen may achieve a height in adulthood that is comparable to that of their family members and national norms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the demonstrated benefits of daily hGH therapy, many GHD patients are not adequately treated, and adherence continues to be a challenge, as reported in a 2021 paper published by Kaplowitz et al. (Kaplowitz P, Manjelievskaia J, Lopez-Gonzalez L, et al. Economic burden of growth hormone deficiency in a US pediatric population. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">J Manag Care Spec Pharm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021; 27(8):1118-1128). The observational retrospective cohort analysis utilized administrative claims data from two databases on over 20,000 pediatric patients diagnosed with GHD. Approximately 68% of commercial patients and approximately 63% of Medicaid patients received daily growth hormone treatment, whereas approximately 32% of commercial patients and approximately 37% of Medicaid patients were untreated. In addition, mean adherence as measured by proportions of days covered, which is defined as the number of days covered by any daily growth hormone prescription during the follow-up period, was approximately 60% in the commercial cohort and approximately 50% in the Medicaid cohort. Only 32% of commercial and 18% of Medicaid patients reported adherence rates greater than 80%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For adult patients with GHD, underdiagnosis and undertreatment are also a concern. Untreated adult GHD (&#8220;AGHD&#8221;) patients can experience reduced quality of life and increased risk of morbidity and mortality. A retrospective cohort study presented at ENDO 2023 analyzed an electronic health records database and selected adult patients with suspected AGHD. Of the 51,588 patients with suspected AGHD, fewer than 4% were treated with growth hormone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the introduction of hGH in 1981, a number of the world&#8217;s largest pharmaceutical companies have developed and marketed daily-administered hGH products. All currently marketed daily hGH products in the United States &#8211; Norditropin</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Novo Nordisk A/S), Humatrope</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Eli Lilly and Company), Genotropin</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Pfizer Inc.), Zomacton</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Ferring Pharmaceuticals, Inc.) and Omnitrope</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Sandoz GmbH) &#8211; contain unmodified somatropin and are administered by subcutaneous injections. The global market for daily hGH products is largely composed of products from Novo Nordisk, Pfizer, Eli Lilly, Sandoz, and Merck KGaA, which together account for most of the global market share. However, according to the FDA drug shortage website, Humatrope has been discontinued due to a business decision which might impact the hGH global market share in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary indications for hGH in children are GHD, idiopathic short stature, chronic kidney disease, Prader-Willi syndrome, small for gestational age, and Turner syndrome. In adults, primary indications for hGH include GHD and AIDS-induced weight loss. We estimate pediatric indications comprise up to 90% of the total hGH market, of which approximately half is for pediatric GHD.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competitive Landscape for Long-Acting Growth Hormone Therapies</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the 1990s, the pharmaceutical industry has employed various approaches to develop long-acting growth hormone products to reduce the burden of daily injections on patients and increase patient compliance with the dosing regimen. These approaches generally fall into two categories: unmodified somatropin and permanent modification of growth hormone:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unmodified somatropin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Two long-acting growth hormone products using encapsulation technologies previously received regulatory approval in the U.S. and Europe, but were subsequently discontinued due to commercial challenges. These include Nutropin Depot</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, formerly marketed by Genentech, and Somatropin Biopartners, developed by LG Life Sciences and Biopartners GmbH. Nutropin Depot was approved by the FDA in 1999 and later withdrawn; Somatropin Biopartners (LB03002) was approved by the European Medicines Agency (&#8220;EMA&#8221;) in 2013, and later withdrawn. We believe that the lack of market acceptance was a result of the various safety and tolerability issues that tend to arise with encapsulation technologies. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permanent modification of growth hormone</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Modification technologies prolong activity in the body by creating analogs of growth hormone through permanent modification of the growth hormone molecule. This modification may alter the molecular size and interaction with the growth hormone receptor and/or change the natural association affinity to endogenous proteins, as well as the distribution in the body. These changes may alter and reduce the efficacy of these drugs compared to unmodified daily somatropin and may also negatively impact the drug&#8217;s safety. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novo Nordisk received regulatory approval in various countries and regions including the U.S., Japan, and EU for once-weekly somapacitan (SOGROYA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) in adult and pediatric patients with GHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pfizer (in collaboration with OPKO Health Inc.) received regulatory approval of once-weekly somatrogon (NGENLA&#153;) in various countries and regions including the U.S., Japan, and EU for pediatric GHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A permanently PEGylated long-acting growth hormone developed by GeneScience Pharmaceuticals Co., Ltd. (Jintrolong</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) is available in China for pediatric GHD, Turner syndrome and idiopathic short stature and the Somatropin Biopartners product (LB03002) is available in Korea. Other experimental growth hormone therapies based on permanent modification are in different stages of clinical development by various companies, including Genexine Inc., I-MAB, Amoytop, UnionGene, Anhui Anke Biotechnology, Alteogen, and JCR Pharmaceuticals Co., Ltd.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: TransCon hGH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH is a prodrug composed of somatropin that is transiently bound to a carrier by a proprietary linker. TransCon hGH is administered once weekly and is designed to maintain the same mode of action as daily therapies by providing sustained release of active, unmodified somatropin, the same recombinant growth hormone molecule used in the daily hGH therapies that have historically been the standard of care.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Growth Hormone (hGH) for Pediatric GHD</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH, marketed under the brand name SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(lonapegsomatropin-tcgd), received regulatory approval in the U.S. for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone, also known as GHD. SKYTROFA has been commercially available for prescription in the United States since October 2021. In the EU, Norway, Iceland, Liechtenstein, and Great Britain (covering England, Wales, Scotland), we received marketing authorization for TransCon hGH &#8211; known by its brand name SKYTROFA (lonapegsomatropin) &#8211; as a once-weekly subcutaneous injection for the treatment of children and adolescents aged 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone. SKYTROFA has been commercially available for prescription in Germany since September 2023.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we announced top-line results from the completed enliGHten Trial, an open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with GHD. The enliGHten Trial enrolled 298 participants (mean age 10.3 years) from the Phase 3 heiGHt Trial of treatment-na&#239;ve pediatric GHD patients and the Phase 3 fliGHt Trial of pediatric GHD patients switching from daily somatropin treatment. Patients in these trials received a total of up to 6 years of treatment with TransCon hGH. At the time of the enliGHten Trial closure, 81 participants were designated as treatment completers, based on their physician&#8217;s determination that treatment for pediatric GHD was no longer required. Of these treatment completers, 59% met or exceeded their average parental height standard deviation score (&#8220;SDS&#8221;), with mean TransCon hGH treatment duration of 3.2 years.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial of TransCon hGH in Japanese Pediatric GHD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the Phase 3 riGHt Trial, we are evaluating TransCon hGH (N=15) compared to somatropin (N=16) as a treatment in Japanese children with GHD. The trial achieved its primary objective with Week 52 top-line results consistent with our pivotal heiGHt Trial and VISEN&#8217;s Phase 3 trial. In the riGHt Trial, TransCon hGH was generally well tolerated with a safety profile that was similar to that of somatropin&#8217;s. Trial subjects continue in the extension period.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Proprietary Auto-Injector</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SKYTROFA includes the SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Auto-Injector and cartridges. The auto-injector provides for room temperature storage, includes an empty-all design, and is expected to last for at least four years. The device enables a single, low-volume injection of less than 0.6 mL for the majority of patients with a thin, 31-gauge needle that is only 4 millimeters in length, which is comparable to needles used to administer daily hGH. We are also working on strategies that will enable the auto-injector to integrate with the digital healthcare system, including Bluetooth connectivity features to allow for easy tracking of dosing adherence over time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148586500_5.jpg" alt="img148586500_5.jpg" style="width:206px;height:345px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Figure: Our state-of-the-art auto-injector is designed to improve treatment compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon Product Candidates &#8211; Endocrinology Rare Diseases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Growth Hormone (hGH) for Other Indications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development in Adult GHD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced the submission of a supplemental Biologics License Application (&#8220;sBLA&#8221;) to the FDA for TransCon hGH to expand its currently approved label to include eligible adults for the treatment of GHD. The submission was based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind), and active-controlled (open-label) trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily hGH in adults with GHD. In December, we announced the FDA accepted the sBLA for review and set a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) goal date of July 27, 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, we announced positive top-line results from foresiGHt. The trial aims to evaluate the metabolic benefits of TransCon hGH in adults, with the primary objective to evaluate change in trunk fat percentage.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foresiGHt Trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake, with approximately equivalent hGH mg/week for TransCon hGH and daily hGH.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH demonstrated superiority on its primary efficacy endpoint at Week 38:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in trunk percent fat as measured by dual x-ray absorptiometry (TransCon hGH -1.67% vs. placebo +0.37%, LS mean difference = -2.04%, p &lt; 0.0001)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH demonstrated superiority on its key secondary efficacy endpoints at Week 38:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in total body lean mass (TransCon hGH +1.60 kg vs placebo -0.10 kg, LS mean difference = 1.70 kg, p &lt; 0.0001)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in trunk fat mass (TransCon hGH -0.48 kg vs placebo +0.22 kg, LS mean difference = -0.70 kg, p = 0.0053)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exploratory post-hoc analysis at Week 38 demonstrated comparable treatment effect of TransCon hGH and daily hGH on target tissues. For patients with average insulin-like Growth Factor 1 (&#8220;IGF-1&#8221;) SDS levels &#8804; 1.75 at Week 38:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in trunk percent fat (TransCon hGH -2.42% vs. daily hGH -2.59%)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in total body lean mass (TransCon hGH +1.70 kg vs daily hGH +1.37 kg)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in trunk fat mass (TransCon hGH -0.90 kg vs daily hGH -0.94 kg)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily hGH.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development in Turner Syndrome</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced positive top-line results from the Phase 2 New InsiGHTS Trial. New InsiGHTS randomized and dosed 49 children with Turner syndrome aged 1 to 10 years old into one of four treatment groups 1:1:1:1 &#8211; one of three starting doses of TransCon hGH (0.24, 0.30, or 0.36 mg/kg/week) or an active comparator of daily somatropin with a starting dose of 0.35 mg/kg/week. Doses were individualized based on IGF-1. On the primary endpoint of annualized height velocity and secondary endpoint of change from baseline in height SDS, children treated with TransCon hGH demonstrated improved growth similar to daily somatropin at Week 26, independent of starting dose. TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily somatropin.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Development Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the third quarter of 2025, we plan to submit an Investigational New Drug (&#8220;IND&#8221;) application or similar for a basket trial evaluating other indications (planned for small for gestational age without catch-up growth (&#8220;SGA&#8221;); idiopathic short stature (&#8220;ISS&#8221;); SHOX deficiency (including Turner syndrome)). In addition, we are investigating other potential indications for TransCon hGH where we believe a long-acting hGH therapy may offer benefits to patients with rare growth disorders, including in combination with our TransCon CNP product candidate in our Phase 2 COACH Trial for children with achondroplasia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon PTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunity in Hypoparathyroidism</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hypoparathyroidism is a rare endocrine disease caused by insufficient levels of parathyroid hormone (&#8220;PTH&#8221;). As reported in a 2016 paper, most patients with hypoparathyroidism (70-80% of cases) develop the disease following damage to or accidental removal of the parathyroid glands during thyroid surgery. Other etiologies include autoimmune disorders, genetic disorders such as autosomal dominant hypocalcemia type 1, and idiopathic causes. Conventional therapy with oral calcium and active vitamin D (also called calcitriol) does not effectively address the short-term symptoms, long-term complications, or quality-of-life impacts of hypoparathyroidism.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications. Short-term symptoms of hypoparathyroidism include weakness; severe muscle cramps (tetany); abnormal sensations such as tingling, burning, and numbness (paresthesia); memory loss; impaired judgment; and headache. A survey published in 2014 of 374 individuals with hypoparathyroidism showed that 72% experienced more than ten symptoms in the preceding twelve months, with symptoms experienced for a mean of 13 &#177; 9 hours a day. Prolonged use of conventional therapy may increase the risk of major complications, such as calcium deposits in the brain, blood vessels, eyes, and soft tissues. According to a systematic review by Gosmanova et al. published in 2021, chronic hypoparathyroidism treated with conventional therapy is associated with higher rates of renal complications compared to the general population, including nephrolithiasis (up to 36%), nephrocalcinosis (up to 38%), and chronic kidney disease (up to 41%). Studies have found that the burden of hypoparathyroidism negatively impacts health-related quality of life (&#8220;QoL&#8221;), physical functioning, and psychological well-being. Compared with an age-matched general population sample, individuals with hypoparathyroidism have reported markedly lower health-related QoL, irrespective of serum calcium level, as measured by the physical (P&lt;0.001) and mental (P&lt;0.001) component scores of the 36-Item Short Form Health Survey (SF-36) as well as the EuroQol-5 Dimensions Visual Analogue Scale. As reported in a 2021 paper, in interviews conducted on 42 individuals with hypoparathyroidism, 98% reported reduced functioning and well-being, including anxiety (81%), feeling sad or depressed (62%), and feeling irritable or short-tempered (43%) despite management with conventional therapy.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hypoparathyroidism also imposes a substantial burden on the healthcare system despite the use of conventional therapy. For example, individuals with hypoparathyroidism may require hospitalizations or emergency department visits due to acute severe hypocalcemia (calcium crashes) and those with post-surgical hypoparathyroidism have an increased risk of hospitalization due to infection than age- and sex-matched controls from the general population. Individuals with hypoparathyroidism also have an increased risk of hospitalization due to renal complications, such as chronic kidney disease and renal failure, compared to age- and sex-matched controls. A retrospective review published in 2019 of clinical burden and healthcare resource utilization showed that 90.7% of individuals had &#8805;1 hypoparathyroidism-related healthcare utilization event during a 12-month period, including 87.8% with &#8805;1 outpatient visit, 41% with &#8805;1 emergency department visit, and 19.5% with &#8805;1 hospitalization. The management of hypoparathyroidism is also associated with substantial economic burdens and consequences of hypoparathyroidism may negatively impact employment status and work productivity.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2022 Guidelines from the Second International Workshop addressing the prevention, diagnosis, and management of hypoparathyroidism was published in September 2022 in the Journal of Bone and Mineral Research and authored by leading clinicians from North America, Europe, and Asia. The authors suggest consideration of PTH replacement therapy in patients whose hypoparathyroidism is inadequately controlled with conventional therapy. Inadequate control is considered to be any one of the following: symptomatic hypocalcemia, hyperphosphatemia, renal insufficiency, hypercalciuria, or poor quality of life. In addition, the guideline indicates that individuals with poor compliance, malabsorption, or intolerant of large doses of calcium and active vitamin D may also benefit from PTH replacement therapy. Based on this current guideline, we believe PTH replacement therapy could be applicable to most patients with hypoparathyroidism.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2015, Takeda&#8217;s NATPARA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(parathyroid hormone) was approved in the U.S. for once-daily subcutaneous injection as an adjunct to vitamin D and calcium in patients with hypoparathyroidism. NATPARA was voluntarily recalled in September 2019 in the U.S. and is now only available to a limited number of patients through a Special Use Program offered by its manufacturer, Takeda. In October 2022, Takeda announced that it would discontinue manufacturing NATPARA/NATPAR globally by the end of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also aware of several academic groups and companies working on making longer-acting agonists of the PTH receptor. In addition, other companies and groups are developing therapies for hypoparathyroidism at the clinical stage, including Calcilytix (a BridgeBio company), Entera Bio, Extend Biosciences, Massachusetts General Hospital, AstraZeneca, MBX Biosciences, and Septerna.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forteo&#174; (teriparatide, PTH [1-34]), approved since 2002 for the treatment of osteoporosis, has sometimes been used for treatment of hypoparathyroidism using multiple daily injections, despite not being approved for this indication. Clinical research conducted by the U.S. National Institutes of Health in subjects receiving continuous exposure to PTH (1-34), administered by an infusion pump demonstrated simultaneous normalization of serum calcium and urinary calcium, as well as normalization of bone turnover.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate hypoparathyroidism affects over 250,000 patients in the U.S. and Europe. In the U.S., we estimate hypoparathyroidism affects approximately 70,000 to 90,000 patients, including 4,000 to 5,000 patients who we estimate have previously been treated with PTH therapy. In Germany, we estimate hypoparathyroidism affects approximately 70,000 patients. Outside of Germany, we estimate hypoparathyroidism affects over 100,000 patients in the rest of Europe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: TransCon PTH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon PTH (palopegteriparatide) is a prodrug of PTH (1-34) that is administered once-daily to achieve and maintain a steady concentration of PTH in the bloodstream within the physiological range. TransCon PTH is designed to provide PTH in the physiological range for 24 hours per day, thereby more fully addressing aspects of the disease, including maintaining normal serum calcium and phosphate levels and normalizing urinary calcium.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By providing steady levels of PTH in the physiological range, we believe TransCon PTH may be a highly differentiated therapy for hypoparathyroidism.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon PTH for the Treatment of Hypoparathyroidism</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, the FDA approved YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the FDA granted Orphan Drug exclusivity to YORVIPATH, providing seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults. YORVIPATH has been commercially available for prescription since late December 2024 in the United States.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, TransCon PTH received regulatory approval in the EU and European Economic Area and is marketed as YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(palopegteriparatide), a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. In addition, YORVIPATH was granted Orphan status in the EU in November 2023. In January 2024, we announced commercial availability of YORVIPATH in Germany and Austria, and we began shipping to customers in February 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, TransCon PTH received regulatory approval in Great Britain as a PTH replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. In addition, in April 2024, we announced that the United Kingdom&#8217;s Medicines &amp; Healthcare products Regulatory Agency granted YORVIPATH Orphan Drug status.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, the FDA allowed us to initiate a U.S. expanded access program (&#8220;EAP&#8221;) for TransCon PTH for eligible adult patients with hypoparathyroidism with prior PTH treatment experience. The EAP closed to new patients on November 29, 2024, in preparation for the U.S. commercial availability of YORVIPATH. Beginning in December 2024, we started enrolling EAP patients into the Ascendis Signature Access Program Ascendis&#8217; patient support program.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients enrolled in the EAP are now working with their healthcare providers (&#8220;HCPs&#8221;) to transition to the commercially available YORVIPATH.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2021, the Ministry of Health, Labour and Welfare in Japan granted Orphan Drug Designation (&#8220;ODD&#8221;) to TransCon PTH for the treatment of hypoparathyroidism.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2020, we were granted Orphan Designation (&#8220;OD&#8221;) by the European Commission (&#8220;EC&#8221;) for TransCon PTH for the treatment of hypoparathyroidism.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development of TransCon PTH for Treatment of Hypoparathyroidism in Adults</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon PTH is being evaluated for the treatment of hypoparathyroidism in adults in the Phase 3 PaTHway Trial, Phase 3 PaTHway Japan Trial, and the Phase 2 PaTH Forward Trial. Last patient, last visit (&#8220;LPLV&#8221;) in the Phase 3 PaTHway Trial occurred in January 2024. LPLV in the Phase 2 PaTH Forward Trial is expected in March of 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced results from the ongoing Phase 2 PaTH Forward Trial of adults with hypoparathyroidism showing that long-term treatment with TransCon PTH (palopegteriparatide; marketed as YORVIPATH) through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population. In contrast, these results suggest that long-term palopegteriparatide treatment promotes attainment of skeletal health parameters in line with those expected with states of parathyroid sufficiency. As of December 31, 2024, 10 patients successfully completed the trial, while 46 out of the 59 patients originally enrolled in the trial continued in the open label (&#8220;OLE&#8221;) portion and had exceeded four and a half years of follow-up. Three patients withdrew from the trial for reasons unrelated to safety or efficacy of the study drug.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we announced two-year (Week 104) results from a post-hoc analysis of the Phase 3 PaTHway Trial demonstrating sustained improvements (nominal p-value &lt;0.05) in renal function in adults with chronic hypoparathyroidism treated with TransCon PTH. The post-hoc analysis examined the impact of treatment with TransCon PTH on renal function using estimated glomerular filtration rate (&#8220;eGFR&#8221;) through Week 104 (n=76) of PaTHway, a Phase 3, double-blind, placebo-controlled trial of 82 dosed adults with chronic hypoparathyroidism randomized 3:1 (TransCon PTH:placebo; both arms initially co-administered with conventional therapy of active vitamin D and calcium), with a 26-week blinded period followed by an ongoing 156-week open-label extension period. Across both treatment arms, TransCon PTH treatment resulted in a mean eGFR increase of 8.9 mL/min/1.73m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p&lt;0.0001) from baseline at Week 52, sustained at Week 104 with a mean change from baseline of 9.0 mL/min/1.73m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (p&lt;0.0001). Treatment was generally well-tolerated, with no new safety signals.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.24%;box-sizing:content-box;"/>
    <td style="width:15.5%;box-sizing:content-box;"/>
    <td style="width:7.28%;box-sizing:content-box;"/>
    <td style="width:15.26%;box-sizing:content-box;"/>
    <td style="width:7.1%;box-sizing:content-box;"/>
    <td style="width:16.26%;box-sizing:content-box;"/>
    <td style="width:7.1%;box-sizing:content-box;"/>
    <td style="width:16.26%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:18.15pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="8" style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">eGFR* Change from Baseline by Study Arm</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #eeece1;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #eeece1;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Baseline</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Study Arm</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">eGFR</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(mL/min/1.73m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>N</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mean</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(p value)</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>N</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mean<br/>(p value)</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>N</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mean<br/>(p value)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="3" style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon PTH / TransCon PTH</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">eGFR &lt; 60<br/></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+11.4<br/>(p=0.0002)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+11.5<br/>(p=0.0003)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+13.4<br/>(p&lt;0.0001)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">eGFR &#8805; 60</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+6.3<br/>(p=0.0002)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+8.6<br/>(p&lt;0.0001)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+6.9<br/>(p&lt;0.0001)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+7.9</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p&lt;0.0001)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+9.3<br/>(p&lt;0.0001)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+8.9<br/>(p&lt;0.0001)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="3" style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Placebo<br/>(first 26 weeks) / TransCon PTH**</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">eGFR &lt; 60</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+0.1<br/>(p=0.9877)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+11.7<br/>(p=0.0018)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+15.6<br/>(p=0.0067)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">eGFR &#8805; 60</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-2.4<br/>(p=0.3280)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+6.5<br/>(p=0.0199)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+7.6<br/>(p=0.0121)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-1.9</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p=0.3468)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+7.6</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p=0.0014)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+9.4<br/>(p=0.0006)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">*eGFR (an assessment of kidney filtering capacity) was calculated by the trial&#8217;s central lab using the Modification of Diet in Renal Disease Study Group (MDRD) equation (Levey, Ann Intern Med 2006). An eGFR level &lt;60 mL/min/1.73m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">is considered the threshold for impaired kidney function.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">**Patients in the placebo arm switched to TransCon PTH following the Week 26 visit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon PTH treatment was associated with clinically meaningful increases (&#8805; 5 mL/min/1.73 m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) in eGFR within 26 weeks that were sustained through Week 104 of PaTHway:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:10.86%;box-sizing:content-box;"/>
    <td style="width:12.84%;box-sizing:content-box;"/>
    <td style="width:12.84%;box-sizing:content-box;"/>
    <td style="width:15.74%;box-sizing:content-box;"/>
    <td style="width:15.72%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:22.2pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="7" style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Proportion of Participants (%) with &#8805; 5 and &#8805; 10 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;Increases in eGFR <br/>from Baseline through Week 104*</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="4" style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">eGFR Change from Baseline</span></p></td>
    <td colspan="6" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Participants</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TransCon PTH / TransCon PTH<br/>(n=61)</span></p></td>
    <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo (first 26 weeks) / TransCon PTH** <br/>(n=21)</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Switch to PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Switch to PTH</span></p></td>
   </tr>
   <tr style="height:8.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;5 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62%</span></p></td>
   </tr>
   <tr style="height:10.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38%</span></p></td>
   </tr>
   <tr style="height:11.1pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="7" style="padding-top:0.02in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;padding-right:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:17.25pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="4" style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">eGFR Change from Baseline</span></p></td>
    <td colspan="6" style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Participants with Baseline eGFR &lt; 60 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TransCon PTH / TransCon PTH<br/>&#160;(n=19)</span></p></td>
    <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo (first 26 weeks) / TransCon PTH** <br/>(n=4)</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Switch to PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Switch to PTH</span></p></td>
   </tr>
   <tr style="height:9.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;5 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</span></p></td>
   </tr>
   <tr style="height:9.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">*Percentages were calculated based on all participants. Patients who did not have an eGFR assessment at the visit were still included in the denominator.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">**Patients in the placebo arm switched to TransCon PTH following the Week 26 visit.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, 58 patients successfully completed the 182 week follow-up in the PaTHway Trial while 15 of the 82 originally enrolled in the trial continue in the OLE portion of the trial. Nine patients withdrew from the trial for reasons unrelated to safety or efficacy of the study drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2023, we announced top-line data from PaTHway Japan, a single-arm Phase 3 trial to evaluate the safety, tolerability, and efficacy of TransCon PTH in adults with hypoparathyroidism. The study achieved its primary objective, with top-line results consistent with our trials in North America and the EU. Twelve out of thirteen patients met the primary multi-component endpoint, which was defined as serum calcium levels in the normal range (8.3&#8211;10.6 mg/dL) and independence from conventional therapy (no active vitamin D and &#8804;600 mg/day of calcium). In this trial, TransCon PTH was generally well-tolerated, with no discontinuations related to study drug. As of December 31, 2024, 12 patients continue in the ongoing 3-year extension portion of the PaTHway Japan Trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, we announced that top-line data from the randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant higher proportion of participants treated with TransCon PTH achieved the primary multi-component endpoint compared to placebo. The primary endpoint, defined as serum calcium levels in the normal range (8.3&#8211;10.6 mg/dL) and independence from conventional therapy (no active vitamin D and &#8804;600 mg/day of calcium) with no increase in prescribed study drug within the 4 weeks prior to the Week 26 visit, was achieved by 78.7% of TransCon PTH-treated patients (48 of 61), compared to 4.8% for patients (1 of 21) in control group (p-value &lt;0.0001). In addition, all key pre-specified secondary endpoints were met with statistical significance. TransCon PTH was generally well tolerated, with no discontinuations related to study drug. Three patients discontinued during the treatment period, two from the placebo arm and one from the TransCon PTH arm. TransCon PTH-treated patients showed a mean decrease in 24-hour urine calcium excretion into the normal range.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon CNP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunity in Achondroplasia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Achondroplasia is the most common genetic form of skeletal dysplasia leading to disproportionate short stature and is associated with a well-delineated range of clinical complications and manifestations, occurring in about one in 10,000 to 30,000 newborns or approximately 250,000 worldwide. Achondroplasia results in severe skeletal complications and comorbidities including spinal stenosis due to premature fusion of the foramen magnum, sleep apnea, chronic ear infections, and muscular complications. Patients often face multiple surgeries to alleviate its many complications. There is significant unmet need for treatments that ameliorate complications and improve quality of life in achondroplasia.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Achondroplasia is primarily caused by gain-of-function variants of the FGFR3 gene resulting in constitutive activation of FGFR3 that leads to an imbalance in the effects of the FGFR3 and C-type natriuretic peptide (&#8220;CNP&#8221;) signaling pathways. In achondroplasia, mutations in FGFR3 result in constitutive activation, suppressing the proliferation and differentiation of chondrocytes resulting in improper cartilage to bone conversion in the growth plate, and dysfunction in the skeletal muscle. Preclinical and clinical data show that the CNP pathway helps to counteract the effects of the FGFR3 mutation downstream.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, BioMarin Pharmaceutical Inc.&#8217;s daily VOXZOGO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vosoritide) was approved by the FDA to increase linear growth in pediatric patients with achondroplasia with open epiphyses. Additionally, BioMarin is developing a long-acting CNP to build on VOXZOGO. Other companies that are developing therapies for achondroplasia include QED Therapeutics (a BridgeBio company), Sanofi, Ribomic, Tyra Biosciences, GeneScience and ProLynx.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changing the Treatment Paradigm of Achondroplasia</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical manifestations of achondroplasia are associated with significant, potentially life-threatening complications and reduced quality of life. While achondroplasia has historically been considered a growth disorder, secondary manifestations beyond linear growth, including reduced muscle strength and stamina, suggest that achondroplasia is also a muscle disorder.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img148586500_6.jpg" alt="img148586500_6.jpg" style="width:624px;height:221px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ACH-AE: Increased incidence of Achondroplasia-related Adverse Events.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">HRQoL: Reduced Health-Related Quality of Life; Height; Reduced height. Muscle Strength/Stamina; Reduced muscular functionality, including reduced strength and stamina.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: TransCon CNP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon CNP (navepegritide) is an investigational prodrug of CNP administered once weekly and designed to provide sustained release of active CNP supporting continuous exposure for the treatment of achondroplasia. TransCon CNP is designed to provide effective shielding of CNP from neutral endopeptidase degradation in subcutaneous tissue and the blood compartment, minimize binding of CNP to the NPR-C receptor to decrease clearance, reduce binding of CNP to the NPR-B receptor in the cardiovascular system to avoid hypotension, and release unmodified CNP, which is small enough in size to allow effective penetration into growth plates. Shorter-acting CNP and CNP analogs in development have resulted in high maximum serum concentration (&#8220;C</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">max</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) levels that may cause adverse hypotensive events. We believe the therapeutically sustained release of TransCon CNP offers advantages that may mitigate this issue, leading to continuous CNP exposure with a lower C</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">max</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to correlate with better therapeutic outcomes.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2019, we were granted ODD by the FDA for TransCon CNP for the treatment of achondroplasia. In July 2020, we received OD from the EC for TransCon CNP for the treatment of achondroplasia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development of TransCon CNP for Achondroplasia</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ongoing pivotal ApproaCH Trial, our long-term extension trial AttaCH, and COACH, are evaluating the safety and efficacy of TransCon CNP in children with achondroplasia. The reACHin Trial is evaluating the safety, tolerability, and efficacy of TransCon CNP in infants with achondroplasia (aged 0 to &lt; 2 years at the time of randomization). The TeACH Trial is evaluating the safety, tolerability, and efficacy of TransCon CNP in adolescents with achondroplasia (aged 12 to 18).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we announced data demonstrating improvements in leg bowing, a common complication in achondroplasia, observed with TransCon CNP compared to worsening observed with placebo in the pivotal ApproaCH Trial.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img148586500_7.jpg" alt="img148586500_7.jpg" style="width:624px;height:211px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced top-line data from ApproaCH, a pivotal, multicenter, randomized, double-blind, placebo-controlled trial of once-weekly TransCon CNP versus placebo in 84 children (aged 2 to 11 years) with achondroplasia. Participants were randomized 2:1 to receive TransCon CNP 100 &#181;g/kg/week or placebo for 52 weeks in the double-blind period, after which all participants could choose to receive TransCon CNP at the 100 &#181;g/kg/week dose in an ongoing open-label extension. In the trial, children treated with once-weekly TransCon CNP demonstrated annualized growth velocity (&#8220;AGV&#8221;) superior to those treated with placebo. TransCon CNP also demonstrated statistically significant improvements in other growth parameters, including height Z-score and change from baseline AGV.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Highlights of the ApproaCH Trial Top-line Data</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary Endpoint</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the primary endpoint of AGV at Week 52, children treated with TransCon CNP (n=57) demonstrated an LS mean AGV of 5.89 cm/year compared to 4.41 cm/year in the placebo arm (n=27), an LS mean difference of 1.49 cm/year (p&lt;0.0001).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sub-group analyses:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Children aged 2 to &lt;5 years treated with TransCon CNP (n=21) demonstrated an LS mean AGV at Week 52 of 6.07 cm/year compared to 5.06 cm/year in the placebo arm (n=10), an LS mean difference of 1.02 cm/year (p=0.0084).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Children aged 5-11 years treated with TransCon CNP (n=36) demonstrated an LS mean AGV at Week 52 of 5.79 cm/year compared to 4.02 cm/year in the placebo arm (n=17), an LS mean difference of 1.78 cm/year (p&lt;0.0001).</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGV Change from Baseline</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Children aged 2 to &lt;5 years, treated with TransCon CNP (n=19) demonstrated a change from baseline AGV at Week 52 of 1.57 cm/year compared to 0.43 cm/year in the placebo arm (n=10), an LS mean difference of 1.15 cm/year (p=0.0047).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Children aged 5-11 years, treated with TransCon CNP (n=35) demonstrated a change from baseline AGV at Week 52 of 2.29 cm/year compared to 0.52 cm/year in the placebo arm (n=17), an LS mean difference of 1.78 cm/year (p&lt;0.0001).</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secondary Endpoints</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the secondary endpoint of change in ACH Height Z-score, children treated with TransCon CNP (n=57) demonstrated an LS mean change from baseline ACH Height Z-score of 0.30 compared to 0.01 in the placebo arm (n=27), an LS mean difference of 0.28 (p&lt;0.0001).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the secondary endpoint of change in CDC Height Z-score, children treated with TransCon CNP (n=55) demonstrated an LS mean change from baseline CDC Height Z-score of 0.15 compared to -0.15 in the placebo arm (n=27), an LS mean difference of 0.30 (p=0.0003).</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safety Results Summary</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon CNP was generally well-tolerated and demonstrated safety profile comparable to those observed in the placebo arm, with generally mild treatment emergent adverse events (&#8220;TEAEs&#8221;), no evidence of hypotensive effect, and a low frequency of injection site reactions (0.41 events per patient year), all mild.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No adverse events (&#8220;AEs&#8221;) led to discontinuation of TransCon CNP or withdrawal from the trial and no serious adverse events (&#8220;SAEs&#8221;) were assessed as related to TransCon CNP.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following our pre-NDA meeting with FDA, we plan to submit a New Drug Application (&#8220;NDA&#8221;) for the treatment of children with achondroplasia during the first quarter of 2025 and submit a Marketing Authorisation Application (&#8220;MAA&#8221;) for the treatment of children with achondroplasia to the EMA during the third quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, we announced new analyses demonstrating benefits beyond linear growth from the blinded and ongoing OLE periods of ACcomplisH, a Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial of TransCon CNP in children aged 2 to 10 years with achondroplasia. In the trial, all 57 patients have now completed one year of treatment with TransCon CNP at 100 &#181;g/kg/week, the dose agreed with regulatory agencies for the active arm in our pivotal ApproaCH Trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We analyzed available data for patients who only received TransCon CNP at the 100 &#181;g/kg/week dose in either the blinded or OLE period and were treated for one year (n=19), compared to those administered placebo for one year (n=15). Results showed that these TransCon CNP-treated patients (data available for 9-16 patients) showed improvements (nominal p-value &lt;0.05) in health-related quality of life and disease impacts compared to those receiving placebo (data available for 5-13 patients).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assessments were performed with the SF-10 (a 10-item non-disease specific survey of a child&#8217;s functional health and well-being that has been validated to assess children aged 5 years and older) and the Achondroplasia Child Experience Measure (&#8220;ACEM&#8221;) a condition-specific clinical outcome measure that assesses the impact of achondroplasia on a child&#8217;s health-related quality of life, with statistically significant improved outcome in TransCon CNP-treatment versus placebo for:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SF-10 Physical Summary (p=0.002, aged 5 years and older)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACEM Daily Living Function (p=0.047)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACEM Emotional Well-being (p=0.045)</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img148586500_8.jpg" alt="img148586500_8.jpg" style="width:624px;height:264px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 46 children switching from placebo or a lower dose of TransCon CNP to the 100 &#181;g/kg/week dose in the OLE demonstrated improved growth after one year of treatment, similar to the growth benefits seen in the 11 children treated with 100 &#181;g/kg/week in the one-year randomized, double-blind period of ACcomplisH.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the CNP pathway may restore normal growth and skeletal muscle function, we believe delayed initiation of therapy could lead to a permanent height deficit. Clinical use of daily growth hormone injection has consistently demonstrated growth improvements in children with achondroplasia, including catch up growth; however, without reports of benefits beyond linear growth. We believe the combination of TransCon hGH and TransCon CNP, taken together once per week, could enable catch up growth beyond normal growth while maintaining potential benefits on skeletal muscle of continuous CNP exposure. COACH, a Phase 2 open-label single-arm trial, is evaluating TransCon CNP and TransCon hGH in children with achondroplasia (age 2 to 11 years). The primary objective is to evaluate the treatment effect on linear growth and safety. Secondary objectives are to evaluate treatment effect on quality of life, radiological endpoints, physical functioning, and body composition. The trial plans to enroll approximately 18 patients (treatment na&#239;ve, n=12; prior treatment with TransCon CNP (100 &#181;g/kg/week) for at least 1 year, n=6). Week 26 top-line data from the COACH Trial are expected in the second quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the third quarter of 2023, we filed an IND amendment with the FDA to initiate reACHin, a Phase 2, multicenter, double-blind, randomized, placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 &#956;g/kg of TransCon CNP once-weekly for 52 weeks in infants with achondroplasia, aged 0 to &lt; 2 years at the time of randomization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, we announced top-line results from ACcomplisH, a Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial evaluating the safety and efficacy of once-weekly TransCon CNP compared to placebo in children with achondroplasia aged 2 to 10 years old.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACcomplisH Trial evaluated 57 children with achondroplasia aged 2 to 10 years old, randomized in a 3:1 ratio to receive either sequential ascending doses of once-weekly TransCon CNP (6 &#181;g/kg/week, 20 &#181;g/kg/week, 50 &#181;g/kg/week, 100 &#181;g/kg/week) or placebo for 52 weeks. The trial met its primary objectives, demonstrating that TransCon CNP at 100 &#181;g/kg/week (n=11) was superior to placebo (n=15) on the primary efficacy endpoint of AGV at 52 weeks (p=0.0218). All 57 randomized children completed the blinded portion of ACcomplisH and continued in the OLE portion of ACcomplisH at the 100 &#181;g/kg/week dose.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, 55 patients completed the OLE portion of the ACcomplisH Trial; 2 patients prematurely withdrew during the OLE. From ACcomplisH OLE, 53 patients transitioned into the Phase 2 AttaCH Trial, a multicenter, long-term, open-label extension trial to continue treatment with TransCon CNP 100 &#181;g/kg/week and 2 patients transitioned into COACH, a TransCon CNP/TransCon hGH combination trial. As of December 31, 2024, 43 patients continue in AttaCH, on long-term OLE treatment; 3 patients prematurely withdrew from treatment and 7 patients transitioned into COACH. With the last subject completing the OLE portion of the ACcomplisH Trial, the ACcomplisH Trial has completed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2019, we initiated the ACHieve Study, a five-year, multi-center natural history study designed to gain insight into the experiences of pediatric patients with achondroplasia. ACHieve was designed to evaluate growth velocity, body proportionality, and comorbidities over time in children with achondroplasia up to eight years old. No study medication was administered in the ACHieve Study. The study ended in the first quarter of 2024. We plan to make the results available in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon Product Candidates&#8212;Oncology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunity in Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancer continues to be one of the leading causes of mortality. Improved understanding of the cellular and molecular mechanisms involved in anti-tumor immune responses has fueled the rapid growth of immuno-oncology therapeutics. Immune checkpoint inhibitors, such as anti-PD-(L)1 and anti-CTLA-4 antibodies, have provided new therapeutic options for patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite recent advances, a high need for new treatment options remains for patients who do not respond to, or who respond inadequately to, current therapies. In addition to insufficient efficacy, many current treatments are limited by toxicities that result in dose reductions, treatment discontinuations, or long-term health risks to patients.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that one approach to improving efficacy while limiting adverse events is to create long-acting product candidates using our sustained systemic release TransCon technology, allowing for more consistent circulating drug levels and potentially avoiding high peak concentrations that are often associated with toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently developing TransCon technology in oncology for a variety of solid tumors, with encouraging early data in platinum resistant ovarian cancer and melanoma. Aside from Proleukin being the only approved IL-2, TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may face competition from other IL-2 type drug candidates in development, including those being developed by Mural, Anaveon, Medicenna, Roche, Innovent, Synthekine, Dragonfly, Sotio, and Aulos. In addition, TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may face competition from drug candidates in development for platinum resistant ovarian cancer, including Merck, Corcept, Novartis, Advenchen Laboratories, Genelux, Daiichi Sankyo and Mereo/OncXerna. In melanoma, TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may face competition from drug candidates in development including from Replimune, Philogen, OncoSec, Immunocore, and Regeneron.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: TransCon Technologies for Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe prolonging the therapeutic activity and targeting the drug activity to the relevant cell types and tissues have the potential to improve treatment outcomes. We believe TransCon is well-suited to improve cancer treatments given the large number of validated targets with known limitations. By applying our unique algorithm for product innovation to clinically validated targets and pathways, we believe TransCon has the potential to improve outcomes currently limited by suboptimal efficacy and systemic toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe TransCon technologies may have the potential to increase the efficacy of small molecules, peptides and proteins without increasing toxicity, which could offer the potential to treat more patients with new combination and multi-agent regimens that would not otherwise be feasible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently investigating one clinical-stage product candidate designed to activate the patient&#8217;s own immune system to eradicate malignant cells. We believe our approach, if successfully developed, has the potential to improve the efficacy of systemically administered, clinically validated therapies while limiting adverse effects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our TransCon product candidate currently being investigated in solid tumors is designed to provide sustained systemic administration, which we believe could provide potent and durable anti-tumor efficacy. Our nonclinical studies have shown sustained activation of cytotoxic immune cells that resulted in robust anti-tumor responses by TransCon product candidates using infrequent administration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Symbol',serif;font-style:italic;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Symbol',serif;font-style:italic;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> for Sustained Systemic Release</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(onvapegleukin alfa) is an investigational long-acting prodrug designed to improve cancer immunotherapy through sustained release of an IL-2 variant that selectively activates IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with minimal binding to IL-2R&#945;. The IL-Believe Trial, a Phase 1/2 clinical trial to evaluate the safety and efficacy of TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in locally advanced or metastatic solid tumors, alone or in combination with pembrolizumab or standard of care chemotherapy, has completed dose escalation and is enrolling patients in multiple indication-specific dose expansion cohorts, including platinum-resistant ovarian cancer (&#8220;PROC&#8221;), cervical cancer, melanoma, non-small cell lung cancer (&#8220;NSCLC&#8221;), and small cell lung cancer (&#8220;SCLC&#8221;) at the RP2D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced initial data showing signs of clinical activity in heavily pre-treated patients with PROC treated (cohort 3) with TransCon IL-2 &#946;/&#947; in combination with chemotherapy in the ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 &#946;/&#947;. As of a cutoff date of July 29, 2024, of the 18 patients (median age 64 years) included in the initial assessment, 14 were efficacy evaluable patients who had one or more post-baseline tumor assessment(s), plus an additional four who discontinued treatment before the first post-baseline tumor assessment due to disease progression or death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the data cutoff, clinical responses were observed in 29% (4/14) of the efficacy evaluable patients (two confirmed and two unconfirmed partial responses in patients who had received three to seven prior lines of treatment &#8211; including patients whose disease had previously progressed on mirvetuximab soravtansine-gynx), suggesting the potential for clinical activity in heavily pre-treated patients. The data suggest that TransCon IL-2 &#946;/&#947; was generally well-tolerated: the most common TEAEs related to combination therapy with TransCon IL-2 &#946;/&#947; plus chemotherapy were fatigue, thrombocytopenia, neutropenia, and anemia. Most TransCon IL-2 &#946;/&#947;-related TEAEs were grade 1 or 2.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we reported updated results from our ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g.</span><span style="color:#58595b;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data included the first presentation of Phase 2 dose expansion Cohort 4 (TransCon IL-2 &#946;&#8260;&#947; in combination with TransCon TLR7/8 Agonist) in post anti-PD-1 melanoma and new analyses of patients from dose escalation cohorts with prior disease progression on checkpoint inhibitors, along with biomarker studies correlating cytotoxic immune cell expansion and observed clinical benefit. As of the April 16, 2024, data cutoff, confirmed clinical partial responses were observed in 40% (two out of five) of efficacy-evaluable patients from Cohort 4, suggesting potential synergy of our two novel immunotherapy candidates in patients who did not derive sufficient benefit from checkpoint inhibitors. Of efficacy-evaluable patients with prior disease progression on checkpoint inhibitors to date (from Phase 1 dose escalation cohorts) in the IL-Believe Trial, confirmed clinical responses (per RECIST v1.1) were observed in 45% (five out of eleven) administered TransCon IL-2 &#946;/&#947; doses &#8805;80 &#956;g/kg every 3 weeks, suggesting clinical benefit in treatment-resistant settings (monotherapy (n=4): 1 confirmed partial response (&#8220;PR&#8221;) in colorectal cancer; combination with pembrolizumab (n=2): 1 confirmed complete response and 1 confirmed PR in small-cell lung cancer; combination with TransCon TLR7/8 Agonist (n=5): 2 confirmed PRs in melanoma). In this trial, TransCon IL-2 &#946;&#8260;&#947; alone or in combination with pembrolizumab or TransCon TLR7/8 Agonist was generally well tolerated with no new safety signals.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, we announced updated data from the ongoing Phase 1 dose escalation cohort from IL-Believe Trial. Forty-six patients were enrolled into dose escalation cohorts: 25 to monotherapy and 21 to combination therapy. As of the August 15, 2023, data cutoff, anti-tumor clinical responses were observed with TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">monotherapy (colorectal cancer with PR) or in combination with pembrolizumab (small cell lung cancer, one with confirmed PR and one ongoing with unconfirmed complete response) in heavily pre-treated patients who previously progressed on checkpoint inhibitors. TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> every three weeks was generally well-tolerated, with no meaningful effect on Tregs and eosinophils.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we announced completion of Phase 1 dose escalation in combination with pembrolizumab of the IL-Believe Trial with a total of 21 patients enrolled and RP2D determined at 120 &#181;g/kg IV every three weeks. Twenty-one patients were enrolled.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we announced completion of the Phase 1 monotherapy dose escalation of the IL-Believe Trial with RP2D determined at 120 &#181;g/kg IV every three weeks with 25 heavily pre-treated patients enrolled and a median of four prior lines of systemic therapies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategic Collaborations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also engage in strategic collaborations to further leverage our TransCon technologies in certain geographies and therapeutic areas with market-leading biopharmaceutical companies. These collaborations aim to make promising treatment options available to more patients and to further monetize both our TransCon technologies and our internal product candidates, particularly into therapeutic areas where we believe a partner may have more expertise, capability, and capital. In addition, we may choose to pursue a collaboration to develop and market our internal, wholly owned product candidates in geographic markets outside our core focus areas of the United States and Europe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novo Nordisk A/S</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we entered into a research and development collaboration and license agreement with Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;) pursuant to which we granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products (including Semaglutide) in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement includes provisions requiring at least one TransCon Semaglutide product and at least one other TransCon technology-based product to be identified, developed and commercialized in metabolic diseases to maintain certain exclusivities in the field, with additional provisions for cardiovascular diseases. Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas. The lead program in the collaboration is a once-monthly TransCon Semaglutide product candidate that will initially target obesity and type 2 diabetes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, we have the potential to receive total payments of up to $285 million in upfront, development and regulatory milestone payments for the lead program. In addition, we have the potential to receive sales-based milestone payments and tiered royalties on global net sales. The $285 million includes an upfront fee of $100 million for the exclusive license. For each additional metabolic or cardiovascular disease product candidate, we will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments. In addition, we have the potential to receive sales-based milestone payments and tiered royalties on global net sales. Novo Nordisk agreed to pay royalties for each potential licensed product developed under the agreement that are an escalating tiered, mid-single digit percentage of the annual net sales of such licensed product and are subject to reduction due to patent valid claim expiration, biosimilar product market share, payment made under certain licenses for third party intellectual property and Inflation Reduction Act price negotiations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, we have agreed to conduct certain pre-agreed early research and development of TransCon product candidates under the collaboration and we are eligible to receive cost reimbursement from Novo Nordisk for its performance of such research and development activities under the agreement with respect to such TransCon product candidates. Novo Nordisk is responsible for any other non-clinical and clinical development, regulatory, commercial manufacturing, and commercialization of such TransCon product candidates, and all costs associated with such activities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of the agreement, we granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. Additionally, we granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize GLP-1 receptor products using the TransCon technology for all indications, except for (i) certain pre-agreed rare endocrine indications, (ii) all indications in respect of the eye and adnexa and (iii) all indications in respect of oncology.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until expiry of the last royalty term and for one-year thereafter, we are not permitted to research, develop, manufacture, commercialize, or otherwise exploit outside of the collaboration, any GLP-1 receptor product or any other licensed products that have been subject to the collaboration. We are also not permitted to undertake any research, development, manufacture, commercialization, or other exploitation of products outside of the collaboration in the metabolic field until expiry of the last royalty term of any licensed products that have been subject to the collaboration in metabolic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the agreement has a royalty term that continues, on a per licensed product and per country basis, until the later of (i) the expiration of the last valid patent claim for any of our patents, joint improvement patents, licensed product patents as well as any improvements made by Novo Nordisk covering the licensed product&#8217;s dosage regimen or target product profile, or (ii) 11 years after the first commercial sale of such licensed product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novo Nordisk has the right to terminate the agreement without cause in its entirety or on a per licensed product basis. We have the right to terminate the agreement in its entirety in case Novo Nordisk brings patent challenges with respect to our patents. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of the agreement due to Novo Nordisk&#8217;s default, some or all of the licenses granted by us to Novo Nordisk to develop, manufacture and commercialize any of the licensed products will automatically terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of the agreement due to certain defaults by us, Novo Nordisk may choose to either (i) have the license granted by us to Novo Nordisk to develop, manufacture and commercialize licensed products terminate in its entirety or on a product-by-product basis; or (ii) continue with respect to the affected licensed product at a reduced payment rate.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Teijin Limited</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, we announced that we entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. Under the terms of the agreement with Teijin Limited, we received an upfront payment of $70 million, with additional development and regulatory milestones of up to $175 million, transfer pricing and commercial milestones. In addition, we are eligible to receive royalties on net sales in Japan, of up to a mid-20&#8217;s percentage, varying by product.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, Teijin Pharma Limited announced the submission of an application for manufacturing and marketing approval of palopegteriparatide for the treatment of hypoparathyroidism in Japan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategic Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, we announced the formation of VISEN, a company established to develop and commercialize our endocrinology rare disease therapies in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;). In connection with the formation of VISEN, we granted VISEN exclusive rights to develop and commercialize certain product candidates based on our proprietary TransCon technologies, including TransCon hGH, TransCon PTH, and TransCon CNP, in Greater China for use in all human indications, subject to certain exceptions. As consideration for the rights granted to VISEN, we received 50.0% ownership in the outstanding shares of VISEN and concurrently with the rights we granted to VISEN, entities affiliated with Vivo Capital and Sofinnova Ventures purchased shares in VISEN for an aggregate purchase price of $40 million in cash. In January 2021, we invested additional $12.5 million in VISEN as part of VISEN&#8217;s $150 million Series B financing. As of December 31, 2024, our ownership in VISEN was 43.9%.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, VISEN announced top-line data from the 26-week randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway China Trial of Palopegteriparatide (TransCon PTH) in adults with chronic hypoparathyroidism. VISEN reported a statistically significant higher proportion of patients treated with palopegteriparatide achieved the primary multi-component endpoint compared to placebo. The primary multi-component endpoint was achieved by 77.6% of palopegteriparatide-treated patients (45 of 58), compared to 0.0% of patients (0 of 22) in the placebo group (p-value &lt;0.0001). Results were consistent with those announced by us for its palopegteriparatide Phase 3 trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, VISEN announced that the BLA for lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Administration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, VISEN announced top-line results from the Phase 2 ACcomplisH China Trial in children with achondroplasia aged 2 to 10 years. VISEN reported that patients dosed with TransCon CNP at the 100 &#956;g CNP/kg/week showed significantly higher AGV than placebo at Week 52.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, VISEN announced data from its pivotal Phase 3 study of TransCon hGH in children with GHD in China. VISEN reported that patients dosed with TransCon hGH demonstrated an annualized height velocity (&#8220;AHV&#8221;) of 10.66 cm/year compared to 9.75 cm/year for the daily hGH at 52 weeks (treatment difference at 0.91 cm/year with a 95 percent confidence interval: 0.37 &#8211; 1.45 cm/year, p=0.0010), reaching its primary objective, demonstrating that TransCon hGH is non-inferior to the daily hGH.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunity in China</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">China is the second largest pharmaceutical market in the world after the United States and represents one of the fastest growing pharmaceutical markets worldwide. In recent years, the Chinese government has initiated a number of regulatory reforms that are expected to accelerate drug development, as well as drive growth and demand for new therapeutics in China. In addition to joining an international organization that standardizes regulations for clinical development, the National Medical Products Administration has introduced initiatives such as fast track review for drugs for unmet medical needs and adopted new rules that streamline the drug approval process in China for global companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purpose of our investment in VISEN is to support our strategy to extend our endocrinology rare disease portfolio globally and establish a presence in China in partnership with collaborators who have significant experience and knowledge of the biopharmaceutical opportunity in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rights Agreements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under three exclusive license agreements, each effective November 7, 2018, and as amended January 4, 2021, between the Company and VISEN (collectively, the &#8220;Rights Agreements&#8221;), VISEN must use diligent efforts to develop and commercialize licensed products in Greater China. Additionally, we and VISEN will conduct certain research and development activities allocated to the respective party under a research and technical development plan, and VISEN will reimburse us for costs of conducting such activities, including costs of our personnel committed to performing such activities in Greater China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into a clinical supply agreement with VISEN in 2018 to provide product supply for use in conducting clinical trials in Greater China. Additionally, during 2023, we entered into a commercial supply agreement governing commercial supply of licensed product (TransCon hGH) to VISEN on the terms and conditions set forth in the Rights Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Rights Agreements, we agreed not to research, develop, or commercialize competing products in Greater China, and VISEN agreed not to grant certain rights under its interest in any inventions or intellectual property arising out of the activities conducted under the Rights Agreements to third-parties, in each case, under the terms and conditions specified in the Rights Agreements. We will have the right to exploit inventions and intellectual property arising out of the activities conducted under the Rights Agreements outside of Greater China. Additionally, we granted VISEN a right of first negotiation to develop and commercialize certain of our endocrinology products in Greater China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Rights Agreements continue in effect for as long as a valid claim of a licensed patent exists in Greater China. VISEN may terminate a Rights Agreement for convenience, for uncured material breach by us of a Rights Agreement and for our bankruptcy or insolvency-related events. We may terminate a Rights Agreement for certain specified material breaches thereof by VISEN, in the event VISEN undergoes a change of control in favor of a competitor, if VISEN challenges the validity of any of the licensed patents and for VISEN&#8217;s bankruptcy or insolvency-related events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated Shareholders Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our investment in VISEN, on January 8, 2021, we entered into an Amended and Restated Shareholders Agreement (the &#8220;Amended Shareholders Agreement&#8221;), amending and restating the Shareholders Agreement dated November 7, 2018, between the Company and the parties set forth therein (the &#8220;Shareholders Agreement&#8221;). In addition to rights previously granted under the Shareholders Agreement, under the Amended Shareholders Agreement, we have the right to designate two individuals for election to the board of directors of VISEN. In addition, VISEN has agreed that certain specified events (including certain liquidation events) shall require the approval of (i) shareholders of VISEN holding at least 50% of VISEN&#8217;s Series B preferred shares, (ii) shareholders of VISEN holding at least 60% of VISEN&#8217;s Series A preferred shares and/or (iii) certain members of VISEN&#8217;s board of directors. The Amended Shareholders Agreement can be terminated by written agreement among the holders of at least 60% of VISEN&#8217;s Series A preferred shares and at least 50% of VISEN&#8217;s Series B preferred shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eyconis, Inc</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, we announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with a $150 million commitment from an investor syndicate that included Frazier, RA Capital Management, venBio, and HealthQuest Capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, we are eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any. As of December 31, 2024, our ownership in Eyconis was 41.6%.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we do not maintain the capability to manufacture finished drug products, we utilize contract manufacturers to manufacture finished drug product of our proprietary TransCon product candidates intended for clinical or commercial use. We source starting materials for our manufacturing activities from one or more suppliers. For the starting materials necessary for our proprietary TransCon product candidate development, we have agreements for the supply of such starting materials with drug manufacturers or suppliers that we believe have sufficient capacity to meet our demands. However, from time to time, we source critical raw materials and services from one or a limited number of suppliers and there is a risk that if such supply or services were interrupted, it would materially harm our business. In addition, we typically order raw materials and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We utilize the services of contract manufacturers to manufacture drug substance required for later phases of clinical development and eventual commercialization for us under all applicable laws and regulations and are subject to long term forecasting obligations and certain minimum purchase requirements for all parts of the commercial supply chain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have analytical and process development capabilities in our own facility. We generally perform analytical and process development for our proprietary TransCon product candidates internally and manufacture internally our TransCon product candidates necessary to conduct the non-GLP preclinical studies thereof. However, we occasionally outsource the manufacture of research and development-stage TransCon product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have, and we do not currently plan to acquire or develop, the facilities or capabilities to manufacture bulk drug substance or filled drug product for use in human clinical trials. We rely on third-party manufacturers to produce the bulk drug substances required for our clinical trials and expect to continue to rely on third-parties to manufacture and test clinical trial drug supplies for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contract suppliers manufacture drug substance and finished drug product for our TransCon product candidates for clinical trial use in effort to comply with current good manufacturing practice (&#8220;cGMP&#8221;), applicable local regulations and similar foreign requirements. cGMP and similar foreign requirements include requirements relating to organization of personnel; buildings and facilities; equipment; control of components and drug product containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products. The manufacturing facilities for our products must be in compliance with cGMP requirements and similar foreign requirements, and for device and device components, the Quality System Regulation (&#8220;QSR&#8221;) requirements, before any product is approved. Our third-party manufacturers may also be subject to periodic inspections of facilities by the FDA, the EU member states competent authorities, and other authorities, including reviews of procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also contract with additional third-parties for the filling, labeling, packaging, testing, storage and distribution of our TransCon product candidates. We employ personnel with the significant scientific, technical, production, quality and project management experience required to oversee our network of third-party suppliers and to manage manufacturing, quality data and information for regulatory compliance purposes.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NOF Manufacturing and Supply Agreement Related to TransCon hGH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 21, 2017, we entered into a multi-year Manufacturing and Supply Agreement (the &#8220;NOF Agreement&#8221;) with NOF Corporation (&#8220;NOF&#8221;). Under the NOF Agreement, NOF has agreed to manufacture and supply the mPEG Linker (the &#8220;NOF hGH Product&#8221;) for our TransCon hGH product candidate. We have agreed to purchase certain quantities of NOF hGH Product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The NOF Agreement is effective as of December 21, 2017. The initial term of the NOF Agreement terminates on December 31, 2025 unless earlier terminated. After the expiration of the initial term of the NOF Agreement, the NOF Agreement continues until it is terminated. The NOF Agreement may be terminated (i) by either party for the other party&#8217;s assignment for the benefit of creditors, insolvency, bankruptcy, liquidation, dissolution, or the taking of any action by the other party under an act for relief from creditors, (ii) by either party for the other party&#8217;s uncured material breach, (iii) by us after the initial term of the NOF Agreement with one year written notice, or (iv) by mutual agreement of the parties. In addition, the NOF Agreement may be terminated by us in the event of a change of 50% or more of the direct or indirect ownership of NOF or manufacturing facilities relevant to the NOF Agreement, if such ownership goes to a third-party materially involved in the treatment of growth related disorders in humans. The NOF Agreement may also be terminated by either party for a continuing event of force majeure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The NOF Agreement contains, among other provisions customary representations and warranties by us and NOF, grants of certain limited license rights related to either party&#8217;s intellectual property in connection with the manufacturing and supply of NOF hGH Product, certain indemnification rights in favor of both parties and customary confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NOF Manufacturing and Supply Agreement Related to TransCon PTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 31, 2020, we entered into a multi-year Manufacturing and Supply Agreement (the &#8220;NOF PTH Agreement&#8221;) with NOF. Under the NOF PTH Agreement, NOF has agreed to manufacture and supply the PEG maleimide (the &#8220;NOF PTH Product&#8221;) for our TransCon PTH product candidate. We have agreed to purchase certain quantities of NOF PTH Product. We may purchase NOF PTH Product from other manufacturers and are not obligated to purchase NOF PTH Product from NOF, other than certain quantities that have been forecasted by us in accordance with a mandatory rolling forecast that we must deliver to NOF from time to time.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The NOF PTH Agreement is effective as of August 31, 2020. The initial term of the NOF PTH Agreement terminates on December 31, 2027 unless earlier terminated. After the expiration of the initial term of the NOF PTH Agreement, the NOF PTH Agreement continues until it is terminated. The NOF PTH Agreement may be terminated (i) by either party for the other party&#8217;s assignment for the benefit of creditors, insolvency, bankruptcy, liquidation, dissolution, or the taking of any action by the other party under an act for relief from creditors, (ii) by either party for the other party&#8217;s uncured material breach, (iii) by us after the initial term of the NOF PTH Agreement with advance written notice, (iv) by NOF after the initial term of the NOF PTH Agreement with advance written notice, (v) by mutual agreement of the parties, or (vi) by us in the event of a change of fifty percent or more of the direct or indirect ownership of NOF or manufacturing facilities relevant to the NOF PTH Agreement, if such ownership goes to any of a pre-defined list of third parties. In addition, the NOF PTH Agreement may be terminated by NOF in the event of a change of fifty percent or more of the direct or indirect ownership of Ascendis, if such ownership goes to any of a pre-defined list of third parties. The NOF PTH Agreement may also be terminated by either party for a continuing event of force majeure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The NOF PTH Agreement contains, among other provisions, customary representations and warranties by us and NOF, grants of certain limited license rights related to either party&#8217;s intellectual property in connection with the manufacturing and supply of NOF PTH Product, certain indemnification rights in favor of both parties and customary confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Carbogen Manufacturing and Supply Agreement Related to TransCon hGH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 26, 2018, we entered into a multi-year Manufacturing and Supply Agreement (the &#8220;Carbogen Agreement&#8221;) with Carbogen Amcis AG (&#8220;Carbogen&#8221;). Under the Carbogen Agreement, Carbogen has agreed to manufacture and supply Linker A (the &#8220;Carbogen Product&#8221;) for our TransCon hGH product candidate. We may purchase Linker A from other manufacturers and are not obligated to purchase Carbogen Product from Carbogen, other than certain quantities that have been forecasted by us in accordance with a mandatory rolling forecast that we must deliver to Carbogen from time to time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Carbogen Agreement is effective as of October 26, 2018. The initial term of the Carbogen Agreement expires five years after the first commercial launch of our TransCon hGH product candidate (the &#8220;Carbogen Initial Term&#8221;) unless earlier terminated. After the expiration of the Carbogen Initial Term of the Carbogen Agreement, the Carbogen Agreement continues until it is terminated. The Carbogen Agreement may be terminated (i) by either party for the other party&#8217;s assignment of the Carbogen Agreement for the benefit of creditors, insolvency, bankruptcy, dissolution, or taking of any action under an act for relief from creditors, (ii) by either party for the other party&#8217;s uncured material breach, (iii) by us after the Carbogen Initial Term of the Carbogen Agreement with one year written notice, (iv) by Carbogen after the Carbogen Initial Term of the Carbogen Agreement with four years written notice or (v) by mutual agreement of the parties. In addition, the Carbogen Agreement may be terminated by us in the event of a change of fifty percent or more of the direct or indirect ownership of Carbogen, if such ownership goes to a third-party materially involved in the treatment of growth-related disorders in humans. The Carbogen Agreement may also be terminated by either party for a continuing event of force majeure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Carbogen Agreement contains, among other provisions, certain representations and warranties by us and Carbogen, grants certain rights to intellectual property relating to, or inventions made in connection with, the manufacturing and supply of Carbogen Product, provides for certain indemnification rights in favor of both parties and includes confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Carbogen Manufacturing and Supply Agreement Related to TransCon PTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 27, 2021, we entered into a multi-year Manufacturing and Supply Agreement (the &#8220;Carbogen PTH Agreement&#8221;) with Carbogen. Under the Carbogen PTH Agreement, Carbogen has agreed to manufacture and supply Linker F (the &#8220;Carbogen PTH Product&#8221;) for our TransCon PTH product candidate. We may purchase Carbogen PTH Product from other manufacturers and are not obligated to purchase Carbogen PTH Product from Carbogen, other than certain quantities that have been forecasted by us in accordance with a mandatory rolling forecast that we must deliver to Carbogen from time to time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Carbogen PTH Agreement is effective as of May 27, 2021. The initial term of the Carbogen PTH Agreement expires five years after the first commercial launch of our TransCon PTH product candidate (the &#8220;Carbogen PTH Initial Term&#8221;) unless earlier terminated. After the expiration of the Carbogen PTH Initial Term of the Carbogen PTH Agreement, the Carbogen PTH Agreement continues until it is terminated. The Carbogen PTH Agreement may be terminated (i) by either party for the other party&#8217;s assignment of the Carbogen PTH Agreement for the benefit of creditors, insolvency, bankruptcy, dissolution, or taking of any action under an act for relief from creditors, (ii) by either party for the other party&#8217;s uncured material breach, (iii) by us after the Carbogen PTH Initial Term with one year written notice, (iv) by Carbogen after the Carbogen PTH Initial Term of the Carbogen PTH Agreement with four years written notice (subject to Carbogen&#8217;s obligation to actively assist in technology transfer to an alternate supplier) or (v) by mutual agreement of the parties. In addition, the Carbogen PTH Agreement may be terminated by us in the event of a change of fifty percent or more of the direct or indirect ownership of Carbogen, if such ownership goes to a third-party materially involved in the treatment of growth-related disorders in humans. The Carbogen PTH Agreement may also be terminated by either party for a continuing event of force majeure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Carbogen PTH Agreement contains, among other provisions, certain representations and warranties by us and Carbogen, grants of certain rights to intellectual property relating to, or inventions made in connection with, the manufacturing and supply of Carbogen PTH Product, certain indemnification rights in favor of both parties and confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phillips Medisize (formerly B&amp;O Medicom and Medicom Innovation Partner)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 12, 2017, we entered into a multi-year Manufacturing and Supply Agreement (the &#8220;Medicom Agreement&#8221;) with Medicom Innovation Partner (&#8220;Medicom&#8221;). Under the Medicom Agreement, Medicom has agreed to exclusively manufacture and supply the auto injector injection device (the &#8220;Medicom Product&#8221;) for our TransCon hGH product candidate. We are obligated to purchase certain quantities that have been forecasted by us in accordance with a mandatory rolling forecast that we must deliver to Medicom from time to time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Medicom Agreement is effective as of January 12, 2017. The term of the Medicom Agreement terminates on June 30, 2025 (&#8220;Medicom Initial Term&#8221;) unless earlier terminated or unless extended unilaterally by us, with notice of extension to be given no later than June 30, 2024, by five years until June 30, 2030 (&#8220;Extended Term&#8221;) after which date it shall continue indefinitely unless terminated. The Medicom Agreement may be terminated (i) by either party for the other party&#8217;s bankruptcy or insolvency-related events, (ii) by either party for the other party&#8217;s uncured material breach, (iii) by us by not extending the Medicom Initial Term into the Extended Term, (iv) by Medicom after the Extended Term of the Medicom Agreement with two year&#8217;s advance written notice or by us after the Extended Term of the Medicom Agreement with one year&#8217;s advance notice, or (v) by Medicom if we purchase less than an agreed volume of the Medicom Product (provided that we may avoid such termination by paying Medicom&#8217;s lost profits up to such agreed minimum volume). In addition, the Medicom Agreement may be terminated by us in the event of a change of control of Medicom, if such control goes to a third-party materially involved in the treatment of certain defined endocrinology diseases in humans. In all events of termination Medicom is obligated to support a tech transfer of manufacture of Medicom Product to an alternate supplier.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Medicom Agreement contains, among other provisions certain representations and warranties by us and Medicom, grants certain limited license rights related to either party&#8217;s intellectual property in connection with the manufacturing and supply of Medicom Product, provides for certain indemnification rights in favor of both parties and includes confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vetter Pharma International GmbH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 14, 2018, we entered into a multi-year Supply Agreement (the &#8220;Vetter Agreement&#8221;) with Vetter Pharma International (&#8220;Vetter&#8221;). Under the Vetter Agreement, Vetter has agreed to manufacture and fill-and-finish drug product in dual-chamber cartridges (the &#8220;Ascendis Product&#8221;) for our TransCon hGH product candidate. Vetter has agreed to supply in accordance with a long-term forecast in addition to a rolling forecast with a binding part that we must deliver to Vetter from time to time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vetter Agreement is effective as of January 1, 2019. The term of the Vetter Agreement expires on the five-year anniversary of the date of first regulatory approval of the TransCon hGH product (the &#8220;Initial Term&#8221;) after which term it shall be automatically renewed for subsequent two-year terms unless terminated. The Vetter Agreement may be terminated (i) by either party for the other party&#8217;s uncured material breach, including certain enumerated events constituting material breach such as bankruptcy or insolvency-related events, (ii) by us with two years&#8217; notice, with effect no earlier than two years after expiry of the Initial Term or (iii) by either party if the other party is taken over by our or a Vetter competitor, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vetter Agreement contains, among other provisions, certain representations and warranties by us and Vetter, grants certain limited license rights in connection with Vetter&#8217;s manufacturing and supply, and our sale, distribution and other use, of Ascendis Product, provides for certain indemnification rights in favor of both parties and includes confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 1, 2022, we entered into a multi-year Supply Agreement (as amended on April 8, 2024, the &#8220;PTH Vetter Agreement&#8221;) with Vetter. Under the PTH Vetter Agreement, Vetter has agreed to manufacture and supply single chamber cartridges pre-filled with TransCon PTH (the &#8220;Ascendis PTH Product&#8221;). Vetter has agreed to supply in accordance with a long-term forecast and a rolling forecast with certain materials that we deliver to Vetter from time to time.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the PTH Vetter Agreement expires five years from the effective date (the &#8220;PTH Initial Term&#8221;), after which it shall automatically renew for subsequent two-year terms unless terminated. The PTH Vetter Agreement may be terminated (i) by either party for the other party&#8217;s uncured material breach, including certain enumerated events constituting material breach such as bankruptcy or insolvency-related events, (ii) by us with two years&#8217; notice, with effect no earlier than the expiry of the PTH Initial Term or (iii) by either party if the other party is taken over by our or a Vetter competitor, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PTH Vetter Agreement includes, among other provisions, certain representations and warranties by us and Vetter, grants limited license rights in connection with Vetter&#8217;s manufacturing and supply, and our sale, distribution, and use of Ascendis PTH Product, provides for indemnification rights for both parties, and includes confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lonza Tech Transfer and Manufacturing Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2019, we entered into a multi-year commercial supply agreement (the &#8220;Lonza Agreement&#8221;) with Lonza Ltd (&#8220;Lonza&#8221;). Under the Lonza Agreement, Lonza has agreed to manufacture and supply drug substance for our TransCon hGH product candidate (the &#8220;TransCon hGH Drug Substance&#8221;). Starting in 2023, we are obligated to purchase a certain minimum annual quantity of TransCon hGH Drug Substance from Lonza. We may also purchase TransCon hGH Drug Substance from other manufacturers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Lonza Agreement secures us a certain capacity of TransCon hGH Drug Substance per year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Lonza Agreement is effective as of December 12, 2019. The initial term of the Lonza Agreement expires seven years after first approval of a drug product manufactured using the TransCon hGH Drug Substance (the &#8220;Lonza Initial Term&#8221;) unless earlier terminated. During the first five years of the Lonza Initial Term, we may decide, in our sole discretion, to extend the term of the Lonza Agreement by two years. The Lonza Agreement may be terminated (i) by either party for the other party&#8217;s bankruptcy or insolvency-related events, (ii) by either party for the other party&#8217;s uncured material breach, (iii) by either party for a continuing event of force majeure, (iv) by either party upon written notice after a specified time period in the event of our change of control, and (v) by either party in the event of the occurrence of certain conditions related to the manufacturing of the TransCon hGH Drug Substance as more fully described in the Lonza Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Lonza Agreement contains, among other provisions, certain warranties by us and Lonza, grants certain limited license rights related to either party&#8217;s intellectual property in connection with the manufacturing and supply of TransCon hGH Drug Substance, provides for certain indemnification rights in favor of both parties and includes confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sharp Corporation Packaging and Supply Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 1, 2019, we entered into a multi-year packaging agreement (the &#8220;Sharp Agreement&#8221;) with Sharp Corporation (&#8220;Sharp&#8221;). Under the Sharp Agreement, Sharp agreed to package, assemble, and label TransCon hGH for commercial use in certain territories, including the United States and the EU. We are non-exclusive to Sharp and may engage other manufacturers to package, assemble, and label TransCon hGH but we are obligated to meet certain minimum spend requirements for TransCon hGH during the first 12-month period after first shipment of TransCon hGH for commercial sale after regulatory approval thereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sharp Agreement is effective as of December 1, 2019. The initial term of the Sharp Agreement expires on December 31, 2025 and will be automatically extended for additional two-year periods unless earlier terminated. The Sharp Agreement may be terminated (i) by either party upon mutual consent, (ii) by either party for the other party&#8217;s uncured material breach, (iii) by either party for the other party&#8217;s bankruptcy or insolvency-related events, (iv) by either party for a continuing event of force majeure, or (v) by either party after the initial term of the Sharp Agreement has been completed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sharp Agreement contains, among other provisions, certain warranties by Sharp, provides for certain indemnification rights in favor of both parties and includes confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bachem Manufacturing and Supply Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 27, 2020, we entered into a multi-year Manufacturing and Supply Agreement (the &#8220;Bachem Agreement&#8221;) with Bachem AG (&#8220;Bachem&#8221;). Under the Bachem Agreement, Bachem has agreed to manufacture and supply PTH drug substance (the &#8220;Bachem Product&#8221;) for our TransCon PTH product candidate. We may purchase Bachem Product from other manufacturers and are not obligated to purchase Bachem Product from Bachem, other than certain quantities that have been forecasted by us in accordance with a mandatory rolling forecast that we must deliver to Bachem from time to time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Bachem Agreement is effective as of December 27, 2020. The initial term of the Bachem Agreement expires on December 31, 2027 (the &#8220;Bachem Initial Term&#8221;) unless earlier terminated. After the expiration of the Bachem Initial Term, provided that market approval is received prior to expiration of the Bachem Initial Term, the Bachem Agreement continues until it is terminated. The Bachem Agreement may be terminated (i) by either party for the other party&#8217;s assignment of the Bachem Agreement for the benefit of creditors, insolvency, bankruptcy, dissolution, or taking of any action under an act for relief from creditors, (ii) by either party for the other party&#8217;s uncured material breach, (iii) by us after the Bachem Initial Term with two years&#8217; written notice, (iv) by Bachem after the Bachem Initial Term with four years&#8217; written notice or (v) by mutual agreement of the parties. In addition, the Bachem Agreement may be terminated by us prior to expiration of the Bachem Initial Term if Bachem is acquired by a company marketing a competing drug to TransCon PTH. The Bachem Agreement may also be terminated by either party for a continuing event of force majeure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Bachem Agreement contains, among other provisions, certain representations and warranties by us and Bachem, grants of certain rights to intellectual property relating to, or inventions made in connection with, the manufacturing and supply of Bachem Product, certain indemnification rights in favor of both parties and confidentiality provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical industry is very competitive and subject to rapid and significant innovation. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical and generic drug companies, universities, and other research institutions. Many of our competitors have greater resources, as well as larger research and development functions and more experienced marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are superior to, or more effectively marketed than, the product candidates that we are currently developing or that we may develop, which could render our products obsolete and noncompetitive. For additional information regarding the companies that may be competitive with our product candidates currently in development, please see the descriptions of our current product candidates included above under the caption &#8220;TransCon Product Candidates.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, many of our competitors have greater experience than we do in conducting preclinical and clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals for drug candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory authority approvals and commence commercial sale of their drugs before their competitors may achieve a significant competitive advantage. Drugs resulting from our research and development efforts or from our joint efforts with collaboration partners therefore may not be commercially competitive with our competitors&#8217; existing products or products under development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware that other companies are developing or evaluating enhanced drug delivery and sustained release technologies, which may be competitive with our TransCon technologies. In particular, we believe Extend Biosciences, Nektar Therapeutics, OPKO Health, Inc., ProLynx Inc., MBX Biosciences and Serina Therapeutics, Inc. are developing technology platforms in the areas of enhanced drug delivery and/or reversible linkers that may be competitive with our TransCon technologies. We also expect that technological developments will occur at a rapid rate and that competition is likely to intensify as various enhanced delivery and sustained released technologies may achieve similar advantages.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We actively seek to protect the intellectual property and proprietary technology that we believe is important to our business, which includes seeking and maintaining patents covering our technology, i.e., TransCon linkers and carriers, specific lead candidate structures, broad product concepts, proprietary processes and any other inventions that are commercially and/or strategically important to the development of our business. We also rely on trade secrets that may be important to the development of our business and actively seek to protect the confidentiality of such trade secrets.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success will depend on our ability to obtain and maintain patents and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable patents or otherwise misappropriate other intellectual property rights of third-parties. For more information, please see &#8220;Item 3 D. Key Information&#8212;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we own a total of 99 patent families, 18 of which are currently in their priority year or international phase. These patent families include granted patents in the United States (62), Europe (36), Australia (54), Brazil (10), Canada (29), China (20), Israel (21), Indonesia (6), India (12), Korea (15), Malaysia (13), New Zealand (18), Japan (52), Mexico (21), Singapore (20), Russia (24), the United Arab Emirates (1) and South Africa (17) and approximately 583 pending national/regional applications in a total of 26 jurisdictions (excluding the member states of the European Patent Convention in which our European patents were validated, Hong Kong, in which certain Europe and China patents are extended, and Macao, in which certain China patents are extended).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">So far, none of our granted patents have been subject to opposition proceedings, appeals or similar actions aiming at revoking or restricting the scope of such granted patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent portfolios for the fields containing our most advanced product candidates, as of December 31, 2024, are summarized below and, except as noted otherwise, the expected expiration dates included in the summary below do not give effect to patent term extensions or adjustments that may be available.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon hGH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our patent portfolio related to TransCon hGH includes eight patent families relating to different aspects of TransCon hGH and eleven patent families covering various aspects of the auto-injector device for the administration of TransCon hGH. The first of these patent families is a composition of matter patent family directed to the particular stoichiometry of TransCon hGH and a related TransCon carrier. As of December 31, 2024, this patent family includes one patent granted in the United States, which is expected to expire in February 2027 (accounting for patent term adjustment).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The second of these patent families is a composition of matter patent family directed to a TransCon linker used in TransCon hGH. As of December 31, 2024, this patent family includes patents granted in the United States, Europe, Australia, Brazil, Canada, Japan and Mexico and one pending patent application in the United States. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in March 2025, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The third of these patent families is a composition of matter patent family directed to a broad class of TransCon hGH lead candidate structures. As of December 31, 2024, this patent family includes patents granted in the United States, Europe, Australia, Brazil, Canada, China, Israel, India, Japan, Mexico, Russia and South Africa and pending patent applications in Europe and the United States. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in April 2029, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fourth of these patent families is a composition of matter patent family directed to specific dry pharmaceutical compositions comprising TransCon hGH. As of December 31, 2024, this patent family includes patents granted in the United States, Europe, Australia, Brazil, Canada, India, Israel, Mexico, Singapore and South Africa and one pending patent application in the United States. The granted patents and any patents granted from the pending patent application in this patent family are expected to expire in December 2030, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fifth of these patent families is a composition of matter patent family directed to a broad class of TransCon hGH lead candidate structures. As of December 31, 2024, this patent family includes patents granted in the United States, Australia, Europe, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore and South Africa and pending patent applications in the United States, Europe, Australia, Brazil, Canada, Israel, Japan, South Korea, Mexico, Russia and Singapore. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in November 2035, absent any patent term adjustments or extensions. One granted EP patent in this family was also used as a basis for requesting a supplementary protection certificate (&#8220;SPC&#8221;) for SKYTROFA in Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, Great Britain, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Lithuania, Luxemburg, Latvia, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia and Slovakia. SPCs have already been granted in Bulgaria, Cyprus, Czech Republic, Denmark, Spain, Finland, France, Greece, Hungary, Iceland, Italy, Lithuania, Latvia, Malta, the Netherlands, Norway, Portugal, Sweden, Slovenia and Slovakia, each of which are expected to expire in January 2037.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The sixth of these patent families is directed to a particular dosage regimen for long-acting growth hormone formulations. As of December 31, 2024, this patent family includes granted patents in the United States and Europe and pending patent applications in the United States and in Europe. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in November 2035, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The seventh of these patent families is directed to potential superior efficacy achieved with TransCon hGH treatment. As of December 31, 2024, this patent family includes a granted patent in Japan and pending patent applications in the United States, Europe, Australia, Canada, China, Israel, Japan, Mexico and Singapore. The granted patent and any patents granted from the pending patent applications in this patent family are expected to expire in March 2040, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The eighth of these patent families is directed to the use of TransCon hGH in the treatment of an inflammation-induced disease, in particular of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, China, Indonesia, Israel, Japan, South Korea, Mexico, Malaysia, New Zealand, Russia, Singapore and South Africa. Any patents granted from the pending patent applications in this patent family are expected to expire in March 2042, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seven of the eleven patent families covering the auto-injector device for the administration of TransCon hGH with a filing date of December 29, 2016, include pending patent applications in the United States, Europe, Australia, Canada, Japan and New Zealand and ten granted patents in the United States, six granted patents in Europe, nine granted patents in Australia, four granted patents in Canada, seven granted patents in New Zealand and thirteen granted patents in Japan as of December 31, 2024. The granted patents in these patent families are expected to expire in December 2036, absent any patent term adjustments or extensions. As of December 31, 2024, another two of the eleven patent families covering the auto-injector device with a filing date of May 23, 2018 and June 29, 2018, respectively, include pending patent applications in the United States, Europe, the United Arab Emirates, Australia, Canada, China, Israel, Japan, South Korea, Mexico, Malaysia, New Zealand, Russia and Singapore and two granted patents in the United States, two granted patents in Australia, two granted patents in Brazil, three granted patents in China, two granted patents in India, three granted patents in Japan, three granted patents in South Korea, one granted patent in Mexico, two granted patents in Malaysia, two granted patents in Russia, two granted patents in Indonesia, two granted patents in Singapore and one granted patent in South Africa. The granted patents in these patent families are expected to expire in March and June 2038, respectively, absent any patent term adjustments or extensions. The tenth patent family includes pending patent applications in the United States, Europe, the United Arab Emirates, Australia, Brazil, Canada, China, Eurasia, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand, Singapore, Taiwan and South Africa. We expect any patents granted from the pending patent applications in this patent family to expire in September 2042, absent any patent term adjustments or extensions. The eleventh patent family is currently in its priority year. We expect any patents granted from this family to expire in May 2045, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the SPCs, three requests for a patent term extension for SKYTROFA were filed based on one granted U.S. patent from the third patent family and two granted patents from the fourth patent family, from which one will be selected for the patent term extension upon allowance. For all of these three requests a preliminary assessment that the patents would be eligible for extension was received from FDA.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon PTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio related to TransCon PTH includes twelve patent families relating to different aspects of TransCon PTH. The first of these patent families is a composition of matter patent family directed to the TransCon linker used in TransCon PTH. As of December 31, 2024, this patent family includes granted patents in the United States, Europe, the United Arab Emirates, Australia, Canada, China, Israel, Japan, Mexico, Russia and South Africa and pending patent applications in Europe, the United States and Brazil. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in January 2029, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The second of these patent families is a composition of matter patent family directed to a broad class of TransCon PTH candidate structures. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, China, Indonesia, Israel, Japan, South Korea, Mexico, Malaysia, New Zealand, Russia, Singapore and Thailand and granted patents in the United States, Australia, China, Europe, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand, Russia, Singapore and South Africa. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in February 2037, absent any patent term adjustments or extensions. The granted EP patent in this family was used as a basis for requesting an SPC for YORVIPATH in Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, Great Britain, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Lithuania, Luxemburg, Latvia, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia and Slovakia. An SPC was already granted in the Netherlands and Malta with an expiration date of November 2038.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The third and fourth of these patent families are method of treatment patent families directed to a particular dosage regimen. As of December 31, 2024, one of these patent families includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, China, Israel, Indonesia, Japan, South Korea, Malaysia, New Zealand, Russia and Thailand and granted patents in the United States, Europe, Australia, China, Indonesia, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore and South Africa. The other one of these patent families includes pending patent applications in the United States, Europe, Australia, Canada and Japan and granted patents in Europe, Australia, China and Japan. We expect any patents granted from the pending patent applications in these patent families to expire in September 2037, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fifth of these patent families is a composition of matter family directed to PTH compounds exhibiting a beneficial pharmacokinetic profile. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, Brazil, Canada, China, Israel, South Korea, New Zealand and Russia and granted patents in the United States, Europe, Australia, China, Japan, South Korea, Mexico, New Zealand, Russia, Singapore and South Africa. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in September 2037, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The sixth patent family relates to a starting dose for treatment with reversible PTH conjugates. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, China, Indonesia, Israel, Japan, South Korea, Mexico, Malaysia, New Zealand, Russia, Singapore, Thailand and South Africa and granted patents in Japan, Malaysia and Russia. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in May 2039, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The seventh patent family relates to a pharmaceutical composition comprising reversible PTH conjugates. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, China, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand, the Philippines, Russia, Singapore, Taiwan, Thailand, Vietnam and South Africa and granted patents in Japan and Russia. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in February 2040, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The eighth and ninth patent families relate to a method of titrating hypoparathyroidism patients off of standard of care within four weeks from the beginning of daily treatment with a PTH compound and the treatment of the physical and mental well-being of hypoparathyroidism patients, respectively. As of December 31, 2024, the eighth family includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, China, Indonesia, Israel, Japan, South Korea, Mexico, Malaysia, New Zealand, Russia, Singapore and South Africa and a granted patent in Russia. The ninth patent family includes pending patent applications in the United States, Europe, Australia, Canada, China, Israel, Japan, South Korea and Mexico. The granted patent and any patents granted from the pending patent applications in this patent family are expected to expire in September 2041, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tenth patent family relates to a reduction in bone mineral density in patients having increased bone mineral density. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, the United Arab Emirates, Australia, Brazil, Canada, China, Eurasia, Israel, Japan, South Korea, Mexico, Malaysia, New Zealand, Singapore and South Africa. We expect any patents granted from the pending patent applications in this patent family to expire in September 2042, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The eleventh patent family covers treatment of hypoparathyroidism initially with a long-acting PTH compound, followed by treatment with an ultra-long-acting PTH compound. As of December 31, 2024, this patent family is in the Patent Cooperation Treaty phase. We expect any patents granted from this patent family to expire in September 2042, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The twelfth family covers treatment of chronic kidney disease. As of December 31, 2024, this patent family is in the Patent Cooperation Treaty phase. We expect any patents granted from this patent family to expire in September 2044, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the SPCs, three requests for a patent term extension for YORVIPATH were filed based on two granted U.S. patents from the third patent family described above and one granted patent from the fifth patent family described above, from which one will be selected for patent term extension upon allowance.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon CNP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio related to TransCon CNP includes fifteen patent families relating to different aspects of TransCon CNP. The first of these patent families is a composition of matter patent family directed to the particular stoichiometry of TransCon CNP and a related TransCon carrier. As of December 31, 2024, this patent family includes a patent granted in the United States, which is expected to expire in February 2027 (accounting for patent term adjustment).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The second of these patent families is a composition of matter patent family directed to the TransCon linker used in TransCon CNP. As of December 31, 2024, this patent family includes granted patents in the United States, Europe, the United Arab Emirates, Australia, Canada, China, Israel, Japan, Mexico, Russia and South Africa and includes pending patent applications in Europe, the United States and Brazil.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in January 2029, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The third of these patent families is a composition of matter patent family directed to a broad class of TransCon CNP candidate structures. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, Australia, Canada, India, Japan, Mexico, Malaysia, Singapore and Thailand and granted patents in China, Israel, South Korea, Malaysia, Russia, Singapore and South Africa. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in January 2036, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fourth to the ninth patent families are composition of matter patent families directed various CNP compounds having beneficial properties. As of December 31, 2024, the first one of these six patent families includes pending patent applications in the United States, Europe and Japan and granted patents in the United States, Australia, Canada, Japan and South Africa. As of December 31, 2024, the second one includes pending patent applications in the United States, Australia and Japan and granted patents in the United States, Europe, Australia, Canada, Japan and South Africa. As of December 31, 2024, the third one includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, Indonesia, India, Japan, South Korea, New Zealand and Singapore and granted patents in the United States, Australia, China, Israel, India, Japan, Mexico, Malaysia, Singapore and South Africa. As of December 31, 2024, the fourth one includes pending patent applications in the United States, Europe and Israel and granted patents in the United States, Australia, Canada and New Zealand. As of December 31, 2024, the fifth one includes pending patent applications in the United States, Europe, Brazil and China and granted patents in the United States, Australia, Canada, China, Israel, New Zealand, South Korea and Singapore. As of December 31, 2024, the sixth one includes pending patent applications in the United States, Europe and Australia and granted patents in the United States, Australia, Canada and Israel. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in January 2037, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tenth patent family covers a combination therapy of TransCon CNP. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, Brazil, Canada, Israel, South Korea and Thailand and granted patents in the United States, Europe, Australia, China, Indonesia, Israel, Japan, South Korea, Mexico, Malaysia, New Zealand, Russia, Singapore and South Africa. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in September 2037, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The eleventh patent family relates to a pharmaceutical composition comprising reversible CNP conjugates. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, China, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand, the Philippines, Russia, Singapore, Taiwan, Thailand, Vietnam and South Africa and granted patents in China, Japan and Russia. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in February 2040, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The twelfth patent family relates to a pharmacologically effective dose of TransCon CNP. As of December 31, 2024, this patent family consists of pending patent applications in the United States, Europe, Australia, Canada, China, Israel, Japan, South Korea and Singapore. We expect any patents granted from the pending patent applications in this patent family to expire in December 2042, absent any patent term adjustments or extensions. One of the priority applications within this family was also claimed by a Patent Cooperation Treaty application relating to improving muscle function. We expect any patents granted from this branch of the patent family to expire in November 2043, absent any patent term adjustments or extension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The thirteenth patent family, which relates to the treatment of spinal deformities, claims priorities from the twelfth patent family. We expect any patents granted from this patent family to expire in March 2044, absent any patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fourteenth patent family relates to a liquid formulation of TransCon CNP. As of December 31, 2024, this patent family includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, China, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand Russia, Singapore and South Africa. We expect any patents granted from the pending patent applications in this patent family to expire in May 2043, absent any patent term adjustment or extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fifteenth patent family relates to the use of TransCon CNP for the prevention or reduction of leg bowing. As of December 31, 2024, this patent family is in its priority year and we expect any patents granted from this patent family to expire in December 2045, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Symbol',serif;font-style:italic;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Symbol',serif;font-style:italic;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our patent portfolio related to TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> includes four patent families. The first of these patent families is a composition of matter patent family directed to a TransCon linker used in TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, this patent family includes patents granted in the United States, Europe, Australia, Brazil, Canada, Japan and Mexico and one pending patent application in the United States. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in March 2025, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The second and third patent family are composition of matter patent families directed to a broad class of TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> lead candidate structures. As of December 31, 2024, the second patent family includes pending patent applications in the United States, Europe, Australia, Brazil, Canada, China, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand, Russia, Singapore, Thailand and South Africa and granted patents in Australia, China, Israel, Japan and Russia. The granted patents and any patents granted from the pending patent applications in this patent family are expected to expire in March 2039. As of December 31, 2024, the third patent family includes pending patent applications in the United States, Europe, Argentina, the United Arab Emirates, Australia, Brazil, Canada, China, Eurasia, Egypt, Indonesia, Israel, India, Japan, South Korea, Mexico, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, Vietnam and South Africa and a granted patent in the United States. The granted patent and any patents granted from the pending patent applications in this patent family are expected to expire in June 2041, absent any patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fourth patent family relates to a pharmaceutical dose of TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, this patent family includes one Patent Cooperation Treaty application. We expect any patents granted in this patent family to expire in May 2044, absent any patent term adjustments or extension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Technologies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio also includes patents and pending patent applications generally relating to our TransCon technologies, including TransCon linkers, TransCon carriers and certain soluble conjugates. We own an aggregate of 16 patent families relating to TransCon linkers, the material components of which are described above. We also own an aggregate of 11 patent families relating to TransCon carriers, the material components of which are described above.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Laws and Regulations Regarding Patent Terms</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent term may be shortened if a patent is terminally disclaimed over another patent or if there are delays in patent prosecution by the patentee. A patent&#8217;s term may be lengthened by a patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in granting a patent. The patent term of a European patent is 20 years from its filing date, which, unlike in the United States, is not subject to patent term adjustments.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of a patent that covers an FDA-approved drug or biologic may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug or biologic is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We anticipate that some of our granted patents may be eligible for patent term extensions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation and Product Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, including any manufacturing changes, safety surveillance, efficacy, quality control, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, sale, import, export and the reporting of safety and other post-market information of pharmaceutical and medical device products such as those we are developing. Medicinal products, including drugs and biologics, must be approved or licensed by the FDA through the NDA or BLA process, before being able to be legally marketed in the US. Product candidates will be subject to similar requirements in other countries prior to marketing in those countries. The processes for obtaining regulatory approvals in the United States, the European Union (&#8220;EU&#8221;) and in other countries, along with subsequent compliance with appropriate federal, state, local and foreign statutes and regulations, require the expenditure of substantial time and resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, sponsors of drugs and biologics are subject to extensive regulation by the FDA, which regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and in the case of biologics, also under the Public Health Service Act (&#8220;PHSA&#8221;) and their implementing regulations, and other federal, state, and local regulatory authorities. The FDCA, PHSA and their implementing regulations set forth, among other things, requirements for the research, testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record keeping, reporting, distribution, import, export, advertising and promotion of our products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs or BLAs, withdrawal of an approval, imposition of a clinical hold on clinical studies, issuance of warning letters or other notices of violation, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s Good Laboratory Practice (&#8220;GLP&#8221;) regulations, where applicable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND which must become effective before human clinical trials may begin; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board (&#8220;IRB&#8221;) at each clinical site before each trial may be initiated;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice (&#8220;GCP&#8221;), requirements to establish the safety and efficacy of the proposed drug or, or safety, purity and potency of the proposed biological product for each indication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an NDA or BLA; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with Current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s or biologic&#8217;s identity, strength, quality and purity;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of potential FDA inspection of selected clinical investigation sites to assess compliance with GCP; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA or BLA to permit commercial marketing of the product for particular indications for use in the United States. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonclinical Studies and Investigational New Drug Applications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonclinical studies include laboratory evaluations of product chemistry, toxicity and formulations, as well as animal studies to assess safety and efficacy. An IND is a request for authorization from the FDA to administer an investigational pharmaceutical product to humans. A sponsor must submit the results of the nonclinical tests, together with chemistry, manufacturing &amp; control information, and any available clinical data or literature, to the FDA as part of an IND. Some nonclinical testing may continue after the IND is submitted. An IND automatically becomes effective and a clinical trial proposed in the IND may begin 30 days after the FDA receives the IND, unless during this 30-day waiting period, the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the sponsor must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. The FDA may impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational pharmaceutical product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety (such as the required subject examinations, processes for tracking adverse events and required laboratory investigations), and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA. In addition, written safety reports regarding serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar pharmaceutical products, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure must be submitted to the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Information about certain clinical trials must be submitted within specific timeframes to the NIH, for public dissemination on their www.clinicaltrials.gov website.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three or four sequential phases, which may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, optimal dosage, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific diseases and to determine optimal dosage. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, typically in well-controlled trials, to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may require, or sponsors may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be conducted after initial marketing approval, and may be used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the development of a new product candidate, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA or BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for FDA to provide advice, and for the sponsor and the FDA to reach consensus on the next phase of development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Approval in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA or BLA requesting approval or licensure to market the product for one or more indications. In most cases, the submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity or original BLA to review and act on the submission. This review typically takes twelve months from the date the NDA or BLA is submitted to the FDA because the FDA has sixty days from receipt to decide whether an application is accepted for filing, as described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA conducts a preliminary review of all NDAs and BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent (which are analogous to the NDA safety and effectiveness requirements) and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may refer an application for a novel drug or biologic to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts as well as consumer representatives, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA or BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA generally accepts data from foreign clinical trials in support of an NDA or BLA if the trials were conducted under an IND. If a foreign clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA or BLA if the study was conducted in accordance with GCP requirements and the FDA is able to validate the data through an on-site inspection, if deemed necessary. Regardless of whether the applicable trials were conducted under an IND, the FDA may accept foreign data as the sole basis for NDA or BLA approval only if (1) the foreign data are applicable to the U.S. population and U.S. medical practice, (2) the studies were performed by clinical investigators with recognized competence, and (3) the data may be considered valid without the need for an on-site inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After evaluating the NDA or BLA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA or BLA identified by the FDA and may require additional clinical data, such as an additional clinical trial or other significant and time-consuming requirements. If a Complete Response Letter is issued, the sponsor must resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug or biologic with specific prescribing information for specific indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA or BLA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may also require one or more post-marketing studies and surveillance programs to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of any post-marketing studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Pediatric Research Equity Act (&#8220;PREA&#8221;) requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and BLAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation of Combination Products in the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain products are comprised of components, such as drug components and device components, that would normally be subject to different regulatory frameworks by the FDA and frequently regulated by different centers at the FDA. These products are known as combination products. Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible for premarket review of the drug product would have primary jurisdiction for the combination product. The FDA has also established the Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. A combination product with a primary mode of action attributable to the drug component generally would be reviewed and approved pursuant to the drug approval processes set forth in the FDCA or PHSA. In reviewing the NDA or BLA for such a product, however, FDA reviewers would consult with their counterparts in the FDA&#8217;s Center for Devices and Radiological Health to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products are subject to cGMP requirements applicable to both drugs and devices, including the QSR currently applicable to medical devices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the Fast Track program is intended to expedite or facilitate the process for reviewing new products that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA or BLA is submitted, the product candidate may be eligible for priority review. An NDA or BLA for a Fast Track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any marketing application for a drug or biologic submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process. An NDA or BLA is eligible for priority review if the product candidate is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. For new-molecular-entity NDAs or original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate or intermediate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled confirmatory clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit, and may require that such studies be well underway prior to granting any accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory studies in a timely manner or if such studies fail to verify the predicted clinical benefit. In addition, the FDA requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track designation, Breakthrough Therapy designation, priority review, and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drugs and biologics manufactured or distributed pursuant to FDA approvals and licenses are subject to pervasive and continuing regulation by the FDA and other government authorities, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes or other labeling claims are subject to prior FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There also are continuing, annual program fee requirements for certain approved prescription drug or biologic products. The FDA may impose a number of post-approval requirements as a condition of approval of an NDA or BLA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, drug and biologics manufacturers and other entities involved in the manufacture and distribution of approved drugs and biologics are required to register their establishments with the FDA and state authorities and are subject to periodic unannounced inspections by the FDA and these state authorities for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval in accordance with the statute and regulations if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending NDAs or BLAs or supplements to approved NDAs or BLAs, or suspension or revocation of product license approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. A company can make only those claims relating to safety and efficacy, purity and potency that are in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgement, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation (&#8220;ODD&#8221;) to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product in the United States. ODD must be requested before submitting an NDA or BLA. After the FDA grants ODD, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. ODD does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. However, ODD does entitle a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same disease or condition for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different product for the same disease or condition or the same product for a different disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the disease or condition for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biosimilars and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Affordable Care Act (&#8220;ACA&#8221;) includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, relatively few biosimilars have been licensed under the BPCIA, although numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until twelve years from the date on which the reference product was first licensed. During this twelve-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Product Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application (&#8220;ANDA&#8221;), or an NDA submitted under Section 505(b)(2), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDCA alternatively provides three years of non-patent exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is a type of non-patent exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing patent term or period of non-patent regulatory exclusivity, including the five-year and three-year non-patent and orphan exclusivities. This six-month exclusivity may be granted if an NDA or BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data does not need to show the product to be effective in the pediatric population studied; rather, if the FDA has requested the study and the clinical study is deemed to fairly respond to the FDA&#8217;s request, the additional protection may be granted. If reports of FDA-requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of non-patent regulatory exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends existing periods of exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To market any product outside of the United States, sponsors need to comply with numerous and different regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Foreign regulatory approval processes include all of the risks associated with FDA approval set forth above, as well as additional country and region-specific regulation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether or not applicants obtain FDA approval for a product, companies must obtain approval of a product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing of the product in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. The approval process varies from country to country, can involve additional testing or studies beyond that required by FDA, and may be longer or shorter than the FDA approval process. The requirements governing the conduct of clinical trials, product licensing, pricing, promotion, and reimbursement vary greatly from country to country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-clinical Studies and Clinical Trials in the EU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to the United States, the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical studies (pharmaco-toxicological) must be conducted in compliance with the principles of GLP as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain medicinal products &#8211; e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on GCP as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (&#8220;EU CTR&#8221;) repeals the EU Clinical Trials Directive, and became applicable on January 31, 2022. Unlike a Directive, the EU CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The EU CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via the Clinical Trials Information System (&#8220;CTIS&#8221;), which is a centralized EU portal and database.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the EU Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;), to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the EU CTR introduced a centralized process and only requires the submission of a single application for multi-center trials. The EU CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. One of the main aims of EU CTR is to increase transparency about clinical trials, which is done by making documents and data from the CTA publicly available through CTIS at the time of decision about the clinical trial. There are few exceptions to this, and release of personal data and company confidential information may be controlled through redaction. The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and EU-wide regulatory requirements may also apply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Authorization in the EU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market our future product candidates in the EU and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EU, medicinal product candidates can only be commercialized after obtaining a marketing authorization (&#8220;MA&#8221;). To obtain regulatory approval of a product candidate under EU regulatory systems, we must submit a MA application (&#8220;MAA&#8221;). The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Centralized MAs&#8221; are issued by the European Commission (&#8220;EC&#8221;) through the centralized procedure based on the opinion of the Committee for Medicinal Products for Human Use of the European Medicine Agency (&#8220;EMA&#8221;), and are valid throughout the EU. The centralized procedure is compulsory for certain types of medicinal products such as (i) medicinal products derived from biotechnological processes, (ii) designated orphan medicinal products, (iii) advanced therapy medicinal products (such as gene therapy, somatic cell therapy and tissue engineered products) and (iv) medicinal products containing a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases or autoimmune diseases and other immune dysfunctions, and viral diseases. The centralized procedure is optional for products containing a new active substance not authorized in the EU before May 20, 2004, or that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health in the EU. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;National MAs&#8221; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data and Marketing Exclusivity in the EU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, new products authorized for marketing (i.e., reference products) generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic and biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial MA of the reference product in the EU. The overall ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications, which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical or biological entity, and products may not qualify for data exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Medicinal Products in the EU</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States, albeit with some key differences in definition. A medicinal product can be designated as an orphan if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life threatening or chronically debilitating condition (2) either (a) such condition affects not more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from the orphan status, would not generate sufficient return in the EU to justify the necessary investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized for marketing in the EU or, if such method exists, the product will be of significant benefit to those affected by that condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan designation must be requested before submitting an MAA. An EU orphan designation entitles a sponsor to incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized procedure. Upon grant of a MA, orphan medicinal products are entitled to a ten years of market exclusivity for the approved indication, which means that the competent authorities cannot accept another MAA, or grant a MA, or accept an application to extend a MA for a similar medicinal product for the similar indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The orphan exclusivity period may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan designation, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, MA may be granted to a similar product for the same indication at any time if (i) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (ii) the applicant consents to a second orphan medicinal product application; or (iii) the applicant cannot supply enough orphan medicinal product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Development in the EU</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, MAAs for new medicinal products have to include the results of studies conducted in the pediatric population, in compliance with a PIP agreed with the EMA&#8217;s Paediatric Committee (&#8220;PDCO&#8221;). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product candidate for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all the EU member states and study results are included in the product information, even when negative, the product is eligible for six months&#8217; supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity is granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements in the EU</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the member states. The holder of a MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance (&#8220;QPPV&#8221;) who is responsible for the establishment and maintenance of that system and oversees the safety profiles of medicinal products and any emerging safety concerns. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (&#8220;PSURs&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All MAA must include a risk management plan (&#8220;RMP&#8221;), describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The RMP must be updated any time new information on the medicinal product becomes available which has a significant impact on the content of the RMP. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and differ from one country to another.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned EU rules are generally applicable in the European Economic Area (&#8220;EEA&#8221;), which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since January 1, 2021, the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) is the UK&#8217;s standalone medicines and medical devices regulator. Between January 1, 2021 and December 31, 2024 and as a result of the Northern Ireland Protocol, different rules applied in Northern Ireland than in England, Wales, and Scotland, together, Great Britain (&#8220;GB&#8221;); broadly, Northern Ireland continued to follow the EU regulatory regime.  On January 1, 2025, a new arrangement called the &#8220;Windsor Framework&#8221; came into effect and reintegrated Northern Ireland under the regulatory authority of the MHRA with respect to medicinal products. The Windsor Framework removes EU licensing processes and EU labelling and serialization requirements in relation to Northern Ireland and introduces a UK-wide licensing process for medicines.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is derived from the now-repealed EU Clinical Trials Directive. The extent to which the regulation of clinical trials in the UK will mirror the EU CTR in the long term is not yet certain, however, on December 12, 2024, the UK government introduced a legislative proposal - the Medicines for Human Use (Clinical Trials) Amendment Regulations 2024 - that, if implemented, will replace the current regulatory framework for clinical trials in the UK. The UK government has provided the legislative proposal to the UK Parliament for its review and approval. Once the legislative proposal is approved (with or without amendment), it will be adopted into UK law which is expected in early 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January 1, 2021, unless the MA holder opted-out. Under the terms of the Windsor Framework, these MAs became valid for the whole of the UK from January 1, 2025. In order to use the centralized procedure to obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore after Brexit, companies established in the UK can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the UK. In addition, an international recognition procedure has been in place since January 1, 2024, which allows the MHRA to take into account the expertise and decision-making of trusted partner agencies, such as the European Medicines Agency, when determining an application for a new UK MA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no pre-MA orphan designation in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the market, i.e., the prevalence of the condition in the UK, rather than the EU, must not be more than five in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in the UK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation of Combination Products in the EU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU regulates medical devices and medicinal products separately, through different legislative instruments, and the applicable requirements will vary depending on the type of drug-device combination product. Guidances have been published to help manufacturers select the right regulatory framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug-delivery products intended to administer a medicinal product where the medicinal product and the device form a single integral product are regulated as medicinal products in the EU. The EMA is responsible for evaluating the quality, safety and efficacy of MAAs submitted through the centralized procedure, including the safety and performance of the medical device in relation to its use with the medicinal product. The EMA or the EU member state national competent authority will assess the product in accordance with the rules for medicinal products described above but the device part must comply with the Medical Devices Regulation (including the general safety and performance requirements provided in Annex I). MAA must include&#8212;where available&#8212;the results of the assessment of the conformity of the device part with the Medical Devices Regulation contained in the manufacturer&#8217;s EU declaration of conformity of the device or the relevant certificate issued by a notified body. If the MAA does not include the results of the conformity assessment and where for the conformity assessment of the device, if used separately, the involvement of a notified body is required, the competent authority must require the applicant to provide a notified body opinion on the conformity of the device.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By contrast, in case of drug-delivery products intended to administer a medicinal product where the device and the medicinal product do not form a single integral product (but are, e.g., co-packaged), the medicinal product is regulated in accordance with the rules for medicinal products described above while the device part is regulated as a medical device and will have to comply with all the requirements set forth by the Medical Devices Regulation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The characteristics of non-integral devices used for the administration of medicinal products may impact the quality, safety and efficacy profile of the medicinal products. To the extent that administration devices are co-packaged with the medicinal product or, in exceptional cases, where the use of a specific type of administration device is specifically provided for in the product information of the medicinal product, additional information may need to be provided in the MAA for the medicinal product on the characteristics of the medical device(s) that may impact on the quality, safety and/or efficacy of the medicinal product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The requirements regarding quality documentation for medicinal products when used with a medical device, including single integral products, co-packaged and referenced products, are outlined in the EMA guideline of July 22, 2021, which became applicable as of January 1, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned EU rules are generally applicable in the EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rest of the World Regulation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America, Asia, or Japan, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with applicable regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to FDA restrictions on marketing of `pharmaceutical products, other U.S. federal, state and foreign healthcare regulatory laws, regulations and industry codes restrict business practices in the biopharmaceutical industry, which include, but are not limited to, state, federal and foreign anti-kickback, false claims, and transparency laws regarding drug pricing and payments or other items of value provided to physicians and other healthcare providers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the strict requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances in light of the prohibitions in the statute. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal civil False Claims Act prohibits any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-covered, uses. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the civil monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. As with the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Physician Payments Sunshine Act imposed, among other things, annual reporting requirements for covered manufacturers for certain payments and &#8220;transfers of value&#8221; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician providers such as physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Covered manufacturers must submit reports by the 90th day of each subsequent calendar year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The majority of states also have anti-kickback and other fraud and abuse laws, which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers. Certain states also require implementation of compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of marketing expenditures and pricing information as well as gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, analogous state and foreign laws, regulations and industry codes may be broader in scope than the provisions described above and may apply regardless of payor. These laws and regulations may differ from one another in significant ways, thus further complicating compliance efforts. For instance, in the EU, many EU member states have adopted specific anti-gift statutes that further limit commercial practices for medicinal products, in particular vis-&#224;-vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many EU member states have adopted regional and national &#8220;Sunshine Acts&#8221; which impose reporting and transparency requirements, similar to the requirements in the United States, on pharmaceutical companies. Certain countries also mandate implementation of commercial compliance programs, or require disclosure of marketing expenditures and pricing information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violation of any of such laws, regulations and industry codes or any other governmental regulations that apply to drug manufacturers may result in significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any drug or medical device products for which we obtain regulatory approval. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of SKYTROFA or any other products for which we receive regulatory approval for commercial sale will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover SKYTROFA or our other product candidates could reduce physician utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#8217;s decision to provide coverage for a drug or medical device product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for new products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or that they will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drugs, medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. In addition, in many foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. In the EU, governments influence the price of products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. Member states may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. The downward pressure on healthcare costs in general, particularly prescription products, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from lower priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in 2010, the ACA and related legislation were enacted, which, among other things, (i) increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, (ii) addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, (iii) extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans, (iv) imposed mandatory discounts for certain Medicare Part D beneficiaries, and (v) subjected drug manufacturers to new annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include the Budget Control Act of 2011, which resulted in reductions in Medicare payments to providers, which went into effect on April 1, 2013 and will stay in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced certain Medicare payments to several types of providers, including hospitals. The legislation also increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Most recently, on August 16, 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including through constraints on reimbursement, imposition of mandatory discounts, restrictions on access to certain products, transparency measures, and programs for importation from other countries or bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar political, economic and regulatory developments are occurring in the EU and may affect the ability of pharmaceutical companies to profitably commercialize their products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could restrict or regulate post-approval activities and affect the ability of pharmaceutical companies to commercialize their products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, potential reductions in prices and changes in reimbursement levels could be the result of different factors, including reference pricing systems, parallel distribution and parallel trade. It could also result from the application of external reference pricing mechanisms, which consist of arbitrage between low-priced and high-priced countries. Reductions in the pricing of our medicinal products in one EU member state could affect the price in other EU member states and, thus, have a negative impact on our financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products in the EU is an essential element of the pricing and reimbursement decision-making process in a number of EU member states. The outcome of HTA has a direct impact on the pricing and reimbursement status granted to the medicinal product. A negative HTA by a leading and recognized HTA body concerning a medicinal product could undermine the prospects to obtain reimbursement for such product not only in the EU member state in which the negative assessment was issued, but also in other EU member states.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2011, Directive 2011/24/EU was adopted at the EU level. This Directive establishes a voluntary network of national authorities or bodies responsible for HTA in the individual EU member states. The network facilitates and supports the exchange of scientific information concerning HTAs. Further to this, on December 13, 2021, Regulation No 2021/2282 on HTA, amending Directive 2011/24/EU, was adopted. While the Regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products: oncology and Advanced Therapy Medicinal Products as of 2025, orphan medicinal products as of 2028 and 2030 for all other medicinal products authorized centrally. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, there may continue to be additional proposals relating to the reform of the U.S. healthcare system and international healthcare systems. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data Privacy and Security</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy, use of AI and data security have become significant concerns around the world including United States, Europe and in many other jurisdictions where we may in the future conduct our operations. As we receive and, process personal and confidential data, we become subject to numerous laws and regulations relating to data privacy, AI and security, such as data breach notification laws, health information laws, AI regulations and consumer protection laws in the United States and abroad including the GDPR and the U.K. GDPR. These laws and regulations are complex and constantly evolving, and any unauthorized access, use, disclosure and other loss of personal data, including by third party vendors providing support services, can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties, restrictions on data processing and reputational damage.</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organizational Structure </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our operations are conducted through our following wholly-owned subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma Endocrinology GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma Ophthalmology Division A/S (Denmark), Ascendis Pharma Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark), Ascendis Pharma Oncology Division A/S (Denmark), Ascendis Pharma Europe A/S (Denmark), Ascendis Pharma UK Limited (United Kingdom), Ascendis Pharma Iberia S.L. (Spain), Ascendis Pharma France SASU (France), Ascendis Pharma Italia SRL (Italy), Ascendis Pharma Sverige AB (Sweden) and Ascendis Pharma Switzerland GmbH (Switzerland). These subsidiaries are also set forth in Exhibit 8.1 to this annual report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, Plants and Equipment </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our material tangible fixed assets relate to leased facilities, which are recognized and measured as right-of-use assets in the consolidated financial statements. We do not own any of our facilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters is located in Hellerup, Denmark. In addition, we have offices and research and development facilities in Germany and the United States. Further, we are establishing commercial infrastructure in Europe and currently have sales and representative offices in Germany, France, Spain, Italy, and the United Kingdom. Since we do not own facilities for manufacturing of our products and product candidates for the potential pivotal clinical studies, and/or for commercial manufacturing, we engage with Contract Manufacturing Organizations (&#8220;CMOs&#8221;) to manufacture commercial and clinical trial supply.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies our current material leased facilities and their related activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:24.52%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:34.42%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:13.46%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:15.64%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Location</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Size (in<br/>square<br/>meters)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Primary usage</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Enforceable<br/>lease period</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option to extend<br/>the lease beyond<br/>enforceable lease<br/>period</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tuborg Boulevard, Hellerup</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,079</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate headquarters, Administration and R&amp;D</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July, 2029 - May, 2038</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Technologiepark, Heidelberg</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,034</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D and laboratory facilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 2026 - January 2027</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rolling 24 months option to extend</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Max-Jarecki-Str., Heidelberg</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,321</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Administration, R&amp;D and laboratory facilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January, 2026</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">United States</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Page Mill, Palo Alto, California</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,765</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Administration</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October, 2033</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option to extend for up to two periods of five years each</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Redwood City, California</span><span style="color:#000000;top:-3.9865pt;white-space:pre-wrap;font-size:5.695pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,681</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D and laboratory facilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April, 2030</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option to extend for additional five years</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">West Windsor Township,<br/>&#160;&#160;&#160;New Jersey</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,097</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling and administration</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December, 2025</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option to extend for additional five years</span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lease in Redwood City, California is subleased to Eyconis, initially until December 2025. See &#8220;Item 7 B. Major Shareholders and Related Party Transactions&#8212;Related Party Transactions&#8221; for more information about Eyconis.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022 we entered into a lease in Germany, comprising 11,390 square meters, with a term of 15 years, expected to commence in 2025, where its main activities will be administration, R&amp;D and laboratory functions. In addition, in December 2024, we entered into additional leases in Denmark, comprising an aggregate of 5,141 square meters, each expected to commence in 2025, with a term of 12 years and with an option to terminate earlier, where the main activities will be administration functions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our existing facilities are adequate for our near-term needs. We believe that suitable additional or alternative space would be available if required in the future on commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4a_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4A Unresolved Staff Comments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_operating_and_financial_review"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating and Financial Review and Prospects</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and related notes appearing elsewhere in this annual report. In addition to historical information, this discussion contains forward-looking statements based on our current expectations that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the &#8220;Item 3 D. Key Information&#8212;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; sections and elsewhere in this annual report.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Results</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Refer to Part I, Item 5 in our Annual Report on Form 20-F for the financial year ended December 31, 2023 (filed with the SEC on February 7, 2024) for additional discussion of our financial condition and results of operations for the year ended December 31, 2022, as well as our financial condition and results of operations for the year ended December 31, 2023, compared to the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of business highlights in 2024, please refer to &#8220;Item 4B. Information on the Company&#8212;Business Overview.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Operations Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income and Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sale of commercial products and clinical trial supply is recognized when the customer has obtained control of the goods and it is probable that we will collect the consideration to which we are entitled for transferring the goods. Control is transferred upon delivery. Cost of sales are recognized when the sales takes place. Rendering of services is recognized as revenue over the service period as stipulated under the applicable agreement. License agreements which transfer rights to our intellectual property (&#8220;IP&#8221;) with significant stand-alone value are classified as &#8220;right-to-use,&#8221; with revenue recognized at the point in time when the customer can use and benefit from the IP.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenses relate to research and development activities and to selling, general, and administration activities. Research and development costs (&#8220;R&amp;D costs&#8221;) consist primarily of product development and pre-commercial manufacturing costs, preclinical and clinical study costs and costs for process optimizations and improvements performed by Clinical Research Organizations (&#8220;CROs&#8221;) and Contract Manufacturing Organizations (&#8220;CMOs&#8221;), salaries and other personnel costs including pension and share-based payment, the cost of facilities, professional fees, cost of obtaining and maintaining our IP portfolio, and depreciation of non-current assets used in research and development activities. Selling, general, and administrative expenses (&#8220;SG&amp;A expenses&#8221;) comprise salaries and other personnel costs including pension and share-based payment, office supplies, cost of facilities, professional fees, and depreciation and amortization of non-current assets related to selling, general, and administrative activities, and pre-commercial and commercial activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material portion of our operating expenses are denominated in other currencies than the Euro, which expose our operating expenses to volatility. We do not currently enter into derivative financial instruments to manage our exposure to foreign exchange risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Assets and Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating assets and liabilities primarily relate to property, plant and equipment, inventories, receivables, prepayments and accruals for development costs, lease liabilities, trade payables, other liabilities, and contract liabilities. Property, plant and equipment primarily relate to leased facilities which are recognized and measured as right-of-use assets. Our receivables and liabilities are exposed to development in foreign currencies, primarily with respect to the U.S. Dollar. Please refer to the &#8220;Foreign Currency Risk&#8221; section under &#8220;Quantitative and Qualitative Disclosures about Market Risk&#8221; in this &#8220;Item 5 A. Operating and Financial Review and Prospects&#8212;Operating Results&#8221; and to Note 17, &#8220;Financial Risk Management,&#8221; for an analysis of our foreign currency exposure.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have built up inventories to support the commercialization of SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as well as the launch of YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition to commercial inventories, manufacturing of pre-launch inventories is initiated for late-stage product candidates and is recognized as inventories. However, since pre-launch inventories are not realizable prior to obtaining marketing approvals, pre-launch inventories are immediately written down to zero through research and development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capital Structure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our capital structure consists of equity and external borrowings obtained through issuance of convertible senior notes (&#8220;convertible notes&#8221;) and royalty funding liabilities. We are not subject to any contractually imposed capital requirements or financial covenants. For further details, please refer to &#8220;Item 5 B. Operating and Financial Review and Prospects&#8212;Liquidity and Capital Resources.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024 and 2023</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Highlights (unaudited)</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,923</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,383</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,323</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,060</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">598,146</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">677,864</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(79,718)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating profit/(loss)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(278,763)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(455,541)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,778</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the year</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(378,084)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(481,447)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,363</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) operating activities</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(306,197)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(467,361)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,164</span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating expenses comprise research and development costs and selling, general and administrative expenses.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compared to the year ended December 31, 2023, revenue for the year ended December 31, 2024, primarily benefited from license revenue related to our exclusive license agreements with Novo Nordisk and Eyconis, continued demand growth for SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. which was offset by higher sales deductions, and the launch of YORVIPATH&#174; in Europe. Operating loss was &#8364;278.8 million, representing an improvement of &#8364;176.8 million compared to December 31, 2023, which, in addition to an increase in revenue, was driven by reduced operating expenses. We had a net loss of &#8364;378.1 million for the year ended December 31, 2024, which, compared to our operating loss, was driven primarily by non-cash financial items. Refer to section &#8220;Finance Income and Finance Expenses&#8221; in below section.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our total equity presented a negative balance of &#8364;105.7 million as of December 31, 2024, compared to a negative balance of &#8364;145.7 million as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further details about our results of operations are described in the following sections.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our revenue for the years ended December 31, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.431%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.162%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.162%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.242%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial products</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,728</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,065</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rendering of services</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,794</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,659</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,865</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical supply</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,776</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,457</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,343</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,077</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,266</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">96,923</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue for the year ended December 31, 2024 was &#8364;363.6 million, representing an increase of &#8364;96.9 million compared to last year. This increase was primarily attributable to higher revenue from licenses associated with our exclusive license agreement with Novo Nordisk, signed in November 2024, which includes a $100 million upfront payment, recognized in 2024, and our exclusive license agreement with Eyconis in January 2024 of &#8364;27.1 million (non-cash) upfront payment adjusted for internal profit, compared to the $70 million upfront payment received from our exclusive license agreement with Teijin in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, revenue was positively impacted from increased sales of SKYTROFA in the U.S. and the commercial launch of YORVIPATH in Europe. Revenue for SKYTROFA was negatively impacted by an adjustment to estimates and assumptions for sales deductions of &#8364;4.7 million, which were attributable to years prior to January 1, 2024. The adjustment was primarily attributable to a different payer and rebate mix than anticipated, and on which provisions for prior years were based.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sale of commercial products were as follows:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue from commercial products</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SKYTROFA&#174;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197,001</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,338</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">YORVIPATH&#174;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,727</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,727</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue from commercial products</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">225,728</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47,065</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Sales</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of sales for the year ended December 31, 2024 was &#8364;44.3 million, representing a decrease of &#8364;0.1 million compared to last year. This decrease was primarily attributable to lower costs under our license and collaboration agreements, partly offset by increased sales of commercial products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies external project costs on the development pipeline and other R&amp;D costs.</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">External project costs</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon hGH</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,776</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,981</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(22,205)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon PTH</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,777</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,580</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(33,803)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon CNP</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,609</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,615</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,994</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b/g</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,414</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,993</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,579)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon TLR7/8 Agonist</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,752</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,482</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(22,730)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ophthalmology</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,721</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,721)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other project costs</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,656</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,025</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">631</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total external project costs</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">151,984</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">246,397</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(94,413)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other research and development costs</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee costs</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,867</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127,002</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,865</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,698</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,925</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6,227)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,455</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,296</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,841)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,834</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7,834)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total other research and development costs</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">155,020</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">167,057</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(12,037)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total research and development costs</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">307,004</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">413,454</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(106,450)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D costs for the year ended December 31, 2024 were &#8364;307.0 million representing a decrease of &#8364;106.5 million compared to last year. This decrease was primarily due to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturity of our endocrinology rare disease pipeline, especially regarding TransCon hGH and TransCon PTH. In addition, 2024 include reversal (income) of prior period write-downs of pre-launch inventories for TransCon PTH of &#8364;12.6 million, due to the commercial launch of YORVIPATH in Europe and the U.S. in 2024;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lower product development activities on our TransCon TLR7/8 Agonist and TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> programs, partly offset by increased clinical trial activities. During the fourth quarter of 2024, we closed enrollment in our BelieveIT-201 clinical trial and to dose expansion cohorts involving TransCon TLR7/8 Agonist in the transcendIT-101 and IL-Believe trials to prioritize our efforts on TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cessation of ophthalmology expenses, including related employee costs, due to the grant of exclusive rights to develop and commercialize TransCon ophthalmology to Eyconis in January 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General, and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies SG&amp;A expenses:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee costs</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,181</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,706</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,475</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,899</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,598</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,699)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,062</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,106</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">956</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total selling, general, and administrative expenses</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">291,142</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">264,410</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">26,732</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SG&amp;A expenses for the year ended December 31, 2024 was &#8364;291.1 million representing an increase of &#8364;26.7 million compared to last year. This increase was primarily due to higher employee related expenses and other general and administrative expenses attributable to organizational growth in support of launch of YORVIPATH in Europe and the U.S., partly offset by lower administrative expenses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance Income and Finance Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the result of finance income and expenses, further disaggregated into cash and non-cash items:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:12.775%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net finance income/(expenses)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance income</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,609</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,857</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18,248)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance expenses</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100,027)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(44,065)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(55,962)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total net finance income/(expenses)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(74,418)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(208)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(74,210)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified in cash and non-cash items</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cash items</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance income received</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,374</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,048</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,674)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance expenses paid</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,205)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,672)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">467</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-cash items</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement gain/(loss) of financial liabilities</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,874</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,654</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,780)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency gain/(loss)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(27,149)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,346</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(39,495)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization charges, accruals, and other items</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(50,312)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(28,584)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,728)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total net finance income/(expenses)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(74,418)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(208)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(74,210)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in non-cash items was driven primarily by translation of U.S. dollar denominated monetary positions into Euro, primarily cash and cash equivalents, convertible notes and royalty funding liabilities. The development was further driven by amortization charges, accruals, and other items, primarily due to our royalty funding liabilities which we entered into in September 2023 and September 2024, and from lower remeasurement gains from financial liabilities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our liquidity and capital resources comprise cash and cash equivalents. As of December 31, 2024, these amounted to &#8364;559.5 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenditures primarily relate to research and development activities and selling, general, and administrative activities to support our business, including our continued development of product and product candidates within Endocrinology Rare Disease and Oncology portfolios, the commercialization of SKYTROFA and YORVIPATH, and expenses made in anticipation of potential future product launches. We manage our liquidity risk by maintaining adequate cash reserves and banking facilities. We monitor the risk of a shortage of funds through a liquidity planning tool to ensure sufficient funds are available to settle liabilities as they become due.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the consolidated statements of financial position presented a negative balance of equity of &#8364;105.7 million. Under Danish corporate law, as Ascendis Pharma A/S, the parent company of the Company, holds a positive balance of equity, the Company is currently not subject to legal or regulatory requirements to re-establish the balance of equity. There is no direct impact from the negative balance of equity to the liquidity and capital resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we believe that our existing capital resources as of December 31, 2024 will be sufficient to meet our projected cash requirements for at least twelve months from the date of this annual report. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, we have funded our operations primarily through the issuance of preference shares, ordinary shares (including public offerings and exercise of warrants), convertible debt securities, payments to us made under collaboration agreements, and our royalty funding agreements. Including our initial public offering, since February 2015, we have completed public offerings of American Depositary Shares (&#8220;ADSs&#8221;), latest in September 2024, with total net proceeds of $2,580.2 million (or &#8364;2.259.0 million at the time of the offerings).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into capped synthetic royalty funding agreements with Royalty Pharma (the &#8220;Purchaser&#8221;), which are presented as part of borrowings, and represents the Company&#8217;s contractual obligations to pay a predetermined percentage of future commercial revenue until reaching a predetermined multiple of proceeds received, according to the detailed provisions of the synthetic royalty funding agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we entered into a $150.0 million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Yorvipath Agreement&#8221;) with the Purchaser. Under the terms of the Royalty Pharma Yorvipath Agreement, we received an upfront payment of $150.0 million (the &#8220;Yorvipath Purchase Price&#8221;) in exchange for a 3% royalty on net revenue from sales of YORVIPATH in the U.S. (the &#8220;Yorvipath Revenue Payments&#8221;). The net proceeds were $148.2 million (&#8364;134.2 million) after deducting offering expenses. The Yorvipath Revenue Payments to the Purchaser will cease upon reaching a multiple of the Yorvipath Purchase Price of 2.0 times, or 1.65 times if the Purchaser receives Yorvipath Revenue Payments in that amount by December 31, 2029. The Royalty Pharma Yorvipath Agreement includes a buy-out option under various terms and conditions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we entered into a $150.0 million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Skytrofa Agreement&#8221;) with the Purchaser. Under the terms of the Royalty Pharma Skytrofa Agreement, we received an upfront payment of $150.0 million (the &#8220;Skytrofa Purchase Price&#8221;) in exchange for a 9.15% royalty on net revenue from sales of SKYTROFA in the U.S., beginning on January 1, 2025 (the &#8220;Skytrofa Revenue Payments&#8221;). The net proceeds were $146.3 million (&#8364;136.3 million) after deducting offering expenses. The Skytrofa Revenue Payments to the Purchaser will cease upon reaching a multiple of the Skytrofa Purchase Price of 1.925 times, or 1.65 times if the Purchaser receives Skytrofa Revenue Payments in that amount by December 31, 2031. The Royalty Pharma Skytrofa Agreement includes a buy-out option under various terms and conditions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 16, &#8220;Financial Assets and Liabilities&#8221; for further information about our royalty funding liabilities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, we issued an aggregate principal amount of $575.0 million of fixed rate 2.25% convertible notes. The net proceeds from the offering of the convertible notes were $557.9 million (&#8364;503.3 million), after deducting the initial purchasers&#8217; discounts and commissions, and transaction costs. The coupon interest is payable semi-annually. Unless earlier converted or redeemed, the convertible notes will mature on April 1, 2028. Refer to Note 16, &#8220;Financial Assets and Liabilities&#8221; for further information about our convertible notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain cash-forecasts to ensure sufficient cash reserves are available to settle liabilities as they come due.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our cash requirements primarily relate to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Semi-annual interest payments and potential repayment (April 1, 2028) of principal amount of convertible notes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments to Royalty Pharma under our royalty funding agreements of 3% on net revenue from sales of YORVIPATH in the U.S., and 9.15% on net revenue from sales of SKYTROFA in the U.S., subject to caps as described in above section;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease obligations related to our office, research and development facilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase obligations under our commercial supply agreements and related activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development activities related to clinical trials for our product candidates in clinical development; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Establishing an integrated organization to support the ongoing commercialization of SKYTROFA and YORVIPATH in the U.S. and Europe.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cash requirements are determined in Euro applying foreign exchange rates at December 31, 2024. Accordingly, actual cash payments are exposed to development in foreign currencies, primarily with respect to the U.S. Dollar. Refer to &#8220;Foreign Currency Risk&#8221; section under &#8220;Quantitative and Qualitative Disclosures about Market Risk,&#8221; above.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our borrowings comprise convertible notes, royalty funding liabilities and lease liabilities. As of December 31, 2024, short-term (payable within twelve months after the reporting date) and long-term (payable beyond twelve months after the reporting date) cash requirements (on an undiscounted basis) for convertible notes and royalty funding liabilities were &#8364;32.3 million and &#8364;1,041.2 million, respectively. Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements and convertible notes are provided above.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the length of non-cancellable leases is up to nine years. Our cash requirements for lease obligations (on an undiscounted basis) are &#8364;16.2 million and &#8364;91.3 million, on short-term and long-term, respectively. In February 2022, we entered into a facility lease in Germany with an enforceable lease term of 15 years, which is expected to commence in 2025. In addition, in December 2024, we entered into additional leases in Denmark, each expected to commence in 2025, with a term of 12 years and with an option to terminate earlier. As of December 31, 2024, when including the impact of the new leases in Germany and Denmark, which is not recognized as lease liabilities in the consolidated statement of financial position as of December 31, 2024, our short-term and long-term cash requirements for lease obligations (on an undiscounted basis) were expected to be &#8364;22.2 million and &#8364;167.5 million, respectively. In addition, our lease obligations establish ancillary contractual commitments in relation to utilities, maintenance, levies, and other services. Further, we have commitments related to short-term leases and leases of low value assets, IT and facility related services. Costs relating to those commitments are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also entered into long-term commercial supply agreements, related to commercial manufacturing of SKYTROFA and YORVIPATH.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial supply agreements may include purchase obligations, usually determined on binding and non-binding supply forecasts, that are subject to continuous negotiation and adjustments according to individual contractual terms and conditions. As of December 31, 2024, our short-term and long-term cash requirements were &#8364;64.7 million and &#8364;60.2 million, respectively, excluding non-binding commitments for purchase of raw materials and intermediates used in the manufacturing process.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our ordinary activities, we engage third-party CROs to perform clinical trial activities, which primarily are studies for more than one year. We are not subject to contingent liabilities from potential milestone payments related to in-licensing of IP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not entered into any off-balance sheet arrangements or any holdings in variable interest entities. In addition, we are not aware of any significant legal claims or disputes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we currently estimate that our existing cash and cash equivalents will be sufficient to fund our operations for at least twelve months from the date of this annual report. However, our operating plan and actual cash requirements may change as a result of many factors. For example our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the manufacturing, selling and marketing costs associated with our products and product candidates, if approved, including the cost and timing of building our sales and marketing capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt, and amount of sales of, or royalties on, approved products and any future products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sales price and the availability of adequate third-party coverage and reimbursement for our products and product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs related to manufacturing of our products and product candidates, including the timing of when we incur such costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to collect payments which are due to us from customers and collaboration partners (if any), which in turn is impacted by the financial standing of any such customers and collaboration partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, timing, scope, results and costs of our preclinical studies and clinical trials and manufacturing activities for our products and product candidates, including the ability to enroll patients in a timely manner for clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time and cost necessary to obtain regulatory approvals for our products and product candidates and the costs of post-marketing studies that could be required by regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cash requirements of any future acquisitions or discovery of products or product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of preclinical and discovery programs that we decide to pursue or initiate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential acquisition and in-licensing of other technologies, products or assets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time and cost necessary to respond to technological and market developments, including further development of our TransCon platform; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of development, regulatory and commercial milestones resulting in the payment to us from collaboration partners of contractual milestone payments and the timing of receipt of such payments, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our progress in the successful commercialization and co-promotion of our products and product candidates, if approved, and our efforts to develop and commercialize our other existing product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market opportunities and patient populations for our products and product candidates, if approved,  and our ability to obtain market acceptance of our products and product candidates, if approved; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of our product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we purchase ADSs prior to granting rights or awards for such shares under our equity incentive plans.  </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional funds may not be available if we need them or on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, scale back or cease our research and development and commercialization activities, preclinical studies and clinical trials. Furthermore, uncertainty about the interest rate environment and an increase in interest rates may make it more difficult, costly or dilutive for us to secure additional financing, which may have a negative impact on earnings and cash flow.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the years ended December 31, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.431%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.162%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.162%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.242%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from / (used in)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(306,197</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(467,361</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,164</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,876</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">286,474</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(279,598</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">443,929</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,292</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">309,637</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(decrease) in cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">144,608</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(46,595</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">191,203</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows used in operating activities for the year ended December 31, 2024 were &#8364;306.2 million, representing a decrease of &#8364;161.2 million compared to last year. This improvement was primarily related to higher revenue and reduced operating expenditures, and to further adjustment for changes to non-operating financial income and expenses, taxes and non-cash items of total &#8364;168.5 million, partly offset by negative impact from working capital balances with &#8364;7.4 million. The negative impact from working capital balances includes $100 million plus indirect taxes related to the upfront payment from our exclusive license agreement with Novo Nordisk, which was subsequently settled in January 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from investing activities for the year ended December 31, 2024 were &#8364;6.9 million, representing a decrease of &#8364;279.6 million compared to last year. This increase was primarily attributable to higher net settlement of marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows from/(used in) Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from financing activities for the year ended December 31, 2024, were &#8364;443.9 million, representing an increase of &#8364;309.6 million compared to the last year. This increase was primarily attributable to our follow-on public offering of ADSs completed in September 2024 with net proceeds of &#8364;290.6 million and increased warrant exercise activity of &#8364;20.2 million. Similar to 2023, we entered into a $150.0 million capped synthetic royalty funding agreement with Royalty Pharma.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development, Patents and Licenses, etc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;Item 4 B. Information on the Company&#8212;Business Overview&#8221; and &#8220;Item 5 A. Operating and Financial Review and Prospects &#8211; Operating Results&#8212;Financial Operations Overview&#8212;Research and Development Costs.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trend Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;Item 5 A. Operating and Financial Review and Prospects&#8212;Operating Results.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E.	Critical Accounting Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are prepared in accordance with the IFRS Accounting Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), and as adopted by the European Union (&#8220;EU&#8221;). A description of critical accounting estimates is provided in Note 3, &#8220;Significant Accounting Judgements and Estimates&#8221; under the Significant Estimation Uncertainties sub-section in the audited consolidated financial statements as of and for the years ended December 31, 2024, 2023 and 2022, of this annual report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_directors_senior_management"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6 Directors, Senior Management and Employees</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors and Senior Management </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a two-tier governance structure consisting of a board of directors and an executive board. The two bodies are separate; however, Jan M&#248;ller Mikkelsen, our President and Chief Executive Officer, is represented on both our board of directors and our executive board. Our executive board is supported by the other members of our senior management. Below is a summary of relevant information concerning our board of directors, executive board and senior management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Members of Our Board of Directors, Executive Board and Senior Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information with respect to each of our current board members as of the date of this annual report. All members of our board of directors are elected for one year and eligible for re-election at each annual general meeting. Our board of directors currently consists of six members.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The business address of our board members is our registered office address at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:32.513%;box-sizing:content-box;"/>
    <td style="width:1.72%;box-sizing:content-box;"/>
    <td style="width:8.558%;box-sizing:content-box;"/>
    <td style="width:1.72%;box-sizing:content-box;"/>
    <td style="width:55.489%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Board Member</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position(s)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Albert Cha</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman and Board Member</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa Bright</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Board Member</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">William Carl Fairey Jr.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Board Member</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lars Holtug, M.Sc.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Board Member</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Siham Imani</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Board Member</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jan M&#248;ller Mikkelsen</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Board Member</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a brief summary of the business experience of our non-employee board members.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Albert Cha, M.D., Ph.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as a member of our board of directors since November 2014 and as the Chairman of our board of directors since May 2021. Dr. Cha is a Managing Partner with Frazier Life Sciences. He previously was a managing partner at Vivo Capital LLC, a healthcare investment firm, where he has served in various positions, most recently as a managing partner. Dr. Cha previously served as a member of the board of directors of KalVista Pharmaceuticals, Inc., Aclaris Therapeutics, a publicly traded dermatology company, Sierra Oncology, Inc., a publicly traded oncology company, Biohaven Pharmaceutical Holding Company Ltd, a publicly traded clinical-stage biopharmaceutical company targeting neurological diseases and Menlo Therapeutics, Inc., a publicly traded late-stage biopharmaceutical company focused on the treatment of pruritus. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lisa Bright </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as a member of our board of directors since April 2017. Ms. Bright has over 30 years of executive experience in global life sciences companies and over five years&#8217; experience serving as a member of the board of directors of a number of public and private companies. Ms. Bright is currently on the board of Immedica Pharma AB, a pharmaceutical company, and serves as Chair of the board of Metadeq Inc, a medical diagnostics company and DRI Capital, a private equity fund. She previously served as the Chair of the board of Resolution Therapeutics Ltd, a biotechnology company, and as a Non-Executive Director of Dechra Pharmaceuticals PLC, a veterinary pharmaceutical company. She is also an Executive Partner to Syncona Limited, an investment trust dedicated to life science investments. Previously, she served as President International for Intercept Pharmaceuticals, Inc., a biopharmaceutical company, from July 2016 to January 2021, and from November 2014 to July 2016 as Chief Commercial and Corporate Affairs Officer and Senior Vice President, Head of EUCA. During her tenure at Intercept, Ms. Bright oversaw the development of the global launch of an orphan medicine in the United States and Europe, including building the commercial organization in the United States and establishing legal affiliates and teams across Europe and Canada. From 2008 to November 2014, Ms. Bright held various leadership positions at Gilead Sciences Ltd., a biopharmaceutical company, including Vice President, Head of Government Affairs, Europe, Asia, Middle East and Australasia, Vice President and Head of HCV Launch Planning, Vice President and Head of Northern Europe and General Manager, UK and Ireland. Prior to Gilead Sciences, Ms. Bright served in various positions of increasing responsibility at GlaxoSmithKline plc from 1997 to 2006 including Vice President Commercial Planning and Operations and Vice President General Manager NZ and Vice President Head of Sales, UK and Ireland. Prior to that, Ms. Bright also worked at Sanofi from 1992 to 1996 and GlaxoSmithKline from 1989 to 1992. Ms. Bright received her B.Sc. in Pharmacology from University College London, United Kingdom.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">William Carl Fairey Jr.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as a member of our board of directors since September 2022. Mr. Fairey currently serves as Executive Chairman of Respira Therapeutics, Inc., a clinical-stage company developing inhaled therapeutics for cardiopulmonary diseases, a position he has held since January 2022. Since August 2021, Mr. Fairey has also served as a director of Mirum Pharmaceuticals, a publicly-traded biotechnology company developing therapies for rare liver diseases; since November 2023, he has served on the board of Aileron Therapeutics (previously Lung Therapeutics, Inc.), a public clinical-stage biopharmaceutical company; and since June 2024, he has served on the board of KalVista, a publicly-traded pharmaceutical company developing therapies for hereditary angioedema. Prior to Respira, Mr. Fairey was Executive Vice President and Chief Commercial Officer of MyoKardia, Inc., a publicly-traded clinical-stage biopharmaceutical company, from January 2019 until November 2020 when the company was acquired by Bristol-Myers Squibb. From January 2018 until January 2019, Mr. Fairey served as Executive Vice President and Chief Operating Officer of ChemoCentryx, Inc., a publicly-traded biopharmaceutical company developing therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. Before ChemoCentryx, between 2001 and 2017, Mr. Fairey served in various positions of increasing responsibility at Actelion Pharmaceuticals, including as President of Actelion&#8217;s U.S. division, as well as Vice President, Asia Pacific Region, Managing Director and Vice President, Australia Asia Pacific Region, President of Actelion Canada, and Vice President, US Sales and Managed Markets. Mr. Fairey began his pharmaceutical career as Business Director, Healthcare Management for the Parke-Davis Division of Warner-Lambert between 1988 and 2000. Mr. Fairey received a B.S. in Biology from the University of Oregon and an M.B.A. from Saint Mary&#8217;s College of California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lars Holtug, M.Sc. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as a member of our board of directors since November 2018. Mr. Holtug was a partner at PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (&#8220;PwC&#8221;) from 1993 to 2015. Mr. Holtug also currently serves as chairman of Erhvervsinvest Management A/S, a private equity firm, Gaming Investment A/S, a gaming solutions provider, and its eleven subsidiaries, and of Caretag A/S, a healthcare technology company. Mr. Holtug also currently serves as a board member of Evaxion Biotech A/S, as well as the Audit Committee Chair and Remuneration Committee member. Previously, he was Chairman of PwC in Denmark from 2005 to 2009. From 2004 to 2015, Mr. Holtug was a member of the Danish Commercial Appeals Board (Erhvervsankenaevnet) and a board member of the Danish Company law association (Dansk Forening for Selskabsret). He was also a member of the Accounting Standards Board of the Federation of State Authorized Accountants in Denmark (Foreningen af Statsautoriserede Revisorer) from 1998 to 2002, and a member of the Auditing Standards Board from 1993 to 1998. Mr. Holtug holds an M.Sc. from Copenhagen Business School and is educated as a state authorized public accountant in Denmark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Siham Imani</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as a member of our board of directors since September 2022. Ms. Imani currently serves as Executive Vice President of Strategy, Sustainability and Growth at Chiesi Farmaceutici S.p.A., a pharmaceutical company. Before joining Chiesi, Ms. Imani was EVP Corporate Strategy &amp; Business Development at Servier, where she contributed to the Group transformation as a leader in Cardio Metabolism and Oncology. Prior to Servier, Ms. Imani held various positions of increasing responsibility at Ipsen, a French pharmaceutical company specializing in oncology, neuroscience and rare diseases, including Vice President European Business Unit Pediatric Endocrinology, Vice President Commercial Transformation &amp; Support, Vice President Corporate Strategic Planning and Executive Committee Secretary, from 2011 until April 2017. Ms. Imani also worked for Pierre Fabre and Biosense Webster, part of the Johnson &amp; Johnson Family of Companies, from 2005 to 2010. Ms. Imani is also a board member at Lapropan, a pharmaceutical company. Ms. Imani received a Master in Economics and a Master in Chemistry from &#201;cole Polytechnique in Palaiseau, France and an M.B.A. from Stanford University.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Board and Senior Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information with respect to each of the members of our senior management as of the date of this annual report. In addition to serving as members of our senior management, Mr. Mikkelsen, Mr. Smith, Mr. Wolff Jensen, and Ms. S&#248;nderbjerg serve as the members of our executive board. The business address of these individuals is our registered office address at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.585%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:5.321%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:66.333%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position(s)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jan M&#248;ller Mikkelsen</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Board Member</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Flemming Steen Jensen</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Product Supply and Quality</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Wolff Jensen, L.L.M.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Legal Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mads Bodenhoff</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Vice President, Head of Finance and Principal Accounting Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stina Singel, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Head of Clinical Development, Oncology</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scott T. Smith</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lotte S&#248;nderbjerg</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Administrative Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kennett Sprog&#248;e, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Head of Innovation and Research</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aimee Shu, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Medical Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jay Donovan Wu</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, U.S. President</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a brief summary of the business experience of our senior management and executive board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jan M&#248;ller Mikkelsen </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">founded Ascendis Pharma and has served as President and Chief Executive Officer as well as a Board member since December 2007 and currently serves on the board of VISEN Pharmaceuticals and as Chairman of the board of Hummingbird Bioscience, Inc. From 2002 to 2006, Mr. Mikkelsen served as President and Chief Executive Officer of LifeCycle Pharma A/S, now Veloxis Pharmaceuticals A/S, which was a publicly traded biotechnology company. From 2000 to 2002, Mr. Mikkelsen was President of the Pharmaceutical Division of Maxygen, Inc. Prior to that, Mr. Mikkelsen co-founded ProFound Pharma A/S, a biopharmaceutical company that was later acquired by Maxygen, Inc., and at ProFound, he served as Co-Chief Executive Officer from 1999 to 2000. From 1988 to 1999, Mr. Mikkelsen held various positions at Novo Nordisk A/S, a global healthcare company, including Vice President of Protein Discovery. Mr. Mikkelsen currently serves as a member of the advisory board of Inspirion Delivery Technologies, a specialty pharmaceutical company. Mr. Mikkelsen received a Cand. Scient. degree in Biochemistry from the University of Odense, Denmark, and pursued his post-doctoral research at Children&#8217;s Hospital in Oakland, CA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">140</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Flemming Steen Jensen </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Executive Vice President, Product Supply and Quality since January 2023 and previously served as our Senior Vice President, Product Supply and Quality from August 2015 until January 2023. Prior to this, Mr. Jensen served as Corporate Vice President for Global Pharma Consulting and Business Development and member of the management team at NNE Pharmaplan A/S, an engineering and consulting company (part of Novo Nordisk A/S), from October 2014 to July 2015. From 1999 to September 2014, Mr. Jensen served as Executive Vice President of Product Supply (Production, Supply Chain, Engineering and Maintenance, Business Improvements, Quality Assurance and Health, Safety and Environment) and member of the Board of Management of ALK-Abello A/S, a pharmaceutical company. From 1986 to 1999, Mr. Jensen held several management positions relating to development, manufacturing and engineering within Novo Nordisk A/S. Mr. Jensen is also a member of various boards of directors of companies in the life sciences industry. Mr. Jensen holds a M.Sc. in Pharmacy from the University of Copenhagen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michael Wolff Jensen, L.L.M. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Executive Vice President, Chief Legal Officer since January 2023 and previously served as our Senior Vice President, Chief Legal Officer from June 2013 until January 2023. Mr. Jensen also currently serves as Chairman of the board of VISEN Pharmaceuticals. In addition, Mr. Jensen served as Chairman of our board of directors from January 2008 to May 2021 and as our Acting Chief Financial Officer from May 2008 to June 2013. Prior to Ascendis Pharma, Mr. Jensen served as Executive Vice President &amp; Chief Financial Officer of LifeCycle Pharma, currently known as Veloxis Pharmaceuticals A/S, a publicly traded biotechnology company, from 2003 to 2008. Prior to joining Veloxis, Mr. Jensen served as Senior Vice President &amp; Chief Financial Officer of Genmab A/S from 2000 to 2003. Mr. Jensen received an L.L.M. degree from the University of Copenhagen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mads Bodenhoff </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was appointed as Senior Vice President, Head of Finance and Principal Accounting Officer at Ascendis Pharma in February 2024. Mr. Bodenhoff served as Senior Vice President and Head of Finance of the Company from June 2021 to March 2024. From March 2018 to June 2021, Mr. Bodenhoff served as Chief Financial Officer at NKT Photonics A/S. From September 2014 to February 2018, Mr. Bodenhoff served as Chief Financial Officer at Xellia Pharmaceuticals, a subsidiary of Novo Holdings A/S. From 2007 to 2014, Mr. Bodenhoff served as Vice President Finance and Vice President Corporate Finance at Novozymes A/S, a global biotechnology company. Prior to this, Mr. Bodenhoff had leading financial roles for Novozymes within China and Asia Pacific and Latin and North America. Mr. Bodenhoff currently serves on the board of 4XROBOTS A/S. Mr. Bodenhoff received a Bachelor in Economics from Handelsh&#248;jskolen in Slagelse and a Master&#8217;s Degree in Business Economics and Auditing from Copenhagen Business School. Mr. Bodenhoff further is educated as a state authorized public accountant in Denmark.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stina Singel, M.D., Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Executive Vice President, Head of Clinical Development, Oncology, since January 2023 and previously served as our Senior Vice President, Head of Clinical Development, Oncology, from January 2022 until January 2023 and as our Head of Clinical Development, Oncology, from May 2020 to January 2022. Prior to joining Ascendis, Dr. Singel served as Senior Vice President and Head of Clinical Development and Drug Safety at Nektar Therapeutics, a biopharmaceutical company, from April 2019 to May 2020. From March 2014 to April 2019, Dr. Singel held various positions of increasing responsibility at Genentech, a biotechnology company, ending her tenure as Senior Medical Director. From 2017 to 2019, Dr. Singel also served as an Adjunct Clinical Instructor at the Stanford University School of Medicine. Prior to Genentech, Dr. Singel was an Attending Physician and Clinical Translational Researcher focused on breast oncology at the University of Texas Southwestern Medical Center from 2010 to 2014 and was a Medical Oncologist at Washington Hematology Oncology, a community practice in Yakima, Washington, from 2008 to 2010. Dr. Singel received her M.D. and Ph.D. degrees from the University of California, San Diego, where she also completed her internal medicine residency and medical oncology fellowship. She received her B.S. in Biology (magna cum laude) from Harvard University.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scott T. Smith </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Executive Vice President and Chief Financial Officer since January 2023 and previously served as our Senior Vice President and Chief Financial Officer from August 2016 until January 2023. Previously, Mr. Smith served as Director of the Healthcare Investment Banking Group at Wedbush Securities, from 2012 to 2016, where he led the healthcare team, and, from 2009 to 2012, Mr. Smith served as a Managing Director at Wedbush. Prior to joining Wedbush, Mr. Smith served as a Director in the Global Healthcare Investment Banking Group at Merrill Lynch where he began his career in 1995. He has also worked in sales, marketing and strategy roles for various companies, including start-ups and a Fortune Global 500 company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">141</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Smith received his M.B.A. from the Stanford University Graduate School of Business and graduated magna cum laude with a B.A. in Economics/Accounting-Physics from Claremont McKenna College.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lotte S&#248;nderbjerg </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Executive Vice President, Chief Administrative Officer since January 2023 and previously served as our Senior Vice President, Chief Administrative Officer from December 2007 until January 2023. Mrs. S&#248;nderbjerg is also Managing Director of Ascendis Pharma GmbH. Prior to joining Ascendis, Mrs. S&#248;nderbjerg served as Senior Director of Human Resources and as Finance Director at Veloxis Pharmaceuticals A/S from 2003 to 2007. Prior to joining Veloxis Pharmaceuticals A/S, Mrs. S&#248;nderbjerg served as Senior Director of Finance and Human Resources at Acadia Pharmaceuticals Inc., a publicly traded biotechnology company, from 1996 to 2003. Prior to her career in biotech, Mrs. S&#248;nderbjerg was the Executive Secretary for the CEO and Board of Directors of Novo Nordisk A/S and PA to leading audit partner in PricewaterhouseCoopers LLP in Denmark. Mrs. S&#248;nderbjerg received a Masters of Arts in International Business Communications from University of Aarhus.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Kennett Sprog&#248;e, Ph.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has held positions of increasing responsibility at Ascendis Pharma since December 2007, including serving as our Executive Vice President, Head of Innovation and Research since January 2023, Senior Vice President, Head of Innovation and Research from 2019 until January 2023, Senior Vice President of Product Innovation since January 2016 and Vice President Product Innovation since June 2014. Prior to joining Ascendis, Dr. Sprog&#248;e conducted research at the University of Copenhagen, where he applied novel hyphenated screening technologies to expedite discovery of drug leads from natural sources. Dr. Sprog&#248;e holds a Ph.D. in Natural Products Chemistry from the University of Copenhagen and a M.Sc. in Pharmacy from the Danish University of Pharmaceutical Sciences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aimee Shu, M.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was named Executive Vice President of Endocrine and Rare Disease Medical Sciences and Chief Medical Officer in November 2024 after holding positions of increasing responsibility since joining the company in July 2017. These include Vice President and Head of Clinical Development, Endocrinology from May 2022 to November 2024, Vice President, Clinical Development, Endocrine Medical Sciences from January 2021 to November 2024, Senior Medical Director, Clinical Development from January 2019 to December 2020 and Medical Director, Clinical Development from July 2017 to December 2018. Dr. Shu has also served as Clinical Associate Professor of Medicine, Division of Endocrinology at Stanford University School of Medicine since November 2016 and has held positions of increasing responsibility at Stanford since November 2012, including Associate Program Director, Endocrinology Training Fellowship Training Program from July 2015 to July 2017 and Clinical Assistant Professor of Medicine, Division of Endocrinology from November 2012 to October 2016. Prior to 2012, Dr. Shu served as Assistant Professor of Medicine, Division of Endocrinology at Baylor College of Medicine from February 2011 to December 2011 and as Assistant Professor of Clinical Medicine at Columbia University College of Physicians &amp; Surgeons from July 2009 to June 2010. Dr. Shu received her A.B. from Princeton University and her M.D. from Harvard Medical School before completing her residency at Brigham and Women&#8217;s Hospital and a Fellowship in Endocrinology at Columbia University Medical Center.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jay Donovan Wu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was appointed as Executive Vice President and U.S. President at Ascendis Pharma in January 2025. Prior to joining Ascendis, Mr. Wu served in various positions of increasing responsibility at Genentech, Inc., a biotechnology company, from July 2012 to January 2025, ending his tenure as Vice President, Head of Rare Diseases Portfolio. Prior to this, Mr. Wu served as a Consultant at Bain &amp; Company. Mr. Wu received a BA in Neuroscience and a BSEc in Finance from the University of Pennsylvania, Wharton School and an MBA from Stanford Graduate School of Business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation of Members of Our Board of Directors and Senior Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary objective of our board of directors and senior management (executive board and non-executive senior management) compensation program is to attract, motivate, reward and retain the managerial talent needed to achieve our business objectives. In addition, the compensation program is intended to compensate all employees at competitive market rates, while recognizing extraordinary accomplishments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">142</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation arrangements for our senior management have been designed to align a portion of their compensation with the achievement of our business objectives and growth strategy. Bonus payments for our senior management are determined with respect to a given year based on quantitative and qualitative goals set for our Company as a whole, as well as on an individual basis. Once the results of the year are known, bonus payments are determined at the discretion of our board and, with respect to senior management reporting to the CEO, in light of recommendations made by the CEO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation to our senior management comprises salaries, participation in annual bonus schemes, pensions (defined contributions plans), and share-based compensation. Compensation to our board of directors comprises fees and salaries for their membership of the board and committee work, as applicable, and share-based compensation. Mr. Mikkelsen did not receive any separate compensation in respect of his service on the board. Share-based compensation is elaborated in further details in Note 7, &#8220;Share-based Payment.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation cost to the board of directors and senior management is summarized below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.492%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.758%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.758%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.758%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.758%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.758%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.758%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.758%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.758%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.457%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Board of Directors </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Executive Board </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-executive Senior Management</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="34" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR &#8216;000)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Compensation</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">482</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">543</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">403</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,148</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,375</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,809</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,286</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,673</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,087</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,169</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,276</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,273</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,334</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,243</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,392</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,266</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,529</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,872</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pensions (defined<br/>&#160;&#160;&#160;contribution plans)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other employee cost</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total compensation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,651</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,819</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,676</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">22,677</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,795</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,322</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">13,727</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14,409</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,211</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors comprised six persons in 2024 and six to seven persons in 2023 and 2022.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Board comprised four persons in 2024, 2023 and 2022.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Wages and salaries for our senior management set forth in the table above includes bonuses of &#8364;3.0 million, &#8364;3.9 million and &#8364;3.2 million for the years ended December 31, 2024, December 31, 2023 and December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 1, 2024, our board of directors granted an aggregate of 20,610 Restricted Stock Units (&#8220;RSUs&#8221;) to certain non-employee board members of the company and 158,875 RSUs to certain members of senior management. The aggregate grant date fair value of the RSUs granted was &#8364;25.3 million. Also on March 1, 2024, our board of directors granted an aggregate of 92,655 Performance Stock Units (&#8220;PSUs&#8221;) to certain members of senior management. The aggregated grant date fair value of the PSUs was &#8364;13.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, a total of 29,072 RSUs and 253,091 RSUs were outstanding for non-employee board members and members of senior management, respectively, and a total of 151,924 PSUs were outstanding for members of senior management.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, a total of 127,886 warrants and 1,835,453 warrants were outstanding for non-employee board members and members of senior management, respectively.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount set aside or accrued by us to provide pension, retirement or similar benefits for the members of our board of directors and members of senior management for the year ended December 31, 2024 was &#8364;0.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Senior Management Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into employment or service agreements with our senior management with the below notice periods:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Mikkelsen&#8217;s employment agreement contains a notice period of six months if terminated by Mr. Mikkelsen and twelve months if terminated by Ascendis Pharma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">143</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in case of a change of control (&#8220;change in control period&#8221;), Ascendis Pharma would for a period of 12 months have to observe an 18 months&#8217; notice period. Should the position and responsibilities be changed during such change of control period (excluding insignificant changes) Mr. Mikkelsen will be entitled to regard his employment as having been terminated by Ascendis Pharma with twelve months&#8217; notice.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Messrs. M. Jensen, F. Jensen and Ms. S&#248;nderbjerg all have notice periods of three months if terminated by them and six months if terminated by Ascendis Pharma. In addition, for Ms. S&#248;nderbjerg, the notice period may be no less than the notice required pursuant to the rules of the Danish Salaried Employees Act with the addition of two months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Bodenhoff&#8217;s notice period may be no less than the notice required pursuant to the rules of the Danish Salaried Employees Act, mutually extended with three months&#8217; notice for Mr. Bodenhoff and six months&#8217; notice by Ascendis Pharma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Sprog&#248;e&#8217;s notice period is one month if terminated by him and six months if terminated by Ascendis Pharma.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Singel&#8217;s, Mr. Wu&#8217;s, and Mr. Smith&#8217;s employment is at-will and may be terminated by both parties at any time. However, the agreement with Mr. Smith provides that, if terminated by Ascendis Pharma without &#8220;cause&#8221; or Mr. Smith resigns for &#8220;good reason&#8221; (as defined in the agreement), he will be eligible to receive continued base salary during a 6 month severance period following termination and continued healthcare coverage during this period. If Mr. Smith&#8217;s termination is due to disability, he will be eligible to continued base salary and healthcare coverage for 120 days following termination, and in the event of his death, his estate will be eligible to a lump sum amount equal to three months base salary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreements with certain of the foregoing senior management contain post-termination non-competition covenants that generally may last for a period of twelve months post-termination and entitle the executives to their base salary, or portion thereof, during the period.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Incentive Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For information of our warrant incentive program, see Note 7, &#8220;Share-based Payment.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below sets forth information regarding outstanding warrants held by those members of our board of directors and senior management who, assuming the exercise of warrants, beneficially own 1% or more of our total outstanding ordinary shares as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.877%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:17.357%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.438%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.698%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.698%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:27.355%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Awards<br/>granted<br/>and<br/>outstanding</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Awards<br/>granted and<br/>outstanding,<br/>but unvested<br/>as of March 1, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Award<br/>Exercise<br/>Price(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Award<br/>Expiration Date</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jan M&#248;ller Mikkelsen</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 18, 2015</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,000</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.6750</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 18, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 14, 2016</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,000</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.4194</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 14, 2026</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 12, 2017</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.5995</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 12, 2027</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 11, 2018</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54.6357</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 11, 2028</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 10, 2019</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,000</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.4993</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 10, 2029</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 10, 2020</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,145</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145.5045</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 10, 2030</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 9, 2021</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,466</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,473</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123.4637</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 9, 2031</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Program and PSU Program</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For information of our RSU and PSU programs, refer to Note 7, &#8220;Share-based Payment.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insurance and Indemnification</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to the Danish Companies Act, the general meeting is allowed to discharge our board members and members of our senior management from liability for any particular financial year based on a resolution relating to the financial statements. This discharge means that the general meeting will discharge such board members and members of our senior management from liability to our company; however, the general meeting cannot discharge any claims by individual shareholders or other third-parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">144</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have entered into agreements with our board members and members of our senior management, pursuant to which, subject to limited exceptions, we have agreed to indemnify such board members and members of our senior management from civil liability, including (i) any damages or fines payable by them as a result of an act or failure to act in the exercise of their duties currently or previously performed by them; (ii) any reasonable costs of conducting a defense against a claim; and (iii) any reasonable costs of appearing in other legal proceedings in which such individuals are involved as current or former board members or members of our senior management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a risk that such agreement will be deemed void under Danish law, either because the agreement is deemed contrary to the rules on discharge of liability in the Danish Companies Act, as set forth above, because the agreement is deemed contrary to sections 19 and 23 of the Danish Act on Damages, which contain mandatory provisions on recourse claims between an employee (including members of our senior management) and the company, or because the agreement is deemed contrary to the general provisions of the Danish Contracts Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to such indemnification, we provide our board members and senior management with directors&#8217; and officers&#8217; liability insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insofar as indemnification of liabilities arising under the Securities Act may be permitted to board members and senior management or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Practices </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is responsible for our overall and strategic management and must ensure proper organization of our business. In addition, our board is obligated to ensure that (i) bookkeeping and financial reporting procedures are satisfactory; (ii) adequate risk management and internal control procedures have been established; (iii) our board of directors receives ongoing information as necessary about our financial position; (iv) our executive board performs its duties properly and as directed by our board of directors; and (v) the financial resources of our company are adequate at all times, and that our company has sufficient liquidity to meet its current and future liabilities as they become due.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In performing its duties, our board of directors is required to act in the interests of our company (including our shareholders) and our associated business as a whole. Our board of directors may generally make any decisions in furtherance of our objectives that are not reserved for either the executive board or the shareholders either by virtue of the articles of association or by operation of Danish law. Typical shareholder decisions that our board of directors cannot resolve alone are: changes to the articles of association, elections of board members, elections of auditors, decisions to scrutinize our company&#8217;s affairs, capital increases and decreases, payment of dividends, purchase of treasury shares, and decisions to merge, demerge or liquidate our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general meeting of shareholders must elect no fewer than three and no more than ten members to our board of directors. The members of our board of directors are elected for a term expiring at the first annual general meeting following their election.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board members may be dismissed at any time at a general meeting of shareholders. A resolution by the general meeting of shareholders to appoint or dismiss board members requires a simple majority of the votes cast and there is no requirement for a specific quorum.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Danish corporate law, employees of companies that have employed at least 35 employees for the preceding three years are entitled to elect members of their board of directors corresponding to one-half of the members of their board of directors elected by the general meeting of shareholders. Board members elected by the employees are elected for terms of four years, and they hold the same rights and obligations as any board member elected by the shareholders. We do not currently have employee representatives on our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">145</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors elects its chairman. Our board of directors forms a quorum when more than half of the members of our board of directors are represented. Resolutions of our board of directors are passed by simple majority. Each board member is entitled to cast one vote. For a complete description of these board governance matters, you should refer to our articles of association, which are incorporated by reference as an exhibit to this annual report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors may also adopt resolutions without a meeting, provided that such resolutions are adopted in writing and submitted to all members of our board of directors and provided that no board member objects to adopting resolutions without conducting a meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a foreign private issuer, our board of directors is not required to hold regularly scheduled meetings at which only independent board members are present and we intend to comply with home country practices, which do not require executive sessions, in lieu of complying with Nasdaq Rule 5605(b)(2).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Mikkelsen is a member of our senior management and a member of our board of directors and has an employment agreement that provides for benefits upon termination of employment in certain circumstances. For information about such agreements, see &#8220;Item 6 B. Directors, Senior Management and Employees&#8212;Compensation&#8212;Senior Management Agreements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the exemption available to foreign private issuers under Nasdaq rules, we do not follow the requirements of the Nasdaq rules with regard to the process of nominating board members, and instead, follow Danish law and practice, in accordance with which our board of directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election. Under the Danish Companies Act, nominations for directors also may be made upon the request of any shareholder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Board</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive board is in charge of the day-to-day management of our operations and is assisted in this respect by the other members of our senior management. The executive board must follow the guidelines and directions issued by the board of directors. Day-to-day management does not include decisions of an unusual nature or of major importance, having regard to the circumstance. Such decisions may only be made by the executive board if specifically authorized by the board of directors, unless it will cause considerable inconvenience to our company&#8217;s activities to wait for authorization by the board of directors. If so, the board of directors must be notified of the decision as soon as possible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Independence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has undertaken a review of the independence of the directors and considered whether any director has a material relationship with us that could compromise their ability to exercise independent judgement in carrying out the responsibilities of a director. As a result of this review, our board of directors determined that Lisa Bright, Albert Cha, M.D., Ph.D., William Carl Fairey Jr., Lars Holtug, and Siham Imani, representing five of our six directors, are &#8220;independent directors&#8221; as that term is defined under the applicable rules and regulations of the SEC and the listing requirements and rules of Nasdaq. In making such determination, our board of directors considered the relationships that each non-employee director has with us and all other facts and circumstances our board of directors deemed relevant in determining the director&#8217;s independence, including the number of ordinary shares beneficially owned by the director and his or her affiliated entities (if any).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">146</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Committees of the Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have an audit committee, a remuneration committee and a nominating and corporate governance committee. We have adopted a charter for each of these committees. Under Danish corporate law, it is not possible to delegate the decision-making authority of the entire board of directors to board committees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit Committee</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit committee consists of Lars Holtug (Chair), Lisa Bright and William Carl Fairey Jr. Each member satisfies the independence requirements of the Nasdaq listing standards, and Lars Holtug qualifies as an &#8220;audit committee financial expert,&#8221; as defined in Item 16A(b) of Form 20-F and as determined by our board of directors. Our audit committee oversees our accounting and financial reporting processes and the audits of our consolidated financial statements. As a foreign private issuer, we are not required to have a formal written audit committee charter that complies with Nasdaq Rule 5605(c)(1) and, although we have adopted an audit committee charter, we comply with home country practices in lieu of Nasdaq Rule 5605(c)(1). Nasdaq Rule 5605(c)(2)(A) requires that U.S. listed companies have an audit committee composed of at least three members, each of whom is an independent director, as defined in the Nasdaq rules. As a foreign private issuer, we are exempt from complying with the Nasdaq requirement to have an audit committee with at least three members, and we comply with home country practices in lieu of Nasdaq Rule 5605(c)(2)(A). However, our audit committee currently comprises three members, all of whom meet the relevant criteria for independence under Nasdaq rules and under Rule 10A-3 of the Exchange Act. Our audit committee is responsible for, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making recommendations to our board of directors regarding the appointment by the general meeting of shareholders of our independent auditors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing the work of the independent auditors, including making recommendations to the board of directors and resolving disagreements between the executive board and the independent auditors relating to financial reporting; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing the independence and quality control procedures of the independent auditors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">discussing material off-balance sheet transactions, arrangements and obligations with the executive board and the independent auditors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing all proposed related-party transactions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">discussing the annual audited consolidated and statutory financial statements with the executive board; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">annually reviewing and reassessing the adequacy of our audit committee charter; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">meeting separately with the independent auditors to discuss critical accounting policies, recommendations on internal controls, the auditor&#8217;s engagement letter and independence letter and other material written communications between the independent auditors and the executive board; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attending to such other matters as are specifically delegated to our audit committee by our board of directors from time to time. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Remuneration Committee</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our remuneration committee consists of Albert Cha, M.D., Ph.D. (Chair), Lisa Bright and Lars Holtug. Each member satisfies the independence requirements of the Nasdaq listing standards. Our remuneration committee assists our board of directors in reviewing and approving or recommending our compensation structure, including all forms of compensation relating to our board of directors and the executive board. As a foreign private issuer, we are not required to have a formal written remuneration committee charter that complies with Nasdaq Rule 5605(d)(1) and, although we have adopted a remuneration committee charter, we comply with home country practices in lieu of Nasdaq Rule 5605(d)(1). Our remuneration committee is responsible for, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and making recommendations to our board of directors with respect to compensation of our executive board and members of our board of directors; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">147</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and approving the compensation, including equity compensation, change-of-control benefits and severance arrangements, of our chief executive officer, chief financial officer and such other members of our executive board as it deems appropriate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing and making recommendations to our board of directors regarding the evaluation of our executive board; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing periodically and making recommendations to our board of directors with respect to any incentive compensation and equity plans, programs or similar arrangements; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attending to such other matters as are specifically delegated to our compensation committee by our board of directors from time to time. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our nominating and corporate governance committee consists of Albert Cha, M.D., Ph.D. (Chair), Lisa Bright and Siham Imani. Each member satisfies the independence requirements of the Nasdaq listing standards. Our nominating and corporate governance committee assists the board of directors in selecting individuals qualified to become our board members and in determining the composition of the board of directors and its committees. Our nominating and corporate governance committee is responsible for, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recommending to our board of directors, persons to be nominated for election or re-election to our board of directors at any meeting of the shareholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing orientation of new members of our board of directors, continuing education for existing members, and succession planning for our board or directors, leadership roles on our board of directors and its committees, and members of our senior management; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing our board of director&#8217;s annual review of its own performance and the performance of its committees; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">considering, preparing and recommending to our board of directors a set of corporate governance guidelines. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For information on the current term of office and the period during which the members of our board of directors, executive board and our senior management have served in office see &#8220;Item 6 A. Directors, Senior Management and Employees&#8212;Directors and Senior Management.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables specify number of employees at the end of period, per their main activity function and geographic location for the past three financial years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Selling, General, and<br/>Administration </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Research and<br/>Development, and<br/>Commercial Manufacturing</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">253</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">413</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">666</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">492</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">525</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,017</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">148</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Selling, General, and<br/>Administration </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Research and<br/>Development, and<br/>Commercial Manufacturing</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">554</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">354</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">525</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">879</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Selling, General, and<br/>Administration </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Research and<br/>Development</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">352</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">487</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">305</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">492</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">797</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general, and administration function includes commercial activities, corporate activities and business development. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the number of employees engaged with selling, general, and administration increased, primarily due to commercial activities, and extension of corporate functions to support those activities. Further, in connection with formation of Eyconis, a separate company, certain employees of Ascendis Pharma, engaged with research and development in the U.S., joined the newly formed company in 2024. See &#8220;Item 7 B. Major Shareholders and Related Party Transactions&#8212;Related Party Transactions&#8221; for more information about Eyconis.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of our employees are represented by a labor union. In certain European countries, employees are covered under collective bargaining agreements. We consider our employee relations to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">E.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Ownership </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;Item 7 A. Major Shareholders and Related Party Transactions&#8212;Major Shareholders.&#8221; Our board of directors and employees are eligible to own shares of the company through a warrant incentive program and a RSU and PSU program. For information of the programs, see Note 7, &#8220;Share-based Payment.&#8221; For information regarding the warrants held by members of our board of directors and senior management who, assuming the exercise of warrants, beneficially own 1% or more of our total outstanding ordinary shares as of December 31, 2024, see &#8220;Item 6 B. Compensation.&#8221;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">F.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_major_shareholders_and_related"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7 Major Shareholders and Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A. Major Shareholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information relating to the beneficial ownership of our shares as of December 31, 2024, by:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding ordinary shares; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each of our board members; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each member of our senior management, including members of our executive board. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">149</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares beneficially owned by each entity, person, member of our board of directors or senior management is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power, as well as any shares that the individual has the right to subscribe for within 60 days of December 31, 2024, through the exercise of any warrants or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares owned by that person.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The percentage of shares beneficially owned is computed on the basis of 60,689,487 ordinary shares outstanding as of December 31, 2024, which includes 845,887 ordinary shares represented by ADSs held by Ascendis Pharma A/S. Ordinary shares that a person has the right to subscribe for within 60 days of December 31, 2024 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights but are not deemed outstanding for purposes of computing the percentage ownership of any other person. Additionally, a person is considered to have the right to subscribe for ordinary shares which are subject to outstanding warrants and vested within 60 days of December 31, 2024, although such warrants may only be exercised in prescribed exercise periods. A person is considered to beneficially own ordinary shares which are subject to RSUs that vest within 60 days of December 31, 2024 and a person is not considered to beneficially own ordinary shares subject to PSUs because these awards are subject to performance-based vesting criteria. Unless otherwise indicated below, the address for each beneficial owner listed is c/o Ascendis Pharma A/S, at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:44.549%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.802%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.802%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.802%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.042%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Address of Beneficial Owner</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Outstanding<br/>Shares<br/>Beneficially<br/>Owned</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Warrants<br/>Exercisable<br/>and RSUs to be<br/>Settled Within<br/>60 Days</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares<br/>Beneficially<br/>Owned</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage of<br/>Beneficial<br/>Ownership</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities affiliated with RA Capital Management,<br/>&#160;&#160;&#160;L.P. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,710,428</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,710,428</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.0</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Westfield Capital Management Company, LP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,528,239</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,528,239</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.1</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities affiliated with FMR LLC </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,114,369</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,114,369</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Avoro Capital Advisors LLC </span><span style="color:#000000;top:-3.9865pt;white-space:pre-wrap;font-size:5.695pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,988,888</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,988,888</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities affiliated with Artisan Partners LP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,411,111</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,411,111</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities affiliated with Janus Henderson Group plc </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,186,694</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,186,694</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Senior Management and Board Members</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jan M&#248;ller Mikkelsen </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">904,651</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,342,901</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Flemming Steen Jensen </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,763</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,905</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">151,668</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Wolff Jensen, L.L.M. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(9)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,342</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,342</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mads Bodenhoff </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(10)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,381</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,574</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stina Singel, M.D., Ph.D. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(11)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,729</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,585</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,314</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scott T. Smith </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(12)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,017</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189,967</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193,984</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lotte S&#248;nderbjerg </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(13)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,763</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">199,342</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205,105</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kennett Sprog&#248;e, Ph.D. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(14)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,793</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140,280</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,073</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aimee Shu, M.D. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(15)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,917</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,732</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,649</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Albert Cha, M.D., Ph.D. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(16)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,087</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,056</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,143</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa Bright </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(17)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,087</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,619</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,706</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">William Carl Fairey Jr. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(18)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,273</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,437</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lars Holtug, M.Sc. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(19)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,593</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,514</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,107</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Siham Imani </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(20)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,273</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,637</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jay Donovan Wu</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:1.067%;text-indent:-4.802%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Indicates beneficial ownership of less than 1% of the total outstanding ordinary shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of 9,710,428 ADSs held by RA Capital Healthcare Fund, L.P. (the &#8220;RA Fund&#8221;) as reported by Amendment No. 15 to Schedule 13G filed with the SEC on November 14, 2024 by RA Capital Management, L.P. (&#8220;RA Capital&#8221;). RA Capital Healthcare Fund GP, LLC is the general partner of the RA Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the controlling persons. RA Capital serves as investment adviser for the RA Fund and may be deemed a beneficial owner of ADSs </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">150</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">held by the RA Fund. The RA Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the RA Fund&#8217;s portfolio. Because the RA Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days&#8217; notice, the RA Fund disclaims beneficial ownership of the securities it holds and therefore disclaims any obligation to report ownership of the reported securities. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners of the ADSs beneficially owned by RA Capital. The address of the RA Fund, the RA Capital, Dr. Kolchinsky and Mr. Shah is c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of 5,528,239 ADSs owned of record by clients of Westfield Capital Management Company, L.P. (&#8220;Westfield&#8221;) in its capacity as investment advisor, as reported by Amendment No. 3 to Schedule 13G filed on February 11, 2025, by Westfield. Westfield&#8217;s clients have the right to receive, or the power to direct the receipt of, dividends or proceeds from the sale of the shares. The address of Westfield is 1 Financial Center, 24th Floor, Boston, MA 02111. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of an aggregate of 5,114,369 ADSs beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its affiliates and other companies as reported on Amendment No. 10 to Schedule 13G filed on February 8, 2024, by FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. FMR LLC has its principal business office at 245 Summer Street, Boston, MA 02210.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of 4,988,888 ADSs held by Avoro Capital Advisors LLC (&#8220;Avoro&#8221;) as reported on Amendment No. 2 Schedule 13G filed on November 14, 2024, by Avoro and Behzad Aghazadeh (&#8220;Dr. Aghazadeh&#8221;). Dr. Aghazadeh is the portfolio manager and controlling person of Avoro. The address of Avoro is 110 Greene Street, Suite 800, New York, NY 10012. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of an aggregate of 4,411,111 ADSs beneficially owned, or that may be deemed to be beneficially owned, by Artisan Partners Limited Partnership (&#8220;APLP&#8221;), Artisan Investments GP LLC (&#8220;Artisan Investments&#8221;), Artisan Partners Holdings LP (&#8220;Artisan Holdings&#8221;) and Artisan Partners Asset Management Inc. (&#8220;APAM&#8221;) as reported by Amendment No. 5 to Schedule 13G filed on November 12, 2024. Artisan Holdings is the sole limited partner of APLP and the sole member of Artisan Investments; Artisan Investments is the general partner of APLP; APAM is the general partner of Artisan Holdings. APLP, Artisan Investments, Artisan Holdings and APAM have shared voting power over 3,771,469 shares and shared dispositive power over 4,411,111 shares. The address of APLP, Artisan Investments, Artisan Holdings, and APAM is 875 East Wisconsin Avenue, Suite 800, Milwaukee, WI 53202. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of an aggregate of 4,186,694 ADSs beneficially owned, or that may be deemed to be beneficially owned, by Janus Henderson Group plc (&#8220;Janus Henderson&#8221;) as reported on Amendment No. 4 to Schedule 13G filed on November 14, 2024. The address of Janus Henderson is 201 Bishopsgate, EC2M 3AE, United Kingdom. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 904,651 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Mr. Mikkelsen and (ii) 438,250 ordinary shares and ADSs beneficially owned by Mr. Mikkelsen, of which 68,470 ordinary shares and ADSs are owned through an entity controlled by Mr. Mikkelsen and 113,548 ordinary shares and ADSs have been pledged as security to lending financial institutions. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 145,905 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Mr. Jensen and (ii) 5,763 ADSs held by Mr. Jensen.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of 139,342 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Mr. Jensen. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 36,381 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Mr. Bodenhoff and (ii) 193 ADSs held by Mr. Bodenhoff. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(11)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 77,585 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Dr. Singel and (ii) 2,729 ADSs held by Dr. Singel. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(12)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 189,967 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Mr. Smith and (ii) 4,017 ADSs held by Mr. Smith</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">151</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(13)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 199,342 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Ms. S&#248;nderbjerg and (ii) 5,763 ADSs held by Ms. S&#248;nderbjerg. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(14)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 140,280 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Dr. Sprog&#248;e, (ii) 6,763 ADSs held by Dr. Sprog&#248;e, and (iii) 30 ADSs held by family members of Dr. Sprog&#248;e.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(15)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 13,732 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Dr. Shu and (ii) 1,917 ADSs held by Dr. Shu. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(16)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 20,056 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Dr. Cha and (ii) 1,087 ADSs held by Dr. Cha</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(17)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 42,619 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Ms. Bright and (ii) 1,087 ADSs held by Ms. Bright. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(18)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 7,273 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Mr. Fairey and (ii) 164 ADSs held by Mr. Fairey. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(19)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 54,514 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Mr. Holtug and (ii) 1,593 ADSs held by Mr. Holtug. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(20)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of (i) 7,273 ordinary shares that may be subscribed pursuant to the exercise of warrants or that may vest pursuant to RSUs within 60 days of December 31, 2024 by Ms. Imani and (ii) 364 ADSs held by Ms. Imani.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Record Holders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, assuming that all of our ordinary shares represented by ADSs are held by residents of the United States, 99.9% of our outstanding ordinary shares were held in the United States by two holders of record and 0.1% of our outstanding ordinary shares were held outside of the United States. At such date, there were outstanding 60,507,426 ADSs, each representing one of our ordinary shares, and in the aggregate representing 99.79% of our outstanding ordinary shares. At such date, there were three holders of record registered with the Bank of New York Mellon, depositary of the ADSs. The actual number of holders is greater than these numbers of record holders and includes beneficial owners whose ADSs are held in street name by brokers and other nominees. This number of holders of record also does not include holders whose shares may be held in trust by other entities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a description of related party transactions we have entered into since January 1, 2024 with any of our board members, our senior management, the owners of more than five percent of our share capital, and any other related parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreements and Grants of Warrants and RSUs/PSUs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into employment agreements with, and granted RSUs and PSUs to, certain members of our senior management. Further, we have issued RSUs to our members of the board of directors. In addition, we are paying fees for board tenure and board committee tenure to the independent members of our board of directors. See &#8220;Item 6 B. Directors, Senior Management and Employees&#8212;Compensation&#8221; for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into indemnification agreements with our board members and members of our senior management. See &#8220;Item 6 B. Directors, Senior Management and Employees&#8212;Compensation&#8212;Insurance and Indemnification&#8221; for a description of these indemnification agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have provided research and development services to VISEN Pharmaceuticals (&#8220;VISEN&#8221;) under our Rights Agreements which will be reimbursed by VISEN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">152</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, under our Rights Agreements, clinical supply agreements, purchase agreement and commercial supply agreement, we have provided and agreed to provide product supply to VISEN for use in Greater China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For quantitative details regarding transactions and outstanding balances with associates, including VISEN, please refer to Note 12, &#8220;Investments in Associates.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eyconis</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 29, 2024, we announced the formation and launch with Frazier Life Sciences of Eyconis, a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with a $150 million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Albert Cha, M.D., Ph.D. the chairman of our board of directors, is a Managing Partner with Frazier Life Sciences.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, we are eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any. Eyconis is based in Redwood City, California and certain employees of Ascendis joined the newly formed company in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the formation of Eyconis, we have provided various administrative and support services under our Transitional Services Agreement. Further, under our Inventory Transfer Agreement and Material Transfer Agreement, we have sold laboratory and office inventory, materials and assigned certain contract manufacturers contracts to Eyconis. In addition, under our Sublease Agreement, we have subleased R&amp;D and laboratory facilities to Eyconis, initially until December 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For quantitative details regarding transactions and outstanding balances with associates, including Eyconis, please refer to Note 12, &#8220;Investments in Associates.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C. Interests of Experts and Counsel</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8 Financial Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements and Other Financial Information </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See the financial statements beginning on page F-1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">153</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not at present plan to pay cash dividends on our ordinary shares. Under Danish law, the distribution of ordinary and extraordinary dividends requires the approval of a company&#8217;s shareholders at a company&#8217;s general meeting. Under the Danish Companies Act the general meeting may authorize the board of directors to resolve to distribute extraordinary dividends after presentation of a company&#8217;s first financial statements. The authorization may be subject to financial and time restrictions. The shareholders may not distribute dividends in excess of the recommendation from the board of directors and may only pay out dividends from our distributable reserves, which are defined as results from operations carried forward and reserves that are not bound by law after deduction of loss carried forward. The decision to pay out extraordinary dividends shall be accompanied by a balance sheet, and the board of directors determine whether it will be sufficient to use the balance sheet from the annual report or if an interim balance sheet for the period from the annual report period until the extraordinary dividend payment shall be prepared. If extraordinary dividends are paid out later than six months following the financial year for the latest annual report, an interim balance sheet showing that there are sufficient funds shall always be prepared. If a resolution to distribute extraordinary dividends is passed more than six months after the balance sheet date as set out in the company&#8217;s latest approved annual report an interim balance sheet showing that sufficient funds are available for distribution must always be prepared.</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Changes </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 22, &#8220;Subsequent Events&#8221; to the audited consolidated financial statements included elsewhere in this annual report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_the_offer_and_listing"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9 The Offer and Listing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Offer and Listing Details </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ADS have been listed on The Nasdaq Global Select Market under the symbol &#8220;ASND&#8221; since January 28, 2015. Prior to that date, there was no public trading market for ADSs or our ordinary shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan of Distribution </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Markets </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ADS have been listed on The Nasdaq Global Select Market under the symbol &#8220;ASND&#8221; since January 28, 2015.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling Shareholders </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">E.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dilution</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">F.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses of the Issue </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">154</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_additional_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10 Additional Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Capital </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Memorandum and Articles of Association </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorizations to Our Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our board of directors is authorized to increase the share capital as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to increase our share capital by up to 9,000,000 shares with pre-emptive subscription rights for existing shareholders. Capital increases according to this authorization shall be carried out by our board of directors by way of cash contributions. This authorization is valid until May 29, 2029. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to increase our share capital by up to 3,825,000 without pre-emptive subscription rights for existing shareholders. Capital increases according to this authorization can be carried out by our board of directors by way of contributions in kind, conversion of debt and/or cash contributions, and must be carried out at market price as determined in accordance with Danish law. This authorization is valid until May 27, 2026. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to issue 111,992 warrants and to increase our share capital by up to 111,912 shares without pre-emptive subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and conditions thereof. This authorization is valid until May 28, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to obtain loans against issuance of convertible bonds which confer the right to subscribe for shares in the Company. The Company&#8217;s existing shareholders shall not have pre-emption rights to such shares. Our board of directors is authorized to increase the share capital by up to nominal DKK 9,000,000 by conversion of the convertible bonds. The convertible bonds shall be offered at a subscription price and a conversion price that correspond in aggregate to at least the market price of the shares at the time of the decision of our board of directors to issue the convertible bonds as determined in accordance with Danish law. The loans shall be paid in cash and our board of directors shall determine the terms and conditions for the convertible bonds. This authorization is valid until May 29, 2027.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to issue 948,124 warrants to members of the executive management and employees, advisors and consultants of the Company or our subsidiaries and to increase our share capital by up to 948,124 shares, without pre-emptive subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and conditions thereof. The exercise price for the warrants shall be determined by the board of directors in consultation with the Company&#8217;s advisors and shall at least be equal to the market price of the shares at the time of issuance as determined in accordance with Danish law. This authorization is valid until May 29, 2027. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to issue 1,000,000 warrants to members of the executive management and employees, advisors and consultants of the Company or our subsidiaries and to increase our share capital by up to 1,000,000 shares, without pre-emptive subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and conditions thereof. The exercise price for the warrants shall be determined by the board of directors in consultation with the Company&#8217;s advisors and shall at least be equal to the market price of the shares at the time of issuance as determined in accordance with Danish law. This authorization is valid until May 29, 2029.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our board of directors exercises its authorizations in full, and all warrants and convertible debt instruments are exercised fully (not including already issued warrants and already issued convertible debt instruments), then our share capital will amount to 84,574,603 shares consisting of 84,574,603 shares with a nominal value of DKK 1 each.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">155</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ADSs are listed on the Nasdaq Global Select Market under the symbol &#8220;ASND.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Owners&#8217; Register</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to maintain an owners&#8217; register (in Danish: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ejerbog</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The owners&#8217; register is maintained by Computershare A/S (Company Registration (CVR) no. 27088899), our Danish share registrar. It is mandatory that the owners&#8217; register is maintained within the European Union and that it is available to public authorities. Pursuant to the Danish Companies Act, public and private limited liability companies are required to register with the Danish Business Authority information regarding shareholders who own at least 5% of the share capital or the voting rights. Pursuant to this provision, we file registrations with the Public Owners&#8217; Register of the Danish Business Authority. Shareholders that exceed the ownership threshold must notify us and we will subsequently file the information with the Danish Business Authority. Reporting is further required when thresholds of 5%, 10%, 15%, 20%, 25%, 50%, 90% or 100%, or 1/3 or 2/3 are reached or no longer reached.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Articles of Association and Danish Corporate Law</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to our articles of association, the following should be emphasized:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Objects Clause</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate object, as set out in article 3 of our articles of association, is to develop ideas and preparations for the combating of disease medically, to manufacture and sell such preparations or ideas, to own shares of companies with the same objects and to perform activities in natural connection with these objects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Provisions Regarding the Board of Directors and the Executive Board</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our articles of association, our board of directors shall be elected by our shareholders at the general meeting and shall be composed of not less than three and no more than 10 members. The members of the board of directors are elected for a term expiring at the first coming annual general meeting following their election. Board members must retire from the board of directors at the annual general meeting following their 75th birthday. Board members are not required to own any shares of our share capital. The board of directors shall appoint and employ an executive board consisting of one to five members to attend to our day-to-day management, and the board of directors shall determine the terms and conditions of the employment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting Rights</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each shareholder is entitled to one vote for each share owned at the time of any general meeting. As compared with Danish citizens, there are no limitations under the articles of association or under Danish law on the rights of foreigners or non-Danish citizens to hold or vote our shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividend Rights</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our shareholders may at general meetings authorize the distribution of ordinary and extraordinary dividends. Our shareholders may not distribute dividends in excess of the recommendation from our board of directors and may only pay out dividends from our distributable reserves, which are defined as results from operations carried forward and reserves that are not bound by law after deduction of loss carried forward.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our shareholders are eligible to receive any dividends declared and paid out. However, we have not to date declared or paid any dividends and we currently intend to retain all available financial resources and any earnings generated by our operations for use in the business and we do not anticipate paying any dividends in the foreseeable future. The payment of any dividends in the future will depend on a number of factors, including our future earnings, capital requirements, financial condition and future prospects, applicable restrictions on the payment of dividends under Danish law and other factors that our board of directors may consider relevant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;Item 10 E. Additional Information&#8212;Taxation&#8221; for a summary of certain tax consequences in respect of dividends or distributions to holders of our ordinary shares or the ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">156</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-emptive Subscription Rights</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Danish law, all shareholders have pre-emptive subscription rights in connection with capital increases that are carried out as cash contributions. An increase in share capital can be resolved by the shareholders at a general meeting or by the board of directors pursuant to an authorization given by the shareholders. In connection with an increase of a company&#8217;s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish pre-emptive rights of the shareholders. Under the Danish Companies Act, such resolution must be adopted by the affirmative vote of shareholders holding at least a two-thirds majority of the votes cast and the share capital represented at the general meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors may resolve to increase our share capital without pre-emptive subscription rights for existing shareholders pursuant to the authorizations set forth above under the caption &#8220;Authorizations to our board of directors.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless future issuances of new shares and/or pre-emptive rights are registered under the Securities Act or with any authority outside Denmark, U.S. shareholders and shareholders in jurisdictions outside Denmark may be unable to exercise their pre-emptive subscription rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rights on Liquidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon a liquidation or winding-up of our company, shareholders will be entitled to participate, in proportion to their respective shareholdings, in any surplus assets remaining after payment of our creditors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Limitations on Holding of Shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no limitations on the right to hold shares under the articles of association or Danish law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liability to Capital Calls by Us</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our articles of association as well as the Danish Companies Act, our shareholders are not obligated to pay further amounts to us. All our shares are fully paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sinking Fund Provisions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no sinking fund provisions or similar obligations relating to our ordinary shares.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 55 of the Danish Companies Act, a shareholder is required to notify us when such shareholder&#8217;s stake represents 5% or more of the voting rights in our company or the nominal value accounts for 5% or more of the share capital, and when a change of a holding already notified entails that the limits of 5%, 10%, 15%, 20%, 25%, 50%, 90% or 100%, or 1/3 or 2/3 are reached or no longer reached. The notification shall be given within two weeks following the date when the limits are reached or are no longer reached.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The notification must include information on the date of acquisition or disposal of the shares, the number and, if applicable, the share class, the full name, address and civil registration (&#8220;CPR&#8221;) number of the shareholder or the name, central business register (&#8220;CVR&#8221;) number and registered office of the enterprise. If the shareholder has no CPR number or CVR number, such notice must be accompanied by other documentation securing unambiguous identification of the shareholder. The notice must also include information on the denomination or nominal value of the shares and the voting rights attaching to the shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to section 58a, we are obligated to collect and store for a period of at least five years certain information regarding the beneficial owners of shares in the company. A beneficial owner is a physical person who ultimately holds or controls, directly or indirectly, a sufficient part of the ownership interests or voting rights or exercises control by other means, except for owners of companies whose ownership interests are traded on a regulated market or a similar market which is subject to a duty of disclosure in accordance with EU law or similar international standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">157</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The legal status of the notification obligations is not fully clarified in relation to ADS holders and an ADS holder may be subject to such obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Meetings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general meeting of shareholders is the highest authority in all matters, subject to the limitations provided by Danish law and the articles of association. The annual general meeting shall be held in the Greater Copenhagen area not later than the end of May in each year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the annual general meeting, the audited annual report is submitted for approval, together with the proposed appropriation of profit/treatment of loss, the election of the board of directors and election of our auditors. In addition, the board of directors reports on our activities during the past year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General meetings are convened by the board of directors with a minimum of two weeks&#8217; notice and a maximum of four weeks&#8217; notice. A convening notice will be forwarded to shareholders recorded in our owners&#8217; register, who have requested such notification and by publication in the Danish Business Authority&#8217;s computerized information system and on the company&#8217;s website.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the latest, two weeks before a general meeting (inclusive of the day of the general meeting), we shall make the following information and documents available on our webpage:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the convening notice, </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the documents that shall be presented at the general meeting, which will, in the case of the annual general meeting include the annual report, and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the agenda and the complete proposals. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders are entitled to attend general meetings, either in person or by proxy, and they or their proxy may be accompanied by one advisor. A shareholder&#8217;s right to attend general meetings and to vote at general meetings is determined on the basis of the shares that the shareholder holds on the registration date. The registration date shall be one week before the general meeting is held. The shares which the individual shareholder holds are calculated on the registration date on the basis of the registration of ownership in the owners&#8217; register as well as notifications concerning ownership which the company has received with a view to update the ownership in the owners&#8217; register. In addition, any shareholder who is entitled to attend a general meeting and who wishes to attend must have requested an admission card from us no later than three days in advance of the general meeting. Any shareholder is entitled to submit proposals to be discussed at the general meetings. However, proposals by the shareholders to be considered at the annual general meeting must be submitted in writing to the board of directors not later than six weeks before the annual general meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Extraordinary general meetings must be held upon resolution of an annual general meeting to hold such a meeting or upon request of the board of directors, our auditors or shareholders representing at least 1/20 of the registered share capital or such lower percentage as our articles of association may provide. Our articles of association do not state such lower percentage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of ADSs are not entitled to directly receive notices or other materials or to attend or vote at general meetings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Resolutions in General Meetings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resolutions made by the general meeting generally may be adopted by a simple majority of the votes cast, subject only to the mandatory provisions of the Danish Companies Act and our articles of association. Resolutions concerning all amendments to the articles of association must be passed by two-thirds of the votes cast as well as two-thirds of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder&#8217;s ownership or voting rights, are subject to approval by a nine-tenth majority of the votes cast and the share capital represented at the general meeting. Decisions to impose or increase any obligations of the shareholders towards the company require unanimity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">158</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Quorum Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Squeeze Out</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to Section 70 of the Danish Companies Act, shares in a company may be redeemed by a shareholder holding more than nine-tenths of the shares and the corresponding voting rights in the company. Furthermore, according to Section 73 of the Danish Companies Act, a minority shareholder may require a majority shareholder holding more than nine-tenths of the shares and the corresponding voting rights to redeem the minority shareholder&#8217;s shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Danish Rules Intended to Prevent Market Abuse</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of July 3, 2016, EU Regulation No 596/2014 on market abuse entered into force and Chapter 10 of the Danish Securities Trading Act was repealed. Pursuant to said Chapter 10, we had adopted an internal code on inside information in respect of the holding of and carrying out of transactions by our board of directors and executive officers and employees in the shares or ADSs or in financial instruments the value of which is determined by the value of the ordinary shares or ADSs, and we had drawn up a list of those persons working for us who could have access to inside information on a regular or incidental basis and had informed such persons of the rules on insider trading and market manipulation, including the sanctions which could be imposed in the event of a violation of those rules. However, said EU Regulation No 596/2014 on market abuse imposes no such requirements on us and we have abandoned our previous practice.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation on Liability</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Danish law, members of the board of directors or senior management may be held liable for damages in the event that loss is caused due to their negligence. They may be held jointly and severally liable for damages to the company, the shareholders and to third parties for acting in violation of the articles of association and Danish law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general meeting is allowed to discharge our board members and members of our senior management from liability for any particular financial year based on a resolution relating to the financial statements. This discharge means that the general meeting will discharge such board members and members of our senior management from liability to us; however, the general meeting cannot discharge any claims by individual shareholders or other third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have entered into agreements with our board members and members of our senior management, pursuant to which, subject to limited exceptions, we have agreed to indemnify such board members and members of senior management from civil liability, including (i) any damages or fines payable by them as a result of an act or failure to act in the exercise of their duties currently or previously performed by them; (ii) any reasonable costs of conducting a defense against a claim; and (iii) any reasonable costs of appearing in other legal proceedings in which such individuals are involved as current or former board members or members of senior management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a risk that such agreement will be deemed void under Danish law, either because the agreement is deemed contrary to the rules on discharge of liability in the Danish Companies Act, as set forth above, because the agreement is deemed contrary to sections 19 and 23 of the Danish Act on Damages, which contain mandatory provisions on recourse claims between an employee (including members of our senior management) and us, or because the agreement is deemed contrary to the general provisions of the Danish Contracts Act.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to such indemnification, we provide our board members and senior management with directors&#8217; and officers&#8217; liability insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">159</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparison of Danish Corporate Law and Our Articles of Association and Delaware Corporate Law</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following comparison between Danish corporate law, which applies to us, and Delaware corporate law, the law under which many publicly traded companies in the United States are incorporated, discusses additional matters not otherwise described in this annual report. This summary is subject to Danish law, including the Danish Companies Act, and Delaware corporate law, including the Delaware General Corporation Law. Further, please note that ADS holders will not be treated as our shareholders and will not have any shareholder rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duties of Board Members</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Public limited liability companies in Denmark are usually subject to a two-tier governance structure with the board of directors having the ultimate responsibility for the overall supervision and strategic management of the company in question and with an executive board/management being responsible for the day-to-day operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each board member and member of the executive board/management is under a fiduciary duty to act in the interest of the company, but shall also take into account the interests of the creditors and the shareholders. Under Danish law, the members of the board of directors and executive management of a limited liability company are liable for losses caused by negligence whether shareholders, creditors or the company itself suffers such losses. They may also be liable for wrongful information given in the annual financial statements or any other public announcements from the company. An investor suing for damages is required to prove its claim with regard to negligence, loss, and causation. Danish courts, when assessing negligence, have been reluctant to impose liability unless the directors and officers neglected clear and specific duties. This is also the case when it comes to liability with regard to public offerings or liability with regard to any other public information issued by the company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise informed business judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Terms of the Members of Our Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, the members of the board of directors of a limited liability company are generally appointed for an individual term of one year. There is no limit on the number of consecutive terms the board members may serve. Pursuant to our articles of association, our board members are appointed by the general meeting of shareholders for a term of one year. Election of board members is, according to our articles of association, an item that shall be included on the agenda for the annual general meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the general meeting, shareholders are entitled at all times to dismiss a board member by a simple majority vote.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It follows from Section 140 of the Danish Companies Act that in limited liability companies that have employed an average of at least 35 employees in the preceding three years, the employees are entitled to elect a minimum of two representatives and alternate members to the company&#8217;s board of directors up to one half the number of the shareholder elected directors. If the number of representatives to be elected by the employees is not a whole number, such number must be rounded up.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our company currently employs more than an average of 35 employees and has done so since 2016. Consequently, from 2018, our employees have been entitled to demand representation on our board of directors. The question will, upon request from the employees, be put to a popular vote among the employees. If more than half of the employees (regardless of whether they participate in the vote) vote in favor of having representation, we must organize an election process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">160</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, Section 141 of the Danish Companies Act allows for group representation on the board of directors of our company, i.e., that employees of our Danish subsidiaries may demand representation on our board. However, our Danish subsidiaries do not currently have employees. The employees of Ascendis Pharma, Inc., Ascendis Pharma Endocrinology, Inc., Ascendis Pharma GmbH, and Ascendis Pharma Endocrinology GmbH may only demand representation on our board of directors provided that our general meeting adopts a resolution to that effect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Delaware General Corporation Law generally provides for a one-year term for directors, but permits directorships to be divided into up to three classes, of relatively equal size, with up to three-year terms, with the years for each class expiring in different years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted by the stockholders. A director elected to serve a term on a &#8220;classified&#8221; board may not be removed by stockholders without cause. There is no limit in the number of terms a director may serve.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Member Vacancies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, in the event of a vacancy, new board members are elected by the shareholders in a general meeting. Thus, a general meeting will have to be convened to fill a vacancy on the board of directors. However, the board of directors may choose to wait to fill vacancies until the next annual general meeting of the company, provided that the remaining board members can still constitute a quorum. It is only a statutory requirement to convene a general meeting to fill vacancies if the number of remaining members on the board is less than three.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) unless (1) otherwise provided in the certificate of incorporation or bylaws of the corporation or (2) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conflict-of-Interest Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, board members may not take part in any matter or decision-making that involves a subject or transaction in relation to which the board member has a conflict of interest with us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested director of that corporation if:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The material facts as to the director&#8217;s relationship or interest are disclosed and a majority of disinterested directors&#8217; consent; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The material facts are disclosed as to the director&#8217;s relationship or interest and a majority of shares entitled to vote thereon consent; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of the board of directors or the stockholders. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Proxy Voting by Board Members</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event that a board member in a Danish limited liability company is unable to participate in a board meeting, the elected alternate, if any, shall be given access to participate in the board meeting. Unless the board of directors has decided otherwise, or as otherwise is set out in the articles of association, the board member in question may in special cases grant a power of attorney to another board member, provided that this is considered safe considering the agenda in question.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">161</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shareholder Rights</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notice of Meeting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. According to the Danish Companies Act, general meetings in limited liability companies shall be convened by the board of directors with a minimum of two weeks&#8217; notice and a maximum of four weeks&#8217; notice as set forth in the articles of association. A convening notice shall be forwarded to shareholders recorded in the company&#8217;s owners&#8217; register, who have requested such notification. There are specific requirements as to the information and documentation required to be disclosed in connection with the convening notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting Rights</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each ordinary share confers the right to cast one vote at the general meeting of shareholders, unless the articles of association provide otherwise. Each holder of ordinary shares may cast as many votes as it holds shares. Shares that are held by the company or its subsidiaries do not confer the right to vote.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, each stockholder is entitled to one vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation, or at elections held under specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event can a quorum consist of less than one third of the shares entitled to vote at a meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders as of the record date for the meeting are entitled to vote at the meeting, and the board of directors may fix a record date that is no more than 60 nor less than ten days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given, or if notice is waived then the record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the stockholders of record entitled to notice or to vote at a meeting of stockholders shall apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shareholder Proposals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. According to the Danish Companies Act, extraordinary general meetings of shareholders will be held whenever the board of directors or the appointed auditor requires. In addition, one or more shareholders representing at least 1/20th of the registered share capital of the company may, in writing, require that a general meeting be convened. If such a demand is forwarded, the board of directors shall convene the general meeting within two weeks thereafter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All shareholders have the right to present proposals for adoption at the annual general meeting, provided that the proposals are made in writing and forwarded at the latest six weeks prior thereto. In the event that the proposal is received at a later date, the board of directors will decide whether the proposal has been forwarded in due time to be included on the agenda.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Delaware law does not specifically grant stockholders the right to bring business before an annual or special meeting of stockholders. However, if a Delaware corporation is subject to the SEC&#8217;s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation&#8217;s securities entitled to vote, may propose a matter for a vote at an annual or special meeting in accordance with those rules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">162</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Action by Written Consent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, it is permissible for shareholders to take action and pass resolutions by written consent in the event of unanimity; however, this will normally not be the case in listed companies and for a listed company, this method of adopting resolutions is generally not feasible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Although permitted by Delaware law, publicly listed companies do not typically permit stockholders of a corporation to take action by written consent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Appraisal Rights</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The concept of appraisal rights does not exist under Danish law, except in connection with statutory redemptions rights according to the Danish Companies Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to Section 73 of the Danish Companies Act, a minority shareholder may require a majority shareholder that holds more than 90% of the company&#8217;s registered share capital and votes to redeem his or her shares. Similarly, a majority shareholder holding more than 90% of the company&#8217;s share capital and votes may, according to Section 70 of the same act, squeeze out the minority shareholders. In the event that the parties cannot agree to the redemption squeeze out price, this shall be determined by an independent evaluator appointed by the court. Additionally, there are specific regulations in Sections 249, 267, 285 and 305 of the Danish Companies Act that require compensation in the event of national or cross-border mergers and demergers. Moreover, shareholders who vote against a cross-border merger or demerger or cross-border conversion are, according to Sections 286, 306 and 318 m of the Danish Companies Act, entitled to have their shares redeemed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Delaware General Corporation Law provides for stockholder appraisal rights, or the right to demand payment in cash of the judicially determined fair value of the stockholder&#8217;s shares, in connection with certain mergers and consolidations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shareholder Suits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, only a company itself can bring a civil action against a third party; an individual shareholder does not have the right to bring an action on behalf of a company. An individual shareholder may, in its own name, have an individual right to take action against such third party in the event that the cause for the liability of that third party also constitutes a negligent act directly against such individual shareholder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have been met. A person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a stockholder at the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Repurchase of Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Danish limited liability companies may not subscribe for newly issued shares in their own capital. Such company may, however, according to the Danish Companies Act Sections 196-201, acquire fully paid shares of its own capital, provided that the board of directors has been authorized thereto by the shareholders acting in a general meeting. Such authorization can only be given for a maximum period of five years and the authorization shall fix (i) the maximum value of the shares and (ii) the minimum and the highest amount that the company may pay for the shares. Shares may generally only be acquired using distributable reserves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">163</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover Provisions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, it is possible to implement limited protective anti-takeover measures. Such provisions may include, among other things, (i) different share classes with different voting rights, (ii) specific requirements to register the shares named in the company&#8217;s owners register and (iii) notification requirements concerning participation in general meetings. We have currently not adopted any such provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 203 of the Delaware General Corporation Law prohibits &#8220;business combinations,&#8221; including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that beneficially owns 15% or more of a corporation&#8217;s voting stock, within three years after the person becomes an interested stockholder, unless:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the transaction that will cause the person to become an interested stockholder is approved by the board of directors of the target prior to the transaction; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after the completion of the transaction in which the person becomes an interested stockholder, the interested stockholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after the person becomes an interested stockholder, the business combination is approved by the board of directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Delaware corporation may elect not to be governed by Section 203 by a provision contained in the original certificate of incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the corporation. Such an amendment is not effective until 12 months following its adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inspection of Books and Records</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. According to Section 150 of the Danish Companies Act, a shareholder may request an inspection of the company&#8217;s books regarding specific issues concerning the management of the company or specific annual reports. If approved by shareholders with simple majority, one or more investigators are elected. If the proposal is not approved by simple majority but 25% of the share capital votes in favor, then the shareholder can request the court to appoint an investigator.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, any stockholder may inspect certain of the corporation&#8217;s books and records, for any proper purpose, during the corporation&#8217;s usual hours of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">164</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-emptive Rights</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, all shareholders have pre-emptive subscription rights in connection with capital increases that are carried out as cash contributions. In connection with an increase of a company&#8217;s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish pre-emptive rights of the shareholders. Under the Danish Companies Act, such resolution must be adopted by the affirmative vote of shareholders holding at least a two-thirds majority of the votes cast and the share capital represented at the general meeting. The board of directors may resolve to increase our share capital without pre-emptive subscription rights for existing shareholders pursuant to the authorizations described above under the caption &#8220;Authorizations to our board of directors.&#8221; Unless future issuances of new shares are registered under the Securities Act or with any authority outside Denmark, U.S. shareholders and shareholders in jurisdictions outside Denmark may be unable to exercise their pre-emptive subscription rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, stockholders have no pre-emptive rights to subscribe for additional issues of stock or to any security convertible into such stock unless, and to the extent that, such rights are expressly provided for in the certificate of incorporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, the distribution of ordinary and extraordinary dividends requires the approval of a company&#8217;s shareholders at a company&#8217;s general meeting. Under the Danish Companies Act the general meeting may authorise the board of directors to resolve to distribute extraordinary dividends after presentation of a company&#8217;s first financial statements. The authorisation may be subject to financial and time restrictions. The shareholders may not distribute dividends in excess of the recommendation from the board of directors and may only pay out dividends from our distributable reserves, which are defined as results from operations carried forward and reserves that are not bound by law after deduction of loss carried forward. The decision to pay out extraordinary dividends shall be accompanied by a balance sheet, and the board of directors determine whether it will be sufficient to use the balance sheet from the annual report or if an interim balance sheet for the period from the annual report period until the extraordinary dividend payment shall be prepared.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a resolution to distribute extraordinary dividends is passed more than six months after the balance sheet date as set out in the company&#8217;s latest approved annual report an interim balance sheet showing that sufficient funds are available for distribution must always be prepared.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, a Delaware corporation may pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year (provided that the amount of the capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In determining the amount of surplus of a Delaware corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard to their historical book value. Dividends may be paid in the form of shares, property or cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shareholder Vote on Certain Reorganizations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, all amendments to the articles of association shall be approved by the general meeting of shareholders with a minimum of two-thirds of the votes cast and two-thirds of the represented share capital. The same applies to solvent liquidations, mergers with the company as the discontinuing entity, mergers with the company as the continuing entity if shares are issued in connection therewith, demergers with the company as the transferor company and demergers with the company as the existing transferee if amendment of the articles of association for any purpose other than the adoption of the transferor company&#8217;s name or secondary name as the transferee company&#8217;s secondary name is required to be made. Under Danish law, it is debatable whether the shareholders must approve a decision to sell all or virtually all of the company&#8217;s business/assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled to vote thereon generally is necessary to approve a merger or consolidation or the sale of all or substantially all of the assets of a corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">165</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Delaware General Corporation Law permits a corporation to include in its certificate of incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, under the Delaware General Corporation Law, no vote of the stockholders of a surviving corporation to a merger is needed, unless required by the certificate of incorporation, if (1) the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (2) the shares of stock of the surviving corporation are not changed in the merger and (3) the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation&#8217;s common stock outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such corporation, but the stockholders will be entitled to appraisal rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendments to Governing Documents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All resolutions made by the general meeting may be adopted by a simple majority of the votes, subject only to the mandatory provisions of the Danish Companies Act and the articles of association. Resolutions concerning all amendments to the articles of association must be passed by two-thirds of the votes cast as well as two-thirds of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder&#8217;s ownership or voting rights, are subject to approval by a nine-tenth majority of the votes cast and the share capital represented at the general meeting. Decisions to impose any or increase any obligations of the shareholders towards the company require unanimity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, a corporation&#8217;s certificate of incorporation may be amended only if adopted and declared advisable by the board of directors and approved by a majority of the outstanding shares entitled to vote (subject to limited exceptions), and the bylaws may be amended with the approval of a majority of the outstanding shares entitled to vote and may, if so provided in the certificate of incorporation, also be amended by the board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Contracts </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise disclosed in this annual report (including the Exhibits), we are not currently party to any material contract, other than contracts entered into in the ordinary course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Controls </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Danish Act on Foreign Investment Screening sets out rules on screening of certain foreign direct investments etc. in Denmark (&#8220;Danish FDI Rules&#8221;). Pursuant to the Danish FDI Rules, a screening mechanism applies to foreign direct investments in certain sensitive sectors where a foreign investor obtains at least 10% ownership or voting rights or equivalent control by other means. The purpose of the Danish FDI Rules is to prevent foreign direct investments and special economic agreements from posing a threat to national security or public order in Denmark, through screening and possible interventions against such investments and agreements. Among the sensitive sectors defined in the Danish FDI rules are companies and entities that are critical infrastructure in Denmark in relation to the production, registration, distribution, and monitoring of prescription drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a contemplated foreign direct investment in Ascendis Pharma A/S is considered to fall within the scope of the mandatory screening mechanism, the foreign investor is required to apply for prior authorization with the Danish Business Authority. FDI filings, notifications, or approvals may under certain circumstances also be required in non-Danish jurisdictions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a foreign investor fails to comply with the Danish FDI Rules, the Danish Business Authority may impose restrictions, including ordering to reverse the investment to suspend the foreign investor&#8217;s voting rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">International trade and financial sanctions are continually evolving. If applicable, such international trade and financial sanctions may under certain circumstances prevent the possibility of export and import of capital, and affect the remittance of dividends, interest and other payments to non-resident holders of shares or ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">166</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, international trade and financial sanctions may restrict the right of non-resident or foreign owners to acquire, transfer, hold or vote the shares and ADSs. Failure to comply with international trade and financial sanctions can lead to criminal and civil liability.</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">E.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxation </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Danish Tax Considerations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion describes the material Danish tax consequences under present law of an investment in the ADSs (representing our ordinary shares). The summary is for general information only and does not purport to constitute exhaustive tax or legal advice. It is specifically noted that the summary does not address all possible tax consequences relating to an investment in the ADSs. The summary is based solely on the tax laws of Denmark in effect on the date of this annual report. Danish tax laws may be subject to change, possibly with retroactive effect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The summary does not cover investors to whom special tax rules apply, and, therefore, may not be relevant, for example, to investors subject to the Danish Tax on Pension Yields Act (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, pension savings), professional investors, certain institutional investors, insurance companies, pension companies, banks, stockbrokers and investors with tax liability on return on pension investments. The summary does not cover taxation of individuals and companies who carry on a business of purchasing and selling shares. The summary only sets out the tax position of the direct owners of the ADSs and further assumes that the direct investors are the beneficial owners of the ADSs and any dividends thereon. Sales are assumed to be sales to a third party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential investors in the ADSs are advised to consult their tax advisors regarding the applicable tax consequences of acquiring, holding and disposing of the ADSs based on their particular circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors who may be affected by the tax laws of other jurisdictions should consult their tax advisors with respect to the tax consequences applicable to their particular circumstances as such consequences may differ significantly from those described herein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Characterization of the ADSs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Danish tax law, ADSs may be qualified as shares or financial instruments depending on the specific terms of the ADS.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We obtained a tax ruling on June 21, 2022, from the Danish Tax Council which confirmed that ADSs issued by us are shares for Danish tax purposes. Based on an analysis of the terms of the Deposit Agreement between 1) the holders of ADSs, 2) Ascendis Pharma A/S and 3) Bank of New York Mellon, the Danish Tax Council found that the voting and economic rights attached to the underlying shares had effectively been transferred to the ADS holders and therefore, the ADSs qualified as shares for Danish tax purposes. The ruling is binding on the Danish tax authorities for 5 years as long as the facts remain as described in the ruling for the duration of the 5-year period and in the absence of a change of law. The ruling further confirmed that the ADSs are to be considered listed shares, as the ADSs are listed on Nasdaq. Accordingly, the remainder of this Danish tax discussion assumes that the ADSs will be treated as listed shares for Danish tax purposes.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taxation of Danish Tax Resident Holders of the ADSs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sale of the ADSs (Individuals)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For individual investors in 2025, gains from the sale of shares are included in the computation of the annual share income subject to 27% tax on the first DKK 63,300 (for cohabiting spouses, a total of DKK 126,600) and at a rate of 42% on share income exceeding DKK 63,300 (for cohabiting spouses over DKK 126,600). Such amounts are subject to annual adjustment and include all share income (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all capital gains and dividends derived by the individual or cohabiting spouses, respectively). The realization principle applies; i.e. the gains or losses are included in the income in the year of disposal.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">167</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gains and losses on the sale of shares are calculated as the difference between the purchase price and the sales price. The purchase price is generally determined using the average method (in Danish &#8220;gennemsnitsmetoden&#8221;) as a proportionate part of the aggregate purchase price for all the shareholder&#8217;s shares in the company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the ADSs, for the purpose of this tax description, are considered listed shares for Danish tax purposes, losses may be offset against received dividends and capital gains on listed shares. Unused losses will automatically be offset against a cohabiting spouse&#8217;s dividends and capital gains on listed shares. Any unused losses can be carried forward. It is a requirement for offsetting of losses, that the ADS holder (or the ADS holder&#8217;s custodian bank) has declared the acquisition of the shares in the tax return for the year of acquisition. Such declaration must specify the identity of the ADS, the number of ADS acquired, the acquisition sum and the date of acquisition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sale of the ADSs (Companies)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of taxation of sales of shares made by corporate shareholders, a distinction is made between Subsidiary Shares, Group Shares, Tax-Exempt Portfolio Shares and Taxable Portfolio Shares (note that the ownership threshold described below is applied on the basis of the number of all shares issued by the company, and not on the basis of the number of the ADSs issued):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Subsidiary Shares&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are generally defined as shares owned by a shareholder holding at least 10% of the nominal share capital of the issuing company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8239;</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Group Shares&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are generally defined as shares in a company in which the shareholder of the company and the issuing company are subject to Danish joint taxation or fulfill the requirements for international joint taxation under Danish law (i.e., the company is controlled by the shareholder).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Tax-Exempt Portfolio Shares&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are defined as shares not admitted to trading on a regulated market owned by a shareholder holding less than 10% of the nominal share capital of the issuing company.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Taxable Portfolio Shares&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are defined as shares that do not qualify as Subsidiary Shares, Group Shares or Tax-Exempt Portfolio Shares.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gains or losses on disposal of Subsidiary Shares and Group Shares and Tax-Exempt Portfolio Shares are not included in the taxable income of the shareholder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special rules apply with respect to Subsidiary Shares and Group Shares to prevent exemption through certain holding company structures just as other anti-avoidance rules may apply. These rules will not be described in further detail.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital gains from the sale of Taxable Portfolio Shares are taxable at a rate of 22% irrespective of ownership period. Losses on such shares are generally deductible. Gains and losses on Taxable Portfolio Shares are generally taxable according to the mark-to-market principle (in Danish &#8220;lagerprincippet&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to the mark-to-market principle, each year&#8217;s taxable gain or loss on Taxable Portfolio Shares is calculated as the difference between the market value of the shares at the beginning and end of the tax year. Thus, taxation will take place on an accrual basis even if no shares have been disposed of and no gains or losses have been realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Taxable Portfolio Shares are sold or otherwise disposed of before the end of the income year, the taxable income of that income year equals the difference between the value of the Taxable Portfolio Shares at the beginning of the income year and the value of the Taxable Portfolio Shares at realization. If the Taxable Portfolio Shares are acquired and realized in the same income year, the taxable income equals the difference between the acquisition sum and the realization sum. If the Taxable Portfolio Shares are acquired in the income year and not realized in the same income year, the taxable income equals the difference between the acquisition sum and the value of the shares at the end of the income years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">168</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change of status from Subsidiary Shares/Group Shares/Tax-Exempt Portfolio Shares to Taxable Portfolio Shares (or vice versa) is for tax purposes deemed to be a disposal of the shares and a reacquisition of the shares at market value at the time of change of status.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends (Individuals)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends on listed shares are taxed as share income, as described above. All share income must be included when calculating whether the amounts described above are exceeded. Dividends paid to individuals are generally subject to 27% withholding tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends (Companies)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For corporate investors, dividends paid on Subsidiary Shares and Group Shares are tax-exempt irrespective of ownership period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends paid on Tax-Exempt Portfolio Shares are partly taxable as 70% of the dividends received are included in the taxable income, which is equivalent to an effective taxation of 15.4% (70% of 22%) irrespective of ownership period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends paid on Taxable Portfolio Shares are subject to the standard corporation tax rate of 22% irrespective of ownership period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The actual withholding tax rate is as a starting point 27%, while it can be reduced (0%, 15.4%, 22%) if certain requirements are met. A claim for repayment can be made within the calendar year in which the dividend distribution was approved or the excess tax will offset the corporation income tax for the year. The statute of limitations is three years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taxation of Shareholders Residing Outside Denmark</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of ADSs issued by Ascendis Pharma A/S are treated as holding listed ordinary shares in the company for Danish tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sale of the ADSs (Individuals and Companies)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of the ADSs not resident in Denmark are normally not subject to Danish taxation on any gains realized on the sale of ADSs, irrespective of the ownership period, subject to certain anti-avoidance rules seeking to prevent that taxable dividend payments are converted to tax exempt capital gains.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Danish share transfer tax or stamp duties are payable on transfer of ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an investor holds the ADSs in connection with a trade or business conducted from a permanent establishment in Denmark, gains on shares may be included in the taxable income of such activities pursuant to the rules applying to Danish tax residents as described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends (Individuals)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends are generally subject to 27% Danish withholding tax. Individuals residing in certain black-listed countries and holding 25% or more of the share capital in the company are subject to 44% withholding tax.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-residents of Denmark are not subject to additional Danish income tax with respect to dividends received on shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of ADSs are entitled to apply for a full or partial refund of Danish withholding tax on dividends withheld by the company, in the situations described below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the holders of the ADSs are considered beneficial owners of the dividends according to the applicable double tax treaty between Denmark and the tax residence country of the ADS holder, the withholding tax rate under such double tax treaty may apply to the extent the tax residency of the ADS holder can be documented.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">169</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For holders of ADSs (as beneficial owners of the dividends on the ordinary shares), if the withholding tax rate applied is higher than the applicable final tax rate (as reduced according to Danish law or an applicable double tax treaty) for the holder of ADSs, a request for a refund of Danish tax in excess hereof can be made in the following situations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduction According to a Tax Treaty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the ADS holder is a resident of a state with which Denmark has entered into a tax treaty, the holder may generally, through certain certification procedures, seek a refund from the Danish tax authorities of the tax withheld in excess of the applicable treaty rate, which is typically 15%. Denmark has entered into tax treaties with approximately 80 countries, including the United States, Switzerland and almost all members of the European Union. The tax treaty between Denmark and the United States generally provides for a 15% tax rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals residing in certain black-listed countries and holding 25% or more of the share capital in the company are not eligible for refund of dividend withholding taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduction According to Danish Tax Law</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the ADS holder holds less than 10% of the nominal share capital (in the form of ordinary shares in the company and not on the basis of the number of the ADSs issued) of the company and the ADS holder is tax resident in a state which has a tax treaty or an international agreement, convention or other administrative agreement on assistance in tax matters according to which the competent authority in the state of the ADS holder is obligated to exchange information with Denmark, dividends are subject to tax at a rate of 15%. If the ADS holder is tax resident outside the European Union, it is an additional requirement for eligibility for the 15% tax rate that the ADS holder together with related ADS holders holds less than 10% of the nominal share capital of the company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note that the reduced tax rate does not affect the withholding rate, which is why the holder must claim a refund as described above in order to benefit from the reduced rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where a non-resident of Denmark holds shares which can be attributed to a permanent establishment in Denmark, dividends are taxable pursuant to the rules applying to Danish tax residents described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals residing in certain black-listed countries and holding 25% or more of the share capital in the company are not eligible for refund of dividend withholding taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends (Companies)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends paid to companies are generally subject to 27% withholding tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies residing in certain black-listed countries and holding Subsidiary Shares or Group Shares are subject to 44% withholding tax, unless it can be proved that the beneficial owner of the dividend is a resident of the European Union or the EEA or a state with which Denmark has entered into a tax treaty. Furthermore, such companies are not eligible for refund of dividend withholding taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-residents of Denmark are not subject to additional Danish income tax with respect to dividends received on shares. Holders of ADSs are entitled to apply for a refund of Danish withholding tax on dividends paid by the company as set out below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the holder of the ADSs is considered the beneficial owner of the dividends according to the applicable double tax treaty between Denmark and the tax residence country of the ADS holder, the withholding tax rate under such double tax treaty may apply to the extent the tax residency of the ADS holder can be documented.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">170</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends from Subsidiary Shares are tax exempt provided that the taxation of the dividends is to be waived or reduced in accordance with the Parent-Subsidiary Directive (2011/96/EEC) or in accordance with a tax treaty with the jurisdiction in which the company investor is resident. If Denmark is to reduce taxation of dividends to a foreign company under a tax treaty, Denmark will not&#8212;as a matter of domestic law&#8212;exercise such right and will in general not impose any tax at all. Further, dividends from Group Shares&#8212;not also being Subsidiary Shares&#8212;are exempt from Danish tax provided the company investor is a resident of the European Union or the EEA and provided the taxation of dividends should have been waived or reduced in accordance with the Parent-Subsidiary Directive (2011/96/EEC) or in accordance with a tax treaty with the country in which the company investor is resident had the shares been Subsidiary Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends paid on both Tax-Exempt and Taxable Portfolio Shares are generally subject to tax at a rate of 22% irrespective of ownership period. While the actual withholding tax rate is as a starting point 27%, it can be reduced if certain requirements are met. If the withholding tax rate applied is higher than the applicable final tax rate for the ADS holder, a request for a refund of Danish tax in excess hereof can be made by the ADS holder in the following situations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduction According to a Tax Treaty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the ADS holder is a resident of a state with which Denmark has entered into a tax treaty, the holder may generally, through certain certification procedures, seek a refund from the Danish tax authorities of the tax withheld in excess of the applicable treaty rate, which is typically 15%. Denmark has entered into tax treaties with approximately 80 countries, including the United States and almost all members of the European Union. The tax treaty between Denmark and the United States generally provides for a 15% rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies residing in certain black-listed countries and holding Subsidiary Shares or Group Shares are not eligible for refund of dividend withholding taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduction According to Danish Tax Law</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the ADS holder holds less than 10% of the nominal share capital (in the form of ordinary shares in the company and not on the basis of the number of the ADSs issued) in the company and the ADS holder is resident in a jurisdiction which has a tax treaty or an international agreement, convention or other administrative agreement on assistance in tax according to which the competent authority in the state of the ADS holder is obligated to exchange information with Denmark, dividends are generally subject to a tax rate of 15%. If the ADS holder is tax resident outside the European Union, it is an additional requirement for eligibility for the 15% tax rate that the ADS holder together with related ADS holders holds less than 10% of the nominal share capital of the company. Note that the reduced tax rate does not affect the withholding rate, hence, in this situation the ADS holder must also in this situation claim a refund as described above in order to benefit from the reduced rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where a non-resident company of Denmark holds ADSs which can be attributed to a permanent establishment in Denmark, dividends are taxable pursuant to the rules applying to Danish tax residents described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies residing in certain black-listed countries and holding Subsidiary Shares or Group Shares are not eligible for refund of dividend withholding taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Transfer Tax and Stamp Duties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Danish share transfer tax or stamp duties are payable on transfer of the shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">171</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material U.S. Federal Income Tax Consequences to U.S. Holders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion describes the material U.S. federal income tax consequences to U.S. Holders (as defined below) under present law of an investment in the ADSs. The effects of any applicable state or local laws, or other U.S. federal tax laws such as estate and gift tax laws, any alternative minimum taxes, or the Medicare contribution tax on net investment income, are not discussed. This summary applies only to U.S. Holders that hold the ADSs as capital assets (generally, property held for investment) and who have the U.S. dollar as their functional currency for U.S. federal income tax purposes. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, U.S. Treasury regulations promulgated thereunder, or the Treasury Regulations, judicial decisions, published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, and the income tax treaty between the United States and Denmark, or the Treaty, all as in effect as of the date of this annual report. All of the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion does not address all U.S. federal income tax consequences relevant to a U.S. Holder&#8217;s particular circumstances or to U.S. Holders subject to particular rules, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. expatriates and certain former citizens or long-term residents of the United States;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">persons whose functional currency is not the U.S. dollar;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">persons holding the ADSs as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">banks, insurance companies, and other financial institutions;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">real estate investment trusts or regulated investment companies;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">brokers, dealers or traders in securities, commodities or currencies;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">partnerships, S corporations or other entities or arrangements treated as partnerships or pass-through entities for U.S. federal income tax purposes, and persons that hold ADSs through such entities or arrangements;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax-exempt organizations, &#8220;individual retirement accounts&#8221; or &#8220;Roth IRAs&#8221;; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">governmental organizations;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">persons who acquired the ADSs pursuant to the exercise of any employee share option or otherwise as compensation;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">persons that own or are deemed to own 10% or more of the company&#8217;s equity by vote or value;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">persons that hold their ADSs through a permanent establishment or fixed base outside the United States; and  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">persons deemed to sell the ADSs under the constructive sale provisions of the Code.  </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL INCOME TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE U.S. FEDERAL GIFT AND ESTATE AND U.S. STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF THE ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8239;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of the ADSs that, for U.S. federal income tax purposes, is or is treated as any of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an individual who is a citizen or resident of the United States;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a corporation, or other entity taxable as a corporation, created or organized under the laws of the United States, any state thereof or the District of Columbia;  </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">172</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a trust that (1) is subject to the supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the Code) or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes.  </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are a partner in a partnership (or other entity or arrangement taxable as a partnership for U.S. federal income tax purposes) that holds the ADSs, your tax treatment generally will depend on your status and the activities of the partnership. Partnerships holding the ADSs and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences applicable to them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The discussion below assumes that the representations contained in the deposit agreement are true and that the obligations in the deposit agreement and any related agreement will be complied with in accordance with their terms. Generally, a holder of an ADS should be treated for the U.S. federal income tax purposes as holding the ordinary shares represented by the ADS. Accordingly, no gain or loss will be recognized upon an exchange of ADSs for ordinary shares. The U.S. Treasury has expressed concerns that intermediaries in the chain of ownership between the holder of an ADS and the issuer of the security underlying the ADS may be taking actions that are inconsistent with the beneficial ownership of the underlying security. Accordingly, the creditability of foreign taxes, if any, as described below, could be affected by actions taken by intermediaries in the chain of ownership between the holders of ADSs and our company if as a result of such actions the holders of ADSs are not properly treated as beneficial owners of underlying ordinary shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taxation of Dividends and Other Distributions on the ADSs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the passive foreign investment company, or PFIC, rules discussed below, the gross amount of any distribution to you with respect to the ADSs will be included in your gross income as dividend income when actually or constructively received to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent the amount of the distribution exceeds our current and accumulated earnings and profits, it will be treated first as a return of your tax basis in the ADSs, and to the extent the amount of the distribution exceeds your tax basis, the excess will be taxed as capital gain. However, we do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect a distribution will generally be reported as ordinary dividend income for such purposes. Any dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are eligible for benefits under the Treaty, or if the ADSs are readily tradable on an established securities market in the United States, dividends a U.S. Holder receives from us generally will be &#8220;qualified dividend income.&#8221; If certain holding period and other requirements, including a requirement that we are not a PFIC in the year of the dividend or the immediately preceding year, are met, qualified dividend income of an individual or other non-corporate U.S. Holder generally will be subject to preferential tax rates. ADSs representing ordinary shares generally are considered for these purposes to be readily tradable on an established securities market in the United States if they are listed on The Nasdaq Global Select Market, as our ADSs currently are. You should consult your tax advisor regarding the availability of these preferential tax rates under your particular circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed above in &#8220;Taxation&#8212;Danish Tax Considerations,&#8221; payments of dividends by us may be subject to Danish withholding tax. The rate of withholding tax applicable to U.S. Holders that are eligible for benefits under the Treaty is reduced to a maximum of 15%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For U.S. federal income tax purposes, U.S. Holders will be treated as having received the amount of withheld Danish taxes, and as then having paid over the withheld taxes to the Danish taxing authorities. As a result of this rule, the amount of dividend income included in gross income for U.S. federal income tax purposes by a U.S. Holder with respect to a payment of dividends may be greater than the amount of cash actually received (or receivable) by the U.S. Holder from us with respect to the payment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">173</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends will generally constitute foreign-source income for foreign tax credit limitation purposes. Subject to the discussion of the PFIC rules below, any tax withheld with respect to distributions on the ADSs at the rate applicable to a U.S. Holder may, subject to a number of complex limitations, be claimed as a foreign tax credit against such U.S. Holder&#8217;s U.S. federal income tax liability or may be claimed as a deduction for U.S. federal income tax purposes. Any amount withheld in excess of the tax rate applicable to a U.S. Holder generally is not eligible to be claimed as a foreign tax credit, regardless of whether such amount is actually refunded or reclaimed. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends distributed by us with respect to the ADSs generally will constitute &#8220;passive category income.&#8221; Certain Treasury Regulations may restrict the availability of a foreign tax credit based on the nature of the tax imposed by the foreign jurisdiction. However, under current IRS guidance, taxpayers generally may elect to determine the creditability of foreign taxes without regard to such restrictions for taxable years ending prior to the year further guidance is issued. The rules with respect to the foreign tax credit are complex and involve the application of rules that depend upon a U.S. Holder&#8217;s particular circumstances. You are urged to consult your tax advisor regarding the availability of the foreign tax credit under your particular circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taxation of Disposition of the ADSs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the PFIC rules discussed below, you will recognize gain or loss on any sale, exchange or other taxable disposition of an ADS equal to the difference between the amount realized (in U.S. dollars) on the disposition of the ADS and your tax basis (in U.S. dollars) in the ADS. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if you have held the ADS for more than one year at the time of sale, exchange or other taxable disposition. Otherwise, such gain or loss will be short-term capital gain or loss. Long-term capital gains recognized by certain non-corporate U.S. Holders, including individuals, generally will be taxable at a reduced rate. The deductibility of capital losses is subject to limitations. Any such gain or loss you recognize generally will be treated as U.S.-source income or loss for foreign tax credit limitation purposes. You should consult your tax advisor regarding the proper treatment of gain or loss in your particular circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Passive Foreign Investment Company</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Code and Treasury Regulations, the determination of PFIC status is fact-specific and cannot be made until after the close of the taxable year in question. Based on our market capitalization and the composition of our income, assets and operations, we do not believe we were a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2024. However, this is a factual determination, and the application of the PFIC rules is subject to uncertainty in several respects, and we cannot assure you we will not be a PFIC for any taxable year. A non-U.S. corporation will be considered a PFIC for any taxable year if either:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at least 75% of its gross income for such taxable year is passive income (as defined in the relevant provisions of the Code), or  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at least 50% of the value of its assets (generally based on an average of the quarterly values of the assets during such taxable year) is attributable to assets that produce or are held for the production of passive income.  </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of the above calculations, if a non-U.S. corporation owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, it will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. Passive income generally includes dividends, interest, rents, royalties and capital gains, but generally excludes rents and royalties which are derived in the active conduct of a trade or business and which are received from a person other than a related person.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A separate determination must be made each taxable year as to whether we are a PFIC (after the close of each such taxable year). Because the value of our assets, including unbooked goodwill, for purposes of the asset test will generally be determined by reference to the market price of the ADSs, our PFIC status will depend in large part on the market price of the ADSs, which may fluctuate significantly. In addition, changes in the composition of our income or assets may cause us to become a PFIC. For these reasons, we cannot assure you we will not be a PFIC for any taxable year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">174</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are a PFIC for any year during which you hold the ADSs, we generally will continue to be treated as a PFIC with respect to you for all succeeding years during which you hold the ADSs, regardless of whether we continue to meet the income or asset tests described above, unless we cease to be a PFIC and you make a &#8220;deemed sale&#8221; election with respect to the ADSs you hold. If such election is made, you will be deemed to have sold the ADSs you hold at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain from such deemed sale would be subject to the consequences described below. After the deemed sale election, the ADSs with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently become a PFIC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each taxable year we are treated as a PFIC with respect to you, you will be subject to special tax rules with respect to any &#8220;excess distribution&#8221; (as defined below) you receive and any gain you realize from a sale or other disposition (including a pledge) of the ADSs, unless you make a &#8220;mark-to-market&#8221; election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable years or your holding period for the ADSs will be treated as an &#8220;excess distribution.&#8221; Under these special tax rules, if you receive any &#8220;excess distribution&#8221; or realize any gain from a sale or other disposition of the ADSs:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the &#8220;excess distribution&#8221; or gain will be allocated ratably over your holding period for the ADSs,  </span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8239;</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount allocated to the current taxable year, and any taxable year before the first taxable year in your holding period in which we were a PFIC, will be treated as ordinary income, and  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount allocated to each other year will be subject to the highest income tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.  </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gains (but not losses) realized on the sale of the ADSs cannot be treated as capital gains, even if you hold the ADSs as capital assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are treated as a PFIC with respect to you for any taxable year, to the extent we own directly or indirectly equity in any non-U.S. corporations that are also PFICs, you will be deemed to own your proportionate share of any such lower-tier PFIC, and you may be subject to the rules described in the preceding two paragraphs with respect to the shares of such lower-tier PFICs you would be deemed to own. As a result, you may incur liability for any &#8220;excess distribution&#8221; described above if we receive a distribution from such lower-tier PFICs or if any shares in such lower-tier PFICs are disposed of (or deemed disposed of). You should consult your tax advisor regarding the application of the PFIC rules to any lower-tier PFICs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alternatively, a U.S. Holder of &#8220;marketable stock&#8221; (as defined below) in a PFIC may make a &#8220;mark-to-market&#8221; election for such stock to elect out of the general tax treatment for PFICs discussed above. If you make a &#8220;mark-to-market&#8221; election for the ADSs, you will include in income for each year we are a PFIC an amount equal to the excess, if any, of the fair market value of the ADSs as of the close of your taxable year over your adjusted basis in such ADSs. You are allowed a deduction for the excess, if any, of the adjusted basis of the ADSs over their fair market value as of the close of the taxable year. However, deductions are allowable only to the extent of any net &#8220;mark-to-market&#8221; gains on the ADSs included in your income for prior taxable years. Amounts included in your income under a &#8220;mark-to-market&#8221; election, as well as gain on the actual sale or other disposition of the ADSs, are treated as ordinary income. Ordinary loss treatment also applies to the deductible portion of any &#8220;mark-to-market&#8221; loss on the ADSs, as well as to any loss realized on the actual sale or disposition of the ADSs to the extent the amount of such loss does not exceed the net &#8220;mark-to-market&#8221; gains previously included for the ADSs. Your basis in the ADSs will be adjusted to reflect any such income or loss amounts. If you make a valid &#8220;mark-to-market&#8221; election, the tax rules that apply to distributions by corporations that are not PFICs would apply to distributions by us, except the lower applicable tax rate for qualified dividend income would not apply. If we cease to be a PFIC when you have a &#8220;mark-to-market&#8221; election in effect, gain or loss realized by you on the sale of the ADSs will be a capital gain or loss and taxed in the manner described above under &#8220;Taxation of Disposition of the ADSs.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">175</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The &#8220;mark-to-market&#8221; election is available only for &#8220;marketable stock,&#8221; which is stock that is traded in other than de minimis quantities on at least 15 days during each calendar quarter, or regularly traded, on a qualified exchange or other market, as defined in applicable Treasury Regulations. Any trades that have as their principal purpose meeting this requirement will be disregarded. The ADSs are listed on The Nasdaq Global Select Market and, accordingly, provided the ADSs are regularly traded, if you are a holder of ADSs, the &#8220;mark-to-market&#8221; election would be available to you if we are a PFIC. Once made, the election cannot be revoked without the consent of the IRS unless the ADSs cease to be &#8220;marketable stock.&#8221; If we are a PFIC for any year in which the U.S. Holder owns ADSs but before a &#8220;mark-to-market&#8221; election is made, the interest charge rules described above will apply to any &#8220;mark-to-market&#8221; gain recognized in the year the election is made. The &#8220;mark-to-market&#8221; election may not be available with respect to the shares of lower-tier PFICs that are treated as owned by you. Consequently, you could be subject to the PFIC rules with respect to income of the lower-tier PFICs the value of which already had been taken into account indirectly via &#8220;mark-to-market&#8221; adjustments. A U.S. Holder should consult its tax advisors as to the availability and desirability of a &#8220;mark-to-market&#8221; election, as well as the impact of such election on interests in any lower-tier PFICs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In certain circumstances, a U.S. Holder of stock in a PFIC can make a &#8220;qualified electing fund election&#8221; to mitigate some of the adverse tax consequences of holding stock in a PFIC by including in income its share of the corporation&#8217;s income on a current basis. However, we do not currently intend to prepare or provide the information that would enable you to make a &#8220;qualified electing fund election.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise provided by the U.S. Treasury, each U.S. shareholder of a PFIC is required to file an annual report containing such information as the U.S. Treasury may require. A U.S. Holder&#8217;s failure to file the annual report will cause the statute of limitations for such U.S. Holder&#8217;s U.S. federal income tax return to remain open with regard to the items required to be included in such report until three years after the U.S. Holder files the annual report, and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the U.S. Holder&#8217;s entire U.S. federal income tax return will remain open during such period. U.S. Holders should consult their tax advisors regarding the requirements of filing such information returns under these rules, taking into account the uncertainty as to whether we are currently treated as or may become a PFIC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8239;</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">YOU ARE STRONGLY URGED TO CONSULT YOUR TAX ADVISOR REGARDING THE APPLICATION OF THE PFIC RULES TO YOUR INVESTMENT IN THE ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Information Reporting and Backup Withholding</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distributions with respect to the ADSs and proceeds from the sale, exchange or other disposition of the ADSs may be subject to information reporting to the IRS and U.S. backup withholding. Certain U.S. Holders are exempt from backup withholding, including corporations and certain tax-exempt organizations. A U.S. Holder will be subject to backup withholding if such holder is not otherwise exempt and such holder:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fails to furnish the holder&#8217;s taxpayer identification number, which for an individual is ordinarily his or her social security number;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">furnishes an incorrect taxpayer identification number;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding.  </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against the U.S. Holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. Holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">176</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Reporting Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax return disclosure obligations (and related penalties for failure to disclose) apply to certain U.S. Holders who hold certain specified foreign financial assets in excess of certain thresholds. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also may include the ADSs. U.S. Holders should consult their tax advisors regarding the possible implications of these tax return disclosure obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">F.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends and Paying Agents </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">G.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements by Experts </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">H.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Documents on Display </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the periodic reporting and other informational requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Under the Exchange Act, we are required to file reports and other information with the SEC. Specifically, we are required to file annually a Form 20-F no later than four months after the close of each fiscal year, which is December 31. The SEC maintains a web site at www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of quarterly reports and proxy statements, and officers, directors and major shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">I.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiary Information </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">J.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Report to Security Holders</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company intends to submit any annual report provided to security holders in electronic format as an exhibit to a report on Form 6-K.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">177</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11 Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our activities expose us to market risks related to changes in foreign currency exchange rates and interest rates. We do not enter into derivative financial instruments to manage our exposure to such risks. Further, we are exposed to credit risk, liquidity risk and inflation risk. For a description of our exposure to market risks, credit risk and liquidity risk, refer to Note 16, &#8220;Financial Assets and Liabilities.&#8221; Inflation affects us as our vendors may pass on any increased costs to us and accordingly increase our R&amp;D costs, SG&amp;A expenses and cost of manufacturing. We do not believe that inflation had a material impact on our results of operation for the years ended December 31, 2024 and 2023.</span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_description_of_securities_other"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12 Description of Securities Other than Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt Securities. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants and Rights. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Securities. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">American Depositary Shares. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Bank of New York Mellon, as depositary, registers and delivers American Depositary Shares, also referred to as ADSs. Each ADS represents one ordinary share (or a right to receive one ordinary share) deposited with The Bank of New York Mellon, London Branch, or any successor, as custodian for the depositary. Each ADS also represents any other securities, cash or other property which may be held by the depositary in respect of the depositary facility. The depositary&#8217;s corporate trust office at which the ADSs are administered and its principal executive office is located at 240 Greenwich Street, New York, New York 10286.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A deposit agreement among us, the depositary and you the ADS holders sets out ADS holder rights as well as the rights and obligations of the depositary. A copy of the deposit agreement is incorporated by reference as an exhibit to this annual report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">178</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fees and Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the deposit agreement, the holders of ADSs will be required to pay the following fees:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Persons depositing or withdrawing ordinary shares or ADSs must pay:</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">For:</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issue of ADSs, including issues resulting from a distribution of ordinary shares or rights or other property</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</span></div></div></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$0.05 (or less) per ADS</span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any cash distribution to you</span></div></div></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the shares had been deposited for issue of ADSs</span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to you</span></div></div></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$0.05 (or less) per ADS per calendar year</span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8202;Depositary services</span></div></div></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registration or transfer fees</span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares</span></div></div></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expenses of the depositary</span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cable, (including SWIFT), telex and facsimile transmissions (when expressly provided in the deposit agreement)</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Converting foreign currency to U.S. dollars</span></div></div></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, share transfer taxes, stamp duty or withholding taxes</span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8202;As necessary</span></div></div></td>
   </tr>
   <tr style="height:4.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Any charges incurred by the depositary or its agents for servicing the deposited securities</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">     </span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As necessary</span></div></div></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide for-fee services until its fees for those services are paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the depositary may make payments to us to reimburse or share revenue from the fees collected from ADS holders, or waive fees and expenses for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the ADS program. In performing its duties under the deposit agreement, the depositary may use brokers, dealers or other service providers that are affiliates of the depositary and that may earn or share fees or commissions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">179</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.067%;text-indent:-11.367%;padding-left:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_defaults_dividend_arrearages"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13 Defaults, Dividend Arrearages and Delinquencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.067%;text-indent:-11.367%;padding-left:10.2%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_material_modification_to_the"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14 Material Modification to the Rights of Security Holders and Use of Proceeds</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A. Material Modifications to the Rights of Securities Holders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B. Use of Proceeds</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.067%;text-indent:-11.367%;padding-left:10.2%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_control_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15 Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A. Disclosure Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our chief executive officer and principal financial and accounting officers, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of December 31, 2024, have concluded that based on the evaluation of these controls and procedures required by Rule 13a-15(b) of the Exchange Act, our disclosure controls and procedures were effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B. Management&#8217;s Annual Report on Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal control over financial reporting is defined in rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the audited consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect material misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. This assessment was performed under the directions and supervision of our Chief Executive Officer and our principal financial and accounting officers and based on the criteria established in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">180</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material weakness is a control deficiency, or a combination of control deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected. These control deficiencies could result in a misstatement of the financial statement accounts or related disclosures that would result in a material misstatement in the annual or interim consolidated financial statements that would not be prevented or detected on a timely basis. Based on management&#8217;s assessment of those criteria, management has concluded that the design and operating effectiveness of our internal control over financial reporting was effective as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C. Attestation Report of the Registered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by Deloitte Statsautoriseret Revisionspartnerselskab, an independent registered public accounting firm, as stated in their report, which appears in Item 18 below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D. Changes in Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the period covered by this annual report that has materially affected, or is reasonably likely to materially affect, internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16a_audit_committee_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16A A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">udit Committee Financial Expert</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Lars Holtug, an independent director under Nasdaq Rule 5605(a)(2) and Rule 10A-3 of the Exchange Act and a member of the Audit Committee, qualifies as an &#8220;audit committee financial expert,&#8221; as defined in Item 16A(b) of Form 20-F and as determined by our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16b_code_of_ethics"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16B Code of Ethics</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a code of business conduct and ethics that applies to all of our employees, members of our senior management and members of our board of directors, including those members of our senior management responsible for financial reporting. Our code of ethics is posted on our Company website at: http://www.ascendispharma.com. We will disclose any substantive amendments to the code of business conduct and ethics, or any waiver of its provisions, on our website. The reference to our website does not constitute incorporation by reference of the information contained at or available through our website.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16c_principal_accountant_fees_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16C Principal Accountant Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth, for each of the years indicated, the fees billed by our independent public accountants and the percentage of each of the fees out of the total amount billed by the accountants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.09%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.418%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.418%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.418%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.658%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended<br/>December 31,<br/>2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended<br/>December 31,<br/>2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">811</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit-related fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,049</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">861</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Fees </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are defined as the standard audit work that needs to be performed each year to issue opinions on our consolidated financial statements and to issue reports on our local statutory financial statements. Also included are services that can only be provided by our auditor, such as reviews of quarterly financial results, consents and comfort letters and any other audit services required for SEC or other regulatory filings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Related Fees </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">include those other assurance services provided by the independent auditor but not restricted to those that can only be provided by the auditor signing the audit report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">181</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Fees </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relate to the aggregate fees billed in each of the last two fiscal years for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Other Fees </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are any additional amounts billed for products and services provided by the principal accountant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Approval Policies and Procedures for Non-Audit Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee has adopted a policy pursuant to which we will not engage our auditors to perform any non-audit services unless the audit committee pre-approves the service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16d_exemptions_from_the_listing"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16D Exemptions from the Listing Standards for Audit Committees</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16e_purchases_of_equity_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16E Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16f_change_in_registrants"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16F Change in Registrant&#8217;s Certifying Accountant</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16g_corporate_governance"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16G Corporate Governance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sarbanes-Oxley Act of 2002, as well as related rules subsequently implemented by the SEC, requires foreign private issuers, including our Company, to comply with various corporate governance practices. In addition, Nasdaq rules provide that foreign private issuers may follow home country practice in lieu of the Nasdaq corporate governance standards, subject to certain exceptions and except to the extent that such exemptions would be contrary to U.S. federal securities laws. In addition to the home country practices described under &#8220;Item 6 C. Directors, Senior Management and Employees&#8212;Board Practices&#8221;, the home country practices followed by our Company in lieu of Nasdaq rules are described below:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not intend to follow Nasdaq&#8217;s quorum requirements applicable to meetings of shareholders. In accordance with Danish corporate law and generally accepted business practice, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not intend to follow Nasdaq&#8217;s requirements regarding the provision of proxy statements for general meetings of shareholders. Danish corporate law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in Denmark. We intend to provide shareholders with an agenda and other relevant documents for the general meeting of shareholders. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not intend to follow Nasdaq&#8217;s requirements regarding shareholder approval for certain issuances of securities under Nasdaq Rule 5635. Pursuant to Danish corporate law, our shareholders have authorized our board of directors to issue securities including in connection with certain events such as the acquisition of shares or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us, rights issues at or below market price, certain private placements and issuance of convertible notes. We intend to take all actions necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act of 2002, the rules adopted by the SEC and Nasdaq&#8217;s listing standards. As a Danish company not listed on a regulated market within the EU/EEA, we do not need to comply with the Danish corporate governance principles nor do we need to explain any deviation from these provisions in our Danish statutory annual report. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">182</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not intend to follow Nasdaq&#8217;s requirements regarding shareholder approval for all equity compensation plans. Generally, Nasdaq Rule 5635(c) requires each issuer to obtain shareholder approval of all equity compensation plans (including warrant incentive plans) and material amendments to such plans. However, pursuant to Nasdaq Rule 5615(a)(3), we have elected to follow our home country&#8217;s practices (in this case, being Danish practices) in lieu of the requirements of Nasdaq Rule 5635(c). Our home country practices do not require us to obtain shareholders&#8217; approval for amendments to our existing warrant incentive program. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are a foreign private issuer, our members of our board of directors, executive board members and senior management are not subject to short-swing profit and insider trading reporting obligations under section 16 of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act. They will, however, be subject to the obligations to report changes in share ownership under section 13 of the Exchange Act and related SEC rules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16h_mine_safety_disclosure"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16H Mine Safety Disclosure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16i_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16I Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16j_insider_trading_policies"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16J Insider Trading Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d561ef5-e0fb-425a-8ce8-a4eaaa9a6bdd" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an insider trading policy governing the purchase, sale, and other dispositions of our securities by directors, senior management, and employees. A copy of the insider trading policy is filed as an exhibit to this annual report.</span></p>
  <div><ix:nonNumeric id="F_f6edaa66-6a2e-4b8a-afd5-de4736af87b3" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_f6edaa66-6a2e-4b8a-afd5-de4736af87b3_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16k_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16K Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to safeguard the confidentiality and integrity of the information we collect and process, prevent unauthorized access to our information technology (&#8220;IT&#8221;) systems and data, and ensure availability of our IT systems and data according to defined business requirements. Our cybersecurity risk management program includes a cybersecurity incident response plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Information Security Policy for Global IT outlines the organizational responsibilities for maintaining a strong security posture for our IT systems and sets forth the IT security measures and controls that are required to be in place. This policy covers all IT systems that process Company information. Our Security Management team is responsible for ensuring internal security compliance and for managing IT vendors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have designed our security program around the International Organization for Standardization/International Electrotechnical Commission (&#8220;ISO/IEC&#8221;) 27001 standard on a strategic and tactical level, while our operational program is maintained in accordance with the Center for Internet Security (&#8220;CIS&#8221;) Critical Security Controls framework. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the ISO/IEC and CIS Controls standards as guides to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><div><ix:nonNumeric id="F_5a92f2d2-bd56-41f3-8436-4f585e417b65" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7574acb-b5a6-4b45-b668-f51683ff4812" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">183</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f6edaa66-6a2e-4b8a-afd5-de4736af87b3_1" continuedAt="F_f6edaa66-6a2e-4b8a-afd5-de4736af87b3_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program includes:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (1) our cybersecurity risk assessment processes; (2) our security controls; and (3) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b0f09b1-2dd0-49dc-b0b3-43fae3defc23" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</span></ix:nonNumeric></span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_450e79d2-8fb3-40ac-ad98-20913eda470c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a defined process for registration, classification and escalation of any incidents to a named IT Incident Manager and incident response team, which includes relevant members of the IT management team, the compliance team, business process owners and potentially external vendors;</span></ix:nonNumeric></span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security awareness campaigns for Company employees via various channels (intranet, direct mail, screen savers, etc.); and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">secure access control measures applied to critical IT systems, equipment and devices, designed to prevent unauthorized users, processes, and devices from assessing IT systems and data.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a1560a2-a921-44ec-bafb-1c24389cef61" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4155bc4-f5d8-4b49-a902-b2a5b1737f11" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated the oversight of cybersecurity and other information technology risks to the executive board. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6fc0155-a7fa-478b-8199-3e7ae591b6e6" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board oversees the Security Management team's implementation of our cybersecurity risk management program.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3001da85-0868-41c7-9199-0dec16ed3bc7" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board receives regular updates from the Security Management team on our cybersecurity risks. In addition, the Security Management team updates the executive board, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</span></p><div><ix:nonNumeric id="F_b78f55f2-1129-46c9-a4b9-fa7b21eecaf5" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_592bf306-3b7f-4af4-9f68-4f979beb8a45" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board reports to the full Board regarding its activities, including those related to cybersecurity.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Security Management team, internal security staff and external experts as part of the Board's continuing education on topics that impact public companies.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c28b6ff-6ada-47c2-ac7a-7ac24f1467e2" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec6a2b35-2af9-438e-88ee-676b4e290eb0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Security Management team is chaired by the Chief Information Officer and includes the Head of IT Compliance, IT Operations/Infrastructure and Cyber Security, and is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5aae3b5-d9d8-4064-b718-20f2c2cf53c9" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responsible</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.</span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b353c8e-6a50-49d8-ad1c-0bbcbb260bd2" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Security Management team's background includes experience in regulatory compliance, cloud computing and infrastructure, and cyber incident response.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Security Management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel, threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us, as well as alerts and reports produced by security tools deployed in our IT environment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive management that is part of the Corporate Management Group signs off on the overall strategic direction for IT security and ensures alignment with our overall business strategy.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also established a Security Organization Unit to ensure alignment across key security functions in our organization. The Security Organization Unit is chaired by the Chief Information Officer and includes representatives from Foundational Technology and IT Compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">184</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f6edaa66-6a2e-4b8a-afd5-de4736af87b3_2" continuedAt="F_f6edaa66-6a2e-4b8a-afd5-de4736af87b3_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is the responsibility of the Security Organization Unit to approve the Company's IT security roadmap, ensure allocation and prioritization of resources, and to act as the escalation point for IT security matters.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A named IT manager is assigned the responsibility of maintaining IT security across our global organization. This responsibility includes defining and driving IT security roadmap initiatives, defining and implementing activities needed to drive an IT security awareness program, supporting the assessment of new IT systems and vendors, and acting as the leader and point person in the event of a major security incident.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_f6edaa66-6a2e-4b8a-afd5-de4736af87b3_3"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operational responsibility resides with the related product teams. The product teams are responsible for ensuring effective and updated security technologies are used in the day-to-day operational procedures, and for maintaining, operating and implementing applications and technologies securely across business areas within the Company.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">185</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT III</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_17_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 17 Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;Item 18 Financial Statements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_18_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 18 Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">186</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASCENDIS PHARMA A/S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:87%;box-sizing:content-box;"/>
    <td style="width:13%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:1.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_profit_or_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_financial_position"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Financial Position at December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_changes_in_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Equity at December 31, 2024, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cash_flow_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Cash Flow Statements for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img148586500_9.jpg" alt="img148586500_9.jpg" style="width:173px;height:32px;"/></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="report_of_independent_registered"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Shareholders and Board of Directors of Ascendis Pharma A/S</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73242443-d02e-482e-9f65-546342dac125" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="dei:AuditorOpinionTextBlock" escape="true" continuedAt="F_73242443-d02e-482e-9f65-546342dac125_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated statements of financial position of Ascendis Pharma A/S and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of profit or (loss) and other comprehensive income or (loss), the consolidated statements of changes in equity, and the consolidated cash flow statements for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_73242443-d02e-482e-9f65-546342dac125_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by COSO.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinions</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on these financial statements and an opinion on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue and provisions &#8211; US commercial sales deductions &#8211; Refer to Notes 2 and 3 to the financial statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter Description</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States (US), the Company has entered into pricing agreements that include sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales rebates attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements. As such, revenue recognition includes variable consideration in the form of sales deductions related to these agreements. Provisions are recognized for the unsettled parts and are a source of significant estimation uncertainty which could have a material impact on reported revenue.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identified US commercial sales deductions as a critical audit matter due to the significant measurement uncertainty involved in developing the estimates used for these provisions for unsettled sales deductions, as the provisions are based on payer channel mix, current contract prices under eligible programs and current inventory levels in the distribution channels. In addition, significant judgments are involved in determining whether a significant reversal in the amount of revenue recognized will not occur due to commercial arrangements generally being settled within 180 days of the transaction date. This led to significant auditor judgment, effort and subjectivity in applying procedures relating to the Company&#8217;s estimate of these provisions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit procedures related to US commercial sales deductions included the following, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We tested the effectiveness of controls over US commercial sales deductions, including controls over the assumptions and data used to estimate these deductions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated whether the accounting treatment of US commercial sales deductions is consistent with the relevant accounting standards and the appropriateness of the Company&#8217;s methodology to develop the estimates used for their sales deductions provisions based on payer channel mix, current contract prices under eligible programs and current inventory levels in the distribution channels;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We selected a sample of US commercial sales deductions claims processed by the Company, and evaluated those claims for consistency with the conditions and terms of the Company&#8217;s commercial and governmental pricing agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We tested the overall reasonableness of the US commercial sales deductions provisions recorded at period-end by developing an independent expectation and comparing our expectation to the amount recorded by management; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated the Company&#8217;s ability to estimate US commercial sales deductions accurately by considering the historical accuracy of the Company&#8217;s estimates in the prior year compared to the actual claims information received in the current year. </span></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Deloitte Statsautoriseret Revisionspartnerselskab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 12, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2007.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_profit_or_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ts of Profit or (Loss) and Other Comprehensive Income or (Loss) for the</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Years Ended December 31</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.002%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.524000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.524000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.524000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Notes</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Consolidated Statement of Profit or (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d479123f-049c-4aaf-8af5-5efc2b59826b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,641</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_294409e8-2cc0-46b5-b56c-19f5aea7c78b" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,718</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d975068-2700-4044-95b0-c7bff4bdee37" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,174</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6, 11</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3fef2e0-7adb-4109-bfad-074b7f80e47a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:CostOfSales" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,258</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3780c981-9c89-4dfb-8447-cec8332a2c4c" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:CostOfSales" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,395</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0931490f-17f9-4006-b99a-25c1722c5277" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:CostOfSales" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,137</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1996ff4-5d9c-489a-b37c-96bbe640bcce" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:GrossProfit" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">319,383</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d35c23c0-2b32-4076-9181-c23d96643d1a" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:GrossProfit" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,323</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_162d2e1b-556e-4f2a-b744-bc1dff426e40" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:GrossProfit" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,037</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6, 11</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e26b4156-a494-4348-bafd-266f57c6ef71" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">307,004</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed631726-d924-4308-a99c-014e29b749bc" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">413,454</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2f8af2a-d760-4b19-b92d-0dbd8394ed14" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">379,624</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6, 11</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b01b3a8e-cc90-4ac6-bb73-f778fdc1b020" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">291,142</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f36b5602-8c3c-41e7-bec9-d03a4ba974f7" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,410</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd6bfe5f-ce67-418b-aed2-521590986db1" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,227</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating profit/(loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72812235-7a26-4dfb-947f-852b7cee3169" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProfitLossFromOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">278,763</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28263699-8413-400c-9274-a0ad8bd28ed3" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProfitLossFromOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">455,541</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a49beeb6-0ce6-428d-9d7d-bf5c90c9a121" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProfitLossFromOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">561,814</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share of profit/(loss) of associates</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_392f85f4-a0c9-49ba-a76e-8d0d9f64bc70" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,060</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43b7da23-b8ac-4de6-8e40-04c10e912a0f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,395</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5601798d-a258-44f7-babc-a6de53b4bf26" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17,697</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da227ebf-0ea6-4c00-a864-757cc575a354" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,609</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80c0e2e8-7fc2-413a-8031-2cf69fadd0dc" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,857</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4533456e-1acf-40c5-8ef5-d582b6cd5167" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,181</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42ff86b6-3fe0-4480-8d01-54d99b1713b1" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,027</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43af2c1a-1e18-48b2-8121-2ef2f4da99ab" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,065</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_404622c5-7ce7-48ac-8840-013174932b04" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,487</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Profit/(loss) before tax</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b1145b2-94e6-4008-924a-0ce8863e8d26" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">373,241</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcd3dfb9-b549-4d30-9c67-2bb6b86a271f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">474,144</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d11da0bd-10d0-42de-b92b-b15a26398339" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">577,817</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes (expenses)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">9</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9334784c-9887-4c0d-bf05-a88efab26303" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,843</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b5eb706-4254-4b20-b391-64889d962588" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,303</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9abfd66-84bd-45b2-b0ce-fa8cf3b12506" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,377</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e9dd2e3-dc3c-4551-9b35-575d34a748b0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378,084</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_157ee21d-42eb-4134-9d69-9a732b49f86a" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">481,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8755360-f866-43ba-ba3a-d0c0bf505586" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attributable to owners of the Company</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08780b29-736e-433d-a83d-d25dccffa402" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378,084</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c67b775-4aad-4098-b757-3793bdb56694" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">481,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_078e4661-a7de-403e-ba4c-b651845201b8" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted earnings/(loss) per share</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eeb9a698-30c6-4f75-983e-484e14d29a7c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:BasicEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_04d021fc-bd78-4859-aaed-7ec4c416d762" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">6.53</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c017cae-0227-4cfc-a8c9-2d09c9f13832" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:BasicEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e68a60c7-a818-4e25-be7f-01737411f22a" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">8.55</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ed19d64-d1a7-4a31-9a61-6558b783b9e7" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:BasicEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a6bf4d20-4c29-4fb6-956c-d06b03898f15" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">10.40</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares used for calculation (basic and diluted) </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5af142f2-1bb4-4ef7-aeca-efe68deab74c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:WeightedAverageShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">57,891,570</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df4ae6a0-4b34-4d5f-9c35-e466cec1e95e" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:WeightedAverageShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">56,287,060</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df87669d-0bb6-45ab-a330-8acae0137258" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:WeightedAverageShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">56,071,793</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Consolidated Statement of Comprehensive Income or (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e7467ab-dad5-4969-8a28-2e5c588830a8" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378,084</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_478cb32e-45c1-4332-adbd-521502cd749f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">481,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f4dd1ce-b58f-48cb-aba8-5f70f4bd8bf1" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other comprehensive income/(loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Items that may be reclassified subsequently to profit<br/>&#160;&#160;&#160;or (loss):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exchange differences on translating foreign operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41e6715d-2e89-4c84-8f17-3e54ae9fb47a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c1b86e3-073d-438e-bd0d-983a23a1b2bf" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,731</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e938d78-a68d-4e9e-81fb-13276070919f" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">327</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other comprehensive income/(loss) for the year, net<br/>&#160;&#160;&#160;of tax</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1391fe61-9717-494d-ae7c-b1ffa56ba76b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b0bd0cd-c841-4f12-9e66-0eeb2ddf659d" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,731</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c7383c1-68ac-46b5-8c62-91a794267d7d" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">327</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive income/(loss) for the year, net<br/>&#160;&#160;&#160;of tax</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bc10815-2fa0-4205-b401-dbea256e62a8" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">377,022</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4752b908-b06b-47c4-8949-33a0429c3e7b" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">484,178</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3241de1e-a861-49e8-93e2-65dcbb131f34" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,521</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attributable to owners of the Company</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d94b77c0-c3d5-462e-8358-9c1dc75a4cb5" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">377,022</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1443d16-679d-4430-8012-81a59b07d8c6" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">484,178</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cb5b562-f535-4531-bffd-485dbb6e122a" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,521</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_981ef46d-800a-489f-82bc-a5ff60bd4f50" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, a total of </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a01ff934-7f29-4f12-9838-7a23d2e50dad" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,204,122</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_55a04b3a-e9dc-42ca-ae23-e6258a34cbc2" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,523,784</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:8pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f38ba907-bea8-4f43-b5f7-0ad48cf170ba" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,864,011</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ebde4fb-8b6c-400c-b3ae-2fed14cbd720" contextRef="C_b870ca23-2010-47dc-89f9-9194ace53db0" name="asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">575,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible senior notes which can potentially be converted into </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2532e96-051e-40dd-9fa1-afba97d0d56c" contextRef="C_99a808e7-1efe-471a-ba2d-6422ec451ea7" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,456,785</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the years presented.</span></ix:footnote></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;" id="statements_of_financial_position"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Financial Position as of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.24%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.92%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.56%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.56%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Notes</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023 (Restated)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">January 1, 2023 (Restated)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5, 10</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_676882a4-2d75-4638-bbd1-4dfcb9c77a31" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,028</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f2d3364-03ae-45be-ba44-fc988fb90336" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,419</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_589fd958-2fd9-4861-8eb2-fb211220f782" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,828</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5, 11</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_279a1b50-6f6e-48ae-a9f0-cf4eed42d3b9" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,714</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_622aab91-b932-4187-809f-7b78f896c4f7" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,634</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_084cf33e-da27-4b65-bb42-3f6c5710074a" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,095</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments in associates</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43a75801-a446-4be2-9273-a8847a427fdd" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:InvestmentsInAssociates" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,575</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_980c6c3b-e596-4b9c-8d92-e02450c398a0" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:InvestmentsInAssociates" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,686</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5214d3b0-47a3-45d2-997f-784799e392c2" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:InvestmentsInAssociates" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,932</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c18bb9b3-66fd-47da-aa16-53ccb60bd8f2" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:OtherNoncurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,317</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8e56e66-8575-4b72-a1ed-bc5d29c3d221" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:OtherNoncurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70808046-e0cf-4475-87b4-4b385a38274d" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:OtherNoncurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,920</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16, 17</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc34b7c6-4b98-4dcb-9bc6-723a2612be53" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:MarketableSecuritiesNonCurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62a04fe8-9b69-41f4-82de-ade1f995608e" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:MarketableSecuritiesNonCurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69813962-ec68-4626-9ef5-779670aa2f2a" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="asnd:MarketableSecuritiesNonCurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,492</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5b8d07c-942b-4fdc-986d-51645b4b693c" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NoncurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,634</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d96335a-f6d9-4330-80ec-545283d4af99" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NoncurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,866</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_592df39d-6fe8-4376-b652-663628839d40" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:NoncurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,267</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">13</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2759b9ee-8802-4e94-85ba-e39abf22fa58" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:Inventories" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,609</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40b093c3-640c-47a0-8b85-489d8e14a1a9" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:Inventories" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,931</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fa26a62-cdd0-4509-ba50-f296557bdcb6" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:Inventories" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,673</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7b6e1d2-57ca-48fb-ae11-796432f0bd72" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentTradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,280</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_303a6812-2e52-48fd-a43a-203a98780c2d" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentTradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,874</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_382097b3-b5ef-4436-b499-30711f816121" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CurrentTradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,910</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax receivables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22287eda-1bd5-4f2e-8fb0-741be382b289" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentTaxAssetsCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e69b6562-90e1-4217-895d-b444dfba7743" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentTaxAssetsCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7255016-a092-43b2-8fff-0447b82b8834" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CurrentTaxAssetsCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">883</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_906b2721-46e6-4886-8010-f6336f45b06d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:OtherCurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,385</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_831a4081-f4f8-4711-96ad-78b29be79f6c" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:OtherCurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,097</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_199ad878-35ff-4014-a37f-42eb7ed9c375" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:OtherCurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,833</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ade22926-d334-4850-9028-7c386a827e27" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentPrepayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,269</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e401866-c4ae-4461-ae46-80951396f0fa" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentPrepayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,578</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61f5ba9c-d6e7-47af-a120-b0300560d6c6" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CurrentPrepayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,717</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16, 17</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec389182-5dbb-4ed6-9881-468323673e14" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:MarketableSecurities1" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffaab183-18e2-4e1c-9a96-7eea9fcc75c4" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:MarketableSecurities1" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,275</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_caa57351-8417-4791-a585-bd145240387d" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="asnd:MarketableSecurities1" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">290,688</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16, 17</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4cbe142-1464-4455-a876-90a4fb08a265" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,543</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75208953-26c9-4ba5-80b9-b728a6b86e17" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26c6c861-b5ba-4cad-92f6-32f39a3a1d2c" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,767</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c692aa4f-ebe9-4720-a0d1-6ba7286a04d2" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,060,861</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bc3769e-460e-4b91-afc4-7d3ba0080ceb" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">702,721</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c07633cd-f507-41e3-830f-c087650184e2" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">923,471</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f93b233f-8982-42da-ba9c-106e0f7c31c2" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:Assets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,179,495</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b4fb44d-7574-4a84-b61c-87d8d0bbab45" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:Assets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">825,587</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23a507de-e21f-48de-ae21-fd24dace1e42" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:Assets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,089,738</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity and liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a1643d-7c7f-40a3-bb9c-1b51fd2a2496" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:IssuedCapital" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,149</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c855bd6-e7de-4717-b7e5-c5bff55a7780" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:IssuedCapital" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,749</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1de2081-8c19-44b6-82ed-be5e61e997ed" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:IssuedCapital" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,675</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Distributable equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ed39ca7-fd71-47f9-aceb-f0a56272ba91" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:DistributableEquity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">113,855</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07c24fc7-73aa-4d3c-9add-a4464165d707" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:DistributableEquity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,446</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42b6f182-c1d6-40a4-9e57-6b2a81baa418" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="asnd:DistributableEquity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">255,673</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd790668-949e-4465-89f0-9f6e1e804383" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105,706</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef27783e-2ebf-4cee-8123-7b88ae2ac3c7" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145,697</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3795a0fc-3033-47f0-99ff-bd301132860f" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,348</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16, 17</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a83b961-54b4-43b6-8b14-ac7c265bb83d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:LongtermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">365,080</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fe891d7-42a9-43d8-ad45-1edeb55f7bd5" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:LongtermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,996</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06324db9-e461-493f-a1a5-d89ab3895f83" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:LongtermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,400</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12c3f237-20f8-42e1-8232-6a6ae2ad66a7" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NoncurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c603b92-996b-41cf-90f1-b6f38706f824" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NoncurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f5c30a7-dd20-4a79-8b75-5e53ccb86d9d" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:NoncurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,213</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">9</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aa87730-017c-46cf-a258-d613b4cf000e" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:DeferredTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,258</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ffbe158-e7ca-41b1-9e0f-c9494aadcac5" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:DeferredTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,830</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a82fc0d-07aa-432d-b4fb-c0d3dabb40b7" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:DeferredTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46b725a9-828e-4071-810d-6df96523363e" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NoncurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">377,338</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_556f4c14-5887-4ee4-8d98-2a04d59d2952" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NoncurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">234,775</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9d6d57b-425c-4fb7-abbd-e4a278a46eb8" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:NoncurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,613</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible notes, matures in April 2028</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16, 17</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55343d14-adc6-4ee3-960d-113d01795303" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:ShorttermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,207</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16f605bc-c449-4a9a-b897-ab5afc18d588" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:ShorttermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">407,095</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33c31fb0-9baf-4529-80e9-43922ebe0918" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:ShorttermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">399,186</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16, 17</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a700999-1910-4bd4-b5fd-2d80d7c4648b" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentDerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a80a850-f6a7-4854-b3a7-e27ae4e96591" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentDerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_850c6404-d676-4a1c-bd80-6f8bb47928b0" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CurrentDerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,950</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2726e0f-1634-4f25-949e-2571d5ec55e2" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:ConvertibleNotesCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">608,877</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_165c922b-2c8e-4822-90e5-0f02ac5c20e0" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:ConvertibleNotesCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">550,391</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9943a8d6-82ce-4009-8273-13bf6b24f302" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="asnd:ConvertibleNotesCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">557,136</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16, 17</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f7817f5-be8f-4ff9-96d2-0a335aec6830" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:ShortTermBorrowingOther" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,329</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_923af3dd-3ff9-4806-b536-4946e4597c7f" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:ShortTermBorrowingOther" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,174</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_937b3cd9-fe7a-46a9-b361-3cd9f805fe0f" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="asnd:ShortTermBorrowingOther" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,791</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10cb667e-45ba-4280-984c-0d067f6c76c0" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">936</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85f364e0-22ad-4ce7-9f7f-8121531aa5f7" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,184</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_803a9650-095b-429c-9575-ef2db55e6637" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16, 17</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_451166a2-9347-4553-9aad-13ddef46ae17" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deb67055-8a85-4ee4-ac53-976b2ed93a91" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,566</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54e300fd-d8b7-4a41-9130-5dd43498563b" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_910484ab-51ec-4b61-a45e-07353c1e772e" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:OtherCurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,956</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60695fa5-1167-441b-b831-7560770cf08c" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:OtherCurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,176</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f794aad9-2a63-4872-87b9-837f20bc715f" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:OtherCurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,989</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax payables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88bd386d-9238-4260-836d-af8aded27434" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,222</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6b826e8-8b76-4bd1-baa0-57dac5ae1ea1" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,299</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ba2ab12-59c9-4705-b8c1-3ab3fc76f27d" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CurrentTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,490</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provisions</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01d7f9a9-6418-4b51-be1e-3cf6ba4ba74d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,149</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cac9b5bc-a669-4d09-ac9d-3ac7b871ead1" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,719</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_399b9146-169e-4bb4-ac80-cafd1f58cce1" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,339</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24842db2-562b-4c04-bfd6-a684889ff996" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:OtherCurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">298,986</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd3efa0e-9e4f-49f5-9e6c-a40915c3d8f3" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:OtherCurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,118</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a7e5e95-c04c-4327-96d6-0bb984adb4a0" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:OtherCurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,641</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fe14837-95ea-4284-9a27-813c694df781" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">907,863</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d72c75d5-ea0e-4320-874c-0aae05cd4401" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">736,509</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d74833a8-604a-4949-a863-f60de5785367" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:CurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">716,777</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f62bdd6-67fa-45e1-815b-d5e815e7ecee" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:Liabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,285,201</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1837bd4c-bdab-4625-83ce-5792ca88d901" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:Liabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">971,284</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7085e38-ade3-403e-81da-e57c0a1e414d" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:Liabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">826,390</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total equity and liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4350065e-2a6d-4b70-9166-2b2d58342a45" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:EquityAndLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,179,495</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d1634f1-4c08-4418-9ecf-dfe6024613dd" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:EquityAndLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">825,587</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2eca86f-a27b-425d-89ae-8dd08e821786" contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6" name="ifrs-full:EquityAndLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,089,738</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></ix:footnote></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;" id="statements_of_changes_in_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.214%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.198%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.198%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.198%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.198%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.198%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.798%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Distributable Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Share<br/>Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Share<br/>Premium</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury<br/>shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Foreign<br/>Currency<br/>Translation<br/>Reserve</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR &#8216;000)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity at January 1, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6910055d-60ce-4630-b0f1-41ca7df630db" contextRef="C_b1fd592a-4621-4c11-bdbc-d9f0a9de718a" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,646</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c7bf10a-8d1a-4145-929e-77524edb75dc" contextRef="C_a71bc062-4b22-4a9f-b52c-19753e5e74b0" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,107,739</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b1397bb-1737-4e8d-ba82-84dfe2264623" contextRef="C_4321d0de-54cc-473c-8f2e-2c4823e23921" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4999b53-044b-41eb-8991-ce05ee281ee2" contextRef="C_5ad9dcf6-e1be-4e09-aa88-8cd0c222bbea" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,779</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c823499-c3e2-4f4b-bd36-5bb2dd9bda56" contextRef="C_fa84436d-cca3-4949-bad3-f7258a333f34" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,235,508</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4371f8df-bfc8-475f-801e-8cf48b1074d1" contextRef="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">883,635</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55be5477-2c79-4f59-a2b8-b3d1cc2fc04c" contextRef="C_bbd12530-7f01-426e-9852-87ca70290753" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c4e6657-a771-4199-8382-e29f41a5d937" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income/(loss),<br/>&#160;&#160;&#160;net of tax</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e430db54-5830-43af-8e5d-f68889734919" contextRef="C_9fb94f08-5f01-4b31-86eb-19c1c44186e4" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">327</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e025749a-761d-4373-9e64-2dd7f4b71bd2" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">327</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive income/(loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2290e31-0ba7-4dc4-b093-223ed840105a" contextRef="C_5ebf1592-e85e-4a79-a0d3-03fb135c3e71" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_117830ee-a769-4612-beda-a9a8d8f035df" contextRef="C_9fb94f08-5f01-4b31-86eb-19c1c44186e4" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">327</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02db0679-a613-4b6e-9b85-603b867a9557" contextRef="C_bbd12530-7f01-426e-9852-87ca70290753" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da478b50-0e4f-48e3-9d71-16f31ed109d3" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,521</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transactions with Owners</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment (Note 7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a874c6f0-244a-44e4-8c9a-8c09e2b54f7a" contextRef="C_bbd12530-7f01-426e-9852-87ca70290753" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,180</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ae06780-80a8-4151-b188-93ca4d42bef8" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,180</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of treasury shares</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99fe0fd6-eadc-457a-8d21-638dcb818747" contextRef="C_5c050805-6399-4923-924c-dd423a9d5ceb" name="ifrs-full:PurchaseOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">134</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3788fe4f-c209-4cc7-8cde-38562e0d6a17" contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f" name="ifrs-full:PurchaseOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,965</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_177c03c0-382c-4e4b-bcbb-cdcd4d4f977a" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:PurchaseOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,099</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transfer under stock incentive programs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1083c75-778f-4fec-9815-162dd1e1f089" contextRef="C_5ebf1592-e85e-4a79-a0d3-03fb135c3e71" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_721228a8-22fc-4b82-a0b1-9e5d44dd0c9f" contextRef="C_bbd12530-7f01-426e-9852-87ca70290753" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital increase</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74aa465b-62bd-489f-8504-d3580bccf9f0" contextRef="C_ae50ae32-8fd9-4440-ae86-c935aac5e3c8" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71d760c1-4822-4ab0-aae7-15c99450ddb6" contextRef="C_7cb30aff-4382-400f-aea5-7f16e02f70c5" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,124</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e02b016e-1451-409c-a654-3ca654c6ff34" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,153</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05e00795-e7cf-420a-8704-cf8a450a7f1c" contextRef="C_9076fd44-ae75-413e-8321-bdfaee1f0a4d" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,675</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_676d35bf-b96b-40a0-90cf-bd2a3819a971" contextRef="C_ca9626d8-b4fd-4cc7-bdcd-fa03f5df98d4" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,112,863</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_674dbc14-fa22-4174-8a3d-e2dce7241deb" contextRef="C_1fbabba9-e169-4afa-9ccc-063e93641d68" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48eedfe1-fe80-4b64-933c-eb0631d2a433" contextRef="C_9c347efe-55f5-41f7-aa5a-2ffa52fa30b2" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,452</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_555b432c-0996-4465-a4d0-60268e2ec193" contextRef="C_481783fd-70ee-498b-bb3d-a524d1a98f13" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,860,493</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85e5cc51-863a-4ba0-a63c-3b9d8901207c" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,348</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62bb4411-8b68-45ca-9b68-da2a56b23d57" contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">481,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e5de1b7-f356-4379-849b-4404798ec5ab" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">481,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income/(loss),<br/>&#160;&#160;&#160;net of tax</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed6641e4-b043-4600-8c42-c0fff0994ffc" contextRef="C_9a087241-0b3a-4cac-b087-23c132bb156a" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,731</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1e4366e-49df-436a-8705-c9c646887aa6" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,731</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive income/(loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b98497e2-22dc-4ca6-88dd-1a4e28f61fb3" contextRef="C_5c050805-6399-4923-924c-dd423a9d5ceb" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bae5a13-85c6-4db5-b4bd-0f96a4b3e3f9" contextRef="C_9a087241-0b3a-4cac-b087-23c132bb156a" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,731</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58e915be-4d42-41a7-9e76-d6c093f92a86" contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">481,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff7bc22c-3739-4d1b-8746-99b29129641e" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">484,178</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transactions with Owners</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment (Note 7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f9fee15-8d78-48c0-8cfb-f1f0f349561b" contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,660</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b55ed47b-5b93-4769-844e-c0fb06963a1c" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,660</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transfer under stock incentive programs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbd8075a-67b5-4396-994b-942e88618282" contextRef="C_5c050805-6399-4923-924c-dd423a9d5ceb" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcbfe633-fcfd-4268-9d5f-82d6d6c816ec" contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net settlement under stock incentive programs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4704b5a8-63be-4ba4-bcf0-f2bd0d56f6f3" contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f" name="asnd:NetSettlementUnderStockIncentivePrograms" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,812</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ead6c646-aa1b-4c03-b054-762a73192997" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:NetSettlementUnderStockIncentivePrograms" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,812</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital increase</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97ca9b5b-83f5-4b54-b2bf-03f46ee8b062" contextRef="C_83fd201b-7c83-4ee4-a0da-02d9df8447b1" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_900b5f90-e3bd-4b0b-8755-7bbb9a866865" contextRef="C_d556afe9-f715-43bc-a19e-5d09f686c664" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,211</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f46134b4-40c4-443b-8a54-c3586793d967" contextRef="C_5ebf1592-e85e-4a79-a0d3-03fb135c3e71" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d75a2792-1f24-4956-b9c3-4dee0e084dba" contextRef="C_bbd12530-7f01-426e-9852-87ca70290753" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_558483bd-f470-470d-9adf-39f0e545777b" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,285</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_602abff0-43f4-4687-8fac-cd16c6c1c010" contextRef="C_d0e6faf1-bbd1-4b27-8ddf-0087e182b6af" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,749</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c81d142b-32af-4686-bd90-81cfc417174c" contextRef="C_be71380a-a9fd-4b8f-a8ae-7f8c29ba0800" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,123,074</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d438816-67b2-4425-bfe6-a49bf0676aee" contextRef="C_bcd65bae-11a9-4b6a-b98a-ae8d9426e936" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4015bb25-6559-44a3-a7fe-2c6a16b88476" contextRef="C_01ae896f-3989-4a7c-b794-121862812d86" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">721</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a5f8a23-0064-445f-91f2-da72269e1789" contextRef="C_ce3072bb-3b3b-4d2a-bccb-396e6f23ec7d" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,277,095</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9beedec4-11ae-48a1-a7af-241672253a32" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145,697</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0b24820-702f-4864-a93f-83223fd73b36" contextRef="C_45262f50-d25a-4678-b31f-4e249ad2d3e3" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378,084</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08ebb0e3-8b8d-4fa6-b616-272f42055225" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378,084</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income/(loss),<br/>&#160;&#160;&#160;net of tax</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cab3244d-b037-44b5-9077-71eb6102c78a" contextRef="C_3ebd12a3-760c-4570-9d25-6d885ea5aee9" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfed79bf-272a-4957-bb3d-f656f2986fba" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive income/(loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34cf4f0f-4507-4527-b072-b23a97c5c5ae" contextRef="C_c1719aa5-a73d-4b30-a0d6-6c4e89f62175" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8c5024d-6926-426c-9239-102456b121a2" contextRef="C_3ebd12a3-760c-4570-9d25-6d885ea5aee9" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b1db8ba-c45a-4008-9947-5dc379289f12" contextRef="C_45262f50-d25a-4678-b31f-4e249ad2d3e3" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378,084</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_869cfa69-72d3-4f14-8680-68e21ad36d99" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">377,022</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transactions with Owners</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment (Note 7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bf814dc-7b82-4d00-be55-c71030652bbb" contextRef="C_45262f50-d25a-4678-b31f-4e249ad2d3e3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,512</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82440a7d-80ae-402a-943a-60d27e14416f" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,512</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transfer under stock incentive programs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5154d24a-82de-436e-be04-d7708ff2774d" contextRef="C_c1719aa5-a73d-4b30-a0d6-6c4e89f62175" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe491bb6-dd1e-4add-904b-dd3fa15c3a03" contextRef="C_45262f50-d25a-4678-b31f-4e249ad2d3e3" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital increase (Note 17)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fb70724-1f2f-484f-b29f-90dac7a86f57" contextRef="C_6b2baac5-581b-4df4-9270-e2e0408d280d" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">400</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d4bbb55-643e-4fc4-b126-e1499206cb47" contextRef="C_694aa851-7e2e-42d3-96e9-18ff2f6e9d67" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">340,392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96cf4c93-9824-4172-8718-ef30fb575647" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">340,792</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of capital increase</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21029507-744b-4539-adf6-44fa469b9e7f" contextRef="C_694aa851-7e2e-42d3-96e9-18ff2f6e9d67" name="asnd:CostsOfCapitalIncreaseDecrease" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,291</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4929a9a-c64a-46ce-a14a-5d70113fcad9" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:CostsOfCapitalIncreaseDecrease" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,291</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_073b776a-dbd7-48be-9fbc-0c9ab9933bdd" contextRef="C_f6d717ce-7ddc-4b83-a7fa-1c03e30a43a3" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,149</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40fff43a-f7e3-48a0-9f84-a70c270638d8" contextRef="C_feba8166-348b-43f4-8af8-7e1499e6fa81" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,444,175</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdb29325-e788-4858-a8ee-598eacf909db" contextRef="C_2b7ffa79-9374-4323-9f4f-2e90fd4a0ef6" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c26bdc7-ef0a-4c3c-bdc2-031c2f16340e" contextRef="C_2390a6d0-d171-4a09-ad5f-63eca2811521" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,783</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b68f566-9dcc-4a78-9d76-298311ea552e" contextRef="C_73eda4e7-aa61-4748-bc17-dba1d8cc2584" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,559,700</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_988b7774-e60d-42e0-afc2-25a1d6b57c03" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105,706</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;" id="cash_flow_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Cash Flow Statements for the Years Ended December 31</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:6.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Notes</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be535eb6-68d2-4664-ab06-8b3ce83168ac" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378,084</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e481f78b-748e-4538-a029-a783fb834964" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">481,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e92b3131-c7c0-4887-a66f-15d03232d7a1" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">583,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reversal of finance income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ed5d40d-4060-4f7b-9e58-8999001f7f76" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,609</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c858da7-227e-4dac-b222-14d897ca9abb" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,857</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8715820a-3b6b-40bb-b87d-9cd7fe78a7d8" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,181</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reversal of finance expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_392782af-2c18-4805-8567-df64dc385d0c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,027</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72995283-4aae-451b-92ee-291ef617ec95" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,065</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_647bf6dc-85c0-4dec-9bd7-24391fa6e26f" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,487</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reversal of (gain)/loss on disposal of property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c34f3021-f57b-46d4-9128-50e016ac17f4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eef1f3d-ce54-47bf-ae60-d80566381bb6" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cf8b3bf-815d-4bd3-8d04-c61ac451c092" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reversal of income taxes (expenses)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40e10656-16c5-408d-a824-46fa6ada8eb2" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,843</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_556782aa-d9ec-4bd1-a127-d94ee328b7cb" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,303</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50450b73-cb34-47de-86f6-8dbdc693384a" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,377</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments for non-cash items:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash consideration relating to revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5231c97-daac-4b1c-ad62-d4e3929664fd" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:AdjustmentsForNonCashConsiderationRegardingRevenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,069</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89d9feaa-903a-48e6-aa2f-ea6ff3d4fb34" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:AdjustmentsForNonCashConsiderationRegardingRevenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,354</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af28e0c5-59b7-4a40-9b62-6b3d9043bd7b" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:AdjustmentsForNonCashConsiderationRegardingRevenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,547</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share of (profit)/loss of associates</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d3e09c6-022a-450c-ae3a-903158698668" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,060</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa5421be-bf0e-4921-81f3-5d58324f0fd8" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,395</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5f42aab-bdf8-4ce8-b195-222cbb43e1b8" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17,697</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34cf1b76-d52d-465e-910e-78cc072cc913" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,512</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92a19335-4bab-49c6-8f06-88dd1452d8dd" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,660</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6595134-8fa2-49f5-aadf-41199672dc3d" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,180</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9754bd3-f62c-4445-a4a8-c80669ae6988" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForDepreciationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,247</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a1731f4-c50f-4e2b-a8f1-9d0b419056a1" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForDepreciationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,428</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f707731-5c8d-41c9-9963-1c9b5aaa7df6" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForDepreciationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,514</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdb5c72d-3551-4a36-a323-81e1be57a2d1" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db8b9112-3ffe-4140-b406-c2c754a8d281" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,834</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5c9170c-17a1-4126-ac4d-1fac26a87d3c" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80ba40d4-450e-4424-b260-4a2e3b784a7d" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForAmortisationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">467</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38c84453-b481-4b00-a0b2-fb1c8e295fe0" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForAmortisationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">483</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f816c248-a235-4dec-82ab-15e04269d30e" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForAmortisationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">444</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in working capital:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e52c9809-8f5e-4664-a388-acfc9c6e084a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,678</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_679dbc29-5a97-448c-b147-74fa5b39e6c3" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,258</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6eafd0d-9c90-4355-b861-8028aca2e170" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,268</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Receivables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3736655f-e265-40c4-81d8-7d55b96a83b4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,607</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c3d23be-bb17-43e5-954f-6b147500d8a7" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,773</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e4243ee-1e89-4b53-889b-3e57485a1481" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,531</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14479db4-2632-4afa-abdd-88c804eee7d5" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25289ec2-f756-4b82-86dd-da5241da0561" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,413</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b9475aa-3500-404e-9ec0-b8d2846c334b" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,409</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dd245e8-7562-4b75-99e0-e0c3b967c9da" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,197</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cd5ff0c-c040-45a5-91eb-77d5b95368b1" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,080</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a350cd9e-95fa-4d0d-a970-023d3b92c457" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,648</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_128aeb78-68a6-4ed8-a9ae-70eec63d4110" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,965</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a055590-7f70-43c4-a86f-999fbd384684" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,551</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_693673be-4d99-4694-a159-c5d0f6aba228" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,943</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase/(decrease) in provisions</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7044cb3c-2025-41df-b971-08b34cb48669" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,968</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fcec2ef-d6d3-47b2-8e6c-8fd77fdd235f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,187</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bbdb0d9-266b-4e63-8f61-780bbbb47042" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,145</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows generated from/(used in) operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e888b4ec-fe3b-4f7a-8255-dbba3e969865" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:CashFlowsFromUsedInOperations" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">299,854</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22526e08-e137-4e1f-9671-e542c3428d17" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:CashFlowsFromUsedInOperations" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">464,271</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cc813a7-05bf-497d-934a-b052268d9b18" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:CashFlowsFromUsedInOperations" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">494,673</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance income received</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04f5cb82-a8d8-488a-8861-3b3329449f94" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,374</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c9e0aa6-5a13-4775-9886-23d5c2ed24b8" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,048</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_833daafc-5628-48b7-b440-d3c8542207b0" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,271</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance expenses paid</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed710cd4-8954-492d-acf1-699170cf1101" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,205</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c067f44-624a-4a82-ac17-1aac0effe4e5" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,672</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c0f4766-2d75-42d3-825b-687943da70e9" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,294</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes received/(paid)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61d53035-5f4f-4fd2-807f-78bbc780b000" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,512</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e2b63cd-2858-478c-8f6a-e6c53ebf3c1b" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,466</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eae1f7f7-07d1-4724-9726-c2afb700f663" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f66eeaa-6530-472b-87d0-7012e9253e90" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">306,197</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_773229e5-8d26-44bb-9495-121ecfc2c67c" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">467,361</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cb7364b-f05f-436a-b774-6db14bf9577c" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">495,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from disposal of property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aa6ae5c-4bfa-4b93-b8b6-4b7d68706ddb" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">950</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5be96d0-93a5-4739-bd27-f32b28af7e42" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb60d06e-fb75-46c1-9355-c3475647ff69" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of intangible assets and property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09200b8a-35a5-458d-ad05-cd060a675b08" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,427</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f4d3bed-b0da-45fd-a9ba-c6306cdd11da" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,442</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1170bcd-31d5-4970-b62d-54abac567315" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,489</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reimbursement for acquisition of property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6fe795a-1d50-46dc-8d3b-08447db91eb5" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a457b6b9-b40d-4c81-a46f-955fc6acbb66" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_757903e8-011f-48f6-9155-750907ec15dd" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,535</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ff7f105-c6af-43bc-870d-306c2a5bfb78" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4355e537-3034-412f-b99e-41f9ad875fc5" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_211577a5-6b77-4a3b-b7f0-ab1098728477" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,842</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Settlement of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c62645e-1597-4d47-a2d6-5ce2133b9acd" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,353</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbcff07e-d6b9-4636-95de-dbddd7270cde" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">288,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_321e06dc-7b08-43d7-b768-b2cd951ab853" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">280,528</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3107799-d9cf-4e94-a46e-98edfa1b2b58" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,876</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e21b4b4a-9dd2-4ad0-922f-b55e0d48e8ae" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">286,474</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56c8cbf0-c2c4-4472-b52f-c2f9d20baad3" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repayment of borrowings</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59a184aa-784a-45d0-84c8-2f6c3c8be4ee" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,365</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acc120ec-206e-430d-9ec8-ae9e52421dbd" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,438</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d81e449-5797-4db3-a29e-8047f170b407" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,356</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net proceeds from borrowings</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cface604-269c-4694-93c2-ccb08b870b81" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,158</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e5b7333-f0a5-4821-8963-30b706100348" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,256</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_761aefb8-6db9-40e0-99bd-a52d4b65da2f" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">503,281</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ff28ef6-057d-48f3-8c52-5f55abab7ac6" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,514</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7e365ec-4117-4f07-b9f5-4c3b217e3b23" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,286</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a6df15a-4013-4789-85a3-77c599de832a" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,153</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from follow-on public offering</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_058bd30a-06c5-45c8-945c-4f2adeec1190" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProceedsFromIssuingShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">309,913</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7d45c2b-a451-476f-87ac-8c7075b9e8f4" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProceedsFromIssuingShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbf13607-c13f-4bea-befa-3235326f175c" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProceedsFromIssuingShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Costs of follow-on public offering</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c415db0a-097f-4371-a3f4-5e199ea81c86" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:PaymentsForShareIssueCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,291</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d471ad52-5963-4fb5-9dff-99b93ef816a6" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:PaymentsForShareIssueCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e14a2adb-292d-44bc-b0b4-5e392b8fe00e" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:PaymentsForShareIssueCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisitions of treasury shares, net of transactions costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_631afa47-80d1-4a71-b623-d0ded0ff1eb9" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c886c09-7edc-409e-bc1b-43d8051b21d2" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_895e44e2-8c14-4fbd-a411-89ed90038913" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,305</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of withholding taxes under stock incentive programs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d968f593-0f81-4e0b-8abf-c927b914f0f9" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ed695d6-394b-4d0d-8234-7d3cd6af1f4b" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,812</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_351b85d2-465b-4d99-8ba9-bc2801073319" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12b077cb-6b62-47b9-b36a-0881e4b6791a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">443,929</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e05ff7e-8b5c-4b04-8c06-80870e2ad74f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,292</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1706848-a554-40fe-972c-907d9accb2d0" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">396,773</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(decrease) in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc86422-71f6-47a5-bf5a-30693aa56b42" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">144,608</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2cc5bc4-4ee4-437a-84a5-1941642f17f1" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,595</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ff41fb8-a01d-4460-97e5-0e68d454b48c" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at January 1</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f42de462-9d16-486e-8b54-f7b1b27023d4" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_098620b8-af07-419c-b37d-794d492523fd" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,767</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dd981f1-1363-4abb-a555-c38f01e878b2" contextRef="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">446,267</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on balances held in foreign currencies</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24e4698b-d74e-4031-b550-774f57c183df" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,771</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8cbbd25-9242-44fa-85b8-d6c3922fd922" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,008</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0602418-ee1f-4783-9d08-835210ac7f4e" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,694</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at December 31</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd433ae0-d166-41be-b7a2-0e8483a244b4" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,543</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d68fed6-a578-4d65-85b1-7d20587476fc" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f9ed319-cf73-4657-be9d-abd5162a1fb1" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,767</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents include:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bank deposits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e16a969-41d5-40de-901a-f9726b32928a" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:BalancesWithBanks" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,543</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3300e367-6bda-4c6d-85ae-eeb34b385c60" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:BalancesWithBanks" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77c8a67b-5780-4a91-8046-f7a236841689" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:BalancesWithBanks" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">427,810</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4331057a-514e-4bdd-a6e4-3776571f49de" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:ShortTermMarketableSecurities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_792a880a-9487-44fe-90b5-aabd1bc46eee" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:ShortTermMarketableSecurities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f48673a-d753-4eaf-9f1a-8745aaf1cb06" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:ShortTermMarketableSecurities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,957</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at December 31</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4089b48-a5cd-449f-8985-278a474364ed" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,543</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36db8fac-949a-4554-985c-1afe953ea266" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3b5c06e-afa1-4548-876d-cbc78a4804f8" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,767</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_985f9a1d-753a-44dc-ae95-058a6db66570" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 1&#8212;General Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S, together with its subsidiaries, is a global biopharmaceutical company focused on applying its  innovative TransCon technology platform to make a meaningful difference for patients. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to Ascendis Pharma A/S and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The address of the Company&#8217;s registered office is Tuborg Boulevard 12, DK-2900 Hellerup, Denmark. The Company&#8217;s registration number in Denmark is 29918791.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 2, 2015, the Company completed an initial public offering which resulted in the listing of American Depositary Shares (&#8220;ADSs&#8221;), representing the Company&#8217;s ordinary shares, under the symbol &#8220;ASND&#8221; in the United States on The Nasdaq Global Select Market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors (or &#8220;Board&#8221;) approved these consolidated financial statements on February 12, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" escape="true" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2&#8212;Summary of Material Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb7aeb04-1cee-4fb8-a3bb-a6cd12a3f1fc" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" escape="true" continuedAt="F_fb7aeb04-1cee-4fb8-a3bb-a6cd12a3f1fc_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Preparation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are prepared in accordance with the IFRS Accounting Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), and as adopted by the European Union (the &#8220;EU&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies applied when preparing the consolidated financial statements are described in detail below and are applied for all group entities. Significant accounting judgements and sources of estimation uncertainties used when exercising the accounting policies are described in Note 3, &#8220;Significant Accounting Judgements and Estimates.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_fb7aeb04-1cee-4fb8-a3bb-a6cd12a3f1fc_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements have been prepared under the historical cost convention, apart from certain financial instruments that are measured at fair value at initial recognition.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New and Amended IFRS Accounting Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has applied amendments to paragraphs 69 to 76 of IAS 1, &#8220;Presentation of Financial Statements,&#8221; which was effective for annual reporting periods beginning on or after January 1, 2024, and must be applied retrospectively. The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. The amendments clarify:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What is meant by a right to defer settlement;  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That a right to defer must exist at the end of the reporting period; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That classification is unaffected by the likelihood that an entity will exercise its deferral right; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. </span></div></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_1" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible senior notes (&#8220;convertible notes&#8221;) include an embedded equity conversion option which is not deemed closely related to the financial liability and was initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the embedded derivative is not an equity instrument under IFRS, the amendments require the convertible notes (presented as part of borrowings in the statement of financial position) and derivative liabilities, presented as non-current liabilities as of December 31, 2023, to be presented as current liabilit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ies. The amendments require presentation of the convertible notes as current liabilities even though: the initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b91440ca-5e55-464b-81bb-7c907d0879d3" contextRef="C_8b7cf227-3c27-4452-bf1e-f4d1f142fedb" name="asnd:ConversionPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">166.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS is not met; the conversion would not require cash settlement; and, the convertible notes do not mature until April 1, 2028. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further details, including (cash) maturity analysis are provided in Note 16, &#8220;Financial Assets and Liabilities.&#8221; On December 31, 2023, the carrying amount of convertible notes and derivative liabilities were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0deddedd-6da5-4d24-a5cc-3ae1ea2ec605" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">407.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc8ad6b2-112e-4ca2-a6cd-8ce2d0228bad" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change to presentation, including a third statement of financial position as of the beginning of the preceding period i.e. January 1, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 31, 2023, lease liabilities were presented separately in the consolidated statements of financial position. As of December 31, 2023, carrying amount of lease liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cbb84d7-e5be-46dc-91e2-0de61883adb9" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NoncurrentLeaseLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">84.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e541dac-d72f-49c4-8d53-0a3a2ca01f35" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentLeaseLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for non-current liabilities and current liabilities, respectively. Since March 31, 2024, lease liabilities are presented as part of borrowings in the consolidated statements of financial position. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change in presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, since March 31, 2024, borrowings comprise convertible notes, royalty funding liabilities, and lease liabilities, where convertible notes are presented separately as &#8220;Current liabilities - Convertible notes, matures in 2028.&#8221; The change to presentation had no other impact on the consolidated financial statements. Refer to Note 16, &#8220;Financial Assets and Liabilities&#8221; for a specification of borrowings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The applied amendments had no other impact on the consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other IFRS Accounting Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other amendments apply for the first time in 2024, but do not have an impact on the consolidated financial statements.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18a09fa7-5e76-46ce-9f92-68abf5e4e062" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfGoingConcernExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors has at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, the Company continues to adopt the going concern basis of accounting in preparing the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10d02710-e3ef-4506-8a94-12c5a2bf9659" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DescriptionOfBasisOfConsolidationExplanatory" escape="true" continuedAt="F_10d02710-e3ef-4506-8a94-12c5a2bf9659_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_10d02710-e3ef-4506-8a94-12c5a2bf9659_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the parent company, Ascendis Pharma A/S, and all enterprises over which the parent company has control. Control of an enterprise exists when the Company has exposure, or rights to, variable returns from its involvement with the enterprise and has the ability to control those returns through its power over the enterprise. Accordingly, the consolidated financial statements include Ascendis Pharma A/S and the subsidiaries listed in Note 20, &#8220;Investments in Group Enterprises&#8221;</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_2" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3930c7dd-d640-444c-abbe-8d7763661439" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consolidation Principles</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries, which are enterprises the Company controls, are fully consolidated from the date upon which control is transferred to the Company. They are deconsolidated from the date control ceases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Control over an enterprise is reassessed if facts and circumstances indicate that there are changes to one or more of the three elements of control, respectively:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the contractual arrangement(s) with the other vote holders of the enterprise; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#8217;s voting rights and potential voting rights; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights arising from other contractual arrangements.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between group enterprises are eliminated in full on consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries apply accounting policies in line with the Company&#8217;s accounting policies. When necessary, adjustments are made to bring the entities&#8217; accounting policies in line with those of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f906a5fb-7f8e-4c16-bf62-f16b079b1cbe" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments in Associates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An associate is an entity over which the Company has significant influence over financial and operational decisions but without having control or joint control. The Company&#8217;s associates are accounted for using the equity method and initially recognized at cost. Thereafter, the carrying amount of the investment is adjusted to recognize changes in the Company&#8217;s share of net assets of the associates since the acquisition or establishment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated statements of profit or loss include the Company&#8217;s share of result after tax of the associates after any adjustments made to bring the associates accounting policies in line with those of the Company. Transactions between the associates and the Company are eliminated proportionally according to the Company&#8217;s interest in the associates. Unrealized gains and losses resulting from transactions between the Company and its associates are eliminated to the extent of the Company&#8217;s interest in the associates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On each reporting date, the Company determines whether there are indications that the investment is impaired. If there is such evidence, the amount of impairment is calculated as the difference between the recoverable amount of the associate and its carrying amount. Any impairment loss is recognized in the consolidated statements of profit or loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_e8b3d959-8217-4e05-be7e-5a21cab7a93c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" escape="true" continuedAt="F_e8b3d959-8217-4e05-be7e-5a21cab7a93c_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Currency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Functional and Presentation Currency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Items included in the consolidated financial statements are measured using the functional currency of each group entity. Functional currency is the currency of the primary economic environment in which the entity operates. The consolidated financial statements are presented in Euros (or &#8220;EUR&#8221;), which is also the functional currency of the parent company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Translation of Transactions and Balances</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On initial recognition, transactions in currencies other than the individual entity&#8217;s functional currency are translated applying the exchange rate in effect at the date of the transaction. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the reporting date are translated using the exchange rate in effect at the reporting date. Monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange rate differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the reporting date, are recognized in profit or loss as finance income or finance expenses. Property, plant and equipment, intangible assets and other non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as of the dates of the initial transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_3" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e8b3d959-8217-4e05-be7e-5a21cab7a93c_1" continuedAt="F_e8b3d959-8217-4e05-be7e-5a21cab7a93c_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Currency Translation of Group Enterprises</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_e8b3d959-8217-4e05-be7e-5a21cab7a93c_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When subsidiaries or associates present their financial statements in a functional currency other than EUR, their statements of profit or loss are translated at average exchange rates. Balance sheet items are translated using the exchange rates at the reporting date. Exchange rate differences arising from translation of foreign entities&#8217; balance sheet items at the beginning of the year to the reporting date exchange rates as well as from translation of statements of profit or loss from average rates to the exchange rates at the reporting date are recognized in other comprehensive income. Similarly, exchange rate differences arising from changes that have been made directly in a foreign subsidiary&#8217;s equity are recognized in other comprehensive income.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_425069b6-592c-48b5-9a66-3b17384bed0a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" escape="true" continuedAt="F_425069b6-592c-48b5-9a66-3b17384bed0a_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Commercial Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue is recognized when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue is measured at the contractual sales price, reflecting the consideration received or receivable from customers, net of value added taxes, and provisions for a variety of sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales deductions attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements. In addition, goods are principally sold on a &#8220;sale-or-return&#8221; basis, where customers may return products in line with the Company&#8217;s return policy. Sales deductions and product returns are considered variable consideration and are estimated at the time of sale using the expected value method. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net contractual price only to the extent that it is probable that a significant reversal will not occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unsettled sales deductions and product returns are recognized as provisions when timing or amount is uncertain. Payable amounts that are absolute are recognized as other liabilities. Sales discounts and deductions that are payable to customers are offset in trade receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other revenue relates to collaboration and license agreements. When contracts with customers are entered into, the goods and/or services promised in the contract are assessed to identify distinct performance obligations. A promise in the agreement is considered a distinct performance obligation if both of the following criteria are met:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct); and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For collaboration and license agreements that contain multiple promises to the customer, the promises are identified and accounted for as separate performance obligations if these are distinct. If promises are not distinct, those goods or services are combined with other promised goods or services until a bundle of goods or services that is distinct is identified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price in the contract is measured at fair value and reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Under license agreements, the transaction price may include up-front payments, royalty and milestone payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales-based royalty and sales-based milestone income promised in exchange for a license of intellectual property is recognized as revenue at the later of the occurrence of subsequent sale or satisfaction of the performance obligation to which some or all of the royalty or milestone has been allocated. Milestone income related to regulatory activities is included in the transaction price at the point in time that it is highly probable that the applicable milestone criteria is met.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_4" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_425069b6-592c-48b5-9a66-3b17384bed0a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is allocated to each performance obligation according to their stand-alone selling prices and is recognized when control of the goods or services is transferred to the customer, either over time or at a point in time, depending on the specific terms and conditions in the contracts. License agreements, which transfer rights to the Company&#8217;s intellectual property (&#8220;IP&#8221;), are classified as &#8220;right-to-access&#8221;, with revenue recognized over time, or as &#8220;right-to-use&#8221; with revenue recognized at a point in time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale of clinical trial supply is recognized as revenue when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery. Rendering of services is recognized as revenue over the service period as stipulated under the applicable agreement.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57b7ee48-27ea-40e2-942b-ad7667e04e4c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs consist primarily of manufacturing costs, preclinical and clinical study costs and costs for process optimizations and improvements performed by Clinical Research Organizations (&#8220;CROs&#8221;) and Contract Manufacturing Organizations (&#8220;CMOs&#8221;), salaries and other personnel costs including pension and share-based payment, the cost of facilities, professional fees, cost of obtaining and maintaining the Company&#8217;s intellectual property portfolio, and depreciation of non-current assets related to research and development activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research costs are incurred at the early stages of the drug development cycle from the initial drug discovery and include a variety of preclinical research activities in order to assess potential drug candidates in non-human subjects, prior to filing an Investigational New Drug Application (&#8220;IND&#8221;), or equivalent. Research costs are recognized in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development activities relate to activities following an IND, or equivalent, and typically involve a single product candidate undergoing a series of studies to illustrate its safety profile and effect on human beings, prior to obtaining the necessary approval from the appropriate authorities. Development activities comprise drug candidates undergoing clinical trials starting in phase I (first time drug is administered in a small group of humans), and further into Phase II and III, which include administration of drugs in larger patient groups. Following, and depending on clinical trial results, a Biologic License Application (&#8220;BLA&#8221;) or New Drug Application (&#8220;NDA&#8221;) may be submitted to the authorities, to apply for marketing approval, which, with a positive outcome will permit the Company to market and sell the products. Long-term extension trials may be ongoing following submission of a BLA or NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development costs also include product development and pre-commercial manufacturing costs related to development product candidates, and write-downs of inventories manufactured for late-stage development product candidates prior to marketing approval being obtained (pre-launch inventories).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the risk related to the development of pharmaceutical products, the Company cannot estimate the future economic benefits associated with individual development activities with sufficient certainty until the development activities have been finalized and the necessary market approval of the final product has been obtained. As a consequence, all development costs are recognized in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f45de26d-7d7b-456f-90e3-04229251f791" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, General, and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses comprise salaries and other personnel costs including pension and share-based payment, office supplies, cost of facilities, professional fees, and depreciation of non-current assets related to selling, general and administrative activities, including pre-commercial and commercial activities. Selling, general, and administrative expenses are recognized in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_1c3282f2-ff71-4888-9c2f-41cc62d77c6c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" escape="true" continuedAt="F_1c3282f2-ff71-4888-9c2f-41cc62d77c6c_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based Incentive Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based incentive programs comprise warrant programs, Restricted Stock Unit programs (&#8220;RSU-programs&#8221;) and Performance Stock Unit Programs (&#8220;PSU-programs&#8221;) which are classified as equity-settled share-based payment transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_5" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1c3282f2-ff71-4888-9c2f-41cc62d77c6c_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of equity-settled transactions is determined by the fair value at the date of grant. For warrant programs, the fair value of each warrant granted is determined using the Black-Scholes option-pricing model. For RSU-programs and PSU-programs, the fair value of each RSU or PSU granted is equal to the closing share price on the date of grant of the underlying ADS. Any social security contributions payable in connection with the grant or exercise of the warrants are recognized as expenses when incurred. The assumptions used for estimating the fair value of share-based payment transactions are disclosed in Note 7, &#8220;Share-based Payment.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost is recognized together with a corresponding increase in equity over the period in which the performance and/or service conditions are fulfilled (i.e., the vesting period). The fair value determined at the grant date of the equity-settled share-based payment is expensed on a straight-line basis over the vesting period for each tranche, based on the best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for grants that do not ultimately vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where an equity-settled grant is cancelled other than upon forfeiture when vesting conditions are not satisfied, the grant is treated as if it vested on the date of the cancellation, and any expense not yet recognized for the grant is recognized immediately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where the terms and conditions for an equity-settled grant are modified, the services measured at the grant date fair value over the vesting period are recognized, subject to performance and/or service conditions that were specified at the initial grant date(s). Additionally, at the date of modification, unvested grants are re-measured and any increase in the total fair value is recognized over the vesting period. If a new grant is substituted for the cancelled grant and designated as a replacement grant on the date that it is granted, the cancelled and new grants are treated as if they were a modification of the original grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad4c2859-40de-43a1-a745-8a367645ec38" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance Income and Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance income and expenses comprise interest income and expenses, realized and unrealized exchange rate gains and losses on transactions denominated in foreign currencies, fair value remeasurement gains and losses on derivative liabilities, and remeasurement gains and losses on royalty funding liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income and interest expenses are stated on an accrual basis using the principal and the effective interest rate. The effective interest rate is the discount rate that is used to discount expected future cash payments or receipts through the expected life of the financial asset or financial liability to the amortized cost (the carrying amount) of such asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_4115c3e5-9699-4004-9b24-44d5fcdfa046" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" escape="true" continuedAt="F_4115c3e5-9699-4004-9b24-44d5fcdfa046_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognized in the consolidated statement of profit or loss by the portion attributable to the profit or loss for the year and recognized directly in equity or other comprehensive income by the portion attributable to entries directly in equity and in other comprehensive income. The current tax payable or receivable is recognized in the consolidated statement of financial position, stated as tax computed on this year&#8217;s taxable income, adjusted for prepaid tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When computing the current tax for the year, the tax rates and tax rules enacted or substantially enacted at the reporting date are used. Current tax payable is based on taxable profit or loss for the year. Taxable profit or loss differs from net profit or loss as reported in the consolidated statements of profit or loss because it excludes items of income or expense that are taxable or deductible in prior or future years. In addition, taxable profit or loss excludes items that are never taxable or deductible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax is recognized according to the balance sheet liability method of all temporary differences between carrying amounts and tax-based values of assets and liabilities, apart from deferred tax on all temporary differences occurring on initial recognition of goodwill or on initial recognition of a transaction which is not a business combination, and for which the temporary difference found at the time of initial recognition neither affects profit or loss nor taxable income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_6" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4115c3e5-9699-4004-9b24-44d5fcdfa046_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax liabilities are recognized on all temporary differences related to investments in subsidiaries and/or associates, unless the Company is able to control when the deferred tax is realized, and it is probable that the deferred tax will not become due and payable as current tax in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets, including the tax base of tax loss carry forwards, are recognized in the statement of financial position at their estimated realizable value, either as a set-off against deferred tax liabilities or as net tax assets for offset against future positive taxable income. Deferred tax assets are only offset against deferred tax liabilities if the entity has a legally enforceable right to offset, and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax jurisdiction. Deferred tax is calculated based on the planned use of each asset and the settlement of each liability, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax is measured using the tax rates and tax rules in the relevant countries that, based on acts in force or acts in reality in force at the reporting date are expected to apply when the deferred tax is expected to crystallize as current tax. Changes in deferred tax resulting from changed tax rates or tax rules are recognized in the consolidated statement of profit or loss unless the deferred tax is attributable to transactions previously recognized directly in equity or other comprehensive income. In the latter case, such changes are also recognized in equity or other comprehensive income. On every reporting date, it is assessed whether sufficient taxable income is likely to arise in the future for the deferred tax asset to be utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f78fa15-dc73-4116-b38e-dd9deceed093" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill acquired in a business combination is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests over the net identifiable assets acquired and liabilities assumed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortized but is subject to impairment testing at least on a yearly basis. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or group of cash-generating units, that are expected to benefit from the synergies of the combination. Each cash-generating unit or group of cash-generating units to which goodwill is allocated represents the lowest level within the Company at which the goodwill is monitored for internal management purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56b69017-e922-4ee6-80cf-be289d3d5d0f" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Software</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Software assets comprise administrative applications and serve general purposes to support the Company&#8217;s operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development costs that are directly attributable to the design, customization, implementation, and testing of identifiable and unique software assets controlled by the Company are recognized as intangible assets from the time that; (1) the software asset is clearly defined and identifiable; (2) technological feasibility, adequate resources to complete, and an internal use of the software asset can be demonstrated; (3) the expenditure attributable to the software asset can be measured reliably; and (4) the Company has the intention to use the software asset internally. The Company does not capitalize software with no alternative use, or where economic benefit depends on marketing approvals of drug candidates and where marketing approvals have not been obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when the development is complete, and the asset is available for use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Software assets are amortized over the period of expected future benefits. Amortization is recognized in research and development costs, and selling, general and administrative expenses, as appropriate. Expenditures that do not meet the criteria above are recognized as an expense as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_7" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_8"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e05d41d-51cc-4b85-8fc6-7650d453143a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment primarily comprises leasehold improvements, office facilities, and process equipment and tools which are located at CMOs. Property, plant and equipment also includes right-of-use assets. Refer to the separate section &#8220;Leases.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be used in operation. Subsequent costs are included in the carrying amount of the asset or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the assets will flow to the Company and costs of the items can be measured reliably. All repair and maintenance costs are charged to the consolidated statement of profit or loss during the financial periods in which they are incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plant and equipment acquired for research and development activities with alternative use, which is expected to be used for more than one year, is capitalized and depreciated over the estimated useful life as research and development costs. Plant and equipment acquired for research and development activities, which has no alternative use, is recognized as research and development costs when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the acquisition or use of the asset involves an obligation to incur costs of decommissioning or restoration of the asset, the estimated related costs are recognized as a provision and as part of the relevant asset&#8217;s cost, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The basis for depreciation is cost less estimated residual value. The residual value is the estimated amount that would be earned if selling the asset today net of selling costs, assuming that the asset is of an age and a condition that is expected after the end of its useful life. Cost of a combined asset is divided into smaller components, with such significant components depreciated individually if their useful lives vary. Depreciation commences when the asset is available for use, which is when it is in the location and condition necessary for it to be capable of operating in the manner intended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d658731-6dd7-4a5c-b239-6bd4d3d9596a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation is calculated on a straight-line basis, based on an asset&#8217;s expected useful life, being within the following ranges:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"/>
          <td style="width:1.94%;box-sizing:content-box;"/>
          <td style="width:17.824%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Process plant and machinery</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_f6bf6a1b-f211-41ee-89f0-c08633e4506c" contextRef="C_696a9b0f-6d34-4970-b7ae-11c29efc2267" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_9af9c195-2f96-40f6-8803-029d589975f4" contextRef="C_407f4eb6-3395-4dbf-ba53-ec52500920d4" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_b6f6c482-2110-4d7f-974a-f5a5e4de32a9" contextRef="C_e44fd0e7-0d85-4f4b-ad6a-35d537142fea" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_224cb0c5-f055-46bc-8f61-892d85b321fc" contextRef="C_73e96a30-9b6d-4a88-a50d-298076e408f4" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_c5810012-cd89-43a3-8014-8f883036b83a" contextRef="C_baadc1e0-f0c2-4168-8df0-bf220f892569" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_4d8c7d8d-cb6d-43fe-8b69-a31e1fe7db96" contextRef="C_6bd94bcb-874a-40fa-b4c0-feb805cf48ce" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_56e6c990-e1b8-4a9b-8913-6580e5ab2844" contextRef="C_ff216df6-44c5-401c-bf8f-32cde3f221b9" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_e855e0d4-c080-4d43-90c5-68c62b5d251a" contextRef="C_2095e981-5419-41f2-8101-1fb2cbaf9c75" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation methods, useful lives and residual amounts are reassessed at least annually.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment is written down to the lower of recoverable amount and carrying amount, as described in the &#8220;Impairment&#8221; section below. Depreciation and impairment losses of property, plant and equipment is recognized in the consolidated statement of profit or loss as cost of sales, research and development costs or as selling, general, and administrative expenses, as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gains and losses on disposal of property, plant and equipment are recognized in the consolidated statement of profit or loss at its net proceeds, as either research and development costs or as selling, general, and administrative expenses, as appropriate.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_126e0b63-eeb9-4ddb-a249-f70727ef4c75" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" escape="true" continuedAt="F_126e0b63-eeb9-4ddb-a249-f70727ef4c75_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Non-current Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The recoverable amount of goodwill is estimated annually irrespective of any recorded indications of impairment. Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_8" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_9"><div><ix:continuation id="F_126e0b63-eeb9-4ddb-a249-f70727ef4c75_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows, or cash-generating units, which for goodwill represent the lowest level within the enterprise at which the goodwill is monitored for internal management purposes. Prior impairments of non-current assets, other than goodwill, are reviewed for possible reversal at each reporting date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c425f913-afba-4b21-90a5-a749f6f1c923" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories comprise raw materials, work in progress and finished goods. The cost of work in progress and finished goods comprise service expenses incurred at CMOs, raw materials consumed, incremental storage and transportation, other direct materials, and a proportion of manufacturing overheads based on normal operation capacity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories are measured at the lower of cost incurred in bringing it to its present location and condition, and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Cost is measured using the first-in, first-out method. Work in progress and finished goods are measured under a standard cost method that takes into account normal levels of consumption, yields, labor, efficiency and capacity utilization. Production processes are complex, where actual yields and consumptions are sensitive to a wide variety of manufacturing conditions. Standard cost variances are reviewed regularly and adjusted to ensure inventories approximate actual cost of production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If net realizable value is lower than cost, a write-down is recognized as the excess amount by which cost exceeds net realizable value, as part of cost of sales, or selling, general, and administrative expenses, as appropriate. The amount of reversal of write-down of inventories arising from an increase in net realizable value is recognized as a reduction in cost of sales in the period in which the reversal occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing of pre-launch inventories is initiated for late-stage product candidates where manufacturing costs are recognized as inventories. However, since pre-launch inventories are not realizable prior to obtaining marketing approval, pre-launch inventories are immediately written down to zero through research and development costs. If marketing approval is obtained, prior write-downs of pre-launch inventories are reversed through research and development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of inventories is recognized as part of cost of sales in the period in which the related revenue is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80dd7616-a0ea-4991-8666-6387bd13da5b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" escape="true" continuedAt="F_80dd7616-a0ea-4991-8666-6387bd13da5b_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receivables</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receivables comprise trade receivables, income tax receivables and other receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_80dd7616-a0ea-4991-8666-6387bd13da5b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade receivables are classified as financial assets at amortized cost, as these are held to collect contractual cash flows and thus give rise to cash flows representing solely payments of principal and interest. Trade receivables are initially recognized at their transaction price and subsequently measured at amortized cost. Income tax receivables, and other receivables related to deposits, VAT and other indirect taxes are measured at cost less impairment. Carrying amounts of receivables usually equals their nominal value less provision for impairments.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c56c396-d11f-427c-9e84-63f527ee5811" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DescriptionOfAccountingPolicyForPrepaymentsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayments comprise advance payments relating to a future financial year. Prepayments are measured at cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_a2217bc6-2836-4528-b277-b17862f0f529" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" escape="true" continuedAt="F_a2217bc6-2836-4528-b277-b17862f0f529_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities may comprise government bonds, treasury bills, commercial papers, and other securities traded on established markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At initial recognition (trade-date), contractual terms of individual securities are analyzed to determine whether these give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding (&#8220;SPPI-test&#8221;). All marketable securities held at the reporting date have passed the SPPI-test.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_9" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_10"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a2217bc6-2836-4528-b277-b17862f0f529_1" continuedAt="F_a2217bc6-2836-4528-b277-b17862f0f529_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities are initially recognized at fair value at trade-date, and subsequently measured at amortized cost under the effective interest method. Interest income is recognized as finance income in the consolidated statement of profit or loss. Marketable securities are subject to an impairment test to accommodate expected credit loss. Gains and losses are recognized as finance income or expenses in the consolidated statement of profit or loss when the specific security or portfolio of securities is derecognized, modified or impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_a2217bc6-2836-4528-b277-b17862f0f529_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities, having maturity profiles of three months or less after the date of acquisition are presented as cash equivalents in the consolidated statements of financial position, where securities having maturities of more than three months after the date of acquisition are presented separately as marketable securities as current (i.e., those maturing within twelve months after the reporting date) or non-current assets, as appropriate.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59348d6d-b8b7-4a06-b592-2d8e00b7a71c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents comprise cash and on-demand deposits with financial institutions, and highly liquid marketable securities with a maturity of three months or less after the date of acquisition (trade-date). Cash and cash equivalents are measured at amortized cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81015df7-fb6c-48f4-89c8-cdf2a4d10c65" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Allowance for Expected Credit Losses on Financial Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial assets comprise receivables (excluding receivables relating to VAT, other indirect tax and income tax), marketable securities, and cash and cash equivalents. Impairment of financial assets is determined on the basis of a forward-looking Expected Credit Loss (&#8220;ECL&#8221;) model. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and the cash flows expected to be received, discounted by an approximation of the original effective interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For receivables, a simplified approach in calculating ECLs is applied. Therefore, changes in credit risks are not tracked, but instead, a loss allowance based on lifetime ECL is assessed at each reporting date. Lifetime ECLs are assessed on historical credit loss experience, adjusted for forward-looking factors specific to the counterparts and the economic environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For cash, cash equivalents and marketable securities, ECLs are assessed for credit losses that result from default events that are possible within the next twelve months (12-month ECL). Credit risk is continuously tracked and monitored in order to identify significant deterioration. For those credit exposures for which there have been a significant increase in credit risk since initial recognition, an allowance is recognized for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_a0fc228b-087e-4d64-90fc-194389a08821" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" escape="true" continuedAt="F_a0fc228b-087e-4d64-90fc-194389a08821_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The share capital comprises the nominal amount of the parent company&#8217;s ordinary shares, each at a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11aca942-c4d6-419d-947c-28148d862940" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:ParValuePerShare" unitRef="U_DkkPerShare" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_797c87e9-9c7b-4fb9-b402-16b12eba55ef" contextRef="C_7571783b-8274-4446-9034-fc8030ee4785" name="ifrs-full:ParValuePerShare" unitRef="U_EurPerShare" decimals="INF" format="ixt:num-dot-decimal">0.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All shares are fully paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share premium comprises the amounts received, attributable to shareholders&#8217; equity, in excess of the nominal amount of the shares issued at the parent company&#8217;s capital increases, reduced by any expenses directly attributable to the capital increases. Under Danish legislation, share premium is an unrestricted reserve that is available to be distributed as dividends to a company&#8217;s shareholders. Also, under Danish legislation, the share premium reserve can be used to offset accumulated deficits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treasury shares reserve comprise nominal amounts of holding of own equity instruments. No gain or loss is recognized in profit or loss on the purchase, sale, transfer or cancellation of the Company&#8217;s own equity instruments. The treasury shares reserve is part of unrestricted reserves and accordingly, reduce the amount available to be distributed as dividends to the Company&#8217;s shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency translation reserve includes exchange rate adjustments relating to the translation of the results and net assets of foreign operations from their functional currencies to the presentation currency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_10" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_11"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a0fc228b-087e-4d64-90fc-194389a08821_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accumulated reserve of a foreign operation is reclassified to the consolidated statement of profit or loss at the time the Company loses control, and thus cease to consolidate such foreign operation. The foreign currency translation reserve is an unrestricted reserve that is available to be distributed as dividends to the Company&#8217;s shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retained earnings/(accumulated deficit) represents the accumulated profits or losses from the Company&#8217;s operations, including corresponding entries to share-based payments recognized in the consolidated statement of profit or loss. In addition, premiums from acquisition and sale of treasury shares are recognized as part of this reserve. A positive reserve is available to be distributed as dividends to the Company&#8217;s shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef8a8b7b-e00a-47be-b5ad-bd748124f94a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible Senior Notes and Embedded Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible senior notes (&#8220;convertible notes&#8221;) are separated into a financial liability and an embedded derivative component based on the terms and conditions of the contract. The embedded derivative component is accounted for separately if it is not deemed closely related to the financial liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes include an embedded equity conversion option which is not deemed closely related to the financial liability, and initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the convertible notes include a redemption option, which entitle the Company to redeem the notes at a cash amount equal to the principal amount of the convertible notes, plus accrued and unpaid interest. The redemption option is closely related to the financial liability, and not separately accounted for. The initial carrying amount of the financial liability component including the redemption option is the residual amount of the proceeds, net of transaction costs, after separating the derivative component.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transaction costs are apportioned between the financial liability and derivative component based on the allocation of proceeds when the instrument is initially recognized. Transaction costs apportioned to the financial liability component form part of the effective interest and are amortized over the expected lifetime of the liability. Transaction costs allocated to the derivative component are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial liability is subsequently measured at amortized cost until it is extinguished on conversion, upon optional redemption or repayment at maturity. Convertible notes are presented as borrowings, together with the derivative liabilities on the statement of financial position, separately under current liabilities as &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible notes, matures in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f206384b-099e-49e3-abae-88125a2ebb8b" contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea" name="ifrs-full:BorrowingsMaturity"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_f0953ad7-90a2-47fc-9164-5ff46af269e8" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock" escape="true" continuedAt="F_f0953ad7-90a2-47fc-9164-5ff46af269e8_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty funding liabilities relate to the Company&#8217;s contractual obligations to pay a predetermined percentage of future revenue from sale of commercial products until reaching a predetermined multiple of proceeds received, pursuant to the detailed provisions of the capped synthetic royalty funding agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where relevant, royalty funding liabilities are separated into a financial liability and embedded derivative components based on the terms and conditions of the applicable royalty funding agreement. Embedded derivative components are accounted for separately, unless these are deemed closely related to the financial liability. The royalty funding agreements include a buy-out option where the value is dependent on non-financial variables that are specific to the Company. Accordingly, the buy-out option is not accounted for separately as a derivative.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial liability is recognized when the Company becomes party to the contractual provisions of the royalty funding agreement and measured at amortized cost until it is extinguished upon exercising a buy-out option or upon achieving the predetermined multiple of proceeds received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_11" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_12"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f0953ad7-90a2-47fc-9164-5ff46af269e8_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effective interest rate is estimated at initial recognition and takes into account incremental transaction costs and anticipated amount and timing of future cash flows, which further depends on future commercial revenue forecasts and the probability of exercising the buy-out option. The amortized cost is remeasured prospectively when there is a material change in expectations to amount and timing of future cash flows, which will increase or decrease future interest expenses. Remeasurement gain or losses are recognized through the profit or loss as finance income or expenses, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty funding liabilities that are classified as a financial liability are presented as part of borrowings in the statement of financial position.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a41af717-ecfa-44a3-b1e2-00b3b5f2adeb" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" escape="true" continuedAt="F_a41af717-ecfa-44a3-b1e2-00b3b5f2adeb_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Right-of-use Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets are recognized at the lease commencement date, defined as the date the underlying asset is available for use. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets include the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any incentives received. In addition, right-of-use assets also include an estimate of costs to be incurred by the Company in dismantling or restoring the underlying asset to the condition if required by the terms and condition of the lease, if any.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets are presented as part of property, plant and equipment, and depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a41af717-ecfa-44a3-b1e2-00b3b5f2adeb_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lease Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the lease commencement date, lease liabilities are recognized and measured at the present value of fixed lease payments and variable lease payments that depend on an index or a rate, whereas variable lease payments and payments related to non-lease components are excluded. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When interest rates implicit in the lease contracts are not readily available, the present value of lease payments are calculated by applying the incremental borrowing rate of the relevant entity holding the lease. Following the commencement date, the incremental borrowing rate is not changed unless the lease term is modified, or if the lease payments are modified and this modification results from a change in floating interest rates. From the lease commencement date and over the lease term, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in lease term, or a change in lease payments, including changes to future payments resulting from a change in an index used to determine such lease payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities are presented as part of borrowings in the statement of financial position.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da6591ec-5107-4942-9107-db415c29305b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions comprise unsettled sales deductions and product returns regarding revenue from sale of commercial products where amount or timing of payment is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions for sales deductions attributed to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements are recognized when the related sales takes place and measured using the expected value method. Payable amounts for managed healthcare organizations and government programs are generally settled within 180 days from the transaction date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions for estimated product returns are measured according to the contractual sales price based on expected product returns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_12" continuedAt="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_13"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59ac6764-1feb-4b64-94d3-ddd22432958f" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Payables and Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses are measured at amortized cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ee6d313-52e5-414e-ac48-0cf4ce70bcc7" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other liabilities comprise payables to public authorities, short-term employee benefits, and sales deductions. Other liabilities are measured at their net-realizable values.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9017fa76-3da4-4ee7-9854-f2dc10938295" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities comprise deferred income from collaboration and license agreements, where consideration received does not match the individual deliverables with respect to amount and satisfied performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities are measured at the fair value of the consideration received and is recognized as revenue in the consolidated statement of profit or loss when the relevant performance obligation, to which the deferred income relates, is satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e472796-5839-4795-94c4-9d8cfbfd14be" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForCashFlowsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Flow Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cash flow statement shows cash flows from operating, investing and financing activities as well as cash and cash equivalents at the beginning and the end of the financial year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from operating activities are presented using the indirect method and calculated as the profit or loss adjusted for non-cash items, working capital changes as well as finance income, finance expenses and income taxes paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from investing activities include payments in connection with acquisition, development, improvement and sale, etc., of property, plant and equipment, investments in associates and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from financing activities comprise payments related to the capital structure of the Company, including changes in the share capital and treasury shares, and issuance and repayments under the Company&#8217;s borrowing activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency is presented separately from cash flows from operating, investing and financing activities. Cash flows in currencies other than the functional currency are recognized in the cash flow statement, using the average exchange rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents comprise cash and on-demand bank deposits with financial institutions and highly liquid marketable securities with a maturity of three months or less after the date of acquisition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a95b5c20-4b3a-4ecb-be8b-c558924b7b74" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic Earnings per Share (&#8220;EPS&#8221;) is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding. The weighted average number of shares takes into account the weighted average number of treasury shares during the year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_067c898f-4e9d-40ca-b526-9f20efb3b9b0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted EPS is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding adjusted for the weighted average effect of changes in treasury shares during the year, and the dilutive effect of outstanding warrants and convertible notes. If the consolidated statement of profit or loss shows a net loss, no adjustment is made for the dilutive effect, as such effect would be anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1_13"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32f2d378-52b1-406c-91d3-f66409384022" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New IFRS Accounting Standards Not Yet Effective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, the IASB issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;), which replaces IAS 1, &#8220;Presentation in Financial Statements.&#8221; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discontinued operations.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are not expected to be affected by other new or amended standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_a1878bf5-0a06-4e97-929f-6d77a1dc6a28" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" escape="true" continuedAt="F_a1878bf5-0a06-4e97-929f-6d77a1dc6a28_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Significant Accounting Judgements and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the application of the Company&#8217;s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management&#8217;s ongoing revisions of critical accounting estimates and underlying assumptions have not revealed any material impact in any of the years presented in these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes to the application of significant accounting judgements, or estimation uncertainties regarding accounting estimates compared to December 31, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Accounting Judgements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant accounting judgements which have a material impact on the consolidated financial statements are described in the following sections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a1878bf5-0a06-4e97-929f-6d77a1dc6a28_1" continuedAt="F_a1878bf5-0a06-4e97-929f-6d77a1dc6a28_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internally Generated Intangible Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Development of Drug Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IAS 38, &#8220;Intangible Assets&#8221; prescribes that intangible assets arising from development projects must be recognized in the consolidated statements of financial position if the criteria for capitalization are met. That means (1) that the development project is clearly defined and identifiable; (2) that technological feasibility, adequate resources to complete and a market for the product or an internal use of the project can be documented; (3) that the expenditure attributable to the development project can be measured reliably; and (4) that the Company has the intent to produce and market the product. Such an intangible asset shall be recognized if it can be demonstrated that the future income from the development project will exceed the aggregate cost of development, production, sale and administration of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the risk associated with drug development, future income from development projects related to drug candidates cannot be determined with sufficient certainty until the development activities have been completed and the necessary marketing approvals have been obtained. Accordingly, the Company does not recognize internally generated intangible assets at this time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Estimation Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue and Provisions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions for Sales Deductions and Product Returns</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales deductions and product returns are considered variable consideration and constrained to the extent that a significant reversal in the amount of recognized revenue will not occur when the uncertainties associated with the rebate or chargeback item are subsequently resolved, or for product returns, when the products are distributed to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions for unsettled sales deductions and product returns are estimated on the basis of a percentage of sales as defined by individual agreements and contracts, and for government rebates by individual state- and plan agreements. Further inputs to the calculations are based on payer channel mix, current contract prices under eligible programs and current inventory levels in the distribution channels. Inputs to the calculations are subject to estimation and assumptions and are based on historical experience and other factors that are relevant, and which are available at the reporting date. Provisions are adjusted to absolute amounts and recognized as other liabilities when estimated sales deductions are processed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, provisions for sales deductions and product returns were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57609a1b-f0d4-4fed-9e1d-7c6ef6d126ff" contextRef="C_f7c738af-0b0d-4113-8fdf-04db859fac4b" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">99.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9077f46b-4ae1-4291-8cc2-ac73b9e41eda" contextRef="C_eea8b977-0335-4240-bf23-27c15cf887d9" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, as of December 31, 2023. The development in total provisions is disclosed in Note 15, &#8220;Provisions.&#8221; Due to the nature of these provisions, it is not practicable to give meaningful sensitivity estimates due to the large volume of variables that contribute to the overall rebates, chargebacks, product returns and other sales deductions. Provisions are reviewed and adjusted regularly considering contractual terms, regulatory obligations, payer trends, historical experiences and market projections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-based Payment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Compensation Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IFRS 2, &#8220;Share-Based Payment&#8221; requires an entity to reflect in its consolidated statement of profit or loss and financial position, the effects of share-based payment transactions. Warrant compensation costs are recognized as cost of sales, research and development costs or selling, general and administrative expenses, as appropriate, over the vesting period, based on management&#8217;s best estimate of the number of warrants that will ultimately vest, which is subject to uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a1878bf5-0a06-4e97-929f-6d77a1dc6a28_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant compensation costs are measured according to the grant date fair value of the warrants granted. Estimating fair values requires the Company to apply generally accepted valuation models and apply these models consistently according to the terms and conditions of the specific warrant program. Under all warrant programs, the Black-Scholes option-pricing model has been applied to determine the fair value of warrants granted. Subjective judgements and assumptions, which are subject to estimation uncertainties, need to be exercised in determining the appropriate input to the valuation model. These inputs include expected volatility of the Company&#8217;s share price for a historic period equaling the expected lifetime of the warrants, reflecting the assumption that the historical volatility over a period similar to the life of the warrants is indicative of future trends, expected forfeitures and expected lifetime of warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant compensation cost recognized in the consolidated statement of profit or loss was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_871ef596-462b-4878-a561-4bd9f1487402" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:WarrantCompensationCost" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b505e398-1d82-40e1-bd00-2548703135bf" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:WarrantCompensationCost" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e17340af-45a1-41fb-81a4-38f760456cb6" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:WarrantCompensationCost" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022, respectively. Changes to inputs applied to the Black-Scholes option-pricing model could affect the warrant compensation cost. Refer to Note 7, &#8220;Share-based Payment,&#8221; for additional details.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation of Embedded Derivatives</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency conversion options embedded in the convertible notes are accounted for separately as derivative liabilities at fair value through profit or loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value cannot be measured based on quoted prices in active markets, or other observable input, and accordingly, derivative liabilities are measured by use of valuation techniques in the form of the Black-Scholes option-pricing model. Subjective judgements and assumptions, which are subject to estimation uncertainties, need to be exercised in determining the appropriate unobservable input to the valuation model (Level 3 in the fair value hierarchy). This includes volatility of the Company&#8217;s share price for a historic period, reflecting the assumption that the historical volatility is indicative of a period similar to the expected lifetime of the options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the valuation of the derivative liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e60f0a0c-5a78-4507-8d60-9bc601bfd30d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f7ae8477-02c2-4bc2-8628-d02fe9ff863e" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of December 31, 2023. Changes in assumptions relating to these factors could affect the reported fair value of derivative liabilities. Refer to Note 16, &#8220;Financial Assets and Liabilities,&#8221; for additional details.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Measurement of Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amount of royalty funding liabilities is measured according to anticipated future cash flows, which further depends on the amount and timing of future revenue from sale of commercial products. Assumptions that impact the amount and timing of future sale of commercial products are subject to estimation uncertainties, and are subject to a number of factors which are not within the Company&#8217;s control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the carrying amount of the royalty funding liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daf0f68f-b14c-43db-a750-fdf1637680db" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:CarryingAmountOfRoyaltyFundingLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">305.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b95f8f8-2bd4-425b-a9eb-9c0c5fbcc530" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:CarryingAmountOfRoyaltyFundingLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">138.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2023. As of December 31, 2024, royalty funding liabilities comprised two agreements compared with one agreement as of December 31, 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will periodically revisit the anticipated amount and timing of future sale of commercial products and to the extent such amount or timing is materially different from the previous estimates, a remeasurement gain or loss is recognized through the profit or loss as finance income or expenses, as appropriate, which would further increase or decrease future interest expenses. Refer to Note 16, &#8220;Financial Assets and Liabilities&#8221; for additional details.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_38853f9d-37f3-4e16-96e6-06f8cffcdddd" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfRevenueExplanatory" escape="true" continuedAt="F_38853f9d-37f3-4e16-96e6-06f8cffcdddd_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 4&#8212;Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06ffef24-98df-4c96-83c0-621c56e90183" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue has been recognized in the consolidated statements of profit or loss with the following amounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial products</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87108864-907d-43bd-baf4-664b2887ab2b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">225,728</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_babf5f1e-2e04-4bed-a6e6-1b37721715b3" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fd3155a-8d83-4c3a-9ff7-2d2bd8f2db96" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,659</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rendering of services</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcfe28ca-2f2f-444a-b555-6940caf64a73" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:RevenueFromRenderingOfServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,794</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2484612d-828b-4dc2-8b44-73789a885d2c" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:RevenueFromRenderingOfServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,659</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a813170-8a7b-4621-a78a-3423c4dc461d" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:RevenueFromRenderingOfServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,434</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical supply</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b87d217b-f0e3-45fd-bf83-850f1f88da7f" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:RevenueFromClinicalSupply" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,776</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3d0106c-0059-4af7-abd8-4e8f6720e8b3" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:RevenueFromClinicalSupply" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2d16f23-2e56-4cd7-ad25-a76fb496548c" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:RevenueFromClinicalSupply" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,534</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f9d7b92-d38b-4820-8185-351d411efaaa" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:LicenceFeeIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,343</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8b1661c-24a9-4230-8800-a6f203af97a2" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:LicenceFeeIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,077</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_728aa7e4-fdd2-498b-b50d-ad48e3c871a2" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:LicenceFeeIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,547</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b460847-bb12-473e-82bd-0d71086e7ae4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,641</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd1f26bb-b773-4ebd-8a1f-fc9cca2eb1ad" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,718</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43b3e61e-d1de-4ae0-bf87-93e73004d5d1" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,174</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Attributable to</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial customers</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fc288f3-0e43-4690-b9ce-d678d29201d0" contextRef="C_4bdf2506-3db5-4bb3-83af-af102c9194d4" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">225,728</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1c612c5-58a0-46cb-9cdb-4b406932b47b" contextRef="C_13fbb09d-e7fc-4533-b7b0-f7775229adc4" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccb1a605-299b-4bd8-8b1a-1972472d9e10" contextRef="C_a0ccec1e-9a89-4166-b4d2-16f6ff5ce9da" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,659</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration partners and license agreements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95d8906e-57d7-410a-829e-3ec9a6ca55c3" contextRef="C_f2f1dbaf-420a-4683-bcef-b0e869189327" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,913</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c09429f-0826-4aba-a2ef-a16965eb0f29" contextRef="C_4b2b9d36-6d18-4c57-b0cf-ce1f8e06c2d6" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,055</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68dcbc4d-0d04-415e-8f88-f1599c5b29f7" contextRef="C_0872112c-3272-422e-80db-297cf18bfc6c" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,515</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab67e9a5-b3ba-4505-9bdf-d1336d916349" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,641</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7199d30-c7cc-4c3d-8e29-a775f3edcd08" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,718</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6431ac0a-97ae-4e0b-bcbd-1bbea7052730" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,174</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified by timing of recognition</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognized over time</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3962702-f85a-4158-ba2c-c964adb2914b" contextRef="C_27d1c1a3-108e-4619-be6f-517ff8d95133" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,794</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6522671b-6ecb-418d-8c59-8196f32e1d51" contextRef="C_f6aae539-4c18-4dfe-8da2-d2171008ea12" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,659</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53f8b4b9-3ffa-453b-8a68-9de66b40593f" contextRef="C_27f6fcda-5a1b-42d3-b991-c9dc1d11267b" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,434</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognized at a point in time</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a94451be-a323-4b9e-8a6d-47f634e7d496" contextRef="C_b3502041-2bf1-4ab4-81d2-63ddd7dc8027" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">351,847</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9480abcb-c6a8-4cf3-a182-9304305e9208" contextRef="C_d9262209-f85f-4e2f-897d-34d234660e65" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,059</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0bacae8-be13-40f1-a932-d17fc4319311" contextRef="C_a10a1719-791f-4cff-8b86-2f3b720e2290" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5576f5af-3c6e-4574-992b-57c3ef4f09e2" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,641</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cdc84a0-f46e-49eb-b467-7bf8fba2b120" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,718</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a754179-34b9-4593-97d4-f4899b738a94" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,174</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified per geographical area</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba08214c-32b5-4f09-b6e4-9a994af72cd1" contextRef="C_75afca32-d330-4c6c-a9ea-5bd565d35e9c" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,336</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6daf54d1-409b-461e-8cfc-acfe645e0462" contextRef="C_9133c0f6-7b07-41ad-a86d-58e8adc23e5f" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">869</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e87e3dc4-7830-4404-82ff-01ef28886f9c" contextRef="C_809a9649-b6e0-488d-b7e5-4e1442b1f755" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">552</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3083bd66-5f97-4baa-9d3b-4a21eee8dff7" contextRef="C_99536d97-e9f4-4fd6-9215-dd6f7d4b7755" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">233,220</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69cbdfb5-8e6f-42aa-8de7-50e028a45bc9" contextRef="C_b1966962-eeea-4f7a-8501-53f2cca4ab33" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">191,677</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f485fa72-0d20-4ad4-9619-74ed5c16e0ac" contextRef="C_226c442b-8147-46aa-8d42-d133bbb66af0" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,156</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rest of world</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50206a57-94c1-4168-a09f-f33a78b9319d" contextRef="C_8e586c11-342f-42e1-8ae7-79f86b29e744" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,085</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30cacb75-9073-43ea-b22b-b2934e9c2a5c" contextRef="C_59c4cbcd-b4e1-4274-bcd8-37e7ffa78cb7" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,172</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_909c87fa-c029-4886-bd17-dcbffaa72157" contextRef="C_9a3e4976-f3f3-4e99-a326-5bb0cb57fee4" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,466</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_182e1ca6-1b26-41b6-90da-4699c5d0b8f0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,641</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_facaa902-cb69-436d-b693-3e12b75aa319" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,718</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0b9a6ef-c95d-432d-a38d-14a0bff480b8" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,174</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, Denmark, the country of domicile, contributed with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83b14a8a-e5bd-40fe-959c-63db4fad3554" contextRef="C_e223f34a-d64a-4201-8c13-a2f49a7b3064" name="ifrs-full:Revenue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">95.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue.</span></div></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Customers</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6456ce00-4282-4a81-aeea-deb8eae597f3" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfRevenueToCommercialCustomersExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue attributable to commercial customers by product were as follows:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue from commercial products</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SKYTROFA&#174;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c420f07-e9e2-4995-ae14-ef5e0b6000b9" contextRef="C_b27a3e9d-f494-4d9d-bd82-cffda92ba702" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">197,001</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c5af821-d126-4bd8-9128-79ce639a27da" contextRef="C_41772ede-2e6a-48e2-9da6-829133e5685d" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_400dba34-67d6-46a7-b491-daf726c04da6" contextRef="C_056508e0-3110-42be-99e5-6e860f20e4ed" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,659</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">YORVIPATH&#174;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90fff74d-bc4e-49dc-9570-286334ba70af" contextRef="C_334ba08e-f8aa-49c1-ba15-fe73942f5b92" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,727</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue from commercial products</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc28d95b-cad7-4c91-acc7-562f3956358d" contextRef="C_8254a47f-7720-4dbd-860f-ccd3f90e8bcd" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">225,728</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da3659b4-8850-4b27-b354-bbb073c2b886" contextRef="C_58152c33-7510-459f-b8e0-76242c88205c" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_577e775d-99a6-4fe6-958d-9cc172b9d8a2" contextRef="C_d3c3de28-899d-4a79-acfe-c562d328512b" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,659</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sales of SKYTROFA&#174; is primarily sold to specialty pharmacies and specialty distributors in the U.S. market, and to wholesalers and pharmacies in Germany. Revenue from sale of SKYTROFA for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, was negatively impacted by an adjustment to estimates and assumptions for sales deductions of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_768f4a82-8b94-4a1c-8079-ac977e5c45a4" contextRef="C_9e913d68-9472-471d-b85b-01401c7287b6" name="ifrs-full:Revenue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was related to periods prior to January 1, 2024. The adjustment was primarily attributable to a different payer and rebate mix than anticipated, and on which provisions for prior years were based.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, TransCon PTH received marketing approval in the EU and European Economic Area countries and is marketed as YORVIPATH&#174;. In August 2024, TransCon PTH received marketing approval in the U.S. and is marketed in the U.S. as YORVIPATH. The Company began selling YORVIPATH, primarily to pharmacies in Europe in the first quarter of 2024, and to specialty pharmacies in the U.S. in December 2024. In addition, the Company began selling YORIVPATH to distributors in the second quarter of 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5be7abd5-7770-4b7b-9f0e-630636c5a8cf" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:NumberOfCommercialCustomers" unitRef="U_CommercialCustomer" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6b5b1647-8d55-4bb1-9089-f8f4fb684ec3" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:NumberOfCommercialCustomers" unitRef="U_CommercialCustomer" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> commercial customers represented more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7ba60cd-2032-486c-b025-d5e9f3628176" contextRef="C_1cc8cf22-cda6-4602-8545-8e4460115453" name="ifrs-full:PercentageOfEntitysRevenue" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_11333208-6727-4227-bb11-178cf79b761c" contextRef="C_223c5789-12ac-442b-9056-83ed832b3d73" name="ifrs-full:PercentageOfEntitysRevenue" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of sales to commercial customers.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_38853f9d-37f3-4e16-96e6-06f8cffcdddd_1" continuedAt="F_38853f9d-37f3-4e16-96e6-06f8cffcdddd_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Partners and License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue attributable to collaboration partners and license agreements relates to Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;), Eyconis, Inc. (&#8220;Eyconis&#8221;), Teijin Limited (&#8220;Teijin&#8221;) and VISEN Pharmaceuticals (&#8220;VISEN&#8221;). Under the collaboration agreements, the Company also provides various research and development services which are invoiced to collaboration partners. Revenue for these activities is presented as part of &#8220;Rendering of services.&#8221; Employment costs related to these activities are presented as Research and Development Costs in the consolidated statement of profit or loss.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novo Nordisk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Company entered into a research and development collaboration and license agreement (the &#8220;Novo Nordisk Agreement&#8221;) with Novo Nordisk pursuant to which the Company granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products (including Semaglutide) in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases (the &#8220;IP&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Novo Nordisk Agreement includes provisions requiring at least one TransCon Semaglutide product and at least one other TransCon technology-based product to be identified, developed and commercialized in metabolic diseases to maintain certain exclusivities in the field, with additional provisions for cardiovascular diseases. Under the terms of the Novo Nordisk Agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas. The lead program in the collaboration is a once-monthly TransCon Semaglutide product candidate that will initially target obesity and type 2 diabetes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Novo Nordisk Agreement, the Company has the potential to receive total payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46d3d757-fcfe-425d-84ff-9f2f646dee56" contextRef="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce" name="asnd:UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" unitRef="U_EUR" scale="6" decimals="-6" format="ixt:num-dot-decimal">285</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in upfront, development and regulatory milestone payments for the lead program. In addition, the Company has the potential to receive sales-based milestone payments and tiered royalties on global net sales. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e2a336c-9e01-4eca-b6c5-fd8dd3ba7395" contextRef="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce" name="asnd:UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" unitRef="U_EUR" scale="6" decimals="-6" format="ixt:num-dot-decimal">285</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million includes an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a83ef26-8868-40f1-a9d6-7a44dede429a" contextRef="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce" name="asnd:UpfrontFeeForExclusiveLicense" unitRef="U_EUR" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the exclusive license. For each additional metabolic or cardiovascular disease product candidate, the Company will be eligible to receive payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b77cccbd-653e-4668-9459-5b04d47928d0" contextRef="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce" name="asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">77.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in development and regulatory milestone payments. In addition, the Company has the potential to receive sales-based milestone payments and tiered royalties on global net sales. Novo Nordisk agreed to pay royalties for each potential licensed product developed under the agreement that are an escalating tiered, mid-single digit percentage of the annual net sales of such licensed product and are subject to reduction due to patent valid claim expiration, biosimilar product market share, payment made under certain licenses for third party intellectual property and Inflation Reduction Act price negotiations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Novo Nordisk Agreement, the Company agreed to conduct certain pre-agreed early research and development of TransCon product candidates under the collaboration and is eligible to receive cost reimbursement from Novo Nordisk for its performance of such research and development activities under the Novo Nordisk Agreement with respect to such TransCon product candidates. Novo Nordisk is responsible for any other non-clinical and clinical development, regulatory, commercial manufacturing, and commercialization of such TransCon product candidates, and all costs associated with such activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of the Novo Nordisk Agreement, the Company granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. Additionally, the Company granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize GLP-1 receptor products using the TransCon technology for all indications, except for (i) certain pre-agreed rare endocrine indications, (ii) all indications in respect of the eye and adnexa and (iii) all indications in respect of oncology.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the Novo Nordisk Agreement has a royalty term that continues, on a per licensed product and per country basis, until the later of (i) the expiration of the last valid patent claim for any of our patents, joint improvement patents, licensed product patents as well as any improvements made by Novo Nordisk covering the licensed product&#8217;s dosage regimen or target product profile, or (ii) 11 years after the first commercial sale of such licensed product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_38853f9d-37f3-4e16-96e6-06f8cffcdddd_2" continuedAt="F_38853f9d-37f3-4e16-96e6-06f8cffcdddd_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IP comprises the patent protected TransCon technology platform, where future activities do not affect its existing stand-alone functionalities. Accordingly, the IP is classified as &#8220;right-to-use&#8221; licenses, with revenue recognized at a point in time, where the licensee is granted access to the IP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, &#8220;Licenses&#8221; includes revenue of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e0b318b-fccd-4118-82b6-7d406666b3f6" contextRef="C_2fbd9ed0-f949-4f61-a72f-c83438fb93d7" name="asnd:UpfrontPaymentReceived" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">95.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the upfront payment, which is allocated to transfer of the Company&#8217;s intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eyconis</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, a separate company created to develop, manufacture, and commercialize TransCon ophth</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">almology assets globally, together with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f005d91-b9ce-4725-bff7-a4c0fe221e9d" contextRef="C_dc50b8f4-013f-4948-b862-ea14c2c8fd6d" name="asnd:CapitalCommitmentFromInvestors" unitRef="U_EUR" scale="6" decimals="-6" format="ixt:num-dot-decimal">150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally (the &#8220;Eyconis Agreement&#8221;) and received, as consideration, an equity position in the newly formed company. In addition, the Company is eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is expected to provide various research and development services, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, &#8220;Licenses&#8221; includes revenue of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adbcdd90-088d-4f5d-905f-26ad8c393e0e" contextRef="C_a91db531-c49c-48c0-bb87-a56fc4db3411" name="asnd:UpfrontPaymentReceived" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the non-cash upfront payment through an equity position in Eyconis, adjusted for internal profit, which is allocated to transfer of the Company&#8217;s intellectual property (the &#8220;IP&#8221;). The internal profit relates to the Company&#8217;s share of the non-cash upfront payment which is recognized as part of &#8220;Investments in associates&#8221; and recognized as revenue from &#8220;Licenses&#8221; as the IP is amortized in the associate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e338087-7865-4412-b060-a1da7f6304a6" contextRef="C_c590a703-806b-44d7-bbfc-d91f2b5829c8" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue from royalties or milestones has been recognized under the Eyconis agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Teijin</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company entered into an exclusive license agreement (the &#8220;Teijin Agreement&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with Teijin  for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease (the &#8220;Licensed Products&#8221;) in Japan. Under the terms of the Teijin Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_500d1c97-3fa9-40f3-8fa4-1715014cae46" contextRef="C_3a4c34db-9705-4e82-a924-1e8c85b0d587" name="asnd:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with additional development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fc7a9d5-04ce-4679-9b02-fdcd0622252a" contextRef="C_3a4c34db-9705-4e82-a924-1e8c85b0d587" name="asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">175</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and commercial milestones. In addition, the Company is eligible to receive royalties on net sales of the Licensed Products in Japan, of up to mid-20&#8217;s percent.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the Company will provide clinical and commercial supply, and development services for joint activities, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, none of the Licensed Products have received marketing authorization in Japan. The Licensed Products (the &#8220;IP&#8221;) are patent protected, where future activities do not affect their existing stand-alone functionalities. Accordingly, all three licenses are classified as &#8220;right-to-use&#8221; licenses, with revenue recognized at a point in time, where the licensee is granted access to the IP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023, &#8220;Licenses&#8221; includes revenue of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d2ac3db-a177-454f-a42e-4ef72fb55e33" contextRef="C_49956232-8f1a-430a-8b06-3dce7628da9c" name="asnd:UpfrontPaymentReceived" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">63.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the upfront payment, which is allocated to transfer of the Company&#8217;s IP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01bc20cc-7ef1-4315-95a7-902b4ba0d4c0" contextRef="C_653f32e5-e4d2-4129-866f-b2bb9319ac6f" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue from royalties o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r milestones has been recognized under the Teijin Agreement.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_38853f9d-37f3-4e16-96e6-06f8cffcdddd_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VISEN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the Company entered into three exclusive license agreements with VISEN. Revenue from collaboration partners and license agreements also includes license income, rendering of services and sale of clinical supply under the VISEN Agreements.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5338362-b7bf-4120-9641-251cf8cd6833" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 5&#8212;Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is managed and operated as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27b09533-5086-4636-b51c-2fe72500289c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:NumberOfReportableOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> business unit. Accordingly, no additional information on business segments or geographical areas is disclosed apart from revenue on geographical areas as disclosed in Note 4, &#8220;Revenue.&#8221; Revenue is specified on geographical areas according to the location of the customer.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55837abe-3d05-4c56-905c-4a95dad77645" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s intangible assets and property, plant and equipment located by region are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intangible assets and property, plant and equipment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa2dca79-f11c-4eb0-a55e-cfc987c5b8ed" contextRef="C_b1595989-ee89-44d6-aafc-6d121568fc57" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,640</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f90b4e9-624c-4747-b8bf-fa9904dc08fa" contextRef="C_39ca7b17-a1b7-43d1-90e6-efe3a598d636" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,464</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df1a8e56-bd35-4839-abde-c23921b89fc0" contextRef="C_4f865b62-7fe6-48cb-a856-16fdbcba2ac2" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,102</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_070a2daf-2a68-4d78-ab83-e22a4e2680bd" contextRef="C_b47e07a7-681a-4a20-87be-95dd4075cfa3" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,589</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total intangible assets and property, plant and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36a31f2c-3f7d-4f4e-803f-da0823a9153d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a41c8c0-8167-4780-8cd8-a38c616f31ef" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,053</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_ad99817b-a41d-42b8-9f90-df4b869212dd" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, intangible assets and property, plant and equipment of &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ac9e3a5-58fd-43bb-8ede-7542a1b41d0d" contextRef="C_f1426637-e196-44bf-aad5-b8473714e9cd" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff10d4cd-b988-4f3f-9957-d613695a3b36" contextRef="C_860b08a9-36e4-40f6-9b25-30137702ac03" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, is located in Denmark, the country of domicile.</span></ix:footnote></div></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_d998943d-59df-4e5b-b8ed-4ffec6f27d72" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" escape="true" continuedAt="F_d998943d-59df-4e5b-b8ed-4ffec6f27d72_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 6&#8212;Employee costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20a67704-2a79-4391-af6a-9ff0f50b9dd3" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Employee costs</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17780eab-30e9-430a-acf5-cc5c7007b3f4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,474</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1edb3c4b-9d19-42e9-a21b-5a3a528a4ae9" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,278</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c10452c-c66e-468b-a4dc-842cae2ce577" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,420</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77b90780-2ea5-4988-9247-c906891493f5" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,512</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48b218f7-7d39-460e-801b-e57b36d0c05a" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,660</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bd1cebf-4027-4cb7-ae52-fbaf26ce4540" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,180</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pensions (defined contribution plans)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d93071a-b4f3-4b04-9355-527d55a1f9e9" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,485</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83381a8c-3aa6-4660-84ca-27471093950f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,403</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70fbecf1-a6be-4e60-872a-479e9b0fad2b" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,163</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04ddf0e1-2cd5-45bb-b6a7-382d1f6a119d" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:SocialSecurityContributions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,003</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7475657-5be7-4dfe-8ca9-8e7f738f4339" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:SocialSecurityContributions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,877</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f90ce80-959b-4ce7-a5cb-605fd2fdfd62" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:SocialSecurityContributions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,627</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other employee costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4207304f-501e-4261-af7a-7e9d127a30df" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:OtherEmployeeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,061</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c40d5750-1385-4725-9c0c-cc9c6b0caa1a" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:OtherEmployeeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,238</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e6c43dc-e9f3-427b-9114-1a494ce9b894" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:OtherEmployeeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,411</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total employee costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdc24f3e-4f8a-44eb-b749-1a7182d09bab" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,535</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00c918d9-8f26-4382-bc0e-768bbb0163df" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,456</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50828be3-01a5-4572-8323-033c41a3424e" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">223,801</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Included in the profit or loss</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bb38e6f-8ad0-4e43-bc60-8e56d265fef5" contextRef="C_4bf7540e-9443-41e7-a47a-27a0973802ce" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,487</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2739aa89-eb38-4b4e-abd2-a4b6bc4e38c2" contextRef="C_7f3a1b06-4e11-46ed-92ce-904b7a6a233b" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,748</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96f86056-d2ac-4ccf-bc46-b35bf9c2a855" contextRef="C_01c97f44-492a-483a-8df7-8e652f65a658" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,239</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98c3ca2d-6671-44a9-8873-fb64d5ce1a48" contextRef="C_232653f8-2ada-40f7-9e2c-695fe89927f8" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,867</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2358cbd-d02b-44c6-8c5f-0f14e8a38889" contextRef="C_2177e743-fed9-4015-b87c-ce85408638ea" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">127,002</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7162a24b-8925-490f-97ce-63a6a927debc" contextRef="C_38539fb6-76a9-4121-aee9-0b1245ac6af1" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,581</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f87882b-1d1f-4928-bc32-b9300b7067b9" contextRef="C_d8c37193-f5ce-4085-a584-6f5700a291cb" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">144,181</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e38095c-3cbe-445e-835e-e38a56814c76" contextRef="C_4d1a30fa-1a02-416f-ac4b-3fd4e5452e6b" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,706</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_752288c1-99ac-47ef-a346-d9a0e3451b14" contextRef="C_600ece57-712e-4eef-9dfc-9e4fee4bc4fb" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,981</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total employee costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c67d1c94-3e89-4015-8261-76f5fba291a5" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,535</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec82cf08-1ef9-4b68-8d78-ecabaf1fd1e9" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,456</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f11ee992-3b40-49d4-9a71-4b5d7f70d421" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">223,801</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average number of employees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbb7d2f7-5f11-4474-857e-d333eabf5d11" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AverageNumberOfEmployees" unitRef="U_Employee" decimals="0" format="ixt:num-dot-decimal">892</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0731ef23-5d0e-4459-ba63-7a5f5654b98a" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AverageNumberOfEmployees" unitRef="U_Employee" decimals="0" format="ixt:num-dot-decimal">851</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2a4d3e5-24ee-4732-aa28-b1053b12bdf3" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AverageNumberOfEmployees" unitRef="U_Employee" decimals="0" format="ixt:num-dot-decimal">719</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes employee costs capitalized as part of inventories.</span></div></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key Management Personnel comprises the Board of Directors, the Executive Board and Non-executive Senior Management. Compensation to Key Management Personnel comprises salaries, participation in annual bonus schemes, pensions (defined contributions plans), and share-based compensation. Share-based compensation is elaborated in further details in Note 7, &#8220;Share-based Payment.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_d998943d-59df-4e5b-b8ed-4ffec6f27d72_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c04d5c9-f527-4ea7-9375-caeccc7d73f9" contextRef="C_f960e0c7-e224-43a0-8029-5e940f7b7580" name="asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation to Key Management Personnel included in total employee costs is summarized below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:20.492%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.758%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.758%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.758%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.758%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.758%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.758%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.758%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.758%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.457%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Board of Directors </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Executive Board </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-executive Senior Management</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="34" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR &#8216;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Compensation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef7e37d5-c649-424e-bf1b-47dd3f134ad8" contextRef="C_ebade161-c91e-4828-aa55-97f5b6c7acab" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94d2e8c8-ce48-4130-a708-6500c36300b7" contextRef="C_6e4e8da6-c1ef-49a7-86f8-5273a8cae8d9" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">543</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f9c9bc7-2bf7-4662-b7cf-4daa1374348d" contextRef="C_79b3b481-791c-4f9d-93a9-e3bfa50ce43f" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48a2a9b7-c9ff-4034-bbf0-b0abe37501db" contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,148</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e2f035e-4814-4ad1-b67f-49949627407f" contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,375</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_503b54e1-52e7-425e-8221-0f192b9e545e" contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,809</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6868f7f5-3174-49cf-ae4a-adbf1c5ffd15" contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,286</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f55e36f9-5571-4146-a766-8a3e0a50ca10" contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,673</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9ab1787-0836-4a77-8d62-bd3fd2b277c4" contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06" name="ifrs-full:WagesAndSalaries" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,087</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30305b6c-0a60-4917-ac27-f30aa21d0b77" contextRef="C_ebade161-c91e-4828-aa55-97f5b6c7acab" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,169</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6564b7cb-99a9-4a1e-8808-270d5f0d9472" contextRef="C_6e4e8da6-c1ef-49a7-86f8-5273a8cae8d9" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,276</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a98bca98-b4a3-4289-ac74-6273d8f55c11" contextRef="C_79b3b481-791c-4f9d-93a9-e3bfa50ce43f" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,273</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_736060a9-1a51-410b-8f07-ede78ae34f5d" contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,334</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_703c7aa4-2c45-464d-819f-64b36abcb9da" contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,243</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbaceb2d-7a75-4a01-a5d5-3c8c285b5c4b" contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,392</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6167149b-af7c-4803-8ccf-742b9dc00ee3" contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,266</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae5df323-3c0c-455d-846f-f7605ce6bd92" contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,529</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef5a653a-9539-497c-805c-2e1258c3b7fe" contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,872</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pensions (defined<br/>&#160;&#160;&#160;contribution plans)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ffddfcf-317f-4e79-83ab-f5a61d62f8fa" contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_910b8dd9-3a44-4f99-9f91-a79e5cf451d4" contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_326dbd0f-4d49-4d09-8848-7af6f340d62d" contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e32ed6db-015a-470e-b0ef-bb73d7dad794" contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe480680-db81-425c-b94b-af822a63aecb" contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3329ffa7-5b95-4fd3-9cac-034801e6eb3d" contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4509718e-a793-4ac9-a1df-f1b1c7e4cd70" contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2" name="ifrs-full:SocialSecurityContributions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00b3680d-4200-4565-8075-297685ab55ef" contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca" name="ifrs-full:SocialSecurityContributions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfd70616-fd8e-4c52-8cf7-39ed0e96b11d" contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb" name="ifrs-full:SocialSecurityContributions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9302859-1f3e-4f7c-9a6d-5751ac199883" contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2" name="ifrs-full:SocialSecurityContributions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b750365d-0d04-4135-acc7-6ed61feb4732" contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c" name="ifrs-full:SocialSecurityContributions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d88b47c-c48d-43d3-b15f-70ce55d9c5a1" contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06" name="ifrs-full:SocialSecurityContributions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other employee cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60288b5c-14d8-485c-bcaa-b77953f0fbe2" contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2" name="ifrs-full:OtherEmployeeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db872c03-4fc8-402e-988f-f83e819f55cd" contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca" name="ifrs-full:OtherEmployeeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_370ff9e7-68e4-4356-866d-4ca2d668b7be" contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb" name="ifrs-full:OtherEmployeeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbe53da4-91e1-42b6-8d0d-c1d651547bd6" contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2" name="ifrs-full:OtherEmployeeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baebdb09-e9d5-4037-ad71-b6de8389baf3" contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c" name="ifrs-full:OtherEmployeeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2bb8e0e-e19a-4de5-9c64-f1f0a57f04f9" contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06" name="ifrs-full:OtherEmployeeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1efdfc72-f442-41bc-b30f-ab52d0b75f32" contextRef="C_ebade161-c91e-4828-aa55-97f5b6c7acab" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,651</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e50a71ae-b75b-4c8c-b322-75891449c296" contextRef="C_6e4e8da6-c1ef-49a7-86f8-5273a8cae8d9" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,819</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6768a265-6cb5-4de4-9f5d-f585b7daf965" contextRef="C_79b3b481-791c-4f9d-93a9-e3bfa50ce43f" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,676</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1665f3b-21ed-42c3-9627-1c2279ea71c8" contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,677</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8145a482-69b1-4a61-9738-aabe1ca4fe89" contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,795</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72c53c28-0ad6-4e53-972e-80ec6f3586b2" contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,322</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baae491f-1c32-4d2e-9e60-27ae9de923bc" contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,727</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2af5c9f1-2f70-4014-93bf-789e47677e3c" contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,409</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38dd210f-59c3-4bbc-aa65-fdab9983e126" contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06" name="ifrs-full:EmployeeBenefitsExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,211</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors comprised six persons in 2024 and six to seven persons in 2023 and 2022.</span></div></div><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Board comprised four persons in 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_20b219b8-3bc9-468f-a949-b49f9be168a9" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" escape="true" continuedAt="F_20b219b8-3bc9-468f-a949-b49f9be168a9_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 7&#8212;Share-based Payment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an incentive to the senior management, other employees, members of the Board and select consultants, Ascendis Pharma A/S has established warrant programs, a RSU program (adopted in December 2021), and a PSU program (adopted in February 2023), which are all classified as equity-settled share-based payment transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to members of senior management, certain other employees and certain members of the Board (&#8220;RSU-holders&#8221;) in accordance with the Company&#8217;s RSU Program adopted in December 2021. Further, RSUs may be granted to select consultants. One RSU represents a right for the RSU-holder to receive one ADS of Ascendis Pharma A/S upon vesting if the vesting conditions are met or waived by the Board at its discretion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to certain members of senior management (the &#8220;PSU-holders&#8221;). In addition, PSUs may be granted to other employees, select consultants and members of the Board. PSUs were granted for the first time in March 2023. One PSU represents a right for the PSU-holder to receive one ADS of Ascendis Pharma A/S upon vesting if the vesting conditions are met or waived by the Board at its discretion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vesting Conditions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs granted vest over a predetermined service period, and accordingly require RSU-holders to be employed, or provide a specified period of service (&#8220;service conditions&#8221;). RSUs vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_810881da-5df9-4e31-b7d8-9518dab9b842" contextRef="C_df13e31f-e944-44b8-beee-0157e82a5356" name="asnd:SharebasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with 1/3 of the RSUs vesting on each anniversary date from the date of grant. RSUs generally cease to vest from the date of termination of employment, or for the Board, termination of board membership, whereas unvested RSUs will lapse.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One PSU represents a right for the PSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting. PSUs vest in a manner similar to the service conditions of the RSUs. For the March 2023 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of performance-based targets as determined by the Board, provided that no more than 10% of each tranche may be directly attributable to accomplishment of financial results achieved in the financial year prior to the vesting date. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c39a83c-f235-4649-a3c1-c2d7fab314f2" contextRef="C_772d30eb-6104-4b18-9139-ee54a0993371" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the March 2024 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than 100%, nor will it result in additional grants.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_20b219b8-3bc9-468f-a949-b49f9be168a9_1" continuedAt="F_20b219b8-3bc9-468f-a949-b49f9be168a9_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs and PSUs generally cease to vest from the date of termination of employment or board membership, as applicable, whereas unvested RSUs or PSUs will be forfeited. The Board may at its discretion and on an individual basis decide to deviate from the vesting conditions, including deciding to accelerate vesting in the event of termination of employment or board membership, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Settlement Options</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All RSUs and PSUs are settled at the time of vesting by transfer of treasury shares that are ADSs repurchased in the market. In jurisdictions where the Company is required to withhold and settle tax with the tax authority on behalf of the RSU/PSU-holders, the Company withholds the number of RSUs or PSUs that are equal to the estimated monetary value of the RSU/PSU-holders tax obligation from the total number of RSUs or PSUs that otherwise would have been transferred to the RSU/PSU holder upon vesting. These settlements are presented as &#8220;Net settlement under stock incentive programs&#8221; in the consolidated statement of equity. The Company may at its sole discretion choose to make a cash settlement instead of delivering ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adjustments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU-holders and PSU-holders are entitled to an adjustment of the number of RSUs or PSUs granted, in the event of certain corporate changes, including among other events, increases or decreases to the share capital at a price below or above market value, the issuance of bonus shares, and changes in the nominal value of each share. In addition, the RSU and PSU Programs contain provisions to accelerate vesting, or compensate with grant of new equity instruments, in the event of restructuring events including change in control events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU and PSU Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_118528ea-a148-43ed-aa84-7a86629d20bc" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number of RSUs and PSUs granted and outstanding:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd429f82-6aad-4c41-a89f-222e90e87902" contextRef="C_0f2a0f3d-caa6-4b26-aaab-9aaaa98975ed" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">148,148</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c0a4b88-deff-4f99-ad72-aef3b62b8d7e" contextRef="C_2c4ca528-c486-4e2a-a517-ae7410edc2c0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">148,148</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c559a2ba-e4cc-4ca6-9082-2394c06484d6" contextRef="C_13311653-2a29-4400-a0d0-0f4bd2ca8d98" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">41,685</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b138b2c2-d880-4530-b592-00d610ac1ce0" contextRef="C_1a2f2ecc-ca46-4afb-a7cd-7481a3e39b7c" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">41,685</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35e534ba-6388-49e0-b734-508579919ff3" contextRef="C_13311653-2a29-4400-a0d0-0f4bd2ca8d98" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">23,971</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c307eca2-b1bd-4e9e-b3b7-d9b25e01b5da" contextRef="C_1a2f2ecc-ca46-4afb-a7cd-7481a3e39b7c" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">23,971</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_540b8f57-bff2-4627-848a-846ec662d3c8" contextRef="C_c4078876-b7b4-4937-95c6-d2ea84904d2b" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">82,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5285beb-688e-45bd-a1b1-836de57168d5" contextRef="C_7f2fe9bf-d689-489c-be69-cbf182477f84" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">82,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3996c24c-6b16-4842-81b6-af4cebffe75c" contextRef="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">609,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7b5ca71-6010-41fc-8ce3-dae554024e83" contextRef="C_eaa235d8-4b02-4581-b70a-16400278b006" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">112,268</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c2e8889-a568-4252-bafd-32584f66d7b9" contextRef="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">722,128</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Settled during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_723f2d26-f1aa-440a-b488-6c3947ce3af9" contextRef="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f" name="asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">18,132</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce8a0d39-34c1-4bf9-af92-d4962bad4812" contextRef="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747" name="asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">18,132</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51f2ca4a-26b1-4209-ba2d-ddd9aa8bd03e" contextRef="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">20,098</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45ccaa42-6cb2-4d4c-b47b-6be6628e7f79" contextRef="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">20,098</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e0e3021-9768-4d6e-85fc-2c7d21db6131" contextRef="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">77,497</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48362209-4337-44a0-a34c-f6de99e30a02" contextRef="C_eaa235d8-4b02-4581-b70a-16400278b006" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">7,245</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6b0e219-12ef-4dc0-be3d-da9305740003" contextRef="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">84,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86f0c31e-a235-4f40-8fe8-af3ded936e45" contextRef="C_3cc100f5-a109-47f1-b3b1-58aae09fcce4" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">576,625</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_524b5811-7556-43cc-8d3e-3fe983ea2ed7" contextRef="C_da8aec68-6586-4ef6-93e5-b5045f7afa40" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">105,023</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca249f1a-cf6e-403e-90d3-63581a9156bb" contextRef="C_ede99a4e-c051-431e-8269-8505ec9267f7" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">681,648</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63bbd27a-1593-4b1b-bba4-f64bb27db432" contextRef="C_df13e31f-e944-44b8-beee-0157e82a5356" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">717,980</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3835b3d1-9ee0-46de-a5d3-adc0887c8bd3" contextRef="C_772d30eb-6104-4b18-9139-ee54a0993371" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">92,655</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc43082c-0ad3-4321-b91a-0be69a3a78a7" contextRef="C_ff4b86e7-7c5f-4451-a272-76662d19dc47" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">810,635</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1337f04-94c0-4056-a696-5dbdabd12c88" contextRef="C_df13e31f-e944-44b8-beee-0157e82a5356" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">212,160</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfc4e683-bb8e-42f2-866a-63e8cc16c281" contextRef="C_772d30eb-6104-4b18-9139-ee54a0993371" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">35,007</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b8945bb-0511-4277-a40b-b3ff139690ee" contextRef="C_ff4b86e7-7c5f-4451-a272-76662d19dc47" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">247,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64f8f47e-bfb5-4c56-bd69-6fba50a59567" contextRef="C_df13e31f-e944-44b8-beee-0157e82a5356" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">88,638</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bcf8d3d-8056-40d7-95d3-86ab9babdf97" contextRef="C_772d30eb-6104-4b18-9139-ee54a0993371" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">6,004</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2615b6d7-fc34-43e6-a49e-07271dee648f" contextRef="C_ff4b86e7-7c5f-4451-a272-76662d19dc47" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">94,642</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51f40a66-5a76-45c6-9930-1c189d278bd5" contextRef="C_c85c746c-f722-410b-b4c5-502ed85c8382" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">993,807</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feac66df-d83d-4086-8e1a-f5a0ce8b2e11" contextRef="C_2d560ff6-c2e3-4c74-9daf-9f9c9310753d" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">156,667</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d808615-7324-4632-ae74-ed91b23768ba" contextRef="C_8cdbb2f3-5894-447e-9e13-0a00148c6b78" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,150,474</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified by vesting date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b2ade5a-b53c-4f03-8059-e2777ae95311" contextRef="C_fc853c6b-d56e-49d4-8dc9-d729edce2941" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">384,098</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2709d42a-888c-4e57-8a4d-008cb70890c9" contextRef="C_e25082d1-732f-40fe-9427-652d8be5beee" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">62,304</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58f98ba1-5ee2-4e64-92b9-045efdfca2ba" contextRef="C_1023a06c-46a7-4e4f-9c42-a6c64923b098" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">446,402</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41dce36d-fd8b-4cfd-bda2-f799b10a9f87" contextRef="C_28fafa94-b070-4d32-863b-5393bdb99f92" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">384,438</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bdcf669-dfb9-4a40-8dec-dbe431d875d4" contextRef="C_207ec930-b486-406c-b0ae-aba7cbf1c9d1" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">63,478</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1e10932-a811-4599-b192-7a5e10de6f0c" contextRef="C_12093c28-729f-40fc-bcf0-fb862cb3c696" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">447,916</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_921ed569-6cb0-402c-a2a4-c7d71d408efa" contextRef="C_6f53dfac-7f4f-46ee-9afc-402949c6590a" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">225,271</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81490454-226d-4e77-af82-2f4ce8653679" contextRef="C_bb236f3a-aca3-4607-b4e7-a59b9fc6910f" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">30,885</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54031dc9-987a-4dc2-8bd5-218a0a07052b" contextRef="C_560f9631-6b06-4d31-b7a4-554f86183c74" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">256,156</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d01abc30-7693-4fb3-a0e9-8d9749b64a57" contextRef="C_c85c746c-f722-410b-b4c5-502ed85c8382" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">993,807</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ba60db4-76f6-419d-9a7b-21a5432b82fc" contextRef="C_2d560ff6-c2e3-4c74-9daf-9f9c9310753d" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">156,667</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bce7237d-93e2-41a8-a8d6-017b85849060" contextRef="C_8cdbb2f3-5894-447e-9e13-0a00148c6b78" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,150,474</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of RSUs and PSUs is determined on the basis of the closing ADS price on the grant date. The fair value of one RSU and one PSU at the date of grant was &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c55a417c-abef-463f-825f-b391acd8ac8b" contextRef="C_8cdbb2f3-5894-447e-9e13-0a00148c6b78" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" unitRef="U_EUR" scale="0" decimals="2" format="ixt:num-dot-decimal">141.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_342e2dd1-4233-4513-baea-7776289621c5" contextRef="C_ede99a4e-c051-431e-8269-8505ec9267f7" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" unitRef="U_EUR" scale="0" decimals="2" format="ixt:num-dot-decimal">105.96</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. </span></div></div></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_20b219b8-3bc9-468f-a949-b49f9be168a9_2" continuedAt="F_20b219b8-3bc9-468f-a949-b49f9be168a9_3"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board and select consultants (&#8220;warrant-holders&#8221;). Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d86fbb41-4cc6-4e55-9ce3-d6ed99a911e5" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:ParValuePerShare" unitRef="U_DkkPerShare" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The exercise price is equal to the fair market value of the Company&#8217;s ordinary shares at the time of grant as determined by the Board. Apart from exercise prices, exercise periods and vesting conditions for board members, the programs are similar.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vesting Conditions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants granted vest over a predetermined service period and require warrant-holders provide a specified period of service. Warrants generally cease to vest from the date of termination. For warrants granted until November 2021, special vesting conditions apply in the event of termination. In relation to board members, the vesting shall cease on the termination date of the board membership regardless of the reason. In relation to consultants, the vesting shall cease on the termination date of the consultancy relationship. The warrant-holder will, however, be entitled to exercise vested warrants in the exercise periods after termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the employment contract is terminated, and the employee has not given the Company good reason to do so, the warrant-holder may keep the right to continued vesting and exercise of warrants as if the employment was still in effect. In such case, any expense not yet recognized for the outstanding warrants is recognized immediately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants Granted Until November 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants granted from 2012 until November 2021, generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e22198e9-7e4c-4016-97f8-457bee947acc" contextRef="C_1668bba6-5e09-4a0b-b002-c5fc87f94355" name="asnd:SharebasedPaymentArrangementVestingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months with 1/48 of the warrants vesting per month from the date of grant. However, effective from January 2015, certain warrants granted to board members vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19dff4a8-4204-4c3d-bba3-be93a2fc4710" contextRef="C_7d04bb96-8341-4c18-bd8d-f80c0f0f0430" name="asnd:SharebasedPaymentArrangementVestingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months with 1/24 of the warrants vesting per month from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants Granted From December 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For warrants granted to employees and consultants, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ede5487e-a90e-4194-93be-2f201c4615a2" contextRef="C_3661dd57-860c-4ba7-8646-271ddab5954a" name="asnd:PercentageOfWarrantsVested" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the warrants vest one year after the date of grant, and the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b410772f-1811-46e9-bee7-a62b64b5a9e7" contextRef="C_13fd56c8-1e8b-413f-83b9-57936192571d" name="asnd:PercentageOfWarrantsVested" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the warrants granted vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca166389-2615-424a-8455-9c39a27d84ed" contextRef="C_2fbbee2c-6ce9-4cf9-b0ca-0215da8f8db4" name="asnd:SharebasedPaymentArrangementVestingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, with 1/36 of the warrants vesting per month, from one year after the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For warrants granted to board members upon the board members accession, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2dac54e-eea7-469c-b622-248b03b81aa5" contextRef="C_802fb420-5428-493a-87b7-02e34b108386" name="asnd:PercentageOfWarrantsVested" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the warrants granted vest one year after the date of grant, and the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ba466a0-132b-48ae-bf51-3ee4be679ee1" contextRef="C_0ec0d4cb-d376-4f19-aa95-a67c8572996a" name="asnd:PercentageOfWarrantsVested" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the warrants granted shall vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ff50c50-ba0b-43f4-9598-5376f6af6889" contextRef="C_2fbbee2c-6ce9-4cf9-b0ca-0215da8f8db4" name="asnd:SharebasedPaymentArrangementVestingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, with 1/36 per month from one year after the date of grant. Regarding subsequent grants of warrants to board members, 50% of the warrants vest one year after the date of grant, and the remaining 50% of the warrants vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91dee683-e581-48fb-8d0b-bcaeb8a118aa" contextRef="C_a75c561c-801d-4844-bed5-502cc157a1d6" name="asnd:SharebasedPaymentArrangementVestingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, with 1/12 per month from one year after the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exercise Periods</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vested warrants may be exercised during certain exercise periods each year, within certain periods after publication of earnings data of a fiscal quarter, interim and annual reports, as per each program&#8217;s terms and conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants expire ten years after the grant date. Warrants not exercised by the warrant-holder during the last exercise period shall become null and void without further notice or compensation or payment of any kind to the warrant-holder. If the warrant-holder is a consultant, advisor or board member, the exercise of warrants is conditional upon the warrant-holder&#8217;s continued service to the Company at the time the warrants are exercised. If the consultant&#8217;s, advisor&#8217;s or board member&#8217;s relationship with the Company should cease without this being attributable to the warrant-holder&#8217;s actions or omissions, the warrant-holder shall be entitled to exercise vested warrants in the pre-defined exercise periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adjustments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant-holders are entitled to an adjustment of the number of warrants issued and/or the exercise price applicable in the event of certain corporate changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_20b219b8-3bc9-468f-a949-b49f9be168a9_3" continuedAt="F_20b219b8-3bc9-468f-a949-b49f9be168a9_4"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events giving rise to an adjustment include, among other things, increases or decreases to the share capital at a price below or above market value, the issuance of bonus shares, changes in the nominal value of each share, and payment of dividends in excess of 10% of the Company&#8217;s equity.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c40d47f-4ea1-4baa-9797-c9314b9f7613" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number and weighted average exercise prices of, and movements, in warrants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrants (number)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price (EUR)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2022</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef04634a-1051-4e30-9c0e-764d75c68068" contextRef="C_5268a2fe-772c-411f-b537-63cfb4081aac" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">7,085,073</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26e64ca4-1b2a-45b4-9338-9db401fd728e" contextRef="C_5268a2fe-772c-411f-b537-63cfb4081aac" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">80.30</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1de2e76-a791-48aa-9f17-4974838716fc" contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">357,092</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e849d0cd-8910-43d0-851f-df96fb82d44f" contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">100.40</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e78baea-0acf-4532-8cdc-b5a966fac88e" contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">214,613</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3291bb26-5b6d-4cae-900f-f02445316d2f" contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">21.83</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_220b730e-f484-471c-83bb-9587d980c2e0" contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">363,541</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d277e7fd-8f1c-4667-ba00-bb35e2eb5ac9" contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">123.62</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4e09cd3-d400-473c-9a29-24dd4936b5b4" contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">6,864,011</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad3cf17b-f5f9-4aea-9544-eab5ed748fca" contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">81.30</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at the reporting date</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_835c0f61-8bd1-44a6-abaa-e9961b0cd639" contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf" name="asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">4,972,026</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a56116c-0437-429f-954e-d02c5fc91813" contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf" name="asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">66.34</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee2d879e-25d2-4395-9cb7-2d3d568bfb02" contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">395,275</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5af62a87-f0c0-4015-9500-c4877e1a0c8f" contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">91.07</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a81dad6e-68e4-481b-8f42-3e59c899623c" contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">555,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_434007e6-bbb5-4916-bb24-6660ed411253" contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.76</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec72a136-10e3-4afa-892c-80e92c46a505" contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">180,358</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5633ee27-2933-47a8-8ff9-1eaf10c5aed2" contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">115.79</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb845efe-2914-4c8b-9e89-7a67260f485c" contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">6,523,784</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34f224c5-87ac-4464-a022-d88d20cbd6f5" contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">86.38</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at the reporting date</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_138d3e29-d750-4984-a6e9-f75d51e41b52" contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e" name="asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">5,273,056</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0766bbdc-72c0-41a0-9fb5-cf0d96270bbc" contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e" name="asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">80.02</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8b6fa18-9737-4aaf-a8d9-d8ebd32f5158" contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">504,105</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b02d144-cfb9-4340-b260-8d8c7189fe75" contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">122.48</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08288339-b76e-458f-85d8-4258f3024e30" contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">682,048</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ea5b0ae-4571-4498-af07-edb36293b306" contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">43.35</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7aed783-493e-49df-9cc5-242f58c3c8df" contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">141,719</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37a72288-6873-48b9-9b7f-20e36ebf1b37" contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">107.85</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_528dbb8b-91be-4349-9a4e-b660d13908bb" contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">6,204,122</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff3d834b-29ef-4813-9c2d-f79ef1d88344" contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">93.25</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at the reporting date</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a434181-d85f-4a40-8d8c-8dd56c08ba85" contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca" name="asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">5,226,643</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed373729-6463-4535-9cf3-17d5f46929bf" contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca" name="asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">89.33</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average share price (listed in $) at the date of exercise was &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_134a41c7-052e-41d3-a106-26de0a3c21ee" contextRef="C_88ae6c08-23fb-4240-bf5e-678082269ff6" name="ifrs-full:WeightedAverageSharePrice2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">135.86</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_945f9c74-4e98-4734-89d4-57b3aebd5ebb" contextRef="C_774802a0-e760-4cd3-bbed-f1a84d8730e8" name="ifrs-full:WeightedAverageSharePrice2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">98.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62a6905c-90bf-468d-816b-7f9533abc191" contextRef="C_5ff345a3-c70a-47dc-8ae4-ca0d2489d12e" name="ifrs-full:WeightedAverageSharePrice2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">113.60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. </span></div></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Board was authorized to grant up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43d8a6b0-fdd4-4b9a-a1e8-c5bbf124a186" contextRef="C_1c836450-3243-4763-a839-055b50eb15c7" name="asnd:NumberOfAdditionalSharesAuthorizedToGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,060,116</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional warrants to employees, board members and select consultants without preemptive subscription rights for the shareholders of Ascendis Pharma A/S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3be73c70-9f26-42e2-ac3a-f1235b7d1cf6" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the weighted average exercise prices and weighted average remaining contractual life for outstanding warrants at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 per grant year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding<br/>Warrants (number</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price (EUR)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Life<br/>(months)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted before </span><span><ix:nonNumeric id="F_1d7b699c-fcfd-4281-bdf0-e4bd3558c480" contextRef="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870" name="asnd:YearOfGrantOfWarrants"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2022</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d07295ab-46f7-4442-906f-701ba3f8b251" contextRef="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,185,556</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c1b70be-9dc7-4947-aa34-e52a9fc95972" contextRef="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">89.67</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_0b43bb82-c946-49f5-8c9b-0fc23ff2a020" contextRef="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870" name="asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted in </span><span><ix:nonNumeric id="F_eed99762-5a40-4e61-96f6-52a51493d165" contextRef="C_74e6cf72-5a9f-4f1c-832e-143795728beb" name="asnd:YearOfGrantOfWarrants"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8331eaad-6572-46ab-aaff-572566080a74" contextRef="C_74e6cf72-5a9f-4f1c-832e-143795728beb" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">235,408</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a84ec60f-9b15-4b2d-b244-6b2a8ce96b2b" contextRef="C_74e6cf72-5a9f-4f1c-832e-143795728beb" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">100.71</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_b08b8dfb-7376-4941-8edc-e3fe0e73fc80" contextRef="C_74e6cf72-5a9f-4f1c-832e-143795728beb" name="asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted in </span><span><ix:nonNumeric id="F_4003afe9-cc6b-48fa-9db1-df3441d18c26" contextRef="C_04565d75-339f-4b1f-80d9-f0daababe60e" name="asnd:YearOfGrantOfWarrants"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acf68c77-d887-43b6-a025-7035c2629ea8" contextRef="C_04565d75-339f-4b1f-80d9-f0daababe60e" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">292,648</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1fe946a-7eb2-497c-905d-d1f25186f1a6" contextRef="C_04565d75-339f-4b1f-80d9-f0daababe60e" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">90.66</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_b1fcf230-670b-46f5-bc2f-deeb1332c915" contextRef="C_04565d75-339f-4b1f-80d9-f0daababe60e" name="asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted in </span><span><ix:nonNumeric id="F_b0a914d9-f67d-447a-ab07-c76eac705c6c" contextRef="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2" name="asnd:YearOfGrantOfWarrants"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea359732-1e81-467b-ac09-03b3eb813bf4" contextRef="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">490,510</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49b2b373-7411-4ac5-b451-97e3909e5643" contextRef="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">122.34</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_037351cb-977f-4a1b-ae79-031004c0269d" contextRef="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2" name="asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fa8d84b-05b2-43ba-9b67-d969188c489d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">6,204,122</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95ae42dc-f01c-4a1e-b091-baac648fad80" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">93.25</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_2168776b-645e-479c-8e73-accc299edfcf" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">65</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the exercise prices of outstanding warrants under the Company&#8217;s warrant programs range from &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bad2185-70be-46cf-996e-1e89f4f6e38f" contextRef="C_f0eb7759-5474-4185-9c25-f280c2655d1d" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a07bf01-4328-453a-b058-1bcdeb587603" contextRef="C_06c71b52-a8d3-4d87-bf07-1b59116e44d0" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">145.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> depending on the grant dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The range of exercise prices for outstanding warrants was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7801cb93-3bef-4248-95d6-6b1d456d7e0f" contextRef="C_8d641cf8-4f3e-4466-b341-181115f04c36" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa03ded5-e973-46a7-994f-0874aa357dc4" contextRef="C_a18ad5cb-63e0-41e5-a54d-935b4eed3032" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">145.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f668064c-0b71-437c-b4ec-179459536c63" contextRef="C_5a3d122d-f872-479f-9175-de42cc96d53a" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8e1c22d-767d-486e-9ca9-c97721f93733" contextRef="C_80c10e22-bf47-4313-871c-4161cd400123" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">145.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively. The weighted average remaining life for outstanding warrants was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_136d4754-7b98-4737-968b-ca8a5b7ed366" contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34468979-5a6e-42a0-ad51-fddcc48f8900" contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_20b219b8-3bc9-468f-a949-b49f9be168a9_4"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Compensation Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant compensation costs are recognized in the consolidated statements of profit or loss over the vesting period of the warrants granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant compensation costs are determined with basis in the grant date fair value of the warrants granted and recognized over the vesting period. Fair value of the warrants is calculated at the grant dates by use of the Black-Scholes option-pricing model with the following assumptions: (1) an exercise price equal to the estimated market price of the Company&#8217;s shares at the date of grant; (2) an expected lifetime of the warrants determined as a weighted average of the time from grant date to date of becoming exercisable and from grant date to expiry of the warrants; (3) a risk-free interest rate equaling the effective interest rate on a Danish government bond with the same lifetime as the warrants; (4) no payment of dividends; and (5) an expected volatility using the Company&#8217;s own share price (from 2021).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_77ca3eb3-857c-4f6d-a272-1d7acf72daf7" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" escape="true" continuedAt="F_77ca3eb3-857c-4f6d-a272-1d7acf72daf7_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the input to the Black-Scholes option-pricing model and the calculated fair values for warrant grants in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:38.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.32%;box-sizing:content-box;"/>
        <td style="width:15.82%;box-sizing:content-box;"/>
        <td style="width:1.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.32%;box-sizing:content-box;"/>
        <td style="width:15.82%;box-sizing:content-box;"/>
        <td style="width:1.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.32%;box-sizing:content-box;"/>
        <td style="width:15.82%;box-sizing:content-box;"/>
        <td style="width:2.18%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf6fc039-b379-46ad-a760-3903e7241408" contextRef="C_99479b14-1e7c-41fa-833c-83e794f18d01" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a41aa667-928d-4521-b8dc-b78a4eb3654c" contextRef="C_0a586051-2c0f-41e7-b728-a06658a765b3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">49</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5e020bd-3d47-4755-8881-0d33772088b0" contextRef="C_af95c18d-a439-48f1-b6d9-6b5ef3fa583e" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e55fe025-4ba0-4e24-a352-8d1b058df41b" contextRef="C_5cafe9c3-115f-42e7-b1fe-9c5f8f86ddce" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21d42d0c-8a72-4a12-a9d3-37a5fe4ddfa2" contextRef="C_fe0a0e9b-7ab2-4d20-a211-cbee6ffa77c2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5f11a38-8b9f-494c-8df7-a9c3569a46a6" contextRef="C_99479b14-1e7c-41fa-833c-83e794f18d01" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.71</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14755aad-66ee-45bb-880e-f248bef4583e" contextRef="C_88ae85e5-4346-454d-9c63-a628775940b7" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.57</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9358be8c-fcca-4676-847e-a30d50ea4498" contextRef="C_0a586051-2c0f-41e7-b728-a06658a765b3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bed234fc-6a8b-44e4-8397-07b7a6914a5e" contextRef="C_af95c18d-a439-48f1-b6d9-6b5ef3fa583e" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.97</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4246a26a-ae3d-44fb-85d6-f7451518037c" contextRef="C_5cafe9c3-115f-42e7-b1fe-9c5f8f86ddce" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.08</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">) - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dd37dd4-eb54-4511-816f-e77b8ea30580" contextRef="C_fe0a0e9b-7ab2-4d20-a211-cbee6ffa77c2" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.54</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life of warrants (years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8109e2e-0868-4dbc-ab84-a25d21323d63" contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" unitRef="U_Y" scale="0" decimals="1" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bde3dee-d978-431e-8f38-59bbb0c38b23" contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" unitRef="U_Y" scale="0" decimals="1" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bad96f5-e8b6-47dc-9594-3a52a65dd5c0" contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" unitRef="U_Y" scale="0" decimals="1" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average exercise price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65e9515d-55cd-4f88-aeef-9f51ac9681d7" contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">122.48</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_251836fb-a03d-464f-af26-2036e0ce4dd6" contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">91.07</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c299dc1-ca8b-47b8-af07-7757dc4336a4" contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">100.40</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of warrants granted in the year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_044cb3ee-2a46-43c3-ad7f-8ccd57214c83" contextRef="C_99479b14-1e7c-41fa-833c-83e794f18d01" name="asnd:FairValueOfWarrantsGranted" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">50.86</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d312af18-cd7f-4820-a9e4-7f5920e3eaf5" contextRef="C_88ae85e5-4346-454d-9c63-a628775940b7" name="asnd:FairValueOfWarrantsGranted" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">70.39</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7accb31-2064-4ad6-ac94-e95f0c1387ba" contextRef="C_0a586051-2c0f-41e7-b728-a06658a765b3" name="asnd:FairValueOfWarrantsGranted" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">37.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ce79bdc-3eff-43e0-a195-5e5907562379" contextRef="C_af95c18d-a439-48f1-b6d9-6b5ef3fa583e" name="asnd:FairValueOfWarrantsGranted" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">52.03</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d18b7671-cee7-4f66-a14e-5f10f6e19249" contextRef="C_5cafe9c3-115f-42e7-b1fe-9c5f8f86ddce" name="asnd:FairValueOfWarrantsGranted" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">36.55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af92f1de-c7b7-4f73-b2d6-f39f5f3cf9c0" contextRef="C_fe0a0e9b-7ab2-4d20-a211-cbee6ffa77c2" name="asnd:FairValueOfWarrantsGranted" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">60.85</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_77ca3eb3-857c-4f6d-a272-1d7acf72daf7_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_8efd4cc8-6918-42ba-809b-5c6a30eaeb23" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfAuditorsRemunerationExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8&#8212; Principal Accountant Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fdfd688b-a950-4be6-8d50-d39d00ee2ab0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock" escape="true" continuedAt="F_fdfd688b-a950-4be6-8d50-d39d00ee2ab0_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth, for each of the years indicated, the fees billed by the Company&#8217;s independent public accountants and the proportion of each of the fees out of the total amount billed by the accountants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Principal accountant fees and services</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_332ac5b8-3369-4ae5-9d0f-1ece187cf6a9" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AuditorsRemunerationForAuditServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">811</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f9db992-feb2-4e62-b4b3-8b0ed1fe82aa" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AuditorsRemunerationForAuditServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cb22c4d-a6a7-4c65-9021-75187af946d9" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AuditorsRemunerationForAuditServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">814</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit-related fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33c9155c-3e64-4745-a716-c458397f9a0f" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:Audit-RelatedFees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d016210-0988-4dd5-9c75-8a19c2f31124" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:Audit-RelatedFees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ffed169-7ea7-425b-84ab-bdd6f16b9cb0" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:Audit-RelatedFees" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23912301-9d8f-4b32-9368-454df243cd8b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AuditorsRemunerationForTaxServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_933c35fd-59f6-4f71-94a2-e5b97038dee5" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AuditorsRemunerationForTaxServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96586f91-da55-46a5-86ed-96bf0bb4134d" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AuditorsRemunerationForTaxServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total principal accountant fees and services</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef5cbee4-d853-4cd7-947f-3b1445da2889" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AuditorsRemuneration" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,049</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5ed2f34-e370-439d-a23f-d09e59ad171d" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AuditorsRemuneration" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">861</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdf363b2-e7d0-40cb-8970-d5815d7f2c36" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AuditorsRemuneration" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">952</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_fdfd688b-a950-4be6-8d50-d39d00ee2ab0_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_ca47d807-0807-4ae0-96cd-c49c873d396d" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" escape="true" continuedAt="F_ca47d807-0807-4ae0-96cd-c49c873d396d_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 9&#8212;Tax on Profit/(Loss) for the Year and Deferred Tax</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81367575-ffe4-40d3-b209-a11fb1a553bf" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" escape="true">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.409%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.177999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.177999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.238%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax on profit/(loss) for the year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current tax (expense)/income</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0235cf9-bf99-4cfc-867a-fbdfc01bbb8d" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:CurrentTaxExpenseIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3a6bcaa-dfc6-4e76-b71a-b0a96fd4d16f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:CurrentTaxExpenseIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4518c68-531e-4ae6-8b17-a9927b87cd18" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:CurrentTaxExpenseIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,723</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current tax, adjustments to prior years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9ade824-2cb2-4dcc-bd5d-39fbfc2ff2cd" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22ecf34c-e7d1-4311-9a5a-77bb1447ed21" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,904</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c48f3c51-bcd5-430a-90e7-8ad15301ddb1" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,654</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax, movement for the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30b21268-cc41-4e0e-a018-3dbe9a1d8fe0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DeferredTaxMovementForTheYear" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,035</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e695f93e-f3f1-4005-9c50-c0aa43f2d5be" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:DeferredTaxMovementForTheYear" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,044</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax, adjustments to prior years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3516a93e-47be-4842-a892-fb3eeb1a9747" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">607</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bba59609-e71a-4ac5-8fa7-a8177ea4d47f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_577dae54-cc99-46bd-a6b9-18be8d6f0acc" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,843</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89ce5b13-4284-4253-bcc7-daff427bacd0" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4b1e187-a8bd-4d12-b087-241e74438ff8" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax for the year can be explained as follows</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Profit/(loss) before tax</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd0f3244-3545-4a35-9fd5-a689122eb28c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">373,241</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3181a03-351f-4f07-a3b9-2ea45ac0027c" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">474,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_488c2f63-68dd-4f22-b13b-f93e3a1707cb" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">577,817</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax at the Danish corporation tax rate of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f767655-6a30-4b68-90d3-7cd4f5f057ef" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ApplicableTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c4693cbc-d796-4501-a0d0-30dbe49837d5" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ApplicableTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d701bd29-4f01-4bdf-be3e-dd8add383690" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ApplicableTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1a9f884-cd59-4850-9d88-51448b5ee40b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,113</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0706e2cc-cb1d-4c00-8875-f6ddc82ecea1" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,312</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e87d4dd-8321-4f3d-a7f3-43b4dd38f534" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">127,120</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax effect of:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-deductible costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08560d8b-b422-40b8-a2ed-c11917461627" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dde9f8c-d497-4540-97c0-18597b334370" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,494</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6292afe3-b77a-4306-a668-d200d79ac5f1" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,094</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional tax deductions</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3a228c6-0a2a-416f-a7ec-d60df726c42b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:TaxEffectOfDeductibleItemsNotExpensed" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,161</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e770e330-0f6c-47dd-acd8-bec795a0ef3e" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:TaxEffectOfDeductibleItemsNotExpensed" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,077</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a05f1e4f-9331-470b-9bcd-f69efb827671" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:TaxEffectOfDeductibleItemsNotExpensed" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,720</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impact from associates</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63a22135-0934-4135-b5c9-4ff148846e3b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:TaxEffectsFromImpactsFromAssociates" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,413</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54aeea28-e32a-426a-bf5b-c10650e11d0e" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:TaxEffectsFromImpactsFromAssociates" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,047</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_836ec5f5-08d1-4739-b6dc-dba4e44b640c" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:TaxEffectsFromImpactsFromAssociates" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,893</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prior year adjustments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cc494c4-4f70-49e2-9dbb-6fb9ca3cc6b4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:TaxEffectsFromPriorYearAdjustment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d38d2a8e-7d5a-45d3-a251-eee82d101d2e" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:TaxEffectsFromPriorYearAdjustment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,294</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other effects including effect of different tax rates</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0f821e1-9f06-44a9-99f2-d8d23882bc55" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7049bee-149e-4e47-b698-1afbca037239" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">882</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39a1bff8-ffc8-461d-8847-44a8120ff543" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,716</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax asset, not recognized</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_476aa8e1-8a0d-4545-bfd3-07fff1164941" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:TaxEffectFromDeferredTaxAssetNotRecognized" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76,627</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23d4373a-b869-4b41-b554-c8b16de638ba" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:TaxEffectFromDeferredTaxAssetNotRecognized" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105,975</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40759b54-36c6-4014-8bcf-4e74c8827a2a" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:TaxEffectFromDeferredTaxAssetNotRecognized" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">122,514</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax on profit/(loss) for the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2b2970e-de59-467f-a144-c184aba01e43" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,843</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a6bab66-e4f5-421a-8203-f18c0eea564e" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9bea764-6b92-4e60-9d51-bcfc945a5648" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce49dfe3-31a5-4b47-92a4-9c19a4e45aed" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:AverageEffectiveTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.30</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6232baa7-6106-456c-bc7f-2311c83a3a5d" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:AverageEffectiveTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.54</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27b95e7d-a644-4579-bcef-a82fd015d9f7" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:AverageEffectiveTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.93</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specification of deferred tax assets/(liabilities)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax deductible losses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70046205-e565-4b41-995b-27c2236898a4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:TaxEffectOfTaxLosses" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">434,997</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f682450c-e3ea-4719-977b-e19af205f065" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:TaxEffectOfTaxLosses" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">521,697</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a52136b-1435-435c-aa06-3d176e6cc579" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:TaxEffectOfTaxLosses" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">433,174</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other temporary differences, assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_942cde62-bedf-4812-ab1a-31bfbf9ac191" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,479</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c475c17-cd76-4022-90ce-2d62fe697cdb" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,256</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77e6b607-81c9-4f41-8f67-7bf3b9071d8d" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax asset, not recognized</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a530cd-d877-4a46-aa19-ad1c56673a79" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:DeferredTaxAssetNotRecognized" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">599,476</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ef27c34-8659-42ec-bc63-daf3307f7ac7" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:DeferredTaxAssetNotRecognized" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">537,953</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50b554f6-5bbc-479f-8a06-c5563909e7e6" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="asnd:DeferredTaxAssetNotRecognized" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">453,135</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other temporary differences, liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ca4387f-76f5-4ce6-9567-a7d81f8e992e" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,258</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d953325f-087b-4831-a9b2-d7e539eac9ba" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,830</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total deferred tax assets/(liabilities) at December 31</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ec45740-235a-4438-a41f-6f58329e883d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NetDeferredTaxAssets" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,258</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91db0156-fbf9-4ce3-80c9-9cb03b5ce52c" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NetDeferredTaxAssets" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,830</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, a deferred tax liability has been recognized in relation to taxable temporary differences in one jurisdiction, as we do not believe we will have any deductible temporary differences nor tax losses to deduct the taxable difference in, when they are expected to reverse.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets have not been recognized in the consolidated statements of financial position as of December 31, 2024 due to uncertainty relating to future utilization. The deferred tax asset can be carried forward without timing limitations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had tax losses carried forward of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_65eb8903-09c3-431e-ad72-f4f505fd0943" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:TaxLossesCarryforwards" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">1,946.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c62d199b-55dd-461c-b27e-2618e4cd4297" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:TaxLossesCarryforwards" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">2,371.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at December 31, 2024 and 2023, respectively. Tax losses can be carried forward infinitely, where certain limitations exist for amounts to be utilized each year. Under Danish tax legislation, tax losses may be partly refunded by the tax authorities to the extent such tax losses arise from research and development activities. the jointly taxed Danish entities had a negative taxable income, and accordingly were entitled to a tax refund of approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36ac07b2-aa23-426b-b38e-1d77d57ce6d3" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncomeTaxesPaidRefund" unitRef="U_EUR" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_37be2f60-1e11-4bf8-a82b-e20829eba6bf" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:IncomeTaxesPaidRefund" unitRef="U_EUR" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_337af029-fc5c-4191-ab7e-e8deb8481043" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncomeTaxesPaidRefund" unitRef="U_EUR" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax losses carried forward at December 31, 2023 (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efa190be-e53a-41c6-b3fc-76926ce59b5e" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:TaxLossesCarryforwards" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">2,371.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) has been reduced with &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec6fb294-31c1-4724-b7ab-6395c8794c03" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:DecreaseInTaxLosseCarryForwards" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">456.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The reduction is as a consequence of two changes of tax principles made in the Danish tax returns for the taxable year 2023 (filed in June 2024). The changes are related to R&amp;D costs (depreciations) and inventory write-down (cost price). This reduction in tax losses is still available as deferred tax assets, that can be recognized for future utilization; only not as a &#8220;Tax deductible losses,&#8221; but as &#8220;Other temporary differences, assets.&#8221;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ca47d807-0807-4ae0-96cd-c49c873d396d_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is entitled to additional tax deductions related to share based payments (Warrants, RSUs and PSUs). Tax deductions can be taken when the warrants/RSUs/PSUs are exercised/transferred. For the year ended December 31, 2024, the Company was entitled to additional tax deductions with a tax value of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c235eccc-bc9d-46eb-81ef-a67ec772b9d8" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:AdditionalTaxDeduction" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aae6638b-b3eb-4f66-95c4-b71cf3b964a2" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:AdditionalTaxDeduction" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4695d285-7871-4dcf-8460-7d29206b4a7d" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:AdditionalTaxDeduction" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively. These future tax deductions depend on the timing and amounts of warrants/RSUs/PSUs exercises/transfers, and accordingly, future additional tax deductions are subject to uncertainties. Refer to Note 7, &#8220;Share-based Payment,&#8221; regarding a description of warrant and RSU/PSU programs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is entitled to additional tax deductions for which deferred tax asset cannot be recognized due the initial recognition exception in IAS 12, &#8220;Income Taxes.&#8221; For the year ended December 31, 2024, the Company is entitled to additional future tax deduction with a tax value of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d7a2c55-f448-4ccc-be8b-64006d21a509" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:AdditionalFutureTaxDeduction" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8d89017-917e-412c-889c-7b13be1f9f08" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:AdditionalFutureTaxDeduction" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0fd8997c-ddc8-4629-a1e9-26853229fc34" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:AdditionalFutureTaxDeduction" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023 and 2022. In addition, the Company is entitled to additional tax deductions related to tax credits. Tax credits can be taken in future taxes. For the year ended December 31, 2024, the Company was entitled to additional tax deduction with a tax value of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f706ac5-33d0-4f1b-aae7-bc29035a4d7c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:AdditionalTaxDeductionsRelatedToTaxCredits" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33828218-6e08-4377-8646-46712536f5a1" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:AdditionalTaxDeductionsRelatedToTaxCredits" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a1bdecdb-99a9-48a6-84c2-2db457dc6394" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:AdditionalTaxDeductionsRelatedToTaxCredits" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 23, 2023, the IASB issued International Tax Reform - Pillar Two Model Rules - Amendments to IAS 12 which clarify that IAS 12 applies to income taxes arising from tax law enacted or substantively enacted to implement the Pillar Two model rules published by the OECD, including tax law that implements Qualified Domestic Minimum Top-up Taxes. The Company has adopted these amendments; however, they are not applicable for the year ended December 31, 2024, as the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s consolidated revenue is currently below the threshold of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34725501-e09e-4e29-8bf1-8eed0b805717" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:RevenueThresholdLimit" unitRef="U_EUR" scale="6" decimals="-6" format="ixt:num-dot-decimal">750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Parent Company, Ascendis Pharma A/S, is jointly taxed with its Danish subsidiaries. The current Danish corporation tax is allocated between the jointly taxed Danish companies in proportion to their taxable income (full absorption with refunds for tax losses). The jointly taxed companies are included in the on-account tax scheme.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e55b86ab-fbc7-4bbc-98ef-9011fd8e3e3e" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" escape="true" continuedAt="F_e55b86ab-fbc7-4bbc-98ef-9011fd8e3e3e_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10&#8212;Intangible Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd220e77-4e57-4ab2-99f9-c4d0863f3f99" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Goodwill</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11515938-7c37-4f6c-90c9-b0c14672361b" contextRef="C_f664c695-e007-4c41-b59a-806a6f163104" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,495</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be477638-01f9-43b8-ad36-5f2a6cd661ef" contextRef="C_0dd10c76-089d-41db-b834-45504dc6b09e" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,222</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9613b7d3-d9e9-4b89-9fdd-132a0fccbf60" contextRef="C_fda59e11-28d9-4e33-b9c1-3a2479007ef5" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,717</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1a34101-eccf-4778-bd17-1f85025c4152" contextRef="C_7e7e620d-71e2-4c5d-bea4-731d5ebd213b" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca229de0-dcee-441a-8d04-08556d3cbd51" contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8d3d642-f912-4aa0-83e5-090349f9eaab" contextRef="C_7e7e620d-71e2-4c5d-bea4-731d5ebd213b" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81a9c3cf-437c-4d35-9b41-2dc09f2b1e74" contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6bb0102-ff19-4fad-ac0f-0680ce64d4b9" contextRef="C_ed783084-e2f1-44fb-b106-1b2f859597c7" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,495</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e63ae5c0-e54f-424f-a324-38a8b9d0b659" contextRef="C_8c791550-835c-4e22-a26b-97ea8127f804" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,296</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1a993e5-26ac-475b-87ad-45f61b09efde" contextRef="C_3816caa9-d60e-4738-924c-a8108f43fcb8" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,791</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dad7698-6463-4043-ac0b-d11dd0f5652c" contextRef="C_9952b4f6-b45f-4d1f-886d-8e1f0d262e6f" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff553040-be96-47a0-af41-a03de1df73fc" contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca50b129-e906-43d3-953b-3c9378f2c08c" contextRef="C_feb4fcb6-91c3-427b-a969-26daa054341f" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,495</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec6a3970-aff8-4bdd-9d1f-5f585382c07c" contextRef="C_b8d9ea02-e435-4914-b63c-68ab0e65dc37" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,372</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01d52a82-534a-44dc-b12b-48aeece51f7e" contextRef="C_e06fb832-2f86-4a43-92b1-f2a822f36e49" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,867</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization and impairment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b69a7843-7429-48be-b480-acb048114134" contextRef="C_a9a130e0-614f-4ba0-8504-fd5085a02099" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">889</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74a18080-de7f-43c3-b67e-fc576664772c" contextRef="C_e49c3b45-39cc-414c-9238-0fc9d4cf659d" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">889</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e00ce504-6750-4733-85be-6cadc399baa5" contextRef="C_d388a1d4-7923-4886-87c3-db6a6873ba8b" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">483</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4e29da2-fb15-431c-b089-f5a967cff5a5" contextRef="C_a29fcdf1-c976-4997-a302-2bd939c278f6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">483</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41c7da1f-f25f-43a7-a7cd-c2cad452d637" contextRef="C_aa8178e7-5d8d-4ed1-9503-6b67ad186cec" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,372</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbf978ba-ffac-44e6-a85d-62e133e62e12" contextRef="C_149a0f63-60f1-4bf3-a3df-4dce7568cfc5" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,372</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2494033-d82a-4ded-a2c5-488768c488e6" contextRef="C_5089591b-f114-41f5-b652-8a708640665f" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">467</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00fe9317-8025-4323-b80d-95113663a170" contextRef="C_3566e5f1-2b87-4f68-9039-a9df104b1f9f" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">467</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d684db7a-27c4-49e8-b31d-fead81355ca6" contextRef="C_4ea532ca-6e45-43f5-a284-db382e2c5785" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,839</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ef7925d-cfa6-447f-9540-d0fd903f8427" contextRef="C_7a48f51e-d7c8-4ea7-acf8-8fd05459ee2e" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,839</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee36581b-c1e8-4da4-81fa-a975611c3c4c" contextRef="C_f1f075ea-35d2-48db-b997-3ec5409d09d7" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,495</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ebad9e2-0791-4f3f-a3fe-4dfa0f47aa28" contextRef="C_37e1d239-86ce-49d1-96d5-a76ae721217a" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">924</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f7f0699-4e7d-4e8a-88ce-903af8717d18" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,419</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65eb6a62-56f4-4167-b27b-45371405f012" contextRef="C_a4416a56-3759-43a1-a9b2-a168da37fe04" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,495</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_434f9ca4-c94d-42d7-a9a1-755e1f22cd4d" contextRef="C_09099e4b-a592-4705-af54-4663f508c0b4" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">533</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_972d59c4-6920-462f-be5a-f0a8d3cf30c3" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,028</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the reporting date, no internally generated intangible assets from development of pharmaceutical drug candidates have been recognized. Thus, all related research and development costs incurred for the years ended December 31, 2024, 2023 and 2022, were recognized in the consolidated statements of profit or loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill relates to the acquisition of Complex Biosystems GmbH (now Ascendis Pharma GmbH) in 2007. Goodwill was calculated as the excess amount of the purchase price to the fair value of identifiable assets acquired, and liabilities assumed at the acquisition date. Ascendis Pharma GmbH was initially a separate technology platform company but is now an integral part of the Company&#8217;s research and development activities. Accordingly, it is not possible to look separately at Ascendis Pharma GmbH when considering the recoverable amount of the goodwill. Goodwill is monitored and tested for impairment on a consolidated level as the Company is considered to represent one cash-generating unit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_e55b86ab-fbc7-4bbc-98ef-9011fd8e3e3e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The recoverable amount of the cash-generating unit is determined based on an estimation of the Company&#8217;s fair value less costs of disposal. The fair value of goodwill has been determined after taking into account the market value of the Company&#8217;s ADSs as of the reporting date. The computation of the market value including an estimation of selling costs, significantly exceeded the carrying amount of the net assets, leaving sufficient value to cover the carrying amount of goodwill. Considering the excess value, no further assumptions are deemed relevant to be applied in determining whether goodwill is impaired. </span></ix:continuation></span><span style=""></span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd122e37-3d25-4f11-b9d8-ba7d0ebb79e0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 11&#8212;Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c93e00b-20d4-432c-96c1-383d44277036" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" escape="true">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plant and<br/>Machinery</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other<br/>Equipment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Leasehold<br/>Improve-<br/>ments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Right-of-Use<br/>Assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b80b933c-ddbf-4ec7-b70b-a2ee52ac4a35" contextRef="C_3421ed33-b354-4de8-ba6c-72beee95c70a" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,944</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f5481ca-69e7-4d9d-b36d-cd90e6f85f7e" contextRef="C_6a0a5caa-b991-40a9-a3ec-b387124678ad" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,203</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daca50d7-1747-4c61-9b7a-2c76490bd711" contextRef="C_8d88cc9c-27a2-4ff0-b63b-b1a040391061" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,130</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8359b01-42d7-404c-ab29-9b92012aee69" contextRef="C_09e22d4c-5ff0-4832-b86c-6b6f62d31ccc" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,466</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_078e92c0-6e38-4d94-863c-f9ae2ae949ac" contextRef="C_fda59e11-28d9-4e33-b9c1-3a2479007ef5" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">175,743</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6e9c41c-b356-44d1-8c8b-8ced4b8ba8f2" contextRef="C_7a98677e-a082-47ea-899e-37bc59fd1b58" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,580</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48b9add3-0554-4401-b89a-73df3cf780b3" contextRef="C_ae64dc13-b337-4595-88a9-3361adbfd7eb" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">503</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c773213-ade5-4057-b074-01e97b499bc1" contextRef="C_65837925-044a-445d-bd2b-f455d164b262" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0a93a8e-628d-45ce-890c-e909860ea477" contextRef="C_cfabba9a-1d15-458c-ad60-0eb6d48d0908" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,547</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db5ee9af-0ab7-427d-bc58-9aa07a7f2e96" contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,858</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fe10b0a-2f94-4b46-a8dc-194e5df8f6dc" contextRef="C_7a98677e-a082-47ea-899e-37bc59fd1b58" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">383</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b7c4c20-7cf0-4736-a9d2-a81bdb4af1ca" contextRef="C_ae64dc13-b337-4595-88a9-3361adbfd7eb" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60051caa-9f64-44e8-a197-bc44ad68a3e5" contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">440</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea3454a9-462b-4cd7-9468-6fc85b43d7c4" contextRef="C_7a98677e-a082-47ea-899e-37bc59fd1b58" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">504</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c9d4dbb-ce95-4f14-9b71-ce71a9ecdc60" contextRef="C_ae64dc13-b337-4595-88a9-3361adbfd7eb" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_010280c6-349f-48c1-a556-c2e2daf0b0fb" contextRef="C_65837925-044a-445d-bd2b-f455d164b262" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">504</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b302fba6-4f9c-46ec-a266-03ba5b433359" contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_347c58b9-6e0d-415a-8bf3-00739d0a3f74" contextRef="C_7a98677e-a082-47ea-899e-37bc59fd1b58" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eea5961-f795-4ccc-86d7-12640df296b1" contextRef="C_ae64dc13-b337-4595-88a9-3361adbfd7eb" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">208</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a42209a8-fe07-47e4-a870-1844ab68eecf" contextRef="C_65837925-044a-445d-bd2b-f455d164b262" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">479</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_282dc470-aae2-4c80-a43e-05630830fec1" contextRef="C_cfabba9a-1d15-458c-ad60-0eb6d48d0908" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,093</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feed8e11-4e62-4042-83db-6a1156f5d2d0" contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,989</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba67eea2-6d92-4c1c-ae5f-8b3875ff8ae5" contextRef="C_bbdc53c3-a7cf-4fbe-959f-538eec284f61" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,436</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42cc5337-aa89-4c92-9a2b-0af5415683ac" contextRef="C_2a779f6c-3cd0-4eeb-9e62-6c93f2d9b872" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,420</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c36b3b2-e9ac-44e9-9c3d-6b70734eda95" contextRef="C_064343af-8b3e-4e2a-a81b-a1a721a1cc58" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,375</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b7af9fb-7b44-452d-a376-206e89405f9c" contextRef="C_f7ae32c9-c10e-4691-be89-cfbdb2954133" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,920</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f449e80-4cff-4cc8-b1ac-148f245297b8" contextRef="C_3816caa9-d60e-4738-924c-a8108f43fcb8" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,151</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a85309b-b036-435f-b2b8-9951920e9ed7" contextRef="C_dff571ea-763a-4c63-ae50-c0952c31cb00" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">299</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ea8b50a-495b-48d6-b2c0-77204cf0c5d1" contextRef="C_c34a3e33-ac79-402f-b220-5f595dd5eff5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">951</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeb18678-3191-4062-b926-2f26af390dc2" contextRef="C_edbced58-0020-4b9f-b70b-56ced58a8fef" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2260cbf-750e-4ec1-83ec-5b546d3a28da" contextRef="C_8868a6a4-46c9-401e-8496-50e9fd14cdcf" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">861</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1db6e764-5853-4de4-80c3-16594cdf0ef9" contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,187</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c481ed92-9721-4e1c-8b13-bad0adc45b2a" contextRef="C_dff571ea-763a-4c63-ae50-c0952c31cb00" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,995</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77ee92dc-f5b2-462a-83e2-fd7a16341278" contextRef="C_c34a3e33-ac79-402f-b220-5f595dd5eff5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,635</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_036035ef-afd1-4798-b69d-4aca6a86dea0" contextRef="C_8868a6a4-46c9-401e-8496-50e9fd14cdcf" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce944e0-5b30-413e-a28b-e9c23c743e6b" contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,719</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e04c0db1-8475-4017-b68d-edd595a25c6c" contextRef="C_dff571ea-763a-4c63-ae50-c0952c31cb00" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0e069f2-2eba-4374-95da-f37c6c33d5d6" contextRef="C_c34a3e33-ac79-402f-b220-5f595dd5eff5" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8821711c-9337-4625-84d3-30523357ac49" contextRef="C_edbced58-0020-4b9f-b70b-56ced58a8fef" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d690ff6-4471-4389-937f-ea61f89ddd3a" contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8667992-7c9d-49bc-b32c-d2474b427140" contextRef="C_dff571ea-763a-4c63-ae50-c0952c31cb00" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8df6c64-c136-42b3-b27d-3011ddc69243" contextRef="C_c34a3e33-ac79-402f-b220-5f595dd5eff5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">306</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f420ce8a-cd4a-4dd0-babf-3b0c5ab5e33e" contextRef="C_edbced58-0020-4b9f-b70b-56ced58a8fef" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">847</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bd55621-ea44-4073-a6bd-107948df2d12" contextRef="C_8868a6a4-46c9-401e-8496-50e9fd14cdcf" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,462</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58d81715-9ea1-4692-90cd-817c39c617e7" contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f50e837d-3987-4420-9c81-28c295b51304" contextRef="C_3168c70b-da00-4f8f-8797-f6fe0d465589" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,933</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9be2332f-c810-49a9-823b-27e726b0ad1d" contextRef="C_dcff91fd-f804-4f83-86d2-4d7c9b912c4e" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,976</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fca54432-7842-4134-9411-459c280206d2" contextRef="C_41603f99-a66e-44cc-8e76-6000fc1c3438" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,298</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67dd8cd2-f0f6-464c-82e3-990a0e1243d9" contextRef="C_7ad7edb9-5f0b-41bd-a762-0755697fa11e" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,154</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a810128-77e0-454a-96e0-ce43c7ab76aa" contextRef="C_e06fb832-2f86-4a43-92b1-f2a822f36e49" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,361</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Depreciation and impairment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40d89ef6-d57c-43cd-904f-79311b6236fe" contextRef="C_ed8dd2df-2263-4f73-959d-fdeab1aa780d" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,584</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5399264-b7c8-44de-990b-8b2d72a9b8bb" contextRef="C_890d9573-96a4-4975-ad2a-83e24165cf64" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,023</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2e10891-774b-4c99-8d26-8b1b368a151e" contextRef="C_59c262f0-8854-4bf0-83be-ade20e2ca796" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,497</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebd19392-db11-4632-80ad-6f77e25b2c5f" contextRef="C_b0636a60-1301-4427-9e48-8459c64a7333" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,544</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cbf4175-3581-47c4-9ce9-f1f3e68beb73" contextRef="C_20d58111-b66a-4385-8104-172f2b4acdf0" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,648</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bd80af8-727f-4b43-85dc-f179ca6bcc92" contextRef="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,569</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3d05926-ddc0-4acc-9641-548a156a374f" contextRef="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,899</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_134d85c8-78d6-4372-ba36-ede4554defdb" contextRef="C_f187930e-0517-474f-8e2c-b180dcc37681" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,085</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad445bb1-54da-405f-8d98-a0a1ee67cafb" contextRef="C_b03741b3-c7aa-47e4-82f2-f5538b555142" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,875</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f914870f-cc80-4bce-af80-a5d3ce0efa45" contextRef="C_e5fb59de-879c-4977-985d-bba088bed9ee" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,428</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e73951e-310c-4442-8627-59fa693fa190" contextRef="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,869</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85191685-6f3d-416f-b034-3c180cc90e75" contextRef="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">405</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bf7b85f-dd94-4c3c-9272-06a7833fd9c5" contextRef="C_f187930e-0517-474f-8e2c-b180dcc37681" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,560</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaac7ec0-4a51-46bf-b7fe-e1fd9aab9356" contextRef="C_e5fb59de-879c-4977-985d-bba088bed9ee" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,834</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfaa5019-43ae-4c51-97f9-12d7318e0e45" contextRef="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c9d76d3-f3c7-4a69-a574-a5f5dd74cc5b" contextRef="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f2ca542-39d2-4db4-9d33-11205b26b03d" contextRef="C_e5fb59de-879c-4977-985d-bba088bed9ee" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4ae7cb1-22dc-4d9b-9c96-5ecd05cfabde" contextRef="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35efa50d-9483-4e8e-8b92-c5171e3c0447" contextRef="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b5237ec-6f08-4504-9230-7b3a39daf552" contextRef="C_f187930e-0517-474f-8e2c-b180dcc37681" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7284188-efe6-48cc-a0e2-751a56782c58" contextRef="C_b03741b3-c7aa-47e4-82f2-f5538b555142" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">807</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65bdc94c-df39-484a-a3eb-552a033fe263" contextRef="C_e5fb59de-879c-4977-985d-bba088bed9ee" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,193</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1c7b42e-64c9-449c-8a44-ebc9aea9ea61" contextRef="C_7d30fefe-a9c7-49d1-868a-e9fe7915fa00" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,784</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20a40011-a557-44be-9a3d-e2f90c2e9fdd" contextRef="C_d7878707-fcf3-4173-a198-76e206226458" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,175</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05999c7b-c2bd-4fbd-a402-99e2fae07e30" contextRef="C_bedad476-b3c2-4ee5-9d07-5861655b6c94" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,946</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53839f07-73d6-42c5-9020-1f85c9bfcbaa" contextRef="C_16d1bca8-ddc8-4770-922a-085d984adaa3" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,612</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad9b5bb3-f6e1-40cb-8350-22d86b87d516" contextRef="C_11acfac4-6200-472e-926e-c7090b67f933" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,517</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fbc15b0-a9f4-424b-ada0-e0a3b72d552b" contextRef="C_6a56e38a-0002-4f9e-838d-06508b6db3f5" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,330</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0f2dbfa-5e27-491b-b4d0-f284e04cfde1" contextRef="C_b4c60161-4bc0-4ca2-859b-eb4baf374e64" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,322</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a65aba7f-c931-4904-9386-6e7688a45096" contextRef="C_d615a83e-1e17-46ec-8765-e218963f27dd" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,283</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c48f9c7-8b0d-4dc4-bde0-789802a07e2a" contextRef="C_97992a0e-7ccc-4554-a974-5d01c776b4ae" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,312</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_599966ba-65ee-49b0-87af-ddb6a247a248" contextRef="C_c82c67d1-a374-44f7-a579-4e1e136065a6" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,247</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d92efc1-c6e1-4606-b2f4-435f80e241c1" contextRef="C_6a56e38a-0002-4f9e-838d-06508b6db3f5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6bd29e7-6087-479f-a3e5-39d93345bb8d" contextRef="C_b4c60161-4bc0-4ca2-859b-eb4baf374e64" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,501</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e801dfb-e27e-4f2b-8297-daf507493686" contextRef="C_97992a0e-7ccc-4554-a974-5d01c776b4ae" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0ad57db-e75c-4723-9b17-cb017139eb16" contextRef="C_c82c67d1-a374-44f7-a579-4e1e136065a6" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,885</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca147b4b-c5c4-4f7f-9af8-4d03c5b7292a" contextRef="C_6a56e38a-0002-4f9e-838d-06508b6db3f5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4f839f0-5275-41f0-8108-039eac2cf6cf" contextRef="C_b4c60161-4bc0-4ca2-859b-eb4baf374e64" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c565908-ce20-445e-89b4-a5fb81cdeaf2" contextRef="C_d615a83e-1e17-46ec-8765-e218963f27dd" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">556</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_017d0f5d-dea1-43eb-af8d-b4da25321852" contextRef="C_97992a0e-7ccc-4554-a974-5d01c776b4ae" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,906</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_058e9762-ea11-4125-9707-21cbbb40a999" contextRef="C_c82c67d1-a374-44f7-a579-4e1e136065a6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,768</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_953c7774-fffa-488e-bc68-ff8c83362878" contextRef="C_2bf202a7-c410-46ac-9503-77f09f3365ef" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_859076e4-e06d-4379-9205-fb2046d6fddf" contextRef="C_cd1cf60b-5c30-41db-bb07-b8145572e517" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,190</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe61c4c1-0d46-42f1-8797-0d4cd561088c" contextRef="C_de19d30c-2832-4cdc-86a5-8ad0e3007775" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,785</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f8a1006-a6de-45f7-9880-6a6ab8d9ba99" contextRef="C_41c2635e-b2f9-4eb1-bb72-637889040d79" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eae771b1-4780-4485-8da6-5a4510f309f2" contextRef="C_dc3e7a3d-39f1-4a98-b6c7-22b916d6a2b2" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84,647</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_284eee4a-6b62-4bc2-b8d1-9f029815e991" contextRef="C_ca101549-cece-44e2-ba4d-877e6b9eb760" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,652</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_025b32ec-fc2e-4ec0-a660-6893560093e0" contextRef="C_8373ab39-153b-4580-8eaa-20b64be0b669" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,245</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ae40c64-88de-4fbe-ae12-805965029534" contextRef="C_cb788b59-28a4-4544-81e7-493092e53b2d" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,429</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f6abfdd-01ac-4bda-9868-59517102e948" contextRef="C_53acf53e-ec11-4160-8b53-30c8a273f237" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,308</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09a7dfc4-d7e0-4c55-a274-b3a754d36e0e" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,634</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_588f240d-167e-4713-af5f-654a08cfd25d" contextRef="C_7e41aefc-f66a-4182-a859-776c8cd1970c" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,003</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7de943ec-a5ab-48f4-b808-4f7511b41427" contextRef="C_e33638fe-cef5-4937-a3e7-51501477ed4a" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c196b17f-c95e-4190-9a94-f7f7a437a3a1" contextRef="C_614a19b6-1595-4cfe-87c5-0d0f93542d8e" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,513</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d56f7224-291d-4207-9eed-474bab60c515" contextRef="C_5c780cf2-8af2-49bf-b6f2-420dbaa22f76" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,412</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d1b44df-a8e8-495d-bed0-defea1537dbf" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,714</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The impairment charge for the year ended December 31, 2023, relates to change in activities at one of our R&amp;D sites and is determined according to its estimated value in use. The R&amp;D site is subleased and is recognized as a right-of-use asset with a carrying amount of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5336b65-9ff2-48c1-9efb-4251dd0df38c" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:RightofuseAssets" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d3ffff4-3380-4587-a654-884cca8ef6c3" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:RightofuseAssets" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2b6d76b-1e42-4410-a707-4422cf925f72" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfDetailedInformationAboutDepreciationsCharges" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation charges are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Depreciation charges</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1446b561-50a3-4372-9e70-b65ffbc2b387" contextRef="C_8ec23a67-4cba-4228-abd5-b5b3f4e8d2dd" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,197</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbfe1d76-710c-4833-9e72-e72cbe94a6ca" contextRef="C_569d3447-2d47-452c-82a9-30b1fb7255bd" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,509</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f11640ad-47de-4a44-ab88-796d262bd014" contextRef="C_586a6210-5549-40bd-9d66-c8900f389cc9" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,245</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62c96db6-c5c5-4a8d-b03e-427eb1f79cbc" contextRef="C_f52014a4-e011-4fe5-9aa6-e94ae66aa8c6" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c71e9d-345f-4b7a-9f37-738d0c0251be" contextRef="C_1c7b2ee3-857c-4937-90c1-54e53d319288" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1bf29c5-f3fa-49f0-9338-d50b07a4bf6a" contextRef="C_7a59ec21-ecbe-4301-8893-0be00de06cef" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,892</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d45b615-5114-4499-9f88-60e9a2df8001" contextRef="C_2cc5cf2b-65b2-4978-a13a-8486ba2a64ef" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,597</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bec49722-74e6-460b-8fc2-e5cd0127e683" contextRef="C_743e733f-a355-45f7-b231-d9ba29e7a99f" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,623</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29b37c42-720c-4389-99fb-a64a75399c17" contextRef="C_e29b5f04-553f-4038-b41c-77cb6a63aa4e" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total depreciation charges</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c02d8343-5637-4554-8174-52399241e82d" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,247</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51337d3f-243f-49bd-962d-8cda63f72014" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,428</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c552feed-faa1-45b6-b1fb-17b477c1f41b" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,514</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes depreciation charges capitalized as part of inventories.</span></div></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_dd8672f9-1ee2-40c6-a3f2-60992ce12467" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 12&#8212;Investments in Associates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s associates relate to investments in Eyconis (principal place of business; U.S.), and VISEN (principal place of business; China). The Company&#8217;s investments in Eyconis and VISEN are accounted for using the equity method in the consolidated financial statements as the Company has determined that it has significant influence over the investments.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, a separate company created to develop, manufacture, and commercialize TransCon ophth</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">almology assets globally, together with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ecade4c-e3c8-43f3-a795-89f9d8caad96" contextRef="C_3069879e-b2eb-487f-8359-3b2b3ac38c1d" name="asnd:CapitalCommitmentFromInvestors" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. As of December 31, 2024, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s present ownership in Eyconis was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fddc7fdb-9c53-4f9b-98e9-f5844142a5d2" contextRef="C_3069879e-b2eb-487f-8359-3b2b3ac38c1d" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">41.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the Company entered into three exclusive license agreements with VISEN for the further development and commercialization of TransCon hGH, TransCon PTH and TransCon CNP in Greater China, and as consideration for the granting of such rights has received a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0066364-3d9f-4ce9-a7aa-b3c410822b9e" contextRef="C_716e887c-c3f0-4b61-9538-8f3e8a6c55f9" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% ownership of VISEN&#8217;s issued and outstanding shares. As of December 31, 2024, the Company&#8217;s present ownership in VISEN was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_166ad95d-df5b-457b-852d-3a7e7fa5f88b" contextRef="C_cf967fba-0da6-4929-9134-641e84170ee5" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">43.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c2fc6d0-d91b-4686-852c-50862f694c5e" contextRef="C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" escape="true" continuedAt="F_6c2fc6d0-d91b-4686-852c-50862f694c5e_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregated profit or loss, total comprehensive income, transactions and outstanding balances with associates as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_6c2fc6d0-d91b-4686-852c-50862f694c5e_1">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:14.883%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:14.883%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Statement of profit or (loss)</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Profit/(loss) for the year from continuing operations</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ea3aa62-cd14-469c-af51-7a1631225a82" contextRef="C_962ef1c5-8d47-4bc2-b07c-320d06c0970d" name="asnd:ProfitLossForTheYear" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,235</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4bb6085-5090-40ec-abff-0112e7bfe4d6" contextRef="C_261c864d-d4ee-42aa-9967-1744c5af33fd" name="asnd:ProfitLossForTheYear" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,873</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive income</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed7594a1-8ea9-402c-b85b-093207af8c0d" contextRef="C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,218</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c7b1c0e-3268-4e64-8de5-20c4802c5be7" contextRef="C_3fbba848-2455-4bc9-8198-43983057fc5c" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,859</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transactions and outstanding balances as of December 31</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Invoicing of goods and services to associates</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8912de0-cf91-495c-815e-f2c1e0b4af8e" contextRef="C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0" name="asnd:SaleOfGoodsAndServicesToAssociate" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,225</ix:nonFraction></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd786beb-99db-4c89-b182-f5929e5b0040" contextRef="C_3fbba848-2455-4bc9-8198-43983057fc5c" name="asnd:SaleOfGoodsAndServicesToAssociate" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,026</ix:nonFraction></span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables from associates</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaad1d32-176d-4702-9fd3-3e723bf3d9e1" contextRef="C_962ef1c5-8d47-4bc2-b07c-320d06c0970d" name="ifrs-full:TradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,759</ix:nonFraction></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ef20a0f-40d0-4e77-9725-03b481fb592f" contextRef="C_261c864d-d4ee-42aa-9967-1744c5af33fd" name="ifrs-full:TradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">991</ix:nonFraction></span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c05bccb-a0c4-4fb9-a70f-842671e57092" contextRef="C_962ef1c5-8d47-4bc2-b07c-320d06c0970d" name="ifrs-full:ContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,936</ix:nonFraction></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87294876-9f52-480c-b700-76c1d4dbf837" contextRef="C_261c864d-d4ee-42aa-9967-1744c5af33fd" name="ifrs-full:ContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,133</ix:nonFraction></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20155d82-be40-4a56-a55a-a4be01509b6b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfInventoriesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 13&#8212;Inventories</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e75ab4ac-bc95-41cf-83c6-cb95be03184d" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials and consumables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d4f3aae-f996-4b53-8b2e-8a5b5a18307b" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,596</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dddb32e2-8f2d-496e-b84a-427d60f304ee" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,566</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff80df2c-0ddf-40fd-a248-a8033a041e85" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:WorkInProgress" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,688</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7863f3a0-2c4b-446e-b5be-9aec4d4bf48b" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:WorkInProgress" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">171,030</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cef49be-76c6-4d3b-adf6-ecdb8ef82bbd" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:FinishedGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,325</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76629677-e1d6-400e-82c3-c7ccee5dabd2" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:FinishedGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,335</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total inventories</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aa64d23-f87d-497d-bc4f-4e6d50a40446" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:InventoriesTotal" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,609</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a196a01-26e0-4f8d-b9b8-7d7444a3c813" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:InventoriesTotal" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,931</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to production lead time, work in progress includes inventories that are not sellable before more than twelve months after the reporting date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories were reduced by write-downs of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e466734-7bc2-4622-b1a0-75dc5ed20eb9" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:InventoryWritedown2011" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba84df0e-bf98-4f45-b26e-2e23e3a98ff0" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:InventoryWritedown2011" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively, which include write-downs on pre-launch inventories.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e594fb7-a378-4bec-ab37-5fb546e0280f" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 14&#8212;Contract Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, contract liabilities comprise unsatisfied performance obligations related to delivery of commercial supply under one of the Company&#8217;s license agreements. Non-current contract liabilities are expected to be recognized as revenue within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8db9becd-33c0-4db2-9b3f-bd33177c8fda" contextRef="C_8e72405c-35f1-4928-85aa-52168ce828ac" name="asnd:ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b93982b7-4d9f-4fb0-aa26-90d456c5d7f1" contextRef="C_9de36237-7daf-4d9a-ba1a-4f2827faaa62" name="asnd:ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue recognized from contract liabilities were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70c9ac52-81d9-4661-a10d-36a22857b4b4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:Revenuerecognizedfromcontractliabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b4cd763-fa0b-4837-9bb8-59ee0656a3d5" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:Revenuerecognizedfromcontractliabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_5e3b647e-e3dc-489e-baa7-7601843322c3" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:Revenuerecognizedfromcontractliabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and primarily related to delivery of clinical supply and research and development services.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_0265d0e7-811d-4c7d-a94f-9cac77ad2bea" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfProvisionsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 15&#8212;Provisions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d65fd89-a4a4-4087-b1b5-2bc222856ce2" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory" escape="true" continuedAt="F_5d65fd89-a4a4-4087-b1b5-2bc222856ce2_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development in provisions is specified below:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:17.824%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Provisions</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_859cad9f-40e9-4000-b067-00aaae6eaf47" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,719</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions related to prior years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38eadd9a-7eec-4232-bcea-78387b91505a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,684</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net additions for the year</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1368c51e-151b-4076-8758-d8fba2d09140" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:NewProvisionsOtherProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,284</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3614360-37fd-4478-93b6-9c9ea537d195" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,462</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea5e0537-9ae3-4cc8-884d-ee08bb28f2e1" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,149</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_5d65fd89-a4a4-4087-b1b5-2bc222856ce2_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_0b0fc337-75cc-4644-b048-e9a0e2653329" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" escape="true" continuedAt="F_0b0fc337-75cc-4644-b048-e9a0e2653329_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 16&#8212;Financial Assets and Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8cf45f1-b6e8-40ac-be47-0ca49567f0f0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial assets and liabilities comprise the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets by category</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77873358-ee18-486a-a9ba-bdc70253dcb8" contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08" name="ifrs-full:TradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,280</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f296c49d-d729-4431-becb-732fd0671e03" contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129" name="ifrs-full:TradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,874</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables (excluding indirect tax receivables)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac538b4b-0914-4b61-b514-dca3c0d83392" contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08" name="ifrs-full:OtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,964</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dbcb4a3-4824-4183-b114-9cdab6db5ce7" contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129" name="ifrs-full:OtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,909</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9a38fd-6547-48ca-8ad1-02794b868990" contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08" name="asnd:MarketableSecuritiesExplanatory" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b13a860c-f88a-487e-a7fb-f9c361eb0066" contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129" name="asnd:MarketableSecuritiesExplanatory" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,275</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6230772b-fca4-4588-a819-ca0a944d567b" contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,543</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9a34943-45d8-4a17-ae32-02bca2c4fa7a" contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f4077c9-7959-4a6c-ae2d-b25ef99bfebf" contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">729,787</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5db12821-9a6f-4b83-a1c3-cad00557d389" contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,222</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9e092e7-10db-4810-b9a1-9b061814816f" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">729,787</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ff0884d-e1f0-460e-93e7-5c1f181dbe82" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,222</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8417440-9aee-48ae-bd2e-9ffa8f67ea8a" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NoncurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,317</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b911ad54-11d0-468b-8b1d-48acf0669e26" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NoncurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,127</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab2ac626-c02f-4252-afed-a5d9f03a73ad" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">727,470</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a1c801f-f424-419b-afad-6c366ccea480" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">437,095</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dc7e2c3-6dab-4e05-b30a-c9aa1ef7a42c" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">729,787</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f35a3333-f8b6-4c7b-bb80-f6f0d9c5920f" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,222</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities by category</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70c8e277-79aa-4103-b883-bffd6d65f2d5" contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,207</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_921ac7f2-6130-4339-a861-85fe03c8face" contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">407,095</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca502908-9239-46ad-9d06-a1528f96693e" contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">305,379</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21e04833-6348-4d32-869e-c30205e439a6" contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08b00be0-1555-4145-b47f-617a6a16d6c7" contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,030</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c11afdc-4bc0-4840-836c-f265cb2f12e3" contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,793</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_295e7158-dbe0-4c30-be73-ffa82c902e5c" contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,394</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8ca1bc7-179d-43d0-bb03-b491c96bf4e8" contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,566</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities (excluding indirect tax and employee related payables)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_598a30cc-c769-4d68-9fa1-4d840c8d2739" contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41" name="ifrs-full:OtherFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48f831b2-d609-4ae1-970b-f4d46beba8f7" contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">953,321</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c5ffef7-0786-4582-969b-0b381694c181" contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">738,831</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da6f140c-18d8-4bad-924d-3f858f63f02a" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78c8227d-8407-4c98-856a-fb740d3d6a08" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a277ff1-1894-45db-ade7-cfe86d69d8eb" contextRef="C_5906116e-01cd-49ba-bcce-49cd3733e697" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9732312c-b5b1-44d5-a771-b5800b00739e" contextRef="C_28990820-f3d2-4e15-9edb-17e010681d57" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_828217d0-2396-48c4-bd05-6cd5ec7a318b" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,103,991</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6881ffbf-e500-42dd-98a8-b6c7689c9b15" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">882,127</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_594f719b-4da8-406b-ae40-e53af7472c3d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NoncurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">365,080</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d99124e7-5c7d-469c-b302-6c183b39342b" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NoncurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,996</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ad21605-3da0-49ca-919a-715121094beb" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:CurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">738,911</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_402712e2-bc1c-4b83-bbe8-1fb440e3aa77" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:CurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">659,131</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4487a15b-9989-4c8d-b30d-8e29adf68045" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,103,991</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb9f4f12-931a-41a3-a95c-9ee865c4476e" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">882,127</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7f1553d-71a8-4189-abca-312345bff609" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance income and expenses are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance income</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80e0e391-9819-4ec4-ba5a-d18296127b00" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:RevenueFromInterest" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,361</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8b5d1fd-bcb6-494a-bdf6-ee80b620f5b0" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:RevenueFromInterest" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,857</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ba4bab0-6cc5-4b27-be20-170f055a134c" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:RevenueFromInterest" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement gain of financial liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e96dc17b-481b-413c-bd96-67806582dce4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,248</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad65709f-bd7e-4382-a4f3-1cb1e7a5df48" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,654</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation (net)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeb5de95-554f-4774-9f7b-69b5331770b0" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:NetForeignExchangeGain" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f441302-e6df-4442-b533-7338b5ad1d43" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:NetForeignExchangeGain" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,346</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7768e7e5-cf15-4d98-bc57-ce27bdc327e9" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:NetForeignExchangeGain" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,755</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total finance income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fb66b91-2127-474d-996c-79c13b78d94e" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,609</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8975902d-40b9-4c3b-b778-6b86d9925bae" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,857</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2d330fc-3e82-4055-8fda-012ecd590d1a" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,181</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4379f4a5-07e3-418d-a1e5-f1a17492e95f" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:InterestExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,504</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc3fe6d6-e679-4fdb-a242-7138c8cb2454" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:InterestExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,065</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb6d32d5-92b3-4b0e-96f6-65e2caa77fce" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:InterestExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement loss of financial liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7614891-f7b0-4445-abc4-d0145cee16b4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,374</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1e14bc4-057b-4e5a-8c1e-9bea245824e4" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,483</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation (net)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eae998b-d4dd-42d2-b406-6c207707ca5b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:NetForeignExchangeLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,149</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddaa9fd1-5158-49ca-bfd2-70cbb1f27c2c" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:NetForeignExchangeLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,322</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total finance expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e97743e-a9ed-43a4-b21d-a787ba269623" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,027</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcb45202-577b-42f3-93c6-b8aab603742f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,065</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_638734a7-fb29-4983-93d2-36163f592fda" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,487</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income and interest expenses relate to financial assets and liabilities measured at amortized cost. Net exchange rate gains and losses primarily relate to U.S. Dollar/Euro fluctuations pertaining to the Company&#8217;s cash, cash equivalents, marketable securities and borrowings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0b0fc337-75cc-4644-b048-e9a0e2653329_1" continuedAt="F_0b0fc337-75cc-4644-b048-e9a0e2653329_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrowings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, the Company issued an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acabe057-a86d-4541-832a-d7fbacd6adb3" contextRef="C_4f2fa65c-bf90-4026-9207-c814f7259be3" name="ifrs-full:NotionalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">575.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of fixed rate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9e21cda-5376-404a-9643-d23b811e9fd3" contextRef="C_d4f709dd-434a-4841-ae2c-e267badec1c5" name="ifrs-full:BorrowingsInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% convertible notes. The net proceeds from the offering of the convertible notes were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9501dd5b-ed63-4cb5-a398-6b456de15fe0" contextRef="C_5123e0db-851b-4c25-82f5-35f4482ea47c" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">557.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b4ecae9-83c2-4fc2-9297-8a44bb004aea" contextRef="C_5123e0db-851b-4c25-82f5-35f4482ea47c" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">503.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), after deducting the initial purchasers&#8217; discounts and commissions, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">transaction costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bfcc2217-4d6a-45ea-9be2-d18a100588ba" contextRef="C_5123e0db-851b-4c25-82f5-35f4482ea47c" name="ifrs-full:BorrowingsMaturity"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes accrue interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_111125fd-b3ac-4e59-a418-54589794b108" contextRef="C_1cf2be05-dcfb-45c8-9384-2927abeec697" name="ifrs-full:BorrowingsInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68743c4b-87a0-421c-b29a-e537286347a2" contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea" name="asnd:BorrowingsInArrearsDefaultPaymentStartDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company&#8217;s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67e8a04e-c48a-4543-a507-413f259c492b" contextRef="C_f52b4a1b-71e1-49b5-9cfd-93e6bb5fe135" name="asnd:ConversionRatePerNote" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">6.0118</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ADSs per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4d67a93-7331-4ac3-a3f5-2094ce616872" contextRef="C_cadf2de7-5782-4672-b259-cd1aa743fad5" name="ifrs-full:NotionalAmount" unitRef="U_EUR" decimals="0" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> principal amount of convertible notes, which represents an initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79e897ee-6925-4b31-98f7-6ded7cd1d2b7" contextRef="C_8b7cf227-3c27-4452-bf1e-f4d1f142fedb" name="asnd:ConversionPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">166.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company&#8217;s option at any time, and from time to time, on or after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f628a4b8-aec7-4481-88e5-bf5cf9e97390" contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea" name="asnd:BorrowingsRedemptionPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 7, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c630e956-72cf-40c4-b1d3-48651bff2e95" contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea" name="asnd:BorrowingsConditionForRedemption"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">but only if the last reported sale price per ADS exceeds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66034f1c-b2e7-4f61-b472-cfe92ba3a1da" contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea" name="asnd:BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the conversion price on each of (i) at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bc4bd74-e075-4afe-91cb-bb8320a2a4db" contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea" name="asnd:BorrowingsThresholdTradingDaysForRedemption" unitRef="U_Days" decimals="0" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trading days, whether or not consecutive, during the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60387d51-97c7-4a6d-aad9-daf163468cbc" contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea" name="asnd:BorrowingsThresholdConsecutiveTradingDaysForRedemption" unitRef="U_Days" decimals="0" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into capped synthetic royalty funding agreements with Royalty Pharma (the &#8220;Purchaser&#8221;), which is presented as royalty funding liabilities, and represents the Company&#8217;s contractual obligations to pay a predetermined percentage of future commercial revenue until reaching a predetermined multiple of proceeds received, according to the detailed provisions of the synthetic royalty funding agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">YORVIPATH Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cbd9ad9-c93c-4626-8b48-5758102594d3" contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b" name="asnd:FundingReceivedInExchangeOfRoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Yorvipath Agreement&#8221;) with the Purchaser. The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcb531f4-2fc9-480b-86bd-0797b6fbfa9a" contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">148.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4187d444-3d64-450b-b0b2-475b8f8f4d99" contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">134.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Royalty Pharma Yorvipath Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78947705-590d-4f58-8a30-70811685e760" contextRef="C_06c5062d-ba03-4445-bb86-eada28395df3" name="asnd:FundingReceivedInExchange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Yorvipath Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4489318-d4a2-4c5f-981b-9d1f07678325" contextRef="C_06c5062d-ba03-4445-bb86-eada28395df3" name="asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net revenue from sales of YORVIPATH in the U.S. (the &#8220;Yorvipath Revenue Payments&#8221;). The Yorvipath Revenue Payments to the Purchaser will cease upon reaching a multiple of the Yorvipath Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f89e4f65-61df-44fd-ba07-215ba0c186b9" contextRef="C_b54750ee-5812-44ea-a167-8b84bead592f" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="1" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bff62ae-4969-4d4b-a258-a6b39e2641e9" contextRef="C_290761ca-44a9-486b-94c7-76f97082cf35" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times if the Purchaser receives Yorvipath Revenue Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3b76536-0929-4ad2-b273-addcca26293c" contextRef="C_06c5062d-ba03-4445-bb86-eada28395df3" name="asnd:RoyaltyPaymentEndingPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Royalty Pharma Yorvipath Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab5fd200-3215-4d51-9a4f-4897890a95fd" contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="1" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to September 30, 2028, and the Company has paid the Purchaser, Yorvipath Revenue Payments equal to the Yorvipath Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b0750e9-9313-48d2-bf08-183ab9c9cb3d" contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SKYTROFA Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acd10862-dff5-4328-af2d-65db01d0a1e4" contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36" name="asnd:FundingReceivedInExchangeOfRoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Skytrofa Agreement&#8221;) with the Purchaser. The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34dc7ee1-ee1f-4842-9139-6601f8b74194" contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">146.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e96fea5-a761-4bc0-99ab-448aa0207c57" contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">136.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting offering expenses.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0b0fc337-75cc-4644-b048-e9a0e2653329_2" continuedAt="F_0b0fc337-75cc-4644-b048-e9a0e2653329_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Royalty Pharma Skytrofa Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8723bbcf-72df-4e82-ae8c-7e3dad69975a" contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36" name="asnd:FundingReceivedInExchange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Skytrofa Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68863c26-9cc0-4f95-922a-b3f2bb2174cd" contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36" name="asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net revenue from sales of SKYTROFA in the U.S., beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc4f6853-2501-435a-97a9-07c666a0a7c2" contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36" name="asnd:RoyaltyPaymentBeginningPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Skytrofa Revenue Payments&#8221;). The Skytrofa Revenue Payments to the Purchaser will cease upon reaching a multiple of the Skytrofa Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a02ddc9c-5002-4b8f-bc4b-a94c211e66f4" contextRef="C_15890a8d-80cb-48ce-91a1-44903b524f91" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="3" format="ixt:num-dot-decimal">1.925</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92499540-afc1-43c5-8bf2-b29c2e5df130" contextRef="C_067306de-0170-4c89-8d3c-7bb661db3689" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times if the Purchaser receives Skytrofa Revenue Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c608dad6-66ef-45bb-b67d-56f3f35ebe51" contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36" name="asnd:RoyaltyPaymentEndingPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Royalty Pharma Skytrofa Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ec7ee46-aa9d-4479-88c3-fa7d9649c7d9" contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="3" format="ixt:num-dot-decimal">1.925</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser, Skytrofa Revenue Payments equal to the Skytrofa Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3644ce9-a4a2-4260-b25c-4a3d4d4e0d72" contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company primarily leases office and laboratory facilities. Lease arrangements contain a range of different terms and conditions and are typically entered into for fixed periods. In order to improve flexibility to the Company&#8217;s operations, lease arrangements may provide the Company with option to extend the lease or terminate the lease within the enforceable lease term. In the Company&#8217;s current lease portfolio, extension and termination options are up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b565bf23-a87e-4b06-87b0-88f60cce7b6a" contextRef="C_9de36237-7daf-4d9a-ba1a-4f2827faaa62" name="asnd:LeaseExtensionPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in addition to the non-cancellable periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d2428b8-4898-475d-9415-d99ef9dfc0cb" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following expenses related to lease activities were recognized in the consolidated statements of profit or loss:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease expenses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35ec2364-84df-4f60-82dc-01aee3864455" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DepreciationRightofuseAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,312</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a953be3-c4d2-4215-831f-9b3a6009886b" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:DepreciationRightofuseAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,875</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33f14531-1960-4acc-bb9a-81951dcc3a94" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:DepreciationRightofuseAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,740</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short term leases and leases of low value assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce3b00e9-4444-4b5c-b12d-beda40fd19dc" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">285</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfebc4cc-ce8d-49ff-a9c3-dc12fadeb492" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3720f646-cc07-42cf-bf2e-52ca336e4fde" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">280</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease interest</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd5c61dc-ac1b-42d6-9d5f-0462975bad70" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:InterestExpenseOnLeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68e529ca-309f-4421-b2bc-1662895399fe" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:InterestExpenseOnLeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,581</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1725034-2ff7-4b98-8634-01fa52c175b1" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:InterestExpenseOnLeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,842</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total lease expenses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37d7de35-2328-4bcc-9a17-b18b582eb07c" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:LeaseExpenses" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,900</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_104cb127-871c-4d49-8373-33992d5d1372" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:LeaseExpenses" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,809</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ceb6d0d-e14b-4e22-b78b-d7a378fc801e" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="asnd:LeaseExpenses" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,862</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, the Company entered into a facility lease in Germany with an enforceable lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f5c13fe-cd8f-4507-ba1f-64c8ec64754d" contextRef="C_de89026c-3236-40fc-8ba9-ac03b1732258" name="asnd:EnforceableLeaseterm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and comprises total lease cash-outflows of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ab94515-a95d-4c7a-a9a0-bc7507806de7" contextRef="C_de89026c-3236-40fc-8ba9-ac03b1732258" name="ifrs-full:CashOutflowForLeases" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">81.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in December 2024, the Company entered into additional leases in Denmark with enforceable lease terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_500d0763-8139-4131-b529-95e706fc5779" contextRef="C_95c2771f-cee1-4eb7-beba-a54cb5701188" name="asnd:EnforceableLeaseterm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years with option to terminate earlier and comprise total lease cash-outflows of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3163975-9224-42a0-a87b-dc0a743824e9" contextRef="C_c14c8f3b-ece8-4326-a6b7-270fcafc68bd" name="ifrs-full:CashOutflowForLeases" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million if not terminated earlier. The leases are expected to commence in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0b0fc337-75cc-4644-b048-e9a0e2653329_3" continuedAt="F_0b0fc337-75cc-4644-b048-e9a0e2653329_4"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing Activities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_3d0680c2-3343-4f6e-86f5-e8ed5968ef07" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in borrowings related to financing activities is specified below:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:19.848%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.623%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.084%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.084%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.084%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.564%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.084%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.824%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.803%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash payments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-cash items</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Beginning<br/>of year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Repay-<br/>ments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net proceeds</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additions/<br/>(disposals)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remeasure-<br/>ments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accretion of<br/>interest</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Foreign<br/>exchange<br/>translation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">End of<br/>year</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="15" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11de38b7-4c05-4204-90a7-6d578cc5696f" contextRef="C_81e30392-2ae2-46f2-9e52-85bbd8e7a714" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">545,472</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd9d8425-410e-4123-b802-954902d8c4a3" contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0" name="asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,819</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ff3fb73-f4e1-4561-9f60-9d51cc7d536b" contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0" name="asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,158</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5d64930-b834-4a52-87dc-f35468bf399d" contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0" name="asnd:IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,248</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59df309c-ad43-427a-a0d1-bfcf0e9831fc" contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0" name="asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,116</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3167cab-89b6-47a6-951c-e5bf4c347017" contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,907</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6541b4e-ff26-49b0-b198-9caebb568d8f" contextRef="C_e89a7181-8fc3-4108-a58d-ec31314fe7a6" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">763,586</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6380a17d-c64c-4a82-bb91-9b7ff0748e51" contextRef="C_a04879c9-d225-42da-8adf-2501801d997b" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,793</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c424b0b4-1313-4e1a-a963-db7d1533eca2" contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f" name="asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,677</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3401c51-d326-4b42-8347-7dfe0c18da63" contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f" name="asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_481722eb-0709-4bec-b331-0a380b8897d4" contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">861</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b783143-9639-49d4-9ab5-9cdd67601e6e" contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f" name="asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23abe8bc-355e-40dc-871f-ee06b91af225" contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,750</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c913175-7815-4c3e-af21-e35fce2a9d54" contextRef="C_a2de7ead-6804-4136-a02b-31e903c48f97" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,030</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afc1da9c-e992-43ba-9d8a-cde9dafbaab9" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">644,265</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40d1e3f7-a59c-4916-b78b-98247bbb0dbd" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,496</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_967bb6be-bbee-4e5f-954a-4a51a319ae0a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,158</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_455af755-505d-4499-80e5-b19e1103b35e" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">861</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50f797f6-84bc-4574-9584-8a14e177bf8b" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,248</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a92221b0-8d6d-46a7-87e2-38fa071e6f35" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,419</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cd7f168-e954-4083-95ac-45ff5929e74d" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,657</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba1e5df7-3ab9-4200-aa9b-29dbdf4b6cee" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">856,616</ix:nonFraction></span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39e0cff5-78ed-451a-8fb9-04f4e6e2cd25" contextRef="C_79e45519-2936-42c5-9260-a018560072ef" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">399,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6708c6c-e1ce-4d23-949a-dda733aa5cd2" contextRef="C_b387065d-0625-4be8-ab94-2a3823e3c97f" name="asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,054</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa1b334d-dbc2-4ac5-bdc6-91de02346ad9" contextRef="C_b387065d-0625-4be8-ab94-2a3823e3c97f" name="asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">136,256</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e39ba808-798f-46ed-a958-a68346bdfab6" contextRef="C_b387065d-0625-4be8-ab94-2a3823e3c97f" name="asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,386</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aca2a850-2717-4c50-9312-4e32d37ebcf2" contextRef="C_b387065d-0625-4be8-ab94-2a3823e3c97f" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,302</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da175139-32fa-4c5b-8ab1-04083cac53d0" contextRef="C_81e30392-2ae2-46f2-9e52-85bbd8e7a714" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">545,472</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa659e5c-392c-4e45-a69c-48381ed85f6b" contextRef="C_e4a0772c-d105-4d5c-9ccb-ae5d02f8ddb4" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,191</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fb5495d-1340-4c6c-bff3-4c124d6e67a1" contextRef="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c" name="asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,006</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6221f48-3b36-4735-8e47-6b47cf45ab21" contextRef="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,973</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac29a002-7b35-4e9a-bfbb-b0e1ee79f6e1" contextRef="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c" name="asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,581</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6640092c-9253-428b-9ca2-0478f83ca18d" contextRef="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,946</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f10d03f0-cd41-45ee-99e6-fee38110d9a5" contextRef="C_a04879c9-d225-42da-8adf-2501801d997b" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,793</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ce9ac0d-4152-4b4f-9906-879aa80c6890" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">508,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01a14b53-85ba-4ed5-8474-f7cd5cfed466" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,060</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b85d0254-b7ee-439c-8d44-059e9de0b224" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">136,256</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40f08418-567a-41a7-ae6c-74ebd44ca1c9" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,973</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7dd8c16-bef2-4ee6-878e-ba0d4758a163" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd9a324d-fbc0-4e05-9df7-b73d8e89eb38" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,967</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3f6681c-49f9-479a-8a55-bbd08fcaff6f" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,248</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b7d2cd3-073a-4df8-a418-702950945bab" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">644,265</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value cannot be measured based on quoted prices in active markets or other observable inputs and accordingly, derivative liabilities are measured by using the Black-Scholes option-pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company&#8217;s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company&#8217;s share price (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6683ac9-cd2c-4c8b-94eb-08d463293be6" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:SharePriceAppliedForValuation" unitRef="U_EurPerShare" scale="0" decimals="1" format="ixt:num-dot-decimal">49.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfe2c238-7bca-47f7-9e55-936b9a67e64e" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:SharePriceAppliedForValuation" unitRef="U_EurPerShare" scale="0" decimals="1" format="ixt:num-dot-decimal">50.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of December 31, 2024 and December 31, 2023, respectively).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional description of fair values, refer to the following section &#8220;Fair Value Measurement.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sensitivity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ecde0dd-3e5e-4ce9-b889-9394921c41e3" contextRef="C_fa785ab0-f0fb-4f0a-875b-f650331743e8" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative increase in volatility, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db5a9261-ccb0-43cb-8eaf-400597a9d37a" contextRef="C_7efbf712-b44b-41d4-8aa1-40e3199ec917" name="asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91d55a71-f0ff-4826-89c6-98e0c533a9f6" contextRef="C_fa785ab0-f0fb-4f0a-875b-f650331743e8" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative decrease in volatility indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, on December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61f7c93d-c90a-4da1-bd49-43caa71d163d" contextRef="C_16b2d798-c4fd-440d-9eb5-813b6bf52dd4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% increase in the share price, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f115537a-8a2a-4627-a24c-4bca0d4fc991" contextRef="C_bdf66293-e3a2-42d2-b55f-314d364082f4" name="asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb598148-44f7-4ab9-875c-b61ddb149430" contextRef="C_16b2d798-c4fd-440d-9eb5-813b6bf52dd4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% decrease in the share price indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value compared to carrying amount of marketable securities, convertible notes, royalty funding liabilities and derivatives, and their level in the fair value hierarchy is summarized in following table, where;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0b0fc337-75cc-4644-b048-e9a0e2653329_4"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_dc417a55-55a8-47e8-bf38-2d1ad546423a" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are unobservable inputs for the asset or liability.</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:9.96%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:9.96%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:9.96%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:9.96%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:9.96%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value level</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(1-3)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e8dd60c-2a8c-4478-87e2-3ead5dbca28e" contextRef="C_368e4795-3132-443f-a38d-3b93be4d5965" name="asnd:MarketableSecuritiesExplanatory" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4c11cc6-b1d2-4de2-8e8d-8e90d3d1615f" contextRef="C_a34d3224-7646-4cf8-a9ef-f7fdd1eb668e" name="asnd:MarketableSecuritiesExplanatory" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ca16879-5a44-493c-8ad3-cca51c55cd00" contextRef="C_0ce01933-8d1d-47b9-bd72-1cbedc695da5" name="asnd:MarketableSecuritiesExplanatory" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,275</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75218d47-cfc1-41c9-bca5-05fd8683210e" contextRef="C_907adb7e-5f6a-4552-b8e4-ca87be7ab73c" name="asnd:MarketableSecuritiesExplanatory" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,266</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c444fe34-a32e-47ab-bad3-70d306d07d81" contextRef="C_e22f7140-0ffe-4e0a-a8d2-1e98ce4c62eb" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19feedd1-c7a4-4110-b8a5-719f1ecd91a7" contextRef="C_f4572716-6c6a-4a6c-bfcd-471d23516aed" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cebabfc3-6c24-493f-8d03-ed173f913f3e" contextRef="C_2aa2a1e6-92a1-4029-9027-67625a630a7b" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,275</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce206159-4719-4ea3-b004-acf79b737cfe" contextRef="C_033bc73d-e8d5-42c6-ac92-2eaa55a1e3f9" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,266</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa9f7a98-0e2f-4e2b-bcaf-8cbfc07e43fa" contextRef="C_6143b456-2c40-4d0d-b967-c6ff15edfac7" name="ifrs-full:NotesAndDebenturesIssued" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,207</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9f3f175-1163-4711-93a4-6e2e5bbb8edf" contextRef="C_37c216bc-caec-48d1-a992-8f1efaf4610a" name="ifrs-full:NotesAndDebenturesIssued" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">438,288</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec29c4dc-5922-41c5-b0a9-9a061839f4ab" contextRef="C_efbe723b-7de5-4c59-b063-c40de816c3c2" name="ifrs-full:NotesAndDebenturesIssued" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">407,095</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22dc5ee0-839d-4e10-8db8-7e8898f3e1d8" contextRef="C_60dcc078-2bdb-4155-9a0b-c75618972125" name="ifrs-full:NotesAndDebenturesIssued" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">385,410</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31352a2b-71bf-4d5a-a0ed-6b787dba6e49" contextRef="C_6143b456-2c40-4d0d-b967-c6ff15edfac7" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">305,379</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71b1f131-76c7-4ffa-944b-f87f4e95e487" contextRef="C_37c216bc-caec-48d1-a992-8f1efaf4610a" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">305,673</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6546fa57-b259-4cc7-8862-aaf5e87d89ff" contextRef="C_efbe723b-7de5-4c59-b063-c40de816c3c2" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99bbe197-68f1-4a8f-a51a-76437ed34df9" contextRef="C_60dcc078-2bdb-4155-9a0b-c75618972125" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,975</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20052840-aa95-47b3-8d33-7fd8f0308d18" contextRef="C_e22f7140-0ffe-4e0a-a8d2-1e98ce4c62eb" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">763,586</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83131a90-d9a0-4072-b1f0-19fa1b499db7" contextRef="C_f4572716-6c6a-4a6c-bfcd-471d23516aed" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">743,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7c1f201-bfb2-487c-bdbe-6633f490515c" contextRef="C_2aa2a1e6-92a1-4029-9027-67625a630a7b" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">545,472</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f3a430b-7d25-4619-934f-2e03b54e5709" contextRef="C_033bc73d-e8d5-42c6-ac92-2eaa55a1e3f9" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">529,385</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e903a8e0-140d-40b2-9916-733857205884" contextRef="C_6143b456-2c40-4d0d-b967-c6ff15edfac7" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78970c03-36ef-4d38-9e05-94a175baa04d" contextRef="C_37c216bc-caec-48d1-a992-8f1efaf4610a" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7015744-452b-4468-b904-5c05d0aa9c98" contextRef="C_efbe723b-7de5-4c59-b063-c40de816c3c2" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7fb05be-4b1f-43cb-b621-65b86fc76be4" contextRef="C_60dcc078-2bdb-4155-9a0b-c75618972125" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b3c01a2-d11b-4ce2-ae96-8756665d49d0" contextRef="C_e22f7140-0ffe-4e0a-a8d2-1e98ce4c62eb" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe4ca3ea-a2a6-47a2-8483-9d4295146826" contextRef="C_f4572716-6c6a-4a6c-bfcd-471d23516aed" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da6a521c-a754-464f-8be1-090cb48cf325" contextRef="C_2aa2a1e6-92a1-4029-9027-67625a630a7b" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43f5fd24-8582-491c-8a75-0e97db66941b" contextRef="C_033bc73d-e8d5-42c6-ac92-2eaa55a1e3f9" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41fe7ca1-9372-4fd8-88f0-d054163d99ba" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies movements in level 3 fair value measurements:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3903e160-ff5d-4371-b0cd-a066789dbf76" contextRef="C_e63719c7-8c13-464f-8f95-1d2f452eab96" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b683d61e-29ff-40ab-b30f-808d8bc2caf8" contextRef="C_7be35a31-a654-4c37-9e6a-3b77cff84b05" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,950</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e9cd61b-f6d8-4bcf-8e5f-92777b8cd022" contextRef="C_acf61556-e87e-41fe-93fa-052e2f231a3b" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b7ee6ad-4538-4a14-b95e-de9568334af4" contextRef="C_7af1f25a-54be-46a2-a19d-533e859fbdd7" name="asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bb71815-1b1c-4ee3-8f38-882121d83582" contextRef="C_c5d54e1a-4387-4b3f-9267-06a2d3748214" name="asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd69fe07-44f7-4618-8784-c3f5ca9b46f8" contextRef="C_eede36b7-749c-4397-a6fe-904bd2d680fa" name="asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,467</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement recognized in financial income or expense</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ac9a8b8-f79b-4c4d-815f-c0887f43c5fd" contextRef="C_7af1f25a-54be-46a2-a19d-533e859fbdd7" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,374</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f34acbd-6e50-4d8f-8c08-8ea3bf470504" contextRef="C_c5d54e1a-4387-4b3f-9267-06a2d3748214" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,654</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53c70fa3-7774-43b0-a761-998e3f7653e0" contextRef="C_eede36b7-749c-4397-a6fe-904bd2d680fa" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,483</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d9f9ec1-e670-40e1-800a-5d68aa1e5663" contextRef="C_9e598379-6e17-4151-b88c-4b34a9189ddb" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55988df7-959d-442a-bfb7-a3de8a7b9fae" contextRef="C_e63719c7-8c13-464f-8f95-1d2f452eab96" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a72632c-d65c-47a1-bfbf-5e436fea3173" contextRef="C_7be35a31-a654-4c37-9e6a-3b77cff84b05" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,950</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_a1ba0f60-b989-474e-99ec-c5781c215246" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" escape="true" continuedAt="F_a1ba0f60-b989-474e-99ec-c5781c215246_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 17 &#8211; Financial Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages capital to ensure that all group enterprises will be able to continue as a going concern while maximizing the return to shareholders through the optimization of debt and equity balances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital Structure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s capital structure consists of equity and external debt obtained through issuance of convertible notes and royalty funding liabilities. The Company is not subject to any contractually imposed capital requirements or financial covenants. The capital structure is reviewed on an ongoing basis for the adequacy of the Company&#8217;s capital compared to the resources required for carrying out ordinary activities</span><span style="color:#404040;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#404040;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development in the Company&#8217;s share capital and treasury shares reserves are described in the following sections. Other equity reserves are described in Note 2, &#8220;Summary of Material Accounting Policies.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The share capital of Ascendis Pharma A/S consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c15aef13-d4e2-4e2b-84e3-ded0317d4470" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,689,487</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> fully paid shares at a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83b37d73-df84-4bed-8f69-8d3dd63a8729" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:ParValuePerShare" unitRef="U_DkkPerShare" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all in the same share class, and which includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dddd84f1-41b3-4810-b588-c2360557291c" contextRef="C_7571783b-8274-4446-9034-fc8030ee4785" name="ifrs-full:NumberOfSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">845,887</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ordinary shares represented by ADSs held by Ascendis Pharma A/S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05759ccc-4928-4667-ae1d-ceb2f7005b76" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in outstanding shares of the Company was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2021</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2020</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Changes in share capital</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4f5a84a-ac81-40a0-8a61-e05923ef40e2" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,707,439</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92995907-43d9-46e3-9cc9-331b35088184" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,152,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daba47d7-e3d2-474a-9c35-9997cba2973a" contextRef="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">56,937,682</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59f197b8-84c9-4e70-9bd8-680a0c6cee0b" contextRef="C_5704c912-f30b-4de5-815d-6a09d374ba34" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,750,386</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ac290c9-2c08-465e-8749-bd5a7c5db0cf" contextRef="C_ae91164c-7a61-4403-923c-7fc72b5f637e" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,985,837</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase through cash contributions</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d06a553-cdde-4fbf-b3da-97d6f0c661b4" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,982,048</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f262e01-3ffb-4ad2-b66d-6b79283ea7c1" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">555,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_489dd187-3bcc-4dc3-9c9e-061f1654acb7" contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">214,613</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59250cd8-3eab-4b71-b816-f022d8ac61d1" contextRef="C_19fef29a-9741-4124-9e26-bd7da6782741" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,187,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_256e4928-1fa9-40b9-9d9e-761116307662" contextRef="C_d35422da-96a1-4b03-a5f4-c8f5b78cbe7a" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,764,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4d1e7ff-c68f-4c58-9f12-e8308254be39" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,689,487</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49f2c905-041e-4db2-8165-f9ea4eb760d2" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,707,439</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4db8d34d-6621-4420-9c1a-32ff9fef6974" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,152,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0ee6348-e757-4c90-8ace-c1f8ac967faf" contextRef="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">56,937,682</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1b82e6c-92f3-4cbf-9bd4-eec38596732e" contextRef="C_7905e7f5-2269-4e2c-bda4-a38c3e7ce9dc" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,750,386</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Treasury Shares Reserve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0191eb41-5159-4cde-b9af-93ba70a8f324" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfTreasurySharesExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in holding of treasury shares was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.241999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominal<br/>value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding in<br/>% of total<br/>outstanding<br/>shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91f6b45d-6e7a-409a-8f90-468790ef7d60" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="ifrs-full:TreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8122861-c898-47e4-a37c-13f3ed692bfd" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="asnd:NumberOfTreasurySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,113,152</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f54c5c9-293e-45b3-9a2b-5622960ea5d5" contextRef="C_69523622-60fc-4677-8a69-32400c599999" name="asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_753c323a-1cfb-4a62-9bfc-b90b024018bf" contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd" name="asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c37d2da-d9d9-4ed7-be94-fbeca2dae78f" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">20,098</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d70fe52-543f-4f11-8bf8-73d8c224eecb" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e88369f6-5d73-4119-b523-6038c70070e8" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:TreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8f74656-246e-497e-9737-dd5e2fc2d887" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:NumberOfTreasurySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,093,054</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9c13697-affe-41e3-a1ed-9525424bab36" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6252024-6cf2-49d4-9fcd-fcb65dd90d99" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1c2af23-9de3-49fc-bd70-79311d3258e0" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">247,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_379f78c0-aaa2-4554-9830-9559da0f1f46" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afb6abae-1391-40a4-8eb7-395313664caa" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:TreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc0f9167-5e7f-43b7-8078-a2a193126f06" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:NumberOfTreasurySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">845,887</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af5e0390-c47c-4451-950b-4ff26dfd34ce" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Risk Management Objectives</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company regularly monitors the access to domestic and international financial markets, manages the financial risks relating to its operations, and analyzes exposures to risk, including market risk, such as foreign currency risk and interest rate risk, credit risk and liquidity risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial risk exposure and risk management policies are described in the following sections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a1ba0f60-b989-474e-99ec-c5781c215246_1" continuedAt="F_a1ba0f60-b989-474e-99ec-c5781c215246_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s activities expose the group enterprises to the financial risks of changes in foreign currency exchange rates and interest rates. Derivative financial instruments are not applied to manage exposure to such risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is exposed to foreign currency exchange risks arising from various currency exposures, primarily with respect to the U.S. Dollar (&#8220;USD&#8221;). Foreign currency exchange risks to the USD are unchanged to prior year, and primarily relate to sales and purchases in foreign currencies, convertible notes and royalty funding liabilities, countered by cash and cash equivalents. The exposure from foreign currency exchange risks is managed by maintaining cash positions in the currencies in which the majority of future expenses are denominated, and payments are made from those reserves.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Sensitivity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table details how a strengthening of the USD against the EUR would impact profit or loss, and equity before tax at the reporting date. A similar weakening of the USD would have the opposite effect. A positive number indicates an increase in profit or loss and equity before tax, while a negative number indicates the opp</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">osite. The sensitivity analysis is deemed representative of the inherent foreign currency exchange risk associated with the operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffffa801-b463-453e-b79b-ad9f0ab982d1" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfForeignCurrencySensitivityAnalysisExplanatory" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Hypothetical impact on consolidated<br/>financial statements</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominal<br/>positions<br/>(net)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase in<br/>foreign<br/>currency<br/>exchange<br/>rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Profit/(loss)<br/>before tax</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity before tax</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR &#8216;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">USD/EUR</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d05e8a5-5063-4876-864c-96a345fe9e4c" contextRef="C_3e1079df-bb69-43bf-854f-2f912ce24f92" name="ifrs-full:NotionalAmount" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">735,064</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e59b69ee-c57d-41b1-9dff-bc4f484514cb" contextRef="C_3e1079df-bb69-43bf-854f-2f912ce24f92" name="asnd:IncreaseDecreaseInForeignCurrencyExchangeRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a286f95d-0e24-4986-b854-1bdb66736629" contextRef="C_5a4ab42e-9a10-4f66-a061-557f147450fd" name="ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,506</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9de7be4-0dbb-4aee-93d4-736f576e3eaa" contextRef="C_5a4ab42e-9a10-4f66-a061-557f147450fd" name="ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,506</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3baa4d68-e09c-409c-8ec7-36615e52f9a6" contextRef="C_adc00162-0324-4973-874c-008dcc36d3e7" name="ifrs-full:NotionalAmount" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">369,091</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cef1e120-7035-4826-ae7d-4332db5b12c9" contextRef="C_adc00162-0324-4973-874c-008dcc36d3e7" name="asnd:IncreaseDecreaseInForeignCurrencyExchangeRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75818a7e-608b-4ac7-bb2c-8ae0cc7b0223" contextRef="C_faa6d408-e3a2-423c-9170-2e7df293488d" name="ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,909</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8a8f241-c2e2-42e4-a45f-5d71d9c88a04" contextRef="C_faa6d408-e3a2-423c-9170-2e7df293488d" name="ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,909</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding convertible notes comprise a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_149191e6-61d7-4370-b9cb-d3d8b5f0252f" contextRef="C_1a5af062-57bb-4ae3-b3ed-605c63a78bb9" name="ifrs-full:BorrowingsInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% coupon fixed rate structure. Further</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the effective interest rate on royalty funding liabilities is estimated at initial recognition and takes into account anticipated amount and timing of future cash flows, which further depends on future commercial revenue forecasts and the probability of exercising the embedded buy-out option. Material changes to anticipated future cash flows could potentially increase or decrease future interest expense. In addition, the interest rate on lease liabilities is fixed at the lease commencement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future indebtedness, including those related to lease arrangements, if any, may be subject to higher interest rates. In addition, future interest income from interest-bearing bank deposits may fall short of expectations due to changes in interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative liabilities are measured at fair value through profit or loss. Since the fair value is exposed from the development in interest rates, the profit or loss is exposed to volatility from such development. The effects of interest rate fluctuations are not considered a material risk to the Company&#8217;s financial position. Accordingly, no interest sensitivity analysis has been presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Credit Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has adopted an investment policy with the primary purpose of preserving capital, fulfilling liquidity needs and diversifying the risks associated with cash, cash equivalents and marketable securities. This investment policy establishes minimum ratings for institutions with which the Company holds cash and cash equivalents, as well as rating and concentration limits for marketable securities held.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a1ba0f60-b989-474e-99ec-c5781c215246_2" continuedAt="F_a1ba0f60-b989-474e-99ec-c5781c215246_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exposure to credit risk primarily relates to cash and cash equivalents. The credit risk on bank deposits is limited because the counterparties, holding significant deposits, are banks with minimum credit-ratings of A3/A- assigned by international credit-rating agencies. The banks are reviewed on a regular basis and deposits may be transferred during the year to mitigate credit risk. In order to mitigate the concentration of credit risks on bank deposits and to preserve capital, a portion of the bank deposits may be placed into investment grade rated marketable securities. The Company&#8217;s investment policy, approved by the Board, only allows investment in marketable securities having investment grade credit-ratings, assigned by international credit-rating agencies. Accordingly, the risk from probability of default is low. On each reporting date, the risk of expected credit loss on bank deposits and marketable securities, if any, including the hypothetical impact arising from the probability of default, is considered in conjunction with the expected loss caused by default by banks or securities with similar credit-ratings and attributes. In line with previous periods, this assessment did not reveal a material impairment loss, and accordingly no provision for expected credit loss has been recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the reporting dates, there are no significant overdue trade receivable balances. As a result, write-down to accommodate expected credit-losses is not deemed material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, the risk of insufficient funds has been addressed through proceeds from sale of the Company&#8217;s securities in private and public offerings, through issuance of convertible notes in 2022, and through royalty funding liabilities in 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity risk is managed by maintaining adequate cash reserves and banking facilities. The risk of shortage of funds is monitored, using a liquidity planning tool, to ensure sufficient funds are available to settle liabilities as they fall due. Besides long term deposits on leases, the Company&#8217;s financial assets are recoverable within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37bc3c64-3973-46e3-85f7-21db2007ec21" contextRef="C_caa0fd3a-8a0c-4ca4-8011-0a2b36ac28ba" name="asnd:RealizedDurationOfFinancialAssetsExplanatory" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the reporting date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Maturity analysis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_276e48b9-cce8-4367-8065-5ffa338e2b89" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:ContractualCashflowsForFinancialLiabilitiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the consolidated statements of financial position:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.04%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.04%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.04%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.04%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&lt; 1 year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1-5 years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&gt;5 years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>contractual<br/>cash-flows</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccba30ac-abfd-4a5f-a019-f39939e6a545" contextRef="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6310ecf6-8f84-4c6a-b6f0-0a40309f6d0e" contextRef="C_18e923c0-37b2-4527-b1aa-aed2087ad549" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,027,558</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad2a09b7-c7ad-45c0-b59c-efd993ad20ef" contextRef="C_c0c25b57-fada-4810-aa6c-9f3de313c6c5" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,660</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_478d2caf-a335-4f87-ab60-74bdea8f3cf7" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:ContractualUndiscountedCashflowOfBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,073,521</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f0bfe59-ffe4-4b9b-a880-3793cedd969d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">763,586</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2340f11c-ba8e-4865-8691-0ea006a9ce06" contextRef="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,482</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_876274cf-ba9e-4572-826a-2b4d86c821c0" contextRef="C_18e923c0-37b2-4527-b1aa-aed2087ad549" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,007</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7511bc03-d0db-4413-8ef3-3f89cdff96e4" contextRef="C_c0c25b57-fada-4810-aa6c-9f3de313c6c5" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,127</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cf9439c-f744-4141-84e4-81c94c22b9c3" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,616</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbbbde9b-6c3e-4ba8-bf9a-85bb1ace108f" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,030</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a3205d2-8048-45c3-9ae7-e5962282bf9e" contextRef="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,705</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c4402c0-60c4-445e-817e-822dfd4f1c7d" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,705</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90b910b9-83b1-48ef-b6e8-351cfe43fae8" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,705</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5dab34a-9840-48a6-8f21-98ea7dcf3e53" contextRef="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">144,490</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79c1aaa3-e71a-43a4-a149-f5f7cc29a196" contextRef="C_18e923c0-37b2-4527-b1aa-aed2087ad549" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,079,565</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_702b68b7-fd30-427e-8168-a6d182a737be" contextRef="C_c0c25b57-fada-4810-aa6c-9f3de313c6c5" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,787</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81649dbc-5da6-4f07-a16c-c47e64f23643" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="asnd:ContractualUndiscountedCashflowOfFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,276,842</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5fb0354-8616-4712-b713-38c42fba56aa" contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">953,321</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70d95e41-b413-4b3e-a94c-e53ddc14449f" contextRef="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,708</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceee9b85-9bfc-4fa3-aa72-dc58a891daac" contextRef="C_17f4bf17-9d0d-4701-ab69-f29d52ef6948" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">742,925</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5757f4dd-0098-464e-a4cb-7f2acd5af467" contextRef="C_21c7c051-dbdf-4831-9602-654f3d0b55c5" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,397</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27363b83-f6f9-4240-8f39-a9bdec9527bc" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:ContractualUndiscountedCashflowOfBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">797,030</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bb527d8-d9f3-42cf-9be6-536e5e952249" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">545,472</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fd6513d-2b72-445c-91e9-66eac775c218" contextRef="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,385</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ef031a4-d83d-48f1-ab06-8e9e21edbf83" contextRef="C_17f4bf17-9d0d-4701-ab69-f29d52ef6948" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9d50403-1e15-43b7-b3e8-8de6a423617b" contextRef="C_21c7c051-dbdf-4831-9602-654f3d0b55c5" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,056</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d942e44e-8696-48a8-a143-ab514840dbf6" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,867</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef960695-0f62-43ad-82d6-b103b5bb93ce" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,793</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aea1094f-a44d-4490-9c79-e4f65d900c1f" contextRef="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,566</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17d039e5-7e7f-43ea-aa02-ed3329034ce1" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,566</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e739746-c2a9-4ec7-a3e1-3cd4bdbb9010" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,566</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abe15b8e-34d6-4dd3-beb9-fdfe44630c0c" contextRef="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,659</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3905de37-5633-4739-91ea-05ba778ee000" contextRef="C_17f4bf17-9d0d-4701-ab69-f29d52ef6948" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">794,351</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a68dfa9-95b3-4c8b-9799-7f34c468e8c1" contextRef="C_21c7c051-dbdf-4831-9602-654f3d0b55c5" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,453</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e45fd74c-181d-496e-aed3-cd327557570a" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="asnd:ContractualUndiscountedCashflowOfFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,006,463</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab958c10-012e-408d-9d35-e82516ff7bce" contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">738,831</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a1ba0f60-b989-474e-99ec-c5781c215246_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Borrowings (excluding lease liabilities)&#8221; comprise convertible notes and royalty funding liabilities. Further details regarding classification of convertible notes as current liabilities in the consolidated statement of financial position are provided in Note 2, &#8220;Summary of Material Accounting Policies,&#8221; section &#8220;New and Amended IFRS Accounting Standards and Interpretations.&#8221; Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements are provided above.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86c67f04-d90c-4c03-a8f6-c25f3254b234" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 18&#8212;Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual commitments for the acquisition of property, plant and equipment were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88df581b-4622-4def-9f75-91a3f313dc66" contextRef="C_614a19b6-1595-4cfe-87c5-0d0f93542d8e" name="ifrs-full:ContractualCapitalCommitments" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76175bd6-dd31-4839-a5ec-95583377670c" contextRef="C_cb788b59-28a4-4544-81e7-493092e53b2d" name="ifrs-full:ContractualCapitalCommitments" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively. Further, with certain suppliers, the Company has agreed minimum commitments related to the manufacturing of product supply, subject to continuous negotiation and adjustments according to the individual contractual terms and conditions. Cost of product supply is recognized when the Company obtains control of the goods. In addition, the Company has commitments related to short-term leases and leases of low value assets, contracts of various lengths in respect of research and development with CROs, and IT and facility related services. Costs relating to those commitments are recognized as services are received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is not aware of any significant legal claims or disputes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5cb20800-4830-47bf-bcad-65403da7dfdf" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 19&#8212;Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors, the Executive Board and non-executive Senior Management (&#8220;Key Management Personnel&#8221;) are considered related parties as they have authority and responsibility for planning and directing the Company&#8217;s operations. Related parties also include undertakings in which such individuals have a controlling or joint controlling interest. Additionally, all group enterprises and associates are considered related parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the Company&#8217;s related parties nor major shareholders hold a controlling, joint controlling, or significant interest in the Group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into employment agreements with and issued warrants, RSUs and PSUs to Key Management Personnel. In addition, the Company pays fees for board tenure and board committee tenure to the independent members of the Board of Directors. For further details, refer to Note 6, &#8220;Employee Costs.&#8221; Indemnification agreements have been entered with members of the Board of Directors, the Executive Board and Non-executive Senior Management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions between the parent company and group enterprises comprise management and license fees, research and development services, administration services, and clinical and commercial supplies. These transactions have been eliminated in the consolidated financial statements. Transactions and outstanding balances with the associates are disclosed in Note 12, &#8220;Investments in Associates.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the parent company Ascendis Pharma A/S is jointly taxed with its Danish subsidiaries, where the current Danish corporation tax is allocated between the jointly taxed Danish companies. For further details, refer to Note 9, &#8220;Tax on Profit/(Loss) for the Year and Deferred Tax.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except for the information disclosed above, the Company has not undertaken any significant transactions with members of the Key Management Personnel, or undertakings in which the identified related parties have a controlling or joint controlling interest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_72083bcf-4b9f-43b6-a43b-b9467ab9a666" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 20&#8212;Investments in Group Enterprises</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_4c8bfd9e-50ed-4184-9344-0fa30aabc163" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S&#8217;s (parent company) investments in group enterprises at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 comprise:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:14.883%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.343%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subsidiaries</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Domicile</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ownership</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_6274b74a-3321-4368-bd79-07ea69cbdd5c" contextRef="C_ce33c6e8-bd62-455a-8699-8dfef4b1bdb2" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma GmbH</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4110687-8a0c-495d-aecc-c37a340e789c" contextRef="C_ce33c6e8-bd62-455a-8699-8dfef4b1bdb2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_0183ddd8-72d6-4fea-aa79-b319a4ec90b7" contextRef="C_30407527-3185-4f61-a488-03f2f38c8ed3" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology GmbH</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c1ad663-887b-4111-9042-1db84d7bee24" contextRef="C_30407527-3185-4f61-a488-03f2f38c8ed3" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_f0a20b48-820f-4416-afa5-d5e684f95cf5" contextRef="C_1e102ae1-1402-4ff8-81ac-0692bcc874ef" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma, Inc.</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dae2174-bc7d-4e80-a36c-5324a433bcea" contextRef="C_1e102ae1-1402-4ff8-81ac-0692bcc874ef" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_2a1e60e6-4186-4ea6-9d1a-b740cbf87477" contextRef="C_41e4375f-476d-430a-af3b-9f5b61fe72c0" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology, Inc.</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d9b5ac4-c381-4f8e-935d-bd1b6681d419" contextRef="C_41e4375f-476d-430a-af3b-9f5b61fe72c0" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_3797efc3-cdea-41aa-bb9f-1ff8430f94a8" contextRef="C_242430a3-5c4f-44b2-aaf8-4987e49091d8" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Ophthalmology Division A/S</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5430e3ce-3b5b-4a07-adc7-07bce0434229" contextRef="C_242430a3-5c4f-44b2-aaf8-4987e49091d8" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_8207fa7c-a19a-4699-9950-bb19ae36db78" contextRef="C_64cd1be6-0716-4e13-b266-fb646a8370c3" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology Division A/S</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c74be73-69e8-472e-9460-f0b99429b60a" contextRef="C_64cd1be6-0716-4e13-b266-fb646a8370c3" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_cfe59321-8bbc-4190-81ab-da2ee1d543a2" contextRef="C_1fb6099b-b6a9-4b5c-bd7a-11c2717591ca" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Bone Diseases A/S</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10abcc59-f297-4380-83e5-70cc925abd3f" contextRef="C_1fb6099b-b6a9-4b5c-bd7a-11c2717591ca" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_e6cefc33-b498-42c9-b7a3-1196294480cd" contextRef="C_842cce4b-c4af-4a45-9074-b4aeeba66138" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Growth Disorders A/S</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6908298-aac1-4129-a85f-373b7f365af9" contextRef="C_842cce4b-c4af-4a45-9074-b4aeeba66138" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_68a1b426-fb5d-4316-b535-474db65a9d28" contextRef="C_c6d5894a-3b43-479b-98c1-26c26fcd5ea8" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Oncology Division A/S</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_766e20a4-92e1-4f43-80b4-ada37fad548f" contextRef="C_c6d5894a-3b43-479b-98c1-26c26fcd5ea8" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_4bcab819-8fa0-47c1-956c-3cc1afde7ab0" contextRef="C_368d07a7-0ac6-4e17-b820-a12da4602974" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Europe A/S</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c58df713-dc72-4ade-93cc-78303f0513b9" contextRef="C_368d07a7-0ac6-4e17-b820-a12da4602974" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_e97dec8c-985b-4c79-8c33-300c6cb544ec" contextRef="C_3925fc10-a57d-420c-9fea-0099a4bfa974" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma UK Limited</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6263fa6-4f0f-4289-bd0b-433a0cd86bbf" contextRef="C_3925fc10-a57d-420c-9fea-0099a4bfa974" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_199a0032-0c3f-4eb4-9f4e-a1cc13642107" contextRef="C_ee56b8dc-dcf9-4371-a111-224749172b3f" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Iberia S.L.</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Spain</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e51a4a15-2123-4fab-a6f9-8ced19937efa" contextRef="C_ee56b8dc-dcf9-4371-a111-224749172b3f" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_94511b8c-a38a-4946-8907-c1f23c26ce34" contextRef="C_6114a2f7-6ec9-4c7c-b156-f0fa2cd47f7f" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma France SASU</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">France</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d20494a-019a-4ea5-aba0-b78f1a4fe586" contextRef="C_6114a2f7-6ec9-4c7c-b156-f0fa2cd47f7f" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_f7c0fe18-e730-4164-947f-a7d16a71c33f" contextRef="C_7b687297-3e1b-4c67-8d9f-f309d8615de2" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Italia SRL</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Italy</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab85dbdb-ab64-47ab-80af-ad38492cbc5c" contextRef="C_7b687297-3e1b-4c67-8d9f-f309d8615de2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_1a90d20d-443c-48c9-8c60-96be8ecdd2b6" contextRef="C_81e385ec-89e0-41e0-9a86-a4f0e9abe54c" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Sverige AB</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sweden</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd0653e5-000d-4821-97b4-41deaa5998ec" contextRef="C_81e385ec-89e0-41e0-9a86-a4f0e9abe54c" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_3202e1a4-7c61-4d28-9346-b9fac85c6f93" contextRef="C_358f6ff6-9ffa-4fee-a3d7-9f7f0de3c554" name="ifrs-full:NameOfSubsidiary"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Switzerland GmbH</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Switzerland</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b87c3477-eb7d-44e3-9c93-db9e62bbf4c1" contextRef="C_358f6ff6-9ffa-4fee-a3d7-9f7f0de3c554" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Associates</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Domicile</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ownership</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_ff84f106-6451-4103-a3f2-2b2a4ba2afdb" contextRef="C_cf967fba-0da6-4929-9134-641e84170ee5" name="ifrs-full:NameOfAssociate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cayman Island</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a30e5b76-5069-4075-b708-c5a16e53dfaf" contextRef="C_cf967fba-0da6-4929-9134-641e84170ee5" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">43.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><ix:nonNumeric id="F_91cfbc4f-c3e3-4abb-8dcc-0d1bdf25535e" contextRef="C_66ac9391-e29a-452b-a56e-75aa88249b65" name="ifrs-full:NameOfAssociate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Eyconis Inc.</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c01f84b4-25ad-4e19-a1b2-f05480d841b6" contextRef="C_66ac9391-e29a-452b-a56e-75aa88249b65" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">41.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d5f3345-ba90-4f3b-89d6-ae47c1765c62" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:DisclosureOfBeneficialOwnershipExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 21&#8212;Ownership</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following investors, or groups of affiliated investors, are known by us to beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a9a26a6-5bf8-44ba-94c1-c5c2ebf2b026" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="asnd:MinimumBeneficialOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s outstanding ordinary shares at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18691ad0-d228-42cb-8c48-d34ae9fac7cd" contextRef="C_fa515c36-ae39-4b8b-a4b2-2f0389428d27" name="asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with RA Capital Management, LLC, USA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7ad2db0-10dd-44c1-a151-7a1833f97147" contextRef="C_1b8ce618-fe68-4762-9808-37cbe7002b0c" name="asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Westfield Capital Management Company, L.P., USA</span></ix:nonNumeric></span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d559f3cb-c1ce-41af-a296-3182a32edc55" contextRef="C_5bb64963-abad-4e25-ab29-a2838c4dfeb9" name="asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with FMR LLC, USA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae9f91b5-b2e8-43c3-be22-a4d97382cf72" contextRef="C_e3aa91fe-cef2-4bec-ad73-cb9c151bddb9" name="asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Avoro Capital Advisors LLC, USA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da550c0a-6787-41fa-96f7-b31a7e8fbaf9" contextRef="C_abc0c365-74db-4b23-b2e7-0dd10c9811b3" name="asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with Artisan Partners LP, USA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee5cfb70-ec48-4f0a-b280-9be799916334" contextRef="C_005327b9-9514-487d-af81-293c04b4477d" name="asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with Janus Henderson Group plc, United Kingdom</span></ix:nonNumeric></span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s American Depository Shares are held through BNY (Nominees) Limited as nominee, of The Bank of New York Mellon, UK (as registered holder of the Company&#8217;s outstanding ADSs).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9f6f1c8-d0f5-4e12-b3c5-156528091aa8" contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 22&#8212;Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No events have occurred after the reporting date that would influence the evaluation of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_19_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following exhibits are filed as part of this annual report:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:7.001%;box-sizing:content-box;"/>
    <td style="width:47.169%;box-sizing:content-box;"/>
    <td style="width:6.001%;box-sizing:content-box;"/>
    <td style="width:10.902%;box-sizing:content-box;"/>
    <td style="width:8.362%;box-sizing:content-box;"/>
    <td style="width:11.362%;box-sizing:content-box;"/>
    <td style="width:9.202%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Description</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Provided<br/>Herewith</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312525025052/d937591dex11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Articles of Association, currently in effect (English translation).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/12/2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312516447629/d65395dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Deposit Agreement dated January 27, 2015 among Ascendis Pharma A/S The Bank of New York Mellon and Owners and Holders of American Depositary Shares.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/2/2016</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-209336</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312516447629/d65395dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of American Depositary Receipt (included in Exhibit 2.1).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex2_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Share Capital and American Depositary Shares.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1(a)</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312514446974/d744944dex103a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Rental Agreement, between Technologiepark Heidelberg II GmbH &amp; Co. KG and Ascendis Pharma GmbH (English translation).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/18/2014</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-201050</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1(b)</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312514446974/d744944dex103b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Supplement No. 1 to Rental Agreement, between Technologiepark Heidelberg II GmbH &amp; Co. KG and Ascendis Pharma GmbH (English translation).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/18/2014</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-201050</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2(a)</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312524005924/d694929dex11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reference is made to Exhibit 1.1.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2(b)</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex4_2b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant Certificate for Warrants</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312515012416/d744944dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement for board members and senior management.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/16/2015</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-201050</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312515401787/d105019dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement dated December 11, 2015 by and among Ascendis Pharma A/S, Fidelity Securities Fund: Fidelity Series Small Cap Opportunities Fund&#8212;Healthcare Sub and Fidelity Stock Selector Small Cap Fund&#8212;Health Care Sub.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/14/2015</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312516447629/d65395dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement dated September 7, 2015 between Ascendis Pharma A/S and Dades AS.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/2/2016</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6&#134;</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312518099514/d445343dex49.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Manufacturing and Supply Agreement dated December 21, 2017, between Ascendis Pharma A/S and NOF Corporation.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/28/2018</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7&#134;</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312518099514/d445343dex410.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Manufacturing and Supply Agreement dated January 12, 2017, between Ascendis Pharma A/S and Medicom Innovation Partner A/S.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/28/2018</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312519096759/d654369dex411.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Supply Agreement dated January 1, 2019, between Ascendis Pharma A/S and Vetter Pharma International GMBH.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/3/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312519096759/d654369dex412.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Manufacturing and Supply Agreement dated October 26, 2018, between Ascendis Pharma A/S and Carbogen Amcis AG.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/3/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:7.001%;box-sizing:content-box;"/>
    <td style="width:47.169%;box-sizing:content-box;"/>
    <td style="width:6.001%;box-sizing:content-box;"/>
    <td style="width:10.902%;box-sizing:content-box;"/>
    <td style="width:8.362%;box-sizing:content-box;"/>
    <td style="width:11.362%;box-sizing:content-box;"/>
    <td style="width:9.202%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Description</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Provided<br/>Herewith</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.10*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312519096759/d654369dex415.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive Licence Agreement dated November 7, 2018, between Ascendis Pharma Growth Disorders A/S and VISEN Pharmaceuticals (CNP).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/3/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.11*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312519096759/d654369dex416.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive Licence Agreement dated November 7, 2018, between Ascendis Pharma Endocrinology Division A/S and VISEN Pharmaceuticals (hGH).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/3/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312519096759/d654369dex417.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive Licence Agreement dated November 7, 2018, between Ascendis Pharma Bone Diseases A/S and VISEN Pharmaceuticals (PTH).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/3/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.13*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312520096870/d841629dex416.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Tech Transfer and Manufacturing Services Agreement dated December 12, 2019 between Ascendis Pharma A/S and Lonza Ltd.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/2/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.14*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312520096870/d841629dex417.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Packaging and Supply Agreement dated December 1, 2019 between Ascendis Pharma A/S and Sharp Corporation.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/2/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.15*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312522062998/d232088dex416.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Manufacturing and Supply Agreement dated December 27, 2020, between Ascendis Pharma A/S and Bachem AG.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/2/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.16*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312522062998/d232088dex417.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Manufacturing and Supply Agreement dated May 27, 2021, between Ascendis Pharma A/S and Carbogen Amcis AG.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/2/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.17*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312522062998/d232088dex418.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Manufacturing and Supply Agreement dated August 31, 2020 between Ascendis Pharma A/S and NOF Corporation.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/2/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.18</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.18*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312521076349/d123790dex417.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Shareholders Agreement dated January 8, 2021, by and among Ascendis Pharma A/S and the parties set forth therein.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/10/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.19*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312521076349/d123790dex418.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment Letter to the Exclusive Licence Agreement dated January 4, 2021 between Ascendis Pharma Growth Disorders A/S and VISEN Pharmaceuticals (CNP).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/10/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.18</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.20*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312521076349/d123790dex419.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment Letter to the Exclusive Licence Agreement dated January 4, 2021 between Ascendis Pharma Endocrinology Division A/S and VISEN Pharmaceuticals (hGH).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/10/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21*</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312521076349/d123790dex420.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment Letter to the Exclusive Licence Agreement dated January 4, 2021 between Ascendis Pharma Bone Diseases A/S and VISEN Pharmaceuticals (PTH).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/10/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.22*</span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000095017024012212/asnd-ex4_22.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Revenue Participation Right Purchase and Sale Agreement dated September 5, 2023 between Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma A/S and Royalty Pharma Development Funding LLC.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/7/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23*</span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex4_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Revenue Participation Right Purchase and Sale Agreement dated September 3, 2024 between</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:7.001%;box-sizing:content-box;"/>
    <td style="width:47.169%;box-sizing:content-box;"/>
    <td style="width:6.001%;box-sizing:content-box;"/>
    <td style="width:10.902%;box-sizing:content-box;"/>
    <td style="width:8.362%;box-sizing:content-box;"/>
    <td style="width:11.362%;box-sizing:content-box;"/>
    <td style="width:9.202%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Description</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Provided<br/>Herewith</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Bone Diseases A/S, Ascendis Pharma A/S and Royalty Pharma Development Funding LLC.</span></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24*</span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex4_24.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Supply Agreement dated October 1, 2022 between Ascendis Pharma A/S and Vetter Pharma International GmbH.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.25*</span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex4_25.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment Number 1 to Supply Agreement dated April 8, 2024 between Ascendis Pharma A/S and Vetter Pharma International GmbH</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.26</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312523053801/d419347dex992.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S Restricted Stock Unit Program.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/28/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-270088</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.27</span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000119312524053484/d667830dex992.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S Performance Stock Unit Program.</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/29/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-277519</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9.35pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.35pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex8_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of Subsidiaries.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.1</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex11_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Policy.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.1</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex12_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.2</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex12_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.1</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex13_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.2</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex13_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.1</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="asnd-ex15_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1612042/000095017024012212/asnd-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S Policy for Recovery of Erroneously Awarded Compensation.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/7/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36815</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EX-101.INS</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EX-101.SCH</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover page interactive data file (formatted as Inline XBRL and included in Exhibit 101).</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="margin-left:1.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Confidential treatment has been granted for certain information contained in this Exhibit. Such information has been omitted and filed separately with the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:1.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Portions of this exhibit, marked by asterisks, have been omitted pursuant to Instruction 4(a) to Exhibits to Form 20-F because they are both (i) not material, and (ii) include information of the type that we treat as private or confidential.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signatures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:60%;border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.96%;box-sizing:content-box;"/>
    <td style="width:91.04%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jan M&#248;ller Mikkelsen</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jan M&#248;ller Mikkelsen</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Board Member (Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 12, 2025</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Scott T. Smith</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scott T. Smith</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Financial Officer (Principal Financial Officer)</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 12, 2025</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>2
<FILENAME>asnd-ex2_3.htm
<DESCRIPTION>EX-2.3
<TEXT>
<html>
 <head>
  <title>EX-2.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 2.3</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF SHARE CAPITAL</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, the registration rights agreement entered into in December 2015 to which we and certain holders of American Depositary Shares, also referred to as ADSs, are parties or the 2015 Registration Rights Agreement, and relevant provisions of the Danish Companies Act (in Danish: Selskabsloven). Because the following is only a summary, it does not contain all of the information that may be important to you. The summary includes certain references to and descriptions of material provisions of our articles of association, the 2015 Registration Rights Agreement and Danish law in effect as of the date of our Annual Report on Form 20-F. The summary below does not purport to be complete and is qualified in its entirety by reference to applicable Danish Law and our articles of association and the 2015 Registration Rights Agreement, copies of which are incorporated by reference into our Annual Report on Form 20-F. Further, please note that ADS holders are not treated as our shareholders and do not have rights as a shareholder. For more information regarding the rights of ADS holders, see &#x201c;Description of American Depositary Shares&#x201d; below.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our company was incorporated on September 21, 2006 as a private limited liability company (in Danish: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anpartsselskab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ApS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) under Danish law and is registered with the Danish Business Authority (in Danish: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erhvervsstyrelsen</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) in Copenhagen, Denmark under registration number 29918791. On December 17, 2007, our company was converted into a public limited liability company (in Danish: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aktieselskab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A/S</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). Our company&#x2019;s headquarters and registered office is Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorizations to our board of directors</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of  December 31, 2024, our board of directors is authorized to increase the share capital as follows:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to increase our share capital by up to 9,000,000 shares with pre-emptive subscription rights for existing shareholders. Capital increases according to this authorization shall be carried out by our board of directors by way of cash contributions. This authorization is valid until May 29, 2029. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to increase our share capital by up to 3,825,000 without pre-emptive subscription rights for existing shareholders. Capital increases according to this authorization can be carried out by our board of directors by way of contributions in kind, conversion of debt and/or cash contributions, and must be carried out at market price as determined in accordance with Danish law. This authorization is valid until May 27, 2026. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to issue 111,992 warrants and to increase our share capital by up to 111,912 shares without pre-emptive subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and conditions thereof. This authorization is valid until May 28, 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to obtain loans against issuance of convertible bonds which confer the right to subscribe for shares in the Company. The Company&#x2019;s existing shareholders shall not have pre-emption rights to such shares. Our board of directors is authorized to increase the share capital by up to nominal DKK 9,000,000 by conversion of the convertible bonds. The convertible bonds shall be offered at a subscription price and a conversion price that correspond in aggregate to at least the market price of the shares at the time of the decision of our board of directors to issue the convertible bonds as determined in accordance with Danish law. The loans shall be paid in cash and our board of directors shall determine the terms and conditions for the convertible bonds. This authorization is valid until May 29, 2027.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to issue 948,124 warrants to members of the executive management and employees, advisors and consultants of the Company or our subsidiaries and to increase our share capital by up to 948,124 shares, without pre-emptive subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and conditions thereof. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercise price for the warrants shall be determined by the board of directors in consultation with the Company&#x2019;s advisors and shall at least be equal to the market price of the shares at the time of issuance as determined in accordance with Danish law. This authorization is valid until May 29, 2027.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to issue 1,000,000 warrants to members of the executive management and employees, advisors and consultants of the Company or our subsidiaries and to increase our share capital by up to 1,000,000 shares, without pre-emptive subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and conditions thereof. The exercise price for the warrants shall be determined by the board of directors in consultation with the Company&#x2019;s advisors and shall at least be equal to the market price of the shares at the time of issuance as determined in accordance with Danish law. This authorization is valid until May 29, 2029.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our board of directors exercises its authorizations in full, and all warrants and convertible debt instruments are exercised fully (not including already issued warrants and already issued convertible debt instruments), then our share capital will amount to 84,574,603 shares consisting of 84,574,603 shares with a nominal value of DKK 1 each.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ADSs are listed on The Nasdaq Global Select Market under the symbol &#x201c;ASND.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our warrants</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our employees, consultants, advisors and board members are eligible to participate in our warrant incentive program. Warrants have been issued by the general meeting or by our board of directors pursuant to valid authorizations in our articles of association and the terms and conditions have, in accordance with the Danish Companies Act, been incorporated in our articles of association as in effect from time to time. Each warrant grants the holder the right to subscribe for one ordinary share against cash payment of the exercise price. The exercise price is determined by our board of directors and historically has not been less than the estimated fair value of our ordinary shares on the date of grant. As of December 31, 2024, our board of directors is authorized to issue 2,060,116 warrants in the period ending May 29, 2029. As of December 31, 2024, there were outstanding 6,204,122 warrants to subscribe for our ordinary shares and such warrants had a weighted-average exercise price of &#x20ac;93.25.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grant of warrants to any participant is at the discretion of our board of directors and based on the recommendation of our management. The board of directors may determine the terms and conditions of the warrants issued, including exercise periods, subscription price and adjustments caused by changes to our company&#x2019;s situation. Warrantholders are entitled to an adjustment of the number of warrants issued and/or the exercise price applicable in the event of certain corporate changes. Events giving rise to an adjustment include, among other things, increases or decreases to our share capital at a price below or above market value, respectively, the issuance of bonus shares, changes in the nominal value of each share and payment of dividends in excess of 10% of our company&#x2019;s equity. For the purpose of implementing the capital increases necessary in connection with the exercise of warrants, our board of directors has been authorized to increase our share capital by one or more issuances of shares with a total nominal value corresponding to the number of warrants issued upon cash payment of the exercise price without any pre-emptive subscription rights to existing shareholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to earlier vesting upon the occurrence of certain exit events, warrants granted under the program from December 2012 until and including November 2021 generally vest 1/48th per month from the date of grant subject to continued service for employees, consultants and grants to board members. However, effective from December 2015, subsequent grants to board members vest 1/24th per month from the date of grant. With respect to employees, in the event that a holder resigns due to our breach of employment terms or we terminate the employment relationship and the holder has not given us good reason to do so, the warrants will continue to vest post-termination in accordance with the same vesting schedule. Otherwise, warrants will cease vesting upon termination of service with respect to employees, board members and consultants.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to earlier vesting, upon the occurrence of certain exit events, for warrants granted under the program as in effect since December 9, 2021, the following vesting applies:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25% of the warrants granted to employees and consultants generally vest one year after the time of grant, and the remaining 75% of the warrants granted generally vest with 1/36 per month from one year after the time of grant. As regards warrants which board members are granted in connection with appointment, 25% of the warrants granted generally vest one year after the time of the grant (the initial grant after the board member&#x2019;s accession), and the remaining 75% of the warrants granted generally vest with 1/36 per month from one year after the time of the grant. Regarding any subsequent grants of warrants to board members (&#x201c;Subsequent Warrants&#x201d;), 50% of the Subsequent Warrants generally vest one year after the time of such subsequent grant and the remaining 50% of the Subsequent Warrants shall generally vest with 1/12 per month from one year after the time of such subsequent grant. Warrants will generally cease vesting upon termination of service with respect to employees, consultants and board members.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vested warrants may be exercised during certain exercise periods each year. For outstanding warrants, there are four annual exercise periods; each exercise period begins two full trading days after the publication of the public release of our earnings data of a fiscal quarter and continues until the end of the second-to-last trading day in which quarter the relevant earnings release is published. The warrants expire ten years after the grant date.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU and PSU program</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has received authorization from stockholders during the period until May 27, 2026 to purchase up to 2,000,000 shares or ADSs representing a corresponding amount of shares in the company as treasury shares. In addition, our board of directors has received authorization from stockholders during the period until May 29, 2028 to purchase up to additional 1,000,000 shares or ADSs representing a corresponding amount of shares in the company as treasury shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has partially exercised this right and the company re-purchased 154,837 ADSs in November 2021 (154,837) and 1,000,000 ADSs in March 2022 (1,000,000), representing a corresponding amount of shares in the company as treasury shares primarily for grants of Restricted Stock Units (&#x201c;RSUs&#x201d;) and/or Performance Stock Units (&#x201c;PSUs&#x201d;) in connection with the implementation of a Restricted Stock Units Program (&#x201c;RSU Program&#x201d;) and a Performance Stock Units program (&#x201c;PSU Program&#x201d;). In 2024, 2023, and 2022, 212,160 ADSs, 20,098 ADSs and 41,685 ADSs, respectively, were transferred to holders under the company&#x2019;s RSU Program. Similarly, in 2024, 35,007 ADSs were transferred to holders under the company&#x2019;s PSU Program.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Program</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs may be granted to members of the senior management team, non-executive directors, and other employees (&#x201c;RSU Participants&#x201d;) employed with the company or another company within the company&#x2019;s group. Our board of directors may also, at its sole discretion, decide to grant RSUs to consultants or members of our board of directors who are then also deemed RSU Participants.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One RSU represents a right for the RSU Participant to receive one ADS upon vesting. ADSs underlying RSUs are deemed to be treasury shares that have been repurchased in the market and, upon vesting, the company may at its sole discretion choose to make a cash settlement instead of delivering ADSs.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors may, in its sole discretion, at any given point in time, decide to grant RSUs and may at its discretion and on an individual basis decide to deviate from the vesting principles and/or the vesting conditions as set forth in the RSU Program.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs are granted to the RSU Participant free of charge. It is a condition for vesting that the RSU Participant is still either employed or retained as consultant within the company or another company within the company&#x2019;s group or serving as member of the board of directors on the vesting date. Subject to earlier vesting, upon the occurrence of certain exit events, for each award of RSUs, 1/3 of such RSUs will vest on each anniversary of the date of grant, subject to continued service.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, our board of directors granted an aggregate of (i) 20,610 RSUs to certain non-employee board members of the company, (ii) 158,875 RSUs to certain members of senior management of the company, and (iii) 538,495 RSUs to certain other employees of the company under the terms of the RSU Program.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PSU Program</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs may be granted to members of the senior management team, non-executive directors and other employees (&#x201c;PSU Participants&#x201d;) employed with the company or another company within the company&#x2019;s group. Our board of directors may also at its sole discretion decide to grant PSUs to consultants or members of our board of directors, who are then also deemed PSU Participants.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One PSU represents a right for the PSU Participant to receive one ADS upon vesting. ADSs underlying PSUs are deemed to be treasury shares that have been repurchased in the market and, upon vesting, the company may at its sole discretion choose to make a cash settlement instead of delivering ADSs.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors may, in its sole discretion, at any given point in time, decide to grant PSUs and may at its discretion and on an individual basis decide to deviate from the vesting principles and/or the vesting conditions as set forth in the company&#x2019;s PSU Program.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs are granted to the PSU Participant free of charge. It is a condition for vesting that the PSU Participant is still either employed or retained as consultant within the company or another company within the company&#x2019;s group or serving as member of the board of directors on the vesting date. Subject to earlier vesting, upon the occurrence of certain exit events, for each award of PSUs 1/3 of such PSUs will vest on each anniversary of the date of grant, subject to continued service and subject to the fulfillment of the performance conditions as determined by our board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All PSUs and any rights or payments in respect thereto will be subject to recoupment by the company to the extent required to comply with applicable law or any policy of the company providing for the reimbursement of incentive compensation.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, our board of directors granted an aggregate of 92,655 PSUs to certain members of senior management of the company under the terms of the PSU Program.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2015 Registration Rights Agreement, we were required to timely register with the Securities and Exchange Commission 1.0 million ordinary shares underlying 1.0 million ADSs (the &#x201c;Fidelity Shares&#x201d;), purchased by Fidelity Securities Fund: Fidelity Series Small Cap Opportunities Fund&#x2014;Healthcare Sub and Fidelity Stock Selector Small Cap Fund&#x2014;Health Care Sub on December 14, 2015. In addition, the owners of the Fidelity Shares are entitled to registration of the Fidelity Shares on Form F-3. In accordance with our obligations under the 2015 Registration Rights Agreement, we filed a resale registration statement in February 2016 to register for resale the Fidelity Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless our ordinary shares are listed on a national securities exchange or trading system and a market for our ordinary shares not held in the form of ADSs exists, any registrable securities sold pursuant to an exercise of the registration rights will be sold in the form of ADSs.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expenses of registration</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2015 Registration Rights Agreement, we agreed to pay certain registration expenses of the holders of the shares registered pursuant to the registration rights described above, excluding, among other things, the expenses of counsel for Fidelity Securities Fund: Fidelity Series Small Cap Opportunities Fund&#x2014;Healthcare Sub and Fidelity Stock Selector Small Cap Fund&#x2014;Health Care Sub.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expiration of registration rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2015 Registration Rights Agreement, the registration rights described above will expire upon the earlier of a change of control event, the disposition of the Fidelity Shares or when the Fidelity Shares can be sold under Rule 144 or Regulation S of the Securities Act during any three-month period.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Owners&#x2019; register</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to maintain an owners&#x2019; register (in Danish: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ejerbog</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The owners&#x2019; register is maintained by Computershare A/S (Company Registration (CVR) no. 27088899), our Danish share registrar. It is mandatory that the owners&#x2019; register is maintained within the European Union and that it is available to public authorities. Pursuant to the Danish Companies Act, public and private limited liability companies are required to register with the Danish Business Authority information regarding shareholders who own at least 5% of the share capital or the voting rights. Pursuant to this provision, we file registrations with the Public Owners&#x2019; Register of the Danish Business Authority. Shareholders that exceed the ownership threshold must notify us and we will subsequently file the information with the Danish Business Authority. Reporting is further required when thresholds of 5%, 10%, 15%, 20%, 25%, 50%, 90% or 100%, or 1/3 or 2/3 are reached or no longer reached.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Articles of association and Danish corporate law</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to our articles of association, the following should be emphasized:</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Objects clause</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate object, as set out in article 3 of our articles of association, is to develop ideas and preparations for the combating of disease medically, to manufacture and sell such preparations or ideas, to own shares of companies with the same objects and to perform activities in natural connection with these objects.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of provisions regarding the board of directors and the executive board</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our articles of association, our board of directors shall be elected by our shareholders at the general meeting and shall be composed of not less than three and no more than 10 members. The members of the board of directors are elected for a term expiring at the first coming annual general meeting following their election. Board members must retire from the board of directors at the annual general meeting following their 75th birthday. Board members are not required to own any shares of our share capital.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors shall appoint and employ an executive board consisting of one to five members to attend to our day-to-day management, and the board of directors shall determine the terms and conditions of the employment.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each shareholder is entitled to one vote for each share owned at the time of any general meeting. As compared with Danish citizens, there are no limitations under the articles of association or under Danish law on the rights of foreigners or non-Danish citizens to hold or vote our shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividend rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our shareholders may at general meetings authorize the distribution of ordinary and extraordinary dividends. Our shareholders may not distribute dividends in excess of the recommendation from our board of directors and may only pay out dividends from our distributable reserves, which are defined as results from operations carried forward and reserves that are not bound by law after deduction of loss carried forward.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our shareholders are eligible to receive any dividends declared and paid out. However, we have not to date declared or paid any dividends and we currently intend to retain all available financial resources and any earnings generated by our operations for use in the business and we do not anticipate paying any dividends in the foreseeable future. The payment of any dividends in the future will depend on a number of factors, including our future earnings, capital requirements, financial condition and future prospects, applicable restrictions on the payment of dividends under Danish law and other factors that our board of directors may consider relevant.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See the section titled &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Item 10 E. Additional Information&#x2014;Taxation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; in our Annual Report on Form 20-F for a summary of certain tax consequences in respect of dividends or distributions to holders of our ordinary shares or the ADSs.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-emptive subscription rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Danish law, all shareholders have pre-emptive subscription rights in connection with capital increases that are carried out as cash contributions. An increase in share capital can be resolved by the shareholders at a general meeting or by the board of directors pursuant to an authorization given by the shareholders. In connection with an increase of a company&#x2019;s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish pre-emptive rights of the shareholders. Under the Danish Companies Act, such resolution must be adopted by the affirmative vote of shareholders holding at least a two-thirds majority of the votes cast and the share capital represented at the general meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors may resolve to increase our share capital without pre-emptive subscription rights for existing shareholders pursuant to the authorizations set forth above under the caption &#x201c;Authorizations to our board of directors.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless future issuances of new shares and/or pre-emptive rights are registered under the Securities Act or with any authority outside Denmark, U.S. shareholders and shareholders in jurisdictions outside Denmark may be unable to exercise their pre-emptive subscription rights.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rights on liquidation</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon a liquidation or winding-up of our company, shareholders will be entitled to participate, in proportion to their respective shareholdings, in any surplus assets remaining after payment of our creditors.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Limitations on holding of shares</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no limitations on the right to hold shares under the articles of association or Danish law.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liability to capital calls by us</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our articles of association as well as the Danish Companies Act, our shareholders are not obligated to pay further amounts to us. All our shares are fully paid.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sinking fund provisions</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no sinking fund provisions or similar obligations relating to our ordinary shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure requirements</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 55 of the Danish Companies Act, a shareholder is required to notify us when such shareholder&#x2019;s stake represents 5% or more of the voting rights in our company or the nominal value accounts for 5% or more of the share capital, and when a change of a holding already notified entails that the limits of 5%, 10%, 15%, 20%, 25%, 50%, 90% or 100%, or 1/3 or 2/3 are reached or no longer reached. The notification shall be given within two weeks following the date when the limits are reached or are no longer reached.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The notification must include information on the date of acquisition or disposal of the shares, the number and, if applicable, the share class, the full name, address and civil registration (&#x201c;CPR&#x201d;) number of the shareholder or the name, central business register (&#x201c;CVR&#x201d;) number and registered office of the enterprise. If the shareholder has no CPR number or CVR number, such notice must be accompanied by other documentation securing unambiguous identification of the shareholder. The notice must also include information on the denomination or nominal value of the shares and the voting rights attaching to the shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to section 58a, we are obligated to collect and store for a period of at least five years certain information regarding the beneficial owners of shares in the company. A beneficial owner is a physical person who ultimately holds or controls, directly or indirectly, a sufficient part of the ownership interests or voting rights or exercises control by other means, except for owners of companies whose ownership interests are traded on a regulated market or a similar market which is subject to a duty of disclosure in accordance with EU law or similar international standards.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The legal status of the notification obligations is not fully clarified in relation to ADS holders and an ADS holder may be subject to such obligations.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General meetings</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general meeting of shareholders is the highest authority in all matters, subject to the limitations provided by Danish law and the articles of association. The annual general meeting shall be held in the Greater Copenhagen area not later than the end of May in each year.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the annual general meeting, the audited annual report is submitted for approval, together with the proposed appropriation of profit/treatment of loss, the election of the board of directors and election of our auditors. In addition, the board of directors reports on our activities during the past year.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General meetings are convened by the board of directors with a minimum of two weeks&#x2019; notice and a maximum of four weeks&#x2019; notice. A convening notice will be forwarded to shareholders recorded in our owners&#x2019; register, who have requested such notification and by publication in the Danish Business Authority&#x2019;s computerized information system and on the company&#x2019;s website.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the latest, two weeks before a general meeting (inclusive of the day of the general meeting), we shall make the following information and documents available on our webpage:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the convening notice,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the documents that shall be presented at the general meeting, which will, in the case of the annual general meeting, include the annual report, and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the agenda and the complete proposals.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders are entitled to attend general meetings, either in person or by proxy, and they or their proxy may be accompanied by one advisor. A shareholder&#x2019;s right to attend general meetings and to vote at general meetings is determined on the basis of the shares that the shareholder holds on the registration date. The registration date shall be one week before the general meeting is held. The shares which the individual shareholder holds are calculated on the registration date on the basis of the registration of ownership in the owners&#x2019; register as well as notifications concerning ownership which the company has received with a view to update the ownership in the owners&#x2019; register. In addition, any shareholder who is entitled to attend a general meeting and who wishes to attend must have requested an admission card from us no later than three days in advance of the general meeting. Any shareholder is entitled to submit proposals to be discussed at the general meetings. However, proposals by the shareholders to be considered at the annual general meeting must be submitted in writing to the board of directors not later than six weeks before the annual general meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Extraordinary general meetings must be held upon resolution of an annual general meeting to hold such a meeting or upon request of the board of directors, our auditors or shareholders representing at least 1/20 of the registered share capital or such lower percentage as our articles of association may provide. Our articles of association do not state such lower percentage.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of ADSs are not entitled to directly receive notices or other materials or to attend or vote at general meetings.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Resolutions in general meetings</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resolutions made by the general meeting generally may be adopted by a simple majority of the votes cast, subject only to the mandatory provisions of the Danish Companies Act and our articles of association. Resolutions concerning all amendments to the articles of association must be passed by two-thirds of the votes cast as well as two-thirds of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder&#x2019;s ownership or voting rights, are subject to approval by a nine-tenth majority of the votes cast and the share capital represented at the general meeting. Decisions to impose or increase any obligations of the shareholders towards the company require unanimity.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Quorum requirements</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Squeeze out</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to Section 70 of the Danish Companies Act, shares in a company may be redeemed by a shareholder holding more than nine-tenths of the shares and the corresponding voting rights in the company. Furthermore, according to Section 73 of the Danish Companies Act, a minority shareholder may require a majority shareholder holding more than nine-tenths of the shares and the corresponding voting rights to redeem the minority shareholder&#x2019;s shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Danish rules intended to prevent market abuse</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of July 3, 2016, EU Regulation No 596/2014 on market abuse entered into force and Chapter 10 of the Danish Securities Trading Act was repealed. Pursuant to said Chapter 10, we had adopted an internal code on inside information in respect of the holding of and carrying out of transactions by our board of directors and executive officers and employees in the shares or ADSs or in financial instruments the value of which is determined by the value of the ordinary shares or ADSs, and we had drawn up a list of those persons working for us who could have access to inside information on a regular or incidental basis and had informed such persons of the rules on insider trading and market manipulation, including the sanctions which could be imposed in the event of a violation of those rules. However, said EU Regulation No 596/2014 on market abuse imposes no such requirements on us and we have abandoned our previous practice.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation on liability</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Danish law, members of the board of directors or senior management may be held liable for damages in the event that loss is caused due to their negligence. They may be held jointly and severally liable for damages to the company, the shareholders and to third parties for acting in violation of the articles of association and Danish law.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general meeting is allowed to discharge our board members and members of our senior management from liability for any particular financial year based on a resolution relating to the financial statements. This discharge means that the general meeting will discharge such board members and members of our senior management from liability to us; however, the general meeting cannot discharge any claims by individual shareholders or other third parties.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have entered into agreements with our board members and members of our senior management, pursuant to which, subject to limited exceptions, we have agreed to indemnify such board members and members of senior management from civil liability, including (i) any damages or fines payable by them as a result of an act or failure to act in the exercise of their duties currently or previously performed by them; (ii) any reasonable costs of conducting a defense against a claim; and (iii) any reasonable costs of appearing in other legal proceedings in which such individuals are involved as current or former board members or members of senior management.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a risk that such agreement will be deemed void under Danish law, either because the agreement is deemed contrary to the rules on discharge of liability in the Danish Companies Act, as set forth above, because the agreement is deemed contrary to sections 19 and 23 of the Danish Act on Damages, which contain mandatory provisions on recourse claims between an employee (including members of our senior management) and us, or because the agreement is deemed contrary to the general provisions of the Danish Contracts Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to such indemnification, we provide our board members and senior management with directors&#x2019; and officers&#x2019; liability insurance.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparison of Danish corporate law and our articles of association and Delaware corporate law</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following comparison between Danish corporate law, which applies to us, and Delaware corporate law, the law under which many publicly traded companies in the United States are incorporated, discusses additional matters not otherwise described in our Annual Report on Form 20-F. This summary is subject to Danish law, including the Danish Companies Act, and Delaware corporate law, including the Delaware General Corporation Law. Further, please note that ADS holders will not be treated as our shareholders and will not have any shareholder rights.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Duties of board members</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Public limited liability companies in Denmark are usually subject to a two-tier governance structure with the board of directors having the ultimate responsibility for the overall supervision and strategic management of the company in question and with an executive board/management being responsible for the day-to-day operations. Each board member and member of the executive board/management is under a fiduciary duty to act in the interest of the company, but shall also take into account the interests of the creditors and the shareholders. Under Danish law, the members of the board of directors and executive management of a limited liability company are liable for losses caused by negligence whether shareholders, creditors or the company itself suffers such losses. They may also be liable for wrongful information given in the annual financial statements or any other public announcements from the company. An investor suing for damages is required to prove its claim with regard to negligence, loss, and causation. Danish courts, when assessing negligence, have been reluctant to impose liability unless the directors and officers neglected clear and specific duties. This is also the case when it comes to liability with regard to public offerings or liability with regard to any other public information issued by the company.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise informed business judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Terms of the members of our board of directors</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, the members of the board of directors of a limited liability company are generally appointed for an individual term of one year. There is no limit on the number of consecutive terms the board members may serve. Pursuant to our articles of association, our board members are appointed by the general meeting of shareholders for a term of one year. Election of board members is, according to our articles of association, an item that shall be included on the agenda for the annual general meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the general meeting, shareholders are entitled at all times to dismiss a board member by a simple majority vote.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It follows from Section 140 of the Danish Companies Act that in limited liability companies that have employed an average of at least 35 employees in the preceding three years, the employees are entitled to elect a minimum of two representatives and alternate members to the company&#x2019;s board of directors up to one half the number of the shareholder elected directors. If the number of representatives to be elected by the employees is not a whole number, such number must be rounded up.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our company currently employs more than an average of 35 employees and has done so since 2016. Consequently, from 2018, our employees have been entitled to demand representation on our board of directors. The question will, upon request from the employees, be put to a popular vote among the employees. If more than half of the employees (regardless of whether they participate in the vote) vote in favor of having representation, we must organize an election process.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, Section 141 of the Danish Companies Act allows for group representation on the board of directors of our company, i.e., that employees of our Danish subsidiaries may demand representation on our board. However, our Danish subsidiaries do not currently have employees. The employees of Ascendis Pharma, Inc., Ascendis Pharma Endocrinology, Inc., Ascendis Pharma GmbH, and Ascendis Pharma Endocrinology GmbH may only demand representation on our board of directors provided that our general meeting adopts a resolution to that effect.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Delaware General Corporation Law generally provides for a one-year term for directors, but permits directorships to be divided into up to three classes, of relatively equal size, with up to three-year terms, with the years for each class expiring in different years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted by the stockholders. A director elected to serve a term on a &#x201c;classified&#x201d; board may not be removed by stockholders without cause. There is no limit in the number of terms a director may serve.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board member vacancies</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, in the event of a vacancy, new board members are elected by the shareholders in a general meeting. Thus, a general meeting will have to be convened to fill a vacancy on the board of directors. However, the board of directors may choose to wait to fill vacancies until the next annual general meeting of the company, provided that the remaining board members can still constitute a quorum. It is only a statutory requirement to convene a general meeting to fill vacancies if the number of remaining members on the board is less than three.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) unless (1) otherwise provided in the certificate of incorporation or bylaws of the corporation or (2) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conflict-of-interest transactions</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, board members may not take part in any matter or decision-making that involves a subject or transaction in relation to which the board member has a conflict of interest with us.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested director of that corporation if:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the material facts as to the director&#x2019;s relationship or interest are disclosed and a majority of disinterested directors&#x2019; consent;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the material facts are disclosed as to the director&#x2019;s relationship or interest and a majority of shares entitled to vote thereon consent; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of the board of directors or the stockholders.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Proxy voting by board members</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event that a board member in a Danish limited liability company is unable to participate in a board meeting, the elected alternate, if any, shall be given access to participate in the board meeting. Unless the board of directors has decided otherwise, or as otherwise is set out in the articles of association, the board member in question may in special cases grant a power of attorney to another board member, provided that this is considered safe considering the agenda in question.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A director of a Delaware corporation may not issue a proxy representing the director&#x2019;s voting rights as a director.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shareholder rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notice of meeting</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. According to the Danish Companies Act, general meetings in limited liability companies shall be convened by the board of directors with a minimum of two weeks&#x2019; notice and a maximum of four weeks&#x2019; notice as set forth in the articles of association. A convening notice shall be forwarded to shareholders recorded in the company&#x2019;s owners&#x2019; register, who have requested such notification. There are specific requirements as to the information and documentation required to be disclosed in connection with the convening notice.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each ordinary share confers the right to cast one vote at the general meeting of shareholders, unless the articles of association provide otherwise. Each holder of ordinary shares may cast as many votes as it holds shares. Shares that are held by the company or its subsidiaries do not confer the right to vote.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, each stockholder is entitled to one vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation, or at elections held under specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event can a quorum consist of less than one third of the shares entitled to vote at a meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders as of the record date for the meeting are entitled to vote at the meeting, and the board of directors may fix a record date that is no more than 60 nor less than ten days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given, or if notice is waived then the record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the stockholders of record entitled to notice or to vote at a meeting of stockholders shall apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shareholder proposals</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. According to the Danish Companies Act, extraordinary general meetings of shareholders will be held whenever the board of directors or the appointed auditor requires. In addition, one or more shareholders representing at least 1/20th of the registered share capital of the company may, in writing, require that a general meeting be convened. If such a demand is forwarded, the board of directors shall convene the general meeting within two weeks thereafter.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All shareholders have the right to present proposals for adoption at the annual general meeting, provided that the proposals are made in writing and forwarded at the latest six weeks prior thereto. In the event that the proposal is received at a later date, the board of directors will decide whether the proposal has been forwarded in due time to be included on the agenda.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Delaware law does not specifically grant stockholders the right to bring business before an annual or special meeting of stockholders. However, if a Delaware corporation is subject to the SEC&#x2019;s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation&#x2019;s securities entitled to vote, may propose a matter for a vote at an annual or special meeting in accordance with those rules.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Action by written consent</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, it is permissible for shareholders to take action and pass resolutions by written consent in the event of unanimity; however, this will normally not be the case in listed companies and for a listed company, this method of adopting resolutions is generally not feasible.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Although permitted by Delaware law, publicly listed companies do not typically permit stockholders of a corporation to take action by written consent.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Appraisal rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The concept of appraisal rights does not exist under Danish law, except in connection with statutory redemptions rights according to the Danish Companies Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to Section 73 of the Danish Companies Act, a minority shareholder may require a majority shareholder that holds more than 90% of the company&#x2019;s registered share capital and votes to redeem his or her shares. Similarly, a majority shareholder holding more than 90% of the company&#x2019;s share capital and votes may, according to Section 70 of the same act, squeeze out the minority shareholders. In the event that the parties cannot agree to the redemption squeeze out price, this shall be determined by an independent evaluator appointed by the court. Additionally, there are specific regulations in Sections 249, 267, 285 and 305 of the Danish Companies Act that require compensation in the event of national or cross-border mergers and demergers. Moreover, shareholders who vote against a cross-border merger or demerger or cross-border conversion are, according to Sections 286, 306 and 318 m of the Danish Companies Act, entitled to have their shares redeemed.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Delaware General Corporation Law provides for stockholder appraisal rights, or the right to demand payment in cash of the judicially determined fair value of the stockholder&#x2019;s shares, in connection with certain mergers and consolidations.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shareholder suits</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, only a company itself can bring a civil action against a third party; an individual shareholder does not have the right to bring an action on behalf of a company. An individual shareholder may, in its own name, have an individual right to take action against such third party in the event that the cause for the liability of that third party also constitutes a negligent act directly against such individual shareholder.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have been met. A person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a stockholder at the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Repurchase of shares</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Danish limited liability companies may not subscribe for newly issued shares in their own capital. Such company may, however, according to the Danish Companies Act Sections 196-201, acquire fully paid shares of its own capital, provided that the board of directors has been authorized thereto by the shareholders acting in a general meeting. Such authorization can only be given for a maximum period of five years and the authorization shall fix (i) the maximum value of the shares and (ii) the minimum and the highest amount that the company may pay for the shares. Shares may generally only be acquired using distributable reserves.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, it is possible to implement limited protective anti-takeover measures. Such provisions may include, among other things, (i) different share classes with different voting rights, (ii) specific requirements to register the shares named in the company&#x2019;s owners register and (iii) notification requirements concerning participation in general meetings. We have currently not adopted any such provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 203 of the Delaware General Corporation Law prohibits &#x201c;business combinations,&#x201d; including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that beneficially owns 15% or more of a corporation&#x2019;s voting stock, within three years after the person becomes an interested stockholder, unless:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the transaction that will cause the person to become an interested stockholder is approved by the board of directors of the target prior to the transaction;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after the completion of the transaction in which the person becomes an interested stockholder, the interested stockholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after the person becomes an interested stockholder, the business combination is approved by the board of directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Delaware corporation may elect not to be governed by Section 203 by a provision contained in the original certificate of incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the corporation. Such an amendment is not effective until 12 months following its adoption.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inspection of books and records</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. According to Section 150 of the Danish Companies Act, a shareholder may request an inspection of the company&#x2019;s books regarding specific issues concerning the management of the company or specific annual reports. If approved by shareholders with simple majority, one or more investigators are elected. If the proposal is not approved by simple majority but 25% of the share capital votes in favor, then the shareholder can request the court to appoint an investigator.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, any stockholder may inspect certain of the corporation&#x2019;s books and records, for any proper purpose, during the corporation&#x2019;s usual hours of business.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-emptive rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, all shareholders have pre-emptive subscription rights in connection with capital increases that are carried out as cash contributions. In connection with an increase of a company&#x2019;s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish pre-emptive rights of the shareholders. Under the Danish Companies Act, such resolution must be adopted by the affirmative vote of shareholders holding at least a two-thirds majority of the votes cast and the share capital represented at the general meeting. The board of directors may resolve to increase our share capital without pre-emptive subscription rights for existing shareholders pursuant to the authorizations described above under the caption &#x201c;Authorizations to our board of directors.&#x201d; Unless future issuances of new shares are registered under the Securities Act or with any authority outside Denmark, U.S. shareholders and shareholders in jurisdictions outside Denmark may be unable to exercise their pre-emptive subscription rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, stockholders have no pre-emptive rights to subscribe for additional issues of stock or to any security convertible into such stock unless, and to the extent that, such rights are expressly provided for in the certificate of incorporation.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, the distribution of ordinary and extraordinary dividends requires the approval of a company&#x2019;s shareholders at a company&#x2019;s general meeting. Under the Danish Companies Act the general meeting may authorise the board of directors to resolve to distribute extraordinary dividends after presentation of a company&#x2019;s first financial statements. The authorisation may be subject to financial and time restrictions. The shareholders may not distribute dividends in excess of the recommendation from the board of directors and may only pay out dividends from our distributable reserves, which are defined as results from operations carried forward and reserves that are not bound by law after deduction of loss carried forward. The decision to pay out extraordinary dividends shall be accompanied by a balance sheet, and the board of directors determine whether it will be sufficient to use the balance sheet from the annual report or if an interim balance sheet for the period from the annual report period until the extraordinary dividend payment shall be prepared.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a resolution to distribute extraordinary dividends is passed more than six months after the balance sheet date as set out in the company's latest approved annual report an interim balance sheet showing that sufficient funds are available for distribution must always be prepared.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, a Delaware corporation may pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year (provided that the amount of the capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In determining the amount of surplus of a Delaware corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard to their historical book value. Dividends may be paid in the form of shares, property or cash.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shareholder vote on certain reorganizations</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under Danish law, all amendments to the articles of association shall be approved by the general meeting of shareholders with a minimum of two-thirds of the votes cast and two-thirds of the represented share capital. The same applies to solvent liquidations, mergers with the company as the discontinuing entity, mergers with the company as the continuing entity if shares are issued in connection therewith, demergers with the company as the transferor company and demergers with the company as the existing transferee if amendment of the articles of association for any purpose other than the adoption of the transferor company&#x2019;s name or secondary name as the transferee company&#x2019;s secondary name is required to be made. Under Danish law, it is debatable whether the shareholders must approve a decision to sell all or virtually all of the company&#x2019;s business/assets.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled to vote thereon generally is necessary to approve a merger or consolidation or the sale of all or substantially all of the assets of a corporation. The Delaware General Corporation Law permits a corporation to include in its certificate of incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, under the Delaware General Corporation Law, no vote of the stockholders of a surviving corporation to a merger is needed, unless required by the certificate of incorporation, if (1) the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (2) the shares of stock of the surviving corporation are not changed in the merger and (3) the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation&#x2019;s common stock outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such corporation, but the stockholders will be entitled to appraisal rights.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendments to governing documents</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All resolutions made by the general meeting may be adopted by a simple majority of the votes, subject only to the mandatory provisions of the Danish Companies Act and the articles of association. Resolutions concerning all amendments to the articles of association must be passed by two-thirds of the votes cast as well as two-thirds of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder&#x2019;s ownership or voting rights, are subject to approval by a nine-tenth majority of the votes cast and the share capital represented at the general meeting. Decisions to impose any or increase any obligations of the shareholders towards the company require unanimity.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Delaware General Corporation Law, a corporation&#x2019;s certificate of incorporation may be amended only if adopted and declared advisable by the board of directors and approved by a majority of the outstanding shares entitled to vote (subject to limited exceptions), and the bylaws may be amended with the approval of a majority of the outstanding shares entitled to vote and may, if so provided in the certificate of incorporation, also be amended by the board of directors.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depositary</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary for the ADSs is The Bank of New York Mellon. The Bank of New York Mellon&#x2019;s depositary office and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">American Depositary Shares</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Bank of New York Mellon, as depositary, registers and delivers the ADSs. Each ADS represents one ordinary share (or a right to receive one ordinary share) deposited with The Bank of New York Mellon, acting through an office located in the United Kingdom, or any successor, as custodian for the depositary. Each ADS also represents any other securities, cash or other property which may be held by the depositary in respect of the depositary facility.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may hold ADSs either (1) directly (a) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (b) by having ADSs registered in your name in the Direct Registration System, or (2) indirectly by holding a security entitlement in ADSs through your broker or other financial institution. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Direct Registration System, or DRS, is a system administered by The Depository Trust Company, also referred to as DTC, pursuant to which the depositary may register the ownership of uncertificated ADSs, which ownership is confirmed by periodic statements sent by the depositary to the registered holders of uncertificated ADSs.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADS holders are not treated as shareholders and do not have shareholder rights. Danish law governs shareholder rights. The depositary is the holder of the ordinary shares underlying the ADSs. As a holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary and you, as an ADS holder, and all other persons directly and indirectly holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. A copy of the deposit agreement is incorporated by reference as an exhibit to our Annual Report on Form 20-F. New York law governs the deposit agreement and the ADSs.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADS. For directions on how to obtain copies of those documents, see the section titled &#x201c;Item 19&#x2014;Exhibits&#x201d; in our Annual Report on Form 20-F.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends and Other Distributions</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How will you receive dividends and other distributions on the ordinary shares?</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary has agreed to pay you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities, after deducting its fees and expenses. As an ADS holder, you will receive these distributions in proportion to the number of ordinary shares your ADSs represent.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We do not expect to declare or pay any cash dividends or cash distributions on our ordinary shares for the foreseeable future. The depositary will convert any cash dividend or other cash distribution we pay on the ordinary shares or any net proceeds from the sale of any ordinary shares, rights, securities or other entitlements into U.S. dollars if it can do so on a reasonable basis and at the then prevailing market rate, and can transfer the U.S. dollars to the United States. If that is not possible and lawful or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. Before making a distribution, any taxes or other governmental charges, together with fees and expenses of the depositary that must be paid, will be deducted. See the section titled &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Item 10 E. Additional Information&#x2014;Taxation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; in our Annual Report on Form 20-F for a summary of certain tax consequences in respect of dividends or distributions to holders of ADSs. It will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ordinary Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution to the extent reasonably practicable and permissible under law. The depositary will only distribute whole ADSs. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new ordinary shares. The depositary may sell a portion of the distributed ordinary shares sufficient to pay its fees and expenses in connection with that distribution.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Elective Distributions in Cash or Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If we offer holders of our ordinary shares the option to receive dividends in either cash or shares, the depositary, after consultation with us, may make such elective distribution available to you as a holder of the ADSs. We must first instruct the depositary to make such elective distribution available to you. As a condition of making a distribution election available to ADS holders, the depositary may require satisfactory assurances from us that doing so would not require registration of any securities under the Securities Act. There can be no assurance that you will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of ordinary shares, or at all.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rights to Purchase Additional Ordinary Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If we offer holders of our securities any rights to subscribe for additional ordinary shares or any other rights, the depositary may make these rights available to ADS holders. If the depositary decides it is not legal and practical to make the rights available but that it is practical to sell the rights, the depositary will use reasonable efforts to sell the rights and distribute the net proceeds in the same way as it does with cash distributions. The depositary will allow rights that are not distributed or sold to lapse. In that case, you will receive no value for them.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the depositary makes rights available to you, it will exercise the rights and purchase the ordinary shares on your behalf and in accordance with your instructions. The depositary will then deposit the ordinary shares and deliver ADSs to you. It will only exercise rights if you pay it the exercise price and any other charges the rights require you to pay and comply with other applicable instructions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. securities laws may restrict transfers and cancellation of the ADSs representing ordinary shares purchased upon exercise of rights. For example, you may not be able to trade these ADSs freely in the United States. In this case, the depositary may deliver restricted depositary shares that have the same terms as the ADSs described in this section except for changes needed to put the necessary restrictions in place.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The depositary will send to you anything else we distribute to holders of deposited securities by any means it determines is equitable and practicable. If it cannot make the distribution proportionally among the owners, the depositary may adopt another equitable and practical method. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Alternatively, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. In addition, the depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither we nor the depositary are responsible for any failure to determine that it may be lawful or feasible to make a distribution available to any ADS holders. We have no obligation to register ADSs, ordinary shares, rights or other securities under the Securities Act. This means that you may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deposit, Withdrawal and Cancellation</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How are ADSs issued?</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary will deliver ADSs if you or your broker deposit ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or share transfer taxes or fees, and delivery of any required endorsements, certifications or other instruments of transfer required by the depositary, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How can ADS holders withdraw the deposited securities?</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may surrender your ADSs at the depositary&#x2019;s corporate trust office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or share transfer taxes or fees, the depositary will transfer and deliver the ordinary shares and any other deposited securities underlying the ADSs to you or a person designated by you at the office of the custodian or through a book-entry delivery. Alternatively, at your request, risk and expense, the depositary will transfer and deliver the deposited securities at its corporate trust office, if feasible.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How can ADS holders interchange between certificated ADSs and uncertificated ADSs?</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may surrender your ADRs to the depositary for the purpose of exchanging your ADRs for uncertificated ADSs. The depositary will cancel the ADRs and will send you a statement confirming that you are the owner of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to you an ADR evidencing those ADSs.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Voting Rights</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How do you vote?</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may instruct the depositary to vote the number of whole deposited ordinary shares your ADSs represent. The depositary will notify you of shareholders&#x2019; meetings or other solicitations of consents and arrange to deliver our voting materials to you if we ask it to do so. Those materials will describe the matters to be voted on and explain how you may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary will try, as far as practical, and subject to the laws of Denmark and our articles of association, to vote or to have its agents vote the ordinary shares or other deposited securities as instructed by ADS holders.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary will only vote or attempt to vote as you instruct or as described above. If we ask the depositary to solicit the ADS holders&#x2019; instructions to vote and an ADS holder fails to instruct the depositary as to the manner in which to vote by the specified date, such ADS holder will be deemed to have given a discretionary proxy to a person designated by us to vote the number of deposited securities represented by its ADSs, unless we notify the depositary that we do not wish to receive a discretionary proxy, there is substantial shareholder opposition to the particular question, or the particular question would have an adverse impact on our shareholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote ordinary shares represented by your ADS. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions provided that any such failure is in good faith. This means that you may not be able to exercise your right to vote and there may be nothing you can do if ordinary shares represented by your ADSs are not voted as you requested.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary to act, we will try to give the depositary notice of any such meeting and details concerning the matters to be voted upon sufficiently in advance of the meeting date.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as described above, you will not be able to exercise your right to vote unless you withdraw the ordinary shares. However, you may not know about the shareholder meeting far enough in advance to withdraw the ordinary shares.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fees and Expenses</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What fees and expenses will you be responsible for paying?</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the deposit agreement, the holders of ADSs will be required to pay the following fees:</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Persons depositing or withdrawing ordinary shares or ADSs must pay:</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">For:</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</font></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issue of ADSs, including issues resulting from a distribution of ordinary shares or rights or other property</font></div></div></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</font></div></div></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$0.05 (or less) per ADS</font></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any cash distribution to you</font></div></div></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the shares had been deposited for issue of ADSs</font></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to you</font></div></div></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$0.05 (or less) per ADS per calendar year</font></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x200a;Depositary services</font></div></div></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registration or transfer fees</font></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares</font></div></div></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expenses of the depositary</font></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cable, (including SWIFT), telex and facsimile transmissions (when expressly provided in the deposit agreement)</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Converting foreign currency to U.S. dollars</font></div></div></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, share transfer taxes, stamp duty or withholding taxes</font></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x200a;As necessary</font></div></div></td>
   </tr>
   <tr style="height:4.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Any charges incurred by the depositary or its agents for servicing the deposited securities</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">     </font></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As necessary</font></div></div></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide for-fee services until its fees for those services are paid.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the depositary may make payments to us to reimburse or share revenue from the fees collected from ADS holders, or waive fees and expenses for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the ADS program. In performing its duties under the deposit agreement, the depositary may use brokers, dealers or other service providers that are affiliates of the depositary and that may earn or share fees or commissions.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of Taxes</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs registered in your name to reflect the sale and pay you any net proceeds, or send you any property, remaining after it has paid the taxes.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reclassifications, Recapitalizations and Mergers</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:39.46%;box-sizing:content-box;"></td>
    <td style="width:60.54%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">If we:</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Then:</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change the nominal or par value of our ordinary shares</font></div></div></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The cash, ordinary shares or other securities received by the depositary will become deposited securities.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reclassify, split up or consolidate any of the deposited securities</font></div></div></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Each ADS will automatically represent its equal share of the new deposited securities.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distribute securities on the ordinary shares that are not distributed to you</font></div></div></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The depositary may also deliver new ADSs or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities. The depositary may also sell the new deposited securities and distribute the net proceeds if we are unable to assure the depositary that the distribution (a) does not require registration under the Securities Act or (b) is exempt from registration under the Securities Act.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:48.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><div class="item-list-element-wrapper" style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recapitalize, reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action</font></div></div></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Any replacement securities received by the depositary shall be treated as newly deposited securities and either the existing ADSs or, if necessary, replacement ADSs distributed by the depositary will represent the replacement securities. The depositary may also sell the replacement securities and distribute the net proceeds if the replacement securities may not be lawfully distributed to all ADS holders.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment and Termination</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How may the deposit agreement be amended?</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How may the deposit agreement be terminated?</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary will terminate the deposit agreement at our direction by mailing notice of termination to the ADS holders then outstanding at least 30 days prior to the date fixed in such notice for such termination. The depositary may also terminate the deposit agreement by mailing a notice of termination to us and the ADS holders if 60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After termination, the depositary and its agents will do the following under the deposit agreement but nothing else: collect distributions on the deposited securities, sell rights and other property, and deliver ordinary shares and other deposited securities upon cancellation of ADSs. Four months after termination, the depositary may sell any remaining deposited securities by public or private sale. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement for the pro rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and has no liability for interest. The depositary&#x2019;s only obligations will be to account for the money and other cash. After termination, our only obligations under the deposit agreement will be to indemnify the depositary and to pay fees and expenses of the depositary that we agreed to pay and we will not have any obligations thereunder to current or former ADS holders.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Obligations and Liability</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Limits on our obligations and the obligations of the depositary; limits on liability to holders of ADSs</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are not liable if either of us is prevented or delayed by law or circumstances beyond our control from performing our obligations under the deposit agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are not liable if either of us exercises, or fails to exercise, discretion permitted under the deposit agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are not liable for any tax consequences to any holders of ADSs on account of their ownership of ADSs;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may rely upon any documents we believe in good faith to be genuine and to have been signed or presented by the proper person.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances. Additionally, we, the depositary and each owner and holder, to the fullest extent permitted by applicable law, waive the right to a jury trial in an action against us or the depositary arising out of or relating to the deposit agreement.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Requirements for Depositary Actions</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before the depositary will deliver or register a transfer of an ADS, make a distribution on an ADS, or permit withdrawal of ordinary shares, the depositary may require:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of share transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any ordinary shares or other deposited securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary may refuse to deliver ADSs or register transfers of ADSs generally when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your Right to Receive the Ordinary Shares Underlying Your ADSs</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time except:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">when temporary delays arise because: (1) the depositary has closed its transfer books or we have closed our transfer books; (2) the transfer of ordinary shares is blocked to permit voting at a shareholders&#x2019; meeting; or (3) we are paying a dividend on our ordinary shares;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">when you owe money to pay fees, taxes and similar charges; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This right of withdrawal is not limited by any other provision of the deposit agreement.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Direct Registration System</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the deposit agreement, all parties to the deposit agreement acknowledge that the DRS and Profile Modification System, or Profile, will apply to uncertificated ADSs upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC under which the depositary may register the ownership of uncertificated ADSs and such ownership will be evidenced by periodic statements sent by the depositary to the registered holders of uncertificated ADSs. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#x2019;s reliance on and compliance with instructions received by the depositary through the DRS/Profile System and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholder Communications; Inspection of Register of Holders of ADSs; ADS Holder Information</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.23
<SEQUENCE>3
<FILENAME>asnd-ex4_23.htm
<DESCRIPTION>EX-4.23
<TEXT>
<html>
 <head>
  <title>EX-4.23</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.23</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN IDENTIFIED CONFIDENTIAL INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT BECAUSE IT IS (I) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE OR CONFIDENTIAL AND (II) NOT MATERIAL.</font><font style="color:#d13438;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].</font><font style="color:#d13438;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Participation Right</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase and Sale Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By and Between</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma Bone Diseases A/S and Ascendis Pharma A/S</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Pharma Development Funding, LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dated as of September 3, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/78804560.7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/93721142.5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;margin-right:1.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   Page</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.9%;box-sizing:content-box;"></td>
    <td style="width:81.8%;box-sizing:content-box;"></td>
    <td style="width:3.3%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 1 DEFINITIONS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Definitions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certain Interpretations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Headings</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 2 PURCHASE, SALE AND ASSIGNMENT OF THE REVENUE PARTICIPATION RIGHT</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase, Sale and Assignment</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Assumed Obligations, Etc.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">True Sale</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 3 CLOSING; PAYMENT OF PURCHASE PRICE</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Closing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of Purchase Price</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bill o</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">f Sale [***].</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Seller Form W-8BEN-E.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Buyer Form W-9.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF THE SELLER</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Existence; Good Standing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorization</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Enforceability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Conflicts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Litigation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compliance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intellectual Property</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title to Revenue Participation Right; No Liens</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indebtedness</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lien Related Representation and Warranties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.14</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brokers&#x2019; Fees</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.15</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign Corrupt Practices Act</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.9%;box-sizing:content-box;"></td>
    <td style="width:81.8%;box-sizing:content-box;"></td>
    <td style="width:3.3%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.16</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional Products</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF THE BUYER</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Existence; Good Standing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorization</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Enforceability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Conflicts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Litigation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brokers&#x2019; Fees</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 6 NO OTHER REPRESENTATIONS AND WARRANTIES</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 7 COVENANTS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Seller Diligence Requirements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reporting</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue Payments; Revenue Payment Details; Buy-Out Payment.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inspections and Audits of the Seller</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intellectual Property Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-Licenses and Intercompany Agreements.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Out-Licenses and Contract Manufacturing Agreements.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disclosures</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Post-Closing Obligation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Efforts to Consummate Transactions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Further Assurances</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Late Payments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Negative Pledge; Preservation of Assets; Lien Cooperation.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 8 INDEMNIFICATION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General Indemnity</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notice of Claims</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Limitations on Liability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third Party Claims</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exclusive Remedy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Treatment for Indemnification Payments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 9 CONFIDENTIALITY</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.9%;box-sizing:content-box;"></td>
    <td style="width:81.8%;box-sizing:content-box;"></td>
    <td style="width:3.3%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Confidentiality</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorized Disclosure.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 10 TERMINATION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term and Expiration; Surviving Payments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mutual Termination</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Survival</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 11 MISCELLANEOUS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notices</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assignment; Transfer Restrictions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendment and Waiver</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entire Agreement</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Third Party Beneficiaries</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Governing</font><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Law</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jurisdiction;</font><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Venue</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Specific Performance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Counterparts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Relationship of the Parties; Cooperation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Parent Guarantee</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Index of Exhibits</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:	Payment Instructions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:	Form of Bill of Sale</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:	Existing Intercompany Agreements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:	[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iv</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.23</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REVENUE PARTICIPATION RIGHT </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchase and sale</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This REVENUE PARTICIPATION RIGHT </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchase and sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), dated as of September 3, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), is made and entered into by and between Royalty Pharma Development Funding, LLC, a Delaware limited liability company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buyer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Ascendis Pharma Bone Diseases A/S, a corporation organized under the laws of Denmark (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seller</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Ascendis Pharma A/S, a public limited liability company (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aktieselskab</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) organized under the laws of Denmark (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of the Seller).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">W I T N E S S E T H</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Seller is in the business of, among other things, developing and Commercializing the Product in the Territory; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Buyer desires to purchase the Revenue Participation Right and receive the Revenue Payments from the Seller, and the Seller desires to sell the Revenue Participation Right and make the Revenue Payments to the Buyer, in each case on the terms and conditions set forth in this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Seller, the Parent and the Buyer hereby agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>DEFINITIONS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.1	Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The following terms, as used herein, shall have the following meanings:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Revenue Participation Right Purchase and Sale Agreement by and among Ascendis Pharma Endocrinology Division A/S, the Parent and the Buyer, dated September 5, 2023.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 Back-Up Security Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning ascribed to &#x201c;Back-Up Security Interest&#x201d; in the 2023 Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Technology</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of the Effective Date or at any time thereafter during the term of this Agreement, Seller&#x2019;s and/or its Affiliates&#x2019; proprietary chemistry, materials and methodologies for transiently covalently coupling a substrate of interest (e.g., a peptide, protein, small molecule or any other drug) to various carriers via a TransCon Linker, thereby allowing release of the transiently linked substrate in a controlled manner over time for a therapeutic or prophylactic effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any particular Person, any other Person directly or indirectly controlling, controlled by or under common control with such particular Person.  For purposes of the foregoing sentence, the term &#x201c;control&#x201d; means direct or indirect ownership of (a) fifty percent (50%) or more, including ownership by trusts with substantially the same beneficial interests, of the voting and equity rights of such Person, firm, trust, corporation, partnership or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other entity or combination thereof, or (b) the power to direct the management of such person, firm, trust, corporation, partnership or other entity or combination thereof, by contract or otherwise. For purposes hereof, any Person shall be deemed to control a partnership, limited liability company, association or other business entity if such Person, directly or indirectly through one or more intermediaries, shall be allocated a majority of partnership, limited liability company, association or other business entity gains or losses or shall be or control the managing director or general partner of such partnership, limited liability company, association or other business entity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Arbitrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.4(d).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized Stability Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the expiry dating period for YORVIPATH from its date of manufacture when YORVIPATH is stored at two (2) degrees Celsius to eight (8) degrees Celsius, for which the Seller or its Affiliates has received Marketing Approval in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Back-Up Security Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 2.3.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bankruptcy Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws affecting the enforcement of creditors&#x2019; rights generally.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bill of Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 3.3.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any day other than (a) a Saturday or Sunday or (b) a day on which banking institutions located in New York or Denmark are permitted or required by applicable law or regulation to remain closed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buy-Out Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.3(d)(ii).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buy-Out Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, (a) in the case of Section 7.3(d)(i), 2.0 times the Purchase Price minus the Revenue Payments paid to the Buyer as of the effective date of the Change of Control, provided, if the Change of Control occurs on or prior to September 30, 2028 and Seller has paid Buyer Revenue Payments equal to the Purchase Price as of the date of the Change of Control, then 1.65 times the Purchase Price minus the Revenue Payments paid to the Buyer as of the effective date of the Change of Control and (b) in the case of Section 7.3(d)(ii), 2.0 times the Purchase Price minus the Revenue Payments paid to the Buyer as of the effective date of the Buy-Out Notice, provided, if the Buy-Out Notice is provided on or prior to September 30, 2028 and Seller has paid Buyer Revenue Payments equal to the Purchase Price as of the date of the Buy-Out Notice, then 1.65 times the Purchase Price minus the Revenue Payments paid to the Buyer as of the effective date of the Buy-Out Notice.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buyer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buyer Indemnified Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 8.1(a).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calendar Quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a period of three (3) consecutive months ending at midnight, Copenhagen, Denmark time on the last day of March, June, September, or December, respectively.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calendar Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a period of twelve (12) consecutive months commencing on January 1 of any year.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) a transaction or series of related transactions that results in the sale or other disposition of all or substantially all of the Parent&#x2019;s and its Affiliates&#x2019; assets, on a consolidated basis; or (b) a merger or consolidation with a Third Party in which the Parent is not the surviving corporation or in which, if the Parent is the surviving corporation, the shareholders of the Parent immediately prior to the consummation of such merger or consolidation do not, immediately after consummation of such merger or consolidation, possess, directly or indirectly through one or more intermediaries, and acting jointly, a majority of the voting power of all of the surviving entity&#x2019;s outstanding stock and other securities and the power to elect a majority of the members of Parent&#x2019;s board of directors; or (c) a transaction or series of related transactions with one or more Third Parties (which may include a tender offer for the Parent&#x2019;s stock or the issuance, sale or exchange of stock of the Parent) if the shareholders of the Parent immediately prior to such transaction(s) do not, immediately after consummation of such transaction(s), possess, directly or indirectly through one or more intermediaries, and acting jointly, a majority of the voting power of all of the Parent&#x2019;s or its successor&#x2019;s outstanding stock and other securities and the power to elect a majority of the members of the Parent&#x2019;s or its successor&#x2019;s board of directors.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Co-Commercialization Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means any written agreement to which the Seller or any of its Affiliates is a party pursuant to which the Seller (or such Affiliate) and the counterparty agree to co-Commercialize the Product in the Territory, including sharing in the net profits (and losses) of such Commercialization, (a) with a Permitted Transferee or (b) with the Seller (or its Affiliate) (i) retaining the sole right to book all co-Commercialization sales of the Product in the Territory and (ii) entitled to at least a fifty percent (50%) share of such net profits (and losses) or alternatively at least a fifty percent (50%) share of net sales of the Product in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Launch</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of both (a) the first sale of a Product by or on behalf of Seller or its Affiliates or any Licensees to a Third Party for end use or consumption of such Product in the Territory after Regulatory Approval required to market and sell such Product has been granted in the Territory, and (b) the availability of sufficient ready-for-sale inventory of Product in commercial quantities for Commercialization in the Territory in all approved dosages.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all activities directed to the distribution, marketing, detailing, promotion, commercial launching, selling and securing of reimbursement of a product (including using, importing, selling and offering for sale of the product ), and shall include post-Marketing Approval studies, post-launch marketing, promoting, detailing, marketing research, distributing, customer service, or transporting a product for sale, and regulatory compliance with respect to the foregoing.  When used as a verb, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialize</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean to engage in Commercialization. For clarity, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; excludes Manufacturing activities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercially Reasonable Efforts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the efforts to be expended by the Seller and its Affiliates with respect to any objective, such reasonable and diligent efforts to accomplish such objective as a recently commercial stage biopharmaceutical enterprise would normally use to accomplish a similar objective under similar circumstances.  It is understood and agreed that with respect to the conduct of the Manufacture of the Product for Commercialization in the Territory and the Commercialization of the Product in the Territory, including the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercial launch of the Product in the Territory, by the Seller and its Affiliates (including through their Licensees and Manufacturers), such efforts shall be substantially equivalent to those efforts and resources commonly used by a recently commercial stage biopharmaceutical enterprise for pharmaceutical products owned by it, which product is at a similar stage in its product life and is of similar market potential taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product and the profitability of the product (excluding the amounts payable to the Buyer pursuant to this Agreement).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial &amp; IP Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.2(a).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Updates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a summary of material updates with respect to the Related Parties&#x2019; Commercialization of the Product in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 9.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract Manufacturing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any agreement or arrangement between the Seller or any of its Affiliates and any Third Party for the Manufacture of a product, including bulk drug product, bulk drug substance and finished product.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Customary Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a customary intercreditor agreement between the Buyer and a senior debt provider providing: (a) [***]; (b) [***]; (c) [***]; and (d) any other provisions reasonably satisfactory to the senior debt provider and the Buyer consistent with clauses (a)-(c) above and consistent with the premise that (i) [***] and (ii) [***]; and (e) the Buyer shall not interfere with such senior debt provider enforcing its rights and remedies as a secured creditor (to the extent such enforcement is not inconsistent with clauses (a)-(d) above).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosing Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 9.1.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Disclosure Schedule, dated as of the Effective Date, delivered to the Buyer by the Seller concurrently with the execution of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distributor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Third Party that has the right, option or obligation to distribute, market and sell the Product (with or without any devices or delivery systems) in one or more regions in the Territory on behalf of a Related Party.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Contract Manufacturing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.9.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Intercompany Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) the Existing Intercompany Distribution Agreement and (b) the Intercompany Agreements set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Intercompany Distribution Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Marketing, Sales and Distribution Agreement between Ascendis Pharma Bone Diseases A/S as supplier and Ascendis Pharma Endocrinology, Inc. as distributor, dated September 1, 2024.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.10(a).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FCPA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 4.15.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Food and Drug Administration, or any successor agency thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any: (a) nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other tribunal); (d) multi-national organization or body; or (e) individual, body or other entity exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gross Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the definition of &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IFRS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means international financial reporting standards as promulgated by the International Accounting Standards Board as adopted in the European Union, consistently applied.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any indebtedness for borrowed money, obligation evidenced by a note, bond, debenture or similar instrument, or guarantee of any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 8.2.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnifying Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 8.2.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In-License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any (a) in-license or (b) settlement agreement or other similar agreement or arrangement, in each case of (a) and (b), between the Seller or any of its Affiliates, on the one hand, and any Third Party, on the other hand, pursuant to which the Seller or any of its Affiliates obtain an in-license or a covenant not to sue or similar grant of rights under any Patents or other Intellectual Property Rights owned or controlled by such Third Party that are necessary for the commercial Manufacture of the Product anywhere in the world for Commercialization in the Territory or the Commercialization of the Product in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all of the following as they exist at any time: (a) Patents; (b) registered and unregistered trademarks, service marks, trade names, trade dress, logos, packaging design, slogans and Internet domain names, and registrations and applications for registration of any of the foregoing; (c) copyrights in both published and unpublished works, including all compilations, databases and computer programs, manuals and other documentation and all copyright registrations and applications, and all derivatives, translations, adaptations and combinations of the above; (d) Know-How; and (e) any and all other intellectual property rights and/or proprietary rights, whether or not patentable, specifically relating to any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property Updates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an updated list of the Patents owned or controlled by the Seller, Parent or any of its Affiliates that relate to the Product in the Territory or the Commercialization of the Product in the Territory and identifying in such list any new Patents issued or filed, amended or supplemented, or any abandonments or other termination of prosecution.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercompany Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any license, settlement agreement or other agreement or arrangement between the Seller or any of its Affiliates, on the one hand, and any of the Seller&#x2019;s Affiliates, on the other hand, pursuant to which the Seller or any of its Affiliates obtains or grants a license, sublicense, or a covenant not to sue or similar grant of rights to any Patents or other Intellectual Property Rights owned or controlled by the Seller or any of its Affiliates that are necessary to commercially Manufacture the Product for Commercialization of the Product in the Territory or to Commercialize the Product in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Judgment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any judgment, order, writ, injunction, citation, award or decree of any nature.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all proprietary or confidential information, know-how and trade secrets, including processes, formulae, models and techniques, rights in research in progress, algorithms, data, databases, data collections, chemical and biological materials (including any compounds, DNA, RNA, clones, vectors, cells and any expression product, progeny, derivatives or improvements thereto), and the results of experimentation and testing, and samples.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any mortgage, lien, pledge, participation interest, charge, adverse claim, security interest, encumbrance or restriction of any kind, including any restriction on use, transfer or exercise of any other attribute of ownership of any kind.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Third Party (other than a Distributor) to whom any Related Party (including, for clarity, another Licensee) has granted a license or sublicense to Commercialize the Product in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all Judgments, damages, losses, claims, costs, liabilities and expenses, including reasonable fees and out-of-pocket expenses of counsel.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Third Party that is a party to any Contract Manufacturing Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means manufacturing, production, formulating, processing, filling, finishing, quality control, quality assurance, stability testing, packaging, labeling, shipping, importing, storage and similar activities with respect to a product (and components thereof or therefor), and regulatory compliance with respect to the foregoing.  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacture</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean to engage in Manufacturing. For clarity, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; excludes Commercialization activities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.2(b).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing Updates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a summary of material updates with respect to the Related Parties&#x2019; and Manufacturers&#x2019; Manufacturing of the Product for Commercialization in the Territory, including updates regarding pursuit of Authorized Stability Periods of at least [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any product, any and all approvals (including drug and/or device approval applications), licenses, registrations or authorizations sufficient to Commercialize such product in accordance with applicable laws (excluding any compassionate or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">emergency use or similar approval or authorization and excluding pricing or reimbursement approvals).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) a material adverse effect on (i) the Commercialization of the Product in the Territory, (ii) any of the Intellectual Property Rights or Marketing Approvals owned or controlled by Seller, Parent or its Affiliates directly related to the Commercialization of the Product in the Territory, (iii) the Seller&#x2019;s ability to commercially Manufacture or have Manufactured the Product for the Commercialization of the Product in the Territory, with a Commercial Launch in the Territory of no later than March 31, 2025, (iv) the legality, validity or enforceability of this Agreement, (v) the ability of the Seller or its Affiliates to perform any of its obligations under this Agreement, or (vi) the rights or remedies of the Buyer under this Agreement; or (b) an adverse effect in any material respect on the timing, duration, or amount of the payment of any of the Revenue Payments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the gross amount invoiced, billed or otherwise recorded for sales of the Product in the Territory by or on behalf of the Seller, its Affiliates, or any Licensee, in each case, to a Third Party in accordance with IFRS consistently applied (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gross Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), less the following amounts, to the extent actually incurred or accrued in calculating revenue from sales of the Product in the Territory  in accordance with IFRS consistently applied, and not reimbursed by or recovered from such Third Party; provided, that any given amount may be taken as a permitted deduction only once:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Sales shall be determined in U.S. dollars.  If Seller, its Affiliates, or any Licensee effects a sale, disposition, or transfer of a Product to a Third Party other than on customary commercial terms or for non-monetary consideration, the Net Sales of such Product to such Third Party shall be deemed to be &#x201c;the fair market value&#x201d; of such Product.  For purposes of the foregoing, &#x201c;fair market value&#x201d; means the value that would have been derived had such Product been sold as a separate product to another customer on customary commercial terms.  Net Sales will not include [***].  Net Sales shall also include [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Out-License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any license between the Seller or any of its Affiliates, on the one hand, and any Third Party, on the other hand, pursuant to which the Seller or any of its Affiliates grants a license or sublicense under any Intellectual Property Right owned or controlled by the Seller or any of its Affiliates to Commercialize the Product in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all patents and patent applications, including any continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any of the foregoing patent applications, any certificate, reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent or other governmental actions which extend any of the subject matter of a patent, and any substitution patent, confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Business Development Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.13.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of the following:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Any Lien granted as a replacement or substitute for any Liens in existence on the Effective Date; provided that any such replacement or substitute Lien (i) does not secure an aggregate amount of Indebtedness or other obligations, if any, greater than that secured on the Effective Date and (ii) does not encumber any property other than the property subject thereto on the Effective Date (plus improvements and accessions to such property);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Liens for taxes not yet due or that are being contested in good faith by appropriate proceedings diligently conducted;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	statutory or common law Liens of landlords, carriers, warehousemen, mechanics, materialmen, repairmen, construction contractors or other like Liens that secure amounts not overdue for a period of more than [***] or that are being contested in good faith by appropriate proceedings diligently conducted;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	in connection with any secured Indebtedness that the Parent, Seller and/or any Affiliate of the Parent or Seller incur from a Third Party, a Lien on the US Product Rights or any &#x201c;proceeds&#x201d; (as defined in the UCC) thereof; provided that any such Third Party enters into a Customary Intercreditor Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Secured Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	the Back-Up Security Interest;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	licenses, sublicenses or similar grants of rights in connection with licensing or collaboration transactions otherwise permitted by this Agreement; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	the 2023 Back-Up Security Interest.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Out-License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) a written Out-License to a Permitted Transferee or with a Distributor (acting solely as a Distributor), or (b) a Co-Commercialization Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Secured Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the definition of &#x201c;Permitted Liens.&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Transferee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any individual, firm, corporation, company, partnership, limited liability company, trust, joint venture, association, estate, trust, Governmental Entity or other entity, enterprise, association or organization.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prime Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the prime rate published by The Wall Street Journal, from time to time, as the prime rate.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any product that (a) contains a parathyroid hormone-based active ingredient or active moiety and (b) has received a Marketing Approval in the Territory for hypoparathyroidism.  &#x201c;Product&#x201d; includes palopegteriparatide, also known as TransCon PTH or YORVIPATH for which the FDA has approved Seller&#x2019;s NDA 216490.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product IP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 4.10(b).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means one hundred and fifty million dollars ($150,000,000).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receiving Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 9.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Governmental Entity, including the FDA, which has responsibility in granting a Marketing Approval.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each of the Seller, its Affiliates, and their respective Licensees, as applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representative</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, (a) any direct or indirect member or partner of such Person and (b) any manager, director, trustee, officer, employee, agent, advisor or other representative (including attorneys, accountants, consultants, contractors, actual and potential lenders, investors, co-investors and assignees, bankers and financial advisers) of such Person.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Participation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the right to receive payment in full of all Revenue Payments, and an undivided ownership interest in all Net Sales occurring from and after the date hereof, including all accounts (as defined in the UCC), general intangibles (as defined in the UCC), payment intangibles (as defined in the UCC) and all other rights to payment on account of, in connection with or arising from such Net Sales, and all proceeds thereof, in an amount equal to the Revenue Percentage.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means for each Calendar Quarter occurring (in whole or in part) during the Revenue Payment Term, an amount payable to the Buyer equal to the product of (a) Net Sales during such Calendar Quarter (or, for any Calendar Quarter occurring in part during the Revenue Payment Term, Net Sales for the calendar days falling within the Revenue Payment Term during such Calendar Quarter) and (b) the Revenue Percentage.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Payment Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period commencing on the date hereof and ending on the earliest to occur of the following: (a) the date on which the product of Net Sales occurring from and after the date hereof and until and including December 31, 2029 multiplied by the Revenue Percentage equals or exceeds 1.65 times the Purchase Price, if such date occurs on or before December 31, 2029, (b) the date on which the product of Net Sales occurring from and after the date hereof multiplied by the Revenue Percentage equals or exceeds 2.0  times the Purchase Price or (c) the date on which the Buy-Out Payment is paid to the Buyer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Percentage</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means 3.0%.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.3(c).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safety Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any recalls, field notifications, market withdrawals, warnings, &#x201c;dear doctor&#x201d; letters, investigator notices, safety alerts or other notices of action relating to an alleged lack of safety or regulatory compliance of the Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seller</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seller Indemnified Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 8.1(b).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any federal, state, local or foreign income, gross receipts, license,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payroll, employment, excise, severance, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, abandoned property, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States of America (including its territories and possessions).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Person that is not the Seller or an Affiliate of the Seller.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UCC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Uniform Commercial Code in the State of New York; provided, that, if with respect to any financing statement or by reason of any provisions of law, the perfection, priority or the effect of perfection, priority or non-perfection of the security interests granted to the Administrative Agent pursuant to this Agreement is governed by the Uniform Commercial Code in a jurisdiction of the United States other than New York, then &#x201c;UCC&#x201d; means the Uniform Commercial Code in such other jurisdiction for purposes of the provisions of this Agreement and any financing statement relating to such perfection, priority or effect of perfection, priority or non-perfection.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">US Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">US Product Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) the Intellectual Property Rights set forth in the sections of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule entitled &#x201c;Existing Patents for US Product Rights Only&#x201d;, &#x201c;Trademarks and Trademark Applications for US Product Rights&#x201d; and &#x201c;Domain Names for US Product Rights&#x201d;; (b) any other Intellectual Property Rights owned or controlled by the Seller or any of its Affiliates at any time during the term of this Agreement that directly relate to the Commercialization of the Product in the Territory and that are registered or pending at the United States Patent and Trademark Office, but excluding those Intellectual Property Rights that are necessary to make, have made, sell, offer for sale, use, import or otherwise exploit the Ascendis Technology in or outside the Territory, (c) Seller&#x2019;s NDA 216490, and (d) any future Marketing Approvals for the Product in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.2	Certain Interpretations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	&#x201c;either&#x201d; and &#x201c;or&#x201d; are not exclusive and &#x201c;include,&#x201d; &#x201c;includes&#x201d; and &#x201c;including&#x201d; are not limiting and shall be deemed to be followed by the words &#x201c;without limitation;&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	&#x201c;extent&#x201d; in the phrase &#x201c;to the extent&#x201d; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#x201c;if;&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	&#x201c;hereof,&#x201d; &#x201c;hereto,&#x201d; &#x201c;herein&#x201d; and &#x201c;hereunder&#x201d; and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	references to a Person are also to its permitted successors and assigns;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	definitions are applicable to the singular as well as the plural forms of such terms;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	references to an &#x201c;Article,&#x201d; &#x201c;Section&#x201d; or &#x201c;Exhibit&#x201d; refer to an Article or Section of, or an Exhibit to, this Agreement, and references to a &#x201c;Schedule&#x201d; refer to the corresponding part of the Disclosure Schedule;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	provisions referring to matters that would or could have, or would or could reasonably be expected to have, or similar phrases, shall be deemed to have such result or expectation with or without the giving of notice or the passage of time, or both;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement or any related document shall be prepared in conformity with IFRS;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	for covenants that are to be undertaken &#x201c;reasonably&#x201d; by the Seller or its Affiliates, such actions (or inactions) shall take into account the Buyer&#x2019;s economic interest in the Revenue Participation Right and the Revenue Payments and the impact of the applicable action (or inaction) on such interest; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	references to &#x201c;$&#x201d; or otherwise to dollar amounts refer to the lawful currency of the United States.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.3	Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The table of contents and the descriptive headings of the several Articles and Sections of this Agreement and the Exhibits and Schedules are for convenience only, do not constitute a part of this Agreement and shall not control or affect, in any way, the meaning or interpretation of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>PURCHASE, SALE AND ASSIGNMENT OF THE REVENUE PARTICIPATION RIGHT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1	Purchase, Sale and Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the Effective Date and upon the terms and subject to the conditions of this Agreement, in exchange for the Buyer&#x2019;s payment of the Purchase Price, the Seller shall (and Parent shall and shall cause its Affiliate(s) to) sell, transfer, assign and convey to the Buyer, and the Buyer shall purchase, acquire and accept from the Seller (either directly or through the Seller&#x2019;s Affiliates), the Revenue Participation Right free and clear of all Liens. From and after the Effective Date, each of the Parent and the Seller relinquishes all of the Seller&#x2019;s, the Parent&#x2019;s and their Affiliates&#x2019; right, title and interest in and to the Revenue Participation Right, and all such right, title and interest shall vest in the Buyer. In addition, the Seller hereby agrees to pay to the Buyer the Revenue Payments on the terms and conditions set forth herein.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2	No Assumed Obligations, Etc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding any provision in this Agreement to the contrary, the Buyer is, on the terms and conditions set forth in this Agreement, only purchasing, acquiring and accepting the Revenue Participation Right and is not assuming any liability or obligation of the Seller, the Parent or its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter.  Except as specifically set forth herein in respect of the Revenue Participation Right, the Buyer does not, by such purchase, acquisition and acceptance of the Revenue Participation Right, acquire any other rights of the Seller, the Parent or its Affiliates, or any other assets of the Seller, the Parent or its Affiliates, in each case, other than to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent of the Back-Up Security Interest granted pursuant to the terms of this Agreement ([***]).  For the avoidance of doubt and notwithstanding anything herein to the contrary, nothing in this provision limits any other obligation of the Buyer, the Parent or the Seller under this Agreement or otherwise, including without limitation any indemnity obligations under ARTICLE 8.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3	True Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. It is the intention of the parties hereto that the sale, transfer, assignment and conveyance of the Revenue Participation Right contemplated by this Agreement be, and is, a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by the Seller (on behalf of itself and, as applicable, its Affiliates) to the Buyer of all of the Seller&#x2019;s and its Affiliates&#x2019; rights, title and interests in and to the Revenue Participation Right (except as otherwise required by IFRS solely for financial reporting purposes or by applicable tax law in Denmark solely for Danish tax purposes). None of the Seller, the Parent nor the Buyer intends the transactions contemplated by this Agreement to be, or for any purpose characterized as, a loan from the Buyer to the Seller, or a pledge, a financing transaction or a borrowing (except as otherwise required by IFRS solely for financial reporting purposes or by applicable tax law in Denmark solely for Danish tax purposes).  It is the intention of the parties hereto that the beneficial interest in and title to the Revenue Participation Right and any &#x201c;proceeds&#x201d; (as such term is defined in the UCC) thereof shall not be part of the Seller&#x2019;s, the Parent&#x2019;s or their Affiliates&#x2019; estates in the event of the filing of a petition by or against the Seller, the Parent or any of their Affiliates under any Bankruptcy Laws.  The Seller and the Parent each (on behalf of itself and, as applicable, its Affiliates) hereby waives, to the maximum extent permitted by applicable law, any right to contest or otherwise assert that the sale contemplated by this Agreement does not constitute a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by the Seller (directly or through one or more of its Affiliates) to the Buyer of all of the Seller&#x2019;s and its Affiliates&#x2019; right, title and interest in and to the Revenue Participation Right under applicable law, which waiver shall, to the maximum extent permitted by applicable law, be enforceable against the Seller, the Parent and their Affiliates in any bankruptcy or insolvency proceeding relating to the Seller, the Parent or any of their Affiliates. Accordingly, the Seller, the Parent and their Affiliates shall treat the sale, transfer, assignment and conveyance of the Revenue Participation Right as a sale of &#x201c;accounts,&#x201d; or &#x201c;payment intangibles&#x201d; (as appropriate) in accordance with the UCC, and each of the Seller and the Parent hereby authorizes the Buyer and its representatives at any time to file one or more financing statements or any amendments to financing statements previously filed by the Buyer (and continuation statements with respect to such financing statements when applicable) naming the Seller (or its Affiliate) as the &#x201c;seller&#x201d; and the Buyer as the &#x201c;buyer&#x201d; in respect of the Revenue Participation Right.  Not in derogation of the foregoing statement of the intent of the parties hereto in this regard, and for the purposes of providing additional assurance to the Buyer, including in the event that, despite the intent of the parties hereto, the sale, transfer, assignment and conveyance contemplated hereby is hereafter held not to be a sale, each of the Seller and the Parent (on its own behalf and on behalf of its Affiliates, as applicable) hereby grants, and by delivery of [***] shall grant, to the Buyer a security interest in, to and under the Revenue Participation Right, the Revenue Payments, the US Product Rights and any &#x201c;proceeds&#x201d; (as defined in the UCC) of each of the foregoing as security for all of the Seller&#x2019;s, the Parent&#x2019;s and their Affiliates&#x2019; obligations under this Agreement [***], including the obligations to pay the Revenue Payments (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Back-Up Security Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and each of the Seller and the Parent (on its own behalf and on behalf of its Affiliates) does hereby authorize the Buyer and its representatives, from and after the Effective Date, to file one or more financing statements (and continuation statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any amendments with respect to such financing statements when applicable) in such manner and such jurisdictions as are necessary or appropriate to perfect such Back-Up Security Interest.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>CLOSING; PAYMENT OF PURCHASE PRICE</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1	Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The purchase and sale of the Revenue Participation Right shall take place remotely via the exchange of documents and signatures on the date hereof or such other place, time and date as the parties hereto may mutually agree.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.2	Payment of Purchase Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the Effective Date, the Buyer shall pay to the Seller the Purchase Price by wire transfer of immediately available funds to the account specified on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, without set-off, reduction or deduction, or withholding for or on account of any Taxes.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.3	Bill of Sale [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  On the Effective Date, upon confirmation of the receipt of the Purchase Price, (a) the Seller shall deliver (and the Seller or the Parent shall cause their Affiliate(s) to deliver) to the Buyer a duly executed bill of sale and agreement evidencing the sale, transfer, assignment and conveyance of the Revenue Participation Right and certain other agreements in form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bill of Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and (b) [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4	Seller Form W-8BEN-E</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.   On or prior to the Effective Date, the Seller shall deliver to the Buyer a valid, properly executed IRS Form W-8BEN-E certifying that the Seller is exempt from U.S. federal backup withholding tax.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5	Buyer Form W-9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.   On or prior to the Effective Date, the Buyer shall deliver to the Seller a valid, properly executed IRS Form W-9 certifying that the Buyer is exempt from U.S. federal withholding and backup withholding tax with respect to the Revenue Payments.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>REPRESENTATIONS AND WARRANTIES OF THE SELLER</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on the Disclosure Schedule attached hereto, the Parent (as to Section 4.1 through Section 4.5) and the Seller each represents and warrants to the Buyer that as of the Effective Date:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.1	Existence; Good Standing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Seller is a corporation, duly organized and validly existing under the laws of Denmark.  The Parent is a public limited liability company (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aktieselskab</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) duly organized and validly existing under the laws of Denmark.  Each of the Seller and the Parent is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in good standing has not and would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.2	Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each of the Seller and the Parent has all requisite corporate power and authority to execute, deliver and perform its respective obligations under this</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement.  The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary corporate action on the part of the Seller and the Parent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3	Enforceability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement has been duly executed and delivered by each of the Seller and the Parent and constitutes the valid and legally binding obligation of each of the Seller and the Parent, enforceable in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4	No Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The execution, delivery and performance by the Seller and the Parent of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i) contravene or conflict with the organizational documents of the Seller or the Parent, (ii) contravene or conflict with or constitute a material default under any material provision of any law binding upon or applicable to the Seller or the Parent or the Revenue Participation Right or (iii) contravene or conflict with or constitute a material default under any material agreement or Judgment binding upon or applicable to the Seller, the Parent or any of its Affiliates.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.5	Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for any filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Seller or any of its Affiliates in connection with (i) the execution and delivery by the Seller and the Parent of this Agreement, (ii) the performance by the Seller and the Parent of its respective obligations under this Agreement, or (iii) the consummation by the Seller or the Parent of any of the transactions contemplated by this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.6	No Litigation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither the Seller nor any of its Affiliates is a party to, and none has received any written notice of, any action, claim, suit, investigation or proceeding pending before any Governmental Entity and, to the knowledge of the Seller, no such action, claim, suit, investigation or proceeding has been threatened against the Seller or any of its Affiliates, that, either individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.7	Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	All applications, submissions, information and data related to the Product submitted or utilized as the basis for any request to any Regulatory Authority by or on behalf of the Seller or any of its Affiliates were true and correct in all material respects as of the date of such submission or request, and any material updates, changes, corrections or modification to such applications, submissions, information or data required under applicable laws or regulations have been submitted to the necessary Regulatory Authorities, in each case, for the Commercialization of the Product in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Seller has provided to the Buyer prior to the Effective Date in the data room available to the Buyer true, correct and complete copies of all material communications sent or received since September 1, 2021 by the Seller and any of its Affiliates to or from any Regulatory Authorities related to the Commercialization of the Product in the Territory or the Manufacture of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Product anywhere in the world for Commercialization in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	To the knowledge of Seller, neither the Seller nor any of its Affiliates has committed any act, made any statement or failed to make any statement in respect of the Product that would reasonably be expected to provide a basis for the FDA to invoke its policy with respect to &#x201c;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#x201d;, or any other Regulatory Authority to invoke similar policies, set forth in any applicable laws or regulations.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Since September 1, 2021 (A) there have been no Safety Notices, (B) to the knowledge of the Seller, there are no unresolved material product complaints with respect to the Product in the Territory, which would result in a Material Adverse Effect, and (C) to the knowledge of the Seller, there are no facts currently in existence that would, individually or in the aggregate, reasonably be expected to result in (1) a material Safety Notice with respect to any Product or (2) a material change in the labeling of the Product in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The Seller and its Affiliates have not experienced any significant failures in the commercial Manufacturing of the Product for Commercialization in the Territory that have not been resolved, or that would, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred again, a Material Adverse Effect. No facts exist with respect to, and the Seller does not expect any impediments to, the Manufacturing of the Product that would, individually or in the aggregate, reasonably be expected to delay Commercial Launch beyond March 31, 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	To the knowledge of the Seller, the Seller and its Affiliates are, and have been, in compliance with all applicable laws administered or issued by the FDA or any similar Regulatory Authority in each country where the Product has been, or is intended to be, Manufactured for Commercialization in the Territory, including the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, applicable requirements in FDA regulations, and any orders issued by FDA or similar Regulator Authorities in each country where the Product has been Manufactured for Commercialization in the Territory, and all other laws regarding ownership, developing, testing, Manufacturing, disposal, Commercializing, and complaint handling or adverse event reporting for the products of the Seller or its Affiliates, except to the extent that such failure to comply with such applicable laws would not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.8	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses and Intercompany Agreements.  There are no In-Licenses or Out-Licenses.  There are no Intercompany Agreements other than the Existing Intercompany Agreements.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.9	Manufacturing Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A true, correct and complete copy of each Contract Manufacturing Agreement (together with any amendment, supplement or modification thereto) pursuant to which commercial Manufacturing of the Product is carried out, or is scheduled or intended to be carried out, for the Commercialization of the Product in the Territory that is currently in effect to which Seller or any of its Affiliates is a party has been provided in the data room and is listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Contract Manufacturing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Each Existing Contract Manufacturing Agreement is in full force and effect in accordance with its terms. There is and has been no breach or default under any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provision of any Existing Contract Manufacturing Agreement either by the Seller or any of its Affiliates or, to the knowledge of the Seller, by the respective counterparty (or any predecessor thereof) thereto, and no termination of any Existing Contract Manufacturing Agreements has been notified or threatened.  No party to any Existing Contract Manufacturing Agreement has assigned all or part of such Existing Contract Manufacturing Agreement to any other Person.  The Existing Contract Manufacturing Agreements, collectively, obligate the Manufacturer that is party thereto to supply the Seller and its Affiliates with sufficient quantities of YORVIPATH to meet Seller&#x2019;s and its Affiliates&#x2019; currently existing Commercialization forecast for YORVIPATH in the Territory in 2025 in accordance with the applicable forecasting mechanisms and commitment schedules in each such Existing Contracts Manufacturing Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.10	Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule lists all of the currently existing Patents owned or controlled by Seller or its Affiliates that directly relate to the Manufacture of the Product for Commercialization of the Product in the Territory or Commercialization of the Product in the Territory (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule, the Seller is the sole and exclusive registered owner of all the Existing Patents. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule specifies the respective patent or patent application numbers as to each listed Patent or patent application within the Existing Patents.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule specifies any Person other than the Seller owning or having an interest in any Existing Patent, including the nature of such interest.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	None of the Seller nor any of its Affiliates is a party to any pending, and, to the knowledge of the Seller, there is no threatened, litigation, interference, reexamination, opposition or like procedure involving any of the Existing Patents or other Intellectual Property Rights owned or controlled by Seller or any of its Affiliates that directly relate to the Manufacture of the Product for Commercialization of the Product in the Territory or Commercialization of the Product in the Territory (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product IP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	All of the issued Patents within the Existing Patents are enforceable, in full force and effect, and have not lapsed, expired or otherwise terminated and, to the knowledge of the Seller, are valid. None of the Seller nor any of its Affiliates has received any written notice relating to the lapse, expiration or other termination of any of the issued Patents within the Existing Patents.  None of the Seller nor any of its Affiliates has received any written notice or written legal opinion from a Third Party that alleges that any Product IP is invalid or unenforceable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	None of the Seller nor any of its Affiliates has received any written notice that there is any, and, to the knowledge of the Seller, there is no, Person who is or claims to be an inventor under any of the Existing Patent who is not a named inventor thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The Seller or its Affiliate has paid all maintenance fees, annuities and like payments required with respect to all of the Existing Patents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	To the knowledge of the Seller, (i) the Commercialization of the Product in the Territory and the Manufacture of the Product for Commercialization of the Product in the Territory has not and will not, infringe, misappropriate or otherwise violate any Patent or other Intellectual</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property Rights of any Third Party as of the Effective Date (without reference to any safe harbor), and (ii) no Person is infringing, misappropriating or otherwise violating, or threatening to infringe, misappropriate or otherwise violate, any Product IP.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.11	Title to Revenue Participation Right; No Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Seller and/or its Affiliates holds all rights, interests, and title necessary to sell, transfer, assign and convey the Revenue Participation Right to the Buyer. From and after the Effective Date, the Buyer will have acquired, subject to the terms and conditions set forth in this Agreement, good and marketable title to the Revenue Participation Right and Revenue Payments, in each case free and clear of all Liens (other than the Back-Up Security Interest, which shall be a first priority Lien). None of the property or assets of the Seller or any of its Affiliates is subject to, or encumbered by, any Lien, other than (i) the Revenue Participation Right and Revenue Payments, which are covered by the immediately preceding sentence and (ii) the 2023 Back-Up Security Interest granted to the Buyer pursuant to the 2023 Agreement.  The Seller, together with the Parent, [***], holds all rights, interests, and title necessary to fully grant or authorize the grant of the Back-Up Security Interest.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.12	Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule sets forth a complete list of the outstanding Indebtedness of, or incurred by, the Seller and its Affiliates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.13	Lien Related Representation and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Seller&#x2019;s exact legal name (as defined in Section 9-503 of the UCC) is, and has since November 2016  been, &#x201c;Ascendis Pharma Bone Diseases A/S&#x201d;. Prior to November 2016, the legal name of Seller was Ascendis Pharma Osteoarthritis Division A/S.  The Seller is, and for the prior ten (10) years has been, a corporation and incorporated in Denmark.  The Parent&#x2019;s exact legal name (as defined in Section 9-503 of the UCC) is, and for the immediately preceding ten (10) years has been, &#x201c;Ascendis Pharma A/S&#x201d;.  The Parent is, and since February 2, 2015 has been, a public limited liability company (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aktieselskab</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) organized under the laws of Denmark.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.14	Brokers&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for Evercore Group L.L.C., there is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Seller or any of its Affiliate who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.15	Foreign Corrupt Practices Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  None of the Seller or its Affiliates nor, to the knowledge of Seller, any of its or their directors, officers, employees or agents have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any &#x201c;foreign official&#x201d; (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FCPA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order to assist the Seller or any of its Affiliates in obtaining or retaining business for or with, or directing business to, any person. None of the Seller or any of its Affiliates nor, to the knowledge of Seller, any of its or their directors, officers, employees or agents have made or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. The Seller further represents that it has maintained, and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has caused each of its Affiliates to maintain, systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) and written policies designed to ensure compliance with the FCPA or any other applicable anti-bribery or anti-corruption law.  To the knowledge of the Seller, neither the Seller nor any of its Affiliates or its or their officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.16	Additional Products</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  [***], in each case other than YORVIPATH.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>REPRESENTATIONS AND WARRANTIES OF THE BUYER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Buyer hereby represents and warrants to the Seller that as of the Effective Date:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1	Existence; Good Standing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Buyer is a limited liability company duly organized, validly existing and in good standing under the laws of Delaware.   The Buyer is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in good standing has not and would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2	Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Buyer has the requisite right, power and authority to execute, deliver and perform its obligations under this Agreement.  The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary action on the part of the Buyer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.3	Enforceability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement has been duly executed and delivered by an authorized person of the Buyer and constitutes the valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.4	No Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The execution, delivery and performance by the Buyer of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i) contravene or conflict with the organizational documents of the Buyer, (ii) contravene or conflict with or constitute a material default under any material provision of any law binding upon or applicable to the Buyer or (iii) contravene or conflict with or constitute a material default under any material agreement or Judgment binding upon or applicable to the Buyer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5	Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for the filing of financial statement(s) in accordance with Section 2.3 or any filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Buyer in connection with (i) the execution and delivery by the Buyer of this Agreement, (ii) the performance by the Buyer of its obligations under this Agreement or (iii) the consummation by the Buyer of any of the transactions contemplated by this Agreement.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.6	No Litigation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  There is no action, claim, suit, investigation or proceeding pending or, to the knowledge of the Buyer, threatened before any Governmental Entity to which the Buyer is a party that would reasonably be expected to prevent or materially and adversely affect the ability of the Buyer to perform its obligations under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.7	Financing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Buyer has sufficient cash to pay the Purchase Price on the Effective Date. The Buyer acknowledges that its obligations under this Agreement are not contingent on obtaining financing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.8	Brokers&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Buyer who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>NO OTHER REPRESENTATIONS AND WARRANTIES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT AND ANY DOCUMENTS OR INSTRUMENTS DELIVERED HEREUNDER, NONE OF THE PARTIES HERETO MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENT RIGHTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>COVENANTS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.1	Seller Diligence Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.   The Seller shall, directly or indirectly through its Affiliates or any Licensees or Manufacturers, use Commercially Reasonable Efforts to Manufacture the Product for Commercialization in the Territory, and  Commercialize the Product in the Territory.  In furtherance of the foregoing, (i) the Seller shall and shall cause its Affiliates to use Commercially Reasonable Efforts to prepare, execute, deliver and file any and all agreements, documents or instruments, or amendments or modifications to any existing agreements, documents or instruments, that are necessary or desirable to (A) secure and maintain any Marketing Approval that is necessary or useful to Manufacture the Product for Commercialization in the Territory and Commercialize the Product in the Territory and (B) obtain an Authorized Stability Period of at least [***], and (ii) the Seller shall not, and shall cause its Affiliates to not, withdraw or abandon, or fail to take any action necessary to prevent the withdrawal or abandonment of, any Marketing Approval for the Product in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.2	Reporting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	From and after the Effective Date, the Seller shall provide the Buyer promptly following the end of each Calendar Quarter, but in any event no later than [***] calendar days</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after the end of such Calendar Quarter, a reasonably detailed report (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial &amp; IP Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) setting forth, with respect to such same period, (i) the Commercial Updates and (ii) the Intellectual Property Updates.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	From and after the Effective Date until receipt of an Authorized Stability Period of at least [***], the Seller shall provide the Buyer promptly following the end of each Calendar Quarter (or, after receipt of an Authorized Stability Period of at least [***], promptly following the end of each Calendar Year), but in any event no later than [***] calendar days after the end of such Calendar Quarter or Calendar Year, as applicable, a reasonably detailed report (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) setting forth, with respect to such same period, the Manufacturing Updates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	In addition to the information provided in the Commercial &amp; IP Reports and Manufacturing Reports, the Seller shall provide the Buyer with such additional information directly related to the Product in the Territory (including with respect to Commercialization (including the anticipated Commercial Launch) and Manufacturing) as the Buyer may reasonably request from time to time in writing, which additional information the Seller may provide orally; provided, that, after receipt of an Authorized Stability Period of at least [***], the Buyer shall make such requests for additional information no more frequently than [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The Seller shall prepare and maintain and shall cause its Affiliates and any Licensees and Manufacturers to prepare and maintain reasonably complete and accurate records of the information to be disclosed in each Commercial &amp; IP Report and Manufacturing Report. In addition, the Seller shall provide the Buyer with prompt (and in any event within [***] Business Days) written notice of (i) any Safety Notices, (ii) any developments that would reasonably be expected to cause the Commercial Launch to occur later than March 31, 2025, and (iii) if Commercial Launch does not occur by March 31, 2025, any developments that would reasonably be expected to further delay Commercial Launch thereafter.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.3	Revenue Payments; Revenue Payment Details; Buy-Out Payment.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	For each Calendar Quarter occurring (in whole or in part) during the Revenue Payment Term, the Seller shall pay to the Buyer the Revenue Payment for each such Calendar Quarter promptly, but in any event no later than [***] calendar days after the end of each such Calendar Quarter.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Provided that the Buyer has complied with its obligations under Section 3.5 of this Agreement (and, if applicable, any assignee has provided Seller with a valid and properly executed IRS Form W-9 or applicable IRS Form W-8 confirming that no withholding is required for U.S. federal income tax purposes), the Seller shall make all payments required to be made by it to the Buyer pursuant to this Agreement in U.S. dollars by wire transfer of immediately available funds, without set-off, reduction or deduction, or withholding for or on account of any Taxes, to the bank account designated in writing from time to time by the Buyer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	For each Calendar Quarter occurring (in whole or in part) during the Revenue Payment Term, the Seller shall provide the Buyer promptly following the end of such Calendar Quarter, but in any event no later than [***] calendar days after the end of such Calendar Quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or promptly after the Seller has issued quarterly or annual financial statements for public use, if later than [***] calendar days after the end of the applicable Calendar Quarter, a report (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) setting forth in reasonable detail (i) Gross Sales and Net Sales for such Calendar Quarter and Calendar Year to date (including a detailed break-down of all permitted deductions from Gross Sales used to determine Net Sales [***]), and (ii) the calculation of the Revenue Payment payable to the Buyer for the applicable Calendar Quarter, identifying [***] sold by the Seller, its Affiliates and each Licensee in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	If at any time during the term of this Agreement:</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Seller or one or more of its Affiliates enters into a definitive agreement for or otherwise obtains knowledge of a Change of Control, the Seller shall provide prompt (and in any event within [***] Business Days) written notice thereof to the Buyer, which notice shall include reasonable detail as to the Change of Control, including the parties to such Change of Control; and if a Change of Control occurs or is consummated, the Seller shall, concurrently with the occurrence or consummation of such Change of Control pay (or cause to be paid) to the Buyer the applicable Buy-Out Payment by wire transfer of immediately available funds to one or more accounts specified by the Buyer; or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Seller desires to pay the Buy-Out Payment and terminate this Agreement, the Seller shall provide the Buyer with written notice (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buy-Out Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that the Seller is electing to make the Buy-Out Payment, which election shall be irrevocable, and the Seller shall, on the [***] Business Days following delivery of such notice pay to the Buyer the applicable Buy-Out Payment amount by wire transfer of immediately available funds to one or more accounts specified by the Buyer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.4	Inspections and Audits of the Seller</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Upon reasonable prior written notice and during normal business hours, the Buyer may cause an inspection and/or audit, by an independent public accounting firm reasonably acceptable to the Seller and subject to a confidentiality agreement between the Seller and such public accounting firm reasonably acceptable to the Seller, the Buyer and such independent public accounting firm, of the Seller&#x2019;s and its Affiliates&#x2019; books of account, for the sole purpose of determining the correctness of the Revenue Payments made under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Any such inspection and/or audit shall be permitted with respect to the Revenue Payments no more frequently than [***] for the Seller&#x2019;s and its Affiliates&#x2019; books of account for any period commencing [***] preceding the Calendar Year in which the Buyer submits the written request for such inspection and/or audit. In connection with any such inspection and/or audit, upon the Buyer&#x2019;s request, the Seller and its Affiliates shall exercise any rights it may have under any Out-License relating to the Product to cause an inspection and/or audit by an independent public accounting firm to be made of the books of account of any counterparty thereto for the purpose of determining the correctness of the Revenue Payments made under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	All of the expenses of any inspection or audit requested by the Buyer hereunder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="docxtextref11"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(including the fees and expenses of such independent public accounting firm designated for such purpose) shall be borne by </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Buyer, if the independent public accounting firm determines that the Revenue Payments previously paid were incorrect by an amount less than or equal to [***] of the Revenue Payments actually paid or (ii) the Seller, if the independent public accounting firm determines that the Revenue Payments previously paid were incorrect by an amount greater than [***] of the Revenue Payments actually paid.  Any such independent public accounting firm shall not disclose to the Buyer the confidential information of the Seller or any counterparty to any Out-License relating to the Product except to the extent such disclosure is either necessary to determine the correctness of a Revenue Payment or otherwise would be included in a Commercial &amp; IP Report, Manufacturing Report or Revenue Report. All information obtained by the Buyer as a result of any such inspection or audit shall be Confidential Information subject to ARTICLE 9.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Notwithstanding the foregoing, in the event Seller disputes any of the inspection and/or audit results of Section 7.4(a), the parties shall work in good faith to resolve the dispute. If the parties are unable to reach a mutually acceptable resolution of any such dispute within [***] days, the dispute shall be submitted for resolution to an independent certified public accounting firm jointly selected by [***] or to such other Person as the parties shall mutually agree (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Arbitrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The decision of Audit Arbitrator shall be final and the costs of such arbitration as well as the initial audit shall be borne between the parties consistent with Section 7.4(c). Not later than [***] days after such decision and in accordance with such decision, the audited party shall pay the additional amounts, with interest from the date originally due in accordance with Section 7.12, or the auditing party shall reimburse the excess payments, as applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.5	Intellectual Property Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Seller shall provide to the Buyer a copy of any written notice received by any Related Party or Manufacturer from a Third Party alleging or claiming that the Commercialization of the Product in the Territory or the Manufacture of the Product for Commercialization in the Territory infringes or misappropriates any Patents or other intellectual property rights of a Third Party, together with copies of material correspondence sent or received by any Related Party or Manufacturer related thereto, as soon as practicable and in any event not more than [***] Business Days following such delivery or receipt.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Seller shall promptly inform the Buyer upon filing or otherwise submitting a written claim to a Third Party of any infringement or misappropriation by such Third Party of any Patent or other Intellectual Property Right owned or controlled by Seller, Parent or its Affiliates that directly relates to the Commercialization of the Product in the Territory or the Manufacture of the Product for Commercialization in the Territory, or if Seller, Parent or its Affiliates receive a written notice from a Third Party alleging that any such Patent or other Intellectual Property Right owned or controlled by Seller, Parent or its Affiliates that directly relates to the Commercialization of the Product in the Territory or the Manufacture of the Product for Commercialization in the Territory is invalid or unenforceable; provided, that, reasonably prior to the Seller&#x2019;s or any of its Affiliate&#x2019;s initiating, or permitting a Licensee to initiate, an enforcement action regarding any suspected infringement or misappropriation by a Third Party of any such Patent or other Intellectual Property Right owned or controlled by Seller, Parent or its Affiliates that directly relates to the Commercialization of the Product in the Territory or the Manufacture of the Product for Commercialization in the Territory, the Seller shall provide the Buyer with written notice of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such enforcement action and thereafter shall provide the Buyer with such additional information on a regular basis.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Seller shall, or shall cause another Related Party to, diligently file, prosecute, and maintain all Patents owned or controlled by Seller or its Affiliates that directly relate to the Commercialization of the Product in the Territory or the Manufacture of the Product for Commercialization in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	If the Seller or any of its Affiliates or Licensees recovers monetary damages from a Third Party, where such damages, whether in the form of judgment or settlement, result from the infringement by such Third Party of any Patents that directly relate to the Commercialization of the Product in the Territory, such recovery will be allocated first to the reimbursement of any expenses incurred by the Seller and its Affiliates or Licensees in bringing such action (including all reasonable attorneys&#x2019; fees), and any remaining amounts will be [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.6	In-Licenses and Intercompany Agreements.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(a) The Seller shall promptly (and in any event within [***] Business Days) provide the Buyer with (i) executed copies of any In-License entered into by the Seller or any of its Affiliates, and (ii) executed copies of each material amendment, supplement, modification or written waiver of any provision of any In-License.  The Seller shall not, and shall cause its Affiliates not to, amend or modify in any material respect, terminate or assign, any In-License that may reasonably materially adversely affect the Buyer&#x2019;s rights or economic interests under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Seller shall, or shall cause its Affiliates (as applicable) to, comply in all material respects with its and their obligations under each In-License and shall not take any action or forego any action that would reasonably be expected to result in a material breach thereof. Promptly, and in any event within [***] Business Days following the Seller&#x2019;s or its Affiliate&#x2019;s notice to a counterparty to any In-License of an alleged breach by such counterparty under any such In-License, the Seller shall provide the Buyer with a copy thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Seller will, or will cause its Affiliates to, (i) maintain the Intercompany Agreements in a manner that permits the Seller and its Affiliates to Commercialize the Product in the Territory and Manufacture the Product for Commercialization in the Territory in accordance with the terms of this Agreement, and (ii) not assign, transfer, terminate, amend or waive any provision of, or otherwise modify, any Intercompany Agreement in any manner except, in the case of clauses (i) and (ii) above, that would not reasonably be expected to have a Material Adverse Effect, or to the extent otherwise required pursuant to a &#x201c;determination,&#x201d; within the meaning of Section 1313(a) of the US Code, or a comparable provision of non-U.S. law. In furtherance of the foregoing, the Seller shall not, and the Parent shall cause [***] not to, assign, transfer, terminate, amend or waive any provision of, or otherwise modify, [***] without obtaining the Buyer&#x2019;s prior written consent (not to be unreasonably conditioned, withheld or delayed), unless any such termination, amendment, waiver or modification is made as required pursuant to applicable law, including a &#x201c;determination&#x201d; within the meaning of Section 1313(a) of the US Code, or a comparable provision of non-U.S. law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.7	Out-Licenses and Contract Manufacturing Agreements.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Except for a Permitted Out-License, the Seller shall not, and shall not permit any of its Affiliates to, enter into an Out-License without the Buyer&#x2019;s prior written consent. The Seller shall notify the Buyer in writing at least [***] prior to the issuance of any public announcement regarding a Permitted Out-License, which notice shall include a copy of the draft public announcement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Seller shall not, and shall cause its Affiliates not to, (i) amend or modify in any material respect, terminate or assign any Out-License (except for a Permitted Out-License) without obtaining the Buyer&#x2019;s prior written consent (not to be unreasonably conditioned, withheld or delayed) or (ii) amend, modify, terminate or assign any Contract Manufacturing Agreement pursuant to which commercial Manufacturing of the Product is carried out, or is intended to be carried out, for the Commercialization of the Product in the Territory if such amendment, modification, termination or assignment of or to such Contract Manufacturing Agreement would reasonably be expected to have a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Seller shall promptly (and in any event within [***] Business Days) provide the Buyer with (i) executed copies of each Out-License, and (ii) executed copies of each material amendment, supplement, modification or written waiver of any provision of an Out-License.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The Seller shall provide the Buyer with prompt (and in any event within [***] Business Days) written notice of a breach by a counterparty to any Out-License of its obligations under any Out-License, in each case of which a member of the Seller&#x2019;s executive or legal team becomes aware.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The Seller shall provide the Buyer with written notice promptly (and in any event within [***] Business Days) following the termination of any Out-License.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.8	Disclosures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for a press release previously approved in form and substance by the Seller and the Buyer or any other public announcement using substantially the same text as such press release, neither the Buyer nor the Seller shall, and each party shall cause its respective Representatives, Affiliates and Affiliates&#x2019; Representatives not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Agreement or the subject matter hereof without the prior written consent of the other party except as may be required by applicable law or stock exchange rule (in which case either party required to make the press release or other public announcement or disclosure shall allow the other party reasonable time to comment on, and, if applicable, reasonably request the disclosing party to seek confidential treatment in respect of portions of, such press release or other public announcement or disclosure in advance of such issuance).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.9	Post-Closing Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Seller shall deliver to the Buyer within [***] Business Days after the Effective Date [***]. For the avoidance of doubt, the contents of [***] are Confidential Information of the Seller and subject to the terms and conditions of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.10	Efforts to Consummate Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the terms and conditions of this Agreement, each of the Seller, the Parent and the Buyer will use, and will cause its respective Affiliates to use, its and their commercially reasonable efforts to take, or cause to be taken, all</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions and to do, or cause to be done, all things reasonably necessary under applicable law to consummate the transactions contemplated by this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.11	Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Seller, the Parent and the Buyer agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to give effect to and carry on the transactions contemplated by this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="docxtextref12"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.12	Late Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A late fee of the lesser of </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> [***] over the Prime Rate, and </font><font id="docxtextref13"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the highest rate permitted under applicable law shall accrue on all unpaid amounts with respect to any payment owed to either party hereunder, including the Purchase Price or any Revenue Payment, from the date such obligation was due until the date payment is made. The imposition and payment of a late fee shall not constitute a waiver of the rights of either party with respect to such payment default.  [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.13	Negative Pledge; Preservation of Assets; Lien Cooperation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Seller and the Parent shall not, and shall not permit any of its respective Affiliates to, create, incur, assume or suffer to exist any Lien on the Revenue Participation Right, the Revenue Payments, the US Product Rights or any &#x201c;proceeds&#x201d; (as defined in the UCC) of each of the Revenue Participation Right, the Revenue Payments and the US Product Rights except for (a) the Back-Up Security Interest and (b) as applicable, any Permitted Lien.  Notwithstanding anything herein to the contrary, none of the Parent, the Seller nor any of their Affiliates shall take any actions, fail to take any actions, permit any actions, fail to permit any actions, enter into any contracts or arrangements, or amend, restate, supplement, waive any rights under or otherwise modify any contracts or arrangements in a manner that would, individually or in the aggregate, reasonably be expected to adversely affect in any material respect the Revenue Participation Right, the Revenue Payments, the commercial Manufacture of the Product for Commercialization in the Territory, the Commercial Launch of the Product in the Territory, or the Commercialization of the Product in the Territory, with the intent to circumvent the provisions of, or obligations under, this Agreement.  For clarity, this Agreement shall not be construed, understood, or interpreted to limit Seller, Parent or its Affiliates&#x2019; rights to (i) enter into any license or other similar arrangements between the Seller or any of its Affiliates, on the one hand, and any Third Party, on the other hand, pursuant to which the Seller or any of its Affiliates grants a license, sublicense or other similar rights under any Intellectual Property Right owned or controlled by the Seller or any of its Affiliates to make, have made, sell, offer for sale, import, use or otherwise exploit (w) the Ascendis Technology outside the Territory, (x) the Ascendis Technology in the Territory for purposes other than the commercial Manufacture or Commercialization of the Product in the Territory to the extent provided under this Agreement, (y) Intellectual Property Rights solely related to a product other than the Product in the Territory or (z) the Product outside the Territory and (ii) enable, permit or grant a Third Party to use or reference the Marketing Approval of the Product in the Territory for purposes outside of the Territory (such actions described in clauses (i) and (ii), a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Business Development Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Buyer agrees to cooperate with Seller, Parent and its Affiliates to reasonably accommodate any Permitted Business Development Transaction or any Permitted Secured Indebtedness, including to adjust, as necessary, the scope or priority of the Back-Up Security Interest. For the avoidance of doubt, for purposes of the 2023 Agreement, the Buyer, in its capacity as a party to the 2023 Agreement, hereby consents to the Seller and the Parent&#x2019;s entry</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">into this Agreement and the grant of the Back-Up Security Interest to the Buyer hereunder, notwithstanding Section 7.13 of the 2023 Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>INDEMNIFICATION</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1	General Indemnity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Subject to Section 8.3, from and after the Effective Date:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link14"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Seller and the Parent hereby agree to, jointly and severally, indemnify, defend and hold harmless the Buyer and its Affiliates and its and their directors, managers, trustees, officers, agents and employees (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buyer Indemnified Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from, against and in respect of all Losses suffered or incurred by the Buyer Indemnified Parties to the extent arising out of or resulting from (i) </font><font id="ole_link2"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any breach of any of the representations or warranties (in each case, when made) of the Seller or the Parent in this Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (including the Bill of Sale [***]) and (ii) any breach of any of the covenants or agreements of the Seller or the Parent in this Agreement (including the Bill of Sale [***]); provided, however, that the foregoing shall exclude any indemnification to any Buyer Indemnified Party to the extent resulting from the gross negligence, willful misconduct, or fraud of any Buyer Indemnified Party.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Buyer hereby agrees to indemnify, defend and hold harmless the Seller and its Affiliates and its and their directors, officers, agents and employees (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seller Indemnified Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from, against and in respect of all Losses suffered or incurred by the Seller Indemnified Parties to the extent arising out of or resulting from (i) any or breach of any of the representations or warranties (in each case, when made) of the Buyer in this Agreement (including the Bill of Sale) or (ii) any breach of any of the covenants or agreements of the Buyer in this Agreement (including the Bill of Sale); provided, however, that the foregoing shall exclude any indemnification to any Seller Indemnified Party to the extent resulting from the gross negligence, willful misconduct, or fraud of any Seller Indemnified Party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2	Notice of Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If either a Buyer Indemnified Party, on the one hand, or a Seller Indemnified Party, on the other hand (such Buyer Indemnified Party on the one hand and such Seller Indemnified Party on the other hand being hereinafter referred to as an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), has suffered or incurred any Losses for which indemnification may be sought under this ARTICLE 8, the Indemnified Party shall so notify the other party from whom indemnification is sought under this ARTICLE 8 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnifying Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) promptly in writing describing such Loss, the amount or estimated amount thereof, if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement (or the Bill of Sale [***]) in respect of which such Loss shall have occurred.  If any claim, action, suit or proceeding is asserted or instituted by or against a Third Party with respect to which an Indemnified Party intends to claim any Loss under this Section 8.2, such Indemnified Party shall promptly notify the Indemnifying Party of such claim, action, suit or proceeding and tender to the Indemnifying Party the defense of such claim, action, suit or proceeding.  A failure by an Indemnified Party to give notice and to tender the defense of such claim, action, suit or proceeding in a timely manner pursuant to this Section 8.2 shall not limit the obligation of the Indemnifying Party under this ARTICLE 8, except to the extent such Indemnifying Party is actually prejudiced thereby.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.3	Limitations on Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No party hereto shall be liable (and no claim for indemnification hereunder shall be asserted) for any indirect, consequential, punitive, special or incidental damages, including loss of profits, under this ARTICLE 8 as a result of any breach or violation of any covenant or agreement of such party (including under this ARTICLE 8) in or pursuant to this Agreement (including the Bill of Sale [***]). Notwithstanding the foregoing, the Buyer shall be entitled to make indemnification claims, in accordance with the procedures set forth in this ARTICLE 8, for Losses that include any portion of the Revenue Payments that the Buyer was entitled to receive but did not receive timely or at all due to any indemnifiable events under this Agreement (including the Bill of Sale [***]), and such portion of the Revenue Payments shall not be deemed indirect, consequential, punitive, special or incidental damages, including loss of profits, for any purpose of this Agreement (including the Bill of Sale [***]).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link7"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.4	Third Party Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon providing notice to an Indemnifying Party by an Indemnified Party pursuant to Section 8.2 of the commencement of any action, suit or proceeding against such Indemnified Party by a Third Party with respect to which such Indemnified Party intends to claim any Loss under this ARTICLE 8, such Indemnifying Party shall have the right to defend such claim, at such Indemnifying Party&#x2019;s expense and with counsel of its choice reasonably satisfactory to the Indemnified Party.  If the Indemnifying Party assumes the defense of such claim, the Indemnified Party shall, at the request of the Indemnifying Party, use commercially reasonable efforts to cooperate in such defense; provided, that the Indemnifying Party shall bear the Indemnified Party&#x2019;s reasonable out-of-pocket costs and expenses incurred in connection with such cooperation.</font><font id="ole_link6"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Indemnified Party may retain separate co-counsel at its expense and may participate in the defense of such claim.  The Indemnifying Party shall not consent to the entry of any Judgment or enter into any settlement with respect to such claim without the prior written consent of the Indemnified Party unless such Judgment or settlement (A) provides for the payment by the Indemnifying Party of money as the sole relief (if any) for the claimant (other than customary and reasonable confidentiality obligations relating to such claim, Judgment or settlement), (B) results in the full and general release of the Indemnified Party from all liabilities arising out of, relating to or in connection with such claim and (C) does not involve a finding or admission of any violation of any law, rule, regulation or Judgment, or the rights of any Person, and has no effect on any other claims that may be made against the Indemnified Party. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event the Indemnifying Party does not or ceases to conduct the defense of such claim in compliance with this Section 8.4, (i) the Indemnified Party may defend against, and consent to the entry of any reasonable Judgment or enter into any reasonable settlement with respect to, such claim in any manner such Indemnified Party reasonably deems appropriate, (ii) subject to the limitations in Section 8.3, the Indemnifying Party shall reimburse the Indemnified Party promptly and periodically for the reasonable out-of-pocket costs of defending against such claim, including reasonable attorneys&#x2019; fees and expenses against reasonably detailed invoices, and (iii) the Indemnifying Party shall remain responsible for any Losses the Indemnified Party may suffer as a result of such claim to the full extent provided in this ARTICLE 8.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5	Exclusive Remedy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth in Section 11.10, from and after the Effective Date, the rights of the parties hereto pursuant to (and subject to the conditions of) this ARTICLE 8 shall be the sole and exclusive remedy of the parties hereto and their respective Affiliates with respect to any claims (whether based in contract, tort or otherwise) resulting from or relating to any breach of the representations, warranties, covenants and agreements made under this Agreement or any certificate, document or instrument delivered hereunder (including the Bill</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Sale [***]), and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert any other claim or action in respect of any such breach.  Notwithstanding the foregoing, claims for fraud shall not be waived or limited in any way by this ARTICLE 8.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.6	Tax Treatment for Indemnification Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any indemnification payments made pursuant to this ARTICLE 8 will be treated as an adjustment to the Purchase Price for U.S. federal income tax purposes to the fullest extent permitted by applicable law, except to the extent otherwise required pursuant to a &#x201c;determination,&#x201d; within the meaning of Section 1313(a) of the US Code.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>CONFIDENTIALITY</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.1	Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as provided in this ARTICLE 9 or otherwise agreed in writing by the parties, the parties agree that, during the term of this Agreement and for [***] years thereafter, each party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receiving Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall (a) keep confidential and shall not publish or otherwise disclose, except as permitted pursuant to Section 9.2, any information furnished to it by or on behalf of the other party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosing Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) pursuant to this Agreement (such information, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of the Disclosing Party), and (b) shall not use the Confidential Information of the Disclosing Party for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder), except in each case ((a) and (b)) for that portion of such information that the Receiving Party can demonstrate by competent proof:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	is independently developed by the Receiving Party or any of its Affiliates without the use of the Confidential Information of the Disclosing Party; or</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	is subsequently disclosed to the Receiving Party on a non-confidential basis by a Third Party who did not receive such Confidential Information from the Disclosing Party and without obligations of confidentiality with respect thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.2	Authorized Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Either party may disclose Confidential Information to the extent such disclosure is reasonably necessary in the following situations:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prosecuting or defending litigation between the parties hereto;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complying with applicable laws and regulations, including regulations promulgated by securities exchanges;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complying with a valid order of a court or administrative body of competent jurisdiction or other Governmental Entity;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosure to its Affiliates and its and its Affiliates&#x2019; Representatives; provided, that each recipient of Confidential Information must be bound by obligations of confidentiality and non-use at least as stringent as those set forth in this Agreement prior to any such disclosure;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosure to its actual or potential investors, lenders or acquirers, and their respective accountants, financial advisors and other professional representatives, provided, that such disclosure shall be made only to the extent customarily required to consummate such investment, financing transaction or acquisition and that each recipient of Confidential Information must be bound by obligations of confidentiality and non-use at least as stringent as those set forth in this Agreement prior to any such disclosure; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon the prior written consent of the Disclosing Party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&#x2019;s Confidential Information pursuant to Section 9.2(a)(ii) or (iii), it will, except where impracticable, give reasonable advance notice to the Disclosing Party of such disclosure and use reasonable efforts to secure confidential treatment of such information.  Without limiting the foregoing, a party may disclose the other party&#x2019;s Confidential Information, without the other party&#x2019;s prior written permission, to the extent it is required to do so by law, regulation, or a court or administrative order or an order of another Governmental Entity; however, prior to such disclosure, the compelled party shall notify the other party (which notice shall include a copy of the relevant portion of any applicable subpoena or order) as promptly as possible after it learns of such requirement to disclose, except to the extent such notification would be impractical or legally impermissible (in which event notification shall be made as soon as reasonably practicable and permissible), provide the other party with reasonable opportunity to pursue legal action to prevent or limit the required disclosure, and, if requested, provide reasonable assistance at the other party&#x2019;s expense in undertaking reasonable legal action to prevent or limit the required disclosure. In the event of any such required disclosure, the party required to disclose the other party&#x2019;s Confidential Information shall disclose only that portion of the other party&#x2019;s Confidential Information that it is legally required to disclose based on the advice of its counsel. The Receiving Party shall continue to hold in confidence hereunder any such disclosed Confidential Information of the Disclosing Party unless and until such information is no longer required to be held in confidence under the terms of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Buyer shall not seek, because of, or based upon, any Confidential Information of the Seller, Patent or any other form of intellectual property protection with respect to, or related to, any such Confidential Information or use the Confidential Information of the Seller to obtain, or seek to obtain, a commercial advantage over the Seller.  Without limiting the foregoing, the Buyer shall not file any Patent application based upon, disclosing or using any of the Confidential Information of the Seller provided hereunder.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>TERMINATION</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1	Term and Expiration; Surviving Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Unless earlier terminated as provided in Section 10.2, this Agreement shall be effective as of the Effective Date and shall continue in full force and effect until such time as the Seller has made all Revenue Payments or the Buy-Out Payment, as applicable, in full under this Agreement, at which time this Agreement shall automatically terminate, except in each case with respect to any rights or obligations that accrued or arose prior to such termination.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2	Mutual Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be terminated by mutual written agreement of the Buyer and the Seller.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.3	Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary in this ARTICLE 10, the following provisions shall survive termination of this Agreement: ARTICLE 1; Section 7.4 (Inspections and Audits of the Seller); Section 7.12 (Late Payments); ARTICLE 8 (Indemnification); ARTICLE 9  (Confidentiality); Section 10.1 (Term and Expiration; Surviving Payments); Section 10.3 (Survival); ARTICLE 11 (Miscellaneous). Termination of this Agreement shall not relieve any party of liability in respect of breaches under this Agreement by any party on or prior to termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>MISCELLANEOUS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1	Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All notices and other communications under this Agreement shall be in writing and shall be by email with PDF attachment, courier service or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a party hereto in accordance with this Section 11.1:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to the Seller or the Parent, to it at</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tuborg Boulevard 12</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DK-2900 Hellerup</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention:  [***]</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email:  [***]</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With a copy to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Latham &amp; Watkins LLP</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">140 Scott Drive</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Menlo Park, California 94025</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention:  Mark V. Roeder</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email:  [***]</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to the Buyer, to it at</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Pharma Development Funding, LLC</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110 E. 59th Street, Suite 3300</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York 10022</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: [***]</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: [***]</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With a copy to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwin Procter LLP</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100 Northern Avenue</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston, Massachusetts 02210</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Robert M. Crawford and Jacqueline Mercier</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: [***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All notices and communications under this Agreement shall be deemed to have been duly given (i) when delivered by hand, if personally delivered, (ii) when received by a recipient, if sent by email, with an acknowledgement of receipt being produced by the recipient&#x2019;s email account, or (iii) one (1) Business Day following sending within the United States by overnight delivery via commercial one-day overnight courier service.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2	Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as otherwise provided herein, all fees, costs and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby shall be paid by the party hereto incurring such fees, costs and expenses.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.3	Assignment; Transfer Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	None of the Parent, the Seller nor any of their Affiliates shall sell, assign or otherwise transfer, including by asset sale, merger, change of control, operation of law, or otherwise, this Agreement or any portion of the US Product Rights to any Person without the prior written consent of the Buyer (not to be unreasonably conditioned, withheld or delayed) except (i) to an Affiliate if such Affiliate transferee agrees in a writing reasonably acceptable to the Buyer that such Affiliate assumes all of the obligations of the Parent and the Seller to the Buyer under this Agreement and the Parent guarantees the performance of such Affiliate or (ii) in connection with a Change of Control. Further, the Parent, the Seller and its Affiliates shall be permitted to assign all or substantially all of the US Product Rights to a Permitted Transferee if such Permitted Transferee agrees in a writing reasonably acceptable to the Buyer that it assumes all of the obligations of the Parent and the Seller to the Buyer under this Agreement.  For clarity, nothing in this Section 11.3 shall prohibit any Out-Licenses permitted by and entered into in accordance with Section 7.7.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Following the closing of the transactions contemplated by this Agreement, the Buyer may assign this Agreement without the prior written consent of the Seller if the Buyer provides a prior written notice to Seller regarding such assignment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	A party assigning this Agreement as set forth in this Section 11.3 will promptly notify the other party of such assignment.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Any purported sale, assignment or transfer in violation of this Section 11.3 shall be null and void.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement shall be binding upon, inure to the benefit of and be enforceable by, the parties hereto and their respective permitted successors and assigns.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.4	Amendment and Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	This Agreement may be amended, restated, modified or supplemented only in a writing signed by each of the Seller, the Parent and the Buyer.  Any provision of this Agreement may be waived only in a writing signed by the parties hereto granting such waiver.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	No failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy.  No course of dealing between the parties hereto shall be effective to amend, modify, supplement or waive any provision of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5	Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement, the Exhibits annexed hereto and the Disclosure Schedule constitute the entire understanding between the parties hereto with respect to the subject matter hereof and supersede all other understandings and negotiations with respect thereto.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.6	No Third Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement is for the sole benefit of the Seller, the Parent and the Buyer and their permitted successors and assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder, except that the Indemnified Parties shall be third party beneficiaries of the benefits provided for in ARTICLE 8.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.7	Governing</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Law</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.8	Jurisdiction;</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Venue</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS RESPECTIVE PROPERTY AND ASSETS, TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN NEW YORK COUNTY, NEW YORK, AND ANY APPELLATE COURT THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, AND THE BUYER AND THE SELLER EACH HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREE THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN ANY SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUCH FEDERAL COURT.  THE BUYER AND THE SELLER EACH HEREBY AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY APPLICABLE LAW.  EACH OF THE BUYER AND THE SELLER HEREBY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION AND VENUE OF SUCH NEW YORK STATE AND FEDERAL COURTS.  NOTHING IN THIS AGREEMENT OR IN ANY OTHER DOCUMENT SHALL AFFECT ANY RIGHT THAT THE BUYER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER DOCUMENT AGAINST THE SELLER OR ITS AFFILIATES OR ITS OR THEIR PROPERTIES IN THE COURTS OF ANY JURISDICTION.  THE BUYER AND THE SELLER EACH AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THAT PROCESS MAY BE SERVED ON THE BUYER OR THE SELLER IN THE SAME MANNER THAT NOTICES MAY BE GIVEN PURSUANT TO Section 11.1 HEREOF.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY NEW YORK STATE OR FEDERAL COURT.  EACH OF THE BUYER AND THE SELLER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each party hereto irrevocably and unconditionally waives any right to trial by jury with respect to any proceeding arising out of, relating to or in connection with this Agreement or any transaction contemplated hereby.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.9	Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any term or provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any situation in any jurisdiction, then, to the extent that the economic and legal substance of the transactions contemplated hereby is not affected in a manner that is materially adverse to either party hereto, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect and the enforceability and validity of the offending term or provision shall not be affected in any other situation or jurisdiction.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.10	Specific Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each of the parties acknowledges and agrees that the other parties may be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated.  Accordingly, notwithstanding Section 8.5, each of the parties agrees that, without posting bond or other undertaking, the other parties shall be entitled to an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity.  Each party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further agrees that, in the event of any action for specific performance in respect of such breach or violation, it shall not assert that the defense that a remedy at law would be adequate.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.11	Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.  Copies of executed counterparts transmitted by telecopy, facsimile or other similar means of electronic transmission, including &#x201c;PDF,&#x201d; shall be considered original executed counterparts, provided receipt of such counterparts is confirmed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.12	Relationship of the Parties; Cooperation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The relationship between the Buyer, on the one hand, and the Seller and the Parent, on the other hand, is solely that of purchaser and seller/guarantor, and no party hereto has any fiduciary or other special relationship with any other party or any of its Affiliates.  This Agreement is not a partnership or similar agreement, and nothing contained herein shall be deemed to constitute the Buyer, the Seller, the Parent or any of their Affiliates as a partnership, an association, a joint venture or any other kind of entity or legal form for any purposes, including any Tax purposes.  The Buyer, the Seller and the Parent acknowledge and agree that the Buyer&#x2019;s interests hereunder (including the Revenue Participation Right) are not equity interests and that the Buyer shall have the rights of a secured party (as defined in the UCC) with respect to the Revenue Participation Right.  The Buyer, the Seller and the Parent agree to treat the transactions contemplated by this Agreement as a sale of the Revenue Participation Right for U.S. federal, state, local and non-U.S. tax purposes (except as otherwise required by IFRS solely for financial reporting purposes or by applicable tax law in Denmark solely for Danish tax purposes), and that they shall not take any position that is inconsistent with this Section 11.12 in any filing with any Governmental Entity or any audit or other tax-related administrative or judicial proceeding unless the other party hereto has consented in writing to such actions or to the extent otherwise required pursuant to a &#x201c;determination,&#x201d; within the meaning of Section 1313(a) of the US Code, or a comparable provision of non-U.S. law.  Each of the Buyer, the Seller and the Parent shall cooperate fully, as and to the extent reasonably requested by the other party, in connection with the filing of tax returns and any audit, litigation or other proceeding with respect to taxes relating to the Revenue Participation Right.  If there is an inquiry by any Governmental Entity of the Buyer, the Seller or the Parent related to the treatment described in this Section 11.12, the parties hereto shall cooperate with each other in responding to such inquiry in a reasonable manner which is consistent with this Section 11.12.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.13	Parent Guarantee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Parent (i) hereby unconditionally guarantees the due and punctual payment and performance of all of the Seller&#x2019;s and its Affiliates&#x2019; obligations and commitments under this Agreement or any related documents, and (ii) hereby further covenants to procure and cause the Seller and its Affiliates to take such actions necessary to support and duly complete the due and punctual payment and performance of the Seller&#x2019;s and its Affiliates&#x2019; obligations and commitments under this Agreement and any related documents in relation to the Buyer&#x2019;s exercise of its rights and remedies under this Agreement and any related documents (collectively, (i) and (ii) this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parent Guaranty</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). This Parent Guaranty is an irrevocable guaranty of payment and performance (and not just of collection) and shall continue in effect notwithstanding any extension or modification of the terms of this Agreement or any related document, any assumption of any such guaranteed obligations by any other party or Person or any other act or event that might otherwise operate as a legal or equitable discharge of the Parent.  The</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parent hereby waives all its rights to subrogation arising out of any payment or performance by The Parent under this Parent Guaranty. The obligations of the Parent hereunder shall be absolute and unconditional, and shall not be affected by or contingent upon (a) the liquidation or dissolution of, or the merger or consolidation of the Seller or any of its Affiliates with or into any corporation or other Person, or any sale or transfer by the Seller or any of its Affiliates or all or any part of its or their property or assets, (b) the bankruptcy, receivership, insolvency, reorganization or similar proceedings involving or affecting the Seller or its Affiliates, or (c) any modification, alteration, amendment, supplement, waiver or addition of or to this Agreement or any related document.  The Parent hereby waives all suretyship defenses and protest, notice of protest, demand for performance, diligence, notice of any other action at any time taken or omitted by the Buyer and, generally, all demands and notices of every kind in connection with this Parent Guaranty, and the Seller&#x2019;s and its Affiliates&#x2019; obligations in this Agreement and any related documents hereby guaranteed, and which the Parent may otherwise assert against the Buyer.  This Parent Guaranty shall continue to be effective or shall be reinstated, as the case may be, if at any time payment or performance of any of the obligations of the Seller or any of its Affiliates under this Agreement or any related document is rescinded or must otherwise be restored or returned by the Company upon the insolvency, bankruptcy or reorganization of the Seller or its Affiliates or otherwise.  The Parent acknowledges that each of the waivers set forth in this Parent Guaranty is made with full knowledge of its significance and consequences and under the circumstances the waivers are reasonable and not contrary to public policy. If any of said waivers is determined to be contrary to any applicable law or public policy, such waivers shall be effective only to the extent permitted and required by applicable law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature Page Follows</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above written.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:48.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.54%;box-sizing:content-box;"></td>
    <td style="width:87.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PARENT</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASCENDIS PHARMA A/S</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jan M&oslash;ller Mikkelsen  <br>/s/ Albert Cha</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Jan M&oslash;ller Mikkelsen</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: CEO</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Albert Cha</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Chairman</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SELLER</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASCENDIS PHARMA BONE DISEASES A/S</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jan M&oslash;ller Mikkelsen  <br>/s/ Michael Wolff Jensen</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Jan M&oslash;ller Mikkelsen</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: CEO</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Michael Wolff Jensen</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Chairman</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BUYER</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty Pharma Development Funding, LLC</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty Pharma Holdings, Ltd., its Manager</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ George W. Lloyd</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: George W. Lloyd</font></p></td>
   </tr>
   <tr style="height:4.3pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Director</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signature Page to Revenue Participation Right Purchase and Sale Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.24
<SEQUENCE>4
<FILENAME>asnd-ex4_24.htm
<DESCRIPTION>EX-4.24
<TEXT>
<html>
 <head>
  <title>EX-4.24</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.24</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN IDENTIFIED CONFIDENTIAL INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT BECAUSE IT IS (I) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE OR CONFIDENTIAL AND (II) NOT MATERIAL.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUPPLY AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for manufacture and supply of single chamber cartridges, pre-filled with TransCon PTH [***] assembled [***]</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effective as of October 1</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2022</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by and between</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASCENDIS PHARMA A/S</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VETTER PHARMA INTERNATIONAL GMBH</font><font style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-1.338%;padding-left:1.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 1: DEFINITIONS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 2: MANUFACTURE AND GOVERNANCE</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 3: MATERIALS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 4: BATCH SIZE AND YIELD</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 5: INSPECTION &amp; ACCEPTANCE</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 6: NON-CONFORMANCE, LOSSES AND RESUPPLY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 7: CAPACITY AGREEMENT, FORECAST AND PURCHASE ORDERS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 8: RELEASE AND DELIVERY</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 9: PRICES AND PAYMENTS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 10: APPROVALS, AUDITS, CHANGES AND REGULATORY</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SERVICES</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 11: INTELLECTUAL PROPERTY</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 12: LIABILITY, INDEMNIFICATION, INSURANCE AND RECALL</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 13: LIMITATIONS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 14: TERM AND TERMINATION</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 15: ANTI-BRIBERY AND DATA PROTECTION</font><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 16: CONFIDENTIALITY</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 17: MISCELLANEOUS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEX 1: SC-TERMS AND CAPACITY AGREEMENT</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEX 2: PRICES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEX 3: EQUIPMENT</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEX 4: COMMERCIAL QUALITY AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS SUPPLY AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, made and entered into as of the date written above (hereinafter, this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a company duly organized and existing under the laws of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and having its place of business located at </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tuborg Boulevard 12, 2900 Hellerup, Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vetter Pharma International GmbH</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a company duly organized and existing under the laws of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Germany</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, having its principal place of business at </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eywiesenstra&szlig;e 5, 88212 Ravensburg, Germany</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International&#x201d;),</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">W I T N E S S E T H:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Ascendis desires the Manufacture and supply of single chamber cartridges, pre-filled with TransCon PTH [***], assembled [***] for use within the Territory;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	NOW, THEREFORE,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, and subject to the terms and conditions of this Agreement, Ascendis and Vetter International agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 1: DEFINITIONS</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all purposes of this Agreement, and all amendments thereto, the following capitalized terms, whether used in the singular or plural, shall have the same and uniform meanings as below defined and specified, unless the context otherwise requires:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall in respect of Ascendis mean any person, firm, company, or entity which is directly or indirectly controlled by Ascendis, and with respect to Vetter International, any person, firm, company, or entity which is under common control of the trustees/executors of the estate of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Helmut Vetter.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all purposes hereof, &#x201c;control&#x201d; shall mean owning more than fifty percent (50%) of the voting stock or interests.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreed Specifications</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean this supply agreement and its Annexes, specifically including the Commercial Quality Agreement.  </font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean an annex attached to this Agreement.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;API</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean TransCon PTH as specified in Appendix 2 of the Commercial Quality Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Ascendis IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 11(2).</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean an appendix attached to the Commercial Quality Agreement.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Article</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean an article of this Agreement (excluding the Commercial Quality Agreement).</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:7.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Ascendis&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall have the meaning set forth first above.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:7.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Disclosed Manufacture IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any generally applicable manufacturing IP of Ascendis disclosed by Ascendis to Vetter International and/or any of its Affiliates under this Agreement and implemented at the Facility upon specific written request of Ascendis. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(11)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the materials provided by Ascendis or on behalf of Ascendis by third party supplier directly engaged by Ascendis including API as further detailed in the Commercial Quality Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(12)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any calendar day other than a Saturday, a Sunday or a calendar day on which commercial banks located in Baden-W&uuml;rttemberg, Germany or Denmark, are authorized or required by law to be closed.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(13)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Commercial Quality Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the commercial quality agreement, including all Appendices, attached hereto as Annex 4, which Vetter International shall cause Vetter Pharma to enter into with respect to the quality of the Product.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(14)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Completion Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 14(1).</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(15)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 16 (2).</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(16)</font><div style="width:100%;display:inline;" id="ole_link4"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font id="ole_link5"></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Liabilities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean damages, liabilities, claims, suits, awards, judgments, costs and/or expenses, including any court costs and/or reasonable attorneys&#x2019; fees.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:10.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:10.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(17)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Deviations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:10.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:10.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(18)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;SCC&#34;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall mean Single Chamber Cartridge.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.204%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.204%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(19)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the date that Product shall be delivered pursuant to the Business Day specified by Ascendis in the Purchase Order confirmed by Vetter International in writing [***].</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.204%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.204%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(20)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Deviations&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall have the meaning set forth in the Commercial Quality Agreement.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.204%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.204%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(21)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Discloser&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall have the meaning set forth in Section 16(1).</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(22)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the day and year set forth first above.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(23)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Medicines Agency</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or any successor agency. </font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(24)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equipment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the equipment in more detail set forth in Annex 3. </font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(25)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facility</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the manufacturing and logistics facilities used for the Manufacture and located in or near [***]. </font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(26)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Food and Drug Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">United States of America,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any successor agency.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(27)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Final Release&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall have the meaning defined in Section 8(2) (b).</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(28)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 17(1).</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(29)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GMP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement. </font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(30)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information of Ascendis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement and referred to by the respective Appendix thereof.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(31)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning as set forth in Section 14(1). </font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(32)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 11(1).</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(33)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JPSC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 2 (6).</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(34)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major Deviations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(35)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacture</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement.</font></div></div>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(36)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;General </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacture Invention</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 11(3).</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(37)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Conformance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Conforming</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean with respect to a Product or batch of Product failure to conform to the Standard and having a significant impact with regard to GMP compliance or the Product quality.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(38)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean Ascendis and Vetter International, and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean either thereof. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(39)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase Order</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean a document issued by Ascendis and sent for confirmation to Vetter International constituting a binding commitment to purchase a specified quantity of Product for delivery on a requested delivery date.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Existing IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 11(1).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(40)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement.  </font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(41)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Recipient&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall have the meaning set forth in Section 16 (1).</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(42)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Approvals</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(43)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory CMC Dossier</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the part of the documentation related to CMC (Chemistry, Manufacturing and Controls) information to be submitted to the authorities to support regulatory applications, including for Regulatory Approvals, relevant to the Manufacture of Product. </font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(44)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 10 (3).</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(45)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Release&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall have the meaning defined in Section 8(2)a).</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(46)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representatives</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any Affiliate and/or any employee, officer, director and trustee/executor of a Party and/or an Affiliate.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(47)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rolling Forecast</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 1.2 of Annex 1.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(48)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 16 (13).</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(49)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean Vetter International&#x2019;s performance of Manufacture services or other related services for Ascendis subcontracted by Vetter International to Vetter Pharma to be performed by Vetter Pharma.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(50)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SC-Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the terms attached as Annex 1.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(51)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean a subsection of an Article.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(52)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOPs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(53)</font><div style="width:100%;display:inline;"><font style="color:#363636;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#34;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard&#34;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall mean, with respect to: (i) the performance of the Manufacturing, meeting the Agreed Specifications, complying with GMP (if and as applicable under the Commercial Quality Agreement), the rules and regulations officially published and promulgated by the FDA and EMA, and applicable SOPs; and (ii) the performance of the Regulatory Services, complying with the rules and regulations officially published and promulgated by the FDA and EMA.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(54)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 14(1).</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(55)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean [***] under consideration of Ascendis&#x2019; obligations as stipulated in Section 2 (3) in case Ascendis wants to market Product in countries with quality requirements deviating from the Standard.  </font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(56)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter Competitor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 10 (7).</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(57)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth first above.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(58)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Commercial Quality Agreement. </font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(59)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter Pharma</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vetter Pharma-Fertigung GmbH &amp; Co. KG</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a company duly organized and existing under the laws of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Germany,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> having its principal place of business at </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sch&uuml;tzenstra&szlig;e 87, 88212 Ravensburg, Germany, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the parent company of Vetter International.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(60)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warehouse</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the warehousing facility of Vetter Pharma located at [***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 2: MANUFACTURE AND GOVERNANCE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.463%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Vetter International shall supply the Product to Ascendis in accordance with the terms of this Agreement, it being understood and agreed that the Manufacture of the Product shall be subcontracted by Vetter International to Vetter Pharma and be performed by Vetter Pharma, all as set forth and more fully described in the Commercial Quality Agreement. Upon Ascendis&#x2019; reasonable request (e.g. Service that relates to the marketing and release of the Product), subject to Vetter International review, overall capacity and using commercial reasonable efforts, Vetter International shall cause Vetter Pharma to perform additional services (e.g. services referring to ongoing stability, reference materials) to the Services. </font></div></div>
  <p style="margin-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.463%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Ascendis wishes to use certain batches (e.g. process qualification batches) manufactured [***] for [***], the following shall apply:</font></div></div>
  <p style="margin-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7743680432747317%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7743680432747317%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacture</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Vetter International shall cause Vetter Pharma to Manufacture the Product and provide the respective batch documentation in accordance with the Standard. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Quality requirements deviating from the Standard.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In case Ascendis wants to market Product in Territory countries with quality requirements deviating from the Standard ([***]), the Parties will have good faith discussions about how to deal with any additional or different country-specific rules and regulations, if any. Ascendis shall [***]. Ascendis shall regularly and in a timely manner inform and keep informed Vetter International and its Affiliates of any such additional or different country rules and regulations applicable to the Product.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equipment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Vetter International shall cause Vetter Pharma to procure the Equipment as listed in Annex 3 which Equipment shall be [***] Ascendis. Such Equipment, including Equipment purchased under previous agreements but used in the commercial Manufacture of Product, shall be [***]. Vetter International shall maintain such Equipment [***] and operate the Equipment in accordance with the SOPs. [***] for repairs and replacement, unless [***]. Vetter International shall [***] maintain, and if necessary, repair or replace, all other equipment needed for the manufacture of Product. If additional Ascendis dedicated equipment needs to be purchased, Vetter International shall address the respective costs towards Ascendis and both Parties shall update Annex 3 accordingly.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Project Management</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  A joint project steering committee (&#x201c;JPSC&#x201d;) shall be formed comprising up to [***] members, including at least [***] from each Party. If possible, meetings of the JPSC shall be aligned with [***]. As needed, the JPSC shall meet [***] to discuss and evaluate the mutual cooperation and in good faith negotiate and decide upon any issues. Meetings may be held as teleconferences, with the intention to have [***] JPSC face-to-face meeting per [***]. Each Party may call for an ad hoc JPSC teleconference as deemed necessary. [***] The members of the JPSC shall attempt to amicably settle and in good faith resolve any dispute in connection with this Agreement and [***].</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 3: MATERIALS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delivery of Ascendis Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ascendis shall supply and deliver or have delivered to the Warehouse [***] (Incoterms 2010), free of charge and at the risk of Ascendis, including with respect to any applicable transport insurance, such quantity of the Ascendis Materials as required to properly undertake the necessary preparations for the Manufacture of the Product and to timely fulfill Purchase Orders, all in accordance with the Commercial Quality Agreement. Such delivery shall include quality certificates for the Ascendis Materials as set forth in the Commercial Quality Agreement, upon which certificates Vetter International and/or its Representatives may fully rely without further investigation. Delivery of Ascendis Materials shall take place according to the timelines specified in the SC Terms. Ascendis may deliver Ascendis Materials (e.g. API) up to [***] earlier than required according to the forecast. If additional freezer capacity is required, both Parties shall enter into good faith discussions regarding the additional procurement and Ascendis shall bear the respective costs. </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Storage.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Vetter International shall store Ascendis Materials at Vetter International's Warehouse under conditions as specified in the Commercial Quality Agreement, and including such security measures as emergency power supply, temperature alarms, and emergency backup freezer capacity. [***] </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Status</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Ascendis Materials shall at all times remain the property of Ascendis. Ascendis shall be and remain responsible and liable for the Ascendis Materials and the quality thereof. Ascendis may, in its sole discretion, provide adequate property insurance for the Ascendis Materials (whether or not included as part of the Product or otherwise), and for all shipment and storage of any thereof, in an amount and on terms satisfactory to Ascendis. [***] In the event that Ascendis chooses to insure Ascendis Materials and Product while in the custody of Vetter International, Vetter International </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees to provide Ascendis&#x2019; insurance company with adequate information regarding its facilities, procedures, SOP&#x2019;s etc.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Ascendis shall provide any and all information with respect to the Ascendis Materials, including, without limitation, all chemical, pharmaceutical and/or biopharmaceutical compositions thereof and, to the extent reasonably known, any impact and interaction thereof on all other materials to be used in the Manufacture of the Product. If the provision of any such information has the effect, including any result of having to take additional security or safety precautions, of increasing the costs in performing obligations under the Commercial Quality Agreement or hereunder, Vetter International shall inform Ascendis thereof. Ascendis shall specifically inform Vetter International if the Ascendis Materials require any special handling or processing. Ascendis shall meet all notice and information requirements set forth herein and in the Commercial Quality Agreement, it being understood and agreed that neither Vetter International nor any of its Representatives shall have any responsibility or liability, including for lack of information or if such information should not be proper for the Manufacture, if the Product has been Manufactured in accordance with the Standard.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delay due to Ascendis Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event of  a delay in the Manufacture of the Product arising from inadequate delivery of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Ascendis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Materials (whether such delay is based on inadequacy of quality, quantity or otherwise) Vetter International may postpone the Delivery Date until such other date that Vetter International may reasonably determine, after good faith consultation of Ascendis, taking into account such factors as Facility capacity, other production commitments and similar business factors, provided, however, that Vetter International shall use commercially reasonable efforts to meet the agreed Delivery Date. [***].</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delay due to</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Vetter Materials.  In the event of  a delay in the Manufacture of the Product arising from inadequate delivery of any Vetter Materials (whether such delay is based on inadequacy of quality, quantity or otherwise) Vetter International may postpone the Delivery Date if Vetter International can document that delay was not due to insufficient safety stock or negligent causes or negligent inactions by Vetter International, until such other date that Vetter International reasonably determines, after good faith consultation of Ascendis, taking into account such factors as Facility capacity, other production commitments and similar business factors, provided, however, that Vetter International shall use commercially reasonable efforts to meet the agreed Delivery Date. </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Testing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All Vetter Materials and all Ascendis Materials shall be tested in accordance with the Commercial Quality Agreement. [***]</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Ascendis Materials shall be used for the Manufacture of the Product only. Vetter International shall notify Ascendis in writing of any surplus of the Ascendis Materials and any such surplus shall, if not usable for the Manufacture of the Product, be disposed of, returned to Ascendis or otherwise handled, all as reasonably directed by and at the cost and/or expense of Ascendis. Upon written request of Ascendis, Vetter International shall provide Ascendis with copies of a computerized inventory list, generated in accordance with the SOPs in respect of the Ascendis Materials stored at the Facility, all as separately agreed by and between the Parties in writing.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vetter Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Vetter International shall cause Vetter Pharma to source the Vetter Materials in volumes sufficient and in due time to meet Ascendis&#x2019; Rolling Forecast and Purchase Orders (according to Annex 1). </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 4: BATCH SIZE AND YIELD</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Batch size. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product shall be Manufactured in validated batch sizes. It is expected that the initial process qualification batch will validate a nominal batch size range of [***] cartridges.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.13%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.337338540102133%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Yield</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Parties acknowledge that the Manufacturing process will yield a lower number of secondary packed cartridges for Delivery than the nominal batch size. After the Manufacture of [***] Product batches of each concentration and batch size, the Parties shall evaluate and mutually agree in writing on acceptable yield targets, taking into account normal fixed and flexible losses, including, for example, [***]. Until agreement on such yield provisions has been reached, Ascendis shall pay the full price regardless of the yield, except in case of Vetter International&#x2019;s [***] (for clarity, the latter as limited by the provisions of Section 6 (7) of this Agreement). Subsequent batches delivered in amounts below the yield targets for the batch shall result in a correspondingly proportionally reduced price. If Manufacturing in larger scale is later validated, the Parties shall mutually agree on acceptable yield targets.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 5: INSPECTION &amp; ACCEPTANCE</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inspection</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Ascendis shall inspect the Product according to the provisions of the Commercial Quality Agreement, and review the batch documentation without delay, but in no event later than [***] after the Release. If the Product should not pass such inspection and/or the batch documentation should not pass such review, Ascendis shall promptly notify Vetter International in writing. If the Product has been shipped from the Warehouse to Ascendis or a third party designated by Ascendis, Ascendis shall, in accordance with the instructions of Vetter International, either return the rejected batch to the Facility or dispose of the Product. </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acceptance.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Product and/or batch documentation not rejected as in the preceding Section described shall be deemed accepted and approved by Ascendis to the extent that either thereof may contain a latent defect. Any Product and/or batch documentation containing a latent defect shall be deemed accepted and approved, unless rejected by written notice to Vetter International within [***]; provided, however, that in case of discovery of a latent defect, [***] that such defect has been caused solely by Vetter International before risk transfer to Ascendis. Ascendis shall notify Vetter International in writing promptly after the discovery of any latent defect. Latent defects include defects which could not, by their nature or by their low relative occurrence, be identified upon initial inspection using GMP statistical sampling techniques. </font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investigation, Dispute. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International shall have the right to investigate any alleged Non-conforming Product.  If, during any calendar quarter, [***] or more batches are rejected by Ascendis, Vetter International shall notify Ascendis and, upon receipt of such notification by Ascendis, the Parties shall meet to discuss, evaluate and analyze the reasons for and implications of the failure of the Manufacture to meet the Agreed Specifications and the rejection by Ascendis. Pending the same, Vetter International shall have the right to [***]. Vetter International shall perform or have performed such investigation, root cause analysis and any corrective action diligently and expeditiously. Prior to the completion thereof, Ascendis may request in writing the recommencement of Manufacture unless in conflict with GMP, subject to [***]. If the Parties disagree as to final disposition, analysis or corrective action, and, if Vetter International disagrees with Ascendis&#x2019; determination, the Parties shall attempt to resolve such disagreement through good faith discussion within the JPSC, failing of which the Parties shall appoint a mutually agreed-upon, independent pharmaceutical laboratory in the European Union to evaluate and determine whether the Product&#x2019;s Manufacture was in accordance with the Standard as of the Delivery Date. The laboratory&#x2019;s determination thereof shall be binding upon both Parties as to the facts evaluated, and the laboratory&#x2019;s charges and related expenses [***].</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Standard</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for those Deviations of which Ascendis will be notified in writing as set forth in the Commercial Quality Agreement, all Product made available to Ascendis for delivery in accordance with Article 8 under this Agreement shall have been Manufactured in accordance with the Standard; [***].  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 6: NON-CONFORMANCE, LOSSES AND RESUPPLY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Primary packaging materials. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than as set out in the Sections below regarding Non-Conforming Product, neither Vetter International nor any of its Representatives shall have any responsibility or liability for any materials manufactured or supplied to the Facility by Ascendis or any third party (including Ascendis Materials and Vetter Materials) or any testing or other services performed by any third party or to undertake any testing or to otherwise certify the Vetter Materials other than as set forth in the Commercial Quality Agreement; provided, however, Vetter International shall transfer or cause to transfer to Ascendis any warranties as received in respect of primary packaging Vetter Materials and assist Ascendis to execute any such warranty claim. [***].</font></div></div>
  <p style="margin-left:4.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vetter International&#x2019;s responsibility for Non-Conforming Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If the Parties agree about the Non-Conformance of a Product or it is otherwise concluded that Product is Non-Conforming, and the Non-Conformance is caused by [***] by Vetter International or its Representatives, Vetter International shall Manufacture a replacement batch [***]. In such a case Vetter International shall additionally be obliged to [***].</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ascendis&#x2019; or third parties&#x2019; responsibility for Non-Conforming Product. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Non-Conforming Product is caused by </font></div></div>
  <p style="margin-left:3.947%;text-indent:-2.811%;padding-left:2.627%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	[***], or</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.947%;text-indent:-2.811%;padding-left:2.627%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	[***], or</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.947%;text-indent:-2.811%;padding-left:2.627%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notification of Non-Conformance. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Conforming Product shall be notified by Ascendis within [***] after the Release of such Non-Conforming Product, otherwise Product shall be deemed accepted, unless Non-Conformance is latent and could not have been found within [***]. Such latent Non-Conformance shall be notified by Ascendis within [***], provided however, that in case of discovery of a latent Non-Conformance, [***] that such Non-Conformance has been caused solely by Vetter International before the risk transfer to Ascendis.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delivery of replacement Products. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International shall, if Ascendis so requests, deliver replacement Product and the corresponding batch documentation [***], and [***]. Vetter International shall at all times keep Ascendis updated about the progress of the scheduling and the re-Manufacture itself.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of any replacement, Ascendis shall supply or have supplied, as set forth in Section 3(1), Vetter International with the necessary Ascendis Materials.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">API loss during storage.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Vetter International and/or any of its Representatives shall [***].</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">API loss in conjunction with the Manufacturing of Product batches. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For loss of API in conjunction with the Manufacturing of Product batches, Vetter International shall compensate Ascendis in connection with Non-Conforming Product caused by [***] up to the following liability caps:</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.8575102053935906%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in case of [***]</font></div></div>
  <p style="margin-left:9.387%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">aa) and for any API loss occurring in connection with the first [***] Product batches Manufactured under this Agreement:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International&#x2019;s compensation obligation shall not exceed [***];</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bb) and for any subsequent API loss:</font></p>
  <p style="margin-left:16.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International&#x2019;s compensation obligation shall not exceed [***],</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided however, in both aforementioned cases of [***] aa) and bb) above, the aggregate amount of compensation [***] shall in no event exceed [***] for all API losses under this Agreement, [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:1.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.8575102053935906%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in case of Vetter International&#x2019;s [***] </font></div></div>
  <p style="margin-left:4.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">aa) and for any API loss occurring in connection with the first [***] Product batches Manufactured under this Agreement:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International&#x2019;s compensation obligation shall not exceed [***]</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bb) and for any subsequent API loss:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International&#x2019;s compensation obligation shall not exceed [***],</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided however, in both aforementioned cases of [***] aa) and bb) above, the aggregate amount of compensation [***] shall in no event exceed [***] for all API losses under this Agreement, [***].</font></p>
  <p style="margin-left:4.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, any compensation payments to be paid or already paid [***] based on Vetter International&#x2019;s [***] shall be deducted from further compensation obligations for Costs and Liabilities caused by Vetter International&#x2019;s and/or any of its Representatives' [***] and vice versa with the effect that Vetter International&#x2019;s aggregate [***] compensation obligation [***] for Costs and Liabilities caused by [***] shall in no event exceed the aggregate [***] cap as stipulated in this Section for [***].</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also for the avoidance of doubt, compensation for API loss within the limitations of liability agreed herein is [***] in cases where Non-Conforming Product is caused by [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 7: CAPACITY AGREEMENT, FORECAST AND PURCHASE ORDERS</font><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Parties agree to the Capacity Agreement attached as Annex 1to this Agreement. Forecast and Purchase Order provisions are governed by the SC-Terms attached as Annex 1.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		ARTICLE 8: RELEASE AND DELIVERY</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Samples for external analysis.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No later than [***]  calendar days prior to the agreed Delivery Date, Vetter International shall send samples to third parties for analysis, as designated by Ascendis and further detailed in the Commercial Quality Agreement. </font></div></div>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Release.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Product shall be released in two steps:</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;Release&#34; by Vetter Pharma according to the Standard and against the Agreed Specifications, as defined in the Commercial Quality Agreement, and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;Final Release&#34; by Ascendis after (i) review of the Release documentation required to be submitted from Vetter International to Ascendis no later [***] before the Delivery Date as further detailed in the Commercial Quality Agreement, and (ii) review of results from inspections and analyses performed by third parties.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both Parties agree to continue their good faith discussions, following the execution of this Agreement, with the intention to update the processes regarding the Release and Final Release (including this Article as well as Sections 5(1).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delivery.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Product shall be delivered [***]  ([***]  Incoterms&#174; 2010). Provided Ascendis has met its obligations regarding delivery of Ascendis Materials (in particular delivery in due time and in sufficient amounts as set forth in Article 3), and Vetter International has met its obligations to submit Release documentation in due time, Vetter International shall deliver Released Product on the Delivery Date.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Storage of Released Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Unless otherwise agreed between the Parties, if Product is not collected by Ascendis within [***] after notification of Final Release, Vetter International shall store such Product [***] and in accordance with its SOPs as specified in this Article 8. However, The Parties agree, that storage of Products, starting from the Delivery Date, will be [***], for clarity meaning that [***]. Upon Ascendis&#x2019; request Vetter International shall [***] store Released Product for up to [***], in which case, [***].</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assistance. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In amplification of the provisions with respect to [***] ([***] Incoterms&#174; 2010) set forth or referred to above, and not in limitation thereof, Vetter International shall directly or indirectly through its Representatives, upon request of Ascendis and in any event at [***], assist in (i) [***]; (ii) [***]; (iii) [***]; and/or (iv) [***]. Ascendis shall, upon request of Vetter International, provide information required for taxation or reporting purposes in respect of [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shipment. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product may only be shipped after Final Release, except under quarantine. Vetter International shall coordinate all shipments with Ascendis' logistics function. [***]. </font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Quarantine shipment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Product not yet Final Released may be shipped under quarantine upon prior written request of Ascendis [***]. Quarantine shipment shall not imply Ascendis' automatic acceptance of a batch, [***].</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delay in delivery</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Vetter International agrees to inform Ascendis no later than [***] after it has become apparent that the delivery of Product may be delayed. In such case Vetter International must inform Ascendis of its plan to solve the issues causing a delay, [***] to solve the issues and confirm a new Delivery Date to Ascendis as soon as possible.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 9: PRICES AND PAYMENTS</font><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.398%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ascendis shall pay to Vetter International such prices for the Product as determined in Annex 2, plus any applicable taxes (e.g. VAT), customs, fees and other duties, if any. [***]. </font></div></div>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Price adjustments.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Vetter International may reasonably adjust its prices no more than [***], and becoming effective as of the next [***], as follows, provided Vetter International notified Ascendis in writing about the respective price adjustments no later than [***]:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the reference value shall be calculated by taking into account of [***]  of the value provided according to [***] published by the German Statistical Federal Office and [***] published by the U.S. Bureau of Labor Statistics (together the &#x201c;PPI&#x201d;) and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the event of an increase or decrease of the PPI [***], Vetter International shall be permitted to [***] and Ascendis shall be entitled to [***].</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Extraordinary price adjustment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any further events with regard to which Vetter International has a reasonable interest to adjusting its prices, such as e.g.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***], </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***], and/or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be addressed by Vetter International at [***]. Vetter International shall provide Ascendis with reasonable evidence showing such increase and the Parties shall [***].</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">       Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Without undue delay, Vetter International shall issue an invoice upon [***] or, in case of Product not yet Final Released, Vetter International shall be entitled to invoice [***]. Payments shall be made in Euros and due [***] of the invoice date (receipt of readily available funds by Vetter International). If Ascendis pays later than [***] of receipt of the invoice, Vetter International shall be entitled to interest of the invoiced amount of [***] (except when payment is subject to a good-faith resolution of any dispute). Ascendis shall add such interest, accumulated in accordance with this Article as of the time of payment due, to the invoiced amount and include such with the payment by Ascendis.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 10: APPROVALS, AUDITS, CHANGES AND REGULATORY SERVICES</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Ascendis shall obtain and maintain, at its cost and risk, all Regulatory Approvals for the Manufacture of the Product. Ascendis shall not distribute or otherwise use the Product without first securing such Regulatory Approvals. Vetter International shall cooperate and make every commercially reasonable effort, [***], in having information and other assistance provided as Ascendis may reasonably request with respect to the Regulatory Approvals.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Facility</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Vetter International shall cause Vetter Pharma to obtain and maintain the necessary manufacturing authorization with respect to the Facility issued by the applicable </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">German</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> health authority in accordance with the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">German Medical Act (Arzneimittelgesetz)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and, upon written request of Ascendis, Vetter International shall make available a copy of such authorization. Ascendis understands and agrees that certain regulatory authorities may still have to approve of the Manufacture of the Product, [***], and that neither Vetter International nor any of its Affiliates warrants to Ascendis any such approval.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Ascendis shall employ Vetter International and/or its Affiliates in preparing such regulatory filings as set forth in the Commercial Quality Agreement and this Agreement which are relevant to the Manufacture and provide certain supporting documents if reasonably required, all as agreed upon by the Parties in the Agreed Specifications and [***] (&#x201c;Regulatory Services&#x201d;). Prior to delivering Regulatory Services, Vetter International or Vetter Pharma shall, on a case by case basis, inform Ascendis in writing [***]. The Parties agree that Vetter International may employ its Affiliates, in particular Vetter Pharma, for assisting Ascendis with regard to the Regulatory Services.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Information.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If Ascendis requires Vetter International to perform Regulatory Services pertaining to any specific legislation, rules, regulations and practices or requirements of regulatory authorities and governmental bodies within the Territory (other than the generally applicable regulatory requirements of BfArM, EMA and FDA), Ascendis shall inform Vetter International and Vetter Pharma of the same. </font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contact.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Ascendis shall be solely liable for all documentation, submissions and communication with governmental, health and regulatory authorities or agencies, relating to the Product and the Regulatory Approvals. Ascendis shall keep the documentation submitted to such governmental and regulatory bodies updated as required by law, applicable regulation and regulatory practices. Neither Vetter International nor any of its Representatives shall have any right or obligation to communicate with any such governmental, health and regulatory bodies regarding the Product unless required to do so by law, the Commercial Quality Agreement or as otherwise requested by Ascendis in writing.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assistance.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Any assistance requested by Ascendis and provided by Vetter International or its Affiliates beyond the Regulatory Services in connection with regulatory submissions and Regulatory Approvals for the Products, shall be subject to the Parties' prior written agreement and the costs of the provision of such assistance shall be borne as mutually agreed by the Parties in writing. Any request for such assistance by Ascendis shall include complete instructions and any other information reasonably necessary for Vetter International to evaluate the required assistance and to calculate costs which would be incurred in performing the same in order for the Parties to discuss and agree upon the terms of the provision of such assistance. </font></div></div>
  <p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audits.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Ascendis may conduct routine and for-cause audits according to the provisions in the Commercial Quality Agreement. During such audits Ascendis may be accompanied by potential business and/or licensing partners subject to reasonable prior notice to Vetter International and provided that any such partner prior to participating in such audit is bound to confidentiality by entering into a 3-way confidentiality agreement with Ascendis and Vetter International, except if such partners or any of their affiliates are a) [***] or b) [***] (&#x201c;Vetter Competitor&#x201d;).</font></div></div>
  <p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Extended Access to Facility. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In case of major and/or critical technical and/or quality related issues, Vetter International shall allow [***] Ascendis [***] access to its Facility as necessary to observe Manufacturing and review documents related to the GMP system and Ascendis Product batches; provided, however, Ascendis shall notify Vetter International at least [***] in advance of such request, unless this would conflict with a planned visit by a third party or internal meeting, in which case Vetter International may reasonably postpone such request by Ascendis. Vetter International shall provide the visiting Ascendis [***] with reasonable office space during regular working hours according to the internal procedures of Vetter International. The visiting Ascendis [***] shall comply with any and all confidentiality, security, safety, quality or similar guidelines that apply to persons present in the Facility and that are communicated by Vetter International or Vetter Pharma.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Costs for audits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any costs and/or expenses associated with any audits performed by any regulatory authority with respect to the Facility, the Manufacture and/or the Product shall be borne by [***], except costs incurred from audits by the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">German</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> health authorities, FDA and/or EMA not directly related to the Product which shall be borne by [***].</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval changes.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Unless mandated by compulsory regulatory changes, the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JPSC shall agree upon significant post-approval changes. [***] shall bear the costs for post-approval changes (e.g. [***]) implemented [***] whereas [***] shall compensate [***] for costs of implementing [***] post approval changes (e.g. [***]). If not expressly governed by this Agreement, any impact of other changes related to prices or other terms of this Agreement shall be negotiated in good faith and agreed upon in the JPSC.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(11)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any and all changes shall be processed in accordance with the change control procedures set forth in the Commercial Quality Agreement, subject to this Section and the succeeding Section. With respect to any change to be made in accordance with the Commercial Quality Agreement, Vetter International and Ascendis shall also mutually agree on any necessary or desired amendments to this Agreement, including, without limitation, price adjustments and compensation for any additional costs, efforts and/or expenses.</font></div></div>
  <p style="text-indent:-4.109%;padding-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(12)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes Dispute.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  In the event of a dispute regarding a change, Ascendis and Vetter International shall discuss in good faith how to proceed; provided, however, Vetter International shall not be required to cause Vetter Pharma to continue the Manufacture of the Product, which may be [***] if Vetter International and Vetter Pharma [***]. If Vetter International and Vetter Pharma [***] such incorporation or non-incorporation of a change [***], then Vetter International shall cause Vetter Pharma to continue the Manufacture of the Product with the incorporation or the non-incorporation of such change, in which event [***].</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 11: INTELLECTUAL PROPERTY</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Existing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as expressly granted under this Agreement, either Party and/or any of its Representatives shall not acquire any right, title or interest in any and all intellectual property meaning (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inventions (whether or not patentable), patents, trade secrets, copyrights, trademarks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential information (including know-how) and any other intellectual property rights, in each case whether registered or unregistered, and (ii) all applications (or rights to apply) for, and renewals or extensions of, any of the rights described in the foregoing section, which exist now, or which come to exist in the future, in any part of the world (individually and collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) of the other Party and/or any of its Representatives. Any right, title or interest in and to such IP (i) existing prior to the Effective Date and/or (ii) that is developed by or for, or otherwise comes to be owned or controlled by a Party or any of its Affiliates, separately from and independently of any activities performed under this Agreement (respectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Existing IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall not in any way be affected by this Agreement.</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].  All [***] hereunder (&#x201c;Developments&#x201d;) that (i) [***], and (ii) [***] (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be [***].</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].  Any [***] that are generally applicable to the development or Manufacture of [***] (&#x201c;General </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacture Invention</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), shall be [***].</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses for Ascendis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Vetter International and/or any of its Affiliates hereby grants Ascendis and/or its Affiliates a [***] solely to the extent [***] necessary for </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.973703479006714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]; and/or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.888805086787551%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].</font></div></div>
  <p style="margin-left:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International confirms that, as of the signature date to this Agreement, [***]. [***].</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses for Vetter</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ascendis hereby grants to Vetter International (and/or any of its Affiliates, as may be reasonably required and subject to the provisions hereof) a [***], but only to the extent needed for, and solely for the purpose of, Vetter International&#x2019;s and/or its Affiliates&#x2019; use thereof in the performance of their respective duties and obligations under this Agreement. Only to the limited extent as may be necessary to enable Vetter International to [***], Ascendis shall grant Vetter International and/or any of its Affiliates a [***]; but only to the extent such can be generally applied within due course of Vetter International and its Affiliate&#x2019;s business, including for other customers, without disclosing Ascendis Confidential Information.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tech Transfer.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Notwithstanding any anything to the contrary in this Agreement, Ascendis shall [***]; provided, however, that such process shall [***]:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]  and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].</font></div></div>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to [***], [***] may [***] if and to the extent granted in this Agreement, [***], [***](&#x201c;Target Specifications&#x201d;), which [***] may include e.g.:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.588888888888889%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(viii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ix)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(xi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***], and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(xii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]. </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, and for clarity, [***], except if and to the extent required for health authorities or regulatory authorities, or as required by applicable law regarding:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***],</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***], or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4.5pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In no event [***] if [***] and/or if their use or if any [***] provided [***] results in a [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Infringement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  [***] shall [***] of any third party claim that the Ascendis Materials, any Information of Ascendis, other matter provided by Ascendis, or the use [***] of any thereof, infringes any IP of any third party. [***] shall [***] of any third party under the patent or intellectual property laws of the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">United States of America</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and/or the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Union</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any member state thereof [***]. </font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 12: LIABILITY, INDEMNIFICATION, INSURANCE AND 	RECALL</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liability. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as expressly set forth in this Agreement, Vetter International and/or any of its Representatives [***] which liability is limited as follows:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in case of [***]</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International&#x2019;s aggregate liability [***].</font></p>
  <p style="margin-left:9.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in case of [***] </font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International&#x2019;s aggregate liability [***].</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">([***]). For clarity, aforementioned liability caps [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, any compensation payments to be paid or already paid [***] based on [***] under this Section shall be deducted from further compensation obligations for Costs and Liabilities [***] with the effect that Vetter International&#x2019;s aggregate [***] compensation obligation [***]  for Costs and Liabilities [***] shall in no event exceed the aggregate [***] cap as stipulated in this Section [***].<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International and/or any of its Representatives [***] as long as each follows the standard manufacturing, storage and other practices used in the German pharmaceutical contract manufacturing industry in performing its respective obligations which means, among other things, that each may rely on the correctness and completeness of the Agreed Specifications, the Information of Ascendis and/or any other information or direction by or on behalf of Ascendis, [***].</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  [***]. </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Procedure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Party shall promptly notify the other Party in writing of any claim, suit or other action brought or threatened in connection with or under this Agreement and shall provide reasonable cooperation in the defense of any thereof. Each Party shall not settle or otherwise resolve any such claim, suit or other action without prior written consent of the other Party.  </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insurance.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis shall self-insure or maintain product liability insurance coverage with a reputable international insurance company, of in the aggregate of [***] per each calendar year during the Term. Vetter International shall maintain and shall cause Vetter Pharma to maintain product liability insurance coverage (to the extent commercially reasonable and practicable and if otherwise, Vetter International shall remain responsible and liable for such coverage herein set forth) with a reputable insurance company, in the aggregate of [***] per each calendar year during the Term, with [***]. Upon request of the other Party, each Party shall provide reasonable documentation and certificates to confirm that such insurance coverage is in effect. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recall Costs.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any Product is recalled and such recall (for clarity, which must not be initiated without order of a Regulatory Authority or the potential risk of receiving such an order from a Regulatory Authority) has solely been caused by [***] shall be liable to compensate [***] direct costs of recall, which liability is limited as follows:</font></div></div>
  <p style="margin-left:4.027%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.13%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4765828726400336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in case of [***]</font></div></div>
  <p style="margin-left:7.36%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International&#x2019;s liability is limited to a maximum of [***] in aggregate per recall,</font></p>
  <p style="margin-left:6.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.13%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4765828726400336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in case of [***]</font></div></div>
  <p style="margin-left:7.36%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International&#x2019;s liability is limited to a maximum of [***] in aggregate per recall.</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, aforementioned liability caps shall not apply in case of [***]. Any loss of API caused in connection with a recall shall be compensated in accordance with the provisions in Section 6 (7) above.</font></p>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, Vetter International and/or any of its Representatives shall have no warranty obligation (in German </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gew&auml;hrleistungsverpflichtung</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), responsibility or liability to Ascendis (or any third party on behalf of Ascendis) for any loss of the Ascendis Materials, Product liability, recall or otherwise beyond what is expressly stipulated in this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 13: LIMITATIONS</font><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Special Damages</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary contained in this Agreement, neither Party nor any of its Representatives shall be responsible or liable to the other Party and/or any of its Representatives for any reason whatsoever (even upon the occurrence of a tort with respect to the Product or otherwise) for loss of profits (except any profits contained in the prices to which Vetter International may be entitled for completion of its contractual obligations), loss of good will, loss of business or special, incidental, indirect, exemplary or consequential damages, except if any of the foregoing arises out of [***] a breach of the confidentiality provisions contained in Article 16 of this Agreement and in any case subject to the liability limitation as stipulated in [***].</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	No Warranty</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as in this Agreement expressly set forth, Ascendis agrees that neither Vetter International nor any of its Representatives makes or has made any other representation, warranty, covenant or agreement (whether express or implied). Any representation, warranty, covenant or agreement set forth in this Agreement is exclusive and in lieu of any other warranties, written or oral, direct, implied or statutory, including, but not limited to, express or implied warranties for merchantability, quality or fitness for a particular purpose.</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary contained in this Agreement, it is expressly agreed by and between the Parties that no Representative of Vetter International shall assume any responsibility or liability, but Vetter International shall be responsible and liable for the performance of any of its Representatives to the same extent as if Vetter International had performed or failed to perform, all as contemplated or required hereunder, and any claim made under this Agreement (for clarity, specifically including the Commercial Quality Agreement) shall exclusively be made against Vetter International.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter International shall have no liability related to any services performed by third party service providers, other than a Vetter International Affiliate, the ones stated in Section 17(7)(a), those approved according to Annex 8 of the Commercial Quality Agreement, or Ascendis, as set forth in Section 6(1).</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 14: TERM AND TERMINATION</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.463%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be in full force and effect for an initial term of five (5) years, commencing as of the Effective Date (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Upon the expiration of the Initial Term and any subsequent term, this Agreement shall automatically be renewed for subsequent terms of two (2) years each (Initial Term and any subsequent term collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). For clarity, any rights or obligations accrued prior to the expiration of the Term or termination of this Agreement (respectively, the &#x201c;Completion Date&#x201d;) shall not prejudice or preclude any remedies either Party may have under this Agreement. </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither Party may terminate this Agreement without cause, except Ascendis may terminate this Agreement without cause with two years&#x2019; written notice and with (earliest) effect from expiry of the Initial Term.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination for cause. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party (as applicable) shall have the right to terminate this Agreement (with immediate effect or, if applicable, after the expiration of an applicable time period) upon prior written notice if the other Party is in major default in the fulfillment of any material obligation under this Agreement. The term &#x201c;major default&#x201d; shall include, but not be limited to</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) if the other Party makes a general assignment (novation) for the benefit of its creditors and not in accordance with Section 17(7), or</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) proceedings are commenced in any court of competent jurisdiction by or against such Party (by any third party but not by the other Party) seeking (a) relief in respect of such Party under any law relating to bankruptcy, insolvency, reorganization, winding up or composition or adjustment of debt, wherein any such proceedings continue undismissed, or an order with respect to any of the foregoing is entered and continues unabated, for a period of more than ninety (90) calendar days; or (b) the appointment of a receiver or trustee of any significant part of the property, of a Party.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) in the case of any other default which can be cured, the failure to commence to remedy the default during a period of ninety (90) calendar days after the giving of written notice specifying such default; and (iii)  the failure to self-insure or provide for or maintain product liability insurance as required under this Agreement, or pay any insurance premiums when due; (iv)failure to establish mutual agreement in accordance with Section 10(12) within forty five (45) calendar days.</font></p>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Specific termination right for cause by Ascendis.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Ascendis shall have a specific termination right for cause (with immediate effect) in case Vetter International and/or Vetter Pharma [***] are being taken over by a competitor of Ascendis (for clarity, meaning [***]),  or if such change of control would create a conflict of interest that is reasonably expected to materially impact the business of Ascendis due to certain past or present lawsuits with such third party, [***] (any such third party in an &#x201c;Unqualified Acquirer&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Specific termination right for cause by Vetter International.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Vetter International shall have a specific termination right for cause (with immediate effect) in case:</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Ascendis is the subject of a change of control by a third party that</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.56%;text-indent:-2.892%;padding-left:2.627%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) is a direct Vetter International competitor [***],</font></p>
  <p style="margin-left:6.533%;text-indent:-2.892%;padding-left:2.627%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) [***], if such change of control would materially impact the business of Vetter International due to [***];</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Vetter International can show Ascendis beyond doubt, by providing reasonable evidence and documentation, that [***]; or</font></p>
  <p style="margin-left:3.227%;text-indent:-3.686%;padding-left:3.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) Vetter International can show Ascendis beyond doubt, by providing reasonable evidence and documentation, that [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each case set forth in Section 14(4) and 14(5): provided that, in the case of (i), a Party may exercise such termination right [***] or [***], and; provided [***], and such termination shall be effective only if the Parties fail to reach an agreement on how to continue the project following such [***] period.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon the Completion Date, Vetter International shall, in its sole discretion, sell to Ascendis and Ascendis shall purchase, at the prices herein provided, any Product for which Purchase Orders have been or are required to be placed in accordance with the SC-Terms on or prior to the Completion Date and, at the purchase prices thereof, all Vetter Materials and other materials ordered as contemplated in or permitted under this Agreement. Ascendis shall be responsible and liable to Vetter International for any amounts related to, based upon or arising out of such termination, including for an orderly cessation of the Manufacture and any related activities, as well as such other amounts accruing prior to the Completion Date; provided, however, it is agreed and understood by Vetter International that any and all expenditures scheduled under the Manufacture not actually made due to such termination shall be deducted from any of the foregoing amounts. Upon the Completion Date, Vetter International shall arrange for delivery to Ascendis, or destruction, of any Ascendis Materials at the Facility, [***]. Upon the Completion Date, Vetter International shall make available, as is and where is, to Ascendis [***]. Vetter International shall have returned to Ascendis all documentation (including copies thereof) constituting Confidential Information of Ascendis and/or any of its Affiliates including all documents and report created by Vetter International or any of its Affiliates during the performance of the Service that are determined to be Confidential Information of Ascendis; provided, however, notwithstanding the foregoing, Vetter International or any of its Affiliates may retain such limited quantity of the Product, the Ascendis Materials (all thereof sufficient for [***]) and such documentation as may be necessary for proper record keeping in satisfaction of legal requirements. Upon the Completion Date, Ascendis shall return to Vetter International any and all documentation (including copies thereof) provided to Ascendis and constituting Confidential Information of Vetter International and/or any of its Affiliates; provided, however, Ascendis may retain such limited number thereof as may be necessary for proper record keeping in satisfaction of legal requirements.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Survival.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] shall survive the Completion Date.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.627%;text-indent:1.356%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 15: ANTI-BRIBERY AND DATA PROTECTION</font><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-Bribery.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Parties shall comply at all times with all applicable laws and regulations in particular with such combating bribery and corruption (&#x201c;Anti-Bribery Laws&#x201d;). The Parties hereby represent and warrant that they have not offered to pay, paid, or accepted, and undertake that they will not offer, pay, or accept, any bribes (including any improper gifts or entertainment) to or by any person (including, in particular, any government or public official of any jurisdiction) to secure or retain a business advantage for the benefit of Vetter International and/or Ascendis under or in connection with this Agreement. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Policies and Procedures.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Parties shall take appropriate steps, in particular maintain and effectively enforce internal policies and procedures, to ensure that the Parties&#x2019; Representatives, agents, or any other person acting on behalf of the Parties will not breach any Anti-Bribery Laws. The Parties shall be responsible for any breach of Anti-Bribery Laws by its Representatives, agents, or any other person acting on behalf of the Parties under or in connection with this Agreement. </font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party represents and warrants to notify the other Party without delay, if in connection with this Agreement</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.122711053182624%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one Party discovers a violation of applicable anticorruption and antitrust laws which are relevant for the performance of this Agreement; or </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.935%;text-indent:3.709%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.606500798434039%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigations against one Party have been initiated by public authorities.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data Protection.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Each Party shall comply with all applicable laws, statutes, regulations relating to personal data protection.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 16: CONFIDENTIALITY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.463%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The confidentiality provisions of this Article shall govern Confidential Information (as defined below) disclosed in connection with this Agreement in every respect.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;Confidential Information&#34; means any proprietary information, samples, technical data, trade secrets or know-how, including, but not limited to, research and product plans, products, services, lists of collaborators and corporate partners, markets, developments, inventions, processes, including manufacturing processes and procedures and processes as may be embodied or evidenced in formulae, manufacturing data, specifications and other related documents, patents and patented designs, copyrights, trademarks, industrial design, improvements, discoveries, ideas, devices, writings, any intellectual property and proprietary information relating to a product, as well as that directly derived or resulting from any of the foregoing, and/or any information or matter that a reasonable business person would or should deem confidential or proprietary, formulas, technology, marketing, finances or other business information disclosed by either Party (the &#x201c;Discloser&#x201d;) (either directly or indirectly in writing, orally or otherwise also during the presence at premises of a Party) to the other Party (the &#x201c;Recipient&#x201d;) whether or not labeled &#x201c;Confidential&#x201d; after the Effective Date.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.463%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party agrees to maintain in confidence, to the same extent that it maintains its own Confidential Information secret, all Confidential Information of another Party. Except with Discloser&#x2019;s prior written consent, Recipient will not, during or subsequent to the term of this Agreement, use Confidential Information for any purpose whatsoever other than for the performance of this Agreement or disclose Confidential Information to any third party other than Representatives who have a need to know in order to perform the Services provided that the Recipient procures that any of such Representatives receiving Confidential Information shall be subject to and bound in writing by confidentiality obligations substantially similar to the terms set forth in this Agreement.  The agreement(s) defining such obligations and binding the Representatives of the Recipient shall be provided to the Discloser by the Recipient upon request. Recipient agrees that Confidential Information shall remain the sole property of Discloser. Recipient further agrees to take all reasonable precautions to prevent any unauthorized disclosure of Confidential Information.  Notwithstanding the above, Recipient's obligation under this Article 16 relating to Confidential Information shall not apply to information which:</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is known to Recipient at the time of disclosure to Recipient by Discloser as evidenced by written records of Recipient,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has become publicly known and made generally available through no wrongful act of Recipient,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been received by Recipient without restriction on disclosure from a third party or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is independently developed by or on behalf of the Recipient other than under this Agreement and without the aid, application or use of Discloser&#x2019;s Confidential Information as evidenced by written documentation.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.463%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding any provision in this Agreement to the contrary, the Recipient may disclose Confidential Information of the Discloser to the extent Recipient is required to do so by any governmental or regulatory authority or court.  In such event, the Recipient shall promptly notify the Discloser when such requirement to disclose has arisen, and cooperate with Discloser so as to enable Discloser to: (i) seek an appropriate protective order; (ii) make the confidential nature of the Confidential Information known to such governmental or regulatory authority or court; and (iii) make any applicable claim of confidentiality in respect of the Confidential Information.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.463%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the termination of this Agreement (irrespective of the reason therefore), or upon Discloser's earlier request, Recipient will deliver on request to Discloser all of Discloser's property, including in particular that relating to Confidential Information, which is in Recipient's possession or control.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.463%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party acknowledges and agrees that Confidential Information may be stored on each Party&#x2019;s customary electronic data processing system and transmitted (sent and received) by each Party to another Party&#x2019;s designated electronic mail address without encryption or other protective measures, unless otherwise agreed in writing. Any electronic mail address received by each Party from another Party shall be deemed a designated address unless otherwise indicated.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.463%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party shall make no tangible copies or reproductions of Confidential Information of another Party unless reasonably required for the performance of this Agreement.  Each Party shall ensure that any notices or marks referring to confidentiality or to proprietary rights as may be found on Confidential Information are reproduced on any and all such copies or reproductions made as hereunder permitted. Each Party agrees that it will, at the reasonable written request of another Party, destroy or otherwise dispose of all tangible records, reproductions or copies containing Confidential Information of such other Party; provided, however, that one (1) copy may be retained and stored for legal purposes.  Digital backup files automatically generated by each Party&#x2019;s customary electronic data processing system shall not be deemed to constitute a retained copy, provided, however that no such backup files may be stored for a period exceeding [***]. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise required by law (including securities laws and regulations), neither Party will make any public announcement or press release regarding the existence or terms of this Agreement or such that mentions the other Party without the prior written consent of the other Party and the content of any such public announcement or press release shall be mutually agreed by the Parties in writing. It is specifically agreed [***].</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party agrees to indemnify, defend and hold the other Party and/or any of its Representatives harmless from and against any and all Costs and Liabilities resulting from or arising out of breach by it and/or any of its Representatives of the provisions of this Article 16.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The obligations of Recipient under this Article 16 shall survive the Completion Date and shall remain in effect for a period of [***] from the Completion Date.  </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ARTICLE 17: MISCELLANEOUS</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No Party shall be responsible or liable to the other Party and/or any of its Representatives, and no default shall be deemed to have occurred, for failure or delay in performing any obligations or for other non-performance if such failure, delay or other non-performance is caused by or arises from any strike, stoppage of labor, lockout or any other labor trouble, shortage of energy or raw material or any significantly prolonged inability to obtain materials or shipping space, due to the material default or significant delay by any supplier or sub-contractor or other events due to internalization of operations and services typically and customarily provided by a third party, fire, flood, lightning, fog, storm, unusual weather conditions, explosion, accident, earthquake, volcanic ash, epidemics, act of God, any public enemy, sabotage, invasion, war (declared or undeclared), riot, embargo, governmental or administrative act or restraint, prohibition on import or export of the Product or materials incorporated therein or parts thereof, or any matter or cause that is unavoidable by or beyond the reasonable control of the affected Party (each, an event of &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). A Party shall be under no obligation to settle a strike, labor stoppage, lockout, or any other labor trouble by entering into any agreement to settle any thereof and until any such matter is settled to the satisfaction of the affected Party, such matter shall continue to be deemed Force Majeure. Any and all of the foregoing shall also apply to a Party to the extent that an Affiliate of such Party is performing or providing any service (including under Section 1(6) referred to) or work in connection with the obligations of a Party. A Party claiming Force Majeure shall promptly notify the other Party specifying the cause and probable duration of the failure, delay or other non-performance. Neither Vetter International nor any of its Representatives shall be under any obligation to fulfill any Purchase Order which has been, or should have been scheduled to be performed during a time period of Force Majeure; provided, however, a Party so affected shall undertake every reasonable effort to fulfill its contractual obligations to the extent reasonably possible under the circumstances.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">United Nations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">United Nations Convention on Contracts for the International Sale of Goods </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall have no application to, and shall be of no force and effect with respect to, the matters set forth or contemplated in this Agreement.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement constitutes the entire agreement with respect to the matters set forth or contemplated in this Agreement and supersedes in any and all respects any prior communication, proposal, quotation, negotiation, conversation, discussion and agreement concerning the matters set forth or contemplated in this Agreement, and any terms and conditions thereof shall be null and void.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conflict.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of any conflict between any provision of the Commercial Quality Agreement and the other provisions of this Agreement, the provisions of the Commercial Quality Agreement shall exclusively govern and control any and all technical, pharmaceutical and/or quality related matters of the Manufacture, whereas the other provisions of this Agreement shall exclusively govern and control any other matters.</font></div></div>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any provision of this Agreement held void, invalid or unenforceable shall be replaced by a mutually agreed provision that is effective, valid and enforceable and in compliance with the lawful purposes and intentions as contained in or determinable under this Agreement. Any matter not initially considered shall be resolved by incorporating such reasonable provision in order to complete this Agreement which approaches to the maximum extent such lawful purposes and intentions. The effectiveness, validity and enforceability of this Agreement shall remain independent of any provision </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which might be or has become void, invalid or unenforceable except if any replacement thereof is not possible and this Agreement would then not have been entered into.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any amendment or modification of the provisions in this Agreement contained, specifically including this Section, shall take effect only by a written document signed and duly executed. The Appendices may be amended from time to time separately and independently of the Commercial Quality Agreement. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither this Agreement nor any right or obligation hereunder of each Party shall be assignable or transferable, except as herein provided, without the prior written consent of the other Party; provided, however, </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a) Vetter International may cause internal logistic and warehousing operations to be performed by an independent subcontractor (currently [***]) and Vetter International shall be and remain responsible and liable for any performance of or failure to perform by such contractor.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b) Ascendis may assign its business related to the Product to [***] and Ascendis may assign this Agreement and its rights and obligations hereunder, to a successor in connection with a merger, consolidation or the sale of all or substantially all of Ascendis&#x2019; business to which the Agreement relates; provided, however, that (i) [***] and (y) [***].</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c) Each Party may assign or transfer any such rights (and, for the avoidance of doubt, to grant of security interests in the same) to any of its Affiliates, or to lenders, shareholders, investors or financial underwriters, so long as such assignment or transfer does not impair or materially diminish the assigning Party`s ability to perform its obligations under this Agreement, provided, however, that the assigning Party shall not be relieved, by action of such assignment or transfer of rights, of any of its obligations hereunder, and the assignee shall, in addition to the assignor, assume confidentiality obligations to the same extent as set forth in this Agreement and accepted by the assignor.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Notices and other communication</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any and all legal notices, requests, demands and other communication hereunder shall be in English (and any and all costs and/or expenses associated with necessary translation shall be borne by the incurring Party), be addressed as follows, or to such other address or fax number as each Party may specify in a notice pursuant to this Section, and be deemed duly given upon receipt if and when such receipt is on a Business Day and during normal business hours of the recipient or otherwise on the then-succeeding Business Day, and if mailed by registered or certified mail, return receipt requested (and for greater certainty, be deemed unduly given if delivered by email): </font></div></div>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Ascendis:		Ascendis Pharma A/S</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn.: Legal Counsel</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tuborg Boulevard 12</font></p>
  <p style="margin-left:19.8%;text-indent:8.562%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D-2900 Hellerup, Denmark</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Vetter International:	Vetter Pharma International GmbH</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Attn. Managing Director</font></p>
  <p style="margin-left:3.333%;text-indent:7.103%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			Eywiesenstra&szlig;e 5,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:7.103%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			D-88212 Ravensburg, Germany</font></p>
  <p style="margin-left:3.333%;text-indent:7.103%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">							With copy to:</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">							</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vetter Pharma-Fertigung GmbH &amp; Co. KG</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">							Attn. Head of Legal Department</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">							Sch&uuml;tzenstra&szlig;e 87,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">						D-88212 Ravensburg, Germany</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Parties agree that documents such as forecasts, Purchase Orders, changes orders, etc. may be submitted by e-mail.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The headlines of the Articles and the Sections are for convenience of reference only and shall not affect the interpretation of this Agreement. Any understanding or interpretation of any legal term contained or referred to in this Agreement shall solely be defined and interpreted in accordance with the laws of</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***], irrespective of any other meanings or interpretations under any other source or body of law as may be found applicable to this Agreement by any court that may claim or assess jurisdiction under any conflict-of-laws provisions or otherwise, any of which other meanings or interpretations shall have no application to and be of no force and effect with respect to the matters herein set forth, referred to or contemplated</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Execution.  This Agreement and any amendments thereto, may be executed in counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Execution may be carried out conventionally (by handwritten ink signature of all counterparts) or electronically (with e&#x2011;signature by all Parties using the DocuSign&#174; electronic signature system). Documents executed conventionally may be exchanged by (i) physical delivery of signed originals or (ii) electronic transmission of scanned or other images of the same, with physical delivery of the signed originals to follow; the Parties intend such transmitted images to have the same meaning, validity and enforceability as original documents bearing a handwritten signature, and a Party receiving a document so signed may rely upon it as if the original had been received. Documents executed electronically shall be deemed fully executed and legally binding upon all Parties' completion of the DocuSign&#174; protocol, and the Parties hereby acknowledge their intent to be so bound.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(11)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Independent Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Party and any of its Affiliates are independent parties and nothing in this Agreement is intended or shall be deemed to create a partnership, a joint venture or a relationship of an agent with its client or an employer with its employee. No Party or any of its Affiliates shall have authority to make any statements, press releases, representations or commitments of any kind, or take any action which shall be binding on the other Party and/or any of its Affiliates, except as may be expressly authorized in writing which authorization shall not be unreasonably withheld.  </font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(12)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Timely Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any failure by either Party to request performance or non-performance by the other Party and/or any of its Affiliates or to claim a breach of this Agreement shall neither be construed as a waiver of any right under this Agreement nor affect any subsequent failure to request performance or non-performance or claim a breach, nor affect the effectiveness, validity and enforceability of this Agreement or any part thereof nor prejudice or preclude such Party with respect to any subsequent action. Any request for performance or non-performance by either Party and/or any of its Affiliates or claim of a breach of this Agreement, including breach of this Section, shall be effective, valid and enforceable only if such request or claim is reduced to writing.</font></div></div>
  <p style="margin-left:6.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(13)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Dispute Resolution, Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Parties shall attempt to amicably settle and in good faith resolve any dispute in connection with this Agreement, by negotiations between designated representatives prior to resorting to any court action. If no amicable settlement and good faith resolution thereof has been achieved within [***], such dispute may be brought by written notice to the executive management representatives who shall use reasonable endeavors to amicably settle and in good faith resolve such dispute within [***] of receipt of said notice. If such settlement fails, either Party may, at its sole discretion, refer any dispute, controversy or claim arising out of or in connection with this Agreement to Arbitration under [***] (&#x201c;Rules&#x201d;). </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.307%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All disputes, controversies or claims arising out of or in connection with the present Agreement shall be finally settled in accordance with the Rules by [***] appointed in accordance with the Rules. The seat of arbitration shall be [***]. The language to be used in the arbitral proceedings shall be English. Annexes to any procedural document may also be provided in the German language.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.307%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.307%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement including the Commercial Quality Agreement and all Annexes and Appendices thereto shall be governed by, construed and interpreted, and all disputes, controversies or claims arising under or in connection with this Agreement shall be resolved in accordance with the substantive law of [***] without recourse to any conflict of laws rules. The arbitral tribunal shall have the authority to order production of documents only in accordance and within the limits of [***] as current on the date of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.307%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.307%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any decision or arbitral award delivered in the arbitration shall be reasoned and in writing, and shall be final and binding on the Parties and enforceable in any competent court of law. The Parties undertake to comply promptly with any award without delay and shall be deemed to have waived their right to any form of recourse insofar as such waiver can validly be made. The existence and content of the arbitral proceedings and any rulings or award shall be kept confidential by the Parties and members of the arbitral tribunal except to the extent that disclosure may be required of a Party to fulfil a legal duty, protect or pursue a legal right, or enforce an award before a state court or other judicial authority. Notwithstanding, before making such information public, the interested Party shall notify the other(s), in writing, and shall afford them a reasonable opportunity to protect their interests if they deem it necessary.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.307%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.307%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The losing Party shall bear the costs of the arbitration, pro rata, if applicable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Page remainder left blank intentionally, immediately followed by signature page.)</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, duly authorized representatives of each Party have executed this Agreement on the days and year at the places below written.</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASCENDIS PHARMA A/S</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">_</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hellerup, Denmark</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">______ (place)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, dated this __</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____ day of ____</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">________ </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(month)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2022</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(signed)___</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/Michael Wolff Jensen</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">_____________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:	___</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michael Wolff Jensen  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">______________________		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:	___</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Legal Officer    </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_______________________		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VETTER PHARMA INTERNATIONAL GMBH</font></p>
  <p style="text-indent:-89.585%;padding-left:47.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-89.585%;padding-left:47.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ravensburg, Germany</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, dated this __</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____ day of ____</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">______ </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(month)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2022</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(signed)__</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/Christine Fuerst</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">____________		(signed)___</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/Nicolai Lehmann          </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">_____<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:	___</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Christine Fuerst</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________		Name:	______</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nicolai Lehmann   </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_______<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sen Director, Key Account Management Europe</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Title:	_______</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key Account Manager</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">____</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.59in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
      <td style="width:33.333%;box-sizing:content-box;"></td>
     </tr>
     <tr style="word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEX 1: SC-TERMS AND CAPACITY AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LONG RANGE FORECAST AND OTHER SUPPLY CHAIN TERMS<br> </font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Certain capitalized terms used herein but not defined in this Annex 1 are defined in the Agreement.)</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.62%;box-sizing:content-box;"></td>
    <td style="width:25.82%;box-sizing:content-box;"></td>
    <td style="width:66.56%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LONG RANGE FORECAST</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CAPACITY AGREEMENT</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1)ASCENDIS has initially provided to Vetter International their aggregate non-binding, unless agreed otherwise as set forth in Section 1 (2) below, Product requirements for a [***] period, see Attachment 1 and 2 to this Annex 1 (&#x201c;Initial Long Range Forecast&#x201d;) and shall thereafter, on or before [***] during the Term, provide a successive update Long Range Forecast thereof (each update, the &#x201c;Updated Long Range Forecast&#x201d;; and the Initial Long Range Forecast  and any Updated Long Range Forecast hereinafter the &#x201c;Long Range Forecast&#x201d;). The Long Range Forecast shall show the [***] (each, the &#x201c;Annual Demand&#x201d;) for a period of [***].</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2) The [***] of any Long Range Forecast as set forth in this Annex 1 shall be binding to ASCENDIS and shall be considered a rolling ASCENDIS capacity reservation commitment for each [***] period, which [***] (hereinafter the &#x201c;ASCENDIS Commitment&#x201d;). [***] of any Long Range Forecast shall be non-binding and for ASCENDIS and Vetter International planning purposes only, provided however, it is agreed and understood by ASCENDIS that [***]. In [***] of every Long Range Forecast or Updated Long Range Forecast the forecast is non-binding (Fig. 2 Attachment 1).</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.556%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3) The aggregate Product quantities set forth in all Long Range Forecast&#x2019;s for the [***] is, unless otherwise specified, assumed to have an average batch size of [***], solely for procurement estimation and capacity reservation purposes of packaging materials.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The capacity agreement is separated in two phases, Long Range Forecasts submitted [***] (Pre-Launch Phase) and Long Range Forecasts submitted [***] (Post-Launch Phase)</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Post-Launch Phase rolling capacity commitments</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(i) [***].</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional batches can be requested by ASCENDIS as set forth in Section 6(4) and 6(5) of this Annex 1.</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.62%;box-sizing:content-box;"></td>
    <td style="width:25.82%;box-sizing:content-box;"></td>
    <td style="width:66.56%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(ii) and [***].</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">From [***], conditions as described above (Post-Launch Phase) will come into effect.</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-Launch Phase capacity commitments:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Market authorization for ASCENDIS&#x2019;s first Product is to be expected in [***]. For the timeframe [***], ASCENDIS will have following flexibility (in batches)</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Maximum [***] Minimum [***]</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Maximum [***] Minimum [***]</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Maximum [***] Minimum [***]</font></div></div><p style="margin-left:6.667%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">First [***] of the Initial Long Range Forecast (in batches:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:16.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:17.375112499612072%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Maximum number of batches [***]</font></div></div><p style="margin-left:6.667%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Minimum number of batches [***]</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:16.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:17.375112499612072%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Maximum number of batches [***]</font></div></div><p style="margin-left:6.667%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Minimum number of batches [***]</font></p><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:16.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:17.264882894641435%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Maximum number of batches [***]</font></div></div><p style="margin-left:6.667%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Minimum number of batches [***]</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">For illustration purposes, Fig.1 and Fig.2 is attached to this Annex 1. It is agreed by the Parties that any such Maximum number of batches and Minimum number of batches per Annual Demand shall apply to the [***] period and that [***].</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4) Vetter International accepts the ASCENDIS Initial Long Range Forecast and hereby commits itself to reserve capacity at the Facility, in an equivalent of the Annual Demand set forth in each of the first [***] of the so accepted Initial Long Range Forecast provided in Attachment 1 and 2 to this Annex 1.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5)  With regard to any Updated Long Range Forecast, Vetter International shall inform ASCENDIS in [***] of each Calendar Year (during the Parties&#x2019; regular business review meeting), if Vetter International is able to provide the capacity requested by ASCENDIS in Calendar Year 3 of any Updated Long Range Forecast, and upon positive</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.62%;box-sizing:content-box;"></td>
    <td style="width:25.82%;box-sizing:content-box;"></td>
    <td style="width:66.56%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">confirmation, Vetter International commits itself to reserve capacity in an equivalent of the Annual Demand set forth in such newly added third Calendar Year and such reservation commitment becomes part of the Vetter Commitment.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vetter International shall confirm the updated forecast before the [***]. If not confirmed the updated forecast is deemed accepted by Vetter International with regards to delivery dates, quantities and without any penalties for Ascendis.</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LONG RANGE FORECAST,</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1) The Parties shall discuss during the business review meeting the total ASCENDIS Annual Demand of Product quantities in batches for each of the following [***] and Vetter International will, in return, indicate to ASCENDIS the current capacity status of [***] being a non-binding information.</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2) Major demand changes (increase/decrease) shall [***]. If the number of batches of Product for each Calendar Year set forth in any updated Long Range Forecast exceed the allotted capacity of the cleanroom and/or production line to be used for the Manufacture, or require the procurement of additional Equipment, dedicated to the Manufacture of the Product of ASCENDIS, Vetter International shall inform ASCENDIS thereof. In such event, each of the Parties shall reasonably determine and agree upon with the other Party, if and to the extent necessary to achieve the increased capacities required by the Long Range Forecast, (i) the organization and timelines of the transfer of the Manufacture of the Product to a different cleanroom and/or production line (ii) the supply of additional Equipment; and/or (iii) any other changes necessary to achieve the increased capacities set forth in, and as required by, the Long Range Forecast [***].</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MONTHLY ROLLING FORECAST</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1) For each Product to be Manufactured, ASCENDIS shall provide Vetter International, [***], with a [***] Monthly Rolling Forecast of the number of batches of Product that ASCENDIS intends to order from Vetter International. Such number of batches as requested to be delivered on the Delivery Date within a certain calendar month during such [***] period (the &#x201c;Initial Monthly Rolling Forecast&#x201d;, and each of the monthly revised forecasts, on a rolling basis, as</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.62%;box-sizing:content-box;"></td>
    <td style="width:25.82%;box-sizing:content-box;"></td>
    <td style="width:66.56%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial Monthly Rolling Forecast updates, hereinafter referred to as a &#x201c;Monthly Rolling Forecast&#x201d;).</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2) The Monthly Rolling Forecast shall show the anticipated demand of ASCENDIS for the Product, indicated per each Product variant for information (different Product concentrations), requested to be delivered on the Delivery Date in each calendar month, beginning on the first (1st) day of the month then-following the month of its submittal and receipt by Vetter International, and ending on the last day of the twenty fourth (24th) calendar month thereafter. Example: [***]. Each Monthly Rolling Forecast must therefore include: (i) requested Product quantities (&#x201c;Product variant&#x201d;) in batch quantities; together with (ii) requested delivery month and the dates desired for such Product quantity.</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3) Requested Product number of batches shall be [***]. [***].</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4) Each Monthly Rolling Forecast shall be [***] and shall [***].   In case the Product Quantities in number of batches in any Monthly Rolling Forecast do not comply with the requirements set forth in this Annex 1, [***]. A decrease in the Monthly Rolling Forecast [***]. In case the Product quantities in the Monthly Rolling Forecast exceed the Maximum Quantity, [***]. Any disputes and/or discrepancies with regards to the Monthly Rolling Forecast shall be discussed by the parties in accordance with this Section 3 of the Annex 1.</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If the Forecast is within the defined Semi-Binding boarders, Vetter International shall confirm the updated rolling forecast within the same month, otherwise in the first week of the upcoming month. If not confirmed the updated forecast is deemed accepted by Vetter International with regards to delivery dates, quantities and without any penalties for Ascendis</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BINDING PERIOD</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Product quantities in number of batches set forth in any Monthly Rolling Forecast in [***] (&#x201c;Binding Period&#x201d;) shall constitute a firm and binding commitment of ASCENDIS, and [***].</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Semi-Binding PERIOD</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.62%;box-sizing:content-box;"></td>
    <td style="width:25.82%;box-sizing:content-box;"></td>
    <td style="width:66.56%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1) The Product quantities in number batches set forth in any Monthly Rolling Forecast in [***] of each Monthly Rolling Forecast (&#x201c;Flexible Period&#x201d;) shall be deemed binding, as herein below set forth:</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Monthly Rolling Forecasts of [***] shall determine the Product quantities in number of batches in the Flexible Period that are fixed as a [***] part of the Annual Reference Quantity (each a &#x201c;[***]&#x201d;):</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Product quantities in number batches provided by ASCENDIS in the Monthly Rolling Forecast for [***] shall [***]</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Product quantities in number batches provided by ASCENDIS in the Monthly Rolling Forecast for [***] shall [***]</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Product quantities in number batches provided by ASCENDIS in the Monthly Rolling Forecast for [***] shall [***]</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The aggregate Product quantities set forth in all Monthly Rolling Forecasts for a Calendar Year have to comply with and meet the Annual Demand of [***], the applicable ASCENDIS Commitment as may be adjusted [***].</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The &#x201c;Annual Reference Quantity&#x201d; for a Calendar Year shall mean the sum of the aggregated Product quantities in number of batches provided by ASCENDIS in [***]. Parties have added [***]  accordingly.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In case of discrepancy between the Monthly Rolling Forecast and the Long Range Forecast, [***] shall apply.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3) [***].</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PURCHASE ORDERS,</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ADDITIONAL QUANTITY,</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">OMITTED PURCHASE ORDERS</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1) Together with each monthly update of the Monthly Rolling Forecast, Purchase Orders shall be issued by ASCENDIS, which Purchase Orders shall correspond to the quantities set forth for the Binding Period of the then-current Monthly Rolling Forecast. ASCENDIS shall therefore place (i) initially, Purchase Orders covering [***]; and (ii) thereafter, Purchase Orders for [***] of the updated Binding Period.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2) The requested Delivery Date indicated in the Purchase Order shall be no earlier than [***] after receipt of the Purchase Order by Vetter International.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.62%;box-sizing:content-box;"></td>
    <td style="width:25.82%;box-sizing:content-box;"></td>
    <td style="width:66.56%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3) Vetter International shall respond (by facsimile, any other written or electronic form) to every Purchase Order placed for the Binding Period within [***], and shall confirm Product quantities which meet the requirements of this Annex 1, and shall provide the Confirmed Delivery Date for the Product so ordered by ASCENDIS. If Vetter International has not responded [***] the orders are deemed accepted by Vetter International with regards to delivery dates, quantities and without any penalties for Ascendis</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4) Subject to the Facility&#x2019;s manufacturing and equipment capacities and other supply commitments, the urgency of the supply needs of ASCENDIS, the Parties may mutually agree that additional quantities of Product may be available in excess of the ASCENDIS Commitment during (x) the Binding Period and/or (y) the Flexible Period and/or (ii) the Maximum Quantity (such quantities, to the extent so in excess, collectively &#x201c;Additional Quantity&#x201d;), and as such, ASCENDIS (1) may place a Purchase Order for the Additional Quantity within the Binding Period; or (2) adjust the Flexible Period of the Monthly Rolling Forecast in accordance with the terms of the Agreement. Vetter shall [***] to accommodate ASCENDIS&#x2019;s request for Additional Quantity.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5) In no event [***] shall acceptance to deliver Additional Quantities set forth in an individual Purchase Order for such Additional Quantity (i) [***]; or (ii) [***].</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6) If, in any given calendar month within the Binding Period, ASCENDIS does not place a Purchase Order in accordance with the then-current Monthly Rolling Forecast related to the Minimum Quantities of the ASCENDIS Commitment in number of batches, [***].</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">REPLACEMENT PRODUCT</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If for any reason ASCENDIS is not in a position to order sufficient quantities of Product in order to comply with its Minimum Quantities in number of batches as set forth in this Agreement or wishes to cancel a slot within the Binding Period, [***]. [***].  The parties shall agree in good faith any amendments to the Agreement that are necessary as result of ASCENDIS exercising such right. Vetter International accepts the switch between the presentation [***] before the requested and confirmed delivery date [***].</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.62%;box-sizing:content-box;"></td>
    <td style="width:25.82%;box-sizing:content-box;"></td>
    <td style="width:66.56%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ANNUAL RECONCILIATION AND CAPACITY COMPENSATION</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1) Until [***] of each Calendar Year, the Parties shall jointly review the Product quantities which have been delivered during such Calendar Year for which ASCENDIS has actually provided Purchase Orders and/or paid for in accordance with this Annex 1 (&#x201c;Annually Ordered Quantity&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2)  in the event that any such review reveals that [***] (i) [***]  and/or (ii) [***], then [***] (each, [***]),</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">multiplied by</font></p><div class="item-list-element-wrapper" style="margin-left:0.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.702995083598927%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.702995083598927%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) [***].</font></div></div><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unless [***]</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(3) In support of Section 8(2) of this Annex 1 above, the following formula shall apply, to calculate [***]:</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average Weighted Batch Price means [***].</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.993538171858953%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></div></div><p style="margin-left:6.533%;text-indent:-7.548%;padding-left:6.56%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">and/or</font></p><div class="item-list-element-wrapper" style="margin-left:6.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.993538171858953%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and/or [***]</font></div></div><p style="margin-left:6.533%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.533%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">and/or</font></p><div class="item-list-element-wrapper" style="margin-left:6.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.993538171858953%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></div></div><p style="margin-left:6.533%;text-indent:-7.548%;padding-left:6.56%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">and</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.993538171858953%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></div></div><p style="margin-left:6.533%;text-indent:-7.548%;padding-left:6.56%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4) Unless specified otherwise in the Agreement, ASCENDIS shall [***]. However, [***].</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FREEDOM OF FILLING DAY</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Based on the information provided in the Monthly Rolling Forecast, Vetter International shall schedule the Manufacture and confirm Delivery Dates, in accordance with Section 6(3) of this Annex 1. Filling days shall be communicated to ASCENDIS. Vetter International shall always try to prioritize Purchase Orders with critical shelf life and [***].</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BATCH SIZE</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.62%;box-sizing:content-box;"></td>
    <td style="width:25.82%;box-sizing:content-box;"></td>
    <td style="width:66.56%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Monthly Rolling Forecast model used under this Agreement is designed for ordering and forecasting within the validated range of the Product batches.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INVENTORY, SAFETY STOCK</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1) Based on the monthly Monthly Rolling Forecast (and, to the extent commercially practicable, on such revised or updated Monthly Rolling Forecasts), [***] (for clarity, [***]). Vetter International shall maintain a stock of Sourced Materials (&#x201c;Inventory&#x201d;) in quantities sufficient for the Manufacture of (i) the quantities of Product set forth for all calendar months of the Binding Period; plus (ii) [***] of the Annual Demand (as set forth in the current Vetter International accepted Long Range Forecast).  The Inventory shall be discussed during the business review meeting. If it has been determined by the business review meeting additional Inventory is required [***]. Any such additional Inventory shall [***].(2) If, and to the extent that, Sourced Materials procured by Vetter International in accordance with this Annex 1 should become obsolete or unfit for the Manufacture of Products, due to (i) [***]; (ii) [***]; (iii) [***]; (iv) [***]; (v) [***] and/or (vi) expiry or termination of this Agreement (not attributed to [***]), and [***], [***]. [***] will use [***] to mitigate the costs (e.g. [***]).</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LATE DELIVERTY ASCENDIS MATERIALS</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If a late delivery without having a safety stock results in the loss of a filling slot, it will be considered as [***], or [***] hereunder, and shall be subject to [***].</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">REVISION</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Any revision of this Annex 1 shall require an amendment of Agreement, as provided in and subject to Section 18(6) of the Agreement.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTACHMENT 1 Initial Long Range Forecast</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment 2:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Detailed tolerances and visualized overview for the Pre-Launch Phase</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fig. 2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fig.3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fig. 4</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEX 2: PRICES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEX 3: EQUIPMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Equipment at Vetter owned by Ascendis Pharma:</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-3.591%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEX 4: COMMERCIAL QUALITY AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:1.2in;min-height:1.85in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.25
<SEQUENCE>5
<FILENAME>asnd-ex4_25.htm
<DESCRIPTION>EX-4.25
<TEXT>
<html>
 <head>
  <title>EX-4.25</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.25</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN IDENTIFIED CONFIDENTIAL INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT BECAUSE IT IS (I) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE OR CONFIDENTIAL AND (II) NOT MATERIAL.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS AMENDMENT NUMBER 1 </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), of the Supply Agreement effective as of October 1</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2022 (such agreement, as amended from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between Ascendis Pharma A/S, a company duly organized and existing under the laws of Denmark, having its principal offices located at Tuborg Boulevard 12, 2900 Hellerup, Denmark (&#x201c;Ascendis&#x201d;), and Vetter Pharma International GmbH, a company duly organized and existing under the laws of Germany, having its principal offices located at Eywiesenstra&szlig;e 5, 88212 Ravensburg, Germany (&#x201c;Vetter&#x201d;), with Ascendis and Vetter hereinafter individually also referred to as a &#x201c;Party&#x201d; and collectively as the &#x201c;Parties&#x201d;,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WITNESSETH:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in accordance with Article 17 (6) (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), the Parties wish to amend the Agreement on the terms set forth herein; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the premises and of the mutual covenants and agreements set forth above and below in this Amendment, and in the Agreement, subject to the terms and conditions hereof, each Party as follows:</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article&nbsp;1:</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDMENTS</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With effect from January 1</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2024 Annex 2 of the Agreement shall be deemed null and void and shall be replaced by the attached Exhibit (Annex 2).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With effect as of January 1</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2024, Section 9 (6) shall be deemed null and void and shall be replaced by the following:</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Payments. Without undue delay, Vetter International shall issue an invoice upon [***] or, in case of Product not yet Final Released, Vetter International shall be entitled to invoice [***]. Payments shall be made in Euros and due [***] of the invoice date (receipt of readily available funds by Vetter International) [***]. After such time period the payments shall be made [***] and due [***] of the invoice date. If Ascendis pays later than [***] of receipt of the invoice, Vetter International shall be entitled to interest of the invoiced amount of [***] (except when payment is subject to a good&#x2011;faith resolution of any dispute). Ascendis shall add such interest, accumulated in accordance with this Article as of the time of payment due, to the invoiced amount and include such with the payment by Ascendis.&#x201d;</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article&nbsp;2:</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MISCELLANEOUS</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized terms not defined herein shall have the same meanings as specified in the Agreement, unless the context otherwise requires. A reference herein to an Article is to an Article of the Agreement, unless the context otherwise requires. Each reference to the term Agreement, in the Agreement, shall be deemed to be a reference to the Agreement as amended or supplemented by this Amendment, unless the context otherwise requires.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as expressly modified by this Amendment, any and all terms and conditions of the Agreement shall remain in full force and effect and shall be applicable to this Amendment. For </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the avoidance of doubt, anything which is not covered in this Amendment, shall be subject to the provisions of the Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Agreement (including [***]) together with this Amendment, constitutes the entire agreement between the Parties with respect to Production of the Product by Vetter and supersedes in all respects all prior proposals, negotiations, conversations, discussions and agreements between the Parties in respect thereof.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Article 16 (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and Article 17 (12) </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Dispute Resolution, Governing Law) </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be deemed incorporated into this Amendment by this reference, save that any reference in any such Article to &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">this Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall be deemed to be a reference to this Amendment.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Page remainder left blank intentionally, immediately followed by the signatures page</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.)</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\156379683.3||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, duly authorized representatives of each of the Parties have on the days and year at the places below written executed this Amendment to be effective on the respective dates as set forth above.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASCENDIS PHARMA A/S</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hellerup, Denmark, dated </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April		</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (month) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">08	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (day), 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(signed) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/Michael Wolff Jensen	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michael Wolff Jensen	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EVP &amp; Chief Legal Officer	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VETTER PHARMA INTERNATIONAL GMBH</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ravensburg, Germany, dated </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April		</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (month) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">08	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (day), 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(signed) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/Christine Fuerst	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(signed) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/Nicolai Lehmann	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Christine Fuerst	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nicolai Lehmann	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sr. Director Key Account Management Europe</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Title: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key Account Manager	</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\156379683.3||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT<br>ANNEX 2: PRICES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2014;CONFIDENTIAL&#x2014;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\156379683.3||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2(B)
<SEQUENCE>6
<FILENAME>asnd-ex4_2b.htm
<DESCRIPTION>EX-4.2(B)
<TEXT>
<html>
 <head>
  <title>EX-4.2(b)</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.49in;z-index:-3;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.2(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font><img src="img62010886_0.jpg" alt="img62010886_0.jpg" style="width:172px;height:58px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">WARRANT CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(non-negotiable instrument)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S (cvr.no. 2991 8791), with its principal business address at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark (hereinafter referred to as &#x201c;Ascendis Pharma&#x201d;), has on 09/12/2021 issued this Warrant Certificate to</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">NAME</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (hereinafter referred to as the &#x201c;Warrantholder&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> whereby the Warrantholder without payment has received and accepted allocation of 1,636 warrants, which confer the right to subscribe [number] ordinary shares in Ascendis Pharma at a subscription price of US$ [price] per ordinary share with a nominal value of DKK 1.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> The other terms applying to the warrants have been set forth in Ascendis Pharma&#x2019;s articles of association clause 4a with appendix 1a, which can be found under &#34;Documents&#34; in the USD Portal.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Hellerup, xx/xx/202x</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Albert Cha</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Albert Cha,<br>Chairman</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.79in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>7
<FILENAME>asnd-ex8_1.htm
<DESCRIPTION>EX-8.1
<TEXT>
<html>
 <head>
  <title>EX-8.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 8.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:81.7%;box-sizing:content-box;"></td>
    <td style="width:1.22%;box-sizing:content-box;"></td>
    <td style="width:17.08%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Jurisdiction of Incorporation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma GmbH</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology GmbH</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma, Inc.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology, Inc.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Ophthalmology Division A/S</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology Division A/S</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Bone Diseases A/S</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Growth Disorders A/S</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Oncology Division A/S</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Europe A/S</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma UK, Limited</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Iberia S.L.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Spain</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma France SASU</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">France</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Italia SRL</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Italy</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Sverige AB</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sweden</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Switzerland GmbH</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Switzerland</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.1
<SEQUENCE>8
<FILENAME>asnd-ex11_1.htm
<DESCRIPTION>EX-11.1
<TEXT>
<html>
 <head>
  <title>EX-11.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 11.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Contents</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:11.422%;box-sizing:content-box;"></td>
    <td style="width:85.537%;box-sizing:content-box;"></td>
    <td style="width:3.041%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:28.35pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Purpose</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:28.35pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Scope &amp; Definitions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:28.35pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Applicability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:28.35pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Explanation of &#x201c;Insider Trading&#x201d;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:56.7pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5.253%;text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">What is Insider Trading?</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:56.7pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5.253%;text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">What information is &#x201c;material&#x201d;?</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:56.7pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5.253%;text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">What is &#x201c;non-public&#x201d; information?</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:56.7pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5.253%;text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Who is an Insider?</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:28.35pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Procedures</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:56.7pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5.253%;text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Supporting requirements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:56.7pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5.253%;text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Prohibition against Insider Trading</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:28.35pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:28.35pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Interpretation, Amendment, and Implementation of this Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">11</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1	Purpose</font><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Insider Trading is illegal for all individuals independent of their country of residence, and individuals outside of the US may be prosecuted for violation of the Insider Trading rules.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;Insider Trading&#x201d; occurs when any person purchases or sells a security (e.g., Company ordinary shares or American Depositary Shares (ADS) representing ordinary shares) while in possession of &#x201c;material non-public information&#x201d; relating to the security. Please see Section 3 below for more information on what constitutes information that is both &#x201c;material&#x201d; and &#x201c;non-public.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Compliance with this Policy is crucial to abide the laws and regulations, as well as preserve the reputation and integrity of Ascendis Pharma (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) and to protect individuals against violating Insider Trading rules and risking criminal charges.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The purpose of this Insider Trading Compliance Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) is to outline your responsibilities to avoid insider trading and implement certain procedures to help you avoid even the appearance of insider trading.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Violation of the Policy by Ascendis Pharma Individuals may cause disciplinary actions, including potentially termination of employment. Further, violations may be reported to relevant law enforcement authorities.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2	Scope &amp; Definitions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Certain definitions used in this Policy:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.48%;box-sizing:content-box;"></td>
    <td style="width:73.52%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #008eb0;padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #008eb0;padding-top:0.04in;border-right:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S and subsidiaries of Ascendis Pharma A/S.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma Individuals:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">All officers, board members, employees and Eligible Consultants of Ascendis Pharma and its subsidiaries.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Eligible Consultants:</font></p></td>
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Consultants who have been i) assigned an @ascendispharma.com e-mail address, ii) granted access to the Ascendis Pharma intranet, or iii) granted a card allowing unaccompanied access to the premises of Ascendis Pharma, whether appointed directly by Ascendis Pharma or through their employment with consultancy service providers retained by Ascendis Pharma, or iv) identified by Ascendis Pharma&#x2019;s Chief Legal Officer.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Event-Specific Blackout:</font></p></td>
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Please refer to section 5.2 of this Policy.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Excluded Transactions:</font></p></td>
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;text-indent:54pt;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">i)	entering into a deposit arrangement with a depositary for purposes of receiving ADSs from the depositary in respect of ordinary shares or warrants or other equity awards exercisable for ordinary shares,</font></p><p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">ii)	exercises of warrants or other equity awards, or the surrender of shares to Ascendis Pharma in payment of the exercise price or in satisfaction of any tax withholding obligations or vesting of</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.48%;box-sizing:content-box;"></td>
    <td style="width:73.52%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #008eb0;padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #008eb0;padding-top:0.04in;border-right:0.5pt solid #008eb0;text-indent:54pt;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="margin-left:10%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">equity-based awards that do not involve a market sale of Ascendis Pharma&#x2019;s securities,</font></p><p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">iii)	purchases of Ascendis Pharma&#x2019;s securities from Ascendis Pharma or sales of Ascendis Pharma&#x2019;s securities to Ascendis Pharma,</font></p><p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">iv)	 a plan adopted to comply with the Exchange Act Rule 10b5-1 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Rule 10b5-1</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), and</font></p><p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">v)	Sell-to-cover-tax transactions that are enforced automatically upon vesting of equity awards, when this is governed by the relevant equity plan rules and necessary in order to comply with tax withholding requirements.</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Insider:</font></p></td>
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma Individuals and anyone else within Ascendis Pharma, or its subsidiaries, who has material, non-public information about Ascendis Pharma and its activities..</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Insider Trading:</font></p></td>
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Refers to the purchase or sale of a security by a person who is in possession of &#x201c;material,&#x201d; &#x201c;non-public&#x201d; information relating to the security, see further explanation in section 4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">SEC:</font></p></td>
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">The U.S. Securities and Exchange Commission.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Securities:<br></font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Includes ordinary shares, American Depositary Shares (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">ADSs</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) representing ordinary shares, stocks, bonds, notes, debentures, options, warrants, equity and other convertible securities, as well as derivative instruments.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;border-left:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Trading Plan</font></p></td>
    <td style="padding-top:0.04in;border-right:0.5pt solid #008eb0;padding-left:0.04in;vertical-align:top;padding-bottom:0.04in;border-bottom:0.5pt solid #008eb0;padding-right:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">transactions under a previously established contract, plan or instruction to trade in Ascendis Pharma&#x2019;s Securities entered into in accordance with Rule 10b5-1</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3	Applicability</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This Policy applies to all Ascendis Pharma Individuals.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma Individuals are responsible for ensuring that members of their household also comply with this Policy.  This includes family members residing with Ascendis Pharma Individuals, anyone else living in the same household as an Ascendis Pharma Individual, and any family members not living with Ascendis Pharma Individuals whose transactions in Ascendis Pharma&#x2019;s securities are directed by Ascendis Pharma Individuals, or subject to their influence and control.  This Policy also applies to any entities controlled by Ascendis Pharma Individuals, including any limited liability companies, corporations, partnerships, or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the account of an Ascendis Pharma Individual.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">For purposes of clarity, this Policy, including, without limitation, the preclearance policy, blackout periods and prohibited transactions, does not apply to venture capital entities or other institutional investors that may be affiliated with a board member of Ascendis Pharma or for Company equity securities that a board member may be deemed to have beneficial ownership of by virtue of such affiliation.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">For purposes of clarity, with the exception of the preclearance requirement, this Policy continues to apply to transactions in Ascendis Pharma&#x2019;s securities even after termination of service to Ascendis Pharma. If you are in possession of material non-public information when your service terminates, you may not trade in Ascendis Pharma&#x2019;s securities until that information has become public or is no longer material.</font></p>
  <p style="text-indent:-4.152%;padding-left:3.987%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4	Explanation of &#x201c;Insider Trading&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-5.634%;padding-left:5.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4.1	What is Insider Trading?</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;Insider Trading&#x201d; refers to the purchase or sale of a Security by a person while in possession of &#x201c;material,&#x201d; &#x201c;non-public&#x201d; information relating to that security. Insider trading is illegal and governed by US securities laws</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;Purchase&#x201d; and &#x201c;sale&#x201d; are defined broadly under applicable US securities laws. &#x201c;Purchase&#x201d; includes not only the actual purchase of a security, but also any contract to purchase or otherwise acquire a security. &#x201c;Sale&#x201d; includes not only the actual sale of a security, but also any contract to sell or otherwise dispose of a security. These definitions extend to a broad range of transactions, including conventional cash-for-share transactions, conversions, the exercise of warrants, transfers, gifts and acquisitions and exercises of options or puts, calls or other derivative securities.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The laws and regulations concerning insider trading are complex, and Ascendis Pharma Individuals are encouraged to seek guidance from the Chief Legal Officer prior to considering a transaction in Company securities.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">It is generally understood that Insider Trading includes the following:</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">-	trading by Insiders while in possession of material, non-public information;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">-	trading by persons other than Insiders while in possession of material, non-public information, if the information either was given in breach of an Insider&#x2019;s duty to keep it confidential or was misappropriated; and</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">-	communicating or tipping material, non-public information to others, including recommending the purchase or sale of a security while in possession of such information.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-5.634%;padding-left:5.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4.2	What information is &#x201c;material&#x201d;?</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Information is considered &#x201c;material&#x201d; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold a security, or if the information is likely to have a significant effect on the market price of the security.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Material information can be positive or negative and can relate to virtually any aspect of a company&#x2019;s business or to any type of security, debt or equity.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Also, information that something is likely to happen in the future&#x2014;or even just that it may happen&#x2014;could be deemed material.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Examples of material information include (but are not limited to) information about:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">the results of clinical trials;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">communications sent to, or received from, the European Medicines Agency or the U.S. Food and Drug Administration,or any other marketing authorization government body;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">dividends;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">corporate earnings or earnings forecasts;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">mergers, acquisitions, tender offers or dispositions;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">major new products or product developments;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">important business developments such as major contract awards or cancellations;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">developments regarding strategic collaborators, including VISEN Pharmaceuticals;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">the status of regulatory submissions;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">management or control changes;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">significant borrowing or financing developments including pending public sales or offerings of debt or equity securities;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">defaults on borrowings;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">bankruptcies;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">cybersecurity or data security incidents; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">significant litigation or regulatory actions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Moreover, material information does not have to be related to a company&#x2019;s business. For example, the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Questions regarding material information should be directed to Ascendis Pharma&#x2019;s Chief Legal Officer.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In all cases, individuals subject to this Policy bear full responsibility for ensuring their compliance with this Policy, and also for ensuring that members of their household (and individuals not residing in their household but whose transactions are subject to their influence or control) and entities under their influence or control are in compliance with this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-5.634%;padding-left:5.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4.3	What is &#x201c;non-public&#x201d; information?</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Information is &#x201c;non-public&#x201d; if it is not available to the general public. In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors in a Regulation FD(fair disclosure)-compliant method, such as through a press release, a filing with the SEC or a Regulation FD-compliant conference call. The Chief Legal Officer shall have sole discretion to decide whether information is public for purposes of this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination. In addition, even after a public announcement, a reasonable period of time may need to lapse in order for the market to react to the information. Generally, one should allow one full trading day following release of the information to the public as a reasonable waiting period before such information is deemed to be public.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-5.634%;padding-left:5.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4.4	Who is an Insider?</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Insiders include Ascendis Pharma Individuals and anyone else within Ascendis Pharma who has material, non-public information about a company.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-4.152%;padding-left:3.987%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5	Procedures</font></p>
  <p style="text-indent:-5.545%;padding-left:5.253%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.1	Supporting requirements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">To minimize the risk of Insider Trading, Ascendis Pharma has put in place below requirements relating to:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Periodic Trading Windows (see 5.1.1)</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Event-specific Blackouts (see 5.2)</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Specific personal pre-clearance procedures for senior management and select functions (see 5.2.2)</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">General handling of material non-public information (see 5.2.3)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The prohibition against Insider Trading and the further instructions contained in sections 5.1.1 - 5.2.2 may be summarized and illustrated in the decision tree shown on the following page (Illustration 1).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img80190973_0.jpg" alt="img80190973_0.jpg" style="width:349px;height:600px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Review of this chart is not a substitute for reading and understanding this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.1.1	Periodic Trading Windows</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma Individuals may only trade during open Periodic Trading Windows. Periodic Trading Windows open on the date falling one (1) full trading day after the public release of earnings data for any financial quarter and close on the date falling twenty-one (21) calendar days prior to the last date of each financial quarter (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Periodic Trading Window</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). For purposes of the foregoing sentence, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">trading</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">day</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; is a day on which U.S. national stock exchanges are open for trading. If, for example, Ascendis Pharma were to make an announcement on Monday prior to 9:30 a.m. Eastern Time, then the Periodic Trading Window would open after the close of trading on Tuesday. If an announcement were made on Monday after 9:30 a.m. Eastern Time, then the Periodic Trading Window would open after the close of trading on Wednesday.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Periodic Trading Windows are illustrated below:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img80190973_1.jpg" alt="img80190973_1.jpg" style="width:556px;height:233px;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In other words: No Ascendis Pharma Individual nor any family members residing with Ascendis Pharma Individuals, anyone else living in the same household as an Ascendis Pharma Individual, nor any family members not living with Ascendis Pharma Individuals whose transactions in Ascendis Pharma&#x2019;s securities are directed by Ascendis Pharma Individuals, or subject to their influence and control, shall purchase or sell any security of Ascendis Pharma outside of open Periodic Trading Windows. Exceptions to Periodic Trading Windows may be approved only by Ascendis Pharma&#x2019;s Chief Legal Officer or, in the case of exceptions for the Chief Legal Officer, the Chief Financial Officer or, in the case of exceptions for directors, the Board of Directors or Audit Committee of the Board of Directors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-5.634%;padding-left:5.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2	Prohibition against Insider Trading</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">No Ascendis Pharma Individual, nor any family members residing with Ascendis Pharma Individuals, anyone else living in the same household as an Ascendis Pharma Individual, nor any family members not living with Ascendis Pharma Individuals whose transactions in Ascendis Pharma&#x2019;s securities are directed by Ascendis Pharma Individuals, shall purchase or sell any type of security while in possession of material, non-public information relating to the security, whether the issuer of such security is Ascendis Pharma or any other company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2.1	Event-Specific Blackouts:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">From time to time, whether during a closed period or an open trading window cf. above 5.1.1, the Board of Directors, the Chief Legal Officer or the Chief Financial Officer of Ascendis Pharma determine  to suspend trading in Ascendis Pharma&#x2019;s securities by some or all Ascendis Pharma Individuals or others because of developments that have not yet been disclosed to the public. Such suspension is referred to as an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Event-Specific Blackout</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;. During an Event-Specific Blackout, all individuals affected should not trade in Ascendis</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Pharma&#x2019;s securities and should not disclose to others that Ascendis Pharma has implemented an Event-Specific Blackout or otherwise suspended trading.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In case of an Event-Specific Blackout, the Ascendis Pharma Individuals subject to the specific blackout will receive an e-mail notification from the Chief Legal Officer or a person authorized by the Chief Legal Officer. Once Ascendis Pharma Individuals are no longer subject to such Event-Specific Blackout, they will receive an e-mail notification confirming the removal of the trading restrictions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, if Ascendis Pharma Individuals do not receive an e-mail notification regarding an Event-Specific Blackout, but are in possession of material non-public information, such Ascendis Pharma Individuals may not trade. Failure by Ascendis Pharma to provide notice does not relieve Ascendis Pharma Individuals of their obligations under this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2.2	Pre-Clearance of all trades by employees in the departments Group Legal and Regulatory, and all senior management (VPs and above management levels) in Ascendis Pharma</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">All transactions in Ascendis Pharma&#x2019;s securities by employees in the departments Group Legal and Regulatory, and all senior management (VPs and above management levels) in Ascendis Pharma, other than Excluded Transactions must be pre-cleared by Ascendis Pharma&#x2019;s Chief Legal Officer or a person authorized by the Chief Legal Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Preclearance should not be understood to represent the legal advice by Ascendis Pharma that the proposed transaction complies with law. Preclearance does not relieve an individual of their responsibility under SEC rules, and </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">none of Ascendis Pharma, the Chief Legal Officer or Chief Financial Officer, or Ascendis Pharma&#x2019;s other employees assume any liability for the legality or consequences of such transaction to the person engaging in such transaction, nor will any of the foregoing have any liability for any delay in reviewing, or refusal of, a request for preclearance submitted pursuant to this Section 5.2.2.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">To request a pre-clearance, Ascendis Pharma Individuals must confirm that they are not aware or in possession of material non-public information either i) by filling out, dating and signing a Pre-Clearance form, which is available on the Ascendis Pharma intranet or through the Computershare portal, and submit it via Ascendis Pharma email to either Ascendis Pharma&#x2019;s Chief Legal Officer, or an authorized individual as per directions from the Chief Legal Officer, or ii) by accepting a statement to that effect when using online tools administered by Ascendis Pharma, if applicable.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Preclearance may be granted for a period of up to five (5) trading days but may also be granted for a shorter period of time. The preclearance period will be indicated in the preclearance email. Notwithstanding receipt of preclearance, if the preclearance person becomes aware of material non-public information, becomes subject to an Event-Specific Blackout or the Period Trading Window closes before the transaction is effected, the transaction may not be completed. Transactions under a previously established Trading Plan (as defined in Section 7) that has been precleared in accordance with this Policy are not subject to further preclearance.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2.3	General handling of Material Non-Public Information</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Access to material non-public information about Ascendis Pharma, including Ascendis Pharma&#x2019;s business, earnings or prospects, should be limited to Ascendis Pharma Individuals on a need-to-know basis.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In addition, such information should not be communicated to anyone outside Ascendis Pharma under any circumstances (except in accordance with the Confidentiality Procedure).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Material non-public information must be handled in accordance with our Confidentiality Procedure.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2.4	Prohibited Transactions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma has determined that there is a heightened legal risk and the appearance of improper or inappropriate conduct if persons subject to this Policy engage in certain types of transactions. Therefore, Ascendis Pharma Individuals shall comply with the following requirements with respect to certain transactions in Ascendis Pharma securities:</font></p>
  <p style="text-indent:-8.696%;padding-left:8%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2.4.1	Short Sales</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Short sales of Ascendis Pharma&#x2019;s Securities are prohibited by this Policy. Short sales of Ascendis Pharma&#x2019;s Securities, or sales of shares that the seller does not own at the time of sale, or sales of shares against which the seller does not deliver the shares within 20 days after the sale, evidence an expectation on the part of the seller that the Securities will decline in value, and, therefore, signal to the market that the seller has no confidence in Ascendis Pharma or its short-term prospects.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:-8.696%;padding-left:8%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2.4.2	Options</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Transactions in puts, calls, or other derivative securities involving Ascendis Pharma&#x2019;s equity securities, on an exchange, on an over-the-counter market, or in any other organized market, are prohibited by this Policy.  A transaction in options is, in effect, a bet on the short-term movement of Ascendis Pharma&#x2019;s shares and, therefore, creates the appearance that an Ascendis Pharma Individual is trading based on material non-public information.  Transactions in options, whether traded on an exchange, on an over-the-counter market, or any other organized market, may also focus an Ascendis Pharma Individual&#x2019;s attention on short-term performance at the expense of Ascendis Pharma&#x2019;s long-term objectives.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="margin-left:8%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-8.696%;padding-left:8%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2.4.3	Hedging Transactions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Hedging transactions involving Ascendis Pharma&#x2019;s Securities, such as prepaid variable forward sale contracts, equity swaps, collars and exchange funds, or other transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Ascendis Pharma&#x2019;s equity Securities, are prohibited by this Policy. Such transactions allow the Ascendis Pharma Individual to continue to own the covered Securities, but without the full risks and rewards of ownership.  When that occurs, the Ascendis Pharma Individual may no longer have the same objectives as Ascendis Pharma&#x2019;s other shareholders.</font></p>
  <p style="text-indent:-8.696%;padding-left:8%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2.4.4	Margin Accounts and Pledging</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma Individuals are prohibited from pledging Ascendis Pharma Securities as collateral for a loan, purchasing Company Securities on margin (i.e. borrowing money to purchase the securities) or placing Company Securities in a margin account.  This prohibition does not apply to cashless exercises of warrants under Ascendis Pharma&#x2019;s equity plans or to situations approved in advance by the Chief Legal Officer or Chief Financial Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-8.696%;padding-left:8%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.2.4.5	Partnership Distributions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;" id="ole_link3"><font id="ole_link4">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Nothing in this Policy is intended to limit the ability of an investment fund, venture capital partnership or other similar entity with which a director is affiliated to distribute Company Securities to its partners, members, or</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">other similar persons.  It is the responsibility of each affected director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances, and applicable securities laws.</font></p>
  <p style="text-indent:-4.152%;padding-left:3.987%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">6	Rule 10b5-1 Trading Plans</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The trading restrictions set forth in this Policy, other than those transactions described under &#x201c;Prohibited Transactions&#x201d; in Section 5.2.4 of this Policy, do not apply to transactions under a previously established contract, plan or instruction to trade in Ascendis Pharma&#x2019;s Securities entered into in accordance with Rule 10b5-1  (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Trading Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) that:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">has been submitted to and preapproved by Ascendis Pharma&#x2019;s Chief Legal Officer or, in the case of exceptions for the Chief Legal Officer, the Chief Financial Officer, or such other person(s) as the Board of Directors may designate from time to time (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Authorizing Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;);</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">includes a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cooling Off Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; for:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:16.667%;text-indent:-4.167%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">directors and officers that extends to the later of 90 days after adoption or modification of a Trading Plan or two business days after filing the Form 20-F or Form 6-K disclosing financial results covering the fiscal quarter in which the Trading Plan was adopted, up to a maximum of 120 days; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:16.667%;text-indent:-4.167%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">employees and any other persons, other than Ascendis Pharma, that extends 30 days after adoption or modification of a Trading Plan;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">for directors and officers, includes a representation in the Trading Plan that the director or officer is (1) not aware of any material non-public information about Ascendis Pharma or its securities; and (2) adopting the Trading Plan in good faith and not as part of a plan or scheme to evade Rule 10b-5;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">has been entered into in good faith at a time when the Ascendis Pharma Individual was not in possession of material non-public information about Ascendis Pharma and not otherwise in a blackout period (</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, during a Periodic Trading Window and not during an Event-Specific Blackout), and the person who entered into the Trading Plan has acted in good faith with respect to the Trading Plan;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">either (1) specifies the amounts, prices, and dates of all security transactions under the Trading Plan, (2) provides a written formula, algorithm, or computer program for determining the amount, price, and date of the transactions, and (3) prohibits the individual from exercising any subsequent influence over the transactions; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">complies with all other applicable requirements of Rule 10b5-1.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Authorizing Officer may impose such other conditions on the implementation and operation of the Trading Plans as he or she deems necessary or advisable. Individuals may not adopt more than one Trading Plan at a time except under the limited circumstances permitted by Rule 10b5-1 and subject to preapproval by the Authorizing Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma Individuals may only modify a Trading Plan outside of a blackout period (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, during a Periodic Trading Window and not during an Event-Specific Blackout) and, in any event, when the individual does not possess material non-public information.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:2.09in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Modifications to and terminations of a Trading Plan are subject to preapproval by the Authorizing Officer and modifications of a Trading Plan that change the amount, price, or timing of the purchase or sale of the securities underlying a Trading Plan will trigger a new Cooling-Off Period.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Ascendis Pharma reserves the right to publicly disclose, announce, or respond to inquiries from the media regarding, the adoption, modification, or termination of a Trading Plan and non-Rule 10b5-1 trading arrangements, or the execution of transactions made under a Trading Plan. Ascendis Pharma also reserves the right from time to time to suspend, discontinue, or otherwise prohibit transactions under a Trading Plan if the Authorizing Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation, or other prohibition is in the best interests of Ascendis Pharma.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Compliance of a Trading Plan with the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, and none</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of Ascendis Pharma, the Authorizing Officer, or Ascendis Pharma&#x2019;s other employees assumes any liability for any delay in reviewing and/or refusing to approve a Trading Plan submitted for approval, nor the legality or consequences relating to a person entering into, informing Ascendis Pharma of, or trading under, a Trading Plan.</font></p>
  <p style="text-indent:-4.152%;padding-left:3.987%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">7	 Interpretation, Amendment, and Implementation of this Policy</font><font style="color:#008eb0;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Chief Legal Officer shall have the authority to interpret and update this Policy and all related policies and procedures.  In particular, such interpretations and updates of this Policy, as authorized by the Chief Legal Officer, may include amendments to or departures from the terms of this Policy, to the extent consistent with the general purpose of this Policy and applicable securities laws.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Actions taken by Ascendis Pharma, the Chief Legal Officer, or any other Company personnel do not constitute legal advice, nor do they insulate you from the consequences of noncompliance with this Policy or with securities laws. Overvej en section som beskriver implementation &#x2013; at alle Ascendis Pharma Individuals skal og har Confirmed compliance with this Policy by Read and Understood in Ascendis Pharma compliance system</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.98in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>9
<FILENAME>asnd-ex12_1.htm
<DESCRIPTION>EX-12.1
<TEXT>
<html>
 <head>
  <title>EX-12.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 12.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Jan M&oslash;ller Mikkelsen, certify that:</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this annual report on Form 20-F of Ascendis Pharma A/S (the &#x201c;Company&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The Company&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a 15(f) and 15d 15(f)) for the Company and have:</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the Company&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the Company&#x2019;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting; and</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The Company&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#x2019;s auditors and the audit committee of the Company&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: February 12, 2025</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.65%;box-sizing:content-box;"></td>
    <td style="width:2.5%;box-sizing:content-box;"></td>
    <td style="width:87.85%;box-sizing:content-box;"></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jan M&oslash;ller Mikkelsen</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Jan M&oslash;ller Mikkelsen</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>10
<FILENAME>asnd-ex12_2.htm
<DESCRIPTION>EX-12.2
<TEXT>
<html>
 <head>
  <title>EX-12.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 12.2</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Scott T. Smith, certify that:</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this annual report on Form 20-F of Ascendis Pharma A/S (the &#x201c;Company&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The Company&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a 15(f) and 15d 15(f)) for the Company and have:</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the Company&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the Company&#x2019;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting; and</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The Company&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#x2019;s auditors and the audit committee of the Company&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: February 12, 2025</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"></td>
    <td style="width:2.5%;box-sizing:content-box;"></td>
    <td style="width:87.5%;box-sizing:content-box;"></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Scott T. Smith</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Scott T. Smith</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Chief Financial Officer and Principal Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>11
<FILENAME>asnd-ex13_1.htm
<DESCRIPTION>EX-13.1
<TEXT>
<html>
 <head>
  <title>EX-13.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 13.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002*</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report on Form 20-F of Ascendis Pharma A/S (the &#x201c;Company&#x201d;) for the year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned Jan M&oslash;ller Mikkelsen, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date:  February 12, 2025</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.65%;box-sizing:content-box;"></td>
    <td style="width:2.5%;box-sizing:content-box;"></td>
    <td style="width:87.85%;box-sizing:content-box;"></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jan M&oslash;ller Mikkelsen</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Jan M&oslash;ller Mikkelsen</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>12
<FILENAME>asnd-ex13_2.htm
<DESCRIPTION>EX-13.2
<TEXT>
<html>
 <head>
  <title>EX-13.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 13.2</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002*</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report on Form 20-F of Ascendis Pharma A/S (the &#x201c;Company&#x201d;) for the year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned Scott T. Smith, as Chief Financial Officer and Principal Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date:  February 12, 2025</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.65%;box-sizing:content-box;"></td>
    <td style="width:2.5%;box-sizing:content-box;"></td>
    <td style="width:87.85%;box-sizing:content-box;"></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Scott T. Smith</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Scott T. Smith</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Chief Financial Officer and Principal Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>13
<FILENAME>asnd-ex15_1.htm
<DESCRIPTION>EX-15.1
<TEXT>
<html>
 <head>
  <title>EX-15.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 15.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement Nos. 333-228576, 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-254101, 333-261550, 333-270088, 333-277519, and 333-281916 on Form S-8 and Registration Statement Nos. 333-209336 and 333-282196 on Form F-3 of our report dated February 12, 2025, relating to the financial statements of Ascendis Pharma A/S and the effectiveness of Ascendis Pharma A/S&#x2019;s internal control over financial reporting appearing in this Annual Report on Form 20-F for the year ended December 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Deloitte Statsautoriseret Revisionspartnerselskab</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> February 12, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img62010886_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62010886_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Z *P# 2(  A$! Q$!_\0
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MI_Q/C7+\6AZKD<\CC&<^_3\Z,CCGKT]_\YK\@;3]I&7XE_\ !5GX2>$/A?\
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M8FOF6"P^>1S.C[? 8+$RH8_%5,:J;J4ZE:GCV/PL^&GPF_X+3?#+1/A=\/\
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M1.?W@X_VC_CS^%!\2Q*!F499E4#=R68@(JC.69V(544%V8A54DC/[%?LV_\
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M\'('[-?@1=1T+]FGP!XJ^.WB&,3P6_BWQ(EU\./AM%,CJD=W$-2M)O&VO6^
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7:E"C2A?EA!62N[MN[;<I-WE)MMO4_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img80190973_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img80190973_0.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" @/!*\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P'^,G_
M "5[XJ_]E(\<_P#J3ZI7F]>D?&3_ )*]\5?^RD>.?_4GU2O-Z_H[ _[E@_\
ML%P__IF!_FGGG_(ZSC_L:9A_ZEU@HHHKJ/+"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#^D"BBBOYG/]0 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:_EL--EU)I4@,&GWL.C7/AR%99V$4-O<:MJ,NYBOVB1AN'8_#7Q!J6D_L/\
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M4>)K;P]H5E+J&L:QJIL-/LX=H>>YGG94!9RL<4:#,DTTK)#!"DDTSI$CN/T
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MZU87%]'#>"W2TEEMA#?68C-U!%;QW(<2>8+:#&W:=TYUE-3$PP6)RVG0I8[
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MC-<UKTO8*M2PM.I46%PM##N=*E"<Y59QE%5$I4G4K%%%%>^?GH4444 %%%%
M!1110 4444 ?T@4445_,Y_J %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!^ _QD_P"2O?%7_LI'CG_U)]4KS>O2/C)_R5[XJ_\
M92/'/_J3ZI7F]?T=@?\ <L'_ -@N'_\ 3,#_ #3SS_D=9Q_V-,P_]2ZP4445
MU'EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!_2!1117\SG^H 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X#_ !D_Y*]\5?\ LI'C
MG_U)]4KS>O2/C)_R5[XJ_P#92/'/_J3ZI7F]?T=@?]RP?_8+A_\ TS _S3SS
M_D=9Q_V-,P_]2ZP4445U'EA1110 4444 %%%% !1110 4444 %%%% !1110
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M%L\S++,-7Q>*RC+<=BJF,G2PJOB/J4JV"HT,;*EU5*JHRVA*4G",OSFHKK?
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M+!_]@N'_ /3,#_-///\ D=9Q_P!C3,/_ %+K!11174>6%%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /#!E/\ \R'S?_PR-^SU_P!$^_\ +K\;_P#S2T?\,C?L]?\ 1/O_ "Z_&_\
M\TM?2%%']M9S_P!#;,__  OQ7_RT/]1^"_\ HD.%_P#PP93_ /,A\W_\,C?L
M]?\ 1/O_ "Z_&_\ \TM'_#(W[/7_ $3[_P NOQO_ /-+7TA11_;6<_\ 0VS/
M_P +\5_\M#_4?@O_ *)#A?\ \,&4_P#S(?-__#(W[/7_ $3[_P NOQO_ /-+
M1_PR-^SU_P!$^_\ +K\;_P#S2U](44?VUG/_ $-LS_\ "_%?_+0_U'X+_P"B
M0X7_ /#!E/\ \R'S?_PR-^SU_P!$^_\ +K\;_P#S2T?\,C?L]?\ 1/O_ "Z_
M&_\ \TM?2%%']M9S_P!#;,__  OQ7_RT/]1^"_\ HD.%_P#PP93_ /,A\W_\
M,C?L]?\ 1/O_ "Z_&_\ \TM'_#(W[/7_ $3[_P NOQO_ /-+7TA11_;6<_\
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MU'X+_P"B0X7_ /#!E/\ \R'S?_PR-^SU_P!$^_\ +K\;_P#S2T?\,C?L]?\
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M,C?L]?\ 1/O_ "Z_&_\ \TM'_#(W[/7_ $3[_P NOQO_ /-+7TA11_;6<_\
M0VS/_P +\5_\M#_4?@O_ *)#A?\ \,&4_P#S(?-__#(W[/7_ $3[_P NOQO_
M /-+1_PR-^SU_P!$^_\ +K\;_P#S2U](44?VUG/_ $-LS_\ "_%?_+0_U'X+
M_P"B0X7_ /#!E/\ \R'S?_PR-^SU_P!$^_\ +K\;_P#S2T?\,C?L]?\ 1/O_
M "Z_&_\ \TM?2%%']M9S_P!#;,__  OQ7_RT/]1^"_\ HD.%_P#PP93_ /,A
M\W_\,C?L]?\ 1/O_ "Z_&_\ \TM'_#(W[/7_ $3[_P NOQO_ /-+7TA11_;6
M<_\ 0VS/_P +\5_\M#_4?@O_ *)#A?\ \,&4_P#S(?-__#(W[/7_ $3[_P N
MOQO_ /-+1_PR-^SU_P!$^_\ +K\;_P#S2U](44?VUG/_ $-LS_\ "_%?_+0_
MU'X+_P"B0X7_ /#!E/\ \R'S?_PR-^SU_P!$^_\ +K\;_P#S2T?\,C?L]?\
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M $3[_P NOQO_ /-+1_PR-^SU_P!$^_\ +K\;_P#S2U](44?VUG/_ $-LS_\
M"_%?_+0_U'X+_P"B0X7_ /#!E/\ \R'S?_PR-^SU_P!$^_\ +K\;_P#S2T?\
M,C?L]?\ 1/O_ "Z_&_\ \TM?2%%']M9S_P!#;,__  OQ7_RT/]1^"_\ HD.%
M_P#PP93_ /,A\W_\,C?L]?\ 1/O_ "Z_&_\ \TM'_#(W[/7_ $3[_P NOQO_
M /-+7TA11_;6<_\ 0VS/_P +\5_\M#_4?@O_ *)#A?\ \,&4_P#S(%%%%>8?
M4!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_8._Y)#XC_[*1K'_ *C'@^OMBNKB;_D?9I_V$O\ ](@>7X8?\D!PK_V*Z?\
MZ=JA1117A'W@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !17R%XE_;3^%OA7Q'X@\,:AH'C^:_\-ZWJN@WTUEI7
MAV2SEO-'OY]/N9+22?Q5;S26TDUN[0/-;P2M$4:2&)R47$_X;Q^$/_0N?$C_
M ,%'AC_YL*]N'#F>3C&<,MQ,H3C&49*,;2C))Q:][9II_P##,^'J^)7 E"K4
MH5N)\LIU:-2=*K"52IS0J4Y.$X2_=[QDFGYH^V**^)_^&\?A#_T+GQ(_\%'A
MC_YL*/\ AO'X0_\ 0N?$C_P4>&/_ )L*K_5G/O\ H5XK_P !C_\ )>?Y]F9_
M\1/X _Z*K*__  95_P#E1]L45\3_ /#>/PA_Z%SXD?\ @H\,?_-A1_PWC\(?
M^A<^)'_@H\,?_-A1_JSGW_0KQ7_@,?\ Y+S_ #[,/^(G\ ?]%5E?_@RK_P#*
MC[8HKXG_ .&\?A#_ -"Y\2/_  4>&/\ YL*/^&\?A#_T+GQ(_P#!1X8_^;"C
M_5G/O^A7BO\ P&/_ ,EY_GV8?\1/X _Z*K*__!E7_P"5'VQ17Q/_ ,-X_"'_
M *%SXD?^"CPQ_P#-A1_PWC\(?^A<^)'_ (*/#'_S84?ZLY]_T*\5_P" Q_\
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MX7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\
M_-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[
M/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_
M ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_
M  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0
MX7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\
M_-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[
M/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_
M ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_
M  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0
MX7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\
M_-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[
M/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_
M ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_
M  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0
MX7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\
M_-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[
M/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_
M ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_
M  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0
MX7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\
M_-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[
M/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_
M ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_
M  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0
MX7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\
M_-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[
M/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_
M ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_
M  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0
MX7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\
M_-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[
M/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_
M ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_
M  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0
MX7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\
M_-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[
M/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_
M ,+\5_\ +0_U'X+_ .B0X7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_
M  R-^SU_T3[_ ,NOQO\ _-+7TA11_;6<_P#0VS/_ ,+\5_\ +0_U'X+_ .B0
MX7_\,&4__,A\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_ ,NOQO\
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M.A_T#5?_  .!_I=T5_FB?\-X?MQ?]'E_M6_^)$?%[_YL*/\ AO#]N+_H\O\
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M_FPH_P!3L3_T&4/_  74#_6.A_T#5?\ P.!_I=T5_FB?\-X?MQ?]'E_M6_\
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M.A_T#5?_  .!_I=T5_FB?\-X?MQ?]'E_M6_^)$?%[_YL*/\ AO#]N+_H\O\
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MP;>XD$%W;3VTNV:&1% -^BBB@ K\3_VN?^3A?B#_ -RI_P"H1X:K]L*_$_\
M:Y_Y.%^(/_<J?^H1X:K[GP__ .1SB?\ L65O_4K!'X/](;_DB\K_ .RHP7_J
MISL_A'HHHK[<^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^@?_@V\_P"3XOBI
M_P!FI>./_5O? ROY^*_H'_X-O/\ D^+XJ?\ 9J7CC_U;WP,KRL\_Y%./_P"O
M#_\ 2HG?E?\ R,,)_P!?5^3/[8:***_)#]!"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _)?X5?\GQZ
MI_V4CXR?^F_QS7ZT5^2_PJ_Y/CU3_LI'QD_]-_CFOUHKZ_C+_?,J_P"Q%@?_
M $[BC\;\%?\ D2\5_P#9>9[_ .HF5!1117R!^R!1110!_+%_P>%_\H?KG_LY
M_P""/_I%XYKZ._X(6_$63X0?\&\/[,_Q:ATB?Q!+\+OV;OV@/B+%H-JK-<ZW
M)X)^(GQF\2II%NJLC-/J3:8+.)5=&,DR@,I((^<?^#PO_E#]<_\ 9S_P1_\
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MZ.VK^#/$W_"__@3;RS19,-G!JOA_XPQ7<DJ.DAU2T@R"WE3<W_P5Q^)'AO\
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M>VOPLAO-(<D8U'PWH_B?6?&*.&#PV_ARYN(P\D*1O_&/_P &C7Q#\;?LG?\
M!3[QO^RA\5;*Z\+K^V)^R)X)^)?@_2+ABHU_4[?P/X7_ &E/A!K4.=L5Q;W_
M ,!?''Q"U<&,22VD]S+:.5D@O57Z%_X+=_ML>(O^"GW[#W_!!#]EGX<:V=2^
M(_\ P4 U[X>?$#XE+;2!_L?Q2T5]#_9L-O?11-NN])_X7)XU^,)8S20PQR^!
M5N[N**>)#:>G_P#!>'P/X=_X)=_\%F?^"-G[>?@331X0^#.DZ!\,O@GXL^P[
M4M[+P=^SWXET[P'XVMYI8@BVMS??LY_%C3?#%@DD<5I/:>&)&AMY5M=02@#[
M!_X/+?VD-7T#]D3]F3]B?P(UWJ'CS]K7X[PZY?>'-*1KO4==\%_!^'3A9: U
MI$V\2Z]\4_'?PYN]&$B$WUYX7NX;4.UM<&+^GC]A+]F71_V,_P!C;]F?]EK1
MDM#'\$/@UX'\"ZO>6046^L^+M.T:WF\<^)!LBA5I?%'C2YU[Q'<NL,0DN=4E
M?RTW;1_'Q\<K=/\ @J1_P=T?";X70J/$7P5_X)K>#O#?B+Q+Y*&ZT@:O\%K=
M/BKJ%]/:LDUM)*W[1_Q,\!_#77S>)#'=VGAM;<>>D-H+G^[>@ HHHH *_$_]
MKG_DX7X@_P#<J?\ J$>&J_;"OQ/_ &N?^3A?B#_W*G_J$>&J^Y\/_P#D<XG_
M +%E;_U*P1^#_2&_Y(O*_P#LJ,%_ZJ<[/X1Z***^W/J HHHH **** "OZ3O^
M"=W["'[!?_!0[]D'QQH^A>'=2^&W[8WP_P!#G\/:[KH\?^,=1TR/7[F">7P-
M\3E\(WVKWFFW/A7Q+-:'3_%.EVMB/[/U&UUZWTM-+2X\/7!_FQKZT_8D_:V\
M;_L5?M#^"OCAX.:XO;+3+C^QO'GA6.?R+;QM\/\ 5)[<>)/#5R6/E+<2Q00Z
MEHEW,KQZ;XBT[2-2:.5;1H9.#,J&(KX62PE>I0Q--JK1E";A&<H:^RJI-1G"
MHKQM).*E9O1-/KP5:C2KQ^L4H5:$U[.HIQ4G",M/:0=FXRAO>-FU=+5IKP+X
ME?#GQE\(O'_C#X8?$/0[KPWXV\">(-2\,^)M$O /.L=5TNX>VN%21"T5U:S;
M%N+&^MGDM-0LIK>^LYIK6XAE>3X7_#3QK\9/B'X-^%?PZT.Y\1^./'OB'3?#
M/AK1K4?/=ZGJ<ZP1M/*?W5G86B&2]U/4;EH[/3-.M[K4+V:&TMIY4_I[_P""
MUG[+/@+]ISX$^ _^"F_[-!M_$=C<^%= ?XI3Z/$ID\1_#JZ5+'P_XUO;.$M+
M#XD^'NHL/"/C2VF234+'2O)AU,V4'@:Z4Y?_  2$_9_^''[%'[,OQ _X*D?M
M/Q?V2]SX5U.V^#NFWD$/]K6G@RZG_LLZIH-E>F%G\8_%S7!!X6\&D-:G_A&)
M'O%O6T+QC=36_!_;<'EBQ<8-XMS^JK"6?/\ 7_A]CR_%9/\ >=)>RZ<^AU_V
M9)8YX=S_ -G4?;O$-I1^J?%[3F^&]O<OMSZ_#J>)?\%)OV)?V"?^">G[+GP^
M\%2^'=4^(_[9OQ"\/65A8^(Y?'?C&TTRREL1"/&_Q4N_!UCK%KI-EH,-^T^A
M^!=$O+7;?W\L$EX-=B\.^)?._G*KZ+_:N_:9^(7[7GQW\=?'?XDW/_$Y\6Z@
M5TG1()WFTOP?X4L"T'AOP?HH=8PNFZ%IWEP&?RHIM4U![_6K\2:GJ=[/+]Z_
M\$[_ /@D9\2?VT_#US\:?'GB^R^"'[-.BW6I)>>/]6MDFUWQ;%H'GMXB?P98
MW\EEI$&AZ*]I<V&N>-M=U"#1M)OXKF"RL?$-UI.N66F]&'E_9> 57,\7.=63
MYZU2I.52U6HK^PH07,W&-G&,*<?>M*:BEHL:L?KV+=/ X>,:<5RTH0C&#=.&
MGM:LG;63=Y2F]+J+;>K_ !_HK^G/P]_P3O\ ^"'OC[6+7X0^!OV]_'5W\6-1
MO8]+T;69_'/@@Z%J_B"Z3[-9Z=87%Y\)](\'ZY:W=ZZ+I^F:-XJ75;^Y>WL;
M769YI527\F_^"@W_  3A^,7_  3]\<Z7IGC"\M?''PR\8RWH^'OQ5T6QGL--
MUN2P2*6\T37M*EFO'\,>*[.&:.XDTB6_O[2^LRUYH^J:C';:BFGZ8;-L)B:R
MPZ]M1K3BY4Z>)H5*$JL5JY4N=)3LM;)\UDW:R;45L!B*--UG[.K2BU&<Z%6%
M6--NUE4Y&^6[:2;TOI?57_/"BOVH_P""9_\ P3.^%'[;?P)_:'^*OC_Q[\0_
M">L?!V]DMM#T[P>WAM=,U1$\'7OB,-JHUK0]4NBQNK9(#]CN+8?9V;CS,./Q
M7KJI8JC6K8FA3;=3"RIQK)Q:475ASPLWI*\5K;;9F%3#U*5.C5FDH8B,I4VF
MFVH24976ZU?7<**_9O\ 9._X)K_"O]H#_@G+^TM^V7XD\=_$'1?'7P3_ .%R
M?V!X6T-O#@\)ZM_PK?X8^'/'.E?VPM_HEYK!^WZAK,]IJ'V+4[7-G%#]F\B?
M?*WXR44,51Q$\13I-N6&J^QJIQ:2G92LF])*SW6@5</4HPHSFDHUX>TIV:;<
M;VNTMG?HPHHK^@OX9?\ !$@_'[]B_P#9H^.OP6\9^*+GXM?&G7M)3QII_BV\
M\/6OPQ\ >"FN?&D/B/Q=*;31HO$DT6DIX>TI+:RBO]0N[^^U-;*&W9IXY+>,
M7C<-@HTY8FI[.%6I[*,FFXJ7+*?O-?"N6+U>G3=E8?"UL4YQH0YY0ASN*:3:
MYHQ]U/=WDM/GT/Y]**_J-^'7_!+W_@C9XS\26OP"TS]O'Q=XW^/U[.-(M[SP
MQXZ^'FFZ)K'BC;<Q1:9X4LI_A_K?AS5?.N8-I\.67CGQ!KUQ*OV6UU:*6ZMP
M/GZ\_P""#'C+P!\=/B+;?''XY>%/AA^Q[\-](TKQ;<_M(ZX-,TB7Q)HFM7%Y
M;V?AC3M%U355TW2/&5G=6$^G:\^HZI<6&FFYT74-.M=>?7M+TB?BCGN7N4XU
M)5J$HP52,:^'JTI5H.2C%T(./-5<I22C",>>5VU%I2:Z7E6,2C*,:=6+ER2E
M2JTYQIR2<FJLE+E@HI-RDWRKK+57_GSHK^J;P=_P1Y_X)@?M6^%_%.B_L8?M
MF^-_$7Q2\):6\DQUCQ%X.\7:?'(EP]K'J_B+P/#X"\!^*)M"N[]H-/7Q!X>U
M*VT> 30/$FHSS0Q7/\T?Q>^$WC3X(?%7QW\&_'VFG3_&WP\\5:IX1UVRAWS0
MRW^F736Z76G2%$:\TW5(?(U#2+M(PM]IUW:742[)TKIP>98;&SJTJ3JPK44I
M5*->E.C5C&7PSY)I-Q>FJO:ZYDN:-\<1@J^&C"<^25.HVH5*52-2#DMX\T6[
M-=GO9VO9GFM%?T6_#/\ X(M?!#X/?!7PW\=/^"EO[3L_[/-AXL@LI+#X;>%Y
M-"TWQ5IES?VLE_;Z#=ZUK^E>+9]<\8I8E+K5O"OA;P+JLNAI:WPFU*\C@N)K
M3VGP'_P2Y_X(]?M87=[X$_92_;2^(9^*D.FW=QIFE:GK?A_5IKU;:VDN+C4E
M\"^*?AY\/_$/BJWTV*,W6HIX7U^QCM+19GO);9"D\7+//<!!S:^LU:-.3C4Q
M-+#5JF&@XNTKU8QLTGIS0YD]TVFF;1RO%2Y4_8PJ32<*-2O3A6DI).-J;E=-
MWVE9K9I,_EIHKZ@_:H_9?\7?L<?M&>*?@)\6G&K2>$=2T>Z.N^&1+9VWB[P7
MK5O:ZKINO^&Y=7M'2":_TFX>VECN(+ZWTCQ!:ZCI4\M\=-FDE_0__@I7_P $
MP?AC^R9\!/@+^TI^SU\1/'?Q0^%7Q:N[2VU35O&:^'Y'L8/&'A6T\8_#;4],
M;PYHVE1QV&N:1:>(EOWOEF6*[BTB""59+ID?MEC\+&>#C[2ZQR;PTU%NG4M!
M32<[6BY1DN52LY-V6MSG6$KN.(ERV^JV]M%M*<;R<?AW:33YFMEKL?BA15BT
MM+K4+NUL+&VGO+V]N(;2SM+6)Y[FZNKF18;>VMX(E:2:>>9TBBBC5GDD9412
MQ K]C_\ @I1_P3?^#W[ ?P5_9XNF^(WCKQ-^T5\6(H;CQ=X3U";PR?!6@VGA
M_P ,6,WCZ\TF+3]%AUL6\/C+6]'TGPV]_JLZW6G)JDDKW-S:LT>E7%4:-;#X
M>;?M<5*I&C&,7+F]E%3J-M:1C&+3;>G3<BG0J5*5:M%+V=!0=23:5N>7+!*^
M\I/9+4_&BBBOO3_@FU^R?X-_;3_:I\,? 7QYXC\3>%?#FN>&/&>N7&L^$3I2
MZW#<>&M#GU2TAA.LZ?JECY,\T0CN-]H[^63Y;HV&JZ]:GAZ-6O5;5.C"52;2
M<FHQ3;:2U;LMD32IRK5(4H).=24813=DY2=E=O;7J?!=%?TG-_P17_9H^ VM
M^/\ QW^W)^U9/\#_ (()\1?%WACX+>'DU?PI9?%;X@>%=!U:[L=,\4:G?W>B
M:W9"ZU2T@M]530?"O@;7+MM&NX-1O[G0'D%FGHWB[_@B)^Q_^T=\'_$'Q/\
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MUXV\)?#[7OB%9:;KEU%>V^G^%_AUH'@C1M9TNX\0^,->OM>TGP5HEO\ 9/\
MP3'_ .#H;4?V8M&^('[)O_!<6+X]>&_VE/AI\0M=MH/BS?\ PDTN2Z3P].UB
MH\%_$3P9X(TOP_KUEK7AW4AJ=WH7B;1?"OB+3O$_AB\M/,OK>33;"?7?*O\
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MMXR^(<GAZ/5]/^ *Z3)KB>$=%UAM)35&TW45TYK\6ZWK6%Z+8RFUG$?[*?\
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MV/Q):Z9>Z%J5BVJ>+O&/Q%T>^OO!?A7P?:ZAJ$]U7W!_P9P_ _XT_ W]D/\
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MBFEZ=J5S!:W>C+XNM;^%]13^Y"B@#^)G_@A#_P $C?VVOB-^WGX^_P""U?\
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MZY'SJ,8.;A&-G[TM8K>WO'NW_!R!%''^W)\,'1 K3_LK>!I9F'621?BQ\;X
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MN]&FN;>*^>:/_0HK^*+X^_\ *ZQ^Q%_V;!XL_P#62/VNZ^8/U$]$_P"#;/\
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M+93_ -O*,_Q>'T]/\V'_ !#'B>6M3Q6XN;V7LYUJ*MYQCF#3=[Z]K+H?DO\
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MAQW4*W3O<K%.LB"X=Y@HD8L?<Z* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HK^>?]LC_@Y_\ ^"37[&OC[7?A=JGQ0\=?M!>/?"MQ/8>)]&_9D\):
M1\1-+T+5[9[B*ZT.X\=>(/%G@?X<WVL6-Q;FSU.QT7Q?JCZ1?N;#5397MO>P
M6NM^Q?\ \',__!*#]M?Q]HGPL\-_%GQ=\"?B+XG6UB\,^&OVE_"^F?#2UU_5
MKMX8HO#FG^-M+\3>+OAP/$DES/%9V.C7?C*UNM<O76U\.KJ\Y"$ _H"HHHH
M**** "BBB@ HHHH *_$_]KG_ ).%^(/_ '*G_J$>&J_;"OQ/_:Y_Y.%^(/\
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M1(6'3;2SGU"XDBM[:61/,Z_I'_98_P""SW[*/[,O[/\ \/-$T[]C6/4_VD?
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M3!+^XC2,R(3(/L6O\^/_ ((2?\K5G_!7S_L8/^"DG_K=7@&O]!R@#Y _9O\
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MS_@DS^T'\<K3]F_X1?MN_"CQ7\7]5\1V_A#P[X?EL_&_AO1/&7BB^N([33-
M\!>/_%GA/0OAWX_U76KV:&PT"S\%^*]>FU_49[?3]&6^O)X8'^]OCY^T=\!/
MV6?AYJ'Q8_:.^+_P]^"GPXTR:&UN?%_Q'\4:7X7TF2_N=WV32M/DU*XAEU;6
MKXHZV&BZ5%>ZM?NK)9V<[@K7XR?LJ?\ !L]_P2[_ &._C=^SU^T7\)?"'Q9E
M^+G[.]_<:YI.N^+OB=>>*-*\>^*)O">J>&+;Q+XZ\,:CICZ%#J>C7NJ-XQT%
M? 5IX'M--\66&EW7V>?2[,Z3+_+E\*_!OB#_ (.DO^"W?QM?XW?$3QA:?\$_
M_P!DRW\87_@CP-X5URXTJ*?X5:1XMA\$?#_1O##I%J>G>'O&7QUU>"+XA_$K
MQ6L,^L3>'=)U;PQHVN6R:+X)GT8 _K<\#_\ !QS_ ,$3_B%XSA\!Z!^WQ\.;
M'7)[R.QCO/&O@?XS_#3P?Y\KE$:3XB?$?X:>%/A_#:[A\U_-XFCL8U(>2X5&
M#']H]%UK1O$FD:9X@\.ZMIFO:#K=A::KHVMZ+?VNJ:1J^F7\"7-CJ6F:E8RS
MV5_87EM)'<6EY:S2V]Q!(DL,CQLK'\(/CC_P;-_\$=?C!\&]5^%/A[]E#P_\
M$]9.AW.F^$?BU\*O$'B_3_B5X.U5E4V6O/JNN>(=;M/'%Q:RHHGLOB)9^*;*
M]MGGB9(;AXKRW_$/_@V*_:<^._[)/[=O[8/_  0R_:%\;3>-_#OP5UCXK:K\
M#-4N[C4);/0/$_PJ\9VNC^-M"\#Q:JQU"P\!_%'PKJJ?%;1= 98;'1+S1=;U
M.VM(=0\7:S-<@']@/Q2_;D_9)^"GQ\^%W[+GQ6^/'@7P/^T%\:X=!N/A5\*=
M;NKV+Q3XXA\3^(=4\*:!)HD$-C/:RKJGB/1=5TBU\ZZA+7=C.K!4"NWRG^TG
M_P %P_\ @E#^R-\1[SX1?'K]M;X7>%_B3I6IQ:+K_A#PWI_CKXJ:KX4UB28V
M[Z5XT'PE\)>.;?P5J-I(,ZE9>*Y]&N-*B:.XU..T@DCD;^-C_@[DU+XHZ5_P
M6._85N?@EXBU'PE\7I_V7?A7I7PU\3:1>2:=JNA>--<_:.^.FB^']3TW4H(9
M[G3+^UU'4()+34[.)K[3IQ'>V)2[@A=?Z0_V:_\ @UH_X)*?"7X&Z-\/OC-\
M 3^TA\4]5\,65K\5/C-X^^(?Q.LO$7B3Q7=6]G<^(]1\'P>$/%OA.Q\ :0-:
MBNCX;'AVRLO$]IHLD5GKOB77[Z34-1O0#]I?V8?VR_V5?VT?"&H^.OV5/CY\
M,OCMX9T2]ATW7[SX?>)K+5[WPUJ-S"UQ:6'BC0RT.N^&;V\MT>YLK77],TZ>
M\MD:XMHY85+C^?7_ (.M_P!LS]G;P3_P34_:-_8^OOCAX:\._M2?$G1/@)XP
M\)?!M-1U&T\;>*?A])^T-X1.M:I:0VUN+:?1)](\'>,DOX9KU5N;+1]3AF@D
MC(27\$?V3?@C=?\ !%C_ (.I/!G[)'P!\4^)-5^ 7QON+'P6NA^([N26^OOA
M/\;_ (<7'C/0?#>N7*2+'K5Y\+?B1IU@-%\0SH;_ %6R\*13WJPW6LZI"?W+
M_P"#LC]B;]EOQ7_P3I^/_P"W)X@^$6CZE^U9\--'_9Z^&_@;XQ2ZQXJBUGP_
MX(O_ -HWPII]WH%OHUOKT/A.XMYK/X@>,(&N+_0+J^5=;G9+I7@LVM@#HO\
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M_:^*/#EG8QW.G1Z==3:WH5[:WNF""_<7;3I:0LU\3;#[1K^#G_@[]_9W\9_
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ML_A'HHHK[<^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?:PLNC>+;+PG9?%OQ3=>+93K6E/J.G6VC_#[PK?^*[][VR9?'O@[09;WQ+
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M_P#4&\8U^\/_  =2H[?\$./VO&5681Z]^S<\A520B']ISX01AG(&%4NZ(&;
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MTZPUK3]*OK 5[?KW_!-7]N&[_P"#M.#_ (*#6_[/_B&7]CE-9\.7+?' >(?
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M/A'Q1INEZW;6\K+::G':3Z/J2S:5J-];S?Q*_LX> /\ @XV_X-[-0\<?L_\
MP<_9:M_^"A_['6H>)-9\2^!$\#>&_$_Q%TZPN+J>>[U'Q!X.T?X?:LOQ;^%V
MN>)+.R@F\4>"?$_AWQ-X//B&627PHVK:MJ%WKVM@']5'_!>WX@^%OAK_ ,$=
M_P#@H)K7BZZTRVL=;_9Y\5_#[2TU2:.*.[\4_$V2R^'_ (3M;-7DC:?4V\0^
M(].FT^&+?)]IA24QM'%(*_+;_@S8\':WX9_X)(^*=:U6#4(;'XA_MA_&3QCX
M:DO8V2VNM$LO ?P<\ 3SZ2S(HET]?$?@;7[621#(HU6VU.(N&C:-/RL_:!_9
MZ_X.(/\ @XA\5?#WX5?M+_ +2?\ @G1^Q7X/\56'B77],\6:-J_A*%]7@74X
M8/%>K>"/%OB"X^,/Q9\<:9HM]J.F^&-)ATWP;\-;*[FBFU.X\-:A>MKC?W$?
MLC?LN?"K]BG]FOX/?LL?!/3;G3/AG\%_"%MX5\/+?S_:=4U.>2ZN]8\1>)M:
MN56..XU_Q=XHU/6O%6OS6\-O:2ZSK-\]I:VEJT-M$ ?Q)?\ !D[XR\,VOQ0_
MX*B?#Z=["'QCKC_L\^,M*C:XB&J:EX9\*^(?C[HFOO%:NXF>PT35/&/AI;BX
M@C:*.X\06L=VZ/+9+)_???7UEIEE>:EJ5Y:Z?IVGVMQ?7]_?7$5I96-E:1/<
M75Y>75P\<%M:VT$<DUQ<32)%#$CR2.J*S#_(V_X(??L]_P#!2;Q)\8?VJOVR
MO^"6_B?PI-^T-^QM=^"5UWX(>+([1;+]H+X8?&;7/B,OBOP,LFKZCI7A_4TM
M9OAAIE[<>%M4U;PS?ZLLJ:QX/\8Z%XY\,^&K;5_WX_:-_;,_X.?_ /@IU\-_
M$?[%7@K_ ()F:G^QSHWQ0TRY\"_&7XL:CX6\<?#>VU3PEJFE"'Q?H^F?$OXS
M:]:>&-!\%>(=&U1[+7$\'6WBSQEJ-JM]X<T#7)KTZKIDX!YO_P &E*77Q8_X
M*L_\%4/VCO"5I+_PJ_5?#'C1([K3XS_8,%U\:/VCV\=^!+022H9UEG\/>!/$
M\FE1F12UG:WS3([HC1_EA\*/^">GAG]M_P#X.,?V_/V.OC1\</B/^SEK/C#]
MHC]MKQ?X*\9> ?[-/B;Q-K]M\7-9^(VAZ0R:Q>VOVC2O%7PUN=;\6QK!-)?R
MFQTZ4Q-%]I*?W[?\$6/^"3W@C_@D=^R/:_!6SU[3?'_QE\?:TOC[X_\ Q1TV
MPN+#3_%7C9[-+'3M \-0WQ.I1>!? FE*-$\,C4!;76J7,NN>+;K2]$OO%%YH
MUA^2'_!>W_@AA^TA^T)^T1\-O^"G_P#P3!US3?"'[;'PK;PQ?^+O!T&L:1X/
MU?XE:Q\.Y$F\ ?$3P9XE\12Q>$!\1M!L+6R\(ZWX>\;SV'A7QIX/T_1[2ZU&
MWGTB[TKQ8 >6_P#$&]\+?^DEG[7_ /X+O#O_ ,N:X[]F+_@WX_X)L_LJ?\%)
M_@;?W/\ P5RG\:_MB?L__%/X9_$32_V:OB+XQ^#&G?%CQ7J&GVUIX[\->&G\
M(WOB@>/[VVUSPV8-4$&B:;>W46@:A;:@(4M+VVDFPM/_ ."R?_!T!I_@]OA)
MJ/\ P1CU'6/C7:Z,NB1_&>7X)_&2#P7<:G;)#I4OBF_LM-\21?#.]U>YNHKK
M56CTCQOI7A9[BXAN[/0T\/PBRN/HG_@AC_P0S_:I^&'[5_C;_@K!_P %6?%$
M'BG]LSQQ+XBU7P%X EUS1?%NK>!];\=Z/+HGBCQ_X_UOP^)O"5GXK@\+7EYX
M&\#^!O UY>^%? OA.[NH8[F.Y71M%\+ 'Q+_ ,'RG_(J_P#!-3_L8/VL_P#T
MW?LYU_=KX)M;>R\&>$;.S@BMK2T\,:!:VMM BQ06]O!I5I%!!#&@"1Q11(L<
M:* J(H50  *_DB_X.R_^"<_[:?\ P4$\/?L*V?['?P'U_P"-]S\*M9_:,N?B
M!%H6O^"="/AN#QG8_!*+PS)<GQEXG\-K=#5I/"^O+"-/:\:$Z=(;H0"2W,W]
M=?ARVGLO#V@V=U&8KFTT;2[:XB)4F*>"Q@BEC)0LI*2(RDJS*2,@D8- '\#?
M_!V3_P I3?\ @D5]/#O_ *T5X6K^_P!K^.'_ (.+?^";O[;?[97_  4$_P""
M;?Q?_9F^ ?B#XK?#CX*C1?\ A:'BC2?$'@?2+7PE]E^-GA_Q//\ ;+3Q/XHT
M/4KSR]!L[G43_9=E?YCB,:YN"L3?V/4 ?C]_P7G^$7[3?[0'_!*O]J+X%_LA
M^ ]:^(WQM^+=C\.O!>E^&/#^M:)H&IW?A&\^*O@J^^(ZI?\ B+5]"TDVMWX!
MT_Q%I>HVMSJ< NM/U&ZA1+EF%M-R7_!OM^PKKG[ '_!,3X)?"7XD_"Z/X6?M
M ^)]0\<_$/\ :#TJXGT;4->O?'FN^-=>MM#.N:MH5_JFF7LFC_#C3_!6A6,=
MCJ-S9VUGIR;"+J:]>7T?_@M3_P /$?\ AAW7?^'7G_"4?\-6?\+(^'O]D_\
M"(?\*Y_MG_A"/[0O/^$SV?\ "T_^*3^S_8_LWVCSO].VX^Q?/NKMO^"0/_#=
M'_# 'P7_ .'D?_"1?\-A?VE\4?\ A9__  E?_""?V[]A_P"%K>-/^$!^V?\
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M/_SC*/\ B&\_8=_Z*I^U;_X7'PA_^<97] ]%']N9M_T'U_OC_P#(A_9>7_\
M0+2^Y_YG\_'_ !#>?L._]%4_:M_\+CX0_P#SC*/^(;S]AW_HJG[5O_A<?"'_
M .<97] ]%']N9M_T'U_OC_\ (A_9>7_] M+[G_F?S\?\0WG[#O\ T53]JW_P
MN/A#_P#.,H_XAO/V'?\ HJG[5O\ X7'PA_\ G&5_0/11_;F;?]!]?[X__(A_
M9>7_ /0+2^Y_YG\_'_$-Y^P[_P!%4_:M_P#"X^$/_P XRC_B&\_8=_Z*I^U;
M_P"%Q\(?_G&5_0/11_;F;?\ 0?7^^/\ \B']EY?_ - M+[G_ )G\_'_$-Y^P
M[_T53]JW_P +CX0__.,H_P"(;S]AW_HJG[5O_A<?"'_YQE?T#T4?VYFW_0?7
M^^/_ ,B']EY?_P! M+[G_F?S\?\ $-Y^P[_T53]JW_PN/A#_ /.,H_XAO/V'
M?^BJ?M6_^%Q\(?\ YQE?T#T4?VYFW_0?7^^/_P B']EY?_T"TON?^9_/Q_Q#
M>?L._P#15/VK?_"X^$/_ ,XRC_B&\_8=_P"BJ?M6_P#A<?"'_P"<97] ]%']
MN9M_T'U_OC_\B']EY?\ ] M+[G_F?S\?\0WG[#O_ $53]JW_ ,+CX0__ #C*
M/^(;S]AW_HJG[5O_ (7'PA_^<97] ]%']N9M_P!!]?[X_P#R(?V7E_\ T"TO
MN?\ F?S\?\0WG[#O_15/VK?_  N/A#_\XRC_ (AO/V'?^BJ?M6_^%Q\(?_G&
M5_0/11_;F;?]!]?[X_\ R(?V7E__ $"TON?^9_/Q_P 0WG[#O_15/VK?_"X^
M$/\ \XRC_B&\_8=_Z*I^U;_X7'PA_P#G&5_0/11_;F;?]!]?[X__ "(?V7E_
M_0+2^Y_YG\_'_$-Y^P[_ -%4_:M_\+CX0_\ SC*/^(;S]AW_ **I^U;_ .%Q
M\(?_ )QE?T#T4?VYFW_0?7^^/_R(?V7E_P#T"TON?^9_/Q_Q#>?L._\ 15/V
MK?\ PN/A#_\ .,H_XAO/V'?^BJ?M6_\ A<?"'_YQE?T#T4?VYFW_ $'U_OC_
M /(A_9>7_P#0+2^Y_P"9_/Q_Q#>?L._]%4_:M_\ "X^$/_SC*/\ B&\_8=_Z
M*I^U;_X7'PA_^<97] ]%']N9M_T'U_OC_P#(A_9>7_\ 0+2^Y_YG\_'_ !#>
M?L._]%4_:M_\+CX0_P#SC*/^(;S]AW_HJG[5O_A<?"'_ .<97] ]%']N9M_T
M'U_OC_\ (A_9>7_] M+[G_F?S\?\0WG[#O\ T53]JW_PN/A#_P#.,H_XAO/V
M'?\ HJG[5O\ X7'PA_\ G&5_0/11_;F;?]!]?[X__(A_9>7_ /0+2^Y_YG\_
M'_$-Y^P[_P!%4_:M_P#"X^$/_P XRC_B&\_8=_Z*I^U;_P"%Q\(?_G&5_0/1
M1_;F;?\ 0?7^^/\ \B']EY?_ - M+[G_ )G\_'_$-Y^P[_T53]JW_P +CX0_
M_.,H_P"(;S]AW_HJG[5O_A<?"'_YQE?T#T4?VYFW_0?7^^/_ ,B']EY?_P!
MM+[G_F?S\?\ $-Y^P[_T53]JW_PN/A#_ /.,H_XAO/V'?^BJ?M6_^%Q\(?\
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M3P].$X.\9).Z?=:A1117G'8%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!^2_P *O^3X]4_[*1\9/_3?
MXYK]:*_)?X5?\GQZI_V4CXR?^F_QS7ZT5]?QE_OF5?\ 8BP/_IW%'XWX*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#"ZK_\R^:^\/\ B-62_P#1*<>?^&+"?_/4_6BBOR7_ .%J_MQ_] OXD?\
MAF]/_P#F&H_X6K^W'_T"_B1_X9O3_P#YAJ/]3,9_T-,B_P#"ZK_\R^:^\/\
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M\+JO_P R^:^\/^(U9+_T2G'G_ABPG_SU/UHHK\E_^%J_MQ_] OXD?^&;T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-_[
M7/\ R;U\0?\ N5/_ %-_#5?2%?-_[7/_ ";U\0?^Y4_]3?PU7IY+_P CG*?^
MQG@/_4JD?+\<?\D7Q?\ ]DOQ!_ZJ<6>;_L'?\DA\1_\ 92-8_P#48\'U]L5\
M3_L'?\DA\1_]E(UC_P!1CP?7VQ75Q-_R/LT_["7_ .D0/+\,/^2 X5_[%=/_
M -.U0HHHKPC[P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\ ?%KP@UT$%T?#'Q&\*:3XPT'[4L3/&MR-+UBU%PJ,RK,'4,0,UZG0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?P6?\%./A/X[_P"#>/\ X*P> ?\ @KW^S-X*U76_V*OVK/$>L>"?
MVK?A#X5:'3]+T3Q7XTD_MSQUX7LH7$6G:;;>.;K2A\9OA.UQ-!IFG?$SPIXE
M\+74NA^$I='T^^^W/^" '[&?Q6_:X^/_ ,6_^"_G[=NA,_QG_:8U371^QWX
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ME\N33+.W@TYX+=K4V\?Z]T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\5>)O#5Z(88=0T&\B$XN/ZCZ* &HB1HL<:JB(JHB(H5$10%5550 JJ  J@
M  # IU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]I5]Z<YMRD_-ML****\0^X"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&,U%%%?FI_3@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8^CZOP1_T&Y[_P" 8?\ ^9/ZL_*Y_:'CG_T(^ __  =F/_SX/2/^&N?V>O\
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M!'_0;GO_ (!A_P#YD_JS\KG]H>.?_0CX#_\ !V8__/@](_X:Y_9Z_P"B@_\
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M!'_0;GO_ (!A_P#YD_JS\KG]H>.?_0CX#_\ !V8__/@](_X:Y_9Z_P"B@_\
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M^C_A@[X0_P#0Q_$C_P &_AC_ .8^CZOP1_T&Y[_X!A__ )D_JS\KG]H>.?\
MT(^ _P#P=F/_ ,^#TC_AKG]GK_HH/_EJ>-__ )FJ/^&N?V>O^B@_^6IXW_\
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M^&#OA#_T,?Q(_P#!OX8_^8^C_A@[X0_]#'\2/_!OX8_^8^CZOP1_T&Y[_P"
M8?\ ^9/ZL_*Y_:'CG_T(^ __  =F/_SX/2/^&N?V>O\ HH/_ ):GC?\ ^9JC
M_AKG]GK_ **#_P"6IXW_ /F:KS?_ (8.^$/_ $,?Q(_\&_AC_P"8^C_A@[X0
M_P#0Q_$C_P &_AC_ .8^CZOP1_T&Y[_X!A__ )D_JS\KG]H>.?\ T(^ _P#P
M=F/_ ,^#TC_AKG]GK_HH/_EJ>-__ )FJ/^&N?V>O^B@_^6IXW_\ F:KS?_A@
M[X0_]#'\2/\ P;^&/_F/H_X8.^$/_0Q_$C_P;^&/_F/H^K\$?]!N>_\ @&'_
M /F3^K/RN?VAXY_]"/@/_P '9C_\^#TC_AKG]GK_ **#_P"6IXW_ /F:H_X:
MY_9Z_P"B@_\ EJ>-_P#YFJ\W_P"&#OA#_P!#'\2/_!OX8_\ F/H_X8.^$/\
MT,?Q(_\ !OX8_P#F/H^K\$?]!N>_^ 8?_P"9/ZL_*Y_:'CG_ -"/@/\ \'9C
M_P#/@](_X:Y_9Z_Z*#_Y:GC?_P"9JC_AKG]GK_HH/_EJ>-__ )FJ\W_X8.^$
M/_0Q_$C_ ,&_AC_YCZ_/'XY^ ]'^&7Q3\4^!]!N=2N])T3^Q/LEQJ\UK<:C)
M_:7AW2-7G^T2V5G86S[+F_F2+R[2+; L2OYDBO*_HY7D7"><8B>&P6,SF56%
M&5>2J/#4X^SC.G3=F\&[OFJQ5O5]-?F>*N//%S@W+Z.9YUDW!5/"U\;3P%-X
M=9GB)O$5:&(Q$$X1SE-0]GA:K<KV345]H_>:BBBOSX_HH**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\E_A5_R?'JG_ &4CXR?^
MF_QS7ZT5^2_PJ_Y/CU3_ +*1\9/_ $W^.:_6BOK^,O\ ?,J_[$6!_P#3N*/Q
MOP5_Y$O%?_9>9[_ZB94%%%%?('[(%%%% !117A-]^U)^S+IE[>:;J7[1?P)T
M_4=/NKBQO["^^+OP_M+VQO;25[>ZL[RUN/$,<]M=6T\<D-Q;S1I+#*CQR(KJ
MR@ ]VHKP ?M8?LLL0J_M*_ !F8@*H^,GPZ)))P  /$>22> !R37N&F:KI>MV
M-OJFC:E8:OIET)#:ZCIEY;W]C<B*5X)3;W=I)+;S".:*2&0QR,$EC>-L.C
M%^BBB@ HHHH **** "BO.?"/QA^$?Q UC4O#W@+XI?#GQOK^C0RW&L:'X1\;
M^&?$NL:5;P74=C//J6F:-J=[>V,,-[+%9RRW4$21W4D=N[+*ZH?1J "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO+\0[W7IKKXO>&M;\=OI6E^.;?Q]IGA6U\0>!I=>%UIU]+?'0I_PP\1_'?\
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MB>S_ .$C\'V?]H2^3K%Y_P *O\ZX?[!;YD\5:[^\;S,R@']M?_!-W4]2UO\
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M297\=7^F^,_V@X%N[=A/JOARX@NC);JMDW]XM '\D7_!Y[_RB@^%_P#V>_\
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M_P!7AAGUO48[?[/H7@+Q=X=UCPSXNN)W\/:WK5C:W[S, ?WMT5_//_P;J?\
M!8/7_P#@JU^RMXKLOC1!I=E^U;^S3JWAWP=\:9M'L8])TOQ[HGB>SU2;P!\5
MK/1852TT/4/% \.>)M'\6:%IRKIEEXI\-:AJNEVFBZ)XAT;0-+_H8H ****
M"OQ/_:Y_Y.%^(/\ W*G_ *A'AJOVPK\3_P!KG_DX7X@_]RI_ZA'AJON?#_\
MY'.)_P"Q96_]2L$?@_TAO^2+RO\ [*C!?^JG.S]L****^&/W@**** "BBB@
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M+%(K))'(FI_M&*\<B, R.C JRL RL"" 017]NO[<D\-M^Q3^V#<W$B0V]O\
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MJKV7_@W!_P"".?\ P42_X)N_M8?M0_&']L#3_AEIO@_XZ?"3^S,_#_QYH7B
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M^N0:%IVM?M!V$<CM&VFQ6:&)Y9ELF_J@^+/PO\&?&[X6_$CX-?$;2DUWX?\
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M>Z-H%I</!;7'B*\TA;BYMH@T\8!^,>C?\'#W_!:?_@I?XU\;Z9_P1Q_X)O\
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M;7^G_#[P187UE/%=6=[9^%-!M;NTN8'$D-Q;7,%@DT$\,BK)%-$Z21NH9&#
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MX4\;^&/#WC+POK$!M=7\-^*M%TWQ#H&JVQ()M]2T?5[:\TZ^@) )BNK:6,D
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MP[?30P37ME\'/@]I?A/X,:9K*F2TU2V\4>)+*1/[2T:X%K_3K^V+_P $@?\
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MXG_M<_\ )POQ!_[E3_U"/#5?MA7XG_M<_P#)POQ!_P"Y4_\ 4(\-5]SX?_\
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MG_H,H?\ @NH'^L=#_H&J_P#@<#_2[HK_ #1/^&\/VXO^CR_VK?\ Q(CXO?\
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M(CXO?_-A1_J=B?\ H,H?^"Z@?ZQT/^@:K_X' _TNZ*_S1/\ AO#]N+_H\O\
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M_P#@<#_2[HK_ #1/^&\/VXO^CR_VK?\ Q(CXO?\ S84?\-X?MQ?]'E_M6_\
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MG_H,H?\ @NH'^L=#_H&J_P#@<#_2[HK_ #1/^&\/VXO^CR_VK?\ Q(CXO?\
MS85^XW_! 3]I;]HWXR?MC?$KPQ\7_C_\;/BKX:L/V:/&.O6/A[XD?%7QWXYT
M.SURU^*7P:T^VUFTTGQ/KVJ6%OJUO8:IJ=C!J,-NEY#9ZC?6T<RPW=PDG-C.
M%\1@\+6Q4L51G&C!S<(PFG))I63>B>O4VPV>4L37I4(T*D75DHJ3E%I7OJTM
M>A_7K1117RY[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'Y+_"K_D^/5/^RD?&3_TW^.:_6BOR7^%7
M_)\>J?\ 92/C)_Z;_'-?K17U_&7^^95_V(L#_P"G<4?C?@K_ ,B7BO\ [+S/
M?_43*@HHHKY _9 HHHH **** "BN&^(/Q/\ AK\)?#\OBSXJ_$/P-\,_"T#B
M.?Q+\0?%N@>#/#\,A!(CEUGQ'J&FZ=&Y )"O<JQ ) Q7S;X"_P""C7_!/7XJ
M>*;#P/\ "_\ ;O\ V-/B1XUU600Z7X/\!?M0?!'QAXIU*4RQP"*P\/\ A[QQ
MJ.K7DAFFBA"6]I(WFRQQXWNH(!]ET45'--%;Q2SSRQP001O---,ZQQ0Q1J7D
MEED<JD<<:*7=W8*B@LQ !- $E%?'MK_P4-_8!O?&!^'EE^W)^Q[=^/UG2U;P
M-:_M,_!:X\8+<R7,5E';GPS%XV?6A.]Y/!:)$;+S&N9HH%4RR(A^P00P#*0R
ML 58$$$$9!!'!!'((X(H 6BLK7-=T3PQH^I^(O$NLZ5X>\/Z+97&I:SKNN:A
M::3H^DZ=:1M+=7^IZG?S6]E865M$K2W%U=3Q00QJSR2*H)KYB\"?M[_L+?%+
MQC%\._AC^VE^R;\1OB!-?P:5#X&\"?M&?![Q?XQEU2Y,HMM-B\,^'_&.H:U)
M?W!@G$%FED;B4PR^7&WEOM /K*BBN/\ 'GQ"\ ?"SPMJGCGXG>./!_PX\$Z'
M#]HUOQAX\\3:+X0\+:/;\_O]4\0>(;W3M)T^'@_O;N[A3@_-Q0!V%%?*7PD_
M;Q_8<^/WBA/ _P "/VS/V4OC7XUDA:XC\(?"3]HCX0_$CQ1);HKL\Z>'_!WC
M#6=6:%%CD9I5M"BJCDL K$?5M !17)^-_'O@;X9^&=2\:?$CQIX3^'W@[1HU
MEUCQ9XW\1Z/X4\,Z5$[B-)=2U[7KRPTNQC>1E17NKJ)6=@H)8@5\]?#;]O;]
MA?XR^*?^$'^$'[:'[)WQ6\:FZCL1X/\ AM^T7\'_ !SXI^VS2RP0V?\ PC_A
MCQCJFK?:I9H)X8[?[)YLDL,L:H7C<  ^L:**\X^)_P 8OA'\$?#O_"7_ !G^
M*?PX^$7A+[2EE_PE'Q/\<>&? /AW[9(K/':?VWXKU32=,^TNB.Z0?:?-959E
M0A20 >CT5\T_!W]M']CK]HC5)-$_9^_:Q_9I^.FM1&99=(^#OQV^%WQ-U2)K
M:!;JX$EAX*\5:W=H8+9TN9@T0,4#K,^V-@Q^EJ "L_5M6TK0=,U#6]=U/3]%
MT;2;.XU'5=7U:]MM.TS3-/M(FGN[[4+^\DAM+*SM8$>:XN;F6."")&DE=44D
M:%?P,_\ !Y-^U-JD^L_L'? WX5_'_P"T_#W7/$GQQN?CS\,? /Q(MKC0=1\3
M^ _$_P $8/!\'Q5\.>']6>*6^\+W=_XJ;1M-\56^-.U'^T[B"UCOK-Y8 #^^
M:BO/_ OQ9^%?Q1_M3_A6?Q+^'_Q$_L/[#_;?_""^,O#GB[^Q_P"T_MG]F_VI
M_8&I:A_9_P#:']GW_P!A^U^3]K^PWGD>9]FFV:?C?Q]X$^&?AZ\\7?$?QKX2
M^'_A/3RBW_B?QOXCT?PIX>L6DW>6+S6M>O+#3;8R;6V":Y0MM;;G!P =;17R
MU\*_VY?V)_CIXNF^'_P1_;#_ &6OC'X]MO.^T>"?A7^T%\)?B%XN@^SM*D_G
M>&_"7B[5]9B\EX9DFWV2^6T,JOM,;@?4M !116#XG\5>&/!.A7_BCQGXCT'P
MCX:TI8'U3Q%XGUC3]!T+34NKJ"RMFO\ 5M5N+2PLUN+VYMK2!KBXC$MU<06\
M9:66-& -ZBO+=>^./P4\+?#D_&#Q/\8/A;X<^$@C\X_%+7OB!X3T?X<B(W,M
MD)3XWU#5[?PR(S>03VF\ZGM^TPRP9\V-T'+?!3]JO]E[]I1=3?\ 9S_:1^ ?
MQ^31(TFUE_@I\8?AY\5%TB*27R$EU-O OB+7A81O/^Y1[LQ*TO[L$O\ +0![
MW17A/QK_ &I/V9/V:K;2[S]HS]HOX$? &TUPR#1;KXU_%WX?_"NVU@Q.(Y1I
M<_CKQ#H,6H&-V5)!:-,4=@K8) KNOAQ\4_AC\8_"]MXX^$7Q&\!_%3P5>7%Q
M:6?B_P"''B_P_P"./"]U=V;*MW;6WB#PQJ.J:3/<6K.BW$,5V\D#.HE52PR
M=Y117R1\3?V_OV$/@IKTOA7XR?ML?LD?"7Q1!)-#-X;^)O[2'P<\!Z]#+;E!
M/%+H_BKQGI6H1R0&2,3(]N&C+IO"[ER ?6]%>9?"GXU_!OX\>&(O&_P.^+7P
MR^,O@N=UCA\7?"GQYX5^(GAB:1XUF2.+7_"&JZQI4CO"Z2JJ799HV5P"K GX
ML_X*T?M VO[/G_!/+]M#Q5H7Q@TCX1_&"T_9/_:&U[X-:F/&>E>$_'$GCCP[
M\--;NM%U'P EW?VFJ7WB'1]:GTB6Q?1(KB\M-1GT\QA)YK?< ?HA9:MI6ISZ
MI;:=J>GZA<Z'J TG6K>RO;:[GT?56T^PU8:9JD4$DDFGZ@=*U72]3%E=K#<G
M3]2L+P1_9KRWDDT*_CY_X- OC]X)F_X)U?%'3?BG\:_"TOQ@^(G[>GQ7U<V'
MQ ^(^DO\2?'.M^+/AK\ K:#5#:^(]9/BCQ-JOB77OM5O%>F.^N]9U?[1$DMS
M>>8M?V#4 %%?&WC3_@HO_P $^/AOXQO?AW\0_P!NW]C;P%\0--O(].U'P-XT
M_:>^"7A;QCI^H32"*&QO?#.N>.+'6K6\EE(CCMI[&.=Y"$5"Q KZUT37-%\2
MZ1IOB#PYK&E^(-!UFS@U'2-;T34+35=(U73[I!+;7VFZE833V5]9W$3+)!<V
MLTL$R,'C=E(- &I17(^-/B!X#^&^DQ:_\1/&WA'P%H4]]#ID&M>-/$FC>%M)
MFU*XAN+BWTZ+4=<O;&SDOI[>SNYX;1)C<2PVMQ*D;)!*R^4?%7]KG]E'X%1>
M#9_C=^T[^SS\'(/B+#;W'P^F^*OQI^&_P]B\=6]VL3VL_@V3Q=XETA/$\-RD
M\+V\NB-?),LT31LPD0D XO\ :L_;T_8\_8=M_ ]U^UK^T!X!^!%O\2IO$5OX
M$E\<W=]:IXGF\)IHLGB./3#96%\7;2$\1Z&UWY@C"C4K;87W-M^K=.U"RU;3
M['5=-N([S3M3L[;4+"[A),5U97D"7-K<1$@$QSP21RH2 2K#(!XK\2?^"O'_
M  30_P"">O\ P52\+_LU:C^V#^TUXL^$/ACX:_\ "Q=>^#WB#X6_&?X(^ -,
M\?6GQ)L?A^^OWG]J_%#P'\0]/\4Z?96?A7PS<Z5<>%WL([:+5IIKV:_BO]/-
MO^TWAC2M/T+PUX>T/2;F2\TK1M#TG2M,NYIH+B6ZT_3K"WL[.YEN+:.&VGDG
MMH8Y7FMX8H)68O%&D;*H -RBO"/C'^U-^S'^SK%#/^T%^T;\!_@5#<QI-;S?
M&/XO?#[X8Q3Q22+#'+#)XV\0Z(DL;RNL2.A96D944EF .5\%OVP_V1_VDKV_
MTW]G;]J7]G+X^:CI2/)J>G_!;XW?#/XIWNG1QK&[R7]KX&\3Z[/9HB30N[7$
M<:JLL;$@2*2 ?1E?'7[*?_!03]B_]N*X\<6O[)7[1'P]^.]Q\-8?#MQX[B\#
M7E_=/X8A\6/K4?AR34Q>Z?8A%U=_#FN+:>69"QTVYWA-J[OL6O\ /C_X,:_^
M1J_X*5_]B_\ LF?^G']HR@#_ $'**** "BBB@ K\3_VN?^3A?B#_ -RI_P"H
M1X:K]L*_$_\ :Y_Y.%^(/_<J?^H1X:K[GP__ .1SB?\ L65O_4K!'X/](;_D
MB\K_ .RHP7_JISL_A'HHHK[<^H"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^@?
M_@V\_P"3XOBI_P!FI>./_5O? ROY^*_H'_X-O/\ D^+XJ?\ 9J7CC_U;WP,K
MRL\_Y%./_P"O#_\ 2HG?E?\ R,,)_P!?5^3/[8:***_)#]!"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH _)?X5?\GQZI_V4CXR?^F_QS7ZT5^2_PJ_Y/CU3_LI'QD_]-_CFOUHKZ_C+
M_?,J_P"Q%@?_ $[BC\;\%?\ D2\5_P#9>9[_ .HF5!1117R!^R!1110 51U.
M]?3M-U'4([*\U*2PL;N]CT[3HTEU#4'M;>2=;*QBEDACDO+IHQ!;1R2Q(\\B
M*\B*2PO5P_Q-^(_@WX._#;XA?%SXBZS#X<^'WPL\#^+/B/XZ\0W$<LMOH7@W
MP1H-_P")O$^LSQ0))/)#I>B:7?7TL<,<DKI RQH[E5(!_!=^S%_P1M_;E_X+
M<?MT?M$?M/\ _!;O1?VE?@#\)/ .HV4?P@^!CW(\(P7UIXIU74K_ $CX;_"O
M4=3L->T;0_A7\.?#>C6=CXXUGPUID/BCQMX@U[2]3N/%"^)7\2ZL?K'_ (*3
M_P#!I7_P3Z\+?L>?'/XJ_LDWGQ;^$WQH^#'PH\7?%#P[%XB^(=YX^\%>.W^'
M'A#4/$.J>%_%&F^)+&YU+3I_%]OI%S':ZWX?U?2X-$UZ\@NSIEUH<,FB-\S^
M$?\ @KG_ ,%\/^"XGQO^+'AK_@D5HO@']D_]F'X6:TVGW/Q-\9Z+X$EUAM&U
M6XO$\*)\3?'GQ!\._$^.#QQX@T^U;7CX0^"O@U;WPO:HUKJ.LZU8QQZYJ_<_
MM ?\$)/^"P'C+]G7X^?%;_@HM_P6R^(?B3P)\+_@A\4/BCXB^#WPD\2?&#Q7
MX \6OX$^'FN^(I]&U2#Q!JOPA\(V&E2C2?(NM3F^%NO7,]C+?*FEVT]]-, #
M] ?^#1']M'XN?M1_\$[O&_PP^,GB35_&^L?LJ?%O_A6O@KQAXBU;4=:\0W?P
MO\2^&M/\5^%/#>KZEJCW-Y>CP9?R^(=!T"62^E6P\(1>'/#EM:65CH%I]H_+
MG_@L]^T?^U?_ ,%@_P#@KWH'_!#']E?XFZI\+/V?/!&K6F@?'OQ!H4EY<:/X
MLUS2/"EK\0_BMXR^(]MIMYHMSXA\(_"'2G'A#PU\-;_6+#1O$'Q-TR9[V\EU
M+5O"USX?]_\ ^#(;_DUG]N'_ ++_ /#O_P!5U<5\N_\ !("U7PA_P=O_ /!2
MO1O'N'\1>(/$?[>5UX*:4+&Z-XB^-WA;QYX>\I71&8K\+3?1J8QN>$M+ODC+
MNX!^I&J?\&;/_!+BX^#-SX&TGQC^TGIWQ9;05@LOCC<_$#1]0OHO%$=G"%U:
M[^'P\,6O@NY\/S:E$TUUX=AM+34CIES/I]KXIM+T6VL6^-_P;0:;_P %2?V6
M_B#^U+_P3P_;;^$GQWNOV=O@?J?B0_LY?'_XA^"O&EC\/9-4\%^,K3P=KG@_
MX6^//%MO;GQ7\+/B#HE]IWQ"^&$6C?;/#VE6NC>)SIUY ^KMI\7]>%?-OA;]
MLC]DWQO\</%/[,WA+]I3X'>(/VBO!4][;>*/@5IOQ.\'W'Q;T>73+)-1U43_
M  ^&K#Q3(FD6,D=UJ\MMI<\.DPRQ/J+VPECW '\%/QV\0_M*_P#!SU_P6)^*
MO[%7AGXS>*/A)_P3I_9-U[Q?+JL?A0G4= OO#'PP\5)X%N?B;/I33Z;I'B[X
MI?&+Q=,\/PVF\3_;K7X>^";N;4=.T74#H/BV+Q/^L/[2G_!G)_P3YUOX!>*-
M)_98\4?'+X;?M%:'X?O]1^&_CKQE\2;?Q=X>\2>,-/M+FXT?2/B'H<WARPLK
M;0]9O1!97>J^#(_#.HZ(YM]6@34(K.ZTC4_SG_X,N;5?"?[4W_!3OP'XSP_Q
M2TSPY\*;6ZD<+',5\*?$7XJ:-X^_=%(Y%#^(M1\--*%2-4=45T5C&!_H/T ?
MS"_\&Y7[0/\ P4 \)_L+_&?P-_P5+^$_Q_\ A/:_LDAM9^'/Q=_:/\"^,/!_
MB;Q9\#[;1?$VJ^(-(U.^\:6]OXA\4S_".Y\):@8/$%];[[GP9XD\)6-E=:E9
MZ7'='^>C]ECX,_M ?\':'[>GQV^-_P"U!\7/B%\)/V ?V:]6TN#P7\(?!6I6
M/VK0[/Q5J&JIX#^''@^SU%+OPU8>.M<\*Z+K?B;XN_&74/#_ (FU8WJ:9X=T
M_28="U?PS;^#_P"O[]O;]K?]FS]J?_@G'_P5+^&G[+/[1_P6^-?Q5\#_ +$_
M[6NE>+_ 'PM^)7A'QEX]\+S6GPE\;Z#J<&M>$=#U:[\1Z2)[_P"TZ!:7UUIT
M-K/K+?8+2YDO8S&O\&G_  01_P""9W_!0[]NCX#?&[QC^Q%_P5#^(?[$6B^!
M_B[9>&OB!\+_  -\2OCWX$C\1ZI>^#=&U30?'NI6WPF\6^'M&U!]0M'U+P]:
MSZE;3ZG"OAJ>/S_LKV\: ']&'[9W_!GQ^R!<_!G7?%/_  3[\:_&7X*?M1^
MK!/%7POD\5?$>7Q7X,\8^*?#4<NJ:;H6KW=]9Z;XA\&:WKVHVUG;Z-XY\/\
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M&V\"^$8-1LM4CT_1OAGX/\/V&J?$K3O!6EV?B[Q9XEUK_A--5UR);7Q%/?\
M]3?_  ;X?\%M;[_@KW\%_B5I'Q4\#:-X!_:6_9T/@FU^* \)-=)X$^(&A^.4
M\1Q^&?'OA+3=1FN]0\.SSW?A/6=.\4>%I]2UF#2K^/3]2L-5^P:_;:3I'Q)_
MP5"_X-3?V?\ ]M;XZ_$G]IO]D;]H&7]ES]H3Q7XG;QW\1/!5SHL?C'X6ZO\
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M5U+6=%LO"\WBSX5?$_PGXNET+6?"FM"YO;K3-/\ %&EZOK%_8ZS9I9_UH?\
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MW[/?P(MK:&*WM[?X-?#""WMX(TBA@AB\$:''%##%&%CBBB152.-%5$10J@
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M]G[]H:^^'5]J?A#Q=KC)J.L_"SQ_\3-2^%OQ&^$OQ#;0;+3=&\:1^'$ \6>
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M?A#P9!HL0\??%34-/;S]=\+:SH6D2S?V!%XIT;7_ *4_X,PO^44'Q0_[/?\
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M-5^V%?B?^US_ ,G"_$'_ +E3_P!0CPU7W/A__P CG$_]BRM_ZE8(_!_I#?\
M)%Y7_P!E1@O_ %4YV?PCT445]N?4!1110 4444 %?T4_L*?\$SOV-/\ @H%^
MQUXN\2_#3Q7\1_!G[6_@72+KP_XDT+6?&&D:CX(L/'GV:XO/"'B&;1%\*1:P
MO@'Q[%9O"TL6IRWFAWL?B"SMY-2ET*)[_P#G6K[:_P""?W[9GBW]AO\ :.\*
M?%_1?MNI>$+EE\,_%3PA;3;(_%OP_P!2N8&U6UCC=T@.M:/)%!KWAJXE:-8=
M:TZV@GE&G7>H0S^?F='%5<+)X*M.CB:356ERNT:KAJZ-1/24:BNDGHI<K>ET
M^O!5*%.O'ZS3C4H33IU.97<%*UJD'NI0>KMJX\R6MCY)\9>#_$WP^\6^)? O
MC31;[P[XN\'Z[JGAKQ+H.I1>3?Z1KFBWDVGZGI]U'EE$UK=P2Q,R,\;[0\3O
M&RN9/!'@KQ5\2/&/A?X?^!M$OO$OC'QGKVE^&?#&@:;&)+[5]<UF\AL--L+=
M69(U>XNIXT,LTD<$*%IIY8H8WD7^FW_@N9^Q_P"#_BO\/O!G_!2W]G-[/Q)X
M7\5Z#X53XMW/AZ,S6FN>&M9M+6U\!?%@*B*\,MK')I_@OQ<DP%S$LOAB2:SM
M9-,U^Y:E_P $6_V8/A_^SA\&O'W_  5(_:>,.@^&?"_AOQ%%\'UU2V1[G3O#
M]N9M%\2^/-,LYRDMUXB\7W[2_#OX?V<3P76H+=:RMO'=1^)=%N8^-9W2>6+'
M*#==R6'6%L^=XY^ZL/;XOB][;F]EK;F]TZ?[,J+'?57*U)+VSKZ<JPJU]K?X
M=O=[<^FVIX5_P4!_X)P_L9?\$^?V4/ EWXV\5?$;QU^V#\0M(M-(T+1=(\8:
M38>!7\2VL%I<>.O&9T-_";:NG@/PD]VFG:5#/JD>IZ_JEWHD$AMH9]9N-*_G
MLKZO_;5_:T\>?MJ?M!^,_CCXX>6S@U2X_LGP/X5%PUQ9>!_ .F3W \-^%[)C
MB-Y;>">6_P!:O8HH$U;Q%J&KZO\ 9[?[=]GB^E?V O\ @E'\??V\X[GQCH^H
M:7\*O@EI6J2:3JWQ7\5V-UJ*7]]:H&U&Q\#^&+>XT^X\6WVE[XAJ,LVK:!H%
MK([VDNOKJ,,EB-\-.678!5LTQ=ZLFZE>I4E>,)U-50HQ2;:@O=48)N4E)Q5F
MDLJT5C,7[/ X=*"7)2A!)2E&&CJU).RO+=RDTDK)N]V_R[HK^FK1O^",7_!/
M?QMJI^%?P_\ ^"G7@WQ!\;9IY]/L-(T[5?A)X@CO]781);Z;8>"M+\:P:UJE
M_:SQW:ZAIFF^*KC4%WI$\5E):3&X_&_]N#]@GXY?L&?$2R\%_%BSL-5\/>)8
MKN]\ ?$CPU]JF\(^-;"Q>!;Z.TDNX8+O3->T@W5I'KOA[48DO-/>YMKFWDU#
M2+[3=5OM,-FN"Q57V%.I*-9Q<HTZU*K0E4@M>:FJL(<ZMK:-Y))MI)7(KX#%
M8>G[6I"+II\LITZE.K&,M%:;IRERN[2]ZR;T3N?$M%?KW_P3N_X)A:%^W)\%
MOCS\6-5^,&K?#JX^#-X]K;:)I_@VS\20Z^$\)WGB7?/?7/B+1WT\E[46FV.U
MN\(YFSD>6?R$KJI8FC6K8BA3FY5,+*G&M'EDE!U(\\$FTE*\5>\6TMGJ85*%
M6G3HU9QM"NI2I/FB^90:C)V3;C9O[23?0**_6_\ 9A_X)EZ'^T+^P'^T-^VG
M>?%W5O"^I_ __A;7V7X?VW@^SU6P\1?\*T^'/A_QW!]H\0R^(;&XTW^UYM:;
M39?+TF\^QQVZW*?:&D,*?DA11Q-&O.O3I3<I8:I[*LN64>6I92Y4Y)*6CWBV
MO,=2A5I1I3J1Y8UX>TIOFB^:%[7LFVM>DK/R"BBOW'\$?\$5?'WQC_9!_9Q_
M:#^"?C;4O&?Q$^//B71=*O\ X?ZAX9M='\)^ /#U[<^,(=:\9^(/&Z:U>W":
M%X>B\,V\UTYT 75Y-J4.F:9;7VKSZ=I]_.)QF&P:IRQ-54HU:GLX2DGR\_+*
M5I22:@N6,FY2M%6U>PZ&&K8ESC1@ZDH0YY135^7FC'1-IR?-)*RNS\.**_I]
M\&_\$.OV)?$>JGX/1_\ !23PAXB_:+6*2WG\(>$+[X5W=U;:Q;VFIW&H6,7P
MV_X3>_\ &6HOI8MXKF]M%UNQU""PLKBZOK;3X]4M'L/D?1_^"$O[22?M&^/O
MA5X]\9^$?A]\$?AMHNG^,?$'[3VN6TUOX&OO!>L?V@=-N= TK4;_ $L7?B:(
MZ5J<?B+0;_7M.TSPJVG74^J>)/L5YX=NO$'%#/,LFYIXATW3@JC5:E6I.=-M
M14J2J0BZO,Y)1C!2G)M<L6=,LKQT5!JCSJ<N3]W4IU%&=N9JHX2:A9:N4FHI
M;R1^'5%?T_6G_!![]F#XV>#O$,O[(G[?OA'XK^//#-HR7MO%?> ?&_A/^U_M
M-PEK;:[/\.=>O]:\':?J"1"&WOY;3Q'(3&^H6MKJ-M-';I_-Q\2OAUXO^$7Q
M!\9_"_Q]I$^@^-/ /B35_"OB72;A6#6FK:->2V5T(I&55N;.9HOM%A>Q!K:_
ML9K>]M7DMKB*1NC"9CA,=*I##U).I2LZE.I3J4JD5+:7)4C%N+[JZ5TG9M&.
M(P>(PJA*M!*$[J$X3A4@VMUS0E))KL[7L[72.(HK]^?@5_P1 "?!K1?V@?VY
M/VE/!W[)'@7Q#::?J.D>&]9CT8^)19ZQ;/=:3#XEUSQ1K^@:#X8\0:A;+'>6
MGA6SM?%6M-;S"UU*'1]8M[S2[;Z!\,_\$1_V&?V@+75M(_94_P""BNC>./'.
MEZ=]JDT83_#GX@R)+!"/,N]0T#PKKWASQ%IVAWEU+!#'JJ07T%A^_0'5KF%X
M!S3SW+:<IIUJDH4Y.%2M3P]>I0A)-)IU84Y0=KZN+DO.YM#*\;-1:IQC*45*
M%.=6E"K)-735.4U-7[22?D?S"T5]!_M#?LY^-_V5/CYXJ^ OQJB2RUSP3K6E
MV^M:CX9)U.QU;P[JMM9:M8>)/"LM^FF#4;35-!OH;_3H[U=/FBN6;3=4CT^_
MM;VWM_O[_@HY_P $M=-_8E^%'P3^.'PZ^,5Y\;_AA\7+]]-?Q'<>$(/"T.E3
MZOX=M?%G@6XLS:Z[KJ:C9^+-!A\0WD<DS6+VO]CQ!4N?MC?9NQX[#1GA(.JF
M\:I/"R49.%51@JCM42<(W@TXJ3BYWM&[T.986NXUY<C2PS2KIM*=-N3@KP;4
MG:2:?*GRVO*R/Q^HI\<;RR)%$CR2R.L<<<:EY)'<A41$4%F=F(554$L2  2:
M_6__ (* ?\$R_#O[!?P*^ 7C3Q5\8M3\0_&KXR_8_P"U/A0_A&QTO3?"RZ7X
M5LM5^(,L/B-/$5]>:I%X6\2:UX?\-VK/HMB-3&I/?.;1K;[)+=7%4:-7#T*D
MFJN*E.-""C*3FZ<>>?PIJ*C%W<I-)+J33H5*E.M5A&].A&,JLFTE%3ERQ6K3
M;D]$E=Z'Y&T45]M?\$^/V2-._;<_:7\.? #5/&][\/+/7?#GB[77\36&A0>(
M[FV?PSHTVJQVRZ7<:GI$4JWC1"%Y3>H85;>J2$;3=:M3P]*I7JOEITH2J5))
M.5H15Y.T4V[)7LDV^B)ITYUJD*5-7G4DH05TKRD[)7;26KW;L?$M%?T/^%_^
M"$EGX9\0?$WQ9^U+^U!X0_9Q_9[\)_$;Q1X'^'_C'QQ'X=\-^*_B?I^@ZI?Z
M;9>)GM_%/B;2O#7@S2]>6QEOM!2?5/$6JZW:02W=II$>CW.F:U?=M\5?^"!'
MA7Q5\)=;^+G[#G[5F@_M"Q:59WEWI?A.2/PKK-IXNDT^U^VW6CZ!\2O!'B*[
MT%/$KQ&&'3M'U'P];6E[=7EO'>ZUHT>)9?->>Y6IQB\3I)QC[7V5;V*G))J$
MJWL_9QDKKFO*T'=3<6FEVK*L<XR:HJ\4Y<GM*?M'%.SDJ?/SN/9V]Y6<4TU?
M^:JBGR1O%(\4J/'+&[1R1R*4DC="5='1@&5U8%65@"I!! (K]V?V6O\ @AWX
M^^(GPIM_V@?VLOC+X5_9&^#]WH]EXAL'\70:=+XIDT746C73]4\4OXBU[PKX
M:^'>FZC'<VEQI\FN:KJ.LR^=':WOA[37N(9CVXK&X;!0C4Q-54XSDHP5I3G4
MD[6C3IP4IS>JORQ=KINRU.:AAJV)DX4:;FXKFD[J,81_FG*348KS;7D?A'17
M]+W_  XW_9@^._AO7'_8C_X* >!OBMX\\-V*75[X8U>^\&>*M.F=4BM2=7OO
MA]JSZ_X-TV]U(NUEJ]QX6\1VYC>&Q2.[<-J#?@WXG_9^\9?"C]H2W_9[^/5K
M)\)?$6F^/?#OA#QO>:Z]B+/PQI>M:EI\,OBQ;^6\@T>_\/)HM^GB*PUF/4DT
M?4-(,-_%J"V<HN!EALSP>+=2%&I+VM*/-4HU*=2E6C'^;V=2,92CJM8II-I.
MS:1I7P6)P_(ZD%R5':%2$XU*;>UN>#E%/R;3T;5TFSZ>^$W_  3B^)/Q$_8J
M^,/[=&L^*_#_ (7^%OPYTO4CX6T...36?%?CS7=*\1:7X<U"![>&:ULO"^A6
M-UJ$S/JE]<WVIWEQ8M:VV@K974>L1?G/7]YOPS_9#_9R\.?\$K?B!^S+HO[8
M?P^\2? O7?\ A*_[6_:@L]4\"2>"M _M3QQ8:U?_ &K4+3QQ=>#T_LO4X(M$
MG^T^+K;;<SJDWDW!6W;^.+]M#X%?"?\ 9T^-]]\-?@O\>O"W[2'@>U\.>'M8
M@^)O@^\\-7^BW6I:M;S2ZAHR7'A3Q'XJT@W&D21I%<*FK/.K2 3P0-@'ARK-
M5CJ^-I2E)N&)J_5U["I3BL-"-.,5*3@DJCDY2E"I)5-7[JBDETX_ /"TL+4C
M&*4J,/;/VL)MUY.;?+%2;<$DDI03A9:R;NW\GU^C'PF_X)Q?$GXB?L5?&']N
MC6?%?A_PO\+?ASI>I'PMH<<<FL^*_'FNZ5XBTOPYJ$#V\,UK9>%]"L;K4)F?
M5+ZYOM3O+BQ:UMM!6RNH]8B^$_ 6A:3XI\<^"_#.OZ]:^%="\1>+/#NA:UXH
MOGMH[+PWI.KZQ9Z?J.O7DE[<V=G':Z/9W$VHW#W=Y:VRPV[M/<P1!Y5_NA^&
M?[(?[.7AS_@E;\0/V9=%_;#^'WB3X%Z[_P )7_:W[4%GJG@23P5H']J>.+#6
MK_[5J%IXXNO!Z?V7J<$6B3_:?%UMMN9U2;R;@K;M><YD\!'"*$I1G6Q=",VJ
M,JG^SJ?[]1:C**J-6C&.M22<G3BY+FBLMP2Q;KN23C3H57%>TC#]]R_N[IR4
MG!.[;TBFESM)V?\ !E17Z7>*/V(/@ZW[?7PK_9!^$?[37A[XS?#WXDZMX&T?
M_A>'@6/PMXETZPO?%23G4K6VM/#/B_6]$OKS0I(DCFM?^$CAF+2@7"VS8#?I
M_P"&/^#>NQLOC)\5+7XK_M"WO@W]G'X<GPEI^B?$:^\/:%X9\1_$37-=\-Z-
MKNMQ:='K>MWOA[PYX?\ #=UK$>B'Q#=3ZV-5UJ*XTRTTY)['47M.BMF^ P\:
M<JU9P]K06(IQE2JJ<Z<IQ@DH<G-[1RDE[-I323DXJ,6UC3R[%UG)4Z:ER571
MFU4IN,9J+F[RY[<JBF^=-QV2;;2?\R5%?J;^VG_P3<;X"_M;_#+]E+]GCXAW
MG[1/B[XN^&_#OB'PUI<6BZ;HNI:0WB6]U2TTW3]7U>VUN]T"ZAEL=%OO%-SK
M3/HMEI7AB6WU+488K$#49_O]/^"(W[+_ ,!=,\-1_MR?\%!OA_\ "KQQXBM(
M=0'@;P]<^%/#PBMTDD2[.D:UX\U8ZUXBL5>-H!KI\":+8P78:W:WN6"&13S?
M 0IT*CJSE]9A[2A3A1K3K3@KIR]C&#J1C=-<THJ+L[-A#+L7.=6"A&/L9*%6
M<ZE.-.,G:T?:.2BW9IVBV]=4?S9T5_2OXU_X()_#KXF?"K5_B?\ L)_MA>%?
MC]+I4%U+:>&[V3PIJVEZ_=VT,EXV@0>/_!&N76GZ#XG^S^3:0:3KOAR&&349
M0NJZAX?@\R2'^:^YMKFRN;BSO+>>TO+2>6VNK6YBD@N;:Y@D:*>WN()526&>
M&5'CEBD59(Y%9'564@;X/'X7'*I]6J.4J34:M.<)TZE-RORJ<*D8R5[.S2:=
MFKW32SQ&$KX5P]M!)5$W3G&49PFE:_+.#E%VNKJ]U=.UFKP5[_\ LH_#+PY\
M:/VG/V??A#XPDU*+PI\3OC)\.? ?B231KJ*RU:/1/%7BS2M%U-],O)[:\AM;
MY;.\F-K<2VES'%,$=X)54H?UZ_9D_P""'UWXC^#%C^T7^VK\?/#O[)WPSUC3
MK+5M(TK6SH-KX@CTG64B.@ZGXN\0^+-:T;PSX*EU?S[>;3= FCUO6[J*Y@M;
M^#1-39[%/I3X,?\ !(KX?Z!\?_V;?VD?V'OVIO!7[57PV^%_[1?P?U?XI^'K
M'6?!USXJ\%^'K'QUIFH7NNG5_#6MSZ5?MI^FVDU]?:!J.E>&]9?3K.YU'1X]
M:,BV$/#B,ZP"CB*=/$/GA"I35:-.JZ$:_)+E@L0H>Q4^:UGS\M[).^AU4<LQ
M;E1G*BN64J<W3<X>U=)R5Y>QYO:<MKW7+>UW:VI^7/\ P5Q_8[^$O[$/[3GA
MOX0_!JY\7W7A35O@WX6\>74GC76;+7-6&MZSXL\=Z+=I%>6&D:+"EB+/PWIY
MAMS:/(DS7+M.ZRJD?Y<5^^7_  <9_P#)]W@C_LV?P#_ZL+XMU\C_ /!/C_@E
MG\</V^[S4_$6BZGI_P +_@KX;U$Z3XD^+?B/3I]5MY-6CA@N;G0?!WAR&\TR
M;Q7KEE:75O>:BDFK:+HNEVTT0U#7+>]NK"QO;P.-A3RC"XS&UU%.A"52M4;;
ME*3:Z)RE*3T48IR?1,G%X:4\QKX;"TKOVC4*<%9)))];*,5NVVDNK1^8M%?T
MW6?_  1F_P""=OB_6F^%'@#_ (*;^$M3^-SW,VD6FBQ:Y\(?$2WGB &*V32;
M/P9I?BW3]8U'4[>^CNHKW1-/\3W&JQ,1;21V\UG.T_XQ_MP?L*?&G]@WXGVG
MP]^+,6EZKI7B.SNM7\ >/_#<LTWAGQOHUE-!!?2V2W4<%_IFKZ//=6MMKVA:
MC!'=Z=/<6L\$FH:1J&E:MJ&V&S7!8NK["E4G&LX\\:=:E5HSG!*_-356$>=6
MN_=;:2;:LKF5? 8G#T_:SA%TT^64Z=2%6,).RY9N$I<KNTM;)MV3;/BVBBBO
M1.,**** "OZ!_P#@V\_Y/B^*G_9J7CC_ -6]\#*_GXK^@?\ X-O/^3XOBI_V
M:EXX_P#5O? RO*SS_D4X_P#Z\/\ ]*B=^5_\C#"?]?5^3/[8:*9++%!%)--)
M'###&\LLLKK'%%%&I>2221R$2-$!9W8A54%F( )KY%^*7[8_PX\#_:=,\*'_
M (3_ ,01[X\:7<+#X=M)AE<W.N[)H[S8=KB/1X;Z*4!HI+VTD^8?F.!R['9E
M5]C@L-5Q$].;D5H03T3J5)6ITX_WIRBF]$[GTV>\1Y'PUA'C<\S/"Y=0M+D5
M:=ZU=Q5W##8:FIXC$U$G=PH4JDDM6DKL^O:*^,/V>+[XF?&?4)?BU\2=2DM_
M"]C<S6_@3P?IL<FG^'I=0B=XKK7IK/S'DU1=*?S+/2KK5;C49DU$WD\$EM)I
M]L6^SZ>88)Y?B982=:E6K4DEB/8WE2I57K*BJC2]I*FFHU&HJ,:G-!.7*Y.>
M'<\CQ'EM/-Z."Q6"P.+E*>7_ %U1IXG%X164,;+#Q<OJ]+$24IX:,JDYU,/[
M.O)4_:J"****X3W0HHHH ***JWTEY%97DNGVT-[?QVMQ)8V=Q=-8V]W>)$[6
MUM/>K;7C6<,\P2*6Z6TNFMT=I1;3E!$P!:HK\+/^"=W_  76^#W[=7[7'QV_
M85\9? WXE_LG?M2? X:X+GX9?%W7/"^J77C&Y\&:Q<Z-\0=,\-:AH$PMKK5_
M"+#3M9-E"+I-?\*WUSXIT&XO=%T?4[N#]TZ "BOP\_:"_P""X'PN^&/_  4L
M^&/_  2R^"GP+^(/[4'[17C0>'AX[O? 'B+P_HO@WX*R:Y!+KU\OC_4M2@OK
MM$\&_#V)?B1XUET^RG31?#=[IMK!_:'B&YFT:U_.O]J'_@[*^"O[-7[5/[0/
M[*@_8C_:%^)_BC]GSXG>,?AIKVO^"?$OA.>PUFX\':W-H=SKEGIOV&YU&QTV
M\N8E:!;T;X_-CCD;S" 0#^M>BOXPO^(R'X6_](T_VO\ _P &/AW_ .4U?KQ_
MP22_X+;>$O\ @K!XS^,O@[PW^RW\:?V>Y?@[X8\*^)KK4OBI=:9<6?B6/Q3J
MNJZ7'8Z0+"QM&6YL&TMKBZ,C.IBN(MH!!) /W%HK\IO^"H'_  62_8O_ ."3
M7A'PWJO[27B+Q-KOQ"\>VM]>?#GX(_"_2++Q%\3?&&GZ=<165]KQMM5U70?#
MGACPK8WLZ6\_B#Q7XAT>&^EAO[3PW;^(-5TZ[TR/\,?^(M_7-#T^T\>_$/\
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M2TV:YTF3Q5J_B&+1K_5-&AT_5+S]VJ* "OXRO^#QG]A7]I#]ISX'?LA_'_\
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MK^0PQR:3:S>.UFO&EFL%M;>:#3+;Q3]AW]@O_@HA_P %P?\ @J3X _X*O?\
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M;A?6WQ-R^+4]N6(JO)(+FU>*>%<K>^Z$:;JJDY;\O-;2]N5*.VA^:-?U\_\
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MGW%]8>#/"AO;>/Q#XTU]X$*6>B^'M/EDO+B6=XA<SK;:;:F74+ZSMYOZ O\
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MK117'_;^0_\ 1)X7_P +I?\ S'Y?GW9[/_$/>/\ _H[F:?\ AAI?_/@_)?\
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MK4;<FYU&G.;;;YI.[>X4445\:?M04444 %%%% !1110 4444 %%%% !1110
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M?^3A?B#_ -RI_P"H1X:K]L*_$_\ :Y_Y.%^(/_<J?^H1X:K[GP__ .1SB?\
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M.]T^SO=/U72[ZQU/3[JW BN7LKG4+&]_;[7_ /@X7\ :VMIXVF_X)]_#F_\
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M$+;Q3\5(K:XU*:*)X&;2)OV4Y/%D%P5D-PN@)IMU<3Q)%&FKQBY-Q;?VIT4
M?R%_\$BO^">O[?7[2/\ P4L\;_\ !</_ (*C^ K+X"?$>Z\(:AX0_9F_9NM4
MGL->\%Z5K'@VY^&?]L>(M NM3U/5/!FC>'_AS?>(M!L?#?BN8>,_%7BOQCXA
M\9ZYIGA:"PTJV\0_UZ444 %%%% !1110 4444 %%%% !1110!^2_PJ_Y/CU3
M_LI'QD_]-_CFOUHK\E_A5_R?'JG_ &4CXR?^F_QS7ZT5]?QE_OF5?]B+ _\
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M2CKE[\$'O;Q/&EKI \&0_$0ZA- ]DM@ELO@FXA\2-(;[Y=-D60@/F,?RP?\
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M\0:A\*SI'A#X>^--"\!^(%?XP2Z_'9OXIT34I-1OA+IFK-=:-#;VD?\ -?\
M\$)/^5JS_@KY_P!C!_P4D_\ 6ZO -'_!RM_RL._\$B?^Q?\ V.__ %N#XDT
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MX/\ 2&_Y(O*_^RHP7_JISL_A'HHHK[<^H"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K^@?_ (-O/^3XOBI_V:EXX_\ 5O? ROY^*_H'_P"#;S_D^+XJ?]FI>./_
M %;WP,KRL\_Y%./_ .O#_P#2HG?E?_(PPG_7U?DS^V&BBBOR0_00HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /R7^%7_)\>J?\ 92/C)_Z;_'-?K17Y+_"K_D^/5/\ LI'QD_\ 3?XY
MK]:*^OXR_P!\RK_L18'_ -.XH_&_!7_D2\5_]EYGO_J)E1^$/_!S1_R@Y_;N
M_P"Q?^"7_K37P6KSG_@U3MX(?^"'G[)TD,,<<EWXF_:/N+IT0*UQ.O[27Q5M
M%FF( ,DBVUK;P!VR1%!$F=J*!]7_ /!>']G?XS?M7_\ !)S]KK]G[]GOP+?_
M !+^,/Q$T;X56W@SP1IE_HNEWVNSZ!\>/A;XLU>.WOO$6IZ/HUN;+P]H.K:G
M(;W4K97BLGBA,EP\,,G&_P#!O;^S+\=/V/\ _@DY^S=^S]^TC\/=1^%OQA\%
M:S\<;GQ1X(U74=!U:^TB#Q3\>/B1XLT"2:^\-:KK>C3#4O#VM:7J<0M=2G:*
M*[2*X$-PDL,?R!^R'Q1_P=Y?\H;?&G_9P'P)_P#3YJM9G[/?A/7O'/\ P:13
M>%O#$,]SKVJ_\$MOCD-,LK4,;G49[+P7\1-0;2[=5=#)/JD5I)I\,1;;+)<K
M&P96*GZ?_P"#DW]DK]HG]M;_ ()B^*?@;^R]\,M4^+?Q6O\ XR?"/Q):>#M'
MU3PYH][-HGA[5M0N-9U!;WQ3K.@Z2L=C#-&\D;Z@L\@<"&*5@0/K_P#X) ?
M?XD?L_\ _!+K]CK]G[X]>!Y/!_Q)\ _!2S\(?$7P%K<VC:RVE:BVIZTU[HVI
M2Z3>ZOH>H1RV=Y&LZVU[>VDT4QC9W!=0 ?@=_P &47CGPOJ?_!.O]I;X<V5Q
MIR^,O!W[9&O>+?$6GP7$+ZF/#WC[X,_"#2_">KZA:AS<P6VH7_P_\7:;I\\B
M+;7+:#>I;L\UK>!/['KBXM[.WGN[N>&UM;6&6XN;FXE2"WM[>!&EFGGFE98X
M888U:2661E2-%9W8*"1_ Y\5?^"/7_!5[_@B#^VAXZ_;(_X(J:'IW[0W[.GQ
M&>_7Q1^SCJ*6NNZ]HOA"[U"771\,/&G@._U_PWX@^(GA;PWJGECX>>-OA?XC
MB^*.G6S?V9JMK;0MK6J>*MK]H3]L#_@Z3_X*;?#W5?V1OA__ ,$WI?V*_"_Q
M2T*X\*?%GXI:EX?\4_#:^O?"FLZ=<Z?XITJW^(OQF\46^F>$_"VLZ=+?0ZQ8
M^#] USXC36CP:9H>N&2[FM-6 /&?^#5BZB^+W_!;3_@J=^T7X,@=_AGKW@;X
M\W6GW6D R>&8HOC/^UKX.\=>!X$N%#Q[[GP_X,UR30@9LS:?:ZDZ"58V9.S^
M(UO!=?\ !\3X(CN(8YXUF\)W"I*@=5GM/^":EQ=VLP# @26]S##/"_6.6-'4
MAE!'],'_  0__P""/_@K_@D#^R_JGPW;Q+IOQ'^/WQ<UC2_&/[07Q1TBSO=/
MT/6=9T:TO+/PKX)\'V>H,M\O@7X>6>JZS;:'?ZI;VFL>(=6UWQ)XGOM/T./6
M[3PQH'Y">,?^";W[;6I?\'8OA7_@H#9? /Q!<?L>V']A_:_C<OB#P.NA0?9?
MV#[KX47&[0G\4)XR;R_B%(GAH[/#;9NF^U+G3LW@ /[':_@"_8%_Y7)/VU/K
M^T?_ .H-X.K^_P!K^.']CO\ X)N_MM_#C_@YT_:E_;D\;? /Q!H/[*?CP_&_
M_A$OC%<>(/ ]QHVM?\)1X2\,Z?H'D:+8^*+KQ9!_:-Y8W4$?VS0+?RFA9KCR
M49&8 ]P_X+#?\$(/VX/^"B'[8,O[0_P _;['[./@!_A?X(\#K\.#JWQ=LMNM
M>&9M=DU+7?)\%:YI^B_\31=4MEWBW^UM]E_?NP$>/C#]D[_@V/\ ^"DGP#_:
MG_9I^.OCK_@J./B#X)^"W[0'P;^+/C'P%_;OQYF_X3?PK\.?B+X<\8>(?"'D
MZQXDGTB7_A)=(T:\T;R]4@FTY_MNV^BDMC*A_M]HH _S_/\ @XU\<^%_AC_P
M<<?\$=_B-XWN-.L_!O@32/V.?%OBK4-7N(;33-+\/>'_ -M_XE:IK&KWUU<O
M';6UMI%A;3ZE+/<NEM$MKON&$*N:_P! .O\ .-_X.S?@Y<?M%?\ !:W_ ()W
M?L^VFOP^%+KXZ_ G]G_X.6WBBXTY]7M_#=Q\3OVLOC!X)AU^?28KS3Y-4AT>
M36UU&73H[^Q>]2V:V2\MFE$R?<_A?]MW_@Z9_8 \*C]CWQ-_P3M\-?MNZK\,
MK*V\%_"C]JC1/"'Q"\>Z%XM\*Z=*FF^%M:\6:[\./%OAO3_$D$.CPVUM$_BJ
MQ^&'C^&TBAN_B%]KUQ=2U"\ /ES_ (.W;N/XT_\ !4C_ ()@_LT?#\KJ?Q3D
M\/\ AVQ^Q^'Y(KOQ)#J?QM^.^C^&/ VEO;J\@M]0DO?"=Y?Z1:W$<<KKJ<=T
MZM:W5N[?IY_P>FV4UU_P2L^"4\10)IO[>GPIO;C<Q#&&3X!_M.Z<HC 4AG^T
M7\!*DJ/+$C;LJ%;AO^"/O_!$G]M3QM^W-JO_  6%_P""R&LZ?J'[2MW??\)+
M\*/@I+/X;UG4?#OB:3P]9Z!X9\;^-$\)W-UX*\(V?PY\*+'HOPT^&FA/J%]H
M&IV]AK^NW6@:YX7M=/U/]Z?^"Q?_  3PMO\ @I_^P-\7OV5K+5]&\,_$+4I=
M \>?!OQ;XA%Z=$\-_%7P/J U'0)M8;3XKF[@T;Q#ILVN>"-<OK>PU.YTO1?%
M.HZK9:9J%]96UK( ;?\ P1NN[:]_X).?\$WIK2>.XB3]BC]FZT>2)@RK<V'P
MI\,6-Y 2.DEM>6\]M,O5)8G0\J:_EK_X/A_$VCP_"K_@GOX.:]@/B#4?B#\?
MO$T&G"6,W(T?1O#GPRTJZO9( WFI U[KMG!#*R".619T1F:&0+XA^Q1^T)_P
M<[?\$D_A?;_L/Q_\$SM4_:@^'7PWNM3M?A/X@O?!_BOXCZ?X2TC6-9U+4$TG
M0?BM\&_&8\.Z]X'?5+R[U?3-%\4&/Q-X9LKY=*EOM!T>WT[1-+\$_P""EG_!
M&3_@O9_P4+\!^&_VXOVJ/!=I\2?VKO%GCG1/AYX+_8_^$FN?#K2/#'[.G[.M
MEX>\:>(;_4M2N=4\;-X<M-3U?QQ/H45EH6E^-?&OB>*WU"]O_'/B/4M7N8=(
M\) ']LW[6'_*%[]I7_M&!\9/_64O$=?@U_P90^,O#6H?\$Z/VF/ -I/IP\7^
M%?VSO$/BG7K&!F.I+X=\;_!/X,:9X5U/4$9G*P7VH^!?%]A8/&8X7_L:[581
M-'<33_T5_M%?"3XB>,O^"7/QU^!/AGPQ=:K\6?%7[ WQ.^$GA_P9#=:;#>ZE
M\1-<_9XUOP=I7AB*]NKV#2(KJ\\2W5OI275QJ$.FI+()I;V.U#3C^&/_ ()K
M_P#!,[_@X._X)%^ =3_;7_9I^!^G^(/&6O\ B[7_ (<_M%?L'>/M4\-:[J/Q
M#^%'AG3/#.N_#[XHZ#9^$/'BVWB;4+?6?$GCK2-'7PMXGTWXE^#]3TIS9>'O
M&W@_QIXIT6$ _OR_;A\>^&OA;^QC^UE\1?&-UI]IX8\%_LW_ !K\0ZS)JEQ#
M:V4UIIOPY\1SFQDEN'2-I-2D6/3[: $RW=U=0VL"23S1QM_)5_P9#_#^_P!-
M_94_;=^*<HF&F^,_V@O '@*S+!1 UY\-?AU)X@U Q':':3R?BKIRS9=D 6$*
MJMYA;YQ_:KUO_@Y6_P""ZFG:9^QUXC_8DA_8 _9@UW7-!O\ XOZYXPTOQ7\/
M-(\0:=8:A8:C92?$#Q3\0-5N/%WCCPWX>UC38==TSP%\*/!*WEYJR64WBB+6
M(+#3+W2?[+_^"=_[#GPP_P""<W[('P<_9(^%4G]IZ1\-=!<^)?&,^G6^F:K\
M1?B%KEQ)J_CKQ_K-M!)<M#=>(_$%U=S:?I\]]J3^'_#\.B^&(-1N[#1+.2@#
M^+K_ ((2?\K5G_!7S_L8/^"DG_K=7@&C_@Y6_P"5AW_@D3_V+_['?_K<'Q)K
M[F_X)&?\$U?VX?V>/^#A;_@I3^V%\9OV?_$/@7]FWXV:S^W)<_"[XIW_ (A\
M"W^E>+H/BG^UOX/^(7@"2STG1?%.I^);,>(_!NFWNN6PU71+!K:"W:#4!:7K
M);,?\%T_^":O[</[57_!:?\ X)M_M,_L_P#[/_B'XD? OX*Z-^S-;?%#XA:9
MXA\"Z9IWA*?P1^U?XY^('BJ.\T[Q#XITC7KPZ/X/U73];F.EZ5?K-!<K!:&X
MO%DMD /G;_@^,\%ZO??##_@G5\1(9)QH'A;Q[^TEX+U*)=WV9]7\>^'O@WKF
MAR388)Y\=E\-_$"V^Y2WERW6QE&\/_:S^SEX[\,?%#]GSX&?$GP5<Z?=^#_'
M_P '_AMXR\+W.DW,-YIDN@>)?!NC:QI+6-U \D,]J+&\@6&6-V5D ()KY:_X
M*C?\$\OAI_P4^_8T^)O[*/Q$N[?P]?\ B!;+Q/\ "[XB-I*:S>_"WXL>&OM$
MOA'QO86+7%G)=0QK=:CX=\26%M?6%SK/@SQ#XET.&_L7U,7</\B_[*OQ*_X.
M:/\ @BGX,B_8R;]@2R_;N^ G@B]U.+X-^+?!=AXE^(]CH/AZ>YO+Z33O"/C;
MX::E:>)=-\'7.KZA/J-EX9^+_@.P\5Z66GT_2!I6A"QM( #^OK]N_P#X*<?L
M7?\ !-31OACXA_;)^*]Q\+-%^+WB+6?#7@J\L_ _CKQ[/>WGAVRL=0U^[N-(
M^'WASQ/KL&EZ/;:GIIO;Y=+E19M0LK:-9;BYBB;[?\-^(-+\6^'=!\5:'+=3
M:+XFT72_$&CS7VF:GHM[+I>LV,&HZ?+>:/K5GI^LZ3=26ES"UQIFK:?8ZG82
ME[6_L[:ZBEA3^%WX8?\ !*G_ (*N?\%P?VW_ (7_ +8?_!:#P+H/[-O[+GP,
MND@\$_LNZ9*VBZOXCT:SU*/79?!_ASP5'K?B_6?#NA^,==LM/'Q:^(/Q#\1V
M/C?Q+I%C9:'X1TY-&M_#]UX-_N[ "@*H"JH 50   !@  <  < #@"@#\(O\
M@YH_Y0<_MW?]B_\ !+_UIKX+5X__ ,&G_P#RA*_9R_[*!^T1_P"KP\;U]D_\
M%X?V=_C-^U?_ ,$G/VNOV?OV>_ M_P#$OXP_$31OA5;>#/!&F7^BZ7?:[/H'
MQX^%OBS5X[>^\1:GH^C6YLO#V@ZMJ<AO=2ME>*R>*$R7#PPR>:?\&[/[+GQ[
M_8W_ ."57P1^ ?[2_P .=2^%7Q=\+^,OC5J6O>"M6U+0-6OM.L?$_P 5_%?B
M#0KB6^\,:MKFCR+J.CZA9WT:V^HS21QSK'.D4RO&H!_-[_P9-6\#?%O_ (*F
M7;0QM<PP_LV6\,Y0&6."Z\3?M&27$*/C<L<\EI:O*@(#M;PE@3&N/[@OVLO^
M36/VE_\ LW_XR_\ JNO$=?RQ?\&JW_!-[]MK]@CX@_\ !0?6/VNO@'X@^"NF
M_&#_ (4-_P *WNM;\0>!]<3Q3_PB>M_'2Z\0_9$\'^*/$4MI_9D'BKP_)+_:
M:67FC4HA;^<T5P(?ZN?VB_#>M^,OV?/CMX/\,Z?)JWB3Q7\&_B?X;\/Z7#)!
M#+J6MZ[X)US2])T^*6ZE@MHI+R_NK>W22XGA@1I TTL<89P ?QS?\&0W_)K/
M[</_ &7_ .'?_JNKBO /^#BK_E9'_P"",?\ W9%_ZWC\0*_4+_@U(_8"_:__
M & _V??VL/"'[7WP3USX)^)/B!\8_!7B3P?I>N:YX.UR76]$TSP3-I=_?P2^
M#O$?B.V@CM[]EMVCO)[:=F.Z.)X\O7CG_!;'_@F]^VU^T[_P7'_X)>_M2_ C
MX!^(/B'\ O@5_P ,I_\ "V/B/IWB#P/INF^#?^$ _:]\9?$3Q?\ ;=,U[Q1I
M/B"]_L3P7J5CKL_]D:1J'GV]PMO9_:;U9+9 #^@O_@KKX3U[QS_P2U_X*'>%
MO#$,]SKVJ_L:_M$C3+*U#&YU&>R^%OB74&TNW570R3ZI%:2:?#$6VRR7*QL&
M5BI_GM_X,HO'/A?4_P#@G7^TM\.;*XTY?&7@[]LC7O%OB+3X+B%]3'A[Q]\&
M?A!I?A/5]0M0YN8+;4+_ .'_ (NTW3YY$6VN6T&]2W9YK6\"?V.7=I:7]K<V
M%_;6][8WMO-:7EG=PQW-K=VES&T-Q;7-O,KPSV\\+O%-#*CQRQNR.K*Q!_@>
M^*O_  1Z_P""KW_!$']M#QU^V1_P14T/3OVAOV=/B,]^OBC]G'44M==U[1?"
M%WJ$NNCX8>-/ =_K_AOQ!\1/"WAO5/+'P\\;?"_Q'%\4=.MF_LS5;6VA;6M4
M\5 ']\=Q<6]G;SW=W/#:VMK#+<7-S<2I!;V]O C2S3SS2LL<,,,:M)++(RI&
MBL[L%!(_ST/^#5BZB^+W_!;3_@J=^T7X,@=_AGKW@;X\W6GW6D R>&8HOC/^
MUKX.\=>!X$N%#Q[[GP_X,UR30@9LS:?:ZDZ"58V9/9OVA/VP/^#I/_@IM\/=
M5_9&^'__  3>E_8K\+_%+0KCPI\6?BEJ7A_Q3\-KZ]\*:SIUSI_BG2K?XB_&
M;Q1;Z9X3\+:SITM]#K%CX/T#7/B--:/!IFAZX9+N:TU;^BW_ ((?_P#!'_P5
M_P $@?V7]4^&[>)=-^(_Q^^+FL:7XQ_:"^*.D6=[I^AZSK.C6EY9^%?!/@^S
MU!EOE\"_#RSU76;;0[_5+>TUCQ#JVN^)/$]]I^AQZW:>&-  /YFOB986>H_\
M'PW@>WOK:*Z@CN_!E^D4R[T6\TO_ ()MR:GIUR >DMGJ%G:W<#?P3P1N.5K_
M $!Z_CB\8_\ !-[]MK4O^#L7PK_P4!LO@'X@N/V/;#^P_M?QN7Q!X'70H/LO
M[!]U\*+C=H3^*$\9-Y?Q"D3PT=GAMLW3?:ESIV;P?V.T ?Y_?_!%"U@N/^#L
M'_@K1--'ODL;C]OJZM6W.OE3O^UM\,;)I,*RJ^;6\N8ML@=!YF\*)$C=?[9?
MVW?^3+_VN_\ LV#X^_\ JJ?%E?S _P#!*G_@F]^VU\ _^#B3_@I%^V/\7O@'
MX@\%?LT_&G_AL+_A6'Q5OO$'@>^TGQ;_ ,+&_:6^'?C?P5]CTG1_%&H^)K/^
MWO"VC:GJ]O\ VIHEA]GAM'AOOLMV\5N_]4/[5GA+Q%X__9=_:2\">$-,EUOQ
M;XU^ ?QB\)>%]&@EMH)]7\1>(_AYXBT?1-,AGO)K:TAEO]2O+:UCENKB"VC>
M4//-%$&=0#^1[_@R._Y,O_;(_P"SG]!_]53X:K[?_P"#O+_E#;XT_P"S@/@3
M_P"GS5:YS_@U/_8+_:X_8%_9=_:<\"?M>?!?6_@IXM\<_'S2/%OA31M<UOPA
MKD^L>';;X>:%H\VIPS^#_$7B*TABCU*UN+4Q7=Q;W)>(NL)B*N?J_P#X.3?V
M2OVB?VUO^"8OBGX&_LO?#+5/BW\5K_XR?"/Q):>#M'U3PYH][-HGA[5M0N-9
MU!;WQ3K.@Z2L=C#-&\D;Z@L\@<"&*5@0 #Q3]B;]MGPI_P $ZO\ @V5_9R_;
M&\8>'[GQ=8?!W]EGPM=:1X/M+Q-.G\6^,_%WQ$;P'X#\.-J#0W3:=8:KXR\3
MZ';ZUJL-G?S:/H9U+5X["]-B;:3\&/V+OV;O^"Z__!Q#X,\1?M;?%G_@IEXT
M_8]_9CU_Q9XA\&>"O"7PKG\;Z)X<\0P:+>-8^(X/#7P3^&'C;X9:'KGA?PQ>
M>=X:@\4?$WQUJWB[5M3M-5LY;V^CAO-2F_HM^$__  2[\=_M"_\ !NY\./\
M@F/^T%9W?P2^+>K_ +-_ASPIJL>IMI6NR_#OXJ>!OB!!\2? UQK#Z#>ZM8:C
MI5IXM\.^'&\0Q:)J,T]WH$^I6EC>0W<R21_@)_P3R^('_!Q+_P $0O".N?L3
MW7_!+G6OVR?@CI'CSQ)KWP]UGP%=ZOJVG:-<^)I+6^U:7PE\5?A_#XGTJ/P'
MX@U6[3Q3'I/C[P7I?B72]6U+Q#!?3Z/*E[I&C '._P#!3G_@V9_96_8&_P""
M=/[6?[:'Q6_:N_:*_:.^/7P^\)^%U\"ZQXQOO#/A'P=-XN\9_$SP;X.L)=5T
M&:+Q9XO\07TUUXFNOL\$OQ%6U4W5Q<3Z;?SQI(O[;?\ !H;_ ,H;?!?_ &<!
M\=O_ $^:57YM_M9?L/\ _!P3_P %TOAEXT'[8OA3X8_L#_L]?"SP;XR^(GP:
M_91\):A9>(O'?QX^.>A>!M6N/AA9>-Y4\9ZU]CL;_P 2W1\/W>O^-_$GA&R\
M&VVH&]TCX5:OJPN/$4'ZR?\ !L%^S1^US^QO_P $_P#QE^S?^V%\ _%'P+\:
M^$OV@?&?BOP;%K_B#P=XAM/%G@;QUX=\(WL=[I\WA'Q/XDAL+K2O%&F^);/4
M;"Y-FODS:7?6_P!HEO;P0 'XA> P8_\ @^-\9K(#&SCQ"45P49A)_P $R+*9
M"H;!8/$1*A (:,[QE>:_H=_X.:/^4'/[=W_8O_!+_P!::^"U?@__ ,%F/^"=
M7_!5K]GC_@L_I?\ P6._X)M?!^;]H"^UW1?#>J/IFA:1IOC;4_ GBSPQ\ [+
M]G/Q5X6\5?#.?5-'\2>(?#/CKX9V$TNEZMX0:^O(+[4]6M&N_#VM6OAZ?4OT
M[_:7\*?\%//^"CO_  ;H?'CX=?M!_LPR^%O^"A'Q-ETG19O@AX<M-%\$1Z]8
M^#OVK/ _B;0M5TC3O$OC?5+#0HF^&&AK?74>L^+%EOKG2+Z^M8XTU*PM& /C
M+_@EIX3U[QS_ ,&@'[0/A;PQ#/=:]JO[.O\ P41&F65J&-SJ,]EKWQ<U!M+M
MU5T,D^J16DFGPQ%MLLERL;!E8J>L_P"#*+QSX7U/_@G7^TM\.;*XTY?&7@[]
MLC7O%OB+3X+B%]3'A[Q]\&?A!I?A/5]0M0YN8+;4+_X?^+M-T^>1%MKEM!O4
MMV>:UO GZN?\&\G[*/QP_9'_ ."3_P &OV=?VI?AA=?#?XH:)XJ^.$_BKX?>
M(;SPWK[PZ/XO^*?BW6M*6^F\/:IK^@WEKK&@ZG;7+6Z7UP#;W)@NXHY/,A7^
M=[XJ_P#!'K_@J]_P1!_;0\=?MD?\$5-#T[]H;]G3XC/?KXH_9QU%+77=>T7P
MA=ZA+KH^&'C3P'?Z_P"&_$'Q$\+>&]4\L?#SQM\+_$<7Q1TZV;^S-5M;:%M:
MU3Q4 ?WQW%Q;V=O/=W<\-K:VL,MQ<W-Q*D%O;V\"-+-//-*RQPPPQJTDLLC*
MD:*SNP4$C_/0_P"#5BZB^+W_  6T_P""IW[1?@R!W^&>O>!OCS=:?=:0#)X9
MBB^,_P"UKX.\=>!X$N%#Q[[GP_X,UR30@9LS:?:ZDZ"58V9/9OVA/VP/^#I/
M_@IM\/=5_9&^'_\ P3>E_8K\+_%+0KCPI\6?BEJ7A_Q3\-KZ]\*:SIUSI_BG
M2K?XB_&;Q1;Z9X3\+:SITM]#K%CX/T#7/B--:/!IFAZX9+N:TU;^BW_@A_\
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M%'^LF=?]!O\ Y;X3_P"4!_8N6?\ 0-_Y6Q'_ ,M/Y2_^(8S_ *O<_P#-;/\
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MZO<_\UL__'[1_P 0QG_5[G_FMG_X_:_JTHH_UDSK_H-_\M\)_P#* _L7+/\
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M )6Q'_RT_E+_ .(8S_J]S_S6S_\ '[1_Q#&?]7N?^:V?_C]K^K2BC_63.O\
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M0QG_ %>Y_P":V?\ X_:_JTHH_P!9,Z_Z#?\ RWPG_P H#^Q<L_Z!O_*V(_\
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MEV[K(?[O*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OQ/_:Y_Y.%^(/\ W*G_ *A'AJOVPK\3_P!KG_DX7X@_]RI_ZA'AJON?
M#_\ Y'.)_P"Q96_]2L$?@_TAO^2+RO\ [*C!?^JG.S]L****^&/W@**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7=I>_9&L[RUN)OEC_@I#_P %>?V-O^"5/_"F?^&MM:^(&C_\+X_X6)_PK_\
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MVT<-_//_ ,&J_P#P6%_8P_9/_9V\,?L!?%[6_B%9_M#_ +1G[=)L_AIIV@^
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M?A!\+?\ A$/L@<J-=^Q+\>#X^_LIE'F"'_A!_P"V]A ;1UDR@_H__91_:_\
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M/%>GZ9\++2\T!+R_N8M)^!WPAANO#_A:S\0:<MGH^N:?X.U3P_<RW7ABRND
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M2B\;?%3XH:+\2M5U6_UG3YDU2\T70]&T.#PW9Z@NBV6HM?0RW=OYO_P<6?\
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MSKU[X,TC4H]&USQ):W%Y>2:O=WMQ\4_M3?\ !FA_P3J^+,FK:S^S5\4/C?\
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MP[*+_5'D^Q:/-;75[?W-K!:3R0_Z&% '\K?[ _\ P0-^.O\ P3A_X+"?%O\
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M?_#/]I+]F']IGQKKGQ:D_9:L_A5J7PN^)GBFZEUWQDOA'QQ<>.M)U'P-XO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7_JISL_;"BBBOAC]X"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_DOZN_*Q_Q G@#_ *!\T_\ #G5_^0/R7_X8.^+W_0Q_#?\ \&_B?_YCZ/\
MA@[XO?\ 0Q_#?_P;^)__ )CZ_6BBC_7C/O\ GYA?_":/_P E_5WY6/\ B!/
M'_0/FG_ASJ__ "!^2_\ PP=\7O\ H8_AO_X-_$__ ,Q]'_#!WQ>_Z&/X;_\
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M  P=\7O^AC^&_P#X-_$__P Q]?K111_KQGW_ #\PO_A-'_Y+^KORL?\ $">
M/^@?-/\ PYU?_D#\E_\ A@[XO?\ 0Q_#?_P;^)__ )CZ/^&#OB]_T,?PW_\
M!OXG_P#F/K]:**/]>,^_Y^87_P )H_\ R7]7?E8_X@3P!_T#YI_X<ZO_ ,@?
MDO\ \,'?%[_H8_AO_P"#?Q/_ /,?1_PP=\7O^AC^&_\ X-_$_P#\Q]?K111_
MKQGW_/S"_P#A-'_Y+^KORL?\0)X _P"@?-/_  YU?_D#\E_^&#OB]_T,?PW_
M /!OXG_^8^C_ (8.^+W_ $,?PW_\&_B?_P"8^OUHHH_UXS[_ )^87_PFC_\
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M+_X31_\ DOZN_*Q_Q G@#_H'S3_PYU?_ ) ****^//V0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% 'Y ?\%^/^4-G_  4)_P"R :O_ .GW0:\@_P"#9?\ Y0<_L(_]B_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^;_ -KG_DWK
MX@_]RI_ZF_AJOI"OF_\ :Y_Y-Z^(/_<J?^IOX:KT\E_Y'.4_]C/ ?^I5(^7X
MX_Y(OB__ +)?B#_U4XL\W_8._P"20^(_^RD:Q_ZC'@^OMBOB?]@[_DD/B/\
M[*1K'_J,>#Z^V*ZN)O\ D?9I_P!A+_\ 2('E^&'_ "0'"O\ V*Z?_IVJ%%%%
M>$?>!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,S5'_#7/[/7_10?_+4\;_\ S-4_[%SG_H4YG_X08K_Y43_KQP7_ -%?PO\
M^'_*?_FL^D**^;_^&N?V>O\ HH/_ ):GC?\ ^9JC_AKG]GK_ **#_P"6IXW_
M /F:H_L7.?\ H4YG_P"$&*_^5!_KQP7_ -%?PO\ ^'_*?_FL^D**^;_^&N?V
M>O\ HH/_ ):GC?\ ^9JC_AKG]GK_ **#_P"6IXW_ /F:H_L7.?\ H4YG_P"$
M&*_^5!_KQP7_ -%?PO\ ^'_*?_FL^D**^;_^&N?V>O\ HH/_ ):GC?\ ^9JC
M_AKG]GK_ **#_P"6IXW_ /F:H_L7.?\ H4YG_P"$&*_^5!_KQP7_ -%?PO\
M^'_*?_FL^D**^;_^&N?V>O\ HH/_ ):GC?\ ^9JC_AKG]GK_ **#_P"6IXW_
M /F:H_L7.?\ H4YG_P"$&*_^5!_KQP7_ -%?PO\ ^'_*?_FL^D**^;_^&N?V
M>O\ HH/_ ):GC?\ ^9JC_AKG]GK_ **#_P"6IXW_ /F:H_L7.?\ H4YG_P"$
M&*_^5!_KQP7_ -%?PO\ ^'_*?_FL^D**^;_^&N?V>O\ HH/_ ):GC?\ ^9JC
M_AKG]GK_ **#_P"6IXW_ /F:H_L7.?\ H4YG_P"$&*_^5!_KQP7_ -%?PO\
M^'_*?_FL^D**^;_^&N?V>O\ HH/_ ):GC?\ ^9JC_AKG]GK_ **#_P"6IXW_
M /F:H_L7.?\ H4YG_P"$&*_^5!_KQP7_ -%?PO\ ^'_*?_FL^D**^;_^&N?V
M>O\ HH/_ ):GC?\ ^9JC_AKG]GK_ **#_P"6IXW_ /F:H_L7.?\ H4YG_P"$
M&*_^5!_KQP7_ -%?PO\ ^'_*?_FL^D**^;_^&N?V>O\ HH/_ ):GC?\ ^9JC
M_AKG]GK_ **#_P"6IXW_ /F:H_L7.?\ H4YG_P"$&*_^5!_KQP7_ -%?PO\
M^'_*?_FL^D**^;_^&N?V>O\ HH/_ ):GC?\ ^9JC_AKG]GK_ **#_P"6IXW_
M /F:H_L7.?\ H4YG_P"$&*_^5!_KQP7_ -%?PO\ ^'_*?_FL^D**^;_^&N?V
M>O\ HH/_ ):GC?\ ^9JC_AKG]GK_ **#_P"6IXW_ /F:H_L7.?\ H4YG_P"$
M&*_^5!_KQP7_ -%?PO\ ^'_*?_FL^D**^;_^&N?V>O\ HH/_ ):GC?\ ^9JC
M_AKG]GK_ **#_P"6IXW_ /F:H_L7.?\ H4YG_P"$&*_^5!_KQP7_ -%?PO\
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M/_P@Q7_RH/\ 7C@O_HK^%_\ P_Y3_P#-9](45\W_ /#7/[/7_10?_+4\;_\
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MM3QO_P#,U1_8N<_]"G,__"#%?_*@_P!>."_^BOX7_P##_E/_ ,UGTA17S?\
M\-<_L]?]%!_\M3QO_P#,U1_PUS^SU_T4'_RU/&__ ,S5']BYS_T*<S_\(,5_
M\J#_ %XX+_Z*_A?_ ,/^4_\ S6?2%%?-_P#PUS^SU_T4'_RU/&__ ,S5'_#7
M/[/7_10?_+4\;_\ S-4?V+G/_0IS/_P@Q7_RH/\ 7C@O_HK^%_\ P_Y3_P#-
M9](45\W_ /#7/[/7_10?_+4\;_\ S-4?\-<_L]?]%!_\M3QO_P#,U1_8N<_]
M"G,__"#%?_*@_P!>."_^BOX7_P##_E/_ ,UGTA17S?\ \-<_L]?]%!_\M3QO
M_P#,U1_PUS^SU_T4'_RU/&__ ,S5']BYS_T*<S_\(,5_\J#_ %XX+_Z*_A?_
M ,/^4_\ S6?2%%?-_P#PUS^SU_T4'_RU/&__ ,S5'_#7/[/7_10?_+4\;_\
MS-4?V+G/_0IS/_P@Q7_RH/\ 7C@O_HK^%_\ P_Y3_P#-9](4445YA]0%%%%
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M#_HE<K_\%U?_ ):?$_\ PP=\(?\ H8_B1_X-_#'_ ,Q]'_#!WPA_Z&/XD?\
M@W\,?_,?7VQ11_K-GW_0TQ7_ (%'_P"1\OS[L/\ B&' '_1*Y7_X+J__ "T^
M)_\ A@[X0_\ 0Q_$C_P;^&/_ )CZ/^&#OA#_ -#'\2/_  ;^&/\ YCZ^V**/
M]9L^_P"AIBO_  */_P CY?GW8?\ $,. /^B5RO\ \%U?_EI\3_\ #!WPA_Z&
M/XD?^#?PQ_\ ,?1_PP=\(?\ H8_B1_X-_#'_ ,Q]?;%%'^LV??\ 0TQ7_@4?
M_D?+\^[#_B&' '_1*Y7_ ."ZO_RT^)_^&#OA#_T,?Q(_\&_AC_YCZ/\ A@[X
M0_\ 0Q_$C_P;^&/_ )CZ^V**/]9L^_Z&F*_\"C_\CY?GW8?\0PX _P"B5RO_
M ,%U?_EI\3_\,'?"'_H8_B1_X-_#'_S'T?\ #!WPA_Z&/XD?^#?PQ_\ ,?7V
MQ11_K-GW_0TQ7_@4?_D?+\^[#_B&' '_ $2N5_\ @NK_ /+3XG_X8.^$/_0Q
M_$C_ ,&_AC_YCZ/^&#OA#_T,?Q(_\&_AC_YCZ^V**/\ 6;/O^AIBO_ H_P#R
M/E^?=A_Q##@#_HE<K_\ !=7_ .6GQ/\ \,'?"'_H8_B1_P"#?PQ_\Q]'_#!W
MPA_Z&/XD?^#?PQ_\Q]?;%%'^LV??]#3%?^!1_P#D?+\^[#_B&' '_1*Y7_X+
MJ_\ RT^)_P#A@[X0_P#0Q_$C_P &_AC_ .8^C_A@[X0_]#'\2/\ P;^&/_F/
MK[8HH_UFS[_H:8K_ ,"C_P#(^7Y]V'_$,. /^B5RO_P75_\ EI\3_P##!WPA
M_P"AC^)'_@W\,?\ S'T?\,'?"'_H8_B1_P"#?PQ_\Q]?;%%'^LV??]#3%?\
M@4?_ )'R_/NP_P"(8< ?]$KE?_@NK_\ +3XG_P"&#OA#_P!#'\2/_!OX8_\
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M$C_P;^&/_F/K[8HH_P!9L^_Z&F*_\"C_ /(^7Y]V'_$,. /^B5RO_P %U?\
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M\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:NP!$$7A*[T2*UB VP6R0PH2D:D_*O\ P:0:CK.D?\$2/VH-6\./-'XATO\
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MYMKRUGU=-4T:#0I]*U/3#^IWP^_X*3?\'7/_  4*\/Z1\2OV1?V&O@;^SO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@NY=$T+2]*DNH%8LL-P]C:P-/$K$L(Y2R!B2!GF@#^$C_@QK_P"15_X*5_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG)^PQH?P6TQOVS?'OQK^-'[1_B[1+;5/B#XG\&>/T\$>#_!GB[58+>^UC3_
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M#GX7>+M&\*22ZCXN_9>^#T&JKKK:OX4\4"_ME3PMIGV2*W6P>%FNB\LHE01
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M/XE_LN:V\7QZAXC\,OX<_OH^&?BS4?'OPW^'_CK6/"6O^ -7\:>"/"GBS5/
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M_P!(;_DB\K_[*C!?^JG.S]L**_GX_P"(D/\ 8=_Z)7^U;_X0_P (?_GYT?\
M$2'^P[_T2O\ :M_\(?X0_P#S\Z^;_L/-O^@"O]T?_DC]I_M3+_\ H*I?>_\
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M_P!AW_HE?[5O_A#_  A_^?G1_P 1(?[#O_1*_P!JW_PA_A#_ //SH_L/-O\
MH K_ '1_^2#^U,O_ .@JE][_ ,C^@>BOY^/^(D/]AW_HE?[5O_A#_"'_ .?G
M1_Q$A_L._P#1*_VK?_"'^$/_ ,_.C^P\V_Z *_W1_P#D@_M3+_\ H*I?>_\
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M_P!AW_HE?[5O_A#_  A_^?G1_P 1(?[#O_1*_P!JW_PA_A#_ //SH_L/-O\
MH K_ '1_^2#^U,O_ .@JE][_ ,C^@>BOY^/^(D/]AW_HE?[5O_A#_"'_ .?G
M1_Q$A_L._P#1*_VK?_"'^$/_ ,_.C^P\V_Z *_W1_P#D@_M3+_\ H*I?>_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /R7^%7_)\>J?\ 92/C)_Z;_'-?K17Y+_"K_D^/5/\ LI'QD_\
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M/L/Q*T3PI+<^*]/\477B/Q6)+6'7H=6\-Z _X/&/&UUX/N?!FG?\$JOCC/\
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M,VO>(;RPTR&]O8-.U"YCCGN8U6UL;RYD9(+::1/X&OV)O^"L_P#P49_X-X_
M5Y^P9_P44_8(^*7Q,^"'PPU;Q/+\%_BMX4OM1TRUTG0]0UG4O$.KV7A/XD76
MA:_\-_BG\-[G4-0N];T&.#6/#'B/P(FHWVD:Z'CCL_#GAJ+]ISXA?\%+/^#J
M?XT_!7X$_#+]E/X@_L>_\$\?A-X_L?&GCCXD?$FUO9[,ZM=V%WHUS\1-:U_6
M]*\):3XV\:Z#X/U/7='^'?PG^&\&KSZ==>+]1U#Q?X@DT+5(M?\ #(!^AO\
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MLL_#-]JLJZ9KVA>)/#FLZ7;:DVGZA?ZIIT>E:?8_CG_P:-?L]?'WX*_M,?\
M!3W5OC)\#_C!\)=*\6_\*L_X134_B;\-/&G@/3_$_P!C\?\ QFN;O_A'KSQ3
MHNE6VM?9;:_L;BY_LV2Y\B"\M)9=L=Q"SY__  6"_88_X*!?\$Z_^"LVF?\
M!<+_ ()Y?"K6/VA/!?B7R-:^.GPM\+Z%J?B?4O"MW'X'T[X=?$K1/$_A'1)+
MWQ5J_P ._B?X5M9O%4/C;PUINH2?#[QG_:^KZQ::+!H_AB^U< ^67_X)!_\
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M--\*^"=2^R>)M&TNRUX^(M-T]+W2XI0#\]?#/_*\[<_]C!XM_P#746LUA?\
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M_P#8LK?^I6"/P?Z0W_)%Y7_V5&"_]5.=G\(]%%%?;GU 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?T#_\ !MY_R?%\5/\ LU+QQ_ZM[X&5_/Q7] __  ;>?\GQ
M?%3_ +-2\<?^K>^!E>5GG_(IQ_\ UX?_ *5$[\K_ .1AA/\ KZOR9_;#1117
MY(?H(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'Y+_"K_D^/5/^RD?&3_TW^.:_6BOR7^%7_)\>J?\
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MNG4TI4G4G334E"=2%-S2=ES22>MK7L]CYJ^-7P$^,7[.GBVU\"?&_P"'VO\
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M5/\ LU+QQ_ZM[X&5_/Q7] __  ;>?\GQ?%3_ +-2\<?^K>^!E>5GG_(IQ_\
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M5+J]C\7^+=,UV]U[3M(O-*MXK&6TDAO[[POX@MH#+=Q$R:5=!E4*I;Y"M_\
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MZ7=V\]EJNF:UKEA?:7?1/9:A!;7:F&OT1_9^_:2^ ?[5GPWTKXO_ +-WQ>\
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M%A\/?B'H_A+QKJ-IIEL#+K$]CH5Q'HRX&J&S8@'[6^)7Q'\#?![X>^-_BO\
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MOXW_ ."D'["WPV_:5T3]CKQW^T[\+_#'[3OB36_!GAO1/@QJFK7,7C+4-?\
MB'!I]SX'T>*V2RDM$U'Q1!J^ERZ1:S7D4MTNHV6U0;J$. ?;55;Z\ATZRO-0
MN2PM[&UN+RX**7<0VT3S2E5'+,$1MJCEC@=ZM5\:?!3]O;]BO]JKQK\6_@_\
M"OV@_A]\7/&OP@M-8A^+WA?PA?:E>7/@RTL=6NO"^JC6;U+*WLX0FK6][IR/
M9WTKSR6]Q+9M+% \R 'A?_!-[_@KS^QM_P %5O\ A<W_  R3K7Q UC_A0_\
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MA!\1[36K&WNIH;35;:RBTG4[.#4+='6*[CM=0M+:]MUG1Q#<P1S1[77-?/\
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M6=YJGA_P9X)UGP@=-\&OJ]K?6.G7_P 1_%%X/$%Q8:C#9*[66HZ=8V_V9/\
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MXVNK=KFXM_AE\;]+AMXU\RUM$\8Z=HGC2/S#'M\,Z%%>F-HIXG'Q3_P<A_\
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MY_9Z_P"B@_\ EJ>-_P#YFJ/^&N?V>O\ HH/_ ):GC?\ ^9JO-_\ A@[X0_\
M0Q_$C_P;^&/_ )CZ/^&#OA#_ -#'\2/_  ;^&/\ YCZYOJ_!'_0;GO\ X!A_
M_F3^K/ROZG]H>.?_ $(^ _\ P=F/_P ^#TC_ (:Y_9Z_Z*#_ .6IXW_^9JC_
M (:Y_9Z_Z*#_ .6IXW_^9JO-_P#A@[X0_P#0Q_$C_P &_AC_ .8^C_A@[X0_
M]#'\2/\ P;^&/_F/H^K\$?\ 0;GO_@&'_P#F3^K/RN?VAXY_]"/@/_P=F/\
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M/ 7BCP7\1M/3X=^,/"EEIGVW4M%O-/OX?$WY_'_@O[_P7I_8#3[+_P %,_\
M@DG=^//!'AR(0:_\7?AGH/C'X>Z?Y,./M>K:Q\5O!'_"]_@!J-[#'YERMEH=
MMX1T^[AB6)9+)#+?J ?7?_!OM^W]^VII7[8'[77_  1E_P""AWCN?XP_&G]D
MG2-6\4?"_P"-&M7EUJOBKQ/X*\*>(O"WAO6-'U[Q5J0BUCQSIVLZ3XZ\"_$+
MX>:_XF@?QQ_8&J>(K7Q/J>H0VFCV>B?UT5^1?_!+#_@M3^QC_P %:?"^OO\
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M  ##_P#S)_5GY7Q_M#QS_P"A'P'_ .#LQ_\ GP>D?\-<_L]?]%!_\M3QO_\
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M]M%=VDC_ + ,DEO.N^&5K?\ ;'^*=S$)8S\LB+-#&[1N&CD"[)%>-F4_Z ]
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M#IW_ ()-?\$__P!A/X2? S]IS]C'1_#O[.OQCN_C/H?@+Q7\'?!GCS4@FO\
MAW5/"?C/Q5I'Q5\.^$=9\1:GKOA74O!FO^"=+T:?4O"D6EZ!=#Q-:75Y%#K5
MI;W-_P"[?LK_ /!('_@M5_P5_P#@SX!_:]_;;_X*Y_&3X&?#_P"/^@Z7\1_!
M7PB\'S^,M=2]^'7B9(-;\-:Y)\*_ OCWX,_!?X=1^+])EL=;T*UT73-?N8="
MN=#N]:LH;Z-M%L_@3_@O=_P0._9-_P""3'[#'P[^-?A7XX?'#XV_M)?%3]I[
MPG\.;K6_B5K/A*RT*;P9/\-?BKXK\57^D^"]&T6'61<1:OX9\+07^MZMXL\3
M-:R:C86<<-H-0>:0 _T$O^":WQN\9?M)_P#!/G]BSX]_$:[CU#XA?%K]F3X,
M>-_'>IPV\=G%JOC+6_ >B7/BC5HK2)WBM8]5ULWVH);QMY<*W(C1450B_;=?
MF!_P12_Y1'_\$Y?^S0/@?_ZA.EU^G] '\07_  =Q?MH_''5_&G[)'_!(W]G+
MQ#=Z!XB_:SE\/^*?BM;:=JMUH5UXWT?QU\0I_A'\%OAKJ>L031PQ>"/$GCC2
M_&.J^,].N4ECU";P[X5-R5TV"_M-2_67]DS_ (-C?^"3O[/'P0T#X=?$G]G+
MPS^TM\2)M#M8OB+\8OBY=Z]J>O\ B;Q#*L-QJESX9TRPU;3='\ Z'!>K);:!
M8^&;"QU>VT5(+?7-<U[4I-0U2^_GV_X.%5L_A%_P<M?\$G?C;XVN+9OAW(?V
M(O$%_?:Q<Q6FEZ+9_#[]L3QL?%*R7-W*MK;6FC:?-I_B6:>X>&TCEU"1KD+&
MDLLG^A#0!_%9^RY_P1._;E_X)3_\%O\ 0/BM_P $]O">K:__ ,$P?BE9Z%8_
M&>R\3_&3P' GAOP/XL_M72?$7P^U?P]XJ\61_$KQUK'P5\2"T^*?P\\36OAB
M^U"Z\/26/A"X\7:UK5[XRBU?XW_X+N?%?X\?\%:_^"V?P,_X(@_"/XBW_@_X
M#^"O$/@BS^)]MHUXC:7JWC6Y\!2?&_XL_$G7[='M;;Q/=_"+X.%]/\'>$=4N
M);6R\:Z+XBMX)[75/$,GV+^PW]HW_@JG^PW^R;^U%\%?V-OCU\7[WP9^T%^T
M+:>#[GX2^"[+X<_$SQJ/$LOQ!\>WOPS\$6,VJ> _"/B;3]!N?$OC/3=1TFPE
M\0SZ7I\0L+J\O[ZSLXQ.W\:_P0U"U^#'_!ZS\3=.^);V^FS?$+QU\4-/\*ZI
MKDZVL,-U\4/V1W\4_#]+&YNI?+DN->L;K3_!VBP12%KO4-9MM)MHA<2I;* ?
MTF>!?^#9G_@B]X,^$=G\)]0_8^T?QZZZ'#I6L_$OQKX[^(]S\5O$.H+ ([KQ
M)/XPT/Q7H4F@:Q>W&Z\>W\%V?AC0;.5O(TS1;&P5+1?Y8_A]IGQ(_P"#9/\
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MO_!Q5_RLC_\ !&/_ +LB_P#6\?B!7]_E '^>]_P;"VOBW]B7_@MG_P %*_\
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M]B[PM\#?B1\6_BA\4/C@?CWKWQ8\0?%+7_"MY(VE^!W^$=IX2GT;PUX8\/:
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MT7=Q!:P>;,GFW$\,$>Z61%;Z6_;9_:2\+? [_@N=XB_:1T^YM/&W@SP)X^^
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MC>\\)>'/$@\'HOBR^N]>\?\ C'Q7XFD\._V!/!X#M=)T+PK<?Z$5% 'Y=?\
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M\,W=R/&4\NDVVM/KXTR[1H;^>]ABE=H_U>HH _G"_P"#7?\ 8O\ VG?V%/\
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M_MWQ!X'UW_A)_P#A ?\ AI#_ (2[[+_PAGBCQ)]E_L7_ (33PQY_]I?8O/\
M[6A^Q_:?)NO(3_@MQ_P0[_:XU/\ ;'\)_P#!7?\ X)&:O::)^UKX4O=$\0?$
M?X5V5_X?\/:QXK\4^&M(F\/K\3/ =WXNNH/!&MZGXA\&"#PC\2?AKXC.G:;X
MWTFVN;RW.OZYXCUS1]6_L>HH _ANU3_@I1_P=0?M;^#F_9>^'7_!,&+]ECXI
M>+K1/!_C']J76_A]\1/AUX?\)V=\+2VU?Q?X,UOXM^([GP-X:N;>PNY)I-1T
MVZ^)VLVJ?;Y/!>D_\)-96!L<_P#X-\/^"+?[;W_!-+_@KC\?/%WQG^&^KWW[
M/MC^S9\2OA9X1_:*.I^$H_#?Q.\6:G\0O@?KD%[HGARU\5:IXTTVPUU?#GBG
M4-*'B#1[2YBT[3D75)(;^9(I?[H:* /P=_X+X_\ !&K2?^"NW[,^@:1X(U;P
MWX'_ &I/@=J6K^)O@9XX\20W*:'K%IK5E%!XM^%'C'4+"&[OM.\*^-)-/T/4
M8-;M].U2[\-^)/#^D7T-G-IEUKUEJ/X-? 3_ (*(?\'0O[ /P_\ #W[+?QE_
MX)9^+_VP9_AS:6W@SP1\7;/P9XW\>:M<^'M-M#8^&K7Q'\2O@5JOB7P/XOT[
M2M,TDP0>(=8M](\5W4,ME_PF.N7FNW:3W?\ >/10!_!A^SK_ ,$?/^"I7_!8
MK]O;P-^WO_P6R\.:9\%_@5\+K_2[OP;^S"#96=WXAT;PMK$>LZ-\*_#OPWAU
MCQ7<> ?A=K.O+=7WQ+\1?$'79_B1XSLQ+I-C;W%IK.F>*O"O]#_[7/\ R<+\
M0?\ N5/_ %"/#5?MA7XG_M<_\G"_$'_N5/\ U"/#5?<^'_\ R.<3_P!BRM_Z
ME8(_!_I#?\D7E?\ V5&"_P#53G9_"/1117VY]0%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>YV/[3W[2>E_#T_"3
M3?V@?C7I_P +6LVTT_#FQ^*7C>T\#_V8^[S-+'A:#6X]%&EREB\NFBR%C+)M
MEDMVD56'AE%3.G"=N>$)\K4H\\5+EDMI*Z=FNC6J*C*4;\LI1NK/E;5T]T[-
M77D] HHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "OZ!_\ @V\_Y/B^*G_9J7CC_P!6]\#*_GXK
M^@?_ (-O/^3XOBI_V:EXX_\ 5O? RO*SS_D4X_\ Z\/_ -*B=^5_\C#"?]?5
M^3/[8:***_)#]!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _)?X5?\GQZI_P!E(^,G_IO\<U^M%?DO
M\*O^3X]4_P"RD?&3_P!-_CFOUHKZ_C+_ 'S*O^Q%@?\ T[BC\;\%?^1+Q7_V
M7F>_^HF5!1117R!^R!1110 4444 %%%% !1110 4444 %%%% !117PE_P4I_
M;L\)_P#!-?\ 8X^*/[8WC?P'XB^)?AKX77W@"QO_  ;X5U+3=(US5'\?_$/P
MO\/+.2SO]75["%=/O?%%OJ-R)E)EM;6:*+$KH: /NVBOB[_@GC^VAX8_X*&_
ML<?!?]L;P;X*U[X=^&OC18^,+[3/!OB;4-/U37-%3P?\0_%WP\N8[^_TI5L+
MAKR]\(W.HP&W4".UO((I/WL<AK[1H **P_$^N1>&/#7B'Q)/!)=0>'M#U;7)
MK:%E26XBTFPN+^2")W^1))DMVC1G^568%N :_&O_ ((W?\%K_A?_ ,%C]-_:
M#U+X:?!+Q]\&D_9\OOAA8ZQ%XY\0^'M>?Q"_Q.M_'MQ82:8= CC%JNECP%=K
M=BZR9C?VQAP(I<@'[84444 %%%% !1110 45^&?[:'_!<OX4_L8?\%*_V6?^
M":OB?X%_$+QIXX_:EOOV?['0/B7H/B/PWI_A3PJ_Q_\ C/K?P9T>36-(U"-M
M7O5\/ZGHDNM:D+)U-U83QV]KBX5C7[F4 %%%% !1110 4444 %%%% !117EW
MQG^-OPB_9U^&WB?XP_'7XD>#OA-\+_!EE]O\3>.?'>NV/A[P]I4+.L-O%)?7
M\L2SW]_<O%8Z5I=H+C4]7U&>VT[3+2[OKF"WD /4:*\)_9F_:0^%/[7?P,^'
M_P"T=\#=9O\ Q%\)?BE8:GJ_@77]2T;4?#UUK>BZ;X@U;PZNK?V)K$%KJ^G6
MVHW.CW%W8V^JV=CJ0L9K9K^PL;II;2'X4_X*E_\ !93]CK_@DOX'T'6/VA-:
M\0>)OB=X]T_5+[X6_ OX=:?!JWQ!\;P:5-!9W>L7,M]<V'A_P=X1L]0NH+:[
M\2^)]5LA=&/4(/#&G>)]6TR\TE #]8:*_B1/_!X?XWTO2(?B7XN_X([?M'>'
M/V>[U;673?C0?BMJ\VD7UO>1Z9-!-"^I_LYZ%X(=9X-3AFM3!\2+A+F.XTQD
MD":DKP?TI?\ !-S_ (*I?L@?\%4/A7JWQ+_9:\9ZG=ZEX.?1K/XH?"[QGI/_
M  COQ,^%NJZ_!>7&D67BK1DN;_3+JRU5--U(:/XD\+ZSX@\+ZM)INI6MEK,F
MH:9J=E9 'Z.4444 %%%% !1110 4444 %%%% !1110 4444 %?B?^US_ ,G"
M_$'_ +E3_P!0CPU7[85^)_[7/_)POQ!_[E3_ -0CPU7W/A__ ,CG$_\ 8LK?
M^I6"/P?Z0W_)%Y7_ -E1@O\ U4YV?PCT5_JT44O]<_\ J6_^7G_WJ?J'^K?_
M %&_^6W_ -W/\I>BO]6BBC_7/_J6_P#EY_\ >H?ZM_\ 4;_Y;?\ W<_REZ*_
MU:**/]<_^I;_ .7G_P!ZA_JW_P!1O_EM_P#=S_*7HK_5HHH_US_ZEO\ Y>?_
M 'J'^K?_ %&_^6W_ -W/\I>BO]6BBC_7/_J6_P#EY_\ >H?ZM_\ 4;_Y;?\
MW<_REZ*_U:**/]<_^I;_ .7G_P!ZA_JW_P!1O_EM_P#=S_*7HK_5HHH_US_Z
MEO\ Y>?_ 'J'^K?_ %&_^6W_ -W/\I>BO]6BBC_7/_J6_P#EY_\ >H?ZM_\
M4;_Y;?\ W<_REZ*_U:**/]<_^I;_ .7G_P!ZA_JW_P!1O_EM_P#=S_*7HK_5
MHHH_US_ZEO\ Y>?_ 'J'^K?_ %&_^6W_ -W/\I>BO]6BBC_7/_J6_P#EY_\
M>H?ZM_\ 4;_Y;?\ W<_REZ*_U:**/]<_^I;_ .7G_P!ZA_JW_P!1O_EM_P#=
MS_*7HK_5HHH_US_ZEO\ Y>?_ 'J'^K?_ %&_^6W_ -W/\I>BO]6BBC_7/_J6
M_P#EY_\ >H?ZM_\ 4;_Y;?\ W<_REZ*_U:**/]<_^I;_ .7G_P!ZA_JW_P!1
MO_EM_P#=S_*7HK_5HHH_US_ZEO\ Y>?_ 'J'^K?_ %&_^6W_ -W/\I>BO]6B
MBC_7/_J6_P#EY_\ >H?ZM_\ 4;_Y;?\ W<_REZ*_U:**/]<_^I;_ .7G_P!Z
MA_JW_P!1O_EM_P#=S_*7HK_5HHH_US_ZEO\ Y>?_ 'J'^K?_ %&_^6W_ -W/
M\I>BO]6BBC_7/_J6_P#EY_\ >H?ZM_\ 4;_Y;?\ W<_REZ*_U:**/]<_^I;_
M .7G_P!ZA_JW_P!1O_EM_P#=S_*7HK_5HHH_US_ZEO\ Y>?_ 'J'^K?_ %&_
M^6W_ -W/\I>BO]6BBC_7/_J6_P#EY_\ >H?ZM_\ 4;_Y;?\ W<_REZ*_U:**
M/]<_^I;_ .7G_P!ZA_JW_P!1O_EM_P#=S_*7HK_5HHH_US_ZEO\ Y>?_ 'J'
M^K?_ %&_^6W_ -W/\I>BO]6BBC_7/_J6_P#EY_\ >H?ZM_\ 4;_Y;?\ W<_R
MEZ*_U:**/]<_^I;_ .7G_P!ZA_JW_P!1O_EM_P#=S_*7HK_5HHH_US_ZEO\
MY>?_ 'J'^K?_ %&_^6W_ -W/\I>BO]6BBC_7/_J6_P#EY_\ >H?ZM_\ 4;_Y
M;?\ W<_REZ_H'_X-O/\ D^+XJ?\ 9J7CC_U;WP,K^V&BN7'<4_7<)7POU#V?
MMZ;A[3ZUS\MVG?E^KPYMMN9>IOA<A^K8BE7^M<_LIJ7)[#EYK)JW-[:5M][/
MT"BBBOD3Z$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#\E_A5_R?'JG_92/C)_Z;_'-?K17Y+_"K_D^
M/5/^RD?&3_TW^.:_6BOK^,O]\RK_ +$6!_\ 3N*/QOP5_P"1+Q7_ -EYGO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN;[X<?&:TEGTW2=0\0:Q96Z0JWQ&NH;#]E_^"G'_  1A_:^_:[_X+@_L#?\
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MN_UBVT[6+GPW, ?V(DA068A54$LQ(   R22>  .23P!7^=Y_P1X\06'[9?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /R7^%7_)\>J?]E(^,G_IO\<U^M%?
MDO\ "K_D^/5/^RD?&3_TW^.:_6BOK^,O]\RK_L18'_T[BC\;\%?^1+Q7_P!E
MYGO_ *B94%%%%?('[(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?B?\ M<_\G"_$'_N5
M/_4(\-5^V%?B?^US_P G"_$'_N5/_4(\-5]SX?\ _(YQ/_8LK?\ J5@C\'^D
M-_R1>5_]E1@O_53G9^V%%%%?#'[P%%%% !1110 4444 %%%% !1110 4444
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M_JO@_P#HI\B_\*J7_P N]?Z>GV7_ !%3.O\ HUO'G_AJQ?\ \QGZT45^2_\
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MI?\ R[U_IZ'_ !%3.O\ HUO'G_AJQ?\ \QGZT45^2_\ PJK]N/\ Z"GQ(_\
M#R:?_P#-S1_PJK]N/_H*?$C_ ,/)I_\ \W-'^J^#_P"BGR+_ ,*J7_R[U_IZ
M'_$5,Z_Z-;QY_P"&K%__ #&?K117Y+_\*J_;C_Z"GQ(_\/)I_P#\W-'_  JK
M]N/_ *"GQ(_\/)I__P W-'^J^#_Z*?(O_"JE_P#+O7^GH?\ $5,Z_P"C6\>?
M^&K%_P#S&?K117Y+_P#"JOVX_P#H*?$C_P /)I__ ,W-'_"JOVX_^@I\2/\
MP\FG_P#S<T?ZKX/_ **?(O\ PJI?_+O7^GH?\14SK_HUO'G_ (:L7_\ ,9^M
M%%?DO_PJK]N/_H*?$C_P\FG_ /S<T?\ "JOVX_\ H*?$C_P\FG__ #<T?ZKX
M/_HI\B_\*J7_ ,N]?Z>A_P 14SK_ *-;QY_X:L7_ /,9^M%%?DO_ ,*J_;C_
M .@I\2/_  \FG_\ S<T?\*J_;C_Z"GQ(_P##R:?_ /-S1_JO@_\ HI\B_P#"
MJE_\N]?Z>A_Q%3.O^C6\>?\ AJQ?_P QGZT45^2__"JOVX_^@I\2/_#R:?\
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M?Z>A_P 14SK_ *-;QY_X:L7_ /,9^M%%?DO_ ,*J_;C_ .@I\2/_  \FG_\
MS<T?\*J_;C_Z"GQ(_P##R:?_ /-S1_JO@_\ HI\B_P#"JE_\N]?Z>A_Q%3.O
M^C6\>?\ AJQ?_P QGZT45^2__"JOVX_^@I\2/_#R:?\ _-S1_P *J_;C_P"@
MI\2/_#R:?_\ -S1_JO@_^BGR+_PJI?\ R[U_IZ'_ !%3.O\ HUO'G_AJQ?\
M\QGZT45^2_\ PJK]N/\ Z"GQ(_\ #R:?_P#-S1_PJK]N/_H*?$C_ ,/)I_\
M\W-'^J^#_P"BGR+_ ,*J7_R[U_IZ'_$5,Z_Z-;QY_P"&K%__ #&?K117Y+_\
M*J_;C_Z"GQ(_\/)I_P#\W-'_  JK]N/_ *"GQ(_\/)I__P W-'^J^#_Z*?(O
M_"JE_P#+O7^GH?\ $5,Z_P"C6\>?^&K%_P#S&?K117Y+_P#"JOVX_P#H*?$C
M_P /)I__ ,W-'_"JOVX_^@I\2/\ P\FG_P#S<T?ZKX/_ **?(O\ PJI?_+O7
M^GH?\14SK_HUO'G_ (:L7_\ ,9^M%%?DO_PJK]N/_H*?$C_P\FG_ /S<T?\
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M_P#\W-'_  JK]N/_ *"GQ(_\/)I__P W-'^J^#_Z*?(O_"JE_P#+O7^GH?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2G.664W*4Y.4I/VE75R;;;\VPHHHKPS[H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^;
M_P!KG_DWKX@_]RI_ZF_AJOI"OF_]KG_DWKX@_P#<J?\ J;^&J]/)?^1SE/\
MV,\!_P"I5(^7XX_Y(OB__LE^(/\ U4XL\W_8._Y)#XC_ .RD:Q_ZC'@^OMBO
MB?\ 8._Y)#XC_P"RD:Q_ZC'@^OMBNKB;_D?9I_V$O_TB!Y?AA_R0'"O_ &*Z
M?_IVJ%%%%>$?>!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7S?^US_P F]?$'_N5/_4W\
M-5](5\W_ +7/_)O7Q!_[E3_U-_#5>GDO_(YRG_L9X#_U*I'R_''_ "1?%_\
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M_P!RI_ZF_AJO3R7_ )'.4_\ 8SP'_J52/E^./^2+XO\ ^R7X@_\ 53BSS?\
M8._Y)#XC_P"RD:Q_ZC'@^OMBOB?]@[_DD/B/_LI&L?\ J,>#Z^V*ZN)O^1]F
MG_82_P#TB!Y?AA_R0'"O_8KI_P#IVJ%%%%>$?>!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ,$VU"E1I1A3IP3;:C"*5VW;4TZ***S.@**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"&N?V>O^B@_P#EJ>-__F:H_P"&N?V>O^B@_P#EJ>-__F:KS?\ X8.^$/\
MT,?Q(_\ !OX8_P#F/H_X8.^$/_0Q_$C_ ,&_AC_YCZ/J_!'_ $&Y[_X!A_\
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M_EJ>-_\ YFJ\W_X8.^$/_0Q_$C_P;^&/_F/H_P"&#OA#_P!#'\2/_!OX8_\
MF/H^K\$?]!N>_P#@&'_^9/ZL_*Y_:'CG_P!"/@/_ ,'9C_\ /@](_P"&N?V>
MO^B@_P#EJ>-__F:H_P"&N?V>O^B@_P#EJ>-__F:KS?\ X8.^$/\ T,?Q(_\
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M?_0CX#_\'9C_ //@](_X:Y_9Z_Z*#_Y:GC?_ .9JC_AKG]GK_HH/_EJ>-_\
MYFJ\W_X8.^$/_0Q_$C_P;^&/_F/H_P"&#OA#_P!#'\2/_!OX8_\ F/H^K\$?
M]!N>_P#@&'_^9/ZL_*Y_:'CG_P!"/@/_ ,'9C_\ /@](_P"&N?V>O^B@_P#E
MJ>-__F:H_P"&N?V>O^B@_P#EJ>-__F:KS?\ X8.^$/\ T,?Q(_\ !OX8_P#F
M/H_X8.^$/_0Q_$C_ ,&_AC_YCZ/J_!'_ $&Y[_X!A_\ YD_JS\KG]H>.?_0C
MX#_\'9C_ //@](_X:Y_9Z_Z*#_Y:GC?_ .9JC_AKG]GK_HH/_EJ>-_\ YFJ\
MW_X8.^$/_0Q_$C_P;^&/_F/H_P"&#OA#_P!#'\2/_!OX8_\ F/H^K\$?]!N>
M_P#@&'_^9/ZL_*Y_:'CG_P!"/@/_ ,'9C_\ /@](_P"&N?V>O^B@_P#EJ>-_
M_F:KW[1M7T[Q!H^E:]I%Q]KTG6]-L=7TN[\J>W^U:=J5K%>V5QY%U%#<P^=;
M312>5<0Q3Q[MDL4<BL@^.?\ A@[X0_\ 0Q_$C_P;^&/_ )CZ[^R_9EL].L[3
M3]/^-O[0]A86%M!96-C9?$F*UL[*SM8D@MK2TMH- CAM[:WA1(8((42*&)$C
MC144 <6,PW##C#^S\QS"G/F?M'C<.JL7&RMR*A2HM23O=R<DTK)+<]K)<R\4
M8U:[XBX<X=KT73C]662YA/"U8U>;WW7ECL7C(3IN&D8TXPDI:N36A],T5\W_
M /#.7_5>/VD/_#H?_>.C_AG+_JO'[2'_ (=#_P"\=>?]5RW_ *&O_EC7\O[W
MF_N\SZ+^U>)?^B3_ /,[@/\ Y6?2%%?-_P#PSE_U7C]I#_PZ'_WCH_X9R_ZK
MQ^TA_P"'0_\ O'1]5RW_ *&O_EC7\O[WF_N\P_M7B7_HD_\ S.X#_P"5GTA1
M7S?_ ,,Y?]5X_:0_\.A_]XZ/^&<O^J\?M(?^'0_^\='U7+?^AK_Y8U_+^]YO
M[O,/[5XE_P"B3_\ ,[@/_E9](45\W_\ #.7_ %7C]I#_ ,.A_P#>.C_AG+_J
MO'[2'_AT/_O'1]5RW_H:_P#EC7\O[WF_N\P_M7B7_HD__,[@/_E9[9XN\7>'
MO GA[4/%?BO4/[*T#2OLGV^_^R7U]Y'VZ^MM-M?]%TVVO+V7S;V\MH?W-M)L
M\SS)-D222+XG_P -<_L]?]%!_P#+4\;_ /S-5FZO^RSH_B#3KC2->^,?Q^UO
M2;OROM>EZO\ $*UU+3KK[//%=0?:+*]\/36TWDW,,-Q%YD3>7/%%*FV2-&'$
M_P##!WPA_P"AC^)'_@W\,?\ S'UZ6#P_"RI2_M#,,RG6]H^5X.A&E25+EA92
MC6HUINHI^TO)247'E2BFFW\SG.9>*TL53?#W#O#-#!?5XJK#.<=5Q6*>*]I5
MYY4ZF!QN#I+#NDZ"C"5*515%5DZCC*$8^D?\-<_L]?\ 10?_ "U/&_\ \S5'
M_#7/[/7_ $4'_P M3QO_ /,U7F__  P=\(?^AC^)'_@W\,?_ #'T?\,'?"'_
M *&/XD?^#?PQ_P#,?77]7X(_Z#<]_P# ,/\ _,G]6?E?R?[0\<_^A'P'_P"#
MLQ_^?!Z1_P -<_L]?]%!_P#+4\;_ /S-4?\ #7/[/7_10?\ RU/&_P#\S5>;
M_P##!WPA_P"AC^)'_@W\,?\ S'T?\,'?"'_H8_B1_P"#?PQ_\Q]'U?@C_H-S
MW_P##_\ S)_5GY7/[0\<_P#H1\!_^#LQ_P#GP>D?\-<_L]?]%!_\M3QO_P#,
MU1_PUS^SU_T4'_RU/&__ ,S5>;_\,'?"'_H8_B1_X-_#'_S'T?\ #!WPA_Z&
M/XD?^#?PQ_\ ,?1]7X(_Z#<]_P# ,/\ _,G]6?E<_M#QS_Z$? ?_ (.S'_Y\
M'I'_  US^SU_T4'_ ,M3QO\ _,U1_P -<_L]?]%!_P#+4\;_ /S-5YO_ ,,'
M?"'_ *&/XD?^#?PQ_P#,?1_PP=\(?^AC^)'_ (-_#'_S'T?5^"/^@W/?_ ,/
M_P#,G]6?E<_M#QS_ .A'P'_X.S'_ .?!Z1_PUS^SU_T4'_RU/&__ ,S5'_#7
M/[/7_10?_+4\;_\ S-5YO_PP=\(?^AC^)'_@W\,?_,?1_P ,'?"'_H8_B1_X
M-_#'_P Q]'U?@C_H-SW_ , P_P#\R?U9^5S^T/'/_H1\!_\ @[,?_GP>D?\
M#7/[/7_10?\ RU/&_P#\S5'_  US^SU_T4'_ ,M3QO\ _,U7F_\ PP=\(?\
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M .A'P'_X.S'_ .?!Z1_PUS^SU_T4'_RU/&__ ,S5'_#7/[/7_10?_+4\;_\
MS-5YO_PP=\(?^AC^)'_@W\,?_,?1_P ,'?"'_H8_B1_X-_#'_P Q]'U?@C_H
M-SW_ , P_P#\R?U9^5S^T/'/_H1\!_\ @[,?_GP>D?\ #7/[/7_10?\ RU/&
M_P#\S5'_  US^SU_T4'_ ,M3QO\ _,U7F_\ PP=\(?\ H8_B1_X-_#'_ ,Q]
M?GC\<_ >C_#+XI^*? ^@W.I7>DZ)_8GV2XU>:UN-1D_M+P[I&KS_ &B6RL["
MV?9<W\R1>7:1;8%B5_,D5Y7]'*\BX3SC$3PV"QF<RJPHRKR51X:G'V<9TZ;L
MW@W=\U6*MZOIK\SQ5QYXN<&Y?1S/.LFX*IX6OC:> IO#K,\1-XBK0Q&(@G".
M<IJ'L\+5;E>R:BOM'[S4445^?']%!1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R7^%7_
M "?'JG_92/C)_P"F_P <U^M%?DO\*O\ D^/5/^RD?&3_ --_CFOUHKZ_C+_?
M,J_[$6!_].XH_&_!7_D2\5_]EYGO_J)E04445\@?L@4444 %%%% 'YP?\%A_
M^44'_!2/_LR#]IS_ -4_XMK^>'_@R7_Y,%_:O_[._N/_ %3'PNK^A[_@L/\
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MJS\*^#?#'@S1-<\+V+?$#Q#X8\=>*O&VLR3P:M=W>HZ%J&HD _T2Z*_SE_\
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M\.OAG\-91XY^+/BGPO&OC2\,.I>&K,V=CX?UC2?&.):?\&6'@5O!$/BG4?\
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M/_LR#]IS_P!4_P"+:_GA_P"#)?\ Y,%_:O\ ^SO[C_U3'PNH _I^_P"'>W[
MO_1CW[('_B-/P8_^8JOXN?\ @\N_9N_9V^!7P-_8=U#X(_ 3X+?!R_\ $'Q7
M^+UEK]]\*_A;X&^'MYK=G8^$/",]E::O<^$="TB;4K:TFGFFM8+UYHK>6:62
M)$>1R?\ 0%K^&/\ X/@O^2 _L#?]E@^-'_J%^#* /ZA?V:_C?\,/V:_^"4?[
M,_Q\^-'BFS\%?"OX2_L)? #QOXY\3WL<\\>F:%HOP/\ !EQ<&WL[2.:]U/4K
MMQ%8:1I&G6]SJ6L:K=66EZ;;7-]>6\$G\M>@_P#!P-_P6W_X*A>.O&^F?\$;
MO^">G@ZT^#'@W67T.Y^)WQ:%AX@UM+DQS7.GR:[X]\:?$#X5? [PIK=_I'D:
MS=_#NVA\<:]I0GLXXO$&K6]Q;S:C^T7[4G[)WQ)_;A_X-OO#O[,GP>C2Z^*'
MC[]@7]D;6/ VE/?IIA\1^(?A?X?^"OQ:L?"$5],/LUO<^,G\"GPK:-?26VG-
M<ZQ%'J-[8V+W%Y!_-I_P01_X+[_LN?\ !*W]EOQ=^P1^WG\)_CA\%?B3\+?B
MUX\\2V^K:5\+[R]O]2D\676F7&J^&/B3X1U*]T/QMX4^(/AS4([BRB%[H-QI
MUUX9M--M;F[TK4=,BM=3 .D_X*0?LN?\',GC7]@O]IKXU?\ !1']N#X/>!/V
M=_A]\+Y?$?C3]G?X</X*T_7?'-I+?Z19)X*U1?@_\*O#WAW5;&[U2XM&NG\1
M_%+Q'"MXR1Z=87T)ACB_9/\ X,]/^4/UM_V<_P#&[_TB\#5^6?\ P51_X*Y_
M'C_@N+^S%\;OV3/^"3O[*/QV\2_LY>&?#6J_$W]JW]I[XB>'K'P9H%_X)^#.
MGM\5U^&'@R/[?J5E::OXFU?PUHEW9:=J'B"S^(7B^;3O^$9TWP&OA_4-:UM?
MT&_X,S/B9X:\4_\ !+GXC_#JRU*UD\5_"S]JWX@KXAT5?EOK/1_&W@OX=Z_X
M:UB>/S9-]CK%Q#XCT^RN=L DN?#VIV_D$V9N+@ _/W_@XL\*Z[_P3'_X++_\
M$_\ _@LE\.=*NXO"7C?7_#?A[XW#2(<S:MXB^%EO;^#?'6EW<Z&)8KOXI_LR
M^)/^$,T6)Q(S/X'UN]=W"K"OL7_!W7^U+KGQE\+_ + W_!,[]G._A\9>,OVQ
M?B%X0^,,VGZ%=A_^$K\/:KJ\/PY_9XTB&:,21WN@_$3Q_P")_$.M6\JJ!'?_
M  \TBY5G1F6OW8_X.#OV(C^W?_P2M_:/^'6AZ2-6^)WPJT9/VB_@Y"D/VB^?
MQY\'K/4M9O='TJ$(S2ZOXU^'MUXZ^'^EH'B7[?XLMWEE6*-P?XX/^#9?X<_%
MK_@IE_P5&\ _M6?M W)\6>!O^":7[+/PF^'G@N6Y@GGTVSUCPGX)G^#O[//A
MR;[3)<2/J-KI]E\1?BU-J+70D?QKX9^WK;K%>^5" ?VM?'7]G[3?V(O^"&O[
M1/[.OP=>1#^SM_P3*_: \&^%=5TZ)[2_UKQ=X3_9O\;/=>+S';O')'KGBSQE
M'>^*K]X'B9M8U:YEB\HLH7^"3_@WP^"__!<OQY\%_P!H+Q+_ ,$COVG/V?O@
M;X,7XH>'-#^,^@_$W0OA?J_BS6/$^F^%!?\ A35XW\>_L]?&"]@\.C2M:U6R
MTQ+#6],M7U*WUTR:4)0;NY_U,/$OAS0_&/ASQ!X1\3Z9;:UX:\5:)JOASQ#H
M]XK-9ZMH>N6$^F:MIEVJ,CM;7]A=7%K.J.C&*5PK*2"/\W?X;>-/VIO^#2C_
M (*)?&G1/&OP=^(GQL_X)K?M(:Y86N@>*M+,:0^(_".F:MJ.H^ /$_AKQ3+$
MGA:T^/\ \+M"U?Q%X6\7?#WQ)>>%8/'5M+=:@SZ3H-]X)\7Z8 ?K-_PS3_P>
MC_\ 20G]D#_PBOV<O_H'J]._X-ZO^",?_!0[_@FO^UW^U#\<_P!KOQ+\!M<\
M*?M#_"V^M=4?X3^+]1U;5;WXK/\ $[1/&%KJ=QX=_P"%=^"=!T?16TV_\<DI
MI'DVMC<W=E8V&E0V;C[-YC^U)_P>2_L@?\*6U/2_V'/@_P#'[XF_M0>-]+&A
M_#70?B5X T+PSX.\'^+==:?2]+O?%:Z-XT\4ZOXNU+2;Z2RO]/\ !O@ZPU&U
M\63R6^C/XJT1IY[B#ZZ_X-F/V./^"A/P6^!_Q._:1_X*(_&#]HS5_'7[0\^B
M2_##]G_XV_%+XEZ_-\*/!.G7.I7VJ>+?$WPW\6:Q<:+X+^(/Q%U"XTUH=+.D
MV_B+PMX0T'3K&].DW/B#6= L0#^H.OG_ /:R_P"36/VE_P#LW_XR_P#JNO$=
M?0%?/_[67_)K'[2__9O_ ,9?_5=>(Z /XH_^#&O_ )%7_@I7_P!C!^R9_P"F
M[]HRO[W*_@C_ .#&O_D5?^"E?_8P?LF?^F[]HRO[W* /D#_@H3_R8+^W#_V:
M!^TM_P"J8\:U_+)_P9'^'M/MOV*_VQ?%<4,2ZKK7[46B^'KVX$0$TNG^&?A/
MX6U+3(9)MQ,D4%SXMU=X8BBB)[F=@S><0G]3?_!0G_DP7]N'_LT#]I;_ -4Q
MXUK^8'_@R7_Y,%_:O_[._N/_ %3'PNH ]?\ ^#S[4M=L?^"4/PNM=(DN4T_6
M?VX/A'IOBA8&D$4VA1?!W]H76+>.]".JM;#Q-I7AV5%F$D?VR*T8()EB=/S!
M_P"";/[.7_!TY?\ ["7[,.I_L0?MO?LG>!?V4M9^%^F:Y\%O!VK>%?@9?:UX
M;\,:Y>7^KW.D:_=^(OV0O&&MS^(K/7;W5XO$#ZGXIU^Z&M"^5]5O !,W]A7_
M  57_8(\-_\ !2S]A7XX_LFZU?P:%X@\8Z);^(/A;XLN Y@\(?%SP;=)K_P_
MUN]$22RMHDVLVJ:#XJB@B>ZN/"6M:];6)AOIK:XA_BS_ ."4O_!=/XJ?\$,]
M%UK_ ()A?\%8_P!G#XZ:#X;^$7B#Q+<_"?Q7X:T;2=5\:>!]*U[7IM1O?#(T
M;7];\.:#\1_@[?Z]<^(O%7@OXD>"O%VL-;Q:I-I.CV/B;PW<:,_AD ^P/C__
M ,$[?^#NS]J3X-?$+]GWX\?MM?L=^/?A#\5- E\,>//"$VA?!/P^FNZ)+<V]
MXUJ-<\*?L::%XDTJ5+JTMKB"_P!$UC3=0MIH(Y+>[B=<U^E?_!//]@/]KG_@
MFS_P0;_;9_9>^.]_\/=5^,&E?#O]M/Q?\+S\+?$VL^*-"BT3QA\"WO/#5I)J
M6H>'O"U_#K!\>P^)IYK2WL66*WN+*:&\>:=XX/QP_P""H7_!QOXX_P""G7A'
M3O\ @GS_ ,$7OA!^T[KOQ*^,.N:,GC#XM:7H=WX.^)$/AWP]XBT_5DTOX66'
M@SQ%J>O>%-'U+4+/2;CQQ\4_&&K^#['PSX275=*OM.@LM7O-?TG^N3_@F1^R
M)\6OV7/V!/A3^SG^U9\8/&_[1_QFN/#&NW'QP\:?$'XD^-OB>;S6_'$UW-J?
M@;PWXD\::G>:S%X&\&:%=67@G0K:Q;3+"YATFYU^#3K*]UN\W '\V/\ P9%V
MWA]/V0OVT[RV(_X2J?\ :0\(6VLCY,CP_:?#'3Y?#).#YF#J-[XMQN&S(.PE
MO,Q_;3))'#')++(D442-)++(RI''&BEGDD=B%1$4%F9B%5022 ":_P WKX3>
M/OV@?^#2S_@HY\>O#GQ-^"_Q5^,'_!,[]IK5[2#P=XU\,+;22ZEX?T?4=0UK
MX>^(/#&LZI=6_A&\^-'PST/6_$G@7QO\/?$VN>"+KQE;R'Q.E]IN@GPGJ<OW
M_P#\% _^#L#X%_M#?LZ^*_V8_P#@F9\'/VD/BE^U+^TMX8U/X3>%KG6_AQ!I
M<G@,>/=,FT+5KCPWX;\,^(/%WBOQY\3X=.U"\L_"&A^']*;1+?6VAUZYUW4+
M?28]!UT _9#_ (.2?&T6K_\ !"3]N7Q-\,_$>G>(;34?#WP0L$UKPIJUKJ^G
MW?A_6_VF/@GI7B=8=1TFZFMI[2?PMJ.J)>>7.\3V,TOFK) [(_\ *)_P1#^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXUU&2&'3_!_PQ_:3^#7CWQ3?2W$JP016?A_PKXTU;5KJ2>9EAA2"T=I)66-
MSD @'UW7PS\)?^"E7[#WQU_:=^(_[&?PG_: \/>,OVFOA%/XXMOB-\*++P]X
MZLM7\+S_  V\0VGA3QO'=:OJ_A;3_#%T= \07UIIMP=-UR]6XEF66Q-U;J\R
M_<U?Y\?_  1C_P"5L[_@J/\ ]C!_P4!_]:7\&T ?Z#E%%<KXV\=>"/AIX6U?
MQS\1_&/A7X?^"O#\,-QKWC#QMXATCPIX6T2WN+NWL+>?5_$&NWEAI.FPSWUU
M:V<,M[=PI+=W-O;HS331HP!U5%>#:S^U3^S!X<^$MG\?/$/[1_P%T+X%:C-=
M6^G_ !IUGXP?#W2_A+?7%CJ5]HU[!9_$:^\10>#KJ:TU?2]3TJZB@UEWM]2T
MZ^L952ZM+B*.G\$_VN?V4?VEKC5;3]G+]IW]GGX_W6APBXUNV^"?QI^&_P 5
M;C1[<O%$)]5A\"^)=>DT^$R3P1B6[6%"\T2;MTB @'T+117@>B?M6_LN>)?#
M/Q!\:^'/VDO@'X@\&_"6VCO/BKXMT3XQ?#S5?#/PRLYOMYBNOB#KUAXBN-*\
M&6THTO4S'/XCN]-B?^SK_:Y^R7'E@'OE%>%?!']J/]F7]IBSUG4/V</VBO@3
M^T#8>')K>W\0WWP1^+GP_P#BM9Z#<7:NUK!K-SX$\0:]#I<URL<C6\5\\#S+
M&YC5@C$;_P 7OCO\#_V??#2^-/CW\9?A3\$?!SW'V1/%GQ>^(?A'X:^&FNMH
M;[,NN^,]8T72VN-I#>2+HR;2#MP<T >K45\T?!C]M+]CG]H_6;SPY^SQ^UE^
MS1\>?$.G6YN]0T'X,?'?X6_%'6;"U"LYN;S2_ _BK7;ZUMPB.QFG@2,*K,6P
MI(^EZ "BBB@ HHHH **** "BBB@ HHHH **** "OQ/\ VN?^3A?B#_W*G_J$
M>&J_;"OQ/_:Y_P"3A?B#_P!RI_ZA'AJON?#_ /Y'.)_[%E;_ -2L$?@_TAO^
M2+RO_LJ,%_ZJ<[/VPHHHKX8_> HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU-^GM=MJ?]D[;H0"PMS* ?T'4444 %%%% !1110 4444 %%%% !7XG_M<_\
M)POQ!_[E3_U"/#5?MA7XG_M<_P#)POQ!_P"Y4_\ 4(\-5]SX?_\ (YQ/_8LK
M?^I6"/P?Z0W_ "1>5_\ 948+_P!5.=G[84445\,?O 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG^SG^RK\'=1\*:O\*/@WXST'4=!N/%GA_P"''B6;Q-X#^$7A/P-XJ-CXRN/
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MU:_X(]>%?$_@?_@EE_P3_P#!_C7PYKWA#Q;X:_92^#6C>(_"WBC1]0\/^(]
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MMI,_AWP_>ZUI/B/QCIFE?V/IWA7POKWA*U\6:9I&M^(OB:DVEV/AFZ_O2HH
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M0OB#H?C7P==:%XUB\.+8Z-_;.F:-X4\::9_H]44 ?Y_G[8'_  7E_P""D/\
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M\.)KN:6:;1/#'Q8\.R^(]2\*6F^5DBTFP\6Z)XA\16D*1H4O?%FI@N\1AC@
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M5+[W_D?T#T5_/Q_Q$A_L._\ 1*_VK?\ PA_A#_\ /SH_XB0_V'?^B5_M6_\
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MW_HE?[5O_A#_  A_^?G1_8>;?] %?[H__)!_:F7_ /052^]_Y'] ]%?S\?\
M$2'^P[_T2O\ :M_\(?X0_P#S\Z/^(D/]AW_HE?[5O_A#_"'_ .?G1_8>;?\
M0!7^Z/\ \D']J9?_ -!5+[W_ )'] ]%?S\?\1(?[#O\ T2O]JW_PA_A#_P#/
MSH_XB0_V'?\ HE?[5O\ X0_PA_\ GYT?V'FW_0!7^Z/_ ,D']J9?_P!!5+[W
M_D?T#T5_/Q_Q$A_L._\ 1*_VK?\ PA_A#_\ /SH_XB0_V'?^B5_M6_\ A#_"
M'_Y^=']AYM_T 5_NC_\ )!_:F7_]!5+[W_D?T#T5_/Q_Q$A_L._]$K_:M_\
M"'^$/_S\Z/\ B)#_ &'?^B5_M6_^$/\ "'_Y^=']AYM_T 5_NC_\D']J9?\
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MFW_0!7^Z/_R0?VIE_P#T%4OO?^1_0/17\_'_ !$A_L._]$K_ &K?_"'^$/\
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M'^SM\/\ X2^&M0T2\\5V&K:!';S?&+PA<Z)>K=Z?,DR+J4%NL=_)%<)^X?\
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MB%[Q_ UI=V=E;1;Y7T\2P0QLO3_0BK^47_@O?_P0\_:"_:M^-OPC_P""DO\
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M"UKIW@\7/@KPAX5U;6;73M7UZ;6K6+PH ?"O_!\7_P DK_X)V_\ 90/VCO\
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MR:/:_$OP/KG@RXU2.W$D)N'T^+6GNUA$T1E:$1B1-VX?P)?\$O?@#_P<B?\
M!'3XQ:O^RC\+OV/=(^)G[-/C?]HSPQXL^)?B:33?!WC+P3JGAU+K0?#7B_XB
M?#?XAV'Q#\*7GA^7Q5\,_#VGR0:7XPC?5-)N-.TFUOO!ND^)?[2TNZ /4O\
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MJ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *_H'_ .#;S_D^+XJ?]FI>./\ U;WP
M,K^?BOZ!_P#@V\_Y/B^*G_9J7CC_ -6]\#*\K//^13C_ /KP_P#TJ)WY7_R,
M,)_U]7Y,_MAHHHK\D/T$**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#\E_A5_P GQZI_V4CXR?\ IO\
M'-?K17Y+_"K_ )/CU3_LI'QD_P#3?XYK]:*^OXR_WS*O^Q%@?_3N*/QOP5_Y
M$O%?_9>9[_ZB94%%%%?('[(%%%% !1110 4444 %%%% !1110 4444 %%%%
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M/$'A3Q1ID-]97-SHVMZ?9W,NGW^FZQ8B\T;5-,U&\_+/_@IC^W1_P25_9O\
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M2O$OC=K=0^H&^T.4?#7XWVQA <V-C?74-A\4&AE=9$T#1-/E6>=9$%S\2_\
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M?A^+?3?!'P$\#Z=XFUS0M.<BQT_7]?TN#1? _A^:W9V:.7PE\/=-@O-/./\
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M+GQ3:V%I:W\@LK^[M=$U;2=274=<CUBQT_3;[3/#FD:996VG7)F]F_X)3?\
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M=MFTS0XI(-.A&FZ'9V-@KPQRN'F6 2RDYD=B!C^CK]G_ /Y5QOC9_P!U(_\
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MD[-&5X1_;*^%W_!0_P#;Y^#OQ:_X*(ZSX ^%WP<^%_P_CL9O!]M9>+;OX?\
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MKVWU+2-;T36/%'[)6H:5J^E:C:22VE_INI6%Q;WEC>VLLMO=6LT4\,CQR*Q
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M[WBRM_PUS^SU_P!%!_\ +4\;_P#S-4?\-<_L]?\ 10?_ "U/&_\ \S5>;_\
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M,'?"'_H8_B1_X-_#'_S'T?\ #!WPA_Z&/XD?^#?PQ_\ ,?1]7X(_Z#<]_P#
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MP1-*7:.&)"$7]@ZKC94UF&7*DY.DLEP:IN=N=T_;XOD<K)+F<;.5DE>^B,?
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MDB@O/#.IZ)H-CJGAS7M.FE.H:7XAT>[M-:T_5E75+:]2^!G/\=/_  2) /\
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M*TKXL>'++4=<T:?Q-X#4Z-HL<.N^*K?Q;=V?A[1-/L=3@\67-C#;748^$_\
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MA)XNM-1,UI)E+J,6DLQ>W;Y95!C/WJ^JZ_FO_P"#G;_@II\./V*/^">GQ8^
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M ,$\? /C^TT_2[6XO;^['P@U_P ._%RX@MK2T26XN'>U\#S@Q11N63<"I7-
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MPN^'?[/^H74_B<:#=WOPX\3OH.BWM[#/'I.@_$8_%32=*N=(>.YFL]#U&_\
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M*R,\7C)XOV*E3A35&#IQ5--1Y;W22=[**M%*[T5VVPK^G#XP_'SX%:G_ ,$
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M;XG>%#\(/A]I@\3?#WQ;H'C3P\=2LKCQ$UYIXUKPWJ&I::;ZT$\)N;3[3Y\
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M'@;QW\.[F.^\&K;&SO;H^&_B+XEB2Y>Y5DO);.["[[1%8 ZK_@HU^P=\)?\
M@I)^R)\5OV4/B]!';:=XWTO^T/!/C&.SCO-7^&7Q0T2.>Y\"_$70E9X93>>'
M]5D\O4[&&ZLQXB\+W_B#PI>74>F:]?AO\M+XR?&C]K#P3\5?V _^"4W[8>A7
M4'Q#_P""97[:^J^$?"'B&\O[F^GF^&OQ2\;_  ,NO#GA2SN;RWAN-7\%Z,O@
MQO$WPM\2[S#J7PW\<>'=)L;33]&\/:/'-_L(5^3_ .V?_P $5_V"OV\OVB?A
M9^U5\>/A_P")_P#A=WPD@\-6NA>+O OC"^\'-KMKX-\2CQ7X4@\9V5C!-:^)
M#H&J/=1:?=7*1WPTR\DTJ>ZFL+;3H+$ \Y_X+]_\$\-?_P""E7_!-CXK?!?X
M=Z=;ZI\;OA[K&A_';X$Z?<3+;C6/B)\/K;5[6Z\*PSR%(8]0\<> ?$/C;P5H
MCW<]MIT'B'7]'N]3NK:QM9YX_@;_ (( ?\%POV??CA^R_P##']C;]JSXC>&?
MV>_VV/V7O"ME\$?%'@7XP7*_#%_B%H?PMBB\'>'-?T"Z\8/IEA-XZM= TRPT
MGXB^!IKRW\767BS2/$&MP^'K?P_=0BR_J?K\=OV^/^"#G_!-#_@HUXGN_B-\
M>_@:^A?&+4!"NJ?&CX/Z_=?#;XB:ZEM9+I]N?%4^G0W?ACQI<VUI#9V]IJ7C
M+PQK^K65KI]G86=_!I\;VD@!]._MA_\ !2[]B']A/X8:Y\4_VCOVA?AYX5T_
M2]*BU+2O!VE>(](\2?$[QQ+>Q-)H^E^ _A[I%]/XD\2WNLL%6TNK:SCT2S@:
M35=;U?2=#M+[5+7^7;_@W0^#WQL_;^_X*,?MG?\ !>WX_>")?!/A+XKW/BOX
M:?LV:+?K(K7:W;>&O"MQJ&A3O:VCZWHWPG^$W@G0/A"WBU(XM-\4^(=7\6""
M%=3\/:G!I_Z+_ 7_ (-,/^"/'P2\56?BS7?AW\8/V@KC3;B6[L-$^/7Q4?6/
M"L5RUP9[=KWPW\.O#WPSTS7K>R0_98M-\2PZSI5U;@'5+'4+C-P?Z1/#?AOP
M[X.\/Z'X2\(Z#HOA7PKX9TG3]!\-^&?#>EV.A^'_  _H6DVL5CI6BZ'HVF06
MNFZ3I.F6,$%GI^G6%M;V=E:PQ6]M#'#&B  VJ*** "BBB@ HHHH **** "BB
MB@ HHHH _)?X5?\ )\>J?]E(^,G_ *;_ !S7ZT5^2_PJ_P"3X]4_[*1\9/\
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MKVHZ_P"(M:_2BB@#^6+XI?\ !&W]KCQE_P ''OPY_P""K&D:E\'U_9B\*_\
M"(?VG87GC+6X?BDW]A_LV:A\)[W[+X43PA-I$N?%%U%)!O\ %,7F:4&NVV3
M6I_J=HHH *_$_P#:Y_Y.%^(/_<J?^H1X:K]L*_$_]KG_ ).%^(/_ '*G_J$>
M&J^Y\/\ _D<XG_L65O\ U*P1^#_2&_Y(O*_^RHP7_JISL_A'HHHK[<^H"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT4?ZXXG_ * Z'_@RH'^KE#_H)J_^ 0/\T3_A@_\ ;B_Z,T_:M_\ $=_B]_\
M,?1_PP?^W%_T9I^U;_XCO\7O_F/K_2[HH_UQQ/\ T!T/_!E0/]7*'_035_\
M ('^:)_PP?\ MQ?]&:?M6_\ B._Q>_\ F/H_X8/_ &XO^C-/VK?_ !'?XO?_
M #'U_I=T4?ZXXG_H#H?^#*@?ZN4/^@FK_P" 0/\ -$_X8/\ VXO^C-/VK?\
MQ'?XO?\ S'T?\,'_ +<7_1FG[5O_ (CO\7O_ )CZ_P!+NBC_ %QQ/_0'0_\
M!E0/]7*'_035_P# ('^:)_PP?^W%_P!&:?M6_P#B._Q>_P#F/H_X8/\ VXO^
MC-/VK?\ Q'?XO?\ S'U_I=T4?ZXXG_H#H?\ @RH'^KE#_H)J_P#@$#_-$_X8
M/_;B_P"C-/VK?_$=_B]_\Q]'_#!_[<7_ $9I^U;_ .([_%[_ .8^O]+NBC_7
M'$_] =#_ ,&5 _U<H?\ 035_\ @?YHG_  P?^W%_T9I^U;_XCO\ %[_YCZ/^
M&#_VXO\ HS3]JW_Q'?XO?_,?7^EW11_KCB?^@.A_X,J!_JY0_P"@FK_X! _S
M1/\ A@_]N+_HS3]JW_Q'?XO?_,?1_P ,'_MQ?]&:?M6_^([_ !>_^8^O]+NB
MC_7'$_\ 0'0_\&5 _P!7*'_035_\ @?YHG_#!_[<7_1FG[5O_B._Q>_^8^C_
M (8/_;B_Z,T_:M_\1W^+W_S'U_I=T4?ZXXG_ * Z'_@RH'^KE#_H)J_^ 0/\
MT3_A@_\ ;B_Z,T_:M_\ $=_B]_\ ,?1_PP?^W%_T9I^U;_XCO\7O_F/K_2[H
MH_UQQ/\ T!T/_!E0/]7*'_035_\  ('^:)_PP?\ MQ?]&:?M6_\ B._Q>_\
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MXO\ HS3]JW_Q'?XO?_,?7^EW11_KCB?^@.A_X,J!_JY0_P"@FK_X! _S1/\
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MC\8^!]-UF6^MH!KO_"&ZWI6DO>66H:]<:7X<;4-?TS]%?@G^V]_P17_X(_\
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M=-97=Y:6%U<R:=;?I%_P<<?LA_$+XO\ _!(7]J;P+^R5\-=._P"$LO\ QO\
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ME:IK6KZOI&IQ>%='\3OIVNQ:']:_L9?M/^,OVQ/^#:"^^._Q%U>[U_X@ZO\
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MP_+K&D>+FTRT$CL(K4:_XKU[4%AC"1K+J$Q5 68D _I[KY4_;/\ VU?V<OV
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MB1X.^'<4=OX@N])UVWTXV$WB^/59&DTJ[%Q%8O:*L3SK/%R7_!+7]O\ T?\
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M_P""MOBG]DS_ (+&?M^?MWZ7^Q7\8/C1K?[3'_#5']H_LZ^$-5U&U\??"?\
MX7-^U)X$^,=W_P )1?6_P^\07=S_ ,()=^&X_ VM^?X4T3SM:U6VFE_LV55T
MV;^FG_@Z%^,]Y^T9_P $ ?V9?C]J'@/6_A=??&CXR?LM_%"\^&WB6:6X\0^
MKGQQ\(OB9XCF\(ZW//INC33:KX?DU!M+OY9=)TR1[FVD9[&U8F%/C7_@@7_R
MM-?\%J/^\C?_ *\4^#=?I_\ \'DG_*(_PY_V=_\ !K_U"?B_0!\-_L[?\',W
M[//[$_[ _P"P)^R=^SW\ /B=^W=^TWX(_9(^#%I\1O _PLU63PQX-\!ZG8>!
M]&EU?PSJOC:R\(?$;6]4\7:%!)O\0:7X9\ :WI7AZZ671M>U_3-?L]3TJP^M
M/V(_^#N7]G;X]_M":+^S;^U_^RW\0OV#_&7B[Q-I?@_PQXC\4^/H_B3X'T[Q
M%KALX-$T_P")]]JOPZ^$'B?X;QZO?WD%C:ZO<>$M=\/6 N+74O$FLZ!HK7FI
MV/V__P &S'['?PE_9E_X)0_LV?$#PIX-T6S^*W[3'@T?&GXN?$(Z9;KXK\72
M^*]8U6^\%Z-?:N\;:A_PC?A#P6^A:5H6AQW"Z/;W0U;7X+./5?$6L7=Y^*O_
M  >Y_!#X=#X1_L6?M%V_AW3;+XJQ_$[QO\'M2\46EG#;ZIK_ ('U/PB/%]AI
M&N7D0274K?PWK/AZXN/#T=WYW]EGQ%KXLV@74KI9@#^[BOY?_P!OG_@Z>_8S
M_9/^,FH_LV_L[?##XD?MW?'G0-:U7PSXG\/_  =NX]"\":%XLT6XEMM4\'Q>
M.Y]#\4:CXM\2:>]M=G4$\ ^"_%FA6#VMS976OQZI:7VGVGT'_P %$?VTOB1\
M!O\ @W;\5?M;:#KVHV/Q?\5_L2_L\6FE>*8;H?V]IOCG]I'2_A7\-KGQ;87D
MC*W]N^'[KXEWOBJUO1NFAO-+%XJ.\01OSR_X,]_V"_A)\,?V#5_;LO\ PMIF
ML_';]I;QC\0=$T;QOJVCV$^K>"_A/\-?%^K_  [3PCX.U.:*:^TNR\2>+O#/
MB36_%UQ87%H/$$L'A_3]1@FB\+Z?*P!SOPS_ .#P3X?>&OBUI/PT_;__ ."=
M?[1?[#&G:W+;1P^*=2\0:Q\2KO1K:Y,8.N>)/ WB;X/?!#QE'X>M/.BEO+KP
MGIOC+5OL[K)9:'>RLD#_ ->_PX^(_@+XP> O!_Q2^%WB[0/'WPZ\?^'M+\5^
M"_&?A;4K?5_#WB7PYK5K'>Z9J^DZC:O)!<VEW;2HZ,K!T;=%*D<T<D:_"_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R7^%7_)\>J?
M]E(^,G_IO\<U^M%?DO\ "K_D^/5/^RD?&3_TW^.:_6BOK^,O]\RK_L18'_T[
MBC\;\%?^1+Q7_P!EYGO_ *B94%%%%?('[(%?QJ?\'E'[:WQY_9W_ &5OV;OV
M<O@_K^L>"_"?[77B3XO6GQE\5>'YIK'5M1\%_"73_AO+;?#-M7@*SZ?HOCN_
M^(IU#Q!#92VUWK>E^#YM!N9Y?#^IZ_INH_V5U^9__!5+_@EK\ /^"LG[-S_
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M:]VVBZ9XMU7X6PZ]X.^, TC[7<#3K[Q)\./#+6,5[=11V4DCW%S>^V?LR_\
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MCPIX1_L6;3K_ ,3^*9+R82>&WOOMJ7ENA2[2#[-NA,L@!]+?\%1_^"F'PO\
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M1\,^/K72[6T\>^#?$45K-.MCXB\+>*HM3TG5+5G*M) EY:O/87=I<S_SU_\
M!X;^U[\/_A+_ ,$U[?\ 91EUZWF^*_[5_P 2/ @TSPC:7=N=2M_AM\)/%ND_
M$GQ)XQU:S\W[1#H<7BOPYX-\.V$CQC^T-7U5C9F9-&U0VORNO_!KO_P4,_8U
M\?\ BO4?^"37_!67QC\#OA;XWU%]0U7P#\0=8^(?@>]@$,,EMIJ^)KCX7P^(
MO WQ1U?3;9WM[#Q/J?PZ\(:CI]O/+!9VR'S9KKZ+_8Z_X-7[*#]HO3OVO_\
M@JW^USXS_P""A?QFTG4=,UC3_!_B*7Q7?>!+S5?#TD+>&G^(/B_Q]XAUWQK\
M2?#FA"&$Z3X#^P^"_"-O%:VVD:MI_B'PR;G0K@ ^J_V!/@)XK_9K_P"#7NU^
M&'CC39-'\5S_ /!.[]K#XH:MIES;R6FH:>OQU\.?&GXW:3IVKVLX6YM=8TW0
MOB%I>FZI9W:QW5A>VDUC/# ]L8(_@W_@R7_Y,%_:O_[._N/_ %3'PNK^M?\
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MN'QG^W1^PW^V?=?LI^/OBMK%]XP\?:)=Z;XUL=1T3XAZQ;26WBKQ?\/OB/\
M#[Q-IGB+3[/QSYTEWKGAB[TQ/L.JW.LW=KXAN]+UJWT#0_T#_;8_X(N_&?\
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MP/\ ^&/_ (KW=UJ+D6\\G@ZXLM3\9^+].@EDU*P\-Z[IMT+%H]6TE+S^OO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'7@+P06N-%TA])LM-\4ZGJNF/-;ZWJ.I>)-!\+V?]3?_  4"_:3_ &HOA?\
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M_'K_ (6C/X->T.K+/!H+?M#Q^-Y3-I"F>W\21_!QM,EWPS1Z3*)8K>3]RO\
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M_P"I6"/P?Z0W_)%Y7_V5&"_]5.=G[84445\,?O 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'Y+_"K_ )/CU3_LI'QD_P#3?XYK
M]:*_)?X5?\GQZI_V4CXR?^F_QS7ZT5]?QE_OF5?]B+ _^G<4?C?@K_R)>*_^
MR\SW_P!1,J"BBBOD#]D"BBB@ KY _P""A/\ R8+^W#_V:!^TM_ZICQK7U_7R
M!_P4)_Y,%_;A_P"S0/VEO_5,>-: /Y#_ /@R4_9A\#0_!C]KO]LJ_P!#@O?B
M/JWQ5TW]FSPUX@NDBEF\.^$/"G@[PE\2_%VFZ,?+$MJ?%6J^._",VO2-)(+J
M/PIH,<*P""[^U?UQ_P#!1#]G;P-^U?\ L._M3? +XA:#:>(-!^('P2\?VEG;
MW2Q^9IGBS2_#U[KG@?Q+ILTD<JVFL^%?&&FZ)XBT>\,<BV^HZ;;O+%-#YD,G
M\8/_  99_MR_"/PAI/[2G[!?CWQ?H?A'XC>/OB)HOQU^"6F:YJ":>_Q)N;CP
MA9^#?B1X9\/27<D5G=^)O#NG^#?!FN6N@6SOK6M:->Z]J5E:W%CX6U66S_J:
M_P""V?\ P4#^$W_!/;_@GY\?/'WC;Q3HUI\3/B'\-O&WPR^ ?@"35[:T\5>/
M_B7XPT.7PSITN@Z86:_O-&\$/KUOXO\ &FI6\/V;2= TV1)+F+4M1TBVO0#^
M?W_@R3^.?C/Q=^RW^V9^S_K=_=7WA#X*?&#X:^.O!$=U<O<+HY^-WAOQ?:^)
M=%TZ.0$V6EC4_A1#KRVD+BV;5O$&L7RPI<WMW+<?(G[5UB/^"+/_  =2?"/]
MI&TQX;_9K_;QUFVUOQE<A19^'[/2_P!H;4)?AS\;EUB[5H49/!'QJM],^/>I
M00J#::;>>'X_)NMWE3_J7_P9T_LC^.?@-_P3M^(GQY\?Z(^@3_M<?%N+QEX!
MM;J*6#4M0^$_P]T,>$O#'B&\AF2.2WMM>\47/CN]T-#&4OO#YTO7K::>RUJU
M8=C_ ,'=W[$;_M(_\$V;/]HWPMI7VSXD?L3^.(?B)YUO"9=1G^#GCU],\'?%
M?3;0(H=(].OD\ _$'4;EY5CM-%\ ZLXC>25"@![%_P '57[:A_9._P""4OQ%
M^'_AW5CI_P 2?VP=?T_]G/PW';7 COX/!&LVUSX@^,FJM;[E>?2+GX>Z/J/@
M'49$;_1KSXAZ0S*ROM/U3_P;Z_L2_P##"?\ P2L_9K^'&M:1_9'Q,^*&@G]H
MCXQ12P?9[]/'WQBM-/UZVT?5H2H,>K>"O 4/@GX?:BFZ1?M?A*9TD9'%?QBV
MW[0.L_\ !QC_ ,%&/^"*O[-^LM?^(_AW^SW^SCX&\0_M8Q7\5V]K=^//!MPW
MB7]J/5;Z2>%/(L/BCI/PQ^&?@O2+DQWJP:SXKLQ]KNH[C*?Z;X 4!5 55 "J
M    ,  #@ #@ < 4 +7\@7_!ZM_RBR^ ?_9__P +/_6=?VJJ_K]K^13_ (/2
M--EO_P#@E1\'+J,L$T7]NWX3ZE/MB:0&*7X&?M*Z.H=U($*^?JT)$KY4N%A
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MGM+N"&ZM;J&6WN;:XB2>WN+>=&BF@GAE5HYH9HV:.6*1621&9'4J2#_GO_\
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M$?\ *W!_P4^_[O4_]7;\-* /[_**** /\Z/_ (-A?^5AW_@IO_V1_P#;0_\
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M#_B3X;7#*D>I:%\2O#^L7UGJ7@S5]&OF>PNUUF"VLKLK%J&D7FHZ1>Z?J%V
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M1_#R)%X5UCQ7XCU+PM;^%-)O;2RO=9T;3O$.I(5LM-A6] /WJ_X-ZKFXN_\
M@B__ ,$_9;F5YI$^#%W;*[G+"WLO'OC&SM8@?[D%K!#!&/X8XU':OY>O^#*'
M_DOW_!3C_L7_ (%?^II\:*_IV_X-V;J"\_X(K_L S6TGF1I\)]?M6;:Z8GL?
MBAX]LKJ/$BJQ\JZMYHMP!1]F^-GC97;^8G_@RA_Y+]_P4X_[%_X%?^II\:*
M/]!RBBB@ HHHH *_$_\ :Y_Y.%^(/_<J?^H1X:K]L*_$_P#:Y_Y.%^(/_<J?
M^H1X:K[GP_\ ^1SB?^Q96_\ 4K!'X/\ 2&_Y(O*_^RHP7_JISL_;"BBBOAC]
MX"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^2(G\UI/VKHH **** "BBB@ K\3_ -KG_DX7X@_]RI_ZA'AJOVPK\3_VN?\
MDX7X@_\ <J?^H1X:K[GP_P#^1SB?^Q96_P#4K!'X/](;_DB\K_[*C!?^JG.S
M]L****^&/W@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#\E_A5_R?'JG_92/C)_Z;_'-?K17Y+_  J_Y/CU3_LI'QD_]-_CFOUH
MKZ_C+_?,J_[$6!_].XH_&_!7_D2\5_\ 9>9[_P"HF5!1117R!^R!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%?Q[_P#!:G_@XT^)WP*_:!_X
M=O\ _!+/X?Q?&[]L^\UVU\$>,_'=IX9?XDV'P_\ '.J1 0?#3X9> ].-W!X]
M^+6EO*LOBFXU^VOO!_@.YMY?#^JZ#XFUQ/$-KX- /["**_@<\*_\$1?^#F[]
MJ325^*W[2O\ P5E\7_ /QGJJ1>(])^%=I^TO\;FF\->(84>2RBU3PS\!(]%^
M#'@B[A>>2/[;\/+[Q-]B0E8XF*B!?'?BE\?_ /@Y?_X-]-6T;XE?M._$6#]O
MC]CFX\2Z#I'B7Q;XK\9Z]\;?"4JS3I:P:1J/Q-\5Z-I/[0/P8\3ZM88T_2M?
M\365_P##J\\4WUK&;;Q[JD8L+D _T1:*^$?^"<?_  4,^ W_  4Y_9=\)?M1
M? &ZU&UT35[V_P##/C3P/XA:R7QA\,?B%H:6KZ_X'\5PZ?<W5I]MMH+[3M8T
MF_MIC;:YX9UC0]=MTMTU'[+;_CE_P=+?\%/OCY_P3H_8]^%7A_\ 9B\2M\/O
MC!^TW\0O$'@V/XG6D-E<^(/ O@+P9X?M]6\8W7@^._MKJVL?%6L7>N>&M&LO
M$+02W&@:==:M>:3]CU]M'U;30#^GNBOXQO\ @D?_ ,$@O^"SO@?XS_LH?MK_
M +5'_!4WXK>,/ASXACT'XL_%_P#9IU7]H?\ :4\<WOB?P]XA^'.KWOA+PCXY
M_P"$BUD>!?%&M:'K&O:%#X@T34+/4O#NE"VU9="UW5OLEC)?>"?\%_OV_?\
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MP\"?'+5(OA\G@S2;6\CTS6_ 7C_X@V.BV!\1QW[/I5]?V%W)<%[M;-H94F<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5;&4HR3V\DEM<.UK>VLL%[I]VD%]8W%O>6\$\?HE% '^='_P;*^)/&7[ /\
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M7NE0SI9ZI>17'^AFZ)(C1R*KHZLCHZAD=&!5E96!#*P)#*0002",&@#\=?\
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MN)6<^[4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^)_[7/\
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M/(_B)XXM]$@_L;P!/\,K#?X%@UM/!\_E>#[F6P;SM(?S9V%_)NO%$P /8/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,#P_P#\U_U=^5C^S_'/_H><!_\ @G,?_G.>;_\ #>/PA_Z%SXD?^"CPQ_\
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M^5C^S_'/_H><!_\ @G,?_G.>;_\ #>/PA_Z%SXD?^"CPQ_\ -A1_PWC\(?\
MH7/B1_X*/#'_ ,V%>D?\,C?L]?\ 1/O_ "Z_&_\ \TM'_#(W[/7_ $3[_P N
MOQO_ /-+1]8X(_Z L]_\#P__ ,U_U=^5C^S_ !S_ .AYP'_X)S'_ .<YYO\
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MX?\ ^:_ZN_*Q_9_CG_T/. __  3F/_SG/-_^&\?A#_T+GQ(_\%'AC_YL*/\
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M#_\ !.8__.<\W_X;Q^$/_0N?$C_P4>&/_FPH_P"&\?A#_P!"Y\2/_!1X8_\
MFPKTC_AD;]GK_HGW_EU^-_\ YI:/^&1OV>O^B??^77XW_P#FEH^L<$?] 6>_
M^!X?_P":_P"KORL?V?XY_P#0\X#_ /!.8_\ SG/-_P#AO'X0_P#0N?$C_P %
M'AC_ .;"C_AO'X0_]"Y\2/\ P4>&/_FPKTC_ (9&_9Z_Z)]_Y=?C?_YI:/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^ _\
MP<*?\$CK+_@J/^Q[<WGPWTRUM_VN_P!G2'6_B!^SSK<?E6M]XK'V6*Y\7?!>
M^U!S&L=C\1+73+%O#EQ<3VL.C?$#2?"U_/?V.B3>(EO?WXHH _G%_P"#;O\
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M[XW66DOJVI:L^E:DGA/XZ>&M$\>3V^LZEXIL]/L_NC_@W'_X)_?$?5Q\1?\
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M?@G1+;P=KFKP3?\ !17P_-!JFK>'8].O]0AET#0Y8[NXF232--9390@'L?\
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M%% '\P/_  =Y?\H;?&G_ &<!\"?_ $^:K7Z__P#!)W_E%E_P33_[, _8W_\
M6=?AS7IG[:G[$?[.W_!03X'7_P"SI^U#X3U3QI\*=2\2>'O%EWH>C^*O$?@V
M]DUOPM<376C7*ZWX6U'2]6CCMYIY&DMDNQ!<!@LT;J ![7\&_A/X(^ OPA^%
M?P,^&>FW&C_#CX,?#?P/\)_A_I%WJ-]K%WI7@CX=>&-+\'^%--N=6U.>ZU+5
M+BQT'1["UFU'4+FXOKV2)KF[GEN)9)& /Y2O^#U;_E%E\ _^S_\ X6?^LZ_M
M55^UW[&_[>G[#.A?LA_LJZ)K?[9_[)^CZSH_[-_P.TK5](U7]HKX0:?JFE:G
MI_PQ\+VE_INI6%WXQAN[&_L;N&6UO+.ZBBN+:XBDAFC21&4>\?MX?\$]_P!E
MO_@I/\(?#GP,_:W\%:QX[^''A3XD:1\6-$TC1/&?BKP-=VWC?0O#'C#P?INI
M2:MX0U72-2N+>'0?'?B2U?3I[E[&:2\BN98&N+2VDB_)C_B$_P#^")7_ $;E
M\0/_ !(CXX?_ #;T ?K_ /\ #PG]@7_H^']D#_Q);X,?_-K7YK_\'!7Q#_;0
MT#_@EUK_ .T9_P $V?C#XC\-^+_AOXE\"?%_Q/XF^#L.B>,-3\??LW:CHNMZ
M9XJN_"=Y'H_B6WNM$TQ?%/A/XJWGB70);8V_@OP=K&K0ZL=,^T1W/E'_ !"?
M_P#!$K_HW+X@?^)$?'#_ .;>OW\^%GPN\%_!KX4_#GX*^ M,DT_X=_"GX>^$
M/A=X+T:^O;O6);'P7X&\-Z=X3\.Z9>:AJ<MS?:I);:'I=G:W%[J$]Q=WS(\]
MW++-+([ 'Y"?\$N?^"Y?[#G[>W[./PR\0:I^T3\*OAI^T58>!M!M/C9\%_BA
MXW\.^ ?&FB>/-*TVVLO%VJ>';'Q1?:0GC3P1J6JQ2:SHGBCPJVIV4.D:MIEI
MXA30?$8U#0;'\ZO^#G?_ (*'?\$ZM<_X)C_&_P#9J?XU?!/X\_M _$S5? %G
M\(/AA\-?'/A7XB>,O!GC?0?'OA_6I/B'K+^$;W7;GX=6GAWPW8>)(%U#6&TB
M3Q8M[=^!+1KJU\1:JD7V7^T]_P &P_\ P1]_:@\9:W\0M1_9^UOX+>,/$MS=
MWVO:A^SUXZU?X;Z)?ZC>2"674(? $D>O?#;1;GS3)*X\.^#M(M[J:>:>_@NY
MV65>T_8R_P"#<7_@D_\ L0^/-"^*WP^^ FH_$WXJ>%+^UU7PEX]^/GB[4?B=
M>^%M5LL/::OH7A6>+2?AQ9:[97:Q:CI?B(>"GU_1-2@@O=#U/39X48 'NG_!
M#/X&_%;]G#_@DO\ L._!_P"-MAJ.C_$SP]\(I=9\0:!K*30ZSX8MO'WC'Q1\
M0_#?A+6K.Y5+G3=9\)^%O%6B>'-6TBX1)]'U#2[G2YD22T91^K]%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%?-_[7/\ R;U\0?\ N5/_ %-_#5=6"PWUS&83"<_L_K6*
MP^&]IR\_L_;U84N?DYH\W+S<W+S1YK6YE>Z\O/,R_L;)<XSCV/UG^RLKS#,O
MJ_M/8_6/J.$K8KV/MO9U?9>U]E[/VGLJG)S<WLYVY7](45\3_L'?\DA\1_\
M92-8_P#48\'U]L5KF>"_L['XK ^U]M]6JNG[7D]GSV2=^3GGR[[<\O4Y>%\[
M_P!9.'\JSWZK]2_M/"QQ/U7VWUCV'-*4>3V_LJ'M+<M^;V-/>W+H%%%%<![P
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\W_ +7/_)O7Q!_[E3_U-_#5?2%?-_[7/_)O
M7Q!_[E3_ -3?PU7IY+_R.<I_[&> _P#4JD?+\<?\D7Q?_P!DOQ!_ZJ<6>;_L
M'?\ )(?$?_92-8_]1CP?7VQ7Q/\ L'?\DA\1_P#92-8_]1CP?7VQ75Q-_P C
M[-/^PE_^D0/+\,/^2 X5_P"Q73_].U0HHHKPC[P**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \\\4_$WPQX(\0Z#H7BVY.A6_B>*9-#\07I5-#GU2UD5;G1[V]SLTN\\F:
MVN;.6^\JSO4>>..X2>V\J7S']K<AOV>?B RD%2/"9!!!!!\;^&B""."".01P
M177?'CX9Q?%?X::]X92.,ZS#'_:_AJ9]H,.O:<DCV:"1N(H]0C>?2[B0@^7;
M7TL@!=%(_'Y/C'\0+/X>>(OA%JM]+J/AC41I]LECK"RRW_AR?1M;T_51#IEQ
M(RW%M"9M,6UFTVY\ZT@5Y&MH+:?S&?[7AO):>8RP.88.LH8G+<QPD\?A:KTJ
M4(XB%6.(H35W%NG&<94IW4ITYN,X)QA+\1\3>-<1PW3SWA_.<'*KE?$W#><4
M<@S3"Q]^ACJN7U<)6R['TFU&I&.(K4:D,51Y94J&*HPJTJSC5KQ_0S]@[_DD
M/B/_ +*1K'_J,>#Z^F;;XE>%]2\;R?#_ $2[_MO7]/L[C4/$(TTK/8^&K6!D
MAC35[X-Y$>HW5W+%;0:5"TM^H\ZXN8;>"$N_XM>&_C9XZ\'?#W4?AUX5U#^P
MM.UC7K[7-5U6PWQ:W<B]TW2=-.G07P?=86BQZ4LLDMFL5[,TS1&Y2W#Q2_I]
M^R3\+C\/OAE;:OJ5N8_$WCHV_B#5#*I%Q;Z:T;'0=.D+ .#%9S2:A-'(HEAO
M-3NH),^2N.GBC)H82KF.;8VLN;&8ET\NPE)^].4HQYJ]>37NPI0C*:IP3YI^
MR4YQ4G!^9X5\:ULWPO#?"&28.2I9+E<<1Q'FV*A^[I0IU)>SP. I)^_6Q5:I
M3I2Q%:4>2C'%3H4:KIQK0^IJ***^!/Z!"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEZ,CVD/YD?U*45_+7_Q%P_\ !.#_ *(I^VY_X;?X$?\ T2='_$7#_P $X/\
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M (;?X$?_ $2='_$7#_P3@_Z(I^VY_P"&W^!'_P!$G1_J-Q=_T(<?_P" 0_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO[37Q!_9O^(O@KX#7NA>%_$UI\3/$]GI^B>'[G1/&LFFQ>$KV$:AJ,&H2?\
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MMG<_\(W_ ,)=_;W_  C7]I?:[VSV?VQ_PC&O_8_+\S=_95UOV;5W?US^'O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTU9ZZ7:6[W/HKP]_RIPW'_8#\3_^O+-6K#_X,X?^<C'_ ':)_P"_/UN>'O\
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MBU%HE"33^*5N'+W4]RU?T=_\&V7P_P#!O[+O_!-[X)>(O'5Y;>'_ !O^W?\
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M**3M!R25[<VG1^OR?F?GUJO_  =F_MXW/QAE\5Z9\(OV>;7X,?VQ(D7P;O\
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M)RESW13E*3DF[^ZWKTV6GZG\4=?4/[&W[7'Q4_88_:'\$?M-?!6W\)W7Q'\
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MHHH _P!N"BBBOX7/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM>8T45]W3IPI0A2IQC"G3A&G3A%)1A""48QBEHHQBDDEHDDC,****L HHHH
M_P!N"BBBOX7/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^SW/VK?_ %>_CVOB.OMS_@IC_P I(/\ @H'_ -GN?M6_^KW\>U\1U_;.5?\
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M\?ZDD$N0<QK?:?97( P?-MXSG (/\:'P8^%'BWX[_%_X6?!'P%!;7'C?XO\
MQ$\&?#+PC%?3&UL&\1^.O$6G>&=&;4+L1R_8]/CU#4X)+^\,;I:6:37+J4B:
MOZ@/^"F7[;/[*/Q=_P"""?\ P3[_ &:?AK\<O!'C'X[_  P_X92_X3_X8:/=
M7DOB;PK_ ,(5^SSX]\+^*O[4@ELHK:/^P_$&IV&DWWEW,NR[NHE3>I+#^8GX
M%?%SQ%\ /C;\(/CKX1AMKGQ3\&OB=X$^*7AZTOGN$L+W6? /BC2_%.G6.H&U
MDBN#I]]=:7%:7Z0RI))9S31JP+5MP7A\9ALCS2'L)T,7+.,[JX>&)I3I*<IU
MF\/4E&:C)TIM1M-:2A\+L%2SDM=.6-VO0_M:^/OPL_X(T_\ !OY\.?A'X(^+
MW[*]A^W1^UC\1?#(\275]\1/#/AOQ1'J*:,7TZ^\8RV7Q%3Q%X$^%7A*Z\2#
M4-.\)Z9X5\,>(O%C_8G;6KS69]'&MO\ /WP:_P"#ECXH_$GXZ? S]G#]D']A
M/]GW]G'PU\7OC1\)/A?);6LM]XTUF+1O%'C31_#$[:-IW@KP[\)?#EGJD5AJ
MEP=-DOO#^NV&CJ\@-E?JOF'Z._:_\8?\$7/^"\O@3X-_&#QE^W#X>_8F_:%^
M'WAV7PQJ5A\5-8\+>&M0TW1;UI/$NJ^!?$>D_$+4?"'AWQK9Z)JS:I=^#O&7
M@;QA:VK3ZUJ%IJ,%_J.HVNA:3\,_"?Q1_P $/O\ @C'KDGQ_^&7QT\3?\%.O
MVR?#J:Q;_"'2?#>G1>%/A+X U.[M[C2_^$EN=9M[/5_"]A>'3[R_LO\ A(8_
M$7Q,U:!9(KWPSX.T:Y>/7X/B,%AL#C<OJ+.\GXDSOC"?UF-7"8ZCFCPL,7.I
M4CAY1DY4LFP^ @E3DJDY6A2C)PBTH0>C=FN64(PTU35[*UUUDW^/<ZS_ (._
M_P#DY#]CW_LB/CK_ -3R&OJ/_@L[;M\6O^#<;_@GI\0? +RW?A3P5'^QCXE\
M31:6JW=AI6FQ_L[>,/A;=6FJ3V\7^B/H'CSQ+I?AJ8R216L>L-]AEA>\:R,/
MP#_P<P?M4_LD?MIS_L>_&7]F+X_> _BCJ/ASPWX_\'^/?!FBSW:>*_"MKX@?
MPKXJ\*WFIV=S90?NEGB\3Z5JR+-(NF:E#91+YOV]G3._X(X?\%@/V;?!7[-'
MC/\ X)B_\%+])EUO]DKQM!XAL/!'CN?3]=UJP\%:5XOU(ZSKO@#Q=8>%()?%
M=GX=;Q5<7?C+P=XW\-)<:_X*\47UV\K0:6FD:EX7[<%EN94^$N#,RH8#%5L7
MPUF%;$XS+/8SIXVIA9XK$T\2J%"I&,YXB,'"I1A;]["3E!OW5)-Q<ZB;24HI
M*5]+V5M>Q_+37]L__!0/P]KWAC_@UC_8ATKQ)'<Q:G)??L\ZTD=Y ]M.FD>)
MHO'_ (D\.H89 '$:^'M6TL0.0/-@\J8 !Q7D?_#M'_@W0^!/BJ/X^>//^"G5
MA\:?@YH=W=>(]-_9X\/?$3P!XR\8>(_[+F::/PIXBA^%5C/\2=0TN_F:WLX;
M:U\.^"=0U"!2\GB2*T^V7L?IO_!9K_@JI^QG^W%_P2+\&>%O@[XZ\(>&OBCJ
M?QB\!ZW:?LYQ7(_X33P)X%\):GX[T31XM7L+"QBT/3I[?PS'X=OK_3=+O+JP
MTF74UTZPNKVVMH[J7T<VSB7$&:\)K+<LS66"P6?X;$8W&XG+L3A:=&HZ=2$*
M*5:$9RY(NM+$U5%4*+5&+J2E5C:5%1C-N4;N-DDT[IM.^GRMWU/J+_@V(\?W
MND?\$E?VP(?A]H.D^,OBG\/OCA\:_%VD^ =22>6T\5:Q??L^_"Z[\"Z;J\%C
M&UY+I?BO6O#=YX<D%N)+R6&PNXX%++"M?FB?^#K+XDJ2K?\ !/S]EL,"00;[
M7@00<$$'2<@@\$'D&ORW_P"",7_!4W6/^"7G[26H^+_$.E:_XR_9_P#BOI-C
MX3^-G@;0+J%-6^S:=>27?AGX@^&;*]GM=,O_ !=X&GN]52QL-0NK*VU?0M>\
M1Z(=0TRYU&TU;3_W,^//[#7_  ;T_M_>./$/[3WPC_X*2>!/V3+SX@7=SXQ\
M?_#?7/%W@?P1ITGB/4;R;5_%.H:/\-OC3)X.\7>'-<U>ZO+G[3I/AR\U7PHM
M^OF>%="2RS!<<&8Y-E.7<2YSBN(\EQN89;FU2AC,OS/"4<?B(86M[/DQ6#Q5
M/ 3]I"4JB4Z$I0DI1C[NKDH4FW"*A))QT:=NZ::OZ*_]7@^!G_!R/^W5\71X
MOO?V:O\ @E-X1^)K>#[33)_'<WP.\,?%SQG<>&M.U0:G-I5UXI7P'X8U*XTK
M3;PZ+JS6MWJBP63OI]T%EWQ,*_D'^.'C76?B3\:OB_\ $7Q%X=7P?X@\??%'
MX@>-==\)+%=0+X7UGQ5XLU;7=3\.K!?10WL*Z)>W\^F"*\ABNHQ:A+B*.974
M?V(^/_\ @I?_ ,$R?^"-_P"Q]X^_9<_X)3>,+G]H3]H_XF13CQ'\<WDGUK1]
M.\175E<:)_PL#Q7X_M-/\-:'X@U'PIILMRWPU\%?#FSN?"^F7\RZGK5U')=:
MQ+XF_BBGGGNIYKFYFEN+FXEDGN+B>1YIYYYG,DLTTLA:26661F>21V9W=BS$
ML2:^GX-P6$IU<TQN!X>GD>!K3H4,%4Q4L7''X^C2C*4ZU?#8JK4^KT54E_LV
MBG4A)N27*N:)O2*<N9I.]K65[:)K?;7_ ()%1117W9F%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '^W!1117\+GH!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?X_?_  4Q_P"4D'_!
M0/\ [/<_:M_]7OX]KXCK[<_X*8_\I(/^"@?_ &>Y^U;_ .KW\>U\1U_;.5?\
MBO+?^P#!_P#J/3."6[]7^84445WB"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_;
M@HHHK^%ST HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img80190973_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img80190973_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I BP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH ^=/'WQ\\1>#_ (J:?\*O#G[-WQZ^+%S=^$=+\97GC7P"_P #],\ Z+IV
MH^(=1\.RV&H:Q\5/C;\--3NM=TF73TU/5-(T+1-9NDT?4=.NK-;V66>VMNM\
M2_$KQGH7Q T+P;I?[/OQ>\9^'-7?2%U#XL^&M:^ EK\/_"ZZE>R6EY)KNF^,
M/C=X4^*EPGA^"-=3U<>&?AIXBDFLIHX]!36]1$VGQ/\ BS/\4[%OAEJOPOAA
MU2&P^+?@Z#XE^&GATG[1XA^%GB2/5/!OB6:RU#5[BT72IO =]XDT3XLW,VGW
M U;5=,^'U_X8T^WU";7O[-O/6Z!=_7_+^OZ1Y#_PLKQG_P +3_X5]_PS[\7O
M^$2W[?\ A>?]M? 3_A5FW^P/[9\S^R/^%W?\+LV?VC_Q2F/^%/>9_;_^D[/^
M$6_XJ6NE^'_Q$\-?$O2-5UGPQ-=O!H?C#QKX#UFUU&RFT[4=,\3^ /%.J^$?
M$5A=V5P!*B+J>D3W.FW8W6NKZ+<Z;K>FS7&F:E9W,W<UX/8^)O!W@'XZ/\*;
M+P=#X<U'XT^'?%7QIA\56<T$6F^,_%_@F7P'X&\<:=?66U&MO%%GX9U#X=ZG
M:O$\C>(]+@U^^%M'+X:U>\N@?]?U_74^-_VZ?^"L'P$_X)\^//!_@/XU?#7X
M^>()O'7A-O%OA[Q-\-O"_P /]9\*W,-OJ]]I&HZ+)>^)_B?X.U)->TF2TM;W
M4+1=)DM([#6M'FAOYY;BX@M?AW_B)B_81_Z)-^UM_P"$)\'/_G\UV'_!Q!^S
M</B_^Q38_&'2-/6Z\5_LV>,K7Q,9UCEFNA\/_',NG^%/&MG:10 OG^UAX(UZ
M\F</!;:9X=OIID55^TVW\(-!G*33:Z>GI_P?Q^7]QW_$3%^PC_T2;]K;_P (
M3X.?_/YH_P"(F+]A'_HDW[6W_A"?!S_Y_-?PXT4$\\O+[OZ_IORM_<=_Q$Q?
ML(_]$F_:V_\ "$^#G_S^:/\ B)B_81_Z)-^UM_X0GP<_^?S7\.-% <\O+[OZ
M_IORM_<=_P 1,7["/_1)OVMO_"$^#G_S^:/^(F+]A'_HDW[6W_A"?!S_ .?S
M7\.-% <\O+[OZ_IORM_<=_Q$Q?L(_P#1)OVMO_"$^#G_ ,_FC_B)B_81_P"B
M3?M;?^$)\'/_ )_-?PXT4!SR\ON_K^F_*W]QW_$3%^PC_P!$F_:V_P#"$^#G
M_P _FOUI_8K_ &U/@_\ MX_!R7XU_!>V\7:9X=L_%VM>"-6T+QWI^B:5XKT3
MQ!HEMIM_-;:G8^'O$7BG2HX[S2M9TG5K"2VUJZ\VQU" S+;W FMXO\PBOZ9/
M^#:G]I/_ (0[X^?%;]F/6]06/1_C+X3C\;>#+:XN3_R/OPXCN9M3T_3+0@+Y
MVM^!]0UK5=3F5BY@\%6*F,JI>,*C-MI/KI\_Z_,_KC^('Q3\<^#?%&EZ!X<_
M9M^-/Q8TG4+.RN;OQO\ #_7?V==-\+Z'-=7US:3Z?JEI\4_CY\-/&DUYIMO!
M%JEZ^B>$-8L)+&]MH].OK_4TO-.M+?B7XE>,]"^(&A>#=+_9]^+WC/PYJ[Z0
MNH?%GPUK7P$M?A_X774KV2TO)-=TWQA\;O"GQ4N$\/P1KJ>KCPS\-/$4DUE-
M''H*:WJ(FT^*E\4_"NI7'BOX0_$VR\<6O@O2?A/XF\3ZK\0(M9U%['PYXH^&
M_B+P!XET'5]'U1I773K2ZTKQ7+X(\:Z;K-[Y1L3X4N].%U;V>M:@LWM=!??U
M_P OZ_I'D/\ PLKQG_PM/_A7W_#/OQ>_X1+?M_X7G_;7P$_X59M_L#^V?,_L
MC_A=W_"[-G]H_P#%*8_X4]YG]O\ ^D[/^$6_XJ6NO\">/?"7Q,\,6?C'P/K$
M>N^'+Z]US3;?4([6^L674O#.O:GX7\0Z==6.IVMEJ-CJ&B^(M&U71M2LKVTM
M[JTU"PN;::)'B85U]>"^!=9^''@CXL^-/@)X6\.:UX:UJ^T*;]HRXN+AKZY\
M+^*KSXI?$'QE;^/[GPS=WFI7_P!FU?2?&&GP:]XVT6VMM)TZRG^(_AW5+"WN
M9M<U)[<'^7_#?\$\Y^+W[:GPS^"GCB_\!>,/"OQ)GU2QM=/O8[[1M(\,W.D:
MC9ZC:1W,-SI]Q?>+M-NY8XG:6RG,UC;LE[:7,:J\:)-)YC_P\M^!/_0I_%K_
M ,$7@[_YO*\]_P""F'PW^UZ-X%^*UE;AI]*N9O!6O3*KO*;"^^TZMH#L4&V.
MWM+U-;CDDE^4S:G;1JR.VV;\?Z_A_P 5?&KQ1X#XZSOAZABLI_L^E5I8O*9U
MLHHSG/+,;2AB,,G4<TZLL.Y5,'4J-)SJX>I)]&?"9OGF:Y?CZ^&C.C[*+4Z+
ME1BVZ52*E'6^O*VX-]7%G[A?\/+?@3_T*?Q:_P#!%X._^;RC_AY;\"?^A3^+
M7_@B\'?_ #>5^'M%?G?_ !,[XJ?]!>2?^&:C_P#+/ZN_*WF_ZTYM_/0_\$1_
MS/W"_P"'EOP)_P"A3^+7_@B\'?\ S>4?\/+?@3_T*?Q:_P#!%X._^;ROP]HH
M_P")G?%3_H+R3_PS4?\ Y9_5WY6/]:<V_GH?^"(_YG[A?\/+?@3_ -"G\6O_
M  1>#O\ YO*/^'EOP)_Z%/XM?^"+P=_\WE?A[11_Q,[XJ?\ 07DG_AFH_P#R
MS^KORL?ZTYM_/0_\$1_S/W"_X>6_ G_H4_BU_P""+P=_\WE'_#RWX$_]"G\6
MO_!%X._^;ROP]HH_XF=\5/\ H+R3_P ,U'_Y9_5WY6/]:<V_GH?^"(_YG[A?
M\/+?@3_T*?Q:_P#!%X._^;ROM3X:?$/P]\5O _A_X@>%C=C0_$=K-<6D6H1P
M0ZA;/;7=Q87EG?0VMS>6\5W9WMI<6TZ0W=Q$)(F,<TB%7/\ +37[$_\ !-'X
MD_;_  [XV^%5]<!KC0KR+Q?H,3R%I6TO5#%I^MPQ1G_5VMAJ,6FS_+D&XUJ8
MG:2-WZSX+^/?%/%O&V'X;XMK9=/"YI@L7#+YX7!0P<X9GAX1Q5*,ZD9R4J=;
M"T,724&DY5YT%%W]V7L9'Q!B\9CHX;&2I.%6G-4G"FH-58VFDVF[IPC-6>\N
M6SZ/Z\3X^>(KOXT>(?A!I/[-WQZU;3/"FJ>%].UWXRPO\#]+^$UO#XIT"SU^
M#5[!O$GQMT/XF>(-+TF.ZETO6V\-_#35[^SUC3[ZSAL+I%MKBYZVV^)7C.?X
MGS> 9?V??B]9>%(WG5/C=<ZU\!'^&%PL.CG4XY(=)L_C==_&A4NKT#P] )_A
M%!(NL,)[E+;0-VN!_C"?XIV7Q5^#MQX6AAU7X7:FGQ#\,_%?2Q#I,5WHEW>>
M'[+Q-\/OB(NHWMQ;ZF]CHNK>#]7^'UWH.C)>RZE=_%;3-9OK'[%X8DU#3O6Z
M_LL^T[^O^6WZ^=]CQWPO\3O&FO>-?$_A;6/V>?C%X&T#P_'KDFE_$OQ1K/P"
MOO!7C4Z3JD%A8Q^&--\#?''QE\2K>3Q-9RR:YH8\7_#WPHL.EVT\'B)M UQK
M;1KCK?AQ\0/#/Q6\!>#_ (D^#+N>]\+>./#VE^)=#GN[.XTZ_6PU6UCNH[;4
M],O$BO=*U6R+M9ZKI5]%#?:7J,%U87L,5U;RQKVM>#_#?Q-X.\/?$;XA_L^>
M'O!T/@>3P/I>A_%32+>TF@&C^*_#WQD\2>.-3UKQ#HMHBQO8W-G\2M&\<67B
M+1XUFBTHW?A_45>ULO$VEV,(&UM=_P _EZ-L_//]K_\ X+6?LS?L3?'#7_@)
M\8/A5^TG>^*=$TOP_K<&N^#?"'PSU+PAXATCQ'I-MJ=IJ/A[4-=^+WAO5KJV
MM9I;K1;\WNAZ>\.M:5J=M$D]M#!=W'S#_P 1,7["/_1)OVMO_"$^#G_S^:^>
M?^#F?]FX:KX-^!/[5VBZ>KWOA74KSX*^/+N..66Y?0-<_M'Q;X!FD,0*6^GZ
M1K5OXVMKB>X!C:]\4:;!')#+(([O^/>@B4FFUI]WI_7S?E;^X[_B)B_81_Z)
M-^UM_P"$)\'/_G\T?\1,7["/_1)OVMO_  A/@Y_\_FOX<:*">>7E]W]?TWY6
M_N._XB8OV$?^B3?M;?\ A"?!S_Y_-'_$3%^PC_T2;]K;_P (3X.?_/YK^'&B
M@.>7E]W]?TWY6_N._P"(F+]A'_HDW[6W_A"?!S_Y_-'_ !$Q?L(_]$F_:V_\
M(3X.?_/YK^'&B@.>7E]W]?TWY6_N._XB8OV$?^B3?M;?^$)\'/\ Y_-'_$3%
M^PC_ -$F_:V_\(3X.?\ S^:_AQHH#GEY?=_7]-^5O[CO^(F+]A'_ *)-^UM_
MX0GP<_\ G\U^UO[-'[1'P]_:O^!OP^_:!^%C:N/ _P 1]+N]1TBU\0VUC9>(
M-,GTS5]0T'6-'UVSTS4M9T^UU?2-:TK4--OX;+5=1M5N+9VM[RXA:.5_\L2O
M[&O^#9S]I/\ MWX<_&_]E37-05]0\"ZU:_%_P':SW)DNI/"_BG[)X>\;6EK;
ML!]GTO0?$=IX;O\ Y"ZOJ'C:[=O+++Y@5&3;L_Z?]?BS^BW4/BGXYLOB7#X$
MMOV;?C3J_A:2^TVT?XT:?KO[.L7PTM[>^LK:ZNM4FTK5?CYIGQB:QT>>>73=
M2C@^$\VIRWMG<R:1IVJZ<UI?W5NV^)7C.?XGS> 9?V??B]9>%(WG5/C=<ZU\
M!'^&%PL.CG4XY(=)L_C==_&A4NKT#P] )_A%!(NL,)[E+;0-VN"EX@\*ZEI?
MQO\ !_Q7'CBUT3P@_P /_$7PM\6>$-9U%[?3_$?B7Q!XP\%:E\+-9T5+AQ8V
M_B'2+R'QKX:^S0F*[\1Q^.;*V(NY]&TN&/VN@T_KI_7Z_@>(:3\7_$LWB3QO
MIOBSX ?&3X=^#?!>G>)M67XK>)K_ ."&N>#/%=CX;O4A23PMH'PS^,_Q ^+D
MDVOZ9]H\0Z%::_\ #'P_>-IEG-9ZO;Z1XCELM!N_4?"WB?0/&_ACPYXS\)ZK
M:Z[X6\7:#H_B?PUK=BS-9:QH&OZ?;ZKHVJV;.J.UKJ&G7=M=V[.B,8ID+*I)
M WJ\%^".L_#C1+CQS^SY\//#FM>#[']G"\\(>#+;0-6:^N+*3PMXD\#Z'XQ\
M*:SX/U#4=2U:[U#P8B:KJW@S3S<W4,NF:WX'\1Z%#86NFZ3ISW +7^OE_P &
MYXOX[_;Y^$OPZ\8^(_ _B/P?\5$UKPQJUWI-\UKHGA.2SN'MI"L=[8RS^-K:
M:6POH#%>6,LUO;RR6L\+RP0R,T2<G_P\M^!/_0I_%K_P1>#O_F\KYC_X*2_#
M?^P_B/X9^)5E;A;/QSHYTS5I45V)\0>&$M[5)IW \N,7.A3Z3;VR-B20Z9=,
MK2(A6'\V:_@WQ!\=/%?@OC/B'AJ6*RCV66YA4C@IU,GHN=7+:ZCBLMJS?.DY
MU,#6H2J-:*HYI-V3/@,QS_-\#C<3A>>BU2J-0;H1NZ<DITV]=W3E&]M+W/W"
M_P"'EOP)_P"A3^+7_@B\'?\ S>4?\/+?@3_T*?Q:_P#!%X._^;ROP]HKXW_B
M9WQ4_P"@O)/_  S4?_EG]7?E;B_UIS;^>A_X(C_F?N%_P\M^!/\ T*?Q:_\
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MX*?%GXE?"'Q= MOXF^&7CGQ1X&UQ(TF2!M1\,:Q>:1<3VIG DELKI[7[38W
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M6+=6N=4GCTKQ4O@U/ DD>DZ?I5A:ZSI&@ZOK@>\U"PUR=0W33L^Z_/\ R?\
M2U/=J\,^-_C$?"ZV\$_$N#P%I_BQ[;Q[X*^'/B;7$A@7Q+X)^'WQ7\8>'O"6
MN^)-)NS:373Z)HOB2;P7XC\;:<ES:V;>%M U'7+@S7/A^QB/N=1S(\D,L<4K
M02/&Z1SJJ.T+LI"2JDBM&[1L0X6161B,,I4D4#/+?CC\/(OBI\)O'7@1HTDN
MM;T*Y_LGS&V)'KU@4U+0I'D!#)&NKV=GYY5E+6YE0G:[ _S$RQ202RP3(\4L
M,CQ2QR(\<D<D;%'1XW571T8%61U5U8%64$$5_3G\"M:^(^O_  D\#WWQ?T1=
M ^*4&E2:+X_M(;=+.POO%?AJ_O/#NL^(]$M(YKA;7PWXNO-*E\5^&;;[1<M!
MX?UK3(I+B=T:5_PT_;0^&X^&_P ?_&$%M!Y&C^+I$\<:,!M"&'Q#)/+J<<42
M@+!!:Z_#J]G;PKE$MX(MFQ2(H_XX^EGPK[; \.<9X>G>>#JU,@S*<8WD\/B?
M:8S+9S:UC3H8B&.I.4KQ=3&THWC)I2^*XOPG-3PV.@O@;P]5I:\L[SI-]E&2
MFM>M1+3K\IT445_#Q\(>E?"SP!%\0?$&I6>H:I+H?A[PUX7\1>-O%>L6UDFI
MWUCX=\,V#7EX=.TR2\T]-0U&]N&M-,L;=[RVB%S>QS3RI;PRL.WT_P %_#+X
MC:3X^_X5S:>.?"WB'P+X8U3QW;6OC7Q/X>\5Z=XK\+:!*G_"06R2Z)X/\'7/
MAOQ#8Z?/#J]C;^7XFT_5(;?4[*:\TJ6VM+F_XKX4_$"#X=^([^^U+2'\0>'/
M$?AGQ!X+\6:'#?#2[O4O#GB6R:TO8[#5/LMX=/O[6=;34;*Y%M,OVBRCAE0P
M2RUVNG^-/AE\.=)\??\ "N;OQSXI\0^.O#&J>!+:Z\:^&/#WA33O"GA;7Y4_
MX2"Y2+1/&'C&Y\2>(;[3X(=(L;CS/#.GZ7#<:G>S6>JRW-I;6'WF1_ZO_P!E
MX7ZX\MY/:9S_ *Q+&6_M7V7U*']B/)^9>UUQ//['^RW[7Z^I_P!OI9-]7OZ%
M#ZO[*'/[*UZ_UGG_ (MO9KZO[&_O?'?E]EK[2_UG]SRFAXJ_9A\:^&KGQ#I%
MGXE\">,?%WA2+1+SQ#X&\'ZCX@U#Q5IVE^(+VTT_3M66UU#PSI6G:A:+<:EI
M']I0Z5J=_J6BP:QIUUK%A8VTDTL%&7]G/Q0UU>:=I7BWP#X@U?0O$_A3PCXT
MTK1M2\027'@;5_&&LIX<T[^V[N^\,V.D:K9VGB&1=%U:\\$ZEXLBL+]D5B\$
MT$\OTK\6_BIX/^"7QV^*WBGPE!XEUGXFZS'X8T.XTK7=/TNU\#:)9G_A%O$6
MMZG;ZO9:U<Z]XBO-3BT+2[+3],ET7PU;Z*^IZI<S:EK0T^R@O?//$/[17AW4
M_$T7B<?$+]H_7+"]^('@SQ=+\.?$/B&S/@GPOI^E>);+Q3KVEQ!_%.L)X[AM
M+NRCL_!EK+HGP]CTT166I7]U/-9"SG^US7ASPXR['YK@L1BE0Q> S/,<OK8&
MEF4JT,/A,+C,XP^7XR.-JUZ3GCZ[P^5_VM@J>'S">'A6J1CA,NGB*];)>ZKA
MLLIU*M.4^6=.M5IRIJKS*,(3K1IS4VU>I+EI>V@HU'%-I0IN4I4/%O'_ ,#=
M;\ :-K6MR>+? _BN'PQXRA\!>*[7PC>^(;N[\,^)KBSU*]@M-2.L>&M$L[BW
MD72-1MAJ&CWFJ6*7]K+8R7"7(\L^)U]%:]\7?#>J>#_COX?M['7$O/B?\6=)
M\>:!+-;6"VMGI%AJ7BJ\FMM8=-2DEM]2:+7+18H;*'4+5I([D->(J1--\ZU^
M9<3TLBIXS#3R"4?JM?"U:E>A"M6KQPM>EFF982E356NY592K9?AL#C9\TFO:
M8N3IQITW"E3\O%1H*<'AVN64&Y14G)0DJM6"5Y:OFIQIS?2\W:RLD5]%_LI?
M$G_A5WQV\":_<7!@T;4=37PQX@+2^5;C2/$>-,DNKL_Q0:5=3VNLE1\V_3DP
M'YC?YTI0<$$=0<COT]CP?QKS\CS?%9!G.59Y@9<N,RC,,)F.'=VDZN#KPKQA
M.V].HX<E2+34H2E&2:;3RH5IX>O1KT_CHU(58]FX24DG;H[6:ZIM']/WQM\&
M>*?B'\(_B+X,\"^+]0\ >.M?\)ZQ:>!O&^FWU[I]SX3\;1VKW7A'7Y)K -<3
MZ?I?B*#3;O5M.\JXM]7TN*\TJ]M;NSO;BVE[[1KB]N])TVXU-=,35)+*W_M6
M+1KZ;4M)@U58E34[;3=0N+2PN+VRMKY;B"WN;FPL;F:*-7N+.UF+P1^/_LV?
M$<_%7X*> O%T\QGU671X])\0,[*TQU[0V;2M2GF"LVQM0EM1JL:$EA;WT)."
M<53^$WA'P9\'_%OQ'^&^C^+Q=ZA\1/''C;]H31/ 5Q:V]I+X1T?QM?:$/'B:
M.ULBIJ.CZG\6;OQ/XUN[R<)>6VL?$"XT^5)((+6ZN?\ 8/*,TPN=Y5EN<X&?
M/@\UP&$S'"R=KNAC*%/$4N9*]IJ%1*<=XR3B]4S]FHU85Z5*O3=X5J<*D7WC
M.*E'\):^9[_7COQ5\4^-O!>J?"K5O"?A*/Q5X?UOXH^'O!'Q4^PZ-J&K>*-"
M\$^+M/UW0]$\4Z&-.O86CLO#OQ,U#P-/XQN+VPU73]'^']WXO\17*:=#HTNI
MVWL59'B"PU#5=!UO3-(UJY\-ZKJ.D:E8:9XBL[6ROKO0=0O+.:WLM:M;'4H;
MC3KRYTNYDBOH+6_MY[*XE@6&ZAE@>1&]$U/F?]N7]GBV_:J_9+^.WP(DMX;C
M5/&_@/4QX2-P_E16_CS0&B\2^ [F6<,CP6T7B[2-&%\T;QM)I[7<#/Y<S@_Y
M@UW:7-A=W5C>036MW97$UI=6UQ#+;W%O<V\C0SP3P3I'/!-%*C1RPS1QRQNK
M)(BNI4?ZLOPDNOB'>?"_X?W'Q;TRRTCXHMX0T!/B)8:9<V-YI<?C2'3;>#Q)
M-I5QILDMF^E7FK1W5[I@B96CL+BWBFBAG22&/_/M_P""TO[-W_#-W_!0'XPV
M.FV!L?!_Q<N8?CCX- V)"]G\0KB]N_$UO:6T:JEE8Z7X_M/%VD:?:1%H8M/L
M+3R1!&PM+<,YK9_?^GZGY24444&84444 %%%% !1110 5^C'_!*']I/_ (9;
M_;O^ _C[4-1;3_!OB+Q-'\,/B$TEU]ETX>#_ (C;?#%SJFKMQYFG^%-4O=*\
M9O&#O,WAV$JLO,$OYSTH)!!'4$$< \CD<'(/T/% +1I]C_5D^+WPPTGXP^ M
M3\":OJ.IZ(EUJ?A?Q!I/B#1/L@UOPUXI\$>*M%\;^#_$NC/?6UY:1:KX>\4^
M'M'UBPEFMID2YLXR4(KHO!'C7PO\1O">@^./!>K1ZYX6\3:?'J>BZI';WEG]
MJM)&9#YMEJ-O9ZC874$T<MM>:?J%I:7]A=PS6E[;6]U#+$GQ_P#\$U?VD#^U
M9^Q-\!/B[?7K7WBNY\'6WA+X@232QR7C^/? LC^%?$M_>K&\@AE\0W>EKXIM
MX6<R+I^NV3. SE1[G\--0^&W@GQWXY_9_P#!F@:KX9U#0K67XZ7=O>23SZ)K
MO_"_/B1\3?$GBC6/"]W=ZIJ$[B/XAV/BNY\0Z-'#IUIX;GUW1HK&PM])U72?
M,#>^S[K_ (*\MKW^1[M7AGC[QB/AY\5/A 8O 6GWVG?&?7M0^%OBSXB64,$6
MN>&;_0_"7B_QY\-K;7IDM#<7OA#4+[3/&7ARS>YO1%H_C'Q;H-M96Q;Q+?RK
M[G7!_%)/'C_#3X@#X67.G6?Q,'@SQ,_P]N-8M$O]'3QM'H]Y)X7&K64DMNMU
MI<FM+91ZC#]HMGDLWF6.XMY"LR SP_\ ;1^&X^(_P \7Q6\'GZOX/C3QQH^
MY?S- BG?58U6,&65IO#\^K)# @;S;O[-\CLJBOYVZ_JJ\*ZK<^+/!OAS6];\
M-WOAJ\\3>&='U75_"&NK%+J6@7.LZ5;W=_X;UE ODR7NE2W,NF:@H3RGG@F
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MH2ZCHB>(K"^\2ZOHQ@T33;W2;G3=6TV[M;Z\58;B/6K*31'B+1ZH?LKR!O\
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M^%M T'1O$6KZ/9WZRVCZS:WMPEI#=:=9RPPW]U'-ZMX4^+WA[PAXE\+P:O\
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MV?\ X(?%_P#:-M_'W@SXG?%3X>?!O5/A[!XV_:#^+?Q'U/Q3IG@'QWXE\/\
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M^)O#^DQ:CI.KZEX@\$0ZA;2WFD:#KUE/Q?[$'[/-K^RI^R=\"?@+';VT&I^
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MK':6MIX=\3Z6PLH+^YU%Y_S%_P""DWQ)_MKX@^&/AG97&ZT\%:0=6U>*.5E
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M?0[_ $T2D1S7?AL:C=>+F@)_>6?A^[X;;M;_ #0W9G=G8Y9V9F(  +,22<*
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M9W_X:L=_\H\U]X?5<3_T#U__  34_P#D3R6BO6O^%!?';_HBOQ:_\-QXQ_\
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M !'#XQ__ #&T$V?9_P!?\.OO/DFBOK;_ (8"_;N_Z,I_:V_\1P^,?_S&T?\
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MBO-6T:PN?A;K7P!\$Z!IFHWOA72=<\0:W8:+\5_%TV@Q:1>"U_M_3K>[UBT
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M?$/Q#\9^"K*!Q$^GCP=)80P+IUMI\T_U_7\P_P ?O^"@G[9?P5_X*]:!\'?
MW[-W@;5-0^*?@#]G'X5>)/"\NL^.KO1?B+9+;:[XP/BOPW\5(?"5I/8>%_AE
MXU^+OQ'\.7'Q"'PFNA_PCWAO5+SQ+X/@O+-=(T7^A;QIK?[0%CXD\-6OP[^&
M7P=\4^$;J"P;QCKGC3XY^-? 7B30KF2_:/5(?#7A70_V=_B1IGBR"STP)>6%
MQJGC'P7)J5^S:=<6NE6Z#5'"8M6MKIIJON_K[['L5%>0ZUK7Q[@^(VEZ9X=^
M&OPAU3X1ROIPUKQOK7QO\9Z#\1K".56_M9M+^%EC^S[XD\,ZN]DP0:='=_&+
M1%U169KF32"H5RSUKX]O\3KC2;_X:_"&V^#*O<BU\>V?QN\9WWQ.FC72S-:-
M<?".;]GW3_"ML\^M8T^Y2/XV7:VNEDZQ%)>78_L,A1Z]17D/A'6OCW>^.O$6
MG^._AK\(?#?PSM?[9_X1+Q=X1^-WC/QMXZUOR-6MX?#_ /PD7PZUG]GWP!X?
M\+_VGH376HZS_9GQ1\8?V%JT-OHME_PD5G<R:_:4? VO?M&ZA!XM;XE_"KX)
M^$KJSTXR^!8? WQ_\=_$.#Q'JVR](L?%MSK_ .S3\,)/!>G&2/3E.J:/:^/K
MD)=7L@T<MI\$>I 7_JS_ *_KR9[917A_AO7_ -I.Z\&^++[Q?\)_@=H?Q!LU
M7_A!?#'AO]H3Q[XJ\&^(V,09QXL\=ZI^S'X-UOP6JSYC5M'^'7CTO$!,51SY
M [;X7>*M>\=?#/X=>-_%/@O4_AQXG\8^!?"/BKQ'\/-:N&N]8\!:]XA\/Z?J
M^L>"]6NFLM-:YU/PMJ%Y<:'?W#:=8--=6,LALK4MY$8!W5%%% !1110 4444
M %%%% 'B>@^!H-/_ &C?BK\2U\6Z=>77BWX)_ #P--X%B*?VMX<@^'GCO]I;
M7[;Q;? 7LD@T[QI)\3[K1]++:=:H;GP#K CO=0820:;[97A^@>&_!MK^TG\6
M/%]CXL6\^(.N? []GOPWXG\"[8@WASP;X5\>_M.:IX$\6%U'GLOC36_&7Q%T
M=5D)B0^ F,(#O/GW"@ HHHH **** $958890P!5@& (#(P=&P<\JRAE/56 (
MP0#2T44 %%%% !1110 5XE^S/XZLOBA^SA^S]\2]-\(Z9X T[XB?!'X4^.K#
MP'HIB.C^";+Q;X$T'7[7PCI)M[#2H#IGAN#4(]&L##I>FQ&ULHC'86:;;>/V
MVO(?V??&/CCXB? 3X(_$#XF^'$\'_$GQS\(?AKXQ^(7A*/2-7\/Q^%O''B;P
M9HNM>+/#B:#X@NKW7M$31->O;_3%TC6[V[U?35M19:E=7%[#-*X'7[_TZ_U?
MY'KU%%% 'D/PUA^*,7C/]H)_B [OX3N?B]HLWP/5IM#D6/X7+\!/@C;ZLD::
M2QO[=#\:H/B_(8?$P77&DD>>W4^&Y_#[-Z]7D/PU\*^/?#WC/]H+5_&'B)];
M\/>._B]HOBKX5::VM:KJJ^$/ 5G\!/@CX(U'P['8ZA#':>&TN?BAX-^)'BPZ
M+H3W&E3R>*'\133+K>OZS!!Z]0 45\P?M6_M&W?[.7@KP9=>%_A]=?%KXL_&
M'XH>&/@A\#OAA#XBM?!>G^,_BCXMT[7]=M(?%7CJ\TO7HO W@3PQX2\)>+_'
MGC[Q;;^&_%FLZ-X,\)ZY/X9\&>-?%!T7PGK7S+:?\%*?"_PDU#XS^"/VY_!6
MG?LU?%+X(C]GK4]5TSX7>(/B+^U-X"^(WA3]JWQ?XJ^''P)USX,ZSX7^"'@'
MXP>.;_Q!\4O OB_X5^(O#5[\ ?#6K>'?'NC16=F-?\.Z]X:\3ZP ?IS17P!<
M?\%0/V*H/ 7A?XBQ?$CQWJNC^*KWXPV2>'O#W[.7[3'B?XJ>$%_9Z\8Q?#[X
M\:K\6?@EX=^#VJ?&7X)>&O@SXWNM,\+_ !0\6_&+P'X&\+^!M9UWPU9^)=7T
MV3Q/X>&I^]_&_P"/^E_"SX=^#O%_A+3=-^)NO_%?QS\-/AM\&] L/$L6EZ#X
MZ\4_%76;&QT'49_&6GZ5XICTSP+H?AV;5OB1XO\ %&DZ%XHOK+X>>%O$.K>&
M_#GBO68]*\/:L ?0:JJ*J(H55 554!555& J@8        &!2U\":;^VMXI\
M:_M.?M,_LK_#C]GGQ7)XT^!?[/&C_&/P!XG^+?B)_A'X-^.WBSQ!XN^)_P /
M]+\+^'E;PIXQ\9^%?AJOCGX9W_AN?XSZUX.NHM87^TO%GP_\!^//A\GA+QAX
MXXG]J+_@I;X)^ _[!7@S]NCP%\,_'/Q<TKXIZE\ M!^&?PZ7PW\3;+5I?$/[
M0'CWPEX$T33?B7<_"OX5?';Q-\-U\*WGB:X@\2,G@#Q5J%_XPTNR^%7@W2_%
M7Q/\9>!?"OB, _3&BOR]^,__  54^ WPK_90\6_M"Z)<6'Q%\<Z+\"OVS_BS
MX5^$NE'XE>&M+\>^)?V!-1N_!O[37@73?B+XM^$&E7'AZP\$_%.S;P+9^+?%
MW@'1+GQ5;RQ^*O"7A+7=*$T47TU^R;^TQ_PU#X7^*_B3_A"?^$&_X5A^T-\8
MO@-]B_X23_A)O[<_X5-XB70/^$K^T_V#X?\ [,_M_=]K_L+R-0_LK'D?VQJ7
M^NH ^J*\/^+'AOP;KGCW]F/5/$_BQ?#FM^#?CCK_ (D^'6CE8F/CWQE=?LV?
MM">$+[PFID!=&L_A]XJ\=^.BT&)2O@MD8^0\P/N%>(?%>V^&T_CS]F67QUJ&
MJ6?BBS^-^OW/P9MM/2Y>TU;XDO\ LW?M!6>J:?KC065W%'I<?P?N_BMJL+WD
M^F6QUK3-(C6]DO)+73=0!/\ 5;^J_I>9[?1110,**** /$/A1HWP^TOQY^TU
M?>#/$=]KGB/Q'\;] UGXM:9=J%M_!WQ!@_9N_9\\/:;X<TLC3;'?8W7PJT'X
M9^+I&-UK)&I^*M17^TH@HT?2?;Z\/^$[_#9_'O[3B^!H=5B\3Q?'#0$^,KZB
M9S9W'Q)/[-G[/<FES:")I9(UTI?A!)\*K>86J00?VY!K+-$;DW$\WN% !17Y
M"6W_  4+_:7\(?'C]IGX=?'W]F?]FKX8?"+]C?X+?#?]I+]HGXS>#_VO_CM\
M7]9T/X&_$Z+X_76E:_X!^$FC_P#!//P[KOC_ ,8>'-/_ &=O&6I>,/!9\0>'
M(K6TO]%7PSXC\5W<MY:6?V'JG[=_[)6BZSJ.@ZM\:-!L+_2?B/X/^$^IRW&D
M>*TTFP\:>//@OJ7[0WAJ&[\0?V =!A\-W'P:T77?'.I^/'U(> _#=CX?\0Z?
MXD\2Z1K>@:QIED ?7%(55BI*@E#N0D E6*LA92?NDJS+D8.UF'0D'\^4_P""
MI7[$W_"O/$OQ-O?B-\0]"T'PKK?PHT#4-!\5?LT?M1>$/BEJ5Y\>=0U+1O@9
M>^#_ ()>*/@SI'QE\?\ ASXT:_HFN>&OA-XN\"^ O$?A7XC^*=!U[POX.UG6
M?$&B:KIMIXIKW_!:#]D+2/BE\(?"UM=?$6^^%'Q(^!W[3_QG\5_&^Y^"G[0V
MD:/\()/V7?BKX&^$/C3P3\2?"-]\%O\ A(O!GB'2/%>N>-K/XEP>/?\ A";_
M .#%WX1\*V7CS2;63XP_#J34@#]<J*\\\%?%7P)\1-?^*7ACP=K4VL:O\&/'
M5K\-/B-&-%U^PL=$\;W?@/P5\2ET.QUG5-+LM&\3O;>#_B'X2O=2OO">H:YI
M>DZGJ%WX8U2]L_%.B:]HVF?%-M_P5F_8#NO#/Q+\9+\<-4M_"OPJL?"6M:YK
M^H_!7X_:5I?B[PKXY^+:? GPQX_^"-UJ?PMM(_VCOACJ'Q:GT_P7-\4?V?3\
M3?AYI=]K7AV\U?Q-8:3XDT'4-1 /T9HKX-7_ (*6_L?S?#G2OB98^,?BGK-A
MJ_Q%\;_">'P#X>_9<_:I\2?M :?X_P#AI8R:I\0]!\1_LOZ#\%=1_:1\)KX'
MTK[%JOBS5O%'PIT?0] TO7O"FI:GJ5M9>,/"L^L?9?@CQKX1^)7@OPC\1? '
MB/1_&/@/Q]X8T#QKX)\7>';^WU3P_P"*O"/BK2K37?#?B/0M3M7DM=1T?7-&
MO[+4],O[:1[>\LKJ"XA=HY%8@'3UXA^S+XJ\)^.OV;OV?/&_@+PA;?#WP-XQ
M^"'PH\5>"_ -F+86G@?PGXA\!Z!J_ASPA:BRAMK,6WAK1[RST6 6EO;VWE62
M^1#%%LC7V^O%OV;?&T_Q+_9U^ ?Q&NO"ECX#NO'_ ,%OA9XVN? ^EP/:Z9X,
MG\5>!M"UV;PIIUM);VDEO8^'9+]M(M()+6V>&WLXXVMX64QJ"Z_)Z?=^7ZGM
M-%%% PHHHH \/_9[\8^'?'/@+7]:\+^"M,\ Z99?'#]ISP==:%I/V/[+?^(O
MAY^TG\6/ 'C#QK+]ATW2H/[3^)7BWPSK?Q%UK?:RWG]L>*K_ /M'4M8U#[5J
M]][A7C?P*\;ZU\0?!.N:]KWAFV\)WUA\9/VBO!$&E6MI=V45WHOPS_:"^)WP
MW\-^)FAO0LSW/C3P[X4TOQC>7:#[)?WFO3WU@6L;FW8^R4"6R]%Y?AT"BBB@
M84444 )M4L'*@LH90V!N"L5+*#U 8HA8 X)52<[1A:** "BBB@ HHHH *\A_
M9]A^*-M\!/@C;_'!WD^-4'PA^&L/Q?DDFT.XDD^*,7@S14^(#O/X99O#<[OX
ML75F:;P^S:'(Q+Z2QL&MR?7J\A_9]\*^/? GP$^"/@CXJ^(G\7_%#P;\(?AK
MX5^)'BR36M5\22>*/'OA[P9HND>,/$3^(M=AM];U]];\0V>HZDVM:S!!JNJM
M<F^U"&.[GF10.OW^G3^E\SUZBBB@ HHHH **** "BBB@#Q#0+;X;)^TC\5[S
M2]0U23XP3_!#]GVV\=:5,ER-%L_AM:>//VFI?A3J&GR-91V;ZIJ?BB\^,UMJ
MZ0:E=W,=II.AM=66GQ26<^I^WUX?H&J?#B7]I/XL:+I?A_5;;XNV'P/_ &>]
M4\<>*II'.AZS\.-7\>_M.6GPK\/Z="=:GC35?#/B;1/C'J.LR)X=TMY;/Q9H
M*R:UKRPQ6/AN3]H3X4^&OC%\+?$/A3Q3K?Q3\/Z?:P3>(;?4_@_\</C3^S[X
MQBU+1K&]FL0GQ ^ OC_X;>/!IADD+7VA?\))_8>J[(1JNG7JP0", ]LHK^8/
M]F']I;XR_LH_L/\ _!,7QSH'BOQ%\7/&_P#P44_91T73+WQC^U;\=?VI/VA]
M;UW_ (*$>,_@]\,?$_[.6FZ/-\3?C?XGT[P7\+_'U_>_&34OBA\/OAMI'@LZ
ME!H.D7WAS5?#YTB>&Z[[7O\ @K3^V5\0H_AC9_LZ? SPAJE[^T!\3=2\(?">
M:3P'X4\;Z]HVG?!W]D/X3_&[]HC2_$WA#XM?MQ_L2>!?$OBW2/C!\0/&WP\T
MFSLOC[X,U;PCX=^"'Q(U/4/!OCV\L));$ _H^HK^<$_\%7/VT-9DTOXE:;X0
M_9.\-?"SP%X1_P""2NO_ !D^'%I>:K\>?%'C/5?^"DOQ_3X">*K#X._M,?"#
MX\+\%+;PW\*KN&X\6^$/'%GX&^+^D?$;3+VSL6M]"^ROJ=_Q_P &/V\/VZ?@
MG\/?C&OQ&\2_##X^:M\5?VOO^"E7[._[,/B:^^'_ ,1](?0?VKO!G[>6G_L_
M?LU_!KQ1I6H_'CQ5<:U\$]9L_$/CKQIH_A?POJOA'6O /P?^$MYX/N?%][=Z
M!=?$?7 #^FZBORR_:4_;R\5Z7XB^%/P)_9QTO5/"7QH^)_[6GA[]E74_BY^U
M-^R7^U)X/_9\\#:B_P //CK\3M;\6^$(?&4/[/&E?M/6GB*S_9\\1>!? 2?
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MXLT/P!>CQU[W\<]?MOB9^T7^U#\/_BA\>OBG^S[\#_V>OV7?V</$%UK'P?\
MB5K_ ,,/%>IW?Q_^+OQ<OOB5>WFM:"+C43-XF\)_L]>$O@U\/]:\*6-M\6_"
M!\<?%J;X(^+O!/Q3U[PSXKT$ _4RBOYMOVF?#'[8WP5_X(Z?\%!_B+X(_:-_
M:2^ VF:>O[1OQZ_9^@^*WBKQ5\4?VQ/AK^S18_!NSB\$?"K4?CG\4?%_BWXE
M^ ?%/BWXMZ)X@^+Z:[XVU/Q]\</A1\(/B%!\$;'5OA3\5O#6E^)OA;^N>M^,
M_$W@G_@H1\,?AQ::YK.J>"?VAOV4/CUX]UOPOJ.LZKJ6F^$/&7[+GQ0_9K\-
MZ#XD\(Z->7D^G>'+'QIX?_:@UO2/B#)I5O96^H:MX1^&\TUM<7]W?WK 'VM7
MD/[/M]\3-4^ GP1U/XU6KV/QDU'X0_#6^^+5E):Z?8R6?Q,N_!FBW'CRU>RT
MC_B56;V_BF3586M=,_XE]NR&&R_T9(J]>KR']GW2/B1X?^ GP1T'XR:B^L?%
M[1/A#\-=(^*FKR7\6JR:I\2--\&:+9^.-1?5(%6#4GOO$\.J7+7\*K%>-*;B
M-0D@ !=>NS].GX]OF>O4444#/%/A7X(;PIXZ_:4UX^+-/\1CXF?&O0O&Z:/9
MRF2Y\!+8?LZ? +X<'PGJR&ZN/(U"\;X?MXYCB$5B#I?C339_LKF8WMW[77A/
MPR\*^&M#\9?M1ZGX-\:66N>)O'7QGT;Q-XUTZ:WCO8/AQXYMOV:OV?\ P5I7
MA?4;.SOK.ZNEN/ _A'P+X_DMI[S3KV>T\:11PSP6SVET?P2_8G_;H_;,TCP3
M\-]!^,?QM^ &M^"_"W[-7[>G[9_Q]^-7Q'^$GQMUKQ7=>%_@;^U[X\^'%MX'
MT&'2/CWXANO"GA_3=*N9M>B\3)I/Q(N/!_@KPAI'PX\+_"OQ#)=VNO:* ?N)
M^U;^SE=_M&^"O!EKX7^(-U\)?BS\'OBAX8^-_P #OB?#X=M?&FG^#/BCX2T[
M7]"M)O%7@6\U308O'/@3Q/X2\6^+_ ?C[PE;^)/">LZSX,\6:Y!X9\9^"O%
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M&/\ @HE^UY\,OA[X-DL/$W@/XG_&'Q9XU^(O@<>.?BIXV_:"^*_PYBNOBO\
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MSZ%X@\>>(?$GQ>^,^E?"31_!?B+Q9:^%/B!8^(+/0O#?V1\2OVS?CNG[)_\
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M%I\!_A'I=_JNF?LW:?JWB+XG>%/BY8_ #PGX0_$CX[>#_P!B+XQ?%?Q5\?\
MXJ?%CXK?LM_\%2_CIHECXW\:^(&LKGXG^!?"O[8VL? '7OAMXO\ !O@I/"G@
M#4O#/B7X/^,/%7A_P/\ #^W\+P^ OA[\09/ 'C[P7X5TWQ5\.O!M[I8!UGP-
M_P""+=E\)/"WAS1I/B%^R_X:U;PS\;?V)/BFE]^S%_P3Y^$O[*^F>*]*_8S^
M),'Q("?$@^$O'_BKX@>/OBA\8K\7-KXL\=:U\2V^''A&1;/4_AW\"O#=W<>+
M!XN["3_@ET_PZ\8:M\6YO%ES\??"_P#9W_!7)?B9^SCIOPL\,V'BCXY^ /\
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MWT_0KGXG_"SXB>#Q\0?A#%I=IX\\;1:'I?CM63Q%\(->OO$7C;P_X1\0^,_
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M>NZ9,VJ_#OP3I6L^*C:Z/9"^\:7&H:CI T/0Y;;PY:4M3_X(G_L[W/@[P#X
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M@+QA\3OB;KNK_M)-8:6GARP^(=C<^*H]"FO]4UO6O"OC#3/AQX1\3FX^'O\
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M#XA>!G^+/QR\9>,O"_B#P=X/ /ZGO!/[(G[)_P -/A1XS^ WPY_9@_9X\ ?
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M^ 'B[7-&^/GPQO+R\\#Z]\3+O3/#6K^!D\?:+J>K3:+\/=9\1\)X<_X)>_\
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MM \$VOB7QWXW\8:G)KL_B?Q9K6M^(H[+4_%%SX5\)^ ?#?A+^;W]I'_@E_\
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MYJMAX6\*>'_%^HOX-\(ZMI]E%X-@\0:M966D:1-?:C;O^?G_  4R_9%\6_M
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MAJP_:Q_9HO?$?P8L/B;JGQA\/VGQV^%MSK?PHTSX*2Z=#\9=1^)6E0^*GO\
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MXG\&:+<:YXK\,ZFNOZ=\</&7P=O?"?AX0^,]=AM/!S2:]%[W^R/^W!=_%_\
M9^_::_:&^/WAZ'X&^%OV>_CQ^U'X-\1Z9KFB7>F:]\/_ (8_L\ZO?IJ%S\2+
M/2O%'Q$TS4_&GAS1=+U-O%^K?#[7-;\%:_>:?+J7@"35/#]YI5]?\ __  2'
M_9S3PA\+O#.E_$/X]Z#JWP1_9D_8\_9C^$7Q!TCQ3X!B\;^ ;']AGQKK'C_X
M$_%W29KOX8WGAG4/BU!XBUJ[_P"$S'B/PQK?PI\8:/O\/:E\*QH=_J^GZE]'
M_!K]B?X9?"GX$_&/]G[Q-XK^)7Q_\*?M">*/C+XN^-NN_&[6/#%[XJ^(NJ?'
M^.ZC^*MMJ,GPS\(?#'PUH6A^($U#4H;'P_X-\,^&M%\+6%]_8OA*RT/0=/T;
M2]- /S:_:"_X+ _$MOAAH6E_LX_LI?&GX>?M)^,/BW^PYX7TKP5^T_X$^"VN
M1Z%\%_VW_B)JW@[X8?'H^#? _P"VE\/M'\:Z1XNNO _Q&\ >'_ J_'GP%X\\
M'?%/1+>V^-.B?#?PF&UJ[^[?V\O^"@?P^_X)T?"?3_C#\;_ 'Q \:>!+:PU>
M?Q?XO\ :]^SQX%T?P]<Z'I!U46%O:_M&_M#?!>?QGXN\706FM2> OA)\(KWX
MK?%OQ1)HNH6&C^$=3NEL6U'S?P9_P2D^#_AZ#2+SQI\<OVF?C9XYT'QS^QWX
MET?XH?%?Q3\*KGQOI_@O]A+QQJGQ&_9W^"D,?@3X.> _!K_#71/&'B;QQK7B
MS5)O",OQ?\?WWCOQ#?>+_BKJU_;^&KOP_P!O^VC_ ,$VOA#^W!XETCQ1\0/B
M1\:?AU>6_P  _CY^S%XIM_A+J?PSL(?'_P $OVCXO!J?$7P=KM]\0OA9\1]=
M\+/,_@C2_LGB+X3ZQ\-_$]_I][K7AOQ7K/B;PEJ3^'T /O[2M3L=;TO3=9TR
M?[3INKV%GJ>GW/E30_:+&_MX[JTG\FXCBN(O-MY8Y/*GBBFCW;)8T<,HOU@^
M%M A\*>&/#GA>WOK_4[?PWH.D:!!J6JFQ.IZA#H^GV^G17VHG3+'3---_=I;
M+/>'3]-T^Q^T22?9+&T@\N"/>H *\/\ V8_"/AKX?_LV?L]^ O!GC33_ (D>
M#_!'P/\ A/X1\*?$/21:#2_'OAKPWX"T#1M"\:::+"_U2Q&G^*=+LK77+,66
MIZC:?9[Z/[-?W<.RXD]PKQ#]F72OASH/[-W[/NA_![Q!JGBWX1Z-\$/A1I7P
ML\5:XI36O$WPYT[P'H%GX(\0:NC:-X=9-4UGPS#IFI:@K>']"*W=S,#HVF$?
M8H 77Y/]/Z_X<]OHHHH&%%%% 'YB?'?]DF+]H#]C+Q/\ O@OXY\%^*UU?]N+
MP_\ &_6-;\9W%S!X727X??\ !4G1?VK/CU\/;IM!T;Q-+/J_AF?PI\1?A9HU
MC/IC6VH>*=(T[3_$EWH=G<ZIJFG?'OB+_@E)\9M0_:K^+GQ'2Y^'7BSX<^/O
MVD?B9^T_X7^('CC]K7]N>VU[P/K/CS]FW4_A!9^ -&_8H\&>(]!_9*'B_0_%
M.IWEC9_M,Z]KOBO4/^%'ZC?_  XU/X ZYK(M/%D'[&_L]V?PVL/ 6OP?"K5M
M5UKPP_QP_:<O-4O-9CGBO(?B3J/[2?Q8U#XRZ3"MQINDR'2M!^+]UXYT/09%
MM98)M#T[3IK74M:MGAUB_P#"OVMOVIOB3\&O'GP(^!OP*^#6D_&CXU_'ZT^,
MGB?3=)\3_$U_A+X:\+?#'X%>$]'UCXA>+(/$,/PY^*<_B7QX?$'CCX:^%/A_
M\-Y/#6CZ1XLU3Q3=WOB/X@>!]!\.ZAJ4P);+T6VWR/R/^#7_  1I^/GPR^*/
MP*O_ !)J7PN^)/@C2-/_ .";7BWXE:YJG[8/[>7@C2_A?\1?V&?@E\(/A3XD
MT+X7_LD?"+4_AQ\ /V@+7Q'K'P&\)>/?A+\8OCCXD\':Q\/O%GC;Q+?^,_@[
M\3/#WA/2/!7B6S!_P2E_;6\:_%CXF_$_]H+Q!^SY\:F\1?LH?M0?LR6?AWQ-
M^T9^U%IW@OQC8^*?CU^S7\5_V=)?#7PZ^&'PX^$?@G]BGP[IW@'X#6GPK\36
MW[,&FW?B_P  ^*]'\-?M!^(?&?[5GQ!U'6=+L];X8_\ !9#XE_#S]FC_ ()I
M^(OBAX.\"?M!>+_VB/@3^P+KO[1?BS1?B'XJT'XS>$?$O[7/C'X>?"G_ (6A
MJ?P4^#G[+/CSX,_#_P !7?BKQFVK>'M;^.?QI_95\)?$C7]-\2?#7X-Q^)?%
M6C6^D744/_!77]IKX(?LP_%_XM?&3X6?L_\ Q1^*7AO]K_\ X*5^"?"?PHT?
MX]_%73O%FM? []C/XT^(?!L]M\.O"?P=_89^+7Q+\>7?P\6U?PQXG\=:O\+-
M!^&GAWP'HWASXS_'?XP_"R\^(/\ PA'A\&<-JG_!(/\ ;,O/#7PS\:ZQXE^&
MWQ&^)GA#Q)^V'I-U\(M1_;G_ &N/@%IR?#;]I;P_\"=/\*:E\1?VZOV3_@1\
M'/VB_P!K'XC>!M0_9^TFR\;:I\=/@]9>(/C1X#\=CPW\0_B1J_BWX2^&OB/X
MO_4?XW?L9?$+4OV4_P!CCX4?!I_A1?>/_P!BCX@_LJ?$?P?X*\<ZM\3/#'P4
M^),W[..DVGAF3P5JGBS6I_VA_BUX*TB72Y;OQ'\/O&7B8_'CQGX3\;^'/!&N
M^*)O'^I6&I:O><!_P4+_ &B/VDXOV;?V1?%'[(NM6?PSUG]J?]I#]E'X=:UX
MXU/Q%X/T;QWX"\ _'+6]*GN8?"-KXY_9[_:<^&MYXEU*UND\/:EJ?B?X?ZU8
M^&K*ZO=9TC3==U*&RMD^>K[_ (+5>+/#/PCU#XV>(OV21/\ #OX@_LS?&7]J
MS]D&ZTC]H#3M2\:?'3X7_ SXR_"'X2^(K#XQ>'KOX/>&-#_9X^)'BG3/CU\*
M?B'X2T#1/$/QH\)3:7K/B'0O$7C+PCKWAO\ L_4 #VC]CG_@GS\9_@)^T9\+
M/CWX]UWX/BWMOA#_ ,%$[;XC^"OAO>>*VTGPC\4_VZ?VU_@A^UEIOA#X8'6?
M".B)XG^&7PXTWP+XP\(:AX[UZ'P%XC\4ZU_8OB2W^&.AV_B35-)\*^>V/_!,
M?XO:5^WKXI^/1G\ ^+OA/XI_:[M_VP+'QIXP_:L_;CL_$O@'6K?X#:5\+8O
MNA?L0^ O%_@W]DGQ9XMLM?T"SAT;]H?QGXPO-1M/A-K&H_#O7/@WXHDTG1]:
M/L/_  40^,?[;W@7]GK]EVR^%'_"NO@C\;/CK^U?^SE\#/BMK_@7XLZ=XOB^
M&FB_$SQQ%I6LV_PD\8?&+]C;X@^&/&=SJT42:-+XG\?_ +.NC'P_IU_>ZOI_
MA+5-4MK*WKXU^"__  6:^*]U\+_ACX@?]G.[^*/@3PM\&?\ @GA\1?V@OB[\
M1?VCO!^C_&:SLOV_?V@_&'[.WA*Y\+?#WX:?LE> /A3\3_%G@[6_!FJ>+O%L
M%J_[.OA74=!CDM]!M-.U;[%I>H 'FN@?\$AOV]?&.F^/M2_:#^)?P&\:>/\
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MXI^ ?C3]D"]^.]EX9\)?ME:%!)K3^)?VC)O@/<6]G9>'M#^'&F:%J'P[UO\
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M"?Q1\3ZP%U_2!+I,3PZ\FB>X44!\_P O\CQ#QA\5_'GAGPWX+US1?V9?C?\
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M!IWPGOY'O2)-/2^T_-^#2_B5XSU#XDW_ (%N_P!GWXO:'X7LWOEM_C-JFM?
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MBO3?V9?C?XNU[Q"Y75OAGX>U_P#9NMO&_@91%-)YGBF_\6?M!^&/AQ=H7B2
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%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img148586500_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_0.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #A Z@# 2(  A$! Q$!_\0
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MDS3HJ..:&49BECD!Z&-U<?FI-25TIIJZ::[IW104444P"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]&G^1/1116PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/(3QTZL?2J-%9Q;B[Q;BULXMIKYJS)NULVCJH_'?C.V ,'B?7(?*#%!#J5U
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M2<UZ]#Q^X?DO]IR/.*+O9^QG@L0D_6=?#-_^ FD<[H-7E1JK6VG)*S^<HO\
M _6NBOS-;]I_XIV=KI,XO=+F%S;SO<)/I<,K2-%<-&K"3?&R$I@$ 8)&[CH-
M6']L3QU %$F@:!>,#AS/]I@#<\[1;29!ZX[5[-+QPX)E)1K?VOA6XTYMULOC
M4252$*D;O#8C$.ZC-7LGK=*]C99Q@]%)U8W2>L+I72?V7+OV/T=HKX(L_P!L
M^\50=1\%VSMCYA8WTT8SCLTXEP,^HR!UKJ=._;+\,SA?[1\)ZG8G^(Q:A!=
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MXO9Q=TUHT?L7X8\3Z'XQT2Q\0^'-0@U+2M0B$D%S P.#QOAF3[T-Q"WR30R
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M[]M+Q<FG27VI^%O#\_E7T5FT=H;^$LLD+R^8'DO74$%,%=A!SGC%?#5:2_\
M(O7?_8:M?_26:O>P'B=Q_0=7DXKS6?)0J3BL14I8NTHI6;^MTJ[=M[-M/JF;
M0S#&I+_::KNF_>:ELTOM)_U<^\+/]N2W+E;_ , R+&/^6MOK85L<<^2VGS=L
M\>:>>]=7;?MN> &9$N_#7B6+=PSVWV&XC0]R?.GLV*CGHI)XP.>/S);H?H?Y
M5!7IT/&_Q(P^LLZP^)4;+EQ.59:[[;RH8:A/6^MI)_,U>;X^%OWREO\ %3IZ
M[?RQB_QZ^EOUIM/VPO@Y.,W-YK5@<?=FTLSM]-MG-<$GZ ]#78:?^TM\&=1
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MF[?[U0Q^#2OIK+%X2C%;ZW:MULC99KE[M_M,%?;FC./_ *5%'VE7XJ_M8_\
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M'BC3_$6G:1:Z.+6>73O%=Y;MIUOJFL>#'FA83ZMX=BOTE1'CMI&E9%:W??M
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MT/T/\J>_WC^'\A3&Z'Z'^59RWAZ_JC+[?_;WZD%%%%9$C7^XW^ZW\C5_6O\
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MKAXI0J:U<.DN>C1^HP&8+$*-.JU&M96>B5166JV2GWBDD]X]4O9****_7SU
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M_MK1QXTUO5+:ZTJP,+ >5I(@C?=??\>MO@)@=*Y;3?A/\:O &L^*;[PGX/\
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M6::T::>J:>C3V,QK_<;_ '6_D:OZU_R$7_Z]K+_TEBJ@_P!QO]UOY&K^M?\
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MZWO/)87!C4P2-&6 \5U;X >._'&@>/4U/3;_ ,.Z_JGPST7P3H-UXV^)\_Q
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MVIZ/3'Z#Z_T-<9IGQ)^'^M>(KCPEI'C'0-1\2VLEW%-HUI?I+>";3\?VA!$
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MIS_?.;ITY1<:E1M^XMI-NTM->;O]EMO?9Z[(^'?%?P=^+T?PS\9_!RS^#_\
MPEFIZC^TO#\8;+XI_P!I^&TTC5/#6H_%32O&C:LSW5PNOIXST/14GT*;2G@
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M"T;5#INHV6CZ1=P^/'TB_N[>5YK74%:ZU?27C@C6X*23HTD>(WQZG\.?C_\
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M//\ M<6OAC0[30;_ %'Q?\$KB'3K#5M$GCUNX\'Z9%J^LZ/=ZY8K>^'#KM]
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M^TQX!GN)&CT;QOX-\3Z9:DLT446NZ!?66IRKDX1Y;G2[0, ,NJJ>B"BO ?\
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M=\)ZH_C&3P7JD]C*7MH-&NGO+%M(C,;6X\Z#9"H"[?O#Q'XE/A]M!"Z)K_B
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MDB22>&-'EC*L)(U8NA5@Z@J<?II^S!_P363]HC]G9?VE/%'[4WP;_9[\$/\
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M$1W7JOS/Q5UKP1XR^'?['^D?&_P=X6\07VKWOPT^,OP<^-G@;3]*O6U_Q+X
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MX=LM1M'U?1-"\1>(Y]8U/5-7U?5?%&I:'IS:OJFJ76KW%Q=+>W$R[9K=##!
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M3\#V?[4?A^U^'<L.IZQ^TQH,^MR#3O&]CI&D_"O6(?#UY8^,=;D\+@:IXD\
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M1="U)[WQ!I_@V[GECN$21KE+>*4.C0(Y0?7X?(L)CL-&>!S7,Z.28K%8:A+
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MT_--:->:/\=VFFTTTUHTU9IK=-/5-=4]@HHHH ^L?!/[>'[9_P -O">@>!/
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M.\.T^5K)<FR[+ISCM5K87"TJ5>MLM:U>-2K+17<V[(\,^,W_ ",MM_V#H/\
MT.6O'VZ'Z'^5>P?&;_D9;;_L'0?^ARUX^W0_0_RK^7^*/^1_FW_8;5_*!MB?
MX]3_ *^K_P!)1!4#=3]3_.IZ@;J?J?YU\_+9^C_(PJ=/G^@E0-U/U/\ .IZ@
M;J?J?YU@1'=>J_,2BBBE+9^C_(J>Z]/U97HHHK*7V?\ "OU%/XG\OR1$_4?3
M^IJ%^@^O]#4S]1]/ZFH7Z#Z_T-8R^W_VZ214C=#]#_*EI&Z'Z'^59/;YQ_-
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M(Y?:83*L'JG_ +3FM*37K]4IXK\+FT<EQ[WA3A_BJ1=O_ >;\+GY%MT/T/\
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MZ,LKRLC/:QH"[ER $@W8&<#YNE;,'[/GPVA;?)I^H7#YS^]U.X" DYXBC,:
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M6DJJH"JH51T"@ #Z 8 KU*/@H[?[1Q%KVHY9IZ<U3&_CRFBRK^:O]U/]7/\
M0_+.#X;^/+W'V?PEKT@."'_LVY"8_P![R\=Q6_#\#OB?<!3'X8N5W=?/FMK;
M;_O?:)HC^0.*_2ZBO3H^"N1Q2^L9MFM6SN_9+"4$[VO;FH5VMN[+654EO5J.
M[N[<J[=XR['YWP?LV_$FY7<UMIEHY(RESJ$&%&.I:W-QDCT"GZUOVO[+/C"4
M 7FLZ';$CYC%+=7&WMC'V6+/K]X#^GWC17J4O!_@^G;VBS/$V_Y_8Y1O_P"$
M]&A^!:RK"IW?M)/?6?7_ +=2/BVS_9-N0V;[Q=:LN?NVVFS[L?[\ET 3C_8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 C=#]#_*BANA^A_E10!!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img148586500_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ++!OT# 2(  A$! Q$!_\0
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MZ.1FO_AOR'_YT^7Y]V?T&?\ $0A\;O\ H@'PK_\ !_XN_P#C]'_$0A\;O^B
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M&:_^&_(?_G3Y?GW9_09_Q$(?&[_H@'PK_P#!_P"+O_C]'_$0A\;O^B ?"O\
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MF'_S9Y?GW8?\33>/W_1R,U_\-^0__.GR_/NS^@S_ (B$/C=_T0#X5_\ @_\
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M_P#.GR_/NS^@S_B(0^-W_1 /A7_X/_%W_P ?H_XB$/C=_P!$ ^%?_@_\7?\
MQ^OY\Z*/^(1^'/\ T2^#_P#"G,/_ )L\OS[L/^)IO'[_ *.1FO\ X;\A_P#G
M3Y?GW9_09_Q$(?&[_H@'PK_\'_B[_P"/T?\ $0A\;O\ H@'PK_\ !_XN_P#C
M]?SYT4?\0C\.?^B7P?\ X4YA_P#-GE^?=A_Q--X_?]'(S7_PWY#_ /.GR_/N
MS^@S_B(0^-W_ $0#X5_^#_Q=_P#'Z/\ B(0^-W_1 /A7_P"#_P 7?_'Z_GSH
MH_XA'X<_]$O@_P#PIS#_ .;/+\^[#_B:;Q^_Z.1FO_AOR'_YT^7Y]V?T&?\
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MC_B(0^-W_1 /A7_X/_%W_P ?K^?.BC_B$?AS_P!$O@__  IS#_YL\OS[L/\
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M/^)IO'[_ *.1FO\ X;\A_P#G3Y?GW9_09_Q$(?&[_H@'PK_\'_B[_P"/T?\
M$0A\;O\ H@'PK_\ !_XN_P#C]?SYT4?\0C\.?^B7P?\ X4YA_P#-GE^?=A_Q
M--X_?]'(S7_PWY#_ /.GR_/NS^@S_B(0^-W_ $0#X5_^#_Q=_P#'Z/\ B(0^
M-W_1 /A7_P"#_P 7?_'Z_GSHH_XA'X<_]$O@_P#PIS#_ .;/+\^[#_B:;Q^_
MZ.1FO_AOR'_YT^7Y]V?T&?\ $0A\;O\ H@'PK_\ !_XN_P#C]'_$0A\;O^B
M?"O_ ,'_ (N_^/U_/G11_P 0C\.?^B7P?_A3F'_S9Y?GW8?\33>/W_1R,U_\
M-^0__.GR_/NS^@S_ (B$/C=_T0#X5_\ @_\ %W_Q^C_B(0^-W_1 /A7_ .#_
M ,7?_'Z_GSHH_P"(1^'/_1+X/_PIS#_YL\OS[L/^)IO'[_HY&:_^&_(?_G3Y
M?GW9_25\*_\ @N/^TG\8OB/X)^%G@W]GWX.R>*_'_B/2_"WA]-3\4^+;#3VU
M75[E+6S6\O"\HMK<RNOF3&-]BY;:<8K$\8?\%Y_V@_ _BWQ3X*UW]G[X1KK?
M@_Q'K?A;65M/$OBVXM5U7P_J=UI.H+;7 E03VXN[280S;$\V,*^U=V!^27_!
M/O\ Y/=_98_[+=X"_P#3W;5Y3^TM_P G&_'_ /[+9\5?_4[UZO$CX9\ OB.M
ME3X6P'U6GDF&S"+]OF/M?K%7'XK#23G]>LZ?LZ$+1Y;\W,W)IV/L:GTB?'"/
MA_@^)EXDYW_:5?C',<BFG@\@>&^HX7)<JS"DU2_L;F5?V^+JJ53VCC*GRQY$
MTY2_:#_B(0^-W_1 /A7_ .#_ ,7?_'Z/^(A#XW?]$ ^%?_@_\7?_ !^OY\Z*
M]O\ XA'X<_\ 1+X/_P *<P_^;/+\^[/CO^)IO'[_ *.1FO\ X;\A_P#G3Y?G
MW9_09_Q$(?&[_H@'PK_\'_B[_P"/T?\ $0A\;O\ H@'PK_\ !_XN_P#C]?SY
MT4?\0C\.?^B7P?\ X4YA_P#-GE^?=A_Q--X_?]'(S7_PWY#_ /.GR_/NS^@S
M_B(0^-W_ $0#X5_^#_Q=_P#'Z/\ B(0^-W_1 /A7_P"#_P 7?_'Z_GSHH_XA
M'X<_]$O@_P#PIS#_ .;/+\^[#_B:;Q^_Z.1FO_AOR'_YT^7Y]V?T&?\ $0A\
M;O\ H@'PK_\ !_XN_P#C]'_$0A\;O^B ?"O_ ,'_ (N_^/U_/G11_P 0C\.?
M^B7P?_A3F'_S9Y?GW8?\33>/W_1R,U_\-^0__.GR_/NS^@S_ (B$/C=_T0#X
M5_\ @_\ %W_Q^C_B(0^-W_1 /A7_ .#_ ,7?_'Z_GSHH_P"(1^'/_1+X/_PI
MS#_YL\OS[L/^)IO'[_HY&:_^&_(?_G3Y?GW9_09_Q$(?&[_H@'PK_P#!_P"+
MO_C]'_$0A\;O^B ?"O\ \'_B[_X_7\^=%'_$(_#G_HE\'_X4YA_\V>7Y]V'_
M !--X_?]'(S7_P -^0__ #I\OS[L_H,_XB$/C=_T0#X5_P#@_P#%W_Q^C_B(
M0^-W_1 /A7_X/_%W_P ?K^?.BC_B$?AS_P!$O@__  IS#_YL\OS[L/\ B:;Q
M^_Z.1FO_ (;\A_\ G3Y?GW9_09_Q$(?&[_H@'PK_ /!_XN_^/T?\1"'QN_Z(
M!\*__!_XN_\ C]?SYT4?\0C\.?\ HE\'_P"%.8?_ #9Y?GW8?\33>/W_ $<C
M-?\ PWY#_P#.GR_/NS^@S_B(0^-W_1 /A7_X/_%W_P ?H_XB$/C=_P!$ ^%?
M_@_\7?\ Q^OY\Z*/^(1^'/\ T2^#_P#"G,/_ )L\OS[L/^)IO'[_ *.1FO\
MX;\A_P#G3Y?GW9_09_Q$(?&[_H@'PK_\'_B[_P"/T?\ $0A\;O\ H@'PK_\
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MW_1R,U_\-^0__.GR_/NS^@S_ (B$/C=_T0#X5_\ @_\ %W_Q^C_B(0^-W_1
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M0^-W_1 /A7_X/_%W_P ?H_XB$/C=_P!$ ^%?_@_\7?\ Q^OY\Z*/^(1^'/\
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M# NE2_L92A7=?B/,57J.I*-2FL/%0@Z<Y5/W[_XB$/C=_P!$ ^%?_@_\7?\
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M $0#X5_^#_Q=_P#'Z_GSHH_XA'X<_P#1+X/_ ,*<P_\ FSR_/NP_XFF\?O\
MHY&:_P#AOR'_ .=/E^?=G]!G_$0A\;O^B ?"O_P?^+O_ (_1_P 1"'QN_P"B
M ?"O_P '_B[_ ./U_/G11_Q"/PY_Z)?!_P#A3F'_ ,V>7Y]V'_$TWC]_T<C-
M?_#?D/\ \Z?+\^[/Z#/^(A#XW?\ 1 /A7_X/_%W_ ,?H_P"(A#XW?]$ ^%?_
M (/_ !=_\?K^?.BC_B$?AS_T2^#_ /"G,/\ YL\OS[L/^)IO'[_HY&:_^&_(
M?_G3Y?GW9_09_P 1"'QN_P"B ?"O_P '_B[_ ./T?\1"'QN_Z(!\*_\ P?\
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M0^-W_1 /A7_X/_%W_P ?H_XB$/C=_P!$ ^%?_@_\7?\ Q^OY\Z*/^(1^'/\
MT2^#_P#"G,/_ )L\OS[L/^)IO'[_ *.1FO\ X;\A_P#G3Y?GW9_09_Q$(?&[
M_H@'PK_\'_B[_P"/T?\ $0A\;O\ H@'PK_\ !_XN_P#C]?SYT4?\0C\.?^B7
MP?\ X4YA_P#-GE^?=A_Q--X_?]'(S7_PWY#_ /.GR_/NS^@S_B(0^-W_ $0#
MX5_^#_Q=_P#'Z/\ B(0^-W_1 /A7_P"#_P 7?_'Z_GSHH_XA'X<_]$O@_P#P
MIS#_ .;/+\^[#_B:;Q^_Z.1FO_AOR'_YT^7Y]V?T&?\ $0A\;O\ H@'PK_\
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MA_\ G3Y?GW9_09_Q$(?&[_H@'PK_ /!_XN_^/T?\1"'QN_Z(!\*__!_XN_\
MC]?SYT4?\0C\.?\ HE\'_P"%.8?_ #9Y?GW8?\33>/W_ $<C-?\ PWY#_P#.
MGR_/NS^@S_B(0^-W_1 /A7_X/_%W_P ?H_XB$/C=_P!$ ^%?_@_\7?\ Q^OY
M\Z*/^(1^'/\ T2^#_P#"G,/_ )L\OS[L/^)IO'[_ *.1FO\ X;\A_P#G3Y?G
MW9_09_Q$(?&[_H@'PK_\'_B[_P"/T?\ $0A\;O\ H@'PK_\ !_XN_P#C]?SY
MT4?\0C\.?^B7P?\ X4YA_P#-GE^?=A_Q--X_?]'(S7_PWY#_ /.GR_/NS^@S
M_B(0^-W_ $0#X5_^#_Q=_P#'Z/\ B(0^-W_1 /A7_P"#_P 7?_'Z_GSHH_XA
M'X<_]$O@_P#PIS#_ .;/+\^[#_B:;Q^_Z.1FO_AOR'_YT^7Y]V?T&?\ $0A\
M;O\ H@'PK_\ !_XN_P#C]'_$0A\;O^B ?"O_ ,'_ (N_^/U_/G11_P 0C\.?
M^B7P?_A3F'_S9Y?GW8?\33>/W_1R,U_\-^0__.GR_/NS^@&__P"#ACXW6EC>
MW7_"@_A3']FM+FX\Q]9\7SK'Y,+R;V@2\@>95V[C$L\+2 %%EC+!Q_2'^RO\
M7M3^/_[-WP.^-NM:7IVBZM\5/AAX.\<ZCIFD/=OI=I=^(M%M=1G33UOFDO(+
M1WF,L%G=7%[/8QR+9RZCJ3P&_N?\Z3Q!_P @'6_^P1J7_I%-7]_7_!-7_E'Y
M^QI_V;A\)O\ U#]+K^=O''AKA[A;%9#@\@R?"Y=#&8?&8G$5:4\54K5)4JE*
ME"#E7Q-6"II3<FHP4G.SY[73_O?Z&?B'QWXDY9QOFO&_%699_5RK'95E^ P^
M)HY90PM"GBL/B,15K*&"R_#5I8ARHQ@I3K2IJFY+V3FU-?R1_P#!7C_E*1^U
M3_V!O@%_ZI+P;7Y\5^@__!7C_E*1^U3_ -@;X!?^J2\&U^?%?O7@G_R;7A[_
M !YQ_P"KS,3^(?I@_P#*0_'O_7OA/_UB^'CZ%T7]D;]J[Q+HVD^(O#O[,?[0
MNO\ A_7],L-:T+7=%^"WQ(U71M:T;5;6*^TO5M)U2Q\-3V6I:9J5E/!>6%_9
MSS6MY:S17%O+)#(CLS7OV2OVJO"VBZMXE\3_ +,W[07ASP[H.GW>KZYK^O?!
MGXCZ1HNC:580/<W^IZMJNH>&[>QT[3[*VCDN+N]O)X;:V@C>6:5(U9A^AO[=
M?[0GQ\^$^C?L%^'?A9\</B_\-/#][_P3B_9<UJ\T+X?_ !+\9^#=&N]9N;7Q
M?8W&K7.E^'=:TVRGU.>RTW3K.:_E@>ZEM;"RMWE:&U@2/\\M>_:U_:J\4Z+J
MWAKQ/^TS^T%XC\.Z]I]WI&N:!KWQF^(^KZ+K.E7\#VU_IFK:5J'B2XL=1T^]
MMI)+>[LKR":VN8)'BFB>-F4^_D^9<5YOA<-F-.EP]1P>(JU;4YRS*6*C0I8J
MI0=W&U)UG"G*2M[BDTGI<^'XJX?\,>%LQQ^0U\1QYB\WP&%PW-B*4.'X9=4Q
MN*RW#XR-HSOB5A85<1&$K_O73BVO>:/GVBO>_A?^R]\>_C3X-\1^/?A5\-M8
M\=>&O"?B7PQX0UR;0;S1;G5H/$7C*\@L/#NFV?AA]3C\4:NU]<W$?FW.CZ-?
MV6FVXEO-4N;*SMYYXO:_B!_P35_;>^%_@C7/B+XS^ VL6?A+PS92ZCXBO](\
M5_#WQ;?:'86ZB2[O=5T#PCXNUWQ%8VMC#NN=0GN=*CBT^TBGN[UH+:WGEC]Z
MOQ#D&%Q*P6)SS)\/C)5UA8X2OF>"I8EXEQI36'5"I7C5==PKT)JDH>T<:U*2
MC:I!R^*P? ?'&8Y=+.,OX-XKQV4PP<LQGFF#X=S?%9='+X5,32GCI8VA@YX:
M.#A5P6,IRQ3JJA&IA,3!S4J%50^&:*Z/PCX0\5>/O$NC>#?!'AW6?%GBSQ#>
MIIVA^'/#VG76K:SJM[(K.MO8Z?9137-PXC22:39&5B@CEGE*0Q2.OV1X\_X)
MG_MR?#7PGJWC;Q9^S_K\/A_0;(ZEK;Z%XE\ ^,M7TC3EC\^6_P!2\,^#?%FO
M^)K*SM[?==7=U<:/'!9VD<MU=/#;PRRIMC,YR?+J^'PN89KEN!Q.+:6%P^,Q
MV%PM?$MS5-+#T:]6%2LW-J"]G&5YM1W:1RY3PEQ7G^"QV99%PQQ#G6798F\R
MQ^4Y+F68X++U&DZTGCL5@\-6H811HQE5;KU*=J474?NIL^/_ !GX#\<_#C6W
M\,_$/P9XL\!^(TM+2_?P_P",_#NL>%];2QU"(3V%Z^E:Y9V-^MI>P$36ER;<
M0W,1$D+NAW5RE?JY_P %F_\ D]G5/^R3_"3_ -16&O$? ?\ P3*_;H^)/A;2
MO&?A;]G[7O[ UVV%YHTOB7Q/X \"ZGJMHZ&6*YL/#WCGQ;X<\0W4%S"%GM)8
M=*=+RWE@N+4S0W$$DGC99Q7EM7AS),]SO'99DBS? X;$I8W'4,)05:O1C5G1
MHU<74I>T<%+17<N75H^KXB\,L_P_'W&/!?!^3<1<7OA;.<PR^4LHR7&YIC7A
M<'BYX6GB\7ALKP^)=!5912<G%4^=\L6WH?"-%=K\0_AOX^^$WBW5O GQ,\(>
M(/ _C#1)V@U+P_XDTVYTS4(,.ZQW$<=PBK=Z?=!#-I^IV;W&G:C;&.[L+JYM
M98YG^A?@K^P;^UM^T+X6_P"$X^$WP8UK7O!SW+V=IXHUC7/"'@70M5N(G>*9
M-#U/Q_XB\+VFOK!/%+;7$NBRW\5O=PS6DSI<PRQ)[>*S;*L%A(9AC<SR_"8"
MK[/V>-Q6-PV'PE3VJYJ7)B:M2%&?M8^]3Y9OG6L;H^0R[A?B;.,UK9%E'#N>
MYIG>&]O]8R?+LHS#'9K0^K24,3[;+\-AZN+I?5YM0K\]&/LI-1J<KT/D6BO7
M_C5\ OC)^SKXM_X0?XU_#[7OA]XE>U2_M;/6([::TU.P<[1?:+K6FW%]H>NV
M22AK>:[T?4;ZW@NXYK2:2.ZAEB3Z>TG_ ()=?MX:WJ-YIFG? '4))+#2= UJ
MYOKGQU\+=/T$67B>WDNM&2'Q-J'CBU\.W6HSVT:3W6C6NJ3:QI<5UISZK860
MU33C=85^(,@PN'P^,Q6>91AL)C*<JV$Q5?,L%1P^*I0E2C.KAZ]2O&E7IQE7
MHQE.E*48RK4DVG4@GVX+@3C?,\?C\JRW@WBK,,TRJO3PN:9;@N'LWQ>/RW%5
M88BI2PV/P=#!U,1@Z]6GA,74IT<13IU)PPN(E&+C1J./QE:?#SQ_?^"M4^)5
MAX&\87OPYT/5H- UOQ_:>&=:N?!6CZ[=+9O;:+JGBJ&R?0M/U:X34+!H-.N[
M^&\E6^LVCA87,)?CZ^J/#T/[4,7[(/CV^\/W.H1?LDW/Q<TC2_'<$>I^#DTZ
MX^*XTK0=0TE)])N;H>.9IETRVT&9;S3K-M!7R(DGG%PDZ!_P^_8A_:I^*NB?
M"[Q)\._@]KGBS0?C)9>/-2^'^K:5JOA=['4-.^&6N0>&O&VH:Y/+KL2^";'2
M->NK;2H;OQS_ ,(Y;ZQ=SPQZ')J0D0F%G.$PT<94S3,\EPM&EF-?!T*BS"E"
M,?8X)8V6'QDL1*E"EF-*A3Q6*KX:$I>SP5)8AM051PUEPEFF8U,IP_#G#O%^
M98S%9!@LVQN'ED6)K5*CQF;2RFECLIIX"&)JXK(,3C,1EN78+,*L*;Q&;8F6
M!C%U98>-3Y4HKZK^.W[$/[4W[-/A_3/%GQH^$>J^$_"NKWHTVR\366N^$?&/
MA_[>ZL\-G>:SX&\0^)=-TRYN527['#J5S:27K07"6BS/;SK'XS\+/A)\3/C=
MXQT_X?\ PE\$^(/'WC'4DDFMM#\/6+W=Q':0O%'<:C?S$QV>E:3://"+W5]4
MN;/3++S8S=7<(=2>K#YOE6+P4\RPN9Y?B<NIJHYYAA\;AJV"@J/\5SQ5.K*A
M%4K/VC=1*%O>L>;CN%^)LLSBEP]F7#N>Y?G]>6'A1R/'91F&$SBM/%V^JQI9
M97P]/&U)8FZ^KQA0;K77LU*Z/.JZOPAX#\<_$&\U+3O 7@SQ9XWU#1M$O_$V
ML6'A#P[K'B6\TKPYI1@&J>(-2M=&L[V>QT333<VPO]5NDBL+,W$ N+B,RQ[O
MK3XF_P#!-[]MGX0>#M6\?^.O@-KMKX3T&.2;7M3\.^)/ GCR30K:!#)=7>M:
M9X#\5>)=6TFRL8@TNI7NH6%O::;"CS7\UO&CNOOO_!(K_DL7[2/_ &9/\>__
M $?X+KQ<SXJR^EP_F>>9+C<MSJ&7P3;P>-H8O#^U<Z<?95*N$J55"7+44N6Z
ME:SM9GUO#WAKGF(XZX<X-XORCB'A&KGU?E2S;)\9EF/6&]E7FL3A\+F=##RJ
MTW.BX*HHNFWS+FNK'Y1T5VGP^^'7COXK^+M'\!?#7PEKWC?QCK]P+;2?#WAS
M3KC4M1NGZRS-% C+;6-I%NN=0U&[>#3]-LXYKV_N;:TAEF3Z\\;_ /!,C]NK
MX>>%=5\9^)?V?/$#:#H=N+K6&\-^)O 'CC6--ML!I)[SPSX)\6^(?$T$5O&3
M/=R/I 6SMHY[FZ,-O;SRQ^MC,[R7+L11PF89OE>!Q6)Y?J^&QF/PF%Q%?FG[
M./L:->K"I5YI^Y'DC*\_=5WH?,93P=Q=G^!Q>:9%PKQ'G669>YK'YCE.1YGF
M.!P3ITO;5%B\7@\+6P^&=.C^]FJU2'+2_>2M#4^#Z*O:9IFI:WJ6G:-HVG7V
MKZQJ]]::9I.DZ9:7%_J6IZE?W$=I8Z=IUC:1RW5[?7MU+%;6EI;12W%S<2QP
MPQO(ZJ?O.]_X)9?M]:?X=F\3W/[.?B$V%OI,FMRZ=;>*?AW?>+1IT2,[R)X$
ML?&%QXWEN!L,8L(O#SW[W&+9+5KAEB-8_.<GRJ5"&:9MEN6SQ+<<-''X["X.
M6(E%Q4HT(XBK3=5IRBFJ:DTY13U:O.1\(\5\34\95X;X8XAX@I9?&,\?4R/)
M<RS:G@834I0EC)X##8B.&C.,)N,JS@I*$FFU%V_/ZBOKC0_V$_VJ?$?BSX;^
M!=*^%R/XP^+OPYG^+'PZ\/7OCKX;:1J?B7P+:HLMQJD,&K^,+'[!J$,/F32>
M&-6-AXJ6"UOYCHOE:??/;_)MS;7-E<W%G>6\]I=VD\MM=6MS%)!<VUS!(T4]
MO<02JDL,\,J-'+%(JR1R*R.H8$#7"YEEV.G.G@L?@L9.G"%6I#"XJAB)TZ=2
MK7HTZDXTJDW"$ZV%Q-*$Y)1E5P]>G%N5*HH\N9</Y]DU.C6SC),WRJCB*U7#
MX>KF66XW TZ^(H8?!8NO0HSQ5&E&K6HX3,<OQ56E!RG3P^/P5:<8T\50E4AH
MKUKQ=\#/BGX"^&OPT^+OC#PO_8/@'XQ?\) WPVU:]UOP[_:'BF#PM>II^NWU
MKX7AU>7Q79Z99W4MNB:KJFAV.FWL=Y8W%A=75O?V<L_DM;T,3A\5"53#5Z.(
MIQJUJ$JE"K"M"-;#59T,11E.G*455H5Z=2C6IM\]*K3G3FHSC**X\;@,=EM:
M&'S'!8O 5ZF&PF,IT,;AJV%K3P>886CCL!BH4Z\*<Y8;&X+$4,9A*ZBZ6)PM
M>CB*,YTJD)R^@M!_9*_:J\4Z+I/B7PQ^S-^T%XC\.Z]I]IJ^AZ_H/P9^(^KZ
M+K.E7\"7-AJ>DZKI_ANXL=1T^]MI([BTO;.>:VN8)$EAE>-E8\]XZ_9X^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU\MD'_(XXX_[*7!?^L;PH?I/&_\ R2G@Y_V;[./_ %['B8%%%%?4GYL%%%%
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MJF'PE2AB*N%E@Z]3TSP+_P H:_C;_P!GL>$__5>^$*ZGX[_&3QSX*_X),?L
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M[CLNRRA5K*G/V:Q&,I*;BU%MV1^5-?KW\4+2;PW_ ,$7/V=-,UA?L=_XZ_;
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MT6\U/3+NS$UM+=JMQ'O]"^*>A?\ !-+]IC7+?XQ:!^T%=?L3ZSXFTW37\:_
M%OV<O%7C[PIX:\1:?I]MI=]+\/-0^%MOHWARVT+46L#J45K=K;SWUU?OJ-U!
MX?FNKG1=/^9PV"KX/ </XC$X?B7*L;@L7QFL/FF59/4S>>$CF/$-:O\ 5,PR
M7^S,RQ<\+FF&I4,1A\;1PL/9QH)+&8>.*A[?]%S/.,%FV>\=8'+\=X><391F
M^5>$4L=PYQ-Q90X6H9G/A_@+!X)9KD7%_P#K%P_E=+,N&\PQ.-P&.R?%9G6=
M>>-J.>58VIEU7ZGS7[2OPJ_:V?XK?LC?!K]K?QOI_P 0O 6L7?AGP7\$_B=X
M0O\ PMXFT+Q%\._$GB+PGIFMW/A[X@:9HNF^(?%KV$%]I,T<GCA[S5;1;NSO
M;91I^L1W-_\ </\ P4>_9WUWXR?'6\\&0_MF_L2_"+X2?"/1_"W@KX8_ CQU
M\<M>\&ZE\/\ 3=(\,Z='-)K?@FT\#ZII.G>(=0N+J[EBO89YKAO#DFBV7G^1
M;1H/SQ_:R_:>^&>I_#W]G+]F_P#9AO\ QW<_"_\ 9BN?$^OZ3\4O&J1:/XO\
M;?$'Q1K_ /;MUXBTG2+=Y)_"WA_1KL3W'AJVDFM-1"ZFT6H:;;3:3;75Y[3\
M7/&W["W[=M_8?''XI_';Q'^R'^T5J6B^'M)^+^E7?P=\7_%CX:_$+7?#^B6.
MC+XR\&)X%GN-5\--?65M:6US::Q=(H32XH?[,>[-UXCUO/ZIG=*?"V;XG"5\
MJP^"PO$N$MD_##QM7"5\;FV&JX#-*W#>&AC<1E]?-\NH5:N,EAJ>)KX#%8BK
M1K^QCBL0J>W]J<&XFCXE<+9?FF#XFS#-\Q\/,T<^+?$>&3X?-,%E'#.-P^>\
M-87Q Q]7*,OSS"<*Y]C,/A<IAF%?+\'G678##XS _6ZN68)XCO\ XWZ-X5T+
M_@FWK_PG^+7[6'[-/[0/Q2^$7Q2\*^)_V>%^$WQ@'C_Q5H_@O7)]*\+^+/ [
M+J^@^'-=F\/:;:WVI>(+73X8]5MK."WME\VRT_P_I=I;<7=_ 3Q?XI_9A_9^
MF_;A_;7\&?LV_!_3_#IUG]G7X.Q_#9_'?C2?PCKTJR#QK??#_P"&,/AO5+PZ
MVLPO++Q/XBN/$FL-%J-ZVK:EHT]_J,4WSO\ M#>.OV0/!'P0T+]GC]F#3)OB
MQXBN/%4'C'XG_M2^/OASH_ACQ/K<EKID%K:^"_AC8ZO9WGC3P;X+EO%74=3L
MI]1L;H7%G]BDN?$%MJNHWA]_^)?Q!_8Q_;@\#_!#QC\9/VB_$/[+?QS^%7PE
M\,?!;QCI%[\'?&?Q=\&^.-'\#F^?1?%'A63P2+:70KW4WU6^N+ZQU>\BABEE
M73([=(].77M;NEA<RP6$P%>-+.</@<9Q-FV9ULSI\+X?&Y[E:K8&%"C6RW(8
MY=F53**6;8B.-J8BM/*\1BJ*Q4WB:-#Z_-TL<3F?#^;YIG6#J8GA',<XRGPZ
MX6X;PO#N(\2,?D_!?$DL)G-3&8O"<0<;3S_A_#\58GA? RRBC@,)1XEP668M
MY;0678O'?V+1CBNC_:,TCX8Z+_P2L\(:#\*_VAM4_:5\*>$OVXK'2=$\6ZU\
M,?$_PNF\$Q:O\#?&&K:I\/\ 2-%\5ZUK=[+HR7<=KXG-Q97%OI[7VNSPK;B:
MVD<MO/'W[+7[;G[-G[,7P:\:?M)WG[*7Q,_9U\&R^!$\-^.O">K:_P#!SQ_+
M;6%I!#XR@\0:%=6FG^&M8U&*RC>_U/Q(\-Y#<W6J:9::7?PFVU74.-_:$^,G
M[&;?\$_])_9<_9Y\9^)[[Q'\//VE=)^(UQJ'C;P5JVB:_P#&CS_ ?BC0/$GQ
M%A.EZ;/X:\-:3!/XETOP]X<T'Q!KB>+8O#G@^TCU&TN)Y([N;"O[[_@GS^U%
M\+OA/?>,_B':_L0?'/X=^#]*\ >/U\-_ ;5_''PV^+L>A1R+;>/XM-^%=AID
MVF>,-;>X>]U[4=5@CNGN#)HTD6IV6GZ5K1SPF#K1P%+%8O#<7X6KA^+L\QV"
MSBADU"MF^#^MX1TZ./QF08?)JE+%83-*5>M"L\)DSGA:U1*K]6Q"KU:?1F>;
M82IG>+RS+,P\*LQPF/\ "O@O)\XX3QG%N-P?"V:_V5FE.MBLDRGC?'\6X?$Y
M;FG#>)P>%K86.:<6>RS+"X>3PRS' RP6&K\_^U1\(OVO?@]^S1\-O"7BKXM^
M _CO^QS#X\EU7X9>-_A5XC\/?$'P5I'C0:9KFEPZ1%XJET2R\<Z$O]DMK*+X
M7>^?P9;WPNHK>.36;,F+[I^._P $K_Q#^QU^Q%\"/ G[4?[+G[-_PZU7]G?P
M-\;O'_@;XQ?&/6/AYXH^)GCKXJV<?B&[\3:KH]AX1\0-KGA;3=3CU6'0;B\U
M/[*=4.HVBZ7"GAS2)(?AKXS?'C]GWX4?LDW_ .Q?^S-XS\7?&FS\>_$O3_BG
M\6_C-XM\)77@#0+B[T>RTJUTCPU\.? ^HW4NO:;"9]"TF\U?4_$)EN/]&G@@
MGU&#4[>+PST>A?&?]E+]K#]GSX1_![]JWXA>*OV?OB[^SKX=N? _PU^.&B>
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M9E=6-?!8S$4Z3J4:5?"5[N6'Q-6,6PHHHKZL_,0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _1W_ ()(
M?\I#_P!G'_L)_$'_ -5'X_K\\]8_Y"VJ?]A&]_\ 2F6OT,_X)(?\I#_V<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME-?*,8LUS?%Y%F=''T,7AJ]2..R[$X3^S\;&K7DZ6'QL\/C\)_5I<^%?@_\
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MU?\ E'Y^QI_V;A\)O_4/TNOX!?$'_(!UO_L$:E_Z135_?U_P35_Y1^?L:?\
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MK1BDOS"_X<N?\$^_^B5^)O\ PZ/Q#_\ FAH_X<N?\$^_^B5^)O\ PZ/Q#_\
MFAKZ^_9B_;#_ &<_VR?"_B+QG^S=\1/^%C^&O">O)X8\0:E_PB/CKPA]@UR3
M3[;54L?L?CSPQX7O[K-A>6\_VFRM;FS'F>4;@3))&OTQ77_K_P <?]%?Q)_X
M><P_^7GE_P#$#O!G_HU7A]_XB.1__,1^5/\ PY<_X)]_]$K\3?\ AT?B'_\
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M)O\ PZ/Q#_\ FAK]5J^3O!/[<?[+?Q%_:*\8_LG>#?BA_;'Q_P# $6MS>+?
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M_-#7ZK44?Z_\<?\ 17\2?^'G,/\ Y>'_ ! [P9_Z-5X??^(CD?\ \Q'Y4_\
M#ES_ ()]_P#1*_$W_AT?B'_\T-'_  Y<_P""??\ T2OQ-_X='XA__-#7ZK44
M?Z_\<?\ 17\2?^'G,/\ Y>'_ ! [P9_Z-5X??^(CD?\ \Q'Y4_\ #ES_ ()]
M_P#1*_$W_AT?B'_\T-'_  Y<_P""??\ T2OQ-_X='XA__-#7ZK44?Z_\<?\
M17\2?^'G,/\ Y>'_ ! [P9_Z-5X??^(CD?\ \Q'Y4_\ #ES_ ()]_P#1*_$W
M_AT?B'_\T-'_  Y<_P""??\ T2OQ-_X='XA__-#7ZK44?Z_\<?\ 17\2?^'G
M,/\ Y>'_ ! [P9_Z-5X??^(CD?\ \Q'Y4_\ #ES_ ()]_P#1*_$W_AT?B'_\
MT-'_  Y<_P""??\ T2OQ-_X='XA__-#7ZK44?Z_\<?\ 17\2?^'G,/\ Y>'_
M ! [P9_Z-5X??^(CD?\ \Q'Y4_\ #ES_ ()]_P#1*_$W_AT?B'_\T-'_  Y<
M_P""??\ T2OQ-_X='XA__-#7ZK44?Z_\<?\ 17\2?^'G,/\ Y>'_ ! [P9_Z
M-5X??^(CD?\ \Q'Y4_\ #ES_ ()]_P#1*_$W_AT?B'_\T-'_  Y<_P""??\
MT2OQ-_X='XA__-#7ZK44?Z_\<?\ 17\2?^'G,/\ Y>'_ ! [P9_Z-5X??^(C
MD?\ \Q'Y4_\ #ES_ ()]_P#1*_$W_AT?B'_\T-<AK_\ P1R_8)L+R*&V^&'B
M1(VMDE(/Q-\?N2[2S*3E]?)^ZBC&<<9[FOV%KS[Q9_R$8?\ KRC_ /1]S1_K
M_P <?]%?Q)_X><P_^7A_Q [P9_Z-5X??^(CD?_S$?D__ ,.?_P!A'_HF7B/_
M ,.5X]_^7U'_  Y__81_Z)EXC_\ #E>/?_E]7VM\>/C_ /"3]F;X<ZE\6OC=
MXM_X0GX?:1?:5INH^(/[!\3>)/L][KE]%INEP_V5X1T;7];F^U7LT</F0:;+
M#!N\RXDAB#2#X0_X?8_\$Q_^CF/_ ##/[0/_ ,ZFC_7_ (X_Z*_B3_P\YA_\
MO#_B!W@S_P!&J\/O_$1R/_YB-G_AS_\ L(_]$R\1_P#ARO'O_P OJ/\ AS_^
MPC_T3+Q'_P"'*\>__+ZOI#]F;]MG]F/]L3_A-O\ AG'XF?\ "Q?^%=?\(W_P
MF7_%&?$'PC_8_P#PEW]O_P#"/?\ (]^%/#']H?VA_P (QKG_ ""OMWV3[#_I
MWV;[39_:/JFC_7_CC_HK^)/_  \YA_\ +P_X@=X,_P#1JO#[_P 1'(__ )B/
MS&_X<_\ ["/_ $3+Q'_X<KQ[_P#+ZC_AS_\ L(_]$R\1_P#ARO'O_P OJ_3F
MBC_7_CC_ **_B3_P\YA_\O#_ (@=X,_]&J\/O_$1R/\ ^8C\QO\ AS_^PC_T
M3+Q'_P"'*\>__+ZC_AS_ /L(_P#1,O$?_ARO'O\ \OJ_3FBC_7_CC_HK^)/_
M  \YA_\ +P_X@=X,_P#1JO#[_P 1'(__ )B/S&_X<_\ ["/_ $3+Q'_X<KQ[
M_P#+ZC_AS_\ L(_]$R\1_P#ARO'O_P OJ_3FOS]^*O\ P50_X)__  6\97_@
M#X@_M*>$[/Q7I5TUCJNG>&M"\=?$*#2K^-O+N-/U35OAYX5\4Z-INH6<NZ#4
M+"]U""\TZXCEM[Z&WGAEC0_U_P"./^BOXD_\/.8?_+P_X@=X,_\ 1JO#[_Q$
M<C_^8CB/^'/_ .PC_P!$R\1_^'*\>_\ R^H_X<__ +"/_1,O$?\ X<KQ[_\
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M/O\ Q$<C_P#F(\Q_X<__ +"/_1,O$?\ X<KQ[_\ +ZC_ (<__L(_]$R\1_\
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MX<__ +"/_1,O$?\ X<KQ[_\ +ZC_ (<__L(_]$R\1_\ ARO'O_R^K].:*/\
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M (X_Z*_B3_P\YA_\O#_B!W@S_P!&J\/O_$1R/_YB/S&_X<__ +"/_1,O$?\
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M$?\ X<KQ[_\ +ZC_ (<__L(_]$R\1_\ ARO'O_R^K].:*/\ 7_CC_HK^)/\
MP\YA_P#+P_X@=X,_]&J\/O\ Q$<C_P#F(_,;_AS_ /L(_P#1,O$?_ARO'O\
M\OJ/^'/_ .PC_P!$R\1_^'*\>_\ R^K].:\<^.7Q_P#A)^S;X*A^(GQI\6_\
M(9X.N/$.B^%(=8_L'Q-XBWZ_XBGDM]'L/[/\)Z-KNJ+]LFBD3[4UBME;[=UU
M<P(0Q/\ 7_CC_HK^)/\ P\YA_P#+P_X@=X,_]&J\/O\ Q$<C_P#F(^*?^'/_
M .PC_P!$R\1_^'*\>_\ R^H_X<__ +"/_1,O$?\ X<KQ[_\ +ZOTYHH_U_XX
M_P"BOXD_\/.8?_+P_P"('>#/_1JO#[_Q$<C_ /F(_,;_ (<__L(_]$R\1_\
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MTL:?:EL6LKC=NM;F= 6'L='^O_''_17\2?\ AYS#_P"7A_Q [P9_Z-5X??\
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M@=X,_P#1JO#[_P 1'(__ )B/S&_X<_\ ["/_ $3+Q'_X<KQ[_P#+ZC_AS_\
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MTUWQ'XEU94++->6'A'PAI/B#Q3=:7:R*(KW6(M';2K*>2&"[O(9IX4D/]?\
MCC_HK^)/_#SF'_R\/^('>#/_ $:KP^_\1'(__F(^7O\ AS_^PC_T3+Q'_P"'
M*\>__+ZC_AS_ /L(_P#1,O$?_ARO'O\ \OJ_3FOF3PI^V5^S'X[^.^L?LT>"
M?B]X>\7?&GP_HU_KVM^$O#=IKNM6>F6&E26L.J1W?C'3M)N/ T6JZ9/>6UOJ
M.@'Q+_;MA<.8+K389HI40_U_XX_Z*_B3_P /.8?_ "\/^('>#/\ T:KP^_\
M$1R/_P"8CYA_X<__ +"/_1,O$?\ X<KQ[_\ +ZC_ (<__L(_]$R\1_\ ARO'
MO_R^K[%\;_M!>"_A[\;/@O\  OQ-I_B.U\0_'NQ^($WP_P#$B6^BMX-GU;X;
MZ58:YKOA;4[Z378=;L?$5WHU^-2T.W3P_<Z?JD%I?Q1ZE'=VKVQ]TH_U_P".
M/^BOXD_\/.8?_+P_X@=X,_\ 1JO#[_Q$<C_^8C\QO^'/_P"PC_T3+Q'_ .'*
M\>__ "^H_P"'/_["/_1,O$?_ (<KQ[_\OJ_3FBC_ %_XX_Z*_B3_ ,/.8?\
MR\/^('>#/_1JO#[_ ,1'(_\ YB/S&_X<_P#["/\ T3+Q'_X<KQ[_ /+ZC_AS
M_P#L(_\ 1,O$?_ARO'O_ ,OJ_3FBC_7_ (X_Z*_B3_P\YA_\O#_B!W@S_P!&
MJ\/O_$1R/_YB/S&_X<__ +"/_1,O$?\ X<KQ[_\ +ZC_ (<__L(_]$R\1_\
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M_K_QQ_T5_$G_ (><P_\ EX?\0.\&?^C5>'W_ (B.1_\ S$?F-_PY_P#V$?\
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M#_B!W@S_ -&J\/O_ !$<C_\ F(\W_P"'/_["/_1,O$?_ (<KQ[_\OJ/^'/\
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M(_\ 1,O$?_ARO'O_ ,OJ/^'/_P"PC_T3+Q'_ .'*\>__ "^K].:*/]?^./\
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M'*\>_P#R^K].:*/]?^./^BOXD_\ #SF'_P O#_B!W@S_ -&J\/O_ !$<C_\
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MM4B\_?/911QS-'['1_K_ ,<?]%?Q)_X><P_^7A_Q [P9_P"C5>'W_B(Y'_\
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M??\ B(Y'_P#,1^8W_#G_ /81_P"B9>(__#E>/?\ Y?4?\.?_ -A'_HF7B/\
M\.5X]_\ E]7Z<U\^>-?VJ?@+\//CC\.?V;O&/CO^Q_C3\6M,?6/A]X,_X1?Q
MEJ'_  D&G1R:S$]Q_P )%I?AV]\*:5B3P]JZ^3K>NZ;.?LF1$5N+4SG^O_''
M_17\2?\ AYS#_P"7A_Q [P9_Z-5X??\ B(Y'_P#,1\D_\.?_ -A'_HF7B/\
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M_17\2?\ AYS#_P"7A_Q [P9_Z-5X??\ B(Y'_P#,1\4_\.?_ -A'_HF7B/\
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MP#H_@KQ+\8+OQ-IOQ'OO%6G>%?%GAA[&/PW>+J6J:%<:]I]_I<T;Z==W"70
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M:DUUXOUN?7M?U34/#NBPWAT73(=-@NF@U0:KIFE@%RT_X+$?\%1/%/[&]O\
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M>:?X)TWQ&8-*\/W?C!M+NKY]%M8K'2&:I^S/^T!_P4J_X)V?!:[_ &3?$O\
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M\4> 5M-'9-%MM4UG0-;L(]972+VW*/:@'V_^TG_P2)_8U_:/U'P+K:^%-3^
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MDEGDDD8 Z>BBOF#]L[XF?$7X1_LQ_%[QK\(/ _C;XB_%:W\*W.D?#GPM\/\
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MK7?#M[<^+K&_@M_!D@;58-.O&URU6:"R6/4+FT6^BU#3X?./#?[-/Q-_9_\
M^"3G_!0'Q5\:M%M_"?Q5_:-B^-/QT\2^!;2_BU&/P%9^*=.M8]&\*75U \\$
MVJ6T=O=:C?&*YG-LNIVVFW)2]T^Z6@#WGP;^U+_P5&^+'[-7A7]JGX>_!O\
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M;[/X/T"XU'QAXW\27*M#,/[,\-V&D65QJ7EI)<&*ZC"6\\/VE5_66@ HHHH
M**** "BBB@ HHHH **** "BBB@#\B_\ @HI_P5K\$?\ !/\ ^(OP\^%][\(O
M$'Q5\3^,O#$7CK6?L?BFS\':=X<\'7>NZKX>T^[L[NXT'Q&VOZW=ZAX?U[_B
M3-!HUM;P65M+-K*F^1(?T_\ AMX]T'XJ_#KP#\4/"OVW_A&/B1X*\*^/?#G]
MI6RV>H_V#XPT*P\0Z/\ ;[199UM;W^S]1M_M5LL\RP3^9$)9 N\^(_M#?L5_
MLN?M6ZCX2U?]H#X/^'_B+JW@<S#PUJEY?^(=$U&SMKB>.ZETR\O?"^LZ'<ZU
MHCW,?VC^P=<EU+15GEN9EL%DN[IIOI;3=-T[1M.L-(TBPLM*TG2K*UTW2]+T
MVU@L=.TW3K&".ULK"PLK6.*VL[*SMHHK>UM;>*."W@CCAAC2-%4 %VOE;]NO
M_DR+]L?_ +-6_:%_]5'XOKZIKYK_ &S="USQ3^Q]^U=X9\,Z-JOB/Q)XC_9K
M^.FA>'O#VA:==ZOKFNZYJ_PO\4Z?I.C:-I.GPW%_JFJZI?W%O8Z=IUC;SW=[
M>3PVUM#+-*B, ?C!^Q!^WKJ/@?\ 84^"GPCTG_@G]^W)\<=0TCX=2^'[;5M#
M^ <-Y\"_'K7&KZK(_P!F^(5QK.JP3>&+B*X>VN-2F\)WL7GPSV[V$B@M7->%
M]"^.'_!,7_@D)XI\6?$;X:_"KQ/\1M7^.EG\0K#X._%O06\>^"?A]HOQ$U;P
MMX9M/#=_IFC:YHZ'6-/M=-O?$,:V6M,NDZCX@FL[II9[>[M5_7'_ ()H>$?%
M?@/]A']FCPAXY\,>(?!GBW0?A\++7/"_BO1=2\.^(M&O/[=UF;[)JVB:O;6>
MI:=<^5+%+Y%Y;0R^7)&^S:ZD^&?\%HOAU\0?BG^P3\0/!WPQ\"^,?B-XNO?&
M7PTNK/PMX#\,:WXO\1W=M8>,-.NKZXMM#\/V.HZG/!96R/<7<T5J\=O C2S,
MD:E@ ;GQ:_;%^)7P"_:"_8;\(^(_#/PYL_V9/VH]$M? FH>(]/T36['Q1X"^
M,=UHUO+X3T>TU!O%J>%[3P9KMYK'AS3=.TZY\.2:C:6=IXANDU:X%A!;-V_[
M2/[5?Q.\%_M9_LH?LF? W0O!>N^+?C%=:YX[^+VI>,]*UW5;;P%\"_"K,-3U
M[2TT/Q/X:^R>(==ET[Q#IGAR\U9M1TG^V=-MK"?3[F;4($K&_;A_9CU;]I;]
M@'4_AKI-AJ%M\5/!W@7P=\1_A<D,5Q;:]IOQ4^&^B6^IZ5IUA'Y8N;/6=;@3
M5_!@)C2XM&\03,##-&KIXC_P3(^'GQN^)GC[XU?MV_M6?#WQ)\./C9\3M,\%
M?!SPEX(\9>%]4\):SX1^'OP[\,^'XO$FJ6F@Z[I&DZGI5E\1?',%QKOV<V\4
M#-IC7%I&MI>1 @'1I^V)^UM^TM\=OCE\+?V&_!7[/MC\/_V</$__  KWQ_\
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M,-1NK&XN=#\06.G:G!!>VSI<6DTMJD=Q ZRPL\;!B >G_LR_ML>+_P!JW]B
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M&_: \>>$O^"A?["7[.?C#X=_ ;7]5^+WPA\>^(/B'\1(?!FLWGC#PSXO\#>
M/'?B.XMOA)XFU37UN?#_ (1NO$F@2"&SUS2M9U1M'O[N-[N"_N&NHN%_X*4:
M1\2/#G[47_!.3]HCPK\%OC!\9O OP&\:?'6X^)6G_!/P1??$/QAH]MXZ\/?#
MO2= N(O#.FR1WEQ!/+I>K3R3EHK:&+3IHY)UN)K2&XI?%[PC\1?B'_P58_X)
MN_'+0_A3\4[;X:Z?\#_B]>^+O$>K> ?$5GI_PZOO%WPK^)C:1X;^(^I1V5SH
M_@SQ2UYK.GZ/-H6LZE!=KK5Q'IL(FN)(ED ._P#%G[8G[4'QH_:<^+?[-?[#
MW@7X)W%K^SQ%HUI\9OC1^T'<>/9_!=KXOUZWGGL_ _A?PUX"FTC7+W5;62QU
M*RO+^?47L_M.F:J_E0VUI83:UWW[*W[8_P 3/&WQ]^*W['G[4/@+P?\ #[]H
M[X8>'['Q[INH_#;5-4U/X7?%+X:ZC)I=K'XK\&OXD?\ X2.PFM+[5;.*\TC4
MS<7,:32K*]M>:7JMG;?+_AZT^,W_  3X_;#_ &LO'-Q^SW\9_P!H+]G3]K3Q
M5HWQ6T?Q5^S_ .#6^(WCGP!X\@@U=_$'ASQ-X%L;ZWUB32[W4]=NX[+5+?S+
M6*QMM+NT8O/K%KIO6?LL?#/XM_'C_@H'\5/V_/B%\'O''P$^'5E\'=.^!?P:
M\$_%*RCT#XG^*XCJ-AJNK^-O%/A);B\N/"]K L%_9VVEW\D<DQU:Q\B6ZDTK
M4)7 .?\ A7^V'_P45_:6^*?[6_PV^ WPX_90T/2?V;_VB_B?\*;#XE?%\_%>
MVT#5]$\+>)-1T/PMX;D\/>#?$6JZWJ_CF6TTN76/%?B6WN/#WAFRM+W34L/#
MSW5P+:OJ?]A/]LKQG^U!X'^-FF_$CX:6'@[X]?LV_$[Q9\(/BGX+\':U!J7A
MG6/%OAAKN!9_!^JZM?"&VM-3U+3]2T>*#5-9N[6UNM/-Z^NS:?>12P^6_P#!
M,_X=?$'P'\0?^"CM[XY\"^,?!EGXY_;V^-7C'P5=^*_#&M^';;QAX1U76[N7
M2_%/A:?6+&SB\0>'-2B99;#7-)>[TR\C97M[J12"? _V0OA3^TUX07_@LG<>
M"?!/BCX??$[XE?M'?'3Q!^SMKWC[PSJWA31?%>HZK?\ Q(D\'>*_"FJ>([&R
MTG6]'FO+[2[O2O$%O)?>'?-N+"[O)9M.=Q( >D_%7]H__@J7\)/@AXX_:>\<
M?!?]DKP=X+\ 1ZCXGU_]G_4O$/C[Q+\8K/P)INJM:W$K_%/PCXJOOA9<>(1I
M9CU@16&@W=B;!9';9JI&@KY[^W[\1M,^,5A_P1I^+FBV=SIVC_%/]M7]E'XC
M:3I]ZRO>6.F>-X?#_B:PL[MT54:YMK75(H)V155I4<JH! 'YIZ]\!-'\4?LA
M>*_!TO\ P3)_;/\ &W[>,_@#48O'GQR^,?A/QSK^AOXMLTO-4\2^-/!GC35O
M%UY#XENKFW:^3P)X-\'>$I=1U#6I].TZ[CU6\1];U?\ 2+X__"/XG:Y\&?\
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M/&OAG7O"6OVT$\EK-<:)XDTNZT;58(;F(B6WEFL;V>..>,B2)V$B$,HKI:*
M/QW\-_\ !-+]HWP1\$[W]EKP3_P4#\2:'^S7=V?B'PY%X4F_9[\$ZE\3M-\!
M^*KG4+C7O!VF_%M_&5M);07PU74(5U3_ (0][^P@O)[;3#96:6=M:?IK\$/@
MYX*_9]^$GP_^"WPZM[VV\&?#?PW8>&M#_M.Z6]U6ZAM%9[G4]6NXX;6&YU;6
M+^6ZU75)K:TLK-]0O+@V=C96IAM8?4Z* "BBB@ HHHH **** "BBB@ HHHH
M\U\1?"'X=^+/B3\.?B[XA\/'4_B#\);+QC8?#O7)M7UV.#PQ#X_TZSTCQ=+:
MZ%;ZG#X=NK_6-*L;?3GU34=)O-2L[+S[;3[NTAN[M)_2J** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC/?VE_\ P9?LO?\ T2U'_"_/B'_T9[^TO_X,OV7O_HEJ/[&QO\^7?^'C*/\
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M_P"B)H_L;&_SY=_X>,H_^;O/\^S#_6S*/^?6??\ B)\5>7_4F\T?15%?.O\
MPO+Q[_T:=^T5_P"#']FW_P"B)H_X7EX]_P"C3OVBO_!C^S;_ /1$T?V-C?Y\
MN_\ #QE'_P W>?Y]F'^MF4?\^L^_\1/BKR_ZDWFCZ*HKYU_X7EX]_P"C3OVB
MO_!C^S;_ /1$T?\ "\O'O_1IW[17_@Q_9M_^B)H_L;&_SY=_X>,H_P#F[S_/
MLP_ULRC_ )]9]_XB?%7E_P!2;S1]%45\Z_\ "\O'O_1IW[17_@Q_9M_^B)H_
MX7EX]_Z-._:*_P#!C^S;_P#1$T?V-C?Y\N_\/&4?_-WG^?9A_K9E'_/K/O\
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MF'^MF4?\^L^_\1/BKR_ZDWFCZ*HKYU_X7EX]_P"C3OVBO_!C^S;_ /1$T?\
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M[_T:=^T5_P"#']FW_P"B)H_X7EX]_P"C3OVBO_!C^S;_ /1$T?V-C?Y\N_\
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M;O/\^S#_ %LRC_GUGW_B)\5>7_4F\T?15%?.O_"\O'O_ $:=^T5_X,?V;?\
MZ(FC_A>7CW_HT[]HK_P8_LV__1$T?V-C?Y\N_P##QE'_ ,W>?Y]F'^MF4?\
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MPO+Q[_T:=^T5_P"#']FW_P"B)H_L;&_SY=_X>,H_^;O/\^S#_6S*/^?6??\
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MF'^MF4?\^L^_\1/BKR_ZDWFCZ*HKYU_X7EX]_P"C3OVBO_!C^S;_ /1$T?\
M"\O'O_1IW[17_@Q_9M_^B)H_L;&_SY=_X>,H_P#F[S_/LP_ULRC_ )]9]_XB
M?%7E_P!2;S1]%45\Z_\ "\O'O_1IW[17_@Q_9M_^B)H_X7EX]_Z-._:*_P#!
MC^S;_P#1$T?V-C?Y\N_\/&4?_-WG^?9A_K9E'_/K/O\ Q$^*O+_J3>:/HJBO
MG7_A>7CW_HT[]HK_ ,&/[-O_ -$31_PO+Q[_ -&G?M%?^#']FW_Z(FC^QL;_
M #Y=_P"'C*/_ )N\_P ^S#_6S*/^?6??^(GQ5Y?]2;S1]%45\Z_\+R\>_P#1
MIW[17_@Q_9M_^B)H_P"%Y>/?^C3OVBO_  8_LV__ $1-']C8W^?+O_#QE'_S
M=Y_GV8?ZV91_SZS[_P 1/BKR_P"I-YH^BJ*^=?\ A>7CW_HT[]HK_P &/[-O
M_P!$31_PO+Q[_P!&G?M%?^#']FW_ .B)H_L;&_SY=_X>,H_^;O/\^S#_ %LR
MC_GUGW_B)\5>7_4F\T?15%?.O_"\O'O_ $:=^T5_X,?V;?\ Z(FC_A>7CW_H
MT[]HK_P8_LV__1$T?V-C?Y\N_P##QE'_ ,W>?Y]F'^MF4?\ /K/O_$3XJ\O^
MI-YH^BJ*^=?^%Y>/?^C3OVBO_!C^S;_]$31_PO+Q[_T:=^T5_P"#']FW_P"B
M)H_L;&_SY=_X>,H_^;O/\^S#_6S*/^?6??\ B)\5>7_4F\T?15%?.O\ PO+Q
M[_T:=^T5_P"#']FW_P"B)H_X7EX]_P"C3OVBO_!C^S;_ /1$T?V-C?Y\N_\
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M;O/\^S#_ %LRC_GUGW_B)\5>7_4F\T?15%?.O_"\O'O_ $:=^T5_X,?V;?\
MZ(FC_A>7CW_HT[]HK_P8_LV__1$T?V-C?Y\N_P##QE'_ ,W>?Y]F'^MF4?\
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MO+W2-&%KIE[=64P!^2/[ $W[$-E_P1+_ &FI_B6_P3_X65<:+\>(/&"^)O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6#_7P_]=8__0UJ-NI^I_G4
MD'^OA_ZZQ_\ H:U&W4_4_P Z /QN_P""MO\ P37^)?[?^F?!N^^%GQ)\,>$O
M$'PMN_%=K<^'?B#<Z_:^#M6TOQ>?#[W6KVEYX=T;Q%>V/B+3&\/QP+%)HMQ;
MZQ:7:0R7^DG3U:]_0/\ 9%^!-Y^S+^S5\'O@/J/BJ7QKJ'PT\(6^@W_B5X9;
M:+4;Q[N[U*Z2PMIY9Y[?1]/GOGTS1+>:5I8='L[&*0(ZE%^C:* "O.?B_P#%
M#PQ\$_A9\0?B[XTN?LOA;X<>$-=\8:VZLJS2V>AZ?/?&RM W$E_J$D4=AI\
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M1$D?CJ/QP(X_W)_X24^.BD-L&UYX4;\TM;^%_P 2_&?_  0H_9D^,%Q'>_\
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MU\C3[6]UJR\>ZAJMQ;6B$06\E]>2&:?R416*QH (XHD3ZX_X*7?\F!_M;_\
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M^$LU;PV-<71;O^R]<US4]&T'[$/$>M#R/#.G:-;7/VS_ $N&<V]IY !^?_\
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MUUGQ%>-;ZG:6%K;SZ8MRNE+%&RPV4?G3^8 ?AWXG\)?M!:W_ ,$O--T3Q/\
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MC2--LXQ#::?IFFVT5E86-K$ORQ6UI:PQ6\$:\)%&JC@5HT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'X5?\ !5W_ ()1?%;]O3XK?"OXG_##XJ>"
M_"O_  BO@M?A]XE\-?$%O$D&F6NF0>)-8\0Q^)_#$GA[1]?^VZ[>_P!OW-AJ
MFEW]MHUO<6^C:*RZT,21P?LG\)/ 7_"J_A3\,OAA_;E]XG_X5Q\/?!?@+_A)
M=43R]3\0_P#"'^&]-\/?VYJ,?GW/EWVK?V=]ONT^TW&VXN)%\^7'F-Z%10 5
M\;_\%!=(^$6O_L:_'K0_COX]U7X7?"K6?"=GI?BCX@Z+X=\0^+;_ ,)M?^)-
M$M= U@>&?"MCJ.N:W9P>)I=&74]/M+80W&F/>+J%S8Z;]LOK;[(K!\4^%O#?
MC?PYK?A#QAH6E>)_"WB73+O1O$'A[7;&WU/1]8TJ_A:"\T_4;"[CEM[JUN(7
M9)(I8V4@YP" 0 ?SH?$;XN?M(?LD_L\_ +7?VD_#/[&7[??[$IU?X6:)\.-6
ML?!MWI/Q5M]-&B'3_ 7B71O!/BC1+_P1<Z]8^%A++IG]E:5>Z];W']H:;J.I
M:0MTU\?0/VY?@-\*/VE/^"PW[(GPB^-?A7_A-/AYX@_9?\=7FK^'O[<\2>'/
MM=SH5W\6]:TJ3^UO">L:#KEO]EU*RM;G9:ZG#'/Y7DW*S6[R1/\ H?X"_P""
M6W[!/PT\9Z'X^\(_L[Z#;>)/#&J#6_#9UGQ9\1O%N@^']76X%Y'J.B>#_%WC
M'7?"&EW<%X%O+::QT*![6\CBNK<Q7$,4B=I^TA_P3\_9%_:Y\5Z'XW_:%^$G
M_"P?%'AOP\GA71=3_P"$]^)OA3[%H*:E?ZNMA]B\$>,_#6GW&-0U.^N/M5W:
M3WI\_P HW!@BABC /QS_ &N_V>_@+_P3 ^,7[)?Q8_8C$WP[^,GQ$^.?A?X8
M^(/@G/XHUOXAV7Q%^$OBB&^M/%6H'2/'.I^*/%6GI;:I;:1X=BU;2-4M'BO/
M%9?3Y8+^RMWA^E?B_J^E:'_P7A_9_P!1UK4]/TC3XOV#M726^U2]MM/LXWE\
M??&^.))+F[EA@1I)&5(U9P7<A5!8@5]G_!+_ ()B_L*?LZ^.--^)7PC_ &?-
M!\/^.=&9Y=%\1:QXH^(/CJ\T2Y>*2 WNBQ?$#Q=XHM-(U%89I8X]1TZWMK^)
M9'$5PFXUO_M'?\$\/V//VM?&^E?$?]H/X0?\+ \9Z+X5L?!.F:S_ ,+ ^*/A
M3[-X8TW5]<UVRTS^SO!/C;PWI4WDZKXDUJZ^VW%C+J$GVWR);N2VMK2&  ^E
MKGXI_#6UT_5M4D\?>$)+'0M'U3Q!J\MIXATN_>QT71+*;4M6U*:WL;FXN3:Z
M?8V\]U<ND+^7#$S$<5_./^Q=\8/VV?&/QF_:4_;Z^&7[ NL?M&:%^TYXC;PY
M\+?&.M_M+?"_X,GP?\(OAYK6IZ%IWA#1] \:VFHZGJD%P^E:)#KNM0VEAI=W
MKGA:1M-A65M2:3]4/"7_  2(_P"">?@23Q#-X2^ %QHDOBKPEK_@77Y;;XP?
M'>234/"?BFU%CXAT5GN?B?.UO;ZM9 V=U+:&"Z:UDFMUG6*>9)/O+X=_#WP9
M\)O GA'X9_#O0+3POX&\">'],\+^%= LI+J>#2]%TBUCM+*W-W?3W>H7]QY4
M8DO-3U.\O-4U.\>?4-3O;N_N;BYE /Y]O^"=OQ ^*_[-_P#P40^/'[/7QZ^"
MES^S3I/[9<6J?M!_";X7W7C[PI\2='T/QM87FK7'B#3O#_C3P<8/#U_%XCTN
MW\4336<5O:ZAIB>$?#>D2:;&DMO=W?[H_M)Q^!)OV>/CK:_%+6]4\,_#2^^$
M'Q'T[X@^)=$T[6=6U;P[X*U+PAJ]AXHUZPT_P[8ZEK=S<Z-HMQ>ZD@TRPNKJ
M/[,9HXCY9(K_ !._9L^"GQD\>_"+XH?$7P4NO>/O@1K]QXF^%7B>W\0>*O#^
MH>%M7O+C2[F[9AX:US1[;7M/NY=%T[[5HGB6#6=$N(X98)M/>"[O([CVJ]LK
M/4K.[T[4;2UU#3]0M;BRO["]MXKJSO;.ZB>"ZM+NUG22"YM;F"1X;BWF1XIH
MG>.1&1B" ?S)IXJ_:%_9/_82T+Q>NH_L7_\ !0G_ ()OZ!8>&ET/1OB!X&US
MP!\1=1\(2^-;.'PY;R>$_$VDZAX1FUFQ\17=O/<V'B?2/$_BO2M9L(;TVS7-
MC<L?HOXM^(M#U;_@JG_P2*^)-EI</@CP-XX_9_\ BN?">G:HEAH4.E/KWP;\
M;2Z)X/6R1X;6RU*U_P"$L\-Z'::3;HB2:A?6>EZ='+,\<-?;>G?\$G_^">NE
M^*(/%MG^S3X9%_;:ROB"WTBY\4?$6^\#0ZNC!DNH_AK?>,;GX=H$QL2V'A<6
MB0EH%@$+-&?I#X__ ++7P _:D\*Z1X,^//PST7Q_H'A_4?[5\/QW%UK.A:IX
M?OS;FTDGT'Q%X6U/0_$6C>?;^7'<Q:9JMK!="WM&N(Y7L[1H0#\I/VW=?T2^
M_P""OG_!,/P_9ZOIMWKN@V_Q/N];TBVO+>;4M(MM;T:[;1YM2LXY&GLDU-=.
MOGL3<)']JCM9I(=Z(6J/P]_PK?\ X?\ /Q%_X37^S_\ A*O^&3-!_P"%4_VI
M]G\O_A,/*\)_VK_9'F_OO^$C_P"$'_X2G['Y7R_V+_PD6_\ ??9J_0/P#_P3
MD_8L^%_B;X:>-? ?P,TCP[XP^$6N>)/$O@;Q3;^*/'UUX@MM;\6Z;IVCZW?>
M(M7U#Q7=W_CQI=-TNSM=/A\>3^);;0T^U-H4.FR:AJ#W6]\5/V"OV2?C;X[\
M6?$WXI_!O2_&/CKQKX=T'PMKWB+4/$?C:WNO[(\,75K=Z"=$@T[Q-96/A75M
M.ELXDB\1>%K71O$4EJ]W8W&JRV5_?6]P ? WQD;P[=?\%QOV/E^'LEO+XST[
M]G_XO']H%="-D\EOX-E\&^,_^%=1>,S9AKB*[/B&\TB:VBU4I<BRN/",L(%C
M<6)DS?\ @DSX?T,?M-_\%9?%7]D:<?$K?MN?$KP__;QM(6U9=#7X@?$74?[(
MCOF0W$6G/?O]LFM(Y$AGN8X)IDD>WMVC_3#]GK]CK]FK]E5?$#_ ;X5Z3X&O
MO%9A_P"$DUV35O$WBSQ3K<5M+)-;VFH^+?&VM^)/$]Q86\TKRP:<^K&PBE(D
MCME=4*]9\)OV=/@W\#-?^+/BCX6>#O\ A%]=^.7CW4_B=\4K[_A(?%.M_P#"
M4>.-8O=1U'4M;^S>(M<U>ST3[3>:K?S?V;X=M](TB'S_ "X-/BBBA2, _+/_
M ()5^ _!?AK]IW_@JAJ&@>%M"T>]L?VL=6\,:?<:?IMM;2:;X;75/%FKCP_I
MIBC4:=HHU*Y>[&EV0@L=\=HOD>78V26^/^P!I]AH?B__ (+'>'M%L[72=!TK
M]I3XE?V7HFFP1V6DZ:)]!\7B9;#3K98[.S218($9+:&-3'!!'C9#&J_K;\,?
M@!\)/@WXD^*WB[X;^$O^$<\0_&_QG-\0OBAJ']O>)M8_X2?Q?<&Y,NK_ &37
MM9U2QT7?]LN/] \/6VDZ6OF?+9+LCVT? G[-WP7^&FI?&?5_!/@S^Q=0_:$\
M2ZCXO^+]Q_PD7BO4O^$N\1:M!>VVH:CY6K:[?P:!]H@U&\3[)X7BT6QB\[=!
M;1O'$R 'X!_LG?\ *O5\;O\ L2/VC/\ U)M5K[@^(#I)_P $);!HW5U'_!.C
MX9H61@P#Q?!;PI'(A*D@-'(CQNO5'5D8!E('Z"?#S]DW]GKX5_ K4_V:/!/P
MVL-/^!NLV7B?3M5^'^J:SXG\4V%_9>,GN9?$EO<ZGXLUO7-?DCU&2\N'&=6W
M63NK:>UJ8HBG*_"C]AG]E;X)?#?XC_"#X;_"BVTCX9_%JUN+'X@>#=6\6>//
M&6D:]97>GWFEW%HL?C7Q3XBFT>VDLK^ZC\C0IM,B26072(MU%#/& ?DI^VG-
MXH?_ ((,_L^#PS-<KH\OP/\ V+;;X@7%FM]/!;^"%\,^ 8]3;5%TIUOSI46O
M1Z'#JL=JZS&+S(&*AGQ!^W)X%^/GB7]AQ/#?QW^.G_!._P"&?[+]TWPKC\#^
M-?A3\'OVAM2U31)++6='N_  ^$]OHWC;X@O/-J-A:MI!;0?">L2KX*O_ !#*
M#8Z>EYJEG^OWP8_8H_9?_9_\"^.OAC\+/A1I^D?#WXF!D\<^#?$'B'QC\0O#
MOB"W>SNK"6QN-,^(OB+Q7;6VF3VE[=07.E6"6FG7*S,T]K(X5AY;X&_X)>?L
M&_#GQIHOC_PG^SSH-MXC\-:I%K?AP:OXK^(GBKP]H&KP2_:+;4=$\&>*_&&M
M^#=*N[6Y"W5G-8:!;O:721W5L8KB-)% /A?Q*M^__!97]C[2/CA?:5J]AI/[
M%$US\)+S6;6\M+'5/C%]K\1+XOUJQT_Q/&EY9^.;JVL;^Y%N\%MK=GIMGX=,
M\,6IPNSO_;9B^&:_\%?/^"9,N@C2!\5I?^%H#XC?8FL_[4;PK'X=8?#5M:C@
M;[6'^U-X^2PDOE#26:!+=FAA"I^LWQ\_9C^ _P"U!X=TKPO\=OAQI'C_ $O0
M-3_MGP]/<W>L:)KWAS5"L:R7WASQ7X8U+1/%/A^><0P"Z;1]9LA=_9K4W0F-
MK;^7Y#X*_P""=?[&GP[\8_#SXA^#_@I8Z5X\^%NO^(?%'@_QG)XQ^(NJ>*(]
M=\4Z1IFA:Q?>)-=UCQ?J&I>.]VE:/96FFVWCNY\26>A WLVA6^FW&J:G+> &
M%X9_833P+\2OC)\6/ /[5/[2WA'QE\=_&#^,?B#JD6G?LL^+=0O)((19>'_#
M-AX@^(_[,7C7Q98^!O!>D)!H7@GP>/$,NB>&M)@6#3[9)9KN>X^\Z** "BBB
M@ HHHH **** "BBB@#^>C_AS-\5O^'F?_#8__"\/#7_"J/\ A>O_  OW^SL>
M)/\ A:7]I_V__P );_PKO[!_9W_"-_\ "*?VA_Q2O]K_ /"5_:/^$._<_P#"
M/>?_ *+7]"]%% !7XZ?\%LO^3;O@5_V>;\ __0?&%?L77CGQL^ 'PD_:+\-Z
M%X1^,GA+_A,?#WAKQGH'Q"T33_[>\3>'OL7B_P +_;!H6K_:_"NLZ'?7/V'[
M?=_Z!=W,^EW/F_Z997'EQ; #\/\ ]J3XNI_P3*_X*%_%OX]-8I%\,/VQ?V9/
M%NNPV7V>>VT>^_:.^"7A^:?PY832JRV@NM>:+3+&=US++J7Q*N;J6(32--<>
M2?&WX$:G\ /^">'_  35T#Q4))/B1X]_X*'_ +/OQE^*U]<H%U&^^(7Q3T?X
MH^*=535]L4*OJFAZ==Z1X6NW1"C-H(\N29 LK_OW\?\ ]E7X ?M2V7@O3_CU
M\.K'XA6?P]\3)XO\(0WFL>)=%_LK75B6!YWD\,ZUHLNI6-S$D2WVB:L]_HFH
M>1;M?:=<-;P&/H/C/\ /A)^T)IG@G1_B_P"$O^$NT[X=?$;PW\6O!UO_ &]X
MFT#^Q_B#X1M]5M?#WB#SO#&LZ+/J']GP:UJ<?]E:K+?:)=_:=U]IMR\-NT0!
M^6/[5931_P#@L]_P3.U[5I[;3-&U'X<?M">'K'4;^ZMK2UNM<D^'7Q&LH-)B
MDGE0-?W=]XCT*QLK;_67U]JME96BSW4RQ5RW[;NOZ)??\%?/^"8?A^SU?3;O
M7=!M_B?=ZWI%M>6\VI:1;:WHUVVCS:E9QR-/9)J:Z=?/8FX2/[5':S20[T0M
M7ZO?M!?LN_ /]JCPSI?A#X^_#;2/B'HFAZFVLZ&+R\UK1-7T/4I(&MIKK1/$
MOAC4]$\2:0US"42[33M6MHKLP6KW,<KV=JT/D'@'_@G)^Q9\+_$WPT\:^ _@
M9I'AWQA\(M<\2>)? WBFW\4>/KKQ!;:WXMTW3M'UN^\1:OJ'BN[O_'C2Z;I=
MG:Z?#X\G\2VVAI]J;0H=-DU#4'N@#Y/^%7_*;O\ :B_[,R^''_J3>!*3_@G,
MRG]M7_@K:H8;A^T)\.&*Y&X*VC>.PK$=0&*L%)&"58#H<?I3I7P ^$FB?&_Q
M1^T=I?A+[+\9O&G@S3?A[XE\9?V]XFF_M+PAI%U87FGZ1_PCUQK,OA6S^SW.
MF6,GV_3]#M=4E\C9/>RQR3+)Y<?V&/V5A^T&O[5$'PHM[#X\#4AK$WCC2?%O
MCW1X[_5/[.ETIM0U;PGI7BJS\$ZS=R6,TD<TVJ^&[QYY2MW,7O$2=0#X"_X)
M,_\ )?/^"LG_ &?G\3/_ %-/B%47_!"+P)X+?_@G5I,TOA3P_<2?$;QK\4(?
M'INM)LKL>,;:#6[WPS#9>(TN894U>PCT"!-)33[U9K(63SP^1BZN?._4KX3?
MLZ?!OX&:_P#%GQ1\+/!W_"+Z[\<O'NI_$[XI7W_"0^*=;_X2CQQK%[J.HZEK
M?V;Q%KFKV>B?:;S5;^;^S?#MOI&D0^?Y<&GQ110I'9^ _P  /A)^S-\.=-^$
MOP1\)?\ "$_#[2+[5M2T[P__ &]XF\2?9[W7+Z74M4F_M7Q=K.OZW-]JO9I)
MO+GU*6&#=Y=O'#$%C !_.Y^PU^T-X&_9W_X(C>*/'WQ1^'.C_&OPW!\6O&7@
MO1_A;XNL]*U+P=XEUCQ+XET5]$TOQ-%X@M-0T6R\+VFLW$_B#5KB\LITB^S3
M26L+ZE/;!M#_ (*3_P##7+_LU?L_Z%\?;[]B+P/X,\0_'7X)V7PK\ ? ?1?B
M1<^./#EQ;1,FFQ^%O$FL>*(_",NA>%] N)[75I?#7A:WTF*S?3++2=46"^LG
MN?W0\%?L4?LN?#[X#:W^S'X9^$6C+\"?$=WJ=_K7P]U[5_%/C#3[V^U>6UN+
MR].I^,-=UW7X+M;JRL[RPN+75H)M)O;6"]TI[*ZB28>$Z7_P21_X)Y:/83:?
M8?LYZ>D<MYI5]#=W'Q$^+U]K&F2Z)J<.LZ=!H.O7_P 0+G7/#NG1:G;PW<^D
MZ#J&G:7?/&JW]G<Q#90!X?\ M\,J_P#!1G_@D 68*#XZ_:E4%B -S>"OA:JK
MD]V8A5'4L0!DD"N:_:9_Y3:?\$VO^R0?M#?^JQ^,%?H]^T9^R%^SG^UG8^$[
M#]H'X:VOC^/P+?W^I^#[L>(?%_A35_#M[JG]G?VE)I>O>"?$'AO6[=+\Z1I3
MW=N-0-M/)IUE+)"TEK"R6E_9/^ *_$?X)_%O_A!)'^(?[.W@J[^'?P=\1R^+
M?'$TOA+P??>'-0\)7>E2:?+XE?2/$LD_A_5;^P?5/%NGZ]K&ZX-ZM^+^.*ZC
M /S+_8/.@)_P4Q_X*<+\4V@'Q^?QQX+'P['B9\Z\WP(.G:O)HJ^"_MQ,YT0:
M&/!3:NFF_NDLU\/!P($P*WP?CL;?_@N5^T9'\'SIB^#KC]E[0[K]H*/P[Y/]
MB+\5/[?\.+I1UQ;8?88_'#VK6TTZQXU&1)_$L]YNO9-::OT=^/O[$G[+/[3^
MJZ3X@^-_PAT;Q?XFT.U-AI?BRRU?Q3X+\7VNG[G<:</%O@/7O#'B273E,L^R
MPGU26T1;FZ1(56ZN!)V?P%_9E^ _[,/AS4O"OP'^&F@_#O2=:OH]3UU].?4=
M2UGQ!J$,;Q07GB'Q-K]]JWB77Y[:.6=;5]8U:]-K]HNC;^4;JX,@!^9O_!*'
MPQX=C^./_!4[QFFBZ:/%EU^WY\;?#$_B+[)$=7?P[8>+];U6TT47Q4SQZ;'J
M6I7M\UI&Z12W4JS3+(\,!B\9_P""?OCWP7\"+;_@M)XL\1:%'-\*_A#^U5\=
M_$=SX%T;2K1M+?PYH%Y\05NO#>C^'UA72((-2TK1K#08;-X(-*BM8K2&\,&G
M6S-%^U?PH^ 'PD^"&I_%+6/A?X2_X1C4?C1\1M>^+7Q+N/[>\3:U_P )+\0?
M$]P]UKGB#R?$.LZM!HWVZ>1Y/[*T"+2M$MMVVSTVW0!1D?#G]F'X$_">]^--
M]X&^'UCITO[1/B_7O'7QHM]3U;Q%XJTWQWXF\42ZI-X@N]1T?Q;K&N:38V.K
M-K>J)=Z%HUEIN@/;WDEJ-,6V6.) #\$_CCX__::\:_\ !+;XA?$>+P9_P3^_
M9W_9!^(?PLN-5\&?"#P;H'CG4_'5II_B?79;S0M)TB]\-ZQX3^%NC?$.^U]K
M&^ALK+PIJ?\ 9NOM>76N6=AJUGJ.FV/H_P"T=9S:=\"/^"!>GW-RU[<6/[0O
M["5G/>/OWW<UMX.\$P2W+^8\C[IW1I6WR.^7.YV.2?T"L_\ @D=_P3LL)=;D
MM_V:="\OQ!9:S87ME/XV^*5WI5I%K^GSZ5JD_A_1[OQS/I7A34I;&XDAMM7\
M+V>CZMISB*XTV]M+FW@FC^DO$'[)WP \4^'?V?\ PIKW@)M1T']EO7O /B?X
M$V3^+/&\+^!]=^&%C8Z;X'OWO;;Q+#J'BIM%L]-LHF@\:77B*VU4PF;68-1G
MEFDD /HNBBB@ HHHH **** "O7[+_CSM/^O:#_T4E>05Z_9?\>=I_P!>T'_H
MI* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Y]XL_P"0C#_UY1_^C[FO0:\^
M\6?\A&'_ *\H_P#T?<T ?(G[6?B?]ISPA\%=;US]D+X=>#OBG\;X-5\/PZ%X
M.\>7UIIWAR]TBXU6"+Q%=7-U>^.OAS;I/8:2UQ=6BMXIM&>=%5;>]8BW?^?G
MXD?\%4?^"P7PC^.GP[_9K^(7[+G[*WA_XU_%>U\.WG@#P7C5]6_MZV\5^(=8
M\*:!)_PD>A_M/:EX3TO[?K^@:M8;-:U[3I+7[)]JO5MK*>VN9OZFJ_F!_P""
MC_\ RG._X)X?]BS^SQ_ZT+\8* /V!_89^(7_  4+\>?\+1_X;R^!7PJ^"O\
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MVC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\
MR)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X
M,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_
M^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]
MHTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\
MB4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/
M_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_
M *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9
ME%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#
M$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D
M_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?
MVC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\
MR)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X
M,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_
M^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]
MHTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\
MB4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/
M_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_
M *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9
ME%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#
M$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D
M_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?
MVC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\
MR)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X
M,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_
M^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]
MHTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\
MB4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/
M_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_
M *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9
ME%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#
M$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D
M_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?
MVC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\
MR)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X
M,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_
M^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]
MHTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\
MB4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/
M_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_
M *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9
ME%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#
M$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D
M_P#X,3_\B4 9E%:?VC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E%:?
MVC2_^@9/_P"#$_\ R)1]HTO_ *!D_P#X,3_\B4 9E>OV7_'G:?\ 7M!_Z*2O
M,C<:60<:;.#@X/\ :!.#V./L@SCTR,UZ;9?\>=I_U[0?^BDH LT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7GWBS_D(P_]>4?_ */N:]!KS[Q9_P A&'_KRC_]
M'W- ',5^8'[1_P#P3>_X:"_;G_9X_;1_X7-_PB/_  H33/AWIW_"M?\ A7?]
MO_\ "5_\(%\0_&'CSSO^$Q_X3K1?["_M;_A*_P"RO+_X176/L/V#[=OO/M7V
M.V_3^B@#XG_;^_8[_P"&YOV?;KX$_P#"Q?\ A5WVGQAX9\5_\)5_PB/_  FV
MS_A'7O6^P?V'_P )/X1W?;/MF/M7]L+]G\O/V:??A=77/V._"GC+]A[1?V(O
M&WB?4]4\-Z=\"OA_\&+WQMHUA%H6J75S\//#OAW2](\8V6CSWFM6^GSG6?#.
MGZ\NAW.H:K;( =+N+Z]A+W$GV'10!_/7>?\ !#7XD:W\!I/V<O$__!0GXE:W
M\*?#UZNK_"SP/_PJ>RL_!W@O69/$D>KW=]KNBK\39[[QI"=,O/$MEINFC7/#
MEAH^MZ\OB*TA(LI=(U#WG]IK_@D?<_M(_"7]ASX87?[0T'A*7]C#P+_P@R:]
M;_"&368_B/;0Z+\*]!LK]M(E^*>FMX0GBL_A?!)=0C5?$\=U<ZQ,\36<5DD%
MQ^S=% 'Y;?M[_P#!-3_AN#XK?L_?$[_A=/\ PK#_ (45<W-Q_8G_  KG_A-?
M^$I^T>)/#_B#9_:7_"=^$O[$V?V%]DW?8-7W?:OM&U?(\F;F?VA/^"6VJ>/?
MVG=6_:\_9L_:B\;?LH?&CQ9H]OHOCC4- \$:3X]\/^([>#2M.T:69=#N?$/A
M$6LVIV>BZ++K$-[=ZQI]]JFEV^M+8V^KM+>R?K?10!^;?[(W_!,[X1_LR^%/
MCAIOBWQ)KG[07C/]I9KU?CGXU^(EE;0+XUL=1DUJ?4-,30K>YO1I]IJ=YXBU
MG4=6GGU;4]4U'4;P7,VHJ+2QBM?B6_\ ^"&WB+P8_C/PS^S+^WU\>OV?_@U\
M0)[J3Q5\)[?3M3\3:?J-M?0BSO+"75-#^)'P\@O+:73&FTAIM7T+5-0N]),-
MCJU]JD4<WVG]_J* /SA_9L_X)>?LT?LZ_LX?$C]G"+3=3^(.B?&NP%G\9/%'
MB:9;37?&QAM;BVTM(!I1@C\.V/ALW5U=>%[739&N=(U"YN-2;4+O4IY;M_AD
M?\$.O&]AX.U+X%^'_P#@H5\;]'_94U;6YM3O?@4W@ZTN3/93ZLFL3:?)XDA\
M<V&A,9KZ&WU"Y*_#]-*N=8C?5Y]$>ZE8#^@2B@#\H_VHO^"4WPW^-O[&_P (
M_P!C'X3>-S\"/ WPB^(>B^/M+UN;P@?B/J&MW.G^&O'VB:M_;-LWBOP09M;\
M2ZKX]O/$FJZZ+\Q+>P2VEKH\-I<VZZ<O[9'_  3$_P"&M?V8/V<OV;_^%W_\
M*_\ ^% 6OA*V_P"$S_X5K_PE?_"6_P#"+?#T> ]__"._\)_X;_L'[=C^U=O]
MNZS]E_X\=UQ_Q^5^K=% '(?#WPI_P@?@'P/X'^W_ -J_\(9X/\->%/[4^R_8
M?[2_X1W1;+2/M_V+[3>?8_MGV/[1]E^UW7V?S/)^TS[/-;\^/B=_P3F_X6-_
MP4+^%/[>7_"X_P"QO^%8Z'H^C?\ "JO^%>_VC_;?]DZ9XLT[[3_PG/\ PG%C
M_9OVC_A)_.\G_A#[_P K[#Y?FR?:=]O^FU% 'YI:[_P3N_MK_@I)X,_X*$_\
M+@^S?\(AX:NO#O\ PJ+_ (5_YW]H?:?A=XL^&WVS_A/O^$VB^R;/^$G_ +:^
MS_\ "%7.[[#_ &=YZ_:?M]OYY^U]_P $A?@_^TM\6H_VAOA]\2?'W[-/Q],U
MG=W_ ,0/AFR-;:MJEE!]C@\1W>DP7V@ZG8^*A8K%9RZYX>\3:&]Y%$)M2MKZ
M^DFO)/UPHH _GH\=?\$/OC1\;DT72OVCO^"F7QL^-/A/0+M]0TSP[KG@34BE
MCJ,D!M7U&RD\2?&3QEIMOJ#6CRVOVYM$FNQ!--$)O*EECD^J/VPO^"5EG^U1
MXD_92UG3OCC=?#O3_P!EO0=*\/6&G7OPZB\;7GC*STB_\*W5K+=ZI!XW\&0:
M+=/!X72"X>'2=2B>6\>XCAB2$6TGZWT4 ?-/[87[._\ PUA^S;\4?V>_^$P_
MX0'_ (65IFC:=_PEW_"/_P#"4_V+_9/BC0_$GG?V!_;?AS^T?M']B_8O+_MJ
MP\K[3]IWR>3Y$N9^Q-^S-_PQW^S'\,_V<?\ A-O^%B_\*Z_X3/\ XK+_ (1O
M_A$?[8_X2[X@^*_'?_(O?V_XG_L_^S_^$G_LK_D.7WVO[#]N_P!&^T_8[?ZI
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *5NI^I_G24K=3]3_.@!**^&OVUO\ @H5^SY^P
M9I/@F^^-,GC#5=5^(-[J5OX8\)_#_1=-USQ+=6.B_81K6NW,.LZ[X;TFQT;2
MY-4TZ&66ZU>*\O9KKRM)L=1:UOA:_37P;^+O@3X]?"_P3\8?AGJSZWX%^(&A
MV^O>'M0EM9K&Y>VE>2"XM;VRN%6:SU'3KZWNM-U&TD!-M?6EQ"'D"!V /2ZX
M[QY\1?A]\+/#ESXQ^)WCKP=\.?"-E/:6MYXI\>>)]$\(>'+2YOYUM;&WN=<\
M07VG:9!/>W+I;VD,MTDEQ.ZQ0J\C!3V-<=X\^'7P^^*?ARY\'?$[P+X.^(WA
M&]GM+J\\+>//#&B>+_#EW<V$ZW5C<7.A^(+'4=,GGLKE$N+2:6U>2WG19862
M10P /!_^&ZOV(O\ H\?]E;_Q(7X1_P#S7UZS\-/C?\%_C1#J]S\'?B]\+_BS
M;^'Y;.#7I_AIX_\ "GCN'1)M12YDT^'5Y?"VK:JFFRWZ6=V]G'>M"]TEK<M
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M=E9@Q_9KEK?[!J>DWE_PG_!5?XPWOP0_8"_:/\7Z3=-::[J_@V#X=Z)+&/\
M2%N_B=K>F> KNXM'.!%=:=HVOZIJT,^Y7@.GF6 M<)"C@'V-\)OBSX ^.7P]
M\.?%7X6Z\?%'@'Q=#?7/ASQ!_9.N:(FJVNG:K?Z+<W4&G>(M-TC5TM&U#3;M
M;.ZGL(K?4;58=1TZ2ZTV[M+N?T6OB#Q'\3/A?_P3F_8H\!:E\0X;ZW\-?!KX
M;?#;X<67A_PW;6M_XA\4^*[31-+\.V.@Z';"XM[74=<US5;>YO+J[ENUB<#4
MM8O+EHXYYF\/M/\ @H=\6O /CGX,:+^UA^QGXG_9L^'_ .T!XTTCX=?#KXDO
M\9/!/Q+AL/&WB6$7'AC0?B5X9T;1]#O_ (?W&JQEDG:ZO=4_LN:WOQ>*+;2M
M4NK, _1G3/B7\.-;\;^)?AGHWQ \$ZO\1_!EGIVH^,/A_IGBO0K_ ,;^%-/U
M>UL[[2;[Q+X4M;^77M"L]4LM1T^\TZYU2PM8;VUOK.XMGEBN8'?MJ_G/T3XL
M_$?X8_\ !9W_ (*"VWPA^!/B+]H'XB>*OAA\![32/!^E^*O#WP_T#3;#2OA%
M\(;[5/$'C+Q_XH6?2O#.C6[-8Z;:^7I^KZIJ>K:G8V6GZ7/NN);?].?V1?VW
M[K]HOXA_&GX%?$SX+:_^SQ^T)\!9?#TWCKX9:SXMT?Q[82Z+XHM?MFCZ[X<\
M9:'8:59:S8R6LNFW4T@TRU@:SUW0[S3KG4K>]E>U /JGP;\;/@U\1=#\2>)O
MA]\6_ACXZ\-^#I[RU\7>(?!OCWPKXGT/PK<Z?:?VA?V_B35M$U6^L-#GL; &
M^O(M3N+62VM!]IF5(?GKJ?!WC3P=\0_#6E^,_A_XL\,^.?!^N133Z)XK\':]
MI?B;PUK$-M=3V-Q-I>NZ+=7NEZA%!>VMS9S26EU,D5U;SV[E989$7\A?V,_'
MOP5^)7[&7[<WB#X*?L[Z'^SEIGA[QO\ M#?#;Q'X?T/Q??>,HO&.O>#_ (5:
M/>OXZNKV^T/06TVYU2W\21V3:-';7B6BZ:LIU.Z-SY=NO[!?[0GPZ_98_P""
M.GP3^.?Q2O+JV\(^"/!/BRYGM--CMY];US4K[XM>,M.T;P]H%G=75G!>:SK6
MIW5M96<4UU;6T1D>[OKFTL+:ZNH0#]??%?B[PIX#\.ZMXO\ '/B?P]X,\):#
M;?;=<\4>*]:TWP[X=T:S\R.'[7JVMZO<V>FZ=;>;+%%Y]Y<PQ>9)&F_<Z@Z.
MD:OI7B#2M,U[0=3T_6]#UO3[+5]&UG2+VVU+2M7TK4K:*\T[4],U&SEFL[_3
M[^SFANK*]M9I;:ZMI8IX)9(I$<_SZ_M[_M@_M(^,?V$/C1)\9?V%O&GP.^%_
MQ5^'UCI_A7XB_P#"WO!OQ#U'1-0UW5-(O?#$/Q,^'NEZ)H7B3P#!K[K;:7%<
M3OJS:7K>H66F:W!ITTK,GT_X^_;IT_\ 87_8W_X)_>)=6^&.K?$S2_BIX6^
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M=@NKK1+?QAH>G7USJ?AF?6+:QO;C2H=:M;*34(+.ZEM%FCMYF3\^-?\ V_\
MXF>,_C1\5/A!^R!^R9KG[3]O\"]5M_#'Q:^(=Y\8/!WP8\$Z1XV;S#J/@SPI
MJ/BK1M;'B_7-%,<MGJL>[1HK74;.^CD<:;_9FK:I\S?\$K?B$?BK^VK_ ,%6
M/'DGA;Q'X&O=<\7_ +,::QX+\76L5IXE\)>(=(\-?%W0_$?AO6(H))K62\T3
M7M,U'36N[.::ROTMDOK*62TN(78 _=&N"?XJ_"^/X@P_"63XD> H_BK<:4VN
MV_PS?QAX>7X@SZ(D;S/K,/@QM1'B.72DAC>5M0336M%C1W,P521I^.]!U?Q3
MX'\9>&/#_B:\\%Z]XC\*>(=!T3QCI]N;N_\ ">KZOI%YI^F^)K&U%W8&YO-!
MO;B'5;:W%]9F::T2,7=N6\Y/Y^_A'^R?X'_9'_X*_?L[^$/"GB3QSX[U_P :
M?LM_%'Q]\2OB-\2/$5UXD\8^/O'FI:MXJT[4_$6JW<Q6&V$UOI=I!;65K&/)
M@B5[RYU'4)+O4;H _HNHHHH X+Q%\5?A?X0\5>%? OBSXD> O"_C?QU*\/@C
MP;XB\8>'M$\5>,9HW$4D/A7P]J6HVVK^(98Y"(WCTBSO'5R$8!CBNHUS7=#\
M,:1J/B#Q+K.E>'M!TBUDO=6UO7-1M-)TC3+*$9EN]1U*_FM[*RM8AS)<7,T4
M2#EG K^;OXU?L9>'OV8_VYO^";7CS4_B5\1?C7\:?C'^T;XPG^)OQ5^(^M75
MY>ZM;>']+\-OX=T'P_H;W=[:^&_#>A1:Q=P:=IQO=5O4C=89-5DLK>PLK+Z[
M_P""G,?_  NK]I+_ ()X_L5ZG<ZG<_#CXV?%+QQ\0?C)X8TN?4K0^*/"7P=T
M32O$6E:!K$EF(DO/#FIAO%%QJUNMR7L'T>SU<I;7-IIMY& ?JE\./C5\&_C%
M#J5Q\(_BU\,_BG;Z/)%%J\_PX\>>%O&\.E2SF58(]2E\,ZKJB6,DS03B)+EH
MFD,,H0,8WPOA?XP_#GQG\0OB9\*?#GB+[=\0?@\_A-?B)X;FTG7=,N=!C\<Z
M,^O^%+N&ZU73+'3M=T[6-+BFEAU/PY>:OI\%S;76G7=S;ZE:W%I%^,_[5GPH
M^$_[%G[</_!./XM?L[> _"7P:D^+WQ=O_P!FWXG>&OAWX>T[PGX5\;^%/'LG
MAG1='?6?#V@6EII,NHZ-J>K2:@FH?81=7E_%I-YJ%TSZ+9S0_0?Q1U$_!;_@
MKC^S5XBMWM]/T+]L+]GGXH_!OQ$LDUM%:ZCXO^!UQ%\2?#VKS!IUE76$TW6;
M+PK82R(([R#4H=.M4N+HGR #]8**** "BBB@ HHHH **** "BBB@ HK\\_VS
M?^"F_P"S+^POXK\#^!_C)+X[U7Q7XYTS_A(+?1? 'ARPUVYT#PLVI7.D0>*/
M$3ZMKWAVW@TJ\U*PU6TM(=*FU?6;B32-0*:5LCB>;[K\(^*_#WCSPIX8\<>$
M=4@USPIXR\/:+XK\,:U:K,EMK'A[Q%IMMJ^BZI;I<10W"0:AIMY;7<*SPQ3+
M',HEBC<,@ .AK*UW7=#\+:'K/B;Q-K.E>'/#?AS2M1UWQ#XAUW4;32-#T+0]
M(M)M0U;6=9U;4)K>PTO2M+L+>XOM1U&^N(+2RM()KFYFBAB=UU:^5OVZ_P#D
MR+]L?_LU;]H7_P!5'XOH DB_;F_8GGECAA_;#_99FFFD2***+]H+X2R2RRR,
M$CCCC3Q<7>1W(5$4%F8A5!) KVCQ7\5?A?X#\&1?$;QS\2/ 7@SX>SQ:7/#X
M\\5^,/#WAWP9-#KAA&BS1>*-7U&ST22+6#<0#2Y$OBFH&>'[(9O-3=_,#^R7
M^TO_ ,$8O#'[&WPI\%_'3X:?"/Q[\?-/\!S:9XZT&P_94U?Q)\4O$'B*;4]2
M/V2R^(G_  K>SL;[77L)K8V^L)\0;7R%C18M7AFA55X3QI\-_C#\,?\ @@1X
MSTCXO:+X@\+1ZU^T#X?\5_"[PCXJ6[@\0>%OA3KGC/PB^@Z;J-A?M]LTTWNN
MP>)_$%G:7$5M(^G:U9WOD*+L.X!_7?:W5M?6UO>V5Q!>6=Y!#=6EW:S1W%M=
M6UQ&LL%Q;SQ,\4\$\3I+#-$[1R1LKHS*P)GK\5]8_P""EWQ7_9_^%/PL^*_Q
M5_8=^(GAG]E#4+/P%X<7XV3?%;P)=>.K'3=8T^TL=%\4:M\"+*QN/$&D:9K*
MPF\L+?4O%-K>"&:QMK^*PU34;'3I_P!!OVC_ -H3QC\'?#_@&X^$OP ^(_[3
M/B[XF>([3P_X9T3X=!++PGI5M=6J70\5?$'XESV.I^&? /@\K-:QP:]JZ26U
MT]P9(0;2UOKJV /J*BOSM^$G[<?CC5OVF=*_9-_:._9QOOV>_BKXP\":G\0_
MAO=Z3\4="^,/@?QQH>AO=_VS;6WB32O#GA&ZTO6+&"PU&Y;3[O17_<Z=<M/-
M;+-I;:EY_+_P4-^,/Q(\9?&72_V1_P!C36OVD/ /P&\<:W\-?'OQ!NOCCX(^
M%$FH>-_"]NESXCT7P%X0UO0/$&L>+EL5;R;*]>?1H-8N);)=/\R"\2Y0 _5*
MBO@GQ=^WUX.^''[)6A?M1_$[X2_&;X<:KXFU2V\&Z!\ O&7@K5/#_P 8]7^)
MVI:IJ6D:)X#L= U:VL6FFUV32[K6=+UDHEI=>%T.K1P->#^R#Y1-_P %"/C)
M\*_%/PF@_:\_8RU[]G/X9_&?Q?H_P^\+?%#3/C5X0^+]GX<\:^)1=/X<T+XE
M>'_#WAO0;SP:VII;@R7T-[KEE9,+P2RNFFW\D(!^IM>1?$+]H'X#?"34M.T;
MXK?&WX1?#'6-7C672=)^(7Q)\&^"]2U.)Y#"DFG6/B36M-NKV-Y08E>VBE5I
M 4!+#%>NU^4FE_\ !/3]G7X:^*?VM/VH/VSM6^&O[1,OQ.UW7_'VH>*?B[\,
M=.CT/X)?#'3;>_N8/!_AJ+Q%XC\=FWM_#6D&WTVQ\2:5_8VO-8:3IEG9P1SJ
M?/ /NCXT?M#_  [^!_PUTWXGZ]+JOBK2O$^M>$?"WP^T3X?6EKXG\1_$WQ?\
M0+VWT_P)X5\!VZW]EI6K:KXMN[J!-'N+O6--T0P.;^^U>RTZ.6[3&^$?[2GA
MOXI>._''PEU;P1\0OA!\8?A]IFA>)=>^%WQ0M_!C^(+CP1XGCV>'_'F@Z[\-
M/&WQ)^'WB#PSJ.J6^JZ!*=)\:76MZ-KFB7]EXAT72$GTB?5/RN_X),?%OPW\
M$OV'8=>^+?B'Q'\./A!\3OVNO&G@/]E>]\5Z?K6J-8> _'TVCV/PZTV>_M]&
MU6ST#2;KQI9>-D3Q+XJ2P\(PZF[/?:G#;ZC8Q3_4O[.5@_@O_@H!^U'\/K_5
M+SXU>)6^ WP!\6^*/V@O$@M4^(GA^6XUGQ_I6A?!3QWIW@^P\-_!_04N-*MF
M\>^$+3X:?#3X6SZKHLUQJ?CBV^('B 1^*;, _3BBBB@ HHHH **** "BBB@
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *5NI^I_G24K=3]3_ #H
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MHZ5X(M=9LT$UO#%J*:1XRN?%$+2W"'4-?\373B*X6S-K+]S?&S]GC1OV5?\
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M9-/-['H]E8PW]YJ%W'->S^TT ?B=^S-_RFT_X*2_]D@_9Y_]5C\'ZZ;X"?\
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M?W&GBY-]I<SRJUEJ4%M>)N>$*?MFB@#\=/\ @HS_ ,GI_P#!)/\ [.%^(O\
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M;!_%5Y\./"?B6#PS\/M+U"P>:'2;O4;75)+=K6[MX#KM]%J/@C^KJB@#X_\
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M %[0?^BDKR"O7[+_ (\[3_KV@_\ 124 6:*** "BBB@ HHHH **** "BBB@
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M_OS;?_&:/^$@UC_G\/\ WYMO_C- &/@^A_(T8/H?R-;'_"0:Q_S^'_OS;?\
MQFC_ (2#6/\ G\/_ 'YMO_C- &/@^A_(T8/H?R-;'_"0:Q_S^'_OS;?_ !FC
M_A(-8_Y_#_WYMO\ XS0!CX/H?R-&#Z'\C6Q_PD&L?\_A_P"_-M_\9H_X2#6/
M^?P_]^;;_P",T 8^#Z'\C1@^A_(UL?\ "0:Q_P _A_[\VW_QFC_A(-8_Y_#_
M -^;;_XS0!CX/H?R-&#Z'\C6Q_PD&L?\_A_[\VW_ ,9H_P"$@UC_ )_#_P!^
M;;_XS0!CX/H?R-&#Z'\C6Q_PD&L?\_A_[\VW_P 9H_X2#6/^?P_]^;;_ .,T
M 8^#Z'\C1@^A_(UL?\)!K'_/X?\ OS;?_&:/^$@UC_G\/_?FV_\ C- &/@^A
M_(T8/H?R-;'_  D&L?\ /X?^_-M_\9H_X2#6/^?P_P#?FV_^,T 8^#Z'\C1@
M^A_(UL?\)!K'_/X?^_-M_P#&:/\ A(-8_P"?P_\ ?FV_^,T 8^#Z'\C1@^A_
M(UL?\)!K'_/X?^_-M_\ &:/^$@UC_G\/_?FV_P#C- &/@^A_(T8/H?R-;'_"
M0:Q_S^'_ +\VW_QFC_A(-8_Y_#_WYMO_ (S0!CX/H?R-&#Z'\C6Q_P )!K'_
M #^'_OS;?_&:/^$@UC_G\/\ WYMO_C- &/@^A_(T8/H?R-;'_"0:Q_S^'_OS
M;?\ QFC_ (2#6/\ G\/_ 'YMO_C- &/@^A_(T8/H?R-;'_"0:Q_S^'_OS;?_
M !FC_A(-8_Y_#_WYMO\ XS0!CX/H?R-&#Z'\C6Q_PD&L?\_A_P"_-M_\9H_X
M2#6/^?P_]^;;_P",T 8^#Z'\C1@^A_(UL?\ "0:Q_P _A_[\VW_QFC_A(-8_
MY_#_ -^;;_XS0!CX/H?R-*P.3P>I['UK7_X2#6/^?P_]^;;_ .,T?\)!K'_/
MX?\ OS;?_&: ,?!]#^1HP?0_D:V/^$@UC_G\/_?FV_\ C-'_  D&L?\ /X?^
M_-M_\9H Q\'T/Y&C!]#^1K8_X2#6/^?P_P#?FV_^,T?\)!K'_/X?^_-M_P#&
M: ,?!]#^1HP?0_D:V/\ A(-8_P"?P_\ ?FV_^,T?\)!K'_/X?^_-M_\ &: ,
M?!]#^1HP?0_D:V/^$@UC_G\/_?FV_P#C-'_"0:Q_S^'_ +\VW_QF@#'P?0_D
M:,'T/Y&MC_A(-8_Y_#_WYMO_ (S1_P )!K'_ #^'_OS;?_&: ,?!]#^1HP?0
M_D:V/^$@UC_G\/\ WYMO_C-'_"0:Q_S^'_OS;?\ QF@#'P?0_D:,'T/Y&MC_
M (2#6/\ G\/_ 'YMO_C-'_"0:Q_S^'_OS;?_ !F@#'P?0_D:,'T/Y&MC_A(-
M8_Y_#_WYMO\ XS1_PD&L?\_A_P"_-M_\9H Q\'T/Y&C!]#^1K8_X2#6/^?P_
M]^;;_P",T?\ "0:Q_P _A_[\VW_QF@#'P?0_D:,'T/Y&MC_A(-8_Y_#_ -^;
M;_XS1_PD&L?\_A_[\VW_ ,9H Q\'T/Y&C!]#^1K8_P"$@UC_ )_#_P!^;;_X
MS1_PD&L?\_A_[\VW_P 9H Q\'T/Y&C!]#^1K8_X2#6/^?P_]^;;_ .,T?\)!
MK'_/X?\ OS;?_&: ,?!]#^1HP?0_D:V/^$@UC_G\/_?FV_\ C-'_  D&L?\
M/X?^_-M_\9H Q\'T/Y&C!]#^1K8_X2#6/^?P_P#?FV_^,T?\)!K'_/X?^_-M
M_P#&: ,?!]#^1HP?0_D:V/\ A(-8_P"?P_\ ?FV_^,T?\)!K'_/X?^_-M_\
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M^;;_ .,T?\)!K'_/X?\ OS;?_&: ,?!]#^1HP?0_D:V/^$@UC_G\/_?FV_\
MC-'_  D&L?\ /X?^_-M_\9H Q\'T/Y&C!]#^1K8_X2#6/^?P_P#?FV_^,T?\
M)!K'_/X?^_-M_P#&: ,?!]#^1HP?0_D:V/\ A(-8_P"?P_\ ?FV_^,T?\)!K
M'_/X?^_-M_\ &: ,?!]#^1HP?0_D:V/^$@UC_G\/_?FV_P#C-'_"0:Q_S^'_
M +\VW_QF@#'P?0_D:,'T/Y&MC_A(-8_Y_#_WYMO_ (S1_P )!K'_ #^'_OS;
M?_&: ,?!]#^1HP?0_D:V/^$@UC_G\/\ WYMO_C-'_"0:Q_S^'_OS;?\ QF@#
M'P?0_D:,'T/Y&MC_ (2#6/\ G\/_ 'YMO_C-'_"0:Q_S^'_OS;?_ !F@#'P?
M0_D:,'T/Y&MC_A(-8_Y_#_WYMO\ XS1_PD&L?\_A_P"_-M_\9H Q\'T/Y&C!
M]#^1K8_X2#6/^?P_]^;;_P",T?\ "0:Q_P _A_[\VW_QF@#'P?0_D:,'T/Y&
MMC_A(-8_Y_#_ -^;;_XS1_PD&L?\_A_[\VW_ ,9H Q\'T/Y&C!]#^1K8_P"$
M@UC_ )_#_P!^;;_XS1_PD&L?\_A_[\VW_P 9H Q\'T/Y&C!]#^1K8_X2#6/^
M?P_]^;;_ .,T?\)!K'_/X?\ OS;?_&: ,?!]#^1HP?0_D:V/^$@UC_G\/_?F
MV_\ C-'_  D&L?\ /X?^_-M_\9H Q\'T/Y&C!]#^1K8_X2#6/^?P_P#?FV_^
M,T?\)!K'_/X?^_-M_P#&: ,?!]#^1HP?0_D:V/\ A(-8_P"?P_\ ?FV_^,T?
M\)!K'_/X?^_-M_\ &: ,?!]#^1HP?0_D:V/^$@UC_G\/_?FV_P#C-'_"0:Q_
MS^'_ +\VW_QF@#'P?0_D:,'T/Y&MC_A(-8_Y_#_WYMO_ (S1_P )!K'_ #^'
M_OS;?_&: ,?!]#^1HP?0_D:V/^$@UC_G\/\ WYMO_C-'_"0:Q_S^'_OS;?\
MQF@#'P?0_D:]>LO^/.T_Z]H/_125YP=?U=@5-X2&!!'DV_((P1Q#GIZ5Z/9?
M\>=I_P!>T'_HI* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y]XL_P"0C#_U
MY1_^C[FO0:\^\6?\A&'_ *\H_P#T?<T ?(G[6?[4OP^_8W^"NM_';XG:/XQU
MWPCH&J^']'O-.\!Z?HFI^(Y;GQ)JL&D6,EM9^(/$/A?3'@BN;A'NVEUB&2.
M,T,4\@$3?DQ_Q$;?L1?]$M_:I_\ "(^$?_S\:_?NOY@?^"C_ /RG._X)X?\
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MP]O;-*;>( ^EZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>$O"0D\-W-K>0V<<&G:GI\=N3<7ND2&7_2=2L=,\P\(?$[]OS]HS]N']N?\
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MG2_$7@'Q;X>U*\2^\(>)7^#<K>#[Z*;2M.N+M89K.UU8QZKH=V&MX;>[CU(
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MKHWV9]*O;C2=1T_5+W5+"_B-K\[_ /!*OX9?'BP_:V_;KU75_P!IK4M>\/\
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M\-=9\3_%WQO86OA?0;#2Y_#_ (JT=#X\GU'Q4)+^W\5^&8;=_#+ 'Z@T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?ST?\ #YGX
MK?\ #S/_ (8X_P"%'^&O^%4?\+U_X4%_:.?$G_"TO[3_ +?_ .$2_P"%B?;_
M .T?^$;_ .$4_M#_ (JK^R/^$4^T?\(=^^_X2'S_ /2J_H7H *^5/VPOVOOA
MS^Q1\*].^+GQ/\.^/_%&@:IXVT/P%9Z3\-=(T+6_$DNN>(;+6+[3V6P\0^)O
M"ED]GY>B7,,K1:E)=_:)K6."SG$DCQ?5=?CI_P %LO\ DV[X%?\ 9YOP#_\
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M-5O]46U,VGI93/\ O+7E7QQ^$'AKX_?"'XB_!;QC?:YIOA;XF^%=4\(:]?\
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M>&M(2YD$UPNF:%IUMI=@L\P2,2S+:6L0ED"()'#,$7.!T%%% !1110 4444
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M\"H?_BJ/[!O_ %M?_ J'_P"*K%HH VO[!O\ UM?_  *A_P#BJ/[!O_6U_P#
MJ'_XJL6B@#:_L&_];7_P*A_^*H_L&_\ 6U_\"H?_ (JL6B@#:_L&_P#6U_\
M J'_ .*H_L&_];7_ ,"H?_BJQ:* -K^P;_UM?_ J'_XJC^P;_P!;7_P*A_\
MBJQ:* -K^P;_ -;7_P "H?\ XJC^P;_UM?\ P*A_^*K%HH VO[!O_6U_\"H?
M_BJ/[!O_ %M?_ J'_P"*K%HH VO[!O\ UM?_  *A_P#BJ/[!O_6U_P# J'_X
MJL6B@#:_L&_];7_P*A_^*H_L&_\ 6U_\"H?_ (JL6B@#:_L&_P#6U_\  J'_
M .*H_L&_];7_ ,"H?_BJQ:* -K^P;_UM?_ J'_XJC^P;_P!;7_P*A_\ BJQ:
M* -K^P;_ -;7_P "H?\ XJC^P;_UM?\ P*A_^*K%HH VO[!O_6U_\"H?_BJ/
M[!O_ %M?_ J'_P"*K%HH VO[!O\ UM?_  *A_P#BJ/[!O_6U_P# J'_XJL6B
M@#:_L&_];7_P*A_^*H_L&_\ 6U_\"H?_ (JL6B@#:_L&_P#6U_\  J'_ .*H
M_L&_];7_ ,"H?_BJQ:* -K^P;_UM?_ J'_XJC^P;_P!;7_P*A_\ BJQ:* -K
M^P;_ -;7_P "H?\ XJC^P;_UM?\ P*A_^*K%HH VO[!O_6U_\"H?_BJ/[!O_
M %M?_ J'_P"*K%HH VO[!O\ UM?_  *A_P#BJ/[!O_6U_P# J'_XJL6B@#:_
ML&_];7_P*A_^*H_L&_\ 6U_\"H?_ (JL6B@#:_L&_P#6U_\  J'_ .*H_L&_
M];7_ ,"H?_BJQ:* -K^P;_UM?_ J'_XJC^P;_P!;7_P*A_\ BJQ:* -K^P;_
M -;7_P "H?\ XJC^P;_UM?\ P*A_^*K%HH VO[!O_6U_\"H?_BJ/[!O_ %M?
M_ J'_P"*K%HH VO[!O\ UM?_  *A_P#BJ/[!O_6U_P# J'_XJL6B@#:_L&_]
M;7_P*A_^*H_L&_\ 6U_\"H?_ (JL6B@#:_L&_P#6U_\  J'_ .*H_L&_];7_
M ,"H?_BJQ:* -K^P;_UM?_ J'_XJC^P;_P!;7_P*A_\ BJQ:* -K^P;_ -;7
M_P "H?\ XJC^P;_UM?\ P*A_^*K%HH VO[!O_6U_\"H?_BJ/[!O_ %M?_ J'
M_P"*K%HH VO[!O\ UM?_  *A_P#BJ/[!O_6U_P# J'_XJL6B@#:_L&_];7_P
M*A_^*H_L&_\ 6U_\"H?_ (JL6B@#:_L&_P#6U_\  J'_ .*H_L&_];7_ ,"H
M?_BJQ:* -K^P;_UM?_ J'_XJC^P;_P!;7_P*A_\ BJQ:* -K^P;_ -;7_P "
MH?\ XJC^P;_UM?\ P*A_^*K%HH VO[!O_6U_\"H?_BJ/[!O_ %M?_ J'_P"*
MK%HH VO[!O\ UM?_  *A_P#BJ/[!O_6U_P# J'_XJL6B@#:_L&_];7_P*A_^
M*H_L&_\ 6U_\"H?_ (JL6B@#:_L&_P#6U_\  J'_ .*H_L&_];7_ ,"H?_BJ
MQ:* -K^P;_UM?_ J'_XJC^P;_P!;7_P*A_\ BJQ:* -K^P;_ -;7_P "H?\
MXJC^P;_UM?\ P*A_^*K%HH VO[!O_6U_\"H?_BJ/[!O_ %M?_ J'_P"*K%HH
M VO[!O\ UM?_  *A_P#BJ/[!O_6U_P# J'_XJL6B@#:_L&_];7_P*A_^*H_L
M&_\ 6U_\"H?_ (JL6B@#:_L&_P#6U_\  J'_ .*H_L&_];7_ ,"H?_BJQ:*
M-K^P;_UM?_ J'_XJC^P;_P!;7_P*A_\ BJQ:* -K^P;_ -;7_P "H?\ XJC^
MP;_UM?\ P*A_^*K%HH VO[!O_6U_\"H?_BJ/[!O_ %M?_ J'_P"*K%HH VO[
M!O\ UM?_  *A_P#BJ/[!O_6U_P# J'_XJL6B@#:_L&_];7_P*A_^*H_L&_\
M6U_\"H?_ (JL6B@#:_L&_P#6U_\  J'_ .*H_L&_];7_ ,"H?_BJQ:* -K^P
M;_UM?_ J'_XJC^P;_P!;7_P*A_\ BJQ:* -K^P;_ -;7_P "H?\ XJC^P;_U
MM?\ P*A_^*K%HH VO[!O_6U_\"H?_BJ/[!O_ %M?_ J'_P"*K%HH VO[!O\
MUM?_  *A_P#BJ/[!O_6U_P# J'_XJL6B@#:_L&_];7_P*A_^*H_L&_\ 6U_\
M"H?_ (JL6B@#:_L&_P#6U_\  J'_ .*H_L&_];7_ ,"H?_BJQ:* -K^P;_UM
M?_ J'_XJC^P;_P!;7_P*A_\ BJQ:* -K^P;_ -;7_P "H?\ XJC^P;_UM?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?>+/^0C#_P!>4?\
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MTW3KGP]JMIXB34[V2"W?3[B2YGDC>&[6$ [7_@F=^TW^UI\=O!_COPI^V3\
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M3O\ 1O#/A/\ LB>R:.X?6YKZZBFN-0>9P#^I;XC_ !8^%GP=T.U\3?%SXE^
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M:QO8;JTCA\&Q+/:M;W-^ET ?L-\.OC)\(?C!976I?"3XJ?#?XI:=8NL5[?\
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M%6LZMXF\6:[KOCS7)=3O6TNUTBQ\/:=IKVMZ ?4-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !17\TW_#O#_@H1_P]V_X:=_X2[_B
MS'_"Y_\ A.?^%H?\+$LO^2+?VG]O_P"%(_\ "'?VG_PE_P#R*'_%MOL'_"/?
M\(I_S%/[4^S?OZ_I9H *_,#_ (*R_';XY? #]G3P'XC_ &>_'L7PW\?^+_V@
M_AI\-?\ A)IO#/A3Q9##H_BZQ\51W<$ND^,-!\1:68C>V6G7,D\-@M^BVIBM
M[F))IED_3^OQT_X+9?\ )MWP*_[/-^ ?_H/C"@#V7_@EI^U'\0/VF_V;[_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME_P2H_9__:"^'?[*OPT\=>._C9;Z+^R#X5?P=\,]0\/Z_P##_3]9UG1O[.\
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M!FFPZ/X2\"^&M%\)^&]+@5%CL=%T#3[?3-.M_P!VD:LZ6MM'YLNQ6FE+RO\
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MI,+"-50&.PL+="$54!7Y5 P!V%% !1110 4444 %%%% !1110 4444 %%%%
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MGA_P]X7TQX(KFX=+18M'ADC@"K-+/(#*WTI10!^=_@C_ ()B_LS^#OV1-?\
MV*;X>//'7P?\0>(-3\5RWOC/7M&?QMIOB*_NK.^MM6T?7/"_AKPO865UHU[8
M6]QI;'195(,]KJ:ZE87-Q:2^5^(/^"0/P8\:Z-X?T;XC_M'_ +:GQ1'@O6-#
MUKX>WOQ'^.>F^+)/A[/H5]:7L,?A/2]1\!OX:MC>QV5OIE]J.I:%JFNG2$_L
MZRU:RA.!^LE% 'QU^U9^Q/\ #?\ :VU7X1^)_%7CGXP?##QU\#=8\1:U\-?B
M#\$_&5CX+\8:!<^*X=#@U^**_P!2\/>);-X-0B\.Z3'(1IZ7*Q036\=REO>7
M<,\NH_L7?#K6?C[^S?\ M):YXU^*>M_$K]F3X?:W\._"-QJVO^';S3_&-CXB
M\):YX/U?Q!\1_,\)?VQKGBF]L_$.H:G-J.C:QX<M)=:,=U-ITEOYMI-]@44
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M_P"O:#_T4E>05Z_9?\>=I_U[0?\ HI* +-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5QWB%-,:]B-[+=QR_94"BWCC=#'YL^"2YSNW;P1TP%]378UY]XL_Y",/
M_7E'_P"C[F@"EY>@?\_.I?\ ?F#_ !H\O0/^?G4O^_,'^-8M% &UY>@?\_.I
M?]^8/\:/+T#_ )^=2_[\P?XUBT4 ;7EZ!_S\ZE_WY@_QH\O0/^?G4O\ OS!_
MC6+10!M>7H'_ #\ZE_WY@_QH\O0/^?G4O^_,'^-8M% &UY>@?\_.I?\ ?F#_
M !H\O0/^?G4O^_,'^-8M% &UY>@?\_.I?]^8/\:/+T#_ )^=2_[\P?XUBT4
M;7EZ!_S\ZE_WY@_QH\O0/^?G4O\ OS!_C6+10!M>7H'_ #\ZE_WY@_QH\O0/
M^?G4O^_,'^-8M% &UY>@?\_.I?\ ?F#_ !H\O0/^?G4O^_,'^-8M% &UY>@?
M\_.I?]^8/\:/+T#_ )^=2_[\P?XUBT4 ;7EZ!_S\ZE_WY@_QH\O0/^?G4O\
MOS!_C6+10!M>7H'_ #\ZE_WY@_QH\O0/^?G4O^_,'^-8M% &UY>@?\_.I?\
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MQH\O0/\ GYU+_OS!_C6+10!M>7H'_/SJ7_?F#_&CR] _Y^=2_P"_,'^-8M%
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M8M% &UY>@?\ /SJ7_?F#_&CR] _Y^=2_[\P?XUBT4 ;7EZ!_S\ZE_P!^8/\
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M\$V>E^,? \WA+5Y3+#=ZEJKP6DD']B7=O/J=U;W5M_6]^PQX_P#B-\5/V/\
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M>*=!\(^(-4NKIY+G4;[7O!VEZ!K%SJ]Q))-K$MZVJ2.[WA8_DIXI_:D^"_\
MP5$^,EWH?Q=_:/\ A)^S]_P3[^$7BBVE3X>>.OC)X'^&WQ._:L\7:-/%>66H
M^(=!UOQ)I/B+P]\+[*98+NRCN+:VGG4Q-:,WBAY;OP%^N_C/PA\0_P!H'1?
MWB?]B;]NKPK\'/A!H>AS^%H+3X/_  H^ _QW\#:U=:+=FQA&E>(-6.IV&BQ>
M'K2"/05T#09H[&R6U$<D$4J>6H!]UU_,W_P6Z_9Y^.^I_!OXS_M ?%;]H/5-
M4^%GA/QK\/\ 2?@-^SYX/M%TCPEHMEKVL:+I.K>*?B7=M:6K^+?%6^YUI-'B
M>WNI-#AN(7M?$<EM)<Z0?U(TG]E_]OFRU73+S4_^"G_B36=-M-0LKG4='?\
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MX<;0-;M-0\0:]_Q.6GUFVN(+VVBFT9C8H\WZ?_#;P%H/PJ^'7@'X7^%?MO\
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M/XC?#G]EW_@HI_P47\&?M(^)/#?PM\9_&[QYX2^*'PF\:_$'5=-\-Z#XZ^&
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M'_HI* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/#=AO%AX>\*:)IGAW0[(2-ND%II.D6MG86V]OF?R;=-S<MDUYIXX_9F_9O\
MB=KZ>*OB3^S[\$/B%XHC\O9XD\<?"CP'XLU]/*\ORMFL:]H&H:BOE^3#Y>+@
M;/*CVXV+CVZB@#.TC1](\/Z98Z)H.EZ=HFC:9;1V>FZ1I%C;:;IFGVD(VQ6M
MC8644-K:6T2_+'!;Q1Q(.%4"O&KO]ES]F74/&#?$*_\ V=?@3>^/VOCJC>.+
MOX1_#^Y\8-J9F:X.HMXFF\//K1OC.[S&[-Z;@S.TADWL6/NU% ' ?$?X3_"S
MXQ:':^&?BY\-/ 'Q3\-V.JP:[9>'OB/X-\.^.-#L]<M;2^T^VUFUTGQ-INJ6
M%OJMO8:IJ5C!J,-NEW%::C?6T<RPW=PDF/XR^ WP-^(OA?PYX(^(/P9^%'CO
MP7X.6T3PCX0\9?#OPAXG\+^%DT_3_P"R+!/#F@:WH]]I.AK9:2!IEHNF6EJ+
M;3_]"A"6W[JO5Z* *>G:=I^D:?8Z3I-C9Z9I>F6=MIVFZ;IUM#9:?I^GV4*6
MUG8V-G;)%;VEG:6\4=O;6UO''#!#&D42)&BJ,[Q+X6\,>--%O?#?C'PYH/BS
MP[J2"+4= \2Z1I^NZ+?QJP=8[W2]4M[JQND5U5PD\$BA@& R :W:* /'?AU^
MSO\ L_\ P@O[C5/A+\"_@[\+M3NXG@NM1^'7PR\%>";^Y@D"AX;B\\-:)IEQ
M-$X1 \<DC(P100=HQKS_  7^#MU\2;+XRW7PF^&ES\8--MGLM.^*T_@3PM-\
M2;"SDTN[T-[2R\<R:4WBBUMGT2_OM'>"#5(XFTN]N]/*&TN9H7]+HH \T^)7
MP7^#OQGL]+T[XP_";X:?%?3]$N9[W1;'XE>!/"WCJSTB\NHE@N;O2[7Q1I6J
M06%S<0(D,\]HD4LT2+'([(H Q=6_9S_9[U_X?Z!\)M=^!'P:UKX5^%-0&K^%
M_AIJWPP\$:C\/_#>JA=54:GH'@V\T.;PYH^H!==UQ1>Z=IMM<A=9U4>;C4;O
MSO9:* ,_2-(TKP_I6F:#H.F:?HFAZ)I]EI&C:-I%E;:;I6D:5IMM%9Z=IFF:
M=9Q0V=AI]A9PPVME96L,5M:VT44$$4<4:(-"BB@#E?&W@3P1\2_#&I^"?B/X
M-\*_$#P9K7V+^V?"/C;P]I'BOPQJW]FZA::MIW]IZ!KMG?Z5?_8-5L+'4[+[
M5:2_9=0LK2]@\NYMH94O>&?#'AKP7X?TCPGX.\/:'X3\+>'[&#3-!\->&=)L
M-!\/Z)IMLNRVT[2-&TNWM=.TVQMT^2"TL[:&WB7Y8XU'%;E% !7ENL_ WX)^
M(_B!I'Q9\0_![X6Z[\5/#ZV2:#\2]9^'WA+5/B!HB::T[:<FD>,K[2)_$>FK
M8-=7+62V>I0BU:XG, C,TF[U*B@#B?B!\-/AQ\6/#S^$OBG\/_!/Q+\*27EM
MJ+^&?B!X4T+QEX>?4+(N;.^?1?$5AJ6FM>6ADD-M<FV,T!D<Q.F]L[.F^%O#
M&C>&+#P3I'AS0=*\&Z5H-KX6TOPEIND:?8^&--\,6.GQZ39>'+#0;6WBTJST
M&STJ*+3+72+>TCT^WT^..RBMTMD6,;M% 'SO:_LA?LFV6G^(](L_V7_V=[32
MO&,4$/B[3+7X*?#6WT_Q5#:ZM8Z];1>([*+PREMKD5OKNEZ9K4$>IQ72PZMI
MUCJ,86\M+>:/9UC]F7]F[Q#:^"+'Q!^S[\$-<LOAG9QZ=\-[/6/A1X#U.U^'
MVGPSV]S#8^"+>]T">'PI9Q7-I:7$=MH*6$,<]K;RJ@DAC9?;Z* /+?&WP-^"
M?Q+\1>'?%_Q&^#WPM\?^+/"#0/X3\4>-OA]X2\5>(O"[VM\FIVS^'=;UW2+_
M %+1&M]2C348&TVYMC#?(EW&5N%$@/B1\#?@I\9%L$^+WP?^%OQ532M_]EI\
M2/A_X3\<KIOF$E_L"^)](U06>\LQ?[.(]Q8DYR:]2HH YSPIX/\ "/@/0[3P
MSX'\+>'/!GANPWBP\/>%-$TSP[H=D)&W2"TTG2+6SL+;>WS/Y-NFYN6R:\T\
M<?LS?LW_ !.U]/%7Q)_9]^"'Q"\41^7L\2>./A1X#\6:^GE>7Y6S6->T#4-1
M7R_)A\O%P-GE1[<;%Q[=10!G:1H^D>'],L=$T'2].T31M,MH[/3=(TBQMM-T
MS3[2$;8K6QL+**&UM+:)?EC@MXHXD'"J!7C2_LM_LRIXO7X@I^SI\"5\?+>C
M4E\;K\(OA^OB]=167SQ?KXE'AX:T+T3@3"Z%Z)Q*/,$F_FO=J* . ^(_PG^%
MGQBT.U\,_%SX:> /BGX;L=5@UVR\/?$?P;X=\<:'9ZY:VE]I]MK-KI/B;3=4
ML+?5;>PU34K&#48;=+N*TU&^MHYEAN[A),?QE\!O@;\1?"_ASP1\0?@S\*/'
M?@OP<MHGA'PAXR^'?A#Q/X7\+)I^G_V18)X<T#6]'OM)T-;+20-,M%TRTM1;
M:?\ Z%"$MOW5>KT4 4].T[3](T^QTG2;&STS2],L[;3M-TW3K:&RT_3]/LH4
MMK.QL;.V2*WM+.TMXH[>VMK>..&"&-(HD2-%4<!/\%_@[=?$FR^,MU\)OAI<
M_&#3;9[+3OBM/X$\+3?$FPLY-+N]#>TLO',FE-XHM;9]$O[[1W@@U2.)M+O;
MO3RAM+F:%_2Z* /-/^%+_!W_ (63_P +E_X5/\-/^%O_ &7[%_PM;_A!/"W_
M  LG['_9?]A_9/\ A.?[*_X2C[+_ &+_ ,2?[/\ VIY7]E_\2_9]D_<UO>,_
M /@3XC:0WA_XA>"O"7CS06E6=M$\9^'-'\4:0TR A)FTW6[.^LC*H)"R&'>H
M) (S76T4 ?.&@_L<?LB>%=0CU;PQ^RM^SAX<U2'_ %6I:#\#OACH^H1<AOW=
MYI_A>WN4Y /RR#D ]17=>,_@3\$/B-K_ (:\5_$+X-_"KQYXH\&?9O\ A#_$
MGC/X>>$?%&O^%/L=ZFI6?_"-:QK>D7VHZ%]EU&*._MO[+N;7R+V-+J+9.BR#
MU6B@#E?&W@3P1\2_#&I^"?B/X-\*_$#P9K7V+^V?"/C;P]I'BOPQJW]FZA::
MMIW]IZ!KMG?Z5?\ V#5;"QU.R^U6DOV74+*TO8/+N;:&5)?!W@OP=\//#6E^
M#/A_X3\,^!O!^AQ30:)X4\':#I?AGPUH\-S=3WUQ#I>A:+:V6EZ?%/>W5S>3
M1VEK"DMU<3W#AI9I';I:* "BBB@ HHHH **** "BBB@ HHHH *X[QY\.OA]\
M4_#ESX.^)W@7P=\1O"-[/:75YX6\>>&-$\7^'+NYL)UNK&XN=#\06.HZ9//9
M7*)<6DTMJ\EO.BRPLDBAAV-% $-O;V]I;P6MK!#;6MM#%;VUM;Q)#;V]O"BQ
MPP00QJL<4,4:K'%%&JI&BJB*%  XO6/A=\,_$7C3PS\2/$'PZ\":[\1/!=O=
MVO@[Q[K'A'P_J?C3PG:W\=S#?6WAGQ3>Z?/KF@V][%>7<5W#I5]:QW$=U<I,
MKK/*&[JB@#Q;Q5^S=^SMX[\61>/?&_P$^"WC+QS 8&@\9^*OA;X&\0^+(6ME
M"6S1>(M7T*\UB,VZJJP%+P&)0%CV@ 5V?BCX:?#GQQK'A#Q#XU\ >"?&&O\
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M5=^*_#&B>(KGP?XNTJ19=+\4^%I]8L;R7P_XCTV55EL-<TE[34[.15>WNHV
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MCO\ PDOV0O\ Z%FC_A1?Q4_Z/._:._\ "2_9"_\ H6:/[/PG_0\RK_P3G?\
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M);]E/_Z&BC_A2OQ-_P"CO/V@?_"6_93_ /H:*/[/PG_0\RK_ ,$YW_\ .?\
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MK_P3G?\ \Y_ZL_*Y_;N:?]$9Q+_X5<'_ /T6'T317SM_PI7XF_\ 1WG[0/\
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MZL_*Y_;N:?\ 1&<2_P#A5P?_ /18?1-%?.W_  I7XF_]'>?M _\ A+?LI_\
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M)O\ T=Y^T#_X2W[*?_T-%']GX3_H>95_X)SO_P"<_P#5GY7/[=S3_HC.)?\
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M .$M^RG_ /0T4?V?A/\ H>95_P""<[_^<_\ 5GY7/[=S3_HC.)?_  JX/_\
MHL/HFBOG;_A2OQ-_Z.\_:!_\);]E/_Z&BC_A2OQ-_P"CO/V@?_"6_93_ /H:
M*/[/PG_0\RK_ ,$YW_\ .?\ JS\KG]NYI_T1G$O_ (5<'_\ T6'T317SM_PI
M7XF_]'>?M _^$M^RG_\ 0T4?\*5^)O\ T=Y^T#_X2W[*?_T-%']GX3_H>95_
MX)SO_P"<_P#5GY7/[=S3_HC.)?\ PJX/_P#HL/HFBOG;_A2OQ-_Z.\_:!_\
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M_$W_ *.\_:!_\);]E/\ ^AHH_P"%*_$W_H[S]H'_ ,);]E/_ .AHH_L_"?\
M0\RK_P $YW_\Y_ZL_*Y_;N:?]$9Q+_X5<'__ $6'T317SM_PI7XF_P#1WG[0
M/_A+?LI__0T4?\*5^)O_ $=Y^T#_ .$M^RG_ /0T4?V?A/\ H>95_P""<[_^
M<_\ 5GY7/[=S3_HC.)?_  JX/_\ HL/HFBOG;_A2OQ-_Z.\_:!_\);]E/_Z&
MBC_A2OQ-_P"CO/V@?_"6_93_ /H:*/[/PG_0\RK_ ,$YW_\ .?\ JS\KG]NY
MI_T1G$O_ (5<'_\ T6'T317SM_PI7XF_]'>?M _^$M^RG_\ 0T4?\*5^)O\
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M@?\ PEOV4_\ Z&BC_A2OQ-_Z.\_:!_\ "6_93_\ H:*/[/PG_0\RK_P3G?\
M\Y_ZL_*Y_;N:?]$9Q+_X5<'_ /T6'T317SM_PI7XF_\ 1WG[0/\ X2W[*?\
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MJX/_ /HL/HFBOG;_ (4K\3?^CO/V@?\ PEOV4_\ Z&BC_A2OQ-_Z.\_:!_\
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M?LI__0T4?\*5^)O_ $=Y^T#_ .$M^RG_ /0T4?V?A/\ H>95_P""<[_^<_\
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M^"<[_P#G/_5GY7/[=S3_ *(SB7_PJX/_ /HL/HFBOG;_ (4K\3?^CO/V@?\
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M_P#5GY7/[=S3_HC.)?\ PJX/_P#HL/HFBOG;_A2OQ-_Z.\_:!_\ "6_93_\
MH:*/^%*_$W_H[S]H'_PEOV4__H:*/[/PG_0\RK_P3G?_ ,Y_ZL_*Y_;N:?\
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M/HFBOG;_ (4K\3?^CO/V@?\ PEOV4_\ Z&BC_A2OQ-_Z.\_:!_\ "6_93_\
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M/_5GY7/[=S3_ *(SB7_PJX/_ /HL/HFBOG;_ (4K\3?^CO/V@?\ PEOV4_\
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M:W7BJP\3:/J.B>!O#FJ^+M%T:7Q5X6\.3Z-KP32+_3X+O5)M5E-B?4OVD/\
M@J!J_A+]@7X#?MN? ?P9H>KP_%WXD>"O"FI>#O'-IJ6N3:99WTOC33/'.A:8
M_ASQ#X7-SXET?Q)X-O\ 0]'U2:Y.G7#Q-<W6B_Z0MO; '[&T5^(/[1G[;'_!
M1S]CCP_X+^.7Q\^!W[+_ (B^"/BCQMI/A/7?AY\)?$OQ'O/C-X#E\217<VB6
M.I^+]>N5\">(M1Q9RV-S>:!X:?2Y=::"P@:.QN8M8.Y\7OVR?^"@O[*-M\,_
MC+^TU\(_V7YOV?/&_CWPOX+\7^%OA/K_ ,2+OXS?"O\ X3.0Q:7/JFN^);J+
MP9XONM*V3_VC#X?\/V\%[?6XTZ"XL+:X36HP#]'OB%^U3\!?A5\8/A?\!/'O
MCO\ L'XL_&;/_"M?"G_"+^,]4_X23%Y+8'_B>Z-X=U'PUH_^EP2Q?\3_ %G2
M_N^9_JV5S]"5^7_[4?[1.L?#G]OK]A;X(67PW^$'B32?C?\ \)[_ &UXV\8>
M#[K6/B1X0_X12T.H:;_PK_Q)%K=C;:!YMR[O=_:])U;>69H/LTA+GX.\=WG[
M?;_\%BO".C6/B']EG_A.XOV4O$&J^"+&^T[XT2?#"V^"EU\8/&%JDOB'2H?$
M:ZR?C9.+22#4-9TB6#PE/96VF0"QQ P !_1C17\YWCN\_;[?_@L5X1T:Q\0_
MLL_\)W%^REX@U7P18WVG?&B3X86WP4NOC!XPM4E\0Z5#XC763\;)Q:20:AK.
MD2P>$I[*VTR 6.(& ^\?&O[6'[3?Q:_:=^*7[-'[%?@[X+&/]GS2_#$GQM^,
M7[0#>.+[P?8>+/&-H^I:)X$\(>&_A_J.CZUJNK1Z=!=2:AJ-UJD-C;75CJEK
M/';-96#ZV ?J!17YH?L[_MU>)]0U#]KCX8_M9>%_!_P\^,'[%.C6OC3XIZE\
M,KW6=8^'/BOX:ZCX.O/'=CXX\&0^("WB#3XQX=M$O+O0];N9;Z&+4M)9IUNI
MM0L-+\>^%7[67_!1SXT?"V']K/P5\"_V:K;]G?4(M6\6^&?@UK/B3XBM^TGX
MQ^&VAWMRLU]I'BO3Y)OAG8^*-<TVRN[GP[I6I^'XX;FX2"*X>&*\MI9 #[D\
M(_M)R?M"_"GPW\7OV,;+X;?&_P ):YK6M:3-JGQ)\<?$WX"V$*Z%<3:??/IJ
M3? 'XC^([^\AU6%[22VU'PQH5F80;RTU2\7;$^-^S#^TMXY^.GCW]HWP#XS^
M&'@SP3-^SSXT\+?#R]\3?#_XL:Y\5/"OBOQCJOAMO$OBS0[&\\1?"#X/ZIIU
MUX#M[WP[IVK&;1[R*[U;5+VVMY(X-+CNM2_-3_@E1\9O#W[/'_!'2[^-WBB2
M!='^&C_'+Q0UO/(8EU34K+Q9JRZ%H,+CD7GB+79=-T&P4$;[W4;=-R[MP_1O
M_@GQ\']>^#W[+/@&#QUOG^+/Q0GUWXZ_&C4[CSO[1U3XJ?&35;CQSXE;5?..
M3J.C1ZII_A69E&&C\/Q,\ES,TMW< 'VK1110 4444 %%%% !1110 4444 %%
M?BM_P^H^%7_#>?\ PQ5_PJ+Q;_9W_"W/^%$?\+:_X2&RW?\ "S_[=_X0[['_
M ,(#_8WF_P#"+_\ ":?\27_A(O\ A+?M?V+_ (G7]@^1_H]?M30 5F:UK6C>
M'-(U/Q!XAU;3-!T'1;&ZU/6-;UJ_M=+TC2=-LH7N+W4=3U*^E@L["QM+>.2>
MZN[J:*WMX4>661$4L-.OQ+_X+-^(M5\46O[%/[)::O?Z'X/_ &M?VJO ?@7X
MDWFF27,5U?>"M/\ $_A+3+C1)O(O+03V,VK>,M)U][9F1Y;_ ,-Z:T=U;+'*
M)@#Z/M?^"OO_  3?N_%4?@V+]J7PDFKRWB6*WEUX7^(]CX5$[NL8>3QW>^#+
M?P1%9AF!?49?$*:>B!I'N5C1F'U;\8_VF_@7\ ?"'@?Q[\5O']GX>\'?$KQC
MX9\!>!O$&G:1XC\8:?XD\4^,=,U36?#-E8OX*T?Q%(MGK&EZ-J-[;:Y<QP:"
M(8$,VIQ-=6BSIXN_9E^!WC'X$:M^S9>_#OPQIGP>U/PM<^$[;PCHFB:18V'A
M^SELI+2SU/P[;26%S9Z9X@T>61=3TC61:37=IJ\,.HLTMP'9_P 1O^"K/P5T
M/]E#_@G_ /L7?!KP%J/CWXAZ#\*?VT?A9;^%Y/&FJZ/JWCC6K4^'?CKXAT_P
M_-J6E:+X:T9_L;7Z>&_#T<&CV,-EI%II5I/Y\EO+=3 ']&5?/GC7]JGX"_#S
MXX_#G]F[QCX[_L?XT_%K3'UCX?>#/^$7\9:A_P )!IT<FLQ/<?\ "1:7X=O?
M"FE8D\/:NODZWKNFSG[)D1%;BU,_YV?%[]L?]O?]D_Q'\%O'7[3GPJ_9CN_V
M?OB_\6/"/PKUC3?@UKOQ-U7XJ_"74_&R7%QIS^(=<\2&V\)^,/[+M+#5#=7.
M@>'--TW4]1TXZ7#>:<-2TJ^N_8OC?^T#JWA3_@IC^QK^SK%\./A'K>A?%_X?
M?%3Q#JWQ \1>$+G4OBOX6N? _A#XA^(])L_ _BM=:MK/1-.N+_084U&WN=#U
M.26WOM36VGM)KI)X0#]-**_(?XG_ +8_[9-[^WO\0/V+OV<_AG\#/$-MH7PB
M\*?$:S\=?%"7QQI&F^"(M3.F'6]<\;7GAS7+N?Q/IS7.HVFA>'?"7ACP]HVL
MWFI:I!J%YX@@TG2-4E;OOV3?VPOCYXM_:C^,/[%O[5G@7X5Z%\9OAGX T[XL
M:+XQ^"&H^)9OAWXR\":AJ6@:4TL.D^,;K4?$>CZC:7/BG1 5O[_S+AWU!#86
MD5G;76H@'Z=45^=OC+Q?_P %._$OC[XIP_"3X4?LN_#/X:>"]6N-,^'%U\==
M<\6>-O%WQIM+.-R/$>G_ /"IO&EEIGP[T;5Y(2-.M/%]G-K]DEW:G4M(0PW6
MST;]@G]J^7]LS]G#PW\9M1\)#P+XH;6_$W@[QIX6@NVU#3=,\5^$M3DT_4#H
M]_(%GNM+O;=K+4+<7"^?9274VFR37ILAJ%V ?9E%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5Z_9?\ 'G:?]>T'_HI*\@KU^R_X\[3_ *]H/_12
M4 6:\$_:KT;5_$7[+W[2/A_P_I6I:[KVN_ 3XPZ-HFB:/8W6IZOK&KZG\//$
M5EINE:5IME%/>ZAJ6H7L\-I8V-I#-=7=U-%;V\4DLB(?>Z* /PA_X-ZOA!\6
M?@K^Q?\ $[PM\9/A?\1/A+XGO_VG_&GB"P\.?$SP3XE\!Z]>Z#=?"GX*Z=:Z
MW::1XITS2M0N=(N=0TK5+"#4H;=[.:\TV_M8YFGL[A(_LS_@JEI'[5&N_L3_
M !3TO]CR7Q$GQ>NY?#\4L'@FXDM/'U]X(DU:"/QC9>!;N!XKNW\1RZ8^Y6TZ
M>WUB328]5@T.7^V9K".3]$J* /\ /D^,W[%?Q7\<?LX?#.Y^&'_!,_\ ;:\/
M_'KPYJ>FK^T)\9/B3IOQ6\6^(_B1KU[HLM@UAX&^&+Z/%=MX0EU.SN?$#>((
M?"<5SX6@73O#.K^)-=>ZM=2O_P!J?VRO@/\ &WQM_P %-_\ @D]\1?#/P3^+
M?B3X?> ? _[/ \>>,M,^&'C74/"_@*[T7XG:MJ^HP>-]9BT)].\'W^B6DEOJ
M&IVGB*?3+S2(FCN+V*V ##^G*B@#\3O^"]W[.GQ>_:1_8CT+0/@KX'\1?$7Q
M7X"^.W@WXDWWA+PEI<VN>)-2\/6'@KXD^$=0?2-&LV;4=4N;.Y\9Z?=O9Z7:
MW]_+;PS&&S=5DDB_/+]IS6OVJ?VL?^"/NF_!]_V%OVDOAK\0/@IXH_9K^'VE
M>#]3\ ^/-?\ &7Q'TOP9X0N]&UWQQHG@V/P#HWB.QT*QNM,B^ULUAJ,%I_:%
MN)K\ QO-_5]10!_+C^V[^S[\>O%G_!"_]C?X1^%O@C\7O$OQ7\+ZE\#I/$OP
MQ\/_  U\9ZS\0O#J:3X'\?6FJOKO@O3M%N?$FD)IEU>6=MJ#:AIMN+*XNK:&
MY,4D\2OS'_!0'_@GO\>_C5^Q)_P2[^(W@?X,^)OB3XM_9I_9V^$7A#XV?L]W
M7]I>%_'6HZ%<?#SX52:MH<>C$Z5XML=<TG5_#.L^%_%6CZ4C>,-/.K1W5AIT
M%SH=\P_JUHH _CY_9R_9#T7XP?M<_ V7X0_\$;?$G[+GP;\%^(_#?C#XH?$K
M]JGQC^V'9>*M(N?#.O1:ZUQ\.%U3XR^"/#U]JA@LK"R\/V&H^$/'=G<:[<_;
M/$%A#X?LKV"3[._X)T? OXS>"/\ @L1_P49^*7C7X._$[PC\._&J?%B/P/\
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M;Q2VL=T+B(2"42+7]"U% '\H?PE^&G[6_P#P2$_;4_:D\8>'/V/OB_\ M>?
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M=_;?U#5=7\0Z9^T7\0=2^*4G@GP[X>T^YTO7]3?P]I$MM#;?$;QAJMEI>O\
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M7EJDLED\SFZ@^J?^"I7[./[0'B_QM_P3'@\%_!/XJ^.1\,O GA71OB%=>!/
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M0VME96L,MS=7,L4$$4DLB(?<Z* /YZOV%OVS_'O[+?['_P (O@-XO_X)Y?\
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M3Q!X<T/1]);Q'8_:=3EN;O4K?5=(CNKO4[C3I+;3/Z J* /Y\OV-/B3^T/\
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M^_,G_P 31]EN?^?>?_OS)_\ $U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\
M@3/_ /%T 1?9;G_GWG_[\R?_ !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!
M,_\ \71_:.H?\_UY_P"!,_\ \70!%]EN?^?>?_OS)_\ $T?9;G_GWG_[\R?_
M !-2_P!HZA_S_7G_ ($S_P#Q=']HZA_S_7G_ ($S_P#Q= $7V6Y_Y]Y_^_,G
M_P 31]EN?^?>?_OS)_\ $U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\ @3/_
M /%T 1?9;G_GWG_[\R?_ !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!,_\
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M_P#Q=']HZA_S_7G_ ($S_P#Q= $7V6Y_Y]Y_^_,G_P 31]EN?^?>?_OS)_\
M$U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\ @3/_ /%T 1?9;G_GWG_[\R?_
M !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!,_\ \71_:.H?\_UY_P"!,_\
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M ($S_P#Q= $7V6Y_Y]Y_^_,G_P 31]EN?^?>?_OS)_\ $U+_ &CJ'_/]>?\
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M4O\ :.H?\_UY_P"!,_\ \71_:.H?\_UY_P"!,_\ \70!%]EN?^?>?_OS)_\
M$T?9;G_GWG_[\R?_ !-2_P!HZA_S_7G_ ($S_P#Q=']HZA_S_7G_ ($S_P#Q
M= $7V6Y_Y]Y_^_,G_P 31]EN?^?>?_OS)_\ $U+_ &CJ'_/]>?\ @3/_ /%T
M?VCJ'_/]>?\ @3/_ /%T 1?9;G_GWG_[\R?_ !-'V6Y_Y]Y_^_,G_P 34O\
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M^_,G_P 31]EN?^?>?_OS)_\ $U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\
M@3/_ /%T 1?9;G_GWG_[\R?_ !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!
M,_\ \71_:.H?\_UY_P"!,_\ \70!%]EN?^?>?_OS)_\ $T?9;G_GWG_[\R?_
M !-2_P!HZA_S_7G_ ($S_P#Q=']HZA_S_7G_ ($S_P#Q= $7V6Y_Y]Y_^_,G
M_P 31]EN?^?>?_OS)_\ $U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\ @3/_
M /%T 1?9;G_GWG_[\R?_ !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!,_\
M\71_:.H?\_UY_P"!,_\ \70!%]EN?^?>?_OS)_\ $T?9;G_GWG_[\R?_ !-2
M_P!HZA_S_7G_ ($S_P#Q=']HZA_S_7G_ ($S_P#Q= $7V6Y_Y]Y_^_,G_P 3
M1]EN?^?>?_OS)_\ $U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\ @3/_ /%T
M 1?9;G_GWG_[\R?_ !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!,_\ \71_
M:.H?\_UY_P"!,_\ \70!%]EN?^?>?_OS)_\ $T?9;G_GWG_[\R?_ !-2_P!H
MZA_S_7G_ ($S_P#Q=']HZA_S_7G_ ($S_P#Q= $7V6Y_Y]Y_^_,G_P 31]EN
M?^?>?_OS)_\ $U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\ @3/_ /%T 1?9
M;G_GWG_[\R?_ !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!,_\ \71_:.H?
M\_UY_P"!,_\ \70!%]EN?^?>?_OS)_\ $T?9;G_GWG_[\R?_ !-2_P!HZA_S
M_7G_ ($S_P#Q=']HZA_S_7G_ ($S_P#Q= $7V6Y_Y]Y_^_,G_P 31]EN?^?>
M?_OS)_\ $U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\ @3/_ /%T 1?9;G_G
MWG_[\R?_ !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!,_\ \71_:.H?\_UY
M_P"!,_\ \70!%]EN?^?>?_OS)_\ $T?9;G_GWG_[\R?_ !-2_P!HZA_S_7G_
M ($S_P#Q=']HZA_S_7G_ ($S_P#Q= $7V6Y_Y]Y_^_,G_P 31]EN?^?>?_OS
M)_\ $U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\ @3/_ /%T 1?9;G_GWG_[
M\R?_ !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!,_\ \71_:.H?\_UY_P"!
M,_\ \70!%]EN?^?>?_OS)_\ $T?9;G_GWG_[\R?_ !-2_P!HZA_S_7G_ ($S
M_P#Q=']HZA_S_7G_ ($S_P#Q= $7V6Y_Y]Y_^_,G_P 31]EN?^?>?_OS)_\
M$U+_ &CJ'_/]>?\ @3/_ /%T?VCJ'_/]>?\ @3/_ /%T 1?9;G_GWG_[\R?_
M !-'V6Y_Y]Y_^_,G_P 34O\ :.H?\_UY_P"!,_\ \71_:.H?\_UY_P"!,_\
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M ($S_P#Q= $7V6Y_Y]Y_^_,G_P 31]EN?^?>?_OS)_\ $U+_ &CJ'_/]>?\
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M4O\ :.H?\_UY_P"!,_\ \71_:.H?\_UY_P"!,_\ \70!%]EN?^?>?_OS)_\
M$T?9;G_GWG_[\R?_ !-2_P!HZA_S_7G_ ($S_P#Q=']HZA_S_7G_ ($S_P#Q
M= $7V6Y_Y]Y_^_,G_P 31]EN?^?>?_OS)_\ $U+_ &CJ'_/]>?\ @3/_ /%T
M?VCJ'_/]>?\ @3/_ /%T 1?9;G_GWG_[\R?_ !-'V6Y_Y]Y_^_,G_P 34O\
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MFF:JNDZE$+2ZDETK4(;[2]/E@5)/NFOR=^.?[1/[''[)G[-G[5/Q\_8ZTO\
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MO+A*_:8/U'_X(G?\HQ_V9_\ NLW_ *T#\5J /U2HHHH **** "BBB@ HHHH
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M\4M;^(^J2[7U34/%K:A86R2ZM.8UFDNF\/PZ)<!9GD*K<^8I4SLH /9_@_\
M\%&/$.I?M!>%/V7/VK/V8?&O[)7QB^(VFZAJ7PRAU3QUX7^*_@#QS_9D=S/<
MZ9IGQ \)V>EZ<NL-;VD[06T=E=6ANHQIMQJ%MJ-YI%KJ?KO_  V;_P 9^?\
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MMGD>4,Q /0J\K^.OQ-_X4K\$?C'\9/[$_P"$E_X5+\*OB%\3?^$<_M+^QO\
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MQ5\(^))KBU\476E)X[\!Z1X T"\N-16UM=*L?!7B!]0M[#5)3I/G7>E1ZI
M?U145^)/[;MS\=_''_!2G]C[]G[X7?M$?$[X%^$/B3\'/B??^.YO ?B"]A6X
MTS0AXAU+4[S3/#=V]UX1F\:W>EZ:VA^'O%6N:)J<_A*6]77]/AFO]*LK>3*\
M*2_%S]CW_@I[^SS^S-IW[2'QX^.?P5_:;^&'Q)U_5O#W[0WC:3XFZ]X-\2>!
M/"WC+Q':ZCX9\6ZA;6^HVMI=R^$H+8Z7##;6R0ZA?_:O[0<6$FG@'[ET444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQM])T2RAL;8W$P56N[ZX6+[3J-_,#<ZA?S7-]=/)<W$LC=Q10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7BO[2?P
MXUSXQ?LZ_'SX1^&;K2K'Q)\4_@K\4_AQX>O==GN[70[/7/''@;7?#.DW6LW.
MGV.J7]OI5O?ZI;S:C/8Z;J-W%:)-);6-W,J6\GM5% 'RU^Q/\$/%?[-W[*OP
M3^!OCG4/#VJ^+?AOX1&@:YJ/A2[U*^\.W=Y_:NI7WFZ3=ZOI.A:E/;>5>1+O
MO-(L9?,60>3M"NWEO_!2O]EKX@_MD?LG^+O@3\,=8\':%XNU_P 2>"=8L]1\
M>:AK>F>'(K;PWXBL]7OH[F\\/^'O%&II/+;6[I:+%H\T<DY59I8(R95^]Z*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_@1)_\ &*S** -/^S5_Z"6F?^!$G_QBC^S5_P"@EIG_ ($2?_&*S** -/\
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M^@EIG_@1)_\ &*S** -/^S5_Z"6F?^!$G_QBC^S5_P"@EIG_ ($2?_&*S**
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M3_LU?^@EIG_@1)_\8H_LU?\ H):9_P"!$G_QBLRB@#3_ +-7_H):9_X$2?\
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M[-7_ *"6F?\ @1)_\8K,HH T_P"S5_Z"6F?^!$G_ ,8H_LU?^@EIG_@1)_\
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M2?\ QBC^S5_Z"6F?^!$G_P 8K,HH T_[-7_H):9_X$2?_&*/[-7_ *"6F?\
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M@EIG_@1)_P#&*/[-7_H):9_X$2?_ !BLRB@#3_LU?^@EIG_@1)_\8H_LU?\
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M1+P+X2_LW3M2T&_O;VW\CP-X9\,VUYYUS#%+YU_#=3Q[=D4L<;,A_0?X,?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/A3\-/V6?&'[#_[0W[,_@CP?\(OC>O[5WP_^$L>F?##1-%\$1_$3X=>,=/\
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M[G7;:6U4%KB.:P1X5!,@4 U^.O\ P6Z^&O@3PW^RA^S)\/O!WA70O ?A"_\
MVY_A+9'1/ FDZ=X/L+,:YX'^,<>HW6FVF@VMC:V%_.UQ)<&]MX$G^U$7#,TH
MW5G?\%5OV:_@-\ ?A+^RA\2/@9\)_ GP?\>?#G]KGX%Z'X8\6_#KPQH_A7Q
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M\*_M:?&;X ^%8OB-H6F^.+7PM\*_"-KX8UO3O#7AN#Q):Z@FAQW>J^,];O\
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MB%-.O9M.U!]#\5:/I^A:LMCJ%L5N+"\:PO[@6U[ RS6LY2>(AXU-<Y_P4_\
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M;]2_^"\#HG_!.?XC*SJK2^._A4D:LP4R./&FGR%$!(+L(XY)"JY(1'?&U6(
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MQ;X8\$>&;$H+WQ%XOU[2O#6A69D)$8NM7UF[LM/MS(00@FN$+$$+G!K\"O\
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MJ?Q?\8?CA\;O$6A1>%+CXP?M!^.U^(7CK3?"D4D<H\-Z%<VNC>'M&T?2W>&
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MLO\ CSM/^O:#_P!%)7D%>OV7_'G:?]>T'_HI* +-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5Q7B1[!;Z(74-S))]DC(:&>.)0GG3X!5X9"6W;B3N ((&,@D]K
M7GWBS_D(P_\ 7E'_ .C[F@#+\S2/^?6__P# N#_Y%H\S2/\ GUO_ /P+@_\
MD6O._'GQ%^'WPL\.7/C'XG>.O!WPY\(V4]I:WGBGQYXGT3PAX<M+F_G6UL;>
MYUSQ!?:=ID$][<NEO:0RW227$[K%"KR,%/@__#=7[$7_ $>/^RM_XD+\(_\
MYKZ /KSS-(_Y];__ ,"X/_D6CS-(_P"?6_\ _ N#_P"1:\8^&7QU^"/QJ_MO
M_A3?QC^%7Q:_X1K^S?\ A(_^%9?$+PCX\_X1_P#MG[?_ &/_ &W_ ,(MJ^J_
MV5_:O]E:I_9OV_R/MW]FW_V7S?L=QY?JE &GYFD?\^M__P"!<'_R+1YFD?\
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M*U* -/S-(_Y];_\ \"X/_D6CS-(_Y];_ /\  N#_ .1:S** -/S-(_Y];_\
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MQ"NBS>)&F@\"-JP\4RQ+X=MY]?,D>E,@T6";52?L,;SKZA0!I^9I'_/K?_\
M@7!_\BT>9I'_ #ZW_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW
M_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW_P#X%P?_ "+6910!
MI^9I'_/K?_\ @7!_\BT>9I'_ #ZW_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_
M\BT>9I'_ #ZW_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW_P#X
M%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW_P#X%P?_ "+6910!I^9I
M'_/K?_\ @7!_\BT>9I'_ #ZW_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>
M9I'_ #ZW_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW_P#X%P?_
M "+6910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW_P#X%P?_ "+6910!I^9I'_/K
M?_\ @7!_\BT>9I'_ #ZW_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>9I'_
M #ZW_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW_P#X%P?_ "+6
M910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW_P#X%P?_ "+6910!I^9I'_/K?_\
M@7!_\BT>9I'_ #ZW_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW
M_P#X%P?_ "+6910!I^9I'_/K?_\ @7!_\BT>9I'_ #ZW_P#X%P?_ "+696?J
M^KZ5X?TK4]>U[4]/T30]$T^]U?6=9U>]MM-TK2-*TVVEO-1U/4]1O)8;.PT^
MPLX9KJ]O;J:*VM;:*6>>6.*-W !T?F:1_P ^M_\ ^!<'_P BT>9I'_/K?_\
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M1VTS)VU &GYFD?\ /K?_ /@7!_\ (M'F:1_SZW__ (%P?_(M9E% &GYFD?\
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MTC_GUO\ _P "X/\ Y%H\S2/^?6__ / N#_Y%K,HH T_,TC_GUO\ _P "X/\
MY%H\S2/^?6__ / N#_Y%K,HH T_,TC_GUO\ _P "X/\ Y%H\S2/^?6__ / N
M#_Y%K,HH T_,TC_GUO\ _P "X/\ Y%H\S2/^?6__ / N#_Y%K,HH T_,TC_G
MUO\ _P "X/\ Y%H\S2/^?6__ / N#_Y%K,HH T_,TC_GUO\ _P "X/\ Y%H\
MS2/^?6__ / N#_Y%K,HH T_,TC_GUO\ _P "X/\ Y%H\S2/^?6__ / N#_Y%
MK,HH T_,TC_GUO\ _P "X/\ Y%H\S2/^?6__ / N#_Y%K,HH T_,TC_GUO\
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M\MGEM[NSN[>6.XMKFWDDAGAD26)WC=6-R@#3\S2/^?6__P# N#_Y%H\S2/\
MGUO_ /P+@_\ D6LRB@#3\S2/^?6__P# N#_Y%H\S2/\ GUO_ /P+@_\ D6LR
MB@#3\S2/^?6__P# N#_Y%H\S2/\ GUO_ /P+@_\ D6LRB@#3\S2/^?6__P#
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M@#2,FDX.+:_!P<$W<) /8D?91D9[9KTVR_X\[3_KV@_]%)7D%>OV7_'G:?\
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MQC=WDEKI.CVMG86\EU=32W-R\5NC3W$LDTI>1V8_U14 %%%% !1110 4444
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M87$UXJM%;:G8:;X<U&&!83 Q .8T/_@J7\8/B-\6?CS\&_@9^PEX[^,/B?X
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MQ4^ ,LLTWC?PAJPM)!)<6V@6%YK6K*%3SH=#U/Q3<6[2ZG:Z*D0!\'?LR_\
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M#IOAK2M<\/:?=7%];1:C"FMW^HZ1<S0:9=61UJ[LM+N?BCQ]J6B_MP?\$8/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^&-"\(>';$;/]$T3PYIEKI&F0,8XXD>2.SM(5DD6-!)(&?:"Q%=710 4444
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M_P#GXT ?T'_VSJ'_ #UA_P# *R_^1Z/[9U#_ )ZP_P#@%9?_ "/7YW?L,_\
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M]9=% &I_;.H?\]8?_ *R_P#D>C^V=0_YZP_^ 5E_\CUET4 :G]LZA_SUA_\
M *R_^1Z/[9U#_GK#_P" 5E_\CUET4 :G]LZA_P ]8?\ P"LO_D>C^V=0_P">
ML/\ X!67_P CUET4 :G]LZA_SUA_\ K+_P"1Z/[9U#_GK#_X!67_ ,CUET4
M:G]LZA_SUA_\ K+_ .1Z/[9U#_GK#_X!67_R/6710!J?VSJ'_/6'_P  K+_Y
M'H_MG4/^>L/_ (!67_R/6710!J?VSJ'_ #UA_P# *R_^1Z/[9U#_ )ZP_P#@
M%9?_ "/6710!J?VSJ'_/6'_P"LO_ )'H_MG4/^>L/_@%9?\ R/6710!J?VSJ
M'_/6'_P"LO\ Y'H_MG4/^>L/_@%9?_(]9=% &I_;.H?\]8?_  "LO_D>C^V=
M0_YZP_\ @%9?_(]9=% &I_;.H?\ /6'_ , K+_Y'H_MG4/\ GK#_ . 5E_\
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MLO\ Y'H_MG4/^>L/_@%9?_(]9=% &I_;.H?\]8?_  "LO_D>C^V=0_YZP_\
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M:IXT5M8T.SMY;[@_V1_VF_BG\5_V;_B9\6OC%X&T>[^('PM^(?QY\&ZOX%^
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MJ?VSJ'_/6'_P"LO_ )'H_MG4/^>L/_@%9?\ R/6710!J?VSJ'_/6'_P"LO\
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M_P#(]']LZA_SUA_\ K+_ .1ZRZ* -3^V=0_YZP_^ 5E_\CT?VSJ'_/6'_P
MK+_Y'K+HH U/[9U#_GK#_P" 5E_\CT?VSJ'_ #UA_P# *R_^1ZRZ* -3^V=0
M_P">L/\ X!67_P CT?VSJ'_/6'_P"LO_ )'K+HH U/[9U#_GK#_X!67_ ,CT
M?VSJ'_/6'_P"LO\ Y'K+HH U/[9U#_GK#_X!67_R/1_;.H?\]8?_  "LO_D>
MLNB@#3.L:@0098<$$'_0[(<'@\BW!'U'->F67_'G:?\ 7M!_Z*2O(*]?LO\
MCSM/^O:#_P!%)0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/O%G_(1A_P"O
M*/\ ]'W->@UY]XL_Y",/_7E'_P"C[F@#F*_F!_X*/_\ *<[_ ()X?]BS^SQ_
MZT+\8*_I^K\(?VU_V,_VD_BY_P %6_V-/VE/A[\-_P#A(/@I\*-"^#5GX_\
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M9A<0GR&U$7,V_P#<0RE7V]5K_P"SO\<?$/\ P2S\-?LQ>%=4'PU^/=O^R/\
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MC&C6FH,/(\I@)Y88I.F_;:^"/[?NO?M$ZKXC\/? [X$?MZ?LHZ[H"V7A_P"
MWQ5TSX%>$?$_PQU6[TO38=6NM+^(7B?0/"_BV)HM=TZ[U31=1L?&&MR_8-;F
MTZ_TY+[3-/UF( \/_:&^/7[6%A_P2:_:F\5_$CX__L\?M%W>L7W@?P%X-^-_
M[+^N7%TP\$>/O%_A[P]XVL/BAIFE>%/"OAWPMK<V@ZF-"CM-&5727Q<VFZM!
M%/8V[ZO]A?\ !$_X2>!/!W_!.SX4ZQI?A_33JWQ@_P"$V\4_$34+BQM9;CQ/
M>_\ ":>*/"]C:ZHSQ,;O3=-\-Z58Z1:6-P9;5(A>2K$LFH7GF_+_ .PM_P $
MD_'/ASX+_MF>#/VF;?0_AKHG[7,&G:;I7P:^'7B&?Q5I/PFM- UO7O$GAG5E
MU.YO]3T_5-7\*:QJ>E1^&8CJ^MRQZ;H6-6UR\N-4G2V\V^"_P7_X+7_L&?#O
MQ!^S1\ _AM\#?CQ\,UU3Q!=_#OXF7_BKPU87G@(>)+F6ZO;S3M"\9?$+P%<J
M6U"\N/$?]A:KX>\5Z;8^(9-0/VG7--N#:7H!^D_C#X8_LG_\$F/V?OVD?VE_
M@A\'Y?"I_P"$>T2^\1^'+#QW\0=4TGQAXC_M]O#WP\TN33_%?BGQ%I'AZS7Q
M7XX6Q:^T/2K:;2])U2^6VMYX8HK)OR]\-_'K_@LC\1OV1_$'_!0S0OCY\&-!
M^&^G:+XS^(=E\ +;X4^%[PW7@#P+J^I6'B&]CUBZ\):MXEMDM+?1==U*"RO/
M'4E]+I&E0W-QJUO<WC11>O\ [)__  1B\3>%_P!D+]J?X:_M >.-.3XT?M::
M9X<BU2^T26?Q#I7P\G\#^('\<>$I+V],MDGB?5;GQS]FUGQ6]IY=H]M8VNG:
M3J$I^U7]UXSX>_9__P""RW@/]DK6O^">&@_ WX,:A\,]1T[Q7\/K?]H.V^*7
MABUDM?AWXTU[4]2\1V*Z5/XMT_Q+/:ZE;ZOK.F?;+GX>MJD7AS56L9-&FU&%
M+F, [?\ :L_X*J_&_7_^"7?P'_:\^ &NP_!GXI^+OVA=-^$_Q'@L_#7A7Q;I
MEK<:9X(^*]_XBTO1[3X@:)XLLET;5M1\-^&O$.F7GDMK5E9R1:7-J+,-26Y\
M2_:6_;6_X*T_LP?"[]F[]K3QO\8/@Q=_#;XWIX>N['X):1X"\,WS6EIJ?A2W
M\6:3;^,-?;P=9:Y->:_H"RW>N77A'QGIEMI>LR-:Z5:0V)BCM_<?VL?^"5/Q
MJ\/?\$OO@1^R'^SUHJ?&KXG^$?VA-+^+'Q&NH/$/A/P9I]W<ZGX%^*MCXEU/
M2+CQ[X@\,V!T72-4\2>'/#FDVOVL:UJ%C%!J\^F12/J8M.]_X*6?L0?M0_M
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MUNSOO&>K^'K233--OM9DL=&@N+F/5[G1;/3D%B;E)88P#]"OVS-5^/6D^'?
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MAMK4'P[UJ+XIZ)XFL-(\6CPS%H-WXE\7ZU:Z)JNK7GB#P]X<O?#]GI/B#1-
M;Q#)/HMS9P@'[4T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^%7_!5W_@J[\5OV"_BM\*_AA\,/A7X+\5?\)5X+7X@^)?$OQ!7Q)/I
MEUID_B36/#T?ACPQ'X>UC0/L6NV7]@7-_JFJ7]SK-O;V^LZ*JZ*<R23_ +)_
M"3Q[_P +4^%/PR^)_P#8=]X8_P"%C_#WP7X]_P"$:U1_,U/P]_PF'AO3?$/]
MAZC)Y%MYE]I/]H_8+M_LUONN+>1O(BSY:GCWX2?"GXJ?V'_PL_X9?#WXC_\
M",7SZIX:_P"$]\%^&_&'_"/:G)Y'F:CH?_"0Z;J/]DWTGV:VWW=A]GN&^SP;
MI#Y4>WT*@ KY6_;K_P"3(OVQ_P#LU;]H7_U4?B^OJFO /VL/!/B?XE_LL_M*
M_#CP3IG]M>,_B!\ /C)X)\(Z-]MT_3?[6\3^*_AUXCT+0-,_M'5[NPTJP^WZ
MK?VEK]MU.^LM/M?-\^]N[:VCEF0 _%C]@[]H3_@HIH7[$GP(\&_ [_@GIH'C
MCPW8^ _L'@7XT^*?VJ?A=HWA[6K<ZUJDJZ_JWPO>#3/&=I9I,]Q:OH_]O6FH
M.85G2Y6-U4^'?M3_ +(/BS]B[_@B;\1OAO\ $#7],U[XA>,OCMX.^*_CE-!D
MGF\.:#X@\5>*O!^F'PYX?GN([=[BQTS2_#FF&ZN$M;6VGUF?5);2.2U:&YG_
M '1_X)]_"KQ[\$/V,_V?OA1\4-!_X1CQ_P""/ XT?Q1H']J:-K7]F:C_ &SJ
MMW]G_M7P]J.K:+>_Z/<P2>=IVHW<'S[/-WJZKX[_ ,%9_@!\6_VF?V+/&_PE
M^"/A+_A-OB#J_BOX?ZEIWA_^WO#/AO[19:'XIL=2U2;^U?%VLZ!HD/V6RADF
M\N?4HII]OEV\<TI6,@'Q7^T+X[_X*/\ [(?[+?A+]LJ?]I#X=^,/#'@^S^%%
MUXZ_9:A^"/A'3/ NE>#O%^H^'_"UCI.D_%9]0NOB?K.IZ7?:WH.EW^I?:K/^
MT)KV^UFTM["STY-/N_TE_:J\5_'&^^&/PX\1_ OXU_!+]FSPQXBUG1M3^)GQ
M@^.?V.?4O"'@35--CO+>'P+X>UBVN? 6L^,[EKAG>V\7Z_I>D1QV+6]O=3->
M->V'EW_!0KX ?%OXX_\ !-WX@? /X6^$O^$H^+.M^%/@CINE^$_[>\,Z)]JO
M?"'Q*^&7B#Q%#_;OB+6=(\-0_P!G:1X>UB[\RXUF*&[^Q^18R7-S<6L,_A'[
M;_[*G[0?C[Q;^Q/\4/"/P:\'?M1^"/V>]#OK+XB?LF^.O&_A[P?HGB3Q)J?A
M>TTJS\70:CXFFE\!:S?^'IH#%%%X@74[.&6TMDM-/U'3]7U=X #!_9Z_;#^)
M&E_MX^ /V7;C]L7X4?MU?"GXO?"_Q=XJT[X@^#-*^$6F^*/AIXQ\'6FK:M-H
M.M7'P4N%\+7EEJ6EZ/))#%J-A#J<HU*TEB%M%IT\FJ^.M^VK\<OC1^T+^TI\
M-]8_;V^&/_!/OQ#\(?BOXG^''PN^"7C[X2?#37XO'NB^'5>'1O&GBKXE?%"3
M[).GC"^@#)IG@G48I(-/F,VE)J,5YHM_=^L_!O\ 9]_:FU7_ (*%?!#]I/Q9
M^R%\-/V9_@OX9^#_ ,1OA])X.^'OCGX5^(-0\'7VH:==RZ=J_C>7PD/#Z:[K
M'BB^GBTFPM/!>C:]I7AS2;*R2^U8/)>W#P?%#X6?MNW>O_&3P)\=/V(O@?\
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MZ26.I64L=U93S0.LA]H_9N^)?[07Q-\->(-3_:&_9F_X9A\1:=KB6&A>%_\
MA<W@GXU?\)'HK6%O</KW]M^!["PL=(V7TMQI_P#9=Y&]VWV;[6'\F9%'T;0!
M\#_LA>#O%WAKX[?\% M7\1^%?$?A_2?&?[2F@Z[X/U36]#U/2M.\5Z'#\&OA
M[I<VL^&KV_M8+;7=*BU.RO-.DU'2Y;JT2_M+FT:87$$L:??%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '\]'_  ^9^*W_  \S_P"&
M./\ A1_AK_A5'_"]?^%!?VCGQ)_PM+^T_P"W_P#A$O\ A8GV_P#M'_A&_P#A
M%/[0_P"*J_LC_A%/M'_"'?OO^$A\_P#TJOZ%Z\]_X5)\*?\ A87_  MS_A67
MP]_X6O\ 8?[+_P"%G?\ "%^&_P#A87]F?8_[._L[_A-/[-_X23[#_9_^@_9/
M[2^S_8_]&\OR/DKT*@ K\//^"RTL_C+Q5_P3H_9[UI+N;X8?'/\ ;,\ Z/\
M$FSM@B1:MIEEXB\(^'K?1[N>2WGC:*ZLO'.N7<-G<>9:S76GP7DMI<R:= UO
M^X=?!7_!0[]CB]_;(^"FF>'O!OB>'P)\9_AAXST7XI?!/QQ<M<+9:'XY\/,_
MDVVJ-:17%S'I>JVLDD+W,%M=2Z9JD&DZRMG?C3&T^[ /LSQ+X)\)^+_!>N?#
MKQ%H-AJ/@CQ)X;U#P?K/AHQM:Z;=^&=4TV72+W1UCLFMGM+2339I+2,64EO)
M:QE3:R0O'&Z_@I_P6!^#G@K]G/\ 8?\ V1/A)\!/"<.@^%/ _P"V[\,?^$#\
M(ZCXC\2:U:P:AJWAWXZ>)C8W7B+Q5JNO^(7LK[Q'JUW(TEYJ=W_9UK<_9;%8
M+&TM;6'V_P 3_$W_ (+*_$'X9ZQ\%H/V0_A9\+OB'XDTBX\)7G[5.G?M(^$_
M^$/T&#4K)M-O_&?ACX<:-)J7Q$T;7K=+B34=&O4NM1DTC484N8M!N#%;P'-_
M;&_8A_:/\4_L6_L;_ CP?KGBS]ICXH_![]IGX6?$?XI^/O&WCNP7Q#K.DZ;I
M/Q3NO&7BF?7OB?XLMK_4M-TK6_%]CI'A[0_[8U37;7P\NE:?964UKIDOV< S
M_P!I3XF?\% _V'-1^ _QN^(O[3/@CX_?#7XA_''P#\*?BI\%;'X%>#_AUI/A
M.#QU'?7$][\./&-C?7WC;4K;3$TG4M.TRX\5:O=7GVV72-0U'3[^RGU*ST_Z
M"^.?[1?QD\'?\%1_V)/V<_#GC'^SO@U\7OAQ\9->^(G@[_A'O"UY_P )#JWA
M3P)\2-9T"[_X2&_T.Z\5:3]@U+0-)N?(T/7-,MKK[)Y-[#<V\]S%-N_\%1?@
M!\6_VB_@E\*/"/P;\)?\)CXA\-?M-?"+XA:WI_\ ;WAGP]]B\(>%QXD&NZO]
MK\5:SH=C<_8?M]I_H%I<SZI<^;_H=E<>7+LPOCG^SI\9/&/_  5'_8D_:,\.
M>#O[1^#7PA^''QDT'XB>,?\ A(?"UG_PCVK>*_ GQ(T;0+3_ (1Z_P!<M?%6
MK?;]2U_2;;S]#T/4[:U^U^=>S6UO!<RP@'C?Q%^+O[</Q+_X*7_%3]DGX&_'
M/PS\)_A;X?\ @1X+^(NHZ_K_ ,,?!?CS4O PNYM%M]1U#P9IM]8:=?\ B+Q7
MXAU;5;+3X8?&&OZAX1T31I-:U :/<:E!I%K)W'[(GQ__ &FO#_[<'QQ_82_:
M2^)GASX\W/@CX1:5\;O GQBTSP#HOPTU^[T*]UKPEH]UX>\3^&/"Z0^&H[F-
M_&5DUM)IL$CI_9MS--J%T-0CM=-])^'_ , /BWHG_!4WX\_M':IX2^R_!GQI
M^S+X*^'OAKQE_;WAF;^TO%^D:[X3O-0TC_A'K?69?%5G]GMM,OI/M^H:':Z7
M+Y&R"]EDDA63"\#_ +.GQDT?_@KE\8_VGM1\'?9_@;XJ_9)TOX8Z#XX_X2'P
MM-]O\<6_BSX5ZG-HG_"-0:Y+XOM=ECX;UJ?^TKW0+?2&^Q>6FH--<6D<X!P_
MQR\9_M%Z+\5/BI'\0?\ @IW^RC^QGH-OJ;)\#OAA!9?!KQ#KFH>&_LS3:3K/
MQ@O/CQ9Z-KUEK&L(MM<W^C^!C-IMM#=W#:9KMQ'!;--[W_P3*_:E\;_M>_LG
M^&/BI\2;70H_'MAXG\7^!/%.I>%U$/A[Q%?^$]4^SV_B/2K17D2RAU33+FP>
MX@AE>U>_CN[JQ2UL;FVLK7\Y/@Y^R[^V!^S[XK^/&AZQ^P=\"?VK?'?Q1^*W
MBWQCX?\ VR/B/\5?ANA;3?%%RBZ:/''A?QCI6O\ Q)73O#D0;49] \(V5G!=
MSRW&F6\<C!-;G^_/^"4_P'^+_P"S;^R)HWPH^./A2+PCX^TCXA?$K4[NS@UC
MPKK5OJ>FZ_XGN=7TS7+>X\'ZKJ^DVL&H6]UB/3FN(;RR6'RKBSM1Y<0 /TAH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O7[+_CSM/^O:#_ -%)
M7D%>OV7_ !YVG_7M!_Z*2@"S1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?>+/
M^0C#_P!>4?\ Z/N:]!KC?$6F7U[>Q2VMN98UM4C+!XEPXEG8KAW4\*ZG.,<]
M<@T <316Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\
M/FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@
M:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM
M&/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_
M ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\
M\^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16
MQ_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@
M_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?
M]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&
MK_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#C
MM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/
M_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\
M/FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@
M:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM
M&/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_
M ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\
M\^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16
MQ_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@
M_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?
M]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&
MK_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#C
MM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/
M_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\
M/FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@
M:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM
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M_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\
M/FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@
M:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM
M&/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_
M ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\
M\^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16
MQ_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@
M_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?
M]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&
MK_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#C
MM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/
M_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\
M/FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@
M:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM
M&/16Q_8&K_\ /FW_ ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_
M ']@_P#CM']@:O\ \^;?]_8/_CM &/16Q_8&K_\ /FW_ ']@_P#CM']@:O\
M\^;?]_8/_CM &/16N=!U902;-L $G$D!. ,G $I)^@!)[50^R77_ #[S?]^W
M_P * *]%6/LEU_S[S?\ ?M_\*/LEU_S[S?\ ?M_\* *]%6/LEU_S[S?]^W_P
MH^R77_/O-_W[?_"@"O15C[)=?\^\W_?M_P#"C[)=?\^\W_?M_P#"@"O15C[)
M=?\ /O-_W[?_  H^R77_ #[S?]^W_P * *]%6/LEU_S[S?\ ?M_\*/LEU_S[
MS?\ ?M_\* *]%6/LEU_S[S?]^W_PH^R77_/O-_W[?_"@"O15C[)=?\^\W_?M
M_P#"C[)=?\^\W_?M_P#"@"O15C[)=?\ /O-_W[?_  H^R77_ #[S?]^W_P *
M *]%6/LEU_S[S?\ ?M_\*/LEU_S[S?\ ?M_\* *]%6/LEU_S[S?]^W_PH^R7
M7_/O-_W[?_"@"O15C[)=?\^\W_?M_P#"C[)=?\^\W_?M_P#"@"O15C[)=?\
M/O-_W[?_  H^R77_ #[S?]^W_P * *]%6/LEU_S[S?\ ?M_\*/LEU_S[S?\
M?M_\* *]%6/LEU_S[S?]^W_PH^R77_/O-_W[?_"@"O15C[)=?\^\W_?M_P#"
MC[)=?\^\W_?M_P#"@"O15C[)=?\ /O-_W[?_  H^R77_ #[S?]^W_P * *]%
M6/LEU_S[S?\ ?M_\*/LEU_S[S?\ ?M_\* *]%6/LEU_S[S?]^W_PH^R77_/O
M-_W[?_"@"O15C[)=?\^\W_?M_P#"C[)=?\^\W_?M_P#"@"O15C[)=?\ /O-_
MW[?_  H^R77_ #[S?]^W_P * *]%6/LEU_S[S?\ ?M_\*/LEU_S[S?\ ?M_\
M* *]%6/LEU_S[S?]^W_PH^R77_/O-_W[?_"@"O15C[)=?\^\W_?M_P#"C[)=
M?\^\W_?M_P#"@"O15C[)=?\ /O-_W[?_  H^R77_ #[S?]^W_P * *]%6/LE
MU_S[S?\ ?M_\*/LEU_S[S?\ ?M_\* *]%6/LEU_S[S?]^W_PH^R77_/O-_W[
M?_"@"O15C[)=?\^\W_?M_P#"C[)=?\^\W_?M_P#"@"O15C[)=?\ /O-_W[?_
M  H^R77_ #[S?]^W_P * *]%6/LEU_S[S?\ ?M_\*/LEU_S[S?\ ?M_\* *]
M%6/LEU_S[S?]^W_PH^R77_/O-_W[?_"@"O15C[)=?\^\W_?M_P#"C[)=?\^\
MW_?M_P#"@"O15C[)=?\ /O-_W[?_  H^R77_ #[S?]^W_P * *]>OV7_ !YV
MG_7M!_Z*2O*5L[MF"K;3$L0H'EMR2< =.YKUBU5DM;9'!5D@A5E/4,L:@@^X
M((H GHK\ /VM_P#@K;\;/@1^U]\:_P!F_P %_#CX67V@?"?3_AC>6OB+Q1#X
MMU#6-9;Q_P" ='\77"7%OI/B;0;*S73;N_N+2$QI.;BW$+.(Y$=I?#O^'UG[
M3'_1./@7_P""/Q__ //%KQ\5GF P=>>&KRJQJT^7F4:3DO?C&<6FG9WC)/RV
M>I^1<3^-W G"&>8WA[.\3F5',LO^K_6*=#+JN(I)8K"T,90<*U.3C)2P^(I2
M>SBVXR2E%I?TX45_,?\ \/K/VF/^B<? O_P1^/\ _P">+1_P^L_:8_Z)Q\"_
M_!'X_P#_ )XM<_\ K-E7\];_ ,$R/!_XF2\+_P#H-S?_ ,,^(_\ DC^G"BOY
MC_\ A]9^TQ_T3CX%_P#@C\?_ /SQ:/\ A]9^TQ_T3CX%_P#@C\?_ /SQ:/\
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M/6_\$R#_ (F2\+_^@W-__#/B/_DC^G"BOYC_ /A]9^TQ_P!$X^!?_@C\?_\
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MZS]IC_HG'P+_ /!'X_\ _GBT?ZS95_/6_P#!,@_XF2\+_P#H-S?_ ,,^(_\
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M&?$?_)'].%%?S'_\/K/VF/\ HG'P+_\ !'X__P#GBT?\/K/VF/\ HG'P+_\
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M?TX45_,?_P /K/VF/^B<? O_ ,$?C_\ ^>+1_P /K/VF/^B<? O_ ,$?C_\
M^>+1_K-E7\];_P $R#_B9+PO_P"@W-__  SXC_Y(_IPHK^8__A]9^TQ_T3CX
M%_\ @C\?_P#SQ:/^'UG[3'_1./@7_P""/Q__ //%H_UFRK^>M_X)D'_$R7A?
M_P!!N;_^&?$?_)'].%%?S'_\/K/VF/\ HG'P+_\ !'X__P#GBT?\/K/VF/\
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M:/\ A]9^TQ_T3CX%_P#@C\?_ /SQ:/\ 6;*OYZW_ ()D'_$R7A?_ -!N;_\
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M_!'X_P#_ )XM'_#ZS]IC_HG'P+_\$?C_ /\ GBT?ZS95_/6_\$R#_B9+PO\
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M_K-E7\];_P $R#_B9+PO_P"@W-__  SXC_Y(_IPHK^8__A]9^TQ_T3CX%_\
M@C\?_P#SQ:/^'UG[3'_1./@7_P""/Q__ //%H_UFRK^>M_X)D'_$R7A?_P!!
MN;_^&?$?_)'].%%?S'_\/K/VF/\ HG'P+_\ !'X__P#GBT?\/K/VF/\ HG'P
M+_\ !'X__P#GBT?ZS95_/6_\$R#_ (F2\+_^@W-__#/B/_DC^G"BOYC_ /A]
M9^TQ_P!$X^!?_@C\?_\ SQ:/^'UG[3'_ $3CX%_^"/Q__P#/%H_UFRK^>M_X
M)D'_ !,EX7_]!N;_ /AGQ'_R1_3A17\Q_P#P^L_:8_Z)Q\"__!'X_P#_ )XM
M'_#ZS]IC_HG'P+_\$?C_ /\ GBT?ZS95_/6_\$R#_B9+PO\ ^@W-_P#PSXC_
M .2/Z<**_F/_ .'UG[3'_1./@7_X(_'_ /\ /%H_X?6?M,?]$X^!?_@C\?\
M_P \6C_6;*OYZW_@F0?\3)>%_P#T&YO_ .&?$?\ R1_3A17\Q_\ P^L_:8_Z
M)Q\"_P#P1^/_ /YXM'_#ZS]IC_HG'P+_ /!'X_\ _GBT?ZS95_/6_P#!,@_X
MF2\+_P#H-S?_ ,,^(_\ DC^G"BOYC_\ A]9^TQ_T3CX%_P#@C\?_ /SQ:/\
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M?_@C\?\ _P \6C_6;*OYZW_@F0?\3)>%_P#T&YO_ .&?$?\ R1_3A17\Q_\
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MH_UFRK^>M_X)D'_$R7A?_P!!N;_^&?$?_)'].%%?S'_\/K/VF/\ HG'P+_\
M!'X__P#GBT?\/K/VF/\ HG'P+_\ !'X__P#GBT?ZS95_/6_\$R#_ (F2\+_^
M@W-__#/B/_DC^G"BOYC_ /A]9^TQ_P!$X^!?_@C\?_\ SQ:/^'UG[3'_ $3C
MX%_^"/Q__P#/%H_UFRK^>M_X)D'_ !,EX7_]!N;_ /AGQ'_R1_3A17\Q_P#P
M^L_:8_Z)Q\"__!'X_P#_ )XM'_#ZS]IC_HG'P+_\$?C_ /\ GBT?ZS95_/6_
M\$R#_B9+PO\ ^@W-_P#PSXC_ .2/Z<**_F/_ .'UG[3'_1./@7_X(_'_ /\
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MUH^QHYI@9\\Z<:=3V_+2G.5.M&G_ $TT5_,?_P /K/VF/^B<? O_ ,$?C_\
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M_P#/%H_X?6?M,?\ 1./@7_X(_'__ ,\6C_6;*OYZW_@F0?\ $R7A?_T&YO\
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M\/K/VF/^B<? O_P1^/\ _P">+1_K-E7\];_P3(/^)DO"_P#Z#<W_ /#/B/\
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M,)-M+E5K-W=C^27_ (*/?\I3/VQ_^P'^SA_ZI3PW7R_7U!_P4>_Y2F?MC_\
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M&E?#^J?\A+4?^OZ[_P#2B2NR?_(OPO\ V&8[_P!,9<?8XW_DW_#G_98\:_\
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MLWNF:+ILE_-"&$4UQ'96$5O;2R(TEM'+=I"R+=SA^K$4L/*KC,1B*4I5(8/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &2>8_\ K><9A17WMI'[(GPNT[]F;X4?M*_%3X_:_P"!=(^*^N>*?#VF^'=
M^"__  G<^FZCX:\1>*=%*SZD/B=X9:>&]MO"\VHB4:7;BW>X%D1,8EN9^=^*
MW[(^D^&_@7I_[2/P:^,&E_&SX3CQ0W@SQ5>-X2O_ (?^*?!GB)Q;&UM-9\,Z
MEK&NDQ3-=V2R21:D)T35=$O(+6[TW4C?6TRP&*C!S<(-*A#$N,:U"514)QC.
M-5T8U'54.6<9-N'NIWE:SME5X&XFHX26-G@L+*G#)<+Q%.A1SC),1F,,DQF'
MH8NAF4\IH9C4S2.&>&Q-&O6E+!IX:E/GQ,:,8S<?BNBBBN0^2"BBO3_BMX7^
M&GA/6M&LOA;\5)_BWHU[X8T[5-8UR?P'K'P^?1/$MS=ZC#J'A9=+UK4=2N-3
M33;6VT^\&NV\T5G>G4FMXK='LI6DI1;C*2<;1<4TYP4GS7MRP<E.:5GS.$9*
M.G-:ZOT4\-4J8?$8F,L.J>&E0C4C4Q>%I8B3Q#FJ;P^$JUH8K%QBZ<O;SPM&
MM##)PEB94HU:;GYA1114G.%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '*^.O^1(\9?\ 8J^(?_31>5_:+_P35_Y1^?L:?]FX?";_
M -0_2Z_BZ\=?\B1XR_[%7Q#_ .FB\K^T7_@FK_RC\_8T_P"S</A-_P"H?I=?
M<\(_P,;_ -?:7_I$S^W/HG_\B7C#_L:99_ZB8@_F$_X*/?\ *4S]L?\ [ ?[
M.'_JE/#=?+]?4'_!1[_E*9^V/_V _P!G#_U2GANOE^O!XB_Y'&*],/\ ^HU$
M_"?I!?\ )V^*O\.0_P#K-Y0?H%\'?VQO!;_".P_9R_:L^&5Y\9O@_H5X;[P+
MKFB:NVD?$WX9RE9V-OX=U.XG@AU32D>18;'2Y]2T=+&SFN=/N;G5=%CT_1+'
MH?#7Q+_X)I_"W46\8>$_@Y^TK\8_$U@!<Z#X4^..L_#32_ -OJ<3A[:6^'@E
MKF[U"W0L?,M=9TK7;&58HUDL'=VE3\W**XHYC72IJ4</5E2BH4JM;#TJM6G&
M-N2*E*+YU"WN*JIJ"TC9))?'X?C[.J5' PQ.%R+-<1E="GA<LS'.,CR[,LQP
M6&H14<+06)Q-&?UNC@DO]BIYC#&1PL;4Z*A2A"G'V?X^_'CQ[^T?\2]8^*'Q
M#N[>75]1C@L-.TRPC>#1_#>@6+2G3/#VB6TDDKV^FV/GSR#S)9)[J\N;S4+N
M66\O+B5_3OVE_CSX0^,O@S]F/P[X7TWQ)87OP7^!V@?#3Q3+KUGI=K:W^NZ4
MD"W%WH#Z?K&J376D.8F\F?48-*O&!7?81Y./DJBL'B:S6(YI\[Q7+[:4M92<
M:BJIWZ/GBK^6FQXL^(\WK0SZ.)Q4L74XEE0GF^(Q*]MB<34P^-AF$*GM9.\)
MO$TXRFTK.'N)*.B^G_A7\:O"O@?]FS]JWX.ZMI_B"X\3?'3_ (49_P (E?:=
M:Z=-H6G?\*R\>ZCXIU[_ (2.ZN=5M-0M/M>GW<<.D?V9I>K_ &B\5X[W[! %
MN&](^"7[3OPWM_@MJG[,O[3'@?Q)XY^#W]N3^+? OB#P%=Z78_$CX8>*;I+A
M+ZZ\._VW)#HNIV%ZUY=W0LM1GAAANKS4ENX]6M-02VL/ABBKIXRO3=+E<;4J
M$\.H2A&4)T:E6I6G3J1DFIIU*LGKJK1<6I1BUU8+BW.<!++70J8:5++,FQ?#
M\,-7PM'$83&9/CLSS'-\5@LQPU:,Z6+IU<;FF)J)SBITG##5*,J=;#4:L?T3
MO/VD/V9_@U\(OB?\._V4_ GQ:NO%WQI\.7?@CQS\4?CE>>$H]9TKP-J""+5/
M#?A?1/!%S=Z7Y.L02W,5U<7$EG.DC0W-T^J_9M.M].Y/X'?M1_#[3_@[J?[-
M'[2WP_UOXC?!:76[CQ5X.U?P=J-EIOQ'^%OB:Y2?[7?>$IM69=)O+2]GGN)W
MTZ]FL[>.?4=7DO!JUIJ$FFK\,45?U_$<\)Q]E&,*<J*HQI05!TIOFJ0E2:<9
MJI)\TG*\G.TE)2C%KL_UZSZ.,PN)H?V;A</A,NQ&44LHP^68..2RRO&595\=
M@L1ETZ<Z.+IXW$3>(Q-7%>VQ,\1&E6C7A4P^&E1_2'P[^TO^S#^S7H?BC4_V
M2/ _QBU/XR^*M#U+PQ9_%?X\W/@F.;X<Z1JT4<5_=>"_#?@J:_TJ[UF58D^S
MWVKB.:UFR99[W29;W0K[Q7X$?'SPE\,?@C^U?\-_$>G^)K_Q#\=_"?@O0_"M
M]I-KIEUI=C?^'=7US4-0G\2W-_K.GWUK!/%J< MI=-L=8FEF683PP*$>3Y(H
MI/'5^:G**IPC2A6ITZ<*<8TXK$4Y4JSY5JYSC+6<G*5U'6T8I9SXVSIXG!5J
M$<OP5#+<%G& P&78' T<-EV%I9]@*^79K5CAZ:3JXO%X?$257&8BI6Q,G2PT
M75=+#4*5/[4_9V_:@\)>"/A[XL_9^^/G@*^^*?[/_C/5X/$W]FZ/J,6F>,_A
M]XPM;;R(_%?@6_N#%!]INXXK:VO],N;RQMI$625+E8+O6]-U[U3P3^T7^Q_^
MS.^J^./V9OAS\:?&?QJN-.OM*\)^+_VA9_ ,6A_#8:E9W-G=Z[X?T7P++=+J
M^MF";[*6U$6;-:S7$,%[96LU_9:G^:]%.GF&(IQII*E*5%.-"K.C"=:C&]TH
M5))OW&VZ;ES.FW>#CI;3 <=Y[E^'R^G2CEE;%9/2E0R;-<7E>#Q6;911<YU:
M=/!8VM3E-+"U:E6K@)5XUYY?4J2G@9X=QI\GVO\ LB?'3XE?#+QU\3O%W_"M
MO$/QX^'7BWPAKL7[2'A?^S=9URUU'P/J,MQ>:SXK\1:G:VFH6ND7&G2S:A</
MKOB&)M.DM;[6K&ZGM?[2?4+3U/PCX]_8C\)>/]*\7?L[_!S]H?XA?&2ZUJQC
M^%'P[^+&I>!A\-/#WCG4-0M%\.7X;PU?:AXM\5_V!J;12Z-I6LW445\8XH]4
MOX[EH]7L?C?X'?'GXE_L[^-5\>?"[6H=)UF73IM%U6VOM/L]6TC7M!N[FTNK
MW0]9TV^BDBN=/O)K&V:4PM;7L+1+)9WEK,!*/I^S_P""B'Q \/3ZAK/P\^ W
M[)_PJ\;7UG>VB?$7X>_!:+2O&FGM?H5N;O3KS4O$.L:5!<R.1/()-'FM9ID4
MW%M,F8STX7%451I0K5W%TJDYI3PD,1.GS2C)RPU24E:4FFW"K^[53]XKN3M]
M'PWQ-E5#)\MPN:9VZ-?+,PQF+I0QW"F"S_%9>\35IUI8CAO'UL33]GB*\XNM
M5P>:Q6 I9A"&-IN4ZM9JG_P4[O+6^_;F^.L]G/'<PI<_#^S>2)@RK=:=\*O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!]W?\ !,S_ )/B^!'_ &$/&W_JL_&E?#^J?\A+4?\ K^N_
M_2B2ON#_ ()F?\GQ? C_ +"'C;_U6?C2OA_5/^0EJ/\ U_7?_I1)79/_ )%^
M%_[#,=_Z8RX^QQO_ ";_ (<_[+'C7_U2< 'US^S/^U;:?!CPI\1/@_\ $CX=
M:?\ %WX#_%LZ<WC3P5<:E+H.KV.I6$]H8/$GAO7+:&9X-3LXK6UNH;:98F.I
MZ1HEYI^K:'<V<UU<>O7/[+_P-^+?PL^(_P >?V1O'/C)Y/@AIX\9?$;X,_&[
MP_I%UK>FZ# =3U47VE>(-"2?PUKVE+I^A:M-'I-[;7LUW86$L>LWUG=S0V=Y
MXY\ /VKXOA-\-/B)\#?B%\,=*^,OP4^)-_::]J_@N\\17W@S5-,\460TV.+7
M]#\5:7I^J75C<20Z/I0FBDL+@B;2M/FM9K15OHM0["\_;*\)>#_@Q\0?@S^S
MM\ ].^#=E\6;6'2?B3XQUSX@:K\3_&/B+P_'9W5E+H]O?7WA_P ,V.E0SP7M
M];D6]A+:6]KJ6JFSL+?4KW^TX>RC5PKH4XXK$4JU.G0JJ%*5"M'%T*MYRIPH
M5X1=.=+VKC/][6Y%&51>RB[<WU>49KPW4R/ 83B;/,NS; 8+),VIX;+*^29M
MA^*\CS23QU;+L'D>=8+#U,!BLNEF-3#8Y+-<U6"ITL1F%)Y50JN$J_UI\<_B
MUXB\2_\ !/;]DF6Q^&WPFN-4^+/BCXR^$#X?T+X1^#+>TT::3QQXGT*TE^&&
MC6VC26W@?Q1?LL<G]K^&;:VU&ZUFYDU!VEO92Y^AO!?PI\'6_P =/A;\'_''
MP@_8,^&_A35_#MEH>M? +4YH_BO^TMYLGA6[OHM4OOB-8?#+3;J/Q/,XL[^2
M74/$EM ]E;WMW!?ZA)-;7S_E]X=_;'T'3?V??A+\&M<^$5WJWBKX"^(O%'C/
MX1_$O2_B/+H*Z#XOUOQ%JOBO2M5UWP=)X-UFU\2VFB:[J%O<2:6^MZ;'J=MI
M\-JUQ9">XE?V?3?^"A_PHM_CM;_M.:C^R1;ZC\;I;.SBU;7X_C=KEMX;FU&#
MP_%X6N=;T3PE<>!=0@T74KG0(4TR,SZCK%K:Q;[I;:74Y9;^3T*>/P<IT:E7
M%0;5/+85(U:-:2C"A14<7&\<-.<INI&_)&<:%6+O.4G&,8_>9;QOPE6QV59E
MFW$N$KU5@?#C!X_#9EEF;UJ5'!Y+DU/#\4T'4PW#N,Q6)QE7,:3<<#1QE#),
MRH5E6QM;$U*-&C0^B/@KXX7X>_!3_@ICX+\/>!?A6=#^ 6K:%X9\*Q:G\-?"
M.IW'BG2+7XB_%/3+*#XI7%SIC/\ $J33[+2[>'3Y_%8OY;,R74D#I+=3.WRG
M\;O#?@^[_P""=_[._P 5;7P)X$T'Q[XW^./Q1;Q'XC\,^#O#WA[4KVR?Q!\1
M9[;1/M>E6%M<IX?TM8+2UT?0_..FZ596-C9V-O#!9VZ1\%\//VS?#_A75/VM
MX/%?P;F\9^!OVL]??6M>\,6GQ'G\+:QX5BC\3^+_ !'I]G8^*H?!VKKJ;VK>
M+I;::Z?0-.%W)807'V:"*:6SJ'PU^US\/%^#E]^S[\3/@'<_$3X3:1\2M8^(
M/PJTZV^+%]X0\6?#F#5;R^G/AN7Q5:>"]6C\4V:V^I:C!<WESHFES7D^IW]X
M88)!IB:7SRQ>&JT(T9XB"7U/%8>*G3K.-*H\>Z]&7NT96A+#J-.+IJ4HM\LX
MQ5V>%B>*^&LSR:AE6(S_  =*'^I_$_#^%IXO+LXG1RK,*O'5;/,GQ4EA\HQ#
MAAJ_#]/#X"A6P*Q&)P\ZBP^)P]"DJM1?3.J^%_V;/!?@3_@EKXR^+G@?PSI_
M@3Q3IOQAOOC#JVD>&(K?4O%ATN;P?%X9O?&EQX=MK?7?%-CH^LWMM+<PW<FI
M3#2)=4M8K6YAN[BSN?1?B9X/C\4^"OV@+OP/^SQ^QG^T1\,AIVNW?@SQ/^RS
MJG@GP)\4_@EI44-_<Z!XC\3V&F^'9_%7B&YL;2&QO-2T )=/J-Y:7\#W4VDW
M4\,7RS\2?V_?#/CG5OV9SI_[,GP_L_!7[.6F^,/#MO\ #7QIJT'Q-\(>+?"_
MBG3O"NCVNF7%KXA\)6T^EZCH-AX7@GL]>GEUR^N-:ECU2=0D-S8W^5X=_;6^
M&'PFD^)GB#]G;]F2V^%7Q!^)GAG6O"%QXIUGXLZOX_TGPMH'B&\LK_5++PKX
M/D\(>&=-M$^V:?9W5@-0N]2CL9K*RA6.73H[C3[K3ZW@5*I!5Z*HN-&+G##U
M%6GR9?0HRY8U,-4I5(.M"=J=:-)QGS5(S3FIKO?%'!-.MF.#IYWE$,IEA\JH
M2QN#R#,:><8R6#X"R7)<5+#4,PX=S#*\QP-;-L)BU#+\ZHY34HXR=?,:&/IR
MQ4,91_/&BBBOFS^=0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#[\_9L_Y,Q_X*%_]@']FW_U;&H5\!U]^?LV?\F8_
M\%"_^P#^S;_ZMC4*^ Z[<5_N^6_]@E7_ -3\:?9<3?\ (B\._P#LD\Q_];SC
M,_:'Q#<?!ZV_X);_ +(#?&;1_B7K&AM\2/BBNE0_#'Q)X7\-:M#JW_"=_%D^
M9J%SXJ\*^*[.XTXV?VE?(MK6UN1<F"3[0T0DC9?C+IGAG7_V _@W9_LNV]YX
M+^!7C_X]6OA[XE^'_%UF=8^(LOQ"N)KK3=/\0>*/%&GZM-HT^@J^@Z0PL]/T
M72YWQX4"2VT:SZ8OP1XW_:;_ .$R_90^#'[,'_"$_P!F_P#"H?%GBGQ1_P )
MQ_PDGVS_ (2'_A)=9\8:M]A_X1K^P+7^R?L7_"5_9_M/_"0:G]I^P>;]G@^U
M>5;6/#_[4MQHW[(OBS]E>Z\'S:BVL_$ZP^)7AOQ^OBEK27PC<6A\-&72K7PX
M= NFNHYSHFI31WMMXBTF6WNM>N)S#.L#17?HO'X:7/3E*"@\HH8=5(TI1JO$
M4J%%2HNHH*IR3E3G2DW>E)/5N&I^A5>.>'JRQ6 JU<*L)5\)LCR"&84,MQ.'
MS7^W\KR/**=?)WF%/"QQOU7%XG!8K*L1*7-EM:C53G6>%4:J_5;XO_!B3X$_
M$7P/\*_@W^S!^RW\1/A-X)T3PU#\0M?^+VM?L^_\+8\?ZIJ3+J/B6XEU?Q]X
M\T'Q?X;NCI=S;OH9CL+'3[;4)WFM;>Z\-C3]/CRIOV5_V;O@GXP_;(^/^D:!
MX)^,GP]^$7@GPMKWPB^'E]JEMXR\&Z9XF\:Z=J0U6S\50M+=V>LV6AZO:VJZ
M+9WUY?/;:'JEP]U:2ZO8Z3J9^&?%W[:7PH^,6K>#?'7[0G[+EI\3OBQX7T33
M="U7QAHWQ=UOP'H'CFVT229](F\6>"+;PEKUM<7$?G,VHMI^L:>FIL\EM)'#
MI"66DV7MO['WQ:\?_%GXK?M(R^ ?AA^S=#X-^(_@&&S\3_LJ"^C^$-KX\\-:
M18ZW8Z/HWPNO-#\-7FFR^,M/%_=Q:SJ_B'[%;W\_B>:ZD;386M;KP[VQQ. K
M8B,*48U54JREA8^RE.6$_P!EJQII4OJE).-.HZ;E2A4Q3E.E&<.:>M3[##<1
M<"YQQ#0PF5X?"9C'&YMB*W#6%_LS$8O$\+Q7#>;T,OC'*UPKEE*>$P6.JY95
MQ.4X;,N):F)Q>6T\7@_K&(CS8_K/@EXL^%W[1'['?[96O^*/V=O@-X>^*/PA
M\ B[TOQIX(^%'A#PNK6'B?3?$USHEQ86=C8LFD>(]&OO#6J++K&E)837%E<:
M6N]KBWN)9/HCQA^RG\!]<_:Z\+:CJ_PV\)Z?\,_A/^Q'X>^-OB#X>^$='TCP
MIIOCSQ?:^+_&]G:OKVG:+96$&JQSVUJ;C5I[F5'U*;2=#TO5VO\ 1)KRPEXZ
MZO/#7[.G["O[3/A_Q/\  !?V99_B7;1>%_!'A/Q/\58_B)\4OB7XDUF"?1]3
MU*\AFT30)M-\-^%M/DL[K3+>"SC@:TB\1:@8(YKN"]UKXM\1?\%)?&%S^T5\
M/?C_ .$?AUI7AX>$O@QI'P/\3^!];\0OXJTKQUX1M=>UG7-76ZU&+0?#LVDO
MJ,NI64EE%'9Z@NFZCHUI=W3ZQ92W.DR7.M@\-2PE/'.G4K\F%G4_V:<9.,<5
MBFY5(5*,)^[!TI3C5C"5>$;J,E--]N*SCA7AS+N%<%QM4P&99P\)P[C,P2X?
MQ=+$5J6'XCXIG+$XW!8[*\!B6\)A*N5U<10S/#X7$9UA:$:D*6*I8B$I^M?L
MH:O\-?VY/&/Q.^ WQ!_9^^"'@1M;\#^)/%WPX\;_  E\!:/\/_$WP^U31[NQ
M@T^PN+_1(;5_$^EPIJD$SMK1FEN9+"2'4TU"WU$?V=+\3?&?PW_9^_8L_8T\
M1>'/V?\ X#^)?BA\5='\4WFK^,/'OPD\'>+3<:-X2U"P&KQ:F+^UCFU/6=4N
MM=T&"TU/41J$UCI=IJ\%I+97%U#./GO0_P!M7X>_";2_B5/^S9^S;I_P?\?_
M !-TK4/#][\0-8^)NJ?$6]\)>'M6E\_4-)\!Z7<^%?#4&@0^<(9[*2>ZU.2*
M>ST^2^_M--.LHX?$_C)^T9_PMKX,?LV_"+_A#O\ A'_^&>]#\;:-_P )#_PD
M/]J_\)=_PF-[X<O/M/\ 9/\ 8>F_V!_9W_"/^7Y/]IZU]L^U[_-M?L^V;@>-
MH4\+42K4JV.]A4C'$0H2BI<^,PTX04JE&G+GIT88B?/.$5%3C3A-N*BO@ZW&
M61X'AK'4J><9=FO&?]AYAA:6?8/),31IXB6,XKX;Q.#P5*KCLHP-98S+\GPN
M?XB..Q.%P\,/2Q=+!83%5*E*C2C[S^WW\._A[I&F_LQ_&7P#X,T+X<GX_P#P
M3T?QGXI\#^$[7[#X3TKQ+#::/=7EYH-B&*:?;7L>NQ6K6-O'#;HNEQ791[V]
MO9I?SKKZB^/W[27_  O+P!^SKX&_X0S_ (1?_A07PUA^'G]J?\)%_;?_  EG
ME6FA6O\ :_V+^PM(_L+=_8OF?V?]KUG'VG;]M/D[I?EVO+QU2E5Q-2I1Y?9S
MC2?NQ<%[3V-/VMHM1M^]Y[V23>L?=:9^:\;X[*LSXFQ^/R5T7@<50RJJWA\+
M/!4I8YY1@%FTHX:='#NDY9JL;*2C1A2G-RG13HRA)E%%%<A\H%%%% !1110
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MS#^S5_T;S\#?_#2^ ?\ YGZ/^&8?V:O^C>?@;_X:7P#_ /,_1_JC7_Z#*/\
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M?P\T5_<-_P ,P_LU?]&\_ W_ ,-+X!_^9^C_ (9A_9J_Z-Y^!O\ X:7P#_\
M,_1_JC7_ .@RC_X*G_\ )>O]/0_XE0SW_HKLH_\ #?C/_EOK_3T_AYHK^X;_
M (9A_9J_Z-Y^!O\ X:7P#_\ ,_1_PS#^S5_T;S\#?_#2^ ?_ )GZ/]4:_P#T
M&4?_  5/_P"2]?Z>A_Q*AGO_ $5V4?\ AOQG_P M]?Z>G\/-%?W#?\,P_LU?
M]&\_ W_PTO@'_P"9^C_AF']FK_HWGX&_^&E\ _\ S/T?ZHU_^@RC_P""I_\
MR7K_ $]#_B5#/?\ HKLH_P##?C/_ );Z_P!/3^'FBO[AO^&8?V:O^C>?@;_X
M:7P#_P#,_1_PS#^S5_T;S\#?_#2^ ?\ YGZ/]4:__091_P#!4_\ Y+U_IZ'_
M !*AGO\ T5V4?^&_&?\ RWU_IZ?P\T5_<-_PS#^S5_T;S\#?_#2^ ?\ YGZ/
M^&8?V:O^C>?@;_X:7P#_ /,_1_JC7_Z#*/\ X*G_ /)>O]/0_P")4,]_Z*[*
M/_#?C/\ Y;Z_T]/X>:*_N&_X9A_9J_Z-Y^!O_AI? /\ \S]'_#,/[-7_ $;S
M\#?_  TO@'_YGZ/]4:__ $&4?_!4_P#Y+U_IZ'_$J&>_]%=E'_AOQG_RWU_I
MZ?P\T5_<-_PS#^S5_P!&\_ W_P -+X!_^9^C_AF']FK_ *-Y^!O_ (:7P#_\
MS]'^J-?_ *#*/_@J?_R7K_3T/^)4,]_Z*[*/_#?C/_EOK_3T_AYHK^X;_AF'
M]FK_ *-Y^!O_ (:7P#_\S]'_  S#^S5_T;S\#?\ PTO@'_YGZ/\ 5&O_ -!E
M'_P5/_Y+U_IZ'_$J&>_]%=E'_AOQG_RWU_IZ?P\T5_<-_P ,P_LU?]&\_ W_
M ,-+X!_^9^C_ (9A_9J_Z-Y^!O\ X:7P#_\ ,_1_JC7_ .@RC_X*G_\ )>O]
M/0_XE0SW_HKLH_\ #?C/_EOK_3T_AYHK^X;_ (9A_9J_Z-Y^!O\ X:7P#_\
M,_1_PS#^S5_T;S\#?_#2^ ?_ )GZ/]4:_P#T&4?_  5/_P"2]?Z>A_Q*AGO_
M $5V4?\ AOQG_P M]?Z>G\/-%?W#?\,P_LU?]&\_ W_PTO@'_P"9^N&\3_LU
M_LZ07\*0? +X*0H;.-BL7PK\"QJ6,UP"Q5-" +$  G&< #H!1_JC7_Z#*/\
MX*G_ /)>O]/0_P")4,]_Z*[*/_#?C/\ Y;Z_T]/XLJ*_LJ_X9Q_9Z_Z(/\&?
M_#7^"/\ Y1T?\,X_L]?]$'^#/_AK_!'_ ,HZ/]4:_P#T&4?_  5/_P"2]?Z>
MA_Q*AGO_ $5V4?\ AOQG_P M]?Z>G\:M%?V5?\,X_L]?]$'^#/\ X:_P1_\
M*.C_ (9Q_9Z_Z(/\&?\ PU_@C_Y1T?ZHU_\ H,H_^"I__)>O]/0_XE0SW_HK
MLH_\-^,_^6^O]/3^-6BO[*O^&<?V>O\ H@_P9_\ #7^"/_E'1_PSC^SU_P!$
M'^#/_AK_  1_\HZ/]4:__091_P#!4_\ Y+U_IZ'_ !*AGO\ T5V4?^&_&?\
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M]GK_ *(/\&?_  U_@C_Y1T?\,X_L]?\ 1!_@S_X:_P $?_*.C_5&O_T&4?\
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MP9_\-?X(_P#E'1_JC7_Z#*/_ (*G_P#)>O\ 3T/^)4,]_P"BNRC_ ,-^,_\
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M_P M]?Z>G\:M%?V5?\,X_L]?]$'^#/\ X:_P1_\ *.C_ (9Q_9Z_Z(/\&?\
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MB#_!G_PU_@C_ .4='_#./[/7_1!_@S_X:_P1_P#*.C_5&O\ ]!E'_P %3_\
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M_P#)>O\ 3T/^)4,]_P"BNRC_ ,-^,_\ EOK_ $]/XU:*_LJ_X9Q_9Z_Z(/\
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M1_PSC^SU_P!$'^#/_AK_  1_\HZ/]4:__091_P#!4_\ Y+U_IZ'_ !*AGO\
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MO\$?_*.C_AG']GK_ *(/\&?_  U_@C_Y1T?ZHU_^@RC_ ."I_P#R7K_3T/\
MB5#/?^BNRC_PWXS_ .6^O]/3^-6BO[*O^&<?V>O^B#_!G_PU_@C_ .4='_#.
M/[/7_1!_@S_X:_P1_P#*.C_5&O\ ]!E'_P %3_\ DO7^GH?\2H9[_P!%=E'_
M (;\9_\ +?7^GI_.!_P30DCB_;?^!4DLB11KJ'C;<\C*B+GX:>- -S,0HR2
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M;Z_T]/XU:*_LJ_X9Q_9Z_P"B#_!G_P -?X(_^4='_#./[/7_ $0?X,_^&O\
M!'_RCH_U1K_]!E'_ ,%3_P#DO7^GH?\ $J&>_P#1791_X;\9_P#+?7^GI_&K
M17]E7_#./[/7_1!_@S_X:_P1_P#*.C_AG']GK_H@_P &?_#7^"/_ )1T?ZHU
M_P#H,H_^"I__ "7K_3T/^)4,]_Z*[*/_  WXS_Y;Z_T]/XU:*_LJ_P"&<?V>
MO^B#_!G_ ,-?X(_^4='_  SC^SU_T0?X,_\ AK_!'_RCH_U1K_\ 091_\%3_
M /DO7^GH?\2H9[_T5V4?^&_&?_+?7^GI_&K17]E7_#./[/7_ $0?X,_^&O\
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M?\,X_L]?]$'^#/\ X:_P1_\ *.C_ (9Q_9Z_Z(/\&?\ PU_@C_Y1T?ZHU_\
MH,H_^"I__)>O]/0_XE0SW_HKLH_\-^,_^6^O]/3^-6BO[*O^&<?V>O\ H@_P
M9_\ #7^"/_E'1_PSC^SU_P!$'^#/_AK_  1_\HZ/]4:__091_P#!4_\ Y+U_
MIZ'_ !*AGO\ T5V4?^&_&?\ RWU_IZ?QJT5_95_PSC^SU_T0?X,_^&O\$?\
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M $0?X,_^&O\ !'_RCH_X9Q_9Z_Z(/\&?_#7^"/\ Y1T?ZHU_^@RC_P""I_\
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M%M-7BU^P\.^)K;4? UGJMII6N0*L&K:/-<V[WNCZA"9H;O2[FTFBN;I'6YE
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M0;I6UGQ+X<D\$V8EN81=7.OZO-%)]JG#7,^[_P $QOAIX_\ @S^POJ?QIO\
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ML?3W[7G[8OQ+^&7QF^#?[)_[-/P]\*_$7]I/XUZ5J_BRR?XB:IJVD_#?X=^
M=#>^CN_&/C)M!0:WJ-K=3:1K=O:6&E75I<[]*GP]Q=3Z?I]Z ?HO17Y1:/\
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MO/@Y:^+-*T*5V%E-\4-11/#5KX#F47Z7#):_$]V\*ZF+:_ENH;>TOKB">=H
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M#P]+XWUVVT* VP!^F=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW'_"1:7X=O?"FE8D\/:NODZWKNFSG[)D1%;BU,_XW?\ !0N\_;5A_P""AG[
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MV,\6G^,M7\(^.M2L=1M_#&OC7[*UT_Q'X0L-&N]+OM+U/3KI'&IZ'=?T=44
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M>&3XB^'?Q@BN[9+;PKINIW<^D^&UO?#N@ZKKXA;2)_$-TPL[N2UO]-,WK?\
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M?V=KWA75]"UZVL]22ULUU73(]2&FZJ+*Q_M&TNC96IA]D\%^"_"?PY\)>'?
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MMM-8_9]1TM]"TWQ-J32:7<Z;XDMY(=5T^S_.WXH_"!/B)\-/$\6I_P#!+/\
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M_P!HOX!1^'-:BT"/P[^T=\+Q\+/$6KI_9]M>IJOAS2%UO7%U#08EG%B;Y9H
ME];W%L(<1;V^CZ** ,7Q)X?TKQ;X=U[PKKT$]SH?B;1=4\/ZS;6M_J&E7-QI
M6M6,^FZC!;ZII%U8ZKIL\MG<S1Q7^F7MGJ%G(RW%E=6]S'%,D'A'PIX=\!^%
M/#'@;PAI-MH/A+P9X>T7PIX7T.R\S['HWAWP[IMMI&B:3:>=)++]FT[3;.VL
MX/-EDD\J%-\CMECT-% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'R?\ \,,_LE_\-!?\-3_\*/\ "7_"^/MG]I_\)SYNM;?[:^R?8_\
MA(O^$6_M7_A"_P#A*/*_>_\ "4?\([_PD/VW_B9?VE_:'^E5]8444 %?E+_P
M5[^'7Q!^)?P ^#.C?#CP+XQ^(&L:7^UG\$_$FIZ5X)\,:WXKU+3O#NE+XJ_M
M37K^QT*QO[JST73?M%O_ &AJEQ%'8V?GP_:)X_-3=^K5% '\_O\ P5G^!_[1
M_AKXX_#7]IC]D/X?^,?&WCCXI_"#XG_LF_%>S\">&=<UJ\TS0?&VB7EKX/\
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M\\,:WX0\1VEM?^,-1NK&XN=#\06.G:G!!>VSI<6DTMJD=Q ZRPL\;!C^K5%
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M8/\ XNK>!Z#\A1@>@_(4 5/[1T__ )_K/_P)@_\ BZ/[1T__ )_K/_P)@_\
MBZMX'H/R%&!Z#\A0!4_M'3_^?ZS_ / F#_XNC^T=/_Y_K/\ \"8/_BZMX'H/
MR%&!Z#\A0!4_M'3_ /G^L_\ P)@_^+H_M'3_ /G^L_\ P)@_^+JW@>@_(48'
MH/R% %3^T=/_ .?ZS_\  F#_ .+H_M'3_P#G^L__  )@_P#BZMX'H/R%&!Z#
M\A0!4_M'3_\ G^L__ F#_P"+H_M'3_\ G^L__ F#_P"+JW@>@_(48'H/R% %
M3^T=/_Y_K/\ \"8/_BZ/[1T__G^L_P#P)@_^+JW@>@_(48'H/R% %3^T=/\
M^?ZS_P# F#_XNC^T=/\ ^?ZS_P# F#_XNK>!Z#\A1@>@_(4 5/[1T_\ Y_K/
M_P "8/\ XNC^T=/_ .?ZS_\  F#_ .+JW@>@_(48'H/R% %3^T=/_P"?ZS_\
M"8/_ (NC^T=/_P"?ZS_\"8/_ (NK>!Z#\A1@>@_(4 5/[1T__G^L_P#P)@_^
M+H_M'3_^?ZS_ / F#_XNK>!Z#\A1@>@_(4 5/[1T_P#Y_K/_ ,"8/_BZ/[1T
M_P#Y_K/_ ,"8/_BZMX'H/R%&!Z#\A0!4_M'3_P#G^L__  )@_P#BZ/[1T_\
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;9@BTM0001;P@@C!!$:@@@\@@\$'I5BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img148586500_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $- L\# 2(  A$! Q$!_\0
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M_MF_#O\ X*A?M@>"?A_^UG^T?X%\&>&_B%I^G^'O"/@_XR^/?#?AK0K$>$]
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MXD#\3_\ YI*^/::652H)Y=@J+U9V/14499F/95!/M1_9N7?]"_ _^$F'\O\
MIWY(+ON_O9]B?\/#OV_O^CX/VM/_ !('XG__ #24?\/#OV_O^CX/VM/_ !('
MXG__ #25\>;AN9#E73&^-U*2)D9&Y& =<CD9 SVI:/[-RY?\R_ ]/^83#^5O
M^7?D@N^[^]GV%_P\._;^_P"CX/VM/_$@?B?_ /-)1_P\._;^_P"CX/VM/_$@
M?B?_ /-)7Q[11_9N7?\ 0OP/_A)A_+_IWY(+ON_O9]A?\/#OV_O^CX/VM/\
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MUI_XD#\3_P#YI*^/:*/[-R[_ *%^!_\ "3#^7_3OR07?=_>S["_X>'?M_?\
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M/UJ>.637F\,0^+XM)6S\,RI^YTV?6-.BTT2:G<1M>6<5Q,UI#YODM,WZ3?\
M#0'[5-KIL7C>77/$ \-32CR=8N/">D_\(Q*[RM L<<QTM;5D:9'A15E_UBE
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M[[O^O^&7W'<?\+1^*O\ T5GXL?\ AS_'G_S04?\ "T?BK_T5GXL?^'/\>?\
MS05P]%'LJ7_/NG_X!'_+R7W!=]W_ %_PR^X[C_A:/Q5_Z*S\6/\ PY_CS_YH
M*/\ A:/Q5_Z*S\6/_#G^//\ YH*X8D 9.?P!8_DH)_2F[U]'_P"_<@_FM'LJ
M?_/N'_@$?+R]/P'KTO\ CY?\#\#N_P#A:/Q5_P"BL_%C_P .?X\_^:"C_A:/
MQ5_Z*S\6/_#G^//_ )H*X>BCV5+_ )]T_P#P"/\ EY+[A7?=_P!?\,ON.X_X
M6C\5?^BL_%C_ ,.?X\_^:"C_ (6C\5?^BL_%C_PY_CS_ .:"N'HH]E2_Y]T_
M_ (_Y>2^X+ON_P"O^&7W'<?\+1^*O_16?BQ_X<_QY_\ -!1_PM'XJ_\ 16?B
MQ_X<_P >?_-!7#%@&5.2[G"(H+.Y'4(B@LQ'<*"12!@2R@_,AVNI!5T;&=KH
MP#*V.S 'VH]E3_Y]P_\  (^7EZ?@.[[O^K?\#\#NO^%H_%7_ **S\6/_  Y_
MCS_YH*/^%H_%7_HK/Q8_\.?X\_\ F@KAZ*/94O\ GW3_ / (_P"7DON%=]W_
M %_PR^X[C_A:/Q5_Z*S\6/\ PY_CS_YH*/\ A:/Q5_Z*S\6/_#G^//\ YH*X
M>D!SZ^G((Z?4#\^A[4>RI?\ /NG_ . 1_P O)?<%WW?]?\,ON.Y_X6C\5?\
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MG^//_F@H_P"%H_%7_HK/Q8_\.?X\_P#F@KAZ*/94O^?=/_P"/^7DON"[[O\
MK_AE]QW'_"T?BK_T5GXL?^'/\>?_ #04?\+1^*O_ $5GXL?^'/\ 'G_S05P]
M%'LJ7_/NG_X!'_+R7W!=]W_7_#+[CZ)^!GQ-^*4OQQ^"D4WQ5^*DT4OQ?^&4
M<L,WQ+\<RPRQ2>-M#22*6*37VCEBD0LDD<BLDB,R.I4D'_953[J_[H_D*_QS
MOV*/@=\3_CS^TE\+?#OPO\-3Z_>>&/&OA'QSXFO'D%GH_AWPMX8\2:;JNIZK
MK6J2(UO81/%:/;6*/NFOKZ2*UMHI9&(7_2_\9_MJ?%KQ+J3VG@BWT[PAIL\J
MVNGVL%C!KFNW)D<1PB6\OHWMA=2NRK'%9V48!*J'=B6/X_XG9%BLYQ>2T\ L
M-!8>ACI8BI4J1IPI>UGA/9*:A&=1N:IU'&U-I*+;<4U?XSBCQ'X8X+E##YKB
M*]?,*T8U*669?16)QKIRTA4J*52E0H0FU:G[>O3E5U=*%11E;]=*_AJ_X.HO
MVI?VFO@;^U7^S/X9^"?[0WQI^#_AS5O@'KVN:MH?PQ^)/BOP/IFJ:R/']]8+
MJFI6GAS4]/COKY+***TCN+H2O' BQQE1G/\ 0+)^TA^U!\/-1MX?%FH:C#-=
M1"ZATKQKX4L[87EJDAC:2$)::=>K#Y@,;2P3KA\C)(Q7\MO_  <N:7\5OVBO
M%GP)_:ATSX?O'X!^&7PPO_AG\0]1T:].IKH.N:IXON=;T[6+K3_*6^L?#5[%
M<K9KJ,YGAM;\+;74R"6*63YO@;A7$Y?Q+@<3C/[/QN G1Q</:TZD*]+VDZ$X
MTDX5Z<.:4I^Y!PC-*6C:;1Y^0>+?"O$6.63VS'),VJ3C3HX+.\-#"3KU9<LH
MT:52E7KTE7G%KV=&M.C5JN2C1A4DTG^ ?_#P[]O[_H^#]K3_ ,2!^)__ ,TE
M'_#P[]O[_H^#]K3_ ,2!^)__ ,TE?'M%?O7]FY=_T+\#_P"$F'\O^G?DC]$N
M^[^]GV%_P\._;^_Z/@_:T_\ $@?B?_\ -)1_P\._;^_Z/@_:T_\ $@?B?_\
M-)7Q[11_9N7?]"_ _P#A)A_+_IWY(+ON_O9]A?\ #P[]O[_H^#]K3_Q('XG_
M /S24?\ #P[]O[_H^#]K3_Q('XG_ /S25\>T4?V;EW_0OP/_ (28?R_Z=^2"
M[[O[V?87_#P[]O[_ */@_:T_\2!^)_\ \TE'_#P[]O[_ */@_:T_\2!^)_\
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MU<CPV(IXG Q<:5?$U<VI.*H8+$3IT^6M*C*$&<S\*OV)_"&N?!/P)\;OC/\
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MY-7T:]TFT\5>&TU2&73'\2^%;B\CUO1%OD$!OK2(&2)MLB_3/QM_:G^$&O\
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M6C_6;AO_ **#)/\ PZX'_P"7^?Y]F')/^67_ ("_\C\6**_:?_B'A_X+"?\
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M6C_6;AO_ **#)/\ PZX'_P"7^?Y]F')/^67_ ("_\C\6**_:?_B'A_X+"?\
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MR_\  7_D?BQ17[3_ /$/#_P6$_Z-(?\ \.Y\'O\ YM:/^(>'_@L)_P!&D/\
M^'<^#W_S:T?ZS<-_]%!DG_AUP/\ \O\ /\^S#DG_ "R_\!?^1^+%?V'_ /!G
MO_R7W]MK_LD7PE_]3'Q37Y+_ /$/#_P6$_Z-(?\ \.Y\'O\ YM:_H/\ ^#:K
M]BG]IG]AG]K?]KCX;?M2?#9_ACXT\6?L\_"3QIX?T=O$?AKQ,-0\-'XB^-=%
M_M);WPOJFK6,(_M/3[NU-O/<1W(:$N8O+9';Y3CG.\FQW"6>8?!9MEN+KRP^
M'E&CA<=A:]5QCC\)*4E3I59S:BM9.UDMRH1DIQ;BTK[M-'[^_P#!/[_DJ_\
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MUKX^^(M$\)?$K4-/TCXE>(?!,_@3PVW@/3M;\'^,O%OAXZ%?:<?&=G?-X?\
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M5%%% PHHHH _.;_@K+_R8)\<_P#KY^%/_JY_AY7Z+I]Q?]U?Y"OSH_X*R_\
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M7%A.++6=&U*UFTW7O#^I"-)9-,US2;I4NM/O41U=5D5H+F%DNK*>ZM)8KB0
MKZM\.? 6NWDNHZMX.\-WVI3X$^IRZ/8C4IPHPJS:A'"EY*J]DDG91V%9B_"+
MX9 Y?P/X>N%Q@Q7EA'?0,O\ =>WO//@=?57C93W!S7HU% %.PT[3]*M(;#2[
M&STVPMD$=O96%M!9VD"#HD-M;I'#$@[*B*!Z5<HKSKQ1\0[;1M5C\*Z!I-[X
MR\;3P1W2^&])DAACTNRF$@AU;Q3K-QFP\-:1(\3)#-=F;4;]@R:-I6J2QR1(
M >BT5Y)#X0^(FOR17?C'X@S:'"8/F\+_  WM+?3+"&<ON#7/BK6K2_\ $FJ-
M%'F(2V*>&+:8DRR::K! EO\ X5+X<8[YM<^),]P/NW3_ !6^(\<R$\'REMO$
M\$$(;^)(H4C;NA% 'J%%>43?#[Q-IK07'@_XG>*K"6!RTFF^+?L_CK0[^(*V
MVWO/[4%MXEA <AA<Z=XFLYQC$OGH/+IFF_$34]&U&Q\/?%'1K7PMJ>I7,=AH
MOB73+N;4/ GB.^F<I;6%IJES!;7>@ZW>8S;Z#K\$+7,F;?2-3UJ16- 'I6J:
M3I6MV4VFZUIFGZOIUP )[#5+*VU"RG Y FM;N.:"4 \@/&P%<2WPB^&9^YX)
MT"!0,".ULEM(5'3:D%J8840  !%0*.P%>C44 <AH_P /O V@7B:CHWA#PYIV
MI(C1IJ=MH]BFIK&WWHUU$PF]$9/)C$^S.3MR377T5EZUK>D>'-*O=;UW4;32
M=)TZ!KB]O[Z98+:WB7 R[L1EW8K'%$@:6:5TAA1Y71& -2BO'(M;^)/CQ))/
M"UC#\.O#$\,R6GB3Q;I;ZAXPU'<62*^TGP8UQ:VNB6I"F:UN/%=U-?RH\377
MA6&,XDTE^%L%S$BZ]XY^)>NS[ +B<>-=4\,)<2%<2N;/P0WABRBCD8LWV>.
M01@[$0* * /4:*\P7X5:5; _V5XJ^).DL1A3%\1/%6K1Q\D_N[/Q-J.NV"<D
MD@6FT]P1Q68[?%CP1&DTDUM\6]!@\][Q4L[#PU\18+<,TD;V<5JUKX1\4301
M QFS6#PC<S@*T,MY<XAF /8J*YSPMXLT'QEI8U?P_?"[MEN)[*[ADAFL]0TO
M4;5@EYI6KZ;=QPW^E:I9N0EUI]_;P74)*,T?ER1N_1T %?F]X=_Y2V_%/_M'
M]\(/_5__ !8K](:_-[P[_P I;?BG_P!H_OA!_P"K_P#BQ7IY=_#S3_L65?\
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MBR'<,M\_?L\Z>-)^(NJ7!M6M[OQM\/-/\::JSF=);FYO_$5ZEE<3P2LRQO\
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MTZO_ ")L!_V,\V_]1<E%U?HOSD.K\UK?_E,!J/\ VCBL/_6EKBOTIK\UK?\
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MX+JUGAN;6YABN+:YMY$F@N()D62&>":-FCEAEC99(Y$9D=&5E8J0:E9592K
M,K JRL 592,$$'@@C@@\$<&O%O\ A'_%'PPFFN/ FGMXH\!2R375W\/%GM[;
M6O#4DC/-<S?#Z\O98+&XT^XD=I7\':M=65M;3%FT'5+*%QI+@'IVN>'M/\0?
MV1_:'G_\237-/\0V7D3>5_Q,--\W[-YV%;S8/WS^9#\N_CYABMRN#\/?$WP3
MXFN)-.L=<@L]=MUC-[X8UV.;0/%&GO*JL$O/#^L)9ZF@#-Y0N([>6SED5Q;W
M,P&X]Y5RJ3E"%.4Y.%/F]G%O2'.^:7*NG,U=]V9QHTH5*M6%.,:E;D]K-)*5
M3V<7&GSOKR1;4;[+0\!\4_#KQ]=77C_3/"^J>#D\+?%$'_A()_$%CJ,NO>'I
M;K0[7PYJDFD0V:M8>(([G3;.&6PMM6N-,73;TR,\M_:L+9?;M)TZ'1]*TS2+
M9Y9+?2M/LM.@DG?S)WAL;:.VB>:3 WRLD2M(^!N<EL#-8WB7QOX1\'P?:/$W
MB/2=&5F2.&&\O(EO;J:7B*VL=/0O?W]U,3B&TLK:XN9CQ%$YKSZZO_''Q,9K
M#0K75_AWX&D:2+4?%&J0OIOCGQ#:[PK6_A+19E-SX7L[N,2*_B/Q!';ZW%%(
MCZ3H4$S1:K;]F*S+$XNA0P]7V2IT%&WLZ4*<JLX4*.&A4K2BKU)QP^'HTD]%
M:#FTZM2K4J>=@<FP67XG%8NA[=U<4YW56O4JPH4ZF)KXRI1PT)MJE2J8O$UZ
M\HJ[YJBIQDJ%*A2I/N9_^%D>/;73[0&7P3\-=4&H:Q?(\JVVO?$&V5DTW0K8
MHJQ7EGX065]4UEQ+)#'XA;2; QFYTV_2'V>LC0=!T?POH^G^'] T^WTO1]*M
MDM;&QME(BAB0EB2S%I)II9&>:YN9WDN+JXDEN;F66>621M>N ]4Q/$OA_3_%
M6@:OX<U1"]AK-A<6%P5"^;$)D*QW,!=65+FUEV7-K(5/E7$44@&4%<?\.O%%
M_?PWOA#Q5(J>/?!P@L]>0B.(:Y8/O31_&>FQH[!]*\1V\+3.$"_V?JT6I:1,
MB2V7S^EUPGC/P/'XG?3]7TS4[CPSXQT+SF\/^*;&&.XFM4GV&ZTO5+*5D@UK
MP[J)CC&I:-=.B2&.*[LKBPU*VM+^W .[HKQR#XIR^&2-/^+>D_\ "$W49AB7
MQ9 ;B_\ AOJ[RNT*3VOB3R@?#CRNADDTSQ='I4MJKI';WVJQJ;MO5['4=/U2
MW2\TR^L]1M)0&CNK&YAN[>164,K)/;O)$X92&!5B"I!'!% %RBHIYX+:)Y[F
M:*W@C&9)IY$BB09QEY)&5%&>,L0,UY5?_%S2+R>;2?AW87'Q+U^.9K22/P[+
M'_PC&E7(C:0GQ'XT=9-!TN*':5GMK:;4];#XBM]&N)3L !TWCOQC#X-T9;F*
MV;5-?U6Y32/"GA^%O]+\0>(;M'^Q6$0&6BM8]CWFK7Q4PZ7I-M>ZC<$0VS9/
M /A5_"'AR#3[RYCO];O;F\UOQ-JD:R*NJ^)-8G:\U>]02LTJVWVA_LNGQ2,3
M;:;;6=J,+ H&/X2\#ZC:ZJ_C/QSJ=OXB\<7%L]K;R6<,D'AWPCIUQL>XT3PA
M97!:>&&9T3^T];O2=9UUHHFNVM;.&UTRT],H *_-[P[_ ,I;?BG_ -H_OA!_
MZO\ ^+%?I#7YO>'?^4MOQ3_[1_?"#_U?_P 6*]/+OX>:?]BRK_ZDX0F7V?\
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MA?39/A_JOQ&M+VSNAH-_HNL7<GAS3DU>YL9]:TB.ST.<ZG+>F46MC>>::?\
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M8*6<@D*N2-S$ D*,D@$XXIU !13!)&SO$LB-)&%,D8=2\8?)0N@.Y0X4E2P
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M?_:/[X0?^K_^+%?I#7YO>'?^4MOQ3_[1_?"#_P!7_P#%BO3R[^'FG_8LJ_\
MJ3A"9?9_Q+]2G_P3^_Y*O_P4G_[/M\5_^JD^$M?I;7YI?\$_O^2K_P#!2?\
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M+X>N$T^^\,O%HDU^J7"ZO<O?Q?IW11L!\,_"K]A_PW\,]1T2_/C&?4X=*O\
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M7[:X2XTM9;R&[M+VZL" =C)^U]\"(O%FH^&)/%DJV>F_"C2OC--XV72=4E\
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MIU*=2+M:4)PDI1:;73=-*"BI_LMU_P ^MS_X#S?_ !%'V6Z_Y];G_P !YO\
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MQN_]1KX=5^CM>GG'_(QK?X,-_P"HM 4=EZ+\C\\O^"KW_*/+]J#_ +$K2/\
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M.OZ?]V_6&ROM=DAC7]>GM+60(LEM;R+'.+F-7AC81W*DLMP@92$G#,S"5<2
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MKK1K>P\/ZCIOB*ZNKR^W0?M,EM;1*JQV\$:HK*JI%&BJK*JLJA5 56555@,
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M@?\ X67P'_\ G T?\._OB;_TDK_X*!_^%E\!_P#YP-'U/ ?]#C#_ /A)CO\
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MW_*_O7^?K_3T_2>BOS8_X=_?$W_I)7_P4#_\++X#_P#S@:/^'?WQ-_Z25_\
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M]J+_ ,33_:Q_^?#1[#)O^ACF'_AIH?\ SW"\OY5_X%Z?W?-_=YGZ845^9_\
MPZ8_9)_Z"?[47_B:?[6/_P ^&C_ATQ^R3_T$_P!J+_Q-/]K'_P"?#1[#)O\
MH8YA_P"&FA_\]PO+^5?^!>G]WS?W>9L?\%9%9OV!/CI@$XN/A2QP"<*/C/\
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M'U/ ?]#C#_\ A)CO_F?^K/RN7?\ *_O7^?K_ $]/TGHK\V/^'?WQ-_Z25_\
M!0/_ ,++X#__ #@:/^'?WQ-_Z25_\% __"R^ _\ \X&CZG@/^AQA_P#PDQW_
M ,S_ -6?E<N_Y7]Z_P _7^GI^D]%?FQ_P[^^)O\ TDK_ ."@?_A9? ?_ .<#
M1_P[^^)O_22O_@H'_P"%E\!__G T?4\!_P!#C#_^$F._^9_ZL_*Y=_RO[U_G
MZ_T]/TGK\WO#O_*6WXI_]H_OA!_ZO_XL5#_P[^^)O_22O_@H'_X67P'_ /G
MUZ9^SQ^Q/8? ?XN^,OCEKO[07[0?[0/Q&\9?#KP[\*Y-9^./B'P3JZ:%X+\,
M^(]:\5V&F:#:^#/ 7@B"V,NMZ_J5U=37:7LDIF !3&3M26!PE#'..8T\14KX
I.6'ITJ>&Q4&YSKX>=W*K2A!1C&G)N\KZ62;:N.[MI:S3W73^OZZ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img148586500_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_3.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D K@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HKS'3?BOX;U3XB>,_AI;QWXU_
MP-H6F>(-7D>W*V3V6JIYELMK.>)90OWT'W37%>$OVH?@GXJT7P1JDGCG0O#=
M[\08$G\->'?$NHVFE>(+U)M1O]+M0--GE68&\N=.N5M20%F"C823B@5UW_K3
M_-'T'17C.H?M$_ G2;O5[#4OBUX"LKW09!%K-K<>)--CGTZ0WAT_9=1M/NC9
M;T&V=2,QS K)M-=)-\6?AE;^+=)\!S^._"\7C+7;&/4]'\-/K%F-7U*PE1I8
MKJTM/-\R:*:-6DB*C,J M&&7F@+KNCT*BOF?6OVLO@YIOCR3X;Z9XEL/$GBB
MSMWGU>VT6]MKFWT)X]272Y+75[I&>*SO!<$A;=R7;:5PIQG'^%O[8?PJ^,/C
MSQGX,\%3SWEEX(U?6]#U/Q7<R16>B7.H^'+:UN=:%@UP$:YM; 72QS7:MY0=
M'!Q@9 NN^_\ P/\ -'UA17D]K\=O@W>^$M3\>6GQ,\&S^#M&O?[.U7Q&FN69
MTJPOS(L0M+FY,@6.X:1U5(S\SYR@89-0_#3XW> OBE\.C\5- U-+;P4+C58_
M[9U-DM+3[-I%T]K/J'GR,(UL9&0R0SLRJT1#'&:!W7?S^7<]>HKR:#X\?!FZ
M\+ZQXUMOB=X+N/">@7HT[6O$$.O6,NF:;?DJ%M+JY24K'.^Y2D?+.#N0,H)%
MG_A=GPC\OPE*/B/X/,?CP@>#677+%O\ A)2=^?[("RDWFWRW$AC!$94B3:10
M!ZA17E,'QS^#ESI_B?58/B7X,DTWP7>QZ=XKOEUVQ%KH-[+((HK;49C*$@DE
ME811Y)#R$(I+'%<O:_M/_ _4?&WPY\ Z/X_T+7-=^*MAXBU'P9_8]Y'?V6IP
M>&1 =107D!>%)R9RMO"["25H)P -G(*Z[H]^HKP_XL_M$?"KX,RZ;I_C'Q/I
M\/B+6=0T*PTGPI;7,,WB/4#X@URRT&TN+;3 WGO;17=]')<2L%5+=)902%P>
MDT3XS?"CQ+K%YX>T#XA^$M8UNP?4H[S2]/UJRN;RWDT=2^JI)%'*Q#:<JEKQ
M1DVX!\W;0%UW1Z917EEQ\<?@]::KH.AW/Q+\%P:OXHLK;4?#NG2:_IZW6LV5
M[,MO9W.GQ&;-Q%=3NL5N4R9G8",-7J= PHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /SJ_:/\$>,9/C_P#!&UT/X[_&OP?H7Q-\37^F>(_#
M/A?QC)IVB1VFEZ7->PKI-L+9SISS2HJW#HSF1,],XKG]>_;!^*_A#0?B=J2^
M#?!4GA[P)\0M)^#G@.^U_P 1^)-0\4^-?$">5%?:YJ^F:/HU_>R1K;XD>/3(
M+JZN+MI99$B@RZ_?_B/X>>$_%?B+PAXJUS3?M>N>!+ZYU+PS=^?-'_9]W=V[
M6MQ)Y<;+'-O@=DVRJRC.0 >:\O\ %'[+GP;\7:!JOAW5/#]Y%;:MXV7XBO?:
M9K6J:7K%CXQ4C&M:7JUC<P7VG3,H\N1+::.*2(E'0C& FSN[.W_#16VO9GPS
MX=_;_P#C7XYT'19_!WP=\#KKNF^'_BKX@^(L/B7Q1K>EZ?IMM\*-0T2WU.+P
M^L>F/?SW.K6>KM<6-OJ=O;2120^5<*A; ZO2_P!OKQ9J/CN_TR^\ ^'O"WA2
M7P1!XH\'0^(+[Q&OBCQW<W?A*+Q';0>'+RST>;P=.[7<O]FMI=QKEOK#;?,C
MM&<[:^J/"?[(7P&\$Q:E%X>\)7%L-7TOQEI&HO<ZWJ^H3W=GX_:QD\6&:YOK
MNXN);C5I-.M));B25Y4>,F)D#$53LOV1_@#X9\3:+X]_L"^1_!EI82Z1I^I^
M)M=O/">CRZ)I<>EVFL1>';R_ET:#4+;38$C>\%JI;:9I 9"SD%:6FO;333:]
M]-?O37=GA?P[M_B/'X+^'O[3'BG]IS5@WB$R>(/&'@K4FTY_AKK.A2V^JWC>
M"_!NA/,D>D^(K>&R$-KJ-G+<7MQ<6=X#!EFQQNO?MV_%KPIX2TSQYKOPD\'O
MX<^*7A_Q+K?P-M]-\67\VL:C)X>22\6P\>P26*0Z.VH:6B723Z8]XMM<2&UF
M&Y<#ZC\._L>_L_:1XLL?'>E^&[V[-I?W&OZ%H-]XEUW5/ ^D:IJ(G>;5=&\)
M7E_/H-G-*MW<&'RK/R8?M,[01H9F)KV7[$_[.]C>>);R/P=>3_\ "3Q75O+9
MWOB+7;[3M$MK^\;4+^V\+Z?=WTUKX<AO;MWDN%TN*WWHQ@!6 ".@=I=U^?;7
M7T>FF_S+G[-_QL\=_$^Y^(/A;XG^%?#?A;QQX U+18[R+P?J]]K?AZ]TKQ'H
M\&KZ7/!>:C:VEVMY$LDMO>P-"8UDB#1N0U?4E<#X4^&?@WP5KGB?Q'X<TO[#
MJ_C Z2?$%S]HFF^VG1+(:=IIV2NR1>1:*(_W84/]YLMS7?4#6BUU_K3\ HHH
MH&%%%% !1110 4444 %%%% !TZTP21G #H2V=H#*=V.N,'G'?%0WEI!?VEU8
MW2L]M>6\UK<(DDD3M#/&T4JK+$R2QL48A9(W21#AD96 (_)'1OA?X*^#?Q"_
M;7\?>!+/Q ?$/P0\-^#=<^'%KX@\?>.]=T+1]6U?X?ZWJ=]YVE:EK]U9W-I?
MZE'%-=0W$-QL10L!B90U NVWW_EIJ?KO17XD_&;]KC]I?X3>&/"LMIXM\*^*
M_$OASX0>"_C1\1P- 71-'6'QG?PP0Z3<ZA>[XI-*V3-#I]GIB)J[RQF2XN-C
M!1Z'%^U)^T9'K]SXY_X2'X<S^!]9^,'Q"^$'ASP1?Z?=:<MB^@^!M0\4:/K^
ML>*&?RXHUU*QBMKIB/*6PEFD96D4$ N97M9].G?_ (<_7.D!##(((Y&001D$
M@C(]""#Z$$5^).F_M,_$[Q_X"A\!?%/QQ?\ AC4;_P")7PMMOBIJ.EZ-/H!\
M,?#3QSJ3VEY<Z!XVLF73=4\*ZO<Q26-CX@T\6]]8VFV::96<M7M7C?Q'\/OV
M6O\ A,=%_9Z^(6H77B7Q0O@FQO\ PUXF\2ZQXZ\ _#4>(=4@TR+Q_J&HZE>Z
MEJ%A=7D%YO@T[^U&L[ZX:.9[9(D8,!S+Y===?N^Y>K\C]3:*_'R[_:*_:<U7
MQK%\#O#7Q$^'DFM^%=<^)%EK7Q9B\.W%_IOBJQ\'_#G2?'-G;VNGPRM:P:K;
MWFH2Z3JSVS-; 6[/$-_!_2+]G[X@ZG\5O@K\-?B+K5O:VNK^+O"NGZMJ4%D'
M%HE[*'CN#;+(2ZPR21-(B,24#[>U TT]/7\+7_,]AHHHH&%%%% !1110!\+?
M$?PQ\<?AS\</&GQ0^%W@#2_B?H_Q.\":3X6FTZ;7(]$OO#/B72)6BMKW4#.!
M'<>&I[0K)=2VSR7\4X9(X2I!/S6?V&_'MAX/\;Z5/H_AGQ#XJ?X)?!_PAX3\
M0O*%DM/%?AWQ[J'BCQ2FF32[9=/M;6WO_)M;Q%BENA"-Q 8@_K[103RK75ZW
MT]=S\@I?V'O%,]IX=N+GP/X2NM8BM/VH9-=O+B6.6XN]2^)<FL2>"YYY6?-P
MQ:[MV9GW?8&):/8R9K!L?V0OCE;Z;/\ #"X\'^&II_&OB30/&K?'Y]:+^)?A
MI;:;HJ:?)X;L("#>2WNC20E-#CMG%C/%J%X;I@R1FOV;HH#E2_KT^?3OIK:Q
M^)\/[(OQUN?$&B:8/ACX.T"U\ Z%#X:F\>V&M*^J_$J4?$)/$LFO7L7RS(;K
M3T:[O1=$S+J4CP1EH-N.[\:_L5_%;Q3HOBGP_P"'SI/@V7Q#J'QNGBUG3KS[
M#+#%XQM? SZ '>S421O?2Z#J5M-,J.]H9A+C#-G]=:^6_&'[1MMX4\;_ !1L
M)-,FO?"'P7\#:/XD\:3:;:3:AKM_K/BBZFAT72-%MHG6,FUBM9)M3:4$QI/&
MX(6-\@N6*^:ZOII?\OE?TM^>_@S]D+XMZ#8V/Q"7X<:CJ&J>%_&7AW5=1^%/
MCWXDMXHM/B%::/H,>@R3*C6T>DZ8-&F;^T/#_G%WO$@7[=&LA(KW[2/A?XQ^
M&?\ P3X^)/@GQCX:TOP_XEFT/Q[J3^$]#N)+_2]/C\0ZY/J-EI%O-"#))&8K
MI(+GRE/EL\PCRJJ:[3PY_P %!OAGXN\*SZCX7\'>./$OC>'QI+X$C^&>@:>-
M4\17FM6^C/XDN7LIX56UN+&VT"*6_FND78CQFVP7.ZL/Q'^VGJEO\2/$_@Z]
M^&>LZ3X*TO1/AGJMIJ_B#0[J74=4N/&C>(6U#P[J&A;]]C>$:&\&G/*#&)HI
M'G5TEB  7*E>_?\ 2[T5[[?GUN?*$'[,?QT\6^#M!\:Z7\*M!\!Z+/;_  WT
MS6/A?X2UQ-/\1:]I'AKP_!;?\)=HFLS_ .B:+K#WWE)%-.CW4^A-*DT?GDK7
M?_L_?L4_%+PS::%8^-M'TG2;K0O 7QJ\+Z!K$FMR>);[PW>?$*5)M'O;:_N4
MCEEO$CE=+R[2WC>"993;@*5+?5GB']N[X)>%/#^GZS<+K1MKWP)HWB^VL[6P
M426MUKNLVV@:1X1O54[+#7Y+VYC::UD %G9*]U(OE(:-$_;)\-^+O#W@+Q[X
M;M!%X5U#XK1_!KXC:7JB2QZ[X.\7ZG!&^FL)D"VEU8VKE6O)XT:.>*Z@,#*R
M. "M!VUVLO7;IYWU^?F? O@C]@OXKIX5&B:]X:UE]1\/VWPP\(ZI)XJ^)4_B
M/0?&-AX5^)&B^)]9U#1M"6WBMX-(;3[&:6WFU&9=2,FVS\IX69A]1^ _V;O'
MWP]_:9T[XAV7@C0)O G_  M3XO7-D+"XM8)_"_A7QKX8\)V&B:G963!5B@2_
MTC44N;.VVM")_-CCS(QK],:*"N5*V^C3^[Y?\'?N?EC^T'^SA\6O$WQ=\;:A
MX:^'_A?QQH_Q,\:_ [Q99>.M:U1;75/AI9_#'4M).N:79VTB^:[7\%I/=6*V
MC^3+YCBY!EV;*MG^S9\6?A=X.^".O^!?AWX;\1>,_!VK?M!V?C/P^NKII,NJ
M0_&/4=372?$$VK8)NQIEI);S7T$C&14F"6Z[D^7]6** Y5=N[U_#6^GS/YR3
MX%\1_#77/!GP'U[P?X;\9_$K4?&7[.>JW^L1OJD_B'P#)X:,5UJFDZ(7LL:A
MIEO9K/+!?65PVG1V0F&H.MWY48_HVK*DT'0YM6@UZ;1M*EUVU@>UM=:DTZS?
M5K:UESYEM!J+0F\A@DR=\,<RQOD[E.:U: 4;7_KO]^X4444%!1110 4444 %
M%%% !1110 4444 %%%?#7Q;_ &\?A?\ "?XEV/@"ZM)O$5H)([3Q-XDT;4;-
M['PA?O=&!X=8B(=S'!&/,G>-E\H@J22*[,%E^,S&K*C@L/4Q-6%.564*:3:A
M"W-)MM+JDE>\FU&*<FD_?X=X6X@XLQ=; <.Y7B<UQ>'PM;&UJ.&4+T\-05ZE
M24JDX03;:A2I\WM*]64:5&%2K*,']RT5\A_!C]M'X1?&CQ9KGA#2+S^Q]0L+
ME(M N-2O+8V?C"W8LIN="G38LQ0A<P$M(06(^X0?KRHQ>"Q6!J^PQE"IAZO+
M&?)5BXRY9Q4HM='HU>ST=XNTDTL<]X=SSAG'/+<_RS%Y5CE2HU_J^+I\DY4:
M].-2G4@TY0G%QDE+DE+V=13I5.6K3G"/S3^T)^T_\/\ X!:)>G5+IM9\:2:9
M->Z'X.TR&>[U"]976&.6\:"-XM.LEED5I)KJ2)GC#>2KG%> ? _]NVX^(WQ'
M\,_#;QG\/G\):GXKT]_['N;6_6]6ZU.WB-U.Q@=EDATTVH)21P+@3G:T03FO
MAO\ :EU!=(_:2^+J:C_:*:;?VMK<FTNI#=).]O!"J.L\.R>TTB\=PRV0?*&!
MV0@M7T?_ ,$Z/AYX%UR[\6?%*]OM$\0>--+OSI&F6<4-V\OA"R,:Y>QGOII7
ME6_1RC7 RZ8>$MT-??U.'\GR_A>>98FC7Q6)KX:A4I8B+J)4L1C*5-T:<5"2
MI4Z=&;FZKK1J^T22A.,IQ@OZ4Q?AQP)PMX1U^),URS'YSFF89+E^,PF:PK8F
M'U;-,]P6'EE^'H4\+.&"PN"R[$5)SQDL:L:\6J;ITZ]*K7HX>'ZU5#-<V]LH
M:XGA@4]&FE2)3]"[**FKG]0\+:'JKR/J%D+HRMN<2S7!0D#&0@E"+Q_=4>O6
MOS<_E(Q/$7Q/^'?A*_T;2_$OC7PWHNH^(9OL^B65_JMI#<:E+E1MMXS(692S
MJJR,%C9CM#ELBN[Z]*_"C]I?]C_QQK?[=?PO\867AGQ#J?PNUJXTP6NMZ+=S
M:A'X-U.Q#27,UU:WS7%I8VL<ZV\R121>7=*SB-0Z[A^L?@/XAZ_:^+;OX4?$
MV.SM_&=IIO\ ;'A[7[$-!HWCGP^DJV\E]91S,6M-8L)66+5--+L2V^ZMU6W!
M"^IF&"P^$P^6U*.)6)J8S"?6:ZA*FX4)RFX*A:+=2-2FXRC451)MI2C[KT^W
MXNX;R;(,MX,Q&69U#.L5Q#P['.\U>'JX2>&RS%5L76PZRKV=*I+%X?%X-X>I
M3QE/&P@Y34*V'<J52T/=****\L^("BBB@ HHHH **** "BBB@ HHHH ****
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M/#VK:?XGTNPW!'U%M,\XSV$1.%\Z>*0F(,5!= H.6 /YK_LU:IXEO_VF/A]
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M)RM]=C/W4[IGG7Q-^.G@[X:SPZ3=RR:MXENTW6F@::#<7K%LB,S1Q"25 [#
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M9V(-FRJDF[]"_P!CW]BSX1?L:^ SX8\ 6#ZGXJUH1WGCSXB:SB[\5>,]:?\
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M8RIPW2Q]2M.G# YAG%"KC:F0J2<91Q&>PP.5XKGC"GCIXAU*$?MOI'\5I8;
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M>5XZNZV8?V5F].I*GC,NQ%2I.E.>&J5I485:E%0PLZTXR]F "@*H 4
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M.VA&U0&N+EU'FW=W,<O/=7#R32NQ+-C 'HE%%(H**** "BBB@ HHHH ****
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MJVG6NIVLB-%#%<ZM&U]:2I<[$8;*XK0/VM?CY+XV\8^,I?&OA);?7O#GPX\
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MKW5-2D_>21"<@N+*WD9Q!$&VDEI6!9N/R1_:'^$MK^VM_P %3/!_@>\\R_\
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MM]HLI7CCG&YN I65E?II\K?H?5-%%% PHHHH **** "BBB@ HHHH *S-:_Y
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M8GZO"*Y:&%IQ2B>Q_#.34Y/ ?A<:S+'<:I!I%I:W]W"B1Q7EQ:1BW>\C1%5
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MQ$OGW-BC%I;FZD<>9!<!601Q,0S*I8YS7MUK=07D0GMW\R%F8(X!"OM.-RY
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M@K_A$O"&DW^F:YXTO!J-W)<^/8;.+Q'JL=OJ#27-BFIWC11!VA?=&B"NA?\
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MUM\.OC9\5[J*\^)_B%/!?AD2K*GA;PY)_P 3&YB63<B7<X)CL9]JA)662Y+
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MBI8[O-M--)4%(92"Y*2RLP7RZ^V/#^@:3X7T>PT'1+2*QTS3;=+>VMXE  5
M 7<CEY)#EG<\LQ/0  ;(      & !P !T '8"BJQV8O%PI8>C0A@\#A[NAA*
M4I37/))3KUZLO?Q&(J67/5FDDK0IPIP2B8Y/D%/+:^)S'%XJKFF<XV,88O,\
M1"%.2HP=Z>#P>'I_N\%@:4FY0P]-RE*;=6O5K56ZC****\T^@"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** (MY]!^O^-&\^@_7_&BB@ WGT'Z_XT;SZ#]?\:** #>?0?K_ (T;SZ#]
M?\:** #>?0?K_C1O/H/U_P :** #>?0?K_C1O/H/U_QHHH -Y]!^O^-&\^@_
M7_&BB@ WGT'Z_P"-&\^@_7_&BB@ WGT'Z_XT;SZ#]?\ &BB@ WGT'Z_XT;SZ
M#]?\:** #>?0?K_C1O/H/U_QHHH -Y]!^O\ C1O/H/U_QHHH -Y]!^O^-&\^
M@_7_ !HHH -Y]!^O^-&\^@_7_&BB@ WGT'Z_XT;SZ#]?\:** #>?0?K_ (T;
MSZ#]?\:** #>?0?K_C1O/H/U_P :** #>?0?K_C1O/H/U_QHHH -Y]!^O^-&
M\^@_7_&BB@ WGT'Z_P"-&\^@_7_&BB@ WGT'Z_XT;SZ#]?\ &BB@ WGT'Z_X
MT;SZ#]?\:** #>?0?K_C1O/H/U_QHHH -Y]!^O\ C1O/H/U_QHHH -Y]!^O^
M-&\^@_7_ !HHH -Y]!^O^-&\^@_7_&BB@ WGT'Z_XT;SZ#]?\:** #>?0?K_
M (T;SZ#]?\:** #>?0?K_C1O/H/U_P :** #>?0?K_C1O/H/U_QHHH -Y]!^
MO^-&\^@_7_&BB@ WGT'Z_P"-&\^@_7_&BB@ WGT'Z_XT;SZ#]?\ &BB@ WGT
M'Z_XT;SZ#]?\:** #>?0?K_C1O/H/U_QHHH -Y]!^O\ C1O/H/U_QHHH -Y]
M!^O^-&\^@_7_ !HHH -Y]!^O^-&\^@_7_&BB@ WGT'Z_XT;SZ#]?\:** #>?
M0?K_ (T;SZ#]?\:** #>?0?K_C1O/H/U_P :** #>?0?K_C1O/H/U_QHHH -
JY]!^O^-&\^@_7_&BB@ WGT'Z_P"-&\^@_7_&BB@ WGT'Z_XT444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img148586500_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_4.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #U J # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK]/>HKS28Y; 6B )%'&0%'..<MDGEL\Y)K<J&X=$AD+R+&/+8EV8*%&.I)Z
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M2I4E<8)%6W\,^&Y(5MY/#^AR0)+<SI ^DV#0I/>\WDRQM;E%ENSS<R!0\_\
MRU+ULJL5]B]Y.3O9ZRM>UUM=)KK=?='*_P":UDEIIMWUUZGX@WNO_M ^"YO'
MNJ)^T/\ %KQ#)\.-"_9D\<Z1I>J7)DL-=U[XK:QI]EXPTO6/DS=^&I;:[EBL
MM"&(=*D*7 D)3%:47Q^^,]A=V'C+PG\4O%WC3X^>(O$_Q/T?QQ^S;?6]Q/X9
M\%^&_#VHW]MHM_I_AHQ*WAZ32M'M['68=8DDV>)'O&@CW$$']KY/#OA^43B7
M0]'D%S'9Q7(DTRR<7$6G,KZ?'.&@(ECL756LTDW+:LJM $(!J&V\*^&+/6[W
MQ-:>'-!M?$FI0I;ZCX@MM'T^#6[^WC $<%[JL5NM_=0Q@ )%/<2(@ "J,"AU
M4]X)[=DMDFG:.UU>Z:E?J@Y'_,_QT]->VA^ WAKQ==2?%FSUWPQ\</&?Q7UK
M7_ _PIC\5ZUK;W%Y>>$]8\1^.]'BU_0=.EDA5-+2)F?R=(*F;0C JOC<!3M
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M1M5L+*[U:UN;^2:./6(;=[>T=I(()) E?LG\,_@]\,_AG\/=+^'OA_0]"GT
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MWQQK/C7P#\1SJ'Q.UOXNZ5X;^+?BKPUX5\;:^_FZCJ'AO34LUT^.2X*K]L6
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MI<[I$@D18 6Y9,)T KXI\(EOB=XJ^'/AO5=0N;'6?B/K\]SXG\2VN)=8N7U
M&X #2$!4M(Y%MX$R%CBB11PM>E?#3P99>#_A=^TCX)\<_$[P?;^+/%MKHT-F
MNBZE]MT^%;:,M:S>>@S(9)52.[0#,".0_3%=?^RE\"]/\+^+=$^(?Q)^)O@?
M4M1\/V1@\,>'] U6*>""XNH4C.HWUQ*R*THC"_9X8QF)\[STS]C&GALM_P!8
M\;1I8E5:E92P;I8'%_OG/!>[.DW04'1CC:M64Y2:I1=*,FG[A^=O%8G./]3\
MOQ6*R_V%+#.GF"KYIE[5!0S*/-3KQ6+=58F>64<-&G"FG6FJ\HIQBZK7TG\*
M/V*_ ?PO\?VGQ&/B3Q+XHU[2XIX](&K2QQ6M@URC1RS"*%F\^4QNZ!G(P&/!
M-?9=007-M=()+:XAN(V&0\$J2H0>X:-F!'XU/7Y=CL=C<PK*MCZ]2O6A"-)2
MJV3A3BVXPC%*,8Q3E)V45JVWJVS]ORS+,MRK#/#Y7AJ.%PTZDJSC0NXU*DU%
M2J2G*4I3DXQA'FE)^[&,5:*211117&>B%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5YUX_>Z.G/# 75)&59MF[)B&-P^49P1U Z_K7HM<MXJU&
MPTS3KB[OHFF2"%Y?)0;GEV D1H/[Q( !Z#/?D&H7YX<JO+FCRKN[JR^;T,ZO
M+[.IS-QCR2YI*]U&SN]-=%?;4^>M7NHQI4EK;!/M$J"-25YC*\^9GJGEXW%C
MT .:\(T?Q!IUWXB2W32[W5M(L;]#>S12);I?74)'FK Y8>;&) VYI JOC@D8
MS],W9L_%_@J^U31M/DLI7%S:3(R*9%<QNI>.0*I88)W$< \#DC'P?XRU/6O!
MVB7MA9Z=?KJ*B1+>2WMY'WN05#QE  &/4'L<DY(KW,).=.KB*3<J%9)4ITW.
M*YHS?ON3T7N/ELXM-<U[W=U\UCJ<*M'"58*&)PTFZT*JIRERN"C[-0CT]I>2
MDI1M+E46NC^^K'QY\'K>6.YCU&!+\$QW-I':R7-SI\Z862"[-O'(D4JGL')(
M&1FIOB#X*\,_%#0$GAO;>XTB50TEQ'(%550;F,F[:T3Q@9990A'4BO@KX$Z7
M=:'X;O+_ %J5AJFJZ@^JSI.WFS+YF2OG$Y9G9?O C<#@$YQ7H5[X_P!9O!XK
MTG3=]IHUQ8V$%V;<%(_M,MQ(LCH$VA9)(@JOM^8J "3WFKET*55?5ZTN:E4A
M^];2BFYTTG!))Z.5XOF;=O.Z>'SFK6HIXRA3Y:]&JWAXQESN*IRDXS;DU:4%
M::Y8VYGHK6?N7@KQC\-OAW8?\(WX3TC4O$)LY&CO-0LHX1"T[$>8OVF5T:7!
M&%"$H ,!L5[OX)\7^&O$SSC3H[BPU-%W3Z;J,*PWJH&Y>-AE+B('JT3MM!!8
M 8-?"/A6?6;>\T_3=(LT-BFW[6[*BEQN!>260KM1=F\D#YCP.N*WOBA\:-.^
M&-UX?U.)?.U*SU:SCM;:U(66_21B)[1'8[3!,@ E+ JBC<>*VQ&6*JX^RFZV
M(K<TG/VO/4<K_P#+Z-O=<I)OETLK.[L<^'SF6&A.6(A'#X3"\D>14'3HQIN,
M6O85+OG5.,M[R;DK-)M,_1:J&I:KIFC6DE_J^H66F64()EN[^ZAM+=."<--.
MZ("0#A=VYL8 )K\LO%7[9WQ1OKL1>%8_#UAYA+W!^QSW]GH=GMYDO;G<3>W:
ML0HBMMH#X&" :\@T'Q]\1/C1<P3^(F?Q$]UJ%WIUAK&L7PT[0',#$.EAH'RP
M"Y*_)";R*4Y3@9&:^BRSPZS+$48XW-<3A\IP;C[1QJSA];G2T]^-*I*E3A%]
M'.K[5QM4I4*L'%O\OXD^D#P]@<95R?A7+L?Q9FT*OU657!T:[R>AC&KK#5,;
MA:.+K5JR5W)4,/\ 5(3A/#XC'X:O"<(_H_XN_:R^%7ANZ73=+GU7QGJS[_*T
M_P ,Z?+<[_+0R,QNIQ!;",(K,90[)@<$Y&?-;W]K3QI,@GT?X.:E!:2QB:&[
MUO5((T:%N1*R6/GE4QCEG4!@5KP"V\">*]*OFT'PQ<Z+8:R]L%:U@M9+P6RW
MB,)+F^NR2MI;B,N/*38KL5CC1<BN+\._"CQ]8:E=^)?$7BB_U+1]3C;3Q-90
MWTNGZ7]@NYH7BN=.AFC$%J2A=)BK;0V)%?!%?787A7@_#TXM+#8R25)N698W
M'RQ-=5(U)*>'PV7T\-AUS>S2I0E4J^TC[5JI*4% _*,P\3?%O,,1556KFN40
M:Q"A3X;R/A^&5X*KAZN#I2I9GF>?XG,\PY:?UB;Q5>EAL/+#S>&A/#4Z=:5:
M/L.M_MO^,O#]W:PWV@^&I1JUREM8PV]Q=2/;W&[:T#NB,LJD\;\[U;:&4 DU
MWMA^V-XHD*_:_AK;F%65))HM8DM6+@?. E[!&F3@E2LC*<@9%>?I\&['4SI6
MMW&D:;XG72H[@:;>6&JZ=8V\:7+#SW>%X1F7&XB253*KX",#@UY]>:I\*;3Q
M3/\ #C6M-O9/%5I:?VW]E;57U%[?3"Q6.XNS"3$HRA5,*-RA>-Q)JOJ7!E>;
MHO(L)SJI&C3^K8JI[:K*2LTZ#S#"S59.+4:$8RFXQE)\\W/E%F?C'A*$,92X
MUSUI8.OF&/68Y1AGE^#HTZD5&I#'4LAS:DL HU82KYA7JTZ$:U6%"*H4E0E5
M^EO%7QA^ '[17PV\0_"OXP6VI^&_#/CJU?P_K>FZO+)8Q7RI<0S26UOJ]B9E
MBS-!&=[A%*Y5B037UUX$TCPGX=\'^&_#G@8:<GA/P]HVG:)H46ERV\]G#INF
M6D-I:1)+;$Q.ZPQ(97^_)(6DD^=V)_'76[#P_+_PE5AX0N=NN- FH^';6_TV
MYNHY9IX9/.1XKUIK.*.)L8F\H9;#'@5>\"77QK^$UA9ZGI%S-9B5+::]5=0$
M^G"XFQ)<#5-&E\V)-.=CA9[!('1CNW!0!7FYEX:Y+B:T\1D]>IE>.J4*:ITL
MUC"-*O2D_:PPU.O/EQ,%3=24E&^,4IN22A--/Z'AOZ2'&^7Y71ROBW#T>*>'
ML+F>*JUY<*5:U7$8#'*C#"8K.,1EU%3RRJ\53P=&C*JX91.%&&'YI5J+C-?M
M,\B1(\DKI''&I=Y'8(B(H)9G9B%55 )+$@  DG%)')'-&DL,B2Q2*'CDC=7C
M=&&0R.I*LI'(9201T-?#=I\8[?XU>$]9^#7Q F?X7>.O%FC&'2-9T^],NBZU
M 9H6^UZ+J2.ACDD95BFL))1,4ED57'0_9?AG1E\.^'-!T%91.-&T?3=+,X##
MSVL;.&V>?#LSCSGC:3#,S#=@L3S7Y9FF59EDV->#S#"NC>DJM*O&I"K0Q,93
ME%3PU6FY4ZU*T;^TISDN9NG)1G"45_3W#/$W#/%^0PSK(,W6,JK&U,)B\LJ8
M6OA<;EO)AZ%91S&AB8TZ^$Q4IU906$K483=.$<3"53#UZ-26Y1117 >P%%%%
M !1110 4444 %%%% !1110 44A(4%F("@$DD@  #)))X  Y)/ %?(?QS_;Q_
M92_9V,MI\2_B_P"&K77XSM3PCH5P/$?BVX?!_=P:%I)N+II,X4I)Y9#$+U!P
M;[!W\E=^26[?D?7M%?DNO_!1_P",7Q/9%_9G_89^.7Q"TN[PVG^-O'4=M\./
M"DT$@8Q7.-4BDNWB? /RR*0&!J9?&/\ P6!\8-&]A\)OV7?A18SJ[9U_Q5K/
MB[4[<'F,2PZ;>QP^80=C * K*3C!%/E>SLO5K3U6_P"'J*ZW6J?5:Z;[KRU\
M^ES]8J*_* >&_P#@K^T;7#?$#]EA)0<+8KX;\0%'&<Y\_P"UX7'3'<'VS36\
M0?\ !8;PH1)-X"_93^*-K'%ODAT_7==\(Z@[ \Q1->7K6Y? R&*X).!S1;S7
MW^G>W?KYA?R?W7[=K]_P9^L-%?DT?^"@7[27PQ;9^T7^P3\7]!TR##7WC+X4
MWUE\1O#]O$@+3SM:6,0OMD2@L )27& !DYKZ2^"G_!0C]DWX\W<6C^#OBIIF
MD>*Y'$9\$^.H9?!7BZ.4\&)M&US[/(\BM\C+#)*0WJ,&AIKI^OY>H77?[]/S
M/M.BFHZ2*KQNKHX#*Z,&5E/0JRD@@]B"0:=2&%?D5\:(_%ZR_MS:?8:%JOB+
MQCJVL_#8Z99V4MR=5L_@]/I=A;ZAK&G6%N/M.M:3IFJQ:O-<Z' 0NI3M-#N!
MW&OUUKROQ3JOPO\ !_COPAK/B.?3=,\?>-I!X#\*3DRC5]>C$C7[Z5%#"V+J
MTL7G:\E>>-H[+S3+O0OS49<KO:^VGI*,OQM835^MM_Q5OUT_X)^%GP\^'?B_
M0_#WBFS\:>"_B9XL_9CTKXV^%/$_B7PO:^#;WPK#XD\':MX UV)M0T/P)IU[
M<7__  C<'BZ32Y=0TV*87TEU''<W%O"5KU/XD?"RR/C#3?%'@WX,?$C1;[Q5
M^SWH?ASP!J&MV=]J/BG28=/\?ZO>:OHVKZG;W-T--:7PO<V,FGVEW(LR:<UO
M;$+/%(@_=2BM76;=[?*]ETULDE?35_*R1'LU:U_P_K2W3_AC\/\ Q!\)/VF-
M2U;X[?#OPCIWBK1M+^!'A/Q)JOP4\0&ZE\OQ9?\ Q3N=-U2&PTB2:58[^_\
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M!QL?C_K7PO\ $FG7/QA:^O\ X=VMSH.DZ&NO*KW3202W[H4>%A;DJR';'<[
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MQ1;QM'X ^)-WXCT>XM]9G\ 6<4^OQWOAF&!=5T@?:C/964ES,RW)@,Z@1R*
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MA/7[[Q/X>LX 2;=E_M2*VW72Y E54"+G"NPYK[&T32=+T71+"PT6QATZP%I
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M-) 9)HU#-IR5%R_O-[;-NW,W>_?7N[-/Y$\T=N6_;O96]7IU_P""?H1XH_9
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M>6AN;&\FF24$<@C> & ) )('3'GL6F^!/!]O:1:/K=[X+6S#,-/TFY:_>[U
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M'TGP==:?XRTC2[*V@TZ :7XE%O;0H]YHTOW-0FDB4>9+ILY-PSDLT@EVY*@
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MTXS7HVG7@*ABRXZ=>_3 Z8/7GOT[T >F6DRG'<XQU_3ISDX.>:\>_:F\:O\
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M6WL;&WAM+.TACM[6VMXUB@MX(4"1111H J1HBA550  *L444 %%%% !1110
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M>>#R#@=3Q7[#?%/X6^%_BWX5O/"_B>T5TD5I-/U&-5%]I-\H/DWEG*1N1U;
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M)PE:HH.$YQCSJ\M%("&&001Z@@C\Q2US'HA1110 4444 %%%>"_&3]HWX?\
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M73K.BRV<RS2;E#VLTI"X<+S7Z%?M0?LVQ_M)Z;\,=(N_&&L>%],\ ?$_P_\
M$/4M/TR:XAMO%MOH0F9/#^K_ &::&1[&6>2.XV[B@EA0LC#BLO\ :@^)NF>&
M=.\/_##PMX/TKXC_ !J^(YGTGX<^#+R*.:+3HXT$=_XS\0W(!GT;PIX;B;[7
MJ%_YD#3M&+6W=I&?;^AY%XD9MA95<%G%'$XO!4E2CA\?A\:J>/JQG']["O2J
MTZV&Q=*DHQA%8JG[:;E*V(C%(_ >._HY<&YAA<MS_@_,LMR_/\;5S"IFW#68
M</U*^19;.A7IK+\1@,=A\7@\RR[&9ASUJ]664UOJ6&A2HPE@:M64W#XO\#?$
MGP3X2U!OAIIWBRXTG4M"M(+J2QL;R2\MX;.]R;:[NHGMTGMWNW(D07PA64#<
MI**6KK[GXFQ^+/$;Z+X5\;:1>^(O#*K/J&HZWI5M;Z;:6LJ@/IEW=Q2.;TSX
MR(P#'&QW!A7<^ _^">N@> O"6HI8>-;_ %+XC>+6?5OB#XIUFVCOX/$WB*XC
M.Y@61=2L]%TUW>WTC38;D0VUJJ#RPY84P_L<^+]#+W>B3^#KN_N;:."^GB@N
MK":<Q#"LHN'>T))^8M-%(Q)ZU]?@L[X0Q<(8EXRC@L7+F@L-BL/!TH4Y1<5[
M5U<+RMN%E5A3Q#HN3ERMP7LW^29OPEXM975Q& J9/C\\RRU.N\RRW,<0L77Q
M,*M&I-T(X;,W4Y54C4J8>MB,OAC%!4_:<E9NK'F-4\82V]M:P>*/%2027%RD
M5O&+NWL=)NKAI 46QO;-9V6$@;42X\OAASD5Q<UC\*+_ %C48;?P[HEY=I?Q
MZCXHOEE,MWJ^IPQJ4L[>Z)BLTC2()]JN%D$DR83EP0.J\1_LG?&CQ1H>I:#J
M6E>#6M[AHCIUPNJ)%+9/%(K&XF2-0CS-C<A@"!2!D$9!ZC0?V*_%\MM:PZ]K
M/ABW6WM8;<HD6HRL3$H'FE;&XMH)I]Q9S),K%CU)Z5ZD,QX7P:E5J9_@Z+CS
M.C++,3&4O:3Y5.7U;#1A.,53DXQ3J.3GSSYE[.FI?,U\B\2\VC2PN'X%SG&N
MK-1Q]#B7+:E*B\+1E>A3_M/,ZM>A7J3Q%-5:JCA8PIT50IQA4]OB)4?'+WQI
M9:CKVI>$_#GA'PKX=CL=)&LZAKDVF-<1V&GY"B0)=21"6X;C88'=#)A5(8J*
MX'PM\,9O%WCC3M4M;;7O&-^MI<R:3H]N\EQ9Q%W;[/J.IS&7[!I>YLN+0W'F
MPVH0A2^5'W[X=_8O\%6EQ;W?C'Q)X@\7K B1G3)Y8[#3##&ZR1VSO:JFH36B
M2*KK!-=E,@9!(!KZQT#PSX?\+62Z?X=T?3]'LU"@Q6%M%!YNP85YY$7S+B0
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MPK!XP\4WD][%IFN,\4@MO#AG=8M/M+=C(B7:PB6XPK,%( K\#KJVUKPUXO\
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MWL\!G526*I1I2483=+!9G3KTX5)+F_VNG)RU27\G^,W%N4\1?2DXVXIR[ /
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M# _ZXJ3AAMXHV\]O%JKOJ2.J6K;EO;>21);[4XIG<^7 AWR;8MGF&4LJI@#
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MO\>[&-/BGXBLI+/P'X(>07>F?!;P)=,);;0+ ,#%)XMU2+RIO%>M1J)))O\
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M=!5<9[+!X:>%X?S>I45&E',\+",<90]M#.(XR$'7I[WAJV72/B?X1\'FZO\
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M110 5@^*?#FG>+_#FM^&-7C,NFZ[IMUIEX@^]Y-U$T;,O^TA(=?]I16]2$@
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MO5:_>V'(KWOVV5MM]N_E:Q^&'[('PO\ %?@2?XB^(_'B>.M%T[2O@+XT\/\
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MCMH[Q=MCY7\'?L:? CP=?P:G'X;N?$%];.LD$GB:_DU>&*5#N22.VE5(@Z,
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MUMXUB@@B!)(2.-55023@#)-7J**!A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img148586500_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_5.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" UO" ,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J6DH
M8U-J7;2;: (Z*?MIII@)2K24HK.2'8=36I**FQ(VBEVTX+5H8JTM"BG;15"&
MT444R0HHI-U(=A:**:>M(H*:U+14,0BU*M1 5*M"&.HHHI@%%(:3)H =12"E
MH **** "FMUIU-;K0 E%%% !1110 4444 %%%% !112$T +12 TM!6P^DI,F
MF[JHD<U-:ES2-3N VGTREH =12#I2T (W2FT^DVBI8Q*2G<T?6H"XVBG;:0C
M% 7$HIII5IV$+112T@!:D7I35 S3ZT0!13:%I@.HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4QZ?
M4;4"9'@T4ZBJ1(VG;J;12:&AU*O>FK2T%#]U+NJ+<:4$TK .;O4;4ZF-2 -W
M-+NJ*@,:M(0]L5!)4C5#.V!3,VRO--Y8-8]_JPA!^:I=0N-BGFO/_$VM&%6^
M:L92L<\YV1JW_BI8R?GK(D\8KN/S_K7E/B#Q<8F8;_UKE7\;-YG^L_6O.J5#
MSW6LSW]?%JL?O_K5B/Q0K?Q5X#;>,BQ'S_K6M;^+"<?/^M<$ZUA?6#VX>(PW
M\5+_ &\#_%7D=OXH+8^?]:TX=>W8^:N26*L:1K<QZ4-<_P!JGKKO^U7G/]N'
M^]^M/77/]JL_KGF;JH>CC7/]JGC6\_Q5YPNN?[53)K?^U^M3]<-.<]%&L?[5
M']K_ .U^M<"NM'^]4@UC_:H^N![0[K^V!ZTO]KC^]7##5SZTY=7/]ZJ6,*50
M[K^UO]JD.JC^]7%_VN?[U+_;'O3^M^8^<[+^U/\ :I?[6]ZXO^U_>D_M;_:J
M/K?F/F.V_M8?WJ=_:_O^M</_ &M_M4O]L?[5+ZT5SG;_ -K_ .U^M U?_:KB
M/[8_VJ5=8_VJ/K0<QV_]K?[5']K?[5<3_;'^U1_;'^U1]:#F.T_M;_:I?[8_
MVJXG^U_]JC^V/>G]:\Q\QVW]L?[5)_:_O7$-K'^U3/[8/]ZCZWYDN1W1U<?W
MOUIC:N/[U</_ &U[TTZT?[U1]<\Q<YW0UC_:H_MK_:K@FUK_ &J:VM_[5'UP
MKF.];6@/XJA?7!_>KA&UL_WOUJ!M</\ >_6G];,I5+'=R:W_ +5,.MC^]^M<
M#)KG^U5>37B/XOUI_6_,Y76L>B?V^!_%4<GB15_CKS.3Q$5S\U9]SXH*_P =
M=$,482Q-CU.3Q0%_C_6HAXN7=]_]:\;NO%Q7/S_K6:?&3!L;_P!:Z88HR^L7
M/H*U\5JQ'SUTFFZZ)<?-7S=I?BXR2+\_ZUZ/X9U\S;/F_6NR->YTTZNI[C8W
MHD4<UIQR9%<9H=[YB+SVKIH9<J*[H5+GK0E=&@K4[[U5XVJ936O,=!(JU*M1
MK4E7$3%IK4ZBJ)&4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:U.IK4 1T44M.Y(E&
MVG8HQ2&-QBBE(Q24##;3L4E&:+CL!IC"G48H8R/;1MJ3%(W%4G8AD+=:K7'W
M35ES56X^Z:F3,F<WK#E4:O'_ !Q>&-7YKUW6_P#5M7B/Q <JLE<-21Y]9V1X
MGXLU=ED?YJX@ZRWF?>K5\83'SG^M<2LC--7CU:ECPJE2S.UL=58D?-^M=!:Z
MDVT<UQ&F;CBNEM5.T5Y%6J8^T.JL]2;(YK>M-2.!S7%VQ*XK6MYBH'->16K6
M.BG4.I_M(XZT]=2/]ZN;^TGUIZW1]:X_;L[HS.G743ZU*FHGUKFENCQS4R7!
MXYJ?;LT]H=/'J1_O5.NH^]<NEP?6ITNCZT>W9/.=*M^?6I%O_>N=2Z]ZE6Y/
MK5>W8U4.A_M#WI/[0]ZP?M1]:3[0?6G[=FJF;XU ^M+_ &@?6L%;@^M.^T'U
MI>W97.;GV\^M*+X^M8/V@^M+]J--URE(W/MY]:/M_O6']H/K1]H/K^M+V[+Y
MC<^W^]'V_P!ZP_M!]:3[0?6CV[#F-W^T/>C[?[UA_:#ZT?:#1]88^<VFU ^M
M1G4#ZUCM<&HFN#ZU/UAB<C:.HGUJ-M1/K6*;@^M,-P?6H>(8N8V6U(\\TPZD
M?6L1K@^M1-<'UJ?K#N/F-QM2/K43ZD?[U8K7)]:A>X/K5_6&<U21L2:D?6JD
MVHGGFLQ[@U7DF)S5*NSS:E0MW&H'!YK%O-2;GYJ?,Q8&LB]SS7;2K,XI5"I?
M:JPSS6(^L,)/O4NI,0#7-S3$2=:]2G4(C4U.]T36&:5?FKV3P3?E]G/I7SOH
M,Q\Y?K7N7@&0MY=>E2DSTZ$KL^B/#$I:-*[6V;Y17">$_P#5)7<V_P!T5[%/
M8^BI;&A'5B/M5:-JL1FNJ)V(G6GTQ:?75$3%HHHJQ!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:D%;(8M%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&Z4M(W2@!M%*M+0)"TUJ
M*:QH&#4VEI*DI!1115#"BBB@EA44E./2HW-!#96FK-NFX-:4M9MXORFL)&3.
M5UIOD;FO&_'7*R5[#KG^K:O'?&WW9*\^J>-BGH> >*U_>/7(1KB0UVOBI?WC
M_6N-_P"6E>#69\E5EJ;6FGD5TMFW KE]/;D5T=FW KPZISIZFQ >E7XZS;<]
M*OQ-Q7DU#TZ+T+&!3EJ-6-2*:Y['?$F6I%J!6J56I6-2PM/4U"K4]6JE$"44
M]:B1JE!JK%HD6G4S=3UI6*0X4N*%I:318E&*6BD,****0[A1110.X&HW[U)4
M3]Z+";&9I&H:FL:FQ%QK=Z92EN:C8UFT5%CN*0XJ,R4W?2L4Q6J!ZE9J@<]:
MW@CFFR-JAD-2,:A8UUPBCS:DB"6LN\Z&M5^E9EZORFO0A$X:DCFM2/!KG)>9
M*Z#5&ZUS[?ZRO5HK4YU+4W-!7]\OUKW#P(N/+KQ3P^O[Y?K7N'@5?N5]%0AH
M>MA7J>\>%3^[2NYM?NBN&\+K^[3Z5W%J/E%>O3B?5T'H:<(X%6$J"&K"]JZ.
M6QZ46/6I%J-14@I%"T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK7N/@1?]77A_AX?ODKW;P"G^KKZ&A(]W!^\T>Z^%H\QI]*[JUB^45R/A6/\
M=I7<V\>%%>Q!GV5&.A+&G%2+0HPM"]:Z#M2L2+3QTJ-:D7I4E"T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA>IGJ"2NRFSEJ%6;H:RKUNM:<YK)O*].F>+69@Z@W6L4_P"L_&MB_P"]8_\
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M-/8^VH_"+NI5I!TIRUVI:&S)5IU-6G4BD%%%% PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!&IM.:FT$L****"HC6ZTE*U)0,***;0 UJ%ZTE*O6J,NH]:<M-
M6G+4%H4]*HWWW35]N@K/O_\ 5FL9!(X7Q(?W;UX1X^;B2O=?$G^K:O!_'_22
MO.K'SN.>AX'XF;,S?6N=MQF3\:Z#Q-_KG^M<_:_ZP5X58^%K?$;EDG2MZS'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ I&Z4M(W2@!M%%%! 4444#0C4T]J<U-/:@H****"F1M24K4
ME6C'J/IZTQ>M.I,M"L:S[]OW9J\_W:SM0^X:YIBEL<+XE;]V]>$>/C_K/QKW
M7Q-]UZ\'\?\ 22O,JGS>.V9X+XF/[YZYZW_UGXUN^)F_?-6!:G]Y7B5D?$5?
MB-^Q[5T%F>E<_8]JWK/M7D5&:TF;$%78ZI6_;Z5=CKR*YZE,GIIZTE%>>=T0
MIZTU:E45/4W1(E3J:A7M4BUHBD3K2M3$Z"I*9JAM.4TVE6IL63K3JB6G4R0;
MI434YN]1,:D0UNM2I45/6I L*:1N](M+6D0$VTE/IK4FP&TQJ<U1-4 (QYIE
M*:CJ6,1JB;I3VZ4QNE(QD-IE/IM-(@A;O43=ZF>H9*ZJ9R5-2M+]VL>^Z&M>
M7O6/??=->I29XM8YO4CUK(4_O*U=2[UCQ_ZRO=HG!'<[?PO_ *Y*^@OA_P#\
MLZ^?/"O^MC^M?0G@ ?+'7LT6?3X#='O7AG_5+]*ZU/NBN3\,_P"K6NL3[M>Q
M#8^WI*T1U.%-IR]J[%L6V2+3J1>E+2+"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "D;I2TC=* &T444$!1110-"-33VIS4T]J"@HHHH*9&U)2M25:,>H\4\4R
MGKUI,M".O%9VH+\AK2?I6=J'W&KEF*6QP/B;[CUX-\0/^6E>\^)?]6]>#?$#
MI)7FU3YS';,^?_$W^N;ZU@6K?O*W_$_^N?ZUSMM_K*\2L?#U?B.CL.U='9#@
M5S6GMTKI+%N!7BU-S6F:\'05<2J=OVJXG:O+K'J4R5:7%(M&ZO/9V1!:E4U$
MO6I%[5)NB45*M1+4JU:-$/6GAJ8O2ES3-4.HHHI%$JT^F)4NVJ)9"U1-4[K4
M++4@AM/6F'BGK2L!,M+2+2U2 3=36:AFI"<U #6--IS4VF P]*C:I":C:H8$
M;4VG-TIM292$/2HVJ0M4;5<3-D35#)4[=:@DKK@<E0J3?=K(OONFM:;[M9-]
M]TUZ5+<\6L<SJ7>LB,9DK7U+O63'_K*]NB<,=SMO"J_OH_K7T)X!^['7SYX5
M_P!;']:^A/ /W8_PKVJ)]/@-T>]>&E_=K]*ZQ!\M<EX9/[M*ZV,_**]>F?<4
MOA' 4J]:2E%=J-&2"EI :6D,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?;TM(CZ044@ZUU+8T9*M.J-:DI@@HHHH&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&4YC6-J#<&M><\5BZ@>M>I2/)JZG.Z@W6LVWYF%7[\]:S[<_OJ]FBCE4;,]
M\(K^]3ZU]"^ 5XCKYZ\(G]]']:^A_ /W8Z]FB?2X#<]R\._ZM:ZA>E<OX=_U
M:_2NI0?**]B"T/N*?PCJ**1JZEL6*M2KTJ!>U3K3$+1136H&.HIM.H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDD>JDCUHB9,1VJ%F%->2F;JT2$2#FI%%1K4RBJ2.:8Y13Z:M.K2Q@QK54G;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>C%'U</A+FZ@5'&V:F5>E:C'+4RU&M24"%HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :U1MWJ1JC;O0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% #'J+O4K"H]M #E%24Q:DH
M:U,W4YC43&@!7>LV^?Y35N1JSKYOE- '-:J_6N6O&^8UT>J=ZY>\^^:0%?\
MBJ:.H%^]4\8I@/P*<%I*7=0 Y>M.IBFGKS2 ?2@4 4_;5 (M/ S3?NT;J5P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -:F[:>>E-H *?4>
M12[Z !ZA:I6.:C9: *\E9MX?E-:,QVBLB^D^4T <[JG>N7O/OFNBU*3.:YVX
M^9C0*Y57K5F/I4*I5F-: %VT$4[;2[: N,%/0FE\NGK'3&.7I3Z:JTZIU8KB
M-24ZBBS"XTBDIQHVUT1(W&T4[;1MJQ#:*=MHVT -HIVVC;0 VBG;:-M #:>M
M)MIVVC03 FDI=M+M-1H-#:<*-M*%JM!ZCJ*7%%(8E%+S1BJ)U%4\U,I^6H%J
M3- *Y#<=ZSV^]5^;D55*<U+-2:T%:L8^6LZU6M*/I7/,QDS-U;_4M7D'CB3Y
M9*]?U;_5'Z5X_P".$^62N*9QS/G#Q]+\TGXUXCKTG[QJ]K^("G=)7B&O?ZQJ
MX)(X9&#_ !&I-M1#[QJ7/%<[3,&F12#K6=<]#6C*>#6;<GK1%#2,JZJO#_K/
MQJQ<U7A_UE=,3>-SK_#?^L2O?OA[_P LZ\ \-M^]3ZU[[\/6YCKIB=D#Z;\"
M_P"KCKV70?NK7C7@3[L=>SZ /E6NJ+.N)W>E_=%;MOTK#TS[HK<M^E;HW+"T
MZFK3J8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3
M&[T^F-WH ;3J:*?@TP&-56?H:M-56X/!I@8]ZW6L"\;K6Y?-UK O.](#,F;F
MH*FFZFH W- BQ'5A5JO$:LQTQ",OM3-M3[3@TW;3 115F/I4:K4JTP)5HYH6
MG;:!6#:::RU+MIWEU0B'RZ7RZG6.EVTF24V6HVJU(M5FJ"D-I=M"]:=3*&[:
M-M.HH$)M]J-OM4@!HVF@!@6C;4BK3MM $06G@8IVVDHW 7/%1N:<U1L:!D3M
M435(]1-WI+0"-J2E:FU0 :CJ3-1U$A .M/!IE.HB4AK-3*>U,K8IDD=6.U5H
MJL?PUA-G-(S]4;]T:\D\;_ZN2O6M5_U)KR3QP?W<GXUR,QD?-OQ"/S25X/XB
M_P!8]>[?$(_-)7A/B+_6-7+,Y9',_P 1I]1G[YJ1:YF9$<G2LVZK2DZ&LRZ/
M6A#,V>BT_P!8*)C2V8_>"M8FL3N?"_\ K4^M?1'PX^]%7SQX7'[Q/K7T/\./
MO1UT1-D?3_@4?)'7L.B-\JUX_P"!?N1UZ_HOW5KHB=$#MM.^Z*V8NE8NF_=%
M;4/W:W1TDJTZFK3JH HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IC=Z?3&[T
M(M/J-:=0 V2J5PW%6Y3UK/NFH R;UNO-85T>M:]X_6L2Y;K1<#/F^]4 JQ)3
M%CH)'1+5R,<5%%'5I5H 2D YZ5)2!>:H>XJ+[5,J]*1%JS''TH3$,6/IQ4RQ
MU(L?%2+'5"N0B.I%CXJ81T%<51)#MQ36'%3E>*C8<4A%6057>K<E5W6DRD1#
MK2T[;1MI#&T4[ I: "BG44 "T^D6EH :W6FMUIS=ZC:F@$;O434YCUJ-C1N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F-WI],84
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M9VK73!G1 [/3_N+6O#]VL?3_ +HK8BZ5NCH)5IU-6G50!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ:M.J@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?':O5=)CVA:ZHFT3K]-Y45LQK\M8^F_=%;"GY16R-T+WIU1[OFI],H6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %0S?=J:H9ONT"9E758EZW6MN[KG]0;K5(DSI9.M,62H)I.33(Y.:8&K">E7
MHEK-MVSBM.&@"95Z4_:*:O:GT *J\]*D5:1:>HH >K5(K=.:AIZ]J )E-2+4
M*U,O:I ?BBE%."T%#<&EJ01T&.D,C:DVFI-M)MI@"T]:C^Z:0R4Q7',W6HF>
MFM+[U6DFIB'RR54DFIDT]4IKB@1+)-UJK+-UJ&2XJO)/0!)))5=GIK2U&7H
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M4ECJ*** $-)MIU% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !4<WW:DILGW: ,>][US.I-
M@FNGON]<MJG4U2),*X?FHXI/FIMRWS5%&WS4Q&W:R=*U89.E85JW(K6A>@"^
MK5(&JLK=*E5J +<=3+5>*K:+0 FVG!?:G;?:@4#'*/:I%[4U:=0 ]:F7%5]U
M+YF* +612,PJJ;BHVNO>IL#9:9A36>J;77O4370]:H1;DEQ5:2YQWJK->>]4
M9KRF!?>Z]ZKR7/O6<UW[U$UQ2 LS7%4Y+BHY)L]ZKL^: 'O-FH6DZTW=4;'K
M0 _S*3?41:DW4 3;J0U'NYIX.:0!1112L,*?3*?0A!2-2T4V VDI],I)@#=*
MBJ6F[*M%(=":LJU55&VI%:F6.E;%5C)S4[?-5=D.:3)L6(9-V*M&$2K5&'AA
M6E;N,5DS*2.:UO0%N$;Y>M>0>-/! F$G[O\ 2OH>6-9%Q7,ZYHJW"M\N:R:,
M['Q-XP^'WS/B/]*\FUGX?N)&_=_I7W1XA\$BXW?N_P!*\_U+X:>8Y_=?I4V'
M8^-+CX?R%O\ 5G\JEM?AO))C]T?RKZR_X53N;_4_I6G8?"<9'[G]*=@Y3YFT
M+X7N67]U^E>L^#_AD8V3]U^E>VZ/\+TCQF(?E7=:+X%CM]I\L#\*:15CD_!7
M@G[.(_DQ^%>RZ!I/V>->,4ND:'';J/EQ700QK$HJK%6)(SY8J59O>JLDE$.6
M:M$4C:M&W5JPKD5D6*GBMF$86J-.4G5:?3%I]22%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%5Q5:WZ"K*YI,JXN>:D6F <T]:0AU%%% @HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!IPGI5N,U3A[5;C-%P)UIU,4T^D@"BBBF 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*>O:@I29Q0!(M.J(-[U(OS4BB2I%I%7I3]M,D2BBB@ HHI-U "T444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M: ,^XK)NEZUL3=ZS+H=:!&)<KUK'NEZUN77>L:[H&8=UWK*N#C-:MYWK'N*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!WI:0T%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9*FJ&2
M@"G+WK-N>]:,W>LNY[T 9%YWK#O.];-YWK%N^](#&N>]9DU:=UWK+F[TP*SU
M&>M.>HCUH &ZTC4M% #*C8U(U0-0 ;J4=*:M3*O% %:X^Z:YK6)]@:NGNA\I
MKC/$#E5:F@.-US4O++<URDVN'>>?UJWXDN"I?FN%N+QO,/-(#O=-U@NX^:O0
MO#USYNWFO%=%NBTJ\UZWX3DW!* /2;%=T:TZZC^4T[35_=K4EY]TU2).?N(_
MFJ*$8>K5RM01+\],1O:;VKK-// KDM._AKJK'[HH VHVXIQYJ*+M4XZ4 1>7
M2[=M2[13'H 16]ZE0U7J:.@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "E6DI5IH!PHI#29-0P)%[5,E0K4J4QDRT]0*8E2+0@+=OUK7
ML^U9%OUK9L^U(#7M^@JVM58.E61WI @6G4U:=0-!1110,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9L^U &Q#]VK([U6A^[5D=Z!H%IU-6G4#04444#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **3=2T %%%% !1110 4444
M%%%% !4,E35#)0!2F[UEW/>M2;O69<J>: ,2\[UC77>MF\4\UBW?>D!D71ZU
MEW!ZUI71ZUES=33 J25%4S*>:9B@!N*:U*S 5"\U "-3%ZTQIO>FK)DT 6HS
MTJ7=\M5XS4W\- %&^;Y37#^(>C5V][]TUP_B+HU 'EWB+JU<9,/WE=EXA_BK
MCY/]8: -?15_>+7JWA5>$KRW11^\7ZUZMX5'"<4 >C::O[L?2K%S]VH=-^X*
MGNONU2),F;K2V_WJ;-UJ2W^\*; W]-7I716B\"N?TWM71VO04A%Q>E.S3:*
M)%:I5J!:G2EU&.HHHK3H(****D HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "E6DI5H&*W2FTYNE-J6(E3K4Z=J@3K4Z=J0$E.6FTY: +MMVK9L
M^U8UJ.E;5GVH&:\/W:LCO5:#[M6?6@ 6G4U:=0-!1110,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4U:=0)!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/:KD?:I&2+3J:M.H$@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(W]/[5T-KT%<]I_:NAM>@H N4C4M(U ,='VJPO:J\?:K"]J!(=1110,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '+VJ9*A7M4R5
M#&2T44$T""IXNU0 U/#UH&:-OVK3M^U9EOVK3M^U4QHT8:N1]JIPU<C[5(R1
M:=35IU D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTWM716GW:P-/7I706J_+0!:HI=M)0#'Q]JL+VJO'VJPM D.HIVVD- Q****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '+VJ9*B5:F6I
M8R2G#I31TIR]*$(6IHZB'-31K5#+EOTK4MNU9MNO3BM.W%(:-&'M5R/M5.'M
M5R/M4C)%IU-6G4"04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM/["F-UH$Q\?:IZ@C[5.O:@2"G+THVTM PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I5ZTE*O6@!ZU*M1+4JU+ D7I3EIJ]*<M" <M6(
MJKK5B*J OV_:M&"LZW[5HP4F-&A#5R/M5.&KD?:I*)%IU-6G4"04444#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:]]YJYR,?O?QKH]?^\U<Y&?WM4!U?A]?WBUZUX77Y5KR?P]]]?K7K?AC[JT
M=[8_ZL?2BZZ&EL_]6*2[Z52$S,D^]4MK]X5%)]ZI;7[PIDG0:?VK?M6^45@:
M?VK>M?NB@"W3&ZTZFMUH$Q\?:K"]JKQ]JL+VH!#J***!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2KUI*5>M #UJ5:B6I5J6!(O2G+3
M5Z4Y:$ Y:L1576K$54!?M^U:,%9UOVK1@I,:-"&KD?:J<-7(^U242+3J:M.H
M$@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% "-4;5(U1M0 UJADJ9JADIH"E<=*R+SO6
MO<=*R+SO38D8MW6/<=ZV+NL>X[U#&9EQWJC)U-7KCO5&3J:D"!N]1M4C=ZB:
MJ0$;5&W>GO4;4P&-TIM.:HZ 'KUI6Z4U>U/;[M &7J/W37G_ (D^Z]>@:C]T
MUY_XD^Z](#RS7_O-7-1_ZVNEU[[S5SD?^M_&F!UGAW[ZUZ[X7^ZM>1^'OOK]
M:]<\+_=6HOJ!W]E_JQ3;OI3K/_5BF770UJA,S)/O5+;?>%12?>J6V^\*9)T&
MG5T%M]T5S^G5T%M]T4#+/84QNM/["F-UH$Q\?:K"]JKQ]JL+VH$AU%%% PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I5ZTE*O6@!ZU*M
M1+4JU+ D7I3EIJ]*<M" <M6(JKK5B*J OV_:M&"LZW[5HP4F-&A#5R/M5.&K
MD?:I*)%IU-6G4"04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBD)H 6BDW4;J %HHHH **** $:HVJ1NE1M0 UJ
MADJ5FJ&1J *=QTK(O.]:UQTK)O.],#$NNIK(N.]:UTW)K*F'6I8&7<=ZHR=Z
MU)H\YJE-'468%%N]1-4\RXJL[540&/4+=ZE/S4UEJP(6IM/9:92 <O:G-]VD
M44]E^7I0!DZA]TUP'B3[KUW^H\*:\]\3/@-2 \OU[[S5SD?^M_&MW7I/F:N?
M@;,OXTP.P\/_ 'U^M>M^%_NI7E'AQ,NM>N>&8\*M '=V7^K%-O.]+:?+&*9>
M-UH$9LGWJEMOO"H7/S58LURPJR3>TZN@MONBL/3UX%;MO]V@98["F-UI])B@
M3%C[587M4*+4RCI0 ZBBG!: &T4[;[4;?:@!M%.V^U&WVH ;13MOM1M]J &T
M4[;[4;?:@!M%.V^U&WVH ;13MOM1M]J &T4[;[4;?:@!M%.V^U&WVH ;13MO
MM1M]J &TY1THV^U*!TH >JTZFJU.'-2QCZD6H\5(M"$.7K5B.JZ]:L1]:H$7
M[?M6C!6=;]JTH%Z4F-%Z&K<?2JL2U:C'%243+3J:M.H$@HHHH&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ $H
M!YIK4+0!+12+TI: "BBB@!&Z5&U2-TJ-J (VZ5!(:G?O56:@"M-WK*O!UK3E
M-9UR,YH P+NLN8\UL7J=:QKC@T 5Y*J35))+5623- %2XJA(W6KTWS53DCH
M8K=*5FI-N*:S&@!C-4?\5.:D H >M2-]VHUITGW:0&3J1^5J\W\5-]ZO1M2^
MXU>;^*NCTP/*->;YVK%M?]:/K6SKWWFK'L_];^-,#O?#*_,M>N>'5PJUY/X9
M^\M>M>'_ +JT,#KX&_=BH;INM.A^Y4=QWH0F46'S5>LEPPJG_%5ZS^\*T).A
ML!P*V816/I_:MN#I4C'TM*>E(*!$B+TJ85$E2T %2+4=2+0 M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %(U+2-28 M2K42U(O:I E7I3
MEZ4Q:D% "K5B+K5=:LQ=:L6Q?M^U:=NO2LZW%:=OVI"N78^@JU'VJM%VJS'V
MJ31$BTZFK3J 04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5L2+3J:M.I @HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[4UNM.7M0 ^FM3J:U #/XJ>M,_BIZT .HHHH 1JA:IFJ!J (7JM+5EZKR=*
M*$PK.N.]:<W>LNZ[T 9-T>M8]QWK6O.]8]UWH S+C[QJKMJS-WJO2N *M(RT
MN::S>],!K57E:GR/569Z &.W6FJ:8S=>:5:=@)@>*CF;Y33J@N&XZT@,35&^
M4UYSXG;[]>@ZHWRGFO.?$S?>YH \VU8_O&JOIO\ K14VK?ZP_6H-+_U@H ]&
M\,_>6O4=#^XM>6^&^JUZCH7W!0!TL?W:@GJ:/[HJ*X[U2$RI_%5NV^\*J?Q5
M;MOO"F2=!I_:MVW^Z*PM/[5O6_W10,D:FU(U,;K0(<E2U$O:I: "I%J.I%H
M6BBB@ HHHH **** "BBB@ I:2G+0 E%.HH ;13J* &T4ZB@!M%.HH ;0.M.I
M5ZT *M2+VIJU(* "BBB@!RU;A[546K4/:@9I6_:M.'I67;]16I;]*D1=C[5.
MO:HHZG7I2'<<M.IJTZ@:"BBB@84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !2'FEHH CVTY124Y: %IK4ZFM0 S^*GK3/XJ>M #J***
M$:H6J9JA:@""2J-P>M7I*HW/>@"A,W6J%P>M79AR:HS4 9=TO6L>X7K6W<+U
MK)NEP: ,F5>:KXJW,.:KT#&XIK+3Z1J2T)17D6JTBU;:H9%IC*+K356K#KUI
MBK0 !:AN$^4U<5:BN%^6@#EM57Y6KSKQ-T:O2=67AJ\X\3+]Z@9YGJJ_O#QW
MJ#34_>"K>J+^\-1::O[P4"/0/#*\K7JF@I\BUYEX9CY6O5-"3Y%H&;T:_**K
MW QFKBK\M5+KO5(EE.KEJO(XJHHYJ_:KR*8C;T]>G%;MO]VL:Q7I6S!]VI;
ME9>*;4C4PBF Y*EVU&@J84"$VTY5XI*<O2F FVC;3J* &[:-M.HH ;MHVTZB
M@!NVC;3J* &[:44M% !1110 4444 %%%% !1110 49HIK=: '9S3E%,6IE[4
M .48I1S24JT /1:N0+TJM'VJW#TIW T+?C%:$-9UOVK1AI,5R]'VS4U11U+4
M%7%6G4U:=0-!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4U^E.IK]* ("W-/C:HVZTZ.@">EI%I: "BBB@ HHHH 0U&U2-TJ-J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &U+'TJ*I8Z0#WJ/^*I&Z5'_ !4F,E3M4RU"G:IEJN@A:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ****3 5:6D6EJ0'T4453 <M6[?M5
M1:MV_:I U+:M*WZ5FVU:5OTH OQ]JE7I44?:I5Z4%CEIU-6G4"04444#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 1NE,:GMTIC4 -IZ]J93U[4 .:H6J5J@?K0!#+WJC<#(-79.]5)ONT
M"ZF3<1UDWB]:V[@=:R;Q?E- SF[Y>O%8DZ_-6]?]ZPK@X8TP($49JW$@JEY@
M6IX[@4@+$D8VUDWZCFKTEQ\M95]/G- &%?8R:SU^]5J\DRQJI'R] &G9]JV+
M?I639KTK8MP,4 2-TJI=?=-7&Z51O#\M '+ZTWRM7F'BAOO<UZ5K3?*U>8^)
MOXJ //;[_6&M'0?]8*S[[_6&M/01^\% 'J?AG^&O1],_U:_2O.?#/\%>C:;]
MP4 :+52GJZW2JDP%4A,K1?>%;VE]JQ(5&ZMW31TIDG3V7W15[^&J5G]T5=_A
MH ;4L=15+'0 ]NE1_P 52-TJ/^*I8R5.U3+4*=JF6JZ"%HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHI,!5I:1:6I ?1115,!RU;M^U
M5%JW;]JD#4MJTK?I6;;5I6_2@"_'VJ5>E11]JE7I06.6G4U:=0)!1110,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,J6.HR*<C4[ 2MTJ/\ BJ3[U&VH8Q4[5,M1+Q4BFJ$.HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHI=M)C$%.Q1BBI$.VTX+24X53&*
MM6H:K**M0K4"-&UK4M^E9MJM:ENM4!=C[5*O2HH^U2KTI%CEIU-6G4"04444
M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $/2HV:I&Z5"WWJ '*U2U M34 !Z4QJ?3&H ;2BDHH >II6%-6G-]V@"C=<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5)5"("O-/CI#3EI#'T444Q!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%%)@%/6F4]:D"1:<M-6G+30#UJU#55:M0U8S3MZTK?M6;;UI6_:D(
MN1]JE7I44=2KTJ64.6G4U:=2!!1110,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&I:1J (VZTY>U
M-;K3E[4 /IK4ZFM0 S^*GK3/XJ>M #J*** $:H6J9JA:@"&;I6-?=#6S-6/?
M=#0!SEZO)K'N%ZUN7BY-9<\><U(&--'UJC)'6S-#5.2&J SMM/5:F:/%,/%
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M @HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9EOTK3M^U!9<C[5*O2HH^U2KTJ6/H.6G4U:=2!!1110,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 93EIM.6@!::U.IK4
M ,I5I&ZTE $@:EJ/-.7M0 YJA:IZC:@"M/\ =K U+[IK>N/NFL+4.])@<Q>?
M>K/D:M.\7YC69**BXB/=3E:FTY:7,%RQ&U3I(*H;L&G>::T3&:7F"H9)!5,W
M!IC3&F%RQ(PJM)2>::;NIV)N1,M-V5+118"+;3UHHIV%<>*?Q4.XTNZDT',3
M<49%0[J3=68KDI--ZTU2:<.:5Q\PZG+3:!6D0)T J5<#%0*U2;JT&3*W-/S5
M=6YIX:@1+2=S2;J=4#$QTI:*<M.X"TZBEH ****8@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBA>M(!0*>HH6GBE8 6GKTIM*M,9(O:K,/:J
MZ]15N&F0R_;]*T[?M6?;]*T8:11;C[5*O2F1]JF7I2+$6G4U:=2$@HHHH&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,I
MRTFVE% "TUJ=36H 8W6DI6ZTE !3U[4RGKVH ?435+434 5I_NFL2_[UMS?=
MK$OA28'.7@Y-9DJUK7B\FLJ:L["(***!S5<HK!UHP:=MH.*I(9$RG%1LIS4K
M-3#6@A%6BG+1BF VBE(Q32:8"&DI:2F381J2G48%9, I<4E/I6!B 4N:*4"I
ML(6BG;:2M$AH>O:GKUIB]J>M,8]:>O2F+3UZ4 /7M4BU&O:I!28Q6I!030*D
MHD'2EI!2TT2%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MH7K12J* 'K3Z:HIU "TJTE*M $L?:K<-5(^U6X: -*WZ"M&&LZW[5HPTF!=C
MJ7-11U)4C%6G4U:=0-!1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M93EHL5RC@,TM"@TM+E&+NI***&%AZ]J>M,7K3UI /6GKTIBT]>E #Z?3*?2
M*<M-I5J2D2T444T)A1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *<O:FTY>U $BTZFK3J "E6DI5H D0U;@-4UJW;]J -2W[5HPUG6]:,-
M)C+D9J6H8^U2K4B'+3J:M.H*04444#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "D-+2-0 FZG4RG4 +1110 4444
M %%%% !36IU-:@!C=:2E;K24 %.6FT]>U "[33&J6HF:@"M/]TUB7W>MN;H:
MQ+_O30'/79P369,:TKP]:RIFJAHBI*6DH!C@M(R]:<M!%220,:;NJ1EJ+I3$
MQZC-+MIJM2L:-21****5RK"9IC4YJ:1WJD5L"T\5&.M.#58A].IHIR]*H8[K
M2@8I%Z4Y:T6P"5'@U*13*RD)CEJ1:8O6GK69(]:>O2F+3UZ4 /IRTVGU+&%.
M6FTY:D:)****I"844450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "A>M%"]: )%I],6GT +2K24JT 2Q]JMPU4C[5;AH&:5OVK1AK.M^U:,-)
MB+L=25''4E2 JTZFK3J"D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **0FD#4 .HHINZ@!U%(*": %HINZG4 ,;O4#')J=N]0-UIDBKUJ=:K*>:
ML(U(H<W2HFJ5NE1-0 S:*5:*510 X4C-2[:8QI,"I?-\IKB/$$GRM79W[?*:
MX3Q$_P KURU7H93//->D^9JX35I/O5V.NR?,U<1JC=:\6I,X),YV\.2:SF7Y
MJOW7>J3=:Y)3,'(:(J=Y(IZFG%N*Y9U#&4BNT8%0NM6'>H'85R^T9/,0,:A;
M+5,W-)MJ?:"YB#R\TJQE:LJHIQ45K&9?,1)(8ZM0Z@4[U4E6JSY6NB,S12.E
MMM:*_P 5;VG^(,8^:O.!,RGK5RVOV4CFNVG,V4CV;2_$&<?-76Z?K(<#FO#M
M-U@J5YKL=)UL_+\U=T9W-HL]<@O!(HYJ<?/7(:7J@8#FNFLK@.!S79"1LF66
MCII7%6.&%0R5V1=S>(BT\=*C7K4BULBAP/-.IJT_;5C'+3UIJTY:3 D2GTQ*
M?4 PHHHIQ$%%%%6(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
M7K10O6@"1:?3%I] "TJTE*M $L?:K<-5(^U6X:!FE;]JT8:SK?M6C#28B['4
ME1QU)4@*M.IJTZ@I!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!K4#K3J* "F4^B@!!TH:EHH ;3J** &-WJ!JG:H&ZTR4(E3IVJ!*G3M2*'MT
MJ)ZE;I43T -IR]J;3E[4P'U"YZU*W2H)*SD!0U!OD-<#XC;Y7KNM1;Y#7 >)
M&X:N.ML8U-CS;7'^9JXO4FY-==KK?,U<;J'>O!J,\N3U,2YYS5%NM:$RYS55
MHZX92.=R(,TUY.*?(N*IS/MSS7%.1DV$DU0&;FJT]QC/-5&NL-UKE<F9\QJK
M)FGJU9<=U[U:CFW=ZCF'<N;\4>94.XTF>:M38[DS?-4<D6ZE5O6IU 85TTZA
M:D9\D)J+:5K6:$'M56:'%>A3F;IC;6X*D5T6EZB5(YKEBVRK=G=;".:]"$C>
M,CU/1M5^[S7<Z3J6X#FO&=+U+:PYKN-%U7I\U=D9'0F>HV]T&4<U*S;JY[3+
M[S .:W86WXKT*4CJ@/IZT%<4+UKIN:L>M25&M2+VK5"'4Y:2G4,$/6GU&M24
M#84444(D****H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "A>M
M%"]: )%I],6GT +2K24JT 2Q]JMPU4C[5;AH&:5OVK1AK.M^U:,-)B+L=25'
M'4E2 JTZFK3J"D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?:K<- S2M^U:,-9UOVK1AI,1=CJ2HXZDJ0%6G4U:=04@HHHH&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN-34NTTR.I:DJPU:=35IU (****!A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ0%6G4U:=04@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4+VIU:(8VI%J.GK3$.HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *?3*?0 ZE6DI5H EC[5=M^U4H^U7;?M0!J6W:K\=4+;M5^.DP
M+4?:GTR/M3ZD!5IU-6G4%(****!A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "4QJ?3&H %J2HUJ2@!&Z5$U2MTJ)J &T4
M44 2QT2?=HCHD^[0!E7W0USE\O6NDON]<Y?=Z ,.XX)JFTF*M73<FLZ9C4N0
MFB59O>IUD#5F;SNJ:.2L9*YDT6Y%#>]4IK4-GBK2R9I>#6$J=R;&/-IX;M5=
MM+'I6^5%,\L5E[$S:,'^QP>U']A@_P -=''"O'%3K"F*KV)-CE?[% _AJ:'2
MPAZ5T;0KVJ!HPM;1HA8K6MHJ8XK1C55Q53S M1M=;:W5&QK&)J><JU!+<"LU
MKL^M-\\MWK90+Y2>:3<:K'+5(N6J18JJQO%$2(:M1+2+'BI%XJ#2Q(J\4UJ-
MU)4[DR04"BBJ()%J05$IJ44$CJ6DIVV@0JFI-U1XXI=U QU2+48[5(M- +11
M15""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "GTRGT .I
M5I*5: )8^U7;?M5*/M5VW[4 :EMVJ_'5"V[5?CI,"U'VI],C[4^I 5:=35IU
M!2"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 E,:GTQJ !:DJ-:DH 1NE1-4K=*B:@!M HH7K0!*E$GW32+1+]TT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 E,:GTQJ !:DJ-:DH 1NE1-4K=*B:@"*GI3*>E $RU'-T
M-2+4<W0T 8M^W6N:U!N3727_ $-<U?C)-"!F-,WS5!4TWWC4-40@I>*2BF/<
M0TE*U)0 4UJ=36ZU+ 2BBBF1U"BBBJ&PIR]*;3EJ&,6E6DHI[E(DR*0TE%,D
M**** ';J>*CJ1:!DBT]:8M/6@0[%&*5:5NE2P&TJTE*M-C)56G4BTM2(*>M,
MIZU8#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G
MTRGT .I5I*5: )8^U7;?M5*/M5VW[4 :EMVJ_'5"V[5?CI,"U'VI],C[4^I
M5:=35IU!2"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *?3*?0 ZE6DI5H
MEC[5=M^U4H^U7;?M0!J6W:K\=4+;M5^.DP+4?:GTR/M3ZD!5IU-6G4%(****
M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I
MC4^F-0 +4E1K4E "-TJ)JE;I434 14]*93TH F6HYNAJ1:CFZ&@#&O\ O7-:
MAU-=+J'W37,7_>J0&/-]ZJ]3S#YJB/2F0-HHHH 1J2E:DH *:W6G4UNM2QB4
M444R>H4444P84Y>E-IR]*GJ4+1115"'4444 %+24M #J=3:=0!(M2+VJ-:>M
M R2FT45+ *5:2E6FQ$B]J?3%[4^I *>M,IZU8#J*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "GTRGT .I5I*5: )8^U7;?M5*/M5V
MW[4 :EMVJ_'5"V[5?CI,"U'VI],C[4^I 5:=35IU!2"BBB@84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 (W2H6'-3-TJ%OO4 "#FIA4*U-0 4QJ?3&H ;3U[4RGKVH =56Y^Z
M:M55N/NF@##OAUK O!UK?ON]8-YWH RI?O5"W>IIOO5 W>J1 VFMUIU-;K3
M:U-;I3FIK=* &T444 %%%% !1110)A3EZ4VG+TJ>I0M%%%4(=1110 4444 2
M+UIZTQ>M/6@!:***0"K4N:B6I*$ ]>U2"HU[5(O6B0QU)2T4D(0-4B5&%YJ5
M>E"&+1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %6
MI*C%/W4 +2K24JT 2Q]JNV_:J4?:KMOVH U+;M5^.J%MVJ_'28%J/M3Z9'VI
M]2 JTZFK3J"D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW7I0!HVR]*T(U]JI6JUHQKQ28R55XIU%%2(5:=35IU!2"BBB@84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E1-WJ6HF[T
M -J1:CJ1: 'MTJ)ZE;I43T -IR]J;3E[4 /JK<?=-6JJW'2@#"U#[IKF[X]:
MZ34/NFN:O^]" R)C\U15)-]ZHZL2"BBB@84444 %%%% !1110 4444$2"G+T
MIM.7I4]1BT4450AU%%% !1110!(M3+4*U,M $E(>E%+0 RBG-TIM #EIRTU:
M<M)C'K4JU$M2K0@'KTI:1>E+3$%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %*M)2K0 Y>M.IJ]:=0 ^E6DI5H FCJ_;]JH1U>M^U &M:]
M*T(Q6?:5HQTF,DHIW\--J0%6G4U:=0-!1110,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 2HF[U+43=Z &U(M1U(M #VZ
M5$]2MTJ)Z &TY>U-IR]J 'U5N/NFK55;C[IH P]0Z&N:OAUKI;_O7-WW>A 8
MTP^:HJEF^]456 4444 %%%% !1110 4444 %%%%!FPIR]*;3EZ5/4H6BBBJ$
M.HHHH **** )%J9:A6IEH 6C)HHH 7-)110 X4HI!TI1292)%J1>U1K4B]J
M8^G4RGTR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I5I
M*5: '+UIU-7K3J 'TJTE*M $T=7[?M5".K]OVH U;7I6A&:S[7[M7XZ3&344
M45(A5IU-6G4%(****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% "5$W>I:B;O0 VI%J.I%H >W2HGJ5NE1/0 VG+VIM.7
MM0 ^JMQ]TU:JK<?=- &'?]ZYN^[UTE_WKF[[O0@,:;[U15+-]ZHJL HHHH *
M*** "BBB@ HHHH ****#-A3EZ4VG+TJ>I0M%%%4(=1110 4444 2+4RU"M3+
M0 M%%% !1110 X=*<M-I:3&B1:D%0KVJ=:$#'8-.HHIB"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "E6DI5H <O6G4U>M.H ?2K24JT 3
M1U?M^U4(ZOV_:@#5M?NU?CJA:_=J_'28R:BBBI$*M.IJTZ@I!1110,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2HF[U+
M43=Z &U(M1U(M #VZ5$]2MTJ)Z &TY>U-IR]J 'U5N/NFK55;C[IH P[_O7-
MWW>NDO\ O7-WW>A 8TWWJBJ6;[U158!1110 4444 %%%% !1110 4444&;"G
M+TIM.7I4]2A:***H0ZBBB@ HHHH D6IEJ%:F6@!:*** "BBB@!PZ4Y::O2G+
M28T/6I5J):E6@;)****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4JTE*M #EZTZFKUIU #Z5:2E6@":.K]OVJA'5^W[4 :MK]VK\=4
M+7[M7XZ3&34445(A5IU-6G4%(****!A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4B%6G4U:=04@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 (W2HF[U*W2HF[T *O:I*C7M4E  W2HFJ5NE1-0 VG+V
MIM.7M0 YNE4[G[IJXW2J=U]TT 8=_P!ZYR][UT-_WKG;S[QH0&5-]ZH:FFZF
MH:L HHHH **** "BBB@ HHHH ****#-A3EZ4VG+TJ>I0M%%%4(=1110 4444
M 2+4RU"M3+0 M%%% !3Z93Z '+VJ1>M1KVJ1>M)C'4JTE*M"$/7I2TB]*6F
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4JTE*M #EZTZ
MFKUIU #Z5:2E6@":.K]OVJA'5^W[4 :MK]VK\=4+7[M7XZ3&34445(A5IU-6
MG4%(****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C=*B
M;O4K=*B;O0 J]JDJ->U24 #=*B:I6Z5$U #:<O:FTY>U #FZ53NONFKC=*IW
M7W30!@ZAWKG;P?,:Z+4.]<[>?>-"W R9AR:BJ:;J:AJQ= HHHH!!1110,***
M* "BBB@ HHHH,V%.7I3:<O2IZE"T4450AU%%% !1110!(M3+4*U,M "T444
M%/IE/H <O:I%ZU&O:I%ZTF,=2K24JT(0]>E+2+TI:8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !2K24JT .7K3J:O6G4 /I5I*5: )HZ
MOV_:J$=7[?M0!JVOW:OQU0M?NU?CI,9-1114B%6G4U:=04@HHHH&%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJVOW:OQU0M?NU?CI,9-1114B%6G4U:=04@HHHH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 (W2HF[U*W2HF[T *O:I*C
M7M4E  W2HFJ5NE1-0 VE6DIZT )5.[/RFKI7BJ-Y]TU2$SG=0;K7.W3=:Z#4
M.]<[==32&4)#S3*<_6FU0@HHHH#H%%%%!'4****!A1110,****"6%.7I3:<O
M2IZE"T4450AU%%% !1110!(M3+4*U,M "T444 %/IE/H <O:I%ZU&O:I%ZTF
M,=2K24JT(0]>E+2+TI:8!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2K24JT .7K3J:O6G4 /I5I*5: )HZOV_:J$=7[?M0!JVOW:OQU0
MM?NU?CI,9-1114B%6G4U:=04@HHHH&%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !2$TM-:@ W4ZFTZ@ HHHH **** "BBB@ HHHH
M **** "BBB@ HI*-U "T444 %%%% !1110 4444 %%%% !1110 44E&Z@!:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** $;I43&I6Z5"WWJ %4U+4*
MU-0 -TJ)JE;I434 -IZTRG+VH >>E4+Q?E-7S5"\;Y35(3.;U+O7.774UT>I
M'K7.774T=1F>_6FTYSS3:8!2[:2G+TH$Q",4E*U)01U"BBB@84444#"BBB@E
MA3EZ4VG+TJ>I0M%%%4(=1110 4444 2+4RU"M3+0 M%%% !3Z93Z '+VJ1>M
M1KVJ1>M)C'4JTE*M"$/7I2TB]*6F 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4JTE*M #EZTZFKUIU #Z5:2E6@":.K]OVJA'5^W[4 :
MMK]VK\=4+7[M7XZ3&34445(A5IU-6G4%(****!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU4(ZOV_:@#5M?NU?CJA:_=J_'28R:BBBI$*M.IJTZ@I!1110,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4#'+TH:A>E#4#&T444$L*<O2FTY>E3U*%HHHJA#J*** "BBB@9(M3+4*U,M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYI5H 510W:EI&H :QI ,BF_Q5(M ";:<JTN!2T 1R_=K)OFZUK3=*Q;\]:I
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M)ZBK3J:M.H*04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% "&DVTZB@!*6BB@!I:DW>](YJ(M0!/NI>#4"OS4JMQ0 ,*B8BGR254EF
M'/- $V^G[Q6<UP/6D-X/6@#0>8#O5:6Y [U1EONO-4;B^Z\T 7YKP#O5<WO/
M6L:XOO>JK7W/6@#I5O?>IX[S/>N7COO>K<-][T#.GCN0>]6HY@:YJ&^]ZOPW
MF<<T"-M9,T[=6?%<9[U923- $^*"M"M3CTH 8!3Z;2[J '44W=1NH =2;12;
MJ-U "[132O-+NI*  +05XZ4JTIZ4 1[?:C;[4ZB@!5%.I%Z4M "&DVTZB@!!
M2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %(U+2-0!&W6G+VIA/-/6@!],>GTQZ (_P"*I$J/^*I$H ?1110!
M'-TK$O\ O6W-TK$O^] '-ZAWK$F^]6WJ'>L2;[U-"94>FTYZ;5$A1110 444
M4 %%%% #6ZT+UH;K0O6@GJ.HHHH-$%%%% @I5I*5:"6.%.IHIU HBKUIU-7K
M3J"QZ]:D6HUZU(M A:*** "BBB@!R]*<M-7I3EI,:'K4JU$M2K0-DE%%%,D*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %6I*C6I*
M 'TJTE*M $\?45HV_:LZ/J*T;?M0+J:D/:KD?:J</:KD?:DRT3+TI:1>E+4B
M8JTZFK3J!H****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1124 ,D%0,IJTW(J/90! H-2[L+1MILORK0!7GFV
MYK+N+S;GFIKZ;;GFN;OK[;GF@"[-J&WO55M4Q_%7/W>J;?XJSGU;G[U '5OJ
M6[/-59;[/>N>74MW>AK_ (ZT :<UUGO5<W%9SWHYYIBW8/>@#9CN:L1WGO6*
MMQZ5(L_O0(Z"&^]ZT+:^Z<URL5P>.:O6]V1B@9V5M=[N]:4$^<<UR5G>=.:V
MK6ZZ<T =!&^<5.O(K,AN!5E;H>M %LC%,W>]0-=#UIC7 H L[O>ES[U4^T"E
M6X% %K)HR:K><*/.% %G)I*K^<*<LPH LJ*&%1+,/6E\S- "TY>E1[J<"<4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU4X>U7(^U)EHF7I2TB]*6I$Q5IU-6G4#04444#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 A.*-U(U)0 [=2U'D4_- "TAI:* &E:;M%244
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M1+<"E^T5A+?>]+]NJ;E&Y]HI&N*Q?MOO2&\]Z -G[1[TGG<]:QOMGO3UN^E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 )C-(R\4ZDH 9MHVT_;2;: %7UI:04M !1110
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M7=0(DHI U+0 44M&V@!ZU.HJ%14ZTT $8I*4\]*55J@!5IVV@"EH ;2K1@T
M4AHD45*HJ)34JFA#8^BBBF2%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "K4E,4&GT /I5INZE5N: +$?45HV_:LZ+YC6E;KTH%U-
M.'M5R/M52$'BK:4F6B9>E+2 TM2)BK3J:M.H&@HHHH&%%%% !1110 4444 %
M%%% !1110 4444 ,;O3*>W>F4 %%%+0 W'-*%IZK3MM $>TT;34FVC;0!'M-
M&*DVTC+0 REW4UJC+4 3[Z<&JON-2*: ):*1>E+0 F:9NH:HRV* ):"*8K=*
MD!&* &$8I*D.*8W>@!NZG*U,P:-IH DW4;J8 <TZ@!U(12T[% $3+2;:D8"D
MVT ,VTX+TI=M/XH 1:=110 4444 %%%% !1110 4444 %%%% !29%%-H =2T
MBTM !29%#=*;0 [(I:93EZ4 +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ=0 FVC;3J* &4%J#Q43-0 YFHW5"6YI5:@";=2[JCS3Z 'BG4U:=0 4444
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M\PI7 KR=33%7FD9Z='R:0$\:UJ6:]*I6Z9K5LXZH#7LUZ5I1]!5&U7I5]>E
M#J:U.IK4 ,I5I.].5: '=J#THH;I0!3NONFN>U+O6_=-\M<]J3=: .:OC\QK
M'F;FM6^8[C61+]XT 1TZFTZ@@?3EZ4VG+TH 6G+3:<M T+36IU-:@;$HHHH)
M%7K3J:O6G52$QK=:2E;K25(PHHHH =3UZ4T=J>HH 5:<O6A5IRKS0 +UJ1>E
M-Q3Z:&.6G+35IRU0"T444""BBBDQH>O:I%J->U2+4C9)1115DA1110 4444
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MI%J1LDHHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM^M75JE;]:NK2*0M%%% Q5J1>E1K4B]* %HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2K24JT /6EI%I:
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M+S.>:YZZD+$U117NKDL:HNQ:K#1EC2K!FI$00QDM6C!$,4Q8=M2-)Y= B9E
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MS0JTH&:>JT@$5:=1TII:@!=M&VF[J<&H 4<4M-W4;J '44W=2[J %I&I::U
M",U-R:5J;0 ZG;:;NIX- ";:-M.HH ;MHVTZB@!NTTC+3Z0\T 1[:=2[:-M
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M<'M5J.'@4@*RP^U2K#TJTL-/\JE<966*IEBJ40U-'%5"(EAJ58/:K"15.L5
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M /6EI%I: "E7K24J]: +,7:M*V[5FQ=JTK;M4L#6M^M75JE;]:NK2*0M%%%
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M6'VI_EU0$*QU*L=2+'4RQT; 1K'4BQ5*L=2+'0 Q(ZF5*-N*<M #MM&VEHH
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MWZU=6J5OUJZM(I"T444#%6I%Z5&M2+TH 6BBB@ HHHH **** "BBB@ HHHH
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M:I8&M;]:NK5*WZU=6D4A:***!BK4B]*C6I%Z4 +1110 4444 %%%% !1110
M4444 %%%% !1110 C4QNE/IK4 -7K3J94BT 5;A.*Q[R+K6],O!K*NH^M '/
M3Q\U4DRM:ES'UK/F3K0!GW#\5C7LG6M:Z7K6%?-R:8&;._S5"KT3-\U5P],1
M?26DFE^6JRR4DK\4R3/U"3@UR^H-R>:Z"^;K7-W[=:!F-<'K54&IKANM55;F
M@1>A-7(FZ5GP/5Z'M0-&K:'I6S;OM%8EL<5I1R4A"ZI<;8SS7EWBZ\.'YKT+
M59,QFO,?%2EM],#RGQ%?-YC<UR4]XV[K75ZY:%I#QWKFI-.);I0!>TBX9G7F
MN^T-N%-<5I-@59>*[734\E!30SK+>]$*CFI&\0^6,;JY>\U'RE/-<Y>:X=Q^
M:AB.^FUWSN-U363B9P:\^L=4,D@YKM=#FW;32&=SIJ!5%7KFX"QUDVMT$C'-
M5[[5 %(S4%%75IM['FN9N+,S,>*TY[P2MUJW868F8<4 96GZ'N<<5U5CI7E(
M.*T]/TD* =M7IH1#'0!S.I+Y<9KAM8D+,:[;69AR*XZ\A\YS5 <V;5II*V='
MT<LP.*T+#1S(PXKJM-T?RPIVU(#=.TT0Q XJKK$_D1GFNBD00PFN*\27'RL*
M0',:EK3)(0&JSH^M.SCYJYJ_5I)C6IH-HV]:H#V;P??-(R9->W^%OGC3->$^
M#83&R5[IX5<+&E.P'HNGQ#RQ4UP-JFHM/DS&*==M\IJ0,;4)MN>:Y^\N#SS6
MKJ+]:PI_F)H IR3,6J2%FS3E@W-5VWM.E $MJ6&*U89",54AA"BI2X2DT!H)
M-[U,DU8IO0O>E74@,<T@.ACDJ425@Q:D/6K*Z@".M4!HR3>]5I),U6:Z![TP
MS9H GJ16Q559*D$E("U]HVU&]Y[U6>6J\DE,#12]YZU:BOSZU@AZD28^M '2
MQZA[U8CO_>N92Y/'-3+>8[T =3'?>]6X[L''-<E'?>]78=0Z<T =7'.#WJ=9
M <5SL.H#UJY'?@XYH V=PHR*SDO >]3+<@T[ 6Z6JZS"I%DS2 4]Z8<T_.:0
MC- #03FG T;:0\4 .W>].R*AW4NZ@"7-&:C#4NZ@!]+4>ZES0 4Y:;3EZ4 %
M--./2FT -R:5:-M*.* "BBB@EA1110(***1J %HS3:=0 9HHHH *;3J92+&2
M57=:L/4$E420%::R5(W6D(S3N! 5I*E--ID" <4>7FEIRTP1$T(J-K<>E6OP
MHQFHO<LI-;#TJ%K45I%:C9:NPC,:U'-1/:BM-EZU&RTAF/+9 ]JJ/I_.<5O-
M'FFF$4@,1-/YZ59CL?:M-8/:I%AHN!G?8?:C[#[5JK#3O)JK$W,C["!VIRV?
MM6KY0H\KVJ;#,P6E.^R5H^5[4OETQE'[+[4?9\5H>72&.D(I+#2^35ORZ7RQ
M2L,J>53A'5G91LJK"&1QU.J=*55I]*X"8HI<FBBX"4Y:6BD,****H04X=*;2
MTP%:DI*6I =1113&%%%%0784=:=31UIU,F]AIH6D/6G 4Q7'+4@49J(5*M-E
M#MM%.7I0PJ  "@KQ2KTHH 9MI-M244 1[:7;3Z* &JM2*.E-I<T 2T4S-.'2
M@!&I*=C-&V@!:*** "F2?=I],DZ4 9UYWKGM0[UOWAZUSNH=Z ,"];K6/,QS
M6I>]ZR)OO&A"(=QIRU&U.JR27-.5C452+3L,D7M3Z8.U.#4A"T444 %"]:*5
M>M #A3MHIJ]:=0,:U%.IC=Z!BT4S-/H$.7M4BU'3EH$2K3EIB]J>M #J***
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MK5A=8"_Q4 =6]XJKUK-N]45<\USEUKP ^]7/:CXCVY^>@#J[C7%7/S52;Q
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MTI-M**8!1MI:3-( VBC;2;J-U "[:0C%+NI#S0(2BBB@D*0C-+10 FVEHHH
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MMI^VC;0,;MHVT[;1MH ;MHVT[;1MH ;MI-II^VC;0 ;:44M% !1110 4444
M%,DI],DH R[SO7/:AWKH;SO7/:AWI,#G+[O61-U-:]]WK(FZFA 5VIU-:G5J
M0.7I4BU&O2I%IL8_TIU-]*=4D]1U%%% PI5ZTE*O6@!R]:=35ZTZ@ IC=Z?3
M&[T#&T^F4^@;'4Y:;3EH)'KVJ1:C7M4BT .HHHH **** "GTRGT .7M4B]:C
M7M4B]:3&.I5I*5:$(>O2EI%Z4M, HHHH **** "BBB@ HHHH **** "BBB@
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M["J<FO-_$6JJF[FNB\2:J(T;YJ\=\5>( K/\U #-4U@%F^:L6340S=:Y2_\
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M10 4444 %%%% !1110 4444 %%%% !3)*?3)* ,N\[USVH=ZZ&\[USVH=Z3
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M4TMI\G2@#E[E=K4VVQN%7KZV*L>*J11E7J66;=FH*T^\ARAJ*S; JQ<-^[I
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M%2]J0#:*7&!24T""G 4FVE% !MI-M. IPS2"XS:*-HJ3;2[: !*E6D44\"D
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M.:=P,YK/VJ-K?%:;8J%@*$!0V%:-Q%6FCS3?)H; C65EJ>.X9>],\FCRR*E
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M :E#4ACE05)MZU$)!3O,I"%8\5&W-.9LTFVJ 8O6I5% 2G=*0!1C-)NI5:@
MV^U&VGTHYH 9LI0M2;:-M #.E.#4-3: )0U/S4"U,M "T444 %/IE/H <O:I
M%ZU&O:I%ZTF,=2K24JT(0]>E+2+TI:8!1110 4444 %(U+2-0 VBBBI8!3EI
MM.6J&+11FBD(****8!1110 4444 %%%%( I5'- 7-/6A .5:D I!2YI@6(>M
M:-OVK,CK1M^U2QFI!VJX@XJG;]JO1CY12$2 8I:7%)0 JTZFK3J"D%%%% PH
MHHH **** "BBB@ HHHH **** *])2T4 %%*M+B@"%JB:K##BHF7F@""D9?:I
M=M)MH K,E1,E7&2HVCYH JM'4,D=7FCJ&2.@1F21^U5FAZUIO%4+1>U4,S'A
MJI+%BM>2.J<T=,DRI%JK(.O%:$L=5)%H$4I!5:2KDBU5D6@"G)5>2K,BU6DX
MH A(I-V*1J9NI7 >TF*K2R9I9&JO(U4!'(<DU"PZT]FIM(!FSVJ-HZFHQ0!3
M>+K56:&M1EXJ"2/K0!B30U2FBQ6W+#5&XA]J ,AL@TZ-NE/FA^:FI&<T#)-U
M0O4Q0U#(M "* :M1Q[JJ1YK0MZ"A&M<KTJG-8[NU;(7*TC0@T <S)I>X]*EL
M])^?[M;ZVH8]*N6ED-PXH0$VBZ;MV\5U=O:A4'%4=/C$8%:ZL-M Q@&VI5N-
MN*KR257>0U-Q&DUYGO56XD,BU55S5B-=U &)J%CYJGBN-UK1-V[Y:]1:T#+T
MK$U330RGBF!X-K^C[-WRUY]JUJ8W;BO=_$VD_*W%>5>(--VR-Q0!P,D9W4]8
M3Z5H2V9$G2GK;=*0% 0X[4,I6M%K>H9+<^E,"EYA%'G&I9+<YZ5"T!I 'VBC
MS*9Y)H\LBA@6$^:IE6JZ\5,LG2@"18Q2M#31,!3_ #0:H"%[>H'MZO[@:'44
MF!EM#@TPQ'-7I%&:6&$.PJ0%L;,LPXKT'PGIA9TXK$T72_,9>*]5\'Z#ED^6
MJ2L!Z)X%TO;Y?%>Y^&[7RXEXKS[P?I/EJGRUZGI4/EQ#BF!K(XC6H)KKGK39
MI,+5!W)8T :"2;JL*U9\#U8\[%!):W5&S5!YU,:;K0!)(]4YFITDU5)9NM A
MDG.:K.N:D:2F%J (?+I&AXJR%IS1\4 9$T>,U6*FM>:'-4I(=O:@"INQ3EN-
MO>HYOEJE--MH U5O*GCO!7.&\V]Z?'J'O0!TZW&ZG;@U8,.H=.:NPWP/>@#1
M\L,:4VH-0Q70]:M+<*:8%:2VQVJ$PU?:0-4;**114V4;35C92&.IL,K%B*3>
M:F:*HFC- "K*:D6;WJ#RS13 M+-4Z35G;JF63%,#16?IS4JW'O67YU+Y_O5
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M;J-WO4>ZC=2L!)NHS46ZC=2 DS2[JBW4;J!$NZC=46ZC=189+NHW5%NHW46
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M%2P"BBBF 4444P"BBC(I %%&11D4 %%&11D4 %*O6DR*%;F@"1:?N-,4TZF
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M"L0.M5I.]:+QU4DBH&5E)S5N+-1QP$FM"WM>* (UC-7+=,&I([7VJS';XIW
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M$R=:M,M,9>M(DIM'43)BKC+[5%(M(HJ,<5$SD58D6H&6J$,\PYIPF-,*T;:
M)?,-+YE0[:7)I 6E:I5-55:I/-Q3L!<0BI1MK.^T;>].^V#UJ1EUHUJ&2 -4
M:W0..:D60-38BG/:@]JS+FS/I71;0U1O:ANU"&<E-8GTJ#["V[I77OIX/:HC
MIHSTI@<]#:E>U7([>M46(]*=]DQ2!&>L'M3O)%7O(]J:T-5<HHM"OI5>2!?2
MK\B&JLE C.F@'I5.6'K6G(M0-'G-0QF4\)J!K=O2MGR,]J=]E!J@,-8V6IDD
M9:TI+454DAQ0 Z*\9<<U?AOCQS6,RE:<LI6G<9U-OJ.,<UIV^I#UKBH[PKWJ
MQ'J17O2"YWD6H@]ZLQW@;O7#PZH?6M"WU3IS00SKEF#4_ALU@0ZEG'-7H[X'
MO0,T#&#3#!GM4<=T&[U824-BG8+D/V>G?9\8JQD4,PQ3)(-@6HF(J61JI32=
M:0MQS2"FB0&JCS&FK-S4LHT58&D==U0POG%7(UW4(10EM2W:LR\LV4=*ZR.U
M#57O; %>E,#SRZWQM3+>Y<-UK;U2QVD\5C>3L8T ;%E>'CFN@L;SIS7(0R;2
M*U[.YQCF@#M;.ZW=ZV;>7.*Y'3[C.*Z*SDW8JAFTARM#5%$WRTYFK-C&-3*5
MC4=-("96IX>JVZCS*&!,S4P]:9N]Z>*2&+MH\OFGJN:E5*=Q%?RZ-F*L%:8P
M%*XK#!Q3U85$[=:C\RF,LLU1EJB\S-&33$.IM%%*Y04445(!1112&%%%%4D(
M*!113)'9HR*;12N [(HR*;13N.P[(HR*;10%AV11D4VBBX6'9%.1N:CI5ZT7
M"Q8#<5'(>M"DXIK=Z0R)NM H:DJB256IXJ*G;J6XQ]12?=J0FHY.E C-O&ZU
MS>I=ZZ*\[USVH=Z8CGKG[U5U;FK5U]ZJ#-M:F@)V^85F7MF)5/%7UDJ3RPXH
M8'#:CH0DS\M<Y?>&QDG;7J\NGB3/%4+C10V>*11XQ>:&R9PM8MSILB=C7M-Y
MX=#9^6L.\\,@Y^6@1Y%+:2^AJI-82,.E>J3>%Q_=JNWA7/\ !^E CR?^QV9O
MNULZ5HI5E^6N]7PG\WW*T[+POL8?)2*L4O#^FE-O%>@Z5;[5'%4-.T?R<?+7
M1VEOLQ0278$^45=CP*KQKM6I=V*8R5FXJ%S09*86S0)C<<U+&M, YJ:.@2%5
M:4=:?MIA% Q<T^HAUJ1: %I5ZTE*O6@!U%%%2P'+VJ1>M1KVJ1>M/H,=1114
MB"GK3*>M6 ZBBB@ IE/IE !2-2TC4F E%%%2 ZD:EI&JQB4444""BBB@ I5I
M** '9IM%% !2J:2B@"56J3=5=3[T\-0!(:,9H7FI%6@"/%31D4QN*C\S;0!I
MPN!BKD,PK"6YQCFK$-U[T =);RCCFM"*3.*YNVNNG-:MO= ]Z -A:7%58IO>
MK"R9J"QU#4;J6@!M.HHH *3=034;-0!)FEJ,-3]U "T44E "T4F110 M%%%
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MU1-3$R,TE*U&,TR; !FC;3A10!$W>HFJ9NE1-3 C/6FM3CUIK4 ,VTNVEI]
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MP%2+,#WK":]]Z?'?<CFD!N?*U031BJD=[[TY[H&F,@F4!JJEOFJ6:7=5?/-
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M29%*K4#'XIU-5J7=0 M%*M+F@!13PU1[A1NH DW4NZHJ5>M $FZG;JCS3LT
M2[J6F"GKTH 6E5J3%% #]U,:G4[R\T 1KG=3UIZP^U/6*@!%[5(%I5BJ98Z
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MGE4C15,M!&:0RJ8Z9TJTRU"RTQ$=%.VBD:J 1NE,:G,:C9CQ2 ;3*&;K3"U
M#FJ-FH9JC9J0",W6HV:AC4;-1<!':H&:GNU5W:D I;YA4\#<BJ9;YA4\+=*
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M$,O'6E<"P1D5!,O!J=7XJ*;[M %%FP:M6?6J4A^:K=FWS"BPF='IZ]*Z"U7
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M-BQ7I6Y;<8K)LH^E;$ J2B_'TIS#-,CJ7&13*(&2F[:L,M,9:H@BVFBI-M%
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M!&JTZG4M AE%/HH"PRBGT4!8913Z* L,HI]% 6"BBB@84444 %%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:%I:* "BBB@ HHHH
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MU&Z@!:,BFECBF[J %W4;J9NHW4 /W4JU&#3UH DHHHH **** "BBB@ HHHH
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M=M&VG44 1M3:5C3=U "T4FZC=0 M%)NHW4 +12;J-U "T4FZC=0 M&T4 T4
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M &?TKT7^SD]*5M/3TH \X_X1G_9_2F_\(S_LUZ*U@N>E)_9JGM0!YW_PC/\
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MTM $-(<T_:*-M #,FC=3]M&V@!FZDYJ3;1MH :I-+NIP6C;[4 ,IM3;33=M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.G+0!)135IU !1110 4E+36H 7(I:93Z "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img148586500_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_6.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '+!0L# 2(  A$! Q$!_\0
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MW_B/\/?_ #L_J[\K?U8?\1&_@#_HUGQA_P"'0T7_ .8ZC_B(W\ ?]&L^,/\
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MW_B/\/?_ #L_J[\K?U8?\1&_@#_HUGQA_P"'0T7_ .8ZC_B(W\ ?]&L^,/\
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M?Y2?2,_Y//QK_P!?<D_]9K)@HHHK]&/Q(**** "BBB@ HHHH **** "BBB@
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M*ED>'R/+\"N$<-DLZDXYI@,5@L-0QV%K9+1P\HXJK7Q519A3=:GF?UN57F.
M^)7[/GQ>^$/@SX2_$+XB>$?^$>\'_'/P[>^*_A9J_P#;_AC5O^$IT#3TTE[R
M_P#[/T/6M3U31/)77=*/V7Q'9:1>R?:L16SF"Y$,7B;X!?%KP?\ !_X;?'SQ
M'X3_ +.^$WQ>U'Q-I/P[\5_V[X:N_P#A(=0\':KJ&B>([?\ L*QUFZ\2Z3_9
MVJ:7?6OFZYHVF07?D>=8275O+#+)^F__  4F_P"3,?\ @DO_ -F\^,__ $E^
M$U4?VG()K?\ X) ?\$V(YX98';X@?M(SJDT;QNT-S\3_ !U<VTP5PI,5Q;RQ
M3P2 ;)89(Y8RR.K'7!\3X_$8/AK$3I8-5,YXIS?),5&-.LHPPF7_ .LOL:F'
M3Q$I1Q$O[&POM9U)5:3]I7Y:4.>G[+FS/@/*,%F?'.#I8C,I4>&. .&^*L!.
MI6PSG5S'.?\ 47ZS0QDHX.$:F#A_K/F'U>E1CAZ\?8X3VF(J^SK_ %CYS\2_
M\$N/V\?!WA_XD^*O%/P!U#0O#?PCLKK4_'NN:AX[^%D&FZ5IECX9LO%]_J6G
M71\<&+Q1IVGZ!J$%SJ%]X4;7+6QNX[W2+N6'6-,U&PM+>B_\$J?V^_$.GC5]
M(_9\U"ZTEO"FB>-DU5O'WPHM=,F\.>(K*;4M*NK?4+SQW;VEQ>R6$!O+S1()
MI-=TJWEM)=5TVR6]LS/]6?\ !=OQ]XPN_P!NB[\.MXAU>'1/"/PD\)Z)H.F6
MNHWMO965AXMT^^U'Q.B6L=P( _B![]K36G2-#JFG6MA8WPN+>R@1;G_!9/XF
M^-[3Q-^Q/X L/$.IZ;X9\,_L;_"KQ_I%GIM]>6+0>*_%MSXH\-ZMJQ>VN(U:
MY_L;P?I-E:3!%GM87U"-)C%?3)7D99Q'Q?F6'X1DJG#E&KQ1@<7F$I/+,RJ4
M\!0PN#PV(C!0_MN$L54KSK).7M,/&C&HERUGAW+$_2Y[P3X;Y)C/$>FZ/&V)
MP_ &:9=D\(+/<BHU\WQ6/S+&X*59U?\ 5:K3R^CA:>&YE#V.-GBIT7+FPJQB
MIX+\]/V?/V$_VM/VI]'U+Q'\"?@OK_C;PYI-W_9]UXCN-6\+>#_#TE^JEYK#
M3M=\<Z]X:TG6+ZT4(U_9Z3>7MSIPGM3?16_VNU\[RKXW? #XR?LX>,W^'_QN
M^'^N_#SQ8MG#J$.G:PMI/;:AI\^1'J&CZSI=U?Z)KE@9%DMWO='U&^MHKN&X
MLY94NK>>&/\ HB_;0^'_ .S-/^S#^PS\#_'O[<M]^RY\,;3]GCP=XQTCP9HO
M[/\ \2?BYX=^+U_K.EZ'?W/Q UG7?AMJ6E>%[Z_35%N-4CL;J*ZN(=0UV[\0
MQB)-;M97^*_VY/C+^RUXS_89^!?P8\%_M9-^U?\ '3X)_%*]DTKQ_P"(O@Y\
M6OAQXI?X0^)M)\3'5O#@O_'.E:M;7,>E:S'X'@2*Y\8))=:5HEB(;,OI<,;7
MDW&F;YKCL!4CEU6IE>8YEC,%["CP[Q)"MEV%HSQ-+#9EB.(*U)Y%C*=2MAXQ
MQ6'H0H?55B(\N)KSH5H&/$_A?PWP_E.;49YU0HY_DV1Y;FOUO%<:<$5<-G68
M8FE@<1C<CP7!V&Q"XLRZK1P^-J3P&-Q=3%?7W@IN>!PE+%X:H?,6C_\ !)[_
M (*#:_KNN>'=*_9RUFXU#PY;Z1<:K-)XX^%MGHJ#7--AU?3X+'Q+>^.;;PYJ
M]^=-N;6[O--TC5;[4=+2ZM5U2ULY+F!).6^"/[!7QX\=_M=^&OV6O&WPP\4>
M'_$VFZWX?UGXJZ!/JWAGPYK>A_"A-?T.W\8>+M"U;7;\Z%K*6F@ZH][HUQH3
M^(3JDFQ]*L-7\N2 _>'_  72^*OQ%3]J/X5^"+7QCX@T_P *>!/@W\./&'A7
M0]-U6^T^QTCQC?ZAXEEG\7VL-K/$L?B=4MK.UMM;3;?6=I96\%I-"!(9?2?V
MO]6N/'/[4G_!%SXN:^B3>.?B;\)?V/=<\8:JDMXW]I7UU\0?#'B)F:.ZNKHY
MCU3Q1K4HN)'EOITNDCO;NZ6VMO*Y,'Q3Q3B\KRC%XJ624%Q+D>;XG!O!X+'^
MURS&8' /&4JE:5;-&L92Q%*%:7LZ<,)/"U?9P]OBHQE4GZ&8< < Y?G_ !%E
MV!AQ3BI<#\5<.8+,XYGFF4^PSW+,VS>&68BCAH8;((RRW$8/$5L-'V]:IF%+
M'X?V]187 SG"C3_/C_@IM^QIJO['_P"T+K6GZ-X$G\&? [QM?74GP/N;KQ9I
MWBBYU[1O#.A^%(?%%U/_ ,3_ %GQ+I\MOK^M$NGB>WTN6=KL_P!EP/80 0^1
M?L+_ +*FJ?ME?M(^"?@K;7]UHGAV\6^\2?$'Q)9?8VO/#O@+P\D<^N7UE'>E
MH7U*^FFL/#^CLUM?16VL:U87E[93Z;;7NWU'_@K#_P I#?VGO^QQT/\ ]03P
MI7TA_P $*=;TBR_;*\7>%[_4;33=7^)7[.GQ/\#>$);B>*"XD\22:MX*\5>7
MIADRSW\6@^%M=O D ,HL[2\DVF*.45ZT\TS?!>&,,W>*CB,WAPK0QBQJHU+J
MI5P5.I'%5:=:OBIU:^&HU%5Q%:=5PQ.(I5,0Z-*G4^KT_GJ60<-YKX\3X;6
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MH_[/*E0YH'G+BCB?BVEQ'DF(X=R?'X1X26)IX7#Y'EV4PX*A@\=A:<,?@:^
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M((KRX\:>'[#2M3OKD7D6EKXRM? 6JO!-JUYIL_C;3K34]<\R]\$]"^$OA_\
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MQ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN)Q.)=6I6]K*KF-6O0PV'H1HT:>"JU'%3^CX@\.>#<3G/%F<PP=?+LHRW/\
M*>&\)DE/C;@GA-/%5<IAF6/S*GFG%&!P. 6'HX5X>&'R6AA<5CL9BYXG$5<S
MH4(U'3_G@O/ _C/3_&4GP[O?"?B2V\?1:^GA1_!,VB:DOBL>)Y;U--B\/#P_
M]F_M5]:FU"2.Q@TQ+5KV:[DCMXH7E=%/Z_?LG_\ !+;]K3P#^T=^SMXS_:#_
M &8GG^"UY\3/#%KXQM_$5W\-_'NCC2-4>2WCC\9>"=.\0>(]2M-*DN9;>"\/
MB+0(+&VGDABOC#(R*?T4^$'C_P#9?_:9_P""OGP_^,WP3\5Z%\5KK1_V3M8U
M?Q!KUOX(\9> 9M9^/?A)=2\(3>(+GPYXQ\/Z%=75Q=_#[5M'BT[['<:T;)+!
M4-ZLNCVTI_(#]@W]I3]HF?\ X*-?![QG>>,_&WB/QE\6_C1X=\)?%6TOM4U5
MU\0^&O%FOOI/BBVUW2/,-N^E^#],U;5-=TG3)K5;#PS+I$$NGP:>EBAB]+&<
M1<19WEF:T,#A,)DM;!<)TLRS;#YOA\?'&_6LSI9G3^J8/]]@)Y?'#QRZO5CC
ML90KRE*KAT\'",:DSP\LX*X*X5S[A[%YIF.8<48?-/$6ODG#N,X<QF45,K^H
MY%B,AKO,<S3PV;4LXEC*F=83#U,JRW&82$(8?&269593HTCY/_;"T/1?#'[6
M_P"U+X;\-Z/I?A[P[X>_:,^-VAZ!H&AZ?::3HNAZ+I/Q,\3V&E:/H^E6$-O8
MZ9I>F6-O!9:?I]E!!:6=I!#;6T,<,:(OW_\ L+?#GX9?M1?L5_MH?L^2?#[P
M)-^T?\//#T/Q[^"_CN#PEX6F^*VM:+H)L;CQ+X$TSQ"=/MO$LVD-?Z#I^AF&
M35[BUCE^)N/)B2TMHI?A3]M[_D]']KS_ +.@^/W_ *M?Q97;?\$\?VB!^S!^
MU[\'?B=J%_\ 8?!TOB!?!GQ&\VY^SV$G@#QLO_"/^(+O5 ?W=Q9^'1=VOBZ.
MVF*Q27_AZR9GCV"1?H,SPN-QO!F%JX"=3^U,%E^5YO@'&<U.MCLMIX?'0P\V
MG^\CC?93PE6-3FA.&(ES)[KXO(,?E>5^)V.H9Q2H?ZOYIG.?<.9Q&=*FZ>&R
MK.ZV,RNMC*2<?W-3*_K%/,</4I<E2E4P=/V<EL_FSX2?#7Q#\9?BC\/?A/X3
MC\SQ'\1O&/AWP;I#-!<7$-K=^(-4MM-74+Q+6.6==.TQ+A]0U.=(R+73[6YN
M9"L<3L/WU\>V7PPTS_@HYJ?P#_9E_87^"W[1_AC]G?\ 9SOOAKK/PYOH_@MX
M!M/$OC+3[?0+WQ?\6O$OB_QEX=UFT\6^+O"/VO2?"MTWB$7/BDZY9^(I[2X@
MN+S5;B_O_!/]F#0_V*_V[/VZ?VC?%^B6\?PF_8V\$^)_BE\*+:&"72;#5-6^
M..G:G+\(_#?AY%F32-1BLO#U_P")? >Y[@VUMXGCTN6.RL[E8CI_S?\ \$6?
M$^M^-OV]OB5XS\37SZGXD\7?!CXV>)_$&I2JB2:AK>OZWX=U75KZ18U6-7N[
M^[N)W5%5%:0A5   ^4S_ #F.=8?.,\P;>(RG(>$H5Z-"=;%T*&*S7B"A0QSC
M6E@<3A<1S8'*(876&(HUJ4LTGR2@TV_T3@_ABIPOC>&>%,S2P7$7%WB+4PN)
MQ5/"Y=B\7E^0<'8O%93&>%IYM@<PP7)FO$=3,'^^P>)P]>&0TG5A4@U%?ES\
M!OV:_CI^T[XINO!GP(^&VO?$77]/LUU#5(M+;3[#3-&LI)&B@N=<\0ZY>Z7X
M>T2*ZF5X;-M6U2S^V3))%:^=)&ZKVG[1'[%/[4?[*-MHE_\ '[X0ZYX"TKQ'
M=R:?HVN_VIX9\4^';O4H[=KO^RF\1>"];\1Z'::M):1W%W;:5>ZA;ZA=6MI?
M7%M;30V%X\'[+_LSZ%\*_"__  1S6?7_ -IC4/V2K3XY?M$:SI/Q-^+>@?#+
MQU\6-<U4:-%JMII7PW-E\.=3TK7_  MI^L:1X3TV_GO[V]&D3:?)KFAW%G-_
MPG)+^=^%_B)^PS\'?V*?VK_V;Y/V_P"\_:;TWXC^ Y=4^#7P[UG]FWXX_#NR
M\$?%;PQ;ZMKGA^Y\-ZOK5MXIT_3?^$D\31^'!=Q3W7A_1+>XTT75]=1P:AJL
MS^E/C3-ZF:XV&#RZIB<!@,_CDL\%0X=XDQ>+Q-&E7HX7'YC#/L-2ED>%^JU*
ME3$1P->G-U,-AY>TQ="K6IQ7B4_"_ARCP_E=7,\ZH8'-\XX0EQ32S3%\:<$9
M=EV"Q&(P>(S#*<EJ\(X[$0XLQ_UZC1HX.>:X2K3C2QV,C['+L7A\/6J/\<?C
M7^SO\8OV=_$'A;PO\7_!Y\+:UXV\&Z+\0/"EO:Z_X7\56VN^$/$-UJ%EHVLV
M&J>#=;\0:5)'?7.EWL:6C7J:A&(DDGM(H[BV>:_^T'^S'\<_V5O%FC^!_CWX
M"N/ 'B?7_#=KXMTC3IM;\,>(H[W0+O4-2TJ&\34O"6M:_I4<HO\ 2;^WN-.F
MOH]3M#%')=V<$-U:23_NU\'OAHG[</P8_P""0?CNVDMKG6/@3\=+_P#9U^*=
MM:6W]I)%X3^&.G-\6/#]CK  #V)D^&?PLM8(7N0UI%=>-H9'6<26]O/[I\3_
M  YHG_!3GQ-^Q%\:[#4-&U;0_ /[;G[0/P@\?W&EV:7NC3_"?PEXA\1?&GP7
M!K4RS/'9MJ'P:^&^AZ>=1NIUL;O5/'4>II:[+^TTV3EEXB8O!XO!T,QPV#A1
MP?\ ;E#B>K1IXF+P6)P=3-X9/+"J56K&G0S*.28F5JTL1*7UG#*G.*C)S]"G
MX+Y?F>79CBLDQV95,5F:X3Q7 >&Q%; U(YG@<SH\-5.)(8^4,/AY5L5DD^*L
M%3YL/#!4X?4<<ZU.;E!4OYF/C=\ _BS^SEXPM/ /QG\*?\(9XPO/#FC^+(M"
M?7?#6O746AZ^L[Z3<7TGAC6=;MM-N[F.VED?2=1GM=7M8_*DO+"W2XMVE\?K
MZ>_;1^-P_:-_:J^.OQG@G6XTKQGX_P!5?PS.$EC,G@S05@\+^"&D2=4E6?\
MX1#1-$%P'CB/GB3]U$,1K\PU^DY74QU;+<!6S.G1I9A5P>'JXVC0A4IT:.*J
M4H3KT:<:M2K44*524J:<ZDI2Y>9VORK\,S^CE6&SS-\-D=7$8C)L/F6-P^5X
MC%U*57$XG 4<14I87$UJE"CAZ+J8BC&%:2IT80AS\D>91YY%%%%=YY(4444
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MBBB@ K]+O^"M'_)X=_\ ]D9_9[_]4WX.K\T:_2[_ (*T?\GAW_\ V1G]GO\
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M6?"%OJ?Q"UGQ*FA:7I8UC4=4TG4=.M[9)+N?6]L<4?Y-45WU^$>'\3CUF=7
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MQ04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM3ZW+^2/WO\ KO\ TM??O[9T?_H*Z;_X'6O_ ,=H_MG1_P#H*Z;_ .!UK_\
M':\!HH_UFK_] M'_ ,#G_7?^EJ?6Y?R1^]_UW_I:^_?VSH__ $%=-_\  ZU_
M^.T?VSH__05TW_P.M?\ X[7@-%'^LU?_ *!:/_@<_P"N_P#2U/K<OY(_>_Z[
M_P!+7W[^V='_ .@KIO\ X'6O_P =H_MG1_\ H*Z;_P"!UK_\=KP&BC_6:O\
M] M'_P #G_7?^EJ?6Y?R1^]_UW_I:^_?VSH__05TW_P.M?\ X[1_;.C_ /05
MTW_P.M?_ ([7@-%'^LU?_H%H_P#@<_Z[_P!+4^MR_DC][_KO_2U]^_MG1_\
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M_KOF_P#S\K_^%F*_^3]?Z6I_9^4?]";*O_"'"_\ RKU_I:ZG_"A?V7?^B+_
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M9^4?]";*O_"'"_\ RKU_I:ZG_"A?V7?^B+_ /_PW7P\_^4]'_"A?V7?^B+_
M/_PW7P\_^4]9=%'^N^;_ //RO_X68K_Y/U_I:G]GY1_T)LJ_\(<+_P#*O7^E
MKJ?\*%_9=_Z(O\ __#=?#S_Y3T?\*%_9=_Z(O\ __#=?#S_Y3UET4?Z[YO\
M\_*__A9BO_D_7^EJ?V?E'_0FRK_PAPO_ ,J]?Z6NI_PH7]EW_HB_P#_\-U\/
M/_E/1_PH7]EW_HB_P#_\-U\//_E/6711_KOF_P#S\K_^%F*_^3]?Z6I_9^4?
M]";*O_"'"_\ RKU_I:ZG_"A?V7?^B+_ /_PW7P\_^4]'_"A?V7?^B+_ /_PW
M7P\_^4]9=%'^N^;_ //RO_X68K_Y/U_I:G]GY1_T)LJ_\(<+_P#*O7^EKJ?\
M*%_9=_Z(O\ __#=?#S_Y3T?\*%_9=_Z(O\ __#=?#S_Y3UET4?Z[YO\ \_*_
M_A9BO_D_7^EJ?V?E'_0FRK_PAPO_ ,J]?Z6NI_PH7]EW_HB_P#_\-U\//_E/
M1_PH7]EW_HB_P#_\-U\//_E/6711_KOF_P#S\K_^%F*_^3]?Z6I_9^4?]";*
MO_"'"_\ RKU_I:ZG_"A?V7?^B+_ /_PW7P\_^4]'_"A?V7?^B+_ /_PW7P\_
M^4]9=%'^N^;_ //RO_X68K_Y/U_I:G]GY1_T)LJ_\(<+_P#*O7^EKJ?\*%_9
M=_Z(O\ __#=?#S_Y3ULZ]\*/V?O%.H'5O$_PU^#GB/56MK2S;4]>\&^"=7U
MVEA;QV=C:F]U#3KBY-M96D,5K:0&3RK:WBC@A5(D51R5%+_77-7)2<ZKE%.*
ME];Q/,HR<7))\]TI.,6TG9N,;WY46L%E:A*FLIRU4YRA*<%@\.H2E!24)2C[
M*TI04YJ#:;BIRMN[ZG_"A?V7?^B+_ /_ ,-U\//_ )3T?\*%_9=_Z(O\ _\
MPW7P\_\ E/6713_UWS?_ )^5_P#PLQ7_ ,GZ_P!+6/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
M?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2
MU/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]
M$7^ ?_ANOAY_\IZRZ*/]=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5
M>O\ 2UU/^%"_LN_]$7^ ?_ANOAY_\IZ/^%"_LN_]$7^ ?_ANOAY_\IZRZ*/]
M=\W_ .?E?_PLQ7_R?K_2U/[/RC_H395_X0X7_P"5>O\ 2UU/^%"_LN_]$7^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.?\ S4'^OW@I_P!&!_\ .J<6?_,9^>?_  WG_P!4J_\ +Y__  /H_P"&\_\
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MPF,P%.IF&-Q6$NZ>*JSC*DYVCRX>NJV%P_PC_P -Y_\ 5*O_ "^?_P #Z/\
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M/K]#**/]3_%/_H\7_G/N'/\ YJ#_ %^\%/\ HP/_ )U3BS_YC/SS_P"&\_\
MJE7_ )?/_P"!]'_#>?\ U2K_ ,OG_P# ^OT,HH_U/\4_^CQ?^<^X<_\ FH/]
M?O!3_HP/_G5.+/\ YC/SS_X;S_ZI5_Y?/_X'T?\ #>?_ %2K_P OG_\  ^OT
M,HH_U/\ %/\ Z/%_YS[AS_YJ#_7[P4_Z,#_YU3BS_P"8S\\_^&\_^J5?^7S_
M /@?1_PWG_U2K_R^?_P/K]#**/\ 4_Q3_P"CQ?\ G/N'/_FH/]?O!3_HP/\
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M_+Y__ ^OT,HH_P!3_%/_ */%_P"<^X<_^:@_U^\%/^C _P#G5.+/_F,_//\
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M@?>-?=FBZ9!HFCZ3HUJ,6ND:;8:9; !5 @L+6*TA "*B#$<2C"HJCHJJ, ?
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M0J14*MYT<-2YJDU.3>'G-N<I)1NYJ2>D4E*Z2LD#E=/1[16KOM_G^&Q^%_\
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MN2FI^TE[VC:A[OVK(7*[)VWM;57=^RW?R1^D=%?B7?\ _!6'X_>%/"\?Q?\
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MGX9O7D\&^/?VN/%'Q \/ZAJ$1T^1_#/BG5O&GB+2;V]@N"K6+MI5];SW,4[
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M3*R#Z.K\JOV@_P#@G'%JO[0_P!_:?_9'N? '[/OQ1^'OCF&X^*LEAIM_X?\
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MMGL-U_PA6FWWAC7Y/%1>(M=:?8G4-)U>]LWLKQM-MK:_MY3X7_P3H^-_A?\
M:._X*D?MU_&7P=IOB'1=$\7_  >^"T9T+Q;IC:-XF\/ZUX9\*_#GPCXH\/:[
MICO+]EU/0?$^@:QI%VJ221/+9-+"[Q2(QZ8Y=6A2Q-7$0E35'#JI%*I2<E4E
M5HQC"M!.<Z?-3G.2C-4Y-QNG9-.N1I2;5K)=MVTK-;K1WUL?T$T5^3/Q/_X*
MA:E)\:_&?P$_9"_9=\?_ +8OC3X7S267Q0UCPOXJT[P%X!\(ZM#/-:7&B_\
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MZZ\-^(H-/U?2DU&+3=5O]#U -INO:?I6LV,UGJVF7]A<6VH:=:7$5Q:RJT0
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M^D.GZ?;^'/\ A7?PEUAM8O);U;=K*SATS-[<27:P&V@5VN%C*.%Z:Q_X*O\
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M_@KZB2?\$XOVG5D174>'?!;@.H8!X_BEX&DC< @@-'(BR(W5'564A@"/H?\
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M<*<HOV2E)3AR7A>*B^:2<HWN)6<>5OE:DWJFT[I+HGJK:>I\B?LG(MM\ _\
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MNFE#DGS>D4M+;?UI?6QZ9^U9_P D#\>?]RO_ .IGX=H_93_Y('X#_P"YH_\
M4S\14?M6?\D#\>?]RO\ ^IGX=H_93_Y('X#_ .YH_P#4S\15^'?\WV_[Q+_[
M^)^X_P#.,_\ WG3_ -\ ^AJ***_6C\+"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KXV_;@_Y)/X>_[*'I/_ *C?BVOLFOC;]N#_
M ))/X>_[*'I/_J-^+:_._%K_ )-QQ?\ ]BFI_P"GJ)^K^!G_ "=S@/\ ['M+
M_P!,5S\J_P#@JYI6M^"/A)_P35_:UT_2KG5M&_9=^)GPRU_Q1':I),UGIVMV
M_P -?$=E>7, D2W%G/J_PVL-$^T3@;=1UG3;2.6+[<XD_;3QA9:=^T7\"-9M
M/AC\5=7\+:5\6? K'P;\7OAMJ<]OKFC6/B&R2;3?%7A74[*[T^ZMM0@AE6:U
MECNK2YMYLI(894=%3PMX+\)_$;]GSPCX%\=>']*\5^#_ !7\)_"NB>(O#NMV
MD=[I>K:7>^%]-BN+2[MY00RL"'CD0I-;S)'<6\D4\4<B?FK8_P#!*;XD?!VX
MU#3OV-OV]_CI^S?\/K_4+G4XOACK.A6'QC\'Z+<WH'VL>'[+6O$GA=;!965<
MW-W'J6K3)'%]OU.^FB2<??\ #E6C6X9X<I5*RPU;"97@72J2ISJ4IPJ8:A4Y
M9J$9SC.%3F:_=RC*,FI6:U^(XH:?$O$*;LXY]F]F[M6>88AVTN[I[:6UU/SR
M_P""D/[-G[3/[#?[/NG_ !F\-?\ !23]M/Q[J-[\1_#G@=M$USXN^/\ 2;*.
MVUS2/$NI2WXNK#QS<3M/ ^A1Q1PE!&ZW#LS HH/W?_P4KTVSU7]O7_@C[:WT
M0FAB^-?Q:U)$8 @7FC7WP)U?3Y>01F"_L;:=3C(:,%2K88=UX<_X)*>'?&7B
MW1O'/[9_[27QG_;/U?PY/#=Z%X5\=7?_  B?PGL;Q5;S[@?#W3=4UO"S2>63
M8VFOV>F7$0FMM8L=8AFQ']3?M&_L@_\ #0'Q_P#V0/CG_P +#_X1+_AE+Q=X
MW\5?\(O_ ,(E_;W_  GO_"9)X)7[!_;?_"3:-_PBW]F_\(=G[5_9'B+[9_:.
M/L]K]DS=?1?7:'M<+SUXU94:>/53$0P_L82>(PSIT81C&$9RY9JW-*G&W/\
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MJ<=X*I-58>SO%5-&I6<TTQ/D=TGRI2;5TW=.RZ7>EM+[]6?//_!2KXB?LO\
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ME[*,FJL'3]WF2BT[.4;$JSC9OE:;>J;3O9=+ZJW;7NC\_P#]F,30_P#!&?\
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M:[J*6EMM/DNQ]'_%W_DD_P 3_P#LGGC7_P!1O4Z^>?V'_P#DD_B'_LH>K?\
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MFK:MSNK6[;NZ5ND=+I>5V%%%%><0%%%% !1110 4444 %%%% !1110 4444
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M-?\ U&]3KR<__P"1%G7_ &*<Q_\ 4.L>[PO_ ,E-P[_V/<H_]6&'/GG]A_\
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M!_\ R[S7WA_JOQ-_T3N>_P#AHS#_ .9ST.BO//\ A;OPG_Z*?\//_"U\-_\
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MN\T3#AGB.I&,Z?#^=SA.*E&<,JQ\HRC))QE&4<.U*,DTTTVFFFM#T.BO//\
MA;OPG_Z*?\//_"U\-_\ RSH_X6[\)_\ HI_P\_\ "U\-_P#RSI?V_D7_ $.\
MH_\ #E@__EWFOO*_U7XF_P"B=SW_ ,-&8?\ S.>AT5YY_P +=^$__13_ (>?
M^%KX;_\ EG1_PMWX3_\ 13_AY_X6OAO_ .6=']OY%_T.\H_\.6#_ /EWFOO#
M_5?B;_HG<]_\-&8?_,YZ'17GG_"W?A/_ -%/^'G_ (6OAO\ ^6='_"W?A/\
M]%/^'G_A:^&__EG1_;^1?]#O*/\ PY8/_P"7>:^\/]5^)O\ HG<]_P##1F'_
M ,SGH=%>>?\ "W?A/_T4_P"'G_A:^&__ )9T?\+=^$__ $4_X>?^%KX;_P#E
MG1_;^1?]#O*/_#E@_P#Y=YK[P_U7XF_Z)W/?_#1F'_S.>AT5YY_PMWX3_P#1
M3_AY_P"%KX;_ /EG1_PMWX3_ /13_AY_X6OAO_Y9T?V_D7_0[RC_ ,.6#_\
MEWFOO#_5?B;_ *)W/?\ PT9A_P#,YZ'7CWQ_UVV\/_!OXAW=R\:?;?#6H:%
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M_P#EG1_PMWX3_P#13_AY_P"%KX;_ /EG1_;^1?\ 0[RC_P .6#_^7>:^\/\
M5?B;_HG<]_\ #1F'_P SGH=%>>?\+=^$_P#T4_X>?^%KX;_^6='_  MWX3_]
M%/\ AY_X6OAO_P"6=']OY%_T.\H_\.6#_P#EWFOO#_5?B;_HG<]_\-&8?_,Y
MZ'17GG_"W?A/_P!%/^'G_A:^&_\ Y9U@Z[\?_@WX?MGN;OXA^&KT)&\BP:%J
M$7B&YE*!<1I#HIOB))"RJ@E,:9+,SJB2.F5;B;AO#4IU\1Q!DE&C3BY3JU<U
MP-.G"*5VY2E722^?5=S;#\'<78NM3P^%X6XBQ%>K)1IT:.29E5J3D]$HPAAG
M)_):;L/C_KMMX?\ @W\0[NY>-/MOAK4-"@61PAEN?$,1T6%(QM8R2 WQE"*I
M.R-V9D17D3RW]C#2;C3O@XUW-&Z1Z[XMUO5K5FX$MO%;Z9HAD3_8^TZ-<1_[
M\;5\\>,/%_C3]K?QII_@SP7I]YH_P]T>\CO+N[O(\K IWPMKVO-"[VXNQ;M<
M0Z+HL-Q([O)/^^?S)Y[3]'?#'AW2_"/A[1_#.BP?9]+T33[?3[.,X+F.W0*9
MIGP/,N+B3?<7,I^::XEDE;+.37YGPWC%QUXB8CC'+H57PMPYDE?AW*LPJ4YT
MH9SFF+Q:K9ABL&JD8RG@L-1A]6<W&//5]G.#:E4A#]CXOR]^&GA/A/#_ #:K
M0_UTXMXCPW%>>972JPK5.'\EP6!>'RO Y@Z<Y0IYCC*\UBU3C*7)15:$TN6E
M4J[M%%%?M!_/(5[]HW_((TK_ +!MC_Z2Q5X-!!)<SQ6\2EI9I$BC4=V=@H_#
M)Y/89)KZ&MX5MX((%^[!#'"O^[&BH/T6OJ>&*<O:8NK9\JA3IWZ.3E*32[M*
M*OVNK[HZ\*G>;Z62^;=_T%FACN(I8)D#Q31O%(AZ,CJ593C!Y!(R"".H(->(
M:[H5QHMRRL&DLY&)MKG'RLIR1'(0-JS* =R\;@-Z#:<#W.HY88IXWAGC2:)Q
MM>.15=&'HRL"#Z\C@\]:]S,\LIYC3BG+V=:G=TJMKVOO":TYH2LNMXO5?:C+
MHJTE52UM);/UW375/[T_FG\YT5ZU>>!=,G8O:S3V1.<QC%Q"/]U9"LH_&9AC
M& .<YO\ PK[_ *B__DA_]VU\G/(<SC)J-&%1+[4*U)1?HJDZ<OOBCC>'JIV4
M4_-25OQ:?X'F]%>D?\*^_P"HO_Y(?_=M'_"OO^HO_P"2'_W;4?V'FG_0+_Y7
MP_\ \N%]7K?R?^31_P#DCS>BO2/^%??]1?\ \D/_ +MH_P"%??\ 47_\D/\
M[MH_L/-/^@7_ ,KX?_Y<'U>M_)_Y-'_Y(\WHKTC_ (5]_P!1?_R0_P#NVC_A
M7W_47_\ )#_[MH_L/-/^@7_ROA__ )<'U>M_)_Y-'_Y(\WHKTC_A7W_47_\
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M%_\ R0_^[:/[#S3_ *!?_*^'_P#EP?5ZW\G_ )-'_P"2/-Z*](_X5]_U%_\
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M1?\ \D/_ +MH_L/-/^@7_P KX?\ ^7!]7K?R?^31_P#DCS>BO2/^%??]1?\
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MQ#_\&WAO_P"9*OT1_P"%??\ 47_\D/\ [MH_X5]_U%__ "0_^[:/^(%<&?\
M1#91_P"!P_\ FOR_/NP_XC7XP_\ 1=9[_P"#\-_\J/SN_P"&'_A/_P!##\0_
M_!MX;_\ F2H_X8?^$_\ T,/Q#_\ !MX;_P#F2K]$?^%??]1?_P D/_NVC_A7
MW_47_P#)#_[MH_X@5P9_T0V4?^!P_P#FOR_/NP_XC7XP_P#1=9[_ .#\-_\
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M?_DCS>BO2/\ A7W_ %%__)#_ .[:/^%??]1?_P D/_NVC^P\T_Z!?_*^'_\
MEP?5ZW\G_DT?_DCS>BO2/^%??]1?_P D/_NVC_A7W_47_P#)#_[MH_L/-/\
MH%_\KX?_ .7!]7K?R?\ DT?_ )(\WHKTC_A7W_47_P#)#_[MH_X5]_U%_P#R
M0_\ NVC^P\T_Z!?_ "OA_P#Y<'U>M_)_Y-'_ .2/&O$7ACP]XNTN?1?$VCZ?
MK>EW',EGJ%NEQ&' .V:(L/,M[B/.8KFW>*XA;YHI$8 U\TZM^QA\'-1N))K1
MO%NA1NY9;72=;MY;>('^",ZWIFL7.S_KI<2/_M5]]_\ "OO^HO\ ^2'_ -VT
M?\*^_P"HO_Y(?_=M?.9WX:99Q)*%3/>%\KS2K3CR4\1BJ>"GB80NW[.&)518
MB-.[;]FJB@Y:N-[,^MX<XTXYX1A4I<-<29UDU"K-U*N%P685*>#J5&DG5G@W
M4EA95;14?:RHNIRKEYN6Z/SN_P"&'_A/_P!##\0__!MX;_\ F2H_X8?^$_\
MT,/Q#_\ !MX;_P#F2K]$?^%??]1?_P D/_NVC_A7W_47_P#)#_[MKY[_ (@5
MP9_T0V4?^!P_^:_+\^[/JO\ B-?C#_T76>_^#\-_\J/SN_X8?^$__0P_$/\
M\&WAO_YDJ/\ AA_X3_\ 0P_$/_P;>&__ )DJ_1'_ (5]_P!1?_R0_P#NVC_A
M7W_47_\ )#_[MH_X@5P9_P!$-E'_ ('#_P":_+\^[#_B-?C#_P!%UGO_ (/P
MW_RH_.[_ (8?^$__ $,/Q#_\&WAO_P"9*C_AA_X3_P#0P_$/_P &WAO_ .9*
MOT1_X5]_U%__ "0_^[:/^%??]1?_ ,D/_NVC_B!7!G_1#91_X'#_ .:_+\^[
M#_B-?C#_ -%UGO\ X/PW_P J/SN_X8?^$_\ T,/Q#_\ !MX;_P#F2H_X8?\
MA/\ ]##\0_\ P;>&_P#YDJ_1'_A7W_47_P#)#_[MH_X5]_U%_P#R0_\ NVC_
M (@5P9_T0V4?^!P_^:_+\^[#_B-?C#_T76>_^#\-_P#*C\[O^&'_ (3_ /0P
M_$/_ ,&WAO\ ^9*C_AA_X3_]##\0_P#P;>&__F2K]$?^%??]1?\ \D/_ +MH
M/P^ &3J^ /\ IP_^[:/^(%<&?]$-E'_@</\ YK\OS[L/^(U^,/\ T76>_P#@
M_#?_ "H_.>X_8E^$L$3R-XB^(0"J3SJWAL8P"?\ H4N.G7\>U?Q)_P#!:O\
M:KU7Q7^W#\+O^"??["EUX@\?ZS\)_B%X;\8?&AM8UL#PYXE^(G@V^LO&6G_#
MG4M4\&IX7U:T\(> ;'39=4^)%S9ZU9W@UV9=)MKC2]:\(O+/_4C_ ,%_?^"E
M6B?\$OOV1-1U3PGXDL+W]I3XT_VMX%_9_P##=Q8"4VVIQ6UNOBOXDZA ;F2-
MM%^&VF:K9:B$GCEM]2\4ZEX4T2Y@>RU6]GMOQ;_X()_\$??$7@[X(ZQ^UM\?
MX=1F_:#_ &E+&7Q#%'XGM)M0\0^$?AYK=W)K5HVI7=Y<?;1XJ^(MS-#XM\42
M71-ZEHVA6%SY6H0:K'+[N1^#/!.48E9G#@W*:>-PNN"45&<H5IQY/;*4L1*G
M"5&+<H2O[2-2U2FXU(1D<V.\6?%#-L#B\NS7C//,5@L72="OA98J%.->E.W/
M"<Z,*<U"25I14USQ<HRO%M/#_8F_X*4_!W]LGPA>7<>C:K\._B+X/^P67Q$\
M":D)[R7PGJ5VUU% ]MJ4-K9SZCH=Y=:??0V-\EC#-$UJ\6MV&CW1CMW_ %P^
M&6K_  @U%(!XXN/&TUE.Y\KQ!X.UKP]<VB*6P%FTR\\/W4^V(<3RP:E<3%LA
M;(,-I_E<OO@I;_\ !//_ (.!-0^"6N.NA?!W]L"=(_#5U=6_E:7./C9/)>:
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MD/\ [MH_X5]_U%__ "0_^[:/^(%<&?\ 1#91_P"!P_\ FOR_/NP_XC7XP_\
M1=9[_P"#\-_\J/SN_P"&'_A/_P!##\0__!MX;_\ F2H_X8?^$_\ T,/Q#_\
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M[_J+_P#DA_\ =M']AYI_T"_^5\/_ /+@^KUOY/\ R:/_ ,D>;UR7C#P'X/\
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M06DUM5 &238@?SOA1_Q K@S_ *(;*/\ P.'_ ,U^7Y]V'_$:_&'_ *+K/?\
MP?AO_E1^>G_##_PG_P"AA^(?_@V\-_\ S)4UOV(OA*@);Q%\0@!R<ZOX:_\
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M8N++4=-U&RN(+NPOK2>:UO+6:*XMY9(I$=NC_P"&'_A/_P!##\0__!MX;_\
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MLU%>,_\ "6:__P __P#Y*V7_ ,C4?\)9K_\ S_\ _DK9?_(U'^LN!_Y]8O\
M\%T?_EX?ZM8[_G[A/_!E;_Y0>S45XS_PEFO_ //_ /\ DK9?_(U'_"6:_P#\
M_P#_ .2ME_\ (U'^LN!_Y]8O_P %T?\ Y>'^K6._Y^X3_P &5O\ Y0>S45XS
M_P )9K__ #__ /DK9?\ R-1_PEFO_P#/_P#^2ME_\C4?ZRX'_GUB_P#P71_^
M7A_JUCO^?N$_\&5O_E![-17C/_"6:_\ \_\ _P"2ME_\C4?\)9K_ /S_ /\
MY*V7_P C4?ZRX'_GUB__  71_P#EX?ZM8[_G[A/_  96_P#E![-17C/_  EF
MO_\ /_\ ^2ME_P#(U'_"6:__ ,__ /Y*V7_R-1_K+@?^?6+_ /!='_Y>'^K6
M._Y^X3_P96_^4'LU%>,_\)9K_P#S_P#_ )*V7_R-1_PEFO\ _/\ _P#DK9?_
M "-1_K+@?^?6+_\ !='_ .7A_JUCO^?N$_\ !E;_ .4'LU%>,_\ "6:__P _
M_P#Y*V7_ ,C4?\)9K_\ S_\ _DK9?_(U'^LN!_Y]8O\ \%T?_EX?ZM8[_G[A
M/_!E;_Y0>S45XS_PEFO_ //_ /\ DK9?_(U'_"6:_P#\_P#_ .2ME_\ (U'^
MLN!_Y]8O_P %T?\ Y>'^K6._Y^X3_P &5O\ Y0>S45XS_P )9K__ #__ /DK
M9?\ R-1_PEFO_P#/_P#^2ME_\C4?ZRX'_GUB_P#P71_^7A_JUCO^?N$_\&5O
M_E![-17C/_"6:_\ \_\ _P"2ME_\C4?\)9K_ /S_ /\ Y*V7_P C4?ZRX'_G
MUB__  71_P#EX?ZM8[_G[A/_  96_P#E![-17C/_  EFO_\ /_\ ^2ME_P#(
MU'_"6:__ ,__ /Y*V7_R-1_K+@?^?6+_ /!='_Y>'^K6._Y^X3_P96_^4'LU
M%>,_\)9K_P#S_P#_ )*V7_R-1_PEFO\ _/\ _P#DK9?_ "-1_K+@?^?6+_\
M!='_ .7A_JUCO^?N$_\ !E;_ .4'LU%>,_\ "6:__P __P#Y*V7_ ,C4?\)9
MK_\ S_\ _DK9?_(U'^LN!_Y]8O\ \%T?_EX?ZM8[_G[A/_!E;_Y0>S45XS_P
MEFO_ //_ /\ DK9?_(U'_"6:_P#\_P#_ .2ME_\ (U'^LN!_Y]8O_P %T?\
MY>'^K6._Y^X3_P &5O\ Y0>S45XS_P )9K__ #__ /DK9?\ R-1_PEFO_P#/
M_P#^2ME_\C4?ZRX'_GUB_P#P71_^7A_JUCO^?N$_\&5O_E![-17C/_"6:_\
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MI;^,_ M_=JT>A^.-%M(;6Z5X++7--\->(OM7AZS_ %^5@P!!R#7^<)_P4/\
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MW_R@]FHKQG_A+-?_ .?_ /\ )6R_^1J/^$LU_P#Y_P#_ ,E;+_Y&H_UEP/\
MSZQ?_@NC_P#+P_U:QW_/W"?^#*W_ ,H/9J*\9_X2S7_^?_\ \E;+_P"1J/\
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M .1J/]9<#_SZQ?\ X+H__+P_U:QW_/W"?^#*W_R@]FHKQG_A+-?_ .?_ /\
M)6R_^1J/^$LU_P#Y_P#_ ,E;+_Y&H_UEP/\ SZQ?_@NC_P#+P_U:QW_/W"?^
M#*W_ ,H/9J*\9_X2S7_^?_\ \E;+_P"1J/\ A+-?_P"?_P#\E;+_ .1J/]9<
M#_SZQ?\ X+H__+P_U:QW_/W"?^#*W_R@]FHKQG_A+-?_ .?_ /\ )6R_^1J/
M^$LU_P#Y_P#_ ,E;+_Y&H_UEP/\ SZQ?_@NC_P#+P_U:QW_/W"?^#*W_ ,H/
M9J*\9_X2S7_^?_\ \E;+_P"1J/\ A+-?_P"?_P#\E;+_ .1J/]9<#_SZQ?\
MX+H__+P_U:QW_/W"?^#*W_R@]FHKQG_A+-?_ .?_ /\ )6R_^1J/^$LU_P#Y
M_P#_ ,E;+_Y&H_UEP/\ SZQ?_@NC_P#+P_U:QW_/W"?^#*W_ ,H/9J*\9_X2
MS7_^?_\ \E;+_P"1J/\ A+-?_P"?_P#\E;+_ .1J/]9<#_SZQ?\ X+H__+P_
MU:QW_/W"?^#*W_R@]FHKQG_A+-?_ .?_ /\ )6R_^1J/^$LU_P#Y_P#_ ,E;
M+_Y&H_UEP/\ SZQ?_@NC_P#+P_U:QW_/W"?^#*W_ ,H/9J*\9_X2S7_^?_\
M\E;+_P"1J/\ A+-?_P"?_P#\E;+_ .1J/]9<#_SZQ?\ X+H__+P_U:QW_/W"
M?^#*W_R@]FHKQG_A+-?_ .?_ /\ )6R_^1J/^$LU_P#Y_P#_ ,E;+_Y&H_UE
MP/\ SZQ?_@NC_P#+P_U:QW_/W"?^#*W_ ,H/9J*\9_X2S7_^?_\ \E;+_P"1
MJ/\ A+-?_P"?_P#\E;+_ .1J/]9<#_SZQ?\ X+H__+P_U:QW_/W"?^#*W_R@
M]FHKQG_A+-?_ .?_ /\ )6R_^1J/^$LU_P#Y_P#_ ,E;+_Y&H_UEP/\ SZQ?
M_@NC_P#+P_U:QW_/W"?^#*W_ ,H/9J*\9_X2S7_^?_\ \E;+_P"1J/\ A+-?
M_P"?_P#\E;+_ .1J/]9<#_SZQ?\ X+H__+P_U:QW_/W"?^#*W_R@]FHKQG_A
M+-?_ .?_ /\ )6R_^1J/^$LU_P#Y_P#_ ,E;+_Y&H_UEP/\ SZQ?_@NC_P#+
MP_U:QW_/W"?^#*W_ ,H/9J*\9_X2S7_^?_\ \E;+_P"1J/\ A+-?_P"?_P#\
ME;+_ .1J/]9<#_SZQ?\ X+H__+P_U:QW_/W"?^#*W_R@]FKR#XZ_&?X??L__
M  I\?_&'XI>)].\'?#WX:^$]=\:>,O$VJ2,EEHOA[P]IT^I:I?2I$DMQ</%:
MP2""SM(I[V^N6ALK*WN+N>&%Z5QXRUV")I'U$ *">;6Q[?6W'3-?P;_\'%'_
M  4%^+_[?'[2_P /_P#@B_\ LAZT_B :AXVT'_AHG4M.,<6CZIXSL7MO$6C^
M!]6U'3X6V^#_ (1Z?;2?$3XF/&E\L?B&PTG3O*@UKP/J6GWG3A<ZPN,J.G2I
M8F/+"52=2I&E&G3IP5W.<E6DTMEI%N[6EKM<N+R7$X.FJE6KAI<TXPA3ISJR
MJ5)R=E&$71BF]WK):)^A\V_LK^$OB;_P<8?\%8?&W[</QV\/:M9?L<?L_P"O
M:9I/PU^'.M+]JT2;2-!OI-0^'?PF,;O/8WM_J<TLOQ+^,\UJ;NVN+[5)-!5[
M72-<\/QV/^B9\./AW::'X<2 V\:-]F50H15"@ !5 "C"J  %7  'IQ7Y/_\
M!,?]C/P?^Q/^SO\ #CX&_#:)8M"\&:8LFIZS<6%DNJ>,/%^I@7?BGQEK<AAD
M=]2U_5C+<B)I9(M,L%L=$L#%IFF6,$7ZVP^)==AB$2WP"@8Q]DLL=,=/L_\
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M_JUCO^?N$_\ !E;_ .4'LU%>,_\ "6:__P __P#Y*V7_ ,C4?\)9K_\ S_\
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M>,_\)9K_ /S_ /\ Y*V7_P C4?\ "6:__P __P#Y*V7_ ,C4?ZRX'_GUB_\
MP71_^7A_JUCO^?N$_P#!E;_Y0>S45XS_ ,)9K_\ S_\ _DK9?_(U'_"6:_\
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M2;7_ (AZM!:&Z\$_#75-LJ>'OAM;-<>*_'>R%M>M]TUWX7T/RCXC_%[]O/\
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M9-5G_?#PYX5T_P .6")#$B>6F<A0"2 #[@8QQVZ5M:/H5GI%O'!!$B!   %
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M3V?L*;3JR3WM.?[M]K7/(Q#^MYI1H+6G@H>WJ=G6J65*+:>\8WG%^>_;]O\
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M1C6HRO&2U7VH2^U":Z2B]&OFKIIN:BFJZ/RK!OI3JP.@**** "BBB@ HHHH
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MG":O&47=-?UHUNGHQ:***@L**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@R^);?QEH!T6!0US?2:C;V\=JQ+*L5TES)#/;3R,I$4$\4<\IP(XW++GY?\
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M?G?_ ,,$?]57_P#+%_\ PQH_X8(_ZJO_ .6+_P#AC1_KAXI_]&=_\Z#PY_\
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M([9'O7KM4=1M5N[6:)AN#1N",9SE2,?KT]Z:=FFNCN*2YDUW/\]#]CO7[O\
MX(U_\'!'BW]GN[74- _9G_;2U72]$\)0/_HNBP0?$[5+O5?@]=6%HKO%<P^
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MY2\.)K"Y(5Y+6[TXH5AN$8D,L[7"2(%E@ED@=99/T&\&_ "UMUAEOXU)4)A
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M^&/@;PYX*TAB@66[AT+3+6RGU2[/674-7NHYM4U*=V:6YU"]N;B5FED=C]\
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M.M;G>'I2J4Z5^2$N5)+\[_\ C/O_ #_PI>FNO[?3J5/0_P#9%^?K7Z)45O\
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M^+IK"X2'L,)!Z07QU)65ZE:7VYOL[J.B7PIFN#P$U4>*Q<W6Q4TKS?PTX_\
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MFS]/\*4I>(O"*:37]KTGKWC3JRB_522:\T?07P8MHK7X1?#&*%0B-X"\*7)
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MQC::WX1\"Z%;Z;:Z1J$.NV^BV^E3I&IOH+WP_J%W*Q)M[ZV&%'Y_:SXAU?\
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MS^WA^WS_ ,'%?Q>UK]F[]DG1]>_9Z_81\.:L(_&_B#69KJRD\3:/YMG]FO\
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MI1H*ZZ.-YKHGU9W8?_;,SQ&(^*EAHK#4FM8N>DZ\DUI=.T+IZQ/<((Q%$B#
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MW1_"&JF^\#ZQ#%O?_B4W?A/5=/TS2+E,07<&BR/%G8Y/+?\ !:#_ ),=UO\
M[*[\#O\ U9.A5\E_MU^.?%_[(/[4'Q\M_A[8WDEQ_P %'OV=/#_@7X=VMO;7
M:VI_:CT#Q-H?P7L[C3_LL1MH[RV^'GQ"M/$]Y=AUGGU6UL_MUKJ#36<4_LX>
MG]8P$,*K*=3$XBK3;Z3I1P:GKTBJ%6K.7?V:^7AXFHL+F-3&.[A3P^'HU4KZ
MTZ[Q4H.W67MZ5&$=+_O';>S\ _9!\3Z]\7/^"P^@_M*ZM<74NA?M#^"/V@O$
M_P ,(K@_)%\(O &IZS\'/ 5Q$G1/[4L_A[=ZHQB"VTXO([J#S_/>^O/WA_8Y
M_:?_ .&L_A?XA^)/_"#_ /" ?V#\4_B#\-/[%_X27_A*OM7_  @FK)I?]M?V
MC_PC_AOR/[5W^?\ V;]@F^PX\K[?>9\P?FYHWPLT/X(?\%4OV%/@_P"&TC71
M?AK_ ,$__$'@RRDCC,?VP:#J'C&PN-2F5F=C=:I=0SZE>22.\DUW=32RN\CL
MQJ?\$Y?VHO@)^S9^S]^T9X-^-WQ-\*?#OQ[\*/VG?CU<>*_AYXCUBPT[Q[*;
M_P 0I=:3;^&_"=S<1:QXKN-:DBET_2$\/6VH+?:E#+9Q/YD;8TQM..)@JE*E
M*3AA\'&A&*DY1HNKBJ<5RQT?NQI1;:?O;6<G?+ 5)82K*E6JQA&>(QD\1*;B
MHRKJA@:K?/+6/O3K2C%25XWNFHJWM?@;_@JSI_CC]EKX-?'/3?@'X@U#XJ?M
M"?%?6_@[\(O@#X<\=:;JEUXA\4:)JMY97-YJ7Q$UKPYX6TC0="@LK/[;J&HW
M6@RFPGO+*V\BXM6O-3L?<_@?^VA\0/%OQZ_X9I_:*_9HU_\ 9M^*NK>!;WXB
M>!O*^(F@?%_P/XW\/Z5>1VFK0:=XS\,:-HL%AK>G[YIY=,U#3HQY-C>[[J.1
MM,34_P 5OV78OV5KO_@EU^RUX*_:\LOB+X5\+^)_VE/B5IG@WXV>";BW\,?\
M*,^)-GXA\0OI.O\ B+QU=7L#^#(;VU.IQ6\ESI.O:;-/IDUWJFFQ#1H+VU^J
MO@]XR^)GP[_:W^&W[)?PH_;HF_;A^#/QH^$OQJN?&$?BB^T'XB>*?@!%X<\%
M7\O@+Q)K?Q;\)W6J3WL/BGQ%)I_AR.RU"Y@\J)YIY=!2?5?#EXSKX/#)XJ%.
MCRNG/%N,YNO94Z$I6=*JI3HM0A&TJ=>"G4EI&JG. J&.Q,OJDZE=2C4A@E*%
M-8:[J8B$+JM1E&G63J3G>%3#S=.G%7E1:A._TM<?\%*?BIXXM/B)\1/V9_V*
M?''Q^_9T^&6KZUI&K_&G_A:GA3X<W'BP^%7*>+-2^%_P\U[0-2U[QWI&D"*Z
M>"[@OM-DU VTEHEM;ZDLMC#YKIWQ?\(_'[_@I3^P-\9O <E\WA/XB_L:_%_Q
M)I,6IVK66IV2W6H7<=YI>IVK%UBU+2-0BN]+OQ!+<6;7=G,]E=W=FT%S+E?\
M$Z/VO_V>?V:_V#M.^&OQR\?^'/A1\3_V6I?B7X7^+/PL\4ZCI^A_$"WURW\?
M^+_$%K%X=\):C-8:OXGN/$UMJEK_ &9_9-I<"\UFXN+!I3-#).^-X8^*7BK]
MH;]OG]@CXKZ]X'U/X)>)/BC^Q1\=->A\(W>J?\)'JGA"#5]5U>/P]?\ ]HW6
MA^&_M\MYI']F>)+9+G0]/\M+^*UFA;RFEDET(TIXJ,,+[*%*&+HPQ#J5'[:/
MU>JXRE&<I*;E&*J\]!0IQC)*47STV5]8E5IX24\6JU2M4P5>>&5.FO83^MT%
M*,9P47!0E)TO9XASJ3E%R4U[.HCZ2?\ X*&?&#XC:W\2+W]D[]BKQI^TC\(_
MA5XFU;PAXA^+'_"V?!_POMO$^O>&R!XFM/A7X6\1Z+J>J_$5-*=9X8)M/N;$
M:K<Q16MFIGOK&.Y^V?V;?VAO '[4GP>\*_&?X;R:@GA_Q+'=V]UI.M6PL=?\
M,^(-)NI-.U_PQX@L5DE6UU?1-2@FM+E8I9K:X18KRSGGL[FWFD_G0_81\!_!
MOPC\"?$WPX^/'_!0W]J/]CWXN? 3QEX_\/?%'X+Z3^T+X(^$WAC3'C\1ZMK5
MCXD\">$?%GP[O=;UG3?$6EWEM<3W.F7^O7.J^(&N[FVC@M]7T:R;]B_^"7'A
MOX+:+^S!)K?P!G^/>H?#?X@_$_Q[XZT_7_VBX/"\'CKQ5J6H7-AH^K>*-.3P
MGI^E6+^$M;O-">[T6XO;"WU6ZE:_N+N*-988TSQV%P]"G45.G).E6A3A54:R
MC5A*,GS5)U).E*4TE4@Z$814>:Z:<9+;+\7B:]6DZM2+5:C4J5*+E0;I3C*"
MY:<*<%5A&FY2I5%B)3ES*-FI<R/T9KS/XT6L5Y\(OB=%,H9$\!^*KI00"!+8
MZ+>7L#8((RD]O&X/52H92" :],KSOXO?\DF^*'_9._&W_J-:G7Q_$,8SR#/(
M22E&63YG&47JI1E@JZ::[--IGV7#TI0S_(YQ;C*.<9;*,EHXRCC:+33[II-'
MS]^Q!<23?"/6(W.5M/'NL6\7M&VA^&;HC_O[<R'\:^Q:^,_V&_\ DDWB'_LH
MFK?^HUX2K[,KY7PH;EX<\(-MM_V/16O:,ZD8KT44DO)'U/BM%1\1>+E%)+^U
MZTK+O*G3E)^KDVWW;85[OH__ ""=+_[!UE_Z315X17N^C_\ ()TO_L'67_I-
M%7[1PS_O&)_Z\Q_]+1^+\3_P,+_U]J?^D(XSQ]_S"?\ M_\ _;.O.Z]$\??\
MPG_M_P#_ &SKSNO/SS_D:8K_ +@?^HU$]'(_^17A?^X__J36"BODG]L#]L7X
M<?L<>!-"\4>,M*\2^,_%7CGQ%;^#OAC\,/ ]B-2\9_$+Q9=&(1Z7H]J[+'%;
MVWGV[ZA?2E_)^T6EI9VVH:K?Z=IMY\+ZY_P5)_:%^%.G)X[_ &C_ /@FM\</
MA%\%H;VRCUSXDZ/X^T7XB7?A;2[^[CM(=8\3>$[7PAX;ET.W1[BUCE74M:M4
M^V3KIT5Q+>O;0W/'2P6)K0C.G33C)N,.:I2INHXNS5*-2<95&GHU34M=-]#K
MK8["T)RIU*C4H*,JG+2JU(TU+6+JSIPG"DFM4ZDHZ>]MJ?L]17,^#/&7A?XA
M^$?#/CSP3K5GXC\(>,="TOQ+X9U[3V=K+5]#UJSAU#3-0M_-2*9([FTGBE\J
M>**XA+&*XBBF1XUZ:N9IIM----IIJS36C33U33W1U)II----)IIW33U336C3
M6J:W"BBBD,**** "BBB@ HKS_P"+/CK_ (5?\*_B7\3/[+_MS_A7?P_\9>.O
M[$^W?V9_;'_"(^'-2U_^R_[2^QZA_9_]H?V?]D^W?8+[[)YWG_8[GR_)?S[]
ME;XZ_P##3/[/7PK^//\ PBW_  A/_"S/#?\ PD/_  BO]M_\))_8G_$POK#[
M'_;G]D:!_:7_ !Y>;]H_L>P_UFSR/DWO?LY^S=;E_=J:IN5U\;BY*-K\WPIN
M]K:6O?0AU8*JJ/-^\E3E54;/6$91C*5[<NDIQ5F[N]TFDVOH&BBBH+"BBB@
MHHHH **** "BBB@ HHHH _._]GG_ ).R^./_ '4S_P!65HE?HA7YW_L\_P#)
MV7QQ_P"ZF?\ JRM$K]$*_)/!C_DE<Q_[*WB;_P!6$C]8\9/^2IR[_LD^&?\
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MNV!%"1H,9PL:J%0=<8 'K7TOH'P\T71HT$5K%N4#ED0DD=^%Z?G]:] 2-(P
MB@ >G^?>GU]FK1A&G",84X1C"%.$5"G"$4HQC"$4HQC%))12225DDC[^G1IT
MXQC"*48I**22225DDE9)::):+HBO#;0P +'&J@>@ JQ110:A1110 UE5P0P!
M!]:\O\<?#S3?$MI*KP1F4JVUMN3D@ 9R<=,]NY^M>I4$ C!Y!H3:=UHT)I25
MFKGY&?%_X%7-E<2WEG$UK=Q'=!=(NQ)-I#(MP(UW$*!M2=2)8B5.'11$>L^!
M_P"U3JW@N[M_ WQ<FG:RA,=MI_BB<O+<V<>"D,6L%-[7UD_R)%JJ;IX<$WWG
MQM+<VWZ*>*O#>F:O93+=Q1G<C#+*N0=I&1QT[G^G?^-?_@M'_P %<?@_^RWX
MDU7]FS]F9=,^.'[5UU=/H<]KH*MXA\,?"/6+MXK:&R\1/I$SS>(?'<DDRQV/
MP]TOSI+:Z4MXKETZ6.RTK5?@LXX#S'$YO+B;@/$4<GXIGRO,<+6C-9#Q)0B[
MSIYS0I+]SB=9.EF5**KJ4G&;YYQKT?B,ZRBIE^(EGN2XFGE^872Q%":;P6;1
M3O['%48:^V=WR8B"]HFWS-?Q8?O5_P %+_\ @L5^RG_P36^%$/BWXE>(X_&'
MQ-\5Z5=77PJ^"G@Z]L;OQIX\N$B5;?4ILS-;^&?!,-U+"NJ^,=5VVD< N(-$
MM->UE8-(N/X]/AQ^S5_P4#_X.$OC3I7[3_[<OBGQ-\)/V1M*U&\G^%7PQT"&
M]T2SN]#NII'CTWX1>&M3@FMTL9XOL]OXH^-7BBVU#6/$JP0Z=HG]J6UHD?A7
MA_V(_P#@FQX[\>_&C1_VJO\ @IEIVN?%_P 4ZU>66KV/PN\6ZE)JL=B(Y8Y]
M.E\>6C Z3<P:*@*:9\)[9HO"UI8^7IVL0>09-#MO[Y_V=_!_@;4O"^CZQX;D
MTRZTH6L%O816$,4%O916T211V M(UB^PFSC5(?L#10O;*@C\J,*JU]]E_$N2
MT<7C<DPN+PU7B?+J=)9K17MHRPTJE.E*I++8XJCAZF+P49U%36/IT>2=X2:@
MJE-&^$Q\<^Q57"XBK&C4P?(ZV5IU(U&W&$G5FZD*4ZU!2E:,HP4-8N7+S1YO
M*?V3OV+_ (6_L_?#SPS\.?A?X#T+X?\ @+PS;K#I'AO0K3[/;([JIN;Z]FE:
M6\U35[^5/M.J:SJEQ>:IJ=TSW6H7EQ.S2']#-+T>TTN".*WB2,(H "J!CC'8
M#_/Y5>MK6&U01Q(% &.!C_/^%6:JI4G4DY3;;;;;;;=WU;>K?F^M^Y];3I0I
M1C&,4E%)))622T226B26B_1:!1114&@4444 ,>-)!AU# ^H!KG-5\*Z5JL;)
M<6T+;@>L:D\GG!(XX_\ U5TU% FD]U<^7/%WP(TZ^$LMD@BD.2-N$YP3U4#'
M7OS[BOS'_;,T[PY^S1\'/BA\</&<$%IX?^&/@SQ%XSU6Z69;&6[AT+3)[N'3
M8WD*V\]_J]U!!I>FQ.CW%S?W=K:P9EF1'_=ER K$C( S_GI7\:O_  =J?M7W
M?A?X _!_]B[P!+=7?C[]IWQW::GXAT?21--J%W\/? &I:=/9:*;> "3SO%GQ
M'U'PDFF1*6^W)X9UFS,4@+;<J^0Y7Q.J>4YSEN#S3!59WG1QM"G7C3BE>=6D
MYIRHU8P3Y*M*4*L)6<9II->+G>$P%; 5_KN&H8FFH/EIUJ<:B]I*T8.',FX2
MYFK2@XR5[IJQRO\ P31_:<\&?MHZ3%^V'HW[-^D_"_XU:!<ZI\*[SQM>Z/X=
MU_4O$%A;6?AS4M8LO#?CE=-T[Q+J?A?SQI]LUCJEK:'3;JUN--LKJ\,5[,_]
M''PK_;3T6QBM]#^(VA7.@7$(6&36-*AGO=.& NY[K2V235K%0,82W_M9V/S$
M+D ?)G_!,_\ X)\:%^S9^R/\%/@TUG;?VYX/\%:;_P )=>P) ZZAX\UPS>(/
M&]^EQ"-MQ#+XIU/4UL9B7<:;'9P^8R1(:^K_ !Y^SF[1R?Z#'>1(I$995$D:
M\G$4T8$\?))(1U7H2*_.\9P#FO#^(J3\..*<5E>#I3E['ACB.=?.N')03]RA
MA:M64LRRJD_BE+#U:]1_#>,;GR^%X;S?**%.KD&:U,.^6,JF69A&6+RV<I*+
M<(-OZQA=?BE2E*<N7[*9]W>&/B!X2\8Z:NJ^&M=TS6;)@,S6%W%<"-BH;RKA
M$8R6TXZ/!.D4R$%6C!! \M^)7[0_A#X9:OX7TW6W>1/$&IRVEU<6[A_[&T^*
M!O,U:YA16EFMX[V6RMY$C D\B6ZN8?.DM!:S?EOK'@?Q3\.+U]6\,ZWJ^@W<
M.06@NKJTF9 V6A^UVBPB:!L$-;W,1BD3*2M("V?*O%/B[Q!XRU"+4_$=^^H7
MT-K':"9E2/,<;NY8QQ!85DD>1WD:)$5F(^4  #X?C3Q5XJX2RB6%SCA6>3<2
M5JU!9;CJ=:CF?#>84J&(HU,?.E7C.%>$I8=^S^IU%]8I1Q$:LJT)PBI<&><;
MYOE&"='%Y0\#FLZE/ZO7C.&*RS$4Z=2G+$.$U*-6+E2?)[&2]I!5%)U(RBD_
MZ$].U*UU.VANK6:.>&:-)8I8G62.2.0;D='0E61U(*LI(8<@G(S^?_[//_)V
M7QQ_[J9_ZLK1*\W_ &3_ -H67P]>67PV\77I.D74JP>&-4N90!I]PYPFB7#N
M0#:7+G&FR,VZWN&%E\\$]JMIZ#^SE.EQ^U;\;I48,'7XE,""",'XDZ(>H)'?
MU_I6&8<899QMCO"'.,NER3_UMKT<?@I24JV7XV.6RE4P]5I1YX.ZJ4*RC&->
MC*,U&$^>G#^CO!W/L'Q#P-XHX["OEE_JGAX8G#R:=3#5UF%)RIRVYHNZE3J)
M)3@T[1ES1C^B]%%?GW^UU^UC\6?AC\4_@]^S3^S5\+_#?Q-_:#^-.E^)O$^F
M/X_UVY\._#GP1X+\(JIU;Q+XHN;!HM4U)9)%N8K;3-+NK:[8VKB(W5Y<6-A=
M_P!&4J4ZT^2"5[2DW*48QC&"<IRE*32C&,4VVWLM+NR/SZM6A0@ZD^:UXQ2C
M%SG*<Y*$(1C%-RE*3222W>ME=GVQXT\!>!OB1H;^&/B)X,\)^/?#4MY8ZA+X
M>\:>'='\4Z')?Z7<QWNFWSZ3KEG?6#WFG7D45W8W+6YFM+F..>W>.5%<1>)O
MAU\/O&FJ^$]=\8^!?!WBS6_ >K'7O VL^)O#&B:]JO@S76\C.M>$]1U2QNKO
MP[JQ^S6V=1T>:SO#]G@S-^ZCV_EW=_M>?MO?LQ?$;X1Z+^W-\*?V>]5^$_QH
M^(.B?"C2/B_^R]K/Q$:Q\#>._%3LGABT\7^&/B4+C6[^PU%[:\$]UIJ64-K:
MP7-W#<7MW:0Z/J?N-]^WM\.[']OFT_8]NO&?P@L- /P._P"$JG\4WWQ#T.+Q
M#<_'S5?BSI/@+P_\!;33I-5@LK?QI+H$UUXA_P"$/=;SQIK']J:3)9:78V5I
M(^K=#PN)C;D:G!4ZE6,Z-13AR1M"KRN+NI:J,XM*35KIQLSG6,PLKJ=Z<W5I
M494ZU-PFIRO.DFI+6+UE":<H)WL^9-+[4NOAYX OO&VE_$N^\#>#[SXCZ)HU
MSX<T7X@77AG1;CQMI'AZ\EGFN]"TOQ7-9/KNGZ-=375U-<Z7:7\-C/+<SR2P
M,\TA;EM8^ GP+\0^.++XFZ_\%OA-KGQ)TV:VN-.^(6L?#GP?J?CBPN+/;]CG
MLO%E[HT^O6LUKL3[-+!?QO!M7RF7:,9R?M)_LZ2:QH_AZ/X^_!637_$6O:GX
M6\/Z&GQ4\"MK&N^)]%O_ .RM8\.:/IBZZ;W4]>TG5/\ B6ZGI%E!/J%A?_Z'
M=6\5Q^[JWXV_:$^ 7PT\06?A/XC_ !P^$'@#Q3J @:P\->-OB7X+\*^(+Y;H
MJ+8V>C:[K5AJ-R+DLH@,-LXF+*(]V1G!1KII1552<6DDIW<+ZI):N-]TM+[F
M[EAVFY.BXJ2<FW3:4VERMMZ<S25F]6DK=#4LO@O\'=.\#W7PRT_X3_#2P^&U
M]<WEY>_#ZR\">%K7P/>7>HWC:AJ%U=>$X-*CT&XN;Z_=[Z\GEL'ENKQVN9V>
M9BYC^''P2^#'P=CU"+X1?"+X8?"R+5C&VJQ?#CP#X4\#QZFT.?*;4$\,Z3I:
MWIBR?+-R)"F3MQFND\0>// WA*#PY<^*O&?A/PS;>,=>TWPMX1N/$'B+1]%@
M\4^)]9M;N^T?PYX<EU*\MH]<U[5;+3[^\TW2-,:ZU"^M;*[N+6WEBMIG3DO!
M?QZ^!GQ(\0:GX3^'?QH^$_CWQ5HJRMK'AGP7\1?!_BGQ!I*P/Y<[:GHVAZQ?
M:C8+#)^[E-U;1"-_E?#<47K.$G>JX2?--^^X-W^*3V;NEJ^J[H?[A3@OW*J)
M<L%[BFE;X8=4K=%T\B'Q7^SY\!/'GBRS\>^./@A\(?&?CK3OLW]G^-/%?PU\
M&>(O%EC]B5%L_L?B/5]%O-8M?LBQHMMY%XGD*B"+8%&.RO/ 7@;4/&.D?$._
M\%^$[[Q_X?TJ^T+0?'-YX<T>Y\8Z)HFIL7U+1](\336;ZUINE:@[,]]I]E>P
MVEVQ+7$,A)-<QX_^.?P3^$]_I&E?%/XP_"SX::IX@V_V#IOC_P"(/A+P;?ZW
MOF:V3^R+/Q%J^FW&I;KA6@7[''-NF5HAEP5KY[_:M_;9^%O[/G[/'QB^,7AG
MQQ\*?''B7X;L?#&F^$7^)'AV!=1^*%_I_P#:FC^ [W^S[V\OU\32:*+GQ3_P
MB5O!'XAU+P]IE]=6L=K:"34[6H0Q-5TX0567.U3IWYN6TFH<J;]U1;:4M>5=
M2*E3#4E5G-TH\EZM7X.9.$7/FDE[SDDG*.G-U1[KXY_9W_9_^)^NVGBGXE_
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MS\_N\A%#G]IAK?6?K_UJ?USF]M[/V%ZGM.:_[GV'+[/ZOR_:Y.37G/C_ /8
M^"_[4/[<'P+\3^-?BG^W9^U+\/?#'A3XC?$CP3\,['X2_$K4M(\7:CJEAK+Z
MI=>*OB7XWUE]=\0^*M'LKG68_#>B>"(KS1[*PT7P_;M9WM@]W))/Z+\%?V[?
MCG\&/^"?O[;_ (I^+VNR_%+XU_L4?&SQK\!=(\7^([6VD/B:]/B?PKX#\$ZI
MXH;3;R236+C2/%WB.\?6&-R9M0T.PT^.;7;V]GO-37ZK_P""/7P\\?\ PR_9
M*U7PW\2? WC#X?>(I/CE\6M7CT'QQX9UKPGK4FE:EJUE)IVIII>O65A?-I]_
M&CR65ZL!MKI%9H)9%4D?*/PY_8U^)/QR^"'_  5_^"'B;PSXK^&U[\<?VR_B
MUXS^%.L^,_#&M^'=*\6QZ/X\LO'G@/Q!H]UJMI8IK/@OQ!KOAW2K63Q)H[7^
MGMIEW/=VC7OEK!+I4JT:F)Q<*RH_5J6+PTHJ-.G&U/ZPHU7&4(J4E.G*3GJ^
M9V?1$4Z5>EAL'4H.O]9K8/%*;E.I)RJ_5G.BIQG)QBX55%4[I<JO%:-DGC3]
MBS]KQ/V/_&WQUU#]O#]H+Q=\=O$7P/\ $WC3QU\+_%6OVNI_LZZWH/B+P#<:
MEXN^&>D?#;[&+70M0.D7>J:-H?B[2[JRAAU065W;:+HL1>:#N?@MX@_:.\/?
M\$:_V?I_V6AX7T[XGZAX(T?2I?&WC'Q!X1\.:#\,?"%UXG\0/XJ^(=S=>-[V
MQ\/W,NA:?!Y%K;7+W3Q7&H1ZE'IVHC3WLYN3UG]K[]M?4/V7-:_9DF_X)]?M
M')^TV/A?JOPHU?QTGA2&?]GW[/%X7/A>]^(>D?$&VO)K36=3GL6N=8L/!FEP
M7L5SJ?D6.G:SJRN+5_*?BU^S-^TAXQ_X)(_L5> ]!^$_CCQ'J'PJ\8>"O&/Q
MU_9UN;+4_!_CWQGX)T/5/%SWOAN;1M0@L?$#7D%Q?V%P?#ZVQOI%N[?7K6QN
MKW0[ !I3DJ,,3+"I/,:<H65"4'25.KR\T*4H1E2;2C3YY1BVVI-1N1>G&56>
M$AC)-974C/\ WB-1595:":4JL*CC62O*K[.$IJUU%S2/$/VJ?BOX._93^'Z?
M$O\ 9]_X+$?'#X]?M)>$]:\+75W\,]>^+EG\8OA)\1C<:YHT/B*QL?!_A^SU
M+PEX-L+#3;R]UNXM=8\2ZY UGI=[X9AF36+B.6+[O_;\^(?QU\;_ !Q_X):^
M#_@?\:?&?P8C_:3@^-%IXQU#P5K6IVFF7'A_7/!/PDN+O5[CP]+>6^D^(-;\
M)>'O$/B;4OA]<>(+6ZF\.>)9[35].-KJ"&6OD[]KG_A-/VAOV2_'WPB_9!_X
M)4?%3X"Z2^E>%M6^(?B+QW\!_"WPE\83:=X2\3Z#XB7PA\+O!7ANUU#QI\0]
M9U76M)T&5]4M$BFETBPUF.\TDR3"X@^R_BO\-?B7X@^/G_!$_P 3:1\-?B)>
M:%\-?"_Q(;XEZDG@?Q0MM\-'U;X0?"&RTZV^(SOI2CP+>7=_I^H:=%9>*O[)
MNFU'3[^P\K[797,,5OV:>&J34/:Q68IJJ\+.3BL#S454A1BH1C[1/V5.?-)-
MNS:E%*(JH_K-*#G[&?\ 9CC[)8N$$WCHPK.G*O-SD_9M*K5I\D6DKI2C)OA?
MVJ? WQ7_ ."=NG?LR_M Z%^U%^U-\9/A;\/OVCETCXZ:;\9?C'XB\7R:G\)O
MBKIFD>'T_P"$FLX8K'PUX@M/ ^IZ5J]QX=O+_0TOK/7/&NGK"KC3K"ZTWZ0_
M;<^(GCKX@_M,?L3?LA?"#Q]XQ\%W'C[QI<_'CXR^(OAUXKU+PIJW_"BOAQ;7
M32:%-X@\/ZKI^I)HOQ"OVU/256VD>"YO],T]G$\:F"3[:_:D^".E_M(?L\?&
M#X'ZL(5B^(W@;6-#T^YG5&BT[Q&D0U'PGK#!XY5SHGBBRT?5T.PD/9*5VL P
M_)'_ ((O:!\1?BS)\2/VMOC-$[^*]*\#_#?]COX>2RW$%U)!X,^"&A:3%X[O
M_M5O-/'??\)7XX@T_4+RZ1A"VLZ5JS027,<PE''2J1J8=XRIR.MA/:T[-13J
M2Q"_V:7*HI-TINO-W^S""TLK]U6E.EBHX*ESJAC/95;J4G[*.%:^M1YG)R2K
M4UAZ:U^*I)ZW;/WIHHHKQSVPHHHH **** "BBB@#\[_V>?\ D[+XX_\ =3/_
M %96B5^B%?G?^SS_ ,G9?''_ +J9_P"K*T2OT0K\D\&/^25S'_LK>)O_ %82
M/UCQD_Y*G+O^R3X9_P#5= *^+/AI^Q__ ,*[_;5_:/\ VP?^%A_VQ_PT#X0^
M'WA7_A7?_")?V?\ \(E_P@GAGPAX=^W_ /"6_P#"37W]O?VK_P (I]L^R_\
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M?$7X;>#?&UY90 NP@M+GQ+HNISVT(:20B.%T0&1R%R[9]$\/>'/#WA'1=/\
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MEE)V2B[7L?Z&H.>115'3KI;NUBF5@P90<@C^A/\ /O5ZO%/<W"BBB@ HHHH
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M$U[5=$T;4-.^S:T\VMQ:EJEI:)HD6HS2M(L?DR=Q\'P%^$OPO Z?\*[\%?\
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M "2;XH?]D[\;?^HUJ=>3G_\ R(LZ_P"Q3F/_ *AUCUL@_P"1[DO_ &-LN_\
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M5(WBU/2K7Q=\)/%?B"WTW48I(H)([^QBU!+6\CD@A=+B*16BC8%!]"W7@O\
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MH6F^$-$T33-*\+Z=H@A:W&CV.@6%K;Z3::4+=F@&GV]I':"%FB$.PE3AZ/\
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MRMR1?:1):_!'69?#OA-]/=V2(Q^)?CIK&L_$O2PD,K7.C6DT;JR0F=/ZO_\
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MVPT'5G+SU[U^TI^S#_PT-XO_ &9?%7_"<?\ "(?\,Y_'?P]\:_L'_"-?V_\
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M=7T?_$<_"S_HJ?\ S"<1_P#SH/G?^('>*/\ T2__ )F^'?\ Y['Z(45^=_\
MPWO_ -4H_P#+Z_\ P.H_X;W_ .J4?^7U_P#@=1_Q'/PL_P"BI_\ ,)Q'_P#.
M@/\ B!WBC_T2_P#YF^'?_GL?HA17YW_\-[_]4H_\OK_\#J/^&]_^J4?^7U_^
M!U'_ !'/PL_Z*G_S"<1__.@/^('>*/\ T2__ )F^'?\ Y['Z(45^=_\ PWO_
M -4H_P#+Z_\ P.H_X;W_ .J4?^7U_P#@=1_Q'/PL_P"BI_\ ,)Q'_P#.@/\
MB!WBC_T2_P#YF^'?_GL?HA17YW_\-[_]4H_\OK_\#J/^&]_^J4?^7U_^!U'_
M !'/PL_Z*G_S"<1__.@/^('>*/\ T2__ )F^'?\ Y['Z(45^=_\ PWO_ -4H
M_P#+Z_\ P.IK?MYW$JM':_"E1<N"L);QH]PHD/W2T$?A.&24 ]426-FZ!QUH
M_P"(Y^%O3B=R?2*R3B*\GT2OE*5WLKM*^[0?\0.\4>O#*BNLGG?#UHKJW;-F
M[+=V3=MDSZT^/FN6>@?!OXBW5Y+%&M[X5U;0[=9) AFO-?M)=&MHH@?FDE\R
M]$@C4$[(W9ML:.R^1_L4Z9<V'P<N+N>-DBUOQEK>IV;,,"6VBLM'T9I$]5%Y
MI%W$2?XXW':O Y-"^.?[5NOZ3+XGTVX\$?#G3YQ.I:TNK'38D90);K3[74'6
M\\1:Q/"7@M[XHVG6>Z9%DL5EGBN?T;\-^'M*\)Z#I'AK1+?[+I.B6%OIUC"6
MWN(+= @>:0@&:XF;=-<SM\\\\DDSDN[$\?#-;&<<<>?Z\4LNQN7<,9+D=?),
MCK9C0EA,7G6+QN(A7Q>8TL-42J4\OITHNC2E-?O)^SG&2J?6:%#LXDHX3@G@
M1\$5,QP68\39SGE#.L\HY=7AB\+DN$P6'E1PN75L33;ISS"I6:K58P?[J'/&
M2=-X>O7VZ***_9C\;"BBB@ I"0.I%0W,HAA>0]%!/Y G\N.:_E7_ ."D/_!Q
M1K/_  34_P""A4?[.'Q)^!5K\4/V>]5^%'P]\;GQ5X$UEM&^,'A/4O$.K^+-
M/\174&F:[>2^#/'FG1P^'[0:1X9N+OX<WEO=SWMS>>,KRU:TLH=\/AJV*FZ=
M"'/44)3Y;I-QC:]N9I-ZWM>[V5W9/GQ.*HX2"J5Y<D'-0YK-I.5[7LFTM+-]
M-WI=K[1_X.!/^"@L?["'[!7Q#UCPOK?]F_&?XR)/\&_@TEI<"+4['Q'XHT^X
M&O>,;8*6G@3P)X4BUC7[:_$+VT?B1/#6FW#0MJ\#U\"_\&TW[!%S^SS^R1I/
MQ6\::,UG\4OVEKJP^)WB WMJ\6IZ5X%6WE7X9>'[IYU6YW/HEY=>,+B*58WM
M[SQA-8S1F:Q,LGX<_M%_M"Z+_P '"/\ P6!_9^^'G@:Y\0O^Q_\ !SPM8>(+
MK3?$5O/H%Y?^&]/32/%7Q<U2[T.5KQ[#5_%_B*?PU\)(WA%P#8Z9IFL13+9R
M22K_ *$_P5\):?X>\.:?#:6UO:P0VUO!;V]O"D$%O;PPK'#!;Q1HL<,,*(L<
M4: )&BJB@*!7JXF+R_+Z6$:<<1BFL1B4]XQ6E&D_1)SDG:TUU3L>3AI+'YA5
MQ:?-0PZ>'PS6TI-)UJL7MJK0B]5**[W/;+*W6VMXXE  50  ,8'I_GMBK=%%
M>&>\%%%% !1110 4444 %%%% !1110!0U*U6[M)86&X,C#!YSD8_^M^/;K7\
M6/\ P=-?L<:AXC^ _@C]KOP':SV/Q _9?\86LVK:QI"RV^L?\*W\;:QI>GR7
ML-U81&]FNO!OCN#PGK6FN\J0:%IFH^,-626W+W+2_P!KIQ@YZ=Z^,OVN_A1X
M,^+'PK\>> /'%A!JG@_QWX1\1^#/%FFS-LCO_#7B;1[W1M;M'D*GRQ<:;>W,
M/F=8BWF+RHKKP.)>%Q5*LKM1FN9+[47[LH_.+:]6<6/PT<5AJM)VO*+Y9?RR
M33A+O[LDFTMU<\2_X))?MJ:?^W=^PW\!OV@/MMG/XL\0^#[31/BA:6D*V<6E
M?%?PFS>'?B':1Z>K$V%A<>)+"]U?0K=N7\.ZIHUTA>*XC=OTZR#T(-?YF7_!
M)G_@JYX8_P""(?Q-_;A_95^/@\:_%3X:Z+\1]1OOANGPOB\.ZRFH_$?P?K$W
M@C6=2LEO?$.GZ7IUG\2_!EMX4UF[N[K5Y!HJ^";?3IK;^U;J2VD_J;_X(C_\
M%H/B7_P5B\:_M87WB?X0>$?@U\./@[-\&K#X::)I.N:QXM\7:C<^.G^+$_B:
MX\8>*;R/1M(OC;67A/PH--LM%\)Z.ME-=:H;F[U))[7[/V9AE=:A/$UZ4/\
M8X.$Z=2Z2<*SAR1C%VDW%U%%V5DHMNQQY?FE&M##8>I-_7)*4)TU%MJ=)2YY
M3EK&*DH.2UN[I);G]&5%-1MR*WJ :=7D'LA1110 4444 %?&?[<G_))O#W_9
M1-)_]1KQ;7V97QG^W)_R2;P]_P!E$TG_ -1KQ;7YWXM?\FXXO_[%-3_T]1/T
M+PH_Y.-PC_V-J?\ Z:JGT1\(?^23?"__ +)WX)_]1K3*]$KSOX0_\DF^%_\
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M&G@;X2:Y=376FOI0M-'>Z'C_ .*]E?)';6_@>Q6?2M#OY"?%EQ->V$_A*_\
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M4M-TFUTZ&.*")$"  !5"@8]@._\ @/:M6BBO./32MH@IDD:R*5< @C&#3Z*
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M32L-TI1I&^9F)_B&_P""$G@_Q1_P4,_X*?\ [7?_  4Z^)6GM+:Z=XGUNQ\
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M>)/%_@OQ)9V,?B"PUR[\.VVN:EX4?58KC0;W3]4LEN1!:ZA%$H2NA\-?$/\
M;P_:._:\_;0^!7PS_:(\/_!'X5_ 7QQX-BL/'%Q\(/ ?Q$\8Z=%XN\%P7FB^
M!O"VD:S8:9H]UI[ZCIOB#7O$WB'Q=/XBUF-9]'TO1FL('F<7/!5N7EJ584U0
M59U'5JU)TX^RQ$<,U"$*,I1?/**2C[3F7O>[\)$,=1YE.E1G5EB)4535*E3A
M4G[7"_6DYSG6C&2]FFW*7LU!^[:5N=_M117Y#?L]?M,_MG>*/@K^V?\ #R7P
MYX+^.O[7G[*WQ0U+X7>#=0M$T+X>^%/BH+]+!O#7B;6]/NM7\.^']&N;*R?5
MM?U;2K?5]!MKRSM+/1+:XM-3EDNY?GW]J#XX?MK?L/\ @71/CCXW_;T^#/QK
MUC0O$?@Y/B9^R[>_"GX0>!Y+O2M>UC3M*\1:=\.M3T35XOB?K-QX;FO)5$\X
MDO'TN"[\3:A:6EGIM[IZQ'+ZDJKH^VH*HY*%.'-4DZKE"$X."A3DXPG&I#EG
M6]E%MM7O&:CI+,J4*2KNCB'2Y)3J3Y::5)1G*G.,W.K'GG"4)\T*/M9*,>:S
M4H.7[]UYW\7O^23?%#_LG?C;_P!1K4Z]$KSOXO?\DF^*'_9._&W_ *C6IU\U
MG_\ R(LZ_P"Q3F/_ *AUCZ;(/^1[DO\ V-LN_P#4RB?._P"PW_R2;Q#_ -E$
MU;_U&O"5?9E?&?[#?_))O$/_ &435O\ U&O"5?9E?)>$_P#R;CA#_L44O_3M
M4^L\5_\ DXW%W_8VJ?\ IJD%>[Z/_P @G2_^P=9?^DT5>$5[OH__ ""=+_[!
MUE_Z315^T\,_[QB?^O,?_2T?BW$_\#"_]?:G_I".,\??\PG_ +?_ /VSKSNO
M1/'W_,)_[?\ _P!LZ\[KS\\_Y&F*_P"X'_J-1/1R/_D5X7_N/_ZDUC\:_P#@
MI9H^E^(OVMO^"6/A_6[*#4]%USXX?%'1]7TZZ4O;:AI>I^'/!=E?V5P@(+P7
M=I/+!,H(+1R,,C.:XK]A?XW0_LA_LH_MJ_!WXA7TM]JO_!._Q]\4K33(=5E8
M#7OAWXA35_&GP>,,A*7B?\)OJ[:Q8:5;RQHL<%UIL5M<")O(L_JC]L[X!_%G
MXL?M-_\ !/7XA> /"G]O^#_@;\8O&7BKXI:O_;OAK2O^$7T'5M,\*V^GW_\
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M\>9M9^)?BGX"0_%#7_ OB#7]=UZ+5=)\5?#ZW\0:7X(U2YO]-U6SG\2+X?\
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M ++U:QNK3S->T?2XKWRO/TZ2[MGCF>+1/V?OBO!_P54^('[1M]X5D@^".O\
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MK1\+ZYJRZEI.E?%GPS\3VO=1\3?V(9"TFD:-"EGIPB;3-&UB]T^QTIV^KO\
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M]#[_ .6MXT_^9RC_ %^X$_Z+7A+_ ,2/)_\ YL#_ %"XZ_Z(OBS_ ,1S./\
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MM9;PYQ#G-.57*,ASK-:4).,ZN6Y7CL=3A);QE/"T*L8R5U=-IZ['T'17SO\
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M'BW_ ,2?,?+^_P"7]65C_B,G%/\ T+N$_P#Q&<N_^0/SO_X9Z_:R_P"BX_\
MF3/B5_\ *2C_ (9Z_:R_Z+C_ .9,^)7_ ,I*_1"BC_B#/"O_ $,>+?\ Q)\Q
M\O[_ )?U96/^(R<4_P#0NX3_ /$9R[_Y _.__AGK]K+_ *+C_P"9,^)7_P I
M*/\ AGK]K+_HN/\ YDSXE?\ RDK]$**/^(,\*_\ 0QXM_P#$GS'R_O\ E_5E
M8_XC)Q3_ -"[A/\ \1G+O_D#\[_^&>OVLO\ HN/_ )DSXE?_ "DH_P"&>OVL
MO^BX_P#F3/B5_P#*2OT0HH_X@SPK_P!#'BW_ ,2?,?+^_P"7]65C_B,G%/\
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MNA^&;4G_ +^VT@_"OL6O-_A%X#C^&OP[\,^#]Z2W6FV32ZI/&!MGU>_FDO\
M4G5LDO$EW<206SL=WV6&!<*%"CTBNG@/*,3D/!O#648R/)C,%E&#IXNGH_98
MF5)5<11NFT_8U:DZ7,G:7)=:,YN.LWP^?<8\29O@Y<^$QN;XRIA:EFO:X:%1
MTL/6LTFO;4J<*O*U>//9ZH*]WT?_ )!.E_\ 8.LO_2:*O"*]WT?_ )!.E_\
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M_P#YC/B/]?>.O^BTXL_\2/./_FP^=_\ AE'X _\ 0A?^73XT_P#FCH_X91^
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MC0M(ULUM+*\I^2_^&2/C)X5DE@^'?QA6QT]G+QK_ &MXI\)2$L2298-#_M:
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MZFGAROHBOG?]J[_D@/CW_N5O_4T\.5\EQ_\ \D)QK_V27$?_ *I\:?6<!?\
M)=<%_P#96<.?^KC!A^RC_P D!\!?]S3_ .IIXCKZ(KYW_91_Y(#X"_[FG_U-
M/$=<A^W9^T)#^R]^R=\:?C''<Q0>(-"\(W6D^!HGE1)KOX@>*I(_#7@R.W@+
MI->?8]=U2TU:^MK7=<#2-.U&Y7RXK:6:._#RG*KP1P/2@KSJ<*\,PBN\IY1@
MHK\61XA5(T>->.*LW:%/BGB6I)]HPS;&RD_N3/K>BOPX_P""8?Q&^/?PE^-/
MQ$_8P_:L^)?CKXB^.]=^$/PF_:9^&/B'XG>*]9\4>(9+'Q7X0T#3OBMX*L=6
M\57E[K4]EX0\:&33-+TB.Z,2GP_XNUR/3[4W&I2M]A_\%$OVN/%/[+/PM\&Z
M7\)M"LO%?[0GQZ^(&B_"'X'^'-1M[FZT\^*->FBMY_$.H6L&S[;::&;NPM[?
M3S<1F\UO6-&2:.?3EU$)]M/!5%BHX6G*%5U%"5.I%VISA."GSW>T8QOSM_#R
MROL?$T\=2EA98J<94HTW.-6G)7J0J0GR>SLOBE*7*H)?%SQMN?H)17Y%V'_!
M-_\ :(\0^'O^$A^)7_!3/]L>+XW7L$%_<7_PS\;6_@_X*:/K<HBGN[.U^$UI
M86D&MZ)9SM<6MK_Q-?# O[=8+F72]-!?3T] _9*^)'[7DWPA_:)^%_[67A76
M['XD? 7_ (2?PWX1^/-GHU]X=\._'7PU%H^N-HWCCPW<+:V$,FK:>=.MY[[4
MM.AL$N(-4T65[2#7+?7-JEAJ?)*=+$TJKA*,:D4IPE:;45.G[2,?:04G9VM-
M74G!1=T0Q53GA"MA:M#VD92IR<J=2-X1YG"HZ<I*E-Q3<;MPE9Q4^9)/]-**
M_*W_ ((S?$/Q_P#%']@_P#XP^)GCGQA\1?%MYXQ^)-K>>*/'7B;6O%WB*ZMK
M#Q?J%M8V]SK?B"]U#4YX+.V1+>TAENGCMX$6*%4C4*.?_;Y^)/Q%\'?MO_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?G?^WO\ \TH_[GK_ -TZOT0K\[_V]_\ FE'_ '/7_NG5^2^.
M?_)K.*?^Z)_ZT>4'ZQX'?\G1X7_[K?\ ZSN;GZ(445R/CCQ_X#^&/AN]\9?$
MKQMX1^'OA#3I+2'4/%7CCQ)HWA/PW83:A=16-A%>ZYK][I^F6LE[>W$%G:1S
MW4;7-U-%;PAYI$1OUM)MI)-MM))*[;>B22U;;T26Y^3-J*<I-))7;;222W;;
MT27=G745F:)K>B^)M%TCQ'X<U?2_$'A[Q!I=AK>@Z]HE_::KHNMZ+JMI%?Z7
MJ^D:I82W%CJ6EZE8W$%Y87]G/-:7EI-%<6\LD,B.TVI:EIVCV%YJNKW]EI6E
MZ?;RW=_J6I74%C86-I I>:YO+RZDBM[:WA0%Y9II$CC4%G8 $TK.]K.][6ZW
M[6[A=6O=6M>]]+;WOM:W4NT5X7X4_:A_9H\>>(H_!_@?]HCX%^,_%LTWV>+P
MOX4^+?@#Q%XBEN-Q3R(]$TCQ!>:F\V\%/*6U+[@5VYXKT3QU\0_ 'PN\.W/C
M#XF>.?!_PZ\)6<]I:WGBCQUXFT7PCX=M;F_G6VL;>YUOQ!>Z?ID$]Y<NEO:0
MRW227$[K%"KR,%-NG44E!PFI2MRQ<9*3OM:+5W?I9:DJI3E%S52#C&_-)2BX
MQMJ[M.RLM[O0["BH+6ZMKZVM[VRN(+NSNX(;JTN[6:.XMKJVN(UE@N+>>)GB
MG@GB=)89HG:.2-E=&96!/(Z9\2?AUK7C7Q)\-='\?>"M6^(W@VST_4/%_@#3
M/%6A7_C7PK8:O:V=[I5]XD\*VM_+KNAV>IV>H6%WI]SJ=A:PWMK?6=Q;/+%<
MPN\I-WLF^57E9-V5TKOLKM*[ZM+=E.45:[2YG:-VES.S=EW=DW9:V3?0[6BB
ML'Q1XJ\,>"/#^K>+/&GB/0?"'A70;1]0USQ-XHUC3] \/Z+81%5DO=6UG5KB
MTT[3K2,LH>YO+F&%"RAG!(RDFVDDVV[)+5MO9)=6QMI)MM))7;>B26[;Z)&]
M17-^$?&/A#X@>'-+\8^ _%7AOQMX1UR&6XT7Q3X1US3/$GAS6((;F:SFGTO7
M-&NKW3-0ABN[:XM99+2ZF2.Y@F@=A+$ZKP/Q&_:)_9^^#NJV.A?%SXZ?!SX6
M:WJ>GC5M-T;XC?$WP5X(U74-*:YGLUU.QT_Q-K>F7=WI[7=K=6HO8(9+8W-M
M/ )/-AD5:4)RER*$G--IQ46Y)K=<J5[KKIH2YPC'GE.,8.S4G)*+3V?,W;7I
MKKT/8J*^6O\ AN7]B?\ Z/"_9:_\2"^$W_S75]*Z3JVE:_I6F:[H6IZ?K6B:
MUI]EJVC:SI-[;:CI6K:5J-M'>:?J>F:A9R36E_I]_:30W5E>VLTMM=6TL<\$
MDD4BL7*G4A9SIS@GLY1E&_72Z5]&G\Q0JTZE_9U(3MOR3C*U]KV;L?G_ /\
M-_?^?^B+U^B%?G?_ ,W]_P"?^B+U^B%?D7A/_P W+_[.UQE_[S3];\5O^;;?
M]FGX._\ >B%?G?\ M[_\TH_[GK_W3J_1"OSO_;W_ .:4?]SU_P"Z=1XY_P#)
MK.*?^Z)_ZT>4!X'?\G1X7_[K?_K.YN?HA117SK^UQ\7?$GP$_9E^.'QG\'V.
MAZEXH^&GP[\0^+M"L/$MM?WF@7>I:3:F>V@U:UTO4M&U&>Q=QB>.SU6PG9>(
M[F,\U^N0@ZDX4XVYIRC"-]%>325WT5V?DM2<:<)U)7Y:<)3E97?+%.3LNKLG
MH?15%?.O[(_Q=\2?'O\ 9E^!_P 9_&%CH>F^*/B7\._#WB[7;#PU;7]GH%IJ
M6K6HGN8-)M=4U+6=1@L4<X@CO-5OYU7B2YD/-> ^+OVL?B+H'_!2WX7?L:V>
MB^"I?AAXV_9KU#XQZKKMSIVNOX\M_$]IXD^(FCQV.GZI%XCA\/1:"UMX1TV1
M[6Y\+W>H&>>^9=46.6"*VTCAZDIUJ:2YJ$:LZFNB5'X[/JU;3N92Q-*-.C5;
MER8B=&%/35RKV]G==$[J[Z'Z$45^-/C+]K']O[Q_^W9^TA^R;^RYHO['EMH/
MP'\.?#7Q.NM?'W3OC3#J^HV'C?P'X'\07<+:C\//$=[9WEY;Z[XHO(K:,>&]
M'ABTF&V26XN[R.6:XR?C;^U%_P %4OV0O!T_QK^/WPA_8R^*_P %_"][I#?$
M*+]GG6_C)HWC70-$U'5K/2'U.)_B5=26DB+<WUM&'M-#U:.V,JSWZVUBES=V
MW0L!5;IQ53#JI6A3G3I2K1C4DJT8SIJTK)2FIJR<E=Z+6U^=YC1BJLG3Q#IT
M:E6G5JQHRE3BZ,W"HVXMR<8.+NU%V2;V/VLHKY+^-G[9_P &_@9^S#I_[5GB
M6\U*_P# /B7PSX3U_P ":7IL$#>)/'%YX]TB#6?!OAW1;.6X6V.K:O97 N9?
M,NOLUA8VU_?SRM;64C'XYT+XP_\ !8KXFZ /B5X,_9R_9!^%7A/488=8\/\
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MWP;^'W_"6V3V5K/+?_\ "&^(M#N=:T'R;R6YL/LNH3R2R?9/M2L(IXP/B/\
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MO[NU^V:9?6>H6OF^?9W=O<I',GF?[<?_  1=_9]\+?"#4OBW^Q_\+!HGQ/\
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M*&#EEN:K$2I_V#G;P'D__!95M,%M^P@OAL9^/;?MK_#(_",Z=D>)%T]5N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-1NXK-_MEO!),NFW=M+*HM;^ST#7[-/,>*8P>S?#O]FO_@H%X;\=^$=?\?\
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M@GF@TVXU+3K:.=E%W;W>HQ&-XY)E'[JU^8WQ%_9X\:_M]_L3_#OP/^T98Q_
MO]I>U32O&?A[7]!\0>#?%,OA?XP>!!/I\?C[PG=?#[Q7K&E:IX9UZ&ZDO;O3
M-(UY;O1=/\01VTDECJ^FZ?=K\D?%C5?^"Q7C/X2Z?\$4^$^@:A\0[74],O\
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M*D6IQE%J44[IGYW_ /-_?^?^B+U^B%?G?_S?W_G_ *(O7Z(5^1>$_P#S<O\
M[.UQE_[S3]9\5O\ FVW_ &:?@[_WHA1117ZT?DX4444 %%%% !1110 4444
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M"VU?1;S3]8TNXFLKJ>.'4=)O['4K&1EN;&\MKJ**9.*^"_P5^&'[//PX\/\
MPC^#GA.V\%?#WPM_:)T3P_;7^KZM]F?5]4O-9U*:?5?$&H:MK>I7-YJ6H7=S
M+=:GJ5Y<'S%A658(H8H_3HI8YXHYX762&:-)8I$.Y)(Y%#HZD<%74AE(Z@@U
M)7ZVJDG#EC-NG)J?*I-PDTFHSLGRMJ,FE+>S=G9GY,Z<5/FE!*I%2AS.*YXQ
M;3E"[7,DY13E&Z3<5=72/$/C]^SA\&/VH?!=C\/?CGX,'C?PEI?B;3/&6F:<
MOB#Q5X7N=/\ $^C6VHV6F:S9:UX-USP]KEK=6MIJVI6Z^1J4<4D5Y,DT<@(Q
MTOQ/^#GPN^-7@>[^&WQ:\#^'_B)X(O1;&XT#Q;9C6H#<6:,EGJ,-S>-)?VNL
M6@>1K76[6[AU>WDDDEAO4ED=V]*HJE4J)02J32IR<J:4I)0E+EYI05_=D^6-
MW&S?+&[T1+I4FYMTZ;=2*C4;A%NI&-[1FVO>BN:5E*Z5W9:L_/+P'_P2B_X)
M[?#;Q;9>./"O[,_A1?$6G7Z:G82^(_$7C_QQI-G?Q2/-!<VWAKQQXN\1>&H7
MMIG$UH$T@):2QV\MLL3VUNT7U;\=?@'\)OVEOAUJ7PG^-GA3_A-? &KWVE:E
MJ&@?V[XE\.?:+W1+V+4=,F_M7PEK.@ZU%]FO(8YO+@U***;;Y=Q'+$60^P45
M<\1B)SA4G7K3J4VG3G.K.4X-.Z<).3E%II-<K5FKF<,-AJ<)TX8>A"G4NJE.
M%*G&$TU9J<%%1E=:/F3NM"CIFFV6C:;I^CZ;#]FT[2K&TTVPM_,EF\BRL;>.
MUM8?.N))9Y?*@BC3S)I9)7V[I)'<LQ\C\-?L[_!WP?\ &OXC_M$^'/!_]G?&
M/XN:1X>T'XA>,/\ A(/%-W_PD&D^%=,T?1]!M/\ A'[[6[KPMI/V#3=!TFV\
M_1-$TVYNOLGG7LUQ//<RS>U45FISCS*,I14X\LTI-<\;J7+*S]Z/-&,K.ZO%
M.UTC5PA+DYH1E[.2E"\4^223BI0NO=DHRE%-6=I-7LV1S1+/#+ YD5)HY(G:
M&::WF"R*48Q7%N\5Q!( 24F@ECFB;#Q.CJK#QCX"_L[?!S]F/P5=_#WX(>#A
MX*\)ZAXDU7Q?J&GOK_BCQ/=ZCXFUN*R@U36=0USQCK?B#7KZ\NX-.L87>[U.
M98X;6&*%(XT"U[710IS4904I*$G%RBI-1DXWY7*-[-QN^5M75W;=@X0<HS<8
MN<5)1FXIRBI6YE&5KI2Y8\R32=E>]D>4_&SX(?"W]HOX;Z]\(_C-X3M_&WP]
M\3/I<NL:!/J.M:,T\VBZK9:WID]OK'AS4M'UW3;BUU+3[69;C3-3LYI(UEM)
MGDL[FYMYOG+XQ_\ !-W]C#]H!_ $GQ?^#T_C.;X8> =%^&'@BXN?B9\7=+N=
M)\$>'C,VDZ1<7.A>/M+GUR>W:XG>76M?DU37KZ21I+_4[I\,/N.BKIXBO2M[
M*M5I\KE*/LZDX6E)*,FN62LY**4FM6DD[I(SJ8?#U>9U:%&JY1C&7M*4)\T8
M2<HQES1=XQDW**>BDVU9MGY:_P##EC_@F=_T;5_YF/X_?_/4K]$_AK\./!GP
MA\ ^$OAA\.]&_P"$>\#>!M$LO#GA;0_[1U75O[+T;3H_*L[/^T]<OM3UB]\F
M,;?M&HZA=W4G66=VYKMZ*=7$XBNE&MB*U:,7=*K5J5$G:UTIR:3MI=:V%2PN
M&H-RH8>A1E)6E*E1ITVU>]FX13:OK9Z7/SO_ .;^_P#/_1%Z_1"OSMA9;C]O
MB22!A+'$TJR.AW*C0_!\VLJL1T,=R#"X[2 J>17Z)5^/^$VJ\2FM5+Q9XR<6
MM5)/^SK-/9I]UH?K_BOH_#=/1Q\*.#E)/1Q:_M&Z:W379ZA7YW_M[_\ -*/^
MYZ_]TZOT0K\\?V]D8I\*I IV*WC=&;L&<>$613[L(W(]E-'CFF_"SBFRO_R)
M'\EQ%E#;^2U?D'@>TO%'A>[M_P CI:]WP]FR2^;T7F?H=7#^/_AQX.^)VC0Z
M%XSTN74+.TOH]3T^YLM4U;0=9TK4(X+BS>[TC7] OM,US2I+S3;W4-%U1;#4
M+>+6?#^J:QX=U>.^T+6-4TZ[[2*6.>*.>%UDAFC26*1#N22.10Z.I'!5U(92
M.H(-25^KRC3K0<9QA5IS2O&2C.$XNS5TTXR3T:T:V9^98+&X[*\90QV7XO%9
M?C\)557#XO!UZN$Q>&K1NE4HUZ,J=:C4C=KFA*,E=J^Y\ZS_ +)W[/\ +]N\
MCX>VNE_:GADL/[!UKQ)X?_X1-E\W[?'\/_[%UBP_X5S:>)/M%Y_PFNF^!?\
MA'],\=?VGK7_  F5GKO]OZY_:)/^R=^S_+]N\CX>VNE_:GADL/[!UKQ)X?\
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MO/\ A-=-\"_\(_IGCK^T]:_X3*SUW^W]<_M'Z*HH_L[+_P#H!P?_ (34/_D
M7B+X@1M;CGC!<O+RVXESE6Y/8\EO]MTY?J]"W;V-.WP1M\ZS_LG?L_R_;O(^
M'MKI?VIX9+#^P=:\2>'_ /A$V7S?M\?P_P#[%UBP_P"%<VGB3[1>?\)KIO@7
M_A'],\=?VGK7_"96>N_V_KG]HD_[)W[/\OV[R/A[:Z7]J>&2P_L'6O$GA_\
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M=%_PB>O_ //A_P"35E_\DT?\(GK_ /SX?^35E_\ )-'U#'?] 6+_ /":M_\
M(!]?P/\ T&X3_P *:/\ \F<[171?\(GK_P#SX?\ DU9?_)-'_")Z_P#\^'_D
MU9?_ "31]0QW_0%B_P#PFK?_ " ?7\#_ -!N$_\ "FC_ /)G.T5T7_")Z_\
M\^'_ )-67_R31_PB>O\ _/A_Y-67_P DT?4,=_T!8O\ \)JW_P @'U_ _P#0
M;A/_  IH_P#R9SM%=%_PB>O_ //A_P"35E_\DT?\(GK_ /SX?^35E_\ )-'U
M#'?] 6+_ /":M_\ (!]?P/\ T&X3_P *:/\ \F<[171?\(GK_P#SX?\ DU9?
M_)-'_")Z_P#\^'_DU9?_ "31]0QW_0%B_P#PFK?_ " ?7\#_ -!N$_\ "FC_
M /)G.T5T7_")Z_\ \^'_ )-67_R31_PB>O\ _/A_Y-67_P DT?4,=_T!8O\
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MB^\9?_$IK?\ SJ.G_B,V!_Z(/P<_\1>C_P#/0_,W_C/O_/\ PI>C_C/O_/\
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M ":LO_DFC_A$]?\ ^?#_ ,FK+_Y)H_X@OCO^B^\9?_$IK?\ SJ#_ (C-@?\
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MCO\ H"Q?_A-6_P#D ^OX'_H-PG_A31_^3.=HKHO^$3U__GP_\FK+_P"2:/\
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MW*,-1R[,\OHXJJ^>N\NKQJPJQPLZCE.,*T8<CDXTZ5&E&%./LO\ PM[X3?\
M14/AW_X6OAK_ .6='_"WOA-_T5#X=_\ A:^&O_EG7C/_  [P\#?]!+XB?^%!
MX-_^9JC_ (=X>!O^@E\1/_"@\&__ #-5U_6?'/\ Z('AW_P\8WR_ZA_7^M^3
MZOX'?]%[Q#_X:,%_\T'LW_"WOA-_T5#X=_\ A:^&O_EG1_PM[X3?]%0^'?\
MX6OAK_Y9UXS_ ,.\/ W_ $$OB)_X4'@W_P"9JC_AWAX&_P"@E\1/_"@\&_\
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MK^L^.?\ T0/#O_AXQOE_U#^O];\GU?P._P"B]XA_\-&"_P#F@]F_X6]\)O\
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M*A\._P#PM?#7_P LZ/\ A;WPF_Z*A\.__"U\-?\ RSKQG_AWAX&_Z"7Q$_\
M"@\&_P#S-4?\.\/ W_02^(G_ (4'@W_YFJ/K/CG_ -$#P[_X>,;Y?]0_K_6Y
M]7\#O^B]XA_\-&"_^:#V;_A;WPF_Z*A\._\ PM?#7_RSH_X6]\)O^BH?#O\
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M_P#DFC_A$]?_ .?#_P FK+_Y)H^H8[_H"Q?_ (35O_D ^OX'_H-PG_A31_\
MDSG:*Z+_ (1/7_\ GP_\FK+_ .2:/^$3U_\ Y\/_ ":LO_DFCZACO^@+%_\
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MR<EIS1Z^%F'$,%&5+ 7E)IIXB47&,?.G"2YG+LYQ23^S(CAABMXHX($6.*)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGXV\U(S'?Z?%<>'?!]^CL)/!\9Y/]^'_  2M_P""E_["OA3]@/\ 8E\%>/\
M]M+]E'P9XE\&?LD?LW^$]=\.^+/VB/A%X>US0]9\.?![P9HVIZ/J^D:MXPL]
M0TW4],O;.>RO["]MX+NSNH);>XBBFB=%_P G3XT? 3XS_LZ^,KKX?_''X:>+
MOACXNM"Y_LGQ7I,]A]M@C*J;W1K_ !)IFO:8S.HCU31+W4--E)Q%=.:_L?\
MV+_^#:?]C;]H_P#9J^ 7QC\4^-_VHK7Q'\4_@M\+OB-KUKX:\=?#2RT2WUGQ
MMX'T'Q+JD&D6NH?!C6+VWTR*]U2>.P@N]1O[F&U6&.>\NI5>=P#^X[_AZ-_P
M38_Z2 ?L4?\ B5'P._\ FXI1_P %1?\ @FP3C_AX#^Q0/^[J/@;C]?'(K^2;
M_B$I_86_Z'[]L/\ \.)\)O\ YP=7;#_@TB_80N+F..X^('[8R1LP#%/B+\)
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MQ=)#I=UK$5]*]M!/<*D#-##+(%1@#^>#_@IK_P %:[WXH_\ !/K2?B;^S?\
M#C]N;X">!OC9\>?V<=+_ &;/VQG\/V/PP\#_ !I\.V'[6_PSTCQ /#LWP_\
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MG4]8AMOB'K_P&^ OQ6T73[G3_$6FZ+?:_J_A;Q)IVE?(_P"R3^WS^UA\4/\
M@J+_ ,%'?V;?'7[./[16H_!;X0>)/V/M#^'&FSR_L0Z?I?[,>F?$+X/^(]>\
M8^,OB5K.@?M#0?$+QQX;^,NKV%IX]\(6O@UOCKXO\-:#%_96O>%?AIK#R^$'
MYS_@F[\3/&G[ WP6\0?L+_';]FS]K'Q#\9_AU^U-\?[?X?>)OA!^S#\9_B;\
M)?VA/ W[0O[0GBSXT^ /BQIG[1^B>$Y/V<? &G+IGQ=_L3QQ#\<OC'\-M4^'
MUSX*UN/QA'IL-O937OH?P"T_Q9^SW_P6._X*3ZO\2OAA\:HO!O[;^@_L%Z[^
MSW\3_!OP-^,/Q,^$6KO\'O@U\0?AC\1=#^('Q8^'/@CQ3\/?@OKWASQ)IT,T
MEE\8O$?@:&^T76=!U;3+J]M]5MQ0!^D?[4_[5'PM_9"^&=I\2?B=_P )'J\W
MB7QIX5^%?PO^'/@328?$/Q,^-'QD\?WDFF?#SX/_  O\/75_I%AJ_CKQMJ<4
MMKIBZSK7A_PQH]G;ZCXD\8>)?#/A#1-=\0Z9XQ=_\%!O ?P\^%WQG^+/[5'P
M3_:+_8O\/? ^/P+<^(8/CWX0\"^*6\7VGQ-U2X\.>!(_A/XD_9?^)7[1?P^^
M*7B?7O%]J_@YOAEX+\::K\6M#\07OAE/$O@+1M,\>> -3\4^$_\ !5WX;_%K
M4/\ AA/]I/X7?#?Q+\9]-_8K_;;\$_'WXN_"GP)I5_XD^)&O?!N_^&OQ0^$W
MC?Q1\,/!NF07FI_$'Q_\.(/B-:^,]'^'FCV;^(O%MCINK6/AF277TT[2=7\<
M_P""@6N>.?\ @H%^ROK+?LM?L^?M&>)-6_9>_:2_8Y_:6LO"7QU^!'Q"_99'
M[22?!OXU:=\2_B%\&/AMX5_:>TCX3?$34-?T;P9X7@U.X\0^)_AWI7PK\0ZU
MXE\*^$?!WC;Q1XEMO'EEX  /L#X=?\%%O#>O?&#X/? [XX?LR?M2_L<^./VB
MM*UV^_9_/[2.C? V?0/BSJ_A7P\_B_Q/X%TW7_V?/CU\?-/\#?$?1?"44_B-
MO GQ@?X;^(]7L++5(/#ECK6IZ-K&GV'ST/\ @MA\$=3\%_M,?$[P3^R]^VO\
M1?A5^QA\6OC1\)/VL/B;X6^&?PHLO!_P4NO@1XBN]'\<>,9[CQK\<?"&J_%G
MPG:Z'INI?$.\L_V>])^+_CWP9X!MK35OBAX'\ ZCXA\*Z/KW$?&WQ+K/_!2;
M]H?_ ()V:/\ !KX'?M*>!OAU^RK^U+H'[:/QW^+7[1_[,GQP_9>L_"</@OX0
M?%[P1X(^#'A#2OVA_ ?PV\0?%+QQXZ\7_$.!_$4OPOTWQ;X,\%:!X7GU?Q)X
MLM+K4?"6G^(/"_V<_@;\;-#_ ."5?_!;/X>:U\'OBEH_Q ^*W[0G_!9'6OA=
MX&U3X?>+=/\ &/Q)T;XH?\+"_P"%::MX!\,W>D0ZUXQTSXA_;;/_ (0:_P##
MMEJ-KXM^UVW]@2ZAY\6\ _4SXH_\%!OAKX1\<?!7X5?![X8?&+]KGXL?'OX/
MZG^T1X#^'G[.R?"&VU!?V?-*G\,V$OQHU_Q;^T#\7_@+\,=%\%WFM^-/"/A_
M1X)_'DGBS7-7\06<6D>&;VUMM3N[#0^)?[>G@'P"_P !/">A?"']H#XJ_'S]
MI/PKKGCGX9?LM^"_!7AGPK\=8O!O@[2M-U7X@^*/B-:_'+QS\'_AE\'M"\!-
MK&DZ%K.I_%CXF>#;36O&&JZ3X)\#2^+O%NL:3HU[^-WQ#^"/PAB_9 _X)U#X
MS_";_@I]\ /VOO@3_P $YO@)I'PA_:D_81^"G[2/B3XL^$?$5CX)^&UU\3_V
M7/'>C_ 7P5\6%L[U?$7PZ\+VOC'X<_ME?!G3/A;>:3XWUBS^&?B8^+K?XNOX
M)X?6?@%^UE/\8?\ @G#^VM_P4E^''[4OB[4-6_X)V^)/V5OVN-3_ &!O&/[3
MW@SXO_ _]H"X^(WA/XO>%/'GCOP3_P $]/'?A[XO^/?!/Q2TS1M0\*?$KPS\
M&_"OC#X8>$/BW8:-XBOO#OASP=IGA&[T< _9'1?^"I?[+O\ PSU^TA^T)\33
M\0_@-!^Q]X\OOA7^TW\(?BSX5LU^,_PE^)9OO#UEX/\ !UQX=^'6O?$/PQX_
MG^+*^,_ MU\'?$OPC\9?$+P-\2H_&FB67ACQ5>ZQ!KNF:-R&@_\ !5GX?1_M
M"?LO_LL_&']EO]L3]FGXX_M?WGBA_@GX3^-?@;X0MIFL^%_!OPW\3_$GQ-XP
MU/QS\)?CC\5O .F1^'K;PP/#'BGX=?\ "47'QP\$>(_%'@2Z\<_"KPSX.\;^
M&_%NH?G7^TC^Q-X'^*W["?[4GC/]@G]FW]K1OB?J_P"TI^R9^T5K$7[7OBK]
MIB3XO_MHR_LA^-/A3XJNM.T[2_VX?B3XD_:*\/0Z3X#\/>(OA3X&TWXN^$?A
M7)XJ\3^!M(@\*Z/K'PPU'P/\0M5C_:<_:F'[1W_!5O\ X(6'P9\"/VB_ _PV
MTGXN_M<ZAJ7Q&_:#^#'Q#_9LOF^(E_\ L>>/#-\*]#^$WQQ\->!OB[XBN_#V
M@O%KOB3XE:9X.?X-R3:EI?AKP5\0/&_B>R\<Z7X' /UZ^''_  4%^#/Q/^"W
M[9?QUT#PS\3K/PC^PY\8/VJ/@I\6=.UC1O"MOXC\0^*OV1$O7^).H?#NTLO&
MFH:9JWA_6Q83?\(/=>)=7\):CJ1:/^WM*\- L4Y6X_X*6?!Z^^%W['OC?X=_
M#3XW_%_XC_MT_!_PY\=?V>?V:?A[HOPX3XXZQ\--7\!>%?B/K_B;QE=^./BA
MX*^!_P -]&^'WA[QGX>M?&'B'QS\:="\+3>*-2T[P;X-U[Q?XIUK0-(U;\=K
M"3XZ_LM?L\_\%L_V16_9$_:I^,'Q[_:=_:J_X*#?&S]FNQ^%OP0^(6M_![XL
M_#+]K_PE+XH\*Z^/VEE\.-^S_P"!]2\"6E_K]IXT\"^.?B%H?Q(U'6O#2>%/
MA[X.\;^-_%?A#PMK/%Z%^R-XY\ Z;_P11_:+^/7PA_;2O/@O\.?^"1'PU_8V
M_: \._LJZ_\ MA_#/]I;]FCXOS>"?@'XT\/^(/&_PX_8]\6^#/VI?%OA34=5
M\'>)OAA\0? _ASPQXJ@\%>)K31M?^(/A2%-&TS6/#@!^O_B;_@KQ^SAX%_99
M_:N_:<^(7@+X[^ [_P#8>\76?@;]J?\ 9O\ $?A?P&?VB/A/XDUC7O#NG>%X
MKG2]%^)>L?"3Q?H7C7PUXN\,_$?P7XU^'WQ@\6^!_$W@?5O,TOQ)/XHTO7/"
M^E]UX"_X*4?#CQ9\?/@Q\!_&/P(_:;^!+_M.Z'\1->_97^*'QO\ !'@/PM\/
M_P!H6#X:Z3IOBK6=)\.:+HGQ0\4_&;X5>+]2\ :A-\0]"\!_M+_"3X%^-KSP
MQHVO6UUX?L/%6DW/AH?C[^WG^RO\,?&O_!([_@JK>_L._LM?MV:O\3_VC-*^
M"^DZEJ7[0-I^V;\2/VAOVF]3^%_BGX=6VBZEX5^&W[6GC/QW^UA:Z1\.]#N=
M<\&P1>,/AU\.WU.S\-7FJ^%M,\3_  ]LO#?BR\_1_P#X*%?#3XC^-?VX_P#@
MC5XM\&_#_P ;>+?"OPO_ &K/C=XB^)GB;PSX4UW7O#WP[\/ZM^RQ\3O#VE:[
MXZUK2K"[TWPCHVIZ_?V&AZ?J>OW.GV5YK%[::9;3R7MS# X!Z[J/_!2;PCJ'
MCWXL>&/@U^S+^UC^TWX$^ 'Q*D^#WQX^.?[/_A#X2>*/AS\,OB=HMY9V_P 1
M/ \'A;Q/\:O!OQ^^,/B3X1VVH65W\2-(_9U^"?QDOM*NY;CPCH\&O?$#2]8\
M(:=?^+?_  44\,>!OB!\9_AK\'_V:OVHOVP_$G[-NB66K_M$-^S-HGP2GTOX
M0ZAJ_A?_ (3?0O!&HZC\=OCK\"XOB#\3-8\&E/$J?#?X*+\4/&FC:=>Z#'XH
MT70;_P 6^#[+7_A?]A'XG>-?^"?/A3]H;]D_XZ_LU?M8^,?B7:_MD_M'_$OX
M,>(O@-^S)\:/C'\./VC/A_\ M*_&'7OBQ\//$5K\>/#?A"3X!?"GQ';7/C>X
M\%^/M/\ VA?BW\*],^'UWX>;7/%?B6P\'2Q>(U\%T#]G+P3^SC^V/_P4,E_:
M[\#?\%,6\+?M'_M,-^T[^S]\:/V&O''_  58U/X8>,O!/C?X9?#OPMX@^'7C
MGX=_\$V/&VHV7@KXE_"GQ7X,U'3I-?\ B[X%T'6/'/A;5M#D\+^(M;\.^'[3
M2?#P!_0U\"_CC\*?VEO@_P##KX^? [QE8?$#X2?%CPMIOC/P#XQTZUU33[?7
M/#^JQF2VN)-+UVQTO7=&OX766SU30]>TO2]=T34[:[TG6M-L-3L[JTA]7KYD
M_8T^$GPN^!?[,'P<^%WP7^#7C;]GOX8^'?"S7/A7X+_$CQ!<^*?'WP]M_$VK
M:EXLU#0O%^NW?Q"^*US>^(!K&N:C>:FLOQ#\5-9W-T]C_:*BV%K;_3= !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-=U0
M%F( '<TZN<\40O<Z5=VP0NEQ;S02H&9=\4L;I(I9"KJ&1BNY65ADD$'%)WL[
M)-V=DW9-]$VDVDWNTG;>SV#T_K\SP;XQ_M8?"7X.)<6FLZXFJ^(XD;R_"V@F
M/4-9,FUBBW:JZVNE(S+CS-3N+4D$M$DI 4_D[\8_VXOBU\3&NM,\.W)^'OAB
M;S(A::)<NVNW=NV],7WB )#<1;XV&Z+2HM/4<I))<+\QL?'W]G'^PM:U#5O"
M5C>6D%Q//<3:=++<WMMYDCR2R-;W%QYMW'O=LE9Y[A<G"E%X'QE?:=?:;,UO
M?6LUM*I(*RH5R02/E)&&''4$\5_"_CIQ=XX8*IB<)C\#4X9X3G.5*EC.&*U;
M%X7&4I/EA''Y_"G1QE*=6\H?5:M#*(UX-QE@ZT5SOX'/\9GT'*%6F\+A&VE/
M"RE.$T]$JF(2C--[<CC14EO![G[!_L;_ !R\':#\+_#7A[Q5XU\.Z/=:=)KK
M3+KGB#3;"Y,E]XAU?4C)*+^[BE9YC=^:7<%I/,WY;<"?N(?'WX+8'_%UOAS_
M .%KX=_^6%?@5\+/@]'X_LDNI$U0AVE4&RFAC4^7)(G ELKGH8R#R><_2O<!
M^R59D ^5XHY_Z?+/_P"4M?KO!.<^,E/@SA&&6\&\)8O+H<,9!#+\5BN)<11Q
M.)P4<JPBPN(Q%%862I5ZU!0J5:2E)4ZDY03?+=^S@*^=+ X)4L%@YTEA,.J<
MYXJ492IJC#DE*/(^64HV<E=V=UKI?]AA\?/@J?\ FJWPY_\ "V\.?UU$5W_A
M_P 4>'?%=@FJ^&=<TG7],EDDBBU'1=1M-4L9)86V31I=V4LT#/$_R2(LA:-@
M5<*1BOQ!M_V1K"25$D3Q2J,<$B\L00/49T0CCZ5^G'[-/P]B^&/@NU\*:>^I
M/IT%U>WR'5)H9[H2W\WGSJ7M[2RB,:R%M@\D.H^\S'!K]*X6S+Q*Q>93I<7<
M,\/91E:PM6<,5E6=ULQQ,L8JE%4J,J%2A2BJ4Z;KRE4YFXRA"-GS-GJ82KF<
MZK6,PN&HTN1M3I5W5ESWC:+BXK1IRN[Z-)=3ZDHHHK]"/1/S$U_XJ?"WPY_P
M5AUOPE??$S]KZ7XHZ#_P3$U+XJ7GP3M?&?AU_P!AJ3X6Z7^TE-IEQ\3+;X;S
M:C!XB?\ :^?Q% _A*'QG+;0^'6^$!707U&.^)C'C?PZ_X+@_L\?$CX+_  ._
M:CM/V>?VQ/"?[(WQP\6> OA];_M3>/?AS\+_  O\+/AQ\0/B+XD7P1H7AWXA
M:%=?&F7XRRZ)!X\N=)\#:E\7OAS\*?B'\!8?%.LVNG6OQ6O5T_Q#/HN3\2?A
M1\4K[_@MGX^^*UC\-?']Y\+KS_@B3XI^%%G\2;7P=XBN/ -U\4KC]K2_\26_
MPUMO&,.G/X=G\?S^'737H?!T6HMXBET5EU1-.:Q83G\[O&_[.7[0MW_P:L?!
M7]GBU^!'QFN?C_I7@7]BBSU3X&V_PO\ &\WQATV[\*?MM_!#Q7XHM;_X9QZ&
MWC6SN/#?A;2=5\2Z_!<:)'+H^@:9J&LZBMMIUE<W,8!^Y?QN_P""@O@[X5_'
MR_\ V8?AQ\!/VC_VL?CAX5^$*?'CXJ>"_P!FSP[\+;V+X-_##4==;P[X0U3X
M@^*OC3\7?@KX+E\6_$/4;+Q%+X ^$?@;Q%XT^,OB71O"FO\ B.V^'T?AU=+U
M35/PV_9M_:XT/XG_ +"'COXR_'+]I']OFW\(^*/^"\?CCX<?!SQA\#OB!K_@
MOXPIX9\5_M0V'ASX&_![QO9_&JXTCQ)X6_9KCM->TW1OB3\';G3M&UO0O",=
MQX<L?"MCJ5G)I*_>-O?>+_V%O^"J?[>?QR^(OP3_ &B_B?\ !C]O7X)_LH^*
M/A)\0_V=_@!\5_VBX] ^)O[*GAKQ?\)_&7P$^(&E_!OPKXTUWX8ZOXFLO'/A
M;XA_#SQ9\2-.\&_"#5[74?&\?_"QH]8T'Q-I^B_EUX>_9T_:SU7_ ()Z:GI/
MC#]E;XV^!OBSXH_X.*/#_P"TIKWP>/@W6?&/B?P?\,]>_;(\)_$36_%LFI>#
M]/U31/%7P[\(://?OJ7Q=\)7>K?"_4M.T>]\2:)XIO\ PVT&J2@'[X:]_P %
M./AM#^V+\4_V$?AW\!/VE?C=^T;\'=/^%_BGQKX>^&N@_!_3_#%E\-?B9X;C
M\0R?%%O'WQ5^-7PR\'6/ACP--J7A?P[XET'7=8T?XF>(]>\662_"3P!\3='\
M.?$'6/!MKXJ_\%*/!/@?Q=\?O"_PM_9Q_:B_:NL?V4+56_:=\:?LY>'?@WJ'
MA+X.:ZO@Y?B+>^!)&^+OQN^#_B/XO?$G1O $UAXI\0?#W]G/PY\9?%WA]-9\
M/^&M9TFQ\<>(=#\+:AX[^R'\,_B1X:_X*]_\%C_B7XC^'WC?P_\ #CXG^ ?^
M"9EG\-?B!K?A37M*\$_$.\\!?"7X\:;XYM? WBN_L(-"\6W/@O4=8TFP\60:
M!?ZA+X<O=4TZUUA+.>^MHY?SS\!?LX?#[]FG]HW_ (**^&OVR?AU_P %1)=.
M^-G[7_Q%_:K^ _Q5_8B\<?\ !67Q!\$OC#\*OC_I&D:E<^#]6\!_\$Z/'FK>
M%? /Q:^#OB;P_K'PZ\:_\+G\&> ==\8Z#_P@^L^%-0\5>"DM[O2 #]CO&_\
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M^";2?LK_ +5FM_\ !/WQM^U7X9^)?P!_::T/QY'\:])\2?$/P+_P3M\?Z/\
M%_Q[\/OC!9W>L^"O%%O\(O"GQ!^%7@OXN^&]$U36+#POX+N/!^MV/I7Q^_8\
M\*>,/V+_ (I_%C]@7]F+]K";QIHG[;_[*/[7OC#P[^UAXH_:1G^//[:EE^R!
MXP^&^OZV/#FC_MI?$CQ3^T)H5U_PB7AG4OAWX#T'XT>&OA9JGB_5OA_;-X5\
M+ZKX%USX=>.?$H!^MGAS]O#1].\,_%?QO^TM^S=^TS^Q%X&^$/PFE^-NN^._
MVE=%^#6J>!M3^'^FG4!XGFTWQG^S1\;/VB_#.D^+_"BVNGRW_P ,?'&J^#_B
M=KT&O:?<>!/!_BZ#3_%$GA[S7PS_ ,%1? -QXE^!%I\6/V9OVM?V:OAK^U'X
MPT3X>?LZ_'?X[^#_ (0:5\-/B=X_\:/$_P +O!-YH7P_^-_Q$^-?P=\4?%RP
MDDO?A[I'[0WPA^$%SJ%S _A?6%T/QQ-9>%KKYZ_;Q\0:]_P5/_8#_;-_97_9
M>^#W[2N@_$+Q)\!M/U_0M7_:5_9C^,W[*7@C7/'>F^+]'\6^&_@=;3?M/>&_
M@QK/BWQ'X_3P;J^@ZIKG@K2/$_PN\$65S#<?$CQWX977_"EEXG\^_:F^(WBK
M_@IM\-_V7/V7/A+^RW^U7\)_%FH?M#?LQ?'C]HG5/V@?V9?C#\"_AY^RW\._
MV=/BKX!^*/C_ $6+XJ?%/P1X.^%WQL^)&HZUI%E\,/AYX8_9S\4?%"U\5B_U
MKQS'J5A\,?#VK>*H@#ZEUS_@K/\ #T_$C]K7X2?"G]E']M#]H;QY^Q+XFDT/
MX^:9\(? 'P@@TO1]('P]TCXBVOBWPOXN^*_QU^%O@WQO%JFG:I-H^D?#GPSX
M@U#X[:GK&C:K<VGPDD\,C3?$6I>E>-O^"G7[->@? S]EKXW_  [@^(W[0DG[
M;VJ>#]$_9)^$7P4\,:;??%_XX:GXKTQ/$>HII.D?$/Q#\.O!_@32_AQX,AUO
MQI\6?%'Q?\;_  Z\(_#K0O#6LV_B/7K7Q"^CZ%JWSQ^P3\+OB9X._:-_X+5:
MYXN^'?CKPMHOQ5_;!TGQ-\+]8\1^$?$&AZ7\2/#<?[+7PH\/2>(? 6H:GI]K
M:>,-#CU_3M0T-]6\/3:C8)K%A>:8UP+VUG@3\HOV3?V?_P!H7]G']E__ (-V
M/VIO'7[//Q[OM+_8?\-?M1_"K]J+X->'_@W\1?$O[0?PMT#]K;P]-X%\._%1
M?V?M&\.WOQ>\30?#SQ1X<\/P>--"\&^"_$/CK3/ GC?5_$UCX8O]$T[6;JS
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M2K;PWJ0^S7</@BZO-.MKZ.UL9O X!_5O\4_BU\/?@?\ "SQS\:OB_P")M/\
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M5_B!\1_!.F>"OB+=^#OQ"_9N_9N^'-O_ ,$T/ OPQ_;H_9A_;>T2XT_]N_\
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MX=UN[O=&A\/:UX7N;?6H[>XOKS4;%)-.E^I:* "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img148586500_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &0!)P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** (;B>.VADN)<B.)2[[1DX'H.YYK$_P"$GTO^]/\ ]^3_ /%5>UG_
M )!=]_UP;^8KRJ@#T?\ X2?2_P"]/_WY/_Q5'_"3Z7_>G_[\G_XJO.** /1_
M^$GTO^]/_P!^3_\ %4?\)/I?]Z?_ +\G_P"*KSBB@#T?_A)]+_O3_P#?D_\
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MZYDU.Q0:8;#7K-[8OJ_VB'329[420B\62(K(JL-#QI^U;^SS\#-%\$V_Q?\
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M#/&OB5(GG.CZ1=7?VLQ1F0.\8NK.VCE"^5)GRW<_(3C% 'V]_P )/I?]Z?\
M[\G_ .*H_P"$GTO^]/\ ]^3_ /%5\6>(?VN?V;/"GCH?#/Q#\8?".E^/6U#3
M=*'A:XN+MM5&HZO,UOIEJT,5I(BR7DR-'#ND"EE.6 YKF=9_;I_9&\/>+I/
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M)=:7<W*IH]A%'/+)=WBW=M;2+"D=M.Y=4<;8G(Z5F?#/]K_]F?XR>,9_A_\
M##XR>#_&7C.VMK^\F\/:3<W9OUM=+FBM[^=5N;.WBECMIIXHY&BD?F1=NX'-
M 'VQ_P )/I?]Z?\ [\G_ .*H_P"$GTO^]/\ ]^3_ /%5^=?[-/Q?\9>)_B=^
MT1\(?B'J9U77?A7XYM;3P]J!M+2S.I^%+_P_H6IK=B*TBA0K;:AK#Z?O,>6-
MOEF+$Y^S: /1_P#A)]+_ +T__?D__%4?\)/I?]Z?_OR?_BJ\XHH ]'_X2?2_
M[T__ 'Y/_P 51_PD^E_WI_\ OR?_ (JO.** /1_^$GTO^]/_ -^3_P#%4?\
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MZA::;&;>&>>VB<I->1O)NF3$:N1N8!2 ?1O_  EW_3E_Y&_^UT?\)=_TY?\
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M +\G_P".4 <;179?\(B__/ZO_?D__'*/^$1?_G]7_OR?_CE '&T5V7_"(O\
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M5>"I_%7B76_%-IH7AOS])U:%/"/C5],AL+J66V$=SI=@\P9]DDGELR_T'?\
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M:V+O$3&2REE)_*S]I_QSXZ^)FC_M*6?Q!\>?'KPM\4?[>71_"/P!^'W@4/\
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M9S>*5FM)XP\L"I^[R&VE2?T^_P"$9TO^[-_W]'_Q-'_",Z7_ '9O^_H_^)H
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M[LW_ ']'_P 35RRT>ST^5IK<2!VC,1WON&QF1SQM'.47GZT :E%%% !1110
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MI0$20W5DTQ$0 /WKJO=7=I8PM<7MU;VENF-\]U-';PKD@#=+*R(N20!EADD
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M*** "BBB@ K^6G_@V7_YRA_]GM:W_P"[-7]2U?RT_P#!LO\ \Y0_^SVM;_\
M=FKZO*/^28XO],@_]64R'\</2?\ [:?U+4445\H6%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%5HKRSG2:2"ZMIDMY)(IWBGBD2"6'_6QS,CD121?\M$<JR?Q 5\^?M9_'3P[
M^S?^SS\4?B_XEO'LK'PMX9NS;S0Q37-PNJZH4TC1V@L[:.:[O'35+^T8VUK#
M)<2J"D2EV6OYP/\ @G'^V+X!;4OCU\$M-^(GC?Q#J7QU^!?BKXUWUMXL^&_Q
M2\!PZ=\=;GPOXCU[XU-IFI>/?#.A6<UC/,NC+IEI87,\L1C*AG,D>0#^LA)$
ME4/&Z2(W*NC!U(]0RD@_@:?7\\7P^_;"_;4_9T\-_ ?6/'_AGX.>/?@A\;?'
MFE_!3X5>%/ UMXB;XQZ?XZUMKY-&O_%VM:AXBN?#%UH=PFB:E/<&PLH)+,3V
MEO=S07 =&TOV5_\ @J5\;/%NJ?'R#X^^)?@C<:]\-_#USJ&@?!WP3\)_C?\
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M>_%OP)\-/$5C\<E\42>6N@?$2_T_Q;'J'A[^Q+6WN+N6Y@L+J6X>6T$T)4J
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MW.57<[$*HSEF( !) J2OY(-8_P""K'Q"_:'_ &?/BQX/^)][X>\9ZMX(\4?
M'XC6GCKX-?!7X^?"7PH-$D^,GACSO"<T/QBTRVU75O$D,&G7/VAM'>6RNH[V
MUBAC=O,4_P!!7[%?[3.M?M7>%/&/Q.%OHVC^"8O%NK^%_"7AQ[#5=.\<:=_P
MCU]<V5_=^++;4I%6--1'V:334BLK1U$=R)E8[=H!]?WFO:'ITRV^H:UI-A.X
MRL%YJ-G:S,"0 5BGF1R"2!PIY(%/N=:T:REB@O-6TRTGFV^3#<W]K!++N.%\
MJ.65'DW'A=H.3P,U_*=^VO\ LJ_&;XB_M8?M@?M3?%+X,_LS_%CX$?!#Q!\-
M6\ Z-\6?$OBJY\;:IX,?P9X<E\4V_@F3P-\1] T;PCJB>+3)+$OCVPA^TK%)
M-!%+;S1.WUA^V%\"_P!EOXDMHGC6\\"^-_CI^U'\3H?#MY\$?"EMK-S!?_!6
M'S;6.&\T6[LY=.T/2-!\,"VU#663Q3<75U?QQ75K:27-U<6L+ ']"8((!!!!
M&00<@CU!'!%+7EWP2\->+_!WPB^&_A7Q_KS^*/&WA[P;H.D>*O$4GW]:UVQT
M^&WU+4G^5/FN[E))C\B_?^Z.E>HT %%%% !17S?^U]^T3I_[)7[,_P 9?VD=
M5\./XOT[X/>#;SQC>>&H]83P_)K$%G<VMN]FFM2Z;J\>G,WVD.+AM-O -FWR
M3NW+_,#KW_!W'\//#'AQ/%.N_L5ZW8Z3=B4:3*?VA-*D.J2QDA8H0OP@ C:0
M[0"Y(&[GIR ?V'45_&EX$_X/!_A9XV\-Q>(W_8H\3:##+K!TB.#4?C]H\GFO
MB8K-!+#\)SYF_P GY8VCB^]DN-N#Z1<_\'67ABUUVW\-3?L0Z]'K-_$MUIEC
M+^T)I23WEBQ8?:\+\(9$B0>7,=I=S^[/// !_7+17\E4'_!U'X:OKG4H-+_8
MHUC44T*18M>GB_:%TM(]+D+M&RR!OA"3(4:-P=NW.TXKSD_\'=O@.W^*-C\-
M+_\ 8:\46[ZAIDVJ0Z_!^T%HMU8B"+[(2)+=OA-;RKD7:$L)#MVL,'.0 ?V-
MT5_(UH'_  ==^ O%.ES:IX?_ &,];U.*UNIX+TP_'[21#:1P320/-+.?A/G.
MY ?+6$XW8W_*<^B^&O\ @YW\(>(]1CTY/V/]:M6N(FELY_\ A>FF7$%R%#LR
MAA\+8BC!48X(.3@=\T ?U045_.!I7_!Q;\,;^"W-W^SIK^GWLLUW#+9_\+1T
MRY\@V80R-YR^"8MZ'<<'RD("DD<XJZG_  <+>"Y?%GAKPU!^S#XCN8?$TK1V
MFKV_Q4TN2"$K+%"WFV[>!HW)#29*K*,;2,YQ0!_1E17XC:9_P66M=3G^S+^S
M9K,,T]TL&GAOB?I[QW:&/S#,[IX)S;A2'4ILF)V9W<X'MFE?\%,H-0@,\WP6
MN+7Y&9$C^(5O<M(0N=J_\4= <GIDC'>@#]3:*_+=O^"E]K'$KS?!74(I& ?R
M&\=VN_RR,[QCPKSQSC'MFN@/_!1735LEU"3X4WB6S! &;QG;@F1UW",#_A&L
M9&&&21]W\@#]***\U^$'Q%C^+/P[\._$"+27T./7_P"UMNEO>KJ+VO\ 96N:
MGHIS>):V:S><VFFX&+:/RQ*(OG*>8_I5 !1110 4444 %%%% !1110 4444
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M*.2-;73]9U:WMY[2Q82EGMD4JS)&V?D%?1U%% !1110 4444 %%%% !1110
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MW_$#_P 2,\._G_R2'I^- ']U]%?PCR_\'P_PLC<I_P .[OB <=_^&C?#@_\
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M?Z7;>+--M+G4(M/O7L[-KFU0K',;2W+ ^4N.;^&G_!/+]GSX7Z186.FMX_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_EI_X-E_^<H?_9[6M_\ NS5_4M7\M/\ P;+_ /.4/_L]K6__ '9J^KRC_DF.
M+_3(/_5E,A_'#TG_ .VG]2U%%%?*%A1110!_,3_P=T_\H<?&G_9?O@5_Z?-4
MK_*4.>W7^=?ZM?\ P=T_\H<?&OK_ ,+]^!6/<_V[J?%?Y2@SSNQT_+U_SR*
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M+U5W&XCK^U-?@9^Q!>Z?<?M*_#V.VO'G=(?%01/E50&\ ^)6(8%$8[5';)R
M3P,U^^= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM/&OP8^&^C?%;QG;W5E=06MOX-UVX\0VUAJ5M=2P);W2N_AC56<02RLB0AF
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MO$.L76GO%X>)CT>VTW3]39-6:T?3Y[FPFM(KAK@%%PO^"MOQG\5_&C]A._\
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M)_Y*5_P2K_[2:?!K_P!0#XIU^N5?D;_P5)_Y*5_P2K_[2:?!K_U /BG7ZY4
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MT+PSX8UR\^(TG@CPEXM76?&3736FK7G]M6HT*V?S=)T[0VO;]/,MK9'FE1:
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MQL_"/GEM7G\,:=?VVEWNLB%4*)9V^H7EK:NTDB2&2=-J,IW#\Y/@):?M%_\
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M\7C3GV7&\QW3;& D7 _6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@\@#G'8_D!7R?\6KA]3A-A&@R9  XSE200"#U')SUX]* /[H_P#@D%=K?_\
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MHY9)TLXKGR_-CMUEEDD$2N$#.QVY)K;EBBGBDAFC26&5&CEBD4.DD;@JZ.K
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M?##Q#>:=9:UXSUC7-8^RS:QJM_?-$]ZR>;<.0 ,  '[M4444 %%%% !1110
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MC49[MGNIKZ:Y:22ZEN7:>2=G>9C(6) /J^BBB@ HHHH **** "BBB@ HHHH
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MI7B#2A?7MCX-\"Z+XH\/KK.EW$FKV;37=[8^,=5D-O%"'CD@BS+(7& #Y/\
MVAO^"N_[45Y<7_B/PYJ>G_ +POX7_97\#?&[P?J6O>!/'/B[0?B_XM\1>"_!
M?B37=,@?P>MXXTS0M8U[4=%;2Y);75+CRHY+>66.&:0_0?[=O_!8GXF?#?\
MX)Z?!KX[_ /PG#J_Q5^*.@^"?%/BZ0;A9?#+P9JOQ!M?!%QXNU.V>[M[H6FK
M:U!-HUI:)+)>P3ZC;M<0^6CM7L?[0W_!-7]K37_"OP^^#'P-^-'PUTOX-Z-^
MS_I/P9N%\:?#FU\0^)/!?B'3-(\-:2/B#X=U&Z\1V<[2.-'U&Z.E6<4$N_4U
M7[<3 6D\;_:7_P""#_B?QS^SUX[^%WP@_:$US1=7\6>#?!7@PV&KQWD^C'2/
M#GC_ $#QW=:=;I)K-O!9:6=:TVZUFVL!NABU"3S5W2MN(!^^/P \6:OX[^"G
MPP\9:]*LVL^)?!FB:QJ<J A9+R\M$EF=0Q) +DGDD^]>OUX)^R_\*O$'P1^
M7PL^%/BKQ'+XMU_P-X0T?P_J>ORAPVHW.GV<5O+/AY[E@KO&SC,\GWC\QKWN
M@ HKQOXJ?%T?#%]-3_A"_&/BLZBK-GPOH.HZPML 91BY:QM[@1,3%PLFTD.A
M&0PKQ_\ X:V_ZHS\7O\ PA_$'_RNH ^Q*\Q\"_!CX6_#/Q3\4O&W@+P3HOA?
MQ7\;/%=CXX^*VN:9%,E[XX\6:9X?TWPK8:[K;232I+?6OA[1],TF)H4A06MG
M"I0N&<^$_P##6W_5&?B]_P"$/X@_^5U8%A^V[H6IZQJN@V/PL^*ESJ^BLBZG
M8Q>#==>XLVD2&11-&M@7CRD\3#>JY#C'49 /N.BOCO\ X:V_ZHS\7O\ PA_$
M'_RNH_X:V_ZHS\7O_"'\0?\ RNH ^Q**X;X>^-1X]\.V^O\ ]A:YX=,[.ITW
MQ!IMUI>H1;7= 7MKR*&4!MFX$H 001D$5W- !1110 4444 %%%% !1110 44
M44 %%%% !1110 5_+3_P;+_\Y0_^SVM;_P#=FK^I:OY:?^#9?_G*'_V>UK?_
M +LU?5Y1_P DQQ?Z9!_ZLID/XX>D_P#VT_J6HHHKY0L**** /YA?^#NXD?\
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MVBPW$B:?JUU\8])TF>]MU=A'/)I\N@S26K2(%<Q-*Y4MMW'&:Q/^%F?M??\
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M&?67XWGKGK^T9\73U_&OUBK\8/\ @WKU2]UK_@D!^R+JFHR&6\NS\?GFD/\
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MV%@>@_(48'H/R%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7\M/_!LO_SE#_[/:UO_ -V:OZEJ_EI_X-E_^<H?_9[6M_\ NS5]7E'_ "3'
M%_ID'_JRF0_CAZ3_ /;3^I:BBBOE"PHHHH _F"_X.\?^4-GC;_LO_P "?_3[
MJ=?YDGP=TG%A'<%>9I"V<=BJD<GL.WXD5_IP?\'=:&3_ ((Y>,8QU?\ :"^
MX_/7M3K_ #:?AMIOV71[&(K@A%) '.<+TP.^/U^E 'T%X0L%!$NWN%! S['Z
M<^F/>OHSPQF) P4\,!QC/3V_S_*O'/"]L([>+ P<[B/8C./<8_R:]CTV=;2#
M(!W/@!5]_P /4\]^<]* /HSX1Z,OB#Q;:O.F_3]-_P!-NV'W56-6VACG_GIL
M^N:^L=#U.3Q=X]B@MVQ9Q3>8PR2L<%NS2%1U  56Z8 %?-?P]G?PIX'GNRNW
M4/$KXB8D"2.V^0^Q +PL!]:^@?A64T/0/$7BNYY:#3IXX9&*Y\Z2&5"RG/?>
MO0\^IS0!)\5_%#>)?&UIH]K(!8Z'$+>,*Q\MI,1KD <;@8CD]03ZU1AO#!<Q
M6\4ORQ*#(>H9L9P"<GH<'ICGCU\6TC5C<7NH:Q</OEGN;B=6+'<=\KNHYZXS
M@>GM6IIOB8SZC,#DH.@)YW''S#Z8^OY8H ^E]'U1MRL"24_UAPN,'MSQG)Z^
ME9=UJ?F:O?.S+Y)2)%(;)\Q'<GGL 6&!G'4?7BM/UK9;"4,<LI!)."1R>1^?
M) Z?A7'W>M2I+)Y,A.9I9"&XRC8(()P,=?7ZYKR,=[V99+#=JOC*UK[*&#JT
M[OYUDOF?H?"K=#@OQ.Q-U%5LKX:RQ/K*6)XGP.-]FO\ %'+7)^43UB_U%5 V
MR*[2XC(!^95/&.,8SQ@_CQ7E7CG5#)!)$K9$<9&/1BI.#SQU)_\ KUYSJOQ
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M'//?@'(_ <5DW,[%'DD<ENH )P3GZC^7%<5J&L);I(C#:YW;![^N>N./\>*
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M_);]EO\ Y2S?\%5/^Q _8._]5?X]K]:: "BBB@ HHHH **** "BBB@ HHHH
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MAQ0!_0#_ ,$&K)HO^"G/[+DKA?E'QI"8&"-_[.WQ;Z]\8[_3U%?Z(=?YY_\
MP0Q98?\ @I]^RG!@[Y%^-7TPO[.?Q=/(Z#H!P!]37^AA0 4444 %?A!\5/\
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M_#5&FE>XO&+SW;^=(\AY+L02<GJ< 8R1_C]K^ 8A%ON"1@*%7)&#P?R_SGV
M/WH_X(97:2_\%5/V5(@VYEC^-YQG.,?LY_%OV'8$?SYK_1#K_.5_X(.W(G_X
M*Q?LM@<!(_C?TZ$_\,X_%W\NYYZ]>N:_T:J "BBB@ HHHH **** "BBB@#D-
M4^(/@+0]6M] UOQOX0T?7;L@6FBZIXET;3]6N2V-HM].N[V&\F+9&!'"V<C'
M6NN!# ,I#*P!5@0001D$$<$$<@C@BOY^OV_?V2/V4?BG\8=?TOPK\(;SXW_M
MV?$)M)NO!7Q+U-K74[S]FQ-/CL+>+5M*\:-H\EE\/A/;007"Z!J.HVFHZH+X
MZG:R?9@V?M?XZ_\ !13X(_L,WG@/X/\ QOT#]ISQKXSF\!Z3K<FN?"/]F7XU
M_&S0IK=IKK32NH^*/AUX2\0Z1::LMQ83>;IMU>)?);^1<M"(;B)F /)?V=?^
M4T__  4F_P"S9/V&?_1'Q@K]B:_GP_X)K_M-?#W]K3_@JK_P4>^+WPQT;XFZ
M%X7N?@!^QCX?CL/BU\+O&WP@\7B^T2/XM1WDLO@[X@:/H?B&+3Y&G0V.HR6"
MVE^HD:UEE6-R/Z#Z "BBB@ HHHH **** "BBB@ K\J_^"W'_ "BW_:S_ .Q;
M\ ?^KA^'=?JI7Y5_\%N/^46_[6?_ &+?@#_U</P[H _4#0_^0+H__8+T_P#]
M)(:U*R]#_P"0+H__ &"]/_\ 22&M2@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH X3XI?\DR^(W_ &(GB[_U']0KS_\ 9C_Y(?X _P"P%8?^DEO7H'Q2
M_P"29?$;_L1/%W_J/ZA7G_[,?_)#_ '_ & K#_TDMZ />Z*** "BBB@ HHHH
M **** "BBB@ HHHH _(?_@O?_P H<_\ @H-_V;_K7_IZT.O\<7X?7(BU)T/\
M1Z?B<]#GTX^M?['7_!>__E#G_P %!O\ LW_6O_3UH=?XUG@^4QZS$!SN)!'X
M@=?SH ^Q= U$P,C9.T;3UX_GGCWZ&OJ7P/KC236$<696NI8;=4Z[FE<1J H]
M"P.>O7WKY#TH%K?C(8J",?@?_P!77TYSFOLO]F/14U#6+SQ3K'&@^"[*34;A
MI!B*2Z\N2."+/&6$LD# 9')')&:]+)\MJYOF>#RZDU%XFLHU*K^&AAX)U,3B
M)M;0H4(U*LGHK1WU/&XASFCP_DN8YQ7BZD<%AY3I4(ZSQ6*J-4L'A*:WE4Q6
M*J4J$(J[O.]K)GW5XP\6Z3X)\)^'_ \$T2ZDT,6JZU#E0PGF6%T21<Y($L+C
M:P]>,GCK[371\2_V?[FYN)5FU/P1KY=N06BT^674)8EZY5/)MX@!@* !VXK\
MX/$WB^[\6^)M6\23RR#^T+R62W4YQ%:^:SPQ#MA Y QSUR37U;^RO=7/BB7Q
M[\. TAA\6>'+N6W;D*E[:P""+!XR[&[8C /?->'XF9C''26;8*+C@^',=EM3
M+(+XJ>39946$J02T]ZM@JN(Q%6R]ZI.4F>)D>48C).'<++%M3S:>+6>YU65V
MZN9XZHJV8V>[C2A4>&I)MVHX>G%;6-18;AH1.NS"JK#&, 8!ZXZGO7+:WXEM
M].M3;.RO<S$JRD@[0<<\\YR#^A]J\FO=.^).F37FD2M=9M+^XM<!ER4CN)%0
M'C(!0 CV/YT+C1]9M,3:C+NE(+,CMEA@$D<=/SKIC)2C&47>,DI)]U))I_--
M->3/LT[I-;-)KT:NOP.@;4;21I)-P#J"V<@>I]<9XSS^72G)K=O]G9]P^4'O
MDD_-C'Y8]_UKQK5-<,,[1#<I9BC#.,<XXYSW/\JH2:LXCVQ2L0!EB"#D]<'W
MYQC^O%,9W&L:I'Y,CAC\Y. 3SD]N>.G^>U>8:C>;_E7) !ZG.3ZYQ_C^58^K
MZ]< !-Y."21D>G;Z#^G7%<-?^([B(/A2< X)]>?0_P#UN3[T +XBO?)@F=R!
M@,02<8VY_+O].U?&_B?6/[4\0P1+(&CCE(/(()# 8..">OK7HOQ(\::B+5H5
M?RM^4P.O/!/3W[G]:\!TJ5GU2WDD8LS3 LQ]2V23_G]* /\ 8(_X-GUV_P#!
M$?\ 8F7IB+]HG_UK'X['_/K7[M5^%7_!M* /^")G[%.#D>5^T1@_]W8?'6OW
M5H **** "BBB@ HHHH **** "BHYIH;>-IIY8X8D&7EF=8XT'JSN551[D@4V
MWN;>[B6>UN(;F!^4FMY8YHG'JLD;,C?@30!^2?\ P5)_Y*5_P2K_ .TFGP:_
M]0#XIU^N5?D;_P %2?\ DI7_  2K_P"TFGP:_P#4 ^*=?KE0 4444 %%%% !
M1110 4444 %%%% 'Y+?LM_\ *6;_ (*J?]B!^P=_ZJ_Q[7ZTUY?X;^#/PT\(
M?$_XE_&7P[X6M-,^)7Q@L?!6F_$?Q3%<W\EWXGLOAWIM[I'@V"ZMY[J6QMUT
M33M1O;:!K&UMGF6=FNFG=49?4* "BBB@ HHHH **** "BBB@ KPG]H/XTI\"
M_ [>,I-(&LHMRMN;0SO;_>V?-O2.0_Q?W3TKW:O@K_@HC_R0F;_L)Q_^TJ<5
M>44]FTG\V!X/_P /1++_ *)PG_@VN?\ Y"H_X>B67_1.$_\ !M<__(5?CI17
M7[&'9_>_Z_X=^5@_8O\ X>B67_1.$_\ !M<__(5'_#T2R_Z)PG_@VN?_ )"K
M\<)98X(I)I6V10QO+(^"=L<:EW;"@L=J@G !)Q@ FOS&UK_@IG\)='_:QT[X
M#2^(O#0\$S:04U/Q:^E>-#K%GXO9+^.'04MH]*-O)')>PV-O]I6UD@ N7<W(
M52Z2Z=*-KK=I+5ZO3S^_U?E8/ZR/^'HEE_T3A/\ P;7/_P A5XSX._;QMO#'
MQ/\ B)\06\%)<+XWEM72P_M"=1:+;V>FVW^M%JS.2UB3\RK]_CH*_D2TG]J+
MX]>*VO/VG-&^(^H0_#G2?VDI?@@/@O\ 8=)'A74_#.D^)O$?A[4O$[:A+II\
M31ZU=)X<@N[2#^UXK(-J%T);>/9$B?J7\<]/^*WB_P"$US'\(/&FF?#CQ-J.
MGVU_-XMOX9+F70=-\B*^O+K3;<:?JL,][% LB1QW5G/"RLV5+[2$H4WJE)VU
MW>J^_P"?1]O(/Z"/^'HEE_T3A/\ P;7/_P A4?\ #T2R_P"B<)_X-KG_ .0J
M_B&\/?M:_M(7/[.WQ?O_  7XVU?XI:=X+^.D7P^T[XY7&D65IXNC^'?]L>&K
M'5?&TGAR'2M.M!/IFDZAJ>J0H?#QBEEMMAMI0#&?JW]@W]H/Q#X\^(/QE^$>
MJ_%?6OCKHG@*V\%:UX8^*/B/2+/0M?U:#Q=INIZG?:?J.FZ?H_A^SBCTMH+>
MVLGATJ)Y8MS3R2/ABE&D^71Z^?7MH];V>JTU\U8/ZS/^'HEE_P!$X3_P;7/_
M ,A4?\/1++_HG"?^#:Y_^0J_'2BM/8P[/[W_ %_P[\K!^Q?_  ]$LO\ HG"?
M^#:Y_P#D*OU8T'4QK>AZ-K(C\D:OI.G:F(LEO*%_9PW0CW$ ML\W;D@$XR0*
M_D<K^LOP!_R(G@K_ +%+PY_Z9[*L:L(PY>5;WOJWM;_@@=;1116(!1110 44
M44 %%%% !1110 4444 %?RT_\&R__.4/_L]K6_\ W9J_J6K^6G_@V7_YRA_]
MGM:W_P"[-7U>4?\ ),<7^F0?^K*9#^.'I/\ ]M/ZEJ***^4+"BBB@#^;W_@Z
MJD\O_@DMXK;./^+\?!(9^NLZG7^;#X0UA;>6!78_? SG/!P/4?S]J_TE/^#K
M9]G_  21\5'U^/?P0'YZSJGY5_F=Z8SK'!(AY$BDCD<;@>OY]#^.<4 ?>?@3
M6[222*&XD5%^]&S-MP.IYS[C;GZU[:WBNUTNTN5M98GNKH");C*DPH5Y9#R5
M8$#D$'KSUKX6T74YO*A;>R$*NU@2.PP<]_SZ=*[[3=8D$D(N9F> 2H95+9)C
M##<H)Q\Q7('('/)%)NR;LW9-V6[MT7F^@'U9HLYO8I;J!C="5MI<$L,X!.6Y
M^;L!SG.:UI+J6TRMT7AMT4NX8D+\H+;220.<8 ZGM7I_C7XD_LB&Q^'P^'WP
M\^)VARV7A6&W\82:<=*N+75_$(O+QY;T?;]8GDC#6\ENBB)81B/A 2V?/;KQ
M9\ -?,JW&@?%I8ESN!C\/*O R1N&H GIP,U^>Y;Q]B,PP=/%U> ^/<NJ3GB(
M2P>-RC!_6*:H8FKAX5)?5\SK4G#$1IQQ%%QFW["K3<U&7-%=<\*HR:6*PLTN
M7WHU)6=TF[7@G[K;3NEJGY'CNKZA8ZC>,Z853(P0KC!&XA<,,')Q^/O5*#4(
M49XMXRHXZ 8XYSD?GCW]J]!U37OV5-. ^T:1\58I$YV[?#_;O_R$".OJ?2L)
M/%7[*8#SKI?Q6+2 X!3P[G![C_B8=>.Y[^^*[_\ 7&II?A#C/7MD]%[VM_S'
MZZ/6W_ )^K+_ *",-_X,?_R!QMGJ*SZPI64!(UF;=V&V&0]<]_?D>G>O%-1=
M];\06VFVCXFUW7;;38)<EE2;4KR&UB< Y!"R3*P'<#\*^\_@A\0OV)]%\7:E
M=^+/ _Q'\26?_".:]':6NI2:3#:P:C+I-_'97#M8ZQ!,?+NGA)^9EPOW6Z'\
M^? 6LVFL?&WX;6&GVSQ6&I?%3P;#86S?,\-I=>*=+CB@8[F+,J-@G<Q)_B/%
M>9E7%%?,\\XM;X>X@R>&2</916I8S.L'AL+AL=/%2SG$3HX.-/%XBM.>$^J4
MY8GVU*E%*O2Y'-.5OMLXK5,/X9\+9<L/4@L3Q9QAFBQS2>$Q<J66<+X"E2P\
MK\TJF#?MOK-X1A'ZS0493;FH?7/_  4#_P""=GQ._8;\)?![Q?XD\3P>--*^
M,OAK2]=T^:QLXK<:1=:O8:9?6ND2^0T@DG8:B8U+L)&^SL=H.<>)_MS_ /!*
M[XG?L<_ _P"!7[1GCKQ?:ZS;_&*YL(X_#,-M#!/H#ZE9:CJ%JLSH_F2E[6R1
MP9(T/[\ 9P"?Z[/CI\._#?[<UQJO[..KM9'5/V</$G[+GC)Q<L6DB\&/X&U#
M4_$PY#%($9;(2J H.%W'.,?F7_P4>\877[:G['OPN7P[$][::?\ M>>&OAEX
M<MXE$B16'AWPEXBT>=+=8RQ",^DS2,#CDDGGI_'/ GTD?$//<7X993G&(P=+
M$T>))U/$G&O+L-1IXOAKB3!T<=P2L.H0C2P<J^$Q&(JUJU#EG4_LN?,VY3OM
MC^&\LP,L=5?/.E#**U'"TN>3D\\PF%QF*QLM&YN%##X*%;V;M&V,A>RY4?F'
M:_\ !+'XN^&?V%M%_;C?Q1:2Z#J&G:=K1\"+:0C4X-$U"^M=/@U)Y5_T@Q_:
M)W4Y0*/);YB<@>O?L5_L2W/[2/P:\7_&[6?C1X>^$7@#P5J5KI>I:KKD-A)
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M:VN@^']+TF;4BP^RQ"ZFEC4?:O[4'[,7@K]J7P':^#O%>HZ]X=U#1=6M-?\
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MD_M"?_._K]/M8_:/^.OA_P#;J^'G@S5+G]IBRUGXR_M$GX7>(5U;P!XCT[X
MCX<S_#/Q#XMTF[\ ^+I-6;0Y+^74-$T*2XU?3=+MIU,FIV+2.C3,_P"\7[(_
MQ%\0?$7X/:6_C.:.[\<^$[RY\)>,[R)%2&[\0:<D4]S/"J\"-H;NW QU96[Y
MJ_;3_N_=_P '^KORL'\;_P#PVY\-O^B6_M7?^(D_M"?_ #OZ_H)\(_\ !<K]
MB'2O"GAC2[W0/VO8KS3?#VBV%W&/V)/VH7$=U9Z;;6\Z!T^&11PDL;J'4E6
MRI((-?MI@>@_(48'H/R%1.<IVO;2^WG;_(#\;/\ A^S^PQ_T!/VOO_$(OVH_
M_G8T?\/V?V&/^@)^U]_XA%^U'_\ .QK]D\#T'Y"C ]!^0J /QL_X?L_L,?\
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MFR?L,_\ HCXP5^Q-?@Y^P7\>O@O^T?\ \%</^"D/Q*^ OQ0\$_%WP!/^SO\
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M(5OX2UC6-6N?$>H3'3O$&JVXM&U&]FFN+X:8\,=FL;2$0A!$JJ!M'B_PZLO
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M";0=$N+^SU>_N$MKJ'3;**ZO60 /E72;:CJU>]][M?=M^%NP'[+K(CDA'1B
MK$*P8A6&5)P3PPY4]".13Z^'_ANWC;P#XN^!GA[6==GUBW\1> ]=MO$L,FHS
M:O*M[HT&@VN@(+R9FDO)-.CN+J+4=5=4EU"4BZN$61\#[@JT[]+?\,G^H'V)
M^P9_R<]X _ZX^(O_ $P:A7]&E?SE_L&?\G/> /\ KCXB_P#3!J%?T:5S5_C7
M^%?FP"BBBL0"BBB@ HHHH _(;_@OA_RAR_X*#8_Z(!K/_I[T*O\ ' \!?#7Q
M_P#$?4I+3P'X3UCQ7>69$MQ;:1;?:)8DSG<Z[TP,<]:_V/\ _@OC_P H<?\
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MFH6"8W%8&CC#O& ,XWW;Y., G\_DGQ/&$\!(YSL6ZVXZC.8AZ]<\9_"OI[X
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M "4K_@E7_P!I-/@U_P"H!\4Z_7*OR-_X*D_\E*_X)5_]I-/@U_Z@'Q3K]<J
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MNG7_ )#6A_\ ZJ_QG=!GBLM=TB[N&*P0WT$TK==L:2*S$#CM7^S#_P %\O\
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MLDT;3QJ<8:2$,9$!R.64#D>HJQ0 4444 %%%% 'Y&_\ !4G_ )*5_P $J_\
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M?_G*'_V>UK?_ +LU?5Y1_P DQQ?Z9!_ZLID/XX>D_P#VT_J6HHHKY0L****
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M0 4444 %%%5S=VJW"VC7-NMTZ[UMC-&+ADY.]82WF%< G<%(X//% %BBBB@
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MW_A+_"?_ $-'AW_P=Z;_ /)-'_"7^$_^AH\._P#@[TW_ .2: .BHKG?^$O\
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M *#.E?\ @QM/_CU']NZ)_P!!G2O_  8VG_QZBZ[K^O\ AU]X&K165_;NB?\
M09TK_P &-I_\>H_MW1/^@SI7_@QM/_CU%UW7]?\ #K[P/MG]@S_DY[P!_P!<
M?$7_ *8-0K^C2OYL_P!A#Q%X?A_:<\ R3:[H\48A\0Y>34[)$&= U #+-. ,
MG@9/6OZ*O^$O\)_]#1X=_P#!WIO_ ,DURU_B7^%?FP.BHKG?^$O\)_\ 0T>'
M?_!WIO\ \DT?\)?X3_Z&CP[_ .#O3?\ Y)K$#HJ*YW_A+_"?_0T>'?\ P=Z;
M_P#)-'_"7^$_^AH\._\ @[TW_P"2: .BHK,L-;T;57DCTS5],U&2)0\L=A?V
MEX\:$[0\BV\LC(I;Y0S  G@'-:= 'Y#?\%\?^4./_!0;O_Q8#6?_ $]Z%7^,
M<R$P$[><G'ZGIFO]G+_@OA_RAR_X*#?]F_ZU_P"GK0Z_QFHDS"!RQRWOCTS]
M>W3CUH Z#P'J)L=4"%MHE(!!Z9RH_P _2OJ[2KXHD;J?0YST&1Z<\\_UKXEM
MIC9WT4P./+D5C@XXZ?R]O;%?5/AK45N[.!U8-N0=\XR/KT[9./44 ?0ND:LR
MBWG1B&BDC<8//R,K>XP<=^V<9YKZ-O-0_M/1XY$8!YK.-S@Y):.) 3GD$Y)/
MI^>*^.-(O/+#0D@Y!QSP,@X^G/;^=?0OA/5!<Z/ K-S;R>3)N.2L99@>_'"#
MKQ[4 :O@GQ(VA>+M+N23Y5Q-]DN1GY6C<MG=R/XE7/4 ?I]X_#X)KOA#XN?#
MQ\R-!;KXLTA#R1LEMV80@\<+8M]WMWK\R]?\S3]2;R\@1R)/$X) '*L<8^I]
M^O/<?=?P1\:1)XT\"ZT\BBR\3:;<^'-4)("-YEC>B(2[B <S7"!=W?ID]?GN
M*</4KY'C:E!?[3@52S/#65W[;+JL,6DM&[SA2G#3?F.+,(2GA*LH?Q*/+7I[
MWYZ,U4LK=6HM?,^4OC.\MYH?A[72N)D1;2Y)!RLD:0JP;W#,1^%?+US<F19&
M).3G'X@YZGZ9_P#UU]P?M >'9-)N/'OA@Q[&T77;V\MDQC%G+<RF$I_LE(#C
M'''IT^#$DR/GP N0W/<'!&/4]Q7M87$4\7AL/BJ33I8FA2Q%-K;DK4XU(V^4
MD=5.:J4X5(_#4A&<?2<5)?@S@?&+XTRX)_NMT_$=/\_X?+Q.9B?63_V:OICQ
MH^-.NR.0%;&.GY?3/^>:^90<R@^LF?\ QZMRSH8ON#\/Y"I*CB^X/P_D*DH
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MP1_UPU#_ -*8:_-*OTM_;]^[X(_ZX:A_Z4PU^:5?\V'T^_\ E*?Q'_P<-?\
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M#.EW=7$4?V9/L\<.7W?J1_PY%_X)7?\ 1G7@'_PH?B-_\VE<5^SK_P II_\
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MNK]:** /R7_X<4_\$E/^C(_A;_X,O'?_ ,UU'_#BG_@DI_T9'\+?_!EX[_\
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M<GCN<?Y_*O\ 9A_X+X\_\$<?^"@_./\ C'_6>?\ N-Z%7^,_9Y\L[3D -UR
M>WZ?X=: ,BY7;)D9YYSVR/0UZY\.]9^4V<C\I@*"<DCZ=NIP>GTKS*>'S 22
M,@Y!'7T Y&/2I-"U!],U&&4<#>%;MP<C^O?M[T ?8MA<[3&^[T!.3R.A^N/3
M\J]G\%7R^;-8[SY5X@9#D_?7CCN.7XP?Y5\\:-?1W5M#,C!MZ@X'N/;CN?\
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MI_RG<^ /_9OVI?\ IF\?U^[]?A!\5/\ E.Y\ ?\ LW[4O_3-X_H _=^BBB@
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M@#NJP3G!Y#NR&8_]\@9[8Z]J -C3G_M#P%:R;SYVD7SQ.QRQ\NYE=E'J,+$
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MN+.*,;AZN$QG$.=8K"UX>SK8?$9EC*U"K!M/DJ4IUI0G&Z3Y9)K1:!1117Z
M?/A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?D/_P %[]W_  YS_P""@VW[W_#/^M8_\'6AY_2O\:^R2/\ LAW+*)O-/'?!
M+DG^7./ZU_LG_P#!?%S'_P $<O\ @H,XZC]G_6OUUK0Q_6O\9FTFE6$J.59B
M2#Q@DD_U/^'2@#24)LW%B3T' 'I_]?C\^E-(B();)P. ?P]/\^QJ .S#!!&.
M0!G.?Z=3VH;=QG^G/U_/_/- &9>0HGSH, G&/\]OUXYKO/ .O+9W(LKB3;'(
M<H6/0Y_ESCW]*XNX0NI /7UZ ^G\O_KUFH\EO*'0E)$.0>>H.1C'_P"KUH ^
MV=(U!8I+>XBD!VNC9!'//MGH"<?@/2O5_$DR:IH,%TI5I+8J2<Y.T[1Z\CYC
M[<>HKXW\(^+7DA%K='+)M )/N!TR1W'Y=#7T7X;UXW=D+:0>9%(H1E()'3(/
MX$#_ #B@#UC0(+V\T?3)+,,)=/DAO8G'&)+<QS(<]00R CISZ8Q7VY^T9X<L
M/$OA?X4_%+[1&!<^';?0M3E4Y#:A9P6%H [ $[@UG,N3SD'C-? ^C>(KG3E;
M3Q((;<J454R7*$$= 3CCU&0!TK[T\&3>%_&?[&OC.SUWQ)8VGB+P3X@.IZ!I
M-U.AO]124ZU=-';H6WE2YA7A1C<H)R17RO$<U@<7P]FZC.3PV;0RZLJ<)U)/
M"YS#ZI-N-.,I<E/$1PU24K<L4G*5DKGG8Y^RJX+$I-^SQ*H344V_9XI>S;LD
MW934'>S2W>FI\/>+6T34+22-;=)[F%2J3J,/D9 !Y&>O<'H/2OE+QK8K<V-Q
M&\?S(&*Y'((P>_X#GC%?5G_$NO"F^R:U9AM\X8*DCC+  D$\Y[5P?COP@@TZ
M:[A"L2C@[<$,,9SZ]S]>U?5'HGY_1DP3[2,8;:<Y&,'%= AC= X8D'OQU^F*
MS=;M9+;4+A64@&1R,_[Q_P BF6$@/R,<D<J.>/Z?_7H _P!?'_@U_P ?\.,O
MV'L=/^,EO_6O_C_7[YU^!?\ P:__ /*#']A[_NY;_P!:_P#V@*_?2@ HHHH
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MDHH _?3_ (-?O^4YW[#W_=RW_K'_ .T!7^NY7^1'_P &OW_*<[]AW_NY;/\
MXA_^T!_6O]=R@ HHHH K7E[9Z=:S7NH7=M8V5NN^XN[R>*UM8$R%WS7$[I%$
MNYE7<[J,D#.2*_ OXH^*?#$G_!<KX#:Q'XCT&32(/@'J,$^JIJ^GMIL,QT?Q
MZ!#+?+<&UCE)= (WE#DNHQ\PS^WGQ7\!Z%\3_AMXV\ >)="T_P 3:-XI\.ZC
MIEUH6JQK+I^HRM"9K&*Y1V5"J:A#:SJS,%22)') 6O\ /.O_ -G?XG67[2-Q
M^S?J>DWEM\1;3X@P>!=7LM%BF\3_ -B7$^I6]G>7V-$:<WFG:1:W)OKR:VD$
M*6D$KO-&BLZ@'^C;!/!=0Q7-M-%<6\\:303P2)+#-%(H>.6*6,LDD;J0R.C%
M64@J2"#4M>:_!KP)=?"_X2_#3X;WNHPZO=^!/ WACPE<ZK;PR6T&HSZ!H]II
MDM[#;RO++!'<O;&9(I))'C5PK.Q!)]*H **** "BOS$_:D_:F_:O^%FK?%#6
M_A=\!-%USX:?!BWTJ\UWQ!XM\=^%O"D7CF/4+.PO)H?#U_X@NM/M]%%C]N>V
MEO+U;^W:YM&C&V2:-!]]_"KQY#\3_AUX/^($&FW6CQ^*]%MM6&EWC;[FQ:8N
MDEO*XCB$A22-]LBQJDB%70%6!(!^6W[.O_*:?_@I-_V;)^PS_P"B/C!7[$U^
M.W[.O_*:?_@I-_V;)^PS_P"B/C!7[$T %%%% !1110 4444 %%13R/%#++'$
M9GCC=TB5@K2,JDA Q!"EB, D8!.37C;?$[Q<K,%^%>KL 2 W]O::N1ZX-N"/
MH>:^:X@XMR3AB6%CF]3,H/&*K*A_9^09_G2:HNFJGM7DN69@L.TZL.58ATG4
MO)TU-0GR^EE^4XW-%5>#CAI>Q<%4^L8_ 8*W/S<O*L;B<.ZE^5W]GS<MO>M=
M7]IKQS]H#_DC_C7_ *]--_\ 3YI=5_\ A9_C#_HE6K_^#_3/_D>N$^)GB;QU
MXU\#:_X7LOACJ=M=:M!:QQ3RZYITD<9M]0L[QBR+"I;*6[*,,.2#VQ7Y1XD^
M(W#&<>'7'V499'B;%YEFO!7%.6Y?A*? O',:F*QV.R/'X7"8>#J<.0IJ=:O5
MITXN<XP4I)RE%7:^LX:X<S/!\19!C,2\LHX;"YUE6)Q%66>Y&XTJ%#'8>K5J
M24<Q<FH4XRDU%-V3LFU8^H+?_CW@_P"N,7_H"U-7B,7Q-\81Q1H?A5JY*1HA
M/]OZ9R54#/\ Q[^U/_X6?XP_Z)5J_P#X/],_^1Z^RI^*W!D:=.+K<1IJ$$U_
MJ)QWHU%)K_DFNYXTN%,Z<I-0RVSDVO\ A>R'J_\ L9>?]69[717E>A>/O$NK
M:I:V%[\/-2TBVN'V2:A-K%C<QVXP3N:**%78<8P&!SCWQZI7UV0\195Q+AJN
M,RF>.G0HUGAZCQ^49ODU555",VHX?.<#@,14ARSC^]ITI4F[Q4^:,DO(Q^78
MK+:L*.+5",YP52/L,9@\9'E;<=:F#KXBG&5T_<E)36[C9ILHHHKW#A"BBB@
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MI2UWT5NK&\58/,<77QN+X6R.IB<1/VE::JYU!2E:*ORPS516D=DDO+>_A_\
MPFOQ?_Z)EI?_ (4=S_\ *BO8-*N+ZZTZSN-2M([&^FMXI+JTBE,Z6\SHK21+
M*R1L_EN2N2BDXS@5H45]KP]P[FV35\15S'C/B'B:%:E&G3P^<8?A^C2PTHRY
MG6I/)\ERRJZDE[C56I4@H_#!/4\7,,QPF,ITX8;)LORR4).4JF#J9A4G53BD
MH3^N8W$Q44[R7)&,F]V^I1117UAY(4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_+3_P;+_\
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M '[Z?\&OW_*<[]A[_NY;_P!8_P#V@*_UW*_R(_\ @U^_Y3G?L/?]W+?^L?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!T _K*HH I:;;FTTZPM&+EK:RM;<F1@TA,,$<9+L  SDK\S  %LD  U=HHH
M^-OVT/V+O"/[:GA+X:>'/$GQ*^*_PCUGX1?%;0?C+X \?_!G7],\-^-O#WC;
MP[I>M:1IM[9:GJNBZ[;)$EIKU]N066\N8R)%"LK?*W_#K3XC?])4?^"FW_AZ
M_ W_ ,Z^OURHH _(W_AUI\1O^DJ/_!3;_P /7X&_^=?1_P .M/B-_P!)4?\
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M"QLI?"?P=^*NM^"O#%S=Q7?P\OI)-7N-*TZ"35+A)8X;B[+R0V\"$1C] _\
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MT^(W_25'_@IM_P"'K\#?_.OK]<J* /R-_P"'6GQ&_P"DJ/\ P4V_\/7X&_\
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M-!U^*ZFT][ZV-G=,EI?W6G3>=;,SF(BYLY@H+'<@5^C8 !^+/[1W_!/7XO\
MPE_9Y^//Q4\-_P#!4S_@I3<>(?AG\&/BC\0=!@U/XS>"I]-GUKP9X'USQ'I<
M.H01?#2"6:RDOM-@2[BBGADD@:1$EC8AQF_LL?L ?&3XT_LS?L]_&#Q5_P %
M2_\ @I-;>)OBG\%/A?\ $/Q#;Z3\9?!=OI<&M^,O!6B^(=4ATZ";X:W$T%C'
M?:A.EI#+<3R1P"-'ED8%C^W/Q%\">'_BE\/O'?PR\617,_A7XB^#?$_@3Q-!
M97+V5Y-X?\7:)?>']9BM+R(&2TN9-.U"Y2"YC!>"4I*@+(*K?"[X<^&?@_\
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M8IH7?[\N['0[J7RKZSTJYF:VDA\N[M[.:5K1@@FBV3(SFV($8D3!B("!APM
M'\7G[(NH2^,/@+^T%X*^&'AGP?\ &#1OAGXAT7XB^-_$OP/^+_QY^-^A_$FT
MT^_\.:9<^'-6@_:">P;1_%*0W<?BN?0O#ME#H$>GZ7)<17!NLPM^Y.H_\%(_
MV7?V@TT+X:?LGV^A_M!_'+2[6YGM?!VC>'IOMOPGG@LRSZGJ\FIV%C;Z=+";
M:86\>ES7D<]Q9>3<#R#EOUOL=+\*Z-;2-ING^']+L[MB)FLK33K*VN6^X1(T
M$<44Q^7:0Q8_+M/3%>6_$WXA?"?X!>'9O'6NZ?H^E0/=0V1ET31[<ZE<R2S1
M12[5TRSDNY4MDN!-=$(RPP%I)-J9:@#^:?X:Z]\)1^T/\)K_ ,#?%#XU:G_P
M4!O_ -K#PUIGQX\ ZIXA\67$>F_!N;QA=Q^,7O? MUJ\WPYTSPG;6(MUM-7T
MFQCUHZ?LF*QSNZUV?@S]GJ+X?_#KX!_MM6?BOXNZM\;+W]I#Q];7EMJ?C_Q[
M<>&SX5M_&/C_ $=/#MSX1EUV;P_-I\GV2RU".[N-&:YB:**"&06QVG^DOP#K
M_P /?'VDZ7X^\+V6C.NNQ-/9:F=-M;;4[E,([MYLEO%>/C>A8GH6&>37:A="
M:#R%327M[8R3B!%M'BA92[RRK"H*(X8R,[A0VXN6.2: /RT_X**V]_X6^(7[
M$7[2_B&PO=3^"O[._CSXE^)?C;86MFFHVZ:-XU^'">%O#NKZAI\P,5Q:>'_$
M%Q'K$CE6FM5M&GMXWF14/SA^T?\ MR_LU?M=_"OXR6O[+.AZ7\>&TW]F?XWQ
MZY\</#OAZ4:;\-(;GPM$/^$2GU74;/3]9@U#Q4L4T-M8V5I<6ES)I+I/)&J1
ME_VG\'_$3P5\3;/Q0-)FM=1TSPYX@O/#.I-?0J;&YNK.&VFDEA%W&L-U9.MT
MBQW$8EMY&5U21BK =39:/X4TR*6VT[2_#UA!>PL\T%G9:=:Q7=OMRS2Q0Q(D
M\.Q\L65X]K')PW(!_)7^WC\./&7[.?\ P2V^)6L_##P;K&M_#']IGX*^"/#O
MQ"\+Z%;3SOX0^(L>L>#_ .SO&2:0S)!I7AQ-$T:[@U?^S%22XUG4DN9].N)9
M);M?IGX#_LJ?M*_&_P#:+_;*U#X7?MN?%7]ESPDWQ+@TO6?!GA#X4_"[QAIO
MBE9?!OA!+V_EU;QYHM]JEK)>6LXLG73YTBB6W62+;*7-?TDFUT?4K#[.UOIE
M_I9!00&&UNK K$V"OE%9+<B-EP5VX1EQ@$5YU\3/BI\/?@QX+O/B'XGN[.P\
M.C6_#NC7>H:? MQYNI^)]<T[PWI2R&PBFDE:74=1LX"[*VQ2"[(BD@ Y;]F7
M]GOPY^S'\)]*^%OAS5]1\0K;7]_KFM^(]6BBM]1\1^)=9,,NMZ[=VMLS6EG-
MJ=U$;F2ULA':0.Y2WBC0 5] U$L\+2R0+-$T\2HTL*R(98UDSY;21@ET5\'8
M6 #8.TG!J6@ HHHH **** "FO]QO]UOY&G44 ?S4?LL?L2_M*_'+_AHVYTG]
MO;XO?!OX3>)OBSK.FZQ\%-"^$?PFUC0M2T:\T:SMM0LAXG\1Z)+XJBBOH3+$
M]Q;WRS1>:3#(I45Y/^TOX+\%?L'_   ^.'P9^'VM^,/AS\(_AIX5_9S^%.EZ
MYHXOW^S^!;7XA:II-YH.NZY#-/K^E:+KFD74^E:QKVAS3^(-)T^XN=0TR5;^
MWMGK^JB"UMK4,MM;P6ZNV]Q!%'$'<C!=A&JAFQQN.3CO56\T?2-1CFAU#2].
MOHKC9]HBO+*VN8Y_+;?'YR31.LFQ_F3>&VMRN#0!_&/^R[\0/B?X>^'?[4OP
MW\.R:CI'[,%QXZ_9O\0W6N_##XC?%;XH2:!\%O$G@KQ?JOQ>U;P[XS^+-P/&
MOGW=Q=:5>WZB]B;2KL);Z6\,"@"M^TSXA\/:'\$=%L?^"='Q/\9>/OV6M1^-
MUL_[1&O?&+Q_\4;#X-Z#X4_X0*]^V:?>_%O3+S7/C9H:MXM32I[@^'88A#>R
MO:P2&T)#?V>0:#H5M#+;V^C:5!;SQK%-!#IUI'#-$J[%CEC2$))&J?*J.I4+
M\H '%1Q^&O#L-G+IT6@Z-%I\[%IK&/2[)+29CU:6V6 0R-P.60GWH _CW\'Z
MWJ&L_L%7%[X^^+'POUW]FS3?C1X2MM.'[-_Q&^,OQ/3P/X6M?$_A*3Q0NH>.
M_BWI&A_$62*U\/M(][??;KN\L[97NK&4W@S5^'Q!\)8_ G[0%O\  WXP_&[6
M_P#@F%<_&/\ 9UCU?QYH_B/QAKT.D>'M2L/&3_M!BR^(/B75S\3K3PY'J6P^
M)KRRU!+_ ,/F*T3PW&J$A?Z^8O#7AV"R;38= T6'3W+,]A%I=C'9NS !F:V6
M 0LS  $E"2  3P*6'PYX>M["32X-"T:'3)BQFTZ+3+*.QE+9W&2T2 6\A;<=
MQ>,YR<]30!^-O_!(B_\ AM/<?M%V'[-7C+QUX]_90L/&V@I\(O$/C#6_$7BB
MQDC?PII$NKP^&/$WC*^U'Q;J^G#6Y-9%W)K4XD@U!)[:W7[+# :_:NJ.GZ7I
MFDP?9=*TZQTRV!S]GT^TM[.#///E6\<<>>3SMSR:O4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7\M/_!LO_SE#_[/:UO_ -V:OZEJ_F&_X-L?"_B;
MPU_P\U_X2/P[KOA_^T_VT=:O=-_MO2-0TK^T+,_\))B[L?M]O!]KMCN7$]OY
MD1W+A^1GZK*&EPQQ<FTFUD-DVKNV8S;LNMEJ[;(A_'#TG^A_3S1117RI8444
M4 ?-?[5_[)/P*_;8^$5Y\#/VBO"3^-?AK?Z]HGB2ZT--2O=):35_#L\MQI-S
M]LT^6&Y46\LTC&,.$?.'! K\N_\ B&Y_X)%?]&WW'_A=>*O_ )/K]V** /PF
M_P"(;C_@D5_T;?<_^%UXK_\ D^C_ (AM_P#@D5_T;?<_^%WXK_\ EA7[LT4
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MM_!9L\\,X\MK1I+A"TL<R_(UN2RR#Y2A'%<-<_%;P5I?Q5T/X)R7BV_C+6/
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M<^!O!]Q%X@N(KO7HI_#.BRQZU=P(D<-SJR263+J-Q#'%&D4UX)I(TC148!5
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img148586500_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $( G # 2(  A$! Q$!_\0
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MJ7MWF^#R#%X2-&O1RNOA*L^;B7*<+5A#$2E#$8B$DI82MAL57]@_X2GXY?\
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M#+JV(QD:F'S+*LWPE>A.BITZ.!_M"7+@Z]*HO=_[,_: _P"AW^#O_AK?&O\
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M1PKJQRY595\92@\,L-A:^:8'#8C&^T6%IU:[<JD84<1*A]?_ -F?M ?]#O\
M!W_PUOC7_P"?#1_9G[0'_0[_  =_\-;XU_\ GPU\2_"?]N3XR^)M%^ 7Q/\
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M'%XG%0Q=7$3<L+1PN$R_&8BM5C0KSG"DH8:EB*M6C3E]:?V9^T!_T._P=_\
M#6^-?_GPT?V9^T!_T._P=_\ #6^-?_GPU^>?Q\T?XV?LV_#?P+X<\%_&3Q=\
M;+K_ (;=^ %I\,O#?B;QE=Z/X\L/!OBO4H5?X.?$[XG-?ZAJ'BKPG=ZJ+NXA
MUSQ-ID^J?\(A<16&J0^(I=.MIYN@\3_M0^.]3URV^%_Q<\ 1^$_B9\+_ -L7
M]E'P'J[_  E^+OBBV\&^(= ^,MU#K7A/Q-#K,GA;0==UW0XHDU'3O%WPV\1:
M/::=KDNG/:7>H&PNXI5Z(9'C<12I8G!5<MQN%J3J)SIX3!4:\*-.I@Z,:\L)
MBE0KN#K8W#T:DHITH5IRC"K5@O:'%4XKRS"5Z^!S7#Y]EF/HTJ'[JMF6:8K"
M5,35HYAB)X2.99?+%X155ALKQF*I0E*->IAJ?/4P^'JR5%?=G]F?M ?]#O\
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M@\51HX&A&ABL54HPP6#IT*N,CC,RQ.'R[#U)XK$X2GB/JK^S/V@/^AW^#O\
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MFZW8_%+[;;V6LZ99W\>AZ)IWA_2+)=,U\W6K75UY=X1_X)T_$/0X/BZ_]M?
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MQ6VE^+-#CBOI-/MH[75[;4[=C /J[_A!?C-_T7=?_#7>%_\ Y.H_X07XS?\
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M1/$WA[4?%?AB'4_#L<$?B32].N&M=4N7U&ZLFTB?5;R1CXA_\$_?^$_\,/\
M#V3]H'XB:?\ ##Q-\-? 'PS^)GP^O/#?@+Q=H?B&Q\!>%[7P?'XB\!GQEH>N
M3?!SQ/X@T*V2#6]1\$F.*2\BL]:M+:VU^RAU6OJC_A!?C-_T7=?_  UWA?\
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M_P"0_P#XNO+\GU/YFC)]3^9H]C#S^\/[1Q7\T/\ P!?U_P ._*WJ'_"56/\
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M9M+96M\TG^9[>&J2JT*=2=G*46VTK*]VMOD%%%%0;A1110 4444 %?E[X_\
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M&GBC6=2U[5_$/B2YW7NNWYU#5YKC4/[-;5+FZBT2RN)Y6TS18]/TT22"U$C
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M^"=!\<>-?C!'\<-5U;PIX=;4O$N@>#?$W[)TO[,ANO#6G-K.K*GPVTKPA?\
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M8@Z5% #(HXX8XX842**)$CBCC4*D<<:A41%4 *B* JJ     ,"GT44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+G[9WQXUW]FW]FO
MXJ_%OPCX.U_X@^-_#GAFZ3P+X,\-:'J/B'5-=\9ZH1IGAJ!]-TNWNKMM+M=4
MN8-1UNY$7E6NDV=W)+(GRY^HZPO$.CV&M:=-::A"LT+*05;."#P0<$<'H?;(
M[T ?DM_P16_:N^,/[2_[)]E9?M!:3XVC^+?PTU>Y\/ZEXS\8:#JVE)\3_#>H
M23ZIX:\9:9J%_:P6NK316\MSX?UIK"206]YI$4LRH;Q-WZ?:I\9/A'HGBQ?
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M\/W\VA:-XGU2.]DL<S=M;M.VSV>UFO+J]GW^7W'\4/V3/$_Q0\*?L_:%XO\
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M[(GC.[USPY<:9%X:TI]3\/&"TM(K'Q19NUR![K>S=FG]]DGOY+?7\3$\5_\
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M[M1R0_EC_P" K_(?UBO_ ,_JO_@R?EY^2^XT?MTW_01UG_P<:E_\D4?;IO\
MH(ZS_P"#C4O_ )(K.HHY(?RQ_P# 5_D+ZQ7_ .?];_P9/_Y+R7W%N.\O1-<O
M)JNL/#(T)MXO[6U$&$)"$E!83Y?S90T@))V@A>,5-]NF_P"@CK/_ (.-2_\
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MDTT3'$UI1C.&(J2C**E&4:TI1E&23C*,E)J46K.,DVFK-.UC1^W3?]!'6?\
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M>W&FW=M>FTDE2&>UU&SN["YB+[[>\MKBVE5)H9$7RWXT?\E!_9^_['#X@_\
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MM;QI#!;V\:0P011J%CBABC58XXT4!41%554 * !BOEZU_P"2R_'?_KE\'?\
MU&_%-?1WA_Q%H'BS1[+Q!X7UO2?$>@ZE&\NGZSH>HVFJZ7>QQRO!(]K?V,T]
MK.(IXI8)?+E;RYHI(GVR(ZCYQM?^2R_'?_KE\'?_ %&_%-=.&WJ_]>O_ '+2
M.#,?]V_[?7_I,SKZ***W/G@HHHH **** "BBB@ HHHH \)^*G_)4?V8/^RH>
M-_\ U27Q&KW:O!?BO-"GQ3_9?1YX(W;XH>-L))-$CG=\$_B,%(1G#$,?E4X^
M9OE7)XKWJ@ HHHH **** "BBB@ HHHH **** "BBB@ KPCXE?\EI_9=_[&7X
MQ_\ JH=7KW>O"/B5_P EI_9=_P"QE^,?_JH=7H ]WHHHH **** "BBB@ HHH
MH **** -[PW_ ,A:W_[:?^BI*]:KR7PW_P A:W_[:?\ HJ2O6JY:_P :_P *
M_-GO97_N\_\ K]+_ -(IA1116)Z1YEX&^,OPQ^)>JZ[HG@;Q?I_B'4_#F7U*
MWM8;^!)+5=3U+1#JFD7-[:6MKXBT,:SHVK:0=?\ #T^J:*-4TZ\T_P"W_:[>
M2%>"^-'_ "4']G[_ +'#X@_^J;\?5Y-^S3^SK\0_A9XG\+7OC6Z\+?V3\*?@
MI<? ?P?/X?U'4=2O?&NES>.(/%*^--<MK[2]-3PQ=C3-(T.Q?0(+OQ!NU:XU
MV?\ M7[%#IS7?HGQ3\'K=_&WX%:S)XC\6B/5/$/C+2VT%-:V>&[+R/A-XX?^
MT;#2Q;;K?5I@#!->_:7#6TUS"8?WVZ/M4:-+$25.HYTXTJK3TDV_93TNE%:J
MTMO=OR/WDSBK*M6PKC*,8U)RIJSO%+]Y!ZI\S5G>/6]N9))HZ>BNW_X5]8?]
M!/7_ /P;/_\ &J/^%?6'_03U_P#\&S__ !JI]M3_ +WW+R_O>;^[S/-_LS$?
MS4O_  *7_P @<17A'Q]_Y!_P>_[.3^!__J32U]7?\*^L/^@GK_\ X-G_ /C5
M?//[1?@RTLM.^#1CU#6F\W]I/X(HWFZF[[5_X2@J63]V-K@.2K#D'D4>VA_>
M^Y>7GYO[O,/[,Q'\U+_P*7_R!Z@W4_4_SI*[@_#^P)/_ !,]?ZG_ )BS_P#Q
MJD_X5]8?]!/7_P#P;/\ _&J/;4_[WW+R_O>;^[S#^S,1_-2_\"E_\@<117;_
M /"OK#_H)Z__ .#9_P#XU1_PKZP_Z">O_P#@V?\ ^-4>VI_WON7E_>\W]WF'
M]F8C^:E_X%+_ .0.(HKM_P#A7UA_T$]?_P#!L_\ \:H_X5]8?]!/7_\ P;/_
M /&J/;4_[WW+R_O>;^[S#^S,1_-2_P# I?\ R!Q%%=O_ ,*^L/\ H)Z__P"#
M9_\ XU1_PKZP_P"@GK__ (-G_P#C5'MJ?][[EY?WO-_=YA_9F(_FI?\ @4O_
M ) XBBNW_P"%?6'_ $$]?_\ !L__ ,:H_P"%?6'_ $$]?_\ !L__ ,:H]M3_
M +WW+R_O>;^[S#^S,1_-2_\  I?_ "!Q%%=O_P *^L/^@GK_ /X-G_\ C5'_
M  KZP_Z">O\ _@V?_P"-4>VI_P![[EY?WO-_=YA_9F(_FI?^!2_^0.(KY[_:
M;\(>(?'7PND\.^%[$:EK$GC7X6:NEJUQ;VH.G^&OBCX/\2:U-YUU)%"&M-&T
MJ_NUB+B2X: 00*\TD:-]FCPC8  ?O3@ 9:5BQP ,L<\L<98]R2:X;XC:CX-^
M&7AA_%OBH:A_9$6M^%-!/V"(WEU_:'C+Q5HW@[1BMOYL6Z#^V-=L#>2[_P#1
M[,3W&V0Q>6Q[:'][[EY>;[O[O,:RW$IIWI:-/64K:.^ON(RH2#&I'1BS#Z,[
M$?H>E689##+%* &,4B2!22 Q1@P!(Y .,$CD5Z*/"-AC #X''$K8X.#W'>E_
MX1*P])/^_K?XT>VA_>^Y>7][IK]WF+^S,1_-2_\  I?_ "!^8.J_L*:7XFT3
M3- \6?%C7-:L? ^O>-O$_P )5M?!^F:"W@K6O'7QHTCXW:G)XC?2]=2?Q_8V
M^O\ A_1] M[0S^$YF\/QWTLUZ^OW<&LV&C;_ +$NG:;'<2Z+\3+O2-2U.VAN
M-<G@\#V$NG7WB:P^/>@?M!Z5KMIITGB07UM;0>)= AT#5+#5M<\0ZOKVA7!N
M;_Q2NMQ/J-S^EO\ PB5AZ2?]_6_QH_X1*P])/^_K?XTO:TKWM*^G3LHK^;2V
MNUMM-T:?4,9MSTK7O:_5]?X??7UUW/R_T/\ 8%\%Z#>:-+9^.M6%GX1\2Z%K
MG@J/_A';:76-)T_2_C?X?^.=]HFL:_J6NZG+K":IK7AO3?#J7>C6/A&V@T>-
M-3U/2=?\1PPZHGWP[F1W=OO.S.<DDY8DGD\GD]3R:](_X1*P])/^_K?XT?\
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MRJ0K$'T@DDDDY))))ZDGDD_6DHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS-1T71M7\K^UM)TS5/($BP_VC86M[Y*RA1*(OM,4OEB0*HD"8#A5W9P,:=%
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M5T:ZUB6WDDU;3+G3=-UB73X=(T'3Y-$BMM#DN;N^TF'7;[]5J*">57OO?O\
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ML5Y_SZ7/_?B7_P"(K:Z[K[T>#[.I_P ^Y_\ @,O\BM15G[%>?\^ES_WXE_\
MB*/L5Y_SZ7/_ 'XE_P#B*+KNOO0>SJ?\^Y_^ R_R*U%6?L5Y_P ^ES_WXE_^
M(H^Q7G_/I<_]^)?_ (BBZ[K[T'LZG_/N?_@,O\BM15G[%>?\^ES_ -^)?_B*
M/L5Y_P ^ES_WXE_^(HNNZ^]![.I_S[G_ . R_P BM15G[%>?\^ES_P!^)?\
MXBC[%>?\^ES_ -^)?_B*+KNOO0>SJ?\ /N?_ (#+_(K459^Q7G_/I<_]^)?_
M (BC[%>?\^ES_P!^)?\ XBBZ[K[T'LZG_/N?_@,O\BM15G[%>?\ /I<_]^)?
M_B*/L5Y_SZ7/_?B7_P"(HNNZ^]![.I_S[G_X#+_(K459^Q7G_/I<_P#?B7_X
MBC[%>?\ /I<_]^)?_B*+KNOO0>SJ?\^Y_P#@,O\ (K459^Q7G_/I<_\ ?B7_
M .(H^Q7G_/I<_P#?B7_XBBZ[K[T'LZG_ #[G_P" R_R*U%6?L5Y_SZ7/_?B7
M_P"(H^Q7G_/I<_\ ?B7_ .(HNNZ^]![.I_S[G_X#+_(K459^Q7G_ #Z7/_?B
M7_XBC[%>?\^ES_WXE_\ B*+KNOO0>SJ?\^Y_^ R_R*U%6?L5Y_SZ7/\ WXE_
M^(H^Q7G_ #Z7/_?B7_XBBZ[K[T'LZG_/N?\ X#+_ "*U>:>*?@W\*O&_BG1/
M&_B[P%H'B'Q?X:^S?\(_XBU&*Z?4]&-I,\]N=/EBNHH[=DEDD+,L>Z9':&<R
MPDQUZI]BO/\ GTN?^_$O_P 11]BO/^?2Y_[\2_\ Q%%UW7WH/9U/^?<__ 9?
MY%<DDDDY)))/J3R3259^Q7G_ #Z7/_?B7_XBC[%>?\^ES_WXE_\ B*+KNOO0
M>SJ?\^Y_^ R_R*U%6?L5Y_SZ7/\ WXE_^(H^Q7G_ #Z7/_?B7_XBBZ[K[T'L
MZG_/N?\ X#+_ "*U%6?L5Y_SZ7/_ 'XE_P#B*/L5Y_SZ7/\ WXE_^(HNNZ^]
M![.I_P ^Y_\ @,O\BM15G[%>?\^ES_WXE_\ B*/L5Y_SZ7/_ 'XE_P#B*+KN
MOO0>SJ?\^Y_^ R_R*U%6?L5Y_P ^ES_WXE_^(H^Q7G_/I<_]^)?_ (BBZ[K[
MT'LZG_/N?_@,O\C5\-_\A:W_ .VG_HJ2O6J\L\/6US'JD#R6\Z(-^6>*15&8
MW RS* ,D@#)ZUZG7-6:<E9W]U?FSW,LC*-":DG%^VD[--.W)3UU"O'OB-\<?
M WPO\7?"KP/XD'B";Q%\8O%P\'>$H-&\/ZAJ=A;WW]G7^I/?^(]9CCCTCP_I
M2I8-:PRZA?)>ZA?W%O:Z78W[+=&V]<N(([F":VE\SRKB*2"3RII;>7RY4:-_
M+GMWBG@DVL=DT,D<L;8>-T=58>%^+/@+HNO6?PETW2==UO1K#X4_%[1/BS;I
MJNI:YXVOM;N-(TGQ-I;Z'<ZSXJUV_P!7MK>[/B-[A;MKV]%D+1+>WL_*E/EJ
ME[+F_>N7+:7PZ:\LN5MVD])\MXJ+YE=<T=SNGSV]Q*^F_P#BCS*SLM8\VM]'
M;1D7PF_:-\#?&'66T;P]IWBC2I+[PK'X_P#"%YXCT^PLK/Q]\/9==O/#<?C7
MPN;'5=2NH](?5;2,?8_$=KH'B!++5-$U&71H[35()*O_ !(!_P"%I?L[G''_
M  FOC@9[9/PC\<X'XX/Y&N#^!7[,@^#6O:9JMUXVD\56G@OX9Q?!GX;6">'X
MM!DT+X=0^*)O$\</B6ZCU74T\4^* T>B:2^N6=KX;T]K#0HYUT".^U._G;W.
MY^'/A&\\;Z?\1+NQO[KQ7I%O/;:5=7/B'Q'/I>F+=6,VF7-QI_AF75F\,66H
M7&GW%Q93ZG;:/%J4MM<3PO=,DT@;2H\/"M-TI2=/V<XQ=FVY2A*"OS<C2U3D
M[.TKJ,7&QG!594X^T24^:#DKK11E&3^'F5]&HJ^UKN]SN****YC<**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\'U+]F7X'ZQJ/B/4]7\#1:I<>*!XA:_AU#7?$]WI]A=>+=2
MTW6?$^J>%M*GUI]-\$ZUKVLZ/I6KZGKG@ZTT+5[G5=/MM2:]%\AG;WBB@#DO
M!7@7PO\ #S0_^$>\)::VG::^HZIK%VT]]J.K:EJFM:Y?3ZGK.M:UK6L7=_K&
MM:QJNH7$UW?ZIJM]>7US*^99V545>J>-),;QG'3\?_U4^B@#PZ/X_P#P9D\4
MW/@__A*I(M7L_' ^&=S<W7AKQ99^&HOB$]O;W4/@P^-;K08?!K>)+I+RTBLM
M)37FO+Z]NK;3[.*>_GBMG]1O-8T&QADGFNDDCAU"#2[@V,,^I/:7UQ(D:0WL
M6G0W4MDJ&16N9KI(8+.(F>[EA@#2#XAU/]G3XO:S'\4?A[,W@73? 7Q*_:>T
M;X[S^.H/$>MWGBG3?#N@>(?A]XPM/#MCX//A:QM(O$EWK?@&UTU]6;Q<;'3M
M.O[C5+9;B_M[>R;Q;P#^Q#\;]$UR+5];U[P#:+)-^SS=:W::5K^I3:;JFN_!
M[XNZGXZ\3:_I6D6'P]\,6^DV>OZ#JDEIH%GK$_B?Q5_: N4\7>-=:%Q'J,(!
M^G?A'Q1X2\>>&/#GC/PCJ]EKGACQ=I-AKOAO5[0LMOJVE:E:)?V5W;I/'#<*
M)K219C#-#%<0C<L\4;HZKG:7X]\#ZW9^*;[1M6&K6_@KQ1?^"_$_]G:=JE[/
MI7BC2VL%U#2)+2VL)+NXGL_[3LFGDLX+FV2.;S3-Y44SQ_ _['_[,7B[X2_$
MD6'B*+/@7X1?#3PAI_A=$T[4M/T6\^//CCP?X<T+X\>)?"4NIPV5QK7AAK/P
M'X?NM&UDZ?:6_P#:OQ!\>6<"-<"^6W[#Q)^SY\:M1\&_M$?#'3K+X?KH_P 8
M/C1J'Q4T#QG<>,]<AN=+LKK7O NN1:/J_A:+P/,?M87PK>6<LUIK]S;$W-O+
MAHS+%& ?=EU?Z39OIT<\A+:K<"VL3;V]Q=H[FVN+SS9I+2&>.TLQ!;2%M0O&
M@L5E:"W:Y%Q=6T4S_MFC>2+G[?I_V<W'V,3_ &NV\DW>\Q_91+OV&X\P&/R-
MWF[P5V[ABOS&\1_L)?$?4M3\47-GXL\%R:?I?BKQGI'P7LYY-?LI/!'P4\6_
M#/XXI+X5O9(=/N@VM1?%GXR6\ :S,EG'\.? OA..*Z&IZ>-.?R+XP?LC>.OA
M[;ZU_8'P^\._$_PQXG^$=_X!T#X1Z+H'B6^\':=\0Y?@9X?^'UU\3+U=)\,Z
ME8Z#XL;6="2PT;6M0TVSBU/0=5U*XU+Q?X4U*V0W@!^T@MX& 954J0"",$$$
M9!! P01R"."*7[-#_<'Y#_"N*^%F@ZGX6^&/PY\,:TBQZQX<\!^$-!U9$F2X
M1-3TCP_IVGWZ+<1LR3JMU;RJLR,R2@!U8A@3WE 'D'@SXR_#3X@W+P>#[_7M
M9MTU#Q#I1UQ? ?CVR\)MJ'A34[_1?$%K'XSU'PQ9^$I7T_5]+U#3&,6M.EQ?
M6LMM:-<2@*?3+>XTF[94M+NRNG> 7*+;W,$S-;&5X!<*L;L6@,T4D(E ,9EC
M>/=O1@/S4A_9$^)K?!;XE?!FXT'PN;WQS=_%Y?\ A-Y/CA\3KSPU-IOQ#^)/
MB'QK917'PKG\-CP]ILITC5K;1M1_LT%[2\CN[ZRN)C.[RV-5_89\5#5?'MWX
M(UCP1\.I/&7B']IQK77O"\.I:;K&B^%?C)\+=#\(^"-.ABTO3M,Q%X:\5Z4W
MB&_T2TU&RT^SEV:MH]R^MRR3( ?>VM?$/X?>']2T31M4\1Z;'K'B73O$VK>'
M=*M?.U/4M=L/!J6<GB>;2+'3(+RZU%M&74+-;N"TBEN?-N(X8H9)B4'7+/I;
M_: MS:YLS&MXIFB5[-I8UEC2[1B'MG>-T=4G6-RK*P&"*_*CQ1^PM\2?$FI^
M,/$NG:#\&/!3>+? GQ-\#:/\/M%U359O"_PWF\7_  H\&^"+?Q-X;U1/ 5C(
MT^O:_P"$KB]\3V6FZ'H+IINH:?<FZU?5K?53?68OV$OB9<^&?^$5U/4OAY_H
M&EZ%H/B#Q#%J?B&>]^/;0?M'> /C%>>,?BI:RZ CV^NZ/X3\*:WX?TJSGOO%
MKW.M^+-9ACUG2/#C""X /U,6ZTAA9%;VQ8:D"=.*W5N1?A4\TFR(?_2@(R)"
M8/,PAWGY>:Q/!WBOPE\0-!A\4>#M5MM=T&XO]<TN#4K6.>.&2_\ #>N:CX:U
MRV"74$$P?3]<TC4=.E)B"/+:N\+20M'(_P"8WBW]AGXP7?B>_G\+ZE\.=/\
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M/U"J-8HD5U2*-5D9WD5455D>0YD=P  S2$DNS9+$_,30!^9WC#]LSXAWNO\
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MM+:**"WAC58XHHTC10J@  O4444 %%%% !1110 4444 %%%% !1110 4444
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MP!5@0001D$$<$$<@C@BEJ.**."*.&%%BAAC2**-%"I''&H1$11@*J* JJ!@
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MB+]EK2KGX[>&OCCXG^*7Q2\:O\/M?^(/BOX7> /$VI^';CPE\._$?Q/\-_\
M"(^++O1KZS\-V7C+4=*C\.SZOIOAKPSXA\4:MX>\,Q>(=7;3]/+0^'O[  /J
M6BBB@ HHHH **** /CG]J;]K9/V;]3\)Z#8?#Z3Q[K>O_#WXW?&#4UO/&6B^
M -$T3X8_L]Z!X>U[XBW\6O:Y:7]OJWC"5/%F@6WA7PA'!9P:I&^M:QKGB+PQ
MH'A_4=53Z;\!^,]#^(_@?P9\0_#$L]QX:\>>%/#OC/P]/<P-;7,VA^*-(L]<
MTF6XMF+-;SR6%];O+ S,T4C-&22N:\$_:D_90\'?M7:%X<\->-_$FOZ-HNAR
M^(X[S3=+T?P#X@L=9T[Q9H4WAS6 UE\0/!WC&TT+Q-9Z7<74?A3Q[X9AT?QG
MX1EOM3.C:Q%;ZKJ5K=?17ACPWHO@WPWX>\(>&K"+2O#OA70])\-Z!ID#2-#I
MVBZ'86^F:580M*\DK16=C:P6\;2.\A2,%W9B20#<HHHH **** "N'^)?C?\
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MW@SQOXON[CQ3X'/@76-"=- T271];TG2]4\: 'ZP4444 %%%% !1110 45\
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M_P""<5_\V!_PT?\ L\?]%Y^#'_AT? __ ,O*/^&C_P!GC_HO/P8_\.CX'_\
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MUY&T4;),I12"BC_5?+_^?V,_\&4/_F</]?,X_P"@;+?_  3BO_FP[7_AH_\
M9X_Z+S\&/_#H^!__ )>4?\-'_L\?]%Y^#'_AT? __P O***/]5\O_P"?V,_\
M&4/_ )G#_7S./^@;+?\ P3BO_FP/^&C_ -GC_HO/P8_\.CX'_P#EY1_PT?\
ML\?]%Y^#'_AT? __ ,O***/]5\O_ .?V,_\ !E#_ .9P_P!?,X_Z!LM_\$XK
M_P"; _X:/_9X_P"B\_!C_P .CX'_ /EY1_PT?^SQ_P!%Y^#'_AT? _\ \O**
M*/\ 5?+_ /G]C/\ P90_^9P_U\SC_H&RW_P3BO\ YL#_ (:/_9X_Z+S\&/\
MPZ/@?_Y>4?\ #1_[/'_1>?@Q_P"'1\#_ /R\HHH_U7R__G]C/_!E#_YG#_7S
M./\ H&RW_P $XK_YL#_AH_\ 9X_Z+S\&/_#H^!__ )>4?\-'_L\?]%Y^#'_A
MT? __P O***/]5\O_P"?V,_\&4/_ )G#_7S./^@;+?\ P3BO_FP/^&C_ -GC
M_HO/P8_\.CX'_P#EY1_PT?\ L\?]%Y^#'_AT? __ ,O***/]5\O_ .?V,_\
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MC/\ P90_^9P_U\SC_H&RW_P3BO\ YL#_ (:/_9X_Z+S\&/\ PZ/@?_Y>4?\
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M  T?^SQ_T7GX,?\ AT? _P#\O***/]5\O_Y_8S_P90_^9P_U\SC_ *!LM_\
M!.*_^;"W8?M ? ?5+VUT[3/C9\(]1U"]FCMK*PL/B1X-O+V[N)6"Q6]K:V^L
MR3W$TC$+'%%&\CL0%4DXKURBBOGLZRVAEM2A"A.K-583E+VLH2:<9)*W)3II
K*SUNF?9<,9WB\ZH8JIBJ>'IRH5:<(+#PJ034X.3<O:5:K;NM+-*W1G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img148586500_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148586500_9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ *H# 2(  A$! Q$!_\0
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C7E.DPW3ZM;K;*XF60$D#H.^:]6[5RX+%O$1;<;6(A+F1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>27
<FILENAME>asnd-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-12T15:28:09.3584+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ascendispharma.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:asnd="http://ascendispharma.com/20241231" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" namespace="http://xbrl.sec.gov/country/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" namespace="http://xbrl.sec.gov/currency/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd" namespace="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" id="StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss">
        <link:definition>100010 - Statement - Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss2" id="StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss2">
        <link:definition>100020 - Statement - Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" id="StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical">
        <link:definition>100030 - Statement - Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition" id="ConsolidatedStatementsOfFinancialPosition">
        <link:definition>100040 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity" id="ConsolidatedStatementsOfChangesInEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements" id="ConsolidatedCashFlowStatements">
        <link:definition>100060 - Statement - Consolidated Cash Flow Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/GeneralInformation" id="GeneralInformation">
        <link:definition>995467 - Disclosure - General Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies" id="DisclosureSummaryOfMaterialAccountingPolicies">
        <link:definition>995477 - Disclosure - Summary of Material Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimates" id="SignificantAccountingJudgementsAndEstimates">
        <link:definition>995487 - Disclosure - Significant Accounting Judgements and Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/Revenue" id="Revenue">
        <link:definition>995497 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformation" id="SegmentInformation">
        <link:definition>995507 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/EmployeeCosts" id="EmployeeCosts">
        <link:definition>995517 - Disclosure - Employee costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPayment" id="ShareBasedPayment">
        <link:definition>995527 - Disclosure - Share-based Payment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServices" id="PrincipalAccountantFeesAndServices">
        <link:definition>995537 - Disclosure - Principal Accountant Fees and Services</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTax" id="TaxOnProfitLossForTheYearAndDeferredTax">
        <link:definition>995547 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>995557 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
        <link:definition>995567 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociates" id="DisclosureInvestmentsInAssociates">
        <link:definition>995577 - Disclosure - Investments in Associates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/Inventories" id="Inventories">
        <link:definition>995587 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/Leases" id="Leases">
        <link:definition>995597 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilities" id="ContractLiabilities">
        <link:definition>995607 - Disclosure - Contract liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisions" id="DisclosureProvisions">
        <link:definition>995617 - Disclosure - Provisions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilities" id="DisclosureFinancialAssetsAndLiabilities">
        <link:definition>995627 - Disclosure - Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagement" id="DisclosureFinancialRiskManagement">
        <link:definition>995637 - Disclosure - Financial Risk Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995647 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>995657 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprises" id="InvestmentsInGroupEnterprises">
        <link:definition>995667 - Disclosure - Investments in Group Enterprises</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/Ownership" id="Ownership">
        <link:definition>995677 - Disclosure - Ownership</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>995687 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995697 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995707 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/RevenueTables" id="RevenueTables">
        <link:definition>995717 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationTables" id="SegmentInformationTables">
        <link:definition>995727 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables" id="DisclosureEmployeeCostsTables">
        <link:definition>995737 - Disclosure - Employee Costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentTables" id="ShareBasedPaymentTables">
        <link:definition>995747 - Disclosure - Share-based Payment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesTables" id="PrincipalAccountantFeesAndServicesTables">
        <link:definition>995757 - Disclosure - Principal Accountant Fees and Services (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxTables" id="TaxOnProfitLossForTheYearAndDeferredTaxTables">
        <link:definition>995767 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <link:definition>995777 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
        <link:definition>995787 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables" id="DisclosureInvestmentsInAssociatesTables">
        <link:definition>995797 - Disclosure - Investments in Associates (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/InventoriesTables" id="InventoriesTables">
        <link:definition>995807 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsTables" id="DisclosureProvisionsTables">
        <link:definition>995817 - Disclosure - Provisions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables" id="DisclosureFinancialAssetsAndLiabilitiesTables">
        <link:definition>995827 - Disclosure - Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables" id="DisclosureFinancialRiskManagementTables">
        <link:definition>995837 - Disclosure - Financial Risk Management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesTables" id="InvestmentsInGroupEnterprisesTables">
        <link:definition>995847 - Disclosure - Investments in Group Enterprises (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" id="DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995857 - Disclosure - Summary of Material Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail" id="DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail">
        <link:definition>995867 - Disclosure - Summary of Material Accounting Policies - Schedule of Asset's Expected Useful Life (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" id="SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail">
        <link:definition>995877 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail" id="RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail">
        <link:definition>995887 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail" id="DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail">
        <link:definition>995897 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail" id="DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail">
        <link:definition>995907 - Disclosure - Revenue - Schedule of Revenue Attributable to Commercial Customers by Product (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail" id="DisclosureRevenueAdditionalInformationDetail">
        <link:definition>995917 - Disclosure - Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail" id="SegmentInformationAdditionalInformationDetail">
        <link:definition>995927 - Disclosure - Segment Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail" id="SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail">
        <link:definition>995937 - Disclosure - Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails" id="DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails">
        <link:definition>995947 - Disclosure - Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail" id="DisclosureEmployeeCostsSummaryOfEmployeeCostDetail">
        <link:definition>995957 - Disclosure - Employee Costs - Summary of Employee Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail" id="DisclosureEmployeeCostsAdditionalInformationDetail">
        <link:definition>995967 - Disclosure - Employee Costs - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail" id="ShareBasedPaymentAdditionalInformationDetail">
        <link:definition>995977 - Disclosure - Share-Based Payment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail" id="ShareBasedPaymentSummaryOfShareBasedPaymentDetail">
        <link:definition>995987 - Disclosure - Share-Based Payment - Summary Of Share Based Payment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail" id="DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail">
        <link:definition>995997 - Disclosure - Share-Based Payment - Summary Of Share Based Payment (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail" id="ShareBasedPaymentScheduleOfWarrantActivityDetail">
        <link:definition>996007 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail" id="ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail">
        <link:definition>996017 - Disclosure - Share-based Payment  - Schedule of Warrant Activity (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail" id="ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail">
        <link:definition>996027 - Disclosure - Share-based Payment - Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail" id="ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail">
        <link:definition>996037 - Disclosure - Share-based Payment  - Summary of Fair Values for Warrant Grants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails" id="PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails">
        <link:definition>996047 - Disclosure - Principal Accountant Fees and Services - Summary of Principal Accountant Fees and Services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail" id="TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail">
        <link:definition>996057 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxParentheticalDetail" id="TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxParentheticalDetail">
        <link:definition>996067 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail" id="TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail">
        <link:definition>996077 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail" id="IntangibleAssetsSummaryOfGoodwillDetail">
        <link:definition>996087 - Disclosure - Intangible Assets - Summary of Goodwill (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" id="PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail">
        <link:definition>996097 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails">
        <link:definition>996107 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail" id="PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail">
        <link:definition>996117 - Disclosure - Property, Plant and Equipment - Summary of Depreciations Charges (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail" id="DisclosureInvestmentsInAssociatesAdditionalInformationDetail">
        <link:definition>996127 - Disclosure - Investments in Associates - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail" id="DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail">
        <link:definition>996137 - Disclosure - Investments in Associates - Schedule of Financial Information of Investments in Associates (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail" id="InventoriesSummaryOfInventoriesExplanatoryDetail">
        <link:definition>996147 - Disclosure - Inventories - Summary of Inventories Explanatory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail" id="DisclosureInventoriesAdditionalInformationDetail">
        <link:definition>996157 - Disclosure - Inventories - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail" id="ContractLiabilitiesAdditionalInformationDetail">
        <link:definition>996167 - Disclosure - Contract Liabilities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail" id="DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail">
        <link:definition>996177 - Disclosure - Provisions - Summary of Development in Provisions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" id="DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
        <link:definition>996187 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail" id="DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail">
        <link:definition>996197 - Disclosure - Financial Assets and Liabilities - Schedule of Financial assets and Financial Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail" id="DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail">
        <link:definition>996207 - Disclosure - Financial Assets and Liabilities - Schedule of Finance Income and Finance Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail" id="DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail">
        <link:definition>996217 - Disclosure - Financial Assets and Liabilities - Summary of Expenses, Related To Lease Activities In The Consolidated Statements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails" id="DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails">
        <link:definition>996227 - Disclosure - Financial Assets and Liabilities - Summary of Development in Borrowings Arising from Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails" id="DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails">
        <link:definition>996237 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails" id="DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails">
        <link:definition>996247 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Remeasurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfNumberOfSharesDetail" id="DisclosureFinancialRiskManagementSummaryOfNumberOfSharesDetail">
        <link:definition>996257 - Disclosure - Financial Risk Management - Summary of Number of Shares (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail" id="DisclosureFinancialRiskManagementAdditionalInformationDetail">
        <link:definition>996267 - Disclosure - Financial Risk Management - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail" id="DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail">
        <link:definition>996277 - Disclosure - Financial Risk Management - Summary of Holding of Treasury Shares (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail" id="DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail">
        <link:definition>996287 - Disclosure - Financial Risk Management - Schedule of Foreign Currency Sensitivity Analysis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail" id="DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail">
        <link:definition>996297 - Disclosure - Financial Risk Management - Summary of Rate Structure of Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail" id="DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail">
        <link:definition>996307 - Disclosure - Financial Risk Management - Schedule of Marketable Securities Specified By Investment Grade Credit Rating (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail" id="DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail">
        <link:definition>996317 - Disclosure - Financial Risk Management - Summary of Marketable securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail" id="DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail">
        <link:definition>996327 - Disclosure - Financial Risk Management - Summary of Contractual Cash Flows for Financial Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>996337 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail" id="InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail">
        <link:definition>996347 - Disclosure - Investments in Group Enterprises - Summary of Investments in Group Enterprises (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail" id="OwnershipAdditionalInformationDetail">
        <link:definition>996357 - Disclosure - Ownership - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>996367 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" xlink:href="asnd-20241231.xsd#StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss2" xlink:href="asnd-20241231.xsd#StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss2" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition" xlink:href="asnd-20241231.xsd#ConsolidatedStatementsOfFinancialPosition" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements" xlink:href="asnd-20241231.xsd#ConsolidatedCashFlowStatements" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail" xlink:href="asnd-20241231.xsd#RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail" xlink:href="asnd-20241231.xsd#DisclosureEmployeeCostsSummaryOfEmployeeCostDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails" xlink:href="asnd-20241231.xsd#PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail" xlink:href="asnd-20241231.xsd#TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail" xlink:href="asnd-20241231.xsd#InventoriesSummaryOfInventoriesExplanatoryDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/CoverPage" xlink:href="asnd-20241231.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" xlink:href="asnd-20241231.xsd#StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity" xlink:href="asnd-20241231.xsd#ConsolidatedStatementsOfChangesInEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="asnd-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/GeneralInformation" xlink:href="asnd-20241231.xsd#GeneralInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies" xlink:href="asnd-20241231.xsd#DisclosureSummaryOfMaterialAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimates" xlink:href="asnd-20241231.xsd#SignificantAccountingJudgementsAndEstimates" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/Revenue" xlink:href="asnd-20241231.xsd#Revenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformation" xlink:href="asnd-20241231.xsd#SegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/EmployeeCosts" xlink:href="asnd-20241231.xsd#EmployeeCosts" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPayment" xlink:href="asnd-20241231.xsd#ShareBasedPayment" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServices" xlink:href="asnd-20241231.xsd#PrincipalAccountantFeesAndServices" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTax" xlink:href="asnd-20241231.xsd#TaxOnProfitLossForTheYearAndDeferredTax" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssets" xlink:href="asnd-20241231.xsd#IntangibleAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipment" xlink:href="asnd-20241231.xsd#PropertyPlantAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociates" xlink:href="asnd-20241231.xsd#DisclosureInvestmentsInAssociates" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/Inventories" xlink:href="asnd-20241231.xsd#Inventories" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/Leases" xlink:href="asnd-20241231.xsd#Leases" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilities" xlink:href="asnd-20241231.xsd#ContractLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisions" xlink:href="asnd-20241231.xsd#DisclosureProvisions" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilities" xlink:href="asnd-20241231.xsd#DisclosureFinancialAssetsAndLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagement" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagement" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingencies" xlink:href="asnd-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/RelatedPartyTransactions" xlink:href="asnd-20241231.xsd#RelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprises" xlink:href="asnd-20241231.xsd#InvestmentsInGroupEnterprises" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/Ownership" xlink:href="asnd-20241231.xsd#Ownership" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/SubsequentEvents" xlink:href="asnd-20241231.xsd#SubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="asnd-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="asnd-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/RevenueTables" xlink:href="asnd-20241231.xsd#RevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationTables" xlink:href="asnd-20241231.xsd#SegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables" xlink:href="asnd-20241231.xsd#DisclosureEmployeeCostsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentTables" xlink:href="asnd-20241231.xsd#ShareBasedPaymentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesTables" xlink:href="asnd-20241231.xsd#PrincipalAccountantFeesAndServicesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxTables" xlink:href="asnd-20241231.xsd#TaxOnProfitLossForTheYearAndDeferredTaxTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsTables" xlink:href="asnd-20241231.xsd#IntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentTables" xlink:href="asnd-20241231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables" xlink:href="asnd-20241231.xsd#DisclosureInvestmentsInAssociatesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/InventoriesTables" xlink:href="asnd-20241231.xsd#InventoriesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsTables" xlink:href="asnd-20241231.xsd#DisclosureProvisionsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables" xlink:href="asnd-20241231.xsd#DisclosureFinancialAssetsAndLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagementTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesTables" xlink:href="asnd-20241231.xsd#InvestmentsInGroupEnterprisesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail" xlink:href="asnd-20241231.xsd#DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail" xlink:href="asnd-20241231.xsd#DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail" xlink:href="asnd-20241231.xsd#DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#DisclosureRevenueAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#SegmentInformationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail" xlink:href="asnd-20241231.xsd#SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails" xlink:href="asnd-20241231.xsd#DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#DisclosureEmployeeCostsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#ShareBasedPaymentAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail" xlink:href="asnd-20241231.xsd#ShareBasedPaymentSummaryOfShareBasedPaymentDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail" xlink:href="asnd-20241231.xsd#DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail" xlink:href="asnd-20241231.xsd#ShareBasedPaymentScheduleOfWarrantActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail" xlink:href="asnd-20241231.xsd#ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail" xlink:href="asnd-20241231.xsd#ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail" xlink:href="asnd-20241231.xsd#ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxParentheticalDetail" xlink:href="asnd-20241231.xsd#TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxParentheticalDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail" xlink:href="asnd-20241231.xsd#IntangibleAssetsSummaryOfGoodwillDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" xlink:href="asnd-20241231.xsd#PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:href="asnd-20241231.xsd#DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail" xlink:href="asnd-20241231.xsd#PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#DisclosureInvestmentsInAssociatesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail" xlink:href="asnd-20241231.xsd#DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#DisclosureInventoriesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#ContractLiabilitiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail" xlink:href="asnd-20241231.xsd#DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails" xlink:href="asnd-20241231.xsd#DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails" xlink:href="asnd-20241231.xsd#DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails" xlink:href="asnd-20241231.xsd#DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfNumberOfSharesDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagementSummaryOfNumberOfSharesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagementAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail" xlink:href="asnd-20241231.xsd#DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail" xlink:href="asnd-20241231.xsd#InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#OwnershipAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="asnd-20241231.xsd#DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoriesTotal" xlink:label="ifrs-full_InventoriesTotal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectsOfDeductibleItemsNotExpensed" xlink:label="asnd_TaxEffectsOfDeductibleItemsNotExpensed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_DKK" xlink:label="currency_DKK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="ifrs-full_AccumulatedImpairmentMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueHierarchyCarryingAmountMember" xlink:label="asnd_FairValueHierarchyCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RealizedDurationOfFinancialAssetsExplanatory" xlink:label="asnd_RealizedDurationOfFinancialAssetsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsAndGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements" xlink:label="asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleDebtCurrentAbstract" xlink:label="asnd_ConvertibleDebtCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProfitLossForTheYear" xlink:label="asnd_ProfitLossForTheYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxLossesCarryforwards" xlink:label="asnd_TaxLossesCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EnforceableLeaseterm" xlink:label="asnd_EnforceableLeaseterm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfAssociate" xlink:label="ifrs-full_NameOfAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_InvestmentsInGroupEnterprisesAbstract" xlink:label="asnd_InvestmentsInGroupEnterprisesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ReserveOfTreasuryShares" xlink:label="asnd_ReserveOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" xlink:label="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CategoriesOfSharesBasedPaymentsDomain" xlink:label="asnd_CategoriesOfSharesBasedPaymentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock" xlink:label="asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedIn2023Member" xlink:label="asnd_GrantedIn2023Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SummaryOfInventoryDisclosureTable" xlink:label="asnd_SummaryOfInventoryDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaBoneDiseaseASMember" xlink:label="asnd_AscendisPharmaBoneDiseaseASMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember" xlink:label="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdditionalFutureTaxDeduction" xlink:label="asnd_AdditionalFutureTaxDeduction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_HighGradeMember" xlink:label="asnd_HighGradeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEuropeASMember" xlink:label="asnd_AscendisPharmaEuropeASMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock" xlink:label="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForTaxServices" xlink:label="ifrs-full_AuditorsRemunerationForTaxServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates" xlink:label="ifrs-full_InvestmentsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaOphthalmologyDivisionASMember" xlink:label="asnd_AscendisPharmaOphthalmologyDivisionASMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:label="ifrs-full_CurrentFinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskAxis" xlink:label="asnd_ForeignCurrencyRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CorporateBondsMember" xlink:label="asnd_CorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="ifrs-full_LongtermBorrowingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TransactionsAndOutstandingBalancesAbstract" xlink:label="asnd_TransactionsAndOutstandingBalancesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory" xlink:label="asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementVestingPeriod" xlink:label="asnd_SharebasedPaymentArrangementVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UsDollarsToEuroMember" xlink:label="asnd_UsDollarsToEuroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfProvisionsExplanatory" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LicensesOfIpMember" xlink:label="asnd_LicensesOfIpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="ifrs-full_FloatingInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsDomain" xlink:label="ifrs-full_PerformanceObligationsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" xlink:label="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractLiabilitiesLineItems" xlink:label="asnd_ContractLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VISENPharmaceuticalMember" xlink:label="asnd_VISENPharmaceuticalMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TeijinMember" xlink:label="asnd_TeijinMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssociatesMember" xlink:label="ifrs-full_AssociatesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WestfieldCapitalManagementCompanyLPUsaMember" xlink:label="asnd_WestfieldCapitalManagementCompanyLPUsaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Germany1Member" xlink:label="asnd_Germany1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfWarrantsOutstanding" xlink:label="asnd_NumberOfWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LeaseExtensionPeriod" xlink:label="asnd_LeaseExtensionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NominalValueAmount" xlink:label="asnd_NominalValueAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaSverigeAbMember" xlink:label="asnd_AscendisPharmaSverigeAbMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="ifrs-full_IncomeTaxesPaidRefund"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="ifrs-full_ConsiderationPaidReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Audit-RelatedFees" xlink:label="asnd_Audit-RelatedFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemuneration" xlink:label="ifrs-full_AuditorsRemuneration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:label="asnd_DisclosureOfAssociatesAndJointVenturesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmericanDepositarySharesMember" xlink:label="asnd_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain" xlink:label="ifrs-full_HedgingInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithFmrLlcMember" xlink:label="asnd_EntitiesAffiliatedWithFmrLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyTwoMember" xlink:label="asnd_TwoThousandAndTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAbstract" xlink:label="ifrs-full_ProfitLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExecutiveBoardMember" xlink:label="asnd_ExecutiveBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExternalCreditGradesDomain" xlink:label="ifrs-full_ExternalCreditGradesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialPapersMember" xlink:label="asnd_CommercialPapersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEndocrinologyDivisionASMember" xlink:label="asnd_AscendisPharmaEndocrinologyDivisionASMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WarrantsGrantedFromDecember2021Member" xlink:label="asnd_WarrantsGrantedFromDecember2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfAssociateLineItems" xlink:label="asnd_DisclosureOfAssociateLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember" xlink:label="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NorthAmerica1Member" xlink:label="asnd_NorthAmerica1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfJointOperation" xlink:label="ifrs-full_NameOfJointOperation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ReversalOfGainLossOnPropertyPlantAndEquipment" xlink:label="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncomeStatementAxis" xlink:label="asnd_IncomeStatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ResearchAndDevelopmentCostsMember" xlink:label="asnd_ResearchAndDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AgencyBondsMember" xlink:label="asnd_AgencyBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReceivablesDueFromAssociates" xlink:label="ifrs-full_ReceivablesDueFromAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BoardOfDirectorsMember" xlink:label="asnd_BoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedIn2022Member" xlink:label="asnd_GrantedIn2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EyconisMember" xlink:label="asnd_EyconisMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FinanceIncomeExpenseAbstract" xlink:label="asnd_FinanceIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NovoNordiskMember" xlink:label="asnd_NovoNordiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPaymentBeginningPeriod" xlink:label="asnd_RoyaltyPaymentBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="ifrs-full_GoodwillMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleNotesCurrent" xlink:label="asnd_ConvertibleNotesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BoardMembersOfGroupMember" xlink:label="asnd_BoardMembersOfGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WarrantsGranted2012UntilNovember2021Member" xlink:label="asnd_WarrantsGranted2012UntilNovember2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageNumberOfEmployees" xlink:label="ifrs-full_AverageNumberOfEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationAbstract" xlink:label="ifrs-full_AuditorsRemunerationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConversionRatePerNote" xlink:label="asnd_ConversionRatePerNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense" xlink:label="ifrs-full_OtherEmployeeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" xlink:label="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfGeneralInformationAbstract" xlink:label="asnd_DisclosureOfGeneralInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PlantAndMachineryMember" xlink:label="asnd_PlantAndMachineryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_USDollarsMember" xlink:label="asnd_USDollarsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="ifrs-full_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="ifrs-full_CashOutflowForLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="ifrs-full_NameOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProcessPlantAndMachineryMember" xlink:label="asnd_ProcessPlantAndMachineryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_YearOfGrantOfWarrants" xlink:label="asnd_YearOfGrantOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SwissFrancToEuroMember" xlink:label="asnd_SwissFrancToEuroMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FinanceIncomeAbstract" xlink:label="asnd_FinanceIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock" xlink:label="asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="ifrs-full_OtherNoncurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PurchaseOfTreasurySharesNominalValue" xlink:label="asnd_PurchaseOfTreasurySharesNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock" xlink:label="asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpfrontFeeForExclusiveLicense" xlink:label="asnd_UpfrontFeeForExclusiveLicense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments" xlink:label="ifrs-full_ReserveOfSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain" xlink:label="ifrs-full_UnobservableInputsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInAssociates" xlink:label="ifrs-full_PurchaseOfInterestsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory" xlink:label="asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecuritiesNonCurrentAssets" xlink:label="asnd_MarketableSecuritiesNonCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods" xlink:label="ifrs-full_FinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SalesMilestonesReceived" xlink:label="asnd_SalesMilestonesReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectOfDeductibleItemsNotExpensed" xlink:label="asnd_TaxEffectOfDeductibleItemsNotExpensed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" xlink:label="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfAdditionalSharesGranted" xlink:label="asnd_NumberOfAdditionalSharesGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SalesDeductionsAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesDeductionsAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectFromDeferredTaxAssetNotRecognized" xlink:label="asnd_TaxEffectFromDeferredTaxAssetNotRecognized"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_OtherCurrentLiabilitiesAbstract" xlink:label="asnd_OtherCurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VestingOfSharesAxis" xlink:label="asnd_VestingOfSharesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ZeroCouponMember" xlink:label="asnd_ZeroCouponMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaFranceSasuMember" xlink:label="asnd_AscendisPharmaFranceSasuMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RevenueThresholdLimit" xlink:label="asnd_RevenueThresholdLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WorkInProgress" xlink:label="ifrs-full_WorkInProgress"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UsGovernmentBondsMember" xlink:label="asnd_UsGovernmentBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="ifrs-full_HedgingInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock" xlink:label="asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilitiesAbstract" xlink:label="ifrs-full_ContractLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitProgramMember" xlink:label="asnd_PerformanceStockUnitProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DeferredTaxAssetNotRecognized" xlink:label="asnd_DeferredTaxAssetNotRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="ifrs-full_TaxEffectOfTaxLosses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EmployeesAndConsultantsMember" xlink:label="asnd_EmployeesAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:label="asnd_DisclosureOfBeneficialOwnershipLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsConditionForRedemption" xlink:label="asnd_BorrowingsConditionForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipAbstract" xlink:label="asnd_DisclosureOfBeneficialOwnershipAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock" xlink:label="asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueOfConvertibleNotes" xlink:label="asnd_FairValueOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaUkLimitedMember" xlink:label="asnd_AscendisPharmaUkLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProfitLossBeforeIncomeTaxAbstract" xlink:label="asnd_ProfitLossBeforeIncomeTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRateRiskMember" xlink:label="ifrs-full_InterestRateRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaIberiaSLMember" xlink:label="asnd_AscendisPharmaIberiaSLMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharePriceAppliedForValuation" xlink:label="asnd_SharePriceAppliedForValuation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractualCapitalCommitments" xlink:label="ifrs-full_ContractualCapitalCommitments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfEmployees1" xlink:label="asnd_NumberOfEmployees1"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LeaseExpenses" xlink:label="asnd_LeaseExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:label="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipTable" xlink:label="asnd_DisclosureOfBeneficialOwnershipTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:label="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedBeforeJanuary12022Member" xlink:label="asnd_GrantedBeforeJanuary12022Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueOfRoyaltyFundingLiabilities" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BritishPoundsToEuroMember" xlink:label="asnd_BritishPoundsToEuroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfReportableOperatingSegments" xlink:label="asnd_NumberOfReportableOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RevenueFromClinicalSupply" xlink:label="asnd_RevenueFromClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfAdditionalSharesAuthorizedToGrant" xlink:label="asnd_NumberOfAdditionalSharesAuthorizedToGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="ifrs-full_AverageEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncomeStatementDomain" xlink:label="asnd_IncomeStatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEndocrinologyGmbhMember" xlink:label="asnd_AscendisPharmaEndocrinologyGmbhMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedInTwoThousandTwentyFourMember" xlink:label="asnd_GrantedInTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="ifrs-full_CountryOfDomicileMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EyconisIncMember" xlink:label="asnd_EyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AssociateAbstract" xlink:label="asnd_AssociateAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock" xlink:label="asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfBasisOfConsolidationExplanatory" xlink:label="asnd_DescriptionOfBasisOfConsolidationExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaIncMember" xlink:label="asnd_AscendisPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaItaliaSrlMember" xlink:label="asnd_AscendisPharmaItaliaSrlMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyFiveMember" xlink:label="asnd_TwoThousandAndTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfCommercialCustomers" xlink:label="asnd_NumberOfCommercialCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyFourMember" xlink:label="asnd_TwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharePriceMeasurementInputMember" xlink:label="asnd_SharePriceMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LowerMediumGradeMember" xlink:label="asnd_LowerMediumGradeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MilestonesMember" xlink:label="asnd_MilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpperMediumGradeMember" xlink:label="asnd_UpperMediumGradeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ClassificationOfRelatedPartyDomain" xlink:label="asnd_ClassificationOfRelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaGmbHMember" xlink:label="asnd_AscendisPharmaGmbHMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativesMember" xlink:label="ifrs-full_DerivativesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyThreeMember" xlink:label="asnd_TwoThousandAndTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PercentageOfWarrantsVested" xlink:label="asnd_PercentageOfWarrantsVested"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RevenueTable" xlink:label="asnd_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaSwitzerlandGmbhMember" xlink:label="asnd_AscendisPharmaSwitzerlandGmbhMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Prime1Member" xlink:label="asnd_Prime1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdditionalTaxDeductionsRelatedToTaxCredits" xlink:label="asnd_AdditionalTaxDeductionsRelatedToTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEndocrinologyIncMember" xlink:label="asnd_AscendisPharmaEndocrinologyIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:label="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExpectedLeaseCommenceYear" xlink:label="asnd_ExpectedLeaseCommenceYear"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AvoroCapitalAdvisorsLlcMember" xlink:label="asnd_AvoroCapitalAdvisorsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NonexecutiveseniorManagementMember" xlink:label="asnd_NonexecutiveseniorManagementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DecreaseInTaxLosseCarryForwards" xlink:label="asnd_DecreaseInTaxLosseCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LicensesMember" xlink:label="asnd_LicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Revenuerecognizedfromcontractliabilities" xlink:label="asnd_Revenuerecognizedfromcontractliabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaGrowthDisordersASMember" xlink:label="asnd_AscendisPharmaGrowthDisordersASMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShortTermMarketableSecurities" xlink:label="asnd_ShortTermMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ClassificationOfRelatedPartyAxis" xlink:label="asnd_ClassificationOfRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentySevenMember" xlink:label="asnd_TwoThousandAndTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndDebenturesIssued" xlink:label="ifrs-full_NotesAndDebenturesIssued"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_OfficeFacilityMember" xlink:label="asnd_OfficeFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionsAbstract" xlink:label="ifrs-full_ProvisionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectsFromPriorYearAdjustment" xlink:label="asnd_TaxEffectsFromPriorYearAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSalesMember" xlink:label="ifrs-full_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShortTermBorrowingOther" xlink:label="asnd_ShortTermBorrowingOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NewIFRSsDomain" xlink:label="ifrs-full_NewIFRSsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfCommitmentsAndContingenciesTable" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FinanceExpensesAbstract" xlink:label="asnd_FinanceExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MinimumBeneficialOwnershipPercentage" xlink:label="asnd_MinimumBeneficialOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipExplanatory" xlink:label="asnd_DisclosureOfBeneficialOwnershipExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory" xlink:label="asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyTargetPercentage" xlink:label="asnd_ForeignCurrencyTargetPercentage"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:label="ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdditionalTaxDeduction" xlink:label="asnd_AdditionalTaxDeduction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DistributableEquity" xlink:label="asnd_DistributableEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership" xlink:label="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived" xlink:label="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember" xlink:label="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="ifrs-full_ClassesOfAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueOfWarrantsGranted" xlink:label="asnd_FairValueOfWarrantsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WarrantCompensationCost" xlink:label="asnd_WarrantCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyConversionOptionMember" xlink:label="asnd_ForeignCurrencyConversionOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInForeignCurrencyExchangeRate" xlink:label="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_InventoriesAbstract" xlink:label="asnd_InventoriesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractLiabilitiestableTable" xlink:label="asnd_ContractLiabilitiestableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpfrontPaymentReceived" xlink:label="asnd_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestOfWorldMember" xlink:label="asnd_RestOfWorldMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsRedemptionPeriod" xlink:label="asnd_BorrowingsRedemptionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ChangesInWorkingCapitalAbstract" xlink:label="asnd_ChangesInWorkingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaOncologyDivisionAsMember" xlink:label="asnd_AscendisPharmaOncologyDivisionAsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate" xlink:label="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltiesAndMilestonesMember" xlink:label="asnd_RoyaltiesAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectsFromImpactsFromAssociates" xlink:label="asnd_TaxEffectsFromImpactsFromAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SummaryOfInventoryDisclosureLineItems" xlink:label="asnd_SummaryOfInventoryDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CostsOfCapitalIncreaseDecrease" xlink:label="asnd_CostsOfCapitalIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SaleOfGoodsAndServicesToAssociate" xlink:label="asnd_SaleOfGoodsAndServicesToAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NetSettlementUnderStockIncentivePrograms" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="ifrs-full_MeasurementDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_OtherEquipmentMember" xlink:label="asnd_OtherEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UsTreasuryBillsMember" xlink:label="asnd_UsTreasuryBillsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DeferredTaxMovementForTheYear" xlink:label="asnd_DeferredTaxMovementForTheYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAvailableforsale" xlink:label="ifrs-full_FinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract" xlink:label="ifrs-full_CapitalCommitmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CategoriesOfSharesBasedPaymentsAxis" xlink:label="asnd_CategoriesOfSharesBasedPaymentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NewProvisionsOtherProvisions" xlink:label="ifrs-full_NewProvisionsOtherProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at fair value, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets by category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InventoriesTotal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InventoriesTotal_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical areas [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [LineItems]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of changes in equity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additions other than through business combinations, intangible assets other than goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through transfers, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure detailed information about marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Detailed Information About Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proportion of ownership interest in subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Addresses, Address Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectsOfDeductibleItemsNotExpensed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effects of Deductible Items Not Expensed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectsOfDeductibleItemsNotExpensed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax effects of deductible items not expensed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectsOfDeductibleItemsNotExpensed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional tax deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of income tax [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax on Profit/(Loss) for the Year and Deferred Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) investing activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="currency_DKK_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Denmark, Kroner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="currency_DKK_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Danish Kroner (DKK) [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(decrease) in provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Repayments of borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of borrowings, classified as financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for employee benefits [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Incentive Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) financing activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings threshold percentage of sale price per share for redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Threshold Percentage Of Sale Price Per Share For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings threshold percentage of sale price per share for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major components of tax expense (income) [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AccumulatedImpairmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated impairment [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AccumulatedImpairmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization and impairment [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueHierarchyCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueHierarchyCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy Carrying Amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueHierarchyCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value hierarchy carrying amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Social security contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Social security costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RealizedDurationOfFinancialAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Realized duration of financial assets explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RealizedDurationOfFinancialAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Duration of Financial Assets Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RealizedDurationOfFinancialAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets Duration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment ending period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payment Ending Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment ending period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Assets at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Assets at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of commitments and contingent liabilities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RightofuseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RightofuseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Right-of-use assets at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RightofuseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Right-of-use assets at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RightofuseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for intangible assets and goodwill [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CounterpartiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparties [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of employee compensation costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of employee compensation costs [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of employee compensation costs [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Tax income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax expense (income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Tax on profit/(loss) for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of income taxes (expenses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes (expenses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Tax on profit/(loss) for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for borrowings [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Senior Notes and Embedded Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of cash flows [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average duration of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average duration of marketable securities explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Marketable Securities Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to reconcile profit (loss) [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for non-cash items:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other equity instruments settled in share based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Other Equity Instruments Settled In Share Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settled during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Settled during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average exercise price of other equity instruments vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments vested in sharebased payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested at the reporting date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other equity instruments transferred in share based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Other Equity Instruments Transferred In Share Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Transferred during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (Holding in % of total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (Holding in % of total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares holding in percentage of total outstanding shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Holding In Percentage Of Total Outstanding Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisposalsIntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Disposals, intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisposalsIntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposals, intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisposalsIntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash consideration relating to revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments for non cash consideration regarding revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Non Cash Consideration Regarding Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Expenses Relating To Lease Activities In The Consolidated Statements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Expenses Relating To Lease Activities In The Consolidated Statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Expenses, Related To Lease Activities In The Consolidated Statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleDebtCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleDebtCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible debt current abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleDebtCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes, matures in April 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossForTheYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit loss for the year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossForTheYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss For The Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossForTheYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Profit / (loss) for the year from continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of associates [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-adjusting events after reporting period [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains on change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value gains, derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timing of transfer of goods or services [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proportion of voting rights held in associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxLossesCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Losses Carryforwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxLossesCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Losses Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxLossesCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax losses carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of associates [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of associates [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of share-based payment arrangements [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained earnings [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities arising from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">End of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ThirdPartyInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Party Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ThirdPartyInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third party investors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ThirdPartyInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Party Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income/(loss) for the year, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive income/(loss), net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EnforceableLeaseterm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Enforceable Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EnforceableLeaseterm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Enforceable leaseterm.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EnforceableLeaseterm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Enforceable LeaseTerm</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for property, plant and equipment [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NameOfAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name of associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NameOfAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for measuring inventories [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExternalCreditGradesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External credit grades [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExternalCreditGradesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External credit grades [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_InvestmentsInGroupEnterprisesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments in group enterprises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_InvestmentsInGroupEnterprisesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Group Enterprises [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ReserveOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury shares reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ReserveOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserve of Treasury Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ReserveOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reserve of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about employee cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Employee Cost Explanatory [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Employee Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount of non-current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CategoriesOfSharesBasedPaymentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Categories Of Shares Based Payments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CategoriesOfSharesBasedPaymentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories Of Shares Based Payments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for share-based payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about financial instruments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of non-adjusting events after reporting period [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Cashflows For Financial Liabilities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual cashflows for financial liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contractual Cash Flows for Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share issue related cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs of follow-on public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedIn2023Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Granted in 2023 member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedIn2023Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted in 2023 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedIn2023Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted in 2023 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Historical volatility for shares, measurement input [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_BusinessContactMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Contact [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_BusinessContactMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Contact [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfInventoryDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of inventory disclosure .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfInventoryDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Inventory Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparties [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaBoneDiseaseASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma bone disease AS.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaBoneDiseaseASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Bone Disease AS [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaBoneDiseaseASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma Bone Diseases A/S [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entities affiliated with RA capital management LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entities Affiliated With RA Capital Management LLC [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entities affiliated with RA capital management LLC [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalFutureTaxDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional future tax deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalFutureTaxDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional future tax deduction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total selling, general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_HighGradeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">High grade member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_HighGradeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">High Grade [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for decrease (increase) in prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of reasonably possible increase in unobservable input, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of offsetting of financial assets and financial liabilities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfEquityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of equity [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Categories of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortisation, intangible assets other than goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortisation, intangible assets other than goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEuropeASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma Europe A/S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEuropeASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Europe A/S [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of share capital [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciations charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Development in Borrowings Related to Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of development in lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of development in lease liabilities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Development In Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AuditorsRemunerationForTaxServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor's remuneration for tax services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AuditorsRemunerationForTaxServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="currency_AllCurrenciesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Currencies [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for increase (decrease) in trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Inventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Inventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Inventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of going concern [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty three to two thousand and twenty six</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Three To Two Thousand And Twenty Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentsInAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in associates reported in separate financial statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentsInAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaOphthalmologyDivisionASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma Ophthalmology Division AS.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaOphthalmologyDivisionASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Ophthalmology Division AS [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaOphthalmologyDivisionASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma Ophthalmology Division A/S [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of related party [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Exercise Prices and Movements in Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current financial assets available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current financial marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Risk [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Risk [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Registration Statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units and performance stock unit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units and Performance Stock Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units and Performance Stock Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current derivative financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate bonds [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for increase (decrease) in deferred income including contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total adjustments for increase (decrease) in deferred income including contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Attribution of expenses by nature to their function [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposals, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Disposals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term borrowings [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings (excluding lease liabilities) [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of interests in other entities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Group Enterprises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TransactionsAndOutstandingBalancesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transactions and outstanding balances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TransactionsAndOutstandingBalancesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transactions and outstanding balances [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TransactionsAndOutstandingBalancesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transactions and outstanding balances as of December 31</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from contracts with customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized as revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Risk Management</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entire disclosure of financial instruments and financial risk management.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Instruments And Financial Risk Management [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of reconciliation of liabilities arising from financing activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about property, plant and equipment [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about property, plant and equipment [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-adjusting events after reporting period [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-adjusting events after reporting period [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for financial instruments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net revenue from sales interest payment in percentage in exchange for funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Rate For Percentage Of Net Sales To Royalty Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange rate for percentage of net sales to royalty payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intangible assets at ending period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Intangible assets at beginning period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings Threshold Trading Days For Redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Threshold Trading Days For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings threshold trading days for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Financial Assets And Liabilities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Assets And Liabilities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for deferred revenues and contract liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for deferred revenues and contract liabilities explanatory [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other temporary differences, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other temporary differences, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement vesting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UsDollarsToEuroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">US dollars to Euro.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UsDollarsToEuroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US dollars to Euro [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UsDollarsToEuroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US dollars to Euro [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross carrying amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross carrying amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred under stock incentive programs (Holding in 1% total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Holding In Percentage Transferred under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares holding in percentage transferred under stock incentive programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of maturity analysis for derivative financial liabilities [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-derivative financial liabilities, undiscounted cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of provisions [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Tax on Profit/Loss and Deferred Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Effect Of Proceeds, Liabilities Arising From Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) through effect of proceeds, liabilities arising from financing activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LicensesOfIpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licenses of IP member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LicensesOfIpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licenses of IP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LicensesOfIpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses of IP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for finance income and costs [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Income and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proportion of ownership interest in associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of ownership in the customer company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual undiscounted cashflow of borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of borrowings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Borrowings (excluding lease liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average duration of marketable securities noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average duration of Marketable securities noncurrent explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Marketable Securities Noncurrent Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of financial instruments by type of interest rate [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average remaining contractual life of outstanding share options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining life for outstanding warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor's remuneration for other services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All other fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of share capital [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of share capital [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other equity instruments vested in share-based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested at the reporting date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting estimates [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of changes in accounting estimates [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FloatingInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Floating interest rate [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PerformanceObligationsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance obligations [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, plant and equipment at ending period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, plant and equipment at beginning period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Exercise, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Effect Of Accretion of Interest Liabilities Arising From Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) in liabilities arising from financing activities resulting from the effect of accretion of interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) in number of ordinary shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase through cash contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected revenue recognition period from non-current contract liabilities .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Revenue Recognition Period From Non-current Contract Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected revenue recognition period from non-current contract liabilities .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Acquired from third-parties (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease In treasury shares acquired from third parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Treasury Shares Acquired From Third Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired from third-parties (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract liabilities [Line Items].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liabilities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VISENPharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">VISEN</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VISENPharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">VISEN pharmaceuticals.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VISENPharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">V I S E N Pharmaceutical [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VISENPharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VISEN Pharmaceuticals [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TeijinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Teijin [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TeijinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Teijin.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AssociatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total for all associates [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AssociatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Associates [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WestfieldCapitalManagementCompanyLPUsaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Westfield Capital Management Company, L.P., USA [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WestfieldCapitalManagementCompanyLPUsaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Westfield Capital Management Company, L.P., USA [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WestfieldCapitalManagementCompanyLPUsaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Westfield Capital Management Company, L.P [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) operating activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expenses [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about intangible assets [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about intangible assets [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for issued capital [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Germany1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Germany [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Germany1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Germany [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Germany1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Germany [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LeaseExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Extension Period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LeaseExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Extension Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LeaseExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional Lease Extension Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">USA [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to acquire or redeem entity's shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisitions of treasury shares, net of transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of other provisions [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of equity [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of equity [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for recognition of revenue [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NominalValueAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nominal Value Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NominalValueAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nominal Value Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NominalValueAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nominal positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Detailed Information About Marketable Securities LineItems.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Detailed Information About Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaSverigeAbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Sverige AB [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaSverigeAbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis pharma sverige AB.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaSverigeAbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma Sverige AB [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of events after reporting period [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of basis of preparation of financial statements [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Preparation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for expenses [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about intangible assets [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about intangible assets [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about financial instruments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about financial instruments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, restricted stock unit, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromRenderingOfServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from rendering of services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromRenderingOfServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rendering of services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of holding of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Holding Of Treasury Shares [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefund_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income taxes paid (refund)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefund_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income taxes paid (refund)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefund_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes refund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales rebates and product returns in U.S. market.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Rebates And Product Returns In U.S. Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales rebates and product returns in U.S. market [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consideration paid (received)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for foreign currency translation [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax expense (income) [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of entity's revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of entity's revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Perentage of sale to commercial customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Audit-RelatedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Audit-related Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Audit-RelatedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Audit-related fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Audit-RelatedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Audit-related fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AuditorsRemuneration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor's remuneration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AuditorsRemuneration_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total principal accountant fees and services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">End of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings (excluding lease liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of marketable securities specified by investment grade credit rating.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for impairment of assets [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Non-current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, restricted stock unit, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about depreciations charges [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities arising from financing activities [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative financial liabilities at fair value remeasurement recognized in financial expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement loss of financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from sale of goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of financial instruments by type of interest rate [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfAssociatesAndJointVenturesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent concepts included in a table. These concepts are used to disclose reportable information about associate and joint ventures associated with domain members defined in one or many axes of the table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfAssociatesAndJointVenturesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of associates and joint ventures [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfAssociatesAndJointVenturesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of associates and joint ventures [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for decrease (increase) in inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for leases [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmericanDepositarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">American depositary shares member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmericanDepositarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">American Depositary Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmericanDepositarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">American Depositary Shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_HedgingInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hedging instruments [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Frazier Life Sciences of Eyconis, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Frazier Life Sciences of Eyconis, Inc. [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of changes in equity [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total issued capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issued capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentShellCompanyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Shell Company Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basic earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total basic earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic earnings/(loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares used for calculation (basic and diluted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithFmrLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entities affiliated with FMR LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithFmrLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entities Affiliated With FMR LLC [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithFmrLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entities affiliated with FMR LLC [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Financial assets at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Financial assets at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity risk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity risk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of liabilities [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Forfeited during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Not later than one year [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within 1 year [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of share-based payment arrangements [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of share-based payment arrangements [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of financial liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of property, plant and equipment [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss) [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement of profit or (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bottom of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bottom of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Acquired from third-parties (Holding in % of total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury Shares Holding In Percentage Of Total Outstanding Shares Acquired From Third-Parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Holding In Percentage Of Total Outstanding Shares Acquired From Third Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired from third-parties (Holding in 1% total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of subsidiaries [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of subsidiaries [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of classes of share capital [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExecutiveBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Executive board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExecutiveBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Board [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExecutiveBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Board [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExternalCreditGradesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External credit grades [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Presentation of leases for lessee [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharePremiumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share premium [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharePremiumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Premium [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialPapersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial papers [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialPapersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial papers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialPapersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial papers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AsiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AsiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asia [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale or issue of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial liabilities by category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEndocrinologyDivisionASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma endocrinology division AS.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEndocrinologyDivisionASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Endocrinology Division AS [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEndocrinologyDivisionASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma Endocrinology Division A/S [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Categories of financial assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through share-based payment transactions, equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment (Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, award type.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share based Payment Arrangement, Award type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for diluted earnings per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for diluted earnings per share explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted EPS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of finance income (cost) [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Finance Income and Finance Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WarrantsGrantedFromDecember2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Granted From December 2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WarrantsGrantedFromDecember2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Granted From December 2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WarrantsGrantedFromDecember2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Granted From December 2021 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of finance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total employee costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Employee benefits expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee benefits expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total employee costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfAssociateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of associate [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfAssociateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Associate [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfAssociateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of associates [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net foreign exchange loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange translation (net)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased payment arrangement, restricted stock unit, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share Based Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entities Affiliated With Artisan Partners Limited Partnership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entities Affiliated With Artisan Partners Limited Partnership [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entities affiliated with Artisan Partners Limited Partnership [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reversal of finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares outstanding at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares outstanding at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numebr of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ordinary shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from royalty funding liabilities excluding offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Royalty Funding Liabilities Excluding Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deduting offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of entity's operating segments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of reconciliation of changes in intangible assets and goodwill [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Goodwill and Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for determining components of cash and cash equivalents [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains (losses) on change in value of foreign currency basis spreads, before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Profit/(loss) before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NorthAmerica1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">North America 1 Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NorthAmerica1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">North America1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NorthAmerica1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">North America [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NameOfJointOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name of joint operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NameOfJointOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum beneficial ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reversal of gain loss on property plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reversal Of Gain Loss On Property Plant And Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of gain and loss on disposal of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings in arrears default payment start date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings In Arrears Default Payment Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings in arrears default payment start date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilutive securities not included in diluted earnings per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Not Included In Diluted Earnings Per Share [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for prepayments explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for prepayments explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of voluntary change in accounting policy [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of share-based payment arrangements [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for Expected Credit Losses on Financial Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Accounting Policy for Allowance for Expected Credit Losses on Financial Assets [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for allowance for expected credit losses on financial assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income statement [Axis].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ResearchAndDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ResearchAndDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ResearchAndDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ResearchAndDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development costs [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets at amortised cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial assets measured at amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial liabilities [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AgencyBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agency bonds [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AgencyBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agency bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AgencyBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agency bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial liabilities [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of Operating Segments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major customers [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major customers [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReceivablesDueFromAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReceivablesDueFromAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables due from associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Board of directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Board Of Directors [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of Directors [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of reconciliation of liabilities arising from financing activities [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted In 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Granted In 2022.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial instruments [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase/(decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in existing provisions, other provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CreditRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit risk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Payments of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of lease liabilities, classified as financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of principal portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of initial application of standards or interpretations [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New and Amended IFRS Accounting Standards and Interpretations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">End of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EyconisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eyconis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EyconisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eyconis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EyconisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eyconis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of marketable securities specified by investment grade credit rating.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FinanceIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance income expense [abstract].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FinanceIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance income expense [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss), attributable to owners of parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Attributable to owners of the Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive income, attributable to owners of parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Attributable to owners of the Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NovoNordiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novo Nordisk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NovoNordiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novo Nordisk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statements, Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment beginning period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty payment beginning period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment beginning period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NewIFRSsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New IFRSs [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NewIFRSsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New IFRSs [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GoodwillMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GoodwillMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to Prior Periods Estimates and Assumptions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of classes of share capital [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Convertible notes current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AccountingProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AccountingProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit/(loss) before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfWarrantActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Warrant Activity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfWarrantActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Warrant Activity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfWarrantActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Warrant Activity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BoardMembersOfGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Board members of group.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BoardMembersOfGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Board members of group [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WarrantsGranted2012UntilNovember2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Granted 2012 Until November 2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WarrantsGranted2012UntilNovember2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Granted 2012 Until November 2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WarrantsGranted2012UntilNovember2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Granted 2012 Until November 2021 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DE_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GERMANY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on balances held in foreign currencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RestatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Currently stated [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RestatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currently stated [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of liabilities [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BalancesWithBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balances with banks</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BalancesWithBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bank deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for trade and other payables [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade Payables and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities (excluding indirect tax and employee related payables)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AverageNumberOfEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Average number of employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AverageNumberOfEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average number of employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notional amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Nominal positions (net)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Nominal positions (net)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of associates [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Europe (excluding Denmark) [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about financial instruments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about financial instruments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AuditorsRemunerationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor's remuneration [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of property, plant and equipment [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current tax assets, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Multiplied to Purchase Price Minus Revenue Interest Payments Paid to Purchaser on Effective Date of Buy-out Notice Provided on or Prior to Period as Buyout Amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor's remuneration for audit services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Audit fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of summary of significant accounting policies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of summary of significant accounting policies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of comprehensive income [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionRatePerNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion rate per note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionRatePerNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Rate Per Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionRatePerNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion rate per note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of accounting judgements and estimates [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Significant Accounting Judgements and Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Values for Warrant Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherEmployeeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other employee expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherEmployeeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other employee costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of related parties [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Categories of related parties [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) in credit derivative, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total increase (decrease) in credit derivative, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in derivative financial liabilities fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about intangible assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carrying amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfGeneralInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of General Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfGeneralInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of general information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through transactions with owners, equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of persons</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option life, share options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life of warrants (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease liabilities [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PlantAndMachineryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Plant and machinery.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PlantAndMachineryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plant and machinery [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PlantAndMachineryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plant and machinery [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major customers [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of maturity analysis for derivative financial liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_USDollarsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. dollars [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_USDollarsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U.S. dollars [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_USDollarsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. dollars [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserve of exchange differences on translation [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation Reserve [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer software [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer software [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of intangible assets, and property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of operating segments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of investments accounted for using equity method [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Information of Investments in Associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease cash-outflows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash outflow for leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of principal portion of liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At fair value [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NameOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name of subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NameOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows from/(used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for depreciation under property, plant and equipment. [Refer: Property, plant and equipment]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for depreciation under property, plant and equipment explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Asset's Expected Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProcessPlantAndMachineryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Process plant and machinery [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProcessPlantAndMachineryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Process plant and machinery [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProcessPlantAndMachineryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Process plant and machinery [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_YearOfGrantOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Year of grant of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_YearOfGrantOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Year of grant of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_YearOfGrantOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Year of grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">American depository shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">American depository shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SwissFrancToEuroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Swiss franc to Euro [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SwissFrancToEuroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Swiss Franc to Euro [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SwissFrancToEuroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Swiss franc to euro member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FinanceIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FinanceIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FinanceIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for other payables explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Other Payables Explanatory [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AddressTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Address Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial instruments [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Country of incorporation of associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domicile</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherNoncurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other non-current receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherNoncurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of risks [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfTreasurySharesNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Acquired from third-parties (Nominal values)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfTreasurySharesNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of treasury shares nominal value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfTreasurySharesNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Treasury Shares Nominal Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfTreasurySharesNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired from third-parties (Nominal value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of subsidiaries [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Investments in Group Enterprises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information for principal accountant fees and service explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Detailed Information For Principal Accountant Fees and Service Explanatory [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Principal Accountant Fees and Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontFeeForExclusiveLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront fee for exclusive license</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontFeeForExclusiveLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee for exclusive license.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserve of share-based payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about depreciations charges.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about depreciations charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Depreciation Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory write-down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory write-downs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_UnobservableInputsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unobservable inputs [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure detailed information about marketable securities table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Detailed Information About Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding received in exchange of royalty payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding received in exchange of royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding received in exchange of royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected volatility, share options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Pharma United States Yorvipath [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty pharma united states yorvipath.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Pharma United States Yorvipath [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfInterestsInAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of interests in associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfInterestsInAssociates_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investments in associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current portion of non-current borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current portion of non-current borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of risks [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of risks [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Diluted earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total diluted earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted earnings/(loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average duration of marketable securities current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average duration of marketable securities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Marketable Securities Current Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of foreign currency sensitivity analysis explanatory [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of foreign currency sensitivity analysis explanatory [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Foreign Currency Sensitivity Analysis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risk free interest rate, share options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesNonCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable securities non current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesNonCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities non current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesNonCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trade payables, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAccountingStandard_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Accounting Standard</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TopOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Top of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TopOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Top of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of treasury shares [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Holding Of Treasury Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesMilestonesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestones received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesMilestonesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesMilestonesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestones received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectOfDeductibleItemsNotExpensed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax effect of deductible items not expensed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectOfDeductibleItemsNotExpensed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax effect of deductible items not expensed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectOfDeductibleItemsNotExpensed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional tax deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Applicable tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Applicable tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount of current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilutive securities not Included In diluted earnings per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Not Included In Diluted Earnings Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Later than three years and not later than five years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After 5 years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement from acquisition of property, plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement From Acquisition of Property Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement for acquisition of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Sharebased Payment Arrangements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of sharebased payment arrangements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax effect of expense not deductible in determining taxable profit (tax loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-deductible costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfAdditionalSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional shares granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfAdditionalSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Shares Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfAdditionalSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net gains (losses) on disposals of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains (losses) on disposals of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of (gain)/loss on disposal of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reversal of (gain)/loss on disposal of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of commitments and contingencies [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of commitments and contingencies [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesDeductionsAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Deductions And Product Returns In US Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesDeductionsAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales deductions and product returns in US market.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesDeductionsAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Deductions And Product Returns In U.S. Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of employee benefits expense [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectFromDeferredTaxAssetNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Effect From Deferred Tax Asset, Not Recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectFromDeferredTaxAssetNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effect From Deferred Tax Asset Not Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectFromDeferredTaxAssetNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset, not recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other current liabilities abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CapitalCommitmentFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital commitment from investors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CapitalCommitmentFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital commitment from investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CapitalCommitmentFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment from investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingOfSharesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Shares [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingOfSharesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_ContactPersonnelName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contact Personnel Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value loss, derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Losses on change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Losses on change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expense from share-based payment transactions with employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ZeroCouponMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Zero Coupon [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ZeroCouponMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zero Coupon [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ZeroCouponMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zero Coupon [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share repurchase program, Number of shares authorized to be repurchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program Number Of Shares Authorized To Be Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share repurchase program, Number of shares authorized to be repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaFranceSasuMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma France SASU [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaFranceSasuMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis pharma france SASU.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaFranceSasuMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma France SASU [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of associates [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence fee income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">"Right-to-use" licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issuing shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from follow-on public offerings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss) before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Profit/(loss) before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit/(loss) before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from borrowings, classified as financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting estimates [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueThresholdLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue threshold limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueThresholdLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue threshold limit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Pharma [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Pharma.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Pharma [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of quantitative information about right-of-use assets [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WorkInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WorkInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current work in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UsGovernmentBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. Government Bonds [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UsGovernmentBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UsGovernmentBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_HedgingInstrumentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hedging instruments [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Marketable Securities Specified By Investment Grade Credit Rating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about marketable securities specified by investment grade credit rating explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Information About Marketable Securities Specified By Investment Grade Credit Rating Explanatory [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ContractLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issued Capital [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issued capital [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance stock unit program member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Stock Unit Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Stock Unit Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for cash flows [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flow Statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DeferredTaxAssetNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset, not recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DeferredTaxAssetNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax asset not recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DeferredTaxAssetNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset, not recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax effect of tax losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax deductible losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred under stock incentive programs (Nominal Value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Transferred Under Stock Incentive Program Nominal Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares transferred under stock incentive program nominal value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PerformanceObligationsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance obligations [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of summary of significant accounting policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of interest rates [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of interest rates [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Later than one year [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EmployeesAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and consultants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EmployeesAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees and Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EmployeesAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and consultants [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statement of comprehensive income, profit or loss location 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of comprehensive income, profit or loss location [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement of comprehensive income, profit or loss location [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding convertible notes, coupon fixed rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EventsAfterReportingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Events after reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EventsAfterReportingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Events After Reporting Period [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Nominal amount of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (Nominal Value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (Nominal value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TreasuryShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Beneficial Ownership [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Beneficial Ownership [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of beneficial ownership [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsConditionForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings condition for redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsConditionForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Condition For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsConditionForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings condition for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current tax expense (income) and adjustments for current tax of prior periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current tax expense (income) and adjustments for current tax of prior periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current tax expense (income) and adjustments for current tax of prior periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit or loss [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retrospective application and retrospective restatement [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retrospective application and retrospective restatement [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Beneficial Ownership [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Beneficial Ownership [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TreasurySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for investment in associates [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of quantitative Information about inventories explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Quantitative Information about Inventories Explanatory [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Inventories Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of convertible notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaUkLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma UK Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaUkLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma UK Limited [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossBeforeIncomeTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit loss before income tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossBeforeIncomeTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit loss before income tax [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossBeforeIncomeTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax for the year can be explained as follows:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables (excluding indirect tax receivables)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InterestRateRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate risk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InterestRateRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest rate risk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaIberiaSLMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma Iberia S.L.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaIberiaSLMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Iberia S L [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaIberiaSLMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma Iberia S.L. [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of property, plant and equipment [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of property, plant and equipment [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accretion of interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceAppliedForValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share price applied for valuation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceAppliedForValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price Applied For Valuation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceAppliedForValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ContractualCapitalCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual capital commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ContractualCapitalCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfEmployees1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of employees1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfEmployees1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of employees1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfEmployees1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of persons</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Multiple of purchase price, were royalty payment will cease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Multiple Of Purchase Price, Were Royalty Payment Will Cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of the purchase price were royalty payment will cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LeaseExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LeaseExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LeaseExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront development and regulatory milestones potentially to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront development and regulatory milestones potentially to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiaries [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of subsidiaries [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of performance obligations [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Beneficial Ownership [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Beneficial Ownership [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Beneficial Ownership [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">No Trading Symbol Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No Trading Symbol Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets and property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedBeforeJanuary12022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted Before January 1 2022 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedBeforeJanuary12022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Granted before january 1, 2022.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedBeforeJanuary12022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted before January 1, 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Royalty Funding Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated depreciation, amortisation and impairment [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and impairment [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net foreign exchange gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange translation (net)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount of royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carrying Amount of Royalty Funding Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount of royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Associates [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of current financial assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of operating segments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BritishPoundsToEuroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">British pounds to Euro.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BritishPoundsToEuroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">British pounds to Euro [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BritishPoundsToEuroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">British pounds to Euro [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfReportableOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of reportable operating segments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfReportableOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of reportable operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfReportableOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other property, plant and equipment [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other equipment [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueFromClinicalSupply_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Clinical Supply</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueFromClinicalSupply_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from clinical supply.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueFromClinicalSupply_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical supply</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfAdditionalSharesAuthorizedToGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional shares authorized to grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfAdditionalSharesAuthorizedToGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Additional Shares Authorized to Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfAdditionalSharesAuthorizedToGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares authorized to grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total average effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Average effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income statement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEndocrinologyGmbhMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma Endocrinology GmbH [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEndocrinologyGmbhMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Endocrinology GmbH [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEndocrinologyGmbhMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma Endocrinology GmbH.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total post-employment benefit expense in profit or loss, defined benefit plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post-employment benefit expense in profit or loss, defined benefit plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pensions (defined contribution plans)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, award type.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Award type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement recognized in financial income or expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Income Or Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remeasurement gain of financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for earnings per share [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic EPS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of quantitative information about right-of-use assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of intangible assets and goodwill [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedInTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted in Two Thousand Twenty Four [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedInTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Granted in two thousand twenty four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_GrantedInTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted in 2024 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current tax expense (income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current tax (expense)/income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CountryOfDomicileMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Country of domicile [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CountryOfDomicileMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denmark [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EyconisIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eyconis Inc [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EyconisIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eyconis Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EyconisIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eyconis Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EyconisIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Eyconis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AssociateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Associate [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AssociateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Associate [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AssociateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VISEN Pharmaceuticals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Revenue to Commercial Customers Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of revenue to commercial customers explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Attributable to Commercial Customers by Product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other current receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for royalty funding liabilities text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Accounting Policy for Royalty Funding Liabilities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Funding Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RightofuseAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-use assets [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RightofuseAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RightofuseAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of leases [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShorttermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShorttermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Summary Of Significant Accounting Policy Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Material Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfBasisOfConsolidationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfBasisOfConsolidationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Basis Of Consolidation [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfBasisOfConsolidationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of basis of consolidation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserve of share-based payments [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Reserve [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, plant and equipment [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma, Inc..</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma, Inc. [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma, Inc [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaItaliaSrlMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Italia SRL [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaItaliaSrlMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis pharma italia SRL.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classified in the statement of financial position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of non-current financial assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two thousand and twenty five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of reconciliation of liabilities arising from financing activities [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfCommercialCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of commercial customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfCommercialCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of commercial customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of intangible assets and property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of intangible assets and property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of intangible assets and property, plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Level 2 of fair value hierarchy [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceMeasurementInputMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share price measurement input [member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceMeasurementInputMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price Measurement Input [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term leases and leases of low value assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expense relating to short-term leases for which recognition exemption has been used</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classified in the statement of financial position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of non-current financial liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of changes in equity [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LowerMediumGradeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lower medium grade.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LowerMediumGradeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lower Medium Grade [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of employee compensation cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of employee compensation costs [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of employee compensation costs [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Country of incorporation of subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domicile</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of revenue [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestones member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpperMediumGradeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upper medium grade.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpperMediumGradeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upper Medium Grade [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ClassificationOfRelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Classification Of Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ClassificationOfRelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classification Of Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WagesAndSalaries_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wages and salaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WagesAndSalaries_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wages and salaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma GmbH.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma GmbH [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma GmbH [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share of profit (loss) of associates accounted for using equity method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share of profit/(loss) of associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Share of (profit)/loss of associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Later than one year and not later than five years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within 1 to 5 years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfWarrantsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of warrants vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfWarrantsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Warrants Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfWarrantsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of warrants vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value Hierarchy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Summary of Fair Value Hierarchy [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of fair value hierarchy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Warrant1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Warrant1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant1 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Warrant1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. SKYTROFA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">United States Skytrofa [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SKYTROFA [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of holding of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Holding Of Treasury Shares [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax expense (income) at applicable tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax at the Danish corporation tax rate of 22%</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue (geographical)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of geographical areas [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Key management personnel of entity or parent [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Key management personnel of entity or parent [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of trade payables and other payables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Trade Payables And Other Payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of accounting profit multiplied by applicable tax rates [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax effect of:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Warrants, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related party transactions [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about depreciations charges [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred under stock incentive programs (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Treasury Shares Transferred Under Stock Incentive Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in treasury shares transferred under stock incentive program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current tax expense (income) and adjustments for current tax of prior periods [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax on profit/(loss) for the year:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for current tax of prior periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current tax, adjustments to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Partners and License Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration partners and license agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration partners and license agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaSwitzerlandGmbhMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Switzerland GmbH [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaSwitzerlandGmbhMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma Switzerland GmbH.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Prime1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Prime1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Prime1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prime1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalTaxDeductionsRelatedToTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional tax deductions related to tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalTaxDeductionsRelatedToTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional tax deductions related to tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEndocrinologyIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Endocrinology Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaEndocrinologyIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma Endocrinology, Inc. [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Issuance Of Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issue of bonds, notes and debentures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for decrease (increase) in trade and other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding received in exchange.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Received In Exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding received in exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Funding received in exchange of royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining life for outstanding warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining contractual life of outstanding other equity instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average remaining contractual life of outstanding other equity instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Life, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of maturity analysis for derivative financial liabilities [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of withholding taxes under stock incentive programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Withholding Taxes Under Stock Incentive Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of withholding taxes under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExpectedLeaseCommenceYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Lease Commence Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExpectedLeaseCommenceYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected lease commence year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExpectedLeaseCommenceYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Lease Commence Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings threshold consecutive trading days for redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Threshold Consecutive Trading Days For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings threshold consecutive trading days for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AvoroCapitalAdvisorsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Avoro Capital Advisors LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AvoroCapitalAdvisorsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Avoro Capital Advisors LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AvoroCapitalAdvisorsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Avoro Capital Advisors LLC [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Impairment charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of financial position [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement of financial position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nominal value common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share nominal value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at December 31</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at January 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items representing the disclosure of summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Summary Of Significant Accounting Policies [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of summary of significant accounting policies [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Useful life measured as period of time, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset's expected useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NonexecutiveseniorManagementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-executive&#160;Senior Management.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NonexecutiveseniorManagementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonexecutivesenior management [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets at fair value, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets at fair value, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity and liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfProvisionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of other provisions [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DecreaseInTaxLosseCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Decrease in tax losse carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DecreaseInTaxLosseCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease in tax losse carry forwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DecreaseInTaxLosseCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in tax losse carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current derivative financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licenses member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_LicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Revenuerecognizedfromcontractliabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognized from contract liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Revenuerecognizedfromcontractliabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RevenueRecognizedFromContractLiabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Revenuerecognizedfromcontractliabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized from contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for amortisation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaGrowthDisordersASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma growth disorders AS.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaGrowthDisordersASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Growth Disorders AS [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaGrowthDisordersASMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma Growth Disorders A/S [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Liabilities at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Liabilities at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through net exchange differences, other provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Development in Borrowings Related to Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of reconciliation of liabilities arising from financing activities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShortTermMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShortTermMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShortTermMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal place of business of associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal place of business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss) from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating profit/(loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency risk domain.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Risk [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Risk [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ClassificationOfRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Classification Of Related Party [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ClassificationOfRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classification Of Related Party [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of related parties [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand and Twenty seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of employees compensation costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of employee compensation costs [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotesAndDebenturesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes and debentures issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotesAndDebenturesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OfficeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OfficeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of liabilities [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for trade and other receivables [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of general information about financial statements [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vested at the reporting date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Levels of fair value hierarchy [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProvisionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Provisions [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Pharma United States Skytrofa [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Pharma United States Skytrofa.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Pharma United States Skytrofa [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive income/(loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Other Equity Instruments Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average fair value at measurement date, other equity instruments granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows from/(used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for provisions [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectsFromPriorYearAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax effects from prior year adjustment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectsFromPriorYearAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effects from Prior Year Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectsFromPriorYearAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior year adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of sales [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance income received, classified as operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance income received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">YORVIPATH [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">United States Yorvipath [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. YORVIPATH.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShortTermBorrowingOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Borrowing, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShortTermBorrowingOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term borrowing, other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShortTermBorrowingOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share capital end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share capital beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential conversion of convertible senior notes into number of ordinary shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Conversion Of Convertible Senior Notes Into Number Of Ordinary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NewIFRSsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New IFRSs [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Commitments And Contingencies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Commitments And Contingencies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting policies [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial assets [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Remeasurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Effect Of Remeasurements Arising From Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">increase decrease through effect of remeasurements arising from financing activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of non-adjusting events after reporting period [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Costs of follow-on public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for share issue costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FinanceExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FinanceExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FinanceExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MinimumBeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum beneficial ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MinimumBeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Beneficial Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MinimumBeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum beneficial ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current financial assets available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current financial marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure of beneficial ownership explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Beneficial Ownership [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfBeneficialOwnershipExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of marketable securities specified by investment grade credit rating.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Detailed Information About Development in provisions [Explanatory]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Development in Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of deiailed information about development in provisions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax assets/(liabilities) at December 31</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyTargetPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign Currency Target Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyTargetPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Target Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyTargetPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency target percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Multiplied to Purchase Price Minus Revenue Interest Payments Paid to Purchaser on Effective Date of Buy-out Notice As Buyout Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting estimates [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of changes in accounting estimates [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Risk Management</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of financial risk management [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of treasury shares outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Treasury Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for deferred tax of prior periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax, adjustments to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalTaxDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional tax deduction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalTaxDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Tax Deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalTaxDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional tax deductions, determined by annual warrants exercises by employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additions other than through business combinations, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments accounted for using equity method [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange differences on translating foreign operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DistributableEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Distributable equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DistributableEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Distributable equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DistributableEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distributable equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise price of outstanding share options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in derivative financial liabilities fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Derivative Financial Liabilities Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in derivative financial liabilities fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance costs paid, classified as operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance expenses paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Major persons or groups of affiliated persons holding minimum beneficial ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major persons or groups of affiliated persons holding minimum beneficial ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum beneficial ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional development and regulatory milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Development and Regulatory Milestones Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional development and regulatory milestones potentially to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecurities1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecurities1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable securities1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecurities1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for intangible assets other than goodwill [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Associates [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Associates [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for research and development expense [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entities affiliated with Janus Henderson Group plc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entities Affiliated With Janus Henderson Group plc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entities affiliated with Janus Henderson Group plc [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial assets [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of intangible assets [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net profit/(loss) for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net profit/(loss) for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net profit/(loss) for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of assets [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through financing cash flows, liabilities arising from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfWarrantsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Of Warrants Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfWarrantsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfWarrantsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants granted in the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical areas [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical areas [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities arising from financing activities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities arising from financing activities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows generated from/(used in) operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum additional development and regulatory milestones potentially to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum additional development and regulatory milestones potentially to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting specified by date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current raw materials and current production supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current raw materials and current production supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials and consumables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WarrantCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant compensation cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WarrantCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WarrantCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyConversionOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign Currency Conversion Option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyConversionOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Conversion Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goods or services transferred at point in time [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income taxes refund (paid)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income taxes paid (refund), classified as operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes received/(paid)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings, maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Levels of fair value hierarchy [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MaturityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other tax effects for reconciliation between accounting profit and tax expense (income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other effects including effect of different tax rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in foreign currency exchange rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in foreign currency exchange rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Foreign Currency Exchange Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of holding of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Holding Of Treasury Shares [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of subsidiaries [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of subsidiaries [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial liabilities measured at amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at amortised cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities measured at amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Movements in Level Three Fair Value Measurements [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of movements in level 3 fair value measurements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Movements in Level 3 Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of segment revenues by destination of major customers explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of segment revenues by destination of major customers explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Recognized in Consolidated Statement of Profit or Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of employee benefits [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_InventoriesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventories.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_InventoriesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventories [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MaturityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NorthAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">North America [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NorthAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">North America [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractLiabilitiestableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract liabilities [Table].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractLiabilitiestableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liabilities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive effect of convertible instruments on weighted average number of ordinary shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goods or services transferred over time [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Level 1 of fair value hierarchy [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Effect Of Repayments, Liabilities Arising From Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) through effect of repayments, liabilities arising from financing activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows from/(used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestOfWorldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rest of world [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestOfWorldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rest of world.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestOfWorldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rest of World [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_UnobservableInputsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unobservable inputs [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsRedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings redemption period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsRedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Redemption Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsRedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings redemption period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ChangesInWorkingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in working capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ChangesInWorkingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes in working capital [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ChangesInWorkingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in working capital:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities measured at fair value through profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at fair value through profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial liabilities measured at fair value through profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of Financial lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Financial Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of financial instruments, classified as investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other temporary differences, assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaOncologyDivisionAsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ascendis Pharma On cology Division AS Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaOncologyDivisionAsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ascendis Pharma Oncology Division AS [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AscendisPharmaOncologyDivisionAsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ascendis Pharma Oncology Division AS [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Contract liabilities at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Contract liabilities at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of each tranche directly attributable to accomplishment of financial results achieved in financial year prior to vesting date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Each Tranche Directly Attributable to Accomplishment of Financial Results Achieved in Financial Year Prior to Vesting Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of each tranche directly attributable to accomplishment of financial results achieved in financial year prior to vesting date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange rate for percentage of revenue to royalty payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Rate For Percentage Of Revenue To Royalty Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest payment in percentage in exchange for funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DENMARK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denmark [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of vesting requirements for share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltiesAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties and milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltiesAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties and Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltiesAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties and Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivables from associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of transactions between related parties [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Attribution of expenses by nature to their function [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RangeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectsFromImpactsFromAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax effects from impacts from associates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectsFromImpactsFromAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effects From Impacts From Associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TaxEffectsFromImpactsFromAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact from associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold improvements [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative financial liabilities at fair value remeasurement recognized in financial income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement gain of financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfInventoryDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Inventory Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfInventoryDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of inventory disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description Of Accounting Policy For Changes In Accounting Policies and Disclosures [policy text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Changes In Accounting Policies and Disclosures [policy text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Accounting Policies and Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FixedInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Coupon fixed rate structure [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FixedInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed interest rate [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FixedInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fixed interest rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CostsOfCapitalIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs of capital increase (decrease).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CostsOfCapitalIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs of capital increase (decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CostsOfCapitalIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cost of capital increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SaleOfGoodsAndServicesToAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of goods and services to associate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SaleOfGoodsAndServicesToAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of goods and services to associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SaleOfGoodsAndServicesToAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Invoicing of goods and services to associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for subsidiaries [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidation Principles Subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Items that may be reclassified subsequently to profit or (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statement of comprehensive income, profit or loss location.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of comprehensive income, profit or loss location [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement of comprehensive income, profit or loss location [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net settlement under stock incentive programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net settlement under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net settlement under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net settlement under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of financial instruments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfInterestRatesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of interest rates [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of revenue from contracts with customers [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Attributable to Commercial Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from sales or maturity of financial instruments, classified as investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MeasurementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other equipment Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other equipment [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UsTreasuryBillsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. Treasury bills [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UsTreasuryBillsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury bills [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UsTreasuryBillsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury bills [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DeferredTaxMovementForTheYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax movement for the year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DeferredTaxMovementForTheYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Movement for The Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DeferredTaxMovementForTheYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax, movement for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of inventories [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of financial instruments by type of interest rate [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction price allocated to remaining performance obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities are expected to be recognized as revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of accounting policy for income tax [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Level 3 of fair value hierarchy [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of intangible assets and goodwill [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MeasurementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of financial instruments by type of interest rate [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Rate Structure Of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of financial assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of auditors' remuneration [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal Accountant Fees and Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of changes in fair value measurement, liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CapitalCommitmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital commitments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from sales of property, plant and equipment, classified as investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from disposal of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial Customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial customers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial customers [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CategoriesOfSharesBasedPaymentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Categories Of Shares Based Payments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CategoriesOfSharesBasedPaymentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories Of Shares Based Payments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NewProvisionsOtherProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New provisions, other provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NewProvisionsOtherProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net additions for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timing of transfer of goods or services [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subclassifications of assets, liabilities and equities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CurrencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Currency [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_InventoriesTotal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_GeographicalAreasDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TaxEffectsOfDeductibleItemsNotExpensed" xlink:to="asnd_TaxEffectsOfDeductibleItemsNotExpensed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_DKK" xlink:to="currency_DKK_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForProvisions" xlink:to="ifrs-full_AdjustmentsForProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:to="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedImpairmentMember" xlink:to="ifrs-full_AccumulatedImpairmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FairValueHierarchyCarryingAmountMember" xlink:to="asnd_FairValueHierarchyCarryingAmountMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SocialSecurityContributions" xlink:to="ifrs-full_SocialSecurityContributions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RealizedDurationOfFinancialAssetsExplanatory" xlink:to="asnd_RealizedDurationOfFinancialAssetsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPaymentEndingPeriod" xlink:to="asnd_RoyaltyPaymentEndingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="ifrs-full_CounterpartiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:to="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:to="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:to="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsIntangibleAssetsAndGoodwill" xlink:to="ifrs-full_DisposalsIntangibleAssetsAndGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:to="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements" xlink:to="asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="asnd_ConvertibleDebtCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ProfitLossForTheYear" xlink:to="asnd_ProfitLossForTheYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsOnChangeInFairValueOfDerivatives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:to="ifrs-full_ProportionOfVotingPowerHeldInAssociate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TaxLossesCarryforwards" xlink:to="asnd_TaxLossesCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ThirdPartyInvestorsMember" xlink:to="asnd_ThirdPartyInvestorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConversionPricePerShare" xlink:to="asnd_ConversionPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EnforceableLeaseterm" xlink:to="asnd_EnforceableLeaseterm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NameOfAssociate" xlink:to="ifrs-full_NameOfAssociate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_ExternalCreditGradesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_InvestmentsInGroupEnterprisesAbstract" xlink:to="asnd_InvestmentsInGroupEnterprisesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ReserveOfTreasuryShares" xlink:to="asnd_ReserveOfTreasuryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" xlink:to="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialLiabilities" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CategoriesOfSharesBasedPaymentsDomain" xlink:to="asnd_CategoriesOfSharesBasedPaymentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock" xlink:to="asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_GrantedIn2023Member" xlink:to="asnd_GrantedIn2023Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SummaryOfInventoryDisclosureTable" xlink:to="asnd_SummaryOfInventoryDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaBoneDiseaseASMember" xlink:to="asnd_AscendisPharmaBoneDiseaseASMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember" xlink:to="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AdditionalFutureTaxDeduction" xlink:to="asnd_AdditionalFutureTaxDeduction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_HighGradeMember" xlink:to="asnd_HighGradeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ComponentsOfEquityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaEuropeASMember" xlink:to="asnd_AscendisPharmaEuropeASMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock" xlink:to="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationForTaxServices" xlink:to="ifrs-full_AuditorsRemunerationForTaxServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_VestingMember" xlink:to="asnd_VestingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:to="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember" xlink:to="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInAssociates" xlink:to="ifrs-full_InvestmentsInAssociates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaOphthalmologyDivisionASMember" xlink:to="asnd_AscendisPharmaOphthalmologyDivisionASMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:to="ifrs-full_CurrentFinancialAssetsAvailableforsale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleSeniorNotes" xlink:to="asnd_ConvertibleSeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CorporateBondsMember" xlink:to="asnd_CorporateBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermBorrowingsMember" xlink:to="ifrs-full_LongtermBorrowingsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TransactionsAndOutstandingBalancesAbstract" xlink:to="asnd_TransactionsAndOutstandingBalancesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory" xlink:to="asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" xlink:to="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:to="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" xlink:to="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory" xlink:to="asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:to="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementVestingPeriod" xlink:to="asnd_SharebasedPaymentArrangementVestingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UsDollarsToEuroMember" xlink:to="asnd_UsDollarsToEuroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:to="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="ifrs-full_DisclosureOfProvisionsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" xlink:to="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_LicensesOfIpMember" xlink:to="asnd_LicensesOfIpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfBorrowings" xlink:to="asnd_ContractualUndiscountedCashflowOfBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationForOtherServices" xlink:to="ifrs-full_AuditorsRemunerationForOtherServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:to="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FloatingInterestRateMember" xlink:to="ifrs-full_FloatingInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="ifrs-full_PerformanceObligationsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" xlink:to="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" xlink:to="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" xlink:to="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractLiabilitiesLineItems" xlink:to="asnd_ContractLiabilitiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_VISENPharmaceuticalMember" xlink:to="asnd_VISENPharmaceuticalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TeijinMember" xlink:to="asnd_TeijinMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssociatesMember" xlink:to="ifrs-full_AssociatesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WestfieldCapitalManagementCompanyLPUsaMember" xlink:to="asnd_WestfieldCapitalManagementCompanyLPUsaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_Germany1Member" xlink:to="asnd_Germany1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfWarrantsOutstanding" xlink:to="asnd_NumberOfWarrantsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_LeaseExtensionPeriod" xlink:to="asnd_LeaseExtensionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NominalValueAmount" xlink:to="asnd_NominalValueAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaSverigeAbMember" xlink:to="asnd_AscendisPharmaSverigeAbMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromRenderingOfServices" xlink:to="ifrs-full_RevenueFromRenderingOfServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefund" xlink:to="ifrs-full_IncomeTaxesPaidRefund_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:to="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DeferredTaxExpenseIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfEntitysRevenue" xlink:to="ifrs-full_PercentageOfEntitysRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_Audit-RelatedFees" xlink:to="asnd_Audit-RelatedFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemuneration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract" xlink:to="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" xlink:to="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="asnd_DisclosureOfAssociatesAndJointVenturesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialLiabilities" xlink:to="ifrs-full_DerivativeFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyFundingLiabilities" xlink:to="asnd_RoyaltyFundingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmericanDepositarySharesMember" xlink:to="asnd_AmericanDepositarySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HedgingInstrumentsDomain" xlink:to="ifrs-full_HedgingInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:to="asnd_FrazierLifeSciencesOfEyconisIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EntitiesAffiliatedWithFmrLlcMember" xlink:to="asnd_EntitiesAffiliatedWithFmrLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiquidityRiskMember" xlink:to="ifrs-full_LiquidityRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="ifrs-full_ClassesOfLiabilitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyTwoMember" xlink:to="asnd_TwoThousandAndTwentyTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ProfitLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ExecutiveBoardMember" xlink:to="asnd_ExecutiveBoardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExternalCreditGradesDomain" xlink:to="ifrs-full_ExternalCreditGradesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CommercialPapersMember" xlink:to="asnd_CommercialPapersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaEndocrinologyDivisionASMember" xlink:to="asnd_AscendisPharmaEndocrinologyDivisionASMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory" xlink:to="asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WarrantsGrantedFromDecember2021Member" xlink:to="asnd_WarrantsGrantedFromDecember2021Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="asnd_DisclosureOfAssociateLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeLoss" xlink:to="ifrs-full_NetForeignExchangeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember" xlink:to="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:to="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" xlink:to="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NorthAmerica1Member" xlink:to="asnd_NorthAmerica1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NameOfJointOperation" xlink:to="ifrs-full_NameOfJointOperation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment" xlink:to="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:to="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory" xlink:to="asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory" xlink:to="asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ResearchAndDevelopmentCostsMember" xlink:to="asnd_ResearchAndDevelopmentCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AgencyBondsMember" xlink:to="asnd_AgencyBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceivablesDueFromAssociates" xlink:to="ifrs-full_ReceivablesDueFromAssociates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BoardOfDirectorsMember" xlink:to="asnd_BoardOfDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_GrantedIn2022Member" xlink:to="asnd_GrantedIn2022Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:to="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentySixMember" xlink:to="asnd_TwoThousandAndTwentySixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EyconisMember" xlink:to="asnd_EyconisMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" xlink:to="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FinanceIncomeExpenseAbstract" xlink:to="asnd_FinanceIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NovoNordiskMember" xlink:to="asnd_NovoNordiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPaymentBeginningPeriod" xlink:to="asnd_RoyaltyPaymentBeginningPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodwillMember" xlink:to="ifrs-full_GoodwillMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleNotesCurrent" xlink:to="asnd_ConvertibleNotesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccountingProfit" xlink:to="ifrs-full_AccountingProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_DisclosureOfWarrantActivityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BoardMembersOfGroupMember" xlink:to="asnd_BoardMembersOfGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WarrantsGranted2012UntilNovember2021Member" xlink:to="asnd_WarrantsGranted2012UntilNovember2021Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfTreasuryShares" xlink:to="ifrs-full_PurchaseOfTreasuryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BalancesWithBanks" xlink:to="ifrs-full_BalancesWithBanks_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialLiabilities" xlink:to="ifrs-full_OtherFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageNumberOfEmployees" xlink:to="ifrs-full_AverageNumberOfEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ifrs-full_AuditorsRemunerationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssetsCurrent" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationForAuditServices" xlink:to="ifrs-full_AuditorsRemunerationForAuditServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConversionRatePerNote" xlink:to="asnd_ConversionRatePerNote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEmployeeExpense" xlink:to="ifrs-full_OtherEmployeeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" xlink:to="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfGeneralInformationAbstract" xlink:to="asnd_DisclosureOfGeneralInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfEmployees" xlink:to="ifrs-full_NumberOfEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PlantAndMachineryMember" xlink:to="asnd_PlantAndMachineryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="ifrs-full_MajorCustomersDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_USDollarsMember" xlink:to="asnd_USDollarsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerSoftwareMember" xlink:to="ifrs-full_ComputerSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AtFairValueMember" xlink:to="ifrs-full_AtFairValueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NameOfSubsidiary" xlink:to="ifrs-full_NameOfSubsidiary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory" xlink:to="asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ProcessPlantAndMachineryMember" xlink:to="asnd_ProcessPlantAndMachineryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_YearOfGrantOfWarrants" xlink:to="asnd_YearOfGrantOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmericanDepositorySharesMember" xlink:to="asnd_AmericanDepositorySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SwissFrancToEuroMember" xlink:to="asnd_SwissFrancToEuroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FinanceIncomeAbstract" xlink:to="asnd_FinanceIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock" xlink:to="asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentReceivables" xlink:to="ifrs-full_OtherNoncurrentReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_TypesOfRisksDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PurchaseOfTreasurySharesNominalValue" xlink:to="asnd_PurchaseOfTreasurySharesNominalValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock" xlink:to="asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UpfrontFeeForExclusiveLicense" xlink:to="asnd_UpfrontFeeForExclusiveLicense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges" xlink:to="asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryWritedown2011" xlink:to="ifrs-full_InventoryWritedown2011_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="ifrs-full_UnobservableInputsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:to="asnd_RoyaltyPharmaUnitedStatesYorvipathMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInterestsInAssociates" xlink:to="ifrs-full_PurchaseOfInterestsInAssociates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermBorrowings" xlink:to="ifrs-full_LongtermBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory" xlink:to="asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MarketableSecuritiesNonCurrentAssets" xlink:to="asnd_MarketableSecuritiesNonCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SalesMilestonesReceived" xlink:to="asnd_SalesMilestonesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TaxEffectOfDeductibleItemsNotExpensed" xlink:to="asnd_TaxEffectOfDeductibleItemsNotExpensed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" xlink:to="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:to="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfAdditionalSharesGranted" xlink:to="asnd_NumberOfAdditionalSharesGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:to="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="asnd_DisclosureOfCommitmentsAndContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SalesDeductionsAndProductReturnsInUSMarketMember" xlink:to="asnd_SalesDeductionsAndProductReturnsInUSMarketMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TaxEffectFromDeferredTaxAssetNotRecognized" xlink:to="asnd_TaxEffectFromDeferredTaxAssetNotRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="asnd_OtherCurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CapitalCommitmentFromInvestors" xlink:to="asnd_CapitalCommitmentFromInvestors_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingOfSharesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_LossesOnChangeInFairValueOfDerivatives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ZeroCouponMember" xlink:to="asnd_ZeroCouponMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaFranceSasuMember" xlink:to="asnd_AscendisPharmaFranceSasuMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicenceFeeIncome" xlink:to="ifrs-full_LicenceFeeIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RevenueThresholdLimit" xlink:to="asnd_RevenueThresholdLimit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPharmaMember" xlink:to="asnd_RoyaltyPharmaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WorkInProgress" xlink:to="ifrs-full_WorkInProgress_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UsGovernmentBondsMember" xlink:to="asnd_UsGovernmentBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock" xlink:to="asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilitiesAbstract" xlink:to="ifrs-full_ContractLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PerformanceStockUnitProgramMember" xlink:to="asnd_PerformanceStockUnitProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DeferredTaxAssetNotRecognized" xlink:to="asnd_DeferredTaxAssetNotRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:to="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearMember" xlink:to="ifrs-full_LaterThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EmployeesAndConsultantsMember" xlink:to="asnd_EmployeesAndConsultantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EventsAfterReportingPeriodMember" xlink:to="asnd_EventsAfterReportingPeriodMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:to="asnd_DisclosureOfBeneficialOwnershipLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsConditionForRedemption" xlink:to="asnd_BorrowingsConditionForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfBeneficialOwnershipAbstract" xlink:to="asnd_DisclosureOfBeneficialOwnershipAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock" xlink:to="asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FairValueOfConvertibleNotes" xlink:to="asnd_FairValueOfConvertibleNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaUkLimitedMember" xlink:to="asnd_AscendisPharmaUkLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ProfitLossBeforeIncomeTaxAbstract" xlink:to="asnd_ProfitLossBeforeIncomeTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateRiskMember" xlink:to="ifrs-full_InterestRateRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaIberiaSLMember" xlink:to="asnd_AscendisPharmaIberiaSLMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharePriceAppliedForValuation" xlink:to="asnd_SharePriceAppliedForValuation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractualCapitalCommitments" xlink:to="ifrs-full_ContractualCapitalCommitments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfEmployees1" xlink:to="asnd_NumberOfEmployees1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_LeaseExpenses" xlink:to="asnd_LeaseExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MarketableSecuritiesExplanatory" xlink:to="asnd_MarketableSecuritiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:to="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfBeneficialOwnershipTable" xlink:to="asnd_DisclosureOfBeneficialOwnershipTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:to="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_GrantedBeforeJanuary12022Member" xlink:to="asnd_GrantedBeforeJanuary12022Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FairValueOfRoyaltyFundingLiabilities" xlink:to="asnd_FairValueOfRoyaltyFundingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeGain" xlink:to="ifrs-full_NetForeignExchangeGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:to="asnd_CarryingAmountOfRoyaltyFundingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleSeniorNotesMember" xlink:to="asnd_ConvertibleSeniorNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BritishPoundsToEuroMember" xlink:to="asnd_BritishPoundsToEuroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfReportableOperatingSegments" xlink:to="asnd_NumberOfReportableOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RevenueFromClinicalSupply" xlink:to="asnd_RevenueFromClinicalSupply_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfAdditionalSharesAuthorizedToGrant" xlink:to="asnd_NumberOfAdditionalSharesAuthorizedToGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageEffectiveTaxRate" xlink:to="ifrs-full_AverageEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncomeStatementDomain" xlink:to="asnd_IncomeStatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaEndocrinologyGmbhMember" xlink:to="asnd_AscendisPharmaEndocrinologyGmbhMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PerformanceStockUnitsMember" xlink:to="asnd_PerformanceStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_GrantedInTwoThousandTwentyFourMember" xlink:to="asnd_GrantedInTwoThousandTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfDomicileMember" xlink:to="ifrs-full_CountryOfDomicileMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EyconisIncMember" xlink:to="asnd_EyconisIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AssociateAbstract" xlink:to="asnd_AssociateAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" xlink:to="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock" xlink:to="asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssetsMember" xlink:to="ifrs-full_RightofuseAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermBorrowings" xlink:to="ifrs-full_ShorttermBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfBasisOfConsolidationExplanatory" xlink:to="asnd_DescriptionOfBasisOfConsolidationExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaIncMember" xlink:to="asnd_AscendisPharmaIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaItaliaSrlMember" xlink:to="asnd_AscendisPharmaItaliaSrlMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyFiveMember" xlink:to="asnd_TwoThousandAndTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfCommercialCustomers" xlink:to="asnd_NumberOfCommercialCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" xlink:to="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyFourMember" xlink:to="asnd_TwoThousandAndTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharePriceMeasurementInputMember" xlink:to="asnd_SharePriceMeasurementInputMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_LowerMediumGradeMember" xlink:to="asnd_LowerMediumGradeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MilestonesMember" xlink:to="asnd_MilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UpperMediumGradeMember" xlink:to="asnd_UpperMediumGradeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_ClassificationOfRelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaGmbHMember" xlink:to="asnd_AscendisPharmaGmbHMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativesMember" xlink:to="ifrs-full_DerivativesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyThreeMember" xlink:to="asnd_TwoThousandAndTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PercentageOfWarrantsVested" xlink:to="asnd_PercentageOfWarrantsVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" xlink:to="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_Warrant1Member" xlink:to="asnd_Warrant1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UnitedStatesSkytrofaMember" xlink:to="asnd_UnitedStatesSkytrofaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RevenueTable" xlink:to="asnd_RevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" xlink:to="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:to="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaSwitzerlandGmbhMember" xlink:to="asnd_AscendisPharmaSwitzerlandGmbhMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_Prime1Member" xlink:to="asnd_Prime1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AdditionalTaxDeductionsRelatedToTaxCredits" xlink:to="asnd_AdditionalTaxDeductionsRelatedToTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaEndocrinologyIncMember" xlink:to="asnd_AscendisPharmaEndocrinologyIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FundingReceivedInExchange" xlink:to="asnd_FundingReceivedInExchange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:to="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" xlink:to="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ExpectedLeaseCommenceYear" xlink:to="asnd_ExpectedLeaseCommenceYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:to="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AvoroCapitalAdvisorsLlcMember" xlink:to="asnd_AvoroCapitalAdvisorsLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RestrictedStockUnitsMember" xlink:to="asnd_RestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NonexecutiveseniorManagementMember" xlink:to="asnd_NonexecutiveseniorManagementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValueMember" xlink:to="ifrs-full_FinancialAssetsAtFairValueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfProvisionsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DecreaseInTaxLosseCarryForwards" xlink:to="asnd_DecreaseInTaxLosseCarryForwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_LicensesMember" xlink:to="asnd_LicensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_Revenuerecognizedfromcontractliabilities" xlink:to="asnd_Revenuerecognizedfromcontractliabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaGrowthDisordersASMember" xlink:to="asnd_AscendisPharmaGrowthDisordersASMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ShortTermMarketableSecurities" xlink:to="asnd_ShortTermMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfAssociate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="asnd_ForeignCurrencyRiskDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ClassificationOfRelatedPartyAxis" xlink:to="asnd_ClassificationOfRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentySevenMember" xlink:to="asnd_TwoThousandAndTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndDebenturesIssued" xlink:to="ifrs-full_NotesAndDebenturesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_OfficeFacilityMember" xlink:to="asnd_OfficeFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_ProvisionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" xlink:to="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TaxEffectsFromPriorYearAdjustment" xlink:to="asnd_TaxEffectsFromPriorYearAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSalesMember" xlink:to="ifrs-full_CostOfSalesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UnitedStatesYorvipathMember" xlink:to="asnd_UnitedStatesYorvipathMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ShortTermBorrowingOther" xlink:to="asnd_ShortTermBorrowingOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:to="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NewIFRSsDomain" xlink:to="ifrs-full_NewIFRSsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="asnd_DisclosureOfCommitmentsAndContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" xlink:to="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FinanceExpensesAbstract" xlink:to="asnd_FinanceExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MinimumBeneficialOwnershipPercentage" xlink:to="asnd_MinimumBeneficialOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:to="ifrs-full_NoncurrentFinancialAssetsAvailableforsale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfBeneficialOwnershipExplanatory" xlink:to="asnd_DisclosureOfBeneficialOwnershipExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:to="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory" xlink:to="asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ForeignCurrencyTargetPercentage" xlink:to="asnd_ForeignCurrencyTargetPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfTreasurySharesOutstanding" xlink:to="asnd_NumberOfTreasurySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:to="ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AdditionalTaxDeduction" xlink:to="asnd_AdditionalTaxDeduction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DistributableEquity" xlink:to="asnd_DistributableEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership" xlink:to="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived" xlink:to="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MarketableSecurities1" xlink:to="asnd_MarketableSecurities1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember" xlink:to="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_CategoriesOfFinancialAssetsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="ifrs-full_ClassesOfAssetsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FairValueOfWarrantsGranted" xlink:to="asnd_FairValueOfWarrantsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:to="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WarrantCompensationCost" xlink:to="asnd_WarrantCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ForeignCurrencyConversionOptionMember" xlink:to="asnd_ForeignCurrencyConversionOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsMaturity" xlink:to="ifrs-full_BorrowingsMaturity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate" xlink:to="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" xlink:to="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" xlink:to="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_InventoriesAbstract" xlink:to="asnd_InventoriesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_MaturityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractLiabilitiestableTable" xlink:to="asnd_ContractLiabilitiestableTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UpfrontPaymentReceived" xlink:to="asnd_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:to="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RestOfWorldMember" xlink:to="asnd_RestOfWorldMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsRedemptionPeriod" xlink:to="asnd_BorrowingsRedemptionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="asnd_ChangesInWorkingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AscendisPharmaOncologyDivisionAsMember" xlink:to="asnd_AscendisPharmaOncologyDivisionAsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate" xlink:to="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DK" xlink:to="country_DK_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltiesAndMilestonesMember" xlink:to="asnd_RoyaltiesAndMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_RangeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TaxEffectsFromImpactsFromAssociates" xlink:to="asnd_TaxEffectsFromImpactsFromAssociates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="asnd_SummaryOfInventoryDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory" xlink:to="asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixedInterestRateMember" xlink:to="ifrs-full_FixedInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CostsOfCapitalIncreaseDecrease" xlink:to="asnd_CostsOfCapitalIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SaleOfGoodsAndServicesToAssociate" xlink:to="asnd_SaleOfGoodsAndServicesToAssociate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NetSettlementUnderStockIncentivePrograms" xlink:to="asnd_NetSettlementUnderStockIncentivePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_TypesOfInterestRatesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementDomain" xlink:to="ifrs-full_MeasurementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_OtherEquipmentMember" xlink:to="asnd_OtherEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UsTreasuryBillsMember" xlink:to="asnd_UsTreasuryBillsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DeferredTaxMovementForTheYear" xlink:to="asnd_DeferredTaxMovementForTheYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:to="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAvailableforsale" xlink:to="ifrs-full_FinancialAssetsAvailableforsale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_CapitalCommitmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CommercialCustomersMember" xlink:to="asnd_CommercialCustomersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CategoriesOfSharesBasedPaymentsAxis" xlink:to="asnd_CategoriesOfSharesBasedPaymentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NewProvisionsOtherProvisions" xlink:to="ifrs-full_NewProvisionsOtherProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmericanDepositarySharesMember" xlink:label="asnd_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain" xlink:to="asnd_AmericanDepositarySharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfWarrantsOutstanding" xlink:label="asnd_NumberOfWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_Warrant1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="asnd_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="asnd_NumberOfWarrantsOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="ifrs-full_OrdinarySharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleDebtCurrentAbstract" xlink:label="asnd_ConvertibleDebtCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_OtherCurrentLiabilitiesAbstract" xlink:label="asnd_OtherCurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShortTermBorrowingOther" xlink:label="asnd_ShortTermBorrowingOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DistributableEquity" xlink:label="asnd_DistributableEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleNotesCurrent" xlink:label="asnd_ConvertibleNotesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates" xlink:label="ifrs-full_InvestmentsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="ifrs-full_OtherNoncurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecuritiesNonCurrentAssets" xlink:label="asnd_MarketableSecuritiesNonCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="ifrs-full_ShorttermBorrowings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="asnd_ConvertibleDebtCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="asnd_ShortTermBorrowingOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_LongtermBorrowings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="asnd_DistributableEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="asnd_OtherCurrentLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentContractLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentContractLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="asnd_ConvertibleNotesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentsInAssociates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="asnd_MarketableSecuritiesNonCurrentAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentTaxLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="asnd_MarketableSecurities1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentProvisions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NetSettlementUnderStockIncentivePrograms" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CostsOfCapitalIncreaseDecrease" xlink:label="asnd_CostsOfCapitalIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_10"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_IssuedCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_SharePremiumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_TreasurySharesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_PurchaseOfTreasuryShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_NetSettlementUnderStockIncentivePrograms" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_CostsOfCapitalIncreaseDecrease" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInAssociates" xlink:label="ifrs-full_PurchaseOfInterestsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ChangesInWorkingCapitalAbstract" xlink:label="asnd_ChangesInWorkingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" xlink:label="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ReversalOfGainLossOnPropertyPlantAndEquipment" xlink:label="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShortTermMarketableSecurities" xlink:label="asnd_ShortTermMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfInterestsInAssociates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_FinanceIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="asnd_ChangesInWorkingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_FinanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ShareIssueRelatedCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForProvisions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_BalancesWithBanks" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="asnd_ShortTermMarketableSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/GeneralInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfGeneralInformationAbstract" xlink:label="asnd_DisclosureOfGeneralInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfGeneralInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimates" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/Revenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/EmployeeCosts" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPayment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServices" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationAbstract" xlink:label="ifrs-full_AuditorsRemunerationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTax" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociates" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/Inventories" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_InventoriesAbstract" xlink:label="asnd_InventoriesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_InventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/Leases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilitiesAbstract" xlink:label="ifrs-full_ContractLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContractLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionsAbstract" xlink:label="ifrs-full_ProvisionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfProvisionsExplanatory" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_DisclosureOfProvisionsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory" xlink:label="asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract" xlink:label="ifrs-full_CapitalCommitmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprises" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_InvestmentsInGroupEnterprisesAbstract" xlink:label="asnd_InvestmentsInGroupEnterprisesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_InvestmentsInGroupEnterprisesAbstract" xlink:to="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/Ownership" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipAbstract" xlink:label="asnd_DisclosureOfBeneficialOwnershipAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipExplanatory" xlink:label="asnd_DisclosureOfBeneficialOwnershipExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfBeneficialOwnershipAbstract" xlink:to="asnd_DisclosureOfBeneficialOwnershipExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfBasisOfConsolidationExplanatory" xlink:label="asnd_DescriptionOfBasisOfConsolidationExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock" xlink:label="asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock" xlink:label="asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfGoingConcernExplanatory" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfBasisOfConsolidationExplanatory" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory" xlink:label="asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/RevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" xlink:label="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationAbstract" xlink:label="ifrs-full_AuditorsRemunerationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock" xlink:label="asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VISENPharmaceuticalMember" xlink:label="asnd_VISENPharmaceuticalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssociatesMember" xlink:label="ifrs-full_AssociatesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_VISENPharmaceuticalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="ifrs-full_AssociatesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/InventoriesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_InventoriesAbstract" xlink:label="asnd_InventoriesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock" xlink:label="asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_InventoriesAbstract" xlink:to="asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionsAbstract" xlink:label="ifrs-full_ProvisionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory" xlink:label="asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements" xlink:label="asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock" xlink:label="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory" xlink:label="asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock" xlink:label="asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock" xlink:label="asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncomeStatementAxis" xlink:label="asnd_IncomeStatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncomeStatementDomain" xlink:label="asnd_IncomeStatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NewIFRSsDomain" xlink:label="ifrs-full_NewIFRSsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="ifrs-full_ClassesOfAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments" xlink:label="ifrs-full_ReserveOfSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ReserveOfTreasuryShares" xlink:label="asnd_ReserveOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_NewIFRSsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ReserveOfTreasuryShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_TreasuryShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_ParValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="asnd_IncomeStatementAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConvertibleSeniorNotes" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConversionPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_BorrowingsMaturity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProcessPlantAndMachineryMember" xlink:label="asnd_ProcessPlantAndMachineryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_OtherEquipmentMember" xlink:label="asnd_OtherEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="asnd_ProcessPlantAndMachineryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="asnd_OtherEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_RightofuseAssetsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SalesDeductionsAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesDeductionsAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WarrantCompensationCost" xlink:label="asnd_WarrantCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="asnd_SalesRebatesAndProductReturnsInUSMarketMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_CurrentProvisions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="srt_RestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="asnd_SalesDeductionsAndProductReturnsInUSMarketMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="asnd_WarrantCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_Revenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="asnd_CarryingAmountOfRoyaltyFundingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="ifrs-full_ClassesOfAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestOfWorldMember" xlink:label="asnd_RestOfWorldMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RevenueFromClinicalSupply" xlink:label="asnd_RevenueFromClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_EuropeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="ifrs-full_Revenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_NorthAmericaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromRenderingOfServices" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="asnd_RestOfWorldMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_RevenueFromClinicalSupply" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_CN" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_LicenceFeeIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_AsiaMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfGeographicalAreasAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_DK" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesSkytrofaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesYorvipathMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_MajorCustomersAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NovoNordiskMember" xlink:label="asnd_NovoNordiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsDomain" xlink:label="ifrs-full_PerformanceObligationsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LicensesOfIpMember" xlink:label="asnd_LicensesOfIpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RevenueTable" xlink:label="asnd_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VISENPharmaceuticalMember" xlink:label="asnd_VISENPharmaceuticalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MilestonesMember" xlink:label="asnd_MilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfCommercialCustomers" xlink:label="asnd_NumberOfCommercialCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TeijinMember" xlink:label="asnd_TeijinMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltiesAndMilestonesMember" xlink:label="asnd_RoyaltiesAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LicensesMember" xlink:label="asnd_LicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpfrontPaymentReceived" xlink:label="asnd_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:label="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpfrontFeeForExclusiveLicense" xlink:label="asnd_UpfrontFeeForExclusiveLicense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived" xlink:label="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SalesMilestonesReceived" xlink:label="asnd_SalesMilestonesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_NovoNordiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_LicensesOfIpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="asnd_RevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_Revenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_VISENPharmaceuticalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_ThirdPartyInvestorsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_MilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_NumberOfCommercialCustomers" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_PerformanceObligationsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_TeijinMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_RoyaltiesAndMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_LicensesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_UpfrontPaymentReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_CounterpartiesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_UpfrontFeeForExclusiveLicense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="srt_RestatementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_SalesMilestonesReceived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_CapitalCommitmentFromInvestors" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfReportableOperatingSegments" xlink:label="asnd_NumberOfReportableOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_NumberOfReportableOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="ifrs-full_CountryOfDomicileMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:label="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NorthAmerica1Member" xlink:label="asnd_NorthAmerica1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Germany1Member" xlink:label="asnd_Germany1Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_CountryOfDomicileMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_EuropeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="asnd_NorthAmerica1Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="asnd_Germany1Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="ifrs-full_CountryOfDomicileMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:label="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_CountryOfDomicileMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BoardOfDirectorsMember" xlink:label="asnd_BoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ResearchAndDevelopmentCostsMember" xlink:label="asnd_ResearchAndDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExecutiveBoardMember" xlink:label="asnd_ExecutiveBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NonexecutiveseniorManagementMember" xlink:label="asnd_NonexecutiveseniorManagementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSalesMember" xlink:label="ifrs-full_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense" xlink:label="ifrs-full_OtherEmployeeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageNumberOfEmployees" xlink:label="ifrs-full_AverageNumberOfEmployees"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_WagesAndSalaries" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_BoardOfDirectorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="asnd_ResearchAndDevelopmentCostsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_ExecutiveBoardMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_NonexecutiveseniorManagementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_CostOfSalesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_SocialSecurityContributions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_OtherEmployeeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_AverageNumberOfEmployees" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfEmployees1" xlink:label="asnd_NumberOfEmployees1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BoardOfDirectorsMember" xlink:label="asnd_BoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExecutiveBoardMember" xlink:label="asnd_ExecutiveBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="asnd_NumberOfEmployees1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_BoardOfDirectorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_NumberOfEmployees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_ExecutiveBoardMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CategoriesOfSharesBasedPaymentsDomain" xlink:label="asnd_CategoriesOfSharesBasedPaymentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WarrantsGranted2012UntilNovember2021Member" xlink:label="asnd_WarrantsGranted2012UntilNovember2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ClassificationOfRelatedPartyDomain" xlink:label="asnd_ClassificationOfRelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BoardMembersOfGroupMember" xlink:label="asnd_BoardMembersOfGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ClassificationOfRelatedPartyAxis" xlink:label="asnd_ClassificationOfRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate" xlink:label="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CategoriesOfSharesBasedPaymentsAxis" xlink:label="asnd_CategoriesOfSharesBasedPaymentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WarrantsGrantedFromDecember2021Member" xlink:label="asnd_WarrantsGrantedFromDecember2021Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitProgramMember" xlink:label="asnd_PerformanceStockUnitProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EmployeesAndConsultantsMember" xlink:label="asnd_EmployeesAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PercentageOfWarrantsVested" xlink:label="asnd_PercentageOfWarrantsVested"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfAdditionalSharesGranted" xlink:label="asnd_NumberOfAdditionalSharesGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfAdditionalSharesAuthorizedToGrant" xlink:label="asnd_NumberOfAdditionalSharesAuthorizedToGrant"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementVestingPeriod" xlink:label="asnd_SharebasedPaymentArrangementVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:label="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_CategoriesOfSharesBasedPaymentsDomain" xlink:to="asnd_WarrantsGranted2012UntilNovember2021Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_BoardMembersOfGroupMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ClassificationOfRelatedPartyAxis" xlink:to="asnd_ClassificationOfRelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_MaturityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_CategoriesOfSharesBasedPaymentsAxis" xlink:to="asnd_CategoriesOfSharesBasedPaymentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_CategoriesOfSharesBasedPaymentsDomain" xlink:to="asnd_WarrantsGrantedFromDecember2021Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_EmployeesAndConsultantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ClassificationOfRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_CategoriesOfSharesBasedPaymentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_PercentageOfWarrantsVested" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_NumberOfAdditionalSharesGranted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_NumberOfAdditionalSharesAuthorizedToGrant" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_SharebasedPaymentArrangementVestingPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyThreeMember" xlink:label="asnd_TwoThousandAndTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VestingOfSharesAxis" xlink:label="asnd_VestingOfSharesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyFourMember" xlink:label="asnd_TwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyFiveMember" xlink:label="asnd_TwoThousandAndTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentySevenMember" xlink:label="asnd_TwoThousandAndTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFourMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_VestingOfSharesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFiveMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySixMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySevenMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_4"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_10"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_DisclosureOfWarrantActivityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_USDollarsMember" xlink:label="asnd_USDollarsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="asnd_USDollarsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_CurrencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_DisclosureOfWarrantActivityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedBeforeJanuary12022Member" xlink:label="asnd_GrantedBeforeJanuary12022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_YearOfGrantOfWarrants" xlink:label="asnd_YearOfGrantOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedIn2022Member" xlink:label="asnd_GrantedIn2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedIn2023Member" xlink:label="asnd_GrantedIn2023Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedInTwoThousandTwentyFourMember" xlink:label="asnd_GrantedInTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:label="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_GrantedBeforeJanuary12022Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_YearOfGrantOfWarrants" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_GrantedIn2022Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_GrantedIn2023Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_GrantedInTwoThousandTwentyFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueOfWarrantsGranted" xlink:label="asnd_FairValueOfWarrantsGranted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_FairValueOfWarrantsGranted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationAbstract" xlink:label="ifrs-full_AuditorsRemunerationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Audit-RelatedFees" xlink:label="asnd_Audit-RelatedFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForTaxServices" xlink:label="ifrs-full_AuditorsRemunerationForTaxServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemuneration" xlink:label="ifrs-full_AuditorsRemuneration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ifrs-full_AuditorsRemunerationForAuditServices" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="asnd_Audit-RelatedFees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ifrs-full_AuditorsRemunerationForTaxServices" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ifrs-full_AuditorsRemunerationForOtherServices" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ifrs-full_AuditorsRemuneration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProfitLossBeforeIncomeTaxAbstract" xlink:label="asnd_ProfitLossBeforeIncomeTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectOfDeductibleItemsNotExpensed" xlink:label="asnd_TaxEffectOfDeductibleItemsNotExpensed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectsOfDeductibleItemsNotExpensed" xlink:label="asnd_TaxEffectsOfDeductibleItemsNotExpensed"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DeferredTaxMovementForTheYear" xlink:label="asnd_DeferredTaxMovementForTheYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="ifrs-full_AverageEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectsFromImpactsFromAssociates" xlink:label="asnd_TaxEffectsFromImpactsFromAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:label="ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="ifrs-full_TaxEffectOfTaxLosses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectsFromPriorYearAdjustment" xlink:label="asnd_TaxEffectsFromPriorYearAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DeferredTaxAssetNotRecognized" xlink:label="asnd_DeferredTaxAssetNotRecognized"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectFromDeferredTaxAssetNotRecognized" xlink:label="asnd_TaxEffectFromDeferredTaxAssetNotRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ProfitLossBeforeIncomeTaxAbstract" xlink:to="ifrs-full_AccountingProfit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="asnd_ProfitLossBeforeIncomeTaxAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ProfitLossBeforeIncomeTaxAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="asnd_TaxEffectOfDeductibleItemsNotExpensed" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ProfitLossBeforeIncomeTaxAbstract" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="asnd_TaxEffectsOfDeductibleItemsNotExpensed" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="asnd_DeferredTaxMovementForTheYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_AverageEffectiveTaxRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="asnd_TaxEffectsFromImpactsFromAssociates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_TaxEffectOfTaxLosses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="asnd_TaxEffectsFromPriorYearAdjustment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="asnd_DeferredTaxAssetNotRecognized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="asnd_TaxEffectFromDeferredTaxAssetNotRecognized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_NetDeferredTaxAssets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxParentheticalDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_ApplicableTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="ifrs-full_IncomeTaxesPaidRefund"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxLossesCarryforwards" xlink:label="asnd_TaxLossesCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DecreaseInTaxLosseCarryForwards" xlink:label="asnd_DecreaseInTaxLosseCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdditionalTaxDeduction" xlink:label="asnd_AdditionalTaxDeduction"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdditionalFutureTaxDeduction" xlink:label="asnd_AdditionalFutureTaxDeduction"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdditionalTaxDeductionsRelatedToTaxCredits" xlink:label="asnd_AdditionalTaxDeductionsRelatedToTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RevenueThresholdLimit" xlink:label="asnd_RevenueThresholdLimit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefund" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="asnd_TaxLossesCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="asnd_DecreaseInTaxLosseCarryForwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="asnd_AdditionalTaxDeduction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="asnd_AdditionalFutureTaxDeduction" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="asnd_AdditionalTaxDeductionsRelatedToTaxCredits" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="asnd_RevenueThresholdLimit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="ifrs-full_GoodwillMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="ifrs-full_AccumulatedImpairmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="ifrs-full_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsAndGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="ifrs-full_GoodwillMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedImpairmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="ifrs-full_ComputerSoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisposalsIntangibleAssetsAndGoodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PlantAndMachineryMember" xlink:label="asnd_PlantAndMachineryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="asnd_PlantAndMachineryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_RightofuseAssetsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_RightofuseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSalesMember" xlink:label="ifrs-full_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ResearchAndDevelopmentCostsMember" xlink:label="asnd_ResearchAndDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:to="ifrs-full_CostOfSalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" xlink:to="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:to="asnd_ResearchAndDevelopmentCostsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfAssociateLineItems" xlink:label="asnd_DisclosureOfAssociateLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VISENPharmaceuticalMember" xlink:label="asnd_VISENPharmaceuticalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="ifrs-full_ConsiderationPaidReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EyconisMember" xlink:label="asnd_EyconisMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EyconisIncMember" xlink:label="asnd_EyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInAssociate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_VISENPharmaceuticalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="asnd_DisclosureOfAssociateLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_EyconisMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="asnd_CapitalCommitmentFromInvestors" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_EyconisIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="ifrs-full_ProportionOfVotingPowerHeldInAssociate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TransactionsAndOutstandingBalancesAbstract" xlink:label="asnd_TransactionsAndOutstandingBalancesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SaleOfGoodsAndServicesToAssociate" xlink:label="asnd_SaleOfGoodsAndServicesToAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:label="asnd_DisclosureOfAssociatesAndJointVenturesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AssociateAbstract" xlink:label="asnd_AssociateAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAbstract" xlink:label="ifrs-full_ProfitLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProfitLossForTheYear" xlink:label="asnd_ProfitLossForTheYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssociatesMember" xlink:label="ifrs-full_AssociatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_TransactionsAndOutstandingBalancesAbstract" xlink:to="asnd_SaleOfGoodsAndServicesToAssociate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="asnd_AssociateAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="asnd_ProfitLossForTheYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="ifrs-full_AssociatesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AssociateAbstract" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfAssociate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_TransactionsAndOutstandingBalancesAbstract" xlink:to="ifrs-full_TradeReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="ifrs-full_ProfitLossAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AssociateAbstract" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_TransactionsAndOutstandingBalancesAbstract" xlink:to="ifrs-full_ContractLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="asnd_TransactionsAndOutstandingBalancesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Equity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SummaryOfInventoryDisclosureTable" xlink:label="asnd_SummaryOfInventoryDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SummaryOfInventoryDisclosureLineItems" xlink:label="asnd_SummaryOfInventoryDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_InventoriesAbstract" xlink:label="asnd_InventoriesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WorkInProgress" xlink:label="ifrs-full_WorkInProgress"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods" xlink:label="ifrs-full_FinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoriesTotal" xlink:label="ifrs-full_InventoriesTotal"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfInventoryDisclosureTable" xlink:to="asnd_SummaryOfInventoryDisclosureLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_InventoriesAbstract" xlink:to="asnd_SummaryOfInventoryDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="ifrs-full_WorkInProgress" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="ifrs-full_FinishedGoods" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="ifrs-full_InventoriesTotal" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_InventoriesAbstract" xlink:label="asnd_InventoriesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_InventoriesAbstract" xlink:to="ifrs-full_InventoryWritedown2011" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractLiabilitiesLineItems" xlink:label="asnd_ContractLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilitiesAbstract" xlink:label="ifrs-full_ContractLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractLiabilitiestableTable" xlink:label="asnd_ContractLiabilitiestableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyTwoMember" xlink:label="asnd_TwoThousandAndTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" xlink:label="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Revenuerecognizedfromcontractliabilities" xlink:label="asnd_Revenuerecognizedfromcontractliabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ContractLiabilitiesLineItems" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContractLiabilitiesAbstract" xlink:to="asnd_ContractLiabilitiestableTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="asnd_TwoThousandAndTwentyTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ContractLiabilitiestableTable" xlink:to="ifrs-full_MaturityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ContractLiabilitiesLineItems" xlink:to="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ContractLiabilitiestableTable" xlink:to="ifrs-full_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ContractLiabilitiesLineItems" xlink:to="asnd_Revenuerecognizedfromcontractliabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ContractLiabilitiestableTable" xlink:to="asnd_ContractLiabilitiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionsAbstract" xlink:label="ifrs-full_ProvisionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NewProvisionsOtherProvisions" xlink:label="ifrs-full_NewProvisionsOtherProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_CurrentProvisions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_NewProvisionsOtherProvisions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_CurrentProvisions_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain" xlink:label="ifrs-full_HedgingInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyConversionOptionMember" xlink:label="asnd_ForeignCurrencyConversionOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativesMember" xlink:label="ifrs-full_DerivativesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain" xlink:label="ifrs-full_UnobservableInputsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="ifrs-full_HedgingInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="ifrs-full_ClassesOfAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_OfficeFacilityMember" xlink:label="asnd_OfficeFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharePriceMeasurementInputMember" xlink:label="asnd_SharePriceMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConversionRatePerNote" xlink:label="asnd_ConversionRatePerNote"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsRedemptionPeriod" xlink:label="asnd_BorrowingsRedemptionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsConditionForRedemption" xlink:label="asnd_BorrowingsConditionForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueOfConvertibleNotes" xlink:label="asnd_FairValueOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPaymentBeginningPeriod" xlink:label="asnd_RoyaltyPaymentBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueOfRoyaltyFundingLiabilities" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LeaseExtensionPeriod" xlink:label="asnd_LeaseExtensionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EnforceableLeaseterm" xlink:label="asnd_EnforceableLeaseterm"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExpectedLeaseCommenceYear" xlink:label="asnd_ExpectedLeaseCommenceYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="ifrs-full_CashOutflowForLeases"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharePriceAppliedForValuation" xlink:label="asnd_SharePriceAppliedForValuation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" xlink:label="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_DK" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="asnd_EventsAfterReportingPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_HedgingInstrumentsDomain" xlink:to="asnd_ForeignCurrencyConversionOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="ifrs-full_DerivativesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotionalAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="asnd_OfficeFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FixedInterestRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_DE" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="asnd_SharePriceMeasurementInputMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsMaturity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesSkytrofaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsInArrearsDefaultPaymentStartDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionRatePerNote" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_HedgingInstrumentsAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsRedemptionPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsConditionForRedemption" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_UnobservableInputsAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdTradingDaysForRedemption" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfConvertibleNotes" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchange" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentBeginningPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentEndingPeriod" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_CarryingAmountOfRoyaltyFundingLiabilities" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfRoyaltyFundingLiabilities" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_LeaseExtensionPeriod" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_EnforceableLeaseterm" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExpectedLeaseCommenceYear" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_SharePriceAppliedForValuation" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReceivablesDueFromAssociates" xlink:label="ifrs-full_ReceivablesDueFromAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_TradeReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_ConvertibleSeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_ReceivablesDueFromAssociates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CurrentFinancialAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CurrentFinancialLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="asnd_MarketableSecuritiesExplanatory" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FinanceIncomeExpenseAbstract" xlink:label="asnd_FinanceIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FinanceIncomeAbstract" xlink:label="asnd_FinanceIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FinanceExpensesAbstract" xlink:label="asnd_FinanceExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceIncomeExpenseAbstract" xlink:to="asnd_FinanceIncomeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceIncomeAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceExpensesAbstract" xlink:to="ifrs-full_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceIncomeExpenseAbstract" xlink:to="asnd_FinanceExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceIncomeAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceExpensesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceIncomeAbstract" xlink:to="ifrs-full_GainsOnChangeInFairValueOfDerivatives" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceExpensesAbstract" xlink:to="ifrs-full_LossesOnChangeInFairValueOfDerivatives" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceIncomeAbstract" xlink:to="ifrs-full_NetForeignExchangeGain" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceExpensesAbstract" xlink:to="ifrs-full_NetForeignExchangeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_FinanceExpensesAbstract" xlink:to="ifrs-full_FinanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LeaseExpenses" xlink:label="asnd_LeaseExpenses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="asnd_LeaseExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="ifrs-full_LongtermBorrowingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="ifrs-full_LongtermBorrowingsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="ifrs-full_LeaseLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="ifrs-full_MeasurementDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueHierarchyCarryingAmountMember" xlink:label="asnd_FairValueHierarchyCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndDebenturesIssued" xlink:label="ifrs-full_NotesAndDebenturesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="asnd_MarketableSecuritiesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_ConvertibleSeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementDomain" xlink:to="asnd_FairValueHierarchyCarryingAmountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_MeasurementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NotesAndDebenturesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementDomain" xlink:to="ifrs-full_AtFairValueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfNumberOfSharesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskAxis" xlink:label="asnd_ForeignCurrencyRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyTargetPercentage" xlink:label="asnd_ForeignCurrencyTargetPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRateRiskMember" xlink:label="ifrs-full_InterestRateRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_DKK" xlink:label="currency_DKK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RealizedDurationOfFinancialAssetsExplanatory" xlink:label="asnd_RealizedDurationOfFinancialAssetsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_ForeignCurrencyRiskAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ForeignCurrencyTargetPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_InterestRateRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="currency_DKK" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FixedInterestRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_LiquidityRiskMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RealizedDurationOfFinancialAssetsExplanatory" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PurchaseOfTreasurySharesNominalValue" xlink:label="asnd_PurchaseOfTreasurySharesNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_3"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding_7"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_11"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_TreasurySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="ifrs-full_TreasuryShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_PurchaseOfTreasurySharesNominalValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="ifrs-full_TreasuryShares_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskAxis" xlink:label="asnd_ForeignCurrencyRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NominalValueAmount" xlink:label="asnd_NominalValueAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UsDollarsToEuroMember" xlink:label="asnd_UsDollarsToEuroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BritishPoundsToEuroMember" xlink:label="asnd_BritishPoundsToEuroMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInForeignCurrencyExchangeRate" xlink:label="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SwissFrancToEuroMember" xlink:label="asnd_SwissFrancToEuroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_ForeignCurrencyRiskAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_NominalValueAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="asnd_UsDollarsToEuroMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotionalAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="asnd_BritishPoundsToEuroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="asnd_SwissFrancToEuroMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="ifrs-full_FloatingInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAvailableforsale" xlink:label="ifrs-full_FinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ZeroCouponMember" xlink:label="asnd_ZeroCouponMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="ifrs-full_FinancialAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FloatingInterestRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="ifrs-full_FinancialAssetsAvailableforsale" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtFairValueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FixedInterestRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="asnd_ZeroCouponMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExternalCreditGradesDomain" xlink:label="ifrs-full_ExternalCreditGradesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Prime1Member" xlink:label="asnd_Prime1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_HighGradeMember" xlink:label="asnd_HighGradeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAvailableforsale" xlink:label="ifrs-full_FinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpperMediumGradeMember" xlink:label="asnd_UpperMediumGradeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LowerMediumGradeMember" xlink:label="asnd_LowerMediumGradeMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_ExternalCreditGradesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract" xlink:to="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExternalCreditGradesDomain" xlink:to="asnd_Prime1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" xlink:to="ifrs-full_FinancialAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_CreditRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExternalCreditGradesDomain" xlink:to="asnd_HighGradeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" xlink:to="ifrs-full_FinancialAssetsAvailableforsale" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:to="ifrs-full_ExternalCreditGradesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtFairValueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExternalCreditGradesDomain" xlink:to="asnd_UpperMediumGradeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExternalCreditGradesDomain" xlink:to="asnd_LowerMediumGradeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:to="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAvailableforsale" xlink:label="ifrs-full_FinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UsTreasuryBillsMember" xlink:label="asnd_UsTreasuryBillsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UsGovernmentBondsMember" xlink:label="asnd_UsGovernmentBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:label="ifrs-full_CurrentFinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialPapersMember" xlink:label="asnd_CommercialPapersMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CorporateBondsMember" xlink:label="asnd_CorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AgencyBondsMember" xlink:label="asnd_AgencyBondsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:to="ifrs-full_FinancialAssetsAvailableforsale" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_LiquidityRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_UsTreasuryBillsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:to="ifrs-full_NoncurrentFinancialAssetsAvailableforsale" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_UsGovernmentBondsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtFairValueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:to="ifrs-full_CurrentFinancialAssetsAvailableforsale" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_CommercialPapersMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_CorporateBondsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_AgencyBondsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_Borrowings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="asnd_ContractualUndiscountedCashflowOfBorrowings" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractualCapitalCommitments" xlink:label="ifrs-full_ContractualCapitalCommitments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfCommitmentsAndContingenciesTable" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract" xlink:label="ifrs-full_CapitalCommitmentsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="ifrs-full_ContractualCapitalCommitments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="asnd_DisclosureOfCommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="asnd_DisclosureOfCommitmentsAndContingenciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaGmbHMember" xlink:label="asnd_AscendisPharmaGmbHMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VISENPharmaceuticalMember" xlink:label="asnd_VISENPharmaceuticalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="ifrs-full_NameOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEndocrinologyGmbhMember" xlink:label="asnd_AscendisPharmaEndocrinologyGmbhMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EyconisIncMember" xlink:label="asnd_EyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaIncMember" xlink:label="asnd_AscendisPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEndocrinologyIncMember" xlink:label="asnd_AscendisPharmaEndocrinologyIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfAssociate" xlink:label="ifrs-full_NameOfAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaOphthalmologyDivisionASMember" xlink:label="asnd_AscendisPharmaOphthalmologyDivisionASMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEndocrinologyDivisionASMember" xlink:label="asnd_AscendisPharmaEndocrinologyDivisionASMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaBoneDiseaseASMember" xlink:label="asnd_AscendisPharmaBoneDiseaseASMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaGrowthDisordersASMember" xlink:label="asnd_AscendisPharmaGrowthDisordersASMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaOncologyDivisionAsMember" xlink:label="asnd_AscendisPharmaOncologyDivisionAsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEuropeASMember" xlink:label="asnd_AscendisPharmaEuropeASMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaUkLimitedMember" xlink:label="asnd_AscendisPharmaUkLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaIberiaSLMember" xlink:label="asnd_AscendisPharmaIberiaSLMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaFranceSasuMember" xlink:label="asnd_AscendisPharmaFranceSasuMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaItaliaSrlMember" xlink:label="asnd_AscendisPharmaItaliaSrlMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaSverigeAbMember" xlink:label="asnd_AscendisPharmaSverigeAbMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaSwitzerlandGmbhMember" xlink:label="asnd_AscendisPharmaSwitzerlandGmbhMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaGmbHMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_VISENPharmaceuticalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_NameOfSubsidiary" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaEndocrinologyGmbhMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_EyconisIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaEndocrinologyIncMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_NameOfAssociate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaOphthalmologyDivisionASMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaEndocrinologyDivisionASMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaBoneDiseaseASMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaGrowthDisordersASMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaOncologyDivisionAsMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaEuropeASMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaUkLimitedMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaIberiaSLMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaFranceSasuMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaItaliaSrlMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaSverigeAbMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaSwitzerlandGmbhMember" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:label="asnd_DisclosureOfBeneficialOwnershipLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MinimumBeneficialOwnershipPercentage" xlink:label="asnd_MinimumBeneficialOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipAbstract" xlink:label="asnd_DisclosureOfBeneficialOwnershipAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipTable" xlink:label="asnd_DisclosureOfBeneficialOwnershipTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember" xlink:label="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership" xlink:label="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WestfieldCapitalManagementCompanyLPUsaMember" xlink:label="asnd_WestfieldCapitalManagementCompanyLPUsaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfJointOperation" xlink:label="ifrs-full_NameOfJointOperation"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithFmrLlcMember" xlink:label="asnd_EntitiesAffiliatedWithFmrLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AvoroCapitalAdvisorsLlcMember" xlink:label="asnd_AvoroCapitalAdvisorsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember" xlink:label="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember" xlink:label="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:to="asnd_MinimumBeneficialOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfBeneficialOwnershipAbstract" xlink:to="asnd_DisclosureOfBeneficialOwnershipTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfBeneficialOwnershipTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_GB" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:to="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfBeneficialOwnershipTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_WestfieldCapitalManagementCompanyLPUsaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:to="ifrs-full_NameOfJointOperation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfBeneficialOwnershipTable" xlink:to="asnd_DisclosureOfBeneficialOwnershipLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_EntitiesAffiliatedWithFmrLlcMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_AvoroCapitalAdvisorsLlcMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_FrazierLifeSciencesOfEyconisIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="asnd_EventsAfterReportingPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_CounterpartiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_CapitalCommitmentFromInvestors" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/CoverPage">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmericanDepositarySharesMember" xlink:label="asnd_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="asnd_AmericanDepositarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfWarrantsOutstanding" xlink:label="asnd_NumberOfWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_Warrant1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="asnd_NumberOfWarrantsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="ifrs-full_OrdinarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NetSettlementUnderStockIncentivePrograms" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CostsOfCapitalIncreaseDecrease" xlink:label="asnd_CostsOfCapitalIncreaseDecrease"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_IssuedCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_SharePremiumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_TreasurySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_PurchaseOfTreasuryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_NetSettlementUnderStockIncentivePrograms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_CostsOfCapitalIncreaseDecrease" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" xlink:label="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VISENPharmaceuticalMember" xlink:label="asnd_VISENPharmaceuticalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssociatesMember" xlink:label="ifrs-full_AssociatesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_VISENPharmaceuticalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="ifrs-full_AssociatesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncomeStatementAxis" xlink:label="asnd_IncomeStatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncomeStatementDomain" xlink:label="asnd_IncomeStatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncomeStatementDomain" xlink:label="asnd_IncomeStatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NewIFRSsDomain" xlink:label="ifrs-full_NewIFRSsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NewIFRSsDomain" xlink:label="ifrs-full_NewIFRSsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="ifrs-full_ClassesOfAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="ifrs-full_ClassesOfAssetsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments" xlink:label="ifrs-full_ReserveOfSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ReserveOfTreasuryShares" xlink:label="asnd_ReserveOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_ReserveOfSharebasedPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_NewIFRSsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ReserveOfTreasuryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_TreasuryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="asnd_IncomeStatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConversionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_BorrowingsMaturity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProcessPlantAndMachineryMember" xlink:label="asnd_ProcessPlantAndMachineryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_OtherEquipmentMember" xlink:label="asnd_OtherEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="asnd_ProcessPlantAndMachineryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="asnd_OtherEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_RightofuseAssetsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SalesDeductionsAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesDeductionsAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WarrantCompensationCost" xlink:label="asnd_WarrantCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="asnd_SalesRebatesAndProductReturnsInUSMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_CurrentProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="asnd_SalesDeductionsAndProductReturnsInUSMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="asnd_WarrantCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_Revenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="asnd_CarryingAmountOfRoyaltyFundingLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="ifrs-full_ClassesOfAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestOfWorldMember" xlink:label="asnd_RestOfWorldMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RevenueFromClinicalSupply" xlink:label="asnd_RevenueFromClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_EuropeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="ifrs-full_Revenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_NorthAmericaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromRenderingOfServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="asnd_RestOfWorldMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_RevenueFromClinicalSupply" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_CN" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_LicenceFeeIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_AsiaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfGeographicalAreasAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_DK" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesSkytrofaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesYorvipathMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RevenueTable" xlink:label="asnd_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NovoNordiskMember" xlink:label="asnd_NovoNordiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsDomain" xlink:label="ifrs-full_PerformanceObligationsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LicensesOfIpMember" xlink:label="asnd_LicensesOfIpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsDomain" xlink:label="ifrs-full_PerformanceObligationsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VISENPharmaceuticalMember" xlink:label="asnd_VISENPharmaceuticalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MilestonesMember" xlink:label="asnd_MilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfCommercialCustomers" xlink:label="asnd_NumberOfCommercialCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TeijinMember" xlink:label="asnd_TeijinMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltiesAndMilestonesMember" xlink:label="asnd_RoyaltiesAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LicensesMember" xlink:label="asnd_LicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpfrontPaymentReceived" xlink:label="asnd_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:label="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpfrontFeeForExclusiveLicense" xlink:label="asnd_UpfrontFeeForExclusiveLicense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived" xlink:label="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SalesMilestonesReceived" xlink:label="asnd_SalesMilestonesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_RevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_NovoNordiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_LicensesOfIpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_Revenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_VISENPharmaceuticalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_ThirdPartyInvestorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_MilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_NumberOfCommercialCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_PerformanceObligationsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_TeijinMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_RoyaltiesAndMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_LicensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_CounterpartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_UpfrontFeeForExclusiveLicense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_RevenueTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_SalesMilestonesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_CapitalCommitmentFromInvestors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfReportableOperatingSegments" xlink:label="asnd_NumberOfReportableOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_NumberOfReportableOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="ifrs-full_CountryOfDomicileMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:label="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NorthAmerica1Member" xlink:label="asnd_NorthAmerica1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Germany1Member" xlink:label="asnd_Germany1Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_CountryOfDomicileMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_EuropeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="asnd_NorthAmerica1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="asnd_Germany1Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="ifrs-full_CountryOfDomicileMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:label="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_CountryOfDomicileMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BoardOfDirectorsMember" xlink:label="asnd_BoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ResearchAndDevelopmentCostsMember" xlink:label="asnd_ResearchAndDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExecutiveBoardMember" xlink:label="asnd_ExecutiveBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NonexecutiveseniorManagementMember" xlink:label="asnd_NonexecutiveseniorManagementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSalesMember" xlink:label="ifrs-full_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense" xlink:label="ifrs-full_OtherEmployeeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageNumberOfEmployees" xlink:label="ifrs-full_AverageNumberOfEmployees"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_WagesAndSalaries" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_BoardOfDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="asnd_ResearchAndDevelopmentCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_ExecutiveBoardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_NonexecutiveseniorManagementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_SocialSecurityContributions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_OtherEmployeeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_EmployeeBenefitsExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_AverageNumberOfEmployees" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfEmployees1" xlink:label="asnd_NumberOfEmployees1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BoardOfDirectorsMember" xlink:label="asnd_BoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExecutiveBoardMember" xlink:label="asnd_ExecutiveBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="asnd_NumberOfEmployees1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_BoardOfDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsLineItems" xlink:to="ifrs-full_NumberOfEmployees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_ExecutiveBoardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CategoriesOfSharesBasedPaymentsDomain" xlink:label="asnd_CategoriesOfSharesBasedPaymentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WarrantsGranted2012UntilNovember2021Member" xlink:label="asnd_WarrantsGranted2012UntilNovember2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ClassificationOfRelatedPartyDomain" xlink:label="asnd_ClassificationOfRelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BoardMembersOfGroupMember" xlink:label="asnd_BoardMembersOfGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ClassificationOfRelatedPartyAxis" xlink:label="asnd_ClassificationOfRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ClassificationOfRelatedPartyDomain" xlink:label="asnd_ClassificationOfRelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate" xlink:label="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CategoriesOfSharesBasedPaymentsAxis" xlink:label="asnd_CategoriesOfSharesBasedPaymentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CategoriesOfSharesBasedPaymentsDomain" xlink:label="asnd_CategoriesOfSharesBasedPaymentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WarrantsGrantedFromDecember2021Member" xlink:label="asnd_WarrantsGrantedFromDecember2021Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitProgramMember" xlink:label="asnd_PerformanceStockUnitProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EmployeesAndConsultantsMember" xlink:label="asnd_EmployeesAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PercentageOfWarrantsVested" xlink:label="asnd_PercentageOfWarrantsVested"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfAdditionalSharesGranted" xlink:label="asnd_NumberOfAdditionalSharesGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfAdditionalSharesAuthorizedToGrant" xlink:label="asnd_NumberOfAdditionalSharesAuthorizedToGrant"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementVestingPeriod" xlink:label="asnd_SharebasedPaymentArrangementVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:label="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_CategoriesOfSharesBasedPaymentsDomain" xlink:to="asnd_WarrantsGranted2012UntilNovember2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_BoardMembersOfGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ClassificationOfRelatedPartyAxis" xlink:to="asnd_ClassificationOfRelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_ClassificationOfRelatedPartyAxis" xlink:to="asnd_ClassificationOfRelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_MaturityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_CategoriesOfSharesBasedPaymentsAxis" xlink:to="asnd_CategoriesOfSharesBasedPaymentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_CategoriesOfSharesBasedPaymentsAxis" xlink:to="asnd_CategoriesOfSharesBasedPaymentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_CategoriesOfSharesBasedPaymentsDomain" xlink:to="asnd_WarrantsGrantedFromDecember2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_EmployeesAndConsultantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ClassificationOfRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_CategoriesOfSharesBasedPaymentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_PercentageOfWarrantsVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_NumberOfAdditionalSharesGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_NumberOfAdditionalSharesAuthorizedToGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_SharebasedPaymentArrangementVestingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyThreeMember" xlink:label="asnd_TwoThousandAndTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VestingOfSharesAxis" xlink:label="asnd_VestingOfSharesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyFourMember" xlink:label="asnd_TwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyFiveMember" xlink:label="asnd_TwoThousandAndTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentySevenMember" xlink:label="asnd_TwoThousandAndTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_VestingOfSharesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_USDollarsMember" xlink:label="asnd_USDollarsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="asnd_USDollarsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_CurrencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_default" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedBeforeJanuary12022Member" xlink:label="asnd_GrantedBeforeJanuary12022Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_YearOfGrantOfWarrants" xlink:label="asnd_YearOfGrantOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedIn2022Member" xlink:label="asnd_GrantedIn2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedIn2023Member" xlink:label="asnd_GrantedIn2023Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_GrantedInTwoThousandTwentyFourMember" xlink:label="asnd_GrantedInTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:label="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_GrantedBeforeJanuary12022Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_YearOfGrantOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_GrantedIn2022Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_GrantedIn2023Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_GrantedInTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueOfWarrantsGranted" xlink:label="asnd_FairValueOfWarrantsGranted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_FairValueOfWarrantsGranted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="ifrs-full_GoodwillMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="ifrs-full_AccumulatedImpairmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="ifrs-full_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsAndGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="ifrs-full_GoodwillMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedImpairmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="ifrs-full_ComputerSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisposalsIntangibleAssetsAndGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PlantAndMachineryMember" xlink:label="asnd_PlantAndMachineryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="asnd_PlantAndMachineryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_RightofuseAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" xlink:label="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:label="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSalesMember" xlink:label="ifrs-full_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ResearchAndDevelopmentCostsMember" xlink:label="asnd_ResearchAndDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" xlink:to="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:to="ifrs-full_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" xlink:to="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:to="asnd_ResearchAndDevelopmentCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfAssociateLineItems" xlink:label="asnd_DisclosureOfAssociateLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VISENPharmaceuticalMember" xlink:label="asnd_VISENPharmaceuticalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="ifrs-full_ConsiderationPaidReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EyconisMember" xlink:label="asnd_EyconisMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EyconisIncMember" xlink:label="asnd_EyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInAssociate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_VISENPharmaceuticalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_EyconisMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="asnd_CapitalCommitmentFromInvestors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_EyconisIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfAssociateLineItems" xlink:to="ifrs-full_ProportionOfVotingPowerHeldInAssociate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:label="asnd_DisclosureOfAssociatesAndJointVenturesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TransactionsAndOutstandingBalancesAbstract" xlink:label="asnd_TransactionsAndOutstandingBalancesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SaleOfGoodsAndServicesToAssociate" xlink:label="asnd_SaleOfGoodsAndServicesToAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AssociateAbstract" xlink:label="asnd_AssociateAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAbstract" xlink:label="ifrs-full_ProfitLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProfitLossForTheYear" xlink:label="asnd_ProfitLossForTheYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssociatesMember" xlink:label="ifrs-full_AssociatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_TransactionsAndOutstandingBalancesAbstract" xlink:to="asnd_SaleOfGoodsAndServicesToAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="asnd_AssociateAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="asnd_ProfitLossForTheYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="ifrs-full_AssociatesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_AssociateAbstract" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_TransactionsAndOutstandingBalancesAbstract" xlink:to="ifrs-full_TradeReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="ifrs-full_ProfitLossAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ComprehensiveIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_AssociateAbstract" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_TransactionsAndOutstandingBalancesAbstract" xlink:to="ifrs-full_ContractLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" xlink:to="asnd_TransactionsAndOutstandingBalancesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Equity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SummaryOfInventoryDisclosureLineItems" xlink:label="asnd_SummaryOfInventoryDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SummaryOfInventoryDisclosureTable" xlink:label="asnd_SummaryOfInventoryDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WorkInProgress" xlink:label="ifrs-full_WorkInProgress"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods" xlink:label="ifrs-full_FinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoriesTotal" xlink:label="ifrs-full_InventoriesTotal"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="asnd_SummaryOfInventoryDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="ifrs-full_WorkInProgress" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="ifrs-full_FinishedGoods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SummaryOfInventoryDisclosureLineItems" xlink:to="ifrs-full_InventoriesTotal" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractLiabilitiesLineItems" xlink:label="asnd_ContractLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractLiabilitiestableTable" xlink:label="asnd_ContractLiabilitiestableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyTwoMember" xlink:label="asnd_TwoThousandAndTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" xlink:label="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Revenuerecognizedfromcontractliabilities" xlink:label="asnd_Revenuerecognizedfromcontractliabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_ContractLiabilitiesLineItems" xlink:to="asnd_ContractLiabilitiestableTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ContractLiabilitiesLineItems" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="asnd_TwoThousandAndTwentyTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_ContractLiabilitiestableTable" xlink:to="ifrs-full_MaturityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ContractLiabilitiesLineItems" xlink:to="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_ContractLiabilitiestableTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ContractLiabilitiesLineItems" xlink:to="asnd_Revenuerecognizedfromcontractliabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain" xlink:label="ifrs-full_HedgingInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyConversionOptionMember" xlink:label="asnd_ForeignCurrencyConversionOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativesMember" xlink:label="ifrs-full_DerivativesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain" xlink:label="ifrs-full_UnobservableInputsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="ifrs-full_HedgingInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain" xlink:label="ifrs-full_HedgingInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="ifrs-full_ClassesOfAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_OfficeFacilityMember" xlink:label="asnd_OfficeFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain" xlink:label="ifrs-full_UnobservableInputsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharePriceMeasurementInputMember" xlink:label="asnd_SharePriceMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConversionRatePerNote" xlink:label="asnd_ConversionRatePerNote"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsRedemptionPeriod" xlink:label="asnd_BorrowingsRedemptionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsConditionForRedemption" xlink:label="asnd_BorrowingsConditionForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueOfConvertibleNotes" xlink:label="asnd_FairValueOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPaymentBeginningPeriod" xlink:label="asnd_RoyaltyPaymentBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueOfRoyaltyFundingLiabilities" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LeaseExtensionPeriod" xlink:label="asnd_LeaseExtensionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EnforceableLeaseterm" xlink:label="asnd_EnforceableLeaseterm"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ExpectedLeaseCommenceYear" xlink:label="asnd_ExpectedLeaseCommenceYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="ifrs-full_CashOutflowForLeases"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SharePriceAppliedForValuation" xlink:label="asnd_SharePriceAppliedForValuation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" xlink:label="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_DK" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="asnd_EventsAfterReportingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_HedgingInstrumentsDomain" xlink:to="asnd_ForeignCurrencyConversionOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="ifrs-full_DerivativesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="asnd_OfficeFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FixedInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_DE" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="asnd_SharePriceMeasurementInputMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsMaturity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesSkytrofaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsInArrearsDefaultPaymentStartDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionRatePerNote" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_HedgingInstrumentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsRedemptionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsConditionForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_UnobservableInputsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdTradingDaysForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfConvertibleNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentBeginningPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentEndingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_CarryingAmountOfRoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfRoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_LeaseExtensionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_EnforceableLeaseterm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExpectedLeaseCommenceYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_SharePriceAppliedForValuation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReceivablesDueFromAssociates" xlink:label="ifrs-full_ReceivablesDueFromAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_TradeReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_ReceivablesDueFromAssociates" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CurrentFinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CurrentFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="asnd_MarketableSecuritiesExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LeaseExpenses" xlink:label="asnd_LeaseExpenses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="asnd_LeaseExpenses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="ifrs-full_LongtermBorrowingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" xlink:label="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="ifrs-full_LongtermBorrowingsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="ifrs-full_LeaseLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="ifrs-full_MeasurementDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FairValueHierarchyCarryingAmountMember" xlink:label="asnd_FairValueHierarchyCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="ifrs-full_MeasurementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndDebenturesIssued" xlink:label="ifrs-full_NotesAndDebenturesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="asnd_MarketableSecuritiesExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MeasurementDomain" xlink:to="asnd_FairValueHierarchyCarryingAmountMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_MeasurementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NotesAndDebenturesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MeasurementDomain" xlink:to="ifrs-full_AtFairValueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskAxis" xlink:label="asnd_ForeignCurrencyRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyTargetPercentage" xlink:label="asnd_ForeignCurrencyTargetPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRateRiskMember" xlink:label="ifrs-full_InterestRateRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_DKK" xlink:label="currency_DKK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RealizedDurationOfFinancialAssetsExplanatory" xlink:label="asnd_RealizedDurationOfFinancialAssetsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_ForeignCurrencyRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ForeignCurrencyTargetPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_InterestRateRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="currency_DKK" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FixedInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_LiquidityRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RealizedDurationOfFinancialAssetsExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PurchaseOfTreasurySharesNominalValue" xlink:label="asnd_PurchaseOfTreasurySharesNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_TreasurySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="ifrs-full_TreasuryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_PurchaseOfTreasurySharesNominalValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskAxis" xlink:label="asnd_ForeignCurrencyRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_NominalValueAmount" xlink:label="asnd_NominalValueAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UsDollarsToEuroMember" xlink:label="asnd_UsDollarsToEuroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_BritishPoundsToEuroMember" xlink:label="asnd_BritishPoundsToEuroMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_IncreaseDecreaseInForeignCurrencyExchangeRate" xlink:label="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_SwissFrancToEuroMember" xlink:label="asnd_SwissFrancToEuroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_ForeignCurrencyRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_NominalValueAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="asnd_UsDollarsToEuroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="asnd_BritishPoundsToEuroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="asnd_SwissFrancToEuroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="ifrs-full_FloatingInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAvailableforsale" xlink:label="ifrs-full_FinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ZeroCouponMember" xlink:label="asnd_ZeroCouponMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="ifrs-full_FinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FloatingInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="ifrs-full_FinancialAssetsAvailableforsale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtFairValueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FixedInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="asnd_ZeroCouponMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:label="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExternalCreditGradesDomain" xlink:label="ifrs-full_ExternalCreditGradesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExternalCreditGradesDomain" xlink:label="ifrs-full_ExternalCreditGradesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Prime1Member" xlink:label="asnd_Prime1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_HighGradeMember" xlink:label="asnd_HighGradeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAvailableforsale" xlink:label="ifrs-full_FinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UpperMediumGradeMember" xlink:label="asnd_UpperMediumGradeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LowerMediumGradeMember" xlink:label="asnd_LowerMediumGradeMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" xlink:to="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_ExternalCreditGradesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_ExternalCreditGradesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExternalCreditGradesDomain" xlink:to="asnd_Prime1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" xlink:to="ifrs-full_FinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_CreditRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:to="ifrs-full_TypesOfRisksAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExternalCreditGradesDomain" xlink:to="asnd_HighGradeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" xlink:to="ifrs-full_FinancialAssetsAvailableforsale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:to="ifrs-full_ExternalCreditGradesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtFairValueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExternalCreditGradesDomain" xlink:to="asnd_UpperMediumGradeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExternalCreditGradesDomain" xlink:to="asnd_LowerMediumGradeMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAvailableforsale" xlink:label="ifrs-full_FinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UsTreasuryBillsMember" xlink:label="asnd_UsTreasuryBillsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_UsGovernmentBondsMember" xlink:label="asnd_UsGovernmentBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:label="ifrs-full_CurrentFinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CommercialPapersMember" xlink:label="asnd_CommercialPapersMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CorporateBondsMember" xlink:label="asnd_CorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AgencyBondsMember" xlink:label="asnd_AgencyBondsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:to="ifrs-full_FinancialAssetsAvailableforsale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_LiquidityRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_UsTreasuryBillsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:to="ifrs-full_NoncurrentFinancialAssetsAvailableforsale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_UsGovernmentBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtFairValueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" xlink:to="ifrs-full_CurrentFinancialAssetsAvailableforsale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" xlink:to="ifrs-full_TypesOfRisksAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_CommercialPapersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_CorporateBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="asnd_AgencyBondsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_Borrowings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_NotLaterThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_LeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="asnd_ContractualUndiscountedCashflowOfBorrowings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfCommitmentsAndContingenciesTable" xlink:label="asnd_DisclosureOfCommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractualCapitalCommitments" xlink:label="ifrs-full_ContractualCapitalCommitments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="asnd_DisclosureOfCommitmentsAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="ifrs-full_ContractualCapitalCommitments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaGmbHMember" xlink:label="asnd_AscendisPharmaGmbHMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_VISENPharmaceuticalMember" xlink:label="asnd_VISENPharmaceuticalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="ifrs-full_NameOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEndocrinologyGmbhMember" xlink:label="asnd_AscendisPharmaEndocrinologyGmbhMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EyconisIncMember" xlink:label="asnd_EyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaIncMember" xlink:label="asnd_AscendisPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEndocrinologyIncMember" xlink:label="asnd_AscendisPharmaEndocrinologyIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfAssociate" xlink:label="ifrs-full_NameOfAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaOphthalmologyDivisionASMember" xlink:label="asnd_AscendisPharmaOphthalmologyDivisionASMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEndocrinologyDivisionASMember" xlink:label="asnd_AscendisPharmaEndocrinologyDivisionASMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaBoneDiseaseASMember" xlink:label="asnd_AscendisPharmaBoneDiseaseASMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaGrowthDisordersASMember" xlink:label="asnd_AscendisPharmaGrowthDisordersASMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaOncologyDivisionAsMember" xlink:label="asnd_AscendisPharmaOncologyDivisionAsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaEuropeASMember" xlink:label="asnd_AscendisPharmaEuropeASMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaUkLimitedMember" xlink:label="asnd_AscendisPharmaUkLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaIberiaSLMember" xlink:label="asnd_AscendisPharmaIberiaSLMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaFranceSasuMember" xlink:label="asnd_AscendisPharmaFranceSasuMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaItaliaSrlMember" xlink:label="asnd_AscendisPharmaItaliaSrlMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaSverigeAbMember" xlink:label="asnd_AscendisPharmaSverigeAbMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AscendisPharmaSwitzerlandGmbhMember" xlink:label="asnd_AscendisPharmaSwitzerlandGmbhMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaGmbHMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_VISENPharmaceuticalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_NameOfSubsidiary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaEndocrinologyGmbhMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="asnd_EyconisIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaEndocrinologyIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_NameOfAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaOphthalmologyDivisionASMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaEndocrinologyDivisionASMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaBoneDiseaseASMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaGrowthDisordersASMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaOncologyDivisionAsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaEuropeASMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaUkLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaIberiaSLMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaFranceSasuMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaItaliaSrlMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaSverigeAbMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="asnd_AscendisPharmaSwitzerlandGmbhMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:label="asnd_DisclosureOfBeneficialOwnershipLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DisclosureOfBeneficialOwnershipTable" xlink:label="asnd_DisclosureOfBeneficialOwnershipTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MinimumBeneficialOwnershipPercentage" xlink:label="asnd_MinimumBeneficialOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember" xlink:label="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership" xlink:label="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_WestfieldCapitalManagementCompanyLPUsaMember" xlink:label="asnd_WestfieldCapitalManagementCompanyLPUsaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfJointOperation" xlink:label="ifrs-full_NameOfJointOperation"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithFmrLlcMember" xlink:label="asnd_EntitiesAffiliatedWithFmrLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AvoroCapitalAdvisorsLlcMember" xlink:label="asnd_AvoroCapitalAdvisorsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember" xlink:label="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember" xlink:label="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:to="asnd_DisclosureOfBeneficialOwnershipTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:to="asnd_MinimumBeneficialOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfBeneficialOwnershipTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_GB" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:to="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfBeneficialOwnershipTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_WestfieldCapitalManagementCompanyLPUsaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfBeneficialOwnershipLineItems" xlink:to="ifrs-full_NameOfJointOperation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_EntitiesAffiliatedWithFmrLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_AvoroCapitalAdvisorsLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_FrazierLifeSciencesOfEyconisIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="asnd_EventsAfterReportingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_CounterpartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_CapitalCommitmentFromInvestors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceCosts" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_Revenue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncome" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="asnd_ConvertibleNotesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_ConvertibleNotesCurrent" xlink:to="ifrs-full_ShorttermBorrowings" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="asnd_ShortTermBorrowingOther" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="asnd_DistributableEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_ConvertibleNotesCurrent" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentReceivables" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_InvestmentsInAssociates" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_LongtermBorrowings" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="asnd_MarketableSecuritiesNonCurrentAssets" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="asnd_MarketableSecurities1" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentProvisions" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentPrepayments" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentReceivables" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTradeReceivables" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleNotesCurrent" xlink:label="asnd_ConvertibleNotesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ShortTermBorrowingOther" xlink:label="asnd_ShortTermBorrowingOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DistributableEquity" xlink:label="asnd_DistributableEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates" xlink:label="ifrs-full_InvestmentsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecuritiesNonCurrentAssets" xlink:label="asnd_MarketableSecuritiesNonCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="ifrs-full_OtherNoncurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_ProfitLoss" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_FinanceIncome" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_FinanceCosts" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ShareIssueRelatedCost" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfInterestsInAssociates" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="15" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForProvisions" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense" order="17" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="18" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" xlink:label="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ReversalOfGainLossOnPropertyPlantAndEquipment" xlink:label="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInAssociates" xlink:label="ifrs-full_PurchaseOfInterestsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_RevenueFromRenderingOfServices" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="asnd_RevenueFromClinicalSupply" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_LicenceFeeIncome" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RevenueFromClinicalSupply" xlink:label="asnd_RevenueFromClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_WagesAndSalaries" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_SocialSecurityContributions" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_OtherEmployeeExpense" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense" xlink:label="ifrs-full_OtherEmployeeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemunerationForAuditServices" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="asnd_Audit-RelatedFees" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemunerationForTaxServices" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemunerationForOtherServices" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemuneration" xlink:label="ifrs-full_AuditorsRemuneration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_Audit-RelatedFees" xlink:label="asnd_Audit-RelatedFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForTaxServices" xlink:label="ifrs-full_AuditorsRemunerationForTaxServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="asnd_TaxEffectOfDeductibleItemsNotExpensed" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="asnd_DeferredTaxMovementForTheYear" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="asnd_TaxEffectsOfDeductibleItemsNotExpensed" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="asnd_TaxEffectsFromImpactsFromAssociates" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="asnd_TaxEffectsFromPriorYearAdjustment" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="asnd_TaxEffectFromDeferredTaxAssetNotRecognized" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectOfDeductibleItemsNotExpensed" xlink:label="asnd_TaxEffectOfDeductibleItemsNotExpensed"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DeferredTaxMovementForTheYear" xlink:label="asnd_DeferredTaxMovementForTheYear"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectsOfDeductibleItemsNotExpensed" xlink:label="asnd_TaxEffectsOfDeductibleItemsNotExpensed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:label="ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectsFromImpactsFromAssociates" xlink:label="asnd_TaxEffectsFromImpactsFromAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectsFromPriorYearAdjustment" xlink:label="asnd_TaxEffectsFromPriorYearAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_TaxEffectFromDeferredTaxAssetNotRecognized" xlink:label="asnd_TaxEffectFromDeferredTaxAssetNotRecognized"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_FinishedGoods" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_WorkInProgress" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoriesTotal" xlink:label="ifrs-full_InventoriesTotal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods" xlink:label="ifrs-full_FinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WorkInProgress" xlink:label="ifrs-full_WorkInProgress"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_ReceivablesDueFromAssociates" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_LeaseLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_CurrentFinancialLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_TradeReceivables" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="asnd_ConvertibleSeniorNotes" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_OtherReceivables" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_OtherFinancialLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="asnd_MarketableSecuritiesExplanatory" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="asnd_RoyaltyFundingLiabilities" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReceivablesDueFromAssociates" xlink:label="ifrs-full_ReceivablesDueFromAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_NetForeignExchangeGain" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_InterestExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_RevenueFromInterest" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_LossesOnChangeInFairValueOfDerivatives" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_NetForeignExchangeLoss" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_LeaseExpenses" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_LeaseExpenses" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_LeaseExpenses" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_LeaseExpenses" xlink:label="asnd_LeaseExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfBorrowings" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_Borrowings" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_LeaseLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_TradeAndOtherPayables" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20241231.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="asnd_NumberOfReportableOperatingSegments" name="NumberOfReportableOperatingSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" name="TreasurySharesHoldingInPercentageOfTotalOutstandingShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_CommercialCustomersMember" name="CommercialCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" name="ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" name="UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" name="DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_LicensesOfIpMember" name="LicensesOfIpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_Revenuerecognizedfromcontractliabilities" name="Revenuerecognizedfromcontractliabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TeijinMember" name="TeijinMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" name="DisclosureOfRevenueToCommercialCustomersExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" name="ExchangeRateForPercentageOfRevenueToRoyaltyPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory" name="DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory" name="DisclosureOfForeignCurrencySensitivityAnalysisExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_Germany1Member" name="Germany1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_UnitedStatesYorvipathMember" name="UnitedStatesYorvipathMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SalesDeductionsAndProductReturnsInUSMarketMember" name="SalesDeductionsAndProductReturnsInUSMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TaxEffectsOfDeductibleItemsNotExpensed" name="TaxEffectsOfDeductibleItemsNotExpensed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfEmployeeCompensationCostsLineItems" name="DisclosureOfEmployeeCompensationCostsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" name="TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory" name="DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RestOfWorldMember" name="RestOfWorldMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TwoThousandAndTwentySevenMember" name="TwoThousandAndTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TransactionsAndOutstandingBalancesAbstract" name="TransactionsAndOutstandingBalancesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_YearOfGrantOfWarrants" name="YearOfGrantOfWarrants" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfHoldingOfTreasurySharesTable" name="DisclosureOfHoldingOfTreasurySharesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CategoriesOfSharesBasedPaymentsAxis" name="CategoriesOfSharesBasedPaymentsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyFundingLiabilities" name="RoyaltyFundingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DeferredTaxAssetNotRecognized" name="DeferredTaxAssetNotRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_SalesMilestonesReceived" name="SalesMilestonesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ThirdPartyInvestorsMember" name="ThirdPartyInvestorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfCommitmentsAndContingenciesTable" name="DisclosureOfCommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_LeaseExtensionPeriod" name="LeaseExtensionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_UpfrontFeeForExclusiveLicense" name="UpfrontFeeForExclusiveLicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract" name="DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CapitalCommitmentFromInvestors" name="CapitalCommitmentFromInvestors" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties" name="TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_CommercialPapersMember" name="CommercialPapersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" name="WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ConvertibleDebtCurrentAbstract" name="ConvertibleDebtCurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" name="WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfAssociatesAndJointVenturesLineItems" name="DisclosureOfAssociatesAndJointVenturesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ForeignCurrencyRiskAxis" name="ForeignCurrencyRiskAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaGmbHMember" name="AscendisPharmaGmbHMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_GrantedBeforeJanuary12022Member" name="GrantedBeforeJanuary12022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PerformanceStockUnitsMember" name="PerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PerformanceStockUnitProgramMember" name="PerformanceStockUnitProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_MarketableSecuritiesNonCurrentAssets" name="MarketableSecuritiesNonCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfGeneralInformationAbstract" name="DisclosureOfGeneralInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NominalValueAmount" name="NominalValueAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_OtherEquipmentMember" name="OtherEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfBeneficialOwnershipAbstract" name="DisclosureOfBeneficialOwnershipAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" name="DisclosureOfHoldingOfTreasurySharesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" name="MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_InventoriesAbstract" name="InventoriesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AmericanDepositorySharesMember" name="AmericanDepositorySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_GrantedIn2022Member" name="GrantedIn2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" name="PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_UsTreasuryBillsMember" name="UsTreasuryBillsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" name="ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_NonexecutiveseniorManagementMember" name="NonexecutiveseniorManagementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TwoThousandAndTwentyThreeMember" name="TwoThousandAndTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SummaryOfInventoryDisclosureLineItems" name="SummaryOfInventoryDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyPharmaMember" name="RoyaltyPharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SaleOfGoodsAndServicesToAssociate" name="SaleOfGoodsAndServicesToAssociate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable" name="DisclosureOfDetailedInformationAboutDepreciationsChargesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" name="IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AscendisPharmaSverigeAbMember" name="AscendisPharmaSverigeAbMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NetSettlementUnderStockIncentivePrograms" name="NetSettlementUnderStockIncentivePrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_RoyaltiesAndMilestonesMember" name="RoyaltiesAndMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaEndocrinologyIncMember" name="AscendisPharmaEndocrinologyIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_USDollarsMember" name="USDollarsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfHoldingOfTreasurySharesAbstract" name="DisclosureOfHoldingOfTreasurySharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AdditionalTaxDeductionsRelatedToTaxCredits" name="AdditionalTaxDeductionsRelatedToTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_BorrowingsInArrearsDefaultPaymentStartDate" name="BorrowingsInArrearsDefaultPaymentStartDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" name="ReimbursementFromAcquisitionOfPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" name="AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_UnitedStatesSkytrofaMember" name="UnitedStatesSkytrofaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AmericanDepositarySharesMember" name="AmericanDepositarySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" name="WeightedAverageDurationOfMarketableSecuritiesExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AscendisPharmaOphthalmologyDivisionASMember" name="AscendisPharmaOphthalmologyDivisionASMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock" name="DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_Audit-RelatedFees" name="Audit-RelatedFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis" name="StatementOfComprehensiveIncomeProfitOrLossLocationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TaxEffectOfDeductibleItemsNotExpensed" name="TaxEffectOfDeductibleItemsNotExpensed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory" name="DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AscendisPharmaOncologyDivisionAsMember" name="AscendisPharmaOncologyDivisionAsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfAdditionalSharesAuthorizedToGrant" name="NumberOfAdditionalSharesAuthorizedToGrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember" name="EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_EyconisIncMember" name="EyconisIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CorporateBondsMember" name="CorporateBondsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SummaryOfInventoryDisclosureTable" name="SummaryOfInventoryDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_FrazierLifeSciencesOfEyconisIncMember" name="FrazierLifeSciencesOfEyconisIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock" name="ContractualCashflowsForFinancialLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_EventsAfterReportingPeriodMember" name="EventsAfterReportingPeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractLiabilitiesLineItems" name="ContractLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaFranceSasuMember" name="AscendisPharmaFranceSasuMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_LicensesMember" name="LicensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfCommercialCustomers" name="NumberOfCommercialCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" name="IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_LeaseExpenses" name="LeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" name="DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" name="IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_AvoroCapitalAdvisorsLlcMember" name="AvoroCapitalAdvisorsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConvertibleSeniorNotesMember" name="ConvertibleSeniorNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements" name="DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_FinanceIncomeAbstract" name="FinanceIncomeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyPaymentEndingPeriod" name="RoyaltyPaymentEndingPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" name="BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_FinanceIncomeExpenseAbstract" name="FinanceIncomeExpenseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_LowerMediumGradeMember" name="LowerMediumGradeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_MarketableSecurities1" name="MarketableSecurities1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_NorthAmerica1Member" name="NorthAmerica1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_VestingMember" name="VestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" name="DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RevenueFromClinicalSupply" name="RevenueFromClinicalSupply" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_RevenueTable" name="RevenueTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" name="ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_NumberOfEmployees1" name="NumberOfEmployees1" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RoyaltyPaymentBeginningPeriod" name="RoyaltyPaymentBeginningPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" name="DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_VISENPharmaceuticalMember" name="VISENPharmaceuticalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" name="AdjustmentsForNonCashConsiderationRegardingRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_MilestonesMember" name="MilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DescriptionOfBasisOfConsolidationExplanatory" name="DescriptionOfBasisOfConsolidationExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" name="DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" name="DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_BorrowingsConditionForRedemption" name="BorrowingsConditionForRedemption" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember" name="StatementOfComprehensiveIncomeProfitOrLossLocationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AgencyBondsMember" name="AgencyBondsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaGrowthDisordersASMember" name="AscendisPharmaGrowthDisordersASMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfAdditionalSharesGranted" name="NumberOfAdditionalSharesGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TaxEffectFromDeferredTaxAssetNotRecognized" name="TaxEffectFromDeferredTaxAssetNotRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_RestrictedStockUnitsMember" name="RestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" name="WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AssociateAbstract" name="AssociateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" name="DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember" name="EntitiesAffiliatedWithJanusHendersonGroupPlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaSwitzerlandGmbhMember" name="AscendisPharmaSwitzerlandGmbhMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" name="DisclosureOfSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory" name="DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementVestingPeriod" name="SharebasedPaymentArrangementVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable" name="DisclosureDetailedInformationAboutMarketableSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfEmployeeCompensationCostsAbstract" name="DisclosureOfEmployeeCompensationCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory" name="DescriptionOfAccountingPolicyForPrepaymentsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TwoThousandAndTwentyFiveMember" name="TwoThousandAndTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_FairValueOfWarrantsGranted" name="FairValueOfWarrantsGranted" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_FairValueHierarchyCarryingAmountMember" name="FairValueHierarchyCarryingAmountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" name="DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" name="ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ConversionRatePerNote" name="ConversionRatePerNote" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" name="MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ProcessPlantAndMachineryMember" name="ProcessPlantAndMachineryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RealizedDurationOfFinancialAssetsExplanatory" name="RealizedDurationOfFinancialAssetsExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_HighGradeMember" name="HighGradeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractLiabilitiestableTable" name="ContractLiabilitiestableTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaEndocrinologyGmbhMember" name="AscendisPharmaEndocrinologyGmbhMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TwoThousandAndTwentyFourMember" name="TwoThousandAndTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_VestingOfSharesAxis" name="VestingOfSharesAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CollaborationPartnersAndLicenseAgreementsMember" name="CollaborationPartnersAndLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DeferredTaxMovementForTheYear" name="DeferredTaxMovementForTheYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfBeneficialOwnershipTable" name="DisclosureOfBeneficialOwnershipTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BorrowingsThresholdTradingDaysForRedemption" name="BorrowingsThresholdTradingDaysForRedemption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_EnforceableLeaseterm" name="EnforceableLeaseterm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfBeneficialOwnershipExplanatory" name="DisclosureOfBeneficialOwnershipExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ProfitLossBeforeIncomeTaxAbstract" name="ProfitLossBeforeIncomeTaxAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ChangesInWorkingCapitalAbstract" name="ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" name="IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_IncomeStatementDomain" name="IncomeStatementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CarryingAmountOfRoyaltyFundingLiabilities" name="CarryingAmountOfRoyaltyFundingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" name="IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_AscendisPharmaItaliaSrlMember" name="AscendisPharmaItaliaSrlMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PlantAndMachineryMember" name="PlantAndMachineryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_Prime1Member" name="Prime1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DecreaseInTaxLosseCarryForwards" name="DecreaseInTaxLosseCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges" name="DisclosureOfDetailedInformationAboutDepreciationsCharges" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfEmployeeCompensationCostsTable" name="DisclosureOfEmployeeCompensationCostsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" name="ContractualUndiscountedCashflowOfFinancialLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_EyconisMember" name="EyconisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_OtherCurrentLiabilitiesAbstract" name="OtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ProfitLossForTheYear" name="ProfitLossForTheYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_EmployeesAndConsultantsMember" name="EmployeesAndConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ShortTermBorrowingOther" name="ShortTermBorrowingOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TaxLossesCarryforwards" name="TaxLossesCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" name="DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TwoThousandAndTwentySixMember" name="TwoThousandAndTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory" name="DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock" name="DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" name="ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ClassificationOfRelatedPartyDomain" name="ClassificationOfRelatedPartyDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock" name="DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_NumberOfTreasurySharesOutstanding" name="NumberOfTreasurySharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory" name="DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfBeneficialOwnershipLineItems" name="DisclosureOfBeneficialOwnershipLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" name="TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_ReserveOfTreasuryShares" name="ReserveOfTreasuryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_BritishPoundsToEuroMember" name="BritishPoundsToEuroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConversionPricePerShare" name="ConversionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" name="DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_NovoNordiskMember" name="NovoNordiskMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" name="PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AdditionalFutureTaxDeduction" name="AdditionalFutureTaxDeduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_GrantedInTwoThousandTwentyFourMember" name="GrantedInTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SharePriceAppliedForValuation" name="SharePriceAppliedForValuation" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" name="BorrowingsThresholdConsecutiveTradingDaysForRedemption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_Warrant1Member" name="Warrant1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" name="DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DistributableEquity" name="DistributableEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_FairValueOfConvertibleNotes" name="FairValueOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" name="SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_InvestmentsInGroupEnterprisesAbstract" name="InvestmentsInGroupEnterprisesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" name="RoyaltyPharmaUnitedStatesSkytrofaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConvertibleNotesCurrent" name="ConvertibleNotesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" name="SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfSharebasedPaymentArrangementsAbstract" name="DisclosureOfSharebasedPaymentArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" name="PaymentOfWithholdingTaxesUnderStockIncentivePrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" name="DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConvertibleSeniorNotes" name="ConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock" name="DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_MinimumBeneficialOwnershipPercentage" name="MinimumBeneficialOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RevenueThresholdLimit" name="RevenueThresholdLimit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_SalesRebatesAndProductReturnsInUSMarketMember" name="SalesRebatesAndProductReturnsInUSMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_FundingReceivedInExchangeOfRoyaltyPayments" name="FundingReceivedInExchangeOfRoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ForeignCurrencyTargetPercentage" name="ForeignCurrencyTargetPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_BoardOfDirectorsMember" name="BoardOfDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" name="AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate" name="PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember" name="TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_GrantedIn2023Member" name="GrantedIn2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaUkLimitedMember" name="AscendisPharmaUkLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived" name="AdditionalDevelopmentAndRegulatoryMilestonesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_FairValueOfRoyaltyFundingLiabilities" name="FairValueOfRoyaltyFundingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock" name="DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ShortTermMarketableSecurities" name="ShortTermMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfWarrantActivityLineItems" name="DisclosureOfWarrantActivityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" name="AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ExpectedLeaseCommenceYear" name="ExpectedLeaseCommenceYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_CategoriesOfSharesBasedPaymentsDomain" name="CategoriesOfSharesBasedPaymentsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PurchaseOfTreasurySharesNominalValue" name="PurchaseOfTreasurySharesNominalValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_UsDollarsToEuroMember" name="UsDollarsToEuroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_UpperMediumGradeMember" name="UpperMediumGradeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaBoneDiseaseASMember" name="AscendisPharmaBoneDiseaseASMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember" name="EntitiesAffiliatedWithRaCapitalManagementLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfCommitmentsAndContingenciesLineItems" name="DisclosureOfCommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" name="DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_NumberOfWarrantsOutstanding" name="NumberOfWarrantsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" name="DisclosureDetailedInformationAboutMarketableSecuritiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ForeignCurrencyRiskDomain" name="ForeignCurrencyRiskDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" name="RestrictedStockUnitsAndPerformanceStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory" name="DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AscendisPharmaIncMember" name="AscendisPharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock" name="DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" name="SharebasedPaymentArrangementRestrictedStockUnitActivityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" name="IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership" name="MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_PercentageOfWarrantsVested" name="PercentageOfWarrantsVested" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TaxEffectsFromPriorYearAdjustment" name="TaxEffectsFromPriorYearAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_AscendisPharmaIberiaSLMember" name="AscendisPharmaIberiaSLMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaEndocrinologyDivisionASMember" name="AscendisPharmaEndocrinologyDivisionASMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_EntitiesAffiliatedWithFmrLlcMember" name="EntitiesAffiliatedWithFmrLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" name="IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_BorrowingsRedemptionPeriod" name="BorrowingsRedemptionPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" name="AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_FinanceExpensesAbstract" name="FinanceExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AscendisPharmaEuropeASMember" name="AscendisPharmaEuropeASMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ReversalOfGainLossOnPropertyPlantAndEquipment" name="ReversalOfGainLossOnPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_FundingReceivedInExchange" name="FundingReceivedInExchange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" name="ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_ExecutiveBoardMember" name="ExecutiveBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_MarketableSecuritiesExplanatory" name="MarketableSecuritiesExplanatory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementAwardTypeDomain" name="SharebasedPaymentArrangementAwardTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WarrantsGrantedFromDecember2021Member" name="WarrantsGrantedFromDecember2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncomeStatementAxis" name="IncomeStatementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WarrantCompensationCost" name="WarrantCompensationCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_TwoThousandAndTwentyTwoMember" name="TwoThousandAndTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" name="DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CostsOfCapitalIncreaseDecrease" name="CostsOfCapitalIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_BoardMembersOfGroupMember" name="BoardMembersOfGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" name="RoyaltyPharmaUnitedStatesYorvipathMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WestfieldCapitalManagementCompanyLPUsaMember" name="WestfieldCapitalManagementCompanyLPUsaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_UsGovernmentBondsMember" name="UsGovernmentBondsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ClassificationOfRelatedPartyAxis" name="ClassificationOfRelatedPartyAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AdditionalTaxDeduction" name="AdditionalTaxDeduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_ZeroCouponMember" name="ZeroCouponMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" name="WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ForeignCurrencyConversionOptionMember" name="ForeignCurrencyConversionOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SharePriceMeasurementInputMember" name="SharePriceMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TaxEffectsFromImpactsFromAssociates" name="TaxEffectsFromImpactsFromAssociates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_OfficeFacilityMember" name="OfficeFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WarrantsGranted2012UntilNovember2021Member" name="WarrantsGranted2012UntilNovember2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfBorrowings" name="ContractualUndiscountedCashflowOfBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" name="DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ShareBasedPaymentArrangementAwardTypeAxis" name="ShareBasedPaymentArrangementAwardTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ResearchAndDevelopmentCostsMember" name="ResearchAndDevelopmentCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfAssociateLineItems" name="DisclosureOfAssociateLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SwissFrancToEuroMember" name="SwissFrancToEuroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncreaseDecreaseInForeignCurrencyExchangeRate" name="IncreaseDecreaseInForeignCurrencyExchangeRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389745296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ASND<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ascendis Pharma A/S<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001612042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">60,689,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">G7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DK<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">DK-2900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Tuborg Boulevard 12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hellerup<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte Statsautoriseret Revisionspartnerselskab<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Copenhagen, Denmark<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated statements of financial position of Ascendis Pharma A/S and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of profit or (loss) and other comprehensive income or (loss), the consolidated statements of changes in equity, and the consolidated cash flow statements for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by COSO.</span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">DK-2900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Tuborg Boulevard 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hellerup<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Jan M&#248;ller Mikkelsen<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">70 22 22 44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=asnd_AmericanDepositarySharesMember', window );">American Depositary Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=asnd_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=asnd_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109379106896">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 363,641<span></span>
</td>
<td class="nump">&#8364; 266,718<span></span>
</td>
<td class="nump">&#8364; 51,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,258<span></span>
</td>
<td class="nump">44,395<span></span>
</td>
<td class="nump">12,137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">319,383<span></span>
</td>
<td class="nump">222,323<span></span>
</td>
<td class="nump">39,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">307,004<span></span>
</td>
<td class="nump">413,454<span></span>
</td>
<td class="nump">379,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">291,142<span></span>
</td>
<td class="nump">264,410<span></span>
</td>
<td class="nump">221,227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(278,763)<span></span>
</td>
<td class="num">(455,541)<span></span>
</td>
<td class="num">(561,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) of associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20,060)<span></span>
</td>
<td class="num">(18,395)<span></span>
</td>
<td class="num">(17,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,609<span></span>
</td>
<td class="nump">43,857<span></span>
</td>
<td class="nump">52,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,027<span></span>
</td>
<td class="nump">44,065<span></span>
</td>
<td class="nump">50,487<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit/(loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(373,241)<span></span>
</td>
<td class="num">(474,144)<span></span>
</td>
<td class="num">(577,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes (expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,843)<span></span>
</td>
<td class="num">(7,303)<span></span>
</td>
<td class="num">(5,377)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(378,084)<span></span>
</td>
<td class="num">(481,447)<span></span>
</td>
<td class="num">(583,194)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Attributable to owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (378,084)<span></span>
</td>
<td class="num">&#8364; (481,447)<span></span>
</td>
<td class="num">&#8364; (583,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings/(loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (6.53)<span></span>
</td>
<td class="num">&#8364; (8.55)<span></span>
</td>
<td class="num">&#8364; (10.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings/(loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (6.53)<span></span>
</td>
<td class="num">&#8364; (8.55)<span></span>
</td>
<td class="num">&#8364; (10.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Number of shares used for calculation (basic and diluted)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">57,891,570<span></span>
</td>
<td class="nump">56,287,060<span></span>
</td>
<td class="nump">56,071,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (378,084)<span></span>
</td>
<td class="num">&#8364; (481,447)<span></span>
</td>
<td class="num">&#8364; (583,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be reclassified subsequently to profit or (loss):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translating foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,062<span></span>
</td>
<td class="num">(2,731)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss) for the year, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,062<span></span>
</td>
<td class="num">(2,731)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(377,022)<span></span>
</td>
<td class="num">(484,178)<span></span>
</td>
<td class="num">(583,521)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Attributable to owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (377,022)<span></span>
</td>
<td class="num">&#8364; (484,178)<span></span>
</td>
<td class="num">&#8364; (583,521)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, a total of </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,204,122</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">6,523,784</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:8pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">6,864,011</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">575,000</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible senior notes which can potentially be converted into </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,456,785</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the years presented.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109381413248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfWarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">6,204,122<span></span>
</td>
<td class="nump">6,523,784<span></span>
</td>
<td class="nump">6,864,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares', window );">Convertible notes</a></td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfWarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">3,456,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential conversion of convertible senior notes into number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=asnd_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=asnd_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109379634480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="nump">&#8364; 4,028<span></span>
</td>
<td colspan="2" class="nump">&#8364; 4,419<span></span>
</td>
<td colspan="2" class="nump">&#8364; 4,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">98,714<span></span>
</td>
<td colspan="2" class="nump">110,634<span></span>
</td>
<td colspan="2" class="nump">129,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociates', window );">Investments in associates</a></td>
<td class="nump">13,575<span></span>
</td>
<td colspan="2" class="nump">5,686<span></span>
</td>
<td colspan="2" class="nump">22,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentReceivables', window );">Other receivables</a></td>
<td class="nump">2,317<span></span>
</td>
<td colspan="2" class="nump">2,127<span></span>
</td>
<td colspan="2" class="nump">1,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecuritiesNonCurrentAssets', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
<td colspan="2" class="nump">7,492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">118,634<span></span>
</td>
<td colspan="2" class="nump">122,866<span></span>
</td>
<td colspan="2" class="nump">166,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">295,609<span></span>
</td>
<td colspan="2" class="nump">208,931<span></span>
</td>
<td colspan="2" class="nump">130,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">166,280<span></span>
</td>
<td colspan="2" class="nump">35,874<span></span>
</td>
<td colspan="2" class="nump">11,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Income tax receivables</a></td>
<td class="nump">1,775<span></span>
</td>
<td colspan="2" class="nump">802<span></span>
</td>
<td colspan="2" class="nump">883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">9,385<span></span>
</td>
<td colspan="2" class="nump">19,097<span></span>
</td>
<td colspan="2" class="nump">12,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepayments</a></td>
<td class="nump">28,269<span></span>
</td>
<td colspan="2" class="nump">38,578<span></span>
</td>
<td colspan="2" class="nump">31,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecurities1', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">7,275<span></span>
</td>
<td colspan="2" class="nump">290,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">559,543<span></span>
</td>
<td colspan="2" class="nump">392,164<span></span>
</td>
<td colspan="2" class="nump">444,767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">1,060,861<span></span>
</td>
<td colspan="2" class="nump">702,721<span></span>
</td>
<td colspan="2" class="nump">923,471<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">1,179,495<span></span>
</td>
<td colspan="2" class="nump">825,587<span></span>
</td>
<td colspan="2" class="nump">1,089,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">8,149<span></span>
</td>
<td colspan="2" class="nump">7,749<span></span>
</td>
<td colspan="2" class="nump">7,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DistributableEquity', window );">Distributable equity</a></td>
<td class="num">(113,855)<span></span>
</td>
<td colspan="2" class="num">(153,446)<span></span>
</td>
<td colspan="2" class="nump">255,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="num">(105,706)<span></span>
</td>
<td colspan="2" class="num">(145,697)<span></span>
</td>
<td colspan="2" class="nump">263,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Borrowings</a></td>
<td class="nump">365,080<span></span>
</td>
<td colspan="2" class="nump">222,996<span></span>
</td>
<td colspan="2" class="nump">95,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">5,000<span></span>
</td>
<td colspan="2" class="nump">5,949<span></span>
</td>
<td colspan="2" class="nump">14,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">7,258<span></span>
</td>
<td colspan="2" class="nump">5,830<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">377,338<span></span>
</td>
<td colspan="2" class="nump">234,775<span></span>
</td>
<td colspan="2" class="nump">109,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleDebtCurrentAbstract', window );"><strong>Convertible notes, matures in April 2028</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Borrowings</a></td>
<td class="nump">458,207<span></span>
</td>
<td colspan="2" class="nump">407,095<span></span>
</td>
<td colspan="2" class="nump">399,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">150,670<span></span>
</td>
<td colspan="2" class="nump">143,296<span></span>
</td>
<td colspan="2" class="nump">157,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleNotesCurrent', window );">Convertible notes current</a></td>
<td class="nump">608,877<span></span>
</td>
<td colspan="2" class="nump">550,391<span></span>
</td>
<td colspan="2" class="nump">557,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_OtherCurrentLiabilitiesAbstract', window );"><strong>Other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShortTermBorrowingOther', window );">Borrowings</a></td>
<td class="nump">33,329<span></span>
</td>
<td colspan="2" class="nump">14,174<span></span>
</td>
<td colspan="2" class="nump">13,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">936<span></span>
</td>
<td colspan="2" class="nump">1,184<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables and accrued expenses</a></td>
<td class="nump">96,394<span></span>
</td>
<td colspan="2" class="nump">94,566<span></span>
</td>
<td colspan="2" class="nump">101,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">67,956<span></span>
</td>
<td colspan="2" class="nump">41,176<span></span>
</td>
<td colspan="2" class="nump">31,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Income tax payables</a></td>
<td class="nump">1,222<span></span>
</td>
<td colspan="2" class="nump">2,299<span></span>
</td>
<td colspan="2" class="nump">5,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">99,149<span></span>
</td>
<td colspan="2" class="nump">32,719<span></span>
</td>
<td colspan="2" class="nump">7,339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Other current liabilities</a></td>
<td class="nump">298,986<span></span>
</td>
<td colspan="2" class="nump">186,118<span></span>
</td>
<td colspan="2" class="nump">159,641<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">907,863<span></span>
</td>
<td colspan="2" class="nump">736,509<span></span>
</td>
<td colspan="2" class="nump">716,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,285,201<span></span>
</td>
<td colspan="2" class="nump">971,284<span></span>
</td>
<td colspan="2" class="nump">826,390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 1,179,495<span></span>
</td>
<td colspan="2" class="nump">&#8364; 825,587<span></span>
</td>
<td colspan="2" class="nump">&#8364; 1,089,738<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible debt current abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleNotesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleNotesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DistributableEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distributable equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DistributableEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MarketableSecurities1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MarketableSecurities1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MarketableSecuritiesNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities non current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MarketableSecuritiesNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_OtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_OtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShortTermBorrowingOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term borrowing, other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShortTermBorrowingOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in associates in an entity's separate financial statements. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389784704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Share Capital [member]</div></th>
<th class="th"><div>Share Premium [member]</div></th>
<th class="th"><div>Treasury shares [member]</div></th>
<th class="th"><div>Foreign Currency Translation Reserve [member]</div></th>
<th class="th"><div>Accumulated Deficit [member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2021</a></td>
<td class="nump">&#8364; 883,635<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 7,646<span></span>
</td>
<td class="nump">&#8364; 2,107,739<span></span>
</td>
<td class="num">&#8364; (21)<span></span>
</td>
<td class="nump">&#8364; 3,779<span></span>
</td>
<td class="num">&#8364; (1,235,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the year</a></td>
<td class="num">(583,194)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(583,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="num">(327)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="num">(583,521)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="num">(583,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment (Note 7)</a></td>
<td class="nump">64,180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Transfer under stock incentive programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Capital increase</a></td>
<td class="nump">10,285<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">74<span></span>
</td>
<td class="nump">10,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2022</a></td>
<td class="nump">263,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,675<span></span>
</td>
<td class="nump">2,112,863<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
<td class="num">(1,860,493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the year</a></td>
<td class="num">(481,447)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(481,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="num">(2,731)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="num">(484,178)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,731)<span></span>
</td>
<td class="num">(481,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment (Note 7)</a></td>
<td class="nump">66,660<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Acquisition of treasury shares</a></td>
<td class="num">(106,099)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Transfer under stock incentive programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NetSettlementUnderStockIncentivePrograms', window );">Net settlement under stock incentive programs</a></td>
<td class="num">(1,812)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Capital increase</a></td>
<td class="nump">5,153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29<span></span>
</td>
<td class="nump">5,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2023</a></td>
<td class="num">(145,697)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,749<span></span>
</td>
<td class="nump">2,123,074<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="num">(2,277,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the year</a></td>
<td class="num">(378,084)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="nump">1,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="num">(377,022)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
<td class="num">(378,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment (Note 7)</a></td>
<td class="nump">95,512<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Transfer under stock incentive programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Capital increase</a></td>
<td class="nump">340,792<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">400<span></span>
</td>
<td class="nump">340,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CostsOfCapitalIncreaseDecrease', window );">Cost of capital increase</a></td>
<td class="num">(19,291)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2024</a></td>
<td class="num">&#8364; (105,706)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 8,149<span></span>
</td>
<td class="nump">&#8364; 2,444,175<span></span>
</td>
<td class="num">&#8364; (113)<span></span>
</td>
<td class="nump">&#8364; 1,783<span></span>
</td>
<td class="num">&#8364; (2,559,700)<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CostsOfCapitalIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of capital increase (decrease).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CostsOfCapitalIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NetSettlementUnderStockIncentivePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net settlement under stock incentive programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NetSettlementUnderStockIncentivePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109383577824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Cash Flow Statements - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the year</a></td>
<td class="num">&#8364; (378,084)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (481,447)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (583,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Reversal of finance income</a></td>
<td class="num">(25,609)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(43,857)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(52,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Reversal of finance expenses</a></td>
<td class="nump">100,027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">44,065<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment', window );">Reversal of (gain)/loss on disposal of property, plant and equipment</a></td>
<td class="num">(91)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Reversal of income taxes (expenses)</a></td>
<td class="nump">4,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AdjustmentsForNonCashConsiderationRegardingRevenue', window );">Non-cash consideration relating to revenue</a></td>
<td class="num">(27,069)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,354)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of (profit)/loss of associates</a></td>
<td class="nump">20,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,395<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment</a></td>
<td class="nump">95,512<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">66,660<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">64,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation</a></td>
<td class="nump">17,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment of property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization</a></td>
<td class="nump">467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">483<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ChangesInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Inventories</a></td>
<td class="num">(86,678)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(78,258)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(55,268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Receivables</a></td>
<td class="num">(118,607)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(32,773)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,531)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepayments</a></td>
<td class="nump">10,392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,413)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities', window );">Contract liabilities</a></td>
<td class="num">(1,197)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,080)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">26,965<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">45,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Increase/(decrease) in provisions</a></td>
<td class="nump">61,968<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash flows generated from/(used in) operations</a></td>
<td class="num">(299,854)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(464,271)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(494,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Finance income received</a></td>
<td class="nump">14,374<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities', window );">Finance expenses paid</a></td>
<td class="num">(15,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15,672)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9,294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes received/(paid)</a></td>
<td class="num">(5,512)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,466)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from/(used in) operating activities</a></td>
<td class="num">(306,197)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(467,361)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(495,699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from disposal of property, plant and equipment</a></td>
<td class="nump">950<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment', window );">Acquisition of intangible assets and property, plant and equipment</a></td>
<td class="num">(1,427)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,442)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment', window );">Reimbursement for acquisition of property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Purchase of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(213,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Settlement of marketable securities</a></td>
<td class="nump">7,353<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">288,865<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">280,528<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash flows from/(used in) investing activities</a></td>
<td class="nump">6,876<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">286,474<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">61,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings</a></td>
<td class="num">(11,365)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,438)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Net proceeds from borrowings</a></td>
<td class="nump">134,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">136,256<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">503,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">30,514<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,286<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from follow-on public offerings</a></td>
<td class="nump">309,913<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Costs of follow-on public offering</a></td>
<td class="num">(19,291)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisitions of treasury shares, net of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(105,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms', window );">Payment of withholding taxes under stock incentive programs</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,812)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows from/(used in) financing activities</a></td>
<td class="nump">443,929<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">134,292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">396,773<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Increase/(decrease) in cash and cash equivalents</a></td>
<td class="nump">144,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(46,595)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(37,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at January 1</a></td>
<td class="nump">392,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">444,767<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">446,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rate changes on balances held in foreign currencies</a></td>
<td class="nump">22,771<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,008)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BalancesWithBanks', window );">Bank deposits</a></td>
<td class="nump">559,543<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">392,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">427,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShortTermMarketableSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at December 31</a></td>
<td class="nump">&#8364; 559,543<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 392,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 444,767<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AdjustmentsForNonCashConsiderationRegardingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non cash consideration regarding revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AdjustmentsForNonCashConsiderationRegardingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of withholding taxes under stock incentive programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of intangible assets and property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement from acquisition of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShortTermMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShortTermMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BalancesWithBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash balances held at banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BalancesWithBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384941648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109381460672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_16k_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16K Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to safeguard the confidentiality and integrity of the information we collect and process, prevent unauthorized access to our information technology (&#8220;IT&#8221;) systems and data, and ensure availability of our IT systems and data according to defined business requirements. Our cybersecurity risk management program includes a cybersecurity incident response plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Information Security Policy for Global IT outlines the organizational responsibilities for maintaining a strong security posture for our IT systems and sets forth the IT security measures and controls that are required to be in place. This policy covers all IT systems that process Company information. Our Security Management team is responsible for ensuring internal security compliance and for managing IT vendors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have designed our security program around the International Organization for Standardization/International Electrotechnical Commission (&#8220;ISO/IEC&#8221;) 27001 standard on a strategic and tactical level, while our operational program is maintained in accordance with the Center for Internet Security (&#8220;CIS&#8221;) Critical Security Controls framework. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the ISO/IEC and CIS Controls standards as guides to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program includes:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (1) our cybersecurity risk assessment processes; (2) our security controls; and (3) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</span></span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a defined process for registration, classification and escalation of any incidents to a named IT Incident Manager and incident response team, which includes relevant members of the IT management team, the compliance team, business process owners and potentially external vendors;</span></span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security awareness campaigns for Company employees via various channels (intranet, direct mail, screen savers, etc.); and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">secure access control measures applied to critical IT systems, equipment and devices, designed to prevent unauthorized users, processes, and devices from assessing IT systems and data.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.</span></span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated the oversight of cybersecurity and other information technology risks to the executive board. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board oversees the Security Management team's implementation of our cybersecurity risk management program.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board receives regular updates from the Security Management team on our cybersecurity risks. In addition, the Security Management team updates the executive board, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board reports to the full Board regarding its activities, including those related to cybersecurity.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Security Management team, internal security staff and external experts as part of the Board's continuing education on topics that impact public companies.</span></p></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Security Management team is chaired by the Chief Information Officer and includes the Head of IT Compliance, IT Operations/Infrastructure and Cyber Security, and is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responsible</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.</span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Security Management team's background includes experience in regulatory compliance, cloud computing and infrastructure, and cyber incident response.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Security Management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel, threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us, as well as alerts and reports produced by security tools deployed in our IT environment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive management that is part of the Corporate Management Group signs off on the overall strategic direction for IT security and ensures alignment with our overall business strategy.</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also established a Security Organization Unit to ensure alignment across key security functions in our organization. The Security Organization Unit is chaired by the Chief Information Officer and includes representatives from Foundational Technology and IT Compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is the responsibility of the Security Organization Unit to approve the Company's IT security roadmap, ensure allocation and prioritization of resources, and to act as the escalation point for IT security matters.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A named IT manager is assigned the responsibility of maintaining IT security across our global organization. This responsibility includes defining and driving IT security roadmap initiatives, defining and implementing activities needed to drive an IT security awareness program, supporting the assessment of new IT systems and vendors, and acting as the leader and point person in the event of a major security incident.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operational responsibility resides with the related product teams. The product teams are responsible for ensuring effective and updated security technologies are used in the day-to-day operational procedures, and for maintaining, operating and implementing applications and technologies securely across business areas within the Company.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated the oversight of cybersecurity and other information technology risks to the executive board. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board oversees the Security Management team's implementation of our cybersecurity risk management program.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board receives regular updates from the Security Management team on our cybersecurity risks. In addition, the Security Management team updates the executive board, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board reports to the full Board regarding its activities, including those related to cybersecurity.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Security Management team, internal security staff and external experts as part of the Board's continuing education on topics that impact public companies.</span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board oversees the Security Management team's implementation of our cybersecurity risk management program.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board receives regular updates from the Security Management team on our cybersecurity risks. In addition, the Security Management team updates the executive board, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board reports to the full Board regarding its activities, including those related to cybersecurity.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Security Management team, internal security staff and external experts as part of the Board's continuing education on topics that impact public companies.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Security Management team is chaired by the Chief Information Officer and includes the Head of IT Compliance, IT Operations/Infrastructure and Cyber Security, and is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responsible</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.</span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Security Management team's background includes experience in regulatory compliance, cloud computing and infrastructure, and cyber incident response.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Security Management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel, threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us, as well as alerts and reports produced by security tools deployed in our IT environment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive management that is part of the Corporate Management Group signs off on the overall strategic direction for IT security and ensures alignment with our overall business strategy.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Security Management team is chaired by the Chief Information Officer and includes the Head of IT Compliance, IT Operations/Infrastructure and Cyber Security, and is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responsible</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Security Management team's background includes experience in regulatory compliance, cloud computing and infrastructure, and cyber incident response.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The executive board reports to the full Board regarding its activities, including those related to cybersecurity.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Security Management team, internal security staff and external experts as part of the Board's continuing education on topics that impact public companies.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109360053136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfGeneralInformationAbstract', window );"><strong>Disclosure of General Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General Information</a></td>
<td class="text"><p id="notes" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 1&#8212;General Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S, together with its subsidiaries, is a global biopharmaceutical company focused on applying its  innovative TransCon technology platform to make a meaningful difference for patients. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to Ascendis Pharma A/S and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The address of the Company&#8217;s registered office is Tuborg Boulevard 12, DK-2900 Hellerup, Denmark. The Company&#8217;s registration number in Denmark is 29918791.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 2, 2015, the Company completed an initial public offering which resulted in the listing of American Depositary Shares (&#8220;ADSs&#8221;), representing the Company&#8217;s ordinary shares, under the symbol &#8220;ASND&#8221; in the United States on The Nasdaq Global Select Market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors (or &#8220;Board&#8221;) approved these consolidated financial statements on February 12, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfGeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of general information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfGeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109380746272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract', window );"><strong>Disclosure of voluntary change in accounting policy [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory', window );">Summary of Material Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2&#8212;Summary of Material Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Preparation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are prepared in accordance with the IFRS Accounting Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), and as adopted by the European Union (the &#8220;EU&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies applied when preparing the consolidated financial statements are described in detail below and are applied for all group entities. Significant accounting judgements and sources of estimation uncertainties used when exercising the accounting policies are described in Note 3, &#8220;Significant Accounting Judgements and Estimates.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements have been prepared under the historical cost convention, apart from certain financial instruments that are measured at fair value at initial recognition.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New and Amended IFRS Accounting Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has applied amendments to paragraphs 69 to 76 of IAS 1, &#8220;Presentation of Financial Statements,&#8221; which was effective for annual reporting periods beginning on or after January 1, 2024, and must be applied retrospectively. The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. The amendments clarify:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What is meant by a right to defer settlement;  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That a right to defer must exist at the end of the reporting period; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That classification is unaffected by the likelihood that an entity will exercise its deferral right; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible senior notes (&#8220;convertible notes&#8221;) include an embedded equity conversion option which is not deemed closely related to the financial liability and was initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the embedded derivative is not an equity instrument under IFRS, the amendments require the convertible notes (presented as part of borrowings in the statement of financial position) and derivative liabilities, presented as non-current liabilities as of December 31, 2023, to be presented as current liabilit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ies. The amendments require presentation of the convertible notes as current liabilities even though: the initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS is not met; the conversion would not require cash settlement; and, the convertible notes do not mature until April 1, 2028. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further details, including (cash) maturity analysis are provided in Note 16, &#8220;Financial Assets and Liabilities.&#8221; On December 31, 2023, the carrying amount of convertible notes and derivative liabilities were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change to presentation, including a third statement of financial position as of the beginning of the preceding period i.e. January 1, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 31, 2023, lease liabilities were presented separately in the consolidated statements of financial position. As of December 31, 2023, carrying amount of lease liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for non-current liabilities and current liabilities, respectively. Since March 31, 2024, lease liabilities are presented as part of borrowings in the consolidated statements of financial position. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change in presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, since March 31, 2024, borrowings comprise convertible notes, royalty funding liabilities, and lease liabilities, where convertible notes are presented separately as &#8220;Current liabilities - Convertible notes, matures in 2028.&#8221; The change to presentation had no other impact on the consolidated financial statements. Refer to Note 16, &#8220;Financial Assets and Liabilities&#8221; for a specification of borrowings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The applied amendments had no other impact on the consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other IFRS Accounting Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other amendments apply for the first time in 2024, but do not have an impact on the consolidated financial statements.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors has at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, the Company continues to adopt the going concern basis of accounting in preparing the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the parent company, Ascendis Pharma A/S, and all enterprises over which the parent company has control. Control of an enterprise exists when the Company has exposure, or rights to, variable returns from its involvement with the enterprise and has the ability to control those returns through its power over the enterprise. Accordingly, the consolidated financial statements include Ascendis Pharma A/S and the subsidiaries listed in Note 20, &#8220;Investments in Group Enterprises&#8221;</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consolidation Principles</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries, which are enterprises the Company controls, are fully consolidated from the date upon which control is transferred to the Company. They are deconsolidated from the date control ceases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Control over an enterprise is reassessed if facts and circumstances indicate that there are changes to one or more of the three elements of control, respectively:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the contractual arrangement(s) with the other vote holders of the enterprise; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#8217;s voting rights and potential voting rights; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights arising from other contractual arrangements.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between group enterprises are eliminated in full on consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries apply accounting policies in line with the Company&#8217;s accounting policies. When necessary, adjustments are made to bring the entities&#8217; accounting policies in line with those of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments in Associates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An associate is an entity over which the Company has significant influence over financial and operational decisions but without having control or joint control. The Company&#8217;s associates are accounted for using the equity method and initially recognized at cost. Thereafter, the carrying amount of the investment is adjusted to recognize changes in the Company&#8217;s share of net assets of the associates since the acquisition or establishment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated statements of profit or loss include the Company&#8217;s share of result after tax of the associates after any adjustments made to bring the associates accounting policies in line with those of the Company. Transactions between the associates and the Company are eliminated proportionally according to the Company&#8217;s interest in the associates. Unrealized gains and losses resulting from transactions between the Company and its associates are eliminated to the extent of the Company&#8217;s interest in the associates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On each reporting date, the Company determines whether there are indications that the investment is impaired. If there is such evidence, the amount of impairment is calculated as the difference between the recoverable amount of the associate and its carrying amount. Any impairment loss is recognized in the consolidated statements of profit or loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Currency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Functional and Presentation Currency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Items included in the consolidated financial statements are measured using the functional currency of each group entity. Functional currency is the currency of the primary economic environment in which the entity operates. The consolidated financial statements are presented in Euros (or &#8220;EUR&#8221;), which is also the functional currency of the parent company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Translation of Transactions and Balances</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On initial recognition, transactions in currencies other than the individual entity&#8217;s functional currency are translated applying the exchange rate in effect at the date of the transaction. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the reporting date are translated using the exchange rate in effect at the reporting date. Monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange rate differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the reporting date, are recognized in profit or loss as finance income or finance expenses. Property, plant and equipment, intangible assets and other non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as of the dates of the initial transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Currency Translation of Group Enterprises</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When subsidiaries or associates present their financial statements in a functional currency other than EUR, their statements of profit or loss are translated at average exchange rates. Balance sheet items are translated using the exchange rates at the reporting date. Exchange rate differences arising from translation of foreign entities&#8217; balance sheet items at the beginning of the year to the reporting date exchange rates as well as from translation of statements of profit or loss from average rates to the exchange rates at the reporting date are recognized in other comprehensive income. Similarly, exchange rate differences arising from changes that have been made directly in a foreign subsidiary&#8217;s equity are recognized in other comprehensive income.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Commercial Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue is recognized when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue is measured at the contractual sales price, reflecting the consideration received or receivable from customers, net of value added taxes, and provisions for a variety of sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales deductions attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements. In addition, goods are principally sold on a &#8220;sale-or-return&#8221; basis, where customers may return products in line with the Company&#8217;s return policy. Sales deductions and product returns are considered variable consideration and are estimated at the time of sale using the expected value method. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net contractual price only to the extent that it is probable that a significant reversal will not occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unsettled sales deductions and product returns are recognized as provisions when timing or amount is uncertain. Payable amounts that are absolute are recognized as other liabilities. Sales discounts and deductions that are payable to customers are offset in trade receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other revenue relates to collaboration and license agreements. When contracts with customers are entered into, the goods and/or services promised in the contract are assessed to identify distinct performance obligations. A promise in the agreement is considered a distinct performance obligation if both of the following criteria are met:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct); and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For collaboration and license agreements that contain multiple promises to the customer, the promises are identified and accounted for as separate performance obligations if these are distinct. If promises are not distinct, those goods or services are combined with other promised goods or services until a bundle of goods or services that is distinct is identified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price in the contract is measured at fair value and reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Under license agreements, the transaction price may include up-front payments, royalty and milestone payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales-based royalty and sales-based milestone income promised in exchange for a license of intellectual property is recognized as revenue at the later of the occurrence of subsequent sale or satisfaction of the performance obligation to which some or all of the royalty or milestone has been allocated. Milestone income related to regulatory activities is included in the transaction price at the point in time that it is highly probable that the applicable milestone criteria is met.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is allocated to each performance obligation according to their stand-alone selling prices and is recognized when control of the goods or services is transferred to the customer, either over time or at a point in time, depending on the specific terms and conditions in the contracts. License agreements, which transfer rights to the Company&#8217;s intellectual property (&#8220;IP&#8221;), are classified as &#8220;right-to-access&#8221;, with revenue recognized over time, or as &#8220;right-to-use&#8221; with revenue recognized at a point in time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale of clinical trial supply is recognized as revenue when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery. Rendering of services is recognized as revenue over the service period as stipulated under the applicable agreement.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs consist primarily of manufacturing costs, preclinical and clinical study costs and costs for process optimizations and improvements performed by Clinical Research Organizations (&#8220;CROs&#8221;) and Contract Manufacturing Organizations (&#8220;CMOs&#8221;), salaries and other personnel costs including pension and share-based payment, the cost of facilities, professional fees, cost of obtaining and maintaining the Company&#8217;s intellectual property portfolio, and depreciation of non-current assets related to research and development activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research costs are incurred at the early stages of the drug development cycle from the initial drug discovery and include a variety of preclinical research activities in order to assess potential drug candidates in non-human subjects, prior to filing an Investigational New Drug Application (&#8220;IND&#8221;), or equivalent. Research costs are recognized in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development activities relate to activities following an IND, or equivalent, and typically involve a single product candidate undergoing a series of studies to illustrate its safety profile and effect on human beings, prior to obtaining the necessary approval from the appropriate authorities. Development activities comprise drug candidates undergoing clinical trials starting in phase I (first time drug is administered in a small group of humans), and further into Phase II and III, which include administration of drugs in larger patient groups. Following, and depending on clinical trial results, a Biologic License Application (&#8220;BLA&#8221;) or New Drug Application (&#8220;NDA&#8221;) may be submitted to the authorities, to apply for marketing approval, which, with a positive outcome will permit the Company to market and sell the products. Long-term extension trials may be ongoing following submission of a BLA or NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development costs also include product development and pre-commercial manufacturing costs related to development product candidates, and write-downs of inventories manufactured for late-stage development product candidates prior to marketing approval being obtained (pre-launch inventories).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the risk related to the development of pharmaceutical products, the Company cannot estimate the future economic benefits associated with individual development activities with sufficient certainty until the development activities have been finalized and the necessary market approval of the final product has been obtained. As a consequence, all development costs are recognized in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, General, and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses comprise salaries and other personnel costs including pension and share-based payment, office supplies, cost of facilities, professional fees, and depreciation of non-current assets related to selling, general and administrative activities, including pre-commercial and commercial activities. Selling, general, and administrative expenses are recognized in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based Incentive Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based incentive programs comprise warrant programs, Restricted Stock Unit programs (&#8220;RSU-programs&#8221;) and Performance Stock Unit Programs (&#8220;PSU-programs&#8221;) which are classified as equity-settled share-based payment transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of equity-settled transactions is determined by the fair value at the date of grant. For warrant programs, the fair value of each warrant granted is determined using the Black-Scholes option-pricing model. For RSU-programs and PSU-programs, the fair value of each RSU or PSU granted is equal to the closing share price on the date of grant of the underlying ADS. Any social security contributions payable in connection with the grant or exercise of the warrants are recognized as expenses when incurred. The assumptions used for estimating the fair value of share-based payment transactions are disclosed in Note 7, &#8220;Share-based Payment.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost is recognized together with a corresponding increase in equity over the period in which the performance and/or service conditions are fulfilled (i.e., the vesting period). The fair value determined at the grant date of the equity-settled share-based payment is expensed on a straight-line basis over the vesting period for each tranche, based on the best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for grants that do not ultimately vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where an equity-settled grant is cancelled other than upon forfeiture when vesting conditions are not satisfied, the grant is treated as if it vested on the date of the cancellation, and any expense not yet recognized for the grant is recognized immediately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where the terms and conditions for an equity-settled grant are modified, the services measured at the grant date fair value over the vesting period are recognized, subject to performance and/or service conditions that were specified at the initial grant date(s). Additionally, at the date of modification, unvested grants are re-measured and any increase in the total fair value is recognized over the vesting period. If a new grant is substituted for the cancelled grant and designated as a replacement grant on the date that it is granted, the cancelled and new grants are treated as if they were a modification of the original grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance Income and Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance income and expenses comprise interest income and expenses, realized and unrealized exchange rate gains and losses on transactions denominated in foreign currencies, fair value remeasurement gains and losses on derivative liabilities, and remeasurement gains and losses on royalty funding liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income and interest expenses are stated on an accrual basis using the principal and the effective interest rate. The effective interest rate is the discount rate that is used to discount expected future cash payments or receipts through the expected life of the financial asset or financial liability to the amortized cost (the carrying amount) of such asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognized in the consolidated statement of profit or loss by the portion attributable to the profit or loss for the year and recognized directly in equity or other comprehensive income by the portion attributable to entries directly in equity and in other comprehensive income. The current tax payable or receivable is recognized in the consolidated statement of financial position, stated as tax computed on this year&#8217;s taxable income, adjusted for prepaid tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When computing the current tax for the year, the tax rates and tax rules enacted or substantially enacted at the reporting date are used. Current tax payable is based on taxable profit or loss for the year. Taxable profit or loss differs from net profit or loss as reported in the consolidated statements of profit or loss because it excludes items of income or expense that are taxable or deductible in prior or future years. In addition, taxable profit or loss excludes items that are never taxable or deductible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax is recognized according to the balance sheet liability method of all temporary differences between carrying amounts and tax-based values of assets and liabilities, apart from deferred tax on all temporary differences occurring on initial recognition of goodwill or on initial recognition of a transaction which is not a business combination, and for which the temporary difference found at the time of initial recognition neither affects profit or loss nor taxable income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax liabilities are recognized on all temporary differences related to investments in subsidiaries and/or associates, unless the Company is able to control when the deferred tax is realized, and it is probable that the deferred tax will not become due and payable as current tax in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets, including the tax base of tax loss carry forwards, are recognized in the statement of financial position at their estimated realizable value, either as a set-off against deferred tax liabilities or as net tax assets for offset against future positive taxable income. Deferred tax assets are only offset against deferred tax liabilities if the entity has a legally enforceable right to offset, and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax jurisdiction. Deferred tax is calculated based on the planned use of each asset and the settlement of each liability, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax is measured using the tax rates and tax rules in the relevant countries that, based on acts in force or acts in reality in force at the reporting date are expected to apply when the deferred tax is expected to crystallize as current tax. Changes in deferred tax resulting from changed tax rates or tax rules are recognized in the consolidated statement of profit or loss unless the deferred tax is attributable to transactions previously recognized directly in equity or other comprehensive income. In the latter case, such changes are also recognized in equity or other comprehensive income. On every reporting date, it is assessed whether sufficient taxable income is likely to arise in the future for the deferred tax asset to be utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill acquired in a business combination is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests over the net identifiable assets acquired and liabilities assumed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortized but is subject to impairment testing at least on a yearly basis. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or group of cash-generating units, that are expected to benefit from the synergies of the combination. Each cash-generating unit or group of cash-generating units to which goodwill is allocated represents the lowest level within the Company at which the goodwill is monitored for internal management purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Software</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Software assets comprise administrative applications and serve general purposes to support the Company&#8217;s operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development costs that are directly attributable to the design, customization, implementation, and testing of identifiable and unique software assets controlled by the Company are recognized as intangible assets from the time that; (1) the software asset is clearly defined and identifiable; (2) technological feasibility, adequate resources to complete, and an internal use of the software asset can be demonstrated; (3) the expenditure attributable to the software asset can be measured reliably; and (4) the Company has the intention to use the software asset internally. The Company does not capitalize software with no alternative use, or where economic benefit depends on marketing approvals of drug candidates and where marketing approvals have not been obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when the development is complete, and the asset is available for use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Software assets are amortized over the period of expected future benefits. Amortization is recognized in research and development costs, and selling, general and administrative expenses, as appropriate. Expenditures that do not meet the criteria above are recognized as an expense as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment primarily comprises leasehold improvements, office facilities, and process equipment and tools which are located at CMOs. Property, plant and equipment also includes right-of-use assets. Refer to the separate section &#8220;Leases.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be used in operation. Subsequent costs are included in the carrying amount of the asset or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the assets will flow to the Company and costs of the items can be measured reliably. All repair and maintenance costs are charged to the consolidated statement of profit or loss during the financial periods in which they are incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plant and equipment acquired for research and development activities with alternative use, which is expected to be used for more than one year, is capitalized and depreciated over the estimated useful life as research and development costs. Plant and equipment acquired for research and development activities, which has no alternative use, is recognized as research and development costs when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the acquisition or use of the asset involves an obligation to incur costs of decommissioning or restoration of the asset, the estimated related costs are recognized as a provision and as part of the relevant asset&#8217;s cost, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The basis for depreciation is cost less estimated residual value. The residual value is the estimated amount that would be earned if selling the asset today net of selling costs, assuming that the asset is of an age and a condition that is expected after the end of its useful life. Cost of a combined asset is divided into smaller components, with such significant components depreciated individually if their useful lives vary. Depreciation commences when the asset is available for use, which is when it is in the location and condition necessary for it to be capable of operating in the manner intended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation is calculated on a straight-line basis, based on an asset&#8217;s expected useful life, being within the following ranges:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:17.824%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Process plant and machinery</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation methods, useful lives and residual amounts are reassessed at least annually.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment is written down to the lower of recoverable amount and carrying amount, as described in the &#8220;Impairment&#8221; section below. Depreciation and impairment losses of property, plant and equipment is recognized in the consolidated statement of profit or loss as cost of sales, research and development costs or as selling, general, and administrative expenses, as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gains and losses on disposal of property, plant and equipment are recognized in the consolidated statement of profit or loss at its net proceeds, as either research and development costs or as selling, general, and administrative expenses, as appropriate.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Non-current Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The recoverable amount of goodwill is estimated annually irrespective of any recorded indications of impairment. Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows, or cash-generating units, which for goodwill represent the lowest level within the enterprise at which the goodwill is monitored for internal management purposes. Prior impairments of non-current assets, other than goodwill, are reviewed for possible reversal at each reporting date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories comprise raw materials, work in progress and finished goods. The cost of work in progress and finished goods comprise service expenses incurred at CMOs, raw materials consumed, incremental storage and transportation, other direct materials, and a proportion of manufacturing overheads based on normal operation capacity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories are measured at the lower of cost incurred in bringing it to its present location and condition, and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Cost is measured using the first-in, first-out method. Work in progress and finished goods are measured under a standard cost method that takes into account normal levels of consumption, yields, labor, efficiency and capacity utilization. Production processes are complex, where actual yields and consumptions are sensitive to a wide variety of manufacturing conditions. Standard cost variances are reviewed regularly and adjusted to ensure inventories approximate actual cost of production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If net realizable value is lower than cost, a write-down is recognized as the excess amount by which cost exceeds net realizable value, as part of cost of sales, or selling, general, and administrative expenses, as appropriate. The amount of reversal of write-down of inventories arising from an increase in net realizable value is recognized as a reduction in cost of sales in the period in which the reversal occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing of pre-launch inventories is initiated for late-stage product candidates where manufacturing costs are recognized as inventories. However, since pre-launch inventories are not realizable prior to obtaining marketing approval, pre-launch inventories are immediately written down to zero through research and development costs. If marketing approval is obtained, prior write-downs of pre-launch inventories are reversed through research and development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of inventories is recognized as part of cost of sales in the period in which the related revenue is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receivables</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receivables comprise trade receivables, income tax receivables and other receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade receivables are classified as financial assets at amortized cost, as these are held to collect contractual cash flows and thus give rise to cash flows representing solely payments of principal and interest. Trade receivables are initially recognized at their transaction price and subsequently measured at amortized cost. Income tax receivables, and other receivables related to deposits, VAT and other indirect taxes are measured at cost less impairment. Carrying amounts of receivables usually equals their nominal value less provision for impairments.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayments comprise advance payments relating to a future financial year. Prepayments are measured at cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities may comprise government bonds, treasury bills, commercial papers, and other securities traded on established markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At initial recognition (trade-date), contractual terms of individual securities are analyzed to determine whether these give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding (&#8220;SPPI-test&#8221;). All marketable securities held at the reporting date have passed the SPPI-test.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities are initially recognized at fair value at trade-date, and subsequently measured at amortized cost under the effective interest method. Interest income is recognized as finance income in the consolidated statement of profit or loss. Marketable securities are subject to an impairment test to accommodate expected credit loss. Gains and losses are recognized as finance income or expenses in the consolidated statement of profit or loss when the specific security or portfolio of securities is derecognized, modified or impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities, having maturity profiles of three months or less after the date of acquisition are presented as cash equivalents in the consolidated statements of financial position, where securities having maturities of more than three months after the date of acquisition are presented separately as marketable securities as current (i.e., those maturing within twelve months after the reporting date) or non-current assets, as appropriate.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents comprise cash and on-demand deposits with financial institutions, and highly liquid marketable securities with a maturity of three months or less after the date of acquisition (trade-date). Cash and cash equivalents are measured at amortized cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Allowance for Expected Credit Losses on Financial Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial assets comprise receivables (excluding receivables relating to VAT, other indirect tax and income tax), marketable securities, and cash and cash equivalents. Impairment of financial assets is determined on the basis of a forward-looking Expected Credit Loss (&#8220;ECL&#8221;) model. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and the cash flows expected to be received, discounted by an approximation of the original effective interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For receivables, a simplified approach in calculating ECLs is applied. Therefore, changes in credit risks are not tracked, but instead, a loss allowance based on lifetime ECL is assessed at each reporting date. Lifetime ECLs are assessed on historical credit loss experience, adjusted for forward-looking factors specific to the counterparts and the economic environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For cash, cash equivalents and marketable securities, ECLs are assessed for credit losses that result from default events that are possible within the next twelve months (12-month ECL). Credit risk is continuously tracked and monitored in order to identify significant deterioration. For those credit exposures for which there have been a significant increase in credit risk since initial recognition, an allowance is recognized for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The share capital comprises the nominal amount of the parent company&#8217;s ordinary shares, each at a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All shares are fully paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share premium comprises the amounts received, attributable to shareholders&#8217; equity, in excess of the nominal amount of the shares issued at the parent company&#8217;s capital increases, reduced by any expenses directly attributable to the capital increases. Under Danish legislation, share premium is an unrestricted reserve that is available to be distributed as dividends to a company&#8217;s shareholders. Also, under Danish legislation, the share premium reserve can be used to offset accumulated deficits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treasury shares reserve comprise nominal amounts of holding of own equity instruments. No gain or loss is recognized in profit or loss on the purchase, sale, transfer or cancellation of the Company&#8217;s own equity instruments. The treasury shares reserve is part of unrestricted reserves and accordingly, reduce the amount available to be distributed as dividends to the Company&#8217;s shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency translation reserve includes exchange rate adjustments relating to the translation of the results and net assets of foreign operations from their functional currencies to the presentation currency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accumulated reserve of a foreign operation is reclassified to the consolidated statement of profit or loss at the time the Company loses control, and thus cease to consolidate such foreign operation. The foreign currency translation reserve is an unrestricted reserve that is available to be distributed as dividends to the Company&#8217;s shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retained earnings/(accumulated deficit) represents the accumulated profits or losses from the Company&#8217;s operations, including corresponding entries to share-based payments recognized in the consolidated statement of profit or loss. In addition, premiums from acquisition and sale of treasury shares are recognized as part of this reserve. A positive reserve is available to be distributed as dividends to the Company&#8217;s shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible Senior Notes and Embedded Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible senior notes (&#8220;convertible notes&#8221;) are separated into a financial liability and an embedded derivative component based on the terms and conditions of the contract. The embedded derivative component is accounted for separately if it is not deemed closely related to the financial liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes include an embedded equity conversion option which is not deemed closely related to the financial liability, and initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the convertible notes include a redemption option, which entitle the Company to redeem the notes at a cash amount equal to the principal amount of the convertible notes, plus accrued and unpaid interest. The redemption option is closely related to the financial liability, and not separately accounted for. The initial carrying amount of the financial liability component including the redemption option is the residual amount of the proceeds, net of transaction costs, after separating the derivative component.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transaction costs are apportioned between the financial liability and derivative component based on the allocation of proceeds when the instrument is initially recognized. Transaction costs apportioned to the financial liability component form part of the effective interest and are amortized over the expected lifetime of the liability. Transaction costs allocated to the derivative component are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial liability is subsequently measured at amortized cost until it is extinguished on conversion, upon optional redemption or repayment at maturity. Convertible notes are presented as borrowings, together with the derivative liabilities on the statement of financial position, separately under current liabilities as &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible notes, matures in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty funding liabilities relate to the Company&#8217;s contractual obligations to pay a predetermined percentage of future revenue from sale of commercial products until reaching a predetermined multiple of proceeds received, pursuant to the detailed provisions of the capped synthetic royalty funding agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where relevant, royalty funding liabilities are separated into a financial liability and embedded derivative components based on the terms and conditions of the applicable royalty funding agreement. Embedded derivative components are accounted for separately, unless these are deemed closely related to the financial liability. The royalty funding agreements include a buy-out option where the value is dependent on non-financial variables that are specific to the Company. Accordingly, the buy-out option is not accounted for separately as a derivative.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial liability is recognized when the Company becomes party to the contractual provisions of the royalty funding agreement and measured at amortized cost until it is extinguished upon exercising a buy-out option or upon achieving the predetermined multiple of proceeds received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effective interest rate is estimated at initial recognition and takes into account incremental transaction costs and anticipated amount and timing of future cash flows, which further depends on future commercial revenue forecasts and the probability of exercising the buy-out option. The amortized cost is remeasured prospectively when there is a material change in expectations to amount and timing of future cash flows, which will increase or decrease future interest expenses. Remeasurement gain or losses are recognized through the profit or loss as finance income or expenses, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty funding liabilities that are classified as a financial liability are presented as part of borrowings in the statement of financial position.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Right-of-use Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets are recognized at the lease commencement date, defined as the date the underlying asset is available for use. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets include the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any incentives received. In addition, right-of-use assets also include an estimate of costs to be incurred by the Company in dismantling or restoring the underlying asset to the condition if required by the terms and condition of the lease, if any.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets are presented as part of property, plant and equipment, and depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lease Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the lease commencement date, lease liabilities are recognized and measured at the present value of fixed lease payments and variable lease payments that depend on an index or a rate, whereas variable lease payments and payments related to non-lease components are excluded. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When interest rates implicit in the lease contracts are not readily available, the present value of lease payments are calculated by applying the incremental borrowing rate of the relevant entity holding the lease. Following the commencement date, the incremental borrowing rate is not changed unless the lease term is modified, or if the lease payments are modified and this modification results from a change in floating interest rates. From the lease commencement date and over the lease term, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in lease term, or a change in lease payments, including changes to future payments resulting from a change in an index used to determine such lease payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities are presented as part of borrowings in the statement of financial position.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions comprise unsettled sales deductions and product returns regarding revenue from sale of commercial products where amount or timing of payment is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions for sales deductions attributed to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements are recognized when the related sales takes place and measured using the expected value method. Payable amounts for managed healthcare organizations and government programs are generally settled within 180 days from the transaction date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions for estimated product returns are measured according to the contractual sales price based on expected product returns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Payables and Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses are measured at amortized cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other liabilities comprise payables to public authorities, short-term employee benefits, and sales deductions. Other liabilities are measured at their net-realizable values.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities comprise deferred income from collaboration and license agreements, where consideration received does not match the individual deliverables with respect to amount and satisfied performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities are measured at the fair value of the consideration received and is recognized as revenue in the consolidated statement of profit or loss when the relevant performance obligation, to which the deferred income relates, is satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Flow Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cash flow statement shows cash flows from operating, investing and financing activities as well as cash and cash equivalents at the beginning and the end of the financial year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from operating activities are presented using the indirect method and calculated as the profit or loss adjusted for non-cash items, working capital changes as well as finance income, finance expenses and income taxes paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from investing activities include payments in connection with acquisition, development, improvement and sale, etc., of property, plant and equipment, investments in associates and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from financing activities comprise payments related to the capital structure of the Company, including changes in the share capital and treasury shares, and issuance and repayments under the Company&#8217;s borrowing activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency is presented separately from cash flows from operating, investing and financing activities. Cash flows in currencies other than the functional currency are recognized in the cash flow statement, using the average exchange rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents comprise cash and on-demand bank deposits with financial institutions and highly liquid marketable securities with a maturity of three months or less after the date of acquisition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic Earnings per Share (&#8220;EPS&#8221;) is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding. The weighted average number of shares takes into account the weighted average number of treasury shares during the year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted EPS is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding adjusted for the weighted average effect of changes in treasury shares during the year, and the dilutive effect of outstanding warrants and convertible notes. If the consolidated statement of profit or loss shows a net loss, no adjustment is made for the dilutive effect, as such effect would be anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New IFRS Accounting Standards Not Yet Effective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, the IASB issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;), which replaces IAS 1, &#8220;Presentation in Financial Statements.&#8221; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discontinued operations.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are not expected to be affected by other new or amended standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389520576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgements and Estimates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract', window );"><strong>Disclosure of voluntary change in accounting policy [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Accounting Judgements and Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Significant Accounting Judgements and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the application of the Company&#8217;s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management&#8217;s ongoing revisions of critical accounting estimates and underlying assumptions have not revealed any material impact in any of the years presented in these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes to the application of significant accounting judgements, or estimation uncertainties regarding accounting estimates compared to December 31, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Accounting Judgements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant accounting judgements which have a material impact on the consolidated financial statements are described in the following sections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internally Generated Intangible Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Development of Drug Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IAS 38, &#8220;Intangible Assets&#8221; prescribes that intangible assets arising from development projects must be recognized in the consolidated statements of financial position if the criteria for capitalization are met. That means (1) that the development project is clearly defined and identifiable; (2) that technological feasibility, adequate resources to complete and a market for the product or an internal use of the project can be documented; (3) that the expenditure attributable to the development project can be measured reliably; and (4) that the Company has the intent to produce and market the product. Such an intangible asset shall be recognized if it can be demonstrated that the future income from the development project will exceed the aggregate cost of development, production, sale and administration of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the risk associated with drug development, future income from development projects related to drug candidates cannot be determined with sufficient certainty until the development activities have been completed and the necessary marketing approvals have been obtained. Accordingly, the Company does not recognize internally generated intangible assets at this time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Estimation Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue and Provisions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions for Sales Deductions and Product Returns</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales deductions and product returns are considered variable consideration and constrained to the extent that a significant reversal in the amount of recognized revenue will not occur when the uncertainties associated with the rebate or chargeback item are subsequently resolved, or for product returns, when the products are distributed to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions for unsettled sales deductions and product returns are estimated on the basis of a percentage of sales as defined by individual agreements and contracts, and for government rebates by individual state- and plan agreements. Further inputs to the calculations are based on payer channel mix, current contract prices under eligible programs and current inventory levels in the distribution channels. Inputs to the calculations are subject to estimation and assumptions and are based on historical experience and other factors that are relevant, and which are available at the reporting date. Provisions are adjusted to absolute amounts and recognized as other liabilities when estimated sales deductions are processed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, provisions for sales deductions and product returns were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, as of December 31, 2023. The development in total provisions is disclosed in Note 15, &#8220;Provisions.&#8221; Due to the nature of these provisions, it is not practicable to give meaningful sensitivity estimates due to the large volume of variables that contribute to the overall rebates, chargebacks, product returns and other sales deductions. Provisions are reviewed and adjusted regularly considering contractual terms, regulatory obligations, payer trends, historical experiences and market projections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-based Payment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Compensation Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IFRS 2, &#8220;Share-Based Payment&#8221; requires an entity to reflect in its consolidated statement of profit or loss and financial position, the effects of share-based payment transactions. Warrant compensation costs are recognized as cost of sales, research and development costs or selling, general and administrative expenses, as appropriate, over the vesting period, based on management&#8217;s best estimate of the number of warrants that will ultimately vest, which is subject to uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant compensation costs are measured according to the grant date fair value of the warrants granted. Estimating fair values requires the Company to apply generally accepted valuation models and apply these models consistently according to the terms and conditions of the specific warrant program. Under all warrant programs, the Black-Scholes option-pricing model has been applied to determine the fair value of warrants granted. Subjective judgements and assumptions, which are subject to estimation uncertainties, need to be exercised in determining the appropriate input to the valuation model. These inputs include expected volatility of the Company&#8217;s share price for a historic period equaling the expected lifetime of the warrants, reflecting the assumption that the historical volatility over a period similar to the life of the warrants is indicative of future trends, expected forfeitures and expected lifetime of warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant compensation cost recognized in the consolidated statement of profit or loss was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022, respectively. Changes to inputs applied to the Black-Scholes option-pricing model could affect the warrant compensation cost. Refer to Note 7, &#8220;Share-based Payment,&#8221; for additional details.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation of Embedded Derivatives</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency conversion options embedded in the convertible notes are accounted for separately as derivative liabilities at fair value through profit or loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value cannot be measured based on quoted prices in active markets, or other observable input, and accordingly, derivative liabilities are measured by use of valuation techniques in the form of the Black-Scholes option-pricing model. Subjective judgements and assumptions, which are subject to estimation uncertainties, need to be exercised in determining the appropriate unobservable input to the valuation model (Level 3 in the fair value hierarchy). This includes volatility of the Company&#8217;s share price for a historic period, reflecting the assumption that the historical volatility is indicative of a period similar to the expected lifetime of the options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the valuation of the derivative liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">143.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of December 31, 2023. Changes in assumptions relating to these factors could affect the reported fair value of derivative liabilities. Refer to Note 16, &#8220;Financial Assets and Liabilities,&#8221; for additional details.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Measurement of Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amount of royalty funding liabilities is measured according to anticipated future cash flows, which further depends on the amount and timing of future revenue from sale of commercial products. Assumptions that impact the amount and timing of future sale of commercial products are subject to estimation uncertainties, and are subject to a number of factors which are not within the Company&#8217;s control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the carrying amount of the royalty funding liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2023. As of December 31, 2024, royalty funding liabilities comprised two agreements compared with one agreement as of December 31, 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will periodically revisit the anticipated amount and timing of future sale of commercial products and to the extent such amount or timing is materially different from the previous estimates, a remeasurement gain or loss is recognized through the profit or loss as finance income or expenses, as appropriate, which would further increase or decrease future interest expenses. Refer to Note 16, &#8220;Financial Assets and Liabilities&#8221; for additional details.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389011792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 4&#8212;Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue has been recognized in the consolidated statements of profit or loss with the following amounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial products</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,728</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rendering of services</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical supply</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,776</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,343</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,077</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Attributable to</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial customers</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,728</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration partners and license agreements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,055</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified by timing of recognition</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognized over time</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognized at a point in time</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,059</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified per geographical area</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,336</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">552</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233,220</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191,677</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rest of world</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,172</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,466</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, Denmark, the country of domicile, contributed with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue.</span></div></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Customers</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue attributable to commercial customers by product were as follows:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue from commercial products</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SKYTROFA&#174;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197,001</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,659</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">YORVIPATH&#174;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,727</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue from commercial products</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">225,728</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">35,659</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sales of SKYTROFA&#174; is primarily sold to specialty pharmacies and specialty distributors in the U.S. market, and to wholesalers and pharmacies in Germany. Revenue from sale of SKYTROFA for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, was negatively impacted by an adjustment to estimates and assumptions for sales deductions of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was related to periods prior to January 1, 2024. The adjustment was primarily attributable to a different payer and rebate mix than anticipated, and on which provisions for prior years were based.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, TransCon PTH received marketing approval in the EU and European Economic Area countries and is marketed as YORVIPATH&#174;. In August 2024, TransCon PTH received marketing approval in the U.S. and is marketed in the U.S. as YORVIPATH. The Company began selling YORVIPATH, primarily to pharmacies in Europe in the first quarter of 2024, and to specialty pharmacies in the U.S. in December 2024. In addition, the Company began selling YORIVPATH to distributors in the second quarter of 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> commercial customers represented more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of sales to commercial customers.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Partners and License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue attributable to collaboration partners and license agreements relates to Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;), Eyconis, Inc. (&#8220;Eyconis&#8221;), Teijin Limited (&#8220;Teijin&#8221;) and VISEN Pharmaceuticals (&#8220;VISEN&#8221;). Under the collaboration agreements, the Company also provides various research and development services which are invoiced to collaboration partners. Revenue for these activities is presented as part of &#8220;Rendering of services.&#8221; Employment costs related to these activities are presented as Research and Development Costs in the consolidated statement of profit or loss.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novo Nordisk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Company entered into a research and development collaboration and license agreement (the &#8220;Novo Nordisk Agreement&#8221;) with Novo Nordisk pursuant to which the Company granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products (including Semaglutide) in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases (the &#8220;IP&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Novo Nordisk Agreement includes provisions requiring at least one TransCon Semaglutide product and at least one other TransCon technology-based product to be identified, developed and commercialized in metabolic diseases to maintain certain exclusivities in the field, with additional provisions for cardiovascular diseases. Under the terms of the Novo Nordisk Agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas. The lead program in the collaboration is a once-monthly TransCon Semaglutide product candidate that will initially target obesity and type 2 diabetes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Novo Nordisk Agreement, the Company has the potential to receive total payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in upfront, development and regulatory milestone payments for the lead program. In addition, the Company has the potential to receive sales-based milestone payments and tiered royalties on global net sales. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million includes an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the exclusive license. For each additional metabolic or cardiovascular disease product candidate, the Company will be eligible to receive payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in development and regulatory milestone payments. In addition, the Company has the potential to receive sales-based milestone payments and tiered royalties on global net sales. Novo Nordisk agreed to pay royalties for each potential licensed product developed under the agreement that are an escalating tiered, mid-single digit percentage of the annual net sales of such licensed product and are subject to reduction due to patent valid claim expiration, biosimilar product market share, payment made under certain licenses for third party intellectual property and Inflation Reduction Act price negotiations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Novo Nordisk Agreement, the Company agreed to conduct certain pre-agreed early research and development of TransCon product candidates under the collaboration and is eligible to receive cost reimbursement from Novo Nordisk for its performance of such research and development activities under the Novo Nordisk Agreement with respect to such TransCon product candidates. Novo Nordisk is responsible for any other non-clinical and clinical development, regulatory, commercial manufacturing, and commercialization of such TransCon product candidates, and all costs associated with such activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of the Novo Nordisk Agreement, the Company granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. Additionally, the Company granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize GLP-1 receptor products using the TransCon technology for all indications, except for (i) certain pre-agreed rare endocrine indications, (ii) all indications in respect of the eye and adnexa and (iii) all indications in respect of oncology.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the Novo Nordisk Agreement has a royalty term that continues, on a per licensed product and per country basis, until the later of (i) the expiration of the last valid patent claim for any of our patents, joint improvement patents, licensed product patents as well as any improvements made by Novo Nordisk covering the licensed product&#8217;s dosage regimen or target product profile, or (ii) 11 years after the first commercial sale of such licensed product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IP comprises the patent protected TransCon technology platform, where future activities do not affect its existing stand-alone functionalities. Accordingly, the IP is classified as &#8220;right-to-use&#8221; licenses, with revenue recognized at a point in time, where the licensee is granted access to the IP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, &#8220;Licenses&#8221; includes revenue of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the upfront payment, which is allocated to transfer of the Company&#8217;s intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eyconis</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, a separate company created to develop, manufacture, and commercialize TransCon ophth</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">almology assets globally, together with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally (the &#8220;Eyconis Agreement&#8221;) and received, as consideration, an equity position in the newly formed company. In addition, the Company is eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is expected to provide various research and development services, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, &#8220;Licenses&#8221; includes revenue of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the non-cash upfront payment through an equity position in Eyconis, adjusted for internal profit, which is allocated to transfer of the Company&#8217;s intellectual property (the &#8220;IP&#8221;). The internal profit relates to the Company&#8217;s share of the non-cash upfront payment which is recognized as part of &#8220;Investments in associates&#8221; and recognized as revenue from &#8220;Licenses&#8221; as the IP is amortized in the associate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue from royalties or milestones has been recognized under the Eyconis agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Teijin</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company entered into an exclusive license agreement (the &#8220;Teijin Agreement&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with Teijin  for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease (the &#8220;Licensed Products&#8221;) in Japan. Under the terms of the Teijin Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with additional development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and commercial milestones. In addition, the Company is eligible to receive royalties on net sales of the Licensed Products in Japan, of up to mid-20&#8217;s percent.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the Company will provide clinical and commercial supply, and development services for joint activities, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, none of the Licensed Products have received marketing authorization in Japan. The Licensed Products (the &#8220;IP&#8221;) are patent protected, where future activities do not affect their existing stand-alone functionalities. Accordingly, all three licenses are classified as &#8220;right-to-use&#8221; licenses, with revenue recognized at a point in time, where the licensee is granted access to the IP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023, &#8220;Licenses&#8221; includes revenue of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the upfront payment, which is allocated to transfer of the Company&#8217;s IP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue from royalties o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r milestones has been recognized under the Teijin Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VISEN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the Company entered into three exclusive license agreements with VISEN. Revenue from collaboration partners and license agreements also includes license income, rendering of services and sale of clinical supply under the VISEN Agreements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389013696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 5&#8212;Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is managed and operated as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> business unit. Accordingly, no additional information on business segments or geographical areas is disclosed apart from revenue on geographical areas as disclosed in Note 4, &#8220;Revenue.&#8221; Revenue is specified on geographical areas according to the location of the customer.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s intangible assets and property, plant and equipment located by region are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intangible assets and property, plant and equipment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,640</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,464</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total intangible assets and property, plant and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">102,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">115,053</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, intangible assets and property, plant and equipment of &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, is located in Denmark, the country of domicile.</span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384939568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract', window );"><strong>Classes of employee benefits expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Employee costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 6&#8212;Employee costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Employee costs</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,474</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,278</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140,420</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,512</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,660</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,180</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pensions (defined contribution plans)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,485</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,403</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,163</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,003</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,877</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,627</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other employee costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,061</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,238</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,411</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total employee costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">292,535</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">258,456</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">223,801</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Included in the profit or loss</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,487</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,748</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,239</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,867</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127,002</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,581</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,181</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,706</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,981</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total employee costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">292,535</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">258,456</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">223,801</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average number of employees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">892</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">719</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes employee costs capitalized as part of inventories.</span></div></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key Management Personnel comprises the Board of Directors, the Executive Board and Non-executive Senior Management. Compensation to Key Management Personnel comprises salaries, participation in annual bonus schemes, pensions (defined contributions plans), and share-based compensation. Share-based compensation is elaborated in further details in Note 7, &#8220;Share-based Payment.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation to Key Management Personnel included in total employee costs is summarized below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:20.492%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.457%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Board of Directors </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Executive Board </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-executive Senior Management</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="34" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR &#8216;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Compensation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">543</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">403</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,148</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,375</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,809</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,286</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,087</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,169</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,276</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,334</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,243</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,392</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,266</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,529</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,872</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pensions (defined<br/>&#160;&#160;&#160;contribution plans)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other employee cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,651</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,819</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,676</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">22,677</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,795</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,322</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">13,727</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14,409</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,211</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors comprised six persons in 2024 and six to seven persons in 2023 and 2022.</span></div></div><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Board comprised four persons in 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389501744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based Payment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 7&#8212;Share-based Payment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an incentive to the senior management, other employees, members of the Board and select consultants, Ascendis Pharma A/S has established warrant programs, a RSU program (adopted in December 2021), and a PSU program (adopted in February 2023), which are all classified as equity-settled share-based payment transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to members of senior management, certain other employees and certain members of the Board (&#8220;RSU-holders&#8221;) in accordance with the Company&#8217;s RSU Program adopted in December 2021. Further, RSUs may be granted to select consultants. One RSU represents a right for the RSU-holder to receive one ADS of Ascendis Pharma A/S upon vesting if the vesting conditions are met or waived by the Board at its discretion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to certain members of senior management (the &#8220;PSU-holders&#8221;). In addition, PSUs may be granted to other employees, select consultants and members of the Board. PSUs were granted for the first time in March 2023. One PSU represents a right for the PSU-holder to receive one ADS of Ascendis Pharma A/S upon vesting if the vesting conditions are met or waived by the Board at its discretion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vesting Conditions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs granted vest over a predetermined service period, and accordingly require RSU-holders to be employed, or provide a specified period of service (&#8220;service conditions&#8221;). RSUs vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with 1/3 of the RSUs vesting on each anniversary date from the date of grant. RSUs generally cease to vest from the date of termination of employment, or for the Board, termination of board membership, whereas unvested RSUs will lapse.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One PSU represents a right for the PSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting. PSUs vest in a manner similar to the service conditions of the RSUs. For the March 2023 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of performance-based targets as determined by the Board, provided that no more than 10% of each tranche may be directly attributable to accomplishment of financial results achieved in the financial year prior to the vesting date. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the March 2024 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than 100%, nor will it result in additional grants.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs and PSUs generally cease to vest from the date of termination of employment or board membership, as applicable, whereas unvested RSUs or PSUs will be forfeited. The Board may at its discretion and on an individual basis decide to deviate from the vesting conditions, including deciding to accelerate vesting in the event of termination of employment or board membership, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Settlement Options</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All RSUs and PSUs are settled at the time of vesting by transfer of treasury shares that are ADSs repurchased in the market. In jurisdictions where the Company is required to withhold and settle tax with the tax authority on behalf of the RSU/PSU-holders, the Company withholds the number of RSUs or PSUs that are equal to the estimated monetary value of the RSU/PSU-holders tax obligation from the total number of RSUs or PSUs that otherwise would have been transferred to the RSU/PSU holder upon vesting. These settlements are presented as &#8220;Net settlement under stock incentive programs&#8221; in the consolidated statement of equity. The Company may at its sole discretion choose to make a cash settlement instead of delivering ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adjustments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU-holders and PSU-holders are entitled to an adjustment of the number of RSUs or PSUs granted, in the event of certain corporate changes, including among other events, increases or decreases to the share capital at a price below or above market value, the issuance of bonus shares, and changes in the nominal value of each share. In addition, the RSU and PSU Programs contain provisions to accelerate vesting, or compensate with grant of new equity instruments, in the event of restructuring events including change in control events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU and PSU Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number of RSUs and PSUs granted and outstanding:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,685</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,685</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,971</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,971</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">609,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,268</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">722,128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Settled during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">576,625</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">105,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">681,648</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717,980</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">810,635</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">212,160</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,007</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,638</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,004</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">993,807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">156,667</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,150,474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified by vesting date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">384,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,304</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">446,402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">384,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,478</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">447,916</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,271</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,885</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">993,807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">156,667</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,150,474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of RSUs and PSUs is determined on the basis of the closing ADS price on the grant date. The fair value of one RSU and one PSU at the date of grant was &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141.01</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.96</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. </span></div></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board and select consultants (&#8220;warrant-holders&#8221;). Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The exercise price is equal to the fair market value of the Company&#8217;s ordinary shares at the time of grant as determined by the Board. Apart from exercise prices, exercise periods and vesting conditions for board members, the programs are similar.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vesting Conditions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants granted vest over a predetermined service period and require warrant-holders provide a specified period of service. Warrants generally cease to vest from the date of termination. For warrants granted until November 2021, special vesting conditions apply in the event of termination. In relation to board members, the vesting shall cease on the termination date of the board membership regardless of the reason. In relation to consultants, the vesting shall cease on the termination date of the consultancy relationship. The warrant-holder will, however, be entitled to exercise vested warrants in the exercise periods after termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the employment contract is terminated, and the employee has not given the Company good reason to do so, the warrant-holder may keep the right to continued vesting and exercise of warrants as if the employment was still in effect. In such case, any expense not yet recognized for the outstanding warrants is recognized immediately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants Granted Until November 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants granted from 2012 until November 2021, generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months with 1/48 of the warrants vesting per month from the date of grant. However, effective from January 2015, certain warrants granted to board members vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months with 1/24 of the warrants vesting per month from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants Granted From December 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For warrants granted to employees and consultants, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the warrants vest one year after the date of grant, and the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the warrants granted vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, with 1/36 of the warrants vesting per month, from one year after the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For warrants granted to board members upon the board members accession, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the warrants granted vest one year after the date of grant, and the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the warrants granted shall vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, with 1/36 per month from one year after the date of grant. Regarding subsequent grants of warrants to board members, 50% of the warrants vest one year after the date of grant, and the remaining 50% of the warrants vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, with 1/12 per month from one year after the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exercise Periods</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vested warrants may be exercised during certain exercise periods each year, within certain periods after publication of earnings data of a fiscal quarter, interim and annual reports, as per each program&#8217;s terms and conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants expire ten years after the grant date. Warrants not exercised by the warrant-holder during the last exercise period shall become null and void without further notice or compensation or payment of any kind to the warrant-holder. If the warrant-holder is a consultant, advisor or board member, the exercise of warrants is conditional upon the warrant-holder&#8217;s continued service to the Company at the time the warrants are exercised. If the consultant&#8217;s, advisor&#8217;s or board member&#8217;s relationship with the Company should cease without this being attributable to the warrant-holder&#8217;s actions or omissions, the warrant-holder shall be entitled to exercise vested warrants in the pre-defined exercise periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adjustments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant-holders are entitled to an adjustment of the number of warrants issued and/or the exercise price applicable in the event of certain corporate changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events giving rise to an adjustment include, among other things, increases or decreases to the share capital at a price below or above market value, the issuance of bonus shares, changes in the nominal value of each share, and payment of dividends in excess of 10% of the Company&#8217;s equity.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number and weighted average exercise prices of, and movements, in warrants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrants (number)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price (EUR)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2022</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,085,073</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.30</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">357,092</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">214,613</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.83</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,541</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123.62</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,864,011</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81.30</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at the reporting date</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,972,026</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">66.34</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">395,275</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.07</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">555,144</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.76</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,358</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115.79</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,523,784</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">86.38</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at the reporting date</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,273,056</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">80.02</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504,105</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.48</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682,048</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.35</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,719</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107.85</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,204,122</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">93.25</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at the reporting date</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,226,643</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">89.33</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average share price (listed in $) at the date of exercise was &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135.86</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.10</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113.60</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. </span></div></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Board was authorized to grant up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,060,116</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional warrants to employees, board members and select consultants without preemptive subscription rights for the shareholders of Ascendis Pharma A/S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the weighted average exercise prices and weighted average remaining contractual life for outstanding warrants at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 per grant year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding<br/>Warrants (number</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price (EUR)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Life<br/>(months)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted before </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2022</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,185,556</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89.67</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted in </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235,408</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.71</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted in </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292,648</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted in </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">490,510</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.34</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,204,122</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">93.25</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">65</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the exercise prices of outstanding warrants under the Company&#8217;s warrant programs range from &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> depending on the grant dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The range of exercise prices for outstanding warrants was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.48</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively. The weighted average remaining life for outstanding warrants was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Compensation Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant compensation costs are recognized in the consolidated statements of profit or loss over the vesting period of the warrants granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant compensation costs are determined with basis in the grant date fair value of the warrants granted and recognized over the vesting period. Fair value of the warrants is calculated at the grant dates by use of the Black-Scholes option-pricing model with the following assumptions: (1) an exercise price equal to the estimated market price of the Company&#8217;s shares at the date of grant; (2) an expected lifetime of the warrants determined as a weighted average of the time from grant date to date of becoming exercisable and from grant date to expiry of the warrants; (3) a risk-free interest rate equaling the effective interest rate on a Danish government bond with the same lifetime as the warrants; (4) no payment of dividends; and (5) an expected volatility using the Company&#8217;s own share price (from 2021).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the input to the Black-Scholes option-pricing model and the calculated fair values for warrant grants in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:38.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:15.82%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:15.82%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:15.82%;box-sizing:content-box;"></td>
        <td style="width:2.18%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.71</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.57</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.40</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.97</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">) - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.54</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life of warrants (years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average exercise price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.48</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.07</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.40</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of warrants granted in the year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.86</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.39</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.34</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.03</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.55</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.85</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389488720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Accountant Fees and Services<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditor's remuneration [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory', window );">Principal Accountant Fees and Services</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8&#8212; Principal Accountant Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth, for each of the years indicated, the fees billed by the Company&#8217;s independent public accountants and the proportion of each of the fees out of the total amount billed by the accountants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Principal accountant fees and services</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">814</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit-related fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total principal accountant fees and services</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,049</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">861</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">952</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of compensation to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuditorsRemunerationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384914800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax on Profit/(Loss) for the Year and Deferred Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeAbstract', window );"><strong>Deferred tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Tax on Profit/(Loss) for the Year and Deferred Tax</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 9&#8212;Tax on Profit/(Loss) for the Year and Deferred Tax</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.409%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.177999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.177999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.238%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax on profit/(loss) for the year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current tax (expense)/income</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,723</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current tax, adjustments to prior years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,904</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,654</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax, movement for the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,035</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,044</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax, adjustments to prior years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,786</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,843</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax for the year can be explained as follows</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Profit/(loss) before tax</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">373,241</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474,144</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">577,817</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax at the Danish corporation tax rate of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82,113</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">104,312</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">127,120</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax effect of:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-deductible costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,740</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,494</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,094</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional tax deductions</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,161</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,077</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,720</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impact from associates</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,413</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,047</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,893</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prior year adjustments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,294</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other effects including effect of different tax rates</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">882</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,716</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax asset, not recognized</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,627</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,514</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax on profit/(loss) for the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,843</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.30</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">0.93</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specification of deferred tax assets/(liabilities)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax deductible losses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">434,997</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">521,697</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433,174</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other temporary differences, assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,479</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,256</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax asset, not recognized</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">599,476</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">537,953</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,135</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other temporary differences, liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,258</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,830</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total deferred tax assets/(liabilities) at December 31</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,258</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,830</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, a deferred tax liability has been recognized in relation to taxable temporary differences in one jurisdiction, as we do not believe we will have any deductible temporary differences nor tax losses to deduct the taxable difference in, when they are expected to reverse.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets have not been recognized in the consolidated statements of financial position as of December 31, 2024 due to uncertainty relating to future utilization. The deferred tax asset can be carried forward without timing limitations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had tax losses carried forward of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">1,946.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,371.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at December 31, 2024 and 2023, respectively. Tax losses can be carried forward infinitely, where certain limitations exist for amounts to be utilized each year. Under Danish tax legislation, tax losses may be partly refunded by the tax authorities to the extent such tax losses arise from research and development activities. the jointly taxed Danish entities had a negative taxable income, and accordingly were entitled to a tax refund of approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax losses carried forward at December 31, 2023 (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,371.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) has been reduced with &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">456.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The reduction is as a consequence of two changes of tax principles made in the Danish tax returns for the taxable year 2023 (filed in June 2024). The changes are related to R&amp;D costs (depreciations) and inventory write-down (cost price). This reduction in tax losses is still available as deferred tax assets, that can be recognized for future utilization; only not as a &#8220;Tax deductible losses,&#8221; but as &#8220;Other temporary differences, assets.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is entitled to additional tax deductions related to share based payments (Warrants, RSUs and PSUs). Tax deductions can be taken when the warrants/RSUs/PSUs are exercised/transferred. For the year ended December 31, 2024, the Company was entitled to additional tax deductions with a tax value of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively. These future tax deductions depend on the timing and amounts of warrants/RSUs/PSUs exercises/transfers, and accordingly, future additional tax deductions are subject to uncertainties. Refer to Note 7, &#8220;Share-based Payment,&#8221; regarding a description of warrant and RSU/PSU programs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is entitled to additional tax deductions for which deferred tax asset cannot be recognized due the initial recognition exception in IAS 12, &#8220;Income Taxes.&#8221; For the year ended December 31, 2024, the Company is entitled to additional future tax deduction with a tax value of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023 and 2022. In addition, the Company is entitled to additional tax deductions related to tax credits. Tax credits can be taken in future taxes. For the year ended December 31, 2024, the Company was entitled to additional tax deduction with a tax value of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, compared to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 23, 2023, the IASB issued International Tax Reform - Pillar Two Model Rules - Amendments to IAS 12 which clarify that IAS 12 applies to income taxes arising from tax law enacted or substantively enacted to implement the Pillar Two model rules published by the OECD, including tax law that implements Qualified Domestic Minimum Top-up Taxes. The Company has adopted these amendments; however, they are not applicable for the year ended December 31, 2024, as the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s consolidated revenue is currently below the threshold of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Parent Company, Ascendis Pharma A/S, is jointly taxed with its Danish subsidiaries. The current Danish corporation tax is allocated between the jointly taxed Danish companies in proportion to their taxable income (full absorption with refunds for tax losses). The jointly taxed companies are included in the on-account tax scheme.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109391238272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10&#8212;Intangible Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Goodwill</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,222</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,296</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,791</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,867</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization and impairment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">889</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">889</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,839</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,839</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">924</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,419</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the reporting date, no internally generated intangible assets from development of pharmaceutical drug candidates have been recognized. Thus, all related research and development costs incurred for the years ended December 31, 2024, 2023 and 2022, were recognized in the consolidated statements of profit or loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill relates to the acquisition of Complex Biosystems GmbH (now Ascendis Pharma GmbH) in 2007. Goodwill was calculated as the excess amount of the purchase price to the fair value of identifiable assets acquired, and liabilities assumed at the acquisition date. Ascendis Pharma GmbH was initially a separate technology platform company but is now an integral part of the Company&#8217;s research and development activities. Accordingly, it is not possible to look separately at Ascendis Pharma GmbH when considering the recoverable amount of the goodwill. Goodwill is monitored and tested for impairment on a consolidated level as the Company is considered to represent one cash-generating unit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The recoverable amount of the cash-generating unit is determined based on an estimation of the Company&#8217;s fair value less costs of disposal. The fair value of goodwill has been determined after taking into account the market value of the Company&#8217;s ADSs as of the reporting date. The computation of the market value including an estimation of selling costs, significantly exceeded the carrying amount of the net assets, leaving sufficient value to cover the carrying amount of goodwill. Considering the excess value, no further assumptions are deemed relevant to be applied in determining whether goodwill is impaired. </span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389521264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 11&#8212;Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plant and<br/>Machinery</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other<br/>Equipment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Leasehold<br/>Improve-<br/>ments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Right-of-Use<br/>Assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,203</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,466</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">383</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">440</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,093</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,989</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">27,436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,420</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19,375</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">123,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">182,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">299</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">951</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,187</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,635</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,719</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,462</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10,976</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20,298</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">130,154</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">183,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Depreciation and impairment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,584</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,544</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,648</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,569</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,899</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,875</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">405</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,834</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,193</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12,784</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,175</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10,946</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">40,612</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">71,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,283</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,247</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,296</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,501</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,885</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">556</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,906</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">9,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,190</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12,785</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">54,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">84,647</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14,652</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">8,429</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">83,308</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">110,634</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12,003</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,513</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">75,412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">98,714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The impairment charge for the year ended December 31, 2023, relates to change in activities at one of our R&amp;D sites and is determined according to its estimated value in use. The R&amp;D site is subleased and is recognized as a right-of-use asset with a carrying amount of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation charges are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Depreciation charges</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,197</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,509</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,245</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,892</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,597</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,623</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total depreciation charges</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,247</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">18,428</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,514</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes depreciation charges capitalized as part of inventories.</span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382533344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Associates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract', window );"><strong>Investments accounted for using equity method [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory', window );">Investments in Associates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 12&#8212;Investments in Associates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s associates relate to investments in Eyconis (principal place of business; U.S.), and VISEN (principal place of business; China). The Company&#8217;s investments in Eyconis and VISEN are accounted for using the equity method in the consolidated financial statements as the Company has determined that it has significant influence over the investments.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, a separate company created to develop, manufacture, and commercialize TransCon ophth</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">almology assets globally, together with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. As of December 31, 2024, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s present ownership in Eyconis was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the Company entered into three exclusive license agreements with VISEN for the further development and commercialization of TransCon hGH, TransCon PTH and TransCon CNP in Greater China, and as consideration for the granting of such rights has received a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% ownership of VISEN&#8217;s issued and outstanding shares. As of December 31, 2024, the Company&#8217;s present ownership in VISEN was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregated profit or loss, total comprehensive income, transactions and outstanding balances with associates as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of associates. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B4<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B4_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389517168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 13&#8212;Inventories</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials and consumables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,596</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,566</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235,688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,030</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,325</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,335</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total inventories</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">295,609</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">208,931</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to production lead time, work in progress includes inventories that are not sellable before more than twelve months after the reporting date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories were reduced by write-downs of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively, which include write-downs on pre-launch inventories.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109391417664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilitiesAbstract', window );"><strong>Contract liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Schedule of Revenue Attributable to Commercial Customers</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 14&#8212;Contract Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, contract liabilities comprise unsatisfied performance obligations related to delivery of commercial supply under one of the Company&#8217;s license agreements. Non-current contract liabilities are expected to be recognized as revenue within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue recognized from contract liabilities were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and primarily related to delivery of clinical supply and research and development services.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384946928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 15&#8212;Provisions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development in provisions is specified below:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:17.824%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Provisions</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,719</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions related to prior years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,684</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net additions for the year</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,284</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,462</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">99,149</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109356324240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 16&#8212;Financial Assets and Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial assets and liabilities comprise the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets by category</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,280</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,874</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables (excluding indirect tax receivables)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,964</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,275</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">559,543</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">392,164</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">439,222</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">439,222</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,317</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">727,470</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">437,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">439,222</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities by category</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458,207</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,379</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,030</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,793</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,394</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,566</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities (excluding indirect tax and employee related payables)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">953,321</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">738,831</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,103,991</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">882,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365,080</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,996</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">738,911</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">659,131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,103,991</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">882,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance income and expenses are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance income</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,857</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,426</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement gain of financial liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,654</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation (net)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,755</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total finance income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">25,609</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,857</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">52,181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,065</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement loss of financial liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation (net)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,149</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total finance expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">44,065</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">50,487</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income and interest expenses relate to financial assets and liabilities measured at amortized cost. Net exchange rate gains and losses primarily relate to U.S. Dollar/Euro fluctuations pertaining to the Company&#8217;s cash, cash equivalents, marketable securities and borrowings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrowings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, the Company issued an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">575.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of fixed rate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% convertible notes. The net proceeds from the offering of the convertible notes were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">557.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), after deducting the initial purchasers&#8217; discounts and commissions, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">transaction costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes accrue interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company&#8217;s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0118</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ADSs per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> principal amount of convertible notes, which represents an initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company&#8217;s option at any time, and from time to time, on or after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 7, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">but only if the last reported sale price per ADS exceeds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the conversion price on each of (i) at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trading days, whether or not consecutive, during the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into capped synthetic royalty funding agreements with Royalty Pharma (the &#8220;Purchaser&#8221;), which is presented as royalty funding liabilities, and represents the Company&#8217;s contractual obligations to pay a predetermined percentage of future commercial revenue until reaching a predetermined multiple of proceeds received, according to the detailed provisions of the synthetic royalty funding agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">YORVIPATH Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Yorvipath Agreement&#8221;) with the Purchaser. The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Royalty Pharma Yorvipath Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Yorvipath Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net revenue from sales of YORVIPATH in the U.S. (the &#8220;Yorvipath Revenue Payments&#8221;). The Yorvipath Revenue Payments to the Purchaser will cease upon reaching a multiple of the Yorvipath Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times if the Purchaser receives Yorvipath Revenue Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Royalty Pharma Yorvipath Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to September 30, 2028, and the Company has paid the Purchaser, Yorvipath Revenue Payments equal to the Yorvipath Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SKYTROFA Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Skytrofa Agreement&#8221;) with the Purchaser. The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Royalty Pharma Skytrofa Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Skytrofa Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net revenue from sales of SKYTROFA in the U.S., beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Skytrofa Revenue Payments&#8221;). The Skytrofa Revenue Payments to the Purchaser will cease upon reaching a multiple of the Skytrofa Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.925</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times if the Purchaser receives Skytrofa Revenue Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Royalty Pharma Skytrofa Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.925</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser, Skytrofa Revenue Payments equal to the Skytrofa Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company primarily leases office and laboratory facilities. Lease arrangements contain a range of different terms and conditions and are typically entered into for fixed periods. In order to improve flexibility to the Company&#8217;s operations, lease arrangements may provide the Company with option to extend the lease or terminate the lease within the enforceable lease term. In the Company&#8217;s current lease portfolio, extension and termination options are up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in addition to the non-cancellable periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following expenses related to lease activities were recognized in the consolidated statements of profit or loss:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease expenses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,312</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,875</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,740</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short term leases and leases of low value assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">353</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease interest</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,303</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,581</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,842</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total lease expenses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,900</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,809</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,862</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, the Company entered into a facility lease in Germany with an enforceable lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and comprises total lease cash-outflows of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in December 2024, the Company entered into additional leases in Denmark with enforceable lease terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years with option to terminate earlier and comprise total lease cash-outflows of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million if not terminated earlier. The leases are expected to commence in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing Activities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in borrowings related to financing activities is specified below:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:19.848%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.623%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.564%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.824%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.803%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash payments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-cash items</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Beginning<br/>of year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Repay-<br/>ments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net proceeds</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additions/<br/>(disposals)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remeasure-<br/>ments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accretion of<br/>interest</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Foreign<br/>exchange<br/>translation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">End of<br/>year</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="15" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">545,472</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,819</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,158</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,248</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,116</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,907</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">763,586</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,793</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,677</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">861</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,303</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,750</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,030</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">644,265</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">26,496</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">134,158</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">861</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,248</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">65,419</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">49,657</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">856,616</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">399,186</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,054</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,256</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,386</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,302</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">545,472</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,191</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,006</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,973</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,581</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,946</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,793</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">508,377</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">26,060</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">136,256</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,973</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,967</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,248</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">644,265</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value cannot be measured based on quoted prices in active markets or other observable inputs and accordingly, derivative liabilities are measured by using the Black-Scholes option-pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company&#8217;s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company&#8217;s share price (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of December 31, 2024 and December 31, 2023, respectively).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional description of fair values, refer to the following section &#8220;Fair Value Measurement.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sensitivity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative increase in volatility, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative decrease in volatility indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, on December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% increase in the share price, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% decrease in the share price indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value compared to carrying amount of marketable securities, convertible notes, royalty funding liabilities and derivatives, and their level in the fair value hierarchy is summarized in following table, where;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are unobservable inputs for the asset or liability.</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value level</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(1-3)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,275</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,266</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,275</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,266</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458,207</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438,288</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407,095</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385,410</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,379</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,673</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,377</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,975</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">763,586</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">743,961</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">545,472</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">529,385</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies movements in level 3 fair value measurements:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,950</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,467</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement recognized in financial income or expense</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,374</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,654</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,483</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">157,950</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109388983248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial Risk Management</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 17 &#8211; Financial Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages capital to ensure that all group enterprises will be able to continue as a going concern while maximizing the return to shareholders through the optimization of debt and equity balances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital Structure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s capital structure consists of equity and external debt obtained through issuance of convertible notes and royalty funding liabilities. The Company is not subject to any contractually imposed capital requirements or financial covenants. The capital structure is reviewed on an ongoing basis for the adequacy of the Company&#8217;s capital compared to the resources required for carrying out ordinary activities</span><span style="color:#404040;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#404040;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development in the Company&#8217;s share capital and treasury shares reserves are described in the following sections. Other equity reserves are described in Note 2, &#8220;Summary of Material Accounting Policies.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The share capital of Ascendis Pharma A/S consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,689,487</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> fully paid shares at a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all in the same share class, and which includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">845,887</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ordinary shares represented by ADSs held by Ascendis Pharma A/S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in outstanding shares of the Company was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2021</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2020</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Changes in share capital</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,707,439</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,152,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,937,682</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,750,386</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,985,837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase through cash contributions</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,982,048</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">555,144</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">214,613</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,187,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,764,549</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">60,689,487</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">57,707,439</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">57,152,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">56,937,682</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">53,750,386</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Treasury Shares Reserve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in holding of treasury shares was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.241999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominal<br/>value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding in<br/>% of total<br/>outstanding<br/>shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,113,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">146</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,093,054</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">113</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">845,887</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Risk Management Objectives</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company regularly monitors the access to domestic and international financial markets, manages the financial risks relating to its operations, and analyzes exposures to risk, including market risk, such as foreign currency risk and interest rate risk, credit risk and liquidity risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial risk exposure and risk management policies are described in the following sections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s activities expose the group enterprises to the financial risks of changes in foreign currency exchange rates and interest rates. Derivative financial instruments are not applied to manage exposure to such risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is exposed to foreign currency exchange risks arising from various currency exposures, primarily with respect to the U.S. Dollar (&#8220;USD&#8221;). Foreign currency exchange risks to the USD are unchanged to prior year, and primarily relate to sales and purchases in foreign currencies, convertible notes and royalty funding liabilities, countered by cash and cash equivalents. The exposure from foreign currency exchange risks is managed by maintaining cash positions in the currencies in which the majority of future expenses are denominated, and payments are made from those reserves.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Sensitivity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table details how a strengthening of the USD against the EUR would impact profit or loss, and equity before tax at the reporting date. A similar weakening of the USD would have the opposite effect. A positive number indicates an increase in profit or loss and equity before tax, while a negative number indicates the opp</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">osite. The sensitivity analysis is deemed representative of the inherent foreign currency exchange risk associated with the operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Hypothetical impact on consolidated<br/>financial statements</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominal<br/>positions<br/>(net)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase in<br/>foreign<br/>currency<br/>exchange<br/>rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Profit/(loss)<br/>before tax</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity before tax</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR &#8216;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">USD/EUR</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">735,064</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,506</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,506</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369,091</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding convertible notes comprise a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% coupon fixed rate structure. Further</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the effective interest rate on royalty funding liabilities is estimated at initial recognition and takes into account anticipated amount and timing of future cash flows, which further depends on future commercial revenue forecasts and the probability of exercising the embedded buy-out option. Material changes to anticipated future cash flows could potentially increase or decrease future interest expense. In addition, the interest rate on lease liabilities is fixed at the lease commencement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future indebtedness, including those related to lease arrangements, if any, may be subject to higher interest rates. In addition, future interest income from interest-bearing bank deposits may fall short of expectations due to changes in interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative liabilities are measured at fair value through profit or loss. Since the fair value is exposed from the development in interest rates, the profit or loss is exposed to volatility from such development. The effects of interest rate fluctuations are not considered a material risk to the Company&#8217;s financial position. Accordingly, no interest sensitivity analysis has been presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Credit Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has adopted an investment policy with the primary purpose of preserving capital, fulfilling liquidity needs and diversifying the risks associated with cash, cash equivalents and marketable securities. This investment policy establishes minimum ratings for institutions with which the Company holds cash and cash equivalents, as well as rating and concentration limits for marketable securities held.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exposure to credit risk primarily relates to cash and cash equivalents. The credit risk on bank deposits is limited because the counterparties, holding significant deposits, are banks with minimum credit-ratings of A3/A- assigned by international credit-rating agencies. The banks are reviewed on a regular basis and deposits may be transferred during the year to mitigate credit risk. In order to mitigate the concentration of credit risks on bank deposits and to preserve capital, a portion of the bank deposits may be placed into investment grade rated marketable securities. The Company&#8217;s investment policy, approved by the Board, only allows investment in marketable securities having investment grade credit-ratings, assigned by international credit-rating agencies. Accordingly, the risk from probability of default is low. On each reporting date, the risk of expected credit loss on bank deposits and marketable securities, if any, including the hypothetical impact arising from the probability of default, is considered in conjunction with the expected loss caused by default by banks or securities with similar credit-ratings and attributes. In line with previous periods, this assessment did not reveal a material impairment loss, and accordingly no provision for expected credit loss has been recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the reporting dates, there are no significant overdue trade receivable balances. As a result, write-down to accommodate expected credit-losses is not deemed material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity Risk Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, the risk of insufficient funds has been addressed through proceeds from sale of the Company&#8217;s securities in private and public offerings, through issuance of convertible notes in 2022, and through royalty funding liabilities in 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity risk is managed by maintaining adequate cash reserves and banking facilities. The risk of shortage of funds is monitored, using a liquidity planning tool, to ensure sufficient funds are available to settle liabilities as they fall due. Besides long term deposits on leases, the Company&#8217;s financial assets are recoverable within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the reporting date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Maturity analysis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the consolidated statements of financial position:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&lt; 1 year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1-5 years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&gt;5 years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>contractual<br/>cash-flows</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,027,558</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,660</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,073,521</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">763,586</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,007</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,616</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,030</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,705</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,705</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,705</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">144,490</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,079,565</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">52,787</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,276,842</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">953,321</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,708</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">742,925</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,397</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">797,030</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">545,472</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,385</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,056</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,867</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,793</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,566</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,566</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,566</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">120,659</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">794,351</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">91,453</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,006,463</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">738,831</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Borrowings (excluding lease liabilities)&#8221; comprise convertible notes and royalty funding liabilities. Further details regarding classification of convertible notes as current liabilities in the consolidated statement of financial position are provided in Note 2, &#8220;Summary of Material Accounting Policies,&#8221; section &#8220;New and Amended IFRS Accounting Standards and Interpretations.&#8221; Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements are provided above.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109379758848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalCommitmentsAbstract', window );"><strong>Capital commitments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 18&#8212;Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual commitments for the acquisition of property, plant and equipment were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively. Further, with certain suppliers, the Company has agreed minimum commitments related to the manufacturing of product supply, subject to continuous negotiation and adjustments according to the individual contractual terms and conditions. Cost of product supply is recognized when the Company obtains control of the goods. In addition, the Company has commitments related to short-term leases and leases of low value assets, contracts of various lengths in respect of research and development with CROs, and IT and facility related services. Costs relating to those commitments are recognized as services are received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is not aware of any significant legal claims or disputes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109388976208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 19&#8212;Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors, the Executive Board and non-executive Senior Management (&#8220;Key Management Personnel&#8221;) are considered related parties as they have authority and responsibility for planning and directing the Company&#8217;s operations. Related parties also include undertakings in which such individuals have a controlling or joint controlling interest. Additionally, all group enterprises and associates are considered related parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the Company&#8217;s related parties nor major shareholders hold a controlling, joint controlling, or significant interest in the Group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into employment agreements with and issued warrants, RSUs and PSUs to Key Management Personnel. In addition, the Company pays fees for board tenure and board committee tenure to the independent members of the Board of Directors. For further details, refer to Note 6, &#8220;Employee Costs.&#8221; Indemnification agreements have been entered with members of the Board of Directors, the Executive Board and Non-executive Senior Management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions between the parent company and group enterprises comprise management and license fees, research and development services, administration services, and clinical and commercial supplies. These transactions have been eliminated in the consolidated financial statements. Transactions and outstanding balances with the associates are disclosed in Note 12, &#8220;Investments in Associates.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the parent company Ascendis Pharma A/S is jointly taxed with its Danish subsidiaries, where the current Danish corporation tax is allocated between the jointly taxed Danish companies. For further details, refer to Note 9, &#8220;Tax on Profit/(Loss) for the Year and Deferred Tax.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except for the information disclosed above, the Company has not undertaken any significant transactions with members of the Key Management Personnel, or undertakings in which the identified related parties have a controlling or joint controlling interest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389521920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Group Enterprises<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_InvestmentsInGroupEnterprisesAbstract', window );"><strong>Investments In Group Enterprises [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory', window );">Investments in Group Enterprises</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 20&#8212;Investments in Group Enterprises</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S&#8217;s (parent company) investments in group enterprises at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 comprise:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subsidiaries</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Domicile</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ownership</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma GmbH</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology GmbH</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma, Inc.</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology, Inc.</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Ophthalmology Division A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology Division A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Bone Diseases A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Growth Disorders A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Oncology Division A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Europe A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma UK Limited</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Iberia S.L.</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Spain</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma France SASU</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">France</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Italia SRL</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Italy</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Sverige AB</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sweden</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Switzerland GmbH</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Switzerland</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Associates</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Domicile</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ownership</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cayman Island</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Eyconis Inc.</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.6</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_InvestmentsInGroupEnterprisesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments in group enterprises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_InvestmentsInGroupEnterprisesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interests in other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 1<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_1&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109391228000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ownership<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfBeneficialOwnershipAbstract', window );"><strong>Disclosure Of Beneficial Ownership [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfBeneficialOwnershipExplanatory', window );">Ownership</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 21&#8212;Ownership</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following investors, or groups of affiliated investors, are known by us to beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s outstanding ordinary shares at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with RA Capital Management, LLC, USA</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Westfield Capital Management Company, L.P., USA</span></span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with FMR LLC, USA</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Avoro Capital Advisors LLC, USA</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with Artisan Partners LP, USA</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with Janus Henderson Group plc, United Kingdom</span></span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s American Depository Shares are held through BNY (Nominees) Limited as nominee, of The Bank of New York Mellon, UK (as registered holder of the Company&#8217;s outstanding ADSs).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfBeneficialOwnershipAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Beneficial Ownership [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfBeneficialOwnershipAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfBeneficialOwnershipExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of beneficial ownership explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfBeneficialOwnershipExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389539728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 22&#8212;Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No events have occurred after the reporting date that would influence the evaluation of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109383653888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Preparation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Preparation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are prepared in accordance with the IFRS Accounting Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), and as adopted by the European Union (the &#8220;EU&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies applied when preparing the consolidated financial statements are described in detail below and are applied for all group entities. Significant accounting judgements and sources of estimation uncertainties used when exercising the accounting policies are described in Note 3, &#8220;Significant Accounting Judgements and Estimates.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements have been prepared under the historical cost convention, apart from certain financial instruments that are measured at fair value at initial recognition.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">New and Amended IFRS Accounting Standards and Interpretations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New IFRS Accounting Standards Not Yet Effective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, the IASB issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;), which replaces IAS 1, &#8220;Presentation in Financial Statements.&#8221; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discontinued operations.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are not expected to be affected by other new or amended standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoingConcernExplanatory', window );">Going Concern</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors has at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, the Company continues to adopt the going concern basis of accounting in preparing the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DescriptionOfBasisOfConsolidationExplanatory', window );">Basis of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the parent company, Ascendis Pharma A/S, and all enterprises over which the parent company has control. Control of an enterprise exists when the Company has exposure, or rights to, variable returns from its involvement with the enterprise and has the ability to control those returns through its power over the enterprise. Accordingly, the consolidated financial statements include Ascendis Pharma A/S and the subsidiaries listed in Note 20, &#8220;Investments in Group Enterprises&#8221;</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory', window );">Consolidation Principles Subsidiaries</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consolidation Principles</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries, which are enterprises the Company controls, are fully consolidated from the date upon which control is transferred to the Company. They are deconsolidated from the date control ceases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Control over an enterprise is reassessed if facts and circumstances indicate that there are changes to one or more of the three elements of control, respectively:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the contractual arrangement(s) with the other vote holders of the enterprise; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#8217;s voting rights and potential voting rights; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights arising from other contractual arrangements.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between group enterprises are eliminated in full on consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries apply accounting policies in line with the Company&#8217;s accounting policies. When necessary, adjustments are made to bring the entities&#8217; accounting policies in line with those of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates', window );">Investments in Associates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments in Associates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An associate is an entity over which the Company has significant influence over financial and operational decisions but without having control or joint control. The Company&#8217;s associates are accounted for using the equity method and initially recognized at cost. Thereafter, the carrying amount of the investment is adjusted to recognize changes in the Company&#8217;s share of net assets of the associates since the acquisition or establishment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated statements of profit or loss include the Company&#8217;s share of result after tax of the associates after any adjustments made to bring the associates accounting policies in line with those of the Company. Transactions between the associates and the Company are eliminated proportionally according to the Company&#8217;s interest in the associates. Unrealized gains and losses resulting from transactions between the Company and its associates are eliminated to the extent of the Company&#8217;s interest in the associates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On each reporting date, the Company determines whether there are indications that the investment is impaired. If there is such evidence, the amount of impairment is calculated as the difference between the recoverable amount of the associate and its carrying amount. Any impairment loss is recognized in the consolidated statements of profit or loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign Currency</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Currency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Functional and Presentation Currency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Items included in the consolidated financial statements are measured using the functional currency of each group entity. Functional currency is the currency of the primary economic environment in which the entity operates. The consolidated financial statements are presented in Euros (or &#8220;EUR&#8221;), which is also the functional currency of the parent company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Translation of Transactions and Balances</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On initial recognition, transactions in currencies other than the individual entity&#8217;s functional currency are translated applying the exchange rate in effect at the date of the transaction. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the reporting date are translated using the exchange rate in effect at the reporting date. Monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange rate differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the reporting date, are recognized in profit or loss as finance income or finance expenses. Property, plant and equipment, intangible assets and other non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as of the dates of the initial transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Currency Translation of Group Enterprises</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When subsidiaries or associates present their financial statements in a functional currency other than EUR, their statements of profit or loss are translated at average exchange rates. Balance sheet items are translated using the exchange rates at the reporting date. Exchange rate differences arising from translation of foreign entities&#8217; balance sheet items at the beginning of the year to the reporting date exchange rates as well as from translation of statements of profit or loss from average rates to the exchange rates at the reporting date are recognized in other comprehensive income. Similarly, exchange rate differences arising from changes that have been made directly in a foreign subsidiary&#8217;s equity are recognized in other comprehensive income.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Commercial Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue is recognized when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue is measured at the contractual sales price, reflecting the consideration received or receivable from customers, net of value added taxes, and provisions for a variety of sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales deductions attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements. In addition, goods are principally sold on a &#8220;sale-or-return&#8221; basis, where customers may return products in line with the Company&#8217;s return policy. Sales deductions and product returns are considered variable consideration and are estimated at the time of sale using the expected value method. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net contractual price only to the extent that it is probable that a significant reversal will not occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unsettled sales deductions and product returns are recognized as provisions when timing or amount is uncertain. Payable amounts that are absolute are recognized as other liabilities. Sales discounts and deductions that are payable to customers are offset in trade receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other revenue relates to collaboration and license agreements. When contracts with customers are entered into, the goods and/or services promised in the contract are assessed to identify distinct performance obligations. A promise in the agreement is considered a distinct performance obligation if both of the following criteria are met:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct); and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For collaboration and license agreements that contain multiple promises to the customer, the promises are identified and accounted for as separate performance obligations if these are distinct. If promises are not distinct, those goods or services are combined with other promised goods or services until a bundle of goods or services that is distinct is identified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price in the contract is measured at fair value and reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Under license agreements, the transaction price may include up-front payments, royalty and milestone payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales-based royalty and sales-based milestone income promised in exchange for a license of intellectual property is recognized as revenue at the later of the occurrence of subsequent sale or satisfaction of the performance obligation to which some or all of the royalty or milestone has been allocated. Milestone income related to regulatory activities is included in the transaction price at the point in time that it is highly probable that the applicable milestone criteria is met.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is allocated to each performance obligation according to their stand-alone selling prices and is recognized when control of the goods or services is transferred to the customer, either over time or at a point in time, depending on the specific terms and conditions in the contracts. License agreements, which transfer rights to the Company&#8217;s intellectual property (&#8220;IP&#8221;), are classified as &#8220;right-to-access&#8221;, with revenue recognized over time, or as &#8220;right-to-use&#8221; with revenue recognized at a point in time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale of clinical trial supply is recognized as revenue when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery. Rendering of services is recognized as revenue over the service period as stipulated under the applicable agreement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs consist primarily of manufacturing costs, preclinical and clinical study costs and costs for process optimizations and improvements performed by Clinical Research Organizations (&#8220;CROs&#8221;) and Contract Manufacturing Organizations (&#8220;CMOs&#8221;), salaries and other personnel costs including pension and share-based payment, the cost of facilities, professional fees, cost of obtaining and maintaining the Company&#8217;s intellectual property portfolio, and depreciation of non-current assets related to research and development activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research costs are incurred at the early stages of the drug development cycle from the initial drug discovery and include a variety of preclinical research activities in order to assess potential drug candidates in non-human subjects, prior to filing an Investigational New Drug Application (&#8220;IND&#8221;), or equivalent. Research costs are recognized in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development activities relate to activities following an IND, or equivalent, and typically involve a single product candidate undergoing a series of studies to illustrate its safety profile and effect on human beings, prior to obtaining the necessary approval from the appropriate authorities. Development activities comprise drug candidates undergoing clinical trials starting in phase I (first time drug is administered in a small group of humans), and further into Phase II and III, which include administration of drugs in larger patient groups. Following, and depending on clinical trial results, a Biologic License Application (&#8220;BLA&#8221;) or New Drug Application (&#8220;NDA&#8221;) may be submitted to the authorities, to apply for marketing approval, which, with a positive outcome will permit the Company to market and sell the products. Long-term extension trials may be ongoing following submission of a BLA or NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development costs also include product development and pre-commercial manufacturing costs related to development product candidates, and write-downs of inventories manufactured for late-stage development product candidates prior to marketing approval being obtained (pre-launch inventories).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the risk related to the development of pharmaceutical products, the Company cannot estimate the future economic benefits associated with individual development activities with sufficient certainty until the development activities have been finalized and the necessary market approval of the final product has been obtained. As a consequence, all development costs are recognized in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, General, and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses comprise salaries and other personnel costs including pension and share-based payment, office supplies, cost of facilities, professional fees, and depreciation of non-current assets related to selling, general and administrative activities, including pre-commercial and commercial activities. Selling, general, and administrative expenses are recognized in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Share-based Incentive Programs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based Incentive Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based incentive programs comprise warrant programs, Restricted Stock Unit programs (&#8220;RSU-programs&#8221;) and Performance Stock Unit Programs (&#8220;PSU-programs&#8221;) which are classified as equity-settled share-based payment transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of equity-settled transactions is determined by the fair value at the date of grant. For warrant programs, the fair value of each warrant granted is determined using the Black-Scholes option-pricing model. For RSU-programs and PSU-programs, the fair value of each RSU or PSU granted is equal to the closing share price on the date of grant of the underlying ADS. Any social security contributions payable in connection with the grant or exercise of the warrants are recognized as expenses when incurred. The assumptions used for estimating the fair value of share-based payment transactions are disclosed in Note 7, &#8220;Share-based Payment.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost is recognized together with a corresponding increase in equity over the period in which the performance and/or service conditions are fulfilled (i.e., the vesting period). The fair value determined at the grant date of the equity-settled share-based payment is expensed on a straight-line basis over the vesting period for each tranche, based on the best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for grants that do not ultimately vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where an equity-settled grant is cancelled other than upon forfeiture when vesting conditions are not satisfied, the grant is treated as if it vested on the date of the cancellation, and any expense not yet recognized for the grant is recognized immediately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where the terms and conditions for an equity-settled grant are modified, the services measured at the grant date fair value over the vesting period are recognized, subject to performance and/or service conditions that were specified at the initial grant date(s). Additionally, at the date of modification, unvested grants are re-measured and any increase in the total fair value is recognized over the vesting period. If a new grant is substituted for the cancelled grant and designated as a replacement grant on the date that it is granted, the cancelled and new grants are treated as if they were a modification of the original grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Finance Income and Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance Income and Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance income and expenses comprise interest income and expenses, realized and unrealized exchange rate gains and losses on transactions denominated in foreign currencies, fair value remeasurement gains and losses on derivative liabilities, and remeasurement gains and losses on royalty funding liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income and interest expenses are stated on an accrual basis using the principal and the effective interest rate. The effective interest rate is the discount rate that is used to discount expected future cash payments or receipts through the expected life of the financial asset or financial liability to the amortized cost (the carrying amount) of such asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognized in the consolidated statement of profit or loss by the portion attributable to the profit or loss for the year and recognized directly in equity or other comprehensive income by the portion attributable to entries directly in equity and in other comprehensive income. The current tax payable or receivable is recognized in the consolidated statement of financial position, stated as tax computed on this year&#8217;s taxable income, adjusted for prepaid tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When computing the current tax for the year, the tax rates and tax rules enacted or substantially enacted at the reporting date are used. Current tax payable is based on taxable profit or loss for the year. Taxable profit or loss differs from net profit or loss as reported in the consolidated statements of profit or loss because it excludes items of income or expense that are taxable or deductible in prior or future years. In addition, taxable profit or loss excludes items that are never taxable or deductible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax is recognized according to the balance sheet liability method of all temporary differences between carrying amounts and tax-based values of assets and liabilities, apart from deferred tax on all temporary differences occurring on initial recognition of goodwill or on initial recognition of a transaction which is not a business combination, and for which the temporary difference found at the time of initial recognition neither affects profit or loss nor taxable income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax liabilities are recognized on all temporary differences related to investments in subsidiaries and/or associates, unless the Company is able to control when the deferred tax is realized, and it is probable that the deferred tax will not become due and payable as current tax in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets, including the tax base of tax loss carry forwards, are recognized in the statement of financial position at their estimated realizable value, either as a set-off against deferred tax liabilities or as net tax assets for offset against future positive taxable income. Deferred tax assets are only offset against deferred tax liabilities if the entity has a legally enforceable right to offset, and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax jurisdiction. Deferred tax is calculated based on the planned use of each asset and the settlement of each liability, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax is measured using the tax rates and tax rules in the relevant countries that, based on acts in force or acts in reality in force at the reporting date are expected to apply when the deferred tax is expected to crystallize as current tax. Changes in deferred tax resulting from changed tax rates or tax rules are recognized in the consolidated statement of profit or loss unless the deferred tax is attributable to transactions previously recognized directly in equity or other comprehensive income. In the latter case, such changes are also recognized in equity or other comprehensive income. On every reporting date, it is assessed whether sufficient taxable income is likely to arise in the future for the deferred tax asset to be utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill acquired in a business combination is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests over the net identifiable assets acquired and liabilities assumed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortized but is subject to impairment testing at least on a yearly basis. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or group of cash-generating units, that are expected to benefit from the synergies of the combination. Each cash-generating unit or group of cash-generating units to which goodwill is allocated represents the lowest level within the Company at which the goodwill is monitored for internal management purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Software</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Software</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Software assets comprise administrative applications and serve general purposes to support the Company&#8217;s operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development costs that are directly attributable to the design, customization, implementation, and testing of identifiable and unique software assets controlled by the Company are recognized as intangible assets from the time that; (1) the software asset is clearly defined and identifiable; (2) technological feasibility, adequate resources to complete, and an internal use of the software asset can be demonstrated; (3) the expenditure attributable to the software asset can be measured reliably; and (4) the Company has the intention to use the software asset internally. The Company does not capitalize software with no alternative use, or where economic benefit depends on marketing approvals of drug candidates and where marketing approvals have not been obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when the development is complete, and the asset is available for use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Software assets are amortized over the period of expected future benefits. Amortization is recognized in research and development costs, and selling, general and administrative expenses, as appropriate. Expenditures that do not meet the criteria above are recognized as an expense as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment primarily comprises leasehold improvements, office facilities, and process equipment and tools which are located at CMOs. Property, plant and equipment also includes right-of-use assets. Refer to the separate section &#8220;Leases.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be used in operation. Subsequent costs are included in the carrying amount of the asset or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the assets will flow to the Company and costs of the items can be measured reliably. All repair and maintenance costs are charged to the consolidated statement of profit or loss during the financial periods in which they are incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plant and equipment acquired for research and development activities with alternative use, which is expected to be used for more than one year, is capitalized and depreciated over the estimated useful life as research and development costs. Plant and equipment acquired for research and development activities, which has no alternative use, is recognized as research and development costs when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the acquisition or use of the asset involves an obligation to incur costs of decommissioning or restoration of the asset, the estimated related costs are recognized as a provision and as part of the relevant asset&#8217;s cost, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The basis for depreciation is cost less estimated residual value. The residual value is the estimated amount that would be earned if selling the asset today net of selling costs, assuming that the asset is of an age and a condition that is expected after the end of its useful life. Cost of a combined asset is divided into smaller components, with such significant components depreciated individually if their useful lives vary. Depreciation commences when the asset is available for use, which is when it is in the location and condition necessary for it to be capable of operating in the manner intended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation is calculated on a straight-line basis, based on an asset&#8217;s expected useful life, being within the following ranges:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:17.824%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Process plant and machinery</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation methods, useful lives and residual amounts are reassessed at least annually.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment is written down to the lower of recoverable amount and carrying amount, as described in the &#8220;Impairment&#8221; section below. Depreciation and impairment losses of property, plant and equipment is recognized in the consolidated statement of profit or loss as cost of sales, research and development costs or as selling, general, and administrative expenses, as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gains and losses on disposal of property, plant and equipment are recognized in the consolidated statement of profit or loss at its net proceeds, as either research and development costs or as selling, general, and administrative expenses, as appropriate.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment of Non-current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Non-current Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The recoverable amount of goodwill is estimated annually irrespective of any recorded indications of impairment. Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows, or cash-generating units, which for goodwill represent the lowest level within the enterprise at which the goodwill is monitored for internal management purposes. Prior impairments of non-current assets, other than goodwill, are reviewed for possible reversal at each reporting date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories comprise raw materials, work in progress and finished goods. The cost of work in progress and finished goods comprise service expenses incurred at CMOs, raw materials consumed, incremental storage and transportation, other direct materials, and a proportion of manufacturing overheads based on normal operation capacity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories are measured at the lower of cost incurred in bringing it to its present location and condition, and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Cost is measured using the first-in, first-out method. Work in progress and finished goods are measured under a standard cost method that takes into account normal levels of consumption, yields, labor, efficiency and capacity utilization. Production processes are complex, where actual yields and consumptions are sensitive to a wide variety of manufacturing conditions. Standard cost variances are reviewed regularly and adjusted to ensure inventories approximate actual cost of production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If net realizable value is lower than cost, a write-down is recognized as the excess amount by which cost exceeds net realizable value, as part of cost of sales, or selling, general, and administrative expenses, as appropriate. The amount of reversal of write-down of inventories arising from an increase in net realizable value is recognized as a reduction in cost of sales in the period in which the reversal occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing of pre-launch inventories is initiated for late-stage product candidates where manufacturing costs are recognized as inventories. However, since pre-launch inventories are not realizable prior to obtaining marketing approval, pre-launch inventories are immediately written down to zero through research and development costs. If marketing approval is obtained, prior write-downs of pre-launch inventories are reversed through research and development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of inventories is recognized as part of cost of sales in the period in which the related revenue is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory', window );">Receivables</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receivables</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receivables comprise trade receivables, income tax receivables and other receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade receivables are classified as financial assets at amortized cost, as these are held to collect contractual cash flows and thus give rise to cash flows representing solely payments of principal and interest. Trade receivables are initially recognized at their transaction price and subsequently measured at amortized cost. Income tax receivables, and other receivables related to deposits, VAT and other indirect taxes are measured at cost less impairment. Carrying amounts of receivables usually equals their nominal value less provision for impairments.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory', window );">Prepayments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayments comprise advance payments relating to a future financial year. Prepayments are measured at cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities may comprise government bonds, treasury bills, commercial papers, and other securities traded on established markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At initial recognition (trade-date), contractual terms of individual securities are analyzed to determine whether these give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding (&#8220;SPPI-test&#8221;). All marketable securities held at the reporting date have passed the SPPI-test.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities are initially recognized at fair value at trade-date, and subsequently measured at amortized cost under the effective interest method. Interest income is recognized as finance income in the consolidated statement of profit or loss. Marketable securities are subject to an impairment test to accommodate expected credit loss. Gains and losses are recognized as finance income or expenses in the consolidated statement of profit or loss when the specific security or portfolio of securities is derecognized, modified or impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities, having maturity profiles of three months or less after the date of acquisition are presented as cash equivalents in the consolidated statements of financial position, where securities having maturities of more than three months after the date of acquisition are presented separately as marketable securities as current (i.e., those maturing within twelve months after the reporting date) or non-current assets, as appropriate.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents comprise cash and on-demand deposits with financial institutions, and highly liquid marketable securities with a maturity of three months or less after the date of acquisition (trade-date). Cash and cash equivalents are measured at amortized cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory', window );">Allowance for Expected Credit Losses on Financial Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Allowance for Expected Credit Losses on Financial Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial assets comprise receivables (excluding receivables relating to VAT, other indirect tax and income tax), marketable securities, and cash and cash equivalents. Impairment of financial assets is determined on the basis of a forward-looking Expected Credit Loss (&#8220;ECL&#8221;) model. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and the cash flows expected to be received, discounted by an approximation of the original effective interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For receivables, a simplified approach in calculating ECLs is applied. Therefore, changes in credit risks are not tracked, but instead, a loss allowance based on lifetime ECL is assessed at each reporting date. Lifetime ECLs are assessed on historical credit loss experience, adjusted for forward-looking factors specific to the counterparts and the economic environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For cash, cash equivalents and marketable securities, ECLs are assessed for credit losses that result from default events that are possible within the next twelve months (12-month ECL). Credit risk is continuously tracked and monitored in order to identify significant deterioration. For those credit exposures for which there have been a significant increase in credit risk since initial recognition, an allowance is recognized for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Shareholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The share capital comprises the nominal amount of the parent company&#8217;s ordinary shares, each at a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All shares are fully paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share premium comprises the amounts received, attributable to shareholders&#8217; equity, in excess of the nominal amount of the shares issued at the parent company&#8217;s capital increases, reduced by any expenses directly attributable to the capital increases. Under Danish legislation, share premium is an unrestricted reserve that is available to be distributed as dividends to a company&#8217;s shareholders. Also, under Danish legislation, the share premium reserve can be used to offset accumulated deficits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treasury shares reserve comprise nominal amounts of holding of own equity instruments. No gain or loss is recognized in profit or loss on the purchase, sale, transfer or cancellation of the Company&#8217;s own equity instruments. The treasury shares reserve is part of unrestricted reserves and accordingly, reduce the amount available to be distributed as dividends to the Company&#8217;s shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency translation reserve includes exchange rate adjustments relating to the translation of the results and net assets of foreign operations from their functional currencies to the presentation currency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accumulated reserve of a foreign operation is reclassified to the consolidated statement of profit or loss at the time the Company loses control, and thus cease to consolidate such foreign operation. The foreign currency translation reserve is an unrestricted reserve that is available to be distributed as dividends to the Company&#8217;s shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retained earnings/(accumulated deficit) represents the accumulated profits or losses from the Company&#8217;s operations, including corresponding entries to share-based payments recognized in the consolidated statement of profit or loss. In addition, premiums from acquisition and sale of treasury shares are recognized as part of this reserve. A positive reserve is available to be distributed as dividends to the Company&#8217;s shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory', window );">Convertible Senior Notes and Embedded Derivative Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible Senior Notes and Embedded Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible senior notes (&#8220;convertible notes&#8221;) are separated into a financial liability and an embedded derivative component based on the terms and conditions of the contract. The embedded derivative component is accounted for separately if it is not deemed closely related to the financial liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes include an embedded equity conversion option which is not deemed closely related to the financial liability, and initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the convertible notes include a redemption option, which entitle the Company to redeem the notes at a cash amount equal to the principal amount of the convertible notes, plus accrued and unpaid interest. The redemption option is closely related to the financial liability, and not separately accounted for. The initial carrying amount of the financial liability component including the redemption option is the residual amount of the proceeds, net of transaction costs, after separating the derivative component.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transaction costs are apportioned between the financial liability and derivative component based on the allocation of proceeds when the instrument is initially recognized. Transaction costs apportioned to the financial liability component form part of the effective interest and are amortized over the expected lifetime of the liability. Transaction costs allocated to the derivative component are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial liability is subsequently measured at amortized cost until it is extinguished on conversion, upon optional redemption or repayment at maturity. Convertible notes are presented as borrowings, together with the derivative liabilities on the statement of financial position, separately under current liabilities as &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible notes, matures in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock', window );">Royalty Funding Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty funding liabilities relate to the Company&#8217;s contractual obligations to pay a predetermined percentage of future revenue from sale of commercial products until reaching a predetermined multiple of proceeds received, pursuant to the detailed provisions of the capped synthetic royalty funding agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where relevant, royalty funding liabilities are separated into a financial liability and embedded derivative components based on the terms and conditions of the applicable royalty funding agreement. Embedded derivative components are accounted for separately, unless these are deemed closely related to the financial liability. The royalty funding agreements include a buy-out option where the value is dependent on non-financial variables that are specific to the Company. Accordingly, the buy-out option is not accounted for separately as a derivative.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial liability is recognized when the Company becomes party to the contractual provisions of the royalty funding agreement and measured at amortized cost until it is extinguished upon exercising a buy-out option or upon achieving the predetermined multiple of proceeds received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effective interest rate is estimated at initial recognition and takes into account incremental transaction costs and anticipated amount and timing of future cash flows, which further depends on future commercial revenue forecasts and the probability of exercising the buy-out option. The amortized cost is remeasured prospectively when there is a material change in expectations to amount and timing of future cash flows, which will increase or decrease future interest expenses. Remeasurement gain or losses are recognized through the profit or loss as finance income or expenses, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty funding liabilities that are classified as a financial liability are presented as part of borrowings in the statement of financial position.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Right-of-use Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets are recognized at the lease commencement date, defined as the date the underlying asset is available for use. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets include the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any incentives received. In addition, right-of-use assets also include an estimate of costs to be incurred by the Company in dismantling or restoring the underlying asset to the condition if required by the terms and condition of the lease, if any.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets are presented as part of property, plant and equipment, and depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lease Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the lease commencement date, lease liabilities are recognized and measured at the present value of fixed lease payments and variable lease payments that depend on an index or a rate, whereas variable lease payments and payments related to non-lease components are excluded. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the consolidated statement of profit or loss when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When interest rates implicit in the lease contracts are not readily available, the present value of lease payments are calculated by applying the incremental borrowing rate of the relevant entity holding the lease. Following the commencement date, the incremental borrowing rate is not changed unless the lease term is modified, or if the lease payments are modified and this modification results from a change in floating interest rates. From the lease commencement date and over the lease term, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in lease term, or a change in lease payments, including changes to future payments resulting from a change in an index used to determine such lease payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities are presented as part of borrowings in the statement of financial position.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions comprise unsettled sales deductions and product returns regarding revenue from sale of commercial products where amount or timing of payment is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions for sales deductions attributed to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements are recognized when the related sales takes place and measured using the expected value method. Payable amounts for managed healthcare organizations and government programs are generally settled within 180 days from the transaction date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions for estimated product returns are measured according to the contractual sales price based on expected product returns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory', window );">Trade Payables and Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Payables and Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses are measured at amortized cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock', window );">Other Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other liabilities comprise payables to public authorities, short-term employee benefits, and sales deductions. Other liabilities are measured at their net-realizable values.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory', window );">Contract Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities comprise deferred income from collaboration and license agreements, where consideration received does not match the individual deliverables with respect to amount and satisfied performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities are measured at the fair value of the consideration received and is recognized as revenue in the consolidated statement of profit or loss when the relevant performance obligation, to which the deferred income relates, is satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory', window );">Cash Flow Statement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Flow Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cash flow statement shows cash flows from operating, investing and financing activities as well as cash and cash equivalents at the beginning and the end of the financial year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from operating activities are presented using the indirect method and calculated as the profit or loss adjusted for non-cash items, working capital changes as well as finance income, finance expenses and income taxes paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from investing activities include payments in connection with acquisition, development, improvement and sale, etc., of property, plant and equipment, investments in associates and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows from financing activities comprise payments related to the capital structure of the Company, including changes in the share capital and treasury shares, and issuance and repayments under the Company&#8217;s borrowing activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency is presented separately from cash flows from operating, investing and financing activities. Cash flows in currencies other than the functional currency are recognized in the cash flow statement, using the average exchange rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents comprise cash and on-demand bank deposits with financial institutions and highly liquid marketable securities with a maturity of three months or less after the date of acquisition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Basic EPS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic Earnings per Share (&#8220;EPS&#8221;) is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding. The weighted average number of shares takes into account the weighted average number of treasury shares during the year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory', window );">Diluted EPS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted EPS is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding adjusted for the weighted average effect of changes in treasury shares during the year, and the dilutive effect of outstanding warrants and convertible notes. If the consolidated statement of profit or loss shows a net loss, no adjustment is made for the dilutive effect, as such effect would be anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for allowance for expected credit losses on financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for deferred revenues and contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for other payables explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for prepayments explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for royalty funding liabilities text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DescriptionOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DescriptionOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investments in associates. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for subsidiaries. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 46<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoingConcernExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoingConcernExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389485664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory', window );">Schedule of Asset's Expected Useful Life</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation is calculated on a straight-line basis, based on an asset&#8217;s expected useful life, being within the following ranges:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:17.824%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Process plant and machinery</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for depreciation under property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109381491744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory', window );">Schedule of Revenue Recognized in Consolidated Statement of Profit or Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue has been recognized in the consolidated statements of profit or loss with the following amounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial products</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,728</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rendering of services</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical supply</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,776</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,343</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,077</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Attributable to</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial customers</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,728</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration partners and license agreements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,055</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified by timing of recognition</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognized over time</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognized at a point in time</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,059</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified per geographical area</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,336</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">552</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233,220</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191,677</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rest of world</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,172</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,466</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">363,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266,718</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, Denmark, the country of domicile, contributed with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfRevenueToCommercialCustomersExplanatory', window );">Schedule of Revenue Attributable to Commercial Customers by Product</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue attributable to commercial customers by product were as follows:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue from commercial products</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SKYTROFA&#174;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197,001</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,659</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">YORVIPATH&#174;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,727</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue from commercial products</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">225,728</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">178,663</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">35,659</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfRevenueToCommercialCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue to commercial customers explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfRevenueToCommercialCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of segment revenues by destination of major customers explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109391329344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Disclosure of intangible assets, and property, plant and equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s intangible assets and property, plant and equipment located by region are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intangible assets and property, plant and equipment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,640</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,464</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total intangible assets and property, plant and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">102,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">115,053</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, intangible assets and property, plant and equipment of &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, is located in Denmark, the country of domicile.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384330032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems', window );"><strong>Disclosure of employee compensation costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock', window );">Summary of Employee Cost</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Employee costs</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,474</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,278</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140,420</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,512</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,660</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,180</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pensions (defined contribution plans)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,485</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,403</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,163</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,003</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,877</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,627</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other employee costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,061</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,238</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,411</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total employee costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">292,535</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">258,456</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">223,801</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Included in the profit or loss</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,487</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,748</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,239</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,867</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127,002</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,581</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,181</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,706</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,981</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total employee costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">292,535</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">258,456</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">223,801</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average number of employees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">892</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">719</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes employee costs capitalized as part of inventories.</span></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel of entity or parent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems', window );"><strong>Disclosure of employee compensation costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock', window );">Summary of Employee Cost</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation to Key Management Personnel included in total employee costs is summarized below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:20.492%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.758%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.457%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Board of Directors </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Executive Board </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-executive Senior Management</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="34" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR &#8216;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Compensation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">543</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">403</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,148</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,375</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,809</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,286</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,087</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,169</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,276</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,334</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,243</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,392</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,266</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,529</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,872</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pensions (defined<br/>&#160;&#160;&#160;contribution plans)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other employee cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,651</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,819</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,676</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">22,677</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,795</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,322</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">13,727</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14,409</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,211</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors comprised six persons in 2024 and six to seven persons in 2023 and 2022.</span></div></div><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Board comprised four persons in 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about employee cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee compensation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfEmployeeCompensationCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109378779088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock', window );">Summary of Share Based Payment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number of RSUs and PSUs granted and outstanding:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,685</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,685</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,971</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,971</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">609,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,268</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">722,128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Settled during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">576,625</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">105,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">681,648</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717,980</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">810,635</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">212,160</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,007</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,638</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,004</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">993,807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">156,667</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,150,474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified by vesting date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">384,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,304</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">446,402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">384,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,478</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">447,916</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,271</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,885</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">993,807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">156,667</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,150,474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of RSUs and PSUs is determined on the basis of the closing ADS price on the grant date. The fair value of one RSU and one PSU at the date of grant was &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141.01</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.96</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Summary of Weighted Average Exercise Prices and Movements in Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number and weighted average exercise prices of, and movements, in warrants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrants (number)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price (EUR)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2022</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,085,073</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.30</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">357,092</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">214,613</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.83</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,541</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123.62</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,864,011</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81.30</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at the reporting date</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,972,026</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">66.34</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">395,275</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.07</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">555,144</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.76</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,358</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115.79</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,523,784</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">86.38</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at the reporting date</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,273,056</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">80.02</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504,105</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.48</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682,048</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.35</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,719</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107.85</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,204,122</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">93.25</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at the reporting date</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,226,643</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">89.33</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average share price (listed in $) at the date of exercise was &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135.86</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.10</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113.60</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. </span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the weighted average exercise prices and weighted average remaining contractual life for outstanding warrants at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 per grant year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding<br/>Warrants (number</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price (EUR)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Life<br/>(months)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted before </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2022</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,185,556</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89.67</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted in </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235,408</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.71</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted in </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292,648</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted in </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">490,510</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.34</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,204,122</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">93.25</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">65</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Fair Values for Warrant Grants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the input to the Black-Scholes option-pricing model and the calculated fair values for warrant grants in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:38.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:15.82%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:15.82%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:15.82%;box-sizing:content-box;"></td>
        <td style="width:2.18%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.71</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.57</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.40</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.97</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">) - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.54</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life of warrants (years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average exercise price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.48</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.07</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.40</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of warrants granted in the year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.86</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.39</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.34</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.03</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.55</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.85</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased payment arrangement, restricted stock unit, activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389428480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Accountant Fees and Services (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditor's remuneration [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock', window );">Summary of Principal Accountant Fees and Services</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth, for each of the years indicated, the fees billed by the Company&#8217;s independent public accountants and the proportion of each of the fees out of the total amount billed by the accountants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Principal accountant fees and services</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">814</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit-related fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total principal accountant fees and services</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,049</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">861</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">952</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information for principal accountant fees and service explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389405936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax on Profit/(Loss) for the Year and Deferred Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeAbstract', window );"><strong>Deferred tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Summary of Tax on Profit/Loss and Deferred Tax</a></td>
<td class="text">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.409%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.177999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.177999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.238%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax on profit/(loss) for the year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current tax (expense)/income</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,723</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current tax, adjustments to prior years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,904</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,654</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax, movement for the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,035</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,044</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax, adjustments to prior years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,786</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,843</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax for the year can be explained as follows</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Profit/(loss) before tax</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">373,241</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474,144</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">577,817</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax at the Danish corporation tax rate of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82,113</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">104,312</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">127,120</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax effect of:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-deductible costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,740</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,494</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,094</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional tax deductions</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,161</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,077</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,720</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impact from associates</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,413</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,047</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,893</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prior year adjustments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,294</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other effects including effect of different tax rates</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">882</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,716</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax asset, not recognized</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,627</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,514</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tax on profit/(loss) for the year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,843</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.30</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">0.93</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specification of deferred tax assets/(liabilities)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax deductible losses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">434,997</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">521,697</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433,174</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other temporary differences, assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,479</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,256</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax asset, not recognized</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">599,476</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">537,953</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,135</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other temporary differences, liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,258</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,830</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total deferred tax assets/(liabilities) at December 31</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,258</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,830</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389486192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory', window );">Summary of Goodwill and Software</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Goodwill</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,222</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,296</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,791</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,867</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization and impairment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">889</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">889</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,839</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,839</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">924</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,419</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109391225088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Summary of Property, Plant and Equipment</a></td>
<td class="text">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plant and<br/>Machinery</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other<br/>Equipment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Leasehold<br/>Improve-<br/>ments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Right-of-Use<br/>Assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,203</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,466</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">383</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">440</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,093</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,989</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">27,436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,420</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19,375</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">123,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">182,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">299</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">951</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,187</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,635</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,719</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,462</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10,976</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20,298</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">130,154</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">183,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Depreciation and impairment</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,584</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,544</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,648</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,569</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,899</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,875</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">405</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,834</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,193</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12,784</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,175</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10,946</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">40,612</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">71,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,283</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,247</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disposals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,296</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,501</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,885</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">556</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,906</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">9,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,190</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12,785</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">54,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">84,647</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14,652</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">8,429</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">83,308</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">110,634</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12,003</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,513</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">75,412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">98,714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges', window );">Summary of Depreciation Charges</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation charges are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Depreciation charges</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,197</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,509</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,245</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,892</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,597</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,623</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total depreciation charges</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,247</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">18,428</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,514</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes depreciation charges capitalized as part of inventories.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about depreciations charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382532288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Associates (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember', window );">Associates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Schedule of Financial Information of Investments in Associates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregated profit or loss, total comprehensive income, transactions and outstanding balances with associates as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows.</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"></td>
      <td style="width:1.62%;box-sizing:content-box;"></td>
      <td style="width:14.883%;box-sizing:content-box;"></td>
      <td style="width:1.62%;box-sizing:content-box;"></td>
      <td style="width:14.883%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Statement of profit or (loss)</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Profit/(loss) for the year from continuing operations</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">59,235</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">41,873</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive income</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">59,218</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">41,859</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transactions and outstanding balances as of December 31</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Invoicing of goods and services to associates</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,225</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,026</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables from associates</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,759</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">991</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,936</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,133</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389464112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock', window );">Summary of Inventories Explanatory</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials and consumables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,596</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,566</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235,688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,030</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,325</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,335</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total inventories</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">295,609</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">208,931</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of quantitative Information about inventories explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389413856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory', window );">Summary of Development in Provisions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development in provisions is specified below:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:17.824%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Provisions</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,719</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions related to prior years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,684</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net additions for the year</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,284</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,462</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">99,149</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deiailed information about development in provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109532216064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory', window );">Schedule of Financial Assets and Financial Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial assets and liabilities comprise the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets by category</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,280</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,874</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables (excluding indirect tax receivables)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,964</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,275</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">559,543</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">392,164</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">439,222</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">439,222</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,317</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">727,470</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">437,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">439,222</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities by category</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458,207</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,379</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,030</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,793</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,394</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,566</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities (excluding indirect tax and employee related payables)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">953,321</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">738,831</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,103,991</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">882,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365,080</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,996</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">738,911</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">659,131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,103,991</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">882,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Schedule of Finance Income and Finance Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance income and expenses are specified below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance income</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,857</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,426</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement gain of financial liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,654</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation (net)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,755</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total finance income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">25,609</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,857</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">52,181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,065</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement loss of financial liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange translation (net)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,149</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total finance expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">44,065</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">50,487</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements', window );">Summary of Expenses, Related To Lease Activities In The Consolidated Statements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following expenses related to lease activities were recognized in the consolidated statements of profit or loss:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease expenses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,312</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,875</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,740</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short term leases and leases of low value assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">353</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease interest</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,303</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,581</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,842</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total lease expenses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,900</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,809</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,862</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Summary of Development in Borrowings Related to Financing Activities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in borrowings related to financing activities is specified below:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:19.848%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.623%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.564%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.824%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.803%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash payments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-cash items</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Beginning<br/>of year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Repay-<br/>ments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net proceeds</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additions/<br/>(disposals)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remeasure-<br/>ments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accretion of<br/>interest</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Foreign<br/>exchange<br/>translation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">End of<br/>year</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="15" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">545,472</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,819</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,158</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,248</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,116</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,907</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">763,586</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,793</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,677</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">861</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,303</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,750</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,030</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">644,265</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">26,496</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">134,158</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">861</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,248</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">65,419</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">49,657</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">856,616</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">399,186</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,054</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,256</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,386</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,302</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">545,472</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,191</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,006</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,973</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,581</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,946</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,793</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financing activities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">508,377</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">26,060</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">136,256</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,973</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,967</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,248</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">644,265</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock', window );">Summary of Fair Value Hierarchy</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are unobservable inputs for the asset or liability.</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value level</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(1-3)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,275</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,266</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,275</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7,266</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458,207</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438,288</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407,095</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385,410</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,379</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,673</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,377</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,975</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">763,586</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">743,961</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">545,472</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">529,385</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock', window );">Movements in Level 3 Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies movements in level 3 fair value measurements:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,950</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,467</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement recognized in financial income or expense</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,374</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,654</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,483</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">157,950</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Expenses Relating To Lease Activities In The Consolidated Statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Assets And Liabilities [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movements in level 3 fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109381492528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of Number of Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in outstanding shares of the Company was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2021</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2020</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Changes in share capital</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,707,439</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,152,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,937,682</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,750,386</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,985,837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase through cash contributions</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,982,048</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">555,144</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">214,613</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,187,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,764,549</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">60,689,487</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">57,707,439</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">57,152,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">56,937,682</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">53,750,386</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTreasurySharesExplanatory', window );">Summary Of Holding Of Treasury Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in holding of treasury shares was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.241999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominal<br/>value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding in<br/>% of total<br/>outstanding<br/>shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,113,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">146</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,093,054</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">113</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">845,887</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory', window );">Summary of Foreign Currency Sensitivity Analysis</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Hypothetical impact on consolidated<br/>financial statements</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominal<br/>positions<br/>(net)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase in<br/>foreign<br/>currency<br/>exchange<br/>rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Profit/(loss)<br/>before tax</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity before tax</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR &#8216;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">USD/EUR</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">735,064</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,506</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,506</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369,091</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock', window );">Summary of Contractual Cash Flows for Financial Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the consolidated statements of financial position:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&lt; 1 year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1-5 years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&gt;5 years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>contractual<br/>cash-flows</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,027,558</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,660</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,073,521</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">763,586</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,007</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,616</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,030</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,705</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,705</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,705</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">144,490</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,079,565</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">52,787</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,276,842</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">953,321</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,708</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">742,925</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,397</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">797,030</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">545,472</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,385</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,056</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,867</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,793</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,566</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,566</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,566</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">120,659</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">794,351</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">91,453</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,006,463</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">738,831</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual cashflows for financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of foreign currency sensitivity analysis explanatory [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389428224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Group Enterprises (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract', window );"><strong>Investments accounted for using equity method [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Summary of Investments in Group Enterprises</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S&#8217;s (parent company) investments in group enterprises at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 comprise:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subsidiaries</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Domicile</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ownership</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma GmbH</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology GmbH</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma, Inc.</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology, Inc.</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Ophthalmology Division A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Endocrinology Division A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Bone Diseases A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Growth Disorders A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Oncology Division A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Europe A/S</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denmark</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma UK Limited</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Iberia S.L.</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Spain</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma France SASU</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">France</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Italia SRL</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Italy</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Sverige AB</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sweden</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ascendis Pharma Switzerland GmbH</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Switzerland</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Associates</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Domicile</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ownership</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cayman Island</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Eyconis Inc.</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.6</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B4<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109358845744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies - Additional Information (Detail)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>kr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 84,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Nominal amount of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">&#8364; 149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value common shares | kr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 143,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible senior notes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity</a></td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">April 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember', window );">American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConversionPricePerShare', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value common shares | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items representing the disclosure of summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109379725472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies - Schedule of Asset's Expected Useful Life (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Process plant and machinery [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Asset's expected useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Other equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Asset's expected useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Leasehold improvements [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Asset's expected useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Asset's expected useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Process plant and machinery [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Asset's expected useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Other equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Asset's expected useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Leasehold improvements [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Asset's expected useful life</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Asset's expected useful life</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=asnd_ProcessPlantAndMachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=asnd_ProcessPlantAndMachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=asnd_OtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=asnd_OtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109358840288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgements and Estimates - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">&#8364; 99,149<span></span>
</td>
<td class="nump">&#8364; 32,719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">&#8364; 7,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WarrantCompensationCost', window );">Warrant compensation cost</a></td>
<td class="nump">19,700<span></span>
</td>
<td class="nump">28,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 55,200<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">363,641<span></span>
</td>
<td class="nump">266,718<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 51,174<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CarryingAmountOfRoyaltyFundingLiabilities', window );">Carrying amount of royalty funding liabilities</a></td>
<td class="nump">305,400<span></span>
</td>
<td class="nump">138,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment to Prior Periods Estimates and Assumptions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=asnd_SalesDeductionsAndProductReturnsInUSMarketMember', window );">Sales Deductions And Product Returns In U.S. Market [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">&#8364; 99,100<span></span>
</td>
<td class="nump">&#8364; 32,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CarryingAmountOfRoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CarryingAmountOfRoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_WarrantCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_WarrantCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=asnd_SalesDeductionsAndProductReturnsInUSMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=asnd_SalesDeductionsAndProductReturnsInUSMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109383028736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Commercial products</a></td>
<td class="nump">&#8364; 225,728<span></span>
</td>
<td class="nump">&#8364; 178,663<span></span>
</td>
<td class="nump">&#8364; 35,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServices', window );">Rendering of services</a></td>
<td class="nump">11,794<span></span>
</td>
<td class="nump">21,659<span></span>
</td>
<td class="nump">4,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RevenueFromClinicalSupply', window );">Clinical supply</a></td>
<td class="nump">3,776<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="nump">8,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">Licenses</a></td>
<td class="nump">122,343<span></span>
</td>
<td class="nump">66,077<span></span>
</td>
<td class="nump">2,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">363,641<span></span>
</td>
<td class="nump">266,718<span></span>
</td>
<td class="nump">51,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">363,641<span></span>
</td>
<td class="nump">266,718<span></span>
</td>
<td class="nump">51,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember', window );">Goods or services transferred over time [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">11,794<span></span>
</td>
<td class="nump">21,659<span></span>
</td>
<td class="nump">4,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">11,794<span></span>
</td>
<td class="nump">21,659<span></span>
</td>
<td class="nump">4,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember', window );">Goods or services transferred at point in time [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">351,847<span></span>
</td>
<td class="nump">245,059<span></span>
</td>
<td class="nump">46,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">351,847<span></span>
</td>
<td class="nump">245,059<span></span>
</td>
<td class="nump">46,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember', window );">Commercial customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">225,728<span></span>
</td>
<td class="nump">178,663<span></span>
</td>
<td class="nump">35,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">225,728<span></span>
</td>
<td class="nump">178,663<span></span>
</td>
<td class="nump">35,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CollaborationPartnersAndLicenseAgreementsMember', window );">Collaboration partners and license agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">137,913<span></span>
</td>
<td class="nump">88,055<span></span>
</td>
<td class="nump">15,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">137,913<span></span>
</td>
<td class="nump">88,055<span></span>
</td>
<td class="nump">15,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">123,336<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">123,336<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember', window );">North America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">233,220<span></span>
</td>
<td class="nump">191,677<span></span>
</td>
<td class="nump">44,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">233,220<span></span>
</td>
<td class="nump">191,677<span></span>
</td>
<td class="nump">44,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=asnd_RestOfWorldMember', window );">Rest of World [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">7,085<span></span>
</td>
<td class="nump">74,172<span></span>
</td>
<td class="nump">6,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">&#8364; 7,085<span></span>
</td>
<td class="nump">&#8364; 74,172<span></span>
</td>
<td class="nump">&#8364; 6,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RevenueFromClinicalSupply">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from clinical supply.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RevenueFromClinicalSupply</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LicenceFeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from licence fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LicenceFeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRenderingOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the rendering of services. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRenderingOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=asnd_CollaborationPartnersAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=asnd_CollaborationPartnersAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=asnd_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=asnd_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389611632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">&#8364; 363,641<span></span>
</td>
<td class="nump">&#8364; 266,718<span></span>
</td>
<td class="nump">&#8364; 51,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DK', window );">Denmark [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">&#8364; 95,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382974768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Attributable to Commercial Customers by Product (Detail) - Commercial customers [member] - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">&#8364; 225,728<span></span>
</td>
<td class="nump">&#8364; 178,663<span></span>
</td>
<td class="nump">&#8364; 35,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesSkytrofaMember', window );">SKYTROFA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">197,001<span></span>
</td>
<td class="nump">&#8364; 178,663<span></span>
</td>
<td class="nump">&#8364; 35,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesYorvipathMember', window );">YORVIPATH [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">&#8364; 28,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=asnd_CommercialCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=asnd_CommercialCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesSkytrofaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesSkytrofaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesYorvipathMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesYorvipathMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109359890976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>CommercialCustomer</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>CommercialCustomer</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>CommercialCustomer</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 363,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 266,718<span></span>
</td>
<td class="nump">&#8364; 51,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfCommercialCustomers', window );">Number of commercial customers | CommercialCustomer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment to Prior Periods Estimates and Assumptions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember', window );">VISEN Pharmaceuticals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">43.90%<span></span>
</td>
<td class="nump">43.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=asnd_NovoNordiskMember', window );">Novo Nordisk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived', window );">Upfront development and regulatory milestones potentially to be received</a></td>
<td class="nump">&#8364; 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_UpfrontFeeForExclusiveLicense', window );">Upfront fee for exclusive license</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived', window );">Maximum additional development and regulatory milestones potentially to be received</a></td>
<td class="nump">&#8364; 77,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember', window );">Third Party Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CapitalCommitmentFromInvestors', window );">Commitment from investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=asnd_TeijinMember', window );">Teijin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_UpfrontPaymentReceived', window );">Upfront payment received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived', window );">Maximum additional development and regulatory milestones potentially to be received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember', window );">Royalties and Milestones [Member] | Third Party Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized as revenue | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember', window );">Royalties and Milestones [Member] | Teijin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=asnd_LicensesMember', window );">Licenses [Member] | Novo Nordisk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=asnd_LicensesMember', window );">Licenses [Member] | Third Party Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=asnd_LicensesMember', window );">Licenses [Member] | Teijin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 63,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember', window );">Commercial customers [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 225,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 178,663<span></span>
</td>
<td class="nump">&#8364; 35,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember', window );">Commercial customers [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Perentage of sale to commercial customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CapitalCommitmentFromInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital commitment from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CapitalCommitmentFromInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum additional development and regulatory milestones potentially to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfCommercialCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of commercial customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfCommercialCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront development and regulatory milestones potentially to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_UpfrontFeeForExclusiveLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee for exclusive license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_UpfrontFeeForExclusiveLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPerformanceObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=asnd_NovoNordiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=asnd_NovoNordiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=asnd_TeijinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=asnd_TeijinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=asnd_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=asnd_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109359918480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfReportableOperatingSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfReportableOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reportable operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfReportableOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389488192">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Intangible assets and property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 102,742<span></span>
</td>
<td class="nump">&#8364; 115,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Denmark [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Intangible assets and property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,900<span></span>
</td>
<td class="nump">32,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Intangible assets and property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">39,640<span></span>
</td>
<td class="nump">46,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=asnd_NorthAmerica1Member', window );">North America [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Intangible assets and property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 63,102<span></span>
</td>
<td class="nump">&#8364; 68,589<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, intangible assets and property, plant and equipment of &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, is located in Denmark, the country of domicile.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Classes of financial instruments [domain]; Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=asnd_NorthAmerica1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=asnd_NorthAmerica1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384933520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Parenthetical) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Intangible assets and property, plant and equipment</a></td>
<td class="nump">&#8364; 102,742<span></span>
</td>
<td class="nump">&#8364; 115,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Denmark [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Intangible assets and property, plant and equipment</a></td>
<td class="nump">&#8364; 27,900<span></span>
</td>
<td class="nump">&#8364; 32,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Classes of financial instruments [domain]; Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109378751792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Costs - Summary of Employee Cost (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>Employee</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems', window );"><strong>Disclosure of employee compensation costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="nump">&#8364; 173,474<span></span>
</td>
<td class="nump">&#8364; 170,278<span></span>
</td>
<td class="nump">&#8364; 140,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment</a></td>
<td class="nump">95,512<span></span>
</td>
<td class="nump">66,660<span></span>
</td>
<td class="nump">64,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Pensions (defined contribution plans)</a></td>
<td class="nump">4,485<span></span>
</td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="nump">15,003<span></span>
</td>
<td class="nump">12,877<span></span>
</td>
<td class="nump">10,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Other employee costs</a></td>
<td class="nump">4,061<span></span>
</td>
<td class="nump">4,238<span></span>
</td>
<td class="nump">4,411<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total employee costs</a></td>
<td class="nump">&#8364; 292,535<span></span>
</td>
<td class="nump">&#8364; 258,456<span></span>
</td>
<td class="nump">&#8364; 223,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageNumberOfEmployees', window );">Average number of employees | Employee</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">851<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=asnd_ResearchAndDevelopmentCostsMember', window );">Research and development expenses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems', window );"><strong>Disclosure of employee compensation costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total employee costs</a></td>
<td class="nump">&#8364; 131,867<span></span>
</td>
<td class="nump">&#8364; 127,002<span></span>
</td>
<td class="nump">&#8364; 122,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expenses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems', window );"><strong>Disclosure of employee compensation costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total employee costs</a></td>
<td class="nump">144,181<span></span>
</td>
<td class="nump">115,706<span></span>
</td>
<td class="nump">93,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_CostOfSalesMember', window );">Cost of sales [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems', window );"><strong>Disclosure of employee compensation costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total employee costs</a></td>
<td class="nump">16,487<span></span>
</td>
<td class="nump">15,748<span></span>
</td>
<td class="nump">7,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_BoardOfDirectorsMember', window );">Board of Directors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems', window );"><strong>Disclosure of employee compensation costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment</a></td>
<td class="nump">2,169<span></span>
</td>
<td class="nump">1,276<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total employee costs</a></td>
<td class="nump">2,651<span></span>
</td>
<td class="nump">1,819<span></span>
</td>
<td class="nump">1,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_ExecutiveBoardMember', window );">Executive Board [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems', window );"><strong>Disclosure of employee compensation costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="nump">4,148<span></span>
</td>
<td class="nump">4,375<span></span>
</td>
<td class="nump">3,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment</a></td>
<td class="nump">18,334<span></span>
</td>
<td class="nump">13,243<span></span>
</td>
<td class="nump">11,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Pensions (defined contribution plans)</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Other employee costs</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total employee costs</a></td>
<td class="nump">22,677<span></span>
</td>
<td class="nump">17,795<span></span>
</td>
<td class="nump">15,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_NonexecutiveseniorManagementMember', window );">Nonexecutivesenior management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems', window );"><strong>Disclosure of employee compensation costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="nump">3,286<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
<td class="nump">6,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment</a></td>
<td class="nump">10,266<span></span>
</td>
<td class="nump">9,529<span></span>
</td>
<td class="nump">8,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Pensions (defined contribution plans)</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Other employee costs</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total employee costs</a></td>
<td class="nump">&#8364; 13,727<span></span>
</td>
<td class="nump">&#8364; 14,409<span></span>
</td>
<td class="nump">&#8364; 15,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfEmployeeCompensationCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee compensation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfEmployeeCompensationCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of personnel employed by the entity during a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [domain]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=asnd_ResearchAndDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=asnd_ResearchAndDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_ExecutiveBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_ExecutiveBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_NonexecutiveseniorManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_NonexecutiveseniorManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389046320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8364; / shares</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>kr / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Share nominal value | kr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments', window );">Weighted average remaining life for outstanding warrants</a></td>
<td class="text">65 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Vesting conditions</a></td>
<td class="text">For the March 2024 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than 100%, nor will it result in additional grants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life for outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">71 months<span></span>
</td>
<td class="text">77 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member', window );">Warrants [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price</a></td>
<td class="nump">&#8364; 11.98<span></span>
</td>
<td class="nump">&#8364; 11.98<span></span>
</td>
<td class="nump">&#8364; 6.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member', window );">Warrants [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price</a></td>
<td class="nump">&#8364; 145.5<span></span>
</td>
<td class="nump">&#8364; 145.5<span></span>
</td>
<td class="nump">&#8364; 145.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CategoriesOfSharesBasedPaymentsAxis=asnd_WarrantsGranted2012UntilNovember2021Member', window );">Warrants Granted 2012 Until November 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CategoriesOfSharesBasedPaymentsAxis=asnd_WarrantsGrantedFromDecember2021Member', window );">Warrants Granted From December 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ClassificationOfRelatedPartyAxis=asnd_BoardMembersOfGroupMember', window );">Board members of group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfAdditionalSharesAuthorizedToGrant', window );">Number of additional shares authorized to grant | shares</a></td>
<td class="nump">2,060,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,060,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ClassificationOfRelatedPartyAxis=asnd_BoardMembersOfGroupMember', window );">Board members of group [member] | Warrants Granted From December 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PercentageOfWarrantsVested', window );">Percentage of warrants vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ClassificationOfRelatedPartyAxis=asnd_EmployeesAndConsultantsMember', window );">Employees and consultants [member] | Warrants Granted From December 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PercentageOfWarrantsVested', window );">Percentage of warrants vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than one year [member] | Warrants Granted 2012 Until November 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than one year [member] | Warrants Granted From December 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than one year [member] | Board members of group [member] | Warrants Granted From December 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PercentageOfWarrantsVested', window );">Percentage of warrants vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than one year [member] | Employees and consultants [member] | Warrants Granted From December 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PercentageOfWarrantsVested', window );">Percentage of warrants vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfAdditionalSharesAuthorizedToGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized to grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfAdditionalSharesAuthorizedToGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PercentageOfWarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrants vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PercentageOfWarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharebasedPaymentArrangementVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based payment arrangement vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharebasedPaymentArrangementVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual life of outstanding other equity instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CategoriesOfSharesBasedPaymentsAxis=asnd_WarrantsGranted2012UntilNovember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CategoriesOfSharesBasedPaymentsAxis=asnd_WarrantsGranted2012UntilNovember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CategoriesOfSharesBasedPaymentsAxis=asnd_WarrantsGrantedFromDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CategoriesOfSharesBasedPaymentsAxis=asnd_WarrantsGrantedFromDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ClassificationOfRelatedPartyAxis=asnd_BoardMembersOfGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ClassificationOfRelatedPartyAxis=asnd_BoardMembersOfGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ClassificationOfRelatedPartyAxis=asnd_EmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ClassificationOfRelatedPartyAxis=asnd_EmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109378808816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment - Summary Of Share Based Payment (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">6,204,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">576,625<span></span>
</td>
<td class="nump">82,492<span></span>
</td>
<td class="nump">148,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year</a></td>
<td class="nump">717,980<span></span>
</td>
<td class="nump">609,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Settled during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement', window );">Transferred during the year</a></td>
<td class="num">(212,160)<span></span>
</td>
<td class="num">(20,098)<span></span>
</td>
<td class="num">(41,685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year</a></td>
<td class="num">(88,638)<span></span>
</td>
<td class="num">(77,497)<span></span>
</td>
<td class="num">(23,971)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">993,807<span></span>
</td>
<td class="nump">576,625<span></span>
</td>
<td class="nump">82,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting specified by date</a></td>
<td class="nump">384,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting specified by date</a></td>
<td class="nump">384,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting specified by date</a></td>
<td class="nump">225,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">105,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year</a></td>
<td class="nump">92,655<span></span>
</td>
<td class="nump">112,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement', window );">Transferred during the year</a></td>
<td class="num">(35,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year</a></td>
<td class="num">(6,004)<span></span>
</td>
<td class="num">(7,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">156,667<span></span>
</td>
<td class="nump">105,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting specified by date</a></td>
<td class="nump">62,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting specified by date</a></td>
<td class="nump">63,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting specified by date</a></td>
<td class="nump">30,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">681,648<span></span>
</td>
<td class="nump">82,492<span></span>
</td>
<td class="nump">148,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year</a></td>
<td class="nump">810,635<span></span>
</td>
<td class="nump">722,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Settled during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement', window );">Transferred during the year</a></td>
<td class="num">(247,167)<span></span>
</td>
<td class="num">(20,098)<span></span>
</td>
<td class="num">(41,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year</a></td>
<td class="num">(94,642)<span></span>
</td>
<td class="num">(84,742)<span></span>
</td>
<td class="num">(23,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">1,150,474<span></span>
</td>
<td class="nump">681,648<span></span>
</td>
<td class="nump">82,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting specified by date</a></td>
<td class="nump">446,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting specified by date</a></td>
<td class="nump">447,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting specified by date</a></td>
<td class="nump">256,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of other equity instruments settled in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of other equity instruments transferred in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based payment arrangement, restricted stock unit, activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389645088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payment - Summary Of Share Based Payment (Parenthetical) (Detail) - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Fair Value of Other Equity Instruments Granted</a></td>
<td class="nump">&#8364; 141.01<span></span>
</td>
<td class="nump">&#8364; 105.96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based payment arrangement, restricted stock unit, activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109378810272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment - Schedule of Warrant Activity (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfWarrantActivityLineItems', window );"><strong>Disclosure Of Warrant Activity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">6,204,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Ending balance</a></td>
<td class="nump">&#8364; 93.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfWarrantActivityLineItems', window );"><strong>Disclosure Of Warrant Activity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">6,523,784<span></span>
</td>
<td class="nump">6,864,011<span></span>
</td>
<td class="nump">7,085,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year</a></td>
<td class="nump">504,105<span></span>
</td>
<td class="nump">395,275<span></span>
</td>
<td class="nump">357,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised during the year</a></td>
<td class="num">(682,048)<span></span>
</td>
<td class="num">(555,144)<span></span>
</td>
<td class="num">(214,613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year</a></td>
<td class="num">(141,719)<span></span>
</td>
<td class="num">(180,358)<span></span>
</td>
<td class="num">(363,541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">6,204,122<span></span>
</td>
<td class="nump">6,523,784<span></span>
</td>
<td class="nump">6,864,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">5,226,643<span></span>
</td>
<td class="nump">5,273,056<span></span>
</td>
<td class="nump">4,972,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Beginning balance</a></td>
<td class="nump">&#8364; 86.38<span></span>
</td>
<td class="nump">&#8364; 81.3<span></span>
</td>
<td class="nump">&#8364; 80.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year</a></td>
<td class="nump">122.48<span></span>
</td>
<td class="nump">91.07<span></span>
</td>
<td class="nump">100.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Exercised during the year</a></td>
<td class="nump">43.35<span></span>
</td>
<td class="nump">17.76<span></span>
</td>
<td class="nump">21.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the year</a></td>
<td class="nump">107.85<span></span>
</td>
<td class="nump">115.79<span></span>
</td>
<td class="nump">123.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Ending balance</a></td>
<td class="nump">93.25<span></span>
</td>
<td class="nump">86.38<span></span>
</td>
<td class="nump">81.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">&#8364; 89.33<span></span>
</td>
<td class="nump">&#8364; 80.02<span></span>
</td>
<td class="nump">&#8364; 66.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfWarrantActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Warrant Activity [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfWarrantActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of other equity instruments vested in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of other equity instruments vested in share-based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382972944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment  - Schedule of Warrant Activity (Parenthetical) (Detail) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=asnd_USDollarsMember', window );">U.S. dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfWarrantActivityLineItems', window );"><strong>Disclosure Of Warrant Activity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price</a></td>
<td class="nump">&#8364; 135.86<span></span>
</td>
<td class="nump">&#8364; 98.1<span></span>
</td>
<td class="nump">&#8364; 113.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfWarrantActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Warrant Activity [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfWarrantActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=asnd_USDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=asnd_USDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109378816992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment - Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of Warrants, Outstanding</a></td>
<td class="nump">6,204,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise, Outstanding</a></td>
<td class="nump">&#8364; 93.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments', window );">Weighted Average Life, Granted</a></td>
<td class="text">65 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedBeforeJanuary12022Member', window );">Granted before January 1, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_YearOfGrantOfWarrants', window );">Year of grant</a></td>
<td class="text">January 1, 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of Warrants, Granted | shares</a></td>
<td class="nump">5,185,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise, Granted</a></td>
<td class="nump">&#8364; 89.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments', window );">Weighted Average Life, Granted</a></td>
<td class="text">57 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedIn2022Member', window );">Granted In 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_YearOfGrantOfWarrants', window );">Year of grant</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="nump">235,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise, Granted</a></td>
<td class="nump">&#8364; 100.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments', window );">Weighted Average Life, Granted</a></td>
<td class="text">90 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedIn2023Member', window );">Granted in 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_YearOfGrantOfWarrants', window );">Year of grant</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="nump">292,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise, Granted</a></td>
<td class="nump">&#8364; 90.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments', window );">Weighted Average Life, Granted</a></td>
<td class="text">101 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedInTwoThousandTwentyFourMember', window );">Granted in 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_YearOfGrantOfWarrants', window );">Year of grant</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="nump">490,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise, Granted</a></td>
<td class="nump">&#8364; 122.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments', window );">Weighted Average Life, Granted</a></td>
<td class="text">114 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual life of outstanding other equity instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_YearOfGrantOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year of grant of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_YearOfGrantOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedBeforeJanuary12022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedBeforeJanuary12022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedIn2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedIn2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedIn2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedIn2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedInTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_GrantedInTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109383074592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment  - Summary of Fair Values for Warrant Grants (Detail) - Warrants [member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life of warrants (years) | yr</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price</a></td>
<td class="nump">&#8364; 122.48<span></span>
</td>
<td class="nump">&#8364; 91.07<span></span>
</td>
<td class="nump">&#8364; 100.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">1.71%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="num">(0.08%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FairValueOfWarrantsGranted', window );">Fair value of warrants granted in the year</a></td>
<td class="nump">&#8364; 50.86<span></span>
</td>
<td class="nump">&#8364; 37.34<span></span>
</td>
<td class="nump">&#8364; 36.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">2.57%<span></span>
</td>
<td class="nump">2.97%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FairValueOfWarrantsGranted', window );">Fair value of warrants granted in the year</a></td>
<td class="nump">&#8364; 70.39<span></span>
</td>
<td class="nump">&#8364; 52.03<span></span>
</td>
<td class="nump">&#8364; 60.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FairValueOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FairValueOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109383020384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Accountant Fees and Services - Summary of Principal Accountant Fees and Services (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditor's remuneration [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Audit fees</a></td>
<td class="nump">&#8364; 811<span></span>
</td>
<td class="nump">&#8364; 739<span></span>
</td>
<td class="nump">&#8364; 814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_Audit-RelatedFees', window );">Audit-related fees</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForTaxServices', window );">Tax fees</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Total principal accountant fees and services</a></td>
<td class="nump">&#8364; 1,049<span></span>
</td>
<td class="nump">&#8364; 861<span></span>
</td>
<td class="nump">&#8364; 952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_Audit-RelatedFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit-related fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_Audit-RelatedFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForAuditServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for auditing services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForAuditServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForTaxServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for tax services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForTaxServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109378965840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract', window );"><strong>Tax on profit/(loss) for the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax (expense)/income</a></td>
<td class="num">&#8364; (3,289)<span></span>
</td>
<td class="num">&#8364; (5,377)<span></span>
</td>
<td class="num">&#8364; (3,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Current tax, adjustments to prior years</a></td>
<td class="num">(126)<span></span>
</td>
<td class="nump">3,904<span></span>
</td>
<td class="num">(1,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DeferredTaxMovementForTheYear', window );">Deferred tax, movement for the year</a></td>
<td class="num">(2,035)<span></span>
</td>
<td class="num">(1,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods', window );">Deferred tax, adjustments to prior years</a></td>
<td class="nump">607<span></span>
</td>
<td class="num">(4,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Current tax expense (income) and adjustments for current tax of prior periods</a></td>
<td class="num">(4,843)<span></span>
</td>
<td class="num">(7,303)<span></span>
</td>
<td class="num">(5,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ProfitLossBeforeIncomeTaxAbstract', window );"><strong>Tax for the year can be explained as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit/(loss) before tax</a></td>
<td class="num">(373,241)<span></span>
</td>
<td class="num">(474,144)<span></span>
</td>
<td class="num">(577,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Tax at the Danish corporation tax rate of 22%</a></td>
<td class="nump">82,113<span></span>
</td>
<td class="nump">104,312<span></span>
</td>
<td class="nump">127,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract', window );"><strong>Tax effect of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Non-deductible costs</a></td>
<td class="num">(9,740)<span></span>
</td>
<td class="num">(8,494)<span></span>
</td>
<td class="num">(17,094)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TaxEffectOfDeductibleItemsNotExpensed', window );">Additional tax deductions</a></td>
<td class="nump">3,161<span></span>
</td>
<td class="nump">9,077<span></span>
</td>
<td class="nump">13,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TaxEffectsFromImpactsFromAssociates', window );">Impact from associates</a></td>
<td class="num">(4,413)<span></span>
</td>
<td class="num">(4,047)<span></span>
</td>
<td class="num">(3,893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TaxEffectsFromPriorYearAdjustment', window );">Prior year adjustments</a></td>
<td class="nump">481<span></span>
</td>
<td class="num">(1,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other effects including effect of different tax rates</a></td>
<td class="nump">182<span></span>
</td>
<td class="num">(882)<span></span>
</td>
<td class="num">(2,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TaxEffectFromDeferredTaxAssetNotRecognized', window );">Deferred tax asset, not recognized</a></td>
<td class="num">(76,627)<span></span>
</td>
<td class="num">(105,975)<span></span>
</td>
<td class="num">(122,514)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax on profit/(loss) for the year</a></td>
<td class="num">&#8364; (4,843)<span></span>
</td>
<td class="num">&#8364; (7,303)<span></span>
</td>
<td class="num">&#8364; (5,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.54%<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Tax deductible losses</a></td>
<td class="nump">&#8364; 434,997<span></span>
</td>
<td class="nump">&#8364; 521,697<span></span>
</td>
<td class="nump">&#8364; 433,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Other temporary differences, assets</a></td>
<td class="nump">164,479<span></span>
</td>
<td class="nump">16,256<span></span>
</td>
<td class="nump">19,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DeferredTaxAssetNotRecognized', window );">Deferred tax asset, not recognized</a></td>
<td class="num">(599,476)<span></span>
</td>
<td class="num">(537,953)<span></span>
</td>
<td class="num">&#8364; (453,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures', window );">Other temporary differences, liabilities</a></td>
<td class="num">(7,258)<span></span>
</td>
<td class="num">(5,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Total deferred tax assets/(liabilities) at December 31</a></td>
<td class="num">&#8364; (7,258)<span></span>
</td>
<td class="num">&#8364; (5,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DeferredTaxAssetNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset, not recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DeferredTaxAssetNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DeferredTaxMovementForTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax movement for the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DeferredTaxMovementForTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ProfitLossBeforeIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit loss before income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ProfitLossBeforeIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TaxEffectFromDeferredTaxAssetNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect From Deferred Tax Asset, Not Recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TaxEffectFromDeferredTaxAssetNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TaxEffectOfDeductibleItemsNotExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effect of deductible items not expensed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TaxEffectOfDeductibleItemsNotExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TaxEffectsFromImpactsFromAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effects from impacts from associates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TaxEffectsFromImpactsFromAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TaxEffectsFromPriorYearAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effects from prior year adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TaxEffectsFromPriorYearAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for the deferred tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Total for all associates [member]; Total for all subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109391412496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Parenthetical) (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382952560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax on Profit/(Loss) for the Year and Deferred Tax - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Income taxes refund</a></td>
<td class="nump">&#8364; 0.7<span></span>
</td>
<td class="nump">&#8364; 0.7<span></span>
</td>
<td class="nump">&#8364; 0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TaxLossesCarryforwards', window );">Tax losses carryforwards</a></td>
<td class="nump">1,946.2<span></span>
</td>
<td class="nump">2,371.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DecreaseInTaxLosseCarryForwards', window );">Decrease in tax losse carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AdditionalTaxDeduction', window );">Additional tax deductions, determined by annual warrants exercises by employees</a></td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AdditionalFutureTaxDeduction', window );">Additional future tax deduction</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AdditionalTaxDeductionsRelatedToTaxCredits', window );">Additional tax deductions related to tax credits</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">&#8364; 8.4<span></span>
</td>
<td class="nump">&#8364; 8.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RevenueThresholdLimit', window );">Revenue threshold limit</a></td>
<td class="nump">&#8364; 750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AdditionalFutureTaxDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional future tax deduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AdditionalFutureTaxDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AdditionalTaxDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional tax deduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AdditionalTaxDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AdditionalTaxDeductionsRelatedToTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional tax deductions related to tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AdditionalTaxDeductionsRelatedToTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DecreaseInTaxLosseCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in tax losse carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DecreaseInTaxLosseCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RevenueThresholdLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue threshold limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RevenueThresholdLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TaxLossesCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Losses Carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TaxLossesCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109378904864">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Summary of Goodwill (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 4,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,028<span></span>
</td>
<td class="nump">&#8364; 4,419<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">533<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,791<span></span>
</td>
<td class="nump">5,717<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,867<span></span>
</td>
<td class="nump">5,791<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Goodwill [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Computer software [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,296<span></span>
</td>
<td class="nump">2,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,372<span></span>
</td>
<td class="nump">2,296<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Amortization and impairment [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,372)<span></span>
</td>
<td class="num">(889)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization Charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(467)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,839)<span></span>
</td>
<td class="num">(1,372)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Amortization and impairment [member] | Computer software [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,372)<span></span>
</td>
<td class="num">(889)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization Charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(467)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1,839)<span></span>
</td>
<td class="num">&#8364; (1,372)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382934896">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 110,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,247)<span></span>
</td>
<td class="num">&#8364; (18,428)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (17,514)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">98,714<span></span>
</td>
<td class="nump">110,634<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182,151<span></span>
</td>
<td class="nump">175,743<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,187<span></span>
</td>
<td class="nump">10,858<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,719)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,742<span></span>
</td>
<td class="num">(3,989)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,361<span></span>
</td>
<td class="nump">182,151<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">175,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Depreciation and impairment [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(71,517)<span></span>
</td>
<td class="num">(46,648)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,247)<span></span>
</td>
<td class="num">(18,428)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,834)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,885<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,768)<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(84,647)<span></span>
</td>
<td class="num">(71,517)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(46,648)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=asnd_PlantAndMachineryMember', window );">Plant and machinery [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,003<span></span>
</td>
<td class="nump">14,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=asnd_PlantAndMachineryMember', window );">Plant and machinery [member] | Gross carrying amount [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,436<span></span>
</td>
<td class="nump">24,944<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">299<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,995)<span></span>
</td>
<td class="num">(383)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,933<span></span>
</td>
<td class="nump">27,436<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=asnd_PlantAndMachineryMember', window );">Plant and machinery [member] | Depreciation and impairment [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,784)<span></span>
</td>
<td class="num">(7,584)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,330)<span></span>
</td>
<td class="num">(2,569)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,869)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,296<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(112)<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,930)<span></span>
</td>
<td class="num">(12,784)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,584)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other equipment [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,786<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other equipment [member] | Gross carrying amount [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,420<span></span>
</td>
<td class="nump">11,203<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">951<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,635)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">306<span></span>
</td>
<td class="num">(208)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,976<span></span>
</td>
<td class="nump">11,420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other equipment [member] | Depreciation and impairment [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,175)<span></span>
</td>
<td class="num">(5,023)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,322)<span></span>
</td>
<td class="num">(1,899)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(405)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,501<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(194)<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,190)<span></span>
</td>
<td class="num">(7,175)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,023)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,513<span></span>
</td>
<td class="nump">8,429<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [member] | Gross carrying amount [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,375<span></span>
</td>
<td class="nump">20,130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">847<span></span>
</td>
<td class="num">(479)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,298<span></span>
</td>
<td class="nump">19,375<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [member] | Depreciation and impairment [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,946)<span></span>
</td>
<td class="num">(4,497)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,283)<span></span>
</td>
<td class="num">(2,085)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,560)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(556)<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,785)<span></span>
</td>
<td class="num">(10,946)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,497)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,412<span></span>
</td>
<td class="nump">83,308<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member] | Gross carrying amount [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">123,920<span></span>
</td>
<td class="nump">119,466<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">861<span></span>
</td>
<td class="nump">7,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,462<span></span>
</td>
<td class="num">(3,093)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">130,154<span></span>
</td>
<td class="nump">123,920<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">119,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member] | Depreciation and impairment [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,612)<span></span>
</td>
<td class="num">(29,544)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,312)<span></span>
</td>
<td class="num">(11,875)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,906)<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at ending period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (54,742)<span></span>
</td>
<td class="num">&#8364; (40,612)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (29,544)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=asnd_PlantAndMachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=asnd_PlantAndMachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109358962752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciations charges</a></td>
<td class="nump">&#8364; 17,247<span></span>
</td>
<td class="nump">&#8364; 18,428<span></span>
</td>
<td class="nump">&#8364; 17,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Carrying amount of right-of-use assets</a></td>
<td class="nump">&#8364; 11,200<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109381572560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Summary of Depreciations Charges (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems', window );"><strong>Disclosure of detailed information about depreciations charges [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciations charges</a></td>
<td class="nump">&#8364; 17,247<span></span>
</td>
<td class="nump">&#8364; 18,428<span></span>
</td>
<td class="nump">&#8364; 17,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis=ifrs-full_CostOfSalesMember', window );">Cost of sales [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems', window );"><strong>Disclosure of detailed information about depreciations charges [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciations charges</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="nump">2,509<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis=asnd_ResearchAndDevelopmentCostsMember', window );">Research and development costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems', window );"><strong>Disclosure of detailed information about depreciations charges [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciations charges</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">10,296<span></span>
</td>
<td class="nump">10,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">Selling General And Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems', window );"><strong>Disclosure of detailed information about depreciations charges [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciations charges</a></td>
<td class="nump">&#8364; 6,597<span></span>
</td>
<td class="nump">&#8364; 5,623<span></span>
</td>
<td class="nump">&#8364; 5,377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis=ifrs-full_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis=ifrs-full_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis=asnd_ResearchAndDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis=asnd_ResearchAndDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389392800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Associates - Additional Information (Detail)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfAssociateLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) of associates | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (20,060)<span></span>
</td>
<td class="num">&#8364; (18,395)<span></span>
</td>
<td class="num">&#8364; (17,697)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember', window );">VISEN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfAssociateLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">43.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_EyconisIncMember', window );">Eyconis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfAssociateLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership</a></td>
<td class="nump">41.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CapitalCommitmentFromInvestors', window );">Commitment from investors | $</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CapitalCommitmentFromInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital commitment from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CapitalCommitmentFromInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfAssociateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of associate [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfAssociateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_EyconisIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_EyconisIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109360045792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Associates - Schedule of Financial Information of Investments in Associates (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Statement of profit or (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="num">&#8364; (377,022)<span></span>
</td>
<td class="num">&#8364; (484,178)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (583,521)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">118,634<span></span>
</td>
<td class="nump">122,866<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">&#8364; 166,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">1,060,861<span></span>
</td>
<td class="nump">702,721<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">923,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">1,179,495<span></span>
</td>
<td class="nump">825,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">1,089,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="num">(105,706)<span></span>
</td>
<td class="num">(145,697)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 263,348<span></span>
</td>
<td colspan="2" class="nump">263,348<span></span>
</td>
<td class="nump">&#8364; 883,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">377,338<span></span>
</td>
<td class="nump">234,775<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">109,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">907,863<span></span>
</td>
<td class="nump">736,509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">716,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">1,179,495<span></span>
</td>
<td class="nump">825,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">&#8364; 1,089,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember', window );">Associates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Statement of profit or (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ProfitLossForTheYear', window );">Profit / (loss) for the year from continuing operations</a></td>
<td class="num">(59,235)<span></span>
</td>
<td class="num">(41,873)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="num">(59,218)<span></span>
</td>
<td class="num">(41,859)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TransactionsAndOutstandingBalancesAbstract', window );"><strong>Transactions and outstanding balances as of December 31</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SaleOfGoodsAndServicesToAssociate', window );">Invoicing of goods and services to associates</a></td>
<td class="nump">18,225<span></span>
</td>
<td class="nump">15,026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables from associate</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">&#8364; 5,936<span></span>
</td>
<td class="nump">&#8364; 7,133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ProfitLossForTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit loss for the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ProfitLossForTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SaleOfGoodsAndServicesToAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of goods and services to associate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SaleOfGoodsAndServicesToAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TransactionsAndOutstandingBalancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transactions and outstanding balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TransactionsAndOutstandingBalancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109381496736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories Explanatory (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SummaryOfInventoryDisclosureLineItems', window );"><strong>Summary of Inventory Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies', window );">Raw materials and consumables</a></td>
<td class="nump">&#8364; 17,596<span></span>
</td>
<td class="nump">&#8364; 18,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Work in progress</a></td>
<td class="nump">235,688<span></span>
</td>
<td class="nump">171,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">42,325<span></span>
</td>
<td class="nump">19,335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoriesTotal', window );">Total inventories</a></td>
<td class="nump">&#8364; 295,609<span></span>
</td>
<td class="nump">&#8364; 208,931<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SummaryOfInventoryDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of inventory disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SummaryOfInventoryDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoriesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoriesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109391320512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory write-downs</a></td>
<td class="nump">&#8364; 15.7<span></span>
</td>
<td class="nump">&#8364; 22.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109383576112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractLiabilitiesLineItems', window );"><strong>Contract Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_Revenuerecognizedfromcontractliabilities', window );">Revenue recognized from contract liabilities</a></td>
<td class="nump">&#8364; 1.4<span></span>
</td>
<td class="nump">&#8364; 13.3<span></span>
</td>
<td class="nump">&#8364; 10.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractLiabilitiesLineItems', window );"><strong>Contract Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities', window );">Expected revenue recognition period from non-current contract liabilities .</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractLiabilitiesLineItems', window );"><strong>Contract Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities', window );">Expected revenue recognition period from non-current contract liabilities .</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ContractLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract liabilities [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ContractLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected revenue recognition period from non-current contract liabilities .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_Revenuerecognizedfromcontractliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized from contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_Revenuerecognizedfromcontractliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109388927488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Summary of Development in Provisions (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">&#8364; 32,719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions', window );">Additions related to prior years</a></td>
<td class="nump">4,684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewProvisionsOtherProvisions', window );">Net additions for the year</a></td>
<td class="nump">57,284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Foreign exchange translation</a></td>
<td class="nump">4,462<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Ending balance</a></td>
<td class="nump">&#8364; 99,149<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in existing other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised for new other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382200272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Additional Information (Detail)<br> &#8364; / shares in Units, $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 03, 2024 </div>
<div>USD ($) </div>
<div>Multiple</div>
</th>
<th class="th">
<div>Feb. 20, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>XBB</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>XBB</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>XBB </div>
<div>Multiple</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>XBB </div>
<div>Multiple</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>Days</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 407,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CarryingAmountOfRoyaltyFundingLiabilities', window );">Carrying amount of royalty funding liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 305,400,000<span></span>
</td>
<td class="nump">&#8364; 138,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharePriceAppliedForValuation', window );">Share price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 49.6<span></span>
</td>
<td class="nump">&#8364; 50.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 150,670,000<span></span>
</td>
<td class="nump">&#8364; 143,296,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesYorvipathMember', window );">Royalty Pharma United States Yorvipath [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments', window );">Funding received in exchange of royalty payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses', window );">Net proceeds after deduting offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 134,200,000<span></span>
</td>
<td class="nump">$ 148.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchange', window );">Funding received in exchange of royalty payments | $</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment', window );">Net revenue from sales interest payment in percentage in exchange for funding</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentEndingPeriod', window );">Royalty payment ending period</a></td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesSkytrofaMember', window );">Royalty Pharma United States Skytrofa [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments', window );">Funding received in exchange of royalty payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses', window );">Net proceeds after deduting offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 136,300,000<span></span>
</td>
<td class="nump">146.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchange', window );">Funding received in exchange of royalty payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment', window );">Net revenue from sales interest payment in percentage in exchange for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentBeginningPeriod', window );">Royalty payment beginning period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2025<span></span>
</td>
<td class="text">Jan.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentEndingPeriod', window );">Royalty payment ending period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2031<span></span>
</td>
<td class="text">Dec. 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember', window );">Derivatives [member] | Historical volatility for shares, measurement input [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember', window );">Derivatives [member] | Share Price Measurement Input [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue', window );">Increase decrease in derivative financial liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=asnd_ForeignCurrencyConversionOptionMember', window );">Foreign Currency Conversion Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue', window );">Increase decrease in derivative financial liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Royalty Pharma United States Yorvipath [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Royalty Pharma United States Skytrofa [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_LeaseExtensionPeriod', window );">Optional Lease Extension Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Royalty Pharma United States Yorvipath [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Royalty Pharma United States Skytrofa [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember', window );">American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConversionPricePerShare', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DK', window );">DENMARK | Office Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_EnforceableLeaseterm', window );">Enforceable Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Total lease cash-outflows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">GERMANY | Office Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_EnforceableLeaseterm', window );">Enforceable Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Total lease cash-outflows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 81,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds From Issuance Of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 503,300,000<span></span>
</td>
<td class="nump">$ 557.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">April 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsInArrearsDefaultPaymentStartDate', window );">Borrowings in arrears default payment start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConversionRatePerNote', window );">Conversion rate per note | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsRedemptionPeriod', window );">Borrowings redemption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">April 7, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsConditionForRedemption', window );">Borrowings condition for redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">but only if the last reported sale price per ADS exceeds 130% of the conversion price on each of (i) at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption', window );">Borrowings threshold percentage of sale price per share for redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsThresholdTradingDaysForRedemption', window );">Borrowings threshold trading days for redemption | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption', window );">Borrowings threshold consecutive trading days for redemption | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member] | American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member] | Fixed interest rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsConditionForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings condition for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsConditionForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsInArrearsDefaultPaymentStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings in arrears default payment start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsInArrearsDefaultPaymentStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsRedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings redemption period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsRedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings threshold consecutive trading days for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings threshold percentage of sale price per share for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsThresholdTradingDaysForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Threshold Trading Days For Redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsThresholdTradingDaysForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CarryingAmountOfRoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CarryingAmountOfRoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConversionRatePerNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion rate per note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConversionRatePerNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_EnforceableLeaseterm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Enforceable leaseterm.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_EnforceableLeaseterm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate for percentage of net sales to royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FundingReceivedInExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received in exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FundingReceivedInExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received in exchange of royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FundingReceivedInExchangeOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in derivative financial liabilities fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_LeaseExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Extension Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_LeaseExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multiple of purchase price, were royalty payment will cease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from royalty funding liabilities excluding offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyPaymentBeginningPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment beginning period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyPaymentBeginningPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyPaymentEndingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment ending period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyPaymentEndingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharePriceAppliedForValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price applied for valuation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharePriceAppliedForValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesYorvipathMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesYorvipathMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesSkytrofaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesSkytrofaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=asnd_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=asnd_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=asnd_ForeignCurrencyConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=asnd_ForeignCurrencyConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=asnd_OfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=asnd_OfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109381303344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Schedule of Financial assets and Financial Liabilities (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 559,543<span></span>
</td>
<td class="nump">&#8364; 392,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">&#8364; 444,767<span></span>
</td>
<td class="nump">&#8364; 444,767<span></span>
</td>
<td class="nump">&#8364; 446,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">729,787<span></span>
</td>
<td class="nump">439,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract', window );"><strong>Classified in the statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current assets</a></td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Current assets</a></td>
<td class="nump">727,470<span></span>
</td>
<td class="nump">437,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">93,030<span></span>
</td>
<td class="nump">98,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,103,991<span></span>
</td>
<td class="nump">882,127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract', window );"><strong>Classified in the statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">365,080<span></span>
</td>
<td class="nump">222,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current liabilities</a></td>
<td class="nump">738,911<span></span>
</td>
<td class="nump">659,131<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">458,207<span></span>
</td>
<td class="nump">407,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding</a></td>
<td class="nump">305,379<span></span>
</td>
<td class="nump">138,377<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">93,030<span></span>
</td>
<td class="nump">98,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables and accrued expenses</a></td>
<td class="nump">96,394<span></span>
</td>
<td class="nump">94,566<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other liabilities (excluding indirect tax and employee related payables)</a></td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities measured at amortized cost</a></td>
<td class="nump">953,321<span></span>
</td>
<td class="nump">738,831<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at fair value, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables from associate</a></td>
<td class="nump">166,280<span></span>
</td>
<td class="nump">35,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables (excluding indirect tax receivables)</a></td>
<td class="nump">3,964<span></span>
</td>
<td class="nump">3,909<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecuritiesExplanatory', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">559,543<span></span>
</td>
<td class="nump">392,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets measured at amortized cost</a></td>
<td class="nump">&#8364; 729,787<span></span>
</td>
<td class="nump">&#8364; 439,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#8220;Presentation of Financial Statements.&#8221; Refer to Note 2 for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MarketableSecuritiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MarketableSecuritiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as &#8216;an accounting mismatch&#8217;) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity&#8217;s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382783408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Schedule of Finance Income and Finance Expenses (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FinanceIncomeAbstract', window );"><strong>Finance income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">&#8364; 14,361<span></span>
</td>
<td class="nump">&#8364; 16,857<span></span>
</td>
<td class="nump">&#8364; 7,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome', window );">Remeasurement gain of financial liabilities</a></td>
<td class="nump">11,248<span></span>
</td>
<td class="nump">14,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange translation (net)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,346<span></span>
</td>
<td class="nump">44,755<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Total finance income</a></td>
<td class="nump">25,609<span></span>
</td>
<td class="nump">43,857<span></span>
</td>
<td class="nump">52,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FinanceExpensesAbstract', window );"><strong>Finance expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expenses</a></td>
<td class="nump">65,504<span></span>
</td>
<td class="nump">44,065<span></span>
</td>
<td class="nump">30,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense', window );">Remeasurement loss of financial liabilities</a></td>
<td class="nump">7,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Foreign exchange translation (net)</a></td>
<td class="nump">27,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total finance expenses</a></td>
<td class="nump">&#8364; 100,027<span></span>
</td>
<td class="nump">&#8364; 44,065<span></span>
</td>
<td class="nump">&#8364; 50,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial liabilities at fair value remeasurement recognized in financial expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial liabilities at fair value remeasurement recognized in financial income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384050688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Summary of Expenses, Related To Lease Activities In The Consolidated Statements (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="nump">&#8364; 12,312<span></span>
</td>
<td class="nump">&#8364; 11,875<span></span>
</td>
<td class="nump">&#8364; 11,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Short term leases and leases of low value assets</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Lease interest</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
<td class="nump">3,842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_LeaseExpenses', window );">Total lease expenses</a></td>
<td class="nump">&#8364; 15,900<span></span>
</td>
<td class="nump">&#8364; 15,809<span></span>
</td>
<td class="nump">&#8364; 15,862<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_LeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_LeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382833712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Summary of Development in Borrowings Arising from Financing Activities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning of year</a></td>
<td class="nump">&#8364; 644,265<span></span>
</td>
<td class="nump">&#8364; 508,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="num">(26,496)<span></span>
</td>
<td class="num">(26,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities', window );">Net proceeds</a></td>
<td class="nump">134,158<span></span>
</td>
<td class="nump">136,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Additions</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities', window );">Remeasurements</a></td>
<td class="num">(11,248)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities', window );">Accretion of interest</a></td>
<td class="nump">65,419<span></span>
</td>
<td class="nump">43,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign exchange translation</a></td>
<td class="nump">49,657<span></span>
</td>
<td class="num">(21,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">End of year</a></td>
<td class="nump">856,616<span></span>
</td>
<td class="nump">644,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Borrowings (excluding lease liabilities) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning of year</a></td>
<td class="nump">545,472<span></span>
</td>
<td class="nump">399,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="num">(11,819)<span></span>
</td>
<td class="num">(12,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities', window );">Net proceeds</a></td>
<td class="nump">134,158<span></span>
</td>
<td class="nump">136,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities', window );">Remeasurements</a></td>
<td class="num">(11,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities', window );">Accretion of interest</a></td>
<td class="nump">62,116<span></span>
</td>
<td class="nump">40,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign exchange translation</a></td>
<td class="nump">44,907<span></span>
</td>
<td class="num">(18,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">End of year</a></td>
<td class="nump">763,586<span></span>
</td>
<td class="nump">545,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning of year</a></td>
<td class="nump">98,793<span></span>
</td>
<td class="nump">109,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="num">(14,677)<span></span>
</td>
<td class="num">(14,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities', window );">Net proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Additions</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities', window );">Accretion of interest</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign exchange translation</a></td>
<td class="nump">4,750<span></span>
</td>
<td class="num">(2,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">End of year</a></td>
<td class="nump">&#8364; 93,030<span></span>
</td>
<td class="nump">&#8364; 98,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of accretion of interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through effect of proceeds, liabilities arising from financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>increase decrease through effect of remeasurements arising from financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through effect of repayments, liabilities arising from financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389382288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Categories of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">&#8364; 729,787<span></span>
</td>
<td class="nump">&#8364; 439,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Categories of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,103,991<span></span>
</td>
<td class="nump">882,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember', window );">Carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Categories of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets at amortised cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Categories of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortised cost</a></td>
<td class="nump">763,586<span></span>
</td>
<td class="nump">545,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Categories of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets at amortised cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Categories of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortised cost</a></td>
<td class="nump">743,961<span></span>
</td>
<td class="nump">529,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1 [member] | Carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Categories of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecuritiesExplanatory', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1 [member] | Fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Categories of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecuritiesExplanatory', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Categories of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="nump">&#8364; 157,950<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member] | Carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Categories of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndDebenturesIssued', window );">Convertible senior notes</a></td>
<td class="nump">458,207<span></span>
</td>
<td class="nump">407,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">305,379<span></span>
</td>
<td class="nump">138,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member] | Fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Categories of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndDebenturesIssued', window );">Convertible senior notes</a></td>
<td class="nump">438,288<span></span>
</td>
<td class="nump">385,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">305,673<span></span>
</td>
<td class="nump">143,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">&#8364; 150,670<span></span>
</td>
<td class="nump">&#8364; 143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MarketableSecuritiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MarketableSecuritiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as &#8216;an accounting mismatch&#8217;) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity&#8217;s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndDebenturesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of notes and debentures issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndDebenturesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109378789872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Movements in Level 3 Fair Value Remeasurements (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract', window );"><strong>Reconciliation of changes in fair value measurement, liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Beginning balance</a></td>
<td class="nump">&#8364; 143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Ending balance</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">&#8364; 143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract', window );"><strong>Reconciliation of changes in fair value measurement, liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Beginning balance</a></td>
<td class="nump">143,296<span></span>
</td>
<td class="nump">157,950<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">142,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense', window );">Remeasurement recognized in financial income or expense</a></td>
<td class="nump">7,374<span></span>
</td>
<td class="num">(14,654)<span></span>
</td>
<td class="nump">15,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Ending balance</a></td>
<td class="nump">&#8364; 150,670<span></span>
</td>
<td class="nump">&#8364; 143,296<span></span>
</td>
<td class="nump">&#8364; 157,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in derivative financial liabilities fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109379693376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management - Summary of Number of Shares (Detail) - shares<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital beginning of year</a></td>
<td class="nump">57,707,439<span></span>
</td>
<td class="nump">57,152,295<span></span>
</td>
<td class="nump">56,937,682<span></span>
</td>
<td class="nump">53,750,386<span></span>
</td>
<td class="nump">47,985,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase through cash contributions</a></td>
<td class="nump">2,982,048<span></span>
</td>
<td class="nump">555,144<span></span>
</td>
<td class="nump">214,613<span></span>
</td>
<td class="nump">3,187,296<span></span>
</td>
<td class="nump">5,764,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital end of year</a></td>
<td class="nump">60,689,487<span></span>
</td>
<td class="nump">57,707,439<span></span>
</td>
<td class="nump">57,152,295<span></span>
</td>
<td class="nump">56,937,682<span></span>
</td>
<td class="nump">53,750,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389456176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>kr / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">57,707,439<span></span>
</td>
<td class="nump">60,689,487<span></span>
</td>
<td class="nump">60,689,487<span></span>
</td>
<td class="nump">57,152,295<span></span>
</td>
<td class="nump">56,937,682<span></span>
</td>
<td class="nump">53,750,386<span></span>
</td>
<td class="nump">53,750,386<span></span>
</td>
<td class="nump">47,985,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | kr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfTreasurySharesOutstanding', window );">Number Of Treasury Shares Outstanding</a></td>
<td class="nump">1,093,054<span></span>
</td>
<td class="nump">845,887<span></span>
</td>
<td class="nump">845,887<span></span>
</td>
<td class="nump">1,113,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Numebr of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,887<span></span>
</td>
<td class="nump">845,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest rate risk [member] | Coupon fixed rate structure [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Outstanding convertible notes, coupon fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RealizedDurationOfFinancialAssetsExplanatory', window );">Financial Assets Duration Period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfTreasurySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfTreasurySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RealizedDurationOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realized duration of financial assets explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RealizedDurationOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109389358496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management - Summary of Holding of Treasury Shares (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfHoldingOfTreasurySharesLineItems', window );"><strong>Disclosure Of Holding Of Treasury Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Beginning balance (Nominal value)</a></td>
<td class="nump">&#8364; 146<span></span>
</td>
<td class="nump">&#8364; 149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue', window );">Transferred under stock incentive programs (Nominal Value)</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Ending balance (Nominal Value)</a></td>
<td class="nump">&#8364; 113<span></span>
</td>
<td class="nump">&#8364; 146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfTreasurySharesOutstanding', window );">Beginning balance (Holding)</a></td>
<td class="nump">1,093,054<span></span>
</td>
<td class="nump">1,113,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram', window );">Transferred under stock incentive programs (Holding)</a></td>
<td class="num">(247,167)<span></span>
</td>
<td class="num">(20,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfTreasurySharesOutstanding', window );">Ending balance (Holding)</a></td>
<td class="nump">845,887<span></span>
</td>
<td class="nump">1,093,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares', window );">Beginning balance (Holding in % of total outstanding shares)</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms', window );">Transferred under stock incentive programs (Holding in 1% total outstanding shares)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares', window );">Ending balance (Holding in % of total outstanding shares)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfHoldingOfTreasurySharesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of holding of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfHoldingOfTreasurySharesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in treasury shares transferred under stock incentive program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfTreasurySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfTreasurySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares holding in percentage of total outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares holding in percentage transferred under stock incentive programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares transferred under stock incentive program nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109379083936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management - Schedule of Foreign Currency Sensitivity Analysis (Detail) - US dollars to Euro [member] - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Nominal positions (net)</a></td>
<td class="num">&#8364; (735,064)<span></span>
</td>
<td class="num">&#8364; (369,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInForeignCurrencyExchangeRate', window );">Increase in foreign currency exchange rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax', window );">Profit/(loss) before tax</a></td>
<td class="num">&#8364; (73,506)<span></span>
</td>
<td class="num">&#8364; (36,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax', window );">Equity before tax</a></td>
<td class="num">&#8364; (73,506)<span></span>
</td>
<td class="num">&#8364; (36,909)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseInForeignCurrencyExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in foreign currency exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseInForeignCurrencyExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on change in value of foreign currency basis spreads, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ForeignCurrencyRiskAxis=asnd_UsDollarsToEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ForeignCurrencyRiskAxis=asnd_UsDollarsToEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384932720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management - Summary of Rate Structure of Marketable Securities (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">&#8364; 729,787<span></span>
</td>
<td class="nump">&#8364; 439,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384959488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management - Schedule of Marketable Securities Specified By Investment Grade Credit Rating (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems', window );"><strong>Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">&#8364; 729,787<span></span>
</td>
<td class="nump">&#8364; 439,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of marketable securities specified by investment grade credit rating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109378874432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management - Summary of Contractual Cash Flows for Financial Liabilities (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">&#8364; 763,586<span></span>
</td>
<td class="nump">&#8364; 545,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">93,030<span></span>
</td>
<td class="nump">98,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">96,705<span></span>
</td>
<td class="nump">94,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total financial liabilities</a></td>
<td class="nump">953,321<span></span>
</td>
<td class="nump">738,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,103,991<span></span>
</td>
<td class="nump">882,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractualUndiscountedCashflowOfBorrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">1,073,521<span></span>
</td>
<td class="nump">797,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">106,616<span></span>
</td>
<td class="nump">114,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">96,705<span></span>
</td>
<td class="nump">94,566<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractualUndiscountedCashflowOfFinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,276,842<span></span>
</td>
<td class="nump">1,006,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within 1 year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">32,303<span></span>
</td>
<td class="nump">11,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">15,482<span></span>
</td>
<td class="nump">14,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">96,705<span></span>
</td>
<td class="nump">94,566<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">144,490<span></span>
</td>
<td class="nump">120,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Within 1 to 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">1,027,558<span></span>
</td>
<td class="nump">742,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">52,007<span></span>
</td>
<td class="nump">51,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,079,565<span></span>
</td>
<td class="nump">794,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">After 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">13,660<span></span>
</td>
<td class="nump">42,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">39,127<span></span>
</td>
<td class="nump">49,056<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">&#8364; 52,787<span></span>
</td>
<td class="nump">&#8364; 91,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ContractualUndiscountedCashflowOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual undiscounted cashflow of borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ContractualUndiscountedCashflowOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual undiscounted cashflow of Financial lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ContractualUndiscountedCashflowOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual undiscounted cashflow of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ContractualUndiscountedCashflowOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual undiscounted cashflow of trade payables and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109384962992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfCommitmentsAndContingenciesLineItems', window );"><strong>Disclosure of commitments and contingencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Contractual commitments</a></td>
<td class="nump">&#8364; 0.3<span></span>
</td>
<td class="nump">&#8364; 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfCommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of commitments and contingencies [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfCommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109359062288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Group Enterprises - Summary of Investments in Group Enterprises (Detail)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGmbHMember', window );">Ascendis Pharma GmbH [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma GmbH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyGmbhMember', window );">Ascendis Pharma Endocrinology GmbH [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Endocrinology GmbH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIncMember', window );">Ascendis Pharma, Inc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyIncMember', window );">Ascendis Pharma Endocrinology, Inc. [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Endocrinology, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOphthalmologyDivisionASMember', window );">Ascendis Pharma Ophthalmology Division A/S [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Ophthalmology Division A/S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyDivisionASMember', window );">Ascendis Pharma Endocrinology Division A/S [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Endocrinology Division A/S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaBoneDiseaseASMember', window );">Ascendis Pharma Bone Diseases A/S [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Bone Diseases A/S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGrowthDisordersASMember', window );">Ascendis Pharma Growth Disorders A/S [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Growth Disorders A/S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOncologyDivisionAsMember', window );">Ascendis Pharma Oncology Division AS [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Oncology Division A/S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEuropeASMember', window );">Ascendis Pharma Europe A/S [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Europe A/S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaUkLimitedMember', window );">Ascendis Pharma UK Limited [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma UK Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIberiaSLMember', window );">Ascendis Pharma Iberia S.L. [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Iberia S.L.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaFranceSasuMember', window );">Ascendis Pharma France SASU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma France SASU<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaItaliaSrlMember', window );">Ascendis Pharma Italia SRL [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Italia SRL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSverigeAbMember', window );">Ascendis Pharma Sverige AB [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Sverige AB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSwitzerlandGmbhMember', window );">Ascendis Pharma Switzerland GmbH [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ascendis Pharma Switzerland GmbH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember', window );">VISEN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfAssociate', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">VISEN Pharmaceuticals<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">43.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_EyconisIncMember', window );">Eyconis Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfAssociate', window );">Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Eyconis Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership</a></td>
<td class="nump">41.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The name of an associate. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The name of a subsidiary. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOphthalmologyDivisionASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOphthalmologyDivisionASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyDivisionASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyDivisionASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaBoneDiseaseASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaBoneDiseaseASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGrowthDisordersASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGrowthDisordersASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOncologyDivisionAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOncologyDivisionAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEuropeASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEuropeASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaUkLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaUkLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIberiaSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIberiaSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaFranceSasuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaFranceSasuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaItaliaSrlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaItaliaSrlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSverigeAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSverigeAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSwitzerlandGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSwitzerlandGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_EyconisIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_EyconisIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46109382859840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ownership - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfBeneficialOwnershipLineItems', window );"><strong>Disclosure of beneficial ownership [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MinimumBeneficialOwnershipPercentage', window );">Minimum beneficial ownership percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember', window );">Entities affiliated with RA capital management LLC [member] | USA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfBeneficialOwnershipLineItems', window );"><strong>Disclosure of beneficial ownership [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership', window );">Minimum beneficial ownership</a></td>
<td class="text">Entities affiliated with RA Capital Management, LLC, USA<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_WestfieldCapitalManagementCompanyLPUsaMember', window );">Westfield Capital Management Company, L.P [member] | USA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfBeneficialOwnershipLineItems', window );"><strong>Disclosure of beneficial ownership [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership', window );">Minimum beneficial ownership</a></td>
<td class="text">Westfield Capital Management Company, L.P., USA<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithFmrLlcMember', window );">Entities affiliated with FMR LLC [member] | USA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfBeneficialOwnershipLineItems', window );"><strong>Disclosure of beneficial ownership [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership', window );">Minimum beneficial ownership</a></td>
<td class="text">Entities affiliated with FMR LLC, USA<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_AvoroCapitalAdvisorsLlcMember', window );">Avoro Capital Advisors LLC [member] | USA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfBeneficialOwnershipLineItems', window );"><strong>Disclosure of beneficial ownership [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership', window );">Minimum beneficial ownership</a></td>
<td class="text">Avoro Capital Advisors LLC, USA<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember', window );">Entities affiliated with Artisan Partners Limited Partnership [member] | USA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfBeneficialOwnershipLineItems', window );"><strong>Disclosure of beneficial ownership [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership', window );">Minimum beneficial ownership</a></td>
<td class="text">Entities affiliated with Artisan Partners LP, USA<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember', window );">Entities affiliated with Janus Henderson Group plc [member] | United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfBeneficialOwnershipLineItems', window );"><strong>Disclosure of beneficial ownership [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership', window );">Minimum beneficial ownership</a></td>
<td class="text">Entities affiliated with Janus Henderson Group plc, United Kingdom<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfBeneficialOwnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Beneficial Ownership [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfBeneficialOwnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Major persons or groups of affiliated persons holding minimum beneficial ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MinimumBeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum beneficial ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MinimumBeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_WestfieldCapitalManagementCompanyLPUsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_WestfieldCapitalManagementCompanyLPUsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithFmrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithFmrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_AvoroCapitalAdvisorsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_AvoroCapitalAdvisorsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>124
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MB[3(-:3]I7,T^SV.="6P!-.%@*!3")CD&KS5E@1&PNAZAS81:T'$-V3@M#_
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M)S-'$B\MX1ZV-D(NM#%J+%)[4O3 TB=SW,1 TN!&84RZ87"W;H[5VOK[QB-
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MEJ^ZE5^T6-G7RV9":Y'9CTLH!)@T-\#O<P$%5O7%/*!^X?#\+U!+ P04
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M&.9X45T"5B]&[=PMUT(9H[;N<2/X4A06 +^O%(2H?K$-'*]B9_\!4$L#!!0
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M J\S>E<^QZ3MD,OQDC*KF__@N;6U1B!9U[3,6V?6@CPM-I_X5YN('0=H[W%
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M-F\\; YHN6J>GW\H*2WSYNN28%8T< /V^Z)D_6T/>(#M>R=7_P%02P,$%
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M08,U\Z&9KJ8U#'!6F)7UH"OX-8-V^O*Z+.HRS^92JSFYEO62)+#8R(.&!["
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M5"?C,UJMMEN^W<&;)BR\S'A:G^&3>QDM/Z#[TM#<ZP]L8/@%M/@/4$L#!!0
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M\ W\E8-77M7C&4X\6-4YS%?$@%O6)YVZE]3CD77]8C5:,Y>P&!(I9S+C2%G
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M^,$[F:0 ENW'@5QQ\@QV6&7-/098EU=CK8XU'0F4*>D*WE[?K4_1,^04(1D
M80 !'!X@_HA"14=Q3D@"Z/OQ@C#R]B)G0%$#V(/@*>HE*]/$E#G4ITEZ>\9.
MITH]?7LBJY+8OL5 X+3I;SO' 1D.M_<DN'%U<8YPX5/2[7<L'65U2B/)\@0O
M#X<)3ULU=L308?>'@*,QI&Y *#^7D[,I"*@6J;FYUN- S.M)5[3.JP[S$#Z!
M+3T?- \7FE(D6Y:T4$DF(FG#F+>0_)@;5ROL1$/*RHT(>TE2E& GK\82&Y9U
MVS"+FJLXSZ0>ESXKB*\$.H2@U..8QJ]HZ)IC8ZP0H>J9>H-_K2VZXI!O4?T
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MX,WX^*L7.V#SG\ +Q?"PU2MX]?'RVV].N$[B?QGZ'2Z)%V$._99^1&="6WP
M/E_U_>!_P0W0;R+P7OT/4$L#!!0    ( .N!3%K4+BZ2BPT  +TH   9
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M@&6*D:['A2FF+5 *"9D+Z^)61!0%@A,MB !@**--'S%+80P(/!JI-TZSXW5
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M!,LG-WJIJ&_:A^(D$516)9MK;+8+ABTEI."5Z5JGD6"ES3D(]QW 7CNN#*M
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M;5,PWH^4_R<R';I]0YU@5O'@!RI/Q#SK/'ILK9$N4<5LOR;^U9EWW9_!MW^
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M.>\! 1M#B(S)?/J*7<X&4P!XFI)C6$M9G@:LY5[7M7N%6.9=7P3Y'E^$!_@
M8T^BQ"+MH_:K8Y6M2I6UB8> /;G_C[\^W/WT_14P;P$I1I=0\G"TZ_9__>GN
MYYO;JX</_K'Q!8)CP3Q A<\=:QS:\T!LL0ZOFJ?"XM8.@U*#CH21), !6)>0
MUC2Y(4\-]+3A2.6Q%"XFFQN)U$[3"@KU:/EY<#]@9&]A(OLX2#UM%#;&YCZJ
M6P2QZ@>!'_EVL,]KFU58Y_>=C47L"8;,Q9I3W0)I9(9$9%S$<]0SR2_P  (2
MX@N! *F-EXMK%%D%H8"VFSEM89\J=A?!37#,Z6 1_!);(C@W=N-2I#9+@#9B
M5ZK$*I885^S//*]0P3'/ZH ]0)@6/[2^L<*N#W,H>[6"H^+)@F\A,[%<BB7V
M R=?H!H2+S<(J8)X<,I'V#CNX">/4M>R.:Y(E=JY/Q5IR8#=Y.P3<,\JE0(@
M8@\ES_4UZ-P^?""D%-!KX@UL$UQ!I.&)WO[O/]N-'4B!I?<(;@IT=@7L\N$?
M/ E^YP@1B&JV$Q"6FZMJ#05Y)'DN+]87=S?JW&MMZ@P"8"G@C*@%UF >A7!*
MA.N'HI:)R,@=1_; [#=8R1*,_P:;&R@3ON-D\"'1&UUMUO"]=F_G+S?DOHE-
M4PY+#_)Z\S/Q2MOT1:A&Y@(3.YP-.FBN#T88\6^A,8(C564_N);"%GXYZ3M3
M<"_KG:,A^Z.M56Q@'0!FPO9V.7#;+@=\H<*NFG+@,.@_IZAP@6N9@O_3GQ*J
M^Y5=G=^S%X3$X^&K]@U[:?3J9<3>;Z%-J2.8!Y5X>-9?;1Y[$/(7Z/\CB@Y2
M2GC.70Z/6>Y^OKE__XG=.J\0E:'$K^L%]FYX?L ^4PGH$VM;WD:TKJN E')8
MD$#:1SBRJDAZ#9L#)6C_! I-56$QJ:XJ'8B@_( 3/2I<2@[KN 7DSJ-(U=1'
MPG7)R0GF@G,0YF&9AU82L+>J'7B)V?NL2-76\A8K;3J(N[<3L=O9ZJXMYW<M
M.:\MK:/U_GZY/^BZR@YT3KN*)QY*BSX6S ]J?,>,?=[*7A#A'J=LPJ)V*%M-
M=9XIJE)7W.4_9]4VFR@UK;(Z2Q"ZXDN<5AIPZZI&M-NB9LRIO@%G(^)-KE*U
M!K;!.#0#L5#DI(R Q'FU@IDJJKH@8(,"J*9WF 6@(EL8RIMUI?-"YF F(1>Y
M%QE?IXB11+PD\V5X= G;Q01\@E-+TWI:+8669NL@> ND'N,QOD16T"[T>-CD
M;+D]"]5A(WH0&!O%' PBU>BX2E&.-+NU3'-SV\0II99^4S''G]#M%%V*WRII
M@P"]10K2<+J\I>*6W'45:P5H/ZW 2]EGEC.;[.N%L,T20B5@QK8=43 5!<VN
M?9(#:@81FF893LH1I?T,FO-Q']*B2+&%=<R0SEP=VZY/#NBW#7B(I\S69.:@
M;J,=/R;P\V6#;MFUI"&4%4%\*:P:$0F(T"JU5<6>M(TKVFAV>J8_O+!X;=LT
M[8P.<UA-(["R!F#:,0X\Y+!7+,XR&@VAL#AJYA@,6FRBG(JJ$44HZ$*-/*6:
MA)=K88YY>EN%A[361@0:C-#O0AER$)C*U$K$5^I-4(_6$Y&JH/O?H)F9U8T;
MQ*X*%/5$NHUUKH)=P\(H3[;T. IR\MR:8*CYVUH\4@@=Y=56'=[U>[:RJI(6
MHTNU165&/@OFUZE:@E .K5H*SJR[ OH0YK6D;"5L^_(-JIYA_6"09P]37/4E
M>-P)BL;S#H;$OE]T56+] ^$M4KF6OC0*&NFSVV(QZ!CN6?;Z7S=--]S)H5TO
MQK>ME:N@Z887;X4&$QL$K.IH:1*PC3QNTQ=Z2-1GW *%XQ$)3B9G&A>@[01:
M-]0+@K[A:Q'PBN=H!ENLVV*G D][G%@\PE:Z6OXB'%J7H25E226<?"0(RCE4
M+2Q.N<P(R:0#F(@MI=*H.\EK E77#3&-*A,.XS6-JP :)W# \#2,!IWKRC*Q
M!=N6H \-!SBJ''I#1@\X-_DJ==!V5S-ZA3V1R6-!O;F"SFU'_5PL:BQ*'8SU
M>L\FRKPS?Q=U5;H]7&!!T36^[L6.;IE[OQ(#4O>%$16B^"&S)4HKYR!V@M&1
MB-0GX<M0DST4 M[7-C_(:ZN6K7Y'42ZA@E+AG<12/B+I3K!(VP44,(H5C]@E
MC;O<EJO\+ XS9%L2A!\M;J,6-D3MUJZI]Q 3T5Y)X?0;='&$8[<4:<Z7_EQK
M!1+UT-"N;U0V8/=-R'QUP?"L8CAJJN'( PR**]B2T,!'3M2<"M@Z@[BQA"FB
M0W1%=+6BTM+H3M'[+RNJ_PV*YP&[JE-?NOW_:HH?/MZ>C2QV%$:5C0$J;5/(
M@4;*QJ.M]!+$G07/B(0'$7OOA7S9AX4E90XTU"J&'D1W]0N)-3LTR3H!0WR@
MB*V3@B>Y^,+M5ZS\W:4H:"WG!/'(;]K"LB0(0Q3*W$THC\ 9U0L\&-(N<EF7
MC@ID7I&=")7M$4EOSJ0;X; !E05-:/!#IJZ>Y'[R17IS!5E(ET'NE-HHEU%]
M>G6)M49&R%B5_AZ(_^+.?S)J9)P(]:T]_OP=&DD\(8G2)Y%L+=8N%R^W7?W$
M="85_&27K#^BT"Q1FDH-P#&]"4"UHV\+ZOUICD$'+]9SH(+1R$_]^,KX-./&
MERT8#P/Y_C(%UK<WO,I=E7QS2P000;9#I.K/:1*+X-L4S\>"B@;K-)I>52Z4
MFF28**0DF'FU(F^C0!5?I+8UF#8P_AE/J8!<57GLX,0GA*LX)D6B,O/P @:1
M^&!8K=V)&RSANW>+$&=&G0$+PO2IP0B?;=V8JSQV%!BD:%E,T*8!T7@<4WCX
M''5S._C*4S7/9CBZ#2S6K4A@KG5H<3D;3.K:OCLXJ]L67PJ&0PUJ3M-4Q?6C
M9*^5BYT6/M>NUUL5#L*0E-J#< RR/R)#30SGL:-%>X1.KX_40S"..QNG]N]+
M_G="DH]R)=A]+$4>NP*Z'L5RI@6J5&J28T\\1DON9>@#ZOVRI(7#JMC0L"+-
MG'_"601<SG4?UI,4@HOJ)#?4H)YOUO1\1%2:IBSDU%<]4H]3,KUU .J;^=IX
M7L2(W5VQ:UY(ZK)_Y#FBVAD'IGTGE6/Z@P!$;OZSHE-=_VSW*(.@-'A;,$3?
M\,/KY7<U42NBSEU!%9WQ5]AJ?RCI^DAW>A-1R-'$%8D[]"N4UW^KJ-@HT+@8
MWXD2Z5P\I3899B()ICW2=!XHV \6K?9TT[9C^UTHNB1HC'7ZNJ/=*'GDSN@L
M*"QB<L4LZP\[W'XI'"Z:>DK_]4/ZJ#6E;W6+=2B4(JOREI*3<'#I1P1M&&OA
M1_T6A+W8]\H)'+G;_OBUUK:\* ![="KS3T2V\6(P.H1LMGGA>K,+<;A9JFJ]
M.>!N#9C8(UK0LRT<C?']O'(E_V=A\NCP>&?C]H%5WP:VL0^[']1 S7S7]#LG
M,C<6K5Q5 L74;5=M&1_//<YC >^ /?U R*5@GJG2M%^ZJG>A/K5+KQ5U91.H
MNO<5KJ9M#G!43W$&X4QN_\S[\,%-WM/1]!_,>.('CF3\W3 /7%6E32"[T[;>
M/KE&X\T/'[IGXBZJZRO7GV[=L,LW  ZU;4\0IH=MCC^&FN[6PU3-LJ2T#6T<
M'+_O"MM587U2WQJ/!A>T(]+%L/4RQ<[!P-<,(#L3S-&B&6!V==A:\/RDT<'Z
M#LC3XCW=U3J+&MYH+C@>UC'JIX* 16?]GL%MR '=X4NK)K?O\T6'SVW)_*XS
M:<KG?_\\<67Z\D)N#[4.Z7O#'T7O.R&5V:@RA$_CR0^]5/HAV)TD[_0N7]N>
M@*(L_Y$&A1ILY"@AFB$L\?%_KUN9_$,Y?3YIWK'Z)W4KQ/^1[,*>D5YV$7#@
MW^/H)I?1Q9'DXFQ])+_X%XPMX9VWY9[WMHL]"*UUWTSF@"PT/>L-WE ;V[)V
MYWWB1@U.Z.;UG$'?"]_GK3?O@61K^_\%VHT.W$OX]=7Z7QBNW)O[S>/N_Q]^
MY.5:YI!!K+!T.%C,3EU'$WX85=CW^)?*&)79KQO!P2X]@/LKA7#V/VB#^A\[
MWOXW4$L#!!0    ( .N!3%HE3UB+B ,  !H(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;)U6VV[;.!!]]U<,5*!( ,&ZVG'B"^!<%LU#BR!INP^+
M?:"EL41$(E62BNN_WR$E*]XB,;8+&#:'Y)R9<X8<>K&3ZEF7B 9^UI702Z\T
MIKD* IV56#,]E@T*6ME*53-#IBH"W2ADN7.JJR .PVE0,RZ\U<+-/:C50K:F
MX@(?%.BVKIG:7V,E=TLO\@X3C[PHC9T(5HN&%?B$YEOSH,@*!I2<UR@TEP(4
M;I?>.KJZ3NU^M^$[QYT^&H-ELI'RV1KW^=(+;4)8868L J.?%[S!JK) E,:/
M'M,;0EK'X_$!_0_'G;ALF,8;6?W)<U,NO9D'.6Y96YE'N?N$/9^)Q<MDI=TW
M[+J]:>I!UFHCZ]Z9,JBYZ'[9SUZ'(X=9^(Y#W#O$+N\ND,OREAFV6BBY V5W
M$YH=.*K.FY+CPA;ER2A:Y>1G5D]8D,0&[D578%)J$1@"MLM!UH-<=R#Q.R!1
M#)^E,*6&.Y%C_F^ @#(:THH/:5W')Q%O,1M#$OD0AW%Z B\9:"8.+WD/C^NL
MDKI5"'(+=*05414%Z(Z^AK_81AM%9^3OM^AWX.G;X/;>7.F&9;CTZ&)H5"_H
MK3Y^B*;A_$3JZ9!Z>@K]OU;H-,@7:1 F'S_,XBB>OX$(7TN$&UDW3.R!:SIA
M@JYD#DSDO5K6T" %PJ;5A*XUM(*;,:RS3*J<Q*SV/@@)+,^YA605\*, ]!D<
M!]6E@@)EH5A3\HP<&/45;>/G7;ULT(8I ULE:^H!+RA:M%!O>+%C+R[ 44Y]
ML*3C</[8.8^=&<VAMVTPW6#&MYS<WD$^, 0CP9!0E<QZ4EMG=_<4U?A81B?V
MQ9SH",-$P3<54HX:B;95M5%65T.:-16C8M@Y_-'RQI7&1:"$-GMB7;CV14?W
M-=&-[:97(WL[[!5)1F=WWQ[[B&$8GH_N?S_HZ*ZURW 6G4-RZ4_3$-*IGT[3
MT1>I3 EK8DBJP#3QHS"&Z<R?S"Y'7Z5QE?Y]C@3B7Z0Q1-'$#R<)G,7GL-96
M4[K]6&]0#1W >?XZF_C_*RSADU#)-)U#?#&^I*9:54Y@VG582.+7!9\J8(6W
MKX<]XG1@#M6A4W:+@AZS9[\[![(51NUMB%S6/.,5CM_J ,%1OR91"_<JZ<Z]
M:]W#[/#PK;M^_[J]>S4_,U5P02GAEES#\<7$ ]6]1)UA9..Z_T8:.J-N6-+C
MC<INH/6MI'O2&S; \'=@]0]02P,$%     @ ZX%,6I:R,IPI!0  " P  !D
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MI8N;5":0'4 66-6(."FHO$IS=;!8% T=@>S+"OT28!QYI\UUEM5FA'-?\?0
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MI8WFIB[W]&O&55G794Z7.\$AA\ !\'Y3EK6YP0W:G[>^_2]02P,$%     @
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MCT#J2CF2BFHY$SRCU[W156MR8956%1&[6R7"76+/02UJL[;*4FZL=!#_<.\
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MS!+_K!-DO*1W"IQ84]CS(;(/Q<!XY%,R3<]!>8MT.HHQCY:E<PWMO7L6@S3
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M3WNV+ST.IG84C<+#J1T.AI4?:6G#9O:Q[HU\KB=/$Q$]R6"DM,:S3'NS2S$
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M5O.+Z.F O$*;R=$.38"TN&XEMZDFV#MM?6/(P$I3F0/$3#SP#%_GP%"<VH8
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M]5RM6W]C'G[6@SU9P)N9UL5?>NC/2MPX6SMOEH,PYLNFZ[_JR\##CD"9?$=
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M >S/#1JB81(NV/XKNO@/4$L#!!0    ( .N!3%IRAMM6EP0  %H*   9
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MP_4;^L>@G;3DS.)2R^^B<.4TNHZ@P!5KI'O4FT^XTS/R>%Q+&WYAT]X=747
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M:&5E=',O<VAE970R,RYX;6R%5%U/VS 4?>^ON H2VJ2*)&[Z25N) A.;!*I
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MPEJRN7>(R4FYU<K9< QS]B*9@VSS4" D9):]XYZ*P8D+VXE?*R?^$SOQCZ5
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M3E6WPGQHJPW_[FQ9M6VUYK>W$I&LI@5XOJI@+?H#'=#_$/'-_P%02P,$%
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MZ.V73R$(A\/A8]$"__E09H=WY T6CQ?X'L<)K<@7I=$SC)*E6RE+R0'I$5B
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M'U*G6T,DG+V693(CZPD-Y9[CF(GCH;>L<@K\ %##^7A[(&,F(471.#@GX\"
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M%/QUHQ#(EA[ _96!IX0?-$'[AN;+_P%02P,$%     @ ZX%,6G/<J8.H P
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M#ND-BLN2'GWP+$#W>T=CH]^P@?%OQ.9?4$L#!!0    ( .N!3%J;>2F9- 4
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M<JR ]95%JKL/-M#_@YG_!U!+ P04    " #K@4Q:(/E=X4X#  "M"   &0
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M4%D#FE]*>I,V';M ]P]E_!]02P,$%     @ ZX%,6FHA10=< P  C <  !D
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MLMJ!WRD,&U$N-%S"+YZ*V.'<%*70NT;,NUOV4)$CH5,OP5C^<8, ES._ T'
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MJAHJ5)B7AH5\0T]& ^DP7) 3Z#8P+H_&7!UC7V+2DWL8]-*FWIZA#LO.3!(
M@@"R<'B \,,3%6V%^#WEXV< &8+(FZL0 84-8*Z&GJA25L")R<=9G!E'?$).
M6Z9NWQ[1JKC@[]%D.5LW]W7'IB-6K'+5G!]=U#@<^(QX^P-#>UH=GY'XHYP^
M^A3W5.5#30CM9G\&,!J<DPF(\I/=&8D5LP1DBY3;ORJ&GI!7CRXJ8LEK*E42
M5[ODQE#-E4O>$;^>27D3GXE)5TE+2'ZL&S8;S!S$DY4RYZ.X4^)EFU=]*!+#
MWYR\I^D-GL4IDBHLU7^)K[AS<.:SPGB97<%N2*20%8^Q+&0]8VWPCY5%<TJT
M[Y1P/MO#X.4-6[B+["<XEU9TSRO#\0!N;R7U(JE2?T&+A'C.Q=RDF7MZ:Y_.
MPZ==2KN3,7^LTMD@TA5L')96M7Q  WV\JMA%VTWMUB/VPFXBY%YL*_@_C:;Y
M.)#^\[#6M\8XG^]J<6/.Z#T07$TKOI;H9Q)/9P><P-/963+[<^E^UA"LQ\1[
M"L#:X"RHJ"#=*,IX0Q'DWT!']V^J_/YP\]N9?AG88M?&F64&N(X'N$X-X,N-
M0O<,9UV<N2#@F RB!*6/QA"+7@Z3%&V.FE;!ABT7;!;A%H'%P80QY*)7-;=4
M'Z1WBW4TI0_NOJKRU:>SF]6NP: A5Q"?H7,/']@WZZ+BB2WD&>+FB\E5P%N(
M]?"L70A6CU;.YP<D0<K+3H+N%,L=[U]%#VG&G(AY]>:&,YA);%; *("D,$^&
M7$Z84T#0UCAG27[)6AHFN<"[C-YJ-Q"7N"D@3 5V'2>(2/DC9UT/^P-/3:U&
M-ERD0,U(-"LX -5#B*4A&025J1;\QC<A,0-<\P"VT8@DZ@7^JS LB+*ZQ3JQ
MAK5RV!$6JW&.(^<>.2^7>+>"-&/K2PXCL];[*J5Z8'@A19CXF[8SX*&E#XV!
MD<%<(0T^-)MF>P*QEN[@))F#,@W09TJI&%)+K/L,%\6GF(M?>+4#C88'%UR]
MQ5H#I^;)FGQ;$ 'BJ.\*V0<8[MMS%!,G7<+QZD*C4\-%;!DIZ?5U0P&YT0!_
MY5*%.H8*@XW"M7!4= PFG9'<H##%IBA)0R7D5C!$YXC3<DBFQ!8+_DS(M5IH
MW4*Y0?<LCN%!94]-UF'Z/6AP#3>O;5 B" 2363D,HGU=$AP4!!2$244"N$-#
M&CX4BF_6I=^:<P+'J5L&#RU-3^!0R$@6ZOY!5G@:!3'.X,8DSN%7HDXMOZ*G
M:--<2683.E06L6#A36J;CJ&6<]I:MG?FMRRG8YD#P9>Z1ICMAZ<R 0QNKD$]
M&MQ98MBO!]SKS4%[3)7#(?T1\W<4QW)MZK(O5. %J&:B:R*$%M'(.*9;B";<
M6ASNL1J8X)X'0'/1R[;<DDDDHGI.I?/=D<[GVR.]DSQO:=E"?:3F[(XOZ'XT
M,T7V+DP\)T_9R*8P95:CIS!_T1B6@R\2"U-G1R5CY.HPXN_!XH&%Q3[LX>);
MN:0&Q^#.':OT054PA_\?>ELCR)N!9660>_4^ 0\'H\!^( .!Y1 %75O4B5@$
M>>W,Y2 ZT]SWF''#MJ[D<>)'+2/2E##^4I,I!DF,<K^Z?#]Q5% ]M.81N&S3
M0^\[*019@E6Y*:R?0 I@T:SSU0OXE0+.I>WE>TS,_D?!$1UN4A=5K#WC[ #*
M0Y4!W3#S9.?[NIS/-W816OB(2;)).ON"QBYV3/R_XVZ8(K_PG0DZ:IJ!(5BQ
MAOOH619COIYV76@$/?^\>$SE7L(L%3M$JD)'>;GBGPQ2[^.5F=EM;KNJD.U,
MOOI#TQ>HTE->XVA<)K+9O'W2@@U,U28(<Z<?"3^/RNSW12$J9(TEFS -+F9P
MJ@\,CY!R835X0@P3[D+@JJ<YE%D<\I(.UN5)XF N&7P"0R1["+YM?1DP_C6@
M@5?4.1$IJA<H;/-:2L#UA^DB">036H,3 A'VY75AV=,,IBR1 E(/<0V%5'1@
MEN^X&HK7]=#AI,I$;HM5/J#$0@8GO<NX?(6\T%I<I:JG2XS4#<%ODD0KMB2[
MG)&C,9O$K<79Y!/0B!;@YJJ+.RXN'\^('GQ/ZG$R0ER\'5;I>$8KU?\8'<"(
M0[''MH#M,:A>T6*XB/,Z3!*CBH0MMUZ::+)A.E!:-D4B;W)VS@.3R%"BW%,3
M \EP:MJ9I_(@$<J5J*)-@5F&'=9V=Y*E:.P/Q%1OV*86"8\,]2AI/K6*6M*8
MN#59%Z-!W;01#XA.V8 S=D+, M$X3\NPV450$R=VAJ^+0QN@0JC8$ :&$C5-
M7-)G7,;/>H23K.$M9A-\@K=<TKTTPUQ+'J8RE[P+6)W0?:J%6  Z1DKK#%:V
MB.A+^@D"&(^!$!U'O.=&G6GO[@.<7]"A;$U9!4.#UDC4XM+:R&B!]9TU&\!3
M4C+[$"KVY#G'"_FAWQBAJ>3IZP#"AUP,<A:UE&A;J9R(QII<3.EZ_R _H6YP
M655L18; JE9\*)2+1L%S&GCA%-AU:A5DTTW,Z#,)2M.[$B:]*[WSM,OYA^QO
M ]@EZU+*K6.>:9HJ!-X;+)MEOZCW7;*"Z=IVD8= SY\><&PU;+$TGC71%F!*
M/I?:TP&VEU.4;!"]!ZG'^)QR*2(BB!.*R!>$=.1JDM^F);IMH,A1[DG"MH^N
MVB,00X6$'E$GJ =IU33N L(:[-J @5FA0.%WQE<,$XOW,5)JK9V)9>98>A9V
MQ'FL(DLJ0,_YS3V5;G3%@FT65=RI)@7#[^$F3QL=NY=0OE)<3<[LUM6Z:-L2
M$QX..0(^796?"JZ;REM3Z"*L1+6V,<U*WCNHH\3OYTTOWT'Q?+[UX?NX4#UI
M?\V.,65_Q17P/ZD.X3Y06R&7*Y-2$#C#6YLF65<@VJL+231@8YC3$*4/BS2[
M]5[/,)'59*(JNY'ZL,CQ27%2EL$5N^G9RC=>:Q0302F,LEC=7:2F<;B"0O;4
MO2C98<,I7%'I!)GI1&O4N0=4M[UPUZBG#+I&?C*#D!+FK'UL@<7>/_6&FM=[
M;76,,^5=SY[[(^?]D;^$ U3$QH?V(.V2QB.8;9QVU..4>>>T[G9G'"BFI0T
MIXYRV5QNU<0C3M,/>]=&=5W=$=[;ECZAT2QLF;W%E:3&?W@!/F?:GJC?9UM(
M8P1FGE5S7] !@UBS]4ZN55-O-.4 1QJ8K=$LGI(O-*A,\V8]J0>Z!?D6EN?S
M/2QOFDT/VENZ3OT+^E3J>)G[(&3D')]Q_H%/-I/NWSB0RUC0[5(ZPW! OIU,
MM+5MM\<96[Z;BHJDE(^&G>,+R<:71.2%;\YL;!VE+:27@&>0N[;\.ZCBW0@
MS'Z*N'MS(DHZ[COB4-R5O7R?/3U_QE@?S$3:6L54KIV^R:8PZX1W+^#=8K6K
M.4^0DDR ):A:-M6H&$%!_5<HHN$1=/#!WV@U7'\)*]ES?3)0"\Q^^<RY/C%$
M0YVT$R>2'LLQ4E#V<#M'+I1\^M6S *S:UA8766OAP] 529C)1JICT"K0-SQ?
MY8>R)Q/-OTH!X!H4@$KN';DC7P_Q,ZYDCS/5)'V3O.'C?+M.\T%M?AYE_M%@
MJ1?"_D4^B\QEC4[9^'%^6W 2U+^1 ".=UAQ>^5Y%TQ),Q),IF9\7;U?V>=^
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M-4I/"_>_-)? AZ>1!'O8X(>RB^'1OUQ]-(^C%4DZ'^?FQBJ9=S1;P_=U7&#
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MEU]_]7WV8GE^F;'9Q\-I S\R,TM@8#?2L['8E\,^3J06IX[GOG'B=)< "I?
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MZ396-;ZG5\K2A/#+BD8R:N= ]D(IN]VX /V03_\ 4$L#!!0    ( .N!3%K
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M@2: 8"5F9QI")R#C7@(BTV_AT$9%-/'<"KU&2I_M$(1CAP:YF-)0*=C'GNV
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M2>%+[$_BO\S>:>Z$C]R##88W'V_?OLD832\((:-!3V33EU9]5%I?H+0&[[;
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MID#O/F_+#@(?T.R#65;6GYS/ ^P5+>:K ?>RQV4_P*4,O6^;L/'H75/8XBG
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M%P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6RE6%MOVS@6?M>O(#S
MP '8FM2%DMHD0"XMIHMVID@RLP^+?: EVA8JB1Z*3N+]]7-(W1-;=; ONE+G
M^IV/Y^C\2:H?U48(C9Z+O*PN9ANMMQ\6BRK9B()7[^56E/!F)57!-=RJ]:+:
M*L%3^U&1+UQ"V*+@63F[/+?/OJO+<[G3>5:*[PI5NZ+@:G\M<OET,:.S]L%=
MMMYH\V!Q>;[E:W$O])_;[PKN%IV4-"M$666R1$JL+F97],-U;-;;!7]EXJD:
M7"/CR5+*'^;F2WHQ(\8@D8M$&PD<3H_B1N2Y$01F_-W(G'4JS8?#ZU;Z9^L[
M^++DE;B1^;^S5&\N9M$,I6+%=[F^DT^_B<:?P,A+9%[9(WIJUI(92G:5ED7S
M,5A09&5]YL]-'$[YP&T^<*W=M2)KY2W7_/)<R2>DS&J09BZLJ_9K,"XK35+N
MM8*W&7RG+S]G)2^3C.?HJJJ$KA O4_0UX\LLSW0F*C1_X,M<5&?G"PWJS$>+
MI!%]78MVCXBF+OHF2[VIT*<R%>E8P +L[(QU6V.OW4F)MR)YCSR*D4M<?T*>
MUSGO67G>$7G?E:A$J;G%AURA7$!^*P10ATL(AT#_X<M**X#.?P_Y7TOW#TLW
MY?2AVO)$7,RV1I%Z%+/+7W^AC'R<L-WO;/>GI%_>0WFFNUP8NP\FL7\X2.<A
M+R;U'/:BE\U[A?D -8DLMBJK!-(; ?',H?:S<OW!,8DSV?.<^:<_[W[])7)I
M^)$0<N:\$KG<HX1KL99J[SPHG@K@@$1DCQ:.B#*&W8@@+\!1Z#M_@!XU6C 7
MSTF^2T$KRLHT@U<::?X\7'.&/!PSWQQ)['SCZH?0Y@6J1+)3M2/61/<C"K$;
M!LX-KS;6U\1<B+]W("D'!%4H"&(<^![R8A=3YK]VIP!L[91($=>(%U+I[']P
MD\A*H]"-<1B%R/=B[+JN\R U?+=Z*>'ELIL<7F2K#,1DI0UT!5 6P)C:@*+_
M?BNKS$#<^5V6[\ S958T0EWLT1".U V=F_&KT VQ'Q+0%V(2!Z>:U7L^!,0P
MF]=2*8N'RKF1Y:. 6-11+S.HO%)J6.\'$78)2"6U\CNYY[G>H]6NM#D=RO9(
M@+TP1M2+X!PZ7TT9CU;$'B8>07&$P]AKT+3E^QHI)I\\2=0. BF>8;<S'! S
M[,4^BGT<,-; :RCQ&+R,,%%L<[D7!K Y^)QVJ@!PE+:0.A*H"9S$@8<]EZ(0
M_(P\ZMP*!?@SN]I( @T(9I WZGO8C=D)>E8\4PB0O#/UJN1NO4%;)5<9X B\
MEM5KF2^Q,-*/*8&2BBF*H@98_Q=21ZEF 290]@ TT, ZR [7F/#$$&<&)4DA
M3&^R%4U0<]!1<_!&:A;H2PF4* ;$+-"G!FN'.'E2P10G"XAPIZE#,U<0\JU(
MZAPL32LVX&)S<(\0<BO/^5)J ;IT*Y_ZV&,4>!A'00CTZ+O,N1,-JFQFU] 2
MCM,[BCS%KA\9,2SP^YJ0"OJH$BQ/-KQ< QX5+ZN\WJ'GI=!G'2-3H"Z?(=_'
M83 FIRX&;H 9B8&9K(T!)#BBG5]M<'K/NG !R +B&]&$!4 OF$7N"^=L51QU
M+@0>\GM+ ^Q'WBF^ >-2/^X^A!"_V YZLQ$E!!, ;&,E%*@?3<*7=?!ET_"M
M^W/C70M1C.X:*GN0J*;7*]-.U]Y^*=$#U#1P>27S++7K[ML"/PCO:0,>ACU#
M[W#+IEK6C5K=T=<F/$$&S=8NUZ7ERX9FDJ%)'>?8Q(T)[J?54#O=8>960.%!
MVFWN#!*AV05$1V%@3J%/G/L-<#<"9!5M6VE[I/K2])J0E)IRVYTX J@%H#XB
MC;:L!2;0/H'6 @<1A6/DMYC(1T89G,6$F%,$J#<GYD[@(>SP$)Z*AUOQ"-RQ
MM14 (>XW\@X?D)QFOX'4]1@Y!()IK08$Z5C=LE<WP,*J4S? 0U:]YCO;O,%6
M7$/ [C#F20:@J)QKL<[*TDBY$[#F'?H=!F+ 2")$6J&K-+7[4K5 '0V\ _<2
M)=K9H:UNF'7@]EA[.[(24)2(8@F=13O3#%JC88>1OVQHSE#@ ZF$+II;V-$8
MG4'[XV,:1!U[S%N./4,,J(]:KHRAIPJ9@1([U"?9!LE\";0<AJAGVXAUC4L#
M1\.[I.FLQGOL.!4,M+I 4'/D,NS';&"I$3JT$EP"3_P8MH0010'#C++3(N>=
M'CDOAK8@8D:QBPGL/<8>&"8"UCG8\2_!7KT2&DOBHB[L!T)'"8B-:1T[0M@@
M=M"JA-X@>J:,Y^:I;U:U3>GQ" ;$]K5U! DC XO'HGTSS]AU74CKX$^P0-2Q
M0'0J"WPV[>)?EKM^RX3B*MGL#Q7XI,##3<Q74_'(@VK?[G3=M^Q*N31O[636
M/#<3NN%W2YV6PYM,[-\/1LP;KM3>QK*0.Z"0SWV;._%J<)D;:UZ6,IK3=][K
M>?4G\^-HCC1'QA!]TY0X(>EPBW_"< 6=LAM%[9"%O,A4( S5)XU;YLP ?<W8
M96>#&$SRWC[9-(R$0HM@VK%; +,E&/7326<\G73G4RQYP^QS1,M$<<5=<<63
MQ?5-/C:="6QS;0T,RNQ;WWD>W$JGI8_[J0:BS>X(P1CJSAO=@Z@,NMZ?MTF'
M$^7\BY<[0QZT#UX0XACVC[;Q[W;85SBGOHM]%K[HO\>]7M^%-YT_Y*YIBYI>
M?-Y.&F=M.S[80EZGMK;N4&87@W^MA5!K^T?9_/ "&JE_NW9/NY_65_6_VGYY
M_<<;& .:C@J"OH)/R?L0ICY5_T6N;[3<VC^W2ZFU+.SE1O!4*+, WJ\DE'-S
M8Q1TO_(O_P%02P,$%     @ ZX%,6@"N2!?A!0  .@X  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&ULG5?;;ALW$'W75PP4Q+ !QMK[Q3<@=F(D19(:
MMM,^%'V@5I2TR(I42*YM]>M[R)763B(+;@%A>1%Y9CAS9H8\N5?ZFYD+8>EA
MT4AS.IQ;NSP:C4PU%PMN#M522/PS57K!+89Z-C)++?C$;UHTHR@(LM&"UW)X
M=N+GKO39B6IM4TMQI<FTBP77JW/1J/O383C<3%S7L[EU$Z.SDR6?B1MAORZO
M-$:C'F52+X0TM9*DQ?1T^#8\.L_=>K_@CUK<FR=]<B<9*_7-#3Y.3H>!4T@T
MHK(.@:.Y$Q>B:1P0U/B^QASV(MW&I_T-^J4_.\XRYD9<J.;/>F+GI\-B2!,Q
MY6UCK]7]![$^3^KP*M48_Z7[;FV>#*EJC56+]69HL*AEU_*'M1V>;"B"9S9$
MZPV1U[L3Y+5\QRT_.]'JGK1;#337\4?UNZ%<+9U3;JS&OS7VV;/+6G)9U;RA
MZ]I\H\]<PA4PNJ7]6SYNA#DX&5G(<:M'U1KSO,.,GL$,(_JLI)T;>B\G8O(C
MP @*]EI&&RW/HYV([T1U2''(* JB9 =>W)\Z]GCQ<WBUJ1IE6BU(3>%$R^M&
M3*B6'<L]7<:@,$U[\]326-TZRQCZBX\Q *'^WF:<3G2R7;0+LB.SY)4X'2**
MC-!W8GBV]RK,@N,=!TOZ@R6[T,]NNMARI_K2+L9"N][-G$/2-E5W@FU7]78N
M8+ [1//2TZ26!$,9R^6DEC,R7I:3:K'P0BV67*[HGAO";ZH:) %S-'!N=+Z,
MW2=RG]!]@L%^I_7!X&+.Y0Q @/>05/%E;7DS^(W+UITPI#1G>9"S)"Y=-TPC
M%I4II1DKXYQE141IS/(T8'&149*SLDA9$>>#C[)"]C(""FK5SN9 -OB L+H>
MM\[WAB*LCEB0%)2F*0L3*!LF+ MCBEE8Y!"44<KR+&%I4@[ 3N%M'8>4!1!=
MLJ3(_Y-^.UR?]JY/7^3ZWZ?T037>&>C>NK.VF'Z>!+MAM_A[OH9W3M[ K_W^
MLZ._*.0L1,]&HTU;R\'^^Z_7>Z^**,R/@R XH-[UMS]B/GJ<=90)DQ+],(R=
M3<E#1,?8Q:69"JT1QRW2#@J/5=4W2*J@-C(_+;6::;XPM$\Q01[06% 6Z&XP
MGCBREY5!5E#&+$@3"@]+>OT?):U%@8!AEN^0!730JTA 4G G/$SH]0Y29#TI
MLI?F Q0QE"A)%RTTEQ48X4HK]*WMBM["22M3;^7';@D?5DN%4+=UY9(DPKVR
MA/2)>#*JJ2?<BDG/@C[T0*(KK::U'>TC#9L#>O^]=6J,!1(P(I,_>'ITQLH\
M/P9?;]Z-,+?%</N4QRD+L@3F#0-Z[2=8&F3>])ON%N_"/5D)[X:/&V.$9U#Z
MC9ON#C?DO1ORE[KAPB4:&*F%/2Y<YKETD8*(T?18BS_5?%PW<,[VB-TI[/FT
MW46E"S_K2OOZ(E;_@[A%T6NU\P!?$X'V70V4CN"HE:J5\*.[_M1PEM-5*OD&
MU*_ON&?\8YUL'E7'I:U2,PD!KK3Z@O"4%@@;-%U%A6$>(9;*\5+)H\%>8X^1
MZ5>":PK?I+YC:&]FCS?]6V6](;5>X6 _)Y7!Y3:]?J70X%QI[4V#@XN'JFE]
MEFH\69_L/* X8G$0NYP0Y2Q-"T(:RK+ 33BBH8[E&=HB&WSZ>3.%*>H"TCXJ
M2Y!37+(P0J0'&0I+1B[%Q(%++A,D$+[RER^&6VNE6]A*/. :;@"".DLNX/0/
MT&6&6I-NDDO?KJ>[9M#9:KNK4.-84G;G*%F:I4[-W&4B%N49*Y*(2M2K. I?
M:-/XY38-0ZA74)Z@[$8IH8G+G/(R=Q:A%"DQR:-M]DQ0.Z%HR)(()1Z1G");
M8[9 IBT+EI?Q_[8G*GN6_6K/;KIK=ML3Q25+2YP"2J8AE5 R];R!OY,L1EHJ
M<!T)MU;^T9/[_$+HF7^U&/)AV%WM^]G^8?2V>P\\+N]>59^YGN'J"K-/L34X
MS%'M=?=2Z096+?WK8*PLWAJ^.\?C3FBW /]/E;*;@1/0/Q?/_@502P,$%
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MHUUMN^^X:3K_PIO6_87I)9<&"EP0->I<G 6@FW;83*PJ?0N:*TL-S0]S^H-
M[0"TOU#*;B?.0/M/,OH'4$L#!!0    ( .N!3%H3?IO :P4  -$H   9
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MPO4#ZOZ",?E\H@.TNQAG_P-02P,$%     @ ZX%,6B)$8&O. P  [A4  !D
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MW?1ESP>P(E5(;A>BM(5_ E=D'211T%?/"N.D4Z#D'&BTB>*-L]S16?RF3#H
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M..B.(,!*T(AU!U#?+!3AOO&SLZ42"TT%*IJBJL58:NTB.C051Z+IQC]\HA,
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M:,A*F1,*4XY$6128_QE#SK8CR[5V'3.RRJ3NL*/A&J]@#O)^/>7*LAN6E!1
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M+OMJ[_.J4*D,R=;FZ5XPJ0H!T\Q4;0=<.ZCQ)6-R9^@)FFHQ^@=02P,$%
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M#H91 5N%], Y47_7P.2QP D^'3S0MC/N("KSGK2P _.]WRKK11-+33D(3:5
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MN?:O%GYD$FS$/PP.JC(FALI*B"?S\&4]<SQS(N 0:P-!\><9;H%S@X3G^%Z
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M;"<^>C=XWNW@_V,_&"M+ALE+[;C/NL0Y*ULX%UL_R,HL8KM9G-: \7"#&:/
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MVM*B!,C?;Q@33P?E!.W;I>O_ %!+ P04    " #K@4Q:4/QR%@H)  "$7@
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MQK6MX]JCUH;L- K:F[#;:MJ]"6<5C5DOC3LJGBY7'-0"R-0" B'5;I2=ZE(
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M/;'O37_%^)M( 21ZSS,J!E8J97%KVR)*(<?BFA5 U9.$\1Q+->4+6Q0<<&Q
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M#C/\V !E#7!^):4Y/-@%FL^7^7]02P,$%     @ ZX%,6A=IBT$%!@  3"8
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MTDPX]1@',J/NUU02CWCLC2T&Z<4!^K/P83WW-G@#1L++$H]B;):&Z,4!\K.
M\#UA[OP'F0EW\P0>Q]@\#<"+@]1G >"T)S]#1MZ^9SR.L7D:?A=AY6?A*\LL
M]A('Y6?OMJQC(+<PR"V.+3\+8)=RG*=>-0 S?Y23H-G^*&?GN7?''0ZV").,
ME9[Q(PZ=%X-ZDZ&\V=4V."Q.0GH60:7GH-YD*&]V#Q@&%T\@/0MP-W3JS62
MF>CO)[<O[6/0LC"T+((HSP+:X\RHJ[Z!9IG[9;K$8QJ;L^%3$4!YQGT,OHH
MY9G'[@HUU#'M>Y8-I28'",\)("F+V,54P$JX<B,>Q=@L#:4F877G! +7W+L3
M&]"=7:C! QN;N,'6Y-BZ<P)N;L[=-1ELY@Z0$C*S!D@[3X.M"8ZM_U1%HVZK
M18\L=?59=?DU*+3@'H=>[$&]R5#>[&H:%$Y.0GU.@JK/0;W)4-[L'C"0GCR!
M^ISXZG/&J;O+#8]D<-V.@=O)WC,XCOX0#E]73@5QMQ !5GYI)1[LV&(8\DUP
M\GU@4!PE0N.'''S-!A6A0WFSRVVP.CD)$3H)*D(']29#>;-[P$!^\@0B= *H
MRSGSEGJ &8V)^WV\Q",>^T@=@_?I 2)TZH.[)U8!-M2[RQ4/8FR2ANY3G.X?
MT&93']-=>@5,)O[.8#R,L6D:ED]QEA^ZB$E]ULZ\>Q<!HPE/W8D,CVQLYH;N
MTP?N;SQX5D]]!9K&U%VM30$SX-J7H+?]:]_.TW!WBDO0#T_88Q5:_,"#GY45
M%+5#>;.+;E [%:<P;:=!-?*@WF0H;W8/&&A/#X3VQTS;J4_D$Q+G[@[(*63'
M>>Y^W8B'/+8D>\_"P]']D1)M"NZ(=N_<F4)F-':?:"#QF,;F;/@YQ67I1TFT
MN(_!EQ&@77.1N! 7ZJ!V80S6ICC6#I[X >%9".]"@#C7W2^,1S;V288&7S,<
M7P^?^#.?7_O]L"[.@W;^\"$A.VOXL#,U#)OA#-L_ WQ274_N&A453:,>4"]Q
M=X.?OQC2FPSES2ZEX>2,GL*$G@5BXFT/A/0F0WFS>\#P>G8@KS]F0L]\R,X8
M<W>-3/%0!A?N&,)[9A8 V;'WH&3^KI%4<.^6"< ,**[$PQU;#H/F&:Z"8X/B
M*/42/][@:S8HA(?R9M?:0'AV$AM5LJ ;58)ZDZ&\V3U@F#][@HTJF8_ZA++<
MVT,+V1&-.Q[O'.51UGO/LL;7!*A^F?GTGGF/& 6,](#H+O?P,,:F:0@_PPD?
MW861 3CO/C)VBA]@\)5P#.S/#?;G./8/7?#DT Z4Q)WS *L)B[W'UN&QC<W=
M+ 1R?"%P. +DP-/Y6$S</3E3R X8*B1D9P\5=JH&U'-<T'Y@>A^K=>)''3K%
M!/4F0WFS*V[ /#^)M\KD0;?6!/4F0WFS>\ 0?GX@X3_J!0$^O4]XG'B4#]G1
M7'A/:L)C'EL3@_DYCOF/%#MS?SO+1 ]8?M:0'<F\;W'PJ,9F;8 [QU5O=,[/
M@?TE[LH7]S_XNC@&_.8&?G,<?@=/^9#RG7MWG@!F6>S"'Q[:V-0-X^8XXP:8
M\3<'L-YHI!G7>_T 9 >,&Q*RL\<-.]6.<YWW@^R_( 2'O8_DS^B]:MJB[;_N
MC&JE>UTU45M%Q;Q:]X."GJP*_>%\\WVH_N3MZP\1^:5[%QVE\8MW7;>LVN*;
MK2Q7Q4H/*(OHPS>WS;/>EKS0Q[I6=>?C7U6K(AKIJ2^ZOJO[NV(V,V+S#.K7
M\[V7\BV5'J.ZUR<VT:P3';HS;.^ONW<TONE?3.C\_;)[=R/P]RE]?@79O\[S
MYU>ZQL GNK;/K[;O@3PW06U>(_F;'DC+51,MU+4.,'[6?<M7;U[,N/FEK=;]
MBP0_56U;+?L?;U4Q5W5GH#^_KG2%MK]T!]B]'_/B_U!+ P04    " #K@4Q:
MX%]J"]D"  #N!P  &0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6RM55U/
MXS 0_"M6D!!(0)J/E@K:2+3A=#P@57#</9SNP4VVC45B!]MIX=_?V@FA[:45
M)_'2VL[.9&?'V1VMA7Q6&8 FKT7.U=C)M"ZO7%<E&11478@2.#Y9"%E0C5NY
M=%4I@:865.2NW^L-W((R[D0C>S:3T4A4.F<<9I*HJBBH?)M +M9CQW/>#Q[8
M,M/FP(U&)5W"(^BG<B9QY[8L*2N *R8XD; 8.S?>5=PW\3;@)X.UVE@3HV0N
MQ+/9W*5CIV<2@AP2;1@H_JU@"GENB#"-EX;3:5]I@)OK=_9O5CMJF5,%4Y'_
M8JG.QL[0(2DL:)7K!['^#HT>FV B<F5_R;J)[3DDJ90610/&# K&ZW_ZVM1A
M ^ -]@#\!N#O L(]@* !!)\%A T@M)6II=@ZQ%33:"3%FD@3C6QF88MIT2B?
M<6/[HY;XE"%.1S.)-TCJMS,RRRG7A/*4W+Y4K$1K-3DG-VG*C$$T)W>\OF7&
MKI,8-&6Y.L60VZ<'<G)\- P&X?4I:1:$<?(C$Y5"0C5R-:9J7N@F35J3.BU_
M3UJ>3^X%UYDBMSR%=)O 18VM4/]=Z,0_R!A#<D$"[XSX/3_L2&CZ>7C0 8\_
M#_</J E:VP++%^SC8RK)A:HD$+' >V[,@!2+_F$1G>-73LK6W[+U%UI_?].Y
MTA*_O3]=%M4IA-TIF'YTI4J:P-C!AJ- KL")CH^\0>^ZJ[Q?219_$=E6Z<.V
M].$A=K0221-FBZQ(DE&YA,X;7M,,+(WIOJO(N_3#RY&[VJQ+1]0P](?;47$7
M5]\+VZ@M)?U62?^@DBF5\HWQ):&%J/ VX$V2IDV>B\5YI8!0I4!W2NO_FXZ'
M@V9'6D>4W]^-B@_F^+]>NAN=L !TQDP4=,GHJWM%>]H.K1O;JW?.)SC,ZMGS
M05-/PGLTG*'S.2R0LG=QB0)D/5WJC1:E[;=SH;%[VV6& QFD"<#G"R'T^\:\
MH!WQT5]02P,$%     @ ZX%,6D %-_/( P  J!$  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S(N>&ULQ5C;;MLX$/T50@6*%F@CB;K83FT#B97=+; !C*3=
M?2CV@9;&EE!)=$G:3O]^AY*B6(XL) "!O-@D-7,X<\@C<3@]</%3I@"*/!1Y
M*6=6JM3VTK9EG$+!Y 7?0HE/UEP43&%7;&RY%<"2RJG(;>HXH5VPK+3FTVIL
M*>93OE-Y5L)2$+DK"B9^7T/.#S/+M1X'[K)-JO2 /9]NV0;N07W?+@7V[!8E
MR0HH9<9+(F ]LZ[<R\CUM$-E\4\&!WG4)CJ5%><_=>=K,K,<'1'D$"L-P?!O
M#PO(<XV$<?QJ0*UV3NUXW'Y$_Z-*'I-9,0D+GO^;)2J=66.+)+!FNUS=\<-?
MT"04:+R8Y[+Z)8?&UK%(O).*%XTS1E!D9?W/'AHBCAS<\(P#;1SHJ8-_QL%K
M'+R7.OB-@U\Q4Z=2\1 QQ>93P0]$:&M$TXV*S,H;T\]*O>[W2N#3#/W4?"EP
M"PGU^Q-9YJQ4A)4)N?FUR[:XMHI\)O?U?B!\32+ G15G3*^7)(N4B0U(\B$"
MQ;+\(]K>?+\C']Z_&WNA_^4C:1HD*\FWE.\D(LNIK3!F/;,=-_%=U_'1,_&Y
ME-SR4J62W)0))%T &Y-M,Z:/&5_30<0(X@OBN9\(=:C?$]#BY>Y>CWOT<G<Z
MD(W7KI]7X7GG\#(9YUSN!.@E2JJU@ 1)KU\)E;16J'=\=+QZ<;-Z/_Y&//)5
M02'_ZUN<>G*_?W+]3KJ46Q;#S$)P"6(/UOS].S=TOO01:Q(L,@36(=UO2?>'
MT.=1'Y=]]-4P806CW\#[N3NB_FAJ[X]YZ;$:^W3<M8KZL +7;ZTZF01M)L%@
M)@LNE=XXDN5Z-Q10K$#T[H1!G-?N!)-@D2&P#G]ARU_XEO(+39)N$BPR!-8A
M?=22/C(COQHF.)*,YTY.U??<B ;.Y$1\SXU<Z@?]VANW:8P'T[A#8IB(T^J;
MF\ >SV#U5S=&40Z+<1#XM?O")%AD"*Q#Z*0E=/*68IR8)-TD6&0(K$.ZZSR=
M(!TS<FQPCE4T\@/O1(\]5JY#)^&)(GO-QA/:KTGWZ#SL#F9SCR5(5F[(GU""
M8#FY0G%>)7CRSJ023!<IY.8!JRX)Y,?M>84.S_+:W6(4+3*%UF68/C%,WU*F
MS>RFF#>)%IE"ZS+_5"NX@Z?B5RC5>W;8#(-G7\X>JR"DWJE0>ZR\T>A$I_91
M"5L QJ6O C!&OBM57=NUH^UUPU559)^,7^MKB*HT?H*I[S!N,=T,\\YAC9#.
MQ0C?':*^%J@[BF^K0GG%%9;=53,%EH#0!OA\S;EZ[.@)VLN9^?]02P,$%
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M00\MZ#+>I/*1O4:T=,A5>'.6BN(O>BUEK1Z:;X1D6:D,%F1)OOL?_RX#<:"
MO2,*I%0@307GB()=*MA-!?N(@E,J.*?VX)8*[JD*7JG@G6J27RKXI_80E I!
MP>Z.CH++<2SCX35GKX@K:4!3#\6 *+2!PB178_=)<OB:@)X<WN=;*B0,1BE0
MDJ-;(=@\B245Z (]P419;%**V!)-DSS.X4N*[O/=C%$C#SX<!_@XIC).TD^
M-/G^B#Y^^"NP/>?J$RH?E/BW%=N(.%^(Z[X$;Y1-_7EI^=W.<G+$<DS0%Y;+
ME4"3?$$7=8 ^A*&*!7F+Q1WI1!S3^26R\6=$+.)H#!J=KFYKU">GJQ.-^K1;
M_>\XOT36\=YGW>H_\'\:I>ATDW$' 78U&.T"SSZ"]R1AX*BAI ;6FK-E D\<
M?4R9$)]T(V0'Y^CA5-H?B'4\IS<]R.N"\BWM#3_\A3WK2L>N2;")2;"I2;#(
M$%B-8*<BV.E"'WYC$C+(G&6 O5(+X)9"%H!WJF-WA^456&H-W@XO;-\O9L?V
MD#B-G!,XV _J<A.-G!O8KAJZAW+33A_.#;<AL%JXW2K<[NGS:5EE\#43B4K?
MNIB[)F>42;")2;"I2;#($%B-8J^BV.N<45]9?C'?<*Y(CH6@4KN2[C#<@Y&/
M<>#93F,B:<0("3RO+C;NMDB_DDPZE<ZESVO-9.QYQ//KAD:&^JP1XU?$^)UA
M&+U+BM^.MN59@==(1Z.V'.1 OYFUQMWF'&&E4^E<5MJ&AL1V_(:AD:$^:ZP$
M%2O!"0O0<4X"S43Q0R=T&YRTY0+BND%C (Z[C3G"2:?2N9QH'+*"T+<;:V-D
MJ-,:*6%%2M@9A\FO32+_Z.@(6]9?8,OUK49&&NGD'-<+FWQTVW&$C["5;(AG
MVTXC@M.V#3JQJ(T6P&G(W@^P6@BQM3_'62<O!&D2/R<IK/%4?ZZR6J;"OLIN
MCHF11D[-9[\Q&<;O6'8DK-U:YXYSC:W8"CUL-\)OJM<Z2P>G;7S2JO >0[B=
M2BT?5NPF0VTYW_9<*VPRU&W5,88ZM<YF2&,K]GR_N6B;ZK7.$-DS1$Y8(6B1
MDE"<+]ZEBIRX9&@$M6O&._8=XZI3ZVRN2'N#I5TV3'5;)VM?+\"=I]7A0;7I
M1T:S9\IUP;GK1CGW5&,4;6(4;6H4+3*%5F=W7RS CMER$#9Y<A\919L819L:
M18M,H=5YWE<I<.<)>?BPH[9?,HN60+)<4?2'QAPM.<O0G.4RR3=)_H+8FO*B
M^*S/QFY[)^C"*:25C#5R#@[\Q@([Z;;\;-:,EAU,H=59VQ<></<Y_[Q:'F[7
M%A0QN+7GU,@!,6[8),9H/<$H6F0*K4[,OO" _<ZT^8W'N8B+GP9%L8-A&RDD
M/*CI\QRG<3Z']3(6*JN.Z;Q8-I&-M:R9K ^,C*)-C*)-C:)%IM#J(V!?Y,#=
MA87[?,N2>9$ME^B%L<5N'*B.$L6]9*H$4NZ<M+QKR@8!(:TLJA%S+>(UYZK1
MBH91M,@46IVI?>4#=Y<<8*XN*.(P"Y-M_)P"-\5Z5[&C):==:<!^,T&.-%)A
MB)O,=%IW-C,FT2)3:/6?@O?U%-)=M1C!EH-#%GWO_%?"'!Z5W-!N%J@T4CZV
MF[N-;I/.I<,H6F0*K4Z'*IS46_8'=?+N01@]4E&=$3A-BX.@2FX+MGZ[GQ##
MQ\7N>@)\N;]]0OBSNH% B'7UH"S-976787_)H3IZB,M"%E]!7TM8)P'C*Y,4
MD6*7NMQPV*ARM"AN.HA+G:O]@\L9&>4OQ44= 1NG30Y^$74:JIJKVT"WQ1V8
M1OL='DRPIGV*!S-=^X@,QCJ<J3V8V;IV9S!S=.WN8.;JVKW!S-.U^X.9KVL/
M!K- UQX.9J'6+PL<L[1?E,OZ6!#XHO4:@]M8ZS<&Q['6<PRN8ZWO&)S'6N\Q
MN(^U_F,( -9& $,(L#8&!&) =#&X)>K2F"X&,'/>KI/U]R-N=QGM2\Q?$M@7
MIG0)H\^Z]&&!X+O[7;L7R=;%;:%G)B7+BL<5A46**P'XOF0P_,L7U4%URV[X
M/U!+ P04    " #K@4Q:W%>70K$"   @!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6RM5=]/VS 0_E>L3$(@;>17$UI((XT6-*1-0@7&P[0'-[FV
M%HZ=V6X#__W.2<A*&RH>]A+[[/L^?W?.G9-*JB>] C#DN>!"CYV5,>6YZ^IL
M!075I[($@3L+J0IJT%1+5Y<*:%Z#"NX&GA>[!67"29-Z[5:EB5P;S@3<*J+7
M14'5RR5P68T=WWE=F+'ERM@%-TU*NH0[, _EK4++[5AR5H#03 JB8#%VOOKG
MD]CZUPX_&51Z:TYL)',IGZQQDX\=SPH"#IFQ#!2'#4R <TN$,OZTG$YWI 5N
MSU_9K^O8,98YU3"1_)'E9C5VA@[)84'7W,QD]0W:>"++ETFNZR^I6E_/(=E:
M&UFT8%10,-&,]+G-PQ; '[P#"%I \%% V +".M!&61W6E!J:)DI61%EO9+.3
M.C<U&J-APM[BG5&XRQ!GTANQ 6&D8J#)%W+7W"61"[*]<?5<<BHH6B_D> J&
M,GZ"WE</,W)\]&D8QH.+$])."!/D?B77FHI<)ZY!C?8D-VOU7#9Z@G?T3"$[
M):'_F01>,.B!3SX.#]_"7<Q,EYZ@2T]0\X7O\/4DY(5,F<ZXU&L%Y-=W!) ;
M X7^W1=LPS[H9[<5>JY+FL'8P1+4H#;@I$>?_-B[Z O]/Y&]2438)2(\Q)[.
M:(6_G0'%*-<$[Y9D4F#ITSF'WFMNZ.*:SK:23>J?1:,X<3?;(?5X#:/XG]<;
MK8-.Z^"@UD=L'/8W+)5<8B9ZY34,T=;!01C%P^&.OGTW_\SW0J]?8-0)C X*
MO&:"8<GF9"EE?Y%$>^<.@C"(=M3M>_FC,(SZQ<6=N/B@N'MI*,?T=>7?IR_>
MN[=@%,7>:$=@CYLW'(7^CD)WJW_9M^,'54LF-.&P0*!W>H8AJJ8?-X:19=W2
MYM)@@ZRG*WS"0%D'W%](:5X-VR6[1S']"U!+ P04    " #K@4Q:5HTK:5L"
M  "X!0  &0   'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6RM5%U/VS 4_2N6
MD1!(H_ELRR"-U!8F>$!"(+:':0]N<MM8.'9FNPW\^_DCS0IK$0][27SM>T[.
MN?&]62ODLZH -'JI&5<37&G=7 2!*BJHB1J(!K@Y60I9$VU"N0I4(X&4#E2S
M( [#45 3RG&>N;U[F6=BK1GE<"^16M<UD:\S8**=X AO-Q[HJM)V(\BSAJS@
M$?13<R]-%/0L):V!*RHXDK"<X&ET,4]MODOX3J%5.VMDG2R$>+;!;3G!H14$
M# IM&8AY;6 .C%DB(^-WQXG[3UK@[GK+_LUY-UX61,%<L!^TU-4$GV-4PI*L
MF7X0[0UT?H:6KQ!,N2=J?>XXQ*A8*RWJ#FP4U)3[-WGIZK #B$8' '$'B-\#
MT@. I ,DSJA7YFQ=$4WR3(H629MMV.S"U<:AC1O*[5]\U-*<4H/3^2W? -="
M4E#H#$W+DMKJ$H9NN;\BMM8G5Z )9:<FX_KI 9T<'YTGH_3R%'4+1#FZHXR9
M7)4%VLBRY$'129AY"?$!"5&,[@37E4+7O(3R+4%@_/2FXJVI6?PAXQ44 Y1$
M7U <QND>0?//PY,/Y"1]C1/'EWRBQC^G"Z6EN;R_]A7*\Z3[>6Q#7ZB&%##!
MIF,5R W@_/@H&H67^TS^)[(WEM/><OH1>V_Y%;62:C@K1;O_:GB:<T=C)\XF
MCX:#<19L=IW\FQ3'@Z]]DE<8[#1!#7+E9H-"A5AS[:].O]N/GZGKNG?[,S.6
M_!3Y2^-GVAV1*\H58K TE.%@/,1(^CGA RT:UVH+H4WCNF5E1BM(FV#.ET+H
M;6 _T _K_ ]02P,$%     @ ZX%,6B)M9UI# P  H@X  !D   !X;"]W;W)K
M<VAE971S+W-H965T-S<N>&ULQ5==;]HP%/TK5B95G;21+TJA@TB%=%JE5:K:
M=7N8]F"2"UAU[,PVT.[7SW9"2JHT RG27L!V[CF^]]C7]AUON7B4*P"%GC+*
MY,19*95?N*Y,5I!AV>,Y,/UEP46&E>Z*I2MS 3BUH(RZ@><-W P3YD1C.W8K
MHC%?*TH8W HDUUF&Q?,4*-].'-_9#=R1Y4J9 3<:YW@)]Z >\ENA>V[%DI(,
MF"2<(0&+B7/I7\2^9P#6XCN!K=QK(Q/*G/-'T[E.)XYG/ (*B3(46/]M8 :4
M&B;MQ^^2U*GF-,#]]H[]LPU>!S/'$F:<_B"I6DV<H8-26. U57=\^P7*@,X,
M7\*IM+]H6]B>CQR4K*7B60G6'F2$%?_XJ11B#^ /W@ $)2!X#>B_ 0A+0'@H
MH%\"^E:9(A2K0XP5CL:";Y$PUIK--*R8%JW#)\RL^[T2^BO1.!7-.%-"BX^^
M$CPGE"@"$GU$EVE*S+I@BJY9L;O,*IW&H#"A[[7%U<,=.CUY-PP'_4_O4=E
MA*$;0JFVE6-7:?_,+&Y2^C(M? G>\,4/T(UV9R71%4LAK1.X.K JNF 7W31H
M98PAZ:'0_X "+^@W.#0['!XVP./#X4%+-&&U5J'E"X]9JY]?M16Z5I#)7TV2
M%Y3]9DISJES('"<P<?2Q(4%LP(E.WOD#[U.37%V2Q1V1U:3L5U+VV]BC.]@
M6X,^N1*^9.0/I&@A>(:2G<3T1>(F50OVH64W1^LF\GMZ@VWVQ6JP"7MAW2AN
M,/)Z9Y51+;BS*KBSUN"F7.EC _$%$I@M ?W,()N#:-P>K4S';H\NR>*.R&H*
M#BH%!]UGVJ!+*;LDBSLBJTEY7DEYWKH9KYYR?<7K_!+UE+/W20Z"\#+U&&<?
MD[40P%1C&J)>D^CMD_OH&;!HTK<5=ZR^'9'5]!U6^@Y;0_S&\\,RO97FV.W9
M)5G<$5E-OE$EWZC[3!]U*6679'%'9#4I?>_E+>G]SUS_Q^R!3?:FZWK6CCQ6
MY*[8"I7=O<=[!F)IBR"I95DS5;QTJ]&JT+JTY<6K\:DIP&Q1\$)35&\W6"P)
MDXC"0E-ZO7-]MXJB("HZBN>V1)C;EX-MKG01"<(8Z.\+SM6N8R:HRM+H+U!+
M P04    " #K@4Q:N5.7=$4#  !_"   &0   'AL+W=O<FMS:&5E=',O<VAE
M970W."YX;6R%5EN/FSH0_BL6E:I6Z@E@"+EL@I1D6[4/K:+-Z3D/51^\, E6
MP::VDVS_?<>&T'2795\2>SSS^9OQ7%B<I?JA"P!#'JI2Z*57&%//?5]G!51,
MCV0- D_V4E7,X%8=?%TK8+DSJDJ?!D'B5XP++UTXV5:E"WDT)1>P540?JXJI
M7VLHY7GIA=Y%<,</A;$"/UW4[  [,%_KK<*=WZ'DO *AN11$P7[IK<+Y)@RL
M@=/XC\-97ZV)=>5>RA]V\RE?>H%E!"5DQD(P_#O!!LK2(B&/GRVHU]UI#:_7
M%_0/SGETYIYIV,CR?YZ;8NE-/9+#GAU+<R?/'Z%U:&SQ,EEJ]TO.K6[@D>RH
MC:Q:8V10<='\LX<V$%<&E#YC0%L#^L@@C)XQB%J#R#G:,'-NW3+#TH629Z*L
M-J+9A8N-LT9ON+#/N#,*3SG:F72KY(G;-]'D'[)KWI+(/;F%$SYQC0]F"!?D
M2NW-+1C&R[?D]:MIE,0W]OC?0AXU$[E>^ 9)66@_:PFL&P+T&0(A)9^E,(4F
M[T4.^=\ /GK3N40O+JWI(.(M9",2A>\(#6A,WG^](V]:JF\'T*,N8)%#CUX.
MV#=VKXW"1/S>YW8#$_?#V.J<ZYIEL/2P_#2H$WCIZU=A$MP,D(P[DO$0>KJ&
M Q>"BP.F>,E$!GT$&XC$0=AJ/Z41G82SA7^ZTMH,7_0M_#Y =]S1'0^BK/*<
M&Q=2!24SD!,C2:VX5.07,-6;50WB^(I]G$SCCOQ?/)*.1S+(XPNV3=9QP1Y)
M3 &.0A^#Y F#\80^1V'249@,4L#>A)U'$'C("B8.0##!A,:@(*4^$I.G88@3
MVL]AVG&8#G+ 0GPA=:9/4F<V"^-9_[4S[Y$@#/XTI^"E]")WH WFA.M$37IH
MFQXLE[4;!-BL&![F5L&=?%KM"%8_UCREP<W65I<P[*+[@0OTBK.2["ZP>N1T
MPQN\:P_*8GR1!@AU*; _*LP"A;/!MCT]ZLMW_ZH!5Z .;BYIDLFC,$T9=-)N
M]JU<QW\D7]N9V">G\TV?_FHVW\SZY&%P&:[^'T+-:/[,%'8'34K8([E@-,'L
M4<VT:S9&UFY@W$N#X\<M"_Q" &45\'PO,3KMQE[0?7.DOP%02P,$%     @
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M?RY__T;);77*^UXJ)3?5R[70M4M>&NC/5U)/$/6;\@*'7T>8_A]02P,$%
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M2A":24$4K";>57@Y'UI[9_"-P4X?C(E5LI3REYW<YA,OL X!A\Q8!HJ?+<R
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MZ6P%0M)<4)H'2O-!:0$H+02E15"TKI;W"V2:^5/+#-#%-%":"TKS0&D^*"T
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MH'N"('7)C>!ZI<@GGD!R"&"CVD:RNY,\=P<1KR&^(![]@[B.Z_<0NOI]=V^
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M,[@VM<G&\?GX;)R&FUT9_Z8-D_,XCONTML!PY_6XSD6'M>32@,"2@-')^#0
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M=@.H<5VQ9<D^S2W1>2#R$W6=QP-7D^MM*?_'# =)']-F&&VUN!^O=U2OF#3
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M .N!3%H:;$<&D ,  *\9   -    >&PO<W1Y;&5S+GAM;-U9T4[;,!3]E2C
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MZNT%]/:3S6X!O3WU]@)Z>^KM!?3VU-L+Z.VIMQ?0VU-O+Z!WH-Y!0.] O8.
MWH%Z!P&] _4. GH'ZAT$] Z3/RL%] [4.PCH':AW$- [4.\@H'>@WD% [TB]
MHX#>D7I' ;TC]8X">D?J'07TCM0["N@=J7<4T#M.#IL(Z!VI=Q30.U+O**!W
MI-Y10.]$O9. WHEZ)P&]$_5. GHGZIT$]$[4.PGHG:AW$M [4>\DH'>:'!84
MT#M1[R2@=Z+>24#O3+VS@-Z9>F<!O3/US@)Z9^J=!?3.U#L+Z)VI=Q;0.U/O
M+*!WIMY90.\\.>PMH'>FWEE [T*]BX#>A7H7 ;T+]2X">A?J703T+M2[".A=
MJ'?Y3KV'\?-0AUO/UYK/_TZJQ\MWZ^WQU^77Q<D+=<6YO:\8GOX"4$L#!!0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ZX%,6B_:D$GN    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MZX%,6IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #K@4Q:+*>!)!P)  !\*   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MZX%,6IN0JRF(!P  EAT  !@              ("!7Q$  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .N!3%I/G>G<5 ,  %,.   8
M          " @1T9  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " #K@4Q:'L5)?_T)  #&,0  &               @(&G'   >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ZX%,6JFJ9/BK!P  @S(
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M965T.2YX;6Q02P$"% ,4    " #K@4Q:6"(A7FLG  #>A@  &0
M    @(%_30  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M .N!3%K4+BZ2BPT  +TH   9              " @2%U  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ ZX%,6D)IZ$^##P  Y#$  !D
M             ("!XX(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " #K@4Q:)4]8BX@#   :"   &0              @(&=D@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .N!3%J6LC*<*04
M  @,   9              " @5R6  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ ZX%,6G3N(TLV$@  ZCH  !D              ("!
MO)L  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #K@4Q:
MG)2LL^T"  "Z!@  &0              @($IK@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( .N!3%J8I3WJ)@H  .(:   9
M      " @4VQ  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ ZX%,6B3D#ONQ!0  A0T  !D              ("!JKL  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #K@4Q:>YR(X,D%   A#0
M&0              @(&2P0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( .N!3%IRAMM6EP0  %H*   9              " @9+'  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ ZX%,6G7O$?LR
M P  V@8  !D              ("!8,P  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " #K@4Q:/NK'<"0#   (!P  &0
M@(')SP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .N!
M3%H9E27 AP(  &X%   9              " @233  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ ZX%,6B%"V+(5$@  E#@  !D
M         ("!XM4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " #K@4Q:B))#Q(P/  "M*0  &0              @($NZ   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .N!3%ISW*F#J ,  %((
M   9              " @?'W  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ ZX%,6IMY*9DT!0  S0P  !D              ("!T/L
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #K@4Q:(/E=
MX4X#  "M"   &0              @($[ 0$ >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( .N!3%IJ(44'7 ,  (P'   9
M  " @< $ 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MZX%,6AKGM1%N @  :P4  !D              ("!4P@! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " #K@4Q:IH0*O2@W  # T@  &0
M            @('X"@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( .N!3%HN) MVP@(  / %   9              " @5=" 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ZX%,6L#+ ?=J!
M/ H  !D              ("!4$4! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " #K@4Q:=PKW@0$#  #J!@  &0              @('Q
M20$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .N!3%HH
MVBS6!04  )<,   9              " @2E- 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ ZX%,6L\W'DM)!P  710  !D
M     ("!95(! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .N!3%JOW[!_1 ,  *4'   9              "
M@7MJ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ ZX%,
M6N3C"'>1 @  @P4  !D              ("!]FT! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " #K@4Q: _W[C(X"  !X!0  &0
M        @(&^< $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( .N!3%IR>,K**P@  -87   9              " @8-S 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ZX%,6@"N2!?A!0  .@X
M !D              ("!Y7L! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " #K@4Q:>EM(#F,#  "?"   &0              @(']@0$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .N!3%H3?IO
M:P4  -$H   9              " @9>% 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ ZX%,6B)$8&O. P  [A4  !D
M ("!.8L! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #K
M@4Q:U-W>/UD%  !<&0  &0              @($^CP$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .N!3%HB>*VQLP8  %,Q   9
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M970U-"YX;6Q02P$"% ,4    " #K@4Q:14J;/<<#  "]#P  &0
M    @($"KP$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M .N!3%KW):0NM (  $@(   9              " @0"S 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ ZX%,6D2=_B0%!P  :2H  !D
M             ("!Z[4! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " #K@4Q:4/QR%@H)  "$7@  &0              @($GO0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( .N!3%IA.;3NK@<
M !U#   9              " @6C& 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ ZX%,6LBDDCR, @  B08  !D              ("!
M3<X! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #K@4Q:
M\1]AG9,$  "J%   &0              @($0T0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .N!3%J15@2ZNP(  !,(   9
M      " @=K5 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ ZX%,6E[R<0ER!   W!4  !D              ("!S-@! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #K@4Q:WWE+<CX$  #'$@
M&0              @(%UW0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( .N!3%INXIU ^0(  !X)   9              " @>KA 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ ZX%,6IW$,58@
M!@  P1H  !D              ("!&N4! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    " #K@4Q:/;.A(I("  #C!@  &0
M@(%QZP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( .N!
M3%KQXEX@S0,  ,H,   9              " @3KN 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ ZX%,6A=IBT$%!@  3"8  !D
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M=#<S+GAM;%!+ 0(4 Q0    ( .N!3%H=+3FZ]08  '$G   9
M  " @9T0 @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
MZX%,6MQ7ET*Q @  ( <  !D              ("!R1<" 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    " #K@4Q:5HTK:5L"  "X!0  &0
M            @(&Q&@( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4
M Q0    ( .N!3%HB;6=:0P,  *(.   9              " @4,= @!X;"]W
M;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ ZX%,6KE3EW1% P
M?P@  !D              ("!O2 " 'AL+W=O<FMS:&5E=',O<VAE970W."YX
M;6Q02P$"% ,4    " #K@4Q:(Y;YLGL6  ![7P$ &0              @($Y
M) ( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( .N!3%KL
M(T=8ZP@  "E!   9              " @>LZ @!X;"]W;W)K<VAE971S+W-H
M965T.# N>&UL4$L! A0#%     @ ZX%,6L"RP6NY P  /PX  !D
M     ("!#40" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .N!3%J#DJLR2 ,  .0*   9              "
M@<%; @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ ZX%,
M6@H:"$"1!0  ?BP  !D              ("!0%\" 'AL+W=O<FMS:&5E=',O
M<VAE970X-RYX;6Q02P$"% ,4    " #K@4Q:^A\".Y$#   &#   &0
M        @($(90( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0
M   ( .N!3%J[">RK)P,  #\(   9              " @=!H @!X;"]W;W)K
M<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ ZX%,6F2;EV=A @  < 4
M !D              ("!+FP" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q0
M2P$"% ,4    " #K@4Q:F)D/_64"  ">!0  &0              @('&;@(
M>&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( .N!3%H2KFT)
M\@0  *@8   9              " @6)Q @!X;"]W;W)K<VAE971S+W-H965T
M.3(N>&UL4$L! A0#%     @ ZX%,6AW\BFUE @  0P8  !D
M ("!BW8" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4    " #K
M@4Q:DPKQ>FP(  !!70  &0              @($G>0( >&PO=V]R:W-H965T
M<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( .N!3%IG?D1XR ,  .D2   9
M          " @<J! @!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#
M%     @ ZX%,6AIL1P:0 P  KQD   T              ( !R84" 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #K@4Q:EXJ[',     3 @  "P
M    @ &$B0( 7W)E;',O+G)E;'-02P$"% ,4    " #K@4Q:F ^ZDWX&  !H
M/@  #P              @ %MB@( >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ ZX%,6OHPA&BY @  Y#<  !H              ( !&)$" 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ZX%,6BJB9?I) @  %38
M !,              ( !"90" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ &< 9P!('   @Y8"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>380</ContextCount>
  <ElementCount>436</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>123</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss</Role>
      <ShortName>Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical</Role>
      <ShortName>Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Cash Flow Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements</Role>
      <ShortName>Consolidated Cash Flow Statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995467 - Disclosure - General Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/GeneralInformation</Role>
      <ShortName>General Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Summary of Material Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies</Role>
      <ShortName>Summary of Material Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Significant Accounting Judgements and Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimates</Role>
      <ShortName>Significant Accounting Judgements and Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Employee costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/EmployeeCosts</Role>
      <ShortName>Employee costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Share-based Payment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPayment</Role>
      <ShortName>Share-based Payment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Principal Accountant Fees and Services</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServices</Role>
      <ShortName>Principal Accountant Fees and Services</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTax</Role>
      <ShortName>Tax on Profit/(Loss) for the Year and Deferred Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Investments in Associates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociates</Role>
      <ShortName>Investments in Associates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Contract liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilities</Role>
      <ShortName>Contract liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisions</Role>
      <ShortName>Provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilities</Role>
      <ShortName>Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Financial Risk Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagement</Role>
      <ShortName>Financial Risk Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Investments in Group Enterprises</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprises</Role>
      <ShortName>Investments in Group Enterprises</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Ownership</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/Ownership</Role>
      <ShortName>Ownership</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/Revenue</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/SegmentInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Employee Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables</Role>
      <ShortName>Employee Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Share-based Payment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentTables</Role>
      <ShortName>Share-based Payment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPayment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Principal Accountant Fees and Services (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesTables</Role>
      <ShortName>Principal Accountant Fees and Services (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServices</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxTables</Role>
      <ShortName>Tax on Profit/(Loss) for the Year and Deferred Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTax</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssets</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipment</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Investments in Associates (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables</Role>
      <ShortName>Investments in Associates (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociates</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/Inventories</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Provisions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsTables</Role>
      <ShortName>Provisions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisions</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilities</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Financial Risk Management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables</Role>
      <ShortName>Financial Risk Management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagement</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Investments in Group Enterprises (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesTables</Role>
      <ShortName>Investments in Group Enterprises (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprises</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Summary of Material Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Material Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Summary of Material Accounting Policies - Schedule of Asset's Expected Useful Life (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail</Role>
      <ShortName>Summary of Material Accounting Policies - Schedule of Asset's Expected Useful Life (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail</Role>
      <ShortName>Significant Accounting Judgements and Estimates - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail</Role>
      <ShortName>Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail</Role>
      <ShortName>Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Revenue - Schedule of Revenue Attributable to Commercial Customers by Product (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail</Role>
      <ShortName>Revenue - Schedule of Revenue Attributable to Commercial Customers by Product (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail</Role>
      <ShortName>Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995937 - Disclosure - Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995947 - Disclosure - Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails</Role>
      <ShortName>Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Employee Costs - Summary of Employee Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail</Role>
      <ShortName>Employee Costs - Summary of Employee Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995977 - Disclosure - Share-Based Payment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail</Role>
      <ShortName>Share-Based Payment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995987 - Disclosure - Share-Based Payment - Summary Of Share Based Payment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail</Role>
      <ShortName>Share-Based Payment - Summary Of Share Based Payment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995997 - Disclosure - Share-Based Payment - Summary Of Share Based Payment (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail</Role>
      <ShortName>Share-Based Payment - Summary Of Share Based Payment (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail</Role>
      <ShortName>Share-based Payment - Schedule of Warrant Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Share-based Payment  - Schedule of Warrant Activity (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail</Role>
      <ShortName>Share-based Payment  - Schedule of Warrant Activity (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Share-based Payment - Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail</Role>
      <ShortName>Share-based Payment - Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Share-based Payment  - Summary of Fair Values for Warrant Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail</Role>
      <ShortName>Share-based Payment  - Summary of Fair Values for Warrant Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Principal Accountant Fees and Services - Summary of Principal Accountant Fees and Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails</Role>
      <ShortName>Principal Accountant Fees and Services - Summary of Principal Accountant Fees and Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail</Role>
      <ShortName>Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996067 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxParentheticalDetail</Role>
      <ShortName>Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996077 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail</Role>
      <ShortName>Tax on Profit/(Loss) for the Year and Deferred Tax - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996087 - Disclosure - Intangible Assets - Summary of Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail</Role>
      <ShortName>Intangible Assets - Summary of Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996097 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996107 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996117 - Disclosure - Property, Plant and Equipment - Summary of Depreciations Charges (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail</Role>
      <ShortName>Property, Plant and Equipment - Summary of Depreciations Charges (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996127 - Disclosure - Investments in Associates - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail</Role>
      <ShortName>Investments in Associates - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996137 - Disclosure - Investments in Associates - Schedule of Financial Information of Investments in Associates (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail</Role>
      <ShortName>Investments in Associates - Schedule of Financial Information of Investments in Associates (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996147 - Disclosure - Inventories - Summary of Inventories Explanatory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail</Role>
      <ShortName>Inventories - Summary of Inventories Explanatory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996157 - Disclosure - Inventories - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail</Role>
      <ShortName>Inventories - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996167 - Disclosure - Contract Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Contract Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996177 - Disclosure - Provisions - Summary of Development in Provisions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail</Role>
      <ShortName>Provisions - Summary of Development in Provisions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996187 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Financial Assets and Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996197 - Disclosure - Financial Assets and Liabilities - Schedule of Financial assets and Financial Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail</Role>
      <ShortName>Financial Assets and Liabilities - Schedule of Financial assets and Financial Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996207 - Disclosure - Financial Assets and Liabilities - Schedule of Finance Income and Finance Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail</Role>
      <ShortName>Financial Assets and Liabilities - Schedule of Finance Income and Finance Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996217 - Disclosure - Financial Assets and Liabilities - Summary of Expenses, Related To Lease Activities In The Consolidated Statements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail</Role>
      <ShortName>Financial Assets and Liabilities - Summary of Expenses, Related To Lease Activities In The Consolidated Statements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996227 - Disclosure - Financial Assets and Liabilities - Summary of Development in Borrowings Arising from Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails</Role>
      <ShortName>Financial Assets and Liabilities - Summary of Development in Borrowings Arising from Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996237 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails</Role>
      <ShortName>Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996247 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Remeasurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails</Role>
      <ShortName>Financial Assets and Liabilities - Movements in Level 3 Fair Value Remeasurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996257 - Disclosure - Financial Risk Management - Summary of Number of Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfNumberOfSharesDetail</Role>
      <ShortName>Financial Risk Management - Summary of Number of Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996267 - Disclosure - Financial Risk Management - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail</Role>
      <ShortName>Financial Risk Management - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996277 - Disclosure - Financial Risk Management - Summary of Holding of Treasury Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail</Role>
      <ShortName>Financial Risk Management - Summary of Holding of Treasury Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996287 - Disclosure - Financial Risk Management - Schedule of Foreign Currency Sensitivity Analysis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail</Role>
      <ShortName>Financial Risk Management - Schedule of Foreign Currency Sensitivity Analysis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996297 - Disclosure - Financial Risk Management - Summary of Rate Structure of Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail</Role>
      <ShortName>Financial Risk Management - Summary of Rate Structure of Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996307 - Disclosure - Financial Risk Management - Schedule of Marketable Securities Specified By Investment Grade Credit Rating (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail</Role>
      <ShortName>Financial Risk Management - Schedule of Marketable Securities Specified By Investment Grade Credit Rating (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996327 - Disclosure - Financial Risk Management - Summary of Contractual Cash Flows for Financial Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail</Role>
      <ShortName>Financial Risk Management - Summary of Contractual Cash Flows for Financial Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996337 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996347 - Disclosure - Investments in Group Enterprises - Summary of Investments in Group Enterprises (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail</Role>
      <ShortName>Investments in Group Enterprises - Summary of Investments in Group Enterprises (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="asnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996357 - Disclosure - Ownership - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail</Role>
      <ShortName>Ownership - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="asnd-20241231.htm">asnd-20241231.htm</File>
    <File>asnd-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img148586500_0.jpg</File>
    <File>img148586500_1.jpg</File>
    <File>img148586500_2.jpg</File>
    <File>img148586500_3.jpg</File>
    <File>img148586500_4.jpg</File>
    <File>img148586500_5.jpg</File>
    <File>img148586500_6.jpg</File>
    <File>img148586500_7.jpg</File>
    <File>img148586500_8.jpg</File>
    <File>img148586500_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
    <BaseTaxonomy items="1109">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>130
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "asnd-20241231.htm": {
   "nsprefix": "asnd",
   "nsuri": "http://ascendispharma.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "asnd-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "asnd-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    }
   },
   "keyStandard": 316,
   "keyCustom": 120,
   "axisStandard": 35,
   "axisCustom": 7,
   "memberStandard": 48,
   "memberCustom": 69,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 380,
   "entityCount": 1,
   "segmentCount": 123,
   "elementCount": 985,
   "unitCount": 14,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 1109,
    "http://xbrl.sec.gov/dei/2024": 46,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
     "longName": "100010 - Statement - Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)",
     "shortName": "Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical",
     "longName": "100030 - Statement - Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)",
     "shortName": "Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:NumberOfWarrantsOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:NumberOfWarrantsOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
     "longName": "100040 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
     "longName": "100050 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_f8fffccb-1bb9-4595-87c7-952664cd5bf3",
      "name": "ifrs-full:Equity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1fd592a-4621-4c11-bdbc-d9f0a9de718a",
      "name": "ifrs-full:Equity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements",
     "longName": "100060 - Statement - Consolidated Cash Flow Statements",
     "shortName": "Consolidated Cash Flow Statements",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/GeneralInformation",
     "longName": "995467 - Disclosure - General Information",
     "shortName": "General Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies",
     "longName": "995477 - Disclosure - Summary of Material Accounting Policies",
     "shortName": "Summary of Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimates",
     "longName": "995487 - Disclosure - Significant Accounting Judgements and Estimates",
     "shortName": "Significant Accounting Judgements and Estimates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/Revenue",
     "longName": "995497 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformation",
     "longName": "995507 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/EmployeeCosts",
     "longName": "995517 - Disclosure - Employee costs",
     "shortName": "Employee costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPayment",
     "longName": "995527 - Disclosure - Share-based Payment",
     "shortName": "Share-based Payment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServices",
     "longName": "995537 - Disclosure - Principal Accountant Fees and Services",
     "shortName": "Principal Accountant Fees and Services",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTax",
     "longName": "995547 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax",
     "shortName": "Tax on Profit/(Loss) for the Year and Deferred Tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssets",
     "longName": "995557 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipment",
     "longName": "995567 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociates",
     "longName": "995577 - Disclosure - Investments in Associates",
     "shortName": "Investments in Associates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/Inventories",
     "longName": "995587 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilities",
     "longName": "995607 - Disclosure - Contract liabilities",
     "shortName": "Contract liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisions",
     "longName": "995617 - Disclosure - Provisions",
     "shortName": "Provisions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilities",
     "longName": "995627 - Disclosure - Financial Assets and Liabilities",
     "shortName": "Financial Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagement",
     "longName": "995637 - Disclosure - Financial Risk Management",
     "shortName": "Financial Risk Management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995647 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/RelatedPartyTransactions",
     "longName": "995657 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprises",
     "longName": "995667 - Disclosure - Investments in Group Enterprises",
     "shortName": "Investments in Group Enterprises",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/Ownership",
     "longName": "995677 - Disclosure - Ownership",
     "shortName": "Ownership",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfBeneficialOwnershipExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfBeneficialOwnershipExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/SubsequentEvents",
     "longName": "995687 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995697 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "995707 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/RevenueTables",
     "longName": "995717 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationTables",
     "longName": "995727 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables",
     "longName": "995737 - Disclosure - Employee Costs (Tables)",
     "shortName": "Employee Costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentTables",
     "longName": "995747 - Disclosure - Share-based Payment (Tables)",
     "shortName": "Share-based Payment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesTables",
     "longName": "995757 - Disclosure - Principal Accountant Fees and Services (Tables)",
     "shortName": "Principal Accountant Fees and Services (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxTables",
     "longName": "995767 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax (Tables)",
     "shortName": "Tax on Profit/(Loss) for the Year and Deferred Tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsTables",
     "longName": "995777 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentTables",
     "longName": "995787 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables",
     "longName": "995797 - Disclosure - Investments in Associates (Tables)",
     "shortName": "Investments in Associates (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/InventoriesTables",
     "longName": "995807 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsTables",
     "longName": "995817 - Disclosure - Provisions (Tables)",
     "shortName": "Provisions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables",
     "longName": "995827 - Disclosure - Financial Assets and Liabilities (Tables)",
     "shortName": "Financial Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables",
     "longName": "995837 - Disclosure - Financial Risk Management (Tables)",
     "shortName": "Financial Risk Management (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesTables",
     "longName": "995847 - Disclosure - Investments in Group Enterprises (Tables)",
     "shortName": "Investments in Group Enterprises (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
     "longName": "995857 - Disclosure - Summary of Material Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Material Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:NoncurrentLeaseLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:NoncurrentLeaseLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
     "longName": "995867 - Disclosure - Summary of Material Accounting Policies - Schedule of Asset's Expected Useful Life (Detail)",
     "shortName": "Summary of Material Accounting Policies - Schedule of Asset's Expected Useful Life (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_696a9b0f-6d34-4970-b7ae-11c29efc2267",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_696a9b0f-6d34-4970-b7ae-11c29efc2267",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail",
     "longName": "995877 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Detail)",
     "shortName": "Significant Accounting Judgements and Estimates - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:CurrentProvisions",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:WarrantCompensationCost",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail",
     "longName": "995887 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Detail)",
     "shortName": "Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
     "longName": "995897 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)",
     "shortName": "Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e223f34a-d64a-4201-8c13-a2f49a7b3064",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "div",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail",
     "longName": "995907 - Disclosure - Revenue - Schedule of Revenue Attributable to Commercial Customers by Product (Detail)",
     "shortName": "Revenue - Schedule of Revenue Attributable to Commercial Customers by Product (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_8254a47f-7720-4dbd-860f-ccd3f90e8bcd",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfRevenueToCommercialCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8254a47f-7720-4dbd-860f-ccd3f90e8bcd",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfRevenueToCommercialCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
     "longName": "995917 - Disclosure - Revenue - Additional Information (Detail)",
     "shortName": "Revenue - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_56b18c35-7b90-45e6-8446-e4893174d8bd",
      "name": "asnd:NumberOfCommercialCustomers",
      "unitRef": "U_CommercialCustomer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "asnd:NumberOfCommercialCustomers",
       "span",
       "p",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail",
     "longName": "995927 - Disclosure - Segment Information - Additional Information (Detail)",
     "shortName": "Segment Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:NumberOfReportableOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:NumberOfReportableOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail",
     "longName": "995937 - Disclosure - Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Detail)",
     "shortName": "Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1595989-ee89-44d6-aafc-6d121568fc57",
      "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails",
     "longName": "995947 - Disclosure - Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Parenthetical) (Details)",
     "shortName": "Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail",
     "longName": "995957 - Disclosure - Employee Costs - Summary of Employee Cost (Detail)",
     "shortName": "Employee Costs - Summary of Employee Cost (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock",
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock",
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
     "longName": "995977 - Disclosure - Share-Based Payment - Additional Information (Detail)",
     "shortName": "Share-Based Payment - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "U_DkkPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_df13e31f-e944-44b8-beee-0157e82a5356",
      "name": "asnd:SharebasedPaymentArrangementVestingPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail",
     "longName": "995987 - Disclosure - Share-Based Payment - Summary Of Share Based Payment (Detail)",
     "shortName": "Share-Based Payment - Summary Of Share Based Payment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0f2a0f3d-caa6-4b26-aaab-9aaaa98975ed",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail",
     "longName": "995997 - Disclosure - Share-Based Payment - Summary Of Share Based Payment (Parenthetical) (Detail)",
     "shortName": "Share-Based Payment - Summary Of Share Based Payment (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_8cdbb2f3-5894-447e-9e13-0a00148c6b78",
      "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8cdbb2f3-5894-447e-9e13-0a00148c6b78",
      "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
     "longName": "996007 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)",
     "shortName": "Share-based Payment - Schedule of Warrant Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5268a2fe-772c-411f-b537-63cfb4081aac",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail",
     "longName": "996017 - Disclosure - Share-based Payment  - Schedule of Warrant Activity (Parenthetical) (Detail)",
     "shortName": "Share-based Payment  - Schedule of Warrant Activity (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_88ae6c08-23fb-4240-bf5e-678082269ff6",
      "name": "ifrs-full:WeightedAverageSharePrice2019",
      "unitRef": "U_EurPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88ae6c08-23fb-4240-bf5e-678082269ff6",
      "name": "ifrs-full:WeightedAverageSharePrice2019",
      "unitRef": "U_EurPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail",
     "longName": "996027 - Disclosure - Share-based Payment - Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants (Detail)",
     "shortName": "Share-based Payment - Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870",
      "name": "asnd:YearOfGrantOfWarrants",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail",
     "longName": "996037 - Disclosure - Share-based Payment  - Summary of Fair Values for Warrant Grants (Detail)",
     "shortName": "Share-based Payment  - Summary of Fair Values for Warrant Grants (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a",
      "name": "ifrs-full:DescriptionOfOptionLifeShareOptionsGranted",
      "unitRef": "U_Y",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a",
      "name": "ifrs-full:DescriptionOfOptionLifeShareOptionsGranted",
      "unitRef": "U_Y",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails",
     "longName": "996047 - Disclosure - Principal Accountant Fees and Services - Summary of Principal Accountant Fees and Services (Details)",
     "shortName": "Principal Accountant Fees and Services - Summary of Principal Accountant Fees and Services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock",
       "div",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock",
       "div",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail",
     "longName": "996057 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Detail)",
     "shortName": "Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxParentheticalDetail",
     "longName": "996067 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Parenthetical) (Detail)",
     "shortName": "Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "ifrs-full:ApplicableTaxRate",
       "ifrs-full:ApplicableTaxRate",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "ifrs-full:ApplicableTaxRate",
       "ifrs-full:ApplicableTaxRate",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail",
     "longName": "996077 - Disclosure - Tax on Profit/(Loss) for the Year and Deferred Tax - Additional Information (Detail)",
     "shortName": "Tax on Profit/(Loss) for the Year and Deferred Tax - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:IncomeTaxesPaidRefund",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "ifrs-full:IncomeTaxesPaidRefund",
       "ifrs-full:IncomeTaxesPaidRefund",
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:IncomeTaxesPaidRefund",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "ifrs-full:IncomeTaxesPaidRefund",
       "ifrs-full:IncomeTaxesPaidRefund",
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail",
     "longName": "996087 - Disclosure - Intangible Assets - Summary of Goodwill (Detail)",
     "shortName": "Intangible Assets - Summary of Goodwill (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a4416a56-3759-43a1-a9b2-a168da37fe04",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail",
     "longName": "996097 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)",
     "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aee0a664-90db-4cac-b252-ca13f6feb6bb",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails",
     "longName": "996107 - Disclosure - Property, Plant and Equipment - Additional Information (Details)",
     "shortName": "Property, Plant and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DepreciationPropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfDetailedInformationAboutDepreciationsCharges",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail",
     "longName": "996117 - Disclosure - Property, Plant and Equipment - Summary of Depreciations Charges (Detail)",
     "shortName": "Property, Plant and Equipment - Summary of Depreciations Charges (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DepreciationPropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfDetailedInformationAboutDepreciationsCharges",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8ec23a67-4cba-4228-abd5-b5b3f4e8d2dd",
      "name": "ifrs-full:DepreciationPropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfDetailedInformationAboutDepreciationsCharges",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail",
     "longName": "996127 - Disclosure - Investments in Associates - Additional Information (Detail)",
     "shortName": "Investments in Associates - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3069879e-b2eb-487f-8359-3b2b3ac38c1d",
      "name": "asnd:CapitalCommitmentFromInvestors",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail",
     "longName": "996137 - Disclosure - Investments in Associates - Schedule of Financial Information of Investments in Associates (Detail)",
     "shortName": "Investments in Associates - Schedule of Financial Information of Investments in Associates (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:ComprehensiveIncome",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_962ef1c5-8d47-4bc2-b07c-320d06c0970d",
      "name": "asnd:ProfitLossForTheYear",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail",
     "longName": "996147 - Disclosure - Inventories - Summary of Inventories Explanatory (Detail)",
     "shortName": "Inventories - Summary of Inventories Explanatory (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock",
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock",
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail",
     "longName": "996157 - Disclosure - Inventories - Additional Information (Detail)",
     "shortName": "Inventories - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:InventoryWritedown2011",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:InventoryWritedown2011",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail",
     "longName": "996167 - Disclosure - Contract Liabilities - Additional Information (Detail)",
     "shortName": "Contract Liabilities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:Revenuerecognizedfromcontractliabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:Revenuerecognizedfromcontractliabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail",
     "longName": "996177 - Disclosure - Provisions - Summary of Development in Provisions (Detail)",
     "shortName": "Provisions - Summary of Development in Provisions (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:CurrentProvisions",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory",
       "div",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
     "longName": "996187 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)",
     "shortName": "Financial Assets and Liabilities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "asnd:ConvertibleSeniorNotes",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "asnd:SharePriceAppliedForValuation",
      "unitRef": "U_EurPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
     "longName": "996197 - Disclosure - Financial Assets and Liabilities - Schedule of Financial assets and Financial Liabilities (Detail)",
     "shortName": "Financial Assets and Liabilities - Schedule of Financial assets and Financial Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:NoncurrentFinancialAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail",
     "longName": "996207 - Disclosure - Financial Assets and Liabilities - Schedule of Finance Income and Finance Expenses (Detail)",
     "shortName": "Financial Assets and Liabilities - Schedule of Finance Income and Finance Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail",
     "longName": "996217 - Disclosure - Financial Assets and Liabilities - Summary of Expenses, Related To Lease Activities In The Consolidated Statements (Detail)",
     "shortName": "Financial Assets and Liabilities - Summary of Expenses, Related To Lease Activities In The Consolidated Statements (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails",
     "longName": "996227 - Disclosure - Financial Assets and Liabilities - Summary of Development in Borrowings Arising from Financing Activities (Details)",
     "shortName": "Financial Assets and Liabilities - Summary of Development in Borrowings Arising from Financing Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_69523622-60fc-4677-8a69-32400c599999",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails",
     "longName": "996237 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)",
     "shortName": "Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e22f7140-0ffe-4e0a-a8d2-1e98ce4c62eb",
      "name": "ifrs-full:FinancialAssetsAtAmortisedCost",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails",
     "longName": "996247 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Remeasurements (Details)",
     "shortName": "Financial Assets and Liabilities - Movements in Level 3 Fair Value Remeasurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7af1f25a-54be-46a2-a19d-533e859fbdd7",
      "name": "asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfNumberOfSharesDetail",
     "longName": "996257 - Disclosure - Financial Risk Management - Summary of Number of Shares (Detail)",
     "shortName": "Financial Risk Management - Summary of Number of Shares (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
     "longName": "996267 - Disclosure - Financial Risk Management - Additional Information (Detail)",
     "shortName": "Financial Risk Management - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_caa0fd3a-8a0c-4ca4-8011-0a2b36ac28ba",
      "name": "asnd:RealizedDurationOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail",
     "longName": "996277 - Disclosure - Financial Risk Management - Summary of Holding of Treasury Shares (Detail)",
     "shortName": "Financial Risk Management - Summary of Holding of Treasury Shares (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_22b1cffe-3381-48dd-9ae6-e3f3769898c7",
      "name": "ifrs-full:TreasuryShares",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail",
     "longName": "996287 - Disclosure - Financial Risk Management - Schedule of Foreign Currency Sensitivity Analysis (Detail)",
     "shortName": "Financial Risk Management - Schedule of Foreign Currency Sensitivity Analysis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "C_3e1079df-bb69-43bf-854f-2f912ce24f92",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfForeignCurrencySensitivityAnalysisExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e1079df-bb69-43bf-854f-2f912ce24f92",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfForeignCurrencySensitivityAnalysisExplanatory",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail",
     "longName": "996297 - Disclosure - Financial Risk Management - Summary of Rate Structure of Marketable Securities (Detail)",
     "shortName": "Financial Risk Management - Summary of Rate Structure of Marketable Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R91": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail",
     "longName": "996307 - Disclosure - Financial Risk Management - Schedule of Marketable Securities Specified By Investment Grade Credit Rating (Detail)",
     "shortName": "Financial Risk Management - Schedule of Marketable Securities Specified By Investment Grade Credit Rating (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R92": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail",
     "longName": "996327 - Disclosure - Financial Risk Management - Summary of Contractual Cash Flows for Financial Liabilities (Detail)",
     "shortName": "Financial Risk Management - Summary of Contractual Cash Flows for Financial Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:Borrowings",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:ContractualCashflowsForFinancialLiabilitiesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_198d936f-6bd1-467c-a662-6a993e1856a7",
      "name": "ifrs-full:Borrowings",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:ContractualCashflowsForFinancialLiabilitiesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "996337 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "C_614a19b6-1595-4cfe-87c5-0d0f93542d8e",
      "name": "ifrs-full:ContractualCapitalCommitments",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_614a19b6-1595-4cfe-87c5-0d0f93542d8e",
      "name": "ifrs-full:ContractualCapitalCommitments",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail",
     "longName": "996347 - Disclosure - Investments in Group Enterprises - Summary of Investments in Group Enterprises (Detail)",
     "shortName": "Investments in Group Enterprises - Summary of Investments in Group Enterprises (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "C_ce33c6e8-bd62-455a-8699-8dfef4b1bdb2",
      "name": "ifrs-full:NameOfSubsidiary",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ce33c6e8-bd62-455a-8699-8dfef4b1bdb2",
      "name": "ifrs-full:NameOfSubsidiary",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail",
     "longName": "996357 - Disclosure - Ownership - Additional Information (Detail)",
     "shortName": "Ownership - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:MinimumBeneficialOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "asnd:DisclosureOfBeneficialOwnershipExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e160c34a-290e-4f9a-863a-46afc6a82950",
      "name": "asnd:MinimumBeneficialOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "asnd:DisclosureOfBeneficialOwnershipExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ifrs-full_AccountingProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccountingProfit",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "terseLabel": "Profit/(loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation, amortisation and impairment [member]",
        "terseLabel": "Depreciation and impairment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r51",
      "r60",
      "r93",
      "r102",
      "r105"
     ]
    },
    "ifrs-full_AccumulatedImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedImpairmentMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated impairment [member]",
        "terseLabel": "Amortization and impairment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r209",
      "r290",
      "r431",
      "r441",
      "r447",
      "r448"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "asnd_AdditionalDevelopmentAndRegulatoryMilestonesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AdditionalDevelopmentAndRegulatoryMilestonesReceived",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional development and regulatory milestones",
        "label": "Additional Development and Regulatory Milestones Received",
        "terseLabel": "Additional development and regulatory milestones potentially to be received"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AdditionalFutureTaxDeduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AdditionalFutureTaxDeduction",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional future tax deduction",
        "documentation": "Additional future tax deduction."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AdditionalTaxDeduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AdditionalTaxDeduction",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional tax deduction.",
        "label": "Additional Tax Deduction",
        "terseLabel": "Additional tax deductions, determined by annual warrants exercises by employees"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AdditionalTaxDeductionsRelatedToTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AdditionalTaxDeductionsRelatedToTaxCredits",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional tax deductions related to tax credits",
        "documentation": "Additional tax deductions related to tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForAmortisationExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for amortisation expense",
        "terseLabel": "Amortization"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForCurrentTaxOfPriorPeriod",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for current tax of prior periods",
        "terseLabel": "Current tax, adjustments to prior years"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in prepaid expenses",
        "terseLabel": "Prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxOfPriorPeriods",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for deferred tax of prior periods",
        "terseLabel": "Deferred tax, adjustments to prior years"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments of tax expense (income) recognised in the period for the deferred tax of prior periods."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation expense",
        "terseLabel": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in deferred income including contract liabilities",
        "totalLabel": "Total adjustments for increase (decrease) in deferred income including contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Trade payables, accrued expenses and other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "asnd_AdjustmentsForNonCashConsiderationRegardingRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AdjustmentsForNonCashConsiderationRegardingRevenue",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash consideration relating to revenue",
        "documentation": "Adjustments for non cash consideration regarding revenue.",
        "label": "Adjustments For Non Cash Consideration Regarding Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Increase/(decrease) in provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments for non-cash items:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "asnd_AgencyBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AgencyBondsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency bonds [Member].",
        "label": "Agency bonds [Member]",
        "terseLabel": "Agency bonds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r333",
      "r343",
      "r376"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r336",
      "r346",
      "r379"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r337",
      "r347",
      "r371",
      "r380",
      "r384",
      "r392"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American depositary shares member.",
        "label": "American Depositary Shares [Member]",
        "terseLabel": "American Depositary Shares [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmericanDepositorySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AmericanDepositorySharesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American depository shares.",
        "label": "American depository shares [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortisation, intangible assets other than goodwill",
        "label": "Amortisation, intangible assets other than goodwill",
        "terseLabel": "Amortization Charge"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount.",
        "label": "Amount Multiplied to Purchase Price Minus Revenue Interest Payments Paid to Purchaser on Effective Date of Buy-out Notice As Buyout Amount",
        "terseLabel": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount.",
        "label": "Amount Multiplied to Purchase Price Minus Revenue Interest Payments Paid to Purchaser on Effective Date of Buy-out Notice Provided on or Prior to Period as Buyout Amount.",
        "terseLabel": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antidilutive securities not included in diluted earnings per share.",
        "label": "Antidilutive Securities Not Included In Diluted Earnings Per Share [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antidilutive securities not Included In diluted earnings per share.",
        "label": "Antidilutive Securities Not Included In Diluted Earnings Per Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "asnd_AscendisPharmaBoneDiseaseASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaBoneDiseaseASMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma bone disease AS.",
        "label": "Ascendis Pharma Bone Disease AS [member]",
        "terseLabel": "Ascendis Pharma Bone Diseases A/S [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaEndocrinologyDivisionASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaEndocrinologyDivisionASMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma endocrinology division AS.",
        "label": "Ascendis Pharma Endocrinology Division AS [member]",
        "terseLabel": "Ascendis Pharma Endocrinology Division A/S [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaEndocrinologyGmbhMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaEndocrinologyGmbhMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ascendis Pharma Endocrinology GmbH [member]",
        "label": "Ascendis Pharma Endocrinology GmbH [Member]",
        "documentation": "Ascendis Pharma Endocrinology GmbH."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaEndocrinologyIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaEndocrinologyIncMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ascendis Pharma Endocrinology Inc [Member]",
        "terseLabel": "Ascendis Pharma Endocrinology, Inc. [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaEuropeASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaEuropeASMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma Europe A/S.",
        "label": "Ascendis Pharma Europe A/S [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaFranceSasuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaFranceSasuMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ascendis Pharma France SASU [member]",
        "documentation": "Ascendis pharma france SASU.",
        "terseLabel": "Ascendis Pharma France SASU [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaGmbHMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma GmbH.",
        "label": "Ascendis Pharma GmbH [member]",
        "terseLabel": "Ascendis Pharma GmbH [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaGrowthDisordersASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaGrowthDisordersASMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma growth disorders AS.",
        "label": "Ascendis Pharma Growth Disorders AS [member]",
        "terseLabel": "Ascendis Pharma Growth Disorders A/S [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaIberiaSLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaIberiaSLMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma Iberia S.L.",
        "label": "Ascendis Pharma Iberia S L [Member]",
        "terseLabel": "Ascendis Pharma Iberia S.L. [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaIncMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma, Inc..",
        "label": "Ascendis Pharma, Inc. [member]",
        "terseLabel": "Ascendis Pharma, Inc [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaItaliaSrlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaItaliaSrlMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ascendis Pharma Italia SRL [member]",
        "documentation": "Ascendis pharma italia SRL."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaOncologyDivisionAsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaOncologyDivisionAsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma On cology Division AS Member",
        "label": "Ascendis Pharma Oncology Division AS [Member]",
        "terseLabel": "Ascendis Pharma Oncology Division AS [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaOphthalmologyDivisionASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaOphthalmologyDivisionASMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma Ophthalmology Division AS.",
        "label": "Ascendis Pharma Ophthalmology Division AS [member]",
        "terseLabel": "Ascendis Pharma Ophthalmology Division A/S [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaSverigeAbMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaSverigeAbMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ascendis Pharma Sverige AB [member]",
        "documentation": "Ascendis pharma sverige AB.",
        "terseLabel": "Ascendis Pharma Sverige AB [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaSwitzerlandGmbhMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaSwitzerlandGmbhMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ascendis Pharma Switzerland GmbH [member]",
        "documentation": "Ascendis Pharma Switzerland GmbH."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AscendisPharmaUkLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AscendisPharmaUkLimitedMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ascendis Pharma UK Limited.",
        "label": "Ascendis Pharma UK Limited [member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AsiaMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]",
        "terseLabel": "Asia [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Assets at end of period",
        "periodStartLabel": "Assets at beginning of period",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r151",
      "r152",
      "r154",
      "r233",
      "r236"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AssociateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AssociateAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Associate [abstract]",
        "label": "Associate [abstract]",
        "terseLabel": "VISEN Pharmaceuticals"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssociatesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total for all associates [member]",
        "terseLabel": "Associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entities over which the investor has significant influence."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r78",
      "r82",
      "r150"
     ]
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value [member]",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r104",
      "r137",
      "r151"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418"
     ]
    },
    "asnd_Audit-RelatedFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "Audit-RelatedFees",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit-related Fees",
        "documentation": "Audit-related fees.",
        "terseLabel": "Audit-related fees"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r329"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r329"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r329"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "ifrs-full_AuditorsRemuneration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AuditorsRemuneration",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor's remuneration",
        "totalLabel": "Total principal accountant fees and services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_AuditorsRemunerationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AuditorsRemunerationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor's remuneration [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AuditorsRemunerationForAuditServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AuditorsRemunerationForAuditServices",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor's remuneration for audit services",
        "terseLabel": "Audit fees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for auditing services."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_AuditorsRemunerationForOtherServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AuditorsRemunerationForOtherServices",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor's remuneration for other services",
        "terseLabel": "All other fees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_AuditorsRemunerationForTaxServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AuditorsRemunerationForTaxServices",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesSummaryOfPrincipalAccountantFeesAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor's remuneration for tax services",
        "terseLabel": "Tax fees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for tax services."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total average effective tax rate",
        "label": "Average effective tax rate",
        "terseLabel": "Effective tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_AverageNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AverageNumberOfEmployees",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average number of employees",
        "terseLabel": "Average number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The average number of personnel employed by the entity during a period."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "asnd_AvoroCapitalAdvisorsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "AvoroCapitalAdvisorsLlcMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avoro Capital Advisors LLC.",
        "label": "Avoro Capital Advisors LLC [Member]",
        "terseLabel": "Avoro Capital Advisors LLC [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_BalancesWithBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BalancesWithBanks",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balances with banks",
        "terseLabel": "Bank deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash balances held at banks."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "totalLabel": "Total basic earnings (loss) per share",
        "terseLabel": "Basic earnings/(loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85"
     ]
    },
    "asnd_BoardMembersOfGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "BoardMembersOfGroupMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board members of group.",
        "label": "Board members of group [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board of directors.",
        "label": "Board Of Directors [member]",
        "terseLabel": "Board of Directors [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period",
        "totalLabel": "Total borrowings",
        "label": "Borrowings",
        "terseLabel": "Borrowings (excluding lease liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "asnd_BorrowingsConditionForRedemption": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "BorrowingsConditionForRedemption",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings condition for redemption.",
        "label": "Borrowings Condition For Redemption",
        "terseLabel": "Borrowings condition for redemption"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsInArrearsDefaultPaymentStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "BorrowingsInArrearsDefaultPaymentStartDate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings in arrears default payment start date.",
        "label": "Borrowings In Arrears Default Payment Start Date",
        "terseLabel": "Borrowings in arrears default payment start date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding convertible notes, coupon fixed rate",
        "terseLabel": "Borrowings, interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ifrs-full_BorrowingsMaturity": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsMaturity",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, maturity"
       }
      },
      "en": {
       "role": {
        "documentation": "The maturity of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "asnd_BorrowingsRedemptionPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "BorrowingsRedemptionPeriod",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings redemption period.",
        "label": "Borrowings Redemption Period",
        "terseLabel": "Borrowings redemption period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "BorrowingsThresholdConsecutiveTradingDaysForRedemption",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings threshold consecutive trading days for redemption.",
        "label": "Borrowings Threshold Consecutive Trading Days For Redemption",
        "terseLabel": "Borrowings threshold consecutive trading days for redemption"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "BorrowingsThresholdPercentageOfSalePricePerShareForRedemption",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings threshold percentage of sale price per share for redemption.",
        "label": "Borrowings Threshold Percentage Of Sale Price Per Share For Redemption",
        "terseLabel": "Borrowings threshold percentage of sale price per share for redemption"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdTradingDaysForRedemption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "BorrowingsThresholdTradingDaysForRedemption",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings Threshold Trading Days For Redemption.",
        "label": "Borrowings Threshold Trading Days For Redemption",
        "terseLabel": "Borrowings threshold trading days for redemption"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r156",
      "r182",
      "r193",
      "r281",
      "r283",
      "r460"
     ]
    },
    "asnd_BritishPoundsToEuroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "BritishPoundsToEuroMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "British pounds to Euro.",
        "label": "British pounds to Euro [member]",
        "terseLabel": "British pounds to Euro [member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact [member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r306",
      "r329"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CapitalCommitmentFromInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "CapitalCommitmentFromInvestors",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital commitment from investors.",
        "label": "Capital commitment from investors",
        "terseLabel": "Commitment from investors"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CapitalCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital commitments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r57",
      "r93",
      "r96",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r198",
      "r209",
      "r210"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r57",
      "r96",
      "r101",
      "r103",
      "r104",
      "r198",
      "r209",
      "r210"
     ]
    },
    "asnd_CarryingAmountOfRoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "CarryingAmountOfRoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of royalty funding liabilities.",
        "label": "Carrying Amount of Royalty Funding Liabilities",
        "terseLabel": "Carrying amount of royalty funding liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash and cash equivalents",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at December 31",
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at January 1"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r115",
      "r144"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) financing activities",
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Cash flows from/(used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r117"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) investing activities",
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Cash flows from/(used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r117"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) operating activities",
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Cash flows from/(used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r106",
      "r117"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) operations",
        "label": "Cash flows from (used in) operations",
        "totalLabel": "Cash flows generated from/(used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r276"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease cash-outflows",
        "label": "Cash outflow for leases",
        "negatedLabel": "Payment of principal portion of liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfCurrentFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of current financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets by category",
        "label": "Categories of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]",
        "terseLabel": "Categories of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial liabilities by category",
        "label": "Categories of financial liabilities [abstract]",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]",
        "terseLabel": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfNoncurrentFinancialAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classified in the statement of financial position",
        "label": "Categories of non-current financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfNoncurrentFinancialLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classified in the statement of financial position",
        "label": "Categories of non-current financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]",
        "terseLabel": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "asnd_CategoriesOfSharesBasedPaymentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "CategoriesOfSharesBasedPaymentsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories Of Shares Based Payments [Axis]",
        "label": "Categories Of Shares Based Payments [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CategoriesOfSharesBasedPaymentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "CategoriesOfSharesBasedPaymentsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories Of Shares Based Payments [Domain]",
        "label": "Categories Of Shares Based Payments [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "asnd_ChangesInWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ChangesInWorkingCapitalAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in working capital.",
        "label": "Changes in working capital [abstract]",
        "terseLabel": "Changes in working capital:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]",
        "terseLabel": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r155",
      "r174"
     ]
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r155",
      "r174"
     ]
    },
    "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfEmployeeBenefitsExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of employee benefits expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]",
        "terseLabel": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r217",
      "r218",
      "r245",
      "r246"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r217",
      "r218",
      "r245",
      "r246"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r211",
      "r212",
      "r213"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r211",
      "r212",
      "r213"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r245",
      "r246"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r245",
      "r246"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets and goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ifrs-full_ClassesOfOtherProvisionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOtherProvisionsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]",
        "terseLabel": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]",
        "terseLabel": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "asnd_ClassificationOfRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ClassificationOfRelatedPartyAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification Of Related Party [Axis]",
        "label": "Classification Of Related Party [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ClassificationOfRelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ClassificationOfRelatedPartyDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification Of Related Party [Domain]",
        "label": "Classification Of Related Party [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "asnd_CollaborationPartnersAndLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "CollaborationPartnersAndLicenseAgreementsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Partners and License Agreements.",
        "label": "Collaboration partners and license agreements [Member]",
        "terseLabel": "Collaboration partners and license agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CommercialCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "CommercialCustomersMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Customers.",
        "label": "Commercial customers [Member]",
        "terseLabel": "Commercial customers [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CommercialPapersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "CommercialPapersMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial papers [Member].",
        "label": "Commercial papers [Member]",
        "terseLabel": "Commercial papers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Items that may be reclassified subsequently to profit or (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total comprehensive income",
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r29",
      "r125",
      "r127",
      "r142",
      "r278"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "totalLabel": "Attributable to owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r31"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer software [member]",
        "terseLabel": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ConsiderationPaidReceived",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration paid (received)",
        "terseLabel": "Consideration received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total contract liabilities",
        "periodEndLabel": "Contract liabilities at end of period",
        "periodStartLabel": "Contract liabilities at beginning of period",
        "label": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r160"
     ]
    },
    "ifrs-full_ContractLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContractLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ContractLiabilitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liabilities [Line Items].",
        "label": "Contract Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractLiabilitiestableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ContractLiabilitiestableTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liabilities [Table].",
        "label": "Contract Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractualCapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContractualCapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual capital commitments",
        "terseLabel": "Contractual commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]"
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "asnd_ContractualCashflowsForFinancialLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ContractualCashflowsForFinancialLiabilitiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Cashflows For Financial Liabilities [Text Block]",
        "documentation": "Contractual cashflows for financial liabilities.",
        "terseLabel": "Summary of Contractual Cash Flows for Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ContractualUndiscountedCashflowOfBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total borrowings",
        "label": "Contractual undiscounted cashflow of borrowings",
        "documentation": "Contractual undiscounted cashflow of borrowings.",
        "terseLabel": "Borrowings",
        "verboseLabel": "Borrowings (excluding lease liabilities)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ContractualUndiscountedCashflowOfFinancialLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual undiscounted cashflow of Financial lease liabilities.",
        "label": "Contractual Undiscounted Cashflow Of Financial Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ContractualUndiscountedCashflowOfFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual undiscounted cashflow of financial liabilities.",
        "label": "Contractual Undiscounted Cashflow Of Financial Liabilities",
        "totalLabel": "Total financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual undiscounted cashflow of trade payables and other payables.",
        "label": "Contractual Undiscounted Cashflow Of Trade Payables And Other Payables",
        "terseLabel": "Trade payables, accrued expenses and other liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ConversionPricePerShare",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion price per share.",
        "label": "Conversion Price Per Share",
        "terseLabel": "Conversion price per share"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConversionRatePerNote": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ConversionRatePerNote",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion rate per note.",
        "label": "Conversion Rate Per Note",
        "terseLabel": "Conversion rate per note"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleDebtCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ConvertibleDebtCurrentAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Current [Abstract]",
        "documentation": "Convertible debt current abstract.",
        "terseLabel": "Convertible notes, matures in April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleNotesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ConvertibleNotesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Current",
        "documentation": "Convertible notes current.",
        "totalLabel": "Convertible notes current"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ConvertibleSeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible senior notes.",
        "label": "Convertible Senior Notes",
        "terseLabel": "Convertible senior notes",
        "verboseLabel": "Convertible Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ConvertibleSeniorNotesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible senior notes [Member].",
        "label": "Convertible Senior Notes [Member]",
        "terseLabel": "Convertible senior notes [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "CorporateBondsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bonds [Member].",
        "label": "Corporate bonds [Member]",
        "terseLabel": "Corporate bonds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of sales",
        "label": "Cost of sales",
        "terseLabel": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r39"
     ]
    },
    "ifrs-full_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of sales [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to goods or services sold. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418"
     ]
    },
    "asnd_CostsOfCapitalIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "CostsOfCapitalIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of capital increase (decrease).",
        "label": "Costs of capital increase (decrease)",
        "negatedLabel": "Cost of capital increase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_CountryOfDomicileMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CountryOfDomicileMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country of domicile [member]",
        "terseLabel": "Denmark [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the country in which the entity is registered and where it has its legal address or registered office."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241"
     ]
    },
    "ifrs-full_CountryOfIncorporationOrResidenceOfAssociate": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CountryOfIncorporationOrResidenceOfAssociate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country of incorporation of associate",
        "terseLabel": "Domicile"
       }
      },
      "en": {
       "role": {
        "documentation": "The country in which an associate of the entity is incorporated. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r80",
      "r135"
     ]
    },
    "ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CountryOfIncorporationOrResidenceOfSubsidiary",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country of incorporation of subsidiary",
        "terseLabel": "Domicile"
       }
      },
      "en": {
       "role": {
        "documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r80",
      "r130",
      "r132"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CreditRiskMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r288"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r138",
      "r278"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current contract liabilities",
        "label": "Current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "terseLabel": "Derivative liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "ifrs-full_CurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financial assets",
        "totalLabel": "Total current financial assets",
        "terseLabel": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_CurrentFinancialAssetsAvailableforsale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentFinancialAssetsAvailableforsale",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financial assets available-for-sale",
        "terseLabel": "Current financial marketable securities",
        "verboseLabel": "Marketable securities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_CurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current financial liabilities",
        "label": "Current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Carrying amount of current lease liabilities",
        "verboseLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current liabilities",
        "label": "Current liabilities",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r140",
      "r278"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current prepayments",
        "label": "Current prepayments",
        "terseLabel": "Prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current provisions",
        "label": "Current provisions",
        "terseLabel": "Provisions",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentRawMaterialsAndCurrentProductionSupplies",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current raw materials and current production supplies",
        "label": "Current raw materials and current production supplies",
        "terseLabel": "Raw materials and consumables"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax assets, current",
        "terseLabel": "Income tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "terseLabel": "Current tax (expense)/income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense (income) and adjustments for current tax of prior periods",
        "terseLabel": "Current tax expense (income) and adjustments for current tax of prior periods",
        "totalLabel": "Current tax expense (income) and adjustments for current tax of prior periods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]"
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense (income) and adjustments for current tax of prior periods [abstract]",
        "terseLabel": "Tax on profit/(loss) for the year:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "terseLabel": "Income tax payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "terseLabel": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r254"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r314",
      "r403"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r314",
      "r403"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r405"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r405"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r407"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r405"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r309",
      "r398"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r310",
      "r399"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r310",
      "r399"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r308",
      "r397"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r400"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r402"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r314",
      "r403"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r317",
      "r406"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r404"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r312",
      "r401"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "DE",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "country_DK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "DK",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DENMARK",
        "terseLabel": "Denmark [member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_DKK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "DKK",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denmark, Kroner",
        "terseLabel": "Danish Kroner (DKK) [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DecreaseInTaxLosseCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DecreaseInTaxLosseCarryForwards",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in tax losse carry forwards",
        "documentation": "Decrease in tax losse carry forwards.",
        "terseLabel": "Decrease in tax losse carry forwards"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deductible temporary differences for which no deferred tax asset is recognised",
        "terseLabel": "Other temporary differences, assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "asnd_DeferredTaxAssetNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DeferredTaxAssetNotRecognized",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset, not recognized.",
        "label": "Deferred tax asset not recognized",
        "terseLabel": "Deferred tax asset, not recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r17",
      "r47"
     ]
    },
    "asnd_DeferredTaxMovementForTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DeferredTaxMovementForTheYear",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax movement for the year.",
        "label": "Deferred Tax Movement for The Year",
        "terseLabel": "Deferred tax, movement for the year"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciations charges",
        "negatedLabel": "Depreciation charge"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r59"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "verboseLabel": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Derivative liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Expense",
        "documentation": "Derivative financial liabilities at fair value remeasurement recognized in financial expense.",
        "terseLabel": "Remeasurement loss of financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Income",
        "documentation": "Derivative financial liabilities at fair value remeasurement recognized in financial income.",
        "terseLabel": "Remeasurement gain of financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement recognized in financial income or expense",
        "label": "Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Income Or Expense",
        "documentation": "Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.",
        "verboseLabel": "Remeasurement gain of financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r279",
      "r282",
      "r291",
      "r298"
     ]
    },
    "asnd_DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for Expected Credit Losses on Financial Assets",
        "label": "Description of Accounting Policy for Allowance for Expected Credit Losses on Financial Assets [text block]",
        "documentation": "Description of accounting policy for allowance for expected credit losses on financial assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for borrowings [text block]",
        "terseLabel": "Convertible Senior Notes and Embedded Derivative Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForCashFlowsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for cash flows [text block]",
        "terseLabel": "Cash Flow Statement"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for cash flows."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "asnd_DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForChangesInAccountingPoliciesAndDisclosuresExpalanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Changes In Accounting Policies and Disclosures [policy text block]",
        "label": "Description Of Accounting Policy For Changes In Accounting Policies and Disclosures [policy text block]",
        "terseLabel": "Changes in Accounting Policies and Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for deferred revenues and contract liabilities.",
        "label": "Description of accounting policy for deferred revenues and contract liabilities explanatory [text block]",
        "terseLabel": "Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for depreciation under property, plant and equipment. [Refer: Property, plant and equipment]",
        "label": "Description of accounting policy for depreciation under property, plant and equipment explanatory",
        "terseLabel": "Schedule of Asset's Expected Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for diluted earnings per share.",
        "label": "Description of accounting policy for diluted earnings per share explanatory",
        "terseLabel": "Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Basic EPS"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for employee benefits [text block]",
        "terseLabel": "Share-based Incentive Programs"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForExpensesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for expenses [text block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for expenses."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for finance income and costs [text block]",
        "terseLabel": "Finance Income and Expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign Currency"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of assets [text block]",
        "terseLabel": "Impairment of Non-current Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of assets."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Income Taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]",
        "terseLabel": "Software"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociates",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for investment in associates [text block]",
        "terseLabel": "Investments in Associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investments in associates. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for issued capital [text block]",
        "terseLabel": "Shareholders' Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for measuring inventories [text block]",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "asnd_DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for other payables explanatory.",
        "label": "Description Of Accounting Policy For Other Payables Explanatory [Text Block]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DescriptionOfAccountingPolicyForPrepaymentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForPrepaymentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for prepayments explanatory.",
        "label": "Description of accounting policy for prepayments explanatory",
        "terseLabel": "Prepayments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "terseLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and Development Costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "asnd_DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for royalty funding liabilities text block.",
        "label": "Description of Accounting Policy for Royalty Funding Liabilities [Text Block]",
        "terseLabel": "Royalty Funding Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSubsidiariesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for subsidiaries [text block]",
        "terseLabel": "Consolidation Principles Subsidiaries"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for subsidiaries. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for trade and other payables [text block]",
        "terseLabel": "Trade Payables and Accrued Expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for trade and other receivables [text block]",
        "terseLabel": "Receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "asnd_DescriptionOfBasisOfConsolidationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DescriptionOfBasisOfConsolidationExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Consolidation",
        "label": "Description Of Basis Of Consolidation [text block]",
        "documentation": "Description of basis of consolidation."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected volatility"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of initial application of standards or interpretations [text block]",
        "terseLabel": "New and Amended IFRS Accounting Standards and Interpretations"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "terseLabel": "Expected life of warrants (years)"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of vesting requirements for share-based payment arrangement",
        "terseLabel": "Vesting conditions"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "totalLabel": "Total diluted earnings (loss) per share",
        "terseLabel": "Diluted earnings/(loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85"
     ]
    },
    "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of convertible instruments on weighted average number of ordinary shares",
        "terseLabel": "Warrants outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed conversion of the entity's convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "asnd_DisclosureDetailedInformationAboutMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureDetailedInformationAboutMarketableSecuritiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Detailed Information About Marketable Securities LineItems.",
        "label": "Disclosure Detailed Information About Marketable Securities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureDetailedInformationAboutMarketableSecuritiesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure detailed information about marketable securities table.",
        "label": "Disclosure Detailed Information About Marketable Securities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure detailed information about marketable securities.",
        "label": "Disclosure Detailed Information About Marketable Securities [Text Block]",
        "verboseLabel": "Summary of Marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "verboseLabel": "Significant Accounting Judgements and Estimates"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "asnd_DisclosureOfAssociateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfAssociateLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of associate [Line Items]",
        "label": "Disclosure of Associate [Line Items]",
        "terseLabel": "Disclosure of associates [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfAssociatesAndJointVenturesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfAssociatesAndJointVenturesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information about associate and joint ventures associated with domain members defined in one or many axes of the table.",
        "label": "Disclosure of associates and joint ventures [line items]",
        "terseLabel": "Disclosure of associates and joint ventures [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAuditorsRemunerationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAuditorsRemunerationExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of auditors' remuneration [text block]",
        "terseLabel": "Principal Accountant Fees and Services"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of compensation to the entity's auditors."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of Preparation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "asnd_DisclosureOfBeneficialOwnershipAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfBeneficialOwnershipAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Beneficial Ownership [abstract]",
        "label": "Disclosure Of Beneficial Ownership [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfBeneficialOwnershipExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfBeneficialOwnershipExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/Ownership"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of beneficial ownership explanatory.",
        "label": "Disclosure Of Beneficial Ownership [text block]",
        "terseLabel": "Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfBeneficialOwnershipLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfBeneficialOwnershipLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Beneficial Ownership [line items]",
        "label": "Disclosure Of Beneficial Ownership [line items]",
        "terseLabel": "Disclosure of beneficial ownership [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfBeneficialOwnershipTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfBeneficialOwnershipTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Beneficial Ownership [table]",
        "label": "Disclosure Of Beneficial Ownership [table]",
        "terseLabel": "Disclosure Of Beneficial Ownership [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [line items]",
        "terseLabel": "Disclosure of changes in accounting estimates [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [table]",
        "terseLabel": "Disclosure of changes in accounting estimates [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the changes in accounting estimates."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting policies [text block]",
        "terseLabel": "Changes in Accounting Policies"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "terseLabel": "Summary of Number of Shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "asnd_DisclosureOfCommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfCommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of commitments and contingencies [line items]",
        "label": "Disclosure of commitments and contingencies [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfCommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfCommitmentsAndContingenciesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Commitments And Contingencies [table]",
        "label": "Disclosure Of Commitments And Contingencies [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of commitments and contingent liabilities [text block]",
        "terseLabel": "Commitments and Contingencies"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "asnd_DisclosureOfDetailedInformationAboutDepreciationsCharges": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutDepreciationsCharges",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about depreciations charges.",
        "label": "Disclosure of detailed information about depreciations charges",
        "terseLabel": "Summary of Depreciation Charges"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutDepreciationsChargesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about depreciations charges [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfDetailedInformationAboutDepreciationsChargesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutDepreciationsChargesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about depreciations charges [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Detailed Information About Development in provisions [Explanatory]",
        "terseLabel": "Summary of Development in Provisions",
        "documentation": "Disclosure of deiailed information about development in provisions."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about employee cost.",
        "label": "Disclosure Of Detailed Information About Employee Cost Explanatory [Text Block]",
        "terseLabel": "Summary of Employee Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Summary of Property, Plant and Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "asnd_DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PrincipalAccountantFeesAndServicesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information for principal accountant fees and service explanatory.",
        "label": "Disclosure of Detailed Information For Principal Accountant Fees and Service Explanatory [Text Block]",
        "terseLabel": "Summary of Principal Accountant Fees and Services"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfDevelopmentInLeaseLiabilitiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Development in Borrowings Related to Financing Activities",
        "documentation": "Disclosure of development in lease liabilities.",
        "label": "Disclosure of development in lease liabilities [Text Block]",
        "terseLabel": "Summary of Development In Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/EmployeeCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of employee benefits [text block]",
        "terseLabel": "Employee costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "asnd_DisclosureOfEmployeeCompensationCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfEmployeeCompensationCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of employees compensation costs.",
        "label": "Disclosure of employee compensation costs [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfEmployeeCompensationCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfEmployeeCompensationCostsLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of employee compensation costs.",
        "label": "Disclosure of employee compensation costs [line items]",
        "terseLabel": "Disclosure of employee compensation costs [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfEmployeeCompensationCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfEmployeeCompensationCostsTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of employee compensation cost.",
        "label": "Disclosure of employee compensation costs [table]",
        "terseLabel": "Disclosure of employee compensation costs [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of entity's operating segments [text block]",
        "terseLabel": "Segment Information"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent Events"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "asnd_DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Expenses Relating To Lease Activities In The Consolidated Statements.",
        "label": "Disclosure of Expenses Relating To Lease Activities In The Consolidated Statements",
        "terseLabel": "Summary of Expenses, Related To Lease Activities In The Consolidated Statements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of finance income (cost) [text block]",
        "terseLabel": "Schedule of Finance Income and Finance Expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities",
        "documentation": "Disclosure Of Financial Assets And Liabilities [text block]",
        "label": "Disclosure Of Financial Assets And Liabilities [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Risk Management",
        "documentation": "Entire disclosure of financial instruments and financial risk management.",
        "label": "Disclosure Of Financial Instruments And Financial Risk Management [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [text block]",
        "terseLabel": "Summary Of Rate Structure Of Marketable Securities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial instruments by type of interest rate. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial instruments, by type of interest rate."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial Assets and Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]",
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]",
        "terseLabel": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r211",
      "r219"
     ]
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Risk Management",
        "label": "Disclosure of financial risk management [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "asnd_DisclosureOfForeignCurrencySensitivityAnalysisExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfForeignCurrencySensitivityAnalysisExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of foreign currency sensitivity analysis explanatory [text block]",
        "label": "Disclosure of foreign currency sensitivity analysis explanatory [text block]",
        "terseLabel": "Summary of Foreign Currency Sensitivity Analysis"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/GeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "General Information"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "asnd_DisclosureOfGeneralInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfGeneralInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of General Information [Abstract]",
        "documentation": "Disclosure of general information."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue (geographical)",
        "label": "Disclosure of geographical areas [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGoingConcernExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGoingConcernExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of going concern [text block]",
        "terseLabel": "Going Concern"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfHoldingOfTreasurySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of holding of treasury shares.",
        "label": "Disclosure Of Holding Of Treasury Shares [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfHoldingOfTreasurySharesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of holding of treasury shares.",
        "label": "Disclosure Of Holding Of Treasury Shares [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfHoldingOfTreasurySharesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of holding of treasury shares.",
        "label": "Disclosure Of Holding Of Treasury Shares [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Tax on Profit/(Loss) for the Year and Deferred Tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Summary of Fair Values for Warrant Grants"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "asnd_DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfInformationAboutMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingExplanatoryTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Marketable Securities Specified By Investment Grade Credit Rating",
        "documentation": "Disclosure of information about marketable securities specified by investment grade credit rating explanatory.",
        "label": "Disclosure Of Information About Marketable Securities Specified By Investment Grade Credit Rating Explanatory [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets [text block]",
        "terseLabel": "Intangible Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]",
        "terseLabel": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInterestsInOtherEntitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprises"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of interests in other entities [text block]",
        "terseLabel": "Investments in Group Enterprises"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for interests in other entities."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of investments accounted for using equity method [text block]",
        "terseLabel": "Schedule of Financial Information of Investments in Associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178"
     ]
    },
    "asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of marketable securities specified by investment grade credit rating.",
        "label": "Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of marketable securities specified by investment grade credit rating.",
        "label": "Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of marketable securities specified by investment grade credit rating.",
        "label": "Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Movements in Level Three Fair Value Measurements [Table Text Block]",
        "documentation": "Disclosure of movements in level 3 fair value measurements.",
        "terseLabel": "Movements in Level 3 Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Summary of Weighted Average Exercise Prices and Movements in Warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]",
        "terseLabel": "Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets and financial liabilities [text block]",
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "Disclosure of intangible assets, and property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue",
        "label": "Disclosure of operating segments [line items]",
        "terseLabel": "Disclosure of operating segments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [table]",
        "terseLabel": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_DisclosureOfPerformanceObligationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPerformanceObligationsLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of performance obligations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_DisclosureOfProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfProvisionsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of provisions [text block]",
        "terseLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "asnd_DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of quantitative Information about inventories explanatory.",
        "label": "Disclosure of Quantitative Information about Inventories Explanatory [Table Text Block]",
        "terseLabel": "Summary of Inventories Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]",
        "terseLabel": "Summary of Goodwill and Software"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Development in Borrowings Related to Financing Activities",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related Party Transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of revenue [text block]",
        "terseLabel": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of revenue from contracts with customers [text block]",
        "terseLabel": "Schedule of Revenue Attributable to Commercial Customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165"
     ]
    },
    "asnd_DisclosureOfRevenueToCommercialCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfRevenueToCommercialCustomersExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Revenue to Commercial Customers Explanatory",
        "documentation": "Disclosure of revenue to commercial customers explanatory.",
        "terseLabel": "Schedule of Revenue Attributable to Commercial Customers by Product"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of segment revenues by destination of major customers explanatory.",
        "label": "Disclosure of segment revenues by destination of major customers explanatory",
        "terseLabel": "Schedule of Revenue Recognized in Consolidated Statement of Profit or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSharebasedPaymentArrangementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfSharebasedPaymentArrangementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Sharebased Payment Arrangements [Abstract]",
        "documentation": "Disclosure of sharebased payment arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPayment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based Payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [text block]",
        "terseLabel": "Investments in Associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of associates. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r150"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [table]",
        "terseLabel": "Disclosure of associates [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to associates."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r150"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [text block]",
        "terseLabel": "Summary of Investments in Group Enterprises"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r149"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]",
        "terseLabel": "Disclosure of subsidiaries [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]",
        "terseLabel": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r149"
     ]
    },
    "asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfSummaryOfFairValueHierarchyTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value Hierarchy",
        "label": "Disclosure of Summary of Fair Value Hierarchy [Table Text Block]",
        "documentation": "Disclosure of summary of fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of summary of significant accounting policies [abstract]",
        "label": "Disclosure of summary of significant accounting policies [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items representing the disclosure of summary of significant accounting policies.",
        "label": "Disclosure Of Summary Of Significant Accounting Policies [line items]",
        "terseLabel": "Disclosure of summary of significant accounting policies [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of summary of significant accounting policies [table]",
        "label": "Disclosure of summary of significant accounting policies [table]",
        "terseLabel": "Disclosure of summary of significant accounting policies [table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Summary Of Significant Accounting Policy Explanatory",
        "documentation": "Disclosure of summary of significant accounting policy.",
        "terseLabel": "Summary of Material Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Summary of Tax on Profit/Loss and Deferred Tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_DisclosureOfTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTreasurySharesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of treasury shares [text block]",
        "terseLabel": "Summary Of Holding Of Treasury Shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of voluntary change in accounting policy [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfWarrantActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DisclosureOfWarrantActivityLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Warrant Activity [line items]",
        "label": "Disclosure Of Warrant Activity [line items]",
        "terseLabel": "Disclosure Of Warrant Activity [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsIntangibleAssetsAndGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals, intangible assets and goodwill",
        "label": "Disposals, intangible assets and goodwill",
        "terseLabel": "Disposals"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets and goodwill resulting from disposals. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "negatedLabel": "Disposals"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "asnd_DistributableEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "DistributableEquity",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributable equity.",
        "label": "Distributable equity",
        "terseLabel": "Distributable equity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r329"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "terseLabel": "Document Financial Statement Error Correction",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r329",
      "r372"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on balances held in foreign currencies",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109"
     ]
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total employee costs",
        "negatedLabel": "Employee benefits expense",
        "label": "Employee benefits expense",
        "totalLabel": "Total employee costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r39",
      "r249"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "EmployeesAndConsultantsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and consultants.",
        "label": "Employees and Consultants [Member]",
        "terseLabel": "Employees and consultants [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EnforceableLeaseterm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "EnforceableLeaseterm",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enforceable Lease Term",
        "documentation": "Enforceable leaseterm.",
        "label": "Enforceable LeaseTerm"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities Affiliated With Artisan Partners Limited Partnership.",
        "label": "Entities Affiliated With Artisan Partners Limited Partnership [Member]",
        "terseLabel": "Entities affiliated with Artisan Partners Limited Partnership [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EntitiesAffiliatedWithFmrLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "EntitiesAffiliatedWithFmrLlcMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities affiliated with FMR LLC.",
        "label": "Entities Affiliated With FMR LLC [member]",
        "terseLabel": "Entities affiliated with FMR LLC [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EntitiesAffiliatedWithJanusHendersonGroupPlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "EntitiesAffiliatedWithJanusHendersonGroupPlcMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities affiliated with Janus Henderson Group plc.",
        "label": "Entities Affiliated With Janus Henderson Group plc [Member]",
        "terseLabel": "Entities affiliated with Janus Henderson Group plc [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EntitiesAffiliatedWithRaCapitalManagementLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "EntitiesAffiliatedWithRaCapitalManagementLlcMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities affiliated with RA capital management LLC.",
        "label": "Entities Affiliated With RA Capital Management LLC [member]",
        "terseLabel": "Entities affiliated with RA capital management LLC [member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity",
        "periodStartLabel": "Equity",
        "terseLabel": "Equity",
        "totalLabel": "Total equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r24",
      "r124",
      "r126",
      "r151",
      "r152",
      "r154"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "Equity and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r333",
      "r343",
      "r376"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r330",
      "r340",
      "r373"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe [member]",
        "label": "Europe [Member]",
        "verboseLabel": "Europe (excluding Denmark) [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EventsAfterReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "EventsAfterReportingPeriodMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Events after reporting period.",
        "label": "Events After Reporting Period [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ExchangeRateForPercentageOfNetSalesToRoyaltyPayment",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenue from sales interest payment in percentage in exchange for funding",
        "label": "Exchange Rate For Percentage Of Net Sales To Royalty Payment",
        "documentation": "Exchange rate for percentage of net sales to royalty payment."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ExchangeRateForPercentageOfRevenueToRoyaltyPayment",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate for percentage of revenue to royalty payment.",
        "label": "Exchange Rate For Percentage Of Revenue To Royalty Payment",
        "terseLabel": "Revenue interest payment in percentage in exchange for funding"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ExecutiveBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ExecutiveBoardMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive board.",
        "label": "Executive Board [member]",
        "terseLabel": "Executive Board [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options",
        "terseLabel": "Exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "asnd_ExpectedLeaseCommenceYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ExpectedLeaseCommenceYear",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Lease Commence Year",
        "documentation": "Expected lease commence year.",
        "label": "Expected Lease Commence Year"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected revenue recognition period from non-current contract liabilities .",
        "label": "Expected Revenue Recognition Period From Non-current Contract Liabilities",
        "terseLabel": "Expected revenue recognition period from non-current contract liabilities ."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term leases and leases of low value assets",
        "label": "Expense relating to short-term leases for which recognition exemption has been used"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_ExternalCreditGradesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExternalCreditGradesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External credit grades [axis]",
        "terseLabel": "External credit grades [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r296"
     ]
    },
    "ifrs-full_ExternalCreditGradesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExternalCreditGradesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External credit grades [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'External credit grades' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r296"
     ]
    },
    "asnd_EyconisIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "EyconisIncMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eyconis Inc [member]",
        "documentation": "Eyconis Inc.",
        "terseLabel": "Eyconis Inc.",
        "verboseLabel": "Eyconis"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EyconisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "EyconisMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eyconis [Member]",
        "documentation": "Eyconis.",
        "terseLabel": "Eyconis"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FairValueHierarchyCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FairValueHierarchyCarryingAmountMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [member]",
        "label": "Fair Value Hierarchy Carrying Amount [member]",
        "documentation": "Fair value hierarchy carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FairValueOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FairValueOfConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of convertible notes.",
        "label": "Fair Value of Convertible Notes",
        "terseLabel": "Fair value of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FairValueOfRoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FairValueOfRoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of royalty funding liabilities.",
        "label": "Fair Value of Royalty Funding Liabilities",
        "terseLabel": "Fair value of royalty funding liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FairValueOfWarrantsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FairValueOfWarrantsGranted",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Warrants Granted",
        "label": "Fair Value Of Warrants Granted",
        "terseLabel": "Fair value of warrants granted in the year"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance costs",
        "label": "Finance costs",
        "terseLabel": "Reversal of finance expenses",
        "totalLabel": "Total finance expenses",
        "verboseLabel": "Finance expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCostsPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance costs paid, classified as operating activities",
        "negatedLabel": "Finance expenses paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "asnd_FinanceExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FinanceExpensesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance expenses.",
        "label": "Finance Expenses [Abstract]",
        "terseLabel": "Finance expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income",
        "totalLabel": "Total finance income",
        "negatedLabel": "Reversal of finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "asnd_FinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FinanceIncomeAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance income.",
        "label": "Finance Income [Abstract]",
        "terseLabel": "Finance income"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FinanceIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FinanceIncomeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance income expense [abstract].",
        "label": "Finance income expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income received, classified as operating activities",
        "terseLabel": "Finance income received"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]"
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "periodEndLabel": "Financial assets at end of period",
        "periodStartLabel": "Financial assets at beginning of period",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r209",
      "r210",
      "r212",
      "r290"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost",
        "totalLabel": "Financial assets measured at amortized cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, class [member]",
        "terseLabel": "Financial assets at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValueMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets at fair value, class [member]",
        "terseLabel": "Financial assets at fair value, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at fair value class. [Refer: Financial assets; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_FinancialAssetsAvailableforsale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAvailableforsale",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets available-for-sale",
        "terseLabel": "Financial marketable securities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-derivative financial assets that are designated as available for sale or are not classified as (a) loans and receivables; (b) held-to-maturity investments; or (c) financial assets at fair value through profit or loss. [Refer: Derivative financial assets; Financial assets at fair value through profit or loss; Held-to-maturity investments]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial liabilities",
        "label": "Financial liabilities",
        "totalLabel": "Total financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCost",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial liabilities measured at amortized cost",
        "label": "Financial liabilities at amortised cost",
        "terseLabel": "Financial liabilities measured at amortized cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, class [member]",
        "terseLabel": "Financial liabilities at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities measured at fair value through profit or loss",
        "label": "Financial liabilities at fair value through profit or loss",
        "totalLabel": "Financial liabilities measured at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as \u2018an accounting mismatch\u2019) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity\u2019s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current finished goods",
        "terseLabel": "Finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r436"
     ]
    },
    "ifrs-full_FixedInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FixedInterestRateMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Coupon fixed rate structure [member]",
        "terseLabel": "Fixed interest rate [member]",
        "label": "Fixed interest rate [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ifrs-full_FloatingInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FloatingInterestRateMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floating interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a non-fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "asnd_ForeignCurrencyConversionOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ForeignCurrencyConversionOptionMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Conversion Option.",
        "label": "Foreign Currency Conversion Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ForeignCurrencyRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ForeignCurrencyRiskAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency risk.",
        "label": "Foreign Currency Risk [axis]",
        "terseLabel": "Foreign Currency Risk [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ForeignCurrencyRiskDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ForeignCurrencyRiskDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency risk domain.",
        "label": "Foreign Currency Risk [domain]",
        "terseLabel": "Foreign Currency Risk [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ForeignCurrencyTargetPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ForeignCurrencyTargetPercentage",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Target Percentage",
        "label": "Foreign Currency Target Percentage",
        "terseLabel": "Foreign currency target percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r337",
      "r347",
      "r380"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r337",
      "r347",
      "r380"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r337",
      "r347",
      "r380"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r337",
      "r347",
      "r380"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r337",
      "r347",
      "r380"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "asnd_FrazierLifeSciencesOfEyconisIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FrazierLifeSciencesOfEyconisIncMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frazier Life Sciences of Eyconis, Inc.",
        "label": "Frazier Life Sciences of Eyconis, Inc. [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FundingReceivedInExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FundingReceivedInExchange",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding received in exchange.",
        "label": "Funding Received In Exchange",
        "terseLabel": "Funding received in exchange",
        "verboseLabel": "Funding received in exchange of royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FundingReceivedInExchangeOfRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "FundingReceivedInExchangeOfRoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding received in exchange of royalty payments.",
        "label": "Funding received in exchange of royalty payments",
        "terseLabel": "Funding received in exchange of royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "GB",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (losses) on change in value of foreign currency basis spreads, before tax",
        "terseLabel": "Equity before tax",
        "verboseLabel": "Profit/(loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on change in value of foreign currency basis spreads, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net gains (losses) on disposals of property, plant and equipment",
        "label": "Gains (losses) on disposals of property, plant and equipment",
        "terseLabel": "Reversal of (gain)/loss on disposal of property, plant and equipment",
        "negatedLabel": "Reversal of (gain)/loss on disposal of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_GainsOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains on change in fair value of derivatives",
        "terseLabel": "Fair value gains, derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]",
        "terseLabel": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r261",
      "r284",
      "r287"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r261",
      "r284",
      "r287"
     ]
    },
    "asnd_Germany1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "Germany1Member",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Germany [Member].",
        "label": "Germany [member]",
        "terseLabel": "Germany [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods or services transferred at point in time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredOverTimeMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods or services transferred over time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodwillMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [member]",
        "terseLabel": "Goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "asnd_GrantedBeforeJanuary12022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "GrantedBeforeJanuary12022Member",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted Before January 1 2022 [member]",
        "documentation": "Granted before january 1, 2022.",
        "terseLabel": "Granted before January 1, 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_GrantedIn2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "GrantedIn2022Member",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted In 2022 [Member]",
        "documentation": "Granted In 2022."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_GrantedIn2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "GrantedIn2023Member",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted in 2023 member.",
        "label": "Granted in 2023 [Member]",
        "terseLabel": "Granted in 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_GrantedInTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "GrantedInTwoThousandTwentyFourMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted in Two Thousand Twenty Four [member]",
        "documentation": "Granted in two thousand twenty four.",
        "terseLabel": "Granted in 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r51",
      "r93",
      "r102",
      "r105",
      "r198",
      "r210",
      "r212",
      "r290"
     ]
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Gross profit",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HedgingInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hedging instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r203"
     ]
    },
    "ifrs-full_HedgingInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HedgingInstrumentsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hedging instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r203"
     ]
    },
    "asnd_HighGradeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "HighGradeMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "High grade member.",
        "label": "High Grade [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Historical volatility for shares, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r329"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment loss recognised in profit or loss, intangible assets and goodwill",
        "label": "Impairment loss recognised in profit or loss, intangible assets and goodwill",
        "terseLabel": "Impairment charge"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "negatedTerseLabel": "Impairment charge"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r54"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncomeStatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncomeStatementAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement [Axis].",
        "label": "Income Statement [Axis]",
        "terseLabel": "Income Statement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncomeStatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncomeStatementDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement.",
        "label": "Income Statement [Domain]",
        "terseLabel": "Income Statement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax income (expense)",
        "label": "Tax expense (income)",
        "negatedTotalLabel": "Tax on profit/(loss) for the year",
        "terseLabel": "Reversal of income taxes (expenses)",
        "negatedLabel": "Income taxes (expenses)",
        "totalLabel": "Tax on profit/(loss) for the year"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r34",
      "r42",
      "r43",
      "r44",
      "r73",
      "r148",
      "r232"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefund",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income taxes paid (refund)",
        "label": "Income taxes paid (refund)",
        "negatedLabel": "Income taxes refund"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes refund (paid)",
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedLabel": "Income taxes received/(paid)"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r110",
      "r266"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Increase/(decrease) in cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCreditDerivativeFairValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in credit derivative, fair value",
        "totalLabel": "Total increase (decrease) in credit derivative, fair value",
        "terseLabel": "Increase decrease in derivative financial liabilities fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the fair value of a credit derivative. [Refer: Credit derivative, fair value]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions",
        "documentation": "Increase decrease in derivative financial liabilities fair value.",
        "label": "Increase Decrease In Derivative Financial Liabilities Fair Value",
        "terseLabel": "Increase decrease in derivative financial liabilities fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInExistingProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions related to prior years",
        "label": "Increase in existing provisions, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in existing other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "asnd_IncreaseDecreaseInForeignCurrencyExchangeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncreaseDecreaseInForeignCurrencyExchangeRate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase in foreign currency exchange rate",
        "documentation": "Increase decrease in foreign currency exchange rate.",
        "label": "Increase Decrease In Foreign Currency Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfNumberOfSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in number of ordinary shares issued",
        "terseLabel": "Increase through cash contributions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquired from third-parties (Holding)",
        "documentation": "Increase decrease In treasury shares acquired from third parties.",
        "label": "Increase Decrease In Treasury Shares Acquired From Third Parties",
        "terseLabel": "Acquired from third-parties (Holding)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred under stock incentive programs (Holding)",
        "label": "Increase Decrease In Treasury Shares Transferred Under Stock Incentive Program",
        "documentation": "Increase decrease in treasury shares transferred under stock incentive program."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of interest",
        "label": "Increase Decrease Through Effect Of Accretion of Interest Liabilities Arising From Financing Activities",
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of accretion of interest."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities",
        "terseLabel": "Foreign exchange translation"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "asnd_IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Effect Of Proceeds, Liabilities Arising From Financing Activities",
        "documentation": "Increase (decrease) through effect of proceeds, liabilities arising from financing activities.",
        "negatedTerseLabel": "Net proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Remeasurements",
        "label": "Increase Decrease Through Effect Of Remeasurements Arising From Financing Activities",
        "documentation": "increase decrease through effect of remeasurements arising from financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments",
        "label": "Increase Decrease Through Effect Of Repayments, Liabilities Arising From Financing Activities",
        "documentation": "Increase (decrease) through effect of repayments, liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill",
        "terseLabel": "Foreign exchange translation"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, other provisions",
        "terseLabel": "Foreign exchange translation"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment",
        "terseLabel": "Foreign exchange translation"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based payment (Note 7)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transactions with owners, equity",
        "terseLabel": "Capital increase"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill",
        "terseLabel": "Transferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, property, plant and equipment",
        "terseLabel": "Transferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r337",
      "r347",
      "r371",
      "r380",
      "r384",
      "r392"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r307",
      "r396"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r307",
      "r396"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r307",
      "r396"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/IntangibleAssetsSummaryOfGoodwillDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total intangible assets and goodwill",
        "label": "Intangible assets and goodwill",
        "periodEndLabel": "Intangible assets at ending period",
        "periodStartLabel": "Intangible assets at beginning period",
        "terseLabel": "Intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "terseLabel": "Interest expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r231",
      "r238"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease interest",
        "verboseLabel": "Accretion of interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_InterestRateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestRateRiskMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate risk [member]",
        "label": "Interest rate risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r226"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventories, net",
        "label": "Current inventories",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r252"
     ]
    },
    "asnd_InventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "InventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories.",
        "label": "Inventories [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InventoriesTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InventoriesTotal",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "totalLabel": "Total inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_InventoryWritedown2011": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InventoryWritedown2011",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "terseLabel": "Inventory write-downs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r66"
     ]
    },
    "ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentsAccountedForUsingEquityMethodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsInAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentsInAssociates",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in associates reported in separate financial statements",
        "terseLabel": "Investments in associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates in an entity's separate financial statements. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "asnd_InvestmentsInGroupEnterprisesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "InvestmentsInGroupEnterprisesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in group enterprises.",
        "label": "Investments In Group Enterprises [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total issued capital",
        "label": "Issued capital",
        "terseLabel": "Share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued Capital [member]",
        "label": "Issued capital [member]",
        "terseLabel": "Share Capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel of entity or parent [member]",
        "terseLabel": "Key management personnel of entity or parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than one year and not later than five years [member]",
        "terseLabel": "Within 1 to 5 years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r297"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than three years and not later than five years [member]",
        "terseLabel": "After 5 years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r297"
     ]
    },
    "asnd_LeaseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "LeaseExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfExpensesRelatedToLeaseActivitiesInTheConsolidatedStatementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expenses.",
        "label": "Lease Expenses",
        "totalLabel": "Total lease expenses"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_LeaseExtensionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "LeaseExtensionPeriod",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Extension Period.",
        "label": "Lease Extension Period",
        "terseLabel": "Optional Lease Extension Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Lease liabilities",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period",
        "verboseLabel": "Lease liabilities",
        "terseLabel": "Carrying amount of lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r277"
     ]
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements [member]",
        "terseLabel": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [member]",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r89",
      "r90",
      "r152"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [member]",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r152"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [member]",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r152"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r152"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r152"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "periodEndLabel": "Liabilities at end of period",
        "negatedLabel": "Liabilities",
        "periodStartLabel": "Liabilities at beginning of period",
        "label": "Liabilities",
        "terseLabel": "Total liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r151",
      "r152",
      "r154",
      "r233",
      "r237"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [axis]",
        "terseLabel": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "ifrs-full_LicenceFeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LicenceFeeIncome",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Licenses",
        "label": "Licence fee income",
        "terseLabel": "\"Right-to-use\" licenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from licence fees."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "asnd_LicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "LicensesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses member.",
        "label": "Licenses [Member]",
        "terseLabel": "Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_LicensesOfIpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "LicensesOfIpMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses of IP member.",
        "label": "Licenses of IP [Member]",
        "terseLabel": "Licenses of IP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiquidityRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiquidityRiskMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity risk [member]",
        "terseLabel": "Liquidity risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r288"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "totalLabel": "Total non-current portion of non-current borrowings",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "ifrs-full_LongtermBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LongtermBorrowingsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfDevelopmentInBorrowingsArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term borrowings [member]",
        "terseLabel": "Borrowings (excluding lease liabilities) [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r277"
     ]
    },
    "ifrs-full_LossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LossesOnChangeInFairValueOfDerivatives",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value loss, derivatives",
        "label": "Losses on change in fair value of derivatives",
        "negatedLabel": "Losses on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "asnd_LowerMediumGradeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "LowerMediumGradeMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower medium grade.",
        "label": "Lower Medium Grade [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major customers [axis]",
        "terseLabel": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorCustomersDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major customers [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "asnd_MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major persons or groups of affiliated persons holding minimum beneficial ownership.",
        "label": "Major persons or groups of affiliated persons holding minimum beneficial ownership",
        "terseLabel": "Minimum beneficial ownership"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MarketableSecurities1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "MarketableSecurities1",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable securities1",
        "documentation": "Marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MarketableSecuritiesExplanatory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "MarketableSecuritiesExplanatory",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities explanatory.",
        "label": "Marketable Securities Explanatory",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MarketableSecuritiesNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "MarketableSecuritiesNonCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities non current assets",
        "documentation": "Marketable securities non current assets.",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r163",
      "r175",
      "r176",
      "r179",
      "r180",
      "r182",
      "r188",
      "r202",
      "r216",
      "r262",
      "r293"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r163",
      "r175",
      "r176",
      "r179",
      "r180",
      "r182",
      "r188",
      "r202",
      "r262",
      "r293",
      "r295"
     ]
    },
    "asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum additional development and regulatory milestones potentially to be received.",
        "label": "Maximum additional development and regulatory milestones potentially to be received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r104",
      "r151"
     ]
    },
    "ifrs-full_MeasurementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MeasurementDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r104",
      "r151"
     ]
    },
    "asnd_MilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "MilestonesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones member.",
        "label": "Milestones [Member]",
        "terseLabel": "Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MinimumBeneficialOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "MinimumBeneficialOwnershipPercentage",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum beneficial ownership percentage.",
        "label": "Minimum Beneficial Ownership Percentage",
        "terseLabel": "Minimum beneficial ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "MultipleOfPurchasePriceWereRoyaltyPaymentWillCease",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Multiple of purchase price, were royalty payment will cease.",
        "label": "Multiple Of Purchase Price, Were Royalty Payment Will Cease",
        "terseLabel": "Multiple of the purchase price were royalty payment will cease"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NameOfAssociate": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NameOfAssociate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of associate",
        "terseLabel": "Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The name of an associate. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r75",
      "r79",
      "r134"
     ]
    },
    "ifrs-full_NameOfJointOperation": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NameOfJointOperation",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of joint operation",
        "terseLabel": "Minimum beneficial ownership"
       }
      },
      "en": {
       "role": {
        "documentation": "The name of a joint operation. [Refer: Total for all joint operations [member]]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_NameOfSubsidiary": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NameOfSubsidiary",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of subsidiary",
        "terseLabel": "Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The name of a subsidiary. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r75",
      "r79",
      "r129",
      "r131"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "terseLabel": "Total deferred tax assets/(liabilities) at December 31"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "ifrs-full_NetForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetForeignExchangeGain",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net foreign exchange gain",
        "terseLabel": "Foreign exchange translation (net)"
       }
      },
      "en": {
       "role": {
        "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r421",
      "r437"
     ]
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetForeignExchangeLoss",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net foreign exchange loss",
        "terseLabel": "Foreign exchange translation (net)"
       }
      },
      "en": {
       "role": {
        "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r421",
      "r437"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NetSettlementUnderStockIncentivePrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NetSettlementUnderStockIncentivePrograms",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net settlement under stock incentive programs.",
        "label": "Net settlement under stock incentive programs",
        "terseLabel": "Net settlement under stock incentive programs",
        "negatedLabel": "Net settlement under stock incentive programs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NewIFRSsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NewIFRSsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New IFRSs [axis]",
        "terseLabel": "New IFRSs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_NewIFRSsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NewIFRSsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New IFRSs [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for IFRSs that have been issued but are not yet effective. It also represents the standard value for the 'New IFRSs' axis if no other member is used. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_NewProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NewProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureProvisionsSummaryOfDevelopmentInProvisionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New provisions, other provisions",
        "terseLabel": "Net additions for the year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised for new other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "terseLabel": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NominalValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NominalValueAmount",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal Value Amount",
        "label": "Nominal Value Amount",
        "terseLabel": "Nominal positions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r337",
      "r347",
      "r371",
      "r380"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]",
        "terseLabel": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "terseLabel": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r139",
      "r278"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentParentheticalDetails",
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts",
        "terseLabel": "Intangible assets and property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Classes of financial instruments [domain]; Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current contract liabilities",
        "label": "Non-current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_NoncurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities",
        "label": "Non-current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "totalLabel": "Total non-current financial assets",
        "label": "Non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssetsAvailableforsale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentFinancialAssetsAvailableforsale",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial assets available-for-sale",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Non-current financial marketable securities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Non-current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "totalLabel": "Total non-current financial liabilities",
        "label": "Non-current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Carrying amount of non-current lease liabilities",
        "verboseLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "terseLabel": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r141",
      "r278"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial liabilities",
        "label": "Non-derivative financial liabilities, undiscounted cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "asnd_NonexecutiveseniorManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NonexecutiveseniorManagementMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-executive\u00a0Senior Management.",
        "label": "Nonexecutivesenior management [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NorthAmerica1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NorthAmerica1Member",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationSummaryOfIntangibleAssetsAndPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "North America 1 Member.",
        "label": "North America1 [Member]",
        "terseLabel": "North America [member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Within 1 year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r175",
      "r176",
      "r188",
      "r293",
      "r297"
     ]
    },
    "ifrs-full_NotesAndDebenturesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotesAndDebenturesIssued",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and debentures issued",
        "terseLabel": "Convertible senior notes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of notes and debentures issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Notional amount",
        "verboseLabel": "Nominal positions (net)",
        "negatedLabel": "Nominal positions (net)"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "asnd_NovoNordiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NovoNordiskMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novo Nordisk [member]",
        "documentation": "Novo Nordisk."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfAdditionalSharesAuthorizedToGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfAdditionalSharesAuthorizedToGrant",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized to grant.",
        "label": "Number of Additional Shares Authorized to Grant",
        "terseLabel": "Number of additional shares authorized to grant"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfAdditionalSharesGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfAdditionalSharesGranted",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares granted.",
        "label": "Number Of Additional Shares Granted",
        "terseLabel": "Number of additional shares granted"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfCommercialCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfCommercialCustomers",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of commercial customers.",
        "label": "Number of commercial customers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfEmployees",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of employees",
        "terseLabel": "Number of persons"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "asnd_NumberOfEmployees1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfEmployees1",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of employees1.",
        "label": "Number of employees1",
        "terseLabel": "Number of persons"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the year",
        "label": "Granted during the period",
        "verboseLabel": "Number of Warrants, Granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r458"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "negatedLabel": "Exercised during the year",
        "terseLabel": "Vesting specified by date"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments forfeited in share-based payment arrangement",
        "negatedLabel": "Forfeited during the year",
        "negatedTerseLabel": "Forfeited during the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Number of Warrants, Outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of other equity instruments settled in share based payment arrangement.",
        "label": "Number Of Other Equity Instruments Settled In Share Based Payment Arrangement",
        "terseLabel": "Settled during the period",
        "negatedLabel": "Settled during the year"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of other equity instruments transferred in share based payment arrangement.",
        "label": "Number Of Other Equity Instruments Transferred In Share Based Payment Arrangement",
        "terseLabel": "Transferred during the period",
        "negatedLabel": "Transferred during the year"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of other equity instruments vested in share-based payment arrangement.",
        "label": "Number of other equity instruments vested in share-based payment arrangement",
        "terseLabel": "Vested at the reporting date"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfReportableOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfReportableOperatingSegments",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reportable operating segments.",
        "label": "Number of reportable operating segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfNumberOfSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total number of shares issued",
        "label": "Number of shares issued",
        "periodEndLabel": "Share capital end of year",
        "periodStartLabel": "Share capital beginning of year",
        "terseLabel": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodStartLabel": "Number of shares outstanding at beginning of period",
        "periodEndLabel": "Number of shares outstanding at end of period",
        "terseLabel": "Numebr of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "asnd_NumberOfTreasurySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfTreasurySharesOutstanding",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (Holding)",
        "periodEndLabel": "Ending balance (Holding)",
        "documentation": "Number of treasury shares outstanding.",
        "label": "Number Of Treasury Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "NumberOfWarrantsOutstanding",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants outstanding",
        "documentation": "Number of warrants outstanding.",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_OfficeFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "OfficeFacilityMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office facility.",
        "label": "Office Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]",
        "terseLabel": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Exchange differences on translating foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r35"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "totalLabel": "Other comprehensive income/(loss) for the year, net of tax",
        "verboseLabel": "Other comprehensive income/(loss), net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258"
     ]
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current financial liabilities",
        "totalLabel": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r145"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "asnd_OtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "OtherCurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Abstract]",
        "documentation": "Other current liabilities abstract.",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_OtherEmployeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherEmployeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other employee expense",
        "terseLabel": "Other employee costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "asnd_OtherEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "OtherEquipmentMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other equipment Member",
        "label": "Other equipment [Member]",
        "verboseLabel": "Other equipment [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial liabilities",
        "terseLabel": "Other liabilities (excluding indirect tax and employee related payables)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_OtherNoncurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current receivables",
        "terseLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other property, plant and equipment [member]",
        "terseLabel": "Other equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "terseLabel": "Other receivables (excluding indirect tax receivables)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)",
        "terseLabel": "Other effects including effect of different tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r335",
      "r345",
      "r378"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r338",
      "r348",
      "r381"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r338",
      "r348",
      "r381"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value per share",
        "terseLabel": "Nominal value common shares",
        "verboseLabel": "Share nominal value"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "PaymentOfWithholdingTaxesUnderStockIncentivePrograms",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of withholding taxes under stock incentive programs.",
        "label": "Payment Of Withholding Taxes Under Stock Incentive Programs",
        "negatedLabel": "Payment of withholding taxes under stock incentive programs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Costs of follow-on public offering",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Payment of principal portion of lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to acquire or redeem entity's shares",
        "negatedLabel": "Acquisitions of treasury shares, net of transaction costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "asnd_PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "PercentageOfEachTrancheDirectlyAttributableToAccomplishmentOfFinancialResultsAchievedInFinancialYearPriorToVestingDate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of each tranche directly attributable to accomplishment of financial results achieved in financial year prior to vesting date.",
        "label": "Percentage of Each Tranche Directly Attributable to Accomplishment of Financial Results Achieved in Financial Year Prior to Vesting Date",
        "terseLabel": "Percentage of each tranche directly attributable to accomplishment of financial results achieved in financial year prior to vesting date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of entity's revenue",
        "terseLabel": "Percentage of entity's revenue",
        "verboseLabel": "Perentage of sale to commercial customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of reasonably possible increase in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "asnd_PercentageOfWarrantsVested": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "PercentageOfWarrantsVested",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of warrants vested.",
        "label": "Percentage Of Warrants Vested",
        "terseLabel": "Percentage of warrants vested"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PerformanceObligationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PerformanceObligationsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance obligations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_PerformanceObligationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PerformanceObligationsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance obligations [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "asnd_PerformanceStockUnitProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "PerformanceStockUnitProgramMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance stock unit program member.",
        "label": "Performance Stock Unit Program [Member]",
        "terseLabel": "Performance Stock Unit Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "PerformanceStockUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance stock units.",
        "label": "Performance Stock Units [Member]",
        "terseLabel": "Performance Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PlantAndMachineryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "PlantAndMachineryMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plant and machinery.",
        "label": "Plant and machinery [member]",
        "terseLabel": "Plant and machinery [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total post-employment benefit expense in profit or loss, defined benefit plans",
        "label": "Post-employment benefit expense in profit or loss, defined benefit plans",
        "terseLabel": "Pensions (defined contribution plans)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [domain]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434"
     ]
    },
    "asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible notes",
        "documentation": "Potential conversion of convertible senior notes into number of ordinary shares.",
        "label": "Potential Conversion Of Convertible Senior Notes Into Number Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_Prime1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "Prime1Member",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime [Member]",
        "label": "Prime1 [Member]",
        "documentation": "Prime1."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PrincipalPlaceOfBusinessOfAssociate": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PrincipalPlaceOfBusinessOfAssociate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal place of business of associate",
        "terseLabel": "Principal place of business"
       }
      },
      "en": {
       "role": {
        "documentation": "The principal place of business of an associate. [Refer: Principal place of business; Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r80",
      "r135"
     ]
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Net proceeds from borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "terseLabel": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Issuance Of Notes",
        "label": "Proceeds from issue of bonds, notes and debentures"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "verboseLabel": "Proceeds from follow-on public offerings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from royalty funding liabilities excluding offering expenses.",
        "label": "Proceeds From Royalty Funding Liabilities Excluding Offering Expenses",
        "terseLabel": "Net proceeds after deduting offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of property, plant and equipment",
        "label": "Proceeds from sales of property, plant and equipment, classified as investing activities",
        "verboseLabel": "Proceeds from disposal of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities",
        "terseLabel": "Settlement of marketable securities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "asnd_ProcessPlantAndMachineryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ProcessPlantAndMachineryMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Process plant and machinery [member]",
        "label": "Process plant and machinery [member]",
        "terseLabel": "Process plant and machinery [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "totalLabel": "Net profit/(loss) for the year",
        "verboseLabel": "Net profit/(loss) for the year",
        "terseLabel": "Net profit/(loss) for the year"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r28",
      "r107",
      "r125",
      "r127",
      "r233",
      "r235",
      "r278",
      "r286"
     ]
    },
    "ifrs-full_ProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) [abstract]",
        "terseLabel": "Statement of profit or (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "totalLabel": "Attributable to owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "asnd_ProfitLossBeforeIncomeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ProfitLossBeforeIncomeTaxAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit loss before income tax.",
        "label": "Profit loss before income tax [abstract]",
        "terseLabel": "Tax for the year can be explained as follows:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Profit/(loss) before tax",
        "terseLabel": "Profit/(loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r249",
      "r250",
      "r299",
      "r300"
     ]
    },
    "asnd_ProfitLossForTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ProfitLossForTheYear",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit loss for the year.",
        "label": "Profit Loss For The Year",
        "verboseLabel": "Profit / (loss) for the year from continuing operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating profit/(loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r427"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property, plant and equipment",
        "label": "Property, plant and equipment",
        "periodEndLabel": "Property, plant and equipment at ending period",
        "periodStartLabel": "Property, plant and equipment at beginning period",
        "terseLabel": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Ownership",
        "verboseLabel": "Percentage of ownership in the customer company"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r136"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary",
        "terseLabel": "Ownership"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r133"
     ]
    },
    "ifrs-full_ProportionOfVotingPowerHeldInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfVotingPowerHeldInAssociate",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of voting rights held in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in an associate held by the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r136"
     ]
    },
    "ifrs-full_ProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProvisionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of financial instruments, classified as investing activities",
        "negatedLabel": "Purchase of marketable securities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of intangible assets and property, plant and equipment",
        "label": "Purchase of intangible assets and property, plant and equipment",
        "documentation": "Purchase of intangible assets and property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfInterestsInAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfInterestsInAssociates",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of interests in associates",
        "negatedLabel": "Investments in associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of interests in associates. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfTreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of treasury shares",
        "negatedLabel": "Acquisition of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "asnd_PurchaseOfTreasurySharesNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "PurchaseOfTreasurySharesNominalValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquired from third-parties (Nominal values)",
        "documentation": "Purchase of treasury shares nominal value.",
        "label": "Purchase Of Treasury Shares Nominal Value",
        "terseLabel": "Acquired from third-parties (Nominal value)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "terseLabel": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r156",
      "r182",
      "r193",
      "r281",
      "r283",
      "r460"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r156",
      "r182",
      "r193",
      "r281",
      "r283",
      "r460"
     ]
    },
    "asnd_RealizedDurationOfFinancialAssetsExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RealizedDurationOfFinancialAssetsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Realized duration of financial assets explanatory.",
        "label": "Realized Duration of Financial Assets Explanatory",
        "terseLabel": "Financial Assets Duration Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReceivablesDueFromAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReceivablesDueFromAssociates",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from associate",
        "label": "Receivables due from associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables due from associates. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]",
        "terseLabel": "Tax effect of:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueRemeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in fair value measurement, liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r330",
      "r340",
      "r373"
     ]
    },
    "asnd_ReimbursementFromAcquisitionOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ReimbursementFromAcquisitionOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement from acquisition of property, plant and equipment.",
        "label": "Reimbursement From Acquisition of Property Plant and Equipment",
        "terseLabel": "Reimbursement for acquisition of property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of borrowings",
        "label": "Repayments of borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "asnd_ResearchAndDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ResearchAndDevelopmentCostsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development costs.",
        "label": "Research And Development Costs [Member]",
        "terseLabel": "Research and development expenses [member]",
        "verboseLabel": "Research and development costs [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "terseLabel": "Research and development costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation [member]",
        "terseLabel": "Foreign Currency Translation Reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r68",
      "r251"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment reserve",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of share-based payments [member]",
        "terseLabel": "Share-based Payment Reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "asnd_ReserveOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ReserveOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares reserve",
        "label": "Reserve of Treasury Shares",
        "documentation": "Reserve of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RestOfWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RestOfWorldMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rest of world [member]",
        "documentation": "Rest of world.",
        "terseLabel": "Rest of World [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RestatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestatedMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currently stated [member]",
        "terseLabel": "Currently stated [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r118",
      "r120",
      "r123",
      "r181",
      "r420"
     ]
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Adjustment to Prior Periods Estimates and Assumptions [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r331",
      "r341",
      "r374"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r332",
      "r342",
      "r375"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r328",
      "r339",
      "r349",
      "r382"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RestrictedStockUnitsAndPerformanceStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RestrictedStockUnitsAndPerformanceStockUnitMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units and performance stock unit.",
        "label": "Restricted Stock Units and Performance Stock Unit [Member]",
        "terseLabel": "Restricted Stock Units and Performance Stock Unit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RestrictedStockUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units.",
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated Deficit [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r251"
     ]
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]",
        "terseLabel": "Retrospective application and retrospective restatement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r118",
      "r120",
      "r123"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "terseLabel": "Revenue",
        "totalLabel": "Total revenue",
        "verboseLabel": "Total revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r143",
      "r199",
      "r229",
      "r234",
      "r239",
      "r240",
      "r243",
      "r249",
      "r250",
      "r278"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [abstract]",
        "terseLabel": "Disclosure of Operating Segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RevenueFromClinicalSupply": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RevenueFromClinicalSupply",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Clinical Supply",
        "documentation": "Revenue from clinical supply.",
        "terseLabel": "Clinical supply"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Recognized as revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinanceIncomeAndFinanceExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "terseLabel": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r230",
      "r238",
      "r418"
     ]
    },
    "ifrs-full_RevenueFromRenderingOfServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromRenderingOfServices",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from rendering of services",
        "terseLabel": "Rendering of services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the rendering of services. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods",
        "terseLabel": "Commercial products"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "asnd_RevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RevenueTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue table.",
        "label": "Revenue [table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RevenueThresholdLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RevenueThresholdLimit",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue threshold limit",
        "documentation": "Revenue threshold limit."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_Revenuerecognizedfromcontractliabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "Revenuerecognizedfromcontractliabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognized from contract liabilities.",
        "label": "RevenueRecognizedFromContractLiabilities",
        "terseLabel": "Revenue recognized from contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ReversalOfGainLossOnPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ReversalOfGainLossOnPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of gain loss on property plant and equipment.",
        "label": "Reversal Of Gain Loss On Property Plant And Equipment",
        "terseLabel": "Reversal of gain and loss on disposal of property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodStartLabel": "Right-of-use assets at beginning of period",
        "periodEndLabel": "Right-of-use assets at end of period",
        "terseLabel": "Carrying amount of right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r173"
     ]
    },
    "ifrs-full_RightofuseAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssetsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets [member]",
        "terseLabel": "Right-of-use assets [member]",
        "verboseLabel": "Right-of-use assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "asnd_RoyaltiesAndMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RoyaltiesAndMilestonesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties and milestones.",
        "label": "Royalties and Milestones [Member]",
        "terseLabel": "Royalties and Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty funding liabilities.",
        "label": "Royalty funding liabilities",
        "terseLabel": "Royalty funding",
        "verboseLabel": "Royalty funding liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPaymentBeginningPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RoyaltyPaymentBeginningPeriod",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment beginning period.",
        "label": "Royalty payment beginning period",
        "terseLabel": "Royalty payment beginning period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPaymentEndingPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RoyaltyPaymentEndingPeriod",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment ending period.",
        "label": "Royalty Payment Ending Period",
        "terseLabel": "Royalty payment ending period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RoyaltyPharmaMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Pharma [member]",
        "documentation": "Royalty Pharma.",
        "label": "Royalty Pharma [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaUnitedStatesSkytrofaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RoyaltyPharmaUnitedStatesSkytrofaMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Pharma United States Skytrofa [Member]",
        "documentation": "Royalty Pharma United States Skytrofa.",
        "terseLabel": "Royalty Pharma United States Skytrofa [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaUnitedStatesYorvipathMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "RoyaltyPharmaUnitedStatesYorvipathMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Pharma United States Yorvipath [Member]",
        "documentation": "Royalty pharma united states yorvipath.",
        "terseLabel": "Royalty Pharma United States Yorvipath [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "asnd_SaleOfGoodsAndServicesToAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SaleOfGoodsAndServicesToAssociate",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of goods and services to associate.",
        "label": "Sale of goods and services to associate",
        "terseLabel": "Invoicing of goods and services to associates"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SaleOrIssueOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer under stock incentive programs",
        "label": "Sale or issue of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "asnd_SalesDeductionsAndProductReturnsInUSMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SalesDeductionsAndProductReturnsInUSMarketMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Deductions And Product Returns In US Market [Member]",
        "documentation": "Sales deductions and product returns in US market.",
        "terseLabel": "Sales Deductions And Product Returns In U.S. Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SalesMilestonesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SalesMilestonesReceived",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestones received.",
        "label": "Sales Milestones Received",
        "terseLabel": "Sales milestones received"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SalesRebatesAndProductReturnsInUSMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SalesRebatesAndProductReturnsInUSMarketMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales rebates and product returns in U.S. market.",
        "label": "Sales Rebates And Product Returns In U.S. Market [Member]",
        "terseLabel": "Sales rebates and product returns in U.S. market [member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total selling, general and administrative expense",
        "label": "Selling, general and administrative expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling General And Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expenses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount of expense relating to selling, general and administrative activities of the entity. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ShareBasedPaymentArrangementAwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ShareBasedPaymentArrangementAwardTypeAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, award type.",
        "label": "Share based Payment Arrangement, Award type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "terseLabel": "Costs of follow-on public offering"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of profit (loss) of associates accounted for using equity method",
        "terseLabel": "Share of profit/(loss) of associates",
        "negatedTerseLabel": "Share of (profit)/loss of associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share premium [member]",
        "terseLabel": "Share Premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "asnd_SharePriceAppliedForValuation": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SharePriceAppliedForValuation",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price applied for valuation.",
        "label": "Share Price Applied For Valuation",
        "verboseLabel": "Share price"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharePriceMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SharePriceMeasurementInputMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price measurement input [member].",
        "label": "Share Price Measurement Input [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ShareRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase program, Number of shares authorized to be repurchased.",
        "label": "Share Repurchase Program Number Of Shares Authorized To Be Repurchased",
        "terseLabel": "Share repurchase program, Number of shares authorized to be repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementAwardTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SharebasedPaymentArrangementAwardTypeDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, award type.",
        "label": "Sharebased Payment Arrangement, Award type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, restricted stock unit, activity.",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, restricted stock unit, activity.",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased payment arrangement, restricted stock unit, activity.",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Text Block]",
        "terseLabel": "Summary of Share Based Payment"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SharebasedPaymentArrangementVestingPeriod",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement vesting period.",
        "label": "Sharebased Payment Arrangement Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ShortTermBorrowingOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ShortTermBorrowingOther",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Borrowing, Other",
        "documentation": "Short term borrowing, other",
        "terseLabel": "Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ShortTermMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ShortTermMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term marketable securities",
        "label": "Short Term Marketable Securities",
        "documentation": "Short-term marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Associates [axis]",
        "terseLabel": "Associates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r150"
     ]
    },
    "ifrs-full_SignificantInvestmentsInAssociatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Associates [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r150"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]",
        "terseLabel": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r149"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r149"
     ]
    },
    "ifrs-full_SocialSecurityContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SocialSecurityContributions",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Social security contributions",
        "terseLabel": "Social security costs"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [LineItems]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_StatementOfComprehensiveIncomeProfitOrLossLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "StatementOfComprehensiveIncomeProfitOrLossLocationAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement of comprehensive income, profit or loss location.",
        "label": "Statement of comprehensive income, profit or loss location [axis]",
        "terseLabel": "Statement of comprehensive income, profit or loss location [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_StatementOfComprehensiveIncomeProfitOrLossLocationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "StatementOfComprehensiveIncomeProfitOrLossLocationMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfDepreciationsChargesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement of comprehensive income, profit or loss location 1.",
        "label": "Statement of comprehensive income, profit or loss location [member]",
        "terseLabel": "Statement of comprehensive income, profit or loss location [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]",
        "terseLabel": "Statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r334",
      "r344",
      "r377"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SummaryOfInventoryDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SummaryOfInventoryDisclosureLineItems",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Inventory Disclosure [Line Items]",
        "documentation": "Summary of inventory disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SummaryOfInventoryDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SummaryOfInventoryDisclosureTable",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of inventory disclosure .",
        "label": "Summary of Inventory Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [abstract]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SwissFrancToEuroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "SwissFrancToEuroMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swiss franc to Euro [member]",
        "label": "Swiss Franc to Euro [Member]",
        "documentation": "Swiss franc to euro member."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "asnd_TaxEffectFromDeferredTaxAssetNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TaxEffectFromDeferredTaxAssetNotRecognized",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect From Deferred Tax Asset, Not Recognized.",
        "label": "Tax Effect From Deferred Tax Asset Not Recognized",
        "terseLabel": "Deferred tax asset, not recognized"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TaxEffectOfDeductibleItemsNotExpensed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TaxEffectOfDeductibleItemsNotExpensed",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of deductible items not expensed.",
        "label": "Tax effect of deductible items not expensed",
        "terseLabel": "Additional tax deductions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)",
        "negatedLabel": "Non-deductible costs",
        "terseLabel": "Non-deductible costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxEffectOfTaxLosses",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax effect of tax losses",
        "terseLabel": "Tax deductible losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "asnd_TaxEffectsFromImpactsFromAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TaxEffectsFromImpactsFromAssociates",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effects from impacts from associates.",
        "label": "Tax Effects From Impacts From Associates",
        "terseLabel": "Impact from associates"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TaxEffectsFromPriorYearAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TaxEffectsFromPriorYearAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effects from prior year adjustment.",
        "label": "Tax Effects from Prior Year Adjustment",
        "terseLabel": "Prior year adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TaxEffectsOfDeductibleItemsNotExpensed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TaxEffectsOfDeductibleItemsNotExpensed",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Effects of Deductible Items Not Expensed",
        "documentation": "Tax effects of deductible items not expensed.",
        "terseLabel": "Additional tax deductions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "Tax at the Danish corporation tax rate of 22%"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "asnd_TaxLossesCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TaxLossesCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Losses Carryforwards.",
        "label": "Tax Losses Carryforwards",
        "verboseLabel": "Tax losses carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TeijinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TeijinMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Teijin [Member]",
        "documentation": "Teijin."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/TaxOnProfitLossForTheYearAndDeferredTaxSummaryOfTaxOnProfitLossAndDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised",
        "terseLabel": "Other temporary differences, liabilities",
        "negatedLabel": "Other temporary differences, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Total for all associates [member]; Total for all subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "asnd_ThirdPartyInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ThirdPartyInvestorsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Party Investors [Member]",
        "documentation": "Third party investors.",
        "terseLabel": "Third Party Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/RevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r156",
      "r182",
      "r193",
      "r281",
      "r283",
      "r460"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables and accrued expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r425"
     ]
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfContractualCashFlowsForFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total trade and other payables",
        "label": "Trade and other payables",
        "verboseLabel": "Trade payables, accrued expenses and other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and accrued expenses",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "ifrs-full_TradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables from associate",
        "label": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction price allocated to remaining performance obligations",
        "terseLabel": "Contract liabilities are expected to be recognized as revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [domain]]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "asnd_TransactionsAndOutstandingBalancesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TransactionsAndOutstandingBalancesAbstract",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesScheduleOfFinancialInformationOfInvestmentsInAssociatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transactions and outstanding balances.",
        "label": "Transactions and outstanding balances [Abstract]",
        "terseLabel": "Transactions and outstanding balances as of December 31"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "ifrs-full_TreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nominal amount of treasury shares",
        "periodEndLabel": "Ending balance (Nominal Value)",
        "periodStartLabel": "Beginning balance (Nominal value)",
        "negatedLabel": "Treasury shares",
        "label": "Treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r256"
     ]
    },
    "asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TreasurySharesHoldingInPercentageOfTotalOutstandingShares",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (Holding in % of total outstanding shares)",
        "periodEndLabel": "Ending balance (Holding in % of total outstanding shares)",
        "documentation": "Treasury shares holding in percentage of total outstanding shares.",
        "label": "Treasury Shares Holding In Percentage Of Total Outstanding Shares"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TreasurySharesHoldingInPercentageOfTotalOutstandingSharesAcquiredFromThirdParties",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquired from third-parties (Holding in % of total outstanding shares)",
        "documentation": "Treasury Shares Holding In Percentage Of Total Outstanding Shares Acquired From Third-Parties.",
        "label": "Treasury Shares Holding In Percentage Of Total Outstanding Shares Acquired From Third Parties",
        "terseLabel": "Acquired from third-parties (Holding in 1% total outstanding shares)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred under stock incentive programs (Holding in 1% total outstanding shares)",
        "label": "Treasury Shares Holding In Percentage Transferred under stock incentive programs",
        "documentation": "Treasury shares holding in percentage transferred under stock incentive programs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TreasurySharesTransferredUnderStockIncentiveProgramNominalValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred under stock incentive programs (Nominal Value)",
        "label": "Treasury Shares Transferred Under Stock Incentive Program Nominal Value",
        "documentation": "Treasury shares transferred under stock incentive program nominal value."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TwoThousandAndTwentyFiveMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty five.",
        "label": "Two thousand and twenty five [Member]",
        "terseLabel": "2025"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TwoThousandAndTwentyFourMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty four.",
        "label": "Two Thousand And Twenty four [Member]",
        "terseLabel": "2024"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TwoThousandAndTwentySevenMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand and Twenty seven [Member]",
        "documentation": "Two Thousand and Twenty seven.",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TwoThousandAndTwentySixMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty six.",
        "label": "Two Thousand And Twenty six [Member]",
        "terseLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TwoThousandAndTwentyThreeMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty three.",
        "label": "Two Thousand And Twenty Three [Member]",
        "terseLabel": "2023"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TwoThousandAndTwentyThreeToTwoThousandAndTwentySixMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty three to two thousand and twenty six",
        "label": "Two Thousand And Twenty Three To Two Thousand And Twenty Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "TwoThousandAndTwentyTwoMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ContractLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty two.",
        "label": "Two Thousand And Twenty Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of interest rates [axis]",
        "terseLabel": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ifrs-full_TypesOfInterestRatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of interest rates [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [axis]",
        "terseLabel": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r187",
      "r200",
      "r207",
      "r208",
      "r247"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r187",
      "r200",
      "r207",
      "r208",
      "r247"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "USA [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_USDollarsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "USDollarsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. dollars [member]",
        "label": "U.S. dollars [member]",
        "terseLabel": "U.S. dollars [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "asnd_UnitedStatesSkytrofaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "UnitedStatesSkytrofaMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. SKYTROFA.",
        "label": "United States Skytrofa [member]",
        "terseLabel": "SKYTROFA [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UnitedStatesYorvipathMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "UnitedStatesYorvipathMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfRevenueAttributableToCommercialCustomersByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "YORVIPATH [member]",
        "label": "United States Yorvipath [member]",
        "documentation": "U.S. YORVIPATH."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r457"
     ]
    },
    "ifrs-full_UnobservableInputsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnobservableInputsDomain",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r457"
     ]
    },
    "asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront development and regulatory milestones potentially to be received",
        "documentation": "Upfront development and regulatory milestones potentially to be received."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UpfrontFeeForExclusiveLicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "UpfrontFeeForExclusiveLicense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront fee for exclusive license",
        "documentation": "Upfront fee for exclusive license."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UpperMediumGradeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "UpperMediumGradeMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfMarketableSecuritiesSpecifiedByInvestmentGradeCreditRatingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper medium grade.",
        "label": "Upper Medium Grade [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UsDollarsToEuroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "UsDollarsToEuroMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfForeignCurrencySensitivityAnalysisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US dollars to Euro.",
        "label": "US dollars to Euro [member]",
        "terseLabel": "US dollars to Euro [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UsGovernmentBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "UsGovernmentBondsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Government Bonds [Member].",
        "label": "US Government Bonds [Member]",
        "terseLabel": "US Government Bonds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UsTreasuryBillsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "UsTreasuryBillsMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Treasury bills [Member].",
        "label": "US Treasury bills [Member]",
        "terseLabel": "US Treasury bills [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesScheduleOfAssetsExpectedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, property, plant and equipment",
        "terseLabel": "Asset's expected useful life"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "asnd_VISENPharmaceuticalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "VISENPharmaceuticalMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureInvestmentsInAssociatesTables",
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/InvestmentsInGroupEnterprisesSummaryOfInvestmentsInGroupEnterprisesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "VISEN",
        "documentation": "VISEN pharmaceuticals.",
        "label": "V I S E N Pharmaceutical [Member]",
        "terseLabel": "VISEN Pharmaceuticals [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_VestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "VestingMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting",
        "label": "Vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_VestingOfSharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "VestingOfSharesAxis",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Of Shares [Axis]",
        "documentation": "Vesting of shares."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wages and salaries",
        "terseLabel": "Wages and salaries"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "asnd_Warrant1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "Warrant1Member",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants.",
        "label": "Warrant1 [member]",
        "terseLabel": "Warrants [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WarrantCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "WarrantCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/SignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant compensation cost.",
        "label": "Warrant Compensation Cost",
        "terseLabel": "Warrant compensation cost"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WarrantsGranted2012UntilNovember2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "WarrantsGranted2012UntilNovember2021Member",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Granted 2012 Until November 2021 [Member]",
        "label": "Warrants Granted 2012 Until November 2021 [Member]",
        "terseLabel": "Warrants Granted 2012 Until November 2021 [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WarrantsGrantedFromDecember2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "WarrantsGrantedFromDecember2021Member",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Granted From December 2021 [Member]",
        "label": "Warrants Granted From December 2021 [Member]",
        "terseLabel": "Warrants Granted From December 2021 [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average duration of marketable securities current",
        "documentation": "Weighted average duration of marketable securities current.",
        "label": "Weighted Average Duration Of Marketable Securities Current Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average duration of marketable securities",
        "documentation": "Weighted average duration of marketable securities explanatory.",
        "label": "Weighted Average Duration Of Marketable Securities Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average duration of marketable securities noncurrent",
        "documentation": "Weighted average duration of Marketable securities noncurrent explanatory.",
        "label": "Weighted Average Duration Of Marketable Securities Noncurrent Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentSummaryOfFairValuesForWarrantGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement",
        "terseLabel": "Exercised during the year",
        "verboseLabel": "Vested at the reporting date"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement",
        "terseLabel": "Forfeited during the year"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Granted during the year",
        "verboseLabel": "Weighted Average Exercise, Granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Weighted Average Exercise, Outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of other equity instruments vested in share-based payment arrangement",
        "label": "Weighted average exercise price of other equity instruments vested in sharebased payment arrangement",
        "terseLabel": "Vested at the reporting date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Other Equity Instruments Granted",
        "label": "Weighted average fair value at measurement date, other equity instruments granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "asnd_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail",
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life for outstanding warrants",
        "documentation": "Weighted average remaining contractual life of outstanding other equity instruments",
        "label": "Weighted average remaining contractual life of outstanding other equity instruments",
        "verboseLabel": "Weighted Average Life, Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "terseLabel": "Weighted average remaining life for outstanding warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageSharePrice2019",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average share price",
        "terseLabel": "Weighted average share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Number of shares used for calculation (basic and diluted)"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "asnd_WestfieldCapitalManagementCompanyLPUsaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "WestfieldCapitalManagementCompanyLPUsaMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/OwnershipAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Westfield Capital Management Company, L.P., USA [member]",
        "label": "Westfield Capital Management Company, L.P., USA [member]",
        "terseLabel": "Westfield Capital Management Company, L.P [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WorkInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WorkInProgress",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/InventoriesSummaryOfInventoriesExplanatoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Current work in progress"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r436"
     ]
    },
    "asnd_YearOfGrantOfWarrants": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "YearOfGrantOfWarrants",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/ShareBasedPaymentScheduleOfWeightedAverageExercisePriceAndWeightedRemainingContractualLifeForOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year of grant of warrants.",
        "label": "Year of grant of warrants",
        "terseLabel": "Year of grant"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "asnd_ZeroCouponMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20241231",
     "localname": "ZeroCouponMember",
     "presentation": [
      "http://ascendispharma.com/20241231/taxonomy/role/DisclosureFinancialRiskManagementSummaryOfRateStructureOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zero Coupon [Member]",
        "documentation": "Zero Coupon [Member].",
        "label": "Zero Coupon [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iiA",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "1",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_1&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "24G",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_24G_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2024-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Offsetting financial assets and financial liabilities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g13A-13F_TI",
   "URIDate": "2024-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2024-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2024-03-27"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2025-01-01",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b",
   "URIDate": "2024-03-27"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2024-03-27"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2024-03-27"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG20C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>131
<FILENAME>0000950170-25-018852-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-018852-xbrl.zip
M4$L#!!0    ( .N!3%JON7MX2$8'  @>80 1    87-N9"TR,#(T,3(S,2YH
M=&WL?5MW4TFRYOO\"H:7,[-FHLC[A:FN6511=#--02U,G3[]U"LR,Q+KE"PQ
MDDSA^?43(1LPM\+&DIT2=/>B+>VMW)>X?1$9E^__]ZNCZ:V7M%A.YK.__)O^
M3OW;+9K5>9O,GO_EW^X=_/3PX;_][Q_^R_?_%>#6_0</']]Z3'_<NE=7DY=T
M?[*LT_GR>$&W_MO!+__]UL/9=#*C6__QX]-'M^[/Z_$1S5:WX-;A:O7B[IT[
M?_SQQW>M3V;+^?1XQ==:?E?G1W=N 9PM_M."4+Z_=1]7=.NN4<:#,J#-,^WO
MFG17I>^<5?I_*'57J7,_F[\X64R>'ZYN_;?ZWV_)K_C:LQE-IW1RZ\%DAK,Z
MP>FM@]=7_9]\F_6[6_>FTUM/Y6?+6T]I28N7U+X[7?1PQ>^#W\EL^9?;YV[]
M#_O=?/'\CLXYWWDEY]P^/>GNJ[*8MLF;<^7C^DRC5+AS>O"=4U<?/=6?GKHZ
M?^KDG1LX?[:]P^]QQ8]&K\_G-__[GYPNAPLNWYS^ZH/SWWD^.?KZU,FK3ZVK
MY3:$Y$+QUZ?/YK/'3/G%I'[\9VVUN+,Z>4%W^$28G9[YYJZ6DX_=$S^!OO,?
MOSPZJ(=TA/#^H_.*("LN/W-!Y@T#RH+5KW]9Y\>SU>+D78(LJ7[W?/[RSME!
M^9E[\X.3]HF33]H[)TY>K8"/O7-'K\]]^\[NK!8X6_;YXFC-^?)*F>?3N3ND
MVF!Y7#Y^T;.#[UQXN7C+7QV79?T*^,MW'^-XL6 9_]2#GQU]YR?'J\4GV2O?
MX:-OJ$&3CR_+!]Y]1<NY,SK^&8^?GG'N77SR/;R[<E\LH1]/IZ>G+U^?+]^O
M5U_AJ_EL?G3ZA,(2)MYY\Z-S)/SXO?T9_83#6&>%UXO@<O;VIG%9:=8FRQ>'
MR+]8JS^Y 6V8WC_\EUO?'Q(V_O];WZ\FJRG]8!0\^/[.Z=_R[1&M<*U,@?[O
M\>3E7V[_-)^M6,7",^;NV[?JZ:>_W%[1J]6=M8:Z(ZO>.5OV^S)O)[>6JY,I
M_>7V"VRBX.^F%Z_^UQ$NGD]F=_%X-?^ODZ,7\P5+U^I_W5Y?LTU>OOZ)W/@4
M3T3 B8]^/WEU5U:FQ>F?D]9HMO[SK0:X->&'?_"OF+'WD#T4M 0NQ0C)^P8Y
M^&)*J:X'<_O6#(_D*C2Y^WC^;(%R>P<G1V4^?3#%YV>/]VKUE#H_^+^:<M8%
M?D/1E@;.=@U99P.Q5-14L0=G;O^P6AS3]W?>N:6/WZ%QB:B7#-$;#<Z["KE8
M_H<72UE[1;&?O\-[;-J:F+>/W1OIH*IU""8K?MR>$5*P""Y@KP&3R5[=_J'C
M='FQF],>,70B*!HC.$H:DL$.09>D;$S-UG=N[K7I?<#F&:>_\DKS]H"_6W[9
MC3[XYX7NLB85:VR1WYDOP'*K )U7X+75H7C;2\+S=_GSC#G[Y">^SP5.'\X:
MO?H[G7S9'2JV#T$;Y<R%[K0S!Y:>"%JR_#XM%BB*V"XXET/-F%+T[Q#[N$U6
M\\5C_N++[N\^3>>3%8.:@Q6NEB)GBPE##EHQ]'@Y$=RU?(&+U8PQ&$V7OV/Y
MX#'NO"MA"^HD*IJ6/WPOIOKN<FT9^:9NK4WW7;%W?[F]9&F>BIE<?W>XD'L6
MA02OM<YWKY:-E<1Z^?-KKC\NY\>+]:<U%+E[]N#K=_C3OY(RO3B6/^], I?Y
MF?FE1E9^9%W1*MD4;K_^*:U)_?K3I,GG/J'%K?5MTT>-Y$\/__XN8=__\>OE
MEO1<F/WT8^.+O7HQG=3)ZA<Z*GR)-N&C:VA[^XV&O_L+KHX7?$OW7DV6MW]X
M^_TC1IZ+9X<X>S*C?Q(N3M?X_LY'E[[ %>5EW_UIBLLEWW)=VX@G_2E-^3+M
M5Z;XV0VL3_MQCHMVNL3R2?_K8G[\8C.7YXL]9X8C7O6 #0\M?V0<R)<_D=>V
M/'<'_\ %F[/5\J_R+[4'B_G1?:KK59EA]&?NYLY[Y+CS,=J_6"NC-YRP!G*K
M'V1UQOD,>]Z0^>S(Z\^O?W?G'5[\%&MFS,%E*($46YO4H$3RK#BU<Z;H'KT?
MES7_2O/G"WQQR.PRO<<>T1F!&,'=_?EX,7]!FR<#O^K%2IRN'T[QB^;_O5GG
MS;$W+ZR]/?4=FKT^\F4TJUH1KUBZ$Y6L+:L37<'Q.Z[-\;LV=ER:/<79<WI?
MESR;OV!9ER-7%>-S:XJ7<R;&Y9P4WQ/!?4Z?$.CM2J[9H.1JLLHRBC-(AFUH
M-Y#)&P:+I;1$$:-VXW+!HPF6R72R8DU[C^T[PU?1H&<1B-GS=<CD].C[5F<^
M>\YVY^C'^6(Q_X-/76Z58':S!$N>*J0LJE;S/PR? @._KBAC(0;2XQ+L8/)\
MMK;+L]7#V4M:KM;R\W!V<%R6DS;!Q1M:K:7IWIGW]NO:>SMXR>^)I;YL61^[
MB^MCMT%];+Q#%SO$R!C/-?:Q4E =:FVV,]1-I;;1""LF\A?\S_GBI^/E:L[
M^3SQ?IH?\3<2"7QS=#\)9R/[,S:#]I:],)\4)$+V3U0)KA#_&_)HA'LKD6NH
M+!;N5T$ZC(]_G;)PWINUG__O\>3%VM*]ISN?K YI\<FS=T:/VMZ,T@5B39:!
M*CE U9"]J99;3\[%H@>FVOSHQ7PFNO-)EU?_H5_U<+D\IO83OIBL<+J? -:9
M6LD5J X[L.[TD%5T4!P20[40M$WC4O!*EI!=U3]6A_<GR_FBB=(]V$_%ZK5+
ME#/T6-@OL3&P8JT(S5132B@YUSXN@??=<0BJJ(09;&#5Z50/D(OQ8)6V,2J#
M50WL/G["Y3^O8-<[44_Z_?D1+S;=0@Q@2W8MA80!F22A9J:+)D@N!_#L'?2F
M76TC"\WET<AZ0WG>CY=TCW^Y^AS$O,R]L$2>B!=Y)+QPK];CH^-U&/$^O5@0
MXUJ)+?+!Q6JR//U[UAX>O<#)8GV?L\9:>KE\;Y7W[OXCI^RG*D](H:H$QG;9
MJ7 *2O<$(2:5C FY]^%BU^+<_'2V+WM.4?]V<'\^G>*^.C-,J.0E=&M=D%VY
M!KD&"QA,BM%GITH<C5!?<U1P!);)JF4?+>2UV<G1 S:#D"P9IX.O/0P<0KQF
M_W<P^W/957<&G>:,Q?H"(2"K,<4*+8>BP6@=HD.;J\5Q>7),[7)#7GZ)M1L3
MP5;^QSDO&U8,:KMKNFMG.K4R+B4_%:<Y]>G7F08X8\F;+R7=X>1TLWBK0N8V
M*&2E56V3@U0U@SK-GGKV#B$;#-'KR.[&P*[&E^\=L;M(YWZ]GT:]QJR]5VS%
M?04G^\1H0H$<"9,VL2<ULE$?TG7[$E3R<,;B^7Q2IF?NK=S;?-[^F$RG'X8L
MCEX<KVAQ,.^K/UB/[$S$HK923+?@4V;\Z")!)FU!(7.'2S64.%P<=ZV_U]KZ
MQX_;YWM,@29V_)R^?TK+%2M\9L.#U;S^_MMLLJ;GK[18I[/.*KWY?F=,0 M.
MUY[ =4DS=2% L4Z#3EIKWY6K=CB__C/NXH_SU6I^M+\>XY:$N*54:ZY@(AKF
MAJZ@!%LD?U8Y9;-68>3MM+VQ%Q?V8M<HYG ^E>=8S%^>,N#.N'?D4ZA:@V4'
M )PA#0DI0LP]A6(R13<P.OG$YL,;&_&D_V/.B^TGKJ1HG&)(:7W7X+))D#PB
M>*-#JI1,PH'3EZYL,':5:-58]NG U8(L;DPT+,U#\<5V1ZF9-EQJTBE"6_$C
MRP^>=$''"SJ4PR_IX:S.CXAU99^LGBP>L6)^-#_-%?\05(L\'N!T3_V\K&+H
MS3E@]>G9AV<4EZS14%I'(MT5NN%(.U :S';,&Q,%6V$_R/? \N8EYI7(0<44
M"T4LT0ZL)!_12YHR01XP//IWG![3WWA!7-3##VL_Y$S]L3,WAXQ^8?MZO*"/
M0:![JS<7WA68G;6U57(M8E&LCC4VP!0:N\Z4L+&6)C]PR.VF"RWLQ56LW:"*
M]=7$J#M45JC@J$0H[ (">C:G/BJMTW#QC<_2[*Q2^^[]OV_4?3D+<KW%PT]Z
MGU1Z@%6"K9]3"QO8X3!@U,5V.-XY]4K\$0QU73VD)H4XI;*V5Y$1LE%-A:IR
M5 .;X$_E,3(EY^(X?Q@_?WMD5Z)<.>9L4!'$6JO88X9+.3KP3>D:8Y",TW$I
M]+7E5-W\GO8(N#Z[F(OF%2E*35^7? Q;)2DC9M=U8M8=EV6_RL#L$%SC37$,
M+XOS'62''9+ RR2>8#-LJ,+ \')_HKA#[?J-P9<VM!R!<G?@>@N0C?;06NBQ
MN1)WM;[\,3/CX5D>R)Y2#I-*%-D.=0(7-4)!TR X8Z@ZKPF'RR<]3<[AG[>)
M-#![20=4I7?%A):/YXQRZ_2X47LXNR^'J?V,BYE4$/_*0BA&Y(-\P46;S'![
MR3TC4!E5BL;QE8MT8JE8V85)$8RMVII2M \#I]M]/HIXUJZ.#[^JAX(*[D_Z
MZ]8M3V;/I"/5=&U1]C. @99<C@&Z[5(JF3.@-0%\*4HB&)WHVV[;YT,+-Y \
MF:MU412O]UVB^ST"HD<PO:,W':TJ9ES*#2V76XK\-[+!V BQ24UKRV(NV6:Z
M;I*)'1'#P 2[6OG%CIH^\CG9F"&0EHB\UU!28I>[6(=9I]Q&SD^^Y%Z-_8*]
MFG&B>)2U;2%!=M$(%&U,*5^899R$\4R*9;A<-?$1Q$B=;6._=1S.?]G^\_@T
M[+J? M9+=ETE\)TOSV*E(04JH'/5U3G-'P9&'T/;L $0"BJ78JX9FC&,4$Q#
M2-@Z&*]T4KKE'$=6G^/6$&QG_QE5#24D"R;$Q/A$L0XE1Y(]HGVSV+"H?237
M-;0+&T#5,G4K54W242Q+(T )!#?IK=Q#[[Y2;@.[\0,UHKHA7:H5ZJ@SQ*S9
M>:B]0RHIL+=G2S32ZS$/+)S/)D<L6$_ZVN*Q 7S2)>2]?+(X8/,XJ1\*Y7N'
M7_]N0>W>ZM?Y1/:C><W];-Z)FJVDKP6"/>T"Z"6=I$&VOCBB9I7=6S_Q,CPU
MRM[>EJRQR;VVKJ%*=,XQ5@*TDI=26K:YFIC&ZZIQ8[D U[;A?S-!6C2-(F&#
MD)231-X J$SAU2DK6UWJ>;B-EET#TAL,1J U+C8&6*%Y9" =6(&3J: H]&H*
M"[0;CER[5_0X@EQ:UZQAUHE!&NI(K21FZM!C;TU3"2$-G#OV+9=[BRK L8>%
M/H"-/LM,#,V<40R@#JFAC9V&+K'_@ER5U]_O#H5JQBI*FK(%UY'8'XX$K>B,
MKEBL=6"':JS,W!'"&U&7JH(!5]@7<Y@[%,\V5^?H+7F*;N3@U><CR6O3_"OK
MQ\GQT59%;(.30S#ZZH.N(,%><,DY*-0\>&5JU3ZB;L.Y,*//>'E'U/3%14UO
M4-2R;L5;]DQ=KDS6JJ"4Q.ZI9WCKFO2(&#C]^!PX?5*FD^=K[_,\21]-*O_J
MLVKR4M+-WBLM9";5NXV?GQU.%J>#BTZ5^'Q/&T]B1FT5*0C:==;0J"!Y]F1[
M\RIY=F55'KF+_J"QC"T#NFMM.;3!-!O$I*-DI?J6V.I0TY"]LA!*B-AT"I4&
M+K#]QFP[U=\*2V%'0K/;H%!Z'POLM.A!,<[16+U.:>#ZOD_-[7L\7UUR=-]
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M(D8(2?IZH5$@0ST@^]:<BKYVW#U,M=;%YT'5SL1FBZM!7I7TW9? .1J&N+D
M%5>PV^CHV_#R;][OR-;"N^@5$?C$:SK'CAKJ$"&5Q*8#Q0L8V%I<V^;"+F6X
MV8NQT#NG7HF%&&^PXK-@E&8=R&@24NX9LLX.*WG;QJN+VTB/YC,G9O:2E:&D
MH!_0;#)?\._WM "RI)8)E0%REI%EUDZ&M%:&(E@4,>2L=F G8LQ\@2^QUJ,6
M/6PR=(C8JB8%754CK<02I"9#@;LQJJ=L?!BXG.LZYX\,.[IW!(55C W=,J2I
M:,$%%:$XDC+27'*O(6LU'+CYHBXI'VN'<N58VGKE?Z?E:AU[.2U2/E]9^L?\
MV>'\>(FSQMSV[ ^^M9,#>DG;;C1Z4ZS4M/%605RWD36!7>[DV=N+5>*NF5WO
M@?WNB[217>%D]A;I;)F(-]/VCHE8O:T6,-8.KJ_C)KF#MXFHFN3ZT%/F+ZCI
M3S7"V;%?L!XR71<;;*,S)I :)R146_ %";3&#*X$A)(32O5"RZ(XLAVN)<5E
M-,6SQ;J-TM;FT6R)*JV'8+(%LFBD4;2!XGWGU5VSP:ED^BX$ZLZ'Q]^CRWU^
M&R]1?-D-[J+]-IL7Z2^.[&P\G+$K<1X!G#6,F50ZUUEK?=9^0@"*VB;%DIQ[
M8\%.'3"QG,>>JLD%55+#Q3F&[/^S2;&FALW% ,6*GTCD(3>&^3X%';POH>9=
M$.NM^FZ#F?:;#[MOAQ6KJL87'Z%C0W!)*T ,%7*WC:RV-=2!APQ^JD_#FR8-
MSPX7M&[3(.&F\]T;'K#%67^_*[&EJEU-W1:@2@F<C"+#4"*8J'K%7D,J S?4
M^)H&JJ^)?NUVODH3?$3/7J(5.\]./ZH6(%1'*?=@=!Q8D&\>P \ U:HU.F1<
MSRY8CX5)@#6R(Z;)L'OF^,4/'#Y^(WUG:2\LZ.?$\.UY[Q]>G=E0:C_-E[MC
M-ZU#2]8*A=A?5J9#,4:![UZ26CSU/K*X?=4I%%]+?6QU*J8D;D8LTAK$1LB^
M!FB&,+FL7#/#54IOK-WZKE1]5)\51F4AJ5"DZB-"*5V2UG4WQ2>31^X8\MFF
MH:?9)1+XF;5?)E/IY3G[UD)TDT+NFW<D694V1<%]';()$51 TVQTR>B!8PEC
M=FH:(&.VAFQ+(06:K&SZ.(+D;0#E>\HU-Z7'RW ;6'</0='F4W8(MC@++N8"
M.54-)E03>F7(B ,K^D_UU3\X+LM)F^#B7>U[;UGY74V6IUF%3V9U/IT_/[D_
M>3F1A>_MJ2I.IH;8-"#K73;E,GC<BW= FK0-*G@<>0_MJXBB#L$FOD87*O0H
M$QFT*E!<77?_I\;'DDW#5<0-K-JW%&Y-579>#42G6(*9,E!4-)!#K:GYPK0:
MCD@C]R*Y(5%#K;1W&2I5DCH! P5=@Q0CA9*IQ##RYN<V4V?&B:1A#B:TQ$I0
M-JAK90>XU08=E>V^]9S:P [,0!O4FPQ*(*K>K(PE5U4*Q)R,JF$!1E-LP&I2
M&;B2_JRGEG24_;#@<L)$:GR_<G0__0QL7<9B@H^)X45@HU6,9Q78-&)TMF/;
MA<CTFVV"A\S'B^.UNW'5 I8-R/6I=W-:[SEC##M?3E;S:TDKVR2X*3&EPCQA
M$DNV\T[JZIEC7+8J&_*VF('WDH>M'=B2?6RZ]L!.@J]6IEXW=A>*U 0D[;R/
M3"X]<OW25[W3=//^[I84"%EVADH!6VP!UPQ"J94_YD"A&TLUCJQ !J@KV)*N
M(&MK(,;2328^>L\(+N0L56C47=&EE8&]UBO%&/]Z5/ZVGSXL-5<]-FF?*SG@
MO'9RL8(R5#+ZS-9ZZU'%RS+T.^_I2@S=<XB](*B&@?&)D0)MZR X3<GIJ(@&
M!K,7'49[6K/V\.#GQZ>\7.EX)9ER^\G/76:#903=M&<=E2I@"PH4,8.[U%16
M ^^#?&W--K^6D0I-.>N"41!M:<!>LI9.$ 9BJ:BI8@_C=2UN-#F=>79RKS5V
M/YDOS_YX+Q#_GK^*>YU%R0I$D^H,1H-ADZ%9R3#\Z9*95V*KC$S5T+MP%XC<
M/V;T^CIXOUQ'/W[!&9YNQ.QE"6Q3[%:@C! H3;I6F<@T;5V&7$72R92 PV5#
MC-G9<X/.1K.>T6A#R &%*,H"^NZ@)I&T5 O%K0>)+\F^.E^8??G4S;&O30EU
M<Q S$\"E%*0"WT)CO@V)+0ZFX1(QOTW>W7H3FA%@CZVVD4F0<F;8@S$#UDY0
M?3#-FN3U>"G"&^[.NZ,6T?6H<A.HZJ1NSVE ,A7(A%BP4=4CU^V-LLMSME/X
M4%*(V3U_^M8E/U^O\DIZJKT]8\N;N&Q&-V2?O6=81!EZ%$?;%G:T=2;PC)![
M2*&&H;M\WO#&^@@R'K3'9 DTZ0@N4&78$#S+N$XYV&YB&SG*_JU,_"M-<&PQ
M\7]5A%X[PUT=K2B>!#&04<&8X/Q>1?B^[5CN@+.:JHTZ6^A>,@%5\NRL)@>A
M^Z@4FJSK<$#W'%56J\6D',O;9VOXZ@6?0<L?3QY+^P-Z-G]V2)/%@^-979/G
M?3-)TRF3^Z\THP5.F7CWVM%D-F&XM6Z[<[;:?BJB;%C=*$9 R7=P9#K[.;&!
M=<U8%X*T?QV7Z#LZ/^*&'%EI:E1#@N!38%+W -F2A^*5\SUB1S=<IN^U-<T<
M1PLCA>ZR MWJNA=S@=)M@*2K[E6W8GP=C4J;F/(AP/;<K_=3 HMQJL0,MM4J
M<].,-!K+$"AA1-53';F^[?R^RYN@Q)_TK?OH.;O9RJ)52Q$MF\6\GK+$2+V$
M&L&8DG5H <W(24-?'2C>8!H?*V%54A=P)D7&V3'EDTP^1.VJJ:FW,'* 84=+
M__G4#6G<VGO6O3&\58XU;K*0UCEB+=;,LFNJ&WC$^M?M9U]WJ^!-:@W2N5E5
MP23+S%9E<DI #PF;(JM4C$-W&ML]>[%5H;K^VHB-LF+*RH0*UK 7X51G5BPH
M>YC*%AVM,2-'&C_7%/'GC7+$S39%-* ,&'6Q'91W3KV2A>S:DM4=*#OIR% 8
MX! 1FV ?*1GTU@^7"S9PJ?T((;W>?=2$$(-%-C[! I)74%7VIEI=R]#MK+\-
M0]@[CB05>A$D9+I$'M%9R*9HZ :3,=T&<B-W[=P73M@.P" =E+3Z!),5L8N5
MI:!*%$^0ELM,X.RWKFYV1 R,L5W>5 N2D&3X'E+5K)U-=QECL6KD;),O[T^]
MHTJ+-5/43H'JG?F:9#Y$:@8TY52)S:JA@;=#SPWN.&<O/^P,N*,ZQWB53-/
M_DL7IX8@.Q,A>--2(2\(=C3:[/3\-YD%L)_0Q.3BNW+@O<1WE94F.[I"C%4R
MSRWB> '"4TZ2 <3R@R==\@ 7="B'7]+#69T?$8/G/ED]63QB6/%H7G'8K(>;
M21LD:X--DL1-W9^V?48K_6"T5]K%2,T-W+SGFL/"XVA]EL:L3ZEFP!62LMAH
MH99<M=>EM3*T&W&!LK5[+^>+^5F1T[WV<K*<+Y:/IG5S;NUG4-QO!_NFWYWK
M3;%HJY:\- DN4DJ-8'WSEN&=Z32PI(\X;_@T,"H*98L*9 C.R=46Y\%F2=;0
MKD(V# ]4K[FYVH//(^_\#EJ1=C5CLL'^?>10Q6@J-*U8,33/Y)7^/$B^*=,3
M&Y.!G?&!\ZRV1"YO*UMY TU%QNG8Q?:3AY1:5EI7&T=.3O[4$+;SX]:>S-;3
MUG8&C/E>6 ,2I)A9/>8896YV@R+S,MD';WD\%WRGM[BO:D5O)N61@M04U'@:
MZ73!=4@]>]#-=.<-8<G#;2^./GMC.SF.E'1*V!.$K+.TYO?2\1*A>!.+C^(D
M#YQX/'I3D!N2OI0QZJ19YJJ4F:DD)3T-J%IMM>L41QZW\.4@9SY[SE;UZ,?Y
M8C'_8^O="3=I51$-NZ9)>H5(=T(F78D*00>GE(FIJ/$Z\XQ<HS&"#$JO 7[=
M4+,F<,FP#*+WD&.7,=81*PZ,7"^D5]?3$9[T^Q,&.:.E$F^.CBTFJY(#,E(#
MX'J!HE4 7=A;]-GG6'>AR? EVKN\_OY;4LUU0;"66C.M@S'!2GV0!>:K!KTQ
M3I;6]$F-''+ZBC*W;MZWVU*8I95*S2=@M*$8A.0N^*. #^NO,74:N8O<D.IE
M"R)T[;GI0]A?RAD=056>[:]E,)5,R)"\\E1EH&<?SOYN+%&96>!CB'EG#!OY
M4%*KT&K/3+NH ;76;.=<=%E'4^S :N5*3=<?\K(3/'BTGS))F(J$?I6U'IQQ
M"DIGQC&Q:E][2K&-O"-_3MN>3MT\3\8#G-+R/K7C>CJPF25P,9=/3VEUO)@Q
M_7\[^ 47O],.26$C&TH$EKG*4I@C8)#4.>4*P\Z05!]X+WS,6.P(R4R]4#2V
M0)0-,5=]AJ+8?ZA.-4HZ5%L'+D[?2J+JSK/5=A1 5Z60K@B.4@,7FX&<?0$5
M7"TMFUKKR'MVGRIF?SQ_.7\\7[3MCZMCTWD)*ZO!;J1$KRLJ,;)8>R=#DW7R
MD*OQT$U2U03OFQXX+'"=.4QGS4K7B+M\''&?9YQ_H'R_TKNR.]"UIEZ=AE =
MPV@? J30"W,#.T#!J(!.C\L(N]8_9J.$<R8$&X%T#E)DVP&Q>2C)1<E"I%P'
MEN!/Y(R^IYD7)T_Z_?D1+S;=;O_?C=(EQ6P5@?+2/C9*=H*TB"XZJ5:KC2$-
M+5 [%^C\0N]LW%C8S>PI=EV]USY!*]G*Z/7*^@0;!(6]M:AMM\-M$U]R3_'I
M_ 2G3/1U$$5B71(.XU.7![^?K!;SCMLG;+XP8?G4#4$]W57TM,Y/-^"23#+-
M[*=;JMZIW/A_PP4YKV63<1P?RG3="G:IWY4BYV2A5.KL<E,*6:=LS< 4^I.A
M$-,IEOEBK=%%&F=R?-8>3:I4@=U[OJ ]WEOHSD<3=6!@'9BH&!@"]"HNLF[&
M>AV0!L9G'X10SG=%?A.MV!E,YHW2#AV08@_:=6)O%S%(?QJD$!!3'<ZV7:DB
M\_6F#TDLB47NOL29YFN$(S[.GDJ<-\6A+A U,95SD9A&;]*1.)3B.VD[<H>T
M;0YG&4<20W U9,^2J-@[DL!#\=+>0P4,70>KU< E,M\RGG8@WZ2S/B=O,W.7
M3N!:)T@-#32CHU8J$>J!]RXVV'[^">N)O>T\WP/[I+$2Q-8JN,*8&6-'T%59
ML@J=13LNE4>:3;E)[1Z1K*D9JI:^3>R[0*'$'WMIQ63OM!V9*-^&3.^,QQQK
MM(D]9E54DVG#%E*7R;2NE>1SQ^I&3H#?A2213:J%9%JBX,!6W:3M58#D$T'0
M@:K"VMS0:>[[(HHC6.U4LE&U@ E)IE7H+//>/7A*#,VR#9H&QF:C%P3>D-N=
M>N_2YD"7(CO(3,[$ZAFR-^+L-5_ZUHW^Y52;WJ!JRT&1XJ<EP^^40:=B5]9D
M9NCL5(\E^C1R8]S/,/3;,_].)V_9^%=:+.>S&4T9O*X?Z<F"?[:W_(U>^VH#
M,+;-XFD40%>D\:RR*3N3VLC1^0OIK#45Y:O>)].)G/./R>KP*;YV/]Y0_EO?
MJ"LQ4DP>BX*N>F'CIY 5I2_0@U?6ZN@L#=PV_PUH_9/TFOO\-EZN._UMT!7Z
M;38O2UJ\Q#*EA[,7QZL/+ONWB4R;$3;Z]SES^+JQ_H/YXK0+Y;F=C/6O=P8T
M8W+.A@:UHI4I01D*-@L]&I_06FG[.S"W?#; P=X,3F;4?L;%;.OE])NT^(BA
M.96 +!IPQE:&L%&!H=BZR=:E--R^WFG^\WQ!D^>SGXX7;*KKR=/)\O=S)N"W
MY7W9KETLG\U_/E[,]]/[J,G;&@HT'XA%JCE(K69HT61JE4P>+]?QNN927.Q&
MOG7X/66DACZ3%)NEQI"0K 7I%PJL$5S,2D7J(^\T[DM 8TO[1Z1042X0L<A4
M-Z, #=.Z%J+0&<3%D6M?/IH:_VS^8G_SX@<HE^I47*\E,!*0GD@FLHN80P83
M&J+RSCH]<"WJMUWM77 '6,B2#@$88++S:#MC%^FL%DF[G%DQX=!IY9]U!]9Z
MY%?VTR;'1SM#DVYT:%VJ+V2NMM*2XI<Z6%,;V6Z,'KEY^(B-H+]X:W5'<61W
M)06*$*OOS$5>,]2(!F((P32=6W7#A19WK__$ (16REM&!1FRUPY<B@U8>;/_
MD&U5KC@7XW!!@XW$D/\/SHZ7?^-7M]XR8/M[_.+7:XPA__7'?6,DC91R8!N3
M$WN>&-GDQ"P7T"F8I$U+PV4R7RXJ**%>XL.OZJ%HE/N3WDD"5LQ\LW5RVW2-
M_G8E4X5!08Y=QJ!F@RSY%B&U'B%1\*8'CV'D6;GW5JRVR[&\<"')>GK/\L>3
MQ])[G)[-GQW29/'@>%8_-@M($LW9/Y1LEKUT^I2UI4;;@%*31C4U -9LP)#T
MXD3-"'!@]#= @<<FI<SYX%OT8&UF(%5TAZ1:AJ[8 2]8**B!NU!<,I3R5PFD
M4'LXDW>XGW")J:D2*5Y.*Q:M0L ^KH= *:AN%+GQ:J>6B]6?E<(=\3=2U/'F
MZ"8C)Q> 9S=0[GI#:CDXZRRR BA69FP:F;&I"Z#&:#3J6D<VN&-&P2[S *.6
MV&_)\(1H56@RVSZRIJH,RE.S%6(I(>A6;$@#@X!K#0%]J]#_-!-5KX)I4%!9
M<,YY*"4%(&QHDLV^;3^#\BHJZRJ$_>=\\7+R E>'VP<R3%E[,2#SSJE7I&S4
MQ1L9\\R4;2E"Z2H"?Y>U#N1<&S@]].O;2]S./H%*C#RTJ6 EN.N,(?%."I@<
M:]>I]!H&'H,S?'^'&\*96;%/(K,_/3O]+BH/V+T#%X+M[+U4-?*POR_9\Y7H
MW?&*%@?SOOJ#)75GQ"^3,<U5\+TK"<$98.M:(930V>I:=@D&%K]O58D[DSFD
MT*<@G>1-51V<)K;V46;SJ!!\PAA\&1C'?95--0?(2E65E,[6LN,HU9&R2U@:
MXP1="S7IE=%PX&3"'>NUK'>YU[)J3:L: ZB4I>I9.KDERY##>^6850I;NG$Y
M94SCL4^8:9.FC*IBR%2@6>:W=:$N8F:(&V)-/IJ<PW!]_4^=$B'2>K+&Z:;E
MN8C$R?OCY4Z78(*N\Q(VDB!_/AARFB-_/DOF(S9M>;:;(V,H[U-=KRH%*[M2
M#J.Z0=5M@RH-U5PQ0=J&%NFOQ@R3<O3C;=5<5TW%,$32;(88A%9V3C&"(]<A
M5V=8FFMPV5@V',/MB6RGWN3Z>.-K2F_3BEHJ3;(7B[3<*A5RP@Q)>GMTPI[B
MP&'.+]M^_Y&8MB3Y;;@XT6)]]Y.T&JNTTX%@E&+OQ!!D$PAJ5%F5$'L>NJ73
M[K4S'\;;8')D6TT"1GL=G.H52NT*>DG!U&+9-1TNU? +C,;!Y-4WFW$3BL5:
MK8.W8-!D<(ZU"ZJF0'69'%8QM4$QR9C <8 =$6U[8239@"+K"N>E*C9*NXL8
MHS<F8ZL#[XAL,'=K-^.03+[F0TV@22K,^",D6S+X*'VYLO%QO)%0U^IS7_!N
M+A: ^/GHQ71^0B0Z_Z?Y;'D\%4.].QZER^SV!PM!R>3ZTBV@;0P36J7H0ZJ]
M#ARTOF98N(/8SZ>LV 1#DF9]+E5&_1J9T"XK6[QQ/0]<;7IM>2O?<MK^A(.P
MFM@BD+?L-S8).9GJ&0R(C8E8K-N%DO@+;[H_61W2XI-G[]86_,U[M"/ H1!2
M*1C DY)*.U6@*&6@^L[\V[.S?F +]XM4:'VDONX1OX[%LT.</9G1/PD7-[OI
M890VO_'33A]+WO?6=C[>X29]<6[2F^2F8EK,":KK3;S=!IF*AZ1M":5[T]K
MOM%PO?_>.N*_LFM-N]KC3X>F2\4$K;'?Y6)4;"0-@DJ^Y>2PX=!##+ZRS+2;
M-XM; ONQLP.G(^0FS?0CZT<L(4,WN7E#/60W7"3N\I:.2?-XOGKSK>P5RM<[
M4VFD$V5CJP(;I2V9-Q&*1@04,\J NGDW<*71T%3:I$;/J64;.@39#G4A5L 0
M# 3,V9)./N#6.[K<X,-W8J6!D*/CA]>\=B83))VQ88C)Q.WWU]P1.(BF&ZH5
M*KK SD4O@+$VB"YIM&1SB<.EI._X+M<-[8F@=>B: U]+!-=L V2O!TQ+&(WS
MN=%P>73CSB0<8=L2/7;%&MW'4EARR4*Q)&.R?0T68RHC]WP[2W61WL\?.' /
M^3'9=5\]Y5<C)VP\V__\!3ZX^H/)*VEI\?:,G;'X)54*.D&G(#X<LT9.*C%,
MJX6B4J:HX53Y)2/8_V"2\(6F[8-Y$)+>C+.31[_^MOQ<&/L2-_6U#8;0E2$]
ML29)GO&BRY9=,54U>$?>-JNS2<,Y8+L\GOB& LHUV> \.W#&65$4%C#9#,K[
MXA45[<>;@K;=E/IQ='BMJ7;&?;5)$GM0AD71>4CD^(/6_/? <;CK+-P;*$OF
MIG1U-X64AU9EB(^O";)-#DPV$0M1#7DX*;XF0/\-$9ZQ"&EED#1HQXK$]9Z
MO?H**F136--$1P-O?1],GL_6RE[V4E[RJU_SQL/9P7%93MH$%^]BPWO+RN(T
M69ZF-[#AWT^I[R6HG N4@#(#SE<):B%H74W4T6==!W;CKT32'^<SNC]92I.N
M>P?[2EPLA>E*.LA.?T?(M8J\6LH,V70+P\'OR_34?;98;X^>O)Z'MAL5J$9%
MJMDJ*"XQ)I/JM:*0  NR9]UUS6VX%+0O"I%^+!9Z$].:/E\(L9OB;53VE).X
MTYK%6W<&]YIOA,7>U((]USAP(L](F^Q7RZO<5>YI/FFMV?('!&>3Y.PHOD T
M[ @XK*T/7-KXU:5%;-( Z1@I.@N=9,B;TAY*BA4J)>]4"C:-O'5S^<[M7V50
MSN@:J[1L:D6J%Y+5D"7\$[SKMJGB_<AU#)_-JGAVN*#3!(I=3W\QQE8?4^85
MV95VSA3(R@=(EEJRIM@6OX7H1@O1W9!,FU#7#)*TB]+R0D9N. --6UND+S..
M;+(_L?DE[>4?LT4]O,=TXV-[F2UA3-&U=P)K&:^[U!IDI !DNXTAIYRVOT5R
M<QK.FN!M3V"PH=3;1\F>JA"R[Y1R-K$/'(;8.;QQ0^Z$S0I#4ZR,HI:JD@S8
M?(=@J:)A1\.;X:(:NS>_:8/!?..,LPHM^.ID1%\Q@#)WT^44R665=1M8*J\4
M^7WRXG!UB-.C^73^_.3^Y.5$5M_3&+ )NJ;@&C1'!,XP9L@Y1';S9;8G=FO[
M<,7OGR?SO>5R+N[XAYMK;X_LC ,0FZZ:!5&KQ!0*.D.AT,'KV'MJV>N1&Q$]
MFQRM([%K#<@*\4F7CI'+)XL#5I>3^B&!WCO\^G<+:D]>L@O'U]A/.8P]],KX
MQZ,N+(?-0LE90\VMZJ:U";%\H_+.XWR&LRH9!=TV XZT9ZC;"FM;4EJ%I)O?
MJ22*/RF+_.@Y%QZP=YF[.I?)^>4W=A:UI280?&=,0^K8,3LH2H8P-6L@!5O
MVVQ+8_W1LQF-G:ZKE=3%;N3;3N&:C[**C /9^7:2Y9%"@>QJA!AZCJRO:K<#
M!X-W9YC7?L]\,AAC[J&"K>SGLSO!7$12 EBS[:;EDN)PVNA;YY.;&3ZR22.(
M:%!3@&RD49,R&;(R$4(,QF.P"D=&SEL9(S$.;0K[J!B9(C8Z<);7SMUU,)15
M;PX5]>%:J0Z:8;;)T%[IO"!&J$ZF# >LD+VR$&-7N5L;_,AYNA=5U*<Y9F?'
M?L%Z.)G1XG,C3P93RT.EF&R2 ZNKZ(UT!9(<Q_6L8J\C($4G/=6KJ</M5.Y>
M&?AV.F":6KW4@D#PTH\CQP2H+4(2OX%-<1@PR_]*17OGPLTTG;*L_I58D^"4
MZ7BO'4UF$R;QNO_3V>[??KJ(S0?5>X!JR ([APYRP\[F/#.\URIZ.]P^P;5E
M)8^C5WLIM-X[K\2.?.T9BF*_GA6 ;YAZ:B//YMR-WGW;'U@T0)\69J26B=WX
MGATS4@\:,)H.-5EG4R_9MI$#U8*E:/'B@\C,X_G+^>/YHFVTR\,YC?&D3"?/
MUZ;C_%4?G<X%WL_$#JL<*W_VMZU._HQ37$J@;#?=IIJH#;P]>:4\@9]G;5X7
MD]DZ3^"O1^4:PGHW0N"04\P$Q9"TQ([2'M]GL,44BY5)/%Y[_,MG")SVIC_A
M1Y\L!ROFY%,W1$D=4HVJ0$,9:=034S+F"#UT4LT%[]/ +7R^)K__NL.Q&X2@
MUKJ"DJG2$R*[AU5#0>VA4[39F>[+>'N2E]S?^9(MG<_>@^0Y#Y3!?D.VQAG-
M>$%:BWD'KE%BY@D5HF&WAK)G[35PZ=$W#;43]6W644T8$7PKC%AK]0QHV"#V
M;GWLC5H;N:?!,!/DMV0^? CDNP934A1W(D%6-@/FUK5R1?<\7'1Q+^?KC& -
M?&)HV@/DWAE*="*9M13Y8^RJD:W>#QS-NI)K>?#'9/7_:,$VHNVO8QF";LU'
M2$%58-0H?[D )O+76'SV;F ]O)?!R@O>S5<QZ<V&U%1DIE1898]21RB2NHO:
M-)16>3GNJ_;Y^5@ [)Y6O#!=R<7L>3EKP#G;V:JD!K9D6\@UG\/ R8Y;R1>Z
MQ/4?2;&B9%I_<,4/%*&<J3]VYLY@T6@#I5)E2@VQ@<J5.:4V($?6F\0@Q QL
MH(9Q%$:0^5B-#D7&#E"5^FK-#D4VD+JFCMT%/7)<X0.9/U]]O(6*BDO*N-UM
M&2?=##N8*8B,YR9]4)H'C $I&FUT')@SWD2<'L[X#3R7MJ6GO:_$E9S/VQ^3
MZ?1]FDGNRS%CU(-Y7_W!NF%7<DEMTJ$B9FA!,:6B39"-8Y6<M$J=S7@M Q<D
M[V-,;J/$]3;W$B"N^XRRV $295!%&^<9@&,?N#W SO6 N)GJ1YN-[U6S"^5C
M V?8Z\^=$)3*&5WIN+\>U6^_/YH<R:[1?L*K7#$6R=_5,NS'BA%5TKZFDT6?
M4PMVX#3_/VD\=.H([XP215>M:P5R5!X<)<,H5^A,J29?I*'C+B9M/:/)?TZV
MT#?EO8Y=^A(=N_2&AH7;RNI0=8:;6F8MQZZAV*+!)T12N==*PVG$ZRK@'4>L
M2*N86X<BPT&=+5V&9'0P/6M3R;A1JZP?S!?$1NNGXX7T(3J1V5;GLQB6]^?3
M*2Z6S^:BYG;&8:/2M$'+2%%V#;R,#F[&0V@I>4(OL'$T:NQ((ZD1D 1134$A
MI"0C>9OFOWJ/H"O:H-%ZEX93B(TF=W]>W\J]UA8D#OG9'V^5H)SSX_%R,N-O
M?^(GQKJG6[:]^*13AL+B*;W\/.0JO6S8RJ%U%FT>V$D?,V1Z,\U$F9(%DTO
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MY)Z3#*,T<E%B)>[9^014+*S.%I:%SNRN^$T7M@\I67E2?B)F*4N\6N'76XF
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M/?3ANN#ZCH,>QL4F+EJEX$B/P$5IA^"PAC\Y,F<-AB^6'W P%?Q>G[G="89
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M]9Y[7B-?3W/GSILH\>.2^'[<'[3&X]':3W2J7'#KT?OSW)GQ6+-N9B"F)H%
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M!IZJ0@@F#.&C  &QLQ_R2JVML&5;P4JCQY9&W9<EC;H@A$*>71!L= X+S2^
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M1N)V:)S7=91CWV" N,,<Z2$)U,4+^).N1?B:+, >'N<Z*F;.Z8>S<]5*&-6
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MD2N(8\B;UHX(9K$IM]@R[2Z>T*1RGIEL*%1*KCV>%7XY<#Z4&6H%#&A6\UN
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MO0F^IJ5A/M)L91"2]EQ"EA?"I2:U4/,C*"=<@O%S&BI8G3)1P#KBH09#8?E
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MY^PJ$@=,M"/K4LQ2(J\L2+$J0B_2ES.Y5XHM%%%8$=@=__7P.?93;*,<<C0
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M1)A6H&[$O@<$A)&GK1K0ICXBQ'U[('S4/O#H,X1Z^T'D+(19JD)^E516LMC
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M.%?AS\Q%0;VXUG* Y8!'X0"&86E1[[Z."B9+W60EB>S]$-.8P9T EP;GC1C
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M@E<UP\!N.71P"&W;8/B!XSJ3+!+>2]8*9=1<UC25/_'Y(=&6X&C@88_?( A
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M)#6FZ?2(\/2/NS8+H2#?2C/=W8"3'*6?*9'GG_-;"7>! #)JM>OT;)S:!_J
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M^*1P*78R8(4-]P*+:/@X=)+H+'G33&;Q;W!O.EMD7DW![/8^D#8WS!_LA41
MHIIY921JD/>6K .G$(7\]F:+BP^-1!&ZS#QR*,N5[<6$>:.@[ :YP)&G$BF;
MG27G*CM7^@MCIE^#?EH/==&-":696D;[VO &]\X78K*A*/4Q:9$A%'53X;,^
MTGC%7ZVH-$Q@_V35%'/<G=*G'$6,OW'%A"E)JZM'W?>C;D5(8I#V&&M3U WE
M-*TC IULA[UC&:<;,U_S".K-WAB"PK!<J],OBK-/A="!C\,\S#0DPT=AW=#
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M-3E#YNC7*T=/;;*H#+\9-W][?MP!]!50SA*?R762,8WU#@0-W5YZ .>J@85
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M@X\HJ?U(:4BT'8Y"OM]9 KT+V>8GTEB*>]);+D64&,#-I)$4ED!$@^$]PE'
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M$%NX:)P^S.CAL) <0FN&MF:-NK6]S^A>8)GBWPZPKT5:Z';EGWP=M</7B^"
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M:2? F2D3,=K. 59Q^4(XH.Z&/6Y0'7J455.43+Z%(1,$(B;]$ <=D23(FF/
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MNL&^D=@2+HYI%2D,/RG7.Y8A61? M K]!J];Y(SN!E69@/[^'G#K P04W>F
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MNM]WG!TIQ (?'C>F@#P9E !B_NB,)#V\Z^"4R4)VD\:1IK"<UDG4#]X]:\<
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M80JQT08EW==U::_OF99[4,26ZQDSEQ<Y!K4,MOEVXH)IU:2B#=I=$$.WR^J
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MHG6AO?+LTA_2QP"0B]-$EU:*)L**,?$)O;A5S@ZQI^PW'QT-HO2$\#X!?#4
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M?=O=!%4/9Z)R?H.4HMPPK2>G)Y1L>-(Y,OH9/9Y==5XS]? O:.\.I[@-D#O
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M:64.NF:^M#P&S&=]8,%11:(: H .M MTZI<7\<]<N,(!57HE.)0'4^_$]<3
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M%RG[GK9*=GK1T1Z_@]\Y2Y[$R<G05!W#U(N,VL6&F?5KT)8GJ[E3S0_1M\,
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MC*YO53$.Z@)9=^_6U1B8[D=B<ZXK^!LC+PCV@HSV=7QY2IDY.F,4QDCV2G!
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M[\8S!U=##Y2+]_)-FA?#H>B>TIOQUHBYT*EL$9=8Z5:\AT.N3CWH#/7QW3(
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ME!(]"X<['U6 J/7=])5X/FR9QS-[M4+)X *%FE->G/I^0)>H+WJ'FL[TJ:0
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M7K!)0$E#:?(,4+&\(N(@;"KER1D_";>J&]'(M0"2@)OTJ",9NW<YJU-<4&F
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MH,^LX%\@NJ(4:NS$X,UC/R70JR1(L<R]32\DL+5!E-G X\1J,5PP9C+/UJ&
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M_(2R)L!)1K)]Y+OI+UW/'_3[WE2TGL(=ZF1*C<,:-W,(1N9@KQAQ]'EJMGJ
M0XMTLHIQ?C&EHZ%).6M^O,DALN>OPA 6$/R@QG!!\3X- Q[['SU/"%?!CX_V
MC@Z?_A"ZJ+U%-NB-DO_TG);3 [QC\R/2#J$'M;;PW#/ S1X^^>'FK,1'>T^.
M#@^>/'W\Z-GAPR>/GL!">7X!/AB[?3^>&;.$<19V=L1%I$G:,BOHX,"2>6P]
M',]7Y!L?[.__T+OJ3=F/1*!#$YKG78$J/.XPLI$9_*1:Y*EP.8I,NHN[GCL3
M#3WRT51'4_TZIDK^G!KJNKRC=R398V>TRM$JO[%5,FA(ZX"948HH1I+["7ML
M7O6ZRUU0P@U<3LF'R-7K\]R26#A_*?:5)EE(A>4BK'](E^V%.8S2[&J,;L:=
M>EP3WW6GQH?*/:J6(A&)/>*Y(5&Y*O9)5GQG?C36T5B_L;%F><'H/.T88*TX
M[?]0WK8PY@SC;L69'+\Z:5@_.*6HNO$$?]?B;,L62%VH6 >G6R P8HG,0Z4P
M$5&I"J_\G'XQKH=Q/7S3]0!#HHP-*HJVB+BJFB;W57\P+0-#A\@0')MD)KP)
M@280)DVQ7DR<G@6RE%+[$]$B=538%;$,PB5YB/YDB;G$O4U6?H>JI>_#((>X
MCIIT#BY?047NE7 32[W=9@H1]")ZE!:OQ]H&1)?*H=&08^FJZ8/;5>Q+#=*Y
MSBD^V%>HXP<NJLYIWO@(1,T<>!GR.+ EAT^9"JI^8E:5K;^7;5T5G#D,J*@1
MB\":P:WQF34(_1 HDCC"F$#)PE$.N!^3]XR[;WUN&CN1[%US\I2S\)\Q?191
M@+>@="@-SBJD"HR/I[6GIB%S':9:/8EA3LHREPD_DTMT^HJ.R*Z=2E[UW)0)
MJ]LFK=1*^H'UDB>WEUU-<A*_HY7*U UGQAFDFQ_%A+HQ!Y QH1TO5KY:G1L6
M&^RF:P<S<8'$YO!N',6Y)2UDM%6"Y[263Y)V,**B1#3KEG2U%;GCMY*T]NVM
M/Q3<!IZ#4"B+!81_,&,%R?\)RBS";K^=!USM8!'VBT'V;JM@F^?EB5M@ *.$
M,-R8Q08GCYB4*=*O"HCU"?1'%TE$094#'[<]#"UUYM8?6*%;;[VI!W?][F/Y
M<%>\@K<2@&P,*L!48O_T3=AP#$'US%(T@YNTSB<..H[&5J+9Q3VM"V=?>3UH
MW-MLVBM8VQNP2\D+8OT'>+O%4K27,/W%YSOVYB&73N'$Z=?KHL/3P<)E_!@F
MN\:2B*-E@1YPFM:=86G[KEPF>6:]*J*.2\J5+8^B0R)DGBP::Y-P]+PH_;HF
MB^8*I*+.WN;,X]_7%[_N2A]Z(3VGPJ,O)\7XVLR0NQ7Y*)5+//?"5 ^9SJA1
M3? ,'(G2 DC>QI?N6<-/@NZ@US4B%_WL"[(/82><TJM8>A8>^&3-B_!L>B\Z
MWO9G91D=N&G>0L0\57@)5M<+DV2\;,,K7C+Y.-2J(,AI%KZ)>VRD]X>;,YE?
MX3-=&F7_KXVG=4S+:>"*1)#!JQ'#O8(\2WCH*06 Y<JW1EA(E/NND>@TI1 C
MK[(!!1N&#?1<?S8'=-O7?#W!X_S]9^;HT7U/=^&#4P'O'WBR]C)3)$S#(IR,
M21E$C:5!$\,#".(17']HZMT(N]H9O^FED!8OUTQA<UZV;R04BPHYE+3-8U\=
M."RT8Z?6<4*618^4FCK6+%M^T,"6.(.B(X<W>\NP3"*M#6F=-N%QM"F"P''#
MSF@3U715VC9IKZ3M6MNAKNGJ<1QSH[>]$<:_0S#^PQ'&?Y=@_+?D( E%CJ?^
M#NXVZ(9ZF\Y@''-LE!O:K'U7MJ=EA4=*52=U7GC986DRUZ(B>L\4SIF< X"D
MD1/ JD[@1R(:?444^<:3KS>*ACQ]/O"D4J0H$_*7D&P,;HNEH?"X9'ZSWN]J
MLX SF9KXX+2;H/?EFE?#)C^6=RL;;7-%_]X_[4CX,4B04$56D?Z].BM./:FE
M)0W+4Q ?P$T^WT:WOB^W"+$D)H"HG=RT\XIEVX>M>TL7!\2+58WQZ"5-'*/#
MORO[].GP!H=)"-C*6F;A8*I%,"#_Q6-#?MTYEJS$Z;=T=6W*=.5]6;N.6$0
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MAEXB8)]:!*/TQ2EO"K6GY.5Y59R;;#38T6"_:Z(,/D\]*DY? 4':%I;SI%[
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M$R0K\M-!5G /K+_(%SE?2RD[>PN/KDO[BJRARWW%KW3>W0 SNBV9[[YSH]M
MWXCXW>;JZE_;O8G>MR(1'P=&A,!-.J:NX$WY,D(K.@VS&B*?RP>A\8GA>&$O
MLJN'/M/U<U96%ZBSTK7!MCM-:CA7.+3!6."<#F/2V; CJ)JU,5!J^0)5FL[H
MX E/(CQ(O'E8#X,Z[R#JGSYT7.*'4^LP]&.,;IE6"P9\M5R-3^J:Y*))IJ[
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M_A\GWJ;DKPRT5K2(,J $Z07_[L]AC%<;)!8LA#(K5U;&:5Y80"2;I_XZKP6
MZNKW5.<1J"*6WL]5FC;S8FSAK\LMX2H\/JP$J>K KRD/EE$ @0@&7!'84E21
M%X+]!2R(!4\EC\4;\@:C=8]%37A,+V;):,!\\*K.V.PSEM$;U#$_V'_POPD%
M ,:$O^S*!%X\R:-8LZ3Z$WDG^(+R:4Z.AS55JJ=(X+EV_:</?HY=/J)*^7N<
M*G%7\Y,ZA$#I@S>&%[+/LR;5*'VE_ *3LNPHLJ5]1\=TN/_@#3QH"W[2E* =
M\/ASE()O98*)HF0:F016\31O,#A>&90<@MVR,+W5HT.Q2ZU ?A#D(C:%X;P8
MCD@&>ZV!PLOY61-)C_<ADEI=891[^-N-DT5](OY&@E?Z:'>RZ$T"HWD%5X,
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M#EQW(:]BZ ;<<LXI&"[_FH1&S:4L3L)BGY]4CF=U=='.R;W48M-@PL\GP-7
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ML9P649M\LJH6KK[$E.7T92Q!83J6X2N.M -^&)!K*NZ..,+P<JVR,1(KDK^
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M]/"6&&GSXI=CA'.!^R^! @&0WKPZCJ,/KWY_<\QU$O0[H__JBE4<'3[Y6]&
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M\12?!U;B+)?W-7%P;_SML.$Q1-N?-?SNX.M2<_D<H9S;2DS^4U%-8#I?>AP
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M#1=ZLZZV6DD) >P%X=N0JHI3+IU4&1Y$?64G3]!M#B8(9U"63Z<&X?HLFS0
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M;/B;CZZX #0_9KG"*"MP[EP&8YVB56;RJWEW,1V#EF[E[[BB2^1.IYY86"U
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M/<,!WVMU:7UROJ-4^*,D3M.-JI"XNG2Z'5X?Y4G"U\PZ^R5L0E9J-&V#)XC
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MSC$IS@QYR%:E[Z5*0E9QLIC!*:$1\]DAX^O$ %KBS!O-@I L"HE=^&,8N!V
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M*VE-%J !GUJO6[/CN/Q2 <#-!>"E-SC7-C08E@5X%?9%6Q+T1]T?LL#6*G\
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M,.9=U9'!O7&<TYS:0[H72)SA "-[>TM/%7'/?>TJ9I.Y\$*[58A%$VY&$I.
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MJ+,:?/P9 9>_<D:71H"\T B0]SEQRDW1J.9-79.B492I]OGKKR,D!7R\D*R
M3OEW3K"?[4@&RCL\K=2<KD!S(G>@Q]@V3NJ =&-"(B:9J%RP5-BNTR3.%ZDD
M%#SJV?1<_7 V2Q1CQB5</8M9K&:+['4[V(INYZ#+"07TCR.D 'R2+(!]CTNV
M="J4N:<P96UW*J?JUE2<NI_$@S3HP!FTXSWCN3!  'HS7@:(A_%^V30&-I [
MWONHE,!BP[O(:XLB\Y:NQP?=CP+-/9P0@_/2:(THUB.0(=XJCHEWVE32KH]Q
MZ)*3L8$2<BIK5R'FM47?/T)EU%@M:'(ZY:VT;9U-A;X_E/\6BVD C7:X7N6@
MJ5>Y5_4J/ZW>(U4)KM)S'OI?5IO0Y*]_.\;S+$\,-%0V"Y*Q]\^<F(IBA0))
MQ*R6$>>/6%8A^1O=*$BWND1CYZGI*8U/<\:R=:B_>V;=Z;Z3T!XG5AYS[3>D
M/OIMK8!5Q4Q';JOH/4P#9:5X<6UK:Y:@<9ZA6^9HULX71@VP($ O;?+TX_78
MZW8=%Q?%TQ>OWO\WZ1H"88C.8T4Q=45[W-_7W;3'S"DM?$I0[)M=XR+&6032
MS[34;+NL<Z#0&N.8UF5^J0M  5V\Y*8Y,:*"15HRG5XY/))@.GIK2+@SURXA
MLW,3"X90+EI80-^UDWKZ[MQBT(],51I>PU-&.7_Z_NSI*YVK6X(,$^5T-(NQ
M872R:>#O?-.)'2Q"_-+JM/./7X06WY2=_5"Y]U::';Y?+(CWY9%NCO9JN8C9
MKIPMDY@X9#K_&;?L1ANTNA6"N\_<4^FZ6VZ5Q@#U(Y\A/X#1ZV+=ZE@R@X_8
ML2P>O:WK^?C*B)J.=P8C$:<B$/4^VED>T>L+%!G-XS2KL//9ZD3WCKOMD^X#
M0:<G W_?]L#6W=UXRI,8&!]LY_ISR$^X-Q*4+ 5CJ5!+R+C6#8G8]G>6P$#'
M*9#R1(F0WZ9Y,E7)TC8>R0+3BL_4G,$X">;S7+;.R!Y8U!E)8OLK&FDT8]0P
M>AZ&;NC!D<.@_ECPR ]':A[X7K9<**_7JK93X>-(.QXQJDN(6-81C) 4@8:J
M# P3Y'.GR,R[I*LT1Y=3;X_Q68#\CY0%/$FJ2AS29L8*N(8F94%:TY' 3P2$
M1HE"H;$VE_,%T7G:<O W!0=#BWMV]OP3_I-L"6R-$*U8I<\=T\WJ\=[C.J#7
MUD>UGOBA DG'&\Z,PHV%HPE^';H$NKF.U;Q"M+R8J#9\=*3$1-Q^HC@^;B);
M?W =[V+UF.M/S%+_%=GC$5')8S.7>9Z.0N(>B3]?D)Z;J<R/EJ1O^L.(> 3P
MWE24:KW07 DH?63L3]&5F?=,J#_*YT.,3=HRL:@4 )N!3T/-Z1*CL4>,SX*P
M@,'I_96/I[#1'@N&N_+'Z$!/W =W^%(MO44^#(-T)DR(6- A@V$>'SI^PO5G
M0#MXQ46/?N8=]Q\XYS$F%I8H@6H"=*G=N,#X%Q4]Q#SE2H67Z-D193-30F>?
M=@<4:X(SXFB*O0,/T%O'C[U3XK-Y IX]]HDEG4N;*S14$&?HJ(XW@'KHM!+F
MD(+YE^KNP']!B2U?77,DAH^,%7M([&J&B0^(J6$8QV./]/^4A$'+4TN P[-K
M-)XXF4QGHQ$:-V+MZ-$BN$T^^*(N&$5;KYCLGXBXLH?"T;!3/:=^#V[3)([H
MK9J#*3E2:S< 0DZW#C7/S4A3 WXK0T_05I 2#][I;D4)_I$;EHJ/E"[:0C<[
M=BV,2"UHCL3R9H&/1+$] <,].'JPW])_Y"V-8O>O)P]T/;!9X*=@'*FE%6CZ
MN</> Q*C%QE]BN;+[0DFTOG&='RF>T,2;LU=76DWFFHPK;;QW6INS;ACX-9&
MC/]7_*8 F17P7-@^><3^5'M1%^F2C!\N_:8_PW/<'BKZ*Z25WD0QD;B$L#V'
M-0N?]LJ.HM_-(F0$MNNO).^#52RX!<$8S(\N:E)=("V$!DV(BRQTE2ISSX0H
MW% Z*S:M:C4-WV"S\+US9%@C$[6W+QU=1:LH_9[;%W&S,0;L38VN<7#4?DW4
M+SP6.7YSTT#Q0OC3WL6+]H$@B[JM:]$L_+_BL#WPGJ'C6<K$^4>0HLSGC+O\
MYNAT[J,Y;XVFU>\932N(I!,O+AZC;<+:E8C(8?\F.][R3D\>%!^0[KACEQQL
MY$#.W[T@?O0Y@/=_[Z0'HI\HQ$=(,OEC+C95:'< ?7/OJ&\NA7F&SHU4&$00
MX"S1(@JP?7C\\. !E,%T01*;B" B BL0I^OXP3U6-FHL -8( VZXQ:B$^1#(
MT^S!,3Q%&/\*_)[==/QU@P"2?%;U^18W&R)+8VN3Q,-7$(S3?!F#S15IY?!:
M$=WXB40L+P.64[H_AS_*N4<+ZR0E_7K/7'A244C*I/L:1CTV#>TYZQ=Z/]_Y
M=8S'CZQ4'5N16IELT2QDHH$=64L #]1QQ,^6&6HH""<FO,H>.]Y-U$4^TEO/
ML48$.MI O7B2QJQX3W=':96DYL9U0C%+%/W3<F2M$E35M--2/T9-E%K%,Q1)
MO(,4(]*-\RRP"W-5MM-NYYBM1Y?\9L1[."=Z\+A7LY%6>#@?<L=7EQI9G=F;
MU^NW6;/3:,4N[SLY[A#CY/.RWXOS3%N]0KDM2/G*,^OI7!AD[[0SJ+Y3.5Z!
M?7#XXAIU/A6RJ2I*+C] T)LLUI$^ VD_ $1JNJG06]>9"KC-JQW/B8&'\9*G
MQ'YJ&0[8H<81RQ">32!XAP/!ATT@N D$[YZ:!(Y)BG/?>YD'8T[C<:3R!>?^
MD" FRHM,K.Y/8ELD;A;&9V;"D#1/K0^U2&CZ4[;^A'=?RY*1EU.2A25LKKXQ
MR'\CP1>)1_,)/+ 8^VT@FL,'17(Z@0B'-Y [LXE5$RJ?!9.(U<"/] +?D6X]
M\\Y([)"P;;'IL5 RWS,$M0RD-@T$[\T4\4II2C!618.1\X^O8"6@RH_79PWQ
MR''TLKY5+XF*)GLD+AR(K/4J/1V'[<NG7Q D:YF9J"-#;,ZR2&%S_,6/C!^&
M?1.NNMC"3RI90*R2(B&_$IW'<8N/EOHYT2T3/(0BKKCPA!K;NA)+947/D)D)
MFAJX[!5=F0<L0(?14C.T( \1?Q,Y?<BM$KH*45I6Y.=M] Y#3K,2H .M0A)K
M#K/C/2E:ZP06G:U82\L-[ZZCB%&<AV,^& FK:\SQ&\4$[K$=]YH5XT'+^^A_
M4F/?]OAX=_;Q_.Q#TTK@3AU):\)9^\R$+=Q@M?LH-Q/3F8OU'2A];B'@C_^"
MBP247=PV:58@U['$&-=0NSE<GA(:!D2D*.'3I--*0*<B(LAP<B>LNQ9$\97T
M 2B:3;)K-@SFW%(4/G?)F+$SRLCXR]$KU;L@4PV6P.]H@I3$T\2?2VZ&CA/2
MP[3I^818"QF#B:%/9GE.>]*^^4,)7A#\+B,# !RA2#)5SHB06'H7'LI_O6D8
M#Z61]5)W$!OK;)_#>\P?W&X,_A7^:6)%W("(1"7,.)WB+58<&641G,M.\X:Y
MS_^27F<F-<>?QNC^8+V:PMD!"1DG%=$F&4'%T/B0^2:W;^, KE:5=)MR7*LZ
MEX9XN:T7(,V</AT8X2EN4KC,@L_>GH\^MN.I>A+$^NO+?=)EH+#Y@"BE?Z.S
MT!C_3EEZ(WCQEFQ*?S3+4Y71ZEYJW\LK;4VW2/_)$O]_Z==0C-X^^>_RVU@;
M7S[2Q78^]><GN04OX*:.M:C9HZ,)F*I(/VDQV?Z_O?;!X?\'7[-A\-):M]_M
M]NN18TDM4?$B3D2+1Q/?%-!:/$-NY\L9$_RJ^UH-0>=L(LSS, L6Q()%B%BY
M08,;YRJ"\NQ++V8I4V,]V:38=3Q;HI,8G;]P\&O>R&+@G3%97D=I%F2Y#H#I
M2 0)#-N.2X CV4H05@S1ICXON"4CA ;V< ][B"VT76'D>^QYG.32O2N?+RK(
M30%6KJ6EA(6-4VTE+(.;!=:/:@O]NY8;(EEY?0@%GZ1%A"8NS5W<CJ631$*N
M*&!!:_D[IYVDTG>G/^BV:':% E)58\0LM3WL\'NV-F[RA3(^Z;%\B8CYM/Q-
M5[8<FF<&Y6E)%WGGJW"YP^(/B*RADJAJG0]NC&.RFI;>7S9Y,Y^.]S[/8.XR
MQO4M1^:-[W7K-QZY%QA4[WMSI;8T Q(=C2[(,F WIO>UTEJ;+-;O4 C-LG3A
MDSZLIJZFLB\IFHB(H")!.]=$ZMJ^;B7AZQBE' :=27X]>QR!U,QI ?2L/V;?
M&B(&9<^=2?1!AD\*]C5GYF6RF9 +85,].!&M4R*U:M,LW7+/';IF#%9J^H<Z
MOVG!S>66[!U+%*D3G&$UR<,B*Y$U(@X=6E-$1R5=UFV6S!DZ)OVLJEU8WY[)
M;>7<,ZU6X,V*^M$PP.U8^I.E)B[.(Q&*+K*3-]-;R3M9(E]X0>&0Y!RQ<&DA
MZ3*)BAK/9;VAVI#&SI1.E [=6'L?7;-M?>G CBSQ_LI5TJW/\FE.:JO ,=CF
M)<:&_I_W'_YX?7YV9\WHN_O*MXJQU&DJCXU##\@4:8FG[M=[4VJSRG7;BR]G
MI-?5K]WA&FW#WM?T:#+$/470CW;_?;) EAF7L*K/I JET@R7E#%+]BU7=")&
M;5!!)I)(FY7>Q/'95ZTY'G' X"+C>.7M3]@9$9XTMI9'\7RNDI%4,101B@FW
M;G8:"HFC#ME99>"5VKG=XT  4<L[XG=.[Z"2V-.]89#$-T6*(:HJA$5R>%O2
MCW]W?"ZTHN<F"^R,3MI$E81FY.;O'&O=JOM=:P2B]5A=M5U]DH6D$(SKKZ3;
M56A]544EDE/<5 :+*?,9G;U7D$M0(3H>[#<_RF%#U< C%9?>7/G )$R4F([V
M:4DV"LEVSK*0A'/B'E-,918L%KK:9$1/Q'/=X_R%&B;V\TU*X0ZG% Z:E,(F
MI7 G!?'9(@E"S?]N)85?@G\CIBW.._@#UV?8?7WF'Y2G7FD*J2/S6N'Z!VW$
M.)[;A*2WBN;#^9-_]^>+QSK,R)GT.LD[]3X4JSZ39'<C8 KN[ZJT(F_NMU+G
M*KU]Q[Q%.B.7@TK52<!.*Z(7#IU)+U4H::,1JFH7.H/'%/L]/SNW,#<EQ!;C
M(2EW5[V^:%]2%M&B1R)?!3"^K765C%+Z,DE@AC*D>4<H C%CQZXR<=K21(B$
MJ42)?D1/&&+G9=Y$G>AX3Q0==:2Q85;!&UEDT'14A-Q3/(8Y.H$Q711ZEI)\
MI,5Z%T0E@K9S)KMK\J/,$_I.F#&X<2X* ?4I? 7/X=?CV5NE$9^;39>S*/+P
M<"+@)$AI,VE+IBUID+A5.SH&0;J@H?573\_34@]BT'H@)5IRLFM,T8*$[C4#
MDN:\7)N-S7K+\:=D6:22M+PW_A#@25#0_U3A1!"CR [  NI<%<\X:%1N%?W^
MV3/WE&I]MM=X'.[W.3E9EUUF; R,6MW^VIVW&Z_3AZP'X"G=#-TVVXJ.IYLE
MQVW.:1MV;H=")S\(_=D%^S6G?$WTA#5)UD";=(3M9!C5.+XD'A9MJ6_MY#6B
M6A#T#KQS_^,K,JP%0Z^U\FL1#OJ/4I5=0&/C(9227_G)V$!CO_&+0I&6%^(G
M+H^UC.G-^9L_+&O:-!DO'G$)RUB$5.&LHH_0&.5WZR:#_8)>.]+8"V\Y"5,C
M3]YO(50-6)1,R!4H]#B:QB"[#5M=,677P/5(9CD9J 7<44&X9=SM=>DWC^L]
MV_NV)H(!MWM'?6^,N*+DG@)C;*R1*XR=H)-/=+[,LP)V<PV.6@UF#9EV!6!-
MY4,MV'3YW*"H(%7Y4B4AP'_8)L'C<J,$^:8-'(*VZ2K&@\UUS2 JNSE:-./>
M(4@28MB4V !ZHP8-%2)<31#*RZ;&K8R90P.DBAO$;\ SD'H]NKFL2:8%-KXI
M+ZP<8<TI.<=*FOX\QA[Y&;PEAD>EGU2H@-0B1@%O^9R.5;S#7'JG+0=4)=IK
M+"7PF=ET]Z"<TC^&7:$_6RORH&?LU)Z33)GF;!A*%A/7\"F=4"* L70O9@%9
M&(='P 8P24V#4\<63LC^CM@@J=I" CEK:F;LKVFG:'G^4(6%8O?FN66(,$"Y
M3 F$X8\1\U-JS(Q>:^X^_3Z<%,%!J9ALYPL8[N@!4'("C!-B$/8B9Q8H%0@4
M@.[((Q<L7M#@X5<P?7KUF@L8^6_/-R&YMY=SOO5K(R;95=S&D7A[PG^ZA_ME
M/NK7M"XT!3NUTJ](S^>(<)[B]A3]!^9\Q'L1 Q;2#6Y#)5">1CT:L&C50" :
M#,C1 :YQ-ZYIA7 .+PV<0ZLK 98,SP[KT7 26-T&YAZOS$\J,$QN-. ?$2W*
M&<PY"$U.)!BNO3KJY8L/A3E:D@#=0]J=7X^/]CGU3+8643N]VRUO'.?#4+6'
MQ&O&+=,!M>T4-V=&LIWT=5>/&VZ?TQ'DX%'/Z?1$ZWZD/_28V#3PMQ*&I0LT
M3. H;I=21]=#J$'@5LN%G0+&_9;IS]$_:J,-A\?K1.L3QD+1;,.6AA@1WQOH
MQ\&GVL*G%&JSI&Z$WP6(7!*GJ:R@.&.LI>)(+_XHE\& 8#&0'@ZOP,'#/G=.
MO?F;A[28A[W.\<%=D[N^8[BZOTTF\M["8)X!]*S<],1T(AGT6PXO,;_%9='D
MPB=3VS>%#NBTTVT.Z(NRM)P3ZCC6>;GC"\.UU31Z@1M>RVAV#X7?(>9R VG\
M_39P)7+9) OL6++ 49,L\-,D"P@ I)Y1^=9A!?@K:1!+,IWDE&P3Q$[WP6/]
M/!%BZ"]2]2B5V"$:(M+8-+@E!KB/)&#XR#RM'Z*GQG9'9/!!IW_XP#TGO1(Y
MJ(?K7QO<_JWC#GIHWN%;_:.[?*QWAV\=;=FW_L_#+*F>K[EQ)YW>@,C6Z<0I
M-QJ_J&=1#A4098!"?_W;R=\J%*EO^B+STC@,QIYA>F5.T,6%UV\D/)^Z=_0#
MW$)UTYCZ@>X)#5I1=N;!>!RJ5='B3J"0-VN_8.;8[=-K]0SH]!ORGSN76-R(
MY\ P^$_/[:/[Q"BA9*U<L"_B+)F7F%(VOH[ L!]#?_0)@!?1N*V7,.GC_^](
M=;5"Y;N1$GWN]G2DE!JIWK;0T7K*N:MPTG3PI<?S([:_9J^^X7%\F6)XMXMM
MKO':$[-LO/^W;3R]34SXYS\]W<JT.;R=/;Q!OSF\G3V\7O>PT7B^,NG\;)KS
M1MUX6W6B^WVW8>Q\B9/Z1A_Y/\/DX?_S56OE;Q:1N%VP &?7/NST^SWX 6Y9
MMW_4Z1[0:ZM.N^\4++C;#NTW%W57+BK?H7?->>W*>;U5?N2>UD^VO+V%QRD?
M#0?9F2-K.,ANG1=S$)Q9<]=V[NR:N[9;YW6SNW:-L^-N/HTDOA+7U\$7N;X:
M_\97-UM+N80/:_%3=_UF[_@)<0XGDMJ\H^X7.QF^8LROQNW)_W>GL'_#\;_"
MN?5.FS/;M3/[I=?K'&JI_"NGK?:O58&;4]RV4VQNWNZ=&6[>H'3S#IJ;MW.G
MV#MISFS7SNR7WH&5>4ZUQG>S1AO[Y?O;+]*I&R9,<UUW[+H>]IHSV[4S^^6H
M<]!8%3M^B(<-L]RY,_OEI'-T,]6F.<=M/L?F[NW>F9'0.VW,BGMB5IR%87-#
M=^V&-N;?[IW9+\>=TYU(\KL]@DM#C+MV?(,FT+)S9_;+J?5%-'=OA\]QT(1:
M=N[,?CGYH291D_>WK>;3N6 D"FU,@@1=0X\\X!*F^Y4\P/_\SR83<"O.K)0)
MV+#B'6/%M:7ES9%M\Y']TNWTBBC:Z<GQ<:.V[MPA-O=NYXX,J7G';OBZ=])<
MO)T[Q>;B[=R1_=(;V/ U7[RC>HG7Q,]^$F.B2<O;V;O:&S1GMFMGUNZ[Q3X'
M_9-NH]?LW"$V%V_WSNR7HU*M3^_TM+EX.W>(O<:BV+DS^^6X9%#T^DU"WD]J
M4#0)>3MX/9O"Y=T[LW;OYTK(@R5T>-1X>'?O[!KNL7MGQ@K9S\4]NMW>8<,]
M=N[L&NB&W3NS7TXK:$5'&\TY^B]ZU-VT<>;1K?IF?C7SYA8M&'GD1T%&'QW=
M8MO^DZ,M>S0U/TU5FIH6[9^"<:26W'M9)32*-_+1W2];[G._4G0:SJ5W^'!9
MM!='.^;>\6/ZNT(7^1#-SG5K9SSS-AX'Z"W.O9S1HCU0&7H"?^!>T,^"E)L!
M2Q^#EW2[%M[>VV<?GNU[ZI^YO+3W1EVJ9<L[BR+O-6@J\M[2'/HX[@[]5OH*
MA_10R/EH1UO4L_:.)]3WOE,;VSO.+TC1I#H-QMRTFDEAEJAT%H=C[C:/CN !
M_F1(2K?\OD/[VI_W%O[G.=&W0E=WN@[80]TI''VUO?0JR$8S;&Y<[K M?;S-
M[=(MFCSTS,PZVTTTWNT/_^OW+OY1C7#7=$D'7R4F'(\"YJO2_CT,(G"><,G-
MN6GH21[:ONFIMV?BY .7SWE-<^[;368?UXY%!W:=_FTRSNEB^70RQ-J<SNG$
MW^)\.BO:IY,H._<_OKKREX\J=+V%;7+[=^GO>I=WNIV3._2?[?4[)W?IXGO'
MUP:=XSN^UO^"?K?]?J?_Y>UNC^_8[K;_G2I;UK:[[=_-;CG8ZE#$W:#/SY-X
M$2=&(3[WL8$!?9TT@;T'^R($"A[O1V/[4Z][6Y:?W;\62P(8_=K*2\/FV5(L
M=Q>N<O7:VJ)-/:P'7[_CGJU2.UQ7I?:][K+<EN8N7YNX6->Y^OK&FT=?=+X_
MZ/QVR8=TMQ,]"\,23_Y1+&%UIU=):&TAZS:3T,]',IO:5K![,OKU: /&0'.<
MVW6<NAK9N[82V3.G>_L\HN_!)AI:^O&T=%T/]>:,MN2,-K1*;\YH2\YH34?T
MYI"VZ9 :9K?]9]0PN^T_HS7,KM$I[SUYW+X;8G,^S?DTY].<SXZ<CT:#:\YH
M>\_H@O.3D)W4W*8=/ZD-&N5)Y_ KUSLVL<OMB5WJK(+OU,'YUMEJ-TQ=^.J9
M"C\!%]NE*.W-T)Z/'S3'L[W'<W38',\V'T^O.9XM/IY^<WNV^7@&_>9XMOAX
MCNJ/9Y.?O/L%F=B-6=.8-:Y9\\U2LK<B _O6A5T->]PR]GAXT$BOYGB:X[GC
M\1PUQ[/%Q]/K-L>SQ<?3/VV.9XN/Y^#DUI93K]/[FC6L-:?_I8=["Q.GBC;P
M56V<KV)<W/9XCCO][U.1N)W%QXUU_)T*%K_!\3=,_1L=>*F^G&O+;?FSV\)O
M9PO+MR@YMBGDVR[2OZXN4X3L7O1K;P, ?W.HVW6HMZ_.K(?C;!+I[STI-?5*
M.W)&3;W2]I]14YRY X?4,+OM/Z.&V6W_&37%F0UY-,5ES?DTY].<SST[GZ8X
M<^O/J"G._&E.:E,KRLY!D\7\T\9IF^+,)HGY/@2U;W0XQTV%U#8?SU%](EES
M/-MQ/,WMV>KCZ0^:X]GBX^EUFR3S73R?C9;3\: QG1K3J2D ;6RGGYX_'C;0
M.5M]/ VZQ#8?SZ"IS]WFXVE4\VT^G>/&LMW!XS&&$_T7O6J_3:/N'].JF4>^
M0ZON<Y7@//PI#<F-@8G21GG(/9N'?DK_&T>>'X;>PBFVZGBVP??5+/;&1%]1
MG'DS_U)YONY)Z:>I2E-N!>UGW-&;.WGK[L-9$'+CYS ?TR=TE_"QBF*:J)_%
M2=-._;NT4]>[.PXNO5%()P:N-55MS492:>U,&X,']+[\JQU$8_7Y4?O@\214
MG]OC(%$C-N!HQ_)Y]'@<I#2_Y2/\=95-#8C=8*$F=Y!^_"LG<I@LS8KYQ;:*
MQC6FH=.BV+*ZS]^Z!OK+^-77;NY]<ESB;'0R^G]QD#/K#]+K"2*40Q+ET>V5
MGMSE/] VRZ_EW-E7Y$]HN8_\\,I?IKK[LTL 9;F&\W1(HG*T6W*"MZMBEV_W
MO]J)U12\F_.ZP:*OG<B/YVLW:SZ:HB7T,S52\Z%*O(->R^MW^X<M;W!"LD7S
MMS0?C4AJ3/(P7'JC>+X(5<8MZI77.^ES.9SF:^U\8;BA;E9/W"_P0Q)(04A/
M#_ U_)5>BTG9(;&",564T.N%R,GX'<PRB')E?OO^S7//Z6-M'^QX[U!<;*>+
MFN-Q0IO!Y>;%>),X\="B.8Y2+X^8]H5!I_Y$94N:D*<F$U+J1DLS?IKEXZ4W
M3O)IYTN<6E_[U+S;R^&?A6#?1]YO?I3[R=([85H]:!$!DGX3Q7DTXO-<M+G8
M?.QGOI" (<7??%I R_.]E#X3JC8$]?F,U"GO0),($8.Z],.<*$/.GRFC1;\/
M5>(/@S# 3^B0[E)*2< 3L?KC/#2U[[/E(B8ES<]FRR0.2 K/.]Y'2UG^:!:H
M2Q ^/;](@CG6%0__@NR^5"T9PJXH42D/3+N1!BDV1!Z(\T3FSZK(.[HB,^]L
MKA*:(,\5*WG^.WWW2H6D"\9Y)O0=))E247%QYDI40C.1.7TM:./"TXG0QT@L
M+>(@REJXSJ.9=^6GI!U.:&IC4BR]5"7YG#75@/X;TKI"JQM%<3*G_4T8!F+O
MI'/P]W\[Z?=ZCWO=SI$WGSX<O]GGJ4)D+>@[BLY2#H\6>TD?ITN/\YG1,2R6
MWEY$:A;O$:E.&=%4Y#TK&M<?/C[J=GE4G\]'3VF_X[W&;()4=JM5/CBL9JHB
M^@!8$FU5V)9C)RZA3R*"5IUJON1C3JGG\I&"6WAK&6NO7VQXE</%T32&:GC0
M7BJ?N-%G.N,4[*["]DH$+1RVX4_;L72BL+=^0I>#3KM?94TSV%RK_ E'2I0X
M)C/K7Z"U<9R3'=P>TF/TDS8K^!M:3%;)0?.PLLB]-6.BNSPGBLZ8XFD?B4I3
M]G'0=4AIGP-P/&(#,U(DB:072>S,PS5$Z7HI'H,_5)J$97@WX3.L:_B)7"Z]
M#<(]S9L%1]HE/F29"9G:4$CX_A-9IJ,D&/+6&S["3^JI'PKN -9.F@KMR(H!
MV6(>9K=XN/2.3SK'#ZJ4T#;'8_G0WN$)'CKJ[;=*>W[8.7G :E/Q9 \/]GO[
MF+*F2 \59@MO;]&&Z%0,\-+MT+7K"<>%98)]:[''XI-:8JUT&=6(* K+5330
MV#U.[?2 /.*M<FC1H<21ZES'P;TOX. ?9XERM,KB-7ITG"?&A.?-9(?*@B1N
M3!_*KN+B7KM. 1 &47CQQ_+52.:=:\XIG<57H'':&>)T8U503_^P/8,:@'DI
M2_OJ,SW!-Y0V-5ZY '=PY_1.?@R;KH?U^:8.'GL43]^=?XEP_0%3OX/\_6G]
M="2-/Q$?>;^ L,HC4N!Q7\Y&,^(Y),%"/PW\[Z0[-:=Y6^]$Z90\*.[$PN9Q
MRJH!*2O,[DDN0$C-(9G23RI4M,'>>)GJMT+ECYE9,^LOM!;8>,10DXS%2YXH
M$?PI?.3Q*"@4&%^,@3%CF/&O17V 1*=?L51BKPC]2R0*!J*5!A/%DHM^U?+B
MT2A/6&I $1NR$18Q[^YU6[2MF-^!_"M25\,XH7%(\OH+FO%GTG8R13*M/Y G
MKN(D'-..D02L[)&Q$6G<E+0 >/7-EJS.D7X3)\, XEFEVO&/&:8+.&8\F)@Q
M69HD[A2K8(F:RTY-\M31/VGS?9* M.1IE,];7AHJM:"9TVZ1/C%+8MHC#P9-
M$$W$*YV*$3W/4T0UDO+4G#A&/*$I>!.B-%$2%R&M)T^F)&EIPC0EDO3J$F?%
M%C3M^;(Z%JF+-&%:A*O"YA%TBTC164*]L3(\%1V=5A.2DH5A5S<MF-.)D,+W
MS]R'.P";$-))\[&6SN(NXO4GL8)6+ZYH[ $<B'Z>BG8Z]>GU>-*>D'G$6LHE
M/>'+N3-AO7CYXL,!WW%-U_KZP &2!5G.BC?KW[ZQ0^05/D5<?"$2TG_F0S^$
MRF@, 34!*5:^A.-]VLZ6"]*3_"P)\H29RT(M,KIKWAZ,A7[W,2D$_*_>XWVF
M*MI_FA=I:3,XYT7G+6U BZA7,P)\7SXF*]JP'+I(^0)F06IT32(\D%HBJ\5L
MQP&M(X%=8G= ?WFTS%1:WC:F7-)2Z0B( X;^E&_U$&R(K9LD%561OT5*_14Q
MOP5T8[FMQ%+M2>F'+&_!30Z)&YTGRO)$YC#F![9VH;]J*YA>IFTTF^;-5+C@
MLQJ1K9S1"D?9^F,RFTF&\A7L5>7/[_%=>PV7WZ6XF?K=?J_E/0EBTGKHB,YG
M9%30#'(QG5Y'HP[;N\>/B:?[N(Q_O/_O_WW_\OT=%:!*$@21JTI*N:3'7S-<
M<WSXV-LF+]?>99S&20#6L"^6]X(E _,VIM9G9R!I:^6S_I"8FP6;7XT#\)E1
M.7A1X1[:R;L@2:@6P6*V3!4QF3-M5</6=8X<TAH>CWB!2T_:3QQ-V^ I]!,N
M'"Y\'H2<0* /O^.]AS]#+/^(!2L+P42Y0XG+ W^%Q*S,4.<,>/_U_!D+7'_!
M-)=Z>[[W) G&4T43U!]8[K>\"S^*)T'+^Q ,XWDP:GD?EXF/1:2C "X7T@]>
M$M>_D)^8DYPG\9ME]/GGO.AWM P85MD(AX_6$7'N)Z3R3EDAKC=TOI4E\6.R
M;&ZV5T82E15S[%&%F$'X51O 41Y;WB+.6.+"RP1YW,YF[*G!)&H4QD2-<[A_
M*PICQ_N3@Z*5K\^(D<R"-(L3[7H=(D;#(9^Q2MC[HQD(63,<JV\Y'K3*XH9J
M27\H,YZ6H^B;J8GX]B!+HRD84,0.8*3]0 N93FE(S156-#L_3&.XI&0(,ZDF
MF66'DUE.FF26)IGE=NL.YE,O34:__HW^T3L\&9P<#;K=__^H\]=B^C=B$5G]
M'\Q&\9*.^H>+SX_UT:)8Z3-(XZ?R>MU1SI\]?=4^>_X("CQKDHA/C0()3JW(
M^+:)9YR-8=(I[SGB5FF3NUGLYZL/_Q6_>>1]T-+OE2("G;4_Z'W[KT).OR%A
M^IC^#I)\;)\7$NUX;T7D76BI^?!")&;QH/5O&;O9EP2250%<)WD;5=?-^\D3
M[X*D/[-Z[VO%9AKG_;?3(MPS\O8B_U(MU-28R] ;X46Z),4RF/HZK$[F,T>]
MZ>;A)7],8R/1*>&$=V)VB("32LS>* 6=7.<&D-D-!UU*:I[/:0#$ ]GD9NV>
M_6H8$/XT./]93>=8;IRGGOI,.@1[M>$*+H5T5XR#3HGTQ-I>G8=XK?#5=!:H
MD&^Z7A/'?B.RCA-:+ZE&L3@7,=<Q;8\_]HU_+<V'HSSS(X4Y9D&:YLIF<PW#
M.![K4#W/M.5AJY _X@U)4W(^J..^[\X_M)_2MHSH<Y(^8,/'Q,/(8*3M;6EV
MM&&()\40V@4X\I-Q$%_ZFM.E2SJO.7M=+^-@S&DF.HNII:TA.9D\FL=C20"@
M;YB4,OCIYT@34%&<3]E) KK4KO[XRMG:!4(_B5^$MUV/9=KQ+A#;(>7/<7ZP
M?Y?_ZX?QE'VQVL/!I\V5$N(QE5Q49+J02?4YF.=SDU8".HS,=ZU'^&LYT(;?
MR'U&B]@FUYEUG^OL'#8MY[X.#M#%%\W%$@^=BQ(MQON3R%.%R'"1NUIXFR11
MJ8X%E.YL#(]YBF_XNL+&?GT>,#-2DB3(5Z[EQ@\=IH&1+./084*B3Y5X#2W<
M,EF0-S81K56V<J@RNKGNV2)IE=B=NHL:NP-*T4T=_2_4,.'<YWZW=\K9A9PH
M17(C LMZ_^R9ZWN&/"N1_HT$''WFMQRQYFZ_RY\ QP\N>?@B=>GYT[L-OU64
M]U/2TEU]R<8_^LR1B%7>B1/^OA[EK;V-,$A,OO8BN(P1!3U# ,A_^DHR<%N<
MF,\!&.)F<R>=6XH-SK*,GA6MZ.G[,_YGHDP!@G'KZ^*4M34'K(9&WF@6A&.R
M(>L"2)(SFRCZ1*#3Q:%HU7[HQK4.^KM!-/'7Q:WV2+J./<YLX:9_?0]I[:FI
M/,UH[S&D27UFE6I?)OL1D_W*4_7']'@Z6AMFD^GV^IAO[V3_?DL:4V1#4F!0
M26/G4'Z1*\[)!9(3,S?EL*&:>D,N<T6YC<[5<B,CJ]DR=%N&I&)?KJ2-X_3<
MI.2KF%1##K647S"9MJ8:M_9.-F&)'0Y+G#9AB28L\37"$L?KPA+'UX8E>C]C
M6.*F0N%"+3*;:'1X?>&EX;T0 IH?MR214SA+ZW9E3YFI:X(/IJU]@24Y ;<!
M&>>.*#@Y+%0C$? BWWNBB^S7ZTOE'L8PL8J)>OU'/0RAS:+R!'K=KD=4?])[
M/'WX:?J02Z-1/Z,G!/UYT->%/ 9?PUFVK2%A3J1]8E6<#^3(A6/D^<6I6CL3
MK63536@<2]$(T9318)%=U []H0H+-5672RI3+6GWL53>M?8L2M5D1":(JF#[
MM)L.1L8(81;C0SM[^4>159GS1N@R)UZF^\VB%JRT8B0BW+"&K:JPQ)P!93R(
M/O*9Z0!2-U0C',#[WW8ZBG6R^,AI:SXT3:YI'?=8=7Q%FQ1BHVS.9ED!\SX:
M-O&,V,2]M1[/=0'C<UWQMEXMI1G-:</2K*U"IE>>%5V/OU44'D:G.NP,^B</
MRIIH9?=JE4Y6DQ[S/K7QQ?21H>>5'2V61!\[.'ZP/5M\V#D>]'O')T>'I_V#
MX\/C_N"!B[G[2:D%S3.TNZ,U0=ZD#;NBW=5'5I%Q5$+Y,""!*Z-N"Z&]T#ZY
M:L4LYPV\_ -B0C>!7,?@*W&\7P?'^U7>[KVYD))$C$@##SHGI]YH_I"KV,L%
MI8<]^X<:V"0:OG^\WW*'-!GNDNK0ZQP6(^\MW%)3>X7*AD%SE9JK]'6NTD4^
M;$NI,^*'R,)^]+5I[K33/1K<7YH[/3GM'Y]T!X/CP6&O>_J52"[>16)[:GAQ
M8;. V0VT"W4CAT9Y_B8.7?!\KOKO=(]KF?6 B/$:9MWK;F;6W;[#K'\%ISXY
M_/J<NKDUS:VINS6#MC'S-]^7@Z/;W)=!YWB=<N.0^YK[<HUR<WQR.^7F'AF6
M.(BGCKW]1%_5QG)JU+T?((%;FUE*[[3*4M8ZBRKLI=<9U(OC;N?PX O%<6]0
M%<>'QXWAU-RD'R25K[E#!X.[WJ%^IU\OHKM$FHV(_F8&LBU#-&[-M)'.#4_Y
MIG[-5? XP<!@/@&@IZ>O=/V.B=Q\#3]G/1]:^12FTNT<="L\J-N[D^^SV^F?
M-#[/YIIMXS5[^NSI7:_9BI2_YIJM?DHN!Y1;YYJU^3=WNV=T8[5^W#VXR25K
M4L>V/'7LM-NDCC6I8SNH44OR]P<-ZG>1SQ'$;93J1MI_$W(KR>9->/BZ M=-
MM1)*723Q!* V(HG1SJM(X;+IVJM"6:,S%Y^; Z*JJ",B6DZFW+1*5P9*-:#-
M'?OX_.QY:K+'6D!Y5I<%/D*IC)#K1Z58@"OV2+M0_\SI4:X9"**_1#![Q(-1
M,^$+7J6WUT7J@OXL,/0T8A=[,O8%VAJ3;E3RYI)^VTOZ+EYW"YP[X(6B!5?
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M88KI=/LD2#\QGU@A[R:W9O=R:_I-;DV36[-[K+R4XN%GK+!P')[,5>:>K)A
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M-2>!"7UECFPSM%EU6SJ6\&FT]G*M_L-BO*3P,)U,:)AIKEKL22*C#H&PA8J
M=QBI/$O,#U)$K.: [GB+R6WXEFW=(S/G[TP3?TS*#N1Y_^=,,;RISOP;PHM6
M718@8!2=+R2"7H(@A)YU%X5TBTS^QA>RSA>R2:4=G Q.!\-;3^:,(;_NH,AN
MP^$\DSHN;>PXQ@-="7K"QNH-TEC%T_%4;,%#;Z^.-4&VD!:QP1@LLGO??#A^
M>.*=36-$Y[G_'NP7"ZK0LXX/Z=7K=O<$ )*169*S77'L:'^,]AFQ)*PU>Z)U
M$ ]P0NE&M<. YI!\ GBCSG08Q8EHBO"FU*4T./O%+::,EF#%GD;Q-D8L0QS1
M-$.O=V0,U[+^894".\2J=K"BD1QV'XB>@3P\^@PPJ5@Y,8I)NT8QX?TTIUP2
MXX4(3Y<D5:<"GTJ\$Y] B5-8"9N4D^C+^ >!).61:@UT3 >W0&^-S*/V=#K>
M^\U+N..ILW$,+\*>5"N*)%A'6_O&4;#J<Z\YK>*4]H ,_^'YT]<7'[W+7J>W
M7W-N SHW')8Y.&1 JVB_#(VU20T11%&ZC2?=P>.3$E S$/*7WH'@9I;.MTJ=
MO$"C-CINS%1E>!Z.E+@X[+WHU\/]1[1?ZQ58Q^-I/8[,(X@3DG5N?9Z/K_/[
MTK?ZE6\9)V_Q,=P\]XGS#YQ+!6]HN^H-K?GB&D:%;P_HV_W2R.(PUOQJ7S?B
M17VX$,3UK/)V3N]U<UO5>#VK\>KDV9@YJ0[UP$WHARMH'/=+4WP_RN(U+:6-
MMEC&Q*^HBFL8A#Q?90X=[P7];4GK^.SP*_8I1AJ>G2'_UC =HKL!X]@Y%X^Q
M.'MK+):2A,FGR*KK#5IZK241XR3;76OMUIA!6Z3R-;KP3B1OE(3'B@PP<8C]
MFS'%O?HH5XO=\!*%< 6!='@OKC(_X?I>5L3)_O6!DUF\WEVR1I%I[M#.W:%M
MVABMS(GG3X#0-SF]6E8'F"L?HT_RT.F!\S%14RGB47$:1/%B%H1-"<'V*"JE
M,'!553' TZ[QOJJ:W$"[G-0:-1K8E[2,3#QAI'%8SF=5%RYQ/N\_([,.\&]2
M 4 :1ZE5@??ZCU6Z)59X16,MV^#*]8K1_=92W_K+ZX^]0(COE53$*AEL/.2[
M':"\2]KI1AE9HA3?TX%XN";@1ZB$+(JJ4HMXV. A6YJXX"9Z4]J>I[2E JJ!
MTN(&_7@KKS *',,4#>"FR#N!)\(>X*AT@+#D)GG"2$7P^R1X/G8KR$H5O&#I
M*D%:,LE]4CE]$MNF0MZMND<1KDXD9=CEMD'I'08DZ?UD3GN )Z&!H_-1Q BC
M'V<J5=4)^L'<@JF3FCL/I+IW!?VT %=GD]6MY.7I%>M$V\B,=MRC8YQM6"SK
M[3D,@@R8,&%-!5A+W$Z,&\QUI (C4-V(&42+4POG\VL1YF)*HGG&C+N?!:EJ
MT3<6I6YH]#,J02IH35>*1QC-8C!=5.CE28K*_O(NLK-1RD6E@EFPL-W%H6(O
MAA877X$/UQ2[N6<^TD.D<!HRYAK& O0(,==1GNJ%:];_>\0U_1<9CX,)/,\1
MA=QJ=:]) -JA!*##)@&H20#:*CE]Q^*]=_%E[+TC(@C23][9PXM[J\)4VCM*
M9@4S'>.U]N$N4WXRDJZ\+FQ66?CYW(&9.!;B-%,R(HK>4]7M+E+;G3_8\!$+
M5ZZZBHOZ=A*($:1;:2C:/_5Y%.8IXFI7<1*.KR DS2PTV% ==BHR^2=Q,G=$
M-H.JYQ-_A&92ICG.7"4CLJ*@QI2^C&8ZP%I%,SLMQ%-OKTB_NE!S?PKTJ[%X
M&5$902HXJ@PD>EEZ.AZJU*(G <.R3X_Y0[+7TGUM5NF/M(?+ME$:BJ6;!4-O
M]&F"\:6?2I,%\[6MU@%^#E9TXW:5Q>70*1NIX#6DNKW /_. ^\K9[L[PGU@B
M=BC+JH],(N[3@HE:0_B<2E[HG=+F@X:*2 T*N.VJQ4%=N0'C-83,9H/T-;=F
MBZ%-Z3U@>SFIT#@LG9QX9_&<1[B&@DF_'6M0(?@QK-IKM[-580XPS70F9>I<
ME@0J@C3N1D8'%KK4N6/8]94%%O>;^:%L[8KU(<F,L+\D2N#/S:K+7!*5K-(3
ME.RC;.8V!:T[V0)01)"/@C T50QH(<$ 89O81W/OMV/I!>TZY'JEUN!TF0:S
MXIE=^$O!J"."E[YK_]X_&7@THU#[?_/%)(DQHBN=00V)F@)*'DWIZ'&59N**
MU>/AMF45JEVU?#=/,?5I6,U5:CXAH'ZL323QT@^ES1R9N&$\I($BHEX>0:Y/
M95V:.?IV@=Y$<3W0OZ-_I7G.K&)%'')<WE-H!>!PF^)^K^4UJ[>/-X(O'[%+
M1=05: ^(V8::,SH^[I0.Z59G\\..H<Q"0:L"2>0OG3<G9E^+N>@]+T1+(4CR
M5=HO6A- A=-.;/B; D'(F@?C-AQ0(3+7IT'F+4@*(9-Q:AM2^5&4NU-G[S*:
M.*W,A'E\HFP_3]XVW?C&%% M? 9*8C@N^".".:1#8&"6A@%9D[2O?H'?J)T[
MZ<P'$*S>:?HM,6]9L!&%>C[FN@6))%&Q&TN%@!3(10C"*25,_'4TT5[]#W:B
M9R/D<])8M.1IC#:5##K9L-1:EEI0+KT@=UD?!R:E_RI-$-::-VYN>!TJE?W^
MJAUT)=!W=9QBA(381 7S(9DY<ADXJZAT\4 JW*=;);!2D/=@Z7OM?'7=15":
M6\420^J#O@,\V(8%5GA!D)J\"5X1-YP@Q4G4(50Q%_4?D9,D68+>+UA>RU$M
M';N+#KVUHGC:^-9U,]:U%L@9H4U.5QJ>2(\WNTOW^.Y<%*QPDSY]$[N[51C>
M+2TBR,H@"@4_U[Q/Z_R,_,LM8]$2-^&\TWQH^&,+O\UAQ7)7Y\*^_F[V^S;8
MZ=Z955701N*G.H&7;\[;/6:$BZQ 0C;X?NM<-<QIV.PQD TT45H\#<)_VPOV
MZYA[P@PX&L>C!)73I;?W GJG,B9C%&KN:&K]EK(*?QRISU*R0&]>^ZIIRG./
M^<OOI!2&HD$M;0=1."<T>3+'X0W%"=)(W%:;K6K%,8"6$:$H*%@@;2'3)7Q&
M_+5JJ:Y5)CEN75B !-.$PCC(BFC:9%5^MUBLU9.J5Q)Z5453@UZR_C%4*G(5
MSI7/, (M*\!P4ZRLD@5XAF"L]DZ4URSL>>VZ]4+,VLVZK2"U$]ZT$<9_4;!$
M]M_0U&YRM@RBM?RR/:IGR(U+8SN6_GM$5E?*2G0 99-SBR0EL:QX J_'+U,'
M$X'!OT"#T0BBL^9."?XXMR8FNB."(Q,7O6>$"(7T=&-XR 'Q QB[K42=8MII
M.T\L/*O#2LF3_(T&_TMR>@4]CI=@_[0R/_T7M [FV@QN(;QT7T[%*!PNRQ)\
M1'].C-RK#FMAK<=Q"IM7XY_C1FN?G_U^$D_(WN?+SF*MUQ/T$X_YJ%,,Z"C<
M,)C7V\O(8\D%RAU;OM7WK4D?V*'T@4&3/M"D#^R>H"NQ;=,#P%I15N[5N%M0
MZCGR<['X LZ5S8CIH$-GLD'FL8QC!=$Z?:_]7/4#;&*F%:MWF'"-IQ&",[)C
M5#15Z8IOR!&'XIDO/H1$.-99A\J1^1!O*F!E4YR;XHIF=QB*<'*XGN<0U9 _
MN*TD8-"@?&:"E?*:]N4/_>A3DB^RD=4PG8>V6B#=HWOQ^X(-=2$!1]TJ:$4[
MUZM9'J+9J(F?AV3%I/&<JV1A5!N%S;C,C>^#*"5/JT/=PO.@M;PZ52N5N Y$
MR=S/=%L.2]@-K6W'TF],:\83I,DK%=*II :4DWDUWX+]8/FM\=1]+0*LL8,M
M(U\K&U9=B2P9'EM=WUA0*_R;MX:+P-2XQJ;*.*N+_LUU'!*Y2EQJ_ZD([*Z]
M*E3P%QW-&VF5UF0(UM>H25I*-6<PJG%Z5R)1Y>VU47Q3/5"-EM<&A(K^=R]?
M.8@,YQ]?22C(_N;INW,)6FM_L'B6V45L8OXTE]]\VN_K\XSJYJ\1J31LFY.Q
M8*X7LA:.;=+":A+43;(#W.R"WO&@&"S#.M%Q#0%B3ATK[9@SPFI>P;HX92E/
MH(BRFVUJ%7/Q.5S?[UK17@3K6T#0YWZ(0QMG^3F9S$WOTC/:7B?;5E/1.1?K
MV,O@7B_.6Y@'&N:&6Q.@R:2./3!5E^*G3N4)_X3&9I=2W[GPD9 QA1).BK3/
MB6;FWCF5/A-OMES$_,1LF<0!W9!Y<3UV72'Z^6L'7W.;#'8]-H6#.Z)L_/'Z
MXOD[S09,S=X7G5[3$_E[J42]DQ65B-GJW*HI?+@MKA9$$>;2H^OI#\,@G4FP
MSZT9+)L-\,-LT%F*GI$Z5G>NXD6HK"#^H!8<W<<DGL[(VFAYKX"!]X\8>39O
M_9&?:T7)#ZYH7TU9QDNN\4[D'5.7P:H#;4(D3O,BH:!NK4[>@I!V7?[U^G47
M\?R5M"OK6)+J\DU)"H$J=6^XC;:(][S2-K"DU*X\N"IF^9Q;$CEI!4XLT\F#
M5PO='OH,*(,1XJU)(;NM<Z]P=M#KQ2Y:G7+0[70?<-EHDLZ"A07=SS-NE\$=
M I"+F-I3T/L:%:THRSD@J7M*Q4=AA[+>1P9D$#KI4W\$9/H^E0)9'OLBGD@7
M:^\/>BG'MQ=Y,IKQ">G)T#1E,A)L(RV:U&ATP;2/ZJQ&*,B'73=A=N2G,R:Z
MWTB_P0F3RM3C39%&4%"4"@7ZWWO]<KZMWH.4G89V4^S=^/?>H/C:!:E$--DG
M'BW(CZ!"&Y MJZ\=]&S[ 4#+NN<@7P)*R^%!Y_3!_59P-2*9;)6A0\L:XT6;
M&QF4T=?Z1VT 3A!S(UXW1ZE)RQO'Q+I4F]A7-$8K!9K\,.9/:;@)H/^N8&0<
M>.?^QU=7_E)?6HOR>UZC^^ZY/(#+M/PQ^XQTBPLRX(AWKBK#';TNBT#L>]SU
M)C7N0V#PH:4,\JMF=-64<*IBPK9FWJ!I"&I+S1S]T0RU[")5Z*;,<1&D-3:D
M"1T&?8-$A.!0L8!)=,JV;)GX[Z]]$]1KOT7&VO%QY^C!&J-A%0-D[W" 9P<G
M^ZW2'(1G.>O=ZS+03-\B;>I9$A^*R9K<6[0!_:F\OX?98WJYV^V1W/F@@9T9
M.H99:)I9.SQC?/."Q,139Q-H:[;44 H#.=[OR_J6$XG7W-69[ASTY,T9[V=(
M?);V,H6?G*B9#G#/%:G[FH8@\.0<\+)<PW>F9=];->:TX'/C!CUK6OEN)VE4
MG'YK.7D)=;U@Q'WO["D#&07IJQ(OAF"?!>&85!+M!!O-XFA,!!7Z:>"C@\^8
MWB;FT>M*)LL*NV7*M"P%0$A5^$KX^S3UHE1(0^7BUP\_31^RK$%;):@I!:LF
MQJV9]=G+/_"1R'(G&NM/O#180>!O$E!V* 'EJ$E :1)0=IX;]U>Y<:%.L])#
MAAIL-*/H .-^68V7K#+BEZ^>X9?,K._ <S'F6,U)/<L$G!K6'A?I<>VXD+8'
MBW^$&@KC:SA[]8=%?J I]KJ=HR-O-'_(">&N+GG:.1[8/QC3>>P#EPZ?IND-
M^AJW;J_P9H^#R8341A10T1/=SFG/CJ'A#T\')F A>+)C?I@!FT@7?43O'!S;
M!CN]SJ&=!%DEOT)'[77W4=H$[9F,<*F=$&T[9G\ EV@4.R,YGVZ?&SZ-E(NH
M@HAF"\0\'<2UZVLTHVWU@[Z50M#W"]R4/-*-C_@6W5L/J2A\@:3*I0HUF%Z(
MQ&4T)2D#T^DZ6FT.<B63D[J\BFE&'$FZFJ2"="'6_\0GDY &)S.2FV76?B0M
M"J78KP3?&MUZ5C);UEH!.-X4R=F1S5X7Q 6Q]*.<^3!]UPG1)FC;.$^+LF9
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MS H)ZE)>)]&9."F\E%(2.#)"C#N].D*MHK\-\_!358FC5R8!XPR5#$PG(5D
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M 'UHFFW"Y+?R&R56,$_5#;RR7#KH..SK3_9*? DG@-ZDBO[>SRV@*/"/]F;
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MEG [^,]/%P'7F:A'@O*\VZ=D![R5T@;J^%8<N.]RV'I<_D;N5DL68.]9S.M
M\!^>F_Z57"3M"C;KR:Y??^2Q\H?F@C\_+[G^#1[U=_CJK98?V1>B.^Z_+R:E
M0:>:!^UG:-]-EU59Y-/D?3XKW%;S"H]F3SSYB_G-QYC],<7LOQMC]F/,_OBN
MAMO*G@A8L*'T"9L%8=(GZNOS)T!CGU;Y!.%HD_)R9XI:2*>@R-NU;>R77;%7
M9L7QJ!-?,['A_+>+,;'A2&3!WHD-L*C!IL93YP82HO?/;(#F#J"6 P[JB]1R
M\&+S*U9R.'PA=33P_KU296A+_W529?9UH.V5,W/(-M<=.R!CYM*QKMR?6XD"
M[\9#2USJD-5WI%EPHW]<[M%UD+70YE$ QPQ1[Z>0XMSM\R7H=;GOAT/N5)#[
MQC,68=BU"AH=*(_KE)"7171R ?7\AB/F56:+KT9JJ%O'6-\,J+XA:Z_'?=6A
M9[MND*K'%>YS!A**E7_*6/;B\_J(,8D _[PA[5?+PR,0=H.6NFC<6+!]:H[F
M]<6!=HGHCYA$S3&YC5FD=TMI^L_8XEU>MQO/[_RV!J!K3ST(N0R??%0[BQB'
MHSM0#L-[?/U)9L;T6UNO^$Q_SI+Q, _KVAXS08Y:AQ@"QDC<E93S"9PO=KPO
M'72DYX[ZZOD; UKP5\]".^8D_K]TFM<8KCZF</7W8[AZ#%<?Y[6Z TGW>4DH
M;)"/22BWF81BTS'_FKDHAW D[KJ2+;C&FX4!='*!T@"^=O,YYXQPTN=GZ=W0
MG3JO.:3]%9(HC.7]Y^# #=GZIY']OO;.RD#D&W5"THX&2R*"A@G;A<#-V340
M4UL2U@(1<I#])3E;UVT]10K3MB#%<W\XZ@3)IY9^!+LGRA R/7G\T1,URIC#
M&+H&VQ#CTN?J9="&D3:]%+<:;EC*6\$:?CEZ]%/>Q)[&&OWS 0<W),YN!2OM
MZY)\#D[Z;JX_N9D'UC^^9E;YO]M\9FLU?G6'SI^J5N[E@_ES[BAA==]'ZHX;
MW6YTQO)=M\]Q=;I5KM!X\JSD%5EGM/LKD_H'SZ_<(IF45]"33\DIZ1'_T^ZZ
M^GS!:!6:L0[ G4 EO_SUY%'R)^"2__?;[1J>^=]I[:I\_EE]GQP9C/KOQS6]
MBR.;WN3NPM1W\SSNBU__[..__W;\\F?[MJ?WLP[N+4_,9YW*6[];0\J#V6D*
ML?IR&0S9S7#S<4./&_KC)^93S=&.DOW))F@(#)@*ZH@-VFW]#;[L  (*ZEQY
M-!H01ZM7F(PA+6O:J^CU\8C?:W'UH]P>Y?8GG-&5P]WTL?D8?G<?MYOQ=NA)
M=X.5#S!<K;?+XQ_V I7?_OI6"W3I%=DM\6 ]7VPWS9>&-'PZE&&(1V\OI>-/
M!@ISX=S/8JP["'%VMU6.H2*@UX*9>I"%48L8M8@_S?I#^VPOW,5-L;[]PW@?
M'[ ^:/DV J6/"2C]PPB4'H'2?^UHZ#LW71:$CG3UL87![FP4;)"LB2"2/4?M
M3<6.P;A#;F55.P4JB3$.OT4:LT52>0,^UXE,P'==TB1^_=156*,SJ>'60KB]
MA=J#FE!>H<6=9(M%Y?!3U$L>?MMSJMGN]=^,]M4:?E'EBO@O6#&8"TP/3:D.
M'QR]G69ML L/]^N"#O43^W \]L]7..&_9E>\A=ZXA<#J:OQW5M$&%%7T'6B#
MH^PZ%MG%R;&@O\.Q %TFO\QG+9)>B+R:.916-1,NXHE:P7*O_"\"[-K[K8@+
MK6*B"SEH\#$[3\H)2AXW.TU>%LFZK)NAIZ^8LC*UF&YZ'Q@HCQX0W,R =.$O
M% :-K[T+O\VI*!L,^X00YFB%^"'%9M'+05];3*ZY!LL'62F7(-I!.H.U- ]/
M0)_P(<054ZBX5E \YA;#6>&:B_(PF$4YS1G",4GXH/M,&/?I]JC*VDU;LN*0
M,MQ/@,-D?OGW?_T_WS]Z^-W3.NK=RA4+>+Q0./ZP9:8@:92&8)V16R/SKV!B
MT1D,)J^I5,FE[Z)T)N81NPB.-A"_,X>5HI/7\WD^)8N1C$M>"GX#N^ELSTJ<
M2?9L9H69TGB9$6THJXJ++(-(DQ84^?=NA[\46H')3^IV\@=:O7!%[#!6CTCD
M?\FS'[;,,FM\:GR1O'AV=@)'!LX13.ZL:A>XBR<Y)_#0[J,K>X*Y@/F"\O=V
MTK;J]MO@B6GJZ*$*SG I#HRL#CM426V[PF"%TF/65G3_PW?03RP_B]=26:'V
M=)G#C$"_IZX6!_$S[/U%A=OS')MO.'"(^]=<77"AA9Z<30E!\O"'[Q'3Q+WX
M.6NFRY-_91]@LO&!U(]G%RDOM-!N< O.\4CQSIZX;2EE>$P!\4BD<J_Y9'=R
M7#HOR&N+K6KB7\'VH(]ZBP>_:L%ZK?KS=JH3$EXQS0H\3_0!=[N" Y]3V:'>
M'I+!9= ;+"&$,_BD*[A57L,2(2XYX4TFM8?* J0IP0\BH8V["]VP11)O21&"
MW#F\7M[F<#2R*O'RGQFBLDL,.F KGB"17T=2^@_83?4LG[)>0]XO/]B;CDG4
M'W^OS%L,!:9T8R! &@0T(^-XS+AJ4X=[ G>O3D!J@-0X6!CZ=O>90B^@OX*I
M/WPBT#&MKV'-&H3Q-,<GN>]UN:;YQ_YT(VHZGS>>Z$^2GM\?G\*\ESC]"6>_
MH$2&H""S>)$]?B9+_+6TXU$7WG<!LQ:.D"2$#2L86<-'W,W08$^Q8EO#TF15
M8F@(,^/A8Z9L%0D3M%TY05@I3<4OR(EL76*9-7H6\RX78L;"Y>@P[IR"/@8_
M*3>LS$$_4,%*X;P6[3R;BK#Q'@%TT8>O\)/I,BL6V/LZF[MF"^I1=>GRU0I9
MU%-,Q04A.]VFR;_!!L#<#IR;JH1AP.R_SQ;T,KH=%P[+O4W+:O;>N0U]#H+5
MK>A?V>P2"?-J^@-V_+ILZ/:?H5Z93UK^"]5%Q_VO,]3W\S5Z3U*4??!_7Z6N
M<OAGSO7GI-]!:&] #SCAIF#DF/#E;]).K(YKVLTX;@?7W#0(2)@'] ?4(C>O
M5#VGN:8<F5?X0\H>U-_8B4:ASY:Q7J[P]1HT3)2B_FH (0J7&"R[% 02K:59
M5F6[("LI^0W^AL=^_/5,59<4FIAC_A:7X-,K<"*6V&HK\VC ?V]/O<#QP)0Z
ML.L'C;B66Q(K"^1PG:L9U]VLE.J#/_!+QN_"N?)/B7;/O79<I8#M/:9W\"J&
MWG.[#A9^Y&T"^ X6\Q[:/(\>/'W^._WCX=/[.\X5[#VLI\0EEF"D-=9,*!I2
M)U<Y[G*IOH1]@&'AD8U/<"K'%]O'>0<915^TRIQ<!=]'JC.G:APZ]O 0TDZ%
MMS=XZ:*YC#H8_[B&^Q9F:(R*C5&QVXF*/7PP1L7&J-AAJ\^?Z)6E\C2#6O7H
M7CX2E7K8P5IOX/8L*XK%#.A.I'T9/<4KR^;R-1I4H'Y@/;J6-MFY00_Q%9^\
M*,M92GX@5LS/RWH-^LR4_#RJ9+QX=G[653/(L9TQULNH>.3Z"J^Y:">P+Y*?
M7;8"'>.MJTC)M&U?_/PV;AM^EE>H^:Y(_3*J$BL80='MJBG!TK"Z53!;6!_#
MP:0)OG:/UR4U*-&@]#3+85,DTA/5*1=L$V^.1$9*9)OT[ K6Y]/  E20SAM\
M(<&JZ-@=B3<\O('0M3!B@R*R2S@0JZ:)^D&"P\3HLO3E]8JLFBI?7./4):CW
MUCCG8+04Q&,>=,_D19:O\$=PMJB?4LH4VS2>-A*_T9IG#/NBQHWO55UX9MV#
M^>+]>GXZJX0T"K/(Z&_2\\[.-.Q#P?XO(FI'HP_=;W%THD2GW8QIVNN,V8-0
MO'AKCN2##YA4;M[6.#FE&F4^%@^&5RV6%];_@=F85=D5^RZ]>P^[FD<9)QGH
MR= A7+XEW"?HB_,?U UTC4,1=4L; 2//&0E-,-XP585>R6>L@(TX=;39+D'
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M[%[3VJ'(B19TFOQKF:^<U=$RZC!-R:)BY#GFY*#RMH933D;]D-(ZI-\4 T:
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M1BZX7$Q\61BJ4G3S+= D!U," Y=MP8F 2(ON7!/Q,>$UH1N._?EZEL2[+R?
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MERPDT7)Y$K-"C_ Y3JMA<"J%J\)-9&L7&UGC(0:#N3@N-30.S%_.V I3>FE
M=@N;_K7(S5B1%-W06FZA>I$0ATO-I:ZSP6:IF.1B4_$UF+T]K;>GRVH%@"PB
M-S<E7-&(1&Y\=YK\'GCX*ZKJ3%$Z3O;['9]ZX9B,?]'"O;0*&"+"%K-FPEX:
M#E$$ W%)IMZBE/1K1[C@9CE0S%!8.[A:J?!V")01TV80\X-C)*\,61SK$BXN
MRL3FFY+@256^H*M0LKLM5@WK41:=R4,=@2I TF/!W]1D[W&(5PZQZ(,][F22
M6_O![I.)FV:8&&[GH\X_0&\I)8K:I$RH3<.7*8(X _JIB!:,P,!X9TJ@=:[
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M,&7=C%,0UW!;,H>UFLFD/80O2$$"$Q0+G=K'Z7J](M.]0/\<%V^QJ.99#OI
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M,(;^FI8K) ]0T6':ZZ2*$H!QR"'RCT->/X.<@2ZL3T##;4Z$[8RZ 2KK_^I
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M_]1[8*^#[IBC'QA 8,=, P&=!!>8.6N#03O,&5ACKAL5\9+J)(RBL;"C&!\
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M-GD64@M&7/21Z!6!0M>NY)GE=45)0# *T,[H$0*0V31YK>?Q^MDS6PFI3]K
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MH;D/:@[ON+=">?/-@V_N3>[?>W0_-8],MKV;G-:N"$6!X@+-0[/*A4E72%!
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M3X,*6E^48=O0AA37Q=:\YHI8/,J$79977<#>Q$8R-"'2]VI3;K1$@)0W>YJ
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MXRD_\PPL<+!QCA\]?)#,LFTM#/TSAGB7T_<@9,N-J4<SEJ$=+],O>)G^ILZ
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M(O-M!:B<5X^>G;^. ;387.VX?K$F]K":/T/M%5D)25@APP])2&\1,Y=U27(
MM!72&H.&%LJ:Q%2) 1 <+A]&Z$P<\8RB-)%2C=A;DI^J \_0)5Z%VC0E"-6%
MUX!#<CXY7E"1#92??BSR-XY;//,>YFML?!U<ET$JXCX-M%'1[8=1(%SQT^0%
MTP:D YU5;HXP9X/Q&%9$R2#R#F.:%O6$U+(0>2 !YWI I ]N*N0W)68%K+/;
MN:0QE72U%?=R7D0735O@Z&@++O/5K')2054@;7&UFK@LSY#3J9PB@10#572"
MS%ZO!4WFBJ@%KROO@5GS+@B"P02'O;I+^-R:@\;UF&N3O<?[D&,7DM4C5<EZ
MM!&T_)32YZM HU;$QSX<:[\E?*9:RK7G:*B%6V2!O\),FX.=XNO@!9YO)6[9
MRX8)EL^]G"GV:3U$G>BF\:GU<)_]0,+W(OEX<K?W2,$42IIY4\^\58^HZ 6#
MUJ(RN1^RCC#BE8X)K_1PQ"N->*6_IG9>ULV))Y6.>-E&%?UZFECBE?#@A%JS
M]#1_M]J5E='AAD5=O')+O-\N(R\<52PD?$3 G L+QSF^[.]1_?0.!?\ P#=2
M-5@55EP%^['941^\"CR@O) *?,I#>@E:Q(IL!Z&L%#^ALM>AE@Y*: MC9HA
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M^ E#X,F/54[N89VDGW[4*7H*]V.9S1 3UWL7KE5>M%+$NT0^9PV(1_?C O;
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M%8]/B*E:%G8E0R&&*+1N3J2RTR@#SUH(6"D@+_ZH/*JC.BU#^=WX:,>+?O-
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M2KW[9P;#3_OF+*.$U2%Y7?Z>JO<>0(8?H;*VT*2']:2M:O9M42B&8KM_M&
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M 65U7=C'5SPB!1"NA!@A!5([38?:$L,1!DJ:(8\LG"#Q%<SK!]EO4<!,5PQ
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M5S:="Z269IDG+B54Y@CU47K08S81B;8H^NL5BX0OL<M2P5]LQ2>RY@0B.AA
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M3%]\J?C$6!F6ETW0R#0" ,R5EXIJ$\+;'Z^*7( XTF+O&N<E$WG]-)R;77L
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M@S53=0M)-=]CG%^F8L6$BXG6^#,%/USH^"; NY]_OA ]$E1>M(C1T:YNH[J
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M21X%=$277AC1*^'826&^4& DG>LXSW)8!QP=H4_J"QH+'(K#T/@2+J8XSCH
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MA6%\B6S= 0WB!R@'  "6XMA"TD2X<I[/YE)Q05T<A'FQ!0''F;> I8W'H+W
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MT%#/O#F^XUQD:8Y\AED->T^$8]3X?'EZ7)V><I&06H':9[80BN@UI:U&#A"
ME/)!#%^KXJ<AYZ![^=*U&Y.0ACR=LQB9NLC64(9R\P'ZI>2X2).%%V64Q$UF
M\)*F_!^F)0>>C_Z06J47+[1FG5-21#@3^JK:I<RI%2I^4HZZ Q$"U$88'..+
MQGE*FGO 8(<D;=P00M3'"@;WT P_A[":0 %8W2/0$D&;\V&;2S%&6POK072N
M ?VY8Q2!CH<L(GOVY@;O@CQ3$&C(A3J+2MAO5%G@0V4<:(]0$<-'MPW3FB#=
M/:%:W.^?BWC#@SSV<KC/+'BS!#U1!T!NJRRH(W+AKZ#++))<BGLZ\KW9>GTB
MG\?0%&_.V3%G<*"@W,B"M$9MV\N0AT0D%\?JZ8JJM6+P_K#9&PY?FZ*=W)Z0
M[=ZN>:_=[!X=W>.U3G,X[+_LZ1ZWST_E?5B]4=ON,/R$U;@>IM.M4(F-I<,G
MZ=B\<WC6N\^U5C^5:6(.(B#F"SL* ^H*U^WB*?+N70!=D*A6M[9@M^B\I^B\
M<0=(B\X6G6N*SF<42[3]WH^5ZWY$&;!"87N!I_F<9<*G+QX,9X6__/U5_Y7%
MST?!SX,/OYZ3B7%X L._V9#LD-UDP]8XCT-WX.N[7XJ'N9GJ5@=:)D<],6'9
M.0SK+<W<M5?+DX+Q"=J1#KKNH+=Q0])G"%:+GC5$S\Y@X [;AQ:L%CWKB)Y'
M _>HVG:QN<SU!+K>"Y:Y?DH33GG@\+45O"SIV#GIZ+:/W.[A]NR>^P-6BYXU
M1$^8TNUNT2R_/V"UZ%E#]#P:NJU!93MS:^RJE^#U=36_^_:88=QVH]<<'!Z9
M_\,<GUL"9@?-(3RT&M.^@3VU76E#M?*AI7!/2N'Z1X=NNS>P8+7H64?T' R'
M[N%@>U%(^P-6BYXU1,^#X1':C1_)'6I-<T\C(0KSW-N#*.'<2F&6CM2 CG2&
MA^YPT-T>-NX/8"V"UA%!>_V^V^]M46G='\!:!*TA@K:' W<XK/3@6U-=O02Q
M7UA6%L%*K4>L/&:IR<ZIR4$7Y+'68<^R.XN@]430WF';[?6&%D$M@M820=NM
MKML=V)BU/9#'SCP^=<91<L6I%<7; UG0_HU9*E=74+?RF:4N.Z<N!]W6P&T?
M6?9G$;2F"-H;#('_67N91=!Z(FA[T';;U8YU)9_!OUA$ZO&:66-YKKKVLJ8S
M/GI 2;G'[%QM!(=MLW7U@_=\:PB>[DYT<U%DT8=HJ>_/38V1BNKS&_? ?BY5
MZ,_NWHBYZ^J.=7=H\MPSFRS('G58OQN[U$6R3U_1 $^W;1)-;_PHYWA0445#
M/^S7\$MRB=T)T@#;$%#+S05L*:0&4S'@3LX0/6;X"ZB 5_ &KGB[!?-%,.?C
MG$K]JKJ+OA.R-8;L-HDM+<=CSC)L X?-C>'T12M(0(B<BGC+IB)K"NR+;>+0
MV&YISLQ2I6C2IRG^]I?#[J!WTAD>-@\=V$4$PR(FSI$8Q+*LJ=F?#J>0+[6'
M@^*E4M/Q"N2F76$3EE+U>AP[]E,JL4K=V0AE75I:D *2QKC[%#<,(Z_VAZ**
ML%,/:) 3 Z1H6\4"N["KME[@W:Z57*>YFW)K*IRCM$#C(BY$VS32U8O^4\@L
ML7VAK""K6I>4VGXPQVAQJ[[Z4&XDAQ : 5&^4D.\X/X>6,(X2[!LKBQ5+!&6
M"528"%8T\B)5E5CA;*O?'&J4H#M6A07F\=\\7N_V\;KUZB?P<I'F8[FXLVP#
ME%#_(UU=."GZAHN>=MAN?B0ZVB'Y&"=11&6PU2WD>W0-=U Q=ZG"R9ZL>NO%
MX1^Q#/)C7Y/O)2R7)8SS&3*Y/V%(<5]6156^CJGJTM+'=::#-2W5W&W?HRKQ
MT[S2;K8'G=JNSFX(-]3I;6-#MGCAPTR'MGCAOOL$=?'"SL.+%]Y>/-5B<"U*
M73_!,>QY'>#=(Z8E!2^$%.RV3+@E!9846%)0!U*POL2Z)0:/@=AUU/4V"@3=
M-<FQ:MT>$O!VRQ:E?[*B]/MBY:DE$;Y/>N3M!/<N,1HO.1P_F<U82N[]>9I@
M.,;&,?=W@; -Q-\4DG&R>SC> J.G!,?FB/5"0VT[G;X[[&Q<7-ZBGJ5IEJ;5
M';%>*$UK#P_=075ZIT4]2],L3=MGQ'JA-*V'Q;[[%O.V8#&XT6YK+08/;O07
M!RS%@,ID['"67H;^YGGZEA=97F1Y45UX4;OM#H\VCDBRF&=)FB5I=4>L%TK2
M.FUWT#^RF&=)FB5ISPVQ7BA).SAR#Y^]Q: ,L;L#YY&:8MA@@ZT&&T1AC)!P
M>#Z?1PO+CBP[LNQH7]E1UQT.-^[D9A'/4C1+T>J.6"^5HK6MP<#2,TO/GAUB
MO51ZYO;Z0XMX-L)@S\P$GT4Y3QM4L)?<Y_9TWSTE$]M#O8TRI%\2!VMW.FZW
M]Z2!OW=)D[8(;&FGI9WU0#U+.]<<QF#@MH9/*OY;TFE)IR6=^X-ZEG2N.8S^
MP.T,GM2W]8Q)IPW">#+KROWJFGRG[@-IN;JY97Z6^=6 >%CF]YC,[W[TH3OH
MNH->NR;XO._LT!)32TR?'>I98GKGO)3!P!VVG[0\CR6FEIA:8KH_J&>)Z5U/
MYVC@'FU>/MW2TAOM-&8CYL=O %?C;F'G&W2M-5N.@G[4'-S0<E2U!2UZ+1X-
MFD>5[48CCV<T;]/Y/@UY\2Y.5[3G]+(L#4>Y:/0%K\FFJKJ7F=$\ESL>YXD?
M4N-<:HI[2^O<U<ZYKL/AJ$3?P%^P>2H"PN@QBJN,\@"G<O[:;K7TSO(YK 1&
MG'L+'!E!XR>3&(Z-QA)#8$NU.RU)]N[%-__IQ;F7+L1)%&#M#(TFJ0>J@>F;
MY74X7H#]L+'+,)QTB/0S%N5/ 1_*'3,1#?XZ7+LCW!"#)<M^Q7?:QG<6_A'&
M<O_U;JAIM&&?>Q/6*/>2>U5J%_YG(X2;<GW<Z)Y0<_$@3$5326P.E\_BDU*;
M]F7*VNP#;<5E*<,P?*SL60[7\62><&J[>TS]H '49H\O3:"OMTV''U:"^K'/
MKMTM&VC*G<JGVO(N-R2;PU,+>-$%L/P#P%E\+0Z>S._>&/9[[$57WH++_FDF
M!I38+!VH@1-+9UN3(]Q,PA9SW\;N'L2*M]=9OL9\]U/12;MH'4\,C[#DD@''
M"X$F^[HQO&*+@>PC#BQ -6TO-2!7/<7]HLAU17MQL[&X*0/H(7$MJG.RN9;1
M OF[X"9$X(%C,"!:,V"VG"8'VIG/YJ('+PZYW/;<8%Z]HONRXJM7+&4KO%XT
M* 59(*$>W(H52KD$Y09F+NEFP<%S@G \AFD$3P.^CJM.V0AV *NY!NCA#D&6
M\<,YBA"27\=RA=A,/>1Z>V)58H6T^!$>TO:["M<8N<]-F0R/'X_<7RVZ+@^;
MRWZU_'@):#5MZCH<WJ,I9[-[='2/USK-X;#_LJ?;?0N;9@OY]YWU9?65-B*T
MK6W- K,.P+S=RE8);ML*A[P8FS8P?;S#T6:V#6[#\V[U9"_#SB_#9C9H>QGL
M97BNEV%]$TLKN[[D2V6!J8"I.S/VJQLS/@9@+2VB@HFW-VQ\Y.#T1Z-*:^+3
M]^D6;?=L2W:U"GN:I67[S!CV)\!E/^%; VA:9+7(:I'5(NO3(^LCEWNR,M^6
MLG"5_QU.<MBS9,>2G5I%+-\M*NMHZ+9:FZ7.6=RUN%L+W+U'TUV+NQ9W:X&[
MAVZW6YED9PU^^R'\Z>A,*_WM%15ZN//T)=&ISJ$[[&Q6HVVWP0/V M@+\)@7
M@-QSG5T=B+T!]@;L^@:L9P'63KES4?41"JI9#[6E9\^$GMTS/+;3!PJW6<4;
MR^+ME7C&5^()3*OV2M@KL4]7HC=T6]7-K9^F+LV&C:DWV/X&&<4TU7$(TF/H
M;Q)SG_",<N QN_PA!45VL/;EFB-W.-G!;@[VL3/#U:F)F@";%AWJ]9K==36'
MG("ME!QJ&:5Q;JHXI%^]N7! E%S!PGS8 G=  86_L?B-+GD34YA[Y %1]+#0
M05$$A[L.S)W!D,EXS%F&110JRCE4Z$O;+R.PSS3@'([?2_TIP?X]J)Y1,J<"
M$(AFEBCL3\$(K-\A:D#@799E'^;,#\<AC AKUM6J_F!^)J]@(HJ>!,:YS\,Y
MPU(^HF!'AO7!SO_FS>8G[\4[R]?)%IBH9<6'%U=@XL[VQMWG-#V]9='92(/9
M1'W9EXRQG13 W4[IUEK#N6;U(Q[;]+$OQV#1_9F@^\95BBVZ6W3?4W2O<PT(
M*UY:\7)G!.BVT@_/$:*VQ,.#B<[.G6_;/<,/E3:MK9&BFL*XWJ+/_K@IZPW'
M&D#-(I]%/HM\%OGVJF#"2Y&@[N8B3+V8GR6Q,_WI9TLL++'8>0Y#K^T.AP.+
MBA85=XZ*@ZY[=+AQKVJ+BA85'QT5#SH=M]/J6Z/4/HE4W[Y;D<H2C]T3CP%(
M5)L5!K"8:#%Q*\)]R^T?MBPJ6E3<.2H>=+ON8:O[2!*5-5(]B41U]LLW2SPL
M\=@Y\1BTW$'KR**B1<6=HV+_T!VT*Y-=+2I:5'S:2IGNT5%E*+ZU4-54GOKT
MN='1@9KWF4X"X'\O%K-1$OVORUD:CC=8R>CMQ)(N2[IV3KJZ+;?7WEX:40U@
M:%%Q7U 1V>CV4GQJ $.+BGN"B@=MMS\\LB:R?1+IOG\^'[X]=$XG21SRS)(1
M2T9V3D;:+7?8[UA4M*BX<U3L=MW>H45%BXJ[1T4,Z1IV;9[A/DA77^?3;.I%
M,QASLK#4PU*/G5./^S2[L+AH<7$K\OW '79LG+Q%Q=VCXH' 16NRV@>AB@J)
MVD(-M:4A&]6H>DE4INT.^MM+4;Q+$;8:@-GB\S/"YU9G>R%D%I\M/C]UXFZE
M-F*M:D\F #ZDV5UU77HK&M:)]#P_PG+/[EO]MGMT: /'+'+6$#D[O8';/;*9
MOQ8Y:XB<!T<]M]>V^9=[*:@)TUUJ]HDR^P59@<V2G?J5'K3(9Y'/(I]%OCJ
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M-!SEHK %#)^D$R^6-D]X%?2.JPP+XCH\G\^3E.H"W;VF;45EQXB*CZY93M-
M5EL*:!EI/X:Q%_O,^40%C0G0ZBM;BF;O2-#-I6CP!@%%R2.Z<6-YS&%Q\D5Q
MKS&6/H4[%83<FTRP=#;2@S"&V^Q[7'05@I4TZ(.H_6;+VNQ#G9GG5]9F]2IN
MV2G_W--+G2<.<M@]//=)/:FR?=<5KK4O?+,-3\[NP6[1>4_1^:'5;BPZ6W2N
M"SKOM,2-E0F?3";4Y5T&#R_O\C)A:\NY[+\[_Q>6+1E4WAXH:TKEB=J@<1LT
M;HMH6.2K Q@M\EGD>R'(9_-CZI4?\[$D,UG,MQ2DCD'6G;X[:&TO#WE_H&JQ
MLX;8V>NZA_VAA:K%SCIBYT'[T.WT#JU9:X^DL4?*.'D.=Z'>-,6FQ:VE.JV6
MV^H,MV=[O8M'=7^ ;]%\/]&\UW-;@[[%<HOE]8+TXV)YO^\>#3JVX,T^>D9%
MHG-L_:/[289L-MR-E&F(29_5RJW-^K1X_FSPO-.R2&Z1_)DC.1#S3ML&X.VE
MF'DALQPQ27%=BN)3RYGU[>LHU_"_9_#R* W_U^5>S!N<I>&X/K3+0M5"U4+5
M0M5"U4)UJU"U-L2G$.YHA(#Y24J%8(X!G"R-PI@)(_<FJ656HK.4QT+50M5"
MU4+50M5"U9KK]B2P4-8:2YG/PDL6V/C"FKL/]@>.C]SLR^T.MU=;:'^@:K&S
MCM@Y=%N][76BVQ^H6NRL(79B<[IAS\;J[9%4I@LWS[W0RF26KM23KK3[;J>U
MQ5#W_8&KQ<^:XN=@6!VD_L+@:O&SAOC9&U2FB%M+V7[Y/G]YFHBV_;DDEMA8
M.%HX6CA:.%HX[B4<K56L7E:Q<S9C'L]3^"?.G(D7QF\/HH3S-T73I-"+G"CT
MJ.]0:,ND6"I33Y6OZQY:+Z9%SGHB9[OG#OH6.RUVUA([#]HM=WAH<T'W06 [
MR].4Q?["E-7L?;!TI99TI3-TV[TCBY\6/VN)G^V.V^T-+%0M=M81.P^Z1V[O
MJ#H&Q)K1ZB65G<X2 ,6?Y.]T_"FL#ON*>[Z?YEZ$?\6!DU"/<>O)W >28ZM3
MKB-*_9;;;6\Q\,?68+58OGLL[QRZ_</JN&Z+Y1;+GPN6M]UAQS:KV,L2<+;2
M\%Z3(5N<TE8:MGC^XO'<5AJV2/[LD?P.E8;A7P]@1W_> 43M#GS>!$J/)*H5
MB[EI\@V$N"ES G;)HF1.\7=AO%3$U[GRN!.DX26+G7D:PK9@0F>T<++4BWDD
M[(W)V/FU>=$$_(LB+X4!XP0F]#(6.#.8/?/2A3-/>(@/<Y@C2YP/>9JXQHBZ
MAC#]P?Z;AY=>!"OBK@.KI6N!J!TG&>P4GTN3A1=E"V<,&@!LTPP0;#K+V\)-
MC/.4[)]R,[ %;S.;J;G<(&<.["+)TYL6XL!!^E/GBCET_:A:,KP%0+Y@<QAR
M!$-W6ITNS53ZJB=F'Z?)S(F2*_@R78F3Y.+GRAC)IH'KB-)!>.GXD<<YDIP)
M:TCR@2@&:P9DQ <D+O[9".. 71\WNB?CB%TW@C!E/N71 );FL_@D"/D\\A;'
M^.L*;6KVX;XCNBEE#3[^D?,L'"\4WM&+#18')PHICE.&J'3)@*Y=(Y(CXFH2
M=[T5NE5)'>MP)]O=;HE2P='(_^))3K4V+#<4QIC9U.!PR[)C+\^2D_(/ &?Q
MM3AX4HF],>SWV(NNO 4_>?56HT@55Z(#-7!BZ6QK<H2;<7 Q]VTT_$',7IV7
M<?.0BC2BD&<-%M$UIA7-6?I*K;ATLTQV<PA+K;Q%=.PG!(,&4:GCD<<9'OPJ
MH]:+[S7[W>'KK9D/'GXAY (-4\X/QN:PUD@3'XG=!*D;(//J'^\T+30P7$S3
M;K5>+PU8(R"44>QS"#PQ"('1(&,X\^8AFE_.&0<>Y,.8&OG*Y.(.=VZPD2B#
M3]=4F/D*W#@J@<F78$HUF/QD!ER<L_4"1],YY2C1O&>^8,?=MBM9,L@"\":(
M#7F,L@VP\K_]Y; [Z)WT^T?-O@/+CX 2+O/>%R1.X@F0]0]. $05;DA,Q!Y(
M:(+OF9?Z OJFE.:!E'$I!"?\"<@8W,B)ZTQ8S%(O$B*1%\#D0$-38C;F.S T
MS^=SD.E(+AOE'.XS![$MC/TH)]D,O\?5AG'.RG/#@<_3),C]C&91?_OP(0P\
M%#JOPFP*DMN'.$C\-(P!PI.%<^ZES'D/^.0A8L"+7V-?_(+K&"> #YSP!A%O
MQE*4TY3$"5->_.NW[^=?/Y[2J[]]/?_WIV^GWW\6&]5E8F9>@+95^!)4PW"N
M7YXG"'44_,8Y0ELO.O+RV)^B'/P?!F_'P/=IY\7=@!OP R7@&8B1&?P_P@9F
M^6^.1T07 @\IO90G,?+B'_C(&*1%)6+CT$D<9DE*VZ,185&>PZ>P<YIR3#(Q
M',PT3?()G+>Q B"Y,4V;)4F$1P=[Q3WP?#R&7>*1B)<1P-ZE%T:HGM$9LRR#
MOTPQV\,Y&*@EC.H=@G"N[V =;H7S<@G"3:04;R*YP4A1!':=D5#$RXE?2KX$
M[ :4)+KK.3&;B.L_\B)R/< K2,(!L> O293;K7YSJ(FR\RL6 7#>>T \IC!U
M.L?J (!'WI6+"'3*?21;W/D&BN#,<T[?7HA5S@$# 1N1<7@QC8_?GHF/KC,%
MC@\8*-=9M237?,&!&7R*H,Z *((Z"Q@_^@/T*T3M"+85.0DJ>Y,<R&62(MV$
M05()&:*>#<;15H';P(%7YB/U%VX-S!0GCM#>G!!FAW](8\2W;H @3()/W,))
M[0VKQ];? ><)'.0(R-L$9CD)*!5PO$!>D<ZZ:($8@5( _ Z.UA/\D5T#%\5'
M5H4DK_K6 @N,(AC()-* +#/&Q(C ?Q"36:!8B(&Y8\!JF#@"1@DO7;'HDOA'
M-N4%3B(A$/<K1+X3Y[0H9*1-Y^?D"E:?NC11>7O Q19HOHF!YWAX%6$C>40L
M?88W#K@6W"3SVN7QCSBYBG'QN;3S7#$:)F9"KN.,_7!0"T;20QP6>1%/X"20
MW\&DQ,!8\(*%O9\!?Y(4K=71@E!LZL&A(J00(8MC0IM?(0<J80 //.0\5\0'
MUCIFF%@"Z 44&"UQH/T!&P :*+YP#@I!;IX# ?3A/7@'/G,I,:& Q6FX*R]-
M06#B;\KVPX"-@.(R0 62'%R@[@M-6G,I:U&Y&'@M IE#EI!QO$G*!"I+NV"%
MY:]XINE\*LF<(&&1H+:T;-<!$14V_)&-TAPWVFFU^P4HD>5$#._3RG9AAZ<@
M3@+P8[BGQ'OP_0L)*." G4[KY/3]!:<_VR< !Y2_>;9B?01FC*(M $#Y\^$>
M^W /:):_=MS^8:O947S4.8"++!DL>AV.FBW]$]QO/-4,,$JQ2;WB-Y9?/+UA
M@:8Z1N(>^INDY$N\_BCQ^O-J[OV6#_&>"[_'L6YF_*@M+?Z/)!DE/X./QD60
MK!? 9AGHCC<0+$$"U,%+$?@ ;[ D)=] ,IB"J)$6]$0X-SQ2/+5HCE5-4^*]
M0#K3Y KOOJ"8P,G%8]R4AW&X]O"$DUJ> J=&II\ M9M(S@'[ !J- C;L"XAA
M"B! B@BD'L;2>B8IP(6.#;-=,E#R@99G(7[R_"GM>&F8&0@*(1!9J?\+LJ?J
MY9,OB)C01 G%\"JHHHP,!)<AIQ5*4G<7,%LB6(^M?ZK@@4N7QW/^VNZW#.YV
M]]M4NCA+=^JW)+U$&\[4.56/JQLEV3"\JB^;TEJ)K0+.:F2[?53:D<)DN(!.
M/@=!&Q8G)1YB[N4=FLLN1E2+<;Z!N,'T8D&,8-=2ZB;AWNF^UB"!P5"04)>0
M)'SN18S6K^U<. 9.2;[CZLG/Y0C?I)BFIA<NWI*P<H4Z[U_;O4-36%&F@&ZO
M^/:-0^XON,MH+2,134HIVN8FAE^_#$4.]$$)U<@G,V ^AYD-BF/2F*PT;!FT
M^'L'C@/E)Y)^G79ST!<?G7"\-*$\6G[3*@F^()4)BS4:_)9UNB.QT]O121I1
M43ET1OFBD>2H99)H+,3E2Q#O$Y"@!9J2R2")A?ZTXHU^P92F^V24YN+'(DN3
ML?>HA&9UT ?2&3W@G<G,4;/=OR.ET>9U@]"XSH@!XI#M&5[^IQ>3YB6N0[]Z
M;?>@0H-FMX(*&=_>F0JM7<6#B- :N.//[>91I[\I%5J_REN)4+==28164<W2
MH/O1H'.TK""V_))DS&D/7(7@'[65_91SE@F0&=J>Q'.Z>"I\*HSATTP:149T
M!#<'0=E0I'T.1>K94*1G$XI48Y*W RO7F6$6OF!Q"#0.Z2-_L38D$%6_4%P&
M"$(=$NO0/B^$.F\"3'B"_IDYB"@8A1 IAH[R77_8-^0[\M]>PXOD8$4K\>O5
M(-X*V4D[@K0D)(65U0A@(6;U^\/FT8J8U6]U#3'+79&SR/.@#?)2DN'2$.4
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MZ#U)/ZQ>#8O!%H.? (/CG$+(J/<JBDNR+9<6-BBI6V,MR5C>3-+C*\S#],.
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MJ3!V/#C@-$ GE["OH KTZ>/YA7GR%QEP7B\-N'.@6#8\(?GL&]?QN!-RGL.
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ME7(^7:V3WVI\R%M/52]"E-$0_K[I.M^F\(]3I_.:8D,8EEXR43%+XM0-Z;^
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MUU\HW\=_-XU.-"AA5>;BJ2$@)'.Z/@NI9(O";5O'2:U.N+_R(94MM%:X4_G
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M*9X#10:/%\<J]3MB([\H5+9F@5RXP#R^[(!;F./EB^L F#SD05M[V<P?$.?
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M?;'E"0#E<+U(K,5'8>BL0KN%G9"]<?N9W:*!4.K7/)++PFB6N_$UD@:W[[,
M8OY=>G-IK ?%71ZC<K 8W@N:1AKU?+/QI'>4.H3O*>PN&1;TN>EO.L/YQ-[A
M_1)#%&O,@;*.HM(<4NN*.7&=3<1E6<P[VI"-4?9,W-N*KO8)+ 8+""J\/@O)
M:YNP>Y9$<Y6M7NPDF+!/:O:T<^278L"GK=?6.T=ID ICYH6W$B#3T'8I&IPS
M R%[H@" *@U7IZD0A>@TC"-6+,&-1_#,;^&R:NNN#;/DF$.GWN9\5(U..66
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MT-80FX_FCT94:O2\526<U-K>,!-E&U6._2"5X*]'OEQ#MTVH(,M6;K6?I_M
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M&(*A#FI^ZCNAN4UBG/N2H48V"-IB\%18<B?UMCT.RMA.<4@0SY#H[!(+8AN
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MFID&;T@GFZBTN8!0ZRO$06]0N&MFS8<5KC%,)A?Q%N9(67X)8B_V[5J*>*[
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M*:?*<H<=<:7M3HYUL3V-USWC/<VP>I<9%N0LY?2J6C+G[Q4Y.AXE$.0[.%
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M<@XPB^%K*7G!KJ V;4 3JR7:PZA"O'8RZ[),@Q6^^[""'(6'V20 YR7%]KU
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M>U*2;I]*;O&YFX]T%,*Q,^JTG7YWS&!M$%AK $UF30;BP;*F+2##4&T05&L
M3.9,!N+!<B9;FDT$:PV@R:S)0#Q8UNP,6X]]5F%=<%H>Q^L/V7,^D+"Y#OAO
M2L<S#S=I;;O;J0(>%;/^^+GF[O4NN]=9?;/Z/GCU/7 &W;'3[1TS6!L$UAI
MDUF3@7BPK,GN]>9!M0; 9,YD(!XL9[*EV42PU@":S)H,Q(-ES>-6YT!A^L3>
M=4YO?PKO^L[T]O>?OHB/']_4W*O>8Z\Z:VW6V@>OM0=.I]-W>D->ZS0)K#6
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M T?R)\]=2.6+;Z$_FUD_LB,^MCZV/K5J[D\^9G\R6_IL/AV\0N>JB\V#:@V
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M#7#)GN1]YP7V)-?3D\RYR$_A2?[H:2E>4W/J[CT>L?>8#7LVEPY>@;/WN&E
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M')8SZ.\KZ5_(M3YY]E,&D4H[$2>T@(F-N:W)%-YL=6/>W;VW*:NP%BLDCRV
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M)[COK;1Q/WA98B=^EMAD\V[5??VIHXO%I"\'NGU(CK$F*W @]V_>H]NR]E_
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M_LZ:[-]T TY+=SN-NJ!8]7I^XPYLKKXJ#]L:9A:9N-9+))R<W?SI"V,^VT!
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M\@77;RG^136$MW3@H9U14*"()+^D*T,WL\7"!94TV>=&?=(\BS5=DL2-"B,
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M)=+6::!!LJTPJ$M0:"RBD- 4,U\N C$T [E$CBRPG.<117F]U4.D!Q6@]Q8
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M:]H*Q;1MU LKA6*OLU\;5;P(]$5.I!9=WJ3[V_ 1EE5%WD!Z6>(J2V),IZU
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M-Z%N[A3JYOG/$:K?4NGC6M/R.UA*%:(A/^V>[$9O3$I CB-&Y.+M^*HL:@R
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M*P/PW?X;T2E):I H\U+PPYD$\B;L@/>[*6UM@LK?!:@\VDRDU"_ +J *? B
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MI:X3X:Q:^36S_7?[4Q3[KZ FP[?$7#4<'P,3QD1[3V-E67ECAWS " Q\^JV
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MX-8N9<V#>V>T2G6*1*2]F'K5;PZ^</NUKZS;#ZV^\D\=I_YS;J."[ 32.(:
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MY#4[!XZ=7HCS?'H.KCS 4@G6S]#%]*-Q+%>-H8:O[:IED[C@764<8T(VNT:
M/6J]+1))$LF=$,F+\Z0H9T4)D')^ 8Y!B2E',7")_ W,5KUHX[=VT21S@Y2Y
M,[!@3GD9\ZFHV,F/L;@&/5FCP6.;ICW"[/=W 2ZOS(*KQ&8Y!Q_6J.9Q!28=
MW&5\;>23V5AFWKLHU^F'XU&3UI8N#>SA%&-?5\@7,K-?5B.=HD?UC)XT^#M
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MCWF<C_4*\=:?SE:^HTM6)4@6;1/!M@2M'ZM70?F[DE)V+:M6:(_5 ;(I62D
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M!F/E";GV46K6&0CKG_0ZH"TQ)?PHFWVU3<^:'*8^;"Z#"#KVN/ K701Z0SM
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M>G]T]N&]\?'3YZ//QY^._F6<GL$O?O_P^6RW]A7+$\2ZQB)232Y"(PH<7LX
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M?Y]:2P?8*H5-&".V7^@AMDW^4J8WNX*H'ACA+SN.65[GJ"GNGBVR79N< ]%
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MKBZT9YT/PC*_@ZA3I1E5FMUK-0Y5FNU-I1E!/D'^QB ?]E'(8SP<@!$S>'=
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M&O@;RO^]5[;C$[ZQ?^"M:]Y%XPPHKDEPO3\<27#]<N':3$PK2+A@IFUCVV4
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MJ M=0_S?<?F+YH;^?_$XN S['!(P$# 0, R'OOM)NP%P(@D]"?U0Z;N?M!L
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M2P?$)[&7E.MN=O#-AJ-Z3UJ%*H64EG?_3VGO[U0]^S&C[0$;]9VW,CC-06%
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M\2 ZX6@!:=1>V8 /$AY(B(2'C[<I!2]\X *4BP[0, 7!1@[2!UFBT468-.B
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MPWT6^Q4R]G<,* 1E)0.4ON_3J 1%6VN=D>BX^[3!XTIP6)@%M=VO$"0'JW,
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MY2C%VH(T*6Z2%"ENDEC')-86I$EQDZ0XJG6S$_1=/&=61J/ &%L 2X[@+%?
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M5YC*C!FG()M8  7S8 U#B,5Z5,R;PN.GZ8IC1I>$"#X;!<AE!BL%AY"*S_W
M H]WI"LWL7"@/,1TVIQ\PO,7)3K-3(0(180BN1*A'I%0VN@D52@0G ZUH/8,
M'*NL"DEX:;GSKI]U\S&AHG=:Z&0A8$DW=QF$%%,U'9-%I>)LPB,32G2<B\[J
MQJIEHA11BBAU1G(] TK190>WH,04(L=J^GYS.#<(ULL$6:28C4">^BLW/P8E
M+\&'X!UDKAV@+QY<C!&8EME)71^C[SC+]%!0WF^J!,?&CBLUS\KCWH) %"6*
M$D7/AJ(M( QMSJED#B7W]\D%C>"DC)!#!1*O!1]*N;,:&26:7#(H5?K5R&+
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M+SPZB_T*.6F-/",$AA)0,P8VHH#(^N#M'):R>T6!9[8?>0DL]$?+HX_UT=:
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M4*-V5&(&2;$1*5*N36(=C5A;D";%39+BJ'+M^X;-TP_W/F26=PPE:RFAQ)(
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MOO34<4?G/6CEB0#7GAX)< 2X@P"',:E26(3(L&^&^ HXG@,8DU1P2FH;CM)
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M2#):A4(P$W9FR.ZW(']"DECJ0M-9B#&0Z2A+\.]O4.AO>&\C(+=I_1;R EJ
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MV+]E72$QQJ[C_O+4RO$+@^,R$LE()$.H1B(=W%F3N#R.;<X2/XX0 1F#OVG
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M<(;YNJFN6_9N'OQR9?>"M=,GX 8##0 /<F20(<?[E:\I)\8PN6-@<F".S'2
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MI[O8%2WZ!(&.M2YWL!.*$I$10-;42O=JFQVMIH 9G1]!(W6W<QR_1OVJAUR
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M*:OE?9MK.E3Y1_,NU(3[!J.CJ=]FRFTW)$PG;?:8&[@L7;GT8W$B3["#(U:
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MAF$M8=VO]M)HQZ4Z,@852<@+_"OEY6>LBL/4%.W]ZE5J["A2;+9]-N,Y6%I
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MIG!A4]FP5NVN25+_E&)[DK*J=_C:"];];-9C7Q^ZW;3FN1[U6Q>U6Z E=C2
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M#HPZ 3KI]W%<7<B1SV.KPR=>4 .*F#W;*QJ .A3 *8 SI/=Q=,!A!7 *X!3
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MA!YQ3"E*%!%NY\35?<J]/Q%C$*7'4MY>.JTHZ DIZ #4L3!&$<C"&'L9@Z;
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M:)Y&B^CG[T!!09E*>992GJ649QGF&I_O^@U (@L %  8^AJ?[_H-0"(+ !0
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M7B_O_#-ZM_4^XWK?TZD%\6O6^R?0C5D7T_SK!,"GBJ/7[Q:Q[C%1W=.S.[.
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M?>ZL_^W=8@Z.$&HU+=5_7F6>;H)2+YO05/Y@O_[M%[J;L2J<0U(? " RW[1
M!]_L!$USX*K]J)'_]J?[@5<_)DAU0\W@,=@H>N,///98+LD#"HLMPP.7N9GP
MG5=ZSY2?>>7WAZ0?:5WOB0QNKS"\W?SM?[R@+PZQVNN8:[<]<+4<U>T(1YT
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MJ.:S69S"LEY>+285W#9W_/S+W"Y"7M!O)XOH84&K<?WYFX_1K^K#_LT5N0K
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M BNP4&"AP$*!A9NP0 LL%%@HL%!@H3@1!18*+!18*$Y$@84""P46BA-18*'
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M[^B3P R71*(4P%3G7E"D?5*(&0#I:*0CY$ '=HX/Z4(41!^BP@U O0JBG[.
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M\8D&)W(R&[45C]LGNN< 10^T[5N)1064"B@54(Y)"2N@/!50- N2!V: N*A
M)(D1BF8)#$E!92Z-\ALK\H_;1;IG0)$#S@Y_&%0%E HH%5".5PDKH#Q]PY!+
MPM(,-'"&T4;I9),4 8;08&.RC/NPFSVF>P84/M"LIKR.V)9[8)454%Z[$E9
M>2J@,)=EL)D"RYJ (!AH6.XS:&.3T$KKQ#< Y7$[4/<,*&(@2"WR.F);[H%5
M5D!Y[4I8 >6I@,)-C(R2#-(&#L+[ ,XI"3DZ;ZWAB;*-HN''[4_=>\J+T;H+
MY5DWJN+/#E_LCW^(P\]-&+D6)PI%=PJC83N#-$JGJ6@K"O L3=^L1K(<>!GD
M6WI"E/SF71RV9R-W_C:/TM=U"2@4R'_/V]DPGZ\&V'T'VIF;SMYU;POEB>U;
M[]HT&I;7NFZ8%Z\I3B37W^QJ^V@W918'>-LDW29U'(Z1AEMJ-!>2,?7-^D;>
MWU,ZPU&.+F0S')?7@TY$M\CDS1^_I=^M)J_,RPH7NV=20KZY=L>#O?^U?;6?
M4O.GB9O&9I*;'X;3%&:3:=MMM)T.VX3&.OS:H!JUDW';#,<-(TPT;KSX?#9I
MVO0YC:]]@7=?P!_8R84ZHTA6_U:M[9/6LF/5VA^_IC"?#3^O]/=29?-D/KVN
MLX.KBKEZYQZ\RU8;6>+I7^>G:3H,ZY^6"X?CN5O";/D<8>$/W=^O7+2*7(EG
MU'H#W >,0I7)X*RPX(7-UB>JC-LHUL!/2>#" ;,DE6IR!T9QAU>[')0SS$JR
M231^&+9A-&GGT_1S_O63FZ9B9?&#.R^&_7XZ=>./G8T7!C)R8X>.YOQ-DY!V
MG.%]9M/YLE,LOEV*[V?W'?P_Z/U@G9H[INR!R/YHUG@YNMTHT%\GL]3HY8E*
MG>"ADWRS%/U3=/TI@^\>]78X0Q&&![Q.LTZ![C&OZC#3NNM9?-^B<T)O56*E
MXM006V?HY=HT'DZF#=[++:QGT$RN'/K<#IK3=.K1VQ4$GUW >8?1B*IA5HRJ
MG8]F#DUOT+QO\0GHU)L/J"FGKGG__:_-)]>B'192.6P_H>)\<<5:9\W9=/)Q
MZD[Q*M?\\NO?5K\WW[HX.9OA%]&Y_I!"]_CB5NEW@^ZYKOEPP[=_2GXZ=]/S
MSAOCMU&^X5.#*ML@>BU8P3 /\;ME1/^<#V?GT*;9;%2(R)IFGRTTNYGA,-M%
MR-&>/-FG[W VFX=J\8OU3K^@8B$:E?G_=38)OS=_P["S^;#0C4.YINJ(;IFP
M7__6=A;YL?@ G#9_ON96T(9=",@\'7JJYLMPAM8[GWV:3(?_ZBA)VWP<EH@
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M^+*R;%75M<PWK^:Z+,N5@[TZX2!!FUT$<HM"K 4BK*9@#1/PJK0.#.'39++
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ML99S30\,*I8-E.S%BFBUU]=CKQ53JH[V74>? 5-B$)R84@_L$$DP*J'@+75
M?%+6<:>-VUB2S!EC$Y4TZ" S!BJ2@F.:@59*L4@MWO/0!Z,92@:*5U#I3:JU
M5@0?*M5:>PO7;.:Q^YQ*$E[XSB9',1#-&*%:$3"T)5*!4U:!C#XZ'RD+QCPE
M7]J?GF&4#5#3*S&I^WUKV'N$REH1K2+:O1#-YR"2,AR\-PD$RPR,4@X43R8$
MJ@(S&RVB'I*L[0VB<3D@I!?]H?KB(RJ@54 [&F6M@%8![7Z;5[RQ0GH/1-)R
M_(O6X 3QX'G&0,PJ2]+&\2\/R13W!M"8T!BB543K7UN)6J][J"1R[>O\VE+(
MM<'63E6V-M@Z!HZC1#99Z 0^>PDB2 4^*@LJ>R>)DU:JS0VZ3RK;/6"#+3-0
MO(=;EEY9@ZT:-[V\V+YB9\7.5X>=Q(=L(H]@RNJM(%&#+=7)1CEOO?,QVPWL
M?%IU\N&P4PT($14Z*W3VUJ54Z*S06:'S2*"3*2J]0L#,@2,,\J3 "8LAI&::
MQI24,'FW1=B'@TXK!JKV=3XX=M8J[MXDX/?2UUGTAS3U='I>!D.J'<!VS)%J
M![!=-;ND61"G%$BG%0@9%&! 3X &:FPLAS;%C;[.P<B@A0J0\1U!T%)>((($
M25B*^#?##>MG!S!\M8'I1QG<Z^P 5I,!+ST94*&N0ET_H2XG%Y2*&:+A$00Q
M"DRB#K)T)"3C6:(;M=XL2D5R5A!8XB 0]L!&E\%F&RRG1$L>^PEU5*J!ZD=]
M7(6Z"G45ZJH>5ZA[+JC3T2"\40F:,P%"<08N(7:E:*EG7"OCW76H,R%ZSS('
M:6RID-();*(<B".$"A.4UZ:G4#>@D@R$[N%:[VL!NSU4BF^UE'MGKVNB^F%^
MY-<SM*8\3+'QY\WGU,Y*QCJZ67JD"=5D]*-P%B>Y_/5_O6%O]B;<XX'.0]+$
M8Y!QE=]KT-'J$ZI.5Y]0=;3ZA*K31^@3:@U3;T+#>\TF(^7@X[[DM'LJ\6--
M8+^TO%-=9'FFHNOM>6;AF8M).O"2!Q"9\+*OR$)B6FN7K.2;2ZHY&/RR\A!E
M.7/01@$F!@M1,YMB2,R*!^\F^O%KFH9AF^+/T[^G=K^ET=R( ;&]V));K?GU
M6'-%G*JC?=?1Y]B$HPDB!G-@C$'$25*#<2("(29X38PEP6Z<6,LD,2S2LAJ:
M09"<P JF04D6C4^R-(+H,^(H-N#]V,A:C?GU&',%G*JC?=?1YVBH:+(UWE&0
M*3$$'"7 ,F^!")ERS,&QS5(:2AAW1"$^*:?Q&I'!!L' J:"$9=QC_-!GP!%"
M#03IQ?;/EV;-M:7BT65#57\\<T\E7JE"/YQ+I0J'S8;2&!)7$3*&E2!"1F<=
M'8.LK?64.)O-1F\E9K++S@KP1!,0D9<#"+@'R2WWT5N;[8/W4CYW-E3THT%A
MM>;78\T5<:J.]EU'G^.L<1]#5LI"S!B2"B<(&'3-$'T2G$:C910;B$-T"F6+
MOQ>F= #$,-43E\!YIX//--C8Z_4WQ0="5\"IQEP!I^IHU='G!9Q,$R6V;"<T
MY7@9:2UX:AEH)_$/,:E,PD8VE.$5@1G0S';+;P@X(1/(WB@6/ _*/KCU^O-F
M0_7 4E41IR_9T%H;>L!LJ.Z/9^ZIQ(^5*M2FOCM5V=K4]^ETPS*:HBQ'NP1?
M#AQG 1QS H*.FD9!3,H;BZ\J2QZS"Z"S0+JA4@+KD'/@U5;8H*0EKL]T@S$Y
M8)KV@6X<4^_=H_ )1V[Q%=FJ%E=DVPFR&2HL$5( 8RJ"2.6<UFP8L"Q",DIR
MI3?J6+UG7&7NP 7'$=F(!H]7@I/6VXQA-"6YS\C&R< 868'M!;J$(S?X"FQ5
MBRNP[:9>5A!.RWX^:[0#$0.#TD,<&#6..**)9/XZL)4>JU9Q"LH358I@*'B-
M89Z4(AM%#0]:]!G8F%0#*GN1(7Z-R%9K:GN31:ZGI-24<^VGVQ<&4_OI[JB?
M;B34^< ):&4Q\LZ>@R/)@HE6"^N5<'*CLK>>DK)O!_%B"4T-U5]ZJ%ZAKD)=
M/Z%.>Z=(] *A+F,L3FT$Z[3'^-U)P9DW+&]4>-534BK4]=%%'+GY5ZBK>ERA
M;G]0YT/2C&L$.%Y:.U!GP)FH@%#MC33"$D7J*2D5[/:2J,:?';[M'_\0AY^;
M,'(M3B'*\Q1&PW8&:=1->*?X9VEZT>0Y#MNSD3M_FT?IZ_KK*GS[_YZWLV$^
M7XVF^PZ@8DUG[[I7@W+[]FW1K=&PO,-U,[YX)W$BN?YF5SGA;GXL#O"V&;E-
MQ,OAK&7J?T_I#$<V>K>2QW!<7@DZL=PBAS=__)9>'+9>!+]"VNXYE)!OKMWQ
M8.]\5:U^^Y2:[(;3YK,;S5,SR<TOO_ZM;=!G-!_*#\,6'0&Z=[P^Q08='/J9
M!B<:/\?OEE_":-*6]/K['WYMSJ;#D%;?^HC>9=:=]'+2;#X&!U4>U3VI_/RA
M_#SK+BR7E*\L;O#%M<W_^#?#E;C0_@T+NI=0GF&),DCI!-4!G$^E0I1G,$QF
M\-Q2%Z)QP6PL43[.[_]7AU8IOD?'Z#ZFGU"V?R^B?3_[S^1:=.#%R'] 06X'
MAG\OHDWQBMO_\6^_H#= 'YLZEW_I_]E=_E]0=* W.O\>:'FG9<>B1%RPQ&*D
M(!C'F%>B+GB7'&BM%3-6,1HV#LY.,5GK1() )%[(:4+%4Q:,)#(%RY3.NN=*
M1.2)O7FANP]*A./O_--Y<M.V2>.('G%C1;%3M>N?\AZ]QJ"9IO8LH7@_I]'Y
M27-!*1"U+OY=S *2RX0>??W3<I_A>.Z6DU,^1]JQ3C7.4)-@R<+*Z^" WER!
MQ'_!$$7W]2WP=QV QN$T=9.--Q_-3\?OKE"1ZQ3O1")3*^^V6H/'7[?B,L[/
MNS.$IN[.TS1RY861'GXM BU2NF"*7^_)_-0=<W +][N,D1ZM =UH=J,"/\&3
M]7&'H^'D"JN]5,.B6)\N:BZ6TEWRL8YUO77SV>3=U3_@M"\^7NAA5WCA,@K_
MK1M]<>?MNS??7VCLU@BDZ->:BEY3M=UJU$YCB;MFC.ULQK;$(FN.H(.U=3^Q
M:K!+/*/6&^ ^6"1')H.SPH(7-EN?J#+._H,MD TO15B:W?LR?C]Y4_-X$]YI
M\<JN;>B_W+0CRQ^F$V3-IT\Q[[V/M5E7G/VZW2<'E[N?(HRMILO8:'$D9F$4
M?YJX:6R&X\:%@#[$C3&*^C*<?6K0DWV:3(?_ZNRH;3ZBP\'@:M(,9ZM+VY+5
M^823E:9=2/:^1:Q!!&T^X!].7?/^^U_+!1C2-NGT;#0Y3ZD=-*<=/;F(X1;/
M+\P%(W@$XV*#[7PTZ\;[+1)GQE!4BQ> Y<.Z3^F[[TZ:'UWXU"S_V@3\[Q!%
M5&[;95?*T]NY;\-TZ%/'H4JXAV\Y'+OI^6+\91RN&4]0=FYT&2/^\'_^3W,[
M7;]S?IZ!KT>CLO<":7<(JC0.EV!#XA!5BDC*+:5I@Z]3:Z+E*H/RA>BK$C(J
MQ4 Y:WFB1BJWA:]_< M^_B%-NV3>%>;]P^^_7W[^@.3=[BGW#HUFD3E(RXK;
M97X!E3O]<XZ*@IHU6R46T O\GF:7NE/^\.?)*;[#>=%4JM^UUY2N7>4;9CB\
MRWR#NY+Q6#?0D^;]&;*.)D\GI]?&A"9U^0%RYDE<Y%!6Y]WB&\7APH:+!?C.
MWI9&..B><+;PW OWT Y1;FYZTJ>I>*C;OI-O]!!KNT>]'<YP%.$!HOG[<I;_
M?#'+AP+@1[[ :X?D%1P7<VTFGS%P=VB0:<T/M&GZN?B>A7%WMCU%)X2A:W,-
M%XLE?Q[&A+=H+XZ^7EZ&3F9YHY/F\N%IG*:(S^=-2 []!WJU;AR=FUG/ARX&
MTU&!D^8G="-?KH]_CLQYU/P5WZ#+/C#"Z& QB@*KF[[(G9WA8X>+?&U";C';
M>,Y?QLTBU)ETQ&.+YUK=%YTJDHS%.RQ3P&MWNGR+DD!>O\NGX1D^XB-^,DKM
M!27!P*W=\OPU8O+HIU_<(YQ?W+N,8@$V5Z<3:=AH-&@^3;Z@>*:#!BD,2FDX
M&Z&T<3@73O]SMQ/D<D96,MT A1**7I%P]?&'?^^_K%O [-.2%RSX<DEU=NRM
M\*/"/5:3E^*@\P.77TVI^83T83R9K9CZ)0EI/DXF<:G517,BLN+)0H6O:=RI
M.V_*,M15"GT1%5]H?'GVA7ZA:E_H'@YAF*^_05E&P>O01E U4\[(\COC:N=(
MW@-:37F9<[SA61KC_<H[G".?FJ8P^3A&<<>+].=D;4_%I;ZWZU\=GIZF.$01
MC<ZK?N_WO1^)^!?HLTSB-W_;A(YGFKG*69[$63J:P AEV]'_DEU<DILGQM07
M@?!R?6 9!R?&,*Q-%G02I2D.56!U-B"D]BE9H5W8[."GE/'>*9")E#:S92L#
M(0R"S,'H; 67<A4'NW8<W]Y6Q+*DX1\ZJ+T2]D*;PMLXGY[BPS_U9"*%N5#@
MZZLM/7*8G<3:13**?B_,BD-=./X5&IT5Y"I?WN2MG::>-/][Q:$6Z(, N?CJ
M?[CQO 3EJ,-R@ QN.G,(41O<]CKYW+L^4QMS%@X5F!$!(O (J*H<?++<L1R$
MIAM%7#H2X;U58'B7$*(&?#01LB&!9/P_P<D+U>>US91'H\],/%Z?>_5:E=?<
MQ&M^*K-WL1Y?:4U/:<W6=$8)L%=K%EVX<R7Z[__*0(I)"J,3.$M2V?$BP'*?
M@&7$NB 4E8Y=1Q"N%(VQ'#ZJ"+(H[\I/0@'3^+'STDKAKB (PD.I+G ?T\]Y
MI?V+OA1;BGJ7E3G 'E*:PV[NK-0'U?EFJP_O5IE*I<XJY7+=@5\&[]-TBHRC
M./W^JY07E&C-,M"N3;9"NHWD6H-3S"OAI;-I8[\PY3E*%0S05$X/HJ4JD7L+
M4ENNJ&425>N954H?FTIM9HCW0SJ#PY"(&PL,O0,R3^' B&Y%D5O'=#2B3,*U
M37+9HPZP "J@.HB042=(<(!8)Z,SV40O7BCIY.IX2.=@Q3JYNIMU#A:T\RXG
M5EEH#][[)NYR-5R=GZVJYZ]\[$)(;8L.\"@(#8LN2)$@I7+\K+(!O&(,F#">
M<&^H<QNE#H:@?\(0&J1@&$MC[ Q&>XW>*7'A*3'<J$IH'H(^+Y+84.^$4HX
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M#G5YL@>X\SQMFGK=I6FA:[574R4CE8R\$#)RJ.VTSM#HHDJ@3!(@#/5@LF#
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M@U$2_:Z_[FN-2ZX]C%Y[V/_\,TZ,GP[_YZ!UXQ:#[.DPWY0]T#HXGCP'(W4
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MWJ.,7Z[\>J"1U0%4!]!W&;]<^?5 (ZL#J Z@[S(^J/SV< 3$O8.]K2_V>B/
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MU(;[NXZFL\%%";-!R/\XGR].\7%:J22/@#R"H_ ([N>U34EYE12H:C&.\T6
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M:GE@#5_NX3.[;U(<MD,GLPTB:0U5*0>J<^T*TMLHQDP6/&BVTHKA&0[=3]T
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M&*K^&1V!^3E>OJZLY"1<4K;!'>T<K7@ @]_PZB.Y__@X'?SG-)?QX/?SEG8
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M_9'HGEZ)0_49J-?91DV6>IUMH.BO,\9Z+\"FEO?O(_H04B3(0ED5E;!<K>P
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M?]]?D5:SU59MAF#%?4@S8Z:62M.:[2[52JKI=SZ-Q2EF-PAPD8 D]J]_/1(
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M"4(XXMP8</"T1A)'8VE(&N.5.5G4>^$3=4@*EZ>.*(TL819IKJ6SU$I^: -
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M,U9ROU.WMMB_=D]SM]C"W*W9DCW<()FL)PQ1">NX!;/*&X$X\7D:@Y?(.R-
M'!C1?*46XBG"T.[/+<K!_YWDKO;C%M3>#:XG [URP\GX;AGYE.V@3_#U?^H/
M_3_6D9BG,6J'&QXO+% ['JNY!",SU3%4+O:'7U]TB6^K90R;.E"+[7]GJ][.
M+&ZI=&O]@)><F_:XZTC@HWL$W],E6*I']-Z]LVLOD6L>N>9A[(R)=2^VW&-U
M.TR]EV[(]\<8SC!Y2IAA_M*U?T_NC[B2$P[9E 7=R8)>MW:D=[=V?.+B/AP4
MNW/Y2U/(!UHM;TWZ'Q,0/M0C.FB#Y4/@RRGWC2WPTD%XN:>M=8&7W:O#<S!
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MD>^^UNSRQ&^9"Z;7X++1[H>?![!4H;+Y^EK(J;X"S( 7M:%)=@^:ZN ,0&A
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MZL*U5POR/9?F5ICG%S9["GF]7]C)>#C7['QQ^>R@</GCJ&^OAI/91Z9?1#"
M_X_SS\,-]NUE$U\T\=*.[#@N\T1[W ]W!7.^U$W=@N35B_DY[HG23+]6J#/.
M2/[>;WFU\C7.;A=$Z=O+'W[^SK%[/HR<$4F/XDK+#=YW@Y3O\@8?B'#J_16
MGF'RE,J1^4O75B"YUU'2)QWZK)YL>9WN2A^^D.R):_OP%MZ=JW_',ASX:=RX
M>_N3?(HIW[7P/V:#ZU"/Z,'E/TR IL!+@9<3@1=6X*7 2X&7 B^[@1=:X.50
M\'):?F_1J.()'XQ+"-X*F13!OO=I_/3+[Q_^\"^Y4^Q+./T?#R+FSYT1ULGU
MW"HEW)/N^01,.GC"R#ZFC\UWR3K$!0=?]Z-S+!Y"H(XGEQRO8_P,^G$5 "@
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M:.;U/&EJ!RFY9<+#<QWP<_"E+BV=]\MWI:5SAULZ%P H %  H !  8 "  4
MGB, E/%]1^[<S<?WQ6^7<="LW6JM('U!^H+TIXST!0 * !0 * !0 *  0 &
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MOC_)KTSW@Q\1-PUM:<M"*B5X]D"6^95IW4NX-KY;TWNZV%F, 0U?ME_Z4PU
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M%XE-4A*J7'8IT\"YW#4=?9YG'" U(#7TFAHD+=1*9HG2!CP5Y@WQ64=B9 Y
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M6O(,= +>J_OC@T-27P$6FV6Q1?T4#-4PY7%J7W<3]Z6&,0.6/US">&!>WDU
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MYR2YKG=W2!)=OU[EN1]?.;&Q&H 53?WSVK_)T<_;Z\*0]GPRG9%9GE[<U$4
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MI,QSDA@#[R%F3GQVFECP'K162;JTT?Y[FR5[/P#L_J>B[K<%Z'[N,/?3]&^
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MZHD'=Q\//WR[5*=?@6(CS'5&'N@U#RS/%+OA@78U<17([;"=M16$2^QU,/P
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M\.%9'QJ_N'J:+R?3+A.9 (1GS9NF'<)[ 5^^A]!UX\&+!YW[=PM7<'+9,0&
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MYO:G\;>=Y?AQ_#]^--\\\.D;WP[;7^$=?6J_Z6I,?_,?'A]/M' K^.F3@<4
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M]ZR[ZJ->^Z?YK)WY19O=S6:\<7+1=3MO?'/?=#YA1'NP!4PZYEC61+-DB!1
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M3M]UD:&_K.*OQG14AJ/1PD7^UWR8*N#'.:>%ZYF 9J?ML%RM/,U*,/!1VTZ
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M*,IFUL=OT9VX$'=:-D5WTMZ>W( ^B>[DT(T0W<E+W0D7CA=& IR('8 [D5Y
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M0KR0#/O<IC3P)!&6)PCWN4,\WW2)I!&S)'.DLF9.D70HY8)%+G&4]+6J+$E
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MN %H&SC%WJ"YV6WQ+T\1V":9:0L\;_-[+E+?Z74M)HT\'G#";!'JPYY\(FC
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MR )_+*F$N('J#229[Q"+>DQ83(72MA_W0#L('.X[EMY[78N23._"SGRXT;/
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ME_#MZ4<4@!H5>*( A +0%@4@AEBA (0"4/O),PI &)PA, @, H/ M!68"5^
M?T60J.K7,+XV9"**0F-UI:"T.431U8OA)5!$?<&XA']6_NCVF%@G4:)N21CG
M2E:A-Y1]V$]/(/X=)&)TK+^= ;5C ZRZO!/-"?[\8UB4<32:%+RZD4 <?3+(
MBKAZ<JX2B.ZOU4F0W>HVT#4?EQ$^69+7.?#G3JCO?6F>>_WRS7I^3A;(!Z]:
MG(?3VV IXY_:L'KY(V83IUJ;(44I\O)8#,OLY.$7T.SUQ[4=5G151 #^L4AN
MQ*@X>=.]L]AYO;NRKRD3?61JF[6HC?;\10W&-M9@?_T+=<R3F5;3L%9#PCPR
M6K7)PV%!5TE?3J"S9\/Q)?7[J&EVS+>3Z\$P$S$HU'&A!B(7I9I DU?M4MWW
MYG$($PCYXRK/AFE(QH8=5?_5];RIFS3(DO#D.B[B(-8GL!U/WC0GCJD+YG8@
MQ'P[W>AC6.I6[SYQ&W<[U/%7O\]9[W74[/@F6_T^KV,Y:]Q&Z7KW^1VVN)3S
MPM-#"4A?Z+[G]--VDQO$ _% /! /Q*/A>#RC*7MK"\IY=J/?](\W[,V26-<X
MK#_UX35BYF.:JR[?.&>W/6"UY=^#O/O/+T.]_^AT0]U5=DRQ=?7 TL9SWM.P
MTDG8, \1NGY(O$-5!PUI#4,RWJM"YO% 1[];L*26B6"5'<%K:COB:$=+J$ZI
M'.]HK$)]ZOHW%:E<I5*A-:U 'YZVH.U:3./FIE?D$;-5:0GPN^BJ'[*\C[T2
MC6,N5N]A $?C0..8B]76(@TTCWTPCP]QH@RT$;219["ZR+/K.%1AI5Q\@A#A
M)BY[:"VX[F8;F=4F+KQY\<(;>]<+;\YN93(LH/3&YUAJ16%FQ<V7['KZ\.UG
M5MQ\S+.;LF>\CXMJ<"GNMV0YOSS[,KY*JF'5YH7QT[LO%S_C8IQ&+0+ Q3@K
M#(&X&&=5E[&EM27[AQ4NQL'%.$W&&A?C8*(\ H/ (# (3%N!055H&Q2?HBKT
M8E7(V2=5Z"P-,YG'*93_:F2\C_62D2Q=I WU/GY";:A9,2EJ0Z@-;=%Q.(@5
M:D.H#;6?5Z,VA'$; H/ (# (3%N!06UH&Q2?H3;T8FW(W2=MZ!=XD<X74J)0
M"].%+KZC)-2P4!0E(92$MN@O7,0*)2&4A-I/IU$2PG -@4%@$!@$IJW H"2T
M#8IOH22TBB3$3--W/-?LAAZG#FM(NM!W)7O&]URD1:3R2L)Y>)[3I<JO8ZD5
MGD=*T7LE:Z6(LOIX[X6G.7W.TC^%\;D,40EJ5 2*2M J2A#K,I.9B!<F!Z$2
MU&AFATH0*D%M@Q'M"X%!8! 8! :5H+;@#!2?HQ+T8B5HY\E!%T+^$%?Q\V=X
MWZL^2XH^E_#GP'@WW@(92HCB3Z."3A1_4/S!-*#=8X7B#XH_3<8:Q1\,S! 8
M! :!06#:"@R*/]N@^#:*/RN)/\QTF.][W9!9S/2\9J0!/4SZ648 8M4*,68^
MO4)L(@'](F1/]8W3CYUI8::Q8^+!A)PH_2R/E55+/PSQPKR?EDD_C0!L%T?N
MH@:$&E#;8$3[0F 0& 0&@4$-J"TX:ZZ/&M"+-:"=)P MK0'])D83^8<NEG_>
MB3S(KO0%?0G?H@S4L/ 392"4@3 #:/=8H0R$,E#3J!W*0(W@(FA?" P"@\ @
M,"@#-19GS?51!GJQ#.2U1@8Z'5X-B]*P:)T(M% (^O+UP]R%8"@#-2'\1!D(
M9: MN@8/L4(9"&6@/:+0* -AB(; (# (# +35F!0!MH*UT<9:"49B)JN8W&_
M&U)FN;[9C&R@T[Z">\-*N?FFBK*2?/1N/JJ7)?#0V1VA_R72H<A'AG>7&32J
M[A;]++UZ4A4J>\H8"&AN +Y0I1%E>=G3G^8JQLV"FA6;HD:TBD9$32T2400,
M<X5:)A*UG8/@;D$-#CA0&\*X#8%!8! 8!*;)P* VM V*[Z,V]&)M:.<I0I4V
M5"D_GU4)L8Y19I6.L_A\^8E&Q&N-Z,F<H8]Y=E/V]/GRT*DJL>GY ^;??;G
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M$ _$ _% /!"/32COWMK">Y[=Z#?]XPU[LR36-0[KQ^I>(T+U::ZZ?..<W?:
MU99_#_+N/[\,M=8[W5!WE1U3;%T]L+2Q##T-*YV$#?,0H>N'Q#M<88^&M(8A
M&>]5(?-XH*/?+5A2<Z>\GK8C>$UM1QSM: G5*959/M S7RK4QYU^4Y'*]<)T
MM*85Z,/3%K1=BVG<ZL\5><1L55H"_"ZZZH<L[V.O1..8B]5[&,#1.- XYF*U
MM4@#S6,?S.-#G"@#;01MY!FL+O+L.@Y56"D7GR!$N(G+'EI+PY-9'P"[X9GK
MS:4:M&0=S#;2!#:J_"[<(FYS*WZWD:EU*(:+:" :B :B@0MKFS4EC MK7Z6[
M[O7B-H0'X4%X$!Y<6+LO"VLY+JS]G?%=+ZR]' X&R6AFQ>Q7669ZO2RMULNR
M)S=!N]L>O]Z,?_SIN>Z>:54TD1@?^\&G?=_2K/U#,^*#^" ^;<7G]=;!HH""
M DKK ,0@!N%!>! >A <%E+T14&P44'YG]JX%E/L#">M$/X/J(PF?D%5.!WF<
M&-[#3<C6%E504VGX:(WX(#Z(3UOQV7=-I4E+\W>;?KZ8%RV'%4HL:%P(# *#
MP" PA[8BIJ4BBM/@4X(;=-X?I;Y%F<TLT[8\DW9##A]P-U2WOK_S$__FZ2??
M5%'FL:QV?R\S^</X=QJ7QD6>7>6B?Y>-LF*1U^G!^ZG-;+0;7A(/P\AE3_!C
MGC["ST+ E@/,]SMXA-^26%F619AKFMZ6NF/;Z0*>V-<PS>$5N=B^08>ST@@/
MPH/P-!>>/?)A*-UL0[IQ#S;]Y04"#C=MBWN\&SJ.ZUEF<P6<"Y5'&?R12O6<
M@J/UE5=0<3!R1 5G8PJ.KQ4<CH"A@K,=!<>UJ;\W"LXN2!DFWV#R33O!1"M#
M8! 8! :!P2R<MN#L=6B#)WZVO(3)^YWN6GWY'!>ED47&Y3 HXC 6>:P*S)#9
M8V4=\4%\$)\]QV??5R_M_ZQA0PC0OD&'D_,(#\*#\" \.X$'!92-LS-*#UE!
MH73W$LIY6L1PK_$]%QHRXUW6'R1QE;MR 8^2(]S_MNFC*>*#^" ^;<4'U0Y4
M.U#M0#M",! ,!*-)?K^=M A5BLVK%.R@50JV>Y7BG48O OST<XQ@9%SD<2KC
M@4B,LULEAV5\K8RO$5RA=YT=YL50I&6UFZV2U2V6R72B2-E3QJ7( Y&J@GR]
M3=3(.)55"@DS3=;JU)&V=[(MK5A"6! 6A 6%DN8+)8>5C?P"[K3&HAI<48/V
MA< @, @, H,K:AJ,,V6K+YG?*ZEEYSN:/".U?(A3 ;_";RBUM+F38?",L" L
MS80%I1:46E!J:1N,:%\(# *#P" P*+6T!6=J'716B[4'62V^Z:#4TNA.AL$S
MPH*P-!,6E%I0:D&II6TPHGTA, @, H/ H-32%IRI==!9+=8>9+6@U')8:T3;
M/N2@E("P[!P65%A084&%I6TPHGTA, @, H/ H,+2%IRI?=#)+'8#DEFRM(#?
MM!1R#@\9J H&XYNZB@M@Y2HT+H9!$DOC5,ILF);P0.-#G/=1,VG:\(2P("P(
MR\YA0?$$=Z?=LA2.N]/N9A8!P4 P$ P$ W>G1>GCQ:S*=P]2^NB5Y: X[G9O
M;FXZA9*=J^RZ>YK+7GRMBJX*KT3>#44INM2AS.2LJZ'V;9.Z)N,F98RR[E@]
M\=W=JR>G!73$,"Z,BY[(^\(X[5Z.S]\QHBPWOL$[H(U&6ETYRW-X4C8LDI%Q
M>B/R4(75J3TJ+:I2M%I0V;^@AYGD P:(2V+5=;L,^B?BM;VA_U"Q,DU*+,>C
M]AX#M@O:AADNF.'2-AC1OA 8! :!06 PPZ4M.)_]AU"3=LZ_7!Z0V+,U-,_3
M2J;YSR_?/AOG:5%6!QZ_S^2P#]]W<)X;I_\1%H2E/; T0G[8]V21P^)PJ$-@
MC(# (# (# +35F!0A]B6#G'Y[A/J$)O5(;Z+VRS-^B/C[!:^+?2N(Y>RI_K"
M^.^X[!EG_4"%.MGC<YS^"$1QKU<4*%A@"(JP("PM@@4%BP,3+)JXP*4].D43
M\M4/WIH0#\0#\4 \<('+Z^[M8:Z<$(Y2P[P-.@ %8R"NE!%K,BQD=;Z,7B1C
M1'&BC)^B+.^+LE2A(0IC6ID0:0CWR&2HY8<X-<YN>W$0EP8UZ<^H/6 TB; @
M+"V"Y<"T!_A7!(FJ?IWKWVC'=-RWSS@U!_[<@8U49?$7O'LETF;Q$^-=ED:Q
M]N-ZR^\2.%BI-72C!SXO4"HUKG*1:A^HUUU*L"<!#B].:]^H-7G]0/BL]H1E
M+RXF[K!C7 YE[\&U=P_-^G'M6,&3:F<+%JP&(A>E2D;&C9;WJYW%S]XM6KWY
MFH!-=[]#-Y[_9UQDN6[3HMX&'II=U<U^9$ -?D"+!B/@3=#3X^)'<01-#^3J
M0=L/IK:5USFG^;#>6I[_)'[6GXW-J-"_?P 3,O3247B$%,-":?N Y^?PS RL
MY:?X9R/-2GBU?J%(CBK+^BF&C\=$[8$=CG>N+T<#_2!1&C>J-GW-] 9Y? V/
M,;2]3_6-5ECBTV9'O1W:'=U:S</XVI")* KM_*X4%#\/55Z5!)X%9=87C(O\
M9Q6PW!X3ZR1*U"T)X[P^S> 8*C/LIR=A7 P2,3K6W\XXRHX-KE(7:Q*^PI]_
M#(LRCD:3\E4W$I6&)X.LB*LGYRH1.JXX";);C86NX+B,\,F2KO8%0\;+G.U]
M:3;3>N?GY,6]:(/%L1[0!+"4\4]M6+W\T>@>5P$@*4J1E\=B6&8G#[^ 9J\_
MKNVP$C-$!. ?B^1&C(J3-]T[BYU'URK[FC+11Z:V68MZ)?&H?C?;)&5YK#--
MVJNYC/6F;L0@2\+MF/$EE%&4PUP5+^E<6R_F.DYKD>D\;#1G(DQMRFUMKO+?
M@6[4>[]J.FWT5*Z '\GZ&!YX9L5"8B P2@'C$4DRX2BY^M\A^*DJKZ7BX$"7
MX6T&L)A[4J3)SN0)FF.'0Z#1%4^J*3:,2[TLARJ%U3.K?5D*@$C_G1GZMYK"
MB30=0A20JP&0._T*3;\"U1-)]'+ZLT53J@*Z>6S<,=^>/*0$NF?KJPDX^FPX
M'LGK=W"S<W\Y5"T1@T(=3P*3L?X\I6-?QP40U"0N1\>3J^>(U/6SO8[OO)T>
MLL>5J<?L[A-W^1!-\$6WS9/8&S6+SMHX<;%-0%IYAM1V9G*@X^A7_>,->W/8
MVMZ<':]6;07688>40=,H:?6P@-GEK&Z-PCX. ;^,CE]HA?N+3;?H&O^"9__V
MU[\P[ITDB<J-W^(?/U12J'0:M;M:CGE<%48,RO$.A-/XW8E2\T./W<AE+>F3
MD[\KDFUVZ"&9XDM=Q?XBLU0'17M%>WV%:0=]^7%<PI/D"EA=Y*JH)GR.C'>]
M6$7&V:V2PRHQ:'(:LM93?LE$'AJ_J7X '_QT?W;RS-4_ORJ'7SV80MJ*(>S&
M,'\O2G5L?%!!/A3YR*#LR& FF[O!*(:QS1SK#PL8#&,QC'W],/92PIN-[QWC
MLA^7/8Q=,19HCW_87V2>[I5HI&BDC0U8[R/._X)XTYB)7S_$J8#@%&+32?PZ
M%:[.?(GA:I-,'L/5IH6K<Y<.['QB?^M9=DVL[N:2B>96]R#RBO?%/E\I=_?O
MW2 +1__\OW_O]LI^\L__#U!+ P04    " #K@4Q:,C' (6LI @"CD"$ $0
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MP9LFQ^NXXF2QDPPG_J'1!Q07FP^B+GQX]Q:]Y"C.PL<(G4 QE)+=EYU\@$.
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MP-_?OV3!_\O5S'%W__)-%FZV$?KFK:6>X;]!!9?$)WCL_"+*!_932F?L7B>
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MY"@-J\="&*_N\,("F[GYU/0@-OKI%.(W\A+O:$A"5';BKT5 %PH<"I=9'FX
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MJDJ4PIUQ7F1Y@O_.SG:8EZ!8]/9CM]WBY&-EY?PVIS6]AF.?@V4(L>DYY%S
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M7H@9D9>;-(CJ',%9A"^6 +W\#;455_)REO=M X45]""[^LP7W0V&E1S< LW
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MTR3+#/+[F=28&G6=PX/_' <H)1KVZQA^#9\@+\,J]<4Y:6R1=G!"^:OO$R@
M(2-6[$>[+*3!+"J5]XTDD8]U\@X.''Z'!,K>?P9W!W+#HJ!*XZ)ZU@PAY^#
MM%ZH+'EX7^V=N*;C[ HNV,]Q@>^="EH77YG5-Q2.K/?([-V(==0S(3[,)>[<
M(B<3N4 HR(9"EH[3AN4QN D7Q(@R6UYOY;>\H)2+"]I(E5#F38X)=(9%'86"
ML(.#Q6-ZSYYCE&;K<%L*Q7U!P94$QL./:=\L@ $S6];/>HE_BG'UB3U_3N,8
M]XKJ Q4./XUBATRJ5OL7V$RO)J;JX YJV>Q;H6> M.Q'^, T"DGK;PN>IG4'
MAUUGJCK;S7&_:BLJJ&#-+1/]*#HX//M& W]X]_Y'Z4A9(>[@H$E"G(CU?6A\
M5+.R@TP+ Q#5 <?2&I-FWAN:"-$"50>GL9'-G1B=()JB$E(OLSS<]$LFHJ?B
MX#!<10E)=L8?TAH%GZ**@PQR'K:SQRA<T8S*FB!C9247F>PM![TJV65(*M8*
M95%U,/6YM2VW.JU2!A])*:*/AW+;CJF?V:LY!Q=@U[.XNA0AB:=?6@H(PFC;
M)#68C'4?C2V"  1FZV6O&@(M0(QA,!^0JI2^(O5NV):(CKP1(&*:-^:<+O">
M31'I6)5MR'"5&],:27=C8(G1E[<=OW_]<'E+@SP7J,@!$E41RR\M;-LVB,)_
MA+$B?IC_W<$#I[:Y:X2Q3D'KFJTL7X8H"CI(E8 7Y<>[F[O/F2\?Z%[U'9P(
MT$GCAYNO@FS@R[C(0FD\A&/J,]%BS;;DP=W+6;<G&0<'P@SC4[/A>A%Q<!!:
M$1,-GT/SMZZXIHOL:FQ05-1BAY,-HY:4H&VP>03OT]U[!<Y\L\1(NJ8O/CQL
M\HQ37:J42*+BMFVS(*I!"K XJ\10H7565,XN)!,LCK1$9*(?.$ F^L6OGQ]:
MO>-^<'!'E8E/Y@D3?V?$X1=M*%9[)LPJUKOZI#CTIT&0$B1\,NX"&Z*PF(-S
M4VF:*3I4Y5)CBJDGKN8BHQVP4@V8O;"X@XP)<K71&U;E2":IX2![NMN3TQ]
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M1[LL!'!R3JP8DI[)#O6)_#W+Y+6 CR9P]FS\;'G#?'ZX2*+(5X& M(LXN)8
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M$XBIVR1GP=?"_IE5='"!L(1GD.W&?[E766:[)1UDIUR\IBG 9.5MN^3@.RN
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M"._U3)T>=  !!YEO>SQIF956F$@, 5T<Z'IVF\>D'6O<_7VLMR!(!Q=HB?!
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M:6H^4O#K#C\PJ8-ETX5 Z09GCK"^9Q,C&4@%CS*52514W+:^C46""15]O7)
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MMV.\H4TB#?V+NKJ?C[JL!7;#RP( DD8R]E+B8"Z<TLZ['TL2$V_-RH2 R^>
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M:VVR %G\\-DFF1]EU@-12L*'CT*QQZ(X5*.D/SXK-TF\@L=I'2.QUZT-Y$Z
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M%L62[NMEIXF_>==P.N?G$#!BJM!HO&\W6S_>C8TO2MP/"C]J/\/A23Q;UOZ
M^_N@UQ@DKY4GM@NY%KJZ!&@#)O;U<]N%(N[#]>@(Q:,M7*$[[&OEIGGVF*+G
M3('[?1K'F%\:$;DOW#>EY5%BHTY5*[W%19&R>/$Z^+"./:P1,RW)-E_:R4$"
MUC[5?@NR WAQU8>O;%Q:QY-R:(2)$[BAX9THQSVXIA^GJ+5TRH0H9=.@]!%&
MSGIU\Q[7_N20A5@,"E/X!'H[<"B%3!KX#=GZOO3%NXZIFF^6PO>V8>\Z0)I5
M+X@.UOLV91TD*%W-'[_C/ :)18_TT\-4X->#X^@Y.>R-P*IZ.*E^[<"H@TJ<
ME;/='!.J,=$@SM4>&(8XL/MQYT'O>8 X&NPZ&=A#ZWB[1Y!HG(,3+<#TM\3#
MPJ%L$8O[C"@+L@_OWO^X[P%77@!IV7CE-U\02^"2/KS:KAA>LITH#]DA!DDI
M1=0C148'SC5^>)XGRXQUB@52?,?@8V53X'<QN9_P641<9!]0^@29NX8>W)3T
M?P!,5TV<\DH\<#-&_W5RV<B=&$6,IR6:)/55!'&N90*/<W\;XN?^/JC]E%Z5
MD0._, G)R3!,K#'4B%(Y#%=$ZJ39^639]\!S%RYPE9OPGM(Y[8 R=^$3Z04)
MZ5 [B8\KH$\_5&S5VQRBKVR$VF[F<'7E1%M:PQP%DVB\>:GOG*")0,+FRL!Q
MF>7A!J)%[$EZ%+.$YG"N33ZH;.@PZ&;669<#G#G#_U64^#GQ":T%^KU,L"7!
MMJP^F8,XE^%G]AB%*W)69Q<)"(-##51<TJ"DING]$A"J4S!E[>79,6 <^,5I
M6Y5Q]Y6PTX;/4?)U "@=RXSR0#I:5J<'U1E%\W/@I:K*:2V3@S["DUDG"-E4
M=S3SA"OER!7MVP$%24?'MAGI1 <I*%+8/R!M[I"?_IN-2--^*,VJ_L9C/3BD
M]R(61E-$K2FED#::2VA#WU*VRRM>_UT&@AU')J[%C7$J._9ZW(RG'-5V6-@:
MR?*-]<,'QYTNHKPJ X=:[;'LB];Q),B7[:1DE8HAQ9*:7P;E76=9@89&XXN<
MMO'PQ;76A;55AMZ%I+77SGT3F/#_LO?NS6TC2;[H5ZFX-_:.'2%WM[UGSXG=
M^Q?U<FM&$K4BW8ZYCAL3$%$DT0T"/  HF?/I3V;6 U4@*,E$58%03\3&CEN6
M,_-75:A'/GXIAT EJU/M$P5'9/LRO]\7IF%BJUE)"B1CAZA7L _@MW.;R^;V
ME8,.=#L$L$*_)@DN:@L4339]%IG1BK25<\FO"S+X.,E/1(^/:MUB:)8T%6)G
M-ENUAB1?ZF=TS$]H*$MH=U.QZYM',[A!%IP&:[I,"K@M%H>,C7T]5%+5X0)R
M/ZR%8%T/[[?@/13N?15!ZFS!&O>J4<L=[8X.DZ/S-A;#WJL@#$:3"T O%=I0
M2"N3:M_$6-CO@[X_BY9=\/K0ROL]:<%V13U*9R3>>X]K=\A4^+GE1+,0>07T
MV]7DXO8.UN(JFG&XE,VB]+ H@[TUD]AA&-Y88"27K2W!GC=,9U#DBOJ-7;$)
MNV"WS!8:INS.&1HK#$NS8DOUWUM6,+7PY/<DZS0A0D28X>]B;M,-0*("O,AK
MVL-NPRR(1_*"16EJTG&&BW%V16*=X^$ R%SQLIHG/(UE!E+=)^],U(9=WWTI
M(R<K2ZMB4I?9E$]J.V'7/]W]=,*^3$;#QZ^C*'\RW'8>Z"O!!_Q>L1)X/*?V
M/]UH55$0Y=JAJ..TNWGM'(K!-O=V6*L5012^S[Y0V<%X32FT#EMRGFE**/%B
M>[<1!1OO6:YT]=5STR]^J^ZZ!:I_?!.>PE\L/G/,BTZ1@#E>)5F"<)#12Q;R
M=]KRI0HF=5 W!UN+X@L(R"GA$[?%B23TG+"%1$\\Z39Z+MD2 N[Z9FYALRM3
MD ZRN_W1>LFK=(+]H&:Q?0[ "V0A(O EKRB!>%1$\*].T3\J]A17 V)M#.C]
M1+91^-E?F,@O\7K)_<PQ373[T<GS10K3&[9?]U WT^4RU":'>%%TL]C*B@II
MM@J$?Y4%:$8]7.<B"U749E:Z#07,WN*:-E!ARF4<H+*>IJ%GYQJ#01??*[CY
MZ$AR5WHXBGUIF3*"[ID?S@$,^:FTFW_TUMMO&)P);-<7% L=V' <?YD<VL_A
M]FIZ<<XFT]'T8G)\5MH=&_P[Q8SD<I'36DYS&5,=4]]+OKJ &U*U+44,]]!Z
M""D<6T_(6#V3S2[YBG'2\)=21O,'A[7524:2RT34Z"#/L)VR<$(]L>GG45:B
M'P"^'>(3]$D0)/"-XAA^ISR3J_3 C"82Q:2L$R:E!:P@IG3MFKNZ4W&544$L
M4OM-IN]@!5;H&,XS7)GCN7@G="GUUL(0E2Q5"%;F[02)[0WM$4Y-U]-HC]H%
MD9GJY[>;M0\@.R5\9EI>S:$R.&#I[N2$1_.2F\+(S!S/9;:F3Y^-F8H)OZ0R
M-(_+=^-B4,SO4XKP^\;+5["XTM^B=,-%'ZFN#U8AD)%$)D0>.0+]Q0W.<GLW
M%^:O<WGI\]LD6#N?SZ7C^:KV.X_0[=Q&>G?M*#'1<'TK]<S0S\B /<QWV@;/
M+:G##M!N4.2'!R9$&F2W2DC88^<\.=;*V[FR;K"UMQ['UV)QUP,5J/Z6/LA1
M.4-R@%+D-4Y@6)(%'SUT<O0KF3)9DDFI;'0:QHGN%%-CC]781'HN*S4VOQNG
M4TQVBE]OD]4>$;YXQ(]N- <C[Q77D?!>NNXQQ4D3BU"5P:LDBYKZ:R'E903L
M/E$/)6S51'-+NL+B.XW*I,36.WP=*3)@_3R<P)<FVM.[GNX'5"MX5+5BFUFT
MU+I[G'W_HV/QO:M!,?3U_V94[4L"Y3[4^3]']7)V, JMF5"?C4RH]CRPP!M"
M,PG(X7W_AW. TI"=4;T,@JMLJ  C,=O&_SC;/J#!].#:WB?E'W5*]IUZM(^+
MLWRU2JJ*\_*>EVOX$9HZA:_U%#_60WWQIFJ&NLU\<*T=8V*U?F88P+ZA">PT
MT(8A*[S%^NB:\FNYN,.F]+J 804A KOK7V)"#Y+ V4Z(WDL2I[,Q.&CKZF4@
MZ%'VG#L =HFJ2) Y@=JF?\F22J:K;P\:FL8[=/*\)^4$>6^D?MDJ?0,6G*C4
M=L\]/T(.C/QN:I5,ZF0C<SQJM8STLB\T'DHU[.2!/AP9O\!RAGM.G<*SQ7C>
MD>M=\9=0]4:AQ%*92C"2=[? [)!/0$ -/_5X+OD*QG.;-^'@^]E^KSV@6PIE
M+:DIH1SS[@'OGFSC.9-*\(]-IHRP+G?1-7,:?>?E793$]WR^R7X\!V\G[B[[
MD58H%W;H),9&.2C:&^^%8TARUJX&BZ,U_\N"(X#X/0FQ2O >#J:*&K_?%7F\
MF<$96&V*K+S*ODQ$U,F);YITL4(HH]?]6JB#GY$^#,%\^6GRDVR<YOD.X!.Y
M.O0)L51"=6U2#9-ZD(B'$ ME8?@/O"*W/#H_..%!JYKAA1S+5B_BXYWQY/%@
M,D-+GMZ'A,@ .Y$S.';NG(E)H>G?[PC_QY.%Y).;;:>8"IN2D:%Z>@L#V$Q:
M(+)QA0E'YJ/U,E:-L#"-A=(0+ ]9_@_>Q3XZ2D:6?Z!D$S;.0G0OX7,.XQ;#
M'4*ZMF4']F[.,R46[Q$J>L#>B2O?^Z"^M+JW]G@NT^2[)1[:S;IU#4#A-^O.
M!R"+3O_-H-IIK5[#0D8*+.6 5;C"O!9XA:C>ZGY?R]3>[<,]3_&B?<F[=:S[
M4 @Y[-)C*S<W9C=S0RSSL1.=YYR0KO9;>2 [Q@<-^L E>09' ]9ZDX,7SMC3
M/"IB'7<9%Y/-PTS]EQ&#P3Z"V*H5$[L\!(2D870OT:8QLJT."F&$R#3/BA'A
MO]06!HX8M35>=-I.<A@0VCH;P6F=K#$*+BYUV&0%5ST]H\(Y30_O<]]L @1_
MHN260%UONAIN-O4YU3U[!@%@=S4]:%G';+?\D$\'8:R5I*2EL'?\^RS=D.<X
MI1)G@X37+Z.PZ2%O2U*?K/DLF2<\/MU>9=BW$F\&GXLHYF?P4DBP>QY25AWX
M\'@V:+"J,]?+.G.]5 9AE^Q$FX2]D&+.9F04$XQ7X6(+X4>N-?K0GNNO#6&G
M6U:;PL@6)HQAPAKV;13ND?<B/8YN$P]_33D0H4B#K/[TFD;IF!PT3L?&ZBUB
M83<+$T=>TU"Z!-BO'<4LWV3VP<&#HX(173,0K@,1KIO[\;XRK'.^+CA2_V("
MW!D@6[AL\?M,-D]L*L9>N*@Y7';&J_M;=>(UN/ZA%E;AF Z<9!:.PF<4NDLE
M#+!WG\,#YY'2K77>G+GJJDLX5JCZ%5Z\E!@A-RXJH_XG?JKZWTF?]L%'O#*$
M:8E6"XBH8FB,K/VUS&&U/1ADK/^]-.F-CV#S.EZ/9)V-F-HC.<>1?*21+*R1
M+*R1K/^]C"MXOIOW/I1VHI<Y,'!>E':!3NJ_XU9K/AL&VL?SSWD>.TG0(T<]
M %N@P*$ :;"^J B#S#@X@JSKT^T4!-6M*K%=?=<[G7UM:<\TAM<U(C!;2,J^
M]JG_"HJ="UW=LF&4Q7_-P:+?P,J-PX3%:XT*BR9!L.SX-N/K"C-.T#\C]K*(
MT1/[)S9=PF_5OP/W9$8,XU7.8F$[EP68]"3?O17J3AKDGOT=8;%'B:O^RY@]
M)=62B>L2$[DN)=PH8=Z$07E&KGKB\Z0,,$RS7')IYI#GJ'6]&OU'6H;MK2S/
M_44#_>,WKJCQ[QOA3L(@5]V,3?TONINR*B\.[T)G:"#GC.[,]TXUTJ7^KTFM
M:-"H[3ZO 3$]?V5R$,;!Y]]#! ;.@F3(N$?3'ML9*"1K>ZGO^4&OHFX1[3[_
M@MZPZ4RXS[=16FTO-[3<W74\EG+97 @V\?@]WYT!4@^&_4"&@<-ZU]E@A@'
MSK3J83[V/'W4B_RF?BJ/Y^:CW5F@#)\\M=?"?)K#WUC=3P/Z^EX*^!#S=:@
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MRCR_OMJG7(>WZ+N7"8-.RWMF=;RK-),) UR.16[%=Y@$+$$D0ETWN3!*)'M
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M[4N2/5-X)LM,.!E$%;&*\ [[2*N2R+<X?B_WR_G7P+W6EZN,^/F5H]?'L%S
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MV=> ROQG!4;BN$+&8HS1P0?UL-E^P#,E(WB"T!>Y^- [5DAV8Y0B'&11B?\
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M0ZE,D6LSAS2,J]HQK,:'*>#-6E)DU;[O]T-TC&ZWK5<+-*^ SJ)U4D5I_?S
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M4SDJDA)FA+I#@*Q-@9N[<M >>FJ V1_LW$J64[(.4;O66<9&?]43N!(V&][
M#]< X4.-0?*:5/KOZ>Y(0%@DD,@^$XG"HCE^ WC,AS9=C;P3P$W%$W+*<&R?
M#;9Z/1X^ [2*QR+K\J]1MHF*[<=/OWSZU"GK04IE0BR3<ME'AI+#I*<X!M:X
MOBB ,F'V=P7PA!#Z=8PX1F:NS@:LO]JP@E>:27?OY89XYSI$RY\M.5/>W;E0
M8Q)[!RL^<X94?H!V%9IRY$OQ[-H_=;DW@/L+TYZ91_]GTF@&*PQ]*SP^Y^N"
M8XDYUM^ND,BR5%P=5ZLUF(PKL5M26:T,SO-:VPE236I]=(HD6F/ M*PP@V&W
M\:O5](=;)VCIBXC9#=I))EI]J[.[0H=*QYHAI08_Y^)_I\LBWRR6JO'?&9&A
MEU?(9\:31:;HT:GOASD4XGIU6>0K.5+98H1,,EVV/&4;>Q=+Z][#19CL,UHB
M"H.("6(NC&1<D;A3'Y$3:V#5;7<.IJJQA_^,M+%_TC&W=N'F.%([NM1K6I/Q
M&.!5 _GGPYNO@;#=9;$ >4/!\=IY8>\R7ODMTCB+BF*+BXS8C_U=YI0>@V:Y
MMQN=-\SJ(%!81QIK7W<[;U#MIM _,K?]!79J4J%.O1]'!BN3Y\Z/8@YK*H<)
MSY*\(*H()P]DD_BB)-F"+$*_(3U_B Z1J6_/0"1D"D:/,*]BEX :2:)[YBE
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M&)/N%(#64@9A>L/'^>#=^IWK]2L:GF^=?BGC.5-]S\?/MWW?]O+P\CP@SS[
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MZ0Q0W;P:W"&VS<N?'2RRH])BY[SUSL]#C<I[HRQLSXH:)%1$!3MP38O?.D=
M]Y:^"%CUV17+U($_)&1#HC1XY?T %QLO^Q:$X15XL,O$LD4LYN0^DFRZ@M2A
MGNGWY7)8G5Z6.K045\3M@S]D=$T_O-%%_?#"'.+'C#QZD*KYNO_V0T38;0 I
M6*=/XL='VXH8 @-73KVM=V@0#\X@^>>>KCD\5"GY_P I_]^3U0G(!7#1WP$J
M)#=()9+D(5ZR@].EYDW]6A6;2LAX[=]J_$3_7_[Q$]^T9R%&<?UV)L*)ZP2=
MD125QB2HZ4$%PIQD6<A6^!SY))EG]**DY(!X@5>@R#KQ>ANRH19>6GX'J@)0
M:9S"EX (^:> #.Q;IST,I\*8LW\K3-\EHI6^#N/%5OH:1(&O/*).EKL_=#,A
M:1$#APV%!L997O4GKW/*GEAGJ,HA!'I2L!3<BT=C<-HK8HY-F/L2!8-P>L:H
M/W'ON&$0(H:*!,[T6Y!M3M8[K4@P8B%%1;YR2C7_;".T2W/'S*<DB*E36CW+
MD.I&](N,_<O/GZ$0"40O$I]%D8$%)9TF1;NFLY9MX<O(.26%A8!NMBTZ1R&O
MYN*8B!56.UZ5[@J\" TU^W4.$V)K3BTRF4K#'OJW_]P'._CF(,DR>0454LQY
MCC(B0V#!=Z"^^K,DQ@RQ_JHWJX'&.2(FG].BW_Q5$(;#I%X]_WG^YV,;^Q>8
MM]R3$S<7&0(;SE7/<Q4.^%&H-!=Q@X=0[*EH;7P7)XL-@<3\WN%>0LFKHH4T
ML_#3(\0RYT\= C<@;J4#@^,$4?Q?19SHO*Q(P_M!J9I=?-RK?Y-OUGGU::%-
MZ=!/B4#L@.KLP3 ,@C7/8C$C[I9@#SVCB ?J"!9"K'%PTEACQ_0Z01LU9T23
M/7ZN#F 5J5I9>CH>;4QF+X<? (&&,>:L3D4A!_<I"99D$C+/ _@,9P2>-^"W
M)@F5X%N* IF^A,&:7<P]<HZ+#T+%FR7YP2L^R<J^%!^%2B#%5W^(CY\=$TEJ
M#GQ)73;*/Y"TN^34R?VK1:*+EYXOA,\4TL#=S][W,T5W%'Y[\,&CBNT8@A#5
MZY@A2B<\3^;C*PG_<LK&LW\Y=^/9 ;$)JXBX;SQ;]F&C5Q>=!*KR\HYLD0^!
M9Q#1TLO>)71F"\I/%$W:X-Y?\Z^<T8$@V.!ZA"A4+'EGZC;711$YC_M.K8N@
M\NL-3*"*F9JGV4$1-D!\7F:RT+]\/5JMYV>T6I?'NZ3%D#TCCYS@JGOD &@I
MVD@ZPTWDX,F>/HGB)*5:XSZBEP/H#$,?9X]_X_\&S;G\BL-C.S#2E9J<>50K
MN.-SO<NCLON.\'2Z(L#ZC"UF.-N^>D$(LH'JI> H[-U4I[A>BWE_I!/_"#._
M.]3DP12.?("0<$\70-]7N?)>YH26ZJ&@$X@)_/U, =7/L@# 8VZHH#\*:?O5
MIL5GC3'.,US ]1]D[,KM&X'-4V:6QQG/;=_P"=6&\X#I?9(0ULR=53M;Q.S7
M^7ZW"ZGRWOE*S6>%&F,^ 7/7F4JIG1*U9KF[ B\F:^F;/-D3ORPHYB*B847_
MM"-)=GBBLV:4#J5_]H3!#-*PD!5$^[&E_-L/<-%EC$:E;W?4Q F[TP5KJ,S9
M:%>-"*B2T _274SIZ(R[3$7OXI3[')+\LLBH'C8C=-%1"C:"DS78+3\,X5C'
M3_\@?/L<#7>/P7%E;-P@X12RH+M3IP,/A$FQ?4<,A(C*<T0A#(9)U2XO0^<<
MT3K77D;6S _+_7KIE>#8Z_1:KC-;^04P<N3?^(%]I*@Z3U&=G#S_Y 2(EMJG
M:P2/%\TC>:,B/F_VE#*=[?C/SGDF;W Y\$G^C2<X'O_ROI"JYY1X?N%1/F_\
MR"+8TFN=ER=>D83G<$^3PL+0@R'SN<N*Q'3V8_XVY"P7Z=OG,E?-]R^%$I;G
MF]$CF#_]Q0=PK@(-\!9N?H[9L-@'JX_>0L<YTPLX3;+?\R?4\M!'WO I[(7*
M)%E6UN<ER^*[]#\-G^80/X&!@>RR'_-5\.&@1K9HC)S?E"6QXM9#&<E^<HZF
M>)G4K5F<B^1(6@S$@F+^UI?MB@(U]0 D* E!9ZS.CQR/.A22Q7\AD.NWVU"9
M1K]*/)ZA)<=! 8P$%3$UNC"/,ME_>"BBQ^1H60Q$@N*D4"N8NK*@B^4]X:_V
M*5UJFE*-_X6>% 93]ZN78PKONIP:PW[#*>&D=H"KV$O\Z2KOWQ8GZ?25_AZL
M-UE9V5ZD2\<ID/!+O904W\E".TR5UB*5#.LXG5-RY&'CI9OOAF1>$$*10A8%
MQTHDO,3[[.@G/[K)I2PQQ'Q(^ ,V+$YRE]+T+:);N EV18#"?536WSG(^<%Z
MN%-T?1+\?AME].Q2T9:P[A+\/R @ Y1=$3LSM'MF/K8NH$*H[&G.+JK'..--
M6?P&S]H-0\*:U42!9ERBG"--HY @=^VEF[LP?F.6^^<4A(?$)F_2^=O,X?8>
MYD_+WV_^]K?*Y2K\'<G.3/Q_[-.LZ%YW- BI="4Y-!)D9H0G,- #?Q4G2?Q&
M>:.2+\V?52+'R#'M-!4NL?\4I_3=]3_![CKVB5;D5R"1[*4I=OMVNPOC R%7
M)"*KH%)&1"$JNT^(A"02"2AAPM925#.'^ZO_>/:@[U4*[6O$CK?@!6:)'_2/
MS&5 -W)&?+)E^]S0"'K-AO1I5_I5IU"K<EG\2_3OQDG71U_'R9$<F*_>/^)$
M+,68*T>@]N7*DOZL6 ]'@BX5:OOMGO5)A&Y<07(L@*"XSM4#W)_\9B+(M9<D
MK$G?%F1W$[$6PY#LV!R*_H;\O7Q@:66\!:3*=*<>X'['9L0+(=GM9I_PL,V:
M;5YQ1[<>C #52H/U6];LG%X:0=Q\A:I!D:B+(,N279R3G=F&K_/VY6J]43L$
MR=G*N48A^-AO2!8JON'%8%Z6+0XJ:C7$N95-H-U\2 @R UTB7NU3HMO#.A22
MQ>>.%+UB485!LG!SLJPR;;'WV\MN;B2$8J*.)+P3M<Y_*(-$@L0C!<H]S44R
MN]$SK1WB_DH6Q5[QE@?EG:KK[)IB34<>9)[1#L.1[*)H\H5G22[@]Q 2M>/Y
M7(K-M!F)!$F3\#@^ZGO+(>E42,@@>NT+(X[^FM&-<']>OQ&XP(D_>:7\MB9'
MO5_F2-2]'+I.A&1?JS;U(@.-E[:'PO;Z3;8>[G[''_?P].8-,7(=2,@7SVN/
M^O<1L[Q=R>LB-39_@#G=$Z;&P;??(8@]S4V1*M1^(VE68J:H(F4Z*H-]R/E+
MEF<R/WK;QHM5^,G]3NO9M0@L208^!M;SNB=041$SC___-0[!7'(?B59Z%DXX
MW6<I?3/ KSEHT_O?=28D]\(-SRIKQ)P)CR.E < XTOU.5R\N^K@ '05:8P4^
M5T!G9.TEL"^\ZGECB]M/@61OBY@AKGRK5/0*D/L=JSR1>#;QC(0>J-"+^ $B
MY(XNQ/MHL2''3F?$+[51P]NKQ\3N24371:]6%F=T0UXR'LPMT^ LP-VC<]0B
MCS5G&TC(@)"<,Y&QYL$Z8KDL49;'#3&6N8_*%H_M+*NMID-"#BHA/28RZ;FZ
M?65&X165,3/"HAH+MX3.HM5F!B1(?Z%+2:=1'NDN%!"!F, D>/6@!9#"2&(U
M% F:QDPXW;9:#D:"JAB&^UN<&W#>2/(K"7WA_,DQM1OK7O(NO.\@44G*O->K
M.'FC>HQ$R96"(=FG=N)R 8::(>0NFP@C"30/Z)9WC^5,2(@P@XR!B/BW7@+U
M>%-=2(H<%@DB8DIE$J1T?1!%9QU3:CT<@?C9! EEK@3,"'#(XD2R:WI(]TCD
MVG5:U(8N@OH46G@##@G3#=$^6,Z/0\SL?I=O(0]I24#HLY<BU+EO;+$,",G^
MFGQ2RB2SWMXNFYF1$ FLMZS:@4ZWJP$A6;II%_)"ALPV669,=]M/V4Q(B'#[
MG9ZXR NO$^('V1>H4I?6,]',T.Z%347E_)+$^]TMB_"@U[D\\MY^E'OD9@1J
MFH!=O&(Z;Z"C@'./@*@CJ])4C[$=J2CG;#)?NT^*Y!0>(WCLZU'HQSAW_-WP
M*EG"CC0>DCHX?$D=0MT^J#((CWOP!*P3UM;$.GW#;AITC,FTLQ9,68=W+X0,
M%=*:9CC[44AVRU06H6,ACM[3(B%/U2O9L-58I=8V1R%!SM3U01^L9#L:(;)V
MG@]+(V:+R1 (-![MNZ<*N9=N5BQ[-$YDZH!:B^HR"1(N8&?Q/DWWA/FDB0]:
MGGR/I:#N=Y"^H"(6P_7YY\]_4=CQ)#!(Z,^]XK:5T[ H \>%_1J 612*B/T6
M0U #7=RAD/&IT,?@/MKMM?F:'29RKJ ?JVC1ZWLI04\)Y'SI>:[;-0')16\I
MGWS_&SG4ERX%<G_D>8ND8]/9P_'^:5Q2=B.0G*9J4HW:B-2$<[\KDW1)(C](
MG^B)W7I7<40HC5EXTUPAEHTCW"/%3@"0>+5BG5.(_RW(-C./MQ,Y/D0?PJ4"
MR_93N$>[J!OHA7?[C)V1[[S(E*3PA X8R;F:DY#^??V%0">H<!+Y$W\;1 $H
MY!#GH@U5M!OK7*#S4/#ICJXMCJ3*J@;,/<O]&JPWS!JN.$:UWY$P5O5E6[SN
MB]?^??24D)T7^$7@I\WSV#@)$M3%8/,972@5 "_AX2E.6>F4X^J?H_@%;.H>
M^RM5WHS*[A S(R&2^#">KE8IR3(6C%8O[!SYLM=BJ\"97M,C)%>>]D&77DOL
M*7M?"\_NAV %%*AE.TR9.[$=%4_Q523$%:O]Y&DT^OQN.3069&15TL4@)+7N
M;#$2"9+'PD40EC++.ZZSNF9BN$KK')K>TR(ASV0+%L4\A;UK@>PV4[A7DJHO
MIML]!+E8/J^JP$AVL.S RR0G?Q%II9)Z !*4;L@N(<N\R6;+DMQ60]TS835H
MX)6$\2XWS-7]E;9Q!S93(-E=65=AR SROA?9! HY8QR'HZCO) QY[QAI^1<=
MG'O&_"TOF*P0AY5?L;!3Y>57=Q+?1Y76JD5/59M'I.542,A@C [$$O0'[9EF
ME(]X4F9=R93\C(3"HL#]$N?/F"5)HE9O(\5 ]P=_\18O-O$^I:\PRN&+-TK[
M Q3!)8M8]M,\^*X*^.\X$9)=5B0-J<^4!-C];E;UUNENDVV\<!N'\?IP$^1%
MV2UU7NU8)'LF'C#N6&<9)ZU.IF(@0A15]I5*N9945>QC$%-.ZT\A(6.]>QI_
MEK]Z00B7^8JJEYXJ0,=NK/NS3U47NEE1T;\0@CWKEZP.SKD7I@C%G9$U]Q#Q
M&K+U5Y\1V/U>" 4<YB0*H A))HF8EX,A.3.B/%B09,LKQ19=T;39IO;A?EUG
M=K_'H*U2,<@JC=!7]G,4,$/?$TE8*#D=7/Y=<>.VGL&Y I^7OB]Z:,MT^"8$
M$G8^QH8?BS1T27?0CW;/EM>\ C>YHB=*E9TK T*R3Z;'^ TI*I9!3BK]_^'>
M%WQ+QIT<;GXL!,O*8O_',DE7AT>/!930EQ<)DKM]Q&)*U*Z=MK,@0;ZL:=;6
M7FP<AP3!ASA:0U;RL02M+A)4!8T$F6I;NKR,&7U!YZ\('NO5LK>=<1+W$IEE
MJGCLY,#U+CB]K[P0;GEUAJC]4"0[S.OI00&+0F*F$+-7:@3R/34.<[^+QAP5
M(5"DFFBG*U(\R*Q(]KYJ5<D+#@>\YK)UC1/[ET/O3R DF_(VLDP@TH]'@K!=
MEI-:5;$?CP1A4X$&V<'O7<7#,*E[@7K[?<D*Z,WH,P2JC@B1BX\D@YY[Z2*N
M=DEJB,\.<R#AB?:11TACBE0-%,%I2O]PXQW2ULT756/=(RJ]K\L-,<>?=IX$
M >H&@5,\G+DN5S26JCV:M709^@O.;=K7\2M)9"I-XT<D8FE!3UJ<>)#DM:+$
M)NR)43@X6?9-Q?=9MK:G=+^B;Y7EANW*T25*_R&\T?X:!U'V&QVZ3U3FF3,N
MP/V1TAFZ><R-HGN@]4CW2#ZG-W$8>@F]B2&04F&1E$(A.11?DCA-35U&+<#=
M[X6Q^8'0$N(Y\DG"'!#W$?P:O$+WF'7B2;ID#30ODOT6[^>O8 "%KGR1%Q[2
M(,\RTGD 'F2MQ(:>&PFAZ$O,UR[X&0)*V#U._++7E/)5UV$N)(2HO<'S:)EV
MIDSI,(3H22[HYVA/+Z*RYC2]<LN_Y*7ZVE&B[Q?<BUE%R:);BLXR8UN]),1/
M.]4-/LD'W)/L(5@RE]-T=;]3J A-$"S'P\H44S2'CUCUEZ$,/.I9D1!'K*P_
M?8M(DFZ"7:&2MZK+KQOMGH&%Y,;Z3055C::KHYU#%@=D.];YD[:(O)I$$5UN
M;G1516>),.YWJ%5#R&/ QV ])J53(CFEM:B(6I8CE$'W0BIWK;(?6[KBS_)I
M)&0VN?NN#@NZ@J-?&^S:EJZ?5M,A(4??1/'//W_Z14Z9(69&0B1%_AN+=^B4
M.5<9B01):7*J)A%=!>[^EM&WW.S4GK7_E$AV6917>?<LR)\I5=O;- NV+7K^
M&*= @O9=&+.>A:(8UAD0U?!($!(BE*<O8;#.^\+KDL]U([ @U4YMP:YJ=.GI
M7!;[U,D2ZTMWV$^ZE^P&HPL50@G)M?_BX)[,P-/G6TCXLQEY75YST)G7*YP)
MK&RN+V>X=G.XYR"(JX9T#^[ YJ\85K.".>M@QZ!=<?Y*-(2T#S.C>Z+(\NU%
M;])D265&0A@J95<QFS-C.Y%[$DCVY4'F1C("NT?EM_OY[6.>0KPD^PR*$JN*
M2J@@W2.Q(,$_@DB5Z"[\B$26'L,==&IE'<H]G;_1>VL5D-!O%'2%$FI>='AX
M>DX]Q3ZT&8QDG\!$3]^LGK(2B0" 9<F%IQ6DYC,SN$UWS)9@'[7=;@XDB-O5
MKM6=MS8S($&ZEEM3"3BU?)1+AV%!S^!2R_5$+D]Z.^A4L[F7NU\(/,4/GU0]
M'RH_NU]NH=1_\^!)F*6"S59I*Y/ ND>$E6B#+H916FKH33>W!,AMA3-@;,JV
MSW-QK<>_(CG<14>D1<P5_2F+'"?;O!5#VNQ:V':L<]]KOIJ)[R>L*0;;@+KO
M50:#9(=*JWU>2*T,>+*J6BD=@P6Q1L%?7?\)&2P21"1='?-;7(Z+$AP).J8;
M6C"70#XA,Z%TN^ME,[F_;QYCJG!ZX6]>N"=Y('+SOFR N%_V49U4-5:5A5>H
M+28]YT/"S%VLZY0S5R0XLTF_Q4?=\UJUZMV<HAFLR>3%JD9>#1H)GXB/,75Z
M;*N(7*MI$*)_Y:5!"N&P9.<5D5GE3566"VL7G=Q^3BR$,5QA1=&7WN]>R418
M2*"Q4TBOCY9#W3[3#.V>XY375TNH"KH-LHR0=$92JHRRWC"=6DC;SHED_[D;
MC*?:ZFV6,E D:)C"_GI$#+JWUAG3&R55\[@1^:#H8-AC,B0[+M3'F1&6)P6M
MBO31?_HQ[O=89$6>,3A=53VV-BJ]>3"2/<P3-1;>=Y(^>8$_(ZM]I(YK:(*Z
MWS'FEYK1HY3G53\E,;0JG)%LGT3I??0\SY]1"MVYU6@D>W8-%YG/0V?SK5B2
MX%45CZ($1X*.,:6H6AJ8)>V&#)G^V4HV4^,RL/+_ 3GR26ME%0'1['2>;$UE
M"%?'>9Z8OKR68102Y,0R/]Q KS7>J>'=RU06H_\C+T)_1R1A30T(?*\,EF^:
MYO54P; &]0EC+_'+1\$TF>]?EL6_A!<"I"- B@]8F>Q?( -_#PE;R](U%)$\
M$D@D2,BS'&6_NS][U5H,30OP?$>6P2H@_M7A6'2&-=+-D\YG>02+JGCGL-,C
MV5]CT$.9IT=_9H_G_G$4NBG=<U''YZ7Z;=-W0O<DJ?:HD[M<Q(Y]Z35%>2W)
M^^D_&Y)C8QV=K_.%MYP$">HVUC9$9C9>B4Y7B6:2W5&!Q%RF] 9F-@=^.)D3
M^%_ GN4XKD@WN7KP3R#9;\'N!$]^Z'T6^V8;E0"+!)$NV=52J3[0E B.A;#\
M2HF]2ET].ZN=Q7@D?% M4'#,+BG^U]B"L<4$2%#NTB(%>V,47@;X;L^"075)
M54I(++LC2I'BFOAZO"2JM="M"ZI;3X6%#(9W PND[?_\:$SCGI4G6WK6EEY$
MM5[PP)9YCJJH%2TX$J/K;W%("4_7=D?U^VJ?""60\Z53RD8^G).[T%O7EUSY
M$<F9^97X:U99H%0Y= \.%;3[$W"7>/\*2 (U7.;+@%4)GJYN#W18D-*+57$0
MK$8AV:DRE$BH<\'CA;42W3P."8*5]!B%'U0$<7[8BZIF\PT)0YYCJ*]_UH1$
M0GL(8EO>>@F41$I9X2R2L#M!8;15@2-!IQ:EJLOTD(*ZEV=%XZK):L4ZVN2E
MSN^VR4.H$F;F(4AVQRJ5 &<"P4- ):=?Q+WI&J\U 9&@4";0"(J\5<)- QX)
M0OIJ6);!YW+<!YD:"YGB[($*A61!E8!I1/Y.O$3'P$IP).B 7<S0&KC1C[;]
M:/<7@;$4K,D@TWT6)#MMU<^L;6EUXRQHM$NZ,_-LF]TF29Q<QTE"6/='V?O2
M/,(].R_>XL4FWJ=>Y%/"+][H<@_T;ZK2*CIH).R9EYL%)5C_#FO"(4'@*LZR
M>#M=S4#RZ:X$"2 "AC)U&IFN%C%]+=;KNMJ7D1K\"TCV792(\V =!2NP"6;*
M=DJ660364^$+6Q,26?* ,K"59&2=L$B[FL3M-@/"O9?7SK7V$FB'NY</M]_I
M]H 3B@4$JI[.$B D.P6%/Y+("_,0,!8-IGVNJ>&1(/1$)2/(3=ZDESE3F%>%
M<I$A'-EJ*!(TV6F@"]X&^ZVV*%0#SOV9@;!9R.OVPB>/*LHJ-Y(<S.GRTR3[
M?9(&DA)QU5^P, G$N.1UH>K92@IN40] @M(UO>G6+'1!_J@T58:S&^W^C%0S
M_V\C/UXF012'\?IP$^0U:29SJZH!VK&8=Y4'Z:DKV^@'(4%-45FY81IB&4H>
M>THK\.TRDWM&9LN[DMO )F]4'0);67V3VXUTCZ2QDW 0[JF&7KBT"G=6K^;$
MQBF1'  AYK((,Y3SMP00"0K-,$J>J,8C85M9!PT3N&?FHI0A+Y4/^T%%#KLN
M/O_\657$T6H4DOWD6\ ZV.G<@SD$DD7?;G=A?"#DBD1DE7>@K =Z&X'=,Y<T
M)/>A703O [* W4>2\73CV^]+%@,#9EB%WTL*ZWY?NA:MD.50#C*A>Y+( QXF
M21:D7@2V5F@/^1!LP45;_',3J+J)]IH-GRU3DA)[-$[V+OG3:W8D4J%RSVMO
MF1P$R;*+F(3\U:\H?6P!C@2=:F,6G:5,!NE>"!6ME5E9'56> +U*PGU>DV;%
MZNX4)=$:4JC?=$CVM%(JL*BO -&.>;[SNGV1/9M9$"(/V7G1DETG[)E8!N#6
M*\9-(A\RW=Z"T*+,_' ?P$(RW5-Z$=\0^MBD5PP12R5#Z HTN:;_ ^$;KUX(
M?U=0;+#YD1#LBQ=$+.Z62O0HW_/[B*7JT.=KM; .*T\YWR7$\],K0N]J*",E
M)U/?69$01YX^.]E"F5*J[<*34=MLT7:X^[OGD:YIPY-Y5,]^"0R2?7KTMI2Q
M6*8G[_ZB*F\B@W0>GY5?2<P0!K;<5W+C91ZO$EF/S-+!NF>C8U-MD  @ *:1
M5?/+]J/=(WNL-W,?T1<O\9+TAJR\?9CQ9_ \HX\[NC_-#'W[H>[1G%".\\$"
M39E-[#B?T;<,U1TA9EEAH)::^OM-YYX<)F,]J]Y\T.FE/:9!(F]%O;',FRRN
M^3HR]O$_UE,A(8--Z+<NP,9^/'ZVGX1A_ 86#EZE&RQ^>>!0H0;6_+9]#D>?
MC[DG96X#*I,II5)2 N-^X3.2TIMJ"8^9&WI5A_$N;XF89JJX'N,()">Y'E-0
M5=(-VKUT#!+$3%$PVG0MJ[%($!6K=,T@#S->[5.B2PO4C7!_UB9K]CB.(U]9
M>J$.@60GRBC>UOQF'H@$11Z^H-=L:D!(EO[5^T><7._3C%XOB2;BJ@F'!(&\
M[C48;M.;/(+D6.Y)M1'J$>X/.HL3GZYN DBNBI41LG(P)'NBLR-;5Q9\L*]O
MUO\;[O>=!\_<1Y]__OQ9U2VU"8-DQ_7*CY515#,2"9+-"TE(V=8$JYJ&(4&O
M'F1Z'\D]%;E5_G:UHI)GNBIB6:!^(/<1R<DPV/1HR75+]Y*]2\O6H;5.HK:$
M,4[D7ES)\F?GP?<6V;8E-)+]Y)6P#=4WZE!(%E]T%>:Y2\(%R*0/J_T]224W
MH!S+SM,A(4?%8'0/S5+I_;+;A<&2:PAS"%6A&E0Z39COA#[]\N0O&S]ONPFQ
MD,2F2D$+G<L\!Q+$ZQPL1ZT.Y5["\F)QJIA"\5?WBQVF 8&4_4XQOWN"R5(!
ME.T==,!(3IE0@R++DN!ESS9H$4_?()J5B@NO[KUN.Q8)HA#)DY -W8+@M>A9
MU!KCEI,@05T\A/^]]R#R@!5AKG=(J%M/6]PJG:9%0AY]22\A/G;X>F'6DR,A
MU0(D,U4:\F>-=V#&N$7,_CS?@UY5J\O;<JA[^?X8O\:/<>)+GQ-R".?I[==Q
MY,/5XM>\C>FUQS1?^4%N-]+]SO#89WXVKL@ZB**RR7C38ZF#1G*:'LG;_=UL
MKC%!B1!(%EW$#.L>VU48)'%YO 7C-?W/:;*(WRK>*PV8\^,-J5=%_$#9)D)>
MSD(#BH1]C'6"6@6[FV9PSGJ\#=]#O&P$LTI^=B]DZ87P2I(,L@0>XXRDDNA5
M'1R^I+>O4+$T\,+P,&&6:>)/DQGQTCBB"LCA(?B#A(=%7(>:T?L"GFG-JOTG
M^PB2\RE$:;'7G?P,UJ'<,ZXH%7A>N[F-GLT@]Z@)%<BHI/N2Q'M5PJH2TCT2
MM5H#GW_^]/F9,E!(M>F690HT0]V*'S@1],JYN:W(B_*O2 ZXQD$W57CVY#*@
MPT1(2,"U)$GI/Q4,DH4_[1-*Z]2R,I@*&@DRK?I*M3!%V<^%A!!77@A6XA2*
M"UQYT1^JMLAU,"3+-P5Y2PT_O5MNF6;%]&IK!DM* 9#L)Z.H?4\_)3@2='@7
ME\(.6U394?5A5$ C08:^M>B!\,+)%LZ#PF94@4&R<)MRT$*[3^M4(_NYG N$
MVSUXWN5V&_$W?&_HLE+Y80J)G>#.H9+WWJ>D9K0'?BN+6UL]F%O/B)"-95&!
M;=04W7 DZ'+S5#HCVWW$LZP-7;HU(_ QME";';I>LH ]>:6BO,S((F8O[+9U
MW]O.C63W2^.J,F3(*@O$,!H+LKD!<^%]SYW4$L.G$=B]E26_\[_NPRP AZJ_
MB(M'X%,2+,G7(-JG/)^EJ-=9A P^>8$ GDRC_'V?5R:@\NIJ?YCN,U NEH0%
MM/K$GT;3A$Y,M?$X=ZQ-4@H6[[.F?H)P>4@X3R8R(3<6_CPGR2M%2*6L6HQT
MSY,5=6V_W7K)H:*WU1YWLK8B?>9!LLMBSU5)$)%UOU;U6/<[G3N%(- =;('T
MR(%K2.$ZJD$AV:5*[=*2G_ZZ]XL&</3Z2K-@"P^+5H[*%I,A(45QQX&=1<B\
MTU^(-6 DJ(@;<1_Y+/6N8APL38;3%80N4$6M$)\Y,L1GEM-I'A/#_1 W^Z0,
M*&G%"R=? A*RYR%OW(*B+7TL@T2"A)@\/R.AQTN]0H:B59>#YA@DB$G2NEC$
M]0WEIE<6QUFRI!S+%A,@0;EZ"&O5$*U-3JJ12)"\]I+D +D]N:ZM2XF20+I7
M(D12?R&@UH:5@&)%J+W=,"1[I&@+(G8! 2]/'DQN=_JT4R!!V](&C]7X7G%)
MY1?Q0[ BDGO9PJ6E'8\$X7INE;:[N136O3@IK$Y?O>4FH&?AH @R4< AV8EJ
M%0^=V4T&B02):BY8QBRED\@+#VD 9>,%O:%UD[!!IG8>+%IT:X9Z<B*>]=_<
MGZKG^4T<AIZRRDGM=R0,"%7,DE=R#%FZ":!:.H&HBFG$KLZ0J0N&P* VDR!!
M'>Q&^XPD\WB5O='[1JL72F&1(*+0>QY))MD/3<GS5EI5Z]F1$$L4B[Q,<K3N
M5&U?-]JYW.3IQ(=/GU\6018V9&?]]_>P.Y:MM>7C$"(H1&=P6RCQZ<W\#$6>
M\K3(KR3;M+:DM9X4"6D@,':ZSU9A_,;:%7NITK0J@42"Q"038BW5]TD##,GR
M\QKR91-Z!;_5H9 LGIE,N=F]9;">9A02Y(#G[RC#LYXWSRP]M11TIA(X=F/=
MJ]#&9J%"6=/GR&=5I.1Q%+U:DG;YBO,+OW@,W=&[P MS_\<=_5M:O_F5@$@8
M7;S,'N/(8SF;<'F]LCMM1;7P/#JH=//8OX/;S>?^0/!X/VN#C18<R?YR46NJ
M)-< <[\;?R=> BED'C@GBPRLQB9(H=POGC>WB:AT@]B[6-U+S@+</3KSMR"E
MUQF]K1<Q1 HKT)"#N5]^I0J27:TD/%+)=(&J\D_4759[S^C\^N4E$L 4V31%
M2P&PB&-=1==V)<T; [&@F.>;PMMX&2?TJL_K'-)KG[Y?P&PE-&56F?_L9T""
M-#LR5-]9YO>H,5Q)#8\$(=Y1!N+(;3K/"'#N):8J[?0QWM+#$S8B2JP'(=D;
MF_2CTEP0M(P3;#DA$I(<CY*N44<=RCVKBI2_(9D7A& N**-&6/NN@(K[G1?R
MBQJ*=1 "IGX>GF=WY9_F.^X)^+RC_V!+91V<EN$>XI(?Z'IKL7YF:"2L7+KW
M&M7XE%TIE /<[X^!\5AY1M$$E%Y3)-:2)M1=)T*RJR!+(S@[WY(@(W[\%GW^
M^=,GE0]0!HL$D><H?@%^ V7E/MKM]6JK"AH38ZJX258MV)08TGHN% 5COER)
M*!W_ZGZ7>)_Y(@(=&ASD7G"J<E;J*S8%AOU0)">K\BPOFA'^%D,L1QADAVY1
M?E;SN-_G8D?HVK;><P1BC^4<I7^/J?*Q\[*-JB^@Y4 D>WQ\913IA952 ?(-
M-0Q"@MI#'*VA9_VQ([$<FR8<$@3$IZPZM:(.A63QU5!ZJL/OMWN6]R'J1+Q!
M4O[?D7^_W7E!PDIU1OZ7)$[3VBR:_)+3? T),6MMHZ&^?-$Z6O6 5@YP+UN_
M$:AN07Q>6>9FS^UITG8(W!&D\^CVG,\]02I%,.*$HA/ERUP>YI#7FM=?+*)W
MM<[MKC-A871150"1=I>0,O$=DF.[*1V6,[GG!!G'/L9\#R6F).M!2/976J-,
M<:_)0#$73)EG"60Y'EC0*Q5%S'DG<^[UF<>YIZN('SFZZ8I^4:I(DR8D%F:,
M=U0TP M,%ZM7AT*R^+L@"M(-8?'5BA-4 4&R;/&"JOHU6CD%E$.1H,EEKW6V
MCAK>_9TT]ZC@_1K0_Y?%T3'YOAEL(8=SC\#"^UY4YKTA_G[):K2SHF*/<<9S
MZYOH6(U"PFZ\?Q_T6_*^SY1^[ 88DN47W&_5WDX![)[-)O2.\^'=1;E>5,2R
M^V@9[GVP^-6>9<633!6$U7-")+O[ $7^%QLO6FRH"@[Q<>#$HVB4/]Q1!-G?
MM>FT;:=!HRKQ:B21?U,[F4H@YTN_7ZX27DMKDF6L+"]X96M5_O20[D_DC 3;
MESU5LUG ,_W[9/G/?9"7'M14X6O:=+O-XYX E3@*32\UJ7;2;08D0D>XO?E=
M326%<(]'-P1LO@&(30H+=V+>MX/^ ZQEBK= SUG=<T1126+B^T%>%#E7H26V
M%!MX)+O]Q0LB9N2$A&/*LKLX]4)=H4WY]K:>QOU^5EH_L5*J12&UZYB]N4FT
M5#4+Z#2!>Y39.X,?NCB"E=+]@7_-2+9/HO0^>I[G)C%55'C+"9 P>1EQ6U2!
MN2(1H;(EU?3<;3\:";+UR#@]<BIHYWH4&#'!\'78OL1A776J_.C^7)67&V@X
M-V1%*$']HJ OO>?H@SY>1\&_=&]EXU#W:(H)GP;[C V\>X1XC[^C\(9-R$-E
MXZ0I\/7@[M'YC;#\/*YN-AS?*ACG1QVN2\H/]!V7QE%$0LB2KI]X&0P2@0M!
MFW0 M*BZ(:\DC(L45W6-2NT0)&@5VES>ANL^$HJ*'DL@*0-#;,8B0923'0YS
MXYU6+X%GJ#;7:2KW@N-_2!)?Q_N=K%B1%,#]DAEY9V17EGR/UXFW+=Y<7+CM
MLTV<P-VYB*\$8(D!OL]L2-BXS/LE.VV,>1/._6Y.TB6)_"#-8_]8VBF9>^E>
M9=[5@B/9CW:=A:3/S-Z3(2$%R\I8DCO",W(5ET8-"LGB66T XK,2(/=INH=W
MAZY1H@H<#SKT[0H7]!59Q0GXLY2(U 'QH%"2^!AZRI[I]%P0?Y+RS%IS@9=.
M4R$A0\7^E/=*I4*@#!DIVP'85_FPF<7]9<&;NH S*]W$H?\0; .9YT$"A3D(
M"G1'"+)E54>+/PJ=G:09@4/-B82E62RQKE>X (!DR0HCAWSY"F $9TK,O;#)
MST"K:OWWGNI%0<9>F/74K1E$.\>K?<J+;%K616P])1*R?(N3/^XC]I@A*K]<
M%<8](SZG>>0F"*JK./*518'E<$@H_ROQU_3R%.IZJ!,PY+#N=Z):&].< SG?
MD273F:X.QV?)%PA%SEMYS%C5/#'UW%/=:BZ^CX1SP,X):I9]_*-Z !*4X!5$
M?&X\U\4I20#='X,GDC#> Q-#1OD$$A.Y?4A53,XT LF^F&I'E<4O>_=7E\WD
M?F?;.>KP^N:D038\;$:9(B*!=+\CU=AT9C#/B<ZJB;+#=$]GB$ 1*VRTND)
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MLE0:'W"ZK[B7O-4N.O?;G<?_\YC.VQ# %F.0,#)[]6[BT*>+3(J@#KT;2#G
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M3:7<:9)F8R5C1[%NRX4YYU[\ :[J,%7BM;M71DW*'LS8Z;8ZA6FK<:C=6+7
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M6XYI(/+WWX)L=W'B)8>;8$4Q(=&2/$>4E0&AO.@!W?;R+WDQA-8/Z]X?P2*
M;-E$K>#TI_?(Q4^]B-W(Y$Q%UZU51VQC-U8.1BYOH,HTO73#@,=4EWTJ^K:!
M'_ ;:*1-"V912YS>%!^YP%%F&XU+\BC1-(H=\TCD,D<5&-0AT>\$'W 0 "MF
MW*54'B3K1F/Z?G-AD:#63*\6G_V8YT+LZJWHW)--1YXN="3,L;=,*C:7&=>U
M5,F^.Z87ZW"W$LFV<R&\NLQ+UX;F6PY'B'B[_7M0)*'TGP\Y:83U<\,E\>_B
MY#D-HG7N3?Q*LDT7)WS[>1&2RKS3AH0/ZPD&UMQ^NY_?/CZQ"V))]AE=0"@-
M]C< (]P26\XR/D5:3X20&$<V,J1R- "Q:'L][NRJGFU[TXTU-GZPJT_G4.]P
M65S(JZ7M35$^7C22^D)(UU6BJQG56I",7QBT>P"T%:F7D[<UV#W563J?)?\#
M.:_J4I.:NM#(K3M"1QT\-1^$1>G*^,G 3FB\_N^]!PEJE!2OI&X9%)8BQN@
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M*@CPAOV0)L5>D M ;3PB>JS-*^P#4-3.0?]KD_"1I.N'5*YB- ),A& I6LT
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M.X_HMCD>FWB1PX2*L'QG@,+@'F5^&NXK2_LXVS?T[P+K'^49_)BD//K8:M_
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M=5Y=<_OR5S.W0]E7LFR!6IO7W/U+A_VY> 1OC;D+AW M$_.+H.!_=_J%K2M
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MCWY1B]D8(,O<>=D6"[IUE'S#*ELY95Z>):6QL4#+3?F$4X"_1.2"QS*Q^1T
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M*4GL[.PT!$A,&5R76:1.0\U[_:.7_H%RKS3E?5+VK+SMLX^\F QQH.UX41>
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M+X;5['C"V+1ET?\1N"C0U]/45P R]@<OC+-%?%<^X86G?'D-XD(_^T*.7&^
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MZ9O=I&&&_T^"N\=QXLW%BU&Y*BY0.^2K(,<+IC:JM*O%NAX0XF*B9*0._PI
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M!#EZ\.L$D)6R[&M/TU!M[(EL4>L2L2!B*&'>MPX( 8NZNDG-Z<<*W@<363"
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M?-W_G^CP$6^Y#3H^ E=5M\0"J*P N$BK2D""8+72(-8%X08<36>50.5D@!R
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M/$_#KT65=/_P?5_>9;X]O'@Y7IU5LMJB,'TLXO)U6ZX&KCR0Y6 (C,@>0\V
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M@% ]?,?[/,P05@)]\O9#D6?XV K(ZP^$DD5);/;3GW_\A8F*PA"Z]1Y$GH=
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MRE?.R.VE8EEU0>IJJ;Q]E3)=[FSKP>RCP:DZM^T'J4_"LY+C&W+*KW&I-^@
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M.+7H*SSCPBWW]M+?HJ"(,$Z/8>S%^)=U/S<I DS?<:,YP$EIX'\DF %^PW/
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M;5!11_TI?OB8RD-L?R]1'"8I9B*>RLQM#W A/L7)UPRE9?V(IWA?""4DLP-
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MA=JQ1F"RQ'B0*U9K!"%+3 1ZB5PCB,"W#NHE;-0K[1H!S183@5K,UP@BEM@
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MT1<@R?3U.ILQO5:[W1L@V=S54I2O-N@09AD;]"%:.QY>DM@O7S'(AVC_XE$
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M?/-XNON$,HJT2DXT94@:-&D&RVKCSID2>CI"%5L)/8XL\\KELW6ZLI+&Z@P
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MNI*-CO*DX2[@K)+O-@ZP3\(81WA[I*)M9RH&90,G_MK;HX_CD'*>+_^P'@S
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M3%H2G;\V_"T  $?S 0 /    87-N9"UE>#$Q7S$N:'1M[7UK=^,VENUGSZ_
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MM;@==OW5-[E\+32_P;JJ9+ZA I]B-C!;.BZ8#F)NR67Q#(2GU <PI'+\?(*
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M;</K>_&H:S."3X>?M7RZ#4U$MVXSMH=PAYC %FS#LD,NV0 )'S86Z0$3!R:
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M, D7/_[;NQ\F^33Z\7\!4$L#!!0    ( .N!3%J:GKB@( @  &@L   /
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MP2XTN:?J[O+ANS8;+L$+8?2'Q#;V;E(7^9@N"H&/'M=SQ@UX\Z$Y1"J!D&:
MG$FEL&,2)[$2XPO%&'K&&)Y);6OL1Y,;+8,=*Z,SR/&U9?MHN1R0!\$\@UDV
MYFH$K(].?55+E.@>\:A[O \'OFOW. ]/X5%07:4"?VA\1IZ_0JM@:=)EJXEP
M^/WB=J+P=.#7>8=LV$Q);7?S^CX_8#^!1;4031^R/VWJ%F63C-=V^RX4UE-
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M<>>#NU#)A))QQF5#M%+DN81D(;7@(@K^Q5_5-S'\84X_[W/P1DM] I"@Z]^
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M3[&3[G,]XW/KE]C)(=T0_O#-R:&_6_Q_4$L#!!0    ( .N!3%I4."8^-04
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MWN^/RU4.V;T7KH<&\U 0O!"0V!6=S)G)B<F!#(2844Z.P>X8!"4'4A6(E7=
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M*X@8&G-H?*T?[:U[=GZ,S4H]3I=R9ER'$5:F7G7;W1=AK8X1<EIJ"#24%/,
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M)4 _A;%H68XLN0$RQRX,=$Y@I^B^4M+)8B.1 DG'=G_]CI*U>.E+VJ'H!L2
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MWYOFHC#NN<O%Y2N\;+AKR5]02P,$%     @ ZX%,6HH?X0 /<   FVL#  X
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M[XWV,8 +.OU#L)UD_/GCE:BK41PNO@HS4O+*IO)ID7J'NGXPQ%%(>*BF*@"
MC3!'P9V8B6TB+UV*OQ#L7^+";&]1'O,;:,#_MZOJ;CT7'PZJ8'\;+DR@[@)^
M8!#?@1O9 X,=).^E?2),G%IJH+K:U(A-26$_&>HL[VC4@G?BD_YAFLS\EOQ-
M:*6HZ>[)X^/#>^E]50%R1T-$<$W36;++Q7G#DPVK[);;PEPU H8>G0K/6:.A
MF'1!9TY60HG<ES;HRE.ADD#5YM#'74M@6QRIJ)NY#O@&,>W?.FO_1<MW9[??
M*8&Z)9:BQ;]/#G<=_8L ?^](#]46J6V&#;;5&.D%H2D*Z-I(^=.N'UWWJ9@:
M*7*J2+1]*7"$_O^)"1OP\0O!JO>G]?"ZFF98)3YTPX$S8QT?<,:?RU]S;L0X
MCPO)MMG(J'HDD_-.WUWQS]^[[@H26XR<"--'3:W:M1S"+.]RW\A3$M7_IX/S
MZ2'6KQ\]7F"11]!D_A]5<O+L\8](Y9Q0L-*O&A>:4DP?6UY5M8#_7EZ8#<;N
MC_HZ):"5>U\;V@3H5UQ1PF=C38&%[U$-$G9L\(^3%@^9<W^(CY4*4+#50$:)
MK)Q2$Q&\*V9F)KBX)X"BJEY3U]1F <DG\9+:E(T1BCIIXC %HG7MP+@(5W],
M#;BL+UGRS,X4$203/&B4 *-N:X?#L+Z8U97K!$E*\1*C@M<1"FE\T4([2^"R
M9;6Y*I-N0ZQG&B1'AX!3M>!)5353DE"7"LIUI=21EG);H&')(*G&UC@H0*K%
MP:#:7_1S**V(X\!!\$T*Q=0W:W"=MJO[BC65-VGJ360/)#S?B'B&#2IHE6$Y
MI3\VK5NJ_71SZ7<H7X-5 -$^7.95$10GXW+0*(*4&(GAS;<%OXOR?$*I&]BV
M<+'OF<W+NH1_591\)FO5PHBZQIFM=T3-?R*-&Y,8"G/6G57?0YKOZ_MR8IK*
MECE2I+C>@VK*43H.E[7@8L[,K.&*)MXUY+%0>Z4<HQ,=;JNLLY[BL+3GL%)(
MBD^8A6WT]%^QI6*QE3[ E^(<C;Q3PD2.?7$0E1!@![M%1+UHQ>M*&3=1]O?V
M=- I:&(>$M;MPS>^PVFTL?HO/$D0PJU)M"8%F3BWP1'M6K.66;@=B,)M(/@4
M#'"*A,6GW J3)YUE_HS&.A8\S'RYK4M9A^1<!#-W-U&VEE0_;@8\Q]V0J?S7
MPXKZ,^7V3.YJ.DI^_PR)U.X%&$!RMHV].36EM)*3=^.2I(7)UV0-C4..@L1E
MM"7GS;0?4_==6K"L78V/R(0WY[45,X5P5Y^WIQ81"3O985'U)<71D5:+RMXE
MPJZV$(X@8Q,SL^L2.<6N%_P)H6>N'B?ZH:UX+[_/K='DL*EHG\-?-F9+)Q&;
MV&M,*QCI5JBX%";$7IF\P"IY7+:T=2>DLE7S>0.'8=;1N>0[S%7>QD,.2>Y8
M[XSZ]0L8FPP. _05$V&G5=,*+4!)30[1),:&BK;$&/ZY0?\!0S.X25_0^L!C
M=CP' =.FEF.2=RW7B6_J*H5/P-#(4LQH^@1^VS.@(2\ON4V'<=.CA<'I].4&
MO\Z.[[77.F(&4=PJ$,73&40Q@RANW>G,.3'BKJGSYD.0%G*'LJN,E7#[995G
M@V:8#H"_M.2:L=?C'D%Q)+J;R&@P7B06JXN\!";U*K ;XYK8?AA]T%EE\4D#
M$*ZA)CEZ1F?7<3]L3UTH2O@7'=<+%]TI*5D_CF0HJ5 83!'K;%?;7EDD72A=
M?$XJ2CF4?XUA<Y_&UC5$YOFIZZLV]@ZL!=Z0MK2D>WT@WJ%M&90..!X;M4RE
MKH&,5TT!CUO,0_N4S&L7DW$U"X2PD3"R^V&X!YNNQO* .2;H/Q&I(M"9'.21
MS916]:;"'LR^0? N'GF,_L 1?,5D",&MMV>=OT;LQ1?+IWZ158F.K;3K]HY8
M!RL,^HL=Z[L0 H K.<CX]C6%8(B0 >%JS'#F"='D*/JE)#?R# ,LZI&XAV<+
M5_32N"UL'!T0-P# @_(*O;7,8B.AI:>4F&X(*E$<;0@:\ZB%YW"<F)@X-W<L
M3.]^O4H)/%[*U2B_?S-7+AD.WG=!P*ZRHD(I,"-"MBZR(01>0NPQ[+\-FR1@
M@D*O9=>\5WDT-URZ01*:G7]0-]&A\#WF*SYWA;COUSZ9.YB"1M7C E7^ (YT
MD+8LPUW9-1WE,2).1<*CYK!5SL$@KDNJZ\,L;TKMVAS+TTB.!C:<;GQEK4P8
M.=+D0:2:\KZ<0H$W;VS-EJ4P<J(J.8=I!&:'6)P*X(%)4+64WJ,]3GU.F\;V
M8_"$I27,BHY%<C9"Q *B^H#X6& H0O27O#:]Z%T0O'.$U=/OR[7;D$E6>=;!
MB0U*E\@JX\";DF+VI@AN2*><!L0K3=T'.-C)/0.BNYU-[MIJQ<C;7BO54-T3
M:N?:Y%N,&(B_C)D4N"W)6) CP^R;=<FWY39(N2'I/SF X8 7P83D<SD9:!M;
MK(CD%(<N967X^"!Y1TNWC(9P55?E^:HK(A  MR:03R(%?&.ID$32+!QXY),>
MKX</DLH5#J7IN5[QR9<6J69AF I3<"G*N!\%-\]%.";Y?BS:S#-+[2K<>BV$
M-XUA(%TC4'9GW<"I2OXFNHVX*@T1M 2WT^&X1(NHM@7L;8E["]3:?\JN%#BG
M[<F#PXW@4^'G:.L4F&JB;;RQ*;H:$D<6ZX.28$WE*3=H?'F+B\5FEW]O;^:R
MV!5^;L;0UM,7#[Y1A*I! *P#H^AGVB=-_GTZKI]]TK(%N4\?B#D-1O3DDKBB
MKSO_2'_J0>DZ*!#_W&IE<M;$QAG6M+'?^ @7WYEC U5&#2U"F 3>.;#-"4IP
M9>.S2$R\%"_$EQ?5UA3MUB,8_+V"64"]!'HL_> .E.!-J'%8JV0V)5I2ER*^
MR?",[W&410U4'?#*K=2O77;.IRQK;$E&!00$+H&%"S=Y>R^1'=DQP7LQO06'
MS:4XX$S.2A6N/39P25=M R8V7LOUQ$)QRPB!>)F$0^S$:*B,U$'NC O%;[*4
MB'\C@X&.8$84@ZL(>UW0!W9EJ7L[<C@8?J%T%,I+1_?M+))8"CTEA<1P=03B
M1TOKGC$$S_2WYZ;QC6#A"BKUX:P%]S.--L,DM2<UJ<<92#%4FM=IM\:E3#'X
MRDONK+!J21<1K%)8>!F9N.-#QM)_>]3T-_ AW]MZ[4S*7HAZ^.UFUW*_7<O/
M=1QNX!]$I4:(LE.&X3)$[""(F,2GY(X,= 1SZDD[P"H=D&]AA'POZK2T)(]^
MF#IV]!,:<$%M#.'>$7==C(7+\0QUPY\HA^US@'.IU7!FKP."X_@U>=,K&-DY
M3%S!EBHS0H(\X;%SM$K"*:;^\,Q/L\_A[=,)3L-!IUA'V8$'/7SX-A</"ZQ(
M9'<"P8NB&Z,5V5C)N]=??L:XW"J,R[,9XS)C7&Z=SGW32D91HGM:I'GT:&?Q
M*1^[>;DS'D_7,**5D1U,P(?!<>GOJEQ>#T^&Q5D;Y&"27!NR\5&K*NFEX*[M
M4V!:[G[5Y\1WI PD[1*.*+A+DK?TXNH&7]HY8OJ!YX8&2HD0V6+5L\QZH6D>
M%!9DZ.VN!:2_IS]"YO33.\7F"M:(LZ4&W>'"]KI$\D.5LZ.N.BJS[#:WR*?[
MTF+^<]"MV,-^>3V;H%XXEL](++E6KDFP+"QIJ%5X:JD\\P!Q0@V2W)74GHPV
M$OSB*1O3_A$^+!V1CMDUMP[U$L"U5./>),?G7(Z(J9XCGCT7IG=O7A!Y2R<Y
ML$VUH2H*9BQ;5Q*L<U>3>/HU(0G7K)";RSV.2%/\G$HBK9096*W4R#>XN60W
MX[ON\QNQQM)<5B3VDE2+YT[H'1+?JCX'5?(O2PDP=1P(#=W,-0Q[LK7B&@9_
M?ASMYBV2,P?$X!PTU&9$_*>][J#W^"+)#^S!@L\:+YURD;RZZ99-GN5,-8(^
M\?5;+J@TG7J04#]Z=1(>=9*JBX=TVH#)"I9X\A9.A[59)&_*%,;>^W'RNLRJ
MM,Y+^*#GVZF+_F.]_"MGR';>3M?1G(EFZA-UC>_"1>N+%PWX=['LNXDKK^@@
MQ>^Q6MD -_E=[8WO+N-S'9HIB&6)5&B0!XEPJ Z/HCV4 /;,KICKWV"1?-OX
M'U_D&T^#S )&^7\VJ]C>(]<7CRZRCMA/P3/[-ZIQ@R58<&8TN,>/HEEX+ ?W
M.,5A4<LV>FYB/VYR+;7)<DR\8M)$;,Q\)4,.;"^,NS.^E$P##VMST:@2U" Q
MB$D[3B-_#7CA!E'VY-0MBC/V"'M=4SB?PV=8UZB-QVGTU/]1^X]KJ,-3%-5V
M75WR"\.7T8H@F0)!%,9BC'D_QLAQ1>/'Z .*MV=3?X/\P%_"Z-.E21%L8><\
MP*W+ XPP4]#'A%.YA%<,P^0]ARWNBED.Z>MQ%Q(:=[S2F"P*1^_._>"0U@5_
MY\8R;2L%1LQT5C%)+RI$Q6!=J,E;]WPGMDD'SDK!F@'D:XH$O _RBDT'*F<!
MXR,G]LEXX5*DDV_QG9C3 ,>H0[]$N-? &2'$&9DOAO!*'965A$QQU/F:UF=D
M)8<3RH?>MX[,97W"-877>]HW.FEFYV-_-<NM-;"<644[QHLK6NR@;K#YLZ##
M8T-*J#Q0R)7QK4];ZG=\>\%H0$:X)?=0MR'%3G=^$0BY[K[["I&[=W0_P.:[
MO:WL;SN,(VXV0_2+0]0%_O+>\?WK'\(3D*4Q(1<$VW.8?D1;AWH/:QR0PF$Z
M]84OG4X=R2K%+/SB!.J;[J5G+Z1E.P;:O*(8F&V]>TA_D]ZAGXJNGLVFW65#
MY0KN:!]4JP<./!SR?LT6U&VSH(9X!'12","%>YB,(J*MQ!(@W&B9<",_6)L/
M'/RG1 /1&J KXEBSZU RF$Y.>(64X6( B*#X+<*M6,Q8RXB8L2\Y1Q7W6.!O
M[<$>1$XD$A*1&;)T,WW(.(2P]+2*W,C*G3YTI)HVNCQ?S5UQYTZ-7[%3HX,(
MKZ@VWKC4J8IET I0E++2\#M]BS*.H.^"\<'2G]Q;K?"[$7GW%=@$?X,1S;U)
M9XG_XR4^%M[/DO^!Q M);)@:ON1Z8;BC*IW$PV-FH9^%_NL+?61?-\BN5H_6
MSW!T#T&86.Z&=7!=>P%B_2\?"!WK^4>D]91D<83)X]2HT[4)D^(_ R;W'S!Y
M=#@C)F?$Y/<8QWI+_;.EEP1HP)EHXA;%L-X,>+5[U024Q],8UV3U#Y$D:'5=
M#Q#G'R@5#O1"B2,[7"KA$"B5YLI;N);?<_Z/ .VB)V-$SE6XCW):-*Z@U47W
M.=[=!.'^G*GD$#N@/ )393F#D%O(9X'A/_@WU<]C=PB#A GG-58E(2KQBI-Q
M!L2X+BVS290<H@\?.4PM<O5]T "[,2O?$%N+D:46*!C0'.S;7\VPC\&^TRCN
M-A&LTQ@W43&@7--A$/6P'G<5X]Y#)L3=S&FCG0W$!@Q8\QGK%N<?U,$:Y57.
MA'EM]MO^B%K!3=/4#?HN7E.,XVP(!R2:=,V%<ZI?1'-E[0<??^7.Z"Z,]5&O
M7"%(>/S2D)!VMQV!JI;'2<P^?+^; 3P!>Y\*5#*$6"&Y;!WB$OJE/-P2UHVL
MMN=YTZ))@;02A+:2(@KMA83O5E91A4Q2[UCE (H:"?E(8$B>@6N452EUDE(Z
M#<\%L@Q#B4Q140J(WD%8^VLQ&R[[JU+VT7#Y983-1( ]OQ?4 UNGQAA>J=N4
M.C)L^[# "(BLI6GLSB!<!X'9P27#(+@$&?6I:& %D#QZ>QW4+#T^1.X[Y"Q:
M\<^0"Z]U<497O(!L7J16>#^S1MP4!DG$,O+!+D"?<9W%IJNU4[/\M>D][Q:9
M:5]_)_Q7:,[.1L=^&QW$"!FW*R28C!7&+_J*!+/%<EVL@ QWY35<((N09V^*
M[]FQ=:L^DD&)0L""KEXW1<(N2[MY8B?FWNSPK[REVUQ3UN2,[^!H3BU=SV*2
M/$K.M<UXB1>M1+P0>T\?<:>5SSX?P^T-($.+X9&8QZEAMP<WRBOJ,+#1?MMY
MBCO$<;#K(AJT:Y^ FU"W+I98@97;<89$XQG"T:+EN\V@FK.73^3P8QO<0+N5
M"=G$[$9.MY#_#'1%KN7'U]HMY/0P()G*F8*3WU<$^"[1/RIWT)JH:5$1T:L:
MWSB7](JKM]=(C_#3^"YY^/:,V]./%#IPJ5R.EHP$G], B,W13.;2C5K0)U$+
M^BD,03B066OMQ]3/0I/8^':[Y,.RN:J\5<Y>[=%=C)C&"\>./%'NL\H_4K6N
M?PM#;*D.,+*@T:2.C>P;V-3\_GR%3PM?(CF$5CD4>[^CC5M4W*7-L5E*%0[R
M5U/I4<@)PC^N%-,OW@<\BKP*TB(T"OWQE<DOF?#RZPP@_$XY*RV&AVJ3Z*CI
M:>0/4042C2;\N.I/U:.[V&E[?8@0:F\VQ59I@DWV*W@O94@S[KX2*IMKI02+
MW,;D41YLL]GSN28>#6<C>(JFF#V@/?> ;AAVA36NC?-$!D'8/@NBM@<C$P;Y
M8[$:\QJHDZ=:-!WQPVNXL.D99WCZ:]2C%P8-DDV.9.GHQ^-#;""JQPR'/FVF
M[I[9X)?L]R-0WEF,\I#BD,%H:KSO^P419N*1X7YI2CR1-SYZ.UF4RII,"SK'
M'$P,C&*42J/2C)$DN,]>6S<S0NUV(=2.9H3:C%#;IQ/W9HQ,1:\).-,(A-$K
M.1^\><)4+LA4$D!ZQRO]QTK[_7/P*%F;S 9G!GD$/FDGMQ38(@S6"@Q-UN&;
M.N<3L+9M-8;#"E_$O4522S8]'43XO%J"]I-Y3>S>3GBGD+#,/Q3Q4,3/YD>+
M_#"=H)LY6S?.,;S7Y\[W(?S?52PP3,8E6669T%'3RE0LR,BXR,F+-O&2H&W.
M5Q6_G%@,:=]6M8/:33B- 4%(/@EHBMOIX0C.7K_T*77!-V&KV@41=/B0)2;5
MJZNR\3;H_SQ>P$(GU!^V_F"E*P$YZT<_C 0#_6N"<%L_ K+0*"2EYXP6$S,Y
ME7.<=RU+7@KS.+79D+0[/HRF-3NWX>'"T(3EUN5]I2YI=G#WV\$=83>BJ!^5
M)#>^;UQD.;3:;"5U2)8-TFUXLK]F1!0&O$E=":]=Y^WV17+A&8ERU_JR7I/"
MTQZ8%])!BR!-A,7Q.":Q):CS0O"KK3QP#:=Z1<<^&S/<&,^-%<.#KA@;7[<"
MM813GX_O_=U,^WA\GQ;"F1,1!<8(&]<M=R#$DE=NMQLYZODI@ZAPU!JHOQF'
M^VX^J,*#:K.I38Y6_0Q!N0WGTWO&.:9VPU1[O<_G;63[$?.@W> XLQ_IWA$(
M94@:E]GUAL\"!=K?)/ ['P_[,?4H2J]<TT\>[J*:7C"2F<OL0UI^=!HTF!U4
MXH>7< <#@A+YS.BSPQ]Z0?*PW'\BJHYF"^.3VHJDT*X3M%? DG&-81&H!%92
M86IDTIX8$OY!1(4W&L_4("BJ;T87T_5]:,R:SII%TOS66?LO2P5@E$0<6<YF
M,F*#B"]++(_4LN <R7UEJ_GM&+UC4^>I%8/.H;XUC2H4=]1 RVXL_ ?>9M&/
M-)@K&32JHIZ$<&!'-.7M&)#[O!.N!M0A9XH^.7[T;)$</WX"_WEZ0DOX\/#D
M^MX8*EGX26S9&&6IBNQBS@FS3YK65=-(1@#,V/I<6[[#$O&_#I*_PT>OR'J.
MLTP7FB ^-WF)B+BQIS&[EO][= EE6^I&FE6.RP:LQ=/'"YC^8UZ&HZ?)>O?.
M"SUU#4+F*NVR#6PV*]?]-13VT?;^-#)-\FF#H%3?L%AHWM7%U217N3%;;<0*
MWJA+G/[:93D&CXA-WZDD(L?@%IM#A$=/'S>+,2-%&WN&6Q_M^JK(,VG</HOF
M.,BBZ?+9OM]W^WX8?Q)*YU[7>T0]<F0;?I5?YH4+/KG#C2&/:%AL7_1::8:F
MDO,8AODO>4&IST9WVFJC&S<DZ6\_^G#%12!FO+HJX2A?:^/Y>$3NG5$@3>9"
MZ(A@.K&%X&PH8NQWZ"M?WJ?L?^$3J.^RQY<V!.,Z!ZG%)\+K)1^&2Q\.8GR:
M\]&\OWM\'X_F3T&XQ[DB(K&6;8^D#9<,(A_;GWT"*BP@PW++--CD8\CR_G:F
MG4)5)-4:3GHL414V:7DKGBOQJR_R-2DI/)P%!JX>&_RM[8B=.VZZ09X&.SM!
MI>B*FFF HR)TTKTW#]N/!\W#UA;]&8P9-HY4PZ')R\P]5[%7,@T88B[Z0FZ]
M(I*!R#@*N+QD 4,6,$:Z"EK6,?&*O0-OV=U$G6+ZKK_RIL!AYJN5C_\KA/Z3
MQJ3HY8DA"1RZQF"M^J]95T=@W$#>>!;1PI.8* 3/Z^3@)C^5->EXM2 5/;RC
MVH&@NDT#ME_T&VI_DZ]#K#5-1JC>P;BEWL_>RQT=#5F9X/VZ@I 8C'=5=5@&
M!0=+U^;%H*7+#%:[76"UXQFL-H/5O@/+YIW=='5Z8;@4@SWFV;G;;^?N&CHT
M[;M($*=NV:1USCP>TM>$N)(RC0NR#Y37Y%=)[/H@.:/F&B$JW4$);I3"\5',
MHV>/'QP?'N%]'*-==92#-;D; M8-BF,G QA#/4XPJI&1%G"@"J1QM"D4&C$"
M0!KVAJ(IZX/87$BIZJ_8>OH$!D,H PM8=CGC'U9H"W#O.ZT(BQ_%D74L]+F7
M<P<6?4@<QW*5D'"=7BC,,/K@"]#L1&K,-9+>;_6?"\-ISH/MU67CKSTL0Z<G
M7R=+$."&#5>:%L2F:XE4#_&K]>6,S?KN?,)!<;$["VK-F^G.%,D,BYW[-2P1
MBC$'822!$BGL/UHR46P6<\@%0SET5UA#-_T6=,NF2.$"?34R)W1-JE60J=NJ
M#H+/L[)U[=5CQ6C-LAK^BJK NQ:KHC.IQ=R&NDP5K)3ER#^U2 F4%.\W;"9-
MNX^M-+?-=RRO?T;6I0R;[B,J?>TV'1-S3'N8W0:W[0&&"3''Q^=-,[<]VG_K
M9Q):60FN$@Y_4"-,Q.^,)/B^+9HD%#$./_S:FJ;C\Q%WJ9<#B?50^<%".K=7
M4L6 Y8<+.LE].UO)_G,C7=Z$_I<1W>2"S_9Q5C-"+#"N(;0(,.)]'=.:OU'L
M!WA)2*D6OXC@/[3B ;.MY,W[I98'R3\MQ\1\ V["%TBW7=1\3;Q\<S![?W?U
M/AHN02R3&%=HIQG<(QQ>CJ*$Y[AU2717.1R!.98'9QTA7R('(>LDR+VI\$58
MA: ;?W$C(\DE>##$B_%;5P ">W"I- ,,>9,J7=$T36B;J&>TJJLU6";8?]6Z
MD0C,&G^E3:I655%45\I\X'35D@HO+O(E5WHUU=K&S:TJBJN7:LUS#S9,/.$>
M31J035(&9>N034ZC>+-JG^3B^]RX-\NY"U[A^- C[FZ PR#I:%P+\S%Y;1:N
MG3F?;P1Q8R3$(FE,(1XH5A$Y[C"+YQ:&#H@#B()%ODB(J/TX-Q,+Y'+;\S*X
MNZ?2?FV%_31JMQ:F(VA'+6&V*X6!4(G3T<D/KAB_C]P><#P+39.6L5._>W'5
M5WK*2HYF:6&9:#X3 ]+@_MSS[4L(_-P,Z ;-@&@+D,?'7G(@KE0BBQ*[8P=A
MAZ -FF4[28@UU0>B8ULM#J[ZZ;^Y_]LL_5]9^KU*1JNIL&'FN->"UC-!W5Q[
MX]43&X61YZYX]NF) WJ'Y\A8.(8:$+B#5 -'5P*>YL$Q;IA;V>FFHZPU=0;G
M'3@^L$:)<Z.G^OB.A66JMM;*,=EB2KILYL9U\V[](W?KIVW!42_JDTZJ?L?>
ML(Y/M_#CQP>/G[A='(1J>Y:A_=C;NR%C[?@TIKKBW2'_9#KXSFRB7'1))![L
MKO-G#=T:\@Y<R$C=;!_GJNH<5@*;%^UD&1U*!'H9(!>@T3** HHI<\/G.=-'
MB$OC>I^%'#S^Z0Y)%4AOW&TT".0-&24)1.;JL5==S:$/?/PG[@1-8H93SZ6.
M;[62\&<' RB2HV/PGLKV(HPUH-^HK#1SJB 0]3<EQ:%$V)95]8$/969KG#,&
M>YXQ&*UC/#IQM7=3A8QC]8O<31@QH(%$C,;D64QJ>V[XW2[<3_B+*/[.<(#2
MG-LH\^FYTMV]PJI26]CR;4.<?Z'6Z=$A8AZ04B%.&<4\AGEYB;W9S@V;H[7K
MBT</[C- 4< _?%G\:"(Y/?96<UP-R960H-=7YK)B*Z#L S0(;Z&+[*H)";3)
M=8:\\G[,>QVJG!&=MPO1^7!&=,Z(SN_B"-[']-XGX9(PF]RK5I$#UQ5N[F(O
M&QAH"\;ME<Q;9EU+H84F""<?U35XW&);HB:D*I^MXZ@!,^@[A'-=VIG]Y588
MQ$,(C1EE,=T$7U:0Q(S:DZJOL<)JL?? I:XY?>CZ *6FKC%@B>@[TW"9-XZ*
M<*8$&4$00/^!9/+QLZ)RT0G:C<40]4MPP.4VH"9+QLBT%VK<)IF]S(6;@K+R
M;4"*+8NV&<A\9/8ZEHY [8TZ&02:"0;F0@D"K!'OWZQ6.34XO)0^-'WJ<TWG
MN]B70;[N!U2JV@Q"$6R,<SLG01O&UGJOK4JX  XO_7X\*L&.$DSHDI%8[MMU
M=>\E^'F9@&2WE*'N)AHB%Z'368,:QWRTB^]$D&MLMLW8=YC#LJ+(AWX,& *]
M0;/DI_&-B#_IZI'9';C$N;3Z7G5MAXY4F!?'/@X!1#1@J?$#./.Y<T3+PPQ%
MV+<Z"?Q:78L]M1/1(8ODEX.S@QZB75,#^@/8DK_"DYLL5TA(_! M:O/MTNU'
M6Z=YHW0AUWR-O7:Y[O0Q?/OMOBCI10<0PZ[[FA8;T49U+<;1#6EP1:EW)9A+
M%B5ON:VP[[2$%<U+>IAV_Q)TA[3U8:4"WU_I 51?"Y<9QDL^HJ)LBJTO6,$!
MW:"IYVQ"AK*+5>+@,\^6XZVS'+GFNG%67-0\$K=1W,0ETR\=%GEKZH2K':9,
M/'?FM6.7#.R3W:;7F$U#9Z,<OP*T&3%P"*#M[!LW=3LY44Z2BD'E4E8C4P ;
M#RRR%=Q?$F$VPDH9K,W6E@[-)]J6-F0+]W>2^L(2?LQ<UF(*\$/ZIC&%=8-9
M^'&#$D.6QR9JEH;<#<R0Y&WCD472I!:5EV$Q&AIZ_M%T*YI8XW5F+L6&< F[
M8O@J\2!W1:MW@Q\OYIHZ%M)'0#Q_?I1W/RB_5H$)AD8U40W0=\FPAD8_2E$U
M@\=I7[&4DY38ST'F,_7!'8L>%N6PS$E.<&D**M%I+D#B=C:/<VQ7KG="WKJZ
MGZ9#U$@NF4T%A44/]U\G2AE(HS9-SR/I07Q7Y=+Y6-DX\1#Y+6<2Y8P<60E'
MZN46!#;!!K[%3$*W)T%O3!^%[N?-%!H6VR B. MX,;&SB"24/2@DEBUJ:F>X
M,V'5M;UBEO_=:),2EV.*A6Y29IL+A<J;-MP:JXZT+U)/7IJ\,,JY'IU6Y'!S
M3'Y40+\KF;BSGL5$LPVME/:B+96AW)NZWA1=D]QC!:<'86E;@<,G5),AT8S[
MW .S9-X=*D*7+I_RG$7X[)) MM4JE_ &OF*5-RF,'9'I,;K1J=,<CX6T0/D,
M>^7Z-IGA(^X-*^A]4]WKRW?QM S:D>+=Y^>8S&ZGGA/&C!0[Q4P#A',,T%<.
M2$F=YZ1@#OP]*=6A.EMBB*+:V#$#DS_ ?0H8ZDFI<7P_.OV"U52W%;9>]6N.
M-$<.4)TZYJAEN8-C#N[40!Y5]VL0+:^9NC)LQX(:,6;;';<(%BY>QI "<4_A
M:1>P.& 6XI?'S <_]B!Q/I7C,4+*!5&Z('1K3_BQD+Q(2V ##,S.^F^"_9*C
MKZ7+0]6VJL_!PI/0X>R_WC;_E?KX*EJN<9%D+(@M7/%3E>8AC4</ZS?F2@Y[
MDV)XUW%YH++Q\?F)L/S@@E#%1K%T<>V(0WRS*:A-.IP\Z*12#31XVD)KNW"4
MM])XR>.,3*.Z%E<L+SN<!\$5M]??-;B%> ]\%%R.@CAC1,<D/G'A>;<GWT#H
M?S@94$/I;T+"[LD;7>Y GV M^4 .(BFK._7-7>Z8D\:N"%S/1>WC%U8I1./T
M'CY6<1.>"SQI<*/!JJ:?]&9HQ[CEXSMR%S_)!&.+;0"GB^,SNS3L8X>M^.)8
M0.=M;Z*M\PYO8W&3%,2<?IG7;4>5>/2#*?";),I_Y,-UK_V]&:AUNX!:CV:@
MU@S4^BX,I-ON5JO1PAY6'V40N7R.Z4W=17:H!M409!)49<!0ALZH1>\;#S_&
M LL1%737"*G[E7$*"]G5R\0S%QRWUA )1'QX>?_/Q,44[V]4<D_-Q)IA]S"A
MCE':\ITE)V$5#)_KY,Z+X>%Y:EU)<+CNA:%EP"!98(:X]"=>@P\AQF.R/>H\
MS)"2(<,T7&397&'N8^D8E.=8[9Z<>ZYY;/<).[2LG* XH8A:WC5=?9E3Y*7/
MDZS;B_:?S6SFB(V=Y:F!CQVB3>QI]X[N2PBIMJ[$01[O^@:0/4Y49B4AB CN
M>=WC/?GTR#06R;WC^V'ME4<%[+C+)8M2V!CGOAA-QDO42@_YL66W7MK:QU%(
MOU7K-5'"7/L>PAY(H@O+/%K?FVH1DFO@'EX66/&@X*1EZ$\%8Y- CP <X-=!
M&[<4OF%R[+M7C8[)&_#Q- )-GJ_7-@//R!+F(> )\!5FF?$2QR/K495'8AC4
MO@U.@[P<=&HA+X_7*ABXY/F0=H\Z='END.F3R!KD.&6UN H#?$1]&DC14IC,
M8ZIYR<6%8^YWNYFC:&&]:!1D\0Q.695V].,Y=K;?L;/3HHC:^V+$82K\)9HH
M@+&:0;U8&/5:^&X"B!@0E8+$^89:20:T?+N:P3GNW?%0SD'R+AA_4(#W:4%
MC>U+$A278&<L#Y0%!5":D>L^'7?[TD6>W504+T%DAW'A8I\C\"+?4!0GYB.D
MWGP>2.+0./3=2O2340HNO@Z0^)5$FAIA;J2^\ESWZ-##]._@$!P!6\/="-?0
M<"2' +4QH.N)/5NS^ZOS;KL[/$%#MM-^544IU?[:.,83:V9!SC<#'4A!W&E2
M +QA-P_!B#$TL+ON!<I &52YXR_NOOL!<HD9$GJS<)'X&-;W.2,1(!FY$4WE
M4;8W0-@NF+PQ&-?DLGV.H?;T6P54KSB^N 2U]W6D_M7KLY?OWKQ]_^;G?R0_
M_Y2<_OWUNS<O3_^1O'K]]N>S-^]/W_UW<O;7TW>OSVZ/^OKZ:V8IUFOJ[?=H
MQMYH"1@FJ<O@<"VGK\X(,H:__HLIR<?"Q_]W57](_@Z&D8;:)G[I%6GP<*;-
M(NW M.VP\_,-*!K[$5LUH1>JER!E;)4:L4".'QTF_U%;6UZAP736U@3$U%?Z
MOR5'A\=/']\B!^ZK2SCX;P@R*1,OZM)2XDY+_(34+AC7HRNU<&5@VF:ZR(GZ
M5W?(0?(:PQ'P5V\S-T+6(0!,MJSO$8.JZW.)V"^2]L&5]_7U>B#O'BVW1I'>
M;0BVE/VC>T<.W%]*>N!_PL59M5XD$J)NNA1#],CL@:6=X"!566Y*IP3\2@03
ME5YO;K9!%,Q%OQ;2#KB6WSB@$GL\8GB$A%V!EF O:1,TJ0OUDTFI:\[L$>S'
MU/^[ZNASHCO'AX;-Z9-C]-BU4;UG[N.'5K1@F8RII7>X*3;M0B5,^G90]S^Z
MY]6[A6^O:"(KTA)J+F4LHN/=\9%>'-DB+.H$(=MB*0/WI 5!O;<,AT@SF;A<
M-]4KFAT,&Z\2Q^!L"S?P!L,H-G;2E"58;GVYKZ]J$\M9FVC3:W4WTPN7=?6!
MLV6\DWRUB#:TI C)FQ5>'GP%?>^"?DYPZG ^N)&5VF]RN?42/.AS+<QEU(QI
MF@Y%QCT\OCX<CK<FRGA0%)"I+;4S$DALE=JLDT#OS:??:Q#I*[O]D,*R8OI\
M.8%S>/%0AIL+;FD#CE)7M*QZ>R.8?#?\@NOCKQBSBZ&08"ZP/GNMK68DS>U"
MTIS,2)H927/K#(7WUY^8K]Z=+?AH;^B'B<D0>2M'%AR@#.T@H<+TPOL:3Y"7
M2O Y=HZ]>O]R$1%.! 4:WO)@]HN@?4\0=5\E71E8&IF8$OP<?UU.F0GD^W#\
MT3D8TVE0#IJ@O3QB[TK>(CB=@US_R,OW^C"Y0Q(=6A>*/FA!@;9<]SI@_,@J
MNH0H$D+^1,DZ!_A?R;,VHY?U C;2UELNTAAMY%,V##XIMEILPZ[K*>XT?Q_+
M-1IFE"2G8?HINM>?ZLL#7 BWV<)JJ9YHX[3AB8N!2<FQ:()SL8,H=.O.7*88
MD;>>U70F0Y*!7V!O#8879>V\*4BE3,,\5.C>GL+VW6Q[OPFFB+T179B:M[BO
M>.+9V8_4Q45Y:$ZY#O*=5/"6R4]8O7-\^."G ^_(AQ][_,4:LX]V_MW;;.^I
M_,EQ'M,AT:W7'%64M#.6F<**#[/.@U4]P(_!8!-I6(!>'99720YBZUT"V-'\
M!=!7JW=](BW/@D_%+W#6,<:$L+<ER<:2$L$@;@+H8X?! 2H0123M[+7@@I,K
M2GOT!H_&HV?\ST<O7K/8-4%WH.OD[_:(T=?/ 'C"!_B*/Y,R>A74+7Y&F/0V
MKM5G9G__"B)-IP7N%PUJ9M&2LGX/2T$;]?=[I]3_?:<CTL&IB>W?2+MDREN!
MRTN)4XRJ!G7/]>CRYJV"J7U(5SX.K7W?.O"/<:'G,)0;,6X(X?S*VD9X8C:V
M;*R8$_$1[VP)E0QX26/[@RV9KKK6:$H,T>R/E6(R$IV3$/1L#^\K..0EB.L^
M?1QJB"IF. HN0R4$J8'; /<:P>X'^TQ^TM-B*(Q]"77, !6*IV4""R(<'-CN
MW!^,<;_#]_I].7@Y&+G,9S.J2#6](WP%B"$..#%=@06!M:(;%PY:U@,RTRB"
M6'7#,&AB-LS *L.V?#F2)! 9?(9%K D52" .K&+2PJ5I<D&Z<)RV13)Y^.!(
M\\'H0ZJO1_N:W0-\EE97<AHK?)^H"DEMG:&;W0@#OG$--%Q[8>J,:*Y67>'(
M=+9B>;,-IY@7!YS7(0C*F<TVQ--/V.EHFS8COGU S:)B 3M76O*FVP ZB69@
MZ%12N*):CW1*IA6&R0JYD(NS#Q[.7X1P\2)F*I[(<A3P083OQ9Y70N2'4\>O
M9/+,OXX[9UTJW__@I9S?]]?"ZA6Y(W+!A=?V/ ?)7RS>#M_^ V=&0BEG3NG6
M? RET'\S[ AS@54TZ'=6YUP@2X'[P>DTDD@D*?&8T#Q;.' X'W783^%LMR7^
M!^FVS^U_0G["8?(:SF9/M?C&NSGJ0;PW'^G?^Z2J;^[-L%"%WJ 6'X#D4$('
M>U,0S6N<68[T>ZS:88L%,3@.EZCT!_N9MB[LEJ*GFDAS2'(\$Q.(.,Q6-=>"
M43.C +-<6E2_K3PK)0]5>GG8CUS10GH1U'@!HMEARM-U22;*N"OMS!&(>&_G
MC^U5R<3!45*@]J'>Q+B<OLZ.Z4YT_P2K-)M=^[KQ?]93/0;Z[,-W&IA :R)R
M<CLJX(2-C7S&#0PL%C2$PML;.D*\_;1"6H;(<HKY89U]@L4*N#=3H]8"E8C*
MD<O%>V _C)MPI >"8? V%K4Q.'E<>=?TO!<#I"VM!KTLQM^(^KCJ+\SH0C,C
M1+_FU \C&RQOS%F()N>H]S?&*4\'[*PP;H/">%U(#>"KOFO^4F!<^ZA)8&==
M$6!4VL#*:3WFD]%NVNC^'P:JD#0U]ZY6Y2LZX[VKP1"!B1@O[9C\P"T&AJSE
M8D2KBQJI'T]J" ,A]$R<A?'I&7!5R3QE?EF$G-2=U-;&#L:GOE(R/\A,DZL>
M&+6_Y7G]1P2NPB#AHPW7,%".C+?-RJ24JT7 4,UD^^2)=E+[F5541U!)+3NJ
M1;V_#M/$XK &?ND4+3]I/BIFPL:F6$OMWLVO=&$I['$)JR4^] ;58E<B*BN0
MD=$E=1%,XFY"%CBQ^71)&TU A7+9][71SB*_<:\5XXP.NEWHH,<S.FA&!WT'
M-LD[US7B;5>#"XRQ,6\D[[6+L\,P"<XO*G2]OC7&1&R7@V$:KATYA<DJX(2+
MHB F#O%1'\6F8!HU$GID6MESH:A71ZEPQD<(M7 O8?X%#,5R^#*\BQP1?]=@
M G0\(T-Z$#^VJQ5V3QVYG=$U<9@UBGWGP6E]98AB,&_9#Y/V5_W@_KB?1S%>
M]]%"BOK8AT(.1\K=%6;36*+1H*N197@D+89T+Q1ED=CL>J\-@N]#*]V4:'VP
MLS[ L\8V%,&<-.H==F<*A72CJFPT:R,U!DM[88J5(* H3E]G9+UZ4+IZ ].B
M2LD5S5*,O2VH9Y*R W$.-,Y)00TW$>T=Q\!^#@1(($6NV-1:V^?UD\3GPV50
MZYY2VI5DW#*&X6Q#GABB1.5P3#3=>6_LQ=2YJYD_SEQ%N38O<:F[1C-I*:CM
MB/]I&.+K2ZENF(Q9Q9VPP0,4D/@3-9HSB.+RT6Q).^GFA*%D>AK22S$N6&Q[
MY7$NAR@%(JRN1\Y6W3<Z5>1L\E>XF(,1L&??4_3U@]-5*5*X3T<")P!<7A)W
M3:>!/Z78"UO&$*:B !&8]\J^6K<[@&;[\*W&SY3&<G\U"EN56Q!7Y(TN8$_%
M4?@X>S8&*B*."S@EUM8P7LEQZ5/1.1X1K0_$^\ \F:H^I^V,SRAJY>%$S!E)
MX&2/ZA_=T<3< 6\3I,/H^Y'\IKVH.!'.:@"-9&>04O7751Q/O\8R7=S(-$42
M)UB>DGQDK)[+^^\G ,#(^Q>^)P5UN+@NBQ"E,3)7MCOKD?V8NB.3[%=,-V'@
M-.NA3GIQTWL!$SK*P_V>.ZA\D7GK08-1*%=J;6T<R&4OC[U$[Q?V4T QH^#(
M1KP^115#DUQE^9RI^OY"8=]BNM_J,_]#$E!7& _HTR](2^(&;&!.2"N0:@4>
M*+8R)ABC]I[3_2@T"Q[VMK+&0<AH@YH=F2)\?!0E^J=U[5U],0WG2J1TCE/7
M$Z!"#^&Z81('U G;!RYKHY9]@"?NY66N+$]L ILIJQ9'6P2YB!4^!>LO1 BN
M_;&/%W9-&.U:#Y-J?RP7U7[75+#<+I)_@DAGM;F2P.'+P 6\/8?X-RJKP!TO
M)$S(&3P71X2>2!2XDI@4;-*0L$%C7R,JP!DP+HH0<?+T$4:N08T64QPDOV P
M0OMD2G>XH:E!Y2^K&,3J$*N4L,<RT=:L-_[W3!?D4<_Z<WSZ(@S:;?71SNH#
M[ZRJ&RM%9+YLF!/6JGPYEL8@;K2N]$U]>O 0]# 6G8_JI0D]O:F18+I'NJ(.
M#A*G-%(F]%MGA7HT^I@N*()%<K5O(T>)0+4$N5"4+#\I&64@K\1W=)AWI,3M
M=^B7-"K683%'71VN8F1MWUT-I!Q'#8%F41A]%9+I(W)",G9M -$240%3<WT[
MY3&VB]VU83I@*EW@X_JC,9V1(G.-%A%"6[9N9AOXP%I$3;$DR5 P=9DVIW*E
M:V2F"<$9]4I\  M7NRCL=A >86NQ5DV#!FCS(5S=3UR+T=F2B3WUD8GX5*WM
MOBZ:$36W"U'S9$;4W.XPPJU U.R)&4"565)QLK3M%59_#1AH2$..,-/,)L+
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ME#Z]I8]&V^"V"_9W@;][S?460[,S*-C[!-4HEA3?&F36!S0M#M,;ZM\/)2*
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M<_$9VN)[\>[GD-KM"ZD=_^$AM3__N*RR[;__CS__>-&NBW___P%02P,$%
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M')W![WN#;Z=##_Z$;]='/6_OV^G9T=?!R>C@=V]PN._!G=\&!_#A[&0XP(?
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M>@P4"D:!V8+6&15/T<9C53@XDGX!)%T(O3/I3UG4=9*.2>CW=8@/:;$:&_/
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MKF+#4;_BZ> C$^\<]+$$E#$]J)(4'G&0SE/U$NRX3@<E%!@U&-^CY&<6>7
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MLFT5J+FXK_" EO>VWL<%O>D4KIS&88#H 7'UYAD5GF1@%I0.4_("PS3RV:Q
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MNZ8\A;KFT3QF&BGP+Z%89M23C)Z)?\AK88#O\&,DKWAP^D&H'+"MF.K&:B)
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M?L@$'9P@')T5Z:3:4TDUHO0NT5=-DF$<GE3N/8&GM4B\_\Q!%*/^40@<4 S
M>(Q#R1H+:2@]!/\WYF5MNIA=,.M;_ <,3YW3- =R2X(*4YK,")"9J"258D^_
MA1A_:8CKJ/D8T( ;)J#'?/N0R_>:7A2^>6H@%O"MH*[:))RTI&MZT(VC[A6J
MW"W2R F %R, B"HZ+ 6(!;DXG2",(^[1%-65"V[F% 76KU+ 8J+&@@@4R''+
M0%/$TL63\&PO$G\LOK^_JD._@'Q1;'>4>L\^:&1D3NFN+N^]&5@MBILC:$C5
M9<9CB42E?_*:U8FMS;=O*&^0EZ@:J"?D#V)QGA>.&F/D^( QMJR7RP/I%XS_
MV&OQP!EN;[[R6F=(U49^VWA!C&\<Y5E!XPI3PE10D?).F+TD85804H=%V<[F
MJ[\YA=ZQP-.PP(F<QTDW]?DVL-$=D.!.#+\ &CP5$\SU/HPS.)J[6?Y9!B43
M"993F&*-DPRI_1!#53-DFN[=@694D(@K$3) $[XI+=M\!!+MKA@]S,4;0HFP
MU(5+&5'8J*<)K4G?2WF-0'5*,@NI2?].+CGF"T[A06,P)D,U#.4Y%E@)_X+<
MS/P<QJ\V 6&LN0H5M5RJ=FARYXWC]4?F=8I\=HFL;BCQAA>+F8NTOB3*(Z2!
M600R6Z<,J(Z>.,U:S[O-+5<<\3+H\4Q<=Y+P0#58T>7L*">7NN-$8D>Z$+0Y
MKEL/8Y^[IYC^'RH"54SV=4=7BK_.,;"JT;OZ79J?*SE9W9*3]QTNPW E)Z[D
MQ)6<//*D.ZZ_S<4"^P*:W+X9I?7):Y]06E)Y":=FA'$I#!K--?@+C&BF\ADF
M)D;!1"?+P&-3Q'BY5$FL,\?[NHTIAMQ1VT?L[+G"E'+XUK] + UX^)1>53P!
M'3C3.$1RA@'$E*Z7:DS&OI=']CCAK-+@-0BS+<(";[Z/H<>4VK>57XFQB((8
MU?KR.V[I"MQ#3:U#X+&(,Q>I?UJP 8H_K)R:X6S1-S2CA.?""92):],L[ +6
MPKN:BBR-<=7J_>=,%A:.#(;%CJ"B3YG&V\>$>DD/QE,XUZ^*8H>]]R+,#@.0
MT25=LB%J_RTB8*C3C/J  GD/9C)1OK"S>3%]/M/S <[62;IIJAM .#OY11!L
MB:'>89(ML^$9!$=QFX1ZC]ME%'O^U5'J"Z#4;WM[':90+50G<3*S>BK#GX$T
M_FX2MIRF<^7]'B<796.#/I$U908U%8+HH@9,#<1GF/Y$8XR7B90A4C50%+>T
MU?U,KOHF16O"#@#4P105)WHZ45%2VQ^\O.TJ6(6-\K>BWZN!T#9*3UIT:]*)
M/(, M2KNX0K*U@"K22I]LJOHY<C3W'&V3$6Z84&%]P>\/PU4952U8ZWL@&26
MG!8D*EQP0%/WVT?*V^+G5MZ/>9\P-S@>^3C5B5G6;M1F:WKB-FVM'63D%DLM
M6W/?S7-R\"7(P5.BQJ[+PLW338;71P/-Y,$0&P&Y;KU_]Y;K+6=8ZQ4XPGP9
MA%EM_--A$C6IQ4BAH"%R%>*Q:9&G^Q:E,D/!#N>Q/L%3:?IQ3+Q5VIE3?RJ#
M/)0,_R9Z7=H8<UKNJ]0/XQ0[H17#Q7K0+(0#W;##$!L[,N@(WL[U%LL-IXZB
M<&$VO,P+.DM$(#&%B$W9XB,"%H0FR:CYB07UX(WF>?LP4R",0S&3M]RV6Y3@
MLNIP(]5A55_ _6"B#/UVI3YDVSK4F;E:X>[IYEB$7&L5K6186[*L@I EQ;&A
M<,%*1U%KL]PCHIJZM P(RL7UNA==(L^Q V?"$YGKU'_=A*RJI/%.UG;DB*J1
M^]XXS]!164!2@'IU\^(5(X@D-JK$#F PHYFX@(=-!2*?BH"<GN@.C4%]HNB@
MEXH0OLW12:EFF*I9N/^HZ8Z\GH>QXM$/4A^GD\+4_6D$3'-.2!AX?9ZEH,Q7
MUZ5/F?#MN*1<C+@>,'E,<L3A;L#2*"N+VC:@6\EDJYQ-]DSY,VQ(;&UNK^T!
M1:-D&3&8NLQ8-'5I@S<];WCMRWF&WNR$. 2,P!3D")DQ@<4\1*BVX.E7ZWR\
M) _9:%*5^1(6QV+94*PWH%\ETGJ2O<"6R>9,D@K7O?&XLK)A24#&6K2F:)W;
M%VJDYGYQ>>V'YM.P\!LOO86Z$'",)/#2*<:2QMC@!7:3G 5C0PSE07>%;5B+
M1Z-+!(0K/XAH8]<U?FEO.5S0PC5^:0%PLU=BFF"AEKE(G_>U:TL[+I#(=[A-
M7,$EBO[198!LBIM+3PAT<3U[+?A-19MJ?"AVQT.N+JAFXK:R;2O]<BLU/,$2
M1^J08N/W*FKD4_R)3K3*K\QPF,&NNQ=J->@*O65Y:I)V*_IC(E%]6G;D4?LQ
M+OS&1Y.CGOV8<T+KR/'YA7-L63%UE-#0[I<6&UO:IT5W.(+WP<;1B)T/7Z(Q
M4+:'!!9$#;@*EY.ZM6UH?EKV&DMY00L0,&,.(90(D2W0]I5$>!1=_!SF"(&"
MWN*T@!E"<VMIH5W^WNKD[VV]ZG!2FTO@<PE\+H'/G5N3)9V@#&L.4,T*&RPX
M[65HJD887D_56)4F0*'=85H%/P\O/RW"P'V=<Z%O]#"UK6[HH^91UUR*L6@O
M[_(;"4 G3AANECQ_!,/3[BAV6DU#UVLK_$PKF^B(\DQ0*2R[2J_B/-3.9OP#
M7:2TK[7O.<T -*(%6NOR&I,3V'@O[C"& UM]6%.[;.F3!Y9T)-C;/,P8400?
M)BK@;<;@Q^T^9Y1QV'RNQC6)"W/0I1";!*E"S7@,L#E31PMU6ICVUC1>'E$
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M;Z8'?:,D+#?&9/;TT:_#*3_5 XMC6-9"VR"(-XO;XKQ;5/N W&-9^T6B-#T
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MQ]9*8OHMY\8J/_1U(W$5LV;)'GBS:#;BG5J7@>)S@0%4V-Q3,,RF(%>#&8A
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M?FBX"2&9ECN&6_Z$HGTNF-$''V@X0]!-B:)/+NE8@61H*C^M5@PF&&FVR C
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MC"KJ'%]P18BK8\B3H)MQH#$6G.515JAC*Y4$9"B2;22&IH./JM8/"#==4G-
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M2O1,A1DS[S9.IPYWK@HV.K%&;=#Q#%F1Q;HG;C'OP[(A]YB\U?92Y9\3F;3
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M7L;$&31-P1#-G-<=X5B6AJ=H"KA\H*8%06>M5*R5RPH9*B)/\BCZY'L(-6,
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M'0!OT4[B1%5 -?]8=X686"\AJ&R,V%WS,\L%.''&3GB@(!5;OJ$K1,P@A<3
MX]_PMN!"Y#[(PLIU3\16N5/L3O$23_&F@*SZW[)$<EEX,IVQNVWR<[JB%TT+
MNA\21 70"@D'4# P ',N\E^6+A'SJ218FXKV#<V8S)W"0^IP' >^AN&793-O
MZ<WX&L_A47?W8']O__W1^Z.]=P?OWR_K2 :V'<F%MG6C(;3;7M9NKW7>7_,"
MP6Z#V;3!UGJ',:#7[3/[]]G=&F\S>YV^EUH7C4V0OI\@#>#<)N6B9$1YP"4W
M:/H:TTS5;%;X,08/TUMF,"0KN8@%H/->8;2I,JDLU #<+D=]Z04CSE%?M:.^
M*;AU+H^%<S6EA)A=GKGX%T@)S./E$=+D:?32 V*&4$P<1+R+,>9 V%&._\5)
MQW1JKV*PVD&IC\47JV%#\RPM!<U2EA>/)?&(B'Z>Q%Q<@;/1HQII%E:^!]&O
M;B7*4\$D8_I@Z0>8:;V304B2<@2+D<Z3QMM=,:A@8B?8>60&L$:W+9Y0>?S3
M9JWC'/5;^)I(L<SI;&E.@?M;A;R,M#C(0I;FP]\TCXTD1MLWS&@+-XW#@K<6
M*U?P+.69VIZIE@'E9/0$#Z:#J:)\K+--+1QC36):/7CBA(2?S?#@_70,_WIS
M8DQ5@TRWFMRLH-(UWZXPJCE W*N>[KJ8C<L#GAF(W.[.L>A=7%Q^_F?OXU5'
M]+Z<#:[AW]-?>N<_:]S<9?_G+Q][UY\O?Q57_<M_(IYNP?;'KOK5+DOO.?HP
M_ @07X_'5;^V< %99N$U-'H\S"3QP"$M"&AU^+\.>IB8/_'BE+5O$J1?.\0U
M=*EN4-?'"6C<"?J8R/]L:F,_R2@?22_+DS)_K)E<FX]%(Q!^RY)@"(8&9IY+
M7M4\5;52VWMMDXZ"!,:3*B]/"G^U;3R/<2?!827J))KR5\J%P]>]HL]$.*WY
MR2-D\^M4V$%OY1T7U)0\=67]KBS(#BO5-&DY_48]G^%5:1(-,O%_R]P>,V_6
MK&^]$]P;)+@WI4[X@_0(A6Z9Y'Y(JLF\)##1?:U BK0(=UW^BYU&L%!@7(AL
MJN'-0=(FP1\LU-IDDED:=OR+<KX*U,%NRDTN6K3IQ8I;)4-8:+WVV;3=BUZ/
MA16?E$^5H#W8,EN]Y(](!506%MZH5&5_;%NU\G N-#GM S1G#X9HR'XH(T42
MK(@)$0YQR4GU.%5,(")<0R/!UTVI-/L1,A=Y*J%CFI3*W^P,#,.C^0 B.,0Z
MF#MB!Y)D&A0&UWP;K%-%!]"SX.60S3*GV#^A6)#F.NJ-1G#PP6Y*Q;U,D/ M
MK7,3P:4\:6VJ+%!IXXA1'#&*(T9QQ"B.&,41HSABE!^9OB-&<<0HRQC4[H%-
MHW'$*):(EE>84;0N<KC!U,O607"_,P92"=A?J>3./NZ39A9&C2=A/*_*D/OZ
M-'Q_[/29H*=:9& J@0J\*KJ9[>CY6!MO'9&H]DO6"""9(,PY5'<R*D*0U0@'
M?M%4.IK(29I/3&\@T_LS13J51M8%VPIQ3DNFII4?Q8)T2-,4/NKQ]_B**VZ3
MY\FRI;@NNC$8Y99-4&"6L?LJLNK#3#0[-8ZRY1MS@DYQTHCQZ@9+F('B.BL8
M//\K4PQ=-8FK*WP-NGAJIJ,?AX;F<E'H+5/?%I06JW2 K0V2&_MQ7@P?W*Q(
M-9BO1LK++(7-&2\MUISJ>K6JRSH0^'>JKD&9S+:+%*=67:GE=MHNGD"&P,XF
M@=<B1_ SU ^:U(+BU5J8BU#=!&E(]^F() ]1HFF]5HCY20(ZAVY$[>=H(*Q;
MJ+JS-5J/W[N)0<Q'U($Z%,/8Q[_KKJ\H\:Y5 A?C%[=BS7<A^9,;%2&91E@C
M$JL\J#F&GT:]Y%-']#_UZ+D?SGK;G:;"U_I@GL)O:!>=/TCE6+F.44[&OI2,
MW12(_BG\)&WK:MW"T)'&H0*I Z8=5;^C\8;=1[4MK:5DF@_'09H6XA'+I_+(
M=%(ETZXJ^3I%FAO+R=JE)3X(A)X7L/A%X<NRNL:[J'%)[85?C<G@IN->,-7!
M\]@-5PDY,34AW1BBEMGYQ*<:=UFH(:I^".5]IT5 FZ*PRGT*!=*%-[5XXK71
MTE7/C+*_>!5%W*E^;@C'7C>3C2NO0U<0%/G91=Z*GC+;YO02*F\@YS[HQ2*@
M,X.-;8K5>-3=(W>@4O"GL^Z-UNBEK_(2-?W.M'_M:F=3 &>5]MN6:1[DR"W+
M9=NE0"7",Q\1.QNG&JII/*LI"E\ 86EQ%'$Q21&(,)<U==N#1<]:+"+-3*%
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MRGGYKXNK4Y/N*BNT4CBN!,V$ 4Y:=TDM+3%4,JE4W:$%T_HML85MX_BKVR+
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M>9R(29Y,XG1^1-(RJ>/"E-_3M8@^!A,F2I$DYCC'8:+V/EEE4G6)[8PVA3X
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M6Y.;AG!>G$SP=T6ID @,Y8Z 3?I5X1U\$!YA/!ESA!_=^(B,ZPYG/=)4I57
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MJ3J&=LFJH5AH(1 *H;RO=O2A'CI$G-;:_&B[(Z(:9I:B!D7TT-"O11$H$:\
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M>:-1$2NM2+$/,%/]J.W]522Y^F4,_AF2R=,/ 5X-::9^0I"8@A$(3(>TGG'
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M3> ^\N\02UOC!ZB/YKJ9UC?H!FRB4M9< 9'9H=PJ/D6WS.TA+H",I>('1#]
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M;'%H*_)29*Z^M^R$5#)0:)$K',X'Q88P2-*!S!E95!DU/*LU#FH'!Q=%)!1
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M4U@%A1A2^P6[I@W;.I&AP"\YN)7$(KI(NT8VQFD"*SB'GNHA0)SL)BDB^+J
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M)9LZ-&!PBL9@ 4X!L["[LZ0@E*=;(C;-14HRE31*2>@/>_&@-^@/8N#6UIY
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M#2,ON[6LC:53I-- $^A',[10.P7P\9[98TVZ?0AJ-YSCW]SM<CZ7KF/#EV?
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MN7/TXI-9M1F%#ZO89%\^G5=XPF<JZV,JWK&G\@%)SJ=IZ*V]SX%L@]SL+^,
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M=W)73YXP3!LR'X0)*[/6J\GYR9<5N-@<Q6:L9D<<Q&:<W=UR3W4.V2G&$3A
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M>XX^V@/52\ 9J1#KU09P<X4G)@QZ+;^A<48DD^6[;[80K+TIZW&L^H.7Q+)
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M^:N&7)[U6KLX=3 J(P*'Z762:FJ#^5?S>9S/#9+EJFIPLC\&4#&DAC\UA5%
M)BLK)90]9'B>55-IB@&A1D:W.GM@T&J3E8P'Q2AMK7'95H1\&IY[&>%:[JO
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M90Y_Y$2N('X@[S-\J%8]QP A\0:Z P4<-<72!>8AT(0Z,AK>)#]N_0DZ3.2
M'\B7D,!7"W>/4C*N><VM6N[S"K9<W#"*)V;6]W-ICR8Y4L?G5"?RP[O(KB1'
MLS-AW<\6PPADA*%06*&-<;GB/:D^<T\_19X\@WNE1HUJ-<L87=]E\T^% P7.
M8CR] H:I^DU=]P/RZZYEV/8CUA&:4_V4-PBU9'B@?Q@.(=-#OQFB.#V%*EWC
M9)V#_0V"Q5^CZ]G%/GF2(?Q#Y=7FWH#EFK83DO>%>I[0D&<N%^.&4^'*?H@,
M3>^MAE3Q6J!X?/D,W)\I,_P!><4F'#J_L3_@=54M/B[Y=_U>8&&C<GHG;P:+
MY -L+L."Y!&=(TZSBF/H8%'J&X'8:+#3D5.GRJO ^ROC.\4:P<4(:.H\XR:O
M6E8GRYC"S3<HO:RO/6?+K?-_!QDYT]5)<HP<F=PG-),_2<T-L7O*=#_JVF"P
MR^/JMA@@CPW4[1VB7?"U_-E^D;PSH S;MW]\Y"?Z<&7LN2W:7"T.<HDJC-@S
MAT^4Z+'&%<9BU9)\X8/A:N->(IT%HM*5Q@62/B #,Y-W/^6RU>0U)@V&C8I[
M]6=_EMGUE@5--MO)UWT]B&1R(XIH;9AP4M7HBQ%WAJA"=+)=(E'-QT&IMZ0P
M!JI-^MQCVC@J,O>P6?-&HIJ;0?\+V[X^-YB"($K=*LRB9:35AE1A/*GUBP_6
M5#6IU-\2?(UX[6\__84F5+G%:567)M37EZ&9TM_H#83Y2YH2,ZXB7".D$9SP
M&7M@U5(3M16A\O-"0C1E??XRS- QS]Y>ML;$(VCO$2&:*]OQ3P_N14"92@9G
MM'P(W]J!0QC^15@>/?8Q76\!>Q;AC4HW&GD6'()4L!D=;")M"A'^<E/\1I^X
M+S(A;$C,<"\IGIGJ*%GCAED+9$MDR^1@.!:34J1&!VX/]'!IGU.K6U]8A;QU
MCL\1L688=CG-DJ"7=B9X&D<]O4N,E68D3-64MI)*6,J?;4J6!0W*>R_E#, >
M;8[;S!RH=\_SM\J1AB(#AX@.G'.K]NJC2G;:VJ,ND83FV? 1H6P/NU$ED+[\
MYH_&F(MR^+H)VJ<4F?ZK.D_0I(B&KM H:&BG0R13DAY6NCHYU98>\7*A*=EX
M]#'<SU]L=K,H&\F?X5V_ET9>^LG7VM;H_&9P_$53RMNX2:(/&D2/+J&'[L4G
MC7:&J#6:"#9\OJ@AGB-.W8[04"A?[R5Y<&E+1,FS1*+O/!W9^:[48JV?)I"^
MV=W)+Q*P_,4QI/"HD*%.X>1#RX[5 <]_LU]_=@RPI7ZC)4;Z9K8$"?L0CP$<
ME#&G4$&4OU9+R_.&2(MQ7]QM+9%'4->088^KP[UWJ@;;#9-(/K*Q%V7M@5>T
MN;*U!.+]X^)!1[EFIPC6/5J%YB0V<'59PA=JKDVJAD8A--7$K;CO;<G7:$@1
MQH##-,79U*?=3VC4BV \L-HWFOW(!ZJ&\:UP!G<ZQ&[2E-=[U"SS2=.A;.LY
MIR:5!CC-[<#$#(=8#?42HS+XY75+C!9-/L6RW[2QH>Z#Z-@&Q4&SF[+H:1Z!
M=<$..D2".1APDD(TD)-$G20H1&D*'+UO5:54P(AS@M3N!I<" L7D IU"U 2V
MC<P%3<O8&5 @K70;9[G%F5Z_DG[_,ALWL\Z/^IB'Y?A\O3=Z&(S!S\86N?X:
M1K!*ZGB^AH@"JR&7H));Z1"+J8IN$=]E)BXV^QHL5:&<?-N'^$RS4/:Q9U67
MD]1(@G0EJEB+0W.@TD:R+ADO'^_=/Y=:B+F;J)02T&1>D'Y71C_TA_T)(%2-
M8YE) S:XV9Z%3:]V/@?4A@[R&'!A(T2^?GAJ8>9CXZ%G?<<#1/R2QA#_+Q6G
MG"RKL#\)DT0-EZI\2$-5/\TZ8VY0/J2?4U=J' N99Y>&8U3QKU2L7 >SG,6V
MBGX[JAK,WLQH"3$LV]E*5/^/F$_./U_V+^O32QF?=/ZUO?L?U2):8@)8L&[H
M389\=)G=BF!NC#LN&V+HE;_RDR"\6?2Z<%HSGXR].K#L;)Q)BA<39.Y>#4@^
M<Y4KY*<.UJ2=!HQ4&I"?MQO#'8D^_HH5K<L8M1[;9;4#F^3(T)."Q!/6UJSS
M7C2%#Y/C;5O"/M\#C6K4 DU8WW3WLUJM?8]_K"/+_JA0);HD/.6&O=)J1Q^V
M1>W=6]L\'HA! 5RUV<+\HEEVGJ95__WK$ZV#4E*WTII5D W-L+ON=W@??:/R
MC.5^?&J$3J6^6B=;$;[M8L^M'0/.,1!>\!*T-3T,VT%1OZ]',"*M^)KPT',H
MIJ,X?7*P!<BD=GKJ[^0Y'>%\V[-]Q 0*SX;]93J6-'1EI5V6QK,XF$N:Y>S,
M4:5QOGD^OFOTK$.I9>]K85W"?2C[@X*$<3D_,"X?^G!$X(+9F^EP<RJF*Y<-
M]<E#N&5V-<,X?0$OV+/0"&H9<#%6<XER=_Y:[O?-HVX:#WKZ<^D-+3^!$_3#
M$2%;:G"F881@^J7JWLOU<S#QB#N1FI>LNVS(9IUDR3[SVR.%&KS2D76EA>\+
MI16FRXRY2_1U[R >Z7K&/VJVI>W;5OYH@H[(W>NU.SQ$-".M?V,Z\!PA\GBB
MR5M!?$RK0B6<AI(@LR3LXJ_.P.91:J.DQ7)!9BQ9YOZ=8\#G#)%8#UZL7,4O
MN^_' (3#6E(;H\%GB2:64MNEY0"P1]^E2U!C?L&^:J@7KC,OTRE\L0P=TJSE
MMOY(9%S1.-J,K%AD/;/><&GJ97.+3NEWMPS)"7=(EP?RXY\#'N(SP85>%)/S
M4UT%)G[D(7:8-OFLOJ] )6A F1]7_.-IM'SJK73I=%K+Y6BQDE2!J"?$+#/0
M)JS#>XCO;:MA,1T*JX#S.%('V_P*]94KA!0EJU?YMH90 I.*R-?[:DL:55@(
MAN_%>#6_E8-4H=[%2W5NEIU/)9UNK]4#S\#NYTA?7L9::%V;>9 8#]=.L_8W
M8=\H):V-I-K,3[BI\*YVZ2C-. KHKG%4;&QM,N!%XQ6N=>3Q^8YXTD H1>,8
M@.O"1BBI&YT_!IC20CMDHGS7V6$/<^Z[4SH.GD/;:_-GU]-D@DB$ROD_1-_L
MVF#+*[#QN/9/O\[<!NNAKU-#F@KIM626N-U9T6ZUQTS)*FIE\AD4Q?HDTVDI
MUOFH%[@$W\F]!$]3L_QP+M9>2$BF1**Y;4QNG_>1'"4*"!W99K#FVQ\#.GD^
MSJ(,'XU]M)$0N3(B/O+2XQ/')WUQ9E>=Z]:9.V3]6ZYLX9Y;K_YTZ\J-9MPM
M=FL(Y,TEWS]_:%MM([*O6SN^(>]G^(#O8*CNF[;Z#&$QB=>(QBD7Q5DWR>M!
M;&2X\PFDDW[BPOO=2)X:6=0N<^+7#E*5ZOE3XWM;97%5WTH\M\XW'&H1M5*R
M\@3')2Y9?"JURJ)(2J.KO,(K"W[D\S]YX^\^4[-W.1"#J,M\]6+ZW]3>7XD1
M8)[6NS1U[:_;&]N^LS*V$Z0QC AWXX3O87;(X+SQ!(C]QG)&GX .@7"C2@4V
MP5[==4<FZ\UC$4YZ">D8P$W77.X.K*NWYQR5:[4@)UZJ79^JB*]C]R%5N*_K
MW(WM+8@X=?1QK\+K7#M%6O3ERYID!PD'L8';XXJ^94\1G96L?(9GHHM&4D@Q
M%1KF4F9OG_U8+TWJ>)8B_<1"RO"[,@;^H)_%&-Y[KXXB)B G7R@^8FDTMR4G
M7EDW[S3ZCS[)$TB'#S((R3.;3>1[E7Z[?&+2LE;/"^G%%MLD_@;U@9PF<:W@
M7:T,QP.EU"4CT)<,>%E11JV1G=+HN-(.?,-)CK)^\$GU?Q"9=?YU;H%Y_:S)
M./A#>?[H<.CJ">"FYT[^S*3^1Q1Y-O+3D=Y/GG"668?]T.**;X$*8Z$W[+?^
M351VW=X/7355J6A.S ]5FZ\_G,_]R?/ZOPC.V.)_2Z3Y$OQ7#_(#)^FAG$=I
M#7(MH;G;EL)8*A-X*.<.>W4, ,]A"SJV@=1CP.;?4SFTG2/V]9!CP/:E%=FB
MM(LW,P0$59V>KJQTV=C\<?W-!0V1$-S0]/XQ &7Y0YCOY#87L(6=KJ.PZ1V]
M?PY2UARDPVAPT/.&KQJ&=[J*SUF7XP2$+@;\>5K;N^=MH^B6P4!T^_H[B2_'
M "VK)63MG9J:I/(6&VON"]>Y+X@VWFPOH3O3# <>*2EP#9XIYK)9@U0!$DYK
M>_;0O<)MK!<Y>&I%!, ?4:()8A"EFO(MW(\*$Y;WYJ'<EG&N3N+,B;X<<9.Y
M$5"NRK;$EJ.B/TX:BY TVAOV[F5"3L):"_X3@G[RFF'A:(1X[:$E0YKZV/NN
M#5UF =>V\R[M7J(ES2H&UQ*;5++_1_#=Q\,_/Y]_5J#25^+PS?/ZGP_.7KYP
M_<?E@+-<'6=]00RU8T"'U^Y%!?!"WOSE"KO71J*?P:RR)$"U=+H(=]V8]67B
MZP_NLU7O;:^]:ZT&3S)9'"D."3R6E=0/NH[189M2_>QOFX\!#8H0A[N_MU<=
MXW/X.M.U.(:_-*:+=YA;-2A)$83>%QPR?YTRFFX&WRS^%,/L 7]9^'\4VB9"
MSJ!MQD/.,-SH5K1TG7<CAZ2&!#28?!)V;S2-[ARN' /J96\]NW#934TC?8)/
M% AJ(Y;-X4O4\:_G6.F&AR$,OV/ FU0ET2=TX4)F;]FA,5W=[/*<;4\9ZE<W
M4[")^J/S2W',U::V8:7,EF*EF;:.=*)E\B?9P1K@CT=_?BX#G*S&R4J\N;!U
M86%R52\A=*'(@4?#Y_ BW61/H(U:E.OQB1X"Y%B%-A!7-4Q*W41NTO3"6Q7+
M9Q 9#I%8)<-X-?6@6S&K2H_._8 .=,I%1+)_^K;1]"KVUYP2J75(I6MQO";'
MNMQ9<.8^\:Y?GH%AI!<]3EF"QS(CZ]/:>-ZN6UV)69A/J%WQ6(!Y(? [^C8%
M'1OQD['-2K3=%4M[5M4*[ZA+$ZF\F=4X+='IY&D3(E*&N=C#&=E5[@[DBB):
MFN8#-TJES99]*0HUQX!GV]]K20Z;#UC>H(-IF7OJ=!SMKB7]B 8C'BP3AZ;4
MR28]BE1UDGL$6I^L'A[[D'XC?U7D^HD!= U 1_R;84@AL[JJ<5S:Z*Y47>;2
MJ)P.+E*/Q/E636'C&'"H?&(G 4QV^K.?!X>$4(YMYK45D6O-X^*&V49UCXIH
MX8,?1/)]A-O*_?GJ]]*YIFV-TVCE0WP?WGRQ9L13&YB7$A7^9/(P!YAG:?X;
M;50"N2$._+P7D[S@0?3@HO=W!ZK1G_;?;^X*"EV(%SX?BT749R";;6P0@O&_
M8H4:%R9D9>44G++L:.UR)_]WPKJ(Q"C8X[XT,"Q#/-GCT!__ME+C43\EV/BH
M77B._JR/.154 1R@;K 0G:QRF+#N-YMUUAL"EA?BB>C$W(IW7FDRP,1P6Y"K
M,Z3'&>39:/.BCL;_J$>:<JT!:-#.FR *(@;;@[^92QM^_]KA[&560,5>A-2Y
M3A"#<_AB6^_T_\S*J&!SY\5<-NM#17*^=UJE;MJ*.$$"C@$1'R;,HCJ=:/P:
M81=W>S7ENIY$-G2]:-J95:/U]"CF1>3(L+X^-"%';@ /;]-=]CZ?O(PSX]8P
M@[5D&G5E+YF.1)#!L<V&],FN?3Z1F^/+U(V,UXUUXQ(3S\?JKAY"+[*WA_M@
M_K#:APO*^3JP@1<R<T]_/JIM5UAWX/#=CLZY2H<=ZJ-:%D([/,)$I([R"NF<
MI*#@NX2,\3BUG KR=JQ:F6:!WPD>YYU_?;9A/W0J+JEPLW9(S<X&/;ZP39?!
M[:4J;*R2MZ. -;F=^!B\(/X%EC6TDW4A-TYP.8YAES]_ MJ2>Y%&V7*,&YCO
MMB@/8YK2P4OEVXE7C3.($U:F:RJ!SN$Q;ON\U;\E(D,7\O=?[.]E4I>[0O\4
MN40?IHKNY=#3 V@(HL-9M![%@==5>8Z;EC4U4%F-#"(Y7%NY+5X+O^KA<A;Z
MAE#T?<9MB7\.\?X&H@S6>@RH0>NDB5P5MNWF9 TC.%;SX.LEQW)<2<3&\A?2
ME>=&!SQ35R;*DB<(IA@'KIB^:OG4BPO,ZG#[0=W8J%8>3%R:_+V7&:4]2_=F
M7G%R,LN?29K^S6/,TN^]P<YV4@T'*78^\VP,$2,XT2RHC=?PX X]KAC,AW*1
M^X=N'G_]R^*8@W@6L LXWEYPE'F.CC&<0)^B<9*8F904ZF NI4V(_!#/YK<J
M7SB*FS]MCR+HM+5'6B=T_KPBG^GOKS&9;-.^W](6U^,9"E[?^;7@L:E^> \Q
MC\O!T1PH+!N3ATH,=3JG"S6Y"\H>V<FNT*$\">7XX(59G=B'LL^%8V!T[X"0
M6VB'B=T@\]&G$QK:O)%<M6/;E; G(\BZ89Z>)8NQ=3]_?]^_]-S2K?RM3*>(
MI>^@/3Y>MX:GB#$&!99_K[.Y%I06N)4^.HU_2%I=,O<<\_XRF':G2.),^H*+
MU9TN@SAF ^R*K$&:\& \E%82TZ$5?^]9J?2XA1XDVP%A-16DSY3K-J_1T%6_
MDO,#]'/JWK7)>P,ECC\?M^>(I^^Y \^PM1'X!*U+^:$IG@*%MG:!'X(E(@C-
MIGD.G+N!0"M?>(?.5:MA(/]54QW OZY02R#5W2/.N8GN=_@8=3XH6O"^4#>3
MG:;YP<U0R52G<H5O II5EOPVP-VWY8_/;,VE.5&2V%,G@.>#DTJG\&V"\K=.
MSSE$Y+",7_*_JT=&0KZ C0'Q>[O7LA9VSX5RT?&1"4 BVZ_46V4]"D2E^J6R
M--*U^?*"K-Q7TX&Y:[G##0(:+F%94IM"'A=EE\]F(AM,.+.7I)-:/!Z9I3CR
MC"@:3 &'/;H]?@L@\1O"+,Q(.=3A/P<I?=/\OYP^[-!E:WH,$&5,,PENS"=@
M:^(Q0 1S%.QP8'#]OW3-L;EI0\-,71XU]#% 6\4F1G_'SOV":6$&16=\(>*6
M0,"+3..F&,F__ -N^>D(?_\3V\MY@3D$Y-MI\?B^W%$_QS;NNWT.[4TWI>)/
MP@:.;^HR3.6U&%V!;,-X7(LP=9]IL%>F]CJ<49X=N/Z7:%*4S-[I3[\_O#_M
M[7\E*6"*U6<-1;E_)(,]\V'BLU:=E%;6.%S+>R_&>+3P4NG;)(C!_V'L/8.:
M:MBN4>S2>R]1JG1!>KU%Z=)[%Y$: 6D2,"0JO2M5NO0:(A ('2$4Z=*"!"E)
MI(,D2HD0X' _[\QWWN?,]^/\RLR>R>R])]=>UUK9U[76 7"B4)B]_6A6-$B$
M#O2UT@SU. L&A)&[-SPZIS5%+D]$=)Z>[.,BG_,27^5A]V^=SP,0DRGR,'8M
M@G$T'A8@)\VKW$(*Q8^K?M&XVQII1)1*]^A;<_4:FS\)YLK=5E#X]4W9.+;/
MY7:GU2IE-P5IQH7DC;^@X *K$'I2-31W3HY1HQ<4]" 7R\L6&R(=/WX-)#[8
M0);_MA%!-_,$ 0IY'(O*8G)>!NE(,V2'_!#YW5U!"CBU)]\CE1/PN,K^?1K-
M./ST.:T1SJO3MV2[W?P[*7>9G@;U6G5;!9+K5V:X)VV/_-R>_4]WRMK3'ML"
MSN(/@MHGU/_,UW5J?P*%]J.E"-[GHE,'!?X&#N@4S+:A$] $.;N+37MP%_#B
M5'X,$LRHE@1OO?KEID:6M-R85_7TP--BW;0*_FC;$>9*U?G2^(RMMC^OM<W,
MAV8+5%+,UQ++[PT,F&!VE">DIE/M1"+X:FR<9HX73<:]NRXHY+LYP/>(W7E!
MA(I-L/"\&FV9-Y1@*AVOR;*"LF&SK@*+$U:<"(65_F4[\V9V1O(%A3D! 4$\
M5%F-G0KSS!$?E%+:3:*ZJ8@VD=E/"/7(4U4?/A%2+Q8>[\(#=E4<-++:/?"G
MGKR5Z-*?O<Q'5-.01W:HI,:M#(1''"5B*<E"<E*8Q_?')0B8@<K%$:@V9U^C
M1!J_6MVS>,$/9FL!PPF"KVC%4R@?TZ"J62=!'?TG_N\Z)7'2;$!)Z2//F&!:
M8'_V-X<P_X@ UT];QUP%)UM'C:/LF/HLS+*)E-!3ZDRZ34I7E(U*_S.>XEW1
MX7D#,9GJ./.@C 8#T0GY4O,RP+S88'"Y(A?,(B2L[7FE5%E^;H#QGIW3\J\C
M]/&ID?T9/#@7F@V@A'"2S30T2$$P'P =V!=;Z\M^])JTMWI!P>)]#* %2UYR
MX#X-;B(\'K$GC!OJ=6:+H#?M07?:E!I5P?#>&G>)-Y9P/C84/QQ&I-Q;%X\K
M=]<^[6BPG15";I,\^\-]T<DXVFO8HNC@ J!>=^I(UXR\JKKZL_;&]D21T4+*
M*_K,(D :FQI2:#\;1)RP$0NVJ(@H#IYD]E)1C$/\['C(.OT=&![27?D<*7,K
M) 'K6U_"K%./4WYTY]6U@-GT2ORY_'#.>C-QJH +(6IV%%2!J2AG*S<&#=M5
M['7+EF3.I/^,#/3/&1$QF]1EY;5.; ^\H/C9<UU;;R6D._:O^?1_HL,[E7U@
M2_!QSB)=LBS1)&;C,U&HTYEYYF#A8(52U>7'V>=?\].WG821F2[<&K-?IS66
MQBHLA@P(14Q +NOFU[3+'SY=-H\%26N1!N3'L30#SH\_V.\\;?QLU+IZ;]]2
M[@MM?PX%;GJ?;Z7-+[/ >=F]$$=<<+YVQ;J02XXP#><T+F2G- X!("JM\Q++
M8RK%J!BSA;2-7_5K0I!RR97V%I6WY5E*UFJ2K Z-?%F!+Z9?O9I-^7\'@VW3
MD?@SL<Y_(^Y<9"37-GN4/A;)0KYKT,Z?WSF?6%8AA,;()5LXHD-@NE\:4!6;
MT?-661.+0X6\'7-^$N7Q:7K"#3-W.KK891J'7TB.$0N(L)< 5JAG\K4O1;0:
M=WTN**@Z*6O!QJ1(G*\F2H-[KAYR%]@^- !@-%QU\&?:FC^9JTCVQ/G:8VC_
M\4(3+RD[-/I9:P-B7M[! 00O:WVXIOF)E'J4-RTGS4WZ\P5CTY>:[*S:0?+
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M=\UM;O"\*9'?4:ZL:]R_ELXLL+$)8,5//M;HW(U("37]$&B]-]1U3NH79N'
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M#DFUL5#FB#>ACQOR#'LP3++ASC1(<8J:((:Y\]!R;$P^&&MRY%.]G\5^Q;Q
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MP4W/<*7:!)](R^"BC4OLDI7=%T2__-&)?"MSDF96*E95:/J6T<P,W!PM<$7
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M/+3XUOQ<'-LT$;9]R5!(]%7O$4QBU6[9&U0!JN+>2OJ(-T7[$QAYVF U[NU
M"F<4TQG H2(2R?U#+O (9E=AC9>VBNM0%6A&3@9SEKQ9IU+,TOSD8F&-<#3<
MOAT2NN1*EJ^L%PNTX8Z%LOJZ_Z!$:WRP.14)EIQ050VF;,%!PYO,L;OMU@K?
M:ZG]=8>;N O Z8N&^'5_C^E\?%2/G%]'KY5V1]T;I_EI4^8]92=74;>;.'^:
M)JN7C(XVZ/"^#8,R;7;#'T;MPD95?#FCW0LW=66?HZ-:>_<&4VWD'V8:??DX
M?A@5I6Q;]5/5*;(DH>B=PX$+&L=J+U&F_\T^NM/S9;UNN>F'L0K%Z\:>[VME
MMX5L!0RR->O5:/N-Y;@'79F/TH@?@Q46N&F"1;^?P]^,+MX3S4T_!1YMSZ%*
M),V%T'>HBHWZRDW4G &N.TI:6SS]Z601D5XF.GDTX.#)(*FGTFH67!*SF)(W
M@GJI-UUQ'Y^& <4'RFV3X92T\?!%,0G=X6#+Q3@QWYL3RMH%Z[3JEU-LRC3$
MH-7NZ!%TI/S!2F;;IZJ[F^ZBMDY-0_D0(6B;-$DH6!XOAPM:O): \U^(ZOJ*
M<C@#,'6AN1/F*/"6%<XGDS$MG%;]/JXYB_I?&D;%9!(TM-5ACV'Z(P>-)0GW
MNR1V;J5+>^<[O^D8=H1BM?02V292/JX;!.OA^?()P3CW]AE4/.0Z,;T6>'TC
M#A?7";D<M2UM/CO-XK.*'6]!%*X?5<T_++!R=@IZP;A=L1AJYB#Y=+_\<C9;
M?6R:EY-!IVFG#4ZJZ%58FE9R)#M[7+HP7?NIGHVP=]NBI'SI Q.F)^GL]";5
MX45& 89H*).0[6>\L+R;8"0/>43KXF>CM95:!D']B,=NIND]%TQR@#]"W!B=
M5A3\R"7:Q@+"G=4XPSK01OG1!2TJ#<3B,X"3RV[<'2#G+D2!H-&$[_UDIIH!
M)Z@W3*H.8S@E=-([3L5=J&_W7UJ?#LDZ8D5^"1ULO[+CWRN#T7[__#T6BOX(
MD>>F#M;#N@0;XU+P>HO6-<&:.)>.9&?)_@+P&:"3.HBKX&0"Y<37R.-L,-_%
M^'/2!&B;') ;_NVI.@N(-X=U&U%?VQ!IZ5*B';,MOHU0XSA"FE2K- _4X++>
MK2)S%&Z^I^#CU3 <R:^ )UJFP_4R)%KANBR!/E\\WOD4C;2/'>'-#&N5[N>P
M(7<_XQ+R-2IVA02'YE29S%?\!<R'Y ?@PH>>:94<QXF2#>/55RDIWQF7#5@<
M"B]^[K6IK"X*P#A*V%D-PAH8]-7]N<R>Z%X0^+@T;!V#C4*G-^+R,14=%>$0
MUEC-VOEHDM3W)AZ;Y?*C5\Z_ACN"(/W?NSXYM>\;9'$IQVF**(X[V:P;5UAX
M(C0B%";*#'2'$5JI3S=T==;RKZCWZ:PEOYRACJJ([[3!OG,V+(OI,H5'=@Q_
M^H*P: Y\"]=(Y9GP%=:]';O)_Y;X&=K&K$H';$>=/^LAR\OOJ\=)0AOG5@>B
MB/=MQ/M<W+6\:4@8#XK_47FP7+X36T3EX#]R):\H7J:=6"T +Z_-7VNB1M,
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M *&R213K&3SM.9=&=I2ET<@<09E^%Q'-G&Y])Y7XZ0^4JRU@8F,KM ZQ55E
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M\=Z8;+5VZYM,_25.[>/EZ@7MF M'[^@PMZL*K\XWIGG'QZ]FDL)<<*9'E6>
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M&-HQ86 ]V[!$(5Z>?3=,;W2[3<K*66YD9FI&@U);"DNS#=I"G-,0&_&CJN!
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M'-J.GO2,:_9,#7Y%H?D6.W+5;C7."A8[DVZ3(0,\X>T]S@P-[@Q',T';1+>
M+EB[1&0=RZE$V$%J:^M<RE!/[OY*AL)N3O-F;AW6-&P+=^1."0ZDN^;/GX38
M'=)K<>T_. ,X-SB+3.2F/,>#?KTL$>N8<;=YW3Z")%'"Z8VU4B%L1HOK5RIZ
M&9]55M5=<"W==FU=N"*&CKZP]H_C1^./@#7 B:<ZXYK&]5 MVGB#8<$N=;XI
MWF29<YHHO!@K^/'_N#7M/\3;H5VY>[AX\=%U,!><:0QUC9>SG'/RG0_V+@[4
M>5-.8>XG4KJW]L7A_PPHW>GVO/XCY%KL4N?";?#_:.;,PME M#@>+1-T45I;
M46ZI6D)H2ZE86U5+J:I,46)I!R%"[4O%U)(VI!E+-;4TZ(2V1-I>0AG4%DLM
MM:0F="*26&J:"-4T*>*ZM_<^W.^;^>[;O??A_WS.P_G^Y_?P/V<0?Z;Y%S-U
M1[<.A1=X?6@6'&)NY%GK8($Q<'X"Q1[^7"E[-];^2F&N^[!;I4RSI:-SUS5^
M2P>H;NI$^[#N>&KMT@X[Q1=] Z@_5])Q*HR.%"1L549.C[*=.CLDTAR&SA^:
M-!N6G=E(D/:X2H(X73<RV[ 8O5Q<4F1P0?*V'7F C"'PD5,?\UD+O[0*P]E@
M#$H&S+M>G$3BQJ=JJBPIC;S&<[GK'0>FU9Y$OF6J3'F%4Q8C!]]/K4@IKB<[
M*<>8.SS>6P,9BHZKXCWG][A4*VP#!#)^TT'E7QG%+;#K:3N AWQ=YJ]_A65\
M:" 6<HY&S'N:6>-D$N$AP@>UY5CZ#K[K"2>1$E&<6:HF/PK=6^N\6/@:UH#+
M:*RU9OKY"LF=*;R[Z=I=G-%4(KRD\6=<*TJ>;K<K6S78&;:O8QN0B;)%].OJ
MUPC)S/V5TE1Z]2HAMT&@#;1$BP]8#04RY1CJ:TE]MG2:HF 2 F</FGH^Q;X.
MKB,-WWD3/?:@-BEL;B(=<7)M*'0,V05R>[\TG]R^B[>)AWS2T#-N <6]((%U
M/E)<^E8KB:C.]FT )7MRL*0)*][UP411JKKI[RF]4"BO2I[99I5@=1I_<LEP
MR58*U?DJW?P1B^%Q9[9A!0T"X?5?-?)M,\ KX*J1TZ#38JUW%8T_W8OVN^C=
M+\E1EUM^B2ESPD)2 XQ/K0I!QVBEW?/-3D:D>)";Z3Z;)NC4&P<^S'%6.KHP
M[_?KHNI@UH0G=?$A)K.QH2C:.]K%><9;9Z+5]F"Z/*I3:AL0C$-_42I!X]18
MRM1R!UJW=4<>Q'$+.S=3)\5BV_/KSD!7RI14)@'3,[+Y!:BKZ<J;"D)[OI?3
M1> <N-M#*@TR_L[L+I-?@V[X[:@?T<&%4ID<$?5@NJBB\.'G/:4/<<G[I5*P
MBGQZQZ$8I;1MP!S,<LB4WW'B,>R@U_+JK;F<S'M'Y)J.Z<T@<.\L8C.2P%D[
M" ,5AN@.&OC=9T4W&\#\RR+O/PM9/E]M_NSE-#'9B,&E>#HJ,@G7_C7'_TAN
M/ZG\%A$"[N#0'STPK[31%3KU'-X&W DDN$U4-S?YZ1V-R [+"NH>N"\B0@<Y
M2J)H"<F#(Q;90F>VJAT=$5:*'@IMN4!9G-S'$0/8;>GR/:HV",QHK.7<VOMX
M>"S5N\C@[!Z?B3)?+/%P65F!;]3/8^SOB5#O9Q83I>Y5X4]:3Q5<9,R@NC\F
M^_\S42+H;Y=-*G \<H-7NCMQGTX!N'UO3.'7E-7Q1I)8ZKWZ+;)OT[*K6A+1
M^I8DIGVK;[U>.AHG3PO@>?O[(R_'Z2-_\ZZ5,?H\<3'UQ+'L'I=WU>(HP]3$
M,-':MY.Y6V>1?+#;V5(L?"&(T$RY@U==TN1*+FJLXN 3N4Q<%NW+<,RSP9ON
MM.8</1&WH5,[A P]_JB1YI%A44!\]5R8LF/^A.868T;[ "WD'E ^/JG7A\0A
M>$\O#EP)?'2[?3AW3O-'=B?"W*=_Q>@]^].!4UIB&-FL4:Y[&P"T(RH[_#5>
M6_+BPI TFURJ'5I1OY2$*!]._Z18/.Z!8K ,G-.*576W 5RV4T;M\42#B.JU
MG0WGO.61U7/91.<\1Z+ P1204K8?V'9&3Q?/Q1S/;Y-WU>R7W1#,=C'4&OOH
MZ];&ZB%JH JO/K?RA[9WS9YJ8//LI.NX(;LK[C$.[=8P402Z<&OF$HY"!?1>
M%9]C\*N6DYLW @BSR'P4?3R*]\POK&HVJMYUM%(D*/FNR4IB?^&3@?Q./ZN<
M@.;E%_FS9/<M0T\;3>'@O'P%7T#4BZ7.)$K*0?<JAW%NQHBF9K6D5"X!U@$2
M(EG?G3(_R* TS7O=!2U$]&/7J)%8\A>QQM,;;S>\=;848.6C:"VA([LVP_R#
MW$'UM":%7B!RQ8K+Y">O4)-)N:@?'YD5!<<]I^B$++3E7#KY^[S2!RX!OF&,
MX=7,X>3ZA/B\$<H,2\\^7+P7!!.[^;Y9,IKWW&2U^YX3>;D)@>2SA@/QM>%P
M[-XQ!+;>UX-!O71Z,S52Y#R@AJ-$.(#I=)^B85;(86QK@:&$_G%-$\:G;FI*
MD$1?0,2'%L.QFKF5/?:.'KNA+W,1J=>BP E5I?!R>,3'>D+IJ:N@,QO[OH[X
M(^CU?:-CZ:,!&J+TB;KEE_)Y(ADD 'E-E'O3SN97[1>?IYN$!YEAJ"G=Q_%4
MV]2XNY.!^9QN56"S%D==?35@U#%QG#FB3.1S\/JHJ5_=V[BS,^Y$P;)O5Q"M
M(UXYZLL#PC3RQ4)"AS1$(AQ; L8[)?-X"Z.3$")*R_ '.70ZD(+@"V$7OA])
M+/5.'(DM'U>R3@T]<KOUC.%;XD^<(MO,POFBV:1 DZ=;R_>W 0JTPX;P*Q.\
M2K4M@2F3+\B,-/TNE]A[+SO2Z*9-5L^%KZ%D,Z)B8X/F,H*)%K]R5$=]W84I
MP:R'OWWL*KP2[D5AC)3]!;DII7VN@'YLJ6#S-D:/=/X_;<__5_V;&TK^K[OY
M;PJU3?\;4$L#!!0    ( .N!3%H:)9F31'4$ %WE!0 2    :6UG,30X-3@V
M-3 P7S$N:G!G[+IY4!-[M#4:!T0%1$#F(2H*,LL\&)-SY  B0HX@\Y #" @(
MB( $#<E1YC$J @*2B C(9&1&I@@)H" @L\PDD1DD <&63"_G>Z^^5_7=4_7N
M?;>^5_6J3*HK?W3WK_?:O?;>:Z6;^X4[#SI^Q=S2'+1O_S[07[POB#L%,@7M
M^V]^_EGDO[O&/NY[D,CA_;V'V ?VG0;M%]EW0&0?EPP"@T#[^/[/ T#_UV??
M_@,'^0[Q'SYR5(!W0-UQT/Y]!P[L/WB C^_@0=[>:-Y^T$$1/M%3VK\?$KOF
MR7\Z](3.@\<%AQ4O5;6+VP[2S^AZW7EXY*B$I)2TS%DEY7,JJGKZ!H9&QB:F
M?YB96URVO&)WW=[!T<G9Q?N&CZ_?3?^ L/"(NY'(J'LQL7'Q"8E)R4\RGF9F
M93_+R7U9^*JHN.1U:5EU36U=?4/CNZ8.$KFSJ_O#QYZAX9'1L?$O$Y,4*NWK
MPN+2\LHJ8VO[^\[N#^#GWC^X]H$._$_H_XI+A(=K_\&#!P[R_X-KW_[(?PX0
M.<AW2ON0Z._7^#U#Q4[K/#A\XM+C@JKV(XJZMG1QKSN#1R7.Z%'.,OZ!]C^0
M_>> /?Q_A>Q_ ON_<4V"! _LX]V\ R(@&(@]Q:[#S-? Q(D^A$D:37)]@\(%
MQ7)!QUJ<"U@F=4!H6/%J4^=XTG>V;P0CFS0G#'0PZHZL[QCK,1]E3W9VYK^Z
M6R\A%!3H)^MV\6L#'_5G(>?T<6"&"_KC  7!$6:Y<T'=:]MKG*,,+DCE,KL,
MLRY$%^""KF?'!&Y3B560\_/'CE*A_!^V4>,)Y_490**WBB-!YLL>>F)^6]#A
M:+YSEU&_O4,1!*+LW&XN6J[2<SSVQ@OBQ[E7(>GH\[?Y4UO\.J:UNW]V"2B^
M'^O1-I*3OZIIZ>XI$?1H(:H3I:^:J9-]C?+:*W34W]/;P5Z5)"1SN]RA=J1L
M8$^0"TJ,A1IB!D& (Q<4PP5)8AA[,.HIX;2Y[[]!Q;F@>2ZH<XZ%)N)-U#:)
M5!$@C(>I39@+.AHFS+FUQ6+6,(2!W! P<?FK+Q$(^8#Y.;SP\X??=VDNKT)0
MP5S0RWUT A?$S]'D@FC?,>1+8%GB\M\H-2ZHG0M*(0)L##3\&A=T'$O"[YVE
M8P"[9YAMO^REF026M2%V[OL=703+\"N,M?+/E?XKP9[C'6I!&6"+ C"6RB?8
MSYK>[6\DCE)>]^:>L32!([L%YH3_1$=/L _]2TQ@QO&$KLV]D^"C7! =0]WD
MP! #^2<P9$7Z$B<)!>:<6 2S)G@P/;D@,6O:#[9<ZC@7)/23EQ43%!&ZSHGY
MEYBP0*(I+9)]7#@. \ 8D5P0F+#4GPS[EXR^Y8*2BAE,3KIY(!<4STK@@O*A
M"/Q=S._X_Q"6!>N/4XQF3B)_!Y$%!IJY(.SX]I(9F'&89<S+/(*?"XHSYIUO
M$(6._H(A#R/97)"%HCX71$*;<D']>*V!9MB+@?\0V+]Q]^?V2RP0BY;C@@:U
M>(GO>$[B@O(@/+ PJG\+F@LJ?)S+!5&(I[B@)3CO]N$_^_V'T ;_C1([K)^#
M%JQ+L&.8Y6Q>]BDVO)SVX7APP0R]61AF\$,?AC[WB O:+N'=P(%EW?\8VO*_
MD8*#6B[DG (GP+Y;\?)/+SG/!2T.\.#^XNHOKO[BZB^N_N+J+Z[^XNHOKO[B
MZB^N_N+J_RZNGOTGEH<TSA!&JDT14*;XQ6#\YF*JD81NCN(02X/R?81E1YT2
MNECG[K&@<6MLB][R<G*Z9VWQJG=T2M9D:#*9D<"2Q._&T&$I*+OYRLA=-&#>
M-!?#LJ@$7)U=X:) /74T B&\&NEB\Z)^?/]UL:F49LM8W5MP@_.$NLB_T):8
M=B@7]/4'Q@?+U)C=SP4-S]1%P3<TN"!E69X1Y_3Z=2+8-CNK#$4*'M2F6)D)
ME7@?[8"SC/]TFMWFO8&N<@0GDRR-V??Z\34% A99K.F^CR7>ZP'1IU&WL0D
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M$G63E,-11YG0=S;3VV3]9?!)*(& %(VN4D$98JHZNOVUJ7".'DYJ-"TA.4O
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MDXSHLZ)F)]3E^9C*3?I\A9YO'JF[("O0F%/8R#.9&/O!$&B(CNP'/X%S/Q#
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M%7I_U?U"9!AUMHIY+0!J&&2PM=BSY#S,XF.4.#4,LXQ18YO@R>^R3*SLP.L
M%]3"BW?-0WK%689.H0@8 *<E=+!U.4<*&%:[T:T,V&-&)!E3)YG0=GIY5H33
MR1#$WZ('86-0QD7N@>"ISRLZ2*^Y'N+;Y@;.0-/8BU%$S[9W%?)&LL52&X3E
M"831X%]J=OD!*PI!!../^AW@J20A:Q[1='DM?T)F \]21-"K.&K+G+-T/Y9U
MR/=>=S%GSL2@AE\K%Y2,L1W%U+00:P*(GLTW'KPK>.JEMO@%4>G3F/SL)K+H
MF6_?:(=]N'=\4;MT/D3!:^'<'76],/WX(M,3<U7([BM/?5=[M*-W&DL./*2D
M#C -$\\;H3H(@S4)@)=VQR+R)G755Y_E22F;J#>5LJODS2UX LXSJ<NG"BXN
M5VQ48>VBW=%1=)DM]H\S'=WA"8%>(MT6'(<[W?9NK V\PG-LQRH96E;T-Z6Z
M<\M-%NF04Z'W2Y?;S@Q^7ZO/'; :523&]WQ;W.TZK/GFFU[K:?]%__!F_A@$
M!9O"4[X9G",65$(R+Q,A9SY#E=%#Q-H<X )5"[R2N(=)0AG2ITAM@B,[CRDS
MPD[Q?N]J&T<B-,!._B$;UJEK/M0+(W&V/ZZ^'7%\#_-"\*0?1P2ESVZ$P!C"
M/,]+Q_)TA!3,9TX290)$^+-3J/*N/&T@'?#8O3(=N[1\SZ8DZ-7/#75OIJE[
MWM6AES,YA$+0XU+F2<[0')]>2"SL!.R&UF2-&4-HX+U6\NSIMXS9%!J>;ZH]
MBLHK7?")=?5;WY&H0,^2*UBE$L_(8O\]GS>EXF4S'F9^)7!/A<<5SFNY:=5^
M>0M.$]Z-3UIT6AQT-1-.T-^$)O>N>$XY=PD<R?JK(#U+XNG(N47QVT#N=6W[
MF^9V64K%'F\K;6KB#(<[6JPSAC^BH.VC5+=FU8$U9!#5[XC/NV_*8*F!V.U;
MXXDU+N_.Z$*L)1W%'U.J $&;"QHD;]6.3 A1&&>E8Y,E(1[8_0GVUT Z6 1Z
ME#.*X=?'\P5.IE4H: */Y^<. 5.F3/=A?P5=.C&99>K_8LW$AEBBWAO$<V$%
MJ^.1+F[956[RNLZNUK839GU-8GL$7H>(C(,*8MJMB/,O$<=00OY!)4BK/]C9
M;5#$S7OV3TCRZ2E^U.@+E(84V-M:((CR4-8=9IKGEFWYMN;R^^J:ZOC/+6E'
M'G-L 0OA?]Z@O<(HPG9_P-R<DT"/S^K1^;ZC3P+V](3? #!-*_:>,R,S.T\K
M?H<HC\1W%Z]^7 ^7_V,BH"=7Y'Z>/!S>0$P>)Y_O9C^&G6(J<,9Q,L-$?]AD
M!HVP :89?==PI46^UTHW.>&2*@-.UL^[, !&;G%!I&P7<'SXFH8HB>P2GUUD
MP1>[A\Y0>KE6M&(2C _TCRPE2TAD9">^]JJ98$CX/5UPKH2H QY9CO9>.L])
MFIU+TMC=8K!XW/4[Z[ZRPL\<T^UCXS7!3J5QJ>#Q!2MAD\<EKAF#\Y"[SNWA
M1@<2D(5)2-\V/PMR$\LJ'GGLW(?M=4*<CO!.B&RVKVWGTH2-)_;#6SNJ6\\;
M5^?Y<[YV!/"ZD9?N4:.H\8ZRF<WU(L(<:A]/"=Y"C\%JL22,H04P2)U+GA5E
MXWB]76&"3)SR.$*_^"V?0CP>^ 09>0V\(J,Q^X[=$.$7BO&E#\BS&Q)"*(^U
MON=# S$#^(G-W00@CWF1%4AOZ$(< %(\X"(KLZ=KB0RA%I.T7L/TVKS\*VKX
MXT @V<O.:$R=926,Y_O2EKYXO257PV;BY:A&D"9E3W97F_T:+<,RHN,[!R9J
M=I]\UM\4Y7SBC5&^MD<0*UC<02'J9ORLP:#FBPQ>8Q.%: N1*@R#2B &&8$.
MLIJ:P7:7A_SJZT9H5<WT;\0-L!!*Y9_7 ]@XUOT2UJT18D"('&?8?][:9:X3
M>A"0I1#_YA@!066!"J>&0UZVTC^A=1DEJ<H-]*]['MB[6>/W6MN>CX6N5OH.
M?)UQUFN3'V&[I.,<4VGJT"#2S^)0.VA7M#<_1,$N^1/]9YN[G6K[7V]_6M\*
M.JI_^V?DJ-H@^5HFI/^-\)$KXNAFF_*T@"%LWY]IP6=[6(K=MXER]*4CG^>?
M5_X5%N#<<,+G^04LQ8V3(.K[KAZ6?#['QE ZKIO!OULL(/EWEZD(Z=FM*5WR
M]0XNZ,8XJ0-Y54.%/?R2I4/G?X\!U, ;[32"(-+[\NA)0(BIR;)AET*.4#2,
MT1/L;-K:Y@'6Q5%]69&21Z>'-PE:+:'4E'RP3=+9A]WPL? D=<5ZL(\5XGT\
M\(.1WZ8)QBI3$2E$RFV#%M05]$G-2I,U+FBR"W'^;<[EN' V?MG[#Z=#R7I$
MX*D0Q!^S'+$KW $'SH6DH)29H4#-;@OP@/*%95>,LL\C*\@ 1?.NTAK9&Q@!
MEJ5_R8H(TM7\77/\N9+L#A>/)$K&*UG2S8AZ^FAK>GFTOT+)_?M@/P+J+(^1
M]J[(KB4J-(/IBK(=@4IK?)H]B=V],\SA0XY"57KW6;YY21?'=[H'4$GOJY0G
M(7DGQD.*GD2\[6MI>II=U'*I)0HJ*T9"XCP4>[;E9MNT8I$AJNF>#WJUH]95
MQWK/9R[[OC.+C"M(S)(P2G5'5*H"G:;[TNT73(!G \)GP8[)VX)$LF#K")T+
M2M(Y)MZ^@%,%XLBC.I"UQ*TW1\OC.T(E_/[NNCTN_E>6=]I[4UT<OUI'2[43
MI,SITZ92UE&]M\ZH99JG">XGS] <8)>T.%,0DVN[(/8;O;PSPRUPP_7[3&.4
M%_%S1;"]1@FV$ZT*Y!&0)1TIR+%"&71-4:!)0X)F,-^K.[*R*S<NOWST&G&:
MW8BYL0+Q9]X%#@W/)]<7S&M-/0GA1SD!KI5?OKC-K-P=1%F_2\?(S'P8[*UW
MQ0@'P,N0PTX-%K4RO.YF)7(GZZUY30UQ_FV;4BTCNQ,_X=CIX"$)WS\%8'?%
M 7&"Q?P?OLKO&6NX4T!V>3N%W[&A)LN OE/WW>0ORXKUA:V-P<DQH0Y])O^N
M!KNP5IAG_=J-47 &C2J9X'@=R&8>#\"+H.4Y?3C]49I)GD4%*FQ0KUE#^5+U
MDQ7<QMSO(Q&-+T8J-90>RFNUB_@/3I6Y3K7XSU/\TCX8(6*1V+/ON:#Z ;YD
MBO/"[)"8+6>LR]%Y__-W14<'>W4_>)9>N3X]V4YC[/RU) ^>6M2K1ALQ%#NA
M^ZCK2QS1<XL__9*>UOR\5OD[B>W8\U8K_:SYDSB39U>>F[9GALE=57%,.]<R
M?N;C^='H6/8R)YP7.)RC@HSL)-9ZH4X"$:=2*)+KE10A@5TD<-];_-/0I-_[
MN]3NSJ:<=+/KT9=HY-[[A>X!B>/"%1/(^U?:GGR+0#Y$AXZ,&QH:-AA*9F>+
MS<S,#&CTC8Y^JH:'A85!TM1_2(KU#*@/]ZG5/NE5U'MR^=.WSB0E&7;*V9Z5
M&^]L$)G7GI=9'(@KNF1?PKIJ?>-=E5199<.]+V5;I8F5:LS1@+X=6(81,4D;
M@B#_7!*EEMJ11OIUY<PU<:+)5^(/'%[X^'?O[8]G"F-[;Y\GS9]_6_V51"FU
M*&"+<4:XH#IAEN[<>@.OV\V\Y8+B(]E9'"-,AS53 WEW>X-8"^/5J7,D1X'3
M1]]\X,G4BM?$4$X.8JIO;7+&%U=OWVID7A\;>Q*,_4CRY71CZFZ ZP$@C2FZ
MBA" "J-['?$24 6@;?L]5(?]-#P-/E]C324>6WD2B*!CD26DN[A3;=BN7(7R
M$M/R )FQ/':II_@LMGCU7D3?J[<!DC)9>+K?1B=CFV+8!7[ !;VUB.'( 34\
MJ22"$F?C*B%"#%T;3@=#\S$7='@\V6NH13)(*7NW-=)\6#TBOV;%Y&%T ^F'
MRYOGZ(%&]Z=9AS)ZB/.X.1F(-/,BY\O<P39-UA^C/I];1"CNWN1'0+9S@LU(
MA-^PWH 84K93033K^TK3Q:S"LEFSX,DM2XA)=-H,[;<S!G3( S.TG6G,N8$'
MNG*(71O-;#'*G*AOSIVGH56=7) _)>S6@.S3*U+2?9<*":I(A)\E94'06K6J
M5M6<T,J^D,(($;?HPH%Y#F\,11"C]$/Q"2AC\C'1CZL^(0EA4'%*16%RZ5B_
MOVW$:W4Y-5\KD<1T:/ZM9O'XW(B;UTGZ\+?L!Q!^YM4U_(FV,UKOL8DRCN^1
MX8AXZ+G!-A.6-^.YB4W>RW\<V6OWB8;D-UIU:9&6;<WT[D0/Z^,&V*@7O2^
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MN6H-WX?QM7;S%8P3K,-P)RH)+HGG5[\FL)9XAWU?%6VL9>T<YAT!O<HPWZS
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M6TWT_B&;(4#;B_J!YR?C/Q=B1/A\P(6 _Y&(#L'^Q[F8>5Q_,+H:ZPY^8#'
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M"R'EE P4Y]LC_%>.$)*NLC#"5R1#*8#4/T+(CW1>_W\RN@J!LA"RLU?TU6<
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ME)R]_2SHG/($0C5?'+]LR4BK*+\M]%8$ :,=T[EUB4E'57]5*J]@_><11-:
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MRU E/7_GB@"SD:%-\XA?;F!GWJ-TC!>L7?_U2T9$/):!L:9@H!)Y&U./<@A
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MYE1AZ%B<)*RD)-0V"[>G#J%"2B)4#=J:_S#@O=IBSR3U;HHE('I)N[&$NP)
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M-#SMV81>D]>G>CV^LC+ZPND<?47V\4&]%QW_G6OF_^.J^0]ZFA5TG0%)-H^
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M?!3N63S9/163'2$(]1G"F>/4NZG=-(N9MLBP^)(7.$MR]Q'0^/$O]9MJ+8Y
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M,P,!5C$3#L?*$YU(EMK:E@&*JHKG%55IEO$D$CT_<6B5,GECE^U)C!'U VV
MBQQ-5[4L8"K\- \6^YD+!$7<'%2/#FH'@\3Q!+4_/4+D:%^L(.C1V2HJ-/*
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M*^FUCK^A1)4+^LH%J;2BD:#8:\R EQ5]L2_T_8$?=MJ^J*2M._I*9!LUHB
M1]DI'!,!&CB5_A,#:K_%'\1%[ R.?F7["L9F(#O1.5R>X-L0U'Z-:08[ >TI
M"G!G$>7^6,VAVT4C?N3UC/,KFFM5YVD;="1AP4&'JK)O+EW263B1JB8QNZ2F
M@OT,:]2(!FK7=S!!\X<SJKW7S*&HW[B B1S@7 _*NJ/@7N_K"JXO@2)>"4P@
M:D(!^7J,9;'3"YO8D.^0T;<?5VT3>E1Y>QVM>CGJNI3Y3EAIU%PDI.#Z*T(
M7(/P&J<ZXI5V@K'<EKT^&!(VLI;P20_IM\?]'7&9E2]GBF904> I?UE2]D =
M^H?-+619,73IH^7GMH\%88]@.>"_^%4MK.^OC)L@R0GKF6U"'-.)L00"P:L!
MT"S 55B,#\O\H?+23Y>X-[;_)'8V4'+6C,P%,7F/VQ[7TTY1:<71\13R,?7W
M/L25SZ8I0]5J+&,WU*24#F!53S1UB#7#&L2]*K503"7#6X%B.5:$W>Q.BP;7
MT);33TC=$M5-0_L[9<):UXT]O-W\'0]YCU-_UFUP^5AL//GL>3<OFK[L%4%V
M(T[*8Q;'JH\.T;G!D,53QK9TE0B:#@.WEPH;<SEI;/"75A$!&_W8;&F/G?5I
MI<B>LR;Z/MOMJF>WW9@75Y]TP/"!_M!O:N/"GE!'J!95 L1R0-B,2W?TK^?T
M^\JSKR FK4K3,!%!V]6"BNP!A4UL4PC78)AM?%^,:\;I,,ZX;H8B3H"&V6>F
M'GV:\YN_T9=S/:O5GVH9*>NA.>]#5K<2FEE7AK9HRH6GV_61]@7,9H:YDHMC
M=G,J(YJER2RC6&ERSF_"BK;)7.XG5[-N>'NU5$_^Q\@OP=(H5T/2DS.EVVJ\
MU"[?=>TZZ]JK>F(M=&58 $<2_&5SC5P=9A<+.(9#+7H-)8O$,4O0=6A8Z<"N
MI.G1<V7WQ-=GJ1,A_/V*Z&6*56 R1W;/H@$QK7",?G\)E\3?_R0JB-?[:W?E
M[EAME^\Z1E[A@EGU!U'T:>,E'&2U"RJP-<E)^&1SZ [(DE65QLI'R@12349Q
M +TBM(/7YFHRM:U'&CA =3P)7W#@4J-W#/Y:_>+6T.KMD;=G",B:H@7,+D3S
M2#@>"+0C);A5_A]:FG!7.)OL\- V]G@IP#T(68)!Y%2F*70%>#O52-:98)K0
MZ_@)#VUR06S3W*6/!25T&VM3OGMAT-87QJ5MLY.Y.H2?!-4].V[^4)/I@=R.
MQ#Q,V_6?CF4@"<'Y ,6(23NRL1@Q,$IG50CE9UD-J#I.XBU@5NMF34&!"Y@!
M(9"2P$;6X<9I#LAZ%N1-4'BA[QK!.X14M1%\3/B,P9ZYI"GBWE[ R)-9/PFA
M2#P4Q8)\$#WT0*"J?8( '6,,4FDJ<;]KRW_-W":5"(&D!4R#SP?F'*+'ACQ8
M\JUJ&GQ46"FL)'05CZW!6((B1/N<C@.APJ->._[ZP[PAUH"%S'E?O2W5:I^;
M%7./YX]9%CJWW+?MVWZSYGE-N=]R/4N5JW W2\9EK15L@;V@)4#$(3190\7B
MMWVV0DF[C)-JYV)9[XJJ1?\BRI!I5W8369(SJ\E,"F/%1CP<$496(QV]-MLR
MF]O;4R;T6SX^EF&WHR@ZZ75.[<@(T: FD7'RMM9D:1.N2#=LARH >I19D&<L
M$*:(.1XJL=4O6M\:G7]H:%-=[_8MCXS%Z7C9=+7;CCKN!U9SJQ\T=:Z *9W_
M/6>T7=D.&]2J+D$DX+O)3RLBF4MA@T[7W7328>&S3(E?>2+6@&IX8#9@F_ZS
M/N<]+IVU>5ZMZ>F<#@)D27BU@)$01.3-3&.D&_<<AR9^&Z&!%MP&9!V#J+G-
MM.R']$6.'WD7'T>ZVG?BK1DX9?3IX6\K>\*[2F,LVT[_\YGO_F0@B#)_<CC)
MV4YWZ%&J+2YB!CM 4_FB3#[5CT-6BP&L3'P9#E1^8FHQQ<(*TY94CRL,:RX]
M)S[$1.1J!*7B,A#SL3Z)7<;X_+'4BPJ78R%A(7U3#RN[SM!X?W91HMV;^+9+
M9CG-6(E804"O$-K%'K^IWAXIP2>>96YFQ ,63<0-=!&I9V;P LUDI";E"FRJ
M;%\W\C5$/<$#=V1=C8@X%R]/<+4^Y.(KNM38)6FC9XD-;[U>KIHE4+"2.85_
M_=0 2V6ER>'O>P 9JU\)*^-@"RF0.RI!&>,]5'UD 7/-[U4(90$#I$E'D)W=
MMO$X1[>J:37Y@-BY48&MJ&X+-55?HFLK."+I@*]JE^:ELSX0KR"TD)?#&[J1
MW9"6@I7(7#=BWHCJ]IE!IY:\=:!94CX]_0!PP\MTLF[% _!0>6R\ 7_,Q+N
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M;*2^,&1IC=;P@&1)MV]/I<;+(TW7-["6QZOI;AL;JZ#,W?3"9J$^N6_Q*S(
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M, ^#:C^%ORAQW]57:&5\;2K<?V_KLUF7_F\$40$W0KYZUNMTOL&Y=<@__2@
M_N&6_<,Y@Z]Y(Q__*29FWY6_B+^^IP?GO/6;?WY\%GC:7-??L\FKOX^S_>4#
MU\ &'W;7C'\;#A"Z;D5I)0]!Z17:J\D6SN]X@E[D9Q"+W)A39:.<FSU>AW[
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M8\5SJMMV,;9TI5C^MV0J>0MUS.1.U0O0_MZC _%GTED1.YJN=0QZJF:G)HP
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M0>%U6^N]4@\0EQ9=%I-.MX+M(A3>;HW9^Z+V2H4ILZM*__;0>$*^H/\KCHD
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M&'N!C]SX1U#*R8I:D)MJQ4OP\.@J0Z7+S>)[QA)%RX'>L@BQW8-".NM86MO
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M&-)I!X'F!PJIUN"1<JLDV/?^)Q7H$5OXVK:SI6BD+7:&VXA+9:Z _-%D#6?
M3U XX;&P*Q"10G/V5Q#T/4U[-0695TZ=.3LL2)8>J18*>^[*)5;C,\5> Q.'
M*%MXW1-E91')FS!..99IT#D0VT PY&O)\:F")3UE=ISET-AWW;"W/"1T[)#8
MF6!3_"#JF75?;I$NKC'G[,VR0+>$*/#]@$W^8XFW=67YL?+?PS,&>/^'1]6G
MI68P"?(%N&HL8LAJE*8(UQ+D%H($O(@,Y$'=(B8656\IONP_IVTGL(B>J=<Q
MI$_ GK ?F+!R[?Q9&'DU)JR-'??@^!)W@]O<L7F+I!AO<J-@1^_,X#)1S<K<
M^!)JSL?RB[1"2M"A.X6DU[&L)Z,.<[^X1T>$1T1ON/W^??LV=YW#;\>?/NI8
MR3, M*X19$7D9QZ9C%./Z"8B:>6A:Q)43$7:6B_UIC:0U\.6\KHXOYJ7)"<O
M:Y-FP5? A719VPFOVL),$X]R\7#:R-\W2*^WW-1F$-74$>%Z 9Y5[TL(7\#T
M<XYJ\H44XA6I#ARO=H1$C8CY554")"R#]PEKQ<X.%T&GD\][@BSILRY+XU^_
M32D,"!V41CID_S+R:VF)P[J-LEOKL(.7+#^/0KD/&:&:JZPSPG?9]9PU"YAH
M@H2H2NT21N+3+^"PKKM@K.:AJP6)<:IO9FHY.?23GT3(/F,R[I@PG%*IT3[2
MB^<5\%,.//\I^]#>UZ6O"UD4":&;O(ZY _9 XV&B&-:!?"/ 9<U]'&T>ZUVQ
M/^A7"D@&FBZ-FRWI@7V,;B![@EH4WA[U(+DPA1O[:2*FS;[?+OV>8\B!+=WC
MITA73 MJFI?,S[D;0+DH(>^'DL IQ0*F27J-\XP[S@:=FC@ZB&444PO*4!^
MO<"X*\Z>I71R8"=_MZQ=9\R>LY9A$5M&#U*)214\Z(KR9\E)S?/VJ*UW8>N+
MCJ$!0Y512]3A[HS=*$F]UQ3LU#PE_(1-(J^/+4Y/920\'&D'E(H2A\>^10=
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M>RC7R$9X+,*X-DMJ.N*_.AJ5,QSZF=:3V0?8_V'L+T2".DXR;M?,N9EK=G!
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M%22WHC4GF3;WO+[DM.<: +34</0Z>GUTEI75C-JTU_8@[_/UG8W1R1<C:7]
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MI*&B+G%K_F(:28%7/;3M'J[!#>N=AB(5O&&YSGZ77CD4C8 V+?W12#$]NNV
MB4WO+$*?+6M!&_ROM HHZUC% /\SN#MW_+72>*!R\E_/L)\U/[-A?=M[K$L<
MR-QA_^HSRQWX+[I>NK#R&0<%_VYV_[\HU*J[7JB/HJ]6=&R[$$FOA%E]H,4+
ML@7S99_8Z0*CB<4H)W6&;'K4N]7^SVS_O$<4493KG2<4\=>$4@K3](6PLF]N
MKM1 ,>*=,D7R&'EYV>R>]27T!W@W=$9*C".@^79 K2R7<^41W:CYP.*U7&R?
M]8)D(Y0M?ZL]>W31N]X]HEM_JOY+DJW&SKPG?N]V#%23WFSW<>%[9?8ZK_\#
M>XM<-28L9K[E N<(PTI%%I3_5SWZE03!EY41N!LB[";;75VUB?#6\6D/5:BZ
MKX,\N%X8U%^&BZ,'B$X(P^C;J@9MHX?/V*@T3@CC)UG0KKDF"71,O99Q7%7,
M,%62U C!T<2I]9COEE ;83=IF:;4KH,'>0O7.5)Y$+DE=S>8E8CC>Q1.9@<-
MC.T0#%43*R;Z_2CVZISH)Q.]/A0Q0[&XMRV"G,?551LP?H4ZI2J/5UA]_B89
M-\E?>Q N&G"TDW?M[/?I^YR]!D>]EKEXY;45K_0CGIJ9%QK0^")'S_>#\ZX-
M^)6(9>)LD&Q@,QMQJK1#^4O([+6@??<OX[?#@0U]M;IEL7E^\.&<PYN"7+<9
MTF^N?&NZ[I^UFJ^P59A4OO=X-V3W!R3L0,0%^A9,XC'PT-[H<GI^6]10H1RW
M*<R."_2/K6#/1M74EGP8"_5-Z[ZW^<3UQ:S]'I\Z#&GB%,U!2:U=BP,YD0L<
MP2:KC2$MF;%#<ZTO\16+;1"'UJ*<K:=. G_6+Z%:ZIB[/"/P#U=A[()/ RY%
MPNORL ;V7>J9P)<- Q]?WF[@]@BWJCNQ*,<88 -K.+*5JQ.>"6E="<BC4 ')
M[P(18UM!2X",MVDRUZJ76CK'-WTV$366FYEKVF>C.M&5_O3R8H;S#N^NJ[2(
MR/5J45C>I$&4L3#Q\?/8>0N_/<8;K/9-V"Y44C;ZE,6=.V\U?=[VH\ZEQV,!
MU_JK6X-NSFZ+M%SQ/7L((7 Z<["NUZ050;:*-:PF#.^YOBJC,6ZB)[2'OO:9
M^Q7+P^[8]'SP53KA Q=R)Z:G./]IY$\_(;2I%B8LH73A8"1][%(]P/]RW@T)
M.6VNXM3+/F'('+L^8<K?NI FG5L!$T'WGFR'I+=^'06^\$_UO7QW:O5-/5\H
M\LB#'<D7:NO9"]EDR$P3UA/3-A&2N0H*\*HNXZ1:E.',:45<30[\E/69_.O;
M)=1Z.1C'L*=WWM IH9\3W[_WQR_7UU5P&FS):Z%@$I!9*'7R./P\ITDL9-,<
M35FRUWD&4><%6X7].WK+JX[,SJ2]K'X>8^UC>=+(&17WX>:-5OT#-UC[$0>T
M"T0XOR_"-&AHL48S8#47SURO?D-8#VLH'2W>=MG#[IG];JI"?H#UPZNA>3^#
M^HEE!<4M7;]/N23*J0Y^B>_HLP'*P\>CBV=8H(]0FB^IP<P,@W'?OPSRL4J,
M^HT)1@2?#H[D]_<KRJ'!"^&>4::9*0=W5/>$6SF?KJF_[]=-?4J_UBO6CF;[
M/%)Q5;F$2[38)=0+SHVOS*TP"K DH&&]:+F5<UM6MHWO7(KCD47_[8.6\Z-X
MY>F7@WQR&13OFTTI#8^Q[@W,.!%&MYIYE#*VY<Z1@X3*XIDLI:/Z3;9;2A5V
M>$[6F-7RT*)=/,/< =I6E]?)RV*JK7R-3@33?JX#+S7P_-X/^Y)HZ9U'^HNK
M^BQOB71]S[68=;6\7?%=I5Q5CT8@ =97[)O:P3)2=UZ^D[EBV!0@M@[>&;Q:
M=\_PW.#[E9M?QR99UTF%TOLF1CT[52]9TK)<JYPCS[-:APA5#VOB@\H]:#]E
MW\M,BY&CDT4B,?5A9^+=H:$?7]^]BW[_:&]JG>5,5\=]*VHKZ_&/VIG]2HLP
M<I4.=];S.O!8C.481*4_*$&;4/"6X.<X47TF)XA:3%G,[DB<)VR>'-LH*DY\
M]VX(0Z6U_&"+7?C$</,[^AWYL+7J(5,'QH#L-HD);+/\K)=I"8'R)WPJ2#J+
MZ,_X-OL.V,S?/-'/E[Y >#[]XW-)T41TD,C658E)G)F/<525A/GJQWWX?<7W
M?,37N_OF51H* 8) +R:BK KL+Z51E>YTA^/5?:6BU_VSM(@2G,F485E;]>--
MJ_E9HKM;B_\]H9_2?F.M/%EOF@/MCH3O8V=I2&HAM$M^7 Y=7$*Q"2B\+L,,
MY+4)D[AHOMD2:NT2ZA;3'F)[@>0VST!E=*N8!YO9JS-T%@1<EHI;-FV?F?4X
M)M?XZ *^4]9IO/TMF1"NZ'/\3U4,N568J-:&6J1H#,,:2LMG-;M(R<83D6-&
MX%FV*K^$@A776^=O3?RW4TG\7=!OFXJUWU\[:W@Y+S@2>Z[8]?,- IH0((%V
MU,)Z<^/HF02E ^,$E 9HJ'5QQO0Y&3D!=I>7754;\-J[3)7>O@-_WA1E"8>S
M,:UI^]TJOA4X"+J+)A77[LRGK/*W:&==Z$[<R# $:3 F2^8](WOL#X62-2#B
M(0#![B[M8X.V7:23?0N=-+:P*AE(*^>6A-DG%O/&_#O*W4.HUC1;BY+^@QR]
M3&W.1+&LN(6U&C8!-&\R,8R#O4*9,8"+M7' Z4#>SNK>P6K63!G&B_.F\H6Z
M7T2K=KJ@?'.+JG0M?.+O]V;(9[2N'">KG9D$:#),*Y(G]?$F= ?UICD3!G/(
MQBE:/M: D 5T2@0-\K"EZ:1="2<)9QJOGA^8IVK..+=&]?SKN+\X9$A$^',)
MY9%XE4;YB&*RD"7LW 9I7D=<H@<*HUX0K,UIT9&1MYAWW%_(*% E,SQ5>:5O
MQN>@<U^.;]_RV-,F.2B&4; 7.J4\X-=9M'8+\QJST_P48GTL<_0)Y[IYRTO^
M&>6Q-N#,5YUIW]KFU_/=Z\ON])&/K_SL^2N]0:VWHO[82R&F$V]]-@+[//<@
MXG]^S";6)GY *3371JALCS5/XKL\\7@&W9PPV0.QI:-H\D#QO>*7C2)',ZED
M2XB)[N"7NI?7S>MCG _7V>WO<NS_?I>XG] OEKPBWS1$5I/FIJ W B9IP0#I
M-/#WV*IZ*$8V'BWS-"1H=6O5YKCV?P0:QSA/*+_P@RKQ]Z*#Z#LB[Y]/?OCQ
M#W0"ZQ(Y08@68%E-N^$5YC<=31^%9#&WJ9)F&%?*I@[X>G'7%#^#BMLEJX)!
M0E)UC//Q1+%#0V?GZ*E6WPJ]#QX[*L2CMH_??-0I;D&H(1<-;[JZK$D V-M$
MOZ>8([>+%X:,"(U+Q1'\^+:L \N=5G9!OF,Q5Z/T6&:U["HG4_=:2NH6RWEE
MB/Q]H Z99XAKYJV@1\N\,@!GMQYF!R!TAJ(#@!(/H$-15'E%05Y!R35*;3Y@
MCU8,#N43DH+_=71:Y<M2%+:7':C<*:GN>O*&T?77];F;DN7(W  Y%2*LFB3#
M02YJO9!,O%E_N% +21;T')+2*BMUX6%8J\EVMC*RU?<=3^XCK(I@;9S&,(/:
M*RV'N'_^:WFQIJ:V.A&%?LN#=BS>X&^6 &YS&VQR#7J*EU );!E!;'$"?/MA
M<DBT6]XP0DCBZL$X"K[.N/4OL^\U@#HV?_*7'6][VRC%KY[$QN]G,D/_HG^=
M5NLT0%=PB3M%.RM26^T'6!NQ[KF7!MQ:HFGB8KE^;I[6-EC4;_4UZU#<O^CL
M/N/MNQ/DUO=TWG5/!LKL7J%O<C4$: H9I3: /-2;6#?%9ISD\%%<,VMD;.>0
MNC-(K@KV!363\M2CH$%E"91)FS4FM]JW21Y<*>VT+1YQ3-UJ558V&Q"+W\SL
M%FHRM1C&??^K/DI4:S[O56^84)CL["N%M9Z-39OL[?O8!P>6AODN)L^/'AUO
MK^<D53N%MO@.P"ZEG=>#2\GDD>I&.#O*-?LO9\H6S19RS=_8%Y]$L&Z^O$-Q
MBKZ>L3Y><66@&#*SU E2L;$I5K#%K] ^@1%=8Q\41]R:MJ%O](^VZ2D]?]*4
MRTG/HT([86B,>6ON;B0^2,LA&HZ^-61G7U,L1XLC%1Z]CIY%4/INW[E30'NQ
ME)"2S<P**NOXC\%G'QK?Z$#.FD>7EU!]7_:]7;PLPEEP!U58M98'XHH_>F!B
MH+P!.\QKV4>FU!=$#::G/86X<I,Z*8EZ=#<?^FH*4<J@EN-09,+MVA\.]',C
M^SQL/+52KM]1%T$=2CR\#5I"%4!89ZA6MAH\>P^0R,T3F1;0GB[;;EWHN@T1
M2\>/G*X$QNHY,FKPX>SOX2/4X)/)X6E>'J,;/I[7B"XZ7V4PNU'S$Q8V^':D
M+YP81ZX0E.1/^EZZ]Q3R5HQ#I@7TP./],U:6<XX.!9TR7%+6ODE?XR[^WJY"
MRMT/].A#N21M3%R?3[C3=O=ME_K_O.6(G76B@N5*M38.>(9;-86(A"I/9K?B
M<'T=A+ZB=$54D]H,L.I(*@#'RFCC6QPQ05*.+N2OQJ50BSJ?OC$>?%=PC&E0
M]3)YIC#[RZ&'A(M,>^8[[IHE%,53HUF @432.<C3!K<*6G2&'LI2L= 1QBE9
M]TSW3_3+G=[]57ZT6;R>R,:H4U+A,RTN)0S7)[2-W;FJX.V;(^:>L\K]:0G%
MD;SX\@HKYOS>"SN 7V2Y;'!=2TM6_Q33J)[//=O+_TW6,%V0Z-#)V4"O;/%-
M3Y4_7,%S*<OQ+[]3.FSVL<8P7.1N*8Y(';G!](4= >_6%H3D_0&QQM'I6*,E
MU"4*TY$BJ60GS_.0Y*OB"K; ?_;2&"Y O?S+V1AL:ZXMB$WB\8-D.<;.1-!&
M?'2$!.6T9?O-OLL(RG,NFNBS^>'9UC&%G:4NH78^57JRA@4,) 0&K\B/=JFX
MK$#)<*7"!Z$7<<18K+8-5V/*9(_!&[EGE*=WJ\ "]*I>G;%?[#.%MP++J^4$
MO?/G2 Y5MRES)49;/K667-YQ)N!KKC50'C_.6T?G-IGL>:X>!(2W&$YE=._6
M[& Q[T]653AVXV2MO6M%@&+47MY]O%)YB7O]"DU1HMU &F'M[ZI^&1>>?@8%
M?T8BP74JZC(B U?]HWI0[1=XO*(OO!.[COXV>M3M9$-MQ?/*6.8NNM1&Y)UU
MTH5&T[V[XJ[/IA4_Z[WFI3.-H3)A& &RQ+7QD %6%/3Q7:3HX:L*GT;H(+;5
M"?NZ'JA-Q>^:MLO=7M<[/^T7XGX@J]1=52AG;?)M>=)A3ZDU),89GBO.[)JU
MQC%?I*K7%B+S>)-X[A-Q.'L?>.3NKJQQ=,>PW/+6UL.WNT"O(Y=NW=9HLZ1M
M3OW[SE:M4XM?FN;B"%H$9&-7#\-.$&ZYHP]A@Z-QD&66UF,HC.AQY"LMZ+1[
MM=5)\)_ZQ.IG[^ZT9AG6\")CGIYWVWRB*WQR<^@C;+<0UN5YJ<J_J-)M+80W
MU3A5HHW*<+&=JW\9;^_#"(>BP7@25$B3@W+/O] ;.6F^N6F@14N4SC\9]+^,
M'')^NUI \FV2[9XIJUZ3^\/X['5C*<(70ORUD:W59?;_L+LIL*)?'2?$&X[+
MSRS>A,DRK!;C$!"<^$?_G"-55CQH8XQQASCY(5$#-;[>*=ZM>VH5!^Y.]+]Q
MO",>\_/[+<:,6<,@(H,%,UM86_@1/(8[./?*6%?9CM_3&./1%I4>+^<E^6N^
M /T++;9:1V W3YBL!B,380>Y@W(X-RS-==&WCU8>85%2,E+R_;(UKOPC=X*H
MR^S&KN9[ ZZ+"MJ@ #L!P!N%P&!M_&?H^B//IW3B$4[+M;M-CH9^:1T)M"H_
M[V/)P34IEW(\!ZRL"_]VWU'9T+7WM@;0K5Z'&'X7497+FB&I,E@+_F+O'E;U
M@BI-".M+U%IMZ-;OEEFRBTQ-J/&J=!NO:@D%<%S LOFN:Q:D^WTRX0OOUKU>
M7+2W\\.>T:92 6>'95;\L;N$/F(*^87WC!(LEG+9PF!R,@N]A)*9078R#YJ6
MSX3)!B1T2MK%=N^M8)WBHGNR$.3=;3V.[H7THFFE=9.!SF+]IW^R7GZ+,&BX
M_P#M HXHKD*F2D_Z0<9J<$3V+AXT:@;&K N#@DM4-7U*]X&3!VZ&VALTYH].
M"G[NL=70YJ.C'T]E8DX>FM-XV^NP#05Z'B6^[U&/JHTQNN^Y(TD,/6%<D\UU
MYO:<3] !6Z/.U"289'*S0Q:7)[SSN9^=]C?]X>U)8L'GP?"_".M8EY(=_3#P
MQG'%0D:3QG'[":@6+#@6WFTW&R8K8B5,CU-6W$PV$!-6UPC-OFG<K"!E,AX%
MD'O8,XM*0_4_DA?\L9_YT":@V!WP*I,_D<6W^IMRO4%"*NQ3XDMZO9--;  C
MTR.03/%P_N7G<Y_]K"*"^F_V-.&&&9UT7WR^-&NF'W!6A ,[ZX!.Z6(L%;:2
M$O7HJ?Z@?Z-LI"NL56!5-6C;O=EW>#ALT>X47>0#ZH^3IJYE&M1\FTS]J_YD
MFY'E@1/?^[_?P+*9YD#6[.HR)'7B;$;U$/F-$4H?JC55:;;8&[FZU8A5BMT@
M3U!R2N3H\*B;6JCBG*HV].; ;I08$#_2^NGB0,$+(+VXY -]":7\W=V&/61"
M/[R$JL+>F'](.H[XN!:DW6&?F ;2?O<,]GS^<@@'.Y5-_B"D5\68OR)HE3.<
M2D-S,>##M'2AIJ(L+?/>D]!L7,I\@]^A4:>NW+K"%E,_']RD"Q?6Y:JU%@/D
M.2P,B=G%Q)"4?F<B&JB&1%W&;R^!G^RS/;\4MK+6ES/\<"T)IS.^CJ#7J>X=
MOW]XI>YQE3NXW&G'&?1N)Z]EL,8E:ZWKY)(;/U1+J&2UWE1R.3W+C:@UG5W8
MF%"V(*?4&U064>S?=M&*SK77,+=5#);^L5&#1M5SWWU;X]]:];H("B58&<9J
M,EU0>I!(U&OCBK\'YW<OW+>2I9[).9QU&@K=T6<VL&GUA^Q 5@@YX\(W(S]1
M[;'M.E=V!ZG^.V?U"=F3 >9H#WQ4_9IL[ )$RU8+FUP:+]F=@/=R6G(QW-8[
MD*/DR+]K+]MNG1^1;.XH-BXF40-ZMU>3_B8/\%((E;PF89K)+Y#+N"29N1PV
M&6W<%? 97)I@\Y0$N$TO=D-^YMWZS:.@>V>QPECC?%_5Z-7P>I-,R070++>B
MF/-BEG2H\H/62YY83V&MNB\,S1&BIUC&:CT*WE;D:+$^4X %;6LJY-PU4.VQ
MBDP?\YA]: Q=SP_H2.:Z?_OR\J7?3NI9OP,.J25UX]4^Y>4FQ]'W<(*U3"3?
M5GW-0I ; V& /5^(V,WJG9[Y$Y(J17YQ)[B=A9YD8;J$R=4XMB\<W$J) !86
M&K5;%9@?'4DBV<V3KR.<#@:"MX)/^QW4_&2=#':W+Z%J(F>$RN5N%S81'@^)
MGE#3,T;HH& =<Q#0NA_FOQ5R5N[TH_CF-N"?;_>(3L)5=V'5FX[,\'A'T\AM
M3/VAJNF<-^6%N9?4MYEKU-VLU<)+O-4<MD0#;Q)"V,#822L>O%REVFK]I7[0
MEG3OR&=$GX:=KA^P'66="KD0-Q!J/U;(HF=>4PR=>%=3T^.,_<R%];XI8@:J
ML>(EE&).50V' >Q6R3H<?@?C.!\*!N(/@[P$6\[:L%JF1L_V?C/0N_5<%7G3
M\$CHG1'XU*#-W(8PCR?;W6AF"[F-JRN[:-O>KU"NR)\T#&;/I^%^Z[6D5G49
M'>XO#4\S]:R\Y4PIGLRF5IT]:W"@ M>I7UU8NI?49 C<<7WVJW[^_W79Z__U
MM0(Z@YC!#_&T$XRSJD:\!<,"X@(M\N(X>+E2EA<GDBTF,VS!U7SW-0_"BGZ3
M>P:V[H6X+;KT:#>1>J1\#!$[']Z'9ONI:M)H5VCY(:7U/:UWFI3F0,8K,O!,
MO1G>!P6HZF+D+,@;BV9@I#C(/>+POPN$C4NH9JRLT:Y%,I)]BQG3G153P@J.
M$<SB^Z_4R.4NWSYUW!]+<$'I+S^TPAR!7'CJ=J%)%2%=[32(R/P]0PSSX$(H
M7[XA52;9"-4@@U%9<D]=T:$AS42&1>"3Z>S1_YKLS'+U(Q*K:C9^H'#H]0E=
MZ3F*SFG:"PO--KP!($F##Y9!SNV&!O?D+&UZUK&&9=XX>ZU=<JIW(6V/VB#N
M&W'@3^OQS+&I(3GFXMW=@4$_?T'=.*3Y+0\TDG^9W:;<H>XFH*HE8F(+H2)K
M=E&I^Y LNY0,C)^M *AC&>!9B:?AMGYXM=S/J F_JQ>':%?>.>B<A_4#U;U"
M_^FA1:S8\'+^4XIVN*BCAW"9?$.RCD A0I9V,\E ZC@Y@26S@:[+T<.L#N]L
M(5M8Z^@NZZ[^,.'-,E@HVT.<I6E-&VZHHRG\CKX=^A)47KS^ZG=_S[==E_]%
M,#5/O7)9Y3";"#J.P7F0LIE0*8BGRHGK0^-)P/ 0PP<T:JM'LQ<B7F+N3-F;
MQ\-^X\:1S89^'S"Q-*NBBIY'T:37\OK:O>>=-R>+F7U8@-@]C%'4@?[L<988
M(S.'+;&;Z;26-S(_S"D$0A;EM 1\VZ.B0E9)&?L]?],X08>RN&7 UF&:4^TG
M)D8Q$)KP8<OVQ%VO"$B$A@F'YZ0X6$]C'#.3!08J3/48#M ;4&^<FZ#> L5+
M_ZO>-:3>-LQP@3SD2;0RQS-/C$T[[+DICF>*"VN>4@OHUZQ(1P:M3"RZ];/Z
M/\6IWX[*?GC+U;S"$!;@CQU>0IT8JG8B'.F7J^*KPS.5IQMK^F?&KS-B0,&O
M=SURZ@)B#=VWGK0-7OTAX?BY6'(PO%S?=T'=S*WDI=M(DLEK$;W:I=FB/MC[
MX%,OPZ64GB]'I_-L/+)2CNA\3<6T(@#WN/_(P-FMA>E.;EZU-<+DBU?TFR_;
M"I5NK"9'0F"W6-3^P[N5)4;+-&%+]-8)@7X%X/6@%''15U"^C%A)#_0<7.BZ
MUGE,_0X@IO'M"CT_3@EV#)4+1JX$6N>9CS"2+W^LJ:E*1*$+RYF[8=OJ_@7J
M240&_NYAK.TVZ/A;22=%;FRMF@GWTWU+]3@[4%1;4?>R[D!]3!I_T=OZMC!K
M_;'6*^1WA!D_,%XQ#'+::>)3BA]0D'+E-+;J4H+2BY[&/PC4MMM+9JT H?0-
MP&K&L;.'BO,H8QM[Y]&&XE#[W*>K6R9]=]A_K=8I3,R*+*?[NO8'^)!.4@BG
M'<T0EIZ$;-EU2)>XL4N&NX$QW"'8 V0*I7Y,$NT6UOACQG& FT)UX22%GXWF
M)G^K;A247=1Y.%"3J%U4?3<LXN&%W(L9<S@V"[U<F/DJ=Q,"AW.'J@!A+%]+
MIMK?K-;OL2RHS]7!N?19!5:]J+6+[!^=PBR:G+[@T44\Q></VCIT<(\/S%V>
M^WK9.@BECD%HB' CWD+=A1#,$V@.ME+4P8O+(E1Z92B#VIXQ>UA: LPH7=G,
MU0V/0;</8;*K.Y)LYM!0?U,[&DUNDSM92]KT/(/U&\OSBLQO,NP*W(O:[XZ,
MCJHGU'U7(%W:\/AX&:_-BG8:Z&[QF+N)W30_EX0WZ[69#3X[R'>0EGDT&S:R
M4VRG=0@M-?:9M5>OYH?48NKOZNQKGIHB5&[-3_I^,64)I2>\U!W'W>H8#:0N
MW[*]VKIQ?"[64-61+-"GYTI:3?8 ZCP9U?_?<8^ZADLFAB*;:&HTL2'+I5\P
M^)B>J1-\^&7ZUC]RB'3K.=.7BI(1"Z>C[^:\!JA6$3J$X]4O7PB?-]:F3+U3
MO)LRCYOJ^SH4?E<[AW1_!_VRU6>WE)"'XW>V;HE; ;\I3A&&D(<)"MT>OG\]
M9X:,@/_R!_YH$P8FAGYH5RA62KWZ"KLI KO68YST*^,@S?PF[%DP9;(IQZ<"
MU!_E+QXP,>]S),H;+7R>)\Z/V':E=6(?JZV@5.=!H?09"SC"2S[@>QZ_%K!+
M7Y9F*5^:HZX]R33<;']J6K(&IEHG2Q=>N"4.=9Y<YHN5+5'&11F7D^Z&8H:B
M_!_^5.GX']%(5"2LRU)K31="C]$&P^HN_%:,0OP6BI,<J0/=6DES&LXE^6L\
MGJ@-)?3V+S+QJO;6&A.,0;)6B,$*;9O@231G"?5"] HMSFBN=XO'.\+[>QFL
M1W36"40FPY$8WW<)S^A,>"3'W;R'X2*C$IU!@[0O(]^O?&@K"JUY[J<=[?HR
MW;NR*N0083>!.LHZO'R<+V U_0(3@DLF:Z.^QM- _!RISXIG]7F@*I5*<VV@
MFE"/OCMH&+UC0.0EB-;[SQW5,P>? G;4ME!.BP1 ^+)L"478Q)+9JKN7E8MZ
MZ_[?EE )IU1/%2R<6@]MT<P2"X=-:'-"F2GR/E:MRZWX3L8I</ .TA(J1A&J
MT@#0L%Z&PA(BRVF)N;8 ]E67:8L H77E](Q6P1K04YCB&!,AUZ;2VNHO/\R?
MCAS;/KB UA^50&!A?WB#@Q\>:T*4DZ@Z^ 'Q9OL_LQ,?+9(D^H0_>,/FX[1T
MV >TDW.;&G'M>'N0QP[':H>-;1]P=!L/B^;-<-;[^8Y.F!^.]P)M[W$2(JCV
MI%_OXC;1?46NX.9,7F3@E6>=0:P8VG]6 ';MKL"L",88*?!D]@M2Y[B3@X(%
M\5DA^CUI&6]HTF&&T3@!\CY!_V<X\67*#)3X[4BVV.ITX>L7+X%;SV,#KURX
MB 1PW#&(Y8RMDL#Z66WD8<,KH 5SA*O+)ZCXU&U4GW!;*!;$G%"_3O]^^X-+
ML9-2]2+LR,<CP77I6D7N)F.C^:I?5+G"0-YPB>(,>2/A%2TABAC+XY\-6.:^
M?AEG0;M4QU-E;53+#)(X%&\%UM3*B7H?SI&Z+#K7_/='Q?.4DSO2A_V.\WR
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MVJ63NAO\L>G)^/97 U$TDVFS3]G!P97.[&?6XTDE%\*:M$;'/<,=VQL#I#_
M6S!9:(RJC$/4)/]&39*W1*ZCM6!X(;01;2FBM2O3OX6Q'F7^F/SY+#A8QI#&
MW\)WZWCV(2DN562LY$8FJ*<@$,V_7*_BV%:L;*R5Q4;77'@?/G0[*S_XRS*,
M%?V',.8U'=H>Q(C\99AM@F$A9ZQ##D_,B6*<V(D<PS5LY"<4O2GF^"/VGW.Y
M;@59GJK5*R6C!ZW%;9_UT-]L55X4$MEF@NM.DOVF=H9*8TIQ[LS);Y.X)VI$
M[ZPR$OU(XN.%-T_;T3BH1(:43 DC4VL<1T>]\\F[Z9/(S=0W(ACJK$0TH@%G
M>8MW\GU[:%>;XUZC;2##*^I]( <ICH^1)&5FY8OC%IL;P7VN*>GY[O7]UXM#
M46'14KN(<ZW7ABX-A.2$[8(M.?SOC$3-U"XU2H:9%L)51H_^-IZ6$\#/8<NP
MH![:ER>/_R>G_G^S&7\>W[<,^_4^9N$C0DU_R3S"1(,ARGN:FIZY9QDV']\-
MHZ0I+D ,^1] 2DL@Z:+J5ZX%V4W*Z("<"'!^$=FM,W<H+R8%&961Z;>>XQX=
M&1TWP4QQGCR<_'#8U"]]W)854F#L-[Z0RJ9]_BSU4!I[J'76 O2)<CYOA"DU
MG7FIL"/3)@CM<02]<;)6"WEP@22;)AE#*0% V5T;Y:[;"-GA"C+66T'E/0X?
M,G>JCCOU<'B&$=Z,)]K*:JZIRRK_N:O1)'T9]C:2)RY$R/>I!8BE'MZ6/5IR
M;?E6*&D9ME8'_*RT1T DY%W"1JZFBKA*:S5<AFVL5!OG,,O"><!#U2NUP1QT
MBM:HP:+<_4K<5TPMMU.\#)L1N:GUEV$N"K]E6)=Z\*M(X3(G5&K*Q00U[2VZ
M :NP6X9MTDCI1D.0G4*?VD$ 2C36V8R5+T!W%3AR20O/$'V RG_XY1=(T=YT
MC<$DVXFQ=Y6D$LBFG;IV2.E27%9RN3+\=@I?IL.G&M7WH Z;O"2&Q3U]VE\U
M7[0OIW'3*I5N+^%U;CN1,/*MA5'?+&C'WG41-7YN1PBU3D*OPN*1,E$U6;L=
MH8,V#+\=\;%;]1)(#\\$SW:X- 9M/S@Y'5<V1JBB[AI8(,9UO&BN;[S+2D7/
M:!Z 3Q[M0.A3M6@M9FJK:;._'T#+L$["^@:$>3C7.GW<^1'JLI2V3MWE*I._
MM*C\+NU)8/@2?IX=HI^S^D#+J5 MQ:IB7N8R;)0ICV1IAKNA%B)J:9GJU93S
M$.\I))(Z- 170(OM02@P=KB!8#0E],CB(,NG#<.S1T<F^PEA:&3#4$V$TEVB
M\HHXYM/4N/K#=L^0;]0TS5AE2@M5431F-/@,Q #+Y;'0I.*\FM_(U>FQYUB)
MZ8E4)+@N.TS\1J9T>=(N#<3[UP(%R2]C+U<&0!T6-/R+ET..F6@!KL])=Z>6
M-$ VGQAQ997J.Z4GE":!WRN$@;EM<XAP(!2]"3!-<2(90;E^+ZPBRK)++G3%
M1OU$WS%+VAW %5P.UIO.5TQ6SU0'YWR2[AD%#K9HTAT!LJ7+B-J95&LJGU$;
MPS_L+_:_YT3LMASV@]C58Q?)S+9A7$13X =\F*YV&R\Y+WJ\WCJ??S.R)!1'
M2XN8Q^>/!NZ-()UY%1HT+97A.VCUHK05AA!&(R]A&78%GLICE7[D):/< 0(!
M>@!@Y0^&*)AG*T4B!7,3=..#X?LI!] F/;)@P@;">-A4WJ(P.G_$@-_ZS;L*
M%\H6/NF9%C4P /?\.=T@6HL+)N1?'!>G>\QR#U"OL\UW9(]G-<=+$Y4ZOOFF
MG#E:N5?$<<F)P9>MZ0J.O(K:)/]E=#]L!96%T%H\'.=&)UK4;O6@]MU./N(^
M8P-R/A^!@-!V(S=8E94^UZ=^G6Q:3.DHSEGJ9F$B>IT"W7"]T>L='%"8.-W?
MSD[%E)QMO+D43\C":*Q#:8P1E[U4(-3#EH=56=2]_ E&.F8-9;\D BV?$K6@
M7?LN 4ES;?14G ??PJUMR+]P/U"8432='=H?GE?84-98<+,J@"-$N;B<%I3]
MN689]I"GIY%:(0+.U>#9EN^4OAHG7P?&=" R%A$-!Y6'H%JPN$NZNP@T^_I]
M1 ,\15,^ITW4 J,^T;KC3%I,C9#LAU\5YUR7]T2]<_BM\ .^(V?HRRH5Q9?0
M09#%*HY1CJM*:>)40GU(%M4N/!)*[%@RE65<%5M@VUWJ/)U+I94T'8HC-&;Y
MJ'KJF]>%6:=8QZXN;XLS"P5_#Y"N7QLH)[$"_ZKLI(H(=04I,SP%4MV.:'1)
M4']'"1G$A&+2AM3KN2 RTXFVQ0BODTF2%+ S68, Q<0D1YB2=%UIOTO_RVV+
MI!RFTQ/<@6I.[XG>MMX[M.L-T"*8HMZX <R5+"J-7<3E,T=*R"&23$$K/<W2
MHB<Z/K+-K#!36L'=(?PPE8?);-"YU]= Q)I=(-]8;T#2?5]E%RMQFS2QO3'X
M\<'?26+54<A#:H]=H9=$;X'8^(>V#9J* P404AMB+R792W+/:@)4V53,UV.D
M+?HMAF-C7KVM=W:=.+I'6,S[%V-T45+*[,! #MC7R*1%M0T8DC@O,%.Z 'X9
ME=/J=8/Y1\! ;H9S)N@<>*WSQ- 9VR?]UD.L%S7SWAE_%L<6U0W<"-+_=&^[
MUM(+9CM&V*G>R)P@;53WVBFV4=L86B6J)[30.-O21O!<TZ.%P=P$CDT%#G?X
M4U'QR9QAU_T##E%QUQ)H!D3_<1M E$(Y9$>[=G'*-"]W='L_=:/J#ZZ%S<P*
MJ1L/$,U4 !X=0:YT,:V-J45TS4WE[)"2]"\2OPO2A'$MRH6)+^7-J^ROSRWH
M((RA,^/?3@U^J@T\-=3Q=?JDXMROWFX7+]%:3&:KYVF0;:ZLI9CB\= <D8&[
MAS 2)XC:UAF!NN,55\%".X$%#N=M.W:3>@WO<^P,FQ63]VGH7=R"Y[Z9FFNI
M6E]XJ0S@G C:4SX3*,5JC:M%B#I$:Z:+)";+Z9#C*XP!Q10T'O#OZ8XPS:<9
M-_^U#-/G[@F+<6U.JM?ULM#QP^HYUX9M D?"?=?/.L@.*]0;$9JG<X8J%4CE
M"16=A;V[!&\5F)!-Y;_U5T>_4@5W-L'O.^F>.6QZ=IBS(ZPT$(J=1YI!IW0,
M(TN@A]YE/OZG!D9NN+_<D[;MN?>WS[(%S6@:3TIXK&Y'.X-H9A55@*A/+E!@
MPD6&E&/BN02U*V@6/KYSF$,H'LE7J#9.!_2C$(JC'L\FEY)F$Z^1:IX,4*PE
M+TQ.]^2[>8[8$S\B(/ME6"KJ/*C3R0-\2,8!%R?S$)F<F\"LJ,TDYE>\6Z@0
MD\[QKE(Z#T3,7J[GJH<>L+HQ_LV>P8T<U^S\@!_]$=<CU)>TY_&*6"45I&MP
MPB[E-6CEC",?X%WM!#SE-OKNT] \TOWK"S['^/YGP[D'@,\I-:;GZGNC&?"I
M[+8<7/M?SZO+:G^:COK5C?-@WZ_>&HRP!E"5<$@*G+J3L5[CB*E+_DE1A*W*
M'Y9A27=5]67DW9W^_93]$2OOW=H1YF2;4^J_ZH:C!0;AS_\1^B?/W$!2!ZN#
M_LF[Q_ZE14X,V\%*U*!D-;2B##+ GKD+5A)6Z*VNSR5B#-$ZDT*7E+_!X;N<
M@\!$JZO#2ZG.5DJ8I#+>680==)R[RS5N9CT<#LSW'K FHXZ4U8\*?0P]]YX8
MZJ>6K! E\#YNT: 1C&J(I I%I ^L6BIU-SJ]ZO]C6_/\_]C;'77#X,2'A!:+
M;4_=O-=>.K'IV-I=F[0::H>U2T/S,Y$V:NOZ!<PW?8PR[8>M47X,H2-O:1UV
M&9:H 4Y__A9?XKT,>WQE&0;M_W>'W_[3X3\=_M/A/QW^T^$_'?[3X3\=_O_N
M\.B_O/EB'G QNZ!M=ETL%B_#0@T3WT_,)'X__V?W[8C_PKYJY/O#VO]NBUW,
MP/QM!5?%>BS#2F:)/<3_>N+G#]O:J9>HO<LPP&<."D6.,N1D%8LFB:2U6FG*
M*L.34$PYK;5!@RYC_OUEEZ#<3MBLO#PA<%,;(J!3+,(,4D:"O)9A=1P>Y!Y-
M?ZY*E(W.H0?E;J3^I3U:4MJH0NZV#$O^I&+<X*Y9H3'4#!4H9VPAA[33@$?_
MOLN&1@'D$;3 ;5&MT"5A[L7$U\O^I?"7MZH878*1<E'2X# FF+>1W"6W[*7]
MA#0G,\X.HES**1LA&O#38H?0Z1[.I"(Z$OC&YUKTS=.WC(1^&R?Z+5$^7P#>
M,9@.*9%/PQO_7-4WBV1>1MZT>1]U6OO;\,KF6R?H0;5R7;;\%Q"C-+*1^K&!
M<OYP9:5R'X!1[HVSPVB3D1>RVQY,+<8(9]-YAB%<\(G-20YHGY-?EAG)SS%#
MLYG(U.H=.]\&6IU>9 B)Z@V(2,4)I;4J!;TE4-W30_8BO.>_Y@&)NYM)0++/
M-4RJO.<+;^.\N9V\SQHJ+V/?LTD72"@&@4>="(:=T9%5)T&G/_P\UW;.C!FM
M^B="$;?"6H21O$#;404B0YXD2B.^YQKQ&4=&WE2E:;3S66U(@+RHO5(L'$H,
MD><J;:@&ZK8159+<1W1I<#&^4F;N_^?7:Y]HH5C(NK%B0B2,\5,Q,=<$PHP.
M45U*!]TD5+Z$S'+2U6HQP](I&*D;V;':[7C.U9Y9RC&)/M&Y/*3X2]WTYO&Q
M:;-X>47IZ+1W,*F2Q:ZCLGM_0.33ZER4AFX2Q$R7!)ME1LJ@>-90>X(.JDKS
M%JB'H&&I]2.6S@3>XKA/>/RQDSX;QS_-A\GS"CZG-A1X^!7&X\\..ED<!RYV
M/WW*JDT?EN(UKK*#G<K9HCX("&:Z%/&4VRJ&6I?R0^$4UIABP^YOP!B&+64V
MS.]\][4U\.PQZ 'P5:<K+*HC_T180[S.N0&'^6S=K.KX9^[;1&$J=?$=S/>T
M:X*5A2B]"E?U.X0!)F0]:PPKU4L#:UY?4%X!/=+*\#XQ'1WF^(P(^^UFO@D8
MO??0];' 0'+0L,^#FJC,HY\FSD0<G3M3B&=#5V@M>AS29;',6TS06*FXB& ^
M3QLYZS?T:6".NM8EL=KAI/SLU)LJG_(WTA.4R,M%^_.6S../_LWDS_?51*>*
M_!D_QE4$P+\8I,.4):JG//%O(EVUL[KCWSOV@Q'WQETPJU&Z0(;4,F-"AL3G
MMVI+T475'R;59J \K9)V?=0E7;GYVI#2^QDD_]:65].$_,L[;DUC3A/*.==Y
MNAPI>Z QZ#:-HS6H_H4)08[PU*:TE17ZT&D3KD'C,NR>0&W,5%K3@!R-$=D#
M\V0X36G% Q@02:$M>Z\>'%6]JE+EJE$Q%VF='ZG5O3]L2^&+-M):M<4(+0@A
M6X8)>4 R&<,/,E(/*)#O:2R>Q*+W.HO.5F7(7!C!BI#WZEXYH6$LGO'75VH_
M6N#$0Z-M:"V'>))@6LM1M9%ZG "\6(;5\B0!7VZC,__GN^LY.5TNDI_Z7=KM
M)L, ?VAF=C-8E2^G0Y[*.1OU9L4RS&X&3<BW$<:,JO-]?T#DX>:4AJ\41/5&
M3[$ VH-5.L#K::T[))5,/<W_:LK6)-IG6FA\N20F VT>7Z\VG(-\BA6[!9#G
M,JR1*]#(^OR[N973#F*GY0SVZ#^?9?$:J25!&(4W!4>7)T/QH$VGJ![;V>]4
M,+8,:X,G7\^,J S/.1V?!=<?F_R.$.I:0$]/2F\/<7@IF3,,)<4:'8WP$BXM
M>3)WJ7[^]Q(9"UH+G.M(N>%CZJ4JX8G+".9H1PC[PRN-!P"S+\4^)TJS2G:M
M&UPPMT5Y@MD=N CNXR&Z/7,T_\>\F2..O1LX%5>SL,\PUY&0]56&S%>*'?&^
MT,_]?HSBUK\,N]JL[04L)!?$ 5-(\R#R6\$)'E ]6,6^_<32!;AB9M_?(HE*
MD$CZHO<4XCM?9&UYJ!]A,QUOM.H;5I:DT$1A?@"UFV=$"^%!)S&251IQ/2H+
M%<8HK44 72._LZH,5;8T$]Y6&"/7EHM2,"QJKRI#CD0JPOEO%5AAS)N__S'X
M1&T3U;LH]XMF.@&!_*;&L$;5)DBE'1,ZN0R3UFG^)JGU$3(ZY,W=#C$[:5^1
M-!+$4& 4&+4!;8;YCQXAGCF#N;$,.Z[ OI>I*_Z;)'!^*[1O?6?89Q<P[^X8
MI$-$^= R+"&)*F \OY8MSI_+/$#FGQ^D;A^?\E-O 1A\E:G/,,H[.KA8=8^(
MD_WE^NZ5I'EWY_&^OP<=OUS-F?9/_RHG,NT\:P=P0Q!.Y020I'-WT8<I2 #;
M@4B^73]-70O=+1J='K<<L&[(Z_@H*XW=_J*AN>[%^3R!;S^S>I8U=KSO!Y^&
MA=*V'7^OM[ASV.'%G"7%'8H'ZOFYZ/U0P013FW((R/Q-GL,NM 4_I\UCUY-_
MZ?NDCFZH9;\<1AV)+P_[%1OWRR0I;!/;T[IMMO8HTVKMX<R;XR@H&E!(&2D.
M% O0[357#\J4F(_(')@H^PG!IM!")/!QK/O>='3PS<@B**'3M]^F\.U' VE?
M6$20=VSOU:2'[IM@*(3:O%*^4X,".E6/>. .JOXR[!LAJ![HGZ"UT#(W3RUB
MM*E("A*J)TG^N2X>+H?"5DZ@(<]:&$2X.USIEPQ^!!JKGY7EVR]=&&O^(Z9:
M9\RZNNN';4=L":T\H;G\DBHO"@O9+2HU^$=2F*E 43;UH;>1!9*0SD"/#@1\
M7G"/N^HYX)&^H&LE$;5[RW8KVKA&#8 2I_<JMG1\4AC_J2#R64"@S]7HX)";
MUT'O"*WR+S29)V@HYBD-%/+KX.=.6B*OWK1587=3BE@3EK>8H#8+"S*"K.!I
MGP8;'A2%+2YQZR6DU5-OHAV2\ZH_#!'CBH->>,Y&B M[+G;M@*F,B[FNJBH:
M$0-=78:]5[33&FC*[0C@#UKK_B**\Q!OQ2GN5:KU&6Q::RM(3T19RS7@AB8Q
M![5'>'48B8.ZYQM/LNV%ND<M4-@\NBKGL4;)GV6:P=8:K?@G\AZC7KM]#"\Q
MJ9Z(1\I30/^[41;>QWI0IWJ)7)U^9:#D7Q1L+*UXI#S)R1245Y?A.3EYI)0'
MJ'U"E91O,(6[_&+U=_"^=+NOG9T(X#0V4[2!=T5 1S0@.PCO2]IX&TTEI\H!
M.68MQ14,Z=!=YT.4GDJ<X%E M-=?I\V22XO(!_U7HF#\XP_$KMC(Q^%FIU[&
M1O[=OCY/."XW7Q"O4"ZM_1'B X+7A>:J(JHUM05A2+%1["(N!FTE,NYG@O@6
M,WI6E(5V.SOG-O6NM( D3N)F(U*C"DS]7W%9])/Q(6VN%[\US#XBQ>@F%U5-
MWG+Y 5%[SK\#TZ M*Q'/C8A:>1MO4 Y+D/J4ZU"VXH?I6U1+2 =@OOXZ>F%*
MI,^\$;'/R2[SQ#2N6->-/[ZE+ZH;Z\,9<IJ&RO!K!JIPW@=O+/H[4_W%A-%Z
M*3H;_"QAS_RC"%!W-3%F!%):YE#>&\A)&H^4"I+53F1X!^YS2E4U<X&Q@0 E
M\M460!O7#+3GF.[]]<)XV*+?<';S'S^/1PQ46?X,[]MK!VH4#IQ#IM& /@8+
M/E,+A,CM0%XG(8VQMH&A@PM+X1,,620X1&MSU:LOM9>_E&),I]7; 0H.RP^(
M(DZKM+S[JLHYX#$HR\=+_O&&XU-6[!!MB+ I'%=6+V'"PY?&TVR2HZO]C_5%
MVQ/XV8%E12XI"][3.G&5*@,\5,3.DOOLG;UP?=>KK/$U+XF1!XX9O'"'_8W>
MJ0R%W "J<.B;=+B=GLS0J9J+E-OQ4KEN #LAH@;<V4;MPJ1%!QZPN^\UN?5K
M 6BU-_X3;!RB@?X26GO!WL 8":&-OHIRLG?[HQV,"RL\!7"RP"LY3,OQIO=3
M<J3O0+75HT&+ARZ_7TC8?_KH'S0GX7BSPHT"_W>H'.+::WY6*:V'.;XA$PR+
ML GY):@ U)%TU(/^8K_?@;20H5/THH"P_4(HT<OL44TB)GD[1X%(69"43PE)
M:9+F#'Y3WE@9<XF@L*:L;&RG32W#+%!810"UE:8_OS[ZE6AU(.36+M*FZD.=
M_#SM%DUB9W]H++GZC,R3_&%IU 3Z)Y+^YM)/F2 O.<9O_#/LP<4P]98\V0)!
MMAT^N&0G9;ZGR?D9<CY@2F]HQDNFE3L@.E B9:1S#93>T(5H:2F8I#%[#6:M
MV+YA7UX/,)=$'2%6N#MF;.K]THLOE665!QMW][_OMB:7)]/$3SPZ,&LP$0PA
M@L];.ZZ0A,R42TE;(,)K] Y:JOT-!J*&LC;"J3,MVM[5%K6>T&*VCWHKM>E&
M$7VK/31HXY_5-^W5Q/H9/K#1#@Q;V=1B01"CDQ1^%V@MAZD[QM3=)$DUO(VZ
M'_RF# <.,]+FO=TRO,^!Z%H)/9E-W9;11OT.N':WIBNZ;%)MS\ENO4E.]&JP
MM%-W]T797BD<G4%F8=B=K?!$1GT(GR9TPSX'X6UQF"Q;,1%YEP;GV.D^!]EM
M D.E1W_Q ,=.\LI\Z\=L!7KR4BYZ>XSWR_F09*)1W8#3[_NB*L7P*DXD:"I9
MY.L:H[Q!N\X@/2A6\L;)W'[G85HGVJ8795W\IC+\5&^8$!?>I)(S?A)F%>U$
MW?+S/O2R*?I*@NW6$Q:9M(,TX#Q)Z"U/!&-F!B785=1>1.UB*B;$!B1T"))P
MS+L<[%4PIH6W56E?.1[:5-H^6R0A;19!_MZ]-R@(:7;IF\B*]P'C(Z(PX:.:
MW&?V-57#)LG:*E_5"PQ)  4C4A'UI+M6D(V4?I_-8%U=;.M&G& !?B_E)..
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MR>A8MW-NU-"?#C:0H>(VF=^!8&50W]!8*3.#4O@(?2*H4ES)3$6OKL/H<]S
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MS<TOKN5]\QT@U3@TV!^?/:K;O3#6UF*EIQ_O\#]GJ3SU_[!!?I8!!/#N<0]
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M%<1NCYD<?T3_1Z-5RB6-%H[PQ$\8]9A.T7O$A$<"5S=<4_3-M9&VD:U\4G"
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MZDP\F.S[_?->V[N4SLZ^7N_2W&$48_]<\"<]4*1>ZE[)AD48+G9:40+WL#?
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M95PCA:V?IBGR>^M_K1>_X6;_!;1G6I,7N.Q,SND"!?:2P"[I!)T)Y2HSF]'
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M?E!WK[XEN'5W3+=7YOEJ'V4<5AG^X>[%TM!?H]W-&O+-C+:D1*VXOR980!7
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M#;G*SK"3(,+E#/"!+YB$_(B\'I%O_^;Q]6U78N/'C&5[/@JTQL*/$O5!796
M@AF\*#:_X8&]/H<Q8HA^H!F'3?4'>'0H&#E.<39@5.EO^;;F#IC5/A<5EFY_
M[J?5)9=!67\K#P4D7/P[%[0_T 15 $V*SS-_*?TW*:3X<QC(X?/+IJYE"!&T
M[J@@X;_ F9&(9C0T(/73['MK."*Z'5G1=G'S>=F0?&@BU.#/RS42R\;OE^F2
MCQ+SB9L1?!?<_/<*<S$L9M>QF5Z1NOL 6?E9Q+I9\%E,T&,(O17D+NA  F4-
MU5BYO^Y!^%(!,,;#=]1*/\W*T@<D=]Q^YE-2GI1XYB/EU M>T?L=C^%^03VK
MG94N (X(!O5&*2G-T;IL@*>*UCH*H) 1,X3L) H+6%H;.<":>*0Z@&B D>J'
M1"A[O\9&PM &+O!SU:RFA#%LQW<8(L18^A"H),@*)8):IULLU4:^#<T3BGI$
M"QK@-K7@OV>UFD582CGU]W&O._S['H)K%^86^BZ2W:HO4A(5E18F6=_*G/9'
MG^@A_M2MC1Y=1!E.66T#U->5 @,R$OLWSM;QP+/,XJG&B/(JZFG54;-H0JHX
M-.INW^=&1ZE0" VU5>PY]WGOZ^F7'/65!KHWY$\8X#(@1\Y,9BF5(MY%]16'
MLJ<=1G7X/>#)T/!;/&RZ:^6[L-8\&3$CLCOA.]E9CEUVLJ/Y'=+5+.ZM!P/"
MGFF+*R4;1N5  "&-46]9/B/17'T[B>$>+G\RJ/6")D:GB#GF9*T%1#HKJ'?2
MR9E:LM7]"OF[T&$GB6AES]D0>W_"%QOC9@_QCP^>V?<OO2G)M%P3"GFJ"Z3P
M+BA)*$#SL=1M8Z/L;!5PMND*Z".\2DROEYM$="0I]3?T>QF<+Z?F$G/#WHB+
M-C?^,C*RIZ3CSPC24R?_DP=^3@Y$G (@X&58E;T$G[TT@?K:0)"EM34W>RF7
M#4OP:^FF@X@'>"OBC&$CQO)QV!Z\=;]LG$T"/C!+(LB,LW4]55OA'G!#.Z>R
M\\\KN9/K.QR[[-L64<\DV?C1"B(//5T7!9:AAP-;V:OG'9*#VQ:PJ5)XTY0B
M,9O"MYD,-:VDFD\I;57CLLNW1SO768C,TLZ=!H+3[/I["<_8XL29B@A_@YPW
M>G,.^^AA]'8,5R(A#J/AU3/X]JZU0UH'0#J#ID2K\*OV55!'5&'==".T&35T
M(DX)YC46!)2]J)J0V:M=VQI>5$SD_=RE'_LL_(0(QRX]E#ND15!7W06!&H>8
MI24B:S2T(WAZ3'.26D3(&%D%"-J)0\4B*PRD1_J3A+.[K0(-I"*=CT+7+Q!#
M<5K7K\,\ _S%W<^?^V=[DX_7UQW/W_,"!:?.<S9!>%$!)WT.:PAQ1*'K7J@<
MAN^["\W=N$\GKD94*JOWOUZ6<.64HL5C85*_\X*ZIS_O_7OIH?1)ZI93+C4E
M9UQIGT%C-1=(%%%DO@KL]*LG-!S44DVM5*V\M? Z6\4RH!+\^^AFU M?%HJ_
MUA6VT^V>@[:WBHM'FJ@7_BQQ*UA9=I/72/JTY_G/>_Y&$'.%(12LV2-'V-!^
MP2B;.(1'/.\A0]@&=DGDT+$B8JL@'8G-W1RU;PIN,T/HIT;SPMRU3EC(7SO,
M\(2-Y7B-\72QQJ'C4PF' ]O2KD(Z0 ZO\=&@X XY4%\BQ5G1#D*NH)M&9;(+
MPKY<H G6>YT:9:0+#%WU":9^7J&(;RAV.&OW*#H,XN8(J\FA$2SC';T%(TDK
M\S9=PY]XS)%\BW.G2_$-^)E(S?>T];H"^JX8=AVZE3$4?*R[V4R%SV0!=4+&
M!EJR:C;S:HG9>P2&>^H9%ET)BOL.WW53+B4'R?Q+N&;*$=F(\NR=N'C]9+,7
MNKL"$IL58:7CX!#U1>3Z9GIA0:PD8B-@R6I'WY!;T'8J*@G+V1E$]-,/+BVX
M3P&@;TI]'>[V0X@=T,2_0X3R C;\EET^9;2E,<72 X:6SQ_.TF)T;.T59%#7
MZY[RG>G#,!K@S9 5\NMR W@9W"\WXV^BVHN[:7I0%&C=/EL^SM_>-S>[CFKN
MA VN>5._4>NDB%LG?/UA2GQ5-E6T&URAKE#[]BMOO0Y[.&^VU BC&%*!PT)Y
MO42$SR&,RHUI/^GNXMP@Z6A>N2KNBP'&6BI!Z2IGQB=X>QZ24EPT8:L/9\0G
MY%@$IBS$.>Q+P4SGEK_;\W!?LKJ0A,(3*M\+9/K_7EAQ)[.774)O'H=W]E/P
M,:P<W'K(>+2"MJ-\/'] 1LQNCKZR(2__,50ZSS(</S9$O;#Z;)"@J>?4P/PW
MQ6OCYK++EJ%54@E;AE570YN 8B6F#6/&:#W&.'-4LX=J$EMDAZ^U3W'!I)AW
M79\G6^)#"W:..AD? SV1R,)PO<\FV]KL/.GE5I ;F]?UR*FY"D/TYLP(0#O*
MS1$DLZ=LI_WXHO=T]P=DH@8QM7KBPIQMJZUB+E4T)Y1!T6WK)YYU;"799K4'
M'*V.O#UTOV?+'WXV;_1F;?^/*R+H ##54MU-)#7CL]G <<%@K_H7* F)EO7H
M%/8:%VQJ$!T/EFOMK+[H83R+I^T <Y6^6?-+'[(V2[T"RZ"Z'S0KKW,FW#5S
MX7I';TW-,*)JR86#SG$/=2./KN&=!:,<05UY.T'&4GL*H&# H54._ 9]9&3
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M&<@6^%W]87*RHS5B!S"6,4OI/9$;0%D_Z1%UZ[IJ-N/S CLKP=_)0WZ@QV:
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MOKSS9[2(F,JNB9[9J2!"UGIBP9!G!$16HV7+Q:9$PU,]7LL1^,Z_YLR7VKT
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M3-NK*(>Z((>JXA6Y0#@NJ@?>9CZM5BU_1\4-T!Q/4U3\T UPGLN5KW@]JN,
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M62X'B_PX,.N#3\4TFG?2,PIPF0U)[FW6!OWLC6"9= &5@>A7$)4)]\>R2BC
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M8BEL"-D?$KI/HH\YW.^T(T;/\_B_%'+,J)4B[?WMH)M1RX*$PU5W'#8VIF]
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MN)7HS/">FP;%I6\G?\%4+M8EN!_<Z:M:2_6!JT!,Q_R'VUKJ:(K/X.R%?4)
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M$8DFRQ#?65X5,7UCXDMI/C15T,_%AP6*IDOU_76?EB-N4BU<[BW!+8R:.D"
M7D-MW:$V .C*"P,41 P:#2#TS"Q'O)%EC>Q8X91H?=0_P NZA2^/B3 '^;Q[
MV #VO=J"O'-/R4<:V *7NA-]!WNG[8#N@8JP5"O5$7[M,-E$?^M5GZ "+2&
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M5P6?"I<CKK/W0.>H^!KHC&<03R1L[=[EUZO>S3%VH+?.[2YAEE6ON4UTRZX
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M,9*[8N 49S!*>5F3-X--HS;@<EPYF513]B)_.6$5;KF_A+XAQI)_@W )A65
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ME^7[2!VON;UP?F,C^33$!6DR?@X*![JUS;?<T3#2U7LK)C_$N+=TB[,><*
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M-^TAV008[1#GB>N?Y@.ERCO07?"V1/OX 5Z4=4V[GHSL(Q.?D!J%@;U;%VJ
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M#9'TH7:,:M[RW+5/3=6T-G:T!2Y37^M=@L4@-I"V#G%/ I>/\6QZU0AI+?P
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MUH=H4LEJ]7[@$DOIHJ"O@D8$8K]L]>X:RJ5I\R)VR6+U0SP[>>'L$NR]&\;
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MTZ>22+LOH3[?O;4C9K-JL5@KVK3,"%MZ.\)0LUQM :7)1RI+G+FGI;2,,3V
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MM T7CJ*B(D0604"(.RI@7$!&P&1<$1&CHB)KQ@4A(&8<0"*$1-D7(:.,,.)
M5 1$!&0)*(1$",LH V%'@I %%01"N@5"2Y+.:4_5^?%639WSGCKU_?G*'TWX
MD>J^G^>^[ONZKD[W\V""GH+^C._K##>)A4NAK.E&XF 5SX6 VIB57Y#_!1PS
MB1DWR5/N=J63M)EW0V8^&9Q<</A_<WAX3L4]A@H.]E%W2X)-CWVG4Z>\0'NC
M1.J^DB]]69R$DK&(NJ<"6G%ND/V)Q]I-\85Y@1E&1H;V:=E1Y'UYTJ?37MX\
MJUTU>XH-%O I;@TX P"3$,I<BHAF<W/ /[;2E%P60#,"\E/RH7!>C2WSP4;A
MY:Y0U_4"/N+OV0-^F7]75,5C=SECKHQ>#%'>!";$<TUX'6_(01)^&TF):8-=
MA<#'E^+5DK.ZTY$H;JU]N*QOO%DR>A!<G):;3]AW_]VFIJ== G;&])-6K8W)
MJV_8G-0TD_"_.X)(D8*;D&,/8&/8))$69#/H)=.@5" :+E&)B0S.]?4(M-]7
M)XP/2S%M,Y1H6YSL#IU0[3%^D>-@VJIE670V.?*\N3W.]OL-<(E[O)1J#!J)
M"VXYTD4*P^I([')*__<[)N[QD\/M0\76YOT'^D,'5=N'BH-]I,4"RS,[O&H/
MZIY_7R@;>X1>![1,?@/TZTV8<;.EBY4KO_^P?JG>,*(D6U3GQ<-H4XT?!=)6
M=L^^S]*^UM(P-W\NA13VR&-BI0/O^2#IM.#@LT-M9H+C=_87C)0.5,C#H%S)
M:JH7N%N$J2<FYEA6>856@_@TCB'%M&EX7;7+_I6LHV'%] ,]MELRWN]'59^?
M.G-@7>(1@R-_RI]OT;"NW*=;>03H#ICWHEROK'A<=4L0];C3]- >YB_V#J0C
M^A=#*RZZWNW^!W-Y#W.L&6/QL70[@)D<5>Q36O5?8Y\"6D1.]:4)N,UU'EUS
MC;X:$%'$6!I430H]_R&OKU2L0I_HV6XHJGW0YY6@;WAI[<467.MAU*JO*MGD
M0851H'MF1%JN8AW<.C<?I_IGKKJ_GXNB&?CX^@[[')L>\AD:(HCW6KQ^_3K'
M*>OFY_ ,DL_'NP/OTV<7&RP8Q6MS=)0;(-O\<1.[!G0<4P=G,#;/^CH>49(.
M#-:;&P-['A:.NY#-GHS;QS'B;>JV]\F_!5^('[@V=?&>R*MIS7J"]2JGW/_R
M";W_=:QJH0R*^WFRI(C@^%00\[T]W,[]$M&;D&339MD\C"#2/?_+\/HNMFRR
M+J*AQ:>,RZKHJQ16>D?%G*E.=IC X\@5?$R6HM9DBT8LV-\@C"<:K.VTYFRF
MV@,6C2[D%1/GX(W )VX:>X-8C3+:C_S1]<AM(94&W V:ISTVOU_LV6*51'Y^
MWKIN9MF&%V[/:S6"FNG?[WHX575:<=9]M^J.%4!_XHQP-?1;=S,-B>C4][<Y
MC0(ZAPX_I10<BO$NXZ0< \WOKYJ=]+SV^I?? V_L'/;95-SC<GT'K1D1AX[A
MP*A8UF2]D+"<>@+ Q. V4'R]$DLW <(T)?8)A?OSO:G5GY--"VWH*\^/FX1\
M.+RJJ?'4B;[F\R,YEX]H6<9_M"$,C,CI0#>TGJ#SG=@?.0/M<YX]G#7.3ZB[
M@'-_(!9A%J/G->!)24:X%GWAR<_#!G7]TM A^T'/F@[7V/D\#M-/>R:])6AA
MR^09I'A)2 ^834B=)2 ]=#$0EMF8&G*X"AAF@4NZ>2:;N*FS#)V!UD7R")U"
MR=]7W7Q[;+P\BH.O5'5-R3Z717L%;$Q>1+EDV>9+70IAGE$/54!U="!([#K7
ME&I_*), /;X)3#?8X76M_)([9Z"/%> +@0.4T7=T<N.]M^;:KL;6&R/]UAM>
MQA4?1EW'Z4$D8.2-?4)*&'GA]_OVT2P")JC?=QO8ER?&+@_P7=/C2)*D#$QM
M)SLZ2P;;S!O:1QHC9H>:AH::^LI>.-]\YDT(NVY5C=[XM<)%A$=Z$E*DOPW6
M"U=\5V<).-WRG*EQ?L.P!M"<)$;K>'H+V_O=^PT%F(3)4.FN9;)K/E/;/R?W
M;GR5+?!X\/%B"R+,'$<;A)J(5S:M#^=J*_6!"G%+#,=LG"C "W +@>IHQ]W?
M5ST:QPSJ)K+(59"7<Y?4QJ%4>O3^Q1ZJPA@WM'I9R.=G"]EPB_RPZ@^;MMVG
M.VV$ PGRF]TSP5?F6\[TSJ1@HH7:Q39M[FY=4X:RXSUAEDL=;<V*9^79H44A
ME\+##*H-,Y=7>+U=<VO'O$DR:IJ;*%R*TZ=>[+::(:8PM6 SI5OGS$1&7?<,
M,W%X&="?.M-JVG+6J;;B);CG0:%@T+M\6RYAD;/EMN>9:U&FF'IA['5*PAMX
M>PJB5A*5[D#KP72D([()F&C'73GKH$AQ86AKJB$13<%X^E@%^NIW?.J<*JE\
M8).]Y'-#_4SKPY0EU7LJG/4C; T6?$:JAZ:M7 ?5^P7E*[T@=T HR<B^*+6^
MG]!(U( N-<O/_;9[0V5&%6=SU^Q/UD,Y/PT@I))RY([SEJ?7*-@WODN@X$>#
MD+NX/UII(<*L\#SZ50"%U-/,.I76CP9=MCUYNXG#>#SPG@2\7=]D4MMR[<6$
MR9*-ZV_WG?IY37@<SHR* \SXR62J-N*Q*+NF6W ;N" C]9IR*V)G>-6X'>"-
MH@TNSRD%3;O'Y'M^@V(:(_YXT26<R*H8&@^_MWM?4\\=YYT4%W$!CX$:-[?N
M96M]=W^XY;V.4:4^E*(6S\Q8]M;'E)"38$$RUO_5:S9HD4*VB=1R8.A.](<;
MA8<;>3:7;?K\^/J^WL;R#X[I[]H&3_V,P0_2WG++F^Y/U15ZP&V8"E5^KN2A
MMM,Q<)^J&FGD)WTAADN?]97RWLJAB'&LSL;YNOA"_^O72<\&QO6\O88%?-NZ
M?WYKLLP-=_^.N_$L,F_(]#3D 8R<ZH3UB!2Z&^3V5$C9P+.+(/.L71INR.4Y
MACTT\_<?2+]Y0ML5O'-5557#F%K@@V=P<RHYF*R3O:GRU^:BL9[_U"&^7#\U
MROP&<U:J"2<?^_J?NQ2?7)QEV89;1S%J\MWM8T4)&L$WTF/S&USZ:\FH+_BE
M80>+BWMN."_R_!,J0+CZ&,\\JZ^B]7*H7Y??W5G+SF=OZ081H3?,26K4<JRD
M0&4>+C5#K$OF9)P:U5'A,[.#$E&9>SH_Z!;OA'N=R<RT\]FXIUV?*5>K=0]/
M;_KG]3;^$,DEPST9 !]4X;43"P\P5O@_B-ORV]>1'90TTWCS4IL-%I,C#,D:
M'>O?CIWXJZ[$\/[HLI]"NG_]BY/QA(-<-,X(=(,9#O(T-:K!17Y C1KSR(4-
MB$V$>4>9P$&-6H8=T%*C'E^I@OD-](YIQ%;5[Q6J47O5J"*\Y33]VF?FS)'K
M6'C5KW0UZG!"5X][&QYX F^C=X[2.H60,^UOHDK+AMZ0 A6J44[9"B>Z>)-B
M'7W&JE/%C$7.^_G[>HXA7#A$C3I'<\=7AQ#F-_R4B<S%*[P:]83W)=#R,Q,Z
M15^%'YOF!LB4&[F7L7!<%EY\6'E&C<IM5^5R@7NJW[GSA@'_%A]S\'6!2O<O
M%V28WA@UJO/"#&O5-$&YA9O,G+DIK Q',%)NI$8=:,/\2\S^8OS8S?MTT5\R
M->HO-:J7>9\O_= -)[9O0J:J!/&48R_G/9._%?S;;#'^)>8*@#GC^(X+G A7
MH]KIX_QWH_(I) &'_/74*+&[IAHU<S[*^C"U^U^!X/1O00] A'ES/R)D@5QY
M%#_K_RE$$6Z#3-ON)#I0%*-&S5OA_N^2S)A46JC0NTJ5^MEJU#1SON+K:U5M
M%KW3N)$+G:U7HU2&&)=31.02_Y+/?P];3M.'$QZXP\O:$6?$5WE\\X:'VO!C
M=R1$Y3:1&@6GH/.>E6;1_R6?_QZU K],C3KX3Y$:M6B4KAR%7RA+?F#P!P;_
M7S%8])\/T/F>_=<S>=LE<98J3Z;!J^B#6O+X5YN[=G/(RVEOG[^YV:\1L)+V
MS\G\COUK_[#.V'MQQX+_"EL#8Z797/$QI2L")+;J$1W(4"&2=-YD"S)?EJ =
MG#8MOXV,U$ONALQ7P'^#_DX;]W8AD$?;C$!MF-:!AUQH[^@J;0-ZPWWH(3)=
M-Q4_(ZFV5FQ%<FUSZK\*<BS+<I0,G>;JT\=D^ ",<A/7#P_')^/_+>[_K@)<
M5TU7*[<2D[@SX<Q*-*PG+&<BXSJ,^;>X_YL2V)S\;1 V*&T4SCOP!0B*EY$'
M",BXGC#^)>K_I@3T#U.ER/#=)625V:A4X_NN/),%" (ZG?XMZO^B!)*><&[\
M>TK_->S_<PD<ZB0Z_'M*_SWN_W,-/ GX <4?4/P!Q1]0_ '%'U#\ <4?4/P!
MQ1]0_ '%'U#\ <4?4/P!Q1]0_ '%'U#\ <4?4/P!Q1]0_ '%'U#\ <4?4/S_
M&Q3_\TD?Z#=T#%Y/DF5\655,PWUH65/VM[R;0I1[G+^FNV;W?DLON.VEM]7I
M6Y=^KW?<O?CBQ0P[P80<SDHUS[Y@VKI19G;_N<W7Q-B*7?4FE>5+-\3K;HPU
MNKYBYZ'5=]=<SS?X[>*O,P&_15K=,#)MHY&+#IJB_8.\F!-_.F[Z5B*=_ 8;
MM;5.";M;RZ 79-9\N\L#/W-^>KKB2 G!?7 ZA#A O_QY(+LN.Q-?+;<;95CL
MRVN]\9J_&JKF#:, 1C([7#)T4&'1D+,<^/Q:(M0/Y%[F<.%_@+GXF=;B2YX]
M.%Z^E^^X._=B]]62:[2W!0-#0N^;-->\RFGV=;P3<2_M/?-K@!K%LE,]S&Q&
M:N <S:+$K0NW*0;6>H" L.Q5CBE%C0H\G^'\*<V !*^ .ZI>6KX3&[2%A !9
MID&4F!V["->M3AYX<,]#S_8*)I>^E+-+:0G-B5PW2,CUI>84L@1_:Y:_-U2F
M!Q%/IL%-4]9_;AJ*ZTK-]+Q6=&F=;J#)D3PRJ?#+-.VSO&L9[1ALR!4QF575
M2OT)D>8D&<P48Z1.BETMX*AD[@YN/:7;&X@MIUI"D1(;G'$_=0&@X.5@.KGB
MBQ3&V3(0'_OP!'@D0:+MM[EC[3W9@<C[?3.&Z3ZO=$O'"4I=MT.J)_1+#,AB
M3GI!<220NQ#>JOR9;$B):9B7O9'=AC& ,+'4\3J(/MU53&SH-X'OBJ/LCO7:
MCE'W%@=RUG9>[+$=]-$;%U/WBJ3^Q+1VF4OWY.@K%/Q\2^EG)XFF<E4NO-Q=
ML9V"$95*-16^\#OZ0O96 #]B<6=*:6O$D^KADWV7JQY3-Y O;!IJ5*. ]"_F
M=J!A80&I)N]S4H%PO,8ZN^_V@MJCP2.]Z3_;]7V;XT);D=,^'"%,ABD(-#Y^
M.6>E<A=@T<1=2/6'W)]" NUM<_O!O[AZ;(*$J \QFG!F "/!$1-50"DZUCWS
MM%_VPG%O8%$A!=MHDOTB<ZY\4_9'-<J_^P^-N1B/ODJZ#LE]7I88%KS[0*=-
M$0D;YGK)@\OJFBG>TZY;$U2K.C!_WMI*^H28Y3RU.6WCFHK;A"[;*(M&DQ,/
M2@/L<[*+QR*&L_V*Q@3M=R.#"TGVG/1"K\,W"P(CKN3Z6_6%SX>I_NH8&O 5
MN%JS>BO+"(O*#Z_?"UMR1<7$U5S1,S5J%?U2Z=)Q857"&^YM[@)8EZ]P#C#$
M83JHYL,[JJ"*<,D@.8&KAPU=.@MA.>NA;IX[9SES?V;C;F_O)O*%9ZT2'XS+
M?6L;Z"+EBLJLAQY,&)R3(WTUVAVR',ELQ"R$6\--,N[[*?90[$2V^0P_<(-7
MURPY%K<.6'&]I5!YM!RSTB;R(R@8.#]6XG6HI[+-9.]G;ON#;3>W+M6<23I,
MMQ)^7VFJC NXH>.9*)PF_-ZS?S(%0!]19>$V(KW)^!&_,'!^+O&:HY^$H3\,
M79^:+7;?WSTC2])^1D$WX';T.>)'3+D)? EZ.?1NY#B@XOP>II">B!S:,^VC
M,E15<D5%-7:3GQ0V\#]T ]A8^1-38M'$'\3RAG7ZX47*W;W83:Q*%ZS!F+DN
MN+AI+GG[BS[3@707HBD4<KBJ^ZIAE\RCCW5^?9JDH6MX?OR]AEPG68D"\$H#
MA;P-TE6<5QJILKBBIT04K$VUZU:C EK*7D)!(_SHB*F"D N/)SS;648)-BD$
M@U3_%IS=RQ[K[L9= U],9N0U\;'S-IX<9G&+86Y!;HM=+*4%UC)21(SC64*I
MBV(#S&=6&#4(4VEV$ G4:,890VY^>0&^>U@UY4!I-/O@,U)-?PIL,<P'[0==
M>S=45YL8,LTXW_><V93=7OQBV9(\C;P,QK-;]!.]WS)!+')NI-=((#RHV4S7
MPFV@==*!-&A:/)<X2UY&X1Y >.4P..@._PWJ)(1;IQ4BY!L80%QAN\]$C9JL
M/OG62##3=D3>'%4KG;IRIXC)H1F.<VSZ:<;4O?VXC0%5.:90T@M(O\&^E$%U
M*&C9>,Y$,]46@_XRE[.U\^J3AR=[\Y.[C_5OYI95I?FXN]U==WO5K%;SDL\$
MB3\/7TF?+%-@$;:[B"?S,;1^HC9=3%+NZ56> H7U\Q8)"*7X0$X2__?*Z\^H
MEX$;K/P)_'O<[KJR+BF._PBB-U81!<#Q?H >H$K;TE:GZEZK*5^@L*,)Z.7]
MTG#_%SYP.]U8:0WN(J";2-=+OACNG##!)%5&NHAP;Z,**2Y-$5=B)"G6.,F!
MX!'NJZX-%79WV_Q&4_[>'(U_%@0A'3OZ\A>$R WIHGR\N1H5+!P($?D6 '9R
M5R"!)TSV[&,^)@:<HD36E[454G$,YTZV?O"E1SX(>G'79KDFY]^.3 B74=Q.
MO>ID6_M?LL[.;KM?5Y4TJG)5K*'77\*+GC*K;'),.CG&M+^%R]E^N 0P\D W
MS4ZY'^A+& G&O\G1@IPESE3KX(+M#R^4*-WM@D?&#(62S661$?"&WJOQ]X/%
MO0GU)7WS<>U/%JB<.XE\?C)75$BOTI0:*4XK?54/N:(LX@(:FGJP&UZ(>^P'
M:DKH+3Y!'M4=MCX'C_8QXEF&P&Q&W A:(R__+WA=\AP!4+85!?73-I9WE\R.
MO:B4_J2+J:/7X^FB9_/54F,)78 1T:7[@%$GI 0.T5K[:!OZ<9N^F.@\OED$
M'9AK&$;W>AT$TUX_+?H09"=/:,BJ\/ :-P0#.>LJ>X)M@RU/=X:YO"^Y'/U!
M0[XK&0Z"]>GUGGC18RYKH=(/^J;83?N;J:D\K, H=?IFSX>I4=!QMG,I"6-$
M]7A*"3E.U _*HL>%=4IJL=KT!I)F3'ZW<G_X$XO;LY'!FUBIEL?3IKW9;);1
M.:0-"R$KK'0G2(27E2DNP.^'UP-V;VJQ2=R*T3ML:[%P28 G-IY*#Q:YGFCU
MJ@-6L3YP++JQ'(M W-JZFE1'MV>FX5ULPI-&AO:#>\L.A12_T9Q).4S3H+W!
M Z?Y@ZWR>I# 8QI#,?*3P.<4Q59\M/*Z12/C#DX?D"5/V9)74O<#";&S40=<
M\>(;25&@YLD:G^T$XX&#HD&??97,-<.!_9U\O0G[$[DV-;0'GW!V"-8>TNO/
MA^+C\,;T(%/F>Z;8J;YTH!81NBDV==NFQ6J4=-ECY16 *-4J@>@>O39U>P:]
M.XW.]"JQ3P+W["%(M)>;>9UG-%Q_K_4M3,MZN1DM&.OFZJ@Q3WC"93(&G6 M
M;1 K)DP:*RQH _B*T5LX<]:H5%^RMS*8W, UG)$94#):><'Y8\.;3*1I#_&Q
M2@^195'AI.,I<6VKJ<^YST>J>FP:O>[F>[7^RB$D*X.1B+GT^L-TOTX .T)&
M.'D#51<8G:P#W_GLD?'F:;<E=?[N$,L\-?+IEWDH38WRK0)94[>?4-)DO'XU
M:M"3QBBD+'NT1"O57 X/R_L^![S!%YA8?GL*#:E1BV^KV&J4']-(J0\]4!R%
MO]>'EL)"&=ES6!;[2Y>2\!Q*&-F3*M[L@W7['4KWZ';TB!0/XHT]*)>\NUE5
M@+3_5N5[UK+<NJY'=56U%3TZS!F^TL !7IX)VLE_53WC&-):B"CE5N 8.HFX
MTM$B2#)$D"1([21U3O5"3<>]AF7XQ$<=H4FE-M)+/#?;WB\ 2WDZT,Y$RGJ:
ME9_W>,R3:E1SOZW+\Q9-?(K()+Z4-1,',R7ARLTW\%7H-X388<WNT#%I*6T-
MU0]"@UB>[PZ(".(ZA@G^D3H/Q)_ N53'X%R;H#6>:<S"H"4"P7SO5/$UJ4WV
M@?8M9#5J?\!_+(-2B@/]E;$7U*A2A(!GHMHBM/]SZ<( C5$B X.!]6C_"'7"
ML"E$4[87P@8$GG2]XEAW&&8E_1?H82/3OZX?^Z0[]!6]G+TA-VC^@S"P+NLG
MZM\V Q=BPA]<W[ASR>_4=6H4N@Q)["7$1OQ#_VR,>)-O/?U?T(SO;SY !>)6
MYO?5WK$QG V4(_)(ER*^%F7Z^X()RKWA(1?LA\Y_\!ZCK2WK"7T[6O[ZT*O*
M+"_W>\.A'A<NWSV(_N0O5T":@&4]%_ @OG<1TV-Q6M3-0"D/;P1%BH[#5E"X
MF)N 0W<HM21)+'H:=Y5-JB=9E^)RO+,X5/N:CYMS=Z4*>RK]=/>4[]R)LHKR
MU[L&O?;KH>B'A15VT@K%3O@]$WA(Y_VD/(XP6@IBOR9@72YTG"NY \6(,9-T
MR(5;C1 *TL?ORAIR5L,=< =B-B]YJU&_NP]RWLHQ,[**J'R^%'.F_^.H= 34
M:$!$Y''T0$@3QI1^F7$+7U%PV]&]!)*)Y^*4^PL&J);=2JQ8MO++-(=3E1Y4
MQ5PAHRXH#.S/VE+3@R_;6->;GW#"/C_ODQ>SBE_;3K^,A;:@I06@I+M9:(Q;
M"_]=,2:LV,-0V$'I$BPOU>T-QQS<7@Q:CF":Z%I#E'-=F!44NZ.X+7TEPF/@
MH%WJ9B#M=PZ:G;.T>.8*L]GSCY7>0X$_8U@V[M-1(TQHJU!I@ P.7?^>'LB_
M@R^WJR<F,!=^@NYJWB:*,^\$T[93-HS,OG /WEK>,Y4+[BE<?,?^[,2@]Q>Y
MYS^<%6F117E>D-+>)M[E=1077FZ,%* '=%^QBV(J-X)RD<X)+P7Q,6I4$'K9
M! [79\/%C/E:]+)=2>*GG; .)>7GET #%-+L:U!=V7^MDILXGUK7T6O-2KS<
ML[;[T ZOIW:GAE&T+Z>([=5WN*+G:E2U^Z10<92Z$K"0TA4[E.NA2*!HI*HP
M3UN'7S^\MI<E3!PVZPB+HA,Z2J;"S&X(F[/Z;C^;&-8-/MT^ZM'Q$:!%UQ2&
M5;WDEH??#%:%RZL0R#*508"3]&$AK8E8D1G/]??1;.*L!N0)SR>$NMS 4N-
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M>8$,^4/("-!L,-<$94UDS  462_48U\2(QQFVFARXZX$OYH$;P0)=T+;W#R
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M@O@ >$:H0C!!K@$O@!>QH5?+&KPP0DL14X)Z  S&N$"5]I5J\ADE[NX;M<?
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MP!Z/"0*4CN$F=KJ+:C0\[<"W_0NU&(,ZK\-9,;J=T!7!JKL044E0NZ%S-0_
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MGYR+!QU6<B5&$K#)I];-_<^:ZV<UO8BGG&"&U,G(0J()NAOJ1U?GN<& 4+(
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ME2BW2X9M54E/+;QC?;QB:%/J6"\OKPVDDQ68TRE@(QEU@NQ.:%+K=Z@#& N
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ML)+2](ZU?F0O*94.H->8F@!?'SP;GT^*+X(K15.P+S](M^=+5TE6QTE.358
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MITMY>4M^FV$=<U?S=?-_WZ]IWJ#9Y1@K8ZDGR_)GT:4(?"*ATDAV72I.Q)@
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M=PND#63+YV!?!1HV]Q)2/*\"=$/RS)E>Q"6D$+$DI5#7@]EW63]L8H_7=UM
M?]^(+# K+N,E_"#6::6P/2\+]]=5W99FV3^ZE/B1N@,6\1N'?[Y>HU%BA T:
MZC5JC>B.=/0_"(2)$+X5MP:>A9*EHPDRE<U;:Y\;'PJ8%-^*+F=/H".%IV^7
MX=,6P(X_#K8DEU'<*^J@E<V7 -G*>1M+[ZJ'\^@!W\;:RS_I_:HRC4*39FCR
M&\SA["W)BDUA%?#W4UVV[=[-/PNC38J.^K-+DH8MZZHB+GXZ&R;L:W\V_E56
M/DWREP141#G?[]BJ*<: )]$#> $#30M90/6+)1U3&1"K4925!Z'E]3 19 1
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M-%.JV[W/L.L[;3T&<NL"XCQ]3]X1-7V-RR47O+J^)2,@%IAKQB?A#:O#G-W
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M)IN/:6M7>;!'3I+KNK['U^<1RS_!H3-"L\H,M)")^,XHQ1V<*>4(E 7F**C
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M[%&YN\QH*O,=?@L3<E3Q@6^>+VW/['^O[<Y?HKD_CY)4LVKF4>D\FX#Q!I+
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MC6NQ961G0G6ZHN9M16E-^0DSS3'9R-N>%5.?[]2=%) I:WYZML^0W=%-S18
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M''DBO;0\[RC'J M!CCMJ]"C;1T_69C2/2IB,!JP"4!D!3>8S+".JJ\!B*\A
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M3/':F,X;P08006#N.^75>ZZ_DL-/";;NPF%E[W)LXXZ]Z'<(.M3>9OJ>_^W
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MS,4P(6CM"^T'!RPX\0_Y]5\5?E7X5>%7A?]A%3;F$ <2]HA$P8\.R'WR]N:
M^%>AK;) (</7I4-Q0\37(Z_H\$Z%EB^R'ND%#^K5.QAX#1%6'^R^F+=F1VYT
M_V(?:B.S0OZD2.9M-O+YB4)0U@#_3J40U%^(H7V" 2N@.)L.3(HBI)V6A)."
M[@6"EMQ:6;2.?A#*A-&=0HP97]&K[^T#MPF4AYH-GD^'FYC'9^7[7WLYY1EZ
M8RW,X--"4\SS1JQAWJCQ7[4^W;31__D6^U7A5X7_]2J\^1@3^$>A<=L?3VQ_
M,]VF ;*SW0+9KKA"WXFH-G0-0Q.):PD0T<J3JS;&X_8)00DTGN9_^?WW%IF
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MAMDU&+Y T(FLU\[U*;);[.G:?K>K9_&+K5YD269 TCLT72$CT,QZ3WK.\^$
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MQA'!>:3FA4=;S&2:$!3;BUG>1Q3@9^&U3.3F7E2L$'2Y.$ ((LPK),G\:'C
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M$@T?DXK@EF^ SKCP6?GBH;/N"!7X==VR88O O>E^K?$G[ UFC@T1=OE%L;O
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M;2/HF/V(VFX-#CDY@E"O1 CZXG!JPF?<'E?2+,?"MX\*0<I061Z$W=T!_F3
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M!_Y-*"&IC(2O14HKWAPUYA.#.7V KUJ(JI0:=S7F0S60_Q#U/P^SU9A6G]N
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M\M??#PZ.19/J"ZJL&;0<FA2(M.'!=Z-<LR+Z3QW6BK)6JBF8G2LE+W4N/#D
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M=:R ZF[+1^WAKX!B[MH<RNQ[47!UYB_TOZQZ3\5&W@U=MVWA=?K/:@SV);I
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M&T&'NO7[^(FGRSI*[6,LG5."7SBRO:V;G,\FHQDRT9'AVO/]4F@IL)HFE!N
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M#.'26""1VF<F::Q5G1VN\YT#94S4*'8/P@$^E2T.SN+XSL)SRCG2F TN(^&
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M5V;L!O3R/"=2,S_=?L#=>4UA^:1$]RV[?;= 4<Q=\MB(.B;_W+$#^%\RSPJ
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M!^K<7P@=M2*U]R-[LIAL8'H*IA'2S<0,^7%A*)(M+S"BELXB=(P(R;H4PM\
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MN?/;HK93K@L/J F,' @OEGTM>P.:,W,HS1Y "66UMUB#?.QA*=U^ J%4#K]
MR$^&R'HQ:@=M FK7[@U6O 1HKJESY1/&T'"]I,>AASM$#8(GCIA7;9?YF>9:
MZ>*Z5<,3#43M9Y&3\TJ?U\;O;!N::Q8]J:IJ6;X_#=U.UVJJ>.3W+-/NSR>^
MKAKO+O#>SQ.I-ZH/AS:HSQ29/2QVS+,#K9->MYS^>?I$!0_PYN4%,(^8VPH0
M1CT#@$,)F+FT :@H-&C!]=V]_&UG(O$E'(Q%R@"644LJ>WR6=-=PHF$5Q7D7
MR+*)G^P;_!TJ)Y'1$AD<>=7N]L,JA>ZRK] !O 1$C%T..)!J"$O@/,GSN>2H
M $*/@FPF;-O2[#3OT.9'%+^]:V\KM5NL:_UJP_=Q2&E']H1889ZI73=\DYI"
M3D[5S?H2:_MZC'XA5&D+0V"<P_:<B2V?[ OYI0\35*+4CA!SI.>;Y]N>J^)*
MI@9RTL;.GV>W@P+D%$9H#YJ);X&QN>XM.?G32PZ+$>PYN=FC,;XW<M.COMFG
M:J-.( GO(.)X%:?QS8?_&37D82E'?)-!Z%J<CTULD-65)R'Z%1)!IO;]'D]\
M/XA]G'CQ_??7^HEHVW6:NRJ):^68>Q'"YJ:,;&:D@]/F^#O'JH3:"^>H[LZJ
M_+RF&0$2OR\N6#*NUY^:NE/&[K]?E[3&=G">2^W]L"]V5P ]VEGF)X^\7/*\
M-9D%ZD4GX8_W* #%LWW%@C/&9I38(1;H^)T2DLWUU4&/^K>EP:X%R4G;)]]D
M64[2C122[:SUKHWE<V%7G+*(T=O/*?,D<#_?7=P0]=9D.3GS.4F<*4Z7(OM7
M4=0&8 )=X:'"E?DU[G0E\K&B8UE!(A4DR4:#E)\AYY[7\HE>^/.K<<1[>6?I
MSQB:*?(#NB4KB2FX@6KU?TB9QT+%($)P'5,@K :H)11AXEN]!)?XXXT5C1N.
M:J5H&#M'^T81PX2^K/^>T(P*D7OI\?4/?-#IW_?MC<#)X#:EK1]E\&3JBXD6
M3#+2B)%+YZ5@L-Z<Y"$L1H3YF06:*ZCJ'TV2L(C71 PO&.TO.4ZU&$Q#B3=>
MB!8;=$_H>>G'M!YV\U'\<#NFNN_.>OM1/;/4*^&UWJHR]"J/?./OOQF8,RNU
M7)V1N89FO<JV5EHKKY]>ON65_QF.>*!=U;_W^J?R2LPRE\^3QMSPLVU\UQNM
MRO-45B$SR:V?7K^&2WE=E1')N"RM?*W1V2<Y3P%/%_P"W3Y%.XLX,8F4@R=?
M)N]L:Q'>8L0!7QB;LMBTAB/PS=X@'Y%6Z>\92Z,'O#::,B#[BRR0>>!B2*C#
M)>]!8IA<^C;77I<@303!"R37(/P>8,&M"X4]H@PT4V(>V"1%][.%9\+BR49R
MBT2"C!9$8E8WC'=NN$8ZMO_N7;+8]SO2MKR&Y;,-E4D?0C5D<[9YUW:9"QA.
M718()TDU!-#E@6B)J!TNY"?T,6-+ EC "[YS9>PG.F51_\V4/^54,^4XQJBK
M+6+TGM[36V&A8;=(S,\\,R(3"T,<D9:4G5X6*!,I 423?U [R$EUY2'Y[2Q0
M"QB[">4"'%9M111'S3#ME)]5:3*K_4=()!67L2_SW9W2D',=R!DGL7[W1T[(
M;F5OQT+Y,G-MJR)>*X<!6[T >0)CC9A[5K<@-0*C=D]:%SI[U5S8ME(-G%AW
M5-'95B!34'FEUAMSPE\,@17T$+Z=6P?C?W3A<(H389TX51/9Z:QZ]GRL2#7!
M)GB):D;)S>JS2^5=PC\01,Y!Q($8PL(A9\"K @X;8.I2%%L)RUWCB*#(AJM?
MO>%IV"N7^H,BX!KU];KD?IBURI/<!EN**%W0 V_; 1215TV!QQ11=X!"3B,R
MVY=&A8+8: ]V69;0>6>6R959(F])>"Y 9^GP-$VSNFYM'Y&C4%D26>:YMC^]
MG/M)Q(' V?#4&$PS"T(>9>1?!\Y6KGO4(OZ81 7;<3+'C""MNBYA1+])NA*Q
M8>M-2^V[6^8O<.FX C/-_I80QX"N9_UO+OR<'4#-AQ'0_;SX5(R0X""X3;]B
MB3_56V2Z[A4F(,Z.!*DJ92=*W-*HP/JX>W#QR68*)''IXO1/%H@K*/_(KROC
MQA),J>:D\(A.9*7'B+L5>H:HYKAR)4H5$CA1H6+KBGUI]-!<VSZ;VC79K?:V
MRK"58U7TF$;?=3]K+>=U8HW_V01FH\6!_.G:C+J1G N<KJ<SC$V,D,,"EOXG
MZE)6AJ>6N5663G\7,XKX_;8?W+3:ASZ,'('Q,DT /#6)^8&B-9AU$)[6C^9C
M"JRCCT79!+A/Z^WPAS2O_?BRL7CR@6.6U5C7:9(R%8BG\'UJG^A^911B<>@K
M.&7P]IG3M\\8$7Z)-Y3W:-,#R#O]80\P34/8(CGKF9M1J/M@_BY7(E@0%JQR
MH^!N8UP#O.]'OTN^T?&V-WFHI@M!MU]_C6M3"SK\SD<H5$2FYU8]3K4TO<C=
MRB'7JDY%68$'.1'\5S5>B-7CCK3\:/.VK0WFEXW5=D.871X5\*Z[UY'IO^Y0
M9\=M:WA32.>HL_IA(S5>T[3<LP2?Y)K5E*)[/XHLK9QE"ZH.IBK7V5U3V^=C
M#W5\S)%]<!HBDB)'S:.8)$@\H.O$0CGHQDD;"XI)0P,>V\\7-WMD4]YS63,,
MS'=OJBN8X6_A<OL_OB=R,Q&U^Q_8)@Z'>/CAMS"4$.RC%E_7<:;N FQ#67LU
M+NLJN2U3=TXJ0-%X_5=P<N4%S0AM;Y<HASN[^Y_YJ@QL"PO&7]J&.[BN?^J>
M7;!:L!ON\AVZ3I8Z]-R:6Z7/K>:-.M^]1[?.)(D*/ZSBH:QXFK>(3E<M"E?(
M5'UOBRMD@=Y),=_&-(PU"*PRQ=2P<FPP8-SM0;%"5)]SW*!V84!Q\<_!-4Q;
M?6OI&LXV$\W;)1U18/O,IU+A4WNTFD;?%X^!X.;WI6.)V?;''[^3/W+]@$G(
M)I_KTO+/K*V%<OIU&%>@PP+^*ZYO42*F4N*R;-SU)5L-J=)#*C?<$,N?Y,YH
M2Y]MZ&ON\@\UZC"MS1G,KBKR\3O/UJ=7JG^F-F8XV^:T*FPY7YRGYJRD:_@7
M34+%"9?1"4$^\ $B_'.EIELFUTC@"C?YLV\2\W/?5#&/6_H-K\N7>SK)/^SC
ML>/?JCT+R-GVT73XT?,<G Y<)[>C>J7B)0]Q1''*"=,S4+WA&/\1?J+=T X/
M(IB<F]CVK P1,ZFGEG5BG7IW/2Q4M!_,9]+ET58M89'R $BVZ6S"='UYV,F4
M?/94QW8;MA"6AKGIY3NP*$+A3%P!@H@:1EK'@T1QE_.I[=%:X?[Y8\9\D0?U
M2FMMN"(H\1\-$A62U'X?8X$>/(@J,H(>0GY:E#AS:GJ%$I89]9[T\7=UI<=:
MYRVT_)M!BE1^Y."?\<<[C\<<Q%P@WO3V<90$UQ&0)2H=DW>6TJI2G8-BE1R?
M?2P\63+LH/W+(W1WX9Q.%C8@_]NB[ VW6Y(DG@ZJH"[6ESQ76.R<]E'HE)0"
MXK**59)JG;N+TX;/2Y*S6\L+ G'&E7E=N325(<7$\BB7_FEB1^0?Q#_$@^CV
MX4NHA$79!U@9I3?C.[IGHR2S^('(_A2<U^: QLCK2;I]^:911$M6F"!O0HOG
M4VINY@V7V_A&=NO?-J!=#-ZD<2-TQIBRZQ"1)D8U-, .-$2QMF\&8.3/NW&^
M_6 !1&@=8.!.$1Q22B05XPCK81S7YRW>3ER'G=1K;"_JVJ"#?7)/1G,@K_>0
MV*US&TK B  8JBA%..D^*38$-A="',*"CP SO"V39D,I>OP<<.J/@7NYLTG&
MM;,96]^W;IU8?+\1YJ?=Z2(X).06.92"':SPT#/),,I.;HTHK.ZS\7B2J]:A
MB',^&^/8:?OY/?!9[OUI@#ZL.C2DW.NK-I89L$T1?NUF]5,PR37%_4[PQ^ZS
M1H^K,NXLRNBL9!AU-5OIK^@CY9'OT1Q(:01J'!K@2W-?RV>>G*2'D\)XZ"Z4
MRRP0']TBB*B5W'9/2@N2'U9V%1L9%[>T([9Y4&\B*[G%TZUNFW[^3-#XAN"
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MH@P014 =PT95VI!&)4,\3X0\^O78<PUGVE/V\FNYFH3!")B'!;J./[:)YX&
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MYYBCR->*W4QUC\2^ 8E-O=SY^J;F6*8%6GW[)M/]4-HO/!<6$[P:@6#QU*@
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M;*TQR-+EEY5_[_PM8\@^P%\NW8!/6.CKQA[2+DQRRGYYI>?0:X_WKV"-O8"
MY*;+XWG;DMQ?OZ_F8D?=%13SU8R^%#5-_IT)O+EQ3/5+Q#'ZDC2A0RA6+[/M
M =J'2[<1XBTC>5Q7.;M2.E3Y,]TB_@>O10(_;ZZ3K[-S^URK'BEQ/??8Z#O=
M\WI:/K:/4RDJ5K[';=;0KB'RSI&=/3)1'1YG^*@I$$$C4>E \=*CX\7'RD4M
MC*^4O?L<?.L"<>N(9,SARWV_##N&JATN[?Z"?@K^E7>A__!3/@/09>NWXFF#
M*V,I VW[H->_]$H3H#7]/X*62F&N%2Z?_;P"M?O*EJOX+1ZSC17?55-GM@Z
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MC;K7TWVU0=U*U/,*\!,^-%>BPNN5EQ:D+($=I#_SC>S(DL*>4JH)4O(%"\[
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M9RE3-[5W=GQXUM 8\TKN5X_#8FP_JPZW9:%W).MK&Z8W(/$J7K05)7FU)\F
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M>&I[#F"7VHO\#]),_J_]2'\,CME-+\[!S-MRQ^I$VU*#,YK3<X"([1FMP3G
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M-G@"!*Z;QRH]M5$+.*9S +O*L M)(.[ZN4W_:9@V?=M7>TLNQ7S!)!;Z*Z8
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MR :]VDH+BR*]APPY1#2?_@;VBP41XKCX[+)J'L!_ZO^:CI>TL+AT#Q4@"0P
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MJKY\R#2<JT"[DM\0CFUR#WCRGNB!]1KV"@_R[^6]',)-REE:+(K,PP5;-UT
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MW)W\9)R5M"M@MJZS$+0H8X.7A@Y>^6 43\A92'@LZ&DB,@:B$AM@"UAFX;'
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M8#6G,^U*+^>]-H\Y[OSLX-5PUAD>/B$2KS03G=Y)E0;8VO# )!4N?@<83/#
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MZ4*+-67%3)$Y A!1,-E"OU5.Y=P4.>.IF2CILDKW"@Y>/RUC6R[_2"O2PDV
M4FO_)0P"Y- $#@B02%_UE'. *^? @=5="/ &NY2' &W]LC)P1=@[9QHNV3J!
M@@BY"-!SJ8&9#G+\:.,+8-0#R3D'2C "M!:A V@297@ #V6"-:D(8"=_"/M1
M3["R=0@0:B)U1;,Z$8"VZ3.HSZ#^WT')FZ"'0Y#LAIWU6<W;J7'[+RFWI-Z1
MS^"F)ZP5[J:1&+T!__[K\<%7>.&QU)'NTV="+,;0+*4V261386%H>2[$6*J1
M%4FQW+'91LW3U4/F; %>;9:I'2Z.\7['_J&R^OFJ87[@%>*NGPW2#!6U)1$
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MO0/X>'L#;I8 SP!W_E]>_S'(_]LQ[MQ\ ]#<!_R^^Y7@#C?@+LT= IH[-P@
M%P!PA^B_=P#\G]>=NP2$1/>([Y.0DMUV:*4&W+U#0'"7D("(B)#PMC7DMAU
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ME$$] F-=3R*R)#.UPWR]M.F9 Z3Z#'+R2^#QHZ2WKU]+/5.6JGG^C/W-AY6
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M5P%#4U#NV6J:?,660J):J2CW6!FOSN0C73SOY1U',.<(<?KY9CT V%397=T
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MZXY0:9*<_C9^+K-QZ65&3LM0SBB@*"J\?[WI0%U[DD74=:C;JF)W!J93%Z0
M"6TUD;996A)TBT-],-#(,8DS^-DE6%53. L4*]Z#\>PQ/MT97<K3E>U[^GCH
M*<E3":X5P_WY7GFUC$0#&J@!+@ E<L6F>TOU4/F2/=6'N0<7?)G7-6"*H7)Q
M$_?VQ.^6&<W5M8F,<HXMBF_C_UR<P/I3D* S->Q0^Z4?7@(;E1T-?5:%%Y^O
ME^ESJ]MI]W&EP<D;-U+P_5@P:Q_W CNZL>][2JGSVME.-\?.*OWAJ@TEP,7
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M9Y6(]G5WV3]>M@4WA$2/V6%)Z]\C2S4:M=LNC?6>^"[D%0<Z=AS_.G301-P
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ME5RG(G?)"8@NGCL\$7&C$+^?_2(&%''0.6T-)R^]-%HZ9ZK]<PA42!IY213
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M$GX?XG\#0(W_:0ZNP%7?;QU7/ZV*[6 MZ\O:O@)P"?>]^/##:RAN2[U)@[!
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M-+IDD0.&*;)6I_MZQN7Z9/_*A?AJM#V0VLTUV(#X$Q AQ-,":Q[K,3VF^?/
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M]COU;SFY*&>Y>VK?W@#Z)(#J]L&8RZ$+\<]%N"310ZAIH!]3_%%9VO;C.?.
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MG\$@E5>0RD%5#HQ!3&L8 Z[9HN$G4+GHU[*K%1Q6M:SI[N3HY,:F*S.C^Q!
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M+<VJNL86ERF;]?H/_K3<M%R7)CDQ9,_"Y'>>8)<)0D5EU-5(37GB:S9-P0W
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MDG5XC%-MZ.(/"QMBZS='",K46N,OQC-%][Z$?3%441@PZ1LN=4H:P+@@E8!
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M$0[DKGHY$@CK,L!:27]$I$WV;B_:6'XUC:NN0)K0D\<AG6PJT:YI+M(ELL]
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M"PP0TO'6!W_ZQY0;[XF],>-IO@6$\_8ZIZAPD=EC#S\G4KUP7B9K^O1I:9"
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MRHU+BI;()_O-Y*ZM>(:H EONG-%-\@VY" FQ/@KDX\XN+)?$TG5<&D%=\+<
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M;+NE8>(=;V"-R!?5%//639/+Y\GU],/EF10!:"093-2U\H<\+'TBDTM<*9I
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MABK@_>OW C/XT\3[L]_O(=N<1EAL 0?];(ZE95L ^^&L-8U_JI8PC%B5U'/
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MKB=0Q] UTC3Y7>5F0?X.-DMZ9?AICM<*)\,)_^CNO%:N+54-OZI@E8$QYEQ
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M3:$6PR3NJO,BH2^HY6DKGT!;EL29'=NVY68>W\]Q#!W(N$"749FZUABD]$Z
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MVM7!.CF1W\G$52Y[#X< 'B> PU)[Q'Q51;5"Z^(0.UD[CJXIVYE//=XL_8(
M7<JKRR0OBXS(@!C5V%8#,2TH(I?<,R+TF8%W@2;(*[CBOB-!X3+#[XIRS"E
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M^L2+/9O_/"[!C=0^?;0@WJ7O&<&7$%X!/]=U6-&<"Y_"5:_*N?&9%YSDG1M
M;IR7T_=A'Q+0B[&Y&.MN9H]^'G-P9SKA6I9YAF4$4*Y3S^^.5>"NUS3A_ONO
M$YDV"68E+^Y0BO7>EXR&W=;RJ$T'L7UV_WTB#NKT+H/GA5>9U[JG@(KTLGP^
M+%1;S=2RODV<\GKO]<$9WVW4N7C["6NT%<)#N$ZP@#L\7LW)QO#]9JH:HN&X
M[.2<5K)*=D*9GX^@-U<*Q]2K;]JB&I\<9+Q'KK26)J (C0@=@WKLGYL7B!J,
M-_A;<J@07/A(3B]ZHL+8(>VZ%VI*YI'JQ"Y#)B6/E);<3_!\HWSCY?)C[4CL
MX8LFUI'23R\&$O=U*E89@X*LTOB=;]2'W]?)B1>.#T(4\Y4D )8E<?#/$0EH
MN4&/FW^$L4,>G__8S#CE0Z!I<NMFJO/*^.%!NG>A[&RW-Y=Y&A[%O:]JH/0A
MUL6/2<LI#H<O/$!G<<%\M;]-SE]I4T!8-L7LD%%1IIU(7K:R8I+G%=U3 #O_
MAS2#;^D^(0[5V:YAJ6GZR1TIM4E64/;=8S4LE*V-A0;LXNJS/^\USY\?Q9TZ
MN:^3_*!2;$GW9U.0;GW?C0=>1/6XRT=JQN/NZ$^,0Z8FC3'?L>"ZC,WM5?]+
M'%P4$5VIA,%'9XQU]\0!9W4XM[D[:3(G4G1C*DN/[5J R(C[YQ5!5MWQ4+'4
M/#E"?^-B8*V!_Y)X?Y]OC&ZO"DV@J]697)WZ19\E?>$.)D^;.;+P*RE+DM/0
M3,+4V-+/%?-@Z'O9JIE17.:X]8[U_I.0+N7ZFYWFW0ZUFS<&*7(]+^'K&M4!
M,?TU@^8"KQ^R*I5+V'LE[7,L]R0(9EYF+[5AC7]@H-#6?P[ \OB/CF\S.K9]
M_J]/&?\3.!<_OA=D^\!/6FLWHF[LG2:'^ZO<5U\*8*VSJ:F6(8^7 ^1_1QZ9
M_J!EH#AH3WHM": FI\BM-GR^"_YI?\TSO8U]C,.516%)C>;W5;P )_YJ:%Y&
M=T[K>(KA9X;Z%JH  XE%][G5I'K8*0!3Q>1[_QQ#^PW5!W0C*A 'CFN3B+1H
M25,!=O%-;+XES;):%:1^MD'$>QR\!*AC9B='AD5D?IH8&^*A8IF3D"[DZ!"D
M2$Q":RK3MKC?7'3/C&1X-\Z!7_&6N&\N,K7C/M_>CJ-%2.&7R*[QXIA,[9O'
M\3JWKQ9HL=;L8V[W?3=-2PKCKX6)S[JD-Y>1OXF&0WQZ7K\]]-W84W%CP=67
MI"5OWA<SU ID.MJ_IM*Z8S6I-,AJ>SL=FJI-!2@!'E+'&F2Y:$D_'[LYE_OX
M^PD3;6PU% V\?>Y=)$6(/4L+>%9R^VTRSB'.LJ^I0J_/;:6Y:>/0ZA@2 9F
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M=J< _NK=__"E\?_&;[P%):V9,DR^4DP5Z6P*[L&0LGD"H)0JQ*V_SK2%G,S
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M#G%]#*V][Q0)':<$B@O[']3^"[/_.6+A_TO,_ANQ_X?7(H ,'^]?\O I 4J
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MF*'Q-$N6<>04Q QNZ(V!]4[_?MJ5JL8OK_Z$\'=I7C7EH1QV>2>VA51HKC+
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M(K-PCAMKM&?W]1@QCBH"2LH%P,P5$?"[I3LQS.U*C?0B112,J7G4PA3AY1/
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M($*UA*HV)^I(!KM+F'E\POR1^/<4CA&!4I\AV*JZ;4S,ETP7YZ=&AO>TJ0"
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MC6TA;V'@5RJ&  I.C6_<1)SS,TJ-A$=;F,+SQ-X.S./;VCI,_$9MQ >@ <8
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MCM8,]W+^E<B.=M=XI;)0:0G?1;XHXF]H'LTJ#CWM/L'-1WTAW8X_98)0.-'
M-!M@9-3G-NV\-SW&H(#DB0T<+K_G# :Q=V+L0PYI]@NN >.TC1ZM(<)T+Y6
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M[,Q9B[+_B."[:L-J_V;OU%/\=4S+SA59?*U)+OQ5W_M>O7*K=B>;BNE"-;[
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MP7:L?#OII"826VAH^!;W!]?7"8  X )@VVEZ5W.V5]U)JO;+M)_@(KEF]W1
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M8:9AAY)H,LDXF2 T=X&'J3S@)LV0S)7WH/D:)Y8OXP@JYVG,"^/ D .3R>\
M8T4"[<T8FJ78,KI.4]_5D'2EBE<KJNO%%=-UQ.(8D-@3F%K0TUKAH1O_  W*
MK73:U]LF&FR!Y"DIQ"VR3;P3$Z^=GD82/7CD<8YWF7Q3<()[)MB/VGAHH57T
M:"'#K3VN;3O##2<O:"59 N(LJC?9>MFO*/>-D2C@+T-^T%36U0;^'M9S\B$Y
MX_=:PY*D*AH@Q[BI_Z6.(.A&K;YFNM#=W<NJQJ!ZX:U/E89!EH51F>5?7>@
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MJF[B-VH2^N_*-[@5M'<*RKW438;2Q5J,)IJN*R*8P@+1I]#!A_+Z7#%]QGA
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MR%( _C4M8 _=X&L>K.VH[+:(=L/M3 2-O"_:']H3%E=1,@=ICR?/W(.%.Z8
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M1*X+RW/P*W\'S\2<"3Z%FL32;?G 6VMR=XR:J<6."#CHYVLR-?O)W;J[->X
MK;]!'(UCO2,$.8%;^2WE%Q%"WPT+\%:3WFPI9.T.LHK#2\)4T;$)>CV6X)B)
M=_?/72CSOQ+F,5383>^H&:O)%]S[N11Z+7)H\G8Q<6L/OBW@= <@\EA#Q%@I
M9H8R34L%,V\+AFPU2D"NU<%OK3V0#14AGB*AR-Y\D-^ZJM4W9I,YBO:HH56\
M5]12"GUY%\@$L- C#'7=[4&1((2YMB>G=U*7*<>N:=Y)7S%ZKO:7L<?11'9>
M77&>Z<16T0WS&2[(9BL>ZD1O94KSADNCM@A.DXZA=<BU1RIKXF:AFUNI(X8>
MZX6R!P=SKE? RP",ZT>SV3P-]66<:F5%TF9FN_<SZ]G> *;.ITDL79[V Q>-
ML#O !QO>T$$*MZLH44J%W&"WZC'JPHD6FMR<%S$./]74K:B^-2X=L^JE&L^U
M'6MRDN9T!/UYFN0@"JO?2E$PY:]:-46Q/-_1%9KF4-#1<<]JNJ"!N,UF9,G]
M7LQZ#74=C%E2N3;\]0<JC&(A&U4R-C9=:,J-)N*QS2OBS6D=X^Y=JT;],JK^
M#3\DOFK53.!NG-'=B$S@_D).AXJ!L'Q PU&<O6+UOJ[K^!BO.K;ND>=N5V0W
M*V)4/PGC)=#JN,=\P*ZVFQ@%>@\Z5[9BF$5GBOP;Y20^50AVT#1O;>DF)YHR
MMIEF_0XPK'7+,8D>O^3%KE6[G5&B6*FQ;Q5C;QDZU%9>7'9N>:R [I.8 9[E
MKJ^?(3\+R='4K44XV<82H5,OO;%<Z!W[1QI([YA;FJ:^*,%AEC+.+._@&LY5
M4IK!KBZ3K]^>9GX3OWH[^"UB&/=P:?L.H++.WM&9K9IM9I_QZJ'^&DW"QV]X
M/M(S>S:6J,:H']@6T^R(.$7J-N'M=(IHG)-OJ1*+CB^SWLIK:O+[[WT XYH7
M>3RDV'';FS0)IIWN"+);^$;;1K37+FMOD5 \E7OSRQN_CDZ3M+*&$&XK_%^Z
M5ECU.$47"BQW[ >&TP'2<$2/;LJ<L(4B>9@?UM\NE'GS?ECV4EMO8EV[RY"2
M2+1F9F_"C6II7M#Q^6L*J+;#Y>5-EZ*S&^ &$N&0?P>@!HO.9@DI\.#N]>>,
M76:4I@D*%H\Z,>XNTAN*->="%AQ(K=\/L\J'PXK1IA3X.(V;OG AG-1BX)K:
MS.8I+-GR53=6Y!WJ??9C;"@TZ*U 2G$H\G [0PU(>%&S&=@9^UU$-8(Y>ON^
MLNZQT+$8.A.E_N\%C%TJ)I<GP)AL(6EBX[:ZX#A3E#8K,%4/(X_@^"[T<#J_
M=,I/&_*A+T4M9A>)"@G+=DQJ0'E@2F=NR>:Q>*[H R+,UA:U[$7_R(;EP6*L
M:DSH.S69,&RCG:_W;OGL5#S-Z.G7G10=-^G#=T*!%;C^P$'<8UN)A7:@M6?^
MV?[?L)E?&2T7(=YOVJZUXTPSULUVLVD9Q%:><8(-Y]1L]'LI4RY&PAC1ZO$#
M3#AI]$RDO.56H2Y*K1'92_^[=4O G1!TD>P\MV#")]-NW$E"FC-YOU97EC<^
M-SB]*R-T2E??DG[D.5&CX..(YA6J#_)IX[NBK0&O2"9E-HD#,@.?ECW4/[?-
ML"7-6*@)2LX$_=88B#'+H5&NR](PL(+PIF&WN,J9'R\:[OKJ)VA/:ZMRKJ78
M'([1R0K6B><EH3L^U"S?U&GU9F4\LPLA5:UL[?Z4WL-7?)'6C7J:5'Z\'1+3
MB7'7#K=\1S'<(<58WTIGK7.\_D1*6Q+#'9KN5F/UC;I^V"]]QH.Y]COYW-LB
MR[&WNR68YW),9 IW "UXV\\+VL@S>C:W\JZ,11EKSSESX BM1AI_ ]OR=HXR
M47A06P3)?M"E!0-MIH?%;H'7YGSV/NTZ7VA(:BX_I3IC15L0(LS)YAZS^_DS
M@)1T8U-9SB8ZK<+VB:88K'RS:>(@BXO0R.C0/K""=AOYD(OQA]6)Q),=&8Z_
M)D(OILXUL4F<NO&%_*6&R1H.!]+R:AS&=3%%;$3O/V4_]TUR,*DO8>S2G+OD
MK2"L'BF4DHH8 6Z!:*DQ'+?9@@$>[S3IBRS-RP87(.++[]M3$,;QR]X"6AE$
MB[]$NAX"1$AW^SGAXR8]=X!B;X>;BHJ!?':JF1=') ]:7I*3M-=_3[GTVZ[[
M-OOZ"05-="/8\0GGEB6\4;L$SD][-3W^^F8J^7MS4QZ"82O?[_7WKZ(O'V2V
M!=9FEQET=\/#5*OC&NSG/3>-YSWMJ: DG\<Z%X/1PL&T2>-'<U_''1^K0>^C
MNFO5"1++:VO%[4S(*Z1[PN;S"HQEX&6R-"_*>2<S$0J!XGF@:][,1(.C45VI
M21'1D3X3P0Z6=OD7(>.41[[$ 7N\;>XHMRT>S6@M"46/H^<UTYF^OAHH;G@-
MBRZHLR=E+R*G*XKHG#+:Y[!+U,^OZ@FX3F*7,3A^10->TM%M:7[!=#A,FU7Q
M4_./X5&>5CI_?OY;)=I]$D%\_"%\OKF2+*<DX0![P&.0//][L@,U#0-R/\C7
M4UNY^%&=J(8M=R\=X:R3RM*R$*Y%@5YK*1;'><L=SVO<H'!9<N4G=QZ3I&>R
M/UIU,FN^;Q'9NIU5<!%9E'Z,VJ,_KYM4??HL1NG!VTA"'%3 GR7N_[W !0O!
M=!%2R#O T(WNB"QK0CW.J?YP7?KVIS>YJPT!NJ@*=6QS]@0?(==OLE/?-N;V
MK*,MTC&$,Y-H^MZ4>'Z01N?RO5,CTS0<'W8/O;=%]X]!:+#JIGE,3^B,>W[T
MJ3B@^#3"7D# WA8MH!Q9VSCQ_E=0A9Q0%J6S!I'NU[S:;P-Z.K+N#YT?O WC
M\7NT(M_9,0L9^H1BPY-_K\DN_RRIR7]D^P=<9TK\LO/B #^:IMB_SBT[(S\T
M\5JZ(>JQE4"9U8C@=@R[J 9[$'1LCK<T0[.$_HE'$9HB-4P,(S:"B$C"L88A
M4F,O- +I/4\9&000&N(0S5.-?D/J+[)_31>E1!Q3\YV1P]2#C8<G;X+$_W_$
MEO^G$+J10\7X#MG4,>F!Y^NJU9:3J)7$0?QURZ]%ZC@V*<(I#^>.S>R.[.\?
MF">&O)U)94TA&LS^:A@@(Y Z;O8;<T(C<]QF'5O9_8:D\AB3!X]>/_VH6UKZ
MZ<4G!QJ9R:R."AD977,9OLF(H,M4HPS9YI]5J6-&8SHQC!_KB/6RF"4XU,G[
M"QD#+).I5QV.95Y4O.I?,O!W8Y\W'6%E^ =T I(C*R88T]'1<D3[Q-1E,1$X
M\D3NW6/+_,)A*N7NGFQI\>43#J?71^;91$Y/RV*>\6WS;5" Z;1[07*6<X&#
MT;=LEI8>'HE,_;*'UPI7F\K-UK+3B0(%D^+YGU[4SZ5U^?0M_3(]5KJ6'+_6
MV!\D#4@<I/=@H8/+W\,HCMX!'ET(*&KEH9B\:5=^*3OK4AS\JRB/@05FOIVR
MY86*---K$4:UW '<*>)[7&("3BEPPNC.C[\;X^X C -LN;^+8Q5(^Q)D2N%E
MR0^";\4P9%_QWS&-%#'%#RQ5V_Y-$S^F;^\,2B_V_A5"%\_006OL8PYEUA%Z
MJ&&0PLH:"ZL%7S471(02_ZZ%0V*@<^5E]*KV-==NW9H_XZ!L:!:Y*QD?+[OH
M2?];BN\MJX.*L(7OO,ZK$I]];C3_TEK*TNS7#U*^'[?#@.4G!6'.S!=U"]F&
ME@=FK@9E1&_<%SZM*@BAI<:*'V"!>MXQ><&)@N*%0.6VR ,@$],W(0%D:_^W
MCMZ>^..YT.!>/W:EL&?F+U?+2[,;!O90GN'\&*9? S28CO10E!!I[4RUN^QZ
M%LB[$F$Q\>4?^@53IWAK8;\FX3%[!N/3K&(I;HD.OX!)1BP2S,"+=P #;#)J
M\9TEBB(A,-_U=!,C%=? )O>95G6^_K>UQ-KQ[V1)IG2R]MHO9Z/9U*/7S-A!
M%:'@4MW-P][K?-?-@2)NP7K.@C'A^E+D^H^,<'NX*MOCMTM+FZT#CZ C]#E)
M99'0R3P2LH31X;EH&55HJ*DIR<1*=):9X9BLH(X59#A4ZB^G]XB-@%.@+SUQ
MKH*B_*2 3N\__\8?-0=BA.O4RM<(D:U2AEE&R9J?W_Y,&J"'/M1%^)EXU8<D
M&\(>KZQ8#*-2:=@?6UF5FV 2>T.?<!X@RQ_2PBZG7)RB/K0_WII$QLK00*<<
MT*5W +-YNT[T27Q(4 [F0(%[P%RK\^U %:F[P?3ZK\_U<^)Q7(@&6B7V;U$[
MPWBU&-:C0DP9E)&EXLN!A>E'BW5DJ6S@R$$\=8<N=0(,Y9BL+#^5_/4-(?6'
M-#6E W'6GXW0LQ6+T48/!?I.RU ST 2[15*]EB9!G@D,A2"J6C7_GLE'^T)C
MWZ9<C(5NN,:XIGCS5]>YK.BDB,BG_O*_1CL7GN)VTE##S"3#ZNV]&06GH_V:
ML*FPQ+$^A'A35_C#:=^&^GG?W](Y C6:B2.S6;\,;^'?#Y9*;,HQU L6M=)F
M(X4TR@5VABLH#O5QH3 WI^I#1$X43@;)2HP-DGO"[B$;TRWY>8GRI]M?8G:B
M0'9ERY@MNP]KI)^-GR4D;(8)H&'>=. MG04!4/LI_0:DXGN>3JK7F97YF/7*
MT55*E4C.$:/-[F2BBN_NJ/NC:*$LUG!L\*40VK@"VK^1%*:!HJ"K)TPO% UQ
M:(*3BO1\>]+:7UM9(E'ZNO;PP9*3*+[24\:K\9?HF5B<@&-/1&S .T7U5KTO
M4#L0-8O7<'3(MNJY(#L@?5?K3(%B'0H&%S_R.ZI-X:+(/-\U]NA)CW8SA,24
M$.O(IUVV8T2+Y"B-J[A,A&-8,C1X)9[O\*@?_?OF[_F?\,!VP+?<5< 8=!>O
MF446.I4J\GMS.^9';9T]"\6]+'A)^LY/<:2.M,9B3<I8M[^\,Z-O%;'?7RFD
MRU%%U3ZB/399@8N)S,6ZZ;XVTZ@)X=9H#U4S.4>ZU<G\Z?Q%MM-96=@1N8BM
M"V\M;RFWL1Z-\4MC8_WWM?C_>]",_U" YF^0=^&N^>YSZ:1Q2M[I@A>%Q,#5
MDIB*H)LBEH0_;M".'<Y&V0RO0 Z93JX;L1$KNM$"RIP9(>310-%CZ80ZRA0H
M\$\7;I+F&[V\B2(=Q[$OC='S$AT!6 I+1C*S!*\X&['OS$);H93UW,43.O/F
M]OG?A183>SKSOP]_&H0"#YF^VJP?+.XRW-.P*V)@D:'\0%JOZG]['TWP<8 .
MJZN!EGHOKVB'C"!R%9DB3_VR'S?[T^V'KJ_ ?!H"=K(KW;>_[:0]]A14]Q[0
M,)* Z2]@7E GE$U/C*R9Z)YGGZ]X*.?//:&?Z*LS!95L2+\$TB6DT(+I4;XD
M#PWZY8VU&"'Z=N[VKO :S>SGX$ A)][?-280G4(WI?EHV?9G#-SS&4X^&X\&
MGH!-4<&Q7GT2J'Y9N16988^0(9*0JK5[UW63#)@!(I3G(R/D>\102N$4C8L,
MMA<#W-Q(4B#PH!^@\F!YU)V;HXD1%^[\U)R]FIWW14^U??5-;4Z8*J=?@[_1
M[Q<AUGK9FSY,3VLV'VE,R_I1U#0N3SFHS5W<2)Z^7JP7:!>0O.**/)@^X<@C
M*@OD5>'#BP%D-'0%>(J*-N$/2MT*WTY<+7UD.1TK)GM>;(G^*>0;C&R!6>MJ
M:F4[P\^(^MNU"E1O>R0(V#^\I&<TZ4Q+@G2!N#9>R P/C>_8I%9XJ(L(OV&P
MMF2 !:6G5OI^W4_XJZB.(7DFK( MDG3=2=%S*.(TC#%G\Q3M25,RD/V];U-5
M[E'RB>Q@W%5O%3<4RA+;S?KA"\7G6_JX<,+;C0A&!7);4#.:]3A_\V<X%Y9L
M-:M=D49>Q&O6XPK4X?M8VY<H^UV"\;8CP8,41=,^O&K=.K"M;@A-WM5H4#'X
M U!6VU4KU/JEG&YVF<QA9M'%7X=KMS!IC/J8;G2/U)AMC&B((E.$RW$0:X(M
MJ?<S=MU0P035Z58D+."Y6OM"V^]N#8'AF^NT]X]'NKUC(]K,L65HN!*V<(LU
M):>(H0V;Y2VP4#Q2'",KCT@=$S"%I7]=O!J/#NAG7)&:=0]:FIUBBD_R5:)B
M;TP3#M^+<46*\0^R1HT[_^2OI6>8A<%K$E)XVS7@6;]0;+&C2-?%0C?+91GU
MO )#HY4,[0G%!'!ZRA386^&KOU5FM%@*-Z3( .H(3E(PM>0?1OXR+=^W/SO(
M35$4AR&Y[7@F@#3$AGJ-,JI+^I4[],KA'Z\-P&+ZZ#L K#I@AFS2L4<7.IG,
M<JC7#(Q[)>*>O92F$BJ <WMJ1O7=*2TWBY+M8><;QIPMKN.*K5_MWA2W,QNM
M0A]*,7O0T+I>72*/B$?/SCFPEINZK?5!GG!P CM(X=SPE9I@AZ$51]G#]9&7
M7^7K4+I'+A@@*G9TS1]%D-C0IX&&J\X*J#66A$FR/"\VQF:B0 J2YEP]F#M
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MS%<MPQ=3) >LH^NBQR&6EV:?58<G)G.H8FLZ17!52$YP2Y+N([!E@1TWLN6
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M9$%]<^ (?;(.^@8]N7%I=B+@=TMG$K7R[4K9=PV.:Z_?.?5D55F(%.S%)M?
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M0/!DL7<,,7B6QC;<4AE9#99_3S-Y(<L ,;0?45AWP4!<3D"6+D$N>D(I9_5
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M+JX\"I8X<*;C@<7YP;ACA:-Z;I'H66' ON++$68;&0!ODX/;Y^3G(ECG8G<
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M"E,]8UE>BV-PB'E%4MW>M['CRXI)VK+4B:_0[22T[?PVV"MG(IYNBC@+(4>
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M&4VB5#Y-C,-1)VKZ)YE#5NEC7Z^>CP4TZ!B??J0?+_7!S8#3XLS_S&:7CU]
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M25>2KC,LO^M[$2U!C2XBGX $48_W3D!?9\_3(,?)LZK4MLC"-7YG I(V!KU
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MC*(0XF "JMNQPFK4M@9J-UZG.J)#L105,F5&#>J8>;CM.(*_X9\K>_A.03'
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MKA5ZG?2R>!QYUW02M@(Z+[F(^!*QK*V?6BAB' X?[_I%2_>B*=E7&XS:^*R
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M[T8[/2S9NH"6H(98:QX*UW@^B"\,:;$H[FBFJ$YX"LD+G0=SI 1ESJ5"A^J
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MU7Y09:_YN*=T]=]][&K.BA8MG7*ZVYGQ\[DEJMQ)_3TYM2 V6+5%(VISY9,
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MN]T9KIB1M+W+SH^V2CZUW'UBU6<5YI(6^3+.I0+)S=L)C/R81'C:>-EZ;O+
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M,+] U<B.CN\=MMCM(X_'[<Q*#S;6AQ_<H64<6!JL92"<5*ME'"I=XNPF8Z,
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M7JL&*,63UX@""@2O,;X#Y/@QCFN?^C(B^U;=UX"=RFD!G0(993*?^3[VX'>
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MK#QW&BG%Z+T#+BE7^'=9M;-&F\2\LXP6/+=>I7MNSCLS%3[[1>N"14_E_'=
M':MR#YBCX/1F?2$$'O>C\^Q?'?]69YB3@>1WO2))\(!/Z%ZX^\TG)(E3/$S9
MEE:>>W8G]Z&V<8^8KO]X$94TB0:\[5)ZCCF'H#]'OPI_KJS-T@MV8+[KO=(K
M(@W/679&LS1Z1>&E>-G\ZNNN!O@@+=OJ_#'.ICL=Q"^3F.3L8%4;2%8IFJ7$
M\:>H2Q$'S/EDF%I(OT$OI<@\>*$TE&4M4HHJDA O#;:FVP^8[10G7\==Z0<;
MBH2U6(X_X,C+29R9<@):\W='$)BB!@0B.MA1A#)IQ\;LVK&-^1F5,:D$E>NT
M([-TJ]73K!#&\$!:VV?N[@#]Q%6GYO"@ER=#U\K!?(;+JDV%RNR3U;>%29?U
M]BD:?#,WU<]\M[;NTZ>'=Z1T_EE7@)=?C:6^^@[8268'S.!3@W)S=[[LJ0JA
M@^WCJXZE('>\^OT34_ 6M9R>WU.&)+FJE<:%6P3R2T"3G9]'9T#>)R,]8F?7
M69+2J!!^YG=%AZ_25U/['GY*^L*(_ ZX'OL!PUO6'D1^NM<M5BVL+#EUB&-Y
MBZ!@B\6@\/ _QS46_>@UY+\\A+9$OA&@U#L))#N*^=)<I%K<,_AE*Z2BK7E<
M7N<YSP.LBLC5H%UC==T7]<97. #Z+IBLT6:%79P7;3+23APB$@ V.S$!A8J/
M4Z)Q"5,PC7D"B*[3UG/KN8[/1(M=)3M!44:IS5GS_MU)4 HNQ^JT!WR718TT
M=[_S6"3ES25KD)NX"[;FL N&T'[&@J%E'"R/VAHL_8<D$J!&=C(3[9V0S8J3
M&T0QN \&)PU(<98S3L 3*<BD)/DX[HP32U,N*4E6A&&'OD1B';J+RF!F[ME!
MY^9;JZ-+$NYR><))\(R-AV;A%>]ILUJN4Z[63W+QS<O5%4JS;<N/-?LPH?R
M"2^+T90Z?J=R@55GX8ZF^<*D/^DAD&!B<S9>,B.*_"2/L!.^8=[/T2#@[IA)
M+%<B8I^AA5LVG*AMX59S:D+)*0]H\FKM2VE>HVSPRA-WY1*UF6\ZZR7$4$B.
MJU/OKZR.N'2;2BVW?$7,&ECUKHE_![@H1,LF+"(:HG]M%N@QG^[821=G2,D5
M;,2@3.5V<%OOVB?&W=@I='@)7&CGG7^>W_:#L3X ^C8 B&(G6(07;?(/865'
M'4%VY=.59I>[)"!_Y ?)7>E$>0']7G+CE ?PV#9P D(FAGK7ND_F\+%^';O[
M^]DX)@>9OZ<_UV(TN:Q-05>??HEHO$G6*-.'3)/,L#(_G!H5SDTNFR+I\FDJ
MM ['.@X)>;NO/T[#FK5;"^F[0-H[Z6;-J+[!"N@H+AVYWWY;8-?CDW/'NL1$
M9VVK"V2S@P%6+P@OR8]ZU43D2GV@.RXYV9CMU#G)O@ Y14TRVUD)W'=$?P&X
MK^2=?GHZQ,=>OY70:HB1IQK@'5D&HJ=[<.(R)7)[V0G<!QW6I1*4T/.16:1S
M+2 9.Z'SW[Q/KF8YJ^*@H+ ,]#U$=ZR0*A1G^W8VKHLQE^>J2\1O04]/F@\W
M"'MAD#D;/O#]@8.A0ZS+=A]37X<LT>"TR5@?Q!YB6)72"2S"KYLAO YN"GR5
MTXU:>PB%</-1:X^J+2L#(MY?$QY]Z"WU'3"6*:#.I94WO$\5\;PU6K7EI^4[
MOP:MU/+>,!WJ6*-#&P0L4GSO]:PD -UGMZ];K*IW;83;8'IE78QIGC^666>T
M>7W:J>,/5_!_=0"I;$<Q'4@ZT1J]V?VFF<PQ>='*4!4>T@6**;-]:=0E@>F8
M<W;]Q@$^\TMR65.&ZKJVHMNU0)(K<":RZTPT2MRZHP\G@TK3T ;Z_[(,4TXN
MMU($FV\:I>OTPM4GU1/S-9#7'<"9R%QE:J+Z?!+HY2$_GI,N/,V(?8'Y*ZV[
M9PGNTT&."L^UIH_U(HVJNWOWG2#HYEDY/>+3+V3*6W'C-*;((E#]\."B36[H
M4RQCR11I$7EM&>1I%_EIC@U5Q+.N]T#!($I@PI1"YMNC(RB?]B9Q\6P=0LFO
MAP4_WYUND+)<X'D]*,RUZTZJLQ-:[L%J/TXN_TZ'VXNGEB8/A^O0LS,*U^AI
MC3==1U2779(C)X1&QGHL=<[AN:G Z9O>->6>BJYX;K!$&&\X\ER1AWSL>TZY
MP+L1H3P%[YN1>]BHF9N[-6^:"^_#LK.)?IX1A%O^G=S\@+5'>89(=X,#?B%)
M(Q%K,M\!G@HQ>SX/K[GU_18K8]J4W)3P-72QY)MF8%[IY/8_5]WO@%;H7J;O
M'/B7^BH#&_=,>.ZT[+8Z1U[M=M]YI2Q/L4X3:<*I,TK5Z*72[6D_/._^A)I(
M,I9S@L!#$-"==1?\<Z2U57BN?0[<BL%FY,O:$(CL3GM[9HL7Z@]=5#O3=7,Q
MDLG:$-135L+9!&%^2"[8TT\$39C= 2F"F?=Z2I.P\$QI0# 13G:R/H>[W)W8
MFXFZ"R>2@XD#9F56. -VO?K5NF/["5Z>IGZFP4:9;>=EP4FE/(0UX7>\!$RG
M=ZLG>B(YQX>DE& EX-=",OT%4\3I]AF._HUBM 3HT CU%9J=!/<CB%^V7]^P
MZ?B82-G4R<WIM&YCZ&'T10W18$LTI#5G^T8\QI)4H &(.=/I,.A4'71&S$&?
M;N;16]W5=KFS/D F.@11-?7;7D1::G5EZJU$K8O!MYLR1V)-TC<+;'_OB+KH
MT^\ \.?0NR[&"/N@-+LGA4;?S//&TQJ,O8)[3+F-T6U])]+L@UJ!N8;6G)>J
M82_:O1MA<%#Z./4F]VC"ALXG91VER%U Q]KB;:T>XPEZ*^V8IW,@O.)Q1#?0
M>N:D^EJ=T;+%>]J#-F^C2,M=_LE-.5_]0FQ2<$/&^-();U'+J[6\OGGO.M;8
MT,9J$[NK5RK@/3[]LG4EP;LK>J.<W'4J.ER70P=E'I+'9!X9FB^2G:.;T#&Z
MM_\%HNDO#8+PU&N1K:1',_*,0#M.9N0@.E45THLI>_D8&#OQ&'B:>O>.P)W;
M5A//%&VT9!DQE-J@M%DS2992KS2, P'8)<'H<(R,1M>&E21 +X!,FR_:R+!N
MI-(:G*\'[JTETV:M&VGP(HD1W"6DZ -V(H245FBG#X!EY8&9!\\7H(BH^<PS
M]XTX;EGE-G#5(DE=3@3P/)JJ[+@!"H2GTMR0M!?LK<F6%"0!C2HZLU4]4\\9
M8K:S&Z3!+Q)!@X.-KM^6#P/](I<S+3::HO\Q091P1T8E9P"IXTHIU(0W&TNB
M2V-&+4P[W&Q]#,Y_3;OVMKFG8>/(?D)9YG33P0YSSGO3'<J'?<O5E66O=HR^
MW)Y[.'*ZXLB,7&-*6_?[L6]!+?S2>_(\CT?W;J7F5,S)Y?O24K]U(F[(_?I*
M8;*L$V9-@+M)Z2AM=L% SDE,B -=,*B)*RO$_8A* ZM+[WCF_BG)_/G%9UNT
M^1Y8E]=#FQ\-J@3("+38,^.C48)7[)S*'(J^[0FJEAYE8>T+MW5IXC[?DC_G
M0,1*/;BF5IZ3IQSRY J%H? &61JP"/+0_,)= $KQC12SZ.)TG=5^B[N3:B4W
M;OP+[%?ZRR+WR""9#5/,BE/W..4[^!*Y1XI;.3U$W>%4>X&#S/*G1#B*L?W+
M+%G2&+0._*(*G#C@@+S2;V9)AY8XTJ&M3 !=P;IRGDQCXQK51!(4K*D]^=4%
M3(#&/'F*X,6<!+F:Z4"U= O4Y&4H2$&58.\RR:OISY"[B 3M[,W*K.\-:]$_
MU-E3ZL^S49Z%#WDQ7RHH<TX4Y*L,HA_T8HHVC6.)FNRTEW 5K(2N)<]1AZR'
MH?Q.$4FR.Z7N5M>[EUTI#JSK3K<Q:X5EW;1N1-\R$OY,Z9=&LG+:B& ++7.^
MLDTJW >=CG%L%?;%HJ*D+1\#T;_,V:3Z/. R(LS?NN"^+K1]2$]!+F^!L0:W
M7/*R&<TW#+]\R>.1U<F2JV&SNU[1;=L8D8C& [\CF_*^9A+N^RT%?720=LL9
MBS7NTT]-M]+<9LA-#$KMJ7+YD,8,'I-)N&>P*S#6*S-?WPK(' !SMN0W]%0:
M:%CFT\,L[^AJG2^-&PPJ_;PFY[?,K;2\=Z#FG>VI'JN6&-//0QWHMI:K_,\+
M;_1:VH@QMI^G.\92<),X?>N%:UN>5>N7#_4ENNB\'XBIK)#AF.6T7$A]9'!T
M6;*9*5/&0TP@)=\BXF],43>"SU>C1HE*]YG"F=WJ<GEX0(QT!O.'MV[_BG#6
MB^G'%^=-=ZGZ>2(.\S",^KJ/? F>\ST]8CI#QY>BFIYNEVR/ND[?/.%2@NRL
MN3#"?%^T.1,+6\"A%\A=HK2Y'@*<@,3B %B6-:,7'U_02!'U RJQ-6':Z/N*
M.'70+UKB4D^(U WA>R>V)@EL?WJP:O_9+0[(E&F\Q6$=CS!#Y+T"?,\*!Z5*
M.O1%0"-\KCX?'(3;8"L@6%D5AN);2_OB8+;+YK!+ (G)VH<%($(:V!>&Y@4T
M>],EFD4H2>P5R7"RO>D6]]91W%@:'I?A! )L)%IRE,,IU.*TMD[;ZE)<F0_.
M;ZM#!J<623.4IAKTNJ6YUSEV[_2*&>%MUSTR4O],=:S,\WS;U$Y#F<34C)3T
M6)5 OX:WVA7HI;S6?N4VE4)M[$I5ZY#L'-<AK2EL=O&&O:^Q*;C52:_R2PR_
MZIGR)?AH;6!_X_;G!;*!OE>/3'AHC>,_/W['O4I@&DX-:R.)F*M1XWGZNMKH
MLH4O-JU2DBJ$G6^K#)%_7-5\3+(W[C,D!WX!/QNKL/L<$/\!!?NPJ@G:]4>T
MX3-WA'\";KG^_6#A].@O%1N^!KUO]5;)G*\@?]M"S#F?@NM6&DFQZWHW(,?]
M0GJ+\,]I0FJA9A;+[^)='XLC$31'%M()?X%@GX380W0!T;= 7075+&Y'3S#9
MR6RS[0\.O;\JG,-B^M/RC@P6;8T>XK^:A-P((C?->%13V1PE.\T[XZ4X!WS>
MY6$@2/XJ^WEP_\L>UKETXCEDC1*K& MH8D E:.V#&G TH$;!CN6E49U@MKGZ
MP9[^_)K^ZV9M:@O4/2P@B@W@4[-EO#':N3@ *]7ZE0:UEM+/&R+]^CLJ!^8V
MF><9S8:$GT+?<D_S@*..71JB=4;-./LWD,07ZQ9I7SQ6N&&>*VS()>LM>A[P
M$\<T3JB^QI:_Q@.B._&W"3S(H%,ESVS[G+HA&T0U=-PP0)6RJL='GB"(@*2A
M#Y\6VI&[;DDGV8(,Q%#J\^TV<89@')'T!QUTJ O_B %W#J;*4+.,$"T(W3!8
M32?\]VTHW0NN\9 W=,N=&IR]D>>0B&D=-SUU93QW7KS6<@G;=S^R]XGHN2/3
M N.U?,"5"VH),QK'U4@.'PM23?SC*F1T^YUAO1'3GH8\MZ^Q(Y:KPQ/>X9%W
MGBB-1@C?,;=J^YZ<\W'1FPBYXS-JFW+GB^QW .*:1E;?^X8TGT6K+Q5ES>^=
MIT/YID34FZM']BD^7E5_<\(AEZE]>]KM&F;9I>RKZ?O4I'3!-X@.2?G<J-QZ
M7C$S JE]W:>F_^I#4TF4C$_Z9Y<;L;\I+^E\=7GT2<[A]U$O'5M"X*4!RM(E
MSPTZ96"-,O@]91-7*B(42U?)L,A"=TLGT2T'D0_+0;ZNU)'J<WN1I?90##)&
M!\57N?VC6V9_=0";)LA00P$W\_@\#Q+%A(^I>7;3HXF2CTX]HHY93#HM?Y6#
MGHWU<<Z80I]%]]> N=?I$D-VYYG%!=?E.HZ "PS+6+7[G3O"<(#^VRWN-N+G
MVJ*2^<>;Q!H!%Y9*[EMK*J^887MB:K%=>BA_Z::+_#*'J>U82S9V#BK1X;$=
M>:_\#L/'I'3&L;IXQEGYW/3JY,;ZQ;*LID4*?F[HOEQ2U Q\:&ZH"CDZ5!)T
MTTYJL_:I24*VVXPSH9 !CT[&=DFDUBX2YNB&4P?FFZXU KQU_7/K:/>H0WX
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M8,(BH--%_TZB$)%@>)$X.OB77K3K2P3)BR/)[NBG6% [(&0M@&?UE+ML#/W
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MV:N_%YG+"3OA(?T8:<"-K/_%[V5=<9QG&3R((E#/6@N"FB*4'>8*]DCP90;
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M=\^#1C5S65)RR7YV-\.Q(VM5$SK \A^HL->T?PL5)/0I%^4IY_?"ZT\U_R\
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MF?GCE&ZL_>68X=U;<5=GNRBOZS"FNY1&912I#G<)K(,<#WKDR)LH0[MGV_:
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M^97:&GR-K0C.0T6ZU3#[*5II+3PK>@H5_'AOQ8O(5M5U116-XH'>M=MCZHS
M=_)77^V!EZ/;)?KBUCL2R\,]Y_CPDKS?@")M!6G,BG?4=]7[ITO]3[\JJ1:^
M(X=-ER+TND?$;MSNZ"[.%C+=U&E)+[]GB_"@TQP/PH=[%K2,4&J^P)%S3S:Q
M(>Z&SIB'B"6A5*,/N,3VPJ^P]/\W!$B!^(S96@<AY/<$>O'^R(!29;'@L I#
MKHV+NN7! "?/\O/:"^1Y4+/UX1T<GF>>J]G\NN1OAPY).NU!K'84"ZO=\4XF
M!*PXP[(S '21)YG8M%:EKGQRQBC6D-RJO)>T88C#=[L-/JX.10'>*5Q!^S'B
MQPJ08W-=?F5##TGQ0P2MNSI4F'A\+"C6VC0YU;L(#NV0%&H##9<HVU*P)<@3
M9FNO!#1L#?%PWM7SSNR*A%<M&NF=4((#.U87-8U6DS []F8TR9S]ZXGB1/^0
M/J_7)>Z2M(.\YK/N7W"Q+T/O2&A/6\])U!Y7>P_0GKZ?_OJ!>%X:HV\$Z\P?
MO!/IH_2*^IE0I^ZUOX<"5."/C!+V]S=CLZH[;F:O,.KEUVT1'JIODKM[[OWG
M@T>_ON,)D4_>P]ZOT 8:T^T3*.'PK0H6<XZ>/B,*80?HR)R]]T8=8UK^7[K.
MI("R3Y!Y7_M7;PILU]:0'RS7_8"WH@@A_:("_DZAHDT("2/S]UU\R)>/U@N0
MIT(I\JPH?3XI].WAU%X8Q#%@['Q!CEW)QXC4L6B C-7/E3M],WI!["HF-0Y.
M;)X*5DSL!"3.G>3.ZG<DX[=U0&!++_L)^?<5:D!+91&GDT]"[2V;RM.HXFJ(
MXY.$/C:Q*?I,G7U>R!3?WDRM=#;=IH:3B/BN;G>%*3-TO.>V2&%!_%[R)372
M(?"!*+DQ6"E)DMT/C>W7JN@M<>ET'/*AG;HZ*P7Z0K.GF.6UCB]JP7N5OP&^
MOC%&<SOQ@8D6C5PJJ54P.:=O.WO <<-M7R[$6C[I@7YBI?JL,Z$5?M_+NZ*U
MKGS(M^L<]+-PYN<*P5?Q+I,\P3"H]IP0S=KA(SKNEFZR!=2EB=X,.]\MTQ^@
M!_9EZ>W 6/71#^]E,7:112D=2]?]E=SR!N=UVID/#V,ZS(<P:UYB8^E@>,?R
M-Z 0&,2G\YT\[Q+GAAN;Y6-=HOM^?Z]T,:BM<XZ>/K\7_QM"1F)]1W'-[?EA
M=0A%D5A-) +^,'K9=[D8C(CN@CJR1UJ5#8HOWMIP1E+7Z;17S^&=DNWK.G3V
MM.2G'I1W=AT0U"*_XT?";R$W5HVZ*5"/2[CBJFD:MU[G@-T97+QW"90" ?J9
M#Z[+9(.-X@ E2*J$5@IZ1S) JQ+Y'#NP4:37;Z-0/Q0O4[*L*WJCQ_WS^24R
M<G-C[?XZQ$K-G[^.?_"]8;2_=Z/AD/&K<Z=(I+E5:[$.V/IS4:0[-V<N5'II
M)E-EK^0^_FR=-'M6>L=:;*Y'H[NOE1O[^&_ JR+UL%J+O(XSV#6&FIDO\1/[
MTSG@.(_7?N'RC<LS6%J*O2BAS-"N&N/L%=C'W@5?&[5B"+,;H?47QW\RE1V(
M:1,<16>6)9S8A (F>&@Q7@:-CG\87[Q<]7=*[VZ1-^?C,?/6_C_"VM?8"!(1
MBPF#7F$U'F#$*C-%:J?3GBF4I'Q#,MA0LXT&M&15;1.OR.:#655PI),DUMQO
ME3 CHE?P=G1OAL.@0L86<I$XZ*"$!]^/T#F#O<=<+'H9L3=-YE*O<(9[LRO@
MKDYVK(U@^$.O18C+^QF!4LV/-''F ?T&4;;,]!\-)<I,/^-*[JA/_M"U]^*!
M5:;9HQBEY.K4J8OE9[=_/ZI;Q>/<(9,BZHO/BIFJMT[MN\7SCV>5C#2<KHCS
M[0?'^9N^_BJ3R\2,)&JNV6<>,I2::_U%IFA]8\"*\1'QCT<=H1<=,_BG3]Z%
M>.F<WMV$"[%7NWWG1.KZ1 XZP@E=!P%ERQNVC3-=R#CJSM46S8[V3IZ@DY&S
M-O:[_POK3_A'ZU_XA_6+9*X^;2ZOB5F@/9_7_(;Y3)SE%#=H$%W1FZ< 07$0
M!)@G>LD3.Y00;07C5I'E#Q0@/ZJ]-&RK9+BU[V;)F585W&\ F?.8$#0C]@0!
MCD.0WTG^HA;P2:4#A,C?*#/X0YY"3;0F2PTEF!7H'$_<64S<H]&1GF(B-C_1
MSLFG96J/Q P6:6)':+W51:B=UG=;596+CVCZ!_0Y6U;7D?:46=90QIK/H"QO
MF"DUO?TIRTM2;;3XY[,-C-3=CD<\)VKR!@/WG1I%K#K_*JJ+XY\HO\SA_B?R
M$VZ)3O>SXD<-FRR14$(/=/\6WN=HQ\ZU%3)/'_D;4&NA9G3'M_I<K\[A*'L+
M_PO%%,Z15ORK]KP"6[J_8#O99!A_<%D#%G><DG:"O@#E">K'Y06P"R@+_H(#
M,57P @-EOWR*S,IEM ;A (G@>!D";(9K"']C-6+C#0Q7&:F1X@<Q\T3^V\-E
MT!ONBG+I>0=X8T20/2Y-YN/I\OR);5MYCJ!-T*K(=ZC&ZE$(H6:*.1W'2"J?
M)OC=)=4DM9DZ(.#)"S@VB]M<?U:,)' 4Z6_Y0<T^ Z'"G5">V6-)/N>-*GRQ
M.5#(<,S4W!ZU:5D(O))CGNRJ\CF3;HTUJ-N<BSRP-A>.K:SHU=QG8K-\#+&R
M.)\5JDIY$Q6M=R(&')^)/W#WPYZNBS<,MJ%5KS7E??D-."&TR=$C+4FO?AR9
M4C,BYCG8F$3F+;*)WMZ$[ZO85A?O?%T1KK/^-R"R7<F:Z!C@@:U.#UR7N)2/
M67UC2=V<F:>$&37[EEN-\ZI,)W)W^&2,B UVQ,(^YJ:G.*W$K+/HP+4J9TH]
M?\Y/Y!YM5T@@$E+2J<Y623)U^O^Y:_]'8N/ZW;S-?RND5*.5W)@R#P[8D;%L
MT"5/N<?-8]0+!&QIMK0H;:"1A$M$"^7W=PLOQ=A+9A_V%%DZU0$1G;L'BC[K
ME_A'2Y]DE2+O.J_A7AO#/%Z'&#'OO8N_&H'O*D**0200*B57Z!C"6A>($E&:
M+E* M %R$&X@_D"WAIV0NK"S.)<C;L(]3]4'T8DPTZ.MRK85*P8]D[X3KAER
M7FU*Z#*_Y=C/CM=7,,W\KO8,YT-]LT?I"&]I/>ZR(6D)LJLLF8$IOR@<#KBK
M':4X4?U2[9:FD]9+'!5A@CV)I17"5R,3"4NY,J[$O>A5GJH]00\=_\GVKQ:<
MS(<\6'Q7+4L[(L\3#%;E@Q>Y,A0%Y=01?2>+NLGM%<.NSH_^(]4(V[M/=7ZE
MR#?%W*5C2^5;$WY?G:#: <IW)\AG![.^X";R5.?2[VBAAU@=O6!S9-$^IWP^
MIYH _S2$6"E^.5!:O 3LJI.2= >];!1V'GD \=RQ3Y; D4@535-B3O!;FWXP
M);';Q0HS7!@"KCV?#(:.0&YZ_)UW6Y6F,"-]A2L8G.6=T'D:$SK/N7R%:\O1
MSRJ/7>'LJI73WZZH6=LAL4]S;D%2USBFW3WJ+?YTH-FV5[_]@A%$1SP]^,#"
M1;F;DAC0L">9<L!3((5H48"V1%MJ.Y$7@(>"!RFWQ<8):./ 4+-F%_T;?W$[
MX/^18_Q]-]3.#;O_HTZ*:7PW3Z>_+?Y^E0Y<_@ XTD12$EI)/OLG'_$&Y!>&
M+8#BN$%L,'9--B-@?R2\#![P(M)&X1?_$M/2$3U^J/\&5&#+J@B,BDW;!-=Z
MM^]F)]R;BVR-8<$$F%78L.D#8M$.&PD4 -^DLH+=V#&%=J4O\"4*)D/-XSA^
M*IO8>R%RP$FF<KC@**>\_:>\A1+[K$.LAX9[DF# ^0.3G-<5DSQS3<^;K0O0
M]0GX=YW:#<DZEC:N[P731Z M^(59(%V%9X%[1%388-Y81^1"@4PKKJ &M9U(
MSW."G)D=&0S \J\UD[K%RDZJ%WAUK<Q6"=<%K4M H29>ACW-6^7N=6_Y!".L
MZVI\RG]T/.)N52^>7^KW3?'_:"M'T.">SIZA0V$ULJ=W2EI][$=5O I-O&_=
M:O/'.H1T_;:#^'X0>$S;(/1T;B"AC,!"F\B[+1'>FR,DK/3-:.N5;0<T>\?C
M*@N)],"\!0$-MADA!D2@R\I+O<$N@'7 N'L8LSYR(HFQYQV09%^Z,D:4PO>,
M1RQQYHBA=1SM5B5.,!T*CH5"M+$*CPFZ^6"6^85UX W[. +#/^T!RMD&;G_U
MPE__Y?_$ ;S\TUH7RVR3X"\.6B7>$>'9*^#/$ +O(#LJAA%Z)O]1?^$$1LYU
MI',4U>8[TK\-_KY'X"HE7&8$?$^F$) ;IXS'8O]LH$=D+):]!7R>.R)93">W
MJNC(Q-J>.V!TQ]D''$&:@JTT,1N^) =!OKI(#^[O&D'X4$W?<Q*OD+BN/*+!
MA[0?>J<OBFAP6L?.<U'R3>DJ#"9![@?Q](H'I_*"W'>[]8LG+V:_:54.E%DH
M=%S'M;2C4N>^37\2_W3D*R.;V+@ #I789W\*/+"[G$K(+;]V=9&,PH0,HK1L
M;_"0'.QN(V3>T@ .GB@5U$1S ,L-Q!/M6 ]5E2G613:G[[R6&A@JC?JK^<J_
M4X&A]DS!Q"!*@SS)VR0.'"8<Y*ZA$68M/&5\P'><OS5&I/N/E93D>0GV[1%H
M1Q3TYRG_[EH;\?10F2VNAL!D&YG#72SC N1$MJ) IO=OPC=6D\BO1V@_B[:V
M'XC0RR67O8$Z:O=G2@X7%/29]'@2F!WI&9O\2@UP@ZNY!C>)O43^LA6, ;6+
M;LK8+2J9'?H'P^\GP 1I-XC,$=:AT%U-J&>8-N?8^!"'X(*<N.-]N0U.E>TC
M]-:(9<==G)VJ4Z."+*ZEHH90&&(]S<=HDS2\(UB'CL@!.#Y*.HI"MVK!"NL*
MFR_BJ%#B*_92R^\CW*IST%96[>F4\(Y*=<^"N6V7F7_!Y?H+8M'F4C/P%..
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MGY'P;]R.F.)=(2Z&SIPIJ)-2L<Z;Q8+F8^6.D/0H_-C="/^M+&F<57-DN?[
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ME*H2*)AS0;3F;_@80 CCXOI@J@]-3V TP%E ;MZII<$AH!XXVDB^;F-OS)_
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MM:4^4B[6IN_EMNN#>&D[+ AIIJ!-4^Y)KJ;9@M$JUTG9!TMF@P\"$3M/\9\
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MW2A_R61/@M<%O93LDMX\((\KO;BLIWY!1%%1R/08S$"*5;Q.=+"K,L7.;Y0
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MNAC&;PS05*ZL=4#MX^UOS;$:S,1./4]MF4"N'3+)RVEHK*!P)G;($O)J!@/
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M2P._ICNP)N6K=/S^005M"=;Q'M)?_&P0,3OI7+@+B!(X/UOQ,Z[(BPSE6W)
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MD6AEG/%(M*>TM&L4G[LWM=[H%Z?UC;?':Q_6ZPJ/C$8//;&;\EI02#W58;A
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MJ4=;1_D9-[#]N+.!+:.^TY^?+#/UHA^!KF[^& TOR8MR83XG'Q>=J2X>!.V
MA(*:&1M/IQF\LMB?IY]1O/R!;H).,ZR[Z3&69Q#.3Z/*5N4)YKA!EU_,<:,/
ME.4)3]M9BLM!T=&\*/$#;%3:T7HP^5QDGG"/3K>=P8_SPV_;^PXS"GKXZ89&
MFL(][<L,AM)A>RA890NV(G0*6:J6;^^2P_@PW!LD+%!R;I[7WPLN5:LXS?7W
M3Z/]&>R]M0%GT \SPIGV.SYP;!'< +NN'C0 )EJT$KU1_(5!V;:AME(\P&*(
M!6_AJJ,ULB9RX"UNO+V;R+P#8HNA"^7B"_SH>M@V1?T$_O0RR?N&9SV=7T)<
M3QWU-!05IFN-0D,PWS&(%&^96N$U47DM&07(A_$W%[/^0X"":W_"+#ZV5@,\
M_R4Q2"\M<$Z=3"1N3OE%C]F_N/)4;4! YR ''<,ZB*K9\E?/\2\8Q%F4X0!*
M+JZ>&#V@$PH5?4"B"!48RV<2=_X=:[_NYC\W[ &HO^2 ?R6F_-O&-8A*"S!H
MP"I3+F:(THU^Z0S(L[]$!S=9U-JN/OF<J)&Y+Y_EXR"[6C=,^3"=.7]E&/[/
M:T@JSWELJAA@(+A%N^$ZIB?#'EC%]H.CS.BQ2/GF6;\BJ*K9!71>J<,*+:,%
M#[C(FR?T"M296(_]\BT'25)G]*..<^4"YU=#YU\)8ME[#C[$NJBCZ4,<(_Y%
M=NT>6EHL2S.J<@W 482KK_4;X3Z514BYP(&G'PF\U-RQJ7:X)I;R9XK@6ANS
M"%Z/8FQ@Q+:[R@>VNT^T&9U^CXRFJH+;(P!<&?/0GV)AX+3S\6Q"(./F ;,@
MI^N0VSJ!D\2-UNW72A(O_@/ C/U6=DTV<K(Q,'C.!!EZ[ZYATW:5<QSH,_X"
M;%LDX;G2I%U<PK>1*B=>(.'LO2A9>.@M^;+3&MG@48P:-CK$D,#W/3 <')XK
M[KM"J'7"6DAW1>(7II,3;8#!C32J_'%@H\7<I2$((,Z%I/K^._L^)>FBWCKF
M60S*__0&\)#.9>YNU]* YS]S0V^23TF^RAQZT7C;]YRQ,_BA%*8209+76'J9
MN,=7I6W6*'V"XH8L]2SA8ZR/)!3J ;_9,9Q8[\!"L41^S.DP'1.QYR8Y7&(Y
M[@DU!S91DXIK"SKO=MW>9EN8]NUW <0Q0@OB.";&Z,ER^+C(@FP[:0<?MT]F
M(22Q9M1R'5X2UO'=&D?<XL;'<;HN8:6LV:V;CV"_7)W;__*9Y25V*^6/GL/J
MGV1?3^,&GQS!#MWP65! S=OMZ'6,O@])[+1[7(%,MX[/9WNI50V???NJMG$E
M$'M6IF>O)SO%9IHC-<"<P-T^0F[E>&MH$\J7J$=962DC^W4;XD1U'M[5B\#1
M'FK,+)*_,-XQ$'RB*@Z5/_Z1L\=:-K$?=;V1(STX?>)KW;,Q=R5(YT>F<[OF
M4ND=WX&]Q(V\V'X4#3+"<5Q(%5I](&[P&'HTV3 ZEBHR<\;VFA( G]YT/)(B
M;6=*KBOUC2]9CMI]D@W5H;V+]<>D/D>U:[Q9(BIE:N$O15G;U$CAQH^X@*!:
M1L/BG"Y:QM42GL*?)BK\QY7D0O 0 "3Z7;3$_\[QXD)86Q^*S $L>")L,EU^
MRJ->LUB\(?0OQZ >@#3J&<*2R#NQ?-I(:\:AMH(R/$[+>U]#"<IQHM$%H8T*
MNXNX3LWU''!_B;R^=]3'%A$5K:Z__FGI:SMZ+K<ZCGN.I<4G%KZVHV4,!/E'
MVB+#GU54S057K9XSX! /6TNLXN&-N7KM7T07Q?KGWC:=*'-38"/3M%-@RA]-
MT9'?V1O19WY32C%#O^/7%#EI%F]:>/WYUOT>S\!M' ;KMLL_ !&TMK)I:![N
M;*N8$FQY>**]=OA23$F"L64]"/A4R4Q,R>O18%#^Y+V)=5H^QSYD4G-G5RRR
M]%$*LBKA\#1RVW,Q:=/)YINN!4;)4X$RJX\"K4]%VD?8&;Q/>,$H$+]CN[<M
M-IK>.8;<9E"QEX:T/K!/>3=H]D#]_$_:>/ A+6<Z(AM?>EB"P^>OHGY!*,,-
M?+#,^<Q&\,$BI 5<:(W0W2>75=TB&$6/.KZ!>,=Z;?0,$4CLM<(I&7 X&JA7
M6UJ>;6RL ]92#-'7%^P(-2$$LV##+9MB]/47N[".6?B4O-6R3XBIR4/M',(K
MSMG+6% '?'-8#[M7N7P5I0!9Q8!N0=(0=!TX3(^XH;24P)D2K/Y7_YF@_)=
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M\4,S]GU6C*]'3=4^=%LEWX-,=F+.C('W6#%]VF8:5'75&6&H(G5&24>'N)\
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MQ$)\'!DF[:Y(690P%SNZV!"%G.)%C;:#'N#$/R@=/^-RA2-C1Q]=*NF/XO7
M9+,$I!4>LJUH$O33ZT@H/>&SO2) <M8YU)-S,]YI"A&_<AB<$M=I'798(V$D
MSA+\O)]26KS++YH>F!7F:]S@5'Z8>.*;YBK2^_DIW2_;.<&80M9 )]@ZP33G
M2$BC2YL%>)(@J'\&^=0YZ8Q=^ D3=&?C+U\S3UY?GA8E_'$P]4-?]TC95%OX
MF5U^Y\A/3QU;I"@0QZ27;>(6$IHLY[RN73@YR;"F-")55*=#XIHDQMJY/$!
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M5/-S$+"\VW>.K77<"0M5')0OZ2[G8HY9&"I:F2#K.D;'2_JP05YWO2!/L?\
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M^1#TUZ\N.?^YU6B/(F+7X [SI1K !U2^XC$WPBG_;"9Z=+GAD=3Q-=M-E::
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M4/ZR2V>#(?+B%J3M9V^7*)PCSSM9T%?)!+AH":T(M[2%L(#.P;V%<80&*:&
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MR,RU!;]1#]*N8=#0]J>0=7HG_4X/5-5PLU)0.^JWH@7?H7[\NM5?'MVGGR,
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MTPLE-$$P0\.H!6JKHOSRW W8RT'K@@G: 3]<[DI36)M@%U*::VDVZ@/_3S9
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M=_G^LWC+':$!MX[F+!(V3*T\==S&)-^- 2W"?FO;>V<>8W7;:[XB.G#K3.L
M+TU>\CYCG1DY)U;Y_/T0E*VGY%Z\"K=69'T$&^45-)>(C+GTJYL98NW20KT@
M KBN?S:37J(R%<V7SV@@CPILL4%2ZM5;A=8YL]=GZOFX0YN\EZXSE4&>J$,F
M-&=4%1WJT&']TG>1<,C0Y35A7^QQ,+Z<LG.2OC9UP&<WT.4.'$=[<4@ZH2VV
M=H[XXOS2<S0UXRGMT?7>%Y]@@Q.3V?*$IW[69=,OY.EEY4'P6R*C^&A3<N/W
M(-K63:([9-"G4 BM$<I5Q\WD%[N\!EF%.I7[H-R&PQB\<CLSP^7F_CG_Q6(!
MNA1YH"^/KO_LJ/-4VX!W]E,OX#FC?M"@(\R8<UMZ)[?UU*+C%'/E<#^ G'D;
M>]G!:WYM>\[LA^?'W1G:;Q[)-$>I7)/%?O?W>2RGM17:/.9-<A7I).[T)]C&
MUDK[N;;KW#"7C0$!W75]4PV]>6?:H2YQ3?HA873[\)@*D=%#]#^^!D/"I<>_
MI:,7&.9A(O]^LIG,@N:AEP.,JZ:8KPTA)*I=YZD3(*MZ2FO!%2FK'>?]I74<
ML;4:7+V:XC_ (!/BH>$ZDV17YB1RIPN@UN5W28DN01.(0F@3KZY=S2NP5@ H
MD,]L"GM7.L NJ,5E%\XS-50#!_XK&M$QMKR"N;IA8;J*8;L0T%FRH7S =Y"5
M^)+I^Q!F,-K=T%V);\C=MUVTNWK 7_CG#72BQ4U%UC9,+:E>'F^__W-+RJ1[
M:TT=*&NM!P9&V2^C&'517OT&^9&Q?[44\O=3K!Z0I:7*XZBC(:>6U*SG(%Y3
M2Z':Y_^'*H:.RA7C&K6D" &#\RA10%#*TNV\7BE%PLPJ&+NFU]S@?S<O/!EC
MU'A[S)CI6-JX]*@:J !<ZAWSYT8*K !^W0W",0Y=ZPZ#+3$"D%A0]_.N><\*
MJVDIBM)>2:B%)XJ6K19$AEG/48 4%P J>-V"[W-RIZ_JSW6669@-"O )6J@P
M%\Y&(9KSJ)NIIQCDIE(G:5#E7DQJZ$-()_9(/WG,ZL#P CP_;!PS8&+1+@H_
M#\YS<90QBZE';*F=?*P3HU0&;C*M%%C@W,M*"FHM.$8>MRQD)PA5%@4EGWE=
MD9^G18994CL3,X<V.S436_N9^]L^1!^X>EB$ICWUXJH-19.N/P%5IS&+3K5-
M)>\F,UVO-$IOOYB1^'TA5]!@;UZW?40Z-,KPR-WM0+4[@8Q?NW )DE_'VY8I
MM@JNF/EK%VS;#EJ8RAX$;OLA4@8P5W 1+C=OA*[98DW;XHD[T:54]!D*[ST!
M77%MW.<9NL9!_B.=\Z/^A&!V5PZO*^(*(MY9/:Y1/R([;B]&;XV$H=U:N2N-
MPOG!<ZT$FNWV.^67U67RX7,K98 T[ J^^-;BQA?^\I=,K^2JP"M9?4<SS\KS
M&BI7"VX1AH,>3\V3<\9HTIZ;LV)U#^+,MC1,:^5YK3?!Y*63$8OP?-(B%]29
M[)[B@;LX0S_I8FG(=L(>NTD^,F(-&Y52MA.N2@>!47#T#<DT^^/;CV\-U[B\
MCD=GIE,89GA/+'6PMKM>AZ5QAREVSE#/*^=^8?/39YH(IUR X9B0F$H .:L'
MH1D8Q)Q<#* U:4&K&N !!W;UDZVU6QVVC;F&:B+6DXEOP[]Q039J@7$UDC$:
MG0PXV9A#&IW83FB]_0G1S]% &Y^=#[.\-AL^>M,1O_E(J';O1.A84N? D_[=
MBIRWZJ\NN$PVTS]U!7^RV5!F,\-%3@D"=A+8SJ%.&Y^[0F1]";*?I_DG;F65
M%/8!?[-MZKJ<%YYU:C8:=&5?$'_+[U&X\V(GC_+^O;FM2+CEV"2O7C4_D:KS
M.8D#U:3,A]%/3S/6:KISX\\"OWZ@EC.W:%ZR#,(6'!.MJ=_<5/:&6I>GM70+
MW';\+W2 (/EACT;XTW77"\,+'@([H 87:".;O[%SZA1YAE,XFRC<4#X]<4#=
M<B=(K\P +0HK2<JU(/U&#D\Q/L8Q\B83XUZ%:HL+WE#?MC)^LZ5U1AE$RBD%
MH=JO*!^I1G1J2 6V5@R <IW I K=EUS!)Q0\M,XXN)E:2F^F^C(<C9K)9;56
M %^1!RZKT8.^'16 ;JP$5D3I&/>O4^0S4?#;-&_I][@1,16 3X&L31C849Z*
MLZ;E%31.<\3',F?*IE/(!652@/+2;QYRROVA1O)],:T%&@IBYLBBN-"]=I"A
M('B.L"F3KV]B5DSSV=HAY0G[B'2?V;73U'@W @-P7WKD.CNEQ:)<O<N/5MC$
MCR:Y2M2O%M4[07ZU+[;/M5Q/FHK]S,Y,STQ76^?(MFR$A-A7QM,3+IM_9G]C
MRVG<8"7L;(8[OE $$:@;X)GK]@O\^?L.Q$3;CV$6Z )U,P41A:&T4-2O7L;L
M1B2-HD,U")4D(KUICB0SDIYEJANC[5P9!/A/! (%>'^ M?!&L =S=\Q@L]>L
M YDBE!, Q;0,:S )\ B,A'(=B_^10D7=/*<QSG,EIQ!9ZBE,NIVG'< *S*8L
ML[6:B!HXTIS(8K6;V'X+9>!KZ;0W&9Z?:[L+![F'WVR4-03;T)KAQ$:<F$ +
M ,9$90C!*->2P89: 1S:18YE+(82!GI\>K2;G<@8QQPS0Z%U75>17=V5953)
M+92S[AF0I78XWBFB 9<\:8N?Y!L]%Y"5Y=1$B^]7JEK*^R%7JFH^6YJE""L$
M ?_DZ.I[_,^.B;1[ N_:?\) <_C5R#[@P-W:;J9M0(\BUU+I#P_LIH4I.,W6
MA'B[(.G=6X6:):!YI!+3*863\C;M=KG #.Q1U S#])JK*?8*;>NY##>*1T.N
M+XN68ZW8;S'@\IF]P% NP/08MFC*,KU=I&ZF#.Q6O1/0G7=&8*\X+M"?XE2I
M#HDV2E'$ 804MIT^6L-5LL!LYM#9!DCF)"S?@554\=%YO\!<+W$VM!/7+S)
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MG'!HFA7@GLY'+'1V@>J5*#]%XQUJG]"$#K705?<&:S;Q&)9O]UR=%5R+J<4
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M!A"SDQW:1 O@IG%T6VA'X3V]V"!#661SK_*N&!A2SH#AZ^6:3B!(%#84&<D
MJM(WUS^CO"P 7#V^!4C0S8 4DW2'<2 -DG3R]TA(: V&!(?\NR!4>G"<)4!"
M=/"5_UY-"L)"]=+_$;'JO[LLPD+4PD"J36IO&-J'9>H-!8ZGD&7 5DCD7FQ
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MW"]"PD+TJZ^/<,D\TRFT@<1]KTZE$*=+ XZQ.<[XUF\8774SUYKF20L =]$
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M@<(T>.OKA.5HS19A7"J7BH19FSDH A5HTSX<%4E% CU][9?^7B,0"^9^LV(
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M&9[X=ROT[+6[6@XA*/_ U_\=Y:^!_P-02P,$%     @ ZX%,6B$0I+X<& ,
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M:;1"F)=[VB9AW,4[U^F<PM.FIN,3!G.DPP,G["*GW$$"ZRLXM*>-'&')@3)
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ML58)&]. G!^ 'IWU]GE2C'4!*&4#)=I?9:3_[6<;&V'FR,ZO0>T'1^C0["$
M>AD,I:^-Y.#]NH )G#BI)?@^I6-V..NM*N?-1N5?:3=_?]&1'KZV<8EEFVPX
M9)?E:[_Z7=O<Z!6L!@.X1,U*TKGW^/.E!]ZGYYX;E&>[DW[K1M",T=*S:HW/
MO$.)1UI;@9*T>,TA18W9 =;H>B/*(E%U@J@F[>QMUY@]]Y*@%N*GG[^-9>#Z
M,S W=$&MZ0'=K&*2(%$5=1FH>KUW+F2*)-.$/A)RIS.CVWLA0L 9B$K;(*!/
M>GM[WQBWQ5[L!&YD!C_S\T&$N!T.;0TS+9F=<]$J^>5$)YZLO=]#CS'V*5?P
M/D?3"C[\S<-'RLQ-[.. O[2KZKU^MW[&VJ",?:/9; [-Z>%IO@ 9$I,=JC(8
M9BHI18NKZPU'>XB2,UO>ZXH@<XNCHPX'_K#Y)-H?L-7=OP1PIWK\6]9Q8LZZ
MC5@"^5-9_*D ]=(QC["/@_9QG,HKQ\%Z9BQ7J'0OEBT*&-;SV5'P^AY=$=;K
MI5A/FC9HY!>:WY@O1O6_(O22'3S'V2)TTI&P+K>28*6@"0/-/84D15.IQ*@F
M;895$#!R%]["3]"1V4+*G?PT\]]09Z?1)U9W#6K?L-KB?L6]T;4:U2:H%BBH
M3[&MZ8H65L!\WO06.;H+95K<&&[P]UT0KP\F4^_X]"T)P+!N T9YVMRS5!ZD
M5PNS\%B>U<F(4@*A_<54";XBSB,>:2NA4"7:DBW62_Q^S]IB#%3!7HRUGUM[
MD"A=3-1K!Z2? 78-?J&MX)Q]V\3.B-[/WO,B-%TL7_CDPL6US9SWKE+1@UT.
M@_ \KGX^W8J2+$!#Y!(UPXBFQ+%X7;D5-YCX9@1J'P8??D>LN)I&/1!25M3_
M?OK!C._*KM14H;ZD=_C/YL^!.J;OGRZ$78P2S!@.K@@J==6(H7%5>@-:=A[Y
M-R/KI]XC(Z/D2NE2IDA1KS[,#4;X^. [S9^/7.T;?$\#)2K]-]HTG#SYC6LE
M>CZ9(IOU@Z$C^'Z+3?OZZ?/K?0XB!3'])[^]DA9W#5^2P[#R68NN:8V% _;;
ML8)^*9@L/BN KP?OV:/?(3X5H-"@=1/XVQ EUB[\\1KT*3*!0E0BO4E1-NN*
M0ZL Z%:ZXF_GKWHW?&XJ,:R5KE9M<_89O/G10BOS"_L</UECN;,(Z3@<]LY/
M,NF>UW26OFY6E?PD"K'0&#E((>['6KT!N-E/O4+=.[L^X)/IY=ZP0S8_?SZX
M4+<R?P9W86*'H,'RE?_ 532Z6C"]'4"E&ZW#@7&6! </OR&'B6K@06;1NK(A
M78@L]'[PK!NGTMR8;<2#I"4Q-?LB$IYY6=(:$WP[F':YN259.PK)XK.K TF;
MT! WV_#Z7UO/E52FZB*]69]!/(,@@NG5A2^4XD3-SM/%^#&$H8P(H=RF4%'X
MT.F28@3P 'YW!R/B#2;938HUOC]#77[QEN'KM<NP(68MCB7;S%TF?BJ1OP[U
MC7N)SXS1&XH^^@+I8VZD0)'-J3/)"WJP].J&B-1=_ -Z:]HCFM[S 2+T#-[I
MX8O)T^TOVF,,0ET:+\;49KNLC3?:CE"B!06N55?= '.&8#GOMHABO3%'MWSR
MLXUMSP_KL><[I;Y]-M J.4,7+1$I_=K^-, _KS:?'+A\+<2])KU_K!+5$1]=
M%/TR?P@W"V6Y<_[$!"$.AW!E00XPX@DF/$.F]S&</BIM;5I.M45$3KV+ZR!Q
M_V*JIQN<CR*7Y7XHU^J@SMXVO/-\>O9FPNS-GU-30-@=5 G<$K3E"EGSR]P!
M)NE^'%4)3&)%,%6(QZ;T/QDD&[0CI% FP%1G//XSI77.GGB$J9L3ER]]*?+W
MN.)#JJ/*+XN-K/+41)]P<ID(BKDN$\<^(L"2F-YL)'!5D$MD:OO *YJNT.Q:
MS.J\SJ1!@ZR.^4GS[(6IMJ3R7%OW%Z\*'491\,#JF:[FL?6X807[/%E:FN8R
M-<=/E?-O'B2<,"MR 20]1T_"8*0%'**C[FX5U!;#ST@E,]4&]?M<A34B;"R.
MTMXYRI@,^*B?+QQ:I?QB3^=)?3+#]\@@ NM:XCO!EO]Y9ZH![QOKSA _D:Z4
M$XCMN=@!4Z1XB$Z?KBY<G!F0EKKE$V&F)OW\5@4)=FQ<*&6@+[8>(:=1FGI:
MKW;]FWW;LW%2I"397J0^E_(.^7FV":;P$'"+(O\RU\U$)J7'[#R-N>3J?F:0
MAJ=X?G!T_OU]ZY6F)Z<<^X(>U!1.#OLCYBYVR,O>F6+_#OKN::$PX%NF+06^
MGR];#28)7 W0UGYZQT$2J>Q+^M@-?;[L5B7]LK.-"9F8'O0BI&\T1ND/E;\\
MCK,K6 B[\OT/PX+$6T<97%&4+%BT=X%M U#[H*E*"CQ(ZFNZ>C:I TY3 GZR
M!N[]B0G!7 N1QV?N1('E2)S+:-PYAY:0.SKX9&YE_5PB#W)CSZ"S,M'@33=I
M5'T]&:"R4L @?@R@P>DZ]+C?J3&S)*:M#Z>R.X)^+C_#5"S]P9,0K@FPTY^?
MTD80 ]-'K$;U&X6'K&/KEIDK7NE5^MG6VCN^.FS]LH*6L%WL(I8MD2Y4RZ\2
M!=P/8Y:B+:IM")FE5TA&@BW2>P%!&0HJNWWU#T>#?LIA(16-]%!:AN+6B<XG
M(%G.C)1UIDW:W<_$2/!;]X5[#5AD&>ASZ:Q<2;#LLW\7>8Y W8A";D/+ UDN
MT1XE]JY2?C8MCK4T@EC+;.(@) C9B:.I]RNI!E<HE%\=T!*7.=W[[=6-6+)G
MLO##9>?:W.K483\%$\K(T6^9[P&--Z:ZT(V3%YTH* P0RW+B5&-"8# 02\/V
M4M-VJ7FH8)IZ=WZ_M'S\5'9H'9CX/*IV7,UT)',GPL$!Z*@H0/0:-%:4W)EP
M7-6ST&4E^6I%NC=RJN'^^;-DEMM8W!L,8["W,JF'JS2E>ZD\D'ZR'2&"["23
M9NTD'<3+$PE(93^FVH.Z,)FK3\9F/%83BDO<1^?\#"J<L\_50)=+UHN8^!X_
M"/!S8P-XS?AYGVB&#&8E@%2F5DC524X=\2"8X&T$%S7@"/;O=G=T"6:;^?H'
M)X5'/0EO?!XJ'1W"G WKE GT)(ZV*PJXC;)]SWELH)PY%3O9B$^QC"NX%TL;
MPWCT**E%%[L3(3A(DB+N1V+[[MRXQQ3HF3J]ZC9;5/=R?*W#CJZM%V)@)]:^
MMJ:@K4NK['@=6!<N(\TRW9FL'2;65$9J#3\-_G<?/;!DX59]8$NWH@98\=J@
MP4KNV&V8D,8'.:[X&]1KG4&R5&:1J*%[Z;70+NZ'\BK3 LIX&56,1A6G@_9-
M_BE5,67,_7K/>1 ]0EK/$@J.[0\J?,<L33-3"0/00:E]P9[SCMX"]_%9 TN_
MU,(]_<^_"7+0H-@*^!6RC__]/""6^?_Z8.*_7M/TXQ+)EK30"-M"\GDYZQ(F
MF,1Q1HL3*@8P;UW_C?E4GHG9T4P?Z1B"?Z7&8#@//T-YD*?'(M$AHY92V\&4
MM*.._SKP'PX8 0Y<Q:3CQ%$R>[)\@L*G$PN;$*1Z'UH=3 .2Z#IXQJ8$&-S7
M)7V?@&0X-8]QA=\&/462W,?6M>.A1ZB>;Y^MYH<G-/KX??8FUJ)'+^<F1E]?
M)/W-3/B5Q)'SLEN3IIM9=1!(H#@(?T9"Z:K?!M-1\;1*F?YY6-7W(8NSGKYV
M->$LK_1R[>$GI#?ME1MEWHGFR%*%,A84/)ES%IG/%9KA:_)R9E4&;E9)]B/Q
M&,H.\",\]^ZV"P^D8]O X( R?2J\G%77!:AG^Q]7OIYG)[ZAAJ2^\S3A0<#C
M:N4)27M)H4; [X952J =4]-CLB[ 55O_E[;^L%2D"NKH'_+IS?Y"B7*'$\F+
MGUV]M]RS&F$BR.+GS5)N&BF,,+_)J3+"I4:S/=,T>11[?JQBA3QSZ6%DK>R>
MP?Z24QSI%[*A( _2\PEY[:FM0!:?=D\>HJUTJZFE14K0[KPL>U: ;6ZT:;3,
MJ/=#M:19[X6Z1/JL@]@KG"*T(2J>.;TA$ LHTXH&<_0=TLS/%8]0[B1@H\R,
M\"-\]=<YT$7%LA7QR]QCW9/Z7QP\]N*_XPS2ZG"T9"/GI*/WQ-Y+%P^H1]YG
M!+,E\:PQ?ED4YT&.H'51@DS!=!148)9?Z3)N&FP> /O&K61RZB.,,I0!J\QN
MJP3:FN<-Y(;E_*LH_&SC^A3+0>_+YPNBN,<PP &>5:4*$'H1H)9@/S7-/6&J
MZO=. (;M=J0I^LT<(.)K^AO"2;*JV93;:UJW.&4\R+_&=6NGC^ND-39IN;8T
M*M'N\V?K"A.;R8[?NX!* ,\Q"!*K\RJ@+3-I0;?_?!1]&MMM'9-$6+XS4!V3
M1'MCOC=@^J7]:ZO6[ 2K;)A;^73U1W/7Q,:.B7:46I5;*_+<F<]V%,\[]"NN
MIHE_M! E$UW":0U7!X;T!\<(#[\]8M\\GI%NJ'^Z?9D329A<,E-2D\V\=;72
M5*=B;7)KJ^G PGL&YW*/6R,EA@X]S* <Z66\>-G=)'?0,:,O1CKQ85!1V,*S
MH/@SB>F2DAR<Q=K#T$6D_"/C)!]74S!C&I]:_2MY[SSW[=\$=</]^9HIM >6
M+C]-.4<5GYW[LC8^.[]\1SJ[QA*Y9150ALLT<WZVC%9L[B*%Z-BEY0[4*VYL
MWRXIF/4>EJH<[]_-3MR30Q:RDOCMYQIZQ@G]D0?9UP8[A+H-# [ 4ZWZ_+29
M@E@VC(!LM>.K,#HTO2,!!J2Q+<?LVV#DW9S"<*_D+3"<XK0R]IG8B)^'MB5W
M[2MBV&'\0&^^R_\ (6B%,)EY240NJ0U'$4'DR..P^$*'UTROE1;V'^-MPR)^
MQ+8S(ZI%\X4+/ @TL8L?C]WM'[5K'EQO_4$O1J3R()+FQY'3W$/E>PC0N7]W
MJIF #*>1^OG7VZ5[-WCR>Y-N>O:357-],#XAB6:GD52P<?#!$[L#[3M5I<?J
MQ,S6G!J[KUIHA?K\ZHBHNN%$IH>Z\!4;"I9A8FX# .DZ)K6N]^C'U X23R#_
MHA?+NS0;/YK 3I@_)LVHR[?VO[-Q"9HC=Y_K*U4TNR$H864\&&,8M$"58-H,
MN#24V/[^YP^T^.#BRRM26AV>J.:/E&LOG&N=]WP7&S$A8T7"B<G&-K(9* %
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M6;8:4S=#8= /QL3<>]S2VC[59N?LFTTF2G9EQFM6GK.;NJG6/L8PO4&H7=E
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MCT&TREB<K]]YK<NME@E26ZL_;ZW\,"\,2L*')G@U5M73$#!2.!3T0[3^7'\
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M]<;U$[<*7OU\A)!$4@\4?WSW8F8BE :\%/J&O'*EI;NL*29E*,RY4OU>#_/
MS:ZZY)2^@2+KT5HKD5+'-'FGN/J3SBC\=RI;@@>A2XWT1<WL<8413(WIBQ^[
MG753B%"4$5, &4QA\>LCN4JYXP5,ZDGWQ_BAL_T#10VSB;O)V[Y>\_0KOT5K
M+FU*\LN&-5N,YI"&.$)4^/L'.BWJ]TC7-]P9EI6+^4Q;NEH)4Y)".L)&/ 63
MG#U)[7&P@_-K7898W7MM0V3]C]Z?/$>>KI2I%@W_!7 K:U=) 5-:&$,S R:,
M#KNOCY &HWJY9DQ<FMDY!L=447GP#C2]V[$IQ$LW-Z[<_W;'+B([[HW.[M0@
MY4Y\%Y7ZW-"+(E,\*C+7?,Q&YP9UP%U^X?UKB<HESX$@P6SNV,"W1\]DXS,'
MG<@#)K=]4_K&T\\)VDK\#_;>,ZJIK6T;C=N"@AA!B@*2K8@@"*B (""Q 0)"
MI$,"9"-2(T1Z@$"V*+TI56G9"(B4B'2IH2,@(EV"E 0!Z0DE+$D[\?U^G.=Y
MWG>,]WG/.#^^<[[-&',-F&.M^Y[SGFM>]W6QUIH3=O"E]X/'E1U?K!NO8TS\
MKG>>NJ:V!#U160KAI7;S?_>SM&-%IRY^.&I_Q5JB1" N:ZMQ4;E[O"1EP8]J
M46G[:K1EKFC6R[NO'&/P,E5W5%I=5GJ/AR''GK:"[FL^"6S1@X%RJD\;L:IL
M=9+&"Z#J"]OP(BL9B>$;*C"AU_ [JAP0#Z8;5CZFV*CFI6%#ZO.C>YQ'?*CF
MTU2 Z8RH(,AOC8J"1;L@P(6 /YEHQGGL#58"^P3[8[,@P$_M[E1C<^6^!EL"
M2"[&I)L-JH+Y@,*[-,7J(J!XUX8:WEQ(X[.AR;G"[=-4X_7,A_Q.:TQ/G&O
M(R8E3-A&)G8[@%XD37V'VXL1S-LYZD1!T=R6F+K5*P=I _/+FWT_*$NS,K&Q
M><;*'3!^N6H'4>.J8K.4.26I(Q2UD[,5@0^ML6,Q??,ICA5\8[U7;(T=)!(O
MA[L^V(P)[))1)&29]CF7"SO!>&"GCVI+EJ8^4M50S37V8OG @ N1;>@HXE%M
M?D"97L:*8HHR[F*&9V$1V\0CF!.4.WA1IA-U;#,$?"N,-*E?0_./S76%E]/<
M52PMDU"6&F\J2"*5&"7%&=V:Y/MUEK._%/0%D5P&G#T Y6<?6"8>T()0/V(5
M@*=JT5KR;[%:8\<R9Z>46J^2).O(,V F=%A;DABYZ]9^>VCG]%6!=X6QSA%+
M53V?@@ZF!#WS6IIY96Y^?W9:HOW!^Z^]ZF+EA+!.BZ[9O(O=*D41K0_DZS]7
M4:WE7D[,4I^7KHSZN9)_F.6:FIIF7U-O[;9%1C>B$OIH$\XR5]L'^#.<1JZ4
M#CWNN2*F_FUX?[BU4WCAJP7?*_6!:8Y6_!+G)=6QELJB2%'=2UX%]I>+3&#;
ME70NGP_[$V-%?PJX4=VO(^B8IVVXJMV6#5[F56H =T:Z#?!AX33^[-%WL=2Y
M^QX&70+4'JRF9)QT?7/&AGE- [Y#U(ITOC) 82'5CS]3_XW^2E W4VA\%M(9
M@FB'"!#=B( ,OFT@ 2*I!2VT)KDCA0BALIA8\G3Z'*+_ZN<96-4(TX>Z:$!-
MJR031>]=7"W-1<$$^HN7J'HG2$O^).>,+U\1;"T3?2H:'"RF<N99ITF$&*;.
M83&R?RM+%:MU^;-@)_GM@_<_P[6,) X&WKJ28V=<^EBBIU?=[_QD 27@%,OE
M1&S12R<@YB7)QD_+0\N%G_I9\TA<44J75U_YU\9#RC)E3SH6 &OS;(W 4:SJ
MO9F):F/,Q*W+,8PRBA)32'F. THDHLKX0R>.?_LE:8\SCRBF.\Z>YKD]U(N!
MM=L?&_I]I-21>IM4M?)VF:18]F8EB)48M= P(L(!F21VB%7Y6XD9Y;F-!:$G
M[$]S@UV!Y:>Z=#YDY6)%.: #2X 1>88$MAB[N*-TDJGWE)(8]>Z1W\'F)@XH
M9GVC=?HHGBM'OQ+!3(NYZR);=L,RM(CL\P7%>CZEW]S%MD/EHLM\UV[3Y&(P
M[[B [B2A+?G.KD>/_XF-G0;FGC-TWZGY7MN^_3'6$I;B*Q^, ^1RVD^M+3'T
M1][.#9AZI\RSS].:;:*['E!_SE1WS%6ZX"T)+^?K=-&F:0&RQ>BK+5J3^^+9
MGS[9R;8ECE^9*;8R=QM\7;CZ=NC9]=MSN X\8$L4"U7"(MG<G/G,ARU2U@F&
M,/6YOP<S]!B.#![V";SP\K0,NY,]QCB6SBKZ]:]!.F0-LMJON=:L1PIM=UM@
MY4"5N-E=3LB-_&.P?3!16DRH:+" K]<V9>GFK:S -_,7O+LNV)MZ^S=X3.&Y
M''V\ZX'7R4_W6&^D1.UK9 3,TH[34U=&4N&5WPM/FD5>U^^U?1_G($ZZ;**O
M-+)!NLWFC9Z#D63H=ZD\J]TA5)J6&N%'#5??7PR58=I(7C%"FP.MA=C+@QNE
MOGQ&J!OI;6*/,@SU2_L+,3F;WS'I5CE&",,;<6F[ 0)X/,X!35IDGZR<TRZD
M!;"%=YD7R]8@D3ER5%&FU PUE:N+Q;]S#T:*J4KT,GHM4\I>;DN[D_6J=A4Z
M$4W'0Z&/:C?+9;I\K6+UPC<EM"T2>F2=J 6I"Q:7A;T^6%MV%, Q[Y"/6&6U
M].V1O,.W! HL!?(,CA?HF!4>;@TQEDG\T'"JXY25\(/*C-2MU:0$W@BKEQ9M
MLP^I514[T.+NY0V^'8//5XI,"3:42SLNT666[Z1.R(TNCQ0I-1(?XB<S35A9
M6J(TT5EB8O,)S&UZ)"N[6<YV<IFM"&C.(>I4@LUI1DE+-#BFI)U]MGK8#T$X
M87W<#?[0^[/*2JV-;[;D7IN1YOUAAP8T#'C! 1T4I#Z$[--R86B$]A K$L.@
M3M #6!.=*J"(<'-NX#C6'G@RIR!YP2E#08")HC1![HYZ; \I[LCK2XT8URG4
M9+ZU_>J:]./]@*\G3NEM 3*\XJ*QADW\(Z'YJ!RYB*L$U?CNX9;Q+K*Y"$0T
MNN\")3>-XF5NH8%]&:<K6&"^U&:[&P<O58J20(3U.B21*PT>MPZU/-ALO.[F
M%*CS:/)(FN.\J?6GVOUXRQ;S :XZ,R386+3.;HF=#-0E6#.TX<FF+#56!%<M
M%$PKL*+9PDPTX%# U*BB;2.%A*O1AY9K0^6U3\,B<JZFMY&ZP]<;357FJ5V-
MTS()FV-S-U#QBM=OMYM6B>TG*1:7%&O5O)RI0#*%7+KP%9&K:PP=YKXO6%&1
M9NVK<&0/&2:F0XFDLG.IE1WUB\_0S%-EF+1Q8TG),;UHQ7>^;[[D#Y])-*4.
M+P4$74S2#WBK]_9P*5'=M:CC,?X89?'52(=32G&?>J<3\*VG_D,*EYH5=<ZZ
MJXH-QD,?S&W<BBDT)EY'EMXJJRD9P"@)8(85"U^8M+I\C1$"4/NRYE^))4 .
M_F)EOV7YN ND4(>R<:5%[/5W<A8K?["R><**(C&/-/--=(2W]3K_W5>P_Z/@
M"B);P3_/SAS&K:8#^[DX9W2>V*]-'&J?C62^0#^#T@V9^SB@MV^2D9_Q=V&[
MVERD>Y\US@$9_0%;0^<6,N,^,-@M&!P'9*KL."+[NI$#ZK!7NEJA[U"0ZI9\
MX?J$>)K,=Y7'%W["[_P8NOK=LK>X_$#B?)S]E0C>Y!)[;#$]SK(RBY@FL,QH
M$H3WY.,"/GL52KI=UU DT.^NS^<<%O7=TN'=VC(\J]OH-_]1(F"A*-OQ+@^/
M^?"3;;4QKHSZ0:*ZK<O4/>_S4JGLG>CK79/RUN^R3CJD__O1?3D';R-5M67P
MRG3,7=GMQ;??\&473>TS)ANNV2O,W)4/K,7U[?U$;<Q,:D!9!WUGF,>J.:"Y
M*MRC'QS0MO PCJK![6;"^)^#)NQ**P[H+S@4D." WG% 0Z,AGL@>"!?7[3B@
M@C+BOUPQR*K,XX"^6!EQ0"TK2+:F_7X=R(HJ;N\@M_;)P-X&2P%&Z/LIM4M<
M(6Y7[VZL94/88?5H-@^< Z*1H#6^N#W>)2)P&L4!=:-:7/-8SF4<T(TJ'/7:
M__)7M%.'.Q>ZRPI@IS6S_L65'OUS(@=TTTZ- ]I/P %K&'XA7.DH-THBB6P>
MZ"]_VK5*WQ.G_U<WQF>(_^3-E3TQR#U7GBOH9_VX3D^7[7N=N)-!9/W&K6Y9
M_.6Q<&R>^8(QLS.S!V?L_HLSR#_%L7I6Y3_%;63O&S$)&LQNX( ,D:'_ZBV/
MX:+'/?U=)C=,8T2F?^.A&.B8.S>R?-SJ_?A?/O&(]$V]#=PX;NG?&#:]O7XD
M^XDKU[S/?W@T6_%FWV5M_!J $,:_^$K\YU&@BLER0#8EW- J0)C'?OES_W]O
MR+=QHH#2+'>>R+Q/[YX^ :#FHE7R/R0:)G?N@<.9!GON]B?A:Q<A\.HFE$H]
M"N7_ >%S,JOU2,KEZ*LT/#47YS2S=Y8# G% U"FL%@<T?]UIT,X<&% N.#R<
MOVQ6*+[9EB,O<%AW?2/M<E),@T>#PM1T+9'_D:)=5)'<U[@RI3*X_V()XLBM
M OW-3AT?8]_Y"_#+)E:>@_H* D4<$*\HW>[72B!4, ?$/]X^P#8;_*\JQ^R$
MD2O-: X(*L\!D9VYA^0==EH=SF4>LGV^ETB-Y.. >IMP!>\*F;+(B0!V%+$%
MRE1#@J$_87K_J<;&UX3=L, !;6T2V2(/B#^AR"7WORW];>EO2W];^MO2WY;^
MMO2WI?^O6T)H[+8E3C Z-9Z,-L*HX[.+43N6-565'C![*CK,+^0&R1K1[>+H
MCO;CUZ!\G[2!WQ8FY!^"R9&F96?#3<]92*0*$<=M1WOT/Y>DF,6DC]&T>J]X
M>>MO35U0[ZS*SHQ#AYK#6YW<!=]49%6;9>5>:/V#NBR8(I0B+<N0-[AOEO'4
M[4-1[V3#,JXMG)6.^Q'+Y$J]=C_J%@>4LOU?U.VDZT!W9KC,'I_*Y9F5PAQ0
MSZ_70:W9 [W0'T:I./(QK@Y,#>)6V<& ^\2*#98 [D\<X-DLB=O,2?Q/-14_
M\E@!_1S0XCR.>;$3MQE*'!KYV]3?IOXV];>IOTW];>IO4W^;^MO4?VW*%]C/
MN/31"](*^W,(<@= 4W<2O]=?+FFG>["R#Q_ [@=D;X+"M$4P0F'@W\-4+A[7
MNVT[BG*KGRXHT,A$1&P^Z4,8W$O[?*3GT-D;IC"KN'S\VB8J2 N=Z&TH8'7J
MY/5%0W%[8VUL4E+]2O[PZBN3ODT48^*J=;K?DS:V<>+*;@:$VH^O+&0=5PHC
M B@M?B[!E:-KHE H>52PIB9&04'A]QC2V!A)=K:FIB9,-88O&'/6/.;DF6@1
M]=?QENIS%G<L[H/ZONST>7A^[3FY^>YLVS=$VL&\!^I.6J+15'_M?1_E6@00
M?MM0^Z*$ N/2<@LO\XR%0KE4=W/#C/&*K,RXJJK4E&3+I/KR98?'UA)**E3,
M/45QTMNM/O[(@IO]NNMRH9^/>\][3!@P"4V9+E"*A_YVTWFW!QZU)ZY,(MYW
M67P_:M,5G&\H=:&U/;P?$W@N2;]'*RDH>1DUQ/[]FL"2"3V@T6?IY=B$'D0?
M/(R';QD DF<(<J^>%:FM.Y"-+]LIF0J47$ T+,2@JQR_]ITXOZR^':.O9)[)
MV&:$Q<B6'5W\GWSI]'?YOXNJKYW^-L%@>LTZJCUJ7<BG>>JCX#O-YT2-H+LQ
MP59-OQT^<)Q[9Q^[R?/\I@3WKD:J6WT1,U1>@CN6]VGC'WX*L2'DG:,EY(^/
M4?L#5:/;:[Y)]5CR_41X*M<"3=V>2\VEJVT]C,&E_/1TO=T?CSF@X[@% 0X(
MS0$QG.S1]B]H/&P'")T#XH!J+!9VOKO@-U4Z<=_ +-W7CE%L%0YH;89U_HR.
MD%72@__).V/_[;=VWSD@P695IC9@Q@L66OY$RAJ,]L!""W332?.?[EE??#W<
M'R%N+>X8M>XGGJGI9B.F_B;P4*^V*M,@D@QK7T-TGI'*-'-.-*"R2O^JLM*8
MWS2DWY2+,/H"[^3_G.?]9+"@IC)#]NO=)>1Y+ @ $8^GLI68R.!$ 4.*?#1Z
M.U[F?MJM^IA7IZ UU=GQXH9H>;U*PZ'QODJ&A%??1>\)[B3%9WBA11;-MTHA
MAQX[@X_$4QXY"]HD*)]ZV5M(MP+/VP]_[3Z=$ ^9'B/ R^HBVF]/>W_/(INJ
MGN'%OW^L]!MUS?/T)ZU;-+Y+W?/,T^ES<RGS/T/-Q)"36(MLAE*IH4*?4Q3K
M,X0_,L_]Y2<GG=Z\M0O#108%<M47[)I9#=M?%YR&M<60=I,1?R3-8-[P:SC?
M8Y9^0?R OY87V'UNJV[6XK]BCB,W<D#+J;AYKE"=#0G9>>-:KQT-JAZLRE:[
M6WWRM\E[[ZO?_WG0XL:!JR]T3K:=E6VC%A>KWS^4&KCRK-'R;<HRIDX/? TE
MIZ+.=X:@FXESSC;X&C6:9:5O+ <KOF[5;7_8S%.H\7!9=.%I*>0)"N[$ES(+
MI5K+! B?ALK"KE>AC/ @/@='G<;M&! W?W+5L78B@(;N%2!_8CD@ (+,33'C
M@,R8W$->)P>4Q8B$_GR+7-D-PV__@=LJ]G+A@"[_-]>;L N!0@Y(+Y8#NK9[
M#+=U'U<VS8L;?,(!?2[JQ#.[0@.Y.IU;1N4XH+Y%#JAE#_I/(0F-,-';PU/P
M+$DEYN*W:QQ0_TTV$7.! ]+EX8 T"D5P6Z=^<B_CYQ;S$@Y("<\![?_! 45P
M+RZVX(#2!SB@)SM[IW0@R[@8W#:&N(5_S#U5E6>/-5O(.@EA+F?9<$"?7!;Q
M3#4\R[2,V8QC@O/8X@/L(BLV$LKF&?_A)(0K8G,=#E*X;0YIQS-'(']'X'_[
M"*R\_D+T3.2=LM6#1#'Y"3]JUOV;/J<7VZQ,F\CLRSFUYBOC&FDC=F6S>/'A
ME1HAUJAM>C239W;@%*G?A8(_ZDKZ9M8]7Y5><ZF:)'O1@K Q:+HWI*,X?[ZZ
M+L)<D2'A^>C3!T1GJ9;=([68EQ>[JE0CP)=GX_(./B-(%X<_,CY4;6LAJS]A
M8)Y[(7\RQN.<N?IX2Z-YZE%D6&""V:W"!C-(*B81[ZR^JH6H+(IL<S:7G2TQ
M#_,T"0]Z\2P_Y>$(PAUV&#/9-GU]2&H<*TVP68'[/I/J>?2I$O[)Q'82";]7
M/F4])7>E$C'5?C37QO:"KN5UH] ' +'=_@PK25MZ25*12IA:R*/N=@0HH'T*
M^\_O9GP^;X/&0HN\7Q@&>AP@!/[E_DCJ>87Z<_4PEB?.8+O)H \^K++F:/32
M=HE4'9Y3X/#XK_"<WKUIS1*;E$L'COR1I@;Z\X;G#=6-QS#1.>6EA8GSN/3A
M'J R$F62ESDK.^)W*77IP>^+SSYMDI*]LZCJ'V5D=4VS?M2>',E*-?!._P3$
MM]C@CII]!&+#M^!UW/&A.?$"<9'*908JY5_= ?UB##-3K<#X<B'L2HMYTK/%
MPV:%40;>!<:*J=:W6$(F2&RH_;^?F6S3$[4<"C$\K>S?:1%O3ZUN*V@;5O(>
M+_/S7D^CBYB4_[0T7/E)*)WS_RFP:.DM)'B-9EVJS<,7W459;HL0Y8DDQ'2,
MOUWC5<=>OV9!L$0C;F6K&WC[#Y[W^^.Q=6F?^-.^]RHRT5US-&NL")A?W_Z-
ME'!,">_)(*%AMVNC!%.AV4RKE*2Z5[3]E,BPT)-+)468=GA$^V>KJQI8 T\_
M#_VYEH?OARF?M@XZWTDB=_BGS7_Y]NU6J5BS_BC1<XI7/%KT-A!0XGXU]V.,
MAQ6R:K#0E[TU"7>K7];M9H0MW&1/>2$/-0N[SU3I1?LA8XG"ZX5-7\3OIY&Z
M#1)L",,6&1.U_!I?N\_V.Y";SCQ$.!G:B 0WX%7Y/V;(3[BP^+\T*I#+CB*D
M"R-]^2&W:Q-4HA\,;:\8_FYZJ17;51NCEMKLXAQH,\7]>37UDGTM?4%;&O/4
MD.%RMO^2UL%VX469Y)$.)R'E3PSEMB[CR]V42U][N@^&MU,4!B(+3^F^#I]1
M=3=..UN[?<@C!;A)=G)J9QHF+=C+>*6)'+>]J7<$_P"#CO!^]&CNU(!\F^,E
MH67GD]\L!==SY$KGY(S]$Q4EZPGA[4RI?P/.@J#_C&>2L/]_ ]K?D/Y_7 2H
MQLD,_Q]FMKKUB^U-".-JI6CGH6J&D;,O;$.Z>CHS]UP<](.G(V1M?&P&S);%
MR%#\,TCI3W?>HIFIMT,*>]],6@[;&[6:<D"P]!-MIU*'-)\)PFV%?#R\KA2Y
M_ZB>X<.@.N@#;A2%_7KC"M_C*:[51AI#VP>>RZ(5WIU]04&GGK(_KZ=WQ]?)
MUQ*2@SP5*K0\4UD;K5(62^15+*SX(FH20V(8)-F\.V&0L11[6N-[8[P"=X1V
M_.()KQ3SW=84L2FB"BHUIJV+SM<2H[4A0^R) 9][8$EJYY%VAO,;<9G<%XL3
MSB*F<2XO':A?-9):'[QU6%^,*KR@D563KLHK]^YL(B'52?LXIA#!0I)+TZ]0
MV^/*+Q6QGAB*XBF8Y B?K$=GYV'RG90MWL>?+EF7VM5=JG8X.636&.@E/*_'
MA]Q^%_.]D6>.7[-[&DSE@.)4WO>XO%NB34791@0C4@)JB14O(GN'K&?:?5RD
MRCYN[+\BF']B;'P5<\\2<CJ\W?%QJ@.2+ZY]L-.A9#@@_)'VV2SWP1*>,>$+
MGY5CES.@>-K7BY:(^"ZGK\LGN">?+-7E.Q513# #Q[2-9A_5X8V^FK)D6:CA
MH]]@H& K^SKFQ[5;C7B*51<Q<H;7X28EVR;3+..R0EGD]MLAAFU==.S!%'C@
M^W;4_D=>IS_G^;AXR$OI"0W\/J'718R^S[P A)1@\L_YN#\:7+*'5*>(Q"S:
M-NN'?I2^WU//9YU;-^)Y7T.E9LQ'1_S(:?GO W]"0*(4P5]+3L9N>%$N8'6\
M%-@O\I<%/UJ9F$G)T,<JR_/</.9=Z6Y!\)_^.,>$:TX)B&L>A.$M8P7*M^4<
MOZ>SGX^VDB\W&L6U&5[N<E0^9<[N)3-+2,$GY\H'\QBDT1*+W4M?78,_VR9G
MR>GFGS&C'SLX:W^:T%X7&65_QODDD_BT@HGUSB(J]3H:,M QE42GG6BGND?E
MD+IV\OMM#[-3<6_KS$,*-/PNF!=8%LC7SM2&9DI\JG=I-UQI>/Q)$+$AU%IX
MKP>?FL$7PF>N\T![DR^2%W-LRCWQ'V9S67-5OZC>X.\B]5>3WRR)Y($0;FDB
M-<=!Q6]!$4.R>2?OZ)RT%[;0XP4-E5U_G!XS*I@-$Y4E+RHXZ4;N>ZCZ=AB]
M.ER$$!"KC%FZT*F_HU<,K+3R>K2E/Q&FJ<SEHRA8&"5(>+F OCS83G;1S9I>
M5_E.J5?>&O@'#!G\5\JY?24&]\]XQ,<*I9JQX\!L/^.+'-#"?W\]=(0#$N*
M?M!PB]KD ;8[>(?1"MN[!/TYJE[) ;T<&(#^(PSI_6,\OO3*_B>M!AW?. C]
MT<(!+9I3!MB.4"T.Z)] "/*/"$>\+9O'@M%@[$11ML^Z!+>]?W% R$9N<_+V
M<T#99K'0GW',K7\!X6W</X,<Z^CKQ!UH)W1/"_ESX(,/!Y3Q].\8_&\? Y0;
MM-8S7+4#]0ZK.5JU8@JD><@CJ\9<[K W$79+]8)WVQD1"Y?94R%KUAH;X8VJ
ME&"7*IK(D[R5M$U=F@K\3;9;T&]WA=32Q@7NTM1ZX\I.2.6]UKA2+W]048CV
M(,9/%JB,Z#*/*&]_ (B>:W=8KBZ3A@/PK3)C)1<Y+V_]!M2#O&Y)'JND@BBJ
MFNB?>5!_3",X&JL7U_DE=G D+Z*+7$0N_JS9)5QX\FI2<O7G #('U D^P#0>
M1IA20ZOY.:"DM^BJG^:3[B14SP<YY-(F!7/[2KW>XS!#P[ $CW?G+13LGR S
M\/_/4]CN[I],KJ)@M+(AM(BT4Q=WIK0UR_F>#Z"\$^B[=--+/^&&XH#GH^]^
M/T_/.M\R#POQ/$I9';[R2=E8F%)Z"'*1\BTI]:(1YH_":_-US39P@VR)&?E4
MR^52S;=S!DUR"::YE@7JO28E<A^PT*<4T7W?)[0MDFBU!Q8PI7-/, G5C\Z+
M!89K^&YA(Z^UMXZ6/5\T>9UZY$&>OG&-6)/TR0>R0R7J7>:.>L(Q*ZZO8UA"
MS"SYF2KTS_U+2#I_.0<T9%W2@OJ7BJ4/+JRY$QR0O2,'5)!7PD?K8T*+U?%1
MT*W#'% M!\2J*%,KNPL\Y8 N)3)P'-"DW%;0UM; 3[$'Q'4>=IZ)<@=.#$??
M8">?6("1#.G=K"SH0T/H$23["P<D0"3;DS#+B]:5U%(B-0JST8DGI8L=@/N2
M&D.13YA*%)M'H3TBA,(:EL[%.?R:N$>&<XP7Y!,<R10Q9!\I+T5.NM7@J[KP
M_)W?8H5,W?%'FU5^^!_^=./0HL58LX3;GEW*'_@,5-_',S>3UO\Z@;R&:[79
M2>3%X.@I'%"8#2I48U3K^FN,L@$KK_%F""4>V5E;[YE)CE>[74L$$.<+ LMF
M5@3;"VR6+L%+DY"V[E>Z780_^&>/7>IJ_I/U&N>&!Z1S 26:X&37##= 3F (
M)I0#:JM?B^]^ULA'08<W7Z7Y5U[O2@Y2\-#2S >,&F^7PE'>GT2N2R%B80(_
M2)DV,]='*W63#L*.1/I>2DX]ZN'^,M6DA[QH=$NB>E%?6C3R[:2;C(N)W8[^
MTA%YA7.3Q+:Q#/H\[M6>TVM4D%*T;XA2A[;$Z'83[L;8JH*?G;CMH-*:JAW$
M:E@IUS!30<]P9-4IIY?=MCE]=[&ZL2H'$1QE)QVAIVNI!?N5\6>.L?=CU6G0
M3F(,^PP'],R,O/%4H71#2Y\"7LWVL67WUXZH&IX6&X*MEO$O9735!BZZPU-3
M:_KXKR[?96YH6!ABYM.@+0,3 _0P8(-Q#-<JC-U'>V<$UAEMO.DX]U*::OF4
MQMMM.Z)P!K"9(T83/%S7'-^L3(N-. ;W(?H1MM1RL6(;?DW3(<4XY:\?:W:V
M(=V0Q)E:D:<,"#,$6&3H8P^RXG<@X<I,)2HNKODT\]Q859D$5K\Q\3X-W(';
M#W=C"P,K?P%/K8>8JN_Z"S$XB[K1KX U@C2)21NX]_S;K3$?&T/HQ)#%SY""
M:X-[W]^7NY>>,:T,OZMKD)&4M##_%J]L^LQ^=U Y>;IZV/9;K='Y'01Z*N N
MZS65W52 *;PYJ 7[:RJDX39-\L6;%9+J[@L?%+U?WJHR\O[PN^;^0/ZF>2+I
MXOJ9S(_UM6$+"FQ;:J=<O6)3J Y[>*96KS-QHN$&Z\_59A'F6:I5PCN<&T$%
M"%TDC[URQ.7VUC.;>:BW 7 [$ESF2.//29R=$FBTH#1<AYHVCC_2,O+( ^!3
M^;4U6Z5] _,<T'$H&C;) ='_  C4;O+ F@SC&O,HC<D!51F]J\YC'JUB96L9
MSB&"7S9+([(59_2IL(0=?)2HJ A(KPBU)UT;I1HO;U3UOGKX'5J5(&;GKG!U
MN5\YPL[^=5SN*L&,5'\_U=VK2'TPBVSRMJ=[]KNGT03"(L340*&D!!4L7]*
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MV=.[O0N/']U3(<^;;/7QS7G87CW=9"<G_ &RHNIVN\K%KK["SJEH6U7(!$G
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MDF:'F&A4([1D4GHAO?3'WJ^OYR<1+ WVV W38$1#H.2IUPX1NF>)-ZK @,S
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M+/Y/O^?5\[SY/R_P@N/%X;O<]V?Y;N<2RVPB@C<@Q4\NCLM"3UVGM3,RBU6
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MN-O=H,;;[_<$MCX:'?MO*"Z@(C<G.(23@/"2<J:;>F@IE 9$)T*-% H<%V(
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MD8ZI_H_JGXK]&X9J+DY*D?4/@U6Q9SJ=M >=].WR!<]VWBNZ[A;"LVN^%Q[
MM' _--=GX7:X<:F,\/8.)M:V[?O7ECH96^^'P0?*]"/,KX'2B3K%3;H-+2V
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M5AM#4S])QZJ:U(>61CBTKEXI%4QJ.B9>7+;UL_DX$@Y$"3\\&UX*>U[H<]H
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M4VW2\>7:I5C''E9S <%.1-L6@7T(A/TN'LZQ+C'(>C@7OR=?_<H^Y =N W#
M()R)M=8V?N&'9+:@COTV>\3H[RL7,WJ&&+O<S:LH_X>]]X!J,FO;1C-CIT6D
M*2@91>G%0A.0C"(@($2ZU(B*"!$0 0D"R2B]CU2E16KH4;J 1 A%0$2ZA)H@
MO264\ @A.0_??\XZ[SLS[W_F/>O[SUG?^K^U>-9B)4_VOO?>=[FNW>Z'=SWD
MXPVMTP:@#[XO?YJ6U\,_(/NX6N6UZZG#5SLLUORK=I96,."X-PJ=H^7@:$:(
MW]HI@7<>A+B'T='YUK*HIQH6&'%T%8I2?#3+B;BSO]:J&A77R\T_+^4V<<=
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M'JARR( U.K6W(HLX<=4A7T7\G;[9XP&D;$63,6&Y_T><<_5.K6W1^'3.2O$
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M_*>!^W0H"1J1<:3.$-Z*^7G(EOQI?7Z+ISC9VGNL)235 XN_\?7&^OR@2DH
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M]<LZS46JPPT6J<_R^CXD&RR4C-C/,=F0W5?-7\$@<V+OK$D!C>+*AI3W,8*
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M_MTT]'^5J&A'_"]VCJ\3!8G?1SVPNQ$NV/D%B07606S[*"B.:"\;TB?0G=G
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M0%<%&1LJ9ST^83GHA9AR9$,<$;$3%=@7F//8Q@?8R7?6K,I"-(*D"<4*,&4
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M[;"^.O?AP@@>ZYKQS]OC)Z>,+E..F^62;/72[_=+=_47!3<^$)":7#!SEK!
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M&YN2D!>JBG/_TI1]?-YUB+=F.YQ5]0@T\=T:_R7(CM+D9AXQ<]C^[$\HPQ8
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M4FPJE0T>AA))(*;QC@LYE4+E,,-JW:Z7#^T2JH] ;KFQH!N?5>B/$:2[1R!
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M/F[=&3KD$G,E<^_<\9@GF-KMO49A);=.+/6")2-HG@2PA[#H\2,0 Y'C4HY
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MRC!I ^8.#0"$;?:G"'0?_-1ZWO+EK]J*5;?CY_=O 'H/+S5/M-D1Y+6%BJN
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MW6QB-B>>AVK\^FI$F2@]8G(N.2BG9#S5:JGAM['(,!E,^-Z-9N@V1YL+V8*
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M:CT-OZ\ B$/ZCT +OXB*C*&*80R2+4:/$WH$ZM75:FTDB\;268':7?F:J_7
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ME'6SXQ^R>2M<IMNWY(>(\(3W%,9?_XE SNGM1_Y77L4'+1R7\O)D!@09S]8
MA'H9\>7>+B#CMGV)H: &0"=RR1EP^D17::\#3(O]DB16\W().EZ=OR%,/KP0
MN2Q'#<"45*2C$V!SV0IF3#C#T?,A4:%.+*+93+TK-'#/9OW^>^1Y^O)EUVU^
M*J)M?EHUI7;5:\I3??R3E?^]/N,N_ZADSKHJR4V^0?3#G:F=C$TC.HO[H0
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M>/\HOY@:F^DJ81)<JF%=P:+_."Q''"5.G3B<F*M2*=:9#Y6>?NYGE?7F"EK
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MV-Y9Y"[GYOK^%/AXM VY[R' .GKP3X;T=I'6I\?1@-\N=%/@U*G;+:_/)P$
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MHJ*B9!:.*2Q/;SI^V@>D2 0>)1$.]CV4-:5^?M0<QAO!+V[*.\QBNFGQXR1
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M(Y?>2+<W)->KRC>%_@=>@WMY'."$9-\F6F\Z%QKK_#UZZ2E^V+*-C']MRIV
M?<[2&I53$-.^56H1<5"(,,Q@#<=/-*B7_M1->/U8[#Q"AQV?OV2FPP:P>1]F
M0QCULN<?$IQ;YU4CYEO9_M5L$FS0:P_9-AN'6N],NO_CS<#[5BYW1;]O<VPA
M.\BC.@6?MFH<#![6/E*?VJ$"EI+AA)=ZB7"W5O2X M,TXFAT(J"=M>L1^$0F
M\2*0%6W4;K-T.!%=V-KCS_1:4]H1EKJ45S+QFS!G]\<^'UTYM/<JWVKQA&,]
MRR#8X_HW[<LZ-R/SZ2-G-\!J%%GXTGKJKP$S8O!7,%W$I.;YVK19/-U6._[/
M[F$XQ.3#]$81#IX4R*#41=E9, IPJ&A=O$I:F.T\6<W["!@)J$!P;KRL=W8=
M_GAV'MXI0 5 0\&SC4<W2 S$!?Q>/X3',X(]L0O#ME6YHJOFU@.^I ]27'Z6
M]E-^\+-VY48F [Y*H&N]N"FU.__FR'./ZJ)\R;*SI)YPKVM1/P0KFZTY6:;(
M9Y\QP<IKYODG0I7O\2O#&TV5UN?MM:@ N^Z@HT![BZA0W3S=48>-6;!%:6$"
M,?5%1: '^QR4KYSKSLW?;F_OP V/'99MOD(889M:D_55%MJCAX."]F.H@$$O
M[8F#36,+_4F%=JT%!ZCVP_&#V3_(VG&%TTT[X8:VVM:W#J'_"*5Q%\+F)SKJ
M2E?B1<Q3/KV]\OM"Y\F$KGFBB<R@UU]6%5W/41M*RS'<R8X"0S2@R"R+1R4T
ML+()"TRGT%^C01=R"F11N-[!UM0V$7&3S#)JO6G?^C-,U3_X:)?9HT&3[SN0
MA4(/*>;H=B1P%/!3 7%D@:/,#J$1[UUH_3=%R 6X,9"@-TR2 6\=T]*(>P0K
M9'2UR!B%+6+"F6?DTAI6]DU+?M$JW*/;?8!A+5F3W3/XN7@89*GY5X_&X2=M
M//B2XUQU%I[7KA*B2U2.H^FMXW:8S!A9!PJJN9?X4OMN;1DW*+^\W3_R_2)?
M$&K9@D)?1;MJ%6(@"LL-AP))HM$[102'HV)"9J-RRK_U2 1M?"[:P]:P-^2:
MX&RD"[9UK6./";+8UAAET[+NM1F25Y^\DY%2X8E2HV^%IZ;0$2ZN>]42I\TK
MZQ:7],K=1>W8 @O74-]6KI0-EU4BB__$NJ*%'>@XS:,0BF$"#9X;AV(!2:,+
MZ@;N&5M9?Q52JB^(7Q187LB#]-,@VX7"R#T*]S1V,SY+A?MP*= T#6E(B2W5
M6VH7M)D*V%^",X1Y$R^5='F ?Z6YVR<IB2\Q)?MM7#N2-L(=?)E>CQ">3%1^
MLUTILYO^M47VT.OZR-";Y<?WN9?)"7LU*O:_#*N387O?/;,G61-G7F:.)OZ9
M'%HO'C.:ZGY:BE^7J'<=Y"Q.'WV996NBWFO4,!PPXY%&"^I# 9?8;++#'A,W
MR JD0+P/9[2!K)34)(/(U2NS2JA28_Z4;.XKFL\>S<T)3_QX[%KU&)'1B^OY
M9YG0; U)^4&<T,ADDNEZ*M=4WH 1 5XS#*PPT/$2*>LRUO$2=:^R5[^[=5E2
M\<<=N^?T"'3O<ZXVS6O73([6L$_+NY*Y&NLM<O$EHL56OP\>[B.2(?7(J X6
M>?=)&J/O,EX6280?\5?U=_N42+V7RMSWRBH0/E7.KD[K=KENOC#(*!2(?NLN
M UE+A,?!&[)2+4XMNA8X!8!CWEK?W<L*2*%&T9]\LE4?I_?Y#_KZ\\7'<%X9
MO/YI-]&S-N$/W%4VZL[F3\>P%\0#*&JS9149[HL;*\=O">H$"@4O"#:EN#Z1
M*?(O%<8J,=W.J$^81]V\;)3C(4WYB^KSRZU(:M/KML"#EA/D.QB_U7&=N0CB
M*)Q5IK(_K)TL'&64Y0=73-!V4SVC*]6E6KFENKDX<T2M?X88I3M[M8T?-RF"
M9%SADTLCQKS*,OKE]I$*8!TI2QTH^:=3.*'3]>-#3[,2DQB61@TZ^^)EN_&H
M]?&C<OI*#(T7+6M2 <-D\1#P?S?.;J!4"(A><)0SB A.(+,N^20@&$%NR^!S
M\_,>%!5":A39%Y?*#$-T9AW91_>^#W7%MU_0FY!5A##.SW@V9-F[3C2@/-P4
M.PJ@OJX2PC_N/NBH)60:*[49$*&EQ;^GN!H*<VJAE0W?E0LQ3DS"I!JVT0A>
MTL/<'#/3R%$_#Z?B?->@T8G9S\C>12("OD9A:P?^W^_AS<N+\4!&"CLLPI2#
M_(BX^Y;"2[+F;76X&F:\O,CV)X*)0+:9JOSNYB:"QO-NJQL;M3;J.C@$-;,Z
MWJW%IEB^&?50:\A K=L_;RWP#(E %WK9AV=6%7FI&6\W%)5XSE@70?E7$67K
MV=&YZ?:0];]'Z=J!KJ%>"@U3UJ-](!8#M@0L#8J,),7A6$.B3T;#!\P4Y_.)
M' ,JX/ET?3;4NSJ2<AOKF&L30V'U%\I)/<EO3@M5PM17I]?5;;KL4P$4^5TR
MS0>SBOZ[@1JAI\D2I0(JLO!3%!$(A0%(UO$Y:5A@I5$)&NSA6/<Q_]-)W439
M^#;EI<$+UD1($DB[@&31=7(IZ22_%6_*LC')P_&F<+UAH&/MT00ZV1P_93+V
M CJVFK^SM\IU&Y)MP.:O1?C8D$:4[&F8K35*JIX-%<+4!;X )JR++,8LL IE
MS(;Q/TN;;SPK*M3KA/^'"2)>__]589]6*BEJ<A&+X< 0[]*HJCL<:].QP LS
MI:F6EDY%F0Y1 > C4L/9P9?C/[GUSI"NJ\&IQIG1WKSKW S6"K(S&+SR&\4<
M.!,Y@" \F.NWQ& ^_+!IY% G3JUB43H#FUJR:?W-X/J)8Z8^^,WG]V'(LRO5
M1KT+=(1AK/3Y_>X(B;$GXP&;]8^3^BN"G_C6QZ'J-].JA/.V+NXDN).>M(BG
M.;P2CGGH1?+'3ENINJC88*OE*CZ.F)1(R7(^5R!%BO?T*WDQQ)6 I+EQ./NY
M-*QYLN&'#[DX.B&H-M:$9]!3CZY'DY<0+M50]Z@B 2?5\OE^-HXMKZ-.JU+.
MJB@NCW>_4L/.'&G?SYJ=Z+$!@V/59!/J0_GAW2T9U:BB#;-7DS9'*<[<[^0%
MRZYSZ'].T($A&S\*YB\\2^->3K$,<,HFKY\A%,.#EZ9Z,<QA5XF7?F>I*54$
M^LU(?EN!CIFE#)Q:&(UOCS0*"3J/F-UJ?:M$!;Q[._W5J;CQ)150.'$XQ]!C
MCI]+LVTS83U55QZH::K,T1QP\-E0[3UO%B.3Q.N77J2H%EBZ8.$;K6-BD;L^
M9/J[:3DZZ^J:6=>3&O@,MXG+VZXU;@[79QWMZ<O+XC@O8V&VBON] 5["7&4F
M.65<6NRWV,QTV(_T^OZ?>2/V[Z2^/F=FPN7,0 27UZ0:_YOG^L[KT]4R*SH+
M/VWM[J4M+,Y=//[!$;3?SRKS[08'4&$A8A9Q!8J$%8R! DM[*SN]7QQ ^6^^
MN_#Z6TMLW MOK2\K#S+__#KM1R8<)^TFPTQC)?48\GTOVV3B7=D5H[%/RRIM
MA#IXTKKO#[6)#VP-!2Q?]1H0=?-!?H?))I 2DFI419E6/Z;PW'T)J]3D@%NO
MI?:8J,27FN7IGY7J%B-YJY]5HX[8V8D(LK)HE\\)9\=M^!*R&T*>'*$"&+X3
M<BC1NW$(DCAAB@I01./@6#O",B6!7$0%7+:B E:<X8CGH7 B/4B'IG ]I7_+
M.&&./8Y<__?DU?]/XH#_BS0W0XH9C0-O[<9)X^ DD0&2J]M>'Q:5"J0/XR+6
MB2E?0R+C*8)77C_SZW'X*JXY[I[S0HKR1 ?F>K8!GTW'*8VE,H4]H DSC<$<
M5Z%6O"B,ZI%X/3(;73>\CJ[3='KM*T6H!5U#^HA'\<,6(43(D4P\#G5MY@^%
M%TU8?5_JV7@T\[E"7 ;D5/F/E%0:U)PH7:V+^.PI??WSV/2W,%/"/G?VDS)S
M_-;'?IF2H(VG&A\$KVN(3^7F&?Z,5IEAFT]/\\LHX!TL)K^@ KIE;WSYZ"Q2
M8L(R9/FL;,1YF+%\<(#9.E^ V?)/?XF!OV&YN:>TKO*'W*>Y681+D#_G:)H9
MBQB!$"R!G.LSIC$1(-@-V-B19N0]I46F#L4PBTE@-Y#U /'EP4#QNO/U1A[=
M$E384P)Z/$<JW9SH:*_1D/[<-<N E%K:76!'NKV_NDL2C26S@(_NGR%D#R#\
M9+>?9*?3>V2;L>K'XR_04'A7BP;B=9@T+,$0WJ6^%$]V#74IF[?7[_PT%68Y
M4]7OY#"[$6(<&UMM>9L*L,1<UU0-8R48MW^!7">1%<3>6&L NQ/*;P  =#U&
MT?P +H!O']?A_C /2.%E)N>9^_=5*F!MQ3##A_-S_0>/,E%4CTB]L8JA:&H:
M3!YO _(UBI&/DP;6(4T0&'Z%TGD3Z];BO+SL7.?%<B7SXTDBQJ_BY T%7E81
M2 P -]#B@ZV+[53W(O.=3XP*"(8@ /SG+(5=]C\=;ZJ/"O@?_"P\@5"$]9(D
MI$ C,*TTQCY@6B>&2J+%H69-5OC/=B(M+%W2Y*$"5ANJ["BT(>KMIO^9-D21
MO3\*JGT4H/Q+2:QOAQH$;G<T2Q1E,L^V,O^U2F4W(T*Z/_;+.4+2D2)I?E4J
MNCN+;&LF<@E3-N)"Z%;K9P-=*.8GG*)=JMUFQFB>.[F5K5KLPN*:_7+0 [U?
M5I=^:+D+)26M.$0>")Y,*?Z[-X]>WXGM9!@09;N9>2Y#)-3&M:D^8RJD$^ZJ
MIA/ZY*7%V@UGAT[QAVH%6ER'>5X[7YHJ9=29]#C?8G_VX'QO6(D]?8DNF^J>
M_'R4)S%>HA9X<[NX0 3ACZNQ=32YQFQS-:E[JNMIJ?$8*@8[6J;5SI,(LRJR
MEBLS\:IT8YMR.;Y*!432-/-,EN2 J;'JZ]6X9I0 YXH8%)"K(46S8X,&I<G_
M3C'H/R8@L,:W)\A_"AO1J=OYW,2.,O7BX2/P.:XG3OMABU5P@G;J[!7*-()@
M@ID>PZ>@RHW*2+L&A##@]0XQXU=^C?:Y5 "S)O<E0A"F<B--Z(X._V)2^L,:
M(MX!&RU=2;;R8CQZ%A:>=^H8!B2LT=@:YH8F/ZFV2T.OBP(FN,636?$.H@GB
MUKOWB<[)KPHV?MXUY?O2G-U[@I=;Q1+)7UON<('[4&2>36(P%E,[M0TY?0'O
MO!,AL?C],@:'XO02 !'"VT8'?)#SI"S<:A5=-RI>?CW31WJP,A4_S$3SLW:B
M2":T.FSZ0./\WFY$ 93'U.. EGK,U&;7_ZUX4UZA=3+P:Z+>L^>5N+"JPW>@
M*OCHX4R&<=FR1XM\N 9:-B0W_Z2?H4L\> <..[!\U)0FY/M-@JG$R%ENYY(@
MX.O;NPS2;.?6*+($S3R\NH%+]D6I_GO09D%!8(H*)4\.D@?AHIQO\U$@?!TQ
MX'*Y-&?F^EYW;>_WHWN9+ X[\I>U#)+3I7@/'RUWR.TZVB0N$8AC,JN3WE)5
M+W#QOYN:V[(7:"]A2+Z=V\?WMW6 K^8_G/NNN+8Z_=PFS[6ILDZMZPEQ^OGM
M'-L$KHQ3-%>UJ[5\FZM6E4A[B=K!&GV]&[N:?U3&,%AN@/ JA:.!E]\PSU%1
M'^-!WV!6.V&:O3[V =C.\_Z#ZU5AL7Y9BWW9)<RV(!X>-76T<(V4YA,H>ZT@
M9:';ZD>6S8P0<VG"+=;E'^/UL-=62K]S9J_L?9$JX[.^<,BK372.1:T'M71D
ME4W3B-0[Z9ZJ^1*L_^SPM?,/WAOSWE4C6&8(59SG.L\0 0[S)X*[)6=;\]2[
ME27QHC)]VT%F+;8.AJ9,/A&G%VO%.N<]V'M:43OY6B6C'?H3FG<WX$SUZJF,
MLZ3$'M//GA8[S2,*B:TUSW>66:YB_3I=SS^LBO_$R#![F[LPJ]\FE7 =#!QX
M323-1<KT61.!L5]@'M:=-E^'8$G#L5!%DTRGW.<U!:#:CG/&IVHJ:*>IKEZ9
M/$.Y*/>?8/F"'G-<I:Z@5%%<%JMK4X@)+.2#R,;3VFW+)S$]RVS",66QYG^?
MV.2-%Z<G?4I#ZI_](+T_?10F0X+)2+M-ICM,%EHTZA".4\U:]^6C4U8# K_4
M^. #V]IBGG MO/MF*$@&+\O.I"_383_*O AC>AH&+##ZIV>^070B7S##1:0.
MY,%0U[APM<2^)_AR4-7X)TY-,P+X:SZ05(!T\ J1A'O%/WRZ(LLH\J7YEK.1
M0[M*@:TW<_SU.G27_AO7MW8W S--?_I<)@/0C;:NF&2#1__<>X^[MW3I6KW8
M!: ,8.EQ *JQ^QG9O_>#N(O\D% 7H4,[$<E3[Y?/@-5F__CTY2'KBFV'4%J>
MBN'0&.5'U!^KR+K?:<V[YMU$(/-8] MO5R/Q 2]=^1@FH=)RO.=8&A60-5W4
MDI(R>E+I*)3?5@6\3((O#=7A'<;@U7.>/!.'8Y59+$;" U?YWJ<KSO545U_E
M.V\/_, <^152U<9YJJIU*U[F!;ZAD4OSH6_<S_R[/;Z9+N2'T_YIMNGI$)<_
M^70C];"1Q^AXP]?R7YXMIT+Z-H>,@^2Z^>Y=O/<IA/[460 GP(.S5?EM9\)[
MU=ZCG'02C_<'&:6OYF!=B(S5$H6Y*%'3&0F#[WMC"3]/^%"Q?FV?93=@A@$;
M1J2,E9"F[.36[^-82[\*]=965;_/\T7L!?L?P'6HR,FYF+'M&:VB-3F=O+G?
M9R-_Y"/[7B2M_2#;G:I,5\HSJ"THQ7_8B7Y_W5OSB$?$6M<Q)>K&'2;%HT.Y
M9;V+:F^9'*=&^TU\/XAZOLMUY>[RM8A:%AX0Z[]KK/)=*=MS4"G;H^Y7!KU_
M8E(!)T>NO8?"V+S"@4<5S_2A-9@'Y$*@7S/--*B"[BA,+T/_')7N^C3[HMMB
M9D;>6;*["\>)S_4J/U4:QIDF(_@C6+YE[B\,+C,Q.32,N57E)#_LH\^%1CZ2
M4LQA>+^M/_I*=&R)2W][WC+AS'LB3+9DXWVM*91UYV+80/IP6";0)+SB:YLK
M05Z_)<4A\5D*7:?$^<+]?>8!OI27\JG>7ONY?=U2,=42KY",>+DY]CR#?5 P
MHY7M"Y';!O-ZP ]&%%:BI6,N4LVW)#90:->\,C/U=XTC,-*J)*G?Z^G=AUY_
M\\(:(OHS=/-&45'PK<."H!6Q/0L_GX7T7ZN:?!'3& :R[<U:HN# 4K+=485>
MY2!?MKK^_ .U+=\>[_?5K[(L&D?[G#XMBZXMDL1VR>P51Q94P%OO, $PLZ8T
MJ6$*0DRE$6L'G$_G+KTG1U8^B)17BHU]/%KU;E@@%9?SZJ4B@F?S&N.;$IF!
M9]E_[5K'%,+UCH]H(IK@G5:4*Q%8M;.I3G 4AS.0M'YJ;1P.1<[!)/6:6II^
M:@)- T'B+&%:[02BG0](#\8WNTZY-+I#8Q5"^P+<: \%([OZO^/R;5<)#KB_
MVYN$O[@I[.ZLQ1&0@(C4E)KA5S>K(:S%[3A@\V_5C2D,E**E;_-[.8\I#%_W
M>O2GI9+B>KC;106P\9MT=5UK/H SSRP,*Q5=3,A7QSK?L*P@^M""5748F#,X
M[V64QY/]15>V[+)$7)NQH7==?K7_@$BI^5OC@6PS4/F_4R:NW@V<[%$%>;T?
M7NQ+5><6Q157I\.2+OR5L#;<S6)0O.*P8/PY=9 *H">+T?H> ^_LA?,&^,Q<
M.*J84AQ^B_BR^@;E9$I8PZW%EK34CSP?P75P3+6 N^9%CB[14ML<;/#[^\*Q
M"1'*L-I>/'-((X<FL#9_V"2QBT?V*/&4/Z(;?!7\'!.SP$UR)2"^VH-?MUW#
M?;MAM\[CU,0*<:I%SASF^3S*":>THCQ-"J&F]A,R,NAKTRGK;A(UA:]\OB(2
M$4R@"V=9N$4VDB7)S7AT>UMA\VJ AN+E])+IV=L.LYUGT5[L;2>!R<7T90P=
M>9=V,]B\V#@Z@SZ=61%LDD&<^/:[ZHOT7MDF->X<&J,>4YG[Q]<W#'O\6?1=
MT8B8^4M=.A(9CQ^Q*QX>V\2%J?80+/WXAJ^?O?5\9;3:]9Q+CU^D1C5"1*'&
MD9CVP=,ZH,3XNU%:D7'C]F^NK1RYM;+HOF[VE,RFN$GO3*6[8]DLW1-F%2;,
M'KTCB;&MKJHE@2/K/,+YZ1=?=M+?U %<>J0&4#_W1_T"XOX;!\LWD7Y75-<B
ML^T/4RL-9VX6)HB=2VM*4?)[R6Y CD7#&8&$P*SM:WA4$O &_!F8).+6I=XX
M#G(E!O>%R&*!G.Z9M?**@T.HJ@'"VM).1BFOJ=H?C[\M9W^3%0<-)[U\V?3N
M_40_JN.%S0"W<WI##E-C QA,K<9]I"NE DXE<V8'9K\OH^OKT UO#:IEJJN?
M/XNAT0<A#[=L&_W">*?YMV6"9#)XZ6/-!I!@A2#) +=E3R,V)Z?4&KM2WV:C
M9\ABQ@8RS^L:C7[)4OC#V!H;&YN39NWF'$BL6D3.U$!>HZ=52%C7!H..V>=6
M99:0XP=L$M:]XS;(MR42"9MZSA$K7!V#WQL0 :E Y9Q<L:5/BYIW*Y](^O#<
M\;1RW4M.[TC6I_S$/&&:7NQ:K,OZZA,-H6L#/F^@\))<EGP889+Z3]^XML9J
MC4F_0$[(#-L%,CAOJ**-#8.?9ZX]:F]NRLBVXT]=!   _)?\G!E&BT8/0FVM
MM#(2[NC*[;]PS'4AD"6K43+%\P;]?M!^X^^-%="=Q;(-\[=(DQL)!KKB0@T&
M0FD0H;>U@?.A>H3>]W 4+-(,/1H0?O>";SC\E6C61>:8*\TJLD*UW[Y?O_$
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M!IZ2"I2(&,FKB;CKZAIMK:/>-I09%J\=I@LPUFX@8QO8 S=,O_YE_4CI6WY
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M>OMR'.G/X1OQ?\(J551&% ECQ-J+&OM"'E#0OX,-V2Z0VX6^QB)_$G?T!HG
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M@K^<RL?]->N^J>V=5V'.%39_%A4GKDYH?JCVT@[$X%2W(BM],>=V&3_\Y1N
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MZGZXE^6WI]!XTQGPZKHV9W)Z'7]](HQH"/H0]3=NJBDKZMX'MA[D FH81K6
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MO]RJ85%O-/4)N481WXSDKZP-3TAM+&*F270T@*DA(K 4V"="5"<_T_2!\N1
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ME(+FAR;B+\W.(>;I SW[-WXZ(:7TJYN&YG3M):*?9SX/>Z>VWYB7,8F&[\S
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M^B<W94M$.,NBRR;%UNZIW=,!+84)>J-UKZ[P@Z4_[E(^=V+,4/J#M? O7UH
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MRX2;L;+8%Q"")/:I2'0I-D9-KI$&VZRG-?:A9%--;PQC7&@R![#44(>]8;,
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MB)KI36,JON#=*:=9;[KV\9AJ?(9/*4^8]PE,@(_DVYC<2V>[;<@_#T&G(:)
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M$<=*1_\)34:Y]ZAY5M!#J@A\PJ$=F>7$Z)9@7- .V_<9L%E^USY?,TCP@;Y
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M+]D)J"4>F]3G8MCBLU:,2\!DT:WWS>0=4Z^H0+#A^H%PKJE@0 '9&ZH0.!3
MMN'DMST'BQD[8H/803&N?[O,.X-^="ZIV&4Y_$M!@<^IEVG.F:P-TVOZ&2,/
M:Z_4XY0$(_A&':&7%MFS#>GZ"Q^PD5RRNY4M+N@7GC+5OL80KS/L<?G^1;Y
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M1V'O"U[4)'^^DR55G9LW+N.8EOWKOD!47FA<U0%" O[F<!8, E#^IB]D+DC
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M[,[<4J5?QJ:<?ZM+K<$)'KNO@0=:5,!*^3*(XBI.!416$,Y1 ?=W*;8+BE3
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MBYBMZ4*P:YYO#JREB.#Y=I!?8'_A*\/!!I.M"AO'"_QO=\[7CG@Y5X642FN
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M*_DE#<< \*4:>!5R*PH7TH:H3NH!7H'=IW5NWK"79Z&T!&92]^,I(6RIDI>
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M@897'O"I'\IK(L^E8SWNDA'E(P5XMF8E=79W<TO+3"/DA?+R\H1:#DO+R:/
MP*I>B*>[YY7 H\D?#SX+OKUTTSR6R_DO%M5E[0>/V,T!%T#:[*?QSEP]<O'F
MSFSY7-TB7-U2XMU2PLGZPFG)(P(?#$QI)$*_W]3;-#7++S7K&^W'JW[6:[[E
MSZHQ7?]J\M3_O+&S[7=Z79E24="&0"!L*7/V($'M*]>Z(O6?9=I<[F4S$:SI
M$ZK.$TQ_ A MK(RG KP@O(O0$,Q1$L9+R[4AI:<YITL]_.M7W12=$>>&)E3-
ME;**O(V]_8<V50:&'AD<HZ6Z/AVM_G&-<4P=]BI9> [1E$J05$?SR&=N/TT=
MP4(])]R'T%";$"4PNVV"A/D*HB9^[L1EH)\2%TX(8>Z&Z:;Z'/'DY9LI=$O*
M5RP/%3FM=P3@H8F&O3/J7+86)3T(Q5<%GSX/\WN[1"TGS<H(3S[#'7? +PTN
M2Q4]3;Y9.E^^:3./>D#G):L[]FC#:A(IYC4WI1XL$B12^U7]X1R:I C<?KPH
M#V/L5Y&$8VQ)^L^+5XPQY8 YYW> .W^=;<TGL.-2[A&LEEJ4&>Q49[LRZR)R
M=F/J@I\(>#>WYG*M)G<_]7D:9CPVWSKLZ98E]-TKX-:S'6RPP*SG_G<F>FA<
M+L9MM>DX.CA2-Z%G+%*(R!FUMW7U.H>5<8G%S;" 38G);HM";O&)4HM^@[Q4
M=EM<O,?PP?4@#FC0>VRI2S!3U'1H4%B[>:X T1/X7:[.MZE@74M_^4X$YV55
M6PL7;H,T20^Y%W.BZX^R"PV M.2(^X&NRR!?VR7UP%G0)T&Z)$79/['V0(,*
MD$/08LUAZG<$.XT<7=N-1?_>](506%<6P >[ _A#M!CI@18'%9!OU0$GF'R@
M O8Z]]$4'LY_*]3@^U/G_*=00V93S(*P2#3;J-^[ZX\35U=/>QS*3=*_<_=P
M$A^/Z%S/)(OF)1&B8!94@"XX#HY#R.Q1 <A0\&2#0+3]K8-0=A\$A>T9D%1%
ML84O?5JL!OUQ*$2$^C&-RL>A:W+FFETV]8M^\PN-4*X35H>[M2[B;]W6YT!@
M$?0>&4$9GLXETR?#U[\.7AW**77?FU_G&4RCI(4$N<KN6V!E"3<0VV \RWX[
M#[ +P>$YZ<A,,%E*$,,@7[](HB/=P(=^#FSE&@N0=@:/RWC#Z^STZD8.0<R$
MRBXM(;S69QZQ:(X%HGWF#[#C[/3=6XOKWX*1LPL](]]CV^+]SI#4Z)),AL>N
M6\EK7OW\$=93$U[OG\*3&_HI;-@Q++>E_12%$%V^CF"RC  R^V>;EB1;R#4Y
MFL46:Y=?+PIYJ21D8&;4XV?BU=-GZXC?^]CJVW[2*I@63 A(QK2D!"'#ON_#
M;DF)/<L'_[1$2KX/LQ\QUA>=<?]"8R9:\##:L$*B7J,4?X"6@6$"W*TRQ@^]
M;O'+U!/>?':/&-7+Z5)&,Z:T-^"[*'9=SHT3E5S:BJ\-GEJO@.:!/X^/= 2J
MM4K=L4QO$56(3A" D#RSX*E*<BJ$T>-AN2K*&7(H%>5DPL+>T5IWS<SPE61=
M)=3,6/LM/[W$^+(V*N AQPQCE@<@=D:D1_V&P(# VG7+O+M7X'Y* G<)4XP:
MD=#>ZTAN J)K/'46Y8[!,<=^,RIJOWM76M% 0B9ZNPTO=NEQMCU,'I.9'%$N
M^2$>5K#MZ>AMO[W^+052ZKKF4+E]CFC3??DSX3J4:PV#[,K?_#.7,WQ8R?5?
M^-[!O5@<&LN'MR+S>4M3 1VP;P.4G)-0K89C-/:F3P.9IY65UAI/2RSI O\<
M#&;6H3\1UV!R1>U>>&>,^8Q%P9!0LN%5H!UN-?_2.7\4#SQ&I#GQI"--<+ZR
M3%4CH8V+[D"RB0I@@]K]A<^-@F.&6=WK3RO>%W6-V-O.R1@D%XATHTICO+R7
MQ+[7?VN [DBO, C+"[WVE)RCZX7:^G6Y:$FL6?@>Y*U%Y6>[3(=*R52JEI:H
M?M#)RI:P\$RV^'RY3D+'V >I5I";VKC[QM?B9M0@3*:O^+%DWWUF._'O_E=D
MG.ZQN!O4\WCGA6^,&@VQ>1CGJ%<;L!9?JA_G9\(G1<&",40!5BC8),YT%/+C
MP\K#@LE]T?-'0>G;,5X0Z0_AN0N/^/PJOF&3U020E4.0::PAC8,OUHHE:%UI
M6>E>B"G.N7LK'5:J-)GA2F[(W]#1C,[/7>L<]F7?37YMKV%;O\Q>=B,T?FK"
MAXEM"OL]8EF.H/?8/[[A=L^OX%7&U.RB'X-[?3VYDHI/YQ#5Q=RCE9>:C$8M
M7J446TT3;4AH?I\61K9A2]9SL;D:XM_]2!Q![Y<ENW7J8$AYI.0'=\M8$X-R
MM7OE]'TZE_,+MRW4'<>F_RI"YO*Z/6MJRI0*"8$6Y&*QP2SBCR.%Y0T51_^V
M5,V+8<_5YTMC9JNY=D9)&N9*](0N$#L7F6KA#.[[=U"Y2N,[-\=%$F(U,Y7C
M^%H&5SZXN 1P6F5D/AE\:VIGWEB?9JL1R;[N&\3L1#",W \5[!H-6%^!6MDJ
M"LGH1G>9%U_18F4:'I!]5HHM-2F4S*XY\LU"W&H*!F=UP.Y$8UN%^E5#KIJ8
M%'_$IG%;^:Z9WS[ J!-0NB++VWQ7I"4GG$&96J./'JTEJ<AWXGNW,U@\%6AY
M$AC^#)\V+J]_;6)G\K!L9T'P7'U&_GI1@-2F64K]CF>.9O*WY!GK'%%O,(5'
MX*@*\E&+SH4W#8@K#Q6N-]]#^DR^]I;[&\#_Z0S8A'29H/\9)H5SS+I0GNV%
M-;+M&#KNFD%]96IP (.N^.L_J5:5OXMTWUETK:LU>K^JW)RN$.2KF;1==[)*
M%X[2'O:I];<G=FEV"O4LNW<RD^,Z3P(O)C)((2TDW[4W'Z9N/BD9C4_UF"A9
M$3$QN%P.U5%R/674B-/4^!MO48V*ZMQ":[0OE8"8R'6(5:Z9QKG1%PAA?&Y'
M7,1U:<GJ^$*#-"6N9F_6%T7&IH4"0U0 P0T\,T")#J(X V/ I&\%D!E:/-]X
M@_N3BI#_GHH2_MNI")^%W8T'>H#X9VHY%\]^;_=SOHKKQ)[;$@;8 H'FM+QP
MO8()8-69N18!]!A0X]MN9=QX_^F9E@TA>+GZ=:# G?7'6O$7H>O@L3%!U4[)
MAO%SI(WX&8?499:_$F;33(&"P&'V@7A<%FOF_12-Y>NA02XNFL,B?;X6>67)
M1P$E/])LO42>KO=+2V=J7AF+5A50#NHF@#H4 JO]TV7\[*3%M-QU^MRP8P[#
M*_V7T&YTM[]\Q5GU!#9'E/V8F]U0UXU$@<YV!WAO"IN6)ZQFO9@S*!G((HGS
M&F.#F&*H "<T060X%N@*2J0"V*D -R+BS13E#J$)+X;5[8*P_WZYVH);ZSD.
M!%^%R2[+LGO:YE1&D?@\:F89C Q>\9I$#H#QYXM%BV^'S MV[-WAMRL<1]>Z
MDSCSAF9G1OD6OK$%G,J>K-8IDB_V&G.]9;-_>6;X_K0N][E$>+KZGNP5.7OI
M\.^W84H]-D.&NHHY],M"X9U.X-I</G/S%:;G&R%2)=46[#+:)N(2"W(FCA=!
M,N?[Y"9\&X&,\N&EJOU0@Z;6 /#Y$EV/\:H)/+O[C^+^.6EMLR_+GF-^X2("
MW^$78?KD+R19ERL<\#,=6]IGACN!,;R)@,T&6Y/Q%UR]^P<WB?<HDS<>PQC;
M! X?4D3@>SOH!W\!'OM<8 ,RJ1;7TUB^E*]W!16P<Q*4'G<<XD[VA*.2HC6E
MV?)04I@[ZB@=9SA9]=_6IJ/9 1_<1^]SDPRH@)5Y@7^ ?W >FRD5$!W4#3X(
M:&R@ NCW=F5/@U8(IPNTY('[G^3Q?T@>N@X_7L!9USE/F:(5-QWL=,>7E(\G
M.=^?O -Q/]Y\_PX_P!:;<E?S8<KL\'7_=F%_G40T E'3E4'[CM%N(!X8=\A
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M6^0)E>OU9^._\0,E%%! X!%+8_%$1_-+)@.O0N4UH P%4PCGJ0!#(]O3F:F
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MN98L2X>M3SG1,LZF>SU7P]*FFE\5K.H14D!-$/(J43"Q2YE"Z!FG*P*9&D"
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M,[2EW]82R+D4BRL;K6&3PR6S[/$_YK:G/L(K+D7J]N+FL6R^XT2<#-T<0N4
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MG@B*?VVK-Y,+D;^>IG;[U62VGW-PZC?K<JGILFK[)^GH&__5JLTAA"'<]?L
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M:O'E /WKY."+JZ*KTF5?'&<FC6ZL'&X3*?=IKRD>&;V$=,0I65U*;AXIX.J
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MF+$7?A0XB!O, .5/K"6(N4R2(]'_>8!=F'!'PGPB"K>"21\YJ .MF9]!K9U
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M%C\[C;LHJ:PH56;#=Q3:TXLM9'8T4YR0"&A".+0(21KF<0#(AVL9LS%<&RF
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M)0XG-R+[X2XY+Y<].P;'8?$^V.U>NM*'297>OG=D4@5X/*ZJA3F<&IYN_S$
M"B+VE\JYXSC7G"-150*1U+1?HG"*;8(M86W8#=ED\R6A'T]ZYK"VR.A&439.
M-5# YY)32?MO[['-%XMV,;>[=!Y6$V@O*TO[;EX-ZUV5F-CXA/,438"G<)I1
MC.=O9#L9)_T335T#2FER*V. IK!')'A#6_ )J":.E<*#TJ T())OQ?)!W$Y(
M!\FZS"HYN8VLB3I"_!;^@@_86KA4X>J'=9T$6V-#U01D^Q3/H/U.,'/+D0:O
M8[,V7L7E0"9B&R]E9(+5FHU*"KM/,$>5+5C#!$68$60[WC_,)[ VX*RFR;Z#
M81WKQ#9&Z,,20T0/6[>7+0;T*2:L0+C\0[@!9-L"9O.JM-(;2,E)PXS9S(*0
MUPY4#F;?C1XDG\#CB*S\+ED&N,/BL6BH71&MN@M& 0-&BN,O*<9(>SO^ARJ=
M.%-;9/4(HK7RM&,H=CVN_B4H#6F&^3(G8:=;X@_1^V_$V!C O#QT&6S9:M'W
M\!QK%41OP;$VG")V_>%;-,QH(9D!,1/(4EX:[L%+-@M59ZG1DDQZS40+]8Q$
M"SC(RRXRAZ?'9+"[$*ABC UKB3HF]) -<DG;N+NBO+>!7,KN  T$!DR2L$BC
M#TV":HFI=%/*$D0L+U7@P*S/M!?N^C30AJ?Z//!/\ %72,\*U\0!J 9HWN<:
M7XEHM)\T$Y%(+ ?\O?U1/!W!#TR.L'[HLG0BJXKEA+C!XNUP)9B&!B??'F "
MK6*!GN"U0PK)3"0;?-(.36$5I8,QK_9TGHHU/FU3"T(!8#\_1%7P_:/#%)F8
M(UC+"J+6@"VGS*3\)L9IMB[$XU1+N$.KD,&$4_)8L@5JVY=(S2I:#]F*^)RA
MQ8BKZUQX\:B\K1$VDR=G4*R18Q(95G\%R*]YTNG??*EHY131 ANRF84$0/KB
M87H;_0Q(8AL@I7N07*UFNA;66;0:HF?6T >TY$[M;L?>?QJ4J0E"8J8IA0"#
M^6Q#G,-KM33/,1.8P,GI[#6CU/D.C79QWD%(*DQJ=HY,$RS^$W&!=11'55<%
M5H,XO#FXZN#1__"]\XT;#M-43]2$.'XVJ"]8C'6!\\ H/A+%[P?D>M/M>&]P
MQ@TD9X>,7@IF1==)JD<X?\&:Z?+Y9'36,%>+M1:'K131B5N=L,6FAF65T7$5
MOU#6JWC 434A'WQ0.C8*DX;;.6 L;T"C"7A 14V,6D!CMGE4W?00!9F/9[XU
M\A@OW"Z()^*;L!9!C%:R4:DP14W T<?\G>INPV:MG ;OX12J[IYHNC[;E;4?
MNG>U9& T9 XN;H++HFT6$51?$2<EBT7!I60"/N&JB59R!FBF)ASB<O&N8=(.
MC^Y$PI1>7M!ARS^3I2M>^XOJ"]KHVLP)*:.->I8TSY$WA\EHU1>8PZ?5A(S\
M.#E-*Z8[F&2$I.SHJ3EEMK-70,6YVF.@2I(IT&/Z*PI@K;'7RB,?)%5:K8!1
M])")BD>-"O.4.8F>,&9C+\T&)EHJB)PB4Q#B<PXA?U!6HZM>NL9%Q-]A>4*:
MH'(GRQ&96X+W+2Q_J4#_<1]Z4$Z=S71J?6MV!CC$ZR<KN!S%%5)5NXB&K*#D
MP]PVR0//=GH_L$-UAWJ480@T>Z^:I,^) DD.R.3'_ZNW<XUJZLKB.%81*$)4
MT-#PN*@H"FAJ>2J8%*D@4J2*0*&6.VVJ&!W,H%"C7N]%GA)Y.*(X5DFH5J)B
M3'DH+6#2O*26:2,D0@EJ7M/R#+FW(ES)39PP'V>UG[IF/NSOYZRS]UG_W_^L
MLS?LQXZ6@>@NQ ^1RM2'-[Q\!KR'338)B2 \X2X;?*\-5?[\DN?#]%O1GR]V
M/_3:X2)XG]<M/$/)(19W3N^WGH,^M@385* ;[6W"$7,B/,0ZDBD$0M"C"JV;
M: GD*[9RZ0>0(IY; )92+'H'%R:I;(OAWFPR?MG(FC>2;@<#@_4?705889+.
M[,/D1@P<GD+<1V:K>AR0U&QGJP#V8<],M^!FB\^!66J50!0(*T$WV)U(Q1H[
M;S$[/&D+U 0=ZV!Y2?1)=->QST4!79CC9"M?7!3.,'B?RI#.KK]X[2FS.UD=
MSEC_?=NKH41[4=^&?\QJG[ :08W[%K)!33E6CAP$*NC-EXI$7H@T\,LQQ(NV
M">[CD;KR[D+1*I$70;$?!O'1'6;6)!];)9]UG,6#/\ B*V)67&=^L2"#NQ&O
MOTEL0LM*#;G'XEZ!\LW\2H2AQ(.[30F66/:P+L<$8(%VYF!8O&T_:4A2,<6F
M!!S@=?#CY1NA3"N7^ 0+W(Y1)6)?&=HDRUY[10]60$F-1 *JK(!\C51.DPXI
MGJT[I^E[#FU7"6/"[5L+_0V4 ,U:4\I<Y_L$/:!(X0 M2A-5#RRVJS8TRZRI
MG7Z(CUJH;%<%;PE,L?7]!KE@PQ6VT!':6CMS4GT( &,50DS,56%;H!*MY)^-
MF1<IH2Y[)?9IJUII2<%!P3A#OCF;=[<02:2[("SM NA=_ :V2@?(P6+ %]D/
M:CST[=((.[]0)=3JS\5.+"C-R#J-'5PEFP$]:;YLOB[A88H='ER@-+TI5/$C
M4%PP[BQ:I<&ORV@K.U3^6&#YU!4W5IPZG'I!Y(M(_H;DU%0 CC8G6/TYKU5I
MJM#3![V-Y6=C'-%9[70C9I;Q2FUD/!,U&ISDX%)J41C5G=CZ^*XHK >K^W@I
MR6_O*&VA6D2UZ^Q4C*0+H:WKS\T?!SD#37R\[-1R\<1+%)S>B@%R9<7<F-\W
MB*5SGN"8=EE7J"4,BL,S#V&J:77_G$&P4".3<>GJ*<'^%[H!F=D)D23 _MN,
M)E8Z%M&L]P44<Z:LO> IW253WTQ%35F/=I_8(!:,<OT&Q%$Q_S,_?I+(LG9"
MFW1(S8E+$Q*T1A?9+=88C<(2D>^(>!D<S :FC]/?"!MG%8F<,5AP_!H1TXG7
M&VLTD4;AA 4=3L9(\K,/ 'D[[([//0V1\5K#:F4YL?$VWIF.<FOTP?6N>_N/
MS'6]<G1%(ZIN$604D"GM5UN;LIM48U\VO'P(.J)"]@..;))$ZTZ+(J+P=T97
MU[]VD+.J*8@I&O.>1E"2Y%GH^UA>*YX?L\7(.T/)J"82C$W_:9Z]%$OCEW7E
MW&(?,J:XL<L5O*^5A*?9]N8R+-1(E]@%G4+\!G(XES2=C?/1CXRDB9>62/@Q
M_=[ZQM,&L!!<.$4OU"ZQN4(IJ'+B%W3 (*RF^8TW'=UW ]J!;A : #>FR D[
M7&$ /3YBTOPOR45^ _EMKUY,E^#OSHC17:"+[>EK!T T1U-Q^:Q!X?0%:YF-
M# 4D(OM89'C0YH>_LD1!!_"3QIHSXJ4F&+ ]!EW$NBN 9SB=HQDN@7+U@'>V
M,[2+M0]S^BY['E[;("PK>-1%O\GF=F>JWZ7_%=D':'KTB*D8G9'3HG$6TV!V
M&X/GX54&;3&=;+].MO4*YCJ4Z[H?LN:%%V)"J?A,1_SEVX=FEXDY,?3E@J]
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ML<CDS/& Y3<\@%'V_M!3<>M_1G"9V&Y?R /N$#=7B/"S[PGL(!X0%8TBC)"
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MI'_C3SFK__K%D-*"!<I$F"Z6152_+F:TK$\(?2,?V#VR\-7O.#/IMA?6$_F
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M)VI/8 !^<^!KN]")BLA+ZN,6!MP)Q(N>+@72-GY:JM2V@9(>G:9<E):;(WL
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M%@9&BGN?0+RU3N!JXR7!V47!$F[_! _H0$K.D916%2/.5X^>KZ8Q0Z=/CZG
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M2]U0=Z& E&7(]2%)"8"S\&S=.33C"+F+.=)2V.B-7[]DC=WQ^:ZQK>9!'1O
M)\8&N(7Y$0_S673K1XC4F3HAJZBP2)!["7N'0[:=%-$#\,5\]@Z8!]R&[KQ=
M[_#:/X(WMV@)A\Z9Z\S0)N>,];]E&A_=?K/YX[76VH1K:C$T\58>0'N>LQ/N
MA=QI]NU56_$ZS;!S(!TKRW8 "Q"[:[$)C<2D2L:8F89:1:Z'ZURC2LZN$8/$
M)M.UX2-8I15OP8FEY-W7CS\5'X,+$W S62+*67LO7D]P>7(]Y?351[C/IQP'
M[FUUM1':%V5E@WH?&T4,1$S>IBV_X@$*"Z4@E14TV"J/TV7EUG"B*7X\0,!?
M E=C/Q+\Q+>G6X]M_*$YC-&"ZK0XFM.^^>KY^PFO?$ZR3Y!X@L_0M<:[VUIP
M$%-)E?.2>!,192$"]],1B3GBL (DS(H"G:+]&,0MO6#>)&J0@(!CVC=$]Y[)
M+G'!97>.F8SDY =L%-;JV09%^F!#6)C'%99M*KHG$"_7Q+KZR 6Z06%!6\LE
MD]Z8=U9W[!!XHZN25/(4..]ZMVJV<I,US.?? G_N(;@4['7DZ\CKP5!5.V(;
M&K%O;5G2BIX:CP(3,$B1$.U38V?3V^6M4MFJ%64GH5T3+.TS=+)[O842QIEL
M]>!MFMR&,>L;7$151-(>C?( V7PPFEO EXH(&DKZ#4U3^XRYQ:;3_<Z,HJ\H
M4:L23N6T:'B(T!]S#/KRP1BCWTW?/2N\*[S0DM&2&W!K3S 38S.L*JC&_]3[
MI1/;],Z=-$@"7L_N^7QGE$Q4Y0$O=CVB4^Z2:C,7&\KFD* =*HX'/%=*G$D6
MMP$YRYV*MQG4*#-T =X-.E\<6.2)GK!Z3\J%J5V96?@[;*/Z3(I_,WDH[^[)
M%Q%QGE'U#; P5U05HA&&*3M:Y=EG:V%3X_L6YKB.'HN=(+8#*P(K,VX@I5N5
M KQDP-0$,YLK> PDO\%:H-LG9+IG=]B@M\!Z\_2*2>?:3?M'+,R+NXA!IK)>
MB5;GX7MI[TX NPK27RE]I3Q)C:* CE6I_9#R#(?$E'R&WPV22>V4&(ILJ_(<
M$E@E/J JK.HF+F# [^UNR_%Y@Y5<%3BZ"+9FV'Z+27L>(-QAO"YR?&?@J<3$
M:]/832UBVW6S\,WSN RL -QH+P(7GX)K:)M,[S86:I?%5L('+\$1@ORD1Z(L
M^04</8.,E_?PVCFFPYP9SK.I,M,,8VEFU.5$./LKZ9] #/T29C3X,D4S3B4T
MZ5WIONJFV@/O?"\\Z_RC\VZWAUANF\?2GM*%'TN0'],2TF7=@2U+8 I=KF-Y
M*TQA4!\0K[7H=[7*C+"=0AY7&BI0)+@?,WB .**CL>&^^Q"S )QZ4DF^7?4H
M_LIP'^?%8:IAJ[8;-9$_JD44LO'BD]N;9V!-5B>XWC:%Z:;N-!, ,WMR1,8(
MHG!$]W.<[XIX8NLA"!'--.#XG1X-2?;N-%XG2$4*;UYR3;65-"K%W%:L3'DQ
M]>2NX,:V/,HN"BV+"EX6ER>,4';K<G?!7)08O.!$ =^7S22K]R!W$G:P;\%V
M-,I.M-MM-Q,<JK,"*K:M>3G"MKTM6QJXS]A-J*_8K/'FT_F=MR9'[=DRUMP=
MKE 9ZSH<78%&[5JSC^+^U139IJ++>_H@TS:DM(4JAJ#G7C:Y9[J_/1',F \&
M'TU,!ES<K6105^\0J/92<'%=]MTK1-.6L^^2)1[N?)8[<>3M]<O73M6HA6V]
MMGWG&1$AP;:2KI$R@]?U1_3=HXUWJ"75"MP[['MA/.Z(4.FO#<##/^6Y.,K5
MJHE+K-\XN7S8RJE[0AJ: VF)J>.SG93GQ8L0A#D)FM=E,PYA@_N$NPG'X.JK
M],F*8U,>D5GB>]Y$%@I!/I_G-T*F'XDEF834RAWM50ZAU.DFX2TW==F^G)JG
M(#5NUEZ:,,8#M@0? /4[G,.DR!F/^9XWQDN\>4"':A7MJN(:PL%VCM:;)*&/
MIJ'S4M^L1-'N$E9URHK,RZAJA5=8%Z54FMU[0\E)L2NO(^X=B-Z>_OG GU>Y
MJ)8N+R&)[?NC]+8?%[H3=>P@Y;<JL6_3AV ;&BJ>"-HA]D[/.TVH,W=#]?2Z
M5+":6;DF.S+&5Z;M+;H,'I"ZK+/T.0>=&X?_96AM\E"E\/C3%..$\?MGPY U
M%+8<LMM+ 5Z.H$=X&G?<&6NG[&3;#%I(\ UR[@<N?P3DB[LC'B\MK_9)FITG
MR92O]I+N!WW+NAWP/$ ^H?]6/>+:$/;M(W3@Q%UDR4:*1NX3H=]L]PVDO56)
M'SVME71Q6$^JH&Q+N?ZC*R?;A)R_2]/Z81WK3I0T8233:X<1=V<#?$FNQPY%
MNP"[%N*W<YY6M1[MB"R"*U&BJ?*?V!?KAFY:B%7%U)\8^^[.R<72ZQX*):24
M:WZCP&K.S,1R>/8"&+8X0(^("#1DFU:RT5!FRAI%<6YCOK<2K<>^ NVO&\"+
ME]2XC4\%0%WE+IR92.P6-\]7<_OB) %DN&Z(J)B1;FV <5V&A)]2"/.=4;7?
MT+LG,[^L')O*"7BV,*'@R@/\*VL*C4C-/:POPS?Z2'\4BR$F'DR?63/;37VI
ME$?9BZ0]I]3P@![41,(FRQK6!S,[>(!HLS6-B64XIV(MCKK@/4:7R]GRP6+(
M5\[RL=$IQ;EP6"=W+Y1!$8'L'E4N$,7Z@H)NG&AH.,MTL-&<3;W' [81?:;L
M62>'+?82!BV$05*'>"R"_R5=I'@3\12N&%M^F'WQ-GB?04D<NASUWN[V^:'E
MD"H9_(G'RU7!9?&U3"6DA'6):V2M.]5-Y?TS )FW8-MK"CLQNN<G5J:^UT78
M,%Y&/S]KZA,]M6O[?GK*]H/E8U^%V5)4NEH36$_W2RVJ!U,H((6NGMCLQZD
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MQUYJJ2FLINQUYP1^'&G:(6ES8W<H\/%I_<UMUX_H=5K+"'M%<;7>3M >$DI
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M/P#HZ#>#Q3D=N6OCNWY_O143NWMDN\'Y>P/;7 B>HC2X)/R$VAWII.0\@L2
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MMI4-V,.CHHRT$06#N4H66/VZ*#SRVJ=W[_>;I]4Y3>%,?N"6^>5D1+UX$M^
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M:(9JXZ<:G3!.UOML/?&H-<Y0_C/RE/XTQHWD"T01P$=O"6O;G:=J<SH8,"?
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M'WW&'^^\Q"X&88;VNM#4@)H3 1WE+\WL$6(6U:96,F>"7^X^$8C;J2!=VQB
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M.;I+,MY!K.<@\@%);D^VRD,UGO=8V(T_M=K6]XAC+6_UQJ_RD:U%;6RG]A?
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MMCM-$2SY,TE,FIMJSI*IB(NZ#,(!=/?!-0#]2EC\D<]4FYQ2_*[SI&289"F
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M4RF#Q=UJ3C>ZO:&-1XD&=K?RW2TY0:W9KK/M-?6SB_ZLA#-AZ<R4T2]C>Z/
M8U/I+:5R92[@29^UVLNYY>MY=.&B6('$OQ[<\9\\XE'N,Y67RP>\+Y<WI[J_
M%_Y]_=&W*$G!AP)*\$G:K0O4]@\SGRB)>@>OU'7BGFHB>Q4NX_C]N[&$=@=9
MF(7;!XJ?#$O?7NKITWQ![5Y'1S, 0E+-X#CT2LGRY3:38$Z.D*ES4)]Q1VL6
MCPV).LP\;DYR*9&VYN>E8*<VZV/(O]H_O]*I-O'V-$F.R %$XYNZ.Y0F23Q;
M3@JC28G.N'"N&VD/\/OMJQ6_%^>*.0+EU(R]*1I?W'+\8L?SGNQ%<1D)3+2_
M:%M%L=WY3<@(A/,58- W)$\50 3@F@C[,%/EU1K8<Z(.[#FX!M&8ZZ7>_>&Y
MTA62+%VGM\3V'W2C$5$0*#L'B2T Y.>@9V=EB(WL_@.R4Q5\VA<HO@D3U#T2
M,UB:^SB,<F6$'J8;8-7$'GN?7V#<T[\SQ/-N'8W?"\DV'%6&-O]9]CR79NQ_
M%#FR50%V326B-' -N<Z=V;/'X:[)UD@P>RT9)HD9*W.<MS>N "*/:.*S/<5-
MD[!N)E/;HW8.W][>M;,R>/JH6*R_K/N6&>V#GB!]>7<)S[.?*3J%Q(<O4:O&
M)&ID$6F6NZG_*9"(W8M, >HPB B2,$S?""!7S"S;/ <YQXSOZ7!D+:$J;?I%
M*LNAOE!HJ8ZSXN!B!O/7O##[A(>GH@3O/C#^P3NSV&.!VKTNZ5D>&WSE7D1]
M*(JUG["'Y>B5IH&AC FA&EV.[G/AF5'J2I7N$VYC&QN/):R5.(P#9V07BNX*
M&<Q&J#\X"C@'O;NHYIV&Z.U9\./\,R9")/H)],\%^8[T\X#45Y5?P.N_5P$E
M+Y*F2%R -D8ZWO4H_"P>USRN20G$]FJ*XF^M7Q7H+?RPH/,)UGUO7"%C2C1A
M.("3_[O]G2W&2$-RQ>5U^G_S 3[JKR='P%')WPM$I,Y!T-!$(:MI>?%C?')4
M!6[*G\[:?/0PWB! ("Z/?&*/+J:RQ,'.0Y'%Q#7 U\NUOCG&)<GZH0_G*.6F
M"QNP58+HI+^(\OP@5:=<7Z57).6V&79V/Z-E_!2B_I]%X4;"UYV7!!URB9Z5
M1_1?Z&^=@_ZS+CO.2"48<0%Q0AAA@J=,D+?H_S[60'>C8N \P&-7U,821YP]
M5( 10#H1$G?:4KE8H4XB'>'Z5EFR/DRB+6]K^PHH0""3P/V-EO#OYR#WS[4-
M>;CM/?>U05IOZ5DGW?0=8I_%DO'7N!W^0 [SGJ?4Q)3_/;#G4%17'P/1%'=S
MSNEJ)'GHQ8N^37!\O'1E3](AXVINX1OE(5F<64WK\E&Y<6BR+)?DS_U"0Z5.
MV7<9[ OTZS_O/!PE5B IF""I O]]2',CMF"=Q#V!&_?G4QPQFGB2@77;KO#$
M-C8FV9?E83'CG/>%K#+<^?6O:;L^Z1=.LZKR7]3\#85FMXK;9\<KR=H-J3,-
M2+;6IDO3M&0DQM6)W=+N%"I4^,,/7HD5P)LI2I1C((G;@\?OX%/+]2GB>=D1
M0%%*?@@ED1%'NOKKNSG,&A?L<OH-[+$W9U![9AEV_RM1%P1O-"MVMU;<MW-P
MG_:;6S#U0C9E+(G&V&<\&E)/J4T/-@89O[47Y)U CM?/ES089],8C@\4A2ID
M4"W8M0D]-P&Y7+^1"+<4BRQZ^1*2*D2B^JM7[4O\:ZT KJ<"#4$[PC;DH^D"
MK"_(CEFC_N?\LYL=;,""(_QW\ESK4:I$\\;?>;G=F^0':&/ !).HAH4W$'PS
M=O?Z5-&Q'_"IC@L+ZAE'_#PQ9PJ6$Q([RR^^Y,\9'8L4W;R:WO<]U0PY\U/T
MWP;KOWLW_U_8$<K?>B5HQ_!BZX_/8M7)3V5)8W UO'4L7/4';+ 3<@DN!31U
M68^2)A'UX3\;G?Y:C)^#&+>XZ1:LTL+N9?&423;8JQFFSMFXQ 5JLZ88))B3
M"N&=QW8EQ]NZIX).6T%*QUE#R]L#>-DUJ]:I9Y\_3^X&B%T4DF?V\XEZH8VA
M9:B/S>["+1FK<_^#O/<,:*KIVH6#J*B4(+T';YI*$Y >"#:**(@H'2("TJ07
M*2&A*+T(""@M*""=@/0:.HA*APB(D(0B31)J@"2<^#S?^YWSOO?SO.?'5_Z<
MGWOV[#U[9LU:Z[IFKUD3*.$8^'; [#6P[->_6S:,IG7A $\56*$9I;/#AB1'
MBBO$<+."!=VGK!*_WRT ?Z[9GD8=@A!LJ(B%1 3A@3MM"'A. !4^)P"O/]4N
M#G&[(V)J$E\^H,?'#WMQN'A;I^FL#'P+B5NP!L\X3\$$NQ0E$J.*CXY )9P[
M#!&[^:4N^^L-BS&36;R;2<25$E1#J^K'M-B?G$9#G4G/67("0'@2('BEVVOY
M3"!0LA80M#,N$+Q'-4>5D54B7.1HS&"7"IUJ=R689+L) ;@!>,^U\]1;Q%7H
M/6<IX083C1$6#=V]]5G"9NX;NE_-'++!P6<*VRU<W^7'*CXPT+\V_ L(!QIX
M2NXF=:M9!7&]RB.9@-X4Z'L5OQ%9AMG'  V2D]J&]T@9"UQAE/>5WU V1-L/
M26#NOJF,*[5,Q('4;/LC)ES[&J$JXS$W7PQVCQ?<6)-</^U?HW;$W/YD<[R$
M<\MS^6RB@GR"U;-W[M;:E0[O](LF/6/TOQ<U:%ZM*7P5/C=86C>]389F/O7>
M^/#HTSH8K]QC]/F3$^2(I5\96*Y(?BNEADHHWC=ZOV6NGC/5A-,%2RX<4\SM
M+^I[\3L?>>>>&WS;($LAW[LX%(09%N**VI34V)N6-_22'-072%VNT?N\.B^(
MN-$+B1.ZFF2.V6@5L9/C<X^J^L&I:MKXL'3N'(/T.?#*/-AAYLZ:5O+->'\
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MH38DD^/N_7H+DYQ ]Y_ D?+4[GK:"+2W,+(W^J5%>RU!: )V1<UL+9P 0D\
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M.O@$S>Y[Z;Q^M1,RMA,?1BMJ$T1_E0AE/+U^6%&8SLKT_3X"< +H%-^J12=
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MSR%H%:K]*W5&RI,QZA:O6Q/@MXJ$Z"FUB'Y#%\+P!9Y)-YR$7)76>T- O7S
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M:IL<CA4C;G6'CO' S+%?FMQF7Y<$NP+"I83D-]R_Q]//*V))[][V"XIE/?F
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MF6KG&O53;2VV#+YTH<6,39U)X(!\Y%MY?']*E.VFS#/'T+N1CZ53[)B4+TN
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M5@U3HTF=T&K%/\4G@$&:"O[G&]?_GAKO7_UL6M][^(^D# V@[3C$S#"U%PU
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MCN]7K:(ZT#-;"]"(=JX 2'?F5AS;[./QZW'JP0.<TM]UKEK>3'RGK.M=7E[
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M>C$[<IC-5:Y?"['B*A$BV.>RW&4(B+H-JN'I1G, 7@^V(,M*_Q9_"5)##G(
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MK<4&WF\Z<JID_YD#%L<V#QV+.6\B(^66&7=73H0#R*SH -/.!!!V0^JKD(U
M7M3G42*:<50;QM*?<*E\C/K\BRL6/M1[<@!OLFT](ABY6NRV$-"NG_^VC3>7
M\-TC['2#6?N=WE;\ER,. /,5S/@$W-VRY@ LDM@7K[(5[:A]'(#5#5,QY\[_
MVYHV_R?KW&30#=_4H]IDF-<)4ZP7['V@/LC("G.\61*A]'[85RD^_6PJM>!P
MR-(&/0*S7<#EJLV"X)FT%AWYUZP7QON%Z5!\(>I90H?GI8'!6VV^:B)O,PO0
MV1KGXP!1><2*;U\20PV$'E T41H0Q_Q=OH[;I<3$\3F_V*_1C-^IFX>W5GG"
M($IPF /^^Y.9A[77P]OV*8$2O)-W[=HDJ#8E05<D>3?GK5/O!E=(GY:][]L=
M0O_.\Y*I-%JY\2Y\X #!I_=>M<?27]OIZQIJ!>JH3X<U@=GI-A?S,&7+]9J?
M^;3USE3L/;1T8O:]<>Q.K\[</:F"%EFJ9R%3]:H[X>2Z16<H>ZUM8?^MS(<#
M03NXQ(W]]Y\V8UOK<-?JI%VN['U:?L^'ST0>H'2+$K!OP/C\! ?@!\=:C5\_
MFN+\/FZRRCCT1/16>OG"QN=O\++R2-E.Q0987F9ZP=U5+:\)*C+D'1QX:;1E
M.Q_1%]P<2N1U4EAX#$CDFD7EPTWF+X::1QZ@&O%1_HG!@@P'D#%WX7SA9Z;=
MF01BLV%UO)W0E+CT'4G31SZ"/Z4?=O-X&>.*D-J-$@9?9\\80_HRBL^ Q['B
MOS(ZW<M2N$@/N+Y_/$+KS/JU"8NFAJ7'Q>@+T*T>E\RR$8SL1S6CI[NW];L?
MN*1DKB1T7QU\X#&AE8.)DD\IU$%E@R]MX\2R _UESL6FP):-07<4>74K-YR)
MDW(&EI%*J2C#IB"#/A;7A.!C3_9$APP8L76L\)J9#V.S>CD (U+5ZW8N"2B"
MXL':9S>B)\L_RJ(,:!N/(HP]''H:#K?<]Y<IPGEX,TG-?K3C-?=LKQZ.TH1S
M "OC+YEJ+=<TYN-^"+19Q81DY:H1BL #8GM88%1;@U8\EQYU(3_S9N:ET*)7
MS>U^1I =0S9Z=-@E.FQ7%"5XMHF+?]7@#^-&1[G>Z=A9[JQ\H'Z,1PF:$R'+
M@?^Q/IS"(H*P_ 'CNBMW5SX%IPZFQ-O:[CS"/G4!%+99S&QU :[]#\*/XVG1
MI6?1OM+C2 1\.1G6@<(KH^*\Q%A/== "UQ"Z=#M?(HI_14Z.GG9@/JW,"PHC
M?X.Y#%7I5 KG.>335$Q*='Y 8:<GO$4J&&HSD$2IV]B9#%XH^]BH=K"2X[BV
MBIH9:6S!H;;^:_5QRY(D==\DO%*.3,5^_I'#WH!]6SQ_KWR@5!@M@JH7/\SF
M_[.7Y40C2B@@*1B\^HTA6*(G4'%-5=3H"L)+I,11^J%,FJ3OEOC1[,FFZ,\#
MJQ),1;8H!_"RN -'-QQ&_3X9;:"L4L@!/,*UH[:UX1%<$+X/XV("5T'RHKCT
M<#& LL$6W":P+5\()B<OH(@:%#1+0.Y/3,?T<PZ@5QO5#B&"=Z6,#+E+_Y,>
MUU$$['OUZB.!;LU4X@ NF2>@*!%E',"F#8B21[=CQV<(<J=GPX8#F,T'++ZN
MBF!S0967 _@^2"0P99=PS"SSOVD@W87-!Z'PDT!KI@Q!)H(N0'DU8=5,CZ7R
MFU%*\Q+4ZCXYJ$E;YT;)DT"/C"SAZCOGGEA4.MW])K5#]C<3N?RA_8S/_JC,
M?^M1\;^]_()4OH^(VU)CU+M6WN!WP<>R3T^^LKB>KL<WU3VG?[Y'Y_[_QQW[
M_VWD*RB&;#ZNY2CV:S#VNJ&6Y-"0CQS OUW(Y.KEF#1Z5D<-,S1I9KS6-8\A
M\OUVRM4/F6$T0T'-K,PBX/W_OB. U]X5,M&HQ#IX%\,\BD=1E\'8NW:[AY<@
M]+-</4P>'0^?0D$H*QO[G)._L*<&P8M:I:B9;JY=9]BSFEZAOOM;<?N55L[U
MBJ]6&MDXXOCTP4KQG'\Y5<R(^(L#>-'/Y2*QTG;L\Z;CX2Q4!Z99P$U%Y5].
MF=/6DS@ DT(5#N"@+IIY/Z5J99<#2(# I6J=7?[E7,;:E"@[UL"%?3@83-^1
M\!S?X0 $6RC&/UFQX-F%YCT<@ ?"E ,H$[B(*[9BW^( ;@"%X4@0/JQ5TZ9J
MD6IVG"KH96/;*^1_8030ISUSN.B@G1L[&?>O$Z;3!R%!B)#G_T]GJ?/_Q;37
MJ.I\DG:*E!_6B=*R?Z((5+TG0<O+D!*M-4J!J:8FN\\=;MT+Y]$IOP!Z3*!
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MDOS!$3)!VOO3C_M8U^N11O)#Z(/?A*E)36#]GB!J#$X"ETE[ZB>WOXA9>77
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M*WB<""Z?G5[\H<ZJ\!IBW*XJ:1/1E5XX6Q.QG5TD%(N;GHOY*"W=8:AN(!$
MHB6:XA:&#K]63T'Y"(U#'?Q<^,GP<C[3^S5XQ9(7L*696XSR9A.(<77+ OT!
M-XXYK'--I-[3!N<,6E'S]PI0K"VL5>IQ%?X"WAG9OLB@A;GN(SU8PM7$P>AS
M[?1F:O=<:!%PBPQH.,8^KGHM\929(%Q;]C346!B^])MQ_4CS9D7S6)-6H-O%
MR)!3^SL+'AYY+M:OWNBQ=11#AY;A'Y?B93>QH>+X$M:T\3['I;K8Z5AU@@!C
MVRUL0ONC_ L&1Y4=3R2*0R<D'K1A2DR[G /<C!F^XMI+&\WF+QUL\J8H(UZO
M8ZZ_"W5KK=[052O*U!LN,=?+W\(:I?"6<1J5B>K'B_O'63X</^FPR;I^'E_7
M@>*&(-I)%Z,Z%IG41:'7-X(L;8)F;I7H/:7W+W#(2]+,X?WP:V>DX[4(C?3D
ME7/W,"CA3%.<.D6]GP6OYF+*C+JQ<]!A3;8ZXXMU,0HC0D69Z- CPYP$QLR*
M_-IL*=TYH;'9N:VDGSIUE6U>+X-)\21^4K>FDC>CC2OI:F3/+>]+[+C4:K45
M[RID% QC>1@V^L/I\85:ELBG3^;\K+(RK%%+62=$DBB8VQ#-S*B'R;\34ZY0
M?PHY3Q-";!4%W]*A\=!<5'$\F_UQ.149A=ML_<VU:_=-J>PESJ"#88@ZV_G%
M!U;*3TX7;9;TQQ7FKF&6].E=I7@KU1EM,V$\)%10S*)$M=*DPRQ.5/0T2[N+
MERNNX_%U<!P$QFA+'=-NCGS=969^/;)(7_ZPYN:@>*JKHXR)9F^^M?[EAX:F
M1B:HO>93+TAR!W==EYK!1Z(6.M.8FF" _E070U0.-<"4V;;;/&W ;%K7%-78
M"^BKVN?WNI]D32I:^.IY!Q1*7G%%2AG/*F*SIHCFN#H,*D'SLJVUAU*&;E=<
M4"N,.M0#$Y'91;I1AT.U,W*ZXMS9;\[\2/O+G3L;=;YCV\4E!&';C>PI2"SL
M5UR&Z=HL$ED]+/!"!9\>EQ.4VC/R"Y*?RP3\\AJU/E\V+-IF]MB'=X_;F2];
M$1!YAYXZJH@BQ3D3!_MXHQS<[[8Z_FOQ:IS)9O3^C-]C#.UK66"Y\YU<T2-Z
M5@*R*7%ZYG97)/;MX.W>7'[$3($^YR61:,)]"^T4Q]TM?GGQUN%<HS)],L#2
M+#^^;;#T>G3[DV)3"+$K2H-#W5/\X5K9FZ*87-LUWRS=UNE8+[4K]7L1XJ/=
MV)N$C&I?<X3) [/QX^8X<]IU\WRN,#"SFJ'.F^7CQQ97$<Q#X%=*C?EI'4/Q
M_"QA1IZ.[2>*56B56WI<==WY95-O OHRYY[[&;S(^+2UM_'8*NOB/9.KETYE
MVL"["A 74A<CQ2$9*4ZLHY@I,@2_$DI?2.BS>VMMYP%5G2BM,7R^+/_"3S'U
M489.VE6M=/VRVK3S332>7*Y]5SIV-'L^D[K!; %G07=1V1(@X3Z+L?+5=MYC
MBZGW \*:_H,=RDMG$KNQ[;\FL*ORL7+][<QH.I[NBSJA\L:L[S[HBK.4@&5:
MG3\^Z^80]TV*CKMO>.G WD#,(N'T[KWB5.&T"723WI*JBHX LV7,KJZ%@5RJ
MJ@=OL?(8$LQJRJRG5U+';2[6_6%;B[0CU24+LG\&PP[.D>J[R8#/T34/;'5&
M;-MYPI;CS,YN=QJ#]U%:RL.Y[*43XFZ(1G<60Y .+$.!VS_3!J%RZ[1@^N%=
MMJ)_UF?Q_WJ ^XR)/#)D@(HV&5 U.TD&'#U%;MC\DS"^90JL1[:3E$Y'*BW0
M)J#706?5I/S"+]''=]K^5!E852(QK7!1&($*8=Q1@,2Q]KV?PE+V3)&[KRT]
M/%(3]7I5Z]77PK.;LA='41.G)*9E,B!%A3!'ZEO\V\@CRLBHQK?O!:E%&OBC
M$,?=HR\U/^(BRV6J?P%]I"K,*WI^ ( .5()0AYJ-684^YA05AC?WRK+BF062
M?R>TM5@2 DM+617A$BQ-'V*3NP5WZ-3]$W^#[ZZG\0CI</%1"<0SBW ='&%1
M=)_IQBWJ/& (G?YCI<.G2J;#QORK7/S?!,#&P6O$\Z6*K[ \BA\C.!B%TY6?
MW$D,+AA?9HF5R;JW/U0XH(WF>=,PNG.=YD6MO%2_._0H9<'NKB7IQ'&*;Q,^
ME3 =>GM*;Y?:EW'?I5;]MZR/_]3R9K>7[B/FQ^-"GJR=<L6R+#%=HL:7'OQX
MGCAW_MX)Y;']"0G/9F%Q7HD JYT%^K??.6E^O*]2XO/IUVU ?@YU].>;<VW,
MH[D5U.B9[J?Z M]Z >Z[%+XJ.Z1"AT-R$'*?37%DLTU,J3D[5:='0@D?4VDH
M#HF#2^.;V<!NF]\V%ZA!T3L"L>UK90/>.V*]DYUY>O"8[3B+N>OP<9BW=QS2
M.^<NJ^@0W4!J W_]XQW9@5!YN=1/K1N\9("ZY1P9P*EMB&E^+M<Y"9(6',(5
MOA;^3OWY.(&3%^CC@8F[2Q-T)#%M1 9$<E*8]POK<QZ"O7,+$'$V<)FK^! ^
M4_.T<Z.B!), %"5R>HD.R!$6IGQ[-V%/.[^Y!?'>>+X>PET10.0XYOZ0\^9U
M3M2U5^'[FZ:6Y=  -G@@Q\>\6,;,!"/(%DA\N$"5EDXS:FQL_3;P3V9\N!P%
MF :B'G?2445MRY5J1&V%G=Y6VGMX;'E"M#P^3SF)9.%$+7T#?YW>,MZ6TSHA
M=<.K*3A4_1(9 -;_M_A\. 9!1/@O,9]E'N:3 07>P*F=,^CE4#.*2.Z$4E$4
M 3J.VA_ G@#.%O^>+SHP'O@)>,\LS-9\+* Z)9''76FRUN"ZG9. 7=]E/SGY
MZBPGE\+/C.(2NXN'"V>E,%?FUW VT%/O"Z'R! \O*'^H(6$$_9L6,H7Q:GCA
MH9BN^*[8U68A7R@ALFQ_V]I[RB+)0)1?[(!197^/08G+;X )IG7P.QK.J,XG
ME1H5![U!X&BS^30?RS%B!8%W+@"'O9_6IK!QR-JX-T;D[=I6%]V0[.&*;52-
ME,P#,/?!_D5SZ\Z$&8-.!TY\ I'=E'3)H)2@VQ','!WP_"P#]7C3>2)4I=3M
M9#5CZK(6'F)\;M$MC<.BP-5 ],-U,4@?8$-.XC#['UDZU% 0K,>= "<#'#_4
MD 'YQF - KQS5N2-XTC>9'EH.(;YLEL+Y^B-!V52.S4E%P<B4L3[O^7#MW;?
M//#3SY;X99RPN&O3(D(&3*^4P=9-I[Z#N;XT1V&ZOV\;/%@4>:/[[OJ8#3O5
M9S#G@L,<*DKZH^@>N^NC*!.6>[Y7HCS7!"V).;Y=MMH*^,R.4.$;>3EZO@@@
MQNZQ$'=-?GC_7I;9S7W;V+0:I*IL/@UF9\5;_LSV1X5\&\Z%T1QQ=777B#\O
M*Q5[WI;^==Z&H3!<2'E@T*:,90-UM44:0K<T%0'O K(HG!HSNY9HU.29.JAV
M'7$$^7?2*'Z58+/\E.VL1H^DBH>TCDVU7(=XMT,OP;MG:\;F?EUV(P-FJ7J1
M<+E&>2UO!N>VYHF^5PPLZ8 7GZXVAM>'MF.0KZ#J,6A01YQ()TE]JD7!?;8
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M\;CA?-<>4=5@PP&%YJ'!OE\&LW4J9PL7-H(=<6OC_H2I@=EYU$P-UU2%W_<
MC9#3J<G@R53-M)! YUO/OO$U56I1#6>];N!4Y_7MIFUY@5]-%"J;;KQPYQ[4
M,7Q*A.BQCUU4R=2=O[S/R7\F/N%L=4_.420[%ZFY:.R]&^A*?18$6IKZ?:R5
ML*5!!@1)_=D5=WK;\G<^]&_(_3\'M_]];^L_CU=#+T,'@+N9H#EC4H]%'!F0
M1P8P2QQ!_X%4!6!+1:!=$]12*NPPV3@<?/(RU!0Y)4ZDC'U-&=RC_Z>W# 6Y
M&6HRPC:H\$8HN\)_JKYM+=2P'ZR=BX</B)YD0-'Y[9 RB.5W[^-SD&^D7F <
MZN!:,S(0V1]*8<#)X%;8H0B"#$"XPPV[P+MF+N!#+IDS)<I])/:QJW?^7]+J
M_B=2[(*(?#]\*58F (]\1@PEL,M/ ?$:XYO$_(+8:B<9=9<-&'P/>>!"!H0W
MH%:8H K=?T^N(P-\YXU0O<\4S1AX$S>"X=[N@,&QG>4QY)-ZFG">UPM+O!DG
MF>W!Q1OL#PUY7/Q$-/9>P9&@.Q(KMO4__)9XG=;F%BGWT-@<T^3;7+T8#Y=?
MDNUWR@KB988&PPX*J;>0Y]T7='*?E=^SUHM\I-?*$%>W^P013SH8(RS,/:KY
M>.@F.3<<$VA2?Y)^X0>2:]1[E@N3>*]750E\YP(9L'D"-=_AWHL#M]-#7ZH5
MMZJT+JM5<B6<[=*&."+= =-C\%/M[Q:5WIK/$T/Q:KP5NSO.SQ]NW*P J 45
M3=V+ZIA]9O&L>&_&OO/%,_F)1*Y[E-<9FD4-SRGW;N5^"6,FO/[^ODWK?%ND
M2OM=7N*K(:#R0,#"^6^^&'O%F8I:C$G<C&]%(SY^'K_E$2-76.0\?5(V-[.$
M-T5YV<BGDBPTX:]]$FYB-5F^=XE[<W4<T[)I;<MX9Z#%_)KY$S+F*.!S#,]O
M\0WO\@[N>M[[^:, JFL1QE.)L0QD@"KAM./Y*J/%,LO1-,I(\ZDCV)FH]?5#
M=Q<WT<^IK',KZ?M/TBZ[^>UV$DW>(Q>$S;%W]XF_[8+4#Q.6'I.P;L?C6,>%
MV%IX15_EAN+*H14#FQ+_(*?[0X_?][,5NDK[8@G=LJ:',<#.4+VX.-U#[+M!
MWYH<Z=DVWV!7?\58[O/=J#V!$_/BOJ]^6EI=3,$':R*;-JFSH<,F_%HGW#;:
MP]C1EZ#@/_O3]T&X,^-IYXI>^*P3?Q;U*3]T&#RD47+VHH08]>?\..4\\W1
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M3ATN.Q*W^;QMO-4CV&O^25U#8VQ;UX.^,[%_ND9+%Q%*2P:\%XE!;>40YL@
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MV%M2*#H<RWPB9(,B,>\/D73+63$N[YH"L6!J#Q)')<&Q:,[>?=BF^^KN9D9
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M(NMG89MGZ:BEEH?JBW_;GJ!^3V[@%+1IQ0?=J<FI.*-"XC/KAE+D5&C"#^B
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M0A?PXBR!NF/VZW  D*6I;L"S:%.R3KK1N;GTN7'A64W2X(86S0?7566'VXJ
MK@+$J3.I;U;I'5%C:=X4"WKSK,D04[B=-UR=#G_(ZE"V',=67%WR:'+2;^B&
MG*#2V-Q]6^I'D@V $Z]H_*EQ @5:((E2I839,0S[*U!$J :FV?3[R6!UTD]Z
M6R#[K[I*M\;LB&L>@1D&<QZ_G&H[9 VNCEX_54]"*@QTGEI"!ZM"M<9:V#KQ
M+FV_L6<6G")?<9B>8"^1Z%51Q,LSY!9L9D0]T9#G;4%3_ ,>AI>1 .I?^F)4
M-.<N7'NI17<M_,>U^ L".?F?F?]%9Q/4OU@^^T?%V3_I= /JYA@0<#TXIQ:W
M%BX9. _JC8O8.NF8-.&Z));((/;8Y[. [(/0-BN&I0"DP9>F9T<27:L$8/$C
M^9]#41ZG[H&P:K^,%YYVEH)7QPO]GM8S=--O%>^)*!W W+,$>DPDT@WJJ*)S
MWR"W*S@9%!V-DQZ>M$A;?31I*G/;>RR!WMC3&4H[RFIL<6V60E,P>0813/'0
MSOED %K7GPSHC0:A%0@H,N"O/@,*"XU?(P-2V7:N6E)X:V&6(1F@ZQ(/PT6]
M!IU<(943R[;( *\5V+[>,ISP,/L%;'RN#W^ ZB$#F/,(W4M]4D\'C:,R[!</
MX6\/Y@/!IU ,2"HP3"=DX@W6X%%HCF(_SI;K6@#R-AGP9@I#!IRQ2LE0\*4:
MG&1F6?_0P4$/[>#9/F-!)]3;9(K-TK1/>V 5*L01L=18_DFTI^?N>$E;<I&&
MTT%6OE30B&T)3Z>5>C<'F"<&_2R^0(0%Y&;C7AYX7LQ&G/AUP,PB<4:PJ0X5
M19F1!QY&>O<AC>+,^(;( '&)Z5LE,9MEJH-8D^KXKA,/2%YC=;2IJFW_KS**
M[@D^(]DF-8CF8979<NZ&(9E]=CR3+3O,^R%#;R$9;$4ZG]0U?:/0)[>^CL8V
M?'(W%NGQZRW/2ZN?L$F]EHMKU3#FN-GO\[$W !W94TFL?)"<4OQHXRF;B+ER
M7@ZHW-%7]J'1KEUB;.9\2_[5AV"K%]?_7_*1_T?RDFG^1A]=Z<XX%E_!3L+&
M-XD(GTM)=!JR/==641-1)*;5OR4C3Y'Z?G]'GFEN!)),&P ,+HG39 "'-GP,
M:"1*%:5Q<CINTL7'2[4GM^0?#TN]3^N?1*L1%@;2UP>TGL^%,G$9.SJLXPX)
MO9ZQK](ME\4O]GP''.XC+S< [B^%P,0/R("HY+M>[ZL_ E .Q]?]7I !FP_H
MQO")85?USC6QB/03WT,=&M2O,&N$.-8$0^/<#PL4:NI3A3Z= TI-LYO0FJ&K
MXN4)04BYT:OS<Q*V_XNY]XQJ*NS618,(B)0("$B-2E5 %"F*F(@H142L=(@*
M2!.B A(@) K2!105%)1($Y02*0&%0(!05*0&*:&$)"H=5D3"$D*X\=OG[G''
M.=\>]_O.W?>.RQCK3]9@O>\[UYSS>9ZYWB)]8=QQ._R&!/X.EK3"(53"E3$Z
MI'HYE\;"@-TI%TVJ[]?J9T$$@SVW_H(JP,<%WC[U//*A^]!3#W;ZQ>2Y=V'V
M'C^K P8I5_@9Q[]:YU)8D4N*37^),-6NI4#91_[&-R:U*N#&[1V8X_2M%ZWC
MH4K69]XV717;H@0F[HY<]@AC1ADL'@NCWEA6%1:ZXFTY5O3&P.:8E?+*7(?_
MQMXT"E!8*J7Y3.BEFW"X;97@_9<B8T>_2[Z<*@PO2B4)^)4ZNQ,?2FU4CBA\
M>[S3)_K6K4,O]\T>V]C_,(T"38++1\F?#_^V+>7[G7/](MVC53/TU.=3@Z0O
MS0E/[U,)K/[&%?#;Y!+1=^C3U:X?Q8^DJE'+:N*O!1?Y*LVE46 /XT7F4Z\[
M#\*$7+<&YS#OF>[?]_AEWLNII"@(=NT?R^=>+OV/"J33/RJ0*V.$7VK_7/F=
M$))=]EFXPIYE<8)!GP*0-WHZQN/)13 7*&+,5'Q,=V*EZB?PS/K,5/0 7Z_$
MKQE2LUUATAG:/=(E)?OV.SIOO,?=0$'1E4--=?1VQ+:9'%W2@&;_Z[[R-PTV
MFY#JP$6ATIK@L[I9_33OEW_\:TVD1+?=>%A7<A"R=H9L&$2^-CI'!_?)9:]?
MHYG$<P_QJ; $]W#:V63[OODR^<OLHE3B4[;Q"Z;2.%;[XK=)M.&X[;F/:4[/
M"(M&"FK&E:4VVX]'Z15@^2Y<)=F0.Z>JT=]X&&TY9P'PWO-@@Z$P8]ZVZHWK
MQ^[6!RCT_VQ7(/54[7OFKH;V<KOY.%G[L!-O&%8%SP>F7,!:'W9:RT6,*?"#
MJ^CQD1F?L3;1<W;@0+G>0F!@4-FB;MZ G&MV=@EZ]Y:N##_ORP^KO/CYLICP
MS$A_-)YCWT>G)+[#W *B8L!*[:)>N;EU%[7(K2UR<>$F?N3I@]:U4J9VQ1OI
MQE9C2OX?D9>IO*-<M6_R'>E^O..]09Z@IV:F?)JZS4\IM-]*V?Y.U_[&<;66
MXIFH0G]CD_>V_D-2SQ>O.X0^>@I1)2"-L7V(+696;+)][SSI.-NG#2&FWN_]
M(3V2(*Y4F'E!IEKHXB1M-LMO=$=B=) /WP&&.W87T&M@\YTH)EX2U$0]Q,K8
M[T27JV>;]YO,"@=\?_2E(N[%38FREZG7'NG^A6YKB%9W=F.Z@^.5$.^0JPKN
MUM[>:GN>W=\=?72K]+:9$[ 8&%$C<\&9K<8JPU/2Y+A0-J$5,>+#N*FZ*_X4
MU5"I*ZB#)Z]:C\J;8:XBV>/?XO!:K_*=/6S?CG0RE%8'J\L<KA"_!7FE_J2I
M(PEP8USS49XD=MA$50A,9*NUD8GZ+7HH*\ 2SXC$"7&A&X6-NEQ9H/&5IU]8
M9)BB!^C9E#417^@^^UGC^^/.=V[.8I\#^R=$4/NW#6 S^D[ >O!<&10G$'"<
M_TN6^&HP.@VC!4 3>3KH>@J'SB=2\]<(FA7L)TQ<,O8 NF]QI9BG9Q.,TG]H
M%E#L'_&][J;P5CG%R'&E %D_N?$=UDV;$/-GX,*Z*1]F_38ADP5TSDW\^QY>
M MB,K##\5S]\_>L?R/C26V@DSC8-5(<M;.RT]KJ[@5_9*,Y77QCX'7]$L'S+
MD]^RO$.W7I7L;M^68?XP9,\P[!./R*.2 1?#91R?P=2>/3G!G"D 19@)_1.#
MH@>"-!]/O7=BQ4WL[C\S_^/$J8L=[PGLIYE\%I$FU-9M)L4<3PF]Q:>W.SEO
MX%8O1L[!NSJ^6*D4"SYS$^HY-X68^O5&SC.&^J&C5G:(#\1"K*J7H%I;(_Z7
M_FP\/Z,(D,]XHD4Z'CQ$J[5]$.3%+IS%PM@+O. 3RFG*4W Z,J((?2)MZZ]@
M]P[N;M7CFY!<_@L&[6=QW)3+Y5@5S,EG<71!L,IWYI7@I6X<H'COB).Z;Z'E
MN6VA4\HK@IN0;TO(0"X4O/(6?.@:D%5PQ_P-RJ%6>I^TF^HV[0)I\T^S#0(_
M2;:,GN9-B.QLCN9[N[!FGFXM]=H+C9=XR=F@<JG[P_8C37,Q,3DQP$8XH)I6
M-'UG.C.S#I;8GG@5H*B^@L8;:>Q^J7W77+1)B.)S5=!OJ@$2Z=.B+\ ?ZR'9
MQG=99[Z6[-AKD(]^>"!,]?*OHVHQ0\=U^-82-R]&9[3/.\_,!2I8B9GJ+ZF%
M:EC_2(-,'57V'#6R:N+K[OL+BT[^BKB$W,JZFBO)7WOU6UI5W'8$;Q.K/LA2
MR_U-N F8)),$&./8G^/7AKQ[RQD+K^G*9YK%C$]Y^03;C.8,"# (P&=BCQB8
M[)AZDO8LSPSF<S6L2OBDN^515N\404%VF1<[J3,\4C;A8*.B=.BCX$](QE;I
M@^@.Y%6)J!$?EKW0"-B^V+UMY7=ON465S&OZU8SFJY2K6_'9Q/"T-GWPA)Y>
MJ(0]I:AU$Q+P:\*WQ3?BWLCNK=P/YB]9NSS:[\%5P7C@#=6UQO?L!=KLCBJ!
M?1#1U!,Z ]]?7I6Z_P29B*N&4>K)8FC*130+NKU>(0GZ8?C2Q_?F*[M_'1H:
M)+]>.'R!&AHHMN[J$=.:J"OT_724X 6H9L]SZ=(7QQ+:L-Z84" 6GTR,"EJC
M6+'/EMWI3E8$@R]Y>Y^_X"0E)[!;'+#OOX?HO\23N,.G+3NQ%.1J,&)M&%<M
MB]V$.$Y.<95T"MQ]D< IQ'")34,UJ>)C=28G$QJ "]1[-69KLA#%7F.JZ55_
MJ>SX::%[I^.C)?A*W:UD"PX]#2'$X&XNQ6*/@(]9/<-+5P!L*JTLC4).<ZE-
MXKH:C)F+<#SB;P/9'6M;'6-O/%:\2BLONQ;XHT7UQ(V)RWLK8.$7^%F&]P]%
M%HF/HU<]M0$\3^/;(GPZ;'L2$%(WP@-Y UYD^"[7+H=%'#'V0W@^U0NJ[/7]
M= K>!&'(/0_*L/ Q^&J/QQ$XGR/P?;XRW!M#\-V@+:-4<3"EL*/8KP:^+^KD
MG'O_CX&@_NZ)M;Z@!8]M6N*_CO>*H33;+VS8.AYZ!YI07"8^YH%/+O?K+AF1
M)0N_^-(> *<UNG-J4>*96VB.ENE[=$9;>BJ>'DJQZ1:&(%[QN3/N?6T;3@F]
MRJAMAR7@MFJ"D0Q]>2P=*[OQ6@\K,#NQMQ=CP4^<S=A=((Q)CANR6H@PHLZ$
M58#Q;NGZTI\#KO:H7PJ(]4[QCCNOP[VX\1(+!RV8J(5K0/<H1X':"/?#5YLL
MB'FS'1EI[=E0)?1A2I9]M)E*U%NTQRY#%:3ET(K7H-< 26#C?A23<=OWY@)1
M^&-MY?O:2&((;@:>!.%%+2*N+=&T;#>*S82 :*5]09L0KPV?"Z -N[YU0KMO
MQ59)(!?C"O)3,8VG3B4&&L_^M!V_V,',(9:,&<9]^;I-C?K<PRTNPP2A.O-W
MYA&,AC@-,I@P")C<C%0IYYHPD4EAO'TQ3&@,7 <4.0-H_'P1^7;"WR5T$OC!
MPT<QE03RAMTH>?8!MR/2Q\RD>X*B14X@2M]I;\G(#@HTG!.S/.!"^S(X]F*7
MX0/*UMOI\Q#Q[X2O31!7=8B$.U\D@J.<WHUDDMJZ/]J6411O9L/689);COLP
MY-L"15CZ]\QP@ ^2:F;"XA.F44J=![' K[;&):<D;Z[FL[1+P-#H(V?4 <^]
MI[=_H>O@*&5P-5S_9=SD&SH8P978A'0WDMV*_Z%B0XM:46MGTK@[1_FJ#7F?
M_&>H;Q,B60VF;$)L+O 1+QO'F -,-B&F:QMW_C$]E#&(ER+/[$< EU#<XUCA
M3<@4THIK2F6:;&A8\;8'\DD[H8G.G>.+X==UKP(#RP^X'"UT17N_RJM]V&66
M+&T8NR<1Z^=]J]XS)3QLCY7F/80&XE]]Y',VCBLOQ@D [-M^@U*EV!Y8;2MY
M)TJ/Y/YVVD..BO/"J2"1(($R(3RH%X*01E>UO+<*J9K+D7M/)E.O$#N/N/1T
M#OS^HT!=N""X1I],DW,!EUI<H,GSU7@I7X?&W53FP-4^KG/^&!K7FH6YD[&%
M[M07]/DC%>7H9^!ZUO;U?GM^N&;PO6'./H'^^QD,W%?+4R4+XI8)^3P5/[82
M+SV?C[C&FQ#*T"2*%[JR]N,_]H7X)^9/^R>&'YHA\/-G8J,H>'327HIK R:7
MCZ!1S1.R%?)K@Q4XP_.NM*;5';23]3_3M;\.R8<9<VK8+W9VWC:\L&]LTK$5
M+\*G%$4X2.-!C%T5Z)(CLI';*.\?T6D/B\78L:LF!QN SJ8<HZR)?9IH,R5F
MPYVI>=4]+UN39E02[GKGC-U?__$:^D4?U.2S&L*Z!7:0+ +706]"F%9<62AO
M^[ZB.;CH1LDFQ*\GVO2RAR)(9H@I[>/3H3!F>>TD0=QMO"T,^+5F8Q29HG,N
MVNXB0R-5*;GREP5JB]2N#3[\QKM@^)8H*.8+2SLRL (J;4)>147-K)MBNY!B
M9&^""%C41!>]24Q6$6Q'R&(U,=Z#S$%B<DK03WLEK@O;;NDAQC,8%7SG'6<M
MJIV(NZV1FG./XAGD,+'W@CD!^^^ZL@BXS-Z$,,CSK,D ,@QC,Z!_C7K-4Q)?
MX)MAY<A&)! JD[*0<=7:/Y*FG+]I^%VW+BVSR;!Z+&OIY-B!ER1/EB"J3-)T
MS5SA!#[Y2<6+$'M$0:4VF+3(?3X=UQB$RZ.7VU0E .]X3F;B"ED([>I1[V[1
M6I-EE._Z.4HOZ8_#)B2P4OH3WN_A(^BQ_\(XL/_5S0B%/_Y.6^)U"7).LO47
MFKV948Y.H 1#3S$PV&W@M[O:NE6K0TW&VCQ<.4OJ=?-=KX!AHDV&%M%D^VRR
M^@/N \?[& O^ QJQ/5@!,(T%BW- "I-OVB>N==P+8E:P;Q"!,$X@.ZP5N6UZ
M]<[(*+):'KNG+\BNX**Y3QCJ]IW*_8:'K,LI6Z4%DO\+P_ZS4$;FD04;3=!0
M3AQX.P]S 0P.+;9G= 6Z"]547*<Y?"R8W:%N%YD?0#N;;FO\K,R/L+^Y>&8(
M.D5S$XX[KV 7L?!OA=#<L_\XJ>E?[UWYY?,BWU'_)-U,_Q?O!?OQHLP]FVD!
MQ#,(UNJ?I=9_UK$![&Y^5[IYW::P)*X?(QEQGU[3D5S:")OKX7O03O1<,ZQR
M]2')'IBRKXM3BDPNJ6&GQ/91)3.]4;>J)I 5UF7,5)];<GL#%O'WZ$2?9AS-
M84\X$-EZ!UUBD]G")\H-J?6!02FYLXU*[%.U[Z?7XIZ]I9AQ5OO&B+$4&3'9
MR]N:GQ]I$J$@_XE3]2"'YSBN&WEP.+8/"5Q Q:H>XO<UES_HTWIFQ]:UL?VJ
M4- 6F&6=!AL88NY_3^",6&U&"&!.D3ZPU5=AT -Y#0-45[81]V!/@,13G>L9
M;$.)O8:$#;AC#WT;X@8J%B_8N(?7RQ^GF9!WJ0M(X+P&DPLP%T$"O+!TS-_!
M<4*OERO_&A1NB5+\XBTU76/+H$OZ/;;UONFR[T"Z:U[8UY9[<,E_(TSZD8EX
M.1(,R*":-[ Q=0_.H],\J"23-Z_@;4LOB,<O<JCVU<[/5,3/9R</;TU_^>#D
MU\NQ>QN,_SUX2X+\713Q+_=I:/\_CLK^)SCQ^[\1G_4P,GPR.<Q>C2%Y,G"R
MX[AF6]QD7J-!#3!!+@P(4Y5AA[5#A?U5Y=BZIM[S)NF^V+T5->!MG]OA>;,!
MHE4#9;GU-1D!-H4I6HG/CVR<^;]4K?]1N?[#EZTQWGRC:.,XD2YTWOPW/H7\
M1=V$"'?R.WV>#QT<(GECI&3V5]H?S2-D*M_IOSW]A%,^KK4)J<$/$'=>0&H[
M_=6FW'9<\QC]5SQ"$3<2!<IO0HK^KI%X<!42*0"R9'DE="#L\/[_*$(Z1Z>!
M2/*6CS<]>19U>.6UH3_G_KQ_S*OA.^D6CXF1GB#\,XA1J@UBJE##L%-!:S6Q
M9]UV]/X8WR0!MKNV+IT3F/YBO_Q:O)ZPT@4ZYH***A:.]<3^ZF'U#Q\R;I4H
M>^K%[:]/N_I.0)VC A),CH:Q!&_/GA/14GZ"S(-53MT+>77,&B=M4SRMA1R0
M<A@/6M'1[BHDW1/:7]GYT2T1=M=XRE=%6W &<7\3(O(PX+K1$8FQXC[;6[D*
M&5J?-,TF'TZIE1M\5':<U7^PP#5E?FGIL<URULL]I7I=W+6NV"WVBIO$6'33
MP\>#I)[)+OS]P-^!!I=8" F%[XW6*V&!GO8I_0QUG;U; QYU*2*>"\*>Q4$M
M[G,DXPM * 6K2=5GL3-CIBJ^%2:)/6K<W5\@Y6HJ'':U5EUGZ?340^$V"+IP
MZ!X1)^WFW[U%QY>S*CW6*CQT*,&I==++JSHU^9ZI9'1C6)_9L?+/NIV[GQQ.
MM&W]8I-2(STSU\OZL$KH/WYCKHDFGRIKN*0(G@FPEZ[7H.!0?O<=U,2NFVR9
MCKWB2\&,>;&4D_A0FHB5!<AQR/-#(<B$',E'E@>"/*-'/?I72RMRTT]YV?:[
MF+04"YRX]O*6! 3KP[T,FAG9^J$,IT5H+ .][^(%AO>[P\3O28X=O'KN3L2M
MVV \^UC+$%:.'53F>?QCHM#HT]W8I9\""5M]1-39.>,Z:RYQZY9LXQ<;M;>9
M/6*C)Y_83KT=,IPF490>[Z,%"5L<#+IEWM. -<#V-8I1B6(+N$LU0]5*;1FS
MD<5R]"M5SQZUGC4W3_4YX+1E#'(NLE>DN0:Z_!3^(-J^@L75\?@XV6C7/NA]
M3/FM]^ZWLP;;)M.*&*[1ON\1D3!S;@#/4&!]^3\GN"RM?T1M>/)%Q!;RT!WR
MIQB>1%0Z/["CIWB47"]++9XB$F*0CF-!-R&^@DTBQX\25NBOH0FXR=<P<9(?
MVV?2)YZD/VFWAU@6U,/JF%]GEB0;Y2C=R8(]:-1#NR*'"&:=\2G;*OM+@\K/
M7B-]WAJIYG!G)R^,B]RX3S + -)87ZF8W?VA:0F;D!T(7S%]F8W*GP&XVMD<
MI3XB4CY%<Z:\<>#MSKMUV,(@M>0[UG+G%6SW=2R%\N.O#CL$JX(]A,,PY@.A
M=CJ3*?%))!7F!K*I)LOGOOQ%:O7"L78:)XVA(AH4\B=G]I>VWIO8D.S/TI%%
MJ9J11@K79Y7LV\@5N/8TVKDY%KV-3PQ'*.=!C4E\PL3>C2=F^OD8R #)D5%V
M1\7!/@8),^Q)\- &/ZK7J7QZ7_W$HW=QL#M2#+^?V\98L4KX4R',>TJRF5R2
M0->O:_&D]?;V7.%1!AP=^AN'ME[:2#[OY%WK6FPV@#MP0;R_7<6X9DCMB&;=
M50A$$K)+L'<[A!>&\^>W7\NL263K<-X"?[_S7%<YS$D'IA:,  K%0P2P2KW)
M=67 Q(?!8^MJE+HW233]O]OK^=^BC\UPNDI<1T<;[E4@]W:[=:_GA^+YK\)J
M_8SK'#^DX:K<0[TC<%E>+VP[]S" Y[S.I-#:\87^JEL&?T>FP*Y0S0+$AVJ#
MLEX5Q?]&B?I-B,D-'D2.?\T,,-/GA%Q'Y-9I"_[1 U_PL_+WC5R,R;H#)J*V
M%C#I@,EP]<$1-I/"Q,6%TN.1LF:"#/PV7YIT;1RCIH^H#YW+D%_K[\D?\Y6>
M';I(.4YL&#,11:%VO3R*FL4WU:E/* (^L:3CM_6^+D_72;YX8V?T_?/QL4IG
ME]."-L&&URXZ/\\UL$Z2'4Z'"-?5_8]I#\NL-*[T)L0")*Z?0:]R"@''!9]U
M-VS7)D0*K@GJ-*EN9;<1FO03X(K F_M,"25&:00)*Q<P=]RU.6OC:Z9#C-O
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MN+"U'*Z?S[R-RHNTSW(K=AS.7JLT9O>6']N(*QF;* &R6="[^AJ()&EQ+@3
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M7<\%H[XM"?(AYP#HUT"F.$?/>G@#-45@MO8,[@_EP8#/A<^*2]^1.-),UW*
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M5%7L<@=4D6.?'*)]V&)H;?< \:1^&-%6&]6948:8,S1\8,2(?1X4G)E9;6-
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MEL#)&?.?]^IK<PR?VSJ%46>)1TVRHJFJ_13[*=)OR#Q5SOADZW)LGCZ7 I;
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M$3J6HL@$'P9FVJLQ86UBKRV%Q)L:Q=36<J5/?0JV6FN6%@JHZ]FCVFD"D-M
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MZ>4B!2 G<+SOCCGK7RLEA@I 2BOAFKU.E*/N?UN]VY$^=QZL%=$J *WX$7;
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M^DP1I&H+7OM'2&QG0+2Y$X-..>U/Y_46X(L);)/FH+8LN=M><@,$1PXW<F!
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M7!J_5#=^Z#O]#[.?W@+08](*^%]!,$\#3D=X1=A\UX_X]WE;CKT6@%ZF5@M
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MJ:W>XJ5-AX0RM;:/N/;M&0@1@,0Q=5=105>&B89>%T+];F9BB"JI3Y(X]JR
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MSRR]8O8)%6X;0Q\AJ4WDZ7)ZWAGKQ@1[AK7"^86-A)A5TBB592_M#SUN-'F
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MQ/+/IL2]<A/AE.[9OR*M[=/M 4^Y2,GN=YR3=*7U&>=9_W7E"_)V1_YQT_6
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M]=&EV.6HM$KNROI1A3PGXP8DV:V<ER"07UBU[*=?$X'N>L-:T5!@>BV"U5!
MKIKIV3H"YZI%NS4@0ZFH%[$G;3<,O#Y;J9I'N=>>*'Q(\QA=OFBOF>'X.\7J
M\=.OWW2B[$>;9R\_]==1?S*Y6*0SN-SI-T9T<#B:H0\O7YF^G1:?D7QD6S2#
ML*A4)P+5$M>/.:R\_"= 9?\[0$4/_Q.@<%8;AH(C0 YOI*,AOP8;W8;8"Y7U
MPFJ+Q2-A*S:3.]?3(8G&<,-%H#9+3%ND6,WZ%<58MJ_>Y6SDRU]H5,EJ^D:\
M'QJ>:NM%55:7H>2=0SN(0!2@O3BD6A  R)'LN4U^,>J3"/ZWI^I[,SH9*87#
M?CHM"VJ&**7U^V;'_8Y$#[NIZ]0UL*J,FC(;M>XY'H2 A]S^,]4U'AW*NFSU
M]+%+EEGYL"GA2X_'T?KN]RMYF3F.(U:QRLY&O%OW0C^XLH=T\:LJ6HK[7XA
MX9H-U!@G,951H%C=17_A'OD-R2DZA9C6O%^L@FT[9/8'URI#CP&1/ ]KGE_>
MLY\YWI#XY7&5F3HY(*$M(L?CEF1%T[7U;T6-V>;W/;W0)#W)*%EMF-=,*Q0J
M;ES8Q-KF4^);$6C3OH0<]!M7:C+><%=@O=+)"<,]82_[RI)3I?2B!LJ\C@RY
M,H^E8ET>3]2KV9TSMGQ:YN1TKGA2_V#G\;??/WM=J3EHUL8)..6:=<"5Y&R0
M98H];69\](.#P=KC )V] 0=.U=OH11!V"20(O$9.^MWF@R%^)X>:#UT&P(Q:
MZ 'X_AEF1+8*L]Z_N,('F1D2P81HO6JD#EP:@$<51:"R*(Y)A)CC63\?DP8W
MX4O%9$.YQ(J4-H]VC\=!"'GOJL.4(N?\(Q](R \E]C99^UU*G/7_1+N4['*Y
MAWMU_UJ&;]A4:ZI96'EI>7_9'M>!QZ6#1]O/[?[TY^/O@Y><71Z7Z506CZ#_
MQR-6EZS1O1>?[#V9=:U,XL6[0Q/K+L'/) P-,SY]_'B[9E_;IOW[TK[_HQ[.
M(GBNK&B*-;XSH&":>: $GDC?_LBWS^M.SJ3''8V'UV,910:OYO?JSGSXY;/Z
M3@3*T(%M/B;<%8'6&_'@"ZYJ93OIN;!<Z-.!V;E*=+:DW:7]KF]<SRB>V?OV
MBM0>P?KF,RA$$"JF$-/5A%@;?C/Q)J=;<M6FMUD;9\EK)]Z?]5??-C0/U;>?
M2)<#)CT&(?K&JF2%Z565W^C,^ZR;4V,'^BLIC9X(*^+[00P&9E6X0>0=A2W[
MNW@XO:ZG&1JG%:S51="'Y?V< M!:']=O+!I"G]P,ZZ6VL7VZCF>\+[-;"%RT
M/YX:VJ.1[83XG1WI<WMNZ?,?&2FA%R\UA/0T,1O*R"LU05][4J$6.-M>G#V?
MWE(+5C,>(>P4J/"".C'[!8>!1S=?8,]MN /MDX@M/\';5YHD.0N).)OUH_T6
MT0&<)I=.J'8_>5EZ9_^ )PL]7[D\,O(D7 UTWCQ=5CC.'HLKGFH4J$WH\,,[
MTV'!F&VHY@,Y;;E/#0&84&&U>F).PH8/29J[EC'ITD_9_H:?6EO'W\.-#O#5
M9:S^V572M<U)[<.FY 0F701ZS7I TP@W,@"VM:[#6S>#V@WH]W&.G!AY9Q'H
M_K&-%J)<."S!]/9X?-A?8>7+.8W$#A,^^W/7A NALOW%#!N:'R5=VEAA=54G
M#2!S6;->/ &6P<AN<'\> VF7C"8F"G7X.7<I,K)P;O2FU:1RIRX\KF$EB4\B
M/85">L,]\;^%R!,P@,-W;H>>I.VKQM[YL%)_];L6C<NY2S/LT656Y+A[-^MX
MGG,*W5&S<K[QSU)V<V[I: :5] .A  OI>:!,EQ9"_ "4!V^T+@6Z#3O U2JH
M?X%3R-9SZ.S,M8VC^?-R6ORD!L)>X%#A%2-3#9VIQHA$=4U*GE,]D_VIRY67
M-R("H?_:/N!Q-F8C#)B'BX5HJ_W59[@#?55&H[H<>J*%[80(I(""ZE/X4A[@
M?4+8-&$'&:_PL[ZQ^J' &3AE%/T.JF7)S(LJ0V#9/YS[C4@Z#KVAZ/!&$>B9
M0$.,S)_7)G[$XWPY^1(=ZEL&*'K@MHS+V#&TDS[UR0I9 35F%-N*0-8W$FW^
MPG[Z/LG=.HRUV24PW%M1AH0>2^MB]/E,L5^V!\> VQ%;\;(".!,'FX3+8<.F
MNX-NEF*3/[3KD\/&I6>4>2$18SH#X:/1C&/9O0B4A%L\PZ617G]OP&WP^ZL!
M-.WW]?LJ:%))(X7^Q*_+AB(P'UYFL2Y=+I^Z?<G>A)7_*VSJ=>V\>Q/S!U.H
MD'@N]\&A;#F_][*!H)-R@CL/3VV_FR%Q8,H7?;-Y;R *57O-*W?RULG3Q]M=
M,^!_VFL2O6<KLO_[5)"%*_318!$H3@2:NG0:L@^KW(J'#%FH5@*9-@GN@W@P
M-@VNC(6BDA:4])3;7@=[]\33:P]3XKFZYA7O*'!9E(E[#V%'/SNFV2?%-7[N
M6@'48&1"IF4$KH*MX2I M_;UI%B$7^5:0MKKEIHVATH;KW(WS5MRX<DDLI%Y
MQ7L*&-)VF\ 8WSDR$ZAGH#,8'X?1&W$T6LNXO+%#\<E P##X1,O& 6&W2<$^
M7N>=Y85XDP;;6('&A"HLSAN10('OP_;\/D"&[I]:NX7P%%CR?[\-3ZP<Z1B3
MK&FH;\H88?@9Q$3;Q86KN2M09$/83SUBXHLV3N'^?B7PV)%&GE[.2.D0[C1Y
M')G=4-!4!L \^1*Q$]6U/&*BL0@$^AQ2.[:3OY?.:8R!V"58,:GTO=,J!4_4
M4Y^G.+Z@5QL1JS?"%7;D!*RI:W$1PXR)])05>E*S)E^9T0V^P&HVP!J> Z+Y
MYNY+*XZ.X_NQ$,:?XUW%V&B7W [A<$;K;^6C+1''A5TFY8'H66,OS(W*2M+<
M!H,G K5T=D80Y6T20@O,7O/B6'>>\:4,?5MN_OW2RS%R$-G^.1PMW>KIR[:N
M^-P2$\B*R/R"7&SZ_"J7;;[QM7XV^%F$+UV,,Y;G7N><Z]LWC?K:MUS<]"8M
MN*S1%]H76I8\\9U[NFK[82__ITL&YJ\_1/TQ5''94#PVT.I%W%1U>*+ZGG1W
MGE-L2+/!P'6^36+.F/S OE/?,R_RM2H0NY<=CQ1F'PAH&,Q@[RK*57XT%/C@
ME400!K.C6';$NT6:2J4AI916^<4GSBJ$*)UZGFSL.9FJL.-W:S<WT!'0M68_
MJCB =/''A?4X-1%H$--NO!R9(+!^AJVQ?<V7B%MITFF[O;=$M:MLQDR]"/ER
M*K*Z4[=%@SW^N=NRDGN4F[T;5^_3E7OT<,QKC1>_.OZ9J.^L>IN^,B,"_=E_
MRA"\AMF((4P9FJT?*:R#8O]9@XA'3"8NNA("93:.J9N*0$-:?)4F-DV92^LM
M:X<-QZAC-2* YY,W-#-_3XO$R0,/%.X'25F!LYRA@;\\=)+77OZ7Q8UT6Z%:
MA/?(S1S"; #0*0:F! ]R)'D7D"4":96M^HI U3F38.%+-;\[EF/)1YYM_<<B
MO?"O6O$]3FS=;RC"!E($*BPF>U>)*5Q%!-HC&%X((,POB4#D?O$H/AJG<-&S
MX-%WOYU %Z^3ZU=1];-@)Q]/Y*K!&4]B',:8JL ^1[?!%3W9Z5SK[KD2$CF1
M<K+R)[OVX=\9#O"7P46N V0C,2YO5HW9>=P#^L3&2JSBQ<8RN#+"<CK8(Q/?
M#:LAM\'B"G1XU(744)K>9B:O;**D\RU!HH>S:7MQD(Q#E71/)EI<:C9BZ9$I
M3<86)R.,NC6LJF.V2M)E0X>JC(?%/(MOW_N4A4_BPUMF(OEU$^XU.HD";XTA
M"ZM)/3V* K,6&]KU#G":3!#VO>IOKYV)\;XB)>^W6<+P<;JU.V%MI&CN8I&C
MG)9S4?ZI_I<#_4[T $O]Q^XO^T=&Z1IKF:<JC@V]JC)XX'_IS]+*!05ZE,1+
M7+?7F"4F]'I&\-3/JG&AXDK"YO85$4B@"A.W8]$_ULM7!T6@IC4(9"&*WOAQ
MB5!S$MSM* )MS1&!#MU4_&?.'VMHG$>NA/W4(8M $^)K X9P2QO6@$%_ES-@
MY#]H7+I$0,+N'1D++5V@$CA'CGG!(DS>['5X]57=6IT-'MO(R2'F;= 8&X9R
M@D$Z[RAA4>+%O^<0-L;RA&\S12!Y2T*Y"/17C0C$?PD'/)C@97F6",2[(38W
M)!T-WQC_<U&X]H]#R%E'B'_RKV:!_[&NSB:N-7_[MKE@NA:5L!JH\:N<,/%W
M[OC>P\ES(A 'X4GHA2/$MZ%_.S'L'^N65-A"3%?7QAAF?DEF]J/MDGC/MR7B
M/GO06E$<G%N;7XDC:0%=!(H-$H$F70G_W! =0OC[TM=HXZ/?P<-_I7\7[WM7
MW,@/3R7KBI$I+N:J"'36DB "[>P1@3I>_.<M_^(CV+^X2,$#(QX:ZPSAO=LB
MD%":* *E7OQ/&^;$;1H][X<86R)$_D4(O ;+S1'N@ C/<'5_T-F85O7?^*S6
M*0MS3K1<.6H?EL4)K,HFW<2$["5RR,E0&;XVU30_7/-"/*6/4K%!37R3P7DF
M>X9L]*@H)M="XPH(W'0*%%!RK1,D5=US_&:VY7OM-YA$=GHL_@#VJL"'^_P%
MX;HU"7 Y"[N2..9+",9VM7N;QE*NU0IO^#P3?F;=D/XJ5B)]LVUKJM=/1MV(
M#B:(3?7#-&[0.EY_<4".9:=:!N@&+Y#?/'AA=[)<;7^-3)&YW+IZ5N !*8/V
M(UL>7-*\:W_HI(W4%HV'>T_8??4H3-_UV1\$E3CH\'EB8DUMBL#9]VHY4RBL
M _KFGF\NU$<1HDOID7_1_V,SXJ],TU^5YG#1\N=[+;SX_I>9E3@9,G:D303:
M[<YJ60^\-[:'20OG%]D!H^7ON:;]*X/$SE63OVM]+L=L'>OMX9S.8_#''8UG
M9M;^0)FHF(AO(_KYI9TW]5/X!@MV@U3SX%#C]Q,\R_L-X6M)E5#+GV"*>E85
M&]F/?8CP\3G+]=VJMLWUU1"U1W9Z?37NCU",X%+#%_B++\)L<?_2NCJEL[F)
MX1<)Y71E[&$+,X14",IAC4(N<_Z@^XM2V^B#-K4A7NA ]SBPFLA#*T)P3$SX
M%P&]5P2Z@MCQTS37J!9O-A1'% OGYZB"/>E"N1%D>*H.O%]H"A F\U>3*E'K
MV8WE797:Y20LQHDW[?N3"96KC;5--;:$V[,$ME)FA3&\^>N1$1N?/O[0S,S6
M+(#K9 XNHOIA_[-MQ:$Z*Z&8N+9"[XASSQUY@OOW#O_S_.M95U*WF?-(=/^B
M\$?&X7]-5'U2BGPX]8CVQSW%D9M=2IH34E\STT 3-[W#[W\MT=&*-L<T)VDP
M&0-9QQ2F/GSI<S(W)XWT41I7]QPI?/;EOX>?'S1X$!>U>=@'LQO%1L2OE.:.
M/A\R3I=QXD;OG[!WJ[H6HRT=R7CML-2J<JI4I?C<Z&>':T\AV8130C/!3J"3
MK\'5SB)A?3AIQ&(D?D>>-WUH%F)A/1'&"VJ;L1,>QT& O\9Y=S]_)M76<$0@
M=9P'8?N7L_R=&US%Y."(0K:>X@HZ9&Q)N,]DT[+P#A2WF8]3Y))W!2/DJ#)*
M2 QGAIY(.-!\6. P8*%K/)]/B.*DRK2;I38BV:$ET-3(%\$5%6,I1W%G*UJ*
M0\Q24YM+2+[G<N-FWQM_;([DJ,+D/07NP(9,\LH<I,T[912GDRLYJL%X#02R
MI4W@TD#.;,0^SVXR-FD^%%W[+G 0/[)U-.IEQ=4;OXU"/J\LMI,%V8@T$6BE
M:V)!6(0_6E5I*#08\+:?)9=X1YO[8EXZZ90L7/\C4'>S0 0:=XQ$^^OGA8V'
MD^J"$-8*[IT]_ZR>I7Z3"X^E[Z;Y<U7%&KF.4W:7YL2MD'FUF=!V>R$^C 3W
MKA%^C,AT-FE(':7475#5"33I/IA\3>I#L:YLS*$,>\VO&?8ZY3H9<&;&?UTL
M\?]%/?'0(Q%G+]9K)1OFA,\SD\1-5_PI$CD!MA\'X3O/^,%W?<863-KUAJ,)
M5AB%\9_*MS'QQC$NK<+#@Q:Z9.]@[_P^JW(3(FG*.Z[B73:_W<Q'M<)+AYIQ
MH+@=$$<W+<=5L6RK9G7"UE\(;@EWUMX/V)/Q(/-!EEF=DQ=Y%!Z^Z?GITJ5[
M-Y%E9A$H8;/MN@".*4S6E3]#SA6!D.F_)'!*(E#-8T!+!"J_Y-&?M:@S=W.2
ML .P84S<Q^OR"7&"$VM@BFVKGLVHA15YRENWYVHQ4+ [W/&GQ\7&6N2-Y<_?
MXYW.36VY]^&T?_23PQZ7SD ;"XOB@ZL.)V.UTK ZJ=KQP;[7DX.++_"[%!*]
M---^O_+S9[NO78"F;(C#_]I57S$C-Q[QM"<EP/Q;PBTBT#0 8!"76>_&:W\(
M'N:E_UW1!23N?CB<Z3,9TK5OIX7B]OZ)1AS!#X$5+-"\^9D)_?2);A>/OAQN
M4/O,PDYLY@4>B_$+J@6\U-O;R=$1WX$/%@+1K?Q*(?IC RMV.7%%]7LU74E%
M(R1RZZC7[[Q-A/(7<3@5.ZU(I=HX71)[JTTE(3X<C;$>H#HYMC2T"7_CE:S,
M46Y] 0B7Z_N,,=)?0AHN5TEZ^W4_FV%_RM3D/YSS+Q\[X_S^+UFX6UG.CZ_X
M:S]AM;!.# AXO=#Z]U^;JE?+0Y3]Y'ESG7=PI];=UF(%2&X/8-^L)[C1:W&4
MFR[[4T6Q+-W"N@P;VX:0AJI.W1X5@1@$":Q5V_IJ?J6C17H),L(@Y"%PJ]="
M#%D[)/MI<-ZD#] 5P,OTB^40[EC(%P-%7&81@3LN,S6FQ\.7O<1:^?##<K7C
M.&H.JIK\QRK7O0/S2_W\VJN"<ZD=SZM&K(L C&L,S".M<\Q8%3:,FDQO@ZE@
M"9<'!))<1#)"AJJGTSKV&W4(1S+MO'V1EY8OD1H6G:IM4]#5!ON<:TEN&TF:
M8%&"5*YU<9TPCM$LP^F(A'<")YA OI&CE7X'=_;EL&!W/\4<(@D((5M\D2;K
MVF1.%N]':X\,2LQ[J:5$5(GQ?.SM,?F^\,WPXR2MN@;ZP$B;::YSTL%+T_WL
MC_*DH6)2;2T]E#T3.EHWN#2T^49X#)O329016$[TQ&:C;FFEIZ_ 58$@/[YV
MQ7-D0VE*J>!8G_ PUO\2KRZ-YC@1LY-//DX.'*1!JJ;\6Y25,*2FXM7U2< ?
MJ@&MYM%7.;U0W6FA1%,O;@O)6V  )/"59.ZKJ_))PFHD.%&B#8F737^0&E"!
ME;OAC9*1JHK;65ZDD\CE[_CVL6$^[[L(=%4G 5*).PN=([?0/\?Z]2W/&4"D
M!*J-E'XC#;X)FXU&G!=^[L=!N C)J75=;.$B,OPBR0OK?Y'G,M6LOF$]._6<
MT'J,N;YG1Y_O\1&V!817-X$>3[K1? (P;(5NI;$6;F@D./+KXN>6NRJB2,_Z
M)WAL/Z2'&>I]<4I;;]@&1BH_L-5XT/EN@$P">WG*?>KZG?Z<Z+EU1!EJ?6Q=
MO=U:X<*%_UB!S./3F-EF.5X69\D?3X2JH&[75D1.PJ4$L 'AX>E<_81"O^G%
MTKPJH/,L3SF.<J2T%E'SGBL"*6'+VAJ@Q&?8L ]UF>U1.XNP-\*&YZI^K-+W
M82.ZVLU<<ZTWOS==11]G+AEWQ@OLR0#<S;TV*\ ZW8O'+"H)J3XW^SST4!K_
M:GTBQ72WYOEW^-_XQ%F=LAFHQ1 NFI.>/&;8-[\PNX+VLX2T^=FF+"_Q]\*3
M12 IZ/&?*JM%QGW50RLP&:09L75.]?<<1IW*\S=F![W#TYY43EU GK Z(L$:
MWPO5^ F6I^@V8<XEN Y\[0_?Q+06_-9+'?&L#%^0!HB,'+)_9;!W.ZFI>Z[0
MS_M#=?=!IBF+'3.7U5VR&3<WE#\H3T\9V0HUP$5HRJJ 8TOLMV^%<0[R+WV]
MG?KV09K!KFGIVZ8MZ?'*1*DPN*)V#<E[1JC#7_L[2\:1CQ;FESD6_^PB8U]&
MH]?Q"667_:8](MC.F:6?D0T!%7[3RI$Y@?V.&T_V^93&0Q1YD?=IL(F>9#HX
MC"[]V23?_U8DK\CM3=("5>]LR2"$9LI%4"\?H#IV#6=^E/N]<%=Q&OO$G<X]
MAG8]0_%U"U6CFQFO:]/7* N1X2@D6DU (A.?(*8W]3Y5+9 9NEX^?G5#/I_6
M;V<I7/0!0_][SO/_SB*&M7WTKQ1A%WW50. OYGNK"E8C*TY@ESHR:3O;X'8@
M0:!)/W :1&SDQ7KH#?1N(YZ_(-'POZIRU\2A_Y+T$8%&X)N*6K>'HB#Q8E+2
M$W,&&K;LFC7CUH681' 0>9:SY,TQPLHZ8MWZ1)5/.UX1H<C^[%V7:.'&Z;OZ
MTB?DWF1K[F"#VA"G=N^.. &O\[>&_A_C>7G:>S(5SGFB%0?[O+0'G(*9G87]
MMPTGQV,)-?AZWA)WM8RO+087Q:!X"D!3XV)V>/\$2^#4HB9289U.7(AZV0,N
MG][F>\QQI$*)'YBRHWZ@TKJXH3Q#!&KS,V3N)6%V4O>F!@P+K'@=63*=F#OJ
MQVV&/E5'<N$J4RZ:!1K\@^PCE'0.+%7+12+NVQ""H517PG%:SZ]*WUMV..I1
MTZ2MT7N=OA4N>!_A:SG^T_BJ&?#C[W)D:;K/W<O=BQY_(U=7**,AX("+PR/1
M3;Z;BAGVUZ=:92\FOUY]/-[#/HOH<C(2C&!&?A8F?S?9\W$PS%?58Y%.I>0;
MNBYN3Y%938TC+62\CMN7V#R@T.SY\%C2UBNGW$:?2B'[SNQZ^>)EXG.W,VYN
M6]S<;+:^V _ZM\]^!<I_4<D4?YK0<H6 %C.,\#U!$K?[.7;A+4Q.'(<$-OR>
M6/*R"*0 G!L_\Z:7(G9F/%@6I\R7N-1+71U<R8<N#EQB69@7A5P"HIY3WU!I
M!?W<TV5ULG:,59-FZ.8KNG]//*'6],XL'BQP'MA;]'P8(+8*CZ4>#D_F6MJV
MLMN;2<'7'A=E):^>"C4BV8/ R/YPU8U+'CU26\PIL[,B4(50HAJW': &\4<F
MUACC*>N$.)K31!XXL>#  ,W+GX,X8%TV I39#%"+37-OF'UKSHDI]QQ!7)Y:
M]$$85YJRI#&*@Q>=N\P<4F96/@$N#&:!4F_8W+X/1SAUKVKCQTX5NMD5V5WT
MMYNTWG+)R'JWRI$MLL?N@$!AKE*"3T#YQAYL';<GL=EPV \8:,'+\'+$.B)1
M>!0@EF%9K<WJ@W3.'\@ZH<;FTTHA2"?.V'PCY851X_C>M_>6VDPS1\9:])^7
M6?MS"+,;%X)8$L;A&R!@QKV?FD#G1]XEA=,5?7 7^ZA=@>GM!9K]8:.FG?0:
M*OWMB+2'30-3JR[#R>=\_4#8Z#5?J)K&V8&O?8=K>[_6-S;W7V5AZ&XOGA6X
M12_@12#(XJ8)[##M[]D@7'Y/\FRSUA2;V :3+(9:]C?K3#-9^V04IV6GH'I
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MLL:FQNHFZKC>5M_CU3U2CZB4/%ICW"//\KNKM>_/GJQELCLEP$^S8:]^AV]
M<08\Y22J+N8 [CP/2N31K5%T)8#85G"(MS/A>3!1OAD,T+GNF1/=*JOM5P;F
M++PXXSOS=VH2K>Q#]?Q?]U7IO.[_04>>)LL*WPM/4/F=#/INI$EM!0>C@/,&
MQF%MP6'2,(]:7ES.['LN.%%6$,P;OZO#O%8W@ Y3"\!%/L-&,I0*#O;_?M<(
MHHKE+]\[?O5-4^*VY7XG1YO4N8?.^BH+KF@E0__MZ_>LRSLQ-V]I46>S9;]T
MED5=]/Z@E7<!)1XH)T;>'_MR>:3]>.N2S5&IP@WXR<N^>9)1.T:K[1=B:8$?
ME,=K?:HU_[1!/Z2T3(8-UWO*?(R!K1X#FHTT.&CS-NA>(.:Y)]#ES%R6S#=T
M0<@!X]:>S;*"/X#H%R%+V U'()*WYLG/9$\CY&@:L#@] 69O.7<.!N]=Z<KW
MZ5R/FQO+QZ#;!><WXYN-L.,,EY_B8/MW[9)'7W F3)H:.FCB[QESN9\<,:JU
M"1,DB#V04H[R&-\;?J76T)X3G1E>#"B?Y>D\&#/J0WCRA33RB^&1._AR -&.
ME^,7SLQQ8MQ'/!&2V"(OGE\S>C)_YQ-NNHR]@MFG=%/VH828]OLU-ADT*+I1
M6=VU'V0W#>V669/X"FNE.4[ &3!9G$$UD"^32 ZKF$E7%03PQ]M0$OTE#4^N
M]M/<M/.T2J@;OMY>C\H[5C-5V^\&UDK]O/8FYQ9ZS0$4.]LK OV!MQ(<*RBZ
M68)4B5DEO1SU1K+]<H+"7TQ[Q\WV>0][>GJ=63/-J8LT5(@?8S+'CNJ\*?#P
MY":IVP:X:2)9IR>EM=<0O)QD(SWCY6"J&HK!9F;ZZR0NA_-E$OJ7+@Y4H?7R
M?'O5N7WA3?N=# C(*>GP&\:J$.C'+^>TEQ2V)?$0'3)QX[*J%](9T$-(S8$P
M-+@MYR3J-C@1IV,(H-K 2!5P4N5S?N"C0L=R .6.,J<,",Z6EHRE1VK1^ABW
M%S6._*2DJV+!OF)ECE,LGF''+"0+Y/4S99*-C((<YXXYW;*ELI;))[63C=XX
M-JFO]O\*J(G^JS MS'[LJ/T#/!X)?FW;/G<ZS%H.^[O C)==PA.!7%-6 UEX
M7=Q9()67TW:;'+>,D0]6H37LK9[LD9J^36:D[]*JK7D>(E0";JEG<=,EV\D
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MC ?#-^U%(*\S() 9"+3P=LVBO\^A*=*K\\N%BY?Z4!%?V6AJQ*232W$>^LU
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M1-O-^?ZZ3AG18(_![$^TW7[DT.C7^TD*5C19X06WK983#T=.OMFW]Y8;Z_S
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M^$<G7#F<J7]_T K^O7 F4)>%C#Q[O)M__W:\LRXG&W)^8-0+)QSDS(</F6G
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ML7558L/& ]QNOH[:N9;4V6)$S:0J-OPY$Q1622]4-##U\DXU =]*'KFK#GR
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M+FAT;5!+ 0(4 Q0    ( .N!3%HR,< A:RD" *.0(0 1              "
M 7=&!P!A<VYD+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( .N!3%H2G;\V_"T
M $?S 0 /              "  1%P"0!A<VYD+65X,3%?,2YH=&U02P$"% ,4
M    " #K@4Q:FIZXH" (  !H+   #P              @ $ZG@D 87-N9"UE
M>#$R7S$N:'1M4$L! A0#%     @ ZX%,6F F\B45"   8BP   \
M     ( !AZ8) &%S;F0M97@Q,E\R+FAT;5!+ 0(4 Q0    ( .N!3%I4."8^
M-04  *8:   /              "  <FN"0!A<VYD+65X,3-?,2YH=&U02P$"
M% ,4    " #K@4Q:<&L,SS0%  ##&@  #P              @ $KM D 87-N
M9"UE>#$S7S(N:'1M4$L! A0#%     @ ZX%,6CDF3@)S P  G0P   \
M         ( !C+D) &%S;F0M97@Q-5\Q+FAT;5!+ 0(4 Q0    ( .N!3%J*
M'^$ #W   )MK P .              "  2R]"0!A<VYD+65X,E\S+FAT;5!+
M 0(4 Q0    ( .N!3%I1S<"J^J<  #?;!@ /              "  6<M"@!A
M<VYD+65X-%\R,RYH=&U02P$"% ,4    " #K@4Q:% N3M(VA  !Y4P@ #P
M            @ &.U0H 87-N9"UE>#1?,C0N:'1M4$L! A0#%     @ ZX%,
M6CY=+XHG#   &&H   \              ( !2'<+ &%S;F0M97@T7S(U+FAT
M;5!+ 0(4 Q0    ( .N!3%IW)O3:400  -\8   /              "  9R#
M"P!A<VYD+65X-%\R8BYH=&U02P$"% ,4    " #K@4Q:5,!P)&0$  "R20
M#@              @ $:B L 87-N9"UE>#A?,2YH=&U02P$"% ,4    " #K
M@4Q:,H2!6.\, 0 N' $ $@              @ &JC L :6UG,30X-3@V-3 P
M7S N:G!G4$L! A0#%     @ ZX%,6AHEF9-$=00 7>4% !(
M ( !R9D, &EM9S$T.#4X-C4P,%\Q+FIP9U!+ 0(4 Q0    ( .N!3%HQ_K9,
MR% !  EY 0 2              "  3T/$0!I;6<Q-#@U.#8U,#!?,BYJ<&=0
M2P$"% ,4    " #K@4Q:'"VS*XK=   (Y0  $@              @ $U8!(
M:6UG,30X-3@V-3 P7S,N:G!G4$L! A0#%     @ ZX%,6L?PC0VQ" $ _0P!
M !(              ( ![ST3 &EM9S$T.#4X-C4P,%\T+FIP9U!+ 0(4 Q0
M   ( .N!3%IY'(FP",$!  3O @ 2              "  =!&% !I;6<Q-#@U
M.#8U,#!?-2YJ<&=02P$"% ,4    " #K@4Q:(1"DOAP8 P .G@, $@
M        @ $("!8 :6UG,30X-3@V-3 P7S8N:G!G4$L! A0#%     @ [(%,
M6DDR/@^:R@$ KO4! !(              ( !5" 9 &EM9S$T.#4X-C4P,%\W
M+FIP9U!+ 0(4 Q0    ( .R!3%H,GB("']8   [O   2              "
M 1[K&@!I;6<Q-#@U.#8U,#!?."YJ<&=02P$"% ,4    " #L@4Q:@  *UD$)
M  #."0  $@              @ %MP1L :6UG,30X-3@V-3 P7SDN:G!G4$L%
3!@     8 !@ V 4  -[*&P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>asnd-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:asnd="http://ascendispharma.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="asnd-20241231.xsd" xlink:type="simple"/>
    <context id="C_802fb420-5428-493a-87b7-02e34b108386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:BoardMembersOfGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_809a9649-b6e0-488d-b7e5-4e1442b1f755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_80c10e22-bf47-4313-871c-4161cd400123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_81e30392-2ae2-46f2-9e52-85bbd8e7a714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_81e385ec-89e0-41e0-9a86-a4f0e9abe54c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaSverigeAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8254a47f-7720-4dbd-860f-ccd3f90e8bcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8373ab39-153b-4580-8eaa-20b64be0b669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_83fd201b-7c83-4ee4-a0da-02d9df8447b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_842cce4b-c4af-4a45-9074-b4aeeba66138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaGrowthDisordersASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_860b08a9-36e4-40f6-9b25-30137702ac03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8868a6a4-46c9-401e-8496-50e9fd14cdcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_88ae6c08-23fb-4240-bf5e-678082269ff6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">asnd:USDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_88ae85e5-4346-454d-9c63-a628775940b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_890d9573-96a4-4975-ad2a-83e24165cf64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_899ab35b-66a6-40e5-96b1-211674a39c3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8b7cf227-3c27-4452-bf1e-f4d1f142fedb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8bdc1384-8c1b-4199-954a-92a67517fd1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8c791550-835c-4e22-a26b-97ea8127f804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8cdbb2f3-5894-447e-9e13-0a00148c6b78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8d641cf8-4f3e-4466-b341-181115f04c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8d88cc9c-27a2-4ff0-b63b-b1a040391061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8e586c11-342f-42e1-8ae7-79f86b29e744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8e72405c-35f1-4928-85aa-52168ce828ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8ec23a67-4cba-4228-abd5-b5b3f4e8d2dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9076fd44-ae75-413e-8321-bdfaee1f0a4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_907adb7e-5f6a-4552-b8e4-ca87be7ab73c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9133c0f6-7b07-41ad-a86d-58e8adc23e5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_95c2771f-cee1-4eb7-beba-a54cb5701188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">asnd:OfficeFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-20</startDate>
            <endDate>2022-02-20</endDate>
        </period>
    </context>
    <context id="C_962ef1c5-8d47-4bc2-b07c-320d06c0970d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_97992a0e-7ccc-4554-a974-5d01c776b4ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_99479b14-1e7c-41fa-833c-83e794f18d01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9952b4f6-b45f-4d1f-886d-8e1f0d262e6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_99536d97-e9f4-4fd6-9215-dd6f7d4b7755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_99a808e7-1efe-471a-ba2d-6422ec451ea7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9a087241-0b3a-4cac-b087-23c132bb156a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9a3e4976-f3f3-4e99-a326-5bb0cb57fee4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9c347efe-55f5-41f7-aa5a-2ffa52fa30b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9de36237-7daf-4d9a-ba1a-4f2827faaa62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9e598379-6e17-4151-b88c-4b34a9189ddb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e913d68-9472-471d-b85b-01401c7287b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9fb94f08-5f01-4b31-86eb-19c1c44186e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a04879c9-d225-42da-8adf-2501801d997b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a0ccec1e-9a89-4166-b4d2-16f6ff5ce9da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a10a1719-791f-4cff-8b86-2f3b720e2290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a18ad5cb-63e0-41e5-a54d-935b4eed3032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a29fcdf1-c976-4997-a302-2bd939c278f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a2de7ead-6804-4136-a02b-31e903c48f97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a34d3224-7646-4cf8-a9ef-f7fdd1eb668e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a4416a56-3759-43a1-a9b2-a168da37fe04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a71bc062-4b22-4a9f-b52c-19753e5e74b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a75c561c-801d-4844-bed5-502cc157a1d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a91db531-c49c-48c0-bb87-a56fc4db3411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a9a130e0-614f-4ba0-8504-fd5085a02099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aa8178e7-5d8d-4ed1-9503-6b67ad186cec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_abc0c365-74db-4b23-b2e7-0dd10c9811b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:EntitiesAffiliatedWithArtisanPartnersLimitedPartnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_acb528c2-5f7d-4cf9-a36c-de007de3786b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_acf61556-e87e-41fe-93fa-052e2f231a3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_adc00162-0324-4973-874c-008dcc36d3e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ForeignCurrencyRiskAxis">asnd:UsDollarsToEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae50ae32-8fd9-4440-ae86-c935aac5e3c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ae64dc13-b337-4595-88a9-3361adbfd7eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ae91164c-7a61-4403-923c-7fc72b5f637e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_aee0a664-90db-4cac-b252-ca13f6feb6bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_af321344-ada0-4c87-bfd0-d2a98cd2590e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_af95c18d-a439-48f1-b6d9-6b5ef3fa583e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b0111fc8-8791-4de0-8ed0-9f981def15ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:ExecutiveBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b03741b3-c7aa-47e4-82f2-f5538b555142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b0636a60-1301-4427-9e48-8459c64a7333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b1595989-ee89-44d6-aafc-6d121568fc57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b1966962-eeea-4f7a-8501-53f2cca4ab33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b1fd592a-4621-4c11-bdbc-d9f0a9de718a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b27a3e9d-f494-4d9d-bd82-cffda92ba702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b3502041-2bf1-4ab4-81d2-63ddd7dc8027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b387065d-0625-4be8-ab94-2a3823e3c97f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b47e07a7-681a-4a20-87be-95dd4075cfa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:NorthAmerica1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b4c60161-4bc0-4ca2-859b-eb4baf374e64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b54750ee-5812-44ea-a167-8b84bead592f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_b870ca23-2010-47dc-89f9-9194ace53db0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b8d9ea02-e435-4914-b63c-68ab0e65dc37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_baadc1e0-f0c2-4168-8df0-bf220f892569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bb236f3a-aca3-4607-b4e7-a59b9fc6910f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bbd12530-7f01-426e-9852-87ca70290753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bbdc53c3-a7cf-4fbe-959f-538eec284f61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bcd65bae-11a9-4b6a-b98a-ae8d9426e936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bdf66293-e3a2-42d2-b55f-314d364082f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_be71380a-a9fd-4b8f-a8ae-7f8c29ba0800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bedad476-b3c2-4ee5-9d07-5861655b6c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c0c25b57-fada-4810-aa6c-9f3de313c6c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c14c8f3b-ece8-4326-a6b7-270fcafc68bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">asnd:OfficeFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c1719aa5-a73d-4b30-a0d6-6c4e89f62175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c34a3e33-ac79-402f-b220-5f595dd5eff5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c4078876-b7b4-4937-95c6-d2ea84904d2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c590a703-806b-44d7-bbfc-d91f2b5829c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c5d54e1a-4387-4b3f-9267-06a2d3748214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c6d5894a-3b43-479b-98c1-26c26fcd5ea8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaOncologyDivisionAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c82c67d1-a374-44f7-a579-4e1e136065a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c85c746c-f722-410b-b4c5-502ed85c8382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c8c66292-7409-42ed-b072-96cc8d5b02e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:ExecutiveBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ca101549-cece-44e2-ba4d-877e6b9eb760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ca9626d8-b4fd-4cc7-bdcd-fa03f5df98d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_caa0fd3a-8a0c-4ca4-8011-0a2b36ac28ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cadf2de7-5782-4672-b259-cd1aa743fad5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cb788b59-28a4-4544-81e7-493092e53b2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cd1cf60b-5c30-41db-bb07-b8145572e517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ce3072bb-3b3b-4d2a-bccb-396e6f23ec7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ce33c6e8-bd62-455a-8699-8dfef4b1bdb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_cf967fba-0da6-4929-9134-641e84170ee5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">asnd:VISENPharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cfabba9a-1d15-458c-ad60-0eb6d48d0908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d0434620-73bd-43f1-9192-7bca1ecaf642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">asnd:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:NonexecutiveseniorManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d0e6faf1-bbd1-4b27-8ddf-0087e182b6af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d35422da-96a1-4b03-a5f4-c8f5b78cbe7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_d388a1d4-7923-4886-87c3-db6a6873ba8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d3c3de28-899d-4a79-acfe-c562d328512b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d4f709dd-434a-4841-ae2c-e267badec1c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_d556afe9-f715-43bc-a19e-5d09f686c664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d615a83e-1e17-46ec-8765-e218963f27dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d7878707-fcf3-4173-a198-76e206226458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d8c37193-f5ce-4085-a584-6f5700a291cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d9262209-f85f-4e2f-897d-34d234660e65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_da8aec68-6586-4ef6-93e5-b5045f7afa40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc3e7a3d-39f1-4a98-b6c7-22b916d6a2b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dc50b8f4-013f-4948-b862-ea14c2c8fd6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_dcff91fd-f804-4f83-86d2-4d7c9b912c4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_de19d30c-2832-4cdc-86a5-8ad0e3007775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_de89026c-3236-40fc-8ba9-ac03b1732258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">asnd:OfficeFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-20</startDate>
            <endDate>2022-02-20</endDate>
        </period>
    </context>
    <context id="C_df13e31f-e944-44b8-beee-0157e82a5356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_dff571ea-763a-4c63-ae50-c0952c31cb00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e06fb832-2f86-4a43-92b1-f2a822f36e49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e160c34a-290e-4f9a-863a-46afc6a82950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e223f34a-d64a-4201-8c13-a2f49a7b3064">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e22f7140-0ffe-4e0a-a8d2-1e98ce4c62eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e25082d1-732f-40fe-9427-652d8be5beee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e29b5f04-553f-4038-b41c-77cb6a63aa4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e33638fe-cef5-4937-a3e7-51501477ed4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e3aa91fe-cef2-4bec-ad73-cb9c151bddb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:AvoroCapitalAdvisorsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e44fd0e7-0d85-4f4b-ad6a-35d537142fea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:OtherEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e49c3b45-39cc-414c-9238-0fc9d4cf659d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e4a0772c-d105-4d5c-9ccb-ae5d02f8ddb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e5fb59de-879c-4977-985d-bba088bed9ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e63719c7-8c13-464f-8f95-1d2f452eab96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e8188af8-6919-44f5-81ea-b527b574937c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:NonexecutiveseniorManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e89a7181-8fc3-4108-a58d-ec31314fe7a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_eaa235d8-4b02-4581-b70a-16400278b006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ebade161-c91e-4828-aa55-97f5b6c7acab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ed783084-e2f1-44fb-b106-1b2f859597c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ed8dd2df-2263-4f73-959d-fdeab1aa780d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_edbced58-0020-4b9f-b70b-56ced58a8fef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ede99a4e-c051-431e-8269-8505ec9267f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ee56b8dc-dcf9-4371-a111-224749172b3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaIberiaSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eea8b977-0335-4240-bf23-27c15cf887d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">asnd:SalesDeductionsAndProductReturnsInUSMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eede36b7-749c-4397-a6fe-904bd2d680fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_efbe723b-7de5-4c59-b063-c40de816c3c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:NovoNordiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_f0eb7759-5474-4185-9c25-f280c2655d1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f11efc41-6c49-4566-86fb-9cec96206a41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f1426637-e196-44bf-aad5-b8473714e9cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f187930e-0517-474f-8e2c-b180dcc37681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f1c55158-db93-42ec-aaad-60afdd713f36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_f1f075ea-35d2-48db-b997-3ec5409d09d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f2f1dbaf-420a-4683-bcef-b0e869189327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f4572716-6c6a-4a6c-bfcd-471d23516aed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f52014a4-e011-4fe5-9aa6-e94ae66aa8c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f52b4a1b-71e1-49b5-9cfd-93e6bb5fe135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f664c695-e007-4c41-b59a-806a6f163104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f6aae539-4c18-4dfe-8da2-d2171008ea12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f6d717ce-7ddc-4b83-a7fa-1c03e30a43a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f7ae32c9-c10e-4691-be89-cfbdb2954133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f7c738af-0b0d-4113-8fdf-04db859fac4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">asnd:SalesDeductionsAndProductReturnsInUSMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f8b920cb-268c-4f19-9195-5e81009361e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:NonexecutiveseniorManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f960e0c7-e224-43a0-8029-5e940f7b7580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fa515c36-ae39-4b8b-a4b2-2f0389428d27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:EntitiesAffiliatedWithRaCapitalManagementLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fa785ab0-f0fb-4f0a-875b-f650331743e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fa84436d-cca3-4949-bad3-f7258a333f34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_faa6d408-e3a2-423c-9170-2e7df293488d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ForeignCurrencyRiskAxis">asnd:UsDollarsToEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fc853c6b-d56e-49d4-8dc9-d729edce2941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fda59e11-28d9-4e33-b9c1-3a2479007ef5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fe0a0e9b-7ab2-4d20-a211-cbee6ffa77c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_feb4fcb6-91c3-427b-a969-26daa054341f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_feba8166-348b-43f4-8af8-7e1499e6fa81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ff216df6-44c5-401c-bf8f-32cde3f221b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ff4b86e7-7c5f-4451-a272-76662d19dc47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_005327b9-9514-487d-af81-293c04b4477d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:EntitiesAffiliatedWithJanusHendersonGroupPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_01ae896f-3989-4a7c-b794-121862812d86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_01c97f44-492a-483a-8df7-8e652f65a658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_033bc73d-e8d5-42c6-ac92-2eaa55a1e3f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_04565d75-339f-4b1f-80d9-f0daababe60e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:GrantedIn2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_056508e0-3110-42be-99e5-6e860f20e4ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_064343af-8b3e-4e2a-a81b-a1a721a1cc58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_067306de-0170-4c89-8d3c-7bb661db3689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_06c5062d-ba03-4445-bb86-eada28395df3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_06c71b52-a8d3-4d87-bf07-1b59116e44d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0872112c-3272-422e-80db-297cf18bfc6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_09099e4b-a592-4705-af54-4663f508c0b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_09e22d4c-5ff0-4832-b86c-6b6f62d31ccc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0a586051-2c0f-41e7-b728-a06658a765b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0ce01933-8d1d-47b9-bd72-1cbedc695da5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0dd10c76-089d-41db-b834-45504dc6b09e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0ec0d4cb-d376-4f19-aa95-a67c8572996a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:BoardMembersOfGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0f2a0f3d-caa6-4b26-aaab-9aaaa98975ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1023a06c-46a7-4e4f-9c42-a6c64923b098">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:GrantedBeforeJanuary12022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_11acfac4-6200-472e-926e-c7090b67f933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_12093c28-729f-40fc-bcf0-fb862cb3c696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_13311653-2a29-4400-a0d0-0f4bd2ca8d98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_13fbb09d-e7fc-4533-b7b0-f7775229adc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_13fd56c8-1e8b-413f-83b9-57936192571d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:EmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_149a0f63-60f1-4bf3-a3df-4dce7568cfc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_15890a8d-80cb-48ce-91a1-44903b524f91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1668bba6-5e09-4a0b-b002-c5fc87f94355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGranted2012UntilNovember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_16b2d798-c4fd-440d-9eb5-813b6bf52dd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_16d1bca8-ddc8-4770-922a-085d984adaa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17f4bf17-9d0d-4701-ab69-f29d52ef6948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_18e923c0-37b2-4527-b1aa-aed2087ad549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_198d936f-6bd1-467c-a662-6a993e1856a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_19fef29a-9741-4124-9e26-bd7da6782741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1a2f2ecc-ca46-4afb-a7cd-7481a3e39b7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1a5af062-57bb-4ae3-b3ed-605c63a78bb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1b8ce618-fe68-4762-9808-37cbe7002b0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:WestfieldCapitalManagementCompanyLPUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1c7b2ee3-857c-4937-90c1-54e53d319288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1c836450-3243-4763-a839-055b50eb15c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:BoardMembersOfGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1cc8cf22-cda6-4602-8545-8e4460115453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1cf2be05-dcfb-45c8-9384-2927abeec697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1e102ae1-1402-4ff8-81ac-0692bcc874ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1fb6099b-b6a9-4b5c-bd7a-11c2717591ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaBoneDiseaseASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1fbabba9-e169-4afa-9ccc-063e93641d68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_207ec930-b486-406c-b0ae-aba7cbf1c9d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2095e981-5419-41f2-8101-1fb2cbaf9c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20d58111-b66a-4385-8104-172f2b4acdf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2177e743-fed9-4015-b87c-ce85408638ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_21c7c051-dbdf-4831-9602-654f3d0b55c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_223c5789-12ac-442b-9056-83ed832b3d73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_226c442b-8147-46aa-8d42-d133bbb66af0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_232653f8-2ada-40f7-9e2c-695fe89927f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2390a6d0-d171-4a09-ad5f-63eca2811521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_242430a3-5c4f-44b2-aaf8-4987e49091d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaOphthalmologyDivisionASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_261c864d-d4ee-42aa-9967-1744c5af33fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_27d1c1a3-108e-4619-be6f-517ff8d95133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_27f6fcda-5a1b-42d3-b991-c9dc1d11267b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_28990820-f3d2-4e15-9edb-17e010681d57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_28fafa94-b070-4d32-863b-5393bdb99f92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_290761ca-44a9-486b-94c7-76f97082cf35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_2a779f6c-3cd0-4eeb-9e62-6c93f2d9b872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2aa2a1e6-92a1-4029-9027-67625a630a7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2b7ffa79-9374-4323-9f4f-2e90fd4a0ef6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2bf202a7-c410-46ac-9503-77f09f3365ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2c4ca528-c486-4e2a-a517-ae7410edc2c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2cc5cf2b-65b2-4978-a13a-8486ba2a64ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2d560ff6-c2e3-4c74-9daf-9f9c9310753d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2fbbee2c-6ce9-4cf9-b0ca-0215da8f8db4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2fbd9ed0-f949-4f61-a72f-c83438fb93d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:NovoNordiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_30407527-3185-4f61-a488-03f2f38c8ed3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaEndocrinologyGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3069879e-b2eb-487f-8359-3b2b3ac38c1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">asnd:EyconisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_3168c70b-da00-4f8f-8797-f6fe0d465589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_334ba08e-f8aa-49c1-ba15-fe73942f5b92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesYorvipathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3421ed33-b354-4de8-ba6c-72beee95c70a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3566e5f1-2b87-4f68-9039-a9df104b1f9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_358f6ff6-9ffa-4fee-a3d7-9f7f0de3c554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaSwitzerlandGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3661dd57-860c-4ba7-8646-271ddab5954a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGrantedFromDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:ClassificationOfRelatedPartyAxis">asnd:EmployeesAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_368d07a7-0ac6-4e17-b820-a12da4602974">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaEuropeASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_368e4795-3132-443f-a38d-3b93be4d5965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_37c216bc-caec-48d1-a992-8f1efaf4610a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_37e1d239-86ce-49d1-96d5-a76ae721217a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3816caa9-d60e-4738-924c-a8108f43fcb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_38539fb6-76a9-4121-aee9-0b1245ac6af1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3925fc10-a57d-420c-9fea-0099a4bfa974">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaUkLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_39ca7b17-a1b7-43d1-90e6-efe3a598d636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3a4c34db-9705-4e82-a924-1e8c85b0d587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_3cc100f5-a109-47f1-b3b1-58aae09fcce4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3e1079df-bb69-43bf-854f-2f912ce24f92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ForeignCurrencyRiskAxis">asnd:UsDollarsToEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3ebd12a3-760c-4570-9d25-6d885ea5aee9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3eec860a-880d-4d1a-8ff7-1ca361a35484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3fb58189-b760-40f5-9cd3-b00fa343a398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3fbba848-2455-4bc9-8198-43983057fc5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_407f4eb6-3395-4dbf-ba53-ec52500920d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:ProcessPlantAndMachineryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_41603f99-a66e-44cc-8e76-6000fc1c3438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_41772ede-2e6a-48e2-9da6-829133e5685d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_41c2635e-b2f9-4eb1-bb72-637889040d79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_41e4375f-476d-430a-af3b-9f5b61fe72c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaEndocrinologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4321d0de-54cc-473c-8f2e-2c4823e23921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_45262f50-d25a-4678-b31f-4e249ad2d3e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_481783fd-70ee-498b-bb3d-a524d1a98f13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_49956232-8f1a-430a-8b06-3dce7628da9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_49d4878a-31c4-4c19-8814-8507aefe88cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:ExecutiveBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4b2b9d36-6d18-4c57-b0cf-ce1f8e06c2d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4bdf2506-3db5-4bb3-83af-af102c9194d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4bf7540e-9443-41e7-a47a-27a0973802ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4d1a30fa-1a02-416f-ac4b-3fd4e5452e6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4ea532ca-6e45-43f5-a284-db382e2c5785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:GrantedInTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4f2fa65c-bf90-4026-9207-c814f7259be3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_4f865b62-7fe6-48cb-a856-16fdbcba2ac2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:NorthAmerica1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5089591b-f114-41f5-b652-8a708640665f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5123e0db-851b-4c25-82f5-35f4482ea47c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_5268a2fe-772c-411f-b537-63cfb4081aac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_53acf53e-ec11-4160-8b53-30c8a273f237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_560f9631-6b06-4d31-b7a4-554f86183c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_569d3447-2d47-452c-82a9-30b1fb7255bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_56b18c35-7b90-45e6-8446-e4893174d8bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5704c912-f30b-4de5-815d-6a09d374ba34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_58152c33-7510-459f-b8e0-76242c88205c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_586a6210-5549-40bd-9d66-c8900f389cc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5906116e-01cd-49ba-bcce-49cd3733e697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_59c262f0-8854-4bf0-83be-ade20e2ca796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_59c4cbcd-b4e1-4274-bcd8-37e7ffa78cb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5a3d122d-f872-479f-9175-de42cc96d53a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5a4ab42e-9a10-4f66-a061-557f147450fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ForeignCurrencyRiskAxis">asnd:UsDollarsToEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5ad9dcf6-e1be-4e09-aa88-8cd0c222bbea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5bb64963-abad-4e25-ab29-a2838c4dfeb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:EntitiesAffiliatedWithFmrLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5c050805-6399-4923-924c-dd423a9d5ceb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5c780cf2-8af2-49bf-b6f2-420dbaa22f76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5cafe9c3-115f-42e7-b1fe-9c5f8f86ddce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5ebf1592-e85e-4a79-a0d3-03fb135c3e71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5feef7fd-c380-41ec-b991-b148e59ce71f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5ff345a3-c70a-47dc-8ae4-ca0d2489d12e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">asnd:USDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_600ece57-712e-4eef-9dfc-9e4fee4bc4fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_606a172c-a572-48ab-a9dd-9b6578193b08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_60dcc078-2bdb-4155-9a0b-c75618972125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6114a2f7-6ec9-4c7c-b156-f0fa2cd47f7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaFranceSasuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6143b456-2c40-4d0d-b967-c6ff15edfac7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_614a19b6-1595-4cfe-87c5-0d0f93542d8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_64cd1be6-0716-4e13-b266-fb646a8370c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaEndocrinologyDivisionASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_653f32e5-e4d2-4129-866f-b2bb9319ac6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_65837925-044a-445d-bd2b-f455d164b262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_66ac9391-e29a-452b-a56e-75aa88249b65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">asnd:EyconisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_694aa851-7e2e-42d3-96e9-18ff2f6e9d67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_69523622-60fc-4677-8a69-32400c599999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_696a9b0f-6d34-4970-b7ae-11c29efc2267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:ProcessPlantAndMachineryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6a0a5caa-b991-40a9-a3ec-b387124678ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6a56e38a-0002-4f9e-838d-06508b6db3f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6b2baac5-581b-4df4-9270-e2e0408d280d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6bd94bcb-874a-40fa-b4c0-feb805cf48ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6e4e8da6-c1ef-49a7-86f8-5273a8cae8d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6f53dfac-7f4f-46ee-9afc-402949c6590a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_716e887c-c3f0-4b61-9538-8f3e8a6c55f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">asnd:VISENPharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_73e96a30-9b6d-4a88-a50d-298076e408f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:OtherEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_73eda4e7-aa61-4748-bc17-dba1d8cc2584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_743e733f-a355-45f7-b231-d9ba29e7a99f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_74e6cf72-5a9f-4f1c-832e-143795728beb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:GrantedIn2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7571783b-8274-4446-9034-fc8030ee4785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_75afca32-d330-4c6c-a9ea-5bd565d35e9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_772d30eb-6104-4b18-9139-ee54a0993371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_774802a0-e760-4cd3-bbed-f1a84d8730e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">asnd:USDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7905e7f5-2269-4e2c-bda4-a38c3e7ce9dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_79b3b481-791c-4f9d-93a9-e3bfa50ce43f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_79e45519-2936-42c5-9260-a018560072ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7a48f51e-d7c8-4ea7-acf8-8fd05459ee2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7a59ec21-ecbe-4301-8893-0be00de06cef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:StatementOfComprehensiveIncomeProfitOrLossLocationAxis">asnd:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7a98677e-a082-47ea-899e-37bc59fd1b58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7ad7edb9-5f0b-41bd-a762-0755697fa11e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7af1f25a-54be-46a2-a19d-533e859fbdd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7b687297-3e1b-4c67-8d9f-f309d8615de2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">asnd:AscendisPharmaItaliaSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7be35a31-a654-4c37-9e6a-3b77cff84b05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7cb30aff-4382-400f-aea5-7f16e02f70c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7d04bb96-8341-4c18-bd8d-f80c0f0f0430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:CategoriesOfSharesBasedPaymentsAxis">asnd:WarrantsGranted2012UntilNovember2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7d30fefe-a9c7-49d1-868a-e9fe7915fa00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7e301002-0bf6-4196-80df-8e9527a1f352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7e41aefc-f66a-4182-a859-776c8cd1970c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">asnd:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7e7e620d-71e2-4c5d-bea4-731d5ebd213b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7efbf712-b44b-41d4-8aa1-40e3199ec917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">asnd:ForeignCurrencyConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7f2fe9bf-d689-489c-be69-cbf182477f84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7f3a1b06-4e11-46ed-92ce-904b7a6a233b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Days">
        <measure>asnd:Days</measure>
    </unit>
    <unit id="U_Segment">
        <measure>asnd:Segment</measure>
    </unit>
    <unit id="U_XBB">
        <measure>iso4217:XBB</measure>
    </unit>
    <unit id="U_Y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_DkkPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:DKK</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_CommercialCustomer">
        <measure>asnd:CommercialCustomer</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Multiple">
        <measure>asnd:Multiple</measure>
    </unit>
    <unit id="U_EurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Employee">
        <measure>asnd:Employee</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:NoTradingSymbolFlag
      contextRef="C_d0434620-73bd-43f1-9192-7bca1ecaf642"
      id="F_79aff695-ba3e-4877-855d-965b2bbc4f62">true</dei:NoTradingSymbolFlag>
    <dei:AmendmentFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_248eefb9-7521-454c-9b3c-9a1e89150e7f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_15aa6fee-b1a7-4e81-82af-61b80378d3cf">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_c807c7d7-9a5b-4210-a450-51316b53fb8a">0001612042</dei:EntityCentralIndexKey>
    <dei:AuditorName
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f487bf8e-d837-43ab-b0e3-34496c9a8875">Deloitte Statsautoriseret Revisionspartnerselskab</dei:AuditorName>
    <dei:DocumentType
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_062eca23-28d3-4fb9-9904-0f75070ffc1f">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_7658db8d-01a8-4c8b-934f-498ff5ee66b6">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_55d2a485-1e34-4633-b3fc-5b793e5f5ef3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_b86ac277-cb11-43f8-9f7d-dbb0b1682957">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_9226a83a-8bc7-4d0e-8741-6f970aae7107">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_98dcaae3-fd64-4f41-bf8b-b6a6e67a9d4b">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f976769d-70ed-4ab8-acac-f9220998cb09">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_bc175d5f-81ab-40c2-b853-0a8be8c6ce69">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_6f4daf37-059f-4ae5-85b4-71c1eb76fa2c">001-36815</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_347d7e8f-a8b9-4062-a8d7-1d328c6141b7">Ascendis Pharma A/S</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_398aa369-698e-406d-8346-37be778566b2">G7</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_81a7d00c-e000-45cb-a8f4-42d62b2109ec">Tuborg Boulevard 12</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_bc216ab5-c002-49e2-a5c2-c598266d2c76">DK-2900</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_31a4ec3a-14a6-484a-ab60-25b261014172">Hellerup</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_49239040-d625-4684-b431-1a142d6fa5c9">DK</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484"
      id="F_96be01a1-7a2b-4b84-a837-fd3532e68f12">Jan M&#xf8;ller Mikkelsen</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484"
      id="F_7ff7728e-8c9c-4fa5-a45e-57c9d7ed40f3">Tuborg Boulevard 12</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484"
      id="F_f77e7dad-4165-44c2-954b-c1095da26ff3">DK-2900</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484"
      id="F_a50715ea-958e-46a1-8775-d61213690866">Hellerup</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484"
      id="F_00516d2d-5a7e-4f44-930c-fb1bcfc76d7c">DK</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484"
      id="F_963efabd-49d5-4d56-871e-c310907ff7e2">+45</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_3eec860a-880d-4d1a-8ff7-1ca361a35484"
      id="F_c3d24f44-af51-4ac1-b8c4-f18a681dd7f0">70 22 22 44</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_d0434620-73bd-43f1-9192-7bca1ecaf642"
      id="F_9401645e-142c-43dc-8d23-a976f331dd87">American Depositary Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_7ce2cf68-65ba-4026-9cd6-ca596af792d0">ASND</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_d0434620-73bd-43f1-9192-7bca1ecaf642"
      id="F_b8daa188-6941-415e-bcbe-fee28efcd0a5">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_bb917abc-69e2-4944-83cd-aef470fe655f">Ordinary shares</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_5969f263-f298-4f36-90f0-229d885a351e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="INF"
      id="F_a5663288-ac11-4e7b-9a0f-a9154df1ae32"
      unitRef="U_shares">60689487</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_7d15c8cb-c7ed-441d-b58c-20571366e834">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_db9e8d1b-a481-4d83-a58f-3e95d9f40db4">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3c74f7e6-5354-4d1d-86f8-19b282e05253">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_4c3f7e24-6b15-4337-babc-2eb15db5669d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3d8ea4e4-3e65-419d-9e07-352e5f81f6b4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_57881f63-3a2a-4d90-9a13-f7be1264b562">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3fbbed3d-e616-49c5-a0a4-c8607b7c28c5">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f0afb559-d48e-41a5-9613-c0b768b93a85">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_06c01ec5-94a5-4ea4-b837-7b685d30d29e">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_be1ce262-75b8-4d64-8e90-f1de1f2a5f16">false</dei:EntityShellCompany>
    <dei:AuditorFirmId
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_eee925cc-e849-4448-b21b-528831b8f9e5">1294</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_4328e719-b7cf-4ff8-90ae-080d3d630eb6">Copenhagen, Denmark</dei:AuditorLocation>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_9d561ef5-e0fb-425a-8ce8-a4eaaa9a6bdd">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f6edaa66-6a2e-4b8a-afd5-de4736af87b3">&lt;p id="item_16k_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 16K Cybersecurity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have developed and implemented a cybersecurity risk management program intended to safeguard the confidentiality and integrity of the information we collect and process, prevent unauthorized access to our information technology (&#x201c;IT&#x201d;) systems and data, and ensure availability of our IT systems and data according to defined business requirements. Our cybersecurity risk management program includes a cybersecurity incident response plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Information Security Policy for Global IT outlines the organizational responsibilities for maintaining a strong security posture for our IT systems and sets forth the IT security measures and controls that are required to be in place. This policy covers all IT systems that process Company information. Our Security Management team is responsible for ensuring internal security compliance and for managing IT vendors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have designed our security program around the International Organization for Standardization/International Electrotechnical Commission (&#x201c;ISO/IEC&#x201d;) 27001 standard on a strategic and tactical level, while our operational program is maintained in accordance with the Center for Internet Security (&#x201c;CIS&#x201d;) Critical Security Controls framework. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the ISO/IEC and CIS Controls standards as guides to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program includes:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a security team principally responsible for managing (1) our cybersecurity risk assessment processes; (2) our security controls; and (3) our response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a defined process for registration, classification and escalation of any incidents to a named IT Incident Manager and incident response team, which includes relevant members of the IT management team, the compliance team, business process owners and potentially external vendors;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;security awareness campaigns for Company employees via various channels (intranet, direct mail, screen savers, etc.); and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;secure access control measures applied to critical IT systems, equipment and devices, designed to prevent unauthorized users, processes, and devices from assessing IT systems and data.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Governance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated the oversight of cybersecurity and other information technology risks to the executive board. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board oversees the Security Management team's implementation of our cybersecurity risk management program.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board receives regular updates from the Security Management team on our cybersecurity risks. In addition, the Security Management team updates the executive board, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board reports to the full Board regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Security Management team, internal security staff and external experts as part of the Board's continuing education on topics that impact public companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Security Management team is chaired by the Chief Information Officer and includes the Head of IT Compliance, IT Operations/Infrastructure and Cyber Security, and is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;responsible&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our Security Management team's background includes experience in regulatory compliance, cloud computing and infrastructure, and cyber incident response.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Security Management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel, threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us, as well as alerts and reports produced by security tools deployed in our IT environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our executive management that is part of the Corporate Management Group signs off on the overall strategic direction for IT security and ensures alignment with our overall business strategy.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have also established a Security Organization Unit to ensure alignment across key security functions in our organization. The Security Organization Unit is chaired by the Chief Information Officer and includes representatives from Foundational Technology and IT Compliance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;It is the responsibility of the Security Organization Unit to approve the Company's IT security roadmap, ensure allocation and prioritization of resources, and to act as the escalation point for IT security matters.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A named IT manager is assigned the responsibility of maintaining IT security across our global organization. This responsibility includes defining and driving IT security roadmap initiatives, defining and implementing activities needed to drive an IT security awareness program, supporting the assessment of new IT systems and vendors, and acting as the leader and point person in the event of a major security incident.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operational responsibility resides with the related product teams. The product teams are responsible for ensuring effective and updated security technologies are used in the day-to-day operational procedures, and for maintaining, operating and implementing applications and technologies securely across business areas within the Company.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_5a92f2d2-bd56-41f3-8436-4f585e417b65">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_c7574acb-b5a6-4b45-b668-f51683ff4812">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_7b0f09b1-2dd0-49dc-b0b3-43fae3defc23">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_450e79d2-8fb3-40ac-ad98-20913eda470c">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_7a1560a2-a921-44ec-bafb-1c24389cef61">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f4155bc4-f5d8-4b49-a902-b2a5b1737f11">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated the oversight of cybersecurity and other information technology risks to the executive board. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board oversees the Security Management team's implementation of our cybersecurity risk management program.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board receives regular updates from the Security Management team on our cybersecurity risks. In addition, the Security Management team updates the executive board, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board reports to the full Board regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Security Management team, internal security staff and external experts as part of the Board's continuing education on topics that impact public companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f6fc0155-a7fa-478b-8199-3e7ae591b6e6">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board oversees the Security Management team's implementation of our cybersecurity risk management program.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3001da85-0868-41c7-9199-0dec16ed3bc7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board receives regular updates from the Security Management team on our cybersecurity risks. In addition, the Security Management team updates the executive board, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board reports to the full Board regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Security Management team, internal security staff and external experts as part of the Board's continuing education on topics that impact public companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_b78f55f2-1129-46c9-a4b9-fa7b21eecaf5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The executive board reports to the full Board regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Security Management team, internal security staff and external experts as part of the Board's continuing education on topics that impact public companies.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_592bf306-3b7f-4af4-9f68-4f979beb8a45">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_6c28b6ff-6ada-47c2-ac7a-7ac24f1467e2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Security Management team is chaired by the Chief Information Officer and includes the Head of IT Compliance, IT Operations/Infrastructure and Cyber Security, and is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;responsible&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our Security Management team's background includes experience in regulatory compliance, cloud computing and infrastructure, and cyber incident response.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Security Management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel, threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us, as well as alerts and reports produced by security tools deployed in our IT environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our executive management that is part of the Corporate Management Group signs off on the overall strategic direction for IT security and ensures alignment with our overall business strategy.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_ec6a2b35-2af9-438e-88ee-676b4e290eb0">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Security Management team is chaired by the Chief Information Officer and includes the Head of IT Compliance, IT Operations/Infrastructure and Cyber Security, and is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;responsible&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f5aae3b5-d9d8-4064-b718-20f2c2cf53c9">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3b353c8e-6a50-49d8-ad1c-0bbcbb260bd2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our Security Management team's background includes experience in regulatory compliance, cloud computing and infrastructure, and cyber incident response.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorOpinionTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_73242443-d02e-482e-9f65-546342dac125">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinions on the Financial Statements and Internal Control over Financial Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated statements of financial position of Ascendis Pharma A/S and subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2024 and 2023, the related consolidated statements of profit or (loss) and other comprehensive income or (loss), the consolidated statements of changes in equity, and the consolidated cash flow statements for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). We also have audited the Company&#x2019;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#x2014; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#x2014; Integrated Framework (2013) issued by COSO.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <ifrs-full:Revenue
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d479123f-049c-4aaf-8af5-5efc2b59826b"
      unitRef="U_EUR">363641000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_294409e8-2cc0-46b5-b56c-19f5aea7c78b"
      unitRef="U_EUR">266718000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_7d975068-2700-4044-95b0-c7bff4bdee37"
      unitRef="U_EUR">51174000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d3fef2e0-7adb-4109-bfad-074b7f80e47a"
      unitRef="U_EUR">44258000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_3780c981-9c89-4dfb-8447-cec8332a2c4c"
      unitRef="U_EUR">44395000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_0931490f-17f9-4006-b99a-25c1722c5277"
      unitRef="U_EUR">12137000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_b1996ff4-5d9c-489a-b37c-96bbe640bcce"
      unitRef="U_EUR">319383000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_d35c23c0-2b32-4076-9181-c23d96643d1a"
      unitRef="U_EUR">222323000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_162d2e1b-556e-4f2a-b744-bc1dff426e40"
      unitRef="U_EUR">39037000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_e26b4156-a494-4348-bafd-266f57c6ef71"
      unitRef="U_EUR">307004000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_ed631726-d924-4308-a99c-014e29b749bc"
      unitRef="U_EUR">413454000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_f2f8af2a-d760-4b19-b92d-0dbd8394ed14"
      unitRef="U_EUR">379624000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_b01b3a8e-cc90-4ac6-bb73-f778fdc1b020"
      unitRef="U_EUR">291142000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_f36b5602-8c3c-41e7-bec9-d03a4ba974f7"
      unitRef="U_EUR">264410000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_bd6bfe5f-ce67-418b-aed2-521590986db1"
      unitRef="U_EUR">221227000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_72812235-7a26-4dfb-947f-852b7cee3169"
      unitRef="U_EUR">-278763000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_28263699-8413-400c-9274-a0ad8bd28ed3"
      unitRef="U_EUR">-455541000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_a49beeb6-0ce6-428d-9d7d-bf5c90c9a121"
      unitRef="U_EUR">-561814000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_392f85f4-a0c9-49ba-a76e-8d0d9f64bc70"
      unitRef="U_EUR">-20060000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_43b7da23-b8ac-4de6-8e40-04c10e912a0f"
      unitRef="U_EUR">-18395000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_5601798d-a258-44f7-babc-a6de53b4bf26"
      unitRef="U_EUR">-17697000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_da227ebf-0ea6-4c00-a864-757cc575a354"
      unitRef="U_EUR">25609000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_80c0e2e8-7fc2-413a-8031-2cf69fadd0dc"
      unitRef="U_EUR">43857000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_4533456e-1acf-40c5-8ef5-d582b6cd5167"
      unitRef="U_EUR">52181000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_42ff86b6-3fe0-4480-8d01-54d99b1713b1"
      unitRef="U_EUR">100027000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_43af2c1a-1e18-48b2-8121-2ef2f4da99ab"
      unitRef="U_EUR">44065000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_404622c5-7ce7-48ac-8840-013174932b04"
      unitRef="U_EUR">50487000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_5b1145b2-94e6-4008-924a-0ce8863e8d26"
      unitRef="U_EUR">-373241000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_dcd3dfb9-b549-4d30-9c67-2bb6b86a271f"
      unitRef="U_EUR">-474144000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_d11da0bd-10d0-42de-b92b-b15a26398339"
      unitRef="U_EUR">-577817000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_9334784c-9887-4c0d-bf05-a88efab26303"
      unitRef="U_EUR">4843000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_2b5eb706-4254-4b20-b391-64889d962588"
      unitRef="U_EUR">7303000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_b9abfd66-84bd-45b2-b0ce-fa8cf3b12506"
      unitRef="U_EUR">5377000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_3e9dd2e3-dc3c-4551-9b35-575d34a748b0"
      unitRef="U_EUR">-378084000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_157ee21d-42eb-4134-9d69-9a732b49f86a"
      unitRef="U_EUR">-481447000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_c8755360-f866-43ba-ba3a-d0c0bf505586"
      unitRef="U_EUR">-583194000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_08780b29-736e-433d-a83d-d25dccffa402"
      unitRef="U_EUR">-378084000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_4c67b775-4aad-4098-b757-3793bdb56694"
      unitRef="U_EUR">-481447000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_078e4661-a7de-403e-ba4c-b651845201b8"
      unitRef="U_EUR">-583194000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="2"
      id="F_eeb9a698-30c6-4f75-983e-484e14d29a7c"
      unitRef="U_EurPerShare">-6.53</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="2"
      id="F_04d021fc-bd78-4859-aaed-7ec4c416d762"
      unitRef="U_EurPerShare">-6.53</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="2"
      id="F_0c017cae-0227-4cfc-a8c9-2d09c9f13832"
      unitRef="U_EurPerShare">-8.55</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="2"
      id="F_e68a60c7-a818-4e25-be7f-01737411f22a"
      unitRef="U_EurPerShare">-8.55</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="2"
      id="F_3ed19d64-d1a7-4a31-9a61-6558b783b9e7"
      unitRef="U_EurPerShare">-10.4</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="2"
      id="F_a6bf4d20-4c29-4fb6-956c-d06b03898f15"
      unitRef="U_EurPerShare">-10.4</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="0"
      id="F_5af142f2-1bb4-4ef7-aeca-efe68deab74c"
      unitRef="U_shares">57891570</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="0"
      id="F_df4ae6a0-4b34-4d5f-9c35-e466cec1e95e"
      unitRef="U_shares">56287060</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="0"
      id="F_df87669d-0bb6-45ab-a330-8acae0137258"
      unitRef="U_shares">56071793</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLoss
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_5e7467ab-dad5-4969-8a28-2e5c588830a8"
      unitRef="U_EUR">-378084000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_478cb32e-45c1-4332-adbd-521502cd749f"
      unitRef="U_EUR">-481447000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_1f4dd1ce-b58f-48cb-aba8-5f70f4bd8bf1"
      unitRef="U_EUR">-583194000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_41e6715d-2e89-4c84-8f17-3e54ae9fb47a"
      unitRef="U_EUR">1062000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_8c1b86e3-073d-438e-bd0d-983a23a1b2bf"
      unitRef="U_EUR">-2731000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_1e938d78-a68d-4e9e-81fb-13276070919f"
      unitRef="U_EUR">-327000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_1391fe61-9717-494d-ae7c-b1ffa56ba76b"
      unitRef="U_EUR">1062000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_6b0bd0cd-c841-4f12-9e66-0eeb2ddf659d"
      unitRef="U_EUR">-2731000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_8c7383c1-68ac-46b5-8c62-91a794267d7d"
      unitRef="U_EUR">-327000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_7bc10815-2fa0-4205-b401-dbea256e62a8"
      unitRef="U_EUR">-377022000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_4752b908-b06b-47c4-8949-33a0429c3e7b"
      unitRef="U_EUR">-484178000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_3241de1e-a861-49e8-93e2-65dcbb131f34"
      unitRef="U_EUR">-583521000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d94b77c0-c3d5-462e-8358-9c1dc75a4cb5"
      unitRef="U_EUR">-377022000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_f1443d16-679d-4430-8012-81a59b07d8c6"
      unitRef="U_EUR">-484178000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_3cb5b562-f535-4531-bffd-485dbb6e122a"
      unitRef="U_EUR">-583521000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="0"
      id="F_a01ff934-7f29-4f12-9838-7a23d2e50dad"
      unitRef="U_shares">6204122</asnd:NumberOfWarrantsOutstanding>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="0"
      id="F_55a04b3a-e9dc-42ca-ae23-e6258a34cbc2"
      unitRef="U_shares">6523784</asnd:NumberOfWarrantsOutstanding>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="0"
      id="F_f38ba907-bea8-4f43-b5f7-0ad48cf170ba"
      unitRef="U_shares">6864011</asnd:NumberOfWarrantsOutstanding>
    <asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares
      contextRef="C_b870ca23-2010-47dc-89f9-9194ace53db0"
      decimals="0"
      id="F_2ebde4fb-8b6c-400c-b3ae-2fed14cbd720"
      unitRef="U_shares">575000</asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_99a808e7-1efe-471a-ba2d-6422ec451ea7"
      decimals="0"
      id="F_a2532e96-051e-40dd-9fa1-afba97d0d56c"
      unitRef="U_shares">3456785</asnd:NumberOfWarrantsOutstanding>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_676882a4-2d75-4638-bbd1-4dfcb9c77a31"
      unitRef="U_EUR">4028000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_9f2d3364-03ae-45be-ba44-fc988fb90336"
      unitRef="U_EUR">4419000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_589fd958-2fd9-4861-8eb2-fb211220f782"
      unitRef="U_EUR">4828000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_279a1b50-6f6e-48ae-a9f0-cf4eed42d3b9"
      unitRef="U_EUR">98714000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_622aab91-b932-4187-809f-7b78f896c4f7"
      unitRef="U_EUR">110634000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_084cf33e-da27-4b65-bb42-3f6c5710074a"
      unitRef="U_EUR">129095000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:InvestmentsInAssociates
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_43a75801-a446-4be2-9273-a8847a427fdd"
      unitRef="U_EUR">13575000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_980c6c3b-e596-4b9c-8d92-e02450c398a0"
      unitRef="U_EUR">5686000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_5214d3b0-47a3-45d2-997f-784799e392c2"
      unitRef="U_EUR">22932000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_c18bb9b3-66fd-47da-aa16-53ccb60bd8f2"
      unitRef="U_EUR">2317000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_d8e56e66-8575-4b72-a1ed-bc5d29c3d221"
      unitRef="U_EUR">2127000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_70808046-e0cf-4475-87b4-4b385a38274d"
      unitRef="U_EUR">1920000</ifrs-full:OtherNoncurrentReceivables>
    <asnd:MarketableSecuritiesNonCurrentAssets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_cc34b7c6-4b98-4dcb-9bc6-723a2612be53"
      unitRef="U_EUR">0</asnd:MarketableSecuritiesNonCurrentAssets>
    <asnd:MarketableSecuritiesNonCurrentAssets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_62a04fe8-9b69-41f4-82de-ade1f995608e"
      unitRef="U_EUR">0</asnd:MarketableSecuritiesNonCurrentAssets>
    <asnd:MarketableSecuritiesNonCurrentAssets
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_69813962-ec68-4626-9ef5-779670aa2f2a"
      unitRef="U_EUR">7492000</asnd:MarketableSecuritiesNonCurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_b5b8d07c-942b-4fdc-986d-51645b4b693c"
      unitRef="U_EUR">118634000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_9d96335a-f6d9-4330-80ec-545283d4af99"
      unitRef="U_EUR">122866000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_592df39d-6fe8-4376-b652-663628839d40"
      unitRef="U_EUR">166267000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_2759b9ee-8802-4e94-85ba-e39abf22fa58"
      unitRef="U_EUR">295609000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_40b093c3-640c-47a0-8b85-489d8e14a1a9"
      unitRef="U_EUR">208931000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_1fa26a62-cdd0-4509-ba50-f296557bdcb6"
      unitRef="U_EUR">130673000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_d7b6e1d2-57ca-48fb-ae11-796432f0bd72"
      unitRef="U_EUR">166280000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_303a6812-2e52-48fd-a43a-203a98780c2d"
      unitRef="U_EUR">35874000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_382097b3-b5ef-4436-b499-30711f816121"
      unitRef="U_EUR">11910000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_22287eda-1bd5-4f2e-8fb0-741be382b289"
      unitRef="U_EUR">1775000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_e69b6562-90e1-4217-895d-b444dfba7743"
      unitRef="U_EUR">802000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_e7255016-a092-43b2-8fff-0447b82b8834"
      unitRef="U_EUR">883000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_906b2721-46e6-4886-8010-f6336f45b06d"
      unitRef="U_EUR">9385000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_831a4081-f4f8-4711-96ad-78b29be79f6c"
      unitRef="U_EUR">19097000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_199ad878-35ff-4014-a37f-42eb7ed9c375"
      unitRef="U_EUR">12833000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_ade22926-d334-4850-9028-7c386a827e27"
      unitRef="U_EUR">28269000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_4e401866-c4ae-4461-ae46-80951396f0fa"
      unitRef="U_EUR">38578000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_61f5ba9c-d6e7-47af-a120-b0300560d6c6"
      unitRef="U_EUR">31717000</ifrs-full:CurrentPrepayments>
    <asnd:MarketableSecurities1
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_ec389182-5dbb-4ed6-9881-468323673e14"
      unitRef="U_EUR">0</asnd:MarketableSecurities1>
    <asnd:MarketableSecurities1
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_ffaab183-18e2-4e1c-9a96-7eea9fcc75c4"
      unitRef="U_EUR">7275000</asnd:MarketableSecurities1>
    <asnd:MarketableSecurities1
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_caa57351-8417-4791-a585-bd145240387d"
      unitRef="U_EUR">290688000</asnd:MarketableSecurities1>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_b4cbe142-1464-4455-a876-90a4fb08a265"
      unitRef="U_EUR">559543000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_75208953-26c9-4ba5-80b9-b728a6b86e17"
      unitRef="U_EUR">392164000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_26c6c861-b5ba-4cad-92f6-32f39a3a1d2c"
      unitRef="U_EUR">444767000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_c692aa4f-ebe9-4720-a0d1-6ba7286a04d2"
      unitRef="U_EUR">1060861000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_0bc3769e-460e-4b91-afc4-7d3ba0080ceb"
      unitRef="U_EUR">702721000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_c07633cd-f507-41e3-830f-c087650184e2"
      unitRef="U_EUR">923471000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_f93b233f-8982-42da-ba9c-106e0f7c31c2"
      unitRef="U_EUR">1179495000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_0b4fb44d-7574-4a84-b61c-87d8d0bbab45"
      unitRef="U_EUR">825587000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_23a507de-e21f-48de-ae21-fd24dace1e42"
      unitRef="U_EUR">1089738000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_e5a1643d-7c7f-40a3-bb9c-1b51fd2a2496"
      unitRef="U_EUR">8149000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_7c855bd6-e7de-4717-b7e5-c5bff55a7780"
      unitRef="U_EUR">7749000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_e1de2081-8c19-44b6-82ed-be5e61e997ed"
      unitRef="U_EUR">7675000</ifrs-full:IssuedCapital>
    <asnd:DistributableEquity
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_5ed39ca7-fd71-47f9-aceb-f0a56272ba91"
      unitRef="U_EUR">-113855000</asnd:DistributableEquity>
    <asnd:DistributableEquity
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_07c24fc7-73aa-4d3c-9add-a4464165d707"
      unitRef="U_EUR">-153446000</asnd:DistributableEquity>
    <asnd:DistributableEquity
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_42b6f182-c1d6-40a4-9e57-6b2a81baa418"
      unitRef="U_EUR">255673000</asnd:DistributableEquity>
    <ifrs-full:Equity
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_fd790668-949e-4465-89f0-9f6e1e804383"
      unitRef="U_EUR">-105706000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_ef27783e-2ebf-4cee-8123-7b88ae2ac3c7"
      unitRef="U_EUR">-145697000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_3795a0fc-3033-47f0-99ff-bd301132860f"
      unitRef="U_EUR">263348000</ifrs-full:Equity>
    <ifrs-full:LongtermBorrowings
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_9a83b961-54b4-43b6-8b14-ac7c265bb83d"
      unitRef="U_EUR">365080000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_4fe891d7-42a9-43d8-ad45-1edeb55f7bd5"
      unitRef="U_EUR">222996000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_06324db9-e461-493f-a1a5-d89ab3895f83"
      unitRef="U_EUR">95400000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_12c3f237-20f8-42e1-8232-6a6ae2ad66a7"
      unitRef="U_EUR">5000000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_7c603b92-996b-41cf-90f1-b6f38706f824"
      unitRef="U_EUR">5949000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_7f5c30a7-dd20-4a79-8b75-5e53ccb86d9d"
      unitRef="U_EUR">14213000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_7aa87730-017c-46cf-a258-d613b4cf000e"
      unitRef="U_EUR">7258000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_7ffbe158-e7ca-41b1-9e0f-c9494aadcac5"
      unitRef="U_EUR">5830000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_3a82fc0d-07aa-432d-b4fb-c0d3dabb40b7"
      unitRef="U_EUR">0</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_46b725a9-828e-4071-810d-6df96523363e"
      unitRef="U_EUR">377338000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_556f4c14-5887-4ee4-8d98-2a04d59d2952"
      unitRef="U_EUR">234775000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_c9d6d57b-425c-4fb7-abbd-e4a278a46eb8"
      unitRef="U_EUR">109613000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:ShorttermBorrowings
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_55343d14-adc6-4ee3-960d-113d01795303"
      unitRef="U_EUR">458207000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_16f605bc-c449-4a9a-b897-ab5afc18d588"
      unitRef="U_EUR">407095000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_33c31fb0-9baf-4529-80e9-43922ebe0918"
      unitRef="U_EUR">399186000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_5a700999-1910-4bd4-b5fd-2d80d7c4648b"
      unitRef="U_EUR">150670000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_8a80a850-f6a7-4854-b3a7-e27ae4e96591"
      unitRef="U_EUR">143296000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_850c6404-d676-4a1c-bd80-6f8bb47928b0"
      unitRef="U_EUR">157950000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <asnd:ConvertibleNotesCurrent
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_b2726e0f-1634-4f25-949e-2571d5ec55e2"
      unitRef="U_EUR">608877000</asnd:ConvertibleNotesCurrent>
    <asnd:ConvertibleNotesCurrent
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_165c922b-2c8e-4822-90e5-0f02ac5c20e0"
      unitRef="U_EUR">550391000</asnd:ConvertibleNotesCurrent>
    <asnd:ConvertibleNotesCurrent
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_9943a8d6-82ce-4009-8273-13bf6b24f302"
      unitRef="U_EUR">557136000</asnd:ConvertibleNotesCurrent>
    <asnd:ShortTermBorrowingOther
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_6f7817f5-be8f-4ff9-96d2-0a335aec6830"
      unitRef="U_EUR">33329000</asnd:ShortTermBorrowingOther>
    <asnd:ShortTermBorrowingOther
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_923af3dd-3ff9-4806-b536-4946e4597c7f"
      unitRef="U_EUR">14174000</asnd:ShortTermBorrowingOther>
    <asnd:ShortTermBorrowingOther
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_937b3cd9-fe7a-46a9-b361-3cd9f805fe0f"
      unitRef="U_EUR">13791000</asnd:ShortTermBorrowingOther>
    <ifrs-full:CurrentContractLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_10cb667e-45ba-4280-984c-0d067f6c76c0"
      unitRef="U_EUR">936000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_85f364e0-22ad-4ce7-9f7f-8121531aa5f7"
      unitRef="U_EUR">1184000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_803a9650-095b-429c-9575-ef2db55e6637"
      unitRef="U_EUR">0</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_451166a2-9347-4553-9aad-13ddef46ae17"
      unitRef="U_EUR">96394000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_deb67055-8a85-4ee4-ac53-976b2ed93a91"
      unitRef="U_EUR">94566000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_54e300fd-d8b7-4a41-9130-5dd43498563b"
      unitRef="U_EUR">101032000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_910484ab-51ec-4b61-a45e-07353c1e772e"
      unitRef="U_EUR">67956000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_60695fa5-1167-441b-b831-7560770cf08c"
      unitRef="U_EUR">41176000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_f794aad9-2a63-4872-87b9-837f20bc715f"
      unitRef="U_EUR">31989000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_88bd386d-9238-4260-836d-af8aded27434"
      unitRef="U_EUR">1222000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_d6b826e8-8b76-4bd1-baa0-57dac5ae1ea1"
      unitRef="U_EUR">2299000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_9ba2ab12-59c9-4705-b8c1-3ab3fc76f27d"
      unitRef="U_EUR">5490000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentProvisions
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_01d7f9a9-6418-4b51-be1e-3cf6ba4ba74d"
      unitRef="U_EUR">99149000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_cac9b5bc-a669-4d09-ac9d-3ac7b871ead1"
      unitRef="U_EUR">32719000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_399b9146-169e-4bb4-ac80-cafd1f58cce1"
      unitRef="U_EUR">7339000</ifrs-full:CurrentProvisions>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_24842db2-562b-4c04-bfd6-a684889ff996"
      unitRef="U_EUR">298986000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_cd3efa0e-9e4f-49f5-9e6c-a40915c3d8f3"
      unitRef="U_EUR">186118000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_9a7e5e95-c04c-4327-96d6-0bb984adb4a0"
      unitRef="U_EUR">159641000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_5fe14837-95ea-4284-9a27-813c694df781"
      unitRef="U_EUR">907863000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_d72c75d5-ea0e-4320-874c-0aae05cd4401"
      unitRef="U_EUR">736509000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_d74833a8-604a-4949-a863-f60de5785367"
      unitRef="U_EUR">716777000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_7f62bdd6-67fa-45e1-815b-d5e815e7ecee"
      unitRef="U_EUR">1285201000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_1837bd4c-bdab-4625-83ce-5792ca88d901"
      unitRef="U_EUR">971284000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_e7085e38-ade3-403e-81da-e57c0a1e414d"
      unitRef="U_EUR">826390000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_4350065e-2a6d-4b70-9166-2b2d58342a45"
      unitRef="U_EUR">1179495000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_8d1634f1-4c08-4418-9ecf-dfe6024613dd"
      unitRef="U_EUR">825587000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_ced4c5ad-b6d2-4224-847c-02eb9a5953b6"
      decimals="-3"
      id="F_f2eca86f-a27b-425d-89ae-8dd08e821786"
      unitRef="U_EUR">1089738000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="C_b1fd592a-4621-4c11-bdbc-d9f0a9de718a"
      decimals="-3"
      id="F_6910055d-60ce-4630-b0f1-41ca7df630db"
      unitRef="U_EUR">7646000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_a71bc062-4b22-4a9f-b52c-19753e5e74b0"
      decimals="-3"
      id="F_7c7bf10a-8d1a-4145-929e-77524edb75dc"
      unitRef="U_EUR">2107739000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_4321d0de-54cc-473c-8f2e-2c4823e23921"
      decimals="-3"
      id="F_8b1397bb-1737-4e8d-ba82-84dfe2264623"
      unitRef="U_EUR">-21000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_5ad9dcf6-e1be-4e09-aa88-8cd0c222bbea"
      decimals="-3"
      id="F_e4999b53-044b-41eb-8991-ce05ee281ee2"
      unitRef="U_EUR">3779000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_fa84436d-cca3-4949-bad3-f7258a333f34"
      decimals="-3"
      id="F_5c823499-c3e2-4f4b-bd36-5bb2dd9bda56"
      unitRef="U_EUR">-1235508000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3"
      decimals="-3"
      id="F_4371f8df-bfc8-475f-801e-8cf48b1074d1"
      unitRef="U_EUR">883635000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_bbd12530-7f01-426e-9852-87ca70290753"
      decimals="-3"
      id="F_55be5477-2c79-4f59-a2b8-b3d1cc2fc04c"
      unitRef="U_EUR">-583194000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_9c4e6657-a771-4199-8382-e29f41a5d937"
      unitRef="U_EUR">-583194000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_9fb94f08-5f01-4b31-86eb-19c1c44186e4"
      decimals="-3"
      id="F_e430db54-5830-43af-8e5d-f68889734919"
      unitRef="U_EUR">-327000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_e025749a-761d-4373-9e64-2dd7f4b71bd2"
      unitRef="U_EUR">-327000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_5ebf1592-e85e-4a79-a0d3-03fb135c3e71"
      decimals="-3"
      id="F_e2290e31-0ba7-4dc4-b093-223ed840105a"
      unitRef="U_EUR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_9fb94f08-5f01-4b31-86eb-19c1c44186e4"
      decimals="-3"
      id="F_117830ee-a769-4612-beda-a9a8d8f035df"
      unitRef="U_EUR">-327000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_bbd12530-7f01-426e-9852-87ca70290753"
      decimals="-3"
      id="F_02db0679-a613-4b6e-9b85-603b867a9557"
      unitRef="U_EUR">-583194000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_da478b50-0e4f-48e3-9d71-16f31ed109d3"
      unitRef="U_EUR">-583521000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_bbd12530-7f01-426e-9852-87ca70290753"
      decimals="-3"
      id="F_a874c6f0-244a-44e4-8c9a-8c09e2b54f7a"
      unitRef="U_EUR">64180000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_6ae06780-80a8-4151-b188-93ca4d42bef8"
      unitRef="U_EUR">64180000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="C_5c050805-6399-4923-924c-dd423a9d5ceb"
      decimals="-3"
      id="F_99fe0fd6-eadc-457a-8d21-638dcb818747"
      unitRef="U_EUR">134000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f"
      decimals="-3"
      id="F_3788fe4f-c209-4cc7-8cde-38562e0d6a17"
      unitRef="U_EUR">105965000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_177c03c0-382c-4e4b-bcbb-cdcd4d4f977a"
      unitRef="U_EUR">106099000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_5ebf1592-e85e-4a79-a0d3-03fb135c3e71"
      decimals="-3"
      id="F_a1083c75-778f-4fec-9815-162dd1e1f089"
      unitRef="U_EUR">6000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_bbd12530-7f01-426e-9852-87ca70290753"
      decimals="-3"
      id="F_721228a8-22fc-4b82-a0b1-9e5d44dd0c9f"
      unitRef="U_EUR">-6000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_ae50ae32-8fd9-4440-ae86-c935aac5e3c8"
      decimals="-3"
      id="F_74aa465b-62bd-489f-8504-d3580bccf9f0"
      unitRef="U_EUR">29000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_7cb30aff-4382-400f-aea5-7f16e02f70c5"
      decimals="-3"
      id="F_71d760c1-4822-4ab0-aae7-15c99450ddb6"
      unitRef="U_EUR">5124000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_e02b016e-1451-409c-a654-3ca654c6ff34"
      unitRef="U_EUR">5153000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="C_9076fd44-ae75-413e-8321-bdfaee1f0a4d"
      decimals="-3"
      id="F_05e00795-e7cf-420a-8704-cf8a450a7f1c"
      unitRef="U_EUR">7675000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_ca9626d8-b4fd-4cc7-bdcd-fa03f5df98d4"
      decimals="-3"
      id="F_676d35bf-b96b-40a0-90cf-bd2a3819a971"
      unitRef="U_EUR">2112863000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_1fbabba9-e169-4afa-9ccc-063e93641d68"
      decimals="-3"
      id="F_674dbc14-fa22-4174-8a3d-e2dce7241deb"
      unitRef="U_EUR">-149000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_9c347efe-55f5-41f7-aa5a-2ffa52fa30b2"
      decimals="-3"
      id="F_48eedfe1-fe80-4b64-933c-eb0631d2a433"
      unitRef="U_EUR">3452000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_481783fd-70ee-498b-bb3d-a524d1a98f13"
      decimals="-3"
      id="F_555b432c-0996-4465-a4d0-60268e2ec193"
      unitRef="U_EUR">-1860493000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="-3"
      id="F_85e5cc51-863a-4ba0-a63c-3b9d8901207c"
      unitRef="U_EUR">263348000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f"
      decimals="-3"
      id="F_62bb4411-8b68-45ca-9b68-da2a56b23d57"
      unitRef="U_EUR">-481447000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_1e5de1b7-f356-4379-849b-4404798ec5ab"
      unitRef="U_EUR">-481447000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_9a087241-0b3a-4cac-b087-23c132bb156a"
      decimals="-3"
      id="F_ed6641e4-b043-4600-8c42-c0fff0994ffc"
      unitRef="U_EUR">-2731000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_c1e4366e-49df-436a-8705-c9c646887aa6"
      unitRef="U_EUR">-2731000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_5c050805-6399-4923-924c-dd423a9d5ceb"
      decimals="-3"
      id="F_b98497e2-22dc-4ca6-88dd-1a4e28f61fb3"
      unitRef="U_EUR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_9a087241-0b3a-4cac-b087-23c132bb156a"
      decimals="-3"
      id="F_3bae5a13-85c6-4db5-b4bd-0f96a4b3e3f9"
      unitRef="U_EUR">-2731000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f"
      decimals="-3"
      id="F_58e915be-4d42-41a7-9e76-d6c093f92a86"
      unitRef="U_EUR">-481447000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_ff7bc22c-3739-4d1b-8746-99b29129641e"
      unitRef="U_EUR">-484178000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f"
      decimals="-3"
      id="F_6f9fee15-8d78-48c0-8cfb-f1f0f349561b"
      unitRef="U_EUR">66660000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_b55ed47b-5b93-4769-844e-c0fb06963a1c"
      unitRef="U_EUR">66660000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_5c050805-6399-4923-924c-dd423a9d5ceb"
      decimals="-3"
      id="F_cbd8075a-67b5-4396-994b-942e88618282"
      unitRef="U_EUR">3000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f"
      decimals="-3"
      id="F_fcbfe633-fcfd-4268-9d5f-82d6d6c816ec"
      unitRef="U_EUR">-3000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <asnd:NetSettlementUnderStockIncentivePrograms
      contextRef="C_5feef7fd-c380-41ec-b991-b148e59ce71f"
      decimals="-3"
      id="F_4704b5a8-63be-4ba4-bcf0-f2bd0d56f6f3"
      unitRef="U_EUR">1812000</asnd:NetSettlementUnderStockIncentivePrograms>
    <asnd:NetSettlementUnderStockIncentivePrograms
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_ead6c646-aa1b-4c03-b054-762a73192997"
      unitRef="U_EUR">1812000</asnd:NetSettlementUnderStockIncentivePrograms>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_83fd201b-7c83-4ee4-a0da-02d9df8447b1"
      decimals="-3"
      id="F_97ca9b5b-83f5-4b54-b2bf-03f46ee8b062"
      unitRef="U_EUR">74000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_d556afe9-f715-43bc-a19e-5d09f686c664"
      decimals="-3"
      id="F_900b5f90-e3bd-4b0b-8755-7bbb9a866865"
      unitRef="U_EUR">10211000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_5ebf1592-e85e-4a79-a0d3-03fb135c3e71"
      decimals="-3"
      id="F_f46134b4-40c4-443b-8a54-c3586793d967"
      unitRef="U_EUR">0</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_bbd12530-7f01-426e-9852-87ca70290753"
      decimals="-3"
      id="F_d75a2792-1f24-4956-b9c3-4dee0e084dba"
      unitRef="U_EUR">0</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_558483bd-f470-470d-9adf-39f0e545777b"
      unitRef="U_EUR">10285000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="C_d0e6faf1-bbd1-4b27-8ddf-0087e182b6af"
      decimals="-3"
      id="F_602abff0-43f4-4687-8fac-cd16c6c1c010"
      unitRef="U_EUR">7749000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_be71380a-a9fd-4b8f-a8ae-7f8c29ba0800"
      decimals="-3"
      id="F_c81d142b-32af-4686-bd90-81cfc417174c"
      unitRef="U_EUR">2123074000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_bcd65bae-11a9-4b6a-b98a-ae8d9426e936"
      decimals="-3"
      id="F_0d438816-67b2-4425-bfe6-a49bf0676aee"
      unitRef="U_EUR">-146000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_01ae896f-3989-4a7c-b794-121862812d86"
      decimals="-3"
      id="F_4015bb25-6559-44a3-a7fe-2c6a16b88476"
      unitRef="U_EUR">721000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_ce3072bb-3b3b-4d2a-bccb-396e6f23ec7d"
      decimals="-3"
      id="F_2a5f8a23-0064-445f-91f2-da72269e1789"
      unitRef="U_EUR">-2277095000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_9beedec4-11ae-48a1-a7af-241672253a32"
      unitRef="U_EUR">-145697000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_45262f50-d25a-4678-b31f-4e249ad2d3e3"
      decimals="-3"
      id="F_e0b24820-702f-4864-a93f-83223fd73b36"
      unitRef="U_EUR">-378084000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_08ebb0e3-8b8d-4fa6-b616-272f42055225"
      unitRef="U_EUR">-378084000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_3ebd12a3-760c-4570-9d25-6d885ea5aee9"
      decimals="-3"
      id="F_cab3244d-b037-44b5-9077-71eb6102c78a"
      unitRef="U_EUR">1062000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_cfed79bf-272a-4957-bb3d-f656f2986fba"
      unitRef="U_EUR">1062000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_c1719aa5-a73d-4b30-a0d6-6c4e89f62175"
      decimals="-3"
      id="F_34cf4f0f-4507-4527-b072-b23a97c5c5ae"
      unitRef="U_EUR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_3ebd12a3-760c-4570-9d25-6d885ea5aee9"
      decimals="-3"
      id="F_b8c5024d-6926-426c-9239-102456b121a2"
      unitRef="U_EUR">1062000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_45262f50-d25a-4678-b31f-4e249ad2d3e3"
      decimals="-3"
      id="F_8b1db8ba-c45a-4008-9947-5dc379289f12"
      unitRef="U_EUR">-378084000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_869cfa69-72d3-4f14-8680-68e21ad36d99"
      unitRef="U_EUR">-377022000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_45262f50-d25a-4678-b31f-4e249ad2d3e3"
      decimals="-3"
      id="F_8bf814dc-7b82-4d00-be55-c71030652bbb"
      unitRef="U_EUR">95512000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_82440a7d-80ae-402a-943a-60d27e14416f"
      unitRef="U_EUR">95512000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_c1719aa5-a73d-4b30-a0d6-6c4e89f62175"
      decimals="-3"
      id="F_5154d24a-82de-436e-be04-d7708ff2774d"
      unitRef="U_EUR">33000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_45262f50-d25a-4678-b31f-4e249ad2d3e3"
      decimals="-3"
      id="F_fe491bb6-dd1e-4add-904b-dd3fa15c3a03"
      unitRef="U_EUR">-33000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_6b2baac5-581b-4df4-9270-e2e0408d280d"
      decimals="-3"
      id="F_9fb70724-1f2f-484f-b29f-90dac7a86f57"
      unitRef="U_EUR">400000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_694aa851-7e2e-42d3-96e9-18ff2f6e9d67"
      decimals="-3"
      id="F_9d4bbb55-643e-4fc4-b126-e1499206cb47"
      unitRef="U_EUR">340392000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_96cf4c93-9824-4172-8718-ef30fb575647"
      unitRef="U_EUR">340792000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <asnd:CostsOfCapitalIncreaseDecrease
      contextRef="C_694aa851-7e2e-42d3-96e9-18ff2f6e9d67"
      decimals="-3"
      id="F_21029507-744b-4539-adf6-44fa469b9e7f"
      unitRef="U_EUR">19291000</asnd:CostsOfCapitalIncreaseDecrease>
    <asnd:CostsOfCapitalIncreaseDecrease
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d4929a9a-c64a-46ce-a14a-5d70113fcad9"
      unitRef="U_EUR">19291000</asnd:CostsOfCapitalIncreaseDecrease>
    <ifrs-full:Equity
      contextRef="C_f6d717ce-7ddc-4b83-a7fa-1c03e30a43a3"
      decimals="-3"
      id="F_073b776a-dbd7-48be-9fbc-0c9ab9933bdd"
      unitRef="U_EUR">8149000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_feba8166-348b-43f4-8af8-7e1499e6fa81"
      decimals="-3"
      id="F_40fff43a-f7e3-48a0-9f84-a70c270638d8"
      unitRef="U_EUR">2444175000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_2b7ffa79-9374-4323-9f4f-2e90fd4a0ef6"
      decimals="-3"
      id="F_bdb29325-e788-4858-a8ee-598eacf909db"
      unitRef="U_EUR">-113000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_2390a6d0-d171-4a09-ad5f-63eca2811521"
      decimals="-3"
      id="F_4c26bdc7-ef0a-4c3c-bdc2-031c2f16340e"
      unitRef="U_EUR">1783000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_73eda4e7-aa61-4748-bc17-dba1d8cc2584"
      decimals="-3"
      id="F_3b68f566-9dcc-4a78-9d76-298311ea552e"
      unitRef="U_EUR">-2559700000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_988b7774-e60d-42e0-afc2-25a1d6b57c03"
      unitRef="U_EUR">-105706000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_be535eb6-68d2-4664-ab06-8b3ce83168ac"
      unitRef="U_EUR">-378084000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_e481f78b-748e-4538-a029-a783fb834964"
      unitRef="U_EUR">-481447000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_e92b3131-c7c0-4887-a66f-15d03232d7a1"
      unitRef="U_EUR">-583194000</ifrs-full:ProfitLoss>
    <ifrs-full:FinanceIncome
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_6ed5d40d-4060-4f7b-9e58-8999001f7f76"
      unitRef="U_EUR">25609000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_8c858da7-227e-4dac-b222-14d897ca9abb"
      unitRef="U_EUR">43857000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_8715820a-3b6b-40bb-b87d-9cd7fe78a7d8"
      unitRef="U_EUR">52181000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_392782af-2c18-4805-8567-df64dc385d0c"
      unitRef="U_EUR">100027000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_72995283-4aae-451b-92ee-291ef617ec95"
      unitRef="U_EUR">44065000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_647bf6dc-85c0-4dec-9bd7-24391fa6e26f"
      unitRef="U_EUR">50487000</ifrs-full:FinanceCosts>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_c34f3021-f57b-46d4-9128-50e016ac17f4"
      unitRef="U_EUR">91000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_8eef1f3d-ce54-47bf-ae60-d80566381bb6"
      unitRef="U_EUR">-5000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_0cf8b3bf-815d-4bd3-8d04-c61ac451c092"
      unitRef="U_EUR">-22000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_40e10656-16c5-408d-a824-46fa6ada8eb2"
      unitRef="U_EUR">4843000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_556782aa-d9ec-4bd1-a127-d94ee328b7cb"
      unitRef="U_EUR">7303000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_50450b73-cb34-47de-86f6-8dbdc693384a"
      unitRef="U_EUR">5377000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <asnd:AdjustmentsForNonCashConsiderationRegardingRevenue
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_c5231c97-daac-4b1c-ad62-d4e3929664fd"
      unitRef="U_EUR">27069000</asnd:AdjustmentsForNonCashConsiderationRegardingRevenue>
    <asnd:AdjustmentsForNonCashConsiderationRegardingRevenue
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_89d9feaa-903a-48e6-aa2f-ea6ff3d4fb34"
      unitRef="U_EUR">2354000</asnd:AdjustmentsForNonCashConsiderationRegardingRevenue>
    <asnd:AdjustmentsForNonCashConsiderationRegardingRevenue
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_af28e0c5-59b7-4a40-9b62-6b3d9043bd7b"
      unitRef="U_EUR">2547000</asnd:AdjustmentsForNonCashConsiderationRegardingRevenue>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_5d3e09c6-022a-450c-ae3a-903158698668"
      unitRef="U_EUR">-20060000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_aa5421be-bf0e-4921-81f3-5d58324f0fd8"
      unitRef="U_EUR">-18395000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_c5f42aab-bdf8-4ce8-b195-222cbb43e1b8"
      unitRef="U_EUR">-17697000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_34cf1b76-d52d-465e-910e-78cc072cc913"
      unitRef="U_EUR">95512000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_92a19335-4bab-49c6-8f06-88dd1452d8dd"
      unitRef="U_EUR">66660000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_b6595134-8fa2-49f5-aadf-41199672dc3d"
      unitRef="U_EUR">64180000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d9754bd3-f62c-4445-a4a8-c80669ae6988"
      unitRef="U_EUR">17247000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_2a1731f4-c50f-4e2b-a8f1-9d0b419056a1"
      unitRef="U_EUR">18428000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_0f707731-5c8d-41c9-9963-1c9b5aaa7df6"
      unitRef="U_EUR">17514000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_cdb5c72d-3551-4a36-a323-81e1be57a2d1"
      unitRef="U_EUR">0</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_db8b9112-3ffe-4140-b406-c2c754a8d281"
      unitRef="U_EUR">7834000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_e5c9170c-17a1-4126-ac4d-1fac26a87d3c"
      unitRef="U_EUR">0</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_80ba40d4-450e-4424-b260-4a2e3b784a7d"
      unitRef="U_EUR">467000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_38c84453-b481-4b00-a0b2-fb1c8e295fe0"
      unitRef="U_EUR">483000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_f816c248-a235-4dec-82ab-15e04269d30e"
      unitRef="U_EUR">444000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_e52c9809-8f5e-4664-a388-acfc9c6e084a"
      unitRef="U_EUR">-86678000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_679dbc29-5a97-448c-b147-74fa5b39e6c3"
      unitRef="U_EUR">-78258000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_e6eafd0d-9c90-4355-b861-8028aca2e170"
      unitRef="U_EUR">-55268000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_3736655f-e265-40c4-81d8-7d55b96a83b4"
      unitRef="U_EUR">-118607000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_7c3d23be-bb17-43e5-954f-6b147500d8a7"
      unitRef="U_EUR">-32773000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_9e4243ee-1e89-4b53-889b-3e57485a1481"
      unitRef="U_EUR">-11531000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_14479db4-2632-4afa-abdd-88c804eee7d5"
      unitRef="U_EUR">10392000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_25289ec2-f756-4b82-86dd-da5241da0561"
      unitRef="U_EUR">-11413000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_7b9475aa-3500-404e-9ec0-b8d2846c334b"
      unitRef="U_EUR">-6409000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_0dd245e8-7562-4b75-99e0-e0c3b967c9da"
      unitRef="U_EUR">-1197000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_4cd5ff0c-c040-45a5-91eb-77d5b95368b1"
      unitRef="U_EUR">-7080000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_a350cd9e-95fa-4d0d-a970-023d3b92c457"
      unitRef="U_EUR">8648000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_128aeb78-68a6-4ed8-a9ae-70eec63d4110"
      unitRef="U_EUR">26965000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_2a055590-7f70-43c4-a86f-999fbd384684"
      unitRef="U_EUR">3551000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_693673be-4d99-4694-a159-c5d0f6aba228"
      unitRef="U_EUR">45943000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_7044cb3c-2025-41df-b971-08b34cb48669"
      unitRef="U_EUR">61968000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_5fcec2ef-d6d3-47b2-8e6c-8fd77fdd235f"
      unitRef="U_EUR">26187000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_8bbdb0d9-266b-4e63-8f61-780bbbb47042"
      unitRef="U_EUR">6145000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_e888b4ec-fe3b-4f7a-8255-dbba3e969865"
      unitRef="U_EUR">-299854000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_22526e08-e137-4e1f-9671-e542c3428d17"
      unitRef="U_EUR">-464271000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_0cc813a7-05bf-497d-934a-b052268d9b18"
      unitRef="U_EUR">-494673000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_04f5cb82-a8d8-488a-8861-3b3329449f94"
      unitRef="U_EUR">14374000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_3c9e0aa6-5a13-4775-9886-23d5c2ed24b8"
      unitRef="U_EUR">17048000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_833daafc-5628-48b7-b440-d3c8542207b0"
      unitRef="U_EUR">8271000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_ed710cd4-8954-492d-acf1-699170cf1101"
      unitRef="U_EUR">15205000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_7c067f44-624a-4a82-ac17-1aac0effe4e5"
      unitRef="U_EUR">15672000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_6c0f4766-2d75-42d3-825b-687943da70e9"
      unitRef="U_EUR">9294000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_61d53035-5f4f-4fd2-807f-78bbc780b000"
      unitRef="U_EUR">5512000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_3e2b63cd-2858-478c-8f6a-e6c53ebf3c1b"
      unitRef="U_EUR">4466000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_eae1f7f7-07d1-4724-9726-c2afb700f663"
      unitRef="U_EUR">3000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_7f66eeaa-6530-472b-87d0-7012e9253e90"
      unitRef="U_EUR">-306197000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_773229e5-8d26-44bb-9495-121ecfc2c67c"
      unitRef="U_EUR">-467361000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_7cb7364b-f05f-436a-b774-6db14bf9577c"
      unitRef="U_EUR">-495699000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_8aa6ae5c-4bfa-4b93-b8b6-4b7d68706ddb"
      unitRef="U_EUR">950000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_d5be96d0-93a5-4739-bd27-f32b28af7e42"
      unitRef="U_EUR">51000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_eb60d06e-fb75-46c1-9355-c3475647ff69"
      unitRef="U_EUR">0</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_09200b8a-35a5-458d-ad05-cd060a675b08"
      unitRef="U_EUR">1427000</asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment>
    <asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_7f4d3bed-b0da-45fd-a9ba-c6306cdd11da"
      unitRef="U_EUR">2442000</asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment>
    <asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_a1170bcd-31d5-4970-b62d-54abac567315"
      unitRef="U_EUR">14489000</asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment>
    <asnd:ReimbursementFromAcquisitionOfPropertyPlantAndEquipment
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_b6fe795a-1d50-46dc-8d3b-08447db91eb5"
      unitRef="U_EUR">0</asnd:ReimbursementFromAcquisitionOfPropertyPlantAndEquipment>
    <asnd:ReimbursementFromAcquisitionOfPropertyPlantAndEquipment
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_a457b6b9-b40d-4c81-a46f-955fc6acbb66"
      unitRef="U_EUR">0</asnd:ReimbursementFromAcquisitionOfPropertyPlantAndEquipment>
    <asnd:ReimbursementFromAcquisitionOfPropertyPlantAndEquipment
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_757903e8-011f-48f6-9155-750907ec15dd"
      unitRef="U_EUR">9535000</asnd:ReimbursementFromAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_7ff7f105-c6af-43bc-870d-306c2a5bfb78"
      unitRef="U_EUR">0</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_4355e537-3034-412f-b99e-41f9ad875fc5"
      unitRef="U_EUR">0</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_211577a5-6b77-4a3b-b7f0-ab1098728477"
      unitRef="U_EUR">213842000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_2c62645e-1597-4d47-a2d6-5ce2133b9acd"
      unitRef="U_EUR">7353000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_fbcff07e-d6b9-4636-95de-dbddd7270cde"
      unitRef="U_EUR">288865000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_321e06dc-7b08-43d7-b768-b2cd951ab853"
      unitRef="U_EUR">280528000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d3107799-d9cf-4e94-a46e-98edfa1b2b58"
      unitRef="U_EUR">6876000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_e21b4b4a-9dd2-4ad0-922f-b55e0d48e8ae"
      unitRef="U_EUR">286474000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_56c8cbf0-c2c4-4472-b52f-c2f9d20baad3"
      unitRef="U_EUR">61732000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_59a184aa-784a-45d0-84c8-2f6c3c8be4ee"
      unitRef="U_EUR">11365000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_acc120ec-206e-430d-9ec8-ae9e52421dbd"
      unitRef="U_EUR">10438000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_4d81e449-5797-4db3-a29e-8047f170b407"
      unitRef="U_EUR">6356000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_cface604-269c-4694-93c2-ccb08b870b81"
      unitRef="U_EUR">134158000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_9e5b7333-f0a5-4821-8963-30b706100348"
      unitRef="U_EUR">136256000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_761aefb8-6db9-40e0-99bd-a52d4b65da2f"
      unitRef="U_EUR">503281000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_8ff28ef6-057d-48f3-8c52-5f55abab7ac6"
      unitRef="U_EUR">30514000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_f7e365ec-4117-4f07-b9f5-4c3b217e3b23"
      unitRef="U_EUR">10286000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_6a6df15a-4013-4789-85a3-77c599de832a"
      unitRef="U_EUR">5153000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_058bd30a-06c5-45c8-945c-4f2adeec1190"
      unitRef="U_EUR">309913000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_f7d45c2b-a451-476f-87ac-8c7075b9e8f4"
      unitRef="U_EUR">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_dbf13607-c13f-4bea-befa-3235326f175c"
      unitRef="U_EUR">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_c415db0a-097f-4371-a3f4-5e199ea81c86"
      unitRef="U_EUR">19291000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_d471ad52-5963-4fb5-9dff-99b93ef816a6"
      unitRef="U_EUR">0</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_e14a2adb-292d-44bc-b0b4-5e392b8fe00e"
      unitRef="U_EUR">0</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_631afa47-80d1-4a71-b623-d0ded0ff1eb9"
      unitRef="U_EUR">0</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_3c886c09-7edc-409e-bc1b-43d8051b21d2"
      unitRef="U_EUR">0</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_895e44e2-8c14-4fbd-a411-89ed90038913"
      unitRef="U_EUR">105305000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d968f593-0f81-4e0b-8abf-c927b914f0f9"
      unitRef="U_EUR">0</asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms>
    <asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_5ed695d6-394b-4d0d-8234-7d3cd6af1f4b"
      unitRef="U_EUR">1812000</asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms>
    <asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_351b85d2-465b-4d99-8ba9-bc2801073319"
      unitRef="U_EUR">0</asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_12b077cb-6b62-47b9-b36a-0881e4b6791a"
      unitRef="U_EUR">443929000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_5e05ff7e-8b5c-4b04-8c06-80870e2ad74f"
      unitRef="U_EUR">134292000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_f1706848-a554-40fe-972c-907d9accb2d0"
      unitRef="U_EUR">396773000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_efc86422-71f6-47a5-bf5a-30693aa56b42"
      unitRef="U_EUR">144608000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_d2cc5bc4-4ee4-437a-84a5-1941642f17f1"
      unitRef="U_EUR">-46595000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_2ff41fb8-a01d-4460-97e5-0e68d454b48c"
      unitRef="U_EUR">-37194000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_f42de462-9d16-486e-8b54-f7b1b27023d4"
      unitRef="U_EUR">392164000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="-3"
      id="F_098620b8-af07-419c-b37d-794d492523fd"
      unitRef="U_EUR">444767000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3"
      decimals="-3"
      id="F_4dd981f1-1363-4abb-a555-c38f01e878b2"
      unitRef="U_EUR">446267000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_24e4698b-d74e-4031-b550-774f57c183df"
      unitRef="U_EUR">22771000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_c8cbbd25-9242-44fa-85b8-d6c3922fd922"
      unitRef="U_EUR">-6008000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_f0602418-ee1f-4783-9d08-835210ac7f4e"
      unitRef="U_EUR">35694000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_dd433ae0-d166-41be-b7a2-0e8483a244b4"
      unitRef="U_EUR">559543000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_4d68fed6-a578-4d65-85b1-7d20587476fc"
      unitRef="U_EUR">392164000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="-3"
      id="F_7f9ed319-cf73-4657-be9d-abd5162a1fb1"
      unitRef="U_EUR">444767000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:BalancesWithBanks
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_5e16a969-41d5-40de-901a-f9726b32928a"
      unitRef="U_EUR">559543000</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_3300e367-6bda-4c6d-85ae-eeb34b385c60"
      unitRef="U_EUR">392164000</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="-3"
      id="F_77c8a67b-5780-4a91-8046-f7a236841689"
      unitRef="U_EUR">427810000</ifrs-full:BalancesWithBanks>
    <asnd:ShortTermMarketableSecurities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_4331057a-514e-4bdd-a6e4-3776571f49de"
      unitRef="U_EUR">0</asnd:ShortTermMarketableSecurities>
    <asnd:ShortTermMarketableSecurities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_792a880a-9487-44fe-90b5-aabd1bc46eee"
      unitRef="U_EUR">0</asnd:ShortTermMarketableSecurities>
    <asnd:ShortTermMarketableSecurities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_3f48673a-d753-4eaf-9f1a-8745aaf1cb06"
      unitRef="U_EUR">16957000</asnd:ShortTermMarketableSecurities>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_e4089b48-a5cd-449f-8985-278a474364ed"
      unitRef="U_EUR">559543000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_36db8fac-949a-4554-985c-1afe953ea266"
      unitRef="U_EUR">392164000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="-3"
      id="F_d3b5c06e-afa1-4548-876d-cbc78a4804f8"
      unitRef="U_EUR">444767000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_985f9a1d-753a-44dc-ae95-058a6db66570">&lt;p id="notes" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 1&#x2014;General Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma A/S, together with its subsidiaries, is a global biopharmaceutical company focused on applying its  innovative TransCon technology platform to make a meaningful difference for patients. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our,&#x201d; refer to Ascendis Pharma A/S and its subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The address of the Company&#x2019;s registered office is Tuborg Boulevard 12, DK-2900 Hellerup, Denmark. The Company&#x2019;s registration number in Denmark is 29918791.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 2, 2015, the Company completed an initial public offering which resulted in the listing of American Depositary Shares (&#x201c;ADSs&#x201d;), representing the Company&#x2019;s ordinary shares, under the symbol &#x201c;ASND&#x201d; in the United States on The Nasdaq Global Select Market.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Board of Directors (or &#x201c;Board&#x201d;) approved these consolidated financial statements on February 12, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_32f38a32-2a5c-4f2c-88bb-20e8fd9d6bb1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 2&#x2014;Summary of Material Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Preparation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements are prepared in accordance with the IFRS Accounting Standards (&#x201c;IFRS&#x201d;), as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), and as adopted by the European Union (the &#x201c;EU&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies applied when preparing the consolidated financial statements are described in detail below and are applied for all group entities. Significant accounting judgements and sources of estimation uncertainties used when exercising the accounting policies are described in Note 3, &#x201c;Significant Accounting Judgements and Estimates.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These consolidated financial statements have been prepared under the historical cost convention, apart from certain financial instruments that are measured at fair value at initial recognition.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;New and Amended IFRS Accounting Standards and Interpretations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has applied amendments to paragraphs 69 to 76 of IAS 1, &#x201c;Presentation of Financial Statements,&#x201d; which was effective for annual reporting periods beginning on or after January 1, 2024, and must be applied retrospectively. The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. The amendments clarify:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;What is meant by a right to defer settlement;  &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;That a right to defer must exist at the end of the reporting period; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;That classification is unaffected by the likelihood that an entity will exercise its deferral right; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The convertible senior notes (&#x201c;convertible notes&#x201d;) include an embedded equity conversion option which is not deemed closely related to the financial liability and was initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since the embedded derivative is not an equity instrument under IFRS, the amendments require the convertible notes (presented as part of borrowings in the statement of financial position) and derivative liabilities, presented as non-current liabilities as of December 31, 2023, to be presented as current liabilit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ies. The amendments require presentation of the convertible notes as current liabilities even though: the initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per ADS is not met; the conversion would not require cash settlement; and, the convertible notes do not mature until April 1, 2028. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Further details, including (cash) maturity analysis are provided in Note 16, &#x201c;Financial Assets and Liabilities.&#x201d; On December 31, 2023, the carrying amount of convertible notes and derivative liabilities were &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comparative amounts have been reclassified to reflect the change to presentation, including a third statement of financial position as of the beginning of the preceding period i.e. January 1, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 31, 2023, lease liabilities were presented separately in the consolidated statements of financial position. As of December 31, 2023, carrying amount of lease liabilities was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, for non-current liabilities and current liabilities, respectively. Since March 31, 2024, lease liabilities are presented as part of borrowings in the consolidated statements of financial position. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comparative amounts have been reclassified to reflect the change in presentation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accordingly, since March 31, 2024, borrowings comprise convertible notes, royalty funding liabilities, and lease liabilities, where convertible notes are presented separately as &#x201c;Current liabilities - Convertible notes, matures in 2028.&#x201d; The change to presentation had no other impact on the consolidated financial statements. Refer to Note 16, &#x201c;Financial Assets and Liabilities&#x201d; for a specification of borrowings.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The applied amendments had no other impact on the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other IFRS Accounting Standards and Interpretations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other amendments apply for the first time in 2024, but do not have an impact on the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Going Concern&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Board of Directors has at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, the Company continues to adopt the going concern basis of accounting in preparing the consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the parent company, Ascendis Pharma A/S, and all enterprises over which the parent company has control. Control of an enterprise exists when the Company has exposure, or rights to, variable returns from its involvement with the enterprise and has the ability to control those returns through its power over the enterprise. Accordingly, the consolidated financial statements include Ascendis Pharma A/S and the subsidiaries listed in Note 20, &#x201c;Investments in Group Enterprises&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Consolidation Principles&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsidiaries, which are enterprises the Company controls, are fully consolidated from the date upon which control is transferred to the Company. They are deconsolidated from the date control ceases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Control over an enterprise is reassessed if facts and circumstances indicate that there are changes to one or more of the three elements of control, respectively:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the contractual arrangement(s) with the other vote holders of the enterprise; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company&#x2019;s voting rights and potential voting rights; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;rights arising from other contractual arrangements.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between group enterprises are eliminated in full on consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsidiaries apply accounting policies in line with the Company&#x2019;s accounting policies. When necessary, adjustments are made to bring the entities&#x2019; accounting policies in line with those of the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments in Associates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An associate is an entity over which the Company has significant influence over financial and operational decisions but without having control or joint control. The Company&#x2019;s associates are accounted for using the equity method and initially recognized at cost. Thereafter, the carrying amount of the investment is adjusted to recognize changes in the Company&#x2019;s share of net assets of the associates since the acquisition or establishment date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated statements of profit or loss include the Company&#x2019;s share of result after tax of the associates after any adjustments made to bring the associates accounting policies in line with those of the Company. Transactions between the associates and the Company are eliminated proportionally according to the Company&#x2019;s interest in the associates. Unrealized gains and losses resulting from transactions between the Company and its associates are eliminated to the extent of the Company&#x2019;s interest in the associates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On each reporting date, the Company determines whether there are indications that the investment is impaired. If there is such evidence, the amount of impairment is calculated as the difference between the recoverable amount of the associate and its carrying amount. Any impairment loss is recognized in the consolidated statements of profit or loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Functional and Presentation Currency&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Items included in the consolidated financial statements are measured using the functional currency of each group entity. Functional currency is the currency of the primary economic environment in which the entity operates. The consolidated financial statements are presented in Euros (or &#x201c;EUR&#x201d;), which is also the functional currency of the parent company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Translation of Transactions and Balances&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On initial recognition, transactions in currencies other than the individual entity&#x2019;s functional currency are translated applying the exchange rate in effect at the date of the transaction. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the reporting date are translated using the exchange rate in effect at the reporting date. Monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Exchange rate differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the reporting date, are recognized in profit or loss as finance income or finance expenses. Property, plant and equipment, intangible assets and other non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as of the dates of the initial transactions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Currency Translation of Group Enterprises&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When subsidiaries or associates present their financial statements in a functional currency other than EUR, their statements of profit or loss are translated at average exchange rates. Balance sheet items are translated using the exchange rates at the reporting date. Exchange rate differences arising from translation of foreign entities&#x2019; balance sheet items at the beginning of the year to the reporting date exchange rates as well as from translation of statements of profit or loss from average rates to the exchange rates at the reporting date are recognized in other comprehensive income. Similarly, exchange rate differences arising from changes that have been made directly in a foreign subsidiary&#x2019;s equity are recognized in other comprehensive income.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Commercial Products&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue is recognized when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue is measured at the contractual sales price, reflecting the consideration received or receivable from customers, net of value added taxes, and provisions for a variety of sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales deductions attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements. In addition, goods are principally sold on a &#x201c;sale-or-return&#x201d; basis, where customers may return products in line with the Company&#x2019;s return policy. Sales deductions and product returns are considered variable consideration and are estimated at the time of sale using the expected value method. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net contractual price only to the extent that it is probable that a significant reversal will not occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unsettled sales deductions and product returns are recognized as provisions when timing or amount is uncertain. Payable amounts that are absolute are recognized as other liabilities. Sales discounts and deductions that are payable to customers are offset in trade receivables.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other revenue relates to collaboration and license agreements. When contracts with customers are entered into, the goods and/or services promised in the contract are assessed to identify distinct performance obligations. A promise in the agreement is considered a distinct performance obligation if both of the following criteria are met:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct); and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For collaboration and license agreements that contain multiple promises to the customer, the promises are identified and accounted for as separate performance obligations if these are distinct. If promises are not distinct, those goods or services are combined with other promised goods or services until a bundle of goods or services that is distinct is identified.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price in the contract is measured at fair value and reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Under license agreements, the transaction price may include up-front payments, royalty and milestone payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sales-based royalty and sales-based milestone income promised in exchange for a license of intellectual property is recognized as revenue at the later of the occurrence of subsequent sale or satisfaction of the performance obligation to which some or all of the royalty or milestone has been allocated. Milestone income related to regulatory activities is included in the transaction price at the point in time that it is highly probable that the applicable milestone criteria is met.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price is allocated to each performance obligation according to their stand-alone selling prices and is recognized when control of the goods or services is transferred to the customer, either over time or at a point in time, depending on the specific terms and conditions in the contracts. License agreements, which transfer rights to the Company&#x2019;s intellectual property (&#x201c;IP&#x201d;), are classified as &#x201c;right-to-access&#x201d;, with revenue recognized over time, or as &#x201c;right-to-use&#x201d; with revenue recognized at a point in time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sale of clinical trial supply is recognized as revenue when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery. Rendering of services is recognized as revenue over the service period as stipulated under the applicable agreement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs consist primarily of manufacturing costs, preclinical and clinical study costs and costs for process optimizations and improvements performed by Clinical Research Organizations (&#x201c;CROs&#x201d;) and Contract Manufacturing Organizations (&#x201c;CMOs&#x201d;), salaries and other personnel costs including pension and share-based payment, the cost of facilities, professional fees, cost of obtaining and maintaining the Company&#x2019;s intellectual property portfolio, and depreciation of non-current assets related to research and development activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research costs are incurred at the early stages of the drug development cycle from the initial drug discovery and include a variety of preclinical research activities in order to assess potential drug candidates in non-human subjects, prior to filing an Investigational New Drug Application (&#x201c;IND&#x201d;), or equivalent. Research costs are recognized in the consolidated statement of profit or loss when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development activities relate to activities following an IND, or equivalent, and typically involve a single product candidate undergoing a series of studies to illustrate its safety profile and effect on human beings, prior to obtaining the necessary approval from the appropriate authorities. Development activities comprise drug candidates undergoing clinical trials starting in phase I (first time drug is administered in a small group of humans), and further into Phase II and III, which include administration of drugs in larger patient groups. Following, and depending on clinical trial results, a Biologic License Application (&#x201c;BLA&#x201d;) or New Drug Application (&#x201c;NDA&#x201d;) may be submitted to the authorities, to apply for marketing approval, which, with a positive outcome will permit the Company to market and sell the products. Long-term extension trials may be ongoing following submission of a BLA or NDA.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development costs also include product development and pre-commercial manufacturing costs related to development product candidates, and write-downs of inventories manufactured for late-stage development product candidates prior to marketing approval being obtained (pre-launch inventories).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to the risk related to the development of pharmaceutical products, the Company cannot estimate the future economic benefits associated with individual development activities with sufficient certainty until the development activities have been finalized and the necessary market approval of the final product has been obtained. As a consequence, all development costs are recognized in the consolidated statement of profit or loss when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Selling, General, and Administrative Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Selling, general, and administrative expenses comprise salaries and other personnel costs including pension and share-based payment, office supplies, cost of facilities, professional fees, and depreciation of non-current assets related to selling, general and administrative activities, including pre-commercial and commercial activities. Selling, general, and administrative expenses are recognized in the consolidated statement of profit or loss when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based Incentive Programs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based incentive programs comprise warrant programs, Restricted Stock Unit programs (&#x201c;RSU-programs&#x201d;) and Performance Stock Unit Programs (&#x201c;PSU-programs&#x201d;) which are classified as equity-settled share-based payment transactions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost of equity-settled transactions is determined by the fair value at the date of grant. For warrant programs, the fair value of each warrant granted is determined using the Black-Scholes option-pricing model. For RSU-programs and PSU-programs, the fair value of each RSU or PSU granted is equal to the closing share price on the date of grant of the underlying ADS. Any social security contributions payable in connection with the grant or exercise of the warrants are recognized as expenses when incurred. The assumptions used for estimating the fair value of share-based payment transactions are disclosed in Note 7, &#x201c;Share-based Payment.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost is recognized together with a corresponding increase in equity over the period in which the performance and/or service conditions are fulfilled (i.e., the vesting period). The fair value determined at the grant date of the equity-settled share-based payment is expensed on a straight-line basis over the vesting period for each tranche, based on the best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for grants that do not ultimately vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Where an equity-settled grant is cancelled other than upon forfeiture when vesting conditions are not satisfied, the grant is treated as if it vested on the date of the cancellation, and any expense not yet recognized for the grant is recognized immediately.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Where the terms and conditions for an equity-settled grant are modified, the services measured at the grant date fair value over the vesting period are recognized, subject to performance and/or service conditions that were specified at the initial grant date(s). Additionally, at the date of modification, unvested grants are re-measured and any increase in the total fair value is recognized over the vesting period. If a new grant is substituted for the cancelled grant and designated as a replacement grant on the date that it is granted, the cancelled and new grants are treated as if they were a modification of the original grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Finance Income and Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Finance income and expenses comprise interest income and expenses, realized and unrealized exchange rate gains and losses on transactions denominated in foreign currencies, fair value remeasurement gains and losses on derivative liabilities, and remeasurement gains and losses on royalty funding liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest income and interest expenses are stated on an accrual basis using the principal and the effective interest rate. The effective interest rate is the discount rate that is used to discount expected future cash payments or receipts through the expected life of the financial asset or financial liability to the amortized cost (the carrying amount) of such asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognized in the consolidated statement of profit or loss by the portion attributable to the profit or loss for the year and recognized directly in equity or other comprehensive income by the portion attributable to entries directly in equity and in other comprehensive income. The current tax payable or receivable is recognized in the consolidated statement of financial position, stated as tax computed on this year&#x2019;s taxable income, adjusted for prepaid tax.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When computing the current tax for the year, the tax rates and tax rules enacted or substantially enacted at the reporting date are used. Current tax payable is based on taxable profit or loss for the year. Taxable profit or loss differs from net profit or loss as reported in the consolidated statements of profit or loss because it excludes items of income or expense that are taxable or deductible in prior or future years. In addition, taxable profit or loss excludes items that are never taxable or deductible.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax is recognized according to the balance sheet liability method of all temporary differences between carrying amounts and tax-based values of assets and liabilities, apart from deferred tax on all temporary differences occurring on initial recognition of goodwill or on initial recognition of a transaction which is not a business combination, and for which the temporary difference found at the time of initial recognition neither affects profit or loss nor taxable income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities are recognized on all temporary differences related to investments in subsidiaries and/or associates, unless the Company is able to control when the deferred tax is realized, and it is probable that the deferred tax will not become due and payable as current tax in the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, including the tax base of tax loss carry forwards, are recognized in the statement of financial position at their estimated realizable value, either as a set-off against deferred tax liabilities or as net tax assets for offset against future positive taxable income. Deferred tax assets are only offset against deferred tax liabilities if the entity has a legally enforceable right to offset, and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax jurisdiction. Deferred tax is calculated based on the planned use of each asset and the settlement of each liability, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax is measured using the tax rates and tax rules in the relevant countries that, based on acts in force or acts in reality in force at the reporting date are expected to apply when the deferred tax is expected to crystallize as current tax. Changes in deferred tax resulting from changed tax rates or tax rules are recognized in the consolidated statement of profit or loss unless the deferred tax is attributable to transactions previously recognized directly in equity or other comprehensive income. In the latter case, such changes are also recognized in equity or other comprehensive income. On every reporting date, it is assessed whether sufficient taxable income is likely to arise in the future for the deferred tax asset to be utilized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill acquired in a business combination is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests over the net identifiable assets acquired and liabilities assumed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortized but is subject to impairment testing at least on a yearly basis. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or group of cash-generating units, that are expected to benefit from the synergies of the combination. Each cash-generating unit or group of cash-generating units to which goodwill is allocated represents the lowest level within the Company at which the goodwill is monitored for internal management purposes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Software assets comprise administrative applications and serve general purposes to support the Company&#x2019;s operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development costs that are directly attributable to the design, customization, implementation, and testing of identifiable and unique software assets controlled by the Company are recognized as intangible assets from the time that; (1) the software asset is clearly defined and identifiable; (2) technological feasibility, adequate resources to complete, and an internal use of the software asset can be demonstrated; (3) the expenditure attributable to the software asset can be measured reliably; and (4) the Company has the intention to use the software asset internally. The Company does not capitalize software with no alternative use, or where economic benefit depends on marketing approvals of drug candidates and where marketing approvals have not been obtained.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when the development is complete, and the asset is available for use.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Software assets are amortized over the period of expected future benefits. Amortization is recognized in research and development costs, and selling, general and administrative expenses, as appropriate. Expenditures that do not meet the criteria above are recognized as an expense as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment primarily comprises leasehold improvements, office facilities, and process equipment and tools which are located at CMOs. Property, plant and equipment also includes right-of-use assets. Refer to the separate section &#x201c;Leases.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be used in operation. Subsequent costs are included in the carrying amount of the asset or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the assets will flow to the Company and costs of the items can be measured reliably. All repair and maintenance costs are charged to the consolidated statement of profit or loss during the financial periods in which they are incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Plant and equipment acquired for research and development activities with alternative use, which is expected to be used for more than one year, is capitalized and depreciated over the estimated useful life as research and development costs. Plant and equipment acquired for research and development activities, which has no alternative use, is recognized as research and development costs when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the acquisition or use of the asset involves an obligation to incur costs of decommissioning or restoration of the asset, the estimated related costs are recognized as a provision and as part of the relevant asset&#x2019;s cost, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The basis for depreciation is cost less estimated residual value. The residual value is the estimated amount that would be earned if selling the asset today net of selling costs, assuming that the asset is of an age and a condition that is expected after the end of its useful life. Cost of a combined asset is divided into smaller components, with such significant components depreciated individually if their useful lives vary. Depreciation commences when the asset is available for use, which is when it is in the location and condition necessary for it to be capable of operating in the manner intended.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation is calculated on a straight-line basis, based on an asset&#x2019;s expected useful life, being within the following ranges:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.824%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Process plant and machinery&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation methods, useful lives and residual amounts are reassessed at least annually.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment is written down to the lower of recoverable amount and carrying amount, as described in the &#x201c;Impairment&#x201d; section below. Depreciation and impairment losses of property, plant and equipment is recognized in the consolidated statement of profit or loss as cost of sales, research and development costs or as selling, general, and administrative expenses, as appropriate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Gains and losses on disposal of property, plant and equipment are recognized in the consolidated statement of profit or loss at its net proceeds, as either research and development costs or as selling, general, and administrative expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Non-current Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The recoverable amount of goodwill is estimated annually irrespective of any recorded indications of impairment. Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows, or cash-generating units, which for goodwill represent the lowest level within the enterprise at which the goodwill is monitored for internal management purposes. Prior impairments of non-current assets, other than goodwill, are reviewed for possible reversal at each reporting date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories comprise raw materials, work in progress and finished goods. The cost of work in progress and finished goods comprise service expenses incurred at CMOs, raw materials consumed, incremental storage and transportation, other direct materials, and a proportion of manufacturing overheads based on normal operation capacity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories are measured at the lower of cost incurred in bringing it to its present location and condition, and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Cost is measured using the first-in, first-out method. Work in progress and finished goods are measured under a standard cost method that takes into account normal levels of consumption, yields, labor, efficiency and capacity utilization. Production processes are complex, where actual yields and consumptions are sensitive to a wide variety of manufacturing conditions. Standard cost variances are reviewed regularly and adjusted to ensure inventories approximate actual cost of production.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If net realizable value is lower than cost, a write-down is recognized as the excess amount by which cost exceeds net realizable value, as part of cost of sales, or selling, general, and administrative expenses, as appropriate. The amount of reversal of write-down of inventories arising from an increase in net realizable value is recognized as a reduction in cost of sales in the period in which the reversal occurs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Manufacturing of pre-launch inventories is initiated for late-stage product candidates where manufacturing costs are recognized as inventories. However, since pre-launch inventories are not realizable prior to obtaining marketing approval, pre-launch inventories are immediately written down to zero through research and development costs. If marketing approval is obtained, prior write-downs of pre-launch inventories are reversed through research and development costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of inventories is recognized as part of cost of sales in the period in which the related revenue is recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Receivables&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Receivables comprise trade receivables, income tax receivables and other receivables.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trade receivables are classified as financial assets at amortized cost, as these are held to collect contractual cash flows and thus give rise to cash flows representing solely payments of principal and interest. Trade receivables are initially recognized at their transaction price and subsequently measured at amortized cost. Income tax receivables, and other receivables related to deposits, VAT and other indirect taxes are measured at cost less impairment. Carrying amounts of receivables usually equals their nominal value less provision for impairments.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepayments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepayments comprise advance payments relating to a future financial year. Prepayments are measured at cost.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities may comprise government bonds, treasury bills, commercial papers, and other securities traded on established markets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At initial recognition (trade-date), contractual terms of individual securities are analyzed to determine whether these give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding (&#x201c;SPPI-test&#x201d;). All marketable securities held at the reporting date have passed the SPPI-test.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities are initially recognized at fair value at trade-date, and subsequently measured at amortized cost under the effective interest method. Interest income is recognized as finance income in the consolidated statement of profit or loss. Marketable securities are subject to an impairment test to accommodate expected credit loss. Gains and losses are recognized as finance income or expenses in the consolidated statement of profit or loss when the specific security or portfolio of securities is derecognized, modified or impaired.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, having maturity profiles of three months or less after the date of acquisition are presented as cash equivalents in the consolidated statements of financial position, where securities having maturities of more than three months after the date of acquisition are presented separately as marketable securities as current (i.e., those maturing within twelve months after the reporting date) or non-current assets, as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents comprise cash and on-demand deposits with financial institutions, and highly liquid marketable securities with a maturity of three months or less after the date of acquisition (trade-date). Cash and cash equivalents are measured at amortized cost.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Allowance for Expected Credit Losses on Financial Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial assets comprise receivables (excluding receivables relating to VAT, other indirect tax and income tax), marketable securities, and cash and cash equivalents. Impairment of financial assets is determined on the basis of a forward-looking Expected Credit Loss (&#x201c;ECL&#x201d;) model. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and the cash flows expected to be received, discounted by an approximation of the original effective interest rate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For receivables, a simplified approach in calculating ECLs is applied. Therefore, changes in credit risks are not tracked, but instead, a loss allowance based on lifetime ECL is assessed at each reporting date. Lifetime ECLs are assessed on historical credit loss experience, adjusted for forward-looking factors specific to the counterparts and the economic environment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For cash, cash equivalents and marketable securities, ECLs are assessed for credit losses that result from default events that are possible within the next twelve months (12-month ECL). Credit risk is continuously tracked and monitored in order to identify significant deterioration. For those credit exposures for which there have been a significant increase in credit risk since initial recognition, an allowance is recognized for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The share capital comprises the nominal amount of the parent company&#x2019;s ordinary shares, each at a nominal value of DKK &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. All shares are fully paid.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share premium comprises the amounts received, attributable to shareholders&#x2019; equity, in excess of the nominal amount of the shares issued at the parent company&#x2019;s capital increases, reduced by any expenses directly attributable to the capital increases. Under Danish legislation, share premium is an unrestricted reserve that is available to be distributed as dividends to a company&#x2019;s shareholders. Also, under Danish legislation, the share premium reserve can be used to offset accumulated deficits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Treasury shares reserve comprise nominal amounts of holding of own equity instruments. No gain or loss is recognized in profit or loss on the purchase, sale, transfer or cancellation of the Company&#x2019;s own equity instruments. The treasury shares reserve is part of unrestricted reserves and accordingly, reduce the amount available to be distributed as dividends to the Company&#x2019;s shareholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation reserve includes exchange rate adjustments relating to the translation of the results and net assets of foreign operations from their functional currencies to the presentation currency.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accumulated reserve of a foreign operation is reclassified to the consolidated statement of profit or loss at the time the Company loses control, and thus cease to consolidate such foreign operation. The foreign currency translation reserve is an unrestricted reserve that is available to be distributed as dividends to the Company&#x2019;s shareholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Retained earnings/(accumulated deficit) represents the accumulated profits or losses from the Company&#x2019;s operations, including corresponding entries to share-based payments recognized in the consolidated statement of profit or loss. In addition, premiums from acquisition and sale of treasury shares are recognized as part of this reserve. A positive reserve is available to be distributed as dividends to the Company&#x2019;s shareholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Convertible Senior Notes and Embedded Derivative Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes (&#x201c;convertible notes&#x201d;) are separated into a financial liability and an embedded derivative component based on the terms and conditions of the contract. The embedded derivative component is accounted for separately if it is not deemed closely related to the financial liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The convertible notes include an embedded equity conversion option which is not deemed closely related to the financial liability, and initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the convertible notes include a redemption option, which entitle the Company to redeem the notes at a cash amount equal to the principal amount of the convertible notes, plus accrued and unpaid interest. The redemption option is closely related to the financial liability, and not separately accounted for. The initial carrying amount of the financial liability component including the redemption option is the residual amount of the proceeds, net of transaction costs, after separating the derivative component.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Transaction costs are apportioned between the financial liability and derivative component based on the allocation of proceeds when the instrument is initially recognized. Transaction costs apportioned to the financial liability component form part of the effective interest and are amortized over the expected lifetime of the liability. Transaction costs allocated to the derivative component are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial liability is subsequently measured at amortized cost until it is extinguished on conversion, upon optional redemption or repayment at maturity. Convertible notes are presented as borrowings, together with the derivative liabilities on the statement of financial position, separately under current liabilities as &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Convertible notes, matures in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalty Funding Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities relate to the Company&#x2019;s contractual obligations to pay a predetermined percentage of future revenue from sale of commercial products until reaching a predetermined multiple of proceeds received, pursuant to the detailed provisions of the capped synthetic royalty funding agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Where relevant, royalty funding liabilities are separated into a financial liability and embedded derivative components based on the terms and conditions of the applicable royalty funding agreement. Embedded derivative components are accounted for separately, unless these are deemed closely related to the financial liability. The royalty funding agreements include a buy-out option where the value is dependent on non-financial variables that are specific to the Company. Accordingly, the buy-out option is not accounted for separately as a derivative.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial liability is recognized when the Company becomes party to the contractual provisions of the royalty funding agreement and measured at amortized cost until it is extinguished upon exercising a buy-out option or upon achieving the predetermined multiple of proceeds received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The effective interest rate is estimated at initial recognition and takes into account incremental transaction costs and anticipated amount and timing of future cash flows, which further depends on future commercial revenue forecasts and the probability of exercising the buy-out option. The amortized cost is remeasured prospectively when there is a material change in expectations to amount and timing of future cash flows, which will increase or decrease future interest expenses. Remeasurement gain or losses are recognized through the profit or loss as finance income or expenses, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities that are classified as a financial liability are presented as part of borrowings in the statement of financial position.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Right-of-use Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets are recognized at the lease commencement date, defined as the date the underlying asset is available for use. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets include the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any incentives received. In addition, right-of-use assets also include an estimate of costs to be incurred by the Company in dismantling or restoring the underlying asset to the condition if required by the terms and condition of the lease, if any.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets are presented as part of property, plant and equipment, and depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Lease Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the lease commencement date, lease liabilities are recognized and measured at the present value of fixed lease payments and variable lease payments that depend on an index or a rate, whereas variable lease payments and payments related to non-lease components are excluded. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the consolidated statement of profit or loss when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When interest rates implicit in the lease contracts are not readily available, the present value of lease payments are calculated by applying the incremental borrowing rate of the relevant entity holding the lease. Following the commencement date, the incremental borrowing rate is not changed unless the lease term is modified, or if the lease payments are modified and this modification results from a change in floating interest rates. From the lease commencement date and over the lease term, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in lease term, or a change in lease payments, including changes to future payments resulting from a change in an index used to determine such lease payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities are presented as part of borrowings in the statement of financial position.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provisions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provisions comprise unsettled sales deductions and product returns regarding revenue from sale of commercial products where amount or timing of payment is uncertain.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provisions for sales deductions attributed to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements are recognized when the related sales takes place and measured using the expected value method. Payable amounts for managed healthcare organizations and government programs are generally settled within 180 days from the transaction date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provisions for estimated product returns are measured according to the contractual sales price based on expected product returns.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trade Payables and Accrued Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trade payables and accrued expenses are measured at amortized cost.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other liabilities comprise payables to public authorities, short-term employee benefits, and sales deductions. Other liabilities are measured at their net-realizable values.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contract Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities comprise deferred income from collaboration and license agreements, where consideration received does not match the individual deliverables with respect to amount and satisfied performance obligations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities are measured at the fair value of the consideration received and is recognized as revenue in the consolidated statement of profit or loss when the relevant performance obligation, to which the deferred income relates, is satisfied.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash Flow Statement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cash flow statement shows cash flows from operating, investing and financing activities as well as cash and cash equivalents at the beginning and the end of the financial year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash flows from operating activities are presented using the indirect method and calculated as the profit or loss adjusted for non-cash items, working capital changes as well as finance income, finance expenses and income taxes paid.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash flows from investing activities include payments in connection with acquisition, development, improvement and sale, etc., of property, plant and equipment, investments in associates and marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash flows from financing activities comprise payments related to the capital structure of the Company, including changes in the share capital and treasury shares, and issuance and repayments under the Company&#x2019;s borrowing activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency is presented separately from cash flows from operating, investing and financing activities. Cash flows in currencies other than the functional currency are recognized in the cash flow statement, using the average exchange rates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents comprise cash and on-demand bank deposits with financial institutions and highly liquid marketable securities with a maturity of three months or less after the date of acquisition.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic Earnings per Share (&#x201c;EPS&#x201d;) is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding. The weighted average number of shares takes into account the weighted average number of treasury shares during the year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted EPS is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding adjusted for the weighted average effect of changes in treasury shares during the year, and the dilutive effect of outstanding warrants and convertible notes. If the consolidated statement of profit or loss shows a net loss, no adjustment is made for the dilutive effect, as such effect would be anti-dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;New IFRS Accounting Standards Not Yet Effective&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2024, the IASB issued IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d; (&#x201c;IFRS 18&#x201d;), which replaces IAS 1, &#x201c;Presentation in Financial Statements.&#x201d; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements are not expected to be affected by other new or amended standards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_fb7aeb04-1cee-4fb8-a3bb-a6cd12a3f1fc">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Preparation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements are prepared in accordance with the IFRS Accounting Standards (&#x201c;IFRS&#x201d;), as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), and as adopted by the European Union (the &#x201c;EU&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies applied when preparing the consolidated financial statements are described in detail below and are applied for all group entities. Significant accounting judgements and sources of estimation uncertainties used when exercising the accounting policies are described in Note 3, &#x201c;Significant Accounting Judgements and Estimates.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These consolidated financial statements have been prepared under the historical cost convention, apart from certain financial instruments that are measured at fair value at initial recognition.&lt;/span&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <asnd:ConversionPricePerShare
      contextRef="C_8b7cf227-3c27-4452-bf1e-f4d1f142fedb"
      decimals="2"
      id="F_b91440ca-5e55-464b-81bb-7c907d0879d3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">166.34</asnd:ConversionPricePerShare>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_0deddedd-6da5-4d24-a5cc-3ae1ea2ec605"
      unitRef="U_EUR">407100000</asnd:ConvertibleSeniorNotes>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_fc8ad6b2-112e-4ca2-a6cd-8ce2d0228bad"
      unitRef="U_EUR">143300000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_9cbb84d7-e5be-46dc-91e2-0de61883adb9"
      unitRef="U_EUR">84600000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_5e541dac-d72f-49c4-8d53-0a3a2ca01f35"
      unitRef="U_EUR">14200000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:DisclosureOfGoingConcernExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_18a09fa7-5e76-46ce-9f92-68abf5e4e062">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Going Concern&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Board of Directors has at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, the Company continues to adopt the going concern basis of accounting in preparing the consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfGoingConcernExplanatory>
    <asnd:DescriptionOfBasisOfConsolidationExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_10d02710-e3ef-4506-8a94-12c5a2bf9659">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the parent company, Ascendis Pharma A/S, and all enterprises over which the parent company has control. Control of an enterprise exists when the Company has exposure, or rights to, variable returns from its involvement with the enterprise and has the ability to control those returns through its power over the enterprise. Accordingly, the consolidated financial statements include Ascendis Pharma A/S and the subsidiaries listed in Note 20, &#x201c;Investments in Group Enterprises&#x201d;&lt;/span&gt;</asnd:DescriptionOfBasisOfConsolidationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3930c7dd-d640-444c-abbe-8d7763661439">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Consolidation Principles&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsidiaries, which are enterprises the Company controls, are fully consolidated from the date upon which control is transferred to the Company. They are deconsolidated from the date control ceases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Control over an enterprise is reassessed if facts and circumstances indicate that there are changes to one or more of the three elements of control, respectively:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the contractual arrangement(s) with the other vote holders of the enterprise; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company&#x2019;s voting rights and potential voting rights; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;rights arising from other contractual arrangements.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between group enterprises are eliminated in full on consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsidiaries apply accounting policies in line with the Company&#x2019;s accounting policies. When necessary, adjustments are made to bring the entities&#x2019; accounting policies in line with those of the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f906a5fb-7f8e-4c16-bf62-f16b079b1cbe">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments in Associates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An associate is an entity over which the Company has significant influence over financial and operational decisions but without having control or joint control. The Company&#x2019;s associates are accounted for using the equity method and initially recognized at cost. Thereafter, the carrying amount of the investment is adjusted to recognize changes in the Company&#x2019;s share of net assets of the associates since the acquisition or establishment date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated statements of profit or loss include the Company&#x2019;s share of result after tax of the associates after any adjustments made to bring the associates accounting policies in line with those of the Company. Transactions between the associates and the Company are eliminated proportionally according to the Company&#x2019;s interest in the associates. Unrealized gains and losses resulting from transactions between the Company and its associates are eliminated to the extent of the Company&#x2019;s interest in the associates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On each reporting date, the Company determines whether there are indications that the investment is impaired. If there is such evidence, the amount of impairment is calculated as the difference between the recoverable amount of the associate and its carrying amount. Any impairment loss is recognized in the consolidated statements of profit or loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_e8b3d959-8217-4e05-be7e-5a21cab7a93c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Functional and Presentation Currency&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Items included in the consolidated financial statements are measured using the functional currency of each group entity. Functional currency is the currency of the primary economic environment in which the entity operates. The consolidated financial statements are presented in Euros (or &#x201c;EUR&#x201d;), which is also the functional currency of the parent company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Translation of Transactions and Balances&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On initial recognition, transactions in currencies other than the individual entity&#x2019;s functional currency are translated applying the exchange rate in effect at the date of the transaction. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the reporting date are translated using the exchange rate in effect at the reporting date. Monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Exchange rate differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the reporting date, are recognized in profit or loss as finance income or finance expenses. Property, plant and equipment, intangible assets and other non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as of the dates of the initial transactions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Currency Translation of Group Enterprises&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When subsidiaries or associates present their financial statements in a functional currency other than EUR, their statements of profit or loss are translated at average exchange rates. Balance sheet items are translated using the exchange rates at the reporting date. Exchange rate differences arising from translation of foreign entities&#x2019; balance sheet items at the beginning of the year to the reporting date exchange rates as well as from translation of statements of profit or loss from average rates to the exchange rates at the reporting date are recognized in other comprehensive income. Similarly, exchange rate differences arising from changes that have been made directly in a foreign subsidiary&#x2019;s equity are recognized in other comprehensive income.&lt;/span&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_425069b6-592c-48b5-9a66-3b17384bed0a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Commercial Products&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue is recognized when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue is measured at the contractual sales price, reflecting the consideration received or receivable from customers, net of value added taxes, and provisions for a variety of sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales deductions attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements. In addition, goods are principally sold on a &#x201c;sale-or-return&#x201d; basis, where customers may return products in line with the Company&#x2019;s return policy. Sales deductions and product returns are considered variable consideration and are estimated at the time of sale using the expected value method. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net contractual price only to the extent that it is probable that a significant reversal will not occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unsettled sales deductions and product returns are recognized as provisions when timing or amount is uncertain. Payable amounts that are absolute are recognized as other liabilities. Sales discounts and deductions that are payable to customers are offset in trade receivables.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other revenue relates to collaboration and license agreements. When contracts with customers are entered into, the goods and/or services promised in the contract are assessed to identify distinct performance obligations. A promise in the agreement is considered a distinct performance obligation if both of the following criteria are met:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct); and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For collaboration and license agreements that contain multiple promises to the customer, the promises are identified and accounted for as separate performance obligations if these are distinct. If promises are not distinct, those goods or services are combined with other promised goods or services until a bundle of goods or services that is distinct is identified.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price in the contract is measured at fair value and reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Under license agreements, the transaction price may include up-front payments, royalty and milestone payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sales-based royalty and sales-based milestone income promised in exchange for a license of intellectual property is recognized as revenue at the later of the occurrence of subsequent sale or satisfaction of the performance obligation to which some or all of the royalty or milestone has been allocated. Milestone income related to regulatory activities is included in the transaction price at the point in time that it is highly probable that the applicable milestone criteria is met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price is allocated to each performance obligation according to their stand-alone selling prices and is recognized when control of the goods or services is transferred to the customer, either over time or at a point in time, depending on the specific terms and conditions in the contracts. License agreements, which transfer rights to the Company&#x2019;s intellectual property (&#x201c;IP&#x201d;), are classified as &#x201c;right-to-access&#x201d;, with revenue recognized over time, or as &#x201c;right-to-use&#x201d; with revenue recognized at a point in time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sale of clinical trial supply is recognized as revenue when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery. Rendering of services is recognized as revenue over the service period as stipulated under the applicable agreement.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_57b7ee48-27ea-40e2-942b-ad7667e04e4c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs consist primarily of manufacturing costs, preclinical and clinical study costs and costs for process optimizations and improvements performed by Clinical Research Organizations (&#x201c;CROs&#x201d;) and Contract Manufacturing Organizations (&#x201c;CMOs&#x201d;), salaries and other personnel costs including pension and share-based payment, the cost of facilities, professional fees, cost of obtaining and maintaining the Company&#x2019;s intellectual property portfolio, and depreciation of non-current assets related to research and development activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research costs are incurred at the early stages of the drug development cycle from the initial drug discovery and include a variety of preclinical research activities in order to assess potential drug candidates in non-human subjects, prior to filing an Investigational New Drug Application (&#x201c;IND&#x201d;), or equivalent. Research costs are recognized in the consolidated statement of profit or loss when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development activities relate to activities following an IND, or equivalent, and typically involve a single product candidate undergoing a series of studies to illustrate its safety profile and effect on human beings, prior to obtaining the necessary approval from the appropriate authorities. Development activities comprise drug candidates undergoing clinical trials starting in phase I (first time drug is administered in a small group of humans), and further into Phase II and III, which include administration of drugs in larger patient groups. Following, and depending on clinical trial results, a Biologic License Application (&#x201c;BLA&#x201d;) or New Drug Application (&#x201c;NDA&#x201d;) may be submitted to the authorities, to apply for marketing approval, which, with a positive outcome will permit the Company to market and sell the products. Long-term extension trials may be ongoing following submission of a BLA or NDA.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development costs also include product development and pre-commercial manufacturing costs related to development product candidates, and write-downs of inventories manufactured for late-stage development product candidates prior to marketing approval being obtained (pre-launch inventories).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to the risk related to the development of pharmaceutical products, the Company cannot estimate the future economic benefits associated with individual development activities with sufficient certainty until the development activities have been finalized and the necessary market approval of the final product has been obtained. As a consequence, all development costs are recognized in the consolidated statement of profit or loss when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f45de26d-7d7b-456f-90e3-04229251f791">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Selling, General, and Administrative Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Selling, general, and administrative expenses comprise salaries and other personnel costs including pension and share-based payment, office supplies, cost of facilities, professional fees, and depreciation of non-current assets related to selling, general and administrative activities, including pre-commercial and commercial activities. Selling, general, and administrative expenses are recognized in the consolidated statement of profit or loss when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_1c3282f2-ff71-4888-9c2f-41cc62d77c6c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based Incentive Programs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based incentive programs comprise warrant programs, Restricted Stock Unit programs (&#x201c;RSU-programs&#x201d;) and Performance Stock Unit Programs (&#x201c;PSU-programs&#x201d;) which are classified as equity-settled share-based payment transactions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost of equity-settled transactions is determined by the fair value at the date of grant. For warrant programs, the fair value of each warrant granted is determined using the Black-Scholes option-pricing model. For RSU-programs and PSU-programs, the fair value of each RSU or PSU granted is equal to the closing share price on the date of grant of the underlying ADS. Any social security contributions payable in connection with the grant or exercise of the warrants are recognized as expenses when incurred. The assumptions used for estimating the fair value of share-based payment transactions are disclosed in Note 7, &#x201c;Share-based Payment.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost is recognized together with a corresponding increase in equity over the period in which the performance and/or service conditions are fulfilled (i.e., the vesting period). The fair value determined at the grant date of the equity-settled share-based payment is expensed on a straight-line basis over the vesting period for each tranche, based on the best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for grants that do not ultimately vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Where an equity-settled grant is cancelled other than upon forfeiture when vesting conditions are not satisfied, the grant is treated as if it vested on the date of the cancellation, and any expense not yet recognized for the grant is recognized immediately.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Where the terms and conditions for an equity-settled grant are modified, the services measured at the grant date fair value over the vesting period are recognized, subject to performance and/or service conditions that were specified at the initial grant date(s). Additionally, at the date of modification, unvested grants are re-measured and any increase in the total fair value is recognized over the vesting period. If a new grant is substituted for the cancelled grant and designated as a replacement grant on the date that it is granted, the cancelled and new grants are treated as if they were a modification of the original grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_ad4c2859-40de-43a1-a745-8a367645ec38">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Finance Income and Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Finance income and expenses comprise interest income and expenses, realized and unrealized exchange rate gains and losses on transactions denominated in foreign currencies, fair value remeasurement gains and losses on derivative liabilities, and remeasurement gains and losses on royalty funding liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest income and interest expenses are stated on an accrual basis using the principal and the effective interest rate. The effective interest rate is the discount rate that is used to discount expected future cash payments or receipts through the expected life of the financial asset or financial liability to the amortized cost (the carrying amount) of such asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_4115c3e5-9699-4004-9b24-44d5fcdfa046">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognized in the consolidated statement of profit or loss by the portion attributable to the profit or loss for the year and recognized directly in equity or other comprehensive income by the portion attributable to entries directly in equity and in other comprehensive income. The current tax payable or receivable is recognized in the consolidated statement of financial position, stated as tax computed on this year&#x2019;s taxable income, adjusted for prepaid tax.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When computing the current tax for the year, the tax rates and tax rules enacted or substantially enacted at the reporting date are used. Current tax payable is based on taxable profit or loss for the year. Taxable profit or loss differs from net profit or loss as reported in the consolidated statements of profit or loss because it excludes items of income or expense that are taxable or deductible in prior or future years. In addition, taxable profit or loss excludes items that are never taxable or deductible.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax is recognized according to the balance sheet liability method of all temporary differences between carrying amounts and tax-based values of assets and liabilities, apart from deferred tax on all temporary differences occurring on initial recognition of goodwill or on initial recognition of a transaction which is not a business combination, and for which the temporary difference found at the time of initial recognition neither affects profit or loss nor taxable income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities are recognized on all temporary differences related to investments in subsidiaries and/or associates, unless the Company is able to control when the deferred tax is realized, and it is probable that the deferred tax will not become due and payable as current tax in the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, including the tax base of tax loss carry forwards, are recognized in the statement of financial position at their estimated realizable value, either as a set-off against deferred tax liabilities or as net tax assets for offset against future positive taxable income. Deferred tax assets are only offset against deferred tax liabilities if the entity has a legally enforceable right to offset, and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax jurisdiction. Deferred tax is calculated based on the planned use of each asset and the settlement of each liability, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax is measured using the tax rates and tax rules in the relevant countries that, based on acts in force or acts in reality in force at the reporting date are expected to apply when the deferred tax is expected to crystallize as current tax. Changes in deferred tax resulting from changed tax rates or tax rules are recognized in the consolidated statement of profit or loss unless the deferred tax is attributable to transactions previously recognized directly in equity or other comprehensive income. In the latter case, such changes are also recognized in equity or other comprehensive income. On every reporting date, it is assessed whether sufficient taxable income is likely to arise in the future for the deferred tax asset to be utilized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_2f78fa15-dc73-4116-b38e-dd9deceed093">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill acquired in a business combination is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests over the net identifiable assets acquired and liabilities assumed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortized but is subject to impairment testing at least on a yearly basis. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or group of cash-generating units, that are expected to benefit from the synergies of the combination. Each cash-generating unit or group of cash-generating units to which goodwill is allocated represents the lowest level within the Company at which the goodwill is monitored for internal management purposes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_56b69017-e922-4ee6-80cf-be289d3d5d0f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Software assets comprise administrative applications and serve general purposes to support the Company&#x2019;s operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development costs that are directly attributable to the design, customization, implementation, and testing of identifiable and unique software assets controlled by the Company are recognized as intangible assets from the time that; (1) the software asset is clearly defined and identifiable; (2) technological feasibility, adequate resources to complete, and an internal use of the software asset can be demonstrated; (3) the expenditure attributable to the software asset can be measured reliably; and (4) the Company has the intention to use the software asset internally. The Company does not capitalize software with no alternative use, or where economic benefit depends on marketing approvals of drug candidates and where marketing approvals have not been obtained.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when the development is complete, and the asset is available for use.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Software assets are amortized over the period of expected future benefits. Amortization is recognized in research and development costs, and selling, general and administrative expenses, as appropriate. Expenditures that do not meet the criteria above are recognized as an expense as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_9e05d41d-51cc-4b85-8fc6-7650d453143a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment primarily comprises leasehold improvements, office facilities, and process equipment and tools which are located at CMOs. Property, plant and equipment also includes right-of-use assets. Refer to the separate section &#x201c;Leases.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be used in operation. Subsequent costs are included in the carrying amount of the asset or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the assets will flow to the Company and costs of the items can be measured reliably. All repair and maintenance costs are charged to the consolidated statement of profit or loss during the financial periods in which they are incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Plant and equipment acquired for research and development activities with alternative use, which is expected to be used for more than one year, is capitalized and depreciated over the estimated useful life as research and development costs. Plant and equipment acquired for research and development activities, which has no alternative use, is recognized as research and development costs when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the acquisition or use of the asset involves an obligation to incur costs of decommissioning or restoration of the asset, the estimated related costs are recognized as a provision and as part of the relevant asset&#x2019;s cost, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The basis for depreciation is cost less estimated residual value. The residual value is the estimated amount that would be earned if selling the asset today net of selling costs, assuming that the asset is of an age and a condition that is expected after the end of its useful life. Cost of a combined asset is divided into smaller components, with such significant components depreciated individually if their useful lives vary. Depreciation commences when the asset is available for use, which is when it is in the location and condition necessary for it to be capable of operating in the manner intended.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation is calculated on a straight-line basis, based on an asset&#x2019;s expected useful life, being within the following ranges:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.824%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Process plant and machinery&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation methods, useful lives and residual amounts are reassessed at least annually.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment is written down to the lower of recoverable amount and carrying amount, as described in the &#x201c;Impairment&#x201d; section below. Depreciation and impairment losses of property, plant and equipment is recognized in the consolidated statement of profit or loss as cost of sales, research and development costs or as selling, general, and administrative expenses, as appropriate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Gains and losses on disposal of property, plant and equipment are recognized in the consolidated statement of profit or loss at its net proceeds, as either research and development costs or as selling, general, and administrative expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <asnd:DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3d658731-6dd7-4a5c-b239-6bd4d3d9596a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation is calculated on a straight-line basis, based on an asset&#x2019;s expected useful life, being within the following ranges:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.824%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Process plant and machinery&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</asnd:DescriptionOfAccountingPolicyForDepreciationUnderPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="C_696a9b0f-6d34-4970-b7ae-11c29efc2267"
      id="F_f6bf6a1b-f211-41ee-89f0-c08633e4506c">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="C_407f4eb6-3395-4dbf-ba53-ec52500920d4"
      id="F_9af9c195-2f96-40f6-8803-029d589975f4">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="C_e44fd0e7-0d85-4f4b-ad6a-35d537142fea"
      id="F_b6f6c482-2110-4d7f-974a-f5a5e4de32a9">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="C_73e96a30-9b6d-4a88-a50d-298076e408f4"
      id="F_224cb0c5-f055-46bc-8f61-892d85b321fc">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="C_baadc1e0-f0c2-4168-8df0-bf220f892569"
      id="F_c5810012-cd89-43a3-8014-8f883036b83a">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="C_6bd94bcb-874a-40fa-b4c0-feb805cf48ce"
      id="F_4d8c7d8d-cb6d-43fe-8b69-a31e1fe7db96">P11Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="C_ff216df6-44c5-401c-bf8f-32cde3f221b9"
      id="F_56e6c990-e1b8-4a9b-8913-6580e5ab2844">P2Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="C_2095e981-5419-41f2-8101-1fb2cbaf9c75"
      id="F_e855e0d4-c080-4d43-90c5-68c62b5d251a">P11Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_126e0b63-eeb9-4ddb-a249-f70727ef4c75">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Non-current Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The recoverable amount of goodwill is estimated annually irrespective of any recorded indications of impairment. Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows, or cash-generating units, which for goodwill represent the lowest level within the enterprise at which the goodwill is monitored for internal management purposes. Prior impairments of non-current assets, other than goodwill, are reviewed for possible reversal at each reporting date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_c425f913-afba-4b21-90a5-a749f6f1c923">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories comprise raw materials, work in progress and finished goods. The cost of work in progress and finished goods comprise service expenses incurred at CMOs, raw materials consumed, incremental storage and transportation, other direct materials, and a proportion of manufacturing overheads based on normal operation capacity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories are measured at the lower of cost incurred in bringing it to its present location and condition, and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Cost is measured using the first-in, first-out method. Work in progress and finished goods are measured under a standard cost method that takes into account normal levels of consumption, yields, labor, efficiency and capacity utilization. Production processes are complex, where actual yields and consumptions are sensitive to a wide variety of manufacturing conditions. Standard cost variances are reviewed regularly and adjusted to ensure inventories approximate actual cost of production.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If net realizable value is lower than cost, a write-down is recognized as the excess amount by which cost exceeds net realizable value, as part of cost of sales, or selling, general, and administrative expenses, as appropriate. The amount of reversal of write-down of inventories arising from an increase in net realizable value is recognized as a reduction in cost of sales in the period in which the reversal occurs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Manufacturing of pre-launch inventories is initiated for late-stage product candidates where manufacturing costs are recognized as inventories. However, since pre-launch inventories are not realizable prior to obtaining marketing approval, pre-launch inventories are immediately written down to zero through research and development costs. If marketing approval is obtained, prior write-downs of pre-launch inventories are reversed through research and development costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of inventories is recognized as part of cost of sales in the period in which the related revenue is recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_80dd7616-a0ea-4991-8666-6387bd13da5b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Receivables&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Receivables comprise trade receivables, income tax receivables and other receivables.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trade receivables are classified as financial assets at amortized cost, as these are held to collect contractual cash flows and thus give rise to cash flows representing solely payments of principal and interest. Trade receivables are initially recognized at their transaction price and subsequently measured at amortized cost. Income tax receivables, and other receivables related to deposits, VAT and other indirect taxes are measured at cost less impairment. Carrying amounts of receivables usually equals their nominal value less provision for impairments.&lt;/span&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory>
    <asnd:DescriptionOfAccountingPolicyForPrepaymentsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_0c56c396-d11f-427c-9e84-63f527ee5811">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepayments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepayments comprise advance payments relating to a future financial year. Prepayments are measured at cost.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</asnd:DescriptionOfAccountingPolicyForPrepaymentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_a2217bc6-2836-4528-b277-b17862f0f529">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities may comprise government bonds, treasury bills, commercial papers, and other securities traded on established markets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At initial recognition (trade-date), contractual terms of individual securities are analyzed to determine whether these give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding (&#x201c;SPPI-test&#x201d;). All marketable securities held at the reporting date have passed the SPPI-test.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities are initially recognized at fair value at trade-date, and subsequently measured at amortized cost under the effective interest method. Interest income is recognized as finance income in the consolidated statement of profit or loss. Marketable securities are subject to an impairment test to accommodate expected credit loss. Gains and losses are recognized as finance income or expenses in the consolidated statement of profit or loss when the specific security or portfolio of securities is derecognized, modified or impaired.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, having maturity profiles of three months or less after the date of acquisition are presented as cash equivalents in the consolidated statements of financial position, where securities having maturities of more than three months after the date of acquisition are presented separately as marketable securities as current (i.e., those maturing within twelve months after the reporting date) or non-current assets, as appropriate.&lt;/span&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_59348d6d-b8b7-4a06-b592-2d8e00b7a71c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents comprise cash and on-demand deposits with financial institutions, and highly liquid marketable securities with a maturity of three months or less after the date of acquisition (trade-date). Cash and cash equivalents are measured at amortized cost.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <asnd:DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_81015df7-fb6c-48f4-89c8-cdf2a4d10c65">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Allowance for Expected Credit Losses on Financial Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial assets comprise receivables (excluding receivables relating to VAT, other indirect tax and income tax), marketable securities, and cash and cash equivalents. Impairment of financial assets is determined on the basis of a forward-looking Expected Credit Loss (&#x201c;ECL&#x201d;) model. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and the cash flows expected to be received, discounted by an approximation of the original effective interest rate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For receivables, a simplified approach in calculating ECLs is applied. Therefore, changes in credit risks are not tracked, but instead, a loss allowance based on lifetime ECL is assessed at each reporting date. Lifetime ECLs are assessed on historical credit loss experience, adjusted for forward-looking factors specific to the counterparts and the economic environment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For cash, cash equivalents and marketable securities, ECLs are assessed for credit losses that result from default events that are possible within the next twelve months (12-month ECL). Credit risk is continuously tracked and monitored in order to identify significant deterioration. For those credit exposures for which there have been a significant increase in credit risk since initial recognition, an allowance is recognized for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</asnd:DescriptionOfAccountingPolicyForAllowanceForExpectedCreditLossesOnFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_a0fc228b-087e-4d64-90fc-194389a08821">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The share capital comprises the nominal amount of the parent company&#x2019;s ordinary shares, each at a nominal value of DKK &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. All shares are fully paid.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share premium comprises the amounts received, attributable to shareholders&#x2019; equity, in excess of the nominal amount of the shares issued at the parent company&#x2019;s capital increases, reduced by any expenses directly attributable to the capital increases. Under Danish legislation, share premium is an unrestricted reserve that is available to be distributed as dividends to a company&#x2019;s shareholders. Also, under Danish legislation, the share premium reserve can be used to offset accumulated deficits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Treasury shares reserve comprise nominal amounts of holding of own equity instruments. No gain or loss is recognized in profit or loss on the purchase, sale, transfer or cancellation of the Company&#x2019;s own equity instruments. The treasury shares reserve is part of unrestricted reserves and accordingly, reduce the amount available to be distributed as dividends to the Company&#x2019;s shareholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation reserve includes exchange rate adjustments relating to the translation of the results and net assets of foreign operations from their functional currencies to the presentation currency.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accumulated reserve of a foreign operation is reclassified to the consolidated statement of profit or loss at the time the Company loses control, and thus cease to consolidate such foreign operation. The foreign currency translation reserve is an unrestricted reserve that is available to be distributed as dividends to the Company&#x2019;s shareholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Retained earnings/(accumulated deficit) represents the accumulated profits or losses from the Company&#x2019;s operations, including corresponding entries to share-based payments recognized in the consolidated statement of profit or loss. In addition, premiums from acquisition and sale of treasury shares are recognized as part of this reserve. A positive reserve is available to be distributed as dividends to the Company&#x2019;s shareholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:ParValuePerShare
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="0"
      id="F_11aca942-c4d6-419d-947c-28148d862940"
      unitRef="U_DkkPerShare">1</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="C_7571783b-8274-4446-9034-fc8030ee4785"
      decimals="INF"
      id="F_797c87e9-9c7b-4fb9-b402-16b12eba55ef"
      unitRef="U_EurPerShare">0.13</ifrs-full:ParValuePerShare>
    <ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_ef8a8b7b-e00a-47be-b5ad-bd748124f94a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Convertible Senior Notes and Embedded Derivative Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes (&#x201c;convertible notes&#x201d;) are separated into a financial liability and an embedded derivative component based on the terms and conditions of the contract. The embedded derivative component is accounted for separately if it is not deemed closely related to the financial liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The convertible notes include an embedded equity conversion option which is not deemed closely related to the financial liability, and initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the convertible notes include a redemption option, which entitle the Company to redeem the notes at a cash amount equal to the principal amount of the convertible notes, plus accrued and unpaid interest. The redemption option is closely related to the financial liability, and not separately accounted for. The initial carrying amount of the financial liability component including the redemption option is the residual amount of the proceeds, net of transaction costs, after separating the derivative component.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Transaction costs are apportioned between the financial liability and derivative component based on the allocation of proceeds when the instrument is initially recognized. Transaction costs apportioned to the financial liability component form part of the effective interest and are amortized over the expected lifetime of the liability. Transaction costs allocated to the derivative component are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial liability is subsequently measured at amortized cost until it is extinguished on conversion, upon optional redemption or repayment at maturity. Convertible notes are presented as borrowings, together with the derivative liabilities on the statement of financial position, separately under current liabilities as &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Convertible notes, matures in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory>
    <ifrs-full:BorrowingsMaturity
      contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea"
      id="F_f206384b-099e-49e3-abae-88125a2ebb8b">April 2028</ifrs-full:BorrowingsMaturity>
    <asnd:DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f0953ad7-90a2-47fc-9164-5ff46af269e8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalty Funding Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities relate to the Company&#x2019;s contractual obligations to pay a predetermined percentage of future revenue from sale of commercial products until reaching a predetermined multiple of proceeds received, pursuant to the detailed provisions of the capped synthetic royalty funding agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Where relevant, royalty funding liabilities are separated into a financial liability and embedded derivative components based on the terms and conditions of the applicable royalty funding agreement. Embedded derivative components are accounted for separately, unless these are deemed closely related to the financial liability. The royalty funding agreements include a buy-out option where the value is dependent on non-financial variables that are specific to the Company. Accordingly, the buy-out option is not accounted for separately as a derivative.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial liability is recognized when the Company becomes party to the contractual provisions of the royalty funding agreement and measured at amortized cost until it is extinguished upon exercising a buy-out option or upon achieving the predetermined multiple of proceeds received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The effective interest rate is estimated at initial recognition and takes into account incremental transaction costs and anticipated amount and timing of future cash flows, which further depends on future commercial revenue forecasts and the probability of exercising the buy-out option. The amortized cost is remeasured prospectively when there is a material change in expectations to amount and timing of future cash flows, which will increase or decrease future interest expenses. Remeasurement gain or losses are recognized through the profit or loss as finance income or expenses, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities that are classified as a financial liability are presented as part of borrowings in the statement of financial position.&lt;/span&gt;&lt;/p&gt;</asnd:DescriptionOfAccountingPolicyForRoyaltyFundingLiabilitiesTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_a41af717-ecfa-44a3-b1e2-00b3b5f2adeb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Right-of-use Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets are recognized at the lease commencement date, defined as the date the underlying asset is available for use. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets include the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any incentives received. In addition, right-of-use assets also include an estimate of costs to be incurred by the Company in dismantling or restoring the underlying asset to the condition if required by the terms and condition of the lease, if any.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets are presented as part of property, plant and equipment, and depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Lease Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the lease commencement date, lease liabilities are recognized and measured at the present value of fixed lease payments and variable lease payments that depend on an index or a rate, whereas variable lease payments and payments related to non-lease components are excluded. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the consolidated statement of profit or loss when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When interest rates implicit in the lease contracts are not readily available, the present value of lease payments are calculated by applying the incremental borrowing rate of the relevant entity holding the lease. Following the commencement date, the incremental borrowing rate is not changed unless the lease term is modified, or if the lease payments are modified and this modification results from a change in floating interest rates. From the lease commencement date and over the lease term, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in lease term, or a change in lease payments, including changes to future payments resulting from a change in an index used to determine such lease payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities are presented as part of borrowings in the statement of financial position.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_da6591ec-5107-4942-9107-db415c29305b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provisions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provisions comprise unsettled sales deductions and product returns regarding revenue from sale of commercial products where amount or timing of payment is uncertain.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provisions for sales deductions attributed to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangements are recognized when the related sales takes place and measured using the expected value method. Payable amounts for managed healthcare organizations and government programs are generally settled within 180 days from the transaction date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provisions for estimated product returns are measured according to the contractual sales price based on expected product returns.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_59ac6764-1feb-4b64-94d3-ddd22432958f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trade Payables and Accrued Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trade payables and accrued expenses are measured at amortized cost.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory>
    <asnd:DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_6ee6d313-52e5-414e-ac48-0cf4ce70bcc7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other liabilities comprise payables to public authorities, short-term employee benefits, and sales deductions. Other liabilities are measured at their net-realizable values.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</asnd:DescriptionOfAccountingPolicyForOtherPayablesExplanatoryTextBlock>
    <asnd:DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_9017fa76-3da4-4ee7-9854-f2dc10938295">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contract Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities comprise deferred income from collaboration and license agreements, where consideration received does not match the individual deliverables with respect to amount and satisfied performance obligations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities are measured at the fair value of the consideration received and is recognized as revenue in the consolidated statement of profit or loss when the relevant performance obligation, to which the deferred income relates, is satisfied.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</asnd:DescriptionOfAccountingPolicyForDeferredRevenuesAndContractLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForCashFlowsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_9e472796-5839-4795-94c4-9d8cfbfd14be">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash Flow Statement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cash flow statement shows cash flows from operating, investing and financing activities as well as cash and cash equivalents at the beginning and the end of the financial year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash flows from operating activities are presented using the indirect method and calculated as the profit or loss adjusted for non-cash items, working capital changes as well as finance income, finance expenses and income taxes paid.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash flows from investing activities include payments in connection with acquisition, development, improvement and sale, etc., of property, plant and equipment, investments in associates and marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash flows from financing activities comprise payments related to the capital structure of the Company, including changes in the share capital and treasury shares, and issuance and repayments under the Company&#x2019;s borrowing activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency is presented separately from cash flows from operating, investing and financing activities. Cash flows in currencies other than the functional currency are recognized in the cash flow statement, using the average exchange rates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents comprise cash and on-demand bank deposits with financial institutions and highly liquid marketable securities with a maturity of three months or less after the date of acquisition.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForCashFlowsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_a95b5c20-4b3a-4ecb-be8b-c558924b7b74">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic Earnings per Share (&#x201c;EPS&#x201d;) is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding. The weighted average number of shares takes into account the weighted average number of treasury shares during the year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <asnd:DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_067c898f-4e9d-40ca-b526-9f20efb3b9b0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted EPS is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding adjusted for the weighted average effect of changes in treasury shares during the year, and the dilutive effect of outstanding warrants and convertible notes. If the consolidated statement of profit or loss shows a net loss, no adjustment is made for the dilutive effect, as such effect would be anti-dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</asnd:DescriptionOfAccountingPolicyForDilutedEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_32f2d378-52b1-406c-91d3-f66409384022">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;New IFRS Accounting Standards Not Yet Effective&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2024, the IASB issued IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d; (&#x201c;IFRS 18&#x201d;), which replaces IAS 1, &#x201c;Presentation in Financial Statements.&#x201d; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements are not expected to be affected by other new or amended standards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_a1878bf5-0a06-4e97-929f-6d77a1dc6a28">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3 &#x2013; Significant Accounting Judgements and Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the application of the Company&#x2019;s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management&#x2019;s ongoing revisions of critical accounting estimates and underlying assumptions have not revealed any material impact in any of the years presented in these consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no changes to the application of significant accounting judgements, or estimation uncertainties regarding accounting estimates compared to December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant Accounting Judgements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant accounting judgements which have a material impact on the consolidated financial statements are described in the following sections.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internally Generated Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Development of Drug Candidates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IAS 38, &#x201c;Intangible Assets&#x201d; prescribes that intangible assets arising from development projects must be recognized in the consolidated statements of financial position if the criteria for capitalization are met. That means (1) that the development project is clearly defined and identifiable; (2) that technological feasibility, adequate resources to complete and a market for the product or an internal use of the project can be documented; (3) that the expenditure attributable to the development project can be measured reliably; and (4) that the Company has the intent to produce and market the product. Such an intangible asset shall be recognized if it can be demonstrated that the future income from the development project will exceed the aggregate cost of development, production, sale and administration of the product.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to the risk associated with drug development, future income from development projects related to drug candidates cannot be determined with sufficient certainty until the development activities have been completed and the necessary marketing approvals have been obtained. Accordingly, the Company does not recognize internally generated intangible assets at this time.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant Estimation Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue and Provisions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Provisions for Sales Deductions and Product Returns&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sales deductions and product returns are considered variable consideration and constrained to the extent that a significant reversal in the amount of recognized revenue will not occur when the uncertainties associated with the rebate or chargeback item are subsequently resolved, or for product returns, when the products are distributed to patients.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provisions for unsettled sales deductions and product returns are estimated on the basis of a percentage of sales as defined by individual agreements and contracts, and for government rebates by individual state- and plan agreements. Further inputs to the calculations are based on payer channel mix, current contract prices under eligible programs and current inventory levels in the distribution channels. Inputs to the calculations are subject to estimation and assumptions and are based on historical experience and other factors that are relevant, and which are available at the reporting date. Provisions are adjusted to absolute amounts and recognized as other liabilities when estimated sales deductions are processed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, provisions for sales deductions and product returns were &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million compared to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, as of December 31, 2023. The development in total provisions is disclosed in Note 15, &#x201c;Provisions.&#x201d; Due to the nature of these provisions, it is not practicable to give meaningful sensitivity estimates due to the large volume of variables that contribute to the overall rebates, chargebacks, product returns and other sales deductions. Provisions are reviewed and adjusted regularly considering contractual terms, regulatory obligations, payer trends, historical experiences and market projections.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrant Compensation Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IFRS 2, &#x201c;Share-Based Payment&#x201d; requires an entity to reflect in its consolidated statement of profit or loss and financial position, the effects of share-based payment transactions. Warrant compensation costs are recognized as cost of sales, research and development costs or selling, general and administrative expenses, as appropriate, over the vesting period, based on management&#x2019;s best estimate of the number of warrants that will ultimately vest, which is subject to uncertainty.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant compensation costs are measured according to the grant date fair value of the warrants granted. Estimating fair values requires the Company to apply generally accepted valuation models and apply these models consistently according to the terms and conditions of the specific warrant program. Under all warrant programs, the Black-Scholes option-pricing model has been applied to determine the fair value of warrants granted. Subjective judgements and assumptions, which are subject to estimation uncertainties, need to be exercised in determining the appropriate input to the valuation model. These inputs include expected volatility of the Company&#x2019;s share price for a historic period equaling the expected lifetime of the warrants, reflecting the assumption that the historical volatility over a period similar to the life of the warrants is indicative of future trends, expected forfeitures and expected lifetime of warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant compensation cost recognized in the consolidated statement of profit or loss was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024, 2023 and 2022, respectively. Changes to inputs applied to the Black-Scholes option-pricing model could affect the warrant compensation cost. Refer to Note 7, &#x201c;Share-based Payment,&#x201d; for additional details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Valuation of Embedded Derivatives&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign currency conversion options embedded in the convertible notes are accounted for separately as derivative liabilities at fair value through profit or loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value cannot be measured based on quoted prices in active markets, or other observable input, and accordingly, derivative liabilities are measured by use of valuation techniques in the form of the Black-Scholes option-pricing model. Subjective judgements and assumptions, which are subject to estimation uncertainties, need to be exercised in determining the appropriate unobservable input to the valuation model (Level 3 in the fair value hierarchy). This includes volatility of the Company&#x2019;s share price for a historic period, reflecting the assumption that the historical volatility is indicative of a period similar to the expected lifetime of the options.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the valuation of the derivative liabilities was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million compared to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;143.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of December 31, 2023. Changes in assumptions relating to these factors could affect the reported fair value of derivative liabilities. Refer to Note 16, &#x201c;Financial Assets and Liabilities,&#x201d; for additional details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Measurement of Royalty Funding Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying amount of royalty funding liabilities is measured according to anticipated future cash flows, which further depends on the amount and timing of future revenue from sale of commercial products. Assumptions that impact the amount and timing of future sale of commercial products are subject to estimation uncertainties, and are subject to a number of factors which are not within the Company&#x2019;s control.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the carrying amount of the royalty funding liabilities was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million compared to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2023. As of December 31, 2024, royalty funding liabilities comprised two agreements compared with one agreement as of December 31, 2023. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company will periodically revisit the anticipated amount and timing of future sale of commercial products and to the extent such amount or timing is materially different from the previous estimates, a remeasurement gain or loss is recognized through the profit or loss as finance income or expenses, as appropriate, which would further increase or decrease future interest expenses. Refer to Note 16, &#x201c;Financial Assets and Liabilities&#x201d; for additional details.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:CurrentProvisions
      contextRef="C_f7c738af-0b0d-4113-8fdf-04db859fac4b"
      decimals="-5"
      id="F_57609a1b-f0d4-4fed-9e1d-7c6ef6d126ff"
      unitRef="U_EUR">99100000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="C_eea8b977-0335-4240-bf23-27c15cf887d9"
      decimals="-5"
      id="F_9077f46b-4ae1-4291-8cc2-ac73b9e41eda"
      unitRef="U_EUR">32700000</ifrs-full:CurrentProvisions>
    <asnd:WarrantCompensationCost
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-5"
      id="F_871ef596-462b-4878-a561-4bd9f1487402"
      unitRef="U_EUR">19700000</asnd:WarrantCompensationCost>
    <asnd:WarrantCompensationCost
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-5"
      id="F_b505e398-1d82-40e1-bd00-2548703135bf"
      unitRef="U_EUR">28800000</asnd:WarrantCompensationCost>
    <asnd:WarrantCompensationCost
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-5"
      id="F_e17340af-45a1-41fb-81a4-38f760456cb6"
      unitRef="U_EUR">55200000</asnd:WarrantCompensationCost>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-5"
      id="F_e60f0a0c-5a78-4507-8d60-9bc601bfd30d"
      unitRef="U_EUR">150700000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_f7ae8477-02c2-4bc2-8628-d02fe9ff863e"
      unitRef="U_EUR">143300000</ifrs-full:DerivativeFinancialLiabilities>
    <asnd:CarryingAmountOfRoyaltyFundingLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-5"
      id="F_daf0f68f-b14c-43db-a750-fdf1637680db"
      unitRef="U_EUR">305400000</asnd:CarryingAmountOfRoyaltyFundingLiabilities>
    <asnd:CarryingAmountOfRoyaltyFundingLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_9b95f8f8-2bd4-425b-a9eb-9c0c5fbcc530"
      unitRef="U_EUR">138400000</asnd:CarryingAmountOfRoyaltyFundingLiabilities>
    <ifrs-full:DisclosureOfRevenueExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_38853f9d-37f3-4e16-96e6-06f8cffcdddd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 4&#x2014;Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue has been recognized in the consolidated statements of profit or loss with the following amounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rendering of services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical supply&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;363,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;266,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;51,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Attributable to&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration partners and license agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;363,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;266,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;51,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified by timing of recognition&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognized over time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognized at a point in time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;363,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;266,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;51,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified per geographical area&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Europe &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rest of world&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;363,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;266,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;51,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, Denmark, the country of domicile, contributed with &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commercial Customers&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue attributable to commercial customers by product were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue from commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;SKYTROFA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;197,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;YORVIPATH&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue from commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;225,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;178,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;35,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue from sales of SKYTROFA&#xae; is primarily sold to specialty pharmacies and specialty distributors in the U.S. market, and to wholesalers and pharmacies in Germany. Revenue from sale of SKYTROFA for the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, was negatively impacted by an adjustment to estimates and assumptions for sales deductions of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which was related to periods prior to January 1, 2024. The adjustment was primarily attributable to a different payer and rebate mix than anticipated, and on which provisions for prior years were based.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, TransCon PTH received marketing approval in the EU and European Economic Area countries and is marketed as YORVIPATH&#xae;. In August 2024, TransCon PTH received marketing approval in the U.S. and is marketed in the U.S. as YORVIPATH. The Company began selling YORVIPATH, primarily to pharmacies in Europe in the first quarter of 2024, and to specialty pharmacies in the U.S. in December 2024. In addition, the Company began selling YORIVPATH to distributors in the second quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; commercial customers represented more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of sales to commercial customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaboration Partners and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue attributable to collaboration partners and license agreements relates to Novo Nordisk A/S (&#x201c;Novo Nordisk&#x201d;), Eyconis, Inc. (&#x201c;Eyconis&#x201d;), Teijin Limited (&#x201c;Teijin&#x201d;) and VISEN Pharmaceuticals (&#x201c;VISEN&#x201d;). Under the collaboration agreements, the Company also provides various research and development services which are invoiced to collaboration partners. Revenue for these activities is presented as part of &#x201c;Rendering of services.&#x201d; Employment costs related to these activities are presented as Research and Development Costs in the consolidated statement of profit or loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Novo Nordisk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the Company entered into a research and development collaboration and license agreement (the &#x201c;Novo Nordisk Agreement&#x201d;) with Novo Nordisk pursuant to which the Company granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products (including Semaglutide) in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases (the &#x201c;IP&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Novo Nordisk Agreement includes provisions requiring at least one TransCon Semaglutide product and at least one other TransCon technology-based product to be identified, developed and commercialized in metabolic diseases to maintain certain exclusivities in the field, with additional provisions for cardiovascular diseases. Under the terms of the Novo Nordisk Agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas. The lead program in the collaboration is a once-monthly TransCon Semaglutide product candidate that will initially target obesity and type 2 diabetes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Novo Nordisk Agreement, the Company has the potential to receive total payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in upfront, development and regulatory milestone payments for the lead program. In addition, the Company has the potential to receive sales-based milestone payments and tiered royalties on global net sales. The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million includes an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the exclusive license. For each additional metabolic or cardiovascular disease product candidate, the Company will be eligible to receive payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in development and regulatory milestone payments. In addition, the Company has the potential to receive sales-based milestone payments and tiered royalties on global net sales. Novo Nordisk agreed to pay royalties for each potential licensed product developed under the agreement that are an escalating tiered, mid-single digit percentage of the annual net sales of such licensed product and are subject to reduction due to patent valid claim expiration, biosimilar product market share, payment made under certain licenses for third party intellectual property and Inflation Reduction Act price negotiations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Novo Nordisk Agreement, the Company agreed to conduct certain pre-agreed early research and development of TransCon product candidates under the collaboration and is eligible to receive cost reimbursement from Novo Nordisk for its performance of such research and development activities under the Novo Nordisk Agreement with respect to such TransCon product candidates. Novo Nordisk is responsible for any other non-clinical and clinical development, regulatory, commercial manufacturing, and commercialization of such TransCon product candidates, and all costs associated with such activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subject to the terms of the Novo Nordisk Agreement, the Company granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. Additionally, the Company granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize GLP-1 receptor products using the TransCon technology for all indications, except for (i) certain pre-agreed rare endocrine indications, (ii) all indications in respect of the eye and adnexa and (iii) all indications in respect of oncology.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unless earlier terminated, the Novo Nordisk Agreement has a royalty term that continues, on a per licensed product and per country basis, until the later of (i) the expiration of the last valid patent claim for any of our patents, joint improvement patents, licensed product patents as well as any improvements made by Novo Nordisk covering the licensed product&#x2019;s dosage regimen or target product profile, or (ii) 11 years after the first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The IP comprises the patent protected TransCon technology platform, where future activities do not affect its existing stand-alone functionalities. Accordingly, the IP is classified as &#x201c;right-to-use&#x201d; licenses, with revenue recognized at a point in time, where the licensee is granted access to the IP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, &#x201c;Licenses&#x201d; includes revenue of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to the upfront payment, which is allocated to transfer of the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Eyconis&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, a separate company created to develop, manufacture, and commercialize TransCon ophth&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;almology assets globally, together with a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally (the &#x201c;Eyconis Agreement&#x201d;) and received, as consideration, an equity position in the newly formed company. In addition, the Company is eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is expected to provide various research and development services, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, &#x201c;Licenses&#x201d; includes revenue of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to the non-cash upfront payment through an equity position in Eyconis, adjusted for internal profit, which is allocated to transfer of the Company&#x2019;s intellectual property (the &#x201c;IP&#x201d;). The internal profit relates to the Company&#x2019;s share of the non-cash upfront payment which is recognized as part of &#x201c;Investments in associates&#x201d; and recognized as revenue from &#x201c;Licenses&#x201d; as the IP is amortized in the associate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue from royalties or milestones has been recognized under the Eyconis agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Teijin&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Company entered into an exclusive license agreement (the &#x201c;Teijin Agreement&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with Teijin  for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease (the &#x201c;Licensed Products&#x201d;) in Japan. Under the terms of the Teijin Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, with additional development and regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and commercial milestones. In addition, the Company is eligible to receive royalties on net sales of the Licensed Products in Japan, of up to mid-20&#x2019;s percent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Further, the Company will provide clinical and commercial supply, and development services for joint activities, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, none of the Licensed Products have received marketing authorization in Japan. The Licensed Products (the &#x201c;IP&#x201d;) are patent protected, where future activities do not affect their existing stand-alone functionalities. Accordingly, all three licenses are classified as &#x201c;right-to-use&#x201d; licenses, with revenue recognized at a point in time, where the licensee is granted access to the IP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2023, &#x201c;Licenses&#x201d; includes revenue of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to the upfront payment, which is allocated to transfer of the Company&#x2019;s IP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue from royalties o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;r milestones has been recognized under the Teijin Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;VISEN&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2018, the Company entered into three exclusive license agreements with VISEN. Revenue from collaboration partners and license agreements also includes license income, rendering of services and sale of clinical supply under the VISEN Agreements.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_06ffef24-98df-4c96-83c0-621c56e90183">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue has been recognized in the consolidated statements of profit or loss with the following amounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rendering of services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical supply&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;363,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;266,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;51,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Attributable to&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration partners and license agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;363,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;266,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;51,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified by timing of recognition&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognized over time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognized at a point in time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;363,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;266,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;51,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified per geographical area&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Europe &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rest of world&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;363,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;266,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;51,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, Denmark, the country of domicile, contributed with &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_87108864-907d-43bd-baf4-664b2887ab2b"
      unitRef="U_EUR">225728000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_babf5f1e-2e04-4bed-a6e6-1b37721715b3"
      unitRef="U_EUR">178663000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_2fd3155a-8d83-4c3a-9ff7-2d2bd8f2db96"
      unitRef="U_EUR">35659000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_bcfe28ca-2f2f-444a-b555-6940caf64a73"
      unitRef="U_EUR">11794000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_2484612d-828b-4dc2-8b44-73789a885d2c"
      unitRef="U_EUR">21659000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_2a813170-8a7b-4621-a78a-3423c4dc461d"
      unitRef="U_EUR">4434000</ifrs-full:RevenueFromRenderingOfServices>
    <asnd:RevenueFromClinicalSupply
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_b87d217b-f0e3-45fd-bf83-850f1f88da7f"
      unitRef="U_EUR">3776000</asnd:RevenueFromClinicalSupply>
    <asnd:RevenueFromClinicalSupply
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_a3d0106c-0059-4af7-abd8-4e8f6720e8b3"
      unitRef="U_EUR">319000</asnd:RevenueFromClinicalSupply>
    <asnd:RevenueFromClinicalSupply
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_d2d16f23-2e56-4cd7-ad25-a76fb496548c"
      unitRef="U_EUR">8534000</asnd:RevenueFromClinicalSupply>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_8f9d7b92-d38b-4820-8185-351d411efaaa"
      unitRef="U_EUR">122343000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_e8b1661c-24a9-4230-8800-a6f203af97a2"
      unitRef="U_EUR">66077000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_728aa7e4-fdd2-498b-b50d-ad48e3c871a2"
      unitRef="U_EUR">2547000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:Revenue
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_1b460847-bb12-473e-82bd-0d71086e7ae4"
      unitRef="U_EUR">363641000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_bd1f26bb-b773-4ebd-8a1f-fc9cca2eb1ad"
      unitRef="U_EUR">266718000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_43b3e61e-d1de-4ae0-bf87-93e73004d5d1"
      unitRef="U_EUR">51174000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_4bdf2506-3db5-4bb3-83af-af102c9194d4"
      decimals="-3"
      id="F_8fc288f3-0e43-4690-b9ce-d678d29201d0"
      unitRef="U_EUR">225728000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_13fbb09d-e7fc-4533-b7b0-f7775229adc4"
      decimals="-3"
      id="F_c1c612c5-58a0-46cb-9cdb-4b406932b47b"
      unitRef="U_EUR">178663000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_a0ccec1e-9a89-4166-b4d2-16f6ff5ce9da"
      decimals="-3"
      id="F_ccb1a605-299b-4bd8-8b1a-1972472d9e10"
      unitRef="U_EUR">35659000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_f2f1dbaf-420a-4683-bcef-b0e869189327"
      decimals="-3"
      id="F_95d8906e-57d7-410a-829e-3ec9a6ca55c3"
      unitRef="U_EUR">137913000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_4b2b9d36-6d18-4c57-b0cf-ce1f8e06c2d6"
      decimals="-3"
      id="F_0c09429f-0826-4aba-a2ef-a16965eb0f29"
      unitRef="U_EUR">88055000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_0872112c-3272-422e-80db-297cf18bfc6c"
      decimals="-3"
      id="F_68dcbc4d-0d04-415e-8f88-f1599c5b29f7"
      unitRef="U_EUR">15515000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_ab67e9a5-b3ba-4505-9bdf-d1336d916349"
      unitRef="U_EUR">363641000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_b7199d30-c7cc-4c3d-8e29-a775f3edcd08"
      unitRef="U_EUR">266718000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_6431ac0a-97ae-4e0b-bcbd-1bbea7052730"
      unitRef="U_EUR">51174000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_27d1c1a3-108e-4619-be6f-517ff8d95133"
      decimals="-3"
      id="F_b3962702-f85a-4158-ba2c-c964adb2914b"
      unitRef="U_EUR">11794000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_f6aae539-4c18-4dfe-8da2-d2171008ea12"
      decimals="-3"
      id="F_6522671b-6ecb-418d-8c59-8196f32e1d51"
      unitRef="U_EUR">21659000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_27f6fcda-5a1b-42d3-b991-c9dc1d11267b"
      decimals="-3"
      id="F_53f8b4b9-3ffa-453b-8a68-9de66b40593f"
      unitRef="U_EUR">4434000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_b3502041-2bf1-4ab4-81d2-63ddd7dc8027"
      decimals="-3"
      id="F_a94451be-a323-4b9e-8a6d-47f634e7d496"
      unitRef="U_EUR">351847000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_d9262209-f85f-4e2f-897d-34d234660e65"
      decimals="-3"
      id="F_9480abcb-c6a8-4cf3-a182-9304305e9208"
      unitRef="U_EUR">245059000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_a10a1719-791f-4cff-8b86-2f3b720e2290"
      decimals="-3"
      id="F_a0bacae8-be13-40f1-a932-d17fc4319311"
      unitRef="U_EUR">46740000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_5576f5af-3c6e-4574-992b-57c3ef4f09e2"
      unitRef="U_EUR">363641000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_8cdc84a0-f46e-49eb-b467-7bf8fba2b120"
      unitRef="U_EUR">266718000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_1a754179-34b9-4593-97d4-f4899b738a94"
      unitRef="U_EUR">51174000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_75afca32-d330-4c6c-a9ea-5bd565d35e9c"
      decimals="-3"
      id="F_ba08214c-32b5-4f09-b6e4-9a994af72cd1"
      unitRef="U_EUR">123336000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_9133c0f6-7b07-41ad-a86d-58e8adc23e5f"
      decimals="-3"
      id="F_6daf54d1-409b-461e-8cfc-acfe645e0462"
      unitRef="U_EUR">869000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_809a9649-b6e0-488d-b7e5-4e1442b1f755"
      decimals="-3"
      id="F_e87e3dc4-7830-4404-82ff-01ef28886f9c"
      unitRef="U_EUR">552000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_99536d97-e9f4-4fd6-9215-dd6f7d4b7755"
      decimals="-3"
      id="F_3083bd66-5f97-4baa-9d3b-4a21eee8dff7"
      unitRef="U_EUR">233220000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_b1966962-eeea-4f7a-8501-53f2cca4ab33"
      decimals="-3"
      id="F_69cbdfb5-8e6f-42aa-8de7-50e028a45bc9"
      unitRef="U_EUR">191677000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_226c442b-8147-46aa-8d42-d133bbb66af0"
      decimals="-3"
      id="F_f485fa72-0d20-4ad4-9619-74ed5c16e0ac"
      unitRef="U_EUR">44156000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_8e586c11-342f-42e1-8ae7-79f86b29e744"
      decimals="-3"
      id="F_50206a57-94c1-4168-a09f-f33a78b9319d"
      unitRef="U_EUR">7085000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_59c4cbcd-b4e1-4274-bcd8-37e7ffa78cb7"
      decimals="-3"
      id="F_30cacb75-9073-43ea-b22b-b2934e9c2a5c"
      unitRef="U_EUR">74172000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_9a3e4976-f3f3-4e99-a326-5bb0cb57fee4"
      decimals="-3"
      id="F_909c87fa-c029-4886-bd17-dcbffaa72157"
      unitRef="U_EUR">6466000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_182e1ca6-1b26-41b6-90da-4699c5d0b8f0"
      unitRef="U_EUR">363641000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_facaa902-cb69-436d-b693-3e12b75aa319"
      unitRef="U_EUR">266718000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_d0b9a6ef-c95d-432d-a38d-14a0bff480b8"
      unitRef="U_EUR">51174000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e223f34a-d64a-4201-8c13-a2f49a7b3064"
      decimals="-5"
      id="F_83b14a8a-e5bd-40fe-959c-63db4fad3554"
      unitRef="U_EUR">95400000</ifrs-full:Revenue>
    <asnd:DisclosureOfRevenueToCommercialCustomersExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_6456ce00-4282-4a81-aeea-deb8eae597f3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue attributable to commercial customers by product were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue from commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;SKYTROFA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;197,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;YORVIPATH&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue from commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;225,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;178,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;35,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfRevenueToCommercialCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_b27a3e9d-f494-4d9d-bd82-cffda92ba702"
      decimals="-3"
      id="F_9c420f07-e9e2-4995-ae14-ef5e0b6000b9"
      unitRef="U_EUR">197001000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_41772ede-2e6a-48e2-9da6-829133e5685d"
      decimals="-3"
      id="F_2c5af821-d126-4bd8-9128-79ce639a27da"
      unitRef="U_EUR">178663000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_056508e0-3110-42be-99e5-6e860f20e4ed"
      decimals="-3"
      id="F_400dba34-67d6-46a7-b491-daf726c04da6"
      unitRef="U_EUR">35659000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_334ba08e-f8aa-49c1-ba15-fe73942f5b92"
      decimals="-3"
      id="F_90fff74d-bc4e-49dc-9570-286334ba70af"
      unitRef="U_EUR">28727000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_8254a47f-7720-4dbd-860f-ccd3f90e8bcd"
      decimals="-3"
      id="F_bc28d95b-cad7-4c91-acc7-562f3956358d"
      unitRef="U_EUR">225728000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_58152c33-7510-459f-b8e0-76242c88205c"
      decimals="-3"
      id="F_da3659b4-8850-4b27-b354-bbb073c2b886"
      unitRef="U_EUR">178663000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_d3c3de28-899d-4a79-acfe-c562d328512b"
      decimals="-3"
      id="F_577e775d-99a6-4fe6-958d-9cc172b9d8a2"
      unitRef="U_EUR">35659000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:Revenue
      contextRef="C_9e913d68-9472-471d-b85b-01401c7287b6"
      decimals="-5"
      id="F_768f4a82-8b94-4a1c-8079-ac977e5c45a4"
      unitRef="U_EUR">4700000</ifrs-full:Revenue>
    <asnd:NumberOfCommercialCustomers
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="INF"
      id="F_5be7abd5-7770-4b7b-9f0e-630636c5a8cf"
      unitRef="U_CommercialCustomer">4</asnd:NumberOfCommercialCustomers>
    <asnd:NumberOfCommercialCustomers
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="INF"
      id="F_6b5b1647-8d55-4bb1-9089-f8f4fb684ec3"
      unitRef="U_CommercialCustomer">4</asnd:NumberOfCommercialCustomers>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="C_1cc8cf22-cda6-4602-8545-8e4460115453"
      decimals="INF"
      id="F_e7ba60cd-2032-486c-b025-d5e9f3628176"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="C_223c5789-12ac-442b-9056-83ed832b3d73"
      decimals="INF"
      id="F_11333208-6727-4227-bb11-178cf79b761c"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <asnd:UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived
      contextRef="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce"
      decimals="-6"
      id="F_46d3d757-fcfe-425d-84ff-9f2f646dee56"
      unitRef="U_EUR">285000000</asnd:UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived>
    <asnd:UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived
      contextRef="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce"
      decimals="-6"
      id="F_5e2a336c-9e01-4eca-b6c5-fd8dd3ba7395"
      unitRef="U_EUR">285000000</asnd:UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived>
    <asnd:UpfrontFeeForExclusiveLicense
      contextRef="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce"
      decimals="-6"
      id="F_4a83ef26-8868-40f1-a9d6-7a44dede429a"
      unitRef="U_EUR">100000000</asnd:UpfrontFeeForExclusiveLicense>
    <asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived
      contextRef="C_f0bbe1ca-4e8d-47d2-995b-064cbd92ccce"
      decimals="-5"
      id="F_b77cccbd-653e-4668-9459-5b04d47928d0"
      unitRef="U_EUR">77500000</asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived>
    <asnd:UpfrontPaymentReceived
      contextRef="C_2fbd9ed0-f949-4f61-a72f-c83438fb93d7"
      decimals="-5"
      id="F_5e0b318b-fccd-4118-82b6-7d406666b3f6"
      unitRef="U_EUR">95300000</asnd:UpfrontPaymentReceived>
    <asnd:CapitalCommitmentFromInvestors
      contextRef="C_dc50b8f4-013f-4948-b862-ea14c2c8fd6d"
      decimals="-6"
      id="F_6f005d91-b9ce-4725-bff7-a4c0fe221e9d"
      unitRef="U_EUR">150000000</asnd:CapitalCommitmentFromInvestors>
    <asnd:UpfrontPaymentReceived
      contextRef="C_a91db531-c49c-48c0-bb87-a56fc4db3411"
      decimals="-5"
      id="F_adbcdd90-088d-4f5d-905f-26ad8c393e0e"
      unitRef="U_EUR">27100000</asnd:UpfrontPaymentReceived>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_c590a703-806b-44d7-bbfc-d91f2b5829c8"
      decimals="INF"
      id="F_8e338087-7865-4412-b060-a1da7f6304a6"
      unitRef="U_USD">0</ifrs-full:RevenueFromContractsWithCustomers>
    <asnd:UpfrontPaymentReceived
      contextRef="C_3a4c34db-9705-4e82-a924-1e8c85b0d587"
      decimals="-6"
      id="F_500d1c97-3fa9-40f3-8fa4-1715014cae46"
      unitRef="U_USD">70000000</asnd:UpfrontPaymentReceived>
    <asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived
      contextRef="C_3a4c34db-9705-4e82-a924-1e8c85b0d587"
      decimals="INF"
      id="F_7fc7a9d5-04ce-4679-9b02-fdcd0622252a"
      unitRef="U_USD">175000000</asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived>
    <asnd:UpfrontPaymentReceived
      contextRef="C_49956232-8f1a-430a-8b06-3dce7628da9c"
      decimals="-5"
      id="F_6d2ac3db-a177-454f-a42e-4ef72fb55e33"
      unitRef="U_EUR">63700000</asnd:UpfrontPaymentReceived>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_653f32e5-e4d2-4129-866f-b2bb9319ac6f"
      decimals="-3"
      id="F_01bc20cc-7ef1-4315-95a7-902b4ba0d4c0"
      unitRef="U_EUR">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_a5338362-b7bf-4120-9641-251cf8cd6833">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 5&#x2014;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is managed and operated as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; business unit. Accordingly, no additional information on business segments or geographical areas is disclosed apart from revenue on geographical areas as disclosed in Note 4, &#x201c;Revenue.&#x201d; Revenue is specified on geographical areas according to the location of the customer.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s intangible assets and property, plant and equipment located by region are specified below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intangible assets and property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Europe &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total intangible assets and property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;102,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;115,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023, intangible assets and property, plant and equipment of &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, is located in Denmark, the country of domicile.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <asnd:NumberOfReportableOperatingSegments
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="INF"
      id="F_27b09533-5086-4636-b51c-2fe72500289c"
      unitRef="U_Segment">1</asnd:NumberOfReportableOperatingSegments>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_55837abe-3d05-4c56-905c-4a95dad77645">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s intangible assets and property, plant and equipment located by region are specified below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intangible assets and property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Europe &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total intangible assets and property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;102,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;115,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023, intangible assets and property, plant and equipment of &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, is located in Denmark, the country of domicile.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="C_b1595989-ee89-44d6-aafc-6d121568fc57"
      decimals="-3"
      id="F_fa2dca79-f11c-4eb0-a55e-cfc987c5b8ed"
      unitRef="U_EUR">39640000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="C_39ca7b17-a1b7-43d1-90e6-efe3a598d636"
      decimals="-3"
      id="F_6f90b4e9-624c-4747-b8bf-fa9904dc08fa"
      unitRef="U_EUR">46464000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="C_4f865b62-7fe6-48cb-a856-16fdbcba2ac2"
      decimals="-3"
      id="F_df1a8e56-bd35-4839-abde-c23921b89fc0"
      unitRef="U_EUR">63102000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="C_b47e07a7-681a-4a20-87be-95dd4075cfa3"
      decimals="-3"
      id="F_070a2daf-2a68-4d78-ab83-e22a4e2680bd"
      unitRef="U_EUR">68589000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_36a31f2c-3f7d-4f4e-803f-da0823a9153d"
      unitRef="U_EUR">102742000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_2a41c8c0-8167-4780-8cd8-a38c616f31ef"
      unitRef="U_EUR">115053000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="C_f1426637-e196-44bf-aad5-b8473714e9cd"
      decimals="-5"
      id="F_2ac9e3a5-58fd-43bb-8ede-7542a1b41d0d"
      unitRef="U_EUR">27900000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="C_860b08a9-36e4-40f6-9b25-30137702ac03"
      decimals="-5"
      id="F_ff10d4cd-b988-4f3f-9957-d613695a3b36"
      unitRef="U_EUR">32900000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_d998943d-59df-4e5b-b8ed-4ffec6f27d72">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 6&#x2014;Employee costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Wages and salaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;140,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pensions (defined contribution plans)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Social security costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;292,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;258,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;223,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Included in the profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;292,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;258,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;223,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Average number of employees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes employee costs capitalized as part of inventories.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Key Management Personnel comprises the Board of Directors, the Executive Board and Non-executive Senior Management. Compensation to Key Management Personnel comprises salaries, participation in annual bonus schemes, pensions (defined contributions plans), and share-based compensation. Share-based compensation is elaborated in further details in Note 7, &#x201c;Share-based Payment.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Compensation to Key Management Personnel included in total employee costs is summarized below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:20.492%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.457%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Board of Directors &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Executive Board &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-executive Senior Management&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="34" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR &#x2018;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Wages and salaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pensions (defined&lt;br/&gt;&#160;&#160;&#160;contribution plans)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Social security costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other employee cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;22,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;17,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;13,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;14,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Directors comprised six persons in 2024 and six to seven persons in 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Board comprised four persons in 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_20a67704-2a79-4391-af6a-9ff0f50b9dd3">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Wages and salaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;140,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pensions (defined contribution plans)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Social security costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;292,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;258,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;223,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Included in the profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;292,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;258,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;223,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Average number of employees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes employee costs capitalized as part of inventories.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock>
    <ifrs-full:WagesAndSalaries
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_17780eab-30e9-430a-acf5-cc5c7007b3f4"
      unitRef="U_EUR">173474000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_1edb3c4b-9d19-42e9-a21b-5a3a528a4ae9"
      unitRef="U_EUR">170278000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_2c10452c-c66e-468b-a4dc-842cae2ce577"
      unitRef="U_EUR">140420000</ifrs-full:WagesAndSalaries>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_77b90780-2ea5-4988-9247-c906891493f5"
      unitRef="U_EUR">95512000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_48b218f7-7d39-460e-801b-e57b36d0c05a"
      unitRef="U_EUR">66660000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_6bd1cebf-4027-4cb7-ae52-fbaf26ce4540"
      unitRef="U_EUR">64180000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_2d93071a-b4f3-4b04-9355-527d55a1f9e9"
      unitRef="U_EUR">4485000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_83381a8c-3aa6-4660-84ca-27471093950f"
      unitRef="U_EUR">4403000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_70fbecf1-a6be-4e60-872a-479e9b0fad2b"
      unitRef="U_EUR">4163000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:SocialSecurityContributions
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_04ddf0e1-2cd5-45bb-b6a7-382d1f6a119d"
      unitRef="U_EUR">15003000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_e7475657-5be7-4dfe-8ca9-8e7f738f4339"
      unitRef="U_EUR">12877000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_2f90ce80-959b-4ce7-a5cb-605fd2fdfd62"
      unitRef="U_EUR">10627000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:OtherEmployeeExpense
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_4207304f-501e-4261-af7a-7e9d127a30df"
      unitRef="U_EUR">4061000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_c40d5750-1385-4725-9c0c-cc9c6b0caa1a"
      unitRef="U_EUR">4238000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_5e6c43dc-e9f3-427b-9114-1a494ce9b894"
      unitRef="U_EUR">4411000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_bdc24f3e-4f8a-44eb-b749-1a7182d09bab"
      unitRef="U_EUR">292535000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_00c918d9-8f26-4382-bc0e-768bbb0163df"
      unitRef="U_EUR">258456000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_50828be3-01a5-4572-8323-033c41a3424e"
      unitRef="U_EUR">223801000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_4bf7540e-9443-41e7-a47a-27a0973802ce"
      decimals="-3"
      id="F_2bb38e6f-8ad0-4e43-bc60-8e56d265fef5"
      unitRef="U_EUR">16487000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_7f3a1b06-4e11-46ed-92ce-904b7a6a233b"
      decimals="-3"
      id="F_2739aa89-eb38-4b4e-abd2-a4b6bc4e38c2"
      unitRef="U_EUR">15748000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_01c97f44-492a-483a-8df7-8e652f65a658"
      decimals="-3"
      id="F_96f86056-d2ac-4ccf-bc46-b35bf9c2a855"
      unitRef="U_EUR">7239000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_232653f8-2ada-40f7-9e2c-695fe89927f8"
      decimals="-3"
      id="F_98c3ca2d-6671-44a9-8873-fb64d5ce1a48"
      unitRef="U_EUR">131867000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_2177e743-fed9-4015-b87c-ce85408638ea"
      decimals="-3"
      id="F_e2358cbd-d02b-44c6-8c5f-0f14e8a38889"
      unitRef="U_EUR">127002000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_38539fb6-76a9-4121-aee9-0b1245ac6af1"
      decimals="-3"
      id="F_7162a24b-8925-490f-97ce-63a6a927debc"
      unitRef="U_EUR">122581000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_d8c37193-f5ce-4085-a584-6f5700a291cb"
      decimals="-3"
      id="F_5f87882b-1d1f-4928-bc32-b9300b7067b9"
      unitRef="U_EUR">144181000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_4d1a30fa-1a02-416f-ac4b-3fd4e5452e6b"
      decimals="-3"
      id="F_0e38095c-3cbe-445e-835e-e38a56814c76"
      unitRef="U_EUR">115706000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_600ece57-712e-4eef-9dfc-9e4fee4bc4fb"
      decimals="-3"
      id="F_752288c1-99ac-47ef-a346-d9a0e3451b14"
      unitRef="U_EUR">93981000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_c67d1c94-3e89-4015-8261-76f5fba291a5"
      unitRef="U_EUR">292535000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_ec82cf08-1ef9-4b68-8d78-ecabaf1fd1e9"
      unitRef="U_EUR">258456000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_f11ee992-3b40-49d4-9a71-4b5d7f70d421"
      unitRef="U_EUR">223801000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="0"
      id="F_fbb7d2f7-5f11-4474-857e-d333eabf5d11"
      unitRef="U_Employee">892</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="0"
      id="F_0731ef23-5d0e-4459-ba63-7a5f5654b98a"
      unitRef="U_Employee">851</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="0"
      id="F_d2a4d3e5-24ee-4732-aa28-b1053b12bdf3"
      unitRef="U_Employee">719</ifrs-full:AverageNumberOfEmployees>
    <asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock
      contextRef="C_f960e0c7-e224-43a0-8029-5e940f7b7580"
      id="F_7c04d5c9-f527-4ea7-9375-caeccc7d73f9">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Compensation to Key Management Personnel included in total employee costs is summarized below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:20.492%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.758%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.457%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Board of Directors &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Executive Board &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-executive Senior Management&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="34" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR &#x2018;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Wages and salaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pensions (defined&lt;br/&gt;&#160;&#160;&#160;contribution plans)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Social security costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other employee cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;22,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;17,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;13,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;14,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Directors comprised six persons in 2024 and six to seven persons in 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Board comprised four persons in 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</asnd:DisclosureOfDetailedInformationAboutEmployeeCostExplanatoryTextBlock>
    <ifrs-full:WagesAndSalaries
      contextRef="C_ebade161-c91e-4828-aa55-97f5b6c7acab"
      decimals="-3"
      id="F_ef7e37d5-c649-424e-bf1b-47dd3f134ad8"
      unitRef="U_EUR">482000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_6e4e8da6-c1ef-49a7-86f8-5273a8cae8d9"
      decimals="-3"
      id="F_94d2e8c8-ce48-4130-a708-6500c36300b7"
      unitRef="U_EUR">543000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_79b3b481-791c-4f9d-93a9-e3bfa50ce43f"
      decimals="-3"
      id="F_2f9c9bc7-2bf7-4662-b7cf-4daa1374348d"
      unitRef="U_EUR">403000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2"
      decimals="-3"
      id="F_48a2a9b7-c9ff-4034-bbf0-b0abe37501db"
      unitRef="U_EUR">4148000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca"
      decimals="-3"
      id="F_9e2f035e-4814-4ad1-b67f-49949627407f"
      unitRef="U_EUR">4375000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb"
      decimals="-3"
      id="F_503b54e1-52e7-425e-8221-0f192b9e545e"
      unitRef="U_EUR">3809000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2"
      decimals="-3"
      id="F_6868f7f5-3174-49cf-ae4a-adbf1c5ffd15"
      unitRef="U_EUR">3286000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c"
      decimals="-3"
      id="F_f55e36f9-5571-4146-a766-8a3e0a50ca10"
      unitRef="U_EUR">4673000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06"
      decimals="-3"
      id="F_a9ab1787-0836-4a77-8d62-bd3fd2b277c4"
      unitRef="U_EUR">6087000</ifrs-full:WagesAndSalaries>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_ebade161-c91e-4828-aa55-97f5b6c7acab"
      decimals="-3"
      id="F_30305b6c-0a60-4917-ac27-f30aa21d0b77"
      unitRef="U_EUR">2169000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_6e4e8da6-c1ef-49a7-86f8-5273a8cae8d9"
      decimals="-3"
      id="F_6564b7cb-99a9-4a1e-8808-270d5f0d9472"
      unitRef="U_EUR">1276000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_79b3b481-791c-4f9d-93a9-e3bfa50ce43f"
      decimals="-3"
      id="F_a98bca98-b4a3-4289-ac74-6273d8f55c11"
      unitRef="U_EUR">1273000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2"
      decimals="-3"
      id="F_736060a9-1a51-410b-8f07-ede78ae34f5d"
      unitRef="U_EUR">18334000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca"
      decimals="-3"
      id="F_703c7aa4-2c45-464d-819f-64b36abcb9da"
      unitRef="U_EUR">13243000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb"
      decimals="-3"
      id="F_cbaceb2d-7a75-4a01-a5d5-3c8c285b5c4b"
      unitRef="U_EUR">11392000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2"
      decimals="-3"
      id="F_6167149b-af7c-4803-8ccf-742b9dc00ee3"
      unitRef="U_EUR">10266000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c"
      decimals="-3"
      id="F_ae5df323-3c0c-455d-846f-f7605ce6bd92"
      unitRef="U_EUR">9529000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06"
      decimals="-3"
      id="F_ef5a653a-9539-497c-805c-2e1258c3b7fe"
      unitRef="U_EUR">8872000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2"
      decimals="-3"
      id="F_9ffddfcf-317f-4e79-83ab-f5a61d62f8fa"
      unitRef="U_EUR">57000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca"
      decimals="-3"
      id="F_910b8dd9-3a44-4f99-9f91-a79e5cf451d4"
      unitRef="U_EUR">54000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb"
      decimals="-3"
      id="F_326dbd0f-4d49-4d09-8848-7af6f340d62d"
      unitRef="U_EUR">46000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2"
      decimals="-3"
      id="F_e32ed6db-015a-470e-b0ef-bb73d7dad794"
      unitRef="U_EUR">98000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c"
      decimals="-3"
      id="F_fe480680-db81-425c-b94b-af822a63aecb"
      unitRef="U_EUR">122000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06"
      decimals="-3"
      id="F_3329ffa7-5b95-4fd3-9cac-034801e6eb3d"
      unitRef="U_EUR">118000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:SocialSecurityContributions
      contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2"
      decimals="-3"
      id="F_4509718e-a793-4ac9-a1df-f1b1c7e4cd70"
      unitRef="U_EUR">118000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca"
      decimals="-3"
      id="F_00b3680d-4200-4565-8075-297685ab55ef"
      unitRef="U_EUR">103000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb"
      decimals="-3"
      id="F_cfd70616-fd8e-4c52-8cf7-39ed0e96b11d"
      unitRef="U_EUR">55000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2"
      decimals="-3"
      id="F_c9302859-1f3e-4f7c-9a6d-5751ac199883"
      unitRef="U_EUR">52000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c"
      decimals="-3"
      id="F_b750365d-0d04-4135-acc7-6ed61feb4732"
      unitRef="U_EUR">45000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06"
      decimals="-3"
      id="F_2d88b47c-c48d-43d3-b15f-70ce55d9c5a1"
      unitRef="U_EUR">89000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:OtherEmployeeExpense
      contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2"
      decimals="-3"
      id="F_60288b5c-14d8-485c-bcaa-b77953f0fbe2"
      unitRef="U_EUR">20000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca"
      decimals="-3"
      id="F_db872c03-4fc8-402e-988f-f83e819f55cd"
      unitRef="U_EUR">20000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb"
      decimals="-3"
      id="F_370ff9e7-68e4-4356-866d-4ca2d668b7be"
      unitRef="U_EUR">20000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2"
      decimals="-3"
      id="F_cbe53da4-91e1-42b6-8d0d-c1d651547bd6"
      unitRef="U_EUR">25000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c"
      decimals="-3"
      id="F_baebdb09-e9d5-4037-ad71-b6de8389baf3"
      unitRef="U_EUR">40000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06"
      decimals="-3"
      id="F_d2bb8e0e-e19a-4de5-9c64-f1f0a57f04f9"
      unitRef="U_EUR">45000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_ebade161-c91e-4828-aa55-97f5b6c7acab"
      decimals="-3"
      id="F_1efdfc72-f442-41bc-b30f-ab52d0b75f32"
      unitRef="U_EUR">2651000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_6e4e8da6-c1ef-49a7-86f8-5273a8cae8d9"
      decimals="-3"
      id="F_e50a71ae-b75b-4c8c-b322-75891449c296"
      unitRef="U_EUR">1819000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_79b3b481-791c-4f9d-93a9-e3bfa50ce43f"
      decimals="-3"
      id="F_6768a265-6cb5-4de4-9f5d-f585b7daf965"
      unitRef="U_EUR">1676000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_c8c66292-7409-42ed-b072-96cc8d5b02e2"
      decimals="-3"
      id="F_c1665f3b-21ed-42c3-9627-1c2279ea71c8"
      unitRef="U_EUR">22677000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_b0111fc8-8791-4de0-8ed0-9f981def15ca"
      decimals="-3"
      id="F_8145a482-69b1-4a61-9738-aabe1ca4fe89"
      unitRef="U_EUR">17795000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_49d4878a-31c4-4c19-8814-8507aefe88cb"
      decimals="-3"
      id="F_72c53c28-0ad6-4e53-972e-80ec6f3586b2"
      unitRef="U_EUR">15322000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_f8b920cb-268c-4f19-9195-5e81009361e2"
      decimals="-3"
      id="F_baae491f-1c32-4d2e-9e60-27ae9de923bc"
      unitRef="U_EUR">13727000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_e8188af8-6919-44f5-81ea-b527b574937c"
      decimals="-3"
      id="F_2af5c9f1-2f70-4014-93bf-789e47677e3c"
      unitRef="U_EUR">14409000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="C_d091e0fb-3626-4115-8dff-5f5b7dcc7d06"
      decimals="-3"
      id="F_38dd210f-59c3-4bbc-aa65-fdab9983e126"
      unitRef="U_EUR">15211000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_20b219b8-3bc9-468f-a949-b49f9be168a9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 7&#x2014;Share-based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As an incentive to the senior management, other employees, members of the Board and select consultants, Ascendis Pharma A/S has established warrant programs, a RSU program (adopted in December 2021), and a PSU program (adopted in February 2023), which are all classified as equity-settled share-based payment transactions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Unit Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to members of senior management, certain other employees and certain members of the Board (&#x201c;RSU-holders&#x201d;) in accordance with the Company&#x2019;s RSU Program adopted in December 2021. Further, RSUs may be granted to select consultants. One RSU represents a right for the RSU-holder to receive one ADS of Ascendis Pharma A/S upon vesting if the vesting conditions are met or waived by the Board at its discretion.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Performance Stock Unit Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PSUs are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to certain members of senior management (the &#x201c;PSU-holders&#x201d;). In addition, PSUs may be granted to other employees, select consultants and members of the Board. PSUs were granted for the first time in March 2023. One PSU represents a right for the PSU-holder to receive one ADS of Ascendis Pharma A/S upon vesting if the vesting conditions are met or waived by the Board at its discretion.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Vesting Conditions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs granted vest over a predetermined service period, and accordingly require RSU-holders to be employed, or provide a specified period of service (&#x201c;service conditions&#x201d;). RSUs vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with 1/3 of the RSUs vesting on each anniversary date from the date of grant. RSUs generally cease to vest from the date of termination of employment, or for the Board, termination of board membership, whereas unvested RSUs will lapse.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One PSU represents a right for the PSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting. PSUs vest in a manner similar to the service conditions of the RSUs. For the March 2023 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of performance-based targets as determined by the Board, provided that no more than 10% of each tranche may be directly attributable to accomplishment of financial results achieved in the financial year prior to the vesting date. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the March 2024 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than 100%, nor will it result in additional grants.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs and PSUs generally cease to vest from the date of termination of employment or board membership, as applicable, whereas unvested RSUs or PSUs will be forfeited. The Board may at its discretion and on an individual basis decide to deviate from the vesting conditions, including deciding to accelerate vesting in the event of termination of employment or board membership, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Settlement Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All RSUs and PSUs are settled at the time of vesting by transfer of treasury shares that are ADSs repurchased in the market. In jurisdictions where the Company is required to withhold and settle tax with the tax authority on behalf of the RSU/PSU-holders, the Company withholds the number of RSUs or PSUs that are equal to the estimated monetary value of the RSU/PSU-holders tax obligation from the total number of RSUs or PSUs that otherwise would have been transferred to the RSU/PSU holder upon vesting. These settlements are presented as &#x201c;Net settlement under stock incentive programs&#x201d; in the consolidated statement of equity. The Company may at its sole discretion choose to make a cash settlement instead of delivering ADSs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSU-holders and PSU-holders are entitled to an adjustment of the number of RSUs or PSUs granted, in the event of certain corporate changes, including among other events, increases or decreases to the share capital at a price below or above market value, the issuance of bonus shares, and changes in the nominal value of each share. In addition, the RSU and PSU Programs contain provisions to accelerate vesting, or compensate with grant of new equity instruments, in the event of restructuring events including change in control events.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;RSU and PSU Activity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the number of RSUs and PSUs granted and outstanding:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;82,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;82,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;609,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;722,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Settled during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;576,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;105,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;681,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;810,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;212,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;993,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;156,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,150,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified by vesting date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;384,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;446,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;384,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;447,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;993,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;156,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,150,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of RSUs and PSUs is determined on the basis of the closing ADS price on the grant date. The fair value of one RSU and one PSU at the date of grant was &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.96&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board and select consultants (&#x201c;warrant-holders&#x201d;). Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The exercise price is equal to the fair market value of the Company&#x2019;s ordinary shares at the time of grant as determined by the Board. Apart from exercise prices, exercise periods and vesting conditions for board members, the programs are similar.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Vesting Conditions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants granted vest over a predetermined service period and require warrant-holders provide a specified period of service. Warrants generally cease to vest from the date of termination. For warrants granted until November 2021, special vesting conditions apply in the event of termination. In relation to board members, the vesting shall cease on the termination date of the board membership regardless of the reason. In relation to consultants, the vesting shall cease on the termination date of the consultancy relationship. The warrant-holder will, however, be entitled to exercise vested warrants in the exercise periods after termination.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event that the employment contract is terminated, and the employee has not given the Company good reason to do so, the warrant-holder may keep the right to continued vesting and exercise of warrants as if the employment was still in effect. In such case, any expense not yet recognized for the outstanding warrants is recognized immediately.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrants Granted Until November 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants granted from 2012 until November 2021, generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months with 1/48 of the warrants vesting per month from the date of grant. However, effective from January 2015, certain warrants granted to board members vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months with 1/24 of the warrants vesting per month from the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrants Granted From December 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For warrants granted to employees and consultants, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the warrants vest one year after the date of grant, and the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the warrants granted vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months, with 1/36 of the warrants vesting per month, from one year after the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For warrants granted to board members upon the board members accession, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the warrants granted vest one year after the date of grant, and the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the warrants granted shall vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months, with 1/36 per month from one year after the date of grant. Regarding subsequent grants of warrants to board members, 50% of the warrants vest one year after the date of grant, and the remaining 50% of the warrants vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months, with 1/12 per month from one year after the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Exercise Periods&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Vested warrants may be exercised during certain exercise periods each year, within certain periods after publication of earnings data of a fiscal quarter, interim and annual reports, as per each program&#x2019;s terms and conditions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants expire ten years after the grant date. Warrants not exercised by the warrant-holder during the last exercise period shall become null and void without further notice or compensation or payment of any kind to the warrant-holder. If the warrant-holder is a consultant, advisor or board member, the exercise of warrants is conditional upon the warrant-holder&#x2019;s continued service to the Company at the time the warrants are exercised. If the consultant&#x2019;s, advisor&#x2019;s or board member&#x2019;s relationship with the Company should cease without this being attributable to the warrant-holder&#x2019;s actions or omissions, the warrant-holder shall be entitled to exercise vested warrants in the pre-defined exercise periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant-holders are entitled to an adjustment of the number of warrants issued and/or the exercise price applicable in the event of certain corporate changes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Events giving rise to an adjustment include, among other things, increases or decreases to the share capital at a price below or above market value, the issuance of bonus shares, changes in the nominal value of each share, and payment of dividends in excess of 10% of the Company&#x2019;s equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrant Activity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the number and weighted average exercise prices of, and movements, in warrants:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Warrants (number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price (EUR)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,085,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;357,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the year &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;214,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;363,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,864,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;81.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested at the reporting date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,972,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;66.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;395,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the year&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;555,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,523,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;86.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested at the reporting date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,273,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;80.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the year &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,204,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;93.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested at the reporting date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,226,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;89.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average share price (listed in $) at the date of exercise was &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135.86&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, the Board was authorized to grant up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,060,116&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional warrants to employees, board members and select consultants without preemptive subscription rights for the shareholders of Ascendis Pharma A/S.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the weighted average exercise prices and weighted average remaining contractual life for outstanding warrants at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 per grant year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;br/&gt;Warrants (number&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price (EUR)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Life&lt;br/&gt;(months)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted before &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,185,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted in &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted in &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted in &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;490,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,204,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;93.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, the exercise prices of outstanding warrants under the Company&#x2019;s warrant programs range from &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; depending on the grant dates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The range of exercise prices for outstanding warrants was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2023 and 2022, respectively. The weighted average remaining life for outstanding warrants was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months, for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrant Compensation Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant compensation costs are recognized in the consolidated statements of profit or loss over the vesting period of the warrants granted.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant compensation costs are determined with basis in the grant date fair value of the warrants granted and recognized over the vesting period. Fair value of the warrants is calculated at the grant dates by use of the Black-Scholes option-pricing model with the following assumptions: (1) an exercise price equal to the estimated market price of the Company&#x2019;s shares at the date of grant; (2) an expected lifetime of the warrants determined as a weighted average of the time from grant date to date of becoming exercisable and from grant date to expiry of the warrants; (3) a risk-free interest rate equaling the effective interest rate on a Danish government bond with the same lifetime as the warrants; (4) no payment of dividends; and (5) an expected volatility using the Company&#x2019;s own share price (from 2021).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the input to the Black-Scholes option-pricing model and the calculated fair values for warrant grants in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023 and 2022:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.08&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;) - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life of warrants (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of warrants granted in the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.86&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <asnd:SharebasedPaymentArrangementVestingPeriod
      contextRef="C_df13e31f-e944-44b8-beee-0157e82a5356"
      id="F_810881da-5df9-4e31-b7d8-9518dab9b842">P3Y</asnd:SharebasedPaymentArrangementVestingPeriod>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement
      contextRef="C_772d30eb-6104-4b18-9139-ee54a0993371"
      id="F_3c39a83c-f235-4649-a3c1-c2d7fab314f2">For the March 2024 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than 100%, nor will it result in additional grants.</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_118528ea-a148-43ed-aa84-7a86629d20bc">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the number of RSUs and PSUs granted and outstanding:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;82,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;82,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;609,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;722,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Settled during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;576,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;105,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;681,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;810,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;212,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;993,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;156,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,150,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified by vesting date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;384,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;446,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;384,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;447,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;993,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;156,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,150,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of RSUs and PSUs is determined on the basis of the closing ADS price on the grant date. The fair value of one RSU and one PSU at the date of grant was &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.96&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_0f2a0f3d-caa6-4b26-aaab-9aaaa98975ed"
      decimals="0"
      id="F_cd429f82-6aad-4c41-a89f-222e90e87902"
      unitRef="U_pure">148148</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_2c4ca528-c486-4e2a-a517-ae7410edc2c0"
      decimals="0"
      id="F_1c0a4b88-deff-4f99-ad72-aef3b62b8d7e"
      unitRef="U_pure">148148</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_13311653-2a29-4400-a0d0-0f4bd2ca8d98"
      decimals="0"
      id="F_c559a2ba-e4cc-4ca6-9082-2394c06484d6"
      unitRef="U_pure">41685</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_1a2f2ecc-ca46-4afb-a7cd-7481a3e39b7c"
      decimals="0"
      id="F_b138b2c2-d880-4530-b592-00d610ac1ce0"
      unitRef="U_pure">41685</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_13311653-2a29-4400-a0d0-0f4bd2ca8d98"
      decimals="0"
      id="F_35e534ba-6388-49e0-b734-508579919ff3"
      unitRef="U_pure">23971</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_1a2f2ecc-ca46-4afb-a7cd-7481a3e39b7c"
      decimals="0"
      id="F_c307eca2-b1bd-4e9e-b3b7-d9b25e01b5da"
      unitRef="U_pure">23971</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_c4078876-b7b4-4937-95c6-d2ea84904d2b"
      decimals="0"
      id="F_540b8f57-bff2-4627-848a-846ec662d3c8"
      unitRef="U_pure">82492</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_7f2fe9bf-d689-489c-be69-cbf182477f84"
      decimals="0"
      id="F_c5285beb-688e-45bd-a1b1-836de57168d5"
      unitRef="U_pure">82492</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f"
      decimals="0"
      id="F_3996c24c-6b16-4842-81b6-af4cebffe75c"
      unitRef="U_pure">609860</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_eaa235d8-4b02-4581-b70a-16400278b006"
      decimals="0"
      id="F_e7b5ca71-6010-41fc-8ce3-dae554024e83"
      unitRef="U_pure">112268</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747"
      decimals="0"
      id="F_1c2e8889-a568-4252-bafd-32584f66d7b9"
      unitRef="U_pure">722128</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f"
      decimals="0"
      id="F_723f2d26-f1aa-440a-b488-6c3947ce3af9"
      unitRef="U_pure">18132</asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747"
      decimals="0"
      id="F_ce8a0d39-34c1-4bf9-af92-d4962bad4812"
      unitRef="U_pure">18132</asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f"
      decimals="0"
      id="F_51f2ca4a-26b1-4209-ba2d-ddd9aa8bd03e"
      unitRef="U_pure">20098</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747"
      decimals="0"
      id="F_45ccaa42-6cb2-4d4c-b47b-6be6628e7f79"
      unitRef="U_pure">20098</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_c693bbe0-1e3f-4f4e-8536-05f89c9d012f"
      decimals="0"
      id="F_5e0e3021-9768-4d6e-85fc-2c7d21db6131"
      unitRef="U_pure">77497</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_eaa235d8-4b02-4581-b70a-16400278b006"
      decimals="0"
      id="F_48362209-4337-44a0-a34c-f6de99e30a02"
      unitRef="U_pure">7245</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_a3247d66-6d5a-4d65-ae2c-0e6fc2bc9747"
      decimals="0"
      id="F_e6b0e219-12ef-4dc0-be3d-da9305740003"
      unitRef="U_pure">84742</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_3cc100f5-a109-47f1-b3b1-58aae09fcce4"
      decimals="0"
      id="F_86f0c31e-a235-4f40-8fe8-af3ded936e45"
      unitRef="U_pure">576625</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_da8aec68-6586-4ef6-93e5-b5045f7afa40"
      decimals="0"
      id="F_524b5811-7556-43cc-8d3e-3fe983ea2ed7"
      unitRef="U_pure">105023</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_ede99a4e-c051-431e-8269-8505ec9267f7"
      decimals="0"
      id="F_ca249f1a-cf6e-403e-90d3-63581a9156bb"
      unitRef="U_pure">681648</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_df13e31f-e944-44b8-beee-0157e82a5356"
      decimals="0"
      id="F_63bbd27a-1593-4b1b-bba4-f64bb27db432"
      unitRef="U_pure">717980</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_772d30eb-6104-4b18-9139-ee54a0993371"
      decimals="0"
      id="F_3835b3d1-9ee0-46de-a5d3-adc0887c8bd3"
      unitRef="U_pure">92655</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_ff4b86e7-7c5f-4451-a272-76662d19dc47"
      decimals="0"
      id="F_dc43082c-0ad3-4321-b91a-0be69a3a78a7"
      unitRef="U_pure">810635</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_df13e31f-e944-44b8-beee-0157e82a5356"
      decimals="0"
      id="F_a1337f04-94c0-4056-a696-5dbdabd12c88"
      unitRef="U_pure">212160</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_772d30eb-6104-4b18-9139-ee54a0993371"
      decimals="0"
      id="F_bfc4e683-bb8e-42f2-866a-63e8cc16c281"
      unitRef="U_pure">35007</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_ff4b86e7-7c5f-4451-a272-76662d19dc47"
      decimals="0"
      id="F_5b8945bb-0511-4277-a40b-b3ff139690ee"
      unitRef="U_pure">247167</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_df13e31f-e944-44b8-beee-0157e82a5356"
      decimals="0"
      id="F_64f8f47e-bfb5-4c56-bd69-6fba50a59567"
      unitRef="U_pure">88638</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_772d30eb-6104-4b18-9139-ee54a0993371"
      decimals="0"
      id="F_0bcf8d3d-8056-40d7-95d3-86ab9babdf97"
      unitRef="U_pure">6004</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_ff4b86e7-7c5f-4451-a272-76662d19dc47"
      decimals="0"
      id="F_2615b6d7-fc34-43e6-a49e-07271dee648f"
      unitRef="U_pure">94642</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_c85c746c-f722-410b-b4c5-502ed85c8382"
      decimals="0"
      id="F_51f40a66-5a76-45c6-9930-1c189d278bd5"
      unitRef="U_pure">993807</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_2d560ff6-c2e3-4c74-9daf-9f9c9310753d"
      decimals="0"
      id="F_feac66df-d83d-4086-8e1a-f5a0ce8b2e11"
      unitRef="U_pure">156667</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_8cdbb2f3-5894-447e-9e13-0a00148c6b78"
      decimals="0"
      id="F_7d808615-7324-4632-ae74-ed91b23768ba"
      unitRef="U_pure">1150474</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_fc853c6b-d56e-49d4-8dc9-d729edce2941"
      decimals="0"
      id="F_4b2ade5a-b53c-4f03-8059-e2777ae95311"
      unitRef="U_pure">384098</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_e25082d1-732f-40fe-9427-652d8be5beee"
      decimals="0"
      id="F_2709d42a-888c-4e57-8a4d-008cb70890c9"
      unitRef="U_pure">62304</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_1023a06c-46a7-4e4f-9c42-a6c64923b098"
      decimals="0"
      id="F_58f98ba1-5ee2-4e64-92b9-045efdfca2ba"
      unitRef="U_pure">446402</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_28fafa94-b070-4d32-863b-5393bdb99f92"
      decimals="0"
      id="F_41dce36d-fd8b-4cfd-bda2-f799b10a9f87"
      unitRef="U_pure">384438</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_207ec930-b486-406c-b0ae-aba7cbf1c9d1"
      decimals="0"
      id="F_3bdcf669-dfb9-4a40-8dec-dbe431d875d4"
      unitRef="U_pure">63478</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_12093c28-729f-40fc-bcf0-fb862cb3c696"
      decimals="0"
      id="F_f1e10932-a811-4599-b192-7a5e10de6f0c"
      unitRef="U_pure">447916</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_6f53dfac-7f4f-46ee-9afc-402949c6590a"
      decimals="0"
      id="F_921ed569-6cb0-402c-a2a4-c7d71d408efa"
      unitRef="U_pure">225271</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_bb236f3a-aca3-4607-b4e7-a59b9fc6910f"
      decimals="0"
      id="F_81490454-226d-4e77-af82-2f4ce8653679"
      unitRef="U_pure">30885</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_560f9631-6b06-4d31-b7a4-554f86183c74"
      decimals="0"
      id="F_54031dc9-987a-4dc2-8bd5-218a0a07052b"
      unitRef="U_pure">256156</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_c85c746c-f722-410b-b4c5-502ed85c8382"
      decimals="0"
      id="F_d01abc30-7693-4fb3-a0e9-8d9749b64a57"
      unitRef="U_pure">993807</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_2d560ff6-c2e3-4c74-9daf-9f9c9310753d"
      decimals="0"
      id="F_7ba60db4-76f6-419d-9a7b-21a5432b82fc"
      unitRef="U_pure">156667</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_8cdbb2f3-5894-447e-9e13-0a00148c6b78"
      decimals="0"
      id="F_bce7237d-93e2-41a8-a8d6-017b85849060"
      unitRef="U_pure">1150474</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="C_8cdbb2f3-5894-447e-9e13-0a00148c6b78"
      decimals="2"
      id="F_c55a417c-abef-463f-825f-b391acd8ac8b"
      unitRef="U_EUR">141.01</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="C_ede99a4e-c051-431e-8269-8505ec9267f7"
      decimals="2"
      id="F_342e2dd1-4233-4513-baea-7776289621c5"
      unitRef="U_EUR">105.96</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:ParValuePerShare
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="0"
      id="F_d86fbb41-4cc6-4e55-9ce3-d6ed99a911e5"
      unitRef="U_DkkPerShare">1</ifrs-full:ParValuePerShare>
    <asnd:SharebasedPaymentArrangementVestingPeriod
      contextRef="C_1668bba6-5e09-4a0b-b002-c5fc87f94355"
      id="F_e22198e9-7e4c-4016-97f8-457bee947acc">P48M</asnd:SharebasedPaymentArrangementVestingPeriod>
    <asnd:SharebasedPaymentArrangementVestingPeriod
      contextRef="C_7d04bb96-8341-4c18-bd8d-f80c0f0f0430"
      id="F_19dff4a8-4204-4c3d-bba3-be93a2fc4710">P24M</asnd:SharebasedPaymentArrangementVestingPeriod>
    <asnd:PercentageOfWarrantsVested
      contextRef="C_3661dd57-860c-4ba7-8646-271ddab5954a"
      decimals="2"
      id="F_ede5487e-a90e-4194-93be-2f201c4615a2"
      unitRef="U_pure">0.25</asnd:PercentageOfWarrantsVested>
    <asnd:PercentageOfWarrantsVested
      contextRef="C_13fd56c8-1e8b-413f-83b9-57936192571d"
      decimals="2"
      id="F_b410772f-1811-46e9-bee7-a62b64b5a9e7"
      unitRef="U_pure">0.75</asnd:PercentageOfWarrantsVested>
    <asnd:SharebasedPaymentArrangementVestingPeriod
      contextRef="C_2fbbee2c-6ce9-4cf9-b0ca-0215da8f8db4"
      id="F_ca166389-2615-424a-8455-9c39a27d84ed">P36M</asnd:SharebasedPaymentArrangementVestingPeriod>
    <asnd:PercentageOfWarrantsVested
      contextRef="C_802fb420-5428-493a-87b7-02e34b108386"
      decimals="2"
      id="F_e2dac54e-eea7-469c-b622-248b03b81aa5"
      unitRef="U_pure">0.25</asnd:PercentageOfWarrantsVested>
    <asnd:PercentageOfWarrantsVested
      contextRef="C_0ec0d4cb-d376-4f19-aa95-a67c8572996a"
      decimals="2"
      id="F_1ba466a0-132b-48ae-bf51-3ee4be679ee1"
      unitRef="U_pure">0.75</asnd:PercentageOfWarrantsVested>
    <asnd:SharebasedPaymentArrangementVestingPeriod
      contextRef="C_2fbbee2c-6ce9-4cf9-b0ca-0215da8f8db4"
      id="F_6ff50c50-ba0b-43f4-9598-5376f6af6889">P36M</asnd:SharebasedPaymentArrangementVestingPeriod>
    <asnd:SharebasedPaymentArrangementVestingPeriod
      contextRef="C_a75c561c-801d-4844-bed5-502cc157a1d6"
      id="F_91dee683-e581-48fb-8d0b-bcaeb8a118aa">P12M</asnd:SharebasedPaymentArrangementVestingPeriod>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_9c40d47f-4ea1-4baa-9797-c9314b9f7613">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the number and weighted average exercise prices of, and movements, in warrants:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Warrants (number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price (EUR)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,085,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;357,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the year &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;214,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;363,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,864,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;81.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested at the reporting date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,972,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;66.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;395,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the year&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;555,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,523,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;86.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested at the reporting date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,273,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;80.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the year &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,204,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;93.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested at the reporting date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,226,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;89.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average share price (listed in $) at the date of exercise was &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135.86&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_5268a2fe-772c-411f-b537-63cfb4081aac"
      decimals="INF"
      id="F_ef04634a-1051-4e30-9c0e-764d75c68068"
      unitRef="U_pure">7085073</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_5268a2fe-772c-411f-b537-63cfb4081aac"
      decimals="2"
      id="F_26e64ca4-1b2a-45b4-9338-9db401fd728e"
      unitRef="U_EurPerShare">80.3</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a"
      decimals="INF"
      id="F_b1de2e76-a791-48aa-9f17-4974838716fc"
      unitRef="U_pure">357092</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a"
      decimals="2"
      id="F_e849d0cd-8910-43d0-851f-df96fb82d44f"
      unitRef="U_EurPerShare">100.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a"
      decimals="INF"
      id="F_4e78baea-0acf-4532-8cdc-b5a966fac88e"
      unitRef="U_pure">214613</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a"
      decimals="2"
      id="F_3291bb26-5b6d-4cae-900f-f02445316d2f"
      unitRef="U_EurPerShare">21.83</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a"
      decimals="INF"
      id="F_220b730e-f484-471c-83bb-9587d980c2e0"
      unitRef="U_pure">363541</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019
      contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a"
      decimals="2"
      id="F_d277e7fd-8f1c-4667-ba00-bb35e2eb5ac9"
      unitRef="U_EurPerShare">123.62</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf"
      decimals="INF"
      id="F_a4e09cd3-d400-473c-9a29-24dd4936b5b4"
      unitRef="U_pure">6864011</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf"
      decimals="2"
      id="F_ad3cf17b-f5f9-4aea-9544-eab5ed748fca"
      unitRef="U_EurPerShare">81.3</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf"
      decimals="INF"
      id="F_835c0f61-8bd1-44a6-abaa-e9961b0cd639"
      unitRef="U_pure">4972026</asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf"
      decimals="2"
      id="F_5a56116c-0437-429f-954e-d02c5fc91813"
      unitRef="U_EurPerShare">66.34</asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398"
      decimals="INF"
      id="F_ee2d879e-25d2-4395-9cb7-2d3d568bfb02"
      unitRef="U_pure">395275</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398"
      decimals="2"
      id="F_5af62a87-f0c0-4015-9500-c4877e1a0c8f"
      unitRef="U_EurPerShare">91.07</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398"
      decimals="INF"
      id="F_a81dad6e-68e4-481b-8f42-3e59c899623c"
      unitRef="U_pure">555144</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398"
      decimals="2"
      id="F_434007e6-bbb5-4916-bb24-6660ed411253"
      unitRef="U_EurPerShare">17.76</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398"
      decimals="INF"
      id="F_ec72a136-10e3-4afa-892c-80e92c46a505"
      unitRef="U_pure">180358</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019
      contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398"
      decimals="2"
      id="F_5633ee27-2933-47a8-8ff9-1eaf10c5aed2"
      unitRef="U_EurPerShare">115.79</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e"
      decimals="INF"
      id="F_eb845efe-2914-4c8b-9e89-7a67260f485c"
      unitRef="U_pure">6523784</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e"
      decimals="2"
      id="F_34f224c5-87ac-4464-a022-d88d20cbd6f5"
      unitRef="U_EurPerShare">86.38</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e"
      decimals="INF"
      id="F_138d3e29-d750-4984-a6e9-f75d51e41b52"
      unitRef="U_pure">5273056</asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e"
      decimals="2"
      id="F_0766bbdc-72c0-41a0-9fb5-cf0d96270bbc"
      unitRef="U_EurPerShare">80.02</asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a"
      decimals="INF"
      id="F_e8b6fa18-9737-4aaf-a8d9-d8ebd32f5158"
      unitRef="U_pure">504105</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a"
      decimals="2"
      id="F_3b02d144-cfb9-4340-b260-8d8c7189fe75"
      unitRef="U_EurPerShare">122.48</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a"
      decimals="INF"
      id="F_08288339-b76e-458f-85d8-4258f3024e30"
      unitRef="U_pure">682048</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a"
      decimals="2"
      id="F_4ea5b0ae-4571-4498-af07-edb36293b306"
      unitRef="U_EurPerShare">43.35</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a"
      decimals="INF"
      id="F_d7aed783-493e-49df-9cc5-242f58c3c8df"
      unitRef="U_pure">141719</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019
      contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a"
      decimals="2"
      id="F_37a72288-6873-48b9-9b7f-20e36ebf1b37"
      unitRef="U_EurPerShare">107.85</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca"
      decimals="INF"
      id="F_528dbb8b-91be-4349-9a4e-b660d13908bb"
      unitRef="U_pure">6204122</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca"
      decimals="2"
      id="F_ff3d834b-29ef-4813-9c2d-f79ef1d88344"
      unitRef="U_EurPerShare">93.25</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca"
      decimals="INF"
      id="F_7a434181-d85f-4a40-8d8c-8dd56c08ba85"
      unitRef="U_pure">5226643</asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca"
      decimals="2"
      id="F_ed373729-6463-4535-9cf3-17d5f46929bf"
      unitRef="U_EurPerShare">89.33</asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="C_88ae6c08-23fb-4240-bf5e-678082269ff6"
      decimals="2"
      id="F_134a41c7-052e-41d3-a106-26de0a3c21ee"
      unitRef="U_EurPerShare">135.86</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="C_774802a0-e760-4cd3-bbed-f1a84d8730e8"
      decimals="2"
      id="F_945f9c74-4e98-4734-89d4-57b3aebd5ebb"
      unitRef="U_EurPerShare">98.1</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="C_5ff345a3-c70a-47dc-8ae4-ca0d2489d12e"
      decimals="2"
      id="F_62a6905c-90bf-468d-816b-7f9533abc191"
      unitRef="U_EurPerShare">113.6</ifrs-full:WeightedAverageSharePrice2019>
    <asnd:NumberOfAdditionalSharesAuthorizedToGrant
      contextRef="C_1c836450-3243-4763-a839-055b50eb15c7"
      decimals="0"
      id="F_43d8a6b0-fdd4-4b9a-a1e8-c5bbf124a186"
      unitRef="U_shares">2060116</asnd:NumberOfAdditionalSharesAuthorizedToGrant>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3be73c70-9f26-42e2-ac3a-f1235b7d1cf6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the weighted average exercise prices and weighted average remaining contractual life for outstanding warrants at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 per grant year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;br/&gt;Warrants (number&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price (EUR)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Life&lt;br/&gt;(months)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted before &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,185,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted in &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted in &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted in &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;490,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,204,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;93.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <asnd:YearOfGrantOfWarrants
      contextRef="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870"
      id="F_1d7b699c-fcfd-4281-bdf0-e4bd3558c480">January 1, 2022</asnd:YearOfGrantOfWarrants>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870"
      decimals="INF"
      id="F_d07295ab-46f7-4442-906f-701ba3f8b251"
      unitRef="U_shares">5185556</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870"
      decimals="2"
      id="F_4c1b70be-9dc7-4947-aa34-e52a9fc95972"
      unitRef="U_EurPerShare">89.67</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments
      contextRef="C_10ed8bd1-a2b8-4dbc-98a9-8acd4feaf870"
      id="F_0b43bb82-c946-49f5-8c9b-0fc23ff2a020">P57M</asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments>
    <asnd:YearOfGrantOfWarrants
      contextRef="C_74e6cf72-5a9f-4f1c-832e-143795728beb"
      id="F_eed99762-5a40-4e61-96f6-52a51493d165">2022</asnd:YearOfGrantOfWarrants>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_74e6cf72-5a9f-4f1c-832e-143795728beb"
      decimals="INF"
      id="F_8331eaad-6572-46ab-aaff-572566080a74"
      unitRef="U_pure">235408</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_74e6cf72-5a9f-4f1c-832e-143795728beb"
      decimals="2"
      id="F_a84ec60f-9b15-4b2d-b244-6b2a8ce96b2b"
      unitRef="U_EurPerShare">100.71</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments
      contextRef="C_74e6cf72-5a9f-4f1c-832e-143795728beb"
      id="F_b08b8dfb-7376-4941-8edc-e3fe0e73fc80">P90M</asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments>
    <asnd:YearOfGrantOfWarrants
      contextRef="C_04565d75-339f-4b1f-80d9-f0daababe60e"
      id="F_4003afe9-cc6b-48fa-9db1-df3441d18c26">2023</asnd:YearOfGrantOfWarrants>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_04565d75-339f-4b1f-80d9-f0daababe60e"
      decimals="INF"
      id="F_acf68c77-d887-43b6-a025-7035c2629ea8"
      unitRef="U_pure">292648</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_04565d75-339f-4b1f-80d9-f0daababe60e"
      decimals="2"
      id="F_a1fe946a-7eb2-497c-905d-d1f25186f1a6"
      unitRef="U_EurPerShare">90.66</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments
      contextRef="C_04565d75-339f-4b1f-80d9-f0daababe60e"
      id="F_b1fcf230-670b-46f5-bc2f-deeb1332c915">P101M</asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments>
    <asnd:YearOfGrantOfWarrants
      contextRef="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2"
      id="F_b0a914d9-f67d-447a-ab07-c76eac705c6c">2024</asnd:YearOfGrantOfWarrants>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2"
      decimals="INF"
      id="F_ea359732-1e81-467b-ac09-03b3eb813bf4"
      unitRef="U_pure">490510</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2"
      decimals="2"
      id="F_49b2b373-7411-4ac5-b451-97e3909e5643"
      unitRef="U_EurPerShare">122.34</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments
      contextRef="C_4f1ad77c-71cd-4cb2-a4c2-50772d3432c2"
      id="F_037351cb-977f-4a1b-ae79-031004c0269d">P114M</asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="INF"
      id="F_5fa8d84b-05b2-43ba-9b67-d969188c489d"
      unitRef="U_pure">6204122</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="2"
      id="F_95ae42dc-f01c-4a1e-b091-baac648fad80"
      unitRef="U_EurPerShare">93.25</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_2168776b-645e-479c-8e73-accc299edfcf">P65M</asnd:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_f0eb7759-5474-4185-9c25-f280c2655d1d"
      decimals="2"
      id="F_5bad2185-70be-46cf-996e-1e89f4f6e38f"
      unitRef="U_EurPerShare">11.98</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_06c71b52-a8d3-4d87-bf07-1b59116e44d0"
      decimals="2"
      id="F_2a07bf01-4328-453a-b058-1bcdeb587603"
      unitRef="U_EurPerShare">145.5</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_8d641cf8-4f3e-4466-b341-181115f04c36"
      decimals="2"
      id="F_7801cb93-3bef-4248-95d6-6b1d456d7e0f"
      unitRef="U_EurPerShare">11.98</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_a18ad5cb-63e0-41e5-a54d-935b4eed3032"
      decimals="2"
      id="F_aa03ded5-e973-46a7-994f-0874aa357dc4"
      unitRef="U_EurPerShare">145.5</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_5a3d122d-f872-479f-9175-de42cc96d53a"
      decimals="2"
      id="F_f668064c-0b71-437c-b4ec-179459536c63"
      unitRef="U_EurPerShare">6.48</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_80c10e22-bf47-4313-871c-4161cd400123"
      decimals="2"
      id="F_c8e1c22d-767d-486e-9ca9-c97721f93733"
      unitRef="U_EurPerShare">145.5</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398"
      id="F_136d4754-7b98-4737-968b-ca8a5b7ed366">P71M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a"
      id="F_34468979-5a6e-42a0-ad51-fddcc48f8900">P77M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_77ca3eb3-857c-4f6d-a272-1d7acf72daf7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the input to the Black-Scholes option-pricing model and the calculated fair values for warrant grants in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023 and 2022:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.08&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;) - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life of warrants (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of warrants granted in the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.86&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x20ac;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_99479b14-1e7c-41fa-833c-83e794f18d01"
      decimals="2"
      id="F_bf6fc039-b379-46ad-a760-3903e7241408"
      unitRef="U_pure">0.50</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_0a586051-2c0f-41e7-b728-a06658a765b3"
      decimals="2"
      id="F_a41aa667-928d-4521-b8dc-b78a4eb3654c"
      unitRef="U_pure">0.49</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_af95c18d-a439-48f1-b6d9-6b5ef3fa583e"
      decimals="2"
      id="F_d5e020bd-3d47-4755-8881-0d33772088b0"
      unitRef="U_pure">0.51</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_5cafe9c3-115f-42e7-b1fe-9c5f8f86ddce"
      decimals="2"
      id="F_e55fe025-4ba0-4e24-a352-8d1b058df41b"
      unitRef="U_pure">0.48</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_fe0a0e9b-7ab2-4d20-a211-cbee6ffa77c2"
      decimals="2"
      id="F_21d42d0c-8a72-4a12-a9d3-37a5fe4ddfa2"
      unitRef="U_pure">0.49</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_99479b14-1e7c-41fa-833c-83e794f18d01"
      decimals="4"
      id="F_a5f11a38-8b9f-494c-8df7-a9c3569a46a6"
      unitRef="U_pure">0.0171</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_88ae85e5-4346-454d-9c63-a628775940b7"
      decimals="4"
      id="F_14755aad-66ee-45bb-880e-f248bef4583e"
      unitRef="U_pure">0.0257</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_0a586051-2c0f-41e7-b728-a06658a765b3"
      decimals="4"
      id="F_9358be8c-fcca-4676-847e-a30d50ea4498"
      unitRef="U_pure">0.024</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_af95c18d-a439-48f1-b6d9-6b5ef3fa583e"
      decimals="4"
      id="F_bed234fc-6a8b-44e4-8397-07b7a6914a5e"
      unitRef="U_pure">0.0297</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_5cafe9c3-115f-42e7-b1fe-9c5f8f86ddce"
      decimals="4"
      id="F_4246a26a-ae3d-44fb-85d6-f7451518037c"
      unitRef="U_pure">-0.0008</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_fe0a0e9b-7ab2-4d20-a211-cbee6ffa77c2"
      decimals="4"
      id="F_2dd37dd4-eb54-4511-816f-e77b8ea30580"
      unitRef="U_pure">0.0254</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_3736e8bc-ddce-4b9c-a3cd-e4e35287f02a"
      decimals="1"
      id="F_b8109e2e-0868-4dbc-ab84-a25d21323d63"
      unitRef="U_Y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_3fb58189-b760-40f5-9cd3-b00fa343a398"
      decimals="1"
      id="F_9bde3dee-d978-431e-8f38-59bbb0c38b23"
      unitRef="U_Y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_899ab35b-66a6-40e5-96b1-211674a39c3a"
      decimals="1"
      id="F_6bad96f5-e8b6-47dc-9594-3a52a65dd5c0"
      unitRef="U_Y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="C_34ec8a7a-5db5-4cc5-8300-ff357fdeddca"
      decimals="2"
      id="F_65e9515d-55cd-4f88-aeef-9f51ac9681d7"
      unitRef="U_EurPerShare">122.48</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="C_af321344-ada0-4c87-bfd0-d2a98cd2590e"
      decimals="2"
      id="F_251836fb-a03d-464f-af26-2036e0ce4dd6"
      unitRef="U_EurPerShare">91.07</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="C_85148e99-f7bc-4376-8eca-d2c2bb6b99cf"
      decimals="2"
      id="F_4c299dc1-ca8b-47b8-af07-7757dc4336a4"
      unitRef="U_EurPerShare">100.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <asnd:FairValueOfWarrantsGranted
      contextRef="C_99479b14-1e7c-41fa-833c-83e794f18d01"
      decimals="2"
      id="F_044cb3ee-2a46-43c3-ad7f-8ccd57214c83"
      unitRef="U_EurPerShare">50.86</asnd:FairValueOfWarrantsGranted>
    <asnd:FairValueOfWarrantsGranted
      contextRef="C_88ae85e5-4346-454d-9c63-a628775940b7"
      decimals="2"
      id="F_d312af18-cd7f-4820-a9e4-7f5920e3eaf5"
      unitRef="U_EurPerShare">70.39</asnd:FairValueOfWarrantsGranted>
    <asnd:FairValueOfWarrantsGranted
      contextRef="C_0a586051-2c0f-41e7-b728-a06658a765b3"
      decimals="2"
      id="F_e7accb31-2064-4ad6-ac94-e95f0c1387ba"
      unitRef="U_EurPerShare">37.34</asnd:FairValueOfWarrantsGranted>
    <asnd:FairValueOfWarrantsGranted
      contextRef="C_af95c18d-a439-48f1-b6d9-6b5ef3fa583e"
      decimals="2"
      id="F_3ce79bdc-3eff-43e0-a195-5e5907562379"
      unitRef="U_EurPerShare">52.03</asnd:FairValueOfWarrantsGranted>
    <asnd:FairValueOfWarrantsGranted
      contextRef="C_5cafe9c3-115f-42e7-b1fe-9c5f8f86ddce"
      decimals="2"
      id="F_d18b7671-cee7-4f66-a14e-5f10f6e19249"
      unitRef="U_EurPerShare">36.55</asnd:FairValueOfWarrantsGranted>
    <asnd:FairValueOfWarrantsGranted
      contextRef="C_fe0a0e9b-7ab2-4d20-a211-cbee6ffa77c2"
      decimals="2"
      id="F_af92f1de-c7b7-4f73-b2d6-f39f5f3cf9c0"
      unitRef="U_EurPerShare">60.85</asnd:FairValueOfWarrantsGranted>
    <ifrs-full:DisclosureOfAuditorsRemunerationExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_8efd4cc8-6918-42ba-809b-5c6a30eaeb23">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 8&#x2014; Principal Accountant Fees and Services&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth, for each of the years indicated, the fees billed by the Company&#x2019;s independent public accountants and the proportion of each of the fees out of the total amount billed by the accountants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Principal accountant fees and services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Audit fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Audit-related fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total principal accountant fees and services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAuditorsRemunerationExplanatory>
    <asnd:DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_fdfd688b-a950-4be6-8d50-d39d00ee2ab0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth, for each of the years indicated, the fees billed by the Company&#x2019;s independent public accountants and the proportion of each of the fees out of the total amount billed by the accountants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Principal accountant fees and services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Audit fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Audit-related fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total principal accountant fees and services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfDetailedInformationForPrincipalAccountantFeesAndServiceExplanatoryTextBlock>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_332ac5b8-3369-4ae5-9d0f-1ece187cf6a9"
      unitRef="U_EUR">811000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_6f9db992-feb2-4e62-b4b3-8b0ed1fe82aa"
      unitRef="U_EUR">739000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_8cb22c4d-a6a7-4c65-9021-75187af946d9"
      unitRef="U_EUR">814000</ifrs-full:AuditorsRemunerationForAuditServices>
    <asnd:Audit-RelatedFees
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_33c9155c-3e64-4745-a716-c458397f9a0f"
      unitRef="U_EUR">147000</asnd:Audit-RelatedFees>
    <asnd:Audit-RelatedFees
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_1d016210-0988-4dd5-9c75-8a19c2f31124"
      unitRef="U_EUR">0</asnd:Audit-RelatedFees>
    <asnd:Audit-RelatedFees
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_7ffed169-7ea7-425b-84ab-bdd6f16b9cb0"
      unitRef="U_EUR">0</asnd:Audit-RelatedFees>
    <ifrs-full:AuditorsRemunerationForTaxServices
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_23912301-9d8f-4b32-9368-454df243cd8b"
      unitRef="U_EUR">91000</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemunerationForTaxServices
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_933c35fd-59f6-4f71-94a2-e5b97038dee5"
      unitRef="U_EUR">122000</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemunerationForTaxServices
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_96586f91-da55-46a5-86ed-96bf0bb4134d"
      unitRef="U_EUR">138000</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemuneration
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_ef5cbee4-d853-4cd7-947f-3b1445da2889"
      unitRef="U_EUR">1049000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_f5ed2f34-e370-439d-a23f-d09e59ad171d"
      unitRef="U_EUR">861000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_fdf363b2-e7d0-40cb-8970-d5815d7f2c36"
      unitRef="U_EUR">952000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_ca47d807-0807-4ae0-96cd-c49c873d396d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 9&#x2014;Tax on Profit/(Loss) for the Year and Deferred Tax&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.409%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.177999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.177999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.238%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax on profit/(loss) for the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current tax (expense)/income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current tax, adjustments to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax, movement for the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax, adjustments to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax for the year can be explained as follows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Profit/(loss) before tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;373,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;577,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax at the Danish corporation tax rate of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;82,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;104,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;127,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax effect of:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-deductible costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additional tax deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impact from associates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prior year adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other effects including effect of different tax rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax asset, not recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax on profit/(loss) for the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;0.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specification of deferred tax assets/(liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax deductible losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;434,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;521,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other temporary differences, assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax asset, not recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;599,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;537,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other temporary differences, liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets/(liabilities) at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, a deferred tax liability has been recognized in relation to taxable temporary differences in one jurisdiction, as we do not believe we will have any deductible temporary differences nor tax losses to deduct the taxable difference in, when they are expected to reverse.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets have not been recognized in the consolidated statements of financial position as of December 31, 2024 due to uncertainty relating to future utilization. The deferred tax asset can be carried forward without timing limitations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had tax losses carried forward of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;1,946.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,371.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million at December 31, 2024 and 2023, respectively. Tax losses can be carried forward infinitely, where certain limitations exist for amounts to be utilized each year. Under Danish tax legislation, tax losses may be partly refunded by the tax authorities to the extent such tax losses arise from research and development activities. the jointly taxed Danish entities had a negative taxable income, and accordingly were entitled to a tax refund of approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for each of the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The tax losses carried forward at December 31, 2023 (&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,371.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) has been reduced with &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;456.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The reduction is as a consequence of two changes of tax principles made in the Danish tax returns for the taxable year 2023 (filed in June 2024). The changes are related to R&amp;amp;D costs (depreciations) and inventory write-down (cost price). This reduction in tax losses is still available as deferred tax assets, that can be recognized for future utilization; only not as a &#x201c;Tax deductible losses,&#x201d; but as &#x201c;Other temporary differences, assets.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is entitled to additional tax deductions related to share based payments (Warrants, RSUs and PSUs). Tax deductions can be taken when the warrants/RSUs/PSUs are exercised/transferred. For the year ended December 31, 2024, the Company was entitled to additional tax deductions with a tax value of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, compared to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2023 and 2022, respectively. These future tax deductions depend on the timing and amounts of warrants/RSUs/PSUs exercises/transfers, and accordingly, future additional tax deductions are subject to uncertainties. Refer to Note 7, &#x201c;Share-based Payment,&#x201d; regarding a description of warrant and RSU/PSU programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is entitled to additional tax deductions for which deferred tax asset cannot be recognized due the initial recognition exception in IAS 12, &#x201c;Income Taxes.&#x201d; For the year ended December 31, 2024, the Company is entitled to additional future tax deduction with a tax value of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, compared to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for each of the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023 and 2022. In addition, the Company is entitled to additional tax deductions related to tax credits. Tax credits can be taken in future taxes. For the year ended December 31, 2024, the Company was entitled to additional tax deduction with a tax value of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, compared to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for each of the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 23, 2023, the IASB issued International Tax Reform - Pillar Two Model Rules - Amendments to IAS 12 which clarify that IAS 12 applies to income taxes arising from tax law enacted or substantively enacted to implement the Pillar Two model rules published by the OECD, including tax law that implements Qualified Domestic Minimum Top-up Taxes. The Company has adopted these amendments; however, they are not applicable for the year ended December 31, 2024, as the Company&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s consolidated revenue is currently below the threshold of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Parent Company, Ascendis Pharma A/S, is jointly taxed with its Danish subsidiaries. The current Danish corporation tax is allocated between the jointly taxed Danish companies in proportion to their taxable income (full absorption with refunds for tax losses). The jointly taxed companies are included in the on-account tax scheme.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_81367575-ffe4-40d3-b209-a11fb1a553bf">
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.409%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.177999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.177999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.238%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax on profit/(loss) for the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current tax (expense)/income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current tax, adjustments to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax, movement for the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax, adjustments to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax for the year can be explained as follows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Profit/(loss) before tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;373,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;577,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax at the Danish corporation tax rate of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;82,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;104,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;127,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax effect of:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-deductible costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additional tax deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impact from associates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prior year adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other effects including effect of different tax rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax asset, not recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tax on profit/(loss) for the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;0.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specification of deferred tax assets/(liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax deductible losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;434,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;521,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other temporary differences, assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax asset, not recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;599,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;537,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other temporary differences, liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets/(liabilities) at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d0235cf9-bf99-4cfc-867a-fbdfc01bbb8d"
      unitRef="U_EUR">-3289000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_b3a6bcaa-dfc6-4e76-b71a-b0a96fd4d16f"
      unitRef="U_EUR">-5377000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_f4518c68-531e-4ae6-8b17-a9927b87cd18"
      unitRef="U_EUR">-3723000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_c9ade824-2cb2-4dcc-bd5d-39fbfc2ff2cd"
      unitRef="U_EUR">-126000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_22ecf34c-e7d1-4311-9a5a-77bb1447ed21"
      unitRef="U_EUR">3904000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_c48f3c51-bcd5-430a-90e7-8ad15301ddb1"
      unitRef="U_EUR">-1654000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <asnd:DeferredTaxMovementForTheYear
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_30b21268-cc41-4e0e-a018-3dbe9a1d8fe0"
      unitRef="U_EUR">-2035000</asnd:DeferredTaxMovementForTheYear>
    <asnd:DeferredTaxMovementForTheYear
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_e695f93e-f3f1-4005-9c50-c0aa43f2d5be"
      unitRef="U_EUR">-1044000</asnd:DeferredTaxMovementForTheYear>
    <ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_3516a93e-47be-4842-a892-fb3eeb1a9747"
      unitRef="U_EUR">607000</ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods>
    <ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_bba59609-e71a-4ac5-8fa7-a8177ea4d47f"
      unitRef="U_EUR">-4786000</ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_577dae54-cc99-46bd-a6b9-18be8d6f0acc"
      unitRef="U_EUR">-4843000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_89ce5b13-4284-4253-bcc7-daff427bacd0"
      unitRef="U_EUR">-7303000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_d4b1e187-a8bd-4d12-b087-241e74438ff8"
      unitRef="U_EUR">-5377000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_cd0f3244-3545-4a35-9fd5-a689122eb28c"
      unitRef="U_EUR">-373241000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_d3181a03-351f-4f07-a3b9-2ea45ac0027c"
      unitRef="U_EUR">-474144000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_488c2f63-68dd-4f22-b13b-f93e3a1707cb"
      unitRef="U_EUR">-577817000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="2"
      id="F_4f767655-6a30-4b68-90d3-7cd4f5f057ef"
      unitRef="U_pure">0.22</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="2"
      id="F_c4693cbc-d796-4501-a0d0-30dbe49837d5"
      unitRef="U_pure">0.22</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="2"
      id="F_d701bd29-4f01-4bdf-be3e-dd8add383690"
      unitRef="U_pure">0.22</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d1a9f884-cd59-4850-9d88-51448b5ee40b"
      unitRef="U_EUR">82113000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_0706e2cc-cb1d-4c00-8875-f6ddc82ecea1"
      unitRef="U_EUR">104312000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_4e87d4dd-8321-4f3d-a7f3-43b4dd38f534"
      unitRef="U_EUR">127120000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_08560d8b-b422-40b8-a2ed-c11917461627"
      unitRef="U_EUR">9740000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_4dde9f8c-d497-4540-97c0-18597b334370"
      unitRef="U_EUR">8494000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_6292afe3-b77a-4306-a668-d200d79ac5f1"
      unitRef="U_EUR">17094000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <asnd:TaxEffectOfDeductibleItemsNotExpensed
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_a3a228c6-0a2a-416f-a7ec-d60df726c42b"
      unitRef="U_EUR">3161000</asnd:TaxEffectOfDeductibleItemsNotExpensed>
    <asnd:TaxEffectOfDeductibleItemsNotExpensed
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_e770e330-0f6c-47dd-acd8-bec795a0ef3e"
      unitRef="U_EUR">9077000</asnd:TaxEffectOfDeductibleItemsNotExpensed>
    <asnd:TaxEffectOfDeductibleItemsNotExpensed
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_a05f1e4f-9331-470b-9bcd-f69efb827671"
      unitRef="U_EUR">13720000</asnd:TaxEffectOfDeductibleItemsNotExpensed>
    <asnd:TaxEffectsFromImpactsFromAssociates
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_63a22135-0934-4135-b5c9-4ff148846e3b"
      unitRef="U_EUR">-4413000</asnd:TaxEffectsFromImpactsFromAssociates>
    <asnd:TaxEffectsFromImpactsFromAssociates
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_54aeea28-e32a-426a-bf5b-c10650e11d0e"
      unitRef="U_EUR">-4047000</asnd:TaxEffectsFromImpactsFromAssociates>
    <asnd:TaxEffectsFromImpactsFromAssociates
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_836ec5f5-08d1-4739-b6dc-dba4e44b640c"
      unitRef="U_EUR">-3893000</asnd:TaxEffectsFromImpactsFromAssociates>
    <asnd:TaxEffectsFromPriorYearAdjustment
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_7cc494c4-4f70-49e2-9dbb-6fb9ca3cc6b4"
      unitRef="U_EUR">481000</asnd:TaxEffectsFromPriorYearAdjustment>
    <asnd:TaxEffectsFromPriorYearAdjustment
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_d38d2a8e-7d5a-45d3-a251-eee82d101d2e"
      unitRef="U_EUR">-1294000</asnd:TaxEffectsFromPriorYearAdjustment>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_d0f821e1-9f06-44a9-99f2-d8d23882bc55"
      unitRef="U_EUR">182000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_a7049bee-149e-4e47-b698-1afbca037239"
      unitRef="U_EUR">-882000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_39a1bff8-ffc8-461d-8847-44a8120ff543"
      unitRef="U_EUR">-2716000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <asnd:TaxEffectFromDeferredTaxAssetNotRecognized
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_476aa8e1-8a0d-4545-bfd3-07fff1164941"
      unitRef="U_EUR">-76627000</asnd:TaxEffectFromDeferredTaxAssetNotRecognized>
    <asnd:TaxEffectFromDeferredTaxAssetNotRecognized
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_23d4373a-b869-4b41-b554-c8b16de638ba"
      unitRef="U_EUR">-105975000</asnd:TaxEffectFromDeferredTaxAssetNotRecognized>
    <asnd:TaxEffectFromDeferredTaxAssetNotRecognized
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_40759b54-36c6-4014-8bcf-4e74c8827a2a"
      unitRef="U_EUR">-122514000</asnd:TaxEffectFromDeferredTaxAssetNotRecognized>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_f2b2970e-de59-467f-a144-c184aba01e43"
      unitRef="U_EUR">4843000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_8a6bab66-e4f5-421a-8203-f18c0eea564e"
      unitRef="U_EUR">7303000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_f9bea764-6b92-4e60-9d51-bcfc945a5648"
      unitRef="U_EUR">5377000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="4"
      id="F_ce49dfe3-31a5-4b47-92a4-9c19a4e45aed"
      unitRef="U_pure">0.013</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="4"
      id="F_6232baa7-6106-456c-bc7f-2311c83a3a5d"
      unitRef="U_pure">0.0154</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="4"
      id="F_27b95e7d-a644-4579-bcef-a82fd015d9f7"
      unitRef="U_pure">0.0093</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_70046205-e565-4b41-995b-27c2236898a4"
      unitRef="U_EUR">434997000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_f682450c-e3ea-4719-977b-e19af205f065"
      unitRef="U_EUR">521697000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_3a52136b-1435-435c-aa06-3d176e6cc579"
      unitRef="U_EUR">433174000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_942cde62-bedf-4812-ab1a-31bfbf9ac191"
      unitRef="U_EUR">164479000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_6c475c17-cd76-4022-90ce-2d62fe697cdb"
      unitRef="U_EUR">16256000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="-3"
      id="F_77e6b607-81c9-4f41-8f67-7bf3b9071d8d"
      unitRef="U_EUR">19961000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <asnd:DeferredTaxAssetNotRecognized
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_64a530cd-d877-4a46-aa19-ad1c56673a79"
      unitRef="U_EUR">-599476000</asnd:DeferredTaxAssetNotRecognized>
    <asnd:DeferredTaxAssetNotRecognized
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_9ef27c34-8659-42ec-bc63-daf3307f7ac7"
      unitRef="U_EUR">-537953000</asnd:DeferredTaxAssetNotRecognized>
    <asnd:DeferredTaxAssetNotRecognized
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="-3"
      id="F_50b554f6-5bbc-479f-8a06-c5563909e7e6"
      unitRef="U_EUR">-453135000</asnd:DeferredTaxAssetNotRecognized>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_7ca4387f-76f5-4ce6-9567-a7d81f8e992e"
      unitRef="U_EUR">7258000</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_d953325f-087b-4831-a9b2-d7e539eac9ba"
      unitRef="U_EUR">5830000</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_8ec45740-235a-4438-a41f-6f58329e883d"
      unitRef="U_EUR">-7258000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_91db0156-fbf9-4ce3-80c9-9cb03b5ce52c"
      unitRef="U_EUR">-5830000</ifrs-full:NetDeferredTaxAssets>
    <asnd:TaxLossesCarryforwards
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-5"
      id="F_65eb8903-09c3-431e-ad72-f4f505fd0943"
      unitRef="U_EUR">1946200000</asnd:TaxLossesCarryforwards>
    <asnd:TaxLossesCarryforwards
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_c62d199b-55dd-461c-b27e-2618e4cd4297"
      unitRef="U_EUR">2371300000</asnd:TaxLossesCarryforwards>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-5"
      id="F_36ac07b2-aa23-426b-b38e-1d77d57ce6d3"
      unitRef="U_EUR">-700000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-5"
      id="F_37be2f60-1e11-4bf8-a82b-e20829eba6bf"
      unitRef="U_EUR">-700000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-5"
      id="F_337af029-fc5c-4191-ab7e-e8deb8481043"
      unitRef="U_EUR">-700000</ifrs-full:IncomeTaxesPaidRefund>
    <asnd:TaxLossesCarryforwards
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_efa190be-e53a-41c6-b3fc-76926ce59b5e"
      unitRef="U_EUR">2371300000</asnd:TaxLossesCarryforwards>
    <asnd:DecreaseInTaxLosseCarryForwards
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_ec6fb294-31c1-4724-b7ab-6395c8794c03"
      unitRef="U_EUR">456800000</asnd:DecreaseInTaxLosseCarryForwards>
    <asnd:AdditionalTaxDeduction
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-5"
      id="F_c235eccc-bc9d-46eb-81ef-a67ec772b9d8"
      unitRef="U_EUR">21700000</asnd:AdditionalTaxDeduction>
    <asnd:AdditionalTaxDeduction
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-5"
      id="F_aae6638b-b3eb-4f66-95c4-b71cf3b964a2"
      unitRef="U_EUR">10600000</asnd:AdditionalTaxDeduction>
    <asnd:AdditionalTaxDeduction
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-5"
      id="F_4695d285-7871-4dcf-8460-7d29206b4a7d"
      unitRef="U_EUR">5200000</asnd:AdditionalTaxDeduction>
    <asnd:AdditionalFutureTaxDeduction
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-5"
      id="F_3d7a2c55-f448-4ccc-be8b-64006d21a509"
      unitRef="U_EUR">11000000</asnd:AdditionalFutureTaxDeduction>
    <asnd:AdditionalFutureTaxDeduction
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-5"
      id="F_e8d89017-917e-412c-889c-7b13be1f9f08"
      unitRef="U_EUR">300000</asnd:AdditionalFutureTaxDeduction>
    <asnd:AdditionalFutureTaxDeduction
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-5"
      id="F_0fd8997c-ddc8-4629-a1e9-26853229fc34"
      unitRef="U_EUR">300000</asnd:AdditionalFutureTaxDeduction>
    <asnd:AdditionalTaxDeductionsRelatedToTaxCredits
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-5"
      id="F_3f706ac5-33d0-4f1b-aae7-bc29035a4d7c"
      unitRef="U_EUR">13800000</asnd:AdditionalTaxDeductionsRelatedToTaxCredits>
    <asnd:AdditionalTaxDeductionsRelatedToTaxCredits
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-5"
      id="F_33828218-6e08-4377-8646-46712536f5a1"
      unitRef="U_EUR">8400000</asnd:AdditionalTaxDeductionsRelatedToTaxCredits>
    <asnd:AdditionalTaxDeductionsRelatedToTaxCredits
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-5"
      id="F_a1bdecdb-99a9-48a6-84c2-2db457dc6394"
      unitRef="U_EUR">8400000</asnd:AdditionalTaxDeductionsRelatedToTaxCredits>
    <asnd:RevenueThresholdLimit
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-6"
      id="F_34725501-e09e-4e29-8bf1-8eed0b805717"
      unitRef="U_EUR">750000000</asnd:RevenueThresholdLimit>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_e55b86ab-fbc7-4bbc-98ef-9011fd8e3e3e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 10&#x2014;Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortization and impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the reporting date, no internally generated intangible assets from development of pharmaceutical drug candidates have been recognized. Thus, all related research and development costs incurred for the years ended December 31, 2024, 2023 and 2022, were recognized in the consolidated statements of profit or loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill relates to the acquisition of Complex Biosystems GmbH (now Ascendis Pharma GmbH) in 2007. Goodwill was calculated as the excess amount of the purchase price to the fair value of identifiable assets acquired, and liabilities assumed at the acquisition date. Ascendis Pharma GmbH was initially a separate technology platform company but is now an integral part of the Company&#x2019;s research and development activities. Accordingly, it is not possible to look separately at Ascendis Pharma GmbH when considering the recoverable amount of the goodwill. Goodwill is monitored and tested for impairment on a consolidated level as the Company is considered to represent one cash-generating unit.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The recoverable amount of the cash-generating unit is determined based on an estimation of the Company&#x2019;s fair value less costs of disposal. The fair value of goodwill has been determined after taking into account the market value of the Company&#x2019;s ADSs as of the reporting date. The computation of the market value including an estimation of selling costs, significantly exceeded the carrying amount of the net assets, leaving sufficient value to cover the carrying amount of goodwill. Considering the excess value, no further assumptions are deemed relevant to be applied in determining whether goodwill is impaired. &lt;/span&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_fd220e77-4e57-4ab2-99f9-c4d0863f3f99">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortization and impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_f664c695-e007-4c41-b59a-806a6f163104"
      decimals="-3"
      id="F_11515938-7c37-4f6c-90c9-b0c14672361b"
      unitRef="U_EUR">3495000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_0dd10c76-089d-41db-b834-45504dc6b09e"
      decimals="-3"
      id="F_be477638-01f9-43b8-ad36-5f2a6cd661ef"
      unitRef="U_EUR">2222000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_fda59e11-28d9-4e33-b9c1-3a2479007ef5"
      decimals="-3"
      id="F_9613b7d3-d9e9-4b89-9fdd-132a0fccbf60"
      unitRef="U_EUR">5717000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_7e7e620d-71e2-4c5d-bea4-731d5ebd213b"
      decimals="-3"
      id="F_e1a34101-eccf-4778-bd17-1f85025c4152"
      unitRef="U_EUR">53000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7"
      decimals="-3"
      id="F_ca229de0-dcee-441a-8d04-08556d3cbd51"
      unitRef="U_EUR">53000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="C_7e7e620d-71e2-4c5d-bea4-731d5ebd213b"
      decimals="-3"
      id="F_f8d3d642-f912-4aa0-83e5-090349f9eaab"
      unitRef="U_EUR">21000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7"
      decimals="-3"
      id="F_81a9c3cf-437c-4d35-9b41-2dc09f2b1e74"
      unitRef="U_EUR">21000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_ed783084-e2f1-44fb-b106-1b2f859597c7"
      decimals="-3"
      id="F_a6bb0102-ff19-4fad-ac0f-0680ce64d4b9"
      unitRef="U_EUR">3495000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_8c791550-835c-4e22-a26b-97ea8127f804"
      decimals="-3"
      id="F_e63ae5c0-e54f-424f-a324-38a8b9d0b659"
      unitRef="U_EUR">2296000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_3816caa9-d60e-4738-924c-a8108f43fcb8"
      decimals="-3"
      id="F_c1a993e5-26ac-475b-87ad-45f61b09efde"
      unitRef="U_EUR">5791000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_9952b4f6-b45f-4d1f-886d-8e1f0d262e6f"
      decimals="-3"
      id="F_7dad7698-6463-4043-ac0b-d11dd0f5652c"
      unitRef="U_EUR">76000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb"
      decimals="-3"
      id="F_ff553040-be96-47a0-af41-a03de1df73fc"
      unitRef="U_EUR">76000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_feb4fcb6-91c3-427b-a969-26daa054341f"
      decimals="-3"
      id="F_ca50b129-e906-43d3-953b-3c9378f2c08c"
      unitRef="U_EUR">3495000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_b8d9ea02-e435-4914-b63c-68ab0e65dc37"
      decimals="-3"
      id="F_ec6a3970-aff8-4bdd-9d1f-5f585382c07c"
      unitRef="U_EUR">2372000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_e06fb832-2f86-4a43-92b1-f2a822f36e49"
      decimals="-3"
      id="F_01d52a82-534a-44dc-b12b-48aeece51f7e"
      unitRef="U_EUR">5867000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_a9a130e0-614f-4ba0-8504-fd5085a02099"
      decimals="-3"
      id="F_b69a7843-7429-48be-b480-acb048114134"
      unitRef="U_EUR">-889000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_e49c3b45-39cc-414c-9238-0fc9d4cf659d"
      decimals="-3"
      id="F_74a18080-de7f-43c3-b67e-fc576664772c"
      unitRef="U_EUR">-889000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="C_d388a1d4-7923-4886-87c3-db6a6873ba8b"
      decimals="-3"
      id="F_e00ce504-6750-4733-85be-6cadc399baa5"
      unitRef="U_EUR">-483000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="C_a29fcdf1-c976-4997-a302-2bd939c278f6"
      decimals="-3"
      id="F_e4e29da2-fb15-431c-b089-f5a967cff5a5"
      unitRef="U_EUR">-483000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_aa8178e7-5d8d-4ed1-9503-6b67ad186cec"
      decimals="-3"
      id="F_41c7da1f-f25f-43a7-a7cd-c2cad452d637"
      unitRef="U_EUR">-1372000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_149a0f63-60f1-4bf3-a3df-4dce7568cfc5"
      decimals="-3"
      id="F_bbf978ba-ffac-44e6-a85d-62e133e62e12"
      unitRef="U_EUR">-1372000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="C_5089591b-f114-41f5-b652-8a708640665f"
      decimals="-3"
      id="F_d2494033-d82a-4ded-a2c5-488768c488e6"
      unitRef="U_EUR">-467000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="C_3566e5f1-2b87-4f68-9039-a9df104b1f9f"
      decimals="-3"
      id="F_00fe9317-8025-4323-b80d-95113663a170"
      unitRef="U_EUR">-467000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_4ea532ca-6e45-43f5-a284-db382e2c5785"
      decimals="-3"
      id="F_d684db7a-27c4-49e8-b31d-fead81355ca6"
      unitRef="U_EUR">-1839000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_7a48f51e-d7c8-4ea7-acf8-8fd05459ee2e"
      decimals="-3"
      id="F_8ef7925d-cfa6-447f-9540-d0fd903f8427"
      unitRef="U_EUR">-1839000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_f1f075ea-35d2-48db-b997-3ec5409d09d7"
      decimals="-3"
      id="F_ee36581b-c1e8-4da4-81fa-a975611c3c4c"
      unitRef="U_EUR">3495000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_37e1d239-86ce-49d1-96d5-a76ae721217a"
      decimals="-3"
      id="F_0ebad9e2-0791-4f3f-a3fe-4dfa0f47aa28"
      unitRef="U_EUR">924000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_2f7f0699-4e7d-4e8a-88ce-903af8717d18"
      unitRef="U_EUR">4419000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_a4416a56-3759-43a1-a9b2-a168da37fe04"
      decimals="-3"
      id="F_65eb6a62-56f4-4167-b27b-45371405f012"
      unitRef="U_EUR">3495000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_09099e4b-a592-4705-af54-4663f508c0b4"
      decimals="-3"
      id="F_434f9ca4-c94d-42d7-a9a1-755e1f22cd4d"
      unitRef="U_EUR">533000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_972d59c4-6920-462f-be5a-f0a8d3cf30c3"
      unitRef="U_EUR">4028000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_dd122e37-3d25-4f11-b9d8-ba7d0ebb79e0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 11&#x2014;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Plant and&lt;br/&gt;Machinery&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other&lt;br/&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Leasehold&lt;br/&gt;Improve-&lt;br/&gt;ments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Right-of-Use&lt;br/&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Disposals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;27,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;11,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;19,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;123,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;182,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Disposals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;10,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;20,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;130,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;183,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Depreciation and impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Disposals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;10,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;40,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;71,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Disposals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;9,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;54,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;84,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;14,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;8,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;83,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;110,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;75,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;98,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The impairment charge for the year ended December 31, 2023, relates to change in activities at one of our R&amp;amp;D sites and is determined according to its estimated value in use. The R&amp;amp;D site is subleased and is recognized as a right-of-use asset with a carrying amount of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation charges are specified below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Depreciation charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general, and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total depreciation charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;17,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;18,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;17,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes depreciation charges capitalized as part of inventories.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_5c93e00b-20d4-432c-96c1-383d44277036">
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Plant and&lt;br/&gt;Machinery&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other&lt;br/&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Leasehold&lt;br/&gt;Improve-&lt;br/&gt;ments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Right-of-Use&lt;br/&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Disposals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;27,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;11,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;19,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;123,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;182,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Disposals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;10,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;20,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;130,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;183,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Depreciation and impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Disposals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;10,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;40,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;71,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Disposals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;9,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;54,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;84,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;14,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;8,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;83,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;110,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;75,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;98,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_3421ed33-b354-4de8-ba6c-72beee95c70a"
      decimals="-3"
      id="F_b80b933c-ddbf-4ec7-b70b-a2ee52ac4a35"
      unitRef="U_EUR">24944000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_6a0a5caa-b991-40a9-a3ec-b387124678ad"
      decimals="-3"
      id="F_9f5481ca-69e7-4d9d-b36d-cd90e6f85f7e"
      unitRef="U_EUR">11203000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_8d88cc9c-27a2-4ff0-b63b-b1a040391061"
      decimals="-3"
      id="F_daca50d7-1747-4c61-9b7a-2c76490bd711"
      unitRef="U_EUR">20130000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_09e22d4c-5ff0-4832-b86c-6b6f62d31ccc"
      decimals="-3"
      id="F_f8359b01-42d7-404c-ab29-9b92012aee69"
      unitRef="U_EUR">119466000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_fda59e11-28d9-4e33-b9c1-3a2479007ef5"
      decimals="-3"
      id="F_078e92c0-6e38-4d94-863c-f9ae2ae949ac"
      unitRef="U_EUR">175743000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_7a98677e-a082-47ea-899e-37bc59fd1b58"
      decimals="-3"
      id="F_d6e9c41c-b356-44d1-8c8b-8ced4b8ba8f2"
      unitRef="U_EUR">2580000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_ae64dc13-b337-4595-88a9-3361adbfd7eb"
      decimals="-3"
      id="F_48b9add3-0554-4401-b89a-73df3cf780b3"
      unitRef="U_EUR">503000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_65837925-044a-445d-bd2b-f455d164b262"
      decimals="-3"
      id="F_4c773213-ade5-4057-b074-01e97b499bc1"
      unitRef="U_EUR">228000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_cfabba9a-1d15-458c-ad60-0eb6d48d0908"
      decimals="-3"
      id="F_c0a93a8e-628d-45ce-890c-e909860ea477"
      unitRef="U_EUR">7547000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7"
      decimals="-3"
      id="F_db5ee9af-0ab7-427d-bc58-9aa07a7f2e96"
      unitRef="U_EUR">10858000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_7a98677e-a082-47ea-899e-37bc59fd1b58"
      decimals="-3"
      id="F_0fe10b0a-2f94-4b46-a8dc-194e5df8f6dc"
      unitRef="U_EUR">383000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_ae64dc13-b337-4595-88a9-3361adbfd7eb"
      decimals="-3"
      id="F_5b7c4c20-7cf0-4736-a9d2-a81bdb4af1ca"
      unitRef="U_EUR">57000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7"
      decimals="-3"
      id="F_60051caa-9f64-44e8-a197-bc44ad68a3e5"
      unitRef="U_EUR">440000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
      contextRef="C_7a98677e-a082-47ea-899e-37bc59fd1b58"
      decimals="-3"
      id="F_ea3454a9-462b-4cd7-9468-6fc85b43d7c4"
      unitRef="U_EUR">504000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
      contextRef="C_ae64dc13-b337-4595-88a9-3361adbfd7eb"
      decimals="-3"
      id="F_3c9d4dbb-ce95-4f14-9b71-ce71a9ecdc60"
      unitRef="U_EUR">-21000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
      contextRef="C_65837925-044a-445d-bd2b-f455d164b262"
      decimals="-3"
      id="F_010280c6-349f-48c1-a556-c2e2daf0b0fb"
      unitRef="U_EUR">-504000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
      contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7"
      decimals="-3"
      id="F_b302fba6-4f9c-46ec-a266-03ba5b433359"
      unitRef="U_EUR">-21000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_7a98677e-a082-47ea-899e-37bc59fd1b58"
      decimals="-3"
      id="F_347c58b9-6e0d-415a-8bf3-00739d0a3f74"
      unitRef="U_EUR">-209000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_ae64dc13-b337-4595-88a9-3361adbfd7eb"
      decimals="-3"
      id="F_8eea5961-f795-4ccc-86d7-12640df296b1"
      unitRef="U_EUR">-208000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_65837925-044a-445d-bd2b-f455d164b262"
      decimals="-3"
      id="F_a42209a8-fe07-47e4-a870-1844ab68eecf"
      unitRef="U_EUR">-479000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_cfabba9a-1d15-458c-ad60-0eb6d48d0908"
      decimals="-3"
      id="F_282dc470-aae2-4c80-a43e-05630830fec1"
      unitRef="U_EUR">-3093000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_f82d8e64-3c1d-4e06-858e-616ec0acd4c7"
      decimals="-3"
      id="F_feed8e11-4e62-4042-83db-6a1156f5d2d0"
      unitRef="U_EUR">-3989000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_bbdc53c3-a7cf-4fbe-959f-538eec284f61"
      decimals="-3"
      id="F_ba67eea2-6d92-4c1c-ae5f-8b3875ff8ae5"
      unitRef="U_EUR">27436000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_2a779f6c-3cd0-4eeb-9e62-6c93f2d9b872"
      decimals="-3"
      id="F_42cc5337-aa89-4c92-9a2b-0af5415683ac"
      unitRef="U_EUR">11420000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_064343af-8b3e-4e2a-a81b-a1a721a1cc58"
      decimals="-3"
      id="F_1c36b3b2-e9ac-44e9-9c3d-6b70734eda95"
      unitRef="U_EUR">19375000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_f7ae32c9-c10e-4691-be89-cfbdb2954133"
      decimals="-3"
      id="F_5b7af9fb-7b44-452d-a376-206e89405f9c"
      unitRef="U_EUR">123920000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_3816caa9-d60e-4738-924c-a8108f43fcb8"
      decimals="-3"
      id="F_9f449e80-4cff-4cc8-b1ac-148f245297b8"
      unitRef="U_EUR">182151000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_dff571ea-763a-4c63-ae50-c0952c31cb00"
      decimals="-3"
      id="F_9a85309b-b036-435f-b2b8-9951920e9ed7"
      unitRef="U_EUR">299000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_c34a3e33-ac79-402f-b220-5f595dd5eff5"
      decimals="-3"
      id="F_4ea8b50a-495b-48d6-b2c0-77204cf0c5d1"
      unitRef="U_EUR">951000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_edbced58-0020-4b9f-b70b-56ced58a8fef"
      decimals="-3"
      id="F_aeb18678-3191-4062-b926-2f26af390dc2"
      unitRef="U_EUR">76000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_8868a6a4-46c9-401e-8496-50e9fd14cdcf"
      decimals="-3"
      id="F_b2260cbf-750e-4ec1-83ec-5b546d3a28da"
      unitRef="U_EUR">861000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb"
      decimals="-3"
      id="F_1db6e764-5853-4de4-80c3-16594cdf0ef9"
      unitRef="U_EUR">2187000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_dff571ea-763a-4c63-ae50-c0952c31cb00"
      decimals="-3"
      id="F_c481ed92-9721-4e1c-8b13-bad0adc45b2a"
      unitRef="U_EUR">5995000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_c34a3e33-ac79-402f-b220-5f595dd5eff5"
      decimals="-3"
      id="F_77ee92dc-f5b2-462a-83e2-fd7a16341278"
      unitRef="U_EUR">1635000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_8868a6a4-46c9-401e-8496-50e9fd14cdcf"
      decimals="-3"
      id="F_036035ef-afd1-4798-b69d-4aca6a86dea0"
      unitRef="U_EUR">89000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb"
      decimals="-3"
      id="F_7ce944e0-5b30-413e-a28b-e9c23c743e6b"
      unitRef="U_EUR">7719000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
      contextRef="C_dff571ea-763a-4c63-ae50-c0952c31cb00"
      decimals="-3"
      id="F_e04c0db1-8475-4017-b68d-edd595a25c6c"
      unitRef="U_EUR">66000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
      contextRef="C_c34a3e33-ac79-402f-b220-5f595dd5eff5"
      decimals="-3"
      id="F_c0e069f2-2eba-4374-95da-f37c6c33d5d6"
      unitRef="U_EUR">-66000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
      contextRef="C_edbced58-0020-4b9f-b70b-56ced58a8fef"
      decimals="-3"
      id="F_8821711c-9337-4625-84d3-30523357ac49"
      unitRef="U_EUR">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
      contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb"
      decimals="-3"
      id="F_3d690ff6-4471-4389-937f-ea61f89ddd3a"
      unitRef="U_EUR">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_dff571ea-763a-4c63-ae50-c0952c31cb00"
      decimals="-3"
      id="F_a8667992-7c9d-49bc-b32c-d2474b427140"
      unitRef="U_EUR">127000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_c34a3e33-ac79-402f-b220-5f595dd5eff5"
      decimals="-3"
      id="F_a8df6c64-c136-42b3-b27d-3011ddc69243"
      unitRef="U_EUR">306000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_edbced58-0020-4b9f-b70b-56ced58a8fef"
      decimals="-3"
      id="F_f420ce8a-cd4a-4dd0-babf-3b0c5ab5e33e"
      unitRef="U_EUR">847000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_8868a6a4-46c9-401e-8496-50e9fd14cdcf"
      decimals="-3"
      id="F_5bd55621-ea44-4073-a6bd-107948df2d12"
      unitRef="U_EUR">5462000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_aee0a664-90db-4cac-b252-ca13f6feb6bb"
      decimals="-3"
      id="F_58d81715-9ea1-4692-90cd-817c39c617e7"
      unitRef="U_EUR">6742000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_3168c70b-da00-4f8f-8797-f6fe0d465589"
      decimals="-3"
      id="F_f50e837d-3987-4420-9c81-28c295b51304"
      unitRef="U_EUR">21933000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_dcff91fd-f804-4f83-86d2-4d7c9b912c4e"
      decimals="-3"
      id="F_9be2332f-c810-49a9-823b-27e726b0ad1d"
      unitRef="U_EUR">10976000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_41603f99-a66e-44cc-8e76-6000fc1c3438"
      decimals="-3"
      id="F_fca54432-7842-4134-9411-459c280206d2"
      unitRef="U_EUR">20298000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_7ad7edb9-5f0b-41bd-a762-0755697fa11e"
      decimals="-3"
      id="F_67dd8cd2-f0f6-464c-82e3-990a0e1243d9"
      unitRef="U_EUR">130154000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_e06fb832-2f86-4a43-92b1-f2a822f36e49"
      decimals="-3"
      id="F_7a810128-77e0-454a-96e0-ce43c7ab76aa"
      unitRef="U_EUR">183361000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_ed8dd2df-2263-4f73-959d-fdeab1aa780d"
      decimals="-3"
      id="F_40d89ef6-d57c-43cd-904f-79311b6236fe"
      unitRef="U_EUR">-7584000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_890d9573-96a4-4975-ad2a-83e24165cf64"
      decimals="-3"
      id="F_b5399264-b7c8-44de-990b-8b2d72a9b8bb"
      unitRef="U_EUR">-5023000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_59c262f0-8854-4bf0-83be-ade20e2ca796"
      decimals="-3"
      id="F_d2e10891-774b-4c99-8d26-8b1b368a151e"
      unitRef="U_EUR">-4497000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_b0636a60-1301-4427-9e48-8459c64a7333"
      decimals="-3"
      id="F_ebd19392-db11-4632-80ad-6f77e25b2c5f"
      unitRef="U_EUR">-29544000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20d58111-b66a-4385-8104-172f2b4acdf0"
      decimals="-3"
      id="F_6cbf4175-3581-47c4-9ce9-f1f3e68beb73"
      unitRef="U_EUR">-46648000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0"
      decimals="-3"
      id="F_2bd80af8-727f-4b43-85dc-f179ca6bcc92"
      unitRef="U_EUR">2569000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f"
      decimals="-3"
      id="F_a3d05926-ddc0-4acc-9641-548a156a374f"
      unitRef="U_EUR">1899000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_f187930e-0517-474f-8e2c-b180dcc37681"
      decimals="-3"
      id="F_134d85c8-78d6-4372-ba36-ede4554defdb"
      unitRef="U_EUR">2085000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_b03741b3-c7aa-47e4-82f2-f5538b555142"
      decimals="-3"
      id="F_ad445bb1-54da-405f-8d98-a0a1ee67cafb"
      unitRef="U_EUR">11875000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_e5fb59de-879c-4977-985d-bba088bed9ee"
      decimals="-3"
      id="F_f914870f-cc80-4bce-af80-a5d3ce0efa45"
      unitRef="U_EUR">18428000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0"
      decimals="-3"
      id="F_1e73951e-310c-4442-8627-59fa693fa190"
      unitRef="U_EUR">2869000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f"
      decimals="-3"
      id="F_85191685-6f3d-416f-b034-3c180cc90e75"
      unitRef="U_EUR">405000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_f187930e-0517-474f-8e2c-b180dcc37681"
      decimals="-3"
      id="F_8bf7b85f-dd94-4c3c-9272-06a7833fd9c5"
      unitRef="U_EUR">4560000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_e5fb59de-879c-4977-985d-bba088bed9ee"
      decimals="-3"
      id="F_aaac7ec0-4a51-46bf-b7fe-e1fd9aab9356"
      unitRef="U_EUR">7834000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0"
      decimals="-3"
      id="F_bfaa5019-43ae-4c51-97f9-12d7318e0e45"
      unitRef="U_EUR">-146000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f"
      decimals="-3"
      id="F_3c9d76d3-f3c7-4a69-a574-a5f5dd74cc5b"
      unitRef="U_EUR">-54000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_e5fb59de-879c-4977-985d-bba088bed9ee"
      decimals="-3"
      id="F_6f2ca542-39d2-4db4-9d33-11205b26b03d"
      unitRef="U_EUR">-200000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_6f9dc171-d6c9-4d1d-b8be-76f28f0b44b0"
      decimals="-3"
      id="F_b4ae7cb1-22dc-4d9b-9c96-5ecd05cfabde"
      unitRef="U_EUR">92000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_15ac27d7-e530-4d4f-92c5-f756c87ab34f"
      decimals="-3"
      id="F_35efa50d-9483-4e8e-8b92-c5171e3c0447"
      unitRef="U_EUR">98000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_f187930e-0517-474f-8e2c-b180dcc37681"
      decimals="-3"
      id="F_4b5237ec-6f08-4504-9230-7b3a39daf552"
      unitRef="U_EUR">196000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_b03741b3-c7aa-47e4-82f2-f5538b555142"
      decimals="-3"
      id="F_d7284188-efe6-48cc-a0e2-751a56782c58"
      unitRef="U_EUR">807000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_e5fb59de-879c-4977-985d-bba088bed9ee"
      decimals="-3"
      id="F_65bdc94c-df39-484a-a3eb-552a033fe263"
      unitRef="U_EUR">1193000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_7d30fefe-a9c7-49d1-868a-e9fe7915fa00"
      decimals="-3"
      id="F_e1c7b42e-64c9-449c-8a44-ebc9aea9ea61"
      unitRef="U_EUR">-12784000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_d7878707-fcf3-4173-a198-76e206226458"
      decimals="-3"
      id="F_20a40011-a557-44be-9a3d-e2f90c2e9fdd"
      unitRef="U_EUR">-7175000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_bedad476-b3c2-4ee5-9d07-5861655b6c94"
      decimals="-3"
      id="F_05999c7b-c2bd-4fbd-a402-99e2fae07e30"
      unitRef="U_EUR">-10946000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_16d1bca8-ddc8-4770-922a-085d984adaa3"
      decimals="-3"
      id="F_53839f07-73d6-42c5-9020-1f85c9bfcbaa"
      unitRef="U_EUR">-40612000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_11acfac4-6200-472e-926e-c7090b67f933"
      decimals="-3"
      id="F_ad9b5bb3-f6e1-40cb-8350-22d86b87d516"
      unitRef="U_EUR">-71517000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_6a56e38a-0002-4f9e-838d-06508b6db3f5"
      decimals="-3"
      id="F_0fbc15b0-a9f4-424b-ada0-e0a3b72d552b"
      unitRef="U_EUR">2330000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_b4c60161-4bc0-4ca2-859b-eb4baf374e64"
      decimals="-3"
      id="F_b0f2dbfa-5e27-491b-b4d0-f284e04cfde1"
      unitRef="U_EUR">1322000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_d615a83e-1e17-46ec-8765-e218963f27dd"
      decimals="-3"
      id="F_a65aba7f-c931-4904-9386-6e7688a45096"
      unitRef="U_EUR">1283000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_97992a0e-7ccc-4554-a974-5d01c776b4ae"
      decimals="-3"
      id="F_0c48f9c7-8b0d-4dc4-bde0-789802a07e2a"
      unitRef="U_EUR">12312000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_c82c67d1-a374-44f7-a579-4e1e136065a6"
      decimals="-3"
      id="F_599966ba-65ee-49b0-87af-ddb6a247a248"
      unitRef="U_EUR">17247000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_6a56e38a-0002-4f9e-838d-06508b6db3f5"
      decimals="-3"
      id="F_4d92efc1-c6e1-4606-b2f4-435f80e241c1"
      unitRef="U_EUR">-5296000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_b4c60161-4bc0-4ca2-859b-eb4baf374e64"
      decimals="-3"
      id="F_a6bd29e7-6087-479f-a3e5-39d93345bb8d"
      unitRef="U_EUR">-1501000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_97992a0e-7ccc-4554-a974-5d01c776b4ae"
      decimals="-3"
      id="F_9e801dfb-e27e-4f2b-8297-daf507493686"
      unitRef="U_EUR">-88000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_c82c67d1-a374-44f7-a579-4e1e136065a6"
      decimals="-3"
      id="F_f0ad57db-e75c-4723-9b17-cb017139eb16"
      unitRef="U_EUR">-6885000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_6a56e38a-0002-4f9e-838d-06508b6db3f5"
      decimals="-3"
      id="F_ca147b4b-c5c4-4f7f-9af8-4d03c5b7292a"
      unitRef="U_EUR">-112000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_b4c60161-4bc0-4ca2-859b-eb4baf374e64"
      decimals="-3"
      id="F_e4f839f0-5275-41f0-8108-039eac2cf6cf"
      unitRef="U_EUR">-194000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_d615a83e-1e17-46ec-8765-e218963f27dd"
      decimals="-3"
      id="F_2c565908-ce20-445e-89b4-a5fb81cdeaf2"
      unitRef="U_EUR">-556000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_97992a0e-7ccc-4554-a974-5d01c776b4ae"
      decimals="-3"
      id="F_017d0f5d-dea1-43eb-af8d-b4da25321852"
      unitRef="U_EUR">-1906000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="C_c82c67d1-a374-44f7-a579-4e1e136065a6"
      decimals="-3"
      id="F_058e9762-ea11-4125-9707-21cbbb40a999"
      unitRef="U_EUR">-2768000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_2bf202a7-c410-46ac-9503-77f09f3365ef"
      decimals="-3"
      id="F_953c7774-fffa-488e-bc68-ff8c83362878"
      unitRef="U_EUR">-9930000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_cd1cf60b-5c30-41db-bb07-b8145572e517"
      decimals="-3"
      id="F_859076e4-e06d-4379-9205-fb2046d6fddf"
      unitRef="U_EUR">-7190000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_de19d30c-2832-4cdc-86a5-8ad0e3007775"
      decimals="-3"
      id="F_fe61c4c1-0d46-42f1-8797-0d4cd561088c"
      unitRef="U_EUR">-12785000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_41c2635e-b2f9-4eb1-bb72-637889040d79"
      decimals="-3"
      id="F_9f8a1006-a6de-45f7-9880-6a6ab8d9ba99"
      unitRef="U_EUR">-54742000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_dc3e7a3d-39f1-4a98-b6c7-22b916d6a2b2"
      decimals="-3"
      id="F_eae771b1-4780-4485-8da6-5a4510f309f2"
      unitRef="U_EUR">-84647000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_ca101549-cece-44e2-ba4d-877e6b9eb760"
      decimals="-3"
      id="F_284eee4a-6b62-4bc2-b8d1-9f029815e991"
      unitRef="U_EUR">14652000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_8373ab39-153b-4580-8eaa-20b64be0b669"
      decimals="-3"
      id="F_025b32ec-fc2e-4ec0-a660-6893560093e0"
      unitRef="U_EUR">4245000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_cb788b59-28a4-4544-81e7-493092e53b2d"
      decimals="-3"
      id="F_0ae40c64-88de-4fbe-ae12-805965029534"
      unitRef="U_EUR">8429000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_53acf53e-ec11-4160-8b53-30c8a273f237"
      decimals="-3"
      id="F_3f6abfdd-01ac-4bda-9868-59517102e948"
      unitRef="U_EUR">83308000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_09a7dfc4-d7e0-4c55-a274-b3a754d36e0e"
      unitRef="U_EUR">110634000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_7e41aefc-f66a-4182-a859-776c8cd1970c"
      decimals="-3"
      id="F_588f240d-167e-4713-af5f-654a08cfd25d"
      unitRef="U_EUR">12003000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_e33638fe-cef5-4937-a3e7-51501477ed4a"
      decimals="-3"
      id="F_7de943ec-a5ab-48f4-b808-4f7511b41427"
      unitRef="U_EUR">3786000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_614a19b6-1595-4cfe-87c5-0d0f93542d8e"
      decimals="-3"
      id="F_c196b17f-c95e-4190-9a94-f7f7a437a3a1"
      unitRef="U_EUR">7513000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_5c780cf2-8af2-49bf-b6f2-420dbaa22f76"
      decimals="-3"
      id="F_d56f7224-291d-4207-9eed-474bab60c515"
      unitRef="U_EUR">75412000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_2d1b44df-a8e8-495d-bed0-defea1537dbf"
      unitRef="U_EUR">98714000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-5"
      id="F_c5336b65-9ff2-48c1-9efb-4251dd0df38c"
      unitRef="U_EUR">11200000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-5"
      id="F_0d3ffff4-3380-4587-a654-884cca8ef6c3"
      unitRef="U_EUR">12500000</ifrs-full:RightofuseAssets>
    <asnd:DisclosureOfDetailedInformationAboutDepreciationsCharges
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_d2b6d76b-1e42-4410-a707-4422cf925f72">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation charges are specified below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Depreciation charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general, and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total depreciation charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;17,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;18,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;17,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes depreciation charges capitalized as part of inventories.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</asnd:DisclosureOfDetailedInformationAboutDepreciationsCharges>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_8ec23a67-4cba-4228-abd5-b5b3f4e8d2dd"
      decimals="-3"
      id="F_1446b561-50a3-4372-9e70-b65ffbc2b387"
      unitRef="U_EUR">3197000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_569d3447-2d47-452c-82a9-30b1fb7255bd"
      decimals="-3"
      id="F_fbfe1d76-710c-4833-9e72-e72cbe94a6ca"
      unitRef="U_EUR">2509000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_586a6210-5549-40bd-9d66-c8900f389cc9"
      decimals="-3"
      id="F_f11640ad-47de-4a44-ab88-796d262bd014"
      unitRef="U_EUR">1245000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_f52014a4-e011-4fe5-9aa6-e94ae66aa8c6"
      decimals="-3"
      id="F_62c96db6-c5c5-4a8d-b03e-427eb1f79cbc"
      unitRef="U_EUR">7453000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_1c7b2ee3-857c-4937-90c1-54e53d319288"
      decimals="-3"
      id="F_25c71e9d-345f-4b7a-9f37-738d0c0251be"
      unitRef="U_EUR">10296000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_7a59ec21-ecbe-4301-8893-0be00de06cef"
      decimals="-3"
      id="F_e1bf29c5-f3fa-49f0-9338-d50b07a4bf6a"
      unitRef="U_EUR">10892000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_2cc5cf2b-65b2-4978-a13a-8486ba2a64ef"
      decimals="-3"
      id="F_3d45b615-5114-4499-9f88-60e9a2df8001"
      unitRef="U_EUR">6597000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_743e733f-a355-45f7-b231-d9ba29e7a99f"
      decimals="-3"
      id="F_bec49722-74e6-460b-8fc2-e5cd0127e683"
      unitRef="U_EUR">5623000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_e29b5f04-553f-4038-b41c-77cb6a63aa4e"
      decimals="-3"
      id="F_29b37c42-720c-4389-99fb-a64a75399c17"
      unitRef="U_EUR">5377000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_c02d8343-5637-4554-8174-52399241e82d"
      unitRef="U_EUR">17247000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_51337d3f-243f-49bd-962d-8cda63f72014"
      unitRef="U_EUR">18428000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_c552feed-faa1-45b6-b1fb-17b477c1f41b"
      unitRef="U_EUR">17514000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_dd8672f9-1ee2-40c6-a3f2-60992ce12467">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 12&#x2014;Investments in Associates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s associates relate to investments in Eyconis (principal place of business; U.S.), and VISEN (principal place of business; China). The Company&#x2019;s investments in Eyconis and VISEN are accounted for using the equity method in the consolidated financial statements as the Company has determined that it has significant influence over the investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, a separate company created to develop, manufacture, and commercialize TransCon ophth&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;almology assets globally, together with a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. As of December 31, 2024, the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s present ownership in Eyconis was&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2018, the Company entered into three exclusive license agreements with VISEN for the further development and commercialization of TransCon hGH, TransCon PTH and TransCon CNP in Greater China, and as consideration for the granting of such rights has received a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% ownership of VISEN&#x2019;s issued and outstanding shares. As of December 31, 2024, the Company&#x2019;s present ownership in VISEN was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregated profit or loss, total comprehensive income, transactions and outstanding balances with associates as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
    <asnd:CapitalCommitmentFromInvestors
      contextRef="C_3069879e-b2eb-487f-8359-3b2b3ac38c1d"
      decimals="-6"
      id="F_0ecade4c-e3c8-43f3-a795-89f9d8caad96"
      unitRef="U_USD">150000000</asnd:CapitalCommitmentFromInvestors>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="C_3069879e-b2eb-487f-8359-3b2b3ac38c1d"
      decimals="3"
      id="F_fddc7fdb-9c53-4f9b-98e9-f5844142a5d2"
      unitRef="U_pure">0.416</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="C_716e887c-c3f0-4b61-9538-8f3e8a6c55f9"
      decimals="3"
      id="F_f0066364-3d9f-4ce9-a7aa-b3c410822b9e"
      unitRef="U_pure">0.50</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="C_cf967fba-0da6-4929-9134-641e84170ee5"
      decimals="3"
      id="F_166ad95d-df5b-457b-852d-3a7e7fa5f88b"
      unitRef="U_pure">0.439</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory
      contextRef="C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0"
      id="F_6c2fc6d0-d91b-4686-852c-50862f694c5e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregated profit or loss, total comprehensive income, transactions and outstanding balances with associates as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows.&lt;/span&gt;&lt;/p&gt;
    &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Statement of profit or (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Profit/(loss) for the year from continuing operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;59,235&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;41,873&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total comprehensive income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;59,218&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;41,859&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Transactions and outstanding balances as of December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Invoicing of goods and services to associates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade receivables from associates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <asnd:ProfitLossForTheYear
      contextRef="C_962ef1c5-8d47-4bc2-b07c-320d06c0970d"
      decimals="-3"
      id="F_8ea3aa62-cd14-469c-af51-7a1631225a82"
      unitRef="U_EUR">-59235000</asnd:ProfitLossForTheYear>
    <asnd:ProfitLossForTheYear
      contextRef="C_261c864d-d4ee-42aa-9967-1744c5af33fd"
      decimals="-3"
      id="F_b4bb6085-5090-40ec-abff-0112e7bfe4d6"
      unitRef="U_EUR">-41873000</asnd:ProfitLossForTheYear>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0"
      decimals="-3"
      id="F_ed7594a1-8ea9-402c-b85b-093207af8c0d"
      unitRef="U_EUR">-59218000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_3fbba848-2455-4bc9-8198-43983057fc5c"
      decimals="-3"
      id="F_5c7b1c0e-3268-4e64-8de5-20c4802c5be7"
      unitRef="U_EUR">-41859000</ifrs-full:ComprehensiveIncome>
    <asnd:SaleOfGoodsAndServicesToAssociate
      contextRef="C_a4c9ac66-6e93-4fae-b47e-db19a4b3acc0"
      decimals="-3"
      id="F_d8912de0-cf91-495c-815e-f2c1e0b4af8e"
      unitRef="U_EUR">18225000</asnd:SaleOfGoodsAndServicesToAssociate>
    <asnd:SaleOfGoodsAndServicesToAssociate
      contextRef="C_3fbba848-2455-4bc9-8198-43983057fc5c"
      decimals="-3"
      id="F_dd786beb-99db-4c89-b182-f5929e5b0040"
      unitRef="U_EUR">15026000</asnd:SaleOfGoodsAndServicesToAssociate>
    <ifrs-full:TradeReceivables
      contextRef="C_962ef1c5-8d47-4bc2-b07c-320d06c0970d"
      decimals="-3"
      id="F_eaad1d32-176d-4702-9fd3-3e723bf3d9e1"
      unitRef="U_EUR">1759000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="C_261c864d-d4ee-42aa-9967-1744c5af33fd"
      decimals="-3"
      id="F_4ef20a0f-40d0-4e77-9725-03b481fb592f"
      unitRef="U_EUR">991000</ifrs-full:TradeReceivables>
    <ifrs-full:ContractLiabilities
      contextRef="C_962ef1c5-8d47-4bc2-b07c-320d06c0970d"
      decimals="-3"
      id="F_4c05bccb-a0c4-4fb9-a70f-842671e57092"
      unitRef="U_EUR">5936000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="C_261c864d-d4ee-42aa-9967-1744c5af33fd"
      decimals="-3"
      id="F_87294876-9f52-480c-b700-76c1d4dbf837"
      unitRef="U_EUR">7133000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfInventoriesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_20155d82-be40-4a56-a55a-a4be01509b6b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 13&#x2014;Inventories&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories are specified below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials and consumables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;295,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;208,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to production lead time, work in progress includes inventories that are not sellable before more than twelve months after the reporting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories were reduced by write-downs of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; respectively, which include write-downs on pre-launch inventories.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <asnd:DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_e75ab4ac-bc95-41cf-83c6-cb95be03184d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories are specified below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials and consumables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;295,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;208,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfQuantitativeInformationAboutInventoriesExplanatoryTableTextBlock>
    <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_0d4f3aae-f996-4b53-8b2e-8a5b5a18307b"
      unitRef="U_EUR">17596000</ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies>
    <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_dddb32e2-8f2d-496e-b84a-427d60f304ee"
      unitRef="U_EUR">18566000</ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies>
    <ifrs-full:WorkInProgress
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_ff80df2c-0ddf-40fd-a248-a8033a041e85"
      unitRef="U_EUR">235688000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_7863f3a0-2c4b-446e-b5be-9aec4d4bf48b"
      unitRef="U_EUR">171030000</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_4cef49be-76c6-4d3b-adf6-ecdb8ef82bbd"
      unitRef="U_EUR">42325000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_76629677-e1d6-400e-82c3-c7ccee5dabd2"
      unitRef="U_EUR">19335000</ifrs-full:FinishedGoods>
    <ifrs-full:InventoriesTotal
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_5aa64d23-f87d-497d-bc4f-4e6d50a40446"
      unitRef="U_EUR">295609000</ifrs-full:InventoriesTotal>
    <ifrs-full:InventoriesTotal
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_7a196a01-26e0-4f8d-b9b8-7d7444a3c813"
      unitRef="U_EUR">208931000</ifrs-full:InventoriesTotal>
    <ifrs-full:InventoryWritedown2011
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-5"
      id="F_3e466734-7bc2-4622-b1a0-75dc5ed20eb9"
      unitRef="U_EUR">15700000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-5"
      id="F_ba84df0e-bf98-4f45-b26e-2e23e3a98ff0"
      unitRef="U_EUR">22900000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_5e594fb7-a378-4bec-ab37-5fb546e0280f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 14&#x2014;Contract Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, contract liabilities comprise unsatisfied performance obligations related to delivery of commercial supply under one of the Company&#x2019;s license agreements. Non-current contract liabilities are expected to be recognized as revenue within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized from contract liabilities were &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and primarily related to delivery of clinical supply and research and development services.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <asnd:ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities
      contextRef="C_8e72405c-35f1-4928-85aa-52168ce828ac"
      id="F_8db9becd-33c0-4db2-9b3f-bd33177c8fda">P1Y</asnd:ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities>
    <asnd:ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities
      contextRef="C_9de36237-7daf-4d9a-ba1a-4f2827faaa62"
      id="F_b93982b7-4d9f-4fb0-aa26-90d456c5d7f1">P2Y</asnd:ExpectedRevenueRecognitionPeriodFromNonCurrentContractLiabilities>
    <asnd:Revenuerecognizedfromcontractliabilities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-5"
      id="F_70c9ac52-81d9-4661-a10d-36a22857b4b4"
      unitRef="U_EUR">1400000</asnd:Revenuerecognizedfromcontractliabilities>
    <asnd:Revenuerecognizedfromcontractliabilities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-5"
      id="F_6b4cd763-fa0b-4837-9bb8-59ee0656a3d5"
      unitRef="U_EUR">13300000</asnd:Revenuerecognizedfromcontractliabilities>
    <asnd:Revenuerecognizedfromcontractliabilities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-5"
      id="F_5e3b647e-e3dc-489e-baa7-7601843322c3"
      unitRef="U_EUR">10500000</asnd:Revenuerecognizedfromcontractliabilities>
    <ifrs-full:DisclosureOfProvisionsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_0265d0e7-811d-4c7d-a94f-9cac77ad2bea">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 15&#x2014;Provisions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development in provisions is specified below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.824%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Provisions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net additions for the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;99,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfProvisionsExplanatory>
    <asnd:DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_5d65fd89-a4a4-4087-b1b5-2bc222856ce2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development in provisions is specified below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.824%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Provisions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net additions for the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;99,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfDetailedInformationAboutDevelopmentInProvisionsExplanatory>
    <ifrs-full:CurrentProvisions
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_859cad9f-40e9-4000-b067-00aaae6eaf47"
      unitRef="U_EUR">32719000</ifrs-full:CurrentProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_38eadd9a-7eec-4232-bcea-78387b91505a"
      unitRef="U_EUR">4684000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_1368c51e-151b-4076-8758-d8fba2d09140"
      unitRef="U_EUR">57284000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_e3614360-37fd-4478-93b6-9c9ea537d195"
      unitRef="U_EUR">4462000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_ea5e0537-9ae3-4cc8-884d-ee08bb28f2e1"
      unitRef="U_EUR">99149000</ifrs-full:CurrentProvisions>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_0b0fc337-75cc-4644-b048-e9a0e2653329">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 16&#x2014;Financial Assets and Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial assets and liabilities comprise the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other receivables (excluding indirect tax receivables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;559,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;392,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;727,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;437,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other liabilities (excluding indirect tax and employee related payables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;953,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;738,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,103,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;882,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;738,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;659,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,103,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;882,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Finance income and expenses are specified below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remeasurement gain of financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation (net)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total finance income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;25,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;52,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remeasurement loss of financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation (net)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total finance expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;44,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;50,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest income and interest expenses relate to financial assets and liabilities measured at amortized cost. Net exchange rate gains and losses primarily relate to U.S. Dollar/Euro fluctuations pertaining to the Company&#x2019;s cash, cash equivalents, marketable securities and borrowings.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2022, the Company issued an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;575.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of fixed rate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% convertible notes. The net proceeds from the offering of the convertible notes were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;557.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), after deducting the initial purchasers&#x2019; discounts and commissions, and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;transaction costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 1, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The convertible notes accrue interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company&#x2019;s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0118&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ADSs per $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; principal amount of convertible notes, which represents an initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company&#x2019;s option at any time, and from time to time, on or after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 7, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;but only if the last reported sale price per ADS exceeds &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the conversion price on each of (i) at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; trading days, whether or not consecutive, during the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalty Funding Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into capped synthetic royalty funding agreements with Royalty Pharma (the &#x201c;Purchaser&#x201d;), which is presented as royalty funding liabilities, and represents the Company&#x2019;s contractual obligations to pay a predetermined percentage of future commercial revenue until reaching a predetermined multiple of proceeds received, according to the detailed provisions of the synthetic royalty funding agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;YORVIPATH Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2024, the Company entered into a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million capped synthetic royalty funding agreement (the &#x201c;Royalty Pharma Yorvipath Agreement&#x201d;) with the Purchaser. The net proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) after deducting offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Royalty Pharma Yorvipath Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (the &#x201c;Yorvipath Purchase Price&#x201d;) in exchange for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty on net revenue from sales of YORVIPATH in the U.S. (the &#x201c;Yorvipath Revenue Payments&#x201d;). The Yorvipath Revenue Payments to the Purchaser will cease upon reaching a multiple of the Yorvipath Purchase Price of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times, or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times if the Purchaser receives Yorvipath Revenue Payments in that amount by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Royalty Pharma Yorvipath Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to September 30, 2028, and the Company has paid the Purchaser, Yorvipath Revenue Payments equal to the Yorvipath Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;SKYTROFA Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2023, the Company entered into a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million capped synthetic royalty funding agreement (the &#x201c;Royalty Pharma Skytrofa Agreement&#x201d;) with the Purchaser. The net proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) after deducting offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Royalty Pharma Skytrofa Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (the &#x201c;Skytrofa Purchase Price&#x201d;) in exchange for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty on net revenue from sales of SKYTROFA in the U.S., beginning on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Skytrofa Revenue Payments&#x201d;). The Skytrofa Revenue Payments to the Purchaser will cease upon reaching a multiple of the Skytrofa Purchase Price of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.925&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times, or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times if the Purchaser receives Skytrofa Revenue Payments in that amount by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Royalty Pharma Skytrofa Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.925&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser, Skytrofa Revenue Payments equal to the Skytrofa Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company primarily leases office and laboratory facilities. Lease arrangements contain a range of different terms and conditions and are typically entered into for fixed periods. In order to improve flexibility to the Company&#x2019;s operations, lease arrangements may provide the Company with option to extend the lease or terminate the lease within the enforceable lease term. In the Company&#x2019;s current lease portfolio, extension and termination options are up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, in addition to the non-cancellable periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following expenses related to lease activities were recognized in the consolidated statements of profit or loss:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short term leases and leases of low value assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total lease expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2022, the Company entered into a facility lease in Germany with an enforceable lease term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, and comprises total lease cash-outflows of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, in December 2024, the Company entered into additional leases in Denmark with enforceable lease terms of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years with option to terminate earlier and comprise total lease cash-outflows of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million if not terminated earlier. The leases are expected to commence in 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financing Activities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The development in borrowings related to financing activities is specified below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:19.848%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.623%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.824%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.803%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-cash items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Beginning&lt;br/&gt;of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Repay-&lt;br/&gt;ments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net proceeds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Additions/&lt;br/&gt;(disposals)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remeasure-&lt;br/&gt;ments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accretion of&lt;br/&gt;interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;br/&gt;exchange&lt;br/&gt;translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;End of&lt;br/&gt;year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="15" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,819&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,248&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;763,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,677&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;644,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;26,496&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;134,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;11,248&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;65,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;49,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;856,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;399,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,054&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,302&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,006&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,946&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;508,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;26,060&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;136,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,248&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;644,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Derivative Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value cannot be measured based on quoted prices in active markets or other observable inputs and accordingly, derivative liabilities are measured by using the Black-Scholes option-pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company&#x2019;s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company&#x2019;s share price (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2024 and December 31, 2023, respectively).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For additional description of fair values, refer to the following section &#x201c;Fair Value Measurement.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sensitivity Analysis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all other inputs and assumptions held constant, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;relative increase in volatility, will increase the fair value of derivative liabilities by approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and indicates a decrease in profit or loss and equity before tax. Similarly, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;relative decrease in volatility indicates the opposite impact.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Similarly, on December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all other inputs and assumptions held constant, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% increase in the share price, will increase the fair value of derivative liabilities by approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and indicates a decrease in profit or loss and equity before tax. Similarly, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% decrease in the share price indicates the opposite impact.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value compared to carrying amount of marketable securities, convertible notes, royalty funding liabilities and derivatives, and their level in the fair value hierarchy is summarized in following table, where;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;inputs are unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(1-3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;438,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;385,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;763,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;743,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;529,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies movements in level 3 fair value measurements:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remeasurement recognized in financial income or expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,654&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;157,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_a8cf45f1-b6e8-40ac-be47-0ca49567f0f0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial assets and liabilities comprise the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other receivables (excluding indirect tax receivables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;559,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;392,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;727,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;437,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other liabilities (excluding indirect tax and employee related payables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;953,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;738,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,103,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;882,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;738,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;659,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,103,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;882,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory>
    <ifrs-full:TradeReceivables
      contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08"
      decimals="-3"
      id="F_77873358-ee18-486a-a9ba-bdc70253dcb8"
      unitRef="U_EUR">166280000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129"
      decimals="-3"
      id="F_f296c49d-d729-4431-becb-732fd0671e03"
      unitRef="U_EUR">35874000</ifrs-full:TradeReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08"
      decimals="-3"
      id="F_ac538b4b-0914-4b61-b514-dca3c0d83392"
      unitRef="U_EUR">3964000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129"
      decimals="-3"
      id="F_9dbcb4a3-4824-4183-b114-9cdab6db5ce7"
      unitRef="U_EUR">3909000</ifrs-full:OtherReceivables>
    <asnd:MarketableSecuritiesExplanatory
      contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08"
      decimals="-3"
      id="F_da9a38fd-6547-48ca-8ad1-02794b868990"
      unitRef="U_EUR">0</asnd:MarketableSecuritiesExplanatory>
    <asnd:MarketableSecuritiesExplanatory
      contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129"
      decimals="-3"
      id="F_b13a860c-f88a-487e-a7fb-f9c361eb0066"
      unitRef="U_EUR">7275000</asnd:MarketableSecuritiesExplanatory>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08"
      decimals="-3"
      id="F_6230772b-fca4-4588-a819-ca0a944d567b"
      unitRef="U_EUR">559543000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129"
      decimals="-3"
      id="F_b9a34943-45d8-4a17-ae32-02bca2c4fa7a"
      unitRef="U_EUR">392164000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_606a172c-a572-48ab-a9dd-9b6578193b08"
      decimals="-3"
      id="F_9f4077c9-7959-4a6c-ae2d-b25ef99bfebf"
      unitRef="U_EUR">729787000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_c32169a6-2f35-42d8-ac7a-b1e2cd646129"
      decimals="-3"
      id="F_5db12821-9a6f-4b83-a1c3-cad00557d389"
      unitRef="U_EUR">439222000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_a9e092e7-10db-4810-b9a1-9b061814816f"
      unitRef="U_EUR">729787000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_9ff0884d-e1f0-460e-93e7-5c1f181dbe82"
      unitRef="U_EUR">439222000</ifrs-full:FinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_e8417440-9aee-48ae-bd2e-9ffa8f67ea8a"
      unitRef="U_EUR">2317000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_b911ad54-11d0-468b-8b1d-48acf0669e26"
      unitRef="U_EUR">2127000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_ab2ac626-c02f-4252-afed-a5d9f03a73ad"
      unitRef="U_EUR">727470000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_5a1c801f-f424-419b-afad-6c366ccea480"
      unitRef="U_EUR">437095000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_7dc7e2c3-6dab-4e05-b30a-c9aa1ef7a42c"
      unitRef="U_EUR">729787000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_f35a3333-f8b6-4c7b-bb80-f6f0d9c5920f"
      unitRef="U_EUR">439222000</ifrs-full:FinancialAssets>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41"
      decimals="-3"
      id="F_70c8e277-79aa-4103-b883-bffd6d65f2d5"
      unitRef="U_EUR">458207000</asnd:ConvertibleSeniorNotes>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8"
      decimals="-3"
      id="F_921ac7f2-6130-4339-a861-85fe03c8face"
      unitRef="U_EUR">407095000</asnd:ConvertibleSeniorNotes>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41"
      decimals="-3"
      id="F_ca502908-9239-46ad-9d06-a1528f96693e"
      unitRef="U_EUR">305379000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8"
      decimals="-3"
      id="F_21e04833-6348-4d32-869e-c30205e439a6"
      unitRef="U_EUR">138377000</asnd:RoyaltyFundingLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41"
      decimals="-3"
      id="F_08b00be0-1555-4145-b47f-617a6a16d6c7"
      unitRef="U_EUR">93030000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8"
      decimals="-3"
      id="F_6c11afdc-4bc0-4840-836c-f265cb2f12e3"
      unitRef="U_EUR">98793000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41"
      decimals="-3"
      id="F_295e7158-dbe0-4c30-be73-ffa82c902e5c"
      unitRef="U_EUR">96394000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8"
      decimals="-3"
      id="F_a8ca1bc7-179d-43d0-bb03-b491c96bf4e8"
      unitRef="U_EUR">94566000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41"
      decimals="-3"
      id="F_598a30cc-c769-4d68-9fa1-4d840c8d2739"
      unitRef="U_EUR">311000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_f11efc41-6c49-4566-86fb-9cec96206a41"
      decimals="-3"
      id="F_48f831b2-d609-4ae1-970b-f4d46beba8f7"
      unitRef="U_EUR">953321000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_db240b79-3dcc-4f72-a8a9-6e8a7a0f8ca8"
      decimals="-3"
      id="F_8c5ffef7-0786-4582-969b-0b381694c181"
      unitRef="U_EUR">738831000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_da6f140c-18d8-4bad-924d-3f858f63f02a"
      unitRef="U_EUR">150670000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_78c8227d-8407-4c98-856a-fb740d3d6a08"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_5906116e-01cd-49ba-bcce-49cd3733e697"
      decimals="-3"
      id="F_9a277ff1-1894-45db-ade7-cfe86d69d8eb"
      unitRef="U_EUR">150670000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_28990820-f3d2-4e15-9edb-17e010681d57"
      decimals="-3"
      id="F_9732312c-b5b1-44d5-a771-b5800b00739e"
      unitRef="U_EUR">143296000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_828217d0-2396-48c4-bd05-6cd5ec7a318b"
      unitRef="U_EUR">1103991000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_6881ffbf-e500-42dd-98a8-b6c7689c9b15"
      unitRef="U_EUR">882127000</ifrs-full:FinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_594f719b-4da8-406b-ae40-e53af7472c3d"
      unitRef="U_EUR">365080000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_d99124e7-5c7d-469c-b302-6c183b39342b"
      unitRef="U_EUR">222996000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_6ad21605-3da0-49ca-919a-715121094beb"
      unitRef="U_EUR">738911000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_402712e2-bc1c-4b83-bbe8-1fb440e3aa77"
      unitRef="U_EUR">659131000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_4487a15b-9989-4c8d-b30d-8e29adf68045"
      unitRef="U_EUR">1103991000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_eb9f4f12-931a-41a3-a95c-9ee865c4476e"
      unitRef="U_EUR">882127000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_f7f1553d-71a8-4189-abca-312345bff609">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Finance income and expenses are specified below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remeasurement gain of financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation (net)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total finance income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;25,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;52,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remeasurement loss of financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange translation (net)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total finance expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;44,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;50,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <ifrs-full:RevenueFromInterest
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_80e0e391-9819-4ec4-ba5a-d18296127b00"
      unitRef="U_EUR">14361000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_b8b5d1fd-bcb6-494a-bdf6-ee80b620f5b0"
      unitRef="U_EUR">16857000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_2ba4bab0-6cc5-4b27-be20-170f055a134c"
      unitRef="U_EUR">7426000</ifrs-full:RevenueFromInterest>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_e96dc17b-481b-413c-bd96-67806582dce4"
      unitRef="U_EUR">11248000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_ad65709f-bd7e-4382-a4f3-1cb1e7a5df48"
      unitRef="U_EUR">14654000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncome>
    <ifrs-full:NetForeignExchangeGain
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_aeb5de95-554f-4774-9f7b-69b5331770b0"
      unitRef="U_EUR">0</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_4f441302-e6df-4442-b533-7338b5ad1d43"
      unitRef="U_EUR">12346000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_7768e7e5-cf15-4d98-bc57-ce27bdc327e9"
      unitRef="U_EUR">44755000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:FinanceIncome
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_2fb66b91-2127-474d-996c-79c13b78d94e"
      unitRef="U_EUR">25609000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_8975902d-40b9-4c3b-b778-6b86d9925bae"
      unitRef="U_EUR">43857000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_f2d330fc-3e82-4055-8fda-012ecd590d1a"
      unitRef="U_EUR">52181000</ifrs-full:FinanceIncome>
    <ifrs-full:InterestExpense
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_4379f4a5-07e3-418d-a1e5-f1a17492e95f"
      unitRef="U_EUR">65504000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_cc3fe6d6-e679-4fdb-a242-7138c8cb2454"
      unitRef="U_EUR">44065000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_fb6d32d5-92b3-4b0e-96f6-65e2caa77fce"
      unitRef="U_EUR">30682000</ifrs-full:InterestExpense>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_e7614891-f7b0-4445-abc4-d0145cee16b4"
      unitRef="U_EUR">7374000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_a1e14bc4-057b-4e5a-8c1e-9bea245824e4"
      unitRef="U_EUR">15483000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialExpense>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_8eae998b-d4dd-42d2-b406-6c207707ca5b"
      unitRef="U_EUR">27149000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_ddaa9fd1-5158-49ca-bfd2-70cbb1f27c2c"
      unitRef="U_EUR">4322000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:FinanceCosts
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_4e97743e-a9ed-43a4-b21d-a787ba269623"
      unitRef="U_EUR">100027000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_dcb45202-577b-42f3-93c6-b8aab603742f"
      unitRef="U_EUR">44065000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_638734a7-fb29-4983-93d2-36163f592fda"
      unitRef="U_EUR">50487000</ifrs-full:FinanceCosts>
    <ifrs-full:NotionalAmount
      contextRef="C_4f2fa65c-bf90-4026-9207-c814f7259be3"
      decimals="-5"
      id="F_acabe057-a86d-4541-832a-d7fbacd6adb3"
      unitRef="U_USD">575000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="C_d4f709dd-434a-4841-ae2c-e267badec1c5"
      decimals="4"
      id="F_d9e21cda-5376-404a-9643-d23b811e9fd3"
      unitRef="U_pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="C_5123e0db-851b-4c25-82f5-35f4482ea47c"
      decimals="-5"
      id="F_9501dd5b-ed63-4cb5-a398-6b456de15fe0"
      unitRef="U_USD">557900000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="C_5123e0db-851b-4c25-82f5-35f4482ea47c"
      decimals="-5"
      id="F_8b4ecae9-83c2-4fc2-9297-8a44bb004aea"
      unitRef="U_EUR">503300000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:BorrowingsMaturity
      contextRef="C_5123e0db-851b-4c25-82f5-35f4482ea47c"
      id="F_bfcc2217-4d6a-45ea-9be2-d18a100588ba">April 1, 2028</ifrs-full:BorrowingsMaturity>
    <ifrs-full:BorrowingsInterestRate
      contextRef="C_1cf2be05-dcfb-45c8-9384-2927abeec697"
      decimals="4"
      id="F_111125fd-b3ac-4e59-a418-54589794b108"
      unitRef="U_pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <asnd:BorrowingsInArrearsDefaultPaymentStartDate
      contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea"
      id="F_68743c4b-87a0-421c-b29a-e537286347a2">2022-10-01</asnd:BorrowingsInArrearsDefaultPaymentStartDate>
    <asnd:ConversionRatePerNote
      contextRef="C_f52b4a1b-71e1-49b5-9cfd-93e6bb5fe135"
      decimals="4"
      id="F_67e8a04e-c48a-4543-a507-413f259c492b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.0118</asnd:ConversionRatePerNote>
    <ifrs-full:NotionalAmount
      contextRef="C_cadf2de7-5782-4672-b259-cd1aa743fad5"
      decimals="0"
      id="F_f4d67a93-7331-4ac3-a3f5-2094ce616872"
      unitRef="U_EUR">1000</ifrs-full:NotionalAmount>
    <asnd:ConversionPricePerShare
      contextRef="C_8b7cf227-3c27-4452-bf1e-f4d1f142fedb"
      decimals="2"
      id="F_79e897ee-6925-4b31-98f7-6ded7cd1d2b7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">166.34</asnd:ConversionPricePerShare>
    <asnd:BorrowingsRedemptionPeriod
      contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea"
      id="F_f628a4b8-aec7-4481-88e5-bf5cf9e97390">April 7, 2025</asnd:BorrowingsRedemptionPeriod>
    <asnd:BorrowingsConditionForRedemption
      contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea"
      id="F_c630e956-72cf-40c4-b1d3-48651bff2e95">but only if the last reported sale price per ADS exceeds 130% of the conversion price on each of (i) at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.</asnd:BorrowingsConditionForRedemption>
    <asnd:BorrowingsThresholdPercentageOfSalePricePerShareForRedemption
      contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea"
      decimals="2"
      id="F_66034f1c-b2e7-4f61-b472-cfe92ba3a1da"
      unitRef="U_pure">1.30</asnd:BorrowingsThresholdPercentageOfSalePricePerShareForRedemption>
    <asnd:BorrowingsThresholdTradingDaysForRedemption
      contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea"
      decimals="0"
      id="F_7bc4bd74-e075-4afe-91cb-bb8320a2a4db"
      unitRef="U_Days">20</asnd:BorrowingsThresholdTradingDaysForRedemption>
    <asnd:BorrowingsThresholdConsecutiveTradingDaysForRedemption
      contextRef="C_1a34a4d4-5cb7-4d3d-a201-2d8a72459dea"
      decimals="0"
      id="F_60387d51-97c7-4a6d-aad9-daf163468cbc"
      unitRef="U_Days">30</asnd:BorrowingsThresholdConsecutiveTradingDaysForRedemption>
    <asnd:FundingReceivedInExchangeOfRoyaltyPayments
      contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b"
      decimals="-5"
      id="F_2cbd9ad9-c93c-4626-8b48-5758102594d3"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchangeOfRoyaltyPayments>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b"
      decimals="-5"
      id="F_dcb531f4-2fc9-480b-86bd-0797b6fbfa9a"
      unitRef="U_USD">148200000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b"
      decimals="-5"
      id="F_4187d444-3d64-450b-b0b2-475b8f8f4d99"
      unitRef="U_EUR">134200000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:FundingReceivedInExchange
      contextRef="C_06c5062d-ba03-4445-bb86-eada28395df3"
      decimals="-5"
      id="F_78947705-590d-4f58-8a30-70811685e760"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchange>
    <asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment
      contextRef="C_06c5062d-ba03-4445-bb86-eada28395df3"
      decimals="2"
      id="F_b4489318-d4a2-4c5f-981b-9d1f07678325"
      unitRef="U_pure">0.03</asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_b54750ee-5812-44ea-a167-8b84bead592f"
      decimals="1"
      id="F_f89e4f65-61df-44fd-ba07-215ba0c186b9"
      unitRef="U_Multiple">2</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_290761ca-44a9-486b-94c7-76f97082cf35"
      decimals="2"
      id="F_5bff62ae-4969-4d4b-a258-a6b39e2641e9"
      unitRef="U_Multiple">1.65</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:RoyaltyPaymentEndingPeriod
      contextRef="C_06c5062d-ba03-4445-bb86-eada28395df3"
      id="F_f3b76536-0929-4ad2-b273-addcca26293c">2029-12-31</asnd:RoyaltyPaymentEndingPeriod>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount
      contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b"
      decimals="1"
      id="F_ab5fd200-3215-4d51-9a4f-4897890a95fd"
      unitRef="U_XBB">2</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount
      contextRef="C_acb528c2-5f7d-4cf9-a36c-de007de3786b"
      decimals="2"
      id="F_5b0750e9-9313-48d2-bf08-183ab9c9cb3d"
      unitRef="U_XBB">1.65</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount>
    <asnd:FundingReceivedInExchangeOfRoyaltyPayments
      contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36"
      decimals="-5"
      id="F_acd10862-dff5-4328-af2d-65db01d0a1e4"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchangeOfRoyaltyPayments>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36"
      decimals="-5"
      id="F_34dc7ee1-ee1f-4842-9139-6601f8b74194"
      unitRef="U_USD">146300000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36"
      decimals="-5"
      id="F_6e96fea5-a761-4bc0-99ab-448aa0207c57"
      unitRef="U_EUR">136300000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:FundingReceivedInExchange
      contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36"
      decimals="-5"
      id="F_8723bbcf-72df-4e82-ae8c-7e3dad69975a"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchange>
    <asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment
      contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36"
      decimals="4"
      id="F_68863c26-9cc0-4f95-922a-b3f2bb2174cd"
      unitRef="U_pure">0.0915</asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment>
    <asnd:RoyaltyPaymentBeginningPeriod
      contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36"
      id="F_bc4f6853-2501-435a-97a9-07c666a0a7c2">2025-01-01</asnd:RoyaltyPaymentBeginningPeriod>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_15890a8d-80cb-48ce-91a1-44903b524f91"
      decimals="3"
      id="F_a02ddc9c-5002-4b8f-bc4b-a94c211e66f4"
      unitRef="U_Multiple">1.925</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_067306de-0170-4c89-8d3c-7bb661db3689"
      decimals="2"
      id="F_92499540-afc1-43c5-8bf2-b29c2e5df130"
      unitRef="U_Multiple">1.65</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:RoyaltyPaymentEndingPeriod
      contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36"
      id="F_c608dad6-66ef-45bb-b67d-56f3f35ebe51">2031-12-31</asnd:RoyaltyPaymentEndingPeriod>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount
      contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36"
      decimals="3"
      id="F_1ec7ee46-aa9d-4479-88c3-fa7d9649c7d9"
      unitRef="U_XBB">1.925</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount
      contextRef="C_f1c55158-db93-42ec-aaad-60afdd713f36"
      decimals="2"
      id="F_d3644ce9-a4a2-4260-b25c-4a3d4d4e0d72"
      unitRef="U_XBB">1.65</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount>
    <asnd:LeaseExtensionPeriod
      contextRef="C_9de36237-7daf-4d9a-ba1a-4f2827faaa62"
      id="F_b565bf23-a87e-4b06-87b0-88f60cce7b6a">P5Y</asnd:LeaseExtensionPeriod>
    <asnd:DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3d2428b8-4898-475d-9415-d99ef9dfc0cb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following expenses related to lease activities were recognized in the consolidated statements of profit or loss:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short term leases and leases of low value assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total lease expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfExpensesRelatingToLeaseActivitiesInTheConsolidatedStatements>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_35ec2364-84df-4f60-82dc-01aee3864455"
      unitRef="U_EUR">12312000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_8a953be3-c4d2-4215-831f-9b3a6009886b"
      unitRef="U_EUR">11875000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_33f14531-1960-4acc-bb9a-81951dcc3a94"
      unitRef="U_EUR">11740000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_ce3b00e9-4444-4b5c-b12d-beda40fd19dc"
      unitRef="U_EUR">285000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_dfebc4cc-ce8d-49ff-a9c3-dc12fadeb492"
      unitRef="U_EUR">353000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_3720f646-cc07-42cf-bf2e-52ca336e4fde"
      unitRef="U_EUR">280000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_fd5c61dc-ac1b-42d6-9d5f-0462975bad70"
      unitRef="U_EUR">3303000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_68e529ca-309f-4421-b2bc-1662895399fe"
      unitRef="U_EUR">3581000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_b1725034-2ff7-4b98-8634-01fa52c175b1"
      unitRef="U_EUR">3842000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <asnd:LeaseExpenses
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_37d7de35-2328-4bcc-9a17-b18b582eb07c"
      unitRef="U_EUR">15900000</asnd:LeaseExpenses>
    <asnd:LeaseExpenses
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_104cb127-871c-4d49-8373-33992d5d1372"
      unitRef="U_EUR">15809000</asnd:LeaseExpenses>
    <asnd:LeaseExpenses
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="-3"
      id="F_7ceb6d0d-e14b-4e22-b78b-d7a378fc801e"
      unitRef="U_EUR">15862000</asnd:LeaseExpenses>
    <asnd:EnforceableLeaseterm
      contextRef="C_de89026c-3236-40fc-8ba9-ac03b1732258"
      id="F_1f5c13fe-cd8f-4507-ba1f-64c8ec64754d">P15Y</asnd:EnforceableLeaseterm>
    <ifrs-full:CashOutflowForLeases
      contextRef="C_de89026c-3236-40fc-8ba9-ac03b1732258"
      decimals="-5"
      id="F_6ab94515-a95d-4c7a-a9a0-bc7507806de7"
      unitRef="U_EUR">81100000</ifrs-full:CashOutflowForLeases>
    <asnd:EnforceableLeaseterm
      contextRef="C_95c2771f-cee1-4eb7-beba-a54cb5701188"
      id="F_500d0763-8139-4131-b529-95e706fc5779">P12Y</asnd:EnforceableLeaseterm>
    <ifrs-full:CashOutflowForLeases
      contextRef="C_c14c8f3b-ece8-4326-a6b7-270fcafc68bd"
      decimals="-5"
      id="F_a3163975-9224-42a0-a87b-dc0a743824e9"
      unitRef="U_EUR">16200000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_3d0680c2-3343-4f6e-86f5-e8ed5968ef07">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The development in borrowings related to financing activities is specified below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:19.848%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.623%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.824%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.803%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-cash items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Beginning&lt;br/&gt;of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Repay-&lt;br/&gt;ments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net proceeds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Additions/&lt;br/&gt;(disposals)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remeasure-&lt;br/&gt;ments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accretion of&lt;br/&gt;interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;br/&gt;exchange&lt;br/&gt;translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;End of&lt;br/&gt;year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="15" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,819&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,248&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;763,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,677&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;644,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;26,496&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;134,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;11,248&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;65,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;49,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;856,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;399,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,054&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,302&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,006&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,946&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;508,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;26,060&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;136,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,248&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;644,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_81e30392-2ae2-46f2-9e52-85bbd8e7a714"
      decimals="-3"
      id="F_11de38b7-4c05-4204-90a7-6d578cc5696f"
      unitRef="U_EUR">545472000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities
      contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0"
      decimals="-3"
      id="F_fd9d8425-410e-4123-b802-954902d8c4a3"
      unitRef="U_EUR">-11819000</asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities
      contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0"
      decimals="-3"
      id="F_6ff3fb73-f4e1-4561-9f60-9d51cc7d536b"
      unitRef="U_EUR">-134158000</asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities
      contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0"
      decimals="-3"
      id="F_c5d64930-b834-4a52-87dc-f35468bf399d"
      unitRef="U_EUR">11248000</asnd:IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities
      contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0"
      decimals="-3"
      id="F_59df309c-ad43-427a-a0d1-bfcf0e9831fc"
      unitRef="U_EUR">62116000</asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="C_a0c6b683-2678-4d0d-be4e-ae715d3adab0"
      decimals="-3"
      id="F_f3167cab-89b6-47a6-951c-e5bf4c347017"
      unitRef="U_EUR">44907000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_e89a7181-8fc3-4108-a58d-ec31314fe7a6"
      decimals="-3"
      id="F_e6541b4e-ff26-49b0-b198-9caebb568d8f"
      unitRef="U_EUR">763586000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_a04879c9-d225-42da-8adf-2501801d997b"
      decimals="-3"
      id="F_6380a17d-c64c-4a82-bb91-9b7ff0748e51"
      unitRef="U_EUR">98793000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities
      contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f"
      decimals="-3"
      id="F_c424b0b4-1313-4e1a-a963-db7d1533eca2"
      unitRef="U_EUR">-14677000</asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities
      contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f"
      decimals="-3"
      id="F_a3401c51-d326-4b42-8347-7dfe0c18da63"
      unitRef="U_EUR">0</asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f"
      decimals="-3"
      id="F_481722eb-0709-4bec-b331-0a380b8897d4"
      unitRef="U_EUR">861000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities
      contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f"
      decimals="-3"
      id="F_9b783143-9639-49d4-9ab5-9cdd67601e6e"
      unitRef="U_EUR">3303000</asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="C_8bdc1384-8c1b-4199-954a-92a67517fd1f"
      decimals="-3"
      id="F_23abe8bc-355e-40dc-871f-ee06b91af225"
      unitRef="U_EUR">4750000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_a2de7ead-6804-4136-a02b-31e903c48f97"
      decimals="-3"
      id="F_0c913175-7815-4c3e-af21-e35fce2a9d54"
      unitRef="U_EUR">93030000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_afc1da9c-e992-43ba-9d8a-cde9dafbaab9"
      unitRef="U_EUR">644265000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_40d1e3f7-a59c-4916-b78b-98247bbb0dbd"
      unitRef="U_EUR">-26496000</asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_967bb6be-bbee-4e5f-954a-4a51a319ae0a"
      unitRef="U_EUR">-134158000</asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_455af755-505d-4499-80e5-b19e1103b35e"
      unitRef="U_EUR">861000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_50f797f6-84bc-4574-9584-8a14e177bf8b"
      unitRef="U_EUR">11248000</asnd:IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_a92221b0-8d6d-46a7-87e2-38fa071e6f35"
      unitRef="U_EUR">65419000</asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_9cd7f168-e954-4083-95ac-45ff5929e74d"
      unitRef="U_EUR">49657000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_ba1e5df7-3ab9-4200-aa9b-29dbdf4b6cee"
      unitRef="U_EUR">856616000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_79e45519-2936-42c5-9260-a018560072ef"
      decimals="-3"
      id="F_39e0cff5-78ed-451a-8fb9-04f4e6e2cd25"
      unitRef="U_EUR">399186000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities
      contextRef="C_b387065d-0625-4be8-ab94-2a3823e3c97f"
      decimals="-3"
      id="F_a6708c6c-e1ce-4d23-949a-dda733aa5cd2"
      unitRef="U_EUR">-12054000</asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities
      contextRef="C_b387065d-0625-4be8-ab94-2a3823e3c97f"
      decimals="-3"
      id="F_aa1b334d-dbc2-4ac5-bdc6-91de02346ad9"
      unitRef="U_EUR">-136256000</asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities
      contextRef="C_b387065d-0625-4be8-ab94-2a3823e3c97f"
      decimals="-3"
      id="F_e39ba808-798f-46ed-a958-a68346bdfab6"
      unitRef="U_EUR">40386000</asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="C_b387065d-0625-4be8-ab94-2a3823e3c97f"
      decimals="-3"
      id="F_aca2a850-2717-4c50-9312-4e32d37ebcf2"
      unitRef="U_EUR">-18302000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_81e30392-2ae2-46f2-9e52-85bbd8e7a714"
      decimals="-3"
      id="F_da175139-32fa-4c5b-8ab1-04083cac53d0"
      unitRef="U_EUR">545472000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_e4a0772c-d105-4d5c-9ccb-ae5d02f8ddb4"
      decimals="-3"
      id="F_aa659e5c-392c-4e45-a69c-48381ed85f6b"
      unitRef="U_EUR">109191000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities
      contextRef="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c"
      decimals="-3"
      id="F_5fb5495d-1340-4c6c-bff3-4c124d6e67a1"
      unitRef="U_EUR">-14006000</asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c"
      decimals="-3"
      id="F_b6221f48-3b36-4735-8e47-6b47cf45ab21"
      unitRef="U_EUR">2973000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities
      contextRef="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c"
      decimals="-3"
      id="F_ac29a002-7b35-4e9a-bfbb-b0e1ee79f6e1"
      unitRef="U_EUR">3581000</asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="C_dae6f490-1dc5-491b-bf36-81c1fc1db25c"
      decimals="-3"
      id="F_6640092c-9253-428b-9ca2-0478f83ca18d"
      unitRef="U_EUR">-2946000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_a04879c9-d225-42da-8adf-2501801d997b"
      decimals="-3"
      id="F_f10d03f0-cd41-45ee-99e6-fee38110d9a5"
      unitRef="U_EUR">98793000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="-3"
      id="F_1ce9ac0d-4152-4b4f-9906-879aa80c6890"
      unitRef="U_EUR">508377000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_01a14b53-85ba-4ed5-8474-f7cd5cfed466"
      unitRef="U_EUR">-26060000</asnd:IncreaseDecreaseThroughEffectOfRepaymentsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_b85d0254-b7ee-439c-8d44-059e9de0b224"
      unitRef="U_EUR">-136256000</asnd:IncreaseDecreaseThroughEffectOfProceedsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_40f08418-567a-41a7-ae6c-74ebd44ca1c9"
      unitRef="U_EUR">2973000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_e7dd8c16-bef2-4ee6-878e-ba0d4758a163"
      unitRef="U_EUR">0</asnd:IncreaseDecreaseThroughEffectOfRemeasurementsArisingFromFinancingActivities>
    <asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_bd9a324d-fbc0-4e05-9df7-b73d8e89eb38"
      unitRef="U_EUR">43967000</asnd:IncreaseDecreaseThroughEffectOfAccretionOfInterestLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_e3f6681c-49f9-479a-8a55-bbd08fcaff6f"
      unitRef="U_EUR">-21248000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_6b7d2cd3-073a-4df8-a418-702950945bab"
      unitRef="U_EUR">644265000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <asnd:SharePriceAppliedForValuation
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="1"
      id="F_a6683ac9-cd2c-4c8b-94eb-08d463293be6"
      unitRef="U_EurPerShare">49.6</asnd:SharePriceAppliedForValuation>
    <asnd:SharePriceAppliedForValuation
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="1"
      id="F_cfe2c238-7bca-47f7-9e55-936b9a67e64e"
      unitRef="U_EurPerShare">50.5</asnd:SharePriceAppliedForValuation>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="C_fa785ab0-f0fb-4f0a-875b-f650331743e8"
      decimals="2"
      id="F_4ecde0dd-3e5e-4ce9-b889-9394921c41e3"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue
      contextRef="C_7efbf712-b44b-41d4-8aa1-40e3199ec917"
      decimals="-5"
      id="F_db5a9261-ccb0-43cb-8eaf-400597a9d37a"
      unitRef="U_EUR">15000000</asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="C_fa785ab0-f0fb-4f0a-875b-f650331743e8"
      decimals="2"
      id="F_91d55a71-f0ff-4826-89c6-98e0c533a9f6"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="C_16b2d798-c4fd-440d-9eb5-813b6bf52dd4"
      decimals="2"
      id="F_61f7c93d-c90a-4da1-bd49-43caa71d163d"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue
      contextRef="C_bdf66293-e3a2-42d2-b55f-314d364082f4"
      decimals="-5"
      id="F_f115537a-8a2a-4627-a24c-4bca0d4fc991"
      unitRef="U_EUR">30800000</asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="C_16b2d798-c4fd-440d-9eb5-813b6bf52dd4"
      decimals="2"
      id="F_bb598148-44f7-4ab9-875c-b61ddb149430"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_dc417a55-55a8-47e8-bf38-2d1ad546423a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;inputs are unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(1-3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;438,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;385,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;763,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;743,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;529,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock>
    <asnd:MarketableSecuritiesExplanatory
      contextRef="C_368e4795-3132-443f-a38d-3b93be4d5965"
      decimals="-3"
      id="F_9e8dd60c-2a8c-4478-87e2-3ead5dbca28e"
      unitRef="U_EUR">0</asnd:MarketableSecuritiesExplanatory>
    <asnd:MarketableSecuritiesExplanatory
      contextRef="C_a34d3224-7646-4cf8-a9ef-f7fdd1eb668e"
      decimals="-3"
      id="F_f4c11cc6-b1d2-4de2-8e8d-8e90d3d1615f"
      unitRef="U_EUR">0</asnd:MarketableSecuritiesExplanatory>
    <asnd:MarketableSecuritiesExplanatory
      contextRef="C_0ce01933-8d1d-47b9-bd72-1cbedc695da5"
      decimals="-3"
      id="F_7ca16879-5a44-493c-8ad3-cca51c55cd00"
      unitRef="U_EUR">7275000</asnd:MarketableSecuritiesExplanatory>
    <asnd:MarketableSecuritiesExplanatory
      contextRef="C_907adb7e-5f6a-4552-b8e4-ca87be7ab73c"
      decimals="-3"
      id="F_75218d47-cfc1-41c9-bca5-05fd8683210e"
      unitRef="U_EUR">7266000</asnd:MarketableSecuritiesExplanatory>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_e22f7140-0ffe-4e0a-a8d2-1e98ce4c62eb"
      decimals="-3"
      id="F_c444fe34-a32e-47ab-bad3-70d306d07d81"
      unitRef="U_EUR">0</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_f4572716-6c6a-4a6c-bfcd-471d23516aed"
      decimals="-3"
      id="F_19feedd1-c7a4-4110-b8a5-719f1ecd91a7"
      unitRef="U_EUR">0</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_2aa2a1e6-92a1-4029-9027-67625a630a7b"
      decimals="-3"
      id="F_cebabfc3-6c24-493f-8d03-ed173f913f3e"
      unitRef="U_EUR">7275000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_033bc73d-e8d5-42c6-ac92-2eaa55a1e3f9"
      decimals="-3"
      id="F_ce206159-4719-4ea3-b004-acf79b737cfe"
      unitRef="U_EUR">7266000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:NotesAndDebenturesIssued
      contextRef="C_6143b456-2c40-4d0d-b967-c6ff15edfac7"
      decimals="-3"
      id="F_aa9f7a98-0e2f-4e2b-bcaf-8cbfc07e43fa"
      unitRef="U_EUR">458207000</ifrs-full:NotesAndDebenturesIssued>
    <ifrs-full:NotesAndDebenturesIssued
      contextRef="C_37c216bc-caec-48d1-a992-8f1efaf4610a"
      decimals="-3"
      id="F_a9f3f175-1163-4711-93a4-6e2e5bbb8edf"
      unitRef="U_EUR">438288000</ifrs-full:NotesAndDebenturesIssued>
    <ifrs-full:NotesAndDebenturesIssued
      contextRef="C_efbe723b-7de5-4c59-b063-c40de816c3c2"
      decimals="-3"
      id="F_ec29c4dc-5922-41c5-b0a9-9a061839f4ab"
      unitRef="U_EUR">407095000</ifrs-full:NotesAndDebenturesIssued>
    <ifrs-full:NotesAndDebenturesIssued
      contextRef="C_60dcc078-2bdb-4155-9a0b-c75618972125"
      decimals="-3"
      id="F_22dc5ee0-839d-4e10-8db8-7e8898f3e1d8"
      unitRef="U_EUR">385410000</ifrs-full:NotesAndDebenturesIssued>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_6143b456-2c40-4d0d-b967-c6ff15edfac7"
      decimals="-3"
      id="F_31352a2b-71bf-4d5a-a0ed-6b787dba6e49"
      unitRef="U_EUR">305379000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_37c216bc-caec-48d1-a992-8f1efaf4610a"
      decimals="-3"
      id="F_71b1f131-76c7-4ffa-944b-f87f4e95e487"
      unitRef="U_EUR">305673000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_efbe723b-7de5-4c59-b063-c40de816c3c2"
      decimals="-3"
      id="F_6546fa57-b259-4cc7-8862-aaf5e87d89ff"
      unitRef="U_EUR">138377000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_60dcc078-2bdb-4155-9a0b-c75618972125"
      decimals="-3"
      id="F_99bbe197-68f1-4a8f-a51a-76437ed34df9"
      unitRef="U_EUR">143975000</asnd:RoyaltyFundingLiabilities>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_e22f7140-0ffe-4e0a-a8d2-1e98ce4c62eb"
      decimals="-3"
      id="F_20052840-aa95-47b3-8d33-7fd8f0308d18"
      unitRef="U_EUR">763586000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_f4572716-6c6a-4a6c-bfcd-471d23516aed"
      decimals="-3"
      id="F_83131a90-d9a0-4072-b1f0-19fa1b499db7"
      unitRef="U_EUR">743961000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_2aa2a1e6-92a1-4029-9027-67625a630a7b"
      decimals="-3"
      id="F_b7c1f201-bfb2-487c-bdbe-6633f490515c"
      unitRef="U_EUR">545472000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_033bc73d-e8d5-42c6-ac92-2eaa55a1e3f9"
      decimals="-3"
      id="F_0f3a430b-7d25-4619-934f-2e03b54e5709"
      unitRef="U_EUR">529385000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_6143b456-2c40-4d0d-b967-c6ff15edfac7"
      decimals="-3"
      id="F_e903a8e0-140d-40b2-9916-733857205884"
      unitRef="U_EUR">150670000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_37c216bc-caec-48d1-a992-8f1efaf4610a"
      decimals="-3"
      id="F_78970c03-36ef-4d38-9e05-94a175baa04d"
      unitRef="U_EUR">150670000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_efbe723b-7de5-4c59-b063-c40de816c3c2"
      decimals="-3"
      id="F_e7015744-452b-4468-b904-5c05d0aa9c98"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_60dcc078-2bdb-4155-9a0b-c75618972125"
      decimals="-3"
      id="F_a7fb05be-4b1f-43cb-b621-65b86fc76be4"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_e22f7140-0ffe-4e0a-a8d2-1e98ce4c62eb"
      decimals="-3"
      id="F_7b3c01a2-d11b-4ce2-ae96-8756665d49d0"
      unitRef="U_EUR">150670000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_f4572716-6c6a-4a6c-bfcd-471d23516aed"
      decimals="-3"
      id="F_fe4ca3ea-a2a6-47a2-8483-9d4295146826"
      unitRef="U_EUR">150670000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_2aa2a1e6-92a1-4029-9027-67625a630a7b"
      decimals="-3"
      id="F_da6a521c-a754-464f-8be1-090cb48cf325"
      unitRef="U_EUR">143296000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_033bc73d-e8d5-42c6-ac92-2eaa55a1e3f9"
      decimals="-3"
      id="F_43f5fd24-8582-491c-8a75-0e97db66941b"
      unitRef="U_EUR">143296000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_41fe7ca1-9372-4fd8-88f0-d054163d99ba">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies movements in level 3 fair value measurements:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remeasurement recognized in financial income or expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,654&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;157,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_e63719c7-8c13-464f-8f95-1d2f452eab96"
      decimals="-3"
      id="F_3903e160-ff5d-4371-b0cd-a066789dbf76"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_7be35a31-a654-4c37-9e6a-3b77cff84b05"
      decimals="-3"
      id="F_b683d61e-29ff-40ab-b30f-808d8bc2caf8"
      unitRef="U_EUR">157950000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_acf61556-e87e-41fe-93fa-052e2f231a3b"
      decimals="-3"
      id="F_9e9cd61b-f6d8-4bcf-8e5f-92777b8cd022"
      unitRef="U_EUR">0</ifrs-full:DerivativeFinancialLiabilities>
    <asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue
      contextRef="C_7af1f25a-54be-46a2-a19d-533e859fbdd7"
      decimals="-3"
      id="F_9b7ee6ad-4538-4a14-b95e-de9568334af4"
      unitRef="U_EUR">0</asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue>
    <asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue
      contextRef="C_c5d54e1a-4387-4b3f-9267-06a2d3748214"
      decimals="-3"
      id="F_2bb71815-1b1c-4ee3-8f38-882121d83582"
      unitRef="U_EUR">0</asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue>
    <asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue
      contextRef="C_eede36b7-749c-4397-a6fe-904bd2d680fa"
      decimals="-3"
      id="F_dd69fe07-44f7-4618-8784-c3f5ca9b46f8"
      unitRef="U_EUR">142467000</asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense
      contextRef="C_7af1f25a-54be-46a2-a19d-533e859fbdd7"
      decimals="-3"
      id="F_0ac9a8b8-f79b-4c4d-815f-c0887f43c5fd"
      unitRef="U_EUR">7374000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense
      contextRef="C_c5d54e1a-4387-4b3f-9267-06a2d3748214"
      decimals="-3"
      id="F_1f34acbd-6e50-4d8f-8c08-8ea3bf470504"
      unitRef="U_EUR">-14654000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense
      contextRef="C_eede36b7-749c-4397-a6fe-904bd2d680fa"
      decimals="-3"
      id="F_53c70fa3-7774-43b0-a761-998e3f7653e0"
      unitRef="U_EUR">15483000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_9e598379-6e17-4151-b88c-4b34a9189ddb"
      decimals="-3"
      id="F_6d9f9ec1-e670-40e1-800a-5d68aa1e5663"
      unitRef="U_EUR">150670000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_e63719c7-8c13-464f-8f95-1d2f452eab96"
      decimals="-3"
      id="F_55988df7-959d-442a-bfb7-a3de8a7b9fae"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_7be35a31-a654-4c37-9e6a-3b77cff84b05"
      decimals="-3"
      id="F_9a72632c-d65c-47a1-bfbf-5e436fea3173"
      unitRef="U_EUR">157950000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_a1ba0f60-b989-474e-99ec-c5781c215246">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 17 &#x2013; Financial Risk Management&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company manages capital to ensure that all group enterprises will be able to continue as a going concern while maximizing the return to shareholders through the optimization of debt and equity balances.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Capital Structure&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s capital structure consists of equity and external debt obtained through issuance of convertible notes and royalty funding liabilities. The Company is not subject to any contractually imposed capital requirements or financial covenants. The capital structure is reviewed on an ongoing basis for the adequacy of the Company&#x2019;s capital compared to the resources required for carrying out ordinary activities&lt;/span&gt;&lt;span style="color:#404040;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#404040;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development in the Company&#x2019;s share capital and treasury shares reserves are described in the following sections. Other equity reserves are described in Note 2, &#x201c;Summary of Material Accounting Policies.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share Capital&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The share capital of Ascendis Pharma A/S consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,689,487&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; fully paid shares at a nominal value of DKK &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all in the same share class, and which includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;845,887&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ordinary shares represented by ADSs held by Ascendis Pharma A/S.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The development in outstanding shares of the Company was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Changes in share capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,707,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,152,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,937,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,750,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,985,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase through cash contributions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,982,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;555,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;214,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,187,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,764,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;60,689,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;57,707,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;57,152,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;56,937,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;53,750,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Treasury Shares Reserve&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The development in holding of treasury shares was as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.241999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Nominal&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Holding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Holding in&lt;br/&gt;% of total&lt;br/&gt;outstanding&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Treasury shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,113,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred under stock incentive programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,093,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred under stock incentive programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;845,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial Risk Management Objectives&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company regularly monitors the access to domestic and international financial markets, manages the financial risks relating to its operations, and analyzes exposures to risk, including market risk, such as foreign currency risk and interest rate risk, credit risk and liquidity risk.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s financial risk exposure and risk management policies are described in the following sections.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Market Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s activities expose the group enterprises to the financial risks of changes in foreign currency exchange rates and interest rates. Derivative financial instruments are not applied to manage exposure to such risks.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Risk Management&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is exposed to foreign currency exchange risks arising from various currency exposures, primarily with respect to the U.S. Dollar (&#x201c;USD&#x201d;). Foreign currency exchange risks to the USD are unchanged to prior year, and primarily relate to sales and purchases in foreign currencies, convertible notes and royalty funding liabilities, countered by cash and cash equivalents. The exposure from foreign currency exchange risks is managed by maintaining cash positions in the currencies in which the majority of future expenses are denominated, and payments are made from those reserves.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Sensitivity Analysis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table details how a strengthening of the USD against the EUR would impact profit or loss, and equity before tax at the reporting date. A similar weakening of the USD would have the opposite effect. A positive number indicates an increase in profit or loss and equity before tax, while a negative number indicates the opp&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;osite. The sensitivity analysis is deemed representative of the inherent foreign currency exchange risk associated with the operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Hypothetical impact on consolidated&lt;br/&gt;financial statements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Nominal&lt;br/&gt;positions&lt;br/&gt;(net)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Increase in&lt;br/&gt;foreign&lt;br/&gt;currency&lt;br/&gt;exchange&lt;br/&gt;rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Profit/(loss)&lt;br/&gt;before tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Equity before tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR &#x2018;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;USD/EUR&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;735,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Outstanding convertible notes comprise a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% coupon fixed rate structure. Further&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the effective interest rate on royalty funding liabilities is estimated at initial recognition and takes into account anticipated amount and timing of future cash flows, which further depends on future commercial revenue forecasts and the probability of exercising the embedded buy-out option. Material changes to anticipated future cash flows could potentially increase or decrease future interest expense. In addition, the interest rate on lease liabilities is fixed at the lease commencement date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future indebtedness, including those related to lease arrangements, if any, may be subject to higher interest rates. In addition, future interest income from interest-bearing bank deposits may fall short of expectations due to changes in interest rates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities are measured at fair value through profit or loss. Since the fair value is exposed from the development in interest rates, the profit or loss is exposed to volatility from such development. The effects of interest rate fluctuations are not considered a material risk to the Company&#x2019;s financial position. Accordingly, no interest sensitivity analysis has been presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Credit Risk Management&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has adopted an investment policy with the primary purpose of preserving capital, fulfilling liquidity needs and diversifying the risks associated with cash, cash equivalents and marketable securities. This investment policy establishes minimum ratings for institutions with which the Company holds cash and cash equivalents, as well as rating and concentration limits for marketable securities held.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The exposure to credit risk primarily relates to cash and cash equivalents. The credit risk on bank deposits is limited because the counterparties, holding significant deposits, are banks with minimum credit-ratings of A3/A- assigned by international credit-rating agencies. The banks are reviewed on a regular basis and deposits may be transferred during the year to mitigate credit risk. In order to mitigate the concentration of credit risks on bank deposits and to preserve capital, a portion of the bank deposits may be placed into investment grade rated marketable securities. The Company&#x2019;s investment policy, approved by the Board, only allows investment in marketable securities having investment grade credit-ratings, assigned by international credit-rating agencies. Accordingly, the risk from probability of default is low. On each reporting date, the risk of expected credit loss on bank deposits and marketable securities, if any, including the hypothetical impact arising from the probability of default, is considered in conjunction with the expected loss caused by default by banks or securities with similar credit-ratings and attributes. In line with previous periods, this assessment did not reveal a material impairment loss, and accordingly no provision for expected credit loss has been recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the reporting dates, there are no significant overdue trade receivable balances. As a result, write-down to accommodate expected credit-losses is not deemed material.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity Risk Management&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Historically, the risk of insufficient funds has been addressed through proceeds from sale of the Company&#x2019;s securities in private and public offerings, through issuance of convertible notes in 2022, and through royalty funding liabilities in 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liquidity risk is managed by maintaining adequate cash reserves and banking facilities. The risk of shortage of funds is monitored, using a liquidity planning tool, to ensure sufficient funds are available to settle liabilities as they fall due. Besides long term deposits on leases, the Company&#x2019;s financial assets are recoverable within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; after the reporting date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Maturity analysis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the consolidated statements of financial position:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&amp;lt; 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1-5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&amp;gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;contractual&lt;br/&gt;cash-flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,027,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,073,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;763,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables, accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;144,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,079,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;52,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,276,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;953,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;742,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;797,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables, accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;120,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;794,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;91,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,006,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;738,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Borrowings (excluding lease liabilities)&#x201d; comprise convertible notes and royalty funding liabilities. Further details regarding classification of convertible notes as current liabilities in the consolidated statement of financial position are provided in Note 2, &#x201c;Summary of Material Accounting Policies,&#x201d; section &#x201c;New and Amended IFRS Accounting Standards and Interpretations.&#x201d; Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements are provided above.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="INF"
      id="F_c15aef13-d4e2-4e2b-84e3-ded0317d4470"
      unitRef="U_shares">60689487</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="INF"
      id="F_83b37d73-df84-4bed-8f69-8d3dd63a8729"
      unitRef="U_DkkPerShare">1</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_7571783b-8274-4446-9034-fc8030ee4785"
      decimals="INF"
      id="F_dddd84f1-41b3-4810-b588-c2360557291c"
      unitRef="U_shares">845887</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_05759ccc-4928-4667-ae1d-ceb2f7005b76">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The development in outstanding shares of the Company was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Changes in share capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,707,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,152,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,937,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,750,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,985,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase through cash contributions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,982,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;555,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;214,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,187,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,764,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;60,689,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;57,707,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;57,152,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;56,937,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;53,750,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="INF"
      id="F_a4f5a84a-ac81-40a0-8a61-e05923ef40e2"
      unitRef="U_shares">57707439</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="INF"
      id="F_92995907-43d9-46e3-9cc9-331b35088184"
      unitRef="U_shares">57152295</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3"
      decimals="INF"
      id="F_daba47d7-e3d2-474a-9c35-9997cba2973a"
      unitRef="U_shares">56937682</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_5704c912-f30b-4de5-815d-6a09d374ba34"
      decimals="INF"
      id="F_59f197b8-84c9-4e70-9bd8-680a0c6cee0b"
      unitRef="U_shares">53750386</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_ae91164c-7a61-4403-923c-7fc72b5f637e"
      decimals="INF"
      id="F_6ac290c9-2c08-465e-8749-bd5a7c5db0cf"
      unitRef="U_shares">47985837</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="0"
      id="F_0d06a553-cdde-4fbf-b3da-97d6f0c661b4"
      unitRef="U_shares">2982048</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="0"
      id="F_6f262e01-3ffb-4ad2-b66d-6b79283ea7c1"
      unitRef="U_shares">555144</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="C_7e301002-0bf6-4196-80df-8e9527a1f352"
      decimals="0"
      id="F_489dd187-3bcc-4dc3-9c9e-061f1654acb7"
      unitRef="U_shares">214613</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="C_19fef29a-9741-4124-9e26-bd7da6782741"
      decimals="INF"
      id="F_59250cd8-3eab-4b71-b816-f022d8ac61d1"
      unitRef="U_shares">3187296</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="C_d35422da-96a1-4b03-a5f4-c8f5b78cbe7a"
      decimals="0"
      id="F_256e4928-1fa9-40b9-9d9e-761116307662"
      unitRef="U_shares">5764549</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="INF"
      id="F_b4d1e7ff-c68f-4c58-9f12-e8308254be39"
      unitRef="U_shares">60689487</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="INF"
      id="F_49f2c905-041e-4db2-8165-f9ea4eb760d2"
      unitRef="U_shares">57707439</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="INF"
      id="F_4db8d34d-6621-4420-9c1a-32ff9fef6974"
      unitRef="U_shares">57152295</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_f8fffccb-1bb9-4595-87c7-952664cd5bf3"
      decimals="INF"
      id="F_b0ee6348-e757-4c90-8ace-c1f8ac967faf"
      unitRef="U_shares">56937682</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_7905e7f5-2269-4e2c-bda4-a38c3e7ce9dc"
      decimals="INF"
      id="F_f1b82e6c-92f3-4cbf-9bd4-eec38596732e"
      unitRef="U_shares">53750386</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:DisclosureOfTreasurySharesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_0191eb41-5159-4cde-b9af-93ba70a8f324">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The development in holding of treasury shares was as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.241999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Nominal&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Holding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Holding in&lt;br/&gt;% of total&lt;br/&gt;outstanding&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Treasury shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,113,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred under stock incentive programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,093,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred under stock incentive programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;845,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfTreasurySharesExplanatory>
    <ifrs-full:TreasuryShares
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="-3"
      id="F_91f6b45d-6e7a-409a-8f90-468790ef7d60"
      unitRef="U_EUR">149000</ifrs-full:TreasuryShares>
    <asnd:NumberOfTreasurySharesOutstanding
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="0"
      id="F_e8122861-c898-47e4-a37c-13f3ed692bfd"
      unitRef="U_shares">1113152</asnd:NumberOfTreasurySharesOutstanding>
    <asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares
      contextRef="C_69523622-60fc-4677-8a69-32400c599999"
      decimals="2"
      id="F_0f54c5c9-293e-45b3-9a2b-5622960ea5d5"
      unitRef="U_pure">0</asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares>
    <asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue
      contextRef="C_56b18c35-7b90-45e6-8446-e4893174d8bd"
      decimals="-3"
      id="F_753c323a-1cfb-4a62-9bfc-b90b024018bf"
      unitRef="U_EUR">-3000</asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue>
    <asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="0"
      id="F_5c37d2da-d9d9-4ed7-be94-fbeca2dae78f"
      unitRef="U_shares">-20098</asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram>
    <asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="2"
      id="F_5d70fe52-543f-4f11-8bf8-73d8c224eecb"
      unitRef="U_pure">0</asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms>
    <ifrs-full:TreasuryShares
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_e88369f6-5d73-4119-b523-6038c70070e8"
      unitRef="U_EUR">146000</ifrs-full:TreasuryShares>
    <asnd:NumberOfTreasurySharesOutstanding
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="0"
      id="F_d8f74656-246e-497e-9737-dd5e2fc2d887"
      unitRef="U_shares">1093054</asnd:NumberOfTreasurySharesOutstanding>
    <asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="3"
      id="F_f9c13697-affe-41e3-a1ed-9525424bab36"
      unitRef="U_pure">0.019</asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares>
    <asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="-3"
      id="F_e6252024-6cf2-49d4-9fcd-fcb65dd90d99"
      unitRef="U_EUR">-33000</asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue>
    <asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="0"
      id="F_c1c2af23-9de3-49fc-bd70-79311d3258e0"
      unitRef="U_shares">-247167</asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram>
    <asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="2"
      id="F_379f78c0-aaa2-4554-9830-9559da0f1f46"
      unitRef="U_pure">0</asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms>
    <ifrs-full:TreasuryShares
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_afb6abae-1391-40a4-8eb7-395313664caa"
      unitRef="U_EUR">113000</ifrs-full:TreasuryShares>
    <asnd:NumberOfTreasurySharesOutstanding
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="0"
      id="F_dc0f9167-5e7f-43b7-8078-a2a193126f06"
      unitRef="U_shares">845887</asnd:NumberOfTreasurySharesOutstanding>
    <asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="3"
      id="F_af5e0390-c47c-4451-950b-4ff26dfd34ce"
      unitRef="U_pure">0.014</asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares>
    <asnd:DisclosureOfForeignCurrencySensitivityAnalysisExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_ffffa801-b463-453e-b79b-ad9f0ab982d1">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Hypothetical impact on consolidated&lt;br/&gt;financial statements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Nominal&lt;br/&gt;positions&lt;br/&gt;(net)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Increase in&lt;br/&gt;foreign&lt;br/&gt;currency&lt;br/&gt;exchange&lt;br/&gt;rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Profit/(loss)&lt;br/&gt;before tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Equity before tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR &#x2018;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;USD/EUR&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;735,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfForeignCurrencySensitivityAnalysisExplanatory>
    <ifrs-full:NotionalAmount
      contextRef="C_3e1079df-bb69-43bf-854f-2f912ce24f92"
      decimals="-3"
      id="F_2d05e8a5-5063-4876-864c-96a345fe9e4c"
      unitRef="U_EUR">735064000</ifrs-full:NotionalAmount>
    <asnd:IncreaseDecreaseInForeignCurrencyExchangeRate
      contextRef="C_3e1079df-bb69-43bf-854f-2f912ce24f92"
      decimals="2"
      id="F_e59b69ee-c57d-41b1-9dff-bc4f484514cb"
      unitRef="U_pure">0.10</asnd:IncreaseDecreaseInForeignCurrencyExchangeRate>
    <ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax
      contextRef="C_5a4ab42e-9a10-4f66-a061-557f147450fd"
      decimals="-3"
      id="F_a286f95d-0e24-4986-b854-1bdb66736629"
      unitRef="U_EUR">-73506000</ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax>
    <ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax
      contextRef="C_5a4ab42e-9a10-4f66-a061-557f147450fd"
      decimals="-3"
      id="F_a9de7be4-0dbb-4aee-93d4-736f576e3eaa"
      unitRef="U_EUR">-73506000</ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax>
    <ifrs-full:NotionalAmount
      contextRef="C_adc00162-0324-4973-874c-008dcc36d3e7"
      decimals="-3"
      id="F_3baa4d68-e09c-409c-8ec7-36615e52f9a6"
      unitRef="U_EUR">369091000</ifrs-full:NotionalAmount>
    <asnd:IncreaseDecreaseInForeignCurrencyExchangeRate
      contextRef="C_adc00162-0324-4973-874c-008dcc36d3e7"
      decimals="2"
      id="F_cef1e120-7035-4826-ae7d-4332db5b12c9"
      unitRef="U_pure">0.10</asnd:IncreaseDecreaseInForeignCurrencyExchangeRate>
    <ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax
      contextRef="C_faa6d408-e3a2-423c-9170-2e7df293488d"
      decimals="-3"
      id="F_75818a7e-608b-4ac7-bb2c-8ae0cc7b0223"
      unitRef="U_EUR">-36909000</ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax>
    <ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax
      contextRef="C_faa6d408-e3a2-423c-9170-2e7df293488d"
      decimals="-3"
      id="F_c8a8f241-c2e2-42e4-a45f-5d71d9c88a04"
      unitRef="U_EUR">-36909000</ifrs-full:GainsLossesOnChangeInValueOfForeignCurrencyBasisSpreadsBeforeTax>
    <ifrs-full:BorrowingsInterestRate
      contextRef="C_1a5af062-57bb-4ae3-b3ed-605c63a78bb9"
      decimals="4"
      id="F_149191e6-61d7-4370-b9cb-d3d8b5f0252f"
      unitRef="U_pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <asnd:RealizedDurationOfFinancialAssetsExplanatory
      contextRef="C_caa0fd3a-8a0c-4ca4-8011-0a2b36ac28ba"
      id="F_37bc3c64-3973-46e3-85f7-21db2007ec21">P12M</asnd:RealizedDurationOfFinancialAssetsExplanatory>
    <asnd:ContractualCashflowsForFinancialLiabilitiesTextBlock
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_276e48b9-cce8-4367-8065-5ffa338e2b89">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the consolidated statements of financial position:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&amp;lt; 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1-5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&amp;gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;contractual&lt;br/&gt;cash-flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,027,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,073,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;763,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables, accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;144,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,079,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;52,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,276,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;953,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;742,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;797,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables, accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;120,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;794,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;91,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,006,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;738,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</asnd:ContractualCashflowsForFinancialLiabilitiesTextBlock>
    <ifrs-full:Borrowings
      contextRef="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb"
      decimals="-3"
      id="F_ccba30ac-abfd-4a5f-a019-f39939e6a545"
      unitRef="U_EUR">32303000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_18e923c0-37b2-4527-b1aa-aed2087ad549"
      decimals="-3"
      id="F_6310ecf6-8f84-4c6a-b6f0-0a40309f6d0e"
      unitRef="U_EUR">1027558000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_c0c25b57-fada-4810-aa6c-9f3de313c6c5"
      decimals="-3"
      id="F_ad2a09b7-c7ad-45c0-b59c-efd993ad20ef"
      unitRef="U_EUR">13660000</ifrs-full:Borrowings>
    <asnd:ContractualUndiscountedCashflowOfBorrowings
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_478d2caf-a335-4f87-ab60-74bdea8f3cf7"
      unitRef="U_EUR">1073521000</asnd:ContractualUndiscountedCashflowOfBorrowings>
    <ifrs-full:Borrowings
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_1f0bfe59-ffe4-4b9b-a880-3793cedd969d"
      unitRef="U_EUR">763586000</ifrs-full:Borrowings>
    <ifrs-full:LeaseLiabilities
      contextRef="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb"
      decimals="-3"
      id="F_2340f11c-ba8e-4865-8691-0ea006a9ce06"
      unitRef="U_EUR">15482000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_18e923c0-37b2-4527-b1aa-aed2087ad549"
      decimals="-3"
      id="F_876274cf-ba9e-4572-826a-2b4d86c821c0"
      unitRef="U_EUR">52007000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_c0c25b57-fada-4810-aa6c-9f3de313c6c5"
      decimals="-3"
      id="F_7511bc03-d0db-4413-8ef3-3f89cdff96e4"
      unitRef="U_EUR">39127000</ifrs-full:LeaseLiabilities>
    <asnd:ContractualUndiscountedCashflowOfFinancialLeaseLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_8cf9439c-f744-4141-84e4-81c94c22b9c3"
      unitRef="U_EUR">106616000</asnd:ContractualUndiscountedCashflowOfFinancialLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_dbbbde9b-6c3e-4ba8-bf9a-85bb1ace108f"
      unitRef="U_EUR">93030000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb"
      decimals="-3"
      id="F_6a3205d2-8048-45c3-9ae7-e5962282bf9e"
      unitRef="U_EUR">96705000</ifrs-full:TradeAndOtherPayables>
    <asnd:ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_0c4402c0-60c4-445e-817e-822dfd4f1c7d"
      unitRef="U_EUR">96705000</asnd:ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_90b910b9-83b1-48ef-b6e8-351cfe43fae8"
      unitRef="U_EUR">96705000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:FinancialLiabilities
      contextRef="C_e53c9c12-d07f-4afc-ade5-88d9011c37cb"
      decimals="-3"
      id="F_d5dab34a-9840-48a6-8f21-98ea7dcf3e53"
      unitRef="U_EUR">144490000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_18e923c0-37b2-4527-b1aa-aed2087ad549"
      decimals="-3"
      id="F_79c1aaa3-e71a-43a4-a149-f5f7cc29a196"
      unitRef="U_EUR">1079565000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_c0c25b57-fada-4810-aa6c-9f3de313c6c5"
      decimals="-3"
      id="F_702b68b7-fd30-427e-8168-a6d182a737be"
      unitRef="U_EUR">52787000</ifrs-full:FinancialLiabilities>
    <asnd:ContractualUndiscountedCashflowOfFinancialLiabilities
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_81649dbc-5da6-4f07-a16c-c47e64f23643"
      unitRef="U_EUR">1276842000</asnd:ContractualUndiscountedCashflowOfFinancialLiabilities>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="C_198d936f-6bd1-467c-a662-6a993e1856a7"
      decimals="-3"
      id="F_f5fb0354-8616-4712-b713-38c42fba56aa"
      unitRef="U_EUR">953321000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:Borrowings
      contextRef="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d"
      decimals="-3"
      id="F_70d95e41-b413-4b3e-a94c-e53ddc14449f"
      unitRef="U_EUR">11708000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_17f4bf17-9d0d-4701-ab69-f29d52ef6948"
      decimals="-3"
      id="F_ceee9b85-9bfc-4fa3-aa72-dc58a891daac"
      unitRef="U_EUR">742925000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_21c7c051-dbdf-4831-9602-654f3d0b55c5"
      decimals="-3"
      id="F_5757f4dd-0098-464e-a4cb-7f2acd5af467"
      unitRef="U_EUR">42397000</ifrs-full:Borrowings>
    <asnd:ContractualUndiscountedCashflowOfBorrowings
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_27363b83-f6f9-4240-8f39-a9bdec9527bc"
      unitRef="U_EUR">797030000</asnd:ContractualUndiscountedCashflowOfBorrowings>
    <ifrs-full:Borrowings
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_3bb527d8-d9f3-42cf-9be6-536e5e952249"
      unitRef="U_EUR">545472000</ifrs-full:Borrowings>
    <ifrs-full:LeaseLiabilities
      contextRef="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d"
      decimals="-3"
      id="F_7fd6513d-2b72-445c-91e9-66eac775c218"
      unitRef="U_EUR">14385000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_17f4bf17-9d0d-4701-ab69-f29d52ef6948"
      decimals="-3"
      id="F_4ef031a4-d83d-48f1-ab06-8e9e21edbf83"
      unitRef="U_EUR">51426000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_21c7c051-dbdf-4831-9602-654f3d0b55c5"
      decimals="-3"
      id="F_b9d50403-1e15-43b7-b3e8-8de6a423617b"
      unitRef="U_EUR">49056000</ifrs-full:LeaseLiabilities>
    <asnd:ContractualUndiscountedCashflowOfFinancialLeaseLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_d942e44e-8696-48a8-a143-ab514840dbf6"
      unitRef="U_EUR">114867000</asnd:ContractualUndiscountedCashflowOfFinancialLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_ef960695-0f62-43ad-82d6-b103b5bb93ce"
      unitRef="U_EUR">98793000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d"
      decimals="-3"
      id="F_aea1094f-a44d-4490-9c79-e4f65d900c1f"
      unitRef="U_EUR">94566000</ifrs-full:TradeAndOtherPayables>
    <asnd:ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_17d039e5-7e7f-43ea-aa02-ed3329034ce1"
      unitRef="U_EUR">94566000</asnd:ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_1e739746-c2a9-4ec7-a3e1-3cd4bdbb9010"
      unitRef="U_EUR">94566000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:FinancialLiabilities
      contextRef="C_abba4c1e-d0ab-429f-b3a5-0ed51ac5188d"
      decimals="-3"
      id="F_abe15b8e-34d6-4dd3-beb9-fdfe44630c0c"
      unitRef="U_EUR">120659000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_17f4bf17-9d0d-4701-ab69-f29d52ef6948"
      decimals="-3"
      id="F_3905de37-5633-4739-91ea-05ba778ee000"
      unitRef="U_EUR">794351000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_21c7c051-dbdf-4831-9602-654f3d0b55c5"
      decimals="-3"
      id="F_4a68dfa9-95b3-4c8b-9799-7f34c468e8c1"
      unitRef="U_EUR">91453000</ifrs-full:FinancialLiabilities>
    <asnd:ContractualUndiscountedCashflowOfFinancialLiabilities
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_e45fd74c-181d-496e-aed3-cd327557570a"
      unitRef="U_EUR">1006463000</asnd:ContractualUndiscountedCashflowOfFinancialLiabilities>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="C_22b1cffe-3381-48dd-9ae6-e3f3769898c7"
      decimals="-3"
      id="F_ab958c10-012e-408d-9d35-e82516ff7bce"
      unitRef="U_EUR">738831000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_86c67f04-d90c-4c03-a8f6-c25f3254b234">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 18&#x2014;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contractual commitments for the acquisition of property, plant and equipment were &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 2023, respectively. Further, with certain suppliers, the Company has agreed minimum commitments related to the manufacturing of product supply, subject to continuous negotiation and adjustments according to the individual contractual terms and conditions. Cost of product supply is recognized when the Company obtains control of the goods. In addition, the Company has commitments related to short-term leases and leases of low value assets, contracts of various lengths in respect of research and development with CROs, and IT and facility related services. Costs relating to those commitments are recognized as services are received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is not aware of any significant legal claims or disputes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="C_614a19b6-1595-4cfe-87c5-0d0f93542d8e"
      decimals="-5"
      id="F_88df581b-4622-4def-9f75-91a3f313dc66"
      unitRef="U_EUR">300000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="C_cb788b59-28a4-4544-81e7-493092e53b2d"
      decimals="-5"
      id="F_76175bd6-dd31-4839-a5ec-95583377670c"
      unitRef="U_EUR">1200000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_5cb20800-4830-47bf-bcad-65403da7dfdf">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 19&#x2014;Related Party Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Directors, the Executive Board and non-executive Senior Management (&#x201c;Key Management Personnel&#x201d;) are considered related parties as they have authority and responsibility for planning and directing the Company&#x2019;s operations. Related parties also include undertakings in which such individuals have a controlling or joint controlling interest. Additionally, all group enterprises and associates are considered related parties.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Neither the Company&#x2019;s related parties nor major shareholders hold a controlling, joint controlling, or significant interest in the Group.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into employment agreements with and issued warrants, RSUs and PSUs to Key Management Personnel. In addition, the Company pays fees for board tenure and board committee tenure to the independent members of the Board of Directors. For further details, refer to Note 6, &#x201c;Employee Costs.&#x201d; Indemnification agreements have been entered with members of the Board of Directors, the Executive Board and Non-executive Senior Management.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Transactions between the parent company and group enterprises comprise management and license fees, research and development services, administration services, and clinical and commercial supplies. These transactions have been eliminated in the consolidated financial statements. Transactions and outstanding balances with the associates are disclosed in Note 12, &#x201c;Investments in Associates.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the parent company Ascendis Pharma A/S is jointly taxed with its Danish subsidiaries, where the current Danish corporation tax is allocated between the jointly taxed Danish companies. For further details, refer to Note 9, &#x201c;Tax on Profit/(Loss) for the Year and Deferred Tax.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Except for the information disclosed above, the Company has not undertaken any significant transactions with members of the Key Management Personnel, or undertakings in which the identified related parties have a controlling or joint controlling interest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_72083bcf-4b9f-43b6-a43b-b9467ab9a666">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 20&#x2014;Investments in Group Enterprises&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma A/S&#x2019;s (parent company) investments in group enterprises at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 comprise:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Domicile&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Ownership&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma GmbH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Germany&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Endocrinology GmbH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Germany&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;USA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Endocrinology, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;USA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Ophthalmology Division A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Endocrinology Division A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Bone Diseases A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Growth Disorders A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Oncology Division A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Europe A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma UK Limited&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Iberia S.L.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Spain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma France SASU&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;France&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Italia SRL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Italy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Sverige AB&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sweden&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Switzerland GmbH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Switzerland&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Associates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Domicile&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Ownership&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;VISEN Pharmaceuticals&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cayman Island&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Eyconis Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;USA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_4c8bfd9e-50ed-4184-9344-0fa30aabc163">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma A/S&#x2019;s (parent company) investments in group enterprises at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 comprise:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Domicile&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Ownership&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma GmbH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Germany&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Endocrinology GmbH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Germany&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;USA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Endocrinology, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;USA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Ophthalmology Division A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Endocrinology Division A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Bone Diseases A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Growth Disorders A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Oncology Division A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Europe A/S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma UK Limited&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Iberia S.L.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Spain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma France SASU&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;France&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Italia SRL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Italy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Sverige AB&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sweden&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma Switzerland GmbH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Switzerland&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Associates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Domicile&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Ownership&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;VISEN Pharmaceuticals&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cayman Island&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Eyconis Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;USA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_ce33c6e8-bd62-455a-8699-8dfef4b1bdb2"
      id="F_6274b74a-3321-4368-bd79-07ea69cbdd5c">Ascendis Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_ce33c6e8-bd62-455a-8699-8dfef4b1bdb2"
      decimals="2"
      id="F_c4110687-8a0c-495d-aecc-c37a340e789c"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_30407527-3185-4f61-a488-03f2f38c8ed3"
      id="F_0183ddd8-72d6-4fea-aa79-b319a4ec90b7">Ascendis Pharma Endocrinology GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_30407527-3185-4f61-a488-03f2f38c8ed3"
      decimals="2"
      id="F_2c1ad663-887b-4111-9042-1db84d7bee24"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_1e102ae1-1402-4ff8-81ac-0692bcc874ef"
      id="F_f0a20b48-820f-4416-afa5-d5e684f95cf5">Ascendis Pharma, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_1e102ae1-1402-4ff8-81ac-0692bcc874ef"
      decimals="2"
      id="F_4dae2174-bc7d-4e80-a36c-5324a433bcea"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_41e4375f-476d-430a-af3b-9f5b61fe72c0"
      id="F_2a1e60e6-4186-4ea6-9d1a-b740cbf87477">Ascendis Pharma Endocrinology, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_41e4375f-476d-430a-af3b-9f5b61fe72c0"
      decimals="2"
      id="F_4d9b5ac4-c381-4f8e-935d-bd1b6681d419"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_242430a3-5c4f-44b2-aaf8-4987e49091d8"
      id="F_3797efc3-cdea-41aa-bb9f-1ff8430f94a8">Ascendis Pharma Ophthalmology Division A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_242430a3-5c4f-44b2-aaf8-4987e49091d8"
      decimals="2"
      id="F_5430e3ce-3b5b-4a07-adc7-07bce0434229"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_64cd1be6-0716-4e13-b266-fb646a8370c3"
      id="F_8207fa7c-a19a-4699-9950-bb19ae36db78">Ascendis Pharma Endocrinology Division A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_64cd1be6-0716-4e13-b266-fb646a8370c3"
      decimals="2"
      id="F_9c74be73-69e8-472e-9460-f0b99429b60a"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_1fb6099b-b6a9-4b5c-bd7a-11c2717591ca"
      id="F_cfe59321-8bbc-4190-81ab-da2ee1d543a2">Ascendis Pharma Bone Diseases A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_1fb6099b-b6a9-4b5c-bd7a-11c2717591ca"
      decimals="2"
      id="F_10abcc59-f297-4380-83e5-70cc925abd3f"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_842cce4b-c4af-4a45-9074-b4aeeba66138"
      id="F_e6cefc33-b498-42c9-b7a3-1196294480cd">Ascendis Pharma Growth Disorders A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_842cce4b-c4af-4a45-9074-b4aeeba66138"
      decimals="2"
      id="F_c6908298-aac1-4129-a85f-373b7f365af9"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_c6d5894a-3b43-479b-98c1-26c26fcd5ea8"
      id="F_68a1b426-fb5d-4316-b535-474db65a9d28">Ascendis Pharma Oncology Division A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_c6d5894a-3b43-479b-98c1-26c26fcd5ea8"
      decimals="2"
      id="F_766e20a4-92e1-4f43-80b4-ada37fad548f"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_368d07a7-0ac6-4e17-b820-a12da4602974"
      id="F_4bcab819-8fa0-47c1-956c-3cc1afde7ab0">Ascendis Pharma Europe A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_368d07a7-0ac6-4e17-b820-a12da4602974"
      decimals="2"
      id="F_c58df713-dc72-4ade-93cc-78303f0513b9"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_3925fc10-a57d-420c-9fea-0099a4bfa974"
      id="F_e97dec8c-985b-4c79-8c33-300c6cb544ec">Ascendis Pharma UK Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_3925fc10-a57d-420c-9fea-0099a4bfa974"
      decimals="2"
      id="F_f6263fa6-4f0f-4289-bd0b-433a0cd86bbf"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_ee56b8dc-dcf9-4371-a111-224749172b3f"
      id="F_199a0032-0c3f-4eb4-9f4e-a1cc13642107">Ascendis Pharma Iberia S.L.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_ee56b8dc-dcf9-4371-a111-224749172b3f"
      decimals="2"
      id="F_e51a4a15-2123-4fab-a6f9-8ced19937efa"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_6114a2f7-6ec9-4c7c-b156-f0fa2cd47f7f"
      id="F_94511b8c-a38a-4946-8907-c1f23c26ce34">Ascendis Pharma France SASU</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_6114a2f7-6ec9-4c7c-b156-f0fa2cd47f7f"
      decimals="2"
      id="F_8d20494a-019a-4ea5-aba0-b78f1a4fe586"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_7b687297-3e1b-4c67-8d9f-f309d8615de2"
      id="F_f7c0fe18-e730-4164-947f-a7d16a71c33f">Ascendis Pharma Italia SRL</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_7b687297-3e1b-4c67-8d9f-f309d8615de2"
      decimals="2"
      id="F_ab85dbdb-ab64-47ab-80af-ad38492cbc5c"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_81e385ec-89e0-41e0-9a86-a4f0e9abe54c"
      id="F_1a90d20d-443c-48c9-8c60-96be8ecdd2b6">Ascendis Pharma Sverige AB</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_81e385ec-89e0-41e0-9a86-a4f0e9abe54c"
      decimals="2"
      id="F_cd0653e5-000d-4821-97b4-41deaa5998ec"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="C_358f6ff6-9ffa-4fee-a3d7-9f7f0de3c554"
      id="F_3202e1a4-7c61-4d28-9346-b9fac85c6f93">Ascendis Pharma Switzerland GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="C_358f6ff6-9ffa-4fee-a3d7-9f7f0de3c554"
      decimals="2"
      id="F_b87c3477-eb7d-44e3-9c93-db9e62bbf4c1"
      unitRef="U_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfAssociate
      contextRef="C_cf967fba-0da6-4929-9134-641e84170ee5"
      id="F_ff84f106-6451-4103-a3f2-2b2a4ba2afdb">VISEN Pharmaceuticals</ifrs-full:NameOfAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="C_cf967fba-0da6-4929-9134-641e84170ee5"
      decimals="3"
      id="F_a30e5b76-5069-4075-b708-c5a16e53dfaf"
      unitRef="U_pure">0.439</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:NameOfAssociate
      contextRef="C_66ac9391-e29a-452b-a56e-75aa88249b65"
      id="F_91cfbc4f-c3e3-4abb-8dcc-0d1bdf25535e">Eyconis Inc.</ifrs-full:NameOfAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="C_66ac9391-e29a-452b-a56e-75aa88249b65"
      decimals="3"
      id="F_c01f84b4-25ad-4e19-a1b2-f05480d841b6"
      unitRef="U_pure">0.416</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <asnd:DisclosureOfBeneficialOwnershipExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_6d5f3345-ba90-4f3b-89d6-ae47c1765c62">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 21&#x2014;Ownership&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following investors, or groups of affiliated investors, are known by us to beneficially own more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s outstanding ordinary shares at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Entities affiliated with RA Capital Management, LLC, USA&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Westfield Capital Management Company, L.P., USA&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Entities affiliated with FMR LLC, USA&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Avoro Capital Advisors LLC, USA&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Entities affiliated with Artisan Partners LP, USA&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Entities affiliated with Janus Henderson Group plc, United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s American Depository Shares are held through BNY (Nominees) Limited as nominee, of The Bank of New York Mellon, UK (as registered holder of the Company&#x2019;s outstanding ADSs).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</asnd:DisclosureOfBeneficialOwnershipExplanatory>
    <asnd:MinimumBeneficialOwnershipPercentage
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      decimals="2"
      id="F_6a9a26a6-5bf8-44ba-94c1-c5c2ebf2b026"
      unitRef="U_pure">0.05</asnd:MinimumBeneficialOwnershipPercentage>
    <asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership
      contextRef="C_fa515c36-ae39-4b8b-a4b2-2f0389428d27"
      id="F_18691ad0-d228-42cb-8c48-d34ae9fac7cd">Entities affiliated with RA Capital Management, LLC, USA</asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership>
    <asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership
      contextRef="C_1b8ce618-fe68-4762-9808-37cbe7002b0c"
      id="F_f7ad2db0-10dd-44c1-a151-7a1833f97147">Westfield Capital Management Company, L.P., USA</asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership>
    <asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership
      contextRef="C_5bb64963-abad-4e25-ab29-a2838c4dfeb9"
      id="F_d559f3cb-c1ce-41af-a296-3182a32edc55">Entities affiliated with FMR LLC, USA</asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership>
    <asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership
      contextRef="C_e3aa91fe-cef2-4bec-ad73-cb9c151bddb9"
      id="F_ae9f91b5-b2e8-43c3-be22-a4d97382cf72">Avoro Capital Advisors LLC, USA</asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership>
    <asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership
      contextRef="C_abc0c365-74db-4b23-b2e7-0dd10c9811b3"
      id="F_da550c0a-6787-41fa-96f7-b31a7e8fbaf9">Entities affiliated with Artisan Partners LP, USA</asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership>
    <asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership
      contextRef="C_005327b9-9514-487d-af81-293c04b4477d"
      id="F_ee5cfb70-ec48-4f0a-b280-9be799916334">Entities affiliated with Janus Henderson Group plc, United Kingdom</asnd:MajorPersonsOrGroupsOfAffiliatedPersonsHoldingMinimumBeneficialOwnership>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="C_e160c34a-290e-4f9a-863a-46afc6a82950"
      id="F_a9f6f1c8-d0f5-4e12-b3c5-156528091aa8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 22&#x2014;Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;No events have occurred after the reporting date that would influence the evaluation of these consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_df87669d-0bb6-45ab-a330-8acae0137258"
          xlink:label="F_df87669d-0bb6-45ab-a330-8acae0137258"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_df4ae6a0-4b34-4d5f-9c35-e466cec1e95e"
          xlink:label="F_df4ae6a0-4b34-4d5f-9c35-e466cec1e95e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5af142f2-1bb4-4ef7-aeca-efe68deab74c"
          xlink:label="F_5af142f2-1bb4-4ef7-aeca-efe68deab74c"
          xlink:type="locator"/>
        <link:footnote id="FNT_981ef46d-800a-489f-82bc-a5ff60bd4f50" xlink:label="FNT_981ef46d-800a-489f-82bc-a5ff60bd4f50" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, a total of </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,204,122</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">6,523,784</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">6,864,011</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">575,000</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible senior notes which can potentially be converted into </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,456,785</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the years presented.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_df87669d-0bb6-45ab-a330-8acae0137258"
          xlink:to="FNT_981ef46d-800a-489f-82bc-a5ff60bd4f50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_df4ae6a0-4b34-4d5f-9c35-e466cec1e95e"
          xlink:to="FNT_981ef46d-800a-489f-82bc-a5ff60bd4f50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5af142f2-1bb4-4ef7-aeca-efe68deab74c"
          xlink:to="FNT_981ef46d-800a-489f-82bc-a5ff60bd4f50"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_c9d6d57b-425c-4fb7-abbd-e4a278a46eb8"
          xlink:label="F_c9d6d57b-425c-4fb7-abbd-e4a278a46eb8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_62a04fe8-9b69-41f4-82de-ade1f995608e"
          xlink:label="F_62a04fe8-9b69-41f4-82de-ade1f995608e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d72c75d5-ea0e-4320-874c-0aae05cd4401"
          xlink:label="F_d72c75d5-ea0e-4320-874c-0aae05cd4401"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cac9b5bc-a669-4d09-ac9d-3ac7b871ead1"
          xlink:label="F_cac9b5bc-a669-4d09-ac9d-3ac7b871ead1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d6b826e8-8b76-4bd1-baa0-57dac5ae1ea1"
          xlink:label="F_d6b826e8-8b76-4bd1-baa0-57dac5ae1ea1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_deb67055-8a85-4ee4-ac53-976b2ed93a91"
          xlink:label="F_deb67055-8a85-4ee4-ac53-976b2ed93a91"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_556f4c14-5887-4ee4-8d98-2a04d59d2952"
          xlink:label="F_556f4c14-5887-4ee4-8d98-2a04d59d2952"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_26c6c861-b5ba-4cad-92f6-32f39a3a1d2c"
          xlink:label="F_26c6c861-b5ba-4cad-92f6-32f39a3a1d2c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_382097b3-b5ef-4436-b499-30711f816121"
          xlink:label="F_382097b3-b5ef-4436-b499-30711f816121"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e69b6562-90e1-4217-895d-b444dfba7743"
          xlink:label="F_e69b6562-90e1-4217-895d-b444dfba7743"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4fe891d7-42a9-43d8-ad45-1edeb55f7bd5"
          xlink:label="F_4fe891d7-42a9-43d8-ad45-1edeb55f7bd5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c07633cd-f507-41e3-830f-c087650184e2"
          xlink:label="F_c07633cd-f507-41e3-830f-c087650184e2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_592df39d-6fe8-4376-b652-663628839d40"
          xlink:label="F_592df39d-6fe8-4376-b652-663628839d40"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0b4fb44d-7574-4a84-b61c-87d8d0bbab45"
          xlink:label="F_0b4fb44d-7574-4a84-b61c-87d8d0bbab45"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_54e300fd-d8b7-4a41-9130-5dd43498563b"
          xlink:label="F_54e300fd-d8b7-4a41-9130-5dd43498563b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_42b6f182-c1d6-40a4-9e57-6b2a81baa418"
          xlink:label="F_42b6f182-c1d6-40a4-9e57-6b2a81baa418"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_70808046-e0cf-4475-87b4-4b385a38274d"
          xlink:label="F_70808046-e0cf-4475-87b4-4b385a38274d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_07c24fc7-73aa-4d3c-9add-a4464165d707"
          xlink:label="F_07c24fc7-73aa-4d3c-9add-a4464165d707"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9a7e5e95-c04c-4327-96d6-0bb984adb4a0"
          xlink:label="F_9a7e5e95-c04c-4327-96d6-0bb984adb4a0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e1de2081-8c19-44b6-82ed-be5e61e997ed"
          xlink:label="F_e1de2081-8c19-44b6-82ed-be5e61e997ed"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_303a6812-2e52-48fd-a43a-203a98780c2d"
          xlink:label="F_303a6812-2e52-48fd-a43a-203a98780c2d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3a82fc0d-07aa-432d-b4fb-c0d3dabb40b7"
          xlink:label="F_3a82fc0d-07aa-432d-b4fb-c0d3dabb40b7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_caa57351-8417-4791-a585-bd145240387d"
          xlink:label="F_caa57351-8417-4791-a585-bd145240387d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_33c31fb0-9baf-4529-80e9-43922ebe0918"
          xlink:label="F_33c31fb0-9baf-4529-80e9-43922ebe0918"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_199ad878-35ff-4014-a37f-42eb7ed9c375"
          xlink:label="F_199ad878-35ff-4014-a37f-42eb7ed9c375"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_084cf33e-da27-4b65-bb42-3f6c5710074a"
          xlink:label="F_084cf33e-da27-4b65-bb42-3f6c5710074a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5214d3b0-47a3-45d2-997f-784799e392c2"
          xlink:label="F_5214d3b0-47a3-45d2-997f-784799e392c2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_75208953-26c9-4ba5-80b9-b728a6b86e17"
          xlink:label="F_75208953-26c9-4ba5-80b9-b728a6b86e17"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_60695fa5-1167-441b-b831-7560770cf08c"
          xlink:label="F_60695fa5-1167-441b-b831-7560770cf08c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_980c6c3b-e596-4b9c-8d92-e02450c398a0"
          xlink:label="F_980c6c3b-e596-4b9c-8d92-e02450c398a0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d8e56e66-8575-4b72-a1ed-bc5d29c3d221"
          xlink:label="F_d8e56e66-8575-4b72-a1ed-bc5d29c3d221"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cd3efa0e-9e4f-49f5-9e6c-a40915c3d8f3"
          xlink:label="F_cd3efa0e-9e4f-49f5-9e6c-a40915c3d8f3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_850c6404-d676-4a1c-bd80-6f8bb47928b0"
          xlink:label="F_850c6404-d676-4a1c-bd80-6f8bb47928b0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7ffbe158-e7ca-41b1-9e0f-c9494aadcac5"
          xlink:label="F_7ffbe158-e7ca-41b1-9e0f-c9494aadcac5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ef27783e-2ebf-4cee-8123-7b88ae2ac3c7"
          xlink:label="F_ef27783e-2ebf-4cee-8123-7b88ae2ac3c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1fa26a62-cdd0-4509-ba50-f296557bdcb6"
          xlink:label="F_1fa26a62-cdd0-4509-ba50-f296557bdcb6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_69813962-ec68-4626-9ef5-779670aa2f2a"
          xlink:label="F_69813962-ec68-4626-9ef5-779670aa2f2a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9f2d3364-03ae-45be-ba44-fc988fb90336"
          xlink:label="F_9f2d3364-03ae-45be-ba44-fc988fb90336"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_23a507de-e21f-48de-ae21-fd24dace1e42"
          xlink:label="F_23a507de-e21f-48de-ae21-fd24dace1e42"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_06324db9-e461-493f-a1a5-d89ab3895f83"
          xlink:label="F_06324db9-e461-493f-a1a5-d89ab3895f83"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4e401866-c4ae-4461-ae46-80951396f0fa"
          xlink:label="F_4e401866-c4ae-4461-ae46-80951396f0fa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1837bd4c-bdab-4625-83ce-5792ca88d901"
          xlink:label="F_1837bd4c-bdab-4625-83ce-5792ca88d901"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_831a4081-f4f8-4711-96ad-78b29be79f6c"
          xlink:label="F_831a4081-f4f8-4711-96ad-78b29be79f6c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0bc3769e-460e-4b91-afc4-7d3ba0080ceb"
          xlink:label="F_0bc3769e-460e-4b91-afc4-7d3ba0080ceb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_589fd958-2fd9-4861-8eb2-fb211220f782"
          xlink:label="F_589fd958-2fd9-4861-8eb2-fb211220f782"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e7085e38-ade3-403e-81da-e57c0a1e414d"
          xlink:label="F_e7085e38-ade3-403e-81da-e57c0a1e414d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8a80a850-f6a7-4854-b3a7-e27ae4e96591"
          xlink:label="F_8a80a850-f6a7-4854-b3a7-e27ae4e96591"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9943a8d6-82ce-4009-8273-13bf6b24f302"
          xlink:label="F_9943a8d6-82ce-4009-8273-13bf6b24f302"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e7255016-a092-43b2-8fff-0447b82b8834"
          xlink:label="F_e7255016-a092-43b2-8fff-0447b82b8834"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_61f5ba9c-d6e7-47af-a120-b0300560d6c6"
          xlink:label="F_61f5ba9c-d6e7-47af-a120-b0300560d6c6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_40b093c3-640c-47a0-8b85-489d8e14a1a9"
          xlink:label="F_40b093c3-640c-47a0-8b85-489d8e14a1a9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7c603b92-996b-41cf-90f1-b6f38706f824"
          xlink:label="F_7c603b92-996b-41cf-90f1-b6f38706f824"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7f5c30a7-dd20-4a79-8b75-5e53ccb86d9d"
          xlink:label="F_7f5c30a7-dd20-4a79-8b75-5e53ccb86d9d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_399b9146-169e-4bb4-ac80-cafd1f58cce1"
          xlink:label="F_399b9146-169e-4bb4-ac80-cafd1f58cce1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9ba2ab12-59c9-4705-b8c1-3ab3fc76f27d"
          xlink:label="F_9ba2ab12-59c9-4705-b8c1-3ab3fc76f27d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8d1634f1-4c08-4418-9ecf-dfe6024613dd"
          xlink:label="F_8d1634f1-4c08-4418-9ecf-dfe6024613dd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_16f605bc-c449-4a9a-b897-ab5afc18d588"
          xlink:label="F_16f605bc-c449-4a9a-b897-ab5afc18d588"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_937b3cd9-fe7a-46a9-b361-3cd9f805fe0f"
          xlink:label="F_937b3cd9-fe7a-46a9-b361-3cd9f805fe0f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7c855bd6-e7de-4717-b7e5-c5bff55a7780"
          xlink:label="F_7c855bd6-e7de-4717-b7e5-c5bff55a7780"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3795a0fc-3033-47f0-99ff-bd301132860f"
          xlink:label="F_3795a0fc-3033-47f0-99ff-bd301132860f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_923af3dd-3ff9-4806-b536-4946e4597c7f"
          xlink:label="F_923af3dd-3ff9-4806-b536-4946e4597c7f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9d96335a-f6d9-4330-80ec-545283d4af99"
          xlink:label="F_9d96335a-f6d9-4330-80ec-545283d4af99"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_165c922b-2c8e-4822-90e5-0f02ac5c20e0"
          xlink:label="F_165c922b-2c8e-4822-90e5-0f02ac5c20e0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f2eca86f-a27b-425d-89ae-8dd08e821786"
          xlink:label="F_f2eca86f-a27b-425d-89ae-8dd08e821786"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_622aab91-b932-4187-809f-7b78f896c4f7"
          xlink:label="F_622aab91-b932-4187-809f-7b78f896c4f7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d74833a8-604a-4949-a863-f60de5785367"
          xlink:label="F_d74833a8-604a-4949-a863-f60de5785367"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f794aad9-2a63-4872-87b9-837f20bc715f"
          xlink:label="F_f794aad9-2a63-4872-87b9-837f20bc715f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ffaab183-18e2-4e1c-9a96-7eea9fcc75c4"
          xlink:label="F_ffaab183-18e2-4e1c-9a96-7eea9fcc75c4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_803a9650-095b-429c-9575-ef2db55e6637"
          xlink:label="F_803a9650-095b-429c-9575-ef2db55e6637"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_85f364e0-22ad-4ce7-9f7f-8121531aa5f7"
          xlink:label="F_85f364e0-22ad-4ce7-9f7f-8121531aa5f7"
          xlink:type="locator"/>
        <link:footnote id="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc" xlink:label="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restatement relates to adoption of amendments to IAS 1, &#x201c;Presentation of Financial Statements.&#x201d; Refer to Note 2 for further details.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c9d6d57b-425c-4fb7-abbd-e4a278a46eb8"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_62a04fe8-9b69-41f4-82de-ade1f995608e"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d72c75d5-ea0e-4320-874c-0aae05cd4401"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cac9b5bc-a669-4d09-ac9d-3ac7b871ead1"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d6b826e8-8b76-4bd1-baa0-57dac5ae1ea1"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_deb67055-8a85-4ee4-ac53-976b2ed93a91"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_556f4c14-5887-4ee4-8d98-2a04d59d2952"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_26c6c861-b5ba-4cad-92f6-32f39a3a1d2c"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_382097b3-b5ef-4436-b499-30711f816121"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e69b6562-90e1-4217-895d-b444dfba7743"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4fe891d7-42a9-43d8-ad45-1edeb55f7bd5"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c07633cd-f507-41e3-830f-c087650184e2"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_592df39d-6fe8-4376-b652-663628839d40"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0b4fb44d-7574-4a84-b61c-87d8d0bbab45"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_54e300fd-d8b7-4a41-9130-5dd43498563b"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_42b6f182-c1d6-40a4-9e57-6b2a81baa418"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_70808046-e0cf-4475-87b4-4b385a38274d"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_07c24fc7-73aa-4d3c-9add-a4464165d707"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9a7e5e95-c04c-4327-96d6-0bb984adb4a0"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e1de2081-8c19-44b6-82ed-be5e61e997ed"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_303a6812-2e52-48fd-a43a-203a98780c2d"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3a82fc0d-07aa-432d-b4fb-c0d3dabb40b7"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_caa57351-8417-4791-a585-bd145240387d"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_33c31fb0-9baf-4529-80e9-43922ebe0918"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_199ad878-35ff-4014-a37f-42eb7ed9c375"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_084cf33e-da27-4b65-bb42-3f6c5710074a"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5214d3b0-47a3-45d2-997f-784799e392c2"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_75208953-26c9-4ba5-80b9-b728a6b86e17"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_60695fa5-1167-441b-b831-7560770cf08c"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_980c6c3b-e596-4b9c-8d92-e02450c398a0"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d8e56e66-8575-4b72-a1ed-bc5d29c3d221"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cd3efa0e-9e4f-49f5-9e6c-a40915c3d8f3"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_850c6404-d676-4a1c-bd80-6f8bb47928b0"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7ffbe158-e7ca-41b1-9e0f-c9494aadcac5"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ef27783e-2ebf-4cee-8123-7b88ae2ac3c7"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1fa26a62-cdd0-4509-ba50-f296557bdcb6"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_69813962-ec68-4626-9ef5-779670aa2f2a"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9f2d3364-03ae-45be-ba44-fc988fb90336"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_23a507de-e21f-48de-ae21-fd24dace1e42"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_06324db9-e461-493f-a1a5-d89ab3895f83"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4e401866-c4ae-4461-ae46-80951396f0fa"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1837bd4c-bdab-4625-83ce-5792ca88d901"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_831a4081-f4f8-4711-96ad-78b29be79f6c"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0bc3769e-460e-4b91-afc4-7d3ba0080ceb"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_589fd958-2fd9-4861-8eb2-fb211220f782"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e7085e38-ade3-403e-81da-e57c0a1e414d"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8a80a850-f6a7-4854-b3a7-e27ae4e96591"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9943a8d6-82ce-4009-8273-13bf6b24f302"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e7255016-a092-43b2-8fff-0447b82b8834"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_61f5ba9c-d6e7-47af-a120-b0300560d6c6"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_40b093c3-640c-47a0-8b85-489d8e14a1a9"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7c603b92-996b-41cf-90f1-b6f38706f824"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7f5c30a7-dd20-4a79-8b75-5e53ccb86d9d"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_399b9146-169e-4bb4-ac80-cafd1f58cce1"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9ba2ab12-59c9-4705-b8c1-3ab3fc76f27d"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8d1634f1-4c08-4418-9ecf-dfe6024613dd"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_16f605bc-c449-4a9a-b897-ab5afc18d588"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_937b3cd9-fe7a-46a9-b361-3cd9f805fe0f"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7c855bd6-e7de-4717-b7e5-c5bff55a7780"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3795a0fc-3033-47f0-99ff-bd301132860f"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_923af3dd-3ff9-4806-b536-4946e4597c7f"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9d96335a-f6d9-4330-80ec-545283d4af99"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_165c922b-2c8e-4822-90e5-0f02ac5c20e0"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f2eca86f-a27b-425d-89ae-8dd08e821786"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_622aab91-b932-4187-809f-7b78f896c4f7"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d74833a8-604a-4949-a863-f60de5785367"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f794aad9-2a63-4872-87b9-837f20bc715f"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ffaab183-18e2-4e1c-9a96-7eea9fcc75c4"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_803a9650-095b-429c-9575-ef2db55e6637"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_85f364e0-22ad-4ce7-9f7f-8121531aa5f7"
          xlink:to="FNT_b53e0bce-64d0-4e37-b68c-a9b0e013f0bc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_fa2dca79-f11c-4eb0-a55e-cfc987c5b8ed"
          xlink:label="F_fa2dca79-f11c-4eb0-a55e-cfc987c5b8ed"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6f90b4e9-624c-4747-b8bf-fa9904dc08fa"
          xlink:label="F_6f90b4e9-624c-4747-b8bf-fa9904dc08fa"
          xlink:type="locator"/>
        <link:footnote id="FNT_ad99817b-a41d-42b8-9f90-df4b869212dd" xlink:label="FNT_ad99817b-a41d-42b8-9f90-df4b869212dd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, intangible assets and property, plant and equipment of &#x20ac;</xhtml:span><xhtml:span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.9</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#x20ac;</xhtml:span><xhtml:span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.9</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, is located in Denmark, the country of domicile.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fa2dca79-f11c-4eb0-a55e-cfc987c5b8ed"
          xlink:to="FNT_ad99817b-a41d-42b8-9f90-df4b869212dd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6f90b4e9-624c-4747-b8bf-fa9904dc08fa"
          xlink:to="FNT_ad99817b-a41d-42b8-9f90-df4b869212dd"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
